PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	SC	GA	UT	PM	OA	HC	HP	DA
J	Westermann, RW; Kerr, ZY; Wehr, P; Amendola, A				Westermann, Robert W.; Kerr, Zachary Y.; Wehr, Peter; Amendola, Annuziato			Increasing Lower Extremity Injury Rates Across the 2009-2010 to 2014-2015 Seasons of National Collegiate Athletic Association Football: An Unintended Consequence of the "Targeting" Rule Used to Prevent Concussions?	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						concussion; knee; ankle injury; football; rule change	SURVEILLANCE SYSTEM; SPORTS; EPIDEMIOLOGY; STATEMENT; PLAYERS	Background: Sports-related concussions (SRCs) have gained increased societal interest in the past decade. The National Collegiate Athletic Association (NCAA) has implemented legislation and rule changes to decrease the incidence and risk of head injury impacts. The targeting rule forbids initiating contact with the crown of a helmet and targeting defenseless players in the head and neck area; however, there are concerns that this rule change has unintentionally led to an increased incidence of lower extremity injuries. Purpose/Hypothesis: The purpose of this study was to evaluate the change in lower extremity injury rates in NCAA football during the 2009-2010 to 2014-2015 seasons. We hypothesized that the lower extremity injury rate has increased across the time period. Study Design: Descriptive epidemiology study. Methods: Sixty-eight NCAA football programs provided 153 team-seasons of data to the NCAA Injury Surveillance Program. Lower extremity injuries (ie, hip/groin, upper leg/thigh, knee, lower leg/Achilles, foot/toes) and SRCs sustained during NCAA football games were examined. We calculated injury rates per 1000 athlete-exposures (AEs) for lower extremity injuries and SRCs. Rate ratios (RRs) compared injury rates between the 2009-2010 to 2011-2012 and 2012-2013 to 2014-2015 seasons. Results: Overall, 2400 lower extremity injuries were reported during the 2009-2010 to 2014-2015 seasons; most were to the knee (33.6%) and ankle (28.5%) and caused by player contact (59.2%). The lower extremity injury rate increased in 2012-2013 to 2014-2015 compared with 2009-2010 to 2011-2012 (23.55 vs 20.45/1000 AEs, respectively; RR, 1.15; 95% CI, 1.06-1.25). This finding was retained when restricted to injuries due to player contact (RR, 1.19; 95% CI, 1.07-1.32) but not for injuries due to noncontact/overuse (RR, 0.96; 95% CI, 0.80-1.14). When examining player contact injury rates by anatomic site, only ankle injuries had an increase (RR, 1.36; 95% CI, 1.13-1.64). The SRC rate also increased in 2012-2013 to 2014-2015 compared with 2009-2010 to 2011-2012 (3.52 vs 2.63/1000 AEs, respectively; RR, 1.34; 95% CI, 1.08-1.66). Conclusion: The lower extremity injury rate has increased in NCAA football athletes. Similarly, SRC rates have increased, although this may be caused by concurrent policies related to better education, identification, and management. Targeting rule changes may be contributing to increased rates of player contact-related ankle injuries. Alongside continued surveillance research to examine longitudinal time trends, more in-depth individual-level examinations of how targeting rule changes influence coaching and player behaviors are warranted.	[Westermann, Robert W.; Kerr, Zachary Y.; Wehr, Peter; Amendola, Annuziato] Univ Iowa Hosp & Clin, Iowa City, IA 52242 USA; [Kerr, Zachary Y.] Datalys Ctr Sports Injury Res & Prevent, Indianapolis, IN USA; [Amendola, Annuziato] Duke Univ, Durham, NC USA	Westermann, RW (corresponding author), Univ Iowa Hosp & Clin, Dept Orthopaed Surg, 200 Hawkins Dr,01008 JPP, Iowa City, IA 52242 USA.	robert-westermann@uiowa.edu		Westermann, Robert/0000-0002-5289-4689; Kerr, Zachary/0000-0003-1423-1259	NCAA; Arthrex Inc.	One or more of the authors has declared the following potential conflict of interest or source of funding: The National Collegiate Athletic Association (NCAA) Injury Surveillance Program data were provided by the Datalys Center for Sports Injury Research and Prevention. The Injury Surveillance Program was funded by the NCAA. The content of this report is solely the responsibility of the authors and does not necessarily reflect the views of the NCAA. Dr Amendola receives intellectual property royalties from Arthrex Inc, Arthrosurface, and Smith & Nephew; has stock or stock options in First Ray Inc; and is a paid consultant for Arthrex Inc.	[Anonymous], 1905, WASHINGTON POST; Barzilai P, 2014, US TODAY SPORTS 0127; Darrow CJ, 2009, AM J SPORT MED, V37, P1798, DOI 10.1177/0363546509333015; Dick R, 2007, J ATHL TRAINING, V42, P221; Dragoo JL, 2013, KNEE, V20, P191, DOI 10.1016/j.knee.2012.07.006; Garraway WM, 2000, BRIT J SPORT MED, V34, P348, DOI 10.1136/bjsm.34.5.348; Golightly YM, 2009, J PHYS ACT HEALTH, V6, P638, DOI 10.1123/jpah.6.5.638; Gorse K, 1997, J ATHL TRAINING, V32, P304; Graham R., 2014, SPORTS RELATED CONCU; Guido Paul, 2007, 50 YEARS COLL FOOTBA; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hagel B, 2004, CLIN J SPORT MED, V14, P193, DOI 10.1097/00042752-200407000-00001; Heck JF, 2004, J ATHL TRAINING, V39, P101; Hershman EB, 2012, AM J SPORT MED, V40, P2200, DOI 10.1177/0363546512458888; Kerr ZY, 2015, MMWR-MORBID MORTAL W, V64, P1330, DOI 10.15585/mmwr.mm6448a2; Kerr ZY, 2014, J ATHL TRAINING, V49, P552, DOI 10.4085/1062-6050-49.3.58; Larsen E, 1999, SCAND J MED SCI SPOR, V9, P285; LEWIS GM, 1969, RES QUART, V40, P717, DOI 10.1080/10671188.1969.10614909; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Parsons JT., 2014, 2014 15 NCAA SPORTS, V25th ed; Redding R, 2013, NCAA FOOTBALL 2013 2; Redding R, 2008, NCAA FOOTBALL 2008 R; Shealy JE, 2000, AM SOC TEST MATER, V1397, P132, DOI 10.1520/STP12871S; Smith MD., 2015, NBC SPORTS      1130; TORG JS, 1985, JAMA-J AM MED ASSOC, V254, P3439, DOI 10.1001/jama.254.24.3439; Wasserman EB, 2016, AM J SPORT MED, V44, P226, DOI 10.1177/0363546515610537; Weir Dr, 2009, NATL FOOTBALL LEAGUE; Wright JM, 2010, CURR SPORT MED REP, V9, P129, DOI 10.1249/JSR.0b013e3181df1179; Zuckerman SL, 2015, AM J SPORT MED, V43, P2654, DOI 10.1177/0363546515599634	30	35	35	0	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	DEC	2016	44	12					3230	3236		10.1177/0363546516659290			7	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	EE8VS	WOS:000389905400027	27511792				2021-06-18	
J	Feeney, JM; Santone, E; DiFiori, M; Kis, L; Jayaraman, V; Montgomery, SC				Feeney, James M.; Santone, Elizabeth; DiFiori, Monica; Kis, Lilla; Jayaraman, Vijay; Montgomery, Stephanie C.			Compared to warfarin, direct oral anticoagulants are associated with lower mortality in patients with blunt traumatic intracranial hemorrhage: A TQIP study	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Traumatic intracranial hemorrhage; direct oral anticoagulants; traumatic brain injury; anticoagulants	ATRIAL-FIBRILLATION PATIENTS; RIVAROXABAN; METAANALYSIS; PREVENTION; DABIGATRAN; EFFICACY; SAFETY; STROKE; TRIAL	BACKGROUND Falls represent the leading cause of traumatic brain injury in adults older than 65, with nearly one third experiencing a fall each year. Evidence suggests that up to 0.5% of anticoagulated patients suffer from intracranial hemorrhage (ICH) annually. Direct oral anticoagulants (DOACs) have become an increasingly popular alternative to warfarin for anticoagulation; however, there is a dearth of research regarding the safety of DOACs, in particular on the outcome of traumatic ICH while taking DOACs. METHODS We queried our Trauma Quality Improvement Project registry for patients who presented with traumatic intracranial hemorrhage during anticoagulant use. Patients were grouped into those prescribed warfarin and patients prescribed DOAC medications. The groups were compared with respect to age, gender, Glasgow Coma Score (GCS) on arrival, Abbreviated Injury Scale (AIS) (head), Injury Severity Score (ISS), mortality, need for operative intervention, hospital and ICU lengths of stay, proportion of patients transfused (and their transfusion requirements), and rates of discharge to skilled nursing facility. Poisson regression was conducted to determine the relationship between mortality and treatment group while controlling for covariates (comorbidities, ISS). RESULTS There were no differences between DOAC and warfarin groups in terms of age, gender, median ISS, median AIS head, or median admission GCS. Mechanisms of injury, median hospital and ICU lengths of stay, ICU free days, and transfusion requirements were also not significantly different. DOAC use was associated with significantly lower mortality (4.9% vs. 20.8%; p < 0.008) and a lower rate of operative intervention (8.2% vs. 26.7%; p = 0.023) when compared with warfarin. Excluding patients who died, the observed rate of discharge to skilled nursing facility was lower in the DOAC group (28.8% compared with 39.7%; p = 0.03). Multivariate Poisson regression analysis demonstrated that warfarin use was associated with an increased mortality when controlling for injury severity, and comorbidities. CONCLUSIONS We report improved mortality and reduced rates of operative intervention in patients with traumatic ICH associated with DOACs compared with a similar group taking warfarin. We also noted an association with decreased rate of discharge to SNF in patients taking DOACs compared with warfarin. LEVEL OF EVIDENCE Therapeutic study, level IV.	[Feeney, James M.; Jayaraman, Vijay; Montgomery, Stephanie C.] St Francis Hosp & Med Ctr, Dept Surg, Hartford, CT USA; [Feeney, James M.; Santone, Elizabeth; Jayaraman, Vijay; Montgomery, Stephanie C.] Univ Connecticut, Sch Med, Farmington, CT USA; [DiFiori, Monica; Kis, Lilla] Trinity Coll, Hartford, CT 06106 USA	Feeney, JM (corresponding author), St Francis Hosp & Med Ctr, 114 Woodland St, Hartford, CT 06103 USA.	feeneymd@yahoo.com					Alonso A, 2014, STROKE, V45, P2286, DOI 10.1161/STROKEAHA.114.006016; Beynon C, 2015, THROMB RES, V136, P560, DOI 10.1016/j.thromres.2015.07.001; Beynon C, 2015, CLIN NEUROL NEUROSUR, V136, P73, DOI 10.1016/j.clineuro.2015.05.035; Caldeira D, 2015, J NEUROL, V262, P516, DOI 10.1007/s00415-014-7462-0; Dempfle CE, 2014, SEMIN HEMATOL, V51, P89, DOI 10.1053/j.seminhematol.2014.03.005; Gordon JL, 2013, J TRAUMA ACUTE CARE, V75, P475, DOI 10.1097/TA.0b013e3182a07391; Hagii J, 2014, STROKE, V45, P2805, DOI 10.1161/STROKEAHA.114.006661; Hankey GJ, 2014, STROKE, V45, P1304, DOI 10.1161/STROKEAHA.113.004506; Hankey GJ, 2014, CURR CARDIOL REP, V16, DOI 10.1007/s11886-014-0480-9; Hart RG, 2012, STROKE, V43, P1511, DOI 10.1161/STROKEAHA.112.650614; Lip GYH, 2012, J AM COLL CARDIOL, V60, P738, DOI 10.1016/j.jacc.2012.03.019; Miller SL, 2008, ANN EMERG MED, V52, P483, DOI 10.1016/j.annemergmed.2008.03.021; Ruff CT, 2014, LANCET, V383, P955, DOI 10.1016/S0140-6736(13)62343-0; Sardar P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077694	14	35	35	2	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	NOV	2016	81	5					843	848		10.1097/TA.0000000000001245			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	EC0IG	WOS:000387782800006	27602897				2021-06-18	
J	Barth, C; Steele, CJ; Mueller, K; Rekkas, VP; Arelin, K; Pampel, A; Burmann, I; Kratzsch, J; Villringer, A; Sacher, J				Barth, Claudia; Steele, Christopher J.; Mueller, Karsten; Rekkas, Vivien P.; Arelin, Katrin; Pampel, Andre; Burmann, Inga; Kratzsch, Juergen; Villringer, Arno; Sacher, Julia			In-vivo Dynamics of the Human Hippocampus across the Menstrual Cycle	SCIENTIFIC REPORTS			English	Article							FUNCTIONAL CONNECTIVITY CHANGES; WHITE-MATTER MICROSTRUCTURE; TRAUMATIC BRAIN-INJURY; POSTMENOPAUSAL WOMEN; SEX-DIFFERENCES; DIFFUSION; VOLUME; DEPRESSION; MRI; HORMONES	Sex hormones fluctuate during the menstrual cycle. Evidence from animal studies suggests similar subtle fluctuations in hippocampal structure, predominantly linked to estrogen. Hippocampal abnormalities have been observed in several neuropsychiatric pathologies with prominent sexual dimorphism. Yet, the potential impact of subtle sex-hormonal fluctuations on human hippocampal structure in health is unclear. We tested the feasibility of longitudinal neuroimaging in conjunction with rigorous menstrual cycle monitoring to evaluate potential changes in hippocampal microstructure associated with physiological sex-hormonal changes. Thirty longitudinal diffusion weighted imaging scans of a single healthy female subject were acquired across two full menstrual cycles. We calculated hippocampal fractional anisotropy (FA), a measure sensitive to changes in microstructural integrity, and investigated potential correlations with estrogen. We observed a significant positive correlation between FA values and estrogen in the hippocampus bilaterally, revealing a peak in FA closely paralleling ovulation. This exploratory, single-subject study demonstrates the feasibility of a longitudinal DWI scanning protocol across the menstrual cycle and is the first to link subtle endogenous hormonal fluctuations to changes in FA in vivo. In light of recent attempts to neurally phenotype single humans, our findings highlight menstrual cycle monitoring in parallel with highly sampled individual neuroimaging data to address fundamental questions about the dynamics of plasticity in the adult brain.	[Barth, Claudia; Steele, Christopher J.; Mueller, Karsten; Arelin, Katrin; Pampel, Andre; Burmann, Inga; Villringer, Arno; Sacher, Julia] Max Planck Inst Human Cognit & Brain Sci, Dept Neurol, Leipzig, Germany; [Steele, Christopher J.] McGill Univ, Douglas Mental Hlth Inst, Dept Psychiat, Cerebral Imaging Ctr, Montreal, PQ, Canada; [Rekkas, Vivien P.] Univ Toronto, CAMH Res Imaging Ctr, Toronto, ON, Canada; [Rekkas, Vivien P.] Univ Toronto, Campbell Family Mental Hlth Res Inst, Ctr Addict & Mental Hlth, Toronto, ON, Canada; [Rekkas, Vivien P.] Univ Toronto, Dept Psychiat, Toronto, ON, Canada; [Arelin, Katrin; Villringer, Arno; Sacher, Julia] Univ Leipzig, Clin Cognit Neurol, Leipzig, Germany; [Arelin, Katrin; Villringer, Arno] Univ Leipzig, Leipzig Res Ctr Civilizat Dis, Leipzig, Germany; [Kratzsch, Juergen] Univ Hosp Leipzig, Inst Lab Med Clin Chem & Mol Diagnost, Leipzig, Germany; [Villringer, Arno] Univ Leipzig, Integrated Res & Treatment Ctr Adipos Dis, Leipzig, Germany; [Villringer, Arno] Berlin Sch Mind & Brain, Mind & Brain Inst, Berlin, Germany	Barth, C; Sacher, J (corresponding author), Max Planck Inst Human Cognit & Brain Sci, Dept Neurol, Leipzig, Germany.; Sacher, J (corresponding author), Univ Leipzig, Clin Cognit Neurol, Leipzig, Germany.	sacher@cbs.mpg.de; sacher@cbs.mpg.de	; Sacher, Julia/M-7060-2016	Steele, Christopher/0000-0003-1656-7928; Barth, Claudia/0000-0001-6544-0945; Sacher, Julia/0000-0003-0944-0558	Society in Science-The Branco Weiss Fellowship; Max Planck SocietyMax Planck Society	The study was supported by a research grant from the Society in Science-The Branco Weiss Fellowship to Dr. Julia Sacher and research funds from the Max Planck Society. We thank Dr. Pierre-Louis Bazin and Dr. Daniel Margulies for critical discussion.	Alexander AL, 2007, NEUROTHERAPEUTICS, V4, P316, DOI 10.1016/j.nurt.2007.05.011; Arelin K, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00044; Barha CK, 2010, BBA-GEN SUBJECTS, V1800, P1056, DOI 10.1016/j.bbagen.2010.01.006; Barth C, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00037; BAUMAN JE, 1981, FERTIL STERIL, V36, P729; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; Behrens TEJ, 2003, MAGN RESON MED, V50, P1077, DOI 10.1002/mrm.10609; Boccardi M, 2006, MENOPAUSE, V13, P584, DOI 10.1097/01.gme.0000196811.88505.10; Campbell S, 2004, AM J PSYCHIAT, V161, P598, DOI 10.1176/appi.ajp.161.4.598; COUTTS JRT, 1982, CLIN ENDOCRINOL, V17, P389, DOI 10.1111/j.1365-2265.1982.tb01604.x; Cox SR, 2015, PSYCHONEUROENDOCRINO, V62, P129, DOI 10.1016/j.psyneuen.2015.08.005; De Bondt T, 2013, EUR RADIOL, V23, P57, DOI 10.1007/s00330-012-2572-5; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; Dinkel J, 2014, AM J NEURORADIOL, V35, P23, DOI 10.3174/ajnr.A3616; Douaud G, 2007, BRAIN, V130, P2375, DOI 10.1093/brain/awm184; Duarte-Guterman P, 2015, HORM BEHAV, V74, P37, DOI 10.1016/j.yhbeh.2015.05.024; First M.B., 1997, COMMUNICATION; First MB, 2002, PSYCHOPATHOLOGY, V35, P67, DOI 10.1159/000065121; Foy MR, 1999, J NEUROPHYSIOL, V81, P925; Franke K, 2015, NEUROIMAGE, V115, P1, DOI 10.1016/j.neuroimage.2015.04.036; Freeman EW, 2014, JAMA PSYCHIAT, V71, P36, DOI 10.1001/jamapsychiatry.2013.2819; Freeman EW, 2006, ARCH GEN PSYCHIAT, V63, P375, DOI 10.1001/archpsyc.63.4.375; Galea LAM, 2008, CAN J EXP PSYCHOL, V62, P247, DOI 10.1037/a0014501; Good CD, 2001, NEUROIMAGE, V14, P21, DOI 10.1006/nimg.2001.0786; Goto M, 2011, J MAGN RESON IMAGING, V33, P48, DOI 10.1002/jmri.22328; Hagemann G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014655; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Herting MM, 2012, CEREB CORTEX, V22, P1979, DOI 10.1093/cercor/bhr246; Hu SY, 2013, NEUROIMAGE, V74, P276, DOI 10.1016/j.neuroimage.2013.02.032; Ingalhalikar M, 2014, P NATL ACAD SCI USA, V111, P823, DOI 10.1073/pnas.1316909110; Kesler SR, 2004, NEUROPSYCHOLOGIA, V42, P1971, DOI 10.1016/j.neuropsychologia.2004.04.021; Kessler RC, 2003, J AFFECT DISORDERS, V74, P5, DOI 10.1016/S0165-0327(02)00426-3; Killgore WDS, 2013, SCI REP-UK, V3, DOI 10.1038/srep03457; Kranz GS, 2014, J NEUROSCI, V34, P15466, DOI 10.1523/JNEUROSCI.2488-14.2014; Laumann TO, 2015, NEURON, V87, P657, DOI 10.1016/j.neuron.2015.06.037; Lee SJ, 2001, ANNU REV PHARMACOL, V41, P569, DOI 10.1146/annurev.pharmtox.41.1.569; Lin M, 2016, MAGN RESON MED, V76, P290, DOI 10.1002/mrm.25816; Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073; Lisofsky N, 2015, NEUROIMAGE, V118, P154, DOI 10.1016/j.neuroimage.2015.06.012; MacQueen GM, 2003, P NATL ACAD SCI USA, V100, P1387, DOI 10.1073/pnas.0337481100; Mitra SW, 2003, ENDOCRINOLOGY, V144, P2055, DOI 10.1210/en.2002-221069; Munk-Olsen T, 2006, JAMA-J AM MED ASSOC, V296, P2582, DOI 10.1001/jama.296.21.2582; Neufang S, 2009, CEREB CORTEX, V19, P464, DOI 10.1093/cercor/bhn100; Pawluski JL, 2009, FRONT NEUROENDOCRIN, V30, P343, DOI 10.1016/j.yfrne.2009.03.007; Peper JS, 2011, NEUROSCIENCE, V191, P28, DOI 10.1016/j.neuroscience.2011.02.014; Petersen N, 2014, NEUROIMAGE, V90, P24, DOI 10.1016/j.neuroimage.2013.12.016; Pletzer B, 2010, BRAIN RES, V1348, P55, DOI 10.1016/j.brainres.2010.06.019; Poldrack RA, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9885; Protopopescu X, 2008, HIPPOCAMPUS, V18, P985, DOI 10.1002/hipo.20468; Qiu LR, 2013, NEUROIMAGE, V83, P593, DOI 10.1016/j.neuroimage.2013.06.074; Raffin E, 2013, FRONT NEUROL NEUROSC, V32, P26, DOI 10.1159/000348818; Sacher J, 2013, MAGN RESON IMAGING, V31, P366, DOI 10.1016/j.mri.2012.06.007; Sagi Y, 2012, NEURON, V73, P1195, DOI 10.1016/j.neuron.2012.01.025; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Sohrabji F, 2006, FRONT NEUROENDOCRIN, V27, P404, DOI 10.1016/j.yfrne.2006.09.003; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Steele CJ, 2013, J NEUROSCI, V33, P1282, DOI 10.1523/JNEUROSCI.3578-12.2013; Steele CJ, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00289; Streitburger DP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044195; Taubert M, 2012, NEUROSCIENTIST, V18, P320, DOI 10.1177/1073858411419048; Videbech P, 2004, AM J PSYCHIAT, V161, P1957, DOI 10.1176/appi.ajp.161.11.1957; Wegienka G, 2005, J WOMENS HEALTH, V14, P248, DOI 10.1089/jwh.2005.14.248; Zatorre RJ, 2012, NAT NEUROSCI, V15, P528, DOI 10.1038/nn.3045; Zhou J, 2005, NEUROENDOCRINOLOGY, V81, P294, DOI 10.1159/000088448	68	35	35	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	OCT 7	2016	6								32833	10.1038/srep32833			9	Multidisciplinary Sciences	Science & Technology - Other Topics	EH8BZ	WOS:000391997900001	27713470	DOAJ Gold, Green Published			2021-06-18	
J	Jorge, RE; Acion, L; Burin, DI; Robinson, RG				Jorge, Ricardo E.; Acion, Laura; Burin, Debora I.; Robinson, Robert G.			Sertraline for Preventing Mood Disorders Following Traumatic Brain Injury A Randomized Clinical Trial	JAMA PSYCHIATRY			English	Article							MAJOR DEPRESSIVE DISORDER; BLUNT HEAD-INJURY; PSYCHIATRIC-DISORDERS; AXIS-I; ASSOCIATION; ILLNESS; RISK; ESCITALOPRAM; RELATIVES; ONSET	IMPORTANCE Prevention is more effective than treatment to decrease the burden of significant medical conditions such as depressive disorders, a major cause of disability worldwide. Traumatic brain injury (TBI) is a candidate for selective strategies to prevent depression given the incidence, prevalence, and functional effect of depression that occurs after TBI. OBJECTIVE To assess the efficacy of sertraline treatment in preventing depressive disorders following TBI. DESIGN, SETTING, AND PARTICIPANTS A double-blind, placebo-controlled, parallel-group randomized clinical trial was conducted at a university hospital from July 3, 2008, to September 17, 2012, with 24 weeks of follow-up. A consecutive sample of 534 patients aged 18 to 85 years, hospitalized for mild, moderate, or severe TBI, was eligible for the study. Ninety-four patients consented to participate and were randomized (46 to placebo and 48 to sertraline), of whom 79 (84%) completed the study. Intention-to-treat data analysis was conducted from July 1, 2014, to December 31, 2015. INTERVENTIONS Placebo or sertraline, 100 mg/d, for 24 weeks or until development of a mood disorder. MAIN OUTCOMES AND MEASURES Time to onset of depressive disorders, as defined by the DSM-IV, associated with TBI. RESULTS Of the 94 patients in the study (38 female and 56 male; 92 white), the number needed to treat to prevent depression after TBI at 24 weeks was 5.9 (95% CI, 3.1-71.1; chi(2) = 4.6; P = .03) for sertraline treatment vs placebo. The influence of sertraline in the course of neuropsychological variables was not detected. The intervention was well tolerated, and adverse effects were mild in both the sertraline and placebo groups. CONCLUSIONS AND RELEVANCE Sertraline appears to be efficacious to prevent the onset of depressive disorders following TBI. Future studies should replicate these findings in a large sample of patients with TBI and depict their long-term physical, cognitive, behavioral, and functional outcomes.	[Jorge, Ricardo E.; Acion, Laura] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, One Baylor Plaza, Houston, TX 77030 USA; [Acion, Laura] Univ Iowa, Iowa Consortium Subst Abuse Res & Evaluat, Iowa City, IA USA; [Acion, Laura] Univ Buenos Aires, CONICET, Fac Ciencias Exactas & Nat, Inst Calculo, Buenos Aires, DF, Argentina; [Burin, Debora I.] Univ Buenos Aires, CONICET, Fac Psicol, Buenos Aires, DF, Argentina; [Robinson, Robert G.] Univ Iowa, Dept Psychiat, Iowa City, IA 52242 USA	Jorge, RE (corresponding author), Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, One Baylor Plaza, Houston, TX 77030 USA.	ricardo.jorge@bcm.edu		Acion, Laura/0000-0001-5213-6012; Burin, D. I./0000-0002-2515-719X	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS055827]	This study was funded by grant R01 NS055827 from the National Institutes of Health.	Ashman TA, 2009, ARCH PHYS MED REHAB, V90, P733, DOI 10.1016/j.apmr.2008.11.005; Barker-Collo S, 2013, BRAIN INJURY, V27, P1124, DOI 10.3109/02699052.2013.801513; Beekman ATF, 2010, CURR OPIN PSYCHIATR, V23, P8, DOI 10.1097/YCO.0b013e328333e17f; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bowen A, 1998, BRAIN INJURY, V12, P177, DOI 10.1080/026990598122656; Brody DL, 2015, MOL CELL NEUROSCI, V66, P91, DOI 10.1016/j.mcn.2015.02.005; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Deb S, 1999, AM J PSYCHIAT, V156, P374; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Faul Mark, 2015, Handb Clin Neurol, V127, P3, DOI 10.1016/B978-0-444-52892-6.00001-5; Finkelstein EA., 2006, INCIDENCE EC BURDEN; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gould KR, 2011, PSYCHOL MED, V41, P2099, DOI 10.1017/S003329171100033X; GUALTIERI T, 1991, Brain Injury, V5, P219, DOI 10.3109/02699059109008093; Hart T, 2012, ARCH PHYS MED REHAB, V93, P1343, DOI 10.1016/j.apmr.2012.03.036; Hertz L, 2015, FRONT BEHAV NEUROSCI, V9, DOI 10.3389/fnbeh.2015.00025; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Hudak AM, 2012, J HEAD TRAUMA REHAB, V27, P87, DOI 10.1097/HTR.0b013e3182114efd; Jorge R, 2002, NEUROREHABILITATION, V17, P311; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; Jorge RE, 2010, ARCH GEN PSYCHIAT, V67, P187, DOI 10.1001/archgenpsychiatry.2009.185; Karpova NN, 2012, SCIENCE, V335; Karpova NN, 2011, SCIENCE, V334, P1731, DOI 10.1126/science.1214592; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Lydersen S, 2009, STAT MED, V28, P1159, DOI 10.1002/sim.3531; McGahuey CA, 2000, J SEX MARITAL THER, V26, P25, DOI 10.1080/009262300278623; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; Reynolds CF, 2007, ARCH GEN PSYCHIAT, V64, P884, DOI 10.1001/archpsyc.64.8.884; Robinson RG, 2008, JAMA-J AM MED ASSOC, V299, P2391, DOI 10.1001/jama.299.20.2391; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; SCHOENHUBER R, 1988, J NEUROL NEUROSUR PS, V51, P722, DOI 10.1136/jnnp.51.5.722; Seel RT, 2010, J HEAD TRAUMA REHAB, V25, P99, DOI 10.1097/HTR.0b013e3181ce3966; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; van Zoonen K, 2014, INT J EPIDEMIOL, V43, P318, DOI 10.1093/ije/dyt175; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340	42	35	38	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-622X	2168-6238		JAMA PSYCHIAT	JAMA Psychiatry	OCT	2016	73	10					1041	1047		10.1001/jamapsychiatry.2016.2189			7	Psychiatry	Psychiatry	DZ5QG	WOS:000385916000009	27626622				2021-06-18	
J	Lynall, RC; Clark, MD; Grand, EE; Stucker, JC; Littleton, AC; Aguilar, AJ; Petschauer, MA; Teel, EF; Mihalik, JP				Lynall, Robert C.; Clark, Michael D.; Grand, Erin E.; Stucker, Jaclyn C.; Littleton, Ashley C.; Aguilar, Alain J.; Petschauer, Meredith A.; Teel, Elizabeth F.; Mihalik, Jason P.			Head Impact Biomechanics in Women's College Soccer	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						CONCUSSION; FOOTBALL; SPORTS INJURY; INJURY PREVENTION; SPORTS SAFETY	SPORTS-RELATED CONCUSSION; FOOTBALL PLAYERS; ACCELERATION MEASUREMENT; CLINICAL MEASURES; KINEMATICS; HISTORY; BRAIN; BALL	Introduction: There are limited nonlaboratory soccer head impact biomechanics data. This is surprising given soccer's global popularity. Epidemiological data suggest that female college soccer players are at a greater concussion injury risk than their male counterparts. Therefore, the purposes of our study were to quantify head impact frequency and magnitude during women's soccer practices and games in the National Collegiate Athletic Association and to characterize these data across event type, playing position, year on the team, and segment of game (first and second halves). Methods: Head impact biomechanics were collected from female college soccer players (n = 22; mean+/-SD age = 19.1+/-0.1 yr, height = 168.0+/-3.5 cm, mass = 63.7+/-6.0 kg). We employed a helmetless head impact measurement device (X2 Biosystems xPatch) before each competition and practice across a single season. Peak linear and rotational accelerations were categorized based on impact magnitude and subsequently analyzed using appropriate nonparametric analyses. Results: Overall, women's college soccer players experience approximately seven impacts per 90 min of game play. The overwhelming majority (similar to 90 %) of all head impacts were categorized into our mildest linear acceleration impact classification (10g-20g). Interestingly, a higher percentage of practice impacts in the 20g-40g range compared with games (11% vs 7%) was observed. Conclusion: Head impact biomechanics studies have provided valuable insights into understanding collision sports and for informing evidence-based rule and policy changes. These have included changing the football kickoff, ice hockey body checking ages, and head-to-head hits in both sports. Given soccer's global popularity, and the growing public concern for the potential long-term neurological implications of collision and contact sports, studying soccer has the potential to impact many athletes and the sports medicine professionals caring for them.	[Lynall, Robert C.; Clark, Michael D.; Grand, Erin E.; Stucker, Jaclyn C.; Teel, Elizabeth F.; Mihalik, Jason P.] Univ North Carolina Chapel Hill, Dept Exercise & Sport Sci, Matthew Gfeller Sport Related Traumat Brain Injur, Chapel Hill, NC USA; [Lynall, Robert C.; Clark, Michael D.; Teel, Elizabeth F.; Mihalik, Jason P.] Univ North Carolina Chapel Hill, Dept Allied Hlth Sci, Human Movement Sci Curriculum, Chapel Hill, NC USA; [Littleton, Ashley C.] Towson Univ, Dept Kinesiol, Towson, MD USA; [Aguilar, Alain J.; Petschauer, Meredith A.] Univ North Carolina Chapel Hill, Dept Exercise & Sport Sci, Chapel Hill, NC USA	Mihalik, JP (corresponding author), 2201 Stallings Evans Sports Med Ctr, Campus Box 8700, Chapel Hill, NC 27599 USA.	jmihalik@email.unc.edu	Lynall, Robert/M-2888-2014	Lynall, Robert/0000-0002-0785-6640; Clark, Michael/0000-0002-5019-0290; Teel, Elizabeth/0000-0002-2846-5884	Princeton UniversityPrinceton University; National Operating Committee on Standards for Athletic Equipment (NOCSAE)	The authors acknowledge Dr. Margot Putukian (Princeton University) for her assistance with funding. This work was indirectly supported with funding by the National Operating Committee on Standards for Athletic Equipment (NOCSAE). The opinions expressed herein are those of the authors and do not necessarily reflect the opinions of the committee.	Abbas K, 2015, BRAIN CONNECT, V5, P91, DOI 10.1089/brain.2014.0279; Bauer JA, 2001, J SPORT SCI, V19, P171, DOI 10.1080/026404101750095312; Berz K, 2013, PHYSICIAN SPORTSMED, V41, P58, DOI 10.3810/psm.2013.05.2015; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Brolinson P Gunnar, 2006, Curr Sports Med Rep, V5, P23; Camarillo DB, 2013, ANN BIOMED ENG, V41, P1939, DOI 10.1007/s10439-013-0801-y; Dezman ZDW, 2013, SPORTS HEALTH, V5, P320, DOI 10.1177/1941738113480935; Dorminy M, 2015, BRAIN INJURY, V29, P1158, DOI 10.3109/02699052.2015.1035324; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Funk JR, 2011, ANN BIOMED ENG, V39, P766, DOI 10.1007/s10439-010-0183-3; Gutierrez GM, 2014, PEDIATR EXERC SCI, V26, P33, DOI 10.1123/pes.2013-0102; Gysland SM, 2012, ANN BIOMED ENG, V40, P14, DOI 10.1007/s10439-011-0421-3; Hanlon E, 2010, J APPL BIOMECH, V26, P424, DOI 10.1123/jab.26.4.424; Hanlon EM, 2012, MED SCI SPORT EXER, V44, P1102, DOI 10.1249/MSS.0b013e3182444d7d; Harpham JA, 2014, ANN BIOMED ENG, V42, P1, DOI 10.1007/s10439-013-0881-8; Johnson B, 2014, J NEUROTRAUM, V31, P1907, DOI 10.1089/neu.2014.3415; Koerte IK, 2015, J NEUROTRAUM, V32, P1287, DOI 10.1089/neu.2014.3715; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; McAllister TW, 2012, NEUROLOGY, V78, P1777, DOI 10.1212/WNL.0b013e3182582fe7; McCaffrey MA, 2007, NEUROSURGERY, V61, P1236, DOI 10.1227/01.neu.0000306102.91506.8b; McCuen E, 2015, J BIOMECH, V48, P3720, DOI 10.1016/j.jbiomech.2015.08.003; Meehan WP, 2016, J NEUROTRAUM, V33, P254, DOI 10.1089/neu.2015.3930; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; National Federation of State High School Associations, 2015, PART STAT; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; Naunheim RS, 2003, MED SCI SPORT EXER, V35, P1406, DOI 10.1249/01.MSS.0000078933.84527.AE; Ng TP, 2006, BIOMED SCI INSTRUM, V42, P25; Ocwieja KE, 2012, ANN BIOMED ENG, V40, P90, DOI 10.1007/s10439-011-0401-7; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Tierney RT, 2008, J ATHL TRAINING, V43, P578, DOI 10.4085/1062-6050-43.6.578; Zetterberg H, 2007, BRIT J SPORT MED, V41, DOI 10.1136/bjsm.2007.037143; Zuckerman SL, 2015, AM J SPORT MED, V43, P2654, DOI 10.1177/0363546515599634	34	35	35	4	56	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	SEP	2016	48	9					1772	1778		10.1249/MSS.0000000000000951			7	Sport Sciences	Sport Sciences	DU5NX	WOS:000382259600017	27187102				2021-06-18	
J	Bharadwaj, VN; Lifshitz, J; Adelson, PD; Kodibagkar, VD; Stabenfeldt, SE				Bharadwaj, Vimala N.; Lifshitz, Jonathan; Adelson, P. David; Kodibagkar, Vikram D.; Stabenfeldt, Sarah E.			Temporal assessment of nanoparticle accumulation after experimental brain injury: Effect of particle size	SCIENTIFIC REPORTS			English	Article							BARRIER PERMEABILITY; SMALL MOLECULES; BIODISTRIBUTION; SURFACE; CORTEX; MOUSE; DRUG; TIME; RAT; METABOLISM	Nanoparticle (NP) based therapeutic and theranostic agents have been developed for various diseases, yet application to neural disease/ injury is restricted by the blood-brain-barrier (BBB). Traumatic brain injury (TBI) results in a host of pathological alterations, including transient breakdown of the BBB, thus opening a window for NP delivery to the injured brain tissue. This study focused on investigating the spatiotemporal accumulation of different sized NPs after TBI. Specifically, animal cohorts sustaining a controlled cortical impact injury received an intravenous injection of PEGylated NP cocktail (20, 40, 100, and 500 nm, each with a unique fluorophore) immediately (0 h), 2 h, 5 h, 12 h, or 23 h after injury. NPs were allowed to circulate for 1 h before perfusion and brain harvest. Confocal microscopy demonstrated peak NP accumulation within the injury penumbra 1 h post-injury. An inverse relationship was found between NP size and their continued accumulation within the penumbra. NP accumulation preferentially occurred in the primary motor and somatosensory areas of the injury penumbra as compared to the parietal association and visual area. Thus, we characterized the accumulation of particles up to 500 nm at different times acutely after injury, indicating the potential of NP-based TBI theranostics in the acute period after injury.	[Bharadwaj, Vimala N.; Kodibagkar, Vikram D.; Stabenfeldt, Sarah E.] Arizona State Univ, Sch Biol & Hlth Syst Engn, Tempe, AZ 85281 USA; [Lifshitz, Jonathan; Adelson, P. David] Phoenix Childrens Hosp, Barrow Neurol Inst, Phoenix, AZ USA; [Lifshitz, Jonathan; Adelson, P. David] Univ Arizona, Coll Med Phoenix, Dept Child Hlth, Phoenix, AZ USA	Kodibagkar, VD; Stabenfeldt, SE (corresponding author), Arizona State Univ, Sch Biol & Hlth Syst Engn, Tempe, AZ 85281 USA.	vikram.kodibagkar@asu.edu; sarah.stabenfeldt@asu.edu	Adelson, David/W-2083-2019		FLINN Foundation; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1DP2HD084067]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [DP2HD084067] Funding Source: NIH RePORTER	Authors would like to thank CLAS-Life Sciences Electron Microscope Lab and Bioimaging facility/Keck division (Arizona State University) for the use of transmission electron microscope and confocal laser scanning microscope, respectively. We thank Karthik Nambiar and David Lowry for the technical assistance in acquiring TEM images. We would also like to thank Dr. Dierdre Meldrum for the use of dynamic light scattering instrument. We would like to extend our thanks to Amanda Witten for assistance with the Figure 1 and Supplementary Figure 1. This study was supported by the FLINN Foundation (S.E.S., V.D.K., J.L., P.D.A.) and NIH (1DP2HD084067; SES).	Adelson PD, 1998, ACT NEUR S, V71, P104; Alexis F, 2008, MOL PHARMACEUT, V5, P505, DOI 10.1021/mp800051m; Alves JL, 2014, J NEUROSCI RES, V92, P141, DOI 10.1002/jnr.23300; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Ban Y, 1997, Mol Vis, V3, P18; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Brigger I, 2002, J PHARMACOL EXP THER, V303, P928, DOI 10.1124/jpet.102.039669; Bryan-Hancock C, 2010, INJURY PREV, V16, pA17, DOI 10.1136/ip.2010.029215.61; Cabral H, 2011, NAT NANOTECHNOL, V6, P815, DOI [10.1038/nnano.2011.166, 10.1038/NNANO.2011.166]; Cai WB, 2007, SMALL, V3, P1840, DOI 10.1002/smll.200700351; Chertok B, 2008, BIOMATERIALS, V29, P487, DOI 10.1016/j.biomaterials.2007.08.050; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Clond MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061819; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Dorr A, 2007, NEUROIMAGE, V35, P1409, DOI 10.1016/j.neuroimage.2006.12.040; Fang C, 2006, EUR J PHARM SCI, V27, P27, DOI 10.1016/j.ejps.2005.08.002; Fang J, 2011, ADV DRUG DELIVER REV, V63, P136, DOI 10.1016/j.addr.2010.04.009; FARACI FM, 1990, CIRC RES, V66, P8, DOI 10.1161/01.RES.66.1.8; GABIZON AA, 1995, ADV DRUG DELIVER REV, V16, P285, DOI 10.1016/0169-409X(95)00030-B; Gabizon AA, 2001, CANCER INVEST, V19, P424, DOI 10.1081/CNV-100103136; Gao XH, 2005, CURR OPIN BIOTECH, V16, P63, DOI 10.1016/j.copbio.2004.11.003; Habgood MD, 2007, EUR J NEUROSCI, V25, P231, DOI 10.1111/j.1460-9568.2006.05275.x; Herculano-Houzel S, 2013, FRONT NEUROANAT, V7, DOI 10.3389/fnana.2013.00035; Jin AY, 2009, CONTRAST MEDIA MOL I, V4, P305, DOI 10.1002/cmmi.292; Kim CK, 2009, NANOSCALE, V1, P61, DOI 10.1039/b9nr00112c; KLEIN B, 1986, AM J PHYSIOL, V251, pH1333; Kobeissy F.H., 2015, NANOPARTICLES NEUROT, DOI [10.1517/14728210902769601, DOI 10.1517/14728210902769601]; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Levchenko TS, 2002, INT J PHARMACEUT, V240, P95, DOI 10.1016/S0378-5173(02)00129-1; Li SD, 2008, MOL PHARMACEUT, V5, P496, DOI 10.1021/mp800049w; Lipka J, 2010, BIOMATERIALS, V31, P6574, DOI 10.1016/j.biomaterials.2010.05.009; Liu DF, 2014, NANOSCALE, V6, P15161, DOI 10.1039/c4nr03942d; LIU DX, 1992, BIOCHIM BIOPHYS ACTA, V1104, P95, DOI 10.1016/0005-2736(92)90136-A; Lotocki G, 2009, J NEUROTRAUM, V26, P1123, DOI 10.1089/neu.2008.0802; Masserini M, 2013, ISRN BIOCH, V2013; Mora-Huertas CE, 2010, INT J PHARMACEUT, V385, P113, DOI 10.1016/j.ijpharm.2009.10.018; Mudshinge SR, 2011, SAUDI PHARM J, V19, P129, DOI 10.1016/j.jsps.2011.04.001; Muller RH, 2001, ADV DRUG DELIVER REV, V47, P3, DOI 10.1016/S0169-409X(00)00118-6; Nishiyama N, 2015, ENCY POLYM NANOMATER, DOI DOI 10.1007/978-3-642-29648-2_226; Ostergaard L, 2014, J CEREBR BLOOD F MET, V34, P1585, DOI 10.1038/jcbfm.2014.131; Pham LDD, 2012, GLIA, V60, P875, DOI 10.1002/glia.22320; Phinikaridou A, 2012, CIRCULATION, V126, P707, DOI 10.1161/CIRCULATIONAHA.112.092098; Ping XJ, 2014, J NEUROTRAUM, V31, P1172, DOI 10.1089/neu.2013.3147; Sangiorgi S, 2013, J NEUROSURG, V118, P763, DOI 10.3171/2012.11.JNS12627; Sawyer AJ, 2013, J NEURAL ENG, V10, DOI 10.1088/1741-2560/10/1/016013; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; SZOKA F, 1978, P NATL ACAD SCI USA, V75, P4194, DOI 10.1073/pnas.75.9.4194; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; Thermo Fisher Scientific, FLUOR SPECTRAVIEWER; Torchilin V, 2011, ADV DRUG DELIVER REV, V63, P131, DOI 10.1016/j.addr.2010.03.011; TORCHILIN VP, 1994, BBA-BIOMEMBRANES, V1195, P11, DOI 10.1016/0005-2736(94)90003-5; Tsai PS, 2009, J NEUROSCI, V29, P14553, DOI 10.1523/JNEUROSCI.3287-09.2009; Xiong Y, 2009, EXPERT OPIN EMERG DR, V14, P67, DOI [10.1517/14728210902769601, 10.1517/14728210902769601 ]; Yamamoto Y, 2001, J CONTROL RELEASE, V77, P27, DOI 10.1016/S0168-3659(01)00451-5; Yardeni T, 2011, LAB ANIMAL, V40, P155, DOI 10.1038/laban0511-155	56	35	35	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	JUL 22	2016	6								29988	10.1038/srep29988			12	Multidisciplinary Sciences	Science & Technology - Other Topics	DR6SS	WOS:000380032200001	27444615	DOAJ Gold, Green Published, Green Accepted			2021-06-18	
J	Broglio, SP; Williams, RM; O'Connor, KL; Goldstick, J				Broglio, Steven P.; Williams, Richelle M.; O'Connor, Kathryn L.; Goldstick, Jason			Football Players' Head-Impact Exposure After Limiting of Full-Contact Practices	JOURNAL OF ATHLETIC TRAINING			English	Article						concussions; traumatic brain injuries; protective equipment	CHRONIC TRAUMATIC ENCEPHALOPATHY; HIGH-SCHOOL FOOTBALL; ICE HOCKEY PLAYERS; NEUROCOGNITIVE PERFORMANCE; BRAIN-INJURY; CONCUSSION; NEURODEGENERATION; SPORT; RISK; BIOMECHANICS	Context: Sporting organizations limit full-contact football practices to reduce concussion risk and based on speculation that repeated head impacts may result in long-term neurode-generation. Objective: To directly compare head-impact exposure in high school football players before and after a statewide restriction on full-contact practices. Design: Cross-sectional study. Setting: High school football field. Patients or Other Participants: Participants were varsity football athletes from a single high school. Before the rule change, 26 athletes (age = 16.2 +/- 0.8 years, height = 179.6 +/- 6.4 cm, weight = 81.9 +/- 13.1 kg) participated. After the rule change, 24 athletes (age = 15.9 +/- 0.8 years, height = 178.3 +/- 6.5 cm, weight = 76.2 +/- 11.6 kg) participated. Nine athletes participated in both years of the investigation. Main Outcome Measure(s): Head-impact exposure was monitored using the Head Impact Telemetry System while the athletes participated in football games and practices in the seasons before and after the rule change. Head-impact frequency, location, and magnitude (ie, linear acceleration, rotational acceleration, and Head Impact Telemetry severity profile [HITsp], respectively) were measured. Results: A total of 15 398 impacts (592 impacts per player per season) were captured before the rule change and 8269 impacts (345 impacts per player per season) after the change. An average 42% decline in impact exposure occurred across all players, with practice-exposure declines occurring among linemen (46% decline); receivers, cornerbacks, and safeties (41% decline); and tight ends, running backs (including fullbacks), and linebackers (39% decline). Impact magnitudes remained largely unchanged between the years. Conclusions: A rule change limiting full-contact high school football practices appears to have been effective in reducing head-impact exposure across all players, with the largest reduction occurring among linemen. This finding is likely associated with the rule modification, particularly because the coaching staff and offensive scheme remained consistent, yet how this reduction influences concussion risk and long-term cognitive health remains unknown.	[Broglio, Steven P.; Williams, Richelle M.; O'Connor, Kathryn L.] Univ Michigan, NeuroTrauma Res Lab, Ann Arbor, MI 48109 USA; [Goldstick, Jason] Univ Michigan, Dept Emergency Med, Ann Arbor, MI 48109 USA; [Broglio, Steven P.; Goldstick, Jason] Univ Michigan, Injury Ctr, Ann Arbor, MI 48109 USA	Broglio, SP (corresponding author), Univ Michigan, Injury Ctr, NeuroTrauma Res Lab, 401 Washtenaw Ave, Ann Arbor, MI 48109 USA.	broglio@umich.edu		Williams, Richelle/0000-0003-4728-7443; Van Pelt, Kathryn/0000-0002-5494-2357	National Institutes of Health National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R15NS081691]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R15NS081691] Funding Source: NIH RePORTER	We thank Brian Lemons and the players and staff at Father Gabriel Richard High School for their support with this project. Dr Broglio and Mrs Williams received funding from the National Institutes of Health National Institute of Neurological Disorders and Stroke (1R15NS081691).	[Anonymous], COLL BARG AGR; [Anonymous], LTD CONT PRACT RUL; [Anonymous], NEW FOOTB PRACT POL; Bazarian JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094734; Bloser F., 1994, NFL MORTALITY STUDY; Brainard LL, 2012, MED SCI SPORT EXER, V44, P297, DOI 10.1249/MSS.0b013e31822b0ab4; Broglio SP, 2006, BRIT J SPORT MED, V40, P802, DOI 10.1136/bjsm.2006.028019; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Broglio SP, 2013, AM J SPORT MED, V41, P2877, DOI 10.1177/0363546513502458; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Castellani RJ, 2015, J NEUROPATH EXP NEUR, V74, P493, DOI 10.1097/NEN.0000000000000193; Cobb Bryan R, 2014, Biomed Sci Instrum, V50, P285; Cobb BR, 2013, ANN BIOMED ENG, V41, P2463, DOI 10.1007/s10439-013-0867-6; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Crisco JJ, 2012, J APPL BIOMECH, V28, P174, DOI 10.1123/jab.28.2.174; Daniel Ray W, 2014, Biomed Sci Instrum, V50, P291; Daniel RW, 2014, J BIOMECH ENG-T ASME, V136, DOI 10.1115/1.4027872; Davis GA, 2015, NEUROSURGERY, V76, P643, DOI 10.1227/NEU.0000000000000722; Gardner A, 2014, BRIT J SPORT MED, V48, P84, DOI 10.1136/bjsports-2013-092646; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Gavett BE, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt42; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Iverson GL, 2015, NEUROSCI BIOBEHAV R, V56, P276, DOI 10.1016/j.neubiorev.2015.05.008; Kerr ZY, 2015, ORTHOP J SPORTS MED, V3, DOI 10.1177/2325967115594578; Kerr ZY, 2015, ORTHOP J SPORTS MED, V3, DOI 10.1177/2325967115610545; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; Mannix R, 2014, ANN CLIN TRANSL NEUR, V1, P433, DOI 10.1002/acn3.70; Maroon JC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117338; Martini D, 2013, MED SCI SPORT EXER, V45, P755, DOI 10.1249/MSS.0b013e3182798758; McCrory P, 2013, BRIT J SPORT MED, V47, P327, DOI 10.1136/bjsports-2013-092248; McCuen E, 2015, J BIOMECH, V48, P3720, DOI 10.1016/j.jbiomech.2015.08.003; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002; McKee AC, 2015, BRAIN PATHOL, V25, P350, DOI 10.1111/bpa.12248; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meehan W, 2015, NEUROLOGY, V85, P1504, DOI 10.1212/WNL.0000000000001893; Mihalik JP, 2012, ANN BIOMED ENG, V40, P141, DOI 10.1007/s10439-011-0405-3; Munce TA, 2015, MED SCI SPORT EXER, V47, P1567, DOI 10.1249/MSS.0000000000000591; National Collegiate Athletic Association, FOOTB PRACT GUID; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Savica R, 2012, MAYO CLIN PROC, V87, P335, DOI 10.1016/j.mayocp.2011.12.016; Solomon GS, 2015, BRAIN INJURY, V29, P164, DOI 10.3109/02699052.2014.965205; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Tsyvaer AT, 1981, BRIT J SPORT MED, V15, P163; Urban JE, 2013, ANN BIOMED ENG, V41, P2474, DOI 10.1007/s10439-013-0861-z; Wall SE, 2006, J NEUROL NEUROSUR PS, V77, P518, DOI 10.1136/jnnp.2004.061044; Wilcox BJ, 2014, J BIOMECH, V47, P109, DOI 10.1016/j.jbiomech.2013.10.004; Young TJ, 2014, CLIN J SPORT MED, V24, P416, DOI 10.1097/JSM.0000000000000055	51	35	35	1	14	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	JUL	2016	51	7					511	518		10.4085/1062-6050-51.7.04			8	Sport Sciences	Sport Sciences	EI9VP	WOS:000392857800002	27333460	Bronze, Green Published			2021-06-18	
J	Israel, I; Ohsiek, A; Al-Momani, E; Albert-Weissenberger, C; Stetter, C; Mencl, S; Buck, AK; Kleinschnitz, C; Samnick, S; Siren, AL				Israel, Ina; Ohsiek, Andrea; Al-Momani, Ehab; Albert-Weissenberger, Christiane; Stetter, Christian; Mencl, Stine; Buck, Andreas K.; Kleinschnitz, Christoph; Samnick, Samuel; Siren, Anna-Leena			Combined [F-18]DPA-714 micro-positron emission tomography and autoradiography imaging of microglia activation after closed head injury in mice	JOURNAL OF NEUROINFLAMMATION			English	Article						Neuroinflammation; TBI; IBA-1; Immunohistochemistry; Focal; Diffuse; Weight drop; TSPO; PET; Autoradiography	TRAUMATIC BRAIN-INJURY; TRANSLOCATOR PROTEIN; RAT MODEL; MOUSE MODEL; BENZODIAZEPINE-RECEPTORS; 18 KDA; PET; NEUROINFLAMMATION; TSPO; LIGAND	Background: Traumatic brain injury (TBI) is a major cause of death and disability. Neuroinflammation contributes to acute damage after TBI and modulates long-term evolution of degenerative and regenerative responses to injury. The aim of the present study was to evaluate the relationship of microglia activation to trauma severity, brain energy metabolism, and cellular reactions to injury in a mouse closed head injury model using combined in vivo PET imaging, ex vivo autoradiography, and immunohistochemistry. Methods: A weight-drop closed head injury model was used to produce a mixed diffuse and focal TBI or a purely diffuse mild TBI (mTBI) in C57BL6 mice. Lesion severity was determined by evaluating histological damage and functional outcome using a standardized neuroscore (NSS), gliosis, and axonal injury by immunohistochemistry. Repeated intra-individual in vivo mu PET imaging with the specific 18-kDa translocator protein (TSPO) radioligand [F-18]DPA-714 was performed on day 1, 7, and 16 and [F-18]FDG-mu PET imaging for energy metabolism on days 2-5 after trauma using freshly synthesized radiotracers. Immediately after [F-18]DPA-714-mu PET imaging on days 7 and 16, cellular identity of the [F-18]DPA-714 uptake was confirmed by exposing freshly cut cryosections to film autoradiography and successive immunostaining with antibodies against the microglia/macrophage marker IBA-1. Results: Functional outcome correlated with focal brain lesions, gliosis, and axonal injury. [F-18]DPA-714-mu PET showed increased radiotracer uptake in focal brain lesions on days 7 and 16 after TBI and correlated with reduced cerebral [F-18]FDG uptake on days 2-5, with functional outcome and number of IBA-1 positive cells on day 7. In autoradiography, [F-18]DPA-714 uptake co-localized with areas of IBA1-positive staining and correlated strongly with both NSS and the number of IBA1-positive cells, gliosis, and axonal injury. After mTBI, numbers of IBA-1 positive cells with microglial morphology increased in both brain hemispheres; however, uptake of [F-18]DPA-714 was not increased in autoradiography or in mu PET imaging. Conclusions: [F-18]DPA-714 uptake in mu PET/autoradiography correlates with trauma severity, brain metabolic deficits, and microglia activation after closed head TBI.	[Israel, Ina; Al-Momani, Ehab; Buck, Andreas K.; Samnick, Samuel] Univ Hosp Wurzburg, Dept Nucl Med, D-97080 Wurzburg, Germany; [Ohsiek, Andrea; Albert-Weissenberger, Christiane; Stetter, Christian; Siren, Anna-Leena] Univ Hosp Wurzburg, Dept Neurosurg, Expt Neurosurg, D-97080 Wurzburg, Germany; [Albert-Weissenberger, Christiane; Mencl, Stine; Kleinschnitz, Christoph] Univ Hosp Wurzburg, Dept Neurol, D-97080 Wurzburg, Germany; [Kleinschnitz, Christoph] Univ Hosp Essen, Dept Neurol, D-45147 Essen, Germany	Siren, AL (corresponding author), Univ Hosp Wurzburg, Dept Neurosurg, Expt Neurosurg, D-97080 Wurzburg, Germany.	siren.a@nch.uni-wuerzburg.de	Siren, Anna-Leena/AAE-1374-2019	Siren, Anna-Leena/0000-0002-2217-0081; Buck, Andreas/0000-0002-6447-0613; Kleinschnitz, Christoph/0000-0002-1650-8875	Interdisciplinary Center for Clinical Research (IZKF) Wurzburg [A226]; German Federal Ministry of Education and Research under the framework of EU-ERA-NET NEURON CnsAFlame [BMBF 01EW1502B]; German Research FoundationGerman Research Foundation (DFG) [SFB 688, TP Z02]	This project was financially supported by the Interdisciplinary Center for Clinical Research (IZKF) Wurzburg (Project A226), the German Federal Ministry of Education and Research under the framework of EU-ERA-NET NEURON CnsAFlame (BMBF 01EW1502B), and the German Research Foundation (SFB 688, TP Z02, A13).	Albert-WeiSSenberger Christiane, 2012, Exp Transl Stroke Med, V4, P1, DOI 10.1186/2040-7378-4-1; Albert-Weissenberger C, 2012, J CEREBR BLOOD F MET, V32, P1747, DOI 10.1038/jcbfm.2012.62; Albert-Weissenberger Christiane, 2010, Exp Transl Stroke Med, V2, P16, DOI 10.1186/2040-7378-2-16; Bennett RE, 2015, J NEUROSCI METH, V245, P25, DOI 10.1016/j.jneumeth.2015.02.005; Boutin H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056441; Brendel M, 2016, J NUCL MED, V57, P954, DOI 10.2967/jnumed.115.167858; Byrnes Kimberly R, 2014, Front Neuroenergetics, V5, P13, DOI 10.3389/fnene.2013.00013; Cao T, 2012, NEUROSCIENCE, V225, P65, DOI 10.1016/j.neuroscience.2012.08.058; Chauveau F, 2009, J NUCL MED, V50, P468, DOI 10.2967/jnumed.108.058669; Chen MK, 2008, PHARMACOL THERAPEUT, V118, P1, DOI 10.1016/j.pharmthera.2007.12.004; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; Coughlin JM, 2015, NEUROBIOL DIS, V74, P58, DOI 10.1016/j.nbd.2014.10.019; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Greuter HNJM, 2005, NUCL MED BIOL, V32, P307, DOI 10.1016/j.nucmedbio.2004.12.005; Grossman R, 2003, NEUROIMAGE, V20, P1971, DOI 10.1016/j.neuroimage.2003.06.003; Gyoneva S, 2015, TRENDS PHARMACOL SCI, V36, P471, DOI 10.1016/j.tips.2015.04.003; Harhausen D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069529; Hemphill MA, 2015, NEURON, V85, P1177, DOI 10.1016/j.neuron.2015.02.041; Hopp S, 2016, ANN NEUROL, V79, P970, DOI 10.1002/ana.24655; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; James ML, 2008, J NUCL MED, V49, P814, DOI 10.2967/jnumed.107.046151; Lavisse S, 2015, EUR J NUCL MED MOL I, V42, P478, DOI 10.1007/s00259-014-2962-9; Li J, 2012, J NEUROTRAUM, V29, P2635, DOI 10.1089/neu.2012.2411; Liu YR, 2010, J NUCL MED, V51, P1788, DOI 10.2967/jnumed.110.078626; Lyoo CH, 2015, J NUCL MED, V56, P701, DOI 10.2967/jnumed.114.146027; Martin A, 2010, J CEREBR BLOOD F MET, V30, P230, DOI 10.1038/jcbfm.2009.205; Menon DK, 2015, NAT REV NEUROL, V11, P71, DOI 10.1038/nrneurol.2014.261; Michell-Robinson MA, 2015, BRAIN, V138, P1138, DOI 10.1093/brain/awv066; Ory D, 2015, NUCL MED BIOL, V42, P753, DOI 10.1016/j.nucmedbio.2015.06.010; Peeters W, 2015, ACTA NEUROCHIR, V157, P1683, DOI 10.1007/s00701-015-2512-7; Rao VLR, 2000, EXP NEUROL, V161, P102, DOI 10.1006/exnr.1999.7269; Selwyn R, 2013, J NEUROTRAUM, V30, P1943, DOI 10.1089/neu.2013.2928; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Teasdale G, 2014, LANCET NEUROL, V13, P844, DOI 10.1016/S1474-4422(14)70120-6; Vallez Garcia D, 2016, J NEUROTRAUMA; Venneti S, 2007, EXP NEUROL, V207, P118, DOI 10.1016/j.expneurol.2007.06.003; Venneti S, 2007, J NEUROCHEM, V102, P2118, DOI 10.1111/j.1471-4159.2007.04690.x; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Wang Y, 2014, MOL PHARMACEUT, V11, P3463, DOI 10.1021/mp500234d; Wang Y, 2014, EUR J NUCL MED MOL I, V41, P1440, DOI 10.1007/s00259-014-2727-5; Yu AS, 2009, J NUCL MED, V50, P966, DOI 10.2967/jnumed.108.060533; Yu I, 2010, J NEUROTRAUM, V27, P1463, DOI 10.1089/neu.2009.1196; Zinnhardt B, 2015, J CEREBR BLOOD F MET, V35, P1711, DOI 10.1038/jcbfm.2015.149	45	35	35	0	7	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	JUN 7	2016	13								140	10.1186/s12974-016-0604-9			13	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	DN7VV	WOS:000377289200002	27266706	DOAJ Gold, Green Published			2021-06-18	
J	Kellermann, I; Kleindienst, A; Hore, N; Buchfelder, M; Brandner, S				Kellermann, Isabel; Kleindienst, Andrea; Hore, Nirjhar; Buchfelder, Michael; Brandner, Sebastian			Early CSF and Serum S100B Concentrations for Outcome Prediction in Traumatic Brain Injury and Subarachnoid Hemorrhage	CLINICAL NEUROLOGY AND NEUROSURGERY			English	Article						Biomarker; S100B; Neurotrauma; Neuroproteins; Cerebrospinal fluid	CEREBROSPINAL-FLUID; S-100 PROTEIN; BIOMARKERS	Objectives: S100B has been proposed as a putative biochemical marker in determining the extent of brain injury and corresponding prognosis in neurotrauma. The aim of this study was to evaluate the prognostic value of S100B early concentrations in serum and cerebrospinal fluid (CSF) in traumatic brain injury (TBI) and subarachnoid hemorrhage (SAH), to determine prognostically relevant threshold values and to evaluate fluctuation following EVD placement. Patients and methods: In 102 patients (45 SAH and 57 TBI) under intensive care unit (ICU) treated between January 2011 and December 2012 with external ventricular drain (EVD) S100B measurements were performed simultaneously in serum and CSF during the first 5 days and before and after EVD exchange. Glasgow coma scale (GCS) was assessed on admission and Glasgow outcome scale (GOS) 6 months later. Results: Peak S100B levels in CSF and serum were measured on the first day after admission and concentrations decreased during the ensuing days post injury gradually. CSF and serum S100B concentrations in TBI patients were significantly higher than in SAH (p < 0.005). Both in TBI and SAH patients S100B concentrations in CSF and serum were significantly higher in patients with an unfavorable outcome (GOS 1-3) in comparison to patients with a good outcome (GOS 4-5). Correlation of S100B concentrations in serum and GOS score at 6 months was significant both in TBI and SAH (p<0.05). Serum S100B concentrations >0.7 mu g/l correlated with 100% mortality. Correlation between S100B in CSF and GOS was significant in SAH (p < 0.05), whereas it was not significant in TBI. After EVD exchange (n = 53) we found a significant increase of S100B concentration in CSF (p < 0.005). Conclusion: Initial S100B levels have a limited prognostic value in neurotrauma with CSF concentrations being highly sensitive to smallest influences like EVD placement. However, high initial S100B levels of >0.7 mu g/dl in serum are associated with 100% mortality, which might help to guide therapy strategies in severe neurotrauma. (C) 2016 Elsevier B.V. All rights reserved.	[Kellermann, Isabel; Kleindienst, Andrea; Hore, Nirjhar; Buchfelder, Michael; Brandner, Sebastian] Univ Erlangen Nurnberg, Dept Neurosurg, D-91054 Erlangen, Germany	Brandner, S (corresponding author), Univ Erlangen Nurnberg, Dept Neurosurg, D-91054 Erlangen, Germany.	isabel.kellermann@web.de; andrea.kleindienst@uk-erlangen.de; nirjhar.hore@uk-erlangen.de; michael.buchfelder@uk-erlangen.de; sebastian.brandner@uk-erlangen.de	Kleindienst, Andrea/F-1674-2014	Kleindienst, Andrea/0000-0003-4758-0324			Bloomfield SM, 2007, NEUROCRIT CARE, V6, P121, DOI 10.1007/s12028-007-0008-x; Brandner S, 2012, Acta Neurochir Suppl, V114, P217, DOI 10.1007/978-3-7091-0956-4_42; Brandner S, 2013, J NEUROTRAUM, V30, P1205, DOI 10.1089/neu.2012.2621; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Egea-Guerrero JJ, 2013, J NEUROTRAUM, V30, P1762, DOI 10.1089/neu.2012.2606; Goyal A, 2013, J NEUROTRAUM, V30, P946, DOI 10.1089/neu.2012.2579; HARDEMARK HG, 1989, ACTA NEUROCHIR, V99, P135, DOI 10.1007/BF01402322; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; Kleindienst A, 2006, J NEUROTRAUM, V23, P1185, DOI 10.1089/neu.2006.23.1185; Kleindienst Andrea, 2010, Cardiovasc Psychiatry Neurol, V2010, P801295, DOI 10.1155/2010/801295; Kochanek PM, 2008, CURR OPIN CRIT CARE, V14, P135, DOI 10.1097/MCC.0b013e3282f57564; PERSSON L, 1988, ACTA NEUROCHIR, V93, P116, DOI 10.1007/BF01402892; Petzold A, 2003, NEUROSCI LETT, V336, P167, DOI 10.1016/S0304-3940(02)01257-0; Rohlwink UK, 2014, CLIN CHEM, V60, P823, DOI 10.1373/clinchem.2013.212472; TAKAYASU M, 1985, J NEUROSURG, V63, P417, DOI 10.3171/jns.1985.63.3.0417; Ucar T, 2004, J TRAUMA, V57, P95, DOI 10.1097/01.TA.0000071352.95491.75	16	35	37	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0303-8467	1872-6968		CLIN NEUROL NEUROSUR	Clin. Neurol. Neurosurg.	JUN	2016	145						79	83		10.1016/j.clineuro.2016.04.005			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	DP0KZ	WOS:000378180000015	27101088				2021-06-18	
J	Harris, JP; Struzyna, LA; Murphy, PL; Adewole, DO; Kuo, E; Cullen, DK				Harris, J. P.; Struzyna, L. A.; Murphy, P. L.; Adewole, D. O.; Kuo, E.; Cullen, D. K.			Advanced biomaterial strategies to transplant preformed micro-tissue engineered neural networks into the brain	JOURNAL OF NEURAL ENGINEERING			English	Article						neurotransplantation; transplantation; bioengineering; cell replacement; axonal tracts; tissue engineering; biomaterials	LONG-TERM SURVIVAL; STEM-CELL TRANSPLANTATION; IN-VITRO; FUNCTIONAL RECOVERY; NEURITE OUTGROWTH; CORTICAL-NEURONS; REGENERATION; CONSTRUCTS; MATURATION; MIGRATION	Objective. Connectome disruption is a hallmark of many neurological diseases and trauma with no current strategies to restore lost long-distance axonal pathways in the brain. We are creating transplantable micro-tissue engineered neural networks (micro-TENNs), which are preformed constructs consisting of embedded neurons and long axonal tracts to integrate with the nervous system to physically reconstitute lost axonal pathways. Approach. We advanced micro-tissue engineering techniques to generate micro-TENNs consisting of discrete populations of mature primary cerebral cortical neurons spanned by long axonal fascicles encased in miniature hydrogel micro-columns. Further, we improved the biomaterial encasement scheme by adding a thin layer of low viscosity carboxymethylcellulose (CMC) to enable needle-less insertion and rapid softening for mechanical similarity with brain tissue. Main results. The engineered architecture of cortical micro-TENNs facilitated robust neuronal viability and axonal cytoarchitecture to at least 22 days in vitro. Micro-TENNs displayed discrete neuronal populations spanned by long axonal fasciculation throughout the core, thus mimicking the general systems-level anatomy of gray matter-white matter in the brain. Additionally, micro-columns with thin CMC-coating upon mild dehydration were able to withstand a force of 893 +/- 457 mN before buckling, whereas a solid agarose cylinder of similar dimensions was predicted to withstand less than 150 mu N of force. This thin CMC coating increased the stiffness by three orders of magnitude, enabling needle-less insertion into brain while significantly reducing the footprint of previous needle-based delivery methods to minimize insertion trauma. Significance. Our novel micro-TENNs are the first strategy designed for minimally invasive implantation to facilitate nervous system repair by simultaneously providing neuronal replacement and physical reconstruction of long-distance axon pathways in the brain. The micro-TENN approach may offer the ability to treat several disorders that disrupt the connectome, including Parkinson's disease, traumatic brain injury, stroke, and brain tumor excision.	[Harris, J. P.; Struzyna, L. A.; Murphy, P. L.; Adewole, D. O.; Kuo, E.; Cullen, D. K.] Univ Penn, Perelman Sch Med, Dept Neurosurg, Ctr Brain Injury & Repair, Philadelphia, PA 19104 USA; [Harris, J. P.; Struzyna, L. A.; Adewole, D. O.; Kuo, E.; Cullen, D. K.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA; [Struzyna, L. A.; Adewole, D. O.] Univ Penn, Sch Engn & Appl Sci, Dept Bioengn, Philadelphia, PA 19104 USA	Cullen, DK (corresponding author), Univ Penn, Perelman Sch Med, Dept Neurosurg, Ctr Brain Injury & Repair, Philadelphia, PA 19104 USA.; Cullen, DK (corresponding author), Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.	dkacy@mail.med.upenn.edu		Harris, James/0000-0002-8458-5434; Adewole, Dayo/0000-0003-4685-6974; Murphy, Patricia/0000-0002-5843-5440	Penn Medicine Neuroscience Center; National Science FoundationNational Science Foundation (NSF) [DGE-1321851]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32-NS043126, T32-GM007517]; Department of Veterans Affairs (RRD Merit Review)US Department of Veterans Affairs [B1097-I]; US Army Medical Research and Materiel Command through the Joint Warfighter Medical Research Program [W81XWH-13-207 004]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM007517] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS043126, U01NS094340] Funding Source: NIH RePORTER	Financial support was provided by the Penn Medicine Neuroscience Center, National Science Foundation (Graduate Research Fellowship DGE-1321851), National Institutes of Health (T32-NS043126 & T32-GM007517), Department of Veterans Affairs (RR&D Merit Review #B1097-I), and the US Army Medical Research and Materiel Command through the Joint Warfighter Medical Research Program (#W81XWH-13-207 004). The authors would like to thank Rob Mauck and Mike Hast in the Penn Center for Musculoskeletal Disorders Core for help in mechanical testing. Additional thanks go to Vincent Wu, Norma Alexis Brown, Alan He, Camila Robles-Oteiza, and Parker Schabel for technical contributions.	BAR A, 1995, FOOD CHEM TOXICOL, V33, P909, DOI 10.1016/0278-6915(95)00069-E; BENARI Y, 1994, PROG BRAIN RES, V102, P261; Bjartmar C, 2003, J NEUROL SCI, V206, P165, DOI 10.1016/S0022-510X(02)00069-2; Borisoff JF, 2003, MOL CELL NEUROSCI, V22, P405, DOI 10.1016/S1044-7431(02)00032-5; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Cancedda L, 2007, J NEUROSCI, V27, P5224, DOI 10.1523/JNEUROSCI.5169-06.2007; Chen G, 1996, J PHYSIOL-LONDON, V494, P451, DOI 10.1113/jphysiol.1996.sp021505; Chen ZJ, 2004, J NEUROSURG, V101, P314, DOI 10.3171/jns.2004.101.2.0314; Coleman MP, 2002, TRENDS NEUROSCI, V25, P532, DOI 10.1016/S0166-2236(02)02255-5; Cullen DK, 2007, J NEUROSCI RES, V85, P3642, DOI 10.1002/jnr.21434; Cullen DK, 2007, J NEURAL ENG, V4, P159, DOI 10.1088/1741-2560/4/2/015; Cullen DK, 2007, ANN BIOMED ENG, V35, P835, DOI 10.1007/s10439-007-9292-z; Cullen DK, 2012, TISSUE ENG PT A, V18, P2280, DOI [10.1089/ten.tea.2011.0534, 10.1089/ten.TEA.2011.0534]; Cullen D. Kacy, 2011, Critical Reviews in Biomedical Engineering, V39, P201; Cullen DK, 2010, BRAIN RES, V1359, P44, DOI 10.1016/j.brainres.2010.08.058; Cummings BJ, 2005, P NATL ACAD SCI USA, V102, P14069, DOI 10.1073/pnas.0507063102; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; Deng L, 2007, J NEUROSCI, V27, P10860, DOI 10.1523/JNEUROSCI.2744-07.2007; Denham M, 2012, FRONT CELL NEUROSCI, V6, DOI 10.3389/fncel.2012.00011; Dubois-Dauphin ML, 2010, BIOMATERIALS, V31, P7032, DOI 10.1016/j.biomaterials.2010.06.017; Elliot J. H., 1974, Rheologica Acta, V13, P670, DOI 10.1007/BF01527058; FAWCETT JW, 1995, EXP BRAIN RES, V106, P275; Feng XH, 2006, IND ENG CHEM RES, V45, P6665, DOI 10.1021/ie060511f; Filous AR, 2010, DEV NEUROBIOL, V70, P826, DOI 10.1002/dneu.20820; Ghanbarzadeh B, 2011, INT J BIOL MACROMOL, V48, P44, DOI 10.1016/j.ijbiomac.2010.09.014; Grealish S, 2014, CELL STEM CELL, V15, P653, DOI 10.1016/j.stem.2014.09.017; Harris JP, 2011, J NEURAL ENG, V8, DOI 10.1088/1741-2560/8/6/066011; Harris JP, 2011, J NEURAL ENG, V8, DOI 10.1088/1741-2560/8/4/046010; Harris James P., 2013, Critical Reviews in Biomedical Engineering, V41, P435; He ZG, 2010, J BIOMED RES, V24, P2, DOI 10.1016/S1674-8301(10)60002-4; Hopkins AM, 2015, PROG NEUROBIOL, V125, P1, DOI 10.1016/j.pneurobio.2014.11.003; Huang JH, 2009, TISSUE ENG PT A, V15, P1677, DOI 10.1089/ten.tea.2008.0294; Irons HR, 2008, J NEURAL ENG, V5, P333, DOI 10.1088/1741-2560/5/3/006; Iwata A, 2006, TISSUE ENG, V12, P101, DOI 10.1089/ten.2006.12.101; Jain A, 2004, J NEUROSCI RES, V77, P299, DOI 10.1002/jnr.20161; Jensen W, 2006, IEEE T BIO-MED ENG, V53, P934, DOI 10.1109/TBME.2006.872824; Karumbaiah L, 2013, BIOMATERIALS, V34, P8061, DOI 10.1016/j.biomaterials.2013.07.016; Kato-Negishi M, 2013, ADV HEALTHC MATER, V2, P1564, DOI 10.1002/adhm.201300052; Kim H J, 2010, BIOCH BIOPHYS ACTA; Kozai TDY, 2014, BIOMATERIALS, V35, P9255, DOI 10.1016/j.biomaterials.2014.07.039; Lancaster MA, 2013, NATURE, V501, P373, DOI 10.1038/nature12517; LaPlaca MC, 2010, ARTECH HSE METH BIOE, P187; Liu K, 2010, NAT NEUROSCI, V13, P1075, DOI 10.1038/nn.2603; Liu WM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031675; Mauck RL, 2000, J BIOMECH ENG-T ASME, V122, P252, DOI 10.1115/1.429656; Mine Y, 2013, NEUROBIOL DIS, V52, P191, DOI 10.1016/j.nbd.2012.12.006; Mingorance A, 2006, FASEB J, V20, P491, DOI 10.1096/fj.05-5121fje; Moore MJ, 2006, BIOMATERIALS, V27, P419, DOI 10.1016/j.biomaterials.2005.07.045; Moshayedi P, 2014, BIOMATERIALS, V35, P3919, DOI 10.1016/j.biomaterials.2014.01.038; NAJAFI K, 1990, IEEE T BIO-MED ENG, V37, P474, DOI 10.1109/10.55638; Nguyen JK, 2014, J NEURAL ENG, V11, DOI 10.1088/1741-2560/11/5/056014; O'Connor SM, 2001, NEUROSCI LETT, V304, P189, DOI 10.1016/S0304-3940(01)01769-4; Orlacchio A, 2010, CURR MED CHEM, V17, P595, DOI 10.2174/092986710790416272; Ouardouz M, 2005, DEV BRAIN RES, V160, P78, DOI 10.1016/j.devbrainres.2005.09.001; Paralikar Kunal J, 2006, Conf Proc IEEE Eng Med Biol Soc, V2006, P2958; Ren HM, 2013, INT J CLIN EXP PATHO, V6, P230; Seymour JP, 2007, BIOMATERIALS, V28, P3594, DOI 10.1016/j.biomaterials.2007.03.024; Shear DA, 2004, BRAIN RES, V1026, P11, DOI 10.1016/j.brainres.2004.07.087; Silva NA, 2010, TISSUE ENG PT A, V16, P45, DOI [10.1089/ten.tea.2008.0559, 10.1089/ten.TEA.2008.0559]; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Sinclair SR, 1999, EUR J NEUROSCI, V11, P4341, DOI 10.1046/j.1460-9568.1999.00867.x; Stabenfeldt SE, 2006, J BIOMED MATER RES A, V77A, P718, DOI 10.1002/jbm.a.30638; Stabenfeldt SE, 2010, TISSUE ENG PT A, V16, P3747, DOI [10.1089/ten.tea.2009.0837, 10.1089/ten.TEA.2009.0837]; Stabenfeldt SE, 2011, ACTA BIOMATER, V7, P4102, DOI 10.1016/j.actbio.2011.07.026; Steinschneider R, 1996, DEV BRAIN RES, V95, P15, DOI 10.1016/0165-3806(96)00052-1; Stichel CC, 1999, EUR J NEUROSCI, V11, P632, DOI 10.1046/j.1460-9568.1999.00466.x; Struzyna LA, 2015, TISSUE ENG PT A, V21, P2744, DOI [10.1089/ten.tea.2014.0557, 10.1089/ten.TEA.2014.0557]; Struzyna LA, 2015, NEURAL REGEN RES, V10, P679, DOI 10.4103/1673-5374.156943; Sudheimer K D, 2014, HUMAN BRAIN ATLAS; Tang XQ, 2007, J NEUROSCI, V27, P6068, DOI 10.1523/JNEUROSCI.1442-07.2007; Tang-Schomer MD, 2014, P NATL ACAD SCI USA, V111, P13811, DOI 10.1073/pnas.1324214111; Tate CC, 2009, J TISSUE ENG REGEN M, V3, P208, DOI 10.1002/term.154; Tate MC, 2004, MOL CELL NEUROSCI, V27, P22, DOI 10.1016/j.mcn.2004.05.001; Tate MC, 2002, CELL TRANSPLANT, V11, P283; Tate MC, 2001, BIOMATERIALS, V22, P1113, DOI 10.1016/S0142-9612(00)00348-3; Tsai EC, 2004, J NEUROTRAUM, V21, P789, DOI 10.1089/0897715041269687; Tsai PS, 2009, J NEUROSCI, V29, P14553, DOI 10.1523/JNEUROSCI.3287-09.2009; Turner JN, 1999, EXP NEUROL, V156, P33, DOI 10.1006/exnr.1998.6983; Vukasinovic J, 2009, BIOMED MICRODEVICES, V11, P1155, DOI 10.1007/s10544-009-9332-6; Wagenaar DA, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-11; Warnock F V, 1965, MECH SOLIDS STRENGTH; Yip PK, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000399; Yoo Sang Jin, 2011, Exp Neurobiol, V20, P110, DOI 10.5607/en.2011.20.2.110	83	35	39	2	40	IOP PUBLISHING LTD	BRISTOL	TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND	1741-2560	1741-2552		J NEURAL ENG	J. Neural Eng.	FEB	2016	13	1							016019	10.1088/1741-2560/13/1/016019			19	Engineering, Biomedical; Neurosciences	Engineering; Neurosciences & Neurology	DF7XD	WOS:000371570200020	26760138	Green Accepted			2021-06-18	
J	Alsalaheen, BA; Whitney, SL; Marchetti, GF; Furman, JM; Kontos, AP; Collins, MW; Sparto, PJ				Alsalaheen, Bara A.; Whitney, Susan L.; Marchetti, Gregory F.; Furman, Joseph M.; Kontos, Anthony P.; Collins, Michael W.; Sparto, Patrick J.			Relationship Between Cognitive Assessment and Balance Measures in Adolescents Referred for Vestibular Physical Therapy After Concussion	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						mild traumatic brain injury; vestibular rehabilitation; dizziness	TRAUMATIC BRAIN-INJURY; SPORT-RELATED CONCUSSION; MINIMAL DETECTABLE CHANGE; DYNAMIC GAIT INDEX; HIGH-SCHOOL; POSTURAL STABILITY; FOOTBALL PLAYERS; NEUROCOGNITIVE FUNCTION; FUNCTIONAL GAIT; SYMPTOMS	Objective:To examine the relationship between cognitive and balance performance in adolescents with concussion.Design:Retrospective case series.Setting:Tertiary.Patients:Sixty patients.Interventions:Correlation analyses were performed to describe the relationship between symptoms, cognitive measure, and balance measure at the time of initiation of vestibular physical therapy.Main Outcome Measures:Cognitive performance was assessed using the Immediate Post-concussion Assessment and Cognitive Testing (ImPACT). The dizziness and balance function measures included dizziness severity rating, Activities-specific Balance Confidence scale (ABC), Dizziness Handicap Inventory (DHI), Functional Gait Assessment, gait speed, Timed UP and GO, Five Times Sit to Stand, and Sensory Organization Test (SOT). To account for multiple comparisons, the False Discovery Rate method was used.Results:Performance measures of balance were significantly correlated with cognitive measures. Greater total symptom scores were related to greater impairment in the ABC and DHI (r = 0.35-0.39, P 0.008) and worse performance in condition 2 of the SOT (r = -0.48, P = 0.004). Among the ImPACT composite scores, lower memory scores were correlated with impaired balance performance measures (r = 0.37-0.59, P 0.012). Lower visual memory was also correlated with worse ABC scores.Conclusions:The significant relationships reported between the cognitive performance scores and balance measures may reflect that similar levels of functioning exist across domains in individuals with protracted recovery who receive vestibular physical therapy.	[Alsalaheen, Bara A.] Univ Michigan Flint, Dept Phys Therapy, Flint, MI 48502 USA; [Whitney, Susan L.; Furman, Joseph M.; Sparto, Patrick J.] Univ Pittsburgh, Dept Phys Therapy, Pittsburgh, PA USA; [Whitney, Susan L.; Furman, Joseph M.; Sparto, Patrick J.] Univ Pittsburgh, Dept Otolaryngol, Pittsburgh, PA 15260 USA; [Whitney, Susan L.] King Saud Univ, Dept Rehabil Sci, Riyadh, Saudi Arabia; [Marchetti, Gregory F.] Duquesne Univ, Dept Phys Therapy, Pittsburgh, PA 15219 USA; [Kontos, Anthony P.; Collins, Michael W.] Univ Pittsburgh, Dept Orthopaed Surg, Pittsburgh, PA USA	Alsalaheen, BA (corresponding author), Univ Michigan Flint, Dept Phys Therapy, 2157 William S White Bldg,303 E Kearsley St, Flint, MI 48502 USA.	alsalahe@umflint.edu	Meijer, Anna/K-5118-2016	Kontos, Anthony/0000-0002-3749-4310; Sparto, Patrick/0000-0002-8351-3789	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30 AG024827] Funding Source: Medline; NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [P30 DC005205, K01 DC012332] Funding Source: Medline; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG024827] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [P30DC005205, K01DC012332] Funding Source: NIH RePORTER		Alsalaheen BA, 2013, PHYSIOTHER RES INT, V18, P100, DOI 10.1002/pri.1532; Alsalaheen BA, 2014, PEDIATR PHYS THER, V26, P191, DOI 10.1097/PEP.0000000000000037; Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Barlow M, 2011, INT J SPORTS PHYS TH, V6, P150; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Berthoz A, 1996, COGNITIVE BRAIN RES, V3, P101, DOI 10.1016/0926-6410(95)00035-6; Blinman TA, 2009, J PEDIATR SURG, V44, P1223, DOI 10.1016/j.jpedsurg.2009.02.027; Broglio SP, 2008, CLIN J SPORT MED, V18, P148, DOI 10.1097/JSM.0b013e318164f42a; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Broglio SP, 2009, CLIN J SPORT MED, V19, P377, DOI 10.1097/JSM.0b013e3181b625fe; Brown KE, 2006, ARCH PHYS MED REHAB, V87, P76, DOI 10.1016/j.apmr.2005.08.003; Cohen JS, 2009, CURR OPIN PEDIATR, V21, P288, DOI 10.1097/MOP.0b013e32832b1195; Collie A, 2003, BRIT J SPORT MED, V37, P556, DOI 10.1136/bjsm.37.6.556; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Dischinger PC, 2009, J TRAUMA, V66, P289, DOI 10.1097/TA.0b013e3181961da2; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Faux S, 2008, PAIN MED, V9, P1001, DOI 10.1111/j.1526-4637.2007.00404.x; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Hanes DA, 2006, J VESTIBUL RES-EQUIL, V16, P75; Harris LR, 2000, EXP BRAIN RES, V135, P12, DOI 10.1007/s002210000504; ISRAEL I, 1993, EXP BRAIN RES, V96, P335; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2004, J INT NEUROPSYCH SOC, V10, P904, DOI 10.1017/S1355617704106139; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; JACOBSON GP, 1990, ARCH OTOLARYNGOL, V116, P424; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Kontos AP, 2012, AM J SPORT MED, V40, P2375, DOI 10.1177/0363546512455400; Lannsjo M, 2009, BRAIN INJURY, V23, P213, DOI 10.1080/02699050902748356; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Lew HL, 2006, AM J PHYS MED REHAB, V85, P619, DOI 10.1097/01.phm.0000223235.09931.c0; Lord SR, 2002, J GERONTOL A-BIOL, V57, pM539, DOI 10.1093/gerona/57.8.M539; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lovell Mark R, 2002, Curr Sports Med Rep, V1, P7; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Maguire EA, 2000, P NATL ACAD SCI USA, V97, P4398, DOI 10.1073/pnas.070039597; Marchetti GF, 2014, J NEUROL PHYS THER, V38, P119, DOI 10.1097/NPT.0000000000000015; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Maskell F, 2007, BRAIN INJURY, V21, P741, DOI 10.1080/02699050701472109; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; NAKAMURA T, 1995, BRAIN, V118, P1157, DOI 10.1093/brain/118.5.1157; Parker TM, 2007, BRIT J SPORT MED, V41, P868, DOI 10.1136/bjsm.2006.033761; PODSIADLO D, 1991, J AM GERIATR SOC, V39, P142, DOI 10.1111/j.1532-5415.1991.tb01616.x; POWELL LE, 1995, J GERONTOL A-BIOL, V50, pM28, DOI 10.1093/gerona/50A.1.M28; Reddy CC, 2009, CURR SPORT MED REP, V8, P10, DOI 10.1249/JSR.0b013e31819539ca; Reddy CC, 2008, PHYS MED REH CLIN N, V19, P247, DOI 10.1016/j.pmr.2007.12.002; Register-Mihalik JK, 2013, J ATHL TRAINING, V48, P645, DOI 10.4085/1062-6050-48.3.20; Risey J, 1990, J Vestib Res, V1, P31; Salbach NM, 2006, ARCH PHYS MED REHAB, V87, P1597, DOI 10.1016/j.apmr.2006.08.336; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2006, APPL NEUROPSYCHOL, V13, P151, DOI 10.1207/s15324826an1303_2; Schautzer F, 2003, ANN NY ACAD SCI, V1004, P316, DOI 10.1196/annals.1303.029; Smith PF, 2005, J VESTIBUL RES-EQUIL, V15, P1; Steffen T, 2008, PHYS THER, V88, P733, DOI 10.2522/ptj.20070214; Vidal PG, 2012, PEDIATR ANN, V41, pE186, DOI 10.3928/00904481-20120827-10; Vitte E, 1996, EXP BRAIN RES, V112, P523; Whitney S. L., 2007, VESTIBULAR REHABILIT, P272; Wrisley DM, 2003, ARCH PHYS MED REHAB, V84, P1528, DOI 10.1016/S0003-9993(03)00274-0	67	35	35	0	26	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	JAN	2016	26	1					46	52		10.1097/JSM.0000000000000185			7	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	DA2JB	WOS:000367620000007	25706663	Green Accepted			2021-06-18	
J	Dretsch, MN; Williams, K; Emmerich, T; Crynen, G; Ait-Ghezala, G; Chaytow, H; Mathura, V; Crawford, FC; Iverson, GL				Dretsch, Michael N.; Williams, Kathy; Emmerich, Tanja; Crynen, Gogce; Ait-Ghezala, Ghania; Chaytow, Helena; Mathura, Venkat; Crawford, Fiona C.; Iverson, Grant L.			Brain-derived neurotropic factor polymorphisms, traumatic stress, mild traumatic brain injury, and combat exposure contribute to postdeployment traumatic stress	BRAIN AND BEHAVIOR			English	Article						BDNF; deployment; genetics; military; posttraumatic stress disorder; psychological health; traumatic brain injury	DOPAMINE-RECEPTOR GENE; DRD2 GENE; COGNITIVE RESERVE; APOE GENOTYPE; ALCOHOL-USE; DISORDER; PTSD; ASSOCIATION; BDNF; DEPLOYMENT	Background In addition to experiencing traumatic events while deployed in a combat environment, there are other factors that contribute to the development of posttraumatic stress disorder (PTSD) in military service members. This study explored the contribution of genetics, childhood environment, prior trauma, psychological, cognitive, and deployment factors to the development of traumatic stress following deployment. Methods Both pre- and postdeployment data on 231 of 458 soldiers were analyzed. Postdeployment assessments occurred within 30days from returning stateside and included a battery of psychological health, medical history, and demographic questionnaires; neurocognitive tests; and blood serum for the D2 dopamine receptor (DRD2), apolipoprotein E (APOE), and brain-derived neurotropic factor (BDNF) genes. Results Soldiers who screened positive for traumatic stress at postdeployment had significantly higher scores in depression (d=1.91), anxiety (d=1.61), poor sleep quality (d=0.92), postconcussion symptoms (d=2.21), alcohol use (d=0.63), traumatic life events (d=0.42), and combat exposure (d=0.91). BDNF Val66 Met genotype was significantly associated with risk for sustaining a mild traumatic brain injury (mTBI) and screening positive for traumatic stress. Predeployment traumatic stress, greater combat exposure and sustaining an mTBI while deployed, and the BDNF Met/Met genotype accounted for 22% of the variance of postdeployment PTSD scores (R-2=0.22, P<0.001). However, predeployment traumatic stress, alone, accounted for 17% of the postdeployment PTSD scores. Conclusion These findings suggest predeployment traumatic stress, genetic, and environmental factors have unique contributions to the development of combat-related traumatic stress in military service members.	[Dretsch, Michael N.] US Army, Aeromed Res Lab, 6901 Farrel Rd, Ft Rucker, AL USA; [Dretsch, Michael N.; Williams, Kathy] Walter Reed Natl Mil Med Ctr, Natl Intrepid Ctr Excellence, 4860 South Palmer Rd, Bethesda, MD 20889 USA; [Dretsch, Michael N.] Headquarters Army Training & Doctrine Command HQ, Human Dimens Div, 950 Jefferson Ave, Ft Eustis, VA 23604 USA; [Emmerich, Tanja; Crynen, Gogce; Ait-Ghezala, Ghania; Chaytow, Helena; Mathura, Venkat; Crawford, Fiona C.] Roskamp Inst, 2040 Whitfield Ave, Sarasota, FL 34243 USA; [Iverson, Grant L.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA; [Iverson, Grant L.] Spaulding Rehabil Hosp, Boston, MA USA; [Iverson, Grant L.] Red Sox Fdn, Boston, MA USA; [Iverson, Grant L.] Massachusetts Gen Hosp, Home Base Program, Boston, MA 02114 USA; [Iverson, Grant L.] Def & Vet Brain Injury Ctr, Bethesda, MD USA; [Iverson, Grant L.] Harvard Univ, Sch Med, Ctr Hlth & Rehabil, Dept Phys Med & Rehabil, 79-96 Thirteenth St, Charlestown, MA 02129 USA	Dretsch, MN (corresponding author), HQ TRADOC, Human Dimens Div, 950 Jefferson Ave, Ft Eustis, VA USA.	michael.n.dretsch.mil@mail.mil		Crynen, Gogce/0000-0001-6066-9900; Ait-Ghezala, Ghania/0000-0002-9836-8617; Chaytow, Helena/0000-0003-2257-7620; Iverson, Grant/0000-0001-7348-9570; Emmerich, Tanja/0000-0001-5064-7150	US Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC)	Funding for this study was provided by the US Army Medical Research and Materiel Command.	Alschuler KN, 2014, PSYCHOL SERV, V11, P273, DOI 10.1037/a0036201; Andero R, 2012, GENES BRAIN BEHAV, V11, P503, DOI 10.1111/j.1601-183X.2012.00801.x; Andersen SB, 2014, J CLIN PSYCHIAT, V75, P1001, DOI 10.4088/JCP.13m08914; Angelucci F, 2014, BRAIN COGNITION, V84, P118, DOI 10.1016/j.bandc.2013.11.012; [Anonymous], 2012, VETERANS HLTH ADM TR; Bliese PD, 2008, J CONSULT CLIN PSYCH, V76, P272, DOI 10.1037/0022-006X.76.2.272; Breslau N, 2006, ARCH GEN PSYCHIAT, V63, P1238, DOI 10.1001/archpsyc.63.11.1238; Burke J R, 1991, Int J Neurol, V25-26, P41; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Carlson JM, 2014, CEREB CORTEX, V24, P2249, DOI 10.1093/cercor/bht089; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Comings DE, 1996, BIOL PSYCHIAT, V40, P368, DOI 10.1016/0006-3223(95)00519-6; Cooper DB, 2011, BRAIN INJURY, V25, P1, DOI 10.3109/02699052.2010.531692; D'Onofrio G, 2011, INT J GERIATR PSYCH, V26, P1062, DOI 10.1002/gps.2644; Delahanty DL, 2006, ANN NY ACAD SCI, V1071, P27, DOI 10.1196/annals.1364.003; Esiri MM, 2012, ALZHEIMERS RES THER, V4, DOI 10.1186/alzrt105; Gerlock AA, 2014, J MARITAL FAM THER, V40, P344, DOI 10.1111/jmft.12017; Gray MJ, 2004, ASSESSMENT, V11, P330, DOI 10.1177/1073191104269954; Gualtieri CT, 2006, ARCH CLIN NEUROPSYCH, V21, P623, DOI 10.1016/j.acn.2006.05.007; Guyker WM, 2013, MIL MED, V178, P377, DOI 10.7205/MILMED-D-12-00223; Hariri AR, 2003, J NEUROSCI, V23, P6690, DOI 10.1523/jneurosci.23-17-06690.2003; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Jonsson EG, 1999, MOL PSYCHIATR, V4, P290, DOI 10.1038/sj.mp.4000532; Kim TY, 2013, DEPRESS ANXIETY, V30, P1194, DOI 10.1002/da.22138; King LA, 2006, MIL PSYCHOL, V18, P89, DOI 10.1207/s15327876mp1802_1; Lawford BR, 2006, EUR PSYCHIAT, V21, P180, DOI 10.1016/j.eurpsy.2005.01.006; Lyons MJ, 2013, AM J MED GENET B, V162, P762, DOI 10.1002/ajmg.b.32154; Mahan AL, 2012, TRENDS NEUROSCI, V35, P24, DOI 10.1016/j.tins.2011.06.007; Valente NLM, 2011, J MOL NEUROSCI, V44, P59, DOI 10.1007/s12031-011-9513-7; Martinowich K, 2008, NEUROPSYCHOPHARMACOL, V33, P73, DOI 10.1038/sj.npp.1301571; Marx BP, 2009, J INT NEUROPSYCH SOC, V15, P840, DOI 10.1017/S1355617709990488; Meerlo P, 2008, SLEEP MED REV, V12, P197, DOI 10.1016/j.smrv.2007.07.007; Montag C, 2008, NEUROIMAGE, V42, P1554, DOI 10.1016/j.neuroimage.2008.06.008; Montag C, 2010, PSYCHIAT RES, V179, P86, DOI 10.1016/j.psychres.2008.08.005; Morris SB, 2002, PSYCHOL METHODS, V7, P105, DOI 10.1037//1082-989X.7.1.105; Noble EP, 2003, AM J MED GENET B, V116B, P103, DOI 10.1002/ajmg.b.10005; NOBLE EP, 1991, ARCH GEN PSYCHIAT, V48, P648; O'Dwyer L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048895; Panza F, 2012, AGEING RES REV, V11, P87, DOI 10.1016/j.arr.2011.06.005; Pivac N, 2012, WORLD J BIOL PSYCHIA, V13, P306, DOI 10.3109/15622975.2011.582883; Pohjalainen T, 1998, MOL PSYCHIATR, V3, P256, DOI 10.1038/sj.mp.4000350; Raber J, 2000, J NEUROSCI, V20, P2064; Ritchie T, 2003, NEUROCHEM RES, V28, P73, DOI 10.1023/A:1021648128758; Rojas SM, 2014, J ANXIETY DISORD, V28, P318, DOI 10.1016/j.janxdis.2014.02.004; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Schwab KA, 2006, NEUROLOGY, V66, pA235; Seripa D, 2011, REJUV RES, V14, P491, DOI 10.1089/rej.2011.1169; Soldan A, 2015, HUM BRAIN MAPP, V36, P2826, DOI 10.1002/hbm.22810; Spinhoven P, 2014, CHILD ABUSE NEGLECT, V38, P1320, DOI 10.1016/j.chiabu.2014.01.017; Stander VA, 2014, CLIN PSYCHOL REV, V34, P87, DOI 10.1016/j.cpr.2013.12.002; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Thompson J, 1997, PHARMACOGENETICS, V7, P479, DOI 10.1097/00008571-199712000-00006; Uher R, 2014, FRONT PSYCHIATRY, V5, DOI 10.3389/fpsyt.2014.00048; Vandrey R, 2014, INT REV PSYCHIATR, V26, P237, DOI 10.3109/09540261.2014.901300; Vasterling JJ, 2010, J TRAUMA STRESS, V23, P41, DOI 10.1002/jts.20487; Voisey J, 2009, DEPRESS ANXIETY, V26, P28, DOI 10.1002/da.20517; Vranceanu Ana-Maria, 2014, J Bone Joint Surg Am, V96, pe20, DOI 10.2106/JBJS.L.00479; Weathers F. W., 1991, PCL M FOR DSM 4; Wong AHC, 2000, EUR J PHARMACOL, V410, P183; Youngner CG, 2012, WEST J EMERG MED, V13, P220, DOI 10.5811/westjem.2012.3.11777; Yurgil KA, 2014, JAMA PSYCHIAT, V71, P149, DOI 10.1001/jamapsychiatry.2013.3080; Zerach G, 2013, ISR J PSYCHIATR REL, V50, P91; Zhang HP, 2006, AM J MED GENET B, V141B, P387, DOI 10.1002/ajmg.b.30332; ZUNG WWK, 1971, PSYCHOSOMATICS, V12, P371; ZUNG WWK, 1965, ARCH GEN PSYCHIAT, V12, P63, DOI 10.1001/archpsyc.1965.01720310065008	65	35	35	0	17	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN, NJ 07030 USA	2162-3279			BRAIN BEHAV	Brain Behav.	JAN	2016	6	1							e00392	10.1002/brb3.392			12	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	DB8OV	WOS:000368777200006	27110438	DOAJ Gold, Green Published			2021-06-18	
J	Silva, S; de Pasquale, F; Vuillaume, C; Riu, B; Loubinoux, I; Geeraerts, T; Seguin, T; Bounes, V; Fourcade, O; Demonet, JF; Peran, P				Silva, Stein; de Pasquale, Francesco; Vuillaume, Corine; Riu, Beatrice; Loubinoux, Isabelle; Geeraerts, Thomas; Seguin, Thierry; Bounes, Vincent; Fourcade, Olivier; Demonet, Jean-Francois; Peran, Patrice			Disruption of posteromedial large-scale neural communication predicts recovery from coma	NEUROLOGY			English	Article							DEFAULT MODE NETWORK; POSTERIOR PARIETAL CORTEX; FUNCTIONAL CONNECTIVITY; RHESUS-MONKEY; VEGETATIVE STATE; BRAIN-FUNCTION; CONSCIOUSNESS; CINGULATE; PARCELLATION; ARCHITECTURE	Objective: We hypothesize that the major consciousness deficit observed in coma is due to the breakdown of long-range neuronal communication supported by precuneus and posterior cingulate cortex (PCC), and that prognosis depends on a specific connectivity pattern in these networks. Methods: We compared 27 prospectively recruited comatose patients who had severe brain injury (Glasgow Coma Scale score <8; 14 traumatic and 13 anoxic cases) with 14 age-matched healthy participants. Standardized clinical assessment and fMRI were performed on average 4 +/- 2 days after withdrawal of sedation. Analysis of resting-state fMRI connectivity involved a hypothesis-driven, region of interest-based strategy. We assessed patient outcome after 3 months using the Coma Recovery Scale-Revised (CRS-R). Results: Patients who were comatose showed a significant disruption of functional connectivity of brain areas spontaneously synchronized with PCC, globally notwithstanding etiology. The functional connectivity strength between PCC and medial prefrontal cortex (mPFC) was significantly different between comatose patients who went on to recover and those who eventually scored an unfavorable outcome 3 months after brain injury (Kruskal-Wallis test, p < 0.001; linear regression between CRS-R and PCC-mPFC activity coupling at rest, Spearman r = 0.93, p < 0.003). Conclusion: In both etiology groups (traumatic and anoxic), changes in the connectivity of PCC-centered, spontaneously synchronized, large-scale networks account for the loss of external and internal self-centered awareness observed during coma. Sparing of functional connectivity between PCC and mPFC may predict patient outcome, and further studies are needed to substantiate this potential prognosis biomarker.	[Silva, Stein; Riu, Beatrice] Univ Teaching Hosp Purpan, Crit Care Unit, Pl Dr Baylac, F-31059 Toulouse 9, France; [Silva, Stein; Vuillaume, Corine; Riu, Beatrice; Geeraerts, Thomas; Seguin, Thierry; Fourcade, Olivier] Univ Teaching Hosp Purpan, Crit Care & Anaesthesiol Dept, F-31059 Toulouse 9, France; [Bounes, Vincent] Univ Teaching Hosp Purpan, SAMU 31, F-31059 Toulouse 9, France; [Silva, Stein; Vuillaume, Corine; Loubinoux, Isabelle; Peran, Patrice] CHU Purpan, INSERM U825, F-31059 Toulouse 9, France; [de Pasquale, Francesco] Santa Lucia Fdn, Dept Radiol, Rome, Italy; [de Pasquale, Francesco] Univ G DAnnunzio, ITAB, Dept Neurosci Imaging & Clin Sci, Chieti, Italy; [Demonet, Jean-Francois] Dept Clin Neurosci CHUV, Leenaards Memory Ctr, Lausanne, Switzerland; [Demonet, Jean-Francois] Univ Lausanne, CH-1015 Lausanne, Switzerland	Silva, S (corresponding author), Univ Teaching Hosp Purpan, Crit Care Unit, Pl Dr Baylac, F-31059 Toulouse 9, France.	silva.s@chu-toulouse.fr	de Pasquale, Francesco/AAB-3440-2019; Peran, Patrice/N-7561-2015; Loubinoux, Isabelle/E-5537-2016	Peran, Patrice/0000-0001-7200-0139; Loubinoux, Isabelle/0000-0003-4461-0890; Demonet, Jean-Francois/0000-0003-0100-6175; DE PASQUALE, Francesco/0000-0003-1109-3305	Association des Traumatises du Crane et de la Face; Institut des Sciences du Cerveau de Toulouse; Institut National de la Sante et de la Recherche MedicaleInstitut National de la Sante et de la Recherche Medicale (Inserm)	Funding was provided by the Association des Traumatises du Crane et de la Face, Institut des Sciences du Cerveau de Toulouse, and Institut National de la Sante et de la Recherche Medicale. The funding sources had no role in the study design, data collection, data analysis, data interpretation, or writing of this report.	Amico E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100012; Andrews-Hanna JR, 2010, NEURON, V65, P550, DOI 10.1016/j.neuron.2010.02.005; Behzadi Y, 2007, NEUROIMAGE, V37, P90, DOI 10.1016/j.neuroimage.2007.04.042; Boly M, 2012, J NEUROSCI, V32, P7082, DOI 10.1523/JNEUROSCI.3769-11.2012; Boly M, 2009, PROG BRAIN RES, V177, P383, DOI 10.1016/S0079-6123(09)17727-0; Calhoun VD, 2001, HUM BRAIN MAPP, V14, P140, DOI 10.1002/hbm.1048; CAVADA C, 1989, J COMP NEUROL, V287, P393, DOI 10.1002/cne.902870402; Cavanna AE, 2006, BRAIN, V129, P564, DOI 10.1093/brain/awl004; Dehaene S, 2011, NEURON, V70, P200, DOI 10.1016/j.neuron.2011.03.018; Dixon ML, 2014, NEUROPSYCHOLOGIA, V62, P321, DOI 10.1016/j.neuropsychologia.2014.05.024; FLETCHER PC, 1995, NEUROIMAGE, V2, P195, DOI 10.1006/nimg.1995.1025; Garrity AG, 2007, AM J PSYCHIAT, V164, P450, DOI 10.1176/appi.ajp.164.3.450; Greicius MD, 2009, CEREB CORTEX, V19, P72, DOI 10.1093/cercor/bhn059; Gusnard DA, 2001, P NATL ACAD SCI USA, V98, P4259, DOI 10.1073/pnas.071043098; Hagmann P, 2008, PLOS BIOL, V6, P1479, DOI 10.1371/journal.pbio.0060159; Hellyer PJ, 2014, J NEUROSCI, V34, P451, DOI 10.1523/JNEUROSCI.1853-13.2014; Horovitz SG, 2009, P NATL ACAD SCI USA, V106, P11376, DOI 10.1073/pnas.0901435106; Laureys S, 1999, NEUROIMAGE, V9, P377, DOI 10.1006/nimg.1998.0414; Leech R, 2014, BRAIN, V137, P12, DOI 10.1093/brain/awt162; Luyt CE, 2012, ANESTHESIOLOGY, V117, P1311, DOI 10.1097/ALN.0b013e318275148c; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; Norton L, 2012, NEUROLOGY, V78, P175, DOI 10.1212/WNL.0b013e31823fcd61; Palacios EM, 2013, J NEUROTRAUM, V30, P1991, DOI 10.1089/neu.2012.2836; PANDYA DN, 1982, J COMP NEUROL, V204, P196, DOI 10.1002/cne.902040208; PETRIDES M, 1984, J COMP NEUROL, V228, P105, DOI 10.1002/cne.902280110; Plum F, 1982, DIAGNOSIS STUPOR COM; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Schiff ND, 2010, TRENDS NEUROSCI, V33, P1, DOI 10.1016/j.tins.2009.11.002; Silva S, 2010, NEUROLOGY, V74, P313, DOI 10.1212/WNL.0b013e3181cbcd96; Soddu A, 2011, FUNCT NEUROL, V26, P37; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Vanhaudenhuyse A, 2011, J COGNITIVE NEUROSCI, V23, P570, DOI 10.1162/jocn.2010.21488; Vanhaudenhuyse A, 2010, BRAIN, V133, P161, DOI 10.1093/brain/awp313; Vincent JL, 2007, NATURE, V447, P83, DOI 10.1038/nature05758; Vogt BA, 2005, PROG BRAIN RES, V150, P205, DOI 10.1016/S0079-6123(05)50015-3; Vogt BA, 2005, J COMP NEUROL, V485, P218, DOI 10.1002/cne.20512; Whitfield-Gabrieli S, 2012, BRAIN CONNECT, V2, P125, DOI 10.1089/brain.2012.0073; Wijdicks EFM, 2005, ANN NEUROL, V58, P585, DOI 10.1002/ana.20611	38	35	37	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	DEC 8	2015	85	23					2036	2044		10.1212/WNL.0000000000002196			9	Clinical Neurology	Neurosciences & Neurology	DF8WV	WOS:000371642200011	26561296	Other Gold, Green Published			2021-06-18	
J	Guo, N; Xu, CS; Guo, W; Du, YP; Feng, JC				Guo, Ning; Xu, Changsheng; Guo, Wei; Du, Yongpeng; Feng, Jicai			Characterization of spatter in underwater wet welding by X-ray transmission method	MATERIALS & DESIGN			English	Article						Welding spatter; Underwater wet welding; X-ray imaging system; FCAW	METAL TRANSFER; FUME FORMATION	The spatter forming mechanism of underwater flux-cored wire wet welding is characterized by using a self-developed X-ray transmission system. Three representative spatter modes, droplet repelled spatter, explosive spatter and molten pool shock spatter, forming during underwater wet welding have been observed. The generation of droplet repelled spatter is due to the excessive repulsive forces for metal transfer. The diameter of this type of spatter is largest relatively, which can reach about 4.5 mm. In addition, explosive spatter, with size about 2.5 mm, is changed from the droplet with high horizontal speed caused by a slight explosion occurs at the touching location of the droplet and molten surface. Moreover, the dimension of molten pool shock spatter is smallest potentially among the spatter types during underwater wet welding, and it is only about 0.8 mm. It is generated from ridgy liquid column on [he molten pool surface because of the relatively severe concussion of the molten pool. The size, macroscopic pattern as well as chemical composition of these three types of spatters are different. (C) 2015 Elsevier Ltd. All rights reserved	[Guo, Ning; Feng, Jicai] Harbin Inst Technol, State Key Lab Adv Welding & Joining, Harbin 150000, Peoples R China; [Guo, Ning; Xu, Changsheng; Guo, Wei; Du, Yongpeng; Feng, Jicai] Harbin Inst Technol Weihai, Shandong Prov Key Lab Special Welding Technol, Weihai 264200, Peoples R China	Guo, N (corresponding author), 2Wenhuaxi Rd, Weihai 264209, Peoples R China.	gn21c@126.com			State Key Development Program for Basic Research of ChinaState Key Development Program for Basic Research of China [2013CB035502]; State Key Lab of Advanced Welding & Joining, Harbin Institute of TechnologyHarbin Institute of Technology [AWJ-M13-12]; Shandong Provincial Science and Technology Development Project [2014GGX103033]; China Postdoctoral Science FoundationChina Postdoctoral Science Foundation [2014 M561343]	We are grateful for the financial support to this study from the State Key Development Program for Basic Research of China (2013CB035502), the State Key Lab of Advanced Welding & Joining, Harbin Institute of Technology (AWJ-M13-12), Shandong Provincial Science and Technology Development Project (2014GGX103033), and China Postdoctoral Science Foundation (2014 M561343).	Baune E, 2001, SCI TECHNOL WELD JOI, V6, P139, DOI 10.1179/136217101101538677; Chen JH, 1996, WELD J, V75, pS311; Ersoy U, 2008, WELD J, V87, P51; Farson D, 1998, WELD J, V77, p315S; Guo N, 2015, MATER LETT, V144, P90, DOI 10.1016/j.matlet.2015.01.033; Haidar J, 1996, J PHYS D APPL PHYS, V29, P2951, DOI 10.1088/0022-3727/29/12/003; Han GM, 2003, MATER DESIGN, V24, P699, DOI 10.1016/S0261-3069(03)00092-X; Heider A, 2013, PHYSCS PROC, V41, P112, DOI 10.1016/j.phpro.2013.03.058; Jenkins NT, 2005, SCI TECHNOL WELD JOI, V10, P537, DOI 10.1179/174329305X48310; Kang MJ, 2003, WELD J, V82, p238S; Labanowski Jerzy, 2011, Welding International, V25, P933, DOI 10.1080/09507116.2010.540847; Li K, 2014, INT J ADV MANUF TECH, V74, P693, DOI 10.1007/s00170-014-5990-5; Liao MT, 1999, INT J ADV MANUF TECH, V15, P49, DOI 10.1007/s001700050038; Liu SY, 2013, INT J HEAT MASS TRAN, V62, P604, DOI 10.1016/j.ijheatmasstransfer.2013.03.051; Molleda F, 2007, MATER CHARACT, V58, P936, DOI 10.1016/j.matchar.2006.09.011; Pires I, 2007, MATER DESIGN, V28, P1623, DOI 10.1016/j.matdes.2006.02.012; Rowe M, 2001, SCI TECHNOL WELD JOI, V6, P387, DOI 10.1179/stw.2001.6.6.387; Shijun Liao, 1999, Communications in Nonlinear Science & Numerical Simulation, V4, P104; Teran G, 2014, MAT SCI ENG A-STRUCT, V599, P105, DOI 10.1016/j.msea.2014.01.078; Wang Yan, 2013, Electric Welding Machine, V43, P96, DOI 10.7512/j.issn.1001-2303.2013.04.23	20	35	39	1	35	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-1275	1873-4197		MATER DESIGN	Mater. Des.	NOV 15	2015	85						156	161		10.1016/j.matdes.2015.06.152			6	Materials Science, Multidisciplinary	Materials Science	CV9CN	WOS:000364585000020					2021-06-18	
J	Jiang, Y; Li, GY; Qian, LX; Liang, S; Destrade, M; Cao, YP				Jiang, Yi; Li, Guoyang; Qian, Lin-Xue; Liang, Si; Destrade, Michel; Cao, Yanping			Measuring the linear and nonlinear elastic properties of brain tissue with shear waves and inverse analysis	BIOMECHANICS AND MODELING IN MECHANOBIOLOGY			English	Article						Supersonic shear wave imaging technique; Inverse method; Brain tissue; Elastic and hyperelastic properties	IN-VIVO; MECHANICAL-PROPERTIES; 4TH-ORDER CONSTANTS; SOFT SOLIDS; EX-VIVO; ELASTOGRAPHY; BEHAVIOR; DEFORMATION; MODULUS; MODEL	We use supersonic shear wave imaging (SSI) technique to measure not only the linear but also the nonlinear elastic properties of brain matter. Here, we tested six porcine brains ex vivo and measured the velocities of the plane shear waves induced by acoustic radiation force at different states of pre-deformation when the ultrasonic probe is pushed into the soft tissue. We relied on an inverse method based on the theory governing the propagation of small-amplitude acoustic waves in deformed solids to interpret the experimental data. We found that, depending on the subjects, the resulting initial shear modulus varies from 1.8 to 3.2 kPa, the stiffening parameter of the hyperelastic Demiray-Fung model from 0.13 to 0.73, and the third- and fourth-order constants of weakly nonlinear elasticity from 1.3 to 20.6 kPa and from 3.1 to 8.7 kPa, respectively. Paired test performed on the experimental results of the left and right lobes of the brain shows no significant difference. These values are in line with those reported in the literature on brain tissue, indicating that the SSI method, combined to the inverse analysis, is an efficient and powerful tool for the mechanical characterization of brain tissue, which is of great importance for computer simulation of traumatic brain injury and virtual neurosurgery.	[Jiang, Yi; Li, Guoyang; Cao, Yanping] Tsinghua Univ, Dept Engn Mech, AML, Inst Biomech & Med Engn, Beijing 100084, Peoples R China; [Qian, Lin-Xue; Liang, Si] Capital Med Univ, Beijing Friendship Hosp, Dept Ultrasound, Beijing 100050, Peoples R China; [Destrade, Michel] Natl Univ Ireland Univ Coll Galway, Sch Math Stat & Appl Math, Galway, Ireland	Cao, YP (corresponding author), Tsinghua Univ, Dept Engn Mech, AML, Inst Biomech & Med Engn, Beijing 100084, Peoples R China.	michel.destrade@nuigalway.ie; caoyanping@tsinghua.edu.cn	cao, yanping/E-3381-2010; Destrade, Michel/O-5825-2019; Li, Guo-Yang/Q-5391-2016	Destrade, Michel/0000-0002-6266-1221; Li, Guo-Yang/0000-0002-5939-9293	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [11172155]; Tsinghua University [2012Z02103]; 973 Program of MOSTNational Basic Research Program of China [2010CB631005]	Supports from the National Natural Science Foundation of China (Grant No. 11172155), Tsinghua University (2012Z02103) and 973 Program of MOST (2010CB631005) are gratefully acknowledged. We also thank the referees for helping us improve greatly previous versions of the article.	Atay SM, 2008, J BIOMECH ENG-T ASME, V130, DOI 10.1115/1.2899575; Bercoff J, 2004, IEEE T ULTRASON FERR, V51, P1523, DOI 10.1109/TUFFC.2004.1367494; Bercoff J, 2004, IEEE T ULTRASON FERR, V51, P396, DOI 10.1109/TUFFC.2004.1295425; Bercoff J, 2004, APPL PHYS LETT, V84, P2202, DOI 10.1063/1.1667613; Brillouin L., 1946, TENSEURS MECANIQUE E; Chatelin S, 2010, BIORHEOLOGY, V47, P255, DOI 10.3233/BIR-2010-0576; DEMIRAY H, 1972, J BIOMECH, V5, P309, DOI 10.1016/0021-9290(72)90047-4; Destrade M, 2010, J APPL MECH-T ASME, V77, DOI 10.1115/1.4001282; Destrade M, 2010, J ACOUST SOC AM, V128, P3334, DOI 10.1121/1.3505102; Destrade M, 2010, J ACOUST SOC AM, V127, P2759, DOI 10.1121/1.3372624; Destrade M, 2010, J ACOUST SOC AM, V127, P2103, DOI 10.1121/1.3337232; Donnelly BR, 1997, J BIOMECH ENG-T ASME, V119, P423, DOI 10.1115/1.2798289; Gefen A, 2003, J NEUROTRAUM, V20, P1163, DOI 10.1089/089771503770802853; Gefen A, 2004, J BIOMECH, V37, P1339, DOI 10.1016/j.jbiomech.2003.12.032; Gennisson JL, 2007, J ACOUST SOC AM, V122, P3211, DOI 10.1121/1.2793605; Green MA, 2008, NMR BIOMED, V21, P755, DOI 10.1002/nbm.1254; Hamilton MF, 2004, J ACOUST SOC AM, V116, P41, DOI 10.1121/1.1736652; Hrapko M, 2006, BIORHEOLOGY, V43, P623; Jiang Y, 2015, MED IMAGE ANAL, V20, P97, DOI 10.1016/j.media.2014.10.010; Karimi A, 2013, P I MECH ENG H, V227, P609, DOI 10.1177/0954411913476779; Kaster T, 2011, J BIOMECH, V44, P1158, DOI 10.1016/j.jbiomech.2011.01.019; Klatt D, 2007, PHYS MED BIOL, V52, P7281, DOI 10.1088/0031-9155/52/24/006; Kleiven Svein, 2002, Stapp Car Crash J, V46, P123; Kruse SA, 2008, NEUROIMAGE, V39, P231, DOI 10.1016/j.neuroimage.2007.08.030; Latorre-Ossa H, 2012, IEEE T ULTRASON FERR, V59, P833, DOI 10.1109/TUFFC.2012.2262; Mace E, 2011, IEEE T MED IMAGING, V30, P550, DOI 10.1109/TMI.2010.2079940; Miga MI, 2000, IEEE T BIO-MED ENG, V47, P266, DOI 10.1109/10.821778; Miller K, 1999, J BIOMECH, V32, P531, DOI 10.1016/S0021-9290(99)00010-X; Miller K, 1997, J BIOMECH, V30, P1115, DOI 10.1016/S0021-9290(97)00092-4; Miller K, 2002, J BIOMECH, V35, P483, DOI 10.1016/S0021-9290(01)00234-2; Miller K, 2000, J BIOMECH, V33, P1369, DOI 10.1016/S0021-9290(00)00120-2; Nicolle S, 2005, BIORHEOLOGY, V42, P209; ODONNELL M, 1994, IEEE T ULTRASON FERR, V41, P314, DOI 10.1109/58.285465; Ogden RW, 2007, CISM COURSES LECT, P1; Pervin F, 2009, J BIOMECH, V42, P731, DOI 10.1016/j.jbiomech.2009.01.023; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; Prevost TP, 2011, ACTA BIOMATER, V7, P4090, DOI 10.1016/j.actbio.2011.06.032; Rashid B, 2013, J MECH BEHAV BIOMED, V28, P71, DOI 10.1016/j.jmbbm.2013.07.017; Rashid B, 2013, J BIOMECH, V46, P1276, DOI 10.1016/j.jbiomech.2013.02.014; Renier M, 2008, APPL PHYS LETT, V93, DOI 10.1063/1.2979875; Roberts DW, 1999, NEUROSURGERY, V45, P1199, DOI 10.1097/00006123-199911000-00037; Sack I, 2009, NEUROIMAGE, V46, P652, DOI 10.1016/j.neuroimage.2009.02.040; Saraf H, 2007, J BIOMECH, V40, P1960, DOI 10.1016/j.jbiomech.2006.09.021; Streitberger KJ, 2011, NMR BIOMED, V24, P385, DOI 10.1002/nbm.1602; Zhang L, 2001, Stapp Car Crash J, V45, P369; Zhang MG, 2014, J MECH PHYS SOLIDS, V68, P179, DOI 10.1016/j.jmps.2014.03.012; Zhang MG, 2014, BIOMECH MODEL MECHAN, V13, P1, DOI 10.1007/s10237-013-0481-4	47	35	38	2	53	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1617-7959	1617-7940		BIOMECH MODEL MECHAN	Biomech. Model. Mechanobiol.	OCT	2015	14	5					1119	1128		10.1007/s10237-015-0658-0			10	Biophysics; Engineering, Biomedical	Biophysics; Engineering	CQ8MT	WOS:000360862600013	25697960				2021-06-18	
J	Ventura, RE; Balcer, LJ; Galetta, SL				Ventura, Rachel E.; Balcer, Laura J.; Galetta, Steven L.			The Concussion Toolbox: The Role of Vision in the Assessment of Concussion	SEMINARS IN NEUROLOGY			English	Article						concussion; vision; testing; head impact; neuro-ophthalmology	TRAUMATIC BRAIN-INJURY; ERROR SCORING SYSTEM; MAGNETIC-RESONANCE-SPECTROSCOPY; SPORTS-RELATED CONCUSSION; TEST-RETEST RELIABILITY; VISUAL SCREENING TOOL; HIGH-SCHOOL; STANDARDIZED ASSESSMENT; EYE-MOVEMENTS; OCULOMOTOR DEFICITS	Concussion may lead to subtle changes in brain function, and tests involving the visual system probe higher cortical functioning and increase our sensitivity in detecting these changes. Concussions are acutely and sometimes more persistently associated with abnormalities in balance, cognition, and vision. The visual system involves roughly half of the brain's circuits, including many regions susceptible to head impacts. After a concussion, the neuro-ophthalmologic exam commonly detects abnormalities in convergence, accommodation, the vestibulo-ocular reflex, ocular muscle balance, saccades, and pursuit. The King-Devick (K-D) test is a visual performance measure that may increase the sensitivity of detecting concussions on the sideline when used in combination with tests of cognition and balance that are part of the Sports Concussion Assessment Tool (3rd ed.; SCAT3). Portable eye movement trackers and pupillometry may in the future improve our neuro-ophthalmic assessment after concussions. Combining visual tasks with neuroimaging and neurophysiology has allowed subtle changes to be detected, may refine our ability to make appropriate return-to-play decisions, and could potentially determine susceptibility to long-term sequelae of concussion.	[Ventura, Rachel E.; Balcer, Laura J.; Galetta, Steven L.] NYU, Sch Med, Dept Neurol, 240 East 38th St,20th Floor, New York, NY 10016 USA	Galetta, SL (corresponding author), NYU, Sch Med, Dept Neurol, 240 East 38th St,20th Floor, New York, NY 10016 USA.	Steven.Galetta@nyumc.org		Ventura, Rachel/0000-0001-8155-0546			Albaugh MD, 2015, J PEDIATR-US, V166, P394, DOI 10.1016/j.jpeds.2014.10.016; Barnes GR, 2008, BRAIN COGNITION, V68, P309, DOI 10.1016/j.bandc.2008.08.020; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Barr WB, 2012, BRAIN INJURY, V26, P58, DOI 10.3109/02699052.2011.608216; Boden BP, 2007, AM J SPORT MED, V35, P1075, DOI 10.1177/0363546507299239; Brahm KD, 2009, OPTOMETRY VISION SCI, V86, P817, DOI 10.1097/OPX.0b013e3181adff2d; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Capo-Aponte JE, 2013, J SPINE S, VS4, DOI [10.4172/2165-7939.S4-004., DOI 10.4172/2165-7939.S4-004]; Capo-Aponte JE, 2012, MIL MED, V177, P804, DOI 10.7205/MILMED-D-12-00061; Chang JO, 2014, CLIN J SPORT MED, V24, P256, DOI 10.1097/JSM.0000000000000016; Cifu DX, 2015, J HEAD TRAUMA REHAB, V30, P21, DOI 10.1097/HTR.0000000000000036; Davenport EM, 2014, J NEUROTRAUM, V31, P1617, DOI 10.1089/neu.2013.3233; De Beaumont L, 2013, J CLIN EXP NEUROPSYC, V35, P596, DOI 10.1080/13803395.2013.800023; Dean PJA, 2013, NEUROREPORT, V24, P677, DOI 10.1097/WNR.0b013e3283637aa4; Drew AS, 2007, NEUROSCI LETT, V417, P61, DOI 10.1016/j.neulet.2007.02.038; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; Finnoff JT, 2009, PM&R, V1, P50, DOI 10.1016/j.pmrj.2008.06.002; FitzGerald DB, 2011, INT J PSYCHOPHYSIOL, V82, P79, DOI 10.1016/j.ijpsycho.2011.02.011; Galetta KM, 2011, NEUROLOGY, V76, P1456, DOI 10.1212/WNL.0b013e31821184c9; Galetta KM, 2015, J NEUROOPHTHALMOL; Galetta KM, 2011, J NEUROL SCI, V309, P34, DOI 10.1016/j.jns.2011.07.039; Galetta MS, 2013, J NEUROL SCI, V328, P28, DOI 10.1016/j.jns.2013.02.008; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Gosselin N, 2012, NEUROSURG FOCUS, V33, P1, DOI DOI 10.3171/2012.10.F0CUS12253; Gosselin N, 2011, J NEUROTRAUM, V28, P329, DOI 10.1089/neu.2010.1493; Grossman EJ, 2013, AM J NEURORADIOL, V34, P951, DOI 10.3174/ajnr.A3358; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Harpham JA, 2014, ANN BIOMED ENG, V42, P1, DOI 10.1007/s10439-013-0881-8; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Heitger MH, 2004, BRAIN, V127, P575, DOI 10.1093/brain/awh066; Heitger MH, 2002, PROG BRAIN RES, V140, P433; Helmer KG, 2014, J NEUROSURG, V120, P864, DOI [10.3171/2013.12.JNS132093, 10.3171/2013.12.JNS132090]; Hutton SB, 2008, BRAIN COGNITION, V68, P327, DOI 10.1016/j.bandc.2008.08.021; Johnson B, 2015, BRAIN IMAGING BEHAV, V9, P564, DOI 10.1007/s11682-014-9316-x; Johnson B, 2012, J NEUROTRAUM, V29, P2297, DOI 10.1089/neu.2011.2294; Jones NS, 2014, CLIN J SPORT MED, V24, P284, DOI 10.1097/JSM.0000000000000031; King D, 2012, J NEUROL SCI, V320, P16, DOI 10.1016/j.jns.2012.05.049; King LA, 2014, ARCH PHYS MED REHAB, V95, P353, DOI 10.1016/j.apmr.2013.10.015; Kirov II, 2013, J NEUROTRAUM, V30, P1200, DOI 10.1089/neu.2012.2696; Kraus MF, 2007, COGN BEHAV NEUROL, V20, P170, DOI 10.1097/WNN.0b013e318142badb; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Liu GT, 2010, NEUROOPHTHALMOLOGY D, P551; Logothetis NK, 2008, NATURE, V453, P869, DOI 10.1038/nature06976; Luoto TM, 2014, J NEUROTRAUM, V31, P728, DOI 10.1089/neu.2013.3174; Maerlender A, 2010, CLIN NEUROPSYCHOL, V24, P1309, DOI 10.1080/13854046.2010.516072; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; Marinides Zoe, 2015, Neurol Clin Pract, V5, P25, DOI 10.1212/CPJ.0000000000000060; Maruta J, 2010, J HEAD TRAUMA REHAB, V25, P293, DOI 10.1097/HTR.0b013e3181e67936; Mayers LB, 2012, J CLIN EXP NEUROPSYC, V34, P235, DOI 10.1080/13803395.2011.630655; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2001, J ATHL TRAINING, V36, P274; McCrory Paul, 2013, Phys Ther Sport, V14, pe1, DOI 10.1016/j.ptsp.2013.03.002; McLeod TCV, 2006, J ATHL TRAINING, V41, P399; McLeod TCV, 2012, AM J SPORT MED, V40, P927, DOI 10.1177/0363546511431573; Meaney DF, 2011, CLIN SPORT MED, V30, P19, DOI 10.1016/j.csm.2010.08.009; Meier TB, 2015, J SCI MED SPORT, V18, P507, DOI 10.1016/j.jsams.2014.07.008; Mucha A, 2014, AM J SPORT MED, V42, P2479, DOI 10.1177/0363546514543775; Nakayama Y, 2014, AM J SPORT MED, V42, P2000, DOI 10.1177/0363546514535901; Pierrot-Deseilligny C, 2003, BRAIN, V126, P1460, DOI 10.1093/brain/awg148; Sasaki Takeshi, 2014, J Neurosurg, V120, P882, DOI 10.3171/2013.12.JNS132092; Schatz P, 2013, ARCH CLIN NEUROPSYCH, V28, P236, DOI 10.1093/arclin/act009; Schneiders AG, 2012, SCAND J MED SCI SPOR, V22, P85, DOI 10.1111/j.1600-0838.2010.01141.x; Sim A, 2008, J NEUROSURG, V108, P511, DOI 10.3171/JNS/2008/108/3/0511; Singh R, 2014, JAMA-J AM MED ASSOC, V311, P1883, DOI 10.1001/jama.2014.3313; Singman EL, 2013, MED INSTRUM, V1, DOI [10.7243/2052-6962-1-3., DOI 10.7243/2052-6962-1-3, 10.7243/2052-6962-1-3]; Suh M, 2006, NEUROSCI LETT, V410, P203, DOI 10.1016/j.neulet.2006.10.001; Suh M, 2006, NEUROSCI LETT, V401, P108, DOI 10.1016/j.neulet.2006.02.074; Thiagarajan P, 2014, J REHABIL RES DEV, V51, P175, DOI 10.1682/JRRD.2013.01.0027; Thiagarajan P, 2011, OPHTHAL PHYSL OPT, V31, P456, DOI 10.1111/j.1475-1313.2011.00831.x; Torres Daniel M, 2013, Neurol Clin Pract, V3, P279; Truong JQ, 2014, BRAIN INJURY, V28, P1283, DOI 10.3109/02699052.2014.915989; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Valovich TC, 2003, J ATHL TRAINING, V38, P51; White OB, 2012, J NEURO-OPHTHALMOL, V32, P266, DOI 10.1097/WNO.0b013e3182688230	79	35	35	3	37	THIEME MEDICAL PUBL INC	NEW YORK	333 SEVENTH AVE, NEW YORK, NY 10001 USA	0271-8235	1098-9021		SEMIN NEUROL	Semin. Neurol.	OCT	2015	35	5					599	606		10.1055/s-0035-1563567			8	Clinical Neurology	Neurosciences & Neurology	CS9AZ	WOS:000362382800015	26444405				2021-06-18	
J	Dretsch, MN; Silverberg, ND; Iverson, GL				Dretsch, Michael N.; Silverberg, Noah D.; Iverson, Grant L.			Multiple Past Concussions Are Associated with Ongoing Post-Concussive Symptoms but Not Cognitive Impairment in Active-Duty Army Soldiers	JOURNAL OF NEUROTRAUMA			English	Article						post-concussion symptoms; military; concussion; neurocognitive; PTSD	TRAUMATIC BRAIN-INJURY; PROFESSIONAL FOOTBALL PLAYERS; POSTTRAUMATIC-STRESS-DISORDER; NEUROPSYCHOLOGICAL PERFORMANCE; POSTCONCUSSIVE SYMPTOMS; RECURRENT CONCUSSION; IRAQI FREEDOM; HISTORY; INSTRUMENT; TBI	The extent to which multiple past concussions are associated with lingering symptoms or mental health problems in military service members is not well understood. The purpose of this study was to examine the association between lifetime concussion history, cognitive functioning, general health, and psychological health in a large sample of fit-for-duty U.S. Army soldiers preparing for deployment. Data on 458 active-duty soldiers were collected and analyzed. A computerized cognitive screening battery (CNS-Vital Signs((R))) was used to assess complex attention (CA), reaction time (RT), processing speed (PS), cognitive flexibility (CF), and memory. Health questionnaires included the Neurobehavioral Symptom Inventory (NSI), PTSD Checklist-Military Version (PCL-M), Zung Depression and Anxiety Scales (ZDS; ZAS), Perceived Stress Scale (PSS), Pittsburgh Sleep Quality Index (PSQI), Epworth Sleepiness Scale (ESS), and the Alcohol Use and Dependency Identification Test (AUDIT). Soldiers with a history of multiple concussions (i.e., three or more concussions) had significantly greater post-concussive symptom scores compared with those with zero (d=1.83, large effect), one (d=0.64, medium effect), and two (d=0.64, medium effect) prior concussions. Although the group with three or more concussions also reported more traumatic stress symptoms, the results revealed that traumatic stress was a mediator between concussions and post-concussive symptom severity. There were no significant differences on neurocognitive testing between the number of concussions. These results add to the accumulating evidence suggesting that most individuals recover from one or two prior concussions, but there is a greater risk for ongoing symptoms if one exceeds this number of injuries.	[Dretsch, Michael N.] US Army Aeromed Res Lab, Ft Rucker, AL USA; [Dretsch, Michael N.] Walter Reed Natl Mil Med Ctr, Natl Intrepid Ctr Excellence, Bethesda, MD 20889 USA; [Silverberg, Noah D.] Univ British Columbia, Div Phys Med & Rehabil, Vancouver, BC V5Z 1M9, Canada; [Silverberg, Noah D.] GF Strong Rehab Ctr, Vancouver, BC, Canada; [Iverson, Grant L.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA; [Iverson, Grant L.] Red Sox Fdn, Boston, MA USA; [Iverson, Grant L.] Massachusetts Gen Hosp, Home Base Program, Boston, MA 02114 USA; [Iverson, Grant L.] Def & Vet Brain Injury Ctr, Bethesda, MD USA	Dretsch, MN (corresponding author), Walter Reed Natl Mil Med Ctr, Natl Intrepid Ctr Excellence, 4860 South Palmer Rd, Bethesda, MD 20889 USA.	Michael.n.dretsch.mil@mail.mil		Iverson, Grant/0000-0001-7348-9570	U.S. Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC); INTRuST Posttraumatic Stress Disorder and Traumatic Brain Injury Clinical Consortium - Department of Defense Psychological Health/Traumatic Brain Injury Research Program [X81XWH-07-CC-CSDoD]; U.S. Army Aeromedical Research Laboratory	The views expressed in this article are those of the authors and do not reflect the official policy of the Department of Defense or the U.S. government. Primary funding for this study was provided by the U.S. Army Medical Research and Materiel Command (provided to Dr. Michael Dretsch as the PI). Dr. Grant Iverson notes that this work was supported in part by the INTRuST Posttraumatic Stress Disorder and Traumatic Brain Injury Clinical Consortium funded by the Department of Defense Psychological Health/Traumatic Brain Injury Research Program (X81XWH-07-CC-CSDoD). The authors wish to thank the U.S. Army Aeromedical Research Laboratory for its support during the time this study was conducted. Preliminary findings from this study were presented at the 2014 Annual Military Health System Research Symposium, Fort Lauderdale, FL.	American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Broglio SP, 2006, BRIT J SPORT MED, V40, P802, DOI 10.1136/bjsm.2006.028019; Brooks BL, 2013, J NEUROTRAUM, V30, P1469, DOI 10.1089/neu.2012.2720; Bryan CJ, 2013, SLEEP, V36, P941, DOI 10.5665/sleep.2730; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Campbell DW, 1970, RADIOLOGY, V94, P198, DOI 10.1148/94.1.198b; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Coldren RL, 2012, MIL MED, V177, P179, DOI 10.7205/MILMED-D-11-00278; Collie A, 2006, BRIT J SPORT MED, V40, P550, DOI 10.1136/bjsm.2005.019802; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; Gaetz M, 2000, BRAIN INJURY, V14, P1077; GOODMAN LA, 1960, J AM STAT ASSOC, V55, P708, DOI 10.2307/2281592; Gualtieri CT, 2006, ARCH CLIN NEUROPSYCH, V21, P623, DOI 10.1016/j.acn.2006.05.007; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Kelly KD, 2001, CLIN J SPORT MED, V11, P77, DOI 10.1097/00042752-200104000-00003; Kelly MP, 2012, ARCH CLIN NEUROPSYCH, V27, P375, DOI 10.1093/arclin/acs036; MacGregor AJ, 2013, J HEAD TRAUMA REHAB, V28, P59, DOI 10.1097/HTR.0b013e3182596382; Miller KJ, 2013, J HEAD TRAUMA REHAB, V28, P31, DOI 10.1097/HTR.0b013e318255ceae; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Orsillo S. M., 2001, PRACTITIONERS GUIDE, P255, DOI DOI 10.1007/0-306-47628-2_20; Pietrzak RH, 2009, J NERV MENT DIS, V197, P748, DOI 10.1097/NMD.0b013e3181b97a75; Rigg JL, 2011, PM&R, V3, pS380, DOI 10.1016/j.pmrj.2011.08.005; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schwab KA, 2006, NEUROLOGY, V66, pA235; Soble JR, 2014, CLIN NEUROPSYCHOL, V28, P614, DOI 10.1080/13854046.2014.894576; Spira JL, 2014, J NEUROTRAUM, V31, P1823, DOI 10.1089/neu.2014.3363; Stemper BD, 2014, PROG NEUROL SURG, V28, P14, DOI 10.1159/000358748; Theriault M, 2011, J CLIN EXP NEUROPSYC, V33, P30, DOI 10.1080/13803391003772873; Thornton AE, 2008, J CLIN EXP NEUROPSYC, V30, P398, DOI 10.1080/13803390701443662; Waldron-Perrine B, 2014, MIL MED, V179, P856, DOI 10.7205/MILMED-D-13-00282; Wall SE, 2006, J NEUROL NEUROSUR PS, V77, P518, DOI 10.1136/jnnp.2004.061044; ZUNG WWK, 1971, PSYCHOSOMATICS, V12, P371; ZUNG WWK, 1971, PSYCHOSOMATICS, V12, P164	42	35	35	0	26	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP 1	2015	32	17					1301	1306		10.1089/neu.2014.3810			6	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CP0KP	WOS:000359564500003	25763565				2021-06-18	
J	Johnson, B; Zhang, K; Hallett, M; Slobounov, S				Johnson, Brian; Zhang, Kai; Hallett, Mark; Slobounov, Semyon			Functional neuroimaging of acute oculomotor deficits in concussed athletes	BRAIN IMAGING AND BEHAVIOR			English	Article						Concussion; Oculomotor; Mild traumatic brain injury; Eye-Tracking	TRAUMATIC BRAIN-INJURY; MEMORY-GUIDED SACCADES; SMOOTH-PURSUIT; EYE-MOVEMENT; VOLITIONAL SACCADES; PREFRONTAL CORTEX; NEUROPHYSIOLOGY; ABNORMALITIES; NEUROANATOMY; PERFORMANCE	In the pursuit to better understand the neural underpinnings of oculomotor deficits following concussion we performed a battery of oculomotor tests while performing simultaneous functional magnetic resonance imaging (fMRI). Based on the increasing evidence that concussion can disrupt multiple brain functional networks, including the oculomotor control networks, a series of classic saccadic and smooth pursuit tasks were implemented. Nine concussed athletes were tested within seven days of injury along with nine age and sex matched healthy normal volunteers. Both behavioral and fMRI data revealed differential results between the concussed and normal volunteer groups. Concussed subjects displayed longer latency time in the saccadic tasks, worse position errors, and fewer numbers of self-paced saccades compared to normal volunteer subjects. Furthermore, the concussed group showed recruitment of additional brain regions and larger activation sites as evidenced by fMRI. As a potential diagnostic and management tool for concussion, oculomotor testing shows promise, and here we try to understand the reasons for this disrupted performance with the aide of advanced neuroimaging tools.	[Johnson, Brian; Zhang, Kai; Slobounov, Semyon] Penn State Univ, Dept Kinesiol, University Pk, PA 16802 USA; [Slobounov, Semyon] Penn State Milton S Hershey Med Ctr, Dept Neurosurg, Hershey, PA 17033 USA; [Hallett, Mark; Slobounov, Semyon] NINDS, NIH, Bethesda, MD 20892 USA	Slobounov, S (corresponding author), Penn State Univ, Dept Kinesiol, Penn 276 Recreat Bldg, University Pk, PA 16802 USA.	sms18@psu.edu	Zhang, Kai/F-3261-2015	Zhang, Kai/0000-0002-5460-6150	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [ZIANS002667] Funding Source: NIH RePORTER		Bartels A, 2008, TRENDS NEUROSCI, V31, P444, DOI 10.1016/j.tins.2008.06.004; Bergman K, 2010, J EMERG NURS, V36, P221, DOI 10.1016/j.jen.2009.07.001; BodisWollner I, 1997, NEUROLOGY, V49, P416, DOI 10.1212/WNL.49.2.416; Boxer AL, 2012, ARCH NEUROL-CHICAGO, V69, P509, DOI 10.1001/archneurol.2011.1021; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Brown MRG, 2006, NEUROIMAGE, V33, P644, DOI 10.1016/j.neuroimage.2006.07.002; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Capo-Aponte JE, 2012, MIL MED, V177, P804, DOI 10.7205/MILMED-D-12-00061; Contreras R, 2008, J BIOL PHYS, V34, P381, DOI 10.1007/s10867-008-9092-1; Dieterich M, 2009, ANN NY ACAD SCI, V1164, P282, DOI 10.1111/j.1749-6632.2008.03718.x; Drew AS, 2007, NEUROSCI LETT, V417, P61, DOI 10.1016/j.neulet.2007.02.038; Ford KA, 2005, J NEUROPHYSIOL, V94, P429, DOI 10.1152/jn.00471.2004; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Heitger MH, 2006, BRAIN INJURY, V20, P807, DOI 10.1080/02699050600676354; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Heitger MH, 2005, BRAIN INJURY, V19, P109, DOI 10.1080/02699050410001720095; Heitger MH, 2004, BRAIN, V127, P575, DOI 10.1093/brain/awh066; Heitger MH, 2002, PROG BRAIN RES, V140, P433; Hellerstein L F, 1995, J Am Optom Assoc, V66, P634; Kaufman LD, 2010, J ALZHEIMERS DIS, V19, P781, DOI 10.3233/JAD-2010-1275; Kraus MF, 2007, COGN BEHAV NEUROL, V20, P170, DOI 10.1097/WNN.0b013e318142badb; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lencer R, 2008, BRAIN COGNITION, V68, P219, DOI 10.1016/j.bandc.2008.08.013; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; McDowell JE, 2008, BRAIN COGNITION, V68, P255, DOI 10.1016/j.bandc.2008.08.016; Muri RM, 2008, BRAIN COGNITION, V68, P284, DOI 10.1016/j.bandc.2008.08.018; Nitschke MF, 2004, HUM BRAIN MAPP, V22, P155, DOI 10.1002/hbm.20025; Ozyurt J, 2006, NEUROREPORT, V17, P1005; PIERROTDESEILLIGNY C, 1993, EXP BRAIN RES, V95, P166; PIERROTDESEILLIGNY C, 1991, EXP BRAIN RES, V83, P607; Raz E, 2011, AM J NEURORADIOL, V32, P1851, DOI 10.3174/ajnr.A2637; Schraa-Tam CKL, 2009, EXP BRAIN RES, V192, P175, DOI 10.1007/s00221-008-1569-4; Sedney CL, 2011, CLIN SPORT MED, V30, P189, DOI 10.1016/j.csm.2010.08.005; Slobounov SM, 2010, EXP BRAIN RES, V202, P341, DOI 10.1007/s00221-009-2141-6; Stern Y, 2009, NEUROPSYCHOLOGIA, V47, P2015, DOI 10.1016/j.neuropsychologia.2009.03.004; Suh M, 2006, NEUROSCI LETT, V401, P108, DOI 10.1016/j.neulet.2006.02.074; Sweeney JA, 2007, NEUROIMAGE, V36, pT54, DOI 10.1016/j.neuroimage.2007.03.018; Theriault M, 2011, J CLIN EXP NEUROPSYC, V33, P30, DOI 10.1080/13803391003772873; Toepper M, 2010, BRAIN RES, V1354, P91, DOI 10.1016/j.brainres.2010.07.065; Van der Stappen A, 2000, ACTA OTO-LARYNGOL, V120, P724, DOI 10.1080/000164800750000243; Wade NJ, 2010, PERCEPTION, V39, P1150; Witt ST, 2010, BRAIN IMAGING BEHAV, V4, P232, DOI 10.1007/s11682-010-9102-3	44	35	35	0	20	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1931-7557	1931-7565		BRAIN IMAGING BEHAV	Brain Imaging Behav.	SEP	2015	9	3					564	573		10.1007/s11682-014-9316-x			10	Neuroimaging	Neurosciences & Neurology	CR8LQ	WOS:000361604300016	25179246				2021-06-18	
J	Lepeta, K; Kaczmarek, L				Lepeta, Katarzyna; Kaczmarek, Leszek			Matrix Metalloproteinase-9 as a Novel Player in Synaptic Plasticity and Schizophrenia	SCHIZOPHRENIA BULLETIN			English	Article						synaptic plasticity; glutamate; extracellular matrix	LONG-TERM POTENTIATION; FRAGILE-X-SYNDROME; MATRIX-METALLOPROTEINASE ACTIVITY; TRAUMATIC BRAIN-INJURY; NEUROTROPHIC FACTOR; GENE-EXPRESSION; DOUBLE-BLIND; FUNCTIONAL POLYMORPHISM; NEGATIVE SYMPTOMS; BIPOLAR DISORDER	Recent findings implicate alterations in glutamate signaling, leading to aberrant synaptic plasticity, in schizophrenia. Matrix metalloproteinase-9 (MMP-9) has been shown to regulate glutamate receptors, be regulated by glutamate at excitatory synapses, and modulate physiological and morphological synaptic plasticity. By means of functional gene polymorphism, gene responsiveness to antipsychotics and blood plasma levels MMP-9 has recently been implicated in schizophrenia. This commentary critically reviews these findings based on the hypothesis that MMP-9 contributes to pathological synaptic plasticity in schizophrenia.	[Lepeta, Katarzyna; Kaczmarek, Leszek] M Nencki Inst Expt Biol, Dept Mol & Cellular Neurobiol, PL-02093 Warsaw, Poland	Kaczmarek, L (corresponding author), M Nencki Inst Expt Biol, Dept Mol & Cellular Neurobiol, 3 Pasteur St, PL-02093 Warsaw, Poland.	l.kaczmarek@nencki.gov.pl	Kaczmarek, Leszek/B-6171-2008	Kaczmarek, Leszek/0000-0002-7207-3490; Lepeta, Katarzyna/0000-0002-6870-0009	European Innovative Economy Operational Program	The Foundation for Polish Science (FNP) TEAM grant financed by the European Innovative Economy Operational Program.	Akil M, 1999, AM J PSYCHIAT, V156, P1580, DOI 10.1176/ajp.156.10.1580; [Anonymous], 2015, REUTERS; Aujla PK, 2014, J COMP NEUROL, V522, P1249, DOI 10.1002/cne.23468; Bilousova TV, 2009, J MED GENET, V46, P94, DOI 10.1136/jmg.2008.061796; Bunney WE, 2000, BRAIN RES REV, V31, P138, DOI 10.1016/S0165-0173(99)00031-4; Chang SH, 2011, PSYCHIAT RES, V187, P341, DOI 10.1016/j.psychres.2010.04.049; Chopra K, 2014, EXPER OPIN THER TAR, P1; Domenici E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009166; Dziembowska M, 2013, AM J MED GENET A, V161, P1897, DOI 10.1002/ajmg.a.36023; Dziembowska M, 2012, J NEUROSCI, V32, P14538, DOI 10.1523/JNEUROSCI.6028-11.2012; Favalli G, 2012, J PSYCHIATR RES, V46, P1, DOI 10.1016/j.jpsychires.2011.09.022; Fragkouli A, 2012, J NEUROCHEM, V121, P239, DOI 10.1111/j.1471-4159.2011.07637.x; Fromer M, 2014, NATURE, V506, P179, DOI 10.1038/nature12929; Fujita Y, 2008, PROG NEURO-PSYCHOPH, V32, P336, DOI 10.1016/j.pnpbp.2007.08.031; Gawlak M, 2009, NEUROSCIENCE, V158, P167, DOI 10.1016/j.neuroscience.2008.05.045; Gkogkas CG, 2014, CELL REP, V9, P1742, DOI 10.1016/j.celrep.2014.10.064; Groszewska A, 2011, PSYCHIATR POL, V45, P317; Gurling HMD, 2001, AM J HUM GENET, V68, P661, DOI 10.1086/318788; Han HY, 2011, PSYCHIAT RES, V190, P163, DOI 10.1016/j.psychres.2011.04.026; Hayashi T, 2009, BRAIN RES, V1280, P172, DOI 10.1016/j.brainres.2009.05.040; Huntley GW, 2012, NAT REV NEUROSCI, V13, P743, DOI 10.1038/nrn3320; Janusz A, 2013, J NEUROSCI, V33, P18234, DOI 10.1523/JNEUROSCI.2207-13.2013; Je HS, 2012, P NATL ACAD SCI USA, V109, P15924, DOI 10.1073/pnas.1207767109; Kaczmarek L, 2002, EMBO J, V21, P6643, DOI 10.1093/emboj/cdf676; Kelly EA, 2014, J COMP NEUROL, V522, P676, DOI 10.1002/cne.23440; Knapska E, 2013, J NEUROSCI, V33, P14591, DOI 10.1523/JNEUROSCI.5239-12.2013; Konopacki FA, 2007, NEUROSCIENCE, V150, P31, DOI 10.1016/j.neuroscience.2007.08.026; Kumarasinghe N, 2013, INT J NEUROPSYCHOPH, V16, P1483, DOI 10.1017/S1461145713000035; Leigh MJS, 2013, J DEV BEHAV PEDIATR, V34, P147, DOI 10.1097/DBP.0b013e318287cd17; Levkovitz Y, 2010, J CLIN PSYCHIAT, V71, P138, DOI 10.4088/JCP.08m04666yel; Lin CY, 2012, NEUROBIOL DIS, V45, P48, DOI 10.1016/j.nbd.2011.08.025; Liu F, 2014, SCHIZOPHR RES, V153, P169, DOI 10.1016/j.schres.2014.01.011; Mackowiak M, 2014, PHARMACOL REP, V66, P830, DOI 10.1016/j.pharep.2014.04.011; Malaspina D, 2001, AM J PSYCHIAT, V158, P440, DOI 10.1176/appi.ajp.158.3.440; Malenka RC, 2004, NEURON, V44, P5, DOI 10.1016/j.neuron.2004.09.012; Mash DC, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001187; Meyer-Lindenberg A, 2012, NAT NEUROSCI, V15, P663, DOI 10.1038/nn.3083; Michaluk P, 2007, CELL DEATH DIFFER, V14, P1255, DOI 10.1038/sj.cdd.4402141; Michaluk P, 2011, J CELL SCI, V124, P3369, DOI 10.1242/jcs.090852; Michaluk P, 2009, J NEUROSCI, V29, P6007, DOI 10.1523/JNEUROSCI.5346-08.2009; Mizoguchi H, 2011, BIOCHEM RES INT, V2011, DOI 10.1155/2011/681385; Moyer CE, 2014, NEUROSCI LETT; Nagy V, 2006, J NEUROSCI, V26, P1923, DOI 10.1523/JNEUROSCI.4359-05.2006; Niitsu T, 2014, PSYCHIAT RES, V215, P268, DOI 10.1016/j.psychres.2013.12.009; O'Dushlaine C, 2015, NAT NEUROSCI, V18, P199, DOI 10.1038/nn.3922; Okulski P, 2007, BIOL PSYCHIAT, V62, P359, DOI 10.1016/j.biopsych.2006.09.012; Oya K, 2014, HUM PSYCHOPHARM CLIN, V29, P483, DOI 10.1002/hup.2426; Paribello C, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-91; Peixoto RT, 2012, NEURON, V76, P396, DOI 10.1016/j.neuron.2012.07.006; Rivera S, 2010, J NEUROSCI, V30, P15337, DOI 10.1523/JNEUROSCI.3467-10.2010; Roberts RC, 1996, NEUROREPORT, V7, P1214, DOI 10.1097/00001756-199604260-00024; Rybakowski JK, 2009, NEUROMOL MED, V11, P128, DOI 10.1007/s12017-009-8072-3; Rybakowski JK, 2009, SCHIZOPHR RES, V109, P90, DOI 10.1016/j.schres.2009.02.005; Samochowiec A, 2010, BRAIN RES, V1327, P103, DOI 10.1016/j.brainres.2010.02.072; Sidhu H, 2014, J NEUROSCI, V34, P9867, DOI 10.1523/JNEUROSCI.1162-14.2014; Smith ACW, 2014, NAT NEUROSCI, V17, P1655, DOI 10.1038/nn.3846; Stawarski M, 2014, BIOMATERIALS, V35, P1402, DOI 10.1016/j.biomaterials.2013.11.033; STJEAN PL, 1995, ANN HUM GENET, V59, P17; Szepesi Z, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098274; Szklarczyk A, 2002, J NEUROSCI, V22, P920, DOI 10.1523/JNEUROSCI.22-03-00920.2002; Szklarczyk A., 2005, BIOTECHNOLOGY INT, V17, P15; Tsilibary E, 2014, PROG BRAIN RES, V214, P135, DOI 10.1016/B978-0-444-63486-3.00006-2; van der Kooij MA, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5995; Wang LW, 2010, NEUROTHERAPEUTICS, V7, P264, DOI 10.1016/j.nurt.2010.05.005; Wang XB, 2008, P NATL ACAD SCI USA, V105, P19520, DOI 10.1073/pnas.0807248105; Wiera G, 2013, HIPPOCAMPUS, V23, P529, DOI 10.1002/hipo.22112; Wilczynski GM, 2008, J CELL BIOL, V180, P1021, DOI 10.1083/jcb.200708213; Wright JW, 2004, BRAIN RES, V1023, P1, DOI 10.1016/j.brainres.2004.06.083; Yamamori H, 2013, NEUROSCI LETT, V556, P37, DOI 10.1016/j.neulet.2013.09.059; Zhang BP, 1999, CIRCULATION, V99, P1788, DOI 10.1161/01.CIR.99.14.1788	70	35	37	0	4	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0586-7614	1745-1701		SCHIZOPHRENIA BULL	Schizophr. Bull.	SEP	2015	41	5					1003	1009		10.1093/schbul/sbv036			7	Psychiatry	Psychiatry	CV0YM	WOS:000363979800002	25837304	Green Published, Bronze			2021-06-18	
J	Lukow, HR; Godwin, EE; Marwitz, JH; Mills, A; Hsu, NH; Kreutzer, JS				Lukow, Herman R.; Godwin, Emilie E.; Marwitz, Jennifer H.; Mills, Ana; Hsu, Nancy H.; Kreutzer, Jeffrey S.			Relationship Between Resilience, Adjustment, and Psychological Functioning After Traumatic Brain Injury: A Preliminary Report	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							CONNOR-DAVIDSON RESILIENCE; EMOTIONAL ADJUSTMENT; POSITIVE EMOTIONS; SELF-AWARENESS; REHABILITATION; INTERVENTION; DEPRESSION; STRESS; SKILLS; SCALE	Objective: To examine the relationship between resilience, psychological distress, adjustment, and community participation after traumatic brain injury (TBI). Setting: Large university health system. Participants: Adult survivors of mild to severe TBI (N = 96). Design: Descriptive, preliminary. Main Measures: The Connor-Davidson Resilience Scale (10-item version) was used to assess resilience, the Brief Symptom Inventory (BSI-18) was used to characterize psychological distress, and the Mayo-Portland Adaptability Index (MPAI-4) was used to measure ability, adjustment, and participation. Results: Resilience scores were substantially lower than those of the general population. Significant relationships were found between resilience, psychological distress, and adjustment. Partial correlations (adjusting for the other MPAI-4 indices) showed significant correlation (P < .05) between MPAI-4 Adjustment and resilience. Partial correlations (adjusting for the other BSI-18 scales) also showed significance for Depression (P < .01) and resilience. Resilience scores differed significantly (P < .001) between individuals meeting BSI-18 caseness criteria for psychological distress (n = 55) and those not meeting criteria (n = 41). Conclusions: Individuals with TBI are at risk for low resilience, which was found to correlate with psychological distress and psychosocial maladjustment. Developing interventions to strengthen resilience skills has the potential to improve postinjury psychosocial adjustment, an important area for future research.	[Lukow, Herman R.; Godwin, Emilie E.; Marwitz, Jennifer H.; Mills, Ana; Hsu, Nancy H.; Kreutzer, Jeffrey S.] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA 23298 USA; [Kreutzer, Jeffrey S.] Virginia Commonwealth Univ, Dept Neurol Surg, Richmond, VA 23298 USA; [Kreutzer, Jeffrey S.] Virginia Commonwealth Univ, Dept Psychiat, Richmond, VA 23298 USA	Marwitz, JH (corresponding author), Virginia Commonwealth Univ, Dept Phys Med & Rehabil, 1200 E Broad St,Rm 3-109,Box 980542, Richmond, VA 23298 USA.	jhmarwit@vcu.edu			National Institute on Disability and Rehabilitation Research (NIDRR) of the US Department of Education [H133A120031, H133P090013]	Supported by grants H133A120031 and H133P090013 from the National Institute on Disability and Rehabilitation Research (NIDRR) of the US Department of Education.	[Anonymous], 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Anson K, 2006, J HEAD TRAUMA REHAB, V21, P248, DOI 10.1097/00001199-200605000-00005; Baum N. L., 2005, J AGGRESS MALTREAT T, V10, P487, DOI [10.1300/J146v10n01_08, DOI 10.1300/J146V10N01_08]; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Benzies K, 2009, CHILD FAM SOC WORK, V14, P103, DOI 10.1111/j.1365-2206.2008.00586.x; Bertisch H, 2014, NEUROREHABILITATION, V34, P573, DOI 10.3233/NRE-141059; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bonanno GA, 2004, AM PSYCHOL, V59, P20, DOI 10.1037/0003-066X.59.1.20; Bonanno GA, 2011, ANNU REV CLIN PSYCHO, V7, P511, DOI 10.1146/annurev-clinpsy-032210-104526; Brody D, 2007, CURRICULUM INQ, V37, P9, DOI 10.1111/j.1467-873X.2007.00379.x; Campbell-Sills L, 2006, BEHAV RES THER, V44, P585, DOI 10.1016/j.brat.2005.05.001; Campbell-Sills L, 2007, J TRAUMA STRESS, V20, P1019, DOI 10.1002/jts.20271; Campbell-Sills L, 2009, J PSYCHIATR RES, V43, P1007, DOI 10.1016/j.jpsychires.2009.01.013; Cazalis F, 2006, BRAIN INJURY, V20, P1019, DOI 10.1080/02699050600664384; Cohen M.S., 1999, FAM SYST HEALTH, V17, P149, DOI DOI 10.1037/H0089879; Connor KM, 2003, DEPRESS ANXIETY, V18, P76, DOI 10.1002/da.10113; Curtis WJ, 2003, DEV PSYCHOPATHOL, V15, P773, DOI 10.1017/S0954579403000373; Davidson JRT, 2005, INT CLIN PSYCHOPHARM, V20, P43, DOI 10.1097/00004850-200501000-00009; Davidson JRT, CD RISC CONNORDAVIDS; Derogatis L., 2000, BRIEF SYMPTOM INVENT; Dodd Z, 2010, THESIS U N TEXAS DEN; Dowrick C, 2008, HEALTH-LONDON, V12, P439, DOI 10.1177/1363459308094419; Edward K.-L., 2005, J AM PSYCHIAT NURSES, V11, P101, DOI [10.1177/1078390305277526, DOI 10.1177/1078390305277526]; Fleminger S, 2008, EUR J ANAESTH, V25, P123, DOI 10.1017/S0265021507003250; Friborg O, 2005, PSYCHOL REP, V97, P77; Glaesser J, 2004, BMC PSYCHIATRY, V4, DOI 10.1186/1471-244X-4-5; Godfrey HPD, 2000, APHASIOLOGY, V14, P433, DOI 10.1080/026870300401441; Godwin EE, 2013, BRAIN INJURY, V27, P637, DOI 10.3109/02699052.2012.750745; Graham DP, 2013, J PSYCHIATR RES, V47, P835, DOI 10.1016/j.jpsychires.2013.02.006; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P333, DOI 10.1097/00001199-200507000-00005; Hawley DR, 2000, AM J FAM THER, V28, P101, DOI 10.1080/019261800261699; Henry JD, 2006, NEUROPSYCHOLOGIA, V44, P1623, DOI 10.1016/j.neuropsychologia.2006.03.020; Hesdorffer DC, 2009, J HEAD TRAUMA REHAB, V24, P452, DOI 10.1097/HTR.0b013e3181c133fd; Hoofien D, 2001, BRAIN INJURY, V15, P189; Iwaniec D., 2006, CHILD FAM SOC WORK, V11, P10, DOI [10.1111/j.1365-2206.2006.00398.x, DOI 10.1111/J.1365-2206.2006.00398.X]; Joseph S., 2008, TRAUMA RECOVERY GROW; Karoly P, 2006, PAIN, V123, P90, DOI 10.1016/j.pain.2006.02.014; Kralik D, 2006, EDUC ACTION RES, V14, P187, DOI 10.1080/09650790600718035; Kreutzer JS, 2010, J HEAD TRAUMA REHAB, V25, P113, DOI 10.1097/HTR.0b013e3181cf0712; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; 김원형, 2010, [JOURNAL OF THE KOREAN NEUROPSYCHIATRIC ASSOCIATION, 신경정신의학], V49, P611; Luthar SS, 2000, DEV PSYCHOPATHOL, V12, P857, DOI 10.1017/S0954579400004156; Malec JF, 2000, J HEAD TRAUMA REHAB, V15, P670, DOI 10.1097/00001199-200002000-00006; Malec JF, 2008, MAYO PORTLAND ADAPTA; Mateer CA, 2006, NEUROREHABILITATION, V21, P315; McCauley SR, 2013, J NEUROTRAUM, V30, P642, DOI 10.1089/neu.2012.2393; McDonald S, 2008, ARCH PHYS MED REHAB, V89, P1648, DOI 10.1016/j.apmr.2008.02.029; McGlone J, 2009, 63 ANN M AM EP SOC O; Meachen SJ, 2008, ARCH PHYS MED REHAB, V89, P958, DOI 10.1016/j.apmr.2007.12.028; Newman R, 2005, PROF PSYCHOL-RES PR, V36, P227, DOI 10.1037/0735-7028.36.3.227; Ong AD, 2006, J PERS SOC PSYCHOL, V91, P730, DOI 10.1037/0022-3514.91.4.730; Ownsworth T, 2005, J HEAD TRAUMA REHAB, V20, P315, DOI 10.1097/00001199-200507000-00004; Perlesz A, 2000, J HEAD TRAUMA REHAB, V15, P909, DOI 10.1097/00001199-200006000-00005; Prigatano GP, 2005, J HEAD TRAUMA REHAB, V20, P19, DOI 10.1097/00001199-200501000-00004; Rajkumar AP, 2008, SOC SCI MED, V67, P844, DOI 10.1016/j.socscimed.2008.05.014; Ramanathan DM, 2011, BRAIN INJURY, V25, P328, DOI 10.3109/02699052.2011.554336; Reeves RR, 2012, J PSYCHOSOC NURS MEN, V50, P32, DOI 10.3928/02793695-20120207-02; Richardson GE, 2002, J CLIN PSYCHOL, V58, P307, DOI 10.1002/jclp.10020; Safaz I, 2008, BRAIN INJURY, V22, P733, DOI 10.1080/02699050802304714; Sawchyn JM, 2005, J HEAD TRAUMA REHAB, V20, P301, DOI 10.1097/00001199-200507000-00003; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Steinhardt MA, 2009, DIABETES EDUCATOR, V35, P274, DOI 10.1177/0145721708329698; Struchen MA, 2008, BRAIN INJURY, V22, P940, DOI 10.1080/02699050802425410; Tedeschi RG, 2005, PROF PSYCHOL-RES PR, V36, P230, DOI 10.1037/0735-7028.36.3.230; Tegner I, 2009, J POETRY THER, V22, P121, DOI 10.1080/08893670903198383; Tugade MM, 2004, J PERS SOC PSYCHOL, V86, P320, DOI 10.1037/0022-3514.86.2.320; Vanderbilt-Adriance E, 2008, CLIN CHILD FAM PSYCH, V11, P30, DOI 10.1007/s10567-008-0031-2; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Whelan-Goodinson R, 2008, J REHABIL MED, V40, P850, DOI 10.2340/16501977-0271; White B, 2008, REHABIL PSYCHOL, V53, P9, DOI 10.1037/0090-5550.53.1.9; White B, 2010, REHABIL PSYCHOL, V55, P23, DOI 10.1037/a0018451; Woodgate R L, 1999, J Pediatr Oncol Nurs, V16, P78, DOI 10.1016/S1043-4542(99)90029-2; Yang CC, 2012, BRAIN INJURY, P1; Yi JP, 2008, BRIT J HEALTH PSYCH, V13, P311, DOI 10.1348/135910707X186994	75	35	37	0	25	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2015	30	4					241	248		10.1097/HTR.0000000000000137			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	CM8JA	WOS:000357944700002	25931185				2021-06-18	
J	Walker, MC				Walker, Matthew Charles			Hippocampal Sclerosis: Causes and Prevention	SEMINARS IN NEUROLOGY			English	Article						hippocampal sclerosis; status epileptics; epilepsy; neuroprotection	TEMPORAL-LOBE EPILEPSY; FEBRILE STATUS EPILEPTICUS; TRAUMATIC BRAIN-INJURY; MAGNETIC-RESONANCE; VOLUME LOSS; ENTORHINAL CORTEX; OXIDATIVE STRESS; GRADING SYSTEM; SEIZURES; INHIBITION	Hippocampal sclerosis is the commonest cause of drug-resistant epilepsy in adults, and is associated with alterations to structures and networks beyond the hippocampus. In addition to being a cause of epilepsy, the hippocampus is vulnerable to damage from seizure activity. In particular, prolonged seizures (status epilepticus) can result in hippocampal sclerosis. The hippocampus is also vulnerable to other insults including traumatic brain injury, and inflammation. Hippocampal sclerosis can occur in association with other brain lesions; the prevailing view is that it is probably a secondary consequence. In such instances, successful surgical treatment usually involves the resection of both the lesion and the involved hippocampus. Experimental data have pointed to numerous neuroprotective strategies to prevent hippocampal sclerosis. Initial neuroprotective strategies aimed at glutamate receptors may be effective, but later, metabolic pathways, apoptosis, reactive oxygen species, and inflammation are involved, perhaps necessitating the use of interventions aimed at multiple targets. Some of the therapies that we use to treat status epilepticus may neuroprotect. However, prevention of neuronal death does not necessarily prevent the later development of epilepsy or cognitive deficits. Perhaps, the most important intervention is the early, aggressive treatment of seizure activity, and the prevention of prolonged seizures.	UCL, UCL Inst Neurol, Dept Clin & Expt Epilepsy, London WC1N 3BG, England	Walker, MC (corresponding author), UCL, UCL Inst Neurol, Dept Clin & Expt Epilepsy, Queen Sq, London WC1N 3BG, England.	m.walker@ucl.ac.uk	Walker, Matthew C/C-1577-2008	Walker, Matthew C/0000-0002-0812-0352	Epilepsy Research UK; FP7-HEALTH project [602102]; Department of Health National Institute for Health Research Biomedical Research Centres' funding scheme	I thank Epilepsy Research UK and FP7-HEALTH project 602102 (EPITARGET) for their support. This work was undertaken at University College London Hospitals/University College London, which receives a proportion of funding from the Department of Health National Institute for Health Research Biomedical Research Centres' funding scheme.	Baird L, 2011, ARCH TOXICOL, V85, P241, DOI 10.1007/s00204-011-0674-5; Barron DS, 2013, NEUROIMAGE-CLIN, V2, P25, DOI 10.1016/j.nicl.2012.11.004; Baulac M, 1998, ANN NEUROL, V44, P223, DOI 10.1002/ana.410440213; Bernasconi N, 2003, BRAIN, V126, P462, DOI 10.1093/brain/awg034; Bernasconi N, 2001, NEUROLOGY, V56, P1335, DOI 10.1212/WNL.56.10.1335; Bianchin MM, 2012, PATHOG GLOB HEALTH, V106, P280, DOI 10.1179/2047773212Y.0000000027; Blumcke I, 2013, EPILEPSIA, V54, P1315, DOI 10.1111/epi.12220; Blumcke I, 2012, BRAIN PATHOL, V22, P347, DOI 10.1111/j.1750-3639.2012.00584.x; Blumcke I, 2002, BRAIN PATHOL, V12, P199; Borelli P, 2008, EPILEPSIA, V49, P1333, DOI 10.1111/j.1528-1167.2008.01694.x; BOUCHET C, 1825, ARCH GEN MED, V9, P510; Brandt C, 2003, NEUROSCIENCE, V118, P727, DOI 10.1016/S0306-4522(03)00027-7; Briellmann RS, 2002, ANN NEUROL, V51, P641, DOI 10.1002/ana.10171; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CENDES F, 1995, NEUROLOGY, V45, P2058, DOI 10.1212/WNL.45.11.2058; Coan AC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085843; Collins R C, 1983, Adv Neurol, V34, P277; Corsellis J A, 1983, Adv Neurol, V34, P129; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Davies KG, 1995, BRIT J NEUROSURG, V9, P759; Davies KG, 1996, EPILEPSY RES, V24, P119, DOI 10.1016/0920-1211(96)00008-3; DEGIORGIO CM, 1992, EPILEPSIA, V33, P23, DOI 10.1111/j.1528-1157.1992.tb02278.x; Delgado-Esteban M, 2007, J NEUROCHEM, V102, P194, DOI 10.1111/j.1471-4159.2007.04450.x; Epstein LG, 2012, EPILEPSIA, V53, P1481, DOI 10.1111/j.1528-1167.2012.03542.x; Fernandez G, 1998, NEUROLOGY, V50, P909, DOI 10.1212/WNL.50.4.909; FRENCH JA, 1993, ANN NEUROL, V34, P774, DOI 10.1002/ana.410340604; Fujikawa DG, 2005, EPILEPSY BEHAV, V7, pS3, DOI 10.1016/j.yebeh.2005.08.003; FUJIKAWA DG, 1994, EPILEPSY RES, V17, P207, DOI 10.1016/0920-1211(94)90051-5; HARDIMAN O, 1988, NEUROLOGY, V38, P1041, DOI 10.1212/WNL.38.7.1041; Hardingham GE, 2010, NAT REV NEUROSCI, V11, P682, DOI 10.1038/nrn2911; Henshall DC, 2005, J CEREBR BLOOD F MET, V25, P1557, DOI 10.1038/sj.jcbfm.9600149; Hetman M, 2004, EUR J BIOCHEM, V271, P2050, DOI 10.1111/j.1432-1033.2004.04133.x; Janszky J, 2005, BRAIN, V128, P395, DOI 10.1093/brain/awh358; Jimenez-Mateos EM, 2008, NEUROBIOL DIS, V32, P442, DOI 10.1016/j.nbd.2008.08.008; JONES RSG, 1989, EXP NEUROL, V104, P155, DOI 10.1016/S0014-4886(89)80009-3; Kasperaviciute D, 2013, BRAIN, V136, P3140, DOI 10.1093/brain/awt233; Keller SS, 2015, ANN NEUROL; Kovac S, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.390; Kovac S, 2013, NEUROPHARMACOLOGY, V69, P96, DOI 10.1016/j.neuropharm.2012.05.012; Lewis DV, 2014, ANN NEUROL, V75, P178, DOI 10.1002/ana.24081; Lewis DV, 2002, PROG BRAIN RES, V135, P263; Li LM, 1999, BRAIN, V122, P799, DOI 10.1093/brain/122.5.799; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Luo Y, 2006, J BIOL CHEM, V281, P16436, DOI 10.1074/jbc.M512430200; MELDRUM B, 1991, EPILEPSY RES, V10, P55, DOI 10.1016/0920-1211(91)90095-W; Meldrum BS, 2002, PROG BRAIN RES, V135, P487; Milder JB, 2010, NEUROBIOL DIS, V40, P238, DOI 10.1016/j.nbd.2010.05.030; Narkilahti S, 2003, EUR J NEUROSCI, V18, P1486, DOI 10.1046/j.1460-9568.2003.02874.x; Ostendorf AP, 2015, CNS DRUGS, V29, P91, DOI 10.1007/s40263-014-0223-x; Pavlov I, 2011, NEUROSCIENCE, V194, P208, DOI 10.1016/j.neuroscience.2011.07.074; Pfleger L, 1880, ALLG Z PSYCHIAT, V36, P359; Pitkanen A, 2004, EXPERT OPIN PHARMACO, V5, P777, DOI 10.1517/14656566.5.4.777; Prasad A, 2002, ANN NEUROL, V51, P175, DOI 10.1002/ana.10085; Rice AC, 1998, EPILEPSIA, V39, P1148, DOI 10.1111/j.1528-1157.1998.tb01305.x; Rowley S, 2013, FREE RADICAL BIO MED, V62, P121, DOI 10.1016/j.freeradbiomed.2013.02.002; Schoene-Bake JC, 2014, HUM BRAIN MAPP, V35, P4718, DOI 10.1002/hbm.22506; Sinjab B, 2013, EPILEPSIA, V54, P2125, DOI 10.1111/epi.12403; Sommer W., 1880, ARCH PSYCHIAT NERVEN, V10, P631, DOI [DOI 10.1007/BF02224538, 10.1007/BF02224538]; Tanaka H, 2000, BRAIN RES, V886, P190, DOI 10.1016/S0006-8993(00)02951-6; Thom M, 2005, BRAIN, V128, P1344, DOI 10.1093/brain/awh475; Thom M, 2010, EPILEPSIA, V51, P1801, DOI 10.1111/j.1528-1167.2010.02681.x; Treiman DM, 2006, EPILEPSY RES, V68, pS77, DOI 10.1016/j.eplepsyres.2005.07.020; Van Paesschen W, 1998, EPILEPSIA, V39, P633; Vespa PM, 2010, NEUROLOGY, V75, P792, DOI 10.1212/WNL.0b013e3181f07334; Vezzani A, 2013, EXP NEUROL, V244, P11, DOI 10.1016/j.expneurol.2011.09.033; Vincent A, 2004, BRAIN, V127, P701, DOI 10.1093/brain/awh077; Wagner J, 2014, J NEUROL NEUROSURG P; Walker M, 2005, BRIT MED J, V331, P673, DOI 10.1136/bmj.331.7518.673; Walker M., 2007, HIPPOCAMPUS BOOK, P769; Watson C, 1996, J EPILEPSY, V9, P56, DOI 10.1016/0896-6974(95)00060-7; Weiss JH, 2000, TRENDS NEUROSCI, V23, P365, DOI 10.1016/S0166-2236(00)01610-6; WYLER AR, 1992, J EPILEPSY, V5, P220, DOI 10.1016/S0896-6974(05)80120-3; Yilmazer-Hanke DM, 2000, J NEUROPATH EXP NEUR, V59, P907, DOI 10.1093/jnen/59.10.907; Yoong M, 2013, EPILEPSIA, V54, P2108, DOI 10.1111/epi.12426	76	35	35	0	3	THIEME MEDICAL PUBL INC	NEW YORK	333 SEVENTH AVE, NEW YORK, NY 10001 USA	0271-8235	1098-9021		SEMIN NEUROL	Semin. Neurol.	JUN	2015	35	3					193	200		10.1055/s-0035-1552618			8	Clinical Neurology	Neurosciences & Neurology	CK1YU	WOS:000356006700003	26060898	Bronze, Green Published			2021-06-18	
J	Mayer, AR; Hanlon, FM; Ling, JM				Mayer, Andrew R.; Hanlon, Faith M.; Ling, Josef M.			Gray Matter Abnormalities in Pediatric Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						traumatic brain injury; gray matter; diffusion tensor imaging; pediatric; prospective	SPORTS-RELATED CONCUSSION; BLUNT HEAD-INJURY; FUNCTIONAL CONNECTIVITY; DIFFUSIONAL KURTOSIS; SYMPTOMS; RECOVERY; MRI; TRACTOGRAPHY; ADOLESCENCE; ANISOTROPY	Pediatric mild traumatic brain injury (pmTBI) is the most prevalent neurological insult in children and is associated with both acute and chronic neuropsychiatric sequelae. However, little is known about underlying pathophysiology changes in gray matter diffusion and atrophy from a prospective stand-point. Fifteen semi-acute pmTBI patients and 15 well-matched healthy controls were evaluated with a clinical and neuroimaging battery, with a subset of participants returning for a second visit. Clinical measures included tests of attention, processing speed, executive function, working memory, memory, and self-reported post-concussive symptoms. Measures of diffusion (fractional anisotropy [FA]) and atrophy were also obtained for cortical and subcortical gray matter structures to characterize effects of injury as a function of time. Patients exhibited decreased scores in the domains of attention and processing speed relative to controls during the semi-acute injury stage, in conjunction with increased anisotropic diffusion in the left superior temporal gyrus and right thalamus. Evidence of increased diffusion in these regions was also present at four months post-injury, with performance on cognitive tests partially normalizing. In contrast, signs of cortical atrophy in bilateral frontal areas and other left-hemisphere cortical areas only emerged at four months post-injury for patients. Current results suggest potentially differential time-courses of recovery for neurobehavioral markers, anisotropic diffusion and atrophy following pmTBI. Importantly, these data suggest that relying on patient self-report or standard clinical assessments may underestimate the time for true injury recovery.	[Mayer, Andrew R.; Hanlon, Faith M.; Ling, Josef M.] Lovelace Biomed & Environm Res Inst, Mind Res Network, Albuquerque, NM USA; [Mayer, Andrew R.] Univ New Mexico, Dept Psychol, Albuquerque, NM 87131 USA; [Mayer, Andrew R.] Univ New Mexico, Sch Med, Dept Neurol, Albuquerque, NM 87131 USA	Mayer, AR (corresponding author), Mind Res Network, Pete & Nancy Domenici Hall,1101 Yale Blvd NE, Albuquerque, NM 87106 USA.	amayer@mrn.org	Meijer, Anna/K-5118-2016		Mind Research Network [DOE]United States Department of Energy (DOE) [DE-FG02-99ER62764]	This research was supported by grants from The Mind Research Network [DOE Grant No. DE-FG02-99ER62764] to A.R.M.	Akpinar E, 2007, J COMPUT ASSIST TOMO, V31, P657, DOI 10.1097/RCT.0b013e318033df1a; Babikian T, 2010, J NEUROTRAUM, V27, P473, DOI 10.1089/neu.2009.1058; Beauchamp MH, 2011, INT J DEV NEUROSCI, V29, P137, DOI 10.1016/j.ijdevneu.2010.12.003; Bell MJ, 2013, CRIT CARE CLIN, V29, P223, DOI 10.1016/j.ccc.2012.11.004; Bigler ED, 2013, NEUROPSYCHOLOGY, V27, P438, DOI 10.1037/a0032837; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; Borich M, 2013, J NEUROTRAUM, V30, P1243, DOI 10.1089/neu.2012.2818; Bouix S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066205; Brown NJ, 2014, PEDIATRICS, V133, pE299, DOI 10.1542/peds.2013-2125; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Conti AC, 1998, J NEUROSCI, V18, P5663; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fieremans E, 2011, NEUROIMAGE, V58, P177, DOI 10.1016/j.neuroimage.2011.06.006; Giza CC, 2001, J ATHL TRAINING, V36, P228; Grieve SM, 2007, AM J NEURORADIOL, V28, P226; Grossman EJ, 2013, AM J NEURORADIOL, V34, P951, DOI 10.3174/ajnr.A3358; Hanten G, 2008, NEUROPSYCHOLOGY, V22, P357, DOI 10.1037/0894-4105.22.3.357; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Keightley ML, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00139; Korgaonkar MS, 2011, HUM BRAIN MAPP, V32, P2161, DOI 10.1002/hbm.21178; Lenroot RK, 2007, NEUROIMAGE, V36, P1065, DOI 10.1016/j.neuroimage.2007.03.053; Ling J, 2012, HUM BRAIN MAPP, V33, P50, DOI 10.1002/hbm.21192; Ling JM, 2013, NEUROLOGY, V81, P2121, DOI 10.1212/01.wnl.0000437302.36064.b1; Little DM, 2010, NEUROLOGY, V74, P558, DOI 10.1212/WNL.0b013e3181cff5d5; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; Maxwell WL, 2006, J NEUROPATH EXP NEUR, V65, P478, DOI 10.1097/01.jnen.0000229241.28619.75; Maxwell WL, 2003, J NEUROPATH EXP NEUR, V62, P272, DOI 10.1093/jnen/62.3.272; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Mayer AR, 2012, J NEUROSCI, V32, P17961, DOI 10.1523/JNEUROSCI.3379-12.2012; McAllister TW, 2010, ANN NY ACAD SCI, V1208, P46, DOI 10.1111/j.1749-6632.2010.05720.x; McCauley SR, 2011, J NEUROTRAUM, V28, P503, DOI 10.1089/neu.2010.1555; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McKinlay A, 2009, J HEAD TRAUMA REHAB, V24, P221, DOI 10.1097/HTR.0b013e3181a40590; Nelson LD, 2013, NEUROPSYCHOL REV, V23, P285, DOI 10.1007/s11065-013-9240-7; Nemati F, 2012, BEHAV BRAIN RES, V229, P168, DOI 10.1016/j.bbr.2012.01.002; Newcombe VFJ, 2013, J CEREBR BLOOD F MET, V33, P855, DOI 10.1038/jcbfm.2013.11; Oni MB, 2010, J CHILD NEUROL, V25, P976, DOI 10.1177/0883073809356034; Palacios EM, 2013, CORTEX, V49, P646, DOI 10.1016/j.cortex.2012.02.011; Pasternak O, 2009, MAGN RESON MED, V62, P717, DOI 10.1002/mrm.22055; PAUS T, 2007, UNDERST COMPLEX SYST, P463; Power JD, 2012, NEUROIMAGE, V59, P2142, DOI 10.1016/j.neuroimage.2011.10.018; Reuter M, 2012, NEUROIMAGE, V61, P1402, DOI 10.1016/j.neuroimage.2012.02.084; Ross DE, 2012, BRAIN INJURY, V26, P1500, DOI 10.3109/02699052.2012.694570; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Van Putten HP, 2005, J NEUROTRAUM, V22, P857; Warner MA, 2010, ARCH NEUROL-CHICAGO, V67, P1336, DOI 10.1001/archneurol.2010.149; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Wu TC, 2010, J NEUROTRAUM, V27, P303, DOI 10.1089/neu.2009.1110; Xu S, 2011, J NEUROTRAUM, V28, P2091, DOI 10.1089/neu.2010.1739; Yang Z, 2012, J NEUROTRAUM, V29, P2124, DOI 10.1089/neu.2012.2395; Yeates KO, 2012, ARCH PEDIAT ADOL MED, V166, P615, DOI 10.1001/archpediatrics.2011.1082; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhou YX, 2013, RADIOLOGY, V267, P880, DOI 10.1148/radiol.13122542; Zhuo JC, 2012, NEUROIMAGE, V59, P467, DOI 10.1016/j.neuroimage.2011.07.050	56	35	35	0	14	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY 15	2015	32	10					723	730		10.1089/neu.2014.3534			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CH3ZP	WOS:000353970200007	25313896				2021-06-18	
J	Collins, JM; King, AE; Woodhouse, A; Kirkcaldie, MTK; Vickers, JC				Collins, Jessica M.; King, Anna E.; Woodhouse, Adele; Kirkcaldie, Matthew T. K.; Vickers, James C.			The effect of focal brain injury on beta-amyloid plaque deposition, inflammation and synapses in the APP/PS1 mouse model of Alzheimer's disease	EXPERIMENTAL NEUROLOGY			English	Article						Brain injury; Alzheimer's disease; Beta-amyloid; APP/PS1; Microglia; Synapses	A-BETA; HEAD-INJURY; TRANSGENIC MICE; GLIAL-CELLS; METALLOTHIONEIN EXPRESSION; PROTEIN DEPOSITION; PRECURSOR PROTEINS; RAPID APPEARANCE; RISK-FACTOR; ASTROCYTES	Traumatic brain injury is a risk factor for Alzheimer's disease (AD), however the effect of such neural damage on the onset and progression of beta-amyloid (A beta) plaque pathology is not well understood. This study utilized an in vivo model of focal brain injury to examine how localized damage may acutely affect the onset and progression of A beta plaque deposition as well as inflammatory and synaptic changes, in the APP/PS1 (APP(SWE), PSEN1dE9) transgenic model of AD relative to wild-type (Wt) mice. Acute focal brain injury in 3- and 9-month-old APP/PS1 and Wt mice was induced by insertion of a needle into the somatosensory neocortex, as compared to sham surgery, and examined at 24 h and 7 d post-injury (PI). Focal brain injury did not induce thioflavine-S stained or (pan-A beta antibody) MOAB-2-labeled plaques at either 24 h or 7 d PI in 3-month-old APP/PS1 mice or Wt mice. Nine-month-old APP/PS1 mice demonstrate cortical A beta plaques but focal injury had no statistically significant (p > 0.05) effect on thioflavine-S or MOAB-2 plaque load surrounding the injury site at 24 h PI or 7 d PI. There was a significant (p < 0.001) increase in cross-sectional cortical area occupied by lba-1 positive microglia in injured mice compared to sham animals, however this response did not differ between APP/PS1 and Wt mice (p > 0.05). For both Wt and APP/PS1 mice alike, synaptophysin puncta near the injury site were significantly reduced 24 h PI (compared to sites distant to the injury and the corresponding area in sham mice; p < 0.01), but not after 7 d PI (p > 0.05). There was no significant effect of genotype on this response (p > 0.05). These results indicate that focal brain injury and the associated microglial response do not acutely alter A beta plaque deposition in the APP/PS1 mouse model. Furthermore the current study demonstrated that the brains of both Wt and APP/PS1 mice are capable of recovering lost synaptophysin immunoreactivity post-injury, the latter in the presence of A beta plaque pathology that causes synaptic degeneration. (C) 2015 Elsevier Inc. All rights reserved.	[Collins, Jessica M.; King, Anna E.; Woodhouse, Adele; Kirkcaldie, Matthew T. K.; Vickers, James C.] Univ Tasmania, Wicking Dementia Res & Educ Ctr, Hobart, Tas 7001, Australia; [Kirkcaldie, Matthew T. K.; Vickers, James C.] Univ Tasmania, Sch Med, Hobart, Tas 7001, Australia	Collins, JM (corresponding author), Univ Tasmania, Wicking Dementia Res & Educ Ctr, Private Bag 34, Hobart, Tas 7001, Australia.	jessica.Collins@utas.edu.au	Kirkcaldie, Matthew TK/J-4418-2012; King, Anna/J-7927-2014; Vickers, James C/J-7464-2014	Kirkcaldie, Matthew TK/0000-0003-3285-0168; King, Anna/0000-0003-1792-0965; Vickers, James C/0000-0001-5671-4879; Collins, Jessica/0000-0002-1938-2470; Woodhouse, Adele/0000-0002-4246-7624	JO and JR Wicking Trust	This study was funded by JO and JR Wicking Trust.	Blizzard CA, 2013, J NEUROTRAUM, V30, P1908, DOI 10.1089/neu.2013.2850; Blizzard CA, 2011, CEREB CORTEX, V21, P281, DOI 10.1093/cercor/bhq091; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Calhoun ME, 1996, J NEUROCYTOL, V25, P821, DOI 10.1007/BF02284844; Chung RS, 2007, CELL MOL LIFE SCI, V64, P2716, DOI 10.1007/s00018-007-7267-8; Chung RS, 2008, J BIOL CHEM, V283, P15349, DOI 10.1074/jbc.M708446200; Chung RS, 2004, J NEUROCHEM, V88, P454, DOI 10.1046/j.1471-4159.2003.02193.x; Chung RS, 2003, J NEUROSCI, V23, P3336; Dickson TC, 2001, NEUROSCIENCE, V105, P99, DOI 10.1016/S0306-4522(01)00169-5; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Funato H, 1998, AM J PATHOL, V152, P983; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GOLDSTEIN ME, 1983, P NATL ACAD SCI-BIOL, V80, P3101, DOI 10.1073/pnas.80.10.3101; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; HARDY J, 1991, TRENDS PHARMACOL SCI, V12, P383, DOI 10.1016/0165-6147(91)90609-V; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Jankowsky JL, 2001, BIOMOL ENG, V17, P157, DOI 10.1016/S1389-0344(01)00067-3; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Katsouri L, 2015, NEUROBIOL AGING, V36, P821, DOI 10.1016/j.neurobiolaging.2014.10.004; King CE, 2001, NEUROPATH APPL NEURO, V27, P115, DOI 10.1046/j.1365-2990.2001.00317.x; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Laurer HL, 2000, EUR J TRAUMA, V26, P95, DOI DOI 10.1007/S000680050007; Lindgren M, 2010, FEBS J, V277, P1380, DOI 10.1111/j.1742-4658.2010.07571.x; Meyer-Luehmann M, 2008, NATURE, V451, P720, DOI 10.1038/nature06616; Mitew S, 2013, NEUROBIOL AGING, V34, P2341, DOI 10.1016/j.neurobiolaging.2013.04.010; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Murai H, 1998, J COMP NEUROL, V392, P428, DOI 10.1002/(SICI)1096-9861(19980323)392:4<428::AID-CNE2>3.0.CO;2-2; Nagele RG, 2004, NEUROBIOL AGING, V25, P663, DOI 10.1016/j.neurobiolaging.2004.01.007; Nakagawa Y, 1999, J COMP NEUROL, V411, P390; Nakagawa Y, 2000, EXP NEUROL, V163, P244, DOI 10.1006/exnr.2000.7375; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; OTSUKA N, 1991, BRAIN RES, V568, P335, DOI 10.1016/0006-8993(91)91422-W; Perez SE, 2013, J COMP NEUROL, V521, P4318, DOI 10.1002/cne.23428; Pierce JES, 1996, J NEUROSCI, V16, P1083; PIKE CJ, 1995, EXP NEUROL, V132, P172, DOI 10.1016/0014-4886(95)90022-5; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; SELKOE DJ, 1989, ANNU REV NEUROSCI, V12, P463, DOI 10.1146/annurev.neuro.12.1.463; Simard AR, 2006, NEURON, V49, P489, DOI 10.1016/j.neuron.2006.01.022; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; Streit WJ, 2004, J NEUROSCI RES, V77, P1, DOI 10.1002/jnr.20093; Tran HT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025475; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Verkhratsky A, 2010, NEUROTHERAPEUTICS, V7, P399, DOI 10.1016/j.nurt.2010.05.017; Wegiel J, 2000, ACTA NEUROPATHOL, V100, P356, DOI 10.1007/s004010000199; Winton MJ, 2011, J NEUROSCI, V31, P7691, DOI 10.1523/JNEUROSCI.6637-10.2011; Woodhouse A, 2009, NEUROBIOL AGING, V30, P864, DOI 10.1016/j.neurobiolaging.2007.09.003; Wyss-Coray T, 2003, NAT MED, V9, P453, DOI 10.1038/nm838; Youmans KL, 2012, J BIOL CHEM, V287, P41774, DOI 10.1074/jbc.M112.407957; Youmans KL, 2012, MOL NEURODEGENER, V7, DOI 10.1186/1750-1326-7-8; Zhao W, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00210; Zhao WJ, 2014, HUM MOL GENET, V23, P1365, DOI 10.1093/hmg/ddt525	55	35	36	1	21	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	MAY	2015	267						219	229		10.1016/j.expneurol.2015.02.034			11	Neurosciences	Neurosciences & Neurology	CH1AZ	WOS:000353754800021	25747037				2021-06-18	
J	Liu, H; Wang, WM; Cheng, F; Yuan, Q; Yang, J; Hu, J; Ren, GH				Liu, Hua; Wang, Wenming; Cheng, Feng; Yuan, Qiang; Yang, Jian; Hu, Jin; Ren, Guanghui			External Ventricular Drains versus Intraparenchymal Intracranial Pressure Monitors in Traumatic Brain Injury: A Prospective Observational Study	WORLD NEUROSURGERY			English	Article						Intracranial pressure monitoring type; Neurological outcome; Traumatic brain injury	GUIDELINES; MANAGEMENT; PLACEMENT; OUTCOMES; CARE	BACKGROUND: Intracranial pressure (ICP) monitoring is the standard of care for patients with traumatic brain injury (TBI) and is used frequently. However, the efficacy of treatment based on the type of ICP monitor used for improving patient outcome has not been assessed prospectively. This study explores whether the type of ICP monitoring device used affects the neurologic outcomes of patients with TBI. METHODS: A prospective, observational study was conducted in 122 patients with TBI >= 13 years old with indications for monitoring who were being treated in neurosurgical intensive care units between January 2009 and December 2012. All enrolled patients required monitoring randomly using an external ventricular drain (EVD) or intraparenchymal fiberoptic monitor (IPM). Patients were placed into 2 groups depending on the type of monitoring device. Clinically relevant outcomes, refractory intracranial hypertension, survival rates, and devicerelated complications were compared between the 2 groups. RESULTS: There was a significant between-group difference in the Glasgow Outcome Scale score 6 months after injury, which was the primary outcome. Refractory intracranial hypertension was diagnosed in 44 of 122 patients, and patients monitored using IPM had a higher percentage of refractory intracranial hypertension (51.7% vs. 21.0%, P < 0.001). The 1-month survival rate was 90.3% in the EVD group and 76.7% in the IPM group (log-rank test, P = 0.04), and patients managed with EVDs had a significantly higher 6-month postinjury survival rate compared with patients treated with IPMs (88.7% vs. 68.3%, log-rank test, P = 0.006). There was no statistically significant difference between the groups in device-related complications (P = 0.448). CONCLUSIONS: Device selection for ICP monitoring provides prognostic discrimination, and use of EVDs may have a bigger advantage in controlling refractory intracranial hypertension. Based on our findings, we recommend routine placement of an EVD in patients with TBI, unless only parenchymal-type monitoring is available.	[Liu, Hua; Wang, Wenming; Cheng, Feng; Yang, Jian; Ren, Guanghui] Jiangsu Univ, Peoples Hosp Kunshan 1, Dept Neurosurg, Suzhou, Peoples R China; [Yuan, Qiang; Hu, Jin] Fudan Univ, Huashan Hosp, Dept Neurosurg, Shanghai 200433, Peoples R China	Liu, H (corresponding author), Jiangsu Univ, Peoples Hosp Kunshan 1, Dept Neurosurg, Suzhou, Peoples R China.	wacilii@163.com					Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Camacho EF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0050708; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; Dash PK, 2010, NEUROTHERAPEUTICS, V7, P100, DOI 10.1016/j.nurt.2009.10.019; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; Guyot LL, 1998, ACT NEUR S, V71, P47; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Jagannathan J, 2008, J NEUROSURG-PEDIATR, V2, P240, DOI 10.3171/PED.2008.2.10.240; Kasotakis G, 2012, J AM COLL SURGEONS, V214, P950, DOI 10.1016/j.jamcollsurg.2012.03.004; Khan SH, 1998, ACT NEUR S, V71, P50; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Mauritz W, 2008, INTENS CARE MED, V34, P1208, DOI 10.1007/s00134-008-1079-7; Mehta A, 2010, DEV NEUROSCI-BASEL, V32, P413, DOI 10.1159/000316804; NORTH B, 1986, NEUROSURGERY, V18, P730, DOI 10.1227/00006123-198606000-00009; O'Neill BR, 2008, SURG NEUROL, V70, P268, DOI 10.1016/j.surneu.2007.05.007; Park YG, 2011, J KOREAN NEUROSURG S, V50, P317, DOI 10.3340/jkns.2011.50.4.317; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Shafi S, 2008, J TRAUMA, V64, P335, DOI 10.1097/TA.0b013e31815dd017; Stein SC, 2010, J NEUROSURG, V112, P1105, DOI 10.3171/2009.8.JNS09738; TEASDALE G, 1974, LANCET, V2, P81; van Mourik MSM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022846; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	23	35	39	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	MAY	2015	83	5					794	800		10.1016/j.wneu.2014.12.040			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	CI2FS	WOS:000354561500034	25541084				2021-06-18	
J	Neumann, D; Babbage, DR; Zupan, B; Willer, B				Neumann, Dawn; Babbage, Duncan R.; Zupan, Barbra; Willer, Barry			A Randomized Controlled Trial of Emotion Recognition Training After Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						affect; emotion recognition; randomized controlled trial; traumatic brain injury; treatment	FACIAL AFFECT RECOGNITION; PERCEPTION DEFICITS; NEUROPSYCHIATRIC INVENTORY; NONVERBAL-COMMUNICATION; INDIVIDUAL-DIFFERENCES; EMPATHY; DEMENTIA; ABILITY; MIND	Objective: To examine the effectiveness of 2 affect recognition interventions (Faces and Stories) in people with a traumatic brain injury. Setting: Postacute rehabilitation facilities. Participants: A total of 203 participants with moderate to severe traumatic brain injury were screened; 71 were eligible and randomized to the Faces (n = 24), Stories (n = 23), and Control interventions (n = 24). Participants were an average of 39.8 years of age and 10.3 years postinjury; 74% of participants were male. Design: Randomized controlled trial with immediate, 3-month, and 6-month follow-up posttests. Interventions were 9 hours of computer-based training with a therapist. Measures: Diagnostic Assessment of Nonverbal Accuracy 2-Adult Faces; Emotional Inference From Stories Test; Empathy (Interpersonal Reactivity Index); and Irritability and Aggression (Neuropsychiatric Inventory). Results: The Faces Intervention did significantly better than the Control Intervention on the Diagnostic Assessment of Nonverbal Accuracy 2-Adult Faces (P = .031) posttreatment; no time effect or group interaction was observed. No other significant differences were noted for the Faces Intervention. No significant differences were observed between the Stories and the Control Interventions; however, a significant time effect was found for the Emotional Inference From Stories Test. Conclusion: The Faces Intervention effectively improved facial affect recognition in participants with chronic post-traumatic brain injury, and changes were maintained for 6 months. Future work should focus on generalizing this skill to functional behaviors.	[Neumann, Dawn] Indiana Univ Sch Med, Dept Phys Med & Rehabil, Indianapolis, IN 46202 USA; [Neumann, Dawn] Rehabil Hosp Indiana, Indianapolis, IN 46254 USA; [Babbage, Duncan R.] Auckland Univ Technol, Ctr Person Ctr Res, Auckland, New Zealand; [Zupan, Barbra] Brock Univ, Dept Appl Linguist, St Catharines, ON L2S 3A1, Canada; [Willer, Barry] SUNY Buffalo, Dept Psychiat, Sch Med, Buffalo, NY 14260 USA	Neumann, D (corresponding author), Rehabil Hosp Indiana, 4141 Shore Dr, Indianapolis, IN 46254 USA.	dmneuman@iupui.edu		Barbra, Zupan/0000-0002-4603-333X; Babbage, Duncan/0000-0002-9259-9246			ALBERT ML, 1973, NEUROLOGY, V23, P658, DOI 10.1212/WNL.23.6.658; Andersen PA, 1998, HDB COMMUNICATION EM, P29; Babbage DR, 2011, NEUROPSYCHOLOGY, V25, P277, DOI 10.1037/a0021908; Beck A. T., 1996, BECK DEPRESSION INVE, VII; Bibby H, 2005, NEUROPSYCHOLOGIA, V43, P99, DOI 10.1016/j.neuropsychologia.2004.04.027; Bornhofen C, 2008, J INT NEUROPSYCH SOC, V14, P511, DOI 10.1017/S1355617708080703; Bornhofen C, 2008, J HEAD TRAUMA REHAB, V23, P103, DOI 10.1097/01.HTR.0000314529.22777.43; Bornhofen C, 2008, NEUROPSYCHOL REHABIL, V18, P22, DOI 10.1080/09602010601061213; Bowers D., 1991, FLORIDA AFFECT BATTE; Braun C M, 1989, Brain Inj, V3, P5, DOI 10.3109/02699058909008068; Brookshire R, 1993, DISCOURSE COMPREHENS, P105; Ciurli P, 2011, J HEAD TRAUMA REHAB, V26, P116, DOI 10.1097/HTR.0b013e3181dedd0e; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; DAVIS MH, 1983, J PERS SOC PSYCHOL, V44, P113, DOI 10.1037/0022-3514.44.1.113; de Sousa A, 2011, CORTEX, V47, P526, DOI 10.1016/j.cortex.2010.02.004; de Sousa A, 2010, NEUROPSYCHOLOGIA, V48, P3585, DOI 10.1016/j.neuropsychologia.2010.08.008; Decety J, 2006, THESCIENTIFICWORLDJO, V6, P1146, DOI 10.1100/tsw.2006.221; Driscoll DM, 2011, J NEUROTRAUM, V28, P319, DOI 10.1089/neu.2010.1523; Dywan JRR, 1995, J INT NEUROPSYCHOL S, V1; Ferstl EC, 2005, J COGNITIVE NEUROSCI, V17, P724, DOI 10.1162/0898929053747658; Guercio JM, 2004, BRAIN INJURY, V18, P593, DOI 10.1080/02699050310001646116; Kilmer RP, 2006, REHABIL PSYCHOL, V51, P232, DOI 10.1037/0090-5550.51.3.232; Knox L, 2009, BRAIN COGNITION, V69, P442, DOI 10.1016/j.bandc.2008.09.009; Masanic CA, 2001, ARCH PHYS MED REHAB, V82, P896, DOI 10.1053/apmr.2001.23833; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; McIntire KA, 1999, N AM J PSYCHOL, V1, P261; Mehrabian A., 1981, SILENT MESSAGES IMPL; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; Munro BH, 2004, STAT METHODS HLTH CA, V1; Neumann D, 2014, J HEAD TRAUMA REHAB, V29, pE18, DOI 10.1097/HTR.0b013e31827fb0b5; Neumann D, 2012, ARCH PHYS MED REHAB, V93, P1414, DOI 10.1016/j.apmr.2012.03.009; NOWICKI S, 1993, J SOC PSYCHOL, V133, P749, DOI 10.1080/00224545.1993.9713934; NOWICKI S, 1994, J NONVERBAL BEHAV, V18, P9, DOI 10.1007/BF02169077; Planalp S, 1996, COGNITION EMOTION, V10, P137, DOI 10.1080/026999396380303; Radice-Neumann D, 2007, BRAIN INJURY, V21, P807, DOI 10.1080/02699050701504281; Radice-Neumann D, 2009, J HEAD TRAUMA REHAB, V24, P313, DOI 10.1097/HTR.0b013e3181b09160; Rao V, 2010, J NEUROPSYCH CLIN N, V22, P166, DOI 10.1176/appi.neuropsych.22.2.166; RIGGIO RE, 1989, PERS INDIV DIFFER, V10, P93, DOI 10.1016/0191-8869(89)90184-0; Shamay-Tsoory SG, 2004, J CLIN EXP NEUROPSYC, V26, P1113, DOI 10.1080/13803390490515531; Shamay-Tsoory SG, 2005, COGN BEHAV NEUROL, V18, P55, DOI 10.1097/01.wnn.0000152228.90129.99; Spell LA, 2000, J NONVERBAL BEHAV, V24, P285, DOI 10.1023/A:1006675230193; Spikman JM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065581; Yim J, 2013, BRAIN INJURY, V27, P1155, DOI 10.3109/02699052.2013.804203; YIRMIYA N, 1992, CHILD DEV, V63, P150, DOI 10.1111/j.1467-8624.1992.tb03603.x; Zupan B., 2009, DEP APPL LING RES DA; Zupan B, 2014, J HEAD TRAUMA REHAB, V29, pE1, DOI 10.1097/HTR.0b013e31829dded6; Zupan B, 2009, J COMMUN DISORD, V42, P1, DOI 10.1016/j.jcomdis.2008.06.001	47	35	36	3	30	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2015	30	3					E12	E23		10.1097/HTR.0000000000000054			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	CH8PJ	WOS:000354298100002	24842590				2021-06-18	
J	Panenka, WJ; Lange, RT; Bouix, S; Shewchuk, JR; Heran, MKS; Brubacher, JR; Eckbo, R; Shenton, ME; Iverson, GL				Panenka, William J.; Lange, Rael T.; Bouix, Sylvain; Shewchuk, Jason R.; Heran, Manraj K. S.; Brubacher, Jeffrey R.; Eckbo, Ryan; Shenton, Martha E.; Iverson, Grant L.			Neuropsychological Outcome and Diffusion Tensor Imaging in Complicated versus Uncomplicated Mild Traumatic Brain Injury	PLOS ONE			English	Article							POST-CONCUSSION SYNDROME; COMPUTED-TOMOGRAPHY; HEAD-INJURY; AXONAL INJURY; MODERATE; CT; PREDICTION; ASSOCIATION; SYMPTOMS; CHILDREN	This study examined whether intracranial neuroimaging abnormalities in those with mild traumatic brain injury (MTBI) (i.e., "complicated" MTBIs) are associated with worse subacute outcomes as measured by cognitive testing, symptom ratings, and/or diffusion tensor imaging (DTI). We hypothesized that (i) as a group, participants with complicated MTBIs would report greater symptoms and have worse neurocognitive outcomes than those with uncomplicated MTBI, and (ii) as a group, participants with complicated MTBIs would show more Diffusion Tensor Imaging (DTI) abnormalities. Participants were 62 adults with MTBIs (31 complicated and 31 uncomplicated) who completed neurocognitive testing, symptom ratings, and DTI on a 3T MRI scanner approximately 6-8 weeks post injury. There were no statistically significant differences between groups on symptom ratings or on a broad range of neuropsychological tests. When comparing the groups using tract-based spatial statistics for DTI, no significant difference was found for axial diffusivity or mean diffusivity. However, several brain regions demonstrated increased radial diffusivity (purported to measure myelin integrity), and decreased fractional anisotropy in the complicated group compared with the uncomplicated group. Finally, when we extended the DTI analysis, using a multivariate atlas based approach, to 32 orthopedic trauma controls (TC), the findings did not reveal significantly more areas of abnormal DTI signal in the complicated vs. uncomplicated groups, although both MTBI groups had a greater number of areas with increased radial diffusivity compared with the trauma controls. This study illustrates that macrostructural neuroimaging changes following MTBI are associated with measurable changes in DTI signal. Of note, however, the division of MTBI into complicated and uncomplicated subtypes did not predict worse clinical outcome at 6-8 weeks post injury.	[Panenka, William J.; Lange, Rael T.; Iverson, Grant L.] Univ British Columbia, Dept Psychiat, Vancouver, BC V5Z 1M9, Canada; [Lange, Rael T.] Walter Reed Natl Mil Med Ctr, Def & Vet Brain Injury Ctr, Bethesda, MD USA; [Bouix, Sylvain; Eckbo, Ryan; Shenton, Martha E.] Harvard Univ, Sch Med, Brigham Womens Hosp, Psychiat Neuroimaging Lab, Boston, MA USA; [Shewchuk, Jason R.; Heran, Manraj K. S.] Univ British Columbia, Dept Radiol, Vancouver, BC V5Z 1M9, Canada; [Brubacher, Jeffrey R.] Univ British Columbia, Dept Emergency Med, Vancouver, BC V5Z 1M9, Canada; [Shenton, Martha E.] VA Boston Healthcare Syst, Brockton, MA USA; [Iverson, Grant L.] Harvard Univ, Sch Med, Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Boston, MA USA; [Iverson, Grant L.] Red Sox Fdn, Boston, MA USA; [Iverson, Grant L.] Massachusetts Gen Hosp, Home Base Program, Boston, MA 02114 USA	Panenka, WJ (corresponding author), Univ British Columbia, Dept Psychiat, Vancouver, BC V5Z 1M9, Canada.	wpanenka@mail.ubc.ca	Shenton, Martha/V-8780-2019	Panenka, William/0000-0001-7143-6512; Iverson, Grant/0000-0001-7348-9570; Brubacher, Jeffrey/0000-0002-4866-4231	Canadian Institute of Health ResearchCanadian Institutes of Health Research (CIHR) [200903MOP-200377-BSB-CAAA-161276]; INTRuST Posttraumatic Stress Disorder and Traumatic Brain Injury Clinical Consortium - Department of Defense Psychological Health/Traumatic Brain Injury Research Program [X81XWH-07-CC-CSDoD]	Primary funding for this study was provided by the Canadian Institute of Health Research (200903MOP-200377-BSB-CAAA-161276); provided to RTL as PI). MES and GLI note that this work was supported in part by the INTRuST Posttraumatic Stress Disorder and Traumatic Brain Injury Clinical Consortium funded by the Department of Defense Psychological Health/Traumatic Brain Injury Research Program (X81XWH-07-CC-CSDoD). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anstey KJ, 2009, AM J GERIAT PSYCHIAT, V17, P542, DOI 10.1097/JGP.0b013e3181a2fd07; Aoki Y, 2012, J NEUROL NEUROSUR PS, V83, P870, DOI 10.1136/jnnp-2012-302742; Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Bay Esther H, 2009, Res Theory Nurs Pract, V23, P42; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Beauchamp MH, 2013, CORTEX, V49, P591, DOI 10.1016/j.cortex.2012.08.015; Beck A.T., 1993; Beck AT., 1996, BECK DEPRESSION INVE, V2; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Borgaro SR, 2003, BRAIN INJURY, V17, P189, DOI 10.1080/0269905021000013183; Brandstack N, 2013, RADIOLOGY, V267, P231, DOI 10.1148/radiol.12112570; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Dagher JH, 2013, BRAIN INJURY, V27, P189, DOI 10.3109/02699052.2012.729288; de Guise E, 2010, CLIN NEUROPSYCHOL, V24, P1113, DOI 10.1080/13854046.2010.506199; Fay TB, 2010, J INT NEUROPSYCH SOC, V16, P94, DOI 10.1017/S1355617709991007; Gardner A, 2012, J NEUROTRAUM, V29, P2521, DOI 10.1089/neu.2012.2628; Gering DT, 2001, J MAGN RESON IMAGING, V13, P967, DOI 10.1002/jmri.1139; Halbauer JD, 2009, J REHABIL RES DEV, V46, P757, DOI 10.1682/JRRD.2008.08.0119; Hanlon RE, 1999, BRAIN INJURY, V13, P873; Hiekkanen H, 2009, BRAIN INJURY, V23, P396, DOI 10.1080/02699050902926259; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Hua K, 2008, NEUROIMAGE, V39, P336, DOI 10.1016/j.neuroimage.2007.07.053; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; Husson EC, 2010, J REHABIL MED, V42, P425, DOI 10.2340/16501977-0566; Iverson G.L., 2007, BRAIN INJURY MED PRI, P373; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 1999, CLIN NEUROPSYCHOL, V13, P437, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT437; IVERSON GL, 2012, REHABIL RES PRACT, V2012, DOI DOI 10.1155/2012/415740; Iverson GL, 2006, BRAIN INJURY, V20, P1335, DOI 10.1080/02699050601082156; Iverson GL, 2013, BRAIN INJURY MEDICINE: PRINCIPLES AND PRACTICE, SECOND EDITION, P470; Iverson GL, 2011, BRAIN INJURY, V25, P1325, DOI 10.3109/02699052.2011.608409; Kaddurah-Daouk R, 2007, MOL PSYCHIATR, V12, P934, DOI 10.1038/sj.mp.4002000; Kashluba S, 2008, ARCH PHYS MED REHAB, V89, P904, DOI 10.1016/j.apmr.2007.12.029; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kumar RG, 2014, AM J PHYS MED REHAB, V93, P687, DOI 10.1097/PHM.0000000000000077; Kurca E, 2006, NEURORADIOLOGY, V48, P661, DOI 10.1007/s00234-006-0109-9; Landman BA, 2007, NEUROIMAGE, V36, P1123, DOI 10.1016/j.neuroimage.2007.02.056; Lange RT, 2014, J NEUROTRAUM, V31, P198, DOI 10.1089/neu.2013.2866; Lange RT, 2012, ARCH CLIN NEUROPSYCH, V27, P480, DOI 10.1093/arclin/acs059; Lange RT, 2012, J HEAD TRAUMA REHAB, V27, P188, DOI 10.1097/HTR.0b013e318217f0ad; Lange RT, 2009, BRAIN INJURY, V23, P83, DOI 10.1080/02699050802635281; Lange RT, 2005, J CLIN EXP NEUROPSYC, V27, P897, DOI 10.1080/1380339049091290; Lannsjo M, 2013, EUR J NEUROL, V20, P124, DOI 10.1111/j.1468-1331.2012.03813.x; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; Levin HS, 2008, J NEUROSURG-PEDIATR, V1, P461, DOI 10.3171/PED/2008/1/6/461; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Matthews SC, 2011, NEUROIMAGE, V54, pS69, DOI 10.1016/j.neuroimage.2010.04.269; Max JE, 2012, J NEUROPSYCH CLIN N, V24, P427, DOI 10.1176/appi.neuropsych.12060149; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; Mori A, 2005, MRI ATLAS HUMAN WHIT; Muller K, 2009, NEUROSURGERY, V64, P698, DOI 10.1227/01.NEU.0000340978.42892.78; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Ono K, 2007, NEUROL MED-CHIR, V47, P291, DOI 10.2176/nmc.47.291; Pandor A, 2012, J NEUROTRAUM, V29, P707, DOI 10.1089/neu.2011.1967; Sadowski-Cron C, 2006, BRAIN INJURY, V20, P1131, DOI 10.1080/02699050600832569; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Shin SY, 2014, NAT GENET, V46, P543, DOI 10.1038/ng.2982; Silverberg ND, 2011, NEUROREHABILITATION, V29, P317, DOI 10.3233/NRE-2011-0708; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; Stern RA, 2003, NEUROPSYCHOLOGICAL A; Stulemeijer M, 2008, J NEUROL NEUROSUR PS, V79, P936, DOI 10.1136/jnnp.2007.131250; Temkin NR, 2003, J NEUROTRAUM, V20, P229, DOI 10.1089/089771503321532815; Thiruppathy SP, 2004, ACTA NEUROCHIR, V146, P1075, DOI 10.1007/s00701-004-0335-z; Tombaugh TN, 1996, TEST MEMORY MALINGER; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; Wakana S, 2007, NEUROIMAGE, V36, P630, DOI 10.1016/j.neuroimage.2007.02.049; Waljas M, 2013, J NEUROTRAUMA; White T, 2003, NAB DEMOGRAPHICALLY; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Winkler AM, 2014, NEUROIMAGE, V92, P381, DOI 10.1016/j.neuroimage.2014.01.060; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906; World Health Organization, 1992, ICD 10 INT STAT CLAS; Yeates KO, 2010, J INT NEUROPSYCH SOC, V16, P953, DOI 10.1017/S1355617710000986; Yuh EL, 2014, J NEUROTRAUM, V31, P1457, DOI 10.1089/neu.2013.3171; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783; Yurgelun-Todd DA, 2011, J HEAD TRAUMA REHAB, V26, P276, DOI 10.1097/HTR.0b013e31822251dc	85	35	35	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 27	2015	10	4							e0122746	10.1371/journal.pone.0122746			27	Multidisciplinary Sciences	Science & Technology - Other Topics	CG9SB	WOS:000353659100011	25915776	DOAJ Gold, Green Published			2021-06-18	
J	Rassovsky, Y; Levi, Y; Agranov, E; Sela-Kaufman, M; Sverdlik, A; Vakil, E				Rassovsky, Yuri; Levi, Yifat; Agranov, Eugenia; Sela-Kaufman, Michal; Sverdlik, Anna; Vakil, Eli			Predicting long-term outcome following traumatic brain injury (TBI)	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Functional outcome; Rehabilitation; Head injury; Traumatic brain injury; Cognitive reserve; Injury severity	INFORMATION-PROCESSING SPEED; SEVERE HEAD-INJURY; COGNITIVE RESERVE; INCOG RECOMMENDATIONS; LIFE-STYLE; ENVIRONMENTAL ENRICHMENT; UNITED-STATES; SEVERITY; DEMENTIA; MEMORY	Objective: Traumatic brain injury (TBI) is the most common cause of brain damage, resulting in long-term disability. The ever increasing life expectancies among TBI patients necessitate a critical examination of the factors that influence long-term outcome. Our objective was to evaluate the contribution of premorbid factors (which were identified in our previous work) and acute injury indices to long-term functioning following TBI. Method: Eighty-nine participants with moderate-to-severe TBI were evaluated at an average of 14.2 years postinjury (range: 1-53 years) with neuropsychological battery, medical examination, clinical interviews, and questionnaires. Results: TBI severity predicted cognitive, social, and daily functioning outcomes. After controlling for injury severity, preinjury intellectual functioning predicted cognitive status, as well as occupational, social, emotional, and daily functioning. Preinjury leisure activity also predicted cognitive, emotional, and daily functioning, whereas socioeconomic status failed to predict any of these variables. Conclusion: Findings offer further support for the cognitive reserve construct in explaining significant variance in TBI outcome, over and above the variance explained by injury severity.	[Rassovsky, Yuri; Levi, Yifat; Vakil, Eli] Bar Ilan Univ, Dept Psychol, IL-52900 Ramat Gan, Israel; [Rassovsky, Yuri; Vakil, Eli] Bar Ilan Univ, Leslie & Susan Gonda Goldschmied Multidisciplinar, IL-52900 Ramat Gan, Israel; [Rassovsky, Yuri] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA; [Agranov, Eugenia; Sverdlik, Anna] Chaim Sheba Med Ctr Tel Hashomer, Ramat Gan, Israel; [Agranov, Eugenia; Sverdlik, Anna] Tel Aviv Univ, Fac Med, IL-69978 Tel Aviv, Israel; [Sela-Kaufman, Michal] Acad Coll Tel Aviv Yaffo, Dept Behav Sci, Tel Aviv, Israel	Rassovsky, Y (corresponding author), Bar Ilan Univ, Dept Psychol, IL-52900 Ramat Gan, Israel.	yurir@biu.ac.il		Rassovsky, Yuri/0000-0002-6362-9944	Israeli Ministry of Defense, Rehabilitation Department; National Institute for the Rehabilitation of the Brain Injured	This work was supported by the Israeli Ministry of Defense, Rehabilitation Department, and the National Institute for the Rehabilitation of the Brain Injured.	Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; Bazarian JJ, 2009, J HEAD TRAUMA REHAB, V24, P439, DOI 10.1097/HTR.0b013e3181c15600; Bigler E. D, 2006, COGNITIVE RESERVE TH; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Chamberlain M. A., 1995, TRAUMATIC BRAIN INJU, P3; CLIFTON GL, 1992, NEUROSURGERY, V31, P975, DOI 10.1227/00006123-199211000-00028; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; DEROGATIS LR, 1976, BRIT J PSYCHIAT, V128, P280, DOI 10.1192/bjp.128.3.280; Derogatis LR, 1975, BRIEF SYMPTOM INVENT; Dik MG, 2003, J CLIN EXP NEUROPSYC, V25, P643, DOI 10.1076/jcen.25.5.643.14583; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Farmer JE, 2002, DEV NEUROPSYCHOL, V22, P455, DOI 10.1207/S15326942DN2202_2; Felmingham KL, 2001, ARCH PHYS MED REHAB, V82, P435, DOI 10.1053/apmr.2001.21985; Fratiglioni L, 2004, LANCET NEUROL, V3, P343, DOI 10.1016/S1474-4422(04)00767-7; Fritsch T, 2007, GERONTOLOGIST, V47, P307, DOI 10.1093/geront/47.3.307; Gollaher K, 1998, BRAIN INJURY, V12, P255, DOI 10.1080/026990598122557; Grafman J., 1989, PREOPERATIVE EVENTS, P277; Grauwmeijer E, 2014, ARCH PHYS MED REHAB, V95, P1268, DOI 10.1016/j.apmr.2014.02.002; Green REA, 2008, J CLIN EXP NEUROPSYC, V30, P163, DOI 10.1080/13803390701300524; Heaton SK, 1993, WISCONSIN CARD SORTI; Hoofien D, 2002, BRAIN INJURY, V16, P9, DOI 10.1080/02699050110088227; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Karver CL, 2014, CHILD NEUROPSYCHOL, V20, P343, DOI 10.1080/09297049.2013.796918; Kave G, 2005, J CLIN EXP NEUROPSYC, V27, P690, DOI 10.1080/13803390490918499; Kelly DF, 1997, J NEUROSURG, V86, P633, DOI 10.3171/jns.1997.86.4.0633; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kesler SR, 2003, APPL NEUROPSYCHOL, V10, P153, DOI 10.1207/S15324826AN1003_04; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; KURTZKE JF, 1984, ANN NEUROL, V16, P265, DOI 10.1002/ana.410160302; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Levi Y, 2013, J INT NEUROPSYCH SOC, V19, P664, DOI 10.1017/S1355617713000192; Levin Harvey S, 1987, NEUROBEHAVIORAL RECO; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Ma VY, 2014, ARCH PHYS MED REHAB, V95, P986, DOI 10.1016/j.apmr.2013.10.032; Macmillan PJ, 2002, BRAIN INJURY, V16, P41, DOI 10.1080/0269905011008812; Manly JJ, 2005, J GERIATR PSYCH NEUR, V18, P213, DOI 10.1177/0891988705281868; MELAMED S, 1985, SCAND J REHABIL MED, P129; Mortimer JA, 2003, J CLIN EXP NEUROPSYC, V25, P671, DOI 10.1076/jcen.25.5.671.14584; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; Pham TM, 1999, BEHAV BRAIN RES, V103, P63, DOI 10.1016/S0166-4328(99)00019-4; Pham TM, 2002, PHARMACOL BIOCHEM BE, V73, P167, DOI 10.1016/S0091-3057(02)00783-9; Ponsford J, 2014, J HEAD TRAUMA REHAB, V29, P321, DOI 10.1097/HTR.0000000000000072; Qiu CX, 2001, ARCH NEUROL-CHICAGO, V58, P2034, DOI 10.1001/archneur.58.12.2034; Rassovsky Y, 2006, J CLIN EXP NEUROPSYC, V28, P581, DOI 10.1080/13803390500434474; Rassovsky Y, 2006, J CLIN EXP NEUROPSYC, V28, P567, DOI 10.1080/13803390500434466; Rey A, 1964, EXAMEN CLIN PSYCHOL; Roe A., 1956, PSYCHOL OCCUPATIONS, P76; Ropacki MT, 2003, ARCH CLIN NEUROPSYCH, V18, P643, DOI 10.1016/S0887-6177(02)00153-1; Rutter M, 1983, DEV NEUROPSYCHIATRY, P83; SALAZAR AM, 1995, NEUROSURG CLIN N AM, V6, P715; Salthouse TA, 2006, PERSPECT PSYCHOL SCI, V1, P68, DOI 10.1111/j.1745-6916.2006.00005.x; Saltychev M, 2013, BRAIN INJURY, V27, P1516, DOI 10.3109/02699052.2013.831131; Sandry J, 2015, J NEUROL, V262, P59, DOI 10.1007/s00415-014-7523-4; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; Satz P, 2011, J CLIN EXP NEUROPSYC, V33, P121, DOI 10.1080/13803395.2010.493151; Scarmeas N, 2003, J CLIN EXP NEUROPSYC, V25, P625, DOI 10.1076/jcen.25.5.625.14576; Scarmeas N, 2001, NEUROLOGY, V57, P2236, DOI 10.1212/WNL.57.12.2236; Schneider EB, 2014, NEUROLOGY, V82, P1636, DOI 10.1212/WNL.0000000000000379; Sela-Kaufman M, 2013, J CLIN EXP NEUROPSYC, V35, P584, DOI 10.1080/13803395.2013.799123; Sherer M, 1999, BRAIN INJURY, V13, P973; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; Simpson GK, 2014, BRAIN IMPAIR, V15, P28, DOI 10.1017/BrImp.2014.7; SPETTELL CM, 1991, ARCH PHYS MED REHAB, V72, P320; Stern Y, 2002, J INT NEUROPSYCH SOC, V8, P448, DOI 10.1017/S1355617702813248; Tate RL, 1999, PSYCHOL MED, V29, P713, DOI 10.1017/S0033291799008466; Tate R, 2014, J HEAD TRAUMA REHAB, V29, P338, DOI 10.1097/HTR.0000000000000068; TEASDALE G, 1974, LANCET, V2, P81; Temkin NR, 2009, J HEAD TRAUMA REHAB, V24, P460, DOI 10.1097/HTR.0b013e3181c13413; Tucker G. J., 2005, TXB TRAUMATIC BRAIN, P309; VAKIL E, 1993, J CLIN PSYCHOL, V49, P883, DOI 10.1002/1097-4679(199311)49:6<883::AID-JCLP2270490616>3.0.CO;2-6; Vakil E, 2005, J CLIN EXP NEUROPSYC, V27, P977, DOI 10.1080/13803390490919245; Valenzuela MJ, 2008, CURR OPIN PSYCHIATR, V21, P296, DOI 10.1097/YCO.0b013e3282f97b1f; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Velikonja D, 2014, J HEAD TRAUMA REHAB, V29, P369, DOI 10.1097/HTR.0000000000000069; WARD LC, 1990, J CLIN PSYCHOL, V46, P436, DOI 10.1002/1097-4679(199007)46:4<436::AID-JCLP2270460411>3.0.CO;2-M; Wechsler D, 1997, WAIS 3 ADM SCORING M; Williams MW, 2014, REHABIL PSYCHOL, V59, P298, DOI 10.1037/a0037164; Williamson D. J. G., 1996, NEUROPSYCHOLOGY CLIN, P9, DOI [10.1037/10198-001, DOI 10.1037/10198-001]; Wilson RS, 2003, J CLIN EXP NEUROPSYC, V25, P634, DOI 10.1076/jcen.25.5.634.14572; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	82	35	36	0	17	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	APR 21	2015	37	4					354	366		10.1080/13803395.2015.1015498			13	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	CI7GP	WOS:000354931400002	25832742				2021-06-18	
J	Long, JA; Watts, LT; Chemello, J; Huang, SL; Shen, Q; Duong, TQ				Long, Justin Alexander; Watts, Lora Talley; Chemello, Jonathan; Huang, Shiliang; Shen, Qiang; Duong, Timothy Q.			Multiparametric and Longitudinal MRI Characterization of Mild Traumatic Brain Injury in Rats	JOURNAL OF NEUROTRAUMA			English	Article						behavioral assessments; diffusion tensor imaging; immunohistochemistry; TBI; controlled cortical impact; quantitative magnetic resonance imaging	DIFFUSE AXONAL INJURY; CEREBRAL-BLOOD-FLOW; IMAGING FINDINGS; NEURONAL DEGENERATION; FLUORO-JADE; PERFUSION; EDEMA; DYNAMICS; HYPOXIA; MODELS	This study reports T-2 and diffusion-tensor magnetic resonance imaging (MRI) studies of a mild open-skull, controlled cortical impact injury in rats (n=6) from 3 h to up to 14 d after traumatic brain injury (TBI). Comparison was made with longitudinal behavioral measurements and end-point histology. The impact was applied over the left primary forelimb somatosensory cortex (S1FL). The major findings were: 1) In the S1FL, T-2 increased and fractional anisotropy (FA) decreased at 3 h after TBI and gradually returned toward normal by Day 14; 2) in the S1FL, the apparent diffusion coefficient (ADC) increased at 3 h, peaked on Day 2, and gradually returned toward normal at Day 14; 3) in the corpus callosum underneath the S1FL, FA decreased at 3 h to Day 2 but returned to normal at Day 7 and 14, whereas T-2 and ADC were normal throughout; 4) heterogeneous hyperintense and hypointense T-2 map intensities likely indicated the presence of hemorrhage but were not independently verified; 5) lesion volumes defined by abnormal T-2, ADC, and FA showed similar temporal patterns, peaking around Day 2 and returning toward normal on Day 14; 6) the temporal profiles of lesion volumes were consistent with behavioral scores assessed by forelimb placement and forelimb foot fault tests; and 7) at 14 d post-TBI, there was substantial tissue recovery by MRI, which could either reflect true tissue recovery or reabsorption of edema. Histology performed 14 d post-TBI, however, showed a small cavitation and significant neuronal degeneration surrounding the cavitation in S1FL. Thus, the observed improvement of behavioral scores likely involves both functional recovery and functional compensation.	[Long, Justin Alexander; Watts, Lora Talley; Chemello, Jonathan; Huang, Shiliang; Shen, Qiang; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA; [Watts, Lora Talley] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA; [Watts, Lora Talley; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Neurol, San Antonio, TX 78229 USA; [Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, San Antonio, TX 78229 USA; [Duong, Timothy Q.] South Texas Vet Hlth Care Syst, San Antonio, TX USA	Duong, TQ (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, Dept Ophthamol, Radiol, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA.	duongt@uthscsa.edu	Shen, Qiang/B-8784-2008; Watts, Lora Talley/A-2724-2012; Duong, Tim/AAL-8357-2021	Shen, Qiang/0000-0002-4287-3403; Watts, Lora Talley/0000-0002-2337-1504; Duong, Tim/0000-0001-6403-2827	NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS45879]; TL1 grant; Clinical Translational Science Awards (CTSA) [KL2 TR001118, UL1TR000149, TL1TR001119]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA054174] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [KL2TR001118, UL1TR000149, TL1TR001119, UL1TR001120] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045879] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG019316] Funding Source: NIH RePORTER	The authors wish to thank Timothy Schallert and Theresa Jones of UT Austin for their assistance in the setup of the behavioral assays utilized in this study. This work was supported in part by NIH/NINDS R01 NS45879 (TQD), a TL1 grant (JAL) and KL2 TR001118 (LTW) via the Clinical Translational Science Awards (CTSA, parent grant UL1TR000149 and TL1TR001119). Images were generated in the Core Optical Imaging Facility which is supported by UTHSCSA, NIH/NCI P30CA54174 and NIH/NIA P01AG19316.	Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Allred RP, 2008, J NEUROSCI METH, V170, P229, DOI 10.1016/j.jneumeth.2008.01.015; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Baskin YK, 2003, J NEUROSCI METH, V129, P87, DOI 10.1016/S0165-0270(03)00212-7; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Danker JF, 2007, BRAIN RES, V1150, P217, DOI 10.1016/j.brainres.2007.02.082; Gardner A, 2012, J NEUROTRAUM, V29, P2521, DOI 10.1089/neu.2012.2628; HERNANDEZ TD, 1988, EXP NEUROL, V102, P318, DOI 10.1016/0014-4886(88)90226-9; Immonen RJ, 2009, NEUROIMAGE, V45, P1, DOI 10.1016/j.neuroimage.2008.11.022; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; Iwamoto Y, 1997, NEUROSURGERY, V40, P163, DOI 10.1097/00006123-199701000-00036; Kou ZF, 2010, J HEAD TRAUMA REHAB, V25, P267, DOI 10.1097/HTR.0b013e3181e54793; Kubin MZ, 1999, EUR J IMMUNOL, V29, P3466, DOI 10.1002/(SICI)1521-4141(199911)29:11<3466::AID-IMMU3466>3.0.CO;2-9; Lescot T, 2010, J NEUROTRAUM, V27, P85, DOI 10.1089/neu.2009.0982; Li SX, 2013, INT J LEGAL MED, V127, P159, DOI 10.1007/s00414-012-0712-8; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; Liu ZHM, 2004, MAGN RESON MED, V52, P277, DOI 10.1002/mrm.20148; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Pasco A, 2007, J NEUROTRAUM, V24, P1321, DOI 10.1089/neu.2006.0136; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Schmidt KF, 2004, J NEURO-ONCOL, V68, P207, DOI 10.1023/B:NEON.0000033364.43142.bf; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Schmued LC, 2000, TOXICOL PATHOL, V28, P91, DOI 10.1177/019262330002800111; Shen Q, 2005, J CEREBR BLOOD F MET, V25, P1265, DOI 10.1038/sj.jcbfm.9600132; Shen Q, 2004, J CEREBR BLOOD F MET, V24, P280, DOI 10.1097/01.WCB.0000110048.43905.E5; Shen Q, 2003, J CEREBR BLOOD F MET, V23, P1479, DOI 10.1097/01.WCB.0000100064.36077.03; Sicard K, 2003, J CEREBR BLOOD F MET, V23, P472, DOI 10.1097/01.WCB.0000054755.93668.20; Sicard KM, 2005, NEUROIMAGE, V25, P850, DOI 10.1016/j.neuroimage.2004.12.010; Soblosky JS, 1996, BEHAV BRAIN RES, V79, P79, DOI 10.1016/0166-4328(95)00264-2; van de Looij Y., 2012, N M R BIOMED, V25, P93; Van Putten HP, 2005, J NEUROTRAUM, V22, P857; Watts LT, 2014, J NEUROTRAUM, V31, P1063, DOI 10.1089/neu.2013.3193; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Xu S, 2011, J NEUROTRAUM, V28, P2091, DOI 10.1089/neu.2010.1739	40	35	35	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR 15	2015	32	8					598	607		10.1089/neu.2014.3563			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CF2BS	WOS:000352352900010	25203249	Green Published			2021-06-18	
J	Hutchison, MG; Comper, P; Meeuwisse, WH; Echemendia, RJ				Hutchison, Michael G.; Comper, Paul; Meeuwisse, Willem H.; Echemendia, Ruben J.			A systematic video analysis of National Hockey League (NHL) concussions, part II: how concussions occur in the NHL	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article						Concussion; Contact sports; Head injuries; Injury Prevention; Ice hockey	INJURY SURVEILLANCE SYSTEM; MENS ICE HOCKEY; DESCRIPTIVE EPIDEMIOLOGY	Background Concussions in sports are a growing cause of concern, as these injuries can have debilitating short-term effects and little is known about the potential long-term consequences. This work aims to describe how concussions occur in the National Hockey League. Methods Case series of medically diagnosed concussions for regular season games over a 3.5-year period during the 2006-2010 seasons. Digital video records were coded and analysed using a standardised protocol. Results 88% (n=174/197) of concussions involved player-to-opponent contact. 16 diagnosed concussions were a result of fighting. Of the 158 concussions that involved player-to-opponent body contact, the most common mechanisms were direct contact to the head initiated by the shoulder 42% of the time (n=66/158), by the elbow 15% (n=24/158) and by gloves in 5% of cases (n=8/158). When the results of anatomical location are combined with initial contact, almost half of these events (n=74/158) were classified as direct contact to the lateral aspect of the head. Conclusions The predominant mechanism of concussion was consistently characterised by player-to-opponent contact, typically directed to the head by the shoulder, elbow or gloves. Also, several important characteristics were apparent: (1) contact was often to the lateral aspect of the head; (2) the player who suffered a concussion was often not in possession of the puck and (3) no penalty was called on the play.	[Hutchison, Michael G.; Comper, Paul] Univ Toronto, Fac Kinesiol & Phys Educ, David L MacIntosh Sport Med Clin, Toronto, ON M5S 2W6, Canada; [Hutchison, Michael G.] St Michaels Hosp, Keenan Res Ctr, Injury Prevent Res Off, Toronto, ON M5B 1W8, Canada; [Comper, Paul] Univ Toronto, Fac Med, Grad Dept Rehabil Sci, Toronto, ON, Canada; [Meeuwisse, Willem H.] Univ Calgary, Fac Kinesiol, Hotchkiss Brain Inst, Sport Injury Prevent Res Ctr, Calgary, AB, Canada; [Echemendia, Ruben J.] Psychol & Neurobehav Associates Inc, State Coll, PA USA; [Echemendia, Ruben J.] Univ Missouri, Kansas City, MO 64110 USA	Hutchison, MG (corresponding author), Univ Toronto, Fac Kinesiol & Phys Educ, David L MacIntosh Sport Med Clin, 55 Harbord St, Toronto, ON M5S 2W6, Canada.	michael.hutchison@utoronto.ca	Echemendia, Ruben/R-6939-2019	Echemendia, Ruben/0000-0001-6116-8462	Ontario Neurotrauma Foundation (ONF); Pashby Sports Safety Fund	This study received funding by Ontario Neurotrauma Foundation (ONF) and The Pashby Sports Safety Fund. The organisations that contributed funds to the research had no role in the design of the study, the collection, analysis and interpretation of the data.	Agel J, 2007, J ATHL TRAINING, V42, P241; Agel J, 2007, J ATHL TRAINING, V42, P249; Andersen TE, 2003, BRIT J SPORT MED, V37, P226, DOI 10.1136/bjsm.37.3.226; Andersen TE, 2004, AM J SPORT MED, V32, p69S, DOI 10.1177/0363546503262023; [Anonymous], MAC OS X VERS 10 5 8; Daneshvar DH, 2011, CLIN SPORT MED, V30, P145, DOI 10.1016/j.csm.2010.09.006; ETTLINGER CF, 1995, AM J SPORT MED, V23, P531, DOI 10.1177/036354659502300503; Flik K, 2005, AM J SPORT MED, V33, P183, DOI 10.1177/0363546504267349; GERBERICH SG, 1987, CHILD NERV SYST, V3, P59, DOI 10.1007/BF00271123; Goodman D, 2001, MED SCI SPORT EXER, V33, P2004, DOI 10.1097/00005768-200112000-00005; Guskiewicz KM, 2011, EXERC SPORT SCI REV, V39, P4, DOI 10.1097/JES.0b013e318201f53e; Hutchison M, BR J SPORTS IN PRESS; Hutchison MG, 2014, BRIT J SPORT MED, V48, P125, DOI 10.1136/bjsports-2012-092059; Koh JO, 2003, BRAIN INJURY, V17, P901, DOI 10.1080/0269905031000088869; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Meaney DF, 2011, CLIN SPORT MED, V30, P19, DOI 10.1016/j.csm.2010.08.009; Meeuwisse WH, 2009, CLIN J SPORT MED, V19, P1, DOI 10.1097/JSM.0b013e3181979c1d; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; SILVER JR, 1988, SPORTS MED, V5, P328, DOI 10.2165/00007256-198805050-00005; Tommasone BA, 2006, J ATHL TRAINING, V41, P470	20	35	35	0	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	APR	2015	49	8					552	U52		10.1136/bjsports-2013-092235			5	Sport Sciences	Sport Sciences	CF4OI	WOS:000352529000013	23637116				2021-06-18	
J	Zhang, YL; Chopp, M; Meng, YL; Zhang, ZG; Doppler, E; Winter, S; Schallert, T; Mahmood, A; Xiong, Y				Zhang, Yanlu; Chopp, Michael; Meng, Yuling; Zhang, Zheng Gang; Doppler, Edith; Winter, Stefan; Schallert, Timothy; Mahmood, Asim; Xiong, Ye			Cerebrolysin improves cognitive performance in rats after mild traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						amyloid precursor protein; Cerebrolysin; cognitive function; mild closed head injury; neuroblast; neurogenesis; traumatic brain injury	AMYLOID PRECURSOR PROTEIN; GENERATED GRANULE CELLS; ODOR RECOGNITION MEMORY; ACUTE ISCHEMIC-STROKE; DOUBLE-BLIND; DENTATE GYRUS; REACTIVE ASTROCYTES; HEAD-INJURY; NEUROTROPHIC TREATMENT; FUNCTIONAL RECOVERY	OBJECT Long-term memory deficits occur after mild traumatic brain injuries (mTBIs), and effective treatment modalities are currently unavailable. Cerebrolysin, a peptide preparation mimicking the action of neurotrophic factors, has beneficial effects on neurodegenerative diseasds and brain injuries. The present study investigated the long-term effects of Cerebrolysin treatment on cognitive function in rats after mTBI. METHODS Rats subjected to closed-head mTBI were treated with saline (n = 11) or Cerebrolysin (2.5 ml/kg, n = 11) starting 24 hours after injury and then daily for 28 days. Sham animals underwent surgery without injury (n = 8). To evaluate cognitive function, the modified Morris water maze (MWM) test and a social odor based novelty recognition task were performed after mTBI. All rats were killed on Day 90 after mTBI, and brain sections were immunostained for histological analyses of amyloid precursor protein (APP), astrogliosis, neuroblasts, and neurogenesis. RESULTS Mild TBI caused long-lasting cognitive memory deficits in the MWM and social odor recognition tests up to 90 days after injury. Compared with saline treatment, Cerebrolysin treatment significantly improved both long-term spatial learning and memory in the MWM test and nonspatial recognition memory in the social odor recognition task up to 90 days after mTBI (p < 0.05). Cerebrolysin significantly increased the number of neuroblasts and promoted neurogenesi in the dentate gyrus, and it reduced APP levels and astrogliosis in the corpus callosum, cortex, dentate gyrus, CA1, and CA3 regions (p < 0.05). CONCLUSIONS These results indicate that Cerebrolysin treatment of mTBI improves long-term cognitive function, and this improvement may be partially related to decreased brain APP accumulation and astrogliosis as well as increased neuroblasts and neurogenesis.	[Zhang, Yanlu; Meng, Yuling; Mahmood, Asim; Xiong, Ye] Henry Ford Hosp, Dept Neurosurg, Detroit, MI 48202 USA; [Chopp, Michael; Zhang, Zheng Gang] Henry Ford Hosp, Dept Neurol, Detroit, MI 48202 USA; [Chopp, Michael] Oakland Univ, Dept Phys, Rochester, MN USA; [Doppler, Edith; Winter, Stefan] EVER Neuro Pharma GmbH, Clin Res & Pharmacol, Unterach, Austria; [Schallert, Timothy] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA; [Schallert, Timothy] Univ Texas Austin, Inst Neurosci, Austin, TX 78712 USA	Xiong, Y (corresponding author), Henry Ford Hlth Syst, Dept Neurosurg, E&R Bldg,Rm 3096,2799 W Grand Blvd, Detroit, MI 48202 USA.	yxiong1@hfhs.org		Xiong, Ye/0000-0001-9770-6031	EVER Neuro Pharma GmbH	This work was funded by EVER Neuro Pharma GmbH, the manufacturer of Cerebrolysin. Edith Doppler and Stefan Winter are employees of EVER Neuro Pharma GmbH in the Clinical Research and Pharmacology department.	Allegri RF, 2012, DRUG TODAY, V48, P25, DOI 10.1358/dot.2012.48(Suppl.A).1739721; Alvarez XA, 2011, EUR J NEUROL, V18, P59, DOI 10.1111/j.1468-1331.2010.03092.x; Alvarez XA, 2006, EUR J NEUROL, V13, P43, DOI 10.1111/j.1468-1331.2006.01222.x; Beaumont A, 1999, NEUROL RES, V21, P742, DOI 10.1080/01616412.1999.11741008; Bernal-Mondragon C, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-104; Bornstein N, 2012, DRUG TODAY, V48, P43, DOI 10.1358/dot.2012.48(Suppl.A).1739723; Bye N, 2011, J NEUROSCI RES, V89, P986, DOI 10.1002/jnr.22635; Chen CC, 2013, BRIT J NEUROSURG, V27, P803, DOI 10.3109/02688697.2013.793287; Chen N., 2013, COCHRANE DB SYST REV, V1, P1; Choi SH, 2006, J NEUROSCI METH, V156, P182, DOI 10.1016/j.jneumeth.2006.03.002; Chopp M, 2008, J NEUROL SCI, V265, P97, DOI 10.1016/j.jns.2007.06.013; Chopp M, 2009, STROKE, V40, pS143, DOI 10.1161/STROKEAHA.108.533141; Corrigan F, 2012, BRAIN RES, V1451, P87, DOI 10.1016/j.brainres.2012.02.045; D'Hooge R, 2001, BRAIN RES REV, V36, P60, DOI 10.1016/S0165-0173(01)00067-4; Dancause N, 2011, PROG BRAIN RES, V192, P273, DOI 10.1016/B978-0-444-53355-5.00015-4; Daneshvar DH, 2011, PHYS MED REH CLIN N, V22, P683, DOI 10.1016/j.pmr.2011.08.009; Darwish H, 2012, BRAIN INJURY, V26, P1763, DOI [10.3109/02699052.2012.741452, 10.3109/02699052.2011.635362]; Dean PJA, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00030; DeWitt DS, 2013, J NEUROTRAUM, V30, P688, DOI 10.1089/neu.2012.2349; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Gao XA, 2011, J NEUROPATH EXP NEUR, V70, P183, DOI 10.1097/NEN.0b013e31820c6878; Gatson JW, 2013, J TRAUMA ACUTE CARE, V74, P470, DOI 10.1097/TA.0b013e31827e1f51; Haber M, 2013, EXP NEUROL, V249, P169, DOI 10.1016/j.expneurol.2013.09.002; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; Hampson RE, 1999, NATURE, V402, P610, DOI 10.1038/45154; Heiss WD, 2012, STROKE, V43, P630, DOI 10.1161/STROKEAHA.111.628537; Hong Z, 2009, INT J STROKE, V4, P406, DOI 10.1111/j.1747-4949.2009.00340.x; Hortobagyi T, 2007, NEUROPATH APPL NEURO, V33, P226, DOI 10.1111/j.1365-2990.2006.00794.x; Israelsson C, 2009, J NEUROTRAUM, V26, P1307, DOI [10.1089/neu.2008.0676, 10.1089/neu.2008-0676]; Itoh T, 2009, NEUROL RES, V31, P103, DOI 10.1179/016164108X323771; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Kallakuri S, 2003, EXP BRAIN RES, V148, P419, DOI 10.1007/s00221-002-1307-2; Kee N, 2007, NAT PROTOC, V2, P3033, DOI 10.1038/nprot.2007.415; Kee N, 2007, NAT NEUROSCI, V10, P355, DOI 10.1038/nn1847; Kerr AL, 2011, J COMMUN DISORD, V44, P538, DOI 10.1016/j.jcomdis.2011.04.011; Kesner RP, 2010, NEUROBIOL LEARN MEM, V93, P111, DOI 10.1016/j.nlm.2009.08.010; Kitabatake Y, 2007, NEUROSURG CLIN N AM, V18, P105, DOI 10.1016/j.nec.2006.10.008; Kleim JA, 2011, J COMMUN DISORD, V44, P521, DOI 10.1016/j.jcomdis.2011.04.006; Kogel D, 2012, EXP BRAIN RES, V217, P471, DOI 10.1007/s00221-011-2932-4; Koehl M, 2011, EUR J NEUROSCI, V33, P1101, DOI 10.1111/j.1460-9568.2011.07609.x; Kohler SJ, 2011, P NATL ACAD SCI USA, V108, P10326, DOI 10.1073/pnas.1017099108; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Kumaran D, 2007, NEUROPSYCHOLOGIA, V45, P2699, DOI 10.1016/j.neuropsychologia.2007.04.007; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; Lang W, 2013, INT J STROKE, V8, P95, DOI 10.1111/j.1747-4949.2012.00901.x; Lapchak PA, 2013, TRANSL STROKE RES, V4, P279, DOI 10.1007/s12975-012-0209-2; Levy DA, 2004, LEARN MEMORY, V11, P794, DOI 10.1101/lm.82504; Levy DA, 2003, LEARN MEMORY, V10, P531, DOI 10.1101/lm.66703; Li SH, 2006, NEUROSCI LETT, V409, P182, DOI 10.1016/j.neulet.2006.09.054; Liu P, 2013, BRAIN RES, V1522, P67, DOI 10.1016/j.brainres.2013.05.032; Livingstone SA, 2007, BEHAV BRAIN RES, V185, P21, DOI 10.1016/j.bbr.2007.07.015; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Lu DY, 2003, J NEUROSURG, V99, P351, DOI 10.3171/jns.2003.99.2.0351; Lu J, 2012, BRAIN INJURY, V26, P1523, DOI 10.3109/02699052.2012.722257; Mahmood A, 2007, NEUROSURGERY, V60, P546, DOI 10.1227/01.NEU.0000255346.25959.99; Marin-Burgin A, 2012, BEHAV BRAIN RES, V227, P391, DOI 10.1016/j.bbr.2011.07.001; Markakis EA, 1999, J COMP NEUROL, V406, P449; Marklund N, 2014, J NEUROTRAUM, V31, P42, DOI 10.1089/neu.2013.2964; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Marmarou CR, 2005, J NEUROTRAUM, V22, P1066, DOI 10.1089/neu.2005.22.1066; Masliah E, 2012, DRUG TODAY, V48, P3, DOI 10.1358/dot.2012.48(Suppl.A).1739716; Meng YL, 2011, J NEUROSURG, V115, P550, DOI 10.3171/2011.3.JNS101721; Menon PK, 2012, CNS NEUROL DISORD-DR, V11, P40; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Ming GL, 2005, ANNU REV NEUROSCI, V28, P223, DOI 10.1146/annurev.neuro.28.051804.101459; Monti JM, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00041; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Namjoshi DR, 2013, DIS MODEL MECH, V6, P1325, DOI 10.1242/dmm.011320; Newcombe VFJ, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1522; Ngwenya LB, 2006, J COMP NEUROL, V498, P204, DOI 10.1002/cne.21045; Nudo RJ, 2011, J COMMUN DISORD, V44, P515, DOI 10.1016/j.jcomdis.2011.04.004; O'Dell SJ, 2011, BEHAV BRAIN RES, V216, P396, DOI 10.1016/j.bbr.2010.08.022; Plosker GL, 2009, DRUG AGING, V26, P893, DOI 10.2165/11203320-000000000-00000; Rockenstein E, 2007, ACTA NEUROPATHOL, V113, P265, DOI 10.1007/s00401-006-0166-5; Rockenstein E, 2006, J NEUROSCI RES, V83, P1252, DOI 10.1002/jnr.20818; Ruether E, 2001, INT CLIN PSYCHOPHARM, V16, P253, DOI 10.1097/00004850-200109000-00002; Shapira M, 2007, MOL CELL NEUROSCI, V34, P571, DOI 10.1016/j.mcn.2006.12.006; Sharma A, 2012, CNS NEUROL DISORD-DR, V11, P7, DOI 10.2174/187152712799960790; Sharma HS, 2010, ANN NY ACAD SCI, V1199, P125, DOI 10.1111/j.1749-6632.2009.05329.x; Signoretti S, 2010, MOL CELL BIOCHEM, V333, P269, DOI 10.1007/s11010-009-0228-9; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Sofroniew MV, 2005, NEUROSCIENTIST, V11, P400, DOI 10.1177/1073858405278321; Spalding KL, 2013, CELL, V153, P1219, DOI 10.1016/j.cell.2013.05.002; Spinetta MJ, 2008, PSYCHOPHARMACOLOGY, V201, P361, DOI 10.1007/s00213-008-1294-5; Squire LR, 2004, ANNU REV NEUROSCI, V27, P279, DOI 10.1146/annurev.neuro.27.070203.144130; Sun D, 2005, J NEUROTRAUM, V22, P95, DOI 10.1089/neu.2005.22.95; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Tashlykov V, 2009, J MOL NEUROSCI, V37, P16, DOI 10.1007/s12031-008-9094-2; Tay SY, 2010, J NEUROTRAUM, V27, P77, DOI 10.1089/neu.2009.1074; Terry AV, 2009, METHODS BEHAV ANAL N, P153; Thome J, 2012, DRUG TODAY, V48, P63, DOI 10.1358/dot.2012.48(Suppl.A).1739724; Ubhi K, 2009, ACTA NEUROPATHOL, V117, P699, DOI 10.1007/s00401-009-0505-4; Vukovic J, 2013, J NEUROSCI, V33, P6603, DOI 10.1523/JNEUROSCI.3064-12.2013; Xiao SF, 2012, AUST NZ J PSYCHIAT, V46, P153, DOI 10.1177/0004867411433213; Xiong Y, 2011, J NEUROSURG, V114, P102, DOI 10.3171/2010.4.JNS10118; Yang SH, 2013, J SURG RES, V184, P981, DOI 10.1016/j.jss.2013.03.075; Zhang CL, 2010, J NEUROSCI RES, V88, P3275, DOI 10.1002/jnr.22495; Zhang L, 2013, STROKE, V44, P1965, DOI 10.1161/STROKEAHA.111.000831; Zhang RL, 2002, STROKE, V33, P2675, DOI 10.1161/01.STR.0000034399.95249.59; Zhang YL, 2013, J NEUROSURG, V118, P1343, DOI 10.3171/2013.3.JNS122061; Zhang ZG, 2009, LANCET NEUROL, V8, P491, DOI 10.1016/S1474-4422(09)70061-4; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033; Ziganshina LE, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007026.pub2; Zohar O, 2011, ACTA NEUROBIOL EXP, V71, P36; Zohar O, 2011, NEUROBIOL DIS, V41, P329, DOI 10.1016/j.nbd.2010.10.001	110	35	35	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	APR	2015	122	4					843	855		10.3171/2014.11.JNS14271			13	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	CE2PW	WOS:000351658500016	25614944	Bronze			2021-06-18	
J	Dent, KA; Christie, KJ; Bye, N; Basrai, HS; Turbic, A; Habgood, M; Cate, HS; Turnley, AM				Dent, Krista A.; Christie, Kimberly J.; Bye, Nicole; Basrai, Harleen S.; Turbic, Alisa; Habgood, Mark; Cate, Holly S.; Turnley, Ann M.			Oligodendrocyte Birth and Death following Traumatic Brain Injury in Adult Mice	PLOS ONE			English	Article							CONTROLLED CORTICAL IMPACT; WHITE-MATTER; PRECURSOR CELLS; AMYLOID-BETA; PROGENITORS; ASTROCYTES; EXPRESSION; AXONS; PROLIFERATION; REMYELINATION	Oligodendrocytes are responsible for producing and maintaining myelin throughout the CNS. One of the pathological features observed following traumatic brain injury (TBI) is the progressive demyelination and degeneration of axons within white matter tracts. While the effect of TBI on axonal health has been well documented, there is limited information regarding the response of oligodendrocytes within these areas. The aim of this study was to characterize the response of both mature oligodendrocytes and immature proliferative oligodendrocyte lineage cells across a 3 month timecourse following TBI. A computer-controlled cortical impact model was used to produce a focal lesion in the left motor cortex of adult mice. Immunohistochemical analyses were performed at 48 hours, 7 days, 2 weeks, 5 weeks and 3 months following injury to assess the prevalence of mature CC-1(+) oligodendrocyte cell death, immature Olig2(+) cell proliferation and longer term survival in the corpus callosum and external capsule. Decreased CC-1 immunoreactivity was observed in white matter adjacent to the site of injury from 2 days to 2 weeks post TBI, with ongoing mature oligodendrocyte apoptosis after this time. Conversely, proliferation of Olig2(+) cells was observed as early as 48 hours post TBI and significant numbers of these cells and their progeny survived and remained in the external capsule within the injured hemisphere until at least 3 months post injury. These findings demonstrate that immature oligodendrocyte lineage cells respond to TBI by replacing oligodendrocytes lost due to damage and that this process occurs for months after injury.	[Dent, Krista A.; Christie, Kimberly J.; Bye, Nicole; Basrai, Harleen S.; Turbic, Alisa; Cate, Holly S.; Turnley, Ann M.] Univ Melbourne, Dept Anat & Neurosci, Parkville, Vic 3052, Australia; [Habgood, Mark] Univ Melbourne, Dept Pharmacol & Therapeut, Parkville, Vic 3052, Australia	Turnley, AM (corresponding author), Univ Melbourne, Dept Anat & Neurosci, Parkville, Vic 3052, Australia.	turnley@unimelb.edu.au		Cate, Holly/0000-0001-6392-9640; Turbic, Alisa/0000-0002-9703-2484	National Health and Medical Research Council of Australia (NHMRC)National Health and Medical Research Council of Australia [GNT 1045125, 628344]; Stem Cells Australia (SCA)	This work was supported by National Health and Medical Research Council of Australia (NHMRC) (www.NHMRC.gov.au), Project grant #GNT 1045125 to AMT, Research Fellowship # 628344 to AMT, and Stem Cells Australia (SCA) (www.stemcellsaustralia.edu.au) to AMT. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bradl M, 2010, ACTA NEUROPATHOL, V119, P37, DOI 10.1007/s00401-009-0601-5; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Buffo A, 2005, P NATL ACAD SCI USA, V102, P18183, DOI 10.1073/pnas.0506535102; Caprariello AV, 2012, ANN NEUROL, V72, P395, DOI 10.1002/ana.23606; Carbonnel WS, 1999, ACTA NEUROPATHOL, V98, P396, DOI 10.1007/s004010051100; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Connor JR, 1996, GLIA, V17, P83, DOI 10.1002/(SICI)1098-1136(199606)17:2<83::AID-GLIA1>3.0.CO;2-7; Conti AC, 1998, J NEUROSCI, V18, P5663; Dewar D, 2003, J CEREBR BLOOD F MET, V23, P263, DOI 10.1097/01.WCB.0000053472.41007.F9; Dimou L, 2008, J NEUROSCI, V28, P10434, DOI 10.1523/JNEUROSCI.2831-08.2008; Dong HX, 2003, J NEUROSCI, V23, P8682; Eghwrudjakpor P O, 2010, Niger J Med, V19, P14; Ek CJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012021; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Flygt J, 2013, EUR J NEUROSCI, V38, P2153, DOI 10.1111/ejn.12179; FOKSEANG J, 1995, DEV BIOL, V171, P1, DOI 10.1006/dbio.1995.1255; Foote AK, 2005, BRAIN, V128, P528, DOI 10.1093/brain/awh417; Hampton DW, 2004, NEUROSCIENCE, V127, P813, DOI 10.1016/j.neuroscience.2004.05.028; Horiuchi M, 2006, J BIOL CHEM, V281, P20095, DOI 10.1074/jbc.M603179200; Hughes EG, 2013, NAT NEUROSCI, V16, P668, DOI 10.1038/nn.3390; Johnson SC, 1994, NEUROPSYCHOLOGY, V8, P307, DOI DOI 10.1037/0894-4105.8.3.301; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Jurewicz A, 2005, BRAIN, V128, P2675, DOI 10.1093/brain/awh627; Kang SH, 2010, NEURON, V68, P668, DOI 10.1016/j.neuron.2010.09.009; Keirstead HS, 1997, J NEUROPATH EXP NEUR, V56, P1191, DOI 10.1097/00005072-199711000-00003; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; KIDD GJ, 1990, J NEUROSCI RES, V26, P409, DOI 10.1002/jnr.490260403; Lau LT, 2001, J NEUROTRAUM, V18, P351, DOI 10.1089/08977150151071035; LEVIN HS, 1990, J NEUROSURG, V73, P77, DOI 10.3171/jns.1990.73.1.0077; LEVINE JM, 1994, J NEUROSCI, V14, P4716; Levine JM, 1999, EXP NEUROL, V160, P333, DOI 10.1006/exnr.1999.7224; Lindner M, 2008, NEUROPATH APPL NEURO, V34, P105, DOI 10.1111/j.1365-2990.2007.00879.x; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Lotocki G, 2011, NEUROSCI LETT, V499, P143, DOI 10.1016/j.neulet.2011.05.056; Mason JL, 2004, AM J PATHOL, V164, P1673, DOI 10.1016/S0002-9440(10)63726-1; Matute C, 2007, J NEUROSCI, V27, P9525, DOI 10.1523/JNEUROSCI.0579-07.2007; McDonald JW, 1998, NAT MED, V4, P291, DOI 10.1038/nm0398-291; McGavern DB, 1999, EXP NEUROL, V158, P171, DOI 10.1006/exnr.1999.7082; MCPHILEMY K, 1990, J NEUROCYTOL, V19, P494, DOI 10.1007/BF01257239; MCPHILEMY K, 1991, NEUROPATH APPL NEURO, V17, P275, DOI 10.1111/j.1365-2990.1991.tb00725.x; McTigue DM, 2001, J NEUROSCI, V21, P3392, DOI 10.1523/JNEUROSCI.21-10-03392.2001; Menn B, 2006, J NEUROSCI, V26, P7907, DOI 10.1523/JNEUROSCI.1299-06.2006; Moore N, 2011, J ONCOL, V2011, DOI 10.1155/2011/396076; Onyszchuk G, 2007, J NEUROSCI METH, V160, P187, DOI 10.1016/j.jneumeth.2006.09.007; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Patel JR, 2011, FEBS LETT, V585, P3730, DOI 10.1016/j.febslet.2011.04.037; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Stone JR, 2004, EXP NEUROL, V190, P59, DOI 10.1016/j.expneurol.2004.05.022; Thorburne SK, 1996, J NEUROCHEM, V67, P1014; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Young KM, 2013, NEURON, V77, P873, DOI 10.1016/j.neuron.2013.01.006; Zhao JW, 2009, EUR J NEUROSCI, V29, P1853, DOI 10.1111/j.1460-9568.2009.06736.x; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	54	35	37	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 23	2015	10	3							e0121541	10.1371/journal.pone.0121541			17	Multidisciplinary Sciences	Science & Technology - Other Topics	CE6ZS	WOS:000351987300265	25798924	DOAJ Gold, Green Published			2021-06-18	
J	Barhon, LI; Batchelor, J; Meares, S; Chekaluk, E; Shores, EA				Barhon, Lucienne Isabel; Batchelor, Jennifer; Meares, Susanne; Chekaluk, Eugene; Shores, E. Arthur			A Comparison of the Degree of Effort Involved in the TOMM and the ACS Word Choice Test Using a Dual-Task Paradigm	APPLIED NEUROPSYCHOLOGY-ADULT			English	Article						symptom validity testing; tests; neuropsychology	MEMORY MALINGERING TOMM; SYMPTOM VALIDITY TEST; NEUROPSYCHOLOGICAL TEST-PERFORMANCE; BRAIN-INJURY; HEAD-INJURY; COGNITIVELY INTACT; NORMATIVE DATA; SIMULATORS; IMPAIRMENT; BIAS	The aims of the current study were to: (a) examine the predictive validity and efficacy of the Advanced Clinical Solutions Word Choice Test (WCT) as a measure of effort relative to the Test of Memory Malingering (TOMM); (b) investigate whether performing a dual (distraction) task would undermine performance on either test; (c) assess the effect of coaching on the diagnostic accuracy of both the WCT and the TOMM; and (d) establish an optimal cut score for the WCT. The current study used a simulation design based on an analogue design in which normal participants were instructed to either apply full effort or simulate a brain injury on the tasks without being detected. Participants included 93 undergraduate university students who were randomly assigned to 1 of 4 conditions: (a) distraction, (b) uncoached traumatic brain injury (TBI) simulators, (c) coached TBI simulators, or (d) full effort. The results demonstrated that the WCT and the TOMM were effective in detecting simulated cognitive impairment. Both tests were resistant to the effects of distraction and were equally effective in detecting coached and uncoached simulators. A cut score of 42 on the WCT was found to provide optimal specificity and sensitivity on the test.	[Barhon, Lucienne Isabel; Batchelor, Jennifer; Meares, Susanne; Chekaluk, Eugene; Shores, E. Arthur] Macquarie Univ, Sydney, NSW 2109, Australia	Barhon, LI (corresponding author), Macquarie Univ, Balaclava Rd, Sydney, NSW 2109, Australia.	lucienne.barhon@students.mq.edu.au		Shores, Edwin A/0000-0003-1553-5131; Meares, Susanne/0000-0002-3859-9974; Batchelor, Jennifer/0000-0003-4438-4993			An KY, 2012, ARCH CLIN NEUROPSYCH, V27, P849, DOI 10.1093/arclin/acs085; Armistead-Jehle P, 2011, APPL NEUROPSYCHOL, V18, P284, DOI 10.1080/09084282.2011.595455; Axelrod BN, 2011, APPL NEUROPSYCHOL, V18, P27, DOI 10.1080/09084282.2010.523369; Batt K, 2008, J INT NEUROPSYCH SOC, V14, P1074, DOI 10.1017/S135561770808137X; Bauer L, 2006, ARCH CLIN NEUROPSYCH, V21, P121, DOI 10.1016/j.acn.2005.06.010; Bender S., 2008, CLIN ASSESSMENT MALI, P69; Brennan A, 2009, CLIN NEUROPSYCHOL, V23, P314, DOI 10.1080/13854040802054151; Cochrane HJ, 1998, BRIT J CLIN PSYCHOL, V37, P31, DOI 10.1111/j.2044-8260.1998.tb01277.x; DenBoer JW, 2007, CLIN NEUROPSYCHOL, V21, P943, DOI 10.1080/13854040601020783; Erdal K, 2004, ARCH CLIN NEUROPSYCH, V19, P73; Gervais RO, 2004, ARCH CLIN NEUROPSYCH, V19, P475, DOI 10.1016/j.acn.2003.05.001; Green P., 1996, WORD MEMORY TEST USE; Green P, 2011, APPL NEUROPSYCHOL, V18, P18, DOI 10.1080/09084282.2010.523365; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Iverson GL, 2010, CLIN NEUROPSYCHOL, V24, P17, DOI 10.1080/13854040903190797; Jelicic M, 2011, J CLIN PSYCHOL, V67, P850, DOI 10.1002/jclp.20805; Kim M., 2010, ARCH CLIN NEUROPSYCH, V25, P410; Klix F, 1982, COGNITIVE RES PSYCHO, P152; Larrabee G. J., 2007, ASSESSMENT MALINGERE, P3; MACLEOD CM, 1991, PSYCHOL BULL, V109, P163, DOI 10.1037/0033-2909.109.2.163; McCarter RJ, 2009, CLIN NEUROPSYCHOL, V23, P1050, DOI 10.1080/13854040802665790; Merten T, 2007, J CLIN EXP NEUROPSYC, V29, P308, DOI 10.1080/13803390600693607; Miller JB, 2011, CLIN NEUROPSYCHOL, V25, P160, DOI 10.1080/13854046.2010.533197; O'Bryant SE, 2006, CLIN NEUROPSYCHOL, V20, P533, DOI 10.1080/13854040590967568; Paivio A., 1991, IMAGES MILD EVOLUTIO; Pearson, 2009, ADV CLIN SOLUTIONS W; Pivovarova E., 2009, INT J FORENSIC MENT, V8, DOI [https://doi.org/10.1080/14999011003635514, DOI 10.1080/14999011003635514, 10.1080/14999011003635514]; Powell MR, 2004, ARCH CLIN NEUROPSYCH, V19, P693, DOI 10.1016/j.acn.2004.04.001; Rees LM, 1998, PSYCHOL ASSESSMENT, V10, P10, DOI 10.1037/1040-3590.10.1.10; Rogers R., 1997, CLIN ASSESSMENT MALI, V2nd; Russeler J, 2008, BMC NEUROL, V8, DOI 10.1186/1471-2377-8-37; Sharland MJ, 2007, ARCH CLIN NEUROPSYCH, V22, P213, DOI 10.1016/j.acn.2006.12.004; SHEPARD RN, 1967, J VERB LEARN VERB BE, V6, P156, DOI 10.1016/S0022-5371(67)80067-7; Sollman MJ, 2011, ARCH CLIN NEUROPSYCH, V26, P774, DOI 10.1093/arclin/acr066; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; SUHR JA, 2007, ASSESSMENT MALINGERE, P287; Teichner G, 2004, ARCH CLIN NEUROPSYCH, V19, P455, DOI 10.1016/S0887-6177(03)00078-7; Tombaugh T. N., 1996, TOMMTEST MEMORY MALI; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Vickery CD, 2004, ARCH CLIN NEUROPSYCH, V19, P37, DOI 10.1016/S0887-6177(02)00170-1; Warrington EK., 1984, RECOGNITION MEMORY T; Weinborn M, 2012, CLIN NEUROPSYCHOL, V26, P832, DOI 10.1080/13854046.2012.686630	42	35	35	0	12	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND	2327-9095	2327-9109		APPL NEUROPSYCH-ADUL	Appl. Neuropsychol.-Adult	MAR 4	2015	22	2					114	123		10.1080/23279095.2013.863775			10	Clinical Neurology; Psychology	Neurosciences & Neurology; Psychology	CC5DR	WOS:000350379400006	25117219				2021-06-18	
J	Zimmer, A; Marcinak, J; Hibyan, S; Webbe, F				Zimmer, Adam; Marcinak, Jaquelyn; Hibyan, Stuart; Webbe, Frank			Normative Values of Major SCAT2 and SCAT3 Components for a College Athlete Population	APPLIED NEUROPSYCHOLOGY-ADULT			English	Article						tests; assessment/diagnosis; sports	POSTURAL STABILITY; SPORT CONCUSSION; HIGH-SCHOOL; SYMPTOMS; INJURY	The Sports Concussion Assessment Tool-2 (SCAT2) is a posttrauma evaluative screener for concussion. Although a revised version (SCAT3) recently was released, the SCAT2 continues in use. Moreover, there have been no reports of normative values with college athletes with the SCAT2 or SCAT3. Similar to the SCAT3, the SCAT2 includes a 22-item self-report symptom scale, the Standardized Assessment of Concussion (SAC), and a hard surface-only version of the Balance Error Scoring System (BESS). The SCAT3 does not employ a total score and adds an optional gait component. The purpose of this study was to develop normative values for collegiate athletes on the SCAT2 and its subparts with respect to sex, collision risk by sport, and concussion history. In preseason, 477 college athletes (332 male, 145 female) completed the SCAT2. The average total score was 91.08 (SD=5.60). The average number of symptoms endorsed was 1.75. Average SAC and BESS scores were 27.17 (SD=2.01) and 25.64 (SD=4.07), respectively. Little or no difference was found in total and component scores due to sex, sport type, or concussion history. When baseline measurement is lacking, these data provide a good benchmark for interpreting SCAT2 and SCAT3 performance.	[Zimmer, Adam; Marcinak, Jaquelyn; Hibyan, Stuart; Webbe, Frank] Florida Inst Technol, Melbourne, FL 32901 USA	Webbe, F (corresponding author), Florida Inst Technol, 150 W Univ Blvd, Melbourne, FL 32901 USA.	Webbe@fit.edu		Webbe, Frank/0000-0002-4370-5698			Alla S, 2009, BRIT J SPORT MED, V43, pI3, DOI 10.1136/bjsm.2009.058339; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Collie A, 2004, BRIT J SPORT MED, V38, P273, DOI 10.1136/bjsm.2003.000293; Crawford JR, 1998, CLIN NEUROPSYCHOL, V12, P482, DOI 10.1076/clin.12.4.482.7241; Echemendia RJ, 2013, BRIT J SPORT MED, V47, P294, DOI 10.1136/bjsports-2013-092186; Echemendia RJ, 2012, CLIN NEUROPSYCHOL, V26, P1077, DOI 10.1080/13854046.2012.721006; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Jinguji TM, 2012, BRIT J SPORT MED, V46, P365, DOI 10.1136/bjsports-2011-090526; Lovell MR, 2006, FOUNDATIONS OF SPORT-RELATED BRAIN INJURIES, P111, DOI 10.1007/0-387-32565-4_6; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lovell MR, 1999, SPORTS-RELATED CONCUSSION, P200; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M., 2000, STANDARDIZED ASSESSM; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McLeod TCV, 2012, AM J SPORT MED, V40, P927, DOI 10.1177/0363546511431573; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Randolph C, 2001, J ATHL TRAINING, V36, P288; Rice SG, 2008, PEDIATRICS, V121, P841, DOI 10.1542/peds.2008-0080; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Schmidt JD, 2012, MED SCI SPORT EXER, V44, P1621, DOI 10.1249/MSS.0b013e318258a9fb; Schneider KJ, 2010, BRIT J SPORT MED, V44, P1112, DOI 10.1136/bjsm.2009.071266; Shehata N, 2009, BRIT J SPORT MED, V43, P730, DOI 10.1136/bjsm.2009.059832	26	35	35	0	17	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	2327-9095	2327-9109		APPL NEUROPSYCH-ADUL	Appl. Neuropsychol.-Adult	MAR 4	2015	22	2					132	140		10.1080/23279095.2013.867265			9	Clinical Neurology; Psychology	Neurosciences & Neurology; Psychology	CC5DR	WOS:000350379400008	25117270				2021-06-18	
J	Raj, R; Skrifvars, MB; Kivisaari, R; Hernesniemi, J; Lappalainen, J; Siironen, J				Raj, Rahul; Skrifvars, Markus B.; Kivisaari, Riku; Hernesniemi, Juha; Lappalainen, Jaakko; Siironen, Jari			Acute Alcohol Intoxication and Long-Term Outcome in Patients with Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						traumatic brain injury; mortality; prognosis; outcome; alcohol	GLASGOW COMA SCALE; SERUM ETHANOL LEVELS; MORTALITY; LEVEL; ABUSE; CLASSIFICATION; EPIDEMIOLOGY; ASSOCIATION; SEVERITY; SURVIVAL	The effect of blood alcohol concentration (BAC) on outcome after traumatic brain injury (TBI) is controversial. We sought to assess the independent effect of positive BAC on long-term outcome in patients with TBI treated in the intensive care unit (ICU). We performed a retrospective analysis of 405 patients with TBI, admitted to the ICU of a large urban Level 1 trauma center between January 2009 and December 2012. Outcome was six-month mortality and unfavorable neurological outcome (defined as a Glasgow Outcome Scale score of 1 [death], 2, [vegetative state], or 3 [severe disability]). Patients were categorized by admission BAC into: no BAC (0.0 parts per thousand; n=99), low BAC (n=140) and high BAC (>= 2.3 parts per thousand; n=166). Logistic regression analysis, adjusting for baseline risk and severity of illness, was used to assess the independent effect of BAC on outcome (using the no BAC group as the reference). Overall six-month mortality was 25% and unfavorable outcome was 46%. Multivariate analysis showed low BAC to independently reduce risk of six-month mortality compared with no BAC (low BAC adjusted odds ratio [AOR] 0.41, 95% confidence interval [CI] 0.19-0.88, p=0.021) and high BAC (AOR 0.58, 95% CI 0.29-1.15, p=0.120). Furthermore, a trend towards reduced risk of six-month unfavorable neurological outcome for patients with positive BAC, compared to patients with negative BAC, was noted, although this did not reach statistical significance (low BAC AOR 0.65, 95% CI 0.34-1.22, p=0.178, and high BAC AOR 0.59, 95% CI 0.32-1.09, p=0.089). In conclusion, low admission BAC (<2.3 parts per thousand) was found to independently reduce risk of six-month mortality for patients with TBI, and a trend towards improved long-term neurological outcome was found for BAC-positive patients. The role of alcohol as a neuroprotective agent warrants further studies.	[Raj, Rahul; Kivisaari, Riku; Hernesniemi, Juha; Lappalainen, Jaakko; Siironen, Jari] Helsinki Univ Hosp, Dept Neurosurg, Helsinki 00029, Finland; [Skrifvars, Markus B.] Helsinki Univ Hosp, Dept Intens Care Med, Helsinki 00029, Finland	Raj, R (corresponding author), Helsinki Univ Hosp, Dept Neurosurg, Topeliuksenkatu 5, Helsinki 00029, Finland.	rahul.br.raj@icloud.com	Raj, Rahul/K-7693-2012	Raj, Rahul/0000-0003-4243-9591	Helsinki University Hospital EVO [TYH2012142]; Medicinska Understodsforeningen Liv och Halsa; Maire Taponen foundation	The study was funded by a Helsinki University Hospital EVO grant (TYH2012142), Medicinska Understodsforeningen Liv och Halsa and the Maire Taponen foundation. No competing financial interests exist.	Alexander S, 2004, J NEUROTRAUM, V21, P575, DOI 10.1089/089771504774129900; Berry C, 2011, AM SURGEON, V77, P1416; Berry C, 2010, AM SURGEON, V76, P1067; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Chen CM, 2012, J STUD ALCOHOL DRUGS, V73, P531, DOI 10.15288/jsad.2012.73.531; Gottesfeld Z, 2002, J NEUROTRAUM, V19, P317, DOI 10.1089/089771502753594882; Hadjibashi AA, 2012, J SURG RES, V173, P212, DOI 10.1016/j.jss.2011.05.029; JURKOVICH GJ, 1993, JAMA-J AM MED ASSOC, V270, P51, DOI 10.1001/jama.270.1.51; Kelly DF, 2000, J NEUROTRAUM, V17, P261, DOI 10.1089/neu.2000.17.261; KELLY DF, 1995, J NEUROTRAUM, V12, P883, DOI 10.1089/neu.1995.12.883; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Lange RT, 2010, BRAIN INJURY, V24, P919, DOI 10.3109/02699052.2010.489794; Lu J. J., 2004, ACTA NEUROCHIR S, V95, P281; Lustenberger T, 2011, J NEUROTRAUM, V28, P1699, DOI 10.1089/neu.2011.1866; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AIR, 2013, LANCET NEUROL, V12, P1200, DOI 10.1016/S1474-4422(13)70234-5; Macewen William, 1879, Glasgow Med J, V11, P1; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Molina PE, 2013, SHOCK, V39, P240, DOI 10.1097/SHK.0b013e318285b86d; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; O'Phelan K, 2008, J TRAUMA, V65, P674, DOI 10.1097/TA.0b013e31817db0a5; Opreanu RC, 2010, J AM COLL SURGEONS, V210, P997, DOI 10.1016/j.jamcollsurg.2010.01.036; Pouw ME, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5913; Raj R., 2014, J NEUROTRAUMA; Salim A, 2009, J TRAUMA, V67, P697, DOI 10.1097/TA.0b013e3181b5dcf2; Salim A, 2009, ARCH SURG-CHICAGO, V144, P865, DOI 10.1001/archsurg.2009.158; Savola O, 2005, ALCOHOL ALCOHOLISM, V40, P269, DOI 10.1093/alcalc/agh159; Shahin H, 2010, J TRAUMA, V69, P1176, DOI 10.1097/TA.0b013e3181edbd47; Shandro JR, 2009, J TRAUMA, V66, P1584, DOI 10.1097/TA.0b013e318182af96; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stuke L, 2007, ANN SURG, V245, P651, DOI 10.1097/01.sla.0000250413.41265.d3; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Talving P, 2010, J TRAUMA, V68, P357, DOI 10.1097/TA.0b013e3181bb80bf; Taylor AN, 2002, J NEUROTRAUM, V19, P1597, DOI 10.1089/089771502762300256; Tien HCN, 2006, ARCH SURG-CHICAGO, V141, P1185, DOI 10.1001/archsurg.141.12.1185	35	35	35	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 15	2015	32	2					95	100		10.1089/neu.2014.3488			6	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AY6QM	WOS:000347690700003	25010885	Green Published			2021-06-18	
J	Katzenberger, RJ; Ganetzky, B; Wassarman, DA				Katzenberger, Rebeccah J.; Ganetzky, Barry; Wassarman, David A.			The gut reaction to traumatic brain injury	FLY			English	Article						bacteria; Drosophila; glucose; innate immune response; intestine; mortality; septate junction; TBI; tight junction; traumatic brain injury	INCREASED INTESTINAL PERMEABILITY; INNATE IMMUNE-RESPONSE; NF-KAPPA-B; INFLAMMATORY RESPONSE; BARRIER DYSFUNCTION; ORGAN DYSFUNCTION; DROSOPHILA MODEL; MUCOSA STRUCTURE; NERVOUS-SYSTEM; DANGER THEORY	Traumatic brain injury (TBI) is a complex disorder that affects millions of people worldwide. The complexity of TBI partly stems from the fact that injuries to the brain instigate non-neurological injuries to other organs such as the intestine. Additionally, genetic variation is thought to play a large role in determining the nature and severity of non-neurological injuries. We recently reported that TBI in flies, as in humans, increases permeability of the intestinal epithelial barrier resulting in hyperglycemia and a higher risk of death. Furthermore, we demonstrated that genetic variation in flies is also pertinent to the complexity of non-neurological injuries following TBI. The goals of this review are to place our findings in the context of what is known about TBI-induced intestinal permeability from studies of TBI patients and rodent TBI models and to draw attention to how studies of the fly TBI model can provide unique insights that may facilitate diagnosis and treatment of TBI.	[Katzenberger, Rebeccah J.; Ganetzky, Barry; Wassarman, David A.] Univ Wisconsin, Genet Lab, Madison, WI 53706 USA	Wassarman, DA (corresponding author), Univ Wisconsin, Genet Lab, Madison, WI 53706 USA.	dawassarman@wisc.edu					Al-Sadi R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085345; Alexiou GA, 2014, BRAIN INJURY, V28, P438, DOI 10.3109/02699052.2014.888769; Bahri S, 2010, DEVELOPMENT, V137, P2023, DOI 10.1242/dev.045088; Bansal V, 2010, J NEUROTRAUM, V27, P2255, DOI 10.1089/neu.2010.1372; Bansal V, 2010, J TRAUMA, V68, P1059, DOI 10.1097/TA.0b013e3181d87373; Bansal V, 2009, J NEUROTRAUM, V26, P1353, DOI 10.1089/neu.2008-0858; Barreau F, 2014, CURR OPIN MICROBIOL, V17, P91, DOI 10.1016/j.mib.2013.12.003; Berglund JJ, 2001, AM J PHYSIOL-GASTR L, V281, pG1487; Beynon AL, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-40; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Bischoff SC, 2014, BMC GASTROENTEROL, V14, DOI 10.1186/s12876-014-0189-7; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Bonnay F, 2013, P NATL ACAD SCI USA, V110, P2957, DOI 10.1073/pnas.1221910110; Borovikova LV, 2000, NATURE, V405, P458; Cao Y, 2013, P NATL ACAD SCI USA, V110, pE1752, DOI 10.1073/pnas.1306220110; Chen G, 2008, INFLAMM RES, V57, P57, DOI 10.1007/s00011-007-7101-7; Chinchore Y, 2012, P NATL ACAD SCI USA, V109, pE605, DOI 10.1073/pnas.1110666109; Chong SL, 2015, INT J ENDOCRINOL, V2015, DOI 10.1155/2015/719476; Cunningham KE, 2012, ANN NY ACAD SCI, V1258, P34, DOI 10.1111/j.1749-6632.2012.06526.x; De-Souza DA, 2005, CRIT CARE MED, V33, P1125, DOI 10.1097/01.CCM.0000162680.52397.97; Doig CJ, 1998, AM J RESP CRIT CARE, V158, P444, DOI 10.1164/ajrccm.158.2.9710092; Elkon B, 2014, PEDIATR CRIT CARE ME, V15, P623, DOI 10.1097/PCC.0000000000000170; Feighery L, 2008, J TRAUMA, V64, P131, DOI 10.1097/TA.0b013e3181568d9f; Feng D, 2007, J INT MED RES, V35, P644, DOI 10.1177/147323000703500509; Furness JB, 2014, ADV EXP MED BIOL, V817, P39, DOI 10.1007/978-1-4939-0897-4_3; Furuse M, 2006, TRENDS CELL BIOL, V16, P181, DOI 10.1016/j.tcb.2006.02.006; Guilhelmelli F, 2013, FRONT MICROBIOL, V4, DOI 10.3389/fmicb.2013.00353; Hang CH, 2003, WORLD J GASTROENTERO, V9, P2776; Haron RH, 2011, MALAYS J MED SCI, V18, P69; Hernandez G, 2007, NEUROCRIT CARE, V7, P40, DOI 10.1007/s12028-007-0026-8; Hindle SJ, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00414; Hoffmann JA, 2002, NAT IMMUNOL, V3, P121, DOI 10.1038/ni0202-121; Izumi Y, 2014, SEMIN CELL DEV BIOL, V36, P186, DOI 10.1016/j.semcdb.2014.09.009; Jin W, 2008, CYTOKINE, V44, P135, DOI 10.1016/j.cyto.2008.07.005; Kabadi SV, 2014, INT J MOL SCI, V15, P1216, DOI 10.3390/ijms15011216; Katzenberger RJ, 2015, JOVE-J VIS EXP, DOI 10.3791/52905; Katzenberger RJ, 2015, ELIFE, V4, DOI 10.7554/eLife.04790; Katzenberger RJ, 2013, P NATL ACAD SCI USA, V110, pE4152, DOI 10.1073/pnas.1316895110; Kemp CD, 2008, AM SURGEON, V74, P866; Land WG, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00349; Lemaitre B, 2007, ANNU REV IMMUNOL, V25, P697, DOI 10.1146/annurev.immunol.25.022106.141615; Ley EJ, 2011, J TRAUMA, V70, P1141, DOI 10.1097/TA.0b013e3182146d66; Lin L, 2015, NAT REV DRUG DISCOV, V14, P543, DOI 10.1038/nrd4626; Lustenberger T, 2013, BRAIN INJURY, V27, P281, DOI 10.3109/02699052.2012.743178; Marchiando AM, 2010, J CELL BIOL, V189, P111, DOI 10.1083/jcb.200902153; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Narasimha M, 2008, J CELL SCI, V121, P747, DOI 10.1242/jcs.019422; Nelson KS, 2010, GENETICS, V185, P831, DOI 10.1534/genetics.110.114959; Petersen AJ, 2013, GENETICS, V194, P133, DOI 10.1534/genetics.113.150854; Petersen AJ, 2012, P NATL ACAD SCI USA, V109, pE656, DOI 10.1073/pnas.1110470109; Peterson LW, 2014, NAT REV IMMUNOL, V14, P141, DOI 10.1038/nri3608; Pilitsis JG, 2001, NEUROL RES, V23, P227, DOI 10.1179/016164101101198389; Pradeu T, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00287; Prisco L, 2012, J NEUROSURG SCI, V56, P131; Pruitt D, 2015, J NEUROTRAU IN PRESS; Qing Q, 2015, J CELL MOL MED, V19, P1366, DOI 10.1111/jcmm.12523; Rera M, 2012, P NATL ACAD SCI USA, V109, P21528, DOI 10.1073/pnas.1215849110; Rera M, 2011, CELL METAB, V14, P623, DOI 10.1016/j.cmet.2011.09.013; Ringel Y, 2013, AM J PHYSIOL-GASTR L, V305, pG529, DOI 10.1152/ajpgi.00207.2012; Rovlias A, 2000, NEUROSURGERY, V46, P335, DOI 10.1097/00006123-200002000-00015; Salim A, 2009, AM SURGEON, V75, P25; Senga K, 2012, MOL BIOL CELL, V23, P2845, DOI 10.1091/mbc.E12-02-0097; Sequeira IR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099256; Soscia SJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009505; Sriram K, 2007, J NEUROIMMUNE PHARM, V2, P140, DOI 10.1007/s11481-007-9070-6; Stoecklein VM, 2012, J LEUKOCYTE BIOL, V92, P539, DOI 10.1189/jlb.0212072; Sun J, 2007, CYTOKINE, V40, P151, DOI 10.1016/j.cyto.2007.09.003; Suzuki T, 2013, CELL MOL LIFE SCI, V70, P631, DOI 10.1007/s00018-012-1070-x; Tan LH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003966; Verstrepen L, 2008, CELL MOL LIFE SCI, V65, P2964, DOI 10.1007/s00018-008-8064-8; Yu ZQ, 2008, DEV BIOL, V319, P56, DOI 10.1016/j.ydbio.2008.04.001; Yuan Q, 2014, NEUROCRIT CARE, V20, P69, DOI 10.1007/s12028-012-9730-0; Zhang X, 2015, JPEN-PARENTER ENTER, V39, P114, DOI 10.1177/0148607113501881; Zygun DA, 2005, CRIT CARE MED, V33, P654, DOI 10.1097/01.ccm.0000155911.01844.54	74	35	38	0	4	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1933-6934	1933-6942		FLY	Fly		2015	9	2					68	74		10.1080/19336934.2015.1085623			7	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	DF3ZP	WOS:000371287400003	26291482	Bronze, Green Published			2021-06-18	
J	Lopez-Rodriguez, AB; Siopi, E; Finn, DP; Marchand-Leroux, C; Garcia-Segura, LM; Jafarian-Tehrani, M; Viveros, MP				Lopez-Rodriguez, Ana Belen; Siopi, Eleni; Finn, David P.; Marchand-Leroux, Catherine; Garcia-Segura, Luis M.; Jafarian-Tehrani, Mehrnaz; Viveros, Maria-Paz			CB1 and CB2 Cannabinoid Receptor Antagonists Prevent Minocycline-Induced Neuroprotection Following Traumatic Brain Injury in Mice	CEREBRAL CORTEX			English	Article						cannabinoid system; diffuse axonal injury; microglial activation; minocycline; neuroprotection; traumatic brain injury	CLOSED-HEAD INJURY; FOCAL CEREBRAL-ISCHEMIA; MICROGLIAL ACTIVATION; PROTECTS NEURONS; KAPPA-B; EDEMA; EXPRESSION; CELLS; NEUROINFLAMMATION; INVOLVEMENT	Traumatic brain injury (TBI) and its consequences represent one of the leading causes of death in young adults. This lesion mediates glial activation and the release of harmful molecules and causes brain edema, axonal injury, and functional impairment. Since glial activation plays a key role in the development of this damage, it seems that controlling it could be beneficial and could lead to neuroprotective effects. Recent studies show that minocycline suppresses microglial activation, reduces the lesion volume, and decreases TBI-induced locomotor hyperactivity up to 3 months. The endocannabinoid system (ECS) plays an important role in reparative mechanisms and inflammation under pathological situations by controlling some mechanisms that are shared with minocycline pathways. We hypothesized that the ECS could be involved in the neuroprotective effects of minocycline. To address this hypothesis, we used a murine TBI model in combination with selective CB1 and CB2 receptor antagonists (AM251 and AM630, respectively). The results provided the first evidence for the involvement of ECS in the neuroprotective action of minocycline on brain edema, neurological impairment, diffuse axonal injury, and microglial activation, since all these effects were prevented by the CB1 and CB2 receptor antagonists.	[Lopez-Rodriguez, Ana Belen; Viveros, Maria-Paz] Univ Complutense Madrid, Fac Biol, Dept Anim Physiol Anim Physiol 2, Inst Invest Sanitaria,Hosp Clin San Carlos IdISSC, E-28040 Madrid, Spain; [Siopi, Eleni; Marchand-Leroux, Catherine; Jafarian-Tehrani, Mehrnaz] Univ Paris 05, Sorbonne Paris Cite, Fac Sci Pharmaceut & Biol, Lab Pharmacol Circulat Cerebrale,EA4475, Paris, France; [Jafarian-Tehrani, Mehrnaz] Univ Paris 05, Sorbonne Paris Cite, UFR Biomed St Peres, CNRS,UMR 8194, Paris, France; [Finn, David P.] Natl Univ Ireland Galway, NCBES Neurosci Cluster, Sch Med, Galway, Ireland; [Finn, David P.] Natl Univ Ireland Galway, Ctr Pain Res, Galway, Ireland; [Lopez-Rodriguez, Ana Belen; Garcia-Segura, Luis M.] CSIC, Inst Cajal, E-28002 Madrid, Spain	Viveros, MP (corresponding author), Univ Complutense Madrid, Fac Biol, Dept Anim Physiol Anim Physiol 2, Calle Jose Antonio Novais 2, E-28040 Madrid, Spain.	pazviver@bio.ucm.es	MARCHAND-LEROUX, Catherine/L-7453-2017; Lopez-Rodriguez, Ana Belen/A-8384-2015; Garcia-Segura, Luis M/U-3711-2017; Lopez-Rodriguez, Ana Belen/H-3631-2017; Viveros, Maria-Paz/S-6855-2016	MARCHAND-LEROUX, Catherine/0000-0003-0113-5348; Garcia-Segura, Luis M/0000-0002-2450-2916; Lopez-Rodriguez, Ana Belen/0000-0002-0747-7966; Finn, David/0000-0001-6186-621X; Jafarian-Tehrani, Mehrnaz/0000-0001-6895-5856; Viveros, Maria-Paz/0000-0002-4119-4636	GRUPOS UCM-BSCH [951579]; Delegacion del Gobierno para el Plan Nacional sobre Drogas [Orden SAS/1250/2009]; Instituto de Salud Carlos IIIInstituto de Salud Carlos IIIEuropean Commission; Redes tematicas de Investigacion Cooperativa en salud, Red de Trastornos Adictivos [RD06/0001/1013, RD2012/0028/0021]; Ministerio de Economia y Competividad, Spain [BFU2011-30217-C03-01]; nonprofitable organization "Fondation des Gueules cassees"	This work has been supported by GRUPOS UCM-BSCH 951579; Delegacion del Gobierno para el Plan Nacional sobre Drogas (Orden SAS/1250/2009); Instituto de Salud Carlos III; Redes tematicas de Investigacion Cooperativa en salud, Red de Trastornos Adictivos (RD06/0001/1013 and RD2012/0028/0021) to M.P.V.; Ministerio de Economia y Competividad, Spain (BFU2011-30217-C03-01) to L.M.G.S., and the nonprofitable organization "Fondation des Gueules cassees" to E.S. and M.J.T.	Bales JW, 2009, NEUROSCI BIOBEHAV R, V33, P981, DOI 10.1016/j.neubiorev.2009.03.011; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Beauchamp K, 2008, MOL MED, V14, P731, DOI 10.2119/2008-00050.Beauchamp; Boto GR, 2009, NEUROSURG REV, V32, P343, DOI 10.1007/s10143-008-0178-9; BROOKS DN, 1972, J NERV MENT DIS, V155, P350; Cabral GA, 2005, J LEUKOCYTE BIOL, V78, P1192, DOI 10.1189/jlb.0405216; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Chen YQ, 2000, J PHARMACOL EXP THER, V293, P807; Chin CL, 2008, BRIT J PHARMACOL, V153, P367, DOI 10.1038/sj.bjp.0707506; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Chu LS, 2010, LIFE SCI, V86, P170, DOI 10.1016/j.lfs.2009.12.001; d'Avila JC, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-31; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Di Filippo C, 2004, J LEUKOCYTE BIOL, V75, P453, DOI 10.1189/jlb.0703303; Dirikoc S, 2007, J NEUROSCI, V27, P9537, DOI 10.1523/JNEUROSCI.1942-07.2007; Diz-Chaves Y, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-71; Eljaschewitsch E, 2006, NEURON, V49, P67, DOI 10.1016/j.neuron.2005.11.027; Elliott MB, 2011, J NEUROTRAUM, V28, P973, DOI 10.1089/neu.2010.1672; Emilien G, 1996, ACTA NEUROL BELG, V96, P89; Esposito G, 2001, J NEUROCHEM, V78, P835, DOI 10.1046/j.1471-4159.2001.00465.x; Ferretti MT, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-62; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Fowler CJ, 2010, EXP NEUROL, V224, P37, DOI 10.1016/j.expneurol.2010.03.021; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; Girgis H, 2013, BRAIN RES, V1491, P78, DOI 10.1016/j.brainres.2012.10.049; Gonzalez JC, 2007, EUR J NEUROSCI, V26, P2481, DOI 10.1111/j.1460-9568.2007.05873.x; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; HANSTOCK CC, 1994, STROKE, V25, P843, DOI 10.1161/01.STR.25.4.843; Hellal F, 2003, J NEUROTRAUM, V20, P841, DOI 10.1089/089771503322385773; HERKENHAM M, 1992, ANN NY ACAD SCI, V654, P19, DOI 10.1111/j.1749-6632.1992.tb25953.x; Homsi S, 2010, J NEUROTRAUM, V27, P911, DOI 10.1089/neu.2009.1223; Homsi S, 2009, BRAIN RES, V1291, P122, DOI 10.1016/j.brainres.2009.07.031; Iwata A, 2004, J NEUROSCI, V24, P4605, DOI 10.1523/JNEUROSCI.0515-03.2004; Klein TW, 2000, P SOC EXP BIOL MED, V225, P1, DOI 10.1046/j.1525-1373.2000.22501.x; Kozela E, 2011, BRIT J PHARMACOL, V163, P1507, DOI 10.1111/j.1476-5381.2011.01379.x; Kozela E, 2010, J BIOL CHEM, V285, P1616, DOI 10.1074/jbc.M109.069294; Kraus RL, 2005, J NEUROCHEM, V94, P819, DOI 10.1111/j.1471-4159.2005.03219.x; Lazovic J, 2005, STROKE, V36, P2226, DOI 10.1161/01.STR.0000182255.08162.6a; Rodriguez ABL, 2011, CEREB CORTEX, V21, P2046, DOI 10.1093/cercor/bhq277; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Mackie K, 2006, ANNU REV PHARMACOL, V46, P101, DOI 10.1146/annurev.pharmtox.46.120604.141254; Marco EM, 2011, FRONT BEHAV NEUROSCI, V5, DOI 10.3389/fnbeh.2011.00063; Garcia-Martinez EM, 2010, BIOCHEM PHARMACOL, V79, P239, DOI 10.1016/j.bcp.2009.07.028; Tolon RM, 2009, BRAIN RES, V1283, P148, DOI 10.1016/j.brainres.2009.05.098; Markovic DS, 2011, BRAIN BEHAV IMMUN, V25, P624, DOI 10.1016/j.bbi.2011.01.015; Marmarou A, 2003, ACT NEUR S, V86, P7; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; McLaughlin PJ, 2003, BEHAV PHARMACOL, V14, P583, DOI 10.1097/00008877-200312000-00002; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; Mejia ROS, 2001, NEUROSURGERY, V48, P1393; Micale V, 2007, PHARMACOL RES, V56, P382, DOI 10.1016/j.phrs.2007.09.008; Molina-Holgado E, 2002, J NEUROSCI, V22, P9742, DOI 10.1523/jneurosci.22-22-09742.2002; Moller T, 2000, J NEUROCHEM, V75, P1539, DOI 10.1046/j.1471-4159.2000.0751539.x; Nagayama T, 1999, J NEUROSCI, V19, P2987; Nikodemova M, 2006, J NEUROCHEM, V96, P314, DOI 10.1111/j.1471-4159.2005.03520.x; Panikashvili D, 2006, NEUROBIOL DIS, V22, P257, DOI 10.1016/j.nbd.2005.11.004; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Paulsen K, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478-811X-9-33; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Piomelli D, 2003, NAT REV NEUROSCI, V4, P873, DOI 10.1038/nrn1247; Plane JM, 2010, ARCH NEUROL-CHICAGO, V67, P1442, DOI 10.1001/archneurol.2010.191; POVLISHOCK JT, 1994, J NEUROTRAUM, V11, P723, DOI 10.1089/neu.1994.11.723; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; Rochat L, 2010, NEUROPSYCHOL REHABIL, V20, P778, DOI 10.1080/09602011.2010.495245; Romero-Perez D, 2008, J AM COLL CARDIOL, V52, P1086, DOI 10.1016/j.jacc.2008.06.028; Roth P, 2000, Crit Care Nurs Q, V23, P14; Royo NC, 1999, NEUROREPORT, V10, P1363, DOI 10.1097/00001756-199904260-00038; Sarker KP, 2000, FEBS LETT, V472, P39, DOI 10.1016/S0014-5793(00)01425-3; Sarne Y, 2011, BRIT J PHARMACOL, V163, P1391, DOI 10.1111/j.1476-5381.2011.01280.x; Shenaq M, 2012, J NEUROL SCI, V323, P134, DOI 10.1016/j.jns.2012.08.036; Siopi E, 2013, NEUROPHARMACOLOGY, V67, P183, DOI 10.1016/j.neuropharm.2012.11.009; Siopi E, 2012, NEUROSCI LETT, V511, P110, DOI 10.1016/j.neulet.2012.01.051; Siopi E, 2012, J NEUROTRAUM, V29, P354, DOI 10.1089/neu.2011.2055; Siopi E, 2011, J NEUROTRAUM, V28, P2135, DOI 10.1089/neu.2010.1738; Smith SR, 2000, J PHARMACOL EXP THER, V293, P136; Soares HD, 1995, J NEUROSCI, V15, P8223; Stella N, 2010, GLIA, V58, P1017, DOI 10.1002/glia.20983; Tikka T, 2001, J NEUROSCI, V21, P2580, DOI 10.1523/JNEUROSCI.21-08-02580.2001; Tikka TM, 2001, J IMMUNOL, V166, P7527, DOI 10.4049/jimmunol.166.12.7527; TOMINAGA T, 1989, STROKE, V20, P513, DOI 10.1161/01.STR.20.4.513; VANEZIS P, 1987, FORENSIC SCI INT, V35, P1, DOI 10.1016/0379-0738(87)90018-1; Walter L, 2003, J NEUROSCI, V23, P1398; Wang HC, 2006, NEUROCRIT CARE, V5, P71, DOI 10.1385/NCC:5:1:71; Weibel E.R., 1979, STEREOLOGICAL METHOD, V1; World Health Organization (WHO), 2006, WORLD HLTH REPORT 20; Wortzel HS, 2012, CURR TREAT OPTION NE, V14, P493, DOI 10.1007/s11940-012-0193-6; Wu X, 2008, J TRAUMA, V64, P1313, DOI 10.1097/TA.0b013e318165c803; Zhang M, 2009, J NEUROIMMUNE PHARM, V4, P249, DOI 10.1007/s11481-009-9148-4	88	35	37	0	19	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	1047-3211	1460-2199		CEREB CORTEX	Cereb. Cortex	JAN	2015	25	1					35	45		10.1093/cercor/bht202			11	Neurosciences	Neurosciences & Neurology	AY2KA	WOS:000347417600004	23960212				2021-06-18	
J	Post, A; Hoshizaki, TB; Gilchrist, MD; Brien, S; Cusimano, M; Marshall, S				Post, Andrew; Hoshizaki, T. B.; Gilchrist, Michael D.; Brien, Susan; Cusimano, Michael; Marshall, Shawn			Traumatic Brain Injuries: The Influence of the Direction of Impact	NEUROSURGERY			English	Article						Biomechanics; Contusion; Subarachnoid hemorrhage; Subdural hematoma; Traumatic brain injury	MULTIBODY DYNAMICS ANALYSIS; HUMAN HEAD; RECONSTRUCTION; BIOMECHANICS; ELEMENT; FALLS; ACCELERATION; MODELS; MILD	BACKGROUND: Head impact direction has been identified as an influential risk factor in the risk of traumatic brain injury (TBI) from animal and anatomic research; however, to date, there has been little investigation into this relationship in human subjects. If a susceptibility to certain types of TBI based on impact direction was found to exist in humans, it would aid in clinical diagnoses as well as prevention methods for these types of injuries. OBJECTIVE: To examine the influence of impact direction on the presence of TBI lesions, specifically, subdural hematomas, subarachnoid hemorrhage, and parenchymal contusions. METHODS: Twenty reconstructions of falls that resulted in a TBI were conducted in a laboratory based on eyewitness, interview, and medical reports. The reconstructions involved impacts to a Hybrid III anthropometric dummy and finite element modeling of the human head to evaluate the brain stresses and strains for each TBI event. RESULTS: The results showed that it is likely that increased risk of incurring a subdural hematoma exists from impacts to the frontal or occipital regions, and parenchymal contusions from impacts to the side of the head. There was no definitive link between impact direction and subarachnoid hemorrhage. In addition, the results indicate that there is a continuum of stresses and strain magnitudes between lesion types when impact location is isolated, with subdural hematoma occurring at lower magnitudes for frontal and occipital region impacts, and contusions lower for impacts to the side. CONCLUSION: This hospital data set suggests that there is an effect that impact direction has on TBI depending on the anatomy involved for each particular lesion.	[Post, Andrew; Hoshizaki, T. B.; Gilchrist, Michael D.; Brien, Susan] Univ Ottawa, Ottawa, ON, Canada; [Gilchrist, Michael D.] Univ Coll Dublin, Sch Mech & Mat Engn, Dublin 2, Ireland; [Brien, Susan] Hull Hosp, Gatineau, PQ, Canada; [Cusimano, Michael] St Michaels Hosp, Toronto, ON M5B 1W8, Canada; [Marshall, Shawn] Ottawa Hosp, Ottawa, ON, Canada	Post, A (corresponding author), 200 Lees Ave,Rm A106, Ottawa, ON K1N 6N5, Canada.	apost@uottawa.ca	Cusimano, Michael/X-4059-2019	Cusimano, Michael/0000-0002-9989-0650	Canadian Institutes of Health Research Strategic Team Grant in Applied Injury ResearchCanadian Institutes of Health Research (CIHR) [TIR-103946]; Ontario Neurotrauma Foundation	This research was supported by the Canadian Institutes of Health Research Strategic Team Grant in Applied Injury Research # TIR-103946 and the Ontario Neurotrauma Foundation. The authors have no personal, financial, or institutional interest in any of the drugs, materials, or devices described in this article.	Adamec J, 2010, J FORENSIC SCI, V55, P1615, DOI 10.1111/j.1556-4029.2010.01445.x; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Chalupnik JD, 1971, NIH692232 U WASH; Deck C, 2008, INT J CRASHWORTHINES, V13, P667, DOI 10.1080/13588260802411523; Doorly M. C., 2006, Computer Methods in Biomechanics and Biomedical Engineering, V9, P371, DOI 10.1080/10255840601003551; Doorly MC, 2009, INT J CRASHWORTHINES, V14, P503, DOI 10.1080/13588260902826554; Doorly M.C., 2007, THESIS U COLL DUBLIN; Frechede B, 2009, MED SCI SPORT EXER, V41, P390, DOI 10.1249/MSS.0b013e318186b1c5; GALBRAITH JA, 1993, J BIOMECH ENG-T ASME, V115, P13, DOI 10.1115/1.2895464; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gennarelli TA, 1972, P 16 STAPP CAR CRASH; Gennarelli Thomas A, 1987, P 31 STAPP CAR CRASH, DOI [10.4271/872197, DOI 10.4271/872197]; Gilchrist MD, 2000, COMPUT MECH, V26, P229, DOI 10.1007/s004660000179; Gilchrist MD, 2001, INT J CRASHWORTHINES, V6, P253, DOI 10.1533/cras.2001.0176; Gurdjian E S, 1964, Clin Neurosurg, V12, P112; Hardy W N, 2001, Stapp Car Crash J, V45, P337; Horgan TJ, 2004, INT J CRASHWORTHINES, V9, P401, DOI 10.1533/ijcr.2004.0299; Horgan TJ, 2003, INT J CRASHWORTHINES, V8, P353, DOI 10.1533/cras.8.4.353.19278; Hoshizaki TB, J NEUROL NE IN PRESS; Huang HM, 1999, J TRAUMA, V47, P538, DOI 10.1097/00005373-199909000-00019; Kang HS, 1997, P 41 STAPP CAR CRASH; Kendall M, 2012, P I MECH ENG P-J SPO, V226, P260, DOI 10.1177/1754337112436901; Kleiven S, 2003, J NEUROTRAUM, V20, P365, DOI 10.1089/089771503765172327; Kleiven S, 2002, J BIOMECH, V35, P153, DOI 10.1016/S0021-9290(01)00202-0; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; LEE MC, 1989, J BIOMECH, V22, P537, DOI 10.1016/0021-9290(89)90005-5; MENDIS KK, 1995, J BIOMECH ENG-T ASME, V117, P279, DOI 10.1115/1.2794182; Miller RT, 1998, P 42 STAPP CAR CRASH; Milne G, 2014, INT J CRASHWORTHINES, V19, P323, DOI 10.1080/13588265.2013.859470; Monson KL, 2003, J BIOMECH ENG-T ASME, V125, P288, DOI 10.1115/1.1554412; Nahum A. M., 1977, P 21 STAPP CAR CRASH; O'Connor C, 2005, PSYCHOL REP, V97, P169, DOI 10.2466/PR0.97.5.169-179; O'Riordain K, 2003, CLIN BIOMECH, V18, P590, DOI 10.1016/S0268-0033(03)00111-6; Ommaya A.K., 1985, BIOMECHANICS TRAUMA, P45; PADGAONKAR AJ, 1975, J APPL MECH-T ASME, V42, P552, DOI 10.1115/1.3423640; Post A, 2013, THESIS U OTTAWA; Post A, 2014, INT J CRASHWORTHINES, V19, P301, DOI 10.1080/13588265.2014.897413; Post A, 2014, J BIOMECH, V47, P1074, DOI 10.1016/j.jbiomech.2013.12.026; Post A, 2014, J NEUROSURG, V120, P453, DOI 10.3171/2013.10.JNS131101; Post A, 2012, P I MECH ENG P-J SPO, V226, P290, DOI 10.1177/1754337112436629; RUAN JS, 1994, THESIS WAYNE STATE U; Rueda MAF, 2009, FORENSIC SCI INT, V191, P52, DOI 10.1016/j.forsciint.2009.06.007; Schreiber DI, 1997, 41 STAPP CAR CRASH C, P277; Sosin DM, 1996, BRAIN INJURY, V10, P47; Styrke J, 2007, J NEUROTRAUM, V24, P1425, DOI 10.1089/neu.2007.0266; van Hoof J., 2003, STAPP CAR CRASH J, V47, P401; VIANO DC, 1989, J BIOMECH, V22, P403, DOI 10.1016/0021-9290(89)90201-7; Willinger R, 2003, INT J VEHICLE DES, V32, P94, DOI 10.1504/IJVD.2003.003239; Willinger R, 1995, P IRCOBI C; Yoganandan N, 2004, CLIN BIOMECH, V19, P225, DOI 10.1016/j.clinbiomech.2003.12.014; Yoganandan N, 2011, CLIN ANAT, V24, P282, DOI 10.1002/ca.21106; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhou C, 1995, 39 STAPP CAR CRASH C, P121	53	35	35	1	14	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JAN	2015	76	1					81	91		10.1227/NEU.0000000000000554			11	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	AW9UC	WOS:000346602000016	25525694	Green Accepted			2021-06-18	
J	Rodriguez, RA				Rodriguez, Rudolph A.			Dialysis for Undocumented Immigrants in the United States	ADVANCES IN CHRONIC KIDNEY DISEASE			English	Article						Undocumented immigrants; ESRD; Ethics	HEALTH-CARE; EXPENDITURES; SYSTEM	The United States offers near-universal coverage for treatment of ESRD. Undocumented immigrants with ESRD are the only subset of patients not covered under a national strategy. There are 2 divergent dialysis treatment strategies offered to undocumented immigrants in the United States, emergent dialysis and chronic outpatient dialysis. Emergent dialysis, offering dialysis only when urgent indications exist, is the treatment strategy in certain states. Differing interpretations of Emergency Medicaid statute by the courts and state and federal government have resulted in the geographic disparity in treatment strategies for undocumented immigrants with ESRD. The Patient Protection and Affordable Care Act of 2010 ignored the health care of undocumented immigrants and will not provide relief to undocumented patients with catastrophic illness like ESRD, cancer, or traumatic brain injuries. The difficult patient and provider decisions are explored in this review. The Renal Physicians Association Position Statement on uncompensated renal-related care for noncitizens is an excellent starting point for a framework to address this ethical dilemma. The practice of "emergent dialysis" will hopefully be found unacceptable in the future because of the fact that it is not cost effective, ethical, or humane. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.	[Rodriguez, Rudolph A.] Univ Washington, Div Nephrol, Seattle, WA 98195 USA	Rodriguez, RA (corresponding author), Puget Sound VA Med Ctr, Nephrol & Renal Dialysis Unit, Bldg 1,Room 229,1660 South Columbian Way, Seattle, WA 98108 USA.	rudyrod@u.washington.edu					[Anonymous], 2000, CLIN NEPHROL, V54, P253; Bernstein N, 2012, NY TIMES; Campbell GA, 2010, AM J KIDNEY DIS, V55, P181, DOI 10.1053/j.ajkd.2009.06.039; Coritsidis GN, 2004, AM J KIDNEY DIS, V43, P424, DOI 10.1053/j.ajkd.2003.11.004; Davidson A., 2013, NY TIMES; DuBard CA, 2007, JAMA-J AM MED ASSOC, V297, P1085, DOI 10.1001/jama.297.10.1085; Garcia-Garcia G, 2005, KIDNEY INT, V68, pS58, DOI 10.1111/j.1523-1755.2005.09710.x; Goldman DP, 2006, HEALTH AFFAIR, V25, P1700, DOI 10.1377/hlthaff.25.6.1700; Gusmano M. K., 2012, UNDOCUMENTED IMMIGRA; Kierans C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054380; Lee P, DISCHARGE DEPORTATIO; Matthews C, 2013, TIME EC         0130; Mohanty SA, 2005, AM J PUBLIC HEALTH, V95, P1431, DOI 10.2105/AJPH.2004.044602; Nzerue C, 2011, AM J KIDNEY DIS, V58, pXXVIII, DOI 10.1053/j.ajkd.2011.08.004; Passel J, 2013, POPULATION DECLINE U; Passel J.S., 2009, PORTRAIT UNAUTHORIZE; Passel JS, 2010, UNAUTHORIZED IMMIGRA; Porter E., 2005, NY TIMES; Raghavan R, 2012, SEMIN DIALYSIS, V25, P267, DOI 10.1111/j.1525-139X.2012.01066.x; Raghavan R, 2011, NEW ENGL J MED, V364, P2183, DOI 10.1056/NEJMp1101195; Renal Physicians Association, RPA POS UNC REN REL; Sack Kevin, 2010, NY TIMES; Sheikh-Hamad D, 2007, TEX MED, V103, P53; Sheikh-Hamad David, 2007, Tex Med, V103, P54; Straube BM, 2009, AM J KIDNEY DIS, V53, P921, DOI 10.1053/j.ajkd.2009.04.010; Sulek JP, 2012, SAN JOSE MERCUR 1005; The Kaiser Commission on Medicaid and the Uninsured, DO MED DISPR SHAR HO; U.S. Department of Homeland Security, CLAR EXIST PRACT REL; Villarejo D, 2010, AM J IND MED, V53, P387, DOI 10.1002/ajim.20796; Wijkstrom J, 2013, AM J KIDNEY DIS, V62, P908, DOI 10.1053/j.ajkd.2013.05.019; Young MJ, 2014, NEW ENGL J MED, V370, P669, DOI 10.1056/NEJMhle1311198; Zarembo A., 2008, LOS ANGELES TIMES	32	35	35	0	8	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1548-5595	1548-5609		ADV CHRONIC KIDNEY D	Adv. Chronic Kidney Dis.	JAN	2015	22	1					60	65		10.1053/j.ackd.2014.07.003			6	Urology & Nephrology	Urology & Nephrology	AY9GA	WOS:000347856400010	25573514				2021-06-18	
J	Chan, JL; Reeves, TM; Phillips, LL				Chan, Julie L.; Reeves, Thomas M.; Phillips, Linda L.			Osteopontin expression in acute immune response mediates hippocampal synaptogenesis and adaptive outcome following cortical brain injury	EXPERIMENTAL NEUROLOGY			English	Article							CLOSED-HEAD INJURY; EXTRACELLULAR-MATRIX MOLECULES; FOCAL CEREBRAL-ISCHEMIA; CELL-ADHESION MOLECULES; SPINAL-CORD-INJURY; UP-REGULATION; TNF-ALPHA; MICROGLIAL ACTIVATION; GENE-EXPRESSION; PROINFLAMMATORY CYTOKINE	Traumatic brain injury (TBI) produces axotomy, deafferentation and reactive synaptogenesis. Inflammation influences synaptic repair, and the novel brain cytokine osteopontin (OPN) has potential to support axon regeneration through exposure of its integrin receptor binding sites. This study explored whether OPN secretion and proteolysis by matrix metalloproteinases (MMPs) mediate the initial degenerative phase of synaptogenesis, targeting reactive neuroglia to affect successful repair. Adult rats received unilateral entorhinal cortex lesion (UEC) modeling adaptive synaptic plasticity. Over the first week postinjury, hippocampal OPN protein and mRNA were assayed and histology was performed. At 1 similar to 2 d, OPN protein increased up to 51 fold, and was localized within activated, mobilized glia. OPN transcript also increased over 50 fold, predominantly within reactive microglia. OPN fragments known to be derived from MMP proteolysis were elevated at 1 d, consistent with prior reports of UEC glial activation and enzyme production. Postinjury minocycline immunosuppression attenuated MMP-9 gelatinase activity, which was correlated with the reduction of neutrophil gelatinase-associated lipocalin (LCN2) expression, and reduced OPN fragment generation. The antibiotic also attenuated removal of synapsin-1 positive axons from the deafferented zone. OPN KO mice subjected to UEC had similar reduction of hippocampal MMP-9 activity, as well as lower synapsin-1 breakdown over the deafferented zone. MAP1B and N-cadherin, surrogates of cytoarchitecture and synaptic adhesion, were not affected. OPN KO mice with UEC exhibited time dependent cognitive deficits during the synaptogenic phase of recovery. This study demonstrates that OPN can mediate immune response during TBI synaptic repair, positively influencing synapse reorganization and functional recovery. (C) 2014 Elsevier Inc. All rights reserved.	[Chan, Julie L.; Reeves, Thomas M.; Phillips, Linda L.] Virginia Commonwealth Univ, Dept Anat & Neurobiol, Richmond, VA 23298 USA	Phillips, LL (corresponding author), Virginia Commonwealth Univ, Dept Anat & Neurobiol, POB 980709, Richmond, VA 23298 USA.	llphilli@vcu.edu		Chan, Julie/0000-0002-0782-6548	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS 044372, NS 056247, NS 057758]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS056247, R01NS044372, R01NS057758, R56NS044372] Funding Source: NIH RePORTER	This work was supported by the NIH awards NS 044372, NS 056247 and NS 057758. We thank Lesley Harris, Raiford Black, Nancy Lee and Terry Smith for excellent technical assistance and Dr. Adele Doperalski for helpful comments on the manuscript. The authors are grateful for the expert support and data analysis in the qtRT-PCR studies provided by Tana Blevins and Dr. Catherine Dumur, Molecular Diagnostic Services Laboratory, Department of Pathology, VCU.	Baratz R, 2011, J NEUROCHEM, V118, P1032, DOI 10.1111/j.1471-4159.2011.07377.x; Belanger Mireille, 2009, Dialogues Clin Neurosci, V11, P281; Borges K, 2008, EPILEPSIA, V49, P1675, DOI 10.1111/j.1528-1167.2008.01613.x; Brundula V, 2002, BRAIN, V125, P1297, DOI 10.1093/brain/awf133; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Cayabyab FS, 2013, J NEUROSCI RES, V91, P920, DOI 10.1002/jnr.23223; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Chabas D, 2001, SCIENCE, V294, P1731, DOI 10.1126/science.1062960; Choi JS, 2007, BRAIN RES, V1151, P195, DOI 10.1016/j.brainres.2007.03.016; Choi JS, 2004, EXP BRAIN RES, V154, P275, DOI 10.1007/s00221-003-1657-4; Correale J, 2004, J NEUROL, V251, P1304, DOI 10.1007/s00415-004-0649-z; Crack P, 2009, J NEURAL TRANSM, V116, P1, DOI 10.1007/s00702-008-0145-1; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Cunningham LA, 2005, GLIA, V50, P329, DOI 10.1002/glia.20169; Degos V, 2013, ANESTHESIOLOGY, V118, P1362, DOI 10.1097/ALN.0b013e31828c23f8; del Zoppo GJ, 2012, J CEREBR BLOOD F MET, V32, P919, DOI 10.1038/jcbfm.2012.11; Derecki NC, 2010, J EXP MED, V207, P1067, DOI 10.1084/jem.20091419; Dityatev A, 2003, NAT REV NEUROSCI, V4, P456, DOI 10.1038/nrn1115; Dityatev A, 2006, CELL TISSUE RES, V326, P647, DOI 10.1007/s00441-006-0217-1; Dumur CI, 2009, LARYNGOSCOPE, V119, P91, DOI 10.1002/lary.20005; Ellison JA, 1998, STROKE, V29, P1698, DOI 10.1161/01.STR.29.8.1698; Ellison JA, 1999, ANN NY ACAD SCI, V890, P204, DOI 10.1111/j.1749-6632.1999.tb07996.x; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; Ethell IM, 2007, J NEUROSCI RES, V85, P2813, DOI 10.1002/jnr.21273; Falo MC, 2006, J NEUROSCI RES, V84, P768, DOI 10.1002/jnr.20986; Falo MC, 2008, J NEUROTRAUM, V25, P769, DOI 10.1089/neu.2008.0511; Fifre A, 2006, J BIOL CHEM, V281, P229, DOI 10.1074/jbc.M507378200; Fuller BF, 2012, ENVIRON HEALTH PERSP, V120, P1684, DOI 10.1289/ehp.1104857; Goussev S, 2003, J NEUROSURG, V99, P188, DOI 10.3171/spi.2003.99.2.0188; GREIF KF, 1988, SYNAPSE, V2, P1, DOI 10.1002/syn.890020102; Griesbach GS, 2009, J NEUROSCI RES, V87, P795, DOI 10.1002/jnr.21893; Guest PC, 2012, PROTEOMICS, V12, P3580, DOI 10.1002/pmic.201200376; Hamby ME, 2010, NEUROTHERAPEUTICS, V7, P494, DOI 10.1016/j.nurt.2010.07.003; HAN HQ, 1991, NATURE, V349, P697, DOI 10.1038/349697a0; Han XD, 2011, J NEUROTRAUM, V28, P995, DOI 10.1089/neu.2010.1563; Hanisch UK, 2002, GLIA, V40, P140, DOI 10.1002/glia.10161; Hardman R, 1997, BRAIN RES, V758, P187, DOI 10.1016/S0006-8993(97)00223-0; Hashimoto M, 2003, J NEUROTRAUM, V20, P287, DOI 10.1089/089771503321532879; Hashimoto M, 2007, J NEUROSCI, V27, P3603, DOI 10.1523/JNEUROSCI.4805-06.2007; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Higo N, 2010, J COMP NEUROL, V518, P2633, DOI 10.1002/cne.22356; Homsi S, 2009, BRAIN RES, V1291, P122, DOI 10.1016/j.brainres.2009.07.031; HWANG S, 1994, J BIOL CHEM, V269, P711; Iczkiewicz J, 2004, MOL BRAIN RES, V132, P64, DOI 10.1016/j.molbrainres.2004.09.013; Israelsson C, 2006, J NEUROSCI RES, V84, P47, DOI 10.1002/jnr.20856; John GR, 2003, NEUROSCIENTIST, V9, P10, DOI 10.1177/1073858402239587; Ju WK, 2000, BRAIN RES, V852, P217, DOI 10.1016/S0006-8993(99)02140-X; Kang WS, 2008, BRAIN RES, V1228, P208, DOI 10.1016/j.brainres.2008.06.106; Keilhoff G, 2007, DEV NEUROBIOL, V67, P1382, DOI 10.1002/dneu.20384; Kelso ML, 2011, NEUROSCI LETT, V488, P60, DOI 10.1016/j.neulet.2010.11.003; Kim HJ, 2005, EXP NEUROL, V192, P60, DOI 10.1016/j.expneurol.2004.10.014; Kloss CUA, 1999, J COMP NEUROL, V411, P162, DOI 10.1002/(SICI)1096-9861(19990816)411:1<162::AID-CNE12>3.0.CO;2-W; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Lee MY, 1999, NEUROSCI LETT, V271, P81, DOI 10.1016/S0304-3940(99)00526-1; Liaw L, 1998, J CLIN INVEST, V101, P1468; Lively S, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-75; LOESCHE J, 1977, BRAIN RES BULL, V2, P31, DOI 10.1016/0361-9230(77)90022-3; Long P, 2012, EUR J NEUROSCI, V36, P2733, DOI 10.1111/j.1460-9568.2012.08189.x; Lu L, 2008, HIPPOCAMPUS, V18, P1074, DOI 10.1002/hipo.20466; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Lucca JJD, 2012, J NEUROL SCI, V318, P146, DOI 10.1016/j.jns.2012.02.002; LUND RD, 1971, SCIENCE, V171, P804, DOI 10.1126/science.171.3973.804; Machado LS, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-56; Maetzler W, 2007, NEUROBIOL DIS, V25, P473, DOI 10.1016/j.nbd.2006.10.020; Matsukawa N, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-126; Mejia ROS, 2001, NEUROSURGERY, V48, P1393; MELLONI RH, 1994, NEUROSCIENCE, V58, P683, DOI 10.1016/0306-4522(94)90448-0; Meunier J., 2001, EUR J PHARMACOL, V698, P193; Milner R, 2002, J NEUROSCI RES, V69, P286, DOI 10.1002/jnr.10321; Misawa H, 2012, J NEUROSCI RES, V90, P732, DOI 10.1002/jnr.22813; Moon C, 2004, J VET MED SCI, V66, P1307, DOI 10.1292/jvms.66.1307; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Morita M, 2008, NEUROSCIENCE, V153, P1135, DOI 10.1016/j.neuroscience.2008.01.078; Nikonenko I, 2003, DEV BRAIN RES, V140, P185, DOI 10.1016/S0165-3806(02)00590-4; Park JM, 2012, J HISTOCHEM CYTOCHEM, V60, P550, DOI 10.1369/0022155412441707; Park KP, 2009, STROKE, V40, P2836, DOI 10.1161/STROKEAHA.109.554824; PATARCA R, 1989, J EXP MED, V170, P145, DOI 10.1084/jem.170.1.145; Pellerin L, 2004, NEUROSCIENTIST, V10, P53, DOI 10.1177/1073858403260159; PHILLIPS LL, 1994, J NEUROTRAUM, V11, P641, DOI 10.1089/neu.1994.11.641; Plantman S, 2012, NEUROREPORT, V23, P647, DOI 10.1097/WNR.0b013e328355380e; Popa-Wagner A, 1999, J CEREBR BLOOD F MET, V19, P425, DOI 10.1097/00004647-199904000-00008; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Power C, 2003, ANN NEUROL, V53, P731, DOI 10.1002/ana.10553; REEVES TM, 1986, EXP BRAIN RES, V65, P167; Rothwell NJ, 2000, TRENDS NEUROSCI, V23, P618, DOI 10.1016/S0166-2236(00)01661-1; Ruoslahti E, 1996, GLYCOBIOLOGY, V6, P489, DOI 10.1093/glycob/6.5.489; Sato K, 2000, BRAIN RES, V872, P219, DOI 10.1016/S0006-8993(00)02460-4; Scatena M, 2007, ARTERIOSCL THROM VAS, V27, P2302, DOI 10.1161/ATVBAHA.107.144824; Shin T, 2005, BRAIN RES, V1041, P95, DOI 10.1016/j.brainres.2005.02.019; Shin YJ, 2011, GLIA, V59, P413, DOI 10.1002/glia.21110; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Siopi E, 2012, NEUROSCI LETT, V511, P110, DOI 10.1016/j.neulet.2012.01.051; Sofroniew M.V., 2000, NEUROSCIENTIST, V5, P400; STEWARD O, 1977, BRAIN RES BULL, V2, P41, DOI 10.1016/0361-9230(77)90023-5; STEWARD O, 1989, Journal of Neurotrauma, V6, P99, DOI 10.1089/neu.1989.6.99; Su JM, 2010, J COMP NEUROL, V518, P229, DOI 10.1002/cne.22228; Suzuki H, 2010, CRIT CARE MED, V38, P612, DOI 10.1097/CCM.0b013e3181c027ae; Takafuji V, 2007, ONCOGENE, V26, P6361, DOI 10.1038/sj.onc.1210463; Takeichi M, 2005, TRENDS CELL BIOL, V15, P216, DOI 10.1016/j.tcb.2005.02.002; Tambuyzer BR, 2012, CELL BIOL INT, V36, P1233, DOI 10.1042/CBI20120172; Truett GE, 2000, BIOTECHNIQUES, V29, P52, DOI 10.2144/00291bm09; Tschesche H, 2001, EUR J BIOCHEM, V268, P1918, DOI 10.1046/j.1432-1327.2001.02066.x; van Velthoven CTJ, 2011, STROKE, V42, P2294, DOI 10.1161/STROKEAHA.110.608315; VENSTROM KA, 1993, FASEB J, V7, P996; Verslegers M, 2013, PROG NEUROBIOL, V105, P60, DOI 10.1016/j.pneurobio.2013.03.004; Vitarbo EA, 2004, NEUROSURGERY, V55, P416, DOI 10.1227/01.NEU.0000130036.52521.2C; von Gertten C, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-69; Wang XK, 1998, J NEUROSCI, V18, P2075; Warren KM, 2012, J NEUROTRAUM, V29, P1922, DOI 10.1089/neu.2012.2383; Weber Georg F., 1996, Cytokine and Growth Factor Reviews, V7, P241, DOI 10.1016/S1359-6101(96)00030-5; Wu AG, 2011, J NEUROTRAUM, V28, P2113, DOI 10.1089/neu.2011.1872; Wung JK, 2007, CURR ALZHEIMER RES, V4, P67, DOI 10.2174/156720507779939869; Yamagata M, 2002, CELL, V110, P649, DOI 10.1016/S0092-8674(02)00910-8; Yamamoto T., 2011, PLOS ONE, V8; Yrjanheikki J, 1999, P NATL ACAD SCI USA, V96, P13496, DOI 10.1073/pnas.96.23.13496; Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769; Zhao C, 2008, NEUROBIOL DIS, V31, P209, DOI 10.1016/j.nbd.2008.04.007; Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a; Ziv Y, 2006, NAT NEUROSCI, V9, P268, DOI 10.1038/nn1629	121	35	36	0	12	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	NOV	2014	261						757	771		10.1016/j.expneurol.2014.08.015			15	Neurosciences	Neurosciences & Neurology	AR4AX	WOS:000343531500082	25151457	Green Accepted			2021-06-18	
J	Nielson, JL; Guandique, CF; Liu, AW; Burke, DA; Lash, AT; Moseanko, R; Hawbecker, S; Strand, SC; Zdunowski, S; Irvine, KA; Brock, JH; Nout-Lomas, YS; Gensel, JC; Anderson, KD; Segal, MR; Rosenzweig, ES; Magnuson, DS; Whittemore, SR; McTigue, DM; Popovich, PG; Rabchevsky, AG; Scheff, SW; Steward, O; Courtine, G; Edgerton, VR; Tuszynski, MH; Beattie, MS; Bresnahan, JC; Ferguson, AR				Nielson, Jessica L.; Guandique, Cristian F.; Liu, Aiwen W.; Burke, Darlene A.; Lash, A. Todd; Moseanko, Rod; Hawbecker, Stephanie; Strand, Sarah C.; Zdunowski, Sharon; Irvine, Karen-Amanda; Brock, John H.; Nout-Lomas, Yvette S.; Gensel, John C.; Anderson, Kim D.; Segal, Mark R.; Rosenzweig, Ephron S.; Magnuson, David S. K.; Whittemore, Scott R.; McTigue, Dana M.; Popovich, Phillip G.; Rabchevsky, Alexander G.; Scheff, Stephen W.; Steward, Oswald; Courtine, Gregoire; Edgerton, V. Reggie; Tuszynski, Mark H.; Beattie, Michael S.; Bresnahan, Jacqueline C.; Ferguson, Adam R.			Development of a Database for Translational Spinal Cord Injury Research	JOURNAL OF NEUROTRAUMA			English	Article						monkeys; rodents; bioinformatics; translation; syndromics	TRAUMATIC BRAIN-INJURY; INDEPENDENCE MEASURE; TIME LIMITS; RECOVERY; SCALE; MULTICENTER; VALIDITY; RELIABILITY; COMPRESSION; SCIM	Efforts to understand spinal cord injury (SCI) and other complex neurotrauma disorders at the pre-clinical level have shown progress in recent years. However, successful translation of basic research into clinical practice has been slow, partly because of the large, heterogeneous data sets involved. In this sense, translational neurological research represents a "big data" problem. In an effort to expedite translation of pre-clinical knowledge into standards of patient care for SCI, we describe the development of a novel database for translational neurotrauma research known as Visualized Syndromic Information and Outcomes for Neurotrauma-SCI (VISION-SCI). We present demographics, descriptive statistics, and translational syndromic outcomes derived from our ongoing efforts to build a multi-center, multi-species pre-clinical database for SCI models. We leveraged archived surgical records, postoperative care logs, behavioral outcome measures, and histopathology from approximately 3000 mice, rats, and monkeys from pre-clinical SCI studies published between 1993 and 2013. The majority of animals in the database have measures collected for health monitoring, such as weight loss/gain, heart rate, blood pressure, postoperative monitoring of bladder function and drug/fluid administration, behavioral outcome measures of locomotion, and tissue sparing postmortem. Attempts to align these variables with currently accepted common data elements highlighted the need for more translational outcomes to be identified as clinical endpoints for therapeutic testing. Last, we use syndromic analysis to identify conserved biological mechanisms of recovery after cervical SCI between rats and monkeys that will allow for more-efficient testing of therapeutics that will need to be translated toward future clinical trials.	[Nielson, Jessica L.; Guandique, Cristian F.; Liu, Aiwen W.; Beattie, Michael S.; Bresnahan, Jacqueline C.; Ferguson, Adam R.] Univ Calif San Francisco, Brain & Spinal Injury Ctr, Dept Neurol Surg, San Francisco, CA 94110 USA; [Burke, Darlene A.; Magnuson, David S. K.; Whittemore, Scott R.] Univ Louisville, Kentucky Spinal Cord Injury Res Ctr, Dept Neurol Surg, Louisville, KY 40292 USA; [Lash, A. Todd] Ohio State Univ, Off Res Off Responsible Res Practices, Columbus, OH 43210 USA; [Moseanko, Rod; Hawbecker, Stephanie; Strand, Sarah C.] Univ Calif Davis, Calif Natl Primate Res Ctr, Davis, CA 95616 USA; [Zdunowski, Sharon; Edgerton, V. Reggie] Univ Calif Los Angeles, Dept Integrat Biol & Physiol, Los Angeles, CA USA; [Irvine, Karen-Amanda] Univ Calif San Francisco, Dept Neurol, San Francisco VA Med Ctr, San Francisco, CA 94110 USA; [Brock, John H.; Rosenzweig, Ephron S.; Tuszynski, Mark H.] Univ Calif San Diego, Dept Neurosci, Ctr Neural Repair, La Jolla, CA 92093 USA; [Nout-Lomas, Yvette S.] Colorado State Univ, Coll Vet Med & Biomed Sci, Dept Clin Sci, Ft Collins, CO 80523 USA; [Gensel, John C.; Rabchevsky, Alexander G.; Scheff, Stephen W.] Univ Kentucky, Chandler Med Ctr, Spinal Cord & Brain Injury Res Ctr, Lexington, KY USA; [Anderson, Kim D.] Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Dept Neurol Surg, Miami, FL 33136 USA; [Segal, Mark R.] Univ Calif San Francisco, Dept Epidemiol & Biostat, Ctr Bioinformat & Mol Biostat, San Francisco, CA 94110 USA; [McTigue, Dana M.; Popovich, Phillip G.] Ohio State Univ, Dept Neurosci, Ctr Brain & Spinal Cord Repair, Columbus, OH 43210 USA; [Scheff, Stephen W.] Univ Kentucky, Dept Anat & Neurobiol, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; [Steward, Oswald] Univ Calif Irvine, Dept Anat & Neurobiol, Reeve Irvine Res Ctr, Irvine, CA 92717 USA; [Steward, Oswald] Univ Calif Irvine, Dept Neurobiol & Behav, Reeve Irvine Res Ctr, Irvine, CA USA; [Steward, Oswald] Univ Calif Irvine, Dept Neurosurg, Reeve Irvine Res Ctr, Irvine, CA USA; [Courtine, Gregoire] Swiss Fed Inst Technol, Ctr Neuroprosthet, CH-1015 Lausanne, Switzerland; [Courtine, Gregoire] Swiss Fed Inst Technol, Brain Mind Inst, CH-1015 Lausanne, Switzerland; [Tuszynski, Mark H.] Vet Adm Med Ctr, La Jolla, CA USA	Ferguson, AR (corresponding author), Univ Calif San Francisco, Brain & Spinal Injury Ctr, Dept Neurol Surg, 1001 Potrero Ave,Bldg 1,Room 101, San Francisco, CA 94110 USA.	adam.ferguson@ucsf.edu	Rosenzweig, Ephron/AAI-7541-2020; courtine, gregoire/AAJ-1694-2020; Anderson, Kim/ABA-2258-2020; Rabchevsky, Alexander/AAQ-2451-2021	courtine, gregoire/0000-0002-5744-4142; Anderson, Kim/0000-0001-9252-161X; Rabchevsky, Alexander/0000-0002-1991-0915; Nielson, Jessica/0000-0002-3677-3959; Ferguson, Adam/0000-0001-7102-1608; Steward, Oswald/0000-0001-7069-8756; , John/0000-0001-8980-108X; Rosenzweig, Ephron/0000-0002-0370-9643; Nout-Lomas, Yvette/0000-0001-6583-2308; Magnuson, David/0000-0003-3816-3676	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS067092, F32NS079030, R01NS038079, R01NS042291, R01NS031193, R01NS032000]; Craig H. Neilsen Foundation [224308]; Wings for Life [WFLUS008/12]; NYS CoRE [CO19772, R21 AG032518, R01 NS052292, P01 RR15576, P30 GM103507, R01 NS073584, R01 NS045734, R01 NS089324, R01 NS059776, P30-NS045758, P01NS010165]; Veterans AdministrationUS Department of Veterans Affairs; Kentucky Spinal Cord and Head Injury Research Trust; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; Research for Cure; Roman Reed Spinal Cord Injury Research Fund of the State of California; Craig H. Neilsen Foundation; American Paralysis Association; Paralyzed Veterans of America; Christopher and Dana Reeve Foundation;  [NIH-N01-NS-3-2353];  [NIH-NO1-NS-3-2354]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20RR015576] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P30GM103507] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS045758, F32NS079030, R01NS073584, R01NS032000, N01NS032353, R01NS089324, R01NS031193, R01NS042291, R01NS045734, R01NS067092, R01NS059776, R01NS052292, R01NS073857, R01NS038079] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R21AG032518] Funding Source: NIH RePORTER	The authors thank, in alphabetical order, Rochelle Deibert, Crystal Forrider, Jenny Haefeli, J. Russell Huie, Amity Lin, Brandon Miller, Vladimir Muraru, Ellen Stuck, AmyTovar, Montina J. Van Meter, and Sergio Veiga for their technical assistance and fruitful discussions regarding database development. This work was supported by NIH grants R01NS067092 (to A. R. F.) and F32NS079030 (to J. L. N.); Craig H. Neilsen Foundation 224308, and Wings for Life WFLUS008/12. Primary data collection was supported by NIH grants R01NS038079, R01NS042291, R01NS031193, and R01NS032000; NYS CoRE CO19772, R21 AG032518, R01 NS052292, P01 RR15576, P30 GM103507, R01 NS073584, R01 NS045734, R01 NS089324, R01 NS059776, P30-NS045758, P01NS010165, NIH-N01-NS-3-2353, and NIH-NO1-NS-3-2354 contract (Facilities of Research Excellence in Spinal Cord Injury), the Veterans Administration, the Kentucky Spinal Cord and Head Injury Research Trust, the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, Research for Cure, the Roman Reed Spinal Cord Injury Research Fund of the State of California, the Craig H. Neilsen Foundation, the American Paralysis Association, Paralyzed Veterans of America, and the Christopher and Dana Reeve Foundation.	Aguilar RM, 2010, EXP NEUROL, V221, P38, DOI 10.1016/j.expneurol.2009.09.028; Anderson KD, 2011, SPINAL CORD, V49, P880, DOI 10.1038/sc.2011.20; Anderson KD, 2004, J NEUROTRAUM, V21, P1371, DOI 10.1089/neu.2004.21.1371; Basso DM, 2006, J NEUROTRAUM, V23, P635, DOI 10.1089/neu.2006.23.635; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Catz A, 1997, SPINAL CORD, V35, P850, DOI 10.1038/sj.sc.3100504; Christopher and Dana Reeve Foundation (CDRF-PRC), 2009, PAR RES CTR PAR FACT; Cook DJ, 2011, EXPERT REV CARDIOVAS, V9, P433, DOI [10.1586/erc.11.34, 10.1586/ERC.11.34]; Ditunno JF, 2000, SPINAL CORD, V38, P234, DOI 10.1038/sj.sc.3100993; Ditunno JE, 2007, NEUROREHAB NEURAL RE, V21, P539, DOI 10.1177/1545968307301880; Ditunno PL, 2001, SPINAL CORD, V39, P654, DOI 10.1038/sj.sc.3101223; Ferguson AR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059712; Ferguson AR, 2011, TRANSL STROKE RES, V2, P438, DOI 10.1007/s12975-011-0121-1; Fouad K, 2012, EXP NEUROL, V235, P91, DOI 10.1016/j.expneurol.2011.02.009; Irvine K.-A., 2010, JOVE-J VIS EXP, DOI [10.3791/2246, DOI 10.3791/2246]; Kalsi-Ryan S, 2009, TOP SPINAL CORD INJ, V14, P34, DOI DOI 10.1310/sci1404-34; Kalsi-Ryan S, 2012, J NEUROTRAUM, V29, P905, DOI 10.1089/neu.2010.1504; Lammertse DP, 2013, SPINAL CORD, V51, P2, DOI 10.1038/sc.2012.137; Landis SC, 2012, NATURE, V490, P187, DOI 10.1038/nature11556; Lemmon V. P., 2014, J NEUROTRAUMA; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; National Institute of Neurological Disorders and Stroke (NINDS), 2014, NINDS COMM DAT EL SP; NIF, 2014, NEUR INF FRAM DEV TO; Nout YS, 2012, NEUROREHAB NEURAL RE, V26, P556, DOI 10.1177/1545968311421934; Nout YS, 2012, NEUROTHERAPEUTICS, V9, P380, DOI 10.1007/s13311-012-0114-0; Pearson K, 1901, PHILOS MAG, V2, P559, DOI 10.1080/14786440109462720; RIVLIN AS, 1977, J NEUROSURG, V47, P577, DOI 10.3171/jns.1977.47.4.0577; Scargle J. D., 2000, J SCI EXPLOR, V14, P16; Steward O, 2012, EXP NEUROL, V233, P597, DOI 10.1016/j.expneurol.2011.06.017; TARLOV IM, 1954, AMA ARCH NEUROL PSY, V71, P588, DOI 10.1001/archneurpsyc.1954.02320410050004; TARLOV IM, 1954, AMA ARCH NEUROL PSY, V71, P271, DOI 10.1001/archneurpsyc.1954.02320390001001; Tator CH, 1998, NEUROSURGERY, V42, P696, DOI 10.1097/00006123-199804000-00007; Watzlawick R, 2014, JAMA NEUROL, V71, P91, DOI 10.1001/jamaneurol.2013.4684; WRATHALL JR, 1985, EXP NEUROL, V88, P108, DOI 10.1016/0014-4886(85)90117-7	35	35	35	0	22	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV 1	2014	31	21					1789	1799		10.1089/neu.2014.3399			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AR0TW	WOS:000343285300004	25077610	Green Published			2021-06-18	
J	Colantonio, A; Kim, H; Allen, S; Asbridge, M; Petgrave, J; Brochu, S				Colantonio, Angela; Kim, Hwan; Allen, Stefan; Asbridge, Mark; Petgrave, Josian; Brochu, Serge			Traumatic Brain Injury and Early Life Experiences Among Men and Women in a Prison Population	JOURNAL OF CORRECTIONAL HEALTH CARE			English	Article						traumatic brain injury; prison; sex differences; gender differences	VIOLENT CRIMINAL BEHAVIOR; SEXUAL-ABUSE; HEAD-INJURY; SUBSTANCE USE; HEALTH; PREVALENCE; REHABILITATION; TBI	This study examined the proportion of men and women reporting previous traumatic brain injury (TBI) in an Ontario (Canada) prison sample by demographic characteristics; adverse life experiences; and criminal, drug, and alcohol use history. Using data from The Cost of Substance Abuse in Canada study based on a random sample from four Ontario prisons, this study found 50.4% of males and 38% of females reporting previous TBI. More TBIs occurred before the first crime for women than for men. Women with TBI experienced more early physical and sexual abuse than those without TBI. Additionally, this study shows high prevalence of early life experiences among persons, particularly women, with a history of TBI. Prisoners and prison staff should be educated on TBI and best practice for rehabilitation of TBI.	[Colantonio, Angela; Petgrave, Josian] Univ Toronto, Toronto, ON, Canada; [Colantonio, Angela] Toronto Rehabil Inst UHN, Toronto, ON, Canada; [Kim, Hwan] Daegu Univ, Jillyang, Gyeongsan Gyeon, South Korea; [Allen, Stefan; Asbridge, Mark] Dalhousie Univ, Halifax, NS, Canada; [Brochu, Serge] Univ Montreal, Montreal, PQ, Canada	Colantonio, A (corresponding author), Univ Toronto, Dept Occupat Sci & Occupat Therapy, 160-500 Univ Ave, Toronto, ON M5G 1V7, Canada.	angela.colantonio@utoronto.ca		Colantonio, Angela/0000-0003-2094-4765	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [TIR-103946] Funding Source: Medline		American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Bogner J, 2009, J HEAD TRAUMA REHAB, V24, P279, DOI 10.1097/HTR.0b013e3181a66356; Brewer-Smyth K, 2004, BIOL PSYCHIAT, V55, P21, DOI 10.1016/S0006-3223(03)00705-4; Canadian Institute for Health Information, 2007, BURD NEUR DIS DIS IN; Chen A, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-76; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Colantonio A, 2007, BRAIN INJURY, V21, P1353, DOI 10.1080/02699050701785054; Colantonio Angela, 2010, Healthc Policy, V5, pe120; Colantonio A, 2010, CAN J NEUROL SCI, V37, P783, DOI 10.1017/S0317167100051441; Collins D., 2006, INT GUIDELINES ESTIM; Corrigan JD, 2007, BRAIN INJURY, V21, P343, DOI 10.1080/02699050701253103; Dahlberg CA, 2007, ARCH PHYS MED REHAB, V88, P1561, DOI 10.1016/j.apmr.2007.07.033; Ferguson PL, 2012, J HEAD TRAUMA REHAB, V27, pE11, DOI 10.1097/HTR.0b013e31824e5f47; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Glasser M, 2001, BRIT J PSYCHIAT, V179, P482, DOI 10.1192/bjp.179.6.482; Graham DP, 2008, ANN NY ACAD SCI, V1141, P148, DOI 10.1196/annals.1441.029; Hawley CA, 2003, BRAIN INJURY, V17, P743, DOI 10.1080/0269905031000089341; Hwang SW, 2008, CAN MED ASSOC J, V179, P779, DOI 10.1503/cmaj.080341; Jackson M, 2011, CORRECTIONS RES PAPE; Lemsky C., 2005, SUBSTANCE ABUSE BRAI; Leon-Carrion J, 2003, BRAIN INJURY, V17, P207, DOI 10.1080/0269905021000010249; McDaniels-Wilson C, 2008, VIOLENCE AGAINST WOM, V14, P1090, DOI 10.1177/1077801208323160; Olson-Madden JH, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/174579; Perkes I, 2011, BRAIN INJURY, V25, P131, DOI 10.3109/02699052.2010.536193; Sarapatta M, 1998, BRAIN INJURY, V12, P821, DOI 10.1080/026990598122061; Shiroma Eric J, 2010, J Correct Health Care, V16, P273, DOI 10.1177/1078345810378253; Shiroma Eric J, 2010, J Correct Health Care, V16, P147, DOI 10.1177/1078345809356538; Slaughter B, 2003, BRAIN INJURY, V17, P731, DOI 10.1080/0269905031000088649; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tsukada M, 2012, BRAIN INJURY, V26, P774; West SL, 2011, NEUROREHABILITATION, V29, P1, DOI 10.3233/NRE-2011-0671; Williams WH, 2010, BRAIN INJURY, V24, P1184, DOI 10.3109/02699052.2010.495697; Yuhasz JE, 2013, J CORRECT HEALTH CAR, V19, P135, DOI 10.1177/1078345812474644	33	35	35	0	36	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1078-3458	1940-5200		J CORRECT HEALTH CAR	J. Correct. Health Care	OCT	2014	20	4					271	279		10.1177/1078345814541529			9	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	AQ3BL	WOS:000342663600002	25033995				2021-06-18	
J	Chen, S; Wu, HJ; Klebe, D; Hong, Y; Zhang, JM				Chen, Sheng; Wu, Haijian; Klebe, Damon; Hong, Yuan; Zhang, Jianmin			Valproic Acid: A New Candidate of Therapeutic Application for the Acute Central Nervous System Injuries	NEUROCHEMICAL RESEARCH			English	Article						Valproic acid; Brain injuries; Histone deacetylases inhibitor; Neuroprotection	HISTONE DEACETYLASE INHIBITORS; TRAUMATIC BRAIN-INJURY; SPINAL-CORD-INJURY; FOCAL CEREBRAL-ISCHEMIA; PROTECTS DOPAMINERGIC-NEURONS; PROMOTES FUNCTIONAL RECOVERY; MOOD STABILIZER; MEDIATED NEUROPROTECTION; BARRIER DISRUPTION; HEMORRHAGIC-SHOCK	Acute central nervous system (CNS) injuries, including stroke, traumatic brain injury (TBI), and spinal cord injury (SCI), are common causes of human disabilities and deaths, but the pathophysiology of these diseases is not fully elucidated and, thus, effective pharmacotherapies are still lacking. Valproic acid (VPA), an inhibitor of histone deacetylation, is mainly used to treat epilepsy and bipolar disorder with few complications. Recently, the neuroprotective effects of VPA have been demonstrated in several models of acute CNS injuries, such as stroke, TBI, and SCI. VPA protects the brain from injury progression via anti-inflammatory, anti-apoptotic, and neurotrophic effects. In this review, we focus on the emerging neuroprotective properties of VPA and explore the underlying mechanisms. In particular, we discuss several potential related factors in VPA research and present the opportunity to administer VPA as a novel neuropective agent.	[Chen, Sheng; Wu, Haijian; Hong, Yuan; Zhang, Jianmin] Zhejiang Univ, Sch Med, Dept Neurosurg, Affiliated Hosp 2, Hangzhou 310009, Zhejiang, Peoples R China; [Klebe, Damon] Loma Linda Univ, Dept Physiol, Loma Linda, CA 92350 USA; [Klebe, Damon] Loma Linda Univ, Dept Pharmacol, Loma Linda, CA 92350 USA	Zhang, JM (corresponding author), Zhejiang Univ, Sch Med, Dept Neurosurg, Affiliated Hosp 2, Hangzhou 310009, Zhejiang, Peoples R China.	zjm135vip@126.com		chen, sheng/0000-0002-8374-136X	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81171096, 81371433, 81371369]	This study was supported by National Natural Science Foundation of China (No. 81171096 and No. 81371433) to JM Zhang and by National Natural Science Foundation of China (No. 81371369) to Y Hong.	Abdanipour Alireza, 2012, Iranian Biomedical Journal, V16, P90, DOI 10.6091/ibj.1060.2012; Ackery A, 2004, J NEUROTRAUM, V21, P1355, DOI 10.1089/neu.2004.21.1355; Ahmad M, 2010, TRANSL STROKE RES, V1, P74, DOI 10.1007/s12975-010-0023-7; Allen SJ, 2013, PHARMACOL THERAPEUT, V138, P155, DOI 10.1016/j.pharmthera.2013.01.004; Ambrozaitis Kazys Vytautas, 2006, Medicina (Kaunas), V42, P255; Baltan S, 2011, TRANSL STROKE RES, V2, P411, DOI 10.1007/s12975-011-0087-z; Bannister AJ, 2011, CELL RES, V21, P381, DOI 10.1038/cr.2011.22; Bauernfeind FG, 2009, J IMMUNOL, V183, P787, DOI 10.4049/jimmunol.0901363; Biermann J, 2010, INVEST OPHTH VIS SCI, V51, P526, DOI 10.1167/iovs.09-3903; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Bredy TW, 2007, LEARN MEMORY, V14, P268, DOI 10.1101/lm.500907; Bryant C, 2009, TRENDS CELL BIOL, V19, P455, DOI 10.1016/j.tcb.2009.06.002; Cannizzaro E, 2007, NEUROPEDIATRICS, V38, P42, DOI 10.1055/s-2007-981448; Castro LMR, 2005, J NEUROCHEM, V95, P1227, DOI 10.1111/j.1471-4159.2005.03457.x; Cavallucci V, 2011, CURR PHARM DESIGN, V17, P215, DOI 10.2174/138161211795049705; Chen PS, 2007, NEUROSCIENCE, V149, P203, DOI 10.1016/j.neuroscience.2007.06.053; Chen PS, 2006, MOL PSYCHIATR, V11, P1116, DOI 10.1038/sj.mp.4001893; Chiu CT, 2013, PHARMACOL REV, V65, P105, DOI 10.1124/pr.111.005512; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; D'Mello SR, 2009, DRUG NEWS PERSPECT, V22, P513, DOI [10.1358/dnp.2009.9.1428871, 10.1358/dnp.2009.22.9.1437959]; Dash PK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011383; DAVIS R, 1994, DRUGS, V47, P332, DOI 10.2165/00003495-199447020-00008; Dinarello CA, 2011, MOL MED, V17, P333, DOI 10.2119/molmed.2011.00116; Eyal S, 2004, EPILEPSIA, V45, P737, DOI 10.1111/j.0013-9580.2004.00104.x; Fann DYW, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.326; Filli L, 2012, ANN NEUROL, V72, P491, DOI 10.1002/ana.23630; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Fukumoto T, 2001, PSYCHOPHARMACOLOGY, V158, P100, DOI 10.1007/s002130100871; Gibbons HM, 2011, NEUROBIOL DIS, V41, P96, DOI 10.1016/j.nbd.2010.08.024; Gottlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969; Graff J, 2013, NAT REV NEUROSCI, V14, P97, DOI 10.1038/nrn3427; Gross O, 2011, IMMUNOL REV, V243, P136, DOI 10.1111/j.1600-065X.2011.01046.x; Hamer HM, 2009, NERVENARZT, V80, P405, DOI 10.1007/s00115-009-2680-x; Hao HH, 2013, NEUROSCI BULL, V29, P484, DOI 10.1007/s12264-013-1355-6; Hao YL, 2004, J NEUROSCI, V24, P6590, DOI 10.1523/JNEUROSCI.5747-03.2004; Harder J, 2009, J IMMUNOL, V183, P5823, DOI 10.4049/jimmunol.0900444; Hasan MR, 2013, NEUROCHEM RES, V38, P1921, DOI 10.1007/s11064-013-1098-9; Hsieh J, 2004, P NATL ACAD SCI USA, V101, P16659, DOI 10.1073/pnas.0407643101; Hunsberger JG, 2012, AM J TRANSL RES, V4, P316; Hwabejire JO, 2013, SURGERY, V154, P234, DOI 10.1016/j.surg.2013.04.008; Imam AM, 2013, SURGERY, V154, P388, DOI 10.1016/j.surg.2013.05.008; Jaffer H, 2011, DRUG DELIV TRANSL RE, V1, P409, DOI 10.1007/s13346-011-0046-y; Jin G, 2012, J TRAUMA ACUTE CARE, V73, P1461, DOI 10.1097/TA.0b013e3182782641; Kabakus N, 2005, J CHILD NEUROL, V20, P582, DOI 10.1177/08830738050200070801; Kao CY, 2013, J NEUROCHEM, V126, P4, DOI 10.1111/jnc.12292; Karp JM, 2009, CELL STEM CELL, V4, P206, DOI 10.1016/j.stem.2009.02.001; Kim HJ, 2007, J PHARMACOL EXP THER, V321, P892, DOI 10.1124/jpet.107.120188; Koenig S, 2008, BLOOD COAGUL FIBRIN, V19, P375, DOI 10.1097/MBC.0b013e3282f3f9ec; KREUZ W, 1990, LANCET, V335, P1350, DOI 10.1016/0140-6736(90)91235-3; Kunz A, 2010, BEST PRACT RES-CLIN, V24, P495, DOI 10.1016/j.bpa.2010.10.001; Kwon KJ, 2013, NEUROCHEM INT, V62, P240, DOI 10.1016/j.neuint.2012.12.019; Lahue RS, 2012, EPIGENETICS-US, V7, P806, DOI 10.4161/epi.20922; Latz E, 2013, NAT REV IMMUNOL, V13, P397, DOI 10.1038/nri3452; Lee JY, 2012, J NEUROCHEM, V121, P818, DOI 10.1111/j.1471-4159.2012.07731.x; Leng Y, 2008, J NEUROSCI, V28, P2576, DOI 10.1523/JNEUROSCI.5467-07.2008; Li XH, 2002, BIPOLAR DISORD, V4, P137, DOI 10.1034/j.1399-5618.2002.40201.x; Li YQ, 2008, J TRAUMA, V64, P863, DOI 10.1097/TA.0b013e318166b822; Liu HD, 2013, NEUROCHEM RES, V38, P2072, DOI 10.1007/s11064-013-1115-z; Liu XS, 2012, NEUROSCIENCE, V220, P313, DOI 10.1016/j.neuroscience.2012.06.012; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Lv L, 2012, EXP NEUROL, V233, P783, DOI 10.1016/j.expneurol.2011.11.042; Lv L, 2011, BRAIN RES, V1396, P60, DOI 10.1016/j.brainres.2011.03.040; Marinova Z, 2009, J NEUROCHEM, V111, P976, DOI 10.1111/j.1471-4159.2009.06385.x; Marsh JD, 2010, J AM COLL CARDIOL, V56, P683, DOI 10.1016/j.jacc.2009.12.072; McConeghy KW, 2012, CNS DRUGS, V26, P613, DOI 10.2165/11634020-000000000-00000; Monti Barbara, 2009, Curr Mol Pharmacol, V2, P95; Mora A, 1999, EUR J BIOCHEM, V266, P886, DOI 10.1046/j.1432-1327.1999.00919.x; Mora A, 2002, BIPOLAR DISORD, V4, P195, DOI 10.1034/j.1399-5618.2002.40301.x; Mukherjee D, 2011, WORLD NEUROSURG, V76, pS85, DOI 10.1016/j.wneu.2011.07.023; Nalivaeva NN, 2009, TRENDS PHARMACOL SCI, V30, P509, DOI 10.1016/j.tips.2009.07.002; Osuka S, 2012, NEUROL MED-CHIR, V52, P186, DOI 10.2176/nmc.52.186; Pan TH, 2005, FEBS LETT, V579, P6716, DOI 10.1016/j.febslet.2005.10.067; Parekkadan B, 2010, ANNU REV BIOMED ENG, V12, P87, DOI 10.1146/annurev-bioeng-070909-105309; Park H, 2013, NAT REV NEUROSCI, V14, P7, DOI 10.1038/nrn3379; Peng GS, 2005, MOL BRAIN RES, V134, P162, DOI 10.1016/j.molbrainres.2004.10.021; Phiel CJ, 2001, J BIOL CHEM, V276, P36734, DOI 10.1074/jbc.M101287200; Piepers S, 2009, ANN NEUROL, V66, P227, DOI 10.1002/ana.21620; Pohlmann-Eden B, 2003, ACTA NEUROL SCAND, V108, P142, DOI 10.1034/j.1600-0404.2003.00149.x; Qian YR, 2010, KOREAN J PHYSIOL PHA, V14, P435, DOI 10.4196/kjpp.2010.14.6.435; Rao R, 2012, ADV CANCER RES, V116, P239, DOI 10.1016/B978-0-12-394387-3.00007-0; Ren M, 2004, J NEUROCHEM, V89, P1358, DOI 10.1111/j.1471-4159.2004.02406.x; Rogawski MA, 2004, NAT REV NEUROSCI, V5, P553, DOI 10.1038/nrn1430; Rosenberg G, 2007, CELL MOL LIFE SCI, V64, P2090, DOI 10.1007/s00018-007-7079-x; Saha RN, 2006, CELL DEATH DIFFER, V13, P539, DOI 10.1038/sj.cdd.4401769; Sancho-Pelluz J, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.4; Segovia J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029695; Shein NA, 2011, MOL MED, V17, P448, DOI 10.2119/molmed.2011.00038; Shults C, 2008, J TRAUMA, V64, P629, DOI 10.1097/TA.0b013e3181650ff3; Sinn DI, 2007, NEUROBIOL DIS, V26, P464, DOI 10.1016/j.nbd.2007.02.006; Strowig T, 2012, NATURE, V481, P278, DOI 10.1038/nature10759; Suda S, 2013, EUR J PHARMACOL, V707, P26, DOI 10.1016/j.ejphar.2013.03.020; SYMINGTON GR, 1978, AM J PSYCHIAT, V135, P352; Tsai LK, 2011, STROKE, V42, P2932, DOI 10.1161/STROKEAHA.110.612788; Tsai LK, 2010, NEUROPSYCHOPHARMACOL, V35, P2225, DOI 10.1038/npp.2010.97; Vaccari JPD, 2009, J CEREBR BLOOD F MET, V29, P1251, DOI 10.1038/jcbfm.2009.46; Vajda FJE, 2002, J CLIN NEUROSCI, V9, P508, DOI 10.1054/jocn.2002.1133; Wang ZF, 2012, STROKE, V43, P2430, DOI 10.1161/STROKEAHA.112.652545; Wang ZF, 2011, J CEREBR BLOOD F MET, V31, P52, DOI 10.1038/jcbfm.2010.195; Wu XF, 2008, INT J NEUROPSYCHOPH, V11, P1123, DOI 10.1017/S1461145708009024; Xuan AG, 2012, LIFE SCI, V90, P463, DOI 10.1016/j.lfs.2012.01.001; Yasuda S, 2009, MOL PSYCHIATR, V14, P51, DOI 10.1038/sj.mp.4002099; Yu FS, 2013, J NEUROSURG, V119, P766, DOI 10.3171/2013.6.JNS13135; Yuan PX, 2001, J BIOL CHEM, V276, P31674, DOI 10.1074/jbc.M104309200; Zhang Z, 2012, NEUROSCIENCE, V221, P140, DOI 10.1016/j.neuroscience.2012.07.013; Zhang ZZ, 2012, EXP EYE RES, V94, P98, DOI 10.1016/j.exer.2011.11.013; Zhang ZZ, 2011, NEUROSCI LETT, V504, P88, DOI 10.1016/j.neulet.2011.09.003	106	35	38	1	14	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190	1573-6903		NEUROCHEM RES	Neurochem. Res.	SEP	2014	39	9					1621	1633		10.1007/s11064-014-1241-2			13	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	AO9WV	WOS:000341711800001	24482021				2021-06-18	
J	Mannings, C; Kalynych, C; Joseph, MM; Smotherman, C; Kraemer, DF				Mannings, Carol; Kalynych, Colleen; Joseph, Madeline Matar; Smotherman, Carmen; Kraemer, Dale F.			Knowledge assessment of sports-related concussion among parents of children aged 5 years to 15 years enrolled in recreational tackle football	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Sports-related concussion; pediatric; parental knowledge; pre-high school-aged athletes	HIGH-SCHOOL; YOUTH; EPIDEMIOLOGY; RECOVERY; PLAYERS	BACKGROUND: Sports-related concussion among professional, collegiate, and, more recently, high school athletes has received much attention from the media and medical community. To our knowledge, there is a paucity of research regarding parental knowledge of sports-related concussion. The aim of this study was to evaluate parental knowledge of concussion in young children who participated in recreational tackle football. METHODS: Parents of children aged 5 years to 15 years attending recreational tackle football games were asked to complete an anonymous questionnaire based on the Centers for Disease Control and Prevention's Heads Up: Concussion in Youth Sports Quiz. The parents were asked about their level of agreement regarding statements that represent definition, symptoms, and treatment of concussion. RESULTS: A total of 310 of 369 parents (84% response rate) voluntarily completed the questionnaire, with 94% believing that their child had never had a concussion. However, only 13% (n = 41) could correctly identify all seven statements. Most did not identify that a concussion is considered a mild traumatic brain injury and can be achieved from something other than a direct blow to the head. Race, sex, and zip code had no significant association with correctly answering statements. Education (r = 0.24, p < 0.0001) and number of years the child played (r = 0.11, p = 0.049) had a small association. Fifty-three percent and 58% of the parents reported that someone had discussed the definition and the symptoms of concussion with them, respectively, with only about half reporting that information came from their health care provider. No parent was able to classify all symptoms listed as correctly related or not related to concussion. However, identification of correct concussion statements correlated with identification of correct symptoms (r = 0.25, p < 0.001). CONCLUSION: While most parents of young athletes demonstrated some knowledge regarding concussion, important misconceptions remain regarding the definition, symptoms, and treatment of concussion. This study highlights the need for health care providers to increase concussion educational efforts. (Copyright (C) 2014 by Lippincott Williams & Wilkins)	[Mannings, Carol; Kalynych, Colleen; Joseph, Madeline Matar] Univ Florida, Coll Med, Dept Emergency Med, Jacksonville, FL 32209 USA; [Smotherman, Carmen; Kraemer, Dale F.] Univ Florida, Coll Med, Ctr Hlth Equ & Qual Res, Jacksonville, FL 32209 USA; [Kraemer, Dale F.] Univ Florida, Coll Med, Dept Neurol, Jacksonville, FL 32209 USA	Mannings, C (corresponding author), Univ Florida, Coll Med, Dept Emergency Med, 655 West 8th St, Jacksonville, FL 32209 USA.	carol.mannings@jax.ufl.edu	Meijer, Anna/K-5118-2016				[Anonymous], CONC; Coghlin Craig J, 2009, J Can Chiropr Assoc, V53, P233; Collie A, 2006, J NEUROL NEUROSUR PS, V77, P241, DOI 10.1136/jnnp.2005.073155; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; DeMatteo CA, 2010, PEDIATRICS, V125, P327, DOI 10.1542/peds.2008-2720; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Gomez JE, 2013, J ADOLESCENT HEALTH, V53, P311, DOI 10.1016/j.jadohealth.2013.06.018; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2011, PM&R, V3, P353, DOI 10.1016/j.pmrj.2010.12.006; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Hunt TN, 2009, J ATHL TRAINING, V44, P405, DOI 10.4085/1062-6050-44.4.405; Jinguji TM, 2011, PHYS MED REH CLIN N, V22, P565, DOI 10.1016/j.pmr.2011.08.001; Koh JO, 2003, BRAIN INJURY, V17, P901, DOI 10.1080/0269905031000088869; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory P, 2013, BRIT J SPORT MED, V47, P268, DOI 10.1136/bjsports-2013-092247; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meehan WP, 2011, CLIN SPORT MED, V30, P133, DOI 10.1016/j.csm.2010.08.004; Stevens Penelope K, 2010, J Trauma Nurs, V17, P178, DOI 10.1097/JTN.0b013e3181ff2789; Theye Fred, 2004, Clin Med Res, V2, P165; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832; Zonfrillo MR, 2012, PEDIATRICS, V130, P1120, DOI 10.1542/peds.2012-1431	24	35	35	0	40	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	SEP	2014	77			1			S18	S22		10.1097/TA.0000000000000371			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	AO2BK	WOS:000341120300005	25153049				2021-06-18	
J	Heo, J; Park, SQ; Cho, SJ; Chang, JC; Park, HK				Heo, Juneyoung; Park, Sukh Que; Cho, Sung Jin; Chang, Jae Chil; Park, Hyung-ki			Evaluation of simultaneous cranioplasty and ventriculoperitoneal shunt procedures Clinical article	JOURNAL OF NEUROSURGERY			English	Article						cranioplasty; ventriculoperitoneal shunt; complication; traumatic brain injury	DECOMPRESSIVE CRANIECTOMY; SUBARACHNOID HEMORRHAGE; COMPLICATIONS; HEMICRANIECTOMY; INFARCTION	Object. Some patients with severe brain swelling treated with decompressive craniectomy may develop hydrocephalus. Consequently, these patients require cranioplasty and a ventriculoperitoneal (VP) shunt to relieve the hydrocephalus. However, there is no consensus as to the timing of the cranioplasty and VP shunt placement in patients requiring both. The authors assessed the results of performing cranioplasty and VP shunt placement at the same time in patients with cranial defects and hydrocephalus. Methods. A retrospective review was performed of 51 patients who had undergone cranioplasty and VP shunt operations after decompressive craniectomy for refractory intracranial hypertension between 2003 and 2012 at the authors' institution. Patient characteristics, data on whether the operations were performed simultaneously, brain bulging, hydrocephalus, cranial defect size, and complications were analyzed. Results. The overall complication rate was 43% (22 of 51 patients). In 32 cases, cranioplasty and VP shunt placement were performed at the same time. Complications included subdural hematoma, subdural fluid collection, and infection. The group undergoing cranioplasty and VP shunt placement at the same time had higher complication rates than the group undergoing the procedures at different times (56% vs 21%, respectively). The severity of complications was also greater in the former group. Patients with severe brain bulging had higher complication rates than did those without brain bulging (51% vs 0%, respectively). Cranial defect size, severity of hydrocephalus, indication for decompressive craniectomy, age, sex, and interval between decompressive craniectomy and subsequent operation did not affect complication rates. Conclusions. Patients undergoing cranioplasty and VP shunt placement at the same time had higher complication rates, especially those with severe brain bulging.	[Heo, Juneyoung; Park, Sukh Que; Cho, Sung Jin; Chang, Jae Chil; Park, Hyung-ki] Soonchunhyang Univ, Seoul Hosp, Dept Neurosurg, Seoul 140743, South Korea	Park, SQ (corresponding author), Soonchunhyang Univ, Seoul Hosp, Dept Neurosurg, 657 Hannam Dong, Seoul 140743, South Korea.	drcolor@schmc.ac.kr			Soonchunhyang University	This work was supported by the Soonchunhyang University Research Fund.	Dujovny M, 1997, SURG NEUROL, V47, P238, DOI 10.1016/S0090-3019(96)00013-4; Dujovny M, 1999, CRIT REV NEUROSURG, V9, P271, DOI 10.1007/s003290050143; Dujovny M, 1997, NEUROL RES, V19, P311, DOI 10.1080/01616412.1997.11740818; FODSTAD H, 1984, ACTA NEUROCHIR, V70, P21, DOI 10.1007/BF01406039; Fodstad H, 1979, Acta Neurochir Suppl (Wien), V28, P514; Gooch MR, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0962; Guresir E, 2009, J NEUROL NEUROSUR PS, V80, P799, DOI 10.1136/jnnp.2008.155630; Guresir E, 2008, NEUROSURGERY, V63, P1088, DOI 10.1227/01.NEU.0000335170.76722.B9; Joseph V, 2009, J NEUROSURG, V111, P650, DOI 10.3171/2009.3.JNS0984; Liao CC, 2002, J CLIN NEUROSCI, V9, P553, DOI 10.1054/jocn.2002.1116; Marion DW, 2006, NEUROSURGERY, V58, P655; Moreira-Gonzalez A, 2003, J CRANIOFAC SURG, V14, P144, DOI 10.1097/00001665-200303000-00003; Rocque BG, 2013, J NEUROSURG-PEDIATR, V12, P120, DOI 10.3171/2013.4.PEDS12605; Schwab S, 1998, STROKE, V29, P1888, DOI 10.1161/01.STR.29.9.1888; SEGAL DH, 1994, NEUROSURGERY, V34, P729, DOI 10.1227/00006123-199404000-00024; Sobani Zain A, 2011, Surg Neurol Int, V2, P123, DOI 10.4103/2152-7806.85055; Wu Y, 2007, NEUROSURGERY, V61, P557, DOI 10.1227/01.NEU.0000290903.07943.AF; Yang XF, 2008, ACTA NEUROCHIR, V150, P1241, DOI 10.1007/s00701-008-0145-9; Yang Xue-Jun, 2003, Chin J Traumatol, V6, P99; Zhou Qing, 2005, Di Yi Jun Yi Da Xue Xue Bao, V25, P254	20	35	37	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	AUG	2014	121	2					313	318		10.3171/2014.2.JNS131480			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	AL9PK	WOS:000339473000012	24655097				2021-06-18	
J	Geng, YJ; Zhang, XF; Zhang, YT; Li, GL				Geng, Yanjuan; Zhang, Xiufeng; Zhang, Yuan-Ting; Li, Guanglin			A novel channel selection method for multiple motion classification using high-density electromyography	BIOMEDICAL ENGINEERING ONLINE			English	Article						Myoelectric control; Channel selection method; Multi-class common spatial pattern; High-density EMG; Pattern recognition	TARGETED MUSCLE REINNERVATION; NEURAL-MACHINE INTERFACE; PATTERN-RECOGNITION; MYOELECTRIC CONTROL; ELECTRODE CONFIGURATION; SURFACE ELECTROMYOGRAM; SIGNAL CLASSIFICATION; PROSTHESIS CONTROL; IDENTIFICATION; INFORMATION	Background: Selecting an appropriate number of surface electromyography (EMG) channels with desired classification performance and determining the optimal placement of EMG electrodes would be necessary and important in practical myoelectric control. In previous studies, several methods such as sequential forward selection (SFS) and Fisher-Markov selector (FMS) have been used to select the appropriate number of EMG channels for a control system. These exiting methods are dependent on either EMG features and/or classification algorithms, which means that when using different channel features or classification algorithm, the selected channels would be changed. In this study, a new method named multi-class common spatial pattern (MCCSP) was proposed for EMG selection in EMG pattern-recognition-based movement classification. Since MCCSP is independent on specific EMG features and classification algorithms, it would be more convenient for channel selection in developing an EMG control system than the exiting methods. Methods: The performance of the proposed MCCSP method in selecting some optimal EMG channels (designated as a subset) was assessed with high-density EMG recordings from twelve mildly-impaired traumatic brain injury (TBI) patients. With the MCCSP method, a subset of EMG channels was selected and then used for motion classification with pattern recognition technique. In order to justify the performance of the MCCSP method against different electrode configurations, features and classification algorithms, two electrode configurations (unipolar and bipolar) as well as two EMG feature sets and two types of pattern recognition classifiers were considered in the study, respectively. And the performance of the proposed MCCSP method was compared with that of two exiting channel selection methods (SFS and FMS) in EMG control system. Results: The results showed that in comparison with the previously used SFS and FMS methods, the newly proposed MCCSP method had better motion classification performance. Moreover, a fixed combination of the selected EMG channels was obtained when using MCCSP. Conclusions: The proposed MCCSP method would be a practicable means in channel selection and would facilitate the design of practical myoelectric control systems in the active rehabilitation of mildly-impaired TBI patients and in other rehabilitation applications such as the multifunctional myoelectric prostheses for limb amputees.	[Geng, Yanjuan; Li, Guanglin] Chinese Acad Sci, Shenzhen Inst Adv Technol, Key Lab Human Machine Intelligence Synerg Syst, Shenzhen, Peoples R China; [Geng, Yanjuan; Zhang, Yuan-Ting; Li, Guanglin] Chinese Acad Sci, SIAT, Key Lab Hlth Informat, Shenzhen, Peoples R China; [Zhang, Xiufeng] Natl Res Ctr Rehabil Tech Aids, Beijing, Peoples R China; [Zhang, Yuan-Ting] Chinese Univ Hong Kong, Dept Biomed Engn, Hong Kong, Hong Kong, Peoples R China; [Geng, Yanjuan; Zhang, Yuan-Ting; Li, Guanglin] Chinese Acad Sci, Shenzhen Inst Adv Technol, Inst Biomed & Hlth Engn, Univ Town Shenzhen, Shenzhen, Peoples R China	Li, GL (corresponding author), Chinese Acad Sci, Shenzhen Inst Adv Technol, Key Lab Human Machine Intelligence Synerg Syst, Shenzhen, Peoples R China.	gl.li@siat.ac.cn		ZHANG, Yuanting/0000-0003-4150-5470	National Key Basic Research Program of ChinaNational Basic Research Program of China [2013CB329505]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [61135004, 51275101]; Guangdong Innovation Research Team Fund for Low-cost Healthcare Technologies; External Cooperation Program of the Chinese Academy of SciencesChinese Academy of Sciences [GJHZ1212]	This work was jointly supported by the National Key Basic Research Program of China (#2013CB329505), the National Natural Science Foundation of China under Grants (#61135004, #51275101), Guangdong Innovation Research Team Fund for Low-cost Healthcare Technologies, and External Cooperation Program of the Chinese Academy of Sciences (GJHZ1212). The authors would like to thank members at Center for Neural Engineering, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences for their assistance in experiment, data preprocessing and language editing. And also we would like to thank the cooperators at Guangdong Provincial Industrial Injury Rehabilitation Center for their assistance in the recruitment of subjects.	Cheng QA, 2011, IEEE T PATTERN ANAL, V33, P1217, DOI 10.1109/TPAMI.2010.195; Daley H, 2012, J ELECTROMYOGR KINES, V22, P478, DOI 10.1016/j.jelekin.2011.12.012; Dideriksen JL, 2010, PHILOS T R SOC A, V368, P2765, DOI 10.1098/rsta.2010.0094; Dipietro L, 2005, IEEE T NEUR SYS REH, V13, P325, DOI 10.1109/TNSRE.2005.850423; Doheny EP, 2010, MED ENG PHYS, V32, P468, DOI 10.1016/j.medengphy.2010.03.004; DORCAS D. S., 1966, MED BIOL ENG, V4, P367, DOI 10.1007/BF02476154; Engelhart K, 1999, MED ENG PHYS, V21, P431, DOI 10.1016/S1350-4533(99)00066-1; Farrell TR, 2008, IEEE T BIO-MED ENG, V55, P2198, DOI 10.1109/TBME.2008.923917; Geng YJ, 2012, IEEE ENG MED BIO, P2772, DOI 10.1109/EMBC.2012.6346539; Geng YJ, 2012, J NEUROENG REHABIL, V9, DOI 10.1186/1743-0003-9-74; Geng YJ, 2013, 35 ANN INT C IEEE EM, P5918; GRAUPE D, 1975, IEEE T SYST MAN CYB, VSMC5, P252, DOI 10.1109/TSMC.1975.5408479; Hahne JM, 2012, IEEE T BIO-MED ENG, V59, P1436, DOI 10.1109/TBME.2012.2188799; Hu XL, 2009, NEUROREHAB NEURAL RE, V23, P837, DOI 10.1177/1545968309338191; Huang H, 2008, IEEE T NEUR SYS REH, V16, P37, DOI 10.1109/TNSRE.2007.910282; HUDGINS B, 1993, IEEE T BIO-MED ENG, V40, P82, DOI 10.1109/10.204774; Kawamoto H, 2003, IEEE SYS MAN CYBERN, P1648; Kendell C, 2012, J NEUROENG REHABIL, V9, DOI 10.1186/1743-0003-9-24; Kuiken TA, 2009, JAMA-J AM MED ASSOC, V301, P619, DOI 10.1001/jama.2009.116; Kvas Gernot, 2008, 2008 6th IEEE International Conference on Industrial Informatics (INDIN), P1437, DOI 10.1109/INDIN.2008.4618330; Li GL, 2010, IEEE T NEUR SYS REH, V18, P185, DOI 10.1109/TNSRE.2009.2039619; Liu J, 2013, IEEE T NEUR SYS REH, V21, P96, DOI 10.1109/TNSRE.2012.2218832; Lock B., 2005, P 2005 MYOEL CONTR P; Nagata K, 2007, ANN INT C IEEE ENG M, P5214; Nazarpour K, 2007, IEEE T BIO-MED ENG, V54, P1762, DOI 10.1109/TBME.2007.894829; Peng HC, 2005, IEEE T PATTERN ANAL, V27, P1226, DOI 10.1109/TPAMI.2005.159; Ramoser H, 2000, IEEE T REHABIL ENG, V8, P441, DOI 10.1109/86.895946; Rojas-Martinez M, 2013, J ELECTROMYOGR KINES, V23, P33, DOI 10.1016/j.jelekin.2012.06.009; Shibanoki T, 2013, IEEE T BIO-MED ENG, V60, P853, DOI 10.1109/TBME.2012.2205990; Tkach D, 2010, J NEUROENG REHABIL, V7, DOI 10.1186/1743-0003-7-21; Wang YJ, 2005, P ANN INT IEEE EMBS, P5392; Wolbrecht ET, 2008, IEEE T NEUR SYS REH, V16, P286, DOI 10.1109/TNSRE.2008.918389; Young AJ, 2012, IEEE T BIO-MED ENG, V59, P645, DOI 10.1109/TBME.2011.2177662; Zhang X, 2012, IEEE T BIO-MED ENG, V59, P1649, DOI 10.1109/TBME.2012.2191551; Zhou P, 2007, J NEUROPHYSIOL, V98, P2974, DOI 10.1152/jn.00178.2007	35	35	37	1	29	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1475-925X			BIOMED ENG ONLINE	Biomed. Eng. Online	JUL 25	2014	13								102	10.1186/1475-925X-13-102			16	Engineering, Biomedical	Engineering	AM6KA	WOS:000339972300001	25060509	DOAJ Gold, Green Published			2021-06-18	
J	Kurowski, BG; Wade, SL; Kirkwood, MW; Brown, TM; Stancin, T; Taylor, HG				Kurowski, Brad G.; Wade, Shari L.; Kirkwood, Michael W.; Brown, Tanya M.; Stancin, Terry; Taylor, H. Gerry			Long-term Benefits of an Early Online Problem-Solving Intervention for Executive Dysfunction After Traumatic Brain Injury in Children A Randomized Clinical Trial	JAMA PEDIATRICS			English	Article							BEHAVIOR RATING INVENTORY; PRELIMINARY EFFICACY; YOUNG-CHILDREN; FAMILY INTERVENTION; SOCIAL COMPETENCE; HEAD-INJURY; FOLLOW-UP; SKILLS; ADOLESCENTS; PREDICTORS	IMPORTANCE Executive dysfunction after traumatic brain injury (TBI) in children is common and leads to significant short-and long-term problems in functioning across multiple settings. We hypothesized that improvements in short-term executive function would be maintained to 24 months after injury and that improvements would increase over time in a counselor-assisted problem-solving (CAPS) intervention. OBJECTIVE To evaluate the efficacy of a CAPS intervention administered within 7 months of complicated mild to severe TBI compared with an Internet resource condition in improving long-term executive dysfunction. DESIGN, SETTING, AND PARTICIPANTS Multisite, assessor-blinded, randomized clinical trial at 3 tertiary pediatric hospitals and 2 tertiary general medical centers. Participants included 132 adolescents aged 12 to 17 years who sustained a moderate to severe TBI 1 to 7 months before study enrollment. INTERVENTION Web-based CAPS intervention. MAIN OUTCOMES AND MEASURES The primary outcome was the parent-reported Global Executive Composite (GEC) of the Behavior Rating Inventory of Executive Function. Secondary outcomes included the Behavioral Regulation Index (BRI) and Metacognition Index (MI) of the GEC. RESULTS In older (> 14 to 17 years) adolescents, the CAPS intervention was associated with lower GEC ratings at 12 (beta = -0.46; P =.03) and 18 (beta = -0.52; P =.02) months after enrollment. Trends were also observed for older adolescents toward lower GEC ratings at 6 months (beta = -0.40; P =.05), lower BRI ratings at 12 (beta = -0.40; P =.06) and 18 (beta = -0.47; P =.04) months, and lower MI ratings at 6 (beta = -0.41; P =.05), 12 (beta = -0.46; P =.03), and 18 (beta = -0.50; P =.03) months. In younger (12-14 years) adolescents, no group differences were found on the GEC, BRI, or MI ratings. CONCLUSIONS AND RELEVANCE Delivery of the CAPS intervention early after TBI in older adolescents improves long-term executive function. This trial is, to our knowledge, one of the few large, randomized clinical treatment trials performed in pediatric TBI to demonstrate the efficacy of an intervention for management of executive dysfunction and long-term benefits of an intervention delivered soon after injury. Use of the CAPS intervention clinically should be considered; however, further research should explore ways to optimize delivery.	[Kurowski, Brad G.; Wade, Shari L.] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Phys Med & Rehabil, Cincinnati, OH 45229 USA; [Kurowski, Brad G.; Wade, Shari L.] Univ Cincinnati, Coll Med, Cincinnati, OH USA; [Kirkwood, Michael W.] Childrens Hosp Colorado, Dept Phys Med & Rehabil, Aurora, CO USA; [Kirkwood, Michael W.] Univ Colorado, Sch Med, Aurora, CO USA; [Brown, Tanya M.] Mayo Clin, Coll Med, Dept Psychiat & Psychol, Rochester, MN USA; [Stancin, Terry] MetroHlth Med Ctr, Dept Pediat, Div Pediat Psychol, Cleveland, OH USA; [Stancin, Terry] Case Western Reserve Univ, Cleveland, OH 44106 USA; [Taylor, H. Gerry] Case Western Reserve Univ, Dept Pediat, Div Dev & Behav Pediat & Psychol, Cleveland, OH 44106 USA; [Taylor, H. Gerry] Univ Hosp Cleveland, Case Med Ctr, Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA	Kurowski, BG (corresponding author), Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Phys Med & Rehabil, 3333 Burnet Ave,MLC 4009, Cincinnati, OH 45229 USA.	brad.kurowski@cchmc.org	Stancin, Terry/L-7993-2019		National Institute of Mental Health, National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01-MH073764]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [2K12 HD001097-16]; Colorado Traumatic Brain Injury Trust Fund Research Program; Colorado Department of Human Services; Division of Vocational Rehabilitation; Traumatic Brain Injury Program; National Institute on Disability Rehabilitation Research, Department of Education [H133B090010]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD001097, K23HD074683] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH073764] Funding Source: NIH RePORTER	This study was supported in part by grant R01-MH073764 from the National Institute of Mental Health, National Institutes of Health (NIH); by grant 2K12 HD001097-16 from the NIH; by a grant from the Colorado Traumatic Brain Injury Trust Fund Research Program, Colorado Department of Human Services, Division of Vocational Rehabilitation, Traumatic Brain Injury Program; and by grant H133B090010 from the National Institute on Disability Rehabilitation Research, Department of Education.	Anderson V, 2005, BRAIN INJURY, V19, P459, DOI 10.1080/02699050400004823; Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; Chan DYK, 2011, DISABIL REHABIL, V33, P2023, DOI 10.3109/09638288.2011.556207; Chapman LA, 2010, REHABIL PSYCHOL, V55, P48, DOI 10.1037/a0018418; Donders J, 2007, J HEAD TRAUMA REHAB, V22, P296, DOI 10.1097/01.HTR.0000290974.01872.82; Donders J, 2010, J NEUROPSYCHOL, V4, P197, DOI 10.1348/174866409X478970; Faul M.D., 2010, TRAUMATIC BRAIN INJU; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Galvin J, 2009, DEV NEUROREHABIL, V12, P352, DOI 10.3109/17518420903087293; Ganesalingam K, 2011, NEUROPSYCHOLOGY, V25, P466, DOI 10.1037/a0022768; Gioia G. A., 2000, BRIEF BEHAV RATING I; Gioia G. A., 2003, BRIEF P BEHAV RATING; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Gioia GA, 2000, CHILD NEUROPSYCHOL, V6, P235, DOI 10.1076/chin.6.3.235.3152; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P1030, DOI 10.1016/S0003-9993(99)90056-4; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; Kehle TJ, 1996, J LEARN DISABIL, V29, P633, DOI 10.1177/002221949602900607; Kurowski BG, 2013, PM&R, V5, P1026, DOI 10.1016/j.pmrj.2013.08.589; Kurowski BG, 2013, PEDIATRICS, V132, pE158, DOI 10.1542/peds.2012-4040; Kurowski BG, 2013, ARCH PHYS MED REHAB, V94, P543, DOI 10.1016/j.apmr.2012.10.029; Kurowski BG, 2011, PM&R, V3, P836, DOI 10.1016/j.pmrj.2011.05.016; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Levin HS, 2005, PEDIATR NEUROL, V33, P79, DOI 10.1016/j.pediatrneurol.2005.02.002; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P223, DOI 10.1016/S0003-9993(96)90102-1; Muscara F, 2008, J NEUROPSYCHOL, V2, P445, DOI 10.1348/174866407X250820; Nadebaum C, 2007, DEV NEUROPSYCHOL, V32, P703, DOI 10.1080/87565640701376086; Sesma HW, 2008, PEDIATRICS, V121, pE1686, DOI 10.1542/peds.2007-2461; Slomine BS, 2006, PEDIATRICS, V117, pE663, DOI 10.1542/peds.2005-1892; Struchen MA, 2008, NEUROREHABILITATION, V23, P185; Styrke J, 2007, J NEUROTRAUM, V24, P1425, DOI 10.1089/neu.2007.0266; Suzman KB, 1997, J BEHAV THER EXP PSY, V28, P203, DOI 10.1016/S0005-7916(97)00023-2; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Taylor HG, 2008, J INT NEUROPSYCH SOC, V14, P734, DOI 10.1017/S1355617708081150; Vriezen ER, 2002, CHILD NEUROPSYCHOL, V8, P296, DOI 10.1076/chin.8.4.296.13505; Wade SL, 2006, REHABIL PSYCHOL, V51, P179, DOI 10.1037/0090-5550.51.3.179; Wade SL, 2014, J HEAD TRAUMA REHAB, V29, P198, DOI 10.1097/HTR.0b013e31828f9fe8; Wade SL, 2011, PEDIATRICS, V128, pE947, DOI 10.1542/peds.2010-3721; Wade SL, 2010, J HEAD TRAUMA REHAB, V25, P409, DOI 10.1097/HTR.0b013e3181fb900d; Wade SL, 2008, J HEAD TRAUMA REHAB, V23, P369, DOI 10.1097/01.HTR.0000341432.67251.48; Wade SL, 2009, J PEDIATR PSYCHOL, V34, P517, DOI 10.1093/jpepsy/jsn081; Wade SL, 2006, J HEAD TRAUMA REHAB, V21, P57, DOI 10.1097/00001199-200601000-00006; Wade SL, 2005, J PEDIATR PSYCHOL, V30, P437, DOI 10.1093/jpepsy/jsi067; Wade SL, 2005, REHABIL PSYCHOL, V50, P337, DOI 10.1037/0090-5550.50.4.337	45	35	35	1	22	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6203	2168-6211		JAMA PEDIATR	JAMA Pediatr.	JUN	2014	168	6					523	531		10.1001/jamapediatrics.2013.5070			9	Pediatrics	Pediatrics	AI4MZ	WOS:000336840800010	24781374	Green Accepted, Bronze			2021-06-18	
J	Calabrese, E; Du, F; Garman, RH; Johnson, GA; Riccio, C; Tong, LC; Long, JB				Calabrese, Evan; Du, Fu; Garman, Robert H.; Johnson, G. Allan; Riccio, Cory; Tong, Lawrence C.; Long, Joseph B.			Diffusion Tensor Imaging Reveals White Matter Injury in a Rat Model of Repetitive Blast-Induced Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						voxelwise analysis; MRI; diffusion tensor imaging; blast neurotrauma; traumatic brain injury	MAGNETIC-RESONANCE HISTOLOGY; CLOSED-HEAD INJURY; AXONAL INJURY; MOUSE MODEL; INTRACRANIAL-PRESSURE; BATTLEFIELD INJURY; OPTIC-NERVE; MRI DATA; EXPOSURE; IRAQ	Blast-induced traumatic brain injury (bTBI) is one of the most common combat-related injuries seen in U.S. military personnel, yet relatively little is known about the underlying mechanisms of injury. In particular, the effects of the primary blast pressure wave are poorly understood. Animal models have proven invaluable for the study of primary bTBI, because it rarely occurs in isolation in human subjects. Even less is known about the effects of repeated primary blast wave exposure, but existing data suggest cumulative increases in brain damage with a second blast. MRI and, in particular, diffusion tensor imaging (DTI), have become important tools for assessing bTBI in both clinical and preclinical settings. Computational statistical methods such as voxelwise analysis have shown promise in localizing and quantifying bTBI throughout the brain. In this study, we use voxelwise analysis of DTI to quantify white matter injury in a rat model of repetitive primary blast exposure. Our results show a significant increase in microstructural damage with a second blast exposure, suggesting that primary bTBI may sensitize the brain to subsequent injury.	[Calabrese, Evan; Johnson, G. Allan] Duke Univ, Med Ctr, Dept Radiol, Ctr In Vivo Microscopy, Durham, NC 27710 USA; [Du, Fu] FD NeuroTechnol Inc, Ellicott City, MD USA; [Garman, Robert H.] Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA USA; [Riccio, Cory; Tong, Lawrence C.; Long, Joseph B.] Walter Reed Army Inst Res, Blast Induced Neurotrauma Branch, Ctr Mil Psychiat & Neurosci, Silver Spring, MD 20910 USA	Long, JB (corresponding author), Walter Reed Army Inst Res, Blast Induced Neurotrauma Branch, Ctr Mil Psychiat & Neurosci, Robert Grant Ave,Bldg 503, Silver Spring, MD 20910 USA.	joseph.long@us.army.mil			CDMRP Psychological Health and Traumatic Brain Injury Research Program [W81XWH-11-2-0127]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41EB015897] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM007171] Funding Source: NIH RePORTER	Blast exposure was performed at the Walter Reed Army Institute of Research under the support of the CDMRP Psychological Health and Traumatic Brain Injury Research Program (W81XWH-11-2-0127). Imaging work was performed at the Duke University Center for In Vivo Microscopy, an NIH/NIBIB Biomedical Technology Resource Center (P41 EB015897). We are grateful to Sally Gewalt and James Cook for assistance with the imaging pipelines. We thank Andrea Edwards, Joseph Andrist, and Donna Wilder for assistance with blast exposures, and Dr. Yi Qi, and Gary Cofer for assistance in specimen preparation and scanning.	Abe O, 2010, NEURORADIOLOGY, V52, P699, DOI 10.1007/s00234-010-0716-3; Alexander AL, 2001, MAGN RESON MED, V45, P770, DOI 10.1002/mrm.1105; Anderson AW, 2001, MAGNET RESON MED, V46, P1174, DOI 10.1002/mrm.1315; Arsigny V, 2006, MAGN RESON MED, V56, P411, DOI 10.1002/mrm.20965; Avants BB, 2008, MED IMAGE ANAL, V12, P26, DOI 10.1016/j.media.2007.06.004; Avants BB, 2011, NEUROIMAGE, V54, P2033, DOI 10.1016/j.neuroimage.2010.09.025; Basser PJ, 1995, NMR BIOMED, V8, P333, DOI 10.1002/nbm.1940080707; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI 10.1089/neu.2009-0898; Bennett RE, 2012, NEUROSCI LETT, V513, P160, DOI 10.1016/j.neulet.2012.02.024; Calabrese E, 2013, NEUROIMAGE, V79, P329, DOI 10.1016/j.neuroimage.2013.04.101; Cenci MA, 2002, NAT REV NEUROSCI, V3, P574, DOI 10.1038/nrn877; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chafi MS, 2010, ANN BIOMED ENG, V38, P490, DOI 10.1007/s10439-009-9813-z; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; DEOLMOS JS, 1994, NEUROTOXICOL TERATOL, V16, P545, DOI 10.1016/0892-0362(94)90033-7; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Goodlett C, 2006, LECT NOTES COMPUT SC, V4191, P260; Hayes JP, 2012, NEUROCASE, V18, P258, DOI 10.1080/13554794.2011.588181; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Johnson GA, 2007, NEUROIMAGE, V37, P82, DOI 10.1016/j.neuroimage.2007.05.013; Johnson GA, 2012, NEUROIMAGE, V62, P1848, DOI 10.1016/j.neuroimage.2012.05.041; Johnson GA, 2011, TOXICOL PATHOL, V39, P85, DOI 10.1177/0192623310389622; Johnson GA, 2002, J MAGN RESON IMAGING, V16, P423, DOI 10.1002/jmri.10175; Johnson GA, 2002, RADIOLOGY, V222, P789, DOI 10.1148/radiol.2223010531; JOHNSON GA, 1993, MAGN RESON QUART, V9, P1; Jones DK, 2010, NMR BIOMED, V23, P803, DOI 10.1002/nbm.1543; Jones DK, 2005, NEUROIMAGE, V26, P546, DOI 10.1016/j.neuroimage.2005.02.013; Kamnaksh A, 2011, J NEUROTRAUM, V28, P2145, DOI 10.1089/neu.2011.1983; Kochunov P, 2001, J COMPUT ASSIST TOMO, V25, P805, DOI 10.1097/00004728-200109000-00023; Landman BA, 2007, NEUROIMAGE, V36, P1123, DOI 10.1016/j.neuroimage.2007.02.056; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Lerch JP, 2012, FRONT NEUROINFORM, V6, DOI 10.3389/fninf.2012.00006; Liu CL, 2011, NEUROIMAGE, V56, P930, DOI 10.1016/j.neuroimage.2011.02.024; Long JB, 2010, IFMBE PROC, V32, P26, DOI 10.1007/978-3-642-14998-6_7; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055823; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Mao JC, 2012, J NEUROTRAUM, V29, P430, DOI 10.1089/neu.2011.1934; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MAZURKIEWICZKWILECKI IM, 1980, PHARMACOL BIOCHEM BE, V12, P35, DOI 10.1016/0091-3057(80)90412-8; Mukherjee P, 2008, AM J NEURORADIOL, V29, P632, DOI 10.3174/ajnr.A1051; Newcombe VFJ, 2007, BRIT J NEUROSURG, V21, P340, DOI 10.1080/02688690701400882; Ni H, 2006, AM J NEURORADIOL, V27, P1776; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Park E, 2011, J NEUROTRAUM, V28, P343, DOI 10.1089/neu.2009.1050; Paxinos G., 2007, RAT BRAIN STEREOTAXI, V6th ed.; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Rooker S, 2003, J NEUROSCI METH, V131, P75, DOI 10.1016/S0165-0270(03)00233-4; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Saljo A, 2009, J NEUROTRAUM, V26, P1345, DOI [10.1089/neu.2008.0856, 10.1089/neu.2008-0856]; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Sponheim SR, 2011, NEUROIMAGE, V54, pS21, DOI 10.1016/j.neuroimage.2010.09.007; STEJSKAL EO, 1965, J CHEM PHYS, V42, P288, DOI 10.1063/1.1695690; Sun SW, 2009, NEUROIMAGE, V44, P611, DOI 10.1016/j.neuroimage.2008.10.032; Sun SW, 2005, MAGN RESON MED, V53, P1447, DOI 10.1002/mrm.20488; Sylvia FR, 2001, MIL MED, V166, P918; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Taylor PA, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3118765; Wang Y, 2011, J NEUROTRAUM, V28, P2171, DOI 10.1089/neu.2011.1990; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Warden DL, 2009, NEUROIMAGE, V47, pT152, DOI 10.1016/j.neuroimage.2009.01.060; Yendiki Anastasia, 2011, Front Neuroinform, V5, P23, DOI 10.3389/fninf.2011.00023; Yushkevich PA, 2008, NEUROIMAGE, V41, P448, DOI 10.1016/j.neuroimage.2008.01.013	69	35	35	0	14	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY 15	2014	31	10					938	950		10.1089/neu.2013.3144			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AH1ES	WOS:000335863200006	24392843	Green Published			2021-06-18	
J	Cockshell, SJ; Mathias, JL				Cockshell, Susan J.; Mathias, Jane L.			Cognitive Functioning in People With Chronic Fatigue Syndrome: A Comparison Between Subjective and Objective Measures	NEUROPSYCHOLOGY			English	Article						chronic fatigue syndrome; cognition; self-report; cognitive tests	TRAUMATIC BRAIN-INJURY; NEUROPSYCHOLOGICAL DEFICITS; PERFORMANCE; DEPRESSION; EVERYDAY; COMPLAINTS; IMPAIRMENT; PATTERNS; QUALITY; MEMORY	Objective: The purpose of this study was to examine the relationship between subjective and objective assessments of memory and attention in people with chronic fatigue syndrome (CFS), using tests that have previously detected deficits in CFS samples and measures of potential confounds. Method: Fifty people with CFS and 50 healthy controls were compared on subjective (memory and attention symptom severity, Cognitive Failures Questionnaire, Everyday Attention Questionnaires) and objective (California Verbal Learning Test, Rey-Osterreith Complex Figure Test, Paced Auditory Serial Addition Test, Stroop task) measures of memory and attention. Fatigue, sleep, depression, and anxiety were also assessed. Results: The CFS group reported experiencing more cognitive problems than the controls, but the two groups did not differ on the cognitive tests. Scores on the subjective and objective measures were not correlated in either group. Depression was positively correlated with increased severity of cognitive problems in both the CFS and control groups. Conclusions: There is little evidence for a relationship between subjective and objective measures of cognitive functioning for both people with CFS and healthy controls, which suggests that they may be capturing different constructs. Problems with memory and attention in everyday life are a significant part of CFS. Depression appears to be related to subjective problems but does not fully explain them.	[Cockshell, Susan J.; Mathias, Jane L.] Univ Adelaide, Sch Psychol, Adelaide, SA 5005, Australia	Mathias, JL (corresponding author), Univ Adelaide, Sch Psychol, North Terrace Campus, Adelaide, SA 5005, Australia.	jane.mathias@adelaide.edu.au		Mathias, Jane/0000-0001-8957-8594			ABBEY SE, 1991, REV INFECT DIS, V13, pS73; ALTAY HT, 1990, INT J PSYCHIAT MED, V20, P141, DOI 10.2190/T6GX-JJ2L-VCVV-T81B; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Bultmann U, 2000, J Occup Health Psychol, V5, P411, DOI 10.1037/1076-8998.5.4.411; Busichio K, 2004, J INT NEUROPSYCH SOC, V10, P278, DOI 10.1017/S1355617704102178; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Capuron L, 2006, NEUROPSYCHOPHARMACOL, V31, P1777, DOI 10.1038/sj.npp.1301005; Claypoole KH, 2007, NEUROPSYCHOLOGY, V21, P507, DOI 10.1037/0894-4105.21.4.507; Cockshell SJ, 2010, PSYCHOL MED, V40, P1253, DOI 10.1017/S0033291709992054; Cockshell SJ, 2013, NEUROPSYCHOLOGY, V27, P230, DOI 10.1037/a0032084; Cockshell SJ, 2012, J CLIN EXP NEUROPSYC, V34, P679, DOI 10.1080/13803395.2012.668176; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Constant EL, 2011, CLIN NEUROL NEUROSUR, V113, P295, DOI 10.1016/j.clineuro.2010.12.002; COPE H, 1995, BRIT J PSYCHIAT, V167, P86, DOI 10.1192/bjp.167.1.86; Cumming G., 2012, UNDERSTANDING NEW ST; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Delis DC, 2000, CALIFORNIA VERBAL LE; DELUCA J, 1993, ARCH NEUROL-CHICAGO, V50, P301, DOI 10.1001/archneur.1993.00540030065016; DELUCA J, 1995, J NEUROL NEUROSUR PS, V58, P38, DOI 10.1136/jnnp.58.1.38; DeLuca J, 1997, J NEUROL NEUROSUR PS, V62, P151, DOI 10.1136/jnnp.62.2.151; Dickson A, 2009, PSYCHOL MED, V39, P1567, DOI 10.1017/S0033291708004960; Duits A, 2008, J NEUROL NEUROSUR PS, V79, P143, DOI 10.1136/jnnp.2007.114595; Fischler B, 1996, NEUROPSYCHOBIOLOGY, V34, P175, DOI 10.1159/000119307; Friedberg F, 2000, J PSYCHOSOM RES, V48, P59, DOI 10.1016/S0022-3999(99)00077-X; Fuentes K, 2001, CLIN NEUROPSYCHOL, V15, P210, DOI 10.1076/clin.15.2.210.1896; FUKUDA K, 1994, ANN INTERN MED, V121, P953, DOI 10.7326/0003-4819-121-12-199412150-00009; GRAFMAN J, 1993, J NEUROL NEUROSUR PS, V56, P684, DOI 10.1136/jnnp.56.6.684; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Jason LA, 1999, ARCH INTERN MED, V159, P2129, DOI 10.1001/archinte.159.18.2129; Knoop H, 2007, J NEUROL NEUROSUR PS, V78, P434, DOI 10.1136/jnnp.2006.100974; Knoop H, 2010, J PSYCHOSOM RES, V68, P489, DOI 10.1016/j.jpsychores.2010.01.022; KRUPP LB, 1994, ARCH NEUROL-CHICAGO, V51, P705, DOI 10.1001/archneur.1994.00540190089021; Lawrie SM, 2000, PSYCHOL MED, V30, P433, DOI 10.1017/S0033291799001816; Mahurin RK, 2004, NEUROPSYCHOLOGY, V18, P232, DOI 10.1037/0894-4105.18.2.232; Majer M, 2008, PSYCHOSOM MED, V70, P829, DOI 10.1097/PSY.0b013e31817b9793; Mantyla T, 2010, APPL NEUROPSYCHOL, V17, P289, DOI 10.1080/09084282.2010.525090; Marshall PS, 1997, PSYCHOSOM MED, V59, P58, DOI 10.1097/00006842-199701000-00008; MARTIN M, 1983, B PSYCHONOMIC SOC, V21, P97; MARTIN M, 1986, HUM LEARN, V5, P63; MCDONALD E, 1993, J NEUROL NEUROSUR PS, V56, P812, DOI 10.1136/jnnp.56.7.812; Metzger FA, 2002, ANN BEHAV MED, V24, P106, DOI 10.1207/S15324796ABM2402_07; Michiels V, 2001, ACTA PSYCHIAT SCAND, V103, P84, DOI 10.1034/j.1600-0447.2001.00017.x; Morriss RK, 1998, J ROY SOC MED, V91, P365, DOI 10.1177/014107689809100706; MossMorris R, 1996, J NEUROL NEUROSUR PS, V60, P474, DOI 10.1136/jnnp.60.5.474; PRASHER D, 1990, J NEUROL NEUROSUR PS, V53, P247, DOI 10.1136/jnnp.53.3.247; Prins JB, 2006, LANCET, V367, P346, DOI 10.1016/S0140-6736(06)68073-2; RAY C, 1993, BRIT J CLIN PSYCHOL, V32, P357, DOI 10.1111/j.2044-8260.1993.tb01068.x; Ray C, 1997, J PSYCHOSOM RES, V43, P405, DOI 10.1016/S0022-3999(97)00111-6; SARGENT CA, 1997, J CHRONIC FATIGUE SY, V3, P53, DOI DOI 10.1300/J092V03N03_04; SCHEFFERS MK, 1992, NEUROLOGY, V42, P1667, DOI 10.1212/WNL.42.9.1667; Schmaling KB, 2003, PSYCHOSOM MED, V65, P129, DOI 10.1097/01.PSY.0000038942.33335.9B; SCHMALING KB, 1994, PSYCHOSOM MED, V56, P383, DOI 10.1097/00006842-199409000-00001; Short K, 2002, J PSYCHOSOM RES, V52, P475, DOI 10.1016/S0022-3999(02)00290-8; Smarr KL., 2003, ARTHRITIS CARE RES, V49, pS134, DOI [10.1002/art.11410, DOI 10.1002/ART.11410]; Smith A, 1996, HUM PSYCHOPHARM CLIN, V11, P161, DOI 10.1002/(SICI)1099-1077(199605)11:3<161::AID-HUP784>3.0.CO;2-5; SMITH AP, 1993, BRIT J PSYCHOL, V84, P411, DOI 10.1111/j.2044-8295.1993.tb02492.x; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Stulemeijer M, 2007, J PSYCHOSOM RES, V63, P637, DOI 10.1016/j.jpsychores.2007.06.023; Sullivan KA, 2012, BRAIN INJURY, V26, P1098, DOI 10.3109/02699052.2012.666367; Thomas Marie, 2009, Open Neurol J, V3, P13, DOI 10.2174/1874205X00903010013; Tiersky LA, 1997, J CLIN EXP NEUROPSYC, V19, P560, DOI 10.1080/01688639708403744; Tiersky LA, 1998, CLIN NEUROPSYCHOL, V12, P503, DOI 10.1076/clin.12.4.503.7237; Tucker-Drob EM, 2011, NEUROPSYCHOLOGY, V25, P368, DOI 10.1037/a0022348; Van den Eede F, 2011, PSYCHIAT RES, V186, P367, DOI 10.1016/j.psychres.2010.07.022; Vercoulen JHMM, 1998, J CLIN EXP NEUROPSYC, V20, P144, DOI 10.1076/jcen.20.2.144.1160; VERCOULEN JHMM, 1994, J PSYCHOSOM RES, V38, P383, DOI 10.1016/0022-3999(94)90099-X; Wagner David L., 2005, P8; Wearden A, 1997, PSYCHOL MED, V27, P81, DOI 10.1017/S0033291796004035; Wearden AJ, 1996, J PSYCHOSOM RES, V41, P197, DOI 10.1016/0022-3999(96)00131-6; Wilson, 1991, NATL ADULT READING T; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	72	35	35	1	31	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	MAY	2014	28	3					394	405		10.1037/neu0000025			12	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	AG3QH	WOS:000335334000010	24364389				2021-06-18	
J	Fon, D; Al-Abboodi, A; Chan, PPY; Zhou, K; Crack, P; Finkelstein, DI; Forsythe, JS				Fon, Deniece; Al-Abboodi, Aswan; Chan, Peggy P. Y.; Zhou, Kun; Crack, Peter; Finkelstein, David I.; Forsythe, John S.			Effects of GDNF-Loaded Injectable Gelatin-Based Hydrogels on Endogenous Neural Progenitor Cell Migration	ADVANCED HEALTHCARE MATERIALS			English	Article						gelatin; hydrogels; neuroblast migration	TRAUMATIC BRAIN-INJURY; NEUROTROPHIC FACTOR; STEM-CELLS; NEURONAL DEATH; ADULT BRAIN; CNS INJURY; PORE-SIZE; EXPRESSION; IMPLANTATION; ASTROCYTES	Brain repair following disease and injury is very limited due to difficulties in recruiting and mobilizing stem cells towards the lesion. More importantly, there is a lack of structural and trophic support to maintain viability of the limited stem/progenitor cells present. This study investigates the effectiveness of an injectable gelatin-based hydrogel in attracting neural progenitor cells (NPCs) from the subventricular zone (SVZ) towards the implant. Glial cell-line-derived neurotrophic factor (GDNF) encapsulated within the hydrogel and porosity within the hydrogel prevents glial scar formation. By directly targeting the hydrogel implant towards the SVZ, neuroblasts can actively migrate towards and along the implant tract. Significantly more doublecortin (DCX)-positive neuroblasts surround implants at 7 d post-implantation (dpi) compared with lesion alone controls, an effect that is enhanced when GDNF is incorporated into the hydrogels. Neuroblasts are not observed at the implant boundary at 21 dpi, indicating that neuroblast migration has halted, and neuroblasts have either matured or have not survived. The development of an injectable gelatin-based hydrogel has significant implications for the treatment of some neurodegenerative diseases and brain injuries. The ability of GDNF and porosity to effectively prevent glial scar formation will allow better integration and interaction between the implant and surrounding neural tissue.	[Fon, Deniece; Zhou, Kun; Forsythe, John S.] Monash Univ, Dept Mat Engn, Clayton, Vic 3800, Australia; [Al-Abboodi, Aswan] Monash Univ, Dept Chem Engn, Clayton, Vic 3800, Australia; [Al-Abboodi, Aswan; Chan, Peggy P. Y.] RMIT Univ, Micro Nanophys Res Lab, Melbourne, Vic 3000, Australia; [Chan, Peggy P. Y.] Melbourne Ctr Nanofabricat, Clayton, Vic 3168, Australia; [Crack, Peter] Univ Melbourne, Dept Pharmacol, Parkville, Vic 3010, Australia; [Finkelstein, David I.] Univ Melbourne, Florey Inst Neurosci & Mental Hlth, Parkville, Vic 3010, Australia	Forsythe, JS (corresponding author), Monash Univ, Dept Mat Engn, Clayton, Vic 3800, Australia.	john.forsythe@monash.edu	Crack, Peter/ABE-2065-2020; Finkelstein, David/B-9617-2009	Crack, Peter/0000-0002-5030-0330; Finkelstein, David/0000-0002-8167-4917; Al-Abboodi, Aswan/0000-0003-1063-9900; Chan, Peggy Pui Yik/0000-0001-6676-9769; Forsythe, John/0000-0003-2849-229X	Australian Research CouncilAustralian Research Council [DP120102570, DP0985433]; ARCAustralian Research Council; MCN Technology Fellowship	Funding for this work was partly provided through Australian Research Council Discovery Project Grants DP120102570 and DP0985433. P.J.C. is supported by the ARC Future Fellowship scheme. This work was performed in part at the Melbourne Centre for Nanofabrication. P.P.Y.C. is grateful for an MCN Technology Fellowship that supported this work, and a RMIT University Senior Research Fellowship.	Al-Abboodi A, 2013, BIOTECHNOL BIOENG, V110, P318, DOI 10.1002/bit.24612; Alexi T, 2000, PROG NEUROBIOL, V60, P409, DOI 10.1016/S0301-0082(99)00032-5; Appel E, 1997, NEUROREPORT, V8, P3309, DOI 10.1097/00001756-199710200-00023; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Arvidsson A, 2003, NEUROBIOL DIS, V14, P542, DOI 10.1016/j.nbd.2003.08.002; Bai F, 2011, BIOMED MATER, V6, DOI 10.1088/1748-6041/6/1/015007; Bonneh-Barkay D, 2009, BRAIN PATHOL, V19, P573, DOI 10.1111/j.1750-3639.2008.00195.x; Brown JP, 2003, J COMP NEUROL, V467, P1, DOI 10.1002/cne.10874; Bryant SJ, 2007, BIOMATERIALS, V28, P2978, DOI 10.1016/j.biomaterials.2006.11.033; Cheng K, 2012, BIOMATERIALS, V33, P5317, DOI 10.1016/j.biomaterials.2012.04.006; Consales C, 2007, BRAIN RES, V1159, P28, DOI 10.1016/j.brainres.2007.04.071; Cunningham JJ, 2012, NAT BIOTECHNOL, V30, P849, DOI 10.1038/nbt.2329; Deguchi K, 2006, J CEREBR BLOOD F MET, V26, P1263, DOI 10.1038/sj.jcbfm.9600275; Deng LX, 2011, EXP NEUROL, V229, P238, DOI 10.1016/j.expneurol.2011.02.001; Duarte EP, 2012, GROWTH FACTORS, V30, P242, DOI 10.3109/08977194.2012.691478; Elias PZ, 2012, J NEUROTRAUM, V29, P2086, DOI 10.1089/neu.2011.2181; Eltzschig HK, 2011, NAT MED, V17, P1391, DOI 10.1038/nm.2507; Ghasemi-Mobarakeh L, 2008, BIOMATERIALS, V29, P4532, DOI 10.1016/j.biomaterials.2008.08.007; Gill SS, 2003, NAT MED, V9, P589, DOI 10.1038/nm850; Gorgieva S., 2011, BIOMATERIALS APPL NA; Hampton DW, 2004, NEUROSCIENCE, V127, P813, DOI 10.1016/j.neuroscience.2004.05.028; Heile Anna, 2011, Dialogues Clin Neurosci, V13, P279; Hernandez-Ortega K, 2011, NEUROSCI BULL, V27, P185, DOI 10.1007/s12264-011-1002-z; Huang KF, 2012, BIOMATERIALS, V33, P2067, DOI 10.1016/j.biomaterials.2011.11.040; Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102; Itoh T, 2009, NEUROL RES, V31, P90, DOI 10.1179/174313208X332995; KRISTT DA, 1987, J NEUROPATH EXP NEUR, V46, P668, DOI 10.1097/00005072-198711000-00006; Lapchak PA, 1997, BRAIN RES, V747, P92, DOI 10.1016/S0006-8993(96)01265-6; Lee F, 2009, J CONTROL RELEASE, V134, P186, DOI 10.1016/j.jconrel.2008.11.028; Lim TC, 2012, BIOMATERIALS, V33, P3446, DOI 10.1016/j.biomaterials.2012.01.037; Lin CH, 2006, EXP NEUROL, V201, P225, DOI 10.1016/j.expneurol.2006.04.014; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; MCKEON RJ, 1991, J NEUROSCI, V11, P3398; Nacher J, 2001, EUR J NEUROSCI, V14, P629, DOI 10.1046/j.0953-816x.2001.01683.x; Nisbet DR, 2010, TISSUE ENG PT A, V16, P2833, DOI [10.1089/ten.tea.2009.0677, 10.1089/ten.TEA.2009.0677]; O'Brien FJ, 2005, BIOMATERIALS, V26, P433, DOI 10.1016/j.biomaterials.2004.02.052; Oh SH, 2007, BIOMATERIALS, V28, P1664, DOI 10.1016/j.biomaterials.2006.11.024; Parent JM, 2002, ANN NEUROL, V52, P802, DOI 10.1002/ana.10393; Powell HM, 2009, TISSUE ENG PT A, V15, P2177, DOI 10.1089/ten.tea.2008.0473; Ratner BD, 2007, POLYM INT, V56, P1183, DOI 10.1002/pi.2319; Rocha SM, 2012, NEUROBIOL DIS, V47, P407, DOI 10.1016/j.nbd.2012.04.014; Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2; Sandhu JK, 2009, NEUROBIOL DIS, V33, P405, DOI 10.1016/j.nbd.2008.11.016; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Sofroniew MV, 2005, NEUROSCIENTIST, V11, P400, DOI 10.1177/1073858405278321; Thored P, 2006, STEM CELLS, V24, P739, DOI 10.1634/stemcells.2005-0281; Toh WS, 2012, BIOMATERIALS, V33, P3835, DOI 10.1016/j.biomaterials.2012.01.065; TOMAC A, 1995, P NATL ACAD SCI USA, V92, P8274, DOI 10.1073/pnas.92.18.8274; Wang LS, 2010, BIOMATERIALS, V31, P8608, DOI 10.1016/j.biomaterials.2010.07.075; Wang LS, 2010, BIOMATERIALS, V31, P1148, DOI 10.1016/j.biomaterials.2009.10.042; Wang W, 2004, BRAIN RES, V1023, P92, DOI 10.1016/j.brainres.2004.07.034; Wong DY, 2008, J NEUROSURG, V109, P715, DOI 10.3171/JNS/2008/109/10/0715; Yang CY, 2009, BIOMATERIALS, V30, P2881, DOI 10.1016/j.biomaterials.2009.01.056; Zhang WR, 2001, BRAIN RES, V903, P253, DOI 10.1016/S0006-8993(01)02364-2; Zhao ZQ, 2004, EXP NEUROL, V190, P356, DOI 10.1016/j.expneurol.2004.06.015	55	35	35	2	24	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2192-2640	2192-2659		ADV HEALTHC MATER	Adv. Healthc. Mater.	MAY	2014	3	5					761	774		10.1002/adhm.201300287			14	Engineering, Biomedical; Nanoscience & Nanotechnology; Materials Science, Biomaterials	Engineering; Science & Technology - Other Topics; Materials Science	AG9HO	WOS:000335730200013	24596339				2021-06-18	
J	Lesniak, M; Polanowska, K; Seniow, J; Czlonkowska, A				Lesniak, Marcin; Polanowska, Katarzyna; Seniow, Joanna; Czlonkowska, Anna			Effects of Repeated Anodal tDCS Coupled With Cognitive Training for Patients With Severe Traumatic Brain Injury: A Pilot Randomized Controlled Trial	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						cognitive rehabilitation; transcranial direct current stimulation; traumatic brain injury	DIRECT-CURRENT STIMULATION; TRANSCRANIAL DC-STIMULATION; DORSOLATERAL PREFRONTAL CORTEX; PRIMARY MOTOR CORTEX; WORKING-MEMORY; HEALTHY-INDIVIDUALS; PARKINSONS-DISEASE; STROKE PATIENTS; EXCITABILITY; REHABILITATION	Objective: To determine whether cumulative anodal transcranial direct current stimulation (A-tDCS) of the left dorsolateral prefrontal cortex (DLPFC) could enhance rehabilitation of memory and attention in patients with traumatic brain injury (TBI). Setting: Inpatient and outpatient neurorehabilitation unit. Participants: Twenty-three adult patients, 4- to 92- months post severe TBI. Design: Participants were randomly allocated to 2 groups. The experimental group received A-tDCS (10 minutes; 1 mA; in the DLPFC), followed by rehabilitative cognitive training, daily for 15 days. Controls received A-tDCS for 25 seconds (sham condition) with the same rehabilitation. Main Measures: Battery of memory and attention tests, which included visual and auditory modalities. Participants were tested twice before beginning rehabilitation (to control for spontaneous recovery), after rehabilitation completion, and 4 months later. Results: Tests scores in both groups were similar at 3 weeks before and immediately before treatment. After treatment, the experimental group exhibited larger effect sizes in 6 of 8 cognitive outcome measures, but they were not significantly different from controls. At follow-up, differences remained insignificant. Conclusion: In contrast to previous studies, our study did not provide sufficient evidence to support the efficacy of repeated A-tDCS for enhancing rehabilitation of memory and attention in patients after severe TBI.	[Lesniak, Marcin; Polanowska, Katarzyna; Seniow, Joanna; Czlonkowska, Anna] Inst Psychiat & Neurol, Dept Neurol 2, PL-02957 Warsaw, Poland; [Czlonkowska, Anna] Med Univ Warsaw, Dept Clin & Expt Pharmacol, Warsaw, Poland	Lesniak, M (corresponding author), Inst Psychiat & Neurol, Dept Neurol 2, 9 Sobieskiego St, PL-02957 Warsaw, Poland.	lesniak@ipin.edu.pl		Seniow, Joanna Seniow/0000-0002-1017-4819; Lesniak, Marcin/0000-0001-9924-9620; Polanowska, Katarzyna/0000-0002-8410-9884; Czlonkowska, Anna/0000-0002-1956-1866	Polish National Science Centre grant [1611/B/P01/2009/37]	The study was supported by Polish National Science Centre grant no. 1611/B/P01/2009/37.	Andelic N, 2010, DISABIL REHABIL, V32, P1122, DOI 10.3109/09638280903410722; Andrews SC, 2011, BRAIN STIMUL, V4, P84, DOI 10.1016/j.brs.2010.06.004; Backhaus S, 2011, ENCY CLIN NEUROPSYCH; Barnes M, 2006, TXB NEURAL REPAIR RE; Bastani A, 2012, CLIN NEUROPHYSIOL, V123, P644, DOI 10.1016/j.clinph.2011.08.029; Berryhill ME, 2012, NEUROSCI LETT, V521, P148, DOI 10.1016/j.neulet.2012.05.074; Berryhill ME, 2010, NEUROSCI LETT, V479, P312, DOI 10.1016/j.neulet.2010.05.087; Blumenfeld RS, 2011, J COGNITIVE NEUROSCI, V23, P257, DOI 10.1162/jocn.2010.21459; Boggio PS, 2009, J NEUROL NEUROSUR PS, V80, P444, DOI 10.1136/jnnp.2007.141853; Boggio PS, 2007, RESTOR NEUROL NEUROS, V25, P123; Boggio PS, 2006, J NEUROL SCI, V249, P31, DOI 10.1016/j.jns.2006.05.062; Cappa SF, 2005, EUR J NEUROL, V12, P665; Cattaneo Z, 2011, NEUROSCIENCE, V183, P64, DOI 10.1016/j.neuroscience.2011.03.058; Chi RP, 2010, BRAIN RES, V1353, P168, DOI 10.1016/j.brainres.2010.07.062; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Demirtas-Tatlidede A, 2012, J HEAD TRAUMA REHAB, V27, P274, DOI 10.1097/HTR.0b013e318217df55; Forn C, 2011, J CLIN EXP NEUROPSYC, V33, P42, DOI 10.1080/13803395.2010.481620; Fregni F, 2005, EXP BRAIN RES, V166, P23, DOI 10.1007/s00221-005-2334-6; Fridriksson J, 2011, STROKE, V42, P819, DOI 10.1161/STROKEAHA.110.600288; Gandiga PC, 2006, CLIN NEUROPHYSIOL, V117, P845, DOI 10.1016/j.clinph.2005.12.003; Gigi A, 2010, J NEUROIMAGING, V20, P163, DOI 10.1111/j.1552-6569.2009.00386.x; Grauwmeijer E, 2012, ARCH PHYS MED REHAB, V93, P993, DOI 10.1016/j.apmr.2012.01.018; Hammer A, 2011, BMC NEUROSC, V12; Israel SL, 2010, J COGNITIVE NEUROSCI, V22, P513, DOI 10.1162/jocn.2009.21198; Jacobson L, 2012, EXP BRAIN RES, V216, P1, DOI 10.1007/s00221-011-2891-9; Jacobsson LJ, 2009, ACTA NEUROL SCAND, V120, P389, DOI 10.1111/j.1600-0404.2009.01238.x; Jo JM, 2009, AM J PHYS MED REHAB, V88, P404, DOI 10.1097/PHM.0b013e3181a0e4cb; Kessler SK, 2012, BRAIN STIMUL, V5, P155, DOI 10.1016/j.brs.2011.02.007; Khedr EM, 2006, MOVEMENT DISORD, V21, P2201, DOI 10.1002/mds.21089; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Lang N, 2005, EUR J NEUROSCI, V22, P495, DOI 10.1111/j.1460-9568.2005.04233.x; Lang N, 2011, J NEUROPHYSIOL, V105, P2802, DOI 10.1152/jn.00617.2010; Liebetanz D, 2002, BRAIN, V125, P2238, DOI 10.1093/brain/awf238; Nitsche MA, 2004, EUR J NEUROSCI, V19, P2720, DOI 10.1111/j.0953-816X.2004.03398.x; Nitsche MA, 2003, J COGNITIVE NEUROSCI, V15, P619, DOI 10.1162/089892903321662994; Nitsche MA, 2005, J PHYSIOL-LONDON, V568, P291, DOI 10.1113/jphysiol.2005.092429; Nitsche MA, 2008, BRAIN STIMUL, V1, P206, DOI 10.1016/j.brs.2008.06.004; Ohn SH, 2008, NEUROREPORT, V19, P43, DOI 10.1097/WNR.0b013e3282f2adfd; Penolazzi B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010623; Poreisz C, 2007, BRAIN RES BULL, V72, P208, DOI 10.1016/j.brainresbull.2007.01.004; Rohling ML, 2009, NEUROPSYCHOLOGY, V23, P20, DOI 10.1037/a0013659; Rossi S, 2009, CLIN NEUROPHYSIOL, V120, P2008, DOI 10.1016/j.clinph.2009.08.016; Stagg CJ, 2011, NEUROPSYCHOLOGIA, V49, P800, DOI 10.1016/j.neuropsychologia.2011.02.009; Tanaka S, 2011, NEUROREHAB NEURAL RE, V25, P565, DOI 10.1177/1545968311402091; Teasdale TW, 1997, BRAIN INJURY, V11, P543, DOI 10.1080/026990597123250; Vallar G, 2011, NEUROPSYCHOL REHABIL, V21, P618, DOI 10.1080/09602011.2011.574050; Villamar MF, 2012, NEUROMODULATION, V15, P326, DOI 10.1111/j.1525-1403.2012.00474.x; Wang L, 2010, J COGNITIVE NEUROSCI, V22, P543, DOI 10.1162/jocn.2009.21210; Wilson Barbara A., 2009, MEMORY REHABILITATIO; Wise EK, 2010, ARCH PHYS MED REHAB, V91, P1357, DOI 10.1016/j.apmr.2010.06.009	52	35	36	0	28	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2014	29	3					E20	E29		10.1097/HTR.0b013e318292a4c2			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AG9SE	WOS:000335759100003	23756431				2021-06-18	
J	Meyers, JE; Miller, RM; Thompson, LM; Scalese, AM; Allred, BC; Rupp, ZW; Dupaix, ZP; Lee, AJ				Meyers, John E.; Miller, Ronald M.; Thompson, Lisa M.; Scalese, Adam M.; Allred, Bonnie C.; Rupp, Zachary W.; Dupaix, Zacharias P.; Lee, Amy Junghyun			Using Likelihood Ratios to Detect Invalid Performance with Performance Validity Measures	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Assessment; Malingering; symptom validity testing; Mild cognitive; Impairment; Test construction	TRAUMATIC BRAIN-INJURY; SYMPTOM VALIDITY; VALIDATION; TESTS; INDICATORS	Larrabee (2008) applied chained likelihood ratios to selected performance validity measures (PVMs) to identify non-valid performances on neuropsychological tests. He presented a method of combining different PVMs with different sensitivities and specificities into an overall probability of non-validity. We applied his methodology to a set of 11 PVMs using a sample of 255 subjects. The results of the study show that in various combinations of two or three PVMs, a high reliability of invalidity can be determined using the chained likelihood ratio method. This study advances the ability of clinicians to chain various PVMs together and calculate the probability that a set of data is invalid.	[Meyers, John E.] Meyers Neuropsychol Serv, Mililani, HI 96857 USA; [Miller, Ronald M.; Thompson, Lisa M.; Scalese, Adam M.; Allred, Bonnie C.; Rupp, Zachary W.; Dupaix, Zacharias P.; Lee, Amy Junghyun] Brigham Young Univ Hawaii, Dept Psychol, Laie, HI USA	Meyers, JE (corresponding author), Meyers Neuropsychol Serv, Mililani, HI 96857 USA.	jmeyersneuro@yahoo.com		Lee, Amy Junghyun/0000-0001-7745-7058			BALDESSARINI RJ, 1983, ARCH GEN PSYCHIAT, V40, P569; Benton A.L., 1983, CONTRIBUTIONS NEUROP; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P19, DOI 10.1076/clin.15.1.19.1907; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; Boone K., 2007, ASSESSMENT FEIGNED C; Boone KB, 2000, ARCH CLIN NEUROPSYCH, V15, P227, DOI 10.1016/S0887-6177(99)00014-1; BRANDT J, 1985, ANN NY ACAD SCI, V444, P502, DOI 10.1111/j.1749-6632.1985.tb37625.x; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Etcoff LM, 1996, NEUROPSYCHOL REV, V6, P171, DOI 10.1007/BF01874896; Green, 2003, WORD MEMORY TEST; Green P, 2009, BRAIN INJURY, V23, P741, DOI 10.1080/02699050903133962; Green Paul, 2007, Phys Med Rehabil Clin N Am, V18, P43, DOI 10.1016/j.pmr.2006.11.002; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2010, CLIN NEUROPSYCHOL, V24, P137, DOI 10.1080/13854040902927546; Greve KW, 2004, ARCH CLIN NEUROPSYCH, V19, P533, DOI 10.1016/j.acn.2003.08.002; Grimes DA, 2005, LANCET, V365, P1500, DOI 10.1016/S0140-6736(05)66422-7; Hamberger MJ, 1999, EPILEPSY RES, V35, P229, DOI 10.1016/S0920-1211(99)00023-6; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2008, CLIN NEUROPSYCHOL, V22, P666, DOI 10.1080/13854040701494987; Larrabee GJ, 2012, J INT NEUROPSYCH SOC, V18, P625, DOI 10.1017/S1355617712000240; Larrabee GJ, 2009, CLIN NEUROPSYCHOL, V23, P841, DOI 10.1080/13854040902796735; Meyers J., 1995, REY COMPLEX FIGURE T; Meyers J E, 2001, Appl Neuropsychol, V8, P234, DOI 10.1207/S15324826AN0804_6; Meyers J E, 1996, Appl Neuropsychol, V3, P89, DOI 10.1207/s15324826an0302_8; Meyers J E, 1999, Appl Neuropsychol, V6, P208, DOI 10.1207/s15324826an0604_3; Meyers J. E, 2013, ELECT MANUAL MEYERS; Meyers JE, 2004, ARCH CLIN NEUROPSYCH, V19, P637, DOI 10.1016/j.acn.2003.08.007; Meyers JE, 1998, ASSESSMENT, V5, P303, DOI 10.1177/107319119800500309; Meyers JE, 2003, ARCH CLIN NEUROPSYCH, V18, P261, DOI 10.1016/S0887-6177(02)00136-1; Meyers JE, 2002, ARCH CLIN NEUROPSYCH, V17, P79, DOI 10.1016/S0887-6177(00)00105-0; Meyers JE, 2002, ARCH CLIN NEUROPSYCH, V17, P157, DOI 10.1016/S0887-6177(00)00107-4; Meyers JE, 2014, APPL NEUROPSYCH-ADUL, V21, P148, DOI 10.1080/09084282.2013.780173; Meyers JE, 2011, ARCH CLIN NEUROPSYCH, V26, P8, DOI 10.1093/arclin/acq083; Meyers JE, 1998, APPL NEUROPSYCHOL, V5, P120, DOI 10.1207/s15324826an0503_2; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Reitan RM., 1985, HALSTEAD REITAN NEUR; Rohling ML, 2003, CLIN NEUROPSYCHOL, V17, P289, DOI 10.1076/clin.17.3.289.18086; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Vickery CD, 2001, ARCH CLIN NEUROPSYCH, V16, P45, DOI 10.1016/S0887-6177(99)00058-X; Victor T, 2009, CLIN NEUROPSYCHOL, V23, P297, DOI 10.1080/13854040802232682; Wechsler D., 1997, WAIS 3 ADM SCORING M	42	35	35	0	4	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	MAY	2014	29	3					224	235		10.1093/arclin/acu001			12	Psychology, Clinical; Psychology	Psychology	AG9WC	WOS:000335769700002	24499725	Bronze			2021-06-18	
J	Huang, BR; Chang, PC; Yeh, WL; Lee, CH; Tsai, CF; Lin, CJ; Lin, HY; Liu, YS; Wu, CYJ; Ko, PY; Huang, SS; Hsu, HC; Lu, DY				Huang, Bor-Ren; Chang, Pei-Chun; Yeh, Wei-Lan; Lee, Chih-Hao; Tsai, Cheng-Fang; Lin, Chingju; Lin, Hsiao-Yun; Liu, Yu-Shu; Wu, Caren Yu-Ju; Ko, Pei-Ying; Huang, Shiang-Suo; Hsu, Horng-Chaung; Lu, Dah-Yuu			Anti-Neuroinflammatory Effects of the Calcium Channel Blocker Nicardipine on Microglial Cells: Implications for Neuroprotection	PLOS ONE			English	Article							ACTIVATED PROTEIN-KINASE; CENTRAL-NERVOUS-SYSTEM; NITRIC-OXIDE SYNTHASE; CEREBRAL-BLOOD-FLOW; FACTOR-KAPPA-B; SIGNALING PATHWAY; GLIOMA-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE/AKT; INTRACEREBRAL HEMORRHAGE; SUBARACHNOID HEMORRHAGE	Background/Objective: Nicardipine is a calcium channel blocker that has been widely used to control blood pressure in severe hypertension following events such as ischemic stroke, traumatic brain injury, and intracerebral hemorrhage. However, accumulating evidence suggests that inflammatory processes in the central nervous system that are mediated by microglial activation play important roles in neurodegeneration, and the effect of nicardipine on microglial activation remains unresolved. Methodology/Principal Findings: In the present study, using murine BV-2 microglia, we demonstrated that nicardipine significantly inhibits microglia-related neuroinflammatory responses. Treatment with nicardipine inhibited microglial cell migration. Nicardipine also significantly inhibited LPS plus IFN-gamma-induced release of nitric oxide (NO), and the expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2). Furthermore, nicardipine also inhibited microglial activation by peptidoglycan, the major component of the Gram-positive bacterium cell wall. Notably, nicardipine also showed significant anti-neuroinflammatory effects on microglial activation in mice in vivo. Conclusion/Significance: The present study is the first to report a novel inhibitory role of nicardipine on neuroinflammation and provides a new candidate agent for the development of therapies for inflammation-related neurodegenerative diseases.	[Huang, Bor-Ren; Hsu, Horng-Chaung] China Med Univ, Grad Inst Clin Med Sci, Taichung, Taiwan; [Huang, Bor-Ren] Taichung Tzu Chi Hosp, Neurosurg Dept, Buddhist Tzu Chi Med Fdn, Taichung, Taiwan; [Huang, Bor-Ren] Tzu Chi Univ, Sch Med, Hualien, Taiwan; [Chang, Pei-Chun] Asia Univ, Dept Bioinformat, Taichung, Taiwan; [Yeh, Wei-Lan] Changhua Christian Hosp, Dept Cell & Tissue Engn, Changhua, Taiwan; [Lee, Chih-Hao] Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, Boston, MA 02115 USA; [Tsai, Cheng-Fang] Asia Univ, Dept Biotechnol, Taichung, Taiwan; [Lin, Chingju] China Med Univ, Sch Med, Dept Physiol, Taichung, Taiwan; [Lin, Hsiao-Yun] Natl Chung Hsing Univ, Dept Life Sci, Taichung 40227, Taiwan; [Liu, Yu-Shu; Wu, Caren Yu-Ju] China Med Univ, Grad Inst Basic Med Sci, Taichung, Taiwan; [Ko, Pei-Ying] China Med Univ, Dept Med Lab Sci & Biotechnol, Taichung, Taiwan; [Huang, Shiang-Suo] Chung Shan Med Univ, Dept Pharmacol, Coll Med, Taichung, Taiwan; [Huang, Shiang-Suo] Chung Shan Med Univ, Inst Med, Coll Med, Taichung, Taiwan; [Hsu, Horng-Chaung] China Med Univ Hosp, Dept Orthoped Surg, Taichung, Taiwan; [Lu, Dah-Yuu] China Med Univ, Grad Inst Neural & Cognit Sci, Taichung, Taiwan	Lu, DY (corresponding author), China Med Univ, Grad Inst Neural & Cognit Sci, Taichung, Taiwan.	dahyuu@mail.cmu.edu.tw	Lu, Dah-Yuu/P-2563-2015		National Science CouncilMinistry of Science and Technology, Taiwan [NSC 101-2320-B-039-048-MY2, NSC 102-2320-B-039-051-MY3, NSC 102-2320-B-039-026-MY3]; Taichung Tzu Chi Hospital; Buddhist Tzu Chi Medical Foundation [TTCRD 101-03]; China Medical UniversityChina Medical University [CMU101-ASIA-10]; Asia University [99-A-01]	This work was supported by grants from the National Science Council (NSC 101-2320-B-039-048-MY2, NSC 102-2320-B-039-051-MY3 and NSC 102-2320-B-039-026-MY3), Taichung Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation (TTCRD 101-03), China Medical University (CMU101-ASIA-10), and Asia University (99-A-01). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amenta F, 2004, CLIN EXP HYPERTENS, V26, P351, DOI 10.1081/CEH-120034139; Amenta F, 1996, J HYPERTENS, V14, pS29, DOI 10.1097/00004872-199610003-00006; Amenta F, 2008, CLIN EXP HYPERTENS, V30, P808, DOI 10.1080/10641960802580190; Babu CS, 2011, INT J DEV NEUROSCI, V29, P93, DOI 10.1016/j.ijdevneu.2010.08.001; Bal-Price A, 2001, J NEUROSCI, V21, P6480; BECKMAN JS, 1994, PROG BRAIN RES, V103, P371; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Casamassima F, 2010, AM J MED GENET B, V153B, P1373, DOI 10.1002/ajmg.b.31122; CHAO CC, 1995, J LEUKOCYTE BIOL, V58, P65; Chen JH, 2012, INT IMMUNOPHARMACOL, V12, P94, DOI 10.1016/j.intimp.2011.10.019; Chen JH, 2011, J CELL BIOCHEM, V112, P2931, DOI 10.1002/jcb.23209; Cho S, 2005, J CEREBR BLOOD F MET, V25, P493, DOI 10.1038/sj.jcbfm.9600058; Czeh M, 2011, DEV NEUROSCI-BASEL, V33, P199, DOI 10.1159/000328989; Degoute CS, 2007, DRUGS, V67, P1053, DOI 10.2165/00003495-200767070-00007; Ding L, 2012, NATURE, V481, P506, DOI 10.1038/nature10738; Gasior M, 1996, J NEURAL TRANSM, V103, P819, DOI 10.1007/BF01273360; Gianino John W, 2012, Mo Med, V109, P384; Guillot-Sestier MV, 2013, CNS NEUROL DISORD-DR, V12, P593; HALEY EC, 1994, J NEUROSURG, V80, P788, DOI 10.3171/jns.1994.80.5.0788; Hashioka S, 2012, NEUROPHARMACOLOGY, V63, P685, DOI 10.1016/j.neuropharm.2012.05.033; Hayashi M, 2000, HYPERTENS RES, V23, P521, DOI 10.1291/hypres.23.521; Henry CJ, 2009, BRAIN BEHAV IMMUN, V23, P309, DOI 10.1016/j.bbi.2008.09.002; Huang BR, 2013, TOXICOL APPL PHARM, V269, P43, DOI 10.1016/j.taap.2013.03.004; Huang SM, 2011, J CELL BIOCHEM, V112, P643, DOI 10.1002/jcb.22966; Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; Kim Sang Yong, 2012, J Cerebrovasc Endovasc Neurosurg, V14, P84, DOI 10.7461/jcen.2012.14.2.84; Knott C, 2000, MOL CELL NEUROSCI, V16, P724, DOI 10.1006/mcne.2000.0914; Koizumi S, 2002, LIFE SCI, V72, P431, DOI 10.1016/S0024-3205(02)02273-7; Koizumi S, 2013, GLIA, V61, P47, DOI 10.1002/glia.22358; Komagiri Y, 2011, CELL CALCIUM, V49, P35, DOI 10.1016/j.ceca.2010.11.006; Leung YM, 2013, BIOMEDICINE-TAIWAN, V3, P130, DOI 10.1016/j.biomed.2012.11.003; Leung YM, 2011, BIOMEDICINE-TAIWAN, V1, P16, DOI 10.1016/j.biomed.2011.10.003; Liang X, 2007, J MOL NEUROSCI, V33, P94, DOI 10.1007/s12031-007-0058-8; Lin C, 2013, NEUROSCIENCE, V231, P216, DOI 10.1016/j.neuroscience.2012.11.051; Lin HY, 2014, NEUROBIOL AGING, V35, P191, DOI 10.1016/j.neurobiolaging.2013.06.020; Lin HY, 2011, J CELL PHYSIOL, V226, P1573, DOI 10.1002/jcp.22489; Lin HY, 2010, INT IMMUNOPHARMACOL, V10, P883, DOI 10.1016/j.intimp.2010.04.026; Liu YX, 2011, NEUROPHARMACOLOGY, V60, P373, DOI 10.1016/j.neuropharm.2010.10.002; Loihl AK, 1998, PROG BRAIN RES, V118, P253; Lu DY, 2007, BRIT J PHARMACOL, V151, P396, DOI 10.1038/sj.bjp.0707187; Lu DY, 2006, BIOCHEM PHARMACOL, V72, P992, DOI 10.1016/j.bcp.2006.06.038; Lu DY, 2013, INT J NEUROPSYCHOPH, V16, P433, DOI 10.1017/S1461145712000338; Lu DY, 2012, NEURO-ONCOLOGY, V14, P1367, DOI 10.1093/neuonc/nos262; Lu DY, 2010, BIOCHEM PHARMACOL, V80, P1201, DOI 10.1016/j.bcp.2010.06.046; Lu DY, 2010, J CELL BIOCHEM, V110, P697, DOI 10.1002/jcb.22580; Lu DY, 2009, EUR J PHARMACOL, V613, P146, DOI 10.1016/j.ejphar.2009.03.001; Maa MC, 2013, BIOMEDICINE-TAIWAN, V3, P1, DOI 10.1016/j.biomed.2012.12.006; Matsui T, 2010, BIOCHEM BIOPH RES CO, V396, P566, DOI 10.1016/j.bbrc.2010.04.149; McGrath JC, 2010, BRIT J PHARMACOL, V160, P1573, DOI 10.1111/j.1476-5381.2010.00873.x; Michelucci A, 2009, J NEUROIMMUNOL, V210, P3, DOI 10.1016/j.jneuroim.2009.02.003; Mikami C, 2001, CEREBROVASC DIS, V11, P44, DOI 10.1159/000047610; Narotam PK, 2008, J NEUROSURG, V109, P1065, DOI 10.3171/JNS.2008.109.12.1065; Olson JK, 2004, J IMMUNOL, V173, P3916, DOI 10.4049/jimmunol.173.6.3916; Patel Anita R, 2013, Int J Physiol Pathophysiol Pharmacol, V5, P73; Politis M, 2011, HUM BRAIN MAPP, V32, P258, DOI 10.1002/hbm.21008; Powers WJ, 2001, NEUROLOGY, V57, P18, DOI 10.1212/WNL.57.1.18; Qian L, 2010, J NEURAL TRANSM, V117, P971, DOI 10.1007/s00702-010-0428-1; Qureshi AI, 2011, NEUROCRIT CARE, V15, P559, DOI 10.1007/s12028-011-9538-3; Qureshi AI, 2006, CRIT CARE MED, V34, P1975, DOI 10.1097/01.CCM.0000220763.85974.E8; Qureshi Ai, 2012, J Vasc Interv Neurol, V5, P6; Rasmuson S., 2011, INT PSYCHOGERIATR, V18, P1; Saijonmaa Outi, 1997, Blood Pressure, V6, P24, DOI 10.3109/08037059709086442; Sanz JM, 2012, BRIT J PHARMACOL, V167, P1702, DOI 10.1111/j.1476-5381.2012.02112.x; Sato Shoichiro, 2012, Rinsho Shinkeigaku, V52, P642; SCHLEIFER KH, 1972, BACTERIOL REV, V36, P407, DOI 10.1128/MMBR.36.4.407-477.1972; Schut Ewout S, 2008, Pract Neurol, V8, P8, DOI 10.1136/jnnp.2007.139725; Su PY, 2013, BIOMEDICINE-TAIWAN, V3, P181, DOI 10.1016/j.biomed.2013.08.001; Tejada JG, 2007, AM J NEURORADIOL, V28, P844; Triggle DJ, 2007, BIOCHEM PHARMACOL, V74, P1, DOI 10.1016/j.bcp.2007.01.016; Tsai CF, 2012, INT J MOL SCI, V13, P9877, DOI 10.3390/ijms13089877; Uslu S, 2012, NEUROCHEM RES, V37, P1554, DOI 10.1007/s11064-012-0750-0; Wang JY, 2003, J NEUROSCI RES, V72, P508, DOI 10.1002/jnr.10597; Yermakova A, 2000, CURR PHARM DESIGN, V6, P1755, DOI 10.2174/1381612003398672; Yong VW, 2010, NEUROSCIENTIST, V16, P408, DOI 10.1177/1073858410371379; Zhang XL, 2012, J INT MED RES, V40, P1036, DOI 10.1177/147323001204000322; Ziv Y, 2006, NAT NEUROSCI, V9, P268, DOI 10.1038/nn1629	76	35	38	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 12	2014	9	3							e91167	10.1371/journal.pone.0091167			10	Multidisciplinary Sciences	Science & Technology - Other Topics	AC9HN	WOS:000332845300055	24621589	DOAJ Gold, Green Published			2021-06-18	
J	Arenth, PM; Russell, KC; Scanlon, JM; Kessler, LJ; Ricker, JH				Arenth, Patricia M.; Russell, Kathryn C.; Scanlon, Joelle M.; Kessler, Lauren J.; Ricker, Joseph H.			Corpus Callosum Integrity and Neuropsychological Performance After Traumatic Brain Injury: A Diffusion Tensor Imaging Study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						cognition; corpus callosum; diffusion tensor imaging; neuropsychology; traumatic brain injury	EDITION CVLT-II; VERBAL-LEARNING TEST; AXONAL INJURY; NEUROPSYCHOMETRIC TESTS; MODERATE; MILD; MEMORY; OUTCOMES; METRICS; LESIONS	Objectives: (1) Detailed analysis of diffusion tensor imaging (DTI) parameters (fractional anisotropy and radial diffusivity) to evaluate white matter integrity in the corpus callosum (CC), and (2) examine correlations between DTI data and performance on multiple measures of cognitive functioning. Participants: Twelve individuals with a history of complicated mild, moderate, or severe traumatic brain injury (TBI) who were an average of 1.7 years postinjury and 12 control participants. Main Measures: Standardized and experimental neuropsychological tests; detailed analysis of DTI parameters. Results: The TBI group demonstrated DTI values suggesting decreased white matter integrity and correlations with severity of injury. Both groups showed correlations between DTI parameters and cognitive measures, with more significant correlations observed for the TBI group. White matter changes in the CC were evident chronically and were related to severity of injury. Conclusions: Diffusion tensor imaging parameters suggesting disruptions in white matter in the CC may be implicated in impaired performance, both in terms of cognitive tasks and reaction time, after TBI.	[Arenth, Patricia M.; Russell, Kathryn C.; Scanlon, Joelle M.; Kessler, Lauren J.; Ricker, Joseph H.] Univ Pittsburgh, Dept Phys Med & Rehabil, Sch Med, Pittsburgh, PA USA; [Arenth, Patricia M.; Russell, Kathryn C.; Ricker, Joseph H.] Univ Pittsburgh, Ctr Neural Basis Cognit, Pittsburgh, PA USA; [Russell, Kathryn C.] Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA USA	Ricker, JH (corresponding author), New York Univ, Sch Med, Dept Rehabil Med, Rusk Rehabil NYUMC, 240 E 38th St,Suite 15-71, New York, NY 10016 USA.	ricker@nyu.edu		Ricker, Joseph/0000-0003-3415-991X	 [NIH-NINDS R01NS048178-01];  [5T32HD040686]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS048178] Funding Source: NIH RePORTER	This research was supported in part by a grant (NIH-NINDS R01NS048178-01) awarded to Dr Ricker. Dr Russell was supported by 5T32HD040686 during the preparation of this article.	Arenth PM, 2012, J CLIN EXP NEUROPSYC, V34, P333, DOI 10.1080/13803395.2011.633896; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Benton A., 1976, MULTILINGUAL APHASIA; Bigler ED, 2011, NEUROREHABILITATION, V28, P63, DOI 10.3233/NRE-2011-0633; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; DeJong J, 2009, ASSESSMENT, V16, P328, DOI 10.1177/1073191109336989; Delis DC, 2000, CALIFORNIA VERBAL LE; DERENZI E, 1962, BRAIN, V85, P665, DOI 10.1093/brain/85.4.665; DEROGATIS LR, 1993, BSI BRIEF S INV ADM; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; Golden CJ, 2002, STROOP COLOR WORD TE; GRANT AD, 1948, J EXP PSYCHOL, V38, P404, DOI DOI 10.1037/H0059831; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jacobs ML, 2008, ARCH CLIN NEUROPSYCH, V23, P113, DOI 10.1016/j.acn.2007.09.003; Jacobs ML, 2007, ARCH CLIN NEUROPSYCH, V22, P143, DOI 10.1016/j.acn.2006.12.002; Jansma JM, 2001, J COGNITIVE NEUROSCI, V13, P730, DOI 10.1162/08989290152541403; Jiang HY, 2006, COMPUT METH PROG BIO, V81, P106, DOI 10.1016/j.cmpb.2005.08.004; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kashluba S, 2008, ARCH PHYS MED REHAB, V89, P904, DOI 10.1016/j.apmr.2007.12.029; Koch K, 2006, BRAIN RES, V1107, P140, DOI 10.1016/j.brainres.2006.06.003; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2010, J HEAD TRAUMA REHAB, V25, P31, DOI 10.1097/HTR.0b013e3181bff331; Kumar R, 2009, BRAIN INJURY, V23, P675, DOI 10.1080/02699050903014915; Lebel C, 2012, MAGN RESON MED, V68, P474, DOI 10.1002/mrm.23254; Leclercq PD, 2001, J NEUROTRAUM, V18, P1, DOI 10.1089/089771501750055721; Ljungqvist J, 2011, BRAIN INJURY, V25, P370, DOI 10.3109/02699052.2011.558038; Mathias JL, 2004, APPL NEUROPSYCHOL, V11, P134, DOI 10.1207/s15324826an1103_2; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; MILNER B, 1963, ARCH NEUROL-CHICAGO, V9, P90, DOI 10.1001/archneur.1963.00460070100010; Mukherjee P, 2008, AM J NEURORADIOL, V29, P632, DOI 10.3174/ajnr.A1051; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Nolte J., 2008, HUMAN BRAIN INTRO IT; Oh JS, 2005, NEUROREPORT, V16, P317, DOI 10.1097/00001756-200503150-00002; Palacios EM, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-24; Reitan RM., 1985, HALSTEAD REITAN NEUR; Ricker JH, 2010, HDB REHABILITATION P, P43, DOI [10.1037/15972-003, DOI 10.1037/15972-003]; Russell KC, 2011, J CLIN EXP NEUROPSYC, V33, P538, DOI 10.1080/13803395.2010.537253; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; SELZER ML, 1971, AM J PSYCHIAT, V127, P1653, DOI 10.1176/ajp.127.12.1653; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Spreen O, 1969, NEUROSENSORY CTR COM; Teasdale G, 1974, LANCET, V2, P480; Thierry AGM, 2004, AM J NEURORADIOL, V25, P370; Tisserand DJ, 2006, BRAIN COGNITION, V60, P216; Warner MA, 2010, J NEUROTRAUM, V27, P2121, DOI 10.1089/neu.2010.1429; Wechsler D., 2001, WECHSLER TEST ADULT; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wolfe PL, 2010, CLIN NEUROPSYCHOL, V24, P153, DOI 10.1080/13854040903107791	54	35	38	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2014	29	2					E1	E10		10.1097/HTR.0b013e318289ede5			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AH9ZH	WOS:000336504600001	23558829	Green Accepted			2021-06-18	
J	Cifu, DX; Walker, WC; West, SL; Hart, BB; Franke, LM; Sima, A; Graham, CW; Carne, W				Cifu, David X.; Walker, William C.; West, Steven L.; Hart, Brett B.; Franke, Laura Manning; Sima, Adam; Graham, Carolyn W.; Carne, William			Hyperbaric oxygen for blast-related postconcussion syndrome: Three-month outcomes	ANNALS OF NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; POST-CONCUSSION SYNDROME; OIF/OEF VETERANS; CHRONIC SEQUELAE; HEAD-INJURIES; WECHSLER TEST; MILD TBI; SYMPTOMS; VALIDITY	Objective Mild traumatic brain injury (mTBI) and postconcussion syndrome (PCS) are common among military combatants. Hyperbaric oxygen (HBO2) is a proposed treatment for these conditions, but it has not been rigorously studied. The objective of this study was to determine the effects of HBO2 by 3 months post compression at 2 commonly employed dosing levels to treat PCS; whether specific subgroups may have benefited; and if no overall effect was found, whether benefit is masked by other conditions. Methods This randomized, double-blind, sham-controlled study was conducted at the Naval Air Station in Pensacola, Florida on 61 male Marines with a history of mTBI and PCS. Intervention consisted of 40 once daily 60-minute hyperbaric chamber compressions at 2.0 atmospheres absolute (ATA) at 1 of 3 randomly preassigned oxygen fractions, resulting in respective blinded groups with an oxygen-breathing exposure equivalent to (1) surface air (sham), (2) 100% oxygen at 1.5ATA, or (3) 100% oxygen at 2.0ATA. The main outcome measure was the Rivermead Post-Concussion Questionnaire-16 (RPQ-16) collected before compressions and at 2 later points. Results The interaction of time by intervention group was not significant for improvement on the RPQ-16. Nor was there evidence of efficacy on the RPQ-16 for any subgroup. No significant time by intervention interaction was found for any functional, cognitive, or psychomotor secondary outcome measure at an unadjusted 0.05 significance level. Interpretation Using a randomized control trial design and analysis including a sham, results showed no evidence of efficacy by 3 months post-compression to treat the symptomatic, cognitive, or behavioral sequelae of PCS after combat-related mTBI. ANN NEUROL 2014;75:277-286	[Cifu, David X.] Dept Vet Affairs, Phys Med & Rehabil Program Off, Washington, DC USA; [Cifu, David X.; Walker, William C.; West, Steven L.; Franke, Laura Manning; Graham, Carolyn W.; Carne, William] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA USA; [Cifu, David X.; Walker, William C.; Franke, Laura Manning; Carne, William] Hunter Holmes McGuire Vet Affairs Med Ctr, Richmond, VA USA; [Cifu, David X.; Walker, William C.; West, Steven L.; Sima, Adam; Graham, Carolyn W.] Ctr Rehabil Sci & Engn, Richmond, VA USA; [Walker, William C.; Franke, Laura Manning; Carne, William] Richmond Def & Vet Brain Injury Ctr, Richmond, VA USA; [Hart, Brett B.] Navy Med Operat Training Ctr, Pensacola, FL USA; [Sima, Adam] Virginia Commonwealth Univ, Dept Biostat, Richmond, VA USA	Carne, W (corresponding author), Richmond VAMC, 1201 Broad Rock Blvd 127, Richmond, VA 23249 USA.	William.Carne@va.gov	Walker, William C/N-3162-2014	Sima, Adam/0000-0001-8426-9987; Cifu, David/0000-0003-1600-9387	Defense Advanced Research Projects Agency grant [N66001-09-2-206]; US Navy Bureau of Medicine and Surgery; US Army Medical Materiel Development Activity; Defense and Veterans Brain Injury CenterUS Department of Veterans Affairs	Funding was provided for the primary study by a Defense Advanced Research Projects Agency grant (N66001-09-2-206). The US Navy Bureau of Medicine and Surgery provided contract funding for temporary duty requirements, and the US Army Medical Materiel Development Activity provided end of study contract funding. W.C.W. and W.C. were additionally supported through contracts from the Defense and Veterans Brain Injury Center. The funding sources had no role in the study design, analysis and interpretation of the data, writing of the paper, or decision to submit the paper for publication.	Ahmed FA, 2013, ELECTROPHORESIS, V34, P2229, DOI 10.1002/elps.201300077; Belanger HG, 2011, CLIN NEUROPSYCHOL, V25, P702, DOI 10.1080/13854046.2011.566892; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; BENTON A L, 1981, Journal of Clinical Neuropsychology, V3, P33, DOI 10.1080/01688638108403111; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; BOHNEN NI, 1995, BRAIN INJURY, V9, P27, DOI 10.3109/02699059509004568; Bradley KA, 2007, ALCOHOL CLIN EXP RES, V31, P1208, DOI 10.1111/j.1530-0277.2007.00403.x; Centers for Disease Control and Prevention, DOD VA COD PROP DOD; Churchill S, 2013, UNDERSEA HYPERBAR M, V40, P165; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; Cifu D, 2011, OVERCOMING POSTDEPLO; Cifu DX, 2013, J HEAD TRAUMA REHABI; Clarke D, 2009, UNDERSEA HYPERBAR M, V36, P13; Conners C., 2000, CONNERS CONTINUOUS P; Cripps A, 2013, J SPORT REHABIL, V22, P67, DOI 10.1123/jsr.22.1.67; Curtis KL, 2009, ASSESSMENT, V16, P401, DOI 10.1177/1073191109338161; Defense and Veterans Brain Injury Center, DOD WORLDW NUMB TBI; Delis DC, 1991, J CONSULT CLIN PSYCH, V3, P19, DOI DOI 10.1037/1040-3590.3.1.19; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Donders J, 2007, J INT NEUROPSYCH SOC, V13, P354, DOI 10.1017/S1355617707070439; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Flaherty S A, 1996, AANA J, V64, P133; Gesell LB, 2008, HYPERBARIC OXYGEN TH; Green REA, 2008, J CLIN EXP NEUROPSYC, V30, P163, DOI 10.1080/13803390701300524; Grieger TA, 2006, AM J PSYCHIAT, V163, P1777, DOI 10.1176/appi.ajp.163.10.1777; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Halbauer JD, 2009, J REHABIL RES DEV, V46, P757, DOI 10.1682/JRRD.2008.08.0119; Harch PG, 2012, J NEUROTRAUM, V29, P168, DOI 10.1089/neu.2011.1895; Harrison JE, 2000, BRIT J CLIN PSYCHOL, V39, P181, DOI 10.1348/014466500163202; Hudak AM, 2005, J NEUROTRAUM, V22, P1319, DOI 10.1089/neu.2005.22.1319; Jacobs ML, 2007, ARCH CLIN NEUROPSYCH, V22, P143, DOI 10.1016/j.acn.2006.12.002; Kaufman KR, 2006, MED ENG PHYS, V28, P234, DOI 10.1016/j.medengphy.2005.05.005; KLOVE H, 1963, MED CLIN N AM, V47, P1647, DOI 10.1016/S0025-7125(16)33515-5; Lange RT, 2013, J NEUROTRAUM, V30, P958, DOI 10.1089/neu.2012.2743; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; Malec JF, 2004, ARCH PHYS MED REHAB, V85, P1989, DOI 10.1016/j.apmr.2004.01.032; Mathias JL, 2007, BRIT J CLIN PSYCHOL, V46, P457, DOI 10.1348/014466507X190197; Mendez MF, 2013, NEUROREHABILITATION, V32, P397, DOI 10.3233/NRE-130861; National Institute of Neurologic Disorders, TBI COMPR EV COMM DA; NEUBAUER RA, 1990, LANCET, V335, P542, DOI 10.1016/0140-6736(90)90777-3; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Pickett TC, 2007, J REHABIL RES DEV, V44, P983, DOI 10.1682/JRRD.2007.01.0001; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Riccio CA, 2002, ARCH CLIN NEUROPSYCH, V17, P235, DOI 10.1016/S0887-6177(01)00111-1; Rockswold SB, 2013, J NEUROSURG, V118, P1317, DOI 10.3171/2013.2.JNS121468; Ruffolo LF, 2000, CLIN NEUROPSYCHOL, V14, P223, DOI 10.1076/1385-4046(200005)14:2;1-Z;FT223; Ruttan L, 2008, ARCH PHYS MED REHAB, V89, pS69, DOI 10.1016/j.apmr.2008.07.007; Scherer MR, 2011, EXP BRAIN RES, V208, P399, DOI 10.1007/s00221-010-2490-1; Spencer RJ, 2010, J REHABIL RES DEV, V47, P521, DOI 10.1682/JRRD.2009.11.0181; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Sundin J, 2010, PSYCHOL MED, V40, P367, DOI 10.1017/S0033291709990791; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Vanderploeg RD, 2012, ARCH PHYS MED REHAB, V93, P1887, DOI 10.1016/j.apmr.2012.05.024; Walker WC, 2013, NEUROREHABIL NEURAL; Walker WC, 2013, J HEAD TRAUMA REHAB, V28, P68, DOI 10.1097/HTR.0b013e318255dfd0; Weaver LK, 2012, UNDERSEA HYPERBAR M, V39, P807; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th ed; Wolf G, 2012, J NEUROTRAUM, V29, P2606, DOI 10.1089/neu.2012.2549	67	35	36	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	FEB	2014	75	2					277	286		10.1002/ana.24067			10	Clinical Neurology; Neurosciences	Neurosciences & Neurology	AD1PD	WOS:000333005000014	24255008				2021-06-18	
J	Whyte, J; Rajan, R; Rosenbaum, A; Katz, D; Kalmar, K; Seel, R; Greenwald, B; Zafonte, R; Demarest, D; Brunner, R; Kaelin, D				Whyte, John; Rajan, Riya; Rosenbaum, Amy; Katz, Douglas; Kalmar, Kathleen; Seel, Ron; Greenwald, Brian; Zafonte, Ross; Demarest, David; Brunner, Robert; Kaelin, Darryl			Zolpidem and Restoration of Consciousness	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						Brain Injuries; Consciousness Disorders; Vegetative State; Minimally Conscious State; Zolpidem	PLACEBO-CONTROLLED TRIAL; ANOXIC BRAIN-INJURY; VEGETATIVE STATE; AROUSAL; COMA; EEG; DISORDERS; SCALE	Objective: Zolpidem has been reported to cause temporary recovery of consciousness in vegetative and minimally conscious patients, but how often and why this occurs are unknown. The authors aimed to determine the frequency of this phenomenon and whether it can be predicted from demographic and clinical variables. Design: This is a placebo-controlled, double-blind, single-dose, crossover study performed by caregivers and replicated by trained professionals, for naive participants. Four previously identified responders were also studied to further characterize the clinical drug response. Results: Eighty-four participants with traumatic and nontraumatic disorders of consciousness of at least 4 mos' duration were studied. Four "definite responders" were identified, but no demographic or clinical features were predictive of the response. Indicators of a drug response included increased movement, social interaction, command following, attempts at communication, and functional object use; typically lasted 1-2 hrs; and sometimes ended with increased somnolence. Adverse events were more common on zolpidem than placebo, but most were rated as mild. Conclusions: Approximately 5% (4.8%) of the participants responded to zolpidem, but the responders could not be distinguished in advance from the non-responders. Future research is needed to understand the mechanism of zolpidem in enhancing consciousness and its potential role in treatment and research.	[Whyte, John; Rajan, Riya] Moss Rehabil Res Inst, Elkins Pk, PA 19027 USA; [Rosenbaum, Amy] Pk Terrace Care Ctr, Rego Pk Queens, NY USA; [Katz, Douglas] Boston Univ, Dept Neurol, Sch Med, Boston, MA 02215 USA; [Katz, Douglas] Braintree Rehabil Hosp, Brain Injury Program, Braintree, MA USA; [Kalmar, Kathleen] Johnson Rehabil Inst Ctr Head Injuries, Edison, NJ USA; [Seel, Ron] Shepherd Ctr, Crawford Res Inst, Atlanta, GA USA; [Seel, Ron] Shepherd Ctr, Brain Injury Program, Atlanta, GA USA; [Greenwald, Brian] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA; [Zafonte, Ross] Harvard Univ, Brigham & Womens Hosp, Dept Phys Med & Rehabil, Spaulding Rehabil Hosp,Massachusetts Gen Hosp,Med, Boston, MA 02115 USA; [Demarest, David] On With Life, Ankeny, IA USA; [Brunner, Robert] Univ Alabama Birmingham, Dept Phys Med & Rehabil, Birmingham, AL USA; [Kaelin, Darryl] Univ Louisville, Div Phys Med & Rehabil, Louisville, KY 40292 USA	Whyte, J (corresponding author), Moss Rehabil Res Inst, 50 Township Line Rd, Elkins Pk, PA 19027 USA.			Whyte, John/0000-0002-4381-1474	National Institute on Disability and Rehabilitation Research (NIDRR), United States Department of Education [H133G080066]	Supported, in part, by grant no. H133G080066 from the National Institute on Disability and Rehabilitation Research (NIDRR), United States Department of Education (J.W., principal investigator). Financial disclosure statements have been obtained, and no conflicts of interest have been reported by the authors or by any individuals in control of the content of this article.	ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; BERLIN I, 1993, J CLIN PSYCHOPHARM, V13, P100; Bernat JL, 2009, ANNU REV MED, V60, P381, DOI 10.1146/annurev.med.60.060107.091250; Brefel-Courbon C, 2007, ANN NEUROL, V62, P102, DOI 10.1002/ana.21110; Brown EN, 2010, NEW ENGL J MED, V363, P2638, DOI 10.1056/NEJMra0808281; CHURCHILL L, 1991, ADV EXP MED BIOL, V295, P101; Clauss R, 2006, NEUROREHABILITATION, V21, P23; Clauss RP, 2010, MED HYPOTHESES, V75, P287, DOI 10.1016/j.mehy.2010.03.005; Clauss RP, 2000, S AFR MED J, V90, P68; Cohen L, 2004, NEW ENGL J MED, V350, P949, DOI 10.1056/NEJM200402263500922; Cohen SI, 2008, AM J PHYS MED REHAB, V87, P229, DOI 10.1097/PHM.0b013e318161971b; Galson S, DRUG SAFETY DRUG APP; Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; GIACINO JT, 1995, J HEAD TRAUMA REHAB, V10, P40; Machado C, 2011, CAN J NEUROL SCI, V38, P341, DOI 10.1017/S0317167100011562; PATAT A, 1994, PSYCHOPHARMACOLOGY, V114, P138, DOI 10.1007/BF02245455; Plum F, 1982, PATHOLOGIC PHYSL SIG; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; ROSENBERG JH, 1995, NEUROLOGY, V45, P1015; Schiff ND, 2007, ANN NEUROL, V62, P5, DOI 10.1002/ana.21158; Schiff ND, 2010, TRENDS NEUROSCI, V33, P1, DOI 10.1016/j.tins.2009.11.002; Seel RT, 2010, ARCH PHYS MED REHAB, V91, P1795, DOI 10.1016/j.apmr.2010.07.218; Shames JL, 2008, ARCH PHYS MED REHAB, V89, P386, DOI 10.1016/j.apmr.2007.08.137; Singh R, 2008, BRAIN INJURY, V22, P103, DOI 10.1080/02699050701829704; Snyman N, 2010, NEUROPEDIATRICS, V41, P223, DOI 10.1055/s-0030-1269893; SURH LC, 1994, NEW ENGL J MED, V330, P572, DOI 10.1056/NEJM199402243300813; van Lier H, 2004, NEUROPHARMACOLOGY, V47, P163, DOI 10.1016/j.neuropharm.2004.03.017; Whyte J, 2009, AM J PHYS MED REHAB, V88, P410, DOI 10.1097/PHM.0b013e3181a0e3a0	30	35	37	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0894-9115	1537-7385		AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	FEB	2014	93	2					101	113		10.1097/PHM.0000000000000069			13	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	AJ5PD	WOS:000337736200001	24434886				2021-06-18	
J	Doti, N; Reuther, C; Scognamiglio, PL; Dolga, AM; Plesnila, N; Ruvo, M; Culmsee, C				Doti, N.; Reuther, C.; Scognamiglio, P. L.; Dolga, A. M.; Plesnila, N.; Ruvo, M.; Culmsee, C.			Inhibition of the AIF/CypA complex protects against intrinsic death pathways induced by oxidative stress	CELL DEATH & DISEASE			English	Article						AIF/CypA complex; mitochondria; neuronal death; oxidative stress; peptide inhibitor	NEURONAL CELL-DEATH; OXYGEN-GLUCOSE DEPRIVATION; FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; CYCLOPHILIN-A; NUCLEAR TRANSLOCATION; APOPTOSIS; AIF; MITOCHONDRIA; NEUROPROTECTION	Delayed neuronal cell death largely contributes to the progressive infarct development and associated functional impairments after cerebral ischemia or brain trauma. Previous studies exposed a key role for the interaction of the mitochondrial protein apoptosis-inducing factor (AIF) and cytosolic cyclophilin A (CypA) in pathways of programmed cell death in neurons in vitro and in vivo. These studies suggested that pro-apoptotic activities of AIF, such as its translocation to the nucleus and subsequent DNA degradation, depend on the physical interaction of AIF with CypA. Hence, this protein complex may represent a new pharmacological target for inhibiting the lethal action of AIF on the brain tissue. In this study, we show that the AIF amino-acid residues 370-394 mediate the protein complex formation of AIF with CypA. The synthetic AIF(370-394) peptide inhibited AIF/CypA complex formation in vitro by binding CypA with a K-D of 12 mu M. Further, the peptide exerted pronounced neuroprotective effects in a model of glutamate-induced oxidative stress in cultured HT-22 cells. In this model system of AIF-dependent cell death, the AIF(370-394) peptide preserved mitochondrial integrity, as detected by measurements of the mitochondrial membrane potential and quantification of mitochondrial fragmentation. Further, the AIF(370-394) peptide inhibited perinuclear accumulation of fragmented mitochondria, mitochondrial release of AIF to the nucleus and glutamate-induced cell death to a similar extent as CypA-siRNA. These data indicate that the targeting of the AIF-CypA axis is an effective strategy of neuroprotection.	[Doti, N.; Scognamiglio, P. L.; Ruvo, M.] CNR, IBB, CIRPEB, I-80134 Naples, Italy; [Doti, N.; Reuther, C.; Dolga, A. M.; Culmsee, C.] Univ Marburg, Inst Pharmacol & Clin Pharm, D-35032 Marburg, Germany; [Doti, N.; Plesnila, N.] Royal Coll Surgeons Ireland, Dept Neurodegenerat, Dublin 2, Ireland; [Plesnila, N.] Univ Munich, Sch Med, Inst Stroke & Dementia Res ISD, D-81377 Munich, Germany	Doti, N (corresponding author), CNR, IBB, CIRPEB, Via Mezzocannone 16, I-80134 Naples, Italy.	nunzianna.doti@cnr.it; nikolaus.plesnila@med.uni-muenchen.de; culmsee@staff.uni-marburg.de	Scognamiglio, Pasqualina Liana/X-9429-2019; Plesnila, Nikolaus/T-7522-2019; Doti, Nunzianna/ABC-9948-2020; Dolga, Amalia/C-9664-2018	Scognamiglio, Pasqualina Liana/0000-0002-1444-8039; Culmsee, Carsten/0000-0002-5121-5015; Dolga, Amalia/0000-0001-5400-5614	National Biophotonics and Imaging Platform Ireland (NBIPI); career enhancement and mobility programme (CEMP); Irish Higher Education Authority (HEA); FIRB MERITMinistry of Education, Universities and Research (MIUR)Fund for Investment in Basic Research (FIRB) [RBNE08NKH7]; PROGETTO CAMPUS from Campania Region	We thank Alexander Seiler (Roche Diagnostics GmbH) for providing the xCELLigence system, Dr. Julia Grohm and Mrs. Katharina Elsasser for the excellent technical support. Furthermore, we thank Mrs. Emma Esser for careful editing of the manuscript. This work has been supported by 'The National Biophotonics and Imaging Platform Ireland (NBIPI), career enhancement and mobility programme (CEMP) a Marie Curie co-funded scheme with the Irish Higher Education Authority (HEA) Program for Third Level Institutions Cycle 4 and the Italian National Research Council'. The project was also partly supported by FIRB MERIT project no. RBNE08NKH7 and 'PROGETTO CAMPUS' from Campania Region to MR.	Artus C, 2010, EMBO J, V29, P1585, DOI 10.1038/emboj.2010.43; Cande C, 2004, ONCOGENE, V23, P1514, DOI 10.1038/sj.onc.1207279; Cao GD, 2003, J CEREBR BLOOD F MET, V23, P1137, DOI 10.1097/01.WCB.0000087090.01171.E7; Cao GD, 2007, J NEUROSCI, V27, P9278, DOI 10.1523/JNEUROSCI.2826-07.2007; Cheung ECC, 2006, EMBO J, V25, P4061, DOI 10.1038/sj.emboj.7601276; Culmsee C, 2005, J NEUROSCI, V25, P10262, DOI 10.1523/JNEUROSCI.2818-05.2005; Diemert S, 2012, J NEUROSCI METH, V203, P69, DOI 10.1016/j.jneumeth.2011.09.012; Dolga AM, 2012, GLIA, V60, P2050, DOI 10.1002/glia.22419; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; Fukui M, 2009, EUR J PHARMACOL, V617, P1, DOI 10.1016/j.ejphar.2009.06.059; Goldner FM, 1996, J COMP NEUROL, V372, P283; Grohm J, 2012, CELL DEATH DIFFER, V19, P1446, DOI 10.1038/cdd.2012.18; Grohm J, 2010, BRAIN BEHAV IMMUN, V24, P831, DOI 10.1016/j.bbi.2009.11.015; Guo XW, 2012, J BIOPHOTONICS, V5, P483, DOI 10.1002/jbio.201200015; Gurbuxani S, 2003, ONCOGENE, V22, P6669, DOI 10.1038/sj.onc.1206794; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; Hangen E, 2010, TRENDS BIOCHEM SCI, V35, P278, DOI 10.1016/j.tibs.2009.12.008; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; KE HM, 1992, J MOL BIOL, V228, P539, DOI 10.1016/0022-2836(92)90841-7; Montague JW, 1997, J BIOL CHEM, V272, P6677, DOI 10.1074/jbc.272.10.6677; Myszka DG, 2004, ANAL BIOCHEM, V329, P316, DOI 10.1016/j.ab.2004.03.028; Pallast S, 2010, J CEREBR BLOOD F MET, V30, P1157, DOI 10.1038/jcbfm.2009.281; Petit PX, 1996, FEBS LETT, V396, P7, DOI 10.1016/0014-5793(96)00988-X; Piao CS, 2012, NEUROBIOL DIS, V46, P745, DOI 10.1016/j.nbd.2012.03.018; Pinton P, 2008, ONCOGENE, V27, P6407, DOI 10.1038/onc.2008.308; Plesnila N, 2004, J CEREBR BLOOD F MET, V24, P458, DOI 10.1097/00004647-200404000-00011; Polster BM, 2013, NEUROCHEM INT, V62, P695, DOI 10.1016/j.neuint.2012.12.002; Sevrioukova IF, 2011, ANTIOXID REDOX SIGN, V14, P2545, DOI 10.1089/ars.2010.3445; Slemmer JE, 2008, AM J PATHOL, V173, P1795, DOI 10.2353/ajpath.2008.080168; SMILEY ST, 1991, P NATL ACAD SCI USA, V88, P3671, DOI 10.1073/pnas.88.9.3671; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Thal SE, 2011, NEUROSCI LETT, V499, P1, DOI 10.1016/j.neulet.2011.05.016; Tobaben S, 2011, CELL DEATH DIFFER, V18, P282, DOI 10.1038/cdd.2010.92; Tremper-Wells B, 2005, J BIOL CHEM, V280, P2165, DOI 10.1074/jbc.M410591200; Utkina-Sosunova IV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062448; Vahsen N, 2004, EMBO J, V23, P4679, DOI 10.1038/sj.emboj.7600461; Wang P, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-7-226; xler EM, 2012, APOPTOSIS, V17, P1027; Xu JM, 2013, MICROSC RES TECHNIQ, V76, P612, DOI 10.1002/jemt.22207; Yu SW, 2009, ASN NEURO, V1, DOI 10.1042/AN20090046; Zhang XC, 2013, FEBS LETT, V587, P666, DOI 10.1016/j.febslet.2013.01.028; Zhu CL, 2007, J EXP MED, V204, P1741, DOI 10.1084/jem.20070193	42	35	36	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2041-4889			CELL DEATH DIS	Cell Death Dis.	JAN	2014	5								e993	10.1038/cddis.2013.518			13	Cell Biology	Cell Biology	AC0YZ	WOS:000332222700017	24434516	DOAJ Gold, Green Published			2021-06-18	
J	Gould, KR; Ponsford, JL; Spitz, G				Gould, Kate Rachel; Ponsford, Jennie Louise; Spitz, Gershon			Association between cognitive impairments and anxiety disorders following traumatic brain injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Craniocerebral trauma; Mental processes; Executive function; Attention; Mental disorders	POSTTRAUMATIC-STRESS-DISORDER; TIME PRESSURE MANAGEMENT; PSYCHIATRIC-DISORDERS; BEHAVIOR THERAPY; PROCESSING SPEED; PREDICTORS; DEPRESSION; SYMPTOMS; STRATEGY; REHABILITATION	This study examined the association between cognitive impairment and anxiety disorders following traumatic brain injury (TBI). Sixty-six participants recruited from a rehabilitation hospital completed the Structured Clinical Interview for the DSM-IV (Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition) and cognitive tests at one year post injury. Prevalence of anxiety disorder was 27.3%. Logistic regression analyses revealed that the attention/working memory, information processing, and executive functions models were significantly associated with anxiety disorder. The memory model was not significant. Processing speed emerged as the strongest model associated with anxiety disorder. The role of cognitive impairment in the etiology of anxiety disorders after TBI is discussed, and treatment implications are explored.	[Gould, Kate Rachel; Ponsford, Jennie Louise; Spitz, Gershon] Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Richmond, Vic, Australia; [Gould, Kate Rachel; Ponsford, Jennie Louise; Spitz, Gershon] Monash Univ, Sch Psychol & Psychiat, Clayton, Vic, Australia; [Gould, Kate Rachel; Ponsford, Jennie Louise] Alfred Hosp, Natl Trauma Res Inst, Ctr Excellence Traumat Brain Injury Res, Melbourne, Vic, Australia	Gould, KR (corresponding author), Monash Epworth Rehabil Res Ctr, 185-187 Hoddle St, Richmond, Vic 3121, Australia.	kate.gould@monash.edu	Spitz, Gershon/H-7755-2014; Gould, Kate/AAA-5511-2020	Spitz, Gershon/0000-0002-7810-1480; Gould, Kate/0000-0002-3564-7408	Transport Accident Commission; Centre of Excellence in Traumatic Brain Injury Research Rehabilitation Fellowship	This research was supported by the Transport Accident Commission. Kate Gould was the 2012 to 2013 recipient of the Centre of Excellence in Traumatic Brain Injury Research Rehabilitation Fellowship.	American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Anson K, 2006, BRAIN INJURY, V20, P1, DOI 10.1080/02699050500309791; Arciniegas David B., 2002, Curr Treat Options Neurol, V4, P43, DOI 10.1007/s11940-002-0004-6; Baddeley AD, 1994, DOORS PEOPLE TEST VI; Beck AT, 1997, BEHAV RES THER, V35, P49, DOI 10.1016/S0005-7967(96)00069-1; Benton A., 1994, MULTILINGUAL APHASIA; Berthier ML, 2001, NEUROPSY NEUROPSY BE, V14, P23; Boals A, 2012, COGNITION EMOTION, V26, P1335, DOI 10.1080/02699931.2011.651100; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; Burgess PW, 1996, NEUROPSYCHOLOGIA, V34, P263, DOI 10.1016/0028-3932(95)00104-2; Burnham K.P., 2002, MODEL SELECTION INFE, V2nd ed.; Campbell TA, 2009, PSYCHIAT ANN, V39, P796, DOI 10.3928/00485713-20090728-01; Cicerone KD, 2002, BRAIN INJURY, V16, P185, DOI 10.1080/02699050110103959; Coughlan AK., 2007, BIRT MEMORY INFORM P; DePrince AP, 2004, PSYCHOL SCI, V15, P488, DOI 10.1111/j.0956-7976.2004.00706.x; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Ehlers A, 2000, BEHAV RES THER, V38, P319, DOI 10.1016/S0005-7967(99)00123-0; Engels AS, 2007, PSYCHOPHYSIOLOGY, V44, P352, DOI 10.1111/j.1469-8986.2007.00518.x; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Fasotti L, 2000, NEUROPSYCHOL REHABIL, V10, P47, DOI 10.1080/096020100389291; First MB., 2002, STRUCTURED CLIN INTE; Fleminger S, 2005, BRIT MED J, V331, P1419, DOI 10.1136/bmj.331.7530.1419; Ghinassi C. W., 2010, ANXIETY; Gould KR, 2011, PSYCHOL MED, V41, P2099, DOI 10.1017/S003329171100033X; Gould KR, 2011, J HEAD TRAUMA REHAB, V26, P79, DOI 10.1097/HTR.0b013e3182036799; Gray J A, 1996, Nebr Symp Motiv, V43, P61; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hiott DW, 2002, NEUROREHABILITATION, V17, P345; Hsieh MY, 2012, NEUROPSYCHOL REHABIL, V22, P585, DOI 10.1080/09602011.2012.678860; Hsieh MY, 2012, DISABIL REHABIL, V34, P408, DOI 10.3109/09638288.2011.607219; Iverson GL, 1999, CLIN NEUROPSYCHOL, V13, P437, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT437; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; Kennedy MRT, 2008, NEUROPSYCHOL REHABIL, V18, P257, DOI 10.1080/09602010701748644; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; Koenen KC, 2009, AM J PSYCHIAT, V166, P50, DOI 10.1176/appi.ajp.2008.08030343; Lange RT, 2005, J CLIN EXP NEUROPSYC, V27, P897, DOI 10.1080/1380339049091290; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; LINN RT, 1994, BRAIN INJURY, V8, P135, DOI 10.3109/02699059409150965; Massana G, 2003, NEUROIMAGE, V19, P80, DOI 10.1016/S1053-8119(03)00036-3; McNally RJ, 1998, COGNITION EMOTION, V12, P479, DOI 10.1080/026999398379682; Monk CS, 2008, ARCH GEN PSYCHIAT, V65, P568, DOI 10.1001/archpsyc.65.5.568; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; Nelson LA, 2009, J HEAD TRAUMA REHAB, V24, P32, DOI 10.1097/HTR.0b013e3181957016; O'Donnell ML, 2004, AM J PSYCHIAT, V161, P507, DOI 10.1176/appi.ajp.161.3.507; Ponsford J, 2004, SCI PRACT NEUROPSYCH, P59; PONSFORD J, 1991, NEUROPSYCHOL REHABIL, V1, P241, DOI DOI 10.1080/09602019108402257; Qin LD, 2012, BRAIN RES, V1484, P50, DOI 10.1016/j.brainres.2012.09.029; Reitan RM., 1985, HALSTEAD REITAN NEUR; Schonberger M, 2011, J INT NEUROPSYCH SOC, V17, P781, DOI 10.1017/S1355617711000701; Shallice, 1997, HAYLING BRIXTON TEST; Shin LM, 2005, ARCH GEN PSYCHIAT, V62, P273, DOI 10.1001/archpsyc.62.3.273; Smith A., 1973, SYMBOL DIGIT MODALIT; Spitz G, 2013, J HEAD TRAUMA REHAB, V28, P116, DOI 10.1097/HTR.0b013e3182452f4f; SPITZER RL, 1983, COMPR PSYCHIAT, V24, P399, DOI 10.1016/0010-440X(83)90032-9; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; The Australian Psychological Society, 2010, EV BAS PSYCH INT TRE; Twamley EW, 2009, J INT NEUROPSYCH SOC, V15, P879, DOI 10.1017/S135561770999049X; Vallat-Azouvi C, 2009, BRAIN INJURY, V23, P585, DOI 10.1080/02699050902970711; VANZOMEREN AH, 1984, CLOSED HEAD INJURY P; Victorian Neurotrauma Initiative, 2009, EC COST SPIN CORD IN; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Whelan-Goodinson R, 2010, J HEAD TRAUMA REHAB, V25, P320, DOI 10.1097/HTR.0b013e3181c8f8e7; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; Whelan-Goodinson R, 2008, J REHABIL MED, V40, P850, DOI 10.2340/16501977-0271; Williams WH, 2002, J TRAUMA STRESS, V15, P397, DOI 10.1023/A:1020185325026; Willmott C, 2009, NEUROPSYCHOLOGY, V23, P424, DOI 10.1037/a0015058; Winkens I, 2009, CLIN REHABIL, V23, P79, DOI 10.1177/0269215508097855; Wood RLL, 2006, J INT NEUROPSYCH SOC, V12, P350, DOI 10.1017/S1355617706060498	70	35	36	0	15	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2014	36	1					1	14		10.1080/13803395.2013.863832			14	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	AI4KT	WOS:000336834800001	24303952				2021-06-18	
J	Hunt, EJF; Wessely, S; Jones, N; Rona, RJ; Greenberg, N				Hunt, Elizabeth J. F.; Wessely, Simon; Jones, Norman; Rona, Roberto J.; Greenberg, Neil			The mental health of the UK Armed Forces: where facts meet fiction	EUROPEAN JOURNAL OF PSYCHOTRAUMATOLOGY			English	Article						Military; combat; service personnel; veterans; reservists; post-traumatic stress disorder; delayed-onset PTSD; mild traumatic brain injury; Trauma Risk Management	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; MILITARY PERSONNEL; PSYCHOLOGICAL SYMPTOMS; US SOLDIERS; LIFE EVENTS; ALCOHOL-USE; IRAQ; DEPLOYMENT; PTSD	A substantial amount of research has been conducted into the mental health of the UK military in recent years. This article summarises the results of the various studies and offers possible explanations for differences in findings between the UK and other allied nations. Post-traumatic stress disorder (PTSD) rates are perhaps surprisingly low amongst British forces, with prevalence rates of around 4% in personnel who have deployed, rising to 6% in combat troops, despite the high tempo of operations in recent years. The rates in personnel currently on operations are consistently lower than these. Explanations for the lower PTSD prevalence in British troops include variations in combat exposures, demographic differences, higher leader to enlisted soldier ratios, shorter operational tour lengths and differences in access to long-term health care between countries. Delayed-onset PTSD was recently found to be more common than previously supposed, accounting for nearly half of all PTSD cases; however, many of these had sub-syndromal PTSD predating the onset of the full disorder. Rates of common mental health disorders in UK troops are similar or higher to those of the general population, and overall operational deployments are not associated with an increase in mental health problems in UK regular forces. However, there does appear to be a correlation between both deployment and increased alcohol misuse and post-deployment violence in combat troops. Unlike for regular forces, there is an overall association between deployment and mental health problems in Reservists. There have been growing concerns regarding mild traumatic brain injury, though this appears to be low in British troops with an overall prevalence of 4.4% in comparison with 15% in the US military. The current strategies for detection and treatment of mental health problems in British forces are also described. The stance of the UK military is that psychological welfare of troops is primarily a chain of command responsibility, aided by medical advice when necessary, and to this end uses third location decompression, stress briefings, and Trauma Risk Management approaches. Outpatient treatment is provided by Field Mental Health Teams and military Departments of Community Mental Health, whilst inpatient care is given in specific NHS hospitals.	[Hunt, Elizabeth J. F.; Jones, Norman; Greenberg, Neil] Kings Coll London, ACDMH, Western Educ Ctr, London SE5 9RJ, England; [Wessely, Simon; Rona, Roberto J.] Kings Coll London, KCMHR, Western Educ Ctr, London SE5 9RJ, England	Hunt, EJF (corresponding author), Kings Coll London, ACDMH, Western Educ Ctr, London SE5 9RJ, England.	lizzie.hunt@gmail.com	Wessely, Simon C/A-8713-2008	Wessely, Simon Charles/0000-0002-6743-9929; greenberg, neil/0000-0003-4550-2971			American Psychiatric Association, 1980, DSM 3 DIAGN STAT MAN; Andrews B, 2007, AM J PSYCHIAT, V164, P1319, DOI 10.1176/appi.ajp.2007.06091491; Batzer WB, 2007, MIL MED, V172, P266; Brailey K, 2007, J TRAUMA STRESS, V20, P495, DOI 10.1002/jts.20234; Brewin CR, 2012, PSYCHOL MED, V42, P2119, DOI 10.1017/S0033291712000189; Browne T, 2007, BRIT J PSYCHIAT, V190, P484, DOI 10.1192/bjp.bp.106.030544; Browne T, 2012, J TRAUMA STRESS, V25, P207, DOI 10.1002/jts.21678; Casper ST, 2008, MED HIST, V52, P327, DOI 10.1017/S0025727300002660; Cooke DJ, 2005, BRIT J PSYCHIAT, V186, P335, DOI 10.1192/bjp.186.4.335; Dandeker C, 2010, ARMED FORCES SOC, V36, P264, DOI 10.1177/0095327X09344068; Fear NT, 2008, AM J PREV MED, V35, P230, DOI 10.1016/j.amepre.2008.05.027; Fear NT, 2007, ADDICTION, V102, P1749, DOI 10.1111/j.1360-0443.2007.01978.x; Fear NT, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-797; Fear NT, 2010, LANCET, V375, P1783, DOI 10.1016/S0140-6736(10)60672-1; Fear NT, 2009, INT J OCCUP ENV HEAL, V15, P291; Freeman T, 2008, PSYCHIAT RES, V158, P374, DOI 10.1016/j.psychres.2007.04.002; Frueh BC, 2007, AM J PUBLIC HEALTH, V97, P2143, DOI 10.2105/AJPH.2007.115436; Frueh BC, 2000, CLIN PSYCHOL REV, V20, P853, DOI 10.1016/S0272-7358(99)00015-X; Goldberg DP, 1998, PSYCHOL MED, V28, P915, DOI 10.1017/S0033291798006874; Goodwin L., ARE COMMON IN PRESS; Goodwin L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078693; Goodwin L, 2012, J NERV MENT DIS, V200, P429, DOI 10.1097/NMD.0b013e31825322fe; Gould M, 2010, J ROY SOC MED, V103, P148, DOI 10.1258/jrsm.2010.090426; Gould M, 2008, PSYCHIATR BULL, V32, P99, DOI 10.1192/pb.bp.107.016337; Gray GC, 2006, PHILOS T R SOC B, V361, P553, DOI 10.1098/rstb.2006.1816; Greenberg N, 2008, Emerg Health Threats J, V1, pe10, DOI 10.3134/ehtj.08.010; Greenberg N, 2008, J R Army Med Corps, V154, P124; Greenberg N, 2008, J ROY SOC MED, V101, P78, DOI 10.1258/jrsm.2007.070024; Greenberg N, 2010, J TRAUMA STRESS, V23, P430, DOI 10.1002/jts.20538; Harvey SB, 2011, ANN EPIDEMIOL, V21, P666, DOI 10.1016/j.annepidem.2011.05.004; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Hooper R, 2008, ADDICT BEHAV, V33, P1067, DOI 10.1016/j.addbeh.2008.03.010; Hosek J, 2011, DEPLOYMENT IRAQ AFGH; Hotopf M, 2006, LANCET, V367, P1731, DOI 10.1016/S0140-6736(06)68662-5; Iversen A. C, 2009, ADV PSYCHIAT TREATME, V15, P100, DOI DOI 10.1192/APT.BP.107.004713; Iversen AC, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-31; Jacobson IG, 2008, JAMA-J AM MED ASSOC, V300, P663, DOI 10.1001/jama.300.6.663; Jones E, 2008, PSYCHOL MED, V38, P1419, DOI 10.1017/S003329170800278X; Jones E, 2004, SOC HIST MED, V17, P463, DOI 10.1093/shm/17.3.463; Jones E, 2002, BMJ-BRIT MED J, V324, P321, DOI 10.1136/bmj.324.7333.321; Jones E, 2007, BMJ-BRIT MED J, V335, P1313, DOI 10.1136/bmj.39420.533461.25; Jones E, 2007, AM J PSYCHIAT, V164, P1641, DOI 10.1176/appi.ajp.2007.07071180; Jones M, 2006, OCCUP MED-OXFORD, V56, P322, DOI 10.1093/occmed/kql023; Jones N, 2003, OCCUP MED-OXFORD, V53, P469, DOI 10.1093/occmed/kqg093; Jones N, 2011, OCCUP MED-OXFORD, V61, P102, DOI 10.1093/occmed/kqq182; Jones N, 2011, J MENT HEALTH, V20, P136, DOI 10.3109/09638237.2010.541299; Jones N., OPERATIONAL IN PRESS; Jones N, 2012, PSYCHIATRY, V75, P49, DOI 10.1521/psyc.2012.75.1.49; Karasek R, 1998, J Occup Health Psychol, V3, P322, DOI 10.1037/1076-8998.3.4.322; Kessler RC, 2008, ANNU REV PUBL HEALTH, V29, P115, DOI 10.1146/annurev.publhealth.29.020907.090847; Killgore WDS, 2006, J PSYCHOSOM RES, V60, P379, DOI 10.1016/j.jpsychores.2006.02.012; Kok BC, 2012, J NERV MENT DIS, V200, P444, DOI 10.1097/NMD.0b013e3182532312; LeardMann CA, 2009, BMJ-BRIT MED J, V338, P1; LEE KA, 1995, AM J PSYCHIAT, V152, P516; Litz BT, 1997, AM J PSYCHIAT, V154, P178; MacManus D, 2012, PSYCHOL MED, V42, P1663, DOI 10.1017/S0033291711002327; Marx BP, 2012, J TRAUMA STRESS, V25, P457, DOI 10.1002/jts.21714; MCGEORGE T, 2006, OCCUPATIONAL HLTH RE, V122, P21; McManus S., 2009, ADULT PSYCHIAT MORBI; Mental Health in the Australian Defence Force, 2010, ADF MENT HLTH PREV W; Messenger K, 2012, J OCCUP ENVIRON MED, V54, P859, DOI 10.1097/JOM.0b013e31824e676b; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; Morley Fletcher W., 1919, DIGITIZED INTERNET A, V1, P461; Mulligan K, 2012, J CONSULT CLIN PSYCH, V80, P331, DOI 10.1037/a0027664; Mulligan K, 2010, BRIT J PSYCHIAT, V197, P405, DOI 10.1192/bjp.bp.110.077263; Murrison A., 2010, FIGHTING FIT MENTAL; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Pinder RJ, 2012, INT J SOC PSYCHIATR, V58, P433, DOI 10.1177/0020764011408534; Pook A, 2008, J R Army Med Corps, V154, P120; Rona R. J., 2007, BRIT MED J, V191, P506; Rona RJ, 2004, J MED SCREEN, V11, P148, DOI 10.1258/0969141041732193; Rona RJ, 2007, INT J EPIDEMIOL, V36, P319, DOI 10.1093/ije/dyl273; Rona RJ, 2012, J PSYCHIATR RES, V46, P1191, DOI 10.1016/j.jpsychires.2012.05.009; Rona RJ, 2012, J HEAD TRAUMA REHAB, V27, P33, DOI 10.1097/HTR.0b013e318212f814; Rona RJ, 2012, J HEAD TRAUMA REHAB, V27, P75, DOI 10.1097/HTR.0b013e31823029f6; Rona RJ, 2009, J TRAUMA STRESS, V22, P11, DOI 10.1002/jts.20383; Rona RJ, 2009, J PSYCHIATR RES, V43, P649, DOI 10.1016/j.jpsychires.2008.09.006; Ryan MAK, 2007, J CLIN EPIDEMIOL, V60, P181, DOI 10.1016/j.jclinepi.2006.05.009; Sareen J, 2007, ARCH GEN PSYCHIAT, V64, P843, DOI 10.1001/archpsyc.64.7.843; Schnurr PP, 2004, J TRAUMA STRESS, V17, P85, DOI 10.1023/B:JOTS.0000022614.21794.f4; Schulte-Herbruggen O, 2012, DTSCH ARZTEBL INT, V109, P557, DOI 10.3238/arztebl.2012.0557; Smith TC, 2008, BMJ-BRIT MED J, V336, P366, DOI 10.1136/bmj.39430.638241.AE; Solomon Z, 2006, AM J PSYCHIAT, V163, P659, DOI 10.1176/appi.ajp.163.4.659; SOLOMON Z, 1989, SOC PSYCH PSYCH EPID, V24, P41, DOI 10.1007/BF01788199; Sundin J, 2010, PSYCHOL MED, V40, P367, DOI 10.1017/S0033291709990791; Sundin J, 2014, BRIT J PSYCHIAT, V204, P202, DOI 10.1192/bjp.bp.113.129569; Sundin J, 2010, INT ARCH OCC ENV HEA, V83, P653, DOI 10.1007/s00420-009-0504-8; Unwin C, 1999, LANCET, V353, P169, DOI 10.1016/S0140-6736(98)11338-7; Wilson J, 2009, AM J EPIDEMIOL, V169, P1362, DOI 10.1093/aje/kwp044; Wittchen HU, 2012, DTSCH ARZTEBL INT, V109, P559, DOI 10.3238/arztebl.2012.0559; Woodhead C, 2011, PSYCHOL MED, V41, P363, DOI 10.1017/S0033291710000759; Woodhead C., 2011, SOCIAL PSYCHIAT PSYC, V46, P559	93	35	35	1	23	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	2000-8198	2000-8066		EUR J PSYCHOTRAUMATO	Eur. J. Psychotraumatol.		2014	5								23617	10.3402/ejpt.v5.23617			15	Psychology, Clinical; Psychiatry	Psychology; Psychiatry	AO2GX	WOS:000341137400001	25206948	DOAJ Gold, Green Published			2021-06-18	
J	Kurtz, P; Claassen, J; Helbok, R; Schmidt, JM; Fernandez, L; Presciutti, M; Stuart, RM; Connolly, ES; Lee, K; Badjatia, N; Mayer, SA				Kurtz, Pedro; Claassen, Jan; Helbok, Raimund; Schmidt, J. Michael; Fernandez, Luis; Presciutti, Mary; Stuart, R. Morgan; Connolly, E. Sander; Lee, Kiwon; Badjatia, Neeraj; Mayer, Stephan A.			Systemic glucose variability predicts cerebral metabolic distress and mortality after subarachnoid hemorrhage: a retrospective observational study	CRITICAL CARE			English	Article							TRAUMATIC BRAIN-INJURY; CRITICALLY-ILL PATIENTS; INTENSIVE INSULIN THERAPY; POSITRON-EMISSION-TOMOGRAPHY; HYPOGLYCEMIC NEURONAL DEATH; GLYCEMIC VARIABILITY; ESTIMATING EQUATIONS; LACTATE/PYRUVATE RATIO; TEMPERATURE MODULATION; CRITICAL ILLNESS	Introduction: Cerebral glucose metabolism and energy production are affected by serum glucose levels. Systemic glucose variability has been shown to be associated with poor outcome in critically ill patients. The objective of this study was to assess whether glucose variability is associated with cerebral metabolic distress and outcome after subarachnoid hemorrhage. Methods: A total of 28 consecutive comatose patients with subarachnoid hemorrhage, who underwent cerebral microdialysis and intracranial pressure monitoring, were studied. Metabolic distress was defined as lactate/pyruvate ratio (LPR) >40. The relationship between daily glucose variability, the development of cerebral metabolic distress and hospital outcome was analyzed using a multivariable general linear model with a logistic link function for dichotomized outcomes. Results: Daily serum glucose variability was expressed as the standard deviation (SD) of all serum glucose measurements. General linear models were used to relate this predictor variable to cerebral metabolic distress and mortality at hospital discharge. A total of 3,139 neuromonitoring hours and 181 days were analyzed. After adjustment for Glasgow Coma Scale (GCS) scores and brain glucose, SD was independently associated with higher risk of cerebral metabolic distress (adjusted odds ratio = 1.5 (1.1 to 2.1), P = 0.02). Increased variability was also independently associated with in hospital mortality after adjusting for age, Hunt Hess, daily GCS and symptomatic vasospasm (P = 0.03). Conclusions: Increased systemic glucose variability is associated with cerebral metabolic distress and increased hospital mortality. Therapeutic approaches that reduce glucose variability may impact on brain metabolism and outcome after subarachnoid hemorrhage.	[Kurtz, Pedro; Claassen, Jan; Helbok, Raimund; Schmidt, J. Michael; Fernandez, Luis; Presciutti, Mary; Stuart, R. Morgan; Connolly, E. Sander; Lee, Kiwon; Badjatia, Neeraj; Mayer, Stephan A.] Milstein Hosp 8 Ctr, Neurol Intens Care Unit, New York, NY 10032 USA	Claassen, J (corresponding author), Milstein Hosp 8 Ctr, Neurol Intens Care Unit, 177 Ft Washington Ave, New York, NY 10032 USA.	jc1439@mail.cumc.columbia.edu	Helbok, Raimund/AAA-8361-2021; Claassen, Jan/AAA-5451-2020	Schmidt, J. Michael/0000-0001-8141-2944	Department of Neurology/Neurosurgery, Columbia University Medical Center	We thank the attending physicians, fellows and nurses of the Division of Neurocritical Care, Department of Neurology/Neurosurgery, Columbia University Medical Center for their overall support of this project.	Ali NA, 2008, CRIT CARE MED, V36, P2316, DOI 10.1097/CCM.0b013e3181810378; Badjatia N, 2005, CRIT CARE MED, V33, P1603, DOI 10.1097/01.CCM.0000168054.60538.2B; Badjatia N, 2009, CRIT CARE MED, V37, P1893, DOI 10.1097/CCM.0b013e31819fffd3; Badjatia N, 2008, STROKE, V39, P3242, DOI 10.1161/STROKEAHA.108.523654; Bagshaw SM, 2009, CRIT CARE, V13, DOI 10.1186/cc7921; Barletta JF, 2013, J CRIT CARE, V28, P798, DOI 10.1016/j.jcrc.2012.12.012; Bederson JB, 2009, STROKE, V40, P994, DOI 10.1161/STROKEAHA.108.191395; Belli A, 2008, ACTA NEUROCHIR, V150, P461, DOI 10.1007/s00701-008-1580-3; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Brownlee M, 2005, DIABETES, V54, P1615, DOI 10.2337/diabetes.54.6.1615; Brunkhorst FM, 2008, NEW ENGL J MED, V358, P125, DOI 10.1056/NEJMoa070716; Brunner R, 2012, CRIT CARE, V16, DOI 10.1186/cc11657; Dossett LA, 2008, AM SURGEON, V74, P679; Egi M, 2006, ANESTHESIOLOGY, V105, P244, DOI 10.1097/00000542-200608000-00006; Finfer S, 2009, NEW ENGL J MED, V360, P1283, DOI 10.1056/NEJMoa0810625; Frontera JA, 2006, STROKE, V37, P199, DOI 10.1161/01.STR.0000194960.73883.0f; Helbok R, 2010, NEUROCRIT CARE, V12, P317, DOI 10.1007/s12028-009-9327-4; Hermanides J, 2010, CRIT CARE MED, V38, P838, DOI 10.1097/CCM.0b013e3181cc4be9; Hlatky R, 2004, J NEUROTRAUM, V21, P894, DOI 10.1089/0897715041526195; Kramer AH, 2012, CRIT CARE, V16, DOI 10.1186/cc11812; Krinsley JS, 2008, CRIT CARE MED, V36, P3008, DOI 10.1097/CCM.0b013e31818b38d2; Krinsley JS, 2013, CRIT CARE, V17, DOI 10.1186/cc12584; Krinsley JS, 2010, CRIT CARE MED, V38, P1206, DOI 10.1097/CCM.0b013e3181d3aba5; Krinsley James Stephen, 2009, J Diabetes Sci Technol, V3, P1292; Kruyt ND, 2009, STROKE, V40, pE424, DOI 10.1161/STROKEAHA.108.529974; Mackenzie IMJ, 2011, INTENS CARE MED, V37, P435, DOI 10.1007/s00134-010-2103-2; Marcoux J, 2008, CRIT CARE MED, V36, P2871, DOI 10.1097/CCM.0b013e318186a4a0; Monnier L, 2006, JAMA-J AM MED ASSOC, V295, P1681, DOI 10.1001/jama.295.14.1681; Nagel A, 2009, J NEUROSURG, V111, P94, DOI 10.3171/2009.1.JNS08587; Oddo M, 2008, CRIT CARE MED, V36, P3233, DOI 10.1097/CCM.0b013e31818f4026; Pan W, 2001, BIOMETRICS, V57, P529, DOI 10.1111/j.0006-341X.2001.00529.x; Pan W, 2001, BIOMETRICS, V57, P120, DOI 10.1111/j.0006-341X.2001.00120.x; Preiser JC, 2009, INTENS CARE MED, V35, P1738, DOI 10.1007/s00134-009-1585-2; PRENTICE RL, 1991, BIOMETRICS, V47, P825, DOI 10.2307/2532642; Ryan EA, 2004, DIABETES, V53, P955, DOI 10.2337/diabetes.53.4.955; Sarrafzadeh A, 2004, J NEUROSURG, V100, P400, DOI 10.3171/jns.2004.100.3.0400; Sarrafzadeh AS, 2004, STROKE, V35, P638, DOI 10.1161/01.STR.0000116101.66624.F1; Sarrafzadeh AS, 2010, J CEREBR BLOOD F MET, V30, P36, DOI 10.1038/jcbfm.2009.199; Schlenk F, 2008, INTENS CARE MED, V34, P1200, DOI 10.1007/s00134-008-1044-5; Schlenk F, 2008, CRIT CARE, V12, DOI 10.1186/cc6776; Wiener RS, 2008, JAMA-J AM MED ASSOC, V300, P933, DOI 10.1001/jama.300.8.933; Suh SW, 2007, GLIA, V55, P1280, DOI 10.1002/glia.20440; Suh SW, 2007, J CLIN INVEST, V117, P910, DOI 10.1172/JCI30077; Van den Berghe G, 2005, NEUROLOGY, V64, P1348, DOI 10.1212/01.WNL.0000158442.08857.FC; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Vespa PM, 2007, CRIT CARE MED, V35, P1153, DOI 10.1097/01.CCM.0000259466.66310.4F; Vespa PM, 2006, CURR OPIN CRIT CARE, V12, P119, DOI 10.1097/01.ccx.0000216577.57180.bd; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; Wartenberg KE, 2006, CRIT CARE MED, V34, P617, DOI 10.1097/01.CCM.0000201903.46435.35; Zazulia AR, 2009, STROKE, V40, P1638, DOI 10.1161/STROKEAHA.108.536037	53	35	39	0	3	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2014	18	3							R89	10.1186/cc13857			8	Critical Care Medicine	General & Internal Medicine	AO2OI	WOS:000341163800003	24887049	DOAJ Gold, Green Published			2021-06-18	
J	Wang, JW; Wang, HD; Cong, ZX; Zhou, XM; Xu, JG; Jia, Y; Ding, Y				Wang, Jia-Wei; Wang, Han-Dong; Cong, Zi-Xiang; Zhou, Xiao-Ming; Xu, Jian-Guo; Jia, Yue; Ding, Yu			Puerarin ameliorates oxidative stress in a rodent model of traumatic brain injury	JOURNAL OF SURGICAL RESEARCH			English	Article						Traumatic brain injury; Puerarin; Oxidative stress; Akt	SPINAL-CORD-INJURY; PC12 CELLS; SIGNALING PATHWAY; SUBARACHNOID HEMORRHAGE; ANTIOXIDANT THERAPIES; INDUCED NEUROTOXICITY; ISOFLAVONE PUERARIN; CEREBRAL-ISCHEMIA; HYDROGEN-PEROXIDE; ESTROGEN-RECEPTOR	Background: A wealth of evidence has suggested that oxidative stress is involved in the secondary brain injury after traumatic brain injury (TBI). Recently, numerous in vivo and in vitro studies were reported that puerarin could inhibit oxidative stress through the activation of phosphatidylinositol 3-kinase (PI3K)-Akt pathway. It is unknown, however, whether puerarin can provide neuroprotection and reduce oxidative stress after TBI. The present study investigated the effects of puerarin on the TBI-induced neurodegeneration, oxidative stress, and the possible role of PI3K-Akt pathway in the neuroprotection of puerarin, in a rat model of TBI. Materials and methods: Rats were randomly distributed into various subgroups undergoing the sham surgery or TBI procedures. Puerarin (200 mg/kg) was given intraperitoneally at 10 min before injury and PI3K-Akt pathway inhibitor LY294002 was also administered intra-cerebroventricular in one subgroup. All rats were killed at 24 h after TBI for examination. Results: Our data indicated that puerarin could significantly reduce TBI-induced neuronal degeneration, accompanied by the partial restoration of the redox disturbance and enhanced expression of phospho-Akt in the pericontusional cortex after TBI. Moreover, PI3K-Akt pathway inhibitor LY294002 could partially abrogate the neuroprotection of puerarin in rats with TBI. Conclusions: These results indicate that puerarin can ameliorate oxidative neurodegeneration after TBI, at least in part, through the activation of PI3K-Akt pathway. (C) 2014 Elsevier Inc. All rights reserved.	[Wang, Jia-Wei; Wang, Han-Dong; Cong, Zi-Xiang; Xu, Jian-Guo; Jia, Yue; Ding, Yu] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210008, Jiangsu, Peoples R China; [Zhou, Xiao-Ming] Second Mil Med Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing, Jiangsu, Peoples R China	Wang, HD (corresponding author), Jinling Hosp, Dept Neurosurg, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.	njhdwang@hotmail.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81070974]; Key Subject of Jiangsu Province [X4200722]	We would like to thank Miss Zhe Zhang for her expert technical assistance. This work was supported by grants from National Natural Science Foundation of China (no. 81070974) and the Key Subject of Jiangsu Province (X4200722).	Adibhatla RM, 2010, ANTIOXID REDOX SIGN, V12, P125, DOI [10.1089/ars.2009.2668, 10.1089/ARS.2009.2668]; [Anonymous], 2008, J NEUROTRAUM, V25, P513; Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; Benedict AL, 2012, J NEUROTRAUM, V29, P2576, DOI 10.1089/neu.2012.2474; Bo J, 2005, NEUROSCI RES, V53, P183, DOI 10.1016/j.neures.2005.06.014; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Chang Y, 2009, J BIOMED SCI, V16, DOI 10.1186/1423-0127-16-9; Chen G, 2009, EXP NEUROL, V216, P398, DOI 10.1016/j.expneurol.2008.12.019; Cherdshewasart W, 2008, PHYTOMEDICINE, V15, P38, DOI 10.1016/j.phymed.2007.07.058; Chong ZZ, 2005, PROG NEUROBIOL, V75, P207, DOI 10.1016/j.pneurobio.2005.02.004; Darakchiev BJ, 1997, ACT NEUR S, V70, P98; De Wilde A, 2006, J CELL PHYSIOL, V209, P786, DOI 10.1002/jcp.20767; Endo H, 2006, STROKE, V37, P2140, DOI 10.1161/01.STR.0000229888.55078.72; Erecinska M, 2004, PROG NEUROBIOL, V73, P397, DOI 10.1016/j.pneurobio.2004.06.003; Ersahin M, 2009, J PINEAL RES, V46, P324, DOI 10.1111/j.1600-079X.2009.00664.x; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Fernandez-Gomez FJ, 2006, NEUROBIOL DIS, V24, P296, DOI 10.1016/j.nbd.2006.07.005; Gao L, 2009, NEUROL RES, V31, P402, DOI 10.1179/174313209X444017; Graeber MB, 2010, SCIENCE, V330, P783, DOI 10.1126/science.1190929; Guerra MC, 2000, LIFE SCI, V67, P2997, DOI 10.1016/S0024-3205(00)00885-7; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Hatic H, 2012, J NEUROTRAUM, V29, P1188, DOI 10.1089/neu.2011.1806; Hwang YP, 2008, TOXICOL APPL PHARM, V233, P371, DOI 10.1016/j.taap.2008.09.006; Jiang B, 2003, CELL BIOL INT, V27, P1025, DOI 10.1016/j.cellbi.2003.09.007; Jin W, 2009, J NEUROTRAUM, V26, P131, DOI 10.1089/neu.2008.0655; JOLLOW DJ, 1974, PHARMACOLOGY, V11, P151, DOI 10.1159/000136485; Kang KW, 2002, MOL PHARMACOL, V62, P1001, DOI 10.1124/mol.62.5.1001; Kim H, 2005, NEUROL RES, V27, P287, DOI 10.1179/016164105X25234; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; Kurella E, 1997, ANN NY ACAD SCI, V834, P661, DOI 10.1111/j.1749-6632.1997.tb52344.x; Li JM, 2010, EUR J PHARMACOL, V649, P195, DOI 10.1016/j.ejphar.2010.09.045; Liu CM, 2012, TOXICOL APPL PHARM, V258, P330, DOI 10.1016/j.taap.2011.11.015; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; LOVELL MA, 1995, NEUROLOGY, V45, P1594, DOI 10.1212/WNL.45.8.1594; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Maiese K, 2012, INT J MOL SCI, V13, P13830, DOI 10.3390/ijms131113830; MIKSICEK RJ, 1995, P SOC EXP BIOL MED, V208, P44; Mustafa AG, 2011, J NEUROCHEM, V117, P579, DOI 10.1111/j.1471-4159.2011.07228.x; Mustafa AG, 2010, J NEUROCHEM, V114, P271, DOI 10.1111/j.1471-4159.2010.06749.x; Nakaso K, 2003, FEBS LETT, V546, P181, DOI 10.1016/S0014-5793(03)00517-9; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; Noshita N, 2001, J CEREBR BLOOD F MET, V21, P1442, DOI 10.1097/00004647-200112000-00009; Noshita N, 2002, NEUROBIOL DIS, V9, P294, DOI 10.1006/nbdi.2002.0482; Penetar DM, 2012, DRUG ALCOHOL DEPEN, V126, P251, DOI 10.1016/j.drugalcdep.2012.04.012; Robillard JM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020676; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Schmued LC, 2005, BRAIN RES, V1035, P24, DOI 10.1016/j.brainres.2004.11.054; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; Streck EL, 2001, NEUROCHEM RES, V26, P1195, DOI 10.1023/A:1013907104585; Vitale DC, 2013, EUR J DRUG METAB PH, V38, P15, DOI 10.1007/s13318-012-0112-y; Wang CX, 2006, NEUROL RES, V28, P436, DOI 10.1179/016164106X115044; Wang Jia-Wei, 2012, Zhongguo Zhong Xi Yi Jie He Za Zhi, V32, P164; Wang Q, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004196.pub2; Wong KH, 2011, J ETHNOPHARMACOL, V134, P584, DOI 10.1016/j.jep.2011.02.001; Xing GH, 2011, BRAIN RES BULL, V85, P212, DOI 10.1016/j.brainresbull.2011.03.024; Xiong FL, 2006, EUR J PHARMACOL, V529, P1, DOI 10.1016/j.ejphar.2005.10.024; Xu XH, 2005, PLANTA MED, V71, P585, DOI 10.1055/s-2005-871261; Xu XH, 2007, J ETHNOPHARMACOL, V113, P421, DOI 10.1016/j.jep.2007.06.012; Yune TY, 2008, J NEUROTRAUM, V25, P1121, DOI 10.1089/neu.2008.0544; Zhang HY, 2008, CELL BIOL INT, V32, P1230, DOI 10.1016/j.cellbi.2008.07.006; Zhang Q, 2012, CELL BIOL INT, V36, P419, DOI 10.1042/CBI20100900; Zhang Y, 2007, PLANTA MED, V73, P341, DOI 10.1055/s-2007-967168; Zhu GQ, 2012, NEUROCHEM INT, V60, P400, DOI 10.1016/j.neuint.2012.01.003; Zou Y, 2013, FREE RADICAL RES, V47, P55, DOI 10.3109/10715762.2012.742518	65	35	40	0	13	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804	1095-8673		J SURG RES	J. Surg. Res.	JAN	2014	186	1					328	337		10.1016/j.jss.2013.08.027			10	Surgery	Surgery	274TJ	WOS:000328628800057	24079811				2021-06-18	
J	Spitz, G; Maller, JJ; Ng, A; O'Sullivan, R; Ferris, NJ; Ponsford, JL				Spitz, Gershon; Maller, Jerome J.; Ng, Amanda; O'Sullivan, Richard; Ferris, Nicholas J.; Ponsford, Jennie L.			Detecting Lesions after Traumatic Brain Injury Using Susceptibility Weighted Imaging: A Comparison with Fluid-Attenuated Inversion Recovery and Correlation with Clinical Outcome	JOURNAL OF NEUROTRAUMA			English	Article						cognition; magnetic resonance imaging; susceptibility-weighted imaging; traumatic brain injury	DIFFUSE AXONAL INJURY; CLOSED-HEAD INJURY; WHITE-MATTER; MRI; CT; CHILDREN; STEM	The development and utilization of newer neuroimaging modalities provides the capability to more accurately detect the extent of pathology after TBI. The current study examined the ability of susceptibility-weighted imaging (SWI) to detect lesions after TBI as well as the relationship to subsequent clinical outcome. The performance of SWI was compared to that of fluid-attenuated inversion recovery (FLAIR). This study comprised 79 individuals with mild-to-severe TBI, 38 of whom completed neuropsychological tests of attention, working memory, processing speed, memory, and executive functions. SWI was found to quantify a greater lesion volume over the entire brain, specifically in frontal, central, limbic, subcortical gray, and parietal brain regions, than did FLAIR. Moreover, SWI was able to identify TBI-related lesions in almost one third of patients for whom FLAIR was unable to detect any lesions. Greater overall SWI volume, as well as frontal SWI volume, was found to relate to the severity of TBI. Conversely, no association was found between FLAIR lesion volume and injury severity. In addition, there was some evidence that higher lesion volume, for both SWI and FLAIR, were associated with poorer memory as well as processing speed impairment. This study suggests that SWI may provide additional sensitivity in the detection of lesions after TBI. Consequently, this imaging sequence may provide a more accurate representation of the severity of individuals' injuries and their subsequent neuropsychological outcomes.	[Spitz, Gershon; Ponsford, Jennie L.] Monash Univ, Sch Psychol & Psychiat, Melbourne, Vic 3004, Australia; [Spitz, Gershon; Ponsford, Jennie L.] Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia; [Maller, Jerome J.] Monash Univ, Cent Clin Sch, Melbourne, Vic 3004, Australia; [Maller, Jerome J.] Alfred Hosp, Monash Alfred Psychiat Res Ctr, Melbourne, Vic, Australia; [Ng, Amanda; Ferris, Nicholas J.] Monash Univ, Melbourne, Vic 3004, Australia; Monash Univ, Monash E Res Ctr, Melbourne, Vic 3004, Australia; [Ng, Amanda] Victorian Life Sci Computat Initiat, Life Sci Computat Ctr, Melbourne, Vic, Australia; [O'Sullivan, Richard] Epworth Med Fdn, Healthcare Imaging Serv, Melbourne, Vic, Australia	Spitz, G (corresponding author), Monash Univ, Sch Psychol & Psychiat, Bldg 17,Clayton Campus,Wellington Rd, Clayton, Vic 3800, Australia.	Gershon.Spitz@monash.edu	Maller, Jerome J/H-4963-2014; Spitz, Gershon/H-7755-2014	Maller, Jerome J/0000-0003-4685-1508; Spitz, Gershon/0000-0002-7810-1480			[Anonymous], 2008, AN SOFTW VERS 9 0 AN; Ashburner J, 2005, NEUROIMAGE, V26, P839, DOI 10.1016/j.neuroimage.2005.02.018; Babikian T, 2005, PEDIATR NEUROL, V33, P184, DOI 10.1016/j.pediatrneurol.2005.03.015; Baddeley A, 1994, DOORS PEOPLE; Beauchamp MH, 2013, CORTEX, V49, P591, DOI 10.1016/j.cortex.2012.08.015; Beauchamp MH, 2011, J NEUROTRAUM, V28, P915, DOI 10.1089/neu.2010.1712; Benton A., 1994, MULTILINGUAL APHASIA; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Bigler ED, 2010, BRAIN IMAGING BEHAV, V4, P270, DOI 10.1007/s11682-010-9105-0; Brett M, 2001, NEUROIMAGE, V14, P486, DOI 10.1006/nimg.2001.0845; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Chan RCK, 2000, BRAIN INJURY, V14, P227, DOI 10.1080/026990500120709; Chastain CA, 2009, J NEUROTRAUM, V26, P1183, DOI 10.1089/neu.2008.0650; Christensen BK, 2008, ARCH PHYS MED REHAB, V89, pS3, DOI 10.1016/j.apmr.2008.10.002; Chu BC, 2007, J CLIN EXP NEUROPSYC, V29, P617, DOI 10.1080/13803390600878893; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Coughhlan AK, 2007, BIRT MEMORY INFORM P; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Ding K, 2008, J NEUROTRAUM, V25, P1433, DOI 10.1089/neu.2008.0683; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Firsching R, 1998, J NEUROSURG, V89, P707, DOI 10.3171/jns.1998.89.5.0707; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; Geurts BHJ, 2012, BRAIN INJURY, V26, P1439, DOI 10.3109/02699052.2012.694563; Giovagnoli AR, 1996, ITAL J NEUROL SCI, V17, P305, DOI 10.1007/BF01997792; Haacke EM, 2009, AM J NEURORADIOL, V30, P19, DOI 10.3174/ajnr.A1400; Haacke EM, 2004, MAGN RESON MED, V52, P612, DOI 10.1002/mrm.20198; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; Kennedy MRT, 2009, J INT NEUROPSYCH SOC, V15, P130, DOI 10.1017/S1355617708090024; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kinsella G, 1996, BRAIN INJURY, V10, P499, DOI 10.1080/026990596124214; Matsukawa H, 2011, ACTA NEUROCHIR, V153, P1687, DOI 10.1007/s00701-011-1002-9; Mittal S, 2009, AM J NEURORADIOL, V30, P232, DOI 10.3174/ajnr.A1461; Mori S., 2005, MRI ATLAS HUMAN WHIT; OEHLER MC, 1995, AM J NEURORADIOL, V16, P1135; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; ORRISON WW, 1994, AM J NEURORADIOL, V15, P351; Paterakis K, 2000, J TRAUMA, V49, P1071, DOI 10.1097/00005373-200012000-00016; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Reitan R., 1988, HALSTEAD REITAN NEUR; Rorden C, 2007, J COGNITIVE NEUROSCI, V19, P1081, DOI 10.1162/jocn.2007.19.7.1081; Rorden C, 2012, NEUROIMAGE, V61, P957, DOI 10.1016/j.neuroimage.2012.03.020; Sehgal V, 2005, J MAGN RESON IMAGING, V22, P439, DOI 10.1002/jmri.20404; Shallice, 1997, HAYLING BRIXTON TEST; Sigmund GA, 2007, PEDIATR NEUROL, V36, P217, DOI 10.1016/j.pediatrneurol.2007.01.003; Skandsen T, 2010, J NEUROSURG, V113, P556, DOI 10.3171/2009.9.JNS09626; Sloan S., 2004, BRAIN IMPAIR, V5, P12, DOI DOI 10.1375/BRIM.5.1.12.35399; Smith A., 1973, SYMBOL DIGIT MODALIT; Spitz G, 2012, NEUROPSYCHOLOGY, V26, P604, DOI 10.1037/a0029239; Tong K., 2011, SUSCEPTIBILITY WEIGH; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th ed; Wu Z, 2010, AM J NEURORADIOL, V31, P1302, DOI 10.3174/ajnr.A2022; Yao B, 2009, NEUROIMAGE, V44, P1259, DOI 10.1016/j.neuroimage.2008.10.029	60	35	37	0	18	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC 15	2013	30	24					2038	2050		10.1089/neu.2013.3021			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	271QK	WOS:000328406500005	23952803				2021-06-18	
J	Swick, D; Honzel, N; Larsen, J; Ashley, V				Swick, Diane; Honzel, Nikki; Larsen, Jary; Ashley, Victoria			Increased response variability as a marker of executive dysfunction in veterans with post-traumatic stress disorder	NEUROPSYCHOLOGIA			English	Article						PTSD; TBI; Go/NoGo; Cognitive control; Inhibitory control; Impulsivity	REACTION-TIME VARIABILITY; TRAUMATIC BRAIN-INJURY; DEFAULT MODE; INDIVIDUAL-DIFFERENCES; RISK-FACTORS; ADHD; MIND; PERFORMANCE; ATTENTION; DISTRIBUTIONS	The stability of cognitive control processes over time can be indexed by trial-to-trial variability in reaction time (RT). Greater RT variability has been interpreted as an indicator of executive dysfunction, inhibitory inefficiency, and excessive mental noise. Previous studies have demonstrated that combat veterans with post-traumatic stress disorder (PTSD) show substantial impairments in inhibitory control, but no studies have examined response variability in this population. In the current experiment, RT variability in the Go/NoGo response inhibition task was assessed for 45 veterans with PTSD and 34 control veterans using the intra-individual coefficient of variation (ICV) and ex-Gaussian analysis of RT distributions. Despite having mean RTs that were indistinguishable from controls, the PTSD patients had significantly greater RT variability as measured by ICV. More variable RTs were in turn associated with a greater number of false alarm errors in the patients, suggesting that less consistent performers were less successful at inhibiting inappropriate responses. RT variability was also highly correlated with self-reported symptoms of PTSD, depression, and attentional impulsiveness. Furthermore, response variability predicted diagnosis even when controlling for PTSD symptom severity. In turn, PTSD severity was correlated with self-rated attentional impulsiveness. Deficits in the top-down cognitive control processes that cause greater response variability might contribute to the maintenance of PTSD symptomology. Thus, the distractibility issues that cause more variable reaction times might also result in greater distress related to the trauma. Published by Elsevier Ltd.	[Swick, Diane; Honzel, Nikki; Larsen, Jary; Ashley, Victoria] Vet Affairs Northern Calif Hlth Care Syst, Res Serv 151, Martinez, CA 94553 USA; [Swick, Diane] Univ Calif Davis, Dept Neurol, Davis, CA 95616 USA	Swick, D (corresponding author), Vet Affairs Northern Calif Hlth Care Syst, Res Serv 151, 150 Muir Rd, Martinez, CA 94553 USA.	swicklab@gmail.com			U.S. Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [W81XWH-08-2-0086]; Clinical Science Research and Development; National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1 TR000002]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000002] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01CX000566] Funding Source: NIH RePORTER	We are grateful to Dr. Andrew Kayser for patient referrals and to all participants for taking part in the study. We thank Dr. Machelle Wilson (University of California, Davis) and Timothy Heron (VA Northern California Health Care System) for statistical advice. We also thank Dr. Catherine Fassbender for her suggestions on data analysis, and the reviewers for their comments on earlier versions of the manuscript. This work was supported by the U.S. Army Medical Research and Materiel Command under W81XWH-08-2-0086 and a VA Merit Review grant from Clinical Science Research and Development. Dr. Wilson is supported by the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), through grant #UL1 TR000002. The contents reported within do not represent the views of the Department of Veterans Affairs or the United States Government. The authors declare that they have no conflicts of interest.	Ashley V, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-86; Aupperle RL, 2012, NEUROPHARMACOLOGY, V62, P686, DOI 10.1016/j.neuropharm.2011.02.008; BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5; Bellgrove MA, 2004, NEUROPSYCHOLOGIA, V42, P1910, DOI 10.1016/j.neuropsychologia.2004.05.007; Carlson KF, 2011, J HEAD TRAUMA REHAB, V26, P103, DOI 10.1097/HTR.0b013e3181e50ef1; Chuah YML, 2006, J NEUROSCI, V26, P7156, DOI 10.1523/JNEUROSCI.0906-06.2006; Danielmeier C, 2011, FRONT PSYCHOL, V2, DOI 10.3389/fpsyg.2011.00233; Daniels JK, 2010, J PSYCHIATR NEUROSCI, V35, P258, DOI 10.1503/jpn.090010; Dockree PM, 2006, EXP BRAIN RES, V168, P218, DOI 10.1007/s00221-005-0079-x; Epstein JN, 2011, NEUROPSYCHOLOGY, V25, P427, DOI 10.1037/a0022155; Fjell AM, 2011, J NEUROSCI, V31, P18060, DOI 10.1523/JNEUROSCI.4735-11.2011; Forbes D, 2001, BEHAV RES THER, V39, P977, DOI 10.1016/S0005-7967(00)00084-X; Fox MD, 2005, P NATL ACAD SCI USA, V102, P9673, DOI 10.1073/pnas.0504136102; Gusnard DA, 2001, P NATL ACAD SCI USA, V98, P4259, DOI 10.1073/pnas.071043098; HEATHCOTE A, 1991, PSYCHOL BULL, V109, P340, DOI 10.1037/0033-2909.109.2.340; Heathcote A, 2004, BEHAV RES METH INS C, V36, P277, DOI 10.3758/BF03195574; Hervey AS, 2006, CHILD NEUROPSYCHOL, V12, P125, DOI 10.1080/09297040500499081; Hester R, 2005, NEUROIMAGE, V27, P602, DOI 10.1016/j.neuroimage.2005.04.035; Hester R., 2013, DRUG ALCOHOL DEPENDE; Honzel N., COGNITIVE A IN PRESS; Iversen AC, 2008, PSYCHOL MED, V38, P511, DOI 10.1017/S0033291708002778; Johnson KA, 2007, NEUROPSYCHOLOGIA, V45, P630, DOI 10.1016/j.neuropsychologia.2006.03.034; Kaiser S, 2008, BRAIN COGNITION, V66, P73, DOI 10.1016/j.bandc.2007.05.007; Kane MJ, 2012, CURR DIR PSYCHOL SCI, V21, P348, DOI 10.1177/0963721412454875; Larson GE, 2009, MIL MED, V174, P737, DOI 10.7205/MILMED-D-02-0308; Lee R. W., 2012, J ATTENTION DISORDER; Lew HL, 2010, NEUROREHABILITATION, V26, P271, DOI 10.3233/NRE-2010-0562; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; Matzke D, 2009, PSYCHON B REV, V16, P798, DOI 10.3758/PBR.16.5.798; MCNALLY RJ, 1990, J ABNORM PSYCHOL, V99, P398, DOI 10.1037/0021-843X.99.4.398; McVay JC, 2012, J EXP PSYCHOL LEARN, V38, P525, DOI 10.1037/a0025896; McVay JC, 2009, PSYCHON B REV, V16, P857, DOI 10.3758/PBR.16.5.857; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Ode S, 2011, COGNITION EMOTION, V25, P307, DOI 10.1080/02699931.2010.494387; Patton JH, 1995, J CLIN PSYCHOL, V51, P768, DOI 10.1002/1097-4679(199511)51:6<768::AID-JCLP2270510607>3.0.CO;2-1; Pittman JOE, 2012, QUAL LIFE RES, V21, P99, DOI 10.1007/s11136-011-9918-3; Polak AR, 2012, J AFFECT DISORDERS, V141, P11, DOI 10.1016/j.jad.2012.01.001; RABBITT PMA, 1966, J EXP PSYCHOL, V71, P264, DOI 10.1037/h0022853; Schmiedek F, 2007, J EXP PSYCHOL GEN, V136, P414, DOI 10.1037/0096-3445.136.3.414; Segalowitz S J, 1997, J Int Neuropsychol Soc, V3, P95; Simmonds DJ, 2007, NEUROPSYCHOLOGIA, V45, P2147, DOI 10.1016/j.neuropsychologia.2007.01.013; Simmons J. P., 2012, DIALOGUE OFFICIAL NE, P1, DOI [10.2139/ssrn.2160588, DOI 10.2139/SSRN.2160588]; Smallwood J, 2007, COGNITION EMOTION, V21, P816, DOI 10.1080/02699930600911531; Smallwood J, 2009, EMOTION, V9, P271, DOI 10.1037/a0014855; Sonuga-Barke EJS, 2007, NEUROSCI BIOBEHAV R, V31, P977, DOI 10.1016/j.neubiorev.2007.02.005; Sripada RK, 2012, PSYCHOSOM MED, V74, P904, DOI 10.1097/PSY.0b013e318273bf33; Stanford MS, 2009, PERS INDIV DIFFER, V47, P385, DOI 10.1016/j.paid.2009.04.008; Stuss DT, 2003, BRAIN, V126, P2363, DOI 10.1093/brain/awg237; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Stuss DT, 1994, NEUROPSYCHOLOGY, V8, P316, DOI DOI 10.1037/0894-4105.8.3.316; Suskauer SJ, 2008, J AM ACAD CHILD PSY, V47, P1141, DOI 10.1097/CHI.0b013e3181825b1f; Swick D, 2012, J INT NEUROPSYCH SOC, V18, P1, DOI DOI 10.1017/S13556177120000458; Tamm L, 2012, NEUROTHERAPEUTICS, V9, P500, DOI 10.1007/s13311-012-0138-5; Tarantino V, 2013, J INT NEUROPSYCH SOC, V19, P820, DOI 10.1017/S1355617713000623; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; vandenBosch RJ, 1996, SCHIZOPHRENIA BULL, V22, P643, DOI 10.1093/schbul/22.4.643; Vasterling JJ, 2009, J INT NEUROPSYCH SOC, V15, P826, DOI 10.1017/S1355617709990683; Vasterling JJ, 1998, NEUROPSYCHOLOGY, V12, P125, DOI 10.1037/0894-4105.12.1.125; Vinogradov S, 1998, SCHIZOPHR RES, V32, P183, DOI 10.1016/S0920-9964(98)00043-7; VRANA SR, 1995, J ANXIETY DISORD, V9, P515, DOI 10.1016/0887-6185(95)00028-M; Weathers F.W., 1994, PTSD CHECKLIST MILIT; West R, 2002, BRAIN COGNITION, V49, P402, DOI 10.1006/brcg.2001.1507; Whelan R, 2008, PSYCHOL REC, V58, P475, DOI 10.1007/BF03395630	63	35	35	0	22	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia	DEC	2013	51	14					3033	3040		10.1016/j.neuropsychologia.2013.10.008			8	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	295AH	WOS:000330088500009	24157540	Green Accepted			2021-06-18	
J	Liu, S; Zhang, LX; Wu, QF; Wu, Q; Wang, T				Liu, Su; Zhang, Lixia; Wu, Qinfeng; Wu, Qi; Wang, Tong			Chemokine CCL2 Induces Apoptosis in Cortex Following Traumatic Brain Injury	JOURNAL OF MOLECULAR NEUROSCIENCE			English	Article						CCL2; Traumatic brain injury; Apoptosis; Chemokine	MONOCYTE CHEMOATTRACTANT PROTEIN-1; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MULTIPLE-SCLEROSIS; TISSUE LOSS; EXPRESSION; MCP-1; RAT; CCR2; ASTROCYTES; CYTOKINE	The chemokine C-C motif ligand 2 (CCL2) is an important mediator of neuroinflammation. Released in response to acute injury, ischemia, and neurodegenerative disease, CCL2 binds primarily to the G-protein-coupled chemokine C-C motif receptor 2 (CCR2) to recruit inflammatory cells to sites of tissue damage. Inflammation is thought to have both beneficial and deleterious consequences following traumatic brain injury (TBI), so we investigated CCL2-CCR2 signaling during the post-TBI period to assess possible neurodegenerative and protective actions. Local TBI in adult rat cortex was induced by Feeney's weight-drop method, and the expression of CCL2 and CCR2 in the tissue around the contusion site was measured by real-time quantitative PCR. Both CCL2 and CCR2 mRNA levels were increased markedly for at least 10 days after injury, peaking on day 3. The CCL2 protein was mainly co-localized with the astroglial marker glial fibrillary acidic protein and CCR2 protein with the neuronal nuclear marker NeuN as revealed by double immunofluorescence staining. A selective CCR2 antagonist, RS504393, reduced TUNEL staining, a marker of apoptosis, and improved performance in the Morris water maze 3 days post-TBI, suggesting that CCL2-CCR2 signaling has deleterious effects on neuronal survival and learning. Targeting the CCL2-CCR2 pathway may provide a novel therapeutic approach for the treatment of TBI.	[Liu, Su] Nanjing Med Univ, Nanjing 210029, Jiangsu, Peoples R China; [Zhang, Lixia; Wang, Tong] Nanjing Med Univ, Affiliated Hosp 1, Dept Rehabil Med, Nanjing 210029, Jiangsu, Peoples R China	Wang, T (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Dept Rehabil Med, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.	wangtong60621@163.com					Bales JW, 2009, NEUROSCI BIOBEHAV R, V33, P981, DOI 10.1016/j.neubiorev.2009.03.011; Banisadr G, 2005, J COMP NEUROL, V492, P178, DOI 10.1002/cne.20729; Berman JW, 1996, J IMMUNOL, V156, P3017; Blaha GR, 2000, NEUROSCIENCE, V99, P483, DOI 10.1016/S0306-4522(00)00214-1; Che XM, 2001, BRAIN RES, V902, P171, DOI 10.1016/S0006-8993(01)02328-9; Clausen F, 2011, EUR J NEUROSCI, V34, P110, DOI 10.1111/j.1460-9568.2011.07723.x; Dalgard CL, 2012, FRONT MOL NEUROSCI, V5, DOI 10.3389/fnmol.2012.00006; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Galasso JM, 2000, EXP NEUROL, V165, P295, DOI 10.1006/exnr.2000.7466; Galindo LT, 2011, NEUROL RES INT, V2011, DOI 10.1155/2011/564089; Ge SJ, 2009, J MOL NEUROSCI, V39, P269, DOI 10.1007/s12031-009-9197-4; Glabinski AR, 1996, J IMMUNOL, V156, P4363; Lian H, 2012, MOL NEURODEGENER, V7, DOI 10.1186/1750-1326-7-47; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Mahad DJ, 2003, SEMIN IMMUNOL, V15, P23, DOI 10.1016/S1044-5323(02)00125-2; McNair ND, 1999, NURS CLIN N AM, V34, P637; Muessel MJ, 2002, MOL BRAIN RES, V103, P12, DOI 10.1016/S0169-328X(02)00158-4; Rhodes JKJ, 2009, J NEUROTRAUM, V26, P507, DOI 10.1089/neu.2008.0686; Sauerbeck A, 2011, EXP NEUROL, V227, P128, DOI 10.1016/j.expneurol.2010.10.003; Semple BD, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-67; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Shojo H, 2010, NEUROSCIENCE, V171, P1273, DOI 10.1016/j.neuroscience.2010.10.018; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; SOZZANI S, 1994, J IMMUNOL, V152, P3615; Tang XQ, 2013, J MOL NEUROSCI, V49, P140, DOI 10.1007/s12031-012-9912-4; Thau-Zuchman O, 2012, J MOL NEUROSCI, V47, P166, DOI 10.1007/s12031-012-9706-8; Umehara F, 1996, ACTA NEUROPATHOL, V91, P343, DOI 10.1007/s004010050435; Van der Voorn P, 1999, AM J PATHOL, V154, P45, DOI 10.1016/S0002-9440(10)65249-2; Wain JH, 2002, CLIN EXP IMMUNOL, V127, P436, DOI 10.1046/j.1365-2249.2002.01764.x; Wang GH, 2011, J NEUROTRAUM, V28, P2123, DOI 10.1089/neu.2011.1939; Weber JT, 2004, CURR NEUROVASC RES, V1, P151, DOI 10.2174/1567202043480134; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Xiong Y, 2010, DISCOV MED, V10, P434; Zhang ZJ, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-136	36	35	39	0	15	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0895-8696	1559-1166		J MOL NEUROSCI	J. Mol. Neurosci.	NOV	2013	51	3					1021	1029		10.1007/s12031-013-0091-8			9	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	235IH	WOS:000325710500044	23934512				2021-06-18	
J	Ley, EJ; Short, SS; Liou, DZ; Singer, MB; Mirocha, J; Melo, N; Bukur, M; Salim, A				Ley, Eric J.; Short, Scott S.; Liou, Douglas Z.; Singer, Matthew B.; Mirocha, James; Melo, Nicolas; Bukur, Marko; Salim, Ali			Gender impacts mortality after traumatic brain injury in teenagers	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Pediatric; traumatic brain injury; gender; puberty	DATA-BANK; IMPROVED OUTCOMES; CLINICAL-TRIALS; PROGESTERONE; INSURANCE; CHILDREN; WOMEN; AGE	BACKGROUND: Gender may influence outcomes following traumatic brain injury (TBI) although the mechanism is unknown. Animal TBI studies suggest that gender differences in endogenous hormone production may be the source. Limited retrospective clinical studies on gender present varied conclusions. Pediatric patients represent a unique population as pubescent children experience up-regulation of endogenous hormones that varies dramatically by gender. Younger children do not have these hormonal differences. The aim of this study was to compare pubescent and prepubescent females with males after isolated TBI to identify independent predictors of mortality. METHODS: We performed a retrospective review of the National Trauma Data Bank Research Data Sets from 2007 and 2008 looking at all blunt trauma patients 18 years or younger who required hospital admission after isolated, moderate-to-severe TBI, defined as head Abbreviated Injury Scale (AIS) score 3 or greater. We excluded all individuals with AIS score of 3 or greater for any other region to limit the confounding effect of comorbidities. Based on the median age of menarche, we defined two age groups as follows: prepubescent (0-12 years) and pubescent (912 years). Analysis was performed to compare trauma profiles and outcomes between groups. Our primary outcome measure was in-hospital mortality. RESULTS: A total of 20,280 patients met inclusion criteria; 10,135 were prepubescent, and 10,145 were pubescent. Overall mortality was 6.9%, and lower mortality was noted among prepubescent patients compared with pubescent (5.2% vs. 8.6%, p < 0.0001). Although female gender did not predict reduced mortality in the prepubescent cohort (adjusted odds ratio, 1.05; 95% confidence interval, 0.85-1.30; p = 0.63), female gender was associated with reduced mortality in the pubescent (adjusted odds ratio, 0.78; 95% confidence interval, 0.65-0.93; p = 0.007). CONCLUSION: In contrast to prepubescent female gender, pubescent female gender predicts reduced mortality following isolated, moderate-to-severe TBI. Endogenous hormonal differences may be a contributing factor and require further investigation. Copyright (C) 2013 by Lippincott Williams & Wilkins	[Ley, Eric J.; Short, Scott S.; Liou, Douglas Z.; Singer, Matthew B.; Melo, Nicolas; Bukur, Marko; Salim, Ali] Cedars Sinai Med Ctr, Div Trauma & Crit Care, Los Angeles, CA 90048 USA; [Mirocha, James] Cedars Sinai Med Ctr, Dept Surg, Los Angeles, CA 90048 USA; [Mirocha, James] Cedars Sinai Med Ctr, Dept Biostat, Los Angeles, CA 90048 USA	Ley, EJ (corresponding author), Cedars Sinai Med Ctr, Dept Surg, 8700 Beverly Blvd,Suite 8215 NT, Los Angeles, CA 90048 USA.	eric.ley@cshs.org		Bukur, Marko/0000-0002-1850-7147			Anderson GD, 2011, J NEUROTRAUM, V28, P1827, DOI 10.1089/neu.2011.1911; Anderson SE, 2005, J PEDIATR-US, V147, P753, DOI 10.1016/j.jpeds.2005.07.016; Berry C, 2011, AM J SURG, V201, P429, DOI 10.1016/j.amjsurg.2010.10.008; Berry C, 2009, J TRAUMA, V67, P950, DOI 10.1097/TA.0b013e3181ba3354; Donders J, 2002, NEUROPSYCHOLOGY, V16, P491, DOI 10.1037//0894-4105.16.4.491; Haider AH, 2012, J AM COLL SURGEONS, V214, P756, DOI 10.1016/j.jamcollsurg.2011.12.013; Junpeng M., 2011, COCHRANE DB SYST REV, V1; Kelley BG, 2011, MOL CELL NEUROSCI, V48, P137, DOI 10.1016/j.mcn.2011.07.002; Kochanek Kenneth D, 2011, Natl Vital Stat Rep, V60, P1; Morrison Wynne E, 2004, Pediatr Crit Care Med, V5, P145, DOI 10.1097/01.PCC.0000112373.71645.2A; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Phillips B, 2008, J TRAUMA, V64, P768, DOI 10.1097/TA.0b013e3181620152; Ringdal KG, 2013, INJURY, V44, P29, DOI 10.1016/j.injury.2011.12.024; Rosen H, 2009, J PEDIATR SURG, V44, P1952, DOI 10.1016/j.jpedsurg.2008.12.026; Roudsari B, 2008, INJURY PREV, V14, P96, DOI 10.1136/ip.2007.017129; Singer MB, 2013, J TRAUMA ACUTE CARE, V74, P312, DOI 10.1097/TA.0b013e31826fc899; Singh M, 2013, NEUROSCIENCE, V239, P84, DOI 10.1016/j.neuroscience.2012.09.056; Stanley RM, 2012, PEDIATRICS, V129, pE24, DOI 10.1542/peds.2011-2074; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; Yeung JHH, 2011, ARCH SURG-CHICAGO, V146, P436, DOI 10.1001/archsurg.2011.46	21	35	38	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	OCT	2013	75	4					682	686		10.1097/TA.0b013e31829d024f			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	300IK	WOS:000330457400020	24064883				2021-06-18	
J	Schreuder, M; Riccio, A; Risetti, M; Dahne, S; Ramsay, A; Williamson, J; Mattia, D; Tangermann, M				Schreuder, Martijn; Riccio, Angela; Risetti, Monica; Daehne, Sven; Ramsay, Andrew; Williamson, John; Mattia, Donatella; Tangermann, Michael			User-centered design in brain-computer interfaces-A case study	ARTIFICIAL INTELLIGENCE IN MEDICINE			English	Article						Brain-computer interface; Event-related potentials; Auditory evoked potentials; Linear discriminant analysis; User-centered design; Assistive technology; Stroke; Traumatic brain injury; Locked-in syndrome	AMYOTROPHIC-LATERAL-SCLEROSIS; LONG-TERM SURVIVAL; LOCKED-IN SYNDROME; COGNITIVE IMPAIRMENT; SPATIAL HEARING; INJURY; ATTENTION; PATTERNS; PEOPLE; HEAD	Objective: The array of available brain-computer interface (BCI) paradigms has continued to grow, and so has the corresponding set of machine learning methods which are at the core of BCI systems. The latter have evolved to provide more robust data analysis solutions, and as a consequence the proportion of healthy BCI users who can use a BCI successfully is growing. With this development the chances have increased that the needs and abilities of specific patients, the end-users, can be covered by an existing BCI approach. However, most end-users who have experienced the use of a BCI system at all have encountered a single paradigm only. This paradigm is typically the one that is being tested in the study that the end-user happens to be enrolled in, along with other end-users. Though this corresponds to the preferred study arrangement for basic research, it does not ensure that the end-user experiences a working BCI. In this study, a different approach was taken; that of a user-centered design. It is the prevailing process in traditional assistive technology. Given an individual user with a particular clinical profile, several available BCI approaches are tested and - if necessary - adapted to him/her until a suitable BCI system is found. Methods: Described is the case of a 48-year-old woman who suffered from an ischemic brain stem stroke, leading to a severe motor- and communication deficit. She was enrolled in studies with two different BCI systems before a suitable system was found. The first was an auditory event-related potential (ERP) paradigm and the second a visual ERP paradigm, both of which are established in literature. Results: The auditory paradigm did not work successfully, despite favorable preconditions. The visual paradigm worked flawlessly, as found over several sessions. This discrepancy in performance can possibly be explained by the user's clinical deficit in several key neuropsychological indicators, such as attention and working memory. While the auditory paradigm relies on both categories, the visual paradigm could be used with lower cognitive workload. Besides attention and working memory, several other neurophysiological and -psychological indicators - and the role they play in the BCIs at hand - are discussed. Conclusion: The user's performance on the first BCI paradigm would typically have excluded her from further ERP-based BCI studies. However, this study clearly shows that, with the numerous paradigms now at our disposal, the pursuit for a functioning BCI system should not be stopped after an initial failed attempt. (C) 2013 The Authors. Published by Elsevier B.V. All rights reserved.	[Schreuder, Martijn; Daehne, Sven] Berlin Inst Technol, Machine Learning Lab, D-10587 Berlin, Germany; [Riccio, Angela; Risetti, Monica; Mattia, Donatella] Fdn Santa Lucia, Neuroelect Imaging & Brain Comp Interface Lab, I-00142 Rome, Italy; [Riccio, Angela] Univ Roma La Sapienza, Dept Psychol, I-00183 Rome, Italy; [Ramsay, Andrew; Williamson, John] Univ Glasgow, Sch Comp Sci, Glasgow G12 8QQ, Lanark, Scotland; [Tangermann, Michael] Univ Freiburg, BrainLinks BrainTools Excellence Cluster, D-79104 Freiburg, Germany	Schreuder, M (corresponding author), Berlin Inst Technol, Machine Learning Lab, Marchsstr 23, D-10587 Berlin, Germany.	schreuder@tu-berlin.de; a.riccio@hsantalucia.it	Riccio, Angela/K-2745-2016; Mattia, Donatella/D-7569-2012; Tangermann, Michael/ABE-4178-2020	Riccio, Angela/0000-0002-4098-9461; Mattia, Donatella/0000-0002-3092-2511; Schreuder, Evert-Jan Martijn/0000-0002-7239-9909	European ICT Programme Project [FP7-224631, BFNT 01GQ0850]; BrainLinks-BrainTools Cluster of Excellence; German Research Foundation (DFG)German Research Foundation (DFG) [EXC 1086]	This work is supported by the European ICT Programme Project FP7-224631, BFNT 01GQ0850, and the BrainLinks-BrainTools Cluster of Excellence funded by the German Research Foundation (DFG, grant number EXC 1086). This paper only reflects the authors' views and funding agencies are not liable for any use that may be made of the information contained herein.	BAUER G, 1979, J NEUROL, V221, P77, DOI 10.1007/BF00313105; Bianchi L, 2010, BRAIN TOPOGR, V23, P180, DOI 10.1007/s10548-010-0143-0; Blankertz B, 2011, NEUROIMAGE, V56, P814, DOI 10.1016/j.neuroimage.2010.06.048; Brainard DH, 1997, SPATIAL VISION, V10, P433, DOI 10.1163/156856897X00357; Brown AW, 2004, NEUROREHABILITATION, V19, P37; CAROSCIO JT, 1987, NEUROL CLIN, V5, P1; Corsi P. M., 1972, THESIS MCGILL U MONT; DENNIS MS, 1993, STROKE, V24, P796, DOI 10.1161/01.STR.24.6.796; FARWELL LA, 1988, ELECTROEN CLIN NEURO, V70, P510, DOI 10.1016/0013-4694(88)90149-6; Halder S, 2010, CLIN NEUROPHYSIOL, V121, P516, DOI 10.1016/j.clinph.2009.11.087; HART S G, 1988, P139; Heaton R., 1993, WISCONSIN CARD SORTI; Heaton R. K., 2000, WCST WISCONSIN CARD; Hill N.J., 2005, ADV NEURAL INFORM PR, P569; Kaufmann T, 2011, J NEURAL ENG, V8, DOI 10.1088/1741-2560/8/5/056016; Kubler A, 2009, ANN NY ACAD SCI, V1157, P90, DOI 10.1111/j.1749-6632.2008.04122.x; Laureys S, 2005, PROG BRAIN RES, V150, P495, DOI 10.1016/S0079-6123(05)50034-7; Ledoit O, 2004, J MULTIVARIATE ANAL, V88, P365, DOI 10.1016/S0047-259X(03)00096-4; Lemm S, 2011, NEUROIMAGE, V56, P387, DOI 10.1016/j.neuroimage.2010.11.004; Leon-Carrion J, 2002, BRAIN INJURY, V16, P555, DOI 10.1080/02699050110119466; Magni E, 1996, EUR J NEUROL, V3, P198, DOI 10.1111/j.1468-1331.1996.tb00423.x; Mun inger JI, 2010, FRONTIERS NEUROSCIEN, P4; Murguialday AR, 2011, CLIN NEUROPHYSIOL, V122, P925, DOI 10.1016/j.clinph.2010.08.019; Nijboer F, 2008, CLIN NEUROPHYSIOL, V119, P1909, DOI 10.1016/j.clinph.2008.03.034; Nijboer F, 2010, FRONT NEUROSCI-SWITZ, V4, DOI 10.3389/fnins.2010.00055; Orsini A., 2003, B PSICOL APPL, V239, P73; Pero S, 2006, BRAIN INJURY, V20, P1207, DOI 10.1080/02699050600983271; Phukan J, 2012, J NEUROL NEUROSUR PS, V83, P102, DOI 10.1136/jnnp-2011-300188; Riccio A, 2012, J NEURAL ENG, V9, DOI 10.1088/1741-2560/9/4/045001; Ringholz GM, 2005, NEUROLOGY, V65, P586, DOI 10.1212/01.wnl.0000172911.39167.b6; Sarro L, 2011, AM J NEURORADIOL, V32, P1866, DOI 10.3174/ajnr.A2658; Schreuder M, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00112; Schreuder M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009813; Sellers EW, 2006, CLIN NEUROPHYSIOL, V117, P538, DOI 10.1016/j.clinph.2005.06.027; Spinnler H., 1987, ITALIAN J NEUROLOGIC; Tangermann M, 2011, INT J BIOELECTROMAGN, V13, P119; Townsend G, 2010, CLIN NEUROPHYSIOL, V121, P1109, DOI 10.1016/j.clinph.2010.01.030; Treder MS, 2011, J NEURAL ENG, V8, DOI 10.1088/1741-2560/8/6/066003; Treder MS, 2010, BEHAV BRAIN FUNCT, V6, DOI 10.1186/1744-9081-6-28; Vianello A, 2011, J CRIT CARE, V26, DOI 10.1016/j.jcrc.2010.06.003; Wightman FL, 1999, J ACOUST SOC AM, V105, P2841, DOI 10.1121/1.426899; Zickler C, 2009, ASSIST TECHNOL RES S, V25, P185, DOI 10.3233/978.1.60750.042.1.185; Zimmermann P, 1995, TEST ATTENTIONAL PER; Zoccolotti P, 2000, CORTEX, V36, P93, DOI 10.1016/S0010-9452(08)70839-6	44	35	37	0	35	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0933-3657	1873-2860		ARTIF INTELL MED	Artif. Intell. Med.	OCT	2013	59	2			SI		71	80		10.1016/j.artmed.2013.07.005			10	Computer Science, Artificial Intelligence; Engineering, Biomedical; Medical Informatics	Computer Science; Engineering; Medical Informatics	256DT	WOS:000327290600003	24076341	Other Gold, Green Accepted			2021-06-18	
J	Hasbani, DM; Topjian, AA; Friess, SH; Kilbaugh, TJ; Berg, RA; Christian, CW; Dlugos, DJ; Huh, J; Abend, NS				Hasbani, Daphne M.; Topjian, Alexis A.; Friess, Stuart H.; Kilbaugh, Todd J.; Berg, Robert A.; Christian, Cindy W.; Dlugos, Dennis J.; Huh, Jimmy; Abend, Nicholas S.			Nonconvulsive Electrographic Seizures are Common in Children With Abusive Head Trauma	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						abusive head trauma; electroencephalographic monitoring; electroencephalography; seizure; traumatic brain injury	CONTINUOUS VIDEO-EEG; INTENSIVE-CARE-UNIT; BRAIN-INJURY; STATUS EPILEPTICUS; YOUNG-CHILDREN; COMATOSE CHILDREN; PREDICTORS	Objective: To determine the prevalence of nonconvulsive seizures in children with abusive head trauma. Design: Retrospective study of children with abusive head trauma undergoing clinically indicated continuous electroencephalographic monitoring. Setting: PICU of a tertiary care hospital. Subjects: Children less than or equal to 2 years old with evidence of abusive head trauma determined by neuroimaging, physical examination, and determination of abuse by the Child Protection Team. Interventions: None. Measurements and Main Results: Thirty-two children with abusive head trauma were identified with a median age of 4 months (interquartile range 3, 5.5 months). Twenty-one of 32 children (66%) underwent electroencephalographic monitoring. Those monitored were more likely to have a lower admission Glasgow Coma Scale (8 vs 15, p = 0.05) and be intubated (16 vs 2, p = 0.002). Electrographic seizures occurred in 12 of 21 children (57%) and constituted electrographic status epilepticus in 8 of 12 children (67%). Electrographic seizures were entirely nonconvulsive in 8 of 12 children (67%). Electroencephalographic background category (discontinuous and slow-disorganized) (p = 0.02) and neuroimaging evidence of ischemia were associated with the presence of electrographic seizures (p = 0.05). Subjects who had electrographic seizures were no more likely to have clinical seizures at admission (67% electrographic seizures vs 33% none, p = 0.6), parenchymal imaging abnormalities (61% electrographic seizures vs 39% none, p = 0.40), or extra-axial imaging abnormalities (56% electrographic seizures vs 44% none, p = 0.72). Four of 21 (19%) children died prior to discharge; none had electrographic seizures, but all had attenuated-featureless electroencephalographic backgrounds. Follow-up outcome data were available for 16 of 17 survivors at a median duration of 9.5 months following PICU admission, and the presence of electrographic seizures or electrographic status epilepticus was not associated with the Glasgow Outcome Scale score (p = 0.10). Conclusions: Electrographic seizures and electrographic status epilepticus are common in children with abusive head trauma. Most seizures have no clinical correlate. Further study is needed to determine whether seizure identification and management improves outcome.	[Hasbani, Daphne M.; Dlugos, Dennis J.; Abend, Nicholas S.] Univ Penn, Childrens Hosp Philadelphia, Dept Pediat & Neurol, Perelman Sch Med,Div Neurol, Philadelphia, PA 19104 USA; [Topjian, Alexis A.; Kilbaugh, Todd J.; Berg, Robert A.; Huh, Jimmy] Univ Penn, Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care Med, Perelman Sch Med,Div Crit Care Med, Philadelphia, PA 19104 USA; [Friess, Stuart H.] Washington Univ, St Louis Childrens Hosp, Sch Med, Div Crit Care Med,Dept Pediat, St Louis, MO 63110 USA; [Christian, Cindy W.] Univ Penn, Childrens Hosp Philadelphia, Dept Pediat, Perelman Sch Med,Div Pediat, Philadelphia, PA 19104 USA	Abend, NS (corresponding author), Univ Penn, Childrens Hosp Philadelphia, Dept Pediat & Neurol, Perelman Sch Med,Div Neurol, Philadelphia, PA 19104 USA.	abend@email.chop.edu		Kilbaugh, Todd/0000-0002-4959-3092	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [U01HL094345, K23NS075363, K08NS064051, R01HD061963, K23NS076550]; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD061963] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [U01HL094345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS075363, K23NS076550, K08NS064051] Funding Source: NIH RePORTER	Supported, in part, by grants U01HL094345 and K23NS075363 (Dr. Topjian), K08NS064051 (to Dr. Friess), R01HD061963 (to Dr. Huh), and K23NS076550 (to Dr. Abend) from the NIH.; Dr. Topjian received grant support from the National Institutes of Health (NIH). Dr. Friess received grant support from NIH. Dr. Christian provided expert opinions and testimony in child abuse cases. The remaining authors have disclosed that they do not have any potential conflicts of interest.	Abend NS, 2011, NEUROLOGY, V76, P1071, DOI 10.1212/WNL.0b013e318211c19e; Abend NS, 2009, NEUROLOGY, V72, P1931, DOI 10.1212/WNL.0b013e3181a82687; Abend NS, 2007, PEDIATR NEUROL, V37, P165, DOI 10.1016/j.pediatrneurol.2007.05.012; Abend NS, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-012-0330-3; Abend NS, 2011, J CLIN NEUROPHYSIOL, V28, P15, DOI 10.1097/WNP.0b013e3182051123; Adelson PD, 2012, J NEUROTRAUM, V29, P639, DOI 10.1089/neu.2011.1952; Alehan FK, 2001, J CHILD NEUROL, V16, P484, DOI 10.1177/088307380101600704; Barlow KM, 2000, DEV MED CHILD NEUROL, V42, P591, DOI 10.1017/S0012162200001110; Barlow KM, 2005, PEDIATRICS, V116, pE174, DOI 10.1542/peds.2004-2739; Bechtel K, 2004, PEDIATRICS, V114, P165, DOI 10.1542/peds.114.1.165; Beghi E, 2010, EPILEPSIA, V51, P671, DOI 10.1111/j.1528-1167.2009.02285.x; Bourgeois M, 2008, CHILD NERV SYST, V24, P169, DOI 10.1007/s00381-007-0493-4; Fujiwara T, 2008, PEDIATRICS, V122, pE841, DOI 10.1542/peds.2008-0387; Goldstein JL, 2011, NEUROCRIT CARE, V15, P63, DOI 10.1007/s12028-010-9468-5; Greiner HM, 2012, PEDIATRICS, V129, pE748, DOI 10.1542/peds.2011-2067; Hosain SA, 2005, PEDIATR NEUROL, V32, P162, DOI 10.1016/j.pediatrneurol.2004.09.008; Hyllienmark L, 2007, EUR J PAEDIATR NEURO, V11, P70, DOI 10.1016/j.ejpn.2006.11.005; JENNETT B, 1975, LANCET, V1, P480; Jette N, 2006, ARCH NEUROL-CHICAGO, V63, P1750, DOI 10.1001/archneur.63.12.1750; Keenan HT, 2004, PEDIATRICS, V114, P633, DOI 10.1542/peds.2003-1020-L; Kemp AM, 2011, ARCH DIS CHILD, V96, P1103, DOI 10.1136/archdischild-2011-300630; King WJ, 2003, CAN MED ASSOC J, V168, P155; Kirkham FJ, 2012, INTENS CARE MED, V38, P853, DOI 10.1007/s00134-012-2529-9; Liesemer K, 2011, J NEUROTRAUM, V28, P755, DOI 10.1089/neu.2010.1518; Maguire S, 2009, ARCH DIS CHILD, V94, P860, DOI 10.1136/adc.2008.150110; Maguire SA, 2011, PEDIATRICS, V128, pE550, DOI 10.1542/peds.2010-2949; McCoy B, 2011, EPILEPSIA, V52, P1973, DOI 10.1111/j.1528-1167.2011.03291.x; Piteau SJ, 2012, PEDIATRICS, V130, P315, DOI 10.1542/peds.2011-1545; Saengpattrachai M, 2006, EPILEPSIA, V47, P1510, DOI 10.1111/j.1528-1167.2006.00624.x; Schreiber JM, 2012, NEUROCRIT CARE, V17, P31, DOI 10.1007/s12028-012-9715-z; Shahwan A, 2010, EPILEPSIA, V51, P1198, DOI 10.1111/j.1528-1167.2009.02517.x; Tay SKH, 2006, EPILEPSIA, V47, P1504, DOI 10.1111/j.1528-1167.2006.00623.x; Topjian AA, 2013, CRIT CARE MED, V41, P215, DOI 10.1097/CCM.0b013e3182668035; Vespa PM, 2010, NEUROLOGY, V75, P792, DOI 10.1212/WNL.0b013e3181f07334; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Williams K, 2011, EPILEPSIA, V52, P1130, DOI 10.1111/j.1528-1167.2011.03070.x	36	35	36	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	SEP	2013	14	7					709	715		10.1097/PCC.0b013e3182917b83			7	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	235GN	WOS:000325705100014	23842589	Green Accepted			2021-06-18	
J	Samini, F; Samarghandian, S; Borji, A; Mohammadi, G; Bakaian, M				Samini, Fariborz; Samarghandian, Saeed; Borji, Abasalt; Mohammadi, Gholamreza; Bakaian, Mandi			Curcumin pretreatment attenuates brain lesion size and improves neurological function following traumatic brain injury in the rat	PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR			English	Article						Curcumin; Brain injury; Rotarod; Inclined-plane test; Rat; Weight drop	FOCAL CEREBRAL-ISCHEMIA; OXIDATIVE STRESS; MITOCHONDRIAL DYSFUNCTION; ANTIOXIDANT ENZYMES; RADICAL SCAVENGERS; LIPID-PEROXIDATION; HEMORRHAGE; MODEL; MICE; EXCITOTOXICITY	Turmeric has been in use since ancient times as a condiment and due to its medicinal properties. Curcumin, the yellow coloring principle in turmeric, is a polyphenolic and a major active constituent Besides anti-inflammatory, thrombolytic and anti-carcinogenic activities, curcumin also possesses strong antioxidant property. The neuroprotective effects of curcumin were evaluated in a weight drop model of cortical contusion trauma in rat. Male Wistar rats (350-400 g, n = 9) were anesthetized with sodium pentobarbital (60 mg/kg i.p.) and subjected to head injury. Five days before injury, animals randomly received an i.p. bolus of either curcumin (50 and 100 mg/kg/day, n = 9) or vehicle (n = 9). Two weeks after the injury and drug treatment, animals were sacrificed and a series of brain sections, stained with hematoxylin and eosin (H&E) were evaluated for quantitative brain lesion volume. Two weeks after the injury, oxidative stress parameter (malondialdehyde) was also measured in the brain. Curcumin (100 mg/kg) significantly reduced the size of brain injury-induced lesions (P < 0.05). Neurological examinations (rotarod and inclined-plane tests) were performed on days 1, 3, 7 and 14 post-brain injury. Control injured rats had a significant neurological deficit during 2 weeks (P < 0.001). The injury increased brain levels of the malondialdehyde by 35.6% and these increases were attenuated by curcumin (100 mg/kg). Curcumin treatment significantly improved the neurological status evaluated during 2 weeks after brain injury. The study demonstrates the protective efficacy of curcumin in rat traumatic brain injury model. (C) 2013 Elsevier Inc. All rights reserved.	[Samini, Fariborz; Bakaian, Mandi] Mashhad Univ Med Sci, Fac Med, Dept Neurosurg, Mashhad, Iran; [Samarghandian, Saeed; Borji, Abasalt] Neyshabur Univ Med Sci, Dept Basic Med Sci, Neyshabur, Iran; [Mohammadi, Gholamreza] Neyshabur Univ Med Sci, Hlth Strateg Res Ctr, Neyshabur, Iran	Samarghandian, S (corresponding author), Neyshabur Univ Med Sci, Dept Basic Med Sci, Neyshabur, Iran.	samarghandians@mums.ac.ir			Research Affairs of Neyshabur University of Medical Sciences	The authors would like to thank the Research Affairs of Neyshabur University of Medical Sciences for financially supporting this work.	Aronowski J, 2011, STROKE, V42, P1781, DOI 10.1161/STROKEAHA.110.596718; Barone F C, 1997, Expert Opin Investig Drugs, V6, P501, DOI 10.1517/13543784.6.5.501; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Cartiera MS, 2010, MOL PHARMACEUT, V7, P86, DOI 10.1021/mp900138a; Eghwrudjakpor P O, 2010, Niger J Med, V19, P14; Farahmand SK, 2013, BIOGERONTOLOGY, V14, P63, DOI 10.1007/s10522-012-9409-0; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Ferguson S, 2010, NEUROSCIENCE, V168, P811, DOI 10.1016/j.neuroscience.2010.01.031; Genet S, 2002, MOL CELL BIOCHEM, V236, P7, DOI 10.1023/A:1016103131408; Ghorbani A, 2012, AVICENNA J PHYTOMEDI, V2, P4; Gill SS, 2010, PLANT PHYSIOL BIOCH, V48, P909, DOI 10.1016/j.plaphy.2010.08.016; Hall ED, 2012, EXP NEUROL, V238, P176, DOI 10.1016/j.expneurol.2012.08.024; He YL, 2012, BRAIN RES, V1433, P127, DOI 10.1016/j.brainres.2011.11.027; Khurana S, 2012, HUM EXP TOXICOL, V31, P686, DOI 10.1177/0960327111433897; Kumar P, 2007, METHOD FIND EXP CLIN, V29, P19, DOI 10.1358/mf.2007.29.1.1063492; Kuroda S, 1996, NEUROBIOL DIS, V3, P149, DOI 10.1006/nbdi.1996.0015; Lekic T, 2011, EXP NEUROL, V227, P96, DOI 10.1016/j.expneurol.2010.09.017; Marklund N, 2001, J CEREBR BLOOD F MET, V21, P1259, DOI 10.1097/00004647-200111000-00002; Matteucci A, 2005, EXP BRAIN RES, V167, P641, DOI 10.1007/s00221-005-0068-0; McIntosh TK, 1996, LAB INVEST, V74, P315; Merrell JG, 2009, CLIN EXP PHARMACOL P, V36, P1149, DOI 10.1111/j.1440-1681.2009.05216.x; Moojen VKM, 2012, BRAIN RES, V1466, P82, DOI 10.1016/j.brainres.2012.05.041; Moon RJ, 2009, ARCH DIS CHILD, V94, P699, DOI 10.1136/adc.2008.145235; Motterlini R, 2000, FREE RADICAL BIO MED, V28, P1303, DOI 10.1016/S0891-5849(00)00294-X; Nagaraju GP, 2012, INTEGR BIOL-UK, V4, P996, DOI 10.1039/c2ib20088k; Nishio S, 1997, ACT NEUR S, V70, P84; Pari L, 2007, FUND CLIN PHARMACOL, V21, P665, DOI 10.1111/j.1472-8206.2007.00542.x; PAXINOS G, 1990, RAT BRAIN STEREOTAXI; Pierre S, 1999, NEUROREPORT, V10, P47, DOI 10.1097/00001756-199901180-00009; Priyadarsini KI, 1997, FREE RADICAL BIO MED, V23, P838, DOI 10.1016/S0891-5849(97)00026-9; Sadeghnia HR, 2012, AFR J PHARM PHARMACO, V6, P2464, DOI 10.5897/AJPP12.085; Seifman MA, 2008, J CEREBR BLOOD F MET, V28, P684, DOI 10.1038/sj.jcbfm.9600603; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; Sharma Deepak, 2012, Anesthesiol Clin, V30, P333, DOI 10.1016/j.anclin.2012.04.003; Sharma V, 2010, METHOD FIND EXP CLIN, V32, P227, DOI 10.1358/mf.2010.32.4.1452090; Shen L, 2009, BIOORG MED CHEM LETT, V19, P5990, DOI 10.1016/j.bmcl.2009.09.076; Singleton RH, 2010, J NEUROTRAUM, V27, P1091, DOI 10.1089/neu.2010.1291; Slemmer JE, 2008, CURR MED CHEM, V15, P404, DOI 10.2174/092986708783497337; Sood PK, 2011, NEUROTOX RES, V20, P351, DOI 10.1007/s12640-011-9249-8; Sun YH, 2011, J NEUROTRAUM, V28, P2513, DOI 10.1089/neu.2011.1958; Tamaddonfard E, 2012, AVICENNA J PHYTOMEDI, V2, P97; Thiyagarajan M, 2004, LIFE SCI, V74, P969, DOI 10.1016/j.lfs.2003.06.042; Wang YL, 2013, AM J CHINESE MED, V41, P59, DOI 10.1142/S0192415X13500055; Wei J, 2012, J TRAUMA ACUTE CARE, V73, P654, DOI 10.1097/TA.0b013e31825133c0; Yang DY, 2010, NEUROL RES, V32, P1041, DOI 10.1179/016164110X12807570510013; Zafonte RD, 2012, JAMA-J AM MED ASSOC, V308, P1993, DOI 10.1001/jama.2012.13256; Zhang C, 1998, J NEUROSCI RES, V52, P342, DOI 10.1002/(SICI)1097-4547(19980501)52:3<342::AID-JNR10>3.0.CO;2-8	47	35	36	1	12	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0091-3057			PHARMACOL BIOCHEM BE	Pharmacol. Biochem. Behav.	SEP	2013	110						238	244		10.1016/j.pbb.2013.07.019			7	Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy	Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy	253TM	WOS:000327112200031	23932920				2021-06-18	
J	Zhang, L; Zhang, F; Weng, ZF; Brown, BN; Yan, HQ; Ma, XM; Vosler, PS; Badylak, SF; Dixon, CE; Cui, XT; Chen, J				Zhang, Ling; Zhang, Feng; Weng, Zhongfang; Brown, Bryan N.; Yan, Hongqu; Ma, Xiecheng Michelle; Vosler, Peter S.; Badylak, Stephen F.; Dixon, C. Edward; Cui, Xinyan Tracy; Chen, Jun			Effect of an Inductive Hydrogel Composed of Urinary Bladder Matrix Upon Functional Recovery Following Traumatic Brain Injury	TISSUE ENGINEERING PART A			English	Article							CONTROLLED CORTICAL IMPACT; EXTRACELLULAR-MATRIX; BIOLOGIC SCAFFOLDS; MACROPHAGE PHENOTYPE; COGNITIVE FUNCTION; PROGENITOR CELLS; TRANSPLANTATION; TISSUE; FGF-2; RECONSTRUCTION	Traumatic brain injury (TBI) is a major public health problem with no effective clinical treatment. Use of bioactive scaffold materials has been shown to be a promising strategy for tissue regeneration and repair in a number of injury models. Of these scaffold materials, urinary bladder matrix (UBM) derived from porcine bladder tissue, has demonstrated desirable properties for supporting and promoting the growth of neural cells in vitro, suggesting its potential as a scaffold for brain tissue repair in the treatment of TBI. Herein we evaluate the biocompatibility of UBM within brain tissue and the effects of UBM delivery upon functional outcome following TBI. A hydrogel form of UBM was injected into healthy rat brains for 1, 3, and 21 days to examine the tissue response to UBM. Multiple measures of tissue injury, including reactive astrocytosis, microglial activation, and neuron degeneration showed that UBM had no deleterious effects on normal brain. Following TBI, the brains were evaluated histologically and behaviorally between sham-operated controls and UBM- and vehicle-treated groups. Application of UBM reduced lesion volume and attenuated trauma-induced myelin disruption. Importantly, UBM treatment resulted in significant neurobehavioral recovery following TBI as demonstrated by improvements in vestibulomotor function; however, no differences in cognitive recovery were observed between the UBM- and vehicle-treated groups. The present study demonstrated that UBM is not only biocompatible within the brain tissue, but also can exert protective effects upon injured brain.	[Zhang, Ling; Cui, Xinyan Tracy] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15261 USA; [Zhang, Feng; Weng, Zhongfang; Vosler, Peter S.; Chen, Jun] Univ Pittsburgh, Sch Med, Ctr Cerebrovasc Dis Res, Dept Neurol, Pittsburgh, PA 15261 USA; [Brown, Bryan N.; Badylak, Stephen F.; Cui, Xinyan Tracy] Univ Pittsburgh, Sch Med, McGowan Inst Regenerat Med, Pittsburgh, PA 15261 USA; [Yan, Hongqu; Ma, Xiecheng Michelle; Dixon, C. Edward] Univ Pittsburgh, Dept Neurosurg, Pittsburgh, PA 15261 USA; [Badylak, Stephen F.] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15261 USA	Cui, XT (corresponding author), Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15261 USA.	xic11@pitt.edu; chenj2@upmc.edu		Cui, Xinyan/0000-0002-0470-2005; Badylak, Stephen/0000-0003-3555-0689; Vosler, Peter/0000-0002-7689-5539	Department of Defense Concept AwardUnited States Department of Defense [PT073219]; NSFNational Science Foundation (NSF) [0748001]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045048] Funding Source: NIH RePORTER	We acknowledge the financial support provided by the Department of Defense Concept Award PT073219 (J.C.), NSF Career Award 0748001 (X.T.C.).	Agrawal V, 2009, J TISSUE ENG REGEN M, V3, P590, DOI 10.1002/term.200; Badylak SF, 2004, TRANSPL IMMUNOL, V12, P367, DOI 10.1016/j.trim.2003.12.016; Badylak SF, 2007, BIOMATERIALS, V28, P3587, DOI 10.1016/j.biomaterials.2007.04.043; Basu A, 2002, GLIA, V40, P109, DOI 10.1002/glia.10118; Brennan EP, 2008, J TISSUE ENG REGEN M, V2, P491, DOI 10.1002/term.123; Brown B, 2006, TISSUE ENG, V12, P519, DOI 10.1089/ten.2006.12.519; Brown BN, 2012, ACTA BIOMATER, V8, P978, DOI 10.1016/j.actbio.2011.11.031; Brown BN, 2009, BIOMATERIALS, V30, P1482, DOI 10.1016/j.biomaterials.2008.11.040; Chen JL, 2005, J CEREBR BLOOD F MET, V25, P281, DOI 10.1038/sj.jcbfm.9600034; Crapo PM, 2012, BIOMATERIALS, V33, P3539, DOI 10.1016/j.biomaterials.2012.01.044; Daly KA, 2009, TISSUE ENG PT A, V15, P3877, DOI [10.1089/ten.tea.2009.0089, 10.1089/ten.TEA.2009.0089]; DeQuach JA, 2011, TISSUE ENG PT A, V17, P2583, DOI [10.1089/ten.tea.2010.0724, 10.1089/ten.TEA.2010.0724]; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Faul M, 2007, J TRAUMA, V63, P1271, DOI 10.1097/TA.0b013e3181493080; Freytes DO, 2008, BIOMATERIALS, V29, P1630, DOI 10.1016/j.biomaterials.2007.12.014; GAGE FH, 1995, P NATL ACAD SCI USA, V92, P11879, DOI 10.1073/pnas.92.25.11879; Gao JL, 2006, EXP NEUROL, V201, P281, DOI 10.1016/j.expneurol.2006.04.039; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hoane MR, 2004, J NEUROTRAUM, V21, P163, DOI 10.1089/089771504322778622; Hodde JP, 2001, WOUNDS, V13, P195; Irving EA, 2001, ACTA NEUROPATHOL, V102, P627, DOI 10.1007/s004010100416; Lazarov-Spiegler O, 1998, MOL MED TODAY, V4, P337, DOI 10.1016/S1357-4310(98)01298-2; LazarovSpiegler O, 1996, FASEB J, V10, P1296; Liu CY, 2003, NEUROSURGERY, V52, P1154, DOI 10.1227/01.NEU.0000057747.93237.8F; Makwana M, 2007, J NEUROSCI, V27, P11201, DOI 10.1523/JNEUROSCI.2255-07.2007; Marcal H, 2012, REGEN MED, V7, P159, DOI [10.2217/RME.12.6, 10.2217/rme.12.6]; Marra KG, 2008, PLAST RECONSTR SURG, V121, P1153, DOI 10.1097/01.prs.0000305517.93747.72; MENEI P, 1993, BIOMATERIALS, V14, P470, DOI 10.1016/0142-9612(93)90151-Q; Ortuzar N, 2011, J NEURAL TRANSM, V118, P135, DOI 10.1007/s00702-010-0496-2; Polikov VS, 2005, J NEUROSCI METH, V148, P1, DOI 10.1016/j.jneumeth.2005.08.015; Ray SK, 2002, HISTOL HISTOPATHOL, V17, P1137, DOI 10.14670/HH-17.1137; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Schwartz M, 2010, BRAIN BEHAV IMMUN, V24, P1054, DOI 10.1016/j.bbi.2010.01.010; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Tate CC, 2009, J TISSUE ENG REGEN M, V3, P208, DOI 10.1002/term.154; WOERLY S, 1990, BIOMATERIALS, V11, P97, DOI 10.1016/0142-9612(90)90123-8; Yan HQ, 2000, BRAIN RES, V887, P134, DOI 10.1016/S0006-8993(00)03002-X; Yoshimura S, 2003, J CLIN INVEST, V112, P1202, DOI 10.1172/JCI200316618; Zantop T, 2006, J ORTHOP RES, V24, P1299, DOI 10.1002/jor.20071	39	35	36	0	22	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1937-3341			TISSUE ENG PT A	Tissue Eng. Part A	SEP	2013	19	17-18					1909	1918		10.1089/ten.tea.2012.0622			10	Cell & Tissue Engineering; Cell Biology; Engineering, Biomedical; Materials Science, Biomaterials	Cell Biology; Engineering; Materials Science	190ES	WOS:000322322600003	23596981	Green Published			2021-06-18	
J	De Beaumont, L; Tremblay, S; Henry, LC; Poirier, J; Lassonde, M; Theoret, H				De Beaumont, Louis; Tremblay, Sebastien; Henry, Luke C.; Poirier, Judes; Lassonde, Maryse; Theoret, Hugo			Motor system alterations in retired former athletes: the role of aging and concussion history	BMC NEUROLOGY			English	Article						Motor learning; Retired athletes; Concussion; Motor cortex; Magnetic resonance spectroscopy	CHRONIC TRAUMATIC ENCEPHALOPATHY; MENTAL-STATE-EXAMINATION; METABOLITE CONCENTRATIONS; COGNITIVE IMPAIRMENT; RECURRENT CONCUSSION; SPORTS CONCUSSION; LONG-TERM; BRAIN; NEUROTRANSMISSION; GLUTAMATE	Background: Retired athletes with a history of sports concussions experience cognitive and motor declines with aging, and the risk of severe neurodegenerative conditions is magnified in this population. The present study investigated the effects of aging on motor system metabolism and function in former university-level athletes who sustained their last concussion several decades prior to testing. Methods: To test the hypothesis that age and remote concussions induce functional as well as metabolic alterations of the motor system, we used proton magnetic resonance spectroscopy to detect metabolic abnormalities in the primary motor cortex and the serial reaction time task (SRTT) to evaluate motor learning. Results: Our results indicate that motor learning is significantly reduced in former concussed athletes relative to controls. In addition, glutamate/H2O ratio in M1 was disproportionately reduced in concussed athletes with advancing age and was found to strongly correlate with motor learning impairments. Conclusion: Findings from this study provide evidence that the acquisition of a repeated motor sequence is compromised in the aging concussed brain and that its physiological underpinnings could implicate disproportionate reductions of M1 glutamate concentrations with advancing age.	[De Beaumont, Louis; Tremblay, Sebastien; Henry, Luke C.; Lassonde, Maryse; Theoret, Hugo] Univ Montreal, Ctr Rech Neuropsychol & Cognit CERNEC, Montreal, PQ, Canada; [Lassonde, Maryse; Theoret, Hugo] CHU St Justine, Montreal, PQ, Canada; [De Beaumont, Louis; Poirier, Judes] Douglas Mental Hlth Univ Inst, Verdun, PQ H4H 1R3, Canada; [De Beaumont, Louis; Tremblay, Sebastien; Theoret, Hugo] Univ Montreal, Dept Psychol, Montreal, PQ H3C 3J7, Canada	Theoret, H (corresponding author), Univ Montreal, Ctr Rech Neuropsychol & Cognit CERNEC, Montreal, PQ, Canada.	hugo.theoret@umontreal.ca		Tremblay, Sebastien/0000-0001-6251-9797; Theoret, Hugo/0000-0002-7458-8797	Canadian Institute of Health Research (CIHR)Canadian Institutes of Health Research (CIHR); Fonds de la recherche en sante du Quebec (FRSQ)Fonds de la Recherche en Sante du Quebec	We want to thank team physician Dr. Suzanne Leclerc for her help in recruiting athletes as well as providing concussion history information. This research was funded by grants from the Canadian Institute of Health Research (CIHR) awarded to ML and HT and by support from the Fonds de la recherche en sante du Quebec (FRSQ) awarded to HT and ML.	Abel EL, 2007, PERCEPT MOTOR SKILL, V104, P1251, DOI 10.2466/PMS.104.4.1251-1254; BENEDETTI MS, 1990, J NEUR TR S, V29, P259; BRAEKHUS A, 1995, J AM GERIATR SOC, V43, P656, DOI 10.1111/j.1532-5415.1995.tb07201.x; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Cantu RC, 2007, NEUROSURGERY, V61, P223, DOI 10.1227/01.NEU.0000255514.73967.90; Catena RD, 2007, GAIT POSTURE, V25, P406, DOI 10.1016/j.gaitpost.2006.05.006; Cavanaugh JT, 2005, SPORTS MED, V35, P935, DOI 10.2165/00007256-200535110-00002; Chantal S, 2004, BRAIN RES, V1003, P26, DOI 10.1016/j.brainres.2003.11.074; Chio A, 2005, BRAIN, V128, P472, DOI 10.1093/brain/awh373; COBO M, 1992, NEUROBIOL AGING, V13, P705, DOI 10.1016/0197-4580(92)90093-D; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; COTMAN CW, 1988, ANNU REV NEUROSCI, V11, P61, DOI 10.1146/annurev.neuro.11.1.61; CRUM RM, 1993, JAMA-J AM MED ASSOC, V269, P2386, DOI 10.1001/jama.269.18.2386; Daselaar SM, 2003, NEUROBIOL AGING, V24, P1013, DOI 10.1016/S0197-4580(03)00030-7; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; De Beaumont L, 2012, CEREB CORTEX, V22, P112, DOI 10.1093/cercor/bhr096; De Beaumont L, 2011, J ATHL TRAINING, V46, P234; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Henry LC, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-105; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Kaiser LG, 2005, NEUROBIOL AGING, V26, P665, DOI 10.1016/j.neurobiolaging.2004.07.001; Kelly JP, 1997, NEUROLOGY, V48, P581; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; McCrory Paul, 2009, J Athl Train, V44, P434, DOI 10.4085/1062-6050-44.4.434; MCENTEE WJ, 1993, PSYCHOPHARMACOLOGY, V111, P391, DOI 10.1007/BF02253527; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Minati L, 2010, J MED PHYS, V35, P154, DOI 10.4103/0971-6203.62128; OLNEY JW, 1969, SCIENCE, V164, P719, DOI 10.1126/science.164.3880.719; Omalu Bennet I, 2010, J Forensic Nurs, V6, P40, DOI 10.1111/j.1939-3938.2009.01064.x; Perez MA, 2007, J NEUROSCI, V27, P1045, DOI 10.1523/JNEUROSCI.4128-06.2007; Petersen R C, 1997, Int Psychogeriatr, V9 Suppl 1, P65, DOI 10.1017/S1041610297004717; Petersen RC, 2005, NEW ENGL J MED, V352, P2379, DOI 10.1056/NEJMoa050151; PROVENCHER SW, 1993, MAGNET RESON MED, V30, P672, DOI 10.1002/mrm.1910300604; Scarmeas N, 2002, NEUROLOGY, V59, P773, DOI 10.1212/WNL.59.5.773; Schmidt W J, 1992, J Neural Transm Suppl, V38, P65; Segovia G, 2001, MECH AGEING DEV, V122, P1, DOI 10.1016/S0047-6374(00)00225-6; Spencer DC, 2003, NEUROLOGY, V60, P1194, DOI 10.1212/01.WNL.0000052822.22994.86; Willingham DB, 2000, MEM COGNITION, V28, P366, DOI 10.3758/BF03198552; Yousry TA, 1997, BRAIN, V120, P141, DOI 10.1093/brain/120.1.141	47	35	35	0	61	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1471-2377		BMC NEUROL	BMC Neurol.	AUG 26	2013	13								109	10.1186/1471-2377-13-109			10	Clinical Neurology	Neurosciences & Neurology	208YX	WOS:000323720100001	23972282	DOAJ Gold, Green Published			2021-06-18	
J	Borich, M; Makan, N; Boyd, L; Virji-Babul, N				Borich, Michael; Makan, Nadia; Boyd, Lara; Virji-Babul, Naznin			Combining Whole-Brain Voxel-Wise Analysis with In Vivo Tractography of Diffusion Behavior after Sports-Related Concussion in Adolescents: A Preliminary Report	JOURNAL OF NEUROTRAUMA			English	Article						adolescents; concussion; diffusion tensor imaging, mild traumatic brain injury; tract-based spatial statistics, tractography	WHITE-MATTER INTEGRITY; INJURY; ANISOTROPY; RECOVERY; MRI; AGE	We have previously shown that sports-related concussion in adolescents is associated with changes in whole-brain properties of white-matter pathways. Here, we assess local changes within these pathways. Twelve adolescents with a clinical diagnosis of subacute concussion and 10 healthy adolescents matched for age, gender, and physical activity completed magnetic resonance imaging scanning. Voxel-wise tract-based spatial statistics and tractography were performed to assess local changes in diffusion-based measures of microstructural properties of white-matter pathways (fractional anisotropy, mean diffusivity, radial diffusivity, and axial diffusivity) between the two groups. Fractional anisotropy values were higher for the concussed group in multiple cluster regions using tract-based spatial statistics, primarily in frontal white-matter regions, including the anterior corona radiata bilaterally. Using these regions of altered diffusion characteristics to seed fiber tractography, significantly reduced axial diffusivity in tracts passing through these areas were detected in the concussed group (p = 0.04). A trend toward reduced mean and radial diffusivity in the concussed group was also observed within the same reconstructed tracts. Diffusion behavior within these tracts was significantly correlated with an assessment of concussion status (Sports Concussion Assessment Tool 2). Fractional anisotropy within the reconstructed tracts was not significantly different between the two groups. These results suggest that subacute concussion in adolescents is associated with altered diffusion properties within regional white-matter tissue and along reconstructed fiber pathways. Combining voxel-wise analysis with fiber tractography provides an alternative objective approach to evaluate and identify subtle changes in white-matter fiber integrity after concussion.	[Borich, Michael; Makan, Nadia; Boyd, Lara; Virji-Babul, Naznin] Univ British Columbia, Dept Phys Therapy, Vancouver, BC V6T 1Z3, Canada; [Virji-Babul, Naznin] Child & Family Res Inst, Vancouver, BC, Canada	Virji-Babul, N (corresponding author), Univ British Columbia, Dept Phys Therapy, 212-2177 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.	nvb31@mail.ubc.ca	Borich, Michael Robert/E-1683-2011	Borich, Michael Robert/0000-0002-0469-6282; Virji-Babul, Naznin/0000-0002-8984-5848	Martha Piper Research Fund from the University of British Columbia; Brain Research Center at the University of British Columbia	This research was supported by the Martha Piper Research Fund from the University of British Columbia, and the Brain Research Center at the University of British Columbia. The authors thank BC Hockey for their support and all the participants, trainers, and coaches who took part in this study. The authors also thank Dr. Alex Rauscher for his assistance with the MRI protocol.	Alexander AL, 2007, NEUROTHERAPEUTICS, V4, P316, DOI 10.1016/j.nurt.2007.05.011; Anderson V, 2009, BRAIN, V132, P45, DOI 10.1093/brain/awn293; Basser PJ, 2000, MAGNET RESON MED, V44, P625, DOI 10.1002/1522-2594(200010)44:4<625::AID-MRM17>3.0.CO;2-O; Basser PJ, 2002, NMR BIOMED, V15, P456, DOI 10.1002/nbm.783; Bauer R, 2004, EXP TOXICOL PATHOL, V56, P65, DOI 10.1016/j.etp.2004.04.002; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Caeyenberghs K, 2011, NEUROREHAB NEURAL RE, V25, P492, DOI 10.1177/1545968310394870; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Giza CC, 2001, J ATHL TRAINING, V36, P228; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Karlin AM, 2011, PM&R, V3, pS369, DOI 10.1016/j.pmrj.2011.07.015; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; LEEMANS A, 2009, P 17 ANN M INT SOC M; Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073; Margulies SS, 2000, J BIOMECH ENG-T ASME, V122, P364, DOI 10.1115/1.1287160; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McAllister TW, 2012, ANN BIOMED ENG, V40, P127, DOI 10.1007/s10439-011-0402-6; MCLEAN A, 1984, NEUROSURGERY, V14, P393, DOI 10.1227/00006123-198404000-00001; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Oishi K., 2011, MRI ATLAS HUMAN WHIT; Reetz K, 2012, NEUROIMAGE, V63, P517, DOI 10.1016/j.neuroimage.2012.07.009; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Virji-Babul N, 2013, PEDIATR NEUROL, V48, P24, DOI 10.1016/j.pediatrneurol.2012.09.005; Wilde EA, 2012, BRAIN IMAGING BEHAV, V6, P319, DOI 10.1007/s11682-012-9174-3	32	35	35	1	16	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2013	30	14					1243	1249		10.1089/neu.2012.2818			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	183MV	WOS:000321821100004	23406264				2021-06-18	
J	Rietdijk, R; Simpson, G; Togher, L; Power, E; Gillett, L				Rietdijk, Rachael; Simpson, Grahame; Togher, Leanne; Power, Emma; Gillett, Lauren			An exploratory prospective study of the association between communication skills and employment outcomes after severe traumatic brain injury	BRAIN INJURY			English	Article						Communication; language; work; employment; traumatic brain injury	QUESTIONNAIRE; ABILITIES; VALIDITY	Primary objective: The aim of this pilot study was to explore possible correlations between measures of functional communication skills in the first year post-injury and later employment outcome. Design: A preliminary observational study employing a prospective longitudinal design. Methods: Fourteen adults with traumatic brain injury completed an assessment involving two functional communication measures: an objective test of cognitive communication skills (Functional Assessment of Verbal Reasoning and Executive Strategies, FAVRES) and self-ratings of communication impairment (LaTrobe Communication Questionnaire, LCQ). Follow-up of participants' employment outcome was conducted 9-18 months after the initial assessment. Results: At follow-up, eight participants had returned to employment (working a similar number of hours to their pre-injury status), five were unemployed and one was lost to follow-up. Employment status at follow-up was strongly correlated with both FAVRES Total Accuracy scores (r=0.833) and Total Rationale scores (r=0.837), but there were no correlations with FAVRES Time and Reasoning scores or with the LCQ. Conclusions: The FAVRES shows initial promise as an assessment that may be associated with successful employment outcome following traumatic brain injury. Further research with larger samples is required to provide further information on the prognostic utility of measures such as the FAVRES and the LCQ.	[Rietdijk, Rachael; Simpson, Grahame; Gillett, Lauren] Liverpool Hlth Serv, Brain Injury Rehabil Unit, Sydney, NSW, Australia; [Rietdijk, Rachael; Togher, Leanne; Power, Emma] Univ Sydney, Fac Hlth Sci, Sydney, NSW 2006, Australia; [Simpson, Grahame] Univ Sydney, Rehabil Studies Unit, Sydney, NSW 2006, Australia	Rietdijk, R (corresponding author), Univ Sydney, Fac Hlth Sci, Cumberland Campus C42,POB 170, Lidcombe, NSW 1825, Australia.	rman7827@uni.sydney.edu.au	Simpson, Grahame K/W-1074-2019; Rietdijk, Rachael/J-6573-2012; Togher, Leanne/AAC-7083-2019; Power, Emma/A-9263-2015	Simpson, Grahame K/0000-0001-8156-9060; Rietdijk, Rachael/0000-0003-4343-4039; Power, Emma/0000-0002-2638-0406; Togher, Leanne/0000-0002-4518-6748			Athanasou J. A., 2003, AUSTR J CAREER DEV, V12, P58, DOI DOI 10.1177/103841620301200108; Douglas JM, 2007, APHASIOLOGY, V21, P1181, DOI 10.1080/02687030600980950; Douglas JM, 2007, J HEAD TRAUMA REHAB, V22, P31, DOI 10.1097/00001199-200701000-00004; Douglas JM, 2000, APHASIOLOGY, V14, P251, DOI 10.1080/026870300401469; Duff MC, 2002, BRAIN INJURY, V16, P773, DOI 10.1080/02699050210128870; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; FRASER RT, 1994, TOP LANG DISORD, V15, P55, DOI 10.1097/00011363-199411000-00006; Hughes J, 2007, CAN J SPEECH-LANG PA, V31, P134; Isaki E, 2000, BRAIN INJURY, V14, P441; Macdonald S, 2005, BRAIN INJURY, V19, P895, DOI 10.1080/02699050400004294; Macdonald S., 2005, FUNCTIONAL ASSESSMEN; MacDonald S, 2010, BRAIN INJURY, V24, P486, DOI 10.3109/02699050903518118; Nightingale EJ, 2007, BRAIN IMPAIR, V8, P101, DOI [10.1375/brim.8.2.101, DOI 10.1375/BRIM.8.2.101]; SPSS, 2009, PASW STAT 18 REL VER; Struchen MA, 2003, J INT NEUROPSYCH SOC, V9, P255; Struchen MA, 2008, BRAIN INJURY, V22, P940, DOI 10.1080/02699050802425410; Tate RL, 1998, AUST NZ J PUBL HEAL, V22, P419, DOI 10.1111/j.1467-842X.1998.tb01406.x; Turkstra LS, 2002, J COMMUN DISORD, V35, P467, DOI 10.1016/S0021-9924(02)00118-1; World Health Organization, 2001, INT CLASS FUNCT DIS	19	35	35	1	24	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUL	2013	27	7-8					812	818		10.3109/02699052.2013.775491			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	169UO	WOS:000320806200007	23758261				2021-06-18	
J	Schneider, KJ; Meeuwisse, WH; Kang, J; Schneider, GM; Emery, CA				Schneider, Kathryn J.; Meeuwisse, Willem H.; Kang, Jian; Schneider, Geoff M.; Emery, Carolyn A.			Preseason Reports of Neck Pain, Dizziness, and Headache as Risk Factors for Concussion in Male Youth Ice Hockey Players	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						dizziness; neck pain; headache; youth; risk factor; concussion	SPORT-RELATED CONCUSSION; INTERNATIONAL-CONFERENCE; CERVICOGENIC HEADACHE; CEREBRAL CONCUSSION; INJURY; DISCOGRAPHY; MANAGEMENT; STATEMENT; FOOTBALL; CHILDREN	Objective: The objective of this study was to determine the risk of concussion in youth male hockey players with preseason reports of neck pain, headaches, and/or dizziness. Design: Secondary data analysis of pooled data from 2 prospective cohort studies. Setting: Ice hockey rinks in Alberta and Quebec, Canada. Participants: A total of 3832 male ice hockey players aged 11 to 14 years (280 teams) participated. Assessment of Risk Factors: Participants recorded baseline preseason symptoms of dizziness, neck pain, and headaches on the Sport Concussion Assessment Tool. Incidence rate ratios (IRR) were estimated using Poisson regression, adjusted for cluster by team, hours of exposure, and other covariates. Main Outcome Measures: Concussions that occurred during the season were recorded using a validated prospective injury surveillance system. Results: Preseason reports of neck pain and headache were risk factors for concussion (IRR = 1.67; 95% confidence interval [CI], 1.15-2.41 and IRR = 1.47; 95% CI, 1.01-2.13). Dizziness was a risk factor for concussion in the Pee Wee nonbody checking cohort (IRR = 3.11; 95% CI, 1.33-7.26). A combination of any 2 symptoms was a risk factor in the Pee Wee nonbody checking cohort (IRR = 3.65; 95% CI, 1.20-11.05) and the Bantam cohort (IRR = 2.40; 95% CI, 1.15-4.97). Conclusions: Male youth athletes reporting headache and neck pain at baseline were at an increased risk of concussion during the season. The risk associated with dizziness and any 2 of dizziness, neck pain, or headaches depended on age group and body checking. Clinical Relevance: Baseline testing may be of benefit to identify individuals with symptoms of dizziness, neck pain, and headaches who may be at a higher risk of concussion during the season.	[Schneider, Kathryn J.; Meeuwisse, Willem H.; Kang, Jian; Emery, Carolyn A.] Univ Calgary, Sport Injury Prevent Res Ctr, Fac Kinesiol, Calgary, AB T2N 1N4, Canada; [Meeuwisse, Willem H.; Emery, Carolyn A.] Univ Calgary, Fac Med, Dept Community Hlth Sci, Calgary, AB T2N 1N4, Canada; [Schneider, Geoff M.] Univ Calgary, Fac Med, Dept Med Sci, Calgary, AB T2N 1N4, Canada; [Emery, Carolyn A.] Univ Calgary, Fac Med, Alberta Childrens Hosp Res Inst Child & Maternal, Calgary, AB T2N 1N4, Canada	Schneider, KJ (corresponding author), Univ Calgary, Sport Injury Prevent Res Ctr, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.	kjschnei@ucalgary.ca	Emery, Carolyn/AAI-2761-2020	Schneider, Kathryn/0000-0002-5951-5899	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); MaxBell Foundation; Alberta Heritage Foundation for Medical Research Studentship Award; Alberta Heritage Foundation for Medical Research Population Health Investigator Award; Professorship in Pediatric Rehabilitation funded by the Children's Hospital Foundation through the Alberta Children's Hospital Research Institute for Child and Maternal Health; International Olympic Committee	Funding was provided by the Canadian Institutes of Health Research and MaxBell Foundation. Kathryn Schneider is funded by an Alberta Heritage Foundation for Medical Research Studentship Award. Carolyn Emery is funded by a Canadian Institutes of Health Research New Investigator Award, Alberta Heritage Foundation for Medical Research Population Health Investigator Award, and a Professorship in Pediatric Rehabilitation funded by the Children's Hospital Foundation through the Alberta Children's Hospital Research Institute for Child and Maternal Health. The Sport Injury Prevention Research Centre is one of the International Research Centres for Prevention of Injury and Protection of Athlete Health supported by the International Olympic Committee.	Armstrong B, 2008, SPORTS MED, V38, P101, DOI 10.2165/00007256-200838020-00002; Balatsouras DG, 2007, INT J PEDIATR OTORHI, V71, P487, DOI 10.1016/j.ijporl.2006.11.024; Benson B, 2009, BRIT J SPORT MED, V43, pi99; Bogduk N, 2004, NEUROL CLIN, V22, P151, DOI 10.1016/S0733-8619(03)00100-2; BOGDUK N, 1986, J NEUROL NEUROSUR PS, V49, P775, DOI 10.1136/jnnp.49.7.775; BOGDUK N, 1988, SPINE, V13, P610; Bogduk N, 2009, LANCET NEUROL, V8, P959, DOI 10.1016/S1474-4422(09)70209-1; Conicella E, 2008, HEADACHE, V48, P1005, DOI 10.1111/j.1526-4610.2007.01052.x; Cooper G, 2007, PAIN MED, V8, P344, DOI 10.1111/j.1526-4637.2006.00201.x; Dreyfuss P, 2009, PM&R, V1, P719, DOI 10.1016/j.pmrj.2009.05.014; El-Metwally A, 2004, PAIN, V110, P550, DOI 10.1016/j.pain.2004.03.021; Emery C, 2009, J SCI MED SPORT, V12, P180; Emery C, 2009, CLIN J SPORT MED, V19, P245; Emery CA, 2003, CLIN J SPORT MED, V13, P256, DOI 10.1097/00042752-200307000-00011; Emery CA, 2006, AM J SPORT MED, V34, P1960, DOI 10.1177/0363546506290061; Emery CA, 2010, JAMA-J AM MED ASSOC, V303, P2265, DOI 10.1001/jama.2010.755; Emery CA, 2010, INJURY PREV, V16, P113, DOI 10.1136/ip.2009.022764; Eviatar L, 1986, Pediatr Neurol, V2, P61, DOI 10.1016/0887-8994(86)90058-5; Falla DL, 2004, SPINE, V29, P2108, DOI 10.1097/01.brs.0000141170.89317.0e; Forsyth R, 1999, Pediatr Rev, V20, P39, DOI 10.1542/pir.20-2-39; Furman JM, 2000, PHYS THER, V80, P179, DOI 10.1093/ptj/80.2.179; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Grubb SA, 2000, SPINE, V25, P1382, DOI 10.1097/00007632-200006010-00010; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Jull G, 1999, CEPHALALGIA, V19, P179, DOI 10.1046/j.1468-2982.1999.1903179.x; Jull G, 2004, MANUAL THER, V9, P89, DOI 10.1016/S1356-689X(03)00086-9; Kelly KD, 2001, CLIN J SPORT MED, V11, P77, DOI 10.1097/00042752-200104000-00003; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Kristjansson E, 2009, J ORTHOP SPORT PHYS, V39, P364, DOI 10.2519/jospt.2009.2834; Lewis DW, 2000, HEADACHE, V40, P200, DOI 10.1046/j.1526-4610.2000.00029.x; LORD SM, 1994, J NEUROL NEUROSUR PS, V57, P1187, DOI 10.1136/jnnp.57.10.1187; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meeuwisse WH, 1998, CLIN J SPORT MED, V8, P164, DOI 10.1097/00042752-199807000-00003; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; OMMAYA AK, 1966, SCIENCE, V153, P211, DOI 10.1126/science.153.3732.211; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Patel DR, 2005, SPORTS MED, V35, P671, DOI 10.2165/00007256-200535080-00002; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Pikus HJ, 1995, HEADACHE, V35, P621, DOI 10.1111/j.1526-4610.1995.hed3510621.x; Reid SA, 2005, MANUAL THER, V10, P4, DOI 10.1016/j.math.2004.03.006; Schellhas KP, 1996, SPINE, V21, P300, DOI 10.1097/00007632-199602010-00009; Schneider KJ, 2010, BRIT J SPORT MED, V44, P1112, DOI 10.1136/bjsm.2009.071266; Shehata N, 2009, BRIT J SPORT MED, V43, P730, DOI 10.1136/bjsm.2009.059832; Stata Corporation, 2008, STAT STAT SOFTW REL; Treleaven J, 2003, J REHABIL MED, V35, P36, DOI 10.1080/16501970306109; Weisleder P, 2001, J CHILD NEUROL, V16, P727, DOI 10.1177/088307380101601004	48	35	35	0	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	JUL	2013	23	4					267	272		10.1097/JSM.0b013e318281f09f			6	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	299AM	WOS:000330366700004	23391986				2021-06-18	
J	Winston, GP; Stretton, J; Sidhu, MK; Symms, MR; Thompson, PJ; Duncan, JS				Winston, Gavin P.; Stretton, Jason; Sidhu, Meneka K.; Symms, Mark R.; Thompson, Pamela J.; Duncan, John S.			Structural correlates of impaired working memory in hippocampal sclerosis	EPILEPSIA			English	Article						Temporal lobe epilepsy; Hippocampal sclerosis; Working memory; Voxel-based morphometry; Diffusion tensor imaging	TEMPORAL-LOBE EPILEPSY; SUPERIOR LONGITUDINAL FASCICULUS; TRAUMATIC BRAIN-INJURY; WHITE-MATTER; PREFRONTAL CORTEX; POSTERIOR CINGULATE; MULTIPLE-SCLEROSIS; WATER DIFFUSION; PARIETAL CORTEX; PERFORMANCE	Purpose: Temporal lobe epilepsy (TLE) has been considered to impair long-term memory, whilst not affecting working memory, but recent evidence suggests that working memory is compromised. Functional MRI (fMRI) studies demonstrate that working memory involves a bilateral frontoparietal network the activation of which is disrupted in hippocampal sclerosis (HS). A specific role of the hippocampus to deactivate during working memory has been proposed with this mechanism faulty in patients with HS. Structural correlates of disrupted working memory in HS have not been explored. Methods: We studied 54 individuals with medically refractory TLE and unilateral HS (29 left) and 28 healthy controls. Subjects underwent 3T structural MRI, a visuospatial n-back fMRI paradigm and diffusion tensor imaging (DTI). Working memory capacity assessed by three span tasks (digit span backwards, gesture span, motor sequences) was combined with performance in the visuospatial paradigm to give a global working memory measure. Gray and white matter changes were investigated using voxel-based morphometry and voxel-based analysis of DTI, respectively. Key Findings: Individuals with left or right HS performed less well than healthy controls on all measures of working memory. fMRI demonstrated a bilateral frontoparietal network during the working memory task with reduced activation of the right parietal lobe in both patient groups. In left HS, gray matter loss was seen in the ipsilateral hippocampus and parietal lobe, with maintenance of the gray matter volume of the contralateral parietal lobe associated with better performance. White matter integrity within the frontoparietal network, in particular the superior longitudinal fasciculus and cingulum, and the contralateral temporal lobe, was associated with working memory performance. In right HS, gray matter loss was also seen in the ipsilateral hippocampus and parietal lobe. Working memory performance correlated with the gray matter volume of both frontal lobes and white matter integrity within the frontoparietal network and contralateral temporal lobe. Significance: Our data provide further evidence that working memory is disrupted in HS and impaired integrity of both gray and white matter is seen in functionally relevant areas. We suggest this forms the structural basis of the impairment of working memory, indicating widespread and functionally significant structural changes in patients with apparently isolated HS.	[Winston, Gavin P.; Stretton, Jason; Sidhu, Meneka K.; Symms, Mark R.; Thompson, Pamela J.; Duncan, John S.] UCL Inst Neurol, Dept Clin & Expt Epilepsy, London WC1N 3BG, England	Winston, GP (corresponding author), UCL Inst Neurol, Dept Clin & Expt Epilepsy, Box 29,Queen Sq, London WC1N 3BG, England.	g.winston@ucl.ac.uk	Winston, Gavin P/E-6778-2011	Winston, Gavin P/0000-0001-9395-1478; Duncan, John S/0000-0002-1373-0681	Wellcome TrustWellcome TrustEuropean Commission [083148]; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0802012]; Wolfson Trust; Epilepsy Society; Department of Health's NIHR Biomedical Research Centres funding schemeNational Institute for Health Research (NIHR); National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0509-10161] Funding Source: researchfish	This work was supported by the Wellcome Trust (programme grant 083148), the Medical Research Council (clinical research training fellowship G0802012 to GPW). The Epilepsy Society MRI scanner was supported by the Big Lottery Fund, Wolfson Trust and Epilepsy Society. This work was undertaken at UCLH/UCL, who received a proportion of funding from the Department of Health's NIHR Biomedical Research Centres funding scheme. We are grateful to the radiographers at the Epilepsy Society MRI Unit-Philippa Bartlett, Jane Burdett, and Elaine Williams-who scanned the patients and to all the patients for their kind participation.	Ahmadi ME, 2009, AM J NEURORADIOL, V30, P1740, DOI 10.3174/ajnr.A1650; Ashburner J, 2007, NEUROIMAGE, V38, P95, DOI 10.1016/j.neuroimage.2007.07.007; Astur R, 2005, APPL PSYCHOPHYS BIOF, V30, P307, DOI 10.1007/s10484-005-6385-z; Astur RS, 2004, BEHAV NEUROSCI, V118, P667, DOI 10.1037/0735-7044.118.4.667; Axmacher N, 2007, J NEUROSCI, V27, P7807, DOI 10.1523/JNEUROSCI.0962-07.2007; Axmacher N, 2009, EUR J NEUROSCI, V29, P1501, DOI 10.1111/j.1460-9568.2009.06676.x; Barch DM, 1997, NEUROPSYCHOLOGIA, V35, P1373, DOI 10.1016/S0028-3932(97)00072-9; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; Braver TS, 1997, NEUROIMAGE, V5, P49, DOI 10.1006/nimg.1996.0247; Burzynska AZ, 2011, CEREB CORTEX, V21, P2261, DOI 10.1093/cercor/bhq293; Callicott JH, 1999, CEREB CORTEX, V9, P20, DOI 10.1093/cercor/9.1.20; Carter CS, 1998, SCIENCE, V280, P747, DOI 10.1126/science.280.5364.747; CAVE CB, 1992, HIPPOCAMPUS, V2, P151, DOI 10.1002/hipo.450020207; Charlton RA, 2006, NEUROLOGY, V66, P217, DOI 10.1212/01.wnl.0000194256.15247.83; Charlton RA, 2010, CORTEX, V46, P474, DOI 10.1016/j.cortex.2009.07.005; Concha L, 2012, NEUROLOGY, V79, P455, DOI 10.1212/WNL.0b013e31826170b6; Cook PA, 2007, J MAGN RESON IMAGING, V25, P1051, DOI 10.1002/jmri.20905; CORCORAN R, 1993, CORTEX, V29, P293, DOI 10.1016/S0010-9452(13)80182-7; Cousijn H, 2012, NEUROIMAGE, V59, P1161, DOI 10.1016/j.neuroimage.2011.09.027; D'Esposito Mark, 2008, Handb Clin Neurol, V88, P237, DOI 10.1016/S0072-9752(07)88011-0; Dineen RA, 2009, BRAIN, V132, P239, DOI 10.1093/brain/awn275; Focke NK, 2008, NEUROIMAGE, V40, P728, DOI 10.1016/j.neuroimage.2007.12.031; Hampson M, 2006, J NEUROSCI, V26, P13338, DOI 10.1523/JNEUROSCI.3408-06.2006; HERMANN BP, 1988, J CLIN EXP NEUROPSYC, V10, P467, DOI 10.1080/01688638808408253; Hirono N, 1998, J NEUROL NEUROSUR PS, V64, P552, DOI 10.1136/jnnp.64.4.552; Jones DK, 2005, NEUROIMAGE, V26, P546, DOI 10.1016/j.neuroimage.2005.02.013; Karlsgodt KH, 2008, BIOL PSYCHIAT, V63, P512, DOI 10.1016/j.biopsych.2007.06.017; Karlsgodt KH, 2005, NEUROIMAGE, V25, P1224, DOI 10.1016/j.neuroimage.2005.01.038; Keller SS, 2008, EPILEPSIA, V49, P741, DOI 10.1111/j.1528-1167.2007.01485.x; Kemmotsu N, 2011, EPILEPSIA, V52, P2257, DOI 10.1111/j.1528-1167.2011.03278.x; Kennedy KM, 2009, NEUROPSYCHOLOGIA, V47, P916, DOI 10.1016/j.neuropsychologia.2009.01.001; Klingberg T, 2002, J COGNITIVE NEUROSCI, V14, P1, DOI 10.1162/089892902317205276; Klingberg T, 2006, NEUROPSYCHOLOGIA, V44, P2171, DOI 10.1016/j.neuropsychologia.2005.11.019; Koenigs M, 2009, J NEUROSCI, V29, P14980, DOI 10.1523/JNEUROSCI.3706-09.2009; Kondo H, 2004, NEUROIMAGE, V21, P2, DOI 10.1016/j.neuroimage.2003.09.046; Kumari V, 2003, NEUROIMAGE, V19, P1002, DOI 10.1016/S1053-8119(03)00110-1; Labate A, 2011, EPILEPSIA, V52, P712, DOI 10.1111/j.1528-1167.2011.03038.x; Liao W, 2011, HUM BRAIN MAPP, V32, P883, DOI 10.1002/hbm.21076; Mainy N, 2007, HUM BRAIN MAPP, V28, P183, DOI 10.1002/hbm.20264; Nagy Z, 2004, J COGNITIVE NEUROSCI, V16, P1227, DOI 10.1162/0898929041920441; Olesen PJ, 2003, COGNITIVE BRAIN RES, V18, P48, DOI 10.1016/j.cogbrainres.2003.09.003; Ostby Y, 2011, NEUROPSYCHOLOGIA, V49, P3854, DOI 10.1016/j.neuropsychologia.2011.10.001; Otte WM, 2012, EPILEPSIA, V53, P659, DOI 10.1111/j.1528-1167.2012.03426.x; Owen AM, 2005, HUM BRAIN MAPP, V25, P46, DOI 10.1002/hbm.20131; Palacios EM, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-24; Riley JD, 2010, EPILEPSIA, V51, P536, DOI 10.1111/j.1528-1167.2009.02508.x; Schon K, 2009, CEREB CORTEX, V19, P2561, DOI 10.1093/cercor/bhp006; Small DM, 2003, NEUROIMAGE, V18, P633, DOI 10.1016/S1053-8119(02)00012-5; Smith EE, 1998, P NATL ACAD SCI USA, V95, P12061, DOI 10.1073/pnas.95.20.12061; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Sperling RA, 2001, ARCH NEUROL-CHICAGO, V58, P115, DOI 10.1001/archneur.58.1.115; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; Stretton J, 2012, NEUROIMAGE, V60, P1696, DOI 10.1016/j.neuroimage.2012.01.126; Stretton J, 2012, EPILEPSY RES, V98, P1, DOI 10.1016/j.eplepsyres.2011.10.009; Takeuchi H, 2010, J NEUROSCI, V30, P3297, DOI 10.1523/JNEUROSCI.4611-09.2010; Vestergaard M, 2011, J COGNITIVE NEUROSCI, V23, P2135, DOI 10.1162/jocn.2010.21592; Vlooswijk MCG, 2011, EPILEPSIA, V52, P1467, DOI 10.1111/j.1528-1167.2011.03108.x; Wilde EA, 2011, INT J PSYCHOPHYSIOL, V82, P86, DOI 10.1016/j.ijpsycho.2011.04.006	59	35	37	1	33	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0013-9580			EPILEPSIA	Epilepsia	JUL	2013	54	7					1143	1153		10.1111/epi.12193			11	Clinical Neurology	Neurosciences & Neurology	173VP	WOS:000321110100002	23614459	Green Published, Other Gold			2021-06-18	
J	Levant, B				Levant, Beth			N-3 (Omega-3) Polyunsaturated Fatty Acids in the Pathophysiology and Treatment of Depression: Pre-Clinical Evidence	CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS			English	Article						Brain-derived neurotrophic factor; corticosterone; docosahexaenoic acid; dopamine; elevated plus maze; forced swim test; neuroimmune; serotonin	FORCED-SWIMMING TEST; TRAUMATIC BRAIN-INJURY; POSTNATAL RAT-BRAIN; DOCOSAHEXAENOIC ACID; MAJOR DEPRESSION; NEUROTROPHIC FACTOR; FEMALE RATS; OMEGA-3-FATTY-ACID DEFICIENCY; DIETARY DEFICIENCY; RECEPTOR-BINDING	A growing literature suggests the association of low tissue levels and/or dietary intake of n-polyunsaturated fatty acids (PUFA) with depressive illnesses. Animal studies show that low tissue and/or dietary n-3 PUFAs can lead to behaviors and neurobiological effects associated with depression and can potentiate the consequences of stress, whereas higher levels have the opposite effect. These data support the involvement of n-3 PUFAs levels in the disease processes underlying depression. In addition, these pre-clinical findings indicate neurobiological mechanisms whereby n-3 PUFAs may contribute to the disease including control of serotonergic and dopaminergic function, modulation of brain-derived neurotrophic factor (BDNF) in the hippocampus, regulation of the hypothalamic-pituitary-adrenal axis, and effects on neuroinflammation. This evidence for a role for n-3 PUFA in the pathophysiology and treatment of depressive illness are reviewed. The implications of these finding for future pre-clinical research and clinical application are discussed.	[Levant, Beth] Univ Kansas, Med Ctr, Dept Pharmacol Toxicol & Therapeut, Kansas City, KS 66160 USA	Levant, B (corresponding author), Univ Kansas, Med Ctr, Dept Pharmacol, MS-1018,3901 Rainbow Blvd, Kansas City, KS 66160 USA.	blevant@kumc.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 MH071599, P30 HD02528, P20 RR016475]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD002528] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20RR016475] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH071599] Funding Source: NIH RePORTER	The author thanks Heather Spalding for expert assistance in the preparation of this manuscript. Supported by NIH R01 MH071599, P30 HD02528, and P20 RR016475.	aan het Rot M, 2009, CAN MED ASSOC J, V180, P305, DOI 10.1503/cmaj.080697; Adachi M, 2008, BIOL PSYCHIAT, V63, P642, DOI 10.1016/j.biopsych.2007.09.019; Anisman H, 2009, J PSYCHIATR NEUROSCI, V34, P4; ARANGO V, 1990, ARCH GEN PSYCHIAT, V47, P1038; Ariel A, 2005, J BIOL CHEM, V280, P43079, DOI 10.1074/jbc.M509796200; Baldessarini R.J., 2001, GOODMAN GILMANS PHAR, P447; Bannenberg G, 2007, THESCIENTIFICWORLDJO, V7, P1440, DOI 10.1100/tsw.2007.188; Bannenberg GL, 2009, CURR OPIN DRUG DISC, V12, P644; Bazan NG, 2005, BRAIN PATHOL, V15, P159; Belzung C, 1998, J NUTR, V128, P1537; BESKOW J, 1976, ACTA PSYCHIAT SCAND, V53, P7, DOI 10.1111/j.1600-0447.1976.tb00054.x; BIEGON A, 1988, BRAIN RES, V442, P199, DOI 10.1016/0006-8993(88)91453-9; Birch EE, 2000, DEV MED CHILD NEUROL, V42, P174, DOI 10.1017/S0012162200000311; Bjornebekk A, 2007, NEUROREPORT, V18, P1039; Blondeau N, 2009, NEUROPSYCHOPHARMACOL, V34, P2548, DOI 10.1038/npp.2009.84; BOURRE JME, 1992, BIOCHIM BIOPHYS ACTA, V1124, P119, DOI 10.1016/0005-2760(92)90087-C; BROWN AS, 1993, J NEURAL TRANSM-GEN, V91, P75, DOI 10.1007/BF01245227; CARPENTER WT, 1971, AM J PSYCHIAT, V128, P31, DOI 10.1176/ajp.128.1.31; Carrie I, 2000, J LIPID RES, V41, P465; Carrie I, 2000, J LIPID RES, V41, P473; CARROLL BJ, 1968, LANCET, V1, P1373; CARROLL BJ, 1976, PSYCHOL MED, V6, P43, DOI 10.1017/S0033291700007480; Chalon S, 2009, NEUROPHARMACOLOGY, V57, P636, DOI 10.1016/j.neuropharm.2009.08.012; Charney D. S., 2004, SCI STKE, V2004, pre5; Chen B, 2001, BIOL PSYCHIAT, V50, P260, DOI 10.1016/S0006-3223(01)01083-6; Chen HF, 2012, J NUTR BIOCHEM, V23, P299, DOI 10.1016/j.jnutbio.2010.12.010; CLANDININ MT, 1980, EARLY HUM DEV, V4, P131, DOI 10.1016/0378-3782(80)90016-X; CLANDININ MT, 1980, EARLY HUM DEV, V4, P121, DOI 10.1016/0378-3782(80)90015-8; Clarke SD, 1999, AM J CLIN NUTR, V70, P566; Cryan JF, 2005, NEUROSCI BIOBEHAV R, V29, P547, DOI 10.1016/j.neubiorev.2005.03.008; Curtis MA, 2011, EUR J NEUROSCI, V33, P1170, DOI 10.1111/j.1460-9568.2011.07616.x; Cysneiros RM, 2010, EPILEPSY BEHAV, V17, P33, DOI 10.1016/j.yebeh.2009.11.006; Davis PF, 2010, NUTR NEUROSCI, V13, P161, DOI 10.1179/147683010X12611460764282; de Urquiza AM, 2000, SCIENCE, V290, P2140; Dean B, 2010, J AFFECT DISORDERS, V120, P245, DOI 10.1016/j.jad.2009.04.027; Delion S, 1996, J NEUROCHEM, V66, P1582; DELION S, 1994, J NUTR, V124, P2466; DeMar JC, 2006, J LIPID RES, V47, P172, DOI 10.1194/jlr.M500362-JLR200; Dinan T, 2009, J PSYCHIATR RES, V43, P471, DOI 10.1016/j.jpsychires.2008.06.003; Drevets WC, 2000, NUCL MED BIOL, V27, P499, DOI 10.1016/S0969-8051(00)00119-0; Duman R. S, 2004, NEUROBIOLOGY MENTAL, P421; Duman RS, 2006, BIOL PSYCHIAT, V59, P1116, DOI 10.1016/j.biopsych.2006.02.013; Dunlop BW, 2007, ARCH GEN PSYCHIAT, V64, P327, DOI 10.1001/archpsyc.64.3.327; Dwivedi Y, 2003, ARCH GEN PSYCHIAT, V60, P804, DOI 10.1001/archpsyc.60.8.804; Dyall SC, 2010, J NEUROSCI RES, V88, P2091, DOI 10.1002/jnr.22390; Farooqui AA, 2007, J NEUROCHEM, V101, P577, DOI 10.1111/j.1471-4159.2006.04371.x; Fedorova I, 2007, PROSTAG LEUKOTR ESS, V77, P269, DOI 10.1016/j.plefa.2007.10.013; Ferraz AC, 2011, BEHAV BRAIN RES, V219, P116, DOI 10.1016/j.bbr.2010.12.028; Ferraz AC, 2008, PROSTAG LEUKOTR ESS, V78, P183, DOI 10.1016/j.plefa.2008.02.001; FILE SE, 1997, CURRENT PROTOCOLS NE; FRANCES H, 1995, LIFE SCI, V57, P1935, DOI 10.1016/0024-3205(95)02180-Q; Frances H, 2000, NEUROSCI LETT, V285, P223, DOI 10.1016/S0304-3940(00)01065-X; Frazer A, 2005, NEUROSCI BIOBEHAV R, V29, P515, DOI 10.1016/j.neubiorev.2005.03.006; Freeman MP, 2011, J CLIN PSYCHIAT, V72, P258, DOI 10.4088/JCP.11ac06830; Gaiteri C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009970; GALLI C, 1971, BIOCHIM BIOPHYS ACTA, V248, P449, DOI 10.1016/0005-2760(71)90233-5; Garlow SJ, 2004, NEUROBIOLOGY MENTAL, P440; Geraldine M, 2010, NEUROCHEM INT, V56, P94, DOI 10.1016/j.neuint.2009.09.006; Gershon AA, 2007, BIOL PSYCHIAT, V61, P145, DOI 10.1016/j.biopsych.2006.05.031; Gordon N, 1997, BRAIN DEV-JPN, V19, P165, DOI 10.1016/S0387-7604(96)00560-8; Green P, 1996, LIPIDS, V31, P859, DOI 10.1007/BF02522981; Gronli J, 2006, PHARMACOL BIOCHEM BE, V85, P842, DOI 10.1016/j.pbb.2006.11.021; GUZE BH, 1991, PSYCHOSOMATICS, V32, P390, DOI 10.1016/S0033-3182(91)72039-2; Hannestad J, 2011, NEUROPSYCHOPHARMACOL, V36, P2452, DOI 10.1038/npp.2011.132; Harauma A, 2011, LIPIDS, V46, P409, DOI 10.1007/s11745-010-3523-z; Harvey PO, 2007, MOL PSYCHIATR, V12, P767, DOI 10.1038/sj.mp.4002021; He CW, 2009, P NATL ACAD SCI USA, V106, P11370, DOI 10.1073/pnas.0904835106; Hirvonen J, 2008, PSYCHOPHARMACOLOGY, V197, P581, DOI 10.1007/s00213-008-1088-9; Laino CH, 2010, EUR J PHARMACOL, V648, P117, DOI 10.1016/j.ejphar.2010.08.047; Horrocks LA, 2004, PROSTAG LEUKOTR ESS, V70, P361, DOI 10.1016/j.plefa.2003.12.011; Huang SY, 2008, J PSYCHIATR RES, V42, P58, DOI 10.1016/j.jpsychires.2006.09.004; INNIS SM, 1992, J PEDIATR-US, V120, pS56, DOI 10.1016/S0022-3476(05)81237-5; Innis SM, 2004, ADV EXP MED BIOL, V554, P27; Joardar A, 2006, J LIPID RES, V47, P571, DOI 10.1194/jlr.M500415-JLR200; Johnson RA, 2003, NEUROSCIENCE, V121, P1, DOI 10.1016/S0306-4522(03)00422-6; Karege F, 2005, MOL BRAIN RES, V136, P29, DOI 10.1016/j.molbrainres.2004.12.020; Kelsey JE, 1998, PHARMACOLOGICAL MANAGEMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS, P95; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; Kram ML, 2002, PROG NEURO-PSYCHOPH, V26, P639, DOI 10.1016/S0278-5846(01)00222-6; Kuperstein F, 2005, J NEUROCHEM, V95, P1550, DOI 10.1111/j.1471-4159.2005.03513.x; Kuperstein F, 2008, J NEUROCHEM, V106, P662, DOI 10.1111/j.1471-4159.2008.05418.x; Lakhwani Lalit, 2007, Acta Pol Pharm, V64, P271; Lee JY, 2003, J LIPID RES, V44, P479, DOI 10.1194/jlr.M200361-JLR200; Levant B, 2008, PSYCHONEUROENDOCRINO, V33, P1279, DOI 10.1016/j.psyneuen.2008.06.012; Levant B, 2007, J NUTR, V137, P130; Levant B, 2006, LIPIDS, V41, P407, DOI 10.1007/s11745-006-5114-6; Levant B, 2006, J NUTR, V136, P2236; Levant B, 2010, PHYSIOL BEHAV, V101, P176, DOI 10.1016/j.physbeh.2010.04.038; Lloyd K G, 1974, Adv Biochem Psychopharmacol, V11, P387; Lu DY, 2010, NEUROPSYCHOPHARMACOL, V35, P2238, DOI 10.1038/npp.2010.98; Maes M, 2009, METAB BRAIN DIS, V24, P27, DOI 10.1007/s11011-008-9118-1; Makrides M, 2010, NESTLE NUTR WORKS SE, V65, P123, DOI 10.1159/000281154; Mann J. J., 1999, NEUROBIOLOGY MENTAL, P385; Mathieu G, 2008, PROSTAG LEUKOTR ESS, V78, P391, DOI 10.1016/j.plefa.2008.05.003; Mathieu G, 2011, PROSTAG LEUKOTR ESS, V85, P129, DOI 10.1016/j.plefa.2011.07.001; McNamara RK, 2008, SYNAPSE, V62, P725, DOI 10.1002/syn.20542; McNamara RK, 2007, BIOL PSYCHIAT, V62, P17, DOI 10.1016/j.biopsych.2006.08.026; McNamara RK, 2006, PROSTAG LEUKOTR ESS, V75, P329, DOI 10.1016/j.plefa.2006.07.010; McNamara RK, 2010, PROSTAG LEUKOTR ESS, V83, P185, DOI 10.1016/j.plefa.2010.08.004; McNamara RK, 2009, PROSTAG LEUKOTR ESS, V81, P223, DOI 10.1016/j.plefa.2009.05.017; McNamara RK, 2009, J PSYCHIATR RES, V43, P656, DOI 10.1016/j.jpsychires.2008.09.011; Miller AH, 2009, BIOL PSYCHIAT, V65, P732, DOI 10.1016/j.biopsych.2008.11.029; MONROE SM, 1991, PSYCHOL BULL, V110, P406, DOI 10.1037/0033-2909.110.3.406; Moriguchi T, 2000, J NEUROCHEM, V75, P2563, DOI 10.1046/j.1471-4159.2000.0752563.x; Moses-Kolko EL, 2012, NEUROPSYCHOPHARMACOL, V37, P1422, DOI 10.1038/npp.2011.328; NAKASHIMA Y, 1993, J LIPID RES, V34, P239; Naliwaiko K, 2004, NUTR NEUROSCI, V7, P91, DOI 10.1080/10284150410001704525; NEMEROFF CB, 1984, SCIENCE, V226, P1342, DOI 10.1126/science.6334362; Nestler EJ, 2006, BIOL PSYCHIAT, V59, P1151, DOI 10.1016/j.biopsych.2005.09.018; NIBUYA M, 1995, J NEUROSCI, V15, P7539; Owens SD, 1999, J NUTR, V129, P2088; PAPP M, 1994, PSYCHOPHARMACOLOGY, V115, P441, DOI 10.1007/BF02245566; PAPP M, 1991, PSYCHOPHARMACOLOGY, V104, P255, DOI 10.1007/BF02244188; Pariante CM, 2001, BIOL PSYCHIAT, V49, P391, DOI 10.1016/S0006-3223(00)01088-X; Park Y, 2012, J NUTR BIOCHEM, V23, P924, DOI 10.1016/j.jnutbio.2011.04.018; Pascual G, 2005, NATURE, V437, P759, DOI 10.1038/nature03988; Pliakas AM, 2001, J NEUROSCI, V21, P7397, DOI 10.1523/JNEUROSCI.21-18-07397.2001; POST RM, 1973, AM J PSYCHIAT, V130, P67, DOI 10.1176/ajp.130.1.67; REDDY PL, 1992, BIOL PSYCHIAT, V31, P112; ROY A, 1992, ARCH GEN PSYCHIAT, V49, P447; Salem N, 2001, LIPIDS, V36, P945, DOI 10.1007/s11745-001-0805-6; Sapolsky RM, 2000, BIOL PSYCHIAT, V48, P755, DOI 10.1016/S0006-3223(00)00971-9; Sargent PA, 2000, ARCH GEN PSYCHIAT, V57, P174, DOI 10.1001/archpsyc.57.2.174; Savitz J, 2009, PROG NEUROBIOL, V88, P17, DOI 10.1016/j.pneurobio.2009.01.009; Schmidt HD, 2011, NEUROPSYCHOPHARMACOL, V36, P2375, DOI 10.1038/npp.2011.151; SHAW DM, 1967, BRIT J PSYCHIAT, V113, P1407, DOI 10.1192/bjp.113.505.1407; Sheline YI, 1996, P NATL ACAD SCI USA, V93, P3908, DOI 10.1073/pnas.93.9.3908; Shelton RC, 2011, MOL PSYCHIATR, V16, P751, DOI 10.1038/mp.2010.52; Shirayama Y, 2002, J NEUROSCI, V22, P3251, DOI 10.1523/JNEUROSCI.22-08-03251.2002; Simopoulos AP, 2002, BIOMED PHARMACOTHER, V56, P365, DOI 10.1016/S0753-3322(02)00253-6; SINCLAIR AJ, 1975, P NUTR SOC, V34, P287, DOI 10.1079/PNS19750051; Siuciak JA, 1997, PHARMACOL BIOCHEM BE, V56, P131, DOI 10.1016/S0091-3057(96)00169-4; SMITH MA, 1995, ENDOCRINOLOGY, V136, P3743, DOI 10.1210/en.136.9.3743; Song C, 2004, STRESS, V7, P43, DOI 10.1080/10253890410001667188; Sprecher H, 2000, BBA-MOL CELL BIOL L, V1486, P219, DOI 10.1016/S1388-1981(00)00077-9; Stillwell W, 2005, REPROD NUTR DEV, V45, P559, DOI 10.1051/rnd:2005046; Stockmeier CA, 2003, J PSYCHIAT RES, V37, P357, DOI 10.1016/S0022-3956(03)00050-5; Takeuchi T, 2003, BRAIN RES, V964, P136, DOI 10.1016/S0006-8993(02)04113-6; Takeuchi T, 2002, BEHAV BRAIN RES, V131, P193, DOI 10.1016/S0166-4328(01)00392-8; Tonelli LH, 2008, ACTA PSYCHIAT SCAND, V117, P198, DOI 10.1111/j.1600-0447.2007.01128.x; Trofimiuk E, 2011, LIPIDS, V46, P417, DOI 10.1007/s11745-011-3551-3; Van Praag HM, 1975, PSYCHOL MED, V4, P21; Vancassel S, 2008, J LIPID RES, V49, P340, DOI 10.1194/jlr.M700328-JLR200; Venna VR, 2009, PSYCHONEUROENDOCRINO, V34, P199, DOI 10.1016/j.psyneuen.2008.08.025; Vetulani J, 1975, NATURE, V22, P181; Vines A, 2012, NEUROPHARMACOLOGY, V62, P184, DOI 10.1016/j.neuropharm.2011.06.017; Willatts P, 1998, LIPIDS, V33, P973, DOI 10.1007/s11745-998-0294-7; Wu A, 2004, J NEUROTRAUM, V21, P1457, DOI 10.1089/neu.2004.21.1457; Wu AG, 2007, J NEUROTRAUM, V24, P1587, DOI 10.1089/neu.2007.0313; Xiao Y, 2005, BRIT J NUTR, V94, P544, DOI 10.1079/BJN20051539; YATES M, 1990, BIOL PSYCHIAT, V27, P489, DOI 10.1016/0006-3223(90)90440-D; YATES M, 1990, J PSYCHOPHARMACOL, V4, P59; Zimmer L, 2000, J LIPID RES, V41, P32; Zimmer L, 1998, NEUROSCI LETT, V240, P177, DOI 10.1016/S0304-3940(97)00938-5; Zimmer L, 2002, AM J CLIN NUTR, V75, P662	155	35	37	2	34	BENTHAM SCIENCE PUBL	BUSUM	PO BOX 294, BUSUM, 1400 AG, NETHERLANDS	1871-5273	1996-3181		CNS NEUROL DISORD-DR	CNS Neurol. Disord.-Drug Targets	JUN	2013	12	4					450	459		10.2174/1871527311312040003			10	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	173UY	WOS:000321108000003	23574159	Green Accepted			2021-06-18	
J	Post, A; Oeur, A; Hoshizaki, B; Gilchrist, MD				Post, Andrew; Oeur, Anna; Hoshizaki, Blaine; Gilchrist, Michael D.			Examination of the relationship between peak linear and angular accelerations to brain deformation metrics in hockey helmet impacts	COMPUTER METHODS IN BIOMECHANICS AND BIOMEDICAL ENGINEERING			English	Article						neurotrauma; impact biomechanics; concussion; ice hockey	HEAD; INJURY; BIOMECHANICS; MODEL	Ice hockey is a contact sport which has a high incidence of brain injury. The current methods of evaluating protective devices use peak resultant linear acceleration as their pass/fail criteria, which are not fully representative of brain injuries as a whole. The purpose of this study was to examine how the linear and angular acceleration loading curves from a helmeted impact influence currently used brain deformation injury metrics. A helmeted Hybrid III headform was impacted in five centric and non-centric impact sites to elicit linear and angular acceleration responses. These responses were examined through the use of a brain model. The results indicated that when the helmet is examined using peak resultant linear acceleration alone, they are similar and protective, but when a 3D brain deformation response is used to examine the helmets, there are risks of brain injury with lower linear accelerations which would pass standard certifications for safety.	[Post, Andrew; Oeur, Anna; Hoshizaki, Blaine] Univ Ottawa, Sch Human Kinet, Ottawa, ON K1N 6N5, Canada; [Gilchrist, Michael D.] Univ Coll Dublin Belfield, Sch Mech & Mat Engn, Dublin 4, Ireland	Post, A (corresponding author), Univ Ottawa, Sch Human Kinet, 200 Lees Ave,Room A106, Ottawa, ON K1N 6N5, Canada.	apost@uottawa.ca; aoeur016@uottawa.ca; thoshiza@uottawa.ca; Michael.gilchrist@ucd.ie	Gilchrist, Michael D/B-6100-2017	Gilchrist, Michael D/0000-0003-1765-429X; Post, Andrew/0000-0002-5960-5552			Adams J H, 1983, Acta Neurochir Suppl (Wien), V32, P15; Anderson RWG, 1999, P INT IRCOBI C BIOM, P107; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bandak F.A., 1994, 38 STAPP CAR CRASH C, P145; Canadian Standard Association, 2009, Z262109200938 CANCSA, P38; CHALUPNIK JD, 1971, 7111 ME U WASH; Doorly M. C., 2006, Computer Methods in Biomechanics and Biomedical Engineering, V9, P371, DOI 10.1080/10255840601003551; Foreman S, 2010, INFLUENCE HEADFORM G; Gasquoine PG, 1997, NEUROPSYCHOL REV, V7, P77, DOI 10.1023/B:NERV.0000005945.58251.c0; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gimbel G, 2008, INT J SPORT SCI ENG, V2, P154; Gimbel GM, 2008, EUR J SPORT SCI, V8, P341, DOI 10.1080/17461390802438763; GURDJIAN ES, 1975, SURG GYNECOL OBSTET, V140, P845; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hardy WN, 2001, STAPP CAR CRASH J; Holbourn AHS, 1943, LANCET, V2, P438; Horgan TJ, 2004, INT J CRASHWORTHINES, V9, P401, DOI 10.1533/ijcr.2004.0299; Horgan TJ, 2003, INT J CRASHWORTHINES, V8, P353, DOI 10.1533/cras.8.4.353.19278; Hoshizaki TB, 2004, NEUROSURGERY, V55, P956, DOI 10.1227/01.NEU.0000137275.50246.0B; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; LEE MC, 1989, J BIOMECH, V22, P537, DOI 10.1016/0021-9290(89)90005-5; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Monson KL, 2003, J BIOMECH ENG-T ASME, V125, P288, DOI 10.1115/1.1554412; Nahum AM, 1977, P 21 STAPP CRASH C; Ommaya AK, 1967, P 11 STAPP CAR CRASH, P670906; PADGAONKAR AJ, 1975, J APPL MECH-T ASME, V42, P552, DOI 10.1115/1.3423640; Prange MT, 2002, P 44 STAPP CAR CRASH; Rousseau P, 2009, P I MECH ENG P-J SPO, V223, P159, DOI 10.1243/17543371JSET36; Rousseau P, 2009, P I MECH ENG P-J SPO, V223, P89, DOI 10.1243/17543371JSET34; Rousseau P, 2009, AM SOC TEST MATER, V1516, P152, DOI 10.1520/JAI101877; Rueda MAF, 2011, COMPUT METHOD BIOMEC, V14, P1021, DOI 10.1080/10255842.2010.504922; Rueda MAF, 2010, INJURY, V41, P533, DOI 10.1016/j.injury.2009.05.009; Schreiber DI, 1997, P 41 STAPP CAR CRASH; THOMAS LM, 1966, J NEUROL NEUROSUR PS, V29, P404, DOI 10.1136/jnnp.29.5.404; UENO K, 1995, J BIOMECH ENG-T ASME, V117, P319, DOI 10.1115/1.2794187; Walsh ES, 2011, SPORTS ENG, V13, P135, DOI 10.1007/s12283-011-0060-9; Wennberg RA, 2003, CAN J NEUROL SCI, V30, P206, DOI 10.1017/S0317167100002596; Willinger R, 2003, INT J VEHICLE DES, V32, P94, DOI 10.1504/IJVD.2003.003239; Yoganandan N, 2004, CLIN BIOMECH, V19, P225, DOI 10.1016/j.clinbiomech.2003.12.014; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhang LY, 2001, NEUROL RES, V23, P144, DOI 10.1179/016164101101198488	41	35	35	0	25	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1025-5842	1476-8259		COMPUT METHOD BIOMEC	Comput. Methods Biomech. Biomed. Eng.	MAY 1	2013	16	5					511	519		10.1080/10255842.2011.627559			9	Computer Science, Interdisciplinary Applications; Engineering, Biomedical	Computer Science; Engineering	146RH	WOS:000319107700006	22185521				2021-06-18	
J	Yan, ZJ; Zhang, P; Hu, YQ; Zhang, HT; Hong, SQ; Zhou, HL; Zhang, MY; Xu, RX				Yan, Zhong-Jie; Zhang, Peng; Hu, Yu-Qin; Zhang, Hong-Tian; Hong, Sun-Quan; Zhou, Hong-Long; Zhang, Mao-Ying; Xu, Ru-Xiang			Neural Stem-Like Cells Derived from Human Amnion Tissue are Effective in Treating Traumatic Brain Injury in Rat	NEUROCHEMICAL RESEARCH			English	Article						Amnion; Neural differentiation; Neural stem cells; Transplantation; Traumatic brain injury	NEUROTROPHIC FACTORS; PROGENITOR CELLS; MESENCHYMAL CELLS; CORD BLOOD; TRANSPLANTATION; EXPRESSION; DEFICITS; MODEL; DIFFERENTIATION; MEMBRANE	Although human amnion derived mesenchymal stem cells (AMSC) are a promising source of stem cells, their therapeutic potential for traumatic brain injury (TBI) has not been widely investigated. In this study, we evaluated the therapeutic potential of AMSC using a rat TBI model. AMSC were isolated from human amniotic membrane and characterized by flow cytometry. After induction, AMSC differentiated in vitro into neural stem-like cells (AM-NSC) that expressed higher levels of the neural stem cell markers, nestin, sox2 and musashi, in comparison to undifferentiated AMSC. Interestingly, the neurotrophic factors, brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), neurotrophin 3 (NT-3), glial cell derived neurotrophic factor (GDNF) and ciliary neurotrophic factor (CNTF) were markedly upregulated after neural stem cell induction. Following transplantation in a rat TBI model, significant improvements in neurological function, brain tissue morphology, and higher levels of BDNF, NGF, NT-3, GDNF and CNTF, were observed in the AM-NSC group compared with the AMSC and Matrigel groups. However, few grafted cells survived with minimal differentiation into neural-like cells. Together, our results suggest that transplantation of AM-NSC promotes functional rehabilitation of rats with TBI, with enhanced expression of neurotrophic factors a likely mechanistic pathway.	[Yan, Zhong-Jie; Zhang, Peng; Hong, Sun-Quan; Zhou, Hong-Long; Zhang, Mao-Ying] Southern Med Univ, Zhujiang Hosp, Inst Neurosurg, Key Lab Brain Funct Repair & Regenerat Guangdong, Guangzhou 510282, Guangdong, Peoples R China; [Yan, Zhong-Jie; Zhang, Peng; Zhang, Hong-Tian; Zhou, Hong-Long; Zhang, Mao-Ying; Xu, Ru-Xiang] Southern Med Univ, Bayi Clin Med Inst, Mil Gen Hosp Beijing PLA, Affiliated Bayi Brain Hosp, Beijing 100700, Peoples R China; [Hu, Yu-Qin] Southern Med Univ, Affiliated Hexian Mem Hosp, Dept Gynecol & Obstet, Guangzhou 511400, Guangdong, Peoples R China	Xu, RX (corresponding author), Southern Med Univ, Bayi Clin Med Inst, Mil Gen Hosp Beijing PLA, Affiliated Bayi Brain Hosp, Beijing 100700, Peoples R China.	xuruxiang_neuron@126.com			Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [U0632008, 81100916]	We thank Health & Biotech (Guangdong, Guangzhou, China) for their kindly presenting human amnion derived mesenchymal stem cells. This research was supported by the Natural Science Foundation of China (U0632008, 81100916).	ABERCROMBIE M, 1946, ANAT REC, V94, P239, DOI 10.1002/ar.1090940210; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Chang YJ, 2010, CELLS TISSUES ORGANS, V192, P93, DOI 10.1159/000295774; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Chen Q, 2005, J NEUROSCI RES, V80, P611, DOI 10.1002/jnr.20494; Ellis P, 2004, DEV NEUROSCI-BASEL, V26, P148, DOI 10.1159/000082134; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Fisher-Shoval Y, 2012, J MOL NEUROSCI, V48, P176, DOI 10.1007/s12031-012-9805-6; Fukuchi Y, 2004, STEM CELLS, V22, P649, DOI 10.1634/stemcells.22-5-649; Gao JL, 2006, EXP NEUROL, V201, P281, DOI 10.1016/j.expneurol.2006.04.039; Gogel S, 2011, GENE THER, V18, P1, DOI 10.1038/gt.2010.130; Hains BC, 2004, EXP NEUROL, V188, P365, DOI 10.1016/j.expneurol.2004.04.001; Hayase M, 2009, J CEREBR BLOOD F MET, V29, P1409, DOI 10.1038/jcbfm.2009.62; Hermann A, 2004, J CELL SCI, V117, P4411, DOI 10.1242/jcs.01307; Jiang JJ, 2010, NEUROSCI RES, V66, P46, DOI 10.1016/j.neures.2009.09.1711; Kaneko Y, 2000, DEV NEUROSCI-BASEL, V22, P139, DOI 10.1159/000017435; Kaplan GB, 2010, BEHAV PHARMACOL, V21, P427, DOI 10.1097/FBP.0b013e32833d8bc9; Kim HJ, 2010, J NEUROTRAUM, V27, P131, DOI [10.1089/neu.2008.0818, 10.1089/neu.2008-0818]; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Lu P, 2003, EXP NEUROL, V181, P115, DOI 10.1016/S0014-4886(03)00037-2; Magatti M, 2009, CELL TRANSPLANT, V18, P899, DOI 10.3727/096368909X471314; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; MOCCHETTI I, 1995, J NEUROTRAUM, V12, P853, DOI 10.1089/neu.1995.12.853; Nakajima K, 2001, BRAIN RES, V916, P76, DOI 10.1016/S0006-8993(01)02866-9; PAXINOS G, 2005, RAT BRAIN STEREOTAXI, P98; Poltavtseva RA, 2012, B EXP BIOL MED+, V153, P586, DOI 10.1007/s10517-012-1772-y; Qian DX, 2010, NEUROCHEM RES, V35, P572, DOI 10.1007/s11064-009-0101-y; Riess P, 2007, J NEUROTRAUM, V24, P216, DOI 10.1089/neu.2006.0141; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Soncini M, 2007, J TISSUE ENG REGEN M, V1, P296, DOI 10.1002/term.40; Tao J, 2012, BRAIN RES, V1448, P1, DOI 10.1016/j.brainres.2012.01.069; Tsai MS, 2007, STEM CELLS, V25, P2511, DOI 10.1634/stemcells.2007-0023; Tsuji H, 2010, CIRC RES, V106, P1613, DOI 10.1161/CIRCRESAHA.109.205260; Warrier S, 2012, PLACENTA, V33, P850, DOI 10.1016/j.placenta.2012.07.001; Wennersten A, 2004, J NEUROSURG, V100, P88, DOI 10.3171/jns.2004.100.1.0088; Yaghoobi MM, 2008, BRAIN RES, V1203, P26, DOI 10.1016/j.brainres.2008.01.086; Yen BL, 2005, STEM CELLS, V23, P3, DOI 10.1634/stemcells.2004-0098; Zhang HT, 2009, NEUROSCI LETT, V458, P116, DOI 10.1016/j.neulet.2009.04.045; Zhang L, 2009, NEUROCHEM RES, V34, P2030, DOI 10.1007/s11064-009-9992-x; Zhu RS, 2007, J NEUROSCI RES, V85, P3064, DOI 10.1002/jnr.21426	40	35	37	1	22	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190	1573-6903		NEUROCHEM RES	Neurochem. Res.	MAY	2013	38	5					1022	1033		10.1007/s11064-013-1012-5			12	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	116SO	WOS:000316903200014	23475428				2021-06-18	
J	Kotchoubey, B; Merz, S; Lang, S; Markl, A; Muller, F; Yu, T; Schwarzbauer, C				Kotchoubey, Boris; Merz, Susanne; Lang, Simone; Markl, Alexandra; Mueller, Friedemann; Yu, Tao; Schwarzbauer, Christian			Global functional connectivity reveals highly significant differences between the vegetative and the minimally conscious state	JOURNAL OF NEUROLOGY			English	Article						Traumatic brain injury; Anoxic brain injury; Coma; Consciousness; Functional connectivity; Unresponsive wakefulness syndrome	CORTICAL CONNECTIVITY; EMPATHY; RECOVERY; PAIN; FMRI	A major challenge in the diagnosis of disorders of consciousness is the differential diagnosis between the vegetative state (VS) and the minimally conscious state (MCS). Clinically, VS is defined by complete unawareness, whereas MCS is defined by the presence of inconsistent but clearly discernible behavioural signs of consciousness. In healthy individuals, pain cries have been reported to elicit functional activation within the pain matrix of the brain, which may be interpreted as empathic reaction. In this study, pain cries were presented to six VS patients, six MCS patients, and 17 age-matched healthy controls. Conventional task-related functional magnetic resonance imaging (fMRI) showed no significant differences in functional activation between the VS and MCS groups. In contrast to this negative finding, the application of a novel data-driven technique for the analysis of the brain's global functional connectivity yielded a positive result. The weighted global connectivity (WGC) was significantly greater in the MCS group compared to the VS group (p < 0.05, family-wise error corrected). Using areas of significant WGC differences as 'seed regions' in a secondary connectivity analysis revealed extended functional networks in both MCS and healthy groups, whereas no such long-range functional connections were observed in the VS group. These results demonstrate the potential of functional connectivity MRI (fcMRI) as a clinical tool for differential diagnosis in disorders of consciousness.	[Kotchoubey, Boris; Markl, Alexandra; Yu, Tao] Univ Tubingen, Inst Med Psychol & Behav Neurobiol, Tubingen, Germany; [Merz, Susanne; Schwarzbauer, Christian] Univ Aberdeen, Aberdeen Coma Sci Grp, Aberdeen AB25 2ZD, Scotland; [Lang, Simone] Heidelberg Univ, Inst Psychol, Dept Clin Psychol & Psychotherapy, Heidelberg, Germany; [Markl, Alexandra; Mueller, Friedemann] Schon Klin, Bad Aibling, Germany	Schwarzbauer, C (corresponding author), Univ Aberdeen, Aberdeen Coma Sci Grp, Lilian Sutton Bldg,Foresterhill, Aberdeen AB25 2ZD, Scotland.	c.schwarzbauer@abdn.ac.uk		Merz, Susanne/0000-0001-8638-0267	Chief Scientist Office of Scotland; Scottish Funding Council (SFC) through the SINAPSE initiative (Scottish Imaging Network: A Platform for Scientific Excellence); German Research Society (Deutsche Forschungsgemeinschaft, DFG)German Research Foundation (DFG); European UnionEuropean Commission; Chief Scientist Office [ETM/127] Funding Source: researchfish	CS would like to thank the Chief Scientist Office of Scotland for partly funding this research. SM and CS acknowledge the support of the Scottish Funding Council (SFC) through the SINAPSE initiative (Scottish Imaging Network: A Platform for Scientific Excellence; http://www.sinapse.ac.uk). BK, SL, AM, FM and TY were supported by the German Research Society (Deutsche Forschungsgemeinschaft, DFG). In addition BK acknowledges the support from the European Union (Grant DECODER).	Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; Avenanti A, 2005, NAT NEUROSCI, V8, P955, DOI 10.1038/nn1481; Baars B J, 1997, THEATER CONSCIOUSNES; Baars BJ., 1988, COGNITIVE THEORY CON; Bekinschtein TA, 2009, NAT NEUROSCI, V12, P1343, DOI 10.1038/nn.2391; Benuzzi F, 2008, J NEUROSCI, V28, P923, DOI 10.1523/JNEUROSCI.4012-07.2008; Block N, 2007, BEHAV BRAIN SCI, V30, P481, DOI 10.1017/S0140525X07002786; Boly M, 2008, ANN NY ACAD SCI, V1129, P119, DOI 10.1196/annals.1417.015; Boly M, 2004, ARCH NEUROL-CHICAGO, V61, P233, DOI 10.1001/archneur.61.2.233; Boly M, 2009, HUM BRAIN MAPP, V30, P2393, DOI 10.1002/hbm.20672; Boly M, 2011, SCIENCE, V332, P858, DOI 10.1126/science.1202043; Bradley M. M., 1999, B2 U FLOR CTR RES PS; Brooks J, 2005, TCE-THE CHEM ENG, P19; Calhoun VD, 2012, NEUROIMAGE, V59, P25, DOI 10.1016/j.neuroimage.2011.06.037; Cole MW, 2010, NEUROIMAGE, V49, P3132, DOI 10.1016/j.neuroimage.2009.11.001; Dam~asio A., 1999, FEELING WHAT HAPPENS; Dehaene S, 2006, TRENDS COGN SCI, V10, P204, DOI 10.1016/j.tics.2006.03.007; Friston K., 1995, HUM BRAIN MAPP, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Gu XS, 2007, NEUROIMAGE, V36, P256, DOI 10.1016/j.neuroimage.2007.02.025; Kotchoubey B, 2011, ADV CLIN NEUROSCI RE, V11, P10; Kotchoubey B., 2009, ENCY NEUROSCIENCE, P61, DOI [10.1016/B978-008045046-9.00620-3, DOI 10.1016/B978-008045046-9.00620-3]; Lang S, 2011, COGN AFFECT BEHAV NE, V11, P386, DOI 10.3758/s13415-011-0035-0; Laureys S, 2005, NAT REV NEUROSCI, V6, P899, DOI 10.1038/nrn1789; Laureys S, 1999, NEUROIMAGE, V9, P377, DOI 10.1006/nimg.1998.0414; Laureys S, 2002, NEUROIMAGE, V17, P732, DOI 10.1006/nimg.2002.1236; Laureys S, 2000, LANCET, V355, P1790, DOI 10.1016/S0140-6736(00)02271-6; Lohmann G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010232; Moriguchi Y, 2007, CEREB CORTEX, V17, P2223, DOI 10.1093/cercor/bhl130; Moulton EA, 2010, BRAIN RES REV, V65, P14, DOI 10.1016/j.brainresrev.2010.05.005; Nichols T, 2003, STAT METHODS MED RES, V12, P419, DOI 10.1191/0962280203sm341ra; Nichols TE, 2002, HUM BRAIN MAPP, V15, P1, DOI 10.1002/hbm.1058; Panksepp J, 2005, CONSCIOUS COGN, V14, P30, DOI 10.1016/j.concog.2004.10.004; Peltier SJ, 2005, NEUROREPORT, V16, P285, DOI 10.1097/00001756-200502280-00017; Perrin JS, 2012, P NATL ACAD SCI USA, V109, P5464, DOI 10.1073/pnas.1117206109; Sander K, 2007, HUM BRAIN MAPP, V28, P1007, DOI 10.1002/hbm.20333; Schnakers C, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-35; Singer T, 2004, SCIENCE, V303, P1157, DOI 10.1126/science.1093535; Tononi G, 2008, BIOL BULL-US, V215, P216, DOI 10.2307/25470707	40	35	35	0	14	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0340-5354	1432-1459		J NEUROL	J. Neurol.	APR	2013	260	4					975	983		10.1007/s00415-012-6734-9			9	Clinical Neurology	Neurosciences & Neurology	122XM	WOS:000317351900004	23128970				2021-06-18	
J	Levin, HS; Robertson, CS				Levin, Harvey S.; Robertson, Claudia S.			Mild Traumatic Brain Injury in Translation	JOURNAL OF NEUROTRAUMA			English	Article						adult brain injury; military injury; traumatic brain injury	FLUID PERCUSSION INJURY; DIFFUSE AXONAL INJURY; HEAD-INJURY; MOUSE MODEL; IMPACT; ENCEPHALOPATHY; RATS; PATHOPHYSIOLOGY; MAGNITUDE; PATHOLOGY	This Introduction to a Special Issue on Mild Traumatic Brain Injury (mTBI) highlights the methodological challenges in outcome studies and clinical trials involving patients who sustain mTBI. Recent advances in brain imaging and portable, computerized cognitive tasks have contributed to protocols that are sensitive to the effects of mTBI and efficient in time for completion. Investigation of civilian mTBI has been extended to single and repeated injuries in athletes and blast-related mTBI in service members and veterans. Despite differences in mechanism of injury, there is evidence for similar effects of acceleration-deceleration and blast mechanisms of mTBI on cognition. Investigation of repetitive mTBI suggests that the effects may be cumulative and that repeated mTBI and repeated subconcussive head trauma may lead to neurodegenerative conditions. Although animal models of mTBI using cortical impact and fluid percussion injury in rodents have been able to reproduce some of the cognitive deficits frequently exhibited by patients after mTBI, modeling post-concussion symptoms is difficult. Recent use of closed head and blast injury animal models may more closely approximate clinical mTBI. Translation of interventions that are developed in animal models to patients with mTBI is a priority for the research agenda. This Special Issue on mTBI integrates basic neuroscience studies using animal models with studies of human mTBI, including the cognitive sequelae, persisting symptoms, brain imaging, and host factors that facilitate recovery.	[Levin, Harvey S.] Michael E DeBakey VA Med Ctr, Dept Vet Affairs, Neurorehabil Neurons Networks Traumat Brain Injur, Houston, TX USA; [Levin, Harvey S.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Robertson, Claudia S.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA	Levin, HS (corresponding author), Baylor Coll Med, Dept Phys Med & Rehabil, 1709 Dryden Rd,Suite 1200, Houston, TX 77030 USA.	hlevin@bcm.edu			National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5P01NS056202]; Department of Defense (Post-Traumatic Stress Disorder and Traumatic Brain Injury (PTSD/TBI) Research Program) [W81XWH-08-2-0133 PT074693P2]; Center of Excellence for Traumatic Brain Injury Award from the Department of Veterans Affairs [26244]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS056202] Funding Source: NIH RePORTER	This research was supported by Grant 5P01NS056202 from the National Institute of Neurological Disorders and Stroke, by award W81XWH-08-2-0133 PT074693P2 from the Department of Defense (Post-Traumatic Stress Disorder and Traumatic Brain Injury (PTSD/TBI) Research Program), and award 26244 from The Center of Excellence for Traumatic Brain Injury Award from the Department of Veterans Affairs. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Neurological Disorders and Stroke, the National Institutes of Health, the Department of Veterans Affairs, or the Department of Defense.	Alder J, 2011, JOVE-J VIS EXP, DOI 10.3791/3063; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Baki SGA, 2009, BRAIN RES, V1280, P98, DOI 10.1016/j.brainres.2009.05.034; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Boake C, 2005, NEUROSURGERY, V56, P994, DOI 10.1227/01.NEU.0000158319.38230.C3; Browne KD, 2011, J NEUROTRAUM, V28, P1747, DOI 10.1089/neu.2011.1913; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Crisco JJ, 2012, J APPL BIOMECH, V28, P174, DOI 10.1123/jab.28.2.174; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Faul M.D., 2010, TRAUMATIC BRAIN INJU; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Gao XA, 2011, J NEUROPATH EXP NEUR, V70, P183, DOI 10.1097/NEN.0b013e31820c6878; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; GRONWALL D, 1975, LANCET, V2, P995; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Hosseini AH, 2009, MED SCI SPORT EXER, V41, P1687, DOI 10.1249/MSS.0b013e31819fcd1b; IOM (Institute of Medicine), 2009, LONG TERM CONS TRAUM, V7; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Kamnaksh A, 2011, J NEUROTRAUM, V28, P2145, DOI 10.1089/neu.2011.1983; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Learoyd AE, 2012, BEHAV BRAIN RES, V226, P197, DOI 10.1016/j.bbr.2011.09.016; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Levin HS, 2005, ARCH GEN PSYCHIAT, V62, P523, DOI 10.1001/archpsyc.62.5.523; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Mayer AR, 2012, BRAIN IMAGING BEHAV, V6, P343, DOI 10.1007/s11682-012-9178-z; McAllister TW, 2012, NEUROLOGY, V78, P1777, DOI 10.1212/WNL.0b013e3182582fe7; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McNamara KCS, 2010, J NEUROTRAUM, V27, P695, DOI 10.1089/neu.2009.1237; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Morey R.A., 2012, HUM BRAIN MAPP; O'Connor WT, 2011, PHARMACOL THERAPEUT, V130, P106, DOI 10.1016/j.pharmthera.2011.01.001; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Shultz SR, 2011, BEHAV BRAIN RES, V224, P326, DOI 10.1016/j.bbr.2011.06.012; Slobounov SM, 2010, EXP BRAIN RES, V202, P341, DOI 10.1007/s00221-009-2141-6; Spain A, 2010, J NEUROTRAUM, V27, P1429, DOI 10.1089/neu.2010.1288; Stern Sarah, 2011, Emerg Nurse, V18, P28; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Walsh JM, 2005, ACCIDENT ANAL PREV, V37, P894, DOI 10.1016/j.aap.2005.04.013; Wang ZQ, 2012, EUR J RADIOL, V81, P277, DOI 10.1016/j.ejrad.2010.12.044; White T, 2009, PSYCHIAT RES-NEUROIM, V174, P110, DOI 10.1016/j.pscychresns.2009.04.014; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Yu SJ, 2009, BRAIN RES, V1287, P157, DOI 10.1016/j.brainres.2009.06.067; Zohar O, 2011, ACTA NEUROBIOL EXP, V71, P36; Zouridakis G, 2012, J MECH MED BIOL, V12, DOI 10.1142/S0219519412400064	66	35	37	0	32	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2013	30	8			SI		610	617		10.1089/neu.2012.2394			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	133PO	WOS:000318151500002	23046349	Green Published			2021-06-18	
J	Spitz, G; Schonberger, M; Ponsford, J				Spitz, Gershon; Schoenberger, Michael; Ponsford, Jennie			The Relations Among Cognitive Impairment, Coping Style, and Emotional Adjustment Following Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						anxiety; brain injury; cognition; coping; depression; neuropsychology	CLOSED-HEAD-INJURY; QUALITY-OF-LIFE; POSTTRAUMATIC-STRESS-DISORDER; PSYCHIATRIC-DISORDERS; SOCIAL SUPPORT; STRATEGIES; RECOVERY; REHABILITATION; APPRAISAL; SYMPTOMS	Objective: To examine the direct, mediated, and moderated associations among cognition, coping, and emotional adjustment following traumatic brain injury (TBI). Design: Cross-sectional, single-group design. Participants: Ninety-seven participants with mild to severe TBI recruited from their rehabilitation hospital and assessed on average 19 months postinjury. Measures: The BIRT Memory and Information Processing Battery, Doors Test from the Doors and People Test, Hayling Sentence Completion Test, Controlled Oral Word Association Test, Trail Making Test, Digit Span, Symbol Digit Modalities Test-Oral Version, Hospital Anxiety and Depression Scale, and the Coping Scale for Adults. Results: Poorer performance on measures of memory, executive functions, and attention and information processing was associated with greater levels of self-reported depression and anxiety. No mediated relation was found between cognition and emotional adjustment. However, the use of adaptive coping strategies was found to moderate the relation between the Hayling A-a measure of information processing speed-and self-reported depression. Conclusions: Greater impairments in cognition directly predicted higher levels of anxiety and depression following TBI. In addition, the results suggest that the use of adaptive coping strategies has a greater effect on levels of depression for individuals with poor information processing speed.	[Spitz, Gershon; Schoenberger, Michael; Ponsford, Jennie] Monash Univ, Sch Psychol & Psychiat, Clayton, Vic 3800, Australia; [Spitz, Gershon; Schoenberger, Michael; Ponsford, Jennie] Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Clayton, Vic, Australia; [Schoenberger, Michael] Univ Freiburg, Inst Psychol, Dept Rehabil Psychol & Psychotherapy, D-79106 Freiburg, Germany	Spitz, G (corresponding author), Monash Univ, Sch Psychol & Psychiat, Clayton Campus, Clayton, Vic 3800, Australia.	Gershon.Spitz@monash.edu	Spitz, Gershon/H-7755-2014	Spitz, Gershon/0000-0002-7810-1480			Aguinis H., 2004, REGRESSION ANAL CATE; Aiken L.S., 1991, MULTIPLE REGRESSION; Anson K, 2006, BRAIN INJURY, V20, P167, DOI 10.1080/02699050500442956; Anson K, 2006, J HEAD TRAUMA REHAB, V21, P248, DOI 10.1097/00001199-200605000-00005; Baddeley A, 1994, DOORS PEOPLE; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Benton A., 1994, MULTILINGUAL APHASIA; Blais MC, 2007, BRAIN INJURY, V21, P357, DOI 10.1080/02699050701311075; BOHNEN N, 1992, INT J NEUROSCI, V64, P97, DOI 10.3109/00207459209000536; BOMBARDIER CH, 1990, BEHAV RES THER, V28, P297, DOI 10.1016/0005-7967(90)90081-S; Bryant RA, 2000, BRAIN INJURY, V14, P175, DOI 10.1080/026990500120826; Bryant RA, 1999, J HEAD TRAUMA REHAB, V14, P588, DOI 10.1097/00001199-199912000-00007; Castaneda AE, 2008, J AFFECT DISORDERS, V106, P1, DOI 10.1016/j.jad.2007.06.006; Chan RCK, 2000, BRAIN INJURY, V14, P227, DOI 10.1080/026990500120709; Christensen BK, 2008, ARCH PHYS MED REHAB, V89, pS3, DOI 10.1016/j.apmr.2008.10.002; Coughhlan AK, 2007, BIRT MEMORY INFORM P; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; Dawson DR, 2007, DISABIL REHABIL, V29, P301, DOI 10.1080/09638280600756687; Deb S, 1999, AM J PSYCHIAT, V156, P374; Deb S, 1999, BRIT J PSYCHIAT, V174, P360, DOI 10.1192/bjp.174.4.360; DESROSIERS G, 1987, INT J CLIN NEUROPSYC, V9, P162; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Frydenberg E., 1996, COPING SCALE ADULTS; Frydenberg E, 2000, ANN M AM ED RES ASS; Giovagnoli AR, 1996, ITAL J NEUROL SCI, V17, P305, DOI 10.1007/BF01997792; Godfrey HPD, 1996, J HEAD TRAUMA REHAB, V11, P29, DOI 10.1097/00001199-199612000-00006; Gould KR, 2011, J HEAD TRAUMA REHAB, V26, P79, DOI 10.1097/HTR.0b013e3182036799; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; Keiski MA, 2007, CLIN NEUROPSYCHOL, V21, P744, DOI 10.1080/13854040600775346; Kendall E, 1996, NEUROPSYCHOL REHABIL, V6, P101, DOI 10.1080/713755502; Kendall E, 2009, SOC SCI MED, V69, P947, DOI 10.1016/j.socscimed.2009.06.021; Kinsella G, 1996, BRAIN INJURY, V10, P499, DOI 10.1080/026990596124214; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Krpan KM, 2007, J CLIN EXP NEUROPSYC, V29, P36, DOI 10.1080/13803390500376816; Lazarus R.S., 1984, STRESS APPRAISAL COP; MALIA K, 1995, BRAIN INJURY, V9, P607, DOI 10.3109/02699059509008219; MOORE A D, 1992, Brain Injury, V6, P89, DOI 10.3109/02699059209008129; Novack TA, 2000, BRAIN INJURY, V14, P987; Parry-Jones BL, 2006, NEUROPSYCHOL REHABIL, V16, P537, DOI 10.1080/09602010500231875; Ponsford J., 1995, TRAUMATIC BRAIN INJU; Reitan R., 1988, HALSTEAD REITAN NEUR; Ruttan L, 2008, ARCH PHYS MED REHAB, V89, pS69, DOI 10.1016/j.apmr.2008.07.007; Shallice, 1997, HAYLING BRIXTON TEST; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Sloan S., 2004, BRAIN IMPAIR, V5, P12, DOI DOI 10.1375/BRIM.5.1.12.35399; Smith A., 1973, SYMBOL DIGIT MODALIT; Snaith R.P., 1994, HOSP ANXIETY DEPRESS; Tomberg T, 2007, BRAIN INJURY, V21, P479, DOI 10.1080/02699050701311737; Tomberg T, 2005, BRAIN INJURY, V19, P1181, DOI 10.1080/02699050500150153; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Whelan-Goodinson R, 2008, J AFFECT DISORD; Wolters G, 2011, J HEAD TRAUMA REHAB, V26, P150, DOI 10.1097/HTR.0b013e3181e421dc; Wolters G, 2010, NEUROPSYCHOL REHABIL, V20, P587, DOI 10.1080/09602011003683836; Wood RLL, 2006, J INT NEUROPSYCH SOC, V12, P350, DOI 10.1017/S1355617706060498	55	35	36	0	48	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2013	28	2					116	125		10.1097/HTR.0b013e3182452f4f			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	105HU	WOS:000316058300005	22495104				2021-06-18	
J	Wu, HM; Huang, SC; Vespa, P; Hovda, DA; Bergsneider, M				Wu, Hsiao-Ming; Huang, Sung-Cheng; Vespa, Paul; Hovda, David A.; Bergsneider, Marvin			Redefining the Pericontusional Penumbra following Traumatic Brain Injury: Evidence of Deteriorating Metabolic Derangements Based on Positron Emission Tomography	JOURNAL OF NEUROTRAUMA			English	Article						blood flow; ischemia; metabolism; PET scanning; traumatic brain injury	CEREBRAL-BLOOD-FLOW; CLOSED-HEAD INJURY; INTRACEREBRAL HEMORRHAGE; COMBINED MICRODIALYSIS; ISCHEMIC PENUMBRA; FDG-PET; THRESHOLDS; DAMAGE; CONTUSIONS; ASTROCYTES	The pathophysiological changes in the pericontusional region after traumatic brain injury (TBI) have classically been considered to be ischemic. Using [F-18] fluorodeoxyglucose (FDG) and triple-oxygen PET studies, we examined the pericontusional "penumbra'' to assess for increased oxygen extraction fraction (OEF), anaerobic metabolism, and tissue viability. Acute (<= 4 days) CT, MRI, and PET studies were performed in eight patients with TBI who had contusions. Four regions-of-interest (ROI) containing the contusion core, pericontusional hypodense gray matter (GM), pericontusional normal-appearing GM, and remote normal-appearing GM, were defined using a semi-automatic method. The correlations of cerebral blood flow (CBF) with OEF, cerebral metabolic rate of oxygen (CMRO2), and cerebral metabolic rate of glucose (CMRglc) were examined. The oxygen-glucose ratio (OGR) in each brain region was evaluated for anaerobic metabolism. The results show that pericontusional tissue had progressively diminishing OEF, CBF, CMRO2, or CMRglc approaching the contusion core. In general, there was a preserved ratio of CBF to CMRO2 in pericontusional hypodense GM. The OGR of the pericontusional hypodense GM was low (<4.0) and was inversely correlated (r=-0.68) with time after injury. A large proportion (% area: 22-76%) of pericontusional hypodense GM tissue had CMRO2 values less than 35 mu mol/100 g/min, with this percentage increased with time after injury.	[Wu, Hsiao-Ming; Huang, Sung-Cheng; Hovda, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; [Huang, Sung-Cheng] Univ Calif Los Angeles, David Geffen Sch Med, Dept Biomath, Los Angeles, CA 90095 USA; [Vespa, Paul; Hovda, David A.; Bergsneider, Marvin] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Los Angeles, CA 90095 USA; [Vespa, Paul; Hovda, David A.; Bergsneider, Marvin] Univ Calif Los Angeles, David Geffen Sch Med, UCLA Brain Injury Res Ctr, Los Angeles, CA 90095 USA; [Wu, Hsiao-Ming] Fu Jen Catholic Univ, Sch Med, New Taipei City, Taiwan	Bergsneider, M (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Box 957039,Semel 18-246, Los Angeles, CA 90095 USA.	mbergsneider@mednet.ucla.edu	Tanne, David/F-2560-2010	Tanne, David/0000-0002-6699-2220	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P01-NS058489, R21-NS059610]; DOEUnited States Department of Energy (DOE) [DE-FC02-02ER63420, DE-FG02-06ER64249]; UCLA Brain Injury Research Center; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS059610, P01NS058489] Funding Source: NIH RePORTER	We wish to acknowledge the contributions of Maria Etchepare, R.N., Jill Hutchinson, R.N., and Larry Pang for technical assistance. This work was supported by NIH grants P01-NS058489 and R21-NS059610, DOE grants DE-FC02-02ER63420 and DE-FG02-06ER64249, and the UCLA Brain Injury Research Center.	ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723; Baron JC, 2001, CEREBROVASC DIS, V11, P2, DOI 10.1159/000049119; Beaumont A, 2006, ACTA NEUROCHIR SUPPL, V96, P30; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P191, DOI 10.1097/01.WCB.0000100045.07481.DE; Cunningham AS, 2005, BRAIN, V128, P1931, DOI 10.1093/brain/awh536; Furlan M, 1996, ANN NEUROL, V40, P216, DOI 10.1002/ana.410400213; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; GRAHAM DI, 1971, LANCET, V1, P265; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; Heiss WD, 2001, BRAIN, V124, P20, DOI 10.1093/brain/124.1.20; Hutchinson P, 2009, ACTA NEUROCHIR, V151, P51, DOI 10.1007/s00701-008-0169-1; Kaufman L., 1990, PARTITIONING MEDOIDS; Keep RF, 2005, STROKE, V36, P1594, DOI 10.1161/01.STR.0000170701.41507.e1; LIN KP, 1994, IEEE T NUCL SCI, V41, P2850, DOI 10.1109/23.340657; Marchal G, 1999, BRAIN, V122, P2387, DOI 10.1093/brain/122.12.2387; McLaughlin MR, 1996, J NEUROSURG, V85, P871, DOI 10.3171/jns.1996.85.5.0871; Menon DK, 2003, ANESTHESIOLOGY, V98, P805, DOI 10.1097/00000542-200304000-00002; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Otori T, 2004, J NEUROTRAUM, V21, P707, DOI 10.1089/0897715041269623; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; Soares HD, 1995, J NEUROSCI, V15, P8223; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; von Oettingen G, 2002, NEUROSURGERY, V50, P781, DOI 10.1097/00006123-200204000-00019; Wu HM, 2005, IEEE T NUCL SCI, V52, P1311, DOI 10.1109/TNS.2005.858239; Wu HM, 2004, NEUROSURGERY, V55, P1306, DOI 10.1227/01.NEU.0000143028.08719.42; Wu HM, 2004, J NEUROTRAUM, V21, P149, DOI 10.1089/089771504322778613; Yu I, 2010, J NEUROTRAUM, V27, P1463, DOI 10.1089/neu.2009.1196; Zazulia AR, 2001, J CEREBR BLOOD F MET, V21, P804, DOI 10.1097/00004647-200107000-00005	34	35	39	0	9	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAR	2013	30	5					352	360		10.1089/neu.2012.2610			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	103CI	WOS:000315891600005	23461651	Green Published			2021-06-18	
J	Schwarzmaier, SM; Zimmermann, R; McGarry, NB; Trabold, R; Kim, SW; Plesnila, N				Schwarzmaier, Susanne M.; Zimmermann, Ricarda; McGarry, Niamh B.; Trabold, Raimund; Kim, Seong-Woong; Plesnila, Nikolaus			In vivo temporal and spatial profile of leukocyte adhesion and migration after experimental traumatic brain injury in mice	JOURNAL OF NEUROINFLAMMATION			English	Article						Leukocytes; Inflammation; Brain trauma; Secondary brain damage; Leukocyte adhesion; Leukocyte-platelet aggregates; 2-photon microscopy; Intravital microscopy; In vivo; Mice	CONTROLLED CORTICAL IMPACT; CEREBRAL-ARTERY OCCLUSION; FLUID PERCUSSION INJURY; ISCHEMIC CELL-DAMAGE; P-SELECTIN; CONTUSION VOLUME; MAC-1 CD11B/CD18; EDEMA FORMATION; RATS; INFLAMMATION	Background: Leukocytes are believed to be involved in delayed cell death following traumatic brain injury (TBI). However, data demonstrating that blood-borne inflammatory cells are present in the injured brain prior to the onset of secondary brain damage have been inconclusive. We therefore investigated both the interaction between leukocytes and the cerebrovascular endothelium using in vivo imaging and the accumulation of leukocytes in the penumbra following experimentally induced TBI. Methods: Experimental TBI was induced in C57/Bl6 mice (n = 42) using the controlled cortical impact (CCI) injury model, and leukocyte-endothelium interactions (LEI) were quantified using both intravital fluorescence microscopy (IVM) of superficial vessels and 2-photon microscopy of cortical vessels for up to 14 h post-CCI. In a separate experimental group, leukocyte accumulation and secondary lesion expansion were analyzed in mice that were sacrificed 15 min, 2, 6, 12, 24, or 48 h after CCI (n = 48). Finally, leukocyte adhesion was blocked with anti-CD18 antibodies, and the effects on LEI and secondary lesion expansion were determined 16 (n = 12) and 24 h (n = 21), respectively, following TBI. Results: One hour after TBI leukocytes and leukocyte-platelet aggregates started to roll on the endothelium of pial venules, whereas no significant LEI were observed in pial arterioles or in sham-operated mice. With a delay of >4 h, leukocytes and aggregates did also firmly adhere to the venular endothelium. In deep cortical vessels (250 mu m) LEIs were much less pronounced. Transmigration of leukocytes into the brain parenchyma only became significant after the tissue became necrotic. Treatment with anti-CD18 antibodies reduced adhesion by 65%; however, this treatment had no effect on secondary lesion expansion. Conclusions: LEI occurred primarily in pial venules, whereas little or no LEI occurred in arterioles or deep cortical vessels. Inhibiting LEI did not affect secondary lesion expansion. Importantly, the majority of migrating leukocytes entered the injured brain parenchyma only after the tissue became necrotic. Our results therefore suggest that neither intravascular leukocyte adhesion nor the migration of leukocytes into cerebral tissue play a significant role in the development of secondary lesion expansion following TBI.	[Schwarzmaier, Susanne M.; Zimmermann, Ricarda; Trabold, Raimund; Kim, Seong-Woong; Plesnila, Nikolaus] Univ Munich, Med Ctr, Walter Brendel Ctr Expt Med, Inst Surg Res, D-81377 Munich, Germany; [Schwarzmaier, Susanne M.; McGarry, Niamh B.; Kim, Seong-Woong; Plesnila, Nikolaus] Royal Coll Surgeons Ireland, Dept Neurodegenerat, Dublin 2, Ireland; [Plesnila, Nikolaus] Univ Munich, Med Ctr, Inst Stroke & Dementia Res ISD, D-81377 Munich, Germany	Plesnila, N (corresponding author), Univ Munich, Med Ctr, Walter Brendel Ctr Expt Med, Inst Surg Res, Marchioninistr 15, D-81377 Munich, Germany.	nikolaus.plesnila@med.uni-muenchen.de	Plesnila, Nikolaus/T-7522-2019				Arumugam TV, 2004, AM J PHYSIOL-HEART C, V287, pH2555, DOI 10.1152/ajpheart.00588.2004; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Carbonell WS, 1998, J NEUROTRAUM, V15, P217, DOI 10.1089/neu.1998.15.217; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; Chen T, 2011, BRAIN RES BULL, V84, P163, DOI 10.1016/j.brainresbull.2010.11.015; CHOPP M, 1994, STROKE, V25, P869, DOI 10.1161/01.STR.25.4.869; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; DIAMOND MS, 1993, J CELL BIOL, V120, P545, DOI 10.1083/jcb.120.2.545; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Edens HA, 2000, ADV DRUG DELIVER REV, V41, P315, DOI 10.1016/S0169-409X(00)00049-1; Engel DC, 2008, J NEUROTRAUM, V25, P739, DOI 10.1089/neu.2007.0480; Etalamy I, 2008, THROMB RES, V121, P843, DOI 10.1016/j.thromres.2007.07.016; Fee D, 2003, J NEUROIMMUNOL, V136, P54, DOI 10.1016/S0165-5728(03)00008-0; Feuerstein GZ, 1997, ANN NY ACAD SCI, V825, P179, DOI 10.1111/j.1749-6632.1997.tb48428.x; Groger M, 2005, J CEREBR BLOOD F MET, V25, P978, DOI 10.1038/sj.jcbfm.9600096; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; HARLAN JM, 1985, BLOOD, V65, P513; Hartl R, 1997, ACT NEUR S, V70, P240; Hartl R, 1997, J CEREBR BLOOD F MET, V17, P1210; He PN, 2006, AM J PHYSIOL-HEART C, V291, pH591, DOI 10.1152/ajpheart.01228.2005; Helmchen F, 2005, NAT METHODS, V2, P932, DOI 10.1038/NMETH818; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Ishikawa M, 2009, NEUROSURGERY, V64, P546, DOI 10.1227/01.NEU.0000337579.05110.F4; Johnson-Leger C, 2000, J CELL SCI, V113, P921; Kataoka H, 2004, J CEREBR BLOOD F MET, V24, P668, DOI 10.1097/01.WCB.0000117812.35136.5B; Kenne E, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-17; Knoblach SM, 2002, J NEUROTRAUM, V19, P1039, DOI 10.1089/089771502760341956; Korthius, 2010, CAPILLARY FLUID EXCH; Kunkel EJ, 2000, J IMMUNOL, V164, P3301, DOI 10.4049/jimmunol.164.6.3301; LEHR HA, 1994, LAB INVEST, V71, P380; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; MATSUO Y, 1994, BRAIN RES, V656, P344, DOI 10.1016/0006-8993(94)91478-8; McKeating EG, 1998, ACT NEUR S, V71, P200; MOORE KL, 1995, J CELL BIOL, V128, P661, DOI 10.1083/jcb.128.4.661; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Plesnila N, 2007, CELL DEATH DIFFER, V14, P1529, DOI 10.1038/sj.cdd.4402159; Prestigiacomo CJ, 1999, STROKE, V30, P1110, DOI 10.1161/01.STR.30.5.1110; Qu CS, 2010, J NEUROTRAUM, V27, P1625, DOI 10.1089/neu.2010.1359; Rothlein R, 1997, NEUROLOGY, V49, pS3, DOI 10.1212/WNL.49.5_Suppl_4.S3; Sahuquillo J, 2001, CURR PHARM DESIGN, V7, P1475, DOI 10.2174/1381612013397311; Schwarzmaier SM, 2010, J NEUROTRAUM, V27, P121, DOI 10.1089/neu.2009.1114; Shojo H, 2010, NEUROSCIENCE, V171, P1273, DOI 10.1016/j.neuroscience.2010.10.018; Soares HD, 1995, J NEUROSCI, V15, P8223; Soriano SG, 1999, STROKE, V30, P134, DOI 10.1161/01.STR.30.1.134; Soriano SG, 1996, ANN NEUROL, V39, P618, DOI 10.1002/ana.410390511; Thal SC, 2007, J NEUROSCI METH, V159, P261, DOI 10.1016/j.jneumeth.2006.07.016; Utagawa A, 2008, BRAIN RES, V1207, P155, DOI 10.1016/j.brainres.2008.02.057; van Buul JD, 2004, ARTERIOSCL THROM VAS, V24, P824, DOI 10.1161/01.ATV.0000122854.76267.5c; VANDERSANDE JJ, 1981, J NEUROSURG, V54, P21, DOI 10.3171/jns.1981.54.1.0021; Whalen MJ, 1999, J NEUROTRAUM, V16, P583, DOI 10.1089/neu.1999.16.583; Whalen MJ, 2000, J LEUKOCYTE BIOL, V67, P160; Whalen MJ, 1999, J NEUROTRAUM, V16, P299, DOI 10.1089/neu.1999.16.299; ZHANG RL, 1994, NEUROLOGY, V44, P1747, DOI 10.1212/WNL.44.9.1747; ZHUANG J, 1993, J TRAUMA, V35, P415, DOI 10.1097/00005373-199309000-00014; Zweckberger K, 2003, J NEUROTRAUM, V20, P1307, DOI 10.1089/089771503322686102; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	59	35	35	0	12	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	FEB 28	2013	10								32	10.1186/1742-2094-10-32			17	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	114OV	WOS:000316752500001	23448240	DOAJ Gold, Green Published, Green Accepted			2021-06-18	
J	Armstead, WM; Riley, J; Vavilala, MS				Armstead, William M.; Riley, John; Vavilala, Monica S.			Dopamine Prevents Impairment of Autoregulation After Traumatic Brain Injury in the Newborn Pig Through Inhibition of Up-regulation of Endothelin-1 and Extracellular Signal-Regulated Kinase Mitogen-Activated Protein Kinase	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						cerebral autoregulation; cerebral perfusion pressure; dopamine; endothelin; signal transduction; traumatic brain injury	CEREBRAL PERFUSION-PRESSURE; K+ CHANNEL FUNCTION; INTRACRANIAL-PRESSURE; ENDOGENOUS TPA; ERK MAPK; AGE; NOREPINEPHRINE; HYPOTENSION; CHILDREN; THERAPY	Objective: Traumatic brain injury contributes to morbidity in children and boys are disproportionately represented. Autoregulation is impaired more in male compared with female piglets after traumatic brain injury through sex-dependent up-regulation of the spasmogen endothelin-1 and extracellular signal-regulated kinase (ERK) mitogen-activated protein kinase (MAPK), a family of three kinases: ERK, p38, and JNK). Elevation of mean arterial pressure leading to increased cerebral perfusion pressure via phenylephrine improves impairment of autoregulation after traumatic brain injury in female but not male piglets through modulation of endothelin-1 and ERK MAPK up-regulation, blocked in females, but aggravated in males. We hypothesized that pressor choice to elevate cerebral perfusion pressure is important in improving cerebral hemodynamics after traumatic brain injury and that dopamine will prevent impairment of autoregulation in both male and female piglets through blockade of endothelin-1 and ERK MAPK. Design: Prospective, randomized animal study. Setting: University laboratory. Subjects: Newborn (1-5 days old) pigs. Interventions: Cerebral perfusion pressure and pial artery diameter were determined before and after lateral fluid percussion brain injury was produced in piglets equipped with a closed cranial window. Dopamine (15 mu g/kg/min IV) was administered 30 mins post fluid percussion injury. Cerebrospinal fluid ERK MAPK was determined by enzyme-linked immunosorbent assay. Measurements and Main Results: Dopamine increased cerebral perfusion pressure equivalently in both sexes and prevented sex-dependent reductions in pial artery diameter after fluid percussion injury. Loss of pial artery dilation during hypotension was greater in male than in female piglets after fluid percussion injury, but dopamine prevented such impairment equivalently in both sexes post injury. endothelin-1 and ERK MAPK release was greater in male compared to female piglets after fluid percussion injury, but dopamine also blocked their up-regulation equivalently in male and female piglets after fluid percussion injury. Conclusions: These data indicate that dopamine is protective of autoregulation after fluid percussion injury in both sexes. These observations advocate for the consideration of development of sex based therapies for treatment of hemodynamic sequalae of pediatric traumatic brain injury. (Pediatr Crit Care Med 2013; 14:e103-e111)	[Armstead, William M.; Riley, John] Univ Penn, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA; [Armstead, William M.] Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; [Vavilala, Monica S.] Univ Washington, Dept Anesthesiol Pediat & Neurol Surg, Seattle, WA 98195 USA	Armstead, WM (corresponding author), Univ Penn, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA.	armsteaw@uphs.upenn.edu		Riley, John/0000-0002-7932-8935	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HD 57355]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD057355] Funding Source: NIH RePORTER	This research was supported, in part, by HD 57355 (Dr. Armstead) from the National Institutes of Health.	Adelson P David, 2003, Pediatr Crit Care Med, V4, pS12; Armstead WM, 2007, J CEREBR BLOOD F MET, V27, P1702, DOI 10.1038/sj.jcbfm.9600473; Armstead WM, 2006, NAT NEUROSCI, V9, P1150, DOI 10.1038/nn1757; Armstead William M, 2005, Pathophysiology, V12, P5, DOI 10.1016/j.pathophys.2005.01.002; Armstead WM, 2012, J NEUROTRAUM, V29, P1794, DOI 10.1089/neu.2012.2328; Armstead WM, 2011, NEUROL RES, V33, P127, DOI 10.1179/016164111X12881719352138; Armstead WM, 2011, J NEUROTRAUM, V28, P105, DOI 10.1089/neu.2010.1581; Armstead WM, 2010, CRIT CARE MED, V38, P1868, DOI 10.1097/CCM.0b013e3181e8ac1a; Armstead WM, 2010, J NEUROTRAUM, V27, P391, DOI 10.1089/neu.2009.1094; Armstead WM, 2009, J CEREBR BLOOD F MET, V29, P524, DOI 10.1038/jcbfm.2008.142; Armstead WM, 1999, STROKE, V30, P153, DOI 10.1161/01.STR.30.1.153; Armstead WM, 1999, AM J PHYSIOL-HEART C, V277, pH1884; Armstead WM, 1997, STROKE, V28, P2273, DOI 10.1161/01.STR.28.11.2273; Armstead WM, 2000, MICROCIRCULATION, V7, P225, DOI 10.1038/sj.mn.7300110; Armstead WM, 1997, STROKE, V28, P2280; Beaumont A, 2001, J NEUROTRAUM, V18, P1359, DOI 10.1089/08977150152725650; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Catala-Temprano A, 2007, J NEUROSURG, V106, P463, DOI 10.3171/ped.2007.106.6.463; Coles JP, 2004, BRAIN, V127, P2479, DOI 10.1093/brain/awh268; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; Di Gennaro JL, 2010, DEV NEUROSCI-BASEL, V32, P420, DOI 10.1159/000322083; Faraci FM, 1998, PHYSIOL REV, V78, P53; Freeman SS, 2008, ANESTHESIOLOGY, V108, P588, DOI 10.1097/ALN.0b013e31816725d7; Johnston AJ, 2004, INTENS CARE MED, V30, P791, DOI 10.1007/s00134-003-2155-7; Keenan Heather T, 2005, Pediatr Crit Care Med, V6, P537, DOI 10.1097/01.PCC.0000164638.44600.67; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Malhotra AK, 2003, J NEUROTRAUM, V20, P827, DOI 10.1089/089771503322385764; Ract C, 2001, INTENS CARE MED, V27, P101, DOI 10.1007/s001340000754; Sookplung P, 2011, NEUROCRIT CARE, V15, P46, DOI 10.1007/s12028-010-9448-9; Steiner LA, 2004, CRIT CARE MED, V32, P1049, DOI 10.1097/01.CCM.0000120054.32845.A6	30	35	36	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1529-7535			PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	FEB	2013	14	2					E103	E111		10.1097/PCC.0b013e3182712b44			9	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	088GC	WOS:000314820800007	23314184	Green Accepted			2021-06-18	
J	Lange, RT; Brickell, T; French, LM; Ivins, B; Bhagwat, A; Pancholi, S; Iverson, GL				Lange, Rael T.; Brickell, Tracey; French, Louis M.; Ivins, Brian; Bhagwat, Aditya; Pancholi, Sonal; Iverson, Grant L.			Risk Factors for Postconcussion Symptom Reporting after Traumatic Brain Injury in US Military Service Members	JOURNAL OF NEUROTRAUMA			English	Article						mild traumatic brain injury; postconcussion symptoms; risk factors; service members	POSTTRAUMATIC-STRESS-DISORDER; MILD HEAD-INJURY; POST-CONCUSSION SYNDROME; MENTAL-HEALTH PROBLEMS; GOOD OLD DAYS; COMPENSATION-SEEKING; EARLY INTERVENTION; TEST-PERFORMANCE; COMBAT VETERANS; POOR EFFORT	The purpose of this study was to identify factors that are predictive of, or associated with, postconcussion symptom reporting after traumatic brain injury (TBI) in the U.S. military. Participants were 125 U.S. military service members (age: M = 29.6 years, standard deviation [SD] = 8.9, range = 18-56 years) who sustained a TBI, divided into two groups based on symptom criteria for postconcussional disorder (PCD): PCD-Present (n = 65) and PCD-Absent (n = 60). Participants completed a neuropsychological evaluation at Walter Reed Army Medical Center (M = 9.4 months after injury, SD = 9.9; range: 1.1 to 44.8). Factors examined included demographic characteristics, injury-related variables, psychological testing, and effort testing. There were no significant group differences for age, sex, education, race, estimated premorbid intelligence, number of deployments, combat versus non-combat related injury, or mechanism of injury (p > 0.098 for all). There were significant main effects for severity of body injury, duration of loss of consciousness, duration of post-traumatic amnesia, intracranial abnormality, time tested post-injury, possible symptom exaggeration, poor effort, depression, and traumatic stress (p < 0.044 for all). PCD symptom reporting was most strongly associated with possible symptom exaggeration, poor effort, depression, and traumatic stress. PCD rarely occurred in the absence of depression, traumatic stress, possible symptom exaggeration, or poor effort (n = 7, 5.6%). Many factors unrelated to brain injury were influential in self-reported postconcussion symptoms in this sample. Clinicians cannot assume uncritically that endorsement of items on a postconcussion symptom checklist is indicative of residual effects from a brain injury.	[Lange, Rael T.; Brickell, Tracey; French, Louis M.; Ivins, Brian; Bhagwat, Aditya; Pancholi, Sonal; Iverson, Grant L.] Def & Vet Brain Injury Ctr, Bethesda, MD USA; [Lange, Rael T.; Brickell, Tracey; French, Louis M.; Bhagwat, Aditya] Walter Reed Natl Mil Med Ctr, Bethesda, MD USA; [Lange, Rael T.; Iverson, Grant L.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; [Pancholi, Sonal] Ft Belvoir Community Hosp, Ft Belvoir, VA USA; [Brickell, Tracey; French, Louis M.] Uniformed Serv Univ Hlth Sci, Bethesda, MD USA; [Lange, Rael T.; Brickell, Tracey; French, Louis M.] Ctr Neurosci & Regenerat Med, Bethesda, MD USA	Lange, RT (corresponding author), Walter Reed Natl Mil Med Ctr, Def & Vet Brain Injury Ctr, 11300 Rockville Pike,Suite 1100, Bethesda, MD 20852 USA.	rlange@dvbic.org	french, louis/AAB-2083-2020	french, louis/0000-0002-9451-0604; Iverson, Grant/0000-0001-7348-9570			Andersson EE, 2007, ACTA NEUROCHIR, V149, P151, DOI 10.1007/s00701-006-1082-0; Belanger HG, 2009, J HEAD TRAUMA REHAB, V24, P4, DOI 10.1097/HTR.0b013e3181957032; Benzinger TLS, 2009, J NEUROTRAUM, V26, P2127, DOI 10.1089/neu.2009-0885; BOHNEN N, 1994, BRAIN INJURY, V8, P701, DOI 10.3109/02699059409151024; Brenner LA, 2010, J HEAD TRAUMA REHAB, V25, P307, DOI 10.1097/HTR.0b013e3181cada03; Brenner LA, 2009, REHABIL PSYCHOL, V54, P239, DOI 10.1037/a0016908; Bryant RA, 2003, BEHAV RES THER, V41, P489, DOI 10.1016/S0005-7967(02)00179-1; Bryant RA, 2008, ARCH GEN PSYCHIAT, V65, P659, DOI 10.1001/archpsyc.65.6.659; Carlson KF, 2010, J TRAUMA STRESS, V23, P17, DOI 10.1002/jts.20483; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cooper DB, 2011, BRAIN INJURY, V25, P1, DOI 10.3109/02699052.2010.531692; Davis CH, 2002, AM J PHYS MED REHAB, V81, P609, DOI 10.1097/00002060-200208000-00009; Deb S, 1998, J NEUROL NEUROSUR PS, V65, P899, DOI 10.1136/jnnp.65.6.899; DeViva JC, 2003, J TRAUMA STRESS, V16, P503, DOI 10.1023/A:1025766713188; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; Dischinger PC, 2009, J TRAUMA, V66, P289, DOI 10.1097/TA.0b013e3181961da2; Evered L, 2003, ASSESSMENT, V10, P420, DOI 10.1177/1073191103259539; Fear NT, 2009, PSYCHOL MED, V39, P1379, DOI 10.1017/S0033291708004595; French LM, 2012, J HEAD TRAUMA REHAB, V27, P63, DOI 10.1097/HTR.0b013e3182248344; Frenisy MC, 2006, J TRAUMA, V60, P1018, DOI 10.1097/01-ta.0000215977.00034.c2; Garden N, 2010, NEUROPSYCHOLOGY, V24, P168, DOI 10.1037/a0017431; Gervais RO, 2008, CLIN NEUROPSYCHOL, V22, P1061, DOI 10.1080/13854040701756930; Gold PB, 1999, J NERV MENT DIS, V187, P680, DOI 10.1097/00005053-199911000-00005; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; Green P., 2003, J TRAUMA, V82; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; Hibbard MR, 2000, BRAIN INJURY, V14, P45, DOI 10.1080/026990500120925; Hill JJ, 2009, AM J PHYS MED REHAB, V88, P605, DOI 10.1097/PHM.0b013e3181ae0f83; Hilsabeck RC, 1998, J CLIN EXP NEUROPSYC, V20, P328, DOI 10.1076/jcen.20.3.328.813; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Hou RH, 2012, J NEUROL NEUROSUR PS, V83, P217, DOI 10.1136/jnnp-2011-300767; Iverson G. L., 2010, J INT SOC NEUROPSYCH, V16, P25; Iverson G.L., 2007, BRAIN INJURY MED PRI, P373; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Iverson GL, 2012, BRAIN INJURY MED PRI; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Iverson GL, 2010, CLIN NEUROPSYCHOL, V24, P17, DOI 10.1080/13854040903190797; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Keane T., 1994, PTSD CHECKLIST CIVIL; Kennedy JE, 2010, NEUROREHABILITATION, V26, P191, DOI 10.3233/NRE-2010-0555; Kennedy JE, 2010, NEUROREHABILITATION, V26, P223, DOI 10.3233/NRE-2010-0558; Lange R. T., 2013, J NEUROTRAU IN PRESS; Lange RT, 2012, J CLIN EXP NEUROPSYC, V34, P453, DOI 10.1080/13803395.2011.648175; Lange RT, 2010, J CLIN EXP NEUROPSYC, V32, P961, DOI 10.1080/13803391003645657; Lange RT, 2011, J HEAD TRAUMA REHAB, V26, P127, DOI 10.1097/HTR.0b013e3181e4622a; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P395, DOI 10.1076/clin.17.3.395.18087; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; Marx BP, 2009, ARCH GEN PSYCHIAT, V66, P996, DOI 10.1001/archgenpsychiatry.2009.109; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McLean SA, 2009, AM J EMERG MED, V27, P182, DOI 10.1016/j.ajem.2008.01.054; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Mickeviciene D, 2004, EUR J NEUROL, V11, P411, DOI 10.1111/j.1468-1331.2004.00816.x; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Morey L. C., 1991, PERSONALITY ASSESSME; Paniak C, 1998, BRAIN INJURY, V12, P1011, DOI 10.1080/026990598121927; Pietrzak RH, 2009, J NERV MENT DIS, V197, P748, DOI 10.1097/NMD.0b013e3181b97a75; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Psychological Corporation, 2001, WECHSL TEST AD READ; Roe C, 2009, DISABIL REHABIL, V31, P1235, DOI 10.1080/09638280802532720; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Seal KH, 2008, AM J PUBLIC HEALTH, V98, P714, DOI 10.2105/AJPH.2007.115519; Shalev AY, 2012, ARCH GEN PSYCHIAT, V69, P166, DOI 10.1001/archgenpsychiatry.2011.127; Sheedy J, 2009, J HEAD TRAUMA REHAB, V24, P333, DOI 10.1097/HTR.0b013e3181aea51f; Smith DW, 1996, PSYCHOL ASSESSMENT, V8, P3, DOI 10.1037/1040-3590.8.1.3; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Stevenson M, 2001, Inj Prev, V7, P10, DOI 10.1136/ip.7.1.10; Stulemeijer M, 2008, J NEUROL NEUROSUR PS, V79, P936, DOI 10.1136/jnnp.2007.131250; Suhr JA, 2005, J INT NEUROPSYCH SOC, V11, P23, DOI 10.1017/S1355617705050010; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; Tsanadis J., 2007, INT NEUR SOC 35 ANN; Tsanadis J, 2007, J INT NEUROPSYCH SOC, V13, P196; Tsanadis J, 2008, CLIN NEUROPSYCHOL, V22, P1080, DOI 10.1080/13854040701796928; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906; Wygant DB, 2007, ARCH CLIN NEUROPSYCH, V22, P489, DOI 10.1016/j.acn.2007.01.027; YOUNGJOHN JR, 1995, CLIN NEUROPSYCHOL, V9, P112, DOI 10.1080/13854049508401593	89	35	35	0	30	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2013	30	4					237	246		10.1089/neu.2012.2685			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	093CM	WOS:000315169300001	23126461				2021-06-18	
J	Yang, J; Ahn, HN; Chang, M; Narasimhan, P; Chan, PH; Song, YS				Yang, Jiwon; Ahn, Hye-na; Chang, Minsun; Narasimhan, Purnima; Chan, Pak H.; Song, Yun Seon			Complement component 3 inhibition by an antioxidant is neuroprotective after cerebral ischemia and reperfusion in mice	JOURNAL OF NEUROCHEMISTRY			English	Article						antioxidant; complement component 3; focal cerebral ischemia; oxidative stress	SUPEROXIDE DISMUTASE ACTIVITY; FIBRILLARY ACIDIC PROTEIN; TRAUMATIC BRAIN-INJURY; N-TERT-BUTYLNITRONE; EXPERIMENTAL STROKE; ALTERNATIVE PATHWAY; LIVER-REGENERATION; OXIDATIVE STRESS; GENE-EXPRESSION; TRANSGENIC MICE	Oxidative stress after stroke is associated with the inflammatory system activation in the brain. The complement cascade, especially the degradation products of complement component 3, is a key inflammatory mediator of cerebral ischemia. We have shown that pro-inflammatory complement component 3 is increased by oxidative stress after ischemic stroke in mice using DNA array. In this study, we investigated whether up-regulation of complement component 3 is directly related to oxidative stress after transient focal cerebral ischemia in mice and oxygen-glucose deprivation in brain cells. Persistent up-regulation of complement component 3 expression was reduced in copper/zinc-superoxide dismutase transgenic mice, and manganese-superoxide dismutase knock-out mice showed highly increased complement component 3 levels after transient focal cerebral ischemia. Antioxidant N-tert-butyl-a-phenylnitrone treatment suppressed complement component 3 expression after transient focal cerebral ischemia. Accumulation of complement component 3 in neurons and microglia was decreased by N-tert-butyl-a-phenylnitrone, which reduced infarct volume and impaired neurological deficiency after cerebral ischemia and reperfusion in mice. Small interfering RNA specific for complement component 3 transfection showed a significant increase in brain cells viability after oxygen-glucose deprivation. Our study suggests that the neuroprotective effect of antioxidants through complement component 3 suppression is a new strategy for potential therapeutic approaches in stroke.	[Yang, Jiwon; Ahn, Hye-na; Song, Yun Seon] Sookmyung Womens Univ, Coll Pharm, Dept Pharmacol, Seoul 140742, South Korea; [Chang, Minsun] Sookmyung Womens Univ, Coll Sci, Dept Med & Pharmaceut Sci, Seoul 140742, South Korea; [Narasimhan, Purnima; Chan, Pak H.; Song, Yun Seon] Stanford Univ, Dept Neurosurg, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA; [Narasimhan, Purnima; Chan, Pak H.; Song, Yun Seon] Stanford Univ, Sch Med, Program Neurosci, Stanford, CA 94305 USA	Song, YS (corresponding author), Sookmyung Womens Univ, Coll Pharm, Dept Pharmacol, Chungpa Ro 47,Gil 100, Seoul 140742, South Korea.	yssong@sookmyung.ac.kr			National Research Foundation of KoreaNational Research Foundation of Korea [KRF-2008-313-E00359]; SRC program [20090063046]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [PO1 NS014543, RO1 NS025372, RO1 NS038653]; James R. Doty Endowment; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038653, P01NS014543, R01NS025372] Funding Source: NIH RePORTER	The authors declare no conflict of interest. This study was supported by National Research Foundation of Korea grant #KRF-2008-313-E00359 and SRC program # 20090063046 to Y.S.S. and by grants PO1 NS014543, RO1 NS025372, and RO1 NS038653, from the National Institutes of Health, and by the James R. Doty Endowment to P. H. C. The authors thank Cheryl Christensen for her editorial assistance and Elizabeth Hoyte for assistance with the figures.	Allen CL, 2009, INT J STROKE, V4, P461, DOI 10.1111/j.1747-4949.2009.00387.x; Amadi-Obi A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045801; Arumugam TV, 2009, NEUROSCIENCE, V158, P1074, DOI 10.1016/j.neuroscience.2008.07.015; Arumugam TV, 2007, P NATL ACAD SCI USA, V104, P14104, DOI 10.1073/pnas.0700506104; Cardinaux JR, 2000, GLIA, V29, P91, DOI 10.1002/(SICI)1098-1136(20000101)29:1<91::AID-GLIA9>3.3.CO;2-9; Cervera A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008433; Chakraborti T, 2000, CELL SIGNAL, V12, P607, DOI 10.1016/S0898-6568(00)00111-X; Cojocaru Inimioara Mihaela, 2008, Rom J Intern Med, V46, P77; Cowell RM, 2003, J NEUROSCI, V23, P9459; Crehan H, 2012, INT J ALZHEIMERS DIS, V2012; Daha MR, 2010, CRIT REV IMMUNOL, V30, P47, DOI 10.1615/CritRevImmunol.v30.i1.30; Daveau M, 2004, J IMMUNOL, V173, P3418, DOI 10.4049/jimmunol.173.5.3418; del Zoppo GJ, 1999, NAT MED, V5, P995, DOI 10.1038/12431; Ducruet AF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038664; Ducruet AF, 2009, EXP NEUROL, V219, P398, DOI 10.1016/j.expneurol.2009.07.018; EPSTEIN CJ, 1987, P NATL ACAD SCI USA, V84, P8044, DOI 10.1073/pnas.84.22.8044; FOLBERGROVA J, 1995, P NATL ACAD SCI USA, V92, P5057, DOI 10.1073/pnas.92.11.5057; FRANK MM, 1991, IMMUNOL TODAY, V12, P322, DOI 10.1016/0167-5699(91)90009-I; Gasque P, 2000, IMMUNOPHARMACOLOGY, V49, P171, DOI 10.1016/S0162-3109(00)80302-1; Ginsberg MD, 2008, NEUROPHARMACOLOGY, V55, P363, DOI 10.1016/j.neuropharm.2007.12.007; Hu HT, 2012, CLIN BIOCHEM, V45, P1320, DOI 10.1016/j.clinbiochem.2012.06.003; Huang YX, 2008, J IMMUNOL, V181, P8068, DOI 10.4049/jimmunol.181.11.8068; Huber-Lang M, 2006, NAT MED, V12, P682, DOI 10.1038/nm1419; Jendrysik MA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028198; JUAN TSC, 1993, P NATL ACAD SCI USA, V90, P2584, DOI 10.1073/pnas.90.7.2584; Kim GW, 2002, STROKE, V33, P809, DOI 10.1161/hs0302.103745; KINOUCHI H, 1991, P NATL ACAD SCI USA, V88, P11158, DOI 10.1073/pnas.88.24.11158; Kuroda S, 1996, NEUROBIOL DIS, V3, P149, DOI 10.1006/nbdi.1996.0015; Lancelot E, 1997, FREE RADICAL BIO MED, V23, P1031, DOI 10.1016/S0891-5849(97)00128-7; LEVISTRAUSS M, 1987, J IMMUNOL, V139, P2361; Lewen A, 1998, J NEUROTRAUM, V15, P521, DOI 10.1089/neu.1998.15.521; Li YB, 1998, BRAIN RES, V814, P164, DOI 10.1016/S0006-8993(98)01082-8; Liu XL, 2003, ACTA ANAESTH SCAND, V47, P958, DOI 10.1034/j.1399-6576.2003.00189.x; Lockwood SF, 2005, CARDIOVASC DRUG REV, V23, P199; Maranto J, 2008, J NEUROIMMUNE PHARM, V3, P43, DOI 10.1007/s11481-007-9096-9; Mastellos D, 2001, J IMMUNOL, V166, P2479, DOI 10.4049/jimmunol.166.4.2479; MIYAJIMA T, 1995, BIOCHEM BIOPH RES CO, V215, P114, DOI 10.1006/bbrc.1995.2440; Mocco J, 2006, CIRC RES, V99, P209, DOI 10.1161/01.RES.0000232544.90675.42; Montalto MC, 2003, AM J PHYSIOL-GASTR L, V285, pG197, DOI 10.1152/ajpgi.00029.2003; Morgan BP, 1996, IMMUNOL TODAY, V17, P461, DOI 10.1016/0167-5699(96)20028-F; Norris JD, 1996, MOL ENDOCRINOL, V10, P1605, DOI 10.1210/mend.10.12.8961270; Nylen K, 2007, STROKE, V38, P1489, DOI 10.1161/STROKEAHA.106.478362; Papp K, 2010, RHEUMATOLOGY, V49, P2273, DOI 10.1093/rheumatology/keq278; Pavlovski D, 2012, FASEB J, V26, P3680, DOI 10.1096/fj.11-202382; Qu H, 2009, MOL IMMUNOL, V47, P185, DOI 10.1016/j.molimm.2009.08.032; Rahpeymai Y, 2006, EMBO J, V25, P1364, DOI 10.1038/sj.emboj.7601004; Schaefer M, 2005, J BIOL CHEM, V280, P42113, DOI 10.1074/jbc.M508146200; Schiff L, 2012, MOL DIAGN THER, V16, P79, DOI 10.2165/11631580-000000000-00000; Sliwa T, 2012, CURR PHARM BIOTECHNO; Song YS, 2007, J CEREBR BLOOD F MET, V27, P764, DOI 10.1038/sj.jcbfm.9600379; Stokowska A, 2011, CEREBROVASC DIS, V32, P114, DOI 10.1159/000328238; Strey CW, 2003, J EXP MED, V198, P913, DOI 10.1084/jem.20030374; Taskapilioglu MO, 2009, J CLIN NEUROSCI, V16, P693, DOI 10.1016/j.jocn.2008.07.077; Tsai TH, 2012, J ATHEROSCLER THROMB, V19, P523, DOI 10.5551/jat.10751; Tsuji M, 2000, NEUROSCI LETT, V282, P41, DOI 10.1016/S0304-3940(00)00844-2; VAKEVA A, 1994, AM J PATHOL, V144, P1357; Vakeva A, 1998, APMIS, V106, P1149; Van Beek J, 2003, ANN NY ACAD SCI, V992, P56; Vibo R, 2007, FREE RADICAL RES, V41, P282, DOI 10.1080/10715760601083235; VIK DP, 1991, BIOCHEMISTRY-US, V30, P1080, DOI 10.1021/bi00218a029; Whiteley W, 2012, STROKE, V43, P86, DOI 10.1161/STROKEAHA.111.634089; WON KA, 1990, MOL CELL BIOL, V10, P3965, DOI 10.1128/MCB.10.8.3965; Xi GH, 2001, STROKE, V32, P162, DOI 10.1161/01.STR.32.1.162; Yamaguchi T, 1998, STROKE, V29, P12, DOI 10.1161/01.STR.29.1.12; Yang CM, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-12; Yang JP, 2009, NEUROSCI LETT, V461, P212, DOI 10.1016/j.neulet.2009.06.060; Yong VW, 2009, NEURON, V64, P55, DOI 10.1016/j.neuron.2009.09.035; Yu SC, 2012, BIOMARKERS, V17, P319, DOI 10.3109/1354750X.2012.668712	68	35	38	0	11	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042			J NEUROCHEM	J. Neurochem.	FEB	2013	124	4					523	535		10.1111/jnc.12111			13	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	079QK	WOS:000314186300010	23199288	Bronze, Green Accepted			2021-06-18	
J	Cantor, JB; Gordon, W; Gumber, S				Cantor, Joshua B.; Gordon, Wayne; Gumber, Shinakee			What is post TBI fatigue?	NEUROREHABILITATION			English	Article						Traumatic Brain Injury; fatigue; epidemiology; assessment; treatment	TRAUMATIC BRAIN-INJURY; EXCESSIVE DAYTIME SLEEPINESS; CLOSED-HEAD-INJURY; QUALITY-OF-LIFE; 1ST 2 YEARS; MULTIPLE-SCLEROSIS; MENTAL FATIGUE; FUNCTIONAL MRI; ATTENTION DEFICITS; COGNITIVE FATIGUE	BACKGROUND: Fatigue is among the most common sequelae of traumatic brain injury (TBI). OBJECTIVES: To summarize the empirical and theoretical literature on Post TBI fatigue (PTBIF) and identify some of the challenges that continue to confront clinicians, researchers and individuals with TBI. METHODS: Qualitative literature review. The epidemiology, characteristics, and correlates of PTBIF are described. Challenges in the operational definition and measurement of fatigue are discussed and the empirical literature on measurement of PTBIF and theoretical models of the potential etiology of PTBIF is summarized. Existing treatments of PTBIF and the research supporting them are reviewed. Future directions for clinical research are presented. RESULTS: Although PTBIF is a high incidence condition after TBI that is related to significant suffering and reduced quality of life, it remains inadequately measured and treated. Its etiology and precipitants are poorly understood and intervention research is inadequate. CONCLUSION: Further research is necessary to develop psychometrically-sound objective and subjective measures of PTBIF and examine the efficacy of treatments for fatigue. Interventions shown to improve fatigue in other populations should be considered in treating PTBIF.	[Cantor, Joshua B.; Gordon, Wayne; Gumber, Shinakee] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA	Cantor, JB (corresponding author), Mt Sinai Sch Med, Dept Rehabil Med, 1 Gustave L Levy Pl,Box 1240, New York, NY 10029 USA.	joshua.cantor@mountsinai.org			National Institute of Disability and Rehabilitation Research, United States Department of Education [H133A020501]	The preparation of this manuscript was supported in part by grant # H133A020501 from the National Institute of Disability and Rehabilitation Research, United States Department of Education.	Aaronson L S, 1999, Image J Nurs Sch, V31, P45; Ashman TA, 2008, J HEAD TRAUMA REHAB, V23, P33, DOI 10.1097/01.HTR.0000308719.70288.22; Barwick F, 2012, CLIN NEUROPHYSIOL, V123, P278, DOI 10.1016/j.clinph.2011.06.027; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Bavisetty S, 2008, NEUROSURGERY, V62, P1080, DOI 10.1227/01.neu.0000325870.60129.6a; Bay E, 2011, J HEAD TRAUMA REHAB, V26, P355, DOI 10.1097/HTR.0b013e3181f20146; Bay E, 2009, WESTERN J NURS RES, V31, P731, DOI 10.1177/0193945909334856; Belmont A., 2006, Annales de Readaptation et de Medecine Physique, V49, P370, DOI 10.1016/j.annrmp.2006.04.018; Benson BW, 2011, CAN MED ASSOC J, V183, P905, DOI 10.1503/cmaj.092190; Borgaro SR, 2005, J HEAD TRAUMA REHAB, V20, P416, DOI 10.1097/00001199-200509000-00003; BROUWER WH, 1985, CORTEX, V21, P111, DOI 10.1016/S0010-9452(85)80019-8; Bushnik T, 2008, J HEAD TRAUMA REHAB, V23, P17, DOI 10.1097/01.HTR.0000308717.80590.22; Bushnik T, 2007, BRAIN INJURY, V21, P559, DOI 10.1080/02699050701426915; Cantor J. B., 2012, J HEAD TRAU IN PRESS; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; Chaudhuri A, 2000, J NEUROL SCI, V179, P34, DOI 10.1016/S0022-510X(00)00411-1; Chaudhuri A, 2004, LANCET, V363, P978, DOI 10.1016/S0140-6736(04)15794-2; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; DAVID A, 1990, BMJ-BRIT MED J, V301, P1199, DOI 10.1136/bmj.301.6762.1199; de Groot MH, 2003, ARCH PHYS MED REHAB, V84, P1714, DOI 10.1053/S0003-9993(03)00346-0; de Joode E., 2011, DISABILITY REHABILIT; DeLuca J, 2008, J NEUROL SCI, V270, P28, DOI 10.1016/j.jns.2008.01.018; DeLuca J, 2005, ISS CLIN COGN NEUROP, P319; Dijkers MP, 2010, J HEAD TRAUMA REHAB, V25, P81, DOI 10.1097/HTR.0b013e3181cd3528; Dijkers MPJM, 2008, J HEAD TRAUMA REHAB, V23, P3, DOI 10.1097/01.HTR.0000308716.80590.6b; Elovic EP, 2005, ISS CLIN COGN NEUROP, P89; Englander J, 2010, BRAIN INJURY, V24, P1379, DOI 10.3109/02699052.2010.523041; Hann DM, 1998, QUAL LIFE RES, V7, P301, DOI 10.1023/A:1024929829627; Hattori N, 2009, J NUCL MED, V50, P1054, DOI 10.2967/jnumed.108.060368; Hicks EJ, 2011, INT J SPEECH-LANG PA, V13, P145, DOI 10.3109/17549507.2011.485329; Jha A, 2008, J HEAD TRAUMA REHAB, V23, P52, DOI 10.1097/01.HTR.0000308721.77911.ea; Johansson B, 2012, BRAIN INJURY, V26, P1621, DOI 10.3109/02699052.2012.700082; Johansson B, 2009, BRAIN INJURY, V23, P1027, DOI 10.3109/02699050903421099; Kaiser PR, 2010, NEUROLOGY, V75, P1780, DOI 10.1212/WNL.0b013e3181fd62a2; Kelly DF, 2006, J NEUROTRAUM, V23, P928, DOI 10.1089/neu.2006.23.928; Kohl AD, 2009, BRAIN INJURY, V23, P420, DOI 10.1080/02699050902788519; Krupp LB, 2010, EXPERT REV NEUROTHER, V10, P1437, DOI 10.1586/ERN.10.99; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; KRUPP LB, 1995, NEUROLOGY, V45, P1956, DOI 10.1212/WNL.45.11.1956; Levine J, 2009, PHYS MED REH CLIN N, V20, P347, DOI 10.1016/j.pmr.2008.12.006; Lundqvist A, 2008, BRAIN INJURY, V22, P295, DOI 10.1080/02699050801966133; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; Merritta C, 2010, INT J REHABIL RES, V33, P109, DOI 10.1097/MRR.0b013e32832e6b37; Mitchell SA, 2010, PM&R, V2, P364, DOI 10.1016/j.pmrj.2010.03.024; Montgomery GH, 2009, HEALTH PSYCHOL, V28, P317, DOI 10.1037/a0013582; Oluellet MC, 2007, ARCH PHYS MED REHAB, V88, P1581, DOI 10.1016/j.apmr.2007.09.006; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Pardini M, 2010, NEUROLOGY, V74, P749, DOI 10.1212/WNL.0b013e3181d25b6b; PAWLIKOWSKA T, 1994, BRIT MED J, V308, P763, DOI 10.1136/bmj.308.6931.763; Riese H, 1999, NEUROPSYCHOL REHABIL, V9, P189, DOI 10.1080/713755600; Schneider KJ, 2010, BRIT J SPORT MED, V44, P1112, DOI 10.1136/bjsm.2009.071266; Schnieders J., 2011, J HEAD TRAUMA REHABI; Schultz BA, 2011, NEUROREHABILITATION, V28, P309, DOI 10.3233/NRE-2011-0659; Schwid SR, 2002, J REHABIL RES DEV, V39, P211; Stuart B., 2011, J EMERGENCY NURSING; Sundstrom A, 2007, BRAIN INJURY, V21, P1049, DOI 10.1080/02699050701630367; Toblin RL, 2012, J AFFECT DISORDERS, V136, P469, DOI 10.1016/j.jad.2011.10.048; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; VANZOMEREN AH, 1984, CLOSED HEAD INJURY P; Whitehead L, 2009, J PAIN SYMPTOM MANAG, V37, P107, DOI 10.1016/j.jpainsymman.2007.08.019; Wiborg JF, 2010, PSYCHOL MED, V40, P1281, DOI 10.1017/S0033291709992212; Wylie G., 2012, 14 ANN M INT NEUR SO, V18, P229; Ziino C, 2006, J INT NEUROPSYCH SOC, V12, P100, DOI 10.1017/S1355617706060139; Ziino C, 2006, NEUROPSYCHOLOGY, V20, P383, DOI 10.1037/0894-4105.20.3.383; Zumstein MA, 2011, J TRAUMA, V71, P120, DOI 10.1097/TA.0b013e3181f2d670	68	35	35	0	25	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2013	32	4					875	883		10.3233/NRE-130912			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	184QF	WOS:000321907100019	23867414				2021-06-18	
J	O'Sullivan, A; Willoughby, RE; Mishchuk, D; Alcarraz, B; Cabezas-Sanchez, C; Condori, RE; David, D; Encarnacion, R; Fatteh, N; Fernandez, J; Franka, R; Hedderwick, S; McCaughey, C; Ondrush, J; Paez-Martinez, A; Rupprecht, C; Velasco-Villa, A; Slupsky, CM				O'Sullivan, Aifric; Willoughby, Rodney E.; Mishchuk, Darya; Alcarraz, Brisa; Cabezas-Sanchez, Cesar; Condori, Rene Edgar; David, Dan; Encarnacion, Rafael; Fatteh, Naaz; Fernandez, Josefina; Franka, Richard; Hedderwick, Sara; McCaughey, Conall; Ondrush, Joanne; Paez-Martinez, Andres; Rupprecht, Charles; Velasco-Villa, Andres; Slupsky, Carolyn M.			Metabolomics of Cerebrospinal Fluid from Humans Treated for Rabies	JOURNAL OF PROTEOME RESEARCH			English	Article						rabies; metabolomics; NMR spectroscopy; cerebrospinal fluid	MAGNETIC-RESONANCE SPECTROSCOPY; TRAUMATIC BRAIN-INJURY; QUINOLINIC ACID; KYNURENINE PATHWAY; N-ACETYLASPARTATE; DIAGNOSIS; VIRUS; METABOLISM; ALCOHOL; DISEASE	Rabies is a rapidly progressive lyssavirus encephalitis that is statistically 100% fatal. There are no clinically effective antiviral drugs for rabies. An immunologically naive teenager survived rabies in 2004 through improvised supportive care; since then, 5 additional survivors have been associated with use of the so-called Milwaukee Protocol (MP). The MP applies critical care focused on the altered metabolic and physiologic states associated with rabies. The aim of this study was to examine the metabolic profile of cerebrospinal fluid (CSF) from rabies patients during clinical progression of rabies encephalitis in survivors and nonsurvivors and to compare these samples with control CSF samples. Unsupervised clustering algorithms distinguished three stages of rabies disease and identified several metabolites that differentiated rabies survivors from those who subsequently died, in particular, metabolites related to energy metabolism and cell volume control. Moreover, for those patients who survived, the trajectory of their metabolic profile tracked toward the control profile and away from the rabies profile. NMR metabolomics of human rabies CSF provide new insights into the mechanisms of rabies pathogenesis, which may guide future therapy of this disease.	[O'Sullivan, Aifric; Mishchuk, Darya; Slupsky, Carolyn M.] Univ Calif Davis, Dept Food Sci & Technol, Davis, CA 95616 USA; [Slupsky, Carolyn M.] Univ Calif Davis, Dept Nutr, Davis, CA 95616 USA; [Willoughby, Rodney E.] Med Coll Wisconsin, Milwaukee, WI 53226 USA; [Alcarraz, Brisa] Hosp Nacl Cayetano Heredia, Lima, Peru; [Cabezas-Sanchez, Cesar; Condori, Rene Edgar] Inst Nacl Salud, Lima, Peru; [David, Dan] Kimron Vet Inst, Bet Dagan, Israel; [Encarnacion, Rafael; Fernandez, Josefina] Hosp Robert Reid Cabral, Santo Domingo, Dominican Rep; [Fatteh, Naaz; Ondrush, Joanne] INOVA Fairfax Hosp, Fairfax, VA USA; [Franka, Richard; Rupprecht, Charles; Velasco-Villa, Andres] Ctr Dis Control & Prevent, Atlanta, GA USA; [Hedderwick, Sara; McCaughey, Conall] Belfast HSC Trust, Royal Hosp, Belfast, Antrim, North Ireland; [Paez-Martinez, Andres] Inst Nacl Salud, Bogota, Colombia	Slupsky, CM (corresponding author), Univ Calif Davis, Dept Food Sci & Technol, Davis, CA 95616 USA.	cslupsky@ucdavis.edu	O'Sullivan, Aifri/AAM-9046-2020; Rupprecht, Charles/AAI-1544-2020	O'Sullivan, Aifric/0000-0002-7441-1983; CABEZAS, CESAR/0000-0001-5120-0713; PAEZ MARTINEZ, ANDRES/0000-0001-7316-3706	Zach Jones Foundation	This work was supported by the Zach Jones Foundation. The authors thank all of the patients and patients' families that were involved in this study. We gratefully acknowledge A. Jansen (Medical College of Wisconsin), J. Blanton, F. Jackson, I. Kuzmin, N. Kuzmina, X. Ma, M. Niezgoda, L. Orciari, O. Urazova, and P. Yager (CDC) for laboratory support and J. Rubin (Centro Medico La Paz, Equatorial Guinea), Y. Caicedo (Hospital Universidad del Valle, Columbia), A. Roy-Berman (Children's Hospital & Research Center, Oakland, CA), C. Glaser (California Department of Public Health, Richmond, CA), Y. Oba (University of Missouri), G. Arroyo Sanchez (Hospital Nacional Cayetano Heredia, Lima, Peru), and S. Lo (Children's Hospital of Wisconsin) for providing CSF samples.	Al-Dirbashi OY, 2007, J INHERIT METAB DIS, V30, P612, DOI 10.1007/s10545-007-0635-6; ALVAREZ L, 1994, PEDIATR INFECT DIS J, V13, P1154, DOI 10.1097/00006454-199412000-00020; ANDERSEN BJ, 1992, BRAIN RES, V585, P184, DOI 10.1016/0006-8993(92)91205-S; [Anonymous], 2005, WHO EXPERT CONSULTAT; AOKI TT, 1975, DIABETES, V24, P463, DOI 10.2337/diabetes.24.5.463; Baslow MH, 2007, J MOL NEUROSCI, V32, P235, DOI 10.1007/s12031-007-0049-9; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Blasco H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013223; Brady MT, 2011, PEDIATRICS, V127, P785, DOI 10.1542/peds.2011-0095; BROUWERS P, 1993, J INFECT DIS, V168, P1380, DOI 10.1093/infdis/168.6.1380; Centers for Disease Control and Prevention, 1977, MMWR-MORBID MORTAL W, V26, P183; Chow SL, 2005, ARCH DIS CHILD, V90, P1188, DOI 10.1136/adc.2005.075317; Clayton TA, 2009, P NATL ACAD SCI USA, V106, P14728, DOI 10.1073/pnas.0904489106; Coen M, 2005, CLIN INFECT DIS, V41, P1582, DOI 10.1086/497836; DAVIS PL, 1984, J ANAL TOXICOL, V8, P209, DOI 10.1093/jat/8.5.209; Debray FG, 2007, CLIN CHEM, V53, P916, DOI 10.1373/clinchem.2006.081166; Faber M, 2002, J VIROL, V76, P3374, DOI 10.1128/JVI.76.7.3374-3381.2002; GRATTANSMITH PJ, 1992, MED J AUSTRALIA, V156, P651, DOI 10.5694/j.1326-5377.1992.tb121465.x; HANSEN EL, 1974, ACTA MED SCAND, V196, P431; HATTWICK MA, 1972, ANN INTERN MED, V76, P931, DOI 10.7326/0003-4819-76-6-931; HEYES MP, 1995, J NEUROL SCI, V133, P112, DOI 10.1016/0022-510X(95)00164-W; Heyes MP, 1998, FASEB J, V12, P881; HIRAOKA A, 1994, BIOL PHARM BULL, V17, P1; Hunter M, 2010, J MED VIROL, V82, P1255, DOI 10.1002/jmv.21785; Janson CG, 2006, NEUROPEDIATRICS, V37, P209, DOI 10.1055/s-2006-924734; Jornvall H, 2000, PHARMACOLOGY, V61, P184, DOI 10.1159/000028399; KEILHOFF G, 1991, NEUROSCIENCE, V42, P379, DOI 10.1016/0306-4522(91)90382-X; KOMOROWSKI RA, 1978, J CLIN MICROBIOL, V8, P89; LAMAS CC, 1980, ACTA NEUROPATHOL, V51, P245, DOI 10.1007/BF00687393; LEWIS GD, 1984, J FORENSIC SCI, V29, P541; LOCKHART BP, 1992, ANTIMICROB AGENTS CH, V36, P1750, DOI 10.1128/AAC.36.8.1750; Madhusudana S. N., 2002, International Journal of Infectious Diseases, V6, P85, DOI 10.1016/S1201-9712(02)90144-X; Medana IM, 2003, J INFECT DIS, V188, P844, DOI 10.1086/377583; Medana IM, 2002, J INFECT DIS, V185, P650, DOI 10.1086/339009; Moffett JR, 2007, PROG NEUROBIOL, V81, P89, DOI 10.1016/j.pneurobio.2006.12.003; Newman HW, 1940, J PHARMACOL EXP THER, V68, P194; PATEL TB, 1979, BIOCHEM J, V184, P539, DOI 10.1042/bj1840539; PORRAS C, 1976, ANN INTERN MED, V85, P44, DOI 10.7326/0003-4819-85-1-44; ROINE RO, 1988, BRAIN, V111, P1505, DOI 10.1093/brain/111.6.1505; Rubin J, 2009, SCAND J INFECT DIS, V41, P372, DOI 10.1080/00365540902798333; RUDDICK JA, 1972, TOXICOL APPL PHARM, V21, P102, DOI 10.1016/0041-008X(72)90032-4; Sinclair AJ, 2010, NMR BIOMED, V23, P123, DOI 10.1002/nbm.1428; Sing T M, 1996, Australas Radiol, V40, P338, DOI 10.1111/j.1440-1673.1996.tb00415.x; Slupsky CM, 2007, ANAL CHEM, V79, P6995, DOI 10.1021/ac0708588; Slupsky CM, 2010, CLIN CANCER RES, V16, P5835, DOI 10.1158/1078-0432.CCR-10-1434; Slupsky CM, 2009, J PROTEOME RES, V8, P5550, DOI 10.1021/pr9006427; STONE TW, 1993, PHARMACOL REV, V45, P309; Stoop MP, 2010, MOL CELL PROTEOMICS, V9, P2063, DOI 10.1074/mcp.M900877-MCP200; Surendran S, 2003, J CHILD NEUROL, V18, P611, DOI 10.1177/08830738030180090701; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Walsh MC, 2006, AM J CLIN NUTR, V84, P531; WARRELL DA, 1976, AM J MED, V60, P180, DOI 10.1016/0002-9343(76)90427-7; Weli SC, 2006, J VIROL, V80, P10270, DOI 10.1128/JVI.01272-06; Weljie AM, 2006, ANAL CHEM, V78, P4430, DOI 10.1021/ac060209g; Willoughby RE, 2008, DEV BIOLOGICALS, V131, P367; Willoughby RE, 2009, J INHERIT METAB DIS, V32, P65, DOI 10.1007/s10545-008-0949-z; Willoughby R. E., 2011, RABIES TREATMENT PRO; Willoughby RE, 2005, NEW ENGL J MED, V352, P2508, DOI 10.1056/NEJMoa050382; Willoughby RE, 2009, VACCINE, V27, P7173, DOI 10.1016/j.vaccine.2009.09.032; Wishart DS, 2008, J CHROMATOGR B, V871, P164, DOI 10.1016/j.jchromb.2008.05.001; Xu QW, 2011, J BIOMOL NMR, V49, P207, DOI 10.1007/s10858-011-9482-8	62	35	36	0	37	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1535-3893	1535-3907		J PROTEOME RES	J. Proteome Res.	JAN	2013	12	1					481	490		10.1021/pr3009176			10	Biochemical Research Methods	Biochemistry & Molecular Biology	065NX	WOS:000313156300048	23163834	Green Accepted			2021-06-18	
J	Ono, M; Zheng, YY; Joshi, B; Sigl, JC; Hogue, CW				Ono, Masahiro; Zheng, Yueying; Joshi, Brijen; Sigl, Jeffrey C.; Hogue, Charles W.			Validation of a Stand-Alone Near-Infrared Spectroscopy System for Monitoring Cerebral Autoregulation During Cardiac Surgery	ANESTHESIA AND ANALGESIA			English	Article							BLOOD-FLOW AUTOREGULATION; TRAUMATIC BRAIN-INJURY; CARDIOPULMONARY BYPASS; CEREBROVASCULAR AUTOREGULATION; PERFUSION-PRESSURE; REACTIVITY; STROKE; TIME; SATURATION	BACKGROUND: Individualizing arterial blood pressure (ABP) targets during cardiopulmonary bypass (CPB) based on cerebral blood flow (CBF) autoregulation monitoring may provide a more effective means for preventing cerebral hypoperfusion than the current standard of care. Autoregulation can be monitored in real time with transcranial Doppler (TCD). We have previously demonstrated that near-infrared spectroscopy (NIRS)-derived regional cerebral oxygen saturation (rS(c)O(2)) provides a clinically suitable surrogate of CBF for autoregulation monitoring. The purpose of this study was to determine the accuracy of a stand-alone "plug-and-play" investigational system for autoregulation monitoring that uses a commercially available NIRS monitor with TCD methods. METHODS: TCD monitoring of middle cerebral artery CBF velocity and NIRS monitoring were performed in 70 patients during CPB. Indices of autoregulation were computed by both a personal computer-based system and an investigational prototype NIRS-based monitor. A moving linear correlation coefficient between slow waves of ABP and CBF velocity (mean velocity index [Mx]) and between ABP and rS(c)O(2), (cerebral oximetry index [COx]) were calculated. When CBF is autoregulated, there is no correlation between CBF and ABP; when CBF is dysregulated, Mx and COx approach 1 (i.e., CBF and ABP are correlated). Linear regression and bias analysis were performed between time-averaged values of Mx and COx derived from the personal computer-based system and from COx measured with the prototype monitor. Values for Mx and COx were categorized in 5 mm Hg bins of ABP for each patient. The lower limit of CBF autoregulation was defined as the ABP where Mx incrementally increased to >= 0.4. RESULTS: There was correlation and good agreement between COx derived from the prototype monitor and Mx (r = 0.510; 95% confidence interval, 0.414-0.595; P < 0.001; bias, -0.07 +/- 0.19). The correlation and bias between the personal computer based COx and the COx from the prototype NIRS monitor were r = 0.957 (95% confidence interval, 0.945-0.966; P < 0.001 and 0.06 +/- 0.06, respectively). The average ABP at the lower limit of autoregulation was 63 +/- 11 mm Hg (95% prediction interval, 52-74 mm Hg). Although the mean ABP at the COx-determined lower limit of autoregulation determined with the prototype monitor was statistically different from that determined by Mx (59 9 mm Hg; 95% prediction interval, 50-68 mm Hg; P = 0.026), the difference was not likely clinically meaningful. CONCLUSIONS: Monitoring CBF autoregulation with an investigational stand-alone NIRS monitor is correlated and in good agreement with TCD-based methods. The availability of such a device would allow widespread autoregulation monitoring as a means of individualizing ABP targets during CPB. (Anesth Analg 2013;116:198-204)	[Ono, Masahiro] Johns Hopkins Univ, Sch Med, Dept Surg, Div Cardiac Surg, Baltimore, MD 21205 USA; [Zheng, Yueying] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Anesthesiol, Hangzhou 310003, Zhejiang, Peoples R China; [Joshi, Brijen] Johns Hopkins Univ, Sch Med, Dept Internal Med, Sinai Med Ctr, Baltimore, MD USA	Hogue, CW (corresponding author), Johns Hopkins Univ Hosp, Dept Anesthesiol & Crit Care Med, 600 N Wolfe St,Tower 711, Baltimore, MD 21287 USA.	chogue2@jhmi.edu	Ono, Masahiro/AAE-3939-2019		Mid-Atlantic Affiliate of the American Heart AssociationAmerican Heart Association [103363]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01HL092259]; Somanetics Corp/Covidien PLC, Boulder, CO; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL092259] Funding Source: NIH RePORTER	This study was supported in part by the Mid-Atlantic Affiliate of the American Heart Association (grant-in-aid no. 103363), by the National Institutes of Health (grant no. R01HL092259, to C. W. H.), and by a direct research grant from Somanetics Corp/Covidien PLC, Boulder, CO. Clinical Trials Registration NCT00769691 at www.clinicaltrials.gov. Covidien has licensed aspects of the investigational software from The Johns Hopkins University.	Aries MJH, 2012, CRIT CARE MED, V40, P2456, DOI 10.1097/CCM.0b013e3182514eb6; Barodka VM, 2011, ANESTH ANALG, V112, P1048, DOI 10.1213/ANE.0b013e3182147e3c; Bijker JB, 2007, ANESTHESIOLOGY, V107, P213, DOI 10.1097/01.anes.0000270724.40897.8e; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Brady KM, 2007, STROKE, V38, P2818, DOI 10.1161/STROKEAHA.107.485706; Brady K, 2010, STROKE, V41, P1951, DOI 10.1161/STROKEAHA.109.575159; Czosnyka M, 2009, NEUROCRIT CARE, V10, P373, DOI 10.1007/s12028-008-9175-7; DAVIS SM, 1983, NEUROLOGY, V33, P391, DOI 10.1212/WNL.33.4.391; Drummond JC, 1997, ANESTHESIOLOGY, V86, P1431, DOI 10.1097/00000542-199706000-00034; Gottesman RF, 2006, STROKE, V37, P2306, DOI 10.1161/01.STR.0000236024.68020.3a; Joshi B, 2012, ANESTH ANALG, V114, P503, DOI 10.1213/ANE.0b013e31823d292a; Joshi B, 2010, ANESTH ANALG, V110, P321, DOI 10.1213/ANE.0b013e3181c6fd12; Kim MB, 2000, J CLIN MONIT COMPUT, V16, P191, DOI 10.1023/A:1009940031063; Lang EW, 2002, J NEUROL NEUROSUR PS, V72, P583, DOI 10.1136/jnnp.72.5.583; Lavinio A, 2007, STROKE, V38, P402, DOI 10.1161/01.STR.0000254551.92209.5c; Lee JK, 2009, STROKE, V40, P1820, DOI 10.1161/STROKEAHA.108.536094; Minhas PS, 2004, NEUROSURGERY, V55, P63, DOI 10.1227/01.NEU.0000126876.10254.05; Moraca R, 2006, J THORAC CARDIOV SUR, V131, P540, DOI 10.1016/j.jtcvs.2005.10.046; MUHONEN MG, 1992, STROKE, V23, P988, DOI 10.1161/01.STR.23.7.988; Murkin JM, 2007, ANESTH ANALG, V104, P51, DOI 10.1213/01.ane.0000246814.29362.f4; MUTCH WAC, 1994, J CEREBR BLOOD F MET, V14, P510, DOI 10.1038/jcbfm.1994.63; Newman MF, 1996, CIRCULATION, V94, P353; Olsen KS, 1996, J NEUROSURG ANESTH, V8, P280, DOI 10.1097/00008506-199610000-00004; Ono M, 2012, BRIT J ANAESTH, V109, P391, DOI 10.1093/bja/aes148; Panerai RB, 1998, PHYSIOL MEAS, V19, P305, DOI 10.1088/0967-3334/19/3/001; Reinhard M, 2004, STROKE, V35, P1381, DOI 10.1161/01.STR.0000127533.46914.31; SCHELL RM, 1993, ANESTH ANALG, V76, P849; SCHWARTZ AE, 1995, ANN THORAC SURG, V60, P165; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; STRANDGAARD S, 1973, BMJ-BRIT MED J, V1, P507, DOI 10.1136/bmj.1.5852.507; Taylor K M, 1990, Semin Thorac Cardiovasc Surg, V2, P300; YAMAMOTO M, 1980, ARCH NEUROL-CHICAGO, V37, P489, DOI 10.1001/archneur.1980.00500570037005; Zweifel C, 2010, J NEUROTRAUM, V27, P1951, DOI 10.1089/neu.2010.1388; Zweifel C, 2010, STROKE, V41, P1963, DOI 10.1161/STROKEAHA.109.577320	34	35	36	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	JAN	2013	116	1					198	204		10.1213/ANE.0b013e318271fb10			7	Anesthesiology	Anesthesiology	065JT	WOS:000313145300025	23223100	Green Accepted			2021-06-18	
J	Planetta, PJ; Schulze, ET; Geary, EK; Corcos, DM; Goldman, JG; Little, DM; Vaillancourt, DE				Planetta, P. J.; Schulze, E. T.; Geary, E. K.; Corcos, D. M.; Goldman, J. G.; Little, D. M.; Vaillancourt, D. E.			Thalamic Projection Fiber Integrity in de novo Parkinson Disease	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							DIFFUSION TENSOR MRI; TRAUMATIC BRAIN-INJURY; WHITE-MATTER; INTRALAMINAR NUCLEI; CLINICAL-DIAGNOSIS; SUBSTANTIA-NIGRA; TRACTOGRAPHY; MICROSTRUCTURE; DEGENERATION; DYSFUNCTION	BACKGROUND AND PURPOSE Postmortem studies of advanced PD have revealed disease-related pathology in the thalamus with an apparent predilection for specific thalamic nuclei. In the present study, we used DTI to investigate in vivo the microstructural integrity of 6 thalamic regions in de novo patients with PD relative to healthy controls. MATERIALS AND METHODS: Forty subjects (20 with early stage untreated PD and 20 age- and sex-matched controls) were studied with a high-resolution DTI protocol at 3T to investigate the integrity of thalamic nuclei projection fibers. Two blinded, independent raters drew ROls in the following 6 thalamic regions: AN, VA, VL, DM, VPL/VPM, and PU. FA values were then calculated from the projection fibers in each region. RESULTS: FA values were reduced significantly in the fibers projecting from the AN, VA, and DM, but not the VPL/VPM and PU, in the PD group compared with the control group. In addition, there was a reduction in FA values that approached significance in the VL of patients with PD. These findings were consistent across both raters. CONCLUSIONS: The present study provides preliminary in vivo evidence of thalamic projection fiber degeneration in de novo PD and sheds light on the extent of disrupted thalamic circuitry as a result of the disease itself.	[Planetta, P. J.; Vaillancourt, D. E.] Univ Florida, Dept Appl Physiol & Kinesiol, Gainesville, FL 32611 USA; [Vaillancourt, D. E.] Univ Florida, Dept Radiol, Gainesville, FL 32611 USA; [Vaillancourt, D. E.] Univ Florida, Dept Biomed Engn, Gainesville, FL 32611 USA; [Schulze, E. T.; Geary, E. K.; Corcos, D. M.] Univ Illinois, Dept Neurol & Rehabil, Chicago, IL USA; [Corcos, D. M.] Univ Illinois, Dept Kinesiol & Nutr, Chicago, IL USA; [Corcos, D. M.] Univ Illinois, Dept Phys Therapy, Chicago, IL USA; [Corcos, D. M.] Univ Illinois, Dept Bioengn, Chicago, IL USA; [Corcos, D. M.; Goldman, J. G.] Rush Univ, Med Ctr, Dept Neurol Sci, Chicago, IL 60612 USA; [Little, D. M.] VISN 17 Ctr Excellence Res Returning War Vet, Dept Vet Affairs, Waco, TX USA; [Little, D. M.] Texas A&M Hlth Sci Ctr, Dept Psychiat & Behav Sci, Bryan, TX USA	Vaillancourt, DE (corresponding author), Univ Florida, Dept Appl Physiol & Kinesiol, POB 118205, Gainesville, FL 32611 USA.	vcourt@ufl.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-NS-52318, R01-NS-58487, R01 N5058487-05]; Department of Defense/Congressionally Directed Medical Research ProgramUnited States Department of Defense [PT 075675]; Michael J. Fox Foundation; Department of DefenseUnited States Department of Defense; Department of Veterans AffairsUS Department of Veterans Affairs; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS058487, R01NS052318, R01NS075012] Funding Source: NIH RePORTER	This work was supported in part by grants from the Department of Defense/Congressionally Directed Medical Research Program (PT 075675) to D.M.L., Michael J. Fox Foundation (D.E.V.), and National Institutes of Health (R01-NS-52318 and R01NS-58487 to D.E.V.).; Daniel Corcos-RELATED: Grant: NIH;* Support for Travel to Meetings for the Study or Other Purposes: NIH.* Deborah Little RELATED: Grant: Department of Defense,* Department of Veterans Affairs.* David Vaillancourt-RELATED: Grant: Scaling and Sequencing Motor Output in Humans,* Comments: NIH R01 (I am PI); UNRELATED: Consultancy: I consult on a project at Northwestern University using diffusion imaging in Parkinson's disease. The project is unrelated to the current project; Grants/Grants Pending: NIH R01 N5058487-05, Comments: Role of Cortex and Cerebellum in Visually-Guided Motor Behavior.* (*Money paid to institution)	Arend I, 2008, PROG BRAIN RES, V171, P475, DOI 10.1016/S0079-6123(08)00669-9; BASSER PJ, 1994, BIOPHYS J, V66, P259, DOI 10.1016/S0006-3495(94)80775-1; Behrens TEJ, 2003, NAT NEUROSCI, V6, P750, DOI 10.1038/nn1075; Blumenfeld H, 2002, NEUROANATOMY CLIN CA; Boska MD, 2007, NEUROBIOL DIS, V26, P590, DOI 10.1016/j.nbd.2007.02.010; Braak H, 2000, J NEUROL, V247, P3; Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9; Brooks D, 2009, BRAIN RES BULL, V78, P97, DOI 10.1016/j.brainresbull.2008.08.014; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Carrera E, 2006, NEUROLOGY, V66, P1817, DOI 10.1212/01.wnl.0000219679.95223.4c; Chan LL, 2007, J NEUROL NEUROSUR PS, V78, P1383, DOI 10.1136/jnnp.2007.121525; Chaudhuri KR, 2006, LANCET NEUROL, V5, P235, DOI 10.1016/S1474-4422(06)70373-8; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Deboy CA, 2007, BRAIN, V130, P2199, DOI 10.1093/brain/awm122; Du GW, 2011, MOVEMENT DISORD, V26, P1627, DOI 10.1002/mds.23643; Emre M, 2003, MOVEMENT DISORD, V18, pS63, DOI 10.1002/mds.10565; Gattellaro G, 2009, AM J NEURORADIOL, V30, P1222, DOI 10.3174/ajnr.A1556; Halliday GM, 2009, PARKINSONISM RELAT D, V15, pS152, DOI 10.1016/S1353-8020(09)70804-1; Henderson JM, 2000, ANN NEUROL, V47, P345, DOI 10.1002/1531-8249(200003)47:3<345::AID-ANA10>3.0.CO;2-V; Henderson JM, 2000, BRAIN, V123, P1410, DOI 10.1093/brain/123.7.1410; Hodaie M, 2007, NEUROSURGERY, V60, P17, DOI 10.1227/01.NEU.0000249209.11967.CB; Hughes AJ, 2001, NEUROLOGY, V57, pS34; HUGHES AJ, 1992, J NEUROL NEUROSUR PS, V55, P181, DOI 10.1136/jnnp.55.3.181; JAHANSHAHI M, 1995, BRAIN, V118, P913, DOI 10.1093/brain/118.4.913; Jiang HY, 2006, COMPUT METH PROG BIO, V81, P106, DOI 10.1016/j.cmpb.2005.08.004; Klein JC, 2010, NEUROIMAGE, V51, P555, DOI 10.1016/j.neuroimage.2010.02.062; Klingberg T, 1999, NEUROREPORT, V10, P2817, DOI 10.1097/00001756-199909090-00022; Kwon HG, 2011, NEURORADIOLOGY, V53, P787, DOI 10.1007/s00234-011-0878-7; Leh SE, 2008, INT J BIOMED IMAGING, V2008, DOI 10.1155/2008/789539; Li W, 2010, AM J NEURORADIOL, V31, P1861, DOI 10.3174/ajnr.A2195; Little DM, 2010, NEUROLOGY, V74, P558, DOI 10.1212/WNL.0b013e3181cff5d5; Mahlknecht P, 2010, NEURODEGENER DIS, V7, P300, DOI 10.1159/000314495; McKeown MJ, 2008, BMC NEUROL, V8, DOI 10.1186/1471-2377-8-8; Metzger CD, 2010, FRONT NEUROANAT, V4, DOI 10.3389/fnana.2010.00138; Minati L, 2008, NMR BIOMED, V21, P2, DOI 10.1002/nbm.1143; Nicoletti G, 2010, NEUROLOGY, V74, P988, DOI 10.1212/WNL.0b013e3181d5a460; Nobili F, 2010, MOVEMENT DISORD, V25, P35, DOI 10.1002/mds.22899; Owen AM, 1998, BRAIN, V121, P949, DOI 10.1093/brain/121.5.949; Peran P, 2010, BRAIN, V133, P3423, DOI 10.1093/brain/awq212; Planetta PJ, 2011, NEURODEGENER DIS MAN, V1, P67, DOI 10.2217/NMT.10.6; Prodoehl J, 2010, MOVEMENT DISORD, V25, P2035, DOI 10.1002/mds.23360; Rub U, 2002, NEUROBIOL AGING, V23, P245, DOI 10.1016/S0197-4580(01)00269-X; Schmahmann JD, 2003, STROKE, V34, P2264, DOI 10.1161/01.STR.0000087786.38997.9E; Spraker MB, 2010, HUM BRAIN MAPP, V31, P1928, DOI 10.1002/hbm.20987; Vaillancourt DE, 2009, NEUROLOGY, V72, P1378, DOI 10.1212/01.wnl.0000340982.01727.6e; Van der Werf YD, 2002, BRAIN RES REV, V39, P107, DOI 10.1016/S0165-0173(02)00181-9; WIMBERGER DM, 1995, J COMPUT ASSIST TOMO, V19, P28, DOI 10.1097/00004728-199501000-00005; Yoshikawa K, 2004, J NEUROL NEUROSUR PS, V75, P481, DOI 10.1136/jnnp.2003.021873; Zhan W, 2012, MOVEMENT DISORD, V27, P90, DOI 10.1002/mds.23917; Zhang DY, 2010, CEREB CORTEX, V20, P1187, DOI 10.1093/cercor/bhp182; Zhou X, 1999, United States Patent, Patent No. [5 1999;864:233, 19995864233]	51	35	35	0	11	AMER SOC NEURORADIOLOGY	DENVILLE	PO BOX 3000, DENVILLE, NJ 07834-9349 USA	0195-6108	1936-959X		AM J NEURORADIOL	Am. J. Neuroradiol.	JAN	2013	34	1					74	79		10.3174/ajnr.A3178			6	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	070WQ	WOS:000313545200014	22766668	Green Accepted, Green Published, Other Gold			2021-06-18	
J	Schirmer, L; Merkler, D; Konig, FB; Bruck, W; Stadelmann, C				Schirmer, Lucas; Merkler, Doron; Koenig, Fatima B.; Brueck, Wolfgang; Stadelmann, Christine			Neuroaxonal Regeneration is More Pronounced in Early Multiple Sclerosis than in Traumatic Brain Injury Lesions	BRAIN PATHOLOGY			English	Article						axonal regeneration; GAP43; multiple sclerosis (MS); neuronal plasticity; traumatic brain injury (TBI)	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; ANTEROGRADE AXONAL-TRANSPORT; SPINAL-CORD; MONOCLONAL-ANTIBODIES; HEAD-INJURY; DAMAGE; PROTEIN; PLASTICITY; PRECURSOR; MOTOR	The extent of irreversible neuroaxonal damage is the key determinant of permanent disability in traumatic and inflammatory conditions of the central nervous system (CNS). Structural damage is nevertheless in part compensated by neuroplastic events. However, it is unknown whether the same kinetics and mechanisms of neuroaxonal de- and regeneration take place in inflammatory and traumatic conditions. We analyzed neuroaxonal degeneration and plasticity in early multiple sclerosis (MS) lesions and traumatic brain injury (TBI). Neuroaxonal degeneration identified by the presence of SMI31+ chromatolytic neurons and SMI32+ axonal profiles were characteristic features of leukocortical TBI lesions. Axonal transport disturbances as determined by amyloid precursor protein (APP)+ spheroids were present in both TBI and MS lesions to a similar degree. Neurons expressing growth-associated protein 43 (GAP43) and synaptophysin (Syn) were found under both pathological conditions. However, axonal swellings immunopositive for GAP43 and Syn clearly prevailed in subcortical MS lesions, suggesting a higher regenerative potential in MS. In this context, GAP43+/APP+ axonal spheroid ratios correlated with macrophage infiltration in TBI and MS lesions, supporting the idea that phagocyte activation might promote neuroplastic events. Furthermore, axonal GAP43+ and Syn+ swellings correlated with prolonged survival after TBI, indicating a sustained regenerative response.	[Schirmer, Lucas; Merkler, Doron; Koenig, Fatima B.; Brueck, Wolfgang; Stadelmann, Christine] Univ Med Ctr Gottingen, Dept Neuropathol, Gottingen, Germany; [Schirmer, Lucas] Tech Univ Munich, Klinikum Rechts Isar, Dept Neurol, D-8000 Munich, Germany; [Merkler, Doron] Univ Hosp Geneva, Div Clin Pathol, Geneva, Switzerland; [Merkler, Doron] Univ Geneva, Dept Pathol & Immunol, Geneva, Switzerland	Stadelmann, C (corresponding author), Inst Neuropathol, Robert Koch Str 40, D-37099 Gottingen, Germany.	cstadelmann@med.uni-goettingen.de	Merkler, Doron/N-9157-2016	Merkler, Doron/0000-0002-0247-2007; Schirmer, Lucas/0000-0001-7142-4116; Stadelmann, Christine/0000-0003-1766-5458	DFG transregional collaborative research center 43German Research Foundation (DFG); DFGGerman Research Foundation (DFG)European Commission [GRK 632]	This work was supported by the DFG transregional collaborative research center 43 "The brain as a target of inflammatory processes." LS was supported by the DFG (GRK 632 "Neuroplasticity").	Bar-Or A, 2011, CNS DRUGS, V25, P783, DOI 10.2165/11587820-000000000-00000; Blaylock Russell L, 2011, Surg Neurol Int, V2, P107, DOI 10.4103/2152-7806.83391; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Charcot J., 1868, GAZ HOP PARIS, V41, P554; Charcot JM, 1868, GAZ HOPITAUX, V141, P557; Charcot JM, 1868, GAZ HOPITAUX, V140, P566; CRAGG BG, 1970, BRAIN RES, V23, P1, DOI 10.1016/0006-8993(70)90345-8; DAHL D, 1989, ACTA NEUROPATHOL, V79, P154, DOI 10.1007/BF00294373; De Stefano N, 1998, BRAIN, V121, P1469, DOI 10.1093/brain/121.8.1469; Doinikow B, 1915, Z GESAMTE NEUROL PSY, V27, P151; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Ferguson B, 1997, BRAIN, V120, P393, DOI 10.1093/brain/120.3.393; Frey D, 2000, J CELL BIOL, V149, P1443, DOI 10.1083/jcb.149.7.1443; Greer JE, 2011, J NEUROSCI, V31, P5089, DOI 10.1523/JNEUROSCI.5103-10.2011; Haider L, 2011, BRAIN, V134, P1914, DOI 10.1093/brain/awr128; Herdegen T, 1997, TRENDS NEUROSCI, V20, P227, DOI 10.1016/S0166-2236(96)01000-4; Kerschensteiner M, 2003, ANN NEUROL, V53, P292, DOI 10.1002/ana.10446; Kerschensteiner M, 2004, J EXP MED, V200, P1027, DOI 10.1084/jem.20040452; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; Kuhlmann T, 2002, BRAIN, V125, P2202, DOI 10.1093/brain/awf235; Li Y, 1998, STROKE, V29, P1972, DOI 10.1161/01.STR.29.9.1972; Lucchinetti C, 2000, ANN NEUROL, V47, P707, DOI 10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q; Lucchinetti CF, 2011, NEW ENGL J MED, V365, P2188, DOI 10.1056/NEJMoa1100648; Mahad D, 2008, BRAIN, V131, P1722, DOI 10.1093/brain/awn105; Mahad DJ, 2009, BRAIN, V132, P1161, DOI 10.1093/brain/awp046; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; Meeuwsen S, 2003, GLIA, V43, P243, DOI 10.1002/glia.10259; Merkler D, 2001, J NEUROSCI, V21, P3665, DOI 10.1523/JNEUROSCI.21-10-03665.2001; Nikic I, 2011, NAT MED, V17, P495, DOI 10.1038/nm.2324; OKADA Y, 1995, CELL, V81, P769, DOI 10.1016/0092-8674(95)90538-3; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Peterson JW, 2001, ANN NEUROL, V50, P389, DOI 10.1002/ana.1123; RADZUN HJ, 1991, LAB INVEST, V65, P306; Raineteau O, 2001, NAT REV NEUROSCI, V2, P263, DOI 10.1038/35067570; Rocca MA, 2010, NEUROLOGY, V74, P142, DOI 10.1212/WNL.0b013e3181c91a00; Schirmer L, 2011, BRAIN PATHOL, V21, P428, DOI 10.1111/j.1750-3639.2010.00466.x; Schirmer L, 2009, ANN NEUROL, V66, P698, DOI 10.1002/ana.21799; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; Singleton RH, 2004, J NEUROSCI, V24, P3543, DOI 10.1523/JNEUROSCI.5048-03.2004; Stadelmann C, 2002, BRAIN, V125, P75, DOI 10.1093/brain/awf015; Stadelmann C, 2011, CURR OPIN NEUROL, V24, P224, DOI 10.1097/WCO.0b013e328346056f; Stagi M, 2005, J NEUROSCI, V25, P352, DOI 10.1523/JNEUROSCI.3887-04.2005; STERNBERGER LA, 1983, P NATL ACAD SCI-BIOL, V80, P6126, DOI 10.1073/pnas.80.19.6126; TETZLAFF W, 1989, J NEUROSCI, V9, P1303; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; Vogt J, 2009, ANN NEUROL, V66, P310, DOI 10.1002/ana.21719; Wegner C, 2006, NEUROLOGY, V67, P960, DOI 10.1212/01.wnl.0000237551.26858.39; Wilkinson AE, 1999, ACTA NEUROPATHOL, V98, P197, DOI 10.1007/s004010051069	50	35	35	0	6	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1015-6305			BRAIN PATHOL	Brain Pathol.	JAN	2013	23	1					2	12		10.1111/j.1750-3639.2012.00608.x			11	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	053CV	WOS:000312248600002	22612622				2021-06-18	
J	Jha, MK; Jeon, S; Suk, K				Jha, Mithilesh Kumar; Jeon, Sangmin; Suk, Kyoungho			Pyruvate Dehydrogenase Kinases in the Nervous System: Their Principal Functions in Neuronal-glial Metabolic Interaction and Neuro-metabolic Disorders	CURRENT NEUROPHARMACOLOGY			English	Article						Aerobic glycolysis; neuro-metabolic disorders; neuronal-glial interaction; oxidative phosphorylation; pyruvate dehydrogenase complex; pyruvate dehydrogenase kinase	TRAUMATIC BRAIN-INJURY; ACTIVATED RECEPTOR-ALPHA; HUMAN SKELETAL-MUSCLE; ALZHEIMERS-DISEASE; ENERGY-METABOLISM; MITOCHONDRIAL DYSFUNCTION; AEROBIC GLYCOLYSIS; LACTATE SHUTTLE; IN-VIVO; PHOSPHORYLATION SITES	Metabolism is involved directly or indirectly in all processes conducted in living cells. The brain, popularly viewed as a neuronal-glial complex, gets most of its energy from the oxygen-dependent metabolism of glucose, and the mitochondrial pyruvate dehydrogenase complex (PDC) plays a key regulatory role during the oxidation of glucose. Pyruvate dehydrogenase kinase (also called PDC kinase or PDK) is a kinase that regulates glucose metabolism by switching off PDC. Four isoforms of PDKs with tissue specific activities have been identified. The metabolisms of neurons and glial cells, especially, those of astroglial cells, are interrelated, and these cells function in an integrated fashion. The energetic coupling between neuronal and astroglial cells is essential to meet the energy requirements of the brain in an efficient way. Accumulating evidence suggests that alterations in the PDKs and/or neuron-astroglia metabolic interactions are associated with the development of several neurological disorders. Here, the authors review the results of recent research efforts that have shed light on the functions of PDKs in the nervous system, particularly on neuron-glia metabolic interactions and neuro-metabolic disorders.	[Jha, Mithilesh Kumar; Jeon, Sangmin; Suk, Kyoungho] Kyungpook Natl Univ, Sch Med, Dept Pharmacol, Brain Sci & Engn Inst, Taegu 700422, South Korea	Suk, K (corresponding author), Kyungpook Natl Univ, Sch Med, Dept Pharmacol, Brain Sci & Engn Inst, 680 Gukchaebosang St, Taegu 700422, South Korea.	ksuk@knu.ac.kr		Jha, Mithilesh Kumar/0000-0002-9526-0053	National Research Foundation (NRF); Ministry of Education, Science and Technology (MEST) of Korean governmentMinistry of Education, Science and Technology, Republic of Korea [2011-0028240]; Korean Health technology R&D Project, Ministry of Health & Welfare, Republic of Korea [A111345]	This work was supported by the National Research Foundation (NRF) grants funded by the Ministry of Education, Science and Technology (MEST) of Korean government (2011-0028240). This study was also supported by a grant of the Korean Health technology R&D Project, Ministry of Health & Welfare, Republic of Korea (A111345).	Aubert A, 2005, P NATL ACAD SCI USA, V102, P16448, DOI 10.1073/pnas.0505427102; Aubert A, 2007, GLIA, V55, P1272, DOI 10.1002/glia.20360; Balmaceda-Aguilera C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032409; Barros LF, 2007, GLIA, V55, P1222, DOI 10.1002/glia.20375; Beal MF, 2005, ANN NEUROL, V58, P495, DOI 10.1002/ana.20624; Blass JP, 2000, ANN NY ACAD SCI, V924, P170; Bonnet S, 2007, CANCER CELL, V11, P37, DOI 10.1016/j.ccr.2006.10.020; Bonvento G, 2005, J CEREBR BLOOD F MET, V25, P1394, DOI 10.1038/sj.jcbfm.9600127; Bowker-Kinley M, 1999, BIOCHEM J, V344, P47, DOI 10.1042/0264-6021:3440047; Bowker-Kinley MM, 1998, BIOCHEM J, V329, P191, DOI 10.1042/bj3290191; BRIGHTMA.MW, 1969, J CELL BIOL, V40, P648, DOI 10.1083/jcb.40.3.648; Caspersen C, 2005, FASEB J, V19, P2040, DOI 10.1096/fj.05-3735fje; Chih CP, 2001, TRENDS NEUROSCI, V24, P573, DOI 10.1016/S0166-2236(00)01920-2; Dang CV, 2008, ERNST SCHERING FOUND, V4, P35, DOI 10.1007/2789_2008_088; DeKosky ST, 1996, NEURODEGENERATION, V5, P417, DOI 10.1006/neur.1996.0056; Denton R M, 1979, Essays Biochem, V15, P37; Denton RM, 1996, ADV ENZYME REGUL, V36, P183, DOI 10.1016/0065-2571(95)00020-8; Devi L, 2006, J NEUROSCI, V26, P9057, DOI 10.1523/JNEUROSCI.1469-06.2006; Di RM, 2010, CHINESE MED J-PEKING, V123, P2358, DOI 10.3760/cma.j.issn.0366-6999.2010.17.014; DIENEL GA, 1988, J BIOL CHEM, V263, P19697; Dienel GA, 2004, NEUROCHEM INT, V45, P321, DOI 10.1016/j.neuint.2003.10.011; DRINGEN R, 1993, BRAIN RES, V623, P208, DOI 10.1016/0006-8993(93)91429-V; Dunford EC, 2011, AM J PHYSIOL-REG I, V300, pR1487, DOI 10.1152/ajpregu.00498.2010; Fiskum G, 2004, J BIOENERG BIOMEMBR, V36, P347, DOI 10.1023/B:JOBB.0000041766.71376.81; Gandhi GK, 2009, J NEUROCHEM, V111, P522, DOI 10.1111/j.1471-4159.2009.06333.x; Genc S, 2011, BMC SYST BIOL, V5, DOI 10.1186/1752-0509-5-162; Gibson GE, 2010, J ALZHEIMERS DIS, V20, pS591, DOI 10.3233/JAD-2010-100336; Gjedde A, 2002, J CEREBR BLOOD F MET, V22, P1, DOI 10.1097/00004647-200201000-00001; Gladden LB, 2004, J PHYSIOL-LONDON, V558, P5, DOI 10.1113/jphysiol.2003.058701; GUDI R, 1995, J BIOL CHEM, V270, P28989, DOI 10.1074/jbc.270.48.28989; Halim ND, 2010, GLIA, V58, P1168, DOI 10.1002/glia.20996; Harris RA, 2002, ADV ENZYME REGUL, V42, P249, DOI 10.1016/S0065-2571(01)00061-9; Harris RA, 1997, J BIOL CHEM, V272, P19746, DOI 10.1074/jbc.272.32.19746; Harris RA, 2001, ADV ENZYME REGUL, V41, P269, DOI 10.1016/S0065-2571(00)00020-0; Hattori N, 2003, J NUCL MED, V44, P1709; Hauptmann S, 2009, NEUROBIOL AGING, V30, P1574, DOI 10.1016/j.neurobiolaging.2007.12.005; Hertz L, 2002, INT REV NEUROBIOL, V51, P1, DOI 10.1016/S0074-7742(02)51003-5; Hillered L, 2008, CRIT CARE MED, V36, P2952, DOI 10.1097/CCM.0b013e3181872178; Holness MJ, 2003, BIOCHEM SOC T, V31, P1143; Holness MJ, 2002, BIOCHEM J, V364, P687, DOI 10.1042/bj20011841; Huang BL, 2003, DIABETES, V52, P1371, DOI 10.2337/diabetes.52.6.1371; Huang BL, 2002, DIABETES, V51, P276, DOI 10.2337/diabetes.51.2.276; Huang BL, 1998, J BIOL CHEM, V273, P17680, DOI 10.1074/jbc.273.28.17680; Hyder F, 2006, J CEREBR BLOOD F MET, V26, P865, DOI 10.1038/sj.jcbfm.9600263; KATOHSEMBA R, 1988, CELL TISSUE RES, V252, P133; Kim JW, 2007, MOL CELL BIOL, V27, P7381, DOI 10.1128/MCB.00440-07; Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002; Korotchkina LG, 2001, J BIOL CHEM, V276, P37223, DOI 10.1074/jbc.M103069200; Laurencikiene J, 2008, CANCER RES, V68, P9247, DOI 10.1158/0008-5472.CAN-08-1343; LeBlanc PJ, 2004, J PHYSIOL-LONDON, V557, P559, DOI 10.1113/jphysiol.2003.058263; Leybaert L, 2005, J CEREBR BLOOD F MET, V25, P2, DOI 10.1038/sj.jcbfm.9600001; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Lovell MA, 2000, FREE RADICAL BIO MED, V29, P714, DOI 10.1016/S0891-5849(00)00346-4; Lu HS, 2005, J BIOL CHEM, V280, P41928, DOI 10.1074/jbc.M508718200; Lu HS, 2002, J BIOL CHEM, V277, P23111, DOI 10.1074/jbc.M202487200; Machius M, 2001, P NATL ACAD SCI USA, V98, P11218, DOI 10.1073/pnas.201220098; MAENG CY, 1994, BIOCHEMISTRY-US, V33, P13801, DOI 10.1021/bi00250a034; Magistretti PJ, 2006, J EXP BIOL, V209, P2304, DOI 10.1242/jeb.02208; Magistretti PJ, 1999, SCIENCE, V283, P496, DOI 10.1126/science.283.5401.496; Manczak M, 2006, HUM MOL GENET, V15, P1437, DOI 10.1093/hmg/ddl066; Mangia S, 2011, J CEREBR BLOOD F MET, V31, P1346, DOI 10.1038/jcbfm.2011.29; Mangia S, 2009, J NEUROCHEM, V109, P55, DOI 10.1111/j.1471-4159.2009.06003.x; Mangia S, 2009, J CEREBR BLOOD F MET, V29, P441, DOI 10.1038/jcbfm.2008.134; MARTINEZHERNANDEZ A, 1977, SCIENCE, V195, P1356, DOI 10.1126/science.14400; MATSUMOTO K, 1995, BIOCHEM BIOPH RES CO, V209, P95, DOI 10.1006/bbrc.1995.1475; McFate T, 2008, J BIOL CHEM, V283, P22700, DOI 10.1074/jbc.M801765200; Michelakis ED, 2008, BRIT J CANCER, V99, P989, DOI 10.1038/sj.bjc.6604554; Michelakis ED, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000677; Mosconi L, 2005, EUR J NUCL MED MOL I, V32, P486, DOI [10.1007/s00259-005-1762-7, 10.1007/s00259-008-1039-z]; Mosconi L, 2009, NEUROLOGY, V72, P513, DOI 10.1212/01.wnl.0000333247.51383.43; Mosconi L, 2008, NEUROBIOL AGING, V29, P676, DOI 10.1016/j.neurobiolaging.2006.12.008; Nakai N, 2000, LIFE SCI, V68, P497, DOI 10.1016/S0024-3205(00)00947-4; Navarro A, 2002, AM J PHYSIOL-REG I, V282, pR985, DOI 10.1152/ajpregu.00537.2001; Nehlig A, 2007, GLIA, V55, P1238, DOI 10.1002/glia.20376; Nicholson RM, 2010, BRAIN RES, V1347, P179, DOI 10.1016/j.brainres.2010.05.084; Nunomura A, 2001, J NEUROPATH EXP NEUR, V60, P759, DOI 10.1093/jnen/60.8.759; Occhipinti R, 2009, J NEUROPHYSIOL, V101, P2528, DOI 10.1152/jn.90377.2008; Ohgaki H, 2007, AM J PATHOL, V170, P1445, DOI 10.2353/ajpath.2007.070011; Opii WO, 2007, J NEUROTRAUM, V24, P772, DOI 10.1089/neu.2006.0229; Pan James G, 2007, Sci STKE, V2007, ppe14; Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012; Park LCH, 1999, J NEUROCHEM, V72, P1948, DOI 10.1046/j.1471-4159.1999.0721948.x; Patel MS, 2006, BIOCHEM SOC T, V34, P217, DOI 10.1042/BST0340217; PATEL MS, 1990, FASEB J, V4, P3224; Pelicano H, 2006, ONCOGENE, V25, P4633, DOI 10.1038/sj.onc.1209597; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; Pellerin L, 2007, GLIA, V55, P1251, DOI 10.1002/glia.20528; Peters SJ, 1998, AM J PHYSIOL-ENDOC M, V275, pE980; Pocernich CB, 2003, NEUROTOX RES, V5, P515, DOI 10.1007/BF03033161; Popov KM, 1997, ADV SEC MESS PHOSPH, V31, P105; POPOV KM, 1993, J BIOL CHEM, V268, P26602; POPOV KM, 1994, J BIOL CHEM, V269, P29720; Pratico D, 2004, J ALZHEIMERS DIS, V6, P385; PRIESTMAN DA, 1994, BIOCHEM J, V300, P659, DOI 10.1042/bj3000659; Prins ML, 2004, J NEUROCHEM, V90, P666, DOI 10.1111/j.1471-4159.2004.02542.x; RANDLE PJ, 1986, BIOCHEM SOC T, V14, P799, DOI 10.1042/bst0140799; Randle PJ, 1998, DIABETES METAB REV, V14, P263, DOI 10.1002/(SICI)1099-0895(199812)14:4&lt;263::AID-DMR233&gt;3.0.CO;2-C; Reddy PH, 2008, TRENDS MOL MED, V14, P45, DOI 10.1016/j.molmed.2007.12.002; REED LJ, 1990, J BIOL CHEM, V265, P8971; Reiman EM, 2004, P NATL ACAD SCI USA, V101, P284, DOI 10.1073/pnas.2635903100; Robertson CL, 2007, J NEUROCHEM, V101, P1248, DOI 10.1111/j.1471-4159.2007.04489.x; Roche TE, 2007, CELL MOL LIFE SCI, V64, P830, DOI 10.1007/s00018-007-6380-z; Roche TE, 2001, PROG NUCLEIC ACID RE, V70, P33, DOI 10.1016/S0079-6603(01)70013-X; Rowles J, 1996, J BIOL CHEM, V271, P22376, DOI 10.1074/jbc.271.37.22376; Sanderson SJ, 1996, EUR J BIOCHEM, V236, P68, DOI 10.1111/j.1432-1033.1996.00068.x; Schurr A, 2007, NEUROSCIENCE, V147, P613, DOI 10.1016/j.neuroscience.2007.05.002; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Silver IA, 1997, NEUROSCIENCE, V78, P589, DOI 10.1016/S0306-4522(96)00600-8; Simpson IA, 2007, J CEREBR BLOOD F MET, V27, P1766, DOI 10.1038/sj.jcbfm.9600521; Smallbone K, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-6; Smolle M, 2006, J BIOL CHEM, V281, P19772, DOI 10.1074/jbc.M601140200; Spriet LL, 2004, J APPL PHYSIOL, V96, P2082, DOI 10.1152/japplphysiol.01318.2003; Stacpoole P.W., 2012, AGING CELL; STACPOOLE PW, 1989, METABOLISM, V38, P1124, DOI 10.1016/0026-0495(89)90051-6; Starkov AA, 2004, J NEUROSCI, V24, P7779, DOI 10.1523/JNEUROSCI.1899-04.2004; Steussy CN, 2001, J BIOL CHEM, V276, P37443, DOI 10.1074/jbc.M104285200; Sugden Mary C., 2006, Archives of Physiology and Biochemistry, V112, P139, DOI 10.1080/13813450600935263; Sugden MC, 1997, J MOL CELL CARDIOL, V29, P1867, DOI 10.1006/jmcc.1997.0425; Sugden MC, 2003, AM J PHYSIOL-ENDOC M, V284, pE855, DOI 10.1152/ajpendo.00526.2002; Sugden MC, 2001, DIABETES, V50, P2729, DOI 10.2337/diabetes.50.12.2729; Sugden MC, 2001, BIOCHEM SOC T, V29, P272, DOI 10.1042/0300-5127:0290272; Sun LJ, 2006, MITOCHONDRION, V6, P136, DOI 10.1016/j.mito.2006.04.003; Takano T, 2006, NAT NEUROSCI, V9, P260, DOI 10.1038/nn1623; TEAGUE WM, 1979, BIOCHEM BIOPH RES CO, V87, P244, DOI 10.1016/0006-291X(79)91672-3; Tokmakov A.A., 2011, J MOL MODEL; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Wang J, 2009, SCI CHINA SER C, V52, P1003, DOI 10.1007/s11427-009-0140-2; Wang Z, 2009, ENDOCR J, V56, P1019, DOI 10.1507/endocrj.K09E-178; Wu PF, 2000, ARCH BIOCHEM BIOPHYS, V381, P1, DOI 10.1006/abbi.2000.1946; Wu PF, 1998, BIOCHEM J, V329, P197, DOI 10.1042/bj3290197; Wynn RM, 2008, J BIOL CHEM, V283, P25305, DOI 10.1074/jbc.M802249200; Wynn RM, 2000, J BIOL CHEM, V275, P30512, DOI 10.1074/jbc.M005075200; Xing GQ, 2012, EXP NEUROL, V234, P31, DOI 10.1016/j.expneurol.2011.12.007; Xing GQ, 2009, NEUROSCI LETT, V454, P38, DOI 10.1016/j.neulet.2009.01.047; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yao J, 2009, P NATL ACAD SCI USA, V106, P14670, DOI 10.1073/pnas.0903563106; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; YU ACH, 1983, J NEUROCHEM, V41, P1484, DOI 10.1111/j.1471-4159.1983.tb00849.x; Zhou QQ, 2009, FEBS LETT, V583, P1132, DOI 10.1016/j.febslet.2009.02.043	141	35	36	0	15	BENTHAM SCIENCE PUBL LTD	SHARJAH	EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES	1570-159X	1875-6190		CURR NEUROPHARMACOL	Curr. Neuropharmacol.	DEC	2012	10	4					393	403					11	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	048KH	WOS:000311909700010	23730261	Green Published			2021-06-18	
J	Mott, TF; McConnon, ML; Rieger, BP				Mott, Timothy F.; McConnon, Michael L.; Rieger, Brian P.			Subacute to Chronic Mild Traumatic Brain Injury	AMERICAN FAMILY PHYSICIAN			English	Article							TASK-FORCE; NEUROPSYCHOLOGY; MANAGEMENT; HEAD; PAIN	Although a universally accepted definition is lacking, mild traumatic brain injury and concussion are classified by transient loss of consciousness, amnesia, altered mental status, a Glasgow Coma Score of 13 to 15, and focal neurologic deficits following an acute closed head injury. Most patients recover quickly, with a predictable clinical course of recovery within the first one to two weeks following traumatic brain injury. Persistent physical, cognitive, or behavioral postconcussive symptoms may be noted in 5 to 20 percent of persons who have mild traumatic brain injury. Physical symptoms include headaches, dizziness, and nausea, and changes in coordination, balance, appetite, sleep, vision, and hearing. Cognitive and behavioral symptoms include fatigue, anxiety, depression, and irritability, and problems with memory, concentration and decision making. Women, older adults, less educated persons, and those with a previous mental health diagnosis are more likely to have persistent symptoms. The diagnostic workup for subacute to chronic mild traumatic brain injury focuses on the history and physical examination, with continuing observation for the development of red flags such as the progression of physical, cognitive, and behavioral symptoms, seizure, progressive vomiting, and altered mental status. Early patient and family education should include information on diagnosis and prognosis, symptoms, and further injury prevention. Symptom-specific treatment, gradual return to activity, and multidisciplinary coordination of care lead to the best outcomes. Psychiatric and medical comorbidities, psychosocial issues, and legal or compensatory incentives should be explored in patients resistant to treatment. (Am Fam Physician. 2012;86(11):1045-1051. Copyright (C) 2012 American Academy of Family Physicians.)	[Mott, Timothy F.] Naval Hosp Pensacola, Family Med Residency Program, Pensacola, FL USA; [Rieger, Brian P.] State Univ New York Upstate Med Univ, Concuss Management Program, Syracuse, NY USA; [Rieger, Brian P.] State Univ New York Upstate Med Univ, Cent New York Concuss Ctr, Syracuse, NY USA	Mott, TF (corresponding author), Pensacola Family Med Residency, 6000 W Hwy 98, Pensacola, FL 32515 USA.	timothy.mott@med.navy.mil					Arciniegas David B, 2005, Neuropsychiatr Dis Treat, V1, P311; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Borg J, 2004, J REHABIL MED, V36, P76, DOI 10.1080/16501960410023840; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; Coronado Victor G, 2010, TRAUMATIC BRAIN INJU; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Gironda RJ, 2009, REHABIL PSYCHOL, V54, P247, DOI 10.1037/a0016906; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; Jones E, 2007, AM J PSYCHIAT, V164, P1641, DOI 10.1176/appi.ajp.2007.07071180; Jotwani V, 2010, CURR SPORT MED REP, V9, P21, DOI 10.1249/JSR.0b013e3181ccb55e; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; McCrea M, 2008, CLIN NEUROPSYCHOL, V22, P10, DOI 10.1080/13854040701760981; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; McCrory P, 2009, PHYSICIAN SPORTSMED, V37, P141, DOI 10.3810/psm.2009.06.1721; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; *MILD TRAUM BRAIN, 1997, NEUROLOGY, V48, P581; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; National Center for Injury Prevention and Control, 2003, C MILD TRAUM BRAIN I; Pertab JL, 2009, BRAIN INJURY, V23, P498, DOI 10.1080/02699050902927984; Ponsford J, 2005, CURR OPIN NEUROL, V18, P692, DOI 10.1097/01.wco.0000186840.61431.44; Quinlan JD, 2010, AM FAM PHYSICIAN, V82, P43; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Silver JM, 2009, AM J PSYCHIAT, V166, P653, DOI 10.1176/appi.ajp.2009.08111676; Snell D, 2009, J CLIN EXP NEUROPSYC, V31, P20, DOI 10.1080/13803390801978849; Soo C, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005239.pub2; United States Department of Veterans Affairs & Department of Defense, 2009, VA DOD CLIN PRACT GU; Whiteside JW, 2006, AM FAM PHYSICIAN, V74, P1357	31	35	35	0	26	AMER ACAD FAMILY PHYSICIANS	KANSAS CITY	8880 WARD PARKWAY, KANSAS CITY, MO 64114-2797 USA	0002-838X	1532-0650		AM FAM PHYSICIAN	Am. Fam. Physician	DEC 1	2012	86	11					1045	1051					7	Primary Health Care; Medicine, General & Internal	General & Internal Medicine	047YL	WOS:000311877300013	23198672				2021-06-18	
J	Matthews, SC; Spadoni, AD; Lohr, JB; Strigo, IA; Simmons, AN				Matthews, Scott C.; Spadoni, Andrea D.; Lohr, James B.; Strigo, Irma A.; Simmons, Alan N.			Diffusion tensor imaging evidence of white matter disruption associated with loss versus alteration of consciousness in warfighters exposed to combat in Operations Enduring and Iraqi Freedom	PSYCHIATRY RESEARCH-NEUROIMAGING			English	Article						Diffusion tensor imaging; Concussion; Loss of consciousness; Depression; PTSD; White matter	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; SPATIAL STATISTICS; VOXELWISE ANALYSIS; INTEGRITY; DEPRESSION; MRI; AFGHANISTAN; DISTORTION; SEQUELAE	The effects on the human brain of mild traumatic brain injury (mTBI), which is defined as a brief alteration (AOC) or loss of consciousness (LOC), are incompletely understood. Major psychiatric illnesses such as major depressive disorder (MDD) and posttraumatic stress disorder (PTSD) are common after mTBI. Prior research suggests that individuals who develop MOD after blast-related mTBI versus those who do not show significant white matter disruption and higher rates of LOC, suggesting that LOC might be uniquely associated with brain changes that increase the risk of developing mental illness after neurotrauma. Therefore, the objective of this study was to examine the effects of LOC, MDD, and PTSD on white matter integrity in individuals who reported experiencing mTBI during combat in Operations Enduring and Iraqi Freedom. We hypothesized that LOC would be associated with significant disruption of white matter, above and beyond putative effects of MOD and PTSD. To test this hypothesis, 46 individuals who experienced blast-related mTBI underwent a detailed clinical assessment and diffusion tensor imaging. As hypothesized, LOC versus AOC individuals displayed significantly lower fractional anisotropy (FA) in 14 regions, which included the superior longitudinal fasciculus and corpus callosum. No regions of significant FA difference were identified between individuals with and without PTSD, or between individuals with and without MDD. These preliminary results show that LOC is associated with detectable alterations in brain microstructure and may suggest a brain basis for psychiatric symptoms and mental illness after mTBI. Published by Elsevier Ireland Ltd.	[Matthews, Scott C.; Spadoni, Andrea D.; Lohr, James B.; Strigo, Irma A.; Simmons, Alan N.] Vet Affairs San Diego Healthcare Syst, La Jolla, CA 92093 USA; [Matthews, Scott C.; Spadoni, Andrea D.; Strigo, Irma A.; Simmons, Alan N.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA; [Matthews, Scott C.; Lohr, James B.; Strigo, Irma A.; Simmons, Alan N.] VA Ctr Excellence Stress & Mental Hlth, La Jolla, CA USA; [Matthews, Scott C.] VA Mental Illness Res Educ & Clin Ctr, La Jolla, CA USA	Matthews, SC (corresponding author), Vet Affairs San Diego Healthcare Syst, 3350 La Jolla Village Dr,Mail Code 116-A, La Jolla, CA 92093 USA.	scmatthews@ucsd.edu	Simmons, Alan N/A-9815-2008; strigo, irina A/L-9882-2016	Simmons, Alan N/0000-0003-3963-2112; strigo, irina A/0000-0002-8799-716X; Spadoni, Andrea/0000-0002-8367-6406	Veterans AdministrationUS Department of Veterans Affairs; Congressionally Directed Medical Research ProgramUnited States Department of Defense; VA Mental Illness Research, Education and Clinical Center; VA Center of Excellence for Stress and Mental Health; VA Clinical Science Research and Development; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32MH018399] Funding Source: NIH RePORTER	We thank Ryan O'Connell, Elena Kosheleva, Martin Paulus, Dean Delis, and Larry Frank for their contributions to this research, which was funded by grants from the Veterans Administration and the Congressionally Directed Medical Research Program and was supported by the VA Mental Illness Research, Education and Clinical Center and the VA Center of Excellence for Stress and Mental Health. Dr. Matthews' VA salary is supported by a CDA-2 from VA Clinical Science Research and Development.	Abe O, 2006, PSYCHIAT RES-NEUROIM, V146, P231, DOI 10.1016/j.pscychresns.2006.01.004; Andersson JLR, 2002, NEUROIMAGE, V16, P177, DOI 10.1006/nimg.2001.1039; Bae JN, 2006, BIOL PSYCHIAT, V60, P1356, DOI 10.1016/j.biopsych.2006.03.052; Bava S, 2010, BRAIN RES, V1327, P38, DOI 10.1016/j.brainres.2010.02.066; Beck AT, 1996, J PERS ASSESS, V67, P588, DOI 10.1207/s15327752jpa6703_13; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; DELACOSTE MC, 1985, J NEUROPATH EXP NEUR, V44, P578, DOI 10.1097/00005072-198511000-00004; Fellgiebel A, 2005, NEUROBIOL AGING, V26, P1193, DOI 10.1016/j.neurobiolaging.2004.11.006; Finkel MF, 2006, J NEUROL SCI, V249, P63, DOI 10.1016/j.jns.2006.06.005; First MB., 1997, STRUCTURED CLIN INTE; Frank LR, 2001, MAGN RESON MED, V45, P935, DOI 10.1002/mrm.1125; Friston KJ, 2005, NEUROIMAGE, V24, P244, DOI 10.1016/j.neuroimage.2004.08.055; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; JEZZARD P, 1995, MAGNET RESON MED, V34, P65, DOI 10.1002/mrm.1910340111; Jones DK, 1999, MAGNET RESON MED, V42, P515, DOI 10.1002/(SICI)1522-2594(199909)42:3<515::AID-MRM14>3.3.CO;2-H; Keane T.M., 1989, PSYCHOL ASSESSMENT J, V1, P53, DOI DOI 10.1037/1040-3590.1.1.53; Kim SJ, 2006, NEUROPSYCHOBIOLOGY, V54, P120, DOI 10.1159/000098262; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Kroenke K, 2010, GEN HOSP PSYCHIAT, V32, P345, DOI 10.1016/j.genhosppsych.2010.03.006; Lange R. T., 2011, J HEAD TRAUMA REHABI; Levin HS, 2011, DEV NEUROPSYCHOL, V36, P273, DOI 10.1080/87565641.2010.549885; Matthews S, 2011, PSYCHIAT RES-NEUROIM, V191, P76, DOI 10.1016/j.pscychresns.2010.09.013; Matthews SC, 2011, NEUROIMAGE, V54, pS69, DOI 10.1016/j.neuroimage.2010.04.269; Mesulam MM, 1998, BRAIN, V121, P1013, DOI 10.1093/brain/121.6.1013; Mollica RF, 2009, ARCH GEN PSYCHIAT, V66, P1221, DOI 10.1001/archgenpsychiatry.2009.127; Peloso PM, 2004, J REHABIL MED, V36, P106, DOI 10.1080/16501960410023868; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Reese TG, 2003, MAGN RESON MED, V49, P177, DOI 10.1002/mrm.10308; Schmahmann JD, 2008, ANN NY ACAD SCI, V1142, P266, DOI 10.1196/annals.1444.017; Schmahmann JD, 2007, BRAIN, V130, P630, DOI 10.1093/brain/awl359; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schuff N, 2011, NEUROIMAGE, V54, pS62, DOI 10.1016/j.neuroimage.2010.05.024; Schwab K., 2006, NEUROLOGY, P66; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2007, NAT PROTOC, V2, P499, DOI 10.1038/nprot.2007.45; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Zou K, 2008, J PSYCHIATR NEUROSCI, V33, P525	43	35	35	0	13	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0925-4927	1872-7506		PSYCHIAT RES-NEUROIM	Psychiatry Res. Neuroimaging	NOV 30	2012	204	2-3					149	154		10.1016/j.pscychresns.2012.04.018			6	Clinical Neurology; Neuroimaging; Psychiatry	Neurosciences & Neurology; Psychiatry	081NP	WOS:000314329200012	23149025	Green Accepted			2021-06-18	
J	Johansson, B; Carlsson, A; Carlsson, ML; Karlsson, M; Nilsson, MK; Nordquist-Brandt, E; Ronnback, L				Johansson, Birgitta; Carlsson, Arvid; Carlsson, Maria L.; Karlsson, Magdalena; Nilsson, Marie K. L.; Nordquist-Brandt, Elisabeth; Ronnback, Lars			Placebo-controlled cross-over study of the monoaminergic stabiliser (-)-OSU6162 in mental fatigue following stroke or traumatic brain injury	ACTA NEUROPSYCHIATRICA			English	Article						brain injuries; drug therapy; mental fatigue; stroke	5-HT2A SEROTONIN; (+)-OSU6162; DISORDERS	Objective Mental fatigue occurring after a stroke or traumatic brain injury (TBI) often results in difficulties returning to work and pursuing social activities. No effective treatment of this condition is available today. In this study, we have tested a novel pharmacological strategy using the monoaminergic stabiliser (-)-OSU6162. Methods (-)-OSU6162 was given orally for 4 weeks in doses increasing from 15 to 45 mg b.i.d. to 12 patients suffering from mental fatigue, following upon stroke (n?=?6) or TBI (n?=?6). (-)-OSU6162 was compared with placebo using a double-blind, randomised cross-over design. Patients included were well rehabilitated physically with no gross impairment in cognitive functions other than those related to the mental fatigue. Results (-)-OSU6162 caused a remarkable improvement in mental stamina, as evaluated by a self-assessment scale on mental fatigue. Statistical significance was reached on the primary endpoint (Mental Fatigue Scale). There was a trend towards improvement in the secondary endpoints processing speed and attention. Principal component analysis showed an overall positive treatment effect in 7 of 12 patients. Beneficial responses were seen already during the first few days of active drug treatment. Increasing dosage caused no further improvement. Adverse reactions consisted of short-lasting mild nausea and attenuated appetite. These side effects disappeared upon dose reduction. Conclusion The monoaminergic stabiliser (-)-OSU6162 offers promise as a candidate for treatment of mental fatigue after a stroke or TBI.	[Johansson, Birgitta] Univ Gothenburg, Dept Clin Neurosci & Rehabil, Inst Neurosci & Physiol, Sahlgrenska Acad, SE-41345 Gothenburg, Sweden	Johansson, B (corresponding author), Univ Gothenburg, Dept Clin Neurosci & Rehabil, Inst Neurosci & Physiol, Sahlgrenska Acad, Dubbsgatan 14,1Tr, SE-41345 Gothenburg, Sweden.	birgitta.johansson@neuro.gu.se		, Birgitta/0000-0003-0240-1142	Arvid Carlsson Foundation; Foundation for Neuropharmacological Research and Education	This research was supported by the Arvid Carlsson Foundation and the Foundation for Neuropharmacological Research and Education.	ASBERG M, 1978, ACTA PSYCHIAT SCAND, P5; Ashman TA, 2008, J HEAD TRAUMA REHAB, V23, P33, DOI 10.1097/01.HTR.0000308719.70288.22; Azmitia EC, 1999, NEUROPSYCHOPHARMACOL, V21, pS33; Belmont A., 2006, Annales de Readaptation et de Medecine Physique, V49, P370, DOI 10.1016/j.annrmp.2006.04.018; Brennan AR, 2008, ANN NY ACAD SCI, V1129, P236, DOI 10.1196/annals.1417.007; Burstein ES, 2011, J NEURAL TRANSM, V118, P1523, DOI 10.1007/s00702-011-0701-y; Carlsson ML, 2011, J NEURAL TRANSM, V118, P1511, DOI 10.1007/s00702-011-0704-8; Chaudhuri A, 2004, LANCET, V363, P978, DOI 10.1016/S0140-6736(04)15794-2; DeLuca J, 2005, ISS CLIN COGN NEUROP, P1; Ekesbo A, 1997, NEUROREPORT, V8, P2567, DOI 10.1097/00001756-199707280-00029; Ellis DC, 2001, DELIS KAPLAN EXECUTI; Gefvert O, 2000, NORD J PSYCHIAT, V54, P93; HOLBROOK M, 1983, AGE AGEING, V12, P166, DOI 10.1093/ageing/12.2.166; Johansson B, 2013, BRAIN INJURY, V23, P1027; Johansson B., 2012, BRAIN INJURY FUNCTIO, V1, P3, DOI [10.5772/27042, DOI 10.5772/27042]; Johansson Birgitta, 2012, ISRN Psychiatry, V2012, P686425, DOI 10.5402/2012/686425; Johansson B, 2010, BRAIN INJURY, V24, P2, DOI 10.3109/02699050903452961; Kohl AD, 2009, BRAIN INJURY, V23, P420, DOI 10.1080/02699050902788519; Lahti RA, 2007, J NEURAL TRANSM, V114, P1143, DOI 10.1007/s00702-007-0784-7; LINDQVIST G, 1993, ACTA PSYCHIAT SCAND, V88, P5, DOI 10.1111/j.1600-0447.1993.tb05611.x; Lundberg T, 2002, NORD J PSYCHIAT, V56, P24; Madison S., 2003, LASDIAGNOS; Posner MI, 2007, ANNU REV PSYCHOL, V58, P1, DOI 10.1146/annurev.psych.58.110405.085516; Reitan RM., 1985, HALSTEAD REITAN NEUR; Rodholm M, 2001, ACTA NEUROL SCAND, V103, P379, DOI 10.1034/j.1600-0404.2001.103006379.x; Rodriguez CA, 2004, J CLIN PHARMACOL, V44, P276, DOI 10.1177/0091270003262792; Ronnback L., 2012, LONG LASTING MENTAL; Ronnback L, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-22; Rung JP, 2008, J NEURAL TRANSM, V115, P899, DOI 10.1007/s00702-008-0038-3; Senn S, 2002, CROSS OVER TRIALS CL; Staub F, 2001, CEREBROVASC DIS, V12, P75, DOI 10.1159/000047685; SVANBORG P, 1994, ACTA PSYCHIAT SCAND, V89, P21, DOI 10.1111/j.1600-0447.1994.tb01480.x; Tedroff J, 1999, NEUROLOGY, V53, P1605, DOI 10.1212/WNL.53.7.1605; Tedroff J, 2000, CLIN EFFECTS OSU6162; Wechsler D., 2003, WECHSLER ADULT INTEL; Ziino C, 2006, J INT NEUROPSYCH SOC, V12, P100, DOI 10.1017/S1355617706060139	36	35	35	0	15	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1601-5215			ACTA NEUROPSYCHIATR	Acta Neuropsychiatr.	OCT	2012	24	5					266	274		10.1111/j.1601-5215.2012.00678.x			9	Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	007IP	WOS:000308882300004	25286991				2021-06-18	
J	Cope, EC; Morris, DR; Scrimgeour, AG; Levenson, CW				Cope, Elise C.; Morris, Deborah R.; Scrimgeour, Angus G.; Levenson, Cathy W.			Use of Zinc as a Treatment for Traumatic Brain Injury in the Rat: Effects on Cognitive and Behavioral Outcomes	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						TBI; zinc supplementation; anhedonia; spatial memory	HIPPOCAMPAL NEUROGENESIS; SUPPLEMENTATION; DEPRESSION; MODEL; CHELATION; DEATH	Background. While treatments for the behavioral deficits associated with traumatic brain injury (TBI) are currently limited, animal models suggest that zinc supplementation may increase resilience to TBI. Objective. This work tests the hypothesis that zinc supplementation after TBI can be used as treatment to improve behavioral outcomes such as anxiety, depression, and learning and memory. Methods. TBI was induced by controlled cortical impact to the medial frontal cortex. After TBI, rats were fed either a zinc adequate (ZA, 30 ppm) or zinc supplemented (ZS, 180 ppm) diet. Additional rats in each dietary group (ZA or ZS) were given a single intraperitoneal (ip) injection of zinc (30 mg/kg) 1 hour following injury. Results. Brain injury resulted in significant increases in anxiety-like and depression-like behaviors as well as impairments in learning and memory. None of the zinc treatments (dietary or ip zinc) improved TBI-induced anxiety. The 2-bottle saccharin preference test for anhedonia revealed that dietary ZS also did not improve depression-like behaviors. However, dietary ZS combined with an early ip zinc injection significantly reduced anhedonia (P < .001). Dietary supplementation after injury, but not zinc injection, significantly improved (P < .05) cognitive behavior as measured by the time spent finding the hidden platform in the Morris water maze test compared with injured rats fed a ZA diet. Conclusions. These data suggest that zinc supplementation may be an effective treatment option for improving behavioral deficits such as cognitive impairment and depression following TBI.	[Levenson, Cathy W.] Florida State Univ, Coll Med, Tallahassee, FL 32306 USA; [Scrimgeour, Angus G.] USA, Environm Med Res Inst, Natick, MA 01760 USA	Levenson, CW (corresponding author), Florida State Univ, Coll Med, Tallahassee, FL 32306 USA.	cathy.levenson@med.fsu.edu		Cope, Elise/0000-0001-6239-690X; Levenson, Cathy W/0000-0003-4463-3136	US Army Medical Research and Material CommandU.S. Army Medical Research & Materiel Command (USAMRMC); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM081382] Funding Source: NIH RePORTER	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work is supported by the US Army Medical Research and Material Command.	Aquilani R, 2009, NUTR NEUROSCI, V12, P219, DOI 10.1179/147683009X423445; Arabi YM, 2011, AM J CLIN NUTR, V93, P569, DOI 10.3945/ajcn.110.005074; Bobilya DJ, 2008, J NUTR BIOCHEM, V19, P129, DOI 10.1016/j.jnutbio.2007.06.014; Cope EC, 2011, PHYSIOL BEHAV, V104, P942, DOI 10.1016/j.physbeh.2011.06.007; Corniola RS, 2008, BRAIN RES, V1237, P52, DOI 10.1016/j.brainres.2008.08.040; de Witt BW, 2011, NEUROREHAB NEURAL RE, V25, P343, DOI 10.1177/1545968310390520; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; Fujimura T, 2012, BRIT J NUTR, V107, P1655, DOI 10.1017/S0007114511004867; Hellmich HL, 2008, NEUROSCI LETT, V440, P155, DOI 10.1016/j.neulet.2008.05.068; Hellmich HL, 2004, NEUROSCI LETT, V355, P221, DOI 10.1016/j.neulet.2003.10.074; Jorge RE, 2005, J HEAD TRAUMA REHAB, V20, P475, DOI 10.1097/00001199-200511000-00001; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Nowak G, 2003, POL J PHARMACOL, V55, P1143; Nowak G, 2003, BRAIN RES BULL, V61, P159, DOI 10.1016/S0361-9230(03)00104-7; Salmond CH, 2005, CURR OPIN CRIT CARE, V11, P111, DOI 10.1097/01.ccx.0000155358.31983.37; Santarelli L, 2003, SCIENCE, V301, P805, DOI 10.1126/science.1083328; Siwek M, 2009, J AFFECT DISORDERS, V118, P187, DOI 10.1016/j.jad.2009.02.014; Snyder JS, 2011, NATURE, V476, P458, DOI 10.1038/nature10287; Sowa-Kucma M, 2008, J NEURAL TRANSM, V115, P1621, DOI 10.1007/s00702-008-0115-7; Stork CJ, 2009, J CEREBR BLOOD F MET, V29, P1399, DOI 10.1038/jcbfm.2009.64; Tassabehji NM, 2008, PHYSIOL BEHAV, V95, P365, DOI 10.1016/j.physbeh.2008.06.017; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Wu AG, 2011, NEUROREHAB NEURAL RE, V25, P332, DOI 10.1177/1545968310397706; Yeiser EC, 2002, NUTR NEUROSCI, V5, P345, DOI 10.1080/1028415021000033811; Young B, 1996, J NEUROTRAUM, V13, P25, DOI 10.1089/neu.1996.13.25	25	35	36	0	15	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1545-9683			NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair	SEP	2012	26	7					907	913		10.1177/1545968311435337			7	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	981MY	WOS:000306973700011	22331212	Green Accepted			2021-06-18	
J	McNett, M; Sarver, W; Wilczewski, P				McNett, Molly; Sarver, Wendy; Wilczewski, Patricia			The prevalence, treatment and outcomes of agitation among patients with brain injury admitted to acute care units	BRAIN INJURY			English	Article						Agitation; traumatic brain injury; intervention	PHARMACOLOGICAL MANAGEMENT; POSTTRAUMATIC AMNESIA; REALITY ORIENTATION; PHYSICAL RESTRAINT; HEAD-INJURY; REHABILITATION	Purpose: Agitation occurs in 70% of patients hospitalized with traumatic brain injury (TBI) and has adverse effects on length of stay and functional outcomes. Treatment involves pharmacological and behavioural interventions. Much research on TBI agitation has been conducted in intensive care or rehabilitation settings. This study aimed to identify agitation prevalence, treatment and outcomes among patients with TBI on acute care wards. Methods: Data abstracted from the trauma registry and medical records of adult patients with TBI admitted to an acute care ward within a Level I trauma centre over 12 months. Findings: From 219 patients, at least one agitation behaviour was present in 41% (n = 90) of patients. Clinically significant agitation was present in 8% (n = 18) of patients. Agitation behaviours included impulsiveness (30%), pulling at devices (21%) and decreased attention span (16%). Common interventions were reorientation (33%), constant supervision (32%) and benzodiazepines (30%). Agitated patients had longer length of stay (p<0.001) and were less likely to be discharged home. Physical restraints, constant supervision, redirection, reorientation and environmental modifications were associated with agitation (p<0.001). Implications: Management of agitation among patients with TBI on acute care wards can present challenges to healthcare staff. Innovative approaches are needed to promote outcomes using available resources.	[McNett, Molly] Metrohlth Med Ctr, Nursing Business Off, Cleveland, OH 44109 USA	McNett, M (corresponding author), Metrohlth Med Ctr, Nursing Business Off, 2500 Metrohlth Dr, Cleveland, OH 44109 USA.	mmcnett@metrohealth.org					Amato S, 2006, REHABIL NURS, V31, P235, DOI 10.1002/j.2048-7940.2006.tb00019.x; Bogner JA, 2001, AM J PHYS MED REHAB, V80, P636, DOI 10.1097/00002060-200109000-00002; BROOKE MM, 1992, ARCH PHYS MED REHAB, V73, P320, DOI 10.1016/0003-9993(92)90003-F; Chang LY, 2008, AM J CRIT CARE, V17, P408; Chew E, 2009, J REHABIL RES DEV, V46, P851, DOI 10.1682/JRRD.2008.09.0120; Cook R, 2002, AUSTR J NEUROSCIENCE, V15, P5; CORRIGAN JD, 1989, J CLIN EXP NEUROPSYC, V11, P261, DOI 10.1080/01688638908400888; De Guise E, 2005, BRAIN INJURY, V19, P263, DOI 10.1080/02699050400004971; Eastwood EA, 1999, NURS ECON, V17, P96; Eisenberg M.E., 2009, CRITICAL REV PHYS RE, V21, P215; Fleminger S, 2008, COCHRANE DATA BASE S, V4; Francisco GE, 2007, BRAIN INJURY, V21, P1007, DOI 10.1080/02699050701559558; Fugate LP, 1997, ARCH PHYS MED REHAB, V78, P924, DOI 10.1016/S0003-9993(97)90051-4; Inouye SK, 1996, JAMA-J AM MED ASSOC, V275, P852, DOI 10.1001/jama.275.11.852; Johnson C C, 1995, Nursing, V25, P39; Lequerica AH, 2007, J HEAD TRAUMA REHAB, V22, P177, DOI 10.1097/01.HTR.0000271118.96780.bc; Lombard LA, 2005, AM J PHYS MED REHAB, V84, P797, DOI 10.1097/01.phm.0000179438.22235.08; Mysiw WJ, 1997, ARCH PHYS MED REHAB, V78, P213, DOI 10.1016/S0003-9993(97)90266-5; Nott MT, 2006, BRAIN INJURY, V20, P1175, DOI 10.1080/02699050601049114; Nott MT, 2010, BRAIN INJURY, V24, P1214, DOI 10.3109/02699052.2010.506858; Rosati DL, 2002, AM J PHYS MED REHAB, V81, P90, DOI 10.1097/00002060-200202000-00003; Sandel ME, 1996, ARCH PHYS MED REHAB, V77, P617, DOI 10.1016/S0003-9993(96)90306-8; Thomas H, 2003, J HEAD TRAUMA REHAB, V18, P292, DOI 10.1097/00001199-200305000-00007; van der Naalt J, 2000, BRAIN INJURY, V14, P781; Weir N, 2006, BRAIN INJURY, V20, P927, DOI 10.1080/02699050600832684; WERNER P, 1989, J AM GERIATR SOC, V37, P1122, DOI 10.1111/j.1532-5415.1989.tb06675.x; Wolf AP, 1996, BRAIN INJURY, V10, P241, DOI 10.1080/026990596124412	27	35	35	0	15	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	AUG	2012	26	9					1155	1162		10.3109/02699052.2012.667587			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	971GI	WOS:000306191400013	22642404				2021-06-18	
J	Rau, TF; Kothiwal, AS; Rova, AR; Brooks, DM; Poulsen, DJ				Rau, Thomas F.; Kothiwal, Aakriti S.; Rova, Annela R.; Brooks, Diane M.; Poulsen, David J.			Treatment with low-dose methamphetamine improves behavioral and cognitive function after severe traumatic brain injury	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	Advanced Technology Applications for Combat Casualty Care Conference (ATACCC)	AUG 15-18, 2011	Fort Lauderdale, FL			Traumatic brain injury; neuroprotection; methamphetamine	SURVIVAL PATHWAY; CELL-DEATH; AKT; RECEPTOR; RATS	BACKGROUND: Methamphetamine increases the release and blocks the reuptake of dopamine. The moderate activation of dopamine receptors may elicit neuroprotective effects. We have recently demonstrated that low doses of methamphetamine reduce neuronal loss after ischemic injury. On the basis of this finding, we hypothesized that methamphetamine could also prevent neuronal loss and improve functional behavior after severe traumatic brain injury (TBI). METHODS: The rat lateral fluid percussion injury model was used to generate severe TBI. Three hours after injury, animals were treated with saline or methamphetamine. Neurological severity scores and foot fault assessments were used to determine whether treatment enhanced recovery after injury. The potential for methamphetamine treatment to improve cognitive function was assessed using the Morris water maze. Forty-eight hours after injury, paraffin-embedded brain sections were TUNEL stained to measure apoptotic cell death. Sections were also stained with antibody to doublecortin to quantify immature neurons within the dentate gyrus. RESULTS: Treatment with low-dose methamphetamine significantly reduced both behavioral and cognitive dysfunction after severe TBI. Methamphetamine-treated animals scored significantly lower on neurological severity scores and had significantly less foot faults after TBI compared with saline-treated control rats. Furthermore, methamphetamine treatment restored learning and memory function to near normal ability after TBI. At 48 hours after injury, apoptotic cell death within the hippocampus was significantly reduced, and the presence of immature neurons was significantly increased in methamphetamine-treated rats compared with saline-treated controls. CONCLUSION: Treatment with low-dose methamphetamine after severe TBI elicits a robust neuroprotective response resulting in significant improvements in behavioral and cognitive functions. (J Trauma Acute Care Surg. 2012; 73: S165-S172. Copyright (C) 2012 by Lippincott Williams & Wilkins)	[Rau, Thomas F.; Kothiwal, Aakriti S.; Rova, Annela R.; Brooks, Diane M.; Poulsen, David J.] Univ Montana, Dept Biomed & Pharmaceut Sci, Missoula, MT 59812 USA	Poulsen, DJ (corresponding author), Univ Montana, Dept Biomed & Pharmaceut Sci, 32 Campus Dr, Missoula, MT 59812 USA.	david.poulsen@umontana.edu					Arden KC, 2004, MOL CELL, V14, P416, DOI 10.1016/S1097-2765(04)00213-8; Brown JM, 2005, J NEUROCHEM, V95, P429, DOI 10.1111/j.1471-4159.2005.03379.x; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cadet JL, 2007, NEUROTOX RES, V11, P183, DOI 10.1007/BF03033567; Cadet JL, 2009, INT REV NEUROBIOL, V88, P101, DOI 10.1016/S0074-7742(09)88005-7; Choi SH, 2006, J NEUROSCI METH, V156, P182, DOI 10.1016/j.jneumeth.2006.03.002; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dhanasekaran A, 2008, AM J PHYSIOL-HEART C, V294, pH724, DOI 10.1152/ajpheart.00979.2007; Doll H, 2009, J NEUROTRAUM, V26, P235, DOI 10.1089/neu.2008.0741; Kihara T, 2002, J NEUROSCI RES, V70, P274, DOI 10.1002/jnr.10426; Lee FJS, 2002, CELL, V111, P219, DOI 10.1016/S0092-8674(02)00962-5; O'Phelan K, 2008, J TRAUMA, V65, P674, DOI 10.1097/TA.0b013e31817db0a5; Plas DR, 2001, J BIOL CHEM, V276, P12041, DOI 10.1074/jbc.M010551200; Rau TF, 2011, NEUROPHARMACOLOGY, V61, P677, DOI 10.1016/j.neuropharm.2011.05.010; Royo NC, 2003, J NEUROPATH EXP NEUR, V62, P801, DOI 10.1093/jnen/62.8.801; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Uchiyama T, 2004, CIRCULATION, V109, P3042, DOI 10.1161/01.CIR.0000130647.29030.90; Wang LL, 2005, MOL PHARMACOL, V67, P489, DOI 10.1124/mol.104.005595; Wang QH, 2003, NEURON, V38, P915, DOI 10.1016/S0896-6273(03)00356-8; Writer BW, 2009, J NEUROPSYCH CLIN N, V21, P362, DOI 10.1176/appi.neuropsych.21.4.362; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950; Zou SW, 2005, J NEUROSCI, V25, P4385, DOI 10.1523/JNEUROSCI.5099-04.2005	23	35	35	0	16	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	2163-0755			J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	AUG	2012	73			1			S165	S172		10.1097/TA.0b013e318260896a			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	992VP	WOS:000307808500028	22847088				2021-06-18	
J	Yuan, F; Ding, J; Chen, H; Guo, Y; Wang, G; Gao, WW; Chen, SW; Tian, HL				Yuan, Fang; Ding, Jun; Chen, Hao; Guo, Yan; Wang, Gan; Gao, Wen-Wei; Chen, Shi-Wen; Tian, Heng-Li			Predicting Progressive Hemorrhagic Injury after Traumatic Brain Injury: Derivation and Validation of a Risk Score Based on Admission Characteristics	JOURNAL OF NEUROTRAUMA			English	Article						prognostic model; progressive hemorrhagic injury; risk score; traumatic brain injury; validation	HEAD TRAUMA; INTRACEREBRAL HEMORRHAGE; INTRACRANIAL HEMORRHAGE; COAGULOPATHY	Previous studies have demonstrated that patients with traumatic brain injury (TBI) who also have progressive hemorrhagic injury (PHI), have a higher risk of clinical deterioration and worse outcomes than do TBI patients without PHI. Therefore, the early prediction of PHI occurrence is useful to evaluate the status of patients with TBI and to improve outcomes. The objective of this study was to develop and validate a prognostic model that uses information available at admission to determine the likelihood of PHI after TBI. Retrospectively collected data were used to develop a PHI prognostic model with a logistic regression analysis. The prediction model was validated in 114 patients from a separate hospital. Eight independent prognostic factors were identified: age >= 57 years (5 points), intra-axial bleeding/brain contusion (4 points), midline shift 5 mm (6 points), platelet (PLT) count <100 x 10(9)/L (10 points), PLT count >= 100 but <150 x 10(9)/L (4 points), prothrombin time > 14 sec (7 points), D-dimer >= 5 mg/L (12 points), and glucose >= 10 mmol/L (10 points). Each patient was assigned a number of points proportional to the regression coefficient. We calculated risk scores for each patient and defined three risk groups: low risk (0-13 points), intermediate risk (14-22 points), and high risk (23-54 points). In the development cohort, the PHI rates after TBI for these three groups were 10.3%, 47.3%, and 85.2%, respectively. In the validation cohort, the corresponding PHI rates were 10.9%, 47.3%, and 86.9%. The C-statistic for the point system was 0.864 (p=0.509 by the Hosmer-Lemeshow test) in the development cohort, and 0.862 (p=0.589 by the Hosmer-Lemeshow test) in the validation cohort. In conclusion, a relatively simple risk score using admission predictors accurately predicted the risk for PHI after TBI.	[Yuan, Fang; Ding, Jun; Chen, Hao; Guo, Yan; Wang, Gan; Gao, Wen-Wei; Chen, Shi-Wen; Tian, Heng-Li] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 6, Dept Neurosurg, Shanghai 200030, Peoples R China	Tian, HL (corresponding author), Shanghai Jiao Tong Univ, Shanghai People Hosp 6, Dept Neurosurg, 600 Yishan Rd, Shanghai 200030, Peoples R China.	tianhengli1964@yahoo.com.cn			Shanghai Science and Technology CommitteeShanghai Science & Technology Committee [10JC1412500]	This study was supported in part by a grant from the Shanghai Science and Technology Committee (grant no. 10JC1412500). We would like to thank Dong-Qing Shen, Department of Neurosurgery at Fengxian Center Hospital, for making the external validation data available for analysis.	Allard CB, 2009, J TRAUMA, V67, P959, DOI 10.1097/TA.0b013e3181ad5d37; Bollinger O, 1891, INT BEITRAGE WEISSEN, P457; Brain Trauma Foundation. American Association of Neurological Surgeons & Congress of Neurological Surgeons, 2007, J NEUROTRAUM, V24, pi, DOI DOI 10.1089/NEU.2007.9999; Chang EF, 2006, NEUROSURGERY, V58, P647, DOI 10.1227/01.NEU.0000197101.68538.E6; Chieregato A, 2005, NEUROSURGERY, V56, P671, DOI 10.1227/01.NEU.0000156200.76331.7A; Doughty R.G., 1938, SOUTH MED J, V31, P254; Engstrom M, 2005, J NEUROTRAUM, V22, P291, DOI 10.1089/neu.2005.22.291; Hiroshi T., 1997, J NEUROSURG, V86, P768; Narayan RK, 2008, J NEUROTRAUM, V25, P629, DOI 10.1089/neu.2007.0385; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Sanus GZ, 2004, NEUROSURG QUART, V14, P97, DOI 10.1097/01.wnq.0000127718.06183.12; Schnuriger B, 2010, J TRAUMA, V68, P881, DOI 10.1097/TA.0b013e3181d3cc58; Seifman MA, 2011, NEUROSURG REV, V34, P393, DOI 10.1007/s10143-010-0304-3; Servadei F, 2000, NEUROSURGERY, V46, P70; Stein DM, 2009, J TRAUMA, V66, P63, DOI 10.1097/TA.0b013e318191bc8a; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; Tian HL, 2010, NEUROSURG REV, V33, P359, DOI 10.1007/s10143-010-0251-z; Tong WS, 2011, NEURORADIOLOGY, V53, P305, DOI 10.1007/s00234-010-0659-8; Wada R, 2007, STROKE, V38, P1257, DOI 10.1161/01.STR.0000259633.59404.f3	20	35	41	1	4	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	2012	29	12					2137	2142		10.1089/neu.2011.2233			6	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	993KZ	WOS:000307859900003	22568757	Green Published			2021-06-18	
J	Leibson, CL; Brown, AW; Long, KH; Ransom, JE; Mandrekar, J; Osler, TM; Malec, JF				Leibson, Cynthia L.; Brown, Allen W.; Long, Kirsten Hall; Ransom, Jeanine E.; Mandrekar, Jay; Osler, Turner M.; Malec, James F.			Medical Care Costs Associated with Traumatic Brain Injury over the Full Spectrum of Disease: A Controlled Population-Based Study	JOURNAL OF NEUROTRAUMA			English	Article						costs; head injury; outcome measures; traumatic brain injury	ROCHESTER EPIDEMIOLOGY PROJECT; UNITED-STATES; HEALTH-CARE; HEAD TRAUMA; FOLLOW-UP; HOSPITALIZATION; OUTCOMES; MILD; MORTALITY; SEVERITY	Data on traumatic brain injury (TBI) economic outcomes are limited. We used Rochester Epidemiology Project (REP) resources to estimate long-term medical costs for clinically-confirmed incident TBI across the full range of severity after controlling for pre-existing conditions and co-occurring injuries. All Olmsted County, Minnesota, residents with diagnoses indicative of potential TBI from 1985-2000 (n = 46,114) were identified, and a random sample (n = 7175) was selected for medical record review to confirm case status, and to characterize as definite (moderate/severe), probable (mild), or possible (symptomatic) TBI. For each case, we identified one age-and sex-matched non-TBI control registered in REP in the same year (-1 year) as case's TBI. Cases with co-occurring non-head injuries were assessed for non-head-injury severity and assigned similar non-head-injury-severity controls. The 1145 case/control pairs for 1988-2000 were followed until earliest death/emigration of either member for medical costs 12 months before and up to 6 years after baseline (i.e., injury date for cases and comparable dates for controls). Differences between case and control costs were stratified by TBI severity, as defined by evidence of brain injury; comparisons used Wilcoxon signed-rank plus multivariate modeling (adjusted for pre-baseline characteristics). From baseline until 6 years, each TBI category exhibited significant incremental costs. For definite and probable TBI, most incremental costs occurred within the first 6 months; significant long-term incremental medical costs were not apparent among 1-year survivors. By contrast, cost differences between possible TBI cases and controls were not as great within the first 6 months, but were substantial among 1-year survivors. Although mean incremental costs were highest for definite cases, probable and possible cases accounted for >90% of all TBI events and 66% of total incremental costs. Preventing probable and possible events might facilitate substantial reductions in TBI-associated medical care costs.	[Leibson, Cynthia L.] Mayo Clin, Div Epidemiol, Dept Hlth Sci Res, Rochester, MN 55905 USA; [Brown, Allen W.] Mayo Clin, Dept Phys Med & Rehabil, Rochester, MN 55905 USA; [Ransom, Jeanine E.; Mandrekar, Jay] Mayo Clin, Dept Hlth Sci Res, Div Biomed Stat & Informat, Rochester, MN 55905 USA; [Long, Kirsten Hall] Long Hlth Econ Consulting, St Paul, MN USA; [Osler, Turner M.] Univ Vermont, Dept Surg, Coll Med, Burlington, VT 05405 USA; [Malec, James F.] Indiana Univ Sch Med, Dept Phys Med & Rehabil, Indianapolis, IN USA; [Malec, James F.] Rehabil Hosp Indiana, Indianapolis, IN USA	Leibson, CL (corresponding author), Mayo Clin, Div Epidemiol, Dept Hlth Sci Res, 200 1st St SW, Rochester, MN 55905 USA.	leibson@mayo.edu		Brown, Allen W./0000-0001-7228-3351	TBI Model System, National Institute on Disability and Rehabilitation Research [H133A020507, H133A070013]; National Research Service Award, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HD-07447]; National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [RO1 AG034676]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R56HD007447, R01HD007447] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG034676] Funding Source: NIH RePORTER	This research was supported by TBI Model System grants to the Mayo Clinic from the National Institute on Disability and Rehabilitation Research (H133A020507 and H133A070013), and a National Research Service Award from the National Institutes of Health (training grant no. HD-07447). The study was made possible by the Rochester Epidemiology Project (grant no. RO1 AG034676 from the National Institute on Aging). The authors thank Patricia K. Perkins and Nancy N. Diehl for invaluable and expert assistance in medical record abstraction and data collection and analysis.	ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Barker-Collo SL, 2009, NEUROEPIDEMIOLOGY, V32, P1, DOI 10.1159/000170084; Basu A, 2006, HEALTH ECON, V15, P1091, DOI 10.1002/hec.1099; Berg J, 2005, EUR J NEUROL, V12, P85, DOI 10.1111/j.1468-1331.2005.01200.x; Birnbaum HG, 2009, PHARMACOECONOMICS, V27, P507, DOI 10.2165/00019053-200927060-00006; Bombardier CH, 2002, ARCH PHYS MED REHAB, V83, P1765, DOI 10.1053/apmr.2002.36085; Borg J, 2004, J REHABIL MED, V36, P76, DOI 10.1080/16501960410023840; Brener I, 2004, J HEAD TRAUMA REHAB, V19, P405, DOI 10.1097/00001199-200409000-00005; BROOKS CA, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199508000-00002; Brown AW, 2004, NEUROREHABILITATION, V19, P37; Buntin MB, 2004, J HEALTH ECON, V23, P525, DOI 10.1016/j.jhealeco.2003.10.005; Cameron CM, 2008, BRAIN INJURY, V22, P437, DOI 10.1080/02699050802060621; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Centers for Disease Control and Prevention, 2003, C MILD TRAUM BRAIN I; Centers for Disease Control and Prevention. National Center for Health Statistics, 2005, BAR INJ DIAGN MATR C; Centers for Disease Control and Prevention. National Center for Health Statistics, 2009, ICD 9 CM OFF GUID CO; Centers for Disease Control and Prevention. National Center for Injury Prevention and Control, 2010, WHAT AR POT LONG TER; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Esposito D, 2009, AM J MANAG CARE, V15, P437; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Flaada JT, 2007, J NEUROTRAUM, V24, P435, DOI 10.1089/neu.2006.0119; Glance LG, 2009, ANN SURG, V249, P1032, DOI 10.1097/SLA.0b013e3181a38f28; H-ICDA, 1973, HOSP AD INT CLASS DI; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Harwood H., 2002, UPDATING ESTIMATES E; Johns Hopkins Bloomberg School of Public Health, 2010, J HOPK ACG SYST; Johns Hopkins Bloomberg School of Public Health, 2002, UPD J HOPK ACG CAS M, V4, P1; KALSBEEK WD, 1980, J NEUROSURG, V53, pS19; Kayani NA, 2009, PUBLIC HEALTH REP, V124, P551, DOI 10.1177/003335490912400412; King DA, 2010, BRIT J SPORT MED, V44, P1016, DOI 10.1136/bjsm.2009.064683; Leibson CL, 1996, NEUROLOGY, V46, P861; Leibson CL, 2001, JAMA-J AM MED ASSOC, V285, P60, DOI 10.1001/jama.285.1.60; Leibson CL, 2006, MOVEMENT DISORD, V21, P1864, DOI 10.1002/mds.21075; Leibson CL, 2011, EPIDEMIOLOGY, V22, P836, DOI 10.1097/EDE.0b013e318231d535; Long KH, 2010, ALIMENT PHARM THER, V32, P261, DOI 10.1111/j.1365-2036.2010.04327.x; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; Manning WG., 1981, HLTH EC HLTH EC, P103; McGarry LJ, 2002, J TRAUMA, V53, P1152, DOI 10.1097/00005373-200212000-00020; Mellick D, 2003, BRAIN INJURY, V17, P55, DOI 10.1080/0269905021000010159; Melton LJ, 1997, NEW ENGL J MED, V337, P1466, DOI 10.1056/NEJM199711133372012; Melton LJ, 1996, MAYO CLIN PROC, V71, P266, DOI 10.4065/71.3.266; Miller T. R., 1994, HEAD NECK INJURY, P211; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Mullahy J, 1998, J HEALTH ECON, V17, P247, DOI 10.1016/S0167-6296(98)00030-7; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Ryu WHA, 2009, CAN J NEUROL SCI, V36, P429, DOI 10.1017/S0317167100007745; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Schootman M, 2003, BRAIN INJURY, V17, P983, DOI 10.1080/0269905031000110427; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Setnik L, 2007, BRAIN INJURY, V21, P1, DOI 10.1080/02699050601111419; Shi JX, 2009, BRAIN INJURY, V23, P602, DOI 10.1080/02699050903014907; Slomine BS, 2006, PEDIATRICS, V117, pE663, DOI 10.1542/peds.2005-1892; Sosin DM, 1996, BRAIN INJURY, V10, P47; St Sauver JL, 2012, MAYO CLIN PROC, V87, P151, DOI 10.1016/j.mayocp.2011.11.009; Thompson JM, 2011, AM J PHYS MED REHAB, V90, P40, DOI 10.1097/PHM.0b013e3181fc7ff3; Thurman DJ, 2001, HEAD TRAUMA, P327; Thurman DJ., 1995, GUIDELINES SURVEILLA; *US DEP HHS, 1989, INT CLASS DIS 9 REV; Vangel SJ, 2005, AM J PHYS MED REHAB, V84, P153, DOI 10.1097/01.PHM.0000154896.55045.E7; Vassallo JL, 2007, BRAIN INJURY, V21, P567, DOI 10.1080/02699050701426832; Ventura T, 2010, ARCH PHYS MED REHAB, V91, P20, DOI 10.1016/j.apmr.2009.08.151; Welch CA, 2009, PSYCHOSOMATICS, V50, P392, DOI 10.1176/appi.psy.50.4.392; WHITLOCK JA, 1995, ARCH PHYS MED REHAB, V76, P1103, DOI 10.1016/S0003-9993(95)80117-0; WILCOXON F, 1945, BIOMETRICS BULL, V1, P80, DOI 10.2307/3001968	70	35	36	0	13	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2012	29	11					2038	2049		10.1089/neu.2010.1713			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	983CX	WOS:000307095800005	22414023	Green Published			2021-06-18	
J	Verrier, JD; Jackson, TC; Bansal, R; Kochanek, PM; Puccio, AM; Okonkwo, DO; Jackson, EK				Verrier, Jonathan D.; Jackson, Travis C.; Bansal, Rashmi; Kochanek, Patrick M.; Puccio, Ava M.; Okonkwo, David O.; Jackson, Edwin K.			The brain in vivo expresses the 2 ',3 '-cAMP-adenosine pathway	JOURNAL OF NEUROCHEMISTRY			English	Article						2'; 3'-cAMP; 3'; 5'-cAMP; adenosine; AMPs; brain	EXTRACELLULAR ADENOSINE ACCUMULATION; MYELIN-ASSOCIATED ENZYME; SMOOTH-MUSCLE-CELL; CEREBRAL-CORTEX; CYCLIC-AMP; DISRUPTION; ASTROCYTES; INJURY	J. Neurochem. (2012) 122, 115125. Abstract Although multiple biochemical pathways produce adenosine, studies suggest that the 2',3'-cAMP-adenosine pathway (2',3'-cAMP?2'-AMP/3'-AMP?adenosine) contributes to adenosine production in some cells/tissues/organs. To determine whether the 2',3'-cAMP-adenosine pathway exists in vivo in the brain, we delivered to the brain (gray matter and white matter separately) via the inflow perfusate of a microdialysis probe either 2',3'-cAMP, 3',5'-cAMP, 2'-AMP, 3'-AMP, or 5'-AMP and measured the recovered metabolites in the microdialysis outflow perfusate with mass spectrometry. In both gray and white matter, 2',3'-cAMP increased 2'-AMP, 3'-AMP and adenosine, and 3',5'-cAMP increased 5'-AMP and adenosine. In both brain regions, 2'-AMP, 3-AMP and 5'-AMP were converted to adenosine. Microdialysis experiments in 2',3'-cyclic nucleotide-3'-phosphodiesterase (CNPase) wild-type mice demonstrated that traumatic brain injury (controlled cortical impact model) activated the brain 2',3'-cAMP-adenosine pathway; similar experiments in CNPase knockout mice indicated that CNPase was involved in the metabolism of endogenous 2',3'-cAMP to 2'-AMP and to adenosine. In CSF from traumatic brain injury patients, 2',3'-cAMP was significantly increased in the initial 12 h after injury and strongly correlated with CSF levels of 2'-AMP, 3'-AMP, adenosine and inosine. We conclude that in vivo, 2',3'-cAMP is converted to 2'-AMP/3'-AMP, and these AMPs are metabolized to adenosine. This pathway exists endogenously in both mice and humans.	[Verrier, Jonathan D.; Jackson, Edwin K.] Univ Pittsburgh, Dept Pharmacol & Chem Biol, Sch Med, Pittsburgh, PA 15219 USA; [Jackson, Travis C.; Kochanek, Patrick M.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Sch Med, Pittsburgh, PA 15219 USA; [Jackson, Travis C.; Kochanek, Patrick M.] Univ Pittsburgh, Dept Crit Care Med, Sch Med, Pittsburgh, PA 15219 USA; [Bansal, Rashmi] Univ Connecticut, Sch Med, Dept Neurosci, New Haven, CT USA; [Puccio, Ava M.; Okonkwo, David O.] Univ Pittsburgh, Dept Neurol Surg, Sch Med, Pittsburgh, PA 15219 USA	Jackson, EK (corresponding author), Univ Pittsburgh, Dept Pharmacol & Chem Biol, Sch Med, 100 Technol Dr,Room 514, Pittsburgh, PA 15219 USA.	edj@pitt.edu	Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; Jackson, Edwin/0000-0002-8101-6009	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS070003, DK068575, DK079307, NS38087, NS30318, NS38878, NS41078]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK068575, P30DK079307] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS030318, P20NS030318, P50NS030318, R01NS038087, R37NS038878, R01NS038878, R21NS070003, R01NS041078] Funding Source: NIH RePORTER	This work was supported by NIH grants NS070003 (PMK/EKJ), DK068575 (EKJ), DK079307 (EKJ), NS38087 (PMK), NS30318 (PMK, DOO), NS38878 (RB) and NS41078 (RB). No author had a conflict of interest.	Ahmad M, 2008, J NEUROSCI RES, V86, P3605, DOI 10.1002/jnr.21809; Azarashvili T, 2009, AM J PHYSIOL-CELL PH, V296, pC1428, DOI 10.1152/ajpcell.00006.2009; BANIK NL, 1979, ANN NEUROL, V5, P539, DOI 10.1002/ana.410050608; Bell MJ, 1998, J NEUROTRAUM, V15, P163, DOI 10.1089/neu.1998.15.163; Brain Trauma Foundation; American Association of Neurological Surgeons; Congress of Neurological Surgeons; Joint Section on Neurotrauma and Critical Care AANS/CNS, 2007, J NEUROTRAUMA S, V24, pS1, DOI DOI 10.1089/NEU.2007.9976; Brundege JM, 1997, NEUROPHARMACOLOGY, V36, P1201, DOI 10.1016/S0028-3908(97)00102-0; Dare E, 2007, PHYSIOL BEHAV, V92, P15, DOI 10.1016/j.physbeh.2007.05.031; Haselkorn ML, 2010, J NEUROTRAUM, V27, P901, DOI 10.1089/neu.2009.1075; Jackson EK, 2011, AM J PHYSIOL-RENAL, V301, pF565, DOI 10.1152/ajprenal.00094.2011; Jackson EK, 2011, AM J PHYSIOL-HEART C, V301, pH391, DOI 10.1152/ajpheart.00336.2011; Jackson EK, 2011, J PHARMACOL EXP THER, V337, P444, DOI 10.1124/jpet.110.178137; Jackson EK, 2010, HYPERTENSION, V56, P151, DOI 10.1161/HYPERTENSIONAHA.110.152454; Jackson EK, 2009, J BIOL CHEM, V284, P33097, DOI 10.1074/jbc.M109.053876; Lappe-Siefke C, 2003, NAT GENET, V33, P366, DOI 10.1038/ng1095; Lauro C, 2008, J IMMUNOL, V180, P7590, DOI 10.4049/jimmunol.180.11.7590; Rao F, 2010, BIOCHEM BIOPH RES CO, V398, P500, DOI 10.1016/j.bbrc.2010.06.107; Ren J, 2009, J PHARMACOL EXP THER, V328, P855, DOI 10.1124/jpet.108.146712; Rosenberg PA, 1996, NEUROSCI LETT, V211, P49, DOI 10.1016/0304-3940(96)12718-X; ROSENBERG PA, 1989, J NEUROSCI, V9, P2654; ROSENBERG PA, 1994, J NEUROSCI, V14, P2953; ROSENBERG PA, 1995, BRAIN RES, V692, P227, DOI 10.1016/0006-8993(95)00668-G; Schmidt S, 1999, MULT SCLER J, V5, P147, DOI 10.1177/135245859900500303; SPRINKLE TJ, 1989, CRIT REV NEUROBIOL, V4, P235; Stone Trevor W, 2009, Handb Exp Pharmacol, P535, DOI 10.1007/978-3-540-89615-9_17; SUDA H, 1984, NEUROCHEM PATHOL, V2, P85, DOI 10.1007/BF02834248; THOMPSON JE, 1994, BIOCHEMISTRY-US, V33, P7408, DOI 10.1021/bi00189a047; THOMPSON RJ, 1992, BIOCHEM SOC T, V20, P621, DOI 10.1042/bst0200621; Verrier JD, 2011, J NEUROCHEM, V118, P979, DOI 10.1111/j.1471-4159.2011.07392.x; VOGEL US, 1988, J NEUROCHEM, V50, P1667, DOI 10.1111/j.1471-4159.1988.tb02461.x	29	35	35	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	JUL	2012	122	1					115	125		10.1111/j.1471-4159.2012.07705.x			11	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	956BG	WOS:000305064100012	22360621	Green Accepted			2021-06-18	
J	Weaver, LK; Cifu, D; Hart, B; Wolf, G; Miller, RS				Weaver, Lindell K.; Cifu, David; Hart, Brett; Wolf, George; Miller, R. Scott			Hyperbaric oxygen for post-concussion syndrome: Design of Department of Defense clinical trials	UNDERSEA AND HYPERBARIC MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY	The current wars in the Middle East have resulted in between 10-20% of U.S. service members with mild traumatic brain injury (mTBI). While anecdotal reports have associated hyperbaric oxygen (HBO2) with improved outcomes after mTBI, controlled research is lacking. The Department of Defense (DoD), in collaboration with the Department of Veterans Affairs (DVA), has a comprehensive program examining this issue. The DoD's four randomized controlled trials will enroll a total of 242 service members with post-concussion syndrome and expose them to a range of control, sham and HBO2 conditions for 40 sessions over a period of eight to 11 weeks. Compression pressures will range from 1.2 atm abs (sham) to 2.4 atm abs, and oxygen concentration will range from room air (sham and control) to 100%. Outcomes measures include both subjective and objective measures performed at baseline, at exposure completion, and at three to 12 months' follow-up. This integrated program of clinical trials investigating the efficacy of HBO2 in service members with persistent symptoms following mTBI exposure will be important to define practice guidelines and, if needed, for the development of definitive clinical trials in this population.	[Weaver, Lindell K.] Intermt LDS Hosp, Salt Lake City, UT USA; [Weaver, Lindell K.] Intermt Med Ctr, Murray, UT USA; [Weaver, Lindell K.] Univ Utah, Sch Med, Salt Lake City, UT USA; [Cifu, David] Stat 4PM& R Program Off, Dept Vet Affairs, Washington, DC USA; [Cifu, David] Virginia Commonwealth Univ, Dept PM & R, Richmond, VA USA; [Hart, Brett] Naval Operat Med Inst NOMI, Detachment Naval Aerosp Med Inst NAMI, Pensacola, FL USA; [Wolf, George] USAF, Sch Aerosp Med, Hyperbar Med Dept, Lackland AFB, TX USA; [Miller, R. Scott] US Army Med Mat Dev Act USAMMDA, Ft Detrick, MD USA	Weaver, LK (corresponding author), Intermt LDS Hosp, Salt Lake City, UT USA.	lindell.weaver@imail.org		Cifu, David/0000-0003-1600-9387	Intermountain Healthcare [W911QY-11-C-0062]; U.S. Army Medical Material Development Command/U.S. Army Medical Research and Material Command (USAMMDA/USAMRMC) [W911QY-11-C-0062]; Defense Advanced Research Projects AgencyUnited States Department of DefenseDefense Advanced Research Projects Agency (DARPA) [N66001-09-2-206]	Dr. Weaver's efforts were supported, in part, through a contact between Intermountain Healthcare and the U.S. Army Medical Material Development Command/U.S. Army Medical Research and Material Command (USAMMDA/USAMRMC) (W911QY-11-C-0062).; Dr. Cifu's efforts were supported, in part, through a Defense Advanced Research Projects Agency grant (N66001-09-2-206).	American Psychiatric Association, 2000, DIAGN STAT MAN METN; Centers for Medicare and Medicaid Services, 2006, CTR MED MED SERV PUB, V100-3; Cifu DX, 2011, OVERCOMING POST DEPL; Clarke D, 2009, UNDERSEA HYPERBAR M, V36, P13; Day SJ, 2000, BRIT MED J, V321, P504, DOI 10.1136/bmj.321.7259.504; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Gesell L.B., 2008, HYPERBARIC OXYGEN TH, V12th; Harch PG, 2012, J NEUROTRAUM, V29, P168, DOI 10.1089/neu.2011.1895; Harch PG, 2002, P 2 INT S HYP OX CER; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jansen T, 2009, UNDERSEA HYPERBAR M, V36, P347; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; McCrory P, 2011, CLIN J SPORT MED, V21, P6, DOI 10.1097/JSM.0b013e318204db50; McDonagh MS, 2003, AHRQ PUBLICATION, P59; Naval Sea Systems Command, 2008, US NAV DIV MAN REV 6; Neubauer RA, 1992, UNDERSEA BIOMED RES, V19, P66; Orrison WW, 2009, J NEUROTRAUM, V26, P689, DOI 10.1089/neu.2008.0636; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Thurmond VA, 2010, ARCH PHYS MED REHAB, V91, P1633, DOI 10.1016/j.apmr.2010.06.034; Undersea and Hyperbaric Medical Society, 2003, HYP OX THER CHRON BR; Weaver LK, 2002, NEW ENGL J MED, V347, P1057, DOI 10.1056/NEJMoa013121; Weaver LK, 2011, UNDERSEA HYPERBAR M, V38, P462; Weaver LK, 1997, UNDERSEA HYPERB ME S, V24, P36; Wright JK, 2009, UNDERSEA HYPERBAR M, V36, P391	25	35	37	0	6	UNDERSEA & HYPERBARIC MEDICAL SOC INC	DURHAM	21 WEST COLONY PLACE, STE 280, DURHAM, NC 27705 USA	1066-2936			UNDERSEA HYPERBAR M	Undersea Hyperb. Med.	JUL-AUG	2012	39	4					807	814					8	Marine & Freshwater Biology; Medicine, Research & Experimental	Marine & Freshwater Biology; Research & Experimental Medicine	250BP	WOS:000326825400005	22908837				2021-06-18	
J	Willie, JT; Lim, MM; Bennett, RE; Azarion, AA; Schwetye, KE; Brody, DL				Willie, Jon T.; Lim, Miranda M.; Bennett, Rachel E.; Azarion, Allan A.; Schwetye, Katherine E.; Brody, David L.			Controlled Cortical Impact Traumatic Brain Injury Acutely Disrupts Wakefulness and Extracellular Orexin Dynamics as Determined by Intracerebral Microdialysis in Mice	JOURNAL OF NEUROTRAUMA			English	Article						circadian rhythm; electroencephalography; electromyography; hypocretin; hypothalamus; microdialysis; orexin; sleep; traumatic brain injury	CLOSED-HEAD INJURY; HYPOCRETIN OREXIN; HUMAN NARCOLEPSY; SLEEP DISORDERS; NEURONS; RAT; DEFICIENCY; PEPTIDES; SYSTEMS; STATES	Among other deficits, traumatic brain injury (TBI) causes impaired arousal and cognitive dysfunction. Hypothalamic orexin neuropeptides (also called hypocretins) regulate levels of arousal, and cerebrospinal fluid orexin levels are reportedly low in TBI patients. We hypothesized that TBI acutely impairs the dynamics of orexin release into brain interstitial fluid, and that these extracellular orexin levels correlate with wakefulness and motor activity. To test this in mice, we combined an electromagnetic controlled cortical impact (CCI) model of experimental TBI with dual intracerebral microdialysis using one catheter in the hypothalamus and one catheter in the hippocampus, plus electroencephalography/electromyography (EEG/EMG), and motor activity monitoring. Baseline data were continuously collected in tethered but relatively freely moving mice for 2 days. Then, ipsilateral CCI or sham surgery was performed, and data collection was continued for 3 additional days. At baseline, extracellular orexin levels in the hypothalamus showed a circadian rhythm, with peak levels during the dark (wake) phase, and a nadir during the light (rest) phase. Following CCI but not sham surgery, orexin levels were depressed in both the hypothalamus and hippocampus, and diurnal fluctuation amplitudes were blunted in the hypothalamus. At baseline, correlations of orexin with wakefulness and motor activity were positive and highly significant. Following CCI but not sham surgery, the mice exhibited reduced wakefulness and motor activity, and correlations between orexin and these measures were diminished. These abnormal orexin dynamics were associated with hypothalamic astrogliosis, but not acute loss of orexin neurons, as assessed by immunohistochemistry 3 days after injury. Future studies involving experimental manipulations of the orexin system will be required to determine its contribution to neurological outcomes following injury.	[Willie, Jon T.] Emory Univ, Sch Med, Dept Neurol Surg, Atlanta, GA USA; [Lim, Miranda M.; Bennett, Rachel E.; Azarion, Allan A.; Schwetye, Katherine E.; Brody, David L.] Univ Penn, Div Sleep Med, Philadelphia, PA 19104 USA	Brody, DL (corresponding author), Washington Univ, Sch Med, 660 S Euclid Ave,Campus Box 8111, St Louis, MO 63110 USA.	brodyd@neuro.wustl.edu	Bennett, Rachel/AAU-6949-2020		Neurosurgery Research Education Fund; Porex Corporation; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS065069]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS065069] Funding Source: NIH RePORTER	Funding for this study was provided by a grant from the Neurosurgery Research Education Fund and Porex Corporation to J.T.W., and the National Institutes of Health R01 NS065069 to D.L.B. We thank Dr. David M. Holtzman and members of the Holtzman Laboratory for allowing us to use their controlled light/dark mouse room and electrophysiological monitoring equipment.	Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Baumann CR, 2009, ANN NEUROL, V66, P555, DOI 10.1002/ana.21836; Baumann CR, 2005, NEUROLOGY, V65, P147, DOI 10.1212/01.wnl.0000167605.02541.f2; Brody DL, 2008, SCIENCE, V321, P1221, DOI 10.1126/science.1161591; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Castriotta RJ, 2009, J CLIN SLEEP MED, V5, P137; Castriotta RJ, 2001, ARCH PHYS MED REHAB, V82, P1403, DOI 10.1053/apmr.2001.26081; Chemelli RM, 1999, CELL, V98, P437, DOI 10.1016/S0092-8674(00)81973-X; Cirrito JR, 2003, J NEUROSCI, V23, P8844; CROMPTON MR, 1971, BRAIN, V94, P165, DOI 10.1093/brain/94.1.165; Deadwyler SA, 2007, J NEUROSCI, V27, P14239, DOI 10.1523/JNEUROSCI.3878-07.2007; Fenzl T, 2009, BEHAV BRAIN RES, V203, P143, DOI 10.1016/j.bbr.2009.04.012; Franklin K.B.J., 2004, MOUSE BRAIN STEREOTA; Hara J, 2001, NEURON, V30, P345, DOI 10.1016/S0896-6273(01)00293-8; Kempf J, 2010, J NEUROL NEUROSUR PS, V81, P1402, DOI 10.1136/jnnp.2009.201913; Kiyashchenko LI, 2002, J NEUROSCI, V22, P5282; LANKFORD DA, 1994, SLEEP, V17, pS25, DOI 10.1093/sleep/17.suppl_8.S25; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; Mieda M, 2004, P NATL ACAD SCI USA, V101, P4649, DOI 10.1073/pnas.0400590101; Mignot E, 2002, ARCH NEUROL-CHICAGO, V59, P1553, DOI 10.1001/archneur.59.10.1553; Mihara Y, 2011, J MOL NEUROSCI, V43, P162, DOI 10.1007/s12031-010-9438-6; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Nishino S, 2000, LANCET, V355, P39, DOI 10.1016/S0140-6736(99)05582-8; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Peyron C, 1998, J NEUROSCI, V18, P9996; Peyron C, 2000, NAT MED, V6, P991, DOI 10.1038/79690; Renger JJ, 2004, BRAIN RES, V1010, P45, DOI 10.1016/j.brainres.2004.02.067; Ronne-Engstrom E, 2001, J NEUROSURG, V94, P397, DOI 10.3171/jns.2001.94.3.0397; Sakurai T, 1998, Cell, V92, P696; Sakurai T, 2011, TRENDS PHARMACOL SCI, V32, P451, DOI 10.1016/j.tips.2011.03.007; Schwetye KE, 2010, NEUROBIOL DIS, V40, P555, DOI 10.1016/j.nbd.2010.06.018; Thannickal TC, 2000, NEURON, V27, P469, DOI 10.1016/S0896-6273(00)00058-1; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Watson NF, 2007, J CLIN SLEEP MED, V3, P363; Willie JT, 2008, NEUROSCIENCE, V156, P819, DOI 10.1016/j.neuroscience.2008.08.048; Willie JT, 2003, NEURON, V38, P715, DOI 10.1016/S0896-6273(03)00330-1; Willie JT, 2001, ANNU REV NEUROSCI, V24, P429, DOI 10.1146/annurev.neuro.24.1.429; Yoshida K, 2006, J COMP NEUROL, V494, P845, DOI 10.1002/cne.20859; Yoshida Y, 2001, EUR J NEUROSCI, V14, P1075, DOI 10.1046/j.0953-816x.2001.01725.x	41	35	39	0	12	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUL	2012	29	10					1908	1921		10.1089/neu.2012.2404			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	971YV	WOS:000306244400395	22607167	Green Published			2021-06-18	
J	Rasouli, J; Lekhraj, R; White, NM; Flamm, ES; Pilla, AA; Strauch, B; Casper, D				Rasouli, Jonathan; Lekhraj, Rukmani; White, Nicholas M.; Flamm, Eugene S.; Pilla, Arthur A.; Strauch, Berish; Casper, Diana			Attenuation of interleukin-1beta by pulsed electromagnetic fields after traumatic brain injury	NEUROSCIENCE LETTERS			English	Article						Pulsed electromagnetic fields; PEMF; Inflammation; Interleukin-1beta; IL-1 beta; Traumatic brain injury; TBI	HEAD-INJURY; ADENOSINE RECEPTORS; CEREBROSPINAL-FLUID; NITRIC-OXIDE; INFLAMMATION; PATHOPHYSIOLOGY; EXPRESSION; INDUCTION; CYTOKINES; DAMAGE	Traumatic Brain Injury (TBI) is a major cause of morbidity and mortality in civilian and military populations. Interleukin-1beta (IL-1 beta) is a pro-inflammatory cytokine with a key role in the inflammatory response following TBI and studies indicate that attenuation of this cytokine improves behavioral outcomes. Pulsed electromagnetic fields (PEMF) can reduce inflammation after soft tissue injuries in animals and humans. Therefore, we explored whether PEMF signals could alter the course of IL-1 beta production in rats subjected to closed-head contusive weight-drop injuries (Marmarou method) and penetrating needle-stick brain injuries. Protein levels, measured by the Biorad assay, were not altered by injuries or PEMF treatment. In addition, we verified that IL-1 beta levels in cerebrospinal fluid (CSF) were proportional to injury severity in the contusion model. Results demonstrate that PEMF treatment attenuated IL-1 beta levels up to 10-fold in CSF within 6 h after contusive injury and also significantly suppressed IL-1 beta within 17-24h after penetrating injury. In contrast, no differences in IL-1 beta were seen between PEMF-treated and control groups in brain homogenates. To the authors' knowledge, this is the first report of the use of PEMF to modulate an inflammatory cytokine after TBI. These results warrant further studies to assess the effects of PEMF on other inflammatory markers and functional outcomes. (C) 2012 Elsevier Ireland Ltd. All rights reserved.	[Casper, Diana] Montefiore Med Ctr, Neurosurg Lab, Bronx, NY 10467 USA; [Rasouli, Jonathan; Lekhraj, Rukmani; White, Nicholas M.; Flamm, Eugene S.; Casper, Diana] Albert Einstein Coll Med, Dept Neurosurg, Bronx, NY 10467 USA; [Pilla, Arthur A.] Columbia Univ, Dept Biomed Engn, New York, NY 10027 USA; [Strauch, Berish] Albert Einstein Coll Med, Dept Plast & Reconstruct Surg, Bronx, NY 10467 USA	Casper, D (corresponding author), Montefiore Med Ctr, Neurosurg Lab, Moses 3,111 E 210th St, Bronx, NY 10467 USA.	diana.casper@einstein.yu.edu	Rasouli, Jonathan/AAF-2742-2020	Rasouli, Jonathan/0000-0002-5085-8422	Ivivi Health Sciences; Ivivi Health Sciences, LLB, San Francisco	A.A.P. receives compensation as a scientific consultant to Ivivi Health Sciences. A.A.P., D.C. and B.S. may receive a small royalty from Ivivi Health Sciences if a recent TBI patent disclosure issues and Ivivi is able to commercialize a TBI product.; The authors would like to thank Don Pang, Valerie Lartchenko, Shahla Powell, and Lily Rasouli for excellent technical assistance and Parviz Lalezari for valuable discussions about this work. This study was funded in part by Ivivi Health Sciences, LLB, San Francisco.	BLACK RA, 1988, J BIOL CHEM, V263, P9437; Brydon L, 2005, BRAIN BEHAV IMMUN, V19, P540, DOI 10.1016/j.bbi.2004.12.003; Calabrese V, 2007, NAT REV NEUROSCI, V8, P766, DOI 10.1038/nrn2214; Cederberg D, 2010, CHILD NERV SYST, V26, P221, DOI 10.1007/s00381-009-1029-x; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; Edwards P, 2005, LANCET, V365, P1957; EPUAP 2002 European Pressure Ulcer Advisory Panel, 2002, DECUBITUS, V4, P49; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; GOSSLING HR, 1992, ORTHOPEDICS, V15, P711; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Helmy A, 2011, PROG NEUROBIOL, V95, P352, DOI 10.1016/j.pneurobio.2011.09.003; Holmin S, 2000, J NEUROSURG, V92, P108, DOI 10.3171/jns.2000.92.1.0108; Homsi S, 2009, BRAIN RES, V1291, P122, DOI 10.1016/j.brainres.2009.07.031; Itoh M, 1991, DECUBITUS, V4, P29; Kamm K, 2006, J TRAUMA, V60, P152, DOI 10.1097/01.ta.0000196345.81169.a1; Kim YM, 1998, J IMMUNOL, V161, P4122; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; McColl BW, 2008, J NEUROSCI, V28, P9451, DOI 10.1523/JNEUROSCI.2674-08.2008; MEDAWAR PB, 1948, BRIT J EXP PATHOL, V29, P58; Nirogi R, 2009, J NEUROSCI METH, V178, P116, DOI 10.1016/j.jneumeth.2008.12.001; PENNINGTON GM, 1993, MIL MED, V158, P101; Pilla A, 2011, BBA-GEN SUBJECTS, V1810, P1236, DOI 10.1016/j.bbagen.2011.10.001; Pinteaux E, 2009, CYTOKINE, V45, P1, DOI 10.1016/j.cyto.2008.10.008; Rohde C, 2010, PLAST RECONSTR SURG, V125, P1620, DOI 10.1097/PRS.0b013e3181c9f6d3; Sanderson KL, 1999, J CEREBR BLOOD F MET, V19, P1118, DOI 10.1097/00004647-199910000-00008; Shiozaki T, 2005, SHOCK, V23, P406, DOI 10.1097/01.shk.0000161385.62758.24; SOSIN DM, 1989, JAMA-J AM MED ASSOC, V262, P2251, DOI 10.1001/jama.262.16.2251; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; Varani K, 2002, BRIT J PHARMACOL, V136, P57, DOI 10.1038/sj.bjp.0704695; Varani K, 2012, BIOELECTROMAGNETICS, V33, P279, DOI 10.1002/bem.20704; YAMASAKI Y, 1995, STROKE, V26, P676, DOI 10.1161/01.STR.26.4.676; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	36	35	37	0	9	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	JUN 21	2012	519	1					4	8		10.1016/j.neulet.2012.03.089			5	Neurosciences	Neurosciences & Neurology	965MX	WOS:000305773000002	22503903				2021-06-18	
J	Clayson, PE; Larson, MJ				Clayson, Peter E.; Larson, Michael J.			Cognitive performance and electrophysiological indices of cognitive control: A validation study of conflict adaptation	PSYCHOPHYSIOLOGY			English	Article						N2; Cognitive control; Neuropsychology; Attention; Executive function; Anterior cingulate; ACC; Event-related potentials (ERPs)	TRAUMATIC BRAIN-INJURY; MEDIAL FRONTAL-CORTEX; ANTERIOR CINGULATE; PARAMETRIC MANIPULATION; RESPONSE-INHIBITION; NEURAL MECHANISMS; ADJUSTMENTS; TASK; SCHIZOPHRENIA; ANXIETY	Psychiatric and neurologic disorders are associated with deficits in the postconflict recruitment of cognitive control. The primary aim of this study was to validate the relationship between cognitive functioning and indices of conflict adaptation. Event-related potentials were obtained from 89 healthy individuals who completed an Eriksen flanker task. Neuropsychological domains tested included memory, verbal fluency, and attention/executive functioning. Behavioral measures and N2 amplitudes showed significant conflict adaptation (i.e., previous-trial congruencies influenced current-trial measures). Higher scores on the attention/executive functioning and verbal fluency domains were associated with larger incongruent-trial N2 conflict adaptation; measures of cognitive functioning were not related to behavioral indices. This study provides initial validation of N2 conflict adaptation effects as cognitive function-related aspects of cognitive control.	[Larson, Michael J.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Larson, Michael J.] Brigham Young Univ, Ctr Neurosci, Provo, UT 84602 USA; [Clayson, Peter E.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA	Larson, MJ (corresponding author), Brigham Young Univ, Dept Psychol, 244 TLRB, Provo, UT 84602 USA.	michael_larson@byu.edu	Clayson, Peter E/F-5438-2011; Clayson, Peter/AAC-9207-2019; Larson, Michael J/C-8543-2012	Clayson, Peter E/0000-0003-4437-6598; Clayson, Peter/0000-0003-4437-6598; Larson, Michael J/0000-0002-8199-8065	Brigham Young University College of Family, Home, and Social Sciences	We gratefully acknowledge the assistance of Joseph Fair, Isaac Prows, Ann Clawson, and William David Walker in data collection. This study was supported by funds from the Brigham Young University College of Family, Home, and Social Sciences.	Amstadter A, 2008, J ANXIETY DISORD, V22, P211, DOI 10.1016/j.janxdis.2007.02.004; Bagiella E, 2010, J HEAD TRAUMA REHAB, V25, P375, DOI 10.1097/HTR.0b013e3181d27fe3; Beck A. T., 1996, BECK DEPRESSION INVE, VII; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Benton A., 1976, MULTILINGUAL APHASIA; Bilder RM, 2000, AM J PSYCHIAT, V157, P549, DOI 10.1176/appi.ajp.157.4.549; Bonnin CA, 2010, NEUROPSYCHOLOGY, V24, P542, DOI 10.1037/a0018384; Botvinick MM, 2001, PSYCHOL REV, V108, P624, DOI 10.1037//0033-295X.108.3.624; Bugg JM, 2008, MEM COGNITION, V36, P1217, DOI 10.3758/MC.36.7.1217; Cernich AN, 2010, CURR TREAT OPTION NE, V12, P412, DOI 10.1007/s11940-010-0085-6; Clayson PE, 2011, PSYCHOPHYSIOLOGY, V48, P1621, DOI 10.1111/j.1469-8986.2011.01265.x; Clayson PE, 2011, NEUROPSYCHOLOGIA, V49, P1953, DOI 10.1016/j.neuropsychologia.2011.03.023; Clayson PE, 2011, BIOL PSYCHOL, V87, P282, DOI 10.1016/j.biopsycho.2011.03.011; Corbetta M, 2002, NAT REV NEUROSCI, V3, P201, DOI 10.1038/nrn755; Danielmeier C, 2009, PSYCHOPHYSIOLOGY, V46, P1288, DOI 10.1111/j.1469-8986.2009.00860.x; Debener S, 2005, J NEUROSCI, V25, P11730, DOI 10.1523/JNEUROSCI.3286-05.2005; DESIMONE R, 1995, ANNU REV NEUROSCI, V18, P193, DOI 10.1146/annurev.neuro.18.1.193; Durston S, 2003, NEUROIMAGE, V20, P2135, DOI 10.1016/j.neuroimage.2003.08.004; Durston S, 2002, NEUROIMAGE, V16, P449, DOI 10.1006/nimg.2002.1074; Egner T, 2005, NAT NEUROSCI, V8, P1784, DOI 10.1038/nn1594; Egner T, 2005, NEUROIMAGE, V24, P539, DOI 10.1016/j.neuroimage.2004.09.007; Egner T, 2007, COGN AFFECT BEHAV NE, V7, P380, DOI 10.3758/CABN.7.4.380; Egner T, 2011, J COGNITIVE NEUROSCI, V23, P3903, DOI 10.1162/jocn_a_00064; Eichele H, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/fnhum.2010.00065; Emre M, 2007, MOVEMENT DISORD, V22, P1689, DOI 10.1002/mds.21507; Enticott PG, 2008, PSYCHIAT RES, V157, P251, DOI 10.1016/j.psychres.2007.04.007; ERIKSEN BA, 1974, PERCEPT PSYCHOPHYS, V16, P143, DOI 10.3758/BF03203267; Etkin A, 2010, AM J PSYCHIAT, V167, P545, DOI 10.1176/appi.ajp.2009.09070931; Fernandez-Duque D, 2008, J EXP PSYCHOL HUMAN, V34, P340, DOI 10.1037/0096-1523.34.2.340; Folstein JR, 2008, PSYCHOPHYSIOLOGY, V45, P152, DOI 10.1111/j.1469-8986.2007.00602.x; Forster SE, 2011, J COGNITIVE NEUROSCI, V23, P923, DOI 10.1162/jocn.2010.21458; Funes MJ, 2010, COGN NEUROPSYCHOL, V27, P360, DOI 10.1080/02643294.2010.532618; GRATTON G, 1992, J EXP PSYCHOL GEN, V121, P480, DOI 10.1037/0096-3445.121.4.480; GRATTON G, 1983, ELECTROEN CLIN NEURO, V55, P468, DOI 10.1016/0013-4694(83)90135-9; Hommel B, 2004, PSYCHOL RES-PSYCH FO, V68, P1, DOI 10.1007/s00426-003-0132-y; Jacobs R, 2007, CORTEX, V43, P792, DOI 10.1016/S0010-9452(08)70507-0; Kerns JG, 2005, AM J PSYCHIAT, V162, P1833, DOI 10.1176/appi.ajp.162.10.1833; Kerns JG, 2004, SCIENCE, V303, P1023, DOI 10.1126/science.1089910; Kerns JG, 2006, NEUROIMAGE, V33, P399, DOI 10.1016/j.neuroimage.2006.06.012; Kwok FY, 2008, BRAIN INJURY, V22, P740, DOI 10.1080/02699050802336989; Ladouceur CD, 2007, DEVELOPMENTAL SCI, V10, P874, DOI 10.1111/j.1467-7687.2007.00639.x; Larson MJ, 2011, INT J PSYCHOPHYSIOL, V82, P69, DOI 10.1016/j.ijpsycho.2011.02.018; Larson MJ, 2011, COGN AFFECT BEHAV NE, V11, P159, DOI 10.3758/s13415-010-0018-6; Larson MJ, 2009, J INT NEUROPSYCH SOC, V15, P927, DOI 10.1017/S1355617709990701; Larson MJ, 2009, NEUROPSYCHOLOGIA, V47, P663, DOI 10.1016/j.neuropsychologia.2008.11.013; Laws K R, 1999, Cogn Neuropsychiatry, V4, P1, DOI 10.1080/135468099396025; Laws KR, 1999, COGN NEUROPSYCHIATRY, V4, P31, DOI DOI 10.1080/135468099396025; Logan GD, 2007, J EXP PSYCHOL HUMAN, V33, P978, DOI 10.1037/0096-1523.33.4.978; Ma XH, 2007, AM J MED GENET B, V144B, P407, DOI 10.1002/ajmg.b.30330; Mayr U, 2003, NAT NEUROSCI, V6, P450, DOI 10.1038/nn1051; Melcher T, 2008, BRAIN RES REV, V59, P96, DOI 10.1016/j.brainresrev.2008.06.003; Nieuwenhuis S, 2006, MEM COGNITION, V34, P1260, DOI 10.3758/BF03193270; Nieuwenhuis S, 2003, COGN AFFECT BEHAV NE, V3, P17, DOI 10.3758/CABN.3.1.17; Notebaert W, 2005, EUR J COGN PSYCHOL, V17, P642, DOI 10.1080/09541440540000095; Osinsky R, 2010, COGN AFFECT BEHAV NE, V10, P372, DOI 10.3758/CABN.10.3.372; Pacheco-Unguetti AP, 2011, J ANXIETY DISORD, V25, P888, DOI 10.1016/j.janxdis.2011.04.010; RABBITT PMA, 1966, J EXP PSYCHOL, V71, P264, DOI 10.1037/h0022853; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Rey A, 1964, EXAMEN CLIN PSYCHOL; Ridderinkhof KR, 2004, SCIENCE, V306, P443, DOI 10.1126/science.1100301; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Rund BR, 2006, ACTA PSYCHIAT SCAND, V113, P350, DOI 10.1111/j.1600-0447.2005.00626.x; Rushe TM, 1999, SCHIZOPHR RES, V37, P21, DOI 10.1016/S0920-9964(98)00129-7; Spielberger CD., 1989, MANUAL STATE TRAIT A, V2; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Sturmer B, 2002, J EXP PSYCHOL HUMAN, V28, P1345, DOI 10.1037//0096-1523.28.6.1345; Thoma P, 2007, SCHIZOPHR RES, V92, P168, DOI 10.1016/j.schres.2007.02.004; Tsaousides T, 2009, MT SINAI J MED, V76, P173, DOI 10.1002/msj.20099; Ullsperger M, 2005, COGN AFFECT BEHAV NE, V5, P467, DOI 10.3758/CABN.5.4.467; van Steenbergen H, 2010, PSYCHOL SCI, V21, P1629, DOI 10.1177/0956797610385951; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Verbruggen F, 2006, PSYCHON B REV, V13, P328, DOI 10.3758/BF03193852; Wechsler D, 1997, WAIS 3 ADM SCORING M; Williams-Gray CH, 2009, BRAIN, V132, P2958, DOI 10.1093/brain/awp245; Yeung N, 2006, PSYCHOL SCI, V17, P164, DOI 10.1111/j.1467-9280.2006.01680.x; Yeung N, 2004, PSYCHOL REV, V111, P931, DOI [10.1037/0033-295X.111.4.931, 10.1037/0033-295x.111.4.931]; Yeung N, 2007, COGN AFFECT BEHAV NE, V7, P347, DOI 10.3758/CABN.7.4.347; Yun DY, 2011, PROG NEURO-PSYCHOPH, V35, P1148, DOI 10.1016/j.pnpbp.2011.03.018; Zgaljardic DJ, 2006, J CLIN EXP NEUROPSYC, V28, P1127, DOI 10.1080/13803390500246910	80	35	36	0	18	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0048-5772	1469-8986		PSYCHOPHYSIOLOGY	Psychophysiology	MAY	2012	49	5					627	637		10.1111/j.1469-8986.2011.01345.x			11	Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental	Psychology; Neurosciences & Neurology; Physiology	923LM	WOS:000302620800005	22292850				2021-06-18	
J	Frassanito, P; Massimi, L; Caldarelli, M; Tamburrini, G; Di Rocco, C				Frassanito, Paolo; Massimi, Luca; Caldarelli, Massimo; Tamburrini, Gianpiero; Di Rocco, Concezio			Complications of delayed cranial repair after decompressive craniectomy in children less than 1 year old	ACTA NEUROCHIRURGICA			English	Article						Paediatric head injury; Infants; Postoperative subdural effusion; Enlarging duraplasty; Autologous cranial bone replacement	DURA-MATER; SUBDURAL COLLECTIONS; CEREBROSPINAL-FLUID; BONE-GRAFTS; CRANIOPLASTY; BRAIN; ADOLESCENTS; HEMATOMA; IMMATURE; HYGROMA	Decompressive craniectomy is an effective treatment option in case of refractory intracranial hypertension after severe head injury. The incidence of complications following cranial repair after decompressive craniectomy for traumatic brain injury is not negligible, particularly in infants and young toddlers. However, only a few dedicated papers can be found in the literature. We describe the complications observed in two boys and one girl under 1 year of age that were treated in the last decade by hemicranial decompressive craniotomy and enlarging hemispheric duraplasty, and subsequent cranial repair by means of autologous bone-flap replacement. Despite good clinical and neurological outcome, the postoperative clinical course was complicated in all cases by early or late evidence of subdural fluid collections associated to the occurrence of hydrocephalus and causing recurrent dislocation and progressive resorption of the autologous bone flap. Infants less than 1 year old, undergoing decompressive craniectomy after traumatic brain injury, experience a high rate of complications following subsequent cranial repair. Subdural collections and resorption of the autologous bone flap are to be considered as extremely common complications.	[Frassanito, Paolo] Catholic Med Sch, Pediat Neurosurg Unit, I-00168 Rome, Italy; [Frassanito, Paolo; Massimi, Luca; Caldarelli, Massimo; Tamburrini, Gianpiero; Di Rocco, Concezio] Catholic Med Sch, Policlin A Gemelli, I-00168 Rome, Italy	Frassanito, P (corresponding author), Catholic Med Sch, Pediat Neurosurg Unit, Largo Agostino Gemelli 8, I-00168 Rome, Italy.	paolo.frassanito@gmail.com	FRASSANITO, Paolo/K-4099-2018	FRASSANITO, Paolo/0000-0003-0071-3126			Adamo MA, 2009, J NEUROSURG-PEDIATR, V3, P334, DOI 10.3171/2008.12.PEDS08310; Bolay H, 2002, NAT MED, V8, P136, DOI 10.1038/nm0202-136; Chang V, 2010, J NEUROSURG, V112, P1120, DOI 10.3171/2009.6.JNS09133; Di Rocco C, 2000, PEDIATR NEUROSURG, V33, P198, DOI 10.1159/000055953; Fong KD, 2003, PLAST RECONSTR SURG, V112, P1312, DOI 10.1097/01.PRS.0000079860.14734.D6; Fox RJ, 1996, NEUROSURGERY, V39, P84, DOI 10.1097/00006123-199607000-00017; FRIEDE RL, 1978, AM J PATHOL, V92, P69; Grant GA, 2004, J NEUROSURG, V100, P163, DOI 10.3171/ped.2004.100.2.0163; Greenwald JA, 2000, PLAST RECONSTR SURG, V105, P1382, DOI 10.1097/00006534-200004040-00018; HAINES DE, 1993, NEUROSURGERY, V32, P111, DOI 10.1227/00006123-199301000-00017; Hannah JA, 1936, J NERV MENT DIS, V84, P169, DOI 10.1097/00005053-193608000-00005; HASEGAWA M, 1992, NEUROSURGERY, V31, P580, DOI 10.1227/00006123-199209000-00024; Honeybul S, 2010, J NEUROTRAUM, V27, P1225, DOI 10.1089/neu.2010.1316; Iwama T, 2003, NEUROSURGERY, V52, P591, DOI 10.1227/01.NEU.0000047891.86938.46; Jannathan J, 2007, J NEUROSURG S, V106, P268; Kristof RA, 2008, J NEUROSURG, V108, P275, DOI 10.3171/JNS/2008/108/2/0275; Mack J, 2009, PEDIATR RADIOL, V39, P200, DOI 10.1007/s00247-008-1084-6; MARKOWITZ S, 1987, J NEUROSCI, V7, P4129, DOI 10.1523/jneurosci.07-12-04129.1987; Miranda P, 2004, NEUROCIRUGIA, V15, P67; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; POSNICK JC, 1993, NEUROSURGERY, V32, P785, DOI 10.1227/00006123-199305000-00011; PROLO DJ, 1991, CLIN ORTHOP RELAT R, P270; RISH BL, 1979, NEUROSURGERY, V4, P381, DOI 10.1227/00006123-197905000-00002; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Valenca MM, 2010, J NEUROSURG, V113, P982, DOI 10.3171/2009.11.JNS09674; Zouros A, 2004, J NEUROSURG, V100, P512, DOI 10.3171/ped.2004.100.5.0512	26	35	35	0	2	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.	MAY	2012	154	5					927	933		10.1007/s00701-011-1253-5			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	934PG	WOS:000303455800023	22198327				2021-06-18	
J	Jones, TA; Liput, DJ; Maresh, EL; Donlan, N; Parikh, TJ; Marlowe, D; Kozlowski, DA				Jones, Theresa A.; Liput, Daniel J.; Maresh, Erin L.; Donlan, Nicole; Parikh, Toral J.; Marlowe, Dana; Kozlowski, Dorothy A.			Use-Dependent Dendritic Regrowth Is Limited after Unilateral Controlled Cortical Impact to the Forelimb Sensorimotor Cortex	JOURNAL OF NEUROTRAUMA			English	Article						dendritic arborization; forelimb deficits; forelimb sensorimotor cortex; synaptic density; traumatic brain injury	TRAUMATIC BRAIN-INJURY; NOGO-A EXPRESSION; LESS-AFFECTED FORELIMB; MOTOR CORTEX; NEURAL PLASTICITY; SYNAPTIC PROTEINS; PYRAMIDAL NEURONS; OXIDATIVE STRESS; ISCHEMIC-STROKE; ADULT-RATS	Compensatory neural plasticity occurs in both hemispheres following unilateral cortical damage incurred by seizures, stroke, and focal lesions. Plasticity is thought to play a role in recovery of function, and is important for the utility of rehabilitation strategies. Such effects have not been well described in models of traumatic brain injury (TBI). We examined changes in immunoreactivity for neural structural and plasticity-relevant proteins in the area surrounding a controlled cortical impact (CCI) to the forelimb sensorimotor cortex (FL-SMC), and in the contralateral homotopic cortex over time (3-28 days). CCI resulted in considerable motor deficits in the forelimb contralateral to injury, and increased reliance on the ipsilateral forelimb. The density of dendritic processes, visualized with immunostaining for microtubule-associated protein-2 (MAP-2), were bilaterally decreased at all time points. Synaptophysin (SYN) immunoreactivity increased transiently in the injured hemisphere, but this reflected an atypical labeling pattern, and it was unchanged in the contralateral hemisphere compared to uninjured controls. The lack of compensatory neuronal structural plasticity in the contralateral homotopic cortex, despite behavioral asymmetries, is in contrast to previous findings in stroke models. In the cortex surrounding the injury (but not the contralateral cortex), decreases in dendrites were accompanied by neurodegeneration, as indicated by Fluoro-Jade B (FJB) staining, and increased expression of the growth-inhibitory protein Nogo-A. These studies indicate that, following unilateral CCI, the cortex undergoes neuronal structural degradation in both hemispheres out to 28 days post-injury, which may be indicative of compromised compensatory plasticity. This is likely to be an important consideration in designing therapeutic strategies aimed at enhancing plasticity following TBI.	[Liput, Daniel J.; Marlowe, Dana; Kozlowski, Dorothy A.] De Paul Univ, Dept Biol Sci, Chicago, IL 60614 USA; [Jones, Theresa A.; Maresh, Erin L.; Donlan, Nicole; Parikh, Toral J.] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA; [Jones, Theresa A.; Maresh, Erin L.; Donlan, Nicole; Parikh, Toral J.] Univ Texas Austin, Inst Neurosci, Austin, TX 78712 USA	Kozlowski, DA (corresponding author), De Paul Univ, Dept Biol Sci, 2325 N Clifton, Chicago, IL 60614 USA.	dkozlows@depaul.edu	Jones, Theresa A/F-1182-2010	Jones, Theresa A/0000-0003-0906-6439; Liput, Daniel/0000-0002-8418-3494	DePaul University Research Council; College of Liberal Arts and Sciences; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS056839] Funding Source: NIH RePORTER	Support for this work was provided by DePaul University Research Council and College of Liberal Arts and Sciences Undergraduate Grants to D. A. K. We thank Dr. R. P. Allred for help with statistical analyses.	Adkins DL, 2006, EXP NEUROL, V200, P356, DOI 10.1016/j.expneurol.2006.02.131; Adkins DL, 2004, NEUROSCIENCE, V128, P473, DOI 10.1016/j.neuroscience.2004.07.019; Allred RP, 2008, FUTUR NEUROL, V3, P189, DOI 10.2217/14796708.3.2.189; Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Ansari MA, 2008, J NEUROTRAUM, V25, P513, DOI 10.1089/neu.2007.0451; BADDELEY AJ, 1986, J MICROSC-OXFORD, V142, P259, DOI 10.1111/j.1365-2818.1986.tb04282.x; Becerra GD, 2007, BEHAV BRAIN RES, V179, P118, DOI 10.1016/j.bbr.2007.01.024; Brown CE, 2008, NEUROSCIENTIST, V14, P139, DOI 10.1177/1073858407309854; Campbell JN, 2011, J NEUROTRAUMA; Carmichael ST, 2002, J NEUROSCI, V22, P6062; Cheatwood JL, 2008, STROKE, V39, P2091, DOI 10.1161/STROKEAHA.107.507426; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; Chu CJ, 2000, EXP NEUROL, V166, P403, DOI 10.1006/exnr.2000.7509; DESALLES AAF, 1987, J NEUROSURG, V66, P102, DOI 10.3171/jns.1987.66.1.0102; Ding JY, 2009, BRAIN RES, V1268, P125, DOI 10.1016/j.brainres.2009.02.060; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DONOGHUE JP, 1982, J COMP NEUROL, V212, P76, DOI 10.1002/cne.902120106; Ferrer I, 2002, Cerebellum, V1, P213, DOI 10.1080/14734220260418448; Folkerts MM, 1998, J NEUROTRAUM, V15, P349, DOI 10.1089/neu.1998.15.349; Funahashi S, 2008, J COMP NEUROL, V506, P141, DOI 10.1002/cne.21541; GrandPre T, 2000, NATURE, V403, P439, DOI 10.1038/35000226; GUNDERSEN HJG, 1987, J MICROSC-OXFORD, V147, P229, DOI 10.1111/j.1365-2818.1987.tb02837.x; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Hall KD, 2010, BRAIN RES, V1323, P161, DOI 10.1016/j.brainres.2010.01.067; Harris NG, 2009, J NEUROSCI RES, V87, P2937, DOI 10.1002/jnr.22115; HERNANDEZ TD, 1988, EXP NEUROL, V102, P318, DOI 10.1016/0014-4886(88)90226-9; Hoane MR, 2007, J NEUROTRAUM, V24, P1108, DOI 10.1089/neu.2006.0254; HOVDA DA, 1996, NEUROTRAUMA, P1459; Hsu JE, 2006, EXP NEUROL, V201, P479, DOI 10.1016/j.expneurol.2006.05.003; Hsu JE, 2005, EUR J NEUROSCI, V22, P2069, DOI 10.1111/j.1460-9568.2005.04370.x; Huh JW, 2003, J NEUROTRAUM, V20, P975, DOI 10.1089/089771503770195821; Ip EY, 2003, J CEREBR BLOOD F MET, V23, P900, DOI 10.1097/01.WCB.0000076702.71231.F2; Jones TA, 1999, J COMP NEUROL, V414, P57; JONES TA, 1994, J NEUROSCI, V14, P2140; JONES TA, 1992, BRAIN RES, V581, P156, DOI 10.1016/0006-8993(92)90356-E; Jones TA, 1996, BRAIN RES, V733, P142, DOI 10.1016/0006-8993(96)00792-5; Jones TA, 2009, STROKE, V40, pS136, DOI 10.1161/STROKEAHA.108.533653; Jortner BS, 1997, NEUROTOXICOLOGY, V18, P161; Josephson A, 2001, EXP NEUROL, V169, P319, DOI 10.1006/exnr.2001.7659; KAAS JH, 1983, ANNU REV NEUROSCI, V6, P325, DOI 10.1146/annurev.ne.06.030183.001545; Kelly DF, 2000, J NEUROTRAUM, V17, P261, DOI 10.1089/neu.2000.17.261; Kleim JA, 2008, J SPEECH LANG HEAR R, V51, pS225, DOI 10.1044/1092-4388(2008/018); Kozlowski DA, 1996, J NEUROSCI, V16, P4776; Lehr RP, 2010, TRAUMATIC BRAIN INJURY: REHABILITATION, TREATMENT, AND CASE MANAGEMENT, 3RD EDITION, P455; Li HH, 2004, J NEUROTRAUM, V21, P1141, DOI 10.1089/0897715041953777; Liu HP, 2002, NEUROSCI LETT, V328, P257, DOI 10.1016/S0304-3940(02)00528-1; Luke LM, 2004, SYNAPSE, V54, P187, DOI 10.1002/syn.20080; Madow WG, 1944, ANN MATH STAT, V15, P1, DOI 10.1214/aoms/1177731312; Marklund N, 2006, EXP NEUROL, V197, P70, DOI 10.1016/j.expneurol.2005.08.029; Mir HM, 2004, BRAIN RES, V1002, P28, DOI 10.1016/j.brainres.2003.12.006; Monnerie H, 2010, EXP NEUROL, V224, P415, DOI 10.1016/j.expneurol.2010.05.001; Moore AH, 2000, J CEREBR BLOOD F MET, V20, P1492, DOI 10.1097/00004647-200010000-00011; Nishibe M, 2010, J NEUROTRAUM, V27, P2221, DOI 10.1089/neu.2010.1456; Nudo RJ, 2007, STROKE, V38, P840, DOI 10.1161/01.STR.0000247943.12887.d2; Passineau MJ, 2000, AM J PHYSIOL-HEART C, V279, pH924; Peters A, 1991, FINE STRUCTURE NERVO; Phillips LL, 2001, RESTOR NEUROL NEUROS, V19, P213; Posmantur RM, 1996, J NEUROTRAUM, V13, P125, DOI 10.1089/neu.1996.13.125; R Development Core Team, 2010, R LANG ENV STAT COMP R LANG ENV STAT COMP R LANG ENV STAT COMP R LANG ENV STAT COMP R LANG ENV STAT COMP R LANG ENV STAT COMP R LANG ENV STAT COMP R LANG ENV STAT COMP R LANG ENV STAT COMP R LANG ENV STAT COMP; Reeves TM, 2000, J NEUROSCI RES, V60, P370, DOI 10.1002/(SICI)1097-4547(20000501)60:3<370::AID-JNR12>3.3.CO;2-2; Schallert T., 1997, BRAIN PLASTICITY ADV, P73; Scheff SW, 2005, J NEUROTRAUM, V22, P719, DOI 10.1089/neu.2005.22.719; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Shin JW, 2006, NEUROSCI LETT, V394, P117, DOI 10.1016/j.neulet.2005.10.032; Stein D.G., 2007, BRAIN INJURY MED PRI, P97; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; Tesseur I, 2000, AM J PATHOL, V157, P1495, DOI 10.1016/S0002-9440(10)64788-8; Thompson SN, 2006, EXP NEUROL, V201, P253, DOI 10.1016/j.expneurol.2006.04.013; Voorhies AC, 2002, BEHAV BRAIN RES, V133, P237, DOI 10.1016/S0166-4328(02)00029-3; Wiley JL, 1996, BRAIN RES, V716, P47, DOI 10.1016/0006-8993(96)00045-5; Wise SP., 1986, SENSORY MOTOR AREAS, P243; Zorner B, 2010, ANN NY ACAD SCI, V1198, pE22, DOI 10.1111/j.1749-6632.2010.05566.x	73	35	35	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2012	29	7					1455	1468		10.1089/neu.2011.2207			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	933TC	WOS:000303384600018	22352953	Green Published			2021-06-18	
J	Won, SJ; Choi, Y; Yoo, BH; Sohn, M; Ying, WH; Swanson, RA; Suh, SW				Won, Seok Joon; Choi, Young; Yoo, Byung Hoon; Sohn, Min; Ying, Weihai; Swanson, Raymond A.; Suh, Sang Won			Prevention of Traumatic Brain Injury-Induced Neuron Death by Intranasal Delivery of Nicotinamide Adenine Dinucleotide	JOURNAL OF NEUROTRAUMA			English	Article						hippocampus; intranasal; microglia; nicotinamide adenine dinucleotide; poly(ADP-ribose) polymerase-1; superoxide; traumatic brain injury	POLY(ADP-RIBOSE) POLYMERASE INHIBITOR; TRANSIENT FOCAL ISCHEMIA; FLUID PERCUSSION INJURY; NAD(+) DEPLETION; MICROGLIAL ACTIVATION; CELL-DEATH; NEUTROPHIL ACCUMULATION; CEREBRAL-ISCHEMIA; GLOBAL-ISCHEMIA; NITRIC-OXIDE	Traumatic brain injury (TBI) is one of the most devastating injuries experienced by military personnel, as well as the general population, and can result in acute and chronic complications such as cognitive impairments. Since there are currently no effective tools for the treatment of TBI, it is of great importance to determine the mechanisms of neuronal death that characterize this insult. Several studies have indicated that TBI-induced neuronal death arises in part due to excessive activation of poly(ADP-ribose) polymerase-1 (PARP-1), which results in nicotinamide adenine dinucleotide (NAD(+)) depletion and subsequent energy failure. In this study, we investigated whether intranasal administration of NAD(+) could reduce neuronal death after TBI. Rats were subjected to a weight-drop TBI model that induces cortical and hippocampal neuronal death. The intranasal administration of NAD(+) (20 mg/kg) immediately after TBI protected neurons in CA1, CA3, and dentate gyrus of the hippocampus, but not in the cortex. In addition, delayed microglial activation normally seen after TBI was reduced by NAD(+) treatment at 7 days after insult. Neuronal superoxide production and PARP-1 accumulation after TBI were not inhibited by NAD+ treatment, indicating that reactive oxygen species (ROS) production and PARP-1 activation are events that occur upstream of NAD(+) depletion. This study suggests that intranasal delivery of NAD(+) represents a novel, inexpensive, and non-toxic intervention for preventing TBI-induced neuronal death.	[Choi, Young; Suh, Sang Won] Hallym Univ, Dept Physiol, Coll Med, Chunchon 200702, South Korea; [Sohn, Min] Inha Univ, Dept Nursing, Chunchon, South Korea; [Won, Seok Joon; Yoo, Byung Hoon; Swanson, Raymond A.; Suh, Sang Won] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA; [Yoo, Byung Hoon] Inje Univ, Sch Med, Sanggye Paik Hosp, Dept Anesthesiol, Seoul, South Korea; [Ying, Weihai] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Neurol, Shanghai 200030, Peoples R China	Suh, SW (corresponding author), Hallym Univ, Dept Physiol, Coll Med, 1 Okcheon Dong, Chunchon 200702, South Korea.	swsuh@hallym.ac.kr		Choi, Bo Young/0000-0002-9579-3503; Swanson, Raymond/0000-0002-3664-5359; SOHN, MIN/0000-0003-4021-2051	U.S. Department of Veterans AffairsUS Department of Veterans Affairs; U.S. Department of DefenseUnited States Department of Defense [W81XWH-05-2-0094]; Hallym University [HRF-2010-033]; Ministry of Health & Welfare, Republic of KoreaMinistry of Health & Welfare, Republic of Korea [A100687]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS041421] Funding Source: NIH RePORTER	This work was supported by the U.S. Department of Veterans Affairs and by the U.S. Department of Defense under contract number W81XWH-05-2-0094, and by the Hallym University (HRF-2010-033), and the Korea Healthcare Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (A100687).	Alano CC, 2004, J BIOL CHEM, V279, P18895, DOI 10.1074/jbc.M313329200; Alano CC, 2010, J NEUROSCI, V30, P2967, DOI 10.1523/JNEUROSCI.5552-09.2010; Bullock R, 1992, Acta Neurochir Suppl (Wien), V55, P49; Cai AL, 2006, EUR J NEUROSCI, V24, P2169, DOI 10.1111/j.1460-9568.2006.05110.x; Carbonell WS, 1999, ANN NY ACAD SCI, V890, P287, DOI 10.1111/j.1749-6632.1999.tb08005.x; Clark RSB, 2007, J NEUROTRAUM, V24, P1399, DOI 10.1089/neu.2007.0305; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Hamby AM, 2007, STROKE, V38, P632, DOI 10.1161/01.STR.0000250742.61241.79; Han HS, 2002, J NEUROSCI, V22, P3921, DOI 10.1523/JNEUROSCI.22-10-03921.2002; Hoane MR, 2006, J NEUROTRAUM, V23, P1535, DOI 10.1089/neu.2006.23.1535; Hoane MR, 2003, J NEUROTRAUM, V20, P1189, DOI 10.1089/089771503770802871; Inamasu J, 2000, J NEUROIMMUNOL, V109, P66, DOI 10.1016/S0165-5728(00)00211-3; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kauppinen TM, 2008, J NEUROSCI, V28, P5827, DOI 10.1523/JNEUROSCI.1236-08.2008; Koshinaga M, 2000, J NEUROTRAUM, V17, P185, DOI 10.1089/neu.2000.17.185; LaPlaca MC, 2001, J NEUROTRAUM, V18, P369, DOI 10.1089/089771501750170912; Lewen A, 1998, J NEUROTRAUM, V15, P521, DOI 10.1089/neu.1998.15.521; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P914, DOI 10.1097/00004647-200108000-00003; Mabuchi T, 2000, STROKE, V31, P1735, DOI 10.1161/01.STR.31.7.1735; Marklund N, 2001, J NEUROTRAUM, V18, P821, DOI 10.1089/089771501316919184; Mikawa S, 1996, J NEUROSURG, V85, P885, DOI 10.3171/jns.1996.85.5.0885; Murakami K, 1998, BRAIN RES, V780, P304, DOI 10.1016/S0006-8993(97)01217-1; Plaschke K, 2000, NEUROSCI LETT, V284, P109, DOI 10.1016/S0304-3940(00)00988-5; Satchell MA, 2003, J NEUROCHEM, V85, P697, DOI 10.1046/j.1471-4159.2003.01707.x; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Schroeter M, 1997, STROKE, V28, P382, DOI 10.1161/01.STR.28.2.382; Sheline CT, 2003, EUR J NEUROSCI, V18, P1402, DOI 10.1046/j.1460-9568.2003.02865.x; Sheline CT, 2000, J NEUROSCI, V20, P3139, DOI 10.1523/JNEUROSCI.20-09-03139.2000; Singh P, 2003, NEUROL INDIA, V51, P215; Suh SW, 2008, J CEREBR BLOOD F MET, V28, P1697, DOI 10.1038/jcbfm.2008.61; Suh SW, 2007, J CLIN INVEST, V117, P910, DOI 10.1172/JCI30077; Suh SW, 2006, J CEREBR BLOOD F MET, V26, P161, DOI 10.1038/sj.jcbfm.9600176; Suh SW, 2003, J NEUROSCI, V23, P10681; Suh SW, 2000, BRAIN RES, V852, P268, DOI 10.1016/S0006-8993(99)02095-8; Thompson HJ, 2005, J CEREBR BLOOD F MET, V25, P163, DOI 10.1038/sj.jcbfm.9600008; Tsuchiyama R, 2009, NEUROL RES, V31, P179, DOI 10.1179/174313209X393609; Weight DG, 1998, PSYCHIAT CLIN N AM, V21, P609, DOI 10.1016/S0193-953X(05)70026-5; Yenari MA, 2006, NEUROCHEM INT, V49, P164, DOI 10.1016/j.neuint.2006.03.016; Ying WJ, 2007, FRONT BIOSCI-LANDMRK, V12, P2728, DOI 10.2741/2267; Ying WH, 2005, J NEUROSCI RES, V79, P216, DOI 10.1002/jnr.20289; Ying WH, 2003, BIOCHEM BIOPH RES CO, V308, P809, DOI 10.1016/S0006-291X(03)01483-9; Zhu KQ, 2005, NEUROREPORT, V16, P1209, DOI 10.1097/00001756-200508010-00015	43	35	35	0	1	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAY	2012	29	7					1401	1409		10.1089/neu.2011.2228			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	933TC	WOS:000303384600014	22352983	Green Published			2021-06-18	
J	Li, SH; Wei, M; Zhou, ZW; Wang, B; Zhao, XL; Zhang, JN				Li, Shenghui; Wei, Ming; Zhou, Ziwei; Wang, Bin; Zhao, Xinliang; Zhang, Jianning			SDF-1 alpha induces angiogenesis after traumatic brain injury	BRAIN RESEARCH			English	Article						Traumatic brain injury; Angiogenesis; Functional recovery; Stromal cell derived factor	UMBILICAL-CORD BLOOD; MARROW-DERIVED CELLS; MESENCHYMAL STEM-CELLS; CENTRAL-NERVOUS-SYSTEM; CD34(+) CELLS; ISCHEMIC CARDIOMYOPATHY; MYOCARDIAL-INFARCTION; CHEMOKINE RECEPTOR; FACTOR-I; TISSUE REGENERATION	This study aimed to investigate the effects of SDF-1 alpha on brain angiogenesis and neurological functional recovery in rats after traumatic brain injury (TB!) and the potentially involved mechanisms. Youth male Wistar rats were injured via lateral fluid percussion injury and then randomly divided into one of 3 groups: I. vehicle treated group; II. SDF-1 alpha neutralizing antibody treated group and III. rhSDF-1 alpha treated group. rhSDF-1 alpha and its neutralizing antibody or normal saline were administered to the brain penumbra via stereotactic injection 30 min after TBI. Modified neurological severity score (mNSS) and Morris water maze (MWM) test were used to assess the neurologic functional recovery (n=6/group). 14 days after injury, animals were euthanized and brain tissues were collected for quantitative real time polymerase chain reaction (qRT-PCR) (n=6/group) and immunohistochemistry (n=6/group) analysis. mNSS and MWM test indicated distinct amelioration of neurological disability in rhSDF-1 alpha group(P<0.05). Microvessel density (MVD) of rhSDF-1 alpha treated animals was remarkably increased around the injured area. On the contrary, MVD of the SDF-1 alpha antibody administrated group was significantly decreased compared to that of vehicle treated animals (P<0.05). The mNSS and MVD had significant negative correlation as tested by Spearman rank correlation coefficient. Immunofluorescence staining showed that CD34 and CXCR4 co-expressed on microvessels. The rhSDF-1 alpha treated animals had greater, contrarily, the SDF-1 alpha antibody treated animals had lesser number of double positive microvessels compared to that of vehicle treated animals. The mRNA expression of CD34 and CXCR4 was obviously elevated in the rhSDF-1 alpha administration group, conversely, declined in SDF-1 alpha antibody treated animals around the injured area compared with that of the vehicle treatment group (P<0.05). These data indicated that SDF-1 alpha could induce angiogenesis after TB!, potentially via SDF-1/CXCR4 axis. (C) 2012 Elsevier B.V. All rights reserved.	[Li, Shenghui; Zhou, Ziwei; Wang, Bin; Zhang, Jianning] Tianjin Med Univ, Gen Hosp, Dept Neurosurg, Tianjin Neurol Inst, Tianjin 300052, Peoples R China; [Wei, Ming] Tianjin Med Univ, Hosp 2, Dept Neurosurg, Tianjin 300211, Peoples R China; [Zhao, Xinliang] Tianjin Yongjiu Hosp, Dept Neurosurg, Binhai New Area, Tianjin 300450, Peoples R China	Zhang, JN (corresponding author), Tianjin Med Univ, Gen Hosp, Dept Neurosurg, Tianjin Neurol Inst, 154 Anshan Rd, Tianjin 300052, Peoples R China.	lishenghui2000@gmail.com; neurowei@yahoo.com.cn; 1985zhouziwei@163.com; tianjinwangb@163.com; zxl6869@126.com; jianningzhang@hotmail.com			National Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30772229]; National 973 ProjectNational Basic Research Program of China [2005CB522605]	We acknowledge Li Liu, Fanglian Chen, Weiyun Cui, Yue Wang for excellent technical support and Jieli Chen, Joshua Marks for careful manuscript revision. This work was supported by the National Science Foundation of China (30772229) and National 973 Project (2005CB522605).	Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Askari AT, 2003, LANCET, V362, P697, DOI 10.1016/S0140-6736(03)14232-8; Barresi V, 2007, ACTA NEUROPATHOL, V114, P147, DOI 10.1007/s00401-007-0251-4; Beck H, 2003, J CEREBR BLOOD F MET, V23, P709, DOI 10.1097/01.WCB.0000065940.18332.8D; Belmadani A, 2005, J NEUROSCI, V25, P3995, DOI 10.1523/JNEUROSCI.4631-04.2005; Burns JM, 2006, J EXP MED, V203, P2201, DOI 10.1084/jem.20052144; Carbonell WS, 1998, J NEUROTRAUM, V15, P217, DOI 10.1089/neu.1998.15.217; Carbonnel WS, 1999, ACTA NEUROPATHOL, V98, P396, DOI 10.1007/s004010051100; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Chen X, 2009, J NEUROTRAUM, V26, P253, DOI 10.1089/neu.2007.0504; Dabusti M, 2003, J HEMATOTH STEM CELL, V12, P425, DOI 10.1089/152581603322286051; Dai SJ, 2010, J MOL CELL CARDIOL, V49, P587, DOI 10.1016/j.yjmcc.2010.07.010; Fagel DM, 2006, EXP NEUROL, V199, P77, DOI 10.1016/j.expneurol.2005.04.006; Fan YF, 2010, ANN NEUROL, V67, P488, DOI 10.1002/ana.21919; Floege J, 2009, J AM SOC NEPHROL, V20, P1659, DOI 10.1681/ASN.2009060621; Franz WM, 2003, LANCET, V362, P675, DOI 10.1016/S0140-6736(03)14240-7; Ghadge SK, 2011, PHARMACOL THERAPEUT, V129, P97, DOI 10.1016/j.pharmthera.2010.09.011; Graham DI, 2000, ACTA NEUROPATHOL, V99, P117, DOI 10.1007/PL00007414; Guo XB, 2009, J NEUROTRAUM, V26, P1337, DOI [10.1089/neu.2008.0733, 10.1089/neu.2008-0733]; Hofmeister CC, 2007, BONE MARROW TRANSPL, V39, P11, DOI 10.1038/sj.bmt.1705538; Itoh T, 2009, NEUROL RES, V31, P90, DOI 10.1179/174313208X332995; Ji JF, 2004, STEM CELLS, V22, P415, DOI 10.1634/stemcells.22-3-415; Jie W, 2010, INT J EXP PATHOL, V91, P436, DOI 10.1111/j.1365-2613.2010.00720.x; Kao CH, 2008, SHOCK, V29, P49, DOI 10.1097/shk.0b013c31805cddce; Lau TT, 2011, EXPERT OPIN BIOL TH, V11, P189, DOI 10.1517/14712598.2011.546338; Laughlin MJ, 2001, NEW ENGL J MED, V344, P1815, DOI 10.1056/NEJM200106143442402; Lazarini F, 2003, GLIA, V42, P139, DOI 10.1002/glia.10139; Li B, 2009, NEUROSURGERY, V65, P179, DOI 10.1227/01.NEU.0000346272.76537.DC; Li MZ, 2008, PROG NEUROBIOL, V84, P116, DOI 10.1016/j.pneurobio.2007.11.003; Li Q, 2006, J NEUROSCI RES, V84, P1656, DOI 10.1002/jnr.21087; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu DY, 2002, CELL TRANSPLANT, V11, P275; Ma Q, 1998, P NATL ACAD SCI USA, V95, P9448, DOI 10.1073/pnas.95.16.9448; Miller RJ, 2008, J NEUROIMMUNOL, V198, P31, DOI 10.1016/j.jneuroim.2008.04.008; Mohle R, 1998, BLOOD, V91, P4523, DOI 10.1182/blood.V91.12.4523.412k04_4523_4530; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Ni G, 2011, EUR J NEUROL, V18, P1304, DOI 10.1111/j.1468-1331.2011.03393.x; Paczkowska E, 2005, EUR J HAEMATOL, V75, P461, DOI 10.1111/j.1600-0609.2005.00536.x; Palmer TD, 2000, J COMP NEUROL, V425, P479, DOI 10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3; Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845; Peterson DA, 2004, J CLIN INVEST, V114, P312, DOI 10.1172/jc1200422540; Petit I, 2007, TRENDS IMMUNOL, V28, P299, DOI 10.1016/j.it.2007.05.007; Qu CS, 2008, BRAIN RES, V1208, P234, DOI 10.1016/j.brainres.2008.02.042; Rosenkranz K, 2010, J NEUROSCI RES, V88, P1223, DOI 10.1002/jnr.22292; Rouhl RPW, 2008, STROKE, V39, P2158, DOI 10.1161/STROKEAHA.107.507251; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Schonemeier B, 2008, J NEUROIMMUNOL, V198, P39, DOI 10.1016/j.jneuroim.2008.04.010; Semenza GL, 2007, J CELL BIOCHEM, V102, P840, DOI 10.1002/jcb.21523; Sharma M, 2011, STEM CELLS DEV, V20, P933, DOI 10.1089/scd.2010.0263; SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180; Shyu WC, 2006, J NEUROSCI, V26, P3444, DOI 10.1523/JNEUROSCI.5165-05.2006; Shyu WC, 2008, J PHARMACOL EXP THER, V324, P834, DOI 10.1124/jpet.107.127746; Taguchi A, 2004, J CLIN INVEST, V114, P330, DOI 10.1172/jci200420622; Tepper OM, 2005, BLOOD, V105, P1068, DOI 10.1182/blood-2004-03-1051; Tysseling VM, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-16; Vorhees CV, 2006, NAT PROTOC, V1, P848, DOI 10.1038/nprot.2006.116; Wang SH, 2010, CARDIOLOGY, V117, P140, DOI 10.1159/000320217; Ward NL, 2004, NEUROL RES, V26, P870, DOI 10.1179/016164104X3798; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Willing AE, 2003, J NEUROSCI RES, V73, P296, DOI 10.1002/jnr.10659; Wright DE, 2002, J EXP MED, V195, P1145, DOI 10.1084/jem.20011284; Zaruba MM, 2010, EXPERT OPIN BIOL TH, V10, P321, DOI 10.1517/14712590903460286; Zhang ZG, 2002, CIRC RES, V90, P284, DOI 10.1161/hh0302.104460; Zhuang Y, 2009, CHINESE MED J-PEKING, V122, P183, DOI 10.3760/cma.j.issn.0366-6999.2009.02.014	64	35	39	1	11	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	MAR 20	2012	1444						76	86		10.1016/j.brainres.2011.12.055			11	Neurosciences	Neurosciences & Neurology	914PD	WOS:000301962600009	22330724				2021-06-18	
J	Clarke, LA; Genat, RC; Anderson, JFI				Clarke, Lisa A.; Genat, Ross C.; Anderson, Jacqueline F. I.			Long-term cognitive complaint and post-concussive symptoms following mild traumatic brain injury: The role of cognitive and affective factors	BRAIN INJURY			English	Article						Cognition; outcome; head injury; mild brain injury; neuropsychological	POSTCONCUSSION-SYNDROME; HEAD-INJURY; DEPRESSION; ANXIETY; AGE	Primary objective: To determine whether neuropsychological test performance or affective factors predict long-term post-concussive symptoms and cognitive complaint following mild traumatic brain injury. Methods and procedures: Participants included 21 individuals with mild traumatic brain injury, 19 individuals with spinal injury but no injury to the brain and 20 neurologically-normal controls. All participants completed measures of post-concussive symptoms, cognitive complaint, depression, anxiety, and personality and were administered a variety of neuropsychological tests. Main outcomes and results: The hypothesis that depression, anxiety and neuroticism would be better predictors of post-concussive symptoms than neuropsychological test performance for all three groups was supported. Contrary to expectations, however, neuropsychological test performance was a unique predictor of cognitive complaint for the mild traumatic brain injury group. Conclusions: It was concluded that long-term post-concussive symptoms are largely representative of psychological symptoms and not brain damage, but that genuine, albeit subtle, cognitive deficits also may be present for long-term periods following mild traumatic brain injury.	[Anderson, Jacqueline F. I.] Univ Melbourne, Melbourne Sch Psychol Sci, Melbourne, Vic 3010, Australia; [Anderson, Jacqueline F. I.] The Alfred, Dept Neurosurg, Melbourne, Vic, Australia; [Anderson, Jacqueline F. I.] The Alfred, Dept Psychol, Melbourne, Vic, Australia	Anderson, JFI (corresponding author), Univ Melbourne, Melbourne Sch Psychol Sci, Melbourne, Vic 3010, Australia.	jfande@unimelb.edu.au		Anderson, Jacqueline/0000-0003-4996-8189	Neurosurgery Department, The Alfred	The authors would like to thank Professor Jeffrey Rosenfeld (Director, Neurosurgery Department, The Alfred) for supporting this research project.	ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Ashman TA, 2006, MT SINAI J MED, V73, P999; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Comijs HC, 2002, J AFFECT DISORDERS, V72, P157, DOI 10.1016/S0165-0327(01)00453-0; Costa P., 1992, REVISED NEO PERSONAL; Fleminger S, 2005, BRIT MED J, V331, P1419, DOI 10.1136/bmj.331.7530.1419; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Gronwall D, 1991, NEUROPSYCHOLOGY, V5, P253, DOI DOI 10.1037/0894-4105.5.4.253; Gunstad J, 2004, ARCH CLIN NEUROPSYCH, V19, P391, DOI 10.1016/S0887-6177(03)00073-8; Khan F, 2003, MED J AUSTRALIA, V178, P290, DOI 10.5694/j.1326-5377.2003.tb05199.x; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1999, BRIT J CLIN PSYCHOL, V38, P15, DOI 10.1348/014466599162638; Lahr Denise, 2007, Cogn Neuropsychiatry, V12, P25, DOI 10.1080/13546800600714791; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; MARTIN M, 1985, PERS INDIV DIFFER, V6, P353, DOI 10.1016/0191-8869(85)90060-1; McAdams D, 2006, PERSON NEW INTRO PER; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; Meares S, 2006, J INT NEUROPSYCH SOC, V12, P792, DOI 10.1017/S1355617706060978; O'Shea M.F., 1996, COGNITIVE AFFECTIVE; Osterrieth PA, 1944, ARCH PSYCHOLOGIE, V30, P206; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Reitan RM., 1985, HALSTEAD REITAN NEUR; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Rohling ML, 2002, ARCH CLIN NEUROPSYCH, V17, P205, DOI 10.1016/S0887-6177(01)00109-3; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Stulemeijer M, 2007, J PSYCHOSOM RES, V63, P637, DOI 10.1016/j.jpsychores.2007.06.023; Stulemeijer M, 2006, J NEUROTRAUM, V23, P1561, DOI 10.1089/neu.2006.23.1561; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; Taylor E.M., 1959, PSYCHOL APPRAISAL CH; Tombaugh TN, 1999, ARCH CLIN NEUROPSYCH, V14, P167, DOI 10.1016/S0887-6177(97)00095-4; Tombaugh TN, 2004, ARCH CLIN NEUROPSYCH, V19, P203, DOI 10.1016/S0887-6177(03)00039-8; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	38	35	36	0	23	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAR	2012	26	3					298	307		10.3109/02699052.2012.654588			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	899XD	WOS:000300849100010	22372417				2021-06-18	
J	Huang, KF; Hsu, WC; Chiu, WT; Wang, JY				Huang, Kuo-Feng; Hsu, Wei-Cherng; Chiu, Wen-Ta; Wang, Jia-Yi			Functional improvement and neurogenesis after collagen-GAG matrix implantation into surgical brain trauma	BIOMATERIALS			English	Article						Brain; Cell proliferation; Collagen-GAG; Neurotrophic factor; Scaffold; Functional recovery	NEURAL STEM-CELLS; HYALURONIC-ACID HYDROGELS; CENTRAL-NERVOUS-SYSTEM; SPINAL-CORD-INJURY; EXTRACELLULAR-MATRIX; NEUROTROPHIC FACTOR; IN-VITRO; SUBVENTRICULAR ZONE; TISSUE REGENERATION; ADULT NEUROGENESIS	Surgical or traumatic brain injury often leads to loss of cerebral parenchyma but there is as yet no clinically effective strategy for neural regeneration. Collagen glycosaminoglycan (collagen-GAG, CG) scaffolds have previously been used in many tissues in vivo but have never been utilized in the brain. Using an animal model, we investigated the effects of the implantation of CG scaffold matrix following surgical brain trauma. Results indicated that implantation of CG scaffold could significantly promote functional recovery following surgical brain trauma. The CG scaffold was found to facilitate proliferation, differentiation and migration of endogenous neural precursor cells (NPCs) both in the intra-matrix zone (IMZ) and lesion boundary zone (LBZ). The tissue concentration of brain-derived neurotrophic factor (BDNF) and glia-derived neurotrophic factor (GDNF) in the cortex demonstrated a sustained increase after implantation of CG scaffold following surgical brain trauma. These results suggest that the utilization of CG scaffolds can be considered as a potential clinical strategy for tissue regeneration and functional recovery after brain injury. (C) 2011 Elsevier Ltd. All rights reserved.	[Wang, Jia-Yi] Taipei Med Univ, Grad Inst Med Sci, Coll Med, Taipei 110, Taiwan; [Huang, Kuo-Feng; Wang, Jia-Yi] Natl Def Med Ctr, Grad Inst Med Sci, Taipei 114, Taiwan; [Huang, Kuo-Feng] Buddhist Tzu Chi Gen Hosp, Div Neurosurg, Dept Surg, Taipei Branch, New Taipei City 23143, Taiwan; [Hsu, Wei-Cherng] Buddhist Tzu Chi Gen Hosp, Dept Ophthamol, Taipei Branch, New Taipei City 23143, Taiwan; [Hsu, Wei-Cherng] Tzu Chi Univ, Sch Med, Hualien 97004, Taiwan; [Chiu, Wen-Ta] Taipei Med Univ, Grad Inst Injury Prevent & Control, Taipei 110, Taiwan; [Wang, Jia-Yi] Natl Def Med Ctr, Dept Physiol, Taipei 114, Taiwan	Wang, JY (corresponding author), Taipei Med Univ, Grad Inst Med Sci, Coll Med, 250 Wu Xing St, Taipei 110, Taiwan.	jywang2010@tmu.edu.tw		Wang, Jia-Yi/0000-0002-9106-3351	National Science Council (NSC)Ministry of Science and Technology, Taiwan [99-2320-B-038-006-MY3]; Buddhist Tzu-Chi General Hospital Taipei branch at Taipei, Taiwan [TCRD-TPE-100-35]	This study was supported in part by a grant from the National Science Council (NSC 99-2320-B-038-006-MY3 to JY Wang) and from the Buddhist Tzu-Chi General Hospital Taipei branch (TCRD-TPE-100-35 to KF Huang) at Taipei, Taiwan, without conflict of interest. We would like to thank Ms. Jia-Hsun Lee and Dr. Shun-Yuan Jiang for data collection and analysis.	Bath KG, 2010, DEV NEUROBIOL, V70, P339, DOI 10.1002/dneu.20781; BIGNAMI A, 1993, ANAT EMBRYOL, V188, P419; Bramham CR, 2005, PROG NEUROBIOL, V76, P99, DOI 10.1016/j.pneurobio.2005.06.003; Brown JP, 2003, J COMP NEUROL, V467, P1, DOI 10.1002/cne.10874; Chen SF, 2008, BRIT J PHARMACOL, V155, P1279, DOI 10.1038/bjp.2008.345; Chen XH, 2003, J NEUROTRAUM, V20, P623, DOI 10.1089/089771503322144545; Crooks Carol Y, 2008, Mo Med, V105, P140; Crooks CY, 2000, MO MED, V105, P4; Deguchi K, 2006, J CEREBR BLOOD F MET, V26, P1263, DOI 10.1038/sj.jcbfm.9600275; Fitch MT, 2008, EXP NEUROL, V209, P294, DOI 10.1016/j.expneurol.2007.05.014; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Hallbergson AF, 2003, J CLIN INVEST, V112, P1128, DOI 10.1172/JCI200320098; Han QQ, 2011, BIOMATERIALS, V32, P5077, DOI 10.1016/j.biomaterials.2011.03.072; Harley BA, 2007, ACTA BIOMATER, V3, P463, DOI 10.1016/j.actbio.2006.12.009; Harley BAC, 2008, BIOPHYS J, V95, P4013, DOI 10.1529/biophysj.107.122598; Harley BAC, 2008, CHEM ENG J, V137, P102, DOI 10.1016/j.cej.2007.09.009; Hejcl A, 2008, PHYSIOL RES, V57, pS121; Horita Y, 2006, J NEUROSCI RES, V84, P1495, DOI 10.1002/jnr.21056; Hou SP, 2005, J NEUROSCI METH, V148, P60, DOI 10.1016/j.jneumeth.2005.04.016; Hsu WC, 2000, INVEST OPHTH VIS SCI, V41, P2404; Jain KK, 2008, DRUG DISCOV TODAY, V13, P1082, DOI 10.1016/j.drudis.2008.09.006; Kee N, 2002, J NEUROSCI METH, V115, P97, DOI 10.1016/S0165-0270(02)00007-9; Kernie SG, 2010, NEUROBIOL DIS, V37, P267, DOI 10.1016/j.nbd.2009.11.002; Kulbatski I, 2005, CURR DRUG TARGETS, V6, P111, DOI 10.2174/1389450053345037; Nielsen J, 2009, J NEUROSCI, V29, P11360, DOI 10.1523/JNEUROSCI.3239-09.2009; Novak U, 2000, J CLIN NEUROSCI, V7, P280, DOI 10.1054/jocn.1999.0212; Park KI, 2002, NAT BIOTECHNOL, V20, P1111, DOI 10.1038/nbt751; Pencea V, 2001, J NEUROSCI, V21, P6706; Picard-Riera N, 2004, J NEUROSCI RES, V76, P223, DOI 10.1002/jnr.20040; Potter W, 2008, FRONT BIOSCI-LANDMRK, V13, P806, DOI 10.2741/2721; Rauch U, 2004, CELL MOL LIFE SCI, V61, P2031, DOI 10.1007/s00018-004-4043-x; Rolls A, 2009, NAT REV NEUROSCI, V10, P235, DOI 10.1038/nrn2591; Romanko MJ, 2004, PROG NEUROBIOL, V74, P77, DOI 10.1016/j.pneurobio.2004.07.001; Sasaki M, 2009, J NEUROSCI, V29, P14932, DOI 10.1523/JNEUROSCI.2769-09.2009; Tenovuo O, 2006, CURR OPIN NEUROL, V19, P528, DOI 10.1097/WCO.0b013e328010944f; Thonhoff JR, 2008, BRAIN RES, V1187, P42, DOI 10.1016/j.brainres.2007.10.046; Tisdall MM, 2007, BRIT J ANAESTH, V99, P61, DOI 10.1093/bja/aem143; vanderLaan LJW, 1997, J NEUROSCI RES, V50, P539, DOI 10.1002/(SICI)1097-4547(19971115)50:4<539::AID-JNR5>3.0.CO;2-F; Viapiano MS, 2006, TRENDS MOL MED, V12, P488, DOI 10.1016/j.molmed.2006.08.007; Wei YT, 2007, BIOMED MATER, V2, pS142, DOI 10.1088/1748-6041/2/3/S11; Wong DY, 2008, J NEUROSURG, V109, P715, DOI 10.3171/JNS/2008/109/10/0715; Yannas IV, 2010, PHILOS T R SOC A, V368, P2123, DOI 10.1098/rsta.2010.0015; YANNAS IV, 1989, P NATL ACAD SCI USA, V86, P933, DOI 10.1073/pnas.86.3.933; YANNAS IV, 1994, J CELL BIOCHEM, V56, P188, DOI 10.1002/jcb.240560212; Zhang HZ, 2007, BRAIN RES, V1132, P29, DOI 10.1016/j.brainres.2006.09.117; Zhong YH, 2008, J R SOC INTERFACE, V5, P957, DOI 10.1098/rsif.2008.0071; Zigova T, 1998, MOL CELL NEUROSCI, V11, P234, DOI 10.1006/mcne.1998.0684	47	35	35	1	10	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0142-9612			BIOMATERIALS	Biomaterials	MAR	2012	33	7					2067	2075		10.1016/j.biomaterials.2011.11.040			9	Engineering, Biomedical; Materials Science, Biomaterials	Engineering; Materials Science	895CN	WOS:000300473900013	22169139				2021-06-18	
J	Brooks, BL; Sherman, EMS; Krol, AL				Brooks, Brian L.; Sherman, Elisabeth M. S.; Krol, Andrea L.			Utility of TOMM Trial 1 as an Indicator of Effort in Children and Adolescents	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Effort; Malingering; Symptom validity; Malingered neurocognitive disorder; Pediatrics; Children	WORD MEMORY TEST; SYMPTOM VALIDITY TESTS; TRAUMATIC BRAIN-INJURY; MALINGERING TOMM; INSUFFICIENT EFFORT; TEST-PERFORMANCE; RECOGNITION; SAMPLE; ADULTS	Although measuring test compliance in a pediatric neuropsychological evaluation is important, increasing demands on clinicians' time and the need for efficiency during assessments may make it difficult to routinely include effort testing. This study investigated whether performance on Trial 1 of the Test of Memory Malingering (TOMM) is predictive of overall performance in children and adolescents with neurological disorders. Participants included 53 children and adolescents between six and 19 years (mean age = 12.4, SD = 4.1) who were followed through a neurology clinic at a tertiary care hospital. Several cutoff scores were examined, with the goal of maximizing positive predictive (accurate detection of failure on the TOMM) and negative predictive (accurate detection of passing the TOMM) values. Every participant who scored >= 36 on Trial 1 (n = 50) went on to pass the TOMM. This study is the first step in providing evidence that performance on Trial I might be used as a quick screening measure of overall performance on the TOMM in children and adolescents. Further research on this topic is warranted.	[Brooks, Brian L.; Sherman, Elisabeth M. S.] Alberta Childrens Prov Gen Hosp, Neurosci Program, Calgary, AB T3B 6A8, Canada; [Brooks, Brian L.; Sherman, Elisabeth M. S.] Univ Calgary, Calgary, AB, Canada; [Krol, Andrea L.] Univ Alberta, Edmonton, AB, Canada	Brooks, BL (corresponding author), Alberta Childrens Prov Gen Hosp, Neurosci Program, 2888 Shaganappi Trail NW, Calgary, AB T3B 6A8, Canada.	brian.brooks@albertahealthservices.ca			Psychological Assessment Resources, Inc.	Drs Brooks and Sherman receive funding from Psychological Assessment Resources, Inc. and book royalities from Oxford University Press.	Bauer L, 2007, ASSESSMENT, V14, P215, DOI 10.1177/1073191106297617; Blaskewitz N, 2008, ARCH CLIN NEUROPSYCH, V23, P379, DOI 10.1016/j.acn.2008.01.008; Bruininks RH., 1996, SIB R SCALES INDEPEN; Carone DA, 2008, BRAIN INJURY, V22, P960, DOI 10.1080/02699050802491297; Cohen M.J., 1997, CHILDRENS MEMORY SCA; Constantinou M, 2003, CHILD NEUROPSYCHOL, V9, P81, DOI 10.1076/chin.9.2.81.14505; Courtney JC, 2003, CHILD NEUROPSYCHOL, V9, P109, DOI 10.1076/chin.9.2.109.14507; Delis D, 1994, CALIFORNIA VERBAL LE; Delis DC, 2000, CALIFORNIA VERBAL LE; Donders J, 2005, CHILD NEUROPSYCHOL, V11, P221, DOI 10.1080/09297040490917298; Donders J, 2007, BRAIN INJURY, V21, P319, DOI 10.1080/02699050701253129; Frazier TW, 2008, ARCH CLIN NEUROPSYCH, V23, P501, DOI 10.1016/j.acn.2008.04.001; Gavett BE, 2005, APPL NEUROPSYCHOL, V12, P1, DOI 10.1207/s15324826an1201_1; Gioia GA, 2000, CHILD NEUROPSYCHOL, V6, P235, DOI 10.1076/chin.6.3.235.3152; Green P, 2003, CHILD NEUROPSYCHOL, V9, P189, DOI 10.1076/chin.9.3.189.16460; Green P, 2009, BRAIN INJURY, V23, P741, DOI 10.1080/02699050903133962; Gunn D, 2010, CHILD NEUROPSYCHOL, V16, P105, DOI 10.1080/09297040903352564; Horner MD, 2006, INT J NEUROSCI, V116, P1181, DOI 10.1080/00207450500514029; Joschko M., 1991, CLIN NEUROPSYCHOL, V5, P53; Kirk JW, 2011, CHILD NEUROPSYCHOL, V17, P242, DOI 10.1080/09297049.2010.533166; Kirkwood M. W., PEDIAT FORE IN PRESS; Kirkwood MW, 2010, CLIN NEUROPSYCHOL, V24, P860, DOI 10.1080/13854040903527287; MacAllister WS, 2009, CHILD NEUROPSYCHOL, V15, P521, DOI 10.1080/09297040902748226; Nagle AM, 2006, ARCH CLIN NEUROPSYCH, V21, P777, DOI 10.1016/j.acn.2006.06.011; O'Bryant SE, 2008, APPL NEUROPSYCHOL, V15, P113, DOI 10.1080/09084280802083921; O'Bryant SE, 2007, CLIN NEUROPSYCHOL, V21, P511, DOI 10.1080/13854040600611368; Rienstra A, 2010, ARCH CLIN NEUROPSYCH, V25, P371, DOI 10.1093/arclin/acq035; Slick D., 1997, VICTORIA SYMPTOM VAL; Tombaugh TN, 1996, TEST MEMORY MALINGER; Wechsler D., 2003, WECHSLER INTELLIGENC; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th ed	33	35	35	0	4	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	JAN	2012	27	1					23	29		10.1093/arclin/acr086			7	Psychology, Clinical; Psychology	Psychology	885TE	WOS:000299802900003	22044946	Green Published			2021-06-18	
J	Cohen, SP; Plunkett, AR; Wilkinson, I; Nguyen, C; Kurihara, C; Flagg, A; Morlando, B; Stone, C; White, RL; Anderson-Barnes, VC; Galvagno, SM				Cohen, Steven P.; Plunkett, Anthony R.; Wilkinson, Indy; Conner Nguyen; Kurihara, Connie; Flagg, Artemus, II; Morlando, Benny; Stone, Christina; White, Ronald L.; Anderson-Barnes, Victoria C.; Galvagno, Samuel M., Jr.			Headaches during war: Analysis of presentation, treatment, and factors associated with outcome	CEPHALALGIA			English	Article						Epidemiology; headache; soldier; war	BACK-PAIN; PREVALENCE; IMPACT; EPIDEMIOLOGY; MIGRAINE; INJURY	Background: Headache is often associated with physical trauma and psychological stress. The aim of this study is to evaluate the impact of headache on personnel deployed in war zones and to identify factors associated with return to duty (RTD). Methods: Outcome data were prospectively collected on 985 personnel medically evacuated out of Operations Iraqi and Enduring Freedom for a primary diagnosis of headache between 2004 and 2009. Electronic medical records were reviewed to examine clinical and treatment patterns and the effect that myriad factors had on RTD. Results: 33.6% of evacuees returned to duty. The most common headaches were post-concussion (34.1%) and migraine (30.0%). Headaches typically associated with trauma such as post-concussion (18.7%), occipital neuralgia (23.1%), and cervicogenic headache (29.7%) had the lowest RTD rates, whereas tension headache (49.6%) was associated with the best outcome. Other variables associated with negative outcome included presence of aura (OR 0.51, 95% CI 0.30-0.88; p 0.02), traumatic brain injury (OR 0.50, 95% CI 0.29-0.87; p = 0.01), opioid (OR 0.41, 95% CI 0.26-0.63; p < 0.001), and beta-blocker (OR 0.26, 95% CI 0.12-0.61; p = 0.002) use, and co-existing psychopathology (p < 0.001 in univariable analysis). Conclusion: Headaches represent a significant cause of unit attrition in personnel deployed in military operations, with physical trauma and co-existing psychopathology associated with poorer outcomes.	[Cohen, Steven P.; Flagg, Artemus, II; Galvagno, Samuel M., Jr.] Johns Hopkins Sch Med, Baltimore, MD USA; [Cohen, Steven P.; Plunkett, Anthony R.; Wilkinson, Indy; Kurihara, Connie; Morlando, Benny; Anderson-Barnes, Victoria C.] Walter Reed Army Med Ctr, Silver Spring, MD USA; [Cohen, Steven P.; Plunkett, Anthony R.; Wilkinson, Indy; White, Ronald L.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; [Conner Nguyen; Stone, Christina; White, Ronald L.] Landstuhl Reg Med Ctr, Landstuhl, Germany; [Galvagno, Samuel M., Jr.] Bloomberg Sch Publ Hlth, Baltimore, MD USA	Cohen, SP (corresponding author), 550 N Broadway,Suite 301, Baltimore, MD 21029 USA.	scohen40@jhmi.edu		Galvagno, Samuel/0000-0001-5563-4092; Merritt, Victoria/0000-0001-5683-4168	John P Murtha Neuroscience and Pain Institute; US ArmyUnited States Department of Defense; Army Regional Anesthesia and Pain Medicine Initiative	This work was supported in part by a Congressional Grant from the John P Murtha Neuroscience and Pain Institute, the US Army, and the Army Regional Anesthesia and Pain Medicine Initiative.	Afari N, 2009, HEADACHE, V49, P1267, DOI 10.1111/j.1526-4610.2009.01517.x; Andrychowski J, 1998, Neurol Neurochir Pol, V32, P871; APRILL C, 1992, SPINE, V17, P744, DOI 10.1097/00007632-199207000-00003; Belasco A, TROOP LEVELS AFGHAN; Bigal Marcelo E, 2004, Curr Neurol Neurosci Rep, V4, P98, DOI 10.1007/s11910-004-0022-8; Bogduk N, 2009, LANCET NEUROL, V8, P959, DOI 10.1016/S1474-4422(09)70209-1; Chibnall JT, 2009, PAIN MED, V10, P1378, DOI 10.1111/j.1526-4637.2009.00738.x; Cohen SP, 2011, CAN MED ASSOC J, V183, pE289, DOI 10.1503/cmaj.100244; Cohen SP, 2011, CLIN J PAIN, V27, P19, DOI 10.1097/AJP.0b013e3181f06b06; Cohen SP, 2010, SPINE, V35, P758, DOI 10.1097/BRS.0b013e3181bb11a8; Cohen SP, 2010, LANCET, V375, P301, DOI 10.1016/S0140-6736(09)61797-9; Cohen SP, 2009, ARCH INTERN MED, V169, P1916, DOI 10.1001/archinternmed.2009.380; Gallagher R Michael, 2007, Expert Rev Neurother, V7, P1279, DOI 10.1586/14737175.7.10.1279; Hecht JS, 2004, J HEAD TRAUMA REHAB, V19, P58, DOI 10.1097/00001199-200401000-00006; Helseth EK, 2008, HEADACHE, V48, P883, DOI 10.1111/j.1526-4610.2007.00962.x; HOEFFLER DF, 1981, MIL MED, V146, P776; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jensen R, 2008, LANCET NEUROL, V7, P354, DOI 10.1016/S1474-4422(08)70062-0; Pop PHM, 2002, EUR J NEUROL, V9, P171, DOI 10.1046/j.1468-1331.2002.00355.x; Robbins MS, 2010, SEMIN NEUROL, V30, P107, DOI 10.1055/s-0030-1249220; Russell MB, 2006, EUR J EPIDEMIOL, V21, P153, DOI 10.1007/s10654-005-6031-3; Saper JR, 2008, HEADACHE, V48, P838, DOI 10.1111/j.1526-4610.2008.01153.x; Stovner LJ, 2007, CEPHALALGIA, V27, P193, DOI 10.1111/j.1468-2982.2007.01288.x; Theeler BJ, 2008, HEADACHE, V48, P876, DOI 10.1111/j.1526-4610.2008.01159.x; Theeler BJ, 2010, HEADACHE, V50, P1262, DOI 10.1111/j.1526-4610.2010.01700.x; Theeler BJ, 2009, HEADACHE, V49, P529, DOI 10.1111/j.1526-4610.2009.01345.x; Torelli P, 2010, NEUROL SCI, V31, P145, DOI 10.1007/s10072-010-0311-8; US Centers for Disease Control and Prevention, INT CLASS DIS; Vincent MB, 2008, CEPHALALGIA, V28, P32, DOI 10.1111/j.1468-2982.2008.01616.x; Weeks R, 2006, HEADACHE, V46, pS110, DOI 10.1111/j.1526-4610.2006.00562.x; WEINER L P, 1969, Headache, V9, P162, DOI 10.1111/j.1526-4610.1969.hed0903162.x; Winsvold BS, 2011, EUR J NEUROL, V18, P504, DOI 10.1111/j.1468-1331.2010.03199.x; Winter AC, 2011, J HEADACHE PAIN, V12, P147, DOI 10.1007/s10194-010-0286-0; Wober Christian, 2010, Handb Clin Neurol, V97, P161, DOI 10.1016/S0072-9752(10)97012-7	34	35	36	0	1	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0333-1024	1468-2982		CEPHALALGIA	Cephalalgia	JAN	2012	32	2					94	108		10.1177/0333102411422382			15	Clinical Neurology; Neurosciences	Neurosciences & Neurology	880SX	WOS:000299428600002	21994113				2021-06-18	
J	Grant, M; Ponsford, J; Bennett, PC				Grant, Michele; Ponsford, Jennie; Bennett, Pauleen C.			The application of Goal Management Training to aspects of financial management in individuals with traumatic brain injury	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Goal Management Training; Rehabilitation; TBI; Executive functions	FRONTAL-LOBE DAMAGE; COGNITIVE REHABILITATION; PREFRONTAL CORTEX; TEST SCORE; BEHAVIOR; INTERVENTION; LESIONS	Executive functions encompass planning, problem-solving and self-monitoring abilities, abilities that are implicit in goal attainment and often compromised in individuals with traumatic brain injury (TBI). Goal Management Training (GMT) is a theoretically based rehabilitation protocol that was developed to improve goal-directed behaviour. To date, there is evidence to support the efficacy of GMT in healthy older adults and in one previously high functioning individual with acquired brain injury. However, there is no evidence that, in individuals with TBI and severe cognitive impairments, GMT leads to sustained improvement on everyday tasks requiring planning and organisation. The current study was conducted to explore the efficacy of GMT in helping individuals with TBI to improve aspects of their day-to-day financial management. Four participants with severe TBI completed a modified GMT module. Outcomes were assessed using Goal Attainment Scaling. Five control participants were also recruited as a comparison group for the Multiple Errands Task which was used to measure generalisation. The outcomes in each case were variable. Overall the results showed that the structured GMT intervention assisted some TBI individuals to improve their performance on financial management tasks, with evidence of generalisation in some cases.	[Grant, Michele; Ponsford, Jennie] Monash Univ, Natl Trauma Res Inst, Clayton, Vic, Australia; [Grant, Michele; Ponsford, Jennie] Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Richmond, Vic, Australia; [Bennett, Pauleen C.] La Trobe Univ, Bendigo, Vic, Australia	Grant, M (corresponding author), Monash Epworth Rehabil Ctr, 185-187 Hoddle St, Richmond, Vic 3121, Australia.	michele.grant@monash.edu	Bennett, Pauleen/C-2138-2016	Bennett, Pauleen/0000-0001-5864-4464			Alderman N, 2003, J INT NEUROPSYCH SOC, V9, P31, DOI 10.1017/S1355617703910046; Becker H, 2000, NURS RES, V49, P176, DOI 10.1097/00006199-200005000-00011; BURKE W H, 1991, Brain Injury, V5, P241, DOI 10.3109/02699059109008095; CICERONE KD, 1987, ARCH PHYS MED REHAB, V68, P111; Crawford JR, 2002, NEUROPSYCHOLOGIA, V40, P1196, DOI 10.1016/S0028-3932(01)00224-X; Crawford JR, 1998, CLIN NEUROPSYCHOL, V12, P482, DOI 10.1076/clin.12.4.482.7241; Cumming G., 2012, UNDERSTANDING NEW ST; Duncan J, 1996, COGNITIVE PSYCHOL, V30, P257, DOI 10.1006/cogp.1996.0008; DUNCAN J, 1986, COGNITIVE NEUROPSYCH, V3, P271, DOI 10.1080/02643298608253360; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; FUSTER JM, 1997, PREFRONTAL CORTEX AN; Goel V, 2000, COGN NEUROPSYCHOL, V17, P415, DOI 10.1080/026432900410775; Goel V, 1997, BRAIN, V120, P1805, DOI 10.1093/brain/120.10.1805; KIRESUK TJ, 1968, COMMUNITY MENT HLT J, V4, P443, DOI 10.1007/BF01530764; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; Levine B, 2007, J INT NEUROPSYCH SOC, V13, P143, DOI 10.1017/S1355617707070178; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Malec JF, 1999, NEUROPSYCHOL REHABIL, V9, P253, DOI 10.1080/096020199389365; Manly T, 2002, NEUROPSYCHOLOGIA, V40, P271, DOI 10.1016/S0028-3932(01)00094-X; Mate-Kole CC, 1999, NURS RES, V48, P220, DOI 10.1097/00006199-199907000-00005; McPherson K. M., 2009, CLIN REHABIL, V23, P269; Robertson IH, 1996, GOAL MANAGEMENT TRAI; Rockwood K, 1997, J CLIN EPIDEMIOL, V50, P581, DOI 10.1016/S0895-4356(97)00014-0; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Sokal R.R., 1995, BIOMETRY PRINCIPLES, V3; Spikman JM, 2000, J CLIN EXP NEUROPSYC, V22, P325, DOI 10.1076/1380-3395(200006)22:3;1-V;FT325; van Hooren SAH, 2007, PATIENT EDUC COUNS, V65, P205, DOI 10.1016/j.pec.2006.07.010; VONCRAMON DY, 1994, NEUROPSYCHOL REHABIL, V4, P399, DOI 10.1080/09602019408401608; Zalla T, 2001, NEUROPSYCHOLOGIA, V39, P759, DOI 10.1016/S0028-3932(01)00019-7	29	35	35	0	28	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2012	22	6					852	873		10.1080/09602011.2012.693455			22	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	039EQ	WOS:000311227300003	22812612				2021-06-18	
J	Hosie, KA; King, AE; Blizzard, CA; Vickers, JC; Dickson, TC				Hosie, Katherine A.; King, Anna E.; Blizzard, Catherine A.; Vickers, James C.; Dickson, Tracey C.			Chronic excitotoxin-induced axon degeneration in a compartmented neuronal culture model	ASN NEURO			English	Article						alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA); distal axons; microfluidic; NMDA	NMDA RECEPTORS; GLUTAMATE RECEPTORS; DEPENDENT NEURODEGENERATION; MOLECULAR-MECHANISMS; HIPPOCAMPAL-NEURONS; CORTICAL-NEURONS; AMPA RECEPTORS; INJURY; DAMAGE; EXOCYTOSIS	Glutamate excitotoxicity is a major pathogenic process implicated in many neurodegenerative conditions, including AD (Alzheimer's disease) and following traumatic brain injury. Occurring predominantly from over-stimulation of ionotropic glutamate receptors located along dendrites, excitotoxic axonal degeneration may also occur in white matter tracts. Recent identification of axonal glutamate receptor subunits within axonal nanocomplexes raises the possibility of direct excitotoxic effects on axons. Individual neuronal responses to excitotoxicity are highly dependent on the complement of glutamate receptors expressed by the cell, and the localization of the functional receptors. To enable isolation of distal axons and targeted excitotoxicity, murine cortical neuron cultures were prepared in compartmented microfluidic devices, such that distal axons were isolated from neuronal cell bodies. Within the compartmented culture system, cortical neurons developed to relative maturity at 11 DIV (days in vitro) as demonstrated by the formation of dendritic spines and clustering of the presynaptic protein synaptophysin. The isolated distal axons retained growth cone structures in the absence of synaptic targets, and expressed glutamate receptor subunits. Glutamate treatment (100 mu M) to the cell body chamber resulted in widespread degeneration within this chamber and degeneration of distal axons in the other chamber. Glutamate application to the distal axon chamber triggered a lesser degree of axonal degeneration without degenerative changes in the untreated somal chamber. These data indicate that in addition to current mechanisms of indirect axonal excitotoxicity, the distal axon may be a primary target for excitotoxicity in neurodegenerative conditions.	[Hosie, Katherine A.; King, Anna E.; Blizzard, Catherine A.; Vickers, James C.; Dickson, Tracey C.] Univ Tasmania, Wicking Dementia Res & Educ Ctr, Menzies Res Inst Tasmania, Hobart, Tas 7000, Australia	Dickson, TC (corresponding author), Univ Tasmania, Wicking Dementia Res & Educ Ctr, Menzies Res Inst Tasmania, Hobart, Tas 7000, Australia.	Tracey.Dickson@utas.edu.au	King, Anna/J-7927-2014; Vickers, James C/J-7464-2014	King, Anna/0000-0003-1792-0965; Vickers, James C/0000-0001-5671-4879; Dickson, Tracey/0000-0002-9196-1661; Blizzard, Catherine/0000-0002-8683-2937	Wicking Dementia Research and Education Centre; National Health and Medical Research CouncilNational Health and Medical Research Council of Australia [APP10039]; Tasmanian Masonic Centenary Medical Research Foundation; Alzheimer's Association AustraliaAlzheimer's Association; Motor Neuron Disease Research Institute of Australia; University of Tasmania	The work was supported by the Wicking Dementia Research and Education Centre, National Health and Medical Research Council [grant number APP10039], Tasmanian Masonic Centenary Medical Research Foundation, and Alzheimer's Association Australia, Motor Neuron Disease Research Institute of Australia, University of Tasmania.	Andrasfalvy BK, 2001, J NEUROSCI, V21, P9151, DOI 10.1523/JNEUROSCI.21-23-09151.2001; Araque A, 2004, GLIA, V47, P241, DOI 10.1002/glia.20026; Arundine M, 2003, CELL CALCIUM, V34, P325, DOI 10.1016/S0143-4160(03)00141-6; Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; Bannerman P, 2007, J NEUROCHEM, V102, P1064, DOI 10.1111/j.1471-4159.2007.04612.x; Bardoni R, 2004, J NEUROSCI, V24, P2774, DOI 10.1523/JNEUROSCI.4637-03.2004; Carriedo SG, 1996, J NEUROSCI, V16, P4069; CHOI DW, 1987, J NEUROSCI, V7, P357; Chung RS, 2005, EXP NEUROL, V193, P481, DOI 10.1016/j.expneurol.2005.01.005; DeLima AD, 1997, J COMP NEUROL, V382, P230, DOI 10.1002/(SICI)1096-9861(19970602)382:2<230::AID-CNE7>3.0.CO;2-4; Diamond JS, 2000, J NEUROPHYSIOL, V83, P2835; Dickson TC, 2000, J NEUROTRAUM, V17, P1095, DOI 10.1089/neu.2000.17.1095; Doble A, 1996, NEUROLOGY, V47, pS233, DOI 10.1212/WNL.47.6_Suppl_4.233S; DOTTI CG, 1988, J NEUROSCI, V8, P1454; Fowler JH, 2006, J NEUROSCI RES, V84, P68, DOI 10.1002/jnr.20859; Fowler JH, 2003, BRAIN RES, V991, P104, DOI 10.1016/j.brainres.2003.08.004; GALLO V, 1995, J NEUROSCI RES, V42, P1, DOI 10.1002/jnr.490420102; Haas MA, 2004, EUR J NEUROSCI, V20, P1436, DOI 10.1111/j.1460-9568.2004.03620.x; Hardingham GE, 2002, NAT NEUROSCI, V5, P405, DOI 10.1038/nn835; Hardingham GE, 2010, NAT REV NEUROSCI, V11, P682, DOI 10.1038/nrn2911; Hynd MR, 2004, NEUROCHEM INT, V45, P583, DOI 10.1016/j.neuint.2004.03.007; Jourdain P, 2007, NAT NEUROSCI, V10, P331, DOI 10.1038/nn1849; Kane-Jackson R, 2003, NEUROSCIENCE, V122, P285, DOI 10.1016/S0306-4522(03)00596-7; King AE, 2007, EUR J NEUROSCI, V26, P2151, DOI 10.1111/j.1460-9568.2007.05845.x; King AE, 2006, J COMP NEUROL, V498, P277, DOI 10.1002/cne.21053; King AE, 2011, NEUROBIOL AGING, V32, P459, DOI 10.1016/j.neurobiolaging.2009.04.004; Lau A, 2010, PFLUG ARCH EUR J PHY, V460, P525, DOI 10.1007/s00424-010-0809-1; Liu YT, 2007, J NEUROSCI, V27, P2846, DOI 10.1523/JNEUROSCI.0116-07.2007; Liu Z, 1996, DEV BRAIN RES, V97, P178, DOI 10.1016/S0165-3806(96)00141-1; Matute C, 1998, P NATL ACAD SCI USA, V95, P10229, DOI 10.1073/pnas.95.17.10229; Matute C, 2007, NEURON GLIA BIOL, V3, P281, DOI 10.1017/S1740925X08000033; Micu I, 2006, NATURE, V439, P988, DOI 10.1038/nature04474; Newpher TM, 2008, NEURON, V58, P472, DOI 10.1016/j.neuron.2008.04.030; Ouardouz M, 2009, ANN NEUROL, V65, P151, DOI 10.1002/ana.21533; Ouardouz M, 2009, ANN NEUROL, V65, P160, DOI 10.1002/ana.21539; Park JS, 1996, NEUROBIOL DIS, V3, P215, DOI 10.1006/nbdi.1996.0022; Passafaro M, 2001, NAT NEUROSCI, V4, P917, DOI 10.1038/nn0901-917; Perlson E, 2009, J NEUROSCI, V29, P9903, DOI 10.1523/JNEUROSCI.0813-09.2009; Pinheiro PS, 2008, NAT REV NEUROSCI, V9, P423, DOI 10.1038/nrn2379; Pitt D, 2003, NEUROLOGY, V61, P1113, DOI 10.1212/01.WNL.0000090564.88719.37; Pitt D, 2010, BRAIN RES, V1309, P146, DOI 10.1016/j.brainres.2009.10.066; Rao A, 1998, J NEUROSCI, V18, P1217; Saggu SK, 2008, EXP NEUROL, V211, P52, DOI 10.1016/j.expneurol.2007.12.022; Sattler R, 2000, J NEUROSCI, V20, P22, DOI 10.1523/JNEUROSCI.20-01-00022.2000; Schoenmann Z, 2010, J NEUROSCI, V30, P6375, DOI 10.1523/JNEUROSCI.0922-10.2010; Smith B, 2011, ASN NEURO, V3, P213, DOI 10.1042/AN20110019; Stys PK, 2000, NEUROSCIENTIST, V6, P230, DOI 10.1177/107385840000600405; Taylor AM, 2005, NAT METHODS, V2, P599, DOI 10.1038/NMETH777; Tovar KR, 2002, NEURON, V34, P253; Underhill SM, 2007, NEUROBIOL DIS, V25, P284, DOI 10.1016/j.nbd.2006.09.011; van Damme P, 2005, NEURODEGENER DIS, V2, P147, DOI 10.1159/000089620; Van Den Bosch L, 2000, J NEUROL SCI, V180, P29, DOI 10.1016/S0022-510X(00)00414-7; van Zundert B, 2004, TRENDS NEUROSCI, V27, P428, DOI 10.1016/j.tins.2004.05.010; Verkhratsky A, 2007, NEUROSCIENTIST, V13, P28, DOI 10.1177/1073858406294270; YOSHIOKA A, 1995, J NEUROCHEM, V64, P2442; Zheng JQ, 1996, J NEUROSCI, V16, P1140	56	35	36	0	11	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1759-0914			ASN NEURO	ASN Neuro		2012	4	1					47	57	e00076	10.1042/AN20110031			11	Neurosciences	Neurosciences & Neurology	925NI	WOS:000302767600005	22356284	DOAJ Gold, Green Published			2021-06-18	
J	Kleffelgaard, I; Roe, C; Soberg, HL; Bergland, A				Kleffelgaard, Ingerid; Roe, Cecilie; Soberg, Helene L.; Bergland, Astrid			Associations among self-reported balance problems, post-concussion symptoms and performance-based tests: a longitudinal follow-up study	DISABILITY AND REHABILITATION			English	Article						Balance problems; mild traumatic brain injury; post-concussion symptoms	TRAUMATIC BRAIN-INJURY; MOBILITY ASSESSMENT-TOOL; DYNAMIC GAIT INDEX; MILD HEAD-INJURY; WALKING SPEED; INTERRATER RELIABILITY; VESTIBULAR DISORDERS; CONCURRENT VALIDITY; DIZZINESS; PEOPLE	Purpose: The main objectives of this study were to describe long-term self-reported balance problems and to explore their associations with post-concussion symptoms and performance-based tests. Method: Prospective study of patients with mild traumatic brain injury (MTBI). Self-reported balance problems and post-concussion symptoms were measured with the Rivermead Post-concussion Symptoms Questionnaire at 1 and 4 years after injury. Performance-based tests were performed 4 years after injury and included posturography, the Dynamic Gait Index (DGI), walking speed tests, and the six-minute walk test. Results: Self-reported balance problems were reported in 31% of patients 4 years after injury and correlated significantly with post-concussion symptoms. The correlations with performance-based tests varied from rho = 0.18 to rho = 0.70 and were strongest for the maximum walking speed test (rho = 0.70) and a dual-task test (rho = 0.43). The DGI had a considerable ceiling effect. Conclusions: Balance problems were long-term consequences of MTBI in one third of this study sample. Self-reported balance problems correlated with post-concussion symptoms and some of the performance-based tests. Future research needs to develop and evaluate appropriate rehabilitation strategies that also address the balance problems.	[Kleffelgaard, Ingerid; Roe, Cecilie; Soberg, Helene L.] Oslo Univ Hosp HF, Dept Phys Med & Rehabil, N-0407 Oslo, Norway; [Bergland, Astrid] Oslo Univ Coll, Dept Physiotherapy, Oslo, Norway; [Roe, Cecilie] Univ Oslo, Fac Med, Oslo, Norway	Kleffelgaard, I (corresponding author), Oslo Univ Hosp HF, Dept Phys Med & Rehabil, N-0407 Oslo, Norway.	ingerid.kleffelgard@oslo-universitetssykehus.no					Allison L., 1999, NEUROLOGY REPORT, V23, P13, DOI DOI 10.1097/01253086-199923010-00010; Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; Bohannon RW, 1997, AGE AGEING, V26, P15, DOI 10.1093/ageing/26.1.15; Brauer SG, 2004, HUM MOVEMENT SCI, V23, P489, DOI 10.1016/j.humov.2004.08.020; Campbell M, 2005, BRAIN INJURY, V19, P1095, DOI 10.1080/02699050500188898; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Chamelian L, 2004, ARCH PHYS MED REHAB, V85, P1662, DOI 10.1016/j.apmr.2004.02.012; Cohen J., 2003, APPL MULTIPLE CORREL; Crooks Carol Y, 2007, Phys Med Rehabil Clin N Am, V18, P681, DOI 10.1016/j.pmr.2007.06.005; Enright Paul L, 2003, Respir Care, V48, P783; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Finch E., 2002, PHYS REHABILITATION; Geurts ACH, 1999, ARCH PHYS MED REHAB, V80, P144, DOI 10.1016/S0003-9993(99)90111-9; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; Heitger MH, 2007, J REHABIL MED, V39, P612, DOI 10.2340/16501977-0100; Hoffer ME, 2004, OTOL NEUROTOL, V25, P135, DOI 10.1097/00129492-200403000-00009; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Jakola AS, 2007, ACTA NEUROL SCAND, V115, P398, DOI 10.1111/j.1600-0404.2007.00827.x; Kaufman KR, 2006, MED ENG PHYS, V28, P234, DOI 10.1016/j.medengphy.2005.05.005; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; LEHMANN JF, 1990, ARCH PHYS MED REHAB, V71, P955; Marchetti GF, 2008, PHYS THER, V88, P640, DOI 10.2522/ptj.20070130; Maskell F, 2006, BRAIN INJURY, V20, P293, DOI 10.1080/02699050500488041; Maskell F, 2007, BRAIN INJURY, V21, P741, DOI 10.1080/02699050701472109; McCulloch Karen, 2007, J Neurol Phys Ther, V31, P104; Moseley AM, 2004, J HEAD TRAUMA REHAB, V19, P341, DOI 10.1097/00001199-200407000-00008; Quinn B, 2000, BRAIN INJURY, V14, P1063; Roe C, 2009, DISABIL REHABIL, V31, P1235, DOI 10.1080/09638280802532720; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Shumway-Cook A, 2001, MOTOR CONTROL THEORY, P405; Sosnoff JJ, 2008, EXP BRAIN RES, V187, P563, DOI 10.1007/s00221-008-1324-x; Stratford P., 1995, PHYSIOTHER CAN, V47, P258, DOI DOI 10.3138/PTC.47.4.258; van Donkelaar P, 2006, EXERC SPORT SCI REV, V34, P77, DOI 10.1249/00003677-200604000-00007; van Loo M, 2003, CLIN REHABIL, V17, P775, DOI 10.1191/0269215503cr677oa; Van Loo MA, 2004, BRAIN INJURY, V18, P1041, DOI 10.1080/02699050410001672314; Whitney Susan, 2003, Physiother Res Int, V8, P178, DOI 10.1002/pri.288; Williams G, 2006, ARCH PHYS MED REHAB, V87, P437, DOI 10.1016/j.apmr.2005.10.028; Williams G, 2005, BRAIN INJURY, V19, P925, DOI 10.1080/02699050500058687; Williams GP, 2006, PHYS THER, V86, P395, DOI 10.1093/ptj/86.3.395; Williams GP, 2005, BRAIN INJURY, V19, P833, DOI 10.1080/02699050500058711; Wrisley DM, 2003, ARCH PHYS MED REHAB, V84, P1528, DOI 10.1016/S0003-9993(03)00274-0	41	35	37	0	23	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0963-8288	1464-5165		DISABIL REHABIL	Disabil. Rehabil.		2012	34	9					788	794		10.3109/09638288.2011.619624			7	Rehabilitation	Rehabilitation	909TG	WOS:000301587200012	22149161				2021-06-18	
J	Hellstrom, M; Pollett, MA; Harvey, AR				Hellstroem, Mats; Pollett, Margaret A.; Harvey, Alan R.			Post-Injury Delivery of rAAV2-CNTF Combined with Short-Term Pharmacotherapy Is Neuroprotective and Promotes Extensive Axonal Regeneration after Optic Nerve Trauma	JOURNAL OF NEUROTRAUMA			English	Article						cAMP; ciliary neurotrophic factor; growth factors; neural injury; RGC; therapeutic approaches for the treatment of CNS injury; viral-mediated transfection	RETINAL GANGLION-CELLS; CILIARY NEUROTROPHIC FACTOR; RECOMBINANT ADENOASSOCIATED VIRUS; SPINAL-CORD-INJURY; LEBERS CONGENITAL AMAUROSIS; OCULAR GENE-TRANSFER; IN-VIVO; VIRAL VECTORS; AAV SEROTYPES; INTRAVITREAL INJECTION	Recombinant adeno-associated viral (rAAV) vectors expressing neurotrophic genes reduce neuronal death and promote axonal regeneration in central nervous system (CNS) injury models. Currently, however, use of rAAV to treat clinical neurotrauma is problematic because there is a delay in the onset of transgene expression. Using the adult rat retina and optic nerve (ON), we have tested whether rAAV gene therapy administered at the time of injury combined with short-term pharmacotherapy has synergistic effects that enhance neuronal survival and regeneration. The ON was transected and a 1.5 cm segment of autologous peripheral nerve (PN) was grafted onto the cut end. At this time, bicistronic rAAV2 encoding ciliary neurotrophic factor (CNTF) and green fluorescent protein (rAAV2-CNTF-GFP) was injected into the injured eye. To provide interim support for axotomized retinal ganglion cells (RGCs) during vector integration and therapeutic transgene expression, rCNTF protein and a cyclic adenosine monophosphate (cAMP) analogue (CPT-cAMP) were injected intravitreally 3 and 10 days postoperatively. For comparison, another rAAV2-CNTF-GFP group received two intravitreal saline injections 3 and 10 days after the PN-ON surgery. A further PN graft group received only postoperative intravitreal injections of rCNTF plus CPT-cAMP. After 4 weeks, regenerating RGCs were retrogradely labelled by applying fluorogold to the distal end of each PN graft. Compared to saline-injected animals, both RGC survival and axonal regrowth were significantly higher in the rCNTF and CPT-cAMP injected rAAV2-CNTF-GFP group; approximately one third of the RGC population survived axotomy, and 27% of these regrew an axon. These values were also higher than those obtained in rats that received only rCNTF plus CPT-cAMP injections. Therefore, we show for the first time that rAAV-mediated gene delivery at the time of, or just after, neurotrauma is most successful when combined with temporary post-injury trophic support, and is potentially a viable treatment strategy for patients after acute CNS injury.	[Hellstroem, Mats; Pollett, Margaret A.; Harvey, Alan R.] Univ Western Australia, Sch Anat & Human Biol, Crawley, WA 6009, Australia	Harvey, AR (corresponding author), Univ Western Australia, Sch Anat & Human Biol, M309,35 Stirling Highway, Crawley, WA 6009, Australia.	alan.harvey@uwa.edu.au	Harvey, Alan/A-4911-2008	, Alan/0000-0002-2590-831X	National Health and Medical Research Council (NHMRC)National Health and Medical Research Council of Australia; Western Australia Neurotrauma Research Program; International Postgraduate Research ScholarshipAustralian Government; University of Western Australia	This study was funded by the National Health and Medical Research Council (NHMRC) and Western Australia Neurotrauma Research Program. M. H. was supported by an International Postgraduate Research Scholarship and a University of Western Australia Completion Scholarship.	AGUAYO AJ, 1991, PHILOS T R SOC B, V331, P337, DOI 10.1098/rstb.1991.0025; Airavaara M, 2010, EXP NEUROL, V225, P104, DOI 10.1016/j.expneurol.2010.05.020; Alcala-Barraza SR, 2010, J DRUG TARGET, V18, P179, DOI 10.3109/10611860903318134; Allocca M, 2008, J CLIN INVEST, V118, P1955, DOI 10.1172/JCI34316; Auricchio A, 2001, HUM MOL GENET, V10, P3075, DOI 10.1093/hmg/10.26.3075; Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268; Benowitz L, 2008, EXP NEUROL, V209, P389, DOI 10.1016/j.expneurol.2007.05.025; BERKELAAR M, 1994, J NEUROSCI, V14, P4368, DOI 10.1523/jneurosci.14-07-04368.1994; Bjorklund T, 2010, MOVEMENT DISORD, V25, pS161, DOI 10.1002/mds.22785; Blits B, 2010, J NEUROSCI METH, V185, P257, DOI 10.1016/j.jneumeth.2009.10.009; Burger C, 2005, HUM GENE THER, V16, P781, DOI 10.1089/hum.2005.16.781; Cen LP, 2007, INVEST OPHTH VIS SCI, V48, P4257, DOI 10.1167/iovs.06-0791; Chen J, 2007, BRAIN, V130, P954, DOI 10.1093/brain/awm049; Cheng L, 2002, J NEUROSCI, V22, P3977, DOI 10.1523/JNEUROSCI.22-10-03977.2002; Cui Q, 2006, MOL NEUROBIOL, V33, P155, DOI 10.1385/MN:33:2:155; Cui Q, 2003, MOL CELL NEUROSCI, V22, P49, DOI 10.1016/S1044-7431(02)00037-4; Cui Q, 2000, NEUROREPORT, V11, P3999, DOI 10.1097/00001756-200012180-00019; Cui Q, 2009, NEUROSCIENCE, V158, P1039, DOI 10.1016/j.neuroscience.2008.07.036; Danias J, 2002, INVEST OPHTH VIS SCI, V43, P587; DITTRICH F, 1994, ANN NEUROL, V35, P151, DOI 10.1002/ana.410350206; Fiandaca MS, 2010, CURR OPIN MOL THER, V12, P519; Filbin MT, 2006, NAT NEUROSCI, V9, P715, DOI 10.1038/nn0606-715; Fisher KJ, 1996, J VIROL, V70, P520, DOI 10.1128/JVI.70.1.520-532.1996; Fitzgerald M, 2010, J NEUROTRAUM, V27, P439, DOI 10.1089/neu.2009.1112; GARCIAVALENZUELA E, 1994, J NEUROBIOL, V25, P431, DOI 10.1002/neu.480250408; Gellrich NC, 2002, BRIT J OPHTHALMOL, V86, P233, DOI 10.1136/bjo.86.2.233; Gogel S, 2011, GENE THER, V18, P1, DOI 10.1038/gt.2010.130; Harvey AR, 2006, PROG RETIN EYE RES, V25, P449, DOI 10.1016/j.preteyeres.2006.07.002; Harvey AR, 2002, MOL CELL NEUROSCI, V21, P141, DOI 10.1006/mcne.2002.1168; Hellstrom M, 2011, MOL CELL NEUROSCI, V46, P507, DOI 10.1016/j.mcn.2010.12.003; Hellstrom M, 2011, CURR GENE THER, V11, P116, DOI 10.2174/156652311794940746; Hellstrom M, 2009, GENE THER, V16, P521, DOI 10.1038/gt.2008.178; Hermening S, 2006, J VIROL METHODS, V136, P30, DOI 10.1016/j.jviromet.2006.03.031; Hermens WTJMC, 1998, PROG NEUROBIOL, V55, P399, DOI 10.1016/S0301-0082(98)00007-0; Hu Y, 2007, MOL CELL NEUROSCI, V34, P88, DOI 10.1016/j.mcn.2006.10.005; Jain KK, 2009, MOL BIOTECHNOL, V42, P367, DOI 10.1007/s12033-009-9166-8; Kim HM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004987; Kong FS, 2010, EXP EYE RES, V90, P546, DOI 10.1016/j.exer.2010.01.011; Kurimoto T, 2010, J NEUROSCI, V30, P15654, DOI 10.1523/JNEUROSCI.4340-10.2010; Leaver SG, 2006, GENE THER, V13, P1328, DOI 10.1038/sj.gt.3302791; Lebherz C, 2008, J GENE MED, V10, P375, DOI 10.1002/jgm.1126; Leibinger M, 2009, J NEUROSCI, V29, P14334, DOI 10.1523/JNEUROSCI.2770-09.2009; Liang FQ, 2001, MOL THER, V3, P241, DOI 10.1006/mthe.2000.0252; Lu P, 2008, EXP NEUROL, V209, P313, DOI 10.1016/j.expneurol.2007.08.004; Ma YP, 2010, CELL MOL BIOENG, V3, P3, DOI 10.1007/s12195-010-0114-2; Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315; Malik JMI, 2005, MOL THER, V11, P373, DOI 10.1016/j.ymthe.2004.11.014; Manfredsson FP, 2009, CURR GENE THER, V9, P375, DOI 10.2174/156652309789753400; MANSOURROBAEY S, 1994, P NATL ACAD SCI USA, V91, P1632, DOI 10.1073/pnas.91.5.1632; Mason MRJ, 2010, MOL THER, V18, P715, DOI 10.1038/mt.2010.19; McCarty DM, 2001, GENE THER, V8, P1248, DOI 10.1038/sj.gt.3301514; Muller A, 2009, MOL CELL NEUROSCI, V41, P233, DOI 10.1016/j.mcn.2009.03.002; Nadal-Nicolas FM, 2009, INVEST OPHTH VIS SCI, V50, P3860, DOI 10.1167/iovs.08-3267; Natkunarajah M, 2008, GENE THER, V15, P463, DOI 10.1038/sj.gt.3303074; Park K, 2004, J NEUROSCI, V24, P10806, DOI 10.1523/JNEUROSCI.3532-04.2004; Park KK, 2009, MOL CELL NEUROSCI, V41, P313, DOI 10.1016/j.mcn.2009.04.002; Planchamp V, 2008, BRAIN, V131, P2606, DOI 10.1093/brain/awn196; Qu J, 2010, EXP EYE RES, V91, P48, DOI 10.1016/j.exer.2010.04.002; Rabinowitz JE, 2002, J VIROL, V76, P791, DOI 10.1128/JVI.76.2.791-801.2002; Rahim AA, 2009, GENE THER, V16, P509, DOI 10.1038/gt.2008.186; Ruitenberg MJ, 2004, NEUROBIOL DIS, V15, P394, DOI 10.1016/j.nbd.2003.11.018; Sampat KM, 2010, CURR OPIN OPHTHALMOL, V21, P178, DOI 10.1097/ICU.0b013e328338679a; SENDTNER M, 1992, NATURE, V358, P502, DOI 10.1038/358502a0; Shen F, 2008, GENE THER, V15, P30, DOI 10.1038/sj.gt.3303048; Simonato M, 2010, EPILEPSIA, V51, P48, DOI 10.1111/j.1528-1167.2010.02609.x; Sweigard JH, 2010, INVEST OPHTH VIS SCI, V51, P2219, DOI 10.1167/iovs.09-4367; Thomas CE, 2000, P NATL ACAD SCI USA, V97, P7482, DOI 10.1073/pnas.120474397; van Adel BA, 2005, J NEUROBIOL, V63, P215, DOI 10.1002/neu.20117; Von Seggern DJ, 2003, MOL THER, V7, P27, DOI 10.1016/S1525-0016(02)00030-8; Wang Z, 2003, GENE THER, V10, P2105, DOI 10.1038/sj.gt.3302133; Yanez-Munoz RJ, 2006, NAT MED, V12, P348, DOI 10.1038/nm1365; Yin YQ, 2003, J NEUROSCI, V23, P2284; Yin YQ, 2009, P NATL ACAD SCI USA, V106, P19587, DOI 10.1073/pnas.0907085106; Yokoi K, 2007, INVEST OPHTH VIS SCI, V48, P3324, DOI 10.1167/iovs.06-1306; Zhu W, 2008, STROKE, V39, P1254, DOI 10.1161/STROKEAHA.107.500801; Zhu W, 2009, J CEREBR BLOOD F MET, V29, P1528, DOI 10.1038/jcbfm.2009.75; Zincarelli C, 2008, MOL THER, V16, P1073, DOI 10.1038/mt.2008.76	77	35	37	0	6	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	DEC	2011	28	12					2475	2483		10.1089/neu.2011.1928			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	865DS	WOS:000298291600007	21861632				2021-06-18	
J	Boyko, M; Zlotnik, A; Gruenbaum, BF; Gruenbaum, SE; Ohayon, S; Kuts, R; Melamed, I; Regev, A; Shapira, Y; Teichberg, VI				Boyko, Matthew; Zlotnik, Alexander; Gruenbaum, Benjamin F.; Gruenbaum, Shaun E.; Ohayon, Sharon; Kuts, Ruslan; Melamed, Israel; Regev, Adi; Shapira, Yoram; Teichberg, Vivian I.			Pyruvate's blood glutamate scavenging activity contributes to the spectrum of its neuroprotective mechanisms in a rat model of stroke	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						glutamate-pyruvate transaminase; middle cerebral artery occlusion; neuroprotection; pyruvate; stroke; traumatic brain injury	CEREBRAL-ARTERY OCCLUSION; OXALOACETATE TRANSAMINASE; CEREBROSPINAL-FLUID; ISCHEMIC-STROKE; AMINO-ACIDS; BRAIN; RELEASE; METABOLISM; TRANSIENT; PROTECTS	In previous studies, we have shown that by increasing the brain-to-blood glutamate efflux upon scavenging blood glutamate with either oxaloacetate or pyruvate, one achieves highly significant neuroprotection particularly in the context of traumatic brain injury. The current study examines, for the first time, how the blood glutamate scavenging properties of glutamatepyruvate transaminase (GPT), alone or in combination with pyruvate, may contribute to the spectrum of its neuroprotective mechanisms and improve the outcome of rats exposed to brain ischemia, as they do after head trauma. Rats that were exposed to permanent middle cerebral artery occlusion (MCAO) and treated with intravenous 250 mg/kg pyruvate had a smaller volume of infarction and reduced brain edema, resulting in an improved neurological outcome and reduced mortality compared to control rats treated with saline. Intravenous pyruvate at the low dose of 31.3 mg/kg did not demonstrate any neuroprotection. However, when combined with 0.6 mg/kg of GPT there was a similar neuroprotection observed as seen with pyruvate at 250 mg/kg. Animals treated with 1.69 g/kg glutamate had a worse neurological outcome and a larger extent of brain edema. The decrease in mortality, infarcted brain volume and edema, as well as the improved neurological outcome following MCAO, was correlated with a decrease in blood glutamate levels. We therefore suggest that the blood glutamate scavenging activity of GPT and pyruvate contributes to the spectrum of their neuroprotective mechanisms and may serve as a new neuroprotective strategy for the treatment of ischemic stroke.	[Boyko, Matthew; Zlotnik, Alexander; Gruenbaum, Benjamin F.; Ohayon, Sharon; Kuts, Ruslan; Shapira, Yoram] Ben Gurion Univ Negev, Soroka Med Ctr, Div Anesthesiol & Crit Care, IL-84833 Beer Sheva, Israel; [Gruenbaum, Shaun E.] Yale Univ, Sch Med, Dept Anesthesiol, New Haven, CT 06510 USA; [Melamed, Israel] Soroka Med Ctr, Dept Neurosurg, IL-84101 Beer Sheva, Israel; [Regev, Adi] Soroka Med Ctr, Clin Res Ctr, IL-84101 Beer Sheva, Israel; [Teichberg, Vivian I.] Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel	Boyko, M (corresponding author), Ben Gurion Univ Negev, Soroka Med Ctr, Div Anesthesiol & Crit Care, 36 Hanoch Albek Str, IL-84833 Beer Sheva, Israel.	matthewboykoresearch@gmail.com		Boyko, Matthew/0000-0003-3116-1643	Nella and Leon Benoziyo Center for Neurological Diseases; Irwin Green Alzheimer's Research Fund; Carl and Micaela Einhorn-Dominic Institute for Brain Research; estate of Lola Asseof	The authors gratefully acknowledge Dr M. Dubilet, Resident, Division of Anesthesiology, Soroka Medical Center, for his help in the laboratory as well as in the histology analysis. The authors further want to thank Valeria Frishman, lab assistant at the Department of Clinical Biochemistry, Soroka Medical Center, Ben-Gurion University of the Negev, for her outstanding help with the biochemical analysis. The help of Shira Ovadia, Director of Animal Resources Unit, is also gratefully acknowledged. Many thanks to A. Alir and to the staff at the Critical Care Unit, Soroka Medical Center, for their support and helpful discussions. The data obtained are part of M.B.'s PhD thesis. This work was supported in part by grants to V.I.T. from the Nella and Leon Benoziyo Center for Neurological Diseases; the Irwin Green Alzheimer's Research Fund, the Carl and Micaela Einhorn-Dominic Institute for Brain Research and the estate of Lola Asseof. V.I.T. is the incumbent of the Louis and Florence Katz Cohen Professorial Chair of Neuropharmacology.	BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; BERL S, 1961, J NEUROCHEM, V7, P186, DOI 10.1111/j.1471-4159.1961.tb13503.x; BERL S, 1962, J BIOL CHEM, V237, P2562; Campos F, 2011, J CEREBR BLOOD F MET, V31, P1378, DOI 10.1038/jcbfm.2011.3; Campos F, 2011, J CEREBR BLOOD F MET, V31, P1387, DOI 10.1038/jcbfm.2011.4; Campos F, 2011, CLIN SCI, V121, P11, DOI 10.1042/CS20100427; Castillo J, 1997, LANCET, V349, P79, DOI 10.1016/S0140-6736(96)04453-4; Castillo J, 1996, STROKE, V27, P1060, DOI 10.1161/01.STR.27.6.1060; Castillo J, 2002, NEUROLOGY, V58, P624, DOI 10.1212/WNL.58.4.624; Daikhin Y, 2000, J NUTR, V130, p1026S, DOI 10.1093/jn/130.4.1026S; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Davalos A, 1997, STROKE, V28, P708, DOI 10.1161/01.STR.28.4.708; Desagher S, 1997, J NEUROSCI, V17, P9060; GOODWIN TW, 1952, BIOCHEM J, V51, P708, DOI 10.1042/bj0510708; Gottlieb M, 2003, J NEUROCHEM, V87, P119, DOI 10.1046/j.1471-4159.2003.01972.x; GRAHAM LT, 1966, ANAL BIOCHEM, V15, P487, DOI 10.1016/0003-2697(66)90110-2; Guyot LL, 2001, NEUROSCI LETT, V299, P37, DOI 10.1016/S0304-3940(01)01510-5; Han F, 2008, NEUROSCI LETT, V430, P275, DOI 10.1016/j.neulet.2007.11.021; Joshi CN, 2004, BRAIN RES PROTOC, V13, P11, DOI 10.1016/j.brainresprot.2003.12.001; KAPLAN B, 1991, STROKE, V22, P1032, DOI 10.1161/01.STR.22.8.1032; Kim JB, 2005, BRAIN RES, V1060, P188, DOI 10.1016/j.brainres.2005.08.029; Koura SS, 1998, ACT NEUR S, V71, P244; Lee JY, 2001, J NEUROSCI, V21; Lloyd-Jones D, 2010, CIRCULATION, V121, pE46, DOI 10.1161/CIRCULATIONAHA.109.192667; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; MENZIES SA, 1992, NEUROSURGERY, V31, P100, DOI 10.1227/00006123-199207000-00014; O'Kane RL, 1999, J BIOL CHEM, V274, P31891, DOI 10.1074/jbc.274.45.31891; ODONNELLTORMEY J, 1987, J EXP MED, V165, P500, DOI 10.1084/jem.165.2.500; Sharma P, 2003, BRAIN RES, V992, P104, DOI 10.1016/j.brainres.2003.08.043; Stover JF, 2005, ACTA NEUROCHIR, V147, P847, DOI 10.1007/s00701-005-0562-y; Teichberg VI, 2009, NEUROSCIENCE, V158, P301, DOI 10.1016/j.neuroscience.2008.02.075; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Wang Q, 2009, NEUROBIOL DIS, V36, P223, DOI 10.1016/j.nbd.2009.07.018; Warlow CP, 1998, LANCET S3, V352, pS1; Xu XH, 2006, LIFE SCI, V78, P704, DOI 10.1016/j.lfs.2005.05.080; Yi JS, 2007, NEUROBIOL DIS, V26, P94, DOI 10.1016/j.nbd.2006.12.007; Zauner A, 1996, ACT NEUR S, V67, P40; Zhang H, 2001, CLIN CHEM, V47, P1458; Zlotnik A, 2008, NEUROCHEM RES, V33, P1044, DOI 10.1007/s11064-007-9548-x; Zlotnik A, 2007, EXP NEUROL, V203, P213, DOI 10.1016/j.expneurol.2006.08.021; Zlotnik A, 2009, J NEUROSURG ANESTH, V21, P235, DOI 10.1097/ANA.0b013e3181a2bf0b	41	35	36	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	NOV	2011	34	9					1432	1441		10.1111/j.1460-9568.2011.07864.x			10	Neurosciences	Neurosciences & Neurology	849TD	WOS:000297147200009	21936878				2021-06-18	
J	Farias, SE; Heidenreich, KA; Wohlauer, MV; Murphy, RC; Moore, EE				Farias, Santiago E.; Heidenreich, Kim A.; Wohlauer, Max V.; Murphy, Robert C.; Moore, Ernest E.			Lipid Mediators in Cerebral Spinal Fluid of Traumatic Brain Injured Patients	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Traumatic brain injury; Free fatty acids; Lipid mediators; Eicosanoids; Mass spectrometry	CORD NEURONS; IN-VIVO; ACID; PHOSPHOLIPIDS; INFLAMMATION; EICOSANOIDS; ACTIVATION; BLOOD; RAT	Background: Enzymatic and nonenzymatic oxidation of polyunsaturated fatty acids leads to the formation of biologically active products known as lipid mediators. In the brain, lipid mediators play an important role in supporting homeostasis and normal function. Thus, levels of these metabolites in normal and pathologic conditions in the brain are particularly relevant in understanding the transition to disease. Methods: In this study, liquid chromatography tandem mass spectrometry was used to analyze lipid mediators in cerebrospinal fluid (CSF) of controls and traumatic brain injured (TBI) patients. Results: Our results showed that the levels of arachidonic acid (AA), docosahexaenoic acid (DHA), 5- and 12-eicosatetraenoic acid (HETE) were significantly increased in the CSF of TBI patients. The magnitude of increase was 10-fold for AA, DHA, and 5-HETE and 17-fold for 12-HETE. Prostaglandins and leukotrienes were not detected in CSF of either control or brain injured patients. Furthermore, this study found that isoprostanes and thromboxanes are present in CSF of brain injured patients. Conclusions: This study clearly shows that certain lipid mediators accumulate in the CSF of TBI patient. This study also suggests the potential use of DHA, AA, 5- and 12-HETE as biochemical markers of brain injury and to monitor the impact of interventions.	[Wohlauer, Max V.; Moore, Ernest E.] Univ Colorado, Dept Surg, Denver Hlth Med Ctr, UCD, Denver, CO 80202 USA; [Farias, Santiago E.; Heidenreich, Kim A.; Murphy, Robert C.] Univ Colorado Denver, Dept Pharmacol, Aurora, CO USA	Moore, EE (corresponding author), Univ Colorado, Dept Surg, Denver Hlth Med Ctr, UCD, Denver, CO 80202 USA.	ernest.moore@dhha.org	Murphy, Robert/AAO-5349-2020	Murphy, Robert/0000-0002-9430-6515	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HL025785, P50GM4922, T32GM008315]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R37HL025785, R01HL025785] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008315] Funding Source: NIH RePORTER	Supported by grants from National Institutes of Health (HL025785, P50GM4922, and T32GM008315).	Axelsen PH, 2010, J LIPID RES, V51, P660, DOI [10.1194/jlr.d001750, 10.1194/jlr.D001750]; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; CAZEVIEILLE C, 1994, NEUROCHEM INT, V24, P395, DOI 10.1016/0197-0186(94)90118-X; Cowley TR, 2008, EUR J NEUROSCI, V27, P2999, DOI 10.1111/j.1460-9568.2008.06251.x; Farias SE, 2008, J LIPID RES, V49, P1990, DOI 10.1194/jlr.M800200-JLR200; Farooqui AA, 2006, NEUROSCIENTIST, V12, P245, DOI 10.1177/1073858405285923; Garrido R, 2001, J NEUROCHEM, V76, P1395, DOI 10.1046/j.1471-4159.2001.00135.x; Graham DI, 2000, ACTA NEUROPATHOL, V99, P117, DOI 10.1007/PL00007414; Hall LM, 1998, J AM SOC MASS SPECTR, V9, P527, DOI 10.1016/S1044-0305(98)00013-0; Hong S, 2003, J BIOL CHEM, V278, P14677, DOI 10.1074/jbc.M300218200; LANGOIS JA, 2006, TRAUMATIC BRAIN INJU; Pilitsis JG, 2003, NEUROSCI LETT, V349, P136, DOI 10.1016/S0304-3940(03)00803-6; Rapoport SI, 1999, NEUROCHEM RES, V24, P1403, DOI 10.1023/A:1022584707352; Saitoh M, 2003, BRAIN RES, V991, P187, DOI 10.1016/j.brainres.2003.08.039; Serhan CN, 2007, ANNU REV IMMUNOL, V25, P101, DOI 10.1146/annurev.immunol.25.022106.141647; SUN GY, 1989, ANN NY ACAD SCI, V559, P37; TEASDALE G, 1974, LANCET, V2, P81; Toborek M, 1999, J NEUROCHEM, V73, P684, DOI 10.1046/j.1471-4159.1999.0730684.x; WESTCOTT JY, 1987, PROSTAGLANDINS, V34, P877, DOI 10.1016/0090-6980(87)90068-2	19	35	36	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	NOV	2011	71	5					1211	1218		10.1097/TA.0b013e3182092c62			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	849IG	WOS:000297118600027	21427623				2021-06-18	
J	Caterino, JM; Raubenolt, A; Cudnik, MT				Caterino, Jeffrey M.; Raubenolt, Amy; Cudnik, Michael T.			Modification of Glasgow Coma Scale Criteria for Injured Elders	ACADEMIC EMERGENCY MEDICINE			English	Article; Proceedings Paper	Annual Meeting of the Society-for-Academic-Emergency-Medicine	MAY, 2010	Phoenix, AZ	Soc Acad Emergency Med			TRAUMATIC BRAIN-INJURY; MISSING DATA; MULTIPLE IMPUTATION; INCREASED MORTALITY; ADVANCED STATISTICS; NONTRAUMA CENTERS; CLINICAL-RESEARCH; GERIATRIC TRAUMA; OLDER-ADULTS; OUTCOMES	Objectives: An abnormal field Glasgow Coma Scale (GCS) score of <= 13 has been used in our emergency medical services (EMS) system to prompt transport to a trauma center. For elders, Ohio has recently adopted a GCS of <= 14 to prompt EMS transport to a trauma center, as older patients respond differently to trauma and may benefit from a different GCS threshold. This study sought to determine if a field GCS of 14 is an appropriate cutoff to initiate transport to a trauma center among injured elders. Methods: This was a retrospective, observational statewide analysis of injured patients 16 years old captured by the Ohio Trauma Registry from 2002 to 2007. Outcomes studied included mortality, traumatic brain injury (TBI), neurosurgical intervention, and endotracheal intubation (ETI). Multiple imputation was performed to account for missing data. Age-stratified sensitivity and specificity for proposed GCS cutoffs of 13 and 14 were calculated. A series of multivariate logistic regression models was then constructed using each outcome as a dependent variable. Independent variables included age, GCS score, sex, blood pressure, injury type, nontrauma center, race, ethnicity, and Injury Severity Score (ISS). Two separate analyses were performed. For each age group, odds ratios (ORs) of each outcome were calculated both for the decrease in GCS from 15 to 14 and for the decrease from 14 to 13. The group of elders with GCS 14 was then compared to adults with GCS 13. Results: A total of 52,412 study patients were identified. For a GCS cutoff of 13, sensitivity among elders for each outcome was >20% less than sensitivity for adults, and specificity was 5% to 10% greater. Increasing the GCS cutoff for elders to 14 resulted in improved sensitivity for all outcomes (approximately 10%), with a decline in specificity to values near that of adults with GCS 13. In the multivariate models for elders, mortality increased with a decrease in GCS both from 15 to 14 (OR = 1.40, 95% confidence interval [CI] = 1.07 to 1.83) and from GCS 14 to 13 (OR = 2.34, 95% CI = 1.57 to 3.52). In adults, mortality did not increase with the drop from GCS 15 to 14 (OR = 1.22, 95% CI = 0.88 to 1.71) or from GCS 14 to 13 (OR = 1.45, 95% CI = 0.91 to 2.30). When comparing elders with GCS 14 to adults with GCS 13, elders had greater odds of mortality (OR = 4.68, 95% CI = 2.90 to 7.54) and TBI (OR = 1.84, 95% CI = 1.45 to 2.34). Conclusions: Changing the EMS trauma triage cutoff for elders from GCS 13 to GCS 14 results in improved sensitivity for clinically relevant outcomes. In injured elders, the decline in GCS from 15 to 14 is associated with increased mortality, a finding not observed in younger adults. Elders with GCS 14 have greater odds of mortality and TBI than adults with GCS 13. These results support recent changes in EMS trauma triage guidelines for elders adopted in Ohio. ACADEMIC EMERGENCY MEDICINE 2011; 18: 1014-1021 (C) 2011 by the Society for Academic Emergency Medicine	[Caterino, Jeffrey M.; Raubenolt, Amy; Cudnik, Michael T.] Ohio State Univ, Dept Emergency Med, Columbus, OH 43210 USA; [Raubenolt, Amy] Michigan State Univ, Dept Emergency Med, Kalamazoo, MI USA	Caterino, JM (corresponding author), Ohio State Univ, Dept Emergency Med, Columbus, OH 43210 USA.	jeffrey.caterino@osumc.edu					American College of Surgeons, 2004, ATLS ADV TRAUM LIF S; Bazarian JJ, 2003, BRAIN INJURY, V17, P553, DOI 10.1080/0269905031000070260; Bouras T, 2007, J NEUROTRAUM, V24, P1355, DOI 10.1089/neu.2005.370; Caterino JM, 2010, AM J EMERG MED, V28, P151, DOI 10.1016/j.ajem.2008.10.027; Chiara Osvaldo, 2003, Curr Opin Crit Care, V9, P510, DOI 10.1097/00075198-200312000-00008; CLARK DE, NATL TRAUMA DATA BAN; Demetriades D, 2001, J TRAUMA, V51, P754, DOI 10.1097/00005373-200110000-00022; Demissie S, 2003, STAT MED, V22, P545, DOI 10.1002/sim.1340; Durham R, 2006, ANN SURG, V243, P775, DOI 10.1097/01.sla.0000219644.52926.f1; *E PRACT MAN GUID, PRACT MAN GUID GER T; Gill M, 2005, ANN EMERG MED, V45, P37, DOI 10.1016/j.annemergmed.2004.07.429; Gill M, 2006, ACAD EMERG MED, V13, P968, DOI 10.1197/j.aem.2006.05.019; Hartl R, 2006, J TRAUMA, V60, P1250, DOI 10.1097/01.ta.0000203717.57821.8d; Haukoos JS, 2007, ACAD EMERG MED, V14, P662, DOI 10.1197/j.aem.2006.11.037; Kerby JD, 2007, J TRAUMA, V63, P1026, DOI 10.1097/TA.0b013e318157d9e8; Kramer AA, 2007, CRIT CARE MED, V35, P2052, DOI 10.1097/01.CCM.0000275267.64078.B0; Ma MHM, 1999, J TRAUMA, V46, P168; Meldon SW, 2002, J TRAUMA, V52, P79, DOI 10.1097/00005373-200201000-00014; MORRIS JA, 1990, J TRAUMA, V30, P1476, DOI 10.1097/00005373-199012000-00006; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Mullins RJ, 1998, JAMA-J AM MED ASSOC, V279, P1727, DOI 10.1001/jama.279.21.1727; Newgard CD, 2007, ACAD EMERG MED, V14, P669, DOI 10.1197/j.aem.2006.11.038; *OH DEP PUBL SAF, OH TRAUM REG DAT EL; ORESKOVICH MR, 1984, J TRAUMA, V24, P565, DOI 10.1097/00005373-198407000-00003; PELLICANE JV, 1992, J TRAUMA, V33, P440, DOI 10.1097/00005373-199209000-00018; Perdue PW, 1998, J TRAUMA, V45, P805, DOI 10.1097/00005373-199810000-00034; Phillips S, 1996, J TRAUMA, V40, P278, DOI 10.1097/00005373-199602000-00018; Richmond TS, 2002, J AM GERIATR SOC, V50, P215, DOI 10.1046/j.1532-5415.2002.50051.x; Ross SE, 1998, J TRAUMA, V45, P42, DOI 10.1097/00005373-199807000-00008; Schafer JL, 2002, PSYCHOL METHODS, V7, P147, DOI 10.1037//1082-989X.7.2.147; Schafer JL, 1999, STAT METHODS MED RES, V8, P3, DOI 10.1191/096228099671525676; Scheetz Linda J, 2003, J Emerg Nurs, V29, P109, DOI 10.1067/men.2003.59; SMITH JS, 1990, J TRAUMA, V30, P1533, DOI 10.1097/00005373-199012000-00017; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Tornetta P, 1999, J TRAUMA, V46, P702, DOI 10.1097/00005373-199904000-00024; Vollmer D G, 1991, Neurosurg Clin N Am, V2, P437; ZIMMERGEMBECK MJ, 1995, J TRAUMA, V39, P922, DOI 10.1097/00005373-199511000-00017; OHIO TRAUMA REGISTRY	39	35	35	0	6	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1069-6563			ACAD EMERG MED	Acad. Emerg. Med.	OCT	2011	18	10					1014	1021		10.1111/j.1553-2712.2011.01164.x			8	Emergency Medicine	Emergency Medicine	835QE	WOS:000296050100001	21951715	Bronze			2021-06-18	
J	Hand, CC; Brines, M				Hand, Carla Cerami; Brines, Michael			Promises and Pitfalls in Erythopoietin-Mediated Tissue Protection: Are Nonerythropoietic Derivatives a Way Forward?	JOURNAL OF INVESTIGATIVE MEDICINE			English	Article						inflammation; cytoprotection; apoptosis; cytokines; innate immune response	RECOMBINANT-HUMAN-ERYTHROPOIETIN; ISCHEMIA-REPERFUSION INJURY; FOCAL CEREBRAL-ISCHEMIA; SQUAMOUS-CELL CARCINOMA; TRAUMATIC BRAIN-INJURY; SPINAL-CORD-INJURY; NEURONS IN-VITRO; CARBAMYLATED ERYTHROPOIETIN; RECEPTOR EXPRESSION; PLATELET REACTIVITY	The essential biological role of erythropoietin (EPO) in maintaining erythrocyte mass has been well understood for many years. Although EPO is required for the maturation of red cells, it also has strong procoagulant effects on the vascular endothelium and platelets, which limit erythrocyte losses after hemorrhage. Like other members of the type 1 cytokine superfamily, EPO has multiple biological activities. For the past 10 years, multiple investigators have shown that EPO acts as a locally produced antagonist of proinflammatory cytokines that are generated by the innate immune response in response to infection, trauma, or metabolic stress. Specifically, EPO inhibits apoptosis of cells surrounding a locus of injury, reduces the influx of inflammatory cells, and recruits tissue-specific stem cells and endothelial progenitor cells. Available evidence suggests that these multiple, nonerythropoietic effects of EPO are mediated by a tissue protective receptor (TPR) that is distinct from the homodimeric receptor responsible for erythropoiesis. Notably, activation of the TPR requires a higher concentration of EPO than is needed for maximal erythropoiesis. Unfortunately, these higher concentrations of EPO also stimulate hematopoietic and procoagulant pathways, which can cause adverse effects and, therefore, potentially limit the clinical use of EPO for tissue protection. To circumvent these problems, the EPO molecule has been successfully modified in a variety of ways to interact only with the TPR. Early clinical experience has shown that these compounds appear to be safe, and proof of concept trials are ready to begin.	[Brines, Michael] Warren Pharmaceut, Ossining, NY 10562 USA; [Hand, Carla Cerami] Univ N Carolina, Chapel Hill, NC USA	Brines, M (corresponding author), Warren Pharmaceut, 712 Kitchawan Rd, Ossining, NY 10562 USA.	mbrines@warrenpharma.com	Brinesd, Michael/AAE-6072-2020	Cerami, Carla/0000-0002-7634-0955; Brines, Michael/0000-0003-4151-4449	National Center for Research ResourcesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [R13 RR023236]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [R13RR023236] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R56AI085201] Funding Source: NIH RePORTER	Supported in part by a grant from the National Center for Research Resources (R13 RR023236).	Abdelrahman M, 2004, SHOCK, V22, P63, DOI 10.1097/01.shk.00001276869.21260.9d; Acs G, 2003, AM J PATHOL, V162, P1789, DOI 10.1016/S0002-9440(10)64314-3; Acs G, 2001, CANCER RES, V61, P3561; Agnello D, 2002, BRAIN RES, V952, P128, DOI 10.1016/S0006-8993(02)03239-0; ANAGNOSTOU A, 1990, P NATL ACAD SCI USA, V87, P5978, DOI 10.1073/pnas.87.15.5978; Arcasoy MO, 2008, BRIT J HAEMATOL, V141, P14, DOI 10.1111/j.1365-2141.2008.07014.x; Baker JE, 2005, VASC PHARMACOL, V42, P233, DOI 10.1016/j.vph.2005.02.004; Bernaudin M, 1999, J CEREBR BLOOD F MET, V19, P643, DOI 10.1097/00004647-199906000-00007; Binbrek AS, 2009, AM J CARDIOL, V104, P1035, DOI 10.1016/j.amjcard.2009.05.050; Bohlius J, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007303.pub2; Bohlius J, 2009, LANCET, V373, P1532, DOI 10.1016/S0140-6736(09)60502-X; BOISSEL JP, 1993, J BIOL CHEM, V268, P15983; Brines M, 2008, J INTERN MED, V264, P405, DOI 10.1111/j.1365-2796.2008.02024.x; Brines M, 2006, KIDNEY INT, V70, P246, DOI 10.1038/sj.ki.5001546; Brines M, 2004, P NATL ACAD SCI USA, V101, P14907, DOI 10.1073/pnas.0406491101; Brines M, 2008, P NATL ACAD SCI USA, V105, P10925, DOI 10.1073/pnas.0805594105; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Brown MS, 2009, PEDIATRICS, V124, pE681, DOI 10.1542/peds.2008-2701; Byts N, 2008, CELL DEATH DIFFER, V15, P783, DOI 10.1038/cdd.2008.1; Cai ZQ, 2004, CIRCULATION, V109, P2050, DOI 10.1161/01.CIR.0000127954.98131.23; Cai ZQ, 2003, CIRCULATION, V108, P79, DOI 10.1161/01.CIR.0000078635.89229.8A; Calvillo L, 2003, P NATL ACAD SCI USA, V100, P4802, DOI 10.1073/pnas.0630444100; Casals-Pascual C, 2008, P NATL ACAD SCI USA, V105, P2634, DOI 10.1073/pnas.0709715105; Celik M, 2002, P NATL ACAD SCI USA, V99, P2258, DOI 10.1073/pnas.042693799; Cheetham JC, 1998, NAT STRUCT BIOL, V5, P861, DOI 10.1038/2302; Cherian L, 2007, J PHARMACOL EXP THER, V322, P789, DOI 10.1124/jpet.107.119628; Chin K, 2000, MOL BRAIN RES, V81, P29, DOI 10.1016/S0169-328X(00)00157-1; Coleman TR, 2006, P NATL ACAD SCI USA, V103, P5965, DOI 10.1073/pnas.0601377103; Depping R, 2005, J THORAC CARDIOV SUR, V130, P877, DOI 10.1016/j.jtcvs.2004.12.041; Diskin CJ, 2008, SEMIN DIALYSIS, V21, P447, DOI 10.1111/j.1525-139X.2008.00443.x; Ehrenreich H, 2007, MOL PSYCHIATR, V12, P206, DOI 10.1038/sj.mp.4001907; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; Ehrenreich H, 2007, BRAIN, V130, P2577, DOI 10.1093/brain/awm203; Ehrenreich H, 2009, STROKE, V40, pE647, DOI 10.1161/STROKEAHA.109.564872; Elliott S, 2006, BLOOD, V107, P1892, DOI 10.1182/blood-2005-10-4066; Elliott S, 1997, BLOOD, V89, P493, DOI 10.1182/blood.V89.2.493; Erbayraktar S, 2003, P NATL ACAD SCI USA, V100, P6741, DOI 10.1073/pnas.1031753100; Erbayraktar S, 2006, MOL MED, V12, P74, DOI 10.2119/2006-00042.Erbayraktar; Fandrey J, 2009, ONCOLOGIST, V14, P34, DOI 10.1634/theoncologist.2009-S1-34; Fantacci M, 2006, P NATL ACAD SCI USA, V103, P17531, DOI 10.1073/pnas.0608814103; FERRARIO M, 2009, INT J CARDIOL; Fiordaliso F, 2005, P NATL ACAD SCI USA, V102, P2046, DOI 10.1073/pnas.0409329102; Fisher JW, 2003, EXP BIOL MED, V228, P1; Fu P, 2009, BIOCHEM BIOPH RES CO, V379, P696, DOI 10.1016/j.bbrc.2008.12.146; Fu ZQ, 2010, J NEUROIMMUNOL, V221, P15, DOI 10.1016/j.jneuroim.2010.01.016; Gorio A, 2005, P NATL ACAD SCI USA, V102, P16379, DOI 10.1073/pnas.0508479102; Grasso G, 2006, J NEUROSURG-SPINE, V4, P310, DOI 10.3171/spi.2006.4.4.310; Grasso G, 2001, J Neurosurg Sci, V45, P7; Grasso G, 2002, P NATL ACAD SCI USA, V99, P5627, DOI 10.1073/pnas.082097299; Gunnarson E, 2009, P NATL ACAD SCI USA, V106, P1602, DOI 10.1073/pnas.0812708106; Haiden N, 2005, THROMB HAEMOSTASIS, V93, P118, DOI 10.1160/TH04-02-0093; Hardee ME, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000549; Haroon ZSA, 2003, AM J PATHOL, V163, P993, DOI 10.1016/S0002-9440(10)63459-1; Imamura R, 2008, CELL TRANSPLANT, V17, P135, DOI 10.3727/000000008783907044; Jerndal M, 2010, J CEREBR BLOOD F MET, V30, P961, DOI 10.1038/jcbfm.2009.267; Jubinsky PT, 1997, BLOOD, V90, P1867, DOI 10.1182/blood.V90.5.1867; Kaiser K, 2006, J INFECT DIS, V193, P987, DOI 10.1086/500844; Kato S, 2010, J PHARMACOL SCI, V112, P167, DOI 10.1254/jphs.09262FP; Kertesz N, 2004, DEV BIOL, V276, P101, DOI 10.1016/j.ydbio.2004.08.025; Kim KH, 2008, J PHARMACOL EXP THER, V324, P160, DOI 10.1124/jpet.107.125773; King VR, 2007, EUR J NEUROSCI, V26, P90, DOI 10.1111/j.1460-9568.2007.05635.x; Kirkeby A, 2008, THROMB HAEMOSTASIS, V99, P720, DOI 10.1160/TH07-03-0208; KONISHI Y, 1993, BRAIN RES, V609, P29, DOI 10.1016/0006-8993(93)90850-M; Kumar SM, 2006, MELANOMA RES, V16, P275, DOI 10.1097/01.cmr.0000222594.60611.c3; Lauria G, 2009, AMYOTROPH LATERAL SC, V10, P410, DOI 10.3109/17482960902995246; Leist M, 2004, SCIENCE, V305, P239, DOI 10.1126/science.1098313; Liu WM, 2004, ONCOGENE, V23, P981, DOI 10.1038/sj.onc.1207294; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Mahmood A, 2007, J NEUROSURG, V107, P392, DOI 10.3171/JNS-07/08/0392; Mancini DM, 2003, CIRCULATION, V107, P294, DOI 10.1161/01.CIR.0000044914.42696.6A; Masuda S, 2000, AM J PHYSIOL-ENDOC M, V278, pE1038; MASUDA S, 1993, J BIOL CHEM, V268, P11208; Mennini T, 2006, MOL MED, V12, P153, DOI 10.2119/2006-00045.Mennini; Minnerup J, 2009, STROKE, V40, P3113, DOI 10.1161/STROKEAHA.109.555789; Miskowiak K, 2007, BIOL PSYCHIAT, V62, P1244, DOI 10.1016/j.biopsych.2007.01.011; Miskowiak KW, 2009, PSYCHOPHARMACOLOGY, V207, P133, DOI 10.1007/s00213-009-1641-1; Mohyeldin A, 2005, NEOPLASIA, V7, P537, DOI 10.1593/neo.04685; Napolitano LM, 2008, J TRAUMA, V65, P285, DOI 10.1097/TA.0b013e31817f2c6e; Paragh G, 2009, AM J PATHOL, V174, P1504, DOI 10.2353/ajpath.2009.080592; Parsa CJ, 2003, J CLIN INVEST, V112, P999, DOI 10.1172/JCI200318200; Pfeffer MA, 2009, NEW ENGL J MED, V361, P2019, DOI 10.1056/NEJMoa0907845; Rafiee P, 2005, BASIC RES CARDIOL, V100, P187, DOI 10.1007/s00395-004-0508-1; Ribatti D, 1999, BLOOD, V93, P2627, DOI 10.1182/blood.V93.8.2627.408k21_2627_2636; ROSTI V, 1993, HAEMATOLOGICA, V78, P208; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Santhanam AVR, 2006, ACTA PHARMACOL SIN, V27, P1389, DOI 10.1111/j.1745-7254.2006.00441.x; Sautina L, 2010, BLOOD, V115, P896, DOI 10.1182/blood-2009-04-216432; Savino C, 2006, J NEUROIMMUNOL, V172, P27, DOI 10.1016/j.jneuroim.2005.10.016; Sinclair AM, 2008, BRIT J CANCER, V98, P1059, DOI 10.1038/sj.bjc.6604220; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Siren AL, 2001, ACTA NEUROPATHOL, V101, P271, DOI 10.1007/s004010000297; Stasko J, 2007, CLIN APPL THROMB-HEM, V13, P410, DOI 10.1177/1076029607303348; Stohlawetz PJ, 2000, BLOOD, V95, P2983, DOI 10.1182/blood.V95.9.2983.009k27_2983_2989; Swift S, 2010, BLOOD, V115, P4254, DOI 10.1182/blood-2009-10-248674; TABIRA T, 1995, INT J DEV NEUROSCI, V13, P241, DOI 10.1016/0736-5748(94)00020-4; Tramontano AF, 2003, BIOCHEM BIOPH RES CO, V308, P990, DOI 10.1016/S0006-291X(03)01503-1; Um M, 2007, CELL SIGNAL, V19, P634, DOI 10.1016/j.cellsig.2006.08.014; van der Meer P, 2009, HEART, V95, P1309, DOI 10.1136/hrt.2008.161091; Vitellaro-Zuccarello L, 2008, NEUROSCIENCE, V151, P452, DOI 10.1016/j.neuroscience.2007.11.004; Viviani B, 2005, J NEUROCHEM, V93, P412, DOI 10.1111/j.1471-4159.2005.03033.x; Wang L, 2007, J BIOL CHEM, V282, P32462, DOI 10.1074/jbc.M706880200; Wang Y, 2007, BRIT J PHARMACOL, V151, P1377, DOI 10.1038/sj.bjp.0707285; WEN DY, 1994, J BIOL CHEM, V269, P22839; Westenfelder C, 2000, KIDNEY INT, V58, P647, DOI 10.1046/j.1523-1755.2000.00211.x; Wiese L, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-3; Wojchowski DM, 1999, EXP CELL RES, V253, P143, DOI 10.1006/excr.1999.4673; Wolf RF, 1997, THROMB HAEMOSTASIS, V78, P1505; Wolf RF, 1997, THROMB HAEMOSTASIS, V77, P1020; Wright GL, 2004, FASEB J, V18, P1031, DOI 10.1096/fj.03-1289fje; Xu X, 2009, SURGERY, V146, P506, DOI 10.1016/j.surg.2009.03.022; Yamaji R, 1996, EUR J BIOCHEM, V239, P494, DOI 10.1111/j.1432-1033.1996.0494u.x; Yasuda Y, 2001, BRIT J CANCER, V84, P836, DOI 10.1054/bjoc.2000.1666; Yasuda Y, 1998, J BIOL CHEM, V273, P25381, DOI 10.1074/jbc.273.39.25381; Yoo JY, 2009, J NEUROSCI RES, V87, P150, DOI 10.1002/jnr.21832; Yuan RR, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001924; Zechariah A, 2010, STROKE, V41, P1008, DOI 10.1161/STROKEAHA.109.574418; Zhang YL, 2009, BRAIN RES, V1294, P153, DOI 10.1016/j.brainres.2009.07.077; Zhu CL, 2009, PEDIATRICS, V124, pE218, DOI 10.1542/peds.2008-3553	118	35	37	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1081-5589	1708-8267		J INVEST MED	J. Invest. Med.	OCT	2011	59	7					1073	1082					10	Medicine, General & Internal; Medicine, Research & Experimental	General & Internal Medicine; Research & Experimental Medicine	823JH	WOS:000295117800014	20683348	Green Accepted			2021-06-18	
J	Mortberg, E; Zetterberg, H; Nordmark, J; Blennow, K; Catry, C; Decraemer, H; Vanmechelen, E; Rubertsson, S				Mortberg, E.; Zetterberg, H.; Nordmark, J.; Blennow, K.; Catry, C.; Decraemer, H.; Vanmechelen, E.; Rubertsson, S.			Plasma tau protein in comatose patients after cardiac arrest treated with therapeutic hypothermia	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article							NEURON-SPECIFIC ENOLASE; AMERICAN-HEART-ASSOCIATION; TRAUMATIC BRAIN-INJURY; ACUTE ISCHEMIC-STROKE; SERUM CLEAVED-TAU; S-100B; DAMAGE; RESUSCITATION; BIOMARKER; CARE	Background: Neurological outcome after cardiac arrest (CA) is difficult to predict in the acute phase. In this pilot study, we assessed blood levels of tau protein as a prognostic marker for the neurological outcome after 6 months in patients treated with hypothermia after resuscitation from CA. Methods: 22 unconscious patients resuscitated after CA were treated with mild hypothermia (32-34 degrees C) for 26 h. Blood samples were collected at 2, 6, 12, 24, 48, and 96 h after CA, and the concentration of tau protein was analyzed. Neurological outcome was assessed with the Glasgow-Pittsburgh cerebral performance category (CPC) scale at intensive care unit (ICU) discharge and after 6 months. The higher of the two CPC scores was used. Results: At ICU discharge, 21/22 patients were alive, of whom 10 had a good (CPC 1-2) outcome. After 6 months, 15/22 patients were alive, of whom 14 had a good outcome. Tau protein levels were higher among those with a poor outcome at 48 h and 96 h. At 96 h sampling, tau concentration predicted a poor outcome (CPC 3-5) with a sensitivity of 71% and a specificity of 93%. Conclusions: Although in a pilot study, a late increase in plasma tau protein seems to be associated with a worse outcome after hypothermia treatment after CA, although more studies are needed.	[Mortberg, E.; Nordmark, J.; Rubertsson, S.] Uppsala Univ, Univ Uppsala Hosp, Dept Surg Sci Anaesthesia & Intens Care, Uppsala, Sweden; [Zetterberg, H.; Blennow, K.] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Psychiat & Neurochem, Molndal, Sweden; [Catry, C.; Decraemer, H.; Vanmechelen, E.] Innogenet, Ghent, Belgium	Mortberg, E (corresponding author), Univ Uppsala Hosp, Dept Surg Sci, SE-75185 Uppsala, Sweden.	erik.mortberg@surgsci.uu.se	Vanmechelen, Eugeen/AAA-8005-2019	Vanmechelen, Eugeen/0000-0002-9466-5366			Al Thenayan E, 2008, NEUROLOGY, V71, P1535, DOI 10.1212/01.wnl.0000334205.81148.31; Aune S, 2011, RESUSCITATION, V82, P431, DOI 10.1016/j.resuscitation.2010.11.021; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; Bitsch A, 2002, EUR NEUROL, V47, P45, DOI 10.1159/000047946; Cummins RO, 1997, RESUSCITATION, V34, P151, DOI 10.1016/S0300-9572(97)01112-X; EDGREN E, 1994, LANCET, V343, P1055, DOI 10.1016/S0140-6736(94)90179-1; Foerch C, 2006, J NEUROL NEUROSUR PS, V77, P181, DOI 10.1136/jnnp.2005.074823; Gabbita SP, 2005, J NEUROTRAUM, V22, P83, DOI 10.1089/neu.2005.22.83; Hansson O, 2010, NEUROBIOL AGING, V31, P357, DOI 10.1016/j.neurobiolaging.2008.03.027; Herlitz J, 2008, NATIONELLT REGISTER; Holzer M, 2002, NEW ENGL J MED, V346, P549; JENNETT B, 1975, LANCET, V1, P480; Lachno DR, 2009, J NUTR HEALTH AGING, V13, P220, DOI 10.1007/s12603-009-0062-5; Ma M, 2008, AM J EMERG MED, V26, P763, DOI 10.1016/j.ajem.2007.10.029; MERCKEN M, 1992, J NEUROCHEM, V58, P548, DOI 10.1111/j.1471-4159.1992.tb09754.x; Mortberg E, 2011, RESUSCITATION, V82, P26, DOI 10.1016/j.resuscitation.2010.10.011; Muller K, 2006, CLIN CHEM LAB MED, V44, P1111, DOI 10.1515/CCLM.2006.211; Nadkarni VM, 2006, JAMA-J AM MED ASSOC, V295, P50, DOI 10.1001/jama.295.1.50; Nolan JP, 2007, ANAESTHESIA, V62, P1207, DOI 10.1111/j.1365-2044.2007.05232.x; Nolan JP, 2008, RESUSCITATION, V79, P350, DOI 10.1016/j.resuscitation.2008.09.017; Okumus N, 2008, PEDIATR NEUROL, V39, P245, DOI 10.1016/j.pediatrneurol.2008.07.004; Petzold A, 2007, J IMMUNOL METHODS, V319, P34, DOI 10.1016/j.jim.2006.09.021; Rossetti AO, 2010, ANN NEUROL, V67, P301, DOI 10.1002/ana.21984; Rundgren M, 2006, INTENS CARE MED, V32, P836, DOI 10.1007/s00134-006-0178-6; Rundgren M, 2010, CRIT CARE MED, V38, P1838, DOI 10.1097/CCM.0b013e3181eaa1e7; Rundgren M, 2009, RESUSCITATION, V80, P784, DOI 10.1016/j.resuscitation.2009.03.025; Shaw GJ, 2002, ANN EMERG MED, V39, P254, DOI 10.1067/mem.2002.121214; Shinozaki K, 2009, RESUSCITATION, V80, P870, DOI 10.1016/j.resuscitation.2009.05.005; Stern P, 2007, TUMOR BIOL, V28, P84, DOI 10.1159/000098441; Sunde K, 2007, RESUSCITATION, V73, P29, DOI 10.1016/j.resuscitation.2006.08.016; Tiainen M, 2005, CRIT CARE MED, V33, P1736, DOI 10.1097/01.CCM.0000171536.63641.D9; Tiainen M, 2003, STROKE, V34, P2881, DOI 10.1161/01.STR.0000103320.90706.35; Vanmechelen E, 2000, NEUROSCI LETT, V285, P49, DOI 10.1016/S0304-3940(00)01036-3; Wennervirta JE, 2009, CRIT CARE MED, V37, P2427, DOI 10.1097/CCM.0b013e3181a0ff84; Wunderlich MT, 2006, CLIN NEUROL NEUROSUR, V108, P558, DOI 10.1016/j.clineuro.2005.12.006; Young GB, 2009, NEW ENGL J MED, V361, P605, DOI 10.1056/NEJMcp0903466	37	35	36	0	3	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0001-5172			ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	OCT	2011	55	9					1132	1138		10.1111/j.1399-6576.2011.02505.x			7	Anesthesiology	Anesthesiology	823DM	WOS:000295102500014	22092212				2021-06-18	
J	Shear, DA; Lu, XCM; Pedersen, R; Wei, G; Chen, ZY; Davis, A; Yao, CP; Dave, J; Tortella, FC				Shear, Deborah A.; Lu, Xi-Chun May; Pedersen, Rebecca; Wei, Guo; Chen, Zhiyong; Davis, Angela; Yao, Changping; Dave, Jitendra; Tortella, Frank C.			Severity Profile of Penetrating Ballistic-Like Brain Injury on Neurofunctional Outcome, Blood-Brain Barrier Permeability, and Brain Edema Formation	JOURNAL OF NEUROTRAUMA			English	Article						BBB; cognitive function; edema; PBBI; traumatic brain injury	CEREBRAL-ARTERY OCCLUSION; CAUDATE-PUTAMEN LESIONS; CEREBROSPINAL-FLUID; HEAD-INJURY; WATER-MAZE; QUINOLINIC ACID; DORSAL STRIATUM; CELL-DEATH; RAT; DEFICITS	This study evaluated the injury severity profile of unilateral, frontal penetrating ballistic-like brain injury (PBBI) on neurofunctional outcome, blood-brain barrier (BBB) permeability, and brain edema formation. The degree of injury severity was determined by the delivery of a water-pressure pulse designed to produce a temporary cavity by rapid (< 40 ms) expansion of the probe's elastic balloon calibrated to equal 5%, 10%, 12.5%, or 15% of total rat brain volume (control groups consisted of sham surgery or insertion of the probe only). Neurofunctional assessments revealed motor and cognitive deficits related to the degree of injury severity, with the most clear-cut profile of PBBI injury severity depicted by the Morris water maze (MWM) results. A biphasic pattern of BBB leakage was detected in the injured hemisphere at all injury severity levels at 4 h post-injury, and again at 48-72 h post-injury, which remained evident out to 7 days post-PBBI in the 10% and 12.5% PBBI groups. Likewise, significant brain edema was detected in the injured hemisphere by 4 h post-injury and remained elevated out to 7 days post-injury in the 10% and 12.5% PBBI groups. However, following 5% PBBI, significant levels of edema were only detected from 24 h to 48h post-injury. These results identify an injury severity profile of BBB permeability, brain edema, and neurofunctional impairment that provides sensitive and clinically relevant outcome metrics for studying potential therapeutics.	[Shear, Deborah A.] Walter Reed Army Inst Res, Ctr Mil Psychiat & Neurosci, MRMC UWI C, Silver Spring, MD 20910 USA	Shear, DA (corresponding author), Walter Reed Army Inst Res, Ctr Mil Psychiat & Neurosci, MRMC UWI C, Bldg 503-2W14, Silver Spring, MD 20910 USA.	Deborah.Shear@AMEDD.ARMY.MIL	Dave, Jitendra R/A-8940-2011; Shear, Deborah/B-3607-2011				Adelson PD, 1998, ACT NEUR S, V71, P104; BAKAY RAE, 1986, NEUROSURGERY, V18, P376, DOI 10.1227/00006123-198603000-00026; BAKAY RAE, 1986, NEUROSURGERY, V18, P234, DOI 10.1227/00006123-198602000-00023; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Beaumont A, 2000, ACTA NEUROCHIR SUPPL, V76, P125; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Belayev L, 1996, BRAIN RES, V739, P88, DOI 10.1016/S0006-8993(96)00815-3; Bland ST, 2000, STROKE, V31, P1144, DOI 10.1161/01.STR.31.5.1144; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; Choi-Lundberg DL, 1998, EXP NEUROL, V154, P261, DOI 10.1006/exnr.1998.6887; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; De Leonibus E, 2003, BEHAV NEUROSCI, V117, P685, DOI 10.1037/0735-7044.117.4.685; Devan BD, 1999, J NEUROSCI, V19, P2789; Devan BD, 1999, BEHAV BRAIN RES, V100, P5, DOI 10.1016/S0166-4328(98)00107-7; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; KIMELBERG HK, 1992, J NEUROTRAUM, V9, pS71; KLATZO I, 1985, BRIT J ANAESTH, V57, P18, DOI 10.1093/bja/57.1.18; Lorberboym M, 2003, J NUCL MED, V44, P1898; Lotocki G, 2009, J NEUROTRAUM, V26, P1123, DOI 10.1089/neu.2008.0802; Louin G, 2006, NEUROPHARMACOLOGY, V50, P182, DOI 10.1016/j.neuropharm.2005.08.020; Lu XCM, 2011, J NEUROTRAUM, V28, P71, DOI 10.1089/neu.2010.1471; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Marmarou A, 1996, J NEUROSURG, V85, P1026, DOI 10.3171/jns.1996.85.6.1026; Marmarou A, 2000, ACT NEUR S, V76, P349; MARMAROU A, 1994, ACTA NEUROCHIR, P421; Mazzini L, 2003, ARCH PHYS MED REHAB, V84, P1637, DOI 10.1053/S0003-9993(03)00314-9; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028-3908(00)00005-8; Shear DA, 1998, EXP NEUROL, V150, P305, DOI 10.1006/exnr.1998.6767; Shear DA, 1998, PROG NEURO-PSYCHOPH, V22, P1217, DOI 10.1016/S0278-5846(98)00070-0; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Shear DA, 2010, J NEUROTRAUM, V27, P1911, DOI 10.1089/neu.2010.1399; Tillerson JL, 2001, J NEUROSCI, V21, P4427, DOI 10.1523/JNEUROSCI.21-12-04427.2001; Tomkins O., 2011, CARDIOVASC PSYC 0222; Wei HH, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-19; Whalen MJ, 1999, J NEUROTRAUM, V16, P583, DOI 10.1089/neu.1999.16.583; Whishaw IQ, 1996, HIPPOCAMPUS, V6, P513, DOI 10.1002/(SICI)1098-1063(1996)6:5<513::AID-HIPO4>3.0.CO;2-J; WHISHAW IQ, 1987, BEHAV BRAIN RES, V24, P125, DOI 10.1016/0166-4328(87)90250-6; Williams AJ, 2005, J NEUROTRAUM, V22, P313, DOI 10.1089/neu.2005.22.313; Williams AJ, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-17; Williams AJ, 2006, NEUROSCI LETT, V408, P183, DOI 10.1016/j.neulet.2006.08.086; Williams AJ, 2006, J NEUROTRAUM, V23, P1828, DOI 10.1089/neu.2006.23.1828; Zhao J, 2007, J NEUROSCI, V27, P10240, DOI 10.1523/JNEUROSCI.1683-07.2007	46	35	35	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2011	28	10					2185	2195		10.1089/neu.2011.1916			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	839OX	WOS:000296378500018	21644814				2021-06-18	
J	Haider, AH; Crompton, JG; Oyetunji, T; Risucci, D; DiRusso, S; Basdag, H; Villegas, CV; Syed, ZU; Haut, ER; Efron, DT				Haider, Adil H.; Crompton, Joseph G.; Oyetunji, Tolulope; Risucci, Donald; DiRusso, Stephen; Basdag, Hatice; Villegas, Cassandra V.; Syed, Zain U.; Haut, Elliott R.; Efron, David T.			Mechanism of injury predicts case fatality and functional outcomes in pediatric trauma patients: the case for its use in trauma outcomes studies	JOURNAL OF PEDIATRIC SURGERY			English	Article						Pediatric trauma; Functional outcomes; Mechanism of injury	SEVERITY SCORE; BRAIN-INJURY; MORTALITY; RACE; DISCHARGE; FALL	Background/Purpose: The mechanism of injury (MOI) may serve as a useful adjunct to injury scoring systems in pediatric trauma outcomes research. The objective is to determine the independent effect of MOI on case fatality and functional outcomes in pediatric trauma patients. Methods: Retrospective review of pediatric patients ages 2 to 18 years in the National Trauma Data Bank from 2002 through 2006 was done. Mechanism of injury was classified by the International Classification of Diseases, Ninth Revision, E codes. The main outcome measures were mortality, discharge disposition (home vs rehabilitation setting), and functional impairment at hospital discharge. Multiple logistic regression was used to adjust for injury severity (using the Injury Severity Score and the presence of shock upon admission in the emergency department), age, sex, and severe head or extremity injury. Results: Thirty-five thousand ninety-seven pediatric patients in the National Trauma Data Bank met inclusion criteria. Each MOI had differences in the adjusted odds of death or functional disabilities as compared with the reference group (fall). The MOI with the greatest risk of death was gunshot wounds (odds ratio [OR], 3.52; 95% confidence interval [CI], 2.23-5.54 95). Pediatric pedestrians struck by a motor vehicle have the highest risk of locomotion (OR, 3.30; 95% CI, 2.89-3.77) and expression (OR, 1.65; 95% CI, 1.22-2.23) disabilities. Conclusion: Mechanism of injury is a significant predictor of clinical and functional outcomes at discharge for equivalently injured patients. These findings have implications for injury prevention, staging, and prognosis of traumatic injury and posttreatment planning. (C) 2011 Published by Elsevier Inc.	[Haider, Adil H.; Basdag, Hatice; Villegas, Cassandra V.; Syed, Zain U.; Haut, Elliott R.; Efron, David T.] Johns Hopkins Univ, Sch Med, Dept Surg, Ctr Trials & Outcomes Res, Baltimore, MD 21287 USA; [Crompton, Joseph G.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA; [Oyetunji, Tolulope] Howard Univ, Coll Med, Dept Surg, Washington, DC 20059 USA; [Risucci, Donald] New York Med Coll, Dept Surg, Valhalla, NY 10595 USA; [DiRusso, Stephen] St Barnabas Hosp Med Ctr, Bronx, NY 10457 USA	Haider, AH (corresponding author), Johns Hopkins Sch Med, Dept Surg, Ctr Surg Trials & Outcomes Res, Baltimore, MD 21212 USA.	ahaider1@jhmi.edu	Haut, Elliott R./J-3948-2019	Oyetunji, Tolulope/0000-0003-3039-7195; Haut, Elliott/0000-0001-7075-771X	National Institutes of Health/NIGMSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [K23GM093112-01]; American College of Surgeons C. James Carrico; Johns Hopkins Dean's Research Fellowship for Medical Students; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [K23GM093112] Funding Source: NIH RePORTER	National Institutes of Health/NIGMS K23GM093112-01 and American College of Surgeons C. James Carrico Fellowship for the study of Trauma and Critical Care (Dr Haider) and Johns Hopkins Dean's Research Fellowship for Medical Students (Ms Villegas).	Arthurs ZM, 2009, J VASC SURG, V49, P988, DOI 10.1016/j.jvs.2008.11.052; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bergeron E, 2006, J TRAUMA, V60, P268, DOI 10.1097/01.ta.0000197651.00482.c5; Burd RS, 2007, J TRAUMA, V62, P1004, DOI 10.1097/01.ta.0000221555.01704.c9; *CENS BUR US, 2006 2008 AM COMM SU; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; Choo B, 2006, BURNS, V32, P20, DOI 10.1016/j.burns.2005.04.033; *COMM INJ SCAL, 1998, ABBR INJ SCAL 1998 R; Furnival RA, 1999, PEDIATR EMERG CARE, V15, P215, DOI 10.1097/00006565-199906000-00013; Haider AH, 2008, ARCH SURG-CHICAGO, V143, P945, DOI 10.1001/archsurg.143.10.945; Haider AH, 2007, ARCH SURG-CHICAGO, V142, P875, DOI 10.1001/archsurg.142.9.875; Haider AH, 2007, J TRAUMA, V62, P1259, DOI 10.1097/TA.0b013e31803c760e; Haider AH, 2009, J SURG RES, V153, P138, DOI 10.1016/j.jss.2008.04.011; KNOPP R, 1988, ANN EMERG MED, V17, P895, DOI 10.1016/S0196-0644(88)80666-8; Love PF, 2009, J TRAUMA, V67, pS12, DOI 10.1097/TA.0b013e3181ac7f22; Maybury RS, 2010, SURGERY, V148, P202, DOI 10.1016/j.surg.2010.05.010; Moore Lynne, 2009, J Emerg Trauma Shock, V2, P73, DOI 10.4103/0974-2700.44774; Narci A, 2009, PEDIATR SURG INT, V25, P25, DOI 10.1007/s00383-008-2287-5; OSBERG JS, 1992, AM J PUBLIC HEALTH, V82, P422, DOI 10.2105/AJPH.82.3.422; Ott R, 2000, J TRAUMA, V49, P729, DOI 10.1097/00005373-200010000-00023; Oyetunji T, 2010, J SURG RES, V159, P627, DOI 10.1016/j.jss.2009.08.026; POLLOCK DA, 1989, JAMA-J AM MED ASSOC, V262, P2280, DOI 10.1001/jama.262.16.2280; Stallion A, 2007, J TRAUMA, V62, P1262; *STAT U NEW YORK B, 1997, GUID UN DAT SET MED; Sullivan T, 2003, J TRAUMA, V55, P1083, DOI 10.1097/01.TA.0000102175.58306.2A; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Tyroch AH, 2000, ARCH SURG-CHICAGO, V135, P1173, DOI 10.1001/archsurg.135.10.1173; WESSON D, 2006, PEDIAT TRAUMA PATHOP, P43	28	35	35	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0022-3468	1531-5037		J PEDIATR SURG	J. Pediatr. Surg.	AUG	2011	46	8					1557	1563		10.1016/j.jpedsurg.2011.04.055			7	Pediatrics; Surgery	Pediatrics; Surgery	808BZ	WOS:000293950100024	21843724				2021-06-18	
J	Dikeos, D; Georgantopoulos, G				Dikeos, Dimitris; Georgantopoulos, Georgios			Medical comorbidity of sleep disorders	CURRENT OPINION IN PSYCHIATRY			English	Article						excessive daytime sleepiness; hypersomnia; insomnia; periodic leg movements in sleep; rapid eye movement behaviour disorder; restless legs syndrome; sleep-related limb movements	RESTLESS LEGS SYNDROME; EXCESSIVE DAYTIME SLEEPINESS; LIMB MOVEMENT-DISORDER; TRAUMATIC BRAIN-INJURY; BEHAVIOR DISORDER; CARDIOVASCULAR-DISEASE; CLINICAL-FEATURES; PARKINSONS-DISEASE; CHRONIC INSOMNIA; IMPACT	Purpose of review Recently published literature indicates that sleep disorders present with medical comorbidities quite frequently. The coexistence of a sleep disorder with a medical disorder has a substantial impact for both the patient and the health system. Recent findings Insomnia and hypersomnia are highly comorbid with medical conditions, such as chronic pain and diabetes, as well as with various cardiovascular, respiratory, gastrointestinal, urinary and neurological disorders. Restless legs syndrome and periodic leg movement syndrome have been associated with iron deficiency, kidney disease, diabetes, and neurological, autoimmune, cardiovascular and respiratory disorders. Rapid eye movement behaviour disorder has been described as an early manifestation of serious central nervous system diseases; thus, close neurological monitoring of patients referring with this complaint is indicated. Summary Identification and management of any sleep disorder in medical patients is important for optimizing the course and prognosis. Of equal importance is the search for undetected medical disorder in patients presenting with sleep disorders.	[Dikeos, Dimitris; Georgantopoulos, Georgios] Univ Athens, Sch Med, Dept Psychiat 1, Athens 11528, Greece	Dikeos, D (corresponding author), Univ Athens, Sch Med, Eginit Hosp, Dept Psychiat 1, 72 Vas Sofias Ave, Athens 11528, Greece.	ddikeos@med.uoa.gr					Abad VC, 2008, SLEEP MED REV, V12, P211, DOI 10.1016/j.smrv.2007.09.001; Abbott RD, 2005, NEUROLOGY, V65, P1442, DOI 10.1212/01.wnl.0000183056.89590.0d; Al-Jahdali Hamdan H, 2010, J Circadian Rhythms, V8, P7, DOI 10.1186/1740-3391-8-7; Allen RP, 2003, SLEEP MED, V4, P101, DOI 10.1016/S1389-9457(03)00010-8; Allen RP, 2005, ARCH INTERN MED, V165, P1286, DOI 10.1001/archinte.165.11.1286; *AM SLEEP DIS ASS, 1997, PER LIMB MOV DIS, P65; American Academy of Sleep Medicine, 2005, INT CLASS SLEEP DIS, V2nd; Ancoli-Israel S, 2006, AM J MANAG CARE, V12, pS221; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Benediktsdottir B, 2010, SLEEP MED, V11, P1043, DOI 10.1016/j.sleep.2010.08.006; Bliwise DL, 2010, ANN NEUROL, V68, P353, DOI 10.1002/ana.22076; Bliwise DL, 2009, SLEEP MED, V10, P540, DOI 10.1016/j.sleep.2008.04.002; Bodkin CL, 2009, J WOMENS HEALTH, V18, P1955, DOI 10.1089/jwh.2008.1348; Bosco D, 2009, J NEUROL SCI, V287, P60, DOI 10.1016/j.jns.2009.09.008; Boulos MI, 2010, CAN J NEUROL SCI, V37, P167, DOI 10.1017/S0317167100009896; Brotini S, 2004, SLEEP MED, V5, P169, DOI 10.1016/j.sleep.2003.10.012; Castriotta RJ, 2009, J CLIN SLEEP MED, V5, P137; Cengic B., 2010, INT UROL NEPHROL; Chasens ER, 2009, DIABETES EDUCATOR, V35, P455, DOI 10.1177/0145721709333857; Chokroverty S, 2010, INDIAN J MED RES, V131, P126; Cuellar NG, 2008, DIABETES EDUCATOR, V34, P218, DOI 10.1177/0145721708314180; Cuellar NG, 2008, J CLIN SLEEP MED, V4, P50; Dang D, 2010, J NEUROL SCI, V290, P146, DOI 10.1016/j.jns.2009.12.007; Dembe AE, 2005, OCCUP ENVIRON MED, V62, P588, DOI 10.1136/oem.2004.016667; Ekbom K, 2009, J INTERN MED, V266, P419, DOI 10.1111/j.1365-2796.2009.02159.x; Ellmore TM, 2010, PARKINSONISM RELAT D, V16, P645, DOI 10.1016/j.parkreldis.2010.08.014; Ferentinos P, 2009, J PSYCHOSOM RES, V66, P37, DOI 10.1016/j.jpsychores.2008.07.009; Focke NK, 2010, SLEEP, V33, P731, DOI 10.1093/sleep/33.6.731; Foley KA, 2010, BEHAV SLEEP MED, V8, P90, DOI 10.1080/15402001003622842; Gagnon JF, 2006, LANCET NEUROL, V5, P424, DOI 10.1016/S1474-4422(06)70441-0; Gao XA, 2010, MOVEMENT DISORD, V25, P2654, DOI 10.1002/mds.23256; Gao X, 2009, NEUROLOGY, V72, P1255, DOI 10.1212/01.wnl.0000345673.35676.1c; Gemignani F, 2007, J PERIPHER NERV SYST, V12, P50, DOI 10.1111/j.1529-8027.2007.00116.x; George CFP, 2003, DRUGS, V63, P379, DOI 10.2165/00003495-200363040-00004; Gjerstad MD, 2002, NEUROLOGY, V58, P1544, DOI 10.1212/WNL.58.10.1544; Gottlieb DJ, 2005, ARCH INTERN MED, V165, P863, DOI 10.1001/archinte.165.8.863; Gureje O, 2009, INT J GERIATR PSYCH, V24, P686, DOI 10.1002/gps.2180; Hanly PJ, 2003, AM J KIDNEY DIS, V41, P403, DOI 10.1053/ajkd.2003.50066; HANYU H, 2010, EUR J NEUROL; Hening WA, 2008, SEMIN ARTHRITIS RHEU, V38, P55, DOI 10.1016/j.semarthrit.2007.09.001; Hornyak M, 2006, SLEEP MED REV, V10, P169, DOI 10.1016/j.smrv.2005.12.003; Ikehara S, 2009, SLEEP, V32, P295, DOI 10.1093/sleep/32.3.295; Iranzo A, 2009, SLEEP MED REV, V13, P385, DOI 10.1016/j.smrv.2008.11.003; Iwanami M, 2010, SLEEP MED, V11, P361, DOI 10.1016/j.sleep.2009.12.006; Kaplan Y, 2008, CAN J NEUROL SCI, V35, P352, DOI 10.1017/S0317167100008957; Katz DA, 1998, ARCH INTERN MED, V158, P1099, DOI 10.1001/archinte.158.10.1099; Kosmadakis GC, 2008, INT J ARTIF ORGANS, V31, P919; Koutsourelakis I, 2009, EUR RESPIR J, V34, P687, DOI 10.1183/09031936.00124708; Krouse HJ, 2008, J ASTHMA, V45, P389, DOI 10.1080/02770900801971800; Kushida C, 2007, QUAL LIFE RES, V16, P617, DOI 10.1007/s11136-006-9142-8; Lee K, 2004, SLEEP MED REV, V8, P199, DOI 10.1016/j.smrv.2003.10.001; Leger D, 2002, SLEEP, V25, P625; Lindberg E, 2001, AM J RESP CRIT CARE, V164, P2031, DOI 10.1164/ajrccm.164.11.2102028; Liu LQ, 2008, PSYCHIAT ANN, V38, P627, DOI 10.3928/00485713-20080901-01; Lo Coco D, 2010, MOVEMENT DISORD, V25, P2658, DOI 10.1002/mds.23261; Lo Coco D, 2009, SLEEP MED, V10, P572, DOI 10.1016/j.sleep.2008.04.014; Longstreth WT, 2009, SLEEP MED, V10, P422, DOI 10.1016/j.sleep.2008.05.009; Loo HV, 2008, J NEUROL SCI, V266, P145, DOI 10.1016/j.jns.2007.09.033; Lopes LA, 2005, DIABETES CARE, V28, P2633, DOI 10.2337/diacare.28.11.2633; MAHOWALD MW, 2005, PRINCIPLES PRACTICE, P897; McWhirter Dewey, 2007, Psychiatry (Edgmont), V4, P26; Merlino G, 2007, SLEEP, V30, P866, DOI 10.1093/sleep/30.7.866; Miyamoto T, 2008, SLEEP, V31, P717, DOI 10.1093/sleep/31.5.717; Nielsen TA, 2005, PRINCIPLES PRACTICE, P936, DOI DOI 10.1016/B0-72-160797-7/50085-9; Novak M, 2004, J PSYCHOSOM RES, V56, P527, DOI 10.1016/j.jpsychores.2004.02.007; Ohayon MM, 2006, ARCH INTERN MED, V166, P1262, DOI 10.1001/archinte.166.12.1262; Ohayon MM, 1997, SLEEP, V20, P340, DOI 10.1093/sleep/20.5.340; Ohayon MM, 2002, J PSYCHOSOM RES, V53, P547, DOI 10.1016/S0022-3999(02)00443-9; Ouellet MC, 2004, NEUROREHAB NEURAL RE, V18, P187, DOI 10.1177/1545968304271405; Paparrigopoulos T, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-531; Paparrigopoulos T, 2009, GEN HOSP PSYCHIAT, V31, P175, DOI 10.1016/j.genhosppsych.2008.09.016; Paparrigopoulos TJ, 2005, INT REV PSYCHIATR, V17, P293, DOI 10.1080/09540260500104540; Parish JM, 2009, CHEST, V135, P563, DOI 10.1378/chest.08-0934; Parker KP, 2003, AM J KIDNEY DIS, V41, P394, DOI 10.1053/ajkd.2003.50049; Peacock J, 2010, INDIAN J MED RES, V131, P338; Pierratos A, 2011, BLOOD PURIFICAT, V31, P146, DOI 10.1159/000321859; POLLMACHER T, 1993, SLEEP, V16, P572; Polydefkis M, 2000, NEUROLOGY, V55, P1115, DOI 10.1212/WNL.55.8.1115; Poryazova R, 2010, EUR NEUROL, V63, P129, DOI 10.1159/000276402; Postuma RB, 2009, NEUROLOGY, V72, P1296, DOI 10.1212/01.wnl.0000340980.19702.6e; Postuma RB, 2010, MOVEMENT DISORD, V25, P2304, DOI 10.1002/mds.23347; Rijsman RM, 1999, SLEEP MED REV, V3, P147, DOI 10.1016/S1087-0792(99)90021-7; Roth T, 2007, SLEEP MED, V8, pS1, DOI 10.1016/S1389-9457(08)70001-7; Roth T, 2009, AM J MANAG CARE, V15, pS6; Sabanayagam C, 2010, SLEEP, V33, P1037, DOI 10.1093/sleep/33.8.1037; Sagberg F, 2006, ACCIDENT ANAL PREV, V38, P28, DOI 10.1016/j.aap.2005.06.018; SALIH AM, 1994, BRIT J RHEUMATOL, V33, P60; Scherfler C, 2011, ANN NEUROL, V69, P400, DOI 10.1002/ana.22245; Schiza SE, 2010, SLEEP MED, V11, P149, DOI 10.1016/j.sleep.2009.07.016; Schlesinger I, 2009, MOVEMENT DISORD, V24, P1587, DOI 10.1002/mds.22486; Shaheen NJ, 2008, DIGEST DIS SCI, V53, P1493, DOI 10.1007/s10620-007-0057-1; Shneerson JM, 2005, SLEEP MED GUIDE SLEE, P125; Sivertsen B, 2009, J PSYCHOSOM RES, V67, P109, DOI 10.1016/j.jpsychores.2009.05.001; Skaer TL, 2010, PHARMACOECONOMICS, V28, P1015, DOI 10.2165/11537390-000000000-00000; Skomro RP, 2001, SLEEP MED, V2, P417, DOI 10.1016/S1389-9457(01)00110-1; Soldatos CR, 2000, J PSYCHOSOM RES, V48, P555, DOI 10.1016/S0022-3999(00)00095-7; Soldatos CR, 2005, SLEEP MED, V6, P5, DOI 10.1016/j.sleep.2004.10.006; Stockner H, 2009, MOVEMENT DISORD, V24, P1906, DOI 10.1002/mds.22483; Stroe AF, 2010, SLEEP MED, V11, P890, DOI 10.1016/j.sleep.2010.04.010; Sundberg R, 2010, RESP MED, V104, P337, DOI 10.1016/j.rmed.2009.10.017; Suzuki K, 2008, J NEUROL SCI, V271, P47, DOI 10.1016/j.jns.2008.03.008; Taylor DJ, 2007, SLEEP, V30, P213, DOI 10.1093/sleep/30.2.213; Taylor-Gjevre RM, 2010, JCR-J CLIN RHEUMATOL, V16, P255, DOI 10.1097/RHU.0b013e3181eeb2df; Taylor-Gjevre RM, 2009, JCR-J CLIN RHEUMATOL, V15, P12, DOI 10.1097/RHU.0b013e318190f94c; Ton TGN, 2009, NEUROEPIDEMIOLOGY, V32, P114, DOI 10.1159/000177037; Ulfberg J, 2007, SLEEP MED, V8, P768, DOI 10.1016/j.sleep.2006.11.015; van der Klaauw AA, 2007, J CLIN ENDOCR METAB, V92, P3898, DOI 10.1210/jc.2007-0944; Vgontzas AN, 2009, DIABETES CARE, V32, P1980, DOI 10.2337/dc09-0284; Walters AS, 2009, SLEEP, V32, P589, DOI 10.1093/sleep/32.5.589; Watson NF, 2005, J CLIN SLEEP MED, V1, P41; Winkelman JW, 2008, NEUROLOGY, V70, P35, DOI 10.1212/01.wnl.0000287072.93277.c9; Winkelman JW, 2006, SLEEP MED, V7, P545, DOI 10.1016/j.sleep.2006.01.004; Yoo SS, 2010, KOREAN J UROL, V51, P757, DOI 10.4111/kju.2010.51.11.757; Zambelis T, 2002, J NEUROL NEUROSUR PS, V72, P821, DOI 10.1136/jnnp.72.6.821; Zervas IM, 2009, MENOPAUSE, V16, P837, DOI 10.1097/gme.0b013e318196063e; Zoccolella S, 2011, SLEEP MED REV, V15, P41, DOI 10.1016/j.smrv.2010.02.004	116	35	35	0	16	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0951-7367	1473-6578		CURR OPIN PSYCHIATR	Curr. Opin. Psychiatr.	JUL	2011	24	4					346	354		10.1097/YCO.0b013e3283473375			9	Psychiatry	Psychiatry	769PS	WOS:000291030800015	21587079				2021-06-18	
J	Tate, RL; Simpson, GK; Soo, CA; Lane-Brown, AT				Tate, Robyn L.; Simpson, Grahame K.; Soo, Cheryl A.; Lane-Brown, Amanda T.			PARTICIPATION AFTER ACQUIRED BRAIN INJURY: CLINICAL AND PSYCHOMETRIC CONSIDERATIONS OF THE SYDNEY PSYCHOSOCIAL REINTEGRATION SCALE (SPRS)	JOURNAL OF REHABILITATION MEDICINE			English	Article						brain injuries; participation; community integration; assessment; psychometric properties	INTERNATIONAL CLASSIFICATION; REHABILITATION; DISABILITY; RECOVERY; OUTCOMES; HEALTH; QUESTIONNAIRE; ICF	Objective: To examine the psychometric qualities and develop the clinical utility of the Sydney Psychosocial Reintegration Scale (SPRS) as a measure of participation in people with traumatic brain injury. Design: Data generated from previous prospective studies. Subjects/patients: Convenience samples of healthy community-based volunteers (n=105) and people with severe brain injury (n=510). Methods: (i) The equivalence of a new 5-point version of the SPRS was determined vs the original 7-point version; (ii) construct validity was tested using Rasch analyses; (iii) normative and comparative data tables were produced, and data examined for floor/ceiling effects; (iv) a reliable change index score was generated. Results: Patterns of psychometric properties for the 5- and 7-point versions were almost identical (e.g. total scores r(s) =0.98). Rasch analyses on Forms A and B found good fit to the model, for person (3.36 and 3.03, respectively) and item (7.78 and 7.25, respectively) separation; reliability coefficients were high (all >= 0.90). Mean infit statistics met standard criteria (between 0.7 and 1.3). No floor/ceiling effects were detected. The reliable change index value was calculated for the total score for Form A using logit scores, and a conversion table provided. Conclusion: The 5-point version of the SPRS demonstrates strong psychometric qualities as a measure of participation after traumatic brain injury.	[Tate, Robyn L.; Simpson, Grahame K.; Soo, Cheryl A.; Lane-Brown, Amanda T.] Univ Sydney, Sydney Med Sch, No Clin Sch, Rehabil Studies Unit, Sydney, NSW 2006, Australia; [Tate, Robyn L.] Royal Rehabil Ctr Sydney, Sydney, NSW, Australia; [Simpson, Grahame K.] Liverpool Hosp, Brain Injury Rehabil Unit, Sydney, NSW, Australia; [Soo, Cheryl A.] Murdoch Childrens Res Inst, Melbourne, Vic, Australia	Tate, RL (corresponding author), Rehabil Studies Unit, POB 6, Ryde, NSW 1680, Australia.	rtate@med.usyd.edu.au	Simpson, Grahame K/W-1074-2019	Simpson, Grahame K/0000-0001-8156-9060	Motor Accidents Authority of New South Wales, Australia	We are grateful to Dr Mike Linacre for helpful advice on the Rasch analyses conducted for this paper. Acknowledgement is also made of the researchers who contributed data on the SPRS. Some of the studies on which this paper is based were supported by the Motor Accidents Authority of New South Wales, Australia.	Andresen EM, 2000, ARCH PHYS MED REHAB, V81, pS15, DOI 10.1053/apmr.2000.20619; Bode RK, 2000, J HEAD TRAUMA REHAB, V15, P637, DOI 10.1097/00001199-200002000-00004; Bogner JA, 2000, J HEAD TRAUMA REHAB, V15, P656, DOI 10.1097/00001199-200002000-00005; Delisa J, 1998, REHABILITATION MED P, P3; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; Fougeyrollas P, 1998, INT J REHABIL RES, V21, P127, DOI 10.1097/00004356-199806000-00002; Kervick RB, 2005, BRAIN INJURY, V19, P881, DOI 10.1080/02699050400025273; Kuipers P, 2004, BRAIN INJURY, V18, P161, DOI 10.1080/0269905031000149524; Lammi MH, 2005, ARCH PHYS MED REHAB, V86, P746, DOI 10.1016/j.apmr.2004.11.004; Ley P., 1972, QUANTITATIVE ASPECTS; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; Magasi S, 2010, ARCH PHYS MED REHAB, V91, pS17, DOI 10.1016/j.apmr.2010.07.011; Magasi S, 2009, J REHABIL MED, V41, P936, DOI 10.2340/16501977-0450; Malec J. F., 2003, MANUAL MAYO PORTLAND; Malec JF, 2003, J HEAD TRAUMA REHAB, V18, P479, DOI 10.1097/00001199-200311000-00002; MCHORNEY CA, 1995, QUAL LIFE RES, V4, P293, DOI 10.1007/BF01593882; Perdices M, 2005, BRAIN IMPAIR, V6, DOI [10.1375/brim.2005.6.3.219, DOI 10.1375/brim.2005.6.3.219]; Perenboom RJM, 2003, DISABIL REHABIL, V25, P577, DOI 10.1080/0963828031000137081; Post MWM, 2008, J REHABIL MED, V40, P620, DOI 10.2340/16501977-0223; Reistetter Timothy A, 2005, Occup Ther Int, V12, P196; Resnik L, 2009, ARCH PHYS MED REHAB, V90, P856, DOI 10.1016/j.apmr.2008.11.010; Simpson G., 2004, BRAIN IMPAIR, V5, DOI [10.1375/brim.5.1.67.35401, DOI 10.1375/BRIM.5.1.67.35401]; Streiner DL., 2003, HLTH MEASUREMENT SCA, V3rd; Tate R, 1999, J HEAD TRAUMA REHAB, V14, P543, DOI 10.1097/00001199-199912000-00003; Tate R, TRAUMATIC B IN PRESS; Tate R. L., 2010, COMPENDIUM TESTS SCA; Tate R.L., 2006, BRAIN IMPAIR, V7, P1, DOI DOI 10.1375/brim.7.1.1; Tate RL, 2004, ARCH PHYS MED REHAB, V85, P538, DOI 10.1016/j.apmr.2003.08.078; Tesio L, 2003, J REHABIL MED, V35, P105, DOI 10.1080/16501970310010448; Whiteneck GG, 1992, CRAIG HANDICAP ASSES; *WHO, 2000, DIS ASS SCHED; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009; WILSON BA, 1999, EXTENDED RIVERMEAD B; World Health Organization, 2001, INT CLASS FUNCT DIS	34	35	35	0	5	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	JUN	2011	43	7					609	618		10.2340/16501977-0829			10	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	787IF	WOS:000292369100006	21667008	DOAJ Gold			2021-06-18	
J	Kean, J; Malec, JF; Altman, IM; Swick, S				Kean, Jacob; Malec, James F.; Altman, Irwin M.; Swick, Shannon			Rasch Measurement Analysis of the Mayo-Portland Adaptability Inventory (MPAI-4) in a Community-Based Rehabilitation Sample	JOURNAL OF NEUROTRAUMA			English	Article						outcome measures; rehabilitation; TBI	BRAIN-INJURY; VALIDITY; MODEL; DIF	The precise measurement of patient outcomes depends upon clearly articulated constructs and refined clinical assessment instruments that work equally well for all subgroups within a population. This is a challenging task in those with acquired brain injury (ABI) because of the marked heterogeneity of the disorder and subsequent outcomes. Alhough essential, the iterative process of instrument refinement is often neglected. This present study was undertaken to examine validity, reliability, dimensionality and item estimate invariance of the Mayo-Portland Adaptability Inventory -4 (MPAI-4), an outcome measure for persons with ABI. The sampled population included 603 persons with traumatic ABI participating in a home-and community-based rehabilitation program. Results indicated that the MPAI-4 is a valid, reliable measure of outcome following traumatic ABI, which measures a broad but unitary core construct of outcome after ABI. Further, the MPAI-4 is composed of items that are unbiased toward selected subgroups except where differences could be expected [ e. g., more chronic traumatic brain injury (TBI) patients are better able to negotiate demands of transportation than more acute TBI patients]. We address the trade-offs between strict unidimensionality and clinical applicability in measuring outcome, and illustrate the advantages and disadvantages of applying single-parameter measurement models to broad constructs.	[Kean, Jacob; Malec, James F.] Indiana Univ, Sch Med, Dept PM&R, Indianapolis, IN 46254 USA; [Altman, Irwin M.] Gent Rehab Walls, Phoenix, AZ USA; [Swick, Shannon] Gent Rehab Walls, Marshall, MI USA	Kean, J (corresponding author), Indiana Univ, Sch Med, Dept PM&R, 4141 Shore Dr, Indianapolis, IN 46254 USA.	jakean@indiana.edu		Kean, Jacob/0000-0002-8577-0586	National Institute for Neurological Diseases and Stroke (NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)	This manuscript was prepared with support from a Small Business Technology Transfer (STTR) grant from the National Institute for Neurological Diseases and Stroke (NINDS).	Baghaei P., 2008, RASCH MEASUREMENT T, V22, P1145, DOI DOI 10.4304/JLTR.2.5.1052-1060; Bohac DL, 1997, BRAIN INJURY, V11, P469, DOI 10.1080/713802185; Clark LA, 1995, PSYCHOL ASSESSMENT, V7, P309, DOI 10.1037/1040-3590.7.3.309; Lezak M. D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI [10.1097/00001199-198703000-00009, DOI 10.1097/00001199-198703000-00009]; Linacre J.M., 1994, RASCH MEASUREMENT T, V7, P328; Linacre JM, 1994, RASCH MEASUREMENT T, V8, P360, DOI DOI 10.HTTPS://D0I.0RG/10.1177/097340820900300217; Linacre JM, 2008, WINSTEPS RASCH MODEL; Malec J., 2008, MANUAL MAYO PORTLAND; Malec JF, 2004, BRAIN INJURY, V18, P563, DOI 10.1080/02699050310001646134; Malec JF, 2002, ARCH PHYS MED REHAB, V83, P1759, DOI 10.1053/apmr.2002.36072; Malec JF, 2003, J HEAD TRAUMA REHAB, V18, P479, DOI 10.1097/00001199-200311000-00002; Malec JF, 2000, J HEAD TRAUMA REHAB, V15, P670, DOI 10.1097/00001199-200002000-00006; MALEC JF, 1995, MAYO CLIN PROC, V70, P1165, DOI 10.4065/70.12.1165; Malec JF, 2000, ARCH PHYS MED REHAB, V81, P1007, DOI 10.1053/apmr.2000.6980; Malec JF., 1994, J HEAD TRAUMA REHAB, V9, P1, DOI [10. 1097/ 00001199- 199412000- 00003, DOI 10.1097/00001199-199412000-00003]; Marais Ida, 2008, J Appl Meas, V9, P200; PEARSON JD, 1995, J ACOUST SOC AM, V97, P1196, DOI 10.1121/1.412231; Scott NW, 2009, J CLIN EPIDEMIOL, V62, P288, DOI 10.1016/j.jclinepi.2008.06.003; Smith Everett V Jr, 2002, J Appl Meas, V3, P205; Smith RM, 2003, J APPL MEAS, V4, P198; Tennant A, 2007, ARTHRIT RHEUM-ARTHR, V57, P1358, DOI 10.1002/art.23108; WILSON M, 1989, PSYCHOL BULL, V105, P276, DOI 10.1037/0033-2909.105.2.276; Zwick R, 1999, J EDUC MEAS, V36, P1, DOI 10.1111/j.1745-3984.1999.tb00543.x	23	35	35	0	8	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAY	2011	28	5					745	753		10.1089/neu.2010.1573			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	762JI	WOS:000290472100275	21332409	Green Published			2021-06-18	
J	Horste, GMZ; Miesbach, TA; Muller, JI; Fledrich, R; Stassart, RM; Kieseier, BC; Coleman, MP; Sereda, MW				Horste, Gerd Meyer Zu; Miesbach, Timo A.; Muller, Johanna I.; Fledrich, Robert; Stassart, Ruth M.; Kieseier, Bernd C.; Coleman, Michael P.; Sereda, Michael W.			The Wlds transgene reduces axon loss in a Charcot-Marie-Tooth disease 1A rat model and nicotinamide delays post-traumatic axonal degeneration	NEUROBIOLOGY OF DISEASE			English	Article						Wallerian-degeneration-slow; Charcot-Marie-Tooth disease 1A; CMT1A; Hereditary neuropathy; Axonal degeneration; Traumatic nerve injury; Nicotinamide	HUMAN NMN ADENYLYLTRANSFERASE; FOCAL CEREBRAL-ISCHEMIA; WALLERIAN DEGENERATION; ADENINE-DINUCLEOTIDE; IN-VIVO; INHERITED NEUROPATHIES; ENZYMATIC-ACTIVITY; ANIMAL-MODELS; NAD(+) LEVELS; BRAIN-INJURY	Charcot-Marie-Tooth disease (CMT) is the most common inherited neuropathy and a duplication of the peripheral myelin protein of 22 kDa (PMP22) gene causes the most frequent subform CMT1A. Clinical impairments are determined by the amount of axonal loss. Axons of the spontaneous mouse mutant Wallerian degeneration slow (Wlds) show markedly reduced degeneration following various types of injuries. Protection is conferred by a chimeric Wlds gene encoding an N-terminal part of ubiquitination factor Ube4b and full length nicotinamide mononucleotide adenylyl transferase 1 (Nmnat1). Nmnat1 enzyme generates nicotinamide adenine dinucleotide (NAD) from nicotinamide mononucleotide. Here, in a Pmp22 transgenic animal model of Charcot-Marie-Tooth disease type 1A (CMT rat), the Wlds transgene reduced axonal loss and clinical impairments without altering demyelination. Furthermore, nicotinamide - substrate precursor of the Nmnat1 enzyme - transiently delayed posttraumatic axonal degeneration in an in vivo model of acute peripheral nerve injury, but to a lower extent than Wlds. In contrast, 8 weeks of nicotinamide treatment did not influence axonal loss or clinical manifestations in the CMT rat. Therefore, nicotinamide can partially substitute for the protective Wlds effect in acute traumatic, but not in chronic secondary axonal injury. Future studies are needed to develop axon protective therapy in CMT1A which may be combined with therapeutic strategies aimed at downregulation of toxic PMP22 overexpression. (C) 2010 Elsevier Inc. All rights reserved.	[Sereda, Michael W.] Max Planck Inst Expt Med, Res Grp Mol & Translat Neurol, Dept Neurogenet, D-37075 Gottingen, Germany; [Horste, Gerd Meyer Zu; Muller, Johanna I.; Kieseier, Bernd C.] Univ Dusseldorf, Dept Neurol, D-40225 Dusseldorf, Germany; [Coleman, Michael P.] Babraham Inst, Mol Signalling Lab, Cambridge CB2 4AT, England; [Sereda, Michael W.] Univ Gottingen, Dept Clin Neurophysiol, D-37075 Gottingen, Germany	Sereda, MW (corresponding author), Max Planck Inst Expt Med, Res Grp Mol & Translat Neurol, Dept Neurogenet, Hermann Rein Str 3, D-37075 Gottingen, Germany.	sereda@em.mpg.de	Stassart, Ruth M/T-7093-2019; Fledrich, Robert/AAF-1590-2020; Fledrich, Robert/M-1911-2019; Meyer zu Horste, Gerd/O-9549-2016	Meyer zu Horste, Gerd/0000-0002-4341-4719	Max Planck SocietyMax Planck SocietyFoundation CELLEX; European UnionEuropean Commission; Departments of Clinical Neurophysiology and Neurology at the University of Gottingen; Del Marmol Foundation; BMBFFederal Ministry of Education & Research (BMBF) [FKZ01ES0801]; Research Commission of the Heinrich-Heine-University Dusseldorf; Fritz-Thyssen foundation	We thank Bianca Wolff and Tatjana Males for excellent technical assistance. We thank members of the Nave lab for continuous discussion and Anne K. Mausberg for critically reading the manuscript. This work was supported by the Max Planck Society and by grants of the European Union (to K.A.N.). M.W.S. was supported in part by the Departments of Clinical Neurophysiology and Neurology at the University of Gottingen, by the Del Marmol Foundation and by BMBF funding (FKZ01ES0801). G.M.z.H. was supported in part by grants from the Research Commission of the Heinrich-Heine-University Dusseldorf and from the Fritz-Thyssen foundation.	Adalbert R, 2005, EUR J NEUROSCI, V21, P271, DOI 10.1111/j.1460-9568.2004.03833.x; Araki T, 2004, SCIENCE, V305, P1010, DOI 10.1126/science.1098014; Avery MA, 2009, J CELL BIOL, V184, P501, DOI 10.1083/jcb.200808042; Babetto E, 2010, J NEUROSCI, V30, P13291, DOI 10.1523/JNEUROSCI.1189-10.2010; Beirowski B, 2004, J NEUROSCI METH, V134, P23, DOI 10.1016/j.jneumeth.2003.10.016; Beirowski B, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-6; Beirowski B, 2009, J NEUROSCI, V29, P653, DOI 10.1523/JNEUROSCI.3814-08.2009; Cai AL, 2006, EUR J NEUROSCI, V24, P2169, DOI 10.1111/j.1460-9568.2006.05110.x; Coleman M, 2005, NAT REV NEUROSCI, V6, P889, DOI 10.1038/nrn1788; Coleman MP, 1998, P NATL ACAD SCI USA, V95, P9985, DOI 10.1073/pnas.95.17.9985; Coleman MP, 2002, TRENDS NEUROSCI, V25, P532, DOI 10.1016/S0166-2236(02)02255-5; Conforti L, 2007, CELL DEATH DIFFER, V14, P116, DOI 10.1038/sj.cdd.4401944; Conforti L, 2009, J CELL BIOL, V184, P491, DOI 10.1083/jcb.200807175; DRAGOVIC J, 1995, RADIOTHER ONCOL, V36, P225, DOI 10.1016/0167-8140(95)01581-Z; Emanuelli M, 2001, J BIOL CHEM, V276, P406, DOI 10.1074/jbc.M008700200; Feng YZ, 2006, BRAIN RES BULL, V69, P117, DOI 10.1016/j.brainresbull.2005.11.011; Ferri A, 2003, CURR BIOL, V13, P669, DOI 10.1016/S0960-9822(03)00206-9; Garavaglia S, 2002, J BIOL CHEM, V277, P8524, DOI 10.1074/jbc.M111589200; Gilley J, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000300; Horste GMZ, 2006, CURR OPIN NEUROL, V19, P464, DOI 10.1097/01.wco.0000245369.44199.27; Kaneko S, 2006, J NEUROSCI, V26, P9794, DOI 10.1523/JNEUROSCI.2116-06.2006; KARLSSON U, 1965, J ULTRA MOL STRUCT R, V12, P160, DOI 10.1016/S0022-5320(65)80014-4; Kimura N, 2006, J NUTR SCI VITAMINOL, V52, P142, DOI 10.3177/jnsv.52.142; LUFT JH, 1961, J BIOPHYS BIOCHEM CY, V9, P409, DOI 10.1083/jcb.9.2.409; LUNN ER, 1989, EUR J NEUROSCI, V1, P27, DOI 10.1111/j.1460-9568.1989.tb00771.x; LUPSKI JR, 2005, PERIPHERAL NEUROPATH, P1659, DOI DOI 10.1016/B978-0-7216-9491-7.50073-9; Mack TGA, 2001, NAT NEUROSCI, V4, P1199, DOI 10.1038/nn770; Magni G, 1999, ADV ENZYMOL RAMB, V73, P135, DOI 10.1002/9780470123195.ch5; Maynard KI, 2001, ANN NY ACAD SCI, V939, P416; Meyer O A, 1979, Neurobehav Toxicol, V1, P233; Horste GMZ, 2007, ANN NEUROL, V61, P61, DOI 10.1002/ana.21026; Nave KA, 2007, NAT CLIN PRACT NEURO, V3, P453, DOI 10.1038/ncpneuro0583; Pareyson D, 2009, ADV EXP MED BIOL, V652, P207, DOI 10.1007/978-90-481-2813-6_14; Passage E, 2004, NAT MED, V10, P396, DOI 10.1038/nm1023; Press C, 2008, J NEUROSCI, V28, P4861, DOI 10.1523/JNEUROSCI.0525-08.2008; RIBCHESTER RR, 1995, EUR J NEUROSCI, V7, P1641, DOI 10.1111/j.1460-9568.1995.tb01159.x; Sadanaga-Akiyoshi F, 2003, NEUROCHEM RES, V28, P1227, DOI 10.1023/A:1024236614015; Sahenk Z, 2005, NEUROLOGY, V65, P681, DOI 10.1212/01.WNL.0000171978.70849.c5; Sahenk Z, 1999, ANN NEUROL, V45, P16, DOI 10.1002/1531-8249(199901)45:1<16::AID-ART5>3.0.CO;2-F; Sakakibara Y, 2002, BRAIN RES, V931, P68, DOI 10.1016/S0006-8993(02)02263-1; Samsam M, 2003, J NEUROSCI, V23, P2833; Sasaki Y, 2006, J NEUROSCI, V26, P8484, DOI 10.1523/JNEUROSCI.2320-06.2006; Sasaki Y, 2009, J NEUROSCI, V29, P6526, DOI 10.1523/JNEUROSCI.1429-09.2009; Sasaki Y, 2009, J NEUROSCI, V29, P5525, DOI 10.1523/JNEUROSCI.5469-08.2009; Sereda M, 1996, NEURON, V16, P1049, DOI 10.1016/S0896-6273(00)80128-2; Sereda MW, 2006, NEUROMOL MED, V8, P205, DOI 10.1385/NMM:8:1:205; Sereda MW, 2003, NAT MED, V9, P1533, DOI 10.1038/nm957; Shy M.E., 2005, PERIPHERAL NEUROPATH, V2, P1623; Timmerman V, 2006, NEUROMOL MED, V8, P1, DOI 10.1385/NMM:8:1:1; TSAO JW, 1994, EUR J NEUROSCI, V6, P516, DOI 10.1111/j.1460-9568.1994.tb00295.x; Wang J, 2005, J CELL BIOL, V170, P349, DOI 10.1083/jcb.200504028; Wang MS, 2001, ANN NEUROL, V50, P773, DOI 10.1002/ana.10039; Wang MS, 2002, ANN NEUROL, V52, P442, DOI 10.1002/ana.10300; Zhai RG, 2008, NATURE, V452, P887, DOI 10.1038/nature06721	54	35	35	0	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	APR	2011	42	1					1	8		10.1016/j.nbd.2010.12.006			8	Neurosciences	Neurosciences & Neurology	726MS	WOS:000287727000001	21168501				2021-06-18	
J	Lavinio, A; Menon, DK				Lavinio, Andrea; Menon, David K.			Intracranial pressure: why we monitor it, how to monitor it, what to do with the number and what's the future?	CURRENT OPINION IN ANESTHESIOLOGY			English	Article						intracranial pressure; monitoring; traumatic brain injury	CEREBRAL PERFUSION-PRESSURE; TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; VENTRICULAR DRAINAGE CATHETERS; CEREBROSPINAL-FLUID; CLINICAL ARTICLE; BLOOD-FLOW; RETROSPECTIVE ANALYSIS; INTENSIVE-CARE; EFFICACY	Purpose of review The review touches upon the current physiopathological concepts relating to the field of intracranial pressure (ICP) monitoring and offers an up-to-date overview of the ICP monitoring technologies and of the signal-analysis techniques relevant to clinical practice. Recent findings Improved ICP probes, antibiotic-impregnated ventricular catheters and multimodality, computerized systems allow ICP monitoring and individualized optimization of brain physiology. Noninvasive technologies for ICP and cerebral perfusion pressure assessment are being tested in the clinical arena. Computerized morphological analysis of the ICP pulse-waveform can provide an indicator of global cerebral perfusion. Summary Current recommendations for the management of traumatic brain injury indicate ICP monitoring in patients who remain comatose after resuscitation if the admission computed tomography scan reveals intracranial abnormalities such as haematomas, contusions and cerebral oedema. The most reliable methods of ICP monitoring are ventricular catheters and intraparenchymal systems. A growing number of these devices are being safely placed by neurointensivists. The consensus is to treat ICP exceeding the 20 mmHg threshold, and to target cerebral perfusion pressure between 50 and 70 mmHg. Recent evidence suggests that such thresholds should be optimized based on multimodality monitoring and individual brain physiology. Noninvasive ICP estimation using transcranial Doppler can have a role as a screening tool in patients with low to intermediate risk of developing intracranial hypertension. However, the technology remains insufficiently accurate and too cumbersome for continuous ICP monitoring.	[Lavinio, Andrea; Menon, David K.] Cambridge Univ Hosp Fdn Trust, Univ Div Anaesthesia, Cambridge, England	Lavinio, A (corresponding author), Addenbrookes Hosp, Dept Anaesthesia, BOX 93,Hills Rd, Cambridge CB2 0QQ, England.	a.lavinio@addenbrookes.nhs.uk	Lavinio, Andrea/M-1778-2016		Royal College of Anaesthetists; Medical Research Council (UK)UK Research & Innovation (UKRI)Medical Research Council UK (MRC); National Institute for Health ResearchNational Institute for Health Research (NIHR); Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986, G9439390] Funding Source: researchfish	D. K. M. is funded by the BOC Professorship of the Royal College of Anaesthetists, the Medical Research Council (UK), and by the National Institute for Health Research.	Al-Tamimi YZ, 2009, NEUROSURGERY, V64, P94, DOI 10.1227/01.NEU.0000328392.98602.5A; Balestreri M, 2006, NEUROCRIT CARE, V4, P8, DOI 10.1385/NCC:4:1:008; BAUER DF, 2010, J TRAUMA; Beer R, 2008, J NEUROL, V255, P1617, DOI 10.1007/s00415-008-0059-8; Belli A, 2008, ACTA NEUROCHIR, V150, P461, DOI 10.1007/s00701-008-1580-3; Birch AA, 2006, NEUROCRIT CARE, V5, P51, DOI 10.1385/NCC:5:1:51; Brady KM, 2010, STROKE, V41, P1957, DOI 10.1161/STROKEAHA.109.575167; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Brandi G, 2010, ACTA NEUROCHIR, V152, P965, DOI 10.1007/s00701-010-0643-4; Bratton SL, 2007, J NEUROTRAUMA S1, V24, P555, DOI DOI 10.1089/NEU.2007.9988; Bremmer R, 2010, NEUROCRIT CARE, V12, P362, DOI 10.1007/s12028-009-9329-2; Citerio G, 2008, NEUROSURGERY, V63, P1152, DOI 10.1227/01.NEU.0000335148.87042.D7; Coles JP, 2007, CRIT CARE MED, V35, P568, DOI 10.1097/01.CCM.0000254066.37187.88; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; Dahlqvist Mats B, 2010, J Med Case Rep, V4, P297, DOI 10.1186/1752-1947-4-297; DAVSON H, 1973, BRAIN, V96, P329, DOI 10.1093/brain/96.2.329; Ehtisham A, 2009, NEUROCRIT CARE, V10, P241, DOI 10.1007/s12028-008-9097-4; Fichtner J, 2010, J NEUROSURG, V112, P840, DOI 10.3171/2009.8.JNS091297; FIZ JA, 1993, CHEST, V104, P1203, DOI 10.1378/chest.104.4.1203; Flibotte JJ, 2004, NEUROCRIT CARE, V1, P61, DOI 10.1385/NCC:1:1:61; Forsyth RJ, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002043.pub2; Geeraerts T, 2008, CRIT CARE, V12, DOI 10.1186/cc7006; Geeraerts T, 2009, BIOMARK MED, V3, P129, DOI 10.2217/BMM.09.6; Georgiadis D, 2001, STROKE, V32, P2088, DOI 10.1161/hs0901.095406; Hetem DJ, 2010, J NEUROSURG, V113, P1309, DOI 10.3171/2010.6.JNS10258; Hu X, 2010, PHYSIOL MEAS, V31, P679, DOI 10.1088/0967-3334/31/5/006; Hutchinson PJA, 2000, BRIT J NEUROSURG, V14, P46; Jaeger M, 2010, CRIT CARE MED, V38, P1343, DOI 10.1097/CCM.0b013e3181d45530; LASSEN NA, 1959, PHYSIOL REV, V39, P183; Lavinio A, 2008, EUR J ANAESTH, V25, P137, DOI 10.1017/S0265021507003298; Leverstein-van Hall MA, 2010, J NEUROSURG, V112, P345, DOI 10.3171/2009.6.JNS09223; Lo CH, 2007, J NEUROSURG, V106, P378, DOI 10.3171/jns.2007.106.3.378; Lozier AP, 2008, NEUROSURGERY, V62, P688, DOI [10.1227/01.NEU.0000017465.78245.6C, 10.1227/01.neu.0000316273.35833.7c]; Maitinez-Manas RM, 2000, J NEUROL NEUROSUR PS, V69, P82, DOI 10.1136/jnnp.69.1.82; Matevosyan K, 2011, J NEUROSURG, V114, P3, DOI 10.3171/2010.7.JNS091699; Muttaiyah S, 2010, J CLIN NEUROSCI, V17, P296, DOI 10.1016/j.jocn.2009.06.016; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; O'Neill BR, 2008, SURG NEUROL, V70, P268, DOI 10.1016/j.surneu.2007.05.007; Petkus V, 2002, ULTRASONICS, V40, P829, DOI 10.1016/S0041-624X(02)00216-0; Piek J, 1996, NEUROSURGERY, V38, P216, DOI 10.1097/00006123-199601000-00051; Querfurth HW, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-106; Schmidt B, 2008, ACTA NEUROCHIR SUPPL, V102, P49, DOI 10.1007/978-3-211-85578-2_10; Schmidt Bernhard, 2002, Eur J Ultrasound, V16, P37, DOI 10.1016/S0929-8266(02)00044-7; Schmidt EA, 2005, ACTA NEUROCHIR SUPPL, V95, P253; Shafi S, 2008, J TRAUMA, V64, P335, DOI 10.1097/TA.0b013e31815dd017; Shimbles S, 2005, ACTA NEUROCHIR SUPPL, V95, P197; Smielewski P, 2008, ACTA NEUROCHIR SUPPL, V102, P145, DOI 10.1007/978-3-211-85578-2_30; Smith M, 2008, ANESTH ANALG, V106, P240, DOI 10.1213/01.ane.0000297296.52006.8e; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Stocchetti N, 2001, INTENS CARE MED, V27, P400, DOI 10.1007/s001340000825; Venkatesh B, 2004, INTENS CARE MED, V30, P510, DOI 10.1007/s00134-003-2102-7; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Zabramski JM, 2003, J NEUROSURG, V98, P725, DOI 10.3171/jns.2003.98.4.0725; Zweifel C, 2010, J NEUROTRAUM, V27, P1951, DOI 10.1089/neu.2010.1388; Zweifel C, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E2	57	35	43	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0952-7907	1473-6500		CURR OPIN ANESTHESIO	Curr. Opin. Anesthesiol.	APR	2011	24	2					117	123		10.1097/ACO.0b013e32834458c5			7	Anesthesiology	Anesthesiology	732AS	WOS:000288154100001	21293261				2021-06-18	
J	Hanten, G; Cook, L; Orsten, K; Chapman, SB; Li, XQ; Wilde, EA; Schnelle, KP; Levin, HS				Hanten, Gerri; Cook, Lori; Orsten, Kimberley; Chapman, Sandra B.; Li, Xiaoqi; Wilde, Elisabeth A.; Schnelle, Kathleen P.; Levin, Harvey S.			Effects of traumatic brain injury on a virtual reality social problem solving task and relations to cortical thickness in adolescence	NEUROPSYCHOLOGIA			English	Article						TBI; Adolescents; Virtual reality; Social problem solving; Brain structure	HUMAN ORBITOFRONTAL CORTEX; TEMPORAL-LOBE ACTIVATIONS; ENVIRONMENT TECHNOLOGY; CEREBRAL-CORTEX; CHILDREN; MEMORY; MODERATE; OUTCOMES; SKILLS; MRI	Social problem solving was assessed in 28 youth ages 12-19 years (15 with moderate to severe traumatic brain injury (TBI), 13 uninjured) using a naturalistic, computerized virtual reality (VR) version of the Interpersonal Negotiations Strategy interview (Yeates, Schultz, & Selman, 1991). In each scenario, processing load condition was varied in terms of number of characters and amount of information. Adolescents viewed animated scenarios depicting social conflict in a virtual microworld environment from an avatar's viewpoint, and were questioned on four problem solving steps: defining the problem, generating solutions, selecting solutions, and evaluating the likely outcome. Scoring was based on a developmental scale in which responses were judged as impulsive, unilateral, reciprocal, or collaborative, in order of increasing score. Adolescents with TBI were significantly impaired on the summary VR-Social Problem Solving (VR-SPS) score in Condition A (2 speakers, no irrelevant information), p = 0.005: in Condition B (2 speakers + irrelevant information), p = 0.035; and Condition C (4 speakers + irrelevant information), p = 0.008. Effect sizes (Cohen's D) were large (A = 1.40, B = 0.96, C = 1.23). Significant group differences were strongest and most consistent for defining the problems and evaluating outcomes. The relation of task performance to cortical thickness of specific brain regions was also explored, with significant relations found with orbitofrontal regions, the frontal pole, the cuneus, and the temporal pole. Results are discussed in the context of specific cognitive and neural mechanisms underlying social problem solving deficits after childhood TBI. (C) 2010 Elsevier Ltd. All rights reserved.	[Hanten, Gerri; Orsten, Kimberley; Li, Xiaoqi; Wilde, Elisabeth A.; Schnelle, Kathleen P.; Levin, Harvey S.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Cook, Lori; Chapman, Sandra B.] Univ Texas Dallas, Ctr Brain Hlth, Dallas, TX 75235 USA; [Wilde, Elisabeth A.; Levin, Harvey S.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; [Wilde, Elisabeth A.] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [Wilde, Elisabeth A.; Levin, Harvey S.] Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA	Hanten, G (corresponding author), Baylor Coll Med, Dept Phys Med & Rehabil, 1709 Dryden Rd,Suite 1200, Houston, TX 77030 USA.	ghanten@bcm.tmc.edu			National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER	This research was supported by grant number R01NS021889 from the National Institute of Neurological Disorders and Stroke. The authors would also like to thank Alyssa Ibarra for her assistance with the task sentence structure analysis.	Adolphs R, 2001, NEUROPSYCHOLOGY, V15, P396, DOI 10.1037//0894-4105.15.3.396; Babu S., 2007, IEEE VIRT REAL C CHA; BEARDSLEE WR, 1987, DEV PSYCHOL, V23, P807, DOI 10.1037/0012-1649.23.6.807; Bechara A, 2005, NAT NEUROSCI, V8, P1458, DOI 10.1038/nn1584; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Biocca F, 2003, PRESENCE-VIRTUAL AUG, V12, P456, DOI 10.1162/105474603322761270; Blascovich J, 2002, PSYCHOL INQ, V13, P103, DOI 10.1207/S15327965PLI1302_01; Bray S, 2010, J NEUROPHYSIOL, V103, P2506, DOI 10.1152/jn.01030.2009; Chapman SB, 2006, BRAIN LANG, V97, P178, DOI 10.1016/j.bandl.2005.10.002; Cho S, 2010, CEREB CORTEX, V20, P524, DOI 10.1093/cercor/bhp121; COBB SVG, 2007, INT J VIRTUAL REALIT, V6, P51; Crockford DN, 2005, BIOL PSYCHIAT, V58, P787, DOI 10.1016/j.biopsych.2005.04.037; Cromby J.J., 1996, P 1 EUR C DIS VIRT R; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; DESPOSITO M, 2008, MENTAL PROCESSES HUM, P7; Dodge K.A., 1985, CHILDRENS PEER RELAT, P3; Dolan RS, 2000, NEUROIMAGE, V11, P203, DOI 10.1006/nimg.2000.0538; Dotsch R, 2008, J EXP SOC PSYCHOL, V44, P1194, DOI 10.1016/j.jesp.2008.03.003; Fischl B, 2004, NEUROIMAGE, V23, pS69, DOI 10.1016/j.neuroimage.2004.07.016; Fischl B, 2001, IEEE T MED IMAGING, V20, P70, DOI 10.1109/42.906426; Freeman D, 2008, BRIT J PSYCHIAT, V192, P258, DOI 10.1192/bjp.bp.107.044677; Gamino JF, 2009, TOP LANG DISORD, V29, P224, DOI 10.1097/TLD.0b013e3181b531da; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Haldane M, 2008, J PSYCHOPHARMACOL, V22, P138, DOI 10.1177/0269881107082955; Han X, 2006, NEUROIMAGE, V32, P180, DOI 10.1016/j.neuroimage.2006.02.051; Hanten G, 2004, ANN NEUROL, V56, P847, DOI 10.1002/ana.20298; Hanten G, 2002, CHILD NEUROPSYCHOL, V8, P107, DOI 10.1076/chin.8.2.107.8729; Hanten G, 2008, NEUROPSYCHOLOGY, V22, P357, DOI 10.1037/0894-4105.22.3.357; Heeter C., 1992, PRESENCE CAMB, V1, P262, DOI DOI 10.1162/PRES.1992.1.2.262; JACOBY S, 2006, 6 INT C DIS VIRT REA; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; Johnson MH, 2005, DEV PSYCHOBIOL, V46, P287, DOI 10.1002/dev.20057; Jovicich J, 2006, NEUROIMAGE, V30, P436, DOI 10.1016/j.neuroimage.2005.09.046; Kim J, 2008, NEUROIMAGE, V39, P1014, DOI 10.1016/j.neuroimage.2007.10.005; Kohlberg L., 1969, STAGE SEQUENCE COGNI; Kringelbach ML, 2005, NAT REV NEUROSCI, V6, P691, DOI 10.1038/nrn1747; Kuperberg GR, 2003, ARCH GEN PSYCHIAT, V60, P878, DOI 10.1001/archpsyc.60.9.878; LAVIOLA JJ, 2008, ADV INFORM KNOWLEDGE, P225; LEE KH, 2009, SOCIAL COGNITION AFF; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; LIVATINO S, 2007, HDB EVALUATION STUDI, P2007; LLOYD J, 2006, P 6 INT C DIS VIRT R; Loomis JM, 1999, BEHAV RES METH INS C, V31, P557, DOI 10.3758/BF03200735; Matheis RJ, 2007, CLIN NEUROPSYCHOL, V21, P146, DOI 10.1080/13854040601100668; McCauley SR, 2010, DEV NEUROPSYCHOL, V35, P318, DOI 10.1080/87565641003696866; Merkley TL, 2008, J NEUROTRAUM, V25, P1343, DOI 10.1089/neu.2008.0615; Mitchell P, 2007, J AUTISM DEV DISORD, V37, P589, DOI 10.1007/s10803-006-0189-8; Moore K, 2002, CYBERPSYCHOL BEHAV, V5, P197, DOI 10.1089/109493102760147178; MORRIS RG, 2006, P 6 INT C DIS VIRT R; Morrison RG, 2004, J COGNITIVE NEUROSCI, V16, P260, DOI 10.1162/089892904322984553; O'Doherty JP, 2007, ANN NY ACAD SCI, V1121, P254, DOI 10.1196/annals.1401.036; Oni MB, 2010, J CHILD NEUROL, V25, P976, DOI 10.1177/0883073809356034; Parsons S, 2004, J AUTISM DEV DISORD, V34, P449, DOI 10.1023/B:JADD.0000037421.98517.8d; Parsons S, 2002, J INTELL DISABIL RES, V46, P430, DOI 10.1046/j.1365-2788.2002.00425.x; Parsons S, 2006, COMPUT EDUC, V47, P186, DOI 10.1016/j.compedu.2004.10.003; Rankin KP, 2006, BRAIN, V129, P2945, DOI 10.1093/brain/awl254; Reinkensmeyer DJ, 2007, 2007 VIRTUAL REHABILITATION, P42; Riva G, 2007, CYBERPSYCHOL BEHAV, V10, P45, DOI 10.1089/cpb.2006.9993; ROLLS ET, 1994, J NEUROL NEUROSUR PS, V57, P1518, DOI 10.1136/jnnp.57.12.1518; Rosas HD, 2002, NEUROLOGY, V58, P695, DOI 10.1212/WNL.58.5.695; Royet JP, 2000, J NEUROSCI, V20, P7752; Salat DH, 2004, CEREB CORTEX, V14, P721, DOI 10.1093/cercor/bhh032; Schacter DL, 1999, HIPPOCAMPUS, V9, P7, DOI 10.1002/(SICI)1098-1063(1999)9:1<7::AID-HIPO2>3.0.CO;2-K; Schilbach L, 2006, NEUROPSYCHOLOGIA, V44, P718, DOI 10.1016/j.neuropsychologia.2005.07.017; Schmidt AT, 2010, NEUROPSYCHOLOGIA, V48, P2869, DOI 10.1016/j.neuropsychologia.2010.05.029; Segonne F, 2004, NEUROIMAGE, V22, P1060, DOI 10.1016/j.neuroimage.2004.03.032; Semel E., 2003, CLIN EVALUATION LANG; Slobounov S, 2006, CYBERPSYCHOL BEHAV, V9, P188, DOI 10.1089/cpb.2006.9.188; Stewart L, 2001, NEUROPSYCHOLOGIA, V39, P1, DOI 10.1016/S0028-3932(00)00084-1; TEASDALE G, 1974, LANCET, V2, P81; Tonks J, 2007, BRAIN INJURY, V21, P731, DOI 10.1080/02699050701426899; Trenholme David, 2008, Virtual Reality, V12, P181, DOI 10.1007/s10055-008-0092-z; Tsujimoto S, 2010, NAT NEUROSCI, V13, P120, DOI 10.1038/nn.2453; Turkstra LS, 2004, NEUROREHABILITATION, V19, P245; Turkstra LS, 2001, J HEAD TRAUMA REHAB, V16, P469, DOI 10.1097/00001199-200110000-00006; Virvou M, 2008, COMPUT EDUC, V50, P154, DOI 10.1016/j.compedu.2006.04.004; Waltz JA, 1999, PSYCHOL SCI, V10, P119, DOI 10.1111/1467-9280.00118; Wechsler D., 2011, WECHLSER ABBREVIATED; Weiderholt JL., 2001, GRAY ORAL READING TE, V4th; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; YEATES KO, 1991, MERRILL PALMER QUART, V37, P369; YEATES KO, 1990, CLIN PSYCHOL REV, V10, P567, DOI 10.1016/0272-7358(90)90097-T	84	35	37	2	21	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia	FEB	2011	49	3					486	497		10.1016/j.neuropsychologia.2010.12.007			12	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	728YH	WOS:000287909900021	21147137	Green Accepted			2021-06-18	
J	Kontos, AP; Elbin, RJ; Covassin, T; Larson, E				Kontos, Anthony P.; Elbin, Robert J., III; Covassin, Tracey; Larson, Elizabeth			Exploring Differences in Computerized Neurocognitive Concussion Testing Between African American and White Athletes	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Head injury; Traumatic brain injury; Cross-cultural; minority; Assessment	NEUROPSYCHOLOGICAL TEST-PERFORMANCE; TRAUMATIC BRAIN-INJURY; DEMOGRAPHIC-VARIABLES; WAIS-III; IMPACT; RACE; EDUCATION; RECOVERY; ACCULTURATION; CHILDREN	The purpose of the current study was to explore potential differences in pre- and post-concussion performance on a computerized neurocognitive concussion test between African American and White high-school and collegiate student-athletes. A prospective case-control design was used to compare baseline and 2- and 7-day post-concussion computerized neurocognitive performance and symptoms between 48 White and 48 African American athletes matched for age, gender, and concussion history. The Immediate Post-Concussion Assessment Cognitive Test (ImPACT) version 2.0 (NeuroHealth System, LLC, Pittsburgh, PA, USA) computer software program was used to assess neurocognitive function (i.e., verbal and visual memory, motor processing speed, and reaction time) and concussion symptoms. Regardless of race/ethnicity, there were significant decrements in computerized neurocognitive performance and increased symptoms following a concussion for the entire sample. African Americans and Whites did not differ significantly on baseline or post-concussion verbal memory, visual memory, reaction time, and total reported symptoms. However, African American participants were 2.4x more likely to have at least one clinically significant cognitive decline on ImPACT at 7 days post-concussion and scored lower at 7 days post-concussion compared with baseline on processing speed than White participants. The authors concluded that the baseline ImPACT test was culturally equivalent and construct valid for use with these two racial/ethnic groups. However, in contrast, the findings support deleterious performance for the African American athletes compared with the White athletes on the ImPACT post-concussion evaluation that is of critical clinical relevance and warrants further research.	[Kontos, Anthony P.] UPMC Ctr Sports Med, UPMC Sports Concuss Program, Pittsburgh, PA 15203 USA; [Kontos, Anthony P.; Larson, Elizabeth] Humboldt State Univ, Arcata, CA 95521 USA; [Elbin, Robert J., III] E Tennessee State Univ, Johnson City, TN 37614 USA; [Covassin, Tracey] Michigan State Univ, E Lansing, MI 48824 USA	Kontos, AP (corresponding author), UPMC Ctr Sports Med, UPMC Sports Concuss Program, Pittsburgh, PA 15203 USA.	akontos@pitt.edu		Kontos, Anthony/0000-0002-3749-4310			BAGLEY C, 1995, SOC SCI MED, V40, P1017, DOI 10.1016/0277-9536(94)00318-N; Barth JT., 1989, MILD HEAD INJURY, P257; Buzzini SRR, 2006, CURR OPIN PEDIATR, V18, P376, DOI 10.1097/01.mop.0000236385.26284.ec; Cantu Robert C, 2006, Neurosurg Focus, V21, pE3; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Feinstein L, 2003, ECONOMICA, V70, P73, DOI 10.1111/1468-0335.t01-1-00272; FERRARO F, 2005, ALZHEIMERS DIS ASS D, V19, P74; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Fullilove MT, 1998, AM J PUBLIC HEALTH, V88, P1297, DOI 10.2105/AJPH.88.9.1297; Gartland S, 2001, BRIT J SPORT MED, V35, P308, DOI 10.1136/bjsm.35.5.308; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; Heaton RK., 1996, NEUROPSYCHOL ASSESS, V2, P141; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Iverson GL, 2002, ARCH CLIN NEUROPSYCH, V17, P770; JENSEN AR, 1982, PERS INDIV DIFFER, V3, P423, DOI 10.1016/0191-8869(82)90007-1; KANE RL, 1992, NEUROPSYCHOL REV, V3, P1, DOI 10.1007/BF01108787; KAUFMAN AS, 1988, J CLIN PSYCHOL, V44, P231, DOI 10.1002/1097-4679(198803)44:2<231::AID-JCLP2270440224>3.0.CO;2-J; Kelly JP, 1997, NEUROLOGY, V48, P581; Kennepohl S, 2004, J INT NEUROPSYCH SOC, V10, P566, DOI 10.1017/S1355617704104128; Kesler SR, 2003, APPL NEUROPSYCHOL, V10, P153, DOI 10.1207/S15324826AN1003_04; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lovell Mark R, 2002, Curr Sports Med Rep, V1, P287; LYNN R, 1990, SOC BEHAV PERSONAL, V18, P299, DOI 10.2224/sbp.1990.18.2.299; Manly JJ, 1998, J INT NEUROPSYCH SOC, V4, P291, DOI 10.1017/S1355617798002914; Manly JJ, 2005, CLIN NEUROPSYCHOL, V19, P270, DOI 10.1080/13854040590945346; Manly JJ, 2002, J INT NEUROPSYCH SOC, V8, P341, DOI 10.1017/S1355617702813157; Mayfield JW, 1997, ARCH CLIN NEUROPSYCH, V12, P111, DOI 10.1016/S0887-6177(96)00016-9; McCrory P, 2005, BRIT J SPORT MED, V39, DOI 10.1136/bjsm.2004.014860; McKay PF, 2003, J BUS PSYCHOL, V18, P1, DOI 10.1023/A:1025062703113; Mehta KM, 2004, J AM GERIATR SOC, V52, P2120, DOI 10.1111/j.1532-5415.2004.52575.x; Nell V, 1999, S AFR J PSYCHOL, V29, P128, DOI 10.1177/008124639902900305; Noble KG, 2005, DEVELOPMENTAL SCI, V8, P74, DOI 10.1111/j.1467-7687.2005.00394.x; O'Bryant SE, 2004, CLIN NEUROPSYCHOL, V18, P229, DOI 10.1080/13854040490501439; Reeves DL, 2007, ARCH CLIN NEUROPSYCH, V22, pS15, DOI 10.1016/j.acn.2006.10.013; Reynolds C.R., 1994, TEST MEMORY LEARNING; Sandifer H, 2005, J MED SPEECH-LANG PA, V13, P1; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Shuttleworth-Edwards AB, 2004, J CLIN EXP NEUROPSYC, V26, P903, DOI 10.1080/13803390490510824; Shuttleworth-Edwards AB, 2008, J CLIN EXP NEUROPSYC, V30, P870, DOI 10.1080/13803390701846914; Shuttleworth-Edwards Ann B, 2009, Phys Sportsmed, V37, P45, DOI 10.3810/psm.2009.12.1741; Stern Y, 1999, NEUROLOGY, V53, P1942, DOI 10.1212/WNL.53.9.1942; Teng EL, 2005, ALZ DIS ASSOC DIS, V19, P267, DOI 10.1097/01.wad.0000190805.13126.8e; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Williams DR, 1997, ANN EPIDEMIOL, V7, P322, DOI 10.1016/S1047-2797(97)00051-3	49	35	35	0	12	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	DEC	2010	25	8					734	744		10.1093/arclin/acq068			11	Psychology, Clinical; Psychology	Psychology	679KE	WOS:000284159500004	20861034	Bronze, Green Published			2021-06-18	
J	Lee, HC; Chuang, HC; Cho, DY; Cheng, KF; Lin, PH; Chen, CC				Lee, Han-Chung; Chuang, Hao-Che; Cho, Der-Yang; Cheng, Kuang-Fu; Lin, Pao-Hsuan; Chen, Chun-Chung			Applying Cerebral Hypothermia and Brain Oxygen Monitoring in Treating Severe Traumatic Brain Injury	WORLD NEUROSURGERY			English	Article						Brain tissue oxygen; Cerebral perfusion pressure; Glasgow Outcome Scale; Hypothermia; Intracranial pressure; Traumatic brain injury; Treatment process capability	SEVERE HEAD-INJURY; PROMISING TREATMENT MODALITY; THERAPEUTIC HYPOTHERMIA; PERFUSION-PRESSURE; TISSUE OXYGEN; INTRACRANIAL-PRESSURE; METABOLISM; OPPORTUNITIES; TEMPERATURE; MANAGEMENT	BACKGROUND: Severe traumatic brain injury (TBI) was to be one of the major health problems encountered in modern medicine and had an incalculable socioeconomic impact. The initial cerebral damage after acute brain injury is often exacerbated by postischemic hyperthermia and worsens the outcome. Hypothermia is one of the current therapies designed to combat this deleterious effect. The brain tissue oxygen (PtiO2)-guided cerebral perfusion pressure (CPP) management was successfully reduced because of cerebral hypoxic episodes following TBI. MATERIALS AND METHODS: Forty-five patients with severe TBI whose Glasgow Coma Scale (GCS) score ranged between 4 and 8 during September 2006 and August 2007 were enrolled in China Medical University Hospital, Taichung, Taiwan. One patient with a GCS score of 3 was excluded for poor outcome. These patients were randomized into three groups. Group A (16 patients) was intracranial pressure/cerebral perfusion pressure (ICP/CPP)-guided management only, Group B (15 patients) was ICP/CPP guided with mild hypothermia, and Group C (14 patients) was combined mild hypothermia and PtiO2 guided with CPP management on patients with severe TBI. All patients were treated with ICP/CPP management (ICP <20 mm Hg, CPP >60 mm Hg). However, the group with PtiO2 monitoring was required to raise the PtiO2 above 20 mm Hg. Length of intensive care unit stay, ICP, PtiO2, Glasgow Outcome Scale (GOS) score, mortality, and complications were analyzed. RESULTS: The ICP values progressively increased in the first 3 days but showed smaller changes in hypothermia groups (Groups B and C) and were significantly lower than those of the normothermia group (Group A) at the same time point. We also found out that the averaged ICP were significantly related to days and the daily variations [measured as (daily observation - daily group mean)(2)] of ICP were shown to the significantly different among three treatment groups after the third posttraumatic day. The values of PtiO2 in Group C tended to rise when the ICP decreased were also observed. A favorable outcome is divided by the result of GOS scores. The percentage of favorable neurologic outcome was 50% in the normothermia group, 60% in the hypothermia-only group, and 71.4% in the PtiO2 group, with statistical significance. The percentage of mortality was 12.5% in the normothermia group, 6.7% in the hypothermia-only group, and 8.5% in the PtiO2 group, without statistical significance in three groups. Complications included pulmonary infections, peptic ulcer, and leukocytopenia (43.8% in the normothermia group, 55.6% in the hypothermia-only group, and 50% in the PtiO2 group). CONCLUSIONS: Therapeutic mild hypothermia combined with PtiO2-guided CPP/ICP management allows reducing elevated ICP before 24 hours after injury, and daily variations of ICP were shown to be significantly different among the three treatment groups after the third posttraumatic day. It means that the hypothermia groups may reduce the ICP earlier and inhibit the elicitation of acute inflammation after cerebral contusion. Our data also provided evidence that early treatment that lowers PtiO2 may improve the outcome and seems the best medical treatment method in these three groups. We concluded that therapeutic mild hypothermia combined with PtiO2-guided CPP/ICP management provides beneficial effects when treating TBI, and a multicenter randomized trial needs to be undertaken.	[Lee, Han-Chung; Chuang, Hao-Che; Cho, Der-Yang; Chen, Chun-Chung] China Med Univ Hosp, Dept Neurosurg, Taichung, Taiwan; [Cheng, Kuang-Fu; Lin, Pao-Hsuan] China Med Univ, Ctr Biostat, Taichung, Taiwan	Chen, CC (corresponding author), China Med Univ Hosp, Dept Neurosurg, Taichung, Taiwan.	braintumorgbm@yahoo.com.tw			China Medical University Hospital, Taichung, Taiwan, Republic of China [DMR 96 IRB55]	This study was supported by grant DMR 96 IRB55 from the China Medical University Hospital, Taichung, Taiwan, Republic of China. The authors declare that the article content was composed in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.	CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chiu WT, 2003, J TRAUMA, V55, P391, DOI 10.1097/01.TA.0000079368.15678.6D; Cho DY, 2006, NEUROSURGERY, V58, P866, DOI 10.1227/01.NEU.0000209892.42585.9B; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; CRUZ J, 1995, CRIT CARE MED, V23, P1412, DOI 10.1097/00003246-199508000-00016; Dings J, 1998, NEUROSURGERY, V43, P1082, DOI 10.1097/00006123-199811000-00045; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; Huang SJ, 2006, J CLIN NEUROSCI, V13, P818, DOI 10.1016/j.jocn.2005.11.034; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; Kochanek PA, 2003, JAMA-J AM MED ASSOC, V289, P3007, DOI 10.1001/jama.289.22.3007; Liu WG, 2006, J INT MED RES, V34, P58, DOI 10.1177/147323000603400107; Maxwell WL, 2005, J NEUROTRAUM, V22, P873, DOI 10.1089/neu.2005.22.873; Meixensberger J, 2003, J NEUROL NEUROSUR PS, V74, P760, DOI 10.1136/jnnp.74.6.760; MEIXENSBERGER J, 1993, ACTA NEUROCHIR, P28; Patterson Jessica, 2005, J Neurosci Nurs, V37, P236; Polderman KH, 2004, INTENS CARE MED, V30, P556, DOI 10.1007/s00134-003-2152-x; Polderman KH, 2004, INTENS CARE MED, V30, P757, DOI 10.1007/s00134-003-2151-y; Prabhakaran P, 2004, J NEUROSURG, V100, P454, DOI 10.3171/ped.2004.100.5.0454; Reilly PL, 2001, J CLIN NEUROSCI, V8, P398, DOI 10.1054/jocn.2001.0916; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Sakurai A, 2003, ACTA NEUROCHIR SUPPL, V86, P251; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; Thompson HJ, 2005, J CEREBR BLOOD F MET, V25, P163, DOI 10.1038/sj.jcbfm.9600008; Tokutomi T, 2003, NEUROSURGERY, V52, P102, DOI 10.1097/00006123-200301000-00013; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; Wang H, 2004, J NEUROSURG, V100, P272, DOI 10.3171/jns.2004.100.2.0272	28	35	40	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	DEC	2010	74	6					654	660		10.1016/j.wneu.2010.06.019			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	793IP	WOS:000292814100025	21492636				2021-06-18	
J	Miotto, EC; Cinalli, FZ; Serrao, VT; Benute, GG; Lucia, MCS; Scaff, M				Miotto, Eliane Correa; Cinalli, Fernanda Zanetti; Serrao, Valeria Trunkl; Benute, Glaucia Guerra; Souza Lucia, Mara Cristina; Scaff, Milberto			Cognitive deficits in patients with mild to moderate traumatic brain injury	ARQUIVOS DE NEURO-PSIQUIATRIA			English	Article						traumatic brain injury; cognitive deficits; mild to moderate level	ATTENTION	Traumatic brain injury (TBI) is one of the most frequent causes of brain damage. Cognitive deficits reported in the literature after moderate to severe TBI include memory, language, executive functions, attention and information processing speed impairments. However, systematic studies on patients with mild TBI are scarce although neuropsychological changes are present. Objective: To investigate the cognitive functioning of patients with mild to moderate TBI. Method: We evaluated 12 patients with mild to moderate TBI using a comprehensive protocol (PN01) of neuropsychological tests. Results: There were significant deficits of episodic memory including immediate and delayed verbal memory recall, verbal recognition, immediate and delayed visual memory recall, naming, verbal fluency and information processing speed. Conclusion: These results emphasize the importance of comprehensive neuropsychological assessments even in cases of mild TBI in order to identify impaired and preserved functions providing adequate managing including rehabilitation programs for each case.	[Miotto, Eliane Correa; Serrao, Valeria Trunkl; Benute, Glaucia Guerra; Souza Lucia, Mara Cristina] Univ Sao Paulo, Sch Med, Hosp Clin, Div Psychol,IC, Sao Paulo, Brazil; [Cinalli, Fernanda Zanetti] Univ Sao Paulo, Sch Med, IC Hosp Clin, Div Psychol, Sao Paulo, Brazil; [Miotto, Eliane Correa; Souza Lucia, Mara Cristina; Scaff, Milberto] Univ Sao Paulo, Sch Med, Dept Neurol, Sao Paulo, Brazil	Miotto, EC (corresponding author), ICHC FMUSP, Div Psychol, Av Dr Eneas de Carvalho 155, BR-05403900 Sao Paulo, Brazil.	ecmiotto@usp.br	Miotto, Eliane C/B-5380-2013; Benute, Glaucia R/P-8050-2016	Miotto, Eliane C/0000-0003-2711-1627; Benute, Glaucia R/0000-0003-4545-1887; Guerra Benute, Glaucia Rosana/0000-0003-0781-1976			BENEDICT RHB, 1997, BRIEF VISUALSPATIAL; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Bigler ED, 2007, NEUROPSYCHOLOGY, V21, P515, DOI 10.1037/0894-4105.21.5.515; Brandt J., 2001, HOPKINS VERBAL LEARN; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; de la Plata CAM, 2008, ARCH PHYS MED REHAB, V89, P896, DOI 10.1016/j.apmr.2007.12.030; Fleminger S, 2008, EUR J ANAESTH, V25, P123, DOI 10.1017/S0265021507003250; Ghajar J, 2008, NEUROREHAB NEURAL RE, V22, P217, DOI 10.1177/1545968308315600; GIL R, 2005, NEUROPSICOLOGIA, P1; Gouveia PA, 2004, NEUROPSICOLOGIA HOJE, P297; Hopkins RO, 2005, NEUROPSYCHOLOGY, V19, P233, DOI 10.1037/0894-4105.19.2.233; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Koizumi MS, 2000, ARQ NEURO-PSIQUIAT, V58, P81, DOI 10.1590/S0004-282X2000000100013; Kurca E, 2006, NEURORADIOLOGY, V48, P661, DOI 10.1007/s00234-006-0109-9; Mathias JL, 2007, NEUROPSYCHOLOGY, V21, P212, DOI 10.1037/0894-4105.21.2.212; Nascimento E., 2004, ESCALA INTELIGENCIA; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; O'Jile JR, 2006, ARCH CLIN NEUROPSYCH, V21, P293, DOI 10.1016/j.acn.2006.03.003; Ringe WK, 2002, ASSESSMENT, V9, P254, DOI 10.1177/1073191102009003004; Saunders JC, 2006, NEUROPSYCHOLOGY, V20, P224, DOI 10.1037/0894-4105.20.2.224; Smith A., 2002, SYMBOL DIGIT MODALIT; Strangman GE, 2008, ARCH PHYS MED REHAB, V89, P974, DOI 10.1016/j.apmr.2008.02.011; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Strauss E., 1998, COMPENDIUM NEUROPSYC, V2nd; TEASDALE G, 1974, LANCET, V2, P81; *WHO, NEUR; Ziino C, 2006, NEUROPSYCHOLOGY, V20, P383, DOI 10.1037/0894-4105.20.3.383	27	35	43	0	15	ASSOC ARQUIVOS NEURO- PSIQUIATRIA	SAO PAULO SP	PR AMADEU AMARAL 47/33, 01327-010 SAO PAULO SP, BRAZIL	0004-282X	1678-4227		ARQ NEURO-PSIQUIAT	Arq. Neuro-Psiquiatr.	DEC	2010	68	6					862	868		10.1590/S0004-282X2010000600006			7	Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	707WA	WOS:000286319900006	21243242	DOAJ Gold			2021-06-18	
J	Shahin, H; Gopinath, SP; Robertson, CS				Shahin, Hazem; Gopinath, Shankar P.; Robertson, Claudia S.			Influence of Alcohol on Early Glasgow Coma Scale in Head-Injured Patients	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Alcohol; Intoxication; Traumatic brain injury; Glasgow Coma Scale	TRAUMATIC BRAIN-INJURY; ACUTE ETHANOL INTOXICATION; RATS; SEVERITY; POTENTIATION; DAMAGE; EXCITOTOXICITY; INGESTION; ISCHEMIA; STROKE	Background: To assess the depressant effects of alcohol on the level of consciousness of patients admitted with head injuries, this study examined the changes that occur in the Glasgow Coma Scale (GCS) of traumatic brain injury patients over time. Methods: The records of 269 head trauma patients consecutively admitted to the neurosurgery intensive care unit were examined retrospectively. Eighty-one patients were excluded because of incomplete data. The remaining 188 patients were further divided into an intoxicated group (blood alcohol concentration [BAC] >= 0.08%, n = 100 [53%]) and a nonintoxicated group (BAC <0.08%, n = 88 [47%]). The GCS in the prehospital setting, in the emergency department, and the highest GCS achieved during the first 24 hours postinjury were compared. Results: The change between emergency department-GCS and the best day 1 GCS in the intoxicated group was greater than the nonintoxicated group and deemed clinically and statistically significant; median change (3 vs. 0) p < 0.001. To assess whether these results were directly related to the BAC%, piecewise regression using a general linear model was used to assess the intercept and slope of alcohol on the changes of GCS with cutting point at BAC% = 0.08. The analysis showed that, in the nonintoxicated range, the effect of alcohol was not significantly related to the changes of GCS. But in the intoxicated range, BAC% was significantly positively related to the changes of GCS. Conclusion: This study concludes that the GCS increases significantly over time in alcohol intoxicated patients with traumatic brain injury.	[Shahin, Hazem] Baylor Coll Med, Dept Neurosurg, BCM 650, Houston, TX 77030 USA	Shahin, H (corresponding author), Baylor Coll Med, Dept Neurosurg, BCM 650, 1709 Dryden Rd,Suite 750, Houston, TX 77030 USA.	shahinhazem@yahoo.com			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P01-NS38660]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS038660] Funding Source: NIH RePORTER	Data collection was funded in part by NIH Grant No P01-NS38660.	ALBIN MS, 1986, CRIT CARE MED, V14, P841, DOI 10.1097/00003246-198610000-00001; ALTURA BM, 1983, SCIENCE, V220, P331, DOI 10.1126/science.6836278; BAUGHMAN VL, 1990, J NEUROSURG ANESTH, V2, P290, DOI 10.1097/00008506-199012000-00007; Blondell RD, 2002, J STUD ALCOHOL, V63, P380, DOI 10.15288/jsa.2002.63.380; BRICKLEY MR, 1995, INJURY, V26, P311, DOI 10.1016/0020-1383(95)00034-7; BRODNER RA, 1981, J TRAUMA, V21, P124, DOI 10.1097/00005373-198102000-00005; CHANDLER LJ, 1993, ALCOHOL CLIN EXP RES, V17, P54, DOI 10.1111/j.1530-0277.1993.tb00726.x; ChathamShowalter PE, 1996, PSYCHOSOMATICS, V37, P285, DOI 10.1016/S0033-3182(96)71567-0; Crews FT, 1998, PHARMACOL BIOCHEM BE, V59, P981, DOI 10.1016/S0091-3057(97)00538-8; Dash PK, 2004, J NEUROTRAUM, V21, P1573, DOI 10.1089/neu.2004.21.1573; DELANEY KA, 2000, HEAD INJURY; DEYKIN D, 1982, NEW ENGL J MED, V306, P852, DOI 10.1056/NEJM198204083061406; ELMER O, 1984, HAEMOSTASIS, V14, P223; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Fiorentino D., 2000, HS809028 NAT HIGHW T; FLAMM ES, 1977, J NEUROSURG, V46, P328, DOI 10.3171/jns.1977.46.3.0328; GALBRAITH S, 1976, BRIT J SURG, V63, P128, DOI 10.1002/bjs.1800630210; Golan JD, 2007, J TRAUMA, V63, P365, DOI 10.1097/TA.0b013e31811ec178; HAUT MJ, 1974, AM J MED, V56, P22, DOI 10.1016/0002-9343(74)90747-5; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HOLT S, 1980, BRIT MED J, V281, P638, DOI 10.1136/bmj.281.6241.638; HUTH JF, 1983, J TRAUMA, V23, P494, DOI 10.1097/00005373-198306000-00009; INGLIS FM, 1990, ACT NEUR S, V51, P277; JAGGER J, 1984, NEUROSURGERY, V15, P303, DOI 10.1227/00006123-198409000-00002; Janis LS, 1998, J NEUROTRAUM, V15, P105, DOI 10.1089/neu.1998.15.105; JENNETT B, 1977, LANCET, V1, P878; Johnston JJE, 2004, EMERG MED J, V21, P185, DOI 10.1136/emj.2003.006130; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KELLY DF, 1995, J NEUROTRAUM, V12, P883, DOI 10.1089/neu.1995.12.883; Kelly DF, 1997, J NEUROSURG, V86, P876, DOI 10.3171/jns.1997.86.5.0876; Kelly MP, 1997, BRAIN INJURY, V11, P391, DOI 10.1080/026990597123386; LAHAYE PA, 2000, TRAUMA, P377; Macewen William, 1879, Glasgow Med J, V11, P1; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MODELL JG, 1990, NEW ENGL J MED, V323, P455, DOI 10.1056/NEJM199008163230706; Morris GF, 1998, NEUROSURGERY, V43, P1369, DOI 10.1097/00006123-199812000-00063; NATH FP, 1986, INJURY, V17, P150, DOI 10.1016/0020-1383(86)90320-7; Pastorek NJ, 2004, J INT NEUROPSYCH SOC, V10, P807, DOI 10.1017/S1355617704106012; PERSSON L, 1977, ACTA NEUROL SCAND, V56, P7; PIKAAR NA, 1987, METABOLISM, V36, P538, DOI 10.1016/0026-0495(87)90163-6; Piriyawat P, 2003, STROKE, V34, P1242, DOI 10.1161/01.STR.0000067706.23777.04; PORIES SE, 1992, J TRAUMA, V32, P60, DOI 10.1097/00005373-199201000-00013; SALCMAN M, 1981, NEUROSURGERY, V8, P15; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; Shapira Y, 1997, J NEUROSURG ANESTH, V9, P118, DOI 10.1097/00008506-199704000-00003; SHAPIRA Y, 1994, STROKE, V25, P1637, DOI 10.1161/01.STR.25.8.1637; SLOAN EP, 1989, J TRAUMA, V29, P1647, DOI 10.1097/00005373-198912000-00011; Sperry JL, 2006, J TRAUMA, V61, P1305, DOI 10.1097/01.ta.0000240113.13552.96; Sternbach GL, 2000, J EMERG MED, V19, P67, DOI 10.1016/S0736-4679(00)00182-7; Strong R, 2000, NEUROPHARMACOLOGY, V39, P515, DOI 10.1016/S0028-3908(99)00156-2; Stuke L, 2007, ANN SURG, V245, P651, DOI 10.1097/01.sla.0000250413.41265.d3; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; TEASDALE G, 1974, LANCET, V2, P81; Tien HCN, 2006, ARCH SURG-CHICAGO, V141, P1185, DOI 10.1001/archsurg.141.12.1185; Tureci E, 2004, NEUROL RES, V26, P108, DOI 10.1179/016164104225013699; WARD RE, 1982, AM J SURG, V144, P153, DOI 10.1016/0002-9610(82)90617-1; YAMAKAMI I, 1995, J NEUROSURG, V82, P813, DOI 10.3171/jns.1995.82.5.0813	57	35	36	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	NOV	2010	69	5					1176	1181		10.1097/TA.0b013e3181edbd47			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	678VK	WOS:000284110100041	21068620	Green Accepted			2021-06-18	
J	Seo, TB; Kim, BK; Ko, IG; Kim, DH; Shin, MS; Kim, CJ; Yoon, JH; Kim, H				Seo, Tae-Beom; Kim, Bo-Kyun; Ko, Il-Gyu; Kim, Dong-Hyun; Shin, Mal-Soon; Kim, Chang-Ju; Yoon, Jin-Hwan; Kim, Hong			Effect of treadmill exercise on Purkinje cell loss and astrocytic reaction in the cerebellum after traumatic brain injury	NEUROSCIENCE LETTERS			English	Article						Cerebellum; Traumatic brain injury; Purkinje cells; Reactive astrocytes; Treadmill exercise	LATERAL FLUID PERCUSSION; CORTICAL IMPACT INJURY; SYNAPTIC PLASTICITY; COGNITIVE FUNCTION; TIME-COURSE; RATS; DEGENERATION; EXCITOTOXICITY; VULNERABILITY; EXPRESSION	The cerebellum is one of the brain areas, which is selectively vulnerable to forebrain traumatic brain injuries (TBI). Physical exercise in animals is known to promote cell survival and functional recovery after brain injuries. However, the detailed pathologic and functional alterations by exercise following an indirect cerebellar injury induced by a TBI are largely unknown. We determined the effects of treadmill exercise on survival of Purkinje neurons and on a population of reactive astrocytes in the gyrus of lobules VIII and IX of the cerebellum after TBI. The rats were divided into four groups: the sham-operation group, the sham-operation with exercise group, the TBI-induction group, and the TBI-induction with exercise group. Cell biological changes of Purkinje neurons following indirect cerebellar injury were analyzed by immunohistochemistry. TBI-induced loss of calbindin-stained Purkinje neurons in the posterior region of the cerebellum and TBI also increased formation of reactive astroyctes in both the granular and molecular layers of the cerebellar posterior region. Treadmill exercise for 10 days after TBI increased the number of calbindin-stained Purkinje neurons and suppressed formation of reactive astroyctes. The present study provides the possibility that treadmill exercise may be an important mediator to enhance survival of Purkinje neurons in TBI-induced indirect cerebellar injury. (C) 2010 Elsevier Ireland Ltd. All rights reserved.	[Kim, Hong] Daegu Haany Univ, Dept Oriental Sports Med, Gyongsan 712715, Gyeongsangbuk D, South Korea; [Seo, Tae-Beom; Kim, Bo-Kyun; Ko, Il-Gyu; Kim, Dong-Hyun; Shin, Mal-Soon; Kim, Chang-Ju] Kyung Hee Univ, Coll Med, Dept Physiol, Seoul 130701, South Korea; [Yoon, Jin-Hwan] Hannam Univ, Dept Sports Sci, Taejon 306791, South Korea	Kim, H (corresponding author), Daegu Haany Univ, Dept Oriental Sports Med, Gyongsan 712715, Gyeongsangbuk D, South Korea.	joshua@dhu.ac.kr	Kim, Chang Ju/M-4216-2017; Kim, Dong-Hyun/AAH-3043-2020	Kim, Chang Ju/0000-0003-4749-5795; Jin-Hwan, yoon/0000-0001-9026-6416	Daegu Haany University Ky.lin Foundation	This research was supported by a grant from Daegu Haany University Ky.lin Foundation in 2008.	Ai JL, 2007, EXP BRAIN RES, V177, P95, DOI 10.1007/s00221-006-0654-9; Ai JL, 2002, NEUROSCI LETT, V332, P155, DOI 10.1016/S0304-3940(02)00945-X; BEDFORD TG, 1979, J APPL PHYSIOL, V47, P1278; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; BRORSON JR, 1994, J NEUROSCI, V14, P187; Carbonnel WS, 1999, ACTA NEUROPATHOL, V98, P396, DOI 10.1007/s004010051100; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; Cotman CW, 2002, TRENDS NEUROSCI, V25, P295, DOI 10.1016/S0166-2236(02)02143-4; D'Hooge R, 2001, BRAIN RES REV, V36, P60, DOI 10.1016/S0165-0173(01)00067-4; Ding Q, 2006, NEUROSCIENCE, V140, P823, DOI 10.1016/j.neuroscience.2006.02.084; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Fukuda K, 1996, J NEUROTRAUM, V13, P255, DOI 10.1089/neu.1996.13.255; GALE SD, 1995, J NEUROTRAUM, V12, P151, DOI 10.1089/neu.1995.12.151; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; Griesbach GS, 2004, BRAIN RES, V1016, P154, DOI 10.1016/j.brainres.2004.04.079; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; Igarashi T, 2007, EXP NEUROL, V203, P258, DOI 10.1016/j.expneurol.2006.08.030; Jang MH, 2002, NEUROSCI LETT, V322, P29, DOI 10.1016/S0304-3940(02)00076-9; Klintsova AY, 2004, BRAIN RES, V1028, P92, DOI 10.1016/j.brainres.2004.09.003; Kramer AF, 1999, NATURE, V400, P418, DOI 10.1038/22682; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; OHearn E, 1997, J NEUROSCI, V17, P8828; Park E, 2007, PROG BRAIN RES, V161, P327, DOI 10.1016/S0079-6123(06)61023-6; Park E, 2006, J NEUROPATH EXP NEUR, V65, P226, DOI 10.1097/01.jnen.0000202888.29705.93; Ploughman M, 2009, STROKE, V40, P1490, DOI 10.1161/STROKEAHA.108.531806; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Spanos GK, 2007, AM J NEURORADIOL, V28, P537; Strahlendorf JC, 1996, BRAIN RES, V729, P197, DOI 10.1016/S0006-8993(96)00367-8; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; van Praag H, 1999, NAT NEUROSCI, V2, P266; Vaynman S, 2004, EUR J NEUROSCI, V20, P2580, DOI 10.1111/j.1460-9568.2004.03720.x; Viscomi MT, 2009, CEREBELLUM, V8, P184, DOI 10.1007/s12311-009-0107-7	39	35	36	0	6	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	SEP 13	2010	481	3					178	182		10.1016/j.neulet.2010.06.087			5	Neurosciences	Neurosciences & Neurology	642NB	WOS:000281220600010	20603186				2021-06-18	
J	Chevignard, MP; Catroppa, C; Galvin, J; Anderson, V				Chevignard, Mathilde P.; Catroppa, Cathy; Galvin, Jane; Anderson, Vicki			Development and Evaluation of an Ecological Task to Assess Executive Functioning Post Childhood TBI: The Children's Cooking Task	BRAIN IMPAIRMENT			English	Article						child; traumatic brain injury; executive functions; ecological assessment; naturalistic task; validity	TRAUMATIC BRAIN-INJURY; BEHAVIOR RATING INVENTORY; PERFORMANCE-BASED MEASURES; FRONTAL-LOBE DAMAGE; YOUNG-CHILDREN; HEAD TRAUMA; OUTCOMES; VALIDITY; TESTS; DEFICITS	Purpose: Traumatic brain injury (TBI) often leads to executive functions deficits, which may be responsible for severe and longstanding disabilities in everyday activities. Sensitivity and ecological validity of neuropsychological tests of executive functions have been questioned. The aims of this study were to pilot an ecological open-ended assessment of executive functions in children, the 'Children's Cooking Task' (CCT), specifically to report its reliability, discriminant validity and concurrent validity. Methods: Twenty-five children with mild (n = 10) or moderate-to-severe TBI (n = 15), and 21 matched controls (aged 8 to 20 years) participated in the study. An open-ended cooking task was designed to test multi-tasking abilities. It required the preparation of two simple recipes using specific instructions. Outcome measures included the number of errors and an overall qualitative analysis of the task. Validating measures of executive functions included the Delis Kaplan Executive Function System, the Six-Part Test and two questionnaires completed by the child's primary care-giver: the Behavior Rating Inventory of Executive Function and the Dysexecutive Questionnaire for Children. Results: Internal consistency of the Children's Cooking Task was high (Cronbach's alpha = .86), as was test-retest reliability (ICC = .89). Children with moderate-to-severe TBI, as well as children with mild TBI made significantly more errors in the Children's Cooking Task in comparison to controls (p < .001). The CCT was correlated with several tests and one questionnaire of executive functioning (Trails, verbal fluency, sorting, 20 questions, Dysexecutive Questionnaire). Discussion and Conclusion: The Children's Cooking Task has good interrater and test-retest reliability, as well as good discriminant and concurrent validity.	[Chevignard, Mathilde P.] Hop Natl St Maurice, Rehabil Dept Children Acquired Brain Injuries, 14 Rue Val dOsne, F-94410 St Maurice, France; [Chevignard, Mathilde P.] Univ Paris 06, Grp Hosp Pitie, ER UPMC 6, F-75252 Paris 05, France; [Chevignard, Mathilde P.; Catroppa, Cathy; Galvin, Jane; Anderson, Vicki] Royal Childrens Hosp, Dept Psychol, Murdoch Childrens Res Inst, Australian Ctr Child Neuropsychol Studies, Melbourne, Vic, Australia; [Galvin, Jane] La Trobe Univ, Sch Occupat Therapy, Melbourne, Vic, Australia; [Galvin, Jane] Royal Childrens Hosp, Victorian Paediat Rehabil Serv, Melbourne, Vic, Australia; [Catroppa, Cathy; Anderson, Vicki] Univ Melbourne, Dept Psychol Sci, Melbourne, Vic 3010, Australia	Chevignard, MP (corresponding author), Hop Natl St Maurice, Rehabil Dept Children Acquired Brain Injuries, 14 Rue Val dOsne, F-94410 St Maurice, France.	m.chevignard@hopital-saint-maurice.fr			Hopital National de Saint Maurice, France; University Paris 6; 'France Traumatisme Cranien - Societe Francaise de Medecine Physique et de Readaptation' (FTC-SOFMER); 'Societe Francophone d'Etude et de Recherche sur les Handicaps de l'Enfance' (SFERHE)	This work was supported by the Hopital National de Saint Maurice, France; by the University Paris 6, and by two grants awarded by 'France Traumatisme Cranien - Societe Francaise de Medecine Physique et de Readaptation' (FTC-SOFMER) and 'Societe Francophone d'Etude et de Recherche sur les Handicaps de l'Enfance' (SFERHE).	Anderson P, 2002, CHILD NEUROPSYCHOL, V8, P71, DOI 10.1076/chin.8.2.71.8724; Anderson V, 1998, NEUROPSYCHOL REHABIL, V8, P319, DOI 10.1080/713755568; Anderson V, 2001, Pediatr Rehabil, V4, P119, DOI 10.1080/13638490110091347; Anderson VA, 2002, CHILD NEUROPSYCHOL, V8, P231, DOI 10.1076/chin.8.4.231.13509; Anderson VA, 2000, BRAIN INJURY, V14, P679; Andresen EM, 2000, ARCH PHYS MED REHAB, V81, pS15, DOI 10.1053/apmr.2000.20619; Atchison BT, 1998, AM J OCCUP THER, V52, P843, DOI 10.5014/ajot.52.10.843; BAUM C, 1993, AM J OCCUP THER, V47, P431, DOI 10.5014/ajot.47.5.431; Burgess P. W., 1996, BEHAV ASSESSMENT DYS; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Chapparo C., 1997, OCCUPATIONAL PERFORM, V1, P189; Chaytor N, 2003, NEUROPSYCHOL REV, V13, P181, DOI 10.1023/B:NERV.0000009483.91468.fb; Chevignard M, 2000, CORTEX, V36, P649, DOI 10.1016/S0010-9452(08)70543-4; Chevignard MP, 2008, NEUROPSYCHOL REHABIL, V18, P461, DOI 10.1080/09602010701643472; Chevignard MP, 2009, DEV NEUROREHABIL, V12, P76, DOI 10.1080/17518420902777019; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Crowe L., 2009, INT NEUR SOC MIDY M, P51; Daniel A. E., 1983, POWER PRIVILEGE PRES; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Denckla MB, 2002, CHILD NEUROPSYCHOL, V8, P304, DOI 10.1076/chin.8.4.304.13512; Donders J, 2007, J HEAD TRAUMA REHAB, V22, P296, DOI 10.1097/01.HTR.0000290974.01872.82; Duncan J, 1996, COGNITIVE PSYCHOL, V30, P257, DOI 10.1006/cogp.1996.0008; Emslie H, 2003, BEHAV ASSESMENT DYSE; Eslinger PJ, 2004, BRAIN COGNITION, V55, P84, DOI 10.1016/s0278-2626(03)00281-1; ESLINGER PJ, 1992, ARCH NEUROL-CHICAGO, V49, P764, DOI 10.1001/archneur.1992.00530310112021; Eslinger PJ, 1999, DEV NEUROPSYCHOL, V15, P157, DOI 10.1080/87565649909540744; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Fortin S, 2003, CORTEX, V39, P273, DOI 10.1016/S0010-9452(08)70109-6; Fry K, 2002, AUSTR OCCUPATIONAL T, V49, P182, DOI 10.1046/j.1440-1630.2002.00337.x; Garth J, 1997, Pediatr Rehabil, V1, P99; Gioia G.A., 2000, BEHAV RATING INVENTO; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Gioia GA, 2002, CHILD NEUROPSYCHOL, V8, P121, DOI 10.1076/chin.8.2.121.8727; Hanten G, 2008, NEUROPSYCHOLOGY, V22, P357, DOI 10.1037/0894-4105.22.3.357; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; Kelly T., 2000, CLIN NEUROPSYCHOL, V1, P38; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Levin HS, 2005, PEDIATR NEUROL, V33, P79, DOI 10.1016/j.pediatrneurol.2005.02.002; LEVIN HS, 1991, DEV NEUROPSYCHOL, V7, P377, DOI 10.1080/87565649109540499; Manchester D, 2004, BRAIN INJURY, V18, P1067, DOI 10.1080/02699050410001672387; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; Masson F, 1996, ARCH PEDIATRIE, V3, P651, DOI 10.1016/0929-693X(96)87085-0; McKinlay A, 2008, BRAIN INJURY, V22, P175, DOI 10.1080/02699050801888824; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; McKinlay A, 2010, CHILD CARE HLTH DEV, V36, P22, DOI 10.1111/j.1365-2214.2009.00947.x; Muscara F, 2008, J NEUROPSYCHOL, V2, P445, DOI 10.1348/174866407X250820; Nadebaum C, 2007, DEV NEUROPSYCHOL, V32, P703, DOI 10.1080/87565640701376086; Nolin P., 2000, Annales de Readaptation et de Medecine Physique, V43, P236, DOI 10.1016/S0168-6054(00)89087-X; Nybo T, 1999, BRAIN INJURY, V13, P759; Pentland L, 1998, NEUROPSYCHOL REHABIL, V8, P301, DOI 10.1080/713755572; PRICE BH, 1990, BRAIN, V113, P1383, DOI 10.1093/brain/113.5.1383; Rocke K, 2008, AM J OCCUP THER, V62, P528, DOI 10.5014/ajot.62.5.528; Roncadin C, 2004, DEV NEUROPSYCHOL, V25, P21; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Sharples PM, 1998, INJURY YOUNG, V263-299; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Silver CH, 2000, J HEAD TRAUMA REHAB, V15, P973, DOI 10.1097/00001199-200008000-00002; Sullivan J, 2006, FORTUNE, V154, P21; TEASDALE G, 1974, LANCET, V2, P81; Toplak ME, 2009, CHILD NEUROPSYCHOL, V15, P53, DOI 10.1080/09297040802070929; Vriezen ER, 2002, CHILD NEUROPSYCHOL, V8, P296, DOI 10.1076/chin.8.4.296.13505; Vriezen ER, 2001, BRAIN COGNITION, V47, P222; Wechsler D., 2003, WECHSLER INTELLIGENC; Wechsler D, 1997, WAIS 3 ADM SCORING M; WELSH MC, 1991, DEV NEUROPSYCHOL, V7, P131, DOI 10.1080/87565649109540483; Wilson BA, 1996, BEHAV ASSESSMENT DYS; Wood RL, 2007, J INT NEUROPSYCH SOC, V13, P90, DOI 10.1017/S1355617707070129	67	35	35	0	21	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1443-9646	1839-5252		BRAIN IMPAIR	Brain Impair.	SEP	2010	11	2			SI		125	143		10.1375/brim.11.2.125			19	Clinical Neurology; Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	V24IS	WOS:000208404700004					2021-06-18	
J	de Groot, YJ; Jansen, NE; Bakker, J; Kuiper, MA; Aerdts, S; Maas, AIR; Wijdicks, EFM; van Leiden, HA; Hoitsma, AJ; Kremer, BHPH; Kompanje, EJO				de Groot, Yorick J.; Jansen, Nichon E.; Bakker, Jan; Kuiper, Michael A.; Aerdts, Stan; Maas, Andrew I. R.; Wijdicks, Eelco F. M.; van Leiden, Hendrik A.; Hoitsma, Andries J.; Kremer, Berry H. P. H.; Kompanje, Erwin J. O.			Imminent brain death: point of departure for potential heart-beating organ donor recognition	INTENSIVE CARE MEDICINE			English	Article						Brain death; Critical care organisation; Neurotrauma; Transplantation; Stroke; Emergency medicine	SCORE COMA SCALE; CARE; DONATION; VALIDATION; CONSCIOUSNESS; PERFORMANCE; WITHDRAWAL; CONSENT; AUDIT; TIME	There is, in European countries that conduct medical chart review of intensive care unit (ICU) deaths, no consensus on uniform criteria for defining a potential organ donor. Although the term is increasingly being used in recent literature, it is seldom defined in detail. We searched for criteria for determination of imminent brain death, which can be seen as a precursor for organ donation. We organized meetings with representatives from the field of clinical neurology, neurotraumatology, intensive care medicine, transplantation medicine, clinical intensive care ethics, and organ procurement management. During these meetings, all possible criteria were discussed to identify a patient with a reasonable probability to become brain dead (imminent brain death). We focused on the practical usefulness of two validated coma scales (Glasgow Coma Scale and the FOUR Score), brain stem reflexes and respiration to define imminent brain death. Further we discussed criteria to determine irreversibility and futility in acute neurological conditions. A patient who fulfills the definition of imminent brain death is a mechanically ventilated deeply comatose patient, admitted to an ICU, with irreversible catastrophic brain damage of known origin. A condition of imminent brain death requires either a Glasgow Coma Score of 3 and the progressive absence of at least three out of six brain stem reflexes or a FOUR score of E0M0B0R0. The definition of imminent brain death can be used as a point of departure for potential heart-beating organ donor recognition on the intensive care unit or retrospective medical chart analysis.	[de Groot, Yorick J.; Bakker, Jan; Kompanje, Erwin J. O.] Erasmus MC Univ, Dept Intens Care, Med Ctr, NL-3000 CA Rotterdam, Netherlands; [Jansen, Nichon E.; van Leiden, Hendrik A.] Dutch Transplant Fdn, Leiden, Netherlands; [Kuiper, Michael A.] Med Ctr Leeuwarden, Dept Intens Care, Leeuwarden, Netherlands; [Aerdts, Stan] Isala Clin, Dept Intens Care, Zwolle, Netherlands; [Maas, Andrew I. R.] Univ Antwerp Hosp, Dept Neurosurg, Antwerp, Belgium; [Wijdicks, Eelco F. M.] Mayo Clin, Div Crit Care Neurol, Rochester, MN USA; [Kremer, Berry H. P. H.] Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, NL-9713 AV Groningen, Netherlands; [Hoitsma, Andries J.] Radboud Univ Nijmegen Med Ctr, Dept Nephrol, Nijmegen, Netherlands	Kompanje, EJO (corresponding author), Erasmus MC Univ, Dept Intens Care, Med Ctr, POB 2040, NL-3000 CA Rotterdam, Netherlands.	e.j.o.kompanje@erasmusmc.nl	Bakker, Jan/A-4011-2009; Kuiper, Michael/AAG-9878-2019; Maas, Andrew IR/C-5584-2013; Hoitsma, A.J./L-4382-2015	Bakker, Jan/0000-0003-2236-7391; Maas, Andrew IR/0000-0003-1612-1264; Kuiper, Michael/0000-0001-6201-7332			[Anonymous], 1968, JAMA, V205, P337; [Anonymous], 2007, ANN REP US ORG PROC; Barber K, 2006, BMJ-BRIT MED J, V332, P1124, DOI 10.1136/bmj.38804.658183.55; Chan JD, 2004, CHEST, V126, P286, DOI 10.1378/chest.126.1.286; Cook D, 2003, NEW ENGL J MED, V349, P1123, DOI 10.1056/NEJMoa030083; *EUROTR INT FDN, 2008, ANN REP EUROTR INT F; Gortmaker SL, 1996, CRIT CARE MED, V24, P432, DOI 10.1097/00003246-199603000-00012; Hoffenberg R, 1997, LANCET, V350, P1320, DOI 10.1016/S0140-6736(97)02306-4; Iyer VN, 2009, MAYO CLIN PROC, V84, P694, DOI 10.1016/S0025-6196(11)60519-3; Kompanje EJO, 2006, INTENS CARE MED, V32, P217, DOI 10.1007/s00134-005-0001-9; LOVEGROVE C, 2006, NAT CLIN PRACT NEURO, V2, P4; Lytle FT, 2009, AM J TRANSPLANT, V9, P1446, DOI 10.1111/j.1600-6143.2009.02575.x; Margarida A, 2009, GUIDE RECOMMENDATION; Molina A, 2008, J MED ETHICS, V34, P688, DOI 10.1136/jme.2007.022921; MOLLARET P., 1959, REV NEUROL [PARIS], V101, P3; MURPHY C, 2008, POTENTIAL DONOR AUDI; Opdam HI, 2004, INTENS CARE MED, V30, P1390, DOI 10.1007/s00134-004-2185-9; RIKER RR, 1995, TRANSPLANTATION, V59, P880; Robertson JA, 1999, HASTINGS CENT REP, V29, P6, DOI 10.2307/3527865; Rodrigue JR, 2006, AM J TRANSPLANT, V6, P190, DOI 10.1111/j.1600-6143.2005.01130.x; Roels L, 2007, AM J TRANSPLANT, V7, P1439, DOI 10.1111/j.1600-6143.2007.01831.x; Rosenberg RN, 2009, JAMA-J AM MED ASSOC, V301, P1172, DOI 10.1001/jama.2009.224; Shafer TJ, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b701; Siminoff LA, 2004, SOC SCI MED, V59, P2325, DOI 10.1016/j.socscimed.2004.03.029; Siminoff LA, 2001, JAMA-J AM MED ASSOC, V286, P71, DOI 10.1001/jama.286.1.71; Simpkin AL, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b991; Sprung CL, 2003, JAMA-J AM MED ASSOC, V290, P790, DOI 10.1001/jama.290.6.790; Stead LG, 2009, NEUROCRIT CARE, V10, P50, DOI 10.1007/s12028-008-9145-0; TEASDALE G, 1974, LANCET, V2, P81; Tuttle-Newhall JE, 2009, AM J TRANSPLANT, V9, P879, DOI 10.1111/j.1600-6143.2009.02565.x; WERTHEIMER P, 1959, PRESSE MED, V67, P87; Wijdicks EFM, 2008, NEUROLOGY, V70, P1234, DOI 10.1212/01.wnl.0000289762.50376.b6; Wijdicks Eelco F M, 2006, Rev Neurol Dis, V3, P109; Wijdicks EF, 2008, COMATOSE PATIENT; Wijdicks EFM, 2005, ANN NEUROL, V58, P585, DOI 10.1002/ana.20611; Wijdicks EFM, 2001, J NEUROL NEUROSUR PS, V70, P127, DOI 10.1136/jnnp.70.1.127; Wolf CA, 2007, MAYO CLIN PROC, V82, P435, DOI 10.4065/82.4.435; Wood KE, 2004, NEW ENGL J MED, V351, P2730, DOI 10.1056/NEJMra013103; Wood KE, 2007, CURR OPIN ANESTHESIO, V20, P97, DOI 10.1097/ACO.0b013e3280895ac8; 2007, TRANSPLANT ACTIVITY	40	35	38	0	3	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	SEP	2010	36	9					1488	1494		10.1007/s00134-010-1848-y			7	Critical Care Medicine	General & Internal Medicine	638PV	WOS:000280908000006	20232039	Green Published, Other Gold			2021-06-18	
J	Lee, JHT; Tigchelaar, S; Liu, J; Stammers, AMT; Streijger, F; Tetzlaff, W; Kwon, BK				Lee, Jae H. T.; Tigchelaar, Seth; Liu, Jie; Stammers, Anthea M. T.; Streijger, Femke; Tetzlaff, Wolfram; Kwon, Brian K.			Lack of neuroprotective effects of simvastatin and minocycline in a model of cervical spinal cord injury	EXPERIMENTAL NEUROLOGY			English	Article						Spinal cord injury; Minocycline; Simvastatin; Cervical contusion; Neuroprotection	TRAUMATIC BRAIN-INJURY; NITRIC-OXIDE SYNTHASE; IMPROVES FUNCTIONAL RECOVERY; WIDE THERAPEUTIC WINDOW; NERVOUS-SYSTEM INJURY; CYTOCHROME-C RELEASE; MESSENGER-RNA LEVELS; REDUCTASE INHIBITORS; MORPHOLOGICAL CONSEQUENCES; ASTROCYTE ACTIVATION	Minocycline, a commonly prescribed tetracycline antibiotic, has shown promise as a potential therapeutic agent in animal models of numerous neurologic disorders such as amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's disease, Huntington's disease, stroke, and spinal cord injury (SCI). Simvastatin is one of many hydroxymethylglutaryl-coenzyme-A reductase inhibitors prescribed to lower cholesterol. These drugs are also known to reduce inflammation and oxidative stress, improve endothelial function, and modulate the immune system in stroke, traumatic brain injury, and SCI. As both drugs have translational potential, we evaluated their neuroprotective properties here in a clinically relevant model of contusive cervical spinal cord injury. Sprague-Dawley rats underwent a unilateral cervical contusion SCI at C5 and were randomized to receive: 1. Minocycline 90 mg/kg x 3 days, 2. Simvastatin 20 mg/kg x 7 days, 3. Simvastatin 20 mg/kg x 7 days then 5 mg/kg x 35 days, or 4. Saline (Control). Behavioral recovery was assessed over 6 weeks using the horizontal ladder test, cylinder rearing test, modified Montoya staircase test and grooming test Forepaw sensitivity was also assessed using the electronic von Frey Aesthesiometer. The corticospinal and rubrospinal tracts were traced and the spinal cords were harvested 7 weeks after injury. The extent of gray matter and white matter sparing and corticospinal and rubrospinal tract sprouting were evaluated in cross sections of the spinal cord. In the end, neither minocycline nor simvastatin treatment was associated with improved performance on the behavioral tests, as compared to saline controls. Performance on the horizontal ladder test, cylinder rearing test, and von Frey sensory test were similar among all groups. Animals treated for 42 days with simvastatin scored significantly higher in the grooming score compared to other groups, but retrieved significantly fewer pellets on the modified Montoya staircase test than control and minocycline treated animals. Histologically, there were no significant differences in white and gray matter sparing and in the extent of corticospinal and rubrospinal sprouting between the four groups. In conclusion, both minocycline and simvastatin failed to improve functional and histological recovery in our model of contusive cervical spinal cord injury. (C) 2010 Elsevier Inc. All rights reserved.	[Kwon, Brian K.] Univ British Columbia, Dept Orthopaed, Blusson Spinal Cord Ctr, VGH,CNOSP, Vancouver, BC V5Z 1M9, Canada; [Lee, Jae H. T.; Tigchelaar, Seth; Liu, Jie; Stammers, Anthea M. T.; Streijger, Femke; Tetzlaff, Wolfram; Kwon, Brian K.] Univ British Columbia, ICORD, Vancouver, BC V5Z 1M9, Canada; [Lee, Jae H. T.; Tetzlaff, Wolfram; Kwon, Brian K.] Univ British Columbia, Dept Zool, Vancouver, BC V5Z 1M9, Canada	Kwon, BK (corresponding author), Univ British Columbia, Dept Orthopaed, Blusson Spinal Cord Ctr, VGH,CNOSP, 6th Floor,818 W 10th Ave, Vancouver, BC V5Z 1M9, Canada.	mailjae@gmail.com; sethtig@interchange.ubc.ca; jliu@icord.org; stammers@icord.org; streijger@icord.org; tetzlaff@icord.org; brian.kwon@vch.ca	Tetzlaff, Wolfram/AAY-4430-2020	Tigchelaar, Seth/0000-0002-2207-9034	Wings for Life Spinal Cord Injury Foundation; Michael Smith FoundationMichael Smith Foundation for Health Research	This work was generously supported by the Wings for Life Spinal Cord Injury Foundation. W.T. is the Rick Hansen Man in Motion Chair in spinal cord injury research. B.K.K. holds a CIHR New Investigator Award and is a Michael Smith Foundation for Health Research Scholar.	Abrahamson EE, 2009, ANN NEUROL, V66, P407, DOI 10.1002/ana.21731; Balduini W, 2003, STROKE, V34, P2007, DOI 10.1161/01.STR.0000080677.24419.88; Balduini W, 2001, STROKE, V32, P2185, DOI 10.1161/hs0901.094287; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; Bretzner F, 2008, EUR J NEUROSCI, V28, P1795, DOI 10.1111/j.1460-9568.2008.06462.x; Chen JL, 2003, ANN NEUROL, V53, P743, DOI 10.1002/ana.10555; Choo AMT, 2009, J NEUROSCI METH, V181, P6, DOI 10.1016/j.jneumeth.2009.04.007; Cui X, 2009, NEUROBIOL DIS, V36, P35, DOI 10.1016/j.nbd.2009.06.012; Dergham P, 2002, J NEUROSCI, V22, P6570; Dery MA, 2009, NEUROSCI LETT, V453, P73, DOI 10.1016/j.neulet.2009.01.062; Diguet E, 2004, EXP NEUROL, V189, P1, DOI 10.1016/j.expneurol.2004.05.016; Endres M, 1998, P NATL ACAD SCI USA, V95, P8880, DOI 10.1073/pnas.95.15.8880; Erschbamer MK, 2005, J COMP NEUROL, V484, P224, DOI 10.1002/cne.20471; Fagan SC, 2004, EXP NEUROL, V186, P248, DOI 10.1016/j.expneurol.2003.12.006; FELGINES C, 1994, LIFE SCI, V54, P361, DOI 10.1016/0024-3205(94)00792-6; Festoff BW, 2006, J NEUROCHEM, V97, P1314, DOI 10.1111/j.1471-4159.2006.03799.x; GEISLER FH, 1991, NEW ENGL J MED, V324, P1829, DOI 10.1056/NEJM199106273242601; Geisler FH, 2001, SPINE, V26, pS87, DOI 10.1097/00007632-200112151-00015; Gensel JC, 2006, J NEUROTRAUM, V23, P36, DOI 10.1089/neu.2006.23.36; Girgis J, 2007, BRAIN, V130, P2993, DOI 10.1093/brain/awm245; Ha KY, 2008, EUR SPINE J, V17, P864, DOI 10.1007/s00586-008-0653-6; Holmberg E, 2008, EXP NEUROL, V214, P78, DOI 10.1016/j.expneurol.2008.07.020; Holmberg E, 2006, J NEUROTRAUM, V23, P1366, DOI 10.1089/neu.2006.23.1366; Hurlbert RJ, 2008, CAN J NEUROL SCI, V35, P41, DOI 10.1017/S031716710000754X; JOLES J, 1992, LAB ANIM, V26, P269, DOI 10.1258/002367792780745689; KASIM SE, 1992, J LIPID RES, V33, P1; Kugi M, 2002, CARDIOVASC DRUG THER, V16, P203, DOI 10.1023/A:1020692220701; KWON BK, 2010, J NEUROTRAUMA; Kwon BK, 2010, J NEUROTRAUM, V27, P21, DOI 10.1089/neu.2009.1048; Lee SM, 2003, J NEUROTRAUM, V20, P1017, DOI 10.1089/089771503770195867; Li B, 2009, NEUROSURGERY, V65, P179, DOI 10.1227/01.NEU.0000346272.76537.DC; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Lutton C, 1999, REPROD NUTR DEV, V39, P481, DOI 10.1051/rnd:19990407; Madura T, 2004, EMBO REP, V5, P412, DOI 10.1038/sj.embor.7400117; Mahmood A, 2009, NEUROSURGERY, V65, P187, DOI 10.1227/01.NEU.0000343540.24780.D6; Mahmood A, 2008, J NEUROTRAUM, V25, P1441, DOI 10.1089/neu.2007.0495; Mann CM, 2010, EXP NEUROL, V221, P285, DOI 10.1016/j.expneurol.2009.11.006; Marchand F, 2009, EUR J PAIN, V13, P673, DOI 10.1016/j.ejpain.2008.08.001; McGirt MJ, 2002, STROKE, V33, P2950, DOI 10.1161/01.STR.0000038986.68044.39; MONTOYA CP, 1991, J NEUROSCI METH, V36, P219, DOI 10.1016/0165-0270(91)90048-5; Nikkhah G, 1998, BEHAV BRAIN RES, V92, P85, DOI 10.1016/S0166-4328(97)00128-9; Ohsawa M, 2008, PAIN, V134, P285, DOI 10.1016/j.pain.2007.04.031; Pannu R, 2005, J NEUROSCI RES, V79, P340, DOI 10.1002/jnr.20345; Pannu R, 2007, J NEUROCHEM, V101, P182, DOI 10.1111/j.1471-4159.2006.04354.x; Piao CS, 2003, J NEUROSCI RES, V73, P537, DOI 10.1002/jnr.10671; Pinzon A, 2008, BRAIN RES, V1243, P146, DOI 10.1016/j.brainres.2008.09.047; Plunet WT, 2008, EXP NEUROL, V213, P28, DOI 10.1016/j.expneurol.2008.04.011; Rabchevsky AG, 2001, J NEUROTRAUM, V18, P513, DOI 10.1089/089771501300227314; Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028-3908(00)00005-8; Shunmugavel A, 2010, J INFLAMM-LOND, V7, DOI 10.1186/1476-9255-7-17; Sironi L, 2003, ARTERIOSCL THROM VAS, V23, P322, DOI 10.1161/01.ATV.0000044458.23905.3B; Soblosky JS, 2001, BEHAV BRAIN RES, V119, P1, DOI 10.1016/S0166-4328(00)00328-4; Stirling DP, 2004, J NEUROSCI, V24, P2182, DOI 10.1523/JNEUROSCI.5275-03.2004; Teng YD, 2004, P NATL ACAD SCI USA, V101, P3071, DOI 10.1073/pnas.0306239101; Tikka TM, 2001, J IMMUNOL, V166, P7527, DOI 10.4049/jimmunol.166.12.7527; Tsuji M, 2004, EXP NEUROL, V189, P58, DOI 10.1016/j.expneurol.2004.01.011; van den Berg MEL, 2010, NEUROEPIDEMIOLOGY, V34, P184, DOI 10.1159/000279335; Wang HC, 2007, EXP NEUROL, V206, P59, DOI 10.1016/j.expneurol.2007.03.031; Wells JEA, 2003, BRAIN, V126, P1628, DOI 10.1093/brain/awg178; Wu HT, 2008, J NEUROTRAUM, V25, P130, DOI 10.1089/neu.2007.0369; Wu HT, 2009, NEUROSURGERY, V65, P1087, DOI 10.1227/01.NEU.0000360130.52812.1D; Yang LC, 2003, J NEUROSCI RES, V74, P278, DOI 10.1002/jnr.10709; Yrjanheikki J, 1999, P NATL ACAD SCI USA, V96, P13496, DOI 10.1073/pnas.96.23.13496; Yune TY, 2007, J NEUROSCI, V27, P7751, DOI 10.1523/JNEUROSCI.1661-07.2007; Zacco A, 2003, J NEUROSCI, V23, P11104; Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a	66	35	36	0	8	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	SEP	2010	225	1			SI		219	230		10.1016/j.expneurol.2010.06.018			12	Neurosciences	Neurosciences & Neurology	643ZD	WOS:000281339300028	20599974				2021-06-18	
J	O'Donnell, ML; Creamer, M; Holmes, ACN; Ellen, S; McFarlane, AC; Judson, R; Silove, D; Bryant, RA				O'Donnell, Meaghan L.; Creamer, Mark; Holmes, Alexander C. N.; Ellen, Steven; McFarlane, Alexander C.; Judson, Rodney; Silove, Derrick; Bryant, Richard A.			Posttraumatic Stress Disorder After Injury: Does Admission to Intensive Care Unit Increase Risk?	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Injury; Posttraumatic stress disorder; Intensive care unit	QUALITY-OF-LIFE; MENTAL-HEALTH; TRAUMA; DELIRIUM; SLEEP; PREVALENCE; VALIDATION; DELUSIONS; SURVIVORS; SYMPTOMS	Background: This study aimed to index the prevalence of posttraumatic stress disorder (PTSD) after injury requiring intensive care unit (ICU) admission to investigate whether an ICU admission after injury increases risk for PTSD and to identify predictors of PTSD after ICU admission. Methods: A two-group (those admitted to the ICU vs. those not admitted to ICU), prospective, cohort study of 829 randomly selected injury patients from five major trauma hospitals across Australia. We collected information on factors that may increase risk for PTSD including demographic variables (gender, age, income, education, and marital status), preinjury mental health status (prior trauma, psychiatric history, and prior social support), and injury characteristics (mild traumatic brain injury, injury severity, length of hospital admission, discharge destination, pain, and perceived threat). PTSD was measured at 12 months by structured clinical interview. Results: ICU patients were significantly more likely to have PTSD at 12 months than trauma controls (17% vs. 7%). Stepwise logistic regressions showed that an ICU admission significantly contributed to the development of PTSD after controlling for demographic, preinjury mental health status, and injury characteristic variables. Conclusions: Injury patients are three times more likely to develop later PTSD if they have an ICU admission. Given we controlled for many risk variables, it seems that an ICU admission itself may contribute to the development of PTSD. Mental health services such as screening and early intervention may be particularly useful for this population.	[O'Donnell, Meaghan L.; Creamer, Mark] Australian Ctr Posttraumat Mental Hlth, Dept Psychiat, E Melnourne, Vic, Australia; [O'Donnell, Meaghan L.; Creamer, Mark; Holmes, Alexander C. N.] Univ Melbourne, Dept Psychiat, Melbourne, Vic, Australia; [O'Donnell, Meaghan L.] Natl Trauma Res Inst, Prahran, Vic, Australia; [Ellen, Steven] Alfred Hosp, Monash Alfred Psychiat Res Ctr, Dept Psychiat, Prahran, Vic 3181, Australia; [McFarlane, Alexander C.] Univ Adelaide, Dept Psychiat, Ctr Vet & Mil Hlth, Adelaide, SA, Australia; [Judson, Rodney] Royal Melbourne Hosp, Trauma Serv, Div Surg Perioperat & Imaging, Melbourne, Vic, Australia; [Silove, Derrick] Univ New S Wales, Psychiat Res & Teaching Unit, Dept Psychiat, Liverpool, NSW, Australia; [Bryant, Richard A.] Univ New S Wales, Sch Psychol, Sydney, NSW, Australia	O'Donnell, ML (corresponding author), Australian Ctr Posttraumat Mental Hlth, Dept Psychiat, Level 1,340 Albert St, Melbourne, Vic 3002, Australia.	mod@unimelb.edu.au	Bryant, Richard/AAA-6479-2019	Bryant, Richard/0000-0002-9607-819X; O'Donnell, Meaghan/0000-0003-4349-0022	NHMRCNational Health and Medical Research Council of Australia [300304]; Victorian Trauma Foundation [V-11]; National Health and Medical Research Council Australian Clinical ResearchNational Health and Medical Research Council of Australia [359284]	Supported by an NHMRC Program grant 300304, a Victorian Trauma Foundation grant V-11, and a National Health and Medical Research Council Australian Clinical Research Fellowship 359284.	BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BERRY J, 2006, HOSP SEPARATIONS DUE; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; BRESLAU N, 1991, ARCH GEN PSYCHIAT, V48, P216; Brewin CR, 2000, J CONSULT CLIN PSYCH, V68, P748, DOI 10.1037/0022-006X.68.5.748; Bryant RA, 2000, AM J PSYCHIAT, V157, P629, DOI 10.1176/appi.ajp.157.4.629; Bryant RA, 2008, ARCH GEN PSYCHIAT, V65, P659, DOI 10.1001/archpsyc.65.6.659; Creamer M, 2001, PSYCHOL MED, V31, P1237, DOI 10.1017/S0033291701004287; DiMartini A, 2007, PSYCHOSOMATICS, V48, P436, DOI 10.1176/appi.psy.48.5.436; Germain A, 2008, SLEEP MED REV, V12, P185, DOI 10.1016/j.smrv.2007.09.003; Girard TD, 2008, CRIT CARE, V12, DOI 10.1186/cc6149; Griffiths J, 2007, INTENS CARE MED, V33, P1506, DOI 10.1007/s00134-007-0730-z; HUSKISSON EC, 1974, LANCET, V2, P1127, DOI 10.1016/S0140-6736(74)90884-8; Jackson JC, 2007, CRIT CARE, V11, DOI 10.1186/cc5707; JENSEN MP, 1986, PAIN, V27, P117, DOI 10.1016/0304-3959(86)90228-9; Jones C, 2001, CRIT CARE MED, V29, P573, DOI 10.1097/00003246-200103000-00019; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; Kessler RC, 2000, J CLIN PSYCHIAT, V61, P4; Koren D, 2002, AM J PSYCHIAT, V159, P855, DOI 10.1176/appi.ajp.159.5.855; Mellman TA, 2002, AM J PSYCHIAT, V159, P1696, DOI 10.1176/appi.ajp.159.10.1696; Mistraletti G, 2008, MINERVA ANESTESIOL, V74, P329; O'Donnell ML, 2008, CLIN PSYCHOL REV, V28, P387, DOI 10.1016/j.cpr.2007.07.008; O'Donnell ML, 2008, J CONSULT CLIN PSYCH, V76, P923, DOI 10.1037/a0012918; O'Donnell ML, 2009, J TRAUMA, V66, P470, DOI 10.1097/TA.0b013e31815d965e; O'Donnell ML, 2005, J TRAUMA, V59, P1328, DOI 10.1097/01.ta.0000197621.94561.4e; O'Donnell ML, 2004, AM J PSYCHIAT, V161, P507, DOI 10.1176/appi.ajp.161.3.507; O'Donnell ML, 2003, CLIN PSYCHOL REV, V23, P587, DOI 10.1016/S0272-7358(03)00036-9; Pandharipande P, 2008, J TRAUMA, V65, P34, DOI 10.1097/TA.0b013e31814b2c4d; PRICE DD, 1983, PAIN, V17, P45, DOI 10.1016/0304-3959(83)90126-4; Schelling G, 2003, CRIT CARE MED, V31, P1971, DOI 10.1097/01.CCM.0000069512.10544.40; SCHUSTER TL, 1990, AM J COMMUN PSYCHOL, V18, P423, DOI 10.1007/BF00938116; SCOTT J, 1976, PAIN, V2, P175, DOI 10.1016/0304-3959(76)90113-5; Sessler CN, 2008, CHEST, V133, P552, DOI 10.1378/chest.07-2026; Shalev AY, 2002, BIOL PSYCHIAT, V51, P532, DOI 10.1016/S0006-3223(02)01335-5; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Talwar Arunabh, 2008, Indian J Chest Dis Allied Sci, V50, P151; Weathers FW, 1999, PSYCHOL ASSESSMENT, V11, P124, DOI 10.1037/1040-3590.11.2.124; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029; World Health Organization, 1997, COMP INT DIAGN INT C; Zatzick D, 2004, ARCH GEN PSYCHIAT, V61, P498, DOI 10.1001/archpsyc.61.5.498; Zatzick DF, 2002, ARCH SURG-CHICAGO, V137, P200, DOI 10.1001/archsurg.137.2.200; 2006, NATL CTR INJURY PREV	43	35	36	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	SEP	2010	69	3					627	632		10.1097/TA.0b013e3181bc0923			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	649HX	WOS:000281760800035	20118816				2021-06-18	
J	Kim, N; Boone, KB; Victor, T; Lu, P; Keatinge, C; Mitchell, C				Kim, Nancy; Boone, Kyle B.; Victor, Tara; Lu, Po; Keatinge, Carolyn; Mitchell, Cary			Sensitivity and Specificity of a Digit Symbol Recognition Trial in the Identification of Response Bias	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Malingering; symptom validity testing; Forensic neuropsychology	TRAUMATIC BRAIN-INJURY; SUSPECT EFFORT; NEUROPSYCHOLOGICAL ASSESSMENT; AMERICAN-ACADEMY; SCORES; METAANALYSIS; PERFORMANCE	Recently published practice standards recommend that multiple effort indicators be interspersed throughout neuropsychological evaluations to assess for response bias, which is most efficiently accomplished through use of effort indicators from standard cognitive tests already included in test batteries. The present study examined the utility of a timed recognition trial added to standard administration of the WAIS-III Digit Symbol subtest in a large sample of "real world" noncredible patients (n=82) as compared with credible neuropsychology clinic patients (n=89). Scores from the recognition trial were more sensitive in identifying poor effort than were standard Digit Symbol scores, and use of an equation incorporating Digit Symbol Age-Corrected Scaled Scores plus accuracy and time scores from the recognition trial was associated with nearly 80% sensitivity at 88.7% specificity. Thus, inclusion of a brief recognition trial to Digit Symbol administration has the potential to provide accurate assessment of response bias.	[Kim, Nancy; Keatinge, Carolyn; Mitchell, Cary] Pepperdine Univ, Los Angeles, CA USA; [Boone, Kyle B.] Alliant Int Univ, Calif Sch Forens Studies, Los Angeles, CA USA; [Victor, Tara] Calif State Univ Dominguez Hills, Dept Psychol, Carson, CA 90747 USA; [Lu, Po] Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90024 USA	Boone, KB (corresponding author), 1000 S Fremont, Alhambra, CA 91803 USA.	kboone@labiomed.org	Victor, Tara/K-6581-2019				Arnold G, 2005, CLIN NEUROPSYCHOL, V19, P105, DOI 10.1080/13854040490888567; Babikian T, 2006, CLIN NEUROPSYCHOL, V20, P145, DOI 10.1080/13854040590947362; BABIKIAN T, 2007, ASSESSMENT FEIGNED C; Back C., 1996, ASSESSMENT, V3, P449, DOI [10.1177/107319119600300411, DOI 10.1177/107319119600300411, DOI 10.1016/S0887-6177(01)00166-4]; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Binder L. M., 1992, HDB NEUROPSYCHOLOGIC, P353; Boone, 2007, ASSESSMENT FEIGNED C; Boone KB, 2005, ARCH CLIN NEUROPSYCH, V20, P301, DOI 10.1016/j.acn.2004.08.001; Boone KB, 2002, J CLIN EXP NEUROPSYC, V24, P561, DOI 10.1076/jcen.24.5.561.1004; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; CARROLL LJ, 2004, J REHABILITATION MED, V37, P61; Dean AC, 2008, CLIN NEUROPSYCHOL, V22, P705, DOI 10.1080/13854040701440493; Dean AC, 2009, CLIN NEUROPSYCHOL, V23, P133, DOI 10.1080/13854040701819050; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P1; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; GOLDBERG HB, 2007, ASSESSMENT FEIGNED C; Heilbronner RL, 2007, CLIN NEUROPSYCHOL, V21, P209, DOI 10.1080/13825580601025932; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Inman TH, 2002, ARCH CLIN NEUROPSYCH, V17, P1, DOI 10.1016/S0887-6177(00)00073-1; Iverson G.L., 1994, ASSESSMENT, V1, P323, DOI [DOI 10.1177/1073191, https://doi.org/10.1177/107319119400100401, DOI 10.1177/107319119400100401]; Kim MS, 2010, ARCH CLIN NEUROPSYCH, V25, P60, DOI 10.1093/arclin/acp088; Larrabee G.J., 2007, ASSESSMENT MALINGERE; Lu PH, 2003, CLIN NEUROPSYCHOL, V17, P426, DOI 10.1076/clin.17.3.426.18083; Nitch S, 2006, CLIN NEUROPSYCHOL, V20, P873, DOI 10.1080/13854040590967603; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Sherman DS, 2002, CLIN NEUROPSYCHOL, V16, P242, DOI 10.1076/clin.16.3.242.13860; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; TRUEBLOOD W, 1994, J CLIN EXP NEUROPSYC, V16, P597, DOI 10.1080/01688639408402671; Victor T, 2009, CLIN NEUROPSYCHOL, V23, P297, DOI 10.1080/13854040802232682	30	35	35	0	2	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	AUG	2010	25	5					420	428		10.1093/arclin/acq040			9	Psychology, Clinical; Psychology	Psychology	627BN	WOS:000280013100007	20562116	Bronze			2021-06-18	
J	Marshall, GT; James, RF; Landman, MP; O'Neill, PJ; Cotton, BA; Hansen, EN; Morris, JA; May, AK				Marshall, Gary T.; James, Robert F.; Landman, Matthew P.; O'Neill, Patrick J.; Cotton, Bryan A.; Hansen, Erik N.; Morris, John A., Jr.; May, Addison K.			Pentobarbital Coma For Refractory Intra-Cranial Hypertension After Severe Traumatic Brain Injury: Mortality Predictions and One-Year Outcomes in 55 Patients	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	36th Critical Care Congress of the Society-of-Critical-Care-Medicine	FEB 18-21, 2007	Orlando, FL	Soc Critical Care Med		Traumatic brain injury; Trauma; Intracranial hypertension; Pentobarbital coma; Hyperosmolar therapy; Barbiturate coma	HEAD-INJURY; DECOMPRESSIVE CRANIECTOMY; BARBITURATE THERAPY; MANAGEMENT; PRESSURE	Objective: To identify predictors of mortality and long-term outcomes in survivors after pentobarbital coma (PBC) in patients failing current treatment standards for severe traumatic brain injuries (TBI). This is a retrospective cohort study of severe TBI patients receiving PBC at Level I Trauma Center and tertiary university hospital. Methods: Four thousand nine hundred thirty-four patients were admitted to the trauma intensive care unit with severe TBI (head Abbreviated Injury Scale >= 3) between April 1998 and December 2004. Six hundred eleven received intracranial pressure (ICP) monitoring and 58 received PBC. Three patients underwent craniotomy for intracranial mass lesion and were excluded. The study group received standardized medical management for severe TBI including opiates, benzodiazepines, elevation of the head of bed, avoidance of hypotension and hypercapnia and hyperosmolar therapy (HOsmRx). In addition, 31 of 55 patients (56%) underwent placement of intraventricular catheters for cerebrospinal fluid drainage. If routine medical management and cerebrospinal fluid diversion failed to control ICP, then the patient was determined to have refractory intracranial hypertension (RICH) and PBC treatment was initiated. PBC was performed with pentobarbital infusion with continuous electroencephalogram monitoring to ensure adequate burst suppression. The measurements include serum sodium (Na+) and osmolality (Osm) were assessed as indicators for initiation of PBC and to estimate the 50% mortality cut-points when controlling for ICP. Follow-up functional outcomes were assessed using the Glasgow Outcome Scale and stratified according to admission Glasgow Coma Scale score and Marshall computed tomography classification. Of the 55 PBC patients, 22 (40%) survived at discharge. 19 of 22 had long-term follow-up (1 year or more) available. Of these, 13 (68%) were normal or functionally independent (Glasgow Outcome Scale score 4 or 5). Serum Na+ and Osm were associated with death (p < 0.05) when controlling for ICP. The 50% mortality cut-points were Na+ of 160 mEq/L and Osm of 330 mOsm/kg H2O. Median minimum cerebral perfusion pressure after PBC was 42 mm Hg in survivors and 34 mm Hg in nonsurvivors (p = 0.013). Conclusions: In patients with severe TBI and RICH, survival at discharge of 40% with good functional outcomes in 68% of survivors at 1 year or more can be achieved with PBC after failure of HOsmRx. Based on 50% mortality cut-points, analysis suggests the limits of HOsmRx to be Na+ of 160 mEq/L and Osm of 330 mOsm/Kg H2O. Maintenance of higher cerebral perfusion pressure after PBC is associated with survival. PBC treatment of RIH may be even more important when other treatments of RIH, such as decompressive craniectomy, are not available.	[Marshall, Gary T.] Univ Pittsburgh, Med Ctr, Dept Surg, Div Trauma & Gen Surg, Pittsburgh, PA 15213 USA; [James, Robert F.] E Carolina Univ, Div Neurosurg, Brody Sch Med, Dept Surg, Greenville, NC USA; [Landman, Matthew P.; Hansen, Erik N.; Morris, John A., Jr.; May, Addison K.] Vanderbilt Univ, Med Ctr, Dept Surg, Div Trauma & Surg Crit Care,Sect Surg Sci, Nashville, TN USA; [O'Neill, Patrick J.] Maricopa Cty Gen Hosp, Dept Surg, Div Burns Trauma & Surg Crit Care, Phoenix, AZ USA; [Cotton, Bryan A.] Univ Texas Hlth Sci Ctr Houston, Dept Surg, Houston, TX USA; [Cotton, Bryan A.] Univ Texas Hlth Sci Ctr Houston, Ctr Translat Injury Res, Houston, TX USA	Marshall, GT (corresponding author), Univ Pittsburgh, Med Ctr, Dept Surg, Div Trauma & Gen Surg, 200 Lothrop St,PUH F1266, Pittsburgh, PA 15213 USA.	marshallgt@upmc.edu		Marshall, Gary/0000-0003-1398-5366			Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P537; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P493; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P507; Cormio M, 1999, J NEUROTRAUM, V16, P927, DOI 10.1089/neu.1999.16.927; COTTON BA, PRACTICE MANAGEMENT; Cotton BA, 2006, SHOCK, V26, P115, DOI 10.1097/01.shk.0000209564.84822.f2; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; Goodman JC, 1996, J NEUROTRAUM, V13, P549, DOI 10.1089/neu.1996.13.549; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; LEE MW, 1994, J NEUROTRAUM, V11, P325, DOI 10.1089/neu.1994.11.325; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; McGarry LJ, 2002, J TRAUMA, V53, P1152, DOI 10.1097/00005373-200212000-00020; McKinley BA, 1998, ACT NEUR S, V71, P177; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; NORDSTROM CH, 1988, J NEUROSURG, V68, P424, DOI 10.3171/jns.1988.68.3.0424; Nordstrom CH, 2003, ANESTHESIOLOGY, V98, P809, DOI 10.1097/00000542-200304000-00004; Ogden AT, 2005, NEUROSURGERY, V57, P207, DOI 10.1227/01.NEU.0000166533.79031.D8; ROBERTS I, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000033; ROCKOFF MA, 1979, ANN NEUROL, V6, P194, DOI 10.1002/ana.410060303; Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2; SCHWARTZ ML, 1984, CAN J NEUROL SCI, V11, P434, DOI 10.1017/S0317167100045960; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Vincent JL, 2005, CRIT CARE MED, V33, P1392, DOI 10.1097/01.CCM.0000166890.93559.2D; WARD JD, 1985, J NEUROSURG, V62, P383, DOI 10.3171/jns.1985.62.3.0383; Yang XF, 2008, ACTA NEUROCHIR, V150, P1241, DOI 10.1007/s00701-008-0145-9; 2000, J NEUROTRAUMA, V17, P479; 2005, RANDOMIZED EVALUATIO; 2004, DECRA INT MULTICENTE	29	35	35	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	AUG	2010	69	2					275	283		10.1097/TA.0b013e3181de74c7			9	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	638JN	WOS:000280890800006	20699736				2021-06-18	
J	Stein, DM; Menaker, J; McQuillan, K; Handley, C; Aarabi, B; Scalea, TM				Stein, Deborah M.; Menaker, Jay; McQuillan, Karen; Handley, Christopher; Aarabi, Bizhan; Scalea, Thomas M.			Risk Factors for Organ Dysfunction and Failure in Patients with Acute Traumatic Cervical Spinal Cord Injury	NEUROCRITICAL CARE			English	Article						Organ failure; Organ dysfunction; Spinal cord injury	SOFA SCORE; RESPIRATORY COMPLICATIONS; MECHANICAL VENTILATION; MORTALITY; BRAIN; MANAGEMENT; PREDICTORS; SYSTEM; NEED	Traumatic injuries to the cervical spine cause significant disability. Much of the morbidity and mortality that occurs in patients afflicted with cervical spinal cord injury (SCI) occurs early after injury due to primary neurologic dysfunction, systemic inflammation, concomitant injuries, treatments to prevent and ameliorate secondary insults, and prolonged immobilization. This study was undertaken to determine the incidence of organ dysfunction and failure using validated measures: the Multiple Organ Dysfunction Score (MODS) and the Sequential Organ Failure Assessment (SOFA). We also sought to determine if certain patient or injury characteristics were associated with the development of organ dysfunction and failure. All patients who sustained isolated blunt cervical SCIs admitted to the R Adams Cowley Shock Trauma Center over a 15-month period were identified. American Spinal Injury Association (ASIA) motor scores, ASIA impairment scale (AIS) scores, and level of injury were recorded. Admission, first daily, worst daily, and aggregate MOD and SOFA scores were assigned for each of six organ systems. A P < 0.05 was considered significant for all statistical tests. Of 1,028 patients admitted with blunt spine injuries between January, 2007 and March, 2008, 40 patients were identified with an isolated cervical SCI that required an ICU length of stay (LOS) > 24 h. Organ failure of at least one organ system occurred in 75% of patients as calculated by MOD score and 85% of patients calculated using SOFA criteria. Multiple organ failure was found in 55% by MOD and 62.5% by SOFA scores. The most frequent system to fail was the cardiovascular system by aggregate MODS (84%), while the respiratory system was the most frequently failed system by aggregate SOFA criteria (70%). There was a strong inverse correlation between ASIA motor score and aggregate MODS and SOFA scores (r = -0.56, P = 0.0002 and r = -0.51, P = 0.0009). AIS was also found to be inversely correlated with the development of organ failure (r = -0.47, P = 0.002 and r = -0.45, P = 0.004) while anatomic level of injury was found to correlate poorly with the incidence of organ failure (r = -0.11, P = 0.5 and r = -0.10, P = 0.5). Only ASIA motor score was significantly associated with sum aggregate organ dysfunction scores when controlling for age and injury severity score (parameter estimate = -0.082, P = 0.0005 for MODS and parameter estimate = -0.057, P = 0.006 for SOFA). This study is the first to describe the incidence of organ dysfunction and failure in patients with isolated acute traumatic cervical SCI using validated organ system dysfunction scores. Respiratory, cardiovascular, neurologic, renal, hepatic, and hematologic dysfunction occurred commonly both on admission and over the ICU stay. Respiratory, cardiovascular, and neurologic failure were frequently found, while renal, hepatic, and hematologic failures were uncommon. Multiple organ failure occurred in the majority of patients. ASIA motor score and AIS were found to strongly correlate with the development of organ dysfunction and failure. Level of injury should be used with caution when describing the risk of complications and the need for medical interventions.	[Stein, Deborah M.] Univ Maryland, Med Ctr, R Adams Cowley Shock Trauma Ctr, Program Trauma,Div Crit Care,Sch Med, Baltimore, MD 21201 USA	Stein, DM (corresponding author), Univ Maryland, Med Ctr, R Adams Cowley Shock Trauma Ctr, Program Trauma,Div Crit Care,Sch Med, 22 S Greene St, Baltimore, MD 21201 USA.	dstein@umm.edu; jmenaker@umm.edu; kmcquillan@umm.edu; chandley@som.umaryland.edu; baarabi@smail.umaryland.edu; tscalea@umm.edu		Stein, Deborah/0000-0003-3683-3963			American Spinal Injury Association International Medical Society of Paraplegia, 2002, INT STAND NEUR FUNCT; Antonelli M, 1999, INTENS CARE MED, V25, P389, DOI 10.1007/s001340050863; Apuzzo MLJ, 2002, NEUROSURGERY, V51, P1; Association for the Advancement of Automotive Medicine, 2005, ABBR INJ SCAL 2005; Berlly M, 2007, J SPINAL CORD MED, V30, P309, DOI 10.1080/10790268.2007.11753946; Bilello JF, 2003, ARCH SURG-CHICAGO, V138, P1127, DOI 10.1001/archsurg.138.10.1127; Bota DP, 2002, INTENS CARE MED, V28, P1619, DOI 10.1007/s00134-002-1491-3; Brown R, 2006, RESP CARE, V51, P853; Chesnut RM, 2004, CRIT CARE CLIN, V20, P25, DOI 10.1016/S0749-0704(03)00090-3; Claxton AR, 1998, CAN J ANAESTH, V45, P144, DOI 10.1007/BF03013253; Como JJ, 2005, J TRAUMA, V59, P912, DOI 10.1097/01.ta.0000187660.03742.a6; Cook R, 2001, CRIT CARE MED, V29, P2046, DOI 10.1097/00003246-200111000-00002; DeVivo MJ, 1999, ARCH PHYS MED REHAB, V80, P1411, DOI 10.1016/S0003-9993(99)90252-6; DEVIVO MJ, 1995, CHEST, V108, P226, DOI 10.1378/chest.108.1.226; Dewar D, 2009, INJURY, V40, P912, DOI 10.1016/j.injury.2009.05.024; FISHBURN MJ, 1990, ARCH PHYS MED REHAB, V71, P197; FLETCHER DJ, 1995, SPINE, V20, P1136, DOI 10.1097/00007632-199505150-00005; Frink M, 2009, SCAND J TRAUMA RESUS, V17, DOI 10.1186/1757-7241-17-49; Furlan JC, 2006, SPINE, V31, P2674, DOI 10.1097/01.brs.0000244569.91204.01; Furlan JC, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.11.E13; Garcia-Lopez P, 2007, SPINAL CORD, V45, P603, DOI 10.1038/sj.sc.3102001; Gris D, 2008, EXP NEUROL, V211, P259, DOI 10.1016/j.expneurol.2008.01.033; Grotz M, 2001, CHIRURG, V72, P723, DOI 10.1007/s001040170130; Gruber A, 1999, CRIT CARE MED, V27, P505, DOI 10.1097/00003246-199903000-00026; Guly HR, 2008, RESUSCITATION, V76, P57, DOI 10.1016/j.resuscitation.2007.06.008; Hadley M, 2002, NEUROSURGERY, V50, pS58; Hassid VJ, 2008, J TRAUMA, V65, P1328, DOI 10.1097/TA.0b013e31818d07e4; Heuer M, 2009, J GASTROINTEST LIVER, V18, P197; JACKSON AB, 1994, ARCH PHYS MED REHAB, V75, P270, DOI 10.1016/0003-9993(94)90027-2; Kattail D, 2009, J TRAUMA, V67, P936, DOI 10.1097/TA.0b013e3181a8b431; Kemp CD, 2008, AM SURGEON, V74, P866; Lan MY, 2006, J FORMOS MED ASSOC, V105, P653, DOI 10.1016/S0929-6646(09)60164-9; LEMONS VR, 1994, SPINE, V19, P2315, DOI 10.1097/00007632-199410150-00011; Licina P, 2005, INJURY, V36, P2, DOI 10.1016/j.injury.2005.06.010; MacDiarmid SA, 2000, BJU INT, V85, P1014, DOI 10.1046/j.1464-410x.2000.00680.x; Maiorov DN, 1998, J NEUROTRAUM, V15, P365, DOI 10.1089/neu.1998.15.365; MARSHALL JC, 1995, CRIT CARE MED, V23, P1638, DOI 10.1097/00003246-199510000-00007; Marshall JC, 1997, SEPSIS, V1, P49, DOI DOI 10.1023/A:1009715402392; McKinley WO, 1999, ARCH PHYS MED REHAB, V80, P1402, DOI 10.1016/S0003-9993(99)90251-4; MOHLER JL, 1986, J UROLOGY, V136, P366, DOI 10.1016/S0022-5347(17)44870-1; *NAT SPIN CORD INJ, 2009, SPIN CORD INJ FACTS; Sauaia A, 2009, SHOCK, V31, P438, DOI 10.1097/SHK.0b013e31818ba4c6; SOLENSKI NJ, 1995, CRIT CARE MED, V23, P1007, DOI 10.1097/00003246-199506000-00004; Teasell RW, 2000, ARCH PHYS MED REHAB, V81, P506, DOI 10.1053/mr.2000.3848; Tuli S, 2007, J SPINAL CORD MED, V30, P482, DOI 10.1080/10790268.2007.11754582; Ulvik A, 2007, CRIT CARE, V11, DOI 10.1186/cc6111; Vaidyanathan S, 2000, SPINAL CORD, V38, P197, DOI 10.1038/sj.sc.3100975; Vincent JL, 1998, CRIT CARE MED, V26, P1793, DOI 10.1097/00003246-199811000-00016; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; Wing PC, 2008, J SPINAL CORD MED, V31, P360, DOI 10.1080/10790268.2008.11760737; Winslow C, 2003, AM J PHYS MED REHAB, V82, P803, DOI 10.1097/01.PHM.0000078184.08835.01; Zimmer MB, 2007, J SPINAL CORD MED, V30, P319, DOI 10.1080/10790268.2007.11753947; Zygun DA, 2005, CRIT CARE MED, V33, P654, DOI 10.1097/01.ccm.0000155911.01844.54; Zygun D, 2006, CRIT CARE, V10, DOI 10.1186/cc5007; INT STANDARDS CLASSI; STANDARD NEUROLOGICA	56	35	38	2	9	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	AUG	2010	13	1					29	39		10.1007/s12028-010-9359-9			11	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	620NF	WOS:000279505900006	20407933				2021-06-18	
J	Ohsumi, A; Nawashiro, H; Otani, N; Ooigawa, H; Toyooka, T; Shima, K				Ohsumi, Atsushi; Nawashiro, Hiroshi; Otani, Naoki; Ooigawa, Hidetoshi; Toyooka, Terushige; Shima, Katsuji			Temporal and Spatial Profile of Phosphorylated Connexin43 after Traumatic Brain Injury in Rats	JOURNAL OF NEUROTRAUMA			English	Article						connexin43; fluid percussion injury; gap junction; traumatic brain injury	GAP-JUNCTIONAL COMMUNICATION; LATERAL FLUID-PERCUSSION; SELECTIVE VULNERABILITY; REACTIVE ASTROCYTES; ACTIVATION; EXPRESSION; INCREASES; NEURONS; PROTEIN; KINASE	Gap junctions are conductive channels formed by membrane proteins termed connexins (Cx), which permit the intercellular exchange of metabolites, ions, and small molecules. Junctional permeability is regulated by pH, membrane potential, and intracellular secondary messengers. The purpose of this study was to elucidate the expression and distribution of astrocytic gap junctions in the hippocampus and the cortex after traumatic brain injury (TBI) in vivo. Adult male Sprague-Dawley rats (300-400 g) were subjected to lateral fluid percussion injury (FPI) at moderate severity (2.6-2.8 atm, 12 msec) using a Dragonfly device model. Phosphorylated gap junction protein levels were quantified using Western blot analysis. Spatial distribution of immunoreactivity for phosphorylated Cx43 (p-Cx43) was analyzed by immunohistochemistry. Our findings showed that p-Cx43 expression in the ipsilateral hippocampus was significantly induced at 1 h after TBI, and remained at a high level until 24 h after injury. The p-Cx43 protein content reached a maximum level at 6 h after injury. In addition, the immunoreactivity for p-Cx43 was localized in the astrocytes surrounding ipsilateral CA3 pyramidal neurons. On the other hand, the protein level in the ipsilateral cortex was not significantly different at any time point after TBI. Double immunostaining using phosphorylated ERK (p-ERK) showed that p-Cx43 and p-ERK immunoreactivities were enhanced in the same astrocytes at 6 h after injury. These findings suggest that astrocytic gap junctions participate in pathophysiological processes in the hippocampus after TBI.	[Ohsumi, Atsushi; Nawashiro, Hiroshi; Otani, Naoki; Ooigawa, Hidetoshi; Toyooka, Terushige; Shima, Katsuji] Natl Def Med Coll, Dept Neurosurg, Tokorozawa, Saitama 359, Japan	Ohsumi, A (corresponding author), Natl Def Med Coll, Dept Neurosurg, Namiki 3-2, Tokorozawa, Saitama 359, Japan.	atsuoh@ndmc.ac.jp					BENNETT MVL, 1991, NEURON, V6, P305, DOI 10.1016/0896-6273(91)90241-Q; Brandes RP, 2002, BRIT J PHARMACOL, V136, P709, DOI 10.1038/sj.bjp.0704776; Bruzzone R, 1997, EUR J NEUROSCI, V9, P1, DOI 10.1111/j.1460-9568.1997.tb01346.x; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; Conti AC, 1998, J NEUROSCI, V18, P5663; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Cottrell GT, 2003, AM J PHYSIOL-CELL PH, V284, pC511, DOI 10.1152/ajpcell.00214.2002; Dermietzel R, 1998, BRAIN RES REV, V26, P176, DOI 10.1016/S0165-0173(97)00031-3; Dietrich WD, 1999, J NEUROTRAUM, V16, P567, DOI 10.1089/neu.1999.16.567; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; ENKVIST MOK, 1994, J NEUROCHEM, V62, P489; Frantseva MV, 2002, J NEUROSCI, V22, P644, DOI 10.1523/JNEUROSCI.22-03-00644.2002; Frantseva MV, 2002, J CEREBR BLOOD F MET, V22, P453, DOI 10.1097/00004647-200204000-00009; Giaume C, 1996, TRENDS NEUROSCI, V19, P319, DOI 10.1016/0166-2236(96)10046-1; Giaume C, 1998, GLIA, V24, P50, DOI 10.1002/(SICI)1098-1136(199809)24:1<50::AID-GLIA6>3.3.CO;2-Z; HOSSMANN KA, 1994, ANN NEUROL, V36, P557, DOI 10.1002/ana.410360404; KATAYAMA Y, 1990, ACT NEUR S, V51, P271; LI W, 2005, J BIOL CHEM, V280, P7914; Lin JHC, 1998, NAT NEUROSCI, V1, P494, DOI 10.1038/2210; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Mandell JW, 2001, GLIA, V34, P283, DOI 10.1002/glia.1062; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Muller T, 1995, INT REV NEUROBIOL, V38, P341, DOI 10.1016/S0074-7742(08)60530-9; Nakase T, 2003, STROKE, V34, P1987, DOI 10.1161/01.STR.0000079814.72027.34; NAWASHIRO H, 1995, NEUROL RES, V17, P455, DOI 10.1080/01616412.1995.11740363; NEDERGAARD M, 1993, J CEREBR BLOOD F MET, V13, P568, DOI 10.1038/jcbfm.1993.74; Oguro K, 2001, J NEUROSCI, V21, P7534; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; Otani N, 2002, J CEREBR BLOOD F MET, V22, P327, DOI 10.1097/00004647-200203000-00010; PEREZVELAZQUEZ JL, 1994, J NEUROSCI, V14, P4308; Rami A, 2000, EXP NEUROL, V170, P297, DOI 10.1006/exnr.2001.7712; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Rouach N, 2000, J CELL BIOL, V149, P1513, DOI 10.1083/jcb.149.7.1513; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Siushansian R, 2001, J COMP NEUROL, V440, P387, DOI 10.1002/cne.1392; Teubner B, 2001, J NEUROSCI, V21, P1117; Zhao XR, 2003, GLIA, V44, P140, DOI 10.1002/glia.10283; Zvalova D, 2004, GLIA, V46, P323, DOI 10.1002/glia.10334	38	35	38	1	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2010	27	7					1255	1263		10.1089/neu.2009.1234			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	631FD	WOS:000280331100010	20412010				2021-06-18	
J	Reid, WM; Rolfe, A; Register, D; Levasseur, JE; Churn, SB; Sun, D				Reid, Wendy Murdock; Rolfe, Andrew; Register, David; Levasseur, Joseph E.; Churn, Severn B.; Sun, Dong			Strain-Related Differences after Experimental Traumatic Brain Injury in Rats	JOURNAL OF NEUROTRAUMA			English	Article						epilepsy; Fischer 344 rat; fluid percussion injury; Sprague-Dawley rat; strain	KINASE-II ACTIVITY; SPRAGUE-DAWLEY RATS; STATUS EPILEPTICUS; FLUID PERCUSSION; PILOCARPINE MODEL; FLUORO-JADE; SPINAL-CORD; SEIZURES; RECOVERY; VULNERABILITY	The present study directly compares the effects of experimental brain injury in two commonly used rat strains: Fisher 344 and Sprague-Dawley. We previously found that Fisher rats have a higher mortality rate and more frequent seizure attacks at the same injury level than Sprague-Dawley rats. Although strain differences in rats are commonly accepted as contributing to variability among studies, there is a paucity of literature addressing strain influence in experimental neurotrauma. Therefore this study compares outcome measures in two rat strains following lateral fluid percussion injury. Fisher 344 and Sprague-Dawley rats were monitored for changes in physiological measurements, intracranial pressure, and electroencephalographic activity. We further analyzed neuronal degeneration and cell death in the injured brain using Fluoro-Jade-B (FJB) histochemistry and caspase-3 immunostaining. Behavioral studies using the beam walk and Morris water maze were conducted to characterize strain differences in both motor and cognitive functional recovery following injury. We found that Fisher rats had significantly higher intracranial pressure, prolonged seizure activity, increased FJB-positive staining in the injured cortex and thalamus, and increased caspase-3 expression than Sprague-Dawley rats. On average, Fisher rats displayed a greater amount of total recording time in seizure activity and had longer ictal durations. The Fisher rats also had increased motor deficits, correlating with the above results. In spite of these results, Fisher rats performed better on cognitive tests following injury. The results demonstrate that different rat strains respond to injury differently, and thus in preclinical neurotrauma studies strain influence is an important consideration when evaluating outcomes.	[Reid, Wendy Murdock; Rolfe, Andrew; Levasseur, Joseph E.; Sun, Dong] Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA 23298 USA; [Register, David; Churn, Severn B.] Virginia Commonwealth Univ, Dept Neurol, Richmond, VA 23298 USA	Reid, WM (corresponding author), Virginia Commonwealth Univ, Dept Neurosurg, POB 980631,Med Coll Virginia Campus, Richmond, VA 23298 USA.	murdockwm@vcu.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS055086]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS055086] Funding Source: NIH RePORTER	This study was funded by the National Institutes of Health grant no. NS055086 (to D.S.).	Alahmed S, 2008, NEUROSCIENCE, V157, P677, DOI 10.1016/j.neuroscience.2008.08.072; Anderson KJ, 2003, J NEUROTRAUM, V20, P1223, DOI 10.1089/089771503770802899; Churn SB, 2000, BRAIN RES, V875, P66, DOI 10.1016/S0006-8993(00)02623-8; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; Clausen F, 2005, ACTA NEUROCHIR, V147, P775, DOI 10.1007/s00701-005-0550-2; DeLorenzo Robert J, 2006, Adv Neurol, V97, P187; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Feeney D M, 1987, Brain Inj, V1, P27, DOI 10.3109/02699058709034441; Fujikawa TG, 2000, EPILEPSIA, V41, P981, DOI 10.1111/j.1528-1157.2000.tb00283.x; GOLDEN GT, 1995, EPILEPSY RES, V20, P151, DOI 10.1016/0920-1211(94)00079-C; HAMM RJ, 1995, EXP NEUROL, V136, P143, DOI 10.1006/exnr.1995.1091; Hort J, 2000, BEHAV BRAIN RES, V112, P77, DOI 10.1016/S0166-4328(00)00163-7; HOVDA DA, 1989, BEHAV NEUROSCI, V103, P574, DOI 10.1037/0735-7044.103.3.574; IWASAKI H, 1995, INT J EXP PATHOL, V76, P171; Jiao XL, 2003, PROG NEURO-PSYCHOPH, V27, P913, DOI 10.1016/S0278-5846(03)00150-7; Kearns DN, 2006, BEHAV BRAIN RES, V169, P193, DOI 10.1016/j.bbr.2006.01.005; Kochan LD, 2000, NEUROSCIENCE, V95, P735; Kurz JE, 2005, BRAIN RES, V1048, P153, DOI 10.1016/j.brainres.2005.04.062; Lei YL, 2009, LIFE SCI, V85, P794, DOI 10.1016/j.lfs.2009.10.010; Levasseur JE, 2000, J NEUROTRAUM, V17, P101, DOI 10.1089/neu.2000.17.101; Mazarati A, 2002, EPILEPSIA, V43, P74, DOI 10.1046/j.1528-1157.43.s.5.25.x; Paulson PE, 2005, EXP NEUROL, V196, P413, DOI 10.1016/j.expneurol.2005.08.015; SCHALLERT T, 1986, BRAIN RES, V379, P104, DOI 10.1016/0006-8993(86)90261-1; Schmued LC, 2000, TOXICOL PATHOL, V28, P91, DOI 10.1177/019262330002800111; Singleton MW, 2005, EPILEPSIA, V46, P1389, DOI 10.1111/j.1528-1167.2005.19205.x; Singleton MW, 2005, DEV BRAIN RES, V156, P67, DOI 10.1016/j.devbrainres.2005.02.001; Statler KD, 2008, EPILEPSY RES, V78, P232, DOI 10.1016/j.eplepsyres.2007.11.001; Sun D, 2009, EXP NEUROL, V216, P56, DOI 10.1016/j.expneurol.2008.11.011; Tan AA, 2009, J NEUROTRAUM, V26, P539, DOI 10.1089/neu.2008.0611; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Tran LD, 2006, J NEUROTRAUM, V23, P1330, DOI 10.1089/neu.2006.23.1330; Uchida S, 2008, EUR J NEUROSCI, V27, P2250, DOI 10.1111/j.1460-9568.2008.06218.x; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Walberer M, 2006, LAB ANIM-UK, V40, P1, DOI 10.1258/002367706775404426; Wasterlain CG, 2002, PROG BRAIN RES, V135, P335; Witgen BM, 2006, J NEUROTRAUM, V23, P1320, DOI 10.1089/neu.2006.23.1320; Xu B, 2004, EUR J NEUROSCI, V20, P403, DOI 10.1111/j.1460-9568.2004.03489.x	37	35	35	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2010	27	7					1243	1253		10.1089/neu.2010.1270			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	631FD	WOS:000280331100009	20392137	Green Published			2021-06-18	
J	Chuang, PY; Conley, YP; Poloyac, SM; Okonkwo, DO; Ren, DX; Sherwood, PR; Hravnak, M; Alexander, SA				Chuang, Pei-Ying; Conley, Yvette P.; Poloyac, Samuel M.; Okonkwo, David O.; Ren, Dianxu; Sherwood, Paula R.; Hravnak, Marilyn; Alexander, Sheila A.			Neuroglobin Genetic Polymorphisms and Their Relationship to Functional Outcomes after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						functional outcomes; neuroglobin; single nucleotide polymorphisms; traumatic brain injury	RATING-SCALE; HEAD-INJURY; BINDING-PROPERTIES; MOUSE NEUROGLOBIN; HEME ENVIRONMENT; NITRIC-OXIDE; IN-VITRO; PROTEIN; OXYGEN; CYTOGLOBIN	Neuroglobin has shown rich neuroprotective effects against cerebral hypoxia, and therefore has the potential to impact outcomes after traumatic brain injury (TBI). However, to date an association between genetic variation within the human neuroglobin (NGB) gene and recovery post-TBI has not been reported. The purpose of this study was to explore the relationship between NGB genotypes and outcomes (as assessed by the Glasgow Outcome Scale [GOS], the Disability Rating Scale [DRS], and the Neurobehavioral Rating Scale-Revised [NRS-R]) after severe TBI. Genotyping using TaqMan allele discrimination for two tagging single nucleotide polymorphisms (tSNPs) that represent the two haplotype blocks for NGB (rs3783988 and rs10133981) was completed on DNA obtained from 196 Caucasian patients recovering from severe TBI. Patients were dichotomized based on the presence of the variant allele for each tSNP. Chi-square and Fisher's exact tests were used to compare characteristics between groups. Multivariate linear regression was used to examine NGB tSNPs and recovery from severe TBI. Subjects with the TT genotype (wild-type) for rs3783988 were more likely to have better GOS and DRS scores at 3, 6, 12, and 24 months, while rs10133981 genotype was not significantly related to functional outcome. After controlling for age, gender, and Glasgow Coma Scale (GCS) score, those subjects with the rs3783988 TT genotype had more than a 2.65-times greater likelihood of better functional outcomes than individuals with genotypes harboring a variant allele. Data suggest that the haplotype block represented by rs3783988 in NGB appears to influence recovery after severe TBI. Represented within this haplotype block of NGB is the region that codes for the oxygen-binding portion of NGB.	[Chuang, Pei-Ying; Conley, Yvette P.; Sherwood, Paula R.; Hravnak, Marilyn; Alexander, Sheila A.] Univ Pittsburgh, Sch Nursing, Acute Tertiary Care Dept, Pittsburgh, PA 15261 USA	Chuang, PY (corresponding author), Univ Pittsburgh, Sch Nursing, Acute Tertiary Care Dept, 3500 Victoria St,312 Victoria Bldg, Pittsburgh, PA 15261 USA.	peiyingc@yahoo.com			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NR04801, R01NR008424, P50NS30318]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL074316] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01NR008424, R01NR004339, R01NR004801] Funding Source: NIH RePORTER	We sincerely thank Dr. Mary E. Kerr, Deputy Director of the National Institute of Nursing Research, National Institutes of Health, for introducing us to this topic and for guiding us in our research. Support for the project was provided by grants from the National Institutes of Health (R01NR04801, R01NR008424, and P50NS30318).	*APPL BIOS, 2006, TAQMAN SNP GEN ASS; Brown JIM, 1998, NEUROSURGERY, V42, P1057, DOI 10.1097/00006123-199805000-00060; Brunori M, 2005, P NATL ACAD SCI USA, V102, P8483, DOI 10.1073/pnas.0408766102; Burmester T, 2000, NATURE, V407, P520, DOI 10.1038/35035093; Burmester T, 2004, NEWS PHYSIOL SCI, V19, P110, DOI 10.1152/nips.01513.2003; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Couture M, 2001, J BIOL CHEM, V276, P36377, DOI 10.1074/jbc.M103907200; Cullen NK, 2009, PM&R, V1, P1069, DOI 10.1016/j.pmrj.2009.09.013; Dewilde S, 2001, J BIOL CHEM, V276, P38949, DOI 10.1074/jbc.M106438200; Duong TTH, 2009, J NEUROCHEM, V108, P1143, DOI 10.1111/j.1471-4159.2008.05846.x; Fordel E, 2004, IUBMB LIFE, V56, P681, DOI 10.1080/15216540500037406; Garry DJ, 2003, LANCET, V362, P342, DOI 10.1016/S0140-6736(03)14055-X; Hamdane D, 2003, J BIOL CHEM, V278, P51713, DOI 10.1074/jbc.M309396200; Hamdane D, 2004, MICRON, V35, P59, DOI 10.1016/j.micron.2003.10.019; Hankeln T, 2005, J INORG BIOCHEM, V99, P110, DOI 10.1016/j.jinorgbio.2004.11.009; Herold S, 2005, COMP BIOCHEM PHYS A, V142, P124, DOI 10.1016/j.cbpb.2005.06.009; Hundahl C, 2006, BRAIN RES, V1085, P19, DOI 10.1016/j.brainres.2006.02.040; *INT HAPMAP PROJ, 2009, HAPMAP GEN BROWS PHA; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; Khan AA, 2007, P NATL ACAD SCI USA, V104, P19114, DOI 10.1073/pnas.0706167104; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Lardinois OM, 2008, BIOCHEMISTRY-US, V47, P10440, DOI 10.1021/bi800771k; Lin Y, 2008, BMC MED GENET, V9, DOI 10.1186/1471-2350-9-110; Mammen PPA, 2002, J HISTOCHEM CYTOCHEM, V50, P1591, DOI 10.1177/002215540205001203; McCauley SR, 2001, J NEUROL NEUROSUR PS, V71, P643, DOI 10.1136/jnnp.71.5.643; Miller SA, 1998, NUCLEIC ACIDS RES, V16, P1215, DOI DOI 10.1093/NAR/16.3.1215; Moens L, 2000, NATURE, V407, P461, DOI 10.1038/35035181; Narotam PK, 2009, J NEUROSURG, V111, P672, DOI 10.3171/2009.4.JNS081150; *NAT I NEUR DIS ST, 2009, PUBL NINDS; Peroni D, 2007, NEUROSCI LETT, V421, P110, DOI 10.1016/j.neulet.2007.05.046; Pesce A, 2003, STRUCTURE, V11, P1087, DOI 10.1016/S0969-2126(03)00166-7; Pesce A, 2002, ACTA CRYSTALLOGR D, V58, P1848, DOI 10.1107/S090744490201260X; Pesce A, 2002, EMBO REP, V3, P1146, DOI 10.1093/embo-reports/kvf248; Povlishock JT, 2000, J NEUROTRAUM, V17, pVII, DOI 10.1089/neu.2000.17.vii; Povlishock JT, 2004, J NEUROTRAUM, V21, pIII; *QIAG CORP, 2007, SAMPL 7 ASS TECHN; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Reuss S, 2002, NEUROSCIENCE, V115, P645, DOI 10.1016/S0306-4522(02)00536-5; Smagghe BJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002039; *SPSS INC, 2008, SPSS BAS 15 0 WIND U; Sun YJ, 2001, P NATL ACAD SCI USA, V98, P15306, DOI 10.1073/pnas.251466698; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Van Doorslaer S, 2003, J BIOL CHEM, V278, P4919, DOI 10.1074/jbc.M210617200; Vanier M, 2000, ARCH PHYS MED REHAB, V81, P796, DOI 10.1053/apmr.2000.4436; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; Vinck E, 2006, J BIOL INORG CHEM, V11, P467, DOI 10.1007/s00775-006-0100-2; Wakasugi K, 2005, ANN NY ACAD SCI, V1053, P220, DOI 10.1196/annals.1344.020; Wakasugi K, 2005, BIOCHEMISTRY-US, V44, P2943, DOI 10.1021/bi0477539; Wakasugi K, 2003, J BIOL CHEM, V278, P36505, DOI 10.1074/jbc.M305519200; Walker FA, 2006, J BIOL INORG CHEM, V11, P391, DOI 10.1007/s00775-006-0095-8; Wang XY, 2008, STROKE, V39, P1869, DOI 10.1161/STROKEAHA.107.506022; Wright J, 2000, GLASGOW OUTCOME SCAL; Xu J, 2009, J INORG BIOCHEM, V103, P1693, DOI 10.1016/j.jinorgbio.2009.09.016	55	35	36	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2010	27	6					999	1006		10.1089/neu.2009.1129			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	612VO	WOS:000278933300004	20345238	Green Published			2021-06-18	
J	Cox, DJ; Davis, M; Singh, H; Barbour, B; Nidiffer, FD; Trude, T; Mourant, R; Moncrief, R				Cox, Daniel J.; Davis, Margaret; Singh, Harsimran; Barbour, Brent; Nidiffer, F. Don; Trude, Tina; Mourant, Ronald; Moncrief, Rick			Driving Rehabilitation for Military Personnel Recovering From Traumatic Brain Injury Using Virtual Reality Driving Simulation: A Feasibility Study	MILITARY MEDICINE			English	Article							ACUSTIMULATION; ONDANSETRON	Objective: To investigate the feasibility of virtual reality drying simulation rehabilitation training (VRDSRT) with military personnel recovering from traumatic brain injury (TBI). Methods: Eleven men with TBI were randomly assigned as controls (n = 5) receiving residential rehabilitation only or the VRDSRT group (n = 6) receiving residential rehabilitation and VRDSRT. All subjects underwent pre- and postassessments including simulator driving, and completing road rage and risky driving questionnaires. Between assessments, VRDSRT subjects received 4-6, 60- to 90-min rehabilitation training sessions involving practicing progressively more complex driving skills (lane position, speed control, etc.) through progressively more demanding traffic. Results: VRDSRT was well received, considered realistic and effective, with no reported simulation sickness. Driving performance improved significantly in the VRDSRT group only (p < 0.01). They also demonstrated a reduction in road rage ( p = 0.01) and risky driving ( p = 0.04) at post-assessment. Conclusion: VRDSRT showed promising results with respect to retraining driving performance and behavior among military personnel recovering from TBI.	[Cox, Daniel J.; Davis, Margaret; Singh, Harsimran; Barbour, Brent] Univ Virginia Hlth Syst, Charlottesville, VA 22908 USA; [Nidiffer, F. Don; Trude, Tina] Virginia NeuroCare, Def & Vet Brain Injury Ctr, Charlottesville, VA 22902 USA; [Mourant, Ronald] Northeastern Univ, Snell Engn Ctr 334, Dept Mech & Ind Engn, Boston, MA 02115 USA; [Moncrief, Rick] MBFARR LLC, San Jose, CA 95140 USA	Cox, DJ (corresponding author), Univ Virginia Hlth Syst, Box 800223, Charlottesville, VA 22908 USA.				DARPA (Defense Advanced Research Projects Agency)United States Department of DefenseDefense Advanced Research Projects Agency (DARPA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK028288] Funding Source: NIH RePORTER	The authors gratefully acknowledge the support offered by Dr. Jeffery Barth (director of research), Mr. Gary Levine (speech therapist), and Ms. Kate Bennett (case manager) all at Lakeview Virginia, NeuroCare, Charlottesville, Virginia 22902. The study was supported by a grant from DARPA (Defense Advanced Research Projects Agency) through a Phase I SBIR (Small Business Innovation Research) Program.	Akinwuntan AE, 2005, NEUROLOGY, V65, P843, DOI 10.1212/01.wnl.0000171749.71919.fa; *ARM FORC HLTH SUR, 2008, MSMR, V15, P2; Coloma M, 2002, ANESTHESIOLOGY, V97, P1387, DOI 10.1097/00000542-200212000-00009; Cox CV, 2009, CHRONICLE DRIVER ED, V57, P9; Cox DJ, 2008, ARCH PEDIAT ADOL MED, V162, P793, DOI 10.1001/archpedi.162.8.793; DePasquale JP, 2001, J SAFETY RES, V32, P1, DOI 10.1016/S0022-4375(00)00050-5; Fear NT, 2008, AM J PREV MED, V35, P230, DOI 10.1016/j.amepre.2008.05.027; Hawley CA, 2001, J NEUROL NEUROSUR PS, V70, P761, DOI 10.1136/jnnp.70.6.761; HU SQ, 1992, GASTROENTEROLOGY, V102, P1854, DOI 10.1016/0016-5085(92)90305-I; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Park NW, 2001, NEUROPSYCHOLOGY, V15, P199, DOI 10.1037/0894-4105.15.2.199; RIKE P, INT TRAFF MED ASS AN; Rizzo A, 2005, PRESENCE-TELEOP VIRT, V14, P119, DOI 10.1162/1054746053967094; ROCCHIO C, 2007, DRIVING BRAIN INJURY; SINGH H, 2010, HDB DRIVING IN PRESS; Tamietto M, 2006, NEUROREHABILITATION, V21, P81; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; White PF, 2005, ANESTH ANALG, V100, P367, DOI 10.1213/01.ANE.0000144425.16116.0A; Zoroya G., 2009, 360000 VETERANS MAY	19	35	37	0	10	ASSOC MILITARY SURG US	BETHESDA	9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA	0026-4075			MIL MED	Milit. Med.	JUN	2010	175	6					411	416		10.7205/MILMED-D-09-00081			6	Medicine, General & Internal	General & Internal Medicine	607FS	WOS:000278485100008	20572473	Bronze			2021-06-18	
J	Tran, ND; Kim, S; Vincent, HK; Rodriguez, A; Hinton, DR; Bullock, MR; Young, HF				Tran, Nam D.; Kim, Stefan; Vincent, Heather K.; Rodriguez, Anthony; Hinton, David R.; Bullock, M. Ross; Young, Harold F.			Aquaporin-1-mediated cerebral edema following traumatic brain injury: effects of acidosis and corticosteroid administration Laboratory investigation	JOURNAL OF NEUROSURGERY			English	Article						aquaporin-1; traumatic brain injury; cerebral cortex; edema	FLUID-PERCUSSION INJURY; AQUAPORIN-4 MESSENGER-RNA; SPINAL-CORD-INJURY; WATER CHANNEL; INTRACRANIAL HYPERTENSION; NEUROBEHAVIORAL FUNCTION; PREFERENTIAL EXPRESSION; CO2 PERMEABILITY; GROWTH-FACTOR; UP-REGULATION	Object. Dysregulation of water homeostasis induces cerebral edema. Edema is a major cause of morbidity and mortality following traumatic brain injury (TBI). Aquaporin-1 (AQP-1), a water channel found in the brain, can function as a transporter for CO2 across the cellular membrane. Additionally, AQP-1's promoter contains a glucocorticoid response element. Thus, AQP-1 may be involved with edema-related brain injury and might be modulated by external conditions such as the pH and the presence of steroids. In this study, the authors investigated the hypotheses that: 1) AQP-1 participates in brain water homeostasis following TBI; 2) secondary injury (for example, acidosis) alters the expression of AQP-1 and exacerbates cerebral edema; and 3) corticosteroids augment brain AQP-1 expression and differentially affect cerebral edema under nonacidotic and acidotic conditions. Methods. Anesthetized Sprague-Dawley rats were subjected to moderate to severe TBI (2.5-3.5 atm) or surgery without injury, and they were randomized to receive a 3-mg/kg bolus of intravenous dexamethasone within 10 minutes after injury or surgery, a 3-mg/kg bolus of dexamethasone followed by 1-mg/kg maintenance doses every 8 hours for 24 hours, or saline boluses at similar time intervals. A second group of animals was subjected to respiratory acidosis with target arterial blood pH 6.8-7.2 for 1 hour following the surgery or injury. To evaluate selective blockage of AQP-1, some animals received a single intraperitoneal dose of HgCl2 (0.3-30.0 mmol/L) within 30 minutes of injury or surgery. At 4 or 24 hours postinjury, animals were killed and their brains were harvested for mRNA, protein, or water content analyses. Results. The authors demonstrated elevated cerebral edema levels at 4 and 24 hours following TBI. Dexamethasone administration within 1 hour of TBI attenuated the cerebral edema under nonacidotic conditions but worsened it under acidotic conditions. Selective blockage of AQP-1 channels with HgCl2 attenuated the edematous effects of corticosteroids and acidosis. Reverse transcriptase polymerase chain reaction and immunohistochemical analyses demonstrated a paucity of AQP-1 in the cerebral cortices of the uninjured animals. In contrast, AQP-1 mRNA and protein levels were higher in the cerebral cortices of animals that sustained a TBI. Conclusions. These findings implicate an important, modifiable role for AQP-1 in water homeostasis within the CNS following TBI. (DOI: 10.3171/2009.8.JNS081704)	[Tran, Nam D.; Young, Harold F.] Virginia Commonwealth Univ, Med Coll Virginia, Dept Neurosurg, Richmond, VA 23298 USA; [Kim, Stefan] Lahey Clin Fdn, Dept Neurosurg, Burlington, MA USA; [Vincent, Heather K.] Univ Florida, Dept Orthoped & Rehabil, Gainesville, FL USA; [Rodriguez, Anthony; Hinton, David R.] Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA; [Bullock, M. Ross] Univ Miami, Dept Neurosurg, Coral Gables, FL 33124 USA	Tran, ND (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Dept Neurosurg, 12902 Magnolia Dr, Tampa, FL 33612 USA.	namdtran@alumni.usc.edu	Vincent, Heather/ABH-4566-2020				Agre P, 2002, J PHYSIOL-LONDON, V542, P3, DOI 10.1113/jphysiol.2002.020818; Alderson P, 1997, BRIT MED J, V314, P1855, DOI 10.1136/bmj.314.7098.1855; Alessandri B, 2002, J NEUROTRAUM, V19, P829, DOI 10.1089/08977150260190429; Amlal H, 2004, AM J PHYSIOL-CELL PH, V286, pC1019, DOI 10.1152/ajpcell.00394.2003; Anderson RE, 2000, BRAIN RES, V856, P220, DOI 10.1016/S0006-8993(99)02435-X; Badaut J, 2003, ACTA NEUROCHIR SUPPL, V86, P495; Badaut J, 2004, NEUROSCIENCE, V128, P27, DOI 10.1016/j.neuroscience.2004.05.042; Badaut T, 2002, J CEREBR BLOOD F MET, V22, P367, DOI 10.1097/00004647-200204000-00001; BETZ A L, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P133; Blank ME, 2003, J PHYSIOL-LONDON, V550, P419, DOI 10.1113/jphysiol.2003.040113; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; Bracken MB, 1997, JAMA-J AM MED ASSOC, V277, P1597, DOI 10.1001/jama.277.20.1597; Clausen T, 2005, J NEUROSURG, V103, P597, DOI 10.3171/jns.2005.103.4.0597; Cooper GJ, 1998, AM J PHYSIOL-CELL PH, V275, pC1481; DEEN PMT, 1992, BIOCHEM BIOPH RES CO, V188, P1267, DOI 10.1016/0006-291X(92)91368-Z; Fedorovich SV, 2003, NEUROCHEM RES, V28, P715, DOI 10.1023/A:1022809716834; Feldmann H, 1979, Acta Neurochir Suppl (Wien), V28, P74; Gao HW, 2006, GLIA, V53, P783, DOI 10.1002/glia.20336; GIANNOTTA SL, 1984, NEUROSURGERY, V15, P497, DOI 10.1227/00006123-198410000-00004; Grady MS, 1999, J NEUROTRAUM, V16, P13, DOI 10.1089/neu.1999.16.13; HALL ED, 1985, J NEUROSURG, V62, P882, DOI 10.3171/jns.1985.62.6.0882; JUNG JS, 1994, P NATL ACAD SCI USA, V91, P13052, DOI 10.1073/pnas.91.26.13052; KIMELBERG HK, 1995, J NEUROSURG, V83, P1051, DOI 10.3171/jns.1995.83.6.1051; LEVIN HS, 1991, NEUROSURGERY, V28, P196, DOI 10.1227/00006123-199102000-00004; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; MARMAROU A, 1992, J NEUROTRAUM, V9, pS551; Marmarou A, 2000, J NEUROSURG, V93, P183, DOI 10.3171/jns.2000.93.2.0183; Marmarou A, 2003, ACT NEUR S, V86, P7; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MOON C, 1997, AM J PHYSIOL-CELL PH, V273, pC1562; Morishima T, 2008, NEUROSCI RES, V61, P18, DOI 10.1016/j.neures.2008.01.005; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; Nakhoul NL, 1998, AM J PHYSIOL-CELL PH, V274, pC543; Nesic O, 2008, J NEUROCHEM, V105, P628, DOI 10.1111/j.1471-4159.2007.05177.x; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P7275, DOI 10.1073/pnas.90.15.7275; Nielsen S, 1997, J NEUROSCI, V17, P171; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; OKIYAMA K, 1995, J NEUROCHEM, V64, P802; Okiyama K, 1998, BRAIN RES, V792, P291, DOI 10.1016/S0006-8993(98)00158-9; OKIYAMA K, 1992, J NEUROSURG, V77, P607, DOI 10.3171/jns.1992.77.4.0607; Oshio K, 2005, NEUROSURGERY, V56, P375, DOI 10.1227/01.NEU.0000148904.57841.6B; Oshio K, 2006, BIOCHEM BIOPH RES CO, V341, P1022, DOI 10.1016/j.bbrc.2006.01.062; Papadopoulos MC, 2004, FASEB J, V18, P1291, DOI 10.1096/fj.04-1723fje; Park CO, 1998, YONSEI MED J, V39, P395, DOI 10.3349/ymj.1998.39.5.395; Perez E, 2007, BRAIN RES, V1128, P164, DOI 10.1016/j.brainres.2006.09.109; Plesnila N, 1999, J NEUROTRAUM, V16, P831, DOI 10.1089/neu.1999.16.831; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Rash JE, 1998, P NATL ACAD SCI USA, V95, P11981, DOI 10.1073/pnas.95.20.11981; Rhodes Jonathan K J, 2003, Curr Opin Crit Care, V9, P86; Ringel F, 2006, NEUROSCI LETT, V398, P306, DOI 10.1016/j.neulet.2006.01.012; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; Saatman KE, 2001, J NEUROPATH EXP NEUR, V60, P183, DOI 10.1093/jnen/60.2.183; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; Sarabia R, 1988, Acta Neurochir Suppl (Wien), V42, P40; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; Shields SD, 2007, PAIN, V131, P8, DOI 10.1016/j.pain.2006.11.018; SIESJO BK, 1992, J NEUROSURG, V77, P337, DOI 10.3171/jns.1992.77.3.0337; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; SIESJO BK, 1992, J NEUROSURG, V77, P169, DOI 10.3171/jns.1992.77.2.0169; Solenov EI, 2002, J NEUROSCI METH, V113, P85, DOI 10.1016/S0165-0270(01)00481-2; Stoenoiu MS, 2003, J AM SOC NEPHROL, V14, P555, DOI 10.1097/01.ASN.0000053420.37216.9E; Sun MC, 2003, J NEUROSURG, V98, P565, DOI 10.3171/jns.2003.98.3.0565; Suzuki R, 2006, ACTA NEUROCHIR SUPPL, V96, P398; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Umenishi F, 2002, BIOCHEM BIOPH RES CO, V292, P771, DOI 10.1006/bbrc.2002.6709; Valadka AB, 2007, NEUROSURGERY, V61, P203, DOI 10.1227/01.NEU.0000255497.26440.01; Venero JL, 1999, NEUROSCIENCE, V94, P239, DOI 10.1016/S0306-4522(99)00182-7; Vizuete ML, 1999, NEUROBIOL DIS, V6, P245, DOI 10.1006/nbdi.1999.0246; Vornov JJ, 1996, J NEUROCHEM, V67, P2379; Zauner A, 2002, J NEUROSURG, V97, P643, DOI 10.3171/jns.2002.97.3.0643	71	35	35	1	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAY	2010	112	5					1095	1104		10.3171/2009.8.JNS081704			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	591BW	WOS:000277273600028	19731985				2021-06-18	
J	Air, EL; Yuan, WH; Holland, SK; Jones, BV; Bierbrauer, K; Altaye, M; Mangano, FT				Air, Ellen L.; Yuan, Weihong; Holland, Scott K.; Jones, Blaise V.; Bierbrauer, Karin; Altaye, Mekibib; Mangano, Francesco T.			Longitudinal comparison of pre- and postoperative diffusion tensor imaging parameters in young children with hydrocephalus Clinical article	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						pediatric hydrocephalus; diffusion tensor imaging; fractional anisotropy; mean diffusivity; axial diffusivity; radial diffusivity; cerebrospinal fluid shunt insertion	TRAUMATIC BRAIN-INJURY; WHITE-MATTER MATURATION; MULTIPLE-SCLEROSIS; CORPUS-CALLOSUM; WATER DIFFUSION; EARLY-CHILDHOOD; SPINA-BIFIDA; ANISOTROPY; DTI; ABNORMALITIES	Object. The goal in this study was to compare the integrity of white matter before and after ventriculoperitoneal (VP) shunt insertion by evaluating the an isotropic diffusion properties with the aid of diffusion tensor (DT) imaging in young children with hydrocephalus. Methods. The authors retrospectively identified 10 children with hydrocephalus who underwent both pre- and postoperative DT imaging studies. The DT imaging parameters (fractional anisotropy [FA], mean diffusivity, axial diffusivity, and radial diffusivity) were computed and compared longitudinally in the splenium and genu of the corpus callosum (gCC) and in the anterior and posterior limbs of the internal capsule (PLIC). The patients' values on DT imaging at the pre- and postshunt stages were compared with the corresponding age-matched controls as well as with a large cohort of healthy children in the database. Results. In the gCC, 7 of 10 children had abnormally low preoperative FA values, 6 of which normalized postoperatively. All 3 of the 10 children who had normal preoperative FA values had normal FA values postoperatively as well. In the PUG, 7 of 10 children had abnormally high FA values, 6 of which normalized postoperatively, whereas the other one had abnormally low postoperative FA. Of the remaining 3 children, 2 had abnormally low preoperative FA values in the PLIC; this normalized in 1 patient after surgery. The other child had a normal preoperative FA value that became abnormally low postoperatively. When comparing the presurgery frequency of abnormally low, normal, and abnormally high FA values to those postsurgery, there. was a statistically significant longitudinal difference in both gCC (p = 0.02) and MAC (p = 0.002). Conclusions. In this first longitudinal DT imaging study of young children with hydrocephalus. DT imaging anisotropy yielded abnormal results in several white matter regions of the brain, and trended toward normalization following VP shunt placement. (DOI: 10.3171/2009.11.PEDS09343)	[Mangano, Francesco T.] Univ Cincinnati, Cincinnati Childrens Hosp, Med Ctr, Div Pediat Neurosurg,Dept Pediat Neurosurg, Cincinnati, OH 44529 USA; [Yuan, Weihong; Holland, Scott K.] Cincinnati Childrens Hosp, Dept Radiol, Pediat Neuroimaging Res Consortium, Med Ctr, Cincinnati, OH USA; [Jones, Blaise V.] Cincinnati Childrens Hosp, Med Ctr, Dept Neuroradiol, Cincinnati, OH USA; [Altaye, Mekibib] Cincinnati Childrens Hosp, Med Ctr, Dept Biostat & Epidemiol, Cincinnati, OH USA; [Air, Ellen L.; Bierbrauer, Karin; Mangano, Francesco T.] Univ Cincinnati, Coll Med, Dept Neurosurg, Cincinnati, OH 44529 USA	Mangano, FT (corresponding author), Univ Cincinnati, Cincinnati Childrens Hosp, Med Ctr, Div Pediat Neurosurg,Dept Pediat Neurosurg, MLC 2016,3333 Burnet Ave, Cincinnati, OH 44529 USA.	francesco.mangano@cchmc.org	Altaye, Mekibib/N-5274-2015	Holland, Scott/0000-0003-3719-0875	CCHMC [SPR103674]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000077] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS066932] Funding Source: NIH RePORTER	The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper. This study was supported in part by the Robert L. McLaurin, M.D., Faculty Development Scholarship in Neurosurgery at CCHMC, and by a CCHMC Trustee Grant (SPR103674).	Assaf Y, 2006, AM J NEURORADIOL, V27, P1717; Bammer R, 2000, MAGNET RESON MED, V44, P583, DOI 10.1002/1522-2594(200010)44:4<583::AID-MRM12>3.0.CO;2-O; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Cascio CJ, 2007, J AM ACAD CHILD PSY, V46, P213, DOI 10.1097/01.chi.0000246064.93200.e8; Del Bigio MR, 2003, ANN NEUROL, V53, P337, DOI 10.1002/ana.10453; DELBIGIO MR, 1994, CAN J NEUROL SCI, V21, P299, DOI 10.1017/S0317167100040865; DELBIGIO MR, 1993, ACTA NEUROPATHOL, V85, P573, DOI 10.1007/BF00334666; Ding XQ, 2008, AM J NEURORADIOL, V29, P1261, DOI 10.3174/ajnr.A1097; Dreha-Kulaczewski S, 2006, NEURORADIOLOGY, V48, P893, DOI 10.1007/s00234-006-0148-2; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; FREEMAN GH, 1951, BIOMETRIKA, V38, P141, DOI 10.2307/2332323; Gao W, 2009, AM J NEURORADIOL, V30, P290, DOI 10.3174/ajnr.A1363; Gilmore JH, 2007, AM J NEURORADIOL, V28, P1789, DOI 10.3174/ajnr.A0751; Hasan KM, 2008, J NEUROSURG-PEDIATR, V2, P75, DOI 10.3171/PED/2008/2/7/075; Hasan KM, 2008, J MAGN RESON IMAGING, V27, P700, DOI 10.1002/jmri.21297; Hermoye L, 2006, NEUROIMAGE, V29, P493, DOI 10.1016/j.neuroimage.2005.08.017; Herweh C, 2009, NEUROIMAGE, V44, P306, DOI 10.1016/j.neuroimage.2008.09.006; Jiang HY, 2006, COMPUT METH PROG BIO, V81, P106, DOI 10.1016/j.cmpb.2005.08.004; Khong PL, 2006, J CLIN ONCOL, V24, P884, DOI 10.1200/JCO.2005.02.4505; Leliefeld PH, 2009, J NEUROSURG-PEDIATR, V4, P56, DOI 10.3171/2009.3.PEDS08337; Mataro M, 2001, NEUROPSYCHOL REV, V11, P169, DOI 10.1023/A:1012904907249; Pierpaoli C, 1996, MAGNET RESON MED, V36, P893, DOI 10.1002/mrm.1910360612; Qiu DQ, 2008, NEUROIMAGE, V41, P223, DOI 10.1016/j.neuroimage.2008.02.023; Rose J, 2007, DEV MED CHILD NEUROL, V49, P745, DOI 10.1111/j.1469-8749.2007.00745.x; Saksena S, 2008, CEREBELLUM, V7, P392, DOI 10.1007/s12311-008-0041-0; Schmithorst VJ, 2005, HUM BRAIN MAPP, V26, P139, DOI 10.1002/hbm.20149; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; van Engelen SJPM, 2008, AM J NEURORADIOL, V29, P816, DOI 10.3174/ajnr.A0921; Werring DJ, 2000, J NEUROL NEUROSUR PS, V69, P269, DOI 10.1136/jnnp.69.2.269; Werring DJ, 1999, NEUROLOGY, V52, P1626, DOI 10.1212/WNL.52.8.1626; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Yuan W, 2007, AM J NEURORADIOL, V28, P1919, DOI 10.3174/ajnr.A0698; Yuan W, 2009, AM J NEURORADIOL, V30, P1792, DOI 10.3174/ajnr.A1663; Yuan W, 2008, J NEUROSURG-PEDIATR, V1, P263, DOI 10.3171/PED/2008/1/4/263; Yung A, 2007, PEDIATR RES, V61, P732, DOI 10.1203/pdr.0b013e31805365db; Zelaya F, 1999, MAGN RESON IMAGING, V17, P331, DOI 10.1016/S0730-725X(98)00192-1	37	35	35	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	APR	2010	5	4					385	391		10.3171/2009.11.PEDS09343			7	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	574AB	WOS:000275959700013	20367345				2021-06-18	
J	Dalemans, RJ; de Witte, LP; Beurskens, AJ; van den Heuvel, WJ; Wade, DT				Dalemans, Ruth J.; de Witte, Luc P.; Beurskens, Anna J.; van den Heuvel, Wim J.; Wade, Derick T.			Psychometric Properties of the Community Integration Questionnaire Adjusted for People With Aphasia	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Aphasia; Feasibility studies; Outcome assessment (health care); Rehabilitation	TRAUMATIC BRAIN-INJURY; SOCIAL-PARTICIPATION; VALIDITY; REHABILITATION; RELIABILITY; INSTRUMENTS; STROKE; SCALE	Dalemans RJ, de Witte LP, Beurskens AJ, van den Heuvel WJ, Wade DT. Psychometric properties of the community integration questionnaire adjusted for people with aphasia. Arch Phys Med Rehabil 2010;91:395-9. Objectives: To describe the feasibility of the Community Integration Questionnaire (CIQ) adjusted for use in people with aphasia and to report its psychometric properties in people with aphasia (internal consistency, factor analysis, test-retest reliability, convergent validity). Design: A cross-sectional, interview-based psychometric study. Test-retest reliability was evaluated in 20 people (minimal to severe aphasia) by 2 different interviewers within a 2-week period. Setting: Community. Participants: In total 490 stroke survivors with (minimal to severe) aphasia were approached, of which 165 (34%) participants returned the answering letter. Participants (N=150) agreed to take part and were interviewed using a structured interview format. Interventions: Not applicable. Main Outcome Measures: Community Integration Questionnaire (CIQ), Frenchay Aphasia Screening Test, Barthel Index, Dartmouth Coop Functional Health Assessment Charts (COOP)-World Organisation of Family Doctors (WONCA) Charts, Life Satisfaction Questionnaire. Results: A total of 150 stroke survivors with aphasia completed the CIQ adjusted for people with aphasia. The CIQ adjusted for people with aphasia was a feasible instrument. Results showed good internal consistency for the CIQ total (standardized Cronbach alpha=.75), excellent test-retest reliability (intraclass correlation coefficient=.96), moderate correlations with the Barthel Index, the COOP-WONCA, and the Life Satisfaction Questionnaire with regard to construct validity. Significant relations were found with regard to age and aphasia severity. Conclusions: The CIQ adjusted for people with aphasia seems to he an adequate instrument to assess participation in people with aphasia.	[Dalemans, Ruth J.] Zuyd Univ, Dept Hlth & Tech, Heerlen, Netherlands; [Dalemans, Ruth J.; de Witte, Luc P.] Zuyd Univ, Res Ctr Technol Care, Heerlen, Netherlands; [Dalemans, Ruth J.; Beurskens, Anna J.] Zuyd Univ, Res Ctr Auton & Participat People Chron Illnesses, Heerlen, Netherlands; [van den Heuvel, Wim J.] Maastricht Univ, Fac Hlth Med & Life Sci, Maastricht, Netherlands; [Wade, Derick T.] Oxford Ctr Enablement, Oxford, England	Dalemans, RJ (corresponding author), Nieuw Eyckholt 300,Postbus 550, NL-6400 AN Heerlen, Netherlands.	r.dalemans@hszuyd.nl	van+den+Heuvel, Wim/AAI-9981-2020; De+Witte, Luc/AAI-3518-2020	De+Witte, Luc/0000-0002-3013-2640; Wade, Derick/0000-0002-1188-8442			Aleligay A, 2008, APHASIOLOGY, V22, P383, DOI 10.1080/02687030701415872; Charlifue S, 2004, NEUROREHABILITATION, V19, P91; Collin C, 1988, Int Disabil Stud, V10, P61; Dalemans R, 2008, CLIN REHABIL, V22, P542, DOI 10.1177/0269215507087462; Dalemans R, 2009, CLIN REHABIL, V23, P948, DOI 10.1177/0269215509337197; Dalemans RJP, 2008, APHASIOLOGY, V22, P1071, DOI 10.1080/02687030701632179; Doig E, 2001, BRAIN INJURY, V15, P747, DOI 10.1080/02699050110034343; Eadie TL, 2006, AM J SPEECH-LANG PAT, V15, P307, DOI 10.1044/1058-0360(2006/030); Enderby P M, 1987, Int Rehabil Med, V8, P166; Fleming J, 1999, BRAIN INJURY, V13, P417; Fugl-Meyer A. R., 1991, CLIN REHABIL, V5, DOI [10.1177/026921559100500105, DOI 10.1177/026921559100500105, 10.1177/026921559100500105.]; Hansen NS, 1998, TOP SPINAL CORD INJ, V4, P56; Hilari K, 2003, STROKE, V34, P1944, DOI 10.1161/01.STR.0000081987.46660.ED; Kaplan CP, 2001, BRAIN INJURY, V15, P725, DOI 10.1080/02699050010005913; Kuipers P, 2004, BRAIN INJURY, V18, P161, DOI 10.1080/0269905031000149524; Nunnally J. C., 1994, PSYCHOMETRIC THEORY; *ONT BRAIN INJ ASS, 2008, COMM INT QUEST SCOR; Reistetter TA, 2005, NEUROREHABILITATION, V20, P139; Reistetter Timothy A, 2005, Occup Ther Int, V12, P196; Salter KL, 2007, INT J REHABIL RES, V30, P339, DOI 10.1097/MRR.0b013e3282f144b7; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; Terwee CB, 2007, J CLIN EPIDEMIOL, V60, P34, DOI 10.1016/j.jclinepi.2006.03.012; van Baalen B, 2006, CLIN REHABIL, V20, P686, DOI 10.1191/0269215506cre982oa; van de Ven L, 2005, DISABIL SOC, V20, P311, DOI 10.1080/09687590500060778; Van der Mei SF, 2007, DISABIL REHABIL, V29, P473, DOI 10.1080/09638280600841257; Van Weel C, 1993, Disabil Rehabil, V15, P96; Wade D T, 1988, Int Disabil Stud, V10, P64; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Winkler D, 2006, J HEAD TRAUMA REHAB, V21, P8, DOI 10.1097/00001199-200601000-00002; Zhang L, 2002, J HEAD TRAUMA REHAB, V17, P497, DOI 10.1097/00001199-200212000-00002	30	35	36	0	7	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAR	2010	91	3					395	399		10.1016/j.apmr.2009.10.021			5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	592YM	WOS:000277417900011	20298830				2021-06-18	
J	Kuehl, MD; Snyder, AR; Erickson, SE; McLeod, TCV				Kuehl, Matthew D.; Snyder, Alison R.; Erickson, Steven E.; McLeod, Tamara C. Valovich			Impact of Prior Concussions on Health-Related Quality of Life in Collegiate Athletes	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						brain injury; athlete; headache; outcomes; HIT-6; SF-36	TRAUMATIC BRAIN-INJURY; PROFESSIONAL FOOTBALL PLAYERS; RECURRENT CONCUSSION; SURVEY SF-36; GENERAL-POPULATION; NCAA CONCUSSION; HIGH-SCHOOL; SELF-REPORT; SYMPTOMS; VALIDITY	Objective: To investigate how self-reported sport-related concussion history affects health-related quality of life in collegiate athletes. Design: Cross sectional. Setting: Division I university, Division II university, and a junior college. Participants: Three hundred two collegiate athletes (210 men, 92 women). Assessment of Risk Factors: Participants completed a demographic information sheet and concussion history form; they were then grouped by number of previous self-reported concussions, designated as 0, 1-2, or 3+. Main Outcome Measures: The Medical Outcomes Short Form (SF-36) and the Headache Impact Test (HIT-6). Results: Significant differences between groups were found for the bodily pain, vitality, and social functioning subscales of the SF-36. The 3+ group had significantly lower scores for bodily pain (48.1 +/- 8.9) compared with the 1-2 group (P = 0.028, 52.1 +/- 7.7) and 0 group (P < 0.01, 53.5 +/- 8.3), for vitality (52.4 +/- 8.4) compared with the 0 group (P = 0.011, 55.9 +/- 8.6), and for social functioning (48.5 +/- 9.4) compared with the 1-2 group (P = 0.028, 51.6 +/- 7.3) and 0 group (P = 0.003, 51.9 +/- 8.1). Significant differences were noted on the HIT-6 total score. The 3+ group reported greater impact of headache (46.7 +/- 6.4) than the 1-2 group (P = 0.05, 44.6 +/- 6.4) and 0 group (P < 0.001, 42.9 +/- 5.8). The 1-2 group also had higher HIT-6 scores than the 0 group (P = 0.033). Conclusions: Results suggest that a collegiate athlete's perception of bodily pain, vitality, social functioning, and headache is adversely affected by previous sport-related concussions. However, by incorporating general and specific outcome measures into the standard evaluation of sport-related concussion, the clinician can better determine how the athlete is responding to treatment and recovery.	[McLeod, Tamara C. Valovich] AT Still Univ, Dept Interdisciplinary Hlth Sci, Athlet Training Program, Mesa, AZ 85206 USA; [Erickson, Steven E.] Arizona State Univ, Dept Sports Med, Tempe, AZ USA	McLeod, TCV (corresponding author), AT Still Univ, Dept Interdisciplinary Hlth Sci, Athlet Training Program, 5850 E Still Circle, Mesa, AZ 85206 USA.	tmcleod@atsu.edu	McLeod, Tamara/AAU-9435-2020				Bayliss MS, 2002, HIT 6 USERS GUIDE; Bourgeois FT, 2007, J AM MED INFORM ASSN, V14, P765, DOI 10.1197/jamia.M2134; Broglio SP, 2006, BRIT J SPORT MED, V40, P802, DOI 10.1136/bjsm.2006.028019; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Bruce JM, 2009, NEUROSURGERY, V64, P100, DOI 10.1227/01.NEU.0000336310.47513.C8; Emanuelson I, 2003, ACTA NEUROL SCAND, V108, P332, DOI 10.1034/j.1600-0404.2003.00155.x; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Heniford BT, 2008, J AM COLL SURGEONS, V206, P638, DOI 10.1016/j.jamcollsurg.2007.11.025; Honkanen K, 1999, AM J EPIDEMIOL, V150, P511; Huffman GR, 2008, J BONE JOINT SURG AM, V90A, P471, DOI 10.2106/JBJS.G.00325; Hutchison M, 2009, CLIN J SPORT MED, V19, P13, DOI 10.1097/JSM.0b013e318190ba06; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Kawata AK, 2005, HEADACHE, V45, P638, DOI 10.1111/j.1526-4610.2005.05130.x; Klasser Gary D, 2005, Gen Dent, V53, P348; Kosinski M, 2003, QUAL LIFE RES, V12, P963, DOI 10.1023/A:1026119331193; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Mainwaring LM, 2004, J SPORT EXERCISE PSY, V26, P119, DOI 10.1123/jsep.26.1.119; McAllister DR, 2001, AM J SPORT MED, V29, P806, DOI 10.1177/03635465010290062201; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; MCHORNEY CA, 1994, MED CARE, V32, P40, DOI 10.1097/00005650-199401000-00004; MCLEOD TCV, 2009, BR J SPORTS MED S1, V43, P93; Ruta D A, 1994, Qual Health Care, V3, P180, DOI 10.1136/qshc.3.4.180; Sallis RE, 2000, MED SCI SPORT EXER, V32, P1820, DOI 10.1097/00005768-200011000-00002; Sim A, 2008, J NEUROSURG, V108, P511, DOI 10.3171/JNS/2008/108/3/0511; Snyder AR, J SPORT REH IN PRESS; Terwindt GM, 2000, NEUROLOGY, V55, P624, DOI 10.1212/WNL.55.5.624; Testa MA, 1996, NEW ENGL J MED, V334, P835, DOI 10.1056/NEJM199603283341306; Tkachuk GA, 2003, HEADACHE, V43, P950, DOI 10.1046/j.1526-4610.2003.03185.x; Ware J. E., 2008, USERS MANUAL SF 36V2; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Yang CC, 2007, J TRAUMA, V62, P657, DOI 10.1097/01.ta.0000203577.68764.b8	37	35	35	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	MAR	2010	20	2					86	91		10.1097/JSM.0b013e3181cf4534			6	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	567XK	WOS:000275481500003	20215889				2021-06-18	
J	Kumar, A; Singh, RL; Babu, GN				Kumar, Alok; Singh, Ram Lakhan; Babu, G. Nagesh			Cell death mechanisms in the early stages of acute glutamate neurotoxicity	NEUROSCIENCE RESEARCH			English	Article						Caspases; Bcl-2 family; GSH; ROS; Peroxynitrite; Nitric oxide synthase	TRAUMATIC BRAIN-INJURY; AMYOTROPHIC-LATERAL-SCLEROSIS; OXIDATIVE STRESS; TRANSGENIC MICE; MOUSE MODEL; BCL-2; RECEPTORS; NEURONS; RAT; BAX	The present study focused on the early stages of acute glutamate (L-Glu)-induced neurotoxic mechanisms, both biochemical, e.g intracellular reactive oxygen species (ROS) and associated parameters as well as gene expression of cell survival/death pathways, i.e Bcl-2 and caspases Stereotactic intracortical injections of L-Glu (1 mu mol/1 mu l) resulted in decreased size of pyramidal neurons in rat after 1 h We also observed that intracellular ROS, calcium (Ca(2+)) and peroxynitrite (ONOO(-)) production were significantly elevated, whereas, mitochondrial transmembrane potential (Delta Psi m) and total glutathione were significantly decreased by L-Glu bolus. The Bcl-2/Bax ratio in the I: Glu-injected rats was found to be significantly lower than the controls. Moreover, acute L-Glu significantly induced mRNA expression of nNOS, iNOS, caspase-3 and caspase-9 It may be concluded from the present Study that acute L-Glu administration, at an early stage. increases intracellular ROS accumulation, Ca(2+) levels and peroxynitrite production and decreases glutathione pool Furthermore, it appears that decreased mitochondrial Bcl-2/Bax ratio might have upregulated the mRNA expression of caspase-3 and caspase-9 which launch cell death cascade. Regarding the chronology of the events. we presume that acute L-GILT increases ROS and decreases Delta Psi m and glutathione rapidly and it is more likely that these events precede gene expression changes, ultimately resulting in neuronal damage/death (C) 2009 Elsevier Ireland Ltd anti the Japan Neuroscience Society All rights reserved	[Kumar, Alok; Babu, G. Nagesh] Sanjay Gandhi Post Grad Inst Med Sci, Dept Neurol, Lucknow 226014, Uttar Pradesh, India; [Singh, Ram Lakhan] Dr RML Avadh Univ, Dept Biochem, Faizabad, Uttar Pradesh, India	Babu, GN (corresponding author), Sanjay Gandhi Post Grad Inst Med Sci, Dept Neurol, Raebareh Rd, Lucknow 226014, Uttar Pradesh, India.			SINGH, RAM LAKHAN/0000-0002-1371-2600	Council of Scientific and Industrial Research, New Delhi, IndiaCouncil of Scientific & Industrial Research (CSIR) - India	We acknowledge the Council of Scientific and Industrial Research, New Delhi, India for financial support to A.K. in the form of a Senior Research Fellowship	Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; BREHE JE, 1976, ANAL BIOCHEM, V74, P189, DOI 10.1016/0003-2697(76)90323-7; Chen R, 2004, J CELL BIOL, V166, P193, DOI 10.1083/jcb.200309146; Dohare P, 2008, NITRIC OXIDE-BIOL CH, V19, P1, DOI 10.1016/j.niox.2008.04.020; Duan Y, 2007, J PHYSL, V15, P741; EMAUS RK, 1986, BIOCHIM BIOPHYS ACTA, V850, P436, DOI 10.1016/0005-2728(86)90112-X; Ha JS, 2009, BRAIN RES, V1273, P138, DOI 10.1016/j.brainres.2009.03.050; Hara A, 1996, VIRCHOWS ARCH, V429, P249; Hochman A, 1998, J NEUROCHEM, V71, P741; KOOY NW, 1994, FREE RADICAL BIO MED, V16, P149, DOI 10.1016/0891-5849(94)90138-4; Lawrence MS, 1997, J CEREBR BLOOD F MET, V17, P740; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; Mu XJ, 1996, ANN NEUROL, V40, P379, DOI 10.1002/ana.410400307; Oyama Y, 1996, BRAIN RES, V728, P121; Pavlovic V, 2009, BRATISL MED J, V110, P205; Pellegrini-Giampietro DE, 2003, TRENDS PHARMACOL SCI, V24, P461, DOI 10.1016/S0165-6147(03)00231-1; Petros AM, 2004, BBA-MOL CELL RES, V1644, P83, DOI 10.1016/j.bbamcr.2003.08.012; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; Raghupathi R, 2003, J NEUROTRAUM, V20, P421, DOI 10.1089/089771503765355504; Raghupathi R, 2002, NEUROSCIENCE, V110, P605, DOI 10.1016/S0306-4522(01)00461-4; Sagara Y, 1998, J NEUROSCI, V18, P6662; Salakou S, 2007, IN VIVO, V21, P123; Vila M, 2001, P NATL ACAD SCI USA, V98, P2837, DOI 10.1073/pnas.051633998; Vukosavic S, 2000, J NEUROSCI, V20, P9119; Yang LC, 1998, J NEUROSCI, V18, P8145; Zimmermann AK, 2007, J BIOL CHEM, V282, P29296, DOI 10.1074/jbc.M702853200	26	35	36	0	4	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0168-0102			NEUROSCI RES	Neurosci. Res.	MAR	2010	66	3					271	278		10.1016/j.neures.2009.11.009			8	Neurosciences	Neurosciences & Neurology	570WJ	WOS:000275708800006	19944120				2021-06-18	
J	Fortin, A; Lefebvre, MB; Ptito, M				Fortin, Audrey; Lefebvre, Mathilde Beaulieu; Ptito, Maurice			Traumatic brain injury and olfactory deficits: The tale of two smell tests!	BRAIN INJURY			English	Article						Olfaction; smell test; UPSIT; Alberta smell test; mild head injury	HEAD TRAUMA; IDENTIFICATION TEST; DEPRESSION; DYSFUNCTION; DISORDERS; SEVERITY; ANOSMIA; TASTE	Primary objective: Olfactory functions are not systematically evaluated following traumatic brain injury (TBI). This study aimed at comparing two smell tests that are used in a clinical setting. Research design: The University of Pennsylvania Smell Identification Test (UPSIT) and the Alberta Smell Test were compared in terms of assessment time, cost and diagnosis. Parameters associated with olfactory loss such as injury severity, type of cerebral lesion and depressive data were considered. Forty-nine TBI patients admitted to an outpatient rehabilitation programme took part in this experiment. Results: The scores of the two smell tests were significantly correlated. Both tests indicated that patients with frontal lesion performed significantly worse than patients with other types of lesion. Mood and injury severity were not associated with olfactory impairment when age was taken into account. Between 40-44% of the patients showing olfactory impairments were not aware of their deficit. Conclusions: Since a significant proportion of the patients showing olfactory impairments were not aware of their deficit, it is recommended than clinicians systematically evaluate olfactory functions using the Alberta Smell test. To refine their diagnosis, the UPSIT can also be used.	[Fortin, Audrey] Ctr Readaptat Lucie Bruneau, CRIR, Montreal, PQ, Canada; [Fortin, Audrey; Lefebvre, Mathilde Beaulieu; Ptito, Maurice] Univ Montreal, Ecole Optometrie, CRIR, Montreal, PQ H3C 3J7, Canada	Fortin, A (corresponding author), Ctr Readaptat Lucie Bruneau, CRIR, Montreal, PQ, Canada.	afortin.crlb@ssss.gouv.qc.ca	Ptito, Maurice/G-3422-2013	Ptito, Maurice/0000-0002-5173-5862	Reseau Provincial de Recherche en Adaptation-Readaptation (REPAR); National Science and Engineering Research Council of Canada (NSERC)Natural Sciences and Engineering Research Council of Canada (NSERC)	This work was supported by a grant from the Reseau Provincial de Recherche en Adaptation-Readaptation (REPAR) to AF and MP. MBL is supported by the National Science and Engineering Research Council of Canada (NSERC).	BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5; Biacabe B, 2000, REV NEUROL-FRANCE, V156, P451; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Buschuter D, 2008, NEUROIMAGE, V42, P498, DOI 10.1016/j.neuroimage.2008.05.004; Callahan CD, 2002, J HEAD TRAUMA REHAB, V17, P251, DOI 10.1097/00001199-200206000-00006; Callahan CD, 1999, J HEAD TRAUMA REHAB, V14, P581, DOI 10.1097/00001199-199912000-00006; CONSTANZO RM, 1991, SMELL TASTE HLTH DIS, P730; Doty RL, 1997, ARCH NEUROL-CHICAGO, V54, P1131, DOI 10.1001/archneur.1997.00550210061014; Doty RL, 2001, ANNU REV PSYCHOL, V52, P423, DOI 10.1146/annurev.psych.52.1.423; DOTY RL, 1984, PHYSIOL BEHAV, V32, P489, DOI 10.1016/0031-9384(84)90269-5; Doty RL, 1995, SMELL IDENTIFICATION; Fujii M, 2002, AURIS NASUS LARYNX, V29, P35, DOI 10.1016/S0385-8146(01)00118-3; Glenn MB, 2001, BRAIN INJURY, V15, P811, DOI 10.1080/02699050010025777; Green P, 2003, BRAIN INJURY, V17, P479, DOI 10.1080/0269905031000070242; Green P, 2001, NEUROREHABILITATION, V16, P237; MARCOTTE AC, 2005, ORIENTATIONS MINISTE; Nordin S, 2008, CURR OPIN ALLERGY CL, V8, P10, DOI 10.1097/ACI.0b013e3282f3f473; PEPIN M, 2008, TRAVAUX COMITE INT T, P27; Reiter ER, 2004, OTOLARYNG CLIN N AM, V37, P1167, DOI 10.1016/j.otc.2004.06.005; Renzi G, 2002, ANN PLAS SURG, V48, P355, DOI 10.1097/00000637-200204000-00003; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; Savic I, 2000, NEURON, V26, P735, DOI 10.1016/S0896-6273(00)81209-X; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; SUMNER D, 1964, BRAIN, V87, P107, DOI 10.1093/brain/87.1.107; Zasler ND, 1992, J HEAD TRAUMA REHAB, V7, P66	25	35	35	1	12	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	2010	24	1					27	33		10.3109/02699050903446815			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	554AA	WOS:000274406700003	20001480				2021-06-18	
J	Jin, W; Ni, HB; Dai, YX; Wang, HD; Lu, TY; Wu, J; Jiang, JA; Liang, WB				Jin, Wei; Ni, Hongbin; Dai, Yuxiang; Wang, Handong; Lu, Tianyu; Wu, Jun; Jiang, Jian; Liang, Weibang			Effects of Tert-Butylhydroquinone on Intestinal Inflammatory Response and Apoptosis following Traumatic Brain Injury in Mice	MEDIATORS OF INFLAMMATION			English	Article							NF-KAPPA-B; NRF2-DRIVEN ANTIOXIDANT RESPONSE; NRF2 ENHANCES SUSCEPTIBILITY; GLUTATHIONE-S-TRANSFERASE; OXIDATIVE STRESS; TRANSCRIPTION FACTOR; NRF2-DEFICIENT MICE; PIVOTAL ROLE; INDUCTION; PROTECTION	Traumatic brain injury (TBI) can induce intestinal inflammatory response and mucosal injury. Antioxidant transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) has been shown in our previous studies to prevent oxidative stress and inflammatory response in gut after TBI. The objective of this study was to test whether tert-butylhydroquinone (tBHQ), an Nrf2 inducer, can protect against TBI-induced intestinal inflammatory response and mucosal injury in mice. Adult male ICR mice were randomly divided into three groups: (1) sham + vehicle group, (2) TBI + vehicle group, and (3) TBI + tBHQ group (n = 12 per group). Closed head injury was adopted using Hall's weight-dropping method. Intestinal mucosa apoptosis and inflammatory-related factors, such as nuclear factor kappa B (NF-kappa B), tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1 beta), interleukin-6 (IL-6) and intercellular adhesion molecule-1 (ICAM-1), were investigated at 24 h after TBI. As a result, we found that oral treatment with 1% tBHQ prior to TBI for one week markedly decreased NF-kappa B activation, inflammatory cytokines production, and ICAM-1 expression in the gut. Administration of tBHQ also significantly attenuated TBI-induced intestinal mucosal apoptosis. The results of the present study suggest that tBHQ administration could suppress the intestinal inflammation and reduce the mucosal damage following TBI.	[Jin, Wei; Ni, Hongbin; Dai, Yuxiang; Lu, Tianyu; Wu, Jun; Jiang, Jian; Liang, Weibang] Nanjing Univ, Dept Neurosurg, Drum Tower Hosp, Sch Med, Nanjing 210008, Jiangsu, Peoples R China; [Wang, Handong] Nanjing Univ, Dept Neurosurg, Jinling Hosp, Sch Med, Nanjing 210002, Jiangsu, Peoples R China	Liang, WB (corresponding author), Nanjing Univ, Dept Neurosurg, Drum Tower Hosp, Sch Med, 321 Zhongshan Rd, Nanjing 210008, Jiangsu, Peoples R China.	njneurosurgery@yahoo.com.cn			Drum Tower Hospital of China	This work was supported by grants from Drum Tower Hospital of China. The authors thank Dr. Li-zhi Xu and Dr. Geng-bao Feng for their technical assistance. W. Jin, H. Ni, and Y. Dai have contributed equally to this work.	Calkins MJ, 2005, P NATL ACAD SCI USA, V102, P244, DOI 10.1073/pnas.0408487101; Chen F, 1999, CLIN CHEM, V45, P7; Doig CJ, 1998, AM J RESP CRIT CARE, V158, P444, DOI 10.1164/ajrccm.158.2.9710092; HALL ED, 1985, J NEUROSURG, V62, P882, DOI 10.3171/jns.1985.62.6.0882; Hang CH, 2005, J SURG RES, V123, P188, DOI 10.1016/j.jss.2004.08.002; Hang CH, 2004, BRAIN RES, V1026, P23, DOI 10.1016/j.brainres.2004.07.090; Hang CH, 2003, WORLD J GASTROENTERO, V9, P2776; Hang CH, 2005, WORLD J GASTROENTERO, V11, P1149, DOI 10.3748/wjg.v11.i8.1149; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Jin W, 2008, CYTOKINE, V44, P135, DOI 10.1016/j.cyto.2008.07.005; Jin W, 2009, J SURG RES, V157, P251, DOI 10.1016/j.jss.2008.08.003; Jin W, 2009, J NEUROTRAUM, V26, P131, DOI 10.1089/neu.2008.0655; Johnson DA, 2002, J NEUROCHEM, V81, P1233, DOI 10.1046/j.1471-4159.2002.00913.x; Khor TO, 2006, CANCER RES, V66, P11580, DOI 10.1158/0008-5472.CAN-06-3562; Koh K, 2009, BIOCHEM BIOPH RES CO, V380, P449, DOI 10.1016/j.bbrc.2009.01.082; Kraft AD, 2004, J NEUROSCI, V24, P1101, DOI 10.1523/JNEUROSCI.3817-03.2004; Lamb JG, 2000, DRUG METAB DISPOS, V28, P1018; Lee JM, 2003, J BIOL CHEM, V278, P12029, DOI 10.1074/jbc.M211558200; Lee JM, 2004, J BIOCHEM MOL BIOL, V37, P139; Li J, 2005, TOXICOL SCI, V83, P313, DOI 10.1093/toxsci/kfi027; Motohashi H, 2004, TRENDS MOL MED, V10, P549, DOI 10.1016/j.molmed.2004.09.003; Munday R, 2004, CARCINOGENESIS, V25, P1721, DOI 10.1093/carcin/bgh162; Munzel PA, 2003, BIOCHEM PHARMACOL, V66, P841, DOI 10.1016/S0006-2952(03)00389-7; Nakamura Y, 2003, BIOCHEMISTRY-US, V42, P4300, DOI 10.1021/bi0340090; Neurath MF, 1996, NAT MED, V2, P998, DOI 10.1038/nm0996-998; Nishizono S, 2000, BIOSCI BIOTECH BIOCH, V64, P1153, DOI 10.1271/bbb.64.1153; Osburn WO, 2006, ARCH BIOCHEM BIOPHYS, V454, P7, DOI 10.1016/j.abb.2006.08.005; Pilitsis JG, 2001, NEUROL RES, V23, P227, DOI 10.1179/016164101101198389; Potten CS, 1997, STEM CELLS, V15, P82, DOI 10.1002/stem.150082; Rangasamy T, 2005, J EXP MED, V202, P47, DOI 10.1084/jem.20050538; Rangasamy T, 2004, J CLIN INVEST, V114, P1248, DOI 10.1172/JCI200421146; Shih AY, 2005, J NEUROSCI, V25, P10321, DOI 10.1523/JNEUROSCI.4014-05.2005; Shih AY, 2005, J BIOL CHEM, V280, P22925, DOI 10.1074/jbc.M414635200; Shohami E, 1999, J NEUROTRAUM, V16, P365, DOI 10.1089/neu.1999.16.365; Thimmulappa RK, 2006, J CLIN INVEST, V116, P984, DOI 10.1172/JCI25790; Yan D, 2010, BIOCHEM PHARMACOL, V80, P144, DOI 10.1016/j.bcp.2010.03.004; Zhang C, 2002, BURNS, V28, P731, DOI 10.1016/S0305-4179(02)00210-3; 1999, WHO TECHNICAL REPORT, V884, P1	38	35	35	0	6	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	0962-9351	1466-1861		MEDIAT INFLAMM	Mediat. Inflamm.		2010	2010								502564	10.1155/2010/502564			7	Cell Biology; Immunology	Cell Biology; Immunology	728IX	WOS:000287868900001	21274455	DOAJ Gold, Green Published			2021-06-18	
J	Calogeropoulou, T; Avlonitis, N; Minas, V; Alexi, X; Pantzou, A; Charalampopoulos, I; Zervou, M; Vergou, V; Katsanou, ES; Lazaridis, I; Alexis, MN; Gravanis, A				Calogeropoulou, Theodora; Avlonitis, Nicolaos; Minas, Vassilios; Alexi, Xanthippi; Pantzou, Athanasia; Charalampopoulos, Ioannis; Zervou, Maria; Vergou, Varvara; Katsanou, Efrosini S.; Lazaridis, Iakovos; Alexis, Michael N.; Gravanis, Achille			Novel Dehydroepiandrosterone Derivatives with Antiapoptotic, Neuroprotective Activity	JOURNAL OF MEDICINAL CHEMISTRY			English	Article							TRAUMATIC BRAIN-INJURY; SPINAL-CORD-INJURY; ESTROGEN-RECEPTOR-BETA; PROSTATE-CANCER CELLS; NERVOUS-SYSTEM; NEUROACTIVE STEROIDS; GABA(A) RECEPTORS; IN-VITRO; HIPPOCAMPAL-NEURONS; PROTEIN EXPRESSION	DHEA analogues with modifications at positions C3 or 07 were synthesized and evaluated for neuroprotective activity against the neural-crest-derived PC12 cell model of serum deprivation-induced apoptosis. The most potent compounds were the spiro-epoxy derivatives 17 beta-spiro[5-androstene-17, 2'-oxiran]-3 beta-ol (20), (20S)-3 beta,21-dihydroxy-17 beta,20-epoxy-5-pregnene (23), and (20R)-3 beta,21-dihydroxy-17 alpha,20-epoxy-5-pregnene (27) with IG(50) values of 0.19 +/- 0.01, 99.0 +/- 4.6, and 6.4 +/- 0.3 nM, respectively. Analogues 20, 23, and 27, up to the micromolar range of concentrations, were unable to activate estrogen receptor alpha and beta (ER alpha and ER beta) or to interfere with ER-dependent gene expression significantly. In addition, they were unable to stimulate the growth of Ishikawa, MCF-7, and LNCaP cells. Our results suggest that the spiro-epoxyneurosteroid derivatives 20, 23, and 27 may prove to be lead molecules for the synthesis of novel neuroprotective agents.	[Calogeropoulou, Theodora; Avlonitis, Nicolaos; Pantzou, Athanasia; Zervou, Maria] Natl Hellen Res Fdn, Inst Organ & Pharmaceut Chem, Athens 11635, Greece; [Alexi, Xanthippi; Katsanou, Efrosini S.; Alexis, Michael N.] Natl Hellen Res Fdn, Inst Biol Res & Biotechnol, Athens 11635, Greece; [Minas, Vassilios; Charalampopoulos, Ioannis; Vergou, Varvara; Lazaridis, Iakovos; Gravanis, Achille] Univ Crete, Sch Med, Dept Pharmacol, Iraklion 71110, Greece	Calogeropoulou, T (corresponding author), Natl Hellen Res Fdn, Inst Organ & Pharmaceut Chem, 48 Vassileos Constantinou Ave, Athens 11635, Greece.	tcalog@eie.gr	Avlonitis, Nicolaos/T-6053-2019; Charalampopoulos, Ioannis/I-6319-2012; Avlonitis, Nicolaos/A-5161-2009; Katsanou, Efrosini/AAU-1502-2020	Charalampopoulos, Ioannis/0000-0003-3415-7332; Katsanou, Efrosini/0000-0002-6381-1332; Alexis, Michael N/0000-0002-4243-7628; Zervou, Maria/0000-0001-5963-4954; Lazaridis, Iakovos/0000-0002-4578-2347	Greek General Secretariat for Research and TechnologyGreek Ministry of Development-GSRT [PENED 2001 ED258]; Bionature EA Ltd.; EmergoMed Co	This work was Supported in part by the Greek General Secretariat for Research and Technology (Programme PENED 2001 ED258) and a grant from Bionature EA Ltd. and EmergoMed Co.	Barger SW, 2000, J NEUROSCI RES, V62, P503, DOI 10.1002/1097-4547(20001115)62:4<503::AID-JNR4>3.0.CO;2-A; Bastianetto S, 1999, MOL BRAIN RES, V66, P35, DOI 10.1016/S0169-328X(99)00002-9; Baulieu EE, 1998, P NATL ACAD SCI USA, V95, P4089, DOI 10.1073/pnas.95.8.4089; Belanger N, 2003, ENDOCRINE, V21, P97, DOI 10.1385/ENDO:21:1:97; Belanger N, 2006, NEUROBIOL AGING, V27, P1684, DOI 10.1016/j.neurobiolaging.2005.09.028; Bhacca NS, 1996, J CHEM CRYSTALLOGR, V26, P483, DOI 10.1007/BF01668309; BOLOGA L, 1987, J NEUROSCI RES, V17, P225, DOI 10.1002/jnr.490170305; Brinton Roberta Diaz, 2006, Current Alzheimer Research, V3, P185; Cardounel A, 1999, P SOC EXP BIOL MED, V222, P145, DOI 10.1046/j.1525-1373.1999.d01-124.x; Charalampopoulos I, 2006, FASEB J, V20, P577, DOI 10.1096/fj.05-5078fje; Charalampopoulos I, 2005, ENDOCRINOLOGY, V146, P3309, DOI 10.1210/en.2005-0263; Charalampopoulos I, 2008, TRENDS ENDOCRIN MET, V19, P300, DOI 10.1016/j.tem.2008.07.004; Charalampopoulos L, 2004, P NATL ACAD SCI USA, V101, P8209, DOI 10.1073/pnas.0306631101; Chavez-Delgado ME, 2005, J BIOMED MATER RES B, V74B, P589, DOI 10.1002/jbm.b.30243; Chen WY, 2006, ARCH INTERN MED, V166, P1027, DOI 10.1001/archinte.166.9.1027; Chu GH, 1998, STEROIDS, V63, P214, DOI 10.1016/S0039-128X(98)00006-3; Compagnone NA, 2000, FRONT NEUROENDOCRIN, V21, P1, DOI 10.1006/frne.1999.0188; Compagnone NA, 2008, J STEROID BIOCHEM, V109, P307, DOI 10.1016/j.jsbmb.2008.03.022; COREY EJ, 1972, J AM CHEM SOC, V94, P6190, DOI 10.1021/ja00772a043; Cutler SM, 2005, EXP NEUROL, V195, P423, DOI 10.1016/j.expneurol.2005.06.003; di Michele F, 2000, NEUROSCI LETT, V284, P65, DOI 10.1016/S0304-3940(00)00965-4; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Fiore C, 2004, J NEUROSCI RES, V75, P391, DOI 10.1002/jnr.10821; Fokialakis N, 2004, CHEM BIOL, V11, P397, DOI 10.1016/j.chembiol.2004.02.014; Forman MS, 2004, NAT MED, V10, P1055, DOI 10.1038/nm1113; Gago N, 2001, GLIA, V36, P295, DOI 10.1002/glia.1117; GAL GS, 1970, Patent No. 3492292; Ghoumari AM, 2005, NEUROSCIENCE, V135, P47, DOI 10.1016/j.neuroscience.2005.05.023; Ghoumari AM, 2003, J NEUROCHEM, V86, P848, DOI 10.1046/j.1471-4159.2003.01881.x; GILL JC, 1986, J MED CHEM, V29, P1537, DOI 10.1021/jm00158a039; GRAVANIS A, 2008, Patent No. 2008155534; Gritzapis AD, 2003, BREAST CANCER RES TR, V80, P1, DOI 10.1023/A:1024462416640; Gubba EM, 2004, MOL BRAIN RES, V127, P48, DOI 10.1016/j.molbrainres.2004.05.004; Guerini V, 2005, CANCER RES, V65, P5445, DOI 10.1158/0008-5472.CAN-04-1941; HANESSIAN S, 1975, CAN J CHEM, V53, P2975, DOI 10.1139/v75-419; HART TW, 1979, J CHEM SOC CHEM COMM, P156, DOI 10.1039/c39790000156; He DN, 2007, PROSTATE, V67, P1318, DOI 10.1002/pros.20615; Henderson BE, 2000, CARCINOGENESIS, V21, P427, DOI 10.1093/carcin/21.3.427; Hoffman SW, 2003, J NEUROTRAUM, V20, P859, DOI 10.1089/089771503322385791; Hogenkamp DJ, 1997, J MED CHEM, V40, P61, DOI 10.1021/jm960021x; Johnson SM, 2007, ENDOCR-RELAT CANCER, V14, P337, DOI 10.1677/ERC-06-0085; Kasiotis KM, 2006, STEROIDS, V71, P249, DOI 10.1016/j.steroids.2005.10.004; Katsanou ES, 2007, J STEROID BIOCHEM, V104, P228, DOI 10.1016/j.jsbmb.2007.03.028; Keller EA, 2004, DEV BRAIN RES, V153, P13, DOI 10.1016/j.devbrainres.2004.07.009; Kimonides VG, 1998, P NATL ACAD SCI USA, V95, P1852, DOI 10.1073/pnas.95.4.1852; KRATNIC S, 2006, TRENDS NEUROSCI, V28, P670; Kulkarni S. K., 1995, Drugs of Today, V31, P433; Labombarda F, 2006, ENDOCRINOLOGY, V147, P1847, DOI 10.1210/en.2005-0955; Lapchak PA, 2004, BRAIN RES, V997, P152, DOI 10.1016/j.brainres.2003.10.047; Lapchak PA, 2000, STROKE, V31, P1953, DOI 10.1161/01.STR.31.8.1953; Lazennec G, 1999, MOL ENDOCRINOL, V13, P969, DOI 10.1210/me.13.6.969; Le Goascogne C, 2000, GLIA, V29, P14, DOI 10.1002/(SICI)1098-1136(20000101)29:1<14::AID-GLIA2>3.3.CO;2-E; Leskiewicz M, 2008, J NEUROSCI RES, V86, P1361, DOI 10.1002/jnr.21591; Loria RM, 1996, J ENDOCRINOL, V150, pS209; LUCHE JL, 1978, J AM CHEM SOC, V100, P2226, DOI 10.1021/ja00475a040; Maggiolini M, 2004, J MOL ENDOCRINOL, V32, P777, DOI 10.1677/jme.0.0320777; Maksay G, 2007, BRIT J PHARMACOL, V151, P1078, DOI 10.1038/sj.bjp.0707316; Marx CE, 2000, BRAIN RES, V871, P104, DOI 10.1016/S0006-8993(00)02452-5; Mattson MP, 2000, NAT REV MOL CELL BIO, V1, P120, DOI 10.1038/35040009; McLachlan JA, 1996, J IMMUNOL, V156, P328; Meffre D, 2007, ENDOCRINOLOGY, V148, P2505, DOI 10.1210/en.2006-1678; Milman A, 2008, EUR NEUROPSYCHOPHARM, V18, P181, DOI 10.1016/j.euroneuro.2007.05.007; Nettles KW, 2008, NAT CHEM BIOL, V4, P241, DOI 10.1038/nchembio.76; Ngatcha BT, 2005, J MED CHEM, V48, P5257, DOI 10.1021/jm058179h; Ngatcha BT, 1999, SYNTHETIC COMMUN, V29, P1065, DOI 10.1080/00397919908086075; ORENTREICH N, 1984, J CLIN ENDOCR METAB, V59, P551, DOI 10.1210/jcem-59-3-551; PARKER KA, 1977, Patent No. 4059575; Pathirathna S, 2005, PAIN, V114, P429, DOI 10.1016/j.pain.2005.01.009; Patte-Mensah C, 2004, J COMP NEUROL, V477, P286, DOI 10.1002/cne.20251; PAUL SM, 1992, FASEB J, V6, P2311; PLUMB JA, 1989, CANCER RES, V49, P4435; Pomata PE, 2000, DEV BRAIN RES, V120, P83, DOI 10.1016/S0165-3806(99)00181-9; ROBEL P, 1994, TRENDS ENDOCRIN MET, V5, P1, DOI 10.1016/1043-2760(94)90114-7; Sapolsky R., 1992, STRESS AGING BRAIN M; Schumacher M, 2004, GROWTH HORM IGF RES, V14, pS18, DOI 10.1016/j.ghir.2004.03.007; Schumacher M, 2003, PROG NEUROBIOL, V71, P3, DOI 10.1016/j.pneurobio.2003.09.004; Schumacher M, 2000, J NEUROCYTOL, V29, P307, DOI 10.1023/A:1007152904926; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Shiau AK, 2002, NAT STRUCT BIOL, V9, P359, DOI 10.1038/nsb787; Skretas G, 2007, J AM CHEM SOC, V129, P8443, DOI 10.1021/ja067754j; Souli C, 2005, J MED CHEM, V48, P5203, DOI 10.1021/jm050271q; Straub RH, 2002, EUR J ENDOCRINOL, V146, P365, DOI 10.1530/eje.0.1460365; Suzuki M, 2004, P NATL ACAD SCI USA, V101, P3202, DOI 10.1073/pnas.0307325101; Takahashi Y, 2006, MOL CARCINOGEN, V45, P18, DOI 10.1002/mc.20153; TAKANO S, 1983, J CHEM SOC CHEM COMM, P760, DOI 10.1039/c39830000760; Todorovic SM, 2004, MOL PHARMACOL, V66, P1223, DOI 10.1124/mol.104.002402; VanLandingham JW, 2006, NEUROPHARMACOLOGY, V51, P1078, DOI 10.1016/j.neuropharm.2006.07.015; Vihko P, 2006, MOL CELL ENDOCRINOL, V248, P141, DOI 10.1016/j.mce.2005.12.005; Wang JM, 2005, J NEUROSCI, V25, P4706, DOI 10.1523/JNEUROSCI.4520-04.2005; Weill-Engerer S, 2002, J CLIN ENDOCR METAB, V87, P5138, DOI 10.1210/jc.2002-020878; Wittmann BM, 2007, CANCER RES, V67, P9549, DOI 10.1158/0008-5472.CAN-07-1590; Xilouri M, 2006, EUR J NEUROSCI, V23, P43, DOI 10.1111/j.1460-9568.2005.04548.x; Xilouri M, 2007, NEUROCHEM INT, V50, P660, DOI 10.1016/j.neuint.2006.12.010	93	35	37	0	8	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0022-2623	1520-4804		J MED CHEM	J. Med. Chem.	NOV 12	2009	52	21					6569	6587		10.1021/jm900468p			19	Chemistry, Medicinal	Pharmacology & Pharmacy	514WW	WOS:000271427900013	19845386				2021-06-18	
J	Bechtel, K; Frasure, S; Marshall, C; Dziura, J; Simpson, C				Bechtel, Kirsten; Frasure, Sarah; Marshall, Clement; Dziura, James; Simpson, Christine			Relationship of Serum S100B Levels and Intracranial Injury in Children With Closed Head Trauma	PEDIATRICS			English	Article						closed head trauma; intracranial injury; pediatric emergency department; S100B	BIOCHEMICAL MARKERS; PROTEIN; CANCER; PREDICT; DAMAGE; RISKS	OBJECTIVE: To determine if serum levels of S100B are higher in children with CHT and ICI as detected by cranial CT and if long bone fractures affect the level of S100B in children with CHT and skeletal injury. METHODS: Children < 18 years of age who presented to an urban pediatric emergency department or were transferred from a referral hospital within 6 hours after accidental closed head trauma and who underwent cranial computed tomography were enrolled prospectively. Mean serum S100B levels for children with or without intracranial injury (ICI) and long-bone fractures were evaluated through analysis of covariance. RESULTS: One hundred fifty-two children, 24 with ICI and 128 without ICI, were enrolled prospectively. Twenty-five children had long-bone fractures. Children with ICI were significantly younger than those without ICI (6.9 vs 9.8 years; P = .01). The time of venipuncture after injury was significantly later in children with ICI (P = .03). Mean S100B levels were significantly greater for children with ICI (212.9 vs 84.4 ng/L; P = .001), children with long-bone fractures (P = .008), and non-white children (P = .03). After controlling for time of venipuncture, long-bone fractures, and race, mean S100B levels were still greater for children with ICI (409 vs 118 ng/L; P = .001). The ability of serum S100B measurements to detect ICI, determined as the area under the curve, was 0.67. CONCLUSIONS: After controlling for time of venipuncture, long-bone fractures, and race, S100B levels were still higher in children with ICI than in those without ICI. However, the ability of serum S100B measurements to detect ICI was poor. Pediatrics 2009; 124:e697-e704	[Bechtel, Kirsten] Yale Univ, Sch Med, Dept Pediat, Sect Pediat Emergency Med, New Haven, CT 06504 USA; [Dziura, James; Simpson, Christine] Yale Univ, Sch Med, Yale Ctr Clin Invest, New Haven, CT 06504 USA; [Marshall, Clement] Brown Univ, Sch Med, Dept Biochem, Providence, RI 02912 USA	Bechtel, K (corresponding author), Yale Univ, Sch Med, Dept Pediat, Sect Pediat Emergency Med, 840 Howard Ave,1st Floor, New Haven, CT 06504 USA.	kirsten.bechtel@yale.edu	Bechtel, Kirsten/K-2147-2019		National Center for Research Resources, a component of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1 RR0249139]	Support for this study was through Clinical and Translational Science Awards grant UL1 RR0249139 from the National Center for Research Resources, a component of the National Institutes of Health.	Akhtar Javed I, 2003, Pediatr Crit Care Med, V4, P322; Akobeng AK, 2007, ACTA PAEDIATR, V96, P644, DOI 10.1111/j.1651-2227.2006.00178.x; Amer-Wahlin I, 2001, CLIN CHIM ACTA, V304, P57, DOI 10.1016/S0009-8981(00)00408-3; Begaz T, 2006, J NEUROTRAUM, V23, P1201, DOI 10.1089/neu.2006.23.1201; Benz MG, 2004, PEDIATRICS, V114, P205, DOI 10.1542/peds.114.1.205; Berger RP, 2007, J NEUROTRAUM, V24, P1793, DOI 10.1089/neu.2007.0316; Berger RP, 2002, J NEUROTRAUM, V19, P1405, DOI 10.1089/089771502320914633; Bergman DA, 1999, PEDIATRICS, V104, P1407; Brenner DJ, 2001, AM J ROENTGENOL, V176, P289, DOI 10.2214/ajr.176.2.1760289; DIETRICH AM, 1993, ANN EMERG MED, V22, P1535, DOI 10.1016/S0196-0644(05)81254-5; Donato R, 2003, MICROSC RES TECHNIQ, V60, P540, DOI 10.1002/jemt.10296; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; HAIMOTO H, 1987, LAB INVEST, V57, P489; Hall EJ, 2002, PEDIATR RADIOL, V32, P700, DOI 10.1007/S00247-002-0774-8; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Homer CJ, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.6.e78; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Listman DA, 2003, CURR OPIN PEDIATR, V15, P299, DOI 10.1097/00008480-200306000-00013; Luckl Jaaos, 2007, Ideggyogy Sz, V60, P284; Maschmann J, 2000, ACTA PAEDIATR, V89, P553, DOI 10.1080/080352500750027844; McAdory BS, 1998, BRAIN RES, V813, P211, DOI 10.1016/S0006-8993(98)01014-2; MOORE BW, 1965, BIOCHEM BIOPH RES CO, V19, P739, DOI 10.1016/0006-291X(65)90320-7; Raabe A, 2004, NEUROL RES, V26, P440, DOI 10.1179/016164104225015958; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; Schutzman SA, 2001, PEDIATRICS, V107, P983, DOI 10.1542/peds.107.5.983; Spinella PC, 2003, CRIT CARE MED, V31, P939, DOI 10.1097/01.CCM.0000053644.16336.52; Unden J, 2005, J TRAUMA, V58, P59, DOI 10.1097/01.TA.0000130613.35877.75; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Zhu H, 2007, J NEUROSCI RES, V85, P2783, DOI 10.1002/jnr.21257	30	35	36	0	3	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	OCT	2009	124	4					E697	E704		10.1542/peds.2008-1493			8	Pediatrics	Pediatrics	500CI	WOS:000270274300052	19786430				2021-06-18	
J	Wang, M; Yoder, KK; Gao, MZ; Mock, BH; Xu, XM; Saykin, AJ; Hutchins, GD; Zheng, QH				Wang, Min; Yoder, Karmen K.; Gao, Mingzhang; Mock, Bruce H.; Xu, Xiao-Ming; Saykin, Andrew J.; Hutchins, Gary D.; Zheng, Qi-Huang			Fully automated synthesis and initial PET evaluation of [C-11]PBR28	BIOORGANIC & MEDICINAL CHEMISTRY LETTERS			English	Article						Translocator protein (TSPO); [C-11]PBR28; Radiosynthesis; Positron emission tomography (PET); Traumatic brain injury (TBI); Brain imaging	PERIPHERAL BENZODIAZEPINE-RECEPTOR; PROTEIN 18 KDA; BINDING; DESIGN; RADIOSYNTHESIS; RADIOLIGAND; LIGANDS; MONKEY; AGENTS; BRAIN	Fully automated synthesis and initial PET evaluation of a TSPO radioligand, [C-11]PBR28 (N-(2[C-11]methoxybenzyl)-N-(4-phenoxypyridin-3-yl)acetamide), are reported. These results facilitate the potential preclinical and clinical PET studies of [C-11]PBR28 in animals and humans. (C) 2009 Elsevier Ltd. All rights reserved.	[Wang, Min; Yoder, Karmen K.; Gao, Mingzhang; Mock, Bruce H.; Saykin, Andrew J.; Hutchins, Gary D.; Zheng, Qi-Huang] Indiana Univ, Sch Med, Dept Radiol, Indianapolis, IN 46202 USA; [Xu, Xiao-Ming] Indiana Univ, Dept Neurosurg, Sch Med, Indianapolis, IN 46202 USA	Zheng, QH (corresponding author), Indiana Univ, Sch Med, Dept Radiol, 1345 W 16th St,Room 202, Indianapolis, IN 46202 USA.	qzheng@iupui.edu	; Saykin, Andrew/A-1318-2007	Xu, Xiao-ming/0000-0002-7229-0081; Saykin, Andrew/0000-0002-1376-8532	Indiana Genomics Initiative (INGEN) of Indiana University; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5R01AG019771, 3P30AG010133-18S1, 5P50NS052606]; Indiana Economic Development Corporation [IEDC 87884]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS052606] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG010133, R01AG019771] Funding Source: NIH RePORTER	This work was supported in part by the Indiana Genomics Initiative (INGEN) of Indiana University, as well as by grants from the NIH 5R01AG019771, 3P30AG010133-18S1, 5P50NS052606, and Indiana Economic Development Corporation (IEDC 87884). We gratefully acknowledge Dr. Robert B. Innis at the NIMH for his assistance. The referees' criticisms and editor's comments for the revision of the manuscript are greatly appreciated.	BENAVIDES J, 1987, BRAIN RES, V421, P167, DOI 10.1016/0006-8993(87)91287-X; Briard E, 2008, J MED CHEM, V51, P17, DOI 10.1021/jm0707370; Brown AK, 2007, J NUCL MED, V48, P2072, DOI 10.2967/jnumed.107.044842; Cheng TE, 2009, J NEUROSCI METH, V176, P24, DOI 10.1016/j.jneumeth.2008.08.031; ELSLAGER EF, 1972, J MED CHEM, V15, P827, DOI 10.1021/jm00278a008; Frese T, 2003, IEEE T MED IMAGING, V22, P258, DOI 10.1109/TMI.2002.808353; Fujimura Y, 2006, J NUCL MED, V47, P43; Imaizumi M, 2008, NEUROIMAGE, V39, P1289, DOI 10.1016/j.neuroimage.2007.09.063; Imaizumi M, 2007, NEUROSCI LETT, V411, P200, DOI 10.1016/j.neulet.2006.09.093; JEWETT DM, 1992, APPL RADIAT ISOTOPES, V43, P1383; Mock BH, 2005, J LABELLED COMPD RAD, V48, pS225; Mock BH, 2005, J LABELLED COMPD RAD, V48, pS224; Mock BH, 1999, NUCL MED BIOL, V26, P467, DOI 10.1016/S0969-8051(98)00087-0; Okubo T, 2004, BIOORGAN MED CHEM, V12, P3569, DOI 10.1016/j.bmc.2004.04.025; Papadopoulos V, 2006, TRENDS PHARMACOL SCI, V27, P402, DOI 10.1016/j.tips.2006.06.005; Probst KC, 2007, NUCL MED BIOL, V34, P439, DOI 10.1016/j.nucmedbio.2007.02.009; Rouze NC, 2003, IEEE T NUCL SCI, V50, P1491, DOI 10.1109/TNS.2003.817378; Rouze NC, 2005, IEEE NUCL SCI CONF R, P2394; Venneti S, 2006, PROG NEUROBIOL, V80, P308, DOI 10.1016/j.pneurobio.2006.10.002; Wang M, 2007, BIOORG MED CHEM LETT, V17, P332, DOI 10.1016/j.bmcl.2006.10.065; Wang M, 2009, EUR J MED CHEM, V44, P2748, DOI 10.1016/j.ejmech.2008.08.001; Wilson AA, 2008, NUCL MED BIOL, V35, P305, DOI 10.1016/j.nucmedbio.2007.12.009; Yasuno F, 2008, BIOL PSYCHIAT, V64, P835, DOI 10.1016/j.biopsych.2008.04.021; Zheng QH, 2005, BIOMED CHROMATOGR, V19, P671, DOI 10.1002/bmc.494; Zheng QH, 2003, NUCL MED BIOL, V30, P405, DOI 10.1016/S0969-8051(02)00447-X	25	35	35	0	8	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0960-894X	1464-3405		BIOORG MED CHEM LETT	Bioorg. Med. Chem. Lett.	OCT 1	2009	19	19					5636	5639		10.1016/j.bmcl.2009.08.051			4	Chemistry, Medicinal; Chemistry, Organic	Pharmacology & Pharmacy; Chemistry	498AH	WOS:000270106700025	19716298	Green Accepted			2021-06-18	
J	Fann, JR; Jones, AL; Dikmen, SS; Temkin, NR; Esselman, PC; Bombardier, CH				Fann, Jesse R.; Jones, Audrey L.; Dikmen, Sureyya S.; Temkin, Nancy R.; Esselman, Peter C.; Bombardier, Charles H.			Depression Treatment Preferences After Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injuries; depression; patient satisfaction; therapeutics	PRIMARY-CARE PATIENTS; COLLABORATIVE CARE; MAJOR DEPRESSION; EXERCISE TREATMENT; PRIME-MD; MANAGEMENT; INTERNET; UTILITY; PEOPLE; WOMEN	Objective: To determine preferences for depression treatment modalities and settings among persons with traumatic brain injury (TBI). Design: Telephone survey. Depression status was determined using the Patient Health Questionnaire-9. Setting: Harborview Medical Center, Seattle, Washington, the level I trauma center serving Washington, Idaho, Montana, and Alaska. Participants: One hundred forty-five adults, English-speaking consecutive patients admitted with complicated mild to severe TBI. Main Outcome Measures: Telephone survey within 12 months post-TBI ascertaining preferences for depression treatment modalities and settings. Results: More patients favored physical exercise or counseling as a depression treatment than other treatment modalities. Group therapy was the least favored modality. Patients favored speaking with a clinician in the clinic or over the telephone and were less likely to communicate with a clinician over the Internet. Subjects with probable major depression or a history of antidepressant use or outpatient mental health treatment were more likely to express a preference for antidepressants for treatment of depression. Conclusions: This study underscores the importance of understanding patient preferences and providing patient education in selecting a treatment for depression after TBI. Future studies should examine psychotherapy and alternative treatment modalities and delivery models for the management of depression in this vulnerable population.	[Fann, Jesse R.; Dikmen, Sureyya S.] Univ Washington, Dept Psychiat & Behav Sci, Sch Med, Seattle, WA 98195 USA; [Fann, Jesse R.; Jones, Audrey L.; Dikmen, Sureyya S.; Esselman, Peter C.; Bombardier, Charles H.] Univ Washington, Dept Rehabil Med, Sch Med, Seattle, WA 98195 USA; [Dikmen, Sureyya S.; Temkin, Nancy R.] Univ Washington, Dept Neurol Surg, Sch Med, Seattle, WA 98195 USA; [Temkin, Nancy R.] Univ Washington, Dept Biostat, Sch Publ Hlth & Community Med, Seattle, WA 98195 USA; [Fann, Jesse R.] Univ Washington, Dept Epidemiol, Sch Publ Hlth & Community Med, Seattle, WA 98195 USA	Fann, JR (corresponding author), Univ Washington, Dept Psychiat & Behav Sci, Sch Med, 1959 NE Pacific St,Box 356560, Seattle, WA 98195 USA.	fann@u.washington.edu		Jones, Audrey/0000-0003-1533-7469	National Center for Medical Rehabilitation Research [R-01 HD39415]; National Institute of Child Health and Human Development (NICHD)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD039415] Funding Source: NIH RePORTER	This study was supported by grant R-01 HD39415 from the National Center for Medical Rehabilitation Research, National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH). The authors thank Erika Pelzer Meghan Keough, and Holly Rau for their assistance with data collection, and Jason Barber for his assistance with data analysis.	Babyak M, 2000, PSYCHOSOM MED, V62, P633, DOI 10.1097/00006842-200009000-00006; Backenstrass M, 2006, GEN HOSP PSYCHIAT, V28, P178, DOI 10.1016/j.genhosppsych.2005.10.001; Bedi N, 2000, BRIT J PSYCHIAT, V177, P312, DOI 10.1192/bjp.177.4.312; Blumenthal JA, 1999, ARCH INTERN MED, V159, P2349, DOI 10.1001/archinte.159.19.2349; Chamelian L, 2006, J NEUROPSYCH CLIN N, V18, P33, DOI 10.1176/appi.neuropsych.18.1.33; Christensen H, 2004, BRIT MED J, V328, P265, DOI 10.1136/bmj.37945.566632.EE; Christensen H, 2002, J MED INTERNET RES, V4, DOI 10.2196/jmir.4.1.e3; Ciechanowski P, 2004, JAMA-J AM MED ASSOC, V291, P1569, DOI 10.1001/jama.291.13.1569; Clarke G, 2005, J MED INTERNET RES, V7, DOI 10.2196/jmir.7.2.e16; Corrigan JD, 2004, J HEAD TRAUMA REHAB, V19, P205, DOI 10.1097/00001199-200405000-00002; Dobscha SK, 2007, PSYCHOSOMATICS, V48, P482, DOI 10.1176/appi.psy.48.6.482; Dunn AL, 2005, AM J PREV MED, V28, P1, DOI 10.1016/j.amepre.2004.09.003; Dwight-Johnson M, 2004, PSYCHIAT SERV, V55, P934, DOI 10.1176/appi.ps.55.8.934; Dwight-Johnson M, 2000, J GEN INTERN MED, V15, P527, DOI 10.1046/j.1525-1497.2000.08035.x; Elkin I, 1999, PSYCHOTHER RES, V9, P437, DOI 10.1080/10503309912331332851; Fann JR, 2005, J HEAD TRAUMA REHAB, V20, P501, DOI 10.1097/00001199-200511000-00003; Foster M, 2003, SOC SCI MED, V56, P2201, DOI 10.1016/S0277-9536(02)00236-8; Gum AM, 2006, GERONTOLOGIST, V46, P14, DOI 10.1093/geront/46.1.14; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Katon W, 2002, J GEN INTERN MED, V17, P741, DOI 10.1046/j.1525-1497.2002.11051.x; Katon W, 1999, ARCH GEN PSYCHIAT, V56, P1109, DOI 10.1001/archpsyc.56.12.1109; KIERNAN RJ, 1987, ANN INTERN MED, V107, P481, DOI 10.7326/0003-4819-107-4-481; Kolakowsky-Hayner SA, 1999, BRAIN INJURY, V13, P571; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Lin P, 2005, ANN BEHAV MED, V30, P164, DOI 10.1207/s15324796abm3002_9; Loh A, 2006, PATIENT EDUC COUNS, V63, P314, DOI 10.1016/j.pec.2006.04.006; Lowe B, 2006, J GEN INTERN MED, V21, P39, DOI 10.1111/j.1525-1497.2005.0266.x; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Rapoport MJ, 2006, J AFFECT DISORDERS, V92, P273, DOI 10.1016/j.jad.2005.05.022; Ricker JH, 2002, J HEAD TRAUMA REHAB, V17, P242, DOI 10.1097/00001199-200206000-00005; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; Sample PL, 1998, BRAIN INJURY, V12, P855, DOI 10.1080/026990598122089; Sample PL, 2005, J HEAD TRAUMA REHAB, V20, P270, DOI 10.1097/00001199-200505000-00009; Scholle Sarah Hudson, 2003, Matern Child Health J, V7, P95, DOI 10.1023/A:1023864810207; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P1621, DOI 10.1053/S0003-9993(03)00270-3; Simon GE, 2004, JAMA-J AM MED ASSOC, V292, P935, DOI 10.1001/jama.292.8.935; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Spitzer RL, 2000, AM J OBSTET GYNECOL, V183, P759, DOI 10.1067/mob.2000.106580; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Tutty S, 2000, Eff Clin Pract, V3, P170; Ugarriza DN, 2006, J PSYCHOSOC NURS, V44, P37, DOI 10.3928/02793695-20060101-08; Unutzer J, 2002, JAMA-J AM MED ASSOC, V288, P2836, DOI 10.1001/jama.288.22.2836; van Schaik DJF, 2004, GEN HOSP PSYCHIAT, V26, P184, DOI 10.1016/j.genhosppsych.2003.12.001; Whiteneck GG, 2004, J HEAD TRAUMA REHAB, V19, P191, DOI 10.1097/00001199-200405000-00001; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014	46	35	36	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2009	24	4					272	278		10.1097/HTR.0b013e3181a66342			7	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	506SK	WOS:000270796000006	19625866				2021-06-18	
J	Gautschi, OP; Cadosch, D; Frey, SP; Skirving, AP; Filgueira, L; Zellweger, R				Gautschi, Oliver P.; Cadosch, Dieter; Frey, Soenke P.; Skirving, Allan P.; Filgueira, Luis; Zellweger, Rene			Serum-mediated osteogenic effect in traumatic brain-injured patients	ANZ JOURNAL OF SURGERY			English	Article						fracture healing; heterotopic ossification; osteogenic effect; traumatic brain injury	HETEROTOPIC OSSIFICATION; SPINAL-CORD; CALLUS FORMATION; HEAD-INJURY; ENHANCED OSTEOGENESIS; BONE; FRACTURE; DIFFERENTIATION	Background: Patients with a traumatic brain injury (TBI) and bone fractures often show an enhanced fracture healing, as well as an increased incidence of heterotopic ossifications (HO). It has been suggested that unknown osteoinductive factors may be released by the injured brain into the systemic blood circulation and act peripherally on the affected tissues. The aim of this study was to investigate whether serum from TBI patients is osteoinductive. Methods: Sixty-one consecutive patients were classified into four groups: TBI and long- bone fracture (group I, n = 12), isolated severe TBI (group II, n = 21), isolated long-bone fracture (group III, n = 19) and controls (group IV, n = 9). Blood samples were collected at 6, 24, 72 and 168 h post-injury. The osteogenic potential was determined by measuring the in vitro proliferation rate of the human fetal osteoblastic cell line hFOB1.19, and primary human osteoblasts. Additionally, serum induced osteoblastic differentiation was assessed by measuring the mRNA expression of specific osteoblastic markers, including alkaline phosphatase, runt-related transcription factor 2, cathepsin K and serine protease 7. Results: The sera of group I induced a higher mean proliferation rate of primary human osteoblasts at all time points of sampling than group III (P < 0.05). Group I had a higher mean proliferation rate of hFOB1.19 cells than all other groups at 6, 24 and 72 h post-injury (P < 0.05). The expression of alkaline phosphatase, cathepsin K and runt-related transcription factor 2 mRNA was increased in group I compared with group III and serine protease 7 was exclusively expressed in group I. Conclusion: The study results strongly support a humoral mechanism in enhanced fracture healing and the induction of HO after TBI. Increased proliferation of osteoblastic cells and an accelerated differentiation of osteoprogenitor cells may be responsible for increased osteogenesis in TBI.	[Gautschi, Oliver P.; Cadosch, Dieter; Frey, Soenke P.; Skirving, Allan P.; Zellweger, Rene] Royal Perth Hosp, Dept Orthopaed & Trauma Surg, Perth, WA, Australia; [Gautschi, Oliver P.; Cadosch, Dieter; Frey, Soenke P.; Skirving, Allan P.; Filgueira, Luis] Univ Western Australia, Sch Anat & Human Biol, Perth, WA 6009, Australia	Gautschi, OP (corresponding author), Kantonsspital, Dept Neurosurg, Rorschacher Str 95, CH-9007 St Gallen, Switzerland.	ogautschi@datacomm.ch	Filgueira, Luis/B-6492-2008	Filgueira, Luis/0000-0002-2266-6650	SUVA Stiftung, Switzerland	This study was supported by the SUVA Stiftung, Switzerland. The study has been approved by the RPH Research Ethics Committee (EC 2005/83).	Arosarena O, 2005, Orthod Craniofac Res, V8, P267, DOI 10.1111/j.1601-6343.2005.00349.x; Banovac K, 1997, SPINAL CORD, V35, P158, DOI 10.1038/sj.sc.3100380; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; BIDNER SM, 1990, J BONE JOINT SURG AM, V72A, P1144, DOI 10.2106/00004623-199072080-00004; Boes M, 2006, J BONE JOINT SURG AM, V88A, P738, DOI 10.2106/JBJS.D.02648; Brighton CT, 1997, J ORTHOP TRAUMA, V11, P244, DOI 10.1097/00005131-199705000-00002; Camozzi V, 2007, J Endocrinol Invest, V30, P13; CANALIS E, 1985, CLIN ORTHOP RELAT R, P246; CHALMERS J, 1975, J BONE JOINT SURG BR, VB 57, P36; CITTAPIETROLUNGO TJ, 1992, ARCH PHYS MED REHAB, V73, P258; CORY AH, 1991, CANCER COMMUN, V3, P207; DEJERINE MME, 1918, ANN MED, V5, P497; Dimitriou R, 2005, INJURY, V36, P1392, DOI 10.1016/j.injury.2005.07.019; Estrores IM, 2004, J SPINAL CORD MED, V27, P434, DOI 10.1080/10790268.2004.11752233; Filgueira L, 2005, BONE, V36, pS463; GARLAND DE, 1983, CLIN ORTHOP RELAT R, P190; GARLAND DE, 1980, CLIN ORTHOP RELAT R, P198; GARLAND DE, 1991, CLIN ORTHOP RELAT R, P13; GARLAND DE, 1988, CLIN ORTHOP RELAT R, V233, P86; Gautschi OP, 2007, J NEUROTRAUM, V24, P154, DOI 10.1089/neu.2006.0166; Giannoudis PV, 2006, INJURY, V37, pS18, DOI 10.1016/j.injury.2006.08.020; Hock JM, 2002, PRINCIPLES BONE BIOL, P463; Kaplan FS, 2004, J AM ACAD ORTHOP SUR, V12, P116, DOI 10.5435/00124635-200403000-00007; Klein BY, 1999, CALCIFIED TISSUE INT, V65, P217, DOI 10.1007/s002239900686; Komori T, 2008, FRONT BIOSCI-LANDMRK, V13, P898, DOI 10.2741/2730; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; KURER MHJ, 1992, PARAPLEGIA, V30, P165, DOI 10.1038/sc.1992.48; Kushwaha V P, 1998, J Am Acad Orthop Surg, V6, P298; Mandelin J, 2006, BONE, V38, P769, DOI 10.1016/j.bone.2005.10.017; NEWMAN RJ, 1987, INJURY, V18, P241, DOI 10.1016/0020-1383(87)90006-4; PERKINS R, 1987, J BONE JOINT SURG BR, V69, P521; Raisz L G, 1978, Recent Prog Horm Res, V34, P335; RENFREE KJ, 1994, SPINE, V19, P740, DOI 10.1097/00007632-199404000-00002; Shehab D, 2002, J NUCL MED, V43, P346; Tsur A, 1996, BRAIN INJURY, V10, P259, DOI 10.1080/026990596124430; van Kuijk AA, 2002, SPINAL CORD, V40, P313, DOI 10.1038/sj.sc.3101309; Wang YH, 2007, AM J PHYSIOL-ENDOC M, V292, pE594, DOI 10.1152/ajpendo.00216.2006; Wildburger R, 1996, UNFALLCHIRURG, V99, P17; WILDBURGER R, 1994, RES EXP MED, V194, P247, DOI 10.1007/BF02576386; Yen ML, 2007, STEM CELLS, V25, P125, DOI 10.1634/stemcells.2006-0295	40	35	43	1	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1445-1433	1445-2197		ANZ J SURG	ANZ J. Surg.	JUN	2009	79	6					449	455		10.1111/j.1445-2197.2008.04803.x			7	Surgery	Surgery	463IL	WOS:000267425500009	19566868				2021-06-18	
J	Allahtavakoli, M; Moloudi, R; Arababadi, MK; Shamsizadeh, A; Javanmardi, K				Allahtavakoli, Mohammad; Moloudi, Roohollah; Arababadi, Mohammad Kazemi; Shamsizadeh, Ali; Javanmardi, Kazem			Delayed post ischemic treatment with Rosiglitazone attenuates infarct volume, neurological deficits and neutrophilia after embolic stroke in rat	BRAIN RESEARCH			English	Article						Cerebral ischemia; Rosiglitazone; Neuroprotection; Delayed therapy	PROLIFERATOR-ACTIVATED RECEPTORS; CEREBRAL-ARTERY OCCLUSION; TRANSIENT FOCAL ISCHEMIA; PPAR-GAMMA AGONIST; BRAIN-INJURY; OXIDATIVE STRESS; INFLAMMATION; NEUROPROTECTION; STRATEGIES; PROTECTION	Rosiglitazone (RGZ), a peroxisome proliferator-activated receptor-gamma (PPAR-gamma), has been shown to provide neuroprotective and anti-inflammatory effects in the acute phase of cerebral ischemia, and traumatic or surgical brain injuries. However, the effect of delayed post ischemia administration of this compound is still unclear. This study was designed to evaluate the neuroprotective effects of RGZ when first administered at 24 h after the embolic model of stroke. Embolic focal cerebral ischemia was induced in rats by placing a preformed clot into the middle cerebral artery (MCA). RGZ (5 mg/kg, intraperitoneally) was injected at 24 and 48 h after MCA embolization. Neurological deficits were evaluated at 24, 48 and 72 h after stroke, and blood and brain tissues were then collected for differential blood cell counts and assessments of infarct volume and DNA fragmentation, respectively. Compared to the control group, the administration of RGZ, starting 24 h after cerebral ischemia, reduced infarct volume by 56% (P < 0.05) and decreased neurological deficits at 72 h after cerebral ischemia (P < 0.05). Also, delayed administration of RGZ prevented neutrophilia in blood (P < 0.005) and significantly decreased DNA fragmentation (P < 0.05), 72 h after MCA occlusion. Therefore, our data demonstrate that treatment with RGZ, starting 24 h after stroke, can reduce ischemic injury, improve neurological outcome, and prevent neutrophilia. These findings may support the idea that RGZ has an extended therapeutic window for the treatment of ischemic stroke, as it targets delayed pathways. Crown Copyright (C) 2009 Published by Elsevier B.V. All rights reserved.	[Allahtavakoli, Mohammad; Moloudi, Roohollah; Arababadi, Mohammad Kazemi; Shamsizadeh, Ali] Rafsanjan Univ Med Sci, Sch Med, Dept Physiol, Rafsanjan, Iran; [Javanmardi, Kazem] Fassa Univ Med Sci, Sch Med, Dept Physiol, Fassa, Iran	Allahtavakoli, M (corresponding author), Rafsanjan Univ Med Sci, Sch Med, Dept Physiol, Shariati St,POB 77175-835, Rafsanjan, Iran.	alahtavakoli@razi.tums.ac.ir	Allahtavakoli, Mohammad/H-6764-2017; javanmardi, kazem/M-8751-2017; Shamsizadeh, Ali/D-3807-2017; Moloudi, Mohammad Raman/C-3150-2016; Kazemi Arababadi, Mohammad/H-5282-2017	Allahtavakoli, Mohammad/0000-0001-6612-9729; javanmardi, kazem/0000-0003-0485-6722; Shamsizadeh, Ali/0000-0001-8329-9156; Moloudi, Mohammad Raman/0000-0003-2883-5213; Kazemi Arababadi, Mohammad/0000-0002-4829-1586; Kazemi Arababadi, Mohammad/0000-0002-4315-8153	Rafsanjan University of Medical Sciences, Iran [3365]	This study was financially supported by the grant no. 3365 from the Research Vice Chancellor of Rafsanjan University of Medical Sciences, Iran.	Ajmo CT, 2006, CURR NEUROVASC RES, V3, P89, DOI 10.2174/156720206776875849; Alexandrova ML, 2005, FREE RADICAL BIO MED, V39, P297, DOI 10.1016/j.freeradbiomed.2005.04.017; Alioglu B, 2008, PEDIATR INT, V50, P281, DOI 10.1111/j.1442-200X.2008.02570.x; Allahtavakoli M, 2006, CLIN EXP PHARMACOL P, V33, P1052, DOI 10.1111/j.1440-1681.2006.04486.x; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Blanquart C, 2003, J STEROID BIOCHEM, V85, P267, DOI 10.1016/S0960-0760(03)00214-0; Bordet R, 2006, BIOCHEM SOC T, V34, P1341, DOI 10.1042/BST0341341; Buck BH, 2008, STROKE, V39, P355, DOI 10.1161/STROKEAHA.107.490128; DiNapoli VA, 2006, J NEUROSCI METH, V154, P233, DOI 10.1016/j.jneumeth.2005.12.026; Dinkel K, 2004, P NATL ACAD SCI USA, V101, P331, DOI 10.1073/pnas.0303510101; Escher P, 2000, MUTAT RES-FUND MOL M, V448, P121, DOI 10.1016/S0027-5107(99)00231-6; Fuenzalida K, 2007, J BIOL CHEM, V282, P37006, DOI 10.1074/jbc.M700447200; Giuliani D, 2006, EUR J PHARMACOL, V538, P48, DOI 10.1016/j.ejphar.2006.03.038; Green AR, 2006, DRUG DISCOV TODAY, V11, P681, DOI 10.1016/j.drudis.2006.06.001; Hartl R, 1996, J CEREBR BLOOD F MET, V16, P1108; Hossmann KA, 2006, CELL MOL NEUROBIOL, V26, P1057, DOI 10.1007/s10571-006-9008-1; Hyong A, 2008, BRAIN RES, V1215, P218, DOI 10.1016/j.brainres.2008.04.025; Iadecola C, 2001, CURR OPIN NEUROL, V14, P89, DOI 10.1097/00019052-200102000-00014; Lee J, 2007, NEUROCHEM RES, V32, P635, DOI 10.1007/s11064-006-9138-3; Leonardo CC, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-34; LOANE DJ, 2007, NEUROBIOL AGING, V18; Margaill I, 2005, FREE RADICAL BIO MED, V39, P429, DOI 10.1016/j.freeradbiomed.2005.05.003; Newcomb JD, 2006, CELL TRANSPLANT, V15, P213, DOI 10.3727/000000006783982043; Park SW, 2007, J PHARMACOL EXP THER, V320, P1002, DOI 10.1124/jpet.106.113472; Schmerbach K, 2008, BRAIN RES, V1208, P225, DOI 10.1016/j.brainres.2008.02.032; Singhal PC, 2000, IMMUNOLOGY, V100, P57, DOI 10.1046/j.1365-2567.2000.00007.x; Stahel PF, 2008, PPAR RES, V2008, DOI 10.1155/2008/538141; Tolman Keith G, 2003, Clin Liver Dis, V7, P369, DOI 10.1016/S1089-3261(03)00020-5; Tureyen K, 2007, J NEUROCHEM, V101, P41, DOI 10.1111/j.1471-4159.2006.04376.x; Williams AJ, 2004, STROKE, V35, P1186, DOI 10.1161/01.STR.0000125721.10606.dc; Yenari MA, 2006, NEUROCHEM INT, V49, P164, DOI 10.1016/j.neuint.2006.03.016; Yi JH, 2008, BRAIN RES, V1244, P164, DOI 10.1016/j.brainres.2008.09.074; Zheng Z, 2003, CURR MOL MED, V3, P361, DOI 10.2174/1566524033479717	33	35	35	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	MAY 19	2009	1271						121	127		10.1016/j.brainres.2009.03.040			7	Neurosciences	Neurosciences & Neurology	449SY	WOS:000266351500012	19332033				2021-06-18	
J	Mok, SA; Lund, K; Campenot, RB				Mok, Sue-Ann; Lund, Karen; Campenot, Robert B.			A retrograde apoptotic signal originating in NGF-deprived distal axons of rat sympathetic neurons in compartmented cultures	CELL RESEARCH			English	Article						nerve growth factor; apoptosis; retrograde apoptotic signal; sympathetic neuron; axon; glycogen synthase kinase 3; c-jun	NERVE GROWTH-FACTOR; PROTEIN-KINASE-C; N-TERMINAL KINASE; GLYCOGEN-SYNTHASE KINASE-3; JUN ACTIVATION DOMAIN; CELL-DEATH; TRANSPORT; SURVIVAL; TRKA; PHOSPHORYLATION	Previous investigations of retrograde survival signaling by nerve growth factor (NGF) and other neurotrophins have supported diverse mechanisms, but all proposed mechanisms have in common the generation of survival signals retrogradely transmitted to the neuronal cell bodies. We report the finding of a retrograde apoptotic signal in axons that is suppressed by local NGF signaling. NGF withdrawal from distal axons alone was sufficient to activate the pro-apoptotic transcription factor, c-jun, in the cell bodies. Providing NGF directly to cell bodies, thereby restoring a source of NGF-induced survival signals, could not prevent c-jun activation caused by NGF withdrawal from the distal axons. This is evidence that c-jun is not activated due to loss of survival signals at the cell bodies. Moreover, blocking axonal transport with colchicine inhibited c-jun activation caused by NGF deprivation suggesting that a retrogradely transported pro-apoptotic signal, rather than loss of a retrogradely transported survival signal, caused c-jun activation. Additional experiments showed that activation of c-jun, pro-caspase-3 cleavage, and apoptosis were blocked by the protein kinase C inhibitors, rottlerin and chelerythrine, only when applied to distal axons suggesting that they block the axon-specific pro-apoptotic signal. The rottlerin-sensitive mechanism was found to regulate glycogen synthase kinase 3 (GSK3) activity. The effect of siRNA knockdown, and pharmacological inhibition of GSK3 suggests that GSK3 is required for apoptosis caused by NGF deprivation and may function as a retrograde carrier of the axon apoptotic signal. The existence of a retrograde death signaling system in axons that is suppressed by neurotrophins has broad implications for neurodevelopment and for discovering treatments for neurodegenerative diseases and neurotrauma.	[Mok, Sue-Ann; Lund, Karen; Campenot, Robert B.] Univ Alberta, Dept Cell Biol, Edmonton, AB T6G 2H7, Canada	Campenot, RB (corresponding author), Univ Alberta, Dept Cell Biol, 5-14 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.	bob.campenot@ualberta.ca		Mok, Sue-Ann/0000-0003-4593-3368	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR)	We thank Norma Jean Valli, Department of Cell Biology, University of Alberta, for her excellent technical assistance. We thank Dr Thomas Simmen, Department of Cell Biology, University of Alberta, for use of his Amaxa Nucleofector. This research was supported by the Canadian Institutes of Health Research.	Ahmed S, 2005, FEBS J, V272, P903, DOI 10.1111/j.1742-4658.2004.04519.x; Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797; Bamji SX, 1998, J CELL BIOL, V140, P911, DOI 10.1083/jcb.140.4.911; Bazenet CE, 1998, P NATL ACAD SCI USA, V95, P3984, DOI 10.1073/pnas.95.7.3984; Beurel E, 2006, PROG NEUROBIOL, V79, P173, DOI 10.1016/j.pneurobio.2006.07.006; Campenot RB, 2004, J NEUROBIOL, V58, P217, DOI 10.1002/neu.10322; CAMPENOT RB, 1982, DEV BIOL, V93, P13, DOI 10.1016/0012-1606(82)90233-0; CAMPENOT RB, 2001, PROTOCOLS NEURAL CEL, P49; Carson C, 2005, J NEUROSCI, V25, P6092, DOI 10.1523/JNEUROSCI.0707-05.2005; Choi BH, 2006, J CELL SCI, V119, P1329, DOI 10.1242/jcs.02837; Crowder RJ, 1998, J NEUROSCI, V18, P2933; Delcroix JD, 2003, NEURON, V39, P69, DOI 10.1016/S0896-6273(03)00397-0; Deppmann CD, 2008, SCIENCE, V320, P369, DOI 10.1126/science.1152677; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; EHLERS MD, 1995, J CELL BIOL, V130, P149, DOI 10.1083/jcb.130.1.149; Eilers A, 2001, J NEUROCHEM, V76, P1439, DOI 10.1046/j.1471-4159.2001.00150.x; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Ham J, 2000, BIOCHEM PHARMACOL, V60, P1015, DOI 10.1016/S0006-2952(00)00372-5; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; Harding TC, 2001, J BIOL CHEM, V276, P4531, DOI 10.1074/jbc.C000815200; Hasaka TP, 2004, J NEUROSCI, V24, P11291, DOI 10.1523/JNEUROSCI.3443-04.2004; He Y, 2005, J CELL BIOL, V168, P697, DOI 10.1083/jcb.200407191; Heerssen HM, 2004, NAT NEUROSCI, V7, P596, DOI 10.1038/nn1242; HENDRY IA, 1974, BRAIN RES, V68, P103, DOI 10.1016/0006-8993(74)90536-8; HENDRY IA, 1977, BRAIN RES, V134, P213, DOI 10.1016/0006-8993(77)91068-X; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hooper C, 2008, J NEUROCHEM, V104, P1433, DOI 10.1111/j.1471-4159.2007.05194.x; Howe CL, 2005, CURR OPIN NEUROBIOL, V15, P40, DOI 10.1016/j.conb.2005.01.010; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Garrido JJ, 2007, FEBS LETT, V581, P1579, DOI 10.1016/j.febslet.2007.03.018; Kaul S, 2003, EUR J NEUROSCI, V18, P1387, DOI 10.1046/j.1460-9568.2003.02864.x; Kim WY, 2006, NEURON, V52, P981, DOI 10.1016/j.neuron.2006.10.031; LEVIMONTALCINI R, 1968, PHYSIOL REV, V48, P534; MacInnis BL, 2002, SCIENCE, V295, P1536, DOI 10.1126/science.1064913; MacInnis BL, 2003, NEUROPHARMACOLOGY, V45, P995, DOI 10.1016/S0028-3908(03)00273-9; Majdan M, 2001, J CELL BIOL, V155, P1275, DOI 10.1083/jcb.200110017; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Melli G, 2006, BRAIN, V129, P1330, DOI 10.1093/brain/awl058; Mok SA, 2007, NEUROPHARMACOLOGY, V52, P270, DOI 10.1016/j.neuropharm.2006.07.032; Okazawa Hitohi, 2002, Am J Alzheimers Dis Other Demen, V17, P79, DOI 10.1177/153331750201700209; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.neuro.14.1.453; Palmada M, 2002, J CELL BIOL, V158, P453, DOI 10.1083/jcb.200112129; Peng J, 2003, IUBMB LIFE, V55, P267, DOI 10.1080/1521654031000121666; Riccio A, 1999, SCIENCE, V286, P2358, DOI 10.1126/science.286.5448.2358; SUTHERLAND C, 1994, FEBS LETT, V338, P37, DOI 10.1016/0014-5793(94)80112-6; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; Toma JG, 1997, DEV BIOL, V184, P1, DOI 10.1006/dbio.1997.8515; Tsui-Pierchala BA, 1999, J NEUROSCI, V19, P8207; Ure DR, 1997, J NEUROSCI, V17, P1282; Virdee K, 1997, J NEUROCHEM, V69, P550; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; Wright KM, 2007, CELL DEATH DIFFER, V14, P625, DOI 10.1038/sj.cdd.4402024; Xu ZH, 2001, MOL CELL BIOL, V21, P4713, DOI 10.1128/MCB.21.14.4713-4724.2001; Zweifel LS, 2005, NAT REV NEUROSCI, V6, P615, DOI 10.1038/nrn1727	56	35	35	0	5	INST BIOCHEMISTRY & CELL BIOLOGY	SHANGHAI	SIBS, CAS, 319 YUEYANG ROAD, SHANGHAI, 200031, PEOPLES R CHINA	1001-0602	1748-7838		CELL RES	Cell Res.	MAY	2009	19	5					546	560		10.1038/cr.2009.11			15	Cell Biology	Cell Biology	452GG	WOS:000266527600005	19188931	Bronze			2021-06-18	
J	Tsuru-Aoyagi, K; Potts, MB; Trivedi, A; Pfankuch, T; Raber, J; Wendland, M; Claus, CP; Koh, SE; Ferriero, D; Noble-Haeusslein, LJ				Tsuru-Aoyagi, Kyoko; Potts, Matthew B.; Trivedi, Alpa; Pfankuch, Timothy; Raber, Jacob; Wendland, Michael; Claus, Catherine P.; Koh, Seong-Eun; Ferriero, Donna; Noble-Haeusslein, Linda J.			Glutathione Peroxidase Activity Modulates Recovery in the Injured Immature Brain	ANNALS OF NEUROLOGY			English	Article							PERINATAL HYPOXIA-ISCHEMIA; DISMUTASE TRANSGENIC MICE; CLOSED-HEAD-INJURY; CELL-DEATH; OPTICAL FRACTIONATOR; NEURONAL LOSS; MURINE BRAIN; MOUSE MODEL; DAMAGE; AGE	Objective: Mice subjected to traumatic brain injury at postnatal day 21 show emerging cognitive deficits that coincide with hippocampal neuronal loss. Here we consider glutathione peroxidase (GPx) activity as a determinant of recovery in the injured immature brain. Methods: Wild-type and transgenic (GPxTg) mice overexpressing GPx were Subjected to traumatic brain injury or sham surgery at postnatal day 21. Animals were killed acutely (3 or 24 hours after injury) to assess oxidative stress and cell injury in the hippocampus or 4 months after injury after behavioral assessments. Results: In the acutely injured brains, a reduction in oxidative stress markers including nitrotyrosine was seen in the injured GPxTg group relative to wild-type control mice. In contrast, cell injury, with marked vulnerability in the dentate gyrus, was apparent despite no differences between genotypes. Magnetic resonance imaging demonstrated an emerging cortical lesion during brain maturation that was also indistinguishable between injured genotypes. Stereological analyses of cortical volumes likewise confirmed no genotypic differences between injured groups. However, behavioral tests beginning 3 months after injury demonstrated improved spatial memory learning in the GPxTg group. Moreover, stereological analysis within hippocampal subregions demonstrated a significantly greater number of neurons within the dentate of the GPx group. Interpretation: Our results implicate GPx in recovery of spatial memory after traumatic brain injury. This recovery may be attributed, in part, to a reduction in early oxidative stress and selective, long-term sparing of neurons in the dentate.	[Tsuru-Aoyagi, Kyoko; Potts, Matthew B.; Trivedi, Alpa; Claus, Catherine P.; Koh, Seong-Eun; Noble-Haeusslein, Linda J.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; [Pfankuch, Timothy; Raber, Jacob] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA; [Raber, Jacob] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA; [Raber, Jacob] Oregon Hlth & Sci Univ, Div Neurosci, Oregon Natl Primate Res Ctr, Portland, OR 97201 USA; [Wendland, Michael] Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA; [Ferriero, Donna] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; [Ferriero, Donna] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; [Noble-Haeusslein, Linda J.] Univ Calif San Francisco, Dept Phys Therapy & Rehabil, San Francisco, CA 94143 USA	Noble-Haeusslein, LJ (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, 521 Parnassus Ave,Room C-224, San Francisco, CA 94143 USA.	linda.noble@ucsf.edu			NIH NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS050159]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS050159] Funding Source: NIH RePORTER	This research was supported by the NIH NINDS (NS050159) L. N. H.	Assaf Y, 1999, J NEUROTRAUM, V16, P1165, DOI 10.1089/neu.1999.16.1165; Bao F, 2003, NEUROSCIENCE, V116, P59, DOI 10.1016/S0306-4522(02)00571-7; Benice TS, 2006, NEUROSCIENCE, V137, P413, DOI 10.1016/j.neuroscience.2005.08.029; Bonthius DJ, 2004, BRAIN RES PROTOC, V14, P45, DOI 10.1016/j.brainresprot.2004.09.003; Camargo EE, 2001, J NUCL MED, V42, P611; Chan PH, 1998, J NEUROSCI, V18, P8292, DOI 10.1523/jneurosci.18-20-08292.1998; Deng Y, 2007, EXP NEUROL, V205, P154, DOI 10.1016/j.expneurol.2007.01.023; Ditelberg JS, 1996, PEDIATR RES, V39, P204, DOI 10.1203/00006450-199602000-00003; Dringen R, 2000, PROG NEUROBIOL, V62, P649, DOI 10.1016/S0301-0082(99)00060-X; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; Fan P, 2003, J NEUROTRAUM, V20, P437, DOI 10.1089/089771503765355513; Ferriero DM, 1996, NEUROBIOL DIS, V3, P64, DOI 10.1006/nbdi.1996.0006; Fullerton HJ, 1998, ANN NEUROL, V44, P357, DOI 10.1002/ana.410440311; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Graham EM, 2004, NEUROBIOL DIS, V17, P89, DOI 10.1016/j.nbd.2004.05.007; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hovatta I, 2005, NATURE, V438, P662, DOI 10.1038/nature04250; Igarashi T, 2007, EXP NEUROL, V203, P258, DOI 10.1016/j.expneurol.2006.08.030; KESNER R, 2007, LEARN MEMORY, V14, P127; Khan JY, 2003, PEDIATR RES, V54, P77, DOI 10.1203/01.PDR.0000065736.69214.20; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Lebesgue D, 2006, J NEUROTRAUM, V23, P1814, DOI 10.1089/neu.2006.23.1814; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; LISTER RG, 1990, PHARMACOL THERAPEUT, V46, P321, DOI 10.1016/0163-7258(90)90021-S; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; McLean CW, 2005, DEV NEUROSCI-BASEL, V27, P169, DOI 10.1159/000085989; Mikawa S, 1996, J NEUROSURG, V85, P885, DOI 10.3171/jns.1996.85.5.0885; Onyszchuk G, 2007, J NEUROSCI METH, V160, P187, DOI 10.1016/j.jneumeth.2006.09.007; PANKSEPP J, 1984, NEUROSCI BIOBEHAV R, V8, P465, DOI 10.1016/0149-7634(84)90005-8; Payton KSE, 2007, DEV NEUROSCI-BASEL, V29, P403, DOI 10.1159/000105481; Pullela R, 2006, DEV NEUROSCI-BASEL, V28, P396, DOI 10.1159/000094166; Schmued LC, 2005, BRAIN RES, V1035, P24, DOI 10.1016/j.brainres.2004.11.054; Sheldon RA, 2004, PEDIATR RES, V56, P656, DOI 10.1203/01.PDR.0000139413.27864.50; Sheldon RA, 2001, NEUROSCI LETT, V304, P165, DOI 10.1016/S0304-3940(01)01788-8; Souza JM, 2000, ARCH BIOCHEM BIOPHYS, V380, P360, DOI 10.1006/abbi.2000.1940; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; Tweedie D, 2007, J NEUROSCI RES, V85, P805, DOI 10.1002/jnr.21160; Vasa RA, 2004, BIOL PSYCHIAT, V55, P208, DOI 10.1016/S0006-3223(03)00708-X; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Witgen BM, 2006, J NEUROTRAUM, V23, P1320, DOI 10.1089/neu.2006.23.1320; Yager JY, 1997, NEUROSCI BIOBEHAV R, V21, P167, DOI 10.1016/S0149-7634(96)00006-1	44	35	35	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	MAY	2009	65	5					540	549		10.1002/ana.21600			10	Clinical Neurology; Neurosciences	Neurosciences & Neurology	453LJ	WOS:000266611700010	19475669	Green Accepted			2021-06-18	
J	Akiyama, Y; Miyata, K; Harada, K; Minamida, Y; Nonaka, T; Koyanagi, I; Asai, Y; Houkin, K				Akiyama, Yukinori; Miyata, Kei; Harada, Kuniaki; Minamida, Yoshihiro; Nonaka, Tadashi; Koyanagi, Izumi; Asai, Yasufumi; Houkin, Kiyohiro			Susceptibility-Weighted Magnetic Resonance Imaging for the Detection of Cerebral Microhemorrhage in Patients With Traumatic Brain Injury	NEUROLOGIA MEDICO-CHIRURGICA			English	Article						susceptibility-weighted magnetic resonance imaging; cerebral microhemorrhage; brain injury	HYPERACUTE INTRACEREBRAL HEMORRHAGE	The sensitivity of susceptibility-weighted magnetic resonance (MR) imaging was compared with conventional MR sequences, including T-2*-weighted imaging, and computed tomography for the detection of cerebral hemorrhages in 15 patients with head injury. Susceptibility-weighted imaging detected a mean of 76 +/- 52 (total 1132) hypointense spotty lesions, compared to a mean of 21 +/- 19 (total 316) detected by T-2*-weighted imaging (p < 0.0001, paired t-test). Susceptibility-weighted imaging is extremely sensitive for the visualization and detection of microhemorrhages.	[Akiyama, Yukinori; Harada, Kuniaki; Minamida, Yoshihiro; Nonaka, Tadashi; Koyanagi, Izumi; Houkin, Kiyohiro] Sapporo Med Univ, Dept Neurosurg, Sapporo, Hokkaido 0608543, Japan; [Akiyama, Yukinori; Miyata, Kei; Asai, Yasufumi] Sapporo Med Univ, Dept Crit Care Med, Sapporo, Hokkaido 0608543, Japan	Akiyama, Y (corresponding author), Sapporo Med Univ, Dept Neurol Surg, Chuo Ku, South 1,West 16, Sapporo, Hokkaido 0608543, Japan.	akiyuki@sapmed.ac.jp	Houkin, Kiyohiro/G-5364-2012		Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [18791342] Funding Source: KAKEN		Atlas SW, 1998, AM J NEURORADIOL, V19, P1471; BRADLEY WG, 1993, RADIOLOGY, V189, P15, DOI 10.1148/radiology.189.1.8372185; Fiebach JB, 2004, STROKE, V35, P502, DOI 10.1161/01.STR.0000114203.75678.88; Liang LX, 1999, AM J NEURORADIOL, V20, P1527; Linfante I, 1999, STROKE, V30, P2263, DOI 10.1161/01.STR.30.11.2263; OGAWA S, 1990, P NATL ACAD SCI USA, V87, P9868, DOI 10.1073/pnas.87.24.9868; Patel MR, 1996, STROKE, V27, P2321, DOI 10.1161/01.STR.27.12.2321; Schellinger PD, 1999, STROKE, V30, P765, DOI 10.1161/01.STR.30.4.765	8	35	45	0	3	JAPAN NEUROSURGICAL SOC	TOKYO	5-25-16 HONGO, BUNKYO-KU, TOKYO, 113-0033, JAPAN	0470-8105	1349-8029		NEUROL MED-CHIR	Neurol. Med.-Chir.	MAR	2009	49	3					97	99		10.2176/nmc.49.97			3	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	423SV	WOS:000264516900001	19318732	Bronze			2021-06-18	
J	Baker, F; Wigram, T; Stott, D; McFerran, K				Baker, Felicity; Wigram, Tony; Stott, David; McFerran, Katrina			Therapeutic songwriting in music therapy, Part II: Comparing the literature with practice across diverse clinical populations	NORDIC JOURNAL OF MUSIC THERAPY			English	Article						songwriting; music therapy methods; lyric creation	TRAUMATIC BRAIN-INJURY; SONGS WRITTEN; ADOLESCENTS; THEMES; PEOPLE	A growing body of literature on therapeutic songwriting with diverse clinical populations indicates that clinicians employ a wide range of approaches. The purpose of this research was to establish trends in the clinical practice of songwriting as implemented across a range of clinical populations. Responses to a 21-question online survey were obtained from 419 professional music therapists practicing in 29 countries which focused on approaches to songwriting within their practice with a single clinical population. Results suggest that, in general, the literature provides good representation for what is occurring in clinical practice. Generally, songs were composed with individual clients in single sessions, with lyrics created prior to the music. Clinicians had a significant role in creating the music with improvised and predetermined musical structures being equally employed. Chi-square or comparable Exact tests (Fisher-Freeman-Halton) were applied to the data and significant associations were found according to clinical populations, particularly with respect the number of sessions required to complete a song, approaches to composing lyrics and music, the context with which songwriting was employed, and the types of allied health professionals involved in the songwriting interventions. There is a distinct absence of songwriting literature as applied in developmental disability, autism spectrum disorder, and aged care contexts so the resulting practice trends offered here contribute to the increasing body of knowledge about songwriting practices.	[Baker, Felicity] Univ Queensland, Sch Mus, Brisbane, Qld, Australia; [Wigram, Tony] Univ Aalborg, Dept Humanities, Inst Commun & Psychol, Aalborg, Denmark; [Wigram, Tony] Anglia Ruskin Univ, Cambridge, England; [McFerran, Katrina] Univ Melbourne, Fac Mus, Melbourne, Vic 3010, Australia; [Stott, David] Univ Hertfordshire, E England RDSU Hertfordshire, Hatfield AL10 9AB, Herts, England; [Stott, David] Univ Bedfordshire, Bedford, England	Baker, F (corresponding author), Univ Queensland, Sch Mus, Brisbane, Qld, Australia.	f.baker1@uq.edu.au		McFerran, Katrina/0000-0003-0699-3683			Aasgaard T, 2001, J PALLIATIVE CARE, V17, P177; Aasgaard T., 2005, SONGWRITING METHODS, P154; Abad V., 2003, AUSTR J MUSIC THERAP, V14, P20; Baker F, 2005, J MUSIC THER, V42, P111, DOI 10.1093/jmt/42.2.111; Baker F., 2006, MUSIC THERAPY METHOD; Baker F., 2005, SONGWRITING METHODS, P116; Baker F., 2005, AUSTR J MUSIC THERAP, V16, P25; Baker F., 2005, SONGWRITING METHODS, P134; BAKER FA, ARTS PSYCHO IN PRESS; Baker F, 2008, NORD J MUSIC THER, V17, P105, DOI 10.1080/08098130809478203; Bruscia K.E., 1987, IMPROVISATIONAL MODE; Dalton TA, 2005, ART PSYCHOTHER, V32, P131, DOI 10.1016/j.aip.2005.02.002; Dalton TA, 2006, MUSIC THER PERSPECT, V24, P94, DOI 10.1093/mtp/24.2.94; Davis E., 2005, SONGWRITING METHODS, P45; Day T., 2005, SONGWRITING METHODS; Derrington P, 2005, SONGWRITING METHODS; DILEO Cheryl, 2005, SONGWRITING METHODS, P226; Edgerton C. D., 1990, MUSIC THERAPY PERSPE, V8, P15; Edwards J., 1998, MUSIC THERAPY PERSPE, V16, P21, DOI DOI 10.1093/mtp/16.1.21; FICKEN T, 1976, J MUSIC THER, V13, P163, DOI 10.1093/jmt/13.4.163; Freed B. S., 1987, MUSIC THERAPY PERSPE, V4, P13, DOI [10.1093/mtp/4.1.13, DOI 10.1093/MTP/4.1.13]; Gallagher L. M., 2002, MUSIC THERAPY PERSPE, V20, P117, DOI DOI 10.1093/MTP/20.2.117; Gfeller K., 1987, MUSIC THERAPY, V6, P28; GLASSMAN LR, 1991, ART PSYCHOTHER, V18, P149, DOI 10.1016/0197-4556(91)90022-3; GOLDSTEIN SL, 1990, ART PSYCHOTHER, V17, P117, DOI 10.1016/0197-4556(90)90021-H; Grocke D., 2007, RECEPTIVE METHODS MU; Hadley S., 1996, AUSTR J MUSIC THERAP, V7, P16; Jones JD, 2005, J MUSIC THER, V42, P94, DOI 10.1093/jmt/42.2.94; KENNELLY J, 1999, MUSIC MED, V3; Krout R., 2005, SONGWRITING METHODS, P206; Krout RE, 2005, MUSIC THER PERSPECT, V23, P118, DOI 10.1093/mtp/23.2.118; Ledger A., 2001, AUSTR J MUSIC THERAP, V12, P21; Lindberg K. A., 1995, MUSIC THERAPY, V13, P93; Mayers KS, 1995, ART PSYCHOTHER, V22, P495, DOI 10.1016/0197-4556(94)00050-6; O'Callaghan C., 1997, MUSIC THERAPY PERSPE, V15, P32, DOI DOI 10.1093/MTP/15.1.32; OBrien E., 2005, SONGWRITING METHODS, P180; OCALLAGHAN C, 1990, AUSTR J MUSIC THERAP, V1, P15; OCallaghan CC, 1996, J MUSIC THER, V33, P74, DOI 10.1093/jmt/33.2.74; Oldfield A., 2005, SONGWRITING METHODS, P24; Robb S. L., 1996, MUSIC THERAPY PERSPE, V14, P30; Roberts M, 2006, AUSTR J MUSIC THERAP, V17, P18; Rolvsjord R., 2005, SONGWRITING METHODS, P97; Silber F., 1995, MUSIC THER PERSPECT, V13, P31, DOI [10.1093/mtp/13.1.31, DOI 10.1093/MTP/13.1.31]; Silverman MJ, 2003, ART PSYCHOTHER, V30, P25, DOI 10.1016/S0197-4556(02)00231-9; Slivka H. H., 1986, MUSIC THERAPY A, V6A, P30; Tamplin J., 2006, NORD J MUSIC THER, V15, P177, DOI [10.1080/08098130609478164, DOI 10.1080/08098130609478164]; TURRY A, 1999, CLIN APPL MUSIC THER, P13; WIGRAM T, 2005, SONGWRITING METHODS, P246; Wigram T., 2004, IMPROVISATION METHOD; Wigram T, 2005, SONGWRITING METHODS; Wigram T., 2005, SONGWRITING METHODS; Williams SL, 2006, NUTR REV, V64, P93, DOI [10.1301/nr.2006.mar.93-108, 10.1111/j.1753-4887.2006.tb00193.x]	52	35	35	0	23	GRIEG ACADEMY	BERGEN	UNIV BERGEN, DEPT MUSIC, LARS HILLES GATE 3, BERGEN, N-5015, NORWAY	0803-9828			NORD J MUSIC THER	Nord. J. Music Ther.		2009	18	1					32	56		10.1080/08098130802496373			25	Rehabilitation	Rehabilitation	442GQ	WOS:000265830100003					2021-06-18	
J	Bottari, C; Dassa, C; Rainville, C; Dutil, E				Bottari, Carolina; Dassa, Clement; Rainville, Constant; Dutil, Elisabeth			The criterion-related validity of the IADL Profile with measures of executive functions, indices of trauma severity and sociodemographic characteristics	BRAIN INJURY			English	Article						Brain injuries; activities of daily living; psychometrics; home visits; executive processes	BRAIN-INJURY REHABILITATION; FRONTAL-LOBE LESIONS; TOWER-OF-LONDON; COMMUNITY INTEGRATION; CONSCIOUSNESS; PERFORMANCE; PREDICTION; DEFICITS; AMNESIA; MODEL	Primary objective: To examine relationships between classical measures of executive functions (EF) and indices of traumatic brain injury (TBI) severity with the IADL Profile, a new performance-based measure of independence in instrumental activities of daily living (IADL) based on EF. This study hypothesized the presence of correlations between classical tests of EF and the IADL Profile, as the latter aims to establish whether the subject's main difficulties pertain to goal formulation, planning, carrying out the task and/or attaining the initial task goal; all important components of EF. Methods and procedures: One hundred subjects with a moderate/severe TBI aged 16-65 years (convenience sample) were recruited. Subjects were tested with the IADL Profile and three measures of EF within their home environment. Data was analysed using Pearson correlations, t-tests and multiple stepwise regressions. Results: Post-traumatic amnesia and working memory emerged as the major determinants of IADL Profile scores. Together, indices of injury severity, measures of EF, education, age and environmental factors accounted for 12-28% of the variance in IADL Profile scores. Conclusions: This study has shown that the IADL Profile's non-structured approach permits the observation of a broad range of behaviours related to EF deficits and thus provides a closer approximation of the person's independence in IADL. Further study is required to demonstrate the IADL Profile's ability to inform more targeted treatment interventions.	[Bottari, Carolina; Dutil, Elisabeth] Univ Montreal, Ecole Readaptat, Montreal, PQ, Canada; [Bottari, Carolina; Rainville, Constant; Dutil, Elisabeth] Ctr Rech Interdisciplinaire Readaptat Montreal Me, Montreal, PQ, Canada; [Dassa, Clement] Univ Montreal, Dept Social & Prevent Med, Montreal, PQ, Canada; [Dassa, Clement] Grp Rech Interdisciplinaire Sante, Montreal, PQ, Canada; [Rainville, Constant] Univ Montreal, Dept Psychol, Montreal, PQ H3C 3J7, Canada	Bottari, C (corresponding author), McGill Univ, Montreal Neurol Inst & Hosp, Dept Neurol & Neurosurgery, Neuropsychol Cognit Neurosci Unit, Room 276,3801 Univ, Montreal, PQ H3A 2B4, Canada.	carolina.bottari@mcgill.ca			Fonds de la recherche en sante du QuebecFonds de la Recherche en Sante du Quebec; Association quebecoise d'etablissements de sante et de services sociaux; Association des etablissements de readaptation en deficience physique du Quebec; Societe d'assurance automobile du Quebec; Quebec Rehabilitation Research Network [6623]	The authors would like to thank Mariama Toure and Caroline Lachapelle for their assistance with data collection, Marie-Pierre Cote and Rejean Prevost for their assistance with data entry and Dr Julie Lamoureux for her assistance with the data analysis. We would also like to thank all participating rehabilitation centres who recruited subjects for this study and the Centre for Interdisciplinary Research in Rehabilitation of Greater Montreal for their support of this study. The research reported here was supported by an operating grant awarded to the authors by the Fonds de la recherche en sante du Quebec, the Association quebecoise d'etablissements de sante et de services sociaux, the Association des etablissements de readaptation en deficience physique du Quebec, the Societe d'assurance automobile du Quebec and the Quebec Rehabilitation Research Network (grant no. 6623).	Ahmed S, 2000, BRAIN INJURY, V14, P765; Boake C, 1996, ARCH PHYS MED REHAB, V77, P765, DOI 10.1016/S0003-9993(96)90254-3; BOTTARI C, 2007, DEV VALIDATION INSTR, P244; BOTTARI C, 2004, PROFIL ACTIVITES INS; BOTTARI C, 2007, CANADIAN J OCCUPAT S; Bottari C, 2009, NEUROPSYCHOL REHABIL, V19, P177, DOI 10.1080/09602010802188435; BROOKS N, 1989, ASSESSMENT BEHAV CON, V7, P61; Burgess P. W., 2002, PRINCIPLES FRONTAL L, P557, DOI 10.1093/acprof:oso/9780195134971.003.0033; Burgess PW, 2006, J INT NEUROPSYCH SOC, V12, P194, DOI 10.1017/S1355617706060310; Burgess PW, 2000, PSYCHOL RES-PSYCH FO, V63, P279, DOI 10.1007/s004269900006; Bush BA, 2003, ARCH PHYS MED REHAB, V84, P1803, DOI 10.1016/S0003-9993(03)00367-8; CANNING N, 2002, NEW PERSPECTIVE MILD, P342; Cattelani R, 2002, BRAIN INJURY, V16, P51, DOI 10.1080/02699050110088821; Chevignard M, 2000, CORTEX, V36, P649, DOI 10.1016/S0010-9452(08)70543-4; Cockburn J, 1995, J Int Neuropsychol Soc, V1, P537; Connelly J, 2006, DISABIL REHABIL, V28, P629, DOI 10.1080/09638280500276513; Crepeau F, 1997, NEUROPSYCHOL REHABIL, V7, P147, DOI 10.1080/713755525; Crocker L, 1986, INTRO CLASSICAL MODE, P527; de Guise E, 2006, J HEAD TRAUMA REHAB, V21, P527, DOI 10.1097/00001199-200611000-00007; Doig E, 2001, BRAIN INJURY, V15, P747, DOI 10.1080/02699050110034343; DUTIL E, 1990, Occupational Therapy in Health Care, V7, P7, DOI 10.1080/J003v07n01_03; DUTIL E, 2005, ADL PROFILE DESCRIPT, P45; Fleming J, 1999, BRAIN INJURY, V13, P417; Fortin S, 2003, CORTEX, V39, P273, DOI 10.1016/S0010-9452(08)70109-6; Godbout L, 1995, NEUROPSYCHOLOGIA, V33, P1671, DOI 10.1016/0028-3932(95)00047-X; Goel V, 1997, BRAIN, V120, P1805, DOI 10.1093/brain/120.10.1805; Golden C., 1978, STROOP COLOR WORD TE; Golden CJ, 1978, DIAGNOSIS REHABILITA; Gordon WA, 2006, AM J PHYS MED REHAB, V85, P343, DOI 10.1097/01.phm.0000202106.01654.61; Grafman J., 1993, J HEAD TRAUMA REHAB, V8, P73, DOI DOI 10.1097/00001199-199303000-00008; Hoofien D, 2002, BRAIN INJURY, V16, P9, DOI 10.1080/02699050110088227; Humphreys GW, 1998, COGN NEUROPSYCHOL, V15, P771; JENNETT B, 1981, MANAGEMENT HEAD INJU, P295; Keith R A, 1987, Adv Clin Rehabil, V1, P6; Knight C, 2002, NEUROPSYCHOL REHABIL, V12, P231, DOI 10.1080/09602010244000039; Le Thiec F., 1999, Annales de Readaptation et de Medecine Physique, V42, P1, DOI 10.1016/S0168-6054(99)80030-0; Leahy BJ, 1998, BRAIN INJURY, V12, P1025, DOI 10.1080/026990598121936; LEVIN HS, 1988, J NEUROSURG, V69, P861, DOI 10.3171/jns.1988.69.6.0861; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; Lezak M. D., 1989, ASSESSMENT BEHAV CON, P113; LEZAK MD, 2004, NEUROPSYCHOLOGICAL A, P1015; LURIA AR, 1973, WORKING BRAIN INTRO, P398; MACLEOD CM, 1991, PSYCHOL BULL, V109, P163, DOI 10.1037/0033-2909.109.2.163; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; OWEN AM, 1990, NEUROPSYCHOLOGIA, V28, P1021, DOI 10.1016/0028-3932(90)90137-D; Phillips LH, 2001, Q J EXP PSYCHOL-A, V54, P579, DOI 10.1080/02724980042000237; Rabbitt P., 1997, METHODOLOGY FRONTAL, P1; RAINVILLE C, 2005, COMMUNICATION DEMENC, P137; ROGERS JC, 1982, AM J OCCUP THER, V36, P709, DOI 10.5014/ajot.36.11.709; ROPACKI MT, 2000, DURATION POSTTRAUMAT; Royall DR, 2005, J GERONTOL A-BIOL, V60, P1059, DOI 10.1093/gerona/60.8.1059; RUSSELL WR, 1946, BRAIN, V69, P280, DOI 10.1093/brain/69.4.280; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; SLOAN S, 1995, TRAUMATIC BRAIN INJU, P65; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Stuss DT, 2001, NEUROPSYCHOLOGIA, V39, P771, DOI 10.1016/S0028-3932(01)00013-6; TEASDALE G, 1974, LANCET, V2, P81; Teasell R, 2007, BRAIN INJURY, V21, P107, DOI 10.1080/02699050701201524; Tulsky DS, 2000, PSYCHOL ASSESSMENT, V12, P253, DOI 10.1037//1040-3590.12.3.253; Unterrainer JM, 2003, COGNITIVE BRAIN RES, V17, P675, DOI 10.1016/S0926-6410(03)00191-5; Vallee M, 2006, ARCH PHYS MED REHAB, V87, P806, DOI 10.1016/j.apmr.2006.02.031; Vanier M, 1991, TEST STROOP; VANIER M, 1998, EVALUATION PROGRAMME; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Whiteneck G, 2004, ARCH PHYS MED REHAB, V85, pS73, DOI 10.1016/j.apmr.2003.08.107; WILSON B, 1991, Brain Injury, V5, P189, DOI 10.3109/02699059109008089; Winkler D, 2006, J HEAD TRAUMA REHAB, V21, P8, DOI 10.1097/00001199-200601000-00002; Yochim BP, 2008, J CLIN EXP NEUROPSYC, V30, P236, DOI 10.1080/13803390701370006; Zalla T, 2001, NEUROPSYCHOLOGIA, V39, P759, DOI 10.1016/S0028-3932(01)00019-7	72	35	35	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	4					322	335	PII 909393459	10.1080/02699050902788436			14	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	425MY	WOS:000264643000007	19277921				2021-06-18	
J	Chevignard, MP; Servant, V; Mariller, A; Abada, G; Pradat-Diehl, P; Laurent-Vannier, A				Chevignard, Mathilde P.; Servant, Violette; Mariller, Aude; Abada, Genevieve; Pradat-Diehl, Pascale; Laurent-Vannier, Anne			Assessment of executive functioning in children after TBI with a naturalistic open-ended task: A pilot study	DEVELOPMENTAL NEUROREHABILITATION			English	Article						Traumatic brain injury; executive functions; ecological assessment; naturalistic task; child		Purpose: Traumatic brain injury (TBI) often leads to executive functions (EF) deficits, resulting in severe longstanding disabilities in daily life activities. The sensitivity and ecological validity of neuropsychological tests have been questioned. The aim of this study was to pilot a novel open-ended naturalistic task and to compare it to other standardized assessments of EF in children post-TBI. Methods: Ten children aged 8-14, with moderate-to-severe TBI, and 18 matched controls participated in the study. The clinical group was assessed using cognitive tests and parent-based questionnaires of EF. An interactive ecological cooking task was designed. Results: Analyses indicated mild-to-moderate executive deficits in the cognitive tests in approximately half of the TBI group. For the experimental cooking task, all quantitative and qualitative variables were significantly impaired for the TBI group compared to the control group and failure in the cooking task was associated with lower scores in cognitive tests of EF. The task was able to discriminate the TBI children from the control group. Conclusion: This pilot study highlights the role of naturalistic assessments, to complement standardized tests in assessing patients' dysexecutive impairments in complex activities of daily living post-childhood TBI.	[Chevignard, Mathilde P.; Servant, Violette; Mariller, Aude; Abada, Genevieve; Laurent-Vannier, Anne] INR A Hop Natl St Maurice, F-94410 St Maurice, France; [Chevignard, Mathilde P.; Pradat-Diehl, Pascale] INSERM, U731, F-75013 Paris, France; [Chevignard, Mathilde P.; Pradat-Diehl, Pascale] Univ Paris 06, F-75013 Paris, France; [Pradat-Diehl, Pascale] Grp Hosp Pitie Salpetriere, AP HP, Serv Med Phys & Readaptat, F-75634 Paris, France	Chevignard, MP (corresponding author), INR A Hop Natl St Maurice, 14 Rue Val Osne, F-94410 St Maurice, France.	m.chevignard@hopital-saint-maurice.fr			"Hopital National de Saint Maurice'' (France)	This work was conducted in fulfilment of the requirements for Violette Servant's Masters degree. It was performed by clinicians in a clinical setting, and was supported by the "Hopital National de Saint Maurice'' (France). We thank all the members of the rehabilitation team who were involved in the project, particularly the occupational therapists and the psychologists. We thank Professor Vicki Anderson, Associate Professor Cathy Catroppa and Doctor Cheryl Soo for their very helpful advice about the article as well as for the English corrections. And we thank the patients, the controls and their families for their valuable participation in this study.	Achenbach TM., 1991, INTEGRATIVE GUIDE 19; Anderson V, 1998, NEUROPSYCHOL REHABIL, V8, P319, DOI 10.1080/713755568; Anderson V, 2001, Pediatr Rehabil, V4, P119, DOI 10.1080/13638490110091347; Anderson VA, 2002, CHILD NEUROPSYCHOL, V8, P231, DOI 10.1076/chin.8.4.231.13509; Anderson VA, 2000, BRAIN INJURY, V14, P679; ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; BECKER MG, 1987, DEV NEUROPSYCHOL, V3, P275, DOI 10.1080/87565648709540381; Bennett PC, 2005, J INT NEUROPSYCH SOC, V11, P376, DOI 10.1017/S1355617705050423; BRUININKS RH, 1985, WOODCOCKJOHNSON PSYC; Burden V., 2003, BEHAV ASSESSMENT DYS; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; CHAPPARO C, 1997, MONOGRAPH OCCUPATION, V1, P189; Chaytor N, 2003, NEUROPSYCHOL REV, V13, P181, DOI 10.1023/B:NERV.0000009483.91468.fb; CHELUNE GJ, 1986, J CLIN EXP NEUROPSYC, V8, P219, DOI 10.1080/01688638608401314; Chevignard M, 2000, CORTEX, V36, P649, DOI 10.1016/S0010-9452(08)70543-4; Chevignard M., 2008, Annales de Readaptation et de Medecine Physique, V51, P74, DOI 10.1016/j.annrmp.2007.10.008; Chevignard MP, 2008, NEUROPSYCHOL REHABIL, V18, P461, DOI 10.1080/09602010701643472; CICCHETTI DV, 1981, AM J MENT DEF, V86, P127; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd, pXXI; COMALLI PE, 1962, J GENET PSYCHOL, V100, P47, DOI 10.1080/00221325.1962.10533572; CRIPE LI, 1998, ECOLOGICAL VALIDITY, P171; Denckla MB, 2002, CHILD NEUROPSYCHOL, V8, P304, DOI 10.1076/chin.8.4.304.13512; Dennis M, 2001, J INT NEUROPSYCH SOC, V7, P683, DOI 10.1017/S1355617701766040; Dennis M., 1989, CLIN NEUROPSYCHOLOGY, P89; Donders J, 2007, J HEAD TRAUMA REHAB, V22, P296, DOI 10.1097/01.HTR.0000290974.01872.82; Duncan J, 1996, COGNITIVE PSYCHOL, V30, P257, DOI 10.1006/cogp.1996.0008; Emanuelson I, 1998, Pediatr Rehabil, V2, P65; Eslinger PJ, 2004, BRAIN COGNITION, V55, P84, DOI 10.1016/s0278-2626(03)00281-1; ESLINGER PJ, 1992, ARCH NEUROL-CHICAGO, V49, P764, DOI 10.1001/archneur.1992.00530310112021; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; ESLINGER PJ, 1991, DEV NEUROPSYCHOL, V7, P257, DOI 10.1080/87565649109540493; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Ewing-Cobbs L, 1998, CHILD NEUROPSYCHOL, V4, P35, DOI 10.1076/chin.4.1.35.3194; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FISHER A, 2003, AMPS ASSESSMENT MOTO, V1; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Fortin S, 2003, CORTEX, V39, P273, DOI 10.1016/S0010-9452(08)70109-6; Franzen M. D., 1996, ECOLOGICAL VALIDITY, P75; Garth J, 1997, Pediatr Rehabil, V1, P99; Gioia G.A., 2000, BEHAV RATING INVENTO; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Gioia GA, 2002, CHILD NEUROPSYCHOL, V8, P121, DOI 10.1076/chin.8.2.121.8727; GRANGER CV, 1998, WEE FIM SYSTEM CLIN; GRATTAN LM, 1991, DEV NEUROPSYCHOL, V7, P283, DOI 10.1080/87565649109540496; Heaton RK, 2002, TEST CLASSEMENT CART; Hoofien D, 2001, BRAIN INJURY, V15, P189; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; JAVOUHEY E, 2006, ARCH PEDIATR, V6, P528; Jonsson CA, 2004, BRAIN INJURY, V18, P921, DOI 10.1080/02699050410001671900; Kelly T., 2000, CLIN NEUROPSYCHOL, V1, P38; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Lawrence V, 2002, J ABNORM CHILD PSYCH, V30, P447, DOI 10.1023/A:1019812829706; Levin H S, 1997, J Int Neuropsychol Soc, V3, P598; Levin HS, 2005, PEDIATR NEUROL, V33, P79, DOI 10.1016/j.pediatrneurol.2005.02.002; LEVIN HS, 1991, DEV NEUROPSYCHOL, V7, P377, DOI 10.1080/87565649109540499; LEVIN HS, 1994, NEUROPSYCHOLOGY, V8, P171, DOI DOI 10.1037/0894-4105.8.2.171; Levine B, 1998, J INT NEUROPSYCH SOC, V4, P247, DOI 10.1017/S1355617798002471; LEZAK MD, 1993, J HEAD TRAUMA REHAB, V8, P24, DOI DOI 10.1097/00001199-199303000-00004; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Lussier F., 1998, APPROCHE NEUROPSYCHO, V47, P42; Manchester D, 2004, BRAIN INJURY, V18, P1067, DOI 10.1080/02699050410001672387; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; MARLOWE WB, 1990, J CLIN EXP NEUROPSYC, V12, P105; Masson F, 1996, ARCH PEDIATRIE, V3, P651, DOI 10.1016/0929-693X(96)87085-0; MATEER CA, 1991, DEV NEUROPSYCHOL, V7, P359, DOI 10.1080/87565649109540498; Max JE, 1999, J INT NEUROPSYCH SOC, V5, P58, DOI 10.1017/S1355617799511089; MUSCARA F, NEUROPSYCHO IN PRESS; Muscara F, 2008, DEV NEUROPSYCHOL, V33, P623, DOI 10.1080/87565640802171162; Muscara F, 2008, J NEUROPSYCHOL, V2, P445, DOI 10.1348/174866407X250820; Nadebaum C, 2007, DEV NEUROPSYCHOL, V32, P703, DOI 10.1080/87565640701376086; Norris G, 2000, NEUROPSYCHOL REHABIL, V10, P33, DOI 10.1080/096020100389282; Nybo T, 2004, J INT NEUROPSYCH SOC, V10, P719, DOI 10.1017/S1355617704105109; Nybo T, 1999, BRAIN INJURY, V13, P759; Owen AM, 1996, EUR J NEUROSCI, V8, P353, DOI 10.1111/j.1460-9568.1996.tb01219.x; Passler MA, 1985, DEV NEUROPSYCHOL, V1, P349, DOI 10.1080/87565648509540320; Pentland L, 1998, NEUROPSYCHOL REHABIL, V8, P301, DOI 10.1080/713755572; Powell KB, 2004, J CHILD NEUROL, V19, P785, DOI 10.1177/08830738040190100801; PRICE BH, 1990, BRAIN, V113, P1383, DOI 10.1093/brain/113.5.1383; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Rey A., 1959, TEST COPIE FIGURE CO; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Sbordone R. J., 1996, ECOLOGICAL VALIDITY, P15; Sbordone RJ, 2001, NEUROREHABILITATION, V16, P199; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Shallice T, 2002, DEV NEUROPSYCHOL, V21, P43, DOI 10.1207/S15326942DN2101_3; Sharples PM, 1998, INJURY YOUNG, V263-299; Silver CH, 2000, J HEAD TRAUMA REHAB, V15, P973, DOI 10.1097/00001199-200008000-00002; Sohlberg M. M., 2001, COGNITIVE REHABILITA; Sparrow S., 1984, VINELAND ADAPTIVE BE; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; TEASDALE G, 1974, LANCET, V2, P81; Todd JA, 1996, NEUROPSYCHOL REHABIL, V6, P81, DOI 10.1080/713755500; Van Heugten CM, 2006, BRAIN INJURY, V20, P895, DOI 10.1080/02699050600832015; VANNIER AL, 2000, CHILD NERV SYST, V16, P760; Vriezen ER, 2002, CHILD NEUROPSYCHOL, V8, P296, DOI 10.1076/chin.8.4.296.13505; Vriezen ER, 2001, BRAIN COGNITION, V47, P222; WELSH MC, 1991, DEV NEUROPSYCHOL, V7, P131, DOI 10.1080/87565649109540483; Wilson B. A., 1991, RIVERMEAD BEHAV MEMO; Wilson BA, 1998, NEUROPSYCHOL REHABIL, V8, P213, DOI 10.1080/713755570; WILSON BA, 1993, J CLIN EXP NEUROPSYC, V15, P474, DOI 10.1080/01688639308402572; Wilson BA, 1996, BEHAV ASSESSMENT DYS; Wood RL, 2006, ARCH CLIN NEUROPSYCH, V21, P429, DOI 10.1016/j.acn.2005.06.014; 2005, WISC 4 ECHELLE INTEL	104	35	36	0	9	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1751-8423	1751-8431		DEV NEUROREHABIL	Dev. Neurorehabil.		2009	12	2					76	91		10.1080/17518420902777019			16	Clinical Neurology; Pediatrics; Rehabilitation	Neurosciences & Neurology; Pediatrics; Rehabilitation	V15FM	WOS:000207787900003	19340660				2021-06-18	
J	Bradbury, CL; Wodchis, WP; Mikulis, DJ; Pano, EG; Hitzig, SL; McGillivray, CF; Ahmad, FN; Craven, BC; Green, RE				Bradbury, Cheryl L.; Wodchis, Walter P.; Mikulis, David J.; Pano, Ephrem G.; Hitzig, Sander L.; McGillivray, Colleen F.; Ahmad, Fahad N.; Craven, B. Catherine; Green, Robin E.			Traumatic Brain Injury in Patients With Traumatic Spinal Cord Injury: Clinical and Economic Consequences	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Rehabilitation; Spinal cord injuries	CLOSED HEAD-INJURY	Objective: To evaluate the clinical and economic burden of traumatic brain injury (TBI) in people with traumatic spinal cord injury (SCI). Design: Prospective, case-matched control study. Setting: Inpatient spinal cord rehabilitation program. Participants: Patients (n=10) diagnosed with traumatic SCI and concomitant TBI matched to an SCI only control group. Interventions: Not applicable. Main Outcome Measures: Inpatient rehabilitation length of stay, health care costs (patient care hours), clinician resource allocation, behavioral and critical incidents, FIM, Personality Assessment Inventory, and neuropsychological assessment findings. Results: Prolonged loss of consciousness, increased rehabilitation costs, and greater demands on clinician recourses (trend) were found in the SCI with TBI group relative to the SCI-only group. Neuropsychological test performance was significantly worse in the SCI with TBI group, while the FIM cognition score did not discriminate because of ceiling effects. Greater evidence of psychopathology was observed in the SCI with TBI group. Conclusions: The presence of TBI in SCI has a range of clinical and economic consequences. This dual diagnosis has the potential to affect SCI rehabilitation negatively, as well as quality of life and reintegration in the community. Specialized care appears to be needed to improve outcomes and to minimize clinical and economic burden, but further research is required.	[Bradbury, Cheryl L.; Wodchis, Walter P.; Pano, Ephrem G.; Hitzig, Sander L.; McGillivray, Colleen F.; Craven, B. Catherine; Green, Robin E.] Toronto Rehabil Inst, Toronto, ON M4G 3V9, Canada; [Wodchis, Walter P.] Univ Toronto, Dept Hlth Policy Management & Evaluat, Toronto, ON M5S 1A1, Canada; [Pano, Ephrem G.; Green, Robin E.] Univ Toronto, Grad Dept Rehabil Sci, Toronto, ON M5S 1A1, Canada; [Mikulis, David J.; McGillivray, Colleen F.; Craven, B. Catherine] Univ Toronto, Dept Med, Toronto, ON M5S 1A1, Canada; [Hitzig, Sander L.] York Univ, Dept Psychol, N York, ON M3J 1P3, Canada; [Mikulis, David J.] Toronto Western Hosp, Toronto, ON M5T 2S8, Canada	Bradbury, CL (corresponding author), Toronto Rehabil Inst, 520 Sutherland Dr, Toronto, ON M4G 3V9, Canada.	bradbury.cheryl@torontorehab.on.ca	Hitzig, Sander/AAN-2287-2020; Craven, Beverley Catharine/D-5001-2015; Mikulis, David J/H-5167-2019; Greiver, Michelle/N-8764-2015	Craven, Beverley Catharine/0000-0001-8234-6803; Greiver, Michelle/0000-0001-8957-0285; Green, Robin/0000-0001-9451-3963; wodchis, walter/0000-0003-2494-7031; McGillivray, Colleen/0000-0002-0982-233X; Mikulis, David/0000-0003-3956-0892	Ontario Neurotrauma Foundation [2005-ABI-392]	Supported by the Ontario Neurotrauma Foundation (grant no 2005-ABI-392).	Arzaga Deborah, 2003, SCI Nurs, V20, P86; COHEN J, 1994, AM PSYCHOL, V49, P997, DOI 10.1037/0003-066X.49.12.997; Cohen J., 1983, APPL MULTIPLE REGRES; DAVIDOFF G, 1988, ARCH PHYS MED REHAB, V69, P869; DAVIDOFF G, 1986, PARAPLEGIA, V24, P97, DOI 10.1038/sc.1986.13; DAVIDOFF GN, 1992, ARCH PHYS MED REHAB, V73, P275; DAVIDOFF GN, 1990, ARCH PHYS MED REHAB, V71, P326; Delis DC, 2000, CALIFORNIA VERBAL LE; Demakis GJ, 2007, ARCH CLIN NEUROPSYCH, V22, P123, DOI 10.1016/j.acn.2006.09.004; FULLERTON DT, 1981, ARCH GEN PSYCHIAT, V38, P1369; Granger CV, 1986, FUNCTIONAL INDEPENDE; Heaton R., 1993, WISCONSIN CARD SORTI; HEINEMANN AW, 1988, ARCH PHYS MED REHAB, V69, P619; Hooper, 1983, HOOPER VISUAL ORG TE; Iida H, 1999, J TRAUMA, V46, P450, DOI 10.1097/00005373-199903000-00018; KELLY AB, 1988, AM J NEURORADIOL, V9, P699; KREUTZER JS, 1988, ARCH PHYS MED REHAB, V69, P764; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Lin KC, 2007, CLIN REHABIL, V21, P1075, DOI 10.1177/0269215507079843; Macciocchi SN, 2004, AM J PHYS MED REHAB, V83, P22, DOI 10.1097/01.PHM.0000104661.86307.91; *MAYO CLIN STAFF, 2007, SPIN CORD INJ; Meyer GJ, 2001, AM PSYCHOL, V56, P128, DOI 10.1037//0003-066X.56.2.128; MICHAEL D B, 1989, Journal of Neurotrauma, V6, P177; Morey L. C., 1991, PERSONALITY ASSESSME; National Spinal Cord Injury Statistical Center, FACTS FIG GLANC; POVOLNY MA, 1993, J REHABIL, V59, P23; Prigatano GP., 1999, PRINCIPLES NEUROPSYC; RICHARDS JS, 1991, ARCH PHYS MED REHAB, V72, P275; RICHARDS JS, 1988, AM J PHYS MED REHAB, V67, P211, DOI 10.1097/00002060-198810000-00005; Ricker J.H., 1999, TOP SPINAL CORD INJ, V5, P76; Rimel R W, 1981, J Neurosurg Nurs, V13, P132; Rosenthal M, 2000, HANDBOOK OF REHABILITATION PSYCHOLOGY, P49, DOI 10.1037/10361-003; SABOE LA, 1991, J TRAUMA, V31, P43, DOI 10.1097/00005373-199101000-00010; SILVER JR, 1980, INJURY, V12, P219, DOI 10.1016/0020-1383(80)90011-X; Smith A., 1982, SYMBOL DIGIT MODALIT; Sommer JL, 2004, BRAIN INJURY, V18, P1297, DOI 10.1080/02699050410001672288; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Sutherland J, 2006, TECHNICAL REPORT DEV; Swaine BR, 1996, BRAIN INJURY, V10, P347, DOI 10.1080/026990596124368; Tolonen A, 2007, J REHABIL MED, V39, P622, DOI 10.2340/16501977-0101; *US DEP HHS, 1999, TRAUM BRAIN INJ US A; WAGNER KA, 1983, ARCH PHYS MED REHAB, V64, P519; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wechsler D., 1997, WECHSLER MEMORY SCAL, VIII; Weschler D, 2001, WECHSLER TEST ADULT; WILMOT CB, 1985, ARCH PHYS MED REHAB, V66, P227, DOI 10.1016/0003-9993(85)90148-0; WILSON BA, 1994, NEUROPSYCHOL REHABIL, V4, P307, DOI 10.1080/09602019408401463	47	35	39	0	10	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	DEC	2008	89	12		2			S77	S84		10.1016/j.apmr.2008.07.008			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	388DB	WOS:000261999400010	19081445				2021-06-18	
J	Case, ME				Case, Mary E.			Inflicted traumatic brain injury in infants and young children	BRAIN PATHOLOGY			English	Article						abusive injuries; head injury; retinal hemorrhages; subdural hemorrhage	DIFFUSE AXONAL INJURY; SHAKEN BABY SYNDROME; NONACCIDENTAL HEAD-INJURY; CHRONIC SUBDURAL-HEMATOMA; RETINAL HEMORRHAGE; NEUROPATHOLOGY; DEATH; MECHANISMS; MORPHOLOGY; DIAGNOSIS	This article will discuss the subject of inflicted or abusive head injury in infants and young children. Inflicted neurotrauma is a very common injury and a frequent problem in attempting to distinguish between inflicted and accidental injury. Inflicted head injury occurs usually in the home in the presence of the individual who has inflicted the injury outside the view of unbiased witnesses. Distinguishing between inflicted and accidental injury may be dependent upon the pathological findings and consideration of the circumstances surrounding the injury. The most common finding in an inflicted head injury is the presence of subdural hemorrhage. Subdural hemorrhage may occur in a variety of distributions and appearances. The natural history of subdural bleeding and the anatomy of the "subdural" will be considered. The anatomy of the dura and its attachment to the skull and to the arachnoid determines how subdural bleeding evolves into the cleaved dural border cell layer and as well as how bridging veins are torn and anatomically where bleeding will occur. Different biomechanical mechanisms result in different distributions of subdural blood and these differences will be discussed.	St Louis Univ, Sch Med, Dept Pathol, Div Forens Pathol, St Louis, MO 63104 USA	Case, ME (corresponding author), St Louis Univ, Sch Med, Dept Pathol, Div Forens Pathol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	mcase@stlouisco.com					ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ASTRUP T, 1965, THROMB DIATH HAEMOST, V14, P401; Barlow Karen, 2004, Pediatr Rehabil, V7, P195, DOI 10.1080/13638490410001715331; BILLMIRE ME, 1985, PEDIATRICS, V75, P340; Bittigau P, 1998, RESTOR NEUROL NEUROS, V13, P11; Bonnier C, 1995, DEV MED CHILD NEUROL, V37, P943; Bonnier C, 2002, BRAIN PATHOL, V12, P320; Borzone M, 1983, J Neurosurg Sci, V27, P161; CAFFEY J, 1972, AM J DIS CHILD, V124, P161, DOI 10.1001/archpedi.1972.02110140011001; CALDER IM, 1984, J CLIN PATHOL, V37, P1095, DOI 10.1136/jcp.37.10.1095; Case ME, 2001, AM J FOREN MED PATH, V22, P112, DOI 10.1097/00000433-200106000-00002; CASE ME, 1996, ANN M NAT ASS MED EX; CASE ME, 2002, ANN M NAT ASS MED EX; CASE MES, 1993, ANN M NAT ASS MED EX; Christian CW, 1999, J PEDIATR-US, V135, P125, DOI 10.1016/S0022-3476(99)70343-4; Cuatico W, 1991, J Neurosurg Sci, V35, P139; Dias MS, 1998, PEDIATR NEUROSURG, V29, P77, DOI 10.1159/000028694; DIERCKX RA, 1989, ACTA NEUROL BELG, V89, P352; DIMAIO DJ, 1993, FORENSIC PATHOLOGY, P304; Dolinak D, 2006, ARCH PATHOL LAB MED, V130, P712; DOLINSKAS CA, 1978, RADIOLOGY, V126, P409, DOI 10.1148/126.2.409; DOLINSKAS CA, 1979, J TRAUMA, V19, P163, DOI 10.1097/00005373-197903000-00006; Douherty W, 1931, JAMA-J AM MED ASSOC, V97, P308; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Emerson MV, 2001, OPHTHALMOLOGY, V108, P36, DOI 10.1016/S0161-6420(00)00474-7; FRASER SG, 1995, EYE, V9, P659, DOI 10.1038/eye.1995.165; GEAN AD, 1994, HEAD TRAUMA, P367; Geddes JF, 2000, NEUROPATH APPL NEURO, V26, P105, DOI 10.1046/j.1365-2990.2000.026002105.x; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; Gilles EE, 1998, PEDIATR NEUROL, V19, P119, DOI 10.1016/S0887-8994(98)00038-1; Gleckman AM, 1999, ARCH PATHOL LAB MED, V123, P146; GOODELL CL, 1963, ARCH NEUROL-CHICAGO, V8, P429, DOI 10.1001/archneur.1963.00460040099009; GREENWALD MJ, 1986, OPHTHALMOLOGY, V93, P618; HADLEY MN, 1989, NEUROSURGERY, V24, P536, DOI 10.1227/00006123-198904000-00008; HAINES DE, 1991, ANAT RECORD, V230, P3, DOI 10.1002/ar.1092300103; HAINES DE, 1993, NEUROSURGERY, V32, P111, DOI 10.1227/00006123-199301000-00017; HARRIS LS, 1969, AM J CLIN PATHOL, V52, P289; Hortobagyi T, 2007, NEUROPATH APPL NEURO, V33, P226, DOI 10.1111/j.1365-2990.2006.00794.x; Hymel KP, 1997, PEDIATR RADIOL, V27, P743, DOI 10.1007/s002470050215; JOHNSON DL, 1993, NEUROSURGERY, V33, P231; Johnson DL, 1995, PEDIATR NEUROSURG, V23, P305, DOI 10.1159/000120976; KANTER RK, 1986, J PEDIATR-US, V108, P430, DOI 10.1016/S0022-3476(86)80890-3; KAWAKAMI Y, 1989, NEUROSURGERY, V25, P25, DOI 10.1227/00006123-198907000-00005; Kivlin J D, 1999, Trans Am Ophthalmol Soc, V97, P545; KLEINMAN P, 1990, AM J RADIOL, V156, P703; Kleinman PK, 1998, DIAGNOSTIC IMAGING C, P285; KRAMER K, 1993, CLIN PEDIATR, V32, P366, DOI 10.1177/000992289303200610; Lee KS, 1998, BRAIN INJURY, V12, P901; Lee Kyeong-Seok, 1996, Journal of Korean Medical Science, V11, P55; LEVIN A, 1998, AM ACAD OPHTHALMOL, V16, P1; LEVIN A, 1986, PEDIATR EMERG CARE, V2, P269; Levin AV, 2002, NEUROSURG CLIN N AM, V13, P201, DOI 10.1016/S1042-3680(02)00004-9; Levin AV, 2000, RECENT ADV PAEDIAT, P151; Levin AV, 1990, OPHTHALMOL CLIN N AM, V3, P249; LINDENBERG R, 1969, ARCH PATHOL, V87, P298; MATAKAS F, 1973, J NEUROL NEUROSUR PS, V36, P497, DOI 10.1136/jnnp.36.4.497; MAYFRANK L, 1993, ACTA NEUROCHIR, V120, P92, DOI 10.1007/BF02001476; MCCLAIN PW, 1993, PEDIATRICS, V91, P338; MCCLELLAND CQ, 1980, CHILD BRAIN, V7, P225; MURATA K, 1993, NEURO MED CHIR TOKYO, V33, P391; Overpeck MD, 1998, NEW ENGL J MED, V339, P1211, DOI 10.1056/NEJM199810223391706; PARENT AD, 1992, PEDIATR NEUROSURG, V18, P266, DOI 10.1159/000120674; PARRISH R, 1996, PED TRAUMA FORENSIC; Prahlow JA, 1998, AM J FOREN MED PATH, V19, P391, DOI 10.1097/00000433-199812000-00019; PRIATT JH, 1995, PEDIATRICS, V96, P780; Reichard RR, 2003, J NEUROPATH EXP NEUR, V62, P237, DOI 10.1093/jnen/62.3.237; ROSENTHAL M, 1990, REHABILITATION ADULT, P521; Salehi-Had H, 2006, PEDIATRICS, V117, pE1039, DOI 10.1542/peds.2005-0811; Sargent S, 1996, J FORENSIC SCI, V41, P314; Shannon P, 1998, ACTA NEUROPATHOL, V95, P625, DOI 10.1007/s004010050849; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; Smith SL, 1998, J NEUROTRAUM, V15, P693, DOI 10.1089/neu.1998.15.693; TOWBIN A, 1967, LANCET, V2, P940; Tzioumi D, 1998, CHILD ABUSE NEGLECT, V22, P1105, DOI 10.1016/S0145-2134(98)00093-3; VOWLES GH, 1987, J CLIN PATHOL, V40, P185, DOI 10.1136/jcp.40.2.185; WEISSGOLD DJ, 1995, SURV OPHTHALMOL, V39, P509; Wells RG, 2002, ARCH PEDIAT ADOL MED, V156, P252, DOI 10.1001/archpedi.156.3.252; WETTERLING T, 1988, ACTA NEUROCHIR, V91, P79, DOI 10.1007/BF01400533; WILBUR LS, 1992, PEDIATRICS, V89, P332; YAMASHIMA T, 1984, J NEUROL NEUROSUR PS, V47, P121, DOI 10.1136/jnnp.47.2.121	87	35	37	1	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1015-6305	1750-3639		BRAIN PATHOL	Brain Pathol.	OCT	2008	18	4					571	582		10.1111/j.1750-3639.2008.00204.x			12	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	347MW	WOS:000259146700012	18782169				2021-06-18	
J	Aquilani, R; Boselli, M; Boschi, F; Viglio, S; Iadarola, P; Dossena, M; Pastoris, O; Verri, M				Aquilani, Roberto; Boselli, Mirella; Boschi, Federica; Viglio, Simona; Iadarola, Paolo; Dossena, Maurizia; Pastoris, Ornella; Verri, Manuela			Branched-chain amino acids may improve recovery from a vegetative or minimally conscious state in patients with traumatic brain injury: A pilot study	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						amino acids; branched-chain; minimally conscious state; rehabilitation	HIPPOCAMPAL ACETYLCHOLINE-RELEASE; AXONAL INJURY; HEAD-INJURY; INSULIN; METABOLISM; MEMORY; DYSFUNCTION; DISABILITY; INHIBITION; RECEPTORS	Objective: To investigate whether Supplementation With branched-chain amino acids (BCAAs) may improve recovery of patients with a posttramatic vegetative or minimally conscious state. Design: Patients were randomly assigned to 15 days of intravenous BCAA Supplementation (n=22., 19.6g/d) or all isonitrogenous placebo (n = 19). Setting: Tertiary care rehabilitation setting. Participants: Patients (N=41: 29 men, 12 women, mean age,49.5 +/- 21y) with a posttraumatic vegetative or minimally conscious state. 47 24 days after the index traumatic event. Intervention: Supplementation with BCAAs. Main Outcome Measure: Disability Rating Scale (DRS) as log(10)DRS. Results: Fifteen days after admission to the rehabilitation department, the log(10)DRS score improved significantly only in patients who had received BCAAs (log(10)DRS score, 1.365 +/- 0.08 to 1.294 +/- 0.05-, P<.001), while the log(10)DRS score in the placebo recipients remained virtually unchanged (log(10)DRS score, 1.373 +/- 10.03 to 1.37 +/- 10.03; P not significant). The difference in improvement of log(10)DRS score between the 2 groups was highly significant (P<.000). Moreover 682% (n 15) of treated patients achieved a log(10))DRS point score of 477 or higher Q as geometric mean) that allowed them to exit the vegetative or minimally Conscious state. Conclusions: Supplemented BCAAs may improve the recovery from a vegetative or minimally conscious state in patients with posttraumatic vegetative or minimally conscious state.	[Pastoris, Ornella] Univ Pavia, Fac Sci MM FF NN, Sez Farmacol & Biotecnol Farmacol, Dipartimento Sci Fisiol Farmacol Cellulari Mol, I-27100 Pavia, Italy; [Aquilani, Roberto] Fdn S Maugeri, Ist Sci Montescano, Serv Fistopatol Metab Nutr, Pavia, Italy; [Aquilani, Roberto] Fdn S Maugeri, Ist Sci Montescano, Nutr Clin, Pavia, Italy; [Boselli, Mirella] Fdn S Maugeri, Ist Sci Montescano, Div Neuroriabilitaz 2, Pavia, Italy; [Viglio, Simona; Iadarola, Paolo] Univ Pavia, Dipartimento Biochim A Castellani, I-27100 Pavia, Italy	Pastoris, O (corresponding author), Univ Pavia, Fac Sci MM FF NN, Sez Farmacol & Biotecnol Farmacol, Dipartimento Sci Fisiol Farmacol Cellulari Mol, Piazza Botta Pavia 1, I-27100 Pavia, Italy.	labmio@unipv.it		Viglio, Simona/0000-0001-5020-478X; Pastoris, Ornella/0000-0003-0273-1010; Boselli, Mirella/0000-0003-4545-5271			Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Ahmed SM, 2000, J NEUROCHEM, V74, P1951, DOI 10.1046/j.1471-4159.2000.741951000000000.x; Aquilani R, 2005, ARCH PHYS MED REHAB, V86, P1729, DOI 10.1016/j.apmr.2005.03.022; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Biolo G, 1997, AM J PHYSIOL-ENDOC M, V273, pE122; CADOUXHUDSON TAD, 1990, ACTA NEUROCHIR, V104, P1, DOI 10.1007/BF01842884; CHAPLIN ER, 1976, J NEUROCHEM, V26, P701, DOI 10.1111/j.1471-4159.1976.tb04440.x; Chen SF, 2004, J CEREBR BLOOD F MET, V24, P1025, DOI 10.1097/01.WCB.0000129415.34520.47; Christie JM, 1999, J NEUROCHEM, V72, P1523, DOI 10.1046/j.1471-4159.1999.721523.x; Clarke D. D., 1998, BASIC NEUROCHEMISTRY, P637; COSTANTINIDIS C, 2002, NAT NEUROSCI, V5, P175; COTMAN CW, 1981, PHYSIOL REV, V61, P684; DAVIS SN, 1995, J CLIN INVEST, V95, P593, DOI 10.1172/JCI117703; EICHENBAUM H, 1992, BEHAV NEURAL BIOL, V57, P2, DOI 10.1016/0163-1047(92)90724-I; ERECINSKA M, 1989, J CEREBR BLOOD F MET, V9, P2, DOI 10.1038/jcbfm.1989.2; FERNSTROM JD, 1978, J NEUROCHEM, V30, P1531, DOI 10.1111/j.1471-4159.1978.tb10489.x; FLIGLEWICZ DP, 1999, HORM METAB RES, V31, P335; GAITONDE MK, 1983, J NEUROCHEM, V41, P1253, DOI 10.1111/j.1471-4159.1983.tb00819.x; GIACINO JT, 1991, ARCH PHYS MED REHAB, V72, P897, DOI 10.1016/0003-9993(91)90008-7; GIACINO JT, 1995, ARCH PHYS MED REHAB, V76, P205; GOLDMANRAKIC PS, 1995, NEURON, V14, P477, DOI 10.1016/0896-6273(95)90304-6; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; Hall ED, 1996, J NEUROSCI RES, V44, P293, DOI 10.1002/(SICI)1097-4547(19960501)44:3<293::AID-JNR10>3.0.CO;2-6; HENNEBERG N, 1994, NEUROSCI LETT, V175, P153, DOI 10.1016/0304-3940(94)91102-9; Hoffman SW, 1997, STROKE, V28, P844, DOI 10.1161/01.STR.28.4.844; Jonas EA, 1997, NATURE, V385, P343, DOI 10.1038/385343a0; Kern W, 2001, NEUROENDOCRINOLOGY, V74, P270, DOI 10.1159/000054694; Kern W, 2002, DRUG DEVELOP RES, V56, P511, DOI 10.1002/ddr.10101; Lamb RG, 1997, J NEUROCHEM, V68, P1904; Layman DK, 2002, CAN J APPL PHYSIOL, V27, P646, DOI 10.1139/h02-038; LEHNINGER AL, 1983, PRINCIPI BIOCH; Ma XH, 2003, J NEUROSCI, V23, P1159; MARKS JL, 1991, ADV EXP MED BIOL, V293, P459; MASTERS BA, 1987, BRAIN RES, V417, P247, DOI 10.1016/0006-8993(87)90449-5; Mattson MP, 1997, NEUROSCI BIOBEHAV R, V21, P193, DOI 10.1016/S0149-7634(96)00010-3; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; MUIR JK, 1995, J NEUROTRAUM, V12, P179, DOI 10.1089/neu.1995.12.179; Park CR, 2000, PHYSIOL BEHAV, V68, P509, DOI 10.1016/S0031-9384(99)00220-6; Park CR, 2001, NEUROSCI BIOBEHAV R, V25, P311, DOI 10.1016/S0149-7634(01)00016-1; Paschen W, 2001, J NEUROCHEM, V79, P719, DOI 10.1046/j.1471-4159.2001.00623.x; Ragozzino ME, 1998, J NEUROSCI, V18, P1595; Ragozzino ME, 1996, P NATL ACAD SCI USA, V93, P4693, DOI 10.1073/pnas.93.10.4693; RAIZADA MK, 1988, NEUROCHEM RES, V13, P297, DOI 10.1007/BF00972477; RAPPAPORT M, 1977, ARCH PHYS MED REHAB, V58, P333; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; Spanswick D, 2000, NAT NEUROSCI, V3, P757, DOI 10.1038/77660; STENOIDEN DL, 1998, BASIC NEUROCHEMISTRY, P565; Stockhorst U, 2004, PHYSIOL BEHAV, V83, P47, DOI 10.1016/j.physbeh.2004.07.022; Sweeney G, 1998, MOL CELL BIOCHEM, V182, P121, DOI 10.1023/A:1006805510749; Tavalin SJ, 1997, J NEUROPHYSIOL, V77, P632; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Volpi E, 1998, J CLIN INVEST, V101, P2000, DOI 10.1172/JCI939; Wan Q, 1997, NATURE, V388, P686, DOI 10.1038/41792; Whyte J, 2005, ARCH PHYS MED REHAB, V86, P453, DOI 10.1016/j.apmr.2004.05.016; Wu HM, 2004, NEUROSURGERY, V55, P1306, DOI 10.1227/01.NEU.0000143028.08719.42; Wu HM, 2004, J NEUROTRAUM, V21, P149, DOI 10.1089/089771504322778613; Xu G, 1998, J BIOL CHEM, V273, P28178, DOI 10.1074/jbc.273.43.28178; YOSHINO A, 1992, J CEREBR BLOOD F MET, V12, P996, DOI 10.1038/jcbfm.1992.137; ZAMPOLINI M, 2005, EUR MED PHYS S1, V41, P81; Zhao WQ, 2001, MOL CELL ENDOCRINOL, V177, P125, DOI 10.1016/S0303-7207(01)00455-5; 1995, N ENGL J MED, V333, P130	62	35	36	0	6	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	SEP	2008	89	9					1642	1647		10.1016/j.apmr.2008.02.023			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	346GR	WOS:000259057300002	18760149				2021-06-18	
J	Bikle, DD				Bikle, D. D.			Integrins, insulin like growth factors, and the skeletal response to load	OSTEOPOROSIS INTERNATIONAL			English	Article						bone; IGF; integrin; mechanical load; osteoblast; osteoclast	I IGF-I; UNLOADING INDUCES RESISTANCE; MESENCHYMAL STEM-CELLS; FOCAL ADHESION KINASE; SMOOTH-MUSCLE-CELLS; BONE-FORMATION; SIMULATED WEIGHTLESSNESS; ALPHA-V-BETA-3 INTEGRIN; PARATHYROID-HORMONE; OSTEOBLASTIC CELLS	Bone loss during skeletal unloading, whether due to neurotrauma resulting in paralysis or prolonged immobilization due to a variety of medical illnesses, accelerates bone loss. In this review the evidence that skeletal unloading leads to bone loss, at least in part, due to disrupted insulin like growth factor (IGF) signaling, resulting in reduced osteoblast proliferation and differentiation, will be examined. The mechanism underlying this disruption in IGF signaling appears to involve integrins, the expression of which is reduced during skeletal unloading. Integrins play an important, albeit not well defined, role in facilitating signaling not only by IGF but also by other growth factors. However, the interaction between selected integrins such as alpha upsilon beta 3 and beta 1 integrins and the IGF receptor are of especial importance with respect to the ability of bone to respond to mechanical load. Disruption of this interaction blocks IGF signaling and results in bone loss.	[Bikle, D. D.] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Bikle, D. D.] Vet Affairs Med Ctr, Special Diagnost & Treatment Ctr, San Francisco, CA 94121 USA	Bikle, DD (corresponding author), Univ Calif San Francisco, San Francisco, CA 94143 USA.	Daniel.bikle@ucsf.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [R01AR055924] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK054793] Funding Source: NIH RePORTER; NIAMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [R01 AR055924] Funding Source: Medline; NIDDK NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01 DK054793, R01 DK54793] Funding Source: Medline		ABRAM AC, 1988, J BIOMECH, V21, P755, DOI 10.1016/0021-9290(88)90284-9; Asthagiri AR, 1999, J BIOL CHEM, V274, P27119, DOI 10.1074/jbc.274.38.27119; BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; Bakker AD, 2001, J BIOMECH, V34, P671, DOI 10.1016/S0021-9290(00)00231-1; Bikle D, 2001, J BONE MINER RES, V16, P2320, DOI 10.1359/jbmr.2001.16.12.2320; BIKLE DD, 1987, ENDOCRINOLOGY, V120, P678, DOI 10.1210/endo-120-2-678; BIKLE DD, 1994, AM J PHYSIOL-ENDOC M, V267, pE822; Borges E, 2000, J BIOL CHEM, V275, P39867, DOI 10.1074/jbc.M007040200; Boudignon BM, 2007, J APPL PHYSIOL, V103, P125, DOI 10.1152/japplphysiol.00111.2007; Boutahar N, 2004, J BIOL CHEM, V279, P30588, DOI 10.1074/jbc.M313244200; CANALIS E, 1985, CLIN ORTHOP RELAT R, P246; Carvalho RS, 2002, J CELL BIOCHEM, V84, P497; Clemmons DR, 2005, MOL ENDOCRINOL, V19, P1, DOI 10.1210/me.2004-0376; Cowles EA, 2000, J BIOMED MATER RES, V52, P725, DOI 10.1002/1097-4636(20001215)52:4<725::AID-JBM18>3.0.CO;2-O; Dufour C, 2007, EXP CELL RES, V313, P394, DOI 10.1016/j.yexcr.2006.10.021; Faccio R, 2005, NAT MED, V11, P284, DOI 10.1038/nm1194; Favelyukis S, 2001, NAT STRUCT BIOL, V8, P1058, DOI 10.1038/nsb721; Fujihara S, 2006, J BONE MINER RES, V21, P956, DOI 10.1359/JBMR.060315; GARETTO LP, 1990, FASEB J, V4, P24; Genetos DC, 2005, J BONE MINER RES, V20, P41, DOI 10.1359/jbmr.041009; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GLOBUS RK, 1984, ENDOCRINOLOGY, V114, P2264, DOI 10.1210/endo-114-6-2264; Globus RK, 1998, J CELL SCI, V111, P1385; GLOBUS RK, 1986, ENDOCRINOLOGY, V118, P733, DOI 10.1210/endo-118-2-733; Gronthos S, 1997, J BONE MINER RES, V12, P1189, DOI 10.1359/jbmr.1997.12.8.1189; Gronthos S, 2001, BONE, V28, P174, DOI 10.1016/S8756-3282(00)00424-5; HALLORAN BP, 1986, ENDOCRINOLOGY, V118, P948, DOI 10.1210/endo-118-3-948; HALLORAN BP, 1988, AM J PHYSIOL, V255, pE875; Horne WC, 2005, IMMUNOL REV, V208, P106, DOI 10.1111/j.0105-2896.2005.00335.x; Ishijima M, 2002, J BONE MINER RES, V17, P661, DOI 10.1359/jbmr.2002.17.4.661; Iwaniec UT, 2005, J APPL PHYSIOL, V98, P690, DOI 10.1152/japplphysiol.00689.2004; JEE WSS, 1983, AM J PHYSIOL, V244, pR310; Jiang J, 2006, BONE, V39, P494, DOI 10.1016/j.bone.2006.02.068; Jorgensen NR, 1997, J CELL BIOL, V139, P497, DOI 10.1083/jcb.139.2.497; Kaiser E, 2001, J CELL BIOCHEM, V83, P617, DOI 10.1002/jcb.1256; Kapur S, 2005, J BIOL CHEM, V280, P20163, DOI 10.1074/jbc.M501460200; KIDDER LS, 1990, BONE MINER, V11, P305, DOI 10.1016/0169-6009(90)90027-D; Kiely PA, 2005, J BIOL CHEM, V280, P7624, DOI 10.1074/jbc.M412889200; Kostenuik PJ, 1999, J BONE MINER RES, V14, P21, DOI 10.1359/jbmr.1999.14.1.21; Kostenuik PJ, 1997, AM J PHYSIOL-ENDOC M, V273, pE1133; Lai CF, 2005, J BONE MINER RES, V20, P330, DOI 10.1359/JBMR.041013; Lai CF, 2001, J BIOL CHEM, V276, P14443, DOI 10.1074/jbc.M010021200; Lane NE, 2005, J BONE MINER RES, V20, P58, DOI 10.1359/JBMR.041017; LANYON LE, 1984, J BIOMECH, V17, P897, DOI 10.1016/0021-9290(84)90003-4; Le Roith D, 2001, ENDOCR REV, V22, P53, DOI 10.1210/er.22.1.53; LEAN JM, 1995, AM J PHYSIOL-ENDOC M, V268, pE318; LEBLANC A, 1985, J APPL PHYSIOL, V58, P1669; Li J, 2003, ENDOCRINOLOGY, V144, P1226, DOI 10.1210/en.2002-220821; Liedert A, 2006, BIOCHEM BIOPH RES CO, V349, P1, DOI 10.1016/j.bbrc.2006.07.214; Long RK, 2005, J BONE MINER RES, V20, pS250; MACHWATE M, 1993, AM J PHYSIOL, V264, pE790; Maile LA, 2006, MOL ENDOCRINOL, V20, P405, DOI 10.1210/me.2005-0241; Maile LA, 2001, J CELL SCI, V114, P1417; Meyers VE, 2005, J BONE MINER RES, V20, P1858, DOI 10.1359/JBMR.050611; Meyers VE, 2004, J CELL BIOCHEM, V93, P697, DOI 10.1002/jcb.20229; Miura Y, 2005, P NATL ACAD SCI USA, V102, P14022, DOI 10.1073/pnas.0409397102; Mizuno M, 2000, J CELL PHYSIOL, V184, P207, DOI 10.1002/1097-4652(200008)184:2<207::AID-JCP8>3.3.CO;2-L; MOREY ER, 1978, SCIENCE, V201, P1138, DOI 10.1126/science.150643; Morinobu M, 2003, J BONE MINER RES, V18, P1706, DOI 10.1359/jbmr.2003.18.9.1706; Moursi AM, 1997, J CELL SCI, V110, P2187; Murphy MG, 2005, J CLIN ENDOCR METAB, V90, P2022, DOI 10.1210/jc.2004-2126; OGANOV VS, 1991, ACTA ASTRONAUT, V23, P129, DOI 10.1016/0094-5765(91)90109-I; PATTERSONBUCKENDAHL P, 1989, AM J PHYSIOL, V257, pR1103; Pavalko FM, 2003, J CELL BIOCHEM, V88, P104, DOI 10.1002/jcb.10284; Pistone M, 1996, CELL BIOL INT, V20, P471, DOI 10.1006/cbir.1996.0062; POWELLBRAXTON L, 1993, GENE DEV, V7, P2609, DOI 10.1101/gad.7.12b.2609; Rawlinson SCF, 1996, BONE, V19, P609, DOI 10.1016/S8756-3282(96)00260-8; Reijnders CMA, 2007, J ENDOCRINOL, V192, P131, DOI 10.1677/joe.1.06880; Robling AG, 2002, J BONE MINER RES, V17, P1545, DOI 10.1359/jbmr.2002.17.8.1545; Robling AG, 2006, ANNU REV BIOMED ENG, V8, P455, DOI 10.1146/annurev.bioeng.8.061505.095721; Ross FP, 2005, IMMUNOL REV, V208, P88, DOI 10.1111/j.0105-2896.2005.00331.x; Sakata T, 2004, J BONE MINER RES, V19, P436, DOI 10.1359/JBMR.0301241; Sakata T, 2003, BONE, V32, P669, DOI 10.1016/S8756-3282(03)00088-7; Schwartz MA, 2001, TRENDS CELL BIOL, V11, P466, DOI 10.1016/S0962-8924(01)02152-3; SHAW SR, 1987, J BIOMECH, V20, P225, DOI 10.1016/0021-9290(87)90289-2; Sheppard D, 2000, MATRIX BIOL, V19, P203, DOI 10.1016/S0945-053X(00)00065-2; Takada Y, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-215; TURNER CH, 1995, AM J PHYSIOL-ENDOC M, V269, pE438; TURNER RT, 1995, AVIAT SPACE ENVIR MD, V66, P770; VICO L, 1988, AM J PHYSIOL, V255, pR243; VICO L, 1992, J BONE MINER RES, V7, pS445, DOI 10.1002/jbmr.5650071415; VICO L, 1991, AVIAT SPACE ENVIR MD, V62, P26; Wang YL, 2007, P NATL ACAD SCI USA, V104, P15941, DOI 10.1073/pnas.0707246104; Wang YM, 2007, J BONE MINER RES, V22, P1329, DOI 10.1359/JBMR.070517; Wang YM, 2006, J BONE MINER RES, V21, P1350, DOI 10.1359/JBMR.060610; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; WEINBAUM S, 1994, J BIOMECH, V27, P339, DOI 10.1016/0021-9290(94)90010-8; WRONSKI TJ, 1983, AM J PHYSIOL, V244, pR305; YAGODOVSKY VS, 1976, AVIAT SPACE ENVIR MD, V47, P734; Zerath E, 1991, Physiologist, V34, pS194; Zhang M, 2002, J BIOL CHEM, V277, P44005, DOI 10.1074/jbc.M208265200; Zhao G, 2000, ENDOCRINOLOGY, V141, P2674, DOI 10.1210/en.141.7.2674; Zheng B, 1998, P NATL ACAD SCI USA, V95, P11217, DOI 10.1073/pnas.95.19.11217; Zimmerman D, 2000, DEV BIOL, V220, P2, DOI 10.1006/dbio.2000.9633; Zou W, 2007, J CELL BIOL, V176, P877, DOI 10.1083/jcb.200611083	96	35	38	0	5	SPRINGER LONDON LTD	ARTINGTON	ASHBOURNE HOUSE, THE GUILDWAY, OLD PORTSMOUTH ROAD, ARTINGTON GU3 1LP, GUILDFORD, ENGLAND	0937-941X			OSTEOPOROSIS INT	Osteoporosis Int.	SEP	2008	19	9					1237	1246		10.1007/s00198-008-0597-z			10	Endocrinology & Metabolism	Endocrinology & Metabolism	336XX	WOS:000258401200003	18373051				2021-06-18	
J	von Baumgarten, L; Trabold, R; Thal, S; Back, T; Plesnila, N				von Baumgarten, Louisa; Trabold, Raimund; Thal, Serge; Back, Tobias; Plesnila, Nikolaus			Role of cortical spreading depressions for secondary brain damage after traumatic brain injury in mice	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						cortical spreading depression; intracranial pressure; mice; regional cerebral blood flow; traumatic brain injury	FOCAL CEREBRAL-ISCHEMIA; PERIINFARCT DEPOLARIZATIONS; RAT-BRAIN; INTRACRANIAL-PRESSURE; ARTERY OCCLUSION; GENE-EXPRESSION; BLOOD-FLOW; GLUCOSE; CORTEX; MICRODIALYSIS	In recent years, several studies have unequivocally shown the occurrence of cortical spreading depressions (CSDs) after stroke and traumatic brain injury (TBI) in humans. The fundamental question, however, is whether CSDs cause or result from secondary brain damage. The aim of the current study was, therefore, to investigate the role of CSDs for secondary brain damage in an experimental model of TBI. C57/BL6 mice were traumatized by controlled cortical impact. Immediately after trauma, each animal showed one heterogeneous direct current (DC) potential shift accompanied by a profound depression of electroencephalogram (EEG) amplitude, and a temporary decrease of ipsi- and contralateral regional cerebral blood flow (rCBF) suggesting bilateral CSDs. Within the next 3 h after TBI, CSDs occurred at a low frequency (0.38 CSD/h per animal, n = 7) and were accompanied by rCBF changes confined to the ipsilateral hemisphere. No significant relationship between the number of SDs and lesion size or intracranial pressure (ICP) could be detected. Even increasing the number of posttraumatic CSDs by application of KCl by more than six times did not increase ICP or contusion volume. We therefore conclude that CSDs may not contribute to posttraumatic secondary brain damage in the normally perfused and oxygenated brain.	[von Baumgarten, Louisa; Trabold, Raimund; Plesnila, Nikolaus] Univ Munich, Inst Surg Res, Med Ctr Grosshadern, D-8000 Munich, Germany; [von Baumgarten, Louisa; Trabold, Raimund; Thal, Serge; Plesnila, Nikolaus] Univ Munich, Med Ctr Grosshadern, Dept Neurosurg, Lab Expt Neurosurg, D-8000 Munich, Germany; [Back, Tobias] Saxon Hosp Arnsdorf, Dept Neurol, Arnsdorf, Germany	Plesnila, N (corresponding author), Klinikum Univ Munchen Grosshadern, Marchioninistr 15, D-81366 Munich, Germany.	plesnila@med.uni-muenchen.de	von Baumgarten, Louisa/A-4636-2016; Plesnila, Nikolaus/T-7522-2019; Thal, Serge/D-6593-2011	Thal, Serge/0000-0002-1222-8729			Back T, 1996, J CEREBR BLOOD F MET, V16, P202, DOI 10.1097/00004647-199603000-00004; BACK T, 1994, J CEREBR BLOOD F MET, V14, P12, DOI 10.1038/jcbfm.1994.3; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Busch E, 1996, J CEREBR BLOOD F MET, V16, P1090, DOI 10.1097/00004647-199611000-00002; Cunningham LA, 2005, GLIA, V50, P329, DOI 10.1002/glia.20169; Dreier JP, 2006, BRAIN, V129, P3224, DOI 10.1093/brain/awl297; Fabricius M, 2006, BRAIN, V129, P778, DOI 10.1093/brain/awh716; Hermann DM, 1999, RESTOR NEUROL NEUROS, V14, P103; Hopwood SE, 2005, J CEREBR BLOOD F MET, V25, P391, DOI 10.1038/sj.jcbfm.9600050; Horiguchi T, 2005, BRAIN RES, V1039, P84, DOI 10.1016/j.brainres.2005.01.047; Jander S, 2001, J CEREBR BLOOD F MET, V21, P218, DOI 10.1097/00004647-200103000-00005; Kitahara Y, 2001, J NEUROSURG ANESTH, V13, P26, DOI 10.1097/00008506-200101000-00005; KOBAYASHI S, 1995, J CEREBR BLOOD F MET, V15, P721, DOI 10.1038/jcbfm.1995.92; Lauritzen M, 2001, CEPHALALGIA, V21, P757, DOI 10.1046/j.1468-2982.2001.00244.x; Mayevsky A, 1996, BRAIN RES, V740, P268, DOI 10.1016/S0006-8993(96)00874-8; MIES G, 1984, EXP NEUROL, V84, P249, DOI 10.1016/0014-4886(84)90222-X; MIES G, 1993, NEUROREPORT, V4, P709, DOI 10.1097/00001756-199306000-00027; MILNER PM, 1958, ELECTROEN CLIN NEURO, V10, P705, DOI 10.1016/0013-4694(58)90073-7; Mun-Bryce S, 2001, BRAIN RES, V888, P248, DOI 10.1016/S0006-8993(00)03068-7; NEDERGAARD M, 1988, BRAIN RES, V449, P395, DOI 10.1016/0006-8993(88)91062-1; NEDERGAARD M, 1986, J CEREBR BLOOD F MET, V6, P607, DOI 10.1038/jcbfm.1986.108; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; Obeidat AS, 1998, EUR J NEUROSCI, V10, P3451, DOI 10.1046/j.1460-9568.1998.00358.x; Ohta K, 2001, STROKE, V32, P535, DOI 10.1161/01.STR.32.2.535; Parkin MC, 2005, J CEREBR BLOOD F MET, V25, P402, DOI 10.1038/sj.jcbfm.9600051; Plesnila N, 2007, CELL DEATH DIFFER, V14, P1529, DOI 10.1038/sj.cdd.4402159; Plesnila N, 2004, J CEREBR BLOOD F MET, V24, P458, DOI 10.1097/00004647-200404000-00011; Rogatsky GG, 2003, J NEUROTRAUM, V20, P1315, DOI 10.1089/089771503322686111; SAITO R, 1995, BRAIN RES, V699, P109, DOI 10.1016/0006-8993(95)00898-Z; Selman WR, 2004, BRAIN RES, V999, P167, DOI 10.1016/j.brainres.2003.11.016; Strong AJ, 2002, STROKE, V33, P2738, DOI 10.1161/01.STR.0000043073.69602.09; Takano T, 2007, NAT NEUROSCI, V10, P754, DOI 10.1038/nn1902; Thal SC, 2007, J NEUROSCI METH, V159, P261, DOI 10.1016/j.jneumeth.2006.07.016; Trabold R, 2006, BRAIN RES, V1071, P237, DOI 10.1016/j.brainres.2005.11.095; Umegaki M, 2005, J NEUROSCI, V25, P1387, DOI 10.1523/JNEUROSCI.4182-04.2005; Urbach A, 2006, EUR J NEUROSCI, V24, P841, DOI 10.1111/j.1460-9568.2006.04862.x; Williams AJ, 2005, J NEUROTRAUM, V22, P313, DOI 10.1089/neu.2005.22.313; ZORNOW MH, 1992, ANESTH ANALG, V75, P232; Zweckberger K, 2003, J NEUROTRAUM, V20, P1307, DOI 10.1089/089771503322686102; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	40	35	35	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JUL	2008	28	7					1353	1360		10.1038/jcbfm.2008.30			8	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	318DZ	WOS:000257073100008	18414497	Bronze			2021-06-18	
J	Flores, AH; Haileyesus, T; Greenspan, AI				Flores, Adrian H.; Haileyesus, Tadesse; Greenspan, Arlene I.			National estimates of outdoor recreational injuries treated in emergency departments, United States, 2004-2005	WILDERNESS & ENVIRONMENTAL MEDICINE			English	Article						outdoor; recreation; injury; prevention; wilderness	WILDERNESS; SAFETY; RISK	Objective.-To provide national estimates of nonfatal outdoor recreational injuries treated in US emergency departments (EDs). Methods.-Outdoor recreational injuries from January 2004 through December 2005 were identified using the National Electronic Injury Surveillance System-All Injury Program, a nationally representative sample of ED visits. National estimates of outdoor recreational injuries were calculated, and activities leading to injury, demographic characteristics, principal diagnoses, and primary body parts affected were described. Results.-From January 2004 through December 2005, an estimated 212 708 (95% CI = 113 808-311 608) persons were treated each year in US EDs for outdoor recreational injuries. The annual rate of injuries was 72.1 per 100 000 population (95% CI = 38.6-105.6). Males accounted for 68.2% of the injuries. The lower limb (27%), upper limb (25%), and head and neck region (23.3%) were the most commonly injured body regions. Fractures (27.4%) and sprains or strains (23.9%) were the most common diagnoses. Traumatic brain injuries were diagnosed in 6.5% of injuries, and 5% of injuries resulted in hospitalization or transfer to another hospital. Conclusions.-The results of this study provide a starting point for further research into the epidemiology of outdoor and wilderness injury. The results reinforce many common perceptions about the nature of these injuries while highlighting the potential severity and long-term consequences of the injuries. The general recommendations of proper planning, preparation, and problem anticipation for outdoor and wilderness injury prevention should be followed to reduce both the number and severity of injuries.	[Flores, Adrian H.; Greenspan, Arlene I.] Ctr Dis Control & Prevent, Div Unintent Injuiry Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA; [Haileyesus, Tadesse] Ctr Dis Control & Prevent, Off Stat & Programming, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA	Greenspan, AI (corresponding author), Ctr Dis Control & Prevent, Div Unintent Injuiry Prevent, Natl Ctr Injury Prevent & Control, 4770 Buford Hwy NE,Mailstop K-63, Atlanta, GA 30341 USA.	agreenspan@cdc.gov					AUERBACH PS, 2001, WILDERNESS MED; Boulware DR, 2003, AM J MED, V114, P288, DOI 10.1016/S0002-9343(02)01494-8; Bowker J. M., 2006, Journal of Agricultural and Applied Economics, V38, P317; Butcher JL, 1996, J TRAUMA, V41, P4, DOI 10.1097/00005373-199607000-00002; Ela GK, 2004, WILD ENVIRON MED, V15, P11, DOI 10.1580/1080-6032(2004)015[0011:EOWSAR]2.0.CO;2; Federiuk CS, 2002, WILD ENVIRON MED, V13, P245, DOI 10.1580/1080-6032(2002)013[0245:SSASII]2.0.CO;2; GENTILE DA, 1992, ANN EMERG MED, V21, P853, DOI 10.1016/S0196-0644(05)81034-0; Gerdes EM, 2006, J TRAUMA, V61, P1517, DOI 10.1097/01.ta.0000209402.40864.b2; Gerson LW, 2004, INJURY PREV, V10, P134, DOI 10.1136/ip.2004.005256; Hargarten S, 1999, WILD ENVIRON MED, V10, P2, DOI 10.1580/1080-6032(1999)010[0002:ICRAWM]2.3.CO;2; Kronisch RL, 2002, SPORTS MED, V32, P523, DOI 10.2165/00007256-200232080-00004; Montalvo R, 1998, WESTERN J MED, V168, P248; *NAT SPORT GOODS A, 10 YEAR HIST SEL SPO; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; *OUTD IND FDN, OUTD RECR PART STUD; PATON BC, 1992, J WILDERNESS MED, V3, P128, DOI 10.1580/0953-9859-3.2.128; Powell C, 2007, WILD ENVIRON MED, V18, P10, DOI 10.1580/1080-6032(2007)18[10:TPORAR]2.0.CO;2; Russell MF, 2004, EMERG MED CLIN N AM, V22, P561, DOI 10.1016/j.emc.2004.01.013; Schonfeld L, 2000, J GERIATR PSYCH NEUR, V13, P124, DOI 10.1177/089198870001300305; Schroeder T, 2001, NATL ELECT INJURY SU; Sholl JM, 2004, EMERG MED CLIN N AM, V22, P265, DOI 10.1016/j.emc.2004.01.001; Shults RA, 2005, PEDIATRICS, V116, pE608, DOI 10.1542/peds.2005-0937; Stephens BD, 2005, WILD ENVIRON MED, V16, P192, DOI 10.1580/1080-6032(2005)16[192:RIIWSN]2.0.CO;2; *US BUR CENS, 2004, CENS POP; *US CONS PROD SAF, WHICH HELM WHIC ACT; *US CONS PROD SAF, 1999, SKI HELM EV POT HEAD; *US DEP AGR FOR SE, AM PART OUTD RECR RE	27	35	35	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1080-6032	1545-1534		WILD ENVIRON MED	Wildern. Environ. Med.	SUM	2008	19	2					91	98		10.1580/07-WEME-OR-152.1			8	Public, Environmental & Occupational Health; Sport Sciences	Public, Environmental & Occupational Health; Sport Sciences	310DR	WOS:000256509600003	18513117	Bronze			2021-06-18	
J	Merenda, A; Gugliotta, M; Holloway, R; Levasseur, JE; Alessandri, B; Sun, D; Bullock, MR				Merenda, Amedeo; Gugliotta, Marinella; Holloway, Rebecca; Levasseur, Joseph E.; Alessandri, Beht; Sun, Dong; Bullock, M. Ross			Validation of brain extracellular glycerol as an indicator of cellular membrane damage due to free radical activity after traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						adult brain injury; axonal injury; head trauma; metabolism; microdialysis	SEVERE HEAD-INJURY; CEREBRAL-ARTERY OCCLUSION; NERVOUS-SYSTEM TRAUMA; LIPID-PEROXIDATION; INTERSTITIAL GLYCEROL; RAT-BRAIN; PHOSPHOLIPID DEGRADATION; SALICYLATE HYDROXYLATION; SUBDURAL-HEMATOMA; HYPERBARIC-OXYGEN	Following severe traumatic brain injury (TBI), increasing oxygen delivery to the brain has been advocated as a useful strategy to reverse mitochondrial dysfunction and improve neurological outcome. However, this might also promote overproduction of free radicals, responsible for lipid peroxidation and hence brain cell damage. Therefore, a method for monitoring this potential adverse effect in humans is desirable. Glycerol, an end product of phospholipid breakdown, easily detectable in the human brain by means of microdialysis, might represent a reliable indicator of free radical induced cell membrane damage. Brain microdialysates were collected from 24 adult male Sprague-Dawley rats over a 3-hour period following sham operation (n = 6), chemical brain injury via administration of Fenton's reagent (n = 6), a powerful hydroxyl radical generator, and lateral fluid percussion injury (FPI; n = 12). In the FPI animals, post-traumatic i.v. administration of either normal saline or the free radical scavenger Tempol (10 mg/kg, followed by an infusion of 30 mg/kg/h over 3 h) was carried out to evaluate the effect of blockade of free radical generation. Samples were analyzed for the presence of glycerol and the marker of hydroxyl radical (OH center dot) by generation of 2,3-DHBA (dihydroxybenzoic acid). Brain tissue staining with TTC (2,3,5-triphenyltetrazoium chloride) was performed for lesion size assessment. Rats subjected to either Fenton's reagent administration or FPI exhibited significantly higher levels of glycerol as compared with shams (p = 0.05). However, when the FPI was followed by Tempol administration, concentration of both glycerol and 2,3-DHBA decreased significantly (p = 0.05). Furthermore, TCC staining revealed a significant reduction of secondary brain tissue damage in Tempol-treated animals (p = 0.05). Our data suggest that injury-induced increases in microdialysate glycerol levels are a valid indicator of free radical activity, and their amelioration following Tempol treatment accords with less histological damage in response to FPI.	[Merenda, Amedeo; Holloway, Rebecca; Levasseur, Joseph E.; Sun, Dong; Bullock, M. Ross] Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA USA; [Merenda, Amedeo] Univ Messina, Dept Neurosurg, Messina, Italy; [Gugliotta, Marinella] Kantonsspital, Dept Neurosurg, Aarau, Switzerland; [Alessandri, Beht] Johannes Gutenberg Univ Mainz, Dept Neurosurg, Inst Neurosurg Pathophysiol, Mainz, Germany	Bullock, MR (corresponding author), Univ Miami, Miller Sch Med, Dept Neurosurg, Lois Pope LIFE Ctr, Room 3-20,1095 NW 14th Terrace, Miami, FL 33136 USA.	rbullock@med.miami.edu		MERENDA, AMEDEO/0000-0002-9270-7470	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 12587] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS012587, P50NS012587] Funding Source: NIH RePORTER		Adams J H, 1983, Acta Neurochir Suppl (Wien), V32, P15; BEDERSON JB, 1986, STROKE, V17, P1304, DOI 10.1161/01.STR.17.6.1304; BERTRAND N, 1992, NEUROSCI LETT, V148, P81, DOI 10.1016/0304-3940(92)90809-L; Bonini MG, 2002, CHEM RES TOXICOL, V15, P506, DOI 10.1021/tx015571z; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; Bremer YA, 2005, PEDIATR RES, V57, P22, DOI 10.1203/01.PDR.0000147736.27672.15; Carroll RT, 2000, CHEM RES TOXICOL, V13, P294, DOI 10.1021/tx990159t; Chatterjee PK, 2000, KIDNEY INT, V58, P658, DOI 10.1046/j.1523-1755.2000.00212.x; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Daugherty WP, 2004, J NEUROSURG, V101, P499, DOI 10.3171/jns.2004.101.3.0499; Daugherty WP, 2004, NEUROSURGERY, V54, P1223, DOI 10.1227/01.NEU.0000119238.68938.5D; Dhillon HS, 1999, NEUROCHEM RES, V24, P751, DOI 10.1023/A:1020779413122; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Doppenberg EMR, 1998, J NEUROTRAUM, V15, P337, DOI 10.1089/neu.1998.15.337; DUCKROW RB, 1981, J NEUROSURG, V54, P607, DOI 10.3171/jns.1981.54.5.0607; Elayan IM, 2000, J NEUROPHYSIOL, V83, P2022; FLOYD RA, 1984, J BIOCHEM BIOPH METH, V10, P221, DOI 10.1016/0165-022X(84)90042-3; Frykholm P, 2001, J NEUROL NEUROSUR PS, V71, P455, DOI 10.1136/jnnp.71.4.455; GELVAN D, 1991, P NATL ACAD SCI USA, V88, P4680, DOI 10.1073/pnas.88.11.4680; GERCKEN G, 1973, PFLUG ARCH EUR J PHY, V344, P207, DOI 10.1007/BF00588461; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GRAHAM DI, 1985, BRIT J ANAESTH, V57, P3, DOI 10.1093/bja/57.1.3; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; HALLIWELL B, 1991, FREE RADICAL BIO MED, V10, P439, DOI 10.1016/0891-5849(91)90052-5; HALLIWELL B, 1985, TRENDS NEUROSCI, V8, P22, DOI 10.1016/0166-2236(85)90010-4; Halliwell B, 1981, AGE PIGMENTS, P1; Hillered L, 1998, J NEUROL NEUROSUR PS, V64, P486, DOI 10.1136/jnnp.64.4.486; Hutchinson PJA, 2000, ZBL NEUROCHIR, V61, P88, DOI 10.1055/s-2000-8265; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; Kwon TH, 2003, J NEUROTRAUM, V20, P337, DOI 10.1089/089771503765172291; Lewen A, 1998, J NEUROTRAUM, V15, P521, DOI 10.1089/neu.1998.15.521; LEWEN A, 1996, J NEUROTRAUM, V13, P600; Marklund N, 1997, NEUROREPORT, V8, P1457, DOI 10.1097/00001756-199704140-00026; Marklund N, 2001, J NEUROTRAUM, V18, P1217, DOI 10.1089/089771501317095250; MINK RB, 1995, CRIT CARE MED, V23, P1398, DOI 10.1097/00003246-199508000-00014; Morimoto T, 1996, J CEREBR BLOOD F MET, V16, P92, DOI 10.1097/00004647-199601000-00011; Muscoli C, 2003, BRIT J PHARMACOL, V140, P445, DOI 10.1038/sj.bjp.0705430; Nishio S, 1997, ACT NEUR S, V70, P84; OLIVER CN, 1990, J NEUROSCI, V10, P1035; Peerdeman SM, 2003, INTENS CARE MED, V29, P1825, DOI 10.1007/s00134-003-1850-8; Rak R, 2000, J NEUROSURG, V92, P646, DOI 10.3171/jns.2000.92.4.0646; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; WILSON JT, 1995, J TRAUMA, V39, P473; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011	47	35	36	0	2	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAY	2008	25	5					527	537		10.1089/neu.2007.0359			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	303PY	WOS:000256054100009	18363507				2021-06-18	
J	Medved, MI; Brockmeier, J				Medved, Maria I.; Brockmeier, Jens			Continuity amid chaos: Neurotrauma, loss of memory, and sense of self	QUALITATIVE HEALTH RESEARCH			English	Article						neurotrauma; narrative; self; memory loss; brain injury	TRAUMATIC BRAIN-INJURY; AWARENESS; PEOPLE	In serious illness or disability, individuals commonly say that their sense of self has dramatically changed. One might expect that the experience of a radically altered sense of self would be even more profound in individuals after neuro-trauma because it is the brain itself that suddenly, and often literally, becomes "strange." The aim of this study was to investigate how people left with autobiographical memory impairments - impairments that also affect the capacity to organize complex linguistic productions such as autobiographical narratives - experience themselves and, specifically, their sense of self. Seven adults who had primarily anterograde memory impairments for 1 year were interviewed. Regardless of the profound changes in their everyday functioning and lives, the stories the participants told evoke a surprising sense of a continuous self. Employing several narrative and discursive techniques, they emphasized sameness and an unbroken connection between their pre- and post- morbid lives. We believe that most individuals felt they did not have to recover their former sense of self because they subjectively seemed to have never lost it.	[Medved, Maria I.] Univ Manitoba, Dept Psychol, Winnipeg, MB R3T 2N2, Canada; [Brockmeier, Jens] Free Univ Berlin, D-1000 Berlin, Germany; [Brockmeier, Jens] Univ E London, London E15 4LZ, England	Medved, MI (corresponding author), Univ Manitoba, Dept Psychol, Winnipeg, MB R3T 2N2, Canada.	medved@cc.umanitoba.ca					ASTROM M, 1993, STROKE, V24, P976, DOI 10.1161/01.STR.24.7.976; Brockmeier J., 2001, NARRATIVE IDENTITY S, V39; Carbaugh D., 2001, NARRATIVE IDENTITY S, P25, DOI DOI 10.1075/SIN.1.03BRU; Croft SE, 1999, WESTERN J COMM, V63, P329, DOI 10.1080/10570319909374645; Eakin P.J., 1999, OUR LIVES BECOME STO; Frank A., 1995, WOUNDED STORYTELLER; Goldstein, 1995, ORGANISM HOLISTIC AP; Gregory R J, 1998, J Psychosoc Nurs Ment Health Serv, V36, P28; Hill H, 1999, BRAIN INJURY, V13, P839, DOI 10.1080/026990599121043; Leduc M, 1999, BRAIN COGNITION, V40, P174; LEZAK MD, 1988, J LEARN DISABIL, V21, P456, DOI 10.1177/002221948802100802; Medved Maria I, 2007, Psychol Health Med, V12, P603, DOI 10.1080/13548500601164404; Medved MI, 2006, MEMORY, V14, P276, DOI 10.1080/09658210500233524; Medved MI, 2004, QUAL HEALTH RES, V14, P741, DOI 10.1177/1049732304265972; MEDVED MI, 2008, CULTURE HLTH ILLNESS; Nochi M, 1998, SOC SCI MED, V46, P869, DOI 10.1016/S0277-9536(97)00211-6; Paterson B, 2002, QUAL HEALTH RES, V12, P399, DOI 10.1177/104973202129119973; POLLACK R, 1994, ED DIMENSIONS ACQUIR, V303, P371; Prigatano GP, 2000, ARCH CLIN NEUROPSYCH, V15, P71, DOI 10.1016/S0887-6177(99)00021-9; Prigatano GP., 1999, PRINCIPLES NEUROPSYC; PRIGATANO GP, 1997, DEPRESSION PHYS ILLN, P341; ROBINSON RG, 1987, STROKE, V17, P1102; Sabat S.R., 2001, EXPERIENCE ALZHEIMER; Schafer R, 1992, RETELLING LIFE NARRA; Sherer M, 2005, J HEAD TRAUMA REHAB, V20, P287, DOI 10.1097/00001199-200507000-00002	25	35	36	0	7	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1049-7323			QUAL HEALTH RES	Qual. Health Res.	APR	2008	18	4					469	479		10.1177/1049732308315731			11	Information Science & Library Science; Social Sciences, Interdisciplinary; Social Sciences, Biomedical	Information Science & Library Science; Social Sciences - Other Topics; Biomedical Social Sciences	279AH	WOS:000254326900004	18354046				2021-06-18	
J	Currier, BL; Maus, TP; Eck, JC; Larson, DR; Yaszemski, MJ				Currier, Bradford L.; Maus, Tim P.; Eck, Jason C.; Larson, Dirk R.; Yaszemski, Michael J.			Relationship of the internal carotid artery to the anterior aspect of the C1 vertebra	SPINE			English	Article						internal carotid artery; atlas; C1 lateral mass screw; C1-C2 transarticular screw	TRANSARTICULAR SCREW FIXATION; COMPUTED-TOMOGRAPHY; ACCURACY; INJURY; FUSION	Study Design. Anatomic study of the internal carotid artery ( ICA) location with respect to C1 based on computed tomography ( CT) scans with contrast medium. Objective. To measure the location of the ICA relative to the anterior aspect of C1 to assess the risk of placing C1 - C2 transarticular or C1 lateral mass screws. Summary of Background Data. Vertebral artery injury is a known risk from placement of screws in C1. A previous case report revealed an ideally placed C1 - C2 transarticular screw abutting and narrowing the ICA. The risk of ICA injury from C1 screws is unknown. Methods. Fifty random head and neck CT scans with contrast medium were retrospectively analyzed. Measurements were taken bilaterally including the closest distance from the ICA lumen to C1 and the distance from the medial edge of the ICA to a line drawn along the medial border of the foramen transversarium. The risk of inserting bicortical C1 - C2 transarticular and C1 lateral mass screws was estimated based on these measurements. Results. The mean distance from the ICA to C1 was 2.88 mm on the left and 2.89 mm on the right. The ICA lumen was medial to the foramen transversarium in 42 ( 84%) of 50 cases ( mean: 2.78 mm on the left and 3.00 mm on the right). The proximity of the ICA to C1 posed moderate risk in 46% of cases and high risk in 12% ( on at least one side). Conclusion. Because of the risk of ICA injury from a drill bit or the tip of a bicortical screw, we recommend preoperative CT scan with contrast medium in all cases in which a screw is to be placed into C1. If the ICA is in close proximity to the anterior border of C1, unicortical fixation or a different fusion technique should be considered.	[Currier, Bradford L.; Eck, Jason C.; Yaszemski, Michael J.] Mayo Clin, Dept Orthoped Surg, Rochester, MN 55905 USA; [Maus, Tim P.] Mayo Clin, Dept Radiol, Rochester, MN 55905 USA; [Larson, Dirk R.] Mayo Clin, Dept Biostat, Rochester, MN 55905 USA	Currier, BL (corresponding author), Mayo Clin, Dept Orthoped Surg, 200 1st St SW, Rochester, MN 55905 USA.	currier.bradford@mayo.edu					Aota Y, 2006, J NEUROSURG-SPINE, V5, P554, DOI 10.3171/spi.2006.5.6.554; Bloch O, 2001, J NEUROSURG, V95, P74, DOI 10.3171/spi.2001.95.1.0074; Currier BL, 2003, SPINE, V28, pE461, DOI 10.1097/01.BRS.0000092385.19307.9E; CURRIER BL, 2004, CURR OPIN ORTHOP, V15, P184; CYR SJ, 2007, SPINE J; Ebraheim NA, 2000, SURG NEUROL, V53, P208, DOI 10.1016/S0090-3019(00)00160-9; Eck JC, 2007, J SPINAL DISORD TECH, V20, P505, DOI 10.1097/BSD.0b013e318031af8b; Gebhard JS, 1998, SPINE, V23, P2185, DOI 10.1097/00007632-199810150-00008; GOEL A, 1994, ACTA NEUROCHIR, V129, P47, DOI 10.1007/BF01400872; GROB D, 1991, J BONE JOINT SURG BR, V73, P972; Harms J, 2001, SPINE, V26, P2467, DOI 10.1097/00007632-200111150-00014; Heller JG, 1996, J BONE JOINT SURG AM, V78A, P1315, DOI 10.2106/00004623-199609000-00004; Kelleher MO, 2006, INT J MED ROBOT COMP, V2, P154, DOI 10.1002/rcs.92; Lambert CC, 2007, BIOMED SCI INSTRUM, V43, P330; Madawi AA, 1997, J NEUROSURG, V86, P961, DOI 10.3171/jns.1997.86.6.0961; Magerl F., 1985, CERVICAL SPINE, P322; Nogueira-Barbosa MH, 2005, EUR SPINE J, V14, P493, DOI 10.1007/s00586-004-0838-6; Paramore CG, 1996, J NEUROSURG, V85, P221, DOI 10.3171/jns.1996.85.2.0221; Reilly TM, 2003, J SPINAL DISORD TECH, V16, P248, DOI 10.1097/00024720-200306000-00004; Weidner A, 2000, SPINE, V25, P2668, DOI 10.1097/00007632-200010150-00020; Wright NM, 1998, J NEUROSURG, V88, P634, DOI 10.3171/jns.1998.88.4.0634; Yamazaki M, 2005, SPINE, V30, P2452, DOI 10.1097/01.brs.0000184306.19870.a8	22	35	41	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0362-2436			SPINE	SPINE	MAR 15	2008	33	6					635	639		10.1097/BRS.0b013e318166e083			5	Clinical Neurology; Orthopedics	Neurosciences & Neurology; Orthopedics	283QP	WOS:000254651900010	18344857				2021-06-18	
J	Chang, MW; Young, MS; Lin, MT				Chang, Ming-Wen; Young, Ming-Shing; Lin, Mao-Tsun			An inclined plane system with microcontroller to determine limb motor function of laboratory animals	JOURNAL OF NEUROSCIENCE METHODS			English	Article						animal model; laboratory animal; inclined plane; motor function; neurologic examination	OPEN-FIELD ACTIVITY; FLUID PERCUSSION; BRAIN-INJURY; ISCHEMIA; DEFICITS; WEIGHT; RATS	This study describes a high-accuracy inclined plane test system for quantitative measurement of the limb motor function of laboratory rats. The system is built around a microcontroller and uses a stepping motor to drive a ball screw, which changes the angle of the inclined plane. Any of the seven inclination speeds can be selected by the user. Two infrared (IR) LED/detector, pairs function as interrupt sensors for objective determination of the moment that the rat loses its grip on the textured flooring of the starting area and slips down the plane. Inclination angle at the moment of IR interrupt (i.e. rat slip) is recorded. A liquid crystal display module shows the inclination speed and the inclination angle. The system can function as a standalone device but a RS232 port allows connection to a personal computer (PC), so data can be sent directly to hard disk for storage and analysis. Experiments can be controlled by a local keypad or by the connected PC. Advantages of the presented system include easy operation, high accuracy, non-dependence on human observation for determination of slip angle, stand-alone capability, low cost and easy modification of the controlling software for different types of experiments. A fully functional prototype of the system is described. The prototype was used experimentally by a-hospital group testing traumatic brain injury experiments, and some of their results are presented for system verification. It is found that the system is stable, accurate and easily used by investigators. (c) 2007 Elsevier B.V. All rights reserved.	[Lin, Mao-Tsun] ChiMei Med Ctr, Dept Med Res, Tainan 710, Taiwan; [Chang, Ming-Wen; Young, Ming-Shing] Natl Cheng Kung Univ, Dept Elect Engn, Tainan 701, Taiwan	Lin, MT (corresponding author), ChiMei Med Ctr, Dept Med Res, Tainan 710, Taiwan.	891201@mail.chimei.org.tw					BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Carter CS, 2002, J GERONTOL A-BIOL, V57, pB193, DOI 10.1093/gerona/57.5.B193; Chio CC, 2007, SHOCK, V28, P284, DOI 10.1097/SHK.0b013e3180311e60; COMBS DJ, 1987, STROKE, V18, P503, DOI 10.1161/01.STR.18.2.503; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; GIULIAN D, 1975, PHYSIOL BEHAV, V14, P109, DOI 10.1016/0031-9384(75)90150-X; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; KAO CH, IN PRESS SHOCK; Koob AO, 2006, J NEUROSCI METH, V157, P330, DOI 10.1016/j.jneumeth.2006.04.020; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; REIS DJ, 1974, PROG CARDIOVASC DIS, V17, P51, DOI 10.1016/0033-0620(74)90038-3; RIVLIN AS, 1977, J NEUROSURG, V47, P577, DOI 10.3171/jns.1977.47.4.0577; RYCK MD, 1989, STROKE, V20, P1383; Spangenberg EMF, 2005, LAB ANIM-UK, V39, P45, DOI 10.1258/0023677052886457; Wang Y, 1997, J NEUROSCI, V17, P4341; Whishaw IQ, 1999, MODERN TECHNIQUES NE, P1243; Yonemori F, 2000, J CEREBR BLOOD F MET, V20, P74, DOI 10.1097/00004647-200001000-00011	17	35	38	0	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	FEB 15	2008	168	1					186	194		10.1016/j.jneumeth.2007.09.013			9	Biochemical Research Methods; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	261EQ	WOS:000253062300026	17953994				2021-06-18	
J	Gagnon, I; Swaine, B; Champagne, F; Lefebvre, H				Gagnon, Isabelle; Swaine, Bonnie; Champagne, Francois; Lefebvre, Helene			Perspectives of adolescents and their parents regarding service needs following a mild traumatic brain injury	BRAIN INJURY			English	Article; Proceedings Paper	Conference of the International-Society-for-Adolescent-Psychology-and-Psychiatry	JUL 04-07, 2007	Montreal, CANADA	Int Soc Adolescent Psychol & Psychiat		adolescent; traumatic brain injury; health service needs; needs assessment	CHILDREN; SUPPORT; INFORMATION; MANAGEMENT; TEENAGERS; CANCER; RECOMMENDATIONS; PERCEPTIONS; PREVENTION; ISSUES	Primary objective: Various guidelines have been developed to implement coherent and uniform management of persons with a mild traumatic brain injury (mTBI), but those have typically been developed for adults or children and may not address or meet the specific needs of adolescents. The purpose of this study was to explore the specific service needs of adolescents (12-18 years) after a mTBI. Study design: Qualitative phenomenological study. Methods and procedures: Individual semi-structured interviews were conducted with 15 adolescents and their parents who had received different levels of care from paediatric trauma centres within the previous 12 months. Main outcomes and results: All adolescents and parents expressed the need to receive information about the injury, its expected recovery and when to return to activities. Many adolescents reported wanting to be seen rapidly, by professionals who genuinely care about them and who acknowledge that they have specific needs that differ from those of younger children. Parents and, to a lesser degree, adolescents think that enhanced communication between the healthcare and school systems would be beneficial following a mTBI to assist in returning to demanding academic activities. Conclusions: Professionals involved in the management of adolescents with mTBI should be aware of their needs in order to provide optimal and developmentally appropriate services.	[Gagnon, Isabelle] McGill Univ, Montreal Childrens Hosp, Ctr Hlth, Phys Therapy Dept, Montreal, PQ H3H 1P3, Canada; [Gagnon, Isabelle; Champagne, Francois] Univ Montreal, Fac Med, Dept Adm Sante, Montreal, PQ H3C 3J7, Canada; [Swaine, Bonnie] Univ Montreal, Fac Med, Ecole Readaptat, Montreal, PQ H3C 3J7, Canada; [Swaine, Bonnie; Lefebvre, Helene] Ctr Rech Interdisciplinaire & Readaptat Montreal, Montreal, PQ, Canada; [Lefebvre, Helene] Univ Montreal, Fac Sci Infirmieres, Montreal, PQ, Canada	Gagnon, I (corresponding author), McGill Univ, Montreal Childrens Hosp, Ctr Hlth, Phys Therapy Dept, 2300 Tupper, Montreal, PQ H3H 1P3, Canada.	isabelle.gagnon6@sympatico.ca					ACKARD DM, 2002, J AM ACAD CHILD ADOL, V41, P393; Armstrong Kira, 2002, Pediatr Rehabil, V5, P149, DOI 10.1080/1363849021000039353; Beresford BA, 2003, J ADOLESCENT HEALTH, V33, P172, DOI 10.1016/S1054-139X(03)00047-8; Bergman DA, 1999, PEDIATRICS, V104, P1407; Blum RW, 2002, PEDIATRICS, V110, P1301; Borg J, 2004, J REHABIL MED, V36, P76, DOI 10.1080/16501960410023840; Brooks BM, 2003, DISABIL REHABIL, V25, P51, DOI 10.1080/09638280210151987; *CAN PED SOC, 2006, PEDIAT CHILD HLTH, V11, P420; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chedekel DS, 2001, J BURN CARE REHABIL, V22, P301, DOI 10.1097/00004630-200107000-00012; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P1, DOI 10.1097/00001199-200102000-00004; Corrigan JD, 2004, J HEAD TRAUMA REHAB, V19, P205, DOI 10.1097/00001199-200405000-00002; Cushman JG, 2001, J TRAUMA, V51, P1016, DOI 10.1097/00005373-200111000-00034; Dunsmore J, 1995, J PSYCHOSOC ONCOL, V13, P39; Esmond G, 2000, Nurs Stand, V14, P47; GAGNON I, 2007, IDENTIFYING SPECIFIC; Giorgi A., 1986, PHENOMENOLOGY PEDAGO, V4, P22; Greenspan AI, 2000, BRAIN INJURY, V14, P417; Guest G, 2006, FIELD METHOD, V18, P59, DOI 10.1177/1525822X05279903; Guskiewicz KM, 2006, BRIT J SPORT MED, V40, P6, DOI 10.1136/bjsm.2005.021683; Hallstrom I., 2001, THEORIA J NURSING TH, V10, P20; HARRIS JR, 1994, J COGNITIVE REHABILI, V12, P4; Hawley CA, 2003, BRAIN INJURY, V17, P105, DOI 10.1080/0269905021000010131; Heinemann AW, 2002, ARCH PHYS MED REHAB, V83, P1052, DOI 10.1053/apmr.2002.34283; Hollis R, 2001, LANCET ONCOL, V2, P43, DOI 10.1016/S1470-2045(00)00195-9; Irwin CE, 2002, J ADOLESCENT HEALTH, V31, P91, DOI 10.1016/S1054-139X(02)00489-5; Ishibashi A, 2001, CANCER NURS, V24, P61, DOI 10.1097/00002820-200102000-00010; Jacobson LD, 2000, FAM PRACT, V17, P156, DOI 10.1093/fampra/17.2.156; Kari J A, 1999, Nurs Stand, V13, P49; Kelly Daniel, 2003, Eur J Oncol Nurs, V7, P53, DOI 10.1054/ejon.2002.0204; Kelly JP, 1997, NEUROLOGY, V48, P581; KING RB, 1980, ADOLESCENT REHABILIT; Malterud K, 2001, LANCET, V358, P483, DOI 10.1016/S0140-6736(01)05627-6; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; Ministere de la sante et des services sociaux du Quebec & Societe d'assurance automobile du Quebec, 2005, OR MIN TRAUM CRAN LE; Neumark-Sztainer D, 2000, AM J HEALTH PROMOT, V14, P232, DOI 10.4278/0890-1171-14.4.232; Nuttall P, 1992, Issues Compr Pediatr Nurs, V15, P199, DOI 10.3109/01460869209078252; Patton M.Q., 2002, QUALITATIVE RES EVAL; PELCHAT D, 1997, RAPP RECH CQRS; PETERSEN DJ, 2001, NEEDS ASSESSMENT PUB; Potter R., 2002, PSYCHIAT B, V26, P377; Rahi JS, 2004, PEDIATRICS, V114, pE477, DOI 10.1542/peds.2004-0240; Ramritu PL, 1999, INT J NURS STUD, V36, P209, DOI 10.1016/S0020-7489(99)00016-4; Rosenzweig-Lipson S, 2000, FASEB J, V14, pA1321; Rossi P. H., 2004, EVALUATION SYSTEMATI; *ROY COLL PEDIAT C, 2003, CR114 ROY COLL PSYCH; Serio CD, 1997, BRAIN INJURY, V11, P1, DOI 10.1080/026990597123764; Sherwin ED, 2000, BRAIN INJURY, V14, P267; Strauss A., 1998, BASICS QUALITATIVE R; Swaine BR, 2001, J HEAD TRAUMA REHAB, V16, P292, DOI 10.1097/00001199-200106000-00008; Symon AG, 2003, MIDWIFERY, V19, P140, DOI 10.1016/S0266-6138(03)00004-4; VANDERMAREN JM, METHODES RECHERCHE E; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Whelan J, 2003, EUR J CANCER, V39, P2573, DOI 10.1016/j.ejca.2003.09.014	55	35	35	0	18	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	2					161	173		10.1080/02699050701867381			13	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	258DW	WOS:000252849600007	18240045				2021-06-18	
J	Morris, LGT; Ziff, DJS; DeLacure, MD				Morris, Luc G. T.; Ziff, David J. S.; DeLacure, Mark D.			Malpractice litigation after surgical injury of the spinal accessory nerve - An evidence-based analysis	ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY			English	Article							CLOSED CLAIMS ANALYSIS; MEDICAL-MALPRACTICE; MEDICOLEGAL ANALYSIS; INFORMED CONSENT; NECK DISSECTIONS; ADVERSE EVENTS; SURGERY; MANAGEMENT; PAYMENTS; ERRORS	Objective: To review the background, case characteristics, and outcomes of malpractice litigation resulting from surgical injury of the spinal accessory nerve. Design: Retrospective review of indemnity insurance cases (part 1) and court trials (part 2) between January 1, 1985, and January 1, 2007. In part 1, records of the Medical Liability Mutual Insurance Company identified 41 lawsuits in New York State; part 2 was a review of a national legal database (WestLaw) that identified 81 court trials. Case details were analyzed, and awards were adjusted for inflation. Results: For part 1, of 41 indemnity insurance cases, 39 (95%) involved a posterior triangle lymph node biopsy. Defendants were mainly general surgeons and otolaryngologists. Most lawsuits against surgeons (22 of 34 [65%]) were settled before trial, and only 4 of 34 (12%) were discontinued. Of these 34 cases, 28 (82%) ultimately compensated the plaintiff. The mean inflation-adjusted pretrial settlement was $264 395, and the mean settlement at trial was $443 538. Cases reaching trial received significantly higher settlements (P=.01). For part 2, 81 cases of alleged surgical injury to the spinal accessory nerve were identified. Defendant physicians were mainly general surgeons and otolaryngologists. Most operations were cervical lymph node biopsies (55 [68%]), followed by sebaceous cyst excisions (6 [7%]), neck dissections (4 [5%]), and other procedures (12 [15%]). Morbidity included weakness (81 patients [100%]), pain (30 patients [37%]), inability to work (20 patients [25%]), need for a nerve repair procedure (16 patients [20%]), deformity (9 patients [11%]), and numbness (4 patients [5%]). Types of malpractice alleged included negligent surgical technique (79 cases [98%]), lack of informed consent (17 cases [21%]), and failure to diagnose the injury (16 cases [20%]). Thirty-seven cases (46%) were decided for the defendant, 32 (40%) were decided for the plaintiff, and 12 (15%) were settled (percentages do not total 100 because of rounding). The mean inflation-adjusted settlement was $356 132, and the mean jury award was $515968. Jury awards were significantly higher than settlements (P=.003). Conclusions: Unintended injury to the spinal accessory nerve after head and neck surgery is a significant source of malpractice litigation. Timely diagnosis and treatment of this complication are essential. Regardless of whether the medical community considers careful surgical technique and nerve preservation to be the standard of care, the legal system clearly treats it as such, awarding compensation in 82% of cases. Strategies for optimal surgical care and litigation risk reduction are discussed.	[Morris, Luc G. T.; DeLacure, Mark D.] NYU, Sch Med, Head & Neck Surg Serv,Dept Otolaryngol, New York Univ Canc Inst, New York, NY 10016 USA; [Ziff, David J. S.] US Court Appeals Second Circuit, New York, NY USA	Morris, LGT (corresponding author), NYU, Sch Med, Head & Neck Surg Serv,Dept Otolaryngol, New York Univ Canc Inst, 550 1st Ave,NBV 5E5, New York, NY 10016 USA.	luc.morris@med.nyu.edu					Baker T., 2005, MED MALPRACTICE MYTH; Bhananker SM, 2006, ANESTHESIOLOGY, V104, P228, DOI 10.1097/00000542-200602000-00005; Brennan TA, 1996, NEW ENGL J MED, V335, P1963, DOI 10.1056/NEJM199612263352606; BROWN H, 1988, ANN SURG, V208, P654, DOI 10.1097/00000658-198811000-00019; Cappiello J, 2005, LARYNGOSCOPE, V115, P259, DOI 10.1097/01.mlg.0000154729.31281.da; Chandawarkar RY, 2003, PLAST RECONSTR SURG, V111, P611, DOI 10.1097/01.PRS.0000041943.47622.EB; Cheney FW, 2006, ANESTHESIOLOGY, V105, P1081, DOI 10.1097/00000542-200612000-00007; DONNER TR, 1993, NEUROSURGERY, V32, P907, DOI 10.1227/00006123-199306000-00004; FRANZ SI, 1907, ARCH PSYCHOL, V2, P1; Hekkenberg RJ, 1997, J OTOLARYNGOL, V26, P155; HUTSON MM, 1991, J BONE JOINT SURG AM, V73A, P160, DOI 10.2106/00004623-199173020-00002; KERN KA, 1994, AM J SURG, V168, P217, DOI 10.1016/S0002-9610(05)80189-8; KING RJ, 1983, ANN ROY COLL SURG, V65, P35; Koybasioglu A, 2000, LARYNGOSCOPE, V110, P73; LOCALIO AR, 1991, NEW ENGL J MED, V325, P245, DOI 10.1056/NEJM199107253250405; Lydiatt DD, 2003, ARCH OTOLARYNGOL, V129, P50, DOI 10.1001/archotol.129.1.50; Lydiatt DD, 2003, HEAD NECK-J SCI SPEC, V25, P429, DOI 10.1002/hed.10254; Lynn-Macrae AG, 2004, LARYNGOSCOPE, V114, P1492, DOI 10.1097/00005537-200408000-00032; Nason RW, 2000, AM J SURG, V180, P241, DOI 10.1016/S0002-9610(00)00449-9; OSGAARD O, 1987, ACTA CHIR SCAND, V153, P171; Peterson GN, 2005, ANESTHESIOLOGY, V103, P33, DOI 10.1097/00000542-200507000-00009; Rogers SO, 2006, SURGERY, V140, P25, DOI 10.1016/j.surg.2006.01.008; SLOAN FA, 1990, LAW SOC REV, V24, P997, DOI 10.2307/3053617; Studdert DM, 2006, NEW ENGL J MED, V354, P2024, DOI 10.1056/NEJMsa054479; TARAGIN MI, 1992, ANN INTERN MED, V117, P780, DOI 10.7326/0003-4819-117-9-780; VALTONEN J, 1974, ACTA CHIR SCAND, V140, P453; WRIGHT TA, 1975, CLIN ORTHOP RELAT R, P15	27	35	35	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0886-4470			ARCH OTOLARYNGOL	Arch. Otolaryngol. Head Neck Surg.	JAN	2008	134	1					102	107		10.1001/archotol.134.1.102			6	Otorhinolaryngology; Surgery	Otorhinolaryngology; Surgery	250PU	WOS:000252313300018	18209145				2021-06-18	
J	Singh, R; Mcdonald, C; Dawson, K; Lewis, S; Pringle, AM; Smith, S; Pentland, B				Singh, Rajiv; Mcdonald, Clare; Dawson, Kirstin; Lewis, Sarah; Pringle, Anne-Marie; Smith, Stephen; Pentland, Brian			Zolpidem in a minimally conscious state	BRAIN INJURY			English	Article						minimally conscious state; zolpidem	SEMI-COMATOSE STATE; TRANSIENT IMPROVEMENT; VEGETATIVE STATE; BRAIN-INJURY; AROUSAL	Background: Case reports of the use of zolpidem in Permanent Vegetative States (PVS) have led to interest by the media and court judgements defining treatment with such drugs. It is uncertain whether this paradoxical effect of zolpidem in raising consciousness may be evident in other low awareness states such as Minimally Conscious State (MCS). Case study: This study treated a 44 year old male with MCS some 4 years after his traumatic brain injury with zolpidem for 1 week on and 1 week off treatment. Assessment with a number of tests by blinded therapists showed that his scores were no better on zolpidem and in some cases were worse on treatment. Conclusions: Ideally a series of individuals is required to assess the effect of zolpidem, but in the light of positive spin stories in the media, negative case reports should also be highlighted. It is imperative that medical treatment in all instances and certainly in low awareness states and end of life decisions is always based on firm evidence.	[Singh, Rajiv; Mcdonald, Clare; Dawson, Kirstin; Lewis, Sarah; Pringle, Anne-Marie; Smith, Stephen; Pentland, Brian] Astley Ainslie Hosp, Dept Rehabil Med, Edinburgh EH9 2HL, Midlothian, Scotland	Singh, R (corresponding author), Astley Ainslie Hosp, Dept Rehabil Med, 133 Grange Loan, Edinburgh EH9 2HL, Midlothian, Scotland.	rajiv.singh@lpct.scot.nhs.uk		singh, rajiv/0000-0002-3173-9591			Clauss P, 2001, SAMJ S AFR MED J, V91, P788; Clauss R, 2006, NEUROREHABILITATION, V21, P23; Clauss R, 2004, NEW ENGL J MED, V351, P511, DOI 10.1056/NEJM200407293510522; Clauss RP, 2004, ARZNEIMITTELFORSCH, V54, P641; Clauss RP, 2000, S AFR MED J, V90, P68; Cohen L, 2004, NEW ENGL J MED, V350, P949, DOI 10.1056/NEJM200402263500922; Crestani F, 2000, BRIT J PHARMACOL, V131, P1251, DOI 10.1038/sj.bjp.0703717; ENNA SJ, 1977, ARCH NEUROL-CHICAGO, V34, P683, DOI 10.1001/archneur.1977.00500230053008; Feldman R. S, 1997, PRINCIPLES NEUROPSYC, P417; Garretto NS, 2004, MOVEMENT DISORD, V19, P967, DOI 10.1002/mds.20085; GillThwaites H, 1997, BRAIN INJURY, V11, P723, DOI 10.1080/026990597123098; Kang-Park MH, 2004, NEUROPHARMACOLOGY, V46, P1, DOI 10.1016/S0028-3908(03)00340-X; Kertesz A., 1982, W APHASIA BATTERY; MASTAIN B, 1995, REV NEUROL, V151, P52; MASTAIN B, 1998, MOVEMENT DISORD, V13, P46; PALMER AM, 1994, NEUROREPORT, V6, P153, DOI 10.1097/00001756-199412300-00039; Rudolph U, 2001, TRENDS PHARMACOL SCI, V22, P188, DOI 10.1016/S0165-6147(00)01646-1; Sanger DJ, 1999, PHARMACOL BIOCHEM BE, V64, P269, DOI 10.1016/S0091-3057(99)00081-7; 2006, GUARDIAN        1207, P4	19	35	36	0	2	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2008	22	1					103	106		10.1080/02699050701829704			4	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	250QF	WOS:000252314400012	18183514				2021-06-18	
J	Stokely, ME; Orr, EL				Stokely, Martha E.; Orr, Edward L.			Acute effects of calvarial damage on dural mast cells, pial vascular permeability, and cerebral cortical histamine levels in rats and mice	JOURNAL OF NEUROTRAUMA			English	Article						animal studies; blood-brain barrier dysfunction; head trauma; inflammation; neurotransmitters	BLOOD-BRAIN-BARRIER; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; INFLAMMATORY MEDIATORS; MIGRAINE HEADACHE; EDEMA FORMATION; MOUSE-BRAIN; LEWIS RATS; STRESS; MATER; DEGRANULATION	Neurological complications after mild head injury can include vasogenic edema and/or subsequent development of epilepsy, conditions associated with elevated histamine. In the present study we assessed the potential of mast cells located in the dura mater to contribute to elevated cortical histamine and breakdown of the blood-brain barrier after minor head injury, modeled by either a parietal craniectomy or producing a groove in (scoring) the parietal bone surface to model a grazing head injury. We measured the following effects at 5-20 min after a unilateral parietal craniectomy (rats) or unilateral scoring of the parietal bone (mice): (1) mast cell integrity in subjacent dura mater; (2) subjacent vs. contralateral histamine in dura mater and cerebral cortex; (3) vascular permeability of cerebral cortical blood vessels subjacent to the injury, and; (4) the effects of an H-2-receptor antagonist on cerebral cortical vascular permeability. Results. Dural mast cells subjacent to the craniectomy became activated (degranulated) concomitant with (1) decreased histamine in dura mater subjacent to the craniectomy; (2) increased histamine in the subjacent cerebral cortex; and (3) extravasation of Evans blue-albumin which stained the subjacent cerebral cortex, indicating a localized breakdown of the blood-brain barrier. Similar results were observed in mice after scoring the parietal bone surface and, additionally, pretreatment with the histamine H-2-receptor antagonist zolantadine (1 h before injury) dose-dependently inhibited extravasation of Evans blue-albumin. We conclude that even a minor grazing injury of the skull, in the absence of penetrating brain injury or concussion, can activate dural mast cells and elevate cortical histamine, a novel mechanism with potential contributions to neurotraumatic complications arising from a relatively minor or grazing head wound.	[Orr, Edward L.] Barry Univ, Sch Nat & Hlth Sci, Grad Program Biomed Sci, Miami Shores, FL 33161 USA; [Stokely, Martha E.] Univ N Texas, Hlth Sci Ctr, Dept Pharmacol & Neurosci, Ft Worth, TX USA; [Stokely, Martha E.] Univ N Texas, Hlth Sci Ctr, N Texas Eye Res Inst, Ft Worth, TX USA	Orr, EL (corresponding author), Barry Univ, Sch Nat & Hlth Sci, Grad Program Biomed Sci, 11300 NE 2nd Ave, Miami Shores, FL 33161 USA.	eorr@mail.barry.edu					Bebo BF, 1996, J NEUROSCI RES, V45, P340; BUTT AM, 1992, BRAIN RES, V569, P100, DOI 10.1016/0006-8993(92)90374-I; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; DIMLICH RVW, 1991, J NEUROCYTOL, V20, P485, DOI 10.1007/BF01252276; DVORAK AM, 1992, INT ARCH ALLERGY IMM, V99, P74, DOI 10.1159/000236338; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; GELLER HM, 1984, CAN J PHYSIOL PHARM, V62, P715, DOI 10.1139/y84-118; Gregory GD, 2005, EUR J IMMUNOL, V35, P3478, DOI 10.1002/eji.200535271; Gregory Greg D, 2005, Novartis Found Symp, V271, P215; Janigro Damir, 2007, Epilepsy Curr, V7, P105, DOI 10.1111/j.1535-7511.2007.00190.x; JOO F, 1994, ACT NEUR S, V60, P76; Kandere-Grzybowska K, 2003, BRAIN RES, V980, P213, DOI 10.1016/S0006-8993(03)02975-5; KELLER JT, 1989, J COMP NEUROL, V290, P310, DOI 10.1002/cne.902900210; Levy D, 2007, PAIN, V130, P166, DOI 10.1016/j.pain.2007.03.012; Levy D, 2006, HEADACHE, V46, pS13, DOI 10.1111/j.1526-4610.2006.00485.x; Long Y, 2003, J NEUROSCI RES, V71, P710, DOI 10.1002/jnr.10524; Lozada A, 2005, NEUROPATH APPL NEURO, V31, P150, DOI 10.1111/j.1365-2990.2004.00622.x; MARKOWITZ S, 1989, BRAIN RES, V477, P157, DOI 10.1016/0006-8993(89)91403-0; MARTINS AN, 1980, STROKE, V11, P469, DOI 10.1161/01.STR.11.5.469; MOHANTY S, 1989, J NEUROL SCI, V90, P87, DOI 10.1016/0022-510X(89)90048-8; Oby E, 2006, EPILEPSIA, V47, P1761, DOI 10.1111/j.1528-1167.2006.00817.x; OLESEN SP, 1987, ACTA PHYSIOL SCAND, V130, P63, DOI 10.1111/j.1748-1716.1987.tb08112.x; Orr E L, 1988, Ann N Y Acad Sci, V540, P723, DOI 10.1111/j.1749-6632.1988.tb27226.x; ORR EL, 1984, J NEUROCHEM, V43, P1497, DOI 10.1111/j.1471-4159.1984.tb05416.x; ORR EL, 1984, J NEUROCHEM, V42, P727, DOI 10.1111/j.1471-4159.1984.tb02743.x; ORR EL, 1988, NEUROCHEM PATHOL, V8, P43; ORR EL, 1989, J NEUROCHEM, V53, P111, DOI 10.1111/j.1471-4159.1989.tb07301.x; Patnaik R, 2000, ACTA NEUROCHIR SUPPL, V76, P535; Powell HC, 1999, BRAIN PATHOL, V9, P219; Rozniecki JJ, 1999, BRAIN RES, V849, P1, DOI 10.1016/S0006-8993(99)01855-7; Sakas DE, 1997, NEUROSURGERY, V41, P661, DOI 10.1097/00006123-199709000-00031; Sarker MH, 2002, J PHYSIOL-LONDON, V540, P209, DOI 10.1113/jphysiol.2001.012912; Sarker MH, 1998, J PHYSIOL-LONDON, V507, P909, DOI 10.1111/j.1469-7793.1998.909bs.x; SHAFF RE, 1979, ANAL BIOCHEM, V94, P425, DOI 10.1016/0003-2697(79)90385-3; SHARMA HS, 1992, NEUROSCIENCE, V50, P445, DOI 10.1016/0306-4522(92)90436-6; STANLEY NC, 1990, J NEUROIMMUNOL, V29, P223, DOI 10.1016/0165-5728(90)90165-J; Theoharides TC, 2002, J CLIN PSYCHOPHARM, V22, P103, DOI 10.1097/00004714-200204000-00001; THEOHARIDES TC, 1995, ENDOCRINOLOGY, V136, P5745, DOI 10.1210/en.136.12.5745; TOSAKI A, 1994, EUR J PHARMACOL, V264, P455, DOI 10.1016/0014-2999(94)00546-X; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; UYAMA O, 1988, J CEREBR BLOOD F MET, V8, P282, DOI 10.1038/jcbfm.1988.59; YONG T, 1994, J NEUROTRAUM, V11, P161, DOI 10.1089/neu.1994.11.161	42	35	35	0	3	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JAN	2008	25	1					52	61		10.1089/neu.2007.0397			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	258IJ	WOS:000252861300005	18355158				2021-06-18	
J	Corral, L; Ventura, JL; Herrero, JI; Monfort, JL; Juncadella, M; Gabarrs, A; Bartolome, C; Javierre, CF; Garcia-Huete, L				Corral, Luisa; Luis Ventura, Jose; Ignacio Herrero, Jose; Luis Monfort, Jose; Juncadella, Montserrat; Gabarrs, Andreu; Bartolome, Carlos; Javierre, Casimiro F.; Garcia-Huete, Lucia			Improvement in GOS and GOSE scores 6 and 12 months after severe traumatic brain injury	BRAIN INJURY			English	Article						severe traumatic brain injury; Glasgow outcome scale; Glasgow coma scale; timing; prognosis	GLASGOW-OUTCOME-SCALE; SEVERE HEAD-INJURY; YOUNG-PEOPLE; FOLLOW-UP; DISABILITY; ADULTS; DAMAGE; CARE	Primary objective: To assess improvements in Glasgow Outcome Scale (GOS) and GOS extended (GOSE) scores between 6 months and 1 year following severe traumatic brain injury (TBI). Methods and procedures: One studied 214 adult patients with severe TBI with Glasgow Coma Scale (GCS) < 9 admitted to Intensive Care Unit (ICU). GOS scores were obtained 6 and 12 months after injury in 195 subjects. Patients were predominantly male (84%) and median age was 35 years. Main outcomes and results: Outcome (GOS and GOSE at 6 months and I year) was better in the high GCS score at admission (6-8) group than in the low score group (3-5). The improvement in GOS scores between 6 months and 1 year was greater in the high GCS score at admission group than in the low score group. At 6 months, 75 patients had died and 120 survived. None died between the 6-12-month assessments; at 12 months, 36% had improved GOS score. Conclusions: GOS scores improved between 6-12 months after severe TBI in 36% of survivors and it is concluded that the expectancy of improvement is incomplete at 6 months. This improvement was greater in patients with better GCS scores (6-8) at admission than in those with worse GCS scores (3-5).	[Corral, Luisa; Luis Ventura, Jose; Ignacio Herrero, Jose] Bellvitge Univ Hosp, Intens Care Unit, Barcelona 08907, Spain; [Luis Monfort, Jose] Bellvitge Univ Hosp, Dept Neuroradiol, Barcelona 08907, Spain; [Juncadella, Montserrat] Bellvitge Univ Hosp, Dept Neuropsychol, Barcelona 08907, Spain; [Gabarrs, Andreu] Bellvitge Univ Hosp, Dept Neurosurg, Barcelona 08907, Spain; [Bartolome, Carlos; Garcia-Huete, Lucia] Bellvitge Univ Hosp, Dept Anaesthesiol, Barcelona 08907, Spain; [Javierre, Casimiro F.] Univ Barcelona, Dept Physiol Sci 2, Barcelona, Spain	Corral, L (corresponding author), Bellvitge Univ Hosp, Intens Care Unit, Feixa Llarga S-N,Hosp Llobregat, Barcelona 08907, Spain.	301301ca@comb.es		Corral, Luisa/0000-0002-2888-7833			Andrews PJD, 2002, J NEUROSURG, V97, P326, DOI 10.3171/jns.2002.97.2.0326; Avesani R, 2005, BRAIN INJURY, V19, P933, DOI 10.1080/02699050400002371; Clayton TJ, 2004, BRIT J ANAESTH, V93, P761, DOI 10.1093/bja/aeh249; Currens JAB, 2000, INJURY, V31, P93, DOI 10.1016/S0020-1383(99)00244-2; de Guise E, 2005, CAN J NEUROL SCI, V32, P186, DOI 10.1017/S0317167100003954; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Hoffmann B, 2002, ACT NEUR S, V79, P33; Hudak AM, 2005, J NEUROTRAUM, V22, P1319, DOI 10.1089/neu.2005.22.1319; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kersel DA, 2001, BRAIN INJURY, V15, P683, DOI 10.1080/02699050010013662; King JT, 2005, J NEUROTRAUM, V22, P947, DOI 10.1089/neu.2005.22.947; LANGLOIS JA, 2003, SURVEILLANCE SUMMARI, V27, P1; Leblanc J, 2006, BRAIN INJURY, V20, P779, DOI 10.1080/02699050600831835; Lippert-Gruner M, 2003, BRAIN INJURY, V17, P49, DOI 10.1080/0269905021000010230; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; Mataro M, 2001, J NEUROTRAUM, V18, P869, DOI 10.1089/089771501750451794; Miller KJ, 2005, J NEUROSURG, V103, P239, DOI 10.3171/jns.2005.103.2.0239; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Ono J, 2001, J CLIN NEUROSCI, V8, P120, DOI 10.1054/jocn.2000.0732; Orient-Lopez F, 2004, REV NEUROLOGIA, V39, P901, DOI 10.33588/rn.3910.2004302; Pettigrew LEL, 2003, J HEAD TRAUMA REHAB, V18, P252, DOI 10.1097/00001199-200305000-00003; Stocchetti N, 1999, INTENS CARE MED, V25, P371, DOI 10.1007/s001340050860; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204; Woischneck D, 1998, ACT NEUR S, V71, P138	34	35	38	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	NOV	2007	21	12					1225	1231		10.1080/02699050701727460			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	249HP	WOS:000252219200002	18236198				2021-06-18	
J	Chaytor, N; Temkin, N; Machamer, J; Dikmen, S				Chaytor, Naomi; Temkin, Nancy; Machamer, Joan; Dikmen, Sureyya			The ecological validity of neuropsychological assessment and the role of depressive symptoms in moderate to severe traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						activities of daily living; everyday functioning; cognition; self-report; depressed mood; validation studies	MAJOR DEPRESSION; CES-D; TESTS; IMPAIRMENT; MEMORY; MILD; SCALE	Evaluating the ecological validity of neuropsychological tests has become an increasingly important topic. Previous research suggests that neuropsychological tests have a moderate level of ecological validity when predicting everyday functioning. The presence of depressive symptoms, however, may impact the relationship between neuropsychological tests and real world performance. The current study empirically tests this hypothesis in a sample of 216 participants with moderate to severe traumatic brain injury (TBI) who completed neuropsychological testing, self-report of mood symptoms, and report of everyday functioning six months post-injury. Contrary to some previous research and clinical lore, results indicated that depression was weakly related to neuropsychological test performance, although it was more strongly related to everyday functioning. Neuropsychological test performance was also significantly related to everyday functioning. The ecological validity of the neuropsychological tests together was not impacted by depressive symptoms, when predicting significant other ratings of functional status. However, patient self-report seems somewhat less related to neuropsychological performance in those with significant depressive symptoms. Neuropsychological test performance was equally related to self and other report of everyday functioning in patients without significant depressive symptoms.	Harborview Med Ctr, Reg Epilepsy Ctr, Seattle, WA 98104 USA; Univ Washington, Dept Neurol, Seattle, WA 98195 USA; Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; Univ Washington, Dept Biostat, Seattle, WA 98195 USA; Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA	Chaytor, N (corresponding author), Harborview Med Ctr, Reg Epilepsy Ctr, POB 359745,325 9th Ave, Seattle, WA 98104 USA.	chaytor@u.washington.edu	Chaytor, Naomi/L-4315-2019	Chaytor, Naomi/0000-0001-8821-289X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS019643] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS19643] Funding Source: Medline		Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; BURT DB, 1995, PSYCHOL BULL, V117, P285, DOI 10.1037/0033-2909.117.2.285; BUSCHKE H, 1973, J VERB LEARN VERB BE, V12, P543, DOI 10.1016/S0022-5371(73)80034-9; Bush BA, 2004, J CLIN PSYCHOL MED S, V11, P195, DOI 10.1023/B:JOCS.0000037613.69367.d4; Chaytor N, 2006, ARCH CLIN NEUROPSYCH, V21, P217, DOI 10.1016/j.acn.2005.12.002; Chaytor N, 2003, NEUROPSYCHOL REV, V13, P181, DOI 10.1023/B:NERV.0000009483.91468.fb; CHOI SC, 1977, BIOMETRIKA, V64, P645, DOI 10.2307/2345351; Christodoulou C, 2005, J INT NEUROPSYCH SOC, V11, P614, DOI 10.1017/S1355617705050733; Dikmen S, 2001, J NEUROTRAUM, V18, P127, DOI 10.1089/08977150150502578; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Evans JJ, 1997, PSYCHOL MED, V27, P635, DOI 10.1017/S0033291797004790; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; Franzen MD, 1997, BIOL NEUROPSYCHOLOGI; Goldstein G., 1995, INT J REHABILITATION, V1, DOI [DOI 10.1007/BF02214959, 10.1007/BF02214959]; GRANT I, 1993, NEUROPSYCHOLOGY, V7, P53; Heaton RK, 2004, J INT NEUROPSYCH SOC, V10, P317, DOI 10.1017/S1355617704102130; HEINRICHS RW, 1990, PROF PSYCHOL-RES PR, V21, P171, DOI 10.1037/0735-7028.21.3.171; Jones JE, 2005, EPILEPSIA, V46, P731, DOI 10.1111/j.1528-1167.2005.49704.x; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; KAITARO T, 1995, BRAIN INJURY, V9, P713, DOI 10.3109/02699059509008227; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Long C.J., 1995, ADV MED PSYCHOTHERAP, V8, P59; LONG CJ, 1997, CRIT ISS NE, P153; McCauley SR, 2006, BRAIN INJURY, V20, P519, DOI 10.1080/02699050600676651; PARIKH RM, 1988, INT J PSYCHIAT MED, V18, P169, DOI 10.2190/BH75-EUYA-4FM1-J7QA; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Rapoport MJ, 2005, J NEUROPSYCH CLIN N, V17, P61, DOI 10.1176/appi.neuropsych.17.1.61; REITAN RM, 1995, CLIN NEUROPSYCHOL, V9, P50, DOI 10.1080/13854049508402057; Reitan RM, 1988, TRAUMATIC BRAIN INJU, VII; Rohling ML, 2002, ARCH CLIN NEUROPSYCH, V17, P205, DOI 10.1016/S0887-6177(01)00109-3; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; Sbordone R. J., 1996, ECOLOGICAL VALIDITY, P15; Sbordone RJ, 1999, STUD NEUROPSYCHOL DE, P227; SBORDONE RJ, 1997, NEUROPSYCHOL HDB, V1; Silver CH, 2000, J HEAD TRAUMA REHAB, V15, P973, DOI 10.1097/00001199-200008000-00002; Spreen O., 1977, NEUROSENSORY CTR COM; SUNDERLAND A, 1983, J VERB LEARN VERB BE, V22, P341, DOI 10.1016/S0022-5371(83)90229-3; Temkin NR, 2007, LANCET NEUROL, V6, P29, DOI 10.1016/S1474-4422(06)70630-5; Temkin NR, 2003, J NEUROTRAUM, V20, P229, DOI 10.1089/089771503321532815; The Psychological Corporation, 1999, WECHSL ABBR SCAL INT; Veiel HOF, 1997, J CLIN EXP NEUROPSYC, V19, P587, DOI 10.1080/01688639708403745; Wechsler D., 1997, WECHSLER ADULT INTEL	42	35	36	1	9	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAY	2007	13	3					377	385		10.1017/S1355617707070592			9	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	162WZ	WOS:000246121500001	17445285				2021-06-18	
J	Liu-Snyder, P; Logan, MP; Shi, R; Smith, DT; Ben Borgens, R				Liu-Snyder, Peishan; Logan, Melissa Peasley; Shi, Riyi; Smith, Daniel T.; Ben Borgens, Richard			Neuroprotection from secondary injury by polyethylene glycol requires its internalization	JOURNAL OF EXPERIMENTAL BIOLOGY			English	Article						PEG; secondary injury; acrolein; endogenous toxins; CNS	SPINAL-CORD-INJURY; AXONAL MEMBRANE DISRUPTION; MOLECULAR REPAIR; NERVE MEMBRANES; CONDUCTION LOSS; WHITE-MATTER; BRAIN-INJURY; ACROLEIN; CELLS; RECOVERY	Polyethylene glycol ( PEG) is well known to both fuse and repair cell membranes. This capability has been exploited for such diverse usages as the construction of hybridomas and as a reparative agent following neurotrauma. The latter development has proceeded through preclinical testing in cases of naturally induced paraplegia in dogs. The mechanisms of action of polymer-mediated neurorepair/neuroprotection are still under investigation. It is likely that the unique interaction of hydrophilic polymers with the mechanical properties of cell membranes in concert with an ability to interfere with mechanisms of secondary injury such as the production of highly reactive oxygen species (ROS or 'free radicals') is the basis for neuroprotection by polymers. Here we provide further evidence that the ability of PEG to reduce or limit secondary injury and/or lipid peroxidation (LPO) of membranes requires entry of PEG into the cytosol, further suggesting a physical interaction with the membranes of organelles such as mitochondria as the initial event leading to neurorepair/neuroprotection. We have evaluated this relationship in vitro using acrolein, a potent endogenous toxin that is a product of LPO. Acrolein can pass through cell membranes with ease, inducing progressive LPO in 'bystander' cells, and the production of even more acrolein by inducing its own production. Immediate application of PEG (10 mmol l(-1), 2000 Da) to poisoned neurons in vitro was unable to rescue them from necrosis and death. Furthermore, three-dimensional confocal microscopy of fluorescently decorated PEG shows that it does not enter these cells for up to 2 h after application. By this time the mechanisms of necrosis are likely irreversible. Additionally, severe oxygen and or glucose deprivation of spinal cord white matter in vitro also initiates LPO. Addition of potent free radical scavengers such as ascorbic acid or superoxide dismutase (SOD) is able to interfere with this process, but PEG is not. Taken together, these data are consistent with the hypothesis that PEG is able to rescue mechanically damaged cells, based on a restructuring of the damaged plasmalemma. Furthermore, in compromised cells with an intact cell membrane, PEG must first gain access to the cytosol where this same capability may be useful in restoring the integrity of cellular organelles such as mitochondria, though the intracellular concentration of the polymer must be significant relative to the concentration of toxins produced by LPO in order to rescue the cell.	Purdue Univ, Sch Vet Med, Ctr Paralysis Res, W Lafayette, IN 47907 USA; Purdue Univ, Coll Engn, Weldon Sch Biomed Engn, W Lafayette, IN 47907 USA; Purdue Univ, Dept Ind & Phys Pharm, W Lafayette, IN 47907 USA	Ben Borgens, R (corresponding author), Purdue Univ, Sch Vet Med, Ctr Paralysis Res, W Lafayette, IN 47907 USA.	cpr@purdue.edu					Borgens RB, 2000, FASEB J, V14, P27; Borgens RB, 2002, J EXP BIOL, V205, P1; Borgens RB, 2001, NEUROSURGERY, V49, P370, DOI 10.1097/00006123-200108000-00021; Borgens RB, 2001, J NEUROSCI RES, V66, P1179; BORGENS RB, 2003, ADV ANATOMY EMBRYOLO, V171; DAVIDSON RL, 1976, SOMAT CELL GENET, V2, P271, DOI 10.1007/BF01538965; Georgiev G, 2004, EUR BIOPHYS J BIOPHY, V33, P742, DOI 10.1007/s00249-004-0421-4; Georgiev GA, 2006, EUR BIOPHYS J BIOPHY, V35, P352, DOI [10.1007/s00249-006-0043-0, 10.1007/S00249-006-0043-0]; Koob AO, 2006, J NEUROSCI RES, V83, P1558, DOI 10.1002/jnr.20837; Koob AO, 2005, J NEUROTRAUM, V22, P1092, DOI 10.1089/neu.2005.22.1092; Laverty PH, 2004, J NEUROTRAUM, V21, P1767, DOI 10.1089/neu.2004.21.1767; Lee J, 1997, BIOCHEMISTRY-US, V36, P6251, DOI 10.1021/bi970404c; Lee Raphael C., 1993, Journal of Burn Care and Rehabilitation, V14, P528, DOI 10.1097/00004630-199309000-00007; LEE RC, 1992, P NATL ACAD SCI USA, V89, P4524, DOI 10.1073/pnas.89.10.4524; LENTZ BR, 1994, CHEM PHYS LIPIDS, V73, P91, DOI 10.1016/0009-3084(94)90176-7; Liu-Snyder P, 2006, J NEUROSCI RES, V84, P209, DOI 10.1002/jnr.20863; Liu-Snyder P, 2006, J NEUROSCI RES, V84, P219, DOI 10.1002/jnr.20862; Luo J, 2004, J NEUROTRAUM, V21, P994, DOI 10.1089/0897715041651097; Luo J, 2002, J NEUROCHEM, V83, P471, DOI 10.1046/j.1471-4159.2002.01160.x; Marks Jeremy D., 2001, FASEB Journal, V15, P1107; McNally HA, 2004, J NEUROCYTOL, V33, P251, DOI 10.1023/B:NEUR.0000030700.48612.0b; NAKAJIMA N, 1994, J BIOMAT SCI-POLYM E, V6, P751, DOI 10.1163/156856295X00139; Nardini M, 2002, TOXICOLOGY, V170, P173, DOI 10.1016/S0300-483X(01)00540-6; PADANLAM JT, 1994, ANN NY ACAD SCI, V92, P111; Palmer JS, 1998, J UROLOGY, V159, P2136, DOI 10.1016/S0022-5347(01)63295-6; Peasley MA, 2003, J NEUROL SCI, V216, P23, DOI 10.1016/S0022-510X(03)00201-6; Peasley MA, 2002, AM J PHYSIOL-CELL PH, V283, pC980, DOI 10.1152/ajpcell.00591.2001; SAPOLSKY RM, 1985, SCIENCE, V229, P1397, DOI 10.1126/science.4035356; Satoh K, 1999, ANAL BIOCHEM, V270, P323, DOI 10.1006/abio.1999.4073; Shi R, 1999, J NEUROPHYSIOL, V81, P2406; Shi R, 1997, NEUROSCIENCE, V77, P553, DOI 10.1016/S0306-4522(96)00477-0; Shi R, 2002, NEUROSCIENCE, V115, P337, DOI 10.1016/S0306-4522(02)00457-8; Shi R, 2000, J NEUROCYTOL, V29, P633, DOI 10.1023/A:1010879219775; Shi R, 1996, J NEUROPHYSIOL, V76, P1572; Shi RY, 1999, J NEUROTRAUM, V16, P727, DOI 10.1089/neu.1999.16.727; Working PK, 1997, ACS SYM SER, V680, P45; Yasuda S, 2005, NATURE, V436, P1025, DOI 10.1038/nature03844	37	35	35	1	9	COMPANY BIOLOGISTS LTD	CAMBRIDGE	BIDDER BUILDING, STATION RD, HISTON, CAMBRIDGE CB24 9LF, ENGLAND	0022-0949	1477-9145		J EXP BIOL	J. Exp. Biol.	APR 15	2007	210	8					1455	1462		10.1242/jeb.02756			8	Biology	Life Sciences & Biomedicine - Other Topics	152HX	WOS:000245353700020	17401128	Bronze			2021-06-18	
J	Eriksson, PO; Haggman-Henrikson, B; Zafar, H				Eriksson, Per-Olof; Haggman-Henrikson, Birgitta; Zafar, Hamayun			Jaw-neck dysfunction in whiplash-associated disorders	ARCHIVES OF ORAL BIOLOGY			English	Article; Proceedings Paper	International Mastication Symposium 2006	JUN, 2006	Univ Queensland, St Lucia, Brisbane, AUSTRALIA	Int Assoc Dent Res, Neurosci Grp, Univ Adelaide	Univ Queensland, St Lucia	dysfunction; endurance; head; human; jaw; neck; whiplash	WIRELESS OPTOELECTRONIC RECORDINGS; OPENING-CLOSING TASKS; HEAD MOVEMENTS; MARKERS; INPUTS; RATS	This paper reports data from recent studies on integrative jaw-neck motor control in healthy subjects and disturbed jaw-neck behaviour in whiplash-associated disorders (WAD). The results show that neck function is an integral part of natural jaw behaviour, and that neck injury can impair jaw function and therefore disturb eating behaviour. We also show preliminary results from implementation of a new approach for rehabilitation of jaw-neck dysfunction and pain in WAD. (c) 2007 Elsevier Ltd. All rights reserved.	Umea Univ, Fac Med, Dept Odontol, Muscle & Motor Control & MotoRehab Lab, SE-90187 Umea, Sweden	Eriksson, PO (corresponding author), Umea Univ, Fac Med, Dept Odontol, Muscle & Motor Control & MotoRehab Lab, SE-90187 Umea, Sweden.	per-olof.eriksson@odont.umu.se	Haggman-Henrikson, Birgitta/C-6998-2008	Haggman-Henrikson, Birgitta/0000-0001-6088-3739; Zafar, Hamayun/0000-0001-9318-3691			Eriksson PO, 2000, J DENT RES, V79, P1378, DOI 10.1177/00220345000790060501; Eriksson PO, 2004, EUR J ORAL SCI, V112, P25, DOI 10.1111/j.0909-8836.2004.00098.x; Eriksson PO, 1998, J ORAL REHABIL, V25, P859, DOI 10.1046/j.1365-2842.1998.00333.x; ERIKSSON PO, 1993, SWED DENT J, V17, pA93; ERIKSSON PO, 2005, CONNS CURRENT THERAP, P1128; Haggman-Henrikson B, 2004, J DENT RES, V83, P864, DOI 10.1177/154405910408301108; Haggman-Henrikson B, 1998, J ORAL REHABIL, V25, P527, DOI 10.1046/j.1365-2842.1998.00292.x; Haggman-Henrikson B, 2002, J DENT RES, V81, P747, DOI 10.1177/154405910208101105; Haggman-Henrikson B, 2004, J DENT RES, V83, P946, DOI 10.1177/154405910408301211; HENRIKSON BH, 2006, J DENT RES, V85, P1001; Igarashi N, 2000, BRAIN RES, V871, P151, DOI 10.1016/S0006-8993(00)02433-1; Josefsson T, 1996, COMPUT METH PROG BIO, V49, P119, DOI 10.1016/0169-2607(96)01715-4; LUND J P, 1991, Critical Reviews in Oral Biology and Medicine, V2, P33; SEPULVEDA W, 1995, ULTRASOUND OBST GYN, V5, P57, DOI 10.1046/j.1469-0705.1995.05010057.x; Zafar H, 2006, SWED DENT J, V30, P9; Zafar H, 2000, ARCH ORAL BIOL, V45, P675, DOI 10.1016/S0003-9969(00)00032-7; Zafar H, 1995, ALPHA AND GAMMA MOTOR SYSTEMS, P502; Zafar H, 2000, J ORAL REHABIL, V27, P227, DOI 10.1046/j.1365-2842.2000.00505.x; Zafar H, 2002, EXP BRAIN RES, V146, P70, DOI 10.1007/s00221-002-1157-y; Zeredo JL, 2003, J DENT RES, V82, P402, DOI 10.1177/154405910308200515; Zeredo JL, 2002, J DENT RES, V81, P39, DOI 10.1177/154405910208100109	21	35	38	0	6	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0003-9969			ARCH ORAL BIOL	Arch. Oral Biol.	APR	2007	52	4					404	408		10.1016/j.archoralbio.2006.12.016			5	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	152FU	WOS:000245347400028	17274944				2021-06-18	
J	Bulger, EM; Nathens, AB; Rivara, FP; MacKenzie, E; Sabath, DR; Jurkovich, GJ				Bulger, Eileen M.; Nathens, Avery B.; Rivara, Frederick P.; MacKenzie, Ellen; Sabath, Daniel R.; Jurkovich, Gregory J.			National variability in out-of-hospital treatment after traumatic injury	ANNALS OF EMERGENCY MEDICINE			English	Article							CARDIAC-ARREST; BRAIN-INJURY; ENDOTRACHEAL INTUBATION; CARE; EMS; RESUSCITATION	Study objective: The optimal out-of-hospital treatment for trauma patients remains a subject of national debate. Researchers designing future studies to address these issues must understand the variability in treatment that exists across the United States. We define the variability in the out-of-hospital treatment provided to trauma patients in the United States. Methods: This was a retrospective analysis of prospectively collected data for a cohort study of trauma outcomes. The study was conducted at 15 urban or suburban regions across the United States, 18 Level I trauma centers and 51 nontrauma centers. We used a weighted population sample based on data from all hospital trauma deaths and a sample of patients discharged between January 2001 and December 2002. Entry criteria included at least 1 body region with an Abbreviated Injury Score greater than 3 and age between 18 and 84 years. Exclusion criteria were patient age greater than 65 years and isolated hip fractures and patients with burns. Results: Complete out-of-hospital data were available for 3,357 patients, representing a weighted population sample of 9,929 patients. Out-of-hospital treatment varied substantially among the regions, including out-of-hospital intubation (5% to 48%), use of neuromuscular blocking agents or sedatives to facilitate intubation (0% to 100%), surgical airway access (0.1% to 3.5%), peripheral and central intravenous access (22% to 95%), and needle thoracentesis (0% to 5%). Conclusion: There is considerable national variability in out-of-hospital procedures performed for trauma patients.	Univ Washington, Harborview Med Ctr, Harborview Injury Prevent & Res Ctr, Seattle, WA 98104 USA; Univ Washington, Dept Surg, Seattle, WA 98195 USA; Univ Washington, Dept Pediat, Seattle, WA 98195 USA; Johns Hopkins Sch Publ Hlth, Baltimore, MD USA	Bulger, EM (corresponding author), Univ Washington, Harborview Med Ctr, Harborview Injury Prevent & Res Ctr, Box 359796,325 9th Ave, Seattle, WA 98104 USA.	ebulger@u.washington.edu					BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BICKELL WH, 1994, NEW ENGL J MED, V331, P1105, DOI 10.1056/NEJM199410273311701; Bulger EM, 2005, J TRAUMA, V58, P718, DOI 10.1097/01.TA.0000159239.14181.BC; Bulger EM, 2002, J EMERG MED, V23, P183, DOI 10.1016/S0736-4679(02)00490-0; COBB LA, 1993, ARCH INTERN MED, V153, P1165, DOI 10.1001/archinte.153.10.1165; Cornwell EE, 2000, ARCH SURG-CHICAGO, V135, P315, DOI 10.1001/archsurg.135.3.315; Davis DP, 2003, J TRAUMA, V55, P713, DOI 10.1097/01.TA.0000037428.65987.12; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; DAVIS R, 2003, US TODAY        0728, pA7; DAVIS R, 2003, US TODAY        0728, pA1; DAVIS R, 2003, US TODAY        0728, pA6; Demetriades D, 1996, ARCH SURG-CHICAGO, V131, P133; Eckstein M, 2000, J TRAUMA, V48, P643, DOI 10.1097/00005373-200004000-00010; FILDES JJ, 2004, NATL TRAUMA DATABANK; Fortune JB, 1997, J TRAUMA, V42, P832, DOI 10.1097/00005373-199705000-00013; Frankel H, 1997, AM J EMERG MED, V15, P630, DOI 10.1016/S0735-6757(97)90174-1; Fredriksson M, 2003, AM J EMERG MED, V21, P276, DOI 10.1016/S0735-6757(03)00082-2; HEDGES JR, 1988, ANN EMERG MED, V17, P469, DOI 10.1016/S0196-0644(88)80238-5; Li J, 1999, AM J EMERG MED, V17, P141, DOI 10.1016/S0735-6757(99)90046-3; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; Raghunathan TL., 2001, SURV METHODOL, V27, P85; Rea TD, 2004, RESUSCITATION, V63, P17, DOI 10.1016/j.resuscitation.2004.03.025; RUBIN DB, 1991, STAT MED, V10, P585, DOI 10.1002/sim.4780100410; Wang HE, 2004, ANN EMERG MED, V44, P439, DOI 10.1016/j.annemergmed.2004.04.008; Wayne M A, 1999, Prehosp Emerg Care, V3, P107, DOI 10.1080/10903129908958916; Winchell RJ, 1997, ARCH SURG-CHICAGO, V132, P592	26	35	35	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644			ANN EMERG MED	Ann. Emerg. Med.	MAR	2007	49	3					293	301		10.1016/j.annemergmed.2006.06.038			9	Emergency Medicine	Emergency Medicine	142GI	WOS:000244637000008	16978737				2021-06-18	
J	Czigner, A; Mihaly, A; Farkas, O; Buki, A; Krisztin-Peva, B; Dobo, E; Barzo, P				Czigner, A.; Mihaly, A.; Farkas, O.; Buki, A.; Krisztin-Peva, B.; Dobo, E.; Barzo, P.			Kinetics of the cellular immune response following closed head injury	ACTA NEUROCHIRURGICA			English	Article						closed head injury; lymphocytes; microglia; inflammation; rat	CENTRAL-NERVOUS-SYSTEM; TRAUMATIC AXONAL INJURY; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; BRAIN INJURY; SPINAL-CORD; INFLAMMATORY RESPONSE; CNS; RAT; MICROGLIA; DAMAGE	Background. The contribution of brain edema to brain swelling in cases of traumatic brain injury (TBI) remains a critical problem. We believe that inflammatory reactions may play a fundamental role in brain swelling following a head injury. Although possible roles of microglia activation and the release of mediators have been suggested, direct evidence of cellular immune reactivity in diffuse brain injury following closed head trauma is lacking. Accordingly, the objective of this study was to assess the temporal pattern of microglia activation and lymphocyte migration in an experimental model of TBI. Method. An impact acceleration TBI model was utilized to induce diffuse brain damage in adult Wistar rats. The animals were separated into three groups: unoperated controls, sham-operated controls and trauma group. At various times after TBI induction (5min-24h), rats were perfused transcardially. Sagittal brain sections were analyzed with immunohistochemical markers of CD3 to reveal the presence of T-lymphocytes, and by immunochemistry for the detection of CD11b to reveal microglia activation within the brain parenchyma. Findings. In the control groups, scattered T-cells were found in the brain parenchyma. In the trauma group, TBI induced microglia activation and a transient biphasic T-cell infiltration of the brain parenchyma in all regions was found, beginning as early as 30min post injury and reaching its maximum values at 45min and 3h after trauma induction. Conclusion. These results lead us to suggest that the acute response to severe head trauma with early edema formation is likely to be associated with inflammatory events which might be triggered by activated microglia and infiltrating lymphocytes. It is difficult to overestimate the clinical significance of these observations, as the early and targeted treatment of patients with severe head injuries with immunosuppressive medication may result in a far more favorable outcome.	Univ Szeged, Dept Neurosurg, Fac Med, H-6725 Szeged, Hungary; Univ Szeged, Dept Anat, Fac Med, H-6725 Szeged, Hungary; Univ Pecs, Fac Med, Dept Neurosurg, H-7622 Pecs, Hungary	Barzo, P (corresponding author), Univ Szeged, Dept Neurosurg, Fac Med, Semmelweis 6, H-6725 Szeged, Hungary.	pbarzo@yahoo.com	Buki, Andras/B-1960-2010; Mihaly, Andras/K-5096-2012	Mihaly, Andras/0000-0002-6802-0169			Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Becher B, 2000, GLIA, V29, P293; BENNUN A, 1981, EUR J IMMUNOL, V11, P195, DOI 10.1002/eji.1830110307; Buki A, 1999, EXP NEUROL, V159, P319, DOI 10.1006/exnr.1999.7139; Buki A, 2000, J NEUROSCI, V20, P2825; COLTON CA, 1987, FEBS LETT, V223, P284, DOI 10.1016/0014-5793(87)80305-8; Csuka E, 2000, NEUROREPORT, V11, P2587, DOI 10.1097/00001756-200008030-00047; Dietrich WD, 2004, ACTA NEUROCHIR SUPPL, V89, P69; DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x; Fee D, 2003, J NEUROIMMUNOL, V136, P54, DOI 10.1016/S0165-5728(03)00008-0; GIULIAN D, 1986, J EXP MED, V164, P594, DOI 10.1084/jem.164.2.594; HART MN, 1995, TRENDS NEUROSCI, V18, P475, DOI 10.1016/0166-2236(95)92767-K; HICKEY WF, 1987, P NATL ACAD SCI USA, V84, P2082, DOI 10.1073/pnas.84.7.2082; Hickey WF, 1999, SEMIN IMMUNOL, V11, P125, DOI 10.1006/smim.1999.0168; HICKEY WF, 1985, CELL IMMUNOL, V91, P528, DOI 10.1016/0008-8749(85)90251-5; HICKEY WF, 1991, J NEUROSCI RES, V28, P254, DOI 10.1002/jnr.490280213; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Horvath KM, 2000, EUR J PHARMACOL, V405, P33, DOI 10.1016/S0014-2999(00)00539-2; Juurlink BHJ, 2000, BRAIN PATHOL, V10, P93; Kalla R, 2001, J COMP NEUROL, V436, P182; KIDA S, 1995, NEUROPATH APPL NEURO, V21, P181, DOI 10.1111/j.1365-2990.1995.tb01048.x; KIDA SY, 1993, ACTA NEUROPATHOL, V85, P646, DOI 10.1007/BF00334675; Klusman I, 1997, BRAIN RES, V762, P173, DOI 10.1016/S0006-8993(97)00381-8; LASSMANN H, 1991, J NEUROSCI RES, V28, P236, DOI 10.1002/jnr.490280211; Lassmann H, 1986, PROGR NEUROPATHOLOGY, V6, P33; Lenzlinger PM, 2001, J NEUROTRAUM, V18, P479, DOI 10.1089/089771501300227288; Ling CY, 2006, J NEUROSCI, V26, P731, DOI 10.1523/JNEUROSCI.3502-05.2006; Marmarou A, 2000, J NEUROSURG, V93, P183, DOI 10.3171/jns.2000.93.2.0183; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARMAROU A, 1994, ACTA NEUROCHIR, P421; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; PATERSON PY, 1982, CLIN IMMUNOL REV, V1, P581; PERRY VH, 1993, TRENDS NEUROSCI, V16, P268, DOI 10.1016/0166-2236(93)90180-T; POVLISHOCK JT, 1986, ACTA NEUROPATHOL, V70, P53, DOI 10.1007/BF00689514; Schwab JM, 2001, J NEUROTRAUM, V18, P881, DOI 10.1089/089771501750451802; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; Streit W. J., 2005, NEUROGLIA, P60; TRAUGOTT U, 1985, CELL IMMUNOL, V91, P240, DOI 10.1016/0008-8749(85)90047-4; WEKERLE H, 1986, TRENDS NEUROSCI, V9, P271, DOI 10.1016/0166-2236(86)90077-9; Weller RO, 1996, BRAIN PATHOL, V6, P275, DOI 10.1111/j.1750-3639.1996.tb00855.x	42	35	36	1	6	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	MAR	2007	149	3					281	289		10.1007/s00701-006-1095-8			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	143TK	WOS:000244747800023	17288002				2021-06-18	
J	Mauritz, W; Janciak, I; Wilbacher, I; Rusnak, M				Mauritz, Walter; Janciak, Ivan; Wilbacher, Ingrid; Rusnak, Martin		Austrian Severe TBI Study Investig	Severe traumatic brain injury in Austria IV: Intensive care management	WIENER KLINISCHE WOCHENSCHRIFT			English	Article						brain injury; traumatic; monitoring; intracranial pressure; cerebral perfusion pressure; hyperventilation; hypertonic saline; glucose levels; outcome	SEVERE HEAD-INJURY; CEREBRAL PERFUSION-PRESSURE; INTRACRANIAL-PRESSURE; HYPOTHERMIA; HYPERGLYCEMIA; SALINE; EPIDEMIOLOGY; HYPERTENSION; GUIDELINES; MANNITOL	OBJECTIVES: The goal of this paper is to describe the ICU management of severe traumatic brain injury (TBI) in Austria. PATIENTS AND METHODS: Data sets from 415 patients included by 5 Austrian hospitals were available. The analysis focused on complications and outcomes of intensive care, monitoring of intracranial pressure (ICP), efficacy of interventions to control ICP, management of hemodynamics and cerebral perfusion pressure (CPP), ventilation, and effects of hyperglycaemia. RESULTS: Overall ICU mortality was 30.8%; 90-day mortality was 35.7%. Final outcome was favorable in 33%, unfavorable in 51%, and in 16% the final outcome was unknown. An ICP monitoring device was used in 64%; most patients received intraparenchymal sensors (77%). Events associated with mortality > 50% were CPP < 50 mm Hg for > 12 hours/day, ICP > 25 mm Hg for > 12 hours/day, and MAP < 70 mm Hg for > 18 hours/day. The use of ICP monitoring was associated with significantly reduced ICU mortality. Interventions that may have improved the outcome included the use of barbiturates (short-term), hypertonic saline, moderate hyperventilation (33 < pCO(2) < 37; p < 0.001 vs. aggressive hyperand normoventilation), and normothermia. Hyperglycaemia was associated with poor outcome. CONCLUSIONS: Our study showed that ICU management of patients with severe TBI mostly follows international guidelines, and that outcome was comparable to or even better than that reported by other authors. Low CPP was associated with poor outcome, and was more often due to low MAP than to elevated ICP. The use of barbiturates and hypertonic saline was more common than expected. CPP should be maintained > 50 mm Hg, the use of catecholamines, fluid loading, barbiturates (short-term), moderate hyperventilation, hypertonic saline, and insulin may improve outcome after severe TBI.	INRO, Med Advisory Board, A-1080 Vienna, Austria; Trauma Hosp Lorenz Boehler, Dept Anesthesia & Crit Care Med, Vienna, Austria	Mauritz, W (corresponding author), INRO, Med Advisory Board, Molkergasse 4-3, A-1080 Vienna, Austria.	walter.mauritz@igeh.org	Rusnak, Martin/K-9349-2016	Rusnak, Martin/0000-0003-3321-1042; Mauritz, Walter/0000-0001-9043-3712			*AM ASS NEUR SURG, 2000, J NEUROTRAUM, V17, P457; American Association for the Surgery of Trauma, 2003, J Trauma, V54, pS235; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Caricato A, 2005, J TRAUMA, V58, P571, DOI 10.1097/01.TA.0000152806.19198.DB; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Citerio Giuseppe, 2003, Curr Opin Crit Care, V9, P120, DOI 10.1097/00075198-200304000-00007; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; Firsching R, 2001, WORLD J SURG, V25, P1221; Forster Nicole, 2004, Curr Opin Anaesthesiol, V17, P371, DOI 10.1097/00001503-200410000-00004; Guyot LL, 1998, ACT NEUR S, V71, P47; Harris OA, 2002, ARCH NEUROL-CHICAGO, V59, P1077, DOI 10.1001/archneur.59.7.1077; Hartl R, 1997, ACT NEUR S, V70, P126; Harutjunyan L, 2005, CRIT CARE, V9, pR530, DOI 10.1186/cc3767; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Jeremitsky E, 2005, J TRAUMA, V58, P47, DOI 10.1097/01.TA.0000135158.42242.B1; Lane PL, 2000, CAN J SURG, V43, P442; Lang E W, 1995, New Horiz, V3, P400; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; Masson F, 2003, BRAIN INJURY, V17, P279, DOI 10.1080/0269905021000030805; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; Mauritz W, 2003, CLIN RES REGUL AFF, V20, P81, DOI 10.1081/CRP-120018744; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; Nordstrom CH, 2003, ANESTHESIOLOGY, V98, P809, DOI 10.1097/00000542-200304000-00004; Polderman KH, 2002, INTENS CARE MED, V28, P1563, DOI 10.1007/s00134-002-1511-3; Procaccio F, 2000, J Neurosurg Sci, V44, P1; ROBERTS I, 2000, COCHRANE DB SYST REV, V2; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; Rovlias A, 2000, NEUROSURGERY, V46, P335, DOI 10.1097/00006123-200002000-00015; Rusnak M, 2007, WIEN KLIN WOCHENSCHR, V119, P23, DOI 10.1007/s00508-006-0760-5; Stocchetti N, 2005, CHEST, V127, P1812, DOI 10.1378/chest.127.5.1812; Stocchetti N, 2001, INTENS CARE MED, V27, P400, DOI 10.1007/s001340000825; Stover JF, 1998, EUR J CLIN PHARMACOL, V54, P529, DOI 10.1007/s002280050508; Vialet R, 2003, CRIT CARE MED, V31, P1683, DOI 10.1097/01.CCM.0000063268.91710.DF; Vukic M, 1999, ACTA NEUROCHIR, V141, P1203, DOI 10.1007/s007010050419; Young Jeffrey S, 2003, Neurosurg Focus, V15, pE2; Zygun DA, 2004, NEUROSURGERY, V55, P877, DOI 10.1227/01.NEU.0000137658.14906.E4	39	35	35	0	10	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0043-5325	1613-7671		WIEN KLIN WOCHENSCHR	Wien. Klin. Wochen.	FEB	2007	119	1-2					46	55		10.1007/s00508-006-0763-2			10	Medicine, General & Internal	General & Internal Medicine	142GQ	WOS:000244637800010	17318750				2021-06-18	
J	Zhang, L; Zhang, WP; Chen, KD; Qian, XD; Fang, SH; Wei, EQ				Zhang, Lei; Zhang, Wei-Ping; Chen, Ke-Da; Qian, Xiao-Dong; Fang, San-Hua; Wei, Er-Qing			Caffeic acid attenuates neuronal damage, astrogliosis and glial scar formation in mouse brain with cryoinjury	LIFE SCIENCES			English	Article						caffeic acid; traumatic brain injury; cryoinjury; neuroprotection; astrogliosis; glial scar	PHENETHYL ESTER; COLD-INJURY; ANTIOXIDANT ACTIVITY; CEREBRAL-ISCHEMIA; CHLOROGENIC ACID; EXPRESSION; 5-LIPOXYGENASE; ASTROCYTES; RECEPTOR; OXYGEN	Traumatic brain injury induces neuron damage in early phase, and astrogliosis and the formation of the glial scar in late phase. Caffeic acid (3, 4-dihydroxycinnamic acid), one of the natural phenolic compounds, exerts neuroprotective effects against ischemic brain injuries with anti-oxidant and anti-inflammatory properties, and by scavenging reactive species. However, whether caffeic acid has protective effects against traumatic brain injury is unknown. Therefore, we determined the effect of caffeic acid on the lesion in the early (1 day) and late phases (7 to 28 days) of cryoinjury in mice. We found that caffeic acid (10 and 50 mg/kg, i.p., for 7 days after cryoinjury) reduced the lesion area and attenuated the neuron loss around the lesion core 1 to 28 days, but attenuated the neuron loss in the lesion core only 1 day after cryoinjury. Moreover, caffeic acid attenuated astrocyte proliferation, glial scar wall formation and glial fibrillary acidic protein (GFAP) protein expression in the late phase of cryoinjury (7 to 28 days). Caffeic acid also inhibited the reduction of superoxide dismutase activity and the increase in malondialdehyde content in the brain 1 day after cryoinjury. These results indicate that caffeic acid exerts a protective effect in traumatic brain injury, especially on glial scar formation in the late phase, which at least is associated with its anti-oxidant ability. (c) 2006 Elsevier Inc. All rights reserved.	Zhejiang Univ, Sch Med, Dept Pharmacol, Hangzhou 310058, Peoples R China	Wei, EQ (corresponding author), Zhejiang Univ, Sch Med, Dept Pharmacol, 388 Yu Hang Tang Rd, Hangzhou 310058, Peoples R China.	weieq200l@yahoo.com	Zhang, Lei/F-2603-2011				Aladag MA, 2006, INT J DEV NEUROSCI, V24, P9, DOI 10.1016/j.ijdevneu.2005.12.002; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; CASTELLUCCIO C, 1995, FEBS LETT, V368, P188, DOI 10.1016/0014-5793(95)00639-Q; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; Flentjar NJ, 2002, EXP NEUROL, V177, P9, DOI 10.1006/exnr.2002.7927; Ge QF, 2006, J NEUROCHEM, V97, P992, DOI 10.1111/j.1471-4159.2006.03828.x; Gorlach C, 2001, J NEUROTRAUM, V18, P833, DOI 10.1089/089771501316919193; Gulcin I, 2006, TOXICOLOGY, V217, P213, DOI 10.1016/j.tox.2005.09.011; Hazell AS, 2002, NEUROCHEM INT, V41, P271, DOI 10.1016/S0197-0186(02)00013-X; Hermann DM, 2004, NEUROSCIENCE, V123, P371, DOI 10.1016/j.neuroscience.2003.09.032; Hirano S, 2004, BIOCHEM BIOPH RES CO, V317, P437, DOI 10.1016/j.bbrc.2004.03.049; Hortobagyi T, 2000, PFLUG ARCH EUR J PHY, V441, P409, DOI 10.1007/s004240000441; Irmak MK, 2003, CELL BIOCHEM FUNCT, V21, P283, DOI 10.1002/cbf.1024; Keller JN, 1999, BRAIN RES, V830, P10, DOI 10.1016/S0006-8993(99)01272-X; Kikuzaki H, 2002, J AGR FOOD CHEM, V50, P2161, DOI 10.1021/jf011348w; Kim JA, 1998, ARCH PHARM RES, V21, P664, DOI 10.1007/BF02976754; Kim SR, 2000, PHYTOCHEMISTRY, V54, P503, DOI 10.1016/S0031-9422(00)00110-2; Kono Y, 1997, BBA-GEN SUBJECTS, V1335, P335, DOI 10.1016/S0304-4165(96)00151-1; KOSHIHARA Y, 1984, BIOCHIM BIOPHYS ACTA, V792, P92; Lee SY, 2006, NEUROSCI RES, V56, P204, DOI 10.1016/j.neures.2006.06.005; Li PG, 2005, HYPERTENS RES, V28, P369, DOI 10.1291/hypres.28.369; Logan A, 2002, ADV EXP MED BIOL, V513, P115; Montpied P, 2003, MOL BRAIN RES, V115, P111, DOI 10.1016/S0169-328X(03)00178-5; Murakami K, 1999, PROG NEUROBIOL, V57, P289, DOI 10.1016/S0301-0082(98)00047-1; Nag S, 2002, TRENDS MOL MED, V8, P38, DOI 10.1016/S1471-4914(01)02221-3; Nardini M, 2001, FREE RADICAL BIO MED, V30, P722, DOI 10.1016/S0891-5849(00)00515-3; Nardini M, 2000, BBA-GEN SUBJECTS, V1474, P219, DOI 10.1016/S0304-4165(00)00009-X; Penkowa M, 2003, J NEUROSCI RES, V73, P481, DOI 10.1002/jnr.10681; Perez-Ortiz JM, 2004, J BIOL CHEM, V279, P8976, DOI 10.1074/jbc.M308518200; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Sewell DL, 2004, J NEUROIMMUNOL, V155, P55, DOI 10.1016/j.jneuroim.2004.06.003; Shin T, 2005, BRAIN RES, V1041, P95, DOI 10.1016/j.brainres.2005.02.019; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Sofroniew MV, 2005, NEUROSCIENTIST, V11, P400, DOI 10.1177/1073858405278321; SONDHEIMER E, 1958, ARCH BIOCHEM BIOPHYS, V74, P131, DOI 10.1016/0003-9861(58)90207-8; Song Y, 2004, NEUROREPORT, V15, P2181, DOI 10.1097/00001756-200410050-00007; Steiner MR, 2002, BBA-MOL CELL BIOL L, V1582, P154, DOI 10.1016/S1388-1981(02)00150-6; Stewart LR, 2001, J NEUROSCI RES, V65, P565, DOI 10.1002/jnr.1186; Tada T, 2004, NEUROCHEM INT, V45, P23, DOI 10.1016/j.neuint.2004.01.002; Tsai SK, 2006, LIFE SCI, V78, P2758, DOI 10.1016/j.lfs.2005.10.017; Turkoglu OF, 2005, SURG NEUROL, V64, P11, DOI 10.1016/j.surneu.2005.07.041; Uz T, 1998, FASEB J, V12, P439; Wei X, 2004, BRAIN, V127, P2629, DOI 10.1093/brain/awh316; Yasuoka N, 2004, DEV BRAIN RES, V151, P129, DOI 10.1016/j.devbrainres.2004.04.006; Yoshida H, 2006, CNS DRUG REV, V12, P9, DOI 10.1111/j.1527-3458.2006.00009.x; Zhang L, 2006, NEUROPATHOLOGY, V26, P99, DOI 10.1111/j.1440-1789.2006.00658.x; Zhou Y, 2006, ACTA PHARMACOL SIN, V27, P1103, DOI 10.1111/j.1745-7254.2006.00406.x	47	35	42	1	7	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0024-3205	1879-0631		LIFE SCI	Life Sci.	JAN 16	2007	80	6					530	537		10.1016/j.lfs.2006.09.039			8	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	131IX	WOS:000243863600004	17074364				2021-06-18	
J	Cormio, M; Citerio, G				Cormio, Manuela; Citerio, Giuseppe			Continuous low dose diclofenac sodium infusion to control fever in neurosurgical critical care	NEUROCRITICAL CARE			English	Article						fever; antipyretic therapy; diclofenac sodium; cerebral perfusion pressure; intracranial pressure; traumatic brain injury; subarachnoid hemorrhage	INTENSIVE-CARE; BRAIN-INJURY; SUBARACHNOID HEMORRHAGE; ANTIPYRETIC THERAPY; CEREBRAL-ISCHEMIA; BODY-TEMPERATURE; FEBRILE PATIENTS; CLINICAL-TRIAL; STROKE; HYPERTHERMIA	Introduction: Aim of this randomized prospective clinical trial is to compare two methods of antipyretics and evaluate their efficacy in controlling fever during the acute phase of brain damage. Methods: Twenty-two febrile comatose patients: 12 severe traumatic brain injury and 10 subarachnoid hemorrhage divided in 2 groups: Diclofenac low-dose infusion (10 patients) and extemporaneous boluses of NSAIDs (CTRL, 12 patients). The primary outcome measure was length of time with temperature > 38 degrees C. Secondary outcome measures were: 1) to assess the effects of each antipyretic strategy on intracranial pressure (ICP), cerebral perfusion pressure (CPP), mean arterial pressure (MAP) and heart rate; 2) to monitor adverse effects of each antipyretic strategy. The baseline characteristics in the two treatment groups were similar. Results: Primary findings: percentage of time per patient with temperature > 38 degrees C was significantly lower (P < 0.0001) in the DCF group, 4% (0-22%), vs. 34% (8-56%) in CTRL group. In addition, mean T degrees, max T degrees were lower in DCF than in CTRL (P < 0.05). Secondary findings: CPP and MAP were significantly higher in DCF group (P < 0.05) while ICP was not different (NS). However, if ICP pre randomization was < 25 mmHg, CTRL suffered a worst ICP (24 +/- 11 vs. +/- 16 +/- 7 P = 0.01), MAP (89 +/- 10 vs. 104 +/- 10 P = 0.01) and CPP (75 +/- 10 vs. 94 +/- 17 P = 0.01) compared to DCF. No differences between the two treatment were recorded when ICP +/- 25 mmHg before randomization. There was no gastrointestinal or intracranial bleeding. Conclusions: Low dose DCF infusion is a potential useful strategy for a successful control temperature better than intermittent NSAIDs dosing, minimizing potentially brain-damaging effects of fever.	Osped San Gerardo, Dipartimento Med Perioperatoria & Terapie Intens, I-20052 Monza, MI, Italy	Citerio, G (corresponding author), Osped San Gerardo, Dipartimento Med Perioperatoria & Terapie Intens, Via Pergolesi 33, I-20052 Monza, MI, Italy.	g.citerio@hsgerardo.org	Citerio, Giuseppe/B-1839-2015	Citerio, Giuseppe/0000-0002-5374-3161			Albrecht RF, 1998, MAYO CLIN PROC, V73, P629; Alderson P, 2004, COCHRANE DB SYST REV, DOI [DOI 10.1002/14651858.CD001048.PUB2, 10.1002/14651858.CD001048.pub2]; BETTINI R, 1986, J INT MED RES, V14, P95, DOI 10.1177/030006058601400208; Boyle M, 1997, Aust Crit Care, V10, P120, DOI 10.1016/S1036-7314(97)70414-4; Brown G, 1996, HEART LUNG, V25, P137, DOI 10.1016/S0147-9563(96)80116-6; Cairns Chris J S, 2002, Curr Opin Crit Care, V8, P106, DOI 10.1097/00075198-200204000-00003; Castillo J, 1997, LANCET, V349, P79, DOI 10.1016/S0140-6736(96)04453-4; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; Corbett D, 2000, BRAIN PATHOL, V10, P145; Cormio M, 2000, INTENS CARE MED, V26, P552, DOI 10.1007/s001340051203; DIETRICH WD, 1992, J NEUROTRAUMA, V9, P475; GARNER JS, 1996, APIC INFECT CONTROL; Hajat C, 2000, STROKE, V31, P410, DOI 10.1161/01.STR.31.2.410; Henker R, 2001, Am J Crit Care, V10, P276; HETHERINGTON JW, 1986, BRIT MED J, V292, P237, DOI 10.1136/bmj.292.6515.237; Kilpatrick MM, 2000, NEUROSURGERY, V47, P850, DOI 10.1097/00006123-200010000-00011; Klein NC, 1996, INFECT DIS CLIN N AM, V10, P211, DOI 10.1016/S0891-5520(05)70295-6; Lenhardt R, 1999, AM J MED, V106, P550, DOI 10.1016/S0002-9343(99)00068-6; LUNDSTAM SOA, 1982, LANCET, V1, P1096; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Mackenzie I, 2000, INTENS CARE MED, V26, P1408, DOI 10.1007/s001340000614; MALKINSON TJ, 1990, AM J PHYSIOL, V258, pR783; MAYBERG MR, 1994, STROKE, V25, P2315, DOI 10.1161/01.STR.25.11.2315; Mayer SA, 2001, NEUROLOGY, V56, P292, DOI 10.1212/WNL.56.3.292; Natale JE, 2000, CRIT CARE MED, V28, P2608, DOI 10.1097/00003246-200007000-00071; Oborilova A, 2002, J PAIN SYMPTOM MANAG, V24, P608; ODonnell J, 1997, CLIN INFECT DIS, V24, P1208, DOI 10.1086/513660; Oliveira J, 2001, NEUROLOGY, V56, P1299, DOI 10.1212/WNL.56.10.1299; PESENTI A, 1986, INTENS CARE MED, V12, P370, DOI 10.1007/BF00292928; Poblete B, 1997, BRIT J ANAESTH, V78, P123; POCOCK SJ, 1992, BMJ-BRIT MED J, V305, P235, DOI 10.1136/bmj.305.6847.235; Reith J, 1996, LANCET, V347, P422, DOI 10.1016/S0140-6736(96)90008-2; Rossi S, 2001, J NEUROL NEUROSUR PS, V71, P448, DOI 10.1136/jnnp.71.4.448; Schwarz S, 2000, NEUROLOGY, V54, P354, DOI 10.1212/WNL.54.2.354; Stocchetti N, 2002, INTENS CARE MED, V28, P1555, DOI 10.1007/s00134-002-1513-1; Thornhill J, 2001, CAN J PHYSIOL PHARM, V79, P254, DOI 10.1139/cjpp-79-3-254; Wang Y, 2000, STROKE, V31, P404, DOI 10.1161/01.STR.31.2.404; WASS CT, 1995, ANESTHESIOLOGY, V83, P325, DOI 10.1097/00000542-199508000-00013; Yu CG, 2001, NEUROSURGERY, V49, P152, DOI 10.1097/00006123-200107000-00023; ZANDSTRA DF, 1983, INTENS CARE MED, V9, P21, DOI 10.1007/BF01693701	40	35	35	0	6	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933			NEUROCRIT CARE	Neurocrit. Care		2007	6	2					82	89		10.1007/s12028-007-0002-3			8	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	179DW	WOS:000247270700002	17522789				2021-06-18	
J	Davis, DP; Fakhry, SM; Wang, HE; Bulger, EM; Domeier, RM; Trask, AL; Bochicchio, GV; Hauda, WE; Robinson, L				Davis, Daniel P.; Fakhry, Samir M.; Wang, Henry E.; Bulger, Eileen M.; Domeier, Robert M.; Trask, Arthur L.; Bochicchio, Grant V.; Hauda, William E.; Robinson, Linda			Paramedic rapid sequence intubation for severe traumatic brain injury: Perspectives from an expert panel	PREHOSPITAL EMERGENCY CARE			English	Article						paramedic; rapid sequence intubation; traumatic brain injury; intubation; prehospital; airway management; neuromuscular blockade	COMA SCALE SCORE; PREHOSPITAL ENDOTRACHEAL INTUBATION; HEAD-INJURY; TRACHEAL INTUBATION; GAG REFLEX; SURVIVAL; FIELD; VENTILATION; MODERATE; DAMAGE	Although early intubation has become standard practice in the prehospital management of severe traumatic brain injury (TBI), many patients cannot be intubated without neuromuscular blockade. Several emergency medical services (EMS) systems have implemented paramedic rapid sequence intubation (RSI) protocols, with published reports documenting apparently conflicting outcomes effects. In response, the Brain Trauma Foundation assembled a panel of experts to interpret the existing literature regarding paramedic RSI for severe TBI and offer guidance for EMS systems considering adding this skill to the paramedic scope of practice. The interpretation of this panel can be summarized as follows: (1) the existing literature regarding paramedic RSI is inconclusive, and apparent differences in outcome can be explained by use of different methodologies and variability in comparison groups; (2) the use of Glasgow Coma Scale score alone to identify TBI patients requiring RSI is limited, with additional research needed to refine our screening criteria; (3) suboptimal RSI technique as well as subsequent hyperventilation may account for some of the mortality increase reported with the procedure; (4) initial and ongoing training as well as experience with RSI appear to affect performance; and (5) the success of a paramedic RSI program is dependent on particular EMS and trauma system characteristics.	Univ Calif San Diego, Dept Emergency Med, San Diego, CA 92103 USA; Inova Fairfax Hosp, Inova Reg Trauma Ctr, Trauma Serv, Falls Church, VA USA; Univ Pittsburgh, Dept Emergency Med, Pittsburgh, PA 15260 USA; Univ Washington, Harborview Med Ctr, Dept Surg, Seattle, WA 98104 USA; Univ Michigan, St Joseph Mercy Hosp Emergency Med, Ann Arbor, MI 48109 USA; R Adams Cowley Shock Trauma Ctr, Baltimore, MD USA; Univ Maryland, Sch Med, Baltimore, MD 21201 USA; Fairfax Cty Police, Helicopter Div, Fairfax, VA USA	Davis, DP (corresponding author), Univ Calif San Diego, Dept Emergency Med, 200 W Arbor Dr,8676, San Diego, CA 92103 USA.	davismd@cox.net		Hauda II, William/0000-0003-1425-7715			Addington WR, 1999, ARCH PHYS MED REHAB, V80, P150, DOI 10.1016/S0003-9993(99)90112-0; Arbabi S, 2004, J TRAUMA, V56, P1029, DOI 10.1097/01.TA.0000123036.20919.4B; Atkinson JLD, 2000, MAYO CLIN PROC, V75, P37, DOI 10.4065/75.1.37; Baker CC, 2005, J TRAUMA, V58, P723; Bazarian JJ, 2003, BRAIN INJURY, V17, P553, DOI 10.1080/0269905031000070260; Bochicchio GV, 2003, J TRAUMA, V54, P307, DOI 10.1097/01.TA.0000046252.97590.BE; Buechler CM, 1998, J TRAUMA, V45, P429, DOI 10.1097/00005373-199809000-00001; Bulger EM, 2005, J TRAUMA, V58, P718, DOI 10.1097/01.TA.0000159239.14181.BC; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Bulger EM, 2002, J EMERG MED, V23, P183, DOI 10.1016/S0736-4679(02)00490-0; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Christensen EF, 2003, BRIT MED J, V327, P533, DOI 10.1136/bmj.327.7414.533; Combes X, 2006, ACAD EMERG MED, V13, P828, DOI 10.1197/j.aem.2006.02.016; DAVIES AE, 1995, LANCET, V345, P487, DOI 10.1016/S0140-6736(95)90584-7; Davis DP, 2006, J TRAUMA, V60, P985, DOI 10.1097/01.ta.0000205860.96209.1c; Davis DP, 2006, AM J EMERG MED, V24, P752, DOI 10.1016/j.ajem.2006.02.014; Davis D, 2004, ARCHAEOLOGY, V57, P8; Davis DP, 2005, J TRAUMA, V59, P484, DOI 10.1097/00005373-200508000-00037; Davis DP, 2006, CRIT CARE MED, V34, P1202, DOI 10.1097/01.CCM.0000208359.74623.1C; Davis DP, 2005, J EMERG MED, V29, P391, DOI 10.1016/j.jemermed.2005.04.012; Davis DP, 2005, J TRAUMA, V58, P933, DOI 10.1097/01.TA.0000162731.53812.58; Davis DP, 2005, ANN EMERG MED, V46, P115, DOI 10.1016/j.annemergmed.2005.01.024; Davis DP, 2005, NEUROCRIT CARE, V2, P165, DOI 10.1385/NCC:2:2:165; Davis DP, 2004, J TRAUMA, V57, P1, DOI 10.1097/01.TA.0000135503.71684.C8; Davis DP, 2004, J TRAUMA, V56, P808, DOI 10.1097/01.TA.0000100217.05066.87; Davis DP, 2003, J TRAUMA, V55, P713, DOI 10.1097/01.TA.0000037428.65987.12; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; Deschamp C, 2001, Air Med J, V20, P38, DOI 10.1016/S1067-991X(01)70059-4; Domeier RM, 2005, PREHOSP EMERG CARE, V9, P114; Dunford JV, 2003, ANN EMERG MED, V42, P721, DOI 10.1016/S0196-0644(03)00660-7; Dutton RP, 2002, J TRAUMA, V53, P857, DOI 10.1097/00005373-200211000-00009; Fakhry SM, 2006, J TRAUMA, V60, P997, DOI 10.1097/01.ta.0000217285.94057.5e; FLOCCARE DJ, 2005, PREHOSP EMERG CARE, V9, P108; FORSSTROM JJ, 1995, ANN MED, V27, P509, DOI 10.3109/07853899509002462; GABRIEL EJ, 2000, GUIDELINES PREHOSPIT, P39; Garrison HG, 2002, ANN EMERG MED, V40, P81, DOI 10.1067/mem.2002.124758; Garza AG, 2003, J EMERG MED, V25, P251, DOI 10.1016/S0736-4679(03)00198-7; Gausche M, 2000, JAMA-J AM MED ASSOC, V283, P783, DOI 10.1001/jama.283.6.783; Gill MR, 2004, ANN EMERG MED, V43, P215, DOI 10.1016/S0196-0644(03)00814-X; GRAHAM DI, 1971, LANCET, V1, P265; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; Haug E, 2004, ACAD EMERG MED, V11, P349, DOI 10.1197/j.aem.2003.12.015; HEDGES JR, 1988, ANN EMERG MED, V17, P469, DOI 10.1016/S0196-0644(88)80238-5; Helm M, 2002, BRIT J ANAESTH, V88, P345, DOI 10.1093/bja/88.3.345; Hesdorffer DC, 2002, J TRAUMA, V52, P1202, DOI 10.1097/00005373-200206000-00031; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; Katz SH, 2001, ANN EMERG MED, V37, P32, DOI 10.1067/mem.2001.112098; Leder SB, 1996, HEAD NECK-J SCI SPEC, V18, P138, DOI 10.1002/(SICI)1097-0347(199603/04)18:2<138::AID-HED5>3.0.CO;2-2; Lockey D, 2001, BRIT MED J, V323, P141, DOI 10.1136/bmj.323.7305.141; MACIVER IN, 1958, LANCET, V1, P390; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; MATEER JR, 1993, ANN EMERG MED, V22, P675, DOI 10.1016/S0196-0644(05)81846-3; McQuillen KK, 2000, PEDIATR EMERG CARE, V16, P401, DOI 10.1097/00006565-200012000-00005; Miner JR, 2002, ACAD EMERG MED, V9, P275, DOI 10.1197/aemj.9.4.275; Murray JA, 2000, J TRAUMA, V49, P1065, DOI 10.1097/00005373-200012000-00015; Ochs M, 2002, ANN EMERG MED, V40, P159, DOI 10.1067/mem.2002.126397; Poste Jennifer C, 2004, Air Med J, V23, P36, DOI 10.1016/j.amj.2004.04.006; Sibbritt David, 2004, Health Care Manag Sci, V7, P163, DOI 10.1023/B:HCMS.0000039379.32963.9e; Sloane C, 2000, J EMERG MED, V19, P259, DOI 10.1016/S0736-4679(00)00235-3; Smith S B, 1991, J Air Med Transp, V10, P11; Spaite DW, 2001, ANN EMERG MED, V37, P657, DOI 10.1067/mem.2001.115215; Stockinger ZT, 2004, J TRAUMA, V56, P531, DOI 10.1097/01.TA.0000111755.94642.29; Teramoto S, 2000, ARCH PHYS MED REHAB, V81, P1517, DOI 10.1053/apmr.2000.9171; Vadeboncoeur TF, 2006, J EMERG MED, V30, P131, DOI 10.1016/j.jemermed.2005.04.019; WALLS RM, 1993, ANN EMERG MED, V22, P1008, DOI 10.1016/S0196-0644(05)82743-X; Wang H E, 2000, Prehosp Emerg Care, V4, P14, DOI 10.1080/10903120090941560; Wang HE, 2005, RESUSCITATION, V67, P69, DOI 10.1016/j.resuscitation.2005.05.008; Wang HE, 2004, ANN EMERG MED, V44, P439, DOI 10.1016/j.annemergmed.2004.04.008; Wang Henry E, 2005, Prehosp Emerg Care, V9, P156; Wayne M A, 1999, Prehosp Emerg Care, V3, P107, DOI 10.1080/10903129908958916; Winchell RJ, 1997, ARCH SURG-CHICAGO, V132, P592	72	35	36	0	3	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1090-3127	1545-0066		PREHOSP EMERG CARE	Prehosp. Emerg. Care		2007	11	1					1	8		10.1080/10903120601021093			8	Emergency Medicine; Public, Environmental & Occupational Health	Emergency Medicine; Public, Environmental & Occupational Health	156CV	WOS:000245626600001	17169868				2021-06-18	
S	Klein, TW; Newton, CA		Shurin, MR; Smolkin, YS		Klein, Thomas W.; Newton, Catherine A.			Therapeutic potential of cannabinoid-based drugs	IMMUNE-MEDIATED DISEASES: FROM THEORY TO THERAPY	Advances in Experimental Medicine and Biology		English	Article; Proceedings Paper	1st International Congress on Immune-Mediated Diseases	OCT 03-08, 2005	Moscow, RUSSIA				CLOSED-HEAD INJURY; MULTIPLE-SCLEROSIS CAMS; CB2 RECEPTOR; DOUBLE-BLIND; ENDOGENOUS CANNABINOIDS; DEXANABINOL HU-211; NEUROPATHIC PAIN; AJULEMIC ACID; BRAIN-INJURY; DELTA-9-TETRAHYDROCANNABINOL	Cannabinoid-based drugs modeled on cannabinoids originally isolated from marijuana are now known to significantly impact the functioning of the endocannabinoid system of mammals. This system operates not only in the brain but also in organs and tissues in the periphery including the immune system. Natural and synthetic cannabinoids are tricyclic terpenes, whereas the endogenous physiological ligands are eicosanoids. Several receptors for these compounds have been extensively described, CB1, and CB2, and are G protein-coupled receptors; however, cannabinoid-based drugs are also demonstrated to function independently of these receptors. Cannabinoids regulate many physiological functions and their impact on immunity is generally antiinflammatory as powerful modulators of the cytokine cascade. This anti-inflammatory potency has led to the testing of these drugs in chronic inflammatory laboratory paradigms and even in some human diseases. Psychoactive and noripsychoactive cannabinoid-based drugs such as Delta(9)-tetrahydrocannabinol, cannabidiol, HU-211, and ajulemic acid have been tested and found moderately effective in clinical trials of multiple sclerosis, traumatic brain injury, arthritis, and neuropathic pain. Furthermore, although clinical trials are not yet reported, preclinical data with cannabinoid-based drugs suggest efficacy in other inflammatory diseases such as inflammatory bowel disease, Alzheimer's disease, atherosclerosis, and osteoporosis.	Univ S Florida, Dept Mol Med, Tampa, FL 33620 USA	Klein, TW (corresponding author), Univ S Florida, Dept Mol Med, Tampa, FL 33620 USA.	tklein@health.usf.edu					ANDAY JK, 2005, PHARM RES, V20, P20; Arevalo-Martin A, 2003, J NEUROSCI, V23, P2511; Baker D, 2006, TRENDS PHARMACOL SCI, V27, P1, DOI 10.1016/j.tips.2005.11.003; Baker D, 2000, NATURE, V404, P84, DOI 10.1038/35003583; Baldwin GC, 1997, AM J RESP CRIT CARE, V156, P1606, DOI 10.1164/ajrccm.156.5.9704146; Blake DR, 2006, RHEUMATOLOGY, V45, P50, DOI 10.1093/rheumatology/kei183; Breivogel CS, 2001, MOL PHARMACOL, V60, P155; Burstein SH, 1998, LIFE SCI, V63, P161, DOI 10.1016/S0024-3205(98)00256-2; Cabral GA, 1998, J NEUROIMMUNOL, V83, P116, DOI 10.1016/S0165-5728(97)00227-0; Calignano A, 1998, NATURE, V394, P277, DOI 10.1038/28393; Chang YH, 2001, J CELL BIOCHEM, V81, P715, DOI 10.1002/jcb.1103; Croxford JL, 2003, J CLIN INVEST, V111, P1231, DOI 10.1172/JCI200317652; Dajani EZ, 1999, J PHARMACOL EXP THER, V291, P31; Derocq JM, 2000, J BIOL CHEM, V275, P15621, DOI 10.1074/jbc.275.21.15621; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Di Filippo C, 2004, J LEUKOCYTE BIOL, V75, P453, DOI 10.1189/jlb.0703303; Di Marzo V, 2006, GUT, V55, P1373, DOI 10.1136/gut.2005.090472; Ehrhard FK, 2002, BRILLS TIBET STU LIB, V2, P29; Elmes SJR, 2005, PAIN, V118, P327, DOI 10.1016/j.pain.2005.09.005; Eubanks LM, 2006, MOL PHARMACEUT, V3, P773, DOI 10.1021/mp060066m; FISCHERSTENGER K, 1993, J PHARMACOL EXP THER, V267, P1558; Fowler CJ, 2005, PHARMACOL BIOCHEM BE, V81, P248, DOI 10.1016/j.pbb.2005.01.023; GAONI Y, 1964, J AM CHEM SOC, V86, P1646, DOI 10.1021/ja01062a046; GERARD CM, 1991, BIOCHEM J, V279, P129, DOI 10.1042/bj2790129; Hanus L, 2001, P NATL ACAD SCI USA, V98, P3662, DOI 10.1073/pnas.061029898; Hohmann AG, 2006, AAPS J, V8, pE693, DOI 10.1208/aapsj080479; Howlett AC, 2004, NEUROPHARMACOLOGY, V47, P345, DOI 10.1016/j.neuropharm.2004.07.030; Ibrahim MM, 2003, P NATL ACAD SCI USA, V100, P10529, DOI 10.1073/pnas.1834309100; Idris AI, 2005, NAT MED, V11, P774, DOI 10.1038/nm1255; Iskedjian M, 2007, CURR MED RES OPIN, V23, P17, DOI 10.1185/030079906X158066; Jarai Z, 1999, P NATL ACAD SCI USA, V96, P14136, DOI 10.1073/pnas.96.24.14136; Karsak M, 2005, HUM MOL GENET, V14, P3389, DOI 10.1093/hmg/ddi370; Karst M, 2003, JAMA-J AM MED ASSOC, V290, P1757, DOI 10.1001/jama.290.13.1757; Kishimoto S, 2004, J BIOCHEM, V135, P517, DOI 10.1093/jb/mvh063; Klein RG, 2000, EVOL ANTHROPOL, V9, P17, DOI 10.1002/(SICI)1520-6505(2000)9:1<17::AID-EVAN3>3.0.CO;2-A; Klein TW, 2006, J NEUROIMMUNE PHARM, V1, P50, DOI 10.1007/s11481-005-9007-x; KLEIN TW, 1993, J PHARMACOL EXP THER, V267, P635; Klein TW, 2003, J LEUKOCYTE BIOL, V74, P486, DOI 10.1189/jlb.0303101; Klein TW, 2005, NAT REV IMMUNOL, V5, P400, DOI 10.1038/nri1602; Klein TW, 1998, IMMUNOL TODAY, V19, P373, DOI 10.1016/S0167-5699(98)01300-0; Knoller N, 2002, CRIT CARE MED, V30, P548, DOI 10.1097/00003246-200203000-00009; Liu JL, 2003, MOL PHARMACOL, V63, P983, DOI 10.1124/mol.63.5.983; Lu TY, 2006, EUR J PHARMACOL, V532, P170, DOI 10.1016/j.ejphar.2005.12.040; LYMAN WD, 1989, J NEUROIMMUNOL, V23, P73, DOI 10.1016/0165-5728(89)90075-1; Maas AIR, 2006, LANCET NEUROL, V5, P38, DOI 10.1016/S1474-4422(05)70253-2; MACKENZIE IRA, 1995, NEUROBIOL AGING, V16, P797, DOI 10.1016/0197-4580(95)00092-S; Malfait AM, 2000, P NATL ACAD SCI USA, V97, P9561, DOI 10.1073/pnas.160105897; Marsicano G, 2003, SCIENCE, V302, P84, DOI 10.1126/science.1088208; MASSA F, 2005, J MOL MED, V26, P26; Mathison R, 2004, BRIT J PHARMACOL, V142, P1247, DOI 10.1038/sj.bjp.0705889; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; Mechoulam R, 2002, TRENDS MOL MED, V8, P58, DOI 10.1016/S1471-4914(02)02276-1; Milton NGN, 2002, NEUROSCI LETT, V332, P127, DOI 10.1016/S0304-3940(02)00936-9; Mitchell VA, 2005, NEUROSCI LETT, V382, P231, DOI 10.1016/j.neulet.2005.03.019; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; NAHAS GG, 1974, SCIENCE, V183, P419, DOI 10.1126/science.183.4123.419; NEWTON CA, 1994, INFECT IMMUN, V62, P4015, DOI 10.1128/IAI.62.9.4015-4020.1994; Nogid A, 2006, CLIN THER, V28, P1764, DOI 10.1016/j.clinthera.2006.11.020; Ofek O, 2006, P NATL ACAD SCI USA, V103, P696, DOI 10.1073/pnas.0504187103; Offertaler L, 2003, MOL PHARMACOL, V63, P699, DOI 10.1124/mol.63.3.699; Pacher P, 2006, PHARMACOL REV, V58, P389, DOI 10.1124/pr.58.3.2; Pacifici R, 2003, JAMA-J AM MED ASSOC, V289, P1929, DOI 10.1001/jama.289.15.1929-b; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Pertwee RG, 2005, AAPS J, V7, pE625, DOI 10.1208/aapsj070364; Pinto L, 2002, GASTROENTEROLOGY, V123, P227, DOI 10.1053/gast.2002.34242; Porter AC, 2002, J PHARMACOL EXP THER, V301, P1020, DOI 10.1124/jpet.301.3.1020; Pryce G, 2003, BRAIN, V126, P2191, DOI 10.1093/brain/awg224; PRYCE G, 2007, BRIT J PHARMACOL, V15, P15; Ramirez BG, 2005, J NEUROSCI, V25, P1904, DOI 10.1523/JNEUROSCI.4540-04.2005; Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508; Rog DJ, 2005, NEUROLOGY, V65, P812, DOI 10.1212/01.wnl.0000176753.45410.8b; Rousseaux C, 2007, NAT MED, V13, P35, DOI 10.1038/nm1521; Salim K, 2005, NEUROPHARMACOLOGY, V48, P1164, DOI 10.1016/j.neuropharm.2005.02.010; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Smith SR, 2000, J PHARMACOL EXP THER, V293, P136; Steffens S, 2005, NATURE, V434, P782, DOI 10.1038/nature03389; Sumariwalla PF, 2004, ARTHRITIS RHEUM-US, V50, P985, DOI 10.1002/art.20050; Sun Y, 2006, BIOCHEM SOC T, V34, P1095, DOI 10.1042/BST0341095; Svendsen KB, 2004, BMJ-BRIT MED J, V329, P253, DOI 10.1136/bmj.38149.566979.AE; Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092-8674(02)01049-8; Tomida I, 2004, BRIT J OPHTHALMOL, V88, P708, DOI 10.1136/bjo.2003.032250; Van Gaal LF, 2005, LANCET, V365, P1389, DOI 10.1016/S0140-6736(05)66374-X; Vaney C, 2004, MULT SCLER, V10, P417, DOI 10.1191/1352458504ms1048oa; Varga K, 1998, FASEB J, V12, P1035; Wade DT, 2004, MULT SCLER, V10, P434, DOI 10.1191/1352458504ms1082oa; Wagner JA, 1998, J MOL MED-JMM, V76, P824, DOI 10.1007/s001090050287; Wang Y, 2001, ANAL BIOCHEM, V294, P73, DOI 10.1006/abio.2001.5015; WIRGUIN I, 1994, IMMUNOPHARMACOLOGY, V28, P209, DOI 10.1016/0162-3109(94)90056-6; Wright K, 2005, GASTROENTEROLOGY, V129, P437, DOI 10.1053/j.gastro.2005.05.026; Yuan M, 2002, J NEUROIMMUNOL, V133, P124, DOI 10.1016/S0165-5728(02)00370-3; Zajicek J, 2003, LANCET, V362, P1517, DOI 10.1016/S0140-6736(03)14738-1; Zajicek JP, 2005, J NEUROL NEUROSUR PS, V76, P1664, DOI 10.1136/jnnp.2005.070136; Zhu LX, 2000, J IMMUNOL, V165, P373, DOI 10.4049/jimmunol.165.1.373; ZHU WG, 1994, J PHARMACOL EXP THER, V270, P1334; Zurier RB, 2003, BIOCHEM PHARMACOL, V65, P649, DOI 10.1016/S0006-2952(02)01604-0; Zurier RB, 1998, ARTHRITIS RHEUM-US, V41, P163, DOI 10.1002/1529-0131(199801)41:1<163::AID-ART20>3.3.CO;2-0; Zygmunt PM, 1999, NATURE, V400, P452	99	35	35	0	19	SPRINGER-VERLAG BERLIN	BERLIN	HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY	0065-2598	2214-8019	978-0-387-72004-3	ADV EXP MED BIOL	Adv.Exp.Med.Biol.		2007	601						395	413					19	Immunology; Medicine, Research & Experimental	Immunology; Research & Experimental Medicine	BGN45	WOS:000248597900043	17713029				2021-06-18	
J	Winocur, G; Palmer, H; Dawson, D; Binns, MA; Bridges, K; Stuss, DT				Winocur, Gordon; Palmer, Heather; Dawson, Deirdre; Binns, Malcolm A.; Bridges, Kristen; Stuss, Donald T.			Cognitive rehabilitation in the elderly: An evaluation of psychosocial factors	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						neuropsychology; aging; frontal lobe; quality of life; cognition; memory	TRAUMATIC BRAIN-INJURY; PHYSICAL-ACTIVITY; LEISURE ACTIVITY; OLDER; PEOPLE; HEALTH; RISK; LIFE; PARTICIPATION; EXERCISE	In this study, we report changes in psychosocial function in two groups of older adults that participated in the experimental trial of our cognitive rehabilitation program. The results, based on tests that measured a range of psychosocial attributes, showed that, following training, participants improved in terms of overall well-being, as well as in specific areas that included perceived happiness, coping strategies, and quality of life. An important finding was that improvements were also observed in long-term follow-up testing. Both groups benefited from training, but the effect was greater in the group that received training before undergoing a control procedure. The results, which show that the benefits of our rehabilitation program extend into the psychosocial domain, underscore the potentially important relationship between psychosocial factors and cognitive performance in older adults.	Rotman Res Inst, Toronto, ON M6A 2E1, Canada; Univ Toronto, Dept Psychol, Toronto, ON, Canada; Univ Toronto, Dept Med Psychiat, Toronto, ON, Canada; Trent Univ, Dept Psychol, Peterborough, ON, Canada; Kunin Lunenfeld Appl Res Unit, Toronto, ON, Canada; Univ Toronto, Dept Med Occupat Sci & Occupat Therapy, Toronto, ON, Canada; Univ Toronto, Dept Med Rehabil Sci, Toronto, ON, Canada; Univ Toronto, Dept Med Neurol, Toronto, ON, Canada	Winocur, G (corresponding author), Rotman Res Inst, 3560 Bathrust St, Toronto, ON M6A 2E1, Canada.	gwinocur@rotman-baycrest.on.ca	Binns, Malcolm/AAQ-9195-2020; Dawson, Deirdre R/I-8882-2014	Binns, Malcolm/0000-0001-9998-6612; Dawson, Deirdre R/0000-0001-7517-6121			Albert MS, 1995, PSYCHOL AGING, V10, P578, DOI 10.1037/0882-7974.10.4.578; Arbuckle TY, 1986, PSYCHOL AGING, V1, P55, DOI 10.1037/0882-7974.1.1.55; Arbuckle TY, 1998, PSYCHOL AGING, V13, P663, DOI 10.1037/0882-7974.13.4.663; Bailis DS, 2002, J GERONTOL B-PSYCHOL, V57, pP531, DOI 10.1093/geronb/57.6.P531; Baltes PB, 1982, AGING COGNITIVE PROC, P353, DOI DOI 10.1007/978-1-4684-4178-9_19; BenYishay Y, 1996, NEUROPSYCHOL REHABIL, V6, P327, DOI 10.1080/713755514; Brink TL., 1982, CLIN GERONTOLOGIST, V1, P37, DOI [10.1300/J018v01n01_06, DOI 10.1300/J018V01N01_06]; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Churchill JD, 2002, NEUROBIOL AGING, V23, P941, DOI 10.1016/S0197-4580(02)00028-3; Colcombe S, 2003, PSYCHOL SCI, V14, P125, DOI 10.1111/1467-9280.t01-1-01430; Colcombe SJ, 2003, J GERONTOL A-BIOL, V58, P176; COPE DN, 1995, BRAIN INJURY, V9, P649, DOI 10.3109/02699059509008224; Coulson I, 2001, ARCH GERONTOL GERIAT, V33, P273, DOI 10.1016/S0167-4943(01)00190-X; Dawson D., 1999, COGNITIVE NEUROREHAB, P94; EMERY CF, 1995, GERONTOLOGIST, V35, P378, DOI 10.1093/geront/35.3.378; FLANAGAN JC, 1978, AM PSYCHOL, V33, P138, DOI 10.1037/0003-066X.33.2.138; FOLKMAN S, 1986, J PERS SOC PSYCHOL, V50, P992, DOI 10.1037/0022-3514.50.5.992; Greenwood CE, 1999, MATURE MED, V2; Hertzog C, 1999, PSYCHOL AGING, V14, P528, DOI 10.1037/0882-7974.14.3.528; Hultsch D., 1998, MEMORY CHANGE AGED; Jennings JM, 2003, EDUC GERONTOL, V29, P71, DOI 10.1080/713844231; KOZMA A, 1980, J GERONTOL, V35, P906, DOI 10.1093/geronj/35.6.906; Kramer AF, 2004, J GERONTOL A-BIOL, V59, P940; KRPAN KK, IN PRESS J INT NEURO; Laurin D, 2001, ARCH NEUROL-CHICAGO, V58, P498, DOI 10.1001/archneur.58.3.498; Levine B, 2007, J INT NEUROPSYCH SOC, V13, P143, DOI 10.1017/S1355617707070178; Menec VH, 1997, J AGING HEALTH, V9, P105, DOI 10.1177/089826439700900106; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; NOSEK MA, 1992, REHABIL COUNS BULL, V36, P21; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P29; Pushkar D, 1997, PSYCHOL AGING, V12, P600, DOI 10.1037/0882-7974.12.4.600; Rath JF, 2003, NEUROPSYCHOL REHABIL, V13, P461, DOI 10.1080/09602010343000039; RATTOK J, 1992, NEUROPSYCHOLOGIA, V6, P395, DOI DOI 10.1037/0894-4105.6.4.395; Rejeski WJ, 2001, J GERONTOL A-BIOL, V56, P23, DOI 10.1093/gerona/56.suppl_2.23; Rodin J, 1985, Annu Rev Gerontol Geriatr, V5, P3; RODIN J, 1992, J GERONTOL, V47, pP373, DOI 10.1093/geronj/47.6.P373; RUFF R M, 1990, Brain Injury, V4, P339, DOI 10.3109/02699059009026187; Ruff RM, 1999, EVALUATION AND TREATMENT OF MILD TRAUMATIC BRAIN INJURY, P99; Scarmeas N, 2001, NEUROLOGY, V57, P2236, DOI 10.1212/WNL.57.12.2236; SCHEIER MF, 1985, HEALTH PSYCHOL, V4, P219, DOI 10.1037/0278-6133.4.3.219; Stuss DT, 2007, J INT NEUROPSYCH SOC, V13, P120, DOI 10.1017/S1355617707070154; STUSS DT, 1984, PSYCHOL BULL, V95, P3, DOI 10.1037/0033-2909.95.1.3; Wilson RS, 2003, CURR DIR PSYCHOL SCI, V12, P87, DOI 10.1111/1467-8721.01236; Wilson RS, 2002, JAMA-J AM MED ASSOC, V287, P742, DOI 10.1001/jama.287.6.742; WILSON RS, 1987, REHABILITATION MEMOR; WINOCUR G, 1990, CAN J PSYCHOL, V44, P435, DOI 10.1037/h0084270; WINOCUR G, 1987, CAN J PSYCHOL, V41, P257, DOI 10.1037/h0084156; Winocur G, 2007, J INT NEUROPSYCH SOC, V13, P166, DOI 10.1017/S1355617707070191	48	35	40	1	13	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JAN	2007	13	1					153	165		10.1017/S135561770707018X			13	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	127PO	WOS:000243599000017	17166314				2021-06-18	
J	Schofield, PW; Butler, TG; Hollis, SJ; Smith, NE; Lee, SJ; Kelso, WM				Schofield, Peter W.; Butler, Tony G.; Hollis, Stephanie J.; Smith, Nadine E.; Lee, Stephen J.; Kelso, Wendy M.			Neuropsychiatric correlates of traumatic brain injury (TBI) among Australian prison entrants	BRAIN INJURY			English	Article						neuropsychiatric; psychiatric; symptoms; prisoners; traumatic brain injury; inmates; criminal; head injury; and brain injury	PSYCHIATRIC-ILLNESS; MENTAL-DISORDERS; SUBSTANCE-ABUSE; PSYCHOTIC SYMPTOMS; FOLLOW-UP; PREVALENCE; SCHIZOPHRENIA; ASSOCIATION; POPULATION; PREDICTION	Primary objective: To investigate the association between reported past traumatic brain injury (TBI) and demographic, neuropsychiatric and criminographic parameters among individuals recently received into custody. Research design: A random sample of men recently received into the New South Wales (Australia) criminal justice system were screened for a history of TBI and the details of up to five separate TBI episodes were obtained. We also screened for depression, psychosis, personality disorder, drug and alcohol use, and 'social connectedness'. Main outcome and results: Among the 200 study participants, 82% reported past TBI. TBI was associated with a history of engagement in contact sports, school expulsion, daily illicit drug use, depression and psychosis. Conclusions: Past TBI is common among prisoners entering the criminal justice system and, amongst other correlates, appears to be highly associated with increased rates of major mental illness.	Univ Newcastle, Ctr Mental Hlth Studies, Newcastle, NSW, Australia; Univ New S Wales, Sch Publ Hlth & Community Med, Kensington, NSW 2033, Australia	Schofield, PW (corresponding author), James Feltcher Hosp, Neuropsychiat Serv, Watt St, Newcastle, NSW 2300, Australia.	peter.schofield@hnehealth.nsw.gov.au	Schofield, Peter/J-7133-2013; Hollis, Stephanie J/B-5977-2011; Butler, Tony/F-4614-2012	Butler, Tony/0000-0002-2679-2769; Schofield, Peter/0000-0001-8298-8590			ANDREWS G, 2002, J PUBLIC HEALTH, V25, P494; *AUSTR BUR STAT, 1997, 12340 AUSTR BUR STAT; Barnfield TV, 1998, BRAIN INJURY, V12, P455, DOI 10.1080/026990598122421; Boles SM, 2003, AGGRESS VIOLENT BEH, V8, P155, DOI 10.1016/S1359-1789(01)00057-X; BOURDON KH, 1992, PUBLIC HEALTH REP, V107, P663; BOYLE MJ, 1991, J ROY SOC MED, V84, P608; Butler T, 2006, AUST NZ J PSYCHIAT, V40, P272, DOI 10.1111/j.1440-1614.2006.01785.x; Butler T, 2005, AUST NZ J PSYCHIAT, V39, P407, DOI 10.1111/j.1440-1614.2005.01589.x; COHEN BJ, 1994, BRIT J PSYCHIAT, V165, P493, DOI 10.1192/bjp.165.4.493; Deb S, 1999, AM J PSYCHIAT, V156, P374; Degenhardt L, 2001, PSYCHOL MED, V31, P659, DOI 10.1017/S0033291701003865; DIRKMEN SS, 1989, MILD HEAD INJURY, P229; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Fann JR, 2002, J NEUROL NEUROSUR PS, V72, P615, DOI 10.1136/jnnp.72.5.615; Fazel S, 2002, LANCET, V359, P545, DOI 10.1016/S0140-6736(02)07740-1; FENTON G, 1993, BRIT J PSYCHIAT, V162, P493, DOI 10.1192/bjp.162.4.493; Fujii DE, 2001, J NEUROPSYCH CLIN N, V13, P61, DOI 10.1176/appi.neuropsych.13.1.61; Jablensky A, 2000, AUST NZ J PSYCHIAT, V34, P221, DOI 10.1046/j.1440-1614.2000.00728.x; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kelly MP, 1997, BRAIN INJURY, V11, P391, DOI 10.1080/026990597123386; Kessler RC, 2002, PSYCHOL MED, V32, P959, DOI 10.1017/S0033291702006074; KOENIG HG, 1993, PSYCHOSOMATICS, V34, P61, DOI 10.1016/S0033-3182(93)71928-3; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; LEWIS DO, 1986, AM J PSYCHIAT, V143, P838; LORANGER AW, 1997, ICD 10 INT PERSONALI; Malaspina D, 2001, AM J PSYCHIAT, V158, P440, DOI 10.1176/appi.ajp.158.3.440; Poulton R, 2000, ARCH GEN PSYCHIAT, V57, P1053, DOI 10.1001/archpsyc.57.11.1053; Sachdev P, 2001, PSYCHOL MED, V31, P231, DOI 10.1017/S0033291701003336; SAMUELS JF, 1994, AM J PSYCHIAT, V151, P1055; *SAS I, 1999, SAS STAT SOFTW VERS; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Schofield PW, 2006, BRAIN INJURY, V20, P499, DOI 10.1080/02699050600664749; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Silver JM, 2005, TXB TRAUMATIC BRAIN; Slaughter B, 2003, BRAIN INJURY, V17, P731, DOI 10.1080/0269905031000088649; SPITZER RL, 1994, JAMA-J AM MED ASSOC, V272, P1749, DOI 10.1001/jama.272.22.1749; TEPLIN LA, 1989, LAW HUMAN BEHAV, V13, P1, DOI 10.1007/BF01056159; Verdoux H, 2002, SCHIZOPHR RES, V54, P59, DOI 10.1016/S0920-9964(01)00352-8; *WHO AUDIT, 2001, ALC US DIS IT TEST G; Yui K, 1999, MOL PSYCHIATR, V4, P512, DOI 10.1038/sj.mp.4000575; Yung AR, 2003, SCHIZOPHR RES, V60, P21, DOI 10.1016/S0920-9964(02)00167-6	41	35	35	1	13	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	DEC	2006	20	13-14					1409	1418		10.1080/02699050601130443			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	130GF	WOS:000243787100011	17378233				2021-06-18	
J	Carnevale, GJ; Anselmi, V; Johnston, MV; Busichio, K; Walsh, V				Carnevale, George J.; Anselmi, Vera; Johnston, Mark V.; Busichio, Kim; Walsh, Vanessa			A natural setting behavior management program for persons with acquired brain injury: A randomized controlled trial	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						behavior therapy; brain injuries; burden of illness; caregivers; rehabilitation; stress; psychological	INDIVIDUALS; DISTRESS	Objective: To investigate the efficacy of a behavior management program delivered in the natural community setting for persons with brain injury and their caregivers. Design: Three-group randomized controlled trial. Setting: Homes and other community settings. Participants: Thirty-seven persons with traumatic and other acquired brain injury and their caregivers. Interventions: Natural Setting Behavior Management (NSBM) involving education and individualized behavior modification program versus education only versus control group. Main Outcome Measures: Changes in frequency of targeted problematic behaviors. Subscale in Questionnaire on Resources and Stress, Maslach Burnout Inventory, and the Neurobehavioral Functioning Inventory. Results: While no significant effects were detected at termination of education only (P<.075) or of NSBM (P<.56), significant treatment effects were found at the main outcome point 3 months after termination of services (P<.002). Rates of disruptive or aggressive behaviors declined significantly in the NSBM group. Differences in caregiver-rated stress, burden, and aggression were not statistically significant. Conclusions: A program of caregiver education and individualized behavior management in natural settings can decrease the frequency of disruptive behavioral challenges. Larger studies are needed to clarify the duration and intensity of education and individualized treatment required to diminish behavioral challenges and to understand relationships with general stress and burden experienced by caregivers.	Rehabil Specialists, Clin Serv Dev, N Haledon, NJ 07508 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ 07103 USA; Kessler Med Rehabil Res & Educ Corp, Nat Setting Behav Management, W Orange, NJ USA; Kessler Med Rehabil Res & Educ Corp, Outcomes Res, W Orange, NJ USA	Carnevale, GJ (corresponding author), Rehabil Specialists, Clin Serv Dev, 33 Sisomac Rd, N Haledon, NJ 07508 USA.	gcarnevale@rehab-specialists.com					Anstey KJ, 2004, J CLIN EPIDEMIOL, V57, P1202, DOI 10.1016/j.jclinepi.2003.11.011; Backman CL, 1999, AM J PHYS MED REHAB, V78, P170, DOI 10.1097/00002060-199903000-00022; Baguley IJ, 2006, J HEAD TRAUMA REHAB, V21, P45, DOI 10.1097/00001199-200601000-00005; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Carnevale GJ, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199602000-00005; Carnevale GJ, 2002, J HEAD TRAUMA REHAB, V17, P83, DOI 10.1097/00001199-200204000-00002; Edlund W, 2004, AM ACAD NEUROLOGY CL; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Harris JKJ, 2001, BRAIN INJURY, V15, P223; Holroyd J., 1987, MANUAL QUESTIONNAIRE; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; JACOBS HE, 1993, BEHAV ANAL GUIDELINE; KAUSAR R, 1996, CLIN REHABIL, V10, P159; Kolakowsky-Hayner SA, 2001, J HEAD TRAUMA REHAB, V16, P374, DOI 10.1097/00001199-200108000-00007; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; Kreutzer JS, 1996, ARCH PHYS MED REHAB, V77, P116, DOI 10.1016/S0003-9993(96)90155-0; LETHBRIDGECEJKU M, 2004, VITAL HLTH STAT 10, V222, P1; Macdonald GM, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub2; Maslach C., 1996, MASLACH BURNOUT INVE, V3rd ed.; Moher David, 2003, Clin Oral Investig, V7, P2; Morris KC, 2001, BRAIN INJURY, V15, P239, DOI 10.1080/02699050010004068; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; ROSENTHAL M, 2000, TRAUMATIC BRAIN INJU; Senn S, 2000, STAT MED, V19, P861, DOI 10.1002/(SICI)1097-0258(20000330)19:6<861::AID-SIM407>3.0.CO;2-F; Smith L.M., 1995, FAMILY SUPPORT PROGR; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Warriner Erin M, 2006, Curr Psychiatry Rep, V8, P73, DOI 10.1007/s11920-006-0083-2; Winer B.J., 1991, STAT PRINCIPLES EXPT	29	35	36	0	13	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	2006	87	10					1289	1297		10.1016/j.apmr.2006.06.010			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	095OA	WOS:000241316000001	17023236				2021-06-18	
J	Giannoudis, PV; Mushtaq, S; Harwood, P; Kambhampati, S; Dimoutsos, M; Stavrou, Z; Pape, HC				Giannoudis, P. V.; Mushtaq, S.; Harwood, P.; Kambhampati, S.; Dimoutsos, M.; Stavrou, Z.; Pape, H. C.			Accelerated bone heating and excessive callus formation in patients with femoral fracture and head injury	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						head injury; femoral fracture; bone heating; callus formation	TRAUMATIC BRAIN-INJURY; ENHANCED OSTEOGENESIS; DIAPHYSIS; ADULTS; LINK	The effect of head injury on systemic physiology, including bone heating is still a topic of vivid discussion. Whether the observed changes genuinely represent accelerated fracture heating or are a form of local heterotopic ossification remains unclear. We aimed to investigate whether in patients with tong bone fractures the presence of head injury is associated with accelerated bone heating and excessive callus formation. In total 67 patients were studied 17 with head injury and 50 without head injury (25 treated with reamed and the other 25 with the unreamed nailing technique). Both groups were comparable in terms of age, sex, ISS. All underwent stabilisation of their femora[ fracture with intramedullary nailing. The quantification of fracture heating response was estimated by taking the radiological ratio of the largest diameter of callus formed into two planes and the adjacent normal diameter of femoral canal. The minimum follow up of the patients was 12 months. In patients with head injury, the mean time to fracture union was significantly shorter than either the reamed or unreamed group (10.5 weeks compared with 20.5 and 26.9 weeks, (p < 0.001). The difference between the mean callus to diaphyseal ratio was statistically significant for both the AP and Lateral projections (AP: mean difference 0.462, 95% CI 0.312 to 0.602, p < 0.0001, LAT: mean difference 0.289, 95% CI 0.142 to 0.436, p < 0.001) with the head injured patients having more florid callus compared to the control group. (C) 2006 Elsevier Ltd. All rights reserved.	Univ Leeds, St Jamess Univ Hosp, Acad Dept Orthopaed Trauma Surg, Leeds LS9 7TF, W Yorkshire, England; Evagelismos Gen Hosp, Dept Microbiol, Athens, Greece; Evagelismos Gen Hosp, Dept Traumat & Orthopaed Surg, Athens, Greece; Pittsburgh Med Sch, Dept Trauma Surg, Pittsburgh, PA USA	Giannoudis, PV (corresponding author), Univ Leeds, St Jamess Univ Hosp, Acad Dept Orthopaed Trauma Surg, Chancellor Wing,Beckett St, Leeds LS9 7TF, W Yorkshire, England.	Pgiannoudi@aol.com	Giannoudis, Peter/AAA-3617-2020; Harwood, Paul/I-2360-2019	Giannoudis, Peter/0000-0002-5205-7696; Pape, Hans-Christoph/0000-0002-2059-4980; kambhampati, srinivas/0000-0002-4978-3590; Harwood, Paul/0000-0003-4564-4689			Association for the Advancement of Automotive Medicine, ABBR INJ SCAL; BAITO K, 2001, INFECT IMMUN, V69, P744; BIDNER SM, 1990, J BONE JOINT SURG AM, V72A, P1144, DOI 10.2106/00004623-199072080-00004; BOULET M, 1961, ARCH BIOCH, V93, P57; BRIGHTON CT, 1991, J BONE JOINT SURG AM, V73A, P832, DOI 10.2106/00004623-199173060-00006; CITTAPIETROLUNGO TJ, 1992, ARCH PHYS MED REHAB, V73, P258; Dattatreyamurty B, 2001, EXP NEUROL, V172, P273, DOI 10.1006/exnr.2001.7728; FEYEN JHM, 1989, J BONE MINER RES, V4, P633, DOI 10.1002/jbmr.5650040422; GARLAND DE, 1983, CLIN ORTHOP RELAT R, P190; GARLAND DE, 1982, CLIN ORTHOP RELAT R, P219; GARLAND DE, 1982, CLIN ORTHOP RELAT R, P38; GARLAND DE, 1980, CLIN ORTHOP RELAT R, P198; Giannoudis PV, 2000, J BONE JOINT SURG BR, V82B, P655, DOI 10.1302/0301-620X.82B5.9899; Giannoudis PV, 1997, INJURY, V28, P15, DOI 10.1016/S0020-1383(96)00146-5; GREENSPAN L, 1985, J TRAUMA, V25, P60, DOI 10.1097/00005373-198501000-00010; ISHIMI Y, 1990, J IMMUNOL, V145, P3297; Klein BY, 1999, CALCIFIED TISSUE INT, V65, P217, DOI 10.1007/s002239900686; Lewen A, 1997, NEUROREPORT, V8, P475, DOI 10.1097/00001756-199701200-00020; Lieberman JR, 2002, J BONE JOINT SURG AM, V84A, P1032, DOI 10.2106/00004623-200206000-00022; LINDHOLM TS, 1987, ACTA ORTHOP SCAND, V49, P485; MALISANO LP, 1994, J ORTHOP TRAUMA, V8, P1, DOI 10.1097/00005131-199402000-00001; NEWMAN RJ, 1987, INJURY, V18, P241, DOI 10.1016/0020-1383(87)90006-4; Pape HC, 2001, J ORTHOP TRAUMA, V15, P229, DOI 10.1097/00005131-200105000-00001; PERKINS R, 1987, J BONE JOINT SURG BR, V69, P521; ROBERTS P H, 1968, Journal of Bone and Joint Surgery British Volume, V50B, P70; RUEDI T, MANUAL INTERNAL FIXA, P151; Sevitt S., 1981, BONE REPAIR FRACTURE; SMITH R, 1987, J BONE JOINT SURG BR, V69, P518; SPENCER RF, 1987, J BONE JOINT SURG BR, V69, P525; WILDBURGER R, 1995, EUR J CLIN CHEM CLIN, V33, P693; WILDBURGER R, 1994, BONE MINER, V27, P183, DOI 10.1016/S0169-6009(08)80192-4; WILDBURGER R, 1994, RES EXP MED, V194, P247, DOI 10.1007/BF02576386; Wildburger R, 1998, J ENDOCRINOL INVEST, V21, P78, DOI 10.1007/BF03350319	33	35	42	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383			INJURY	Injury-Int. J. Care Inj.	SEP	2006	37			3			S18	S24		10.1016/j.injury.2006.08.020			7	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	096JW	WOS:000241374400003	16963358				2021-06-18	
J	Ross, AP; Christian, SL; Zhao, HWW; Drew, KL				Ross, Austin P.; Christian, Sherri L.; Zhao, Huiwen W.; Drew, Kelly L.			Persistent tolerance to oxygen and nutrient deprivation and N-methyl-D-aspartate in cultured hippocampal slices from hibernating Arctic ground squirrel	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						channel arrest; excitotoxicity; hibernation; ischemia; Na+K+ ATPase; neuroprotection	ANOXIC TURTLE BRAIN; INTRACELLULAR CALCIUM; ISCHEMIA-REPERFUSION; IN-VITRO; HYPOXIA; NEURONS; INJURY; RECEPTORS; PROTEIN; NEUROPROTECTION	Hibernating Arctic ground squirrel (hAGS), Spermophilus parryii, survive profound decreases in cerebral perfusion during torpor and return to normal blood flow during intermittent rewarming periods without neurologic damage. Hibernating AGS tolerate traumatic brain injury in vivo, and acute hippocampal slices from hibernating animals tolerate oxygen and glucose deprivation. It remains unclear, however, if neuroprotection results from intrinsic tissue properties or from differences in response to acute trauma associated with slice preparation. The goal of this work was therefore to determine whether an intrinsic tissue tolerance persists in chronic culture of AGS hippocampal slices at 37 degrees C. A second goal was to address N-methyl-D-aspartate (NMDA) receptor involvement and channel arrest as potential mechanisms of intrinsic tissue tolerance. Baseline neuronal survival and tolerance to oxygen and nutrient deprivation (OND), an in vitro model of ischemia-reperfusion, were assessed in the CA1 region of hippocampal slices from juvenile, hAGS and interbout euthermic AGS (ibeAGS). Early in culture (insult onset at 3 h), slices from both hAGS and ibeAGS tolerate OND (4 h deprivation followed by 20 h recovery) and 500 mu mol/L NMDA plus 20mmol/L KCI. Later in culture (insult onset at 24 h), tolerance persists in slices from hAGS but not in slices from ibeAGS. Ouabain (Na+ K+ ATPase inhibitor) administered 24 h in culture enhances survival of slices from hAGS (assessed 24 h later). Thus, tolerance to OND in slices from hAGS is due to intrinsic tissue properties likely involving NMDA receptors and ion channel arrest.	Univ Alaska Fairbanks, Alaskan Basic Neurosci Program, Inst Arctic Biol, Fairbanks, AK 99775 USA	Drew, KL (corresponding author), Univ Alaska Fairbanks, Alaskan Basic Neurosci Program, Inst Arctic Biol, POB 757000, Fairbanks, AK 99775 USA.	ffkld@uaf.edu	Drew, Kelly L/B-7995-2013		NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [1P20RR16466, 2P20RR16466] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NIH-NS41069] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20RR016466] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U54NS041069] Funding Source: NIH RePORTER		Aarts M, 2002, SCIENCE, V298, P846, DOI 10.1126/science.1072873; Arora S, 2005, STROKE, V36, P1232, DOI 10.1161/01.STR.0000165902.18021.5b; ASTRUP J, 1981, STROKE, V12, P726, DOI 10.1161/01.STR.12.6.726; Bengzon J, 1997, P NATL ACAD SCI USA, V94, P10432, DOI 10.1073/pnas.94.19.10432; Bickler PE, 2004, NEUROSCIENCE, V127, P673, DOI 10.1016/j.neuroscience.2004.05.035; Bickler PE, 2000, J NEUROSCI, V20, P3522; Bickler PE, 2003, NEUROSCIENCE, V118, P25, DOI 10.1016/S0306-4522(02)00763-7; BICKLER PE, 1992, AM J PHYSIOL, V263, pR1298; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Bonde C, 2003, NEUROCHEM INT, V43, P381, DOI 10.1016/S0197-0186(03)00025-1; Bonde C, 2003, NEUROCHEM INT, V43, P371, DOI 10.1016/S0197-0186(03)00024-X; Bonde C, 2002, NEUROSCI LETT, V327, P49, DOI 10.1016/S0304-3940(02)00382-8; CHIH CP, 1989, AM J PHYSIOL, V257, pR854; DAVE KR, 2005, IN PRESS STROKE; Dirnagl U, 2003, TRENDS NEUROSCI, V26, P248, DOI 10.1016/S0166-2236(03)00071-7; DOLL CJ, 1993, AM J PHYSIOL, V265, pR929; Drew KL, 2001, FREE RADICAL BIO MED, V31, P563, DOI 10.1016/S0891-5849(01)00628-1; EDWARDS RA, 1989, AM J PHYSIOL, V257, pR1354; Frantseva MV, 1999, J NEUROSCI METH, V89, P25, DOI 10.1016/S0165-0270(99)00030-8; Frerichs KU, 1998, J CEREBR BLOOD F MET, V18, P168, DOI 10.1097/00004647-199802000-00007; Gentile NT, 1996, NEUROCHEM RES, V21, P947, DOI 10.1007/BF02532345; HOCHACHKA PW, 1986, SCIENCE, V231, P234, DOI 10.1126/science.2417316; IGELMUND P, 1996, ADAPTATIONS COLD; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; Kleindorfer D, 2004, STROKE, V35, pE27, DOI 10.1161/01.STR.0000109767.11426.17; Laake JH, 1999, BRAIN RES PROTOC, V4, P173, DOI 10.1016/S1385-299X(99)00021-5; Lindell SL, 2005, AM J PHYSIOL-GASTR L, V288, pG473, DOI 10.1152/ajpgi.00223.2004; Lipton Stuart A, 2004, NeuroRx, V1, P101, DOI 10.1007/BF03206570; LYMAN CP, 1948, J EXP ZOOL, V109, P55, DOI 10.1002/jez.1401090105; Ma YL, 2005, AM J PHYSIOL-REG I, V289, pR1297, DOI 10.1152/ajpregu.00260.2005; MacDonald JA, 1999, BIOCHEM BIOPH RES CO, V254, P424, DOI 10.1006/bbrc.1998.9960; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Pek M, 1997, J EXP BIOL, V200, P1913; PENGELLEY ET, 1961, CAN J ZOOL, V39, P98; PEREZPINZON MA, 1992, AM J PHYSIOL, V262, pR712; Stenzel-Poore MP, 2003, LANCET, V362, P1028, DOI 10.1016/S0140-6736(03)14412-1; STRASSER U, 1995, J NEUROSCI METH, V57, P177, DOI 10.1016/0165-0270(94)00147-9; WALLIS RA, 1995, BRAIN RES, V674, P75, DOI 10.1016/0006-8993(94)01438-N; WILLIS JS, 1971, COMP BIOCHEM PHYSIOL, V39, P437, DOI 10.1016/0300-9629(71)90307-0; Zhang L, 1997, J NEUROCHEM, V69, P1983; Zhou F, 2001, AM J PATHOL, V158, P2145, DOI 10.1016/S0002-9440(10)64686-X	41	35	36	0	8	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	SEP	2006	26	9					1148	1156		10.1038/sj.jcbfm.9600271			9	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	077FX	WOS:000240015300006	16395285	Bronze			2021-06-18	
J	Kyung, KS; Gon, JH; Geun, KY; Sup, JJ; Suk, WJ; Ho, KJ				Kyung, Kang Soo; Gon, Jeon Hyo; Geun, Kim Yong; Sup, Jung Jin; Suk, Woo Jae; Ho, Kim Jae			6-Shogaol, a natural product, reduces cell death and restores motor function in rat spinal cord injury	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						apoptotic cell death; function recovery; inflammation; myelination; neuroprotection; spinal cord injury	TRAUMATIC BRAIN-INJURY; NERVOUS-SYSTEM INJURY; ACTIVATION; PATHOPHYSIOLOGY; DEGENERATION; INFLAMMATION; MACROPHAGES; APOPTOSIS; AXONS; PEROXYNITRITE	Spinal cord injury (SCI) results in progressive waves of secondary injuries, which via the activation of a barrage of noxious pathological mechanisms exacerbate the injury to the spinal cord. Secondary injuries are associated with edema, inflammation, excitotoxicity, excessive cytokine release, caspase activation and cell apoptosis. This study was aimed at investigating the possible neuroprotective effects of 6-shogaol purified from Zingiber officinale by comparing an experimental SCI rat group with SCI control rats. Shogaol attenuated apoptotic cell death, including poly(ADP-ribose) polymerase activity, and reduced astrogliosis and hypomyelination which occurs in areas of active cell death in the spinal cords of SCI rats. The foremost protective effect of shogaol in SCI would therefore be manifested in the suppression of the acute secondary apoptotic cell death. However, it does not attenuate active microglia and macrophage infiltration. This finding is supported by a lack of histopathological changes in the areas of the lesion in the shogaol-treated SCI rats. Moreover, shogaol-mediated neuroprotection has been linked with shogaol's attenuation of p38 mitogen-activated protein kinase, p-SAPK/JNK and signal transducer, and with transcription-3 activation. Our results demonstrate that shogaol administrated immediately after SCI significantly diminishes functional deficits. The shogaol-treated group recovered hindlimb reflexes more rapidly and a higher percentage of these rats regained responses compared with the untreated injured rats. The overall hindlimb functional improvement of hindlimbs, as measured by the Basso, Beattie and Bresnahan scale, was significantly enhanced in the shogaol-treated group relative to the SCI control rats. Our data show that the therapeutic outcome of shogaol probably results from its comprehensive effects of blocking apoptotic cell death, resulting in the protection of white matter, oligodendrocytes and neurons, and inhibiting astrogliosis. Our finding that the administration of shogaol prevents secondary pathological events in traumatic SCIs and promotes recovery of motor functions in an animal model raises the issue of whether shogaol could be used therapeutically in humans after SCI.	Pusan Natl Univ, Sch Med, Dept Physiol, Pusan 602739, South Korea; Korea Res Inst Biosci & Biotechnol, Taejon, South Korea	Kyung, KS (corresponding author), Pusan Natl Univ, Sch Med, Dept Physiol, 1-10 Ami Dong, Pusan 602739, South Korea.	skkang@pusan.ac.kr	Mat Zain, Mazatulikhma/B-2025-2010				ANDERSON DK, 1993, ANN EMERG MED, V22, P987, DOI 10.1016/S0196-0644(05)82739-8; Bareyre FM, 2003, TRENDS NEUROSCI, V26, P555, DOI 10.1016/j.tins.2003.08.004; BLIGHT AR, 1983, NEUROSCIENCE, V10, P521, DOI 10.1016/0306-4522(83)90150-1; Blight AR, 2002, NAT NEUROSCI, V5, P1051, DOI 10.1038/nn939; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; BRUCK W, 1990, ACTA NEUROPATHOL, V80, P415; BRUCK W, 1991, J NEUROL SCI, V103, P182, DOI 10.1016/0022-510X(91)90162-Z; Burkle A, 2001, BIOESSAYS, V23, P795, DOI 10.1002/bies.1115; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; Caroleo MC, 2001, J NEUROIMMUNOL, V113, P193, DOI 10.1016/S0165-5728(00)00441-0; DAVID S, 1981, SCIENCE, V214, P931, DOI 10.1126/science.6171034; Emery E, 1998, J NEUROSURG, V89, P911, DOI 10.3171/jns.1998.89.6.0911; Grossman SD, 2001, EXP NEUROL, V168, P273, DOI 10.1006/exnr.2001.7628; HOLSTEGE G, 1991, PROG BRAIN RES, V87, P307; Honmou O, 1996, J NEUROSCI, V16, P3199; Hulsebosch CE, 2002, ADV PHYSIOL EDUC, V26, P238, DOI 10.1152/advan.00039.2002; Hurlbert RJ, 2001, SPINE, V26, pS39, DOI 10.1097/00007632-200112151-00009; Jander S, 2001, BRAIN PATHOL, V11, P27; Jones LL, 2003, EXP NEUROL, V182, P399, DOI 10.1016/S0014-4886(03)00087-6; Jurynec MJ, 2003, MOL CELL NEUROSCI, V23, P69, DOI 10.1016/S1044-7431(03)00019-8; KANG SK, 2006, STEM CELLS DEV, V15; Kiefer R, 2001, PROG NEUROBIOL, V64, P109, DOI 10.1016/S0301-0082(00)00060-5; Kim DSHL, 2004, BIOORG MED CHEM LETT, V14, P1287, DOI 10.1016/j.bmcl.2003.12.041; Kim DSHL, 2002, PLANTA MED, V68, P375, DOI 10.1055/s-2002-26757; Kobrine A I, 1975, Surg Neurol, V3, P261; Lai MD, 2005, INT J MOL MED, V15, P725; LaPlaca MC, 2001, J NEUROTRAUM, V18, P369, DOI 10.1089/089771501750170912; Li M, 2000, NEUROSCIENCE, V99, P333, DOI 10.1016/S0306-4522(00)00173-1; Liao CH, 2005, BIOCHEM BIOPH RES CO, V329, P1306, DOI 10.1016/j.bbrc.2005.02.110; Liu DX, 2000, J NEUROCHEM, V75, P2144, DOI 10.1046/j.1471-4159.2000.0752144.x; McTigue DM, 1998, J NEUROSCI RES, V53, P368, DOI 10.1002/(SICI)1097-4547(19980801)53:3<368::AID-JNR11>3.0.CO;2-1; MCTIGUE DM, 2002, PROG BRAIN RES, V128, P3; Omura T, 2005, BRAIN RES, V1057, P29, DOI 10.1016/j.brainres.2005.07.008; POPVICH PG, 1997, J COMP NEUROL, V377, P443; Ruemmele FM, 1999, BIOCHEM BIOPH RES CO, V260, P159, DOI 10.1006/bbrc.1999.0734; SANDLER AN, 1976, J NEUROSURG, V45, P638, DOI 10.3171/jns.1976.45.6.0638; Schwab ME, 1996, PHYSIOL REV, V76, P319; Scott GS, 2005, P NATL ACAD SCI USA, V102, P3483, DOI 10.1073/pnas.0500307102; Scott GS, 1999, ANN NEUROL, V45, P120, DOI 10.1002/1531-8249(199901)45:1<120::AID-ART18>3.0.CO;2-I; Skaper SD, 2003, ANN NY ACAD SCI, V993, P217, DOI 10.1111/j.1749-6632.2003.tb07532.x; Springer JE, 1999, NAT MED, V5, P943, DOI 10.1038/11387; Sribnick EA, 2005, J NEUROSCI RES, V82, P283, DOI 10.1002/jnr.20622; Taoka Y, 1997, NEUROSCIENCE, V79, P1177, DOI 10.1016/S0306-4522(97)00011-0; Taoka Y, 1998, PROG NEUROBIOL, V56, P341, DOI 10.1016/S0301-0082(98)00049-5; TATOR CH, 1995, BRAIN PATHOL, V5, P407, DOI 10.1111/j.1750-3639.1995.tb00619.x; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Teng YD, 2004, P NATL ACAD SCI USA, V101, P3071, DOI 10.1073/pnas.0306239101; Teng YD, 1997, J NEUROSCI, V17, P4359; TETZLAFF W, 1994, PROG BRAIN RES, V103, P271; Tikka T, 2001, J NEUROSCI, V21, P2580, DOI 10.1523/JNEUROSCI.21-08-02580.2001; Whalen MJ, 2000, ACT NEUR S, V76, P61; Xu J, 2001, J NEUROTRAUM, V18, P523, DOI 10.1089/089771501300227323; Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769	53	35	36	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	AUG	2006	24	4					1042	1052		10.1111/j.1460-9568.2006.04908.x			11	Neurosciences	Neurosciences & Neurology	076TE	WOS:000239979800009	16930431				2021-06-18	
J	Bond, CE; Patel, P; Crouch, L; Tetlow, N; Day, T; Abu-Hayyeh, S; Williamson, C; Greenfield, SA				Bond, C. E.; Patel, P.; Crouch, L.; Tetlow, N.; Day, T.; Abu-Hayyeh, S.; Williamson, C.; Greenfield, S. A.			Astroglia up-regulate transcription and secretion of 'readthrough' acetylcholinesterase following oxidative stress	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						astrocyte; degeneration; hypoxia; neurotoxicity; rat; RNA	ALZHEIMERS-DISEASE; BUTYRYLCHOLINESTERASE; ASTROCYTES; EXPRESSION; VARIANTS; NEURONS; ROLES; BRAIN	Novel and diverse functions of glial cells are currently the focus of much attention [A. Volterra and J. Meldolesi (2005)Nature Rev. 6, 626-640]. Here we present evidence that rat astroglia release acetylcholinesterase (AChE) as part of their response to hypoxic damage. Exposure of astroglia to tert-butyl hydroperoxide, and hence oxidative stress, subsequently leads to a switching in mRNA from the classical membrane-bound T-AChE to a preferential increase in the splice variant for a soluble form, R-AChE, This change in expression is reflected in increased perinuclear and reduced cytoplasmic AChE staining of the insulted glial cells, with a concomitant and marked increase in extracellular secretion that peaks at 1 h post-treatment. An analogous increase in R-AChE, over a similar time scale, occurs in response to psychological stress [D. Kaufer et al. (1998)Nature 93, 373-377], as well as to head injury and stroke [E. Shohami et al. (1999)J. Neurotrauma 6, 365-76]. The data presented here suggest that glial cells may be key chemical intermediaries in such situations and, perhaps more generally in pathological conditions involving oxidative stress, such as neurodegeneration.	Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England; Univ London Imperial Coll Sci Technol & Med, Inst Reprod & Dev Biol, London W12 0NN, England	Bond, CE (corresponding author), Univ Oxford, Dept Pharmacol, Mansfield Rd, Oxford OX1 3QT, England.	cherie.bond@pharm.ox.ac.uk		Williamson, Catherine/0000-0002-6226-7611			Allen Matthew, 1994, Clinical Materials, V16, P189; ARENDT T, 1992, NEUROCHEM INT, V21, P381, DOI 10.1016/0197-0186(92)90189-X; Coleman BA, 1996, J BIOL CHEM, V271, P4410; Day T, 2002, NEUROSCIENCE, V111, P649, DOI 10.1016/S0306-4522(02)00031-3; Desagher S, 1996, J NEUROSCI, V16, P2553; Dori A, 2005, CEREB CORTEX, V15, P419, DOI 10.1093/cercor/bhh145; Dringen R, 1998, GLIA, V23, P139, DOI 10.1002/(SICI)1098-1136(199806)23:2<139::AID-GLIA5>3.0.CO;2-1; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; Eriksson M, 2000, J BIOL CHEM, V275, P19964, DOI 10.1074/jbc.M001592200; Greenfield S, 2002, NEUROSCIENCE, V113, P485, DOI 10.1016/S0306-4522(02)00194-X; Grisaru D, 1999, EUR J BIOCHEM, V264, P672, DOI 10.1046/j.1432-1327.1999.00693.x; HEDREEN JC, 1985, J HISTOCHEM CYTOCHEM, V33, P134, DOI 10.1177/33.2.2578498; Kaufer D, 1998, NATURE, V393, P373, DOI 10.1038/30741; Keymer JE, 1999, EUR J NEUROSCI, V11, P1049, DOI 10.1046/j.1460-9568.1999.00510.x; Marchetti B, 2005, BRAIN RES REV, V48, P129, DOI 10.1016/j.brainresrev.2004.12.002; Meshorer E, 2004, J BIOL CHEM, V279, P29740, DOI 10.1074/jbc.M402752200; Patel P, 2003, PLACENTA, V24, P39, DOI 10.1053/plac.2002.0879; Pick M, 2004, ANN NY ACAD SCI, V1018, P85, DOI 10.1196/annals.1296.010; Saez-Valero J, 2003, NEUROSCI LETT, V348, P123, DOI 10.1016/S0304-3940(03)00790-0; Shohami E, 1999, J NEUROTRAUM, V16, P365, DOI 10.1089/neu.1999.16.365; Soreq H, 2001, NAT REV NEUROSCI, V2, P294, DOI 10.1038/35067589; Toiber D, 2005, NEUROCHEM RES, V30, P909, DOI 10.1007/s11064-005-6963-8; Volterra A, 2005, NAT REV NEUROSCI, V6, P626, DOI 10.1038/nrn1722; Whyte KA, 2003, EXP NEUROL, V184, P496, DOI 10.1016/S0014-4886(03)00386-8	24	35	37	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	JUL	2006	24	2					381	386		10.1111/j.1460-9568.2006.04898.x			6	Neurosciences	Neurosciences & Neurology	065IH	WOS:000239152900006	16903848				2021-06-18	
J	Kurpius, D; Wilson, N; Fuller, L; Hoffman, A; Dailey, ME				Kurpius, Dana; Wilson, Nicholas; Fuller, Leah; Hoffman, Amara; Dailey, Michael E.			Early activation, motility, and homing of neonatal microglia to injured neurons does not require protein synthesis	GLIA			English	Article						brain slice; time-lapse; motility; migration; anisomycin; CNS trauma; LFA-1; ED1	HIPPOCAMPAL SLICE CULTURES; NF-KAPPA-B; ADHESION MOLECULE EXPRESSION; TRAUMATIC BRAIN-INJURY; NECROSIS-FACTOR-ALPHA; FACIAL MOTOR NUCLEUS; IN-VITRO; EXTRACELLULAR-MATRIX; RAT-BRAIN; CELLS	Neuronal injury in CNS tissues induces a rapid activation and mobilization of resident microglia (MG). It is widely assumed that changes in gene expression drive the morphological transformation of MG and regulate their mobilization during activation. Here, we used acutely excised neonatal rat brain slices to test whether the morphological transformation and homing of MG to injured neurons requires gene expression and de novo protein synthesis. Traumatic injury during excision of live brain tissue slices induces a rapid and transient translocation of a transcription factor, NF-kappa B, to nuclei in MG. This is followed within 4-8 h by an increase in immunolabeling for cell adhesion molecules and lysosomal proteins, accompanied by changes in cell morphology. Application of anisomycin, a protein synthesis inhibitor, prevents the increase in immunolabeling for markers of MG activation but not the morphological transformation. Confocal time-lapse imaging in live tissue slices indicates that MG cell motility (branch extension and retraction) and locomotion are unaffected by anisomycin at early postinjury time-points (< 4 h), while at later timepoints (4-8 h postinjury) MG locomotion but not motility is inhibited. Thus, activated MG rapidly localize to injure pyramidal neuron cell bodies by 4-h postinjury, even in the presence of anisomycin. Moreover, this early MG activation and homing to injured neurons is unaffected in tissue slices from beta 2 integrin deficient mice. These results indicate that gene activation and new protein synthesis coincide with, but are not necessary for, the rapid morphological transformation and early migration-dependent homing of activated MG to injured neurons in CNS tissues. (c) 2006 Wiley-Liss, Inc.	Univ Iowa, Dept Biol Sci, Iowa City, IA 52242 USA	Dailey, ME (corresponding author), Univ Iowa, Dept Biol Sci, 369 Biol Bldg, Iowa City, IA 52242 USA.	Michael-e-dailey@uiowa.edu			NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [S10 RR017941] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS43468, R01 NS043468] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [S10RR017941] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS043468] Funding Source: NIH RePORTER		Abd-El-Basset EM, 2004, MED PRIN PRACT, V13, P325, DOI 10.1159/000080469; AKIYAMA H, 1990, J NEUROIMMUNOL, V30, P81, DOI 10.1016/0165-5728(90)90055-R; Bellander BM, 2004, J NEUROTRAUM, V21, P605, DOI 10.1089/089771504774129937; Bernardino L, 2005, J NEUROSCI, V25, P6734, DOI 10.1523/JNEUROSCI.1510-05.2005; Bianco F, 2005, BRAIN RES REV, V48, P144, DOI 10.1016/j.brainresrev.2004.12.004; Boucsein C, 2000, EUR J NEUROSCI, V12, P2049, DOI 10.1046/j.1460-9568.2000.00100.x; Brauer AU, 2004, FEBS LETT, V563, P41, DOI 10.1016/S0014-5793(04)00244-3; Brockhaus J, 1996, GLIA, V16, P81, DOI 10.1002/(SICI)1098-1136(199601)16:1<81::AID-GLIA9>3.0.CO;2-E; Carbonell WS, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-5; Carbonell WS, 2005, J NEUROSCI, V25, P7040, DOI 10.1523/JNEUROSCI.5171-04.2005; DAILEY ME, 2005, IMAGING NEUROSCIENCE; Dalmau I, 1998, HIPPOCAMPUS, V8, P458, DOI 10.1002/(SICI)1098-1063(1998)8:5<458::AID-HIPO6>3.3.CO;2-E; DAMOISEAUX JGMC, 1994, IMMUNOLOGY, V83, P140; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Dong JH, 2004, GLIA, V47, P102, DOI 10.1002/glia.10355; Elkabes S, 1996, J NEUROSCI, V16, P2508; Eugenin EA, 2001, P NATL ACAD SCI USA, V98, P4190, DOI 10.1073/pnas.051634298; Farber K, 2005, BRAIN RES REV, V48, P133, DOI 10.1016/j.brainresrev.2004.12.003; GRAEBER MB, 1990, J NEUROIMMUNOL, V27, P121, DOI 10.1016/0165-5728(90)90061-Q; Grossmann R, 2002, GLIA, V37, P229, DOI 10.1002/glia.10031; Hailer NP, 1996, GLIA, V18, P319, DOI 10.1002/(SICI)1098-1136(199612)18:4<319::AID-GLIA6>3.0.CO;2-S; Hailer NP, 1997, HIPPOCAMPUS, V7, P341, DOI 10.1002/(SICI)1098-1063(1997)7:3<341::AID-HIPO8>3.0.CO;2-N; Hanisch UK, 2002, GLIA, V40, P140, DOI 10.1002/glia.10161; Heppner FL, 1998, EUR J NEUROSCI, V10, P3284, DOI 10.1046/j.1460-9568.1998.00379.x; Honda S, 2001, J NEUROSCI, V21, P1975, DOI 10.1523/JNEUROSCI.21-06-01975.2001; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Kalla R, 2001, J COMP NEUROL, V436, P182; KALTSCHMIDT C, 1994, J NEUROIMMUNOL, V55, P99, DOI 10.1016/0165-5728(94)90151-1; Kloss CUA, 1999, J COMP NEUROL, V411, P162, DOI 10.1002/(SICI)1096-9861(19990816)411:1<162::AID-CNE12>3.0.CO;2-W; Kloss CUA, 2001, EXP NEUROL, V168, P32, DOI 10.1006/exnr.2000.7575; Koenigsknecht J, 2004, J NEUROSCI, V24, P9838, DOI 10.1523/JNEUROSCI.2557-04.2004; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; KURPIUS D, 2005, IMAGING NEUROSCIENCE; Milner R, 2003, J IMMUNOL, V170, P3850, DOI 10.4049/jimmunol.170.7.3850; Milner R, 2002, J NEUROSCI, V22, P1562, DOI 10.1523/JNEUROSCI.22-05-01562.2002; MONETA ME, 1993, J NEUROIMMUNOL, V45, P203, DOI 10.1016/0165-5728(93)90181-W; NAKAJIMA K, 2005, NEUROGLIA; Nasu-Tada K, 2005, GLIA, V52, P98, DOI 10.1002/glia.20224; Nelson DE, 2004, SCIENCE, V306, P704, DOI 10.1126/science.1099962; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; Olsen IM, 2005, BMC BIOL, V3, DOI 10.1186/1741-7007-3-25; Origasa M, 2001, MOL BRAIN RES, V88, P1, DOI 10.1016/S0169-328X(01)00005-5; Petersen MA, 2004, GLIA, V46, P195, DOI 10.1002/glia.10362; Raivich G, 1999, BRAIN RES REV, V30, P77, DOI 10.1016/S0165-0173(99)00007-7; Rappert A, 2002, J IMMUNOL, V168, P3221, DOI 10.4049/jimmunol.168.7.3221; Rappert A, 2004, J NEUROSCI, V24, P8500, DOI 10.1523/JNEUROSCI.2451-04.2004; Saccani S, 2001, J EXP MED, V193, P1351, DOI 10.1084/jem.193.12.1351; Sanz O, 2002, J NEUROSCI RES, V67, P772, DOI 10.1002/jnr.10140; Sasaki Y, 2001, BIOCHEM BIOPH RES CO, V286, P292, DOI 10.1006/bbrc.2001.5388; Schiefer J, 1999, J NEUROCYTOL, V28, P439, DOI 10.1023/A:1007048903862; Stence N, 2001, GLIA, V33, P256, DOI 10.1002/1098-1136(200103)33:3<256::AID-GLIA1024>3.0.CO;2-J; STREIT WJ, 1993, GLIA, V7, P68, DOI 10.1002/glia.440070112; STREIT WJ, 1987, J NEUROCYTOL, V16, P249, DOI 10.1007/BF01795308; Ullrich O, 2001, NAT CELL BIOL, V3, P1035, DOI 10.1038/ncb1201-1035; WILSON RW, 1993, J IMMUNOL, V151, P1571; Witting A, 2000, J NEUROCHEM, V75, P1060, DOI 10.1046/j.1471-4159.2000.0751060.x; Yu NC, 1998, NEUROIMMUNOMODULAT, V5, P42, DOI 10.1159/000026325; Zuckerman SH, 1998, INFLAMMATION, V22, P95, DOI 10.1023/A:1022351908951	59	35	38	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	JUL	2006	54	1					58	70		10.1002/glia.20355			13	Neurosciences	Neurosciences & Neurology	050JZ	WOS:000238084900006	16715500				2021-06-18	
J	Rinne, MB; Pasanen, ME; Vartiainen, MV; Lehto, TM; Sarajuuri, JM; Alaranta, HT				Rinne, Marjo B.; Pasanen, Matti E.; Vartiainen, Matti V.; Lehto, Tommi M.; Sarajuuri, Jaana M.; Alaranta, Hannu T.			Motor performance in physically well-recovered men with traumatic brain injury	JOURNAL OF REHABILITATION MEDICINE			English	Article; Proceedings Paper	5th World Congress on Traumatic Brain Injury	MAY, 2003	STOCKHOLM, SWEDEN			brain injury; motor skills; psychomotor performance; rehabilitation	INTERRATER RELIABILITY; TEST BATTERY; IDENTIFICATION; POPULATION; MODERATE; ADULTS; MILD	Objective: The primary aim of this study was to compare the motor performance of physically well-recovered men with traumatic brain injury with that of healthy men. Design: Cross-sectional study in a national rehabilitation centre. Methods: Static and dynamic balance, agility and rhythm co-ordination of men with traumatic brain injury ( n = 34) and healthy controls ( n = 36) were assessed. Between-group differences in dynamic balance and agility were analysed by analysis of covariance and differences in static balance and rhythm co-ordination by logistic regression analysis. Cut-off points for clinical screening were determined by receiver operating characteristics analyses. Results: Men with traumatic brain injury had impaired balance and agility compared with healthy men and in a rhythm co-ordination test they had difficulties in starting and sustaining simultaneous rhythmical movements of hands and feet. In receiver operating characteristics analyses a running figure-of-eight test ( agility), tandem walking forwards ( dynamic balance) and rhythm co-ordination test with fast tempo were found the most sensitive and specific for distinguishing between men with traumatic brain injury and the healthy men. Conclusions: The impairments in motor performance of physically well-recovered patients with traumatic brain injury were obvious. The results of this study extend the knowledge of problems in motor performance among patients with traumatic brain injury and provide further information for clinical rehabilitation.	UKK Inst Hlth Promot Res, FI-33501 Tampere, Finland; Kapyla Rehabil Ctr, Helsinki, Finland	Rinne, MB (corresponding author), UKK Inst Hlth Promot Res, POB 30, FI-33501 Tampere, Finland.	marjo.rinne@uta.fi	Sarajuuri, Jaana/AAD-8665-2019	Sarajuuri, Jaana/0000-0002-6432-0295			Alaranta H, 2000, Wien Med Wochenschr, V150, P444; Azouvi P, 2004, NEUROPSYCHOLOGIA, V42, P1260, DOI 10.1016/j.neuropsychologia.2004.01.001; Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Dombovy ML, 1997, BRAIN INJURY, V11, P305, DOI 10.1080/026990597123467; Feinstein AR, 1985, CLIN EPIDEMIOLOGY AR; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; Hillier SL, 1997, BRAIN INJURY, V11, P649; Laukkanen R, 1993, MED SCI; Masanic CA, 1998, ARCH PHYS MED REHAB, V79, P811, DOI 10.1016/S0003-9993(98)90361-6; MCGUIRE SA, 1995, NEUROLOGY, V45, pA328; NEWTON RA, 1995, BRAIN INJURY, V9, P445, DOI 10.3109/02699059509008204; PELOSO PM, 1987, J REHAB MED S, V43, P22; Quinn B, 2000, BRAIN INJURY, V14, P1063; Rinne MB, 2001, INT J SPORTS MED, V22, P192, DOI 10.1055/s-2001-16384; RMITAGE P, 2002, STAT METHODS MED RES; Sosin DM, 1996, BRAIN INJURY, V10, P47; Suni JH, 1998, PHYS THER, V78, P134, DOI 10.1093/ptj/78.2.134; TEGNER Y, 1986, AM J SPORT MED, V14, P156, DOI 10.1177/036354658601400212	20	35	35	0	7	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	JUL	2006	38	4					224	229		10.1080/16501970600582989			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	057QK	WOS:000238610100004	16801204	DOAJ Gold			2021-06-18	
J	Huang, SJ; Chang, L; Han, YY; Lee, YC; Tu, YK				Huang, Sheng-Jean; Chang, Lin; Han, Yin-Yi; Lee, Yuan-Chi; Tu, Yong-Kwang			Efficacy and safety of hypertonic saline solutions in the treatment of severe head injury	SURGICAL NEUROLOGY			English	Article						severe head injury; intracranial pressure; hypertonic saline; cerebral blood flow	ELEVATED INTRACRANIAL-PRESSURE; LACTATED RINGERS SOLUTION; MALIGNANT CEREBRAL EDEMA; TRAUMATIC BRAIN-INJURY; HEMORRHAGIC-SHOCK; INTRACEREBRAL HEMORRHAGE; WATER-CONTENT; BLOOD-FLOW; RESUSCITATION; MANNITOL	Background: The present study was undertaken to evaluate the efficacy and safety of hypertonic saline (HS) in the treatment of intracranial hypertension after severe head injury. Methods: This prospective, observational study was performed in an 11-bed neurosurgery intensive care unit of a teaching hospital. From February 2002 to September 2004, 18 severely head-injured patients with elevated intracranial pressure (ICP) and Glasgow Coma Scale scores of 5 to 8 (mean, 5.9 +/- 1.2) were admitted to the unit and treated according to a standard protocol. One dose per day of 3% saline was administered by rapid infusion (300 mL/20 min) when ICP values exceeded 20 min Hg. After infusion, cerebral blood flow, ICP, blood pressure, end-tidal carbon dioxide, and heart rate were monitored continuously for 60 minutes and recorded. Serum osmolarity, sodium, potassium, chloride, arterial carbon dioxide pressure, arterial oxygen pressure, hemoglobin, lactic acid, and pH were measured immediately before infusion (zero time) and 20 and 60 minutes after infusion. Mean arterial pressure, cerebral perfusion pressure (CPP), mean flow velocity (MFV), and pulsatility index (PI) were also recorded and analyzed. Results: Intracranial pressure fell immediately after initiation of infusion with further significant decreases observed at 20 and 60 minutes (30.4 +/- 8.5, 24.3 +/- 7.4, and 23.8 +/- 8.3 mm Hg, respectively; P < .01). At these respective times CPP increased significantly (78.7 +/- 8.7. 83.2 +/- 7.8, and 87.2 +/- 12.8 min Hg), PI dropped rapidly (1.51 +/- 0.42, 1.38 +/- 0.32, and 1.34 +/- 0.33) and MFV increased (66.26 +/- 25.91, 71.92 +/- 28.13, and 68.74 +/- 28.44). Serum sodium increased from 141.3 +/- 7.2 to 146.3 +/- 7.2 mmol/L after 20 minutes and returned to 144.3 +/- 7.36 mmol/L at 60 minutes. Potassium concentrations decreased significantly from 3.9 +/- 0.39 to 3.55 +/- 0.35 mmoUL after 20 minutes (P < .01). Lactic acid values at 0, 20, and 60 minutes were 1.6 +/- 0.5, 1.47 +/- 0.48, and 1.38 +/- 0.53 mmol/L, respectively (P < .01). Conclusion: Rapid infusion of single dose daily of HS is a safe alternative for the treatment of elevated ICP in severe head injury. Further evaluations of long-term consequences and complications and of maximal tolerance to this treatment are required. (c) 2006 Elsevier Inc. All rights reserved.	Natl Taiwan Univ Hosp, Dept Surg, Div Neurosurg, Taipei 100, Taiwan; Natl Taiwan Univ Hosp, Dept Traumatol, Taipei 100, Taiwan	Tu, YK (corresponding author), Natl Taiwan Univ Hosp, Dept Surg, Div Neurosurg, Taipei 100, Taiwan.	yktu@ha.mc.ntu.edu.tw		HAN, YIN-YI/0000-0001-8831-7835; Tu, Yong-kwang/0000-0003-2113-1176			ANISH B, 2004, CURR OPIN CRIT CARE, V10, P126; Bacher A, 1998, CRIT CARE MED, V26, P108, DOI 10.1097/00003246-199801000-00024; BINGAMAN WE, 1995, NEUROL CLIN, V13, P479, DOI 10.1016/S0733-8619(18)30031-8; BLECK TP, 1995, MAYO CLIN PROC, V70, P195, DOI 10.4065/70.2.195; CARDEN DL, 1989, RESUSCITATION, V17, P153, DOI 10.1016/0300-9572(89)90067-1; DAVIS JW, 1994, J TRAUMA, V36, P168, DOI 10.1097/00005373-199402000-00002; DUCEY JP, 1989, J TRAUMA, V29, P1510, DOI 10.1097/00005373-198911000-00010; DUCEY JP, 1990, CRIT CARE MED, V18, P744, DOI 10.1097/00003246-199007000-00013; FENSTERMACHER JD, 1966, AM J PHYSIOL, V211, P341; FRASER PA, 1990, J PHYSIOL-LONDON, V423, P343, DOI 10.1113/jphysiol.1990.sp018026; FRESHMAN SP, 1993, J TRAUMA, V35, P344, DOI 10.1097/00005373-199309000-00003; Gemma M, 1997, J NEUROSURG ANESTH, V9, P329, DOI 10.1097/00008506-199710000-00007; GOULIN GD, 1994, ANESTH ANALG, V79, P1036; GUNNAR W, 1988, SURGERY, V103, P398; Hariri R J, 1994, Neurosurg Clin N Am, V5, P687; Hartl R, 1997, ACT NEUR S, V70, P126; Horn P, 1999, NEUROL RES, V21, P758, DOI 10.1080/01616412.1999.11741010; HUANG SJ, 2005, CRIT CARE MED, V31, pY2559; JOSE IS, 2004, CLEVE CLIN J MED S1, V71, pS9; Kempski O, 2005, CRIT CARE MED, V33, P259, DOI 10.1097/01.CCM.0000151046.70094.4C; Kempski O, 1997, J TRAUMA, V42, pS38, DOI 10.1097/00005373-199705001-00007; Kempski O, 1996, ACT NEUR S, V66, P114; Khanna S, 2000, CRIT CARE MED, V28, P1144, DOI 10.1097/00003246-200004000-00038; Lang E W, 1994, Neurosurg Clin N Am, V5, P573; Laureno R, 1997, ANN INTERN MED, V126, P57, DOI 10.7326/0003-4819-126-1-199701010-00008; Maeda T, 2003, ACT NEUR S, V86, P329; Marion DW, 1997, CONT NEUROSURG, V19, P1; MATTEUCCI MJ, 1993, J TRAUMA, V34, P1, DOI 10.1097/00005373-199301000-00001; MOSS GS, 1988, AM J SURG, V155, P425, DOI 10.1016/S0002-9610(88)80106-5; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Peterson B, 2000, CRIT CARE MED, V28, P1136, DOI 10.1097/00003246-200004000-00037; PRIEN T, 1993, ZBL CHIR, V118, P257; PROUGH DS, 1985, CRIT CARE MED, V13, P407, DOI 10.1097/00003246-198505000-00008; PROUGH DS, 1986, J NEUROSURG, V64, P627, DOI 10.3171/jns.1986.64.4.0627; Qureshi AI, 1999, NEUROSURGERY, V44, P1055, DOI 10.1097/00006123-199905000-00064; Qureshi AI, 1999, J TRAUMA, V47, P659, DOI 10.1097/00005373-199910000-00009; Qureshi AI, 1998, CRIT CARE MED, V26, P440, DOI 10.1097/00003246-199803000-00011; Qureshi AI, 1998, J NEUROSURG ANESTH, V10, P188, DOI 10.1097/00008506-199807000-00010; Rabinovici R, 1996, J SURG RES, V60, P176, DOI 10.1006/jsre.1996.0028; RAPOPORT SI, 1979, BRAIN RES, V172, P354, DOI 10.1016/0006-8993(79)90546-8; REED RL, 1991, J TRAUMA, V31, P8, DOI 10.1097/00005373-199101000-00002; SCHMOKER JD, 1991, J TRAUMA, V31, P1607, DOI 10.1097/00005373-199112000-00007; Schwarz S, 1998, STROKE, V29, P1550, DOI 10.1161/01.STR.29.8.1550; Schwarz S, 2002, STROKE, V33, P136, DOI 10.1161/hs0102.100877; SHACKFORD SR, 1994, J TRAUMA, V37, P899, DOI 10.1097/00005373-199412000-00005; SMITH HP, 1986, J NEUROSURG, V65, P820, DOI 10.3171/jns.1986.65.6.0820; Suarez JI, 1998, CRIT CARE MED, V26, P1118, DOI 10.1097/00003246-199806000-00038; TEASDALE G, 1974, LANCET, V2, P81; TODD MM, 1985, J NEUROSURG, V63, P944, DOI 10.3171/jns.1985.63.6.0944; Tollofsrud S, 1998, ACTA ANAESTH SCAND, V42, P145, DOI 10.1111/j.1399-6576.1998.tb05100.x; Tollofsrud S, 1998, ACTA ANAESTH SCAND, V42, P154, DOI 10.1111/j.1399-6576.1998.tb05101.x; Toung TJK, 2005, CRIT CARE MED, V33, P203, DOI 10.1097/01.CCM.0000150659.15558.23; Tseng MY, 2003, STROKE, V34, P1389, DOI 10.1161/01.STR.0000071526.45277.44; WORTHLEY LIG, 1988, J NEUROSURG, V68, P478, DOI 10.3171/jns.1988.68.3.0478; ZORNOW MH, 1989, J TRAUMA, V29, P484, DOI 10.1097/00005373-198904000-00011; Zornow MH, 1996, J NEUROSURG ANESTH, V8, P175, DOI 10.1097/00008506-199604000-00021	56	35	42	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0090-3019			SURG NEUROL	Surg. Neurol.	JUN	2006	65	6					539	546		10.1016/j.surneu.2005.11.019			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	052NI	WOS:000238240000005	16720165				2021-06-18	
J	King, KA; Hough, MS; Walker, MM; Rastatter, M; Holbert, D				King, Kristin A.; Hough, Monica S.; Walker, Marianna M.; Rastatter, Michael; Holbert, Don			Mild traumatic brain injury: Effects on naming in word retrieval and discourse	BRAIN INJURY			English	Article						brain injury; word retrieval; naming; discourse	CLOSED HEAD-INJURY; ADULTS	Primary objective: To investigate differences between a group with mild traumatic brain injury (MTBI) and a control group relative to standard scores and error type during word retrieval in both naming and discourse tasks. Methods and procedures: Ten participants with MTBI were age-, gender- and education-matched with 10 participants without injury. Pre-experimental tasks for the participants with MTBI included the Scales of Cognitive Ability for Traumatic Brain Injury and the Raven's Coloured Progressive Matrices and both groups received the Peabody Picture Vocabulary Test-III. Experimental tasks included the Test of Adolescent/ Adult Word Finding and the Test of Word Finding in Discourse. Main outcomes and results: Few participants (three on each experimental task) demonstrated psychometrically-based word retrieval deficits (standard score < 85); however, a significant difference in performance for the TAWF as compared to the TWFD was observed between groups. More word finding errors occurred with confrontational naming than with discourse tasks for both groups, with latency as the primary error type. Conclusions: Confrontational naming tasks may be more sensitive to subtle language difficulties occurring after MTBI. The study of adults with MTBI and their performance on semantically-based tasks offers important information for the advancement of therapeutic intervention and education.	E Carolina Univ, Dept Commun Sci & Disorders, Greenville, NC USA; E Carolina Univ, Dept Biostat, Greenville, NC USA	King, KA (corresponding author), 108 A Sunshine Lane, Winterville, NC 28590 USA.	kak1002@ecu.edu		Walker, Marianna/0000-0002-6342-9088			Adamovich B. B., 1992, SCALES COGNITIVE ABI; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Barrow IM, 2003, J TRAUMA, V54, P888, DOI 10.1097/01.TA.0000057150.60668.7C; BASSETT SS, 1990, J PEDIATR PSYCHOL, V15, P225, DOI 10.1093/jpepsy/15.2.225; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; BERNAD PG, 1991, CLIN ELECTROENCEPHAL, V22, P203, DOI 10.1177/155005949102200408; COELHO C A, 1991, Brain Injury, V5, P381, DOI 10.3109/02699059109008111; Colohan A. R. T., 1986, J HEAD TRAUMA REHAB, V1, P13; Dunn L., 1998, PEABODY PICTURE VOCA; EVANS RW, 1992, TRAUMATIC BRAIN INJU, V3, P427; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; German D. J, 1990, TEST ADOLESCENT ADUL; German D.J., 1991, TEST WORD FINDING DI; German J. D., 1987, LANG SPEECH HEAR SER, V8, P217; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; JEANETTE B, 1974, LANCET, V2, P81; JORDAN F M, 1990, Brain Injury, V4, P147, DOI 10.3109/02699059009026159; Jordan F M, 1988, Brain Inj, V2, P179, DOI 10.3109/02699058809150943; Kaplan E., 1983, BOSTON NAMING TEST; Laforce R, 2001, PERCEPT MOTOR SKILL, V93, P281, DOI 10.2466/PMS.93.5.281-288; Levin H., 1979, J PEDIATR PSYCHOL, V4, P389, DOI DOI 10.1093/JPEPSY/4.4.389; LEVIN HS, 1981, BRAIN LANG, V12, P360, DOI 10.1016/0093-934X(81)90025-0; LILES BZ, 1989, J SPEECH HEAR DISORD, V54, P356, DOI 10.1044/jshd.5403.356; MCDONALD S, 1992, Brain Injury, V6, P283, DOI 10.3109/02699059209029670; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; Paniak C, 1998, J CLIN EXP NEUROPSYC, V20, P852, DOI 10.1076/jcen.20.6.852.1108; Raven L. C., 1956, RAVENS COLOURED PROG; Spreen O., 1977, NEUROSENSORY CTR COM; Ylvisaker M., 1986, J HEAD TRAUMA REHAB, V1, P48	29	35	36	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUN	2006	20	7					725	732		10.1080/02699050600743824			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	062LV	WOS:000238947200007	16809205				2021-06-18	
J	Klonoff, PS; Watt, LM; Dawson, LK; Henderson, SW; Gehrels, JA; Wethe, JV				Klonoff, Pamela S.; Watt, Lisa M.; Dawson, Lauren K.; Henderson, Steven W.; Gehrels, Jo-Ann; Wethe, Jennifer Voreis			Psychosocial outcomes 1-7 years after comprehensive milieu-oriented neurorehabilitation: The role of pre-injury status	BRAIN INJURY			English	Article						outcome; neurorehabilitation; brain injury; work; driving	TRAUMATIC BRAIN-INJURY; 11 YEARS POSTDISCHARGE; TERM-FOLLOW-UP; COMMUNITY INTEGRATION; REHABILITATION; PREDICTORS; EMPLOYMENT; VARIABLES; RETURN; SEVERITY	Primary objective: To explore pre-injury variables related to post-discharge psychosocial status and identify factors related to work and driving outcomes. Methods and procedures: Ninety-three brain-injured patients attended a holistic milieu-oriented neurorehabilitation program and were contacted 1-7 years post-discharge. Experimental interventions: Questionnaire data addressing pre-injury and post-injury work, driving, income, marital status and living situation. Main outcomes and results: 74.3% were involved in competitive work and/or school with 86.0% productive at follow-up. Post-injury income decreased significantly compared with pre-injury levels. Pre-injury relationship status did not differ significantly from post-injury; 81.1% remaining in a stable relationship or married at follow-up. Pre-injury and post-injury accident rates were related; 73.1% drove at follow-up. Higher education, non-right hemispheric injury, shorter treatment length and return to work related to driving. Younger age, higher education, non-right hemispheric injury and driving post-injury related to positive work status. Conclusions: Pre-injury psychosocial data provide an important context for understanding post-discharge outcome after brain injury. Holistic milieu-oriented rehabilitation facilitates long-term successful work, driving and relationship stability.	Barrow Neurol Inst, Ctr Trasit Neurorehabil, Catholic Healthcare W, Phoenix, AZ 85013 USA	Klonoff, PS (corresponding author), Barrow Neurol Inst, St Josephs Hosp & Med Ctr, CTN,222 W Thomas Rd,Suite 401, Phoenix, AZ 85013 USA.	pamela.klonoff@chw.edu					Ashley MJ, 1997, BRAIN INJURY, V11, P677; Cattelani R, 2002, BRAIN INJURY, V16, P51, DOI 10.1080/02699050110088821; Chesnut RM, 1999, J HEAD TRAUMA REHAB, V14, P176, DOI 10.1097/00001199-199904000-00007; Coleman RD, 2002, ARCH PHYS MED REHAB, V83, P1415, DOI 10.1053/apmr.2002.35111; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Feinstein A, 2001, MED SCI LAW, V41, P116, DOI 10.1177/002580240104100206; Formisano R, 2005, BRAIN INJURY, V19, P159, DOI 10.1080/02699050400017163; Franulic A, 2004, BRAIN INJURY, V18, P119, DOI 10.1080/0269905031000149515; Goranson TE, 2003, BRAIN INJURY, V17, P759, DOI 10.1080/0269905031000088513; Hartman-Maeir A, 2003, DISABIL REHABIL, V25, P35, DOI 10.1080/0963828021000007897; Haselkorn JK, 1998, ARCH PHYS MED REHAB, V79, P738, DOI 10.1016/S0003-9993(98)90349-5; Hoofien D, 2002, BRAIN INJURY, V16, P9, DOI 10.1080/02699050110088227; Johnstone B, 2003, ARCH PHYS MED REHAB, V84, P161, DOI 10.1053/apmr.2003.50098; Johnstone B, 2003, ARCH PHYS MED REHAB, V84, P238, DOI 10.1053/apmr.2003.50097; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Klonoff PS, 1998, ARCH PHYS MED REHAB, V79, P684, DOI 10.1016/S0003-9993(98)90045-4; Klonoff PS, 2001, BRAIN INJURY, V15, P413, DOI 10.1080/02699050010005968; Klonoff PS, 2000, ARCH PHYS MED REHAB, V81, P1535, DOI 10.1053/apmr.2000.9177; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Leon-Carrion J, 2005, BRAIN INJURY, V19, P213, DOI 10.1080/02699050400017205; Macmillan PJ, 2002, BRAIN INJURY, V16, P41, DOI 10.1080/0269905011008812; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Novack TA, 2000, BRAIN INJURY, V14, P987; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; PETERS L C, 1990, Brain Injury, V4, P39, DOI 10.3109/02699059009026147; Pietrapiana P, 2005, BRAIN INJURY, V19, P197, DOI 10.1080/02699050400017197; Schultheis MT, 2002, J HEAD TRAUMA REHAB, V17, P38, DOI 10.1097/00001199-200202000-00006; SUNDET K, 1995, SCAND J PSYCHOL, V36, P47, DOI 10.1111/j.1467-9450.1995.tb00967.x; Wagner AK, 2002, ARCH PHYS MED REHAB, V83, P107, DOI 10.1053/apmr.2002.27470; Wagner AK, 2000, J TRAUMA, V49, P411, DOI 10.1097/00005373-200009000-00005; Wehman P, 2003, ARCH PHYS MED REHAB, V84, P192, DOI 10.1053/apmr.2003.50027; Wood RL, 1997, BRAIN INJURY, V11, P491, DOI 10.1080/713802183	35	35	35	0	1	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUN	2006	20	6					601	612		10.1080/02699050600744301			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	062LU	WOS:000238947100005	16754285				2021-06-18	
J	Slobounov, S; Slobounov, E; Newell, K				Slobounov, Semyon; Slobounov, Elena; Newell, Karl			Application of virtual reality graphics in assessment of concussion	CYBERPSYCHOLOGY & BEHAVIOR			English	Article; Proceedings Paper	4th International Workshop on Virtual Rehabilitation (IWVR2005)	SEP, 2005	Los Angeles, CA				TRAUMATIC BRAIN-INJURY	Abnormal balance in individuals suffering from traumatic brain injury (TBI) has been documented in numerous recent studies. However, specific mechanisms causing balance deficits have not been systematically examined. This paper demonstrated the destabilizing effect of visual field motion, induced by virtual reality graphics in concussed individuals but not in normal controls. Fifty five student-athletes at risk for concussion participated in this study prior to injury and 10 of these subjects who suffered MTBI were tested again on day 3, day 10, and day 30 after the incident. Postural responses to visual field motion were recorded using a virtual reality (VR) environment in conjunction with balance (AMTI force plate) and motion tracking (Flock of Birds) technologies. Two experimental conditions were introduced where subjects passively viewed VR scenes or actively manipulated the visual field motion. Long-lasting destabilizing effects of visual field motion were revealed, although subjects were asymptomatic when standard balance tests were introduced. The findings demonstrate that advanced VR technology may detect residual symptoms of concussion at least 30 days post-injury.	Penn State Univ, Dept Kinesiol, University Pk, PA 16802 USA	Slobounov, S (corresponding author), Penn State Univ, Dept Kinesiol, University Pk, PA 16802 USA.	sms18@psu.edu					Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Jamet M, 2004, NEUROSCI LETT, V359, P61, DOI 10.1016/j.neulet.2004.02.010; Keshner E., 2000, J VESTIBUL RES-EQUIL, P1; KESHNER E, 2004, INT C DIS VIRT REAL; Keshner EA, 2004, ASSIST TECHNOL, V16, P54, DOI 10.1080/10400435.2004.10132074; MACH E, 1975, GRUNDLINIEN LEHRE BE; Nakamura S, 1999, PERCEPTION, V28, P893, DOI 10.1068/p2939; ROSENBERG JR, 1989, PROG BIOPHYS MOL BIO, V53, P1, DOI 10.1016/0079-6107(89)90004-7; Slobounov S, 2005, NEUROSCI LETT, V383, P251, DOI 10.1016/j.neulet.2005.04.039; Stuss D. T., 2002, PR FRONTAL LOBE FUNC, P392, DOI DOI 10.1093/ACPROF:OSO/9780195134971.003.0025; Thompson J, 2005, NEUROSCI LETT, V377, P158, DOI 10.1016/j.neulet.2004.11.090; WARREN R, 1976, J EXP PSYCHOL HUMAN, V2, P448, DOI 10.1037/0096-1523.2.3.448	12	35	35	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1094-9313			CYBERPSYCHOL BEHAV	CyberPsychol. Behav.	APR	2006	9	2					188	191		10.1089/cpb.2006.9.188			4	Communication; Psychology, Applied	Communication; Psychology	041PX	WOS:000237469200017	16640477				2021-06-18	
J	Hynes, LM; Dickey, JP				Hynes, LM; Dickey, JP			Is there a relationship between whiplash-associated disorders and concussion in hockey? A preliminary study	BRAIN INJURY			English	Article						whiplash associated disorders; concussion; hockey; atheletic injuries; brain injuries; whiplash; return to PLA	ICE HOCKEY; CONTACT SPORTS; INJURY; HEAD; KINEMATICS	Primary objective: To examine the relationship between the occurrence of whiplash-associated disorders and concussion symptoms in hockey players. Research design: Prospective cohort observational study to examine the relationship between whiplash associated disorders and concussion in actual hockey play. Methods and procedures: Twenty hockey teams were followed prospectively for one season. Team therapists completed acute and 7-10 day follow-up evaluation questionnaires for all of the players who received either a whiplash mechanism or a concussion. Main outcomes and results: 183 players were registered for this study; 13 received either a whiplash mechanistic injury or a concussion injury. Initial injuries ranged from WAD I to WAD III and all subjects reported concussion symptoms. Only three subjects reported full resolution of both WAD and concussion symptoms at the 7-10 day follow-up evaluation. Conclusions: There is a strong association between whiplash induced neck injuries and the symptoms of concussion in hockey injuries. Both should be evaluated when dealing with athletes/patients suffering from either injury.	Univ Guelph, ANNU 334, Guelph, ON N1G 2W1, Canada	Dickey, JP (corresponding author), Univ Guelph, ANNU 334, Guelph, ON N1G 2W1, Canada.	jdickey@uoguelph.ca	Dickey, James P/K-6776-2013	Dickey, James P/0000-0002-4101-835X			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Blouin JS, 2003, EXP BRAIN RES, V150, P458, DOI 10.1007/s00221-003-1466-9; Brault JR, 2000, CLIN BIOMECH, V15, P426, DOI 10.1016/S0268-0033(99)00097-2; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Cantu RC, 2000, SEMIN NEUROL, V20, P173, DOI 10.1055/s-2000-9825; Castro WHM, 2001, INT J LEGAL MED, V114, P316, DOI 10.1007/s004140000193; Cholewicki J, 1998, ACCIDENT ANAL PREV, V30, P469, DOI 10.1016/S0001-4575(97)00103-6; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Cooper MT, 2003, CLIN SPORT MED, V22, P427, DOI 10.1016/S0278-5919(02)00110-2; Gaetz M, 2000, BRAIN INJURY, V14, P815; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Goldsmith W, 2004, AM J FOREN MED PATH, V25, P89, DOI 10.1097/01.paf.0000127407.28071.63; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Kaneoka K, 1999, SPINE, V24, P763, DOI 10.1097/00007632-199904150-00006; Kelly KD, 2001, CLIN J SPORT MED, V11, P77, DOI 10.1097/00042752-200104000-00003; Koh JO, 2003, BRAIN INJURY, V17, P901, DOI 10.1080/0269905031000088869; Kumar S, 2002, SPINE, V27, P1044, DOI 10.1097/00007632-200205150-00009; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Luan F, 2000, CLIN BIOMECH, V15, P649, DOI 10.1016/S0268-0033(00)00031-0; Marchie A, 2003, CAN MED ASSOC J, V169, P124; McClune T, 2002, EMERG MED J, V19, P499, DOI 10.1136/emj.19.6.499; Schick DM, 2003, AM J SPORT MED, V31, P47, DOI 10.1177/03635465030310011901; Sim F H, 1978, Am J Sports Med, V6, P378, DOI 10.1177/036354657800600612; Spitzer W, 1995, SPINE, V20, P1, DOI DOI 10.1097/00007632-199504151-00001; STUART MJ, 1995, AM J SPORT MED, V23, P458, DOI 10.1177/036354659502300415; Wojtys EM, 1999, AM J SPORT MED, V27, P676, DOI 10.1177/03635465990270052401; Young WF, 2001, POSTGRAD MED, V109, P179, DOI 10.3810/pgm.2001.03.881	28	35	35	0	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	FEB	2006	20	2					179	188		10.1080/02699050500443707			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	003KX	WOS:000234681700008	16421067				2021-06-18	
J	Sanui, M; King, DR; Feinstein, AJ; Varon, AJ; Cohn, SM; Proctor, KG				Sanui, M; King, DR; Feinstein, AJ; Varon, AJ; Cohn, SM; Proctor, KG			Effects of arginine vasopressin during resuscitation from hemorrhagic hypotension after traumatic brain injury	CRITICAL CARE MEDICINE			English	Article; Proceedings Paper	Annual Meeting of the American-Society-of-Anesthesiologists	OCT 23-27, 2004	Las Vegas, NV	Amer Soc Anesthesiologists		shock; intracranial pressure; brain tissue Po-2; CO2 reactivity; cerebral perfusion pressure; swine	CEREBRAL PERFUSION-PRESSURE; ARTERIAL-HYPERTENSION; FLUID RESUSCITATION; VASODILATORY SHOCK; BISPECTRAL INDEX; LIVER TRAUMA; BLOOD-FLOW; OXYGEN; AUTOREGULATION; PATIENT	Objective: Two series of experiments were designed to evaluate whether early arginine vasopressin improves acute outcome following resuscitation from traumatic brain injury and severe hemorrhagic hypotension Design: Prospective randomized, blinded animal study. Setting. University laboratory. Subjects: Thirty-three swine. Interventions. In series 1 (n = 19), after traumatic brain injury with hemorrhage and 12 mins of shock (mean arterial pressure approximate to 20 mm Hg), survivors (n = 16) were initially resuscitated with 10 mL/kg crystalloid. After 30 mins, crystalloid and blood with either 0.1 unit.kg(-1).hr(-1) arginine vasopressin or placebo was titrated to a mean arterial pressure target >= 60 mm Hg. After 90 mins, all received mannitol and the target was cerebral perfusion pressure >= 60 mm Hg. To test cerebrovascular function, 7.5% inhaled CO2 was administered periodically. In series 2 (n = 14), the identical protocol was followed except the shock period was 20 mins and survivors (n = 10) received a bolus of either arginine vasopressin (0.2 units/kg) or placebo during the initial fluid resuscitation. Measurements and Main Results: In series 1, by 300 mins after traumatic brain injury with arginine vasopressin (n = 8) vs. placebo (n = 8), the fluid and transfusion requirements were reduced (both p <.01), intracranial pressure was improved (11 +/- 1 vs. 23 +/- 2 mmHg; p <.0001), and the CO2-evoked intracranial pressure elevation was reduced (7 +/- 2 vs. 26 +/- 3 mm Hg, p <.001), suggesting improved compliance. In series 2, with arginine vasopressin vs. placebo, cerebral perfusion pressure was more rapidly corrected (p <.05). With arginine vasopressin, five of five animals survived 300 mins, whereas three of five placebo animals died. The survival time with placebo was 54 +/- 4 mins (p <.05 vs. arginine vasopressin). Conclusions. Early supplemental arginine vasopressin rapidly corrected cerebral perfusion pressure, improved cerebrovascular compliance, and prevented circulatory collapse during fluid resuscitation of hemorrhagic shock after traumatic brain injury.	Univ Miami, Div Surg Crit Care, Daughtry Family Dept Surg, Miller Sch Med,Ryder Trauma Ctr, Miami, FL 33136 USA; Univ Miami, Dept Anesthesiol, Div Trauma Anesthesia & Crit Care, Miller Sch Med, Miami, FL 33136 USA; Univ Miami, Dept Surg, Div Trauma & Surg Crit Care, Miller Sch Med, Miami, FL 33136 USA	Proctor, KG (corresponding author), Univ Miami, Div Trauma, Daughtry Family Dept Surg, Miller Sch Med,Ryder Trauma Ctr, 1800 NW 10th Ave, Miami, FL 33136 USA.	sanui@omiya.jichi.ac.jp; cohn@uthscsa.edu; kproctor@miami.edu		Feinstein, Ara/0000-0001-6214-5334; King, David/0000-0003-1028-1478	NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32 GM08749-01] Funding Source: Medline		Argenziano M, 1997, CIRCULATION, V96, P286; BICKELL WH, 1994, NEW ENGL J MED, V331, P1105, DOI 10.1056/NEJM199410273311701; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P471; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P493; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P507; Chieregato A, 2003, ACTA NEUROCHIR SUPPL, V86, P361; Crookes BA, 2004, J TRAUMA, V57, P547, DOI 10.1097/01.TA.0000135162.85859.4C; DeWitt DS, 2000, CRIT CARE MED, V28, P3933, DOI 10.1097/00003246-200012000-00036; Dunser MW, 2003, CRIT CARE MED, V31, P1394, DOI 10.1097/01.CCM.0000059722.94182.79; Fowler R, 2002, EMERG MED CLIN N AM, V20, P953, DOI 10.1016/S0733-8627(02)00038-X; Hayashida M, 2003, BRIT J ANAESTH, V90, P694, DOI 10.1093/bja/aeg107; Hemphill JC, 2001, NEUROSURGERY, V48, P377, DOI 10.1097/00006123-200102000-00028; Holmes CL, 2001, CHEST, V120, P989, DOI 10.1378/chest.120.3.989; Holtzer S, 2001, CRIT CARE MED, V29, P1609, DOI 10.1097/00003246-200108000-00018; Huang Wei-dong, 2003, Chin J Traumatol, V6, P139; Kiening KL, 1997, NEUROL RES, V19, P233, DOI 10.1080/01616412.1997.11740805; King DR, 2004, SURGERY, V136, P355, DOI 10.1016/j.surg.2004.05.011; Krismer AC, 2005, ANAESTHESIST, V54, P220, DOI 10.1007/s00101-004-0793-y; Kroppenstedt SN, 2003, CRIT CARE MED, V31, P2211, DOI 10.1097/01.CCM.0000080482.06856.62; Kroppenstedt SN, 2000, CRIT CARE MED, V28, P3792, DOI 10.1097/00003246-200012000-00004; Landry DW, 1997, CIRCULATION, V95, P1122; Lang EW, 2003, CRIT CARE MED, V31, P267, DOI 10.1097/00003246-200301000-00042; Malay MB, 2004, CRIT CARE MED, V32, P1327, DOI 10.1097/01.CCM.0000128578.37822.F1; Malhotra AK, 2003, J NEUROTRAUM, V20, P827, DOI 10.1089/089771503322385764; MARSHALL WJ, 1969, ARCH NEUROL-CHICAGO, V21, P545, DOI 10.1001/archneur.1969.00480170117012; Masamoto K, 2003, BRAIN RES, V979, P104, DOI 10.1016/S0006-8993(03)02882-8; Meixensberger J, 2003, J NEUROL NEUROSUR PS, V74, P760, DOI 10.1136/jnnp.74.6.760; Morales D, 1999, CIRCULATION, V100, P226, DOI 10.1161/01.CIR.100.3.226; Myles PS, 2004, ANESTH ANALG, V98, P706; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Sahuquillo J, 1996, ACTA NEUROCHIR, V138, P435, DOI 10.1007/BF01420306; Stadlbauer KH, 2003, ANESTHESIOLOGY, V98, P699, DOI 10.1097/00000542-200303000-00018; Szmydynger-Chodobska J, 2004, J NEUROTRAUM, V21, P1090, DOI 10.1089/0897715041651033; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P521, DOI [10.1089/neu.2000.17.521, DOI 10.1089/NEU.2000.17.521]; Voelckel WG, 2003, CRIT CARE MED, V31, P1160, DOI 10.1097/01.CCM.0000060014.75282.69; Wenzel V, 2004, NEW ENGL J MED, V350, P105, DOI 10.1056/NEJMoa025431; Westphal M, 2003, CRIT CARE MED, V31, P1502, DOI 10.1097/01.CCM.0000063042.15272.84; Yeh CC, 2003, ANESTH ANALG, V97, P577, DOI 10.1213/01.ANE.0000070231.16378.A6; Zhao LX, 2004, J NEUROSCI, V24, P2226, DOI 10.1523/JNEUROSCI.4922-03.2004; Zhu Yan-xiang, 2003, Chin J Traumatol, V6, P152	41	35	36	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	FEB	2006	34	2					433	438		10.1097/01.CCM.0000196206.83534.39			6	Critical Care Medicine	General & Internal Medicine	008UF	WOS:000235065500021	16424725				2021-06-18	
J	Kim, H; Colantonio, A; Chipman, M				Kim, Hwan; Colantonio, Angela; Chipman, Mary			Traumatic brain injury occurring at work	NEUROREHABILITATION			English	Article; Proceedings Paper	1st International Conference on Vocational Outcomes in Traumatic Brain Injury	APR 14-16, 2005	Vancouver, CANADA			brain injury; occupational; epidemiology; Ontario Trauma Registry	CONSTRUCTION-INDUSTRY; HEAD-INJURIES; OUTCOMES	Introduction: Traumatic brain injury (TBI) occurring in the workplace carries major economic repercussions such as lost wages and hospital costs. Little is known about the profile of risk factors for work-related traumatic brain injury. Aims: This study describes the pre-injury demographic characteristics, injury- related characteristics and outcomes of work-related TBI and compares them with those of non work-related TBI. This study aims to provide profiles of work-related TBI to improve our understanding and awareness of TBI in the workplace and to better inform prevention efforts. Methods: Cross-sectional study using the Comprehensive Data Set (CDS) of Ontario (Canada) Trauma Registry (OTR) from 1993 to 2001. Cases with the ICD-9-CM codes for head injury were included in the database of serious injuries from lead trauma hospitals. Results: The study identified 950 (7.3%) people with work-related TBI. Pre-injury demographics and injury-related characteristics of work-related TBI were significantly different from non work-related TBI such as age, gender, mechanisms of injury, Injury Severity Score, length of stay and in-hospital death. Discussion: This research provides the first comprehensive overview of work-related TBI based on Canadian data. It identifies high risk profiles to better target prevention.	Univ Toronto, Dept Rehabil Sci, Toronto, ON, Canada; Univ Toronto, Grad Dept Occupat Sci & Occupat Therapy, Toronto, ON, Canada; Toronto Rehabil Inst, Toronto, ON, Canada; Univ Toronto, Dept Publ Hlth Sci, Toronto, ON, Canada	Kim, H (corresponding author), Grad Dept Rehabil Sci, 500 Univ Ave,Room 962, Toronto, ON M5G 1V7, Canada.	hwan.kim@utoronto.ca					ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; Bogner JA, 2001, ARCH PHYS MED REHAB, V82, P571, DOI 10.1053/apmr.2001.22340; *CIHI, 2001, ONT TRAUM REG 2001 R; *CIHI, 2002, ONT TRAUM REG B WORK; *CIHI, 2004, ONT TRAUM REG B MAJ; COLEMAN VP, 1986, J OCCUP ACCID, V8, P161, DOI 10.1016/0376-6349(86)90002-7; DEJONG G, 1982, ARCH PHYS MED REHAB, V63, P68; Fann JR, 2002, J NEUROL NEUROSUR PS, V72, P615, DOI 10.1136/jnnp.72.5.615; Garber BG, 1996, J TRAUMA, V40, P733, DOI 10.1097/00005373-199605000-00008; HEYER NJ, 1994, AM J PUBLIC HEALTH, V84, P1106, DOI 10.2105/AJPH.84.7.1106; Hsiao H, 2001, ERGONOMICS, V44, P537, DOI 10.1080/00140130110034480; Janicak CA, 1998, J OCCUP ENVIRON MED, V40, P347, DOI 10.1097/00043764-199804000-00009; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; KISNER SM, 1994, J OCCUP ENVIRON MED, V36, P137, DOI 10.1097/00043764-199402000-00008; KRAUS JF, 1985, J OCCUP ENVIRON MED, V27, P757; Lane PL, 1997, ACCIDENT ANAL PREV, V29, P53, DOI 10.1016/S0001-4575(96)00061-9; Langlois JA., 2004, TRAUMATIC BRAIN INJU; McGuire LM, 1998, BRAIN INJURY, V12, P207, DOI 10.1080/026990598122683; O'Connor C, 2005, PSYCHOL REP, V97, P169, DOI 10.2466/PR0.97.5.169-179; Peele PB, 2005, J OCCUP ENVIRON MED, V47, P424, DOI 10.1097/01.jom.0000158700.50594.0f; Pickett William, 2004, Chronic Dis Can, V25, P32; *STAT CAN, 2003, LAB FORC HIST REV; Tricco AC, 2006, BRAIN INJURY, V20, P719, DOI 10.1080/02699050600664640; Woo B. H., 2000, REHABILITATION PEOPL; *WSIB, 2004, STAT S 2004 ANN REP	25	35	35	0	4	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135			NEUROREHABILITATION	Neurorehabilitation		2006	21	4					269	278					10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	145VU	WOS:000244894700002	17361044				2021-06-18	
J	Marsh, NV; Martinovich, WM				Marsh, NV; Martinovich, WM			Executive dysfunction and domestic violence	BRAIN INJURY			English	Article						traumatic brain injury; domestic violence; executive dysfunction	HEAD-INJURY; AGGRESSION; BEHAVIOR; DEFICITS	Primary objective: To replicate previous studies which have reported a high prevalence of traumatic brain injury (TBI) in partner-abusive men and to extend research in this area by determining the prevalence of executive dysfunctions, which have been linked with both TBI and violent behaviour. Research design: Thirty-eight men with criminal convictions for violence and who were receiving treatment for abusing their partners were assessed. Methods and procedures: Subjects with a self-reported history of TBI (n = 22) were compared to the non-TBI group (n = 16) on various psychological measures. Main outcomes and results: The two groups were not significantly different on the variables of age, pre-morbid IQ, self-esteem and alcohol use. The TBI group scored more poorly than the non-TBI group on a measure of current IQ and two of the three measures of executive functioning. Conclusion: The presence of executive dysfunction has implications for the design of successful intervention programmes with this sub-group of batterers.	Univ New England, Sch Psychol, Armidale, NSW 2351, Australia; Univ Waikato, Dept Psychol, Hamilton, New Zealand	Marsh, NV (corresponding author), Univ New England, Sch Psychol, Armidale, NSW 2351, Australia.	nigel.marsh@une.edu.au	Marsh, Nigel V./F-5433-2019	Marsh, Nigel V./0000-0002-4060-6432			ANDERSON RM, 1994, PRACTITIONERS GUIDE; BOLL TJ, 1994, DIAGNOSTIC INTERVIEW, P46; Brower MC, 2001, J NEUROL NEUROSUR PS, V71, P720, DOI 10.1136/jnnp.71.6.720; Cohen R A, 1999, Violence Vict, V14, P397; Cohen RA, 2003, J INT NEUROPSYCH SOC, V9, P760, DOI 10.1017/S1355617703950090; Duncan J, 1997, COGNITIVE NEUROPSYCH, V14, P713, DOI 10.1080/026432997381420; Ehrensaft MK, 2003, J CONSULT CLIN PSYCH, V71, P741, DOI 10.1037/0022-006X.71.4.741; Felson RB, 2000, SOC PSYCHOL QUART, V63, P86, DOI 10.2307/2695883; Filley CM, 2001, NEUROPSY NEUROPSY BE, V14, P1; GILANDAS A, 1984, HDB NEUROPSYCHOLOGIC; Golden CJ, 1996, AGGRESS VIOLENT BEH, V1, P3, DOI 10.1016/1359-1789(95)00002-X; Holtzworth-Munroe A, 2000, COGNITIVE THER RES, V24, P135, DOI 10.1023/A:1005489807454; Jelicic M, 2001, INT J NEUROSCI, V110, P73, DOI 10.3109/00207450108994222; Krakowski M, 2003, J NEUROPSYCH CLIN N, V15, P294, DOI 10.1176/appi.neuropsych.15.3.294; Marsh NV, 2002, J CLIN EXP NEUROPSYC, V24, P434, DOI 10.1076/jcen.24.4.434.1030; MORSE PA, 1992, CLIN SYNDROMES ADULT, P84; Paschall MJ, 2002, AGGRESS VIOLENT BEH, V7, P215, DOI 10.1016/S1359-1789(00)00044-6; ROSENBAUM A, 1994, J CONSULT CLIN PSYCH, V62, P1187, DOI 10.1037/0022-006X.62.6.1187; ROSENBAUM A, 1989, AM J PSYCHIAT, V146, P1048; Rosenberg M., 1965, SOC ADOLESCENT SELF, DOI 10.1126/science.148.3671.804; SELZER ML, 1975, J STUD ALCOHOL, V36, P117, DOI 10.15288/jsa.1975.36.117; Shallice, 1997, HAYLING BRIXTON TEST; SHEPARD M, 1992, J FAM VIOLENCE, V7, P167, DOI 10.1007/BF00979025; Spreen O., 1998, COMPENDIUM NEUROPSYC; STATISTICS NEW ZEALAND, 1997, NZ SOC EC IND OCC ST; Tateno A, 2003, J NEUROPSYCH CLIN N, V15, P155, DOI 10.1176/appi.neuropsych.15.2.155; White R, 1992, CLIN SYNDROMES ADULT; Wilson, 1991, NATL ADULT READING T; Wilson BA, 1996, BEHAV ASSESSMENT DYS	29	35	37	0	11	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	2006	20	1					61	66		10.1080/02699050500110645			6	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	001AQ	WOS:000234505000007	16403701				2021-06-18	
J	Young, MJ				Young, MJ			Stem cells in the mammalian eye: a tool for retinal repair	APMIS			English	Article						stem cells; retina; regeneration; development	FIBROBLAST-GROWTH-FACTOR; ROD PHOTORECEPTOR DIFFERENTIATION; FIBRILLARY ACIDIC PROTEIN; NEURAL PROGENITOR CELLS; RAT RETINA; DOPAMINERGIC-NEURONS; FATE DETERMINATION; POLYMER SCAFFOLDS; ROYAL-COLLEGE; ANIMAL-MODEL	Degenerative diseases and traumatic injuries of the central nervous system (CNS) are major causes of long-term disability, whether such insults impact the brain, retina, or spinal cord. Substantial tissue destruction can be sustained by these complex structures without loss of life, while the lack of effective CNS regeneration frequently results in a marked degradation in quality of life. Only recently has it become clear that an enormous potential for regeneration is present within the mammalian CNS. The challenge now presented to researchers is to harness this potential to treat disease. Recent studies showing that stem and progenitor cells can be isolated from the mammalian retina have prompted many researchers to develop strategies aimed at restoring function to the diseased retina. This review summarizes a number of issues related to this goal, including retinal development, transplantation immunology, tissue engineering, and large animal studies. The application of these divergent disciplines to stem cell technology is vital to the development of the novel strategies needed to make retinal transplantation a clinical success.	Harvard Univ, Sch Med, Dept Ophthalmol, Schepens Eye Res Inst, Boston, MA 02114 USA	Young, MJ (corresponding author), Harvard Univ, Sch Med, Dept Ophthalmol, Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA.	mikey@vision.eri.harvard.edu					Ahmad I, 1997, DEV BIOL, V185, P92, DOI 10.1006/dbio.1997.8546; Alexiades MR, 1997, DEVELOPMENT, V124, P1119; Atala A, 2000, WORLD J UROL, V18, P364, DOI 10.1007/s003450000152; Bhattacharya S, 2003, INVEST OPHTH VIS SCI, V44, P2764, DOI 10.1167/iovs.02-0899; Brundin P, 2001, NAT MED, V7, P512, DOI 10.1038/87796; Brustle O, 1998, NAT BIOTECHNOL, V16, P1040, DOI 10.1038/3481; Cai JL, 2002, DEV BIOL, V251, P221, DOI 10.1006/dbio.2002.0828; Cao W, 1997, INVEST OPHTH VIS SCI, V38, P1358; Carrier RL, 1999, BIOTECHNOL BIOENG, V64, P580, DOI 10.1002/(SICI)1097-0290(19990905)64:5<580::AID-BIT8>3.0.CO;2-X; Castillo BV, 1997, EXP NEUROL, V146, P1, DOI 10.1006/exnr.1997.6534; CASTILLO BV, 1995, CURR EYE RES, V14, P677, DOI 10.3109/02713689508998495; Cepko CL, 1996, P NATL ACAD SCI USA, V93, P589, DOI 10.1073/pnas.93.2.589; Chu Y, 1998, AUST NZ J OPHTHALMOL, V26, P87, DOI 10.1046/j.1440-1606.1998.00068.x; Colthurst MJ, 2000, BIOMATERIALS, V21, P649, DOI 10.1016/S0142-9612(99)00220-3; Cook AD, 1997, J BIOMED MATER RES, V35, P513; Davis AA, 2000, MOL CELL NEUROSCI, V15, P11, DOI 10.1006/mcne.1999.0806; deRaad S, 1996, OPHTHALMIC RES, V28, P99, DOI 10.1159/000267881; DOWLING JE, 1970, INVEST OPHTH VISUAL, V9, P655; Dyer MA, 2003, NAT GENET, V34, P53, DOI 10.1038/ng1144; Emgard M, 2002, NEUROSCIENCE, V115, P1177, DOI 10.1016/S0306-4522(02)00480-3; Ezzeddine ZD, 1997, DEVELOPMENT, V124, P1055; Flax JD, 1998, NAT BIOTECHNOL, V16, P1033, DOI 10.1038/3473; FREED LE, 1994, BIO-TECHNOL, V12, P689, DOI 10.1038/nbt0794-689; GAGE FH, 1995, P NATL ACAD SCI USA, V92, P11879, DOI 10.1073/pnas.92.25.11879; Giordano GG, 1997, J BIOMED MATER RES, V34, P87, DOI 10.1002/(SICI)1097-4636(199701)34:1<87::AID-JBM12>3.0.CO;2-M; Goumans MJ, 2003, MOL CELL, V12, P817, DOI 10.1016/S1097-2765(03)00386-1; Hadlock T, 1998, ARCH OTOLARYNGOL, V124, P1081, DOI 10.1001/archotol.124.10.1081; HICKS D, 1992, J NEUROSCI, V12, P2022; Humayun MS, 2000, INVEST OPHTH VIS SCI, V41, P3100; Hyatt GA, 1996, P NATL ACAD SCI USA, V93, P13298, DOI 10.1073/pnas.93.23.13298; Inoue T, 2002, DEVELOPMENT, V129, P831; Karlsson J, 2002, BRAIN RES, V955, P268, DOI 10.1016/S0006-8993(02)03601-6; KELLEY MW, 1994, DEVELOPMENT, V120, P2091; Kelley MW, 1999, NEUROREPORT, V10, P2389, DOI 10.1097/00001756-199908020-00031; Klassen H, 2004, PROG RETIN EYE RES, V23, P149, DOI 10.1016/j.preteyeres.2004.01.002; KLASSEN H, 1987, P NATL ACAD SCI USA, V84, P6958, DOI 10.1073/pnas.84.19.6958; Klassen H, 2001, NEUROSCI LETT, V312, P180, DOI 10.1016/S0304-3940(01)02215-7; Klassen HJ, 2004, INVEST OPHTH VIS SCI, V45, P4167, DOI 10.1167/iovs.04-0511; Lai LX, 2002, MOL REPROD DEV, V62, P300, DOI 10.1002/mrd.10146; Langer R, 2000, ACCOUNTS CHEM RES, V33, P94, DOI 10.1021/ar9800993; Lavik EB, 2005, BIOMATERIALS, V26, P3187, DOI 10.1016/j.biomaterials.2004.08.022; Lavik EB, 2001, J BIOMED MATER RES, V58, P291, DOI 10.1002/1097-4636(2001)58:3<291::AID-JBM1019>3.0.CO;2-N; Lebrin F, 2004, EMBO J, V23, P4018, DOI 10.1038/sj.emboj.7600386; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Levine EM, 1997, J NEUROSCI, V17, P6277; Li ZY, 1998, INVEST OPHTH VIS SCI, V39, P808; Libby RT, 1996, INVEST OPHTH VIS SCI, V37, P1651; Little CW, 1998, EXP NEUROL, V149, P151, DOI 10.1006/exnr.1997.6642; Little CW, 1996, INVEST OPHTH VIS SCI, V37, P204; Love RM, 2002, CELL TRANSPLANT, V11, P653, DOI 10.3727/000000002783985431; LUND R, 2000, NERVOUS CONTROL EYE; Lund RD, 1997, OPHTHALMIC RES, V29, P305, DOI 10.1159/000268029; Mooney DJ, 1997, J BIOMED MATER RES, V37, P413, DOI 10.1002/(SICI)1097-4636(19971205)37:3<413::AID-JBM12>3.0.CO;2-C; Mooney DT, 1996, BIOMATERIALS, V17, P115, DOI 10.1016/0142-9612(96)85756-5; Morrow EM, 1999, DEVELOPMENT, V126, P23; Niklason LE, 1999, SCIENCE, V284, P489, DOI 10.1126/science.284.5413.489; Park KW, 2001, ANIM BIOTECHNOL, V12, P173, DOI 10.1081/ABIO-100108344; Petters RM, 1997, NAT BIOTECHNOL, V15, P965, DOI 10.1038/nbt1097-965; Pittack C, 1997, DEVELOPMENT, V124, P805; Pomahac B, 1998, CRIT REV ORAL BIOL M, V9, P333, DOI 10.1177/10454411980090030601; Rapaport DH, 1998, SEMIN CELL DEV BIOL, V9, P241, DOI 10.1006/scdb.1998.0232; REH TA, 1994, PERSPECT DEV NEUROBI, V2, P183; Reh TA, 1998, J NEUROBIOL, V36, P206, DOI 10.1002/(SICI)1097-4695(199808)36:2<206::AID-NEU8>3.0.CO;2-5; Rothermel A, 2003, INVEST OPHTH VIS SCI, V44, P2221, DOI 10.1167/iovs.02-0915; Sakaguchi DS, 1997, DEV DYNAM, V209, P387, DOI 10.1002/(SICI)1097-0177(199708)209:4<387::AID-AJA6>3.0.CO;2-E; Scharenberg CW, 2002, BLOOD, V99, P507, DOI 10.1182/blood.V99.2.507; STENKAMP DL, 1993, INVEST OPHTH VIS SCI, V34, P2425; Takahashi M, 1998, MOL CELL NEUROSCI, V12, P340, DOI 10.1006/mcne.1998.0721; Temenoff JS, 2000, BIOMATERIALS, V21, P431, DOI 10.1016/S0142-9612(99)00213-6; Tomita M, 2005, STEM CELLS, V23, P1579, DOI 10.1634/stemcells.2005-0111; Tropepe V, 2000, SCIENCE, V287, P2032, DOI 10.1126/science.287.5460.2032; Tsai RYL, 2002, GENE DEV, V16, P2991, DOI 10.1101/gad.55671; TURNER DL, 1990, NEURON, V4, P833, DOI 10.1016/0896-6273(90)90136-4; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; Warfvinge K, 2005, ARCH OPHTHALMOL-CHIC, V123, P1385, DOI 10.1001/archopht.123.10.1385; Yaszemski MJ, 1996, BIOMATERIALS, V17, P175, DOI 10.1016/0142-9612(96)85762-0; Young MJ, 2000, MOL CELL NEUROSCI, V16, P197, DOI 10.1006/mcne.2000.0869; YOUNG RW, 1985, ANAT REC, V212, P199, DOI 10.1002/ar.1092120215	78	35	37	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0903-4641	1600-0463		APMIS	APMIS	NOV	2005	113	11-12					845	857		10.1111/j.1600-0463.2005.apm_334.x			13	Immunology; Microbiology; Pathology	Immunology; Microbiology; Pathology	012QG	WOS:000235353500011	16480454	Bronze			2021-06-18	
J	Tsai, SJ				Tsai, SJ			Central N-acetyl aspartylglutamate deficit: a possible pathogenesis of schizophrenia	MEDICAL SCIENCE MONITOR			English	Article						N-acetylaspartate; N-acetyl aspartylglutamate; schizophrenia; glutamate; type 3 metabotropic glutamate receptor; N-methyl-D-aspartate receptor; glutamate carboxypeptidase II	PROTON-MAGNETIC-RESONANCE; METABOTROPIC GLUTAMATE-RECEPTOR; LINKED ACIDIC DIPEPTIDASE; TRAUMATIC BRAIN-INJURY; L-ASPARTIC ACID; PREFRONTAL CORTEX; GENE-EXPRESSION; FRONTAL-LOBE; RAT-BRAIN; MITOCHONDRIAL DYSFUNCTION	The "glutamate hypothesis" of schizophrenia has emerged from the finding that phencyclidine (PCP) induces psychotic-like behaviors in rodents, possibly by blocking the N-methyl-D-aspartate (NMDA) subtype of glutainate receptor, thereby causing increased glutamate release. N-acetyl aspartylglutamate (NAAG), an endogenous peptide abundant in mammalian nervous systems, is localized in certain brain cells, including cortical and hippocampal pyramidal neurons. NAAG is synthesized from N-acetylaspartate (NAA) and glutamate, and NAA availability may limit the rate of NAAG synthesis. Although NAAG is known to have some neurotransmitter-like functions, NAA does not. NAAG is a highly selective agonist of the type 3 metabotropic glutamate receptor (mGluR3, a presynaptic autoreceptor) and can inhibit glutamate release. In addition, at low levels, NAAG is an NMDA receptor antagonist, and blocking of NMDA receptors may increase glutamatc release. Taken together, low central NAAG levels may antagonize the effect of glutamate at NMDA receptors and decrease its agonistic effect on presynaptic rnGluR3; both activities could increase glutamate release, similar to the increase demonstrated in the PCP model of schizophrenia. In this report, it is suggested that the central NAAG deficit, possibly through decreased synthesis or increased degradation of NAAG, may play a role in the pathogenesis of schizophrenia. Evidence is presented and discussed from magnetic resonance, postmortem, animal model, schizophrenia treatment, and genetic studies. The central NAAG deficit model of schizophrenia could explain the disease process, from the perspectives of both neurodevelopment and neurodegeneration, and may point to potential treatments for schizophrenia.	Taipei Vet Gen Hosp, Dept Psychiat, Taipei 11217, Taiwan; Natl Yang Ming Univ, Sch Med, Div Psychiat, Taipei 112, Taiwan	Tsai, SJ (corresponding author), Taipei Vet Gen Hosp, Dept Psychiat, 201,Shihpai Rd,Sec 2, Taipei 11217, Taiwan.	sjtsai@vghtpe.gov.tw	Tsai, Shih-Jen/AAK-7944-2020	Tsai, Shih-Jen/0000-0002-9987-022X			Arciniegas DB, 2003, INT REV PSYCHIATR, V15, P328, DOI 10.1080/09540260310001606719; Baslow MH, 2003, NEUROCHEM RES, V28, P941, DOI 10.1023/A:1023250721185; Ben-Shachar D, 2002, J NEUROCHEM, V83, P1241, DOI 10.1046/j.1471-4159.2002.01263.x; Bertolino A, 2001, BIOL PSYCHIAT, V49, P39, DOI 10.1016/S0006-3223(00)00997-5; Bertolino A, 2002, CEREB CORTEX, V12, P983, DOI 10.1093/cercor/12.9.983; Bertolino A, 1998, BIOL PSYCHIAT, V43, P641, DOI 10.1016/S0006-3223(97)00555-6; Black K, 2001, SCHIZOPHR RES, V47, P215, DOI 10.1016/S0920-9964(00)00144-4; Braus DF, 2001, PHARMACOPSYCHIATRY, V34, P251, DOI 10.1055/s-2001-18037; Brooks WM, 1998, BIOL PSYCHIAT, V43, P263, DOI 10.1016/S0006-3223(97)00462-9; Bruno V, 1998, NEUROSCIENCE, V85, P751, DOI 10.1016/S0306-4522(97)00531-9; Callicott JH, 2000, AM J PSYCHIAT, V157, P1646, DOI 10.1176/appi.ajp.157.10.1646; Callicott JH, 1998, BIOL PSYCHIAT, V44, P941, DOI 10.1016/S0006-3223(98)00264-9; Cartmell J, 1999, J PHARMACOL EXP THER, V291, P161; Chavez-Noriega LE, 2002, CNS NEUROL DISORD-DR, V1, P261, DOI 10.2174/1568007023339337; Clark JB, 1998, DEV NEUROSCI-BASEL, V20, P271, DOI 10.1159/000017321; Coyle JT, 2004, PSYCHOPHARMACOLOGY, V174, P32, DOI 10.1007/s00213-003-1709-2; Coyle JT, 1997, NEUROBIOL DIS, V4, P231, DOI 10.1006/nbdi.1997.0153; CUMMINGS JL, 1988, PSYCHOSOMATICS, V29, P16, DOI 10.1016/S0033-3182(88)72418-4; Deicken RF, 1999, SCHIZOPHR RES, V37, P217, DOI 10.1016/S0920-9964(98)00173-X; Deicken RF, 2003, AM J PSYCHIAT, V160, P873, DOI 10.1176/appi.ajp.160.5.873; Deicken RF, 2000, REV NEUROSCIENCE, V11, P147; Demougeot C, 2001, J NEUROCHEM, V77, P408, DOI 10.1046/j.1471-4159.2001.00285.x; Ende G, 2000, SCHIZOPHR RES, V41, P389, DOI 10.1016/S0920-9964(99)00089-4; Ernst T, 2000, NEUROLOGY, V54, P1344, DOI 10.1212/WNL.54.6.1344; Farber NB, 1995, BIOL PSYCHIAT, V38, P788, DOI 10.1016/0006-3223(95)00046-1; Flores C, 2003, NEUROPSYCHOPHARMACOL, V28, P1227, DOI 10.1038/sj.npp.1300129; Fukuzako H, 1995, PSYCHIAT RES-NEUROIM, V61, P193, DOI 10.1016/0925-4927(95)02622-5; Gehl LM, 2004, J NEUROCHEM, V90, P989, DOI 10.1111/j.1471-4159.2004.02578.x; Ghose S, 2004, NEUROPSYCHOPHARMACOL, V29, P117, DOI 10.1038/sj.npp.1300304; Govindaraju V, 2004, AM J NEURORADIOL, V25, P730; Haas GL, 1998, J PSYCHIAT RES, V32, P151, DOI 10.1016/S0022-3956(98)00008-9; Harrison PJ, 2005, MOL PSYCHIATR, V10, P40, DOI 10.1038/sj.mp.4001558; Harte MK, 2004, BIOL PSYCHIAT, V56, P296, DOI 10.1016/j.biopsych.2004.06.009; Heimberg C, 1998, PSYCHIAT RES-NEUROIM, V83, P105, DOI 10.1016/S0925-4927(98)00034-1; Ho BC, 2003, ARCH GEN PSYCHIAT, V60, P585, DOI 10.1001/archpsyc.60.6.585; JAKOBS C, 1991, J INHERIT METAB DIS, V14, P653, DOI 10.1007/BF01799929; JENKINS BG, 1993, NEUROLOGY, V43, P2689, DOI 10.1212/WNL.43.12.2689; Keshavan MS, 2003, SCHIZOPHRENIA BULL, V29, P757, DOI 10.1093/oxfordjournals.schbul.a007045; Kilbride J, 1998, EUR J PHARMACOL, V356, P149, DOI 10.1016/S0014-2999(98)00526-3; Kodsi MH, 1997, NEUROSCI LETT, V231, P103, DOI 10.1016/S0304-3940(97)00482-5; Konradi C, 2003, PHARMACOL THERAPEUT, V97, P153, DOI 10.1016/S0163-7258(02)00328-5; KRYSTAL JH, 1994, ARCH GEN PSYCHIAT, V51, P199, DOI 10.1001/archpsyc.1994.03950030035004; KRYSTAL JH, IN PRESS PSYCHOPHARM; LAUTENSCHLAGER NT, 2001, CURR PSYCHIAT REP, V3, P3219; LUBY ED, 1959, ARCH NEURO PSYCHIATR, V81, P363, DOI 10.1001/archneurpsyc.1959.02340150095011; MacKay S, 1996, RADIOLOGY, V198, P537, DOI 10.1148/radiology.198.2.8596863; Mathew SJ, 2003, BIOL PSYCHIAT, V54, P727, DOI 10.1016/S0006-3223(03)00004-0; MEYERHOFF JL, 1989, BRAIN RES, V505, P130, DOI 10.1016/0006-8993(89)90123-6; MEYERHOFF JL, 1985, BRAIN RES, V346, P392, DOI 10.1016/0006-8993(85)90877-7; Michael N, 2003, NEUROPSYCHOPHARMACOL, V28, P720, DOI 10.1038/sj.npp.1300085; Middleton FA, 2002, J NEUROSCI, V22, P2718, DOI 10.1523/JNEUROSCI.22-07-02718.2002; MIYAKE M, 1981, J NEUROCHEM, V36, P804, DOI 10.1111/j.1471-4159.1981.tb01665.x; MIYAKE M, 1982, CLIN CHIM ACTA, V120, P119; Moghaddam B, 1998, SCIENCE, V281, P1349, DOI 10.1126/science.281.5381.1349; Molina V, 2005, SCHIZOPHR RES, V73, P209, DOI 10.1016/j.schres.2004.02.001; Moreno A, 2001, J NEUROCHEM, V77, P347, DOI 10.1046/j.1471-4159.2001.00282.x; Nudmamud S, 2003, BIOL PSYCHIAT, V53, P1138, DOI 10.1016/S0006-3223(02)01742-0; Ohrmann P, 2005, SCHIZOPHR RES, V73, P153, DOI 10.1016/j.schres.2004.08.021; Okamura N, 2003, BRAIN RES, V992, P114, DOI 10.1016/j.brainres.2003.08.045; Olney JW, 1999, J PSYCHIAT RES, V33, P523, DOI 10.1016/S0022-3956(99)00029-1; Olszewski RT, 2004, J NEUROCHEM, V89, P876, DOI 10.1111/j.1471-4159.2004.02358.x; Passani LA, 1997, MOL CHEM NEUROPATHOL, V31, P97, DOI 10.1007/BF02815236; Poland RE, 1999, J PSYCHIATR RES, V33, P41, DOI 10.1016/S0022-3956(98)00043-0; Reneman L, 2002, AM J NEURORADIOL, V23, P231; Reynolds LM, 2005, SCHIZOPHR RES, V73, P147, DOI 10.1016/j.schres.2004.02.003; Sawa A, 2003, MOL MED, V9, P3, DOI 10.1007/BF03402101; Schoepp Darryle D., 2002, Current Drug Targets - CNS and Neurological Disorders, V1, P215, DOI 10.2174/1568007024606177; Schoepp DD, 1999, NEUROPHARMACOLOGY, V38, P1431, DOI 10.1016/S0028-3908(99)00092-1; Schweinsburg BC, 2001, ALCOHOL CLIN EXP RES, V25, P924, DOI 10.1111/j.1530-0277.2001.tb02299.x; Sigmundsson T, 2003, SCHIZOPHR RES, V64, P63, DOI 10.1016/S0920-9964(02)00533-9; Slusher BS, 1999, NAT MED, V5, P1396, DOI 10.1038/70971; Stanley JA, 2000, BIOL PSYCHIAT, V48, P357, DOI 10.1016/S0006-3223(00)00949-5; STANLEY JA, 1995, MAGNET RESON MED, V34, P17, DOI 10.1002/mrm.1910340105; STAUCH BL, 1989, NEUROSCI LETT, V100, P295, DOI 10.1016/0304-3940(89)90702-7; Thomas AG, 2000, J PHARMACOL EXP THER, V295, P16; TSAI GC, 1995, PROG NEUROBIOL, V46, P531, DOI 10.1016/0301-0082(95)00014-M; TSAI GC, 1995, ARCH GEN PSYCHIAT, V52, P829; Tsai SJ, 2005, SCHIZOPHR RES, V76, P359, DOI 10.1016/j.schres.2004.12.018; Tsuang M, 2000, BIOL PSYCHIAT, V47, P210, DOI 10.1016/S0006-3223(99)00289-9; Tyson RL, 1998, NEUROSCI LETT, V251, P181, DOI 10.1016/S0304-3940(98)00527-8; WESTBROOK GL, 1986, J NEUROSCI, V6, P3385; Wroblewska B, 1997, J NEUROCHEM, V69, P174; WROBLEWSKA B, 1993, J NEUROCHEM, V61, P943, DOI 10.1111/j.1471-4159.1993.tb03606.x	83	35	35	0	6	INT SCIENTIFIC LITERATURE, INC	ALBERTSON	1125 WILLIS AVE, ALBERTSON, NY 11507 USA	1234-1010			MED SCI MONITOR	Med. Sci. Monitor	SEP	2005	11	9					HY39	HY45					7	Medicine, Research & Experimental	Research & Experimental Medicine	965CV	WOS:000231928500001	16127367				2021-06-18	
J	Slobounov, S; Sebastianelli, W; Moss, R				Slobounov, S; Sebastianelli, W; Moss, R			Alteration of posture-related cortical potentials in mild traumatic brain injury	NEUROSCIENCE LETTERS			English	Article						movement-related cortical potentials (MRCP); mild traumatic brain injury (MTBI); posture; balance	MOVEMENT-RELATED POTENTIALS; INSTABILITY; CONCUSSION; TIME; MRI; EEG	This paper presents additional evidence showing the persistent functional deficits in concussed athletes as revealed by altered movement-related cortical potentials (MRCP) preceding whole body postural movements at, least 30 days post-injury. Eight student-athletes participated in this study (a) prior to injury; and (b) 3, 10 and 30 days after MTBI. EEG was recorded while subjects produced static balance tasks and dynamic postural movements. All subjects were cleared for sport participation within 10 days post-injury based upon neurological and neuropsychological assessments as well as upon clinical symptoms resolution. There was a persistent reduction of MRCP amplitude prior to initiation of postural movement up to 30 days post-injury, although abnormal postural responses basically recovered within 10 days post-injury. The frontal lobe MRCP effects were larger than posterior areas. This supports the notion that behavioral symptoms resolution may not be indicative of brain injury resolution. Overall, persistent alteration of movement-related cortical potentials after MTBI may indicate residual disturbance of neuronal networks involved in preparation and execution of postural movements and a lower threshold for brain re/injury. (c) 2005 Published by Elsevier Ireland Ltd.	Penn State Univ, University Pk, PA 16802 USA	Slobounov, S (corresponding author), Penn State Univ, 19 Recreat Hall, University Pk, PA 16802 USA.	sms18@psu.edu					Barth JT, 2001, J ATHL TRAINING, V36, P253; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Geurts ACH, 1999, ARCH PHYS MED REHAB, V80, P144, DOI 10.1016/S0003-9993(99)90111-9; GEVINS AS, 1979, SCIENCE, V203, P665, DOI 10.1126/science.760212; GRUNEWALD G, 1983, BIOL PSYCHOL, V31, P71; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Jahanshahi M., 2003, BEREITSCHAFTSPOTENTI, P1, DOI [10.1007/978-1-4615-0189-3_1, DOI 10.1007/978-1-4615-0189-3]; JENNINGS JR, 1987, PSYCHOPHYSIOLOGY, V24, P474, DOI 10.1111/j.1469-8986.1987.tb00320.x; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; KORNHUBE.HH, 1965, PFLUG ARCH GES PHYS, V284, P1, DOI 10.1007/BF00412364; KRISTEVA R, 1990, ELECTROEN CLIN NEURO, V75, P410, DOI 10.1016/0013-4694(90)90086-Y; Madeleine P, 2004, ARCH PHYS MED REHAB, V85, P432, DOI 10.1016/j.apmr.2003.03.003; MCCALLUM WC, 1993, NATO ADV SCI INST SE, V254, P1; NIEMANN J, 1994, COGNITIVE PSYCHOPHYS, P265; Saitou K, 1996, ELECTROEN CLIN NEURO, V98, P449, DOI 10.1016/0013-4694(96)95004-X; SHIBASAKI H, 1980, ELECTROEN CLIN NEURO, V49, P213, DOI 10.1016/0013-4694(80)90216-3; Slobounov S, 2005, CLIN NEUROPHYSIOL, V116, P315, DOI 10.1016/j.clinph.2004.09.007; Slobounov S, 2004, CLIN NEUROPHYSIOL, V115, P2391, DOI 10.1016/j.clinph.2004.05.021; Slobounov S, 2002, CLIN NEUROPHYSIOL, V113, P185, DOI 10.1016/S1388-2457(01)00737-4; Slobounov SM, 1998, EXP BRAIN RES, V123, P461, DOI 10.1007/s002210050590; Slobounov SM, 1998, J GERONTOL A-BIOL, V53, pB71, DOI 10.1093/gerona/53A.1.B71; SLOBUNOV S, 2000, MOT CONTROL, V45, P247; Stuss D. T., 2002, PR FRONTAL LOBE FUNC, P392, DOI DOI 10.1093/ACPROF:OSO/9780195134971.003.0025; Thatcher RW, 2001, CLIN NEUROPHYSIOL, V112, P1729, DOI 10.1016/S1388-2457(01)00609-5; Thompson J, 2005, NEUROSCI LETT, V377, P158, DOI 10.1016/j.neulet.2004.11.090; Wiese H, 2004, CLIN NEUROPHYSIOL, V115, P2677, DOI 10.1016/j.clinph.2004.06.015; Wiese H, 2004, CLIN NEUROPHYSIOL, V115, P289, DOI 10.1016/S1388-2457(03)00348-1	28	35	35	1	6	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	AUG 5	2005	383	3					251	255		10.1016/j.neulet.2005.04.039			5	Neurosciences	Neurosciences & Neurology	940LJ	WOS:000230145700011	15876490				2021-06-18	
J	Alves, OL; Bullock, R; Clausen, T; Reinert, M; Reeves, TM				Alves, OL; Bullock, R; Clausen, T; Reinert, M; Reeves, TM			Concurrent monitoring of cerebral electrophysiology and metabolism after traumatic brain injury: An experimental and clinical study	JOURNAL OF NEUROTRAUMA			English	Article						cerebral monitoring; electrophysiology; extracellular glutamate; metabolic dysfunction; microdialysis; traumatic brain injury	SINGLE-UNIT ACTIVITY; HUMAN HEAD-INJURY; SPREADING DEPRESSION; EXTRACELLULAR GLUTAMATE; NEUROSURGICAL PATIENTS; SUBSTRATE DELIVERY; NEURONS; RAT; MECHANISMS; ISCHEMIA	Multiparameter cerebral monitoring has been widely applied in traumatic brain injury to study posttramnatic pathophysiology and to manage head-injured patients (e.g., combining 02 and pH sensors with cerebral microdialysis). Because a comprehensive approach towards understanding injury processes will also require functional measures, we have added electrophysiology to these monitoring modalities by attaching a recording electrode to the microdialysis probe. These dual-function (microdialysis/electrophysiology) probes were placed in rats following experimental fluid percussion brain injuries, and in a series of severely head-injured human patients. Electrical activity (cell firing, EEG) was monitored concurrently with microdialysis sampling of extracellular glutamate, glucose and lactate. Electrophysiological parameters (firing rate, serial correlation, field potential occurrences) were analyzed offline and compared to dialysate concentrations. In rats, these probes demonstrated an injury-induced suppression of neuronal firing (from a control level of 2.87 to 0.41 spikes/sec postinjury), which was associated with increases in extracellular glutamate and lactate, and decreases in glucose levels. When placed in human patients, the probes detected sparse and slowly firing cells (mean = 0.21 spike/sec), with most units (70%) exhibiting a lack of serial correlation in the spike train. In some patients, spontaneous field potentials were observed, suggesting synchronously firing neuronal populations. In both the experimental and clinical application, the addition of the recording electrode did not appreciably affect the performance of the microdialysis probe. The results suggest that this technique provides a functional monitoring capability which cannot be obtained when electrophysiology is measured with surface or epidural EEG alone.	Virginia Commonwealth Univ, Dept Anat & Neurobiol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA 23298 USA; Univ Porto, Fac Med, P-4100 Oporto, Portugal; Univ Halle Wittenberg, Dept Anesthesiol & Intens Care Med, Halle An Der Saale, Saale, Germany; Univ Bern, Inselspital, Dept Neurosurg, CH-3012 Bern, Switzerland	Reeves, TM (corresponding author), Virginia Commonwealth Univ, Dept Anat & Neurobiol, Med Coll Virginia Campus, Richmond, VA 23298 USA.	tmreeves@hsc.vcu.edu	Reinert, Michael/AAA-3929-2019; Reinert, Michael/E-4964-2011	Reinert, Michael/0000-0002-0971-9543; 	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS12587] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS012587, P01NS012587] Funding Source: NIH RePORTER		Alessandri B, 2000, ACTA NEUROCHIR SUPPL, V76, P425; ANDERSEN BJ, 1992, BRAIN RES, V585, P190, DOI 10.1016/0006-8993(92)91206-T; ANDERSEN BJ, 1992, BRAIN RES, V585, P184, DOI 10.1016/0006-8993(92)91205-S; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Chen T, 2000, J NEUROTRAUM, V17, P135, DOI 10.1089/neu.2000.17.135; Clausen T, 2001, BRAIN RES, V908, P35, DOI 10.1016/S0006-8993(01)02566-5; Clausen T, 2001, CURR PHARM DESIGN, V7, P1517, DOI 10.2174/1381612013397267; COX DR, 1966, STAT ANAL SERIES EVE; CREUTZFELDT OD, 1974, HDB ELECTROENCEPHALO, V20, P5; Detari L, 1997, BRAIN RES, V759, P112, DOI 10.1016/S0006-8993(97)00252-7; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DURING MJ, 1993, LANCET, V341, P1607; FEENEY DM, 1979, ARCH NEUROL-CHICAGO, V36, P8, DOI 10.1001/archneur.1979.00500370038005; Fried I, 1999, J NEUROSURG, V91, P697, DOI 10.3171/jns.1999.91.4.0697; Golarai G, 2001, J NEUROSCI, V21, P8523; GRAHN DA, 1989, AM J PHYSIOL, V256, pR840; Grenier F, 2003, NEUROSCIENCE, V119, P277, DOI 10.1016/S0306-4522(03)00101-5; Hillered L, 1999, SCAND J CLIN LAB INV, V59, P9, DOI 10.1080/00365519950185904; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KOSTOPOULOS G, 1984, ELECTROEN CLIN NEURO, V57, P69, DOI 10.1016/0013-4694(84)90009-9; Lebedev MA, 2000, EXP BRAIN RES, V130, P195, DOI 10.1007/s002210050022; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Liou AKF, 2003, PROG NEUROBIOL, V69, P103, DOI 10.1016/S0301-0082(03)00005-4; Ludvig N, 2001, BRAIN RES, V900, P252, DOI 10.1016/S0006-8993(01)02319-8; MACGREGOR RJ, 1997, NEURAL MODELING ELEC; Matz P G, 1997, Clin Neurosurg, V44, P267; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Mayevsky A, 1996, BRAIN RES, V740, P268, DOI 10.1016/S0006-8993(96)00874-8; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; Murthy VN, 1996, J NEUROPHYSIOL, V76, P3968; Nunez P., 1981, ELECT FIELDS BRAIN; OBRENOVITCH TP, 1995, J NEUROPHYSIOL, V73, P2107; Obrenovitch TP, 1997, J NEUROTRAUM, V14, P677, DOI 10.1089/neu.1997.14.677; PERKEL DH, 1967, BIOPHYS J, V7, P391, DOI 10.1016/S0006-3495(67)86596-2; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; Ray SK, 2002, HISTOL HISTOPATHOL, V17, P1137, DOI 10.14670/HH-17.1137; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; Rogatsky G, 1996, J Basic Clin Physiol Pharmacol, V7, P23; Rose ME, 2002, BRAIN RES, V935, P40, DOI 10.1016/S0006-8993(02)02445-9; Somjen GG, 2001, PHYSIOL REV, V81, P1065; Strong AJ, 2002, STROKE, V33, P2738, DOI 10.1161/01.STR.0000043073.69602.09; Tavalin SJ, 1995, J NEUROPHYSIOL, V74, P2767; Velasco AL, 2000, NEURAL PLAST, V7, P49, DOI 10.1155/NP.2000.49; WINDHORST U, 1982, PFLUG ARCH EUR J PHY, V393, P148, DOI 10.1007/BF00582938; Zauner A, 1997, NEUROL RES, V19, P265, DOI 10.1080/01616412.1997.11740812; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011; Zhang FY, 2002, J NEUROSURG, V97, P963, DOI 10.3171/jns.2002.97.4.0963	49	35	38	1	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2005	22	7					733	749		10.1089/neu.2005.22.733			17	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	945VQ	WOS:000230530800002	16004577				2021-06-18	
J	Arbogast, KB; Margulies, SS; Christian, CW				Arbogast, KB; Margulies, SS; Christian, CW			Initial neurologic presentation in young children sustaining inflicted and unintentional fatal head injuries	PEDIATRICS			English	Article						abuse; accidents; falls; head injuries; lucid interval	TRAUMATIC BRAIN-INJURY; SHAKEN BABY SYNDROME; COMA SCALE; INFANT; FALLS; TIME	Background. It remains unclear if fatal brain injuries in young children are characterized by immediate rapid deterioration or can present after an initial period of lucidity. This issue has legal implications in child abuse, for which understanding the clinical course affects perpetrator identification. Objective. To determine patterns of neurologic presentation on hospital admission in infants and toddlers who die of inflicted and unintentional injury. Design/Methods. Data on children < 48 months of age who sustained a fatal head injury from 1986-2002 were extracted from the Pennsylvania Trauma Outcomes Study. Only those with external-causes-of-injury codes for inflicted injury, falls, and motor vehicle crashes (MVCs) with a recorded Glasgow Coma Scale (GCS) on admission were included. The GCS was compared across mechanisms and age groups (0-11, 12-23, 24-35, and 36-47 months). Results. Of the 314 fatally injured children, 37% sustained inflicted injury, 13% sustained a fall, and 49% sustained an MVC. At admission, 6.8% of all children had a GCS score of > 7, and 1.9% presented with a GCS score of > 12 ( lucid). The incidence of admission a GCS score of > 7 varied by mechanism. Overall, children with inflicted injury were 3 times more likely to present with a GCS score of > 7 than those injured in MVCs ( odds ratio [OR]: 3.6; 95% confidence interval [CI]: 1.2-10.3), but incidence of a GCS score of > 7 did not differ between inflicted injuries and falls. Similarly, when considering only those children >= 24 months old, a GCS score of > 7 did not differ by mechanism. In contrast, in those < 24 months old, children who died as a result of inflicted injury were > 10 times more likely to have a GCS score of > 7 than those who died as a result of a MVC (OR: 9.36; 95% CI: 1.3-80.9). Conclusions. The data suggest an age- and mechanism-dependent presentation of neurologic status in children with fatal head injury. Although infrequent, young victims of fatal head trauma may present as lucid (GCS score: > 12) before death. Furthermore, children < 48 months old sustaining inflicted injury are 3 times more likely to be assessed with a moderate GCS score 7) than those in MVCs. This effect is amplified in the youngest children (< 24 months old): those with inflicted injury were 10 times more likely to present with moderate GCS scores than those in MVCs. In addition, this youngest age group seems to be overrepresented in those who present as lucid (GCS score: > 12 [5 of 6]). It is unclear whether these differences are the result of inadequate tests to evaluate consciousness in younger children or differences in biomechanical mechanisms of inflicted trauma.	Childrens Hosp Philadelphia, TraumaLink Interdisciplinary Pediat Injury Contro, Philadelphia, PA 19104 USA; Univ Penn, Dept Pediat, Div Emergency Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; Univ Penn, Dept Pediat, Div Gen Pediat, Philadelphia, PA 19104 USA	Arbogast, KB (corresponding author), Childrens Hosp Philadelphia, TraumaLink Interdisciplinary Pediat Injury Contro, 34th St & Civ Ctr Blvd,3535 TraumaLink,10th Floor, Philadelphia, PA 19104 USA.	arbogast@email.chop.edu		Arbogast, Kristy/0000-0002-1694-4562			Denton S, 2003, AM J FOREN MED PATH, V24, P371, DOI 10.1097/01.paf.0000097851.18478.16; DeRoss AL, 2002, J TRAUMA, V52, P708, DOI 10.1097/00005373-200204000-00017; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Durham SR, 2000, J NEUROTRAUM, V17, P729, DOI 10.1089/neu.2000.17.729; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; MORRAY JP, 1984, CRIT CARE MED, V12, P1018, DOI 10.1097/00003246-198412000-00002; Nance ML, 2003, J TRAUMA, V55, P631, DOI 10.1097/01.TA.0000035090.99483.0A; NASHELSKY MB, 1995, AM J FOREN MED PATH, V16, P154, DOI 10.1097/00000433-199506000-00016; Page RB, 2004, NEUROSURGERY, V54, P143, DOI 10.1227/01.NEU.0000097514.60813.1B; Plunkett J, 2001, AM J FOREN MED PATH, V22, P1, DOI 10.1097/00000433-200103000-00001; Prange MT, 2003, J NEUROSURG, V99, P143, DOI 10.3171/jns.2003.99.1.0143; Prins ML, 2003, J NEUROTRAUM, V20, P123, DOI 10.1089/08977150360547053; Raghupathi R, 2004, J NEUROTRAUM, V21, P307, DOI 10.1089/089771504322972095; RAIMONDI AJ, 1984, CHILD BRAIN, V11, P12; SIMPSON D, 1982, LANCET, V2, P450; Starling SP, 2004, ARCH PEDIAT ADOL MED, V158, P454, DOI 10.1001/archpedi.158.5.454; Willman KY, 1997, CHILD ABUSE NEGLECT, V21, P929, DOI 10.1016/S0145-2134(97)00054-9	17	35	36	0	4	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	JUL	2005	116	1					180	184		10.1542/peds.2004-2671			5	Pediatrics	Pediatrics	941IC	WOS:000230207500050	15995050				2021-06-18	
J	Ufberg, JW; Bushra, JS; Karras, DJ; Satz, WA; Kueppers, F				Ufberg, JW; Bushra, JS; Karras, DJ; Satz, WA; Kueppers, F			Aspiration of gastric contents: association with prehospital intubation	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article							COMMUNITY-ACQUIRED PNEUMONIA; RAPID-SEQUENCE INTUBATION; TRAUMATIC BRAIN-INJURY; ENDOTRACHEAL INTUBATION; PULMONARY ASPIRATION; HEAD-INJURY; COMPLICATIONS; FIELD; EMERGENCY; SURVIVAL	We prospectively compared the incidence of pulmonary aspiration of gastric contents between patients endotracheally intubated in the prehospital (PH) setting and those intubated in the emergency department (ED). Tracheal aspirates were collected using a standard Leukens trap from all patients as soon as possible after endotracheal intubation. Tracheal aspirates were then tested for the presence of pepsin, a sensitive and specific marker of gastric contents, using a fibrinogen digestion technique. Over 8 months, 168 patients were enrolled. The pepsin assay was positive in 10 of 20 (50%) patients intubated in the PH group, as opposed to 33 of 148 (22%) of those intubated in the ED (chi(2) p =.008; odds ratio, 3.5; 95% CI, 1.34-9.08). Patients endotracheally intubated in the PH setting are more likely to have aspirated gastric contents than those intubated in the ED. (c) 2005 Elsevier Inc. All rights reserved.	Temple Univ, Sch Med, Dept Emergency Med, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Internal Med, Sect Pulm & Crit Care Med, Philadelphia, PA 19140 USA	Ufberg, JW (corresponding author), Temple Univ, Sch Med, Dept Emergency Med, Philadelphia, PA 19140 USA.	jacob.ufberg@verizon.net					ALDRICH T, 1980, SOUTHERN MED J, V73, P456, DOI 10.1097/00007611-198004000-00017; Badellino MM, 1996, CRIT CARE MED, V24, P1881, DOI 10.1097/00003246-199611000-00019; Bochicchio GV, 2003, J TRAUMA, V54, P307, DOI 10.1097/01.TA.0000046252.97590.BE; BUSHRA JA, 2002, ACAD EMERG MED, V9, P405; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; Gausche M, 2000, JAMA-J AM MED ASSOC, V283, P783, DOI 10.1001/jama.283.6.783; Karch SB, 1996, AM J EMERG MED, V14, P617, DOI 10.1016/S0735-6757(96)90073-X; Katz SH, 2001, ANN EMERG MED, V37, P32, DOI 10.1067/mem.2001.112098; Krishnan U, 2002, J PEDIATR GASTR NUTR, V35, P303, DOI 10.1097/00005176-200209000-00012; KUEPPERS F, 2002, RESP CRIT CARE MDD, V165, pA828; LANDAY MJ, 1978, AM J ROENTGENOL, V131, P587, DOI 10.2214/ajr.131.4.587; Marik PE, 2001, NEW ENGL J MED, V344, P665, DOI 10.1056/NEJM200103013440908; MARRIE TJ, 1989, REV INFECT DIS, V11, P586; Metheny NA, 2002, AM J CRIT CARE, V11, P150, DOI 10.4037/ajcc2002.11.2.150; MOINE P, 1994, CHEST, V105, P1487, DOI 10.1378/chest.105.5.1487; Ochs M, 2002, ANN EMERG MED, V40, P159, DOI 10.1067/mem.2002.126397; OLSSON GL, 1986, ACTA ANAESTH SCAND, V30, P84, DOI 10.1111/j.1399-6576.1986.tb02373.x; OSWALT JL, 1992, AM J EMERG MED, V10, P511, DOI 10.1016/0735-6757(92)90173-U; RASHKIN MC, 1986, CHEST, V89, P165, DOI 10.1378/chest.89.2.165; REDAN JA, 1991, J TRAUMA, V31, P371, DOI 10.1097/00005373-199103000-00010; ROY TM, 1989, CHEST, V96, P852, DOI 10.1378/chest.96.4.852; Sayre MR, 1998, ANN EMERG MED, V31, P228, DOI 10.1016/S0196-0644(98)70312-9; SCHWARTZ DE, 1995, ANESTHESIOLOGY, V82, P367, DOI 10.1097/00000542-199502000-00007; Sloane C, 2000, J EMERG MED, V19, P259, DOI 10.1016/S0736-4679(00)00235-3; TARYLE DA, 1979, CHEST, V75, P541, DOI 10.1378/chest.75.5.541; Thibodeau LG, 1997, AM J EMERG MED, V15, P562, DOI 10.1016/S0735-6757(97)90157-1; TORRES A, 1991, AM REV RESPIR DIS, V144, P312, DOI 10.1164/ajrccm/144.2.312; UFBERG JW, 2004, IN PRESS AM J EMERG; WARNER MA, 1993, ANESTHESIOLOGY, V78, P56, DOI 10.1097/00000542-199301000-00010; Winchell RJ, 1997, ARCH SURG-CHICAGO, V132, P592	30	35	35	0	2	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0735-6757			AM J EMERG MED	Am. J. Emerg. Med.	MAY	2005	23	3					379	382		10.1016/j.ajem.2005.02.005			4	Emergency Medicine	Emergency Medicine	936YH	WOS:000229891000027	15915418				2021-06-18	
J	Basta, D; Todt, I; Scherer, H; Clarke, A; Ernst, A				Basta, D; Todt, I; Scherer, H; Clarke, A; Ernst, A			Postural control in otolith disorders	HUMAN MOVEMENT SCIENCE			English	Article						otolith disorder; trunk sway; minor head trauma; postural control	CLINICAL BALANCE TESTS; TRUNK SWAY MEASURES; HEAD TRAUMA; DIFFERENTIAL-DIAGNOSIS; SPATIAL ORIENTATION; VESTIBULAR DEFICIT; SUPPORT-SURFACE; STABILITY; INJURY; POSTUROGRAPHY	It was the aim of the present paper to investigate the influence of otolith disorders on human postural control by different methods. The 33 patients of our study had undergone a minor head injury and suffered subsequently from an utricular or sacculo-utricular disorder as evidenced by vestibular evoked myogenic potential recordings and eccentric rotation recordings of the otolith-ocular responses. Postural control was assessed by performing stance/gait tests (standard balance deficit test, SBDT) and by evaluating trunk sway (using angular velocity sensors). Moreover, classical tests of the posterior column of the spinal tract (Romberg/Unterberger) and the dynamic posturography (sensory organization test, SOT) were included. It could be shown that SBDT tasks with reduced proprioceptive and visual cues (e.g. standing on foam, eyes closed) are most sensitive for an otolith disorder. The patients showed an increased trunk sway in the pitch plane (i.e. linear motion as adequate utricular stimulus) and an increase in sway velocities (i.e. tilting movements as adequate saccular stimulus) compared to controls. The SOT was most sensitive for combined (sacculo-utricular) otolith disorders (78%) while vestibulospinal tests are not enough sensitive. In essence, otolith disorders evidently impair human postural control and have been possibly underestimated as a source of posttraumatic postural imbalance as yet. (c) 2005 Elsevier B.V. All rights reserved.	Ukb, Dept Otolaryngol, Charite Med Sch, D-12683 Berlin, Germany; Benjamin Franklin Med Ctr, Charite Med Sch, Dept Otolaryngol, Vestibular Res Lab, Berlin, Germany	Ernst, A (corresponding author), Ukb, Dept Otolaryngol, Charite Med Sch, Warener Str 7, D-12683 Berlin, Germany.	arneborge@ukb.de					Akin F W, 2001, J Am Acad Audiol, V12, P445; Allum JHJ, 2003, AUDIOL NEURO-OTOL, V8, P286, DOI 10.1159/000071999; Allum JHJ, 2002, GAIT POSTURE, V16, P264, DOI 10.1016/S0966-6362(02)00011-5; Allum JHJ, 2001, GAIT POSTURE, V14, P227, DOI 10.1016/S0966-6362(01)00132-1; Allum JHJ, 2001, GAIT POSTURE, V14, P217, DOI 10.1016/S0966-6362(01)00142-4; Allum JHJ, 1999, J VESTIBUL RES-EQUIL, V9, P223; Allum JHJ, 1998, GAIT POSTURE, V8, P214, DOI 10.1016/S0966-6362(98)00027-7; Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; BLACK FO, 1984, ACTA OTO-LARYNGOL, P110; Bronstein AM, 2002, BRIT MED BULL, V63, P213, DOI 10.1093/bmb/63.1.213; BUCHELE W, 1979, AGRESSOLOGIE, V20, P221; Carpenter MG, 2001, EXP BRAIN RES, V140, P95, DOI 10.1007/s002210100802; Choy NL, 2003, J GERONTOL A-BIOL, V58, P525; Clarke AH, 2003, J VESTIBUL RES-EQUIL, V13, P215; Clarke AH, 1998, EXP BRAIN RES, V121, P457, DOI 10.1007/s002210050481; Colebatch JG, 2002, ADV EXP MED BIOL, V508, P105; COLEBATCH JG, 1994, J NEUROL NEUROSUR PS, V57, P190, DOI 10.1136/jnnp.57.2.190; Ernst A, 2005, OTOLARYNG HEAD NECK, V132, P554, DOI 10.1016/j.otohns.2004.09.034; ERNST A, 1998, AUDIOLOGY NEUROTOLOG; Fitzgerald DC, 1996, J TRAUMA, V40, P488, DOI 10.1097/00005373-199603000-00034; Gottshall K, 2003, LARYNGOSCOPE, V113, P1746, DOI 10.1097/00005537-200310000-00016; Guyot JP, 2001, ANN OTO RHINOL LARYN, V110, P562, DOI 10.1177/000348940111000611; INGERSOLL CD, 1992, MED SCI SPORT EXER, V24, P739; Kaufman GD, 2001, EXP BRAIN RES, V137, P397; King N, 1997, BRIT J CLIN PSYCHOL, V36, P161, DOI 10.1111/j.2044-8260.1997.tb01405.x; Lahat E, 1996, PEDIATR NEUROL, V15, P299, DOI 10.1016/S0887-8994(96)00221-4; Mergner T, 2003, ANN NY ACAD SCI, V1004, P303, DOI 10.1196/annals.1303.028; Paige GD, 2002, ANN NY ACAD SCI, V956, P314, DOI 10.1111/j.1749-6632.2002.tb02830.x; PETERSEN H, 1995, ACTA OTO-LARYNGOL, P443; RUBIN AM, 1995, AM J OTOL, V16, P216; Sans A, 2001, ADV OTO-RHINO-LARYNG, V58, P1; Sjostrom H, 2003, SPINE, V28, P1725, DOI 10.1097/00007632-200308010-00018; Welgampola MS, 2003, J NEUROL NEUROSUR PS, V74, P771, DOI 10.1136/jnnp.74.6.771; ZAMANI F, 2005, KLINISCHE ANWENDUNG	34	35	37	0	10	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0167-9457	1872-7646		HUM MOVEMENT SCI	Hum. Mov. Sci.	APR	2005	24	2					268	279		10.1016/j.humov.2005.04.002			12	Neurosciences; Psychology; Psychology, Experimental; Sport Sciences	Neurosciences & Neurology; Psychology; Sport Sciences	964GZ	WOS:000231868600009	15953652				2021-06-18	
J	Chan, RCK				Chan, RCK			Sustained attention in patients with mild traumatic brain injury	CLINICAL REHABILITATION			English	Article							CLOSED-HEAD-INJURY; EVERYDAY ATTENTION; FRONTAL LESIONS; SCHIZOPHRENIA; PERFORMANCE; DEFICITS; TASK; VALIDITY	Objective: To demonstrate that two tests of sustained attention were sensitive to attention deficits in patients with mild traumatic brain injury (TBI). Design: A cross-sectional study recruiting 51 patients with TBI and 51 matched controls. Outcome measures: The Sustained Attention to Response Task (SART) and Monotone Counting Test. Results: The patient groups performed significantly worse than the normal controls in both sustained attention tests. The SART performance was also correlated with pathology severity in the patient group in terms of loss of consciousness (r = 0.247, p = 0.05). A cut-off of less than 1 standard deviation (SD) gives optimal diagnostic information in terms of sensitivity in the present sample (0.61 for Monotone Counting Test; 0.75 for SART). Conclusion: These findings suggest that the SART and Monotone Counting Test are sensitive to patients with mild TBI. The SART-assessed sustained attention is also sensitive enough to detect attention impairment in this clinical group regardless of diagnosis and may provide clinicians with an alternative method of assessing sustained attention in these clinical groups.	Sun Yat Sen Univ, Dept Psychol, Neuropsychol & Appl Cognit Neurosci Lab, Guangzhou 510275, Peoples R China; Univ Hong Kong, Dept Psychiat, Hong Kong, Hong Kong, Peoples R China	Chan, RCK (corresponding author), Sun Yat Sen Univ, Dept Psychol, Neuropsychol & Appl Cognit Neurosci Lab, Guangzhou 510275, Peoples R China.	rckchan2003@yahoo.com.hk	Chan, Raymond CK/B-6717-2009	Chan, Raymond CK/0000-0002-3414-450X			Chan RCK, 2004, CLIN NEUROPSYCHOL, V18, P114, DOI 10.1080/13854040490507208; Chan RCK, 2003, BRAIN INJURY, V17, P131, DOI 10.1080/0269905021000010168; Chan RCK, 2002, CLIN REHABIL, V16, P900, DOI 10.1191/0269215502cr574oa; Chan RCK, 2000, BRAIN INJURY, V14, P227, DOI 10.1080/026990500120709; Chan RCK, 2002, J CLIN EXP NEUROPSYC, V24, P695, DOI 10.1076/jcen.24.5.695.1003; Chan RCK, 2001, BRAIN INJURY, V15, P819, DOI 10.1080/02699050119721; Chen EYH, 2001, EUR ARCH PSY CLIN N, V251, P1, DOI 10.1007/s004060170059; Chen EYH, 1997, SCHIZOPHR RES, V24, P299, DOI 10.1016/S0920-9964(96)00120-X; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; HOLDNACK JA, 1995, NEUROPSY NEUROPSY BE, V8, P282; Kurtz MM, 2001, SCHIZOPHR RES, V48, P307, DOI 10.1016/S0920-9964(00)00060-8; LEVIN HS, 1989, J NEUROL NEUROSUR PS, V52, P1162, DOI 10.1136/jnnp.52.10.1162; Manly T, 1999, NEUROPSYCHOLOGIA, V37, P661, DOI 10.1016/S0028-3932(98)00127-4; Norman D.A., 1986, CONSCIOUSNESS SELF R, V4, P1, DOI DOI 10.1007/978-1-4757-0629-1_1; Robertson I H, 1996, J Int Neuropsychol Soc, V2, P525; Robertson I. H., 1994, TEST EVERYDAY ATTENT; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Rueckert L, 1996, NEUROPSYCHOLOGIA, V34, P953, DOI 10.1016/0028-3932(96)00016-4; Snedecor G.W., 1980, STAT METHODS, V7th; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; TEASDALE G, 1974, LANCET, V2, P81; WILKINS AJ, 1987, NEUROPSYCHOLOGIA, V25, P359, DOI 10.1016/0028-3932(87)90024-8	22	35	36	1	3	ARNOLD, HODDER HEADLINE PLC	LONDON	338 EUSTON ROAD, LONDON NW1 3BH, ENGLAND	0269-2155			CLIN REHABIL	Clin. Rehabil.	MAR	2005	19	2					188	193		10.1191/0269215505cr838oa			6	Rehabilitation	Rehabilitation	901TY	WOS:000227306000009	15759534				2021-06-18	
J	Hunter, JV; Thornton, RJ; Wang, ZJ; Levin, HS; Roberson, G; Brooks, WM; Swank, PR				Hunter, JV; Thornton, RJ; Wang, ZJ; Levin, HS; Roberson, G; Brooks, WM; Swank, PR			Late proton MR spectroscopy in children after traumatic brain injury: Correlation with cognitive outcomes	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							MAGNETIC-RESONANCE-SPECTROSCOPY; METABOLITE CONCENTRATIONS; IN-VIVO; N-ACETYLASPARTATE; AXONAL INJURY; HEAD-INJURY; QUANTITATION; ASYMMETRY	BACKGROUND AND PURPOSE: Proton MR spectroscopy has demonstrated reduced levels of N-acetylaspartate (NAA) in normal-appearing occipital and frontal regions of patients with acute nonpenetrating traumatic brain injury (TBI). We studied the relationship of frontoparietal NAA, choline (Cho), and creatine (Cr) to test the hypothesis that reduction in NAA is predictive of cognitive outcome. METHODS: Proton spectra were collected by using conventional 2D chemical shift imaging in five healthy children and seven children (6 weeks to 3 years) with severe (n = 4), moderate (n = 2), or mild (n = 1) TBI. Spectra in the anterior and posterior regions of the left and right frontoparietal areas were averaged for analysis by using LCModel, with a phantom-established basis function, for quantification of NAA, Cho, and Cr concentrations. Intellectual function, expressive language, and arithmetic capability were measured within 4 months of imaging. RESULTS: NAA/Cho concentration was lower in TBI patients than in control subjects, but no group differences were present for Cho or Cr. Hemispheric levels for NAA, Cho, and Cr were higher on the left than on the right, but we found no effect of region and no interactions. Cognition was lower in the TBI group than the control group and correlated with NAA levels. Left frontal Cho was also correlated with arithmetic scores, whereas Cr was not significantly correlated. CONCLUSION. NAA levels remain low after TBI and are related to cognitive function. Neurometabolite values are greater in the left frontoparietal region than in the right, and the left frontal Cho level is related to arithmetic ability.	Texas Childrens Hosp, Baylor Coll Med, Dept OI, Houston, TX 77030 USA; Texas Childrens Hosp, Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Dept Pediat, Houston, TX 77225 USA; Univ Kansas, Med Ctr, Hoglund Imaging Ctr, Kansas City, KS 66103 USA	Hunter, JV (corresponding author), Texas Childrens Hosp, Baylor Coll Med, Dept OI, 6621 Fannin St, Houston, TX 77030 USA.		Wang, Zhiyue J/L-3851-2014	Wang, Zhiyue J/0000-0002-5649-2900; brooks, william/0000-0001-6227-7636	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS045573, R01NS021889] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21 NS045573, R21 NS-45573, R01 NS021889, R01 NS-21889] Funding Source: Medline		Ashwal S, 2000, PEDIATR NEUROL, V23, P114, DOI 10.1016/S0887-8994(00)00176-4; Brenner T, 2003, PEDIATR NEUROL, V28, P104, DOI 10.1016/S0887-8994(02)00491-5; Brooks WM, 2001, J HEAD TRAUMA REHAB, V16, P149, DOI 10.1097/00001199-200104000-00005; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Cady EB, 1996, MAGN RESON MED, V36, P878, DOI 10.1002/mrm.1910360610; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; Condon B, 1998, J NEUROTRAUM, V15, P563, DOI 10.1089/neu.1998.15.563; Donders J, 2000, J HEAD TRAUMA REHAB, V15, P792, DOI 10.1097/00001199-200004000-00004; Friedman SD, 1998, AM J NEURORADIOL, V19, P1879; Garnett MR, 2001, CURR OPIN NEUROL, V14, P753, DOI 10.1097/00019052-200112000-00012; Gonen O, 1998, MAGNET RESON MED, V40, P684, DOI 10.1002/mrm.1910400506; HUPPI PS, 1991, PEDIATR RES, V30, P574; HUPPI PS, 1995, PEDIATR RES, V37, P145; KREIS R, 1993, J MAGN RESON SER B, V102, P9, DOI 10.1006/jmrb.1993.1056; Maton B, 2001, J NEUROIMAGING, V11, P194, DOI 10.1111/j.1552-6569.2001.tb00033.x; Moore CM, 2002, SCHIZOPHR RES, V57, P35, DOI 10.1016/S0920-9964(01)00302-4; Pouwels PJW, 1998, MAGN RESON MED, V39, P53, DOI 10.1002/mrm.1910390110; PROVENCHER S, 2003, LCMODEL 1 LCMGUI 2 U; PROVENCHER SW, 1993, MAGNET RESON MED, V30, P672, DOI 10.1002/mrm.1910300604; Rubin Y, 1997, J NEUROTRAUM, V14, P441, DOI 10.1089/neu.1997.14.441; Semel E. M., 1995, CLIN EVALUATION LANG; Sinson G, 2001, AM J NEURORADIOL, V22, P143; Sowell ER, 2003, NAT NEUROSCI, V6, P309, DOI 10.1038/nn1008; Sowell ER, 2002, DEV MED CHILD NEUROL, V44, P4, DOI 10.1017/S0012162201001591; Sowell ER, 2002, CEREB CORTEX, V12, P17, DOI 10.1093/cercor/12.1.17; TEASDALE G, 1974, LANCET, V2, P81; TONG KA, 2002, P 10 ANN M ISMRM HON, P46; Wechsler D., 2011, WECHLSER ABBREVIATED; WOODCOCK RW, 1990, WOODCOCKJOHNSON TEST	29	35	36	0	3	AMER SOC NEURORADIOLOGY	OAK BROOK	2210 MIDWEST RD, OAK BROOK, IL 60521 USA	0195-6108			AM J NEURORADIOL	Am. J. Neuroradiol.	MAR	2005	26	3					482	488					7	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	906GK	WOS:000227628500008	15760852				2021-06-18	
J	Luukinen, H; Viramo, P; Herala, M; Kervinen, K; Kesaniemi, YA; Savola, O; Winqvist, S; Jokelainen, J; Hillbom, M				Luukinen, H; Viramo, P; Herala, M; Kervinen, K; Kesaniemi, YA; Savola, O; Winqvist, S; Jokelainen, J; Hillbom, M			Fall-related brain injuries and the risk of dementia in elderly people: a population-based study	EUROPEAN JOURNAL OF NEUROLOGY			English	Article						ApoE epsilon 4; brain injury; dementia; falling aged	APOLIPOPROTEIN-E EPSILON-4; SEVERE HEAD-INJURY; AMYLOID PROTEIN DEPOSITION; ONSET ALZHEIMERS-DISEASE; COGNITIVE DECLINE; E POLYMORPHISM; OLDER-ADULTS; E GENOTYPE; TRAUMA; AGE	Severe head injury in early adulthood may increase the risk of dementia in older age, but it is not known whether head injury in later life also increases the risk of dementia. A representative sample (82%) of persons aged 70 years or older with a Mini-Mental State Examination (MMSE) test score of greater than or equal to26 (n = 325) were followed-up for 9 years to record all their fall-related head injuries resulting in traumatic brain injury (TBI). At the end of the follow-up period, 152 persons (81% of the surviving population) were examined for clinical dementia, according to DSM-IV criteria. Eight persons sustained a TBI and 34 developed dementia. Brain injury was associated with younger age at detection of dementia even when adjusted for sex and educational status (low educational status significantly associated with dementia); age-specific hazard ratio (95% confidence interval) 2.80 (1.35-5.81). In a population scoring greater than or equal to28 points in the baseline MMSE an apolipoprotein E (ApoE) epsilon4 phenotype was also associated with younger age at the time of detecting dementia; 3.56 (1.35-9.34), and the effect of brain injury and ApoE epsilon4 phenotype was synergistic; 7.68 (2.32-25.3). We conclude that fall-related TBI predicts earlier onset of dementia and the effect is especially high amongst subjects who carry the ApoE epsilon4 allele.	Oulu Univ, Dept Publ Hlth Sci & Gen Practice, FIN-90014 Oulu, Finland; Oulu Univ Hosp, Unit Gen Practice, Oulu, Finland; Tornio Hlth Ctr, Tornio, Finland; Univ Oulu, Dept Internal Med, SF-90220 Oulu, Finland; Univ Oulu, Bioctr, SF-90220 Oulu, Finland; Univ Hosp Oulu, Dept Neurosurg, Oulu, Finland; Univ Hosp Oulu, Dept Neurol, Oulu, Finland	Luukinen, H (corresponding author), Oulu Univ, Dept Publ Hlth Sci & Gen Practice, PB 5000, FIN-90014 Oulu, Finland.	heikki.luukinen@oulu.fi		Jokelainen, Jari/0000-0003-4629-0560			AMADUCCI LA, 1986, NEUROLOGY, V36, P922, DOI 10.1212/WNL.36.7.922; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; BROE GA, 1990, NEUROLOGY, V40, P1698, DOI 10.1212/WNL.40.11.1698; CHANDRA V, 1987, NEUROLOGY, V37, P1295, DOI 10.1212/WNL.37.8.1295; CHANDRA V, 1989, NEUROLOGY, V39, P1576, DOI 10.1212/WNL.39.12.1576; Commenges D, 1998, STAT MED, V17, P1973, DOI 10.1002/(SICI)1097-0258(19980915)17:17<1973::AID-SIM892>3.0.CO;2-5; de Kruijk JR, 2001, BRAIN INJURY, V15, P99, DOI 10.1080/026990501458335; EHNHOLM C, 1986, J LIPID RES, V27, P227; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.278.16.1349; FERINISTRAMBI L, 1990, NEUROEPIDEMIOLOGY, V9, P39, DOI 10.1159/000110750; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FRATIGLIONI L, 1993, ANN NEUROL, V33, P258, DOI 10.1002/ana.410330306; GEDYE A, 1989, J AM GERIATR SOC, V37, P970, DOI 10.1111/j.1532-5415.1989.tb07283.x; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; GRAVES AB, 1990, AM J EPIDEMIOL, V131, P491, DOI 10.1093/oxfordjournals.aje.a115523; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; HEYMAN A, 1984, ANN NEUROL, V15, P335, DOI 10.1002/ana.410150406; HOLTZMAN DM, 1995, P NATL ACAD SCI USA, V92, P9480, DOI 10.1073/pnas.92.21.9480; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Juva K, 2000, NEUROLOGY, V54, P412, DOI 10.1212/WNL.54.2.412; Katzman R, 1996, NEUROLOGY, V46, P889; KATZMAN R, 1989, ANN NEUROL, V25, P317, DOI 10.1002/ana.410250402; Kutner KC, 2000, NEUROSURGERY, V47, P651, DOI 10.1097/00006123-200009000-00026; KUUSISTO J, 1994, BRIT MED J, V309, P636, DOI 10.1136/bmj.309.6955.636; LAMMI UK, 1989, SCAND J SOC MED, V17, P67, DOI 10.1177/140349488901700111; Launer LJ, 1999, NEUROLOGY, V52, P78, DOI 10.1212/WNL.52.1.78; Luukinen H, 1999, NEUROLOGY, V52, P557, DOI 10.1212/WNL.52.3.557; LUUKINEN H, 1995, J AM GERIATR SOC, V43, P871, DOI 10.1111/j.1532-5415.1995.tb05529.x; LUUKINEN H, 1994, J CLIN EPIDEMIOL, V47, P843, DOI 10.1016/0895-4356(94)90187-2; Luukinen H, 1999, J AM GERIATR SOC, V47, P1451, DOI 10.1111/j.1532-5415.1999.tb01566.x; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; MAYEUX R, 1993, ANN NEUROL, V33, P494, DOI 10.1002/ana.410330513; MAZZUCCHI A, 1992, J NEUROL, V239, P256; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; MORRIS JC, 1989, NEUROLOGY, V39, P1159, DOI 10.1212/wnl.43.12.2457; MORTIMER JA, 1985, NEUROLOGY, V35, P264, DOI 10.1212/WNL.35.2.264; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; OMeara ES, 1997, AM J EPIDEMIOL, V146, P373, DOI 10.1093/oxfordjournals.aje.a009290; PENTLAND B, 1986, AGE AGEING, V15, P193, DOI 10.1093/ageing/15.4.193; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; RASMUSSON DX, 1995, BRAIN INJURY, V9, P213, DOI 10.3109/02699059509008194; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; ROSEN WG, 1984, AM J PSYCHIAT, V141, P1356; Salib E, 1997, INT J GERIATR PSYCH, V12, P363, DOI 10.1002/(SICI)1099-1166(199703)12:3<363::AID-GPS515>3.0.CO;2-F; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; SHALAT SL, 1987, NEUROLOGY, V37, P1630, DOI 10.1212/WNL.37.10.1630; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; VANDUIJN CM, 1992, AM J EPIDEMIOL, V135, P775, DOI 10.1093/oxfordjournals.aje.a116364; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; WILLIAMS DB, 1991, NEUROLOGY, V41, P1554, DOI 10.1212/WNL.41.10.1554	56	35	35	0	5	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1351-5101			EUR J NEUROL	Eur. J. Neurol.	FEB	2005	12	2					86	92		10.1111/j.1468-1331.2004.00953.x			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	892ID	WOS:000226642900002	15679695				2021-06-18	
J	Bauer, L; Yantz, CL; Ryan, LM; Warden, DL; McCaffrey, RJ				Bauer, L; Yantz, CL; Ryan, LM; Warden, DL; McCaffrey, RJ			An examination of the california verbal learning test II to detect incomplete effort in a traumatic brain-injury sample	APPLIED NEUROPSYCHOLOGY			English	Article						California Verbal Learning Test II; effort testing; traumatic brain-injury		Clinical neuropsychologists are frequently called on to distinguish people who appear impaired on neuropsychological testing due to putting forth incomplete effort from those who have genuine cognitive deficits. Because traditional measures of effort are becoming accessible over the Internet and within the legal community and their purpose may be obvious to potential malingerers, nontraditional effort measures have been newly investigated. Using discriminant function analysis, this study explores whether five California Verbal Learning Test-Second Edition (CVLT-II) variables could differentiate between head-injured patients who were putting forth full effort and those who were putting forth incomplete effort. The discriminant function seemed to best predict those who put forth adequate effort while testing (95.6% correct) but not those who failed to put forth adequate effort during testing (only 13.8% correct). Hence, although the overall classification rate was moderately impressive (75.8%), the model's sensitivity in classification of the incomplete effort group was low. Cautious applications for these findings are discussed.	SUNY Albany, Dept Psychol, Albany, NY 12222 USA; SUNY Albany, Dept Psychol, New York, NY USA; Walter Reed Army Med Ctr, Defense & Vet Brain Injury Ctr, Washington, DC 20307 USA; Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA	McCaffrey, RJ (corresponding author), SUNY Albany, Dept Psychol, Albany, NY 12222 USA.	rm188@albany.edu					Allen L, 1999, ARCH CLIN NEUROPSYCH, V14, P789, DOI 10.1016/S0887-6177(99)80328-X; AMRTENS M, 2001, J FORENSIC NEUROPSYC, V2, P1; Ashendorf L, 2003, CLIN NEUROPSYCHOL, V17, P255, DOI 10.1076/clin.17.2.255.16502; Delis DC, 2000, CALIFORNIA VERBAL LE; Delis DC, 1987, CALIFORNIA VERBAL LE; GREEN OP, 2003, GREENS WORD MEMORY T; Green P., 2003, J FORENSIC NEUROPSYC, V2, P97, DOI DOI 10.1300/J151V02N03_05; GREEN P, 1996, WORD MEMORY TEST MAN; Hartman DE, 2002, ARCH CLIN NEUROPSYCH, V17, P709, DOI 10.1016/S0887-6177(01)00172-X; IVERSON G, 1999, J COGNITIVE REHABILI, V17, P21; Millis SR, 1995, PSYCHOL ASSESSMENT, V7, P463; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Rees LM, 1998, PSYCHOL ASSESSMENT, V10, P10, DOI 10.1037/1040-3590.10.1.10; Slick DJ, 2000, J CLIN EXP NEUROPSYC, V22, P569, DOI 10.1076/1380-3395(200010)22:5;1-9;FT569; Sweet JJ, 2000, ARCH CLIN NEUROPSYCH, V15, P105, DOI 10.1016/S0887-6177(98)00153-X; Tabachnick B., 2001, USING MULTIVARIATE S; Tombaugh T.N., 2003, J FORENSIC NEUROPSYC, V2, P69, DOI [DOI 10.1300/J151V02N03_04, 10.1300/J151v02n03_04]; Tombaugh TN, 1996, TEST MEMORY MALINGER; TRUEBLOOD W, 1994, J CLIN EXP NEUROPSYC, V16, P597, DOI 10.1080/01688639408402671; CLIN PSYCHOL, V17, P263	20	35	36	0	3	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0908-4282	1532-4826		APPL NEUROPSYCHOL	Appl. Neuropsychol.		2005	12	4					202	207		10.1207/s15324826an1204_3			6	Clinical Neurology; Psychology	Neurosciences & Neurology; Psychology	006EH	WOS:000234877800003	16422661				2021-06-18	
J	Hepp, U; Moergeli, H; Buchi, S; Wittmann, L; Schnyder, U				Hepp, U; Moergeli, H; Buchi, S; Wittmann, L; Schnyder, U			Coping with serious accidental injury: A one-year follow-up study	PSYCHOTHERAPY AND PSYCHOSOMATICS			English	Article						posttraumatic stress disorder; coping, accidents; sense of coherence; intensive care unit	POSTTRAUMATIC-STRESS-DISORDER; MOTOR-VEHICLE ACCIDENTS; TRAUMATIC BRAIN-INJURY; ADMINISTERED PTSD SCALE; COHERENCE; SENSE; SYMPTOMS; RESPONSIBILITY; SEVERITY; VICTIMS	Background: The aim of this study was to analyze changes of coping strategies in severely injured accident victims over time and to compare patients with high and low posttraumatic stress disorder (PTSD) symptom levels with regard to their coping patterns and accident-related cognitions. Methods: 106 consecutive patients with severe accidental injuries admitted to a trauma surgery intensive care unit (ICU) were assessed within 1 month after the trauma and 6 and 12 months later. Assessments included a clinical interview, the Freiburg Questionnaire of Coping with Illness, the patients' accident-related cognitions, the Clinician-Administered PTSD Scale, the 90-item revised Symptom Checklist (SCL- 90-R), and the Sense of Coherence Questionnaire (SOC). Patients who met the criteria for either full or subsyndromal PTSD at least once over the observation period (36 subjects; 34.0%) were assigned to a highly symptomatic group HSG), the remainder (70 subjects; 66.0%) to a less symptomatic group. Results: Overall, active problem-focused coping was predominant immediately after the accident and declined over time, with a stronger decrease in the HSG. Patients in the HSG scored higher on the SCL Global Severity Index and lower on the SOC. The patients' subjective appraisal of accident severity was higher in the HSG, whereas there was no group difference with regard to accident-related variables such as type of accident, injury severity and mild to moderate traumatic brain injury. Conclusions: Active problem- focused coping, although utilized most frequently and often regarded as protective, might be an inadequate strategy in face of acute stress following a severe accident. Clinicians should not expect their patients to cope very actively in the acute ICU phase. In the subsequent rehabilitation, active coping seems to be more adaptive. Copyright (c) 2005 S. Karger AG, Basel.	Univ Zurich Hosp, Dept Psychiat, CH-8091 Zurich, Switzerland	Hepp, U (corresponding author), Univ Zurich Hosp, Dept Psychiat, Culmannstr 8, CH-8091 Zurich, Switzerland.	Urs.Hepp@usz.ch		Schnyder, Ulrich/0000-0003-3556-7990			American Psychiatric Association, 1987, DIAGN STAT MAN MENT; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; ANTONOVSKY A, 1993, SOC SCI MED, V36, P725, DOI 10.1016/0277-9536(93)90033-Z; Antonovsky A., 1987, UNRAVELING MYSTERY H; BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; BLAKE DD, 1990, BEHAV THERAPIST, V8, P187; BLANCHARD EB, 1995, J NERV MENT DIS, V183, P495, DOI 10.1097/00005053-199508000-00001; Breslau N, 1997, ARCH GEN PSYCHIAT, V54, P1044; Brewin CR, 2000, J CONSULT CLIN PSYCH, V68, P748, DOI 10.1037/0022-006X.68.5.748; Bryant RA, 2000, AM J PSYCHIAT, V157, P629, DOI 10.1176/appi.ajp.157.4.629; Bryant RA, 2000, BRAIN INJURY, V14, P175, DOI 10.1080/026990500120826; Bryant RA, 1999, BRAIN INJURY, V13, P15, DOI 10.1080/026990599121836; Buchi S, 1998, J RHEUMATOL, V25, P869; Chung MC, 2001, AUST NZ J PSYCHIAT, V35, P528, DOI 10.1046/j.1440-1614.2001.00922.x; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; Delahanty DL, 1997, J CONSULT CLIN PSYCH, V65, P560, DOI 10.1037/0022-006X.65.4.560; Derogatis LR, 1986, SCL 90 R ADM SCORING; Franke G, 1995, SCL 90 R SYMPTOMCHEC; Frommberger U, 1999, J PSYCHOSOM RES, V46, P343, DOI 10.1016/S0022-3999(98)00117-2; Fuglsang AK, 2002, PSYCHOTHER PSYCHOSOM, V71, P214; Geyer S, 1997, SOC SCI MED, V44, P1771, DOI 10.1016/S0277-9536(96)00286-9; Ginzburg K, 2002, PSYCHOSOM MED, V64, P748, DOI 10.1097/01.PSY.0000021949.04969.2E; GREEN MM, 1993, MED J AUSTRALIA, V159, P529, DOI 10.5694/j.1326-5377.1993.tb138006.x; Harvey AG, 1998, BRAIN INJURY, V12, P147, DOI 10.1080/026990598122773; Heim E, 1998, PSYCHOTHER PSYCH MED, V48, P321; Hickling EJ, 1999, J TRAUMA STRESS, V12, P345, DOI 10.1023/A:1024784711484; Lazarus R.S., 1984, STRESS APPRAISAL COP; LAZARUS RS, 1993, PSYCHOSOM MED, V55, P234, DOI 10.1097/00006842-199305000-00002; Malt U F, 1992, Psychiatr Med, V10, P135; Malt U F, 1992, Psychiatr Med, V10, P117; Mayou RA, 2000, BRIT J PSYCHIAT, V177, P540, DOI 10.1192/bjp.177.6.540; Moore A D, 1994, Int J Rehabil Res, V17, P39, DOI 10.1097/00004356-199403000-00004; Muthny FA., 1989, FREIBURGER FRAGEBOGE; Nilsson B, 2003, SCAND J PUBLIC HEALT, V31, P297, DOI 10.1080/14034940210164920; Roesch SC, 2001, J PSYCHOSOM RES, V50, P205, DOI 10.1016/S0022-3999(01)00188-X; Schnyder U, 2000, PSYCHOTHER PSYCHOSOM, V69, P296, DOI 10.1159/000012411; Schnyder U, 2003, AM J PSYCHIAT, V160, P2025, DOI 10.1176/appi.ajp.160.11.2025; Schnyder U, 2002, J TRAUMA STRESS, V15, P487, DOI 10.1023/A:1020922023090; Schnyder U, 2001, AM J PSYCHIAT, V158, P594, DOI 10.1176/appi.ajp.158.4.594; Sharkansky EJ, 2000, J ABNORM PSYCHOL, V109, P188, DOI 10.1037/0021-843X.109.2.188; SOLOMON Z, 1988, J PERS SOC PSYCHOL, V55, P279, DOI 10.1037/0022-3514.55.2.279; SPURRELL MT, 1993, SOC PSYCH PSYCH EPID, V28, P194, DOI 10.1007/BF00797323; Stein MB, 1997, AM J PSYCHIAT, V154, P1114; TEASDALE G, 1974, LANCET, V2, P81	45	35	36	0	9	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0033-3190			PSYCHOTHER PSYCHOSOM	Psychother. Psychosom.		2005	74	6					379	386		10.1159/000087786			8	Psychiatry; Psychology	Psychiatry; Psychology	975LU	WOS:000232664800008	16244515				2021-06-18	
J	Sayyah, M; Beheshti, S; Shokrgozar, MA; Eslami-Far, A; Deljoo, Z; Khabiri, AR; Rohani, AH				Sayyah, M; Beheshti, S; Shokrgozar, MA; Eslami-Far, A; Deljoo, Z; Khabiri, AR; Rohani, AH			Antiepileptogenic and anticonvulsant activity of interleukin-1 beta in amygdala-kindled rats	EXPERIMENTAL NEUROLOGY			English	Article						amygdala kindling; interleukin-1 beta; seizure; nitric oxide; prostaglandins	PENTYLENETETRAZOL-INDUCED SEIZURES; NITRIC-OXIDE SYNTHASE; MESSENGER-RNA; KAINIC ACID; INFLAMMATORY CYTOKINES; SYNAPTIC-TRANSMISSION; RECEPTOR ANTAGONIST; TNF-ALPHA; BRAIN; EPILEPSY	Ischaemic, excitotoxic and traumatic brain injuries have been associated with the occurrence of epileptic seizures. Microglia, the principal immune cells in the brain, produce a variety of proinflammatory and cytotoxic factors especially interleukin-1 (IL-1) early after an acute insult. We studied the effect of intracerebroventricularly administered IL-1beta on seizure acquisition and on fully kindled seizures in amygdala kindling model of epilepsy. IL-1beta (0.01 ng/rat) retarded acquisition of kindled behavioral seizures and growth of afterdischarges (AD). IL-1beta (0.01-10 ng/rat) also exhibited significant anticonvulsant effect on established kindled seizures and AD duration. This effect began 0.5 h after administration and was continued up to 72 h. Pretreatment of the kindled animals with nitric oxide synthase inhibitor, N-G-nitro-L-arginine methyl ester, or cyclooxygenase inhibitor, piroxicam, reversed the anticonvulsant effect of IL-1beta at early time points. Although most of the previous studies indicate a proconvulsant or convulsant property of IL-1, our results support a protective and antiepileptogenic role of IL-1beta. (C) 2004 Elsevier Inc. All rights reserved.	Inst Pasteur, Dept Physiol & Pharmacol, Tehran 13164, Iran; Univ Tehran, Fac Sci, Dept Physiol, Tehran, Iran; Inst Pasteur, Natl Cell Bank Iran, Tehran, Iran; Inst Pasteur, Dept Clin Res, Tehran, Iran; Inst Pasteur, Dept Parasitol, Tehran, Iran	Sayyah, M (corresponding author), Inst Pasteur, Dept Physiol & Pharmacol, Pasteur Ave, Tehran 13164, Iran.	sayyah@pasteur.ac.ir	shokrgozar, mohammad ali/L-4149-2017; Sayyah, Mohammad/K-4871-2017; Beheshti, Siamak/AAB-2169-2021	shokrgozar, mohammad ali/0000-0001-5123-4155; Sayyah, Mohammad/0000-0003-0603-2444; Beheshti, Siamak/0000-0002-5128-8935			Akarsu ES, 1998, EPILEPSY RES, V30, P63; AKARSU ES, 1992, METHOD FIND EXP CLIN, V14, P517; Alexander CB, 1998, EUR J PHARMACOL, V344, P15, DOI 10.1016/S0014-2999(97)01551-3; Avital A, 2003, HIPPOCAMPUS, V13, P826, DOI 10.1002/hipo.10135; Bengzon J, 1997, P NATL ACAD SCI USA, V94, P10432, DOI 10.1073/pnas.94.19.10432; CARSON FL, 1990, AM SOC CLIN PATHOL, P170; Coogan A, 1997, NEUROREPORT, V8, P2107, DOI 10.1097/00001756-199707070-00004; De Simoni MG, 2000, EUR J NEUROSCI, V12, P2623, DOI 10.1046/j.1460-9568.2000.00140.x; de Vasconcelos AP, 2000, EPILEPSIA, V41, P363; DelBel EA, 1997, BRAZ J MED BIOL RES, V30, P971, DOI 10.1590/S0100-879X1997000800010; Eriksson C, 1998, MOL BRAIN RES, V58, P195, DOI 10.1016/S0169-328X(98)00125-9; Gahring LC, 1997, NEUROBIOL DIS, V3, P263, DOI 10.1006/nbdi.1996.0123; Herman ST, 2002, NEUROLOGY, V59, pS21, DOI 10.1212/WNL.59.9_suppl_5.S21; Jayakumar AR, 1999, BRAIN RES BULL, V48, P387, DOI 10.1016/S0361-9230(99)00011-8; Jelenkovic A, 2002, ANN NY ACAD SCI, V962, P296, DOI 10.1111/j.1749-6632.2002.tb04075.x; KATSUKI H, 1990, EUR J PHARMACOL, V181, P323, DOI 10.1016/0014-2999(90)90099-R; Krueger JM, 1998, ANN NY ACAD SCI, V856, P148, DOI 10.1111/j.1749-6632.1998.tb08323.x; Marangoz C, 2001, JPN J PHARMACOL, V86, P297, DOI 10.1254/jjp.86.297; MCNAMARA JO, 1980, PROG NEUROBIOL, V15, P139, DOI 10.1016/0301-0082(80)90006-4; Medeiros FD, 1997, ARQ NEURO-PSIQUIAT, V55, P677; MILLER LG, 1991, MOL PHARMACOL, V39, P105; MINAMI M, 1991, BIOCHEM BIOPH RES CO, V176, P593, DOI 10.1016/S0006-291X(05)80225-6; Murray CA, 1998, J NEUROSCI, V18, P2974; OPP MR, 1991, AM J PHYSIOL, V260, pR453; Paoletti AM, 1998, EXP NEUROL, V149, P349, DOI 10.1006/exnr.1997.6741; Plata-Salaman CR, 2000, MOL BRAIN RES, V75, P248, DOI 10.1016/S0169-328X(99)00306-X; Porter R. J., 2001, BASIC CLIN PHARM, P395; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; RONDOUIN G, 1992, NEUROREPORT, V3, P805, DOI 10.1097/00001756-199209000-00021; Ross FM, 2003, J NEUROIMMUNOL, V144, P61, DOI 10.1016/j.jneuroim.2003.08.030; Roth J, 1998, LIFE SCI, V62, pPL345, DOI 10.1016/S0024-3205(98)00179-9; Rothwell N, 2003, BRAIN BEHAV IMMUN, V17, P152, DOI 10.1016/S0889-1591(02)00098-3; Rothwell NJ, 2000, TRENDS NEUROSCI, V23, P618, DOI 10.1016/S0166-2236(00)01661-1; ROTHWELL NJ, 1995, TRENDS NEUROSCI, V18, P130, DOI 10.1016/0166-2236(95)93890-A; Sayyah M, 2003, EPILEPSY RES, V57, P175, DOI 10.1016/j.eplepsyres.2003.11.002; SHENG JG, 1994, J NEUROCHEM, V63, P1872; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Temkin NR, 2001, DRUGS, V61, P1045, DOI 10.2165/00003495-200161080-00002; Vereker E, 2000, J NEUROSCI, V20, P6811, DOI 10.1523/JNEUROSCI.20-18-06811.2000; Vezzani A, 2002, EPILEPSIA, V43, P30, DOI 10.1046/j.1528-1157.43.s.5.14.x; Vezzani A, 2000, P NATL ACAD SCI USA, V97, P11534, DOI 10.1073/pnas.190206797; YABUUCHI K, 1993, MOL BRAIN RES, V20, P153, DOI 10.1016/0169-328X(93)90121-5; YU BJ, 1994, J PHARMACOL EXP THER, V271, P590; ZEISE ML, 1992, REGUL PEPTIDES, V39, P1, DOI 10.1016/0167-0115(92)90002-C	44	35	43	0	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JAN	2005	191	1					145	153		10.1016/j.expneurol.2004.08.032			9	Neurosciences	Neurosciences & Neurology	886KK	WOS:000226225900015	15589521				2021-06-18	
J	Dash, PK; Moore, AN; Moody, MR; Treadwell, R; Felix, JL; Clifton, GL				Dash, PK; Moore, AN; Moody, MR; Treadwell, R; Felix, JL; Clifton, GL			Post-trauma administration of caffeine plus ethanol reduces contusion volume and improves working memory in rats	JOURNAL OF NEUROTRAUMA			English	Article						caffeinol; combination therapy; hippocampus; prefrontal cortex; trace fear conditioning; working memory	TRAUMATIC BRAIN-INJURY; OUTCOME FOLLOWING MODERATE; CORTICAL IMPACT INJURY; PREFRONTAL CORTEX; HEAD TRAUMA; DEFICITS; DAMAGE; TRACE; MODEL; INTOXICATION	It has been demonstrated that ethanol exerts dose-dependent effects, both beneficial and detrimental, on the outcome of traumatic brain injury (TBI). Recently, it has been reported that co-administration of caffeine (10 mg/kg) and a low amount of alcohol (0.65 g/kg; caffeinol) reduces cortical infarct volume up to 80%, and improves motor coordination, following a rodent model of reversible common carotid/middle cerebral artery occlusion. However, the protective effects of caffeinol following other CNS insults, nor its influence on cognitive function, have been examined. Using a controlled cortical impact model of brain injury, the effect of caffeinol administration on TBI-associated motor and cognitive deficits was assessed. When given 15 min following injury, caffeinol reduced cortical tissue loss and improved working memory. However, no influence on motor skills, Morris water maze performance or associative learning and memory was observed. Delayed administration (6 h post-injury) of caffeinol containing a dose of ethanol (I g/kg) previously demonstrated to improve motor performance eliminated the working memory benefit and cortical protection. These results indicate that early administration of caffeinol may be beneficial in lessening some of the deficits and cortical tissue loss associated with brain trauma.	Univ Texas, Sch Med, Smith Ctr Neurol Res, Dept Neurobiol, Houston, TX 77225 USA; Univ Texas, Sch Med, Smith Ctr Neurol Res, Dept Anat, Houston, TX 77225 USA	Dash, PK (corresponding author), Univ Texas, Sch Med, Smith Ctr Neurol Res, Dept Neurobiol, POB 20708, Houston, TX 77225 USA.	p.dash@uth.tmc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035457] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS35457] Funding Source: Medline		ALBIN MS, 1986, CRIT CARE MED, V14, P841, DOI 10.1097/00003246-198610000-00001; Aronowski J, 1996, J CEREBR BLOOD F MET, V16, P705, DOI 10.1097/00004647-199607000-00022; Baddeley A, 2010, CURR BIOL, V20, pR136, DOI 10.1016/j.cub.2009.12.014; Clifton GL, 2001, J NEUROSURG, V95, P751, DOI 10.3171/jns.2001.95.5.0751; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; DASH PK, 1995, J NEUROSCI, V15, P2030; Devasagayam TPA, 1996, BBA-BIOMEMBRANES, V1282, P63, DOI 10.1016/0005-2736(96)00040-5; DeWitt D S, 1995, New Horiz, V3, P376; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FLAMM ES, 1977, J NEUROSURG, V46, P328, DOI 10.3171/jns.1977.46.3.0328; FULLER MG, 1994, J NEUROPSYCH CLIN N, V6, P143; Hamm RJ, 1996, J NEUROTRAUM, V13, P317, DOI 10.1089/neu.1996.13.317; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Ikonomidou C, 1996, METAB BRAIN DIS, V11, P125, DOI 10.1007/BF02069500; Janis LS, 1998, J NEUROTRAUM, V15, P105, DOI 10.1089/neu.1998.15.105; Katoh H, 1998, ACT NEUR S, V71, P247; Kelly DF, 1997, J NEUROSURG, V86, P876, DOI 10.3171/jns.1997.86.5.0876; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Lesort M, 1997, NEUROSCI LETT, V221, P213, DOI 10.1016/S0304-3940(96)13310-3; Levin HS, 2002, ANN NEUROL, V52, P82, DOI 10.1002/ana.10252; LOVINGER DM, 1989, SCIENCE, V243, P1721, DOI 10.1126/science.2467382; MARTINEZSERRANO A, 1989, BIOCHEM BIOPH RES CO, V161, P965, DOI 10.1016/0006-291X(89)91337-5; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; McEchron MD, 1998, HIPPOCAMPUS, V8, P638, DOI 10.1002/(SICI)1098-1063(1998)8:6<638::AID-HIPO6>3.0.CO;2-Q; McLaughlin J, 2002, BEHAV NEUROSCI, V116, P37, DOI 10.1037//0735-7044.116.1.37; MEANEY DF, 1994, J NEUROTRAUM, V11, P599, DOI 10.1089/neu.1994.11.599; Murphy BL, 1996, J NEUROSCI, V16, P7768; Ongini E, 1996, TRENDS PHARMACOL SCI, V17, P364, DOI 10.1016/S0165-6147(96)10045-6; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Piriyawat P, 2003, STROKE, V34, P1242, DOI 10.1161/01.STR.0000067706.23777.04; Quinn JJ, 2002, HIPPOCAMPUS, V12, P495, DOI 10.1002/hipo.10029; Ragozzino ME, 2002, LEARN MEMORY, V9, P18, DOI 10.1101/lm.45802; Rao VLR, 2001, BRAIN RES, V911, P96; ROLLS ET, 1994, J NEUROL NEUROSUR PS, V57, P1518, DOI 10.1136/jnnp.57.12.1518; Rose ME, 2002, BRAIN RES, V943, P15, DOI 10.1016/S0006-8993(02)02471-X; Runyan JD, 2004, J NEUROSCI, V24, P1288, DOI 10.1523/JNEUROSCI.4880-03.2004; Sebastiao AM, 1996, PROG NEUROBIOL, V48, P167, DOI 10.1016/0301-0082(95)00035-6; Sebastiao AM, 2000, TRENDS PHARMACOL SCI, V21, P341, DOI 10.1016/S0165-6147(00)01517-0; Shapira Y, 1997, J NEUROSURG ANESTH, V9, P118, DOI 10.1097/00008506-199704000-00003; STROEMER RP, 1995, STROKE, V26, P2135, DOI 10.1161/01.STR.26.11.2135; Strong R, 2000, NEUROPHARMACOLOGY, V39, P515, DOI 10.1016/S0028-3908(99)00156-2; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Vitaz TW, 2003, SURG NEUROL, V60, P285, DOI 10.1016/S0090-3019(03)00378-1; Whitten RJ, 1996, ALCOHOL CLIN EXP RES, V20, P1313, DOI 10.1111/j.1530-0277.1996.tb01128.x; Wilde EA, 2004, J NEUROTRAUM, V21, P137, DOI 10.1089/089771504322778604; WORLEY PF, 1993, J NEUROSCI, V13, P4776; YAMAKAMI I, 1995, J NEUROSURG, V82, P813, DOI 10.3171/jns.1995.82.5.0813; Zink BJ, 1998, J NEUROSURG, V89, P983, DOI 10.3171/jns.1998.89.6.0983	53	35	37	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2004	21	11					1573	1583		10.1089/neu.2004.21.1573			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	872IL	WOS:000225200800005	15684650				2021-06-18	
J	Kamineni, S; Ankem, H; Sanghavi, S				Kamineni, S; Ankem, H; Sanghavi, S			Anatomical considerations for percutaneous proximal humeral fracture fixation	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						proximal humerus; fracture; percutaneous pin fixation; neurovascular injury	4-PART FRACTURES; 3-PART; NECK; HEAD	Purpose: To investigate the hypothesis that percutaneous wire fixation of proximal humeral fractures is prone to regional neurovascular injury. Materials and Methods: 40 cadaveric shoulders had percutaneous wires inserted from anterior and lateral humeral shaft entry points into the humeral head. The shoulders were then dissected to identify the neurovascular structures in this area. Results: The axillary nerve trunk and posterior circumflex humeral artery were found to be within the field of dissection. The axillary nerve was damaged on three occasions by the lateral wires, two of which were direct nerve penetrations. The anterior wires caused a single perineural injury of a terminal branch. The main neurovascular leash was 57 mm (range 35-70 mm) from the acromion tip laterally and 51 mm (range 35-85 mm) anteriorly, with a width of 6 mm (range 4-13 mm) laterally, and 12 mm (range 7-15 mm) anteriorly. Conclusions: Percutaneous wire stabilisation is an attractive fixation option but this study highlights the close proximity of the important neurovasculature. Such fixation should be performed utilising a limited open approach, with dissection to bone under direct vision, with the subsequent use of a drill-sleeve for soft-tissue protection. (C) 2003 Elsevier Ltd. All rights reserved.	Univ London Imperial Coll Sci Technol & Med, Dept Orthopaed Surg, London W6 8RF, England; Hillingdon Gen Hosp, Dept Orthopaed, Uxbridge UB8 3NN, Middx, England	Kamineni, S (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Orthopaed Surg, Charing Cross Campus, London W6 8RF, England.						BROOKS CH, 1993, J BONE JOINT SURG BR, V75, P132; Burkhart SS, 1996, ARTHROSCOPY, V12, P634, DOI 10.1016/S0749-8063(96)90206-6; Burkhead W Z Jr, 1992, J Shoulder Elbow Surg, V1, P31, DOI 10.1016/S1058-2746(09)80014-1; CLIFFORD PC, 1980, INJURY, V12, P91, DOI 10.1016/0020-1383(80)90129-1; GERBER C, 1990, J BONE JOINT SURG AM, V72A, P1486, DOI 10.2106/00004623-199072100-00009; HAGG O, 1984, SURG SHOULDER, P354; JABERG H, 1992, J BONE JOINT SURG AM, V74A, P508, DOI 10.2106/00004623-199274040-00006; MUNST P, 1992, ORTHOPADE, V21, P121; NEER CS, 1970, J BONE JOINT SURG AM, VA 52, P1090, DOI 10.2106/00004623-197052060-00002; Resch H, 1997, J BONE JOINT SURG BR, V79B, P295, DOI 10.1302/0301-620X.79B2.6958; STABLEFORTH PG, 1984, J BONE JOINT SURG BR, V66, P104	11	35	38	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383			INJURY	Injury-Int. J. Care Inj.	NOV	2004	35	11					1133	1136		10.1016/j.injury.2003.08.008			4	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	866QG	WOS:000224787400009	15488504				2021-06-18	
J	Guskiewicz, KM; Bruce, SL; Cantu, RC; Ferrara, MS; Kelly, JP; McCrea, M; Putukian, M; Valovich, TC				Guskiewicz, KM; Bruce, SL; Cantu, RC; Ferrara, MS; Kelly, JP; McCrea, M; Putukian, M; Valovich, TC			Recommendations on management of sport-related concussion: Summary of the National Athletic Trainers' Association position statement	NEUROSURGERY			English	Article							NEUROPSYCHOLOGICAL TEST-PERFORMANCE; COMPUTERIZED COGNITIVE ASSESSMENT; COLLEGIATE FOOTBALL PLAYERS; POSTURAL STABILITY; SAFE RETURN; HEAD-INJURY; MILD; RECOVERY; PATHOPHYSIOLOGY; CONSCIOUSNESS		Univ N Carolina, Dept Exercise & Sport Sci, Sports Med Res Lab, Chapel Hill, NC 27599 USA; Calif State Univ Penn, California, PA USA; Emerson Hosp, Neurosurg Serv, Concord, MA USA; Brigham & Womens Hosp, Neurol Sports Injury Ctr, Boston, MA 02115 USA; Univ Georgia, Athens, GA 30602 USA; Univ Colorado, Sch Med, Dept Neurosurg, Denver, CO USA; Waukesha Mem Hosp, Program Neurosci, Neuropsychol Serv, Waukesha, WI USA; Princeton Univ, Princeton, NJ 08544 USA; Arizona Sch Hlth Sci, Dept Sport Hlth Care, Mesa, AZ USA	Guskiewicz, KM (corresponding author), Univ N Carolina, Dept Exercise & Sport Sci, Sports Med Res Lab, 211 Fetzer Gym CB 8700, Chapel Hill, NC 27599 USA.	gus@email.unc.edu	Bruce, Scott L./AAQ-1907-2020; McLeod, Tamara/AAU-9435-2020	Bruce, Scott L./0000-0002-3251-073X; Guskiewicz, Kevin/0000-0002-8682-2130			Adams J, 2001, J PEDIATR SURG, V36, P119, DOI 10.1053/jpsu.2001.20026; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bailes JE, 2001, J ATHL TRAINING, V36, P236; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Daniel JC, 1999, NEUROPSY NEUROPSY BE, V12, P167; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P167, DOI 10.1136/jnnp.73.2.167; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; GUSKIEWICZ KM, 2004, AM J MED SPORTS, V6, P13; Halstead PD, 2001, J ATHL TRAINING, V36, P322; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Kelly JP, 1997, NEUROLOGY, V48, P581; Kelly JP, 2001, J ATHL TRAINING, V36, P249; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Makdissi M, 2001, BRIT J SPORT MED, V35, P354, DOI 10.1136/bjsm.35.5.354; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrea M, 2001, J ATHL TRAINING, V36, P274; McCrea M, 2001, CLIN J SPORT MED, V11, P176, DOI 10.1097/00042752-200107000-00008; McCrory P, 2002, BRIT J SPORT MED, V36, P316, DOI 10.1136/bjsm.36.5.316; McCrory PR, 2000, CLIN J SPORT MED, V10, P235, DOI 10.1097/00042752-200010000-00002; MUELLER FO, 2002, 19 NAT CTR CAT SPORT; Oliaro S, 2001, J ATHL TRAINING, V36, P257; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Pottinger LS, 1999, ARCH CLIN NEUROPSYCH, V14, P39, DOI 10.1093/arclin/14.1.39a; Riemann BL, 2000, J ATHL TRAINING, V35, P19	43	35	37	0	4	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	OCT	2004	55	4					891	895		10.1227/01.NEU.0000143800.49798.19			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	860AI	WOS:000224309100035	15458597				2021-06-18	
J	Kunihara, T; Matsuzaki, K; Shiiya, N; Saijo, Y; Yasuda, K				Kunihara, T; Matsuzaki, K; Shiiya, N; Saijo, Y; Yasuda, K			Naloxone lowers cerebrospinal fluid levels of excitatory amino acids after thoracoabdominal aortic surgery	JOURNAL OF VASCULAR SURGERY			English	Article							TRAUMATIC BRAIN-INJURY; SPINAL-CORD ISCHEMIA; CEREBRAL-ISCHEMIA; EXTRACELLULAR GLUTAMATE; ANEURYSM REPAIR; ASPARTIC ACID; RELEASE; CSF; RECEPTOR; STROKE	Objective: Although naloxone has been used to prevent ischemic spinal cord injury (SCI), its effect on excitatory amino acids (EAAs) has not been understood. We investigated the clinical significance of naloxone by measuring EAAs in the cerebrospinal fluid (CSF) in patients undergoing thoracoabdominal aortic surgery. Methods and subjects: Twenty-seven patients (15 men and 12 women; mean age, 66 +/- 12 years) undergoing prosthetic replacement of the thoracoabdominal aorta (n = 19) or the descending thoracic aorta (n = 8) from April 1997 to June 2003 under distal perfusion and mild hypothermia were enrolled in this cohort study with historical controls. Their etiology was 7 dissections and 20 nondissections. In 16 patients (naloxone group), intravenous infusion of naloxone (1 mug/kg/h) was continued until the patients became alert. In the remaining 11 patients (control group) naloxone was not given. CSF drainage was used in all patients. CSF levels of EAAs, glutamate, aspartate, and glycine were measured at 6 points in time until 72 hours postoperatively, using a high-performance liquid chromatography method. Results: In 5 patients with SCI (2 patients in control group, 3 in naloxone group), CSF levels of glutamate and glycine continued to increase even at 72 hours postoperatively, and were significantly more elevated than those in patients without SCI (P <.0001, glutamate; P =.0006, glycine). Postoperative maximum levels of CSF glutamate and glycine were also significantly higher in patients with postoperative SCI than in patients without SCI (glutamate: 215.3% +/- 158.6% vs 32.9% +/- 37.3% increase from baseline, P <.0001; glycine: 309.1% +/- 218.2% vs 89.2% +/- 103.1% increase from baseline, P =.0036). CSF levels of glutamate and aspartate in naloxone group were significantly lower than those in control group (P =.0161, glutamate; P <.0001, aspartate). Postoperative maximum level of CSF aspartate was also significantly lower in the naloxone group than in the control group (8.3% +/- 75.5% vs 119.7% +/- 120.6% increase from baseline, P =.0077). In multivariate logistic regression analysis, postoperative maximum CSF glutamate > 100% from baseline (P <.001) and postoperative maximum level of CSF glycine (P =.005) were identified as the independent risk factors for SCI. Both SCI (P <.001) and postoperative maximum level of CSF glycine (P =.005) were the independent predictors for postoperative maximum level of CSF glutamate > 100% from baseline. Conclusions: CSF levels of EA.As are elevated in patients with SCI. CSF glutamate is the strongest independent predictor of SCL Naloxone is effective in lowering CSF levels of EAAs.	Hokkaido Univ Hosp, Dept Cardiovasc Surg, Kita Ku, Sapporo, Hokkaido 0608648, Japan; Hokkaido Univ, Grad Sch Med, Dept Publ Hlth, Sapporo, Hokkaido, Japan	Kunihara, T (corresponding author), Hokkaido Univ Hosp, Dept Cardiovasc Surg, Kita Ku, N14,W5, Sapporo, Hokkaido 0608648, Japan.	kunihara@med.hokudai.ac.jp	Saijo, Yasuaki/J-3796-2019	Saijo, Yasuaki/0000-0002-6211-8202			ACHER CW, 1994, J VASC SURG, V19, P236, DOI 10.1016/S0741-5214(94)70099-0; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; BAKER CJ, 1995, NEUROSURGERY, V36, P994, DOI 10.1227/00006123-199505000-00016; BASKIN DS, 1981, LANCET, V2, P272; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; BLIN O, 1994, J NEUROL NEUROSUR PS, V57, P119, DOI 10.1136/jnnp.57.1.119-a; Brock MV, 1997, ANN THORAC SURG, V64, P999, DOI 10.1016/S0003-4975(97)00621-8; Brown JIM, 1998, J NEUROTRAUM, V15, P253, DOI 10.1089/neu.1998.15.253; BULLOCK R, 1995, STROKE, V26, P2187, DOI 10.1161/01.STR.26.11.2187; Castillo J, 1996, STROKE, V27, P1060, DOI 10.1161/01.STR.27.6.1060; COLLIER HOJ, 1974, NATURE, V248, P24, DOI 10.1038/248024a0; Coselli JS, 2002, J VASC SURG, V35, P631, DOI 10.1067/mva.2002.122024; Csernansky JG, 1996, NEUROLOGY, V46, P1715, DOI 10.1212/WNL.46.6.1715; FADEN AI, 1982, NEUROLOGY, V32, P1083, DOI 10.1212/WNL.32.10.1083; FADEN AI, 1981, ANN NEUROL, V10, P326, DOI 10.1002/ana.410100403; GRAHAM LT, 1967, J NEUROCHEM, V14, P465, DOI 10.1111/j.1471-4159.1967.tb09545.x; GUERREROMUNOZ F, 1979, SCIENCE, V206, P89, DOI 10.1126/science.39340; HONEY CR, 1985, NEUROSCI LETT, V61, P135, DOI 10.1016/0304-3940(85)90414-8; HOSOBUCHI Y, 1982, SCIENCE, V215, P69, DOI 10.1126/science.6274019; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; KASHIWAGI S, 1994, J NEUROL NEUROSUR PS, V57, P1442, DOI 10.1136/jnnp.57.11.1442; KIM JP, 1987, EUR J PHARMACOL, V138, P133, DOI 10.1016/0014-2999(87)90349-9; MARZULLO G, 1981, SCIENCE, V208, P1171; MATSUMOTO K, 1993, J CEREBR BLOOD F MET, V13, P586, DOI 10.1038/jcbfm.1993.76; MENDELSOHN LG, 1985, J PHARMACOL EXP THER, V233, P597; NAKAMURA R, 1994, BRAIN RES, V654, P279, DOI 10.1016/0006-8993(94)90490-1; OBRENOVITCH TP, 1995, CEREBROVAS BRAIN MET, V7, P1; OLNEY JW, 1969, SCIENCE, V164, P719, DOI 10.1126/science.164.3880.719; PETEL J, 1990, J NEUROCHEM, V54, P849; REDMOND JM, 1995, ANN THORAC SURG, V59, P579; ROKKAS CK, 1995, J THORAC CARDIOV SUR, V110, P27, DOI 10.1016/S0022-5223(05)80006-6; ROKKAS CK, 1994, ANN THORAC SURG, V58, P312, DOI 10.1016/0003-4975(94)92200-4; SHIMADA N, 1989, J CEREBR BLOOD F MET, V9, P603, DOI 10.1038/jcbfm.1989.86; UEDA Y, 1992, STROKE, V23, P253, DOI 10.1161/01.STR.23.2.253; WAHL F, 1994, J NEUROCHEM, V63, P1003; XUE D, 1994, J CEREBR BLOOD F MET, V14, P251, DOI 10.1038/jcbfm.1994.32	36	35	36	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0741-5214			J VASC SURG	J. Vasc. Surg.	OCT	2004	40	4					681	690		10.1016/j.jvs.2004.07.005			10	Surgery; Peripheral Vascular Disease	Surgery; Cardiovascular System & Cardiology	902WZ	WOS:000227388700014	15472595				2021-06-18	
J	Levin, HS; Hanten, G; Zhang, LF; Swank, PR; Hunter, J				Levin, HS; Hanten, G; Zhang, LF; Swank, PR; Hunter, J			Selective impairment of inhibition after TBI in children	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; CLOSED-HEAD INJURY; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; INFERIOR PREFRONTAL CORTEX; COGNITIVE-DEVELOPMENT; RESPONSE-INHIBITION; WORKING-MEMORY; PERFORMANCE; GO; MATURATION	Inhibition was studied in 12 children who had sustained a severe traumatic brain injury (TBI) at least 1year earlier and in 15 control children. On the flanker task, which involved pressing a button corresponding to the direction of an arrow, the TBI group performed less accurately than controls under interference (flankers were incongruent with arrow) and go-no-go (adjacent stimulus signaled child to withhold response) conditions, but not neutral or facilitation (flankers were congruent) conditions. Response latency was related to age and task condition, but not to group. Severe TBI in children may disrupt development of distributed networks mediating inhibition.	Univ Texas, Hlth Sci Ctr, Cognit Neurosci Lab, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Dept Psychiat & Behav Sci, Houston, TX 77225 USA; Univ Texas, Hlth Sci Ctr, Dept Neurosurg, Houston, TX USA; Univ Texas, Hlth Sci Ctr, Dept Radiol, Houston, TX USA; Univ Texas, Hlth Sci Ctr, Dept Pediat, Houston, TX 77225 USA; Baylor Coll Med, Houston, TX 77030 USA	Levin, HS (corresponding author), Univ Texas, Hlth Sci Ctr, Cognit Neurosci Lab, Dept Phys Med & Rehabil, 6560 Fannin St,Ste 1144,Box 67, Houston, TX 77030 USA.	hlevin@bcm.tmc.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS21889] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER		Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; BJORKLUND DF, 1990, DEV REV, V10, P48, DOI 10.1016/0273-2297(90)90004-N; Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; Bunge SA, 2002, NEURON, V33, P301, DOI 10.1016/S0896-6273(01)00583-9; Burgess PW, 1996, NEUROPSYCHOLOGIA, V34, P263, DOI 10.1016/0028-3932(95)00104-2; CASE R, 1992, BRAIN COGNITION, V20, P51, DOI 10.1016/0278-2626(92)90061-P; Casey BJ, 2000, BIOL PSYCHOL, V54, P241, DOI 10.1016/S0301-0511(00)00058-2; Casey BJ, 1997, J COGNITIVE NEUROSCI, V9, P835, DOI 10.1162/jocn.1997.9.6.835; COHEN JD, 1992, PSYCHOL REV, V99, P45, DOI 10.1037/0033-295X.99.1.45; DEMPSTER FN, 1992, DEV REV, V12, P45, DOI 10.1016/0273-2297(92)90003-K; Dennis M, 2001, J INT NEUROPSYCH SOC, V7, P683, DOI 10.1017/S1355617701766040; Dennis M., 1995, TRAUMATIC HEAD INJUR, P165; Diamond A., 2002, PRINCIPLES FRONTAL L, P466, DOI DOI 10.1093/ACPROF:OSO/9780195134971.003.0029; DREWE E A, 1975, Cortex, V11, P8; ERIKSEN BA, 1974, PERCEPT PSYCHOPHYS, V16, P143, DOI 10.3758/BF03203267; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Herskovits EH, 1999, RADIOLOGY, V213, P389, DOI 10.1148/radiology.213.2.r99nv45389; Huttenlocher PR, 1997, J COMP NEUROL, V387, P167, DOI 10.1002/(SICI)1096-9861(19971020)387:2<167::AID-CNE1>3.0.CO;2-Z; JENNETT B, 1975, LANCET, V1, P480; Kawashima R, 1996, BRAIN RES, V728, P79, DOI 10.1016/0006-8993(96)00389-7; Konishi S, 1998, EUR J NEUROSCI, V10, P1209, DOI 10.1046/j.1460-9568.1998.00167.x; Konishi S, 1999, CEREB CORTEX, V9, P745, DOI 10.1093/cercor/9.7.745; Konrad KN, 2000, BRAIN INJURY, V14, P859; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; Levin HS, 2002, ANN NEUROL, V52, P82, DOI 10.1002/ana.10252; Luna B, 2001, NEUROIMAGE, V13, P786, DOI 10.1006/nimg.2000.0743; Max JE, 1998, J AM ACAD CHILD PSY, V37, P841, DOI 10.1097/00004583-199808000-00014; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; PETRIDES M, 1986, J NEUROSCI, V6, P2054; *PSYCH SOFTW TOOLS, 2002, E PRIM COMP SOFTW; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Rubia K, 2000, NEUROSCI BIOBEHAV R, V24, P13, DOI 10.1016/S0149-7634(99)00055-X; Schachar R, 2004, DEV NEUROPSYCHOL, V25, P179, DOI 10.1207/s15326942dn2501&2_10; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Sowell ER, 1999, NAT NEUROSCI, V2, P859, DOI 10.1038/13154; STARKSTEIN SE, 1990, ANN NEUROL, V27, P652, DOI 10.1002/ana.410270612; Tamm L, 2002, J AM ACAD CHILD PSY, V41, P1231, DOI 10.1097/00004583-200210000-00013; Yakovlev P.I., 1967, RETIONAL DEV BRAIN E, P3; Ylvisaker M., 1998, TRAUMATIC BRAIN INJU, P221	40	35	35	0	5	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	AUG	2004	26	5					589	597		10.1080/13803390490504434			9	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	862HE	WOS:000224480800001	15370381				2021-06-18	
J	Schmitt, DM; Hertel, J; Evans, TA; Olmsted, LC; Putukian, M				Schmitt, DM; Hertel, J; Evans, TA; Olmsted, LC; Putukian, M			Effect of an acute bout of soccer heading on postural control and self-reported concussion symptoms	INTERNATIONAL JOURNAL OF SPORTS MEDICINE			English	Article; Proceedings Paper	Meeting and Clinical Symposium of the National-Athletic-Trainer-Association	JUN 15-28, 2002	Dallas, TX			balance; cerebral concussion; football	BRAIN-INJURY; NEUROPSYCHOLOGICAL IMPAIRMENT; COLLEGIATE; STABILITY	Our purpose was to determine if an acute bout of heading soccer balls adversely affected postural control and self-reported symptoms of cerebral concussion. Thirty-one college-aged soccer players were randomly placed into either a kicking group or a heading group. Subjects either kicked or headed 18 soccer balls over the course of 40 minutes. Subjects had their postural control assessed while standing on a force plate and completed a concussion symptoms checklist on three separate occasions: prior to, immediately following, and 24 hours after kicking or heading. There were no significant differences between the heading and kicking groups on the postural control measures prior to, immediately following, and 24 hours after kicking/heading. The heading group did, however, report significantly more concussion symptoms than the kicking group immediately after heading, but not 24 hours after heading. The number of previous concussions sustained by subjects did not influence the effects of heading. An acute bout of soccer heading appears to cause an increase in self-reported symptoms of cerebral concussion lasting less than 24 hours but no quantifiable deficits in postural control. Further research is needed to investigate the cumulative effects of soccer heading on postural control and other objective measures of brain function.	Penn State Univ, Athlet Training Res Lab, University Pk, PA 16802 USA	Hertel, J (corresponding author), Penn State Univ, Athlet Training Res Lab, 269 Recreat Bldg, University Pk, PA 16802 USA.	jnh3@psu.edu					Abreau F, 1990, NEUROPSYCHOLOGY, V4, P175, DOI 10.1037/0894-4105.4.3.175; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Baroff GS, 1998, J HEAD TRAUMA REHAB, V13, P45, DOI 10.1097/00001199-199804000-00007; Downs DS, 2002, J SPORT MED PHYS FIT, V42, P103; Green GA, 1998, CLIN SPORT MED, V17, P795, DOI 10.1016/S0278-5919(05)70120-4; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; Johnson PD, 2002, CLIN J SPORT MED, V12, P12, DOI 10.1097/00042752-200201000-00006; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Kirkendall DT, 2001, J ATHL TRAINING, V36, P328; Kirkendall DT, 2001, SPORTS MED, V31, P369, DOI 10.2165/00007256-200131050-00006; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23, P770, DOI 10.1076/jcen.23.6.770.1029; Putukian M, 2000, CLIN J SPORT MED, V10, P104, DOI 10.1097/00042752-200004000-00004; Randolph C, 2001, J ATHL TRAINING, V36, P288; SORTLAND O, 1989, NEURORADIOLOGY, V31, P44; TYSVAER AT, 1992, SPORTS MED, V14, P200, DOI 10.2165/00007256-199214030-00006; TYSVAER AT, 1989, ACTA NEUROL SCAND, V80, P151, DOI 10.1111/j.1600-0404.1989.tb03858.x; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; TYSVAER AT, 1989, AM J SPORT MED, V17, P573, DOI 10.1177/036354658901700421	23	35	35	0	8	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0172-4622	1439-3964		INT J SPORTS MED	Int. J. Sports Med.	JUL	2004	25	5					326	331		10.1055/s-2004-819941			6	Sport Sciences	Sport Sciences	837OY	WOS:000222646200001	15241710				2021-06-18	
J	Palchak, MJ; Holmes, JF; Vance, CW; Gelber, RE; Schauer, BA; Harrison, MJ; Willis-Shore, J; Wootton-Gorges, SL; Derlet, RW; Kuppermann, N				Palchak, MJ; Holmes, JF; Vance, CW; Gelber, RE; Schauer, BA; Harrison, MJ; Willis-Shore, J; Wootton-Gorges, SL; Derlet, RW; Kuppermann, N			Does an isolated history of loss of consciousness or amnesia predict brain injuries in children after blunt head trauma?	PEDIATRICS			English	Article; Proceedings Paper	Annual Meeting of the Society-for-Academic-Emergency-Medicine (SAEM)	MAY 19-23, 2002	ST LOUIS, MO	Soc Acad Emergency Med		traumatic brain injury; loss of consciousness and/or amnesia; CT; cranial tomography; emergency department evaluation; children	COMPUTED-TOMOGRAPHY SCANS; GLASGOW COMA SCALE; INTRACRANIAL INJURY; EMERGENCY PHYSICIANS; CLINICAL PREDICTORS; SKULL FRACTURE; CANCER RISKS; CT; ABNORMALITIES; EVENTS	Background. A history of loss of consciousness (LOC) is frequently used as an indication for cranial computed tomography (CT) in the emergency department (ED) evaluation of children with blunt head trauma. Objective. We sought to determine whether an isolated LOC and/or amnesia is predictive of traumatic brain injury (TBI) in children with blunt head trauma. Methods. We prospectively enrolled children < 18 years old presenting to a level I trauma center ED between July 1998 and September 2001 with blunt head trauma. We evaluated the association of LOC and/or amnesia with 1) TBI identified on CT and 2) TBI requiring acute intervention. We defined the latter by a neurosurgical procedure, antiepileptic medication for > 1 week, persistent neurologic deficits, or hospitalization for > 2 nights. We then investigated the association of LOC and/or amnesia with TBI in those patients without other symptoms or signs of TBI ("isolated" LOC and/or amnesia). Results. Of eligible children, 2043 (77%) were enrolled, 1271 (62%) of whom underwent CT; 1159 (91%) of these 1271 had their LOC and/or amnesia status known. A total of 801 (39%) of the 2043 enrolled children had a documented history of LOC and/or amnesia. Of the 745 with documented LOC and/or amnesia who underwent CT, 70 (9.4%; 95% confidence interval [CI]: 7.4%, 11.7%) had TBI identified on CT versus 11 of 414 (2.7%; 95% CI: 1.3%, 4.7%) without LOC and/or amnesia ( difference: 6.7%; 95% CI: 4.1%, 9.3%). Of the 801 children known to have had LOC and/or amnesia ( regardless of whether they underwent CT), 77 (9.6%; 95% CI: 7.7%, 11.9%) had TBI requiring acute intervention versus 11 of 1115 (1%; 95% CI: 0.5%, 1.8%) of those without LOC and/or amnesia ( difference: 8.6%; 95% CI: 6.5%, 10.7%). For those with an isolated LOC and/or amnesia without other signs or symptoms of TBI, however, 0 of 142 (95% CI: 0%, 2.1%) had TBI identified on CT, and 0 of 164 ( 95% CI: 0%, 1.8%) had TBI requiring acute intervention. Conclusions. Isolated LOC and/or amnesia, defined by the absence of other clinical findings suggestive of TBI, are not predictive of either TBI on CT or TBI requiring acute intervention. Elimination of an isolated LOC and/or amnesia as an indication for CT may decrease unnecessary CT use in those patients without an appreciable risk of TBI.	Univ Calif Davis, Med Ctr, Sch Med, Dept Internal Med,Div Emergency Med, Sacramento, CA 95817 USA; Univ Calif Davis, Sch Med, Dept Pediat, Sacramento, CA 95817 USA; Univ Calif Davis, Sch Med, Dept Radiol, Sacramento, CA 95817 USA; Oregon Hlth & Sci Univ, Sch Med, Dept Emergency Med, Portland, OR 97201 USA	Palchak, MJ (corresponding author), Univ Calif Davis, Med Ctr, Sch Med, Dept Internal Med,Div Emergency Med, 2315 Stockton Blvd,PSSB 2100, Sacramento, CA 95817 USA.	mjpalchak@ucdavis.edu; nkuppermann@ucdavis.edu					Abdel-Dayem HM, 1998, CLIN NUCL MED, V23, P309, DOI 10.1097/00003072-199805000-00009; Aitken ME, 1998, ARCH PEDIAT ADOL MED, V152, P1176; Batchelor J, 2002, EMERG MED J, V19, P515, DOI 10.1136/emj.19.6.515; Bergman DA, 1999, PEDIATRICS, V104, P1407; Brenner DJ, 2002, PEDIATR RADIOL, V32, P228, DOI 10.1007/s00247-002-0671-1; Brenner DJ, 2001, AM J ROENTGENOL, V176, P289, DOI 10.2214/ajr.176.2.1760289; BRUCE DA, 1979, CHILD BRAIN, V5, P174; Cote CJ, 2000, PEDIATRICS, V105, P805, DOI 10.1542/peds.105.4.805; DAVIS RL, 1994, ANN EMERG MED, V24, P640, DOI 10.1016/S0196-0644(94)70273-X; DIETRICH AM, 1993, ANN EMERG MED, V22, P1535, DOI 10.1016/S0196-0644(05)81254-5; DURCH JS, 1993, EMERGENCY MED SERVIC; Graham ID, 1998, ACAD EMERG MED, V5, P134, DOI 10.1111/j.1553-2712.1998.tb02598.x; Greenes DS, 1997, ANN EMERG MED, V30, P253, DOI 10.1016/S0196-0644(97)70158-6; Greenes DS, 1998, ANN EMERG MED, V32, P680, DOI 10.1016/S0196-0644(98)70067-8; Greenes DS, 2001, PEDIATR EMERG CARE, V17, P88, DOI 10.1097/00006565-200104000-00002; Greenes DS, 1999, PEDIATRICS, V104, P861, DOI 10.1542/peds.104.4.861; Gruskin KD, 1999, ARCH PEDIAT ADOL MED, V153, P15; Hall EJ, 2002, PEDIATR RADIOL, V32, P700, DOI 10.1007/S00247-002-0774-8; Haydel MJ, 2003, ANN EMERG MED, V42, P507, DOI 10.1067/S0196-0644(03)00512-2; Hoffman GM, 2002, PEDIATRICS, V109, P236, DOI 10.1542/peds.109.2.236; Homer CJ, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.6.e78; Hoyert D. L., 2001, NATL VITAL STAT REPO, V49; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P389, DOI 10.1001/jama.271.5.389; JAMES HE, 1986, PEDIATR ANN, V15, P16, DOI 10.3928/0090-4481-19860101-05; KADISH HA, 1995, ANN EMERG MED, V26, P37, DOI 10.1016/S0196-0644(95)70235-0; Klassen TP, 2000, ACAD EMERG MED, V7, P739, DOI 10.1111/j.1553-2712.2000.tb02260.x; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Langlois J., 2001, TRAUMATIC BRAIN INJU, P1; LIEHLAI MW, 1992, J PEDIATR-US, V120, P195, DOI 10.1016/S0022-3476(05)80426-3; LOBATO RD, 1991, J NEUROSURG, V75, P256, DOI 10.3171/jns.1991.75.2.0256; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; Mattioli C, 2003, J NEUROSURG, V98, P37, DOI 10.3171/jns.2003.98.1.0037; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; *NAT CTR INJ PREV, 1999, TRAUM BRAIN INJ US R; National Center for Injury Prevention and Control, 2002, TRAUM BRAIN INJ US A; Ng SM, 2002, J PAEDIATR CHILD H, V38, P388, DOI 10.1046/j.1440-1754.2002.00012.x; Palchak MJ, 2003, ANN EMERG MED, V42, P492, DOI 10.1067/S0196-0644(03)00425-6; Peduzzi P, 1995, J CLIN EPIDEMIOL, V48, P1503, DOI 10.1016/0895-4356(95)00048-8; Peduzzi P, 1996, J CLIN EPIDEMIOL, V49, P1373, DOI 10.1016/S0895-4356(96)00236-3; Quayle KS, 1997, PEDIATRICS, V99, part. no., DOI 10.1542/peds.99.5.e11; RAMUNDO ML, 1995, PEDIATR EMERG CARE, V11, P1, DOI 10.1097/00006565-199502000-00001; Ratan SK, 2001, CLIN PEDIATR, V40, P375, DOI 10.1177/000992280104000702; RIVARA F, 1987, PEDIATRICS, V80, P579; ROSENBERG NM, 1988, PEDIATR EMERG CARE, V14, P436; Schunk JE, 1996, PEDIATR EMERG CARE, V12, P160, DOI 10.1097/00006565-199606000-00004; SCHUTZMAN SA, 1993, ANN EMERG MED, V22, P535, DOI 10.1016/S0196-0644(05)81938-9; Schutzman SA, 2001, PEDIATRICS, V107, P983, DOI 10.1542/peds.107.5.983; Schutzman SA, 2001, ANN EMERG MED, V37, P65, DOI 10.1067/mem.2001.109440; Seidel JS, 1999, ANN EMERG MED, V33, P206, DOI 10.1016/S0196-0644(99)70395-1; Sharma P, 2001, J Indian Med Assoc, V99, P81; Simon B, 2001, J TRAUMA, V51, P231, DOI 10.1097/00005373-200108000-00004; STEIN SC, 1992, J TRAUMA, V33, P11, DOI 10.1097/00005373-199207000-00003; Stiell IG, 2001, ANN EMERG MED, V38, P317, DOI 10.1067/mem.2001.116795; Svensson E, 1996, NEUROL RES, V18, P487; TEASDALE GM, 1990, BRIT MED J, V300, P363, DOI 10.1136/bmj.300.6721.363	55	35	35	0	3	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	JUN	2004	113	6					E507	E513		10.1542/peds.113.6.e507			7	Pediatrics	Pediatrics	825TP	WOS:000221781500062	15173529	Bronze			2021-06-18	
J	Xiang, H; Stallones, L; Smith, GA				Xiang, H; Stallones, L; Smith, GA			Downhill skiing injury fatalities among children	INJURY PREVENTION			English	Article							HEAD-INJURIES	Objective: Young skiers are at increased risk for injury, however, epidemiological data on skiing related fatal injuries among child skiers are scarce. This study aimed to provide information needed to develop injury control and prevention programs. Design and setting: Study subjects came from Colorado, USA and were identified using a death certificate based surveillance system. Fatal injuries were limited to events that occurred at established commercial ski resorts in Colorado, and subjects were classified as child skiers (0-17 years) or adult skiers (greater than or equal to18 years). Main outcome measure: Type and external cause, time, and week day of injury, gender and residency of the decedents. Results: During the study period from 1980-2001, 149 fatal injuries associated with downhill skiing were identified; 21 (14.1%) occurred among child skiers aged less than or equal to17 years. The age of the youngest decedent was 7 years. In females the proportion of fatal Injuries among child skiers was nearly three times that of adults. Traumatic brain injuries were the leading cause of death (67% of all deaths) among children, while multiple internal injuries and traumatic brain injuries accounted for almost equal proportions of fatal injuries among adults. Collision was the leading external mechanism of fatal injuries, accounting for more than two thirds of fatal Injuries in both child and adult skiers. Conclusions: Traumatic brain injury was the leading cause and collision was the leading external injury mechanism of fatal injuries associated with downhill skiing among child skiers. This underscores the importance of brain injury prevention strategies, including the use of ski helmets and prevention of collisions on ski slopes.	Ohio State Univ, Columbus Childrens Res Inst, Ctr Injury Res & Policy, Columbus, OH 43210 USA; Ohio State Univ, Coll Med & Publ Hlth, Columbus Childrens Hosp, Columbus, OH 43210 USA; Colorado State Univ, Dept Psychol, Colorado Injury Control Res Ctr, Ft Collins, CO 80523 USA	Xiang, H (corresponding author), Columbus Childrens Hosp, Ctr Injury Res & Policy, 700 Childrens Dr, Columbus, OH 43205 USA.	xiangh@pediatrics.ohio-state.edu	Xiang, Huiyun/E-4335-2011; Stallones, Lorann/AAC-6248-2021	Stallones, Lorann/0000-0001-7616-582X	ODCDC CDC HHS [R49/CCR811509] Funding Source: Medline		BLITZER CM, 1984, AM J SPORT MED, V12, P142, DOI 10.1177/036354658401200210; BROWN JM, 1997, CONT PEDIAT, V14, P115; Conn JM, 2003, INJURY PREV, V9, P117, DOI 10.1136/ip.9.2.117; Deibert MC, 1998, J BONE JOINT SURG AM, V80A, P25, DOI 10.2106/00004623-199801000-00006; Ferrera PC, 1999, AM J EMERG MED, V17, P575, DOI 10.1016/S0735-6757(99)90199-7; FURRER M, 1995, J TRAUMA, V39, P737, DOI 10.1097/00005373-199510000-00024; Goulet C, 1999, AM J SPORT MED, V27, P644, DOI 10.1177/03635465990270051701; JAFFIN B, 1981, MT SINAI J MED, V48, P353; JENKINS R, 1983, P 5 INT S PHIL, P358; Levy AS, 2002, J TRAUMA, V53, P695, DOI 10.1097/00005373-200210000-00013; Macnab A J, 1996, Inj Prev, V2, P286, DOI 10.1136/ip.2.4.286; MORROW PL, 1988, J TRAUMA, V28, P95, DOI 10.1097/00005373-198801000-00014; *NAT CTR INJ PREV, 2002, CDC INJ RES AG; *NIH, 1992, SPORTS INJ YOUTH SUR; SAS Institute Inc., 2000, SAS STAT US GUID VER; SHERRY E, 1988, MED J AUSTRALIA, V149, P615, DOI 10.5694/j.1326-5377.1988.tb120803.x; Shorter NA, 1996, J TRAUMA, V40, P997, DOI 10.1097/00005373-199606000-00024; Thompson DC, 1996, JAMA-J AM MED ASSOC, V276, P1968, DOI 10.1001/jama.276.24.1968; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; TOUGH SC, 1993, AM J FOREN MED PATH, V14, P17, DOI 10.1097/00000433-199303000-00004; TOUGH SC, 1993, AM J FOREN MED PATH, V14, P12, DOI 10.1097/00000433-199303000-00003; US Consumer Product Safety Commission, 1999, SKIING HELM EV POT R; Weston J T, 1977, J Forensic Sci, V22, P222; Xiang HY, 2003, INJURY, V34, P892, DOI 10.1016/S0020-1383(03)00055-X	24	35	35	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1353-8047	1475-5785		INJURY PREV	Inj. Prev.	APR	2004	10	2					99	102		10.1136/ip.2003.004655			4	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	820AX	WOS:000221359900012	15066975	Green Published, Bronze			2021-06-18	
J	Marciano, PG; Brettschneider, J; Manduchi, E; Davis, JE; Eastman, S; Raghupathi, R; Saatman, KE; Speed, TP; Stoeckert, CJ; Eberwine, JH; McIntosh, TK				Marciano, PG; Brettschneider, J; Manduchi, E; Davis, JE; Eastman, S; Raghupathi, R; Saatman, KE; Speed, TP; Stoeckert, CJ; Eberwine, JH; McIntosh, TK			Neuron-specific mRNA complexity responses during hippocampal apoptosis after traumatic brain injury	JOURNAL OF NEUROSCIENCE			English	Article						apoptosis; traumatic brain injury; hippocampus; CA3; dentate; single-cell amplification; microarray; cell death; differential expression; real-time quantitative PCR	CONTROLLED CORTICAL IMPACT; DIFFERENTIAL EXPRESSION; GENE-EXPRESSION; SPATIAL MEMORY; HEAD-INJURY; CELL LOSS; PROTEIN; SINGLE; DEATH; CLEAVAGE	In an effort to understand the complexity of genomic responses within selectively vulnerable regions after experimental brain injury, we examined whether single apoptotic neurons from both the CA3 and dentate differed from those in an uninjured brain. The mRNA from individual active caspase 3(+)/terminal deoxynucleotidyl transferase-mediated biotinylated UTP nick end labeling [TUNEL(-)] and active caspase 3(+)/TUNEL(+) pyramidal and granule neurons in brain-injured mice were amplified and compared with those from nonlabeled neurons in uninjured brains. Gene analysis revealed that overall expression of mRNAs increased with activation of caspase 3 and decreased to below uninjured levels with TUNEL reactivity. Cell type specificity of the apoptotic response was observed with both regionally distinct expression of mRNAs and differences in those mRNAs that were maximally regulated. Immunohistochemical analysis for two of the most highly differentially expressed genes (prion and Sos2) demonstrated a correlation between the observed differential gene expression after traumatic brain injury and corresponding protein translation.	Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Dept Neurosci, Philadelphia, PA 19104 USA; Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Penn, Ctr Bioinformat, Philadelphia, PA 19104 USA; Vet Adm Med Ctr, Philadelphia, PA 19104 USA; Univ Calif Berkeley, Dept Stat, Berkeley, CA 94720 USA; Incyte Genom, Palo Alto, CA 94304 USA	Eberwine, JH (corresponding author), Univ Penn, Dept Pharmacol, 37B John Morgan,3620 Hamilton Walk, Philadelphia, PA 19104 USA.	eberwine@mail.med.upenn.edu	Lazarus, Michael/G-3130-2010; Eberwine, James/B-2247-2010; Speed, Terence P/B-8085-2009	Lazarus, Michael/0000-0003-3863-4474; Speed, Terence P/0000-0002-5403-7998; Manduchi, Elisabetta/0000-0002-4110-3714	NATIONAL HUMAN GENOME RESEARCH INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI) [K25HG002296] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040978, P50NS008803] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG009900, R37AG009900] Funding Source: NIH RePORTER; NHGRI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI) [K25 HG002296, HG02296] Funding Source: Medline; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG 9900, R01 AG009900, R37 AG009900] Funding Source: Medline; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM34790] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS040978, P50 NS08803, P50 NS008803, R01-NS40978] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R01-41699] Funding Source: Medline		ADAMS R, 1994, IEEE T PATTERN ANAL, V16, P641, DOI 10.1109/34.295913; Alnemri ES, 1997, J CELL BIOCHEM, V64, P33, DOI 10.1002/(SICI)1097-4644(199701)64:1<33::AID-JCB6>3.0.CO;2-0; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Beer R, 2001, J NEUROCHEM, V78, P862, DOI 10.1046/j.1471-4159.2001.00460.x; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Beer R, 2000, J CEREBR BLOOD F MET, V20, P669, DOI 10.1097/00004647-200004000-00004; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; Brown DR, 1997, EXP NEUROL, V146, P104, DOI 10.1006/exnr.1997.6505; Brown DR, 2002, J NEUROSCI RES, V67, P211, DOI 10.1002/jnr.10118; Brown SB, 1997, BIOCHEM J, V323, P233, DOI 10.1042/bj3230233; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; BUCKLEY MJ, 2000, SPOT USERS GUIDE; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1997, J NEUROSCI, V17, P9172; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Conti AC, 1998, J NEUROSCI, V18, P5663; Crino PB, 1996, P NATL ACAD SCI USA, V93, P14152, DOI 10.1073/pnas.93.24.14152; Cryns VL, 1996, J BIOL CHEM, V271, P31277, DOI 10.1074/jbc.271.49.31277; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dudoit S, 2002, STAT SINICA, V12, P111; EBERWINE J, 1992, P NATL ACAD SCI USA, V89, P3010, DOI 10.1073/pnas.89.7.3010; EBERWINE J, 1992, METHOD ENZYMOL, V216, P80; Eldadah BA, 2000, J NEUROTRAUM, V17, P811, DOI 10.1089/neu.2000.17.811; Esteban LM, 2000, MOL CELL BIOL, V20, P6410, DOI 10.1128/MCB.20.17.6410-6413.2000; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Inohara N, 1999, J BIOL CHEM, V274, P270, DOI 10.1074/jbc.274.1.270; JOHNSTON R, 2004, IN PRESS GENOME RES; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; Ma JY, 2002, SCIENCE, V298, P1781, DOI 10.1126/science.1073725; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; Morrison B, 2000, NEUROSCIENCE, V96, P131, DOI 10.1016/S0306-4522(99)00537-0; NIMNUAL A, 2002, SCI STKE, V145, pPE36; O'Dell DM, 2000, J NEUROSCI, V20, P4821; OLTON DS, 1979, NEUROPSYCHOLOGIA, V17, P669, DOI 10.1016/0028-3932(79)90042-3; Oyesiku NM, 1999, BRAIN RES, V833, P161, DOI 10.1016/S0006-8993(99)01501-2; Phillips Jennifer, 1996, Methods (Orlando), V10, P283, DOI 10.1006/meth.1996.0104; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; RAGHUPATHI R, 1995, BRAIN PATHOL, V5, P437, DOI 10.1111/j.1750-3639.1995.tb00622.x; Raghupathi R, 2003, J NEUROTRAUM, V20, P421, DOI 10.1089/089771503765355504; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Rao VLR, 2003, J NEUROSCI RES, V71, P208, DOI 10.1002/jnr.10486; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Smith PM, 2002, J SPORT SCI, V20, P27; Soille P., 1999, MORPHOLOGICAL IMAGE; Song QZ, 1997, P NATL ACAD SCI USA, V94, P157, DOI 10.1073/pnas.94.1.157; SOSIN DM, 1989, JAMA-J AM MED ASSOC, V262, P2251, DOI 10.1001/jama.262.16.2251; Walz R, 1999, EPILEPSIA, V40, P1679, DOI 10.1111/j.1528-1157.1999.tb01583.x; Williams S, 2001, ACTA NEUROPATHOL, V102, P581, DOI 10.1007/s004010100410; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15; YANG YH, 2002, J COMPUT GRAPH STAT, V11, P1; YANG YH, 2002, MICROARRAYS OPTICAL, P141; Yue HB, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.8.e41	60	35	37	0	1	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474	1529-2401		J NEUROSCI	J. Neurosci.	MAR 24	2004	24	12					2866	2876		10.1523/JNEUROSCI.5051-03.2004			11	Neurosciences	Neurosciences & Neurology	807KR	WOS:000220500900002	15044525	Green Published, Other Gold			2021-06-18	
J	Bezeau, SC; Bogod, NM; Mateer, CA				Bezeau, SC; Bogod, NM; Mateer, CA			Sexually intrusive behaviour following brain injury: approaches to assessment and rehabilitation	BRAIN INJURY			English	Article							VIEWING TIME; METAANALYSIS; AGGRESSION; THERAPY	Sexually intrusive behaviour, which may range from inappropriate commentary to rape, is often observed following a traumatic brain injury. It may represent novel behaviour patterns or an exacerbation of pre-injury personality traits, attitudes, and tendencies. Sexually intrusive behaviour poses a risk to staff and residents of residential facilities and to the community at large, and the development of a sound assessment and treatment plan for sexually intrusive behaviour is therefore very important. A comprehensive evaluation is best served by drawing on the fields of neuropsychology, forensic psychology, and cognitive rehabilitation. The paper discusses the types of brain damage that commonly lead to sexually intrusive behaviour, provides guidance for its assessment, and presents a three-stage treatment model. The importance of a multidisciplinary approach to both assessment and treatment is emphasized. Finally, a case example is provided to illustrate the problem and the possibilities for successful management.	Univ Victoria, Dept Psychol, Victoria, BC V8W 3P5, Canada	Bezeau, SC (corresponding author), Univ Victoria, Dept Psychol, POB 3050, Victoria, BC V8W 3P5, Canada.	scottb_ca@yahoo.com	McCarthy, Jodie/B-5760-2012				BENNETT TL, 1997, NEUROPSYCHOLOGY HDB, V2, P123; BOLLER F, 1982, SEXUAL DYSFUNCTION N; Bradford JMW, 2001, CAN J PSYCHIAT, V46, P26, DOI 10.1177/070674370104600104; CHAMPAGNE MP, 1982, SEX DISABIL, V5, P172, DOI 10.1007/BF01116416; CHOW TW, 1999, SCI PRACT NEUROPSYCH, P3; Cicerone KD, 1997, ARCH CLIN NEUROPSYCH, V12, P173, DOI 10.1016/S0887-6177(96)00022-4; DEATON A, 1988, REHABIL PSYCHOL, V31, P231; DUCHARME S, 1987, REHABIL PSYCHOL, P419; EMORY LE, 1995, J HEAD TRAUMA REHAB, V10, P47; Eslinger PJ, 1998, EUR NEUROL, V39, P193, DOI 10.1159/000007933; Fleming JM, 1996, BRAIN INJURY, V10, P1; GoldmanRakic PS, 1996, PHILOS T ROY SOC B, V351, P1445, DOI 10.1098/rstb.1996.0129; HALL GCN, 1995, J CONSULT CLIN PSYCH, V63, P802, DOI 10.1037/0022-006X.63.5.802; Hanson R.K., 1997, DEV BRIEF ACTUARIAL; Hanson RK, 1998, J CONSULT CLIN PSYCH, V66, P348, DOI 10.1037/0022-006X.66.2.348; Harris GT, 1996, BEHAV RES THER, V34, P389, DOI 10.1016/0005-7967(95)00070-4; Hayman LA, 1998, J NEUROPSYCH CLIN N, V10, P354, DOI 10.1176/jnp.10.3.354; Kaufer D.I., 1999, SCI PRACT NEUROPSYCH; KOSTELJANETZ M, 1981, ACTA NEUROL SCAND, V63, P169; Laws D R, 2001, Sex Abuse, V13, P275, DOI 10.1023/A:1017522515854; LAWS DR, 1995, J RES TREATMENT, V7, P155; LILLY R, 1983, NEUROLOGY, V33, P1141, DOI 10.1212/WNL.33.9.1141; Maletzky BM, 2002, BEHAV MODIF, V26, P123, DOI 10.1177/0145445502262001; MALLOY P, 1993, ARCH CLIN NEUROPSYCH, V8, P185, DOI 10.1016/0887-6177(93)90035-Y; Marlatt G. A., 1985, RELAPSE PREVENTION M; MATEER C, 2000, UNPUB PREVALENCE SEX; Mateer C A, 1999, Semin Clin Neuropsychiatry, V4, P50; Mateer C. A., 1997, NEUROPSYCHOL REHABIL, P285; Mateer C. A., 1999, COGNITIVE NEUROREHAB, P314; MILLER BL, 1986, J NEUROL NEUROSUR PS, V49, P867, DOI 10.1136/jnnp.49.8.867; OTT BR, 1995, CLIN NEUROPHARMACOL, V18, P443, DOI 10.1097/00002826-199510000-00007; Pithers WD, 1999, J INTERPERS VIOLENCE, V14, P257, DOI 10.1177/088626099014003004; PITHERS WD, 1983, SEXUAL AGGRESSOR CUR, P214; Ponsford J, 1999, NEUROPSYCHOL REHABIL, V9, P517, DOI 10.1080/096020199389563; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; Quinsey VL, 1996, ETHOL SOCIOBIOL, V17, P341, DOI 10.1016/S0162-3095(96)00060-X; Raymond NC, 1999, AM J PSYCHIAT, V156, P786; Redoute J, 2000, HUM BRAIN MAPP, V11, P162, DOI 10.1002/1097-0193(200011)11:3<162::AID-HBM30>3.0.CO;2-A; Rolls ET, 1999, NEUROCASE, V5, P301, DOI 10.1080/13554799908411984; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Simpson G, 2001, J HEAD TRAUMA REHAB, V16, P556, DOI 10.1097/00001199-200112000-00004; Simpson G, 1999, J HEAD TRAUMA REHAB, V14, P567, DOI 10.1097/00001199-199912000-00005; SIMPSON GK, 1999, YOU ME ED PROGRAM SE; Sohlberg M. M., 2001, COGNITIVE REHABILITA; SOHLBERG MM, 1993, J HEAD TRAUMA REHAB, V8, P45, DOI DOI 10.1097/00001199-199303000-00006; Starkstein SE, 2001, FRONTAL-SUBCORTICAL CIRCUITS IN PSYCHIATRIC AND NEUROLOGICAL DISORDERS, P163; Stuss D.T., 1986, FRONTAL LOBES; Wesolowski M. D., 1993, BEHAV RESIDENTIAL TR, V8, P89, DOI DOI 10.1002/BIN; Williams WH, 2003, NEUROPSYCHOL REHABIL, V13, P133, DOI 10.1080/09602010244000417; WITTIG P, 1999, THESIS ROYAL ROADS U; WONG TM, 1998, AVOIDING ETHICAL MIS, P187	51	35	35	1	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAR	2004	18	3					299	313		10.1080/02699050310001617398			15	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	763NH	WOS:000188091900006	14726288				2021-06-18	
J	Fainardi, E; Chieregato, A; Antonelli, V; Fagioli, L; Servadei, F				Fainardi, E; Chieregato, A; Antonelli, V; Fagioli, L; Servadei, F			Time course of CT evolution in traumatic subarachnoid haemorrhage: a study of 141 patients	ACTA NEUROCHIRURGICA			English	Article						head injury subarachnoid haemorrhage; worst CT scan; CT evolution	SEVERE HEAD-INJURY; COMPUTED TOMOGRAPHIC SCAN; FOLLOW-UP; PRACTICAL SCALE; HEMATOMAS; MODERATE; COMA; PRESSURE; BLOOD	Background. Evidence of tSAH on an admission CT scan seems to be an early predictor of evolving posttraumatic lesions. Detection of these changes requires serial CT scanners. The goal of our study was to determine the optimal timing of follow-up CT scans in head injured patients with traumatic subarachnoid haemorrhage (tSAH). Method. We reviewed the initial and follow-up CT scans in 141 patients with closed head injuries and evidence of tSAH on the initial CT scan. We used the Marshall classification to determine diffuse and focal injuries. The "worst CT scan", defined as the CT examination in which midline shift, cistern compression and/or intracranial focal lesions were greater. was also determined. Any worsening of the admission CT findings, occurring when the "worst CT examination" did not correspond to the initial CT study. was considered as a "CT evolution". Any "CT evolution" associated with a variation from a lower to a higher score in the Marshall classification score was indicated as a "significant CT evolution". Findings. The median time between injury and the first CT scan was 1.3 (IQR 1.5) hours. A CT evolution was found in 83/141 (58.9%) patients in whom the median time between the initial and worst CT scans was 27.7 hours (IQR 69.2 hours). The worst CT studies were seen more often at 12-24 hours and at 24-48 hours after the admission CT scan than in later studies. A similar temporal profile was observed when the timing of the "worst CT scan" was evaluated in 38/83 (45.8%) subjects with a "significant CT evolution". Interpretation. Our findings show that an early admission CT scan did not represent the full extent of the posttraumatic damage in more than half of our patients. They also suggest that to identify these changes in head injured patients with tSAH, CT scans should be repeated at 12-24 and possibly also at 24-48 hours from the admission CT examination to allow early detection and evacuation of evolving intracranial lesions.	Arcispedale St Anna, Dipartimento Neurosci, Unita Operat Neuroradiol, I-44100 Ferrara, Italy; Osped Gen Provinciale M Bufalini, Cesena, Italy	Fainardi, E (corresponding author), Arcispedale St Anna, Dipartimento Neurosci, Unita Operat Neuroradiol, Corso della Giovecca 203, I-44100 Ferrara, Italy.	henryfai@tin.it		Servadei, Franco/0000-0002-3595-3464; Antonelli, Vincenzo/0000-0003-4231-529X			CHESNUT R, 1999, TRAUMATIC BRAIN INJU, P81; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; GAETANI P, 1995, J NEUROL NEUROSUR PS, V59, P635, DOI 10.1136/jnnp.59.6.635; GREENE KA, 1995, J NEUROSURG, V83, P445, DOI 10.3171/jns.1995.83.3.0445; JENNETT B, 1975, LANCET, V1, P480; KAKARIEKA A, 1995, CEREBROVASC DIS, V5, P403, DOI 10.1159/000107892; KAKARIEKA A, 1994, ACTA NEUROCHIR, V129, P1, DOI 10.1007/BF01400864; Lee TT, 1997, ACTA NEUROCHIR, V139, P1042, DOI 10.1007/BF01411558; Lobato RD, 1997, ACTA NEUROCHIR, V139, P385, DOI 10.1007/BF01808871; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MARSHALL LF, 1991, J NEUROSURG S, V75, P28; MARTIN NA, 1992, J NEUROSURG, V77, P575, DOI 10.3171/jns.1992.77.4.0575; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Servadei E, 2000, BRIT J NEUROSURG, V14, P110; SERVADEI F, 1995, NEUROSURGERY, V37, P899, DOI 10.1227/00006123-199511000-00008; Servadei F, 2002, BRIT J NEUROSURG, V16, P36, DOI 10.1080/02688690120114255; Servadei F, 2000, NEUROSURGERY, V46, P70; SHIGEMORI M, 1990, Neurologia Medico-Chirurgica, V30, P396, DOI 10.2176/nmc.30.396; SOLONIUK D, 1986, J TRAUMA, V26, P787, DOI 10.1097/00005373-198609000-00003; Sullivan TP, 1999, AM J NEURORADIOL, V20, P107; TEASDALE G, 1974, LANCET, V2, P81; UNTERBERG A, 1993, NEUROSURGERY, V32, P17, DOI 10.1227/00006123-199301000-00003; Wilberger JE, 2000, NEUROSURGERY, V46, P76; YAMAKI T, 1990, ACTA NEUROCHIR, V103, P112, DOI 10.1007/BF01407516	26	35	38	0	4	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	MAR	2004	146	3					257	263		10.1007/s00701-003-0207-y			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	809VR	WOS:000220664700012	15015048				2021-06-18	
J	McIntosh, A; McCrory, P; Finch, CF				McIntosh, A; McCrory, P; Finch, CF			Performance enhanced headgear: a scientific approach to the development of protective headgear	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							FOOTBALL; RUGBY	Background: There is a continuing debate about the performance of protective headgear in rugby union, rugby league, and Australian rules football. Objectives: To examine the impact energy attenuation performance of foam that could be incorporated into headgear and examine the performance of prototypes of modified headgear. Methods: Impact tests were conducted on polyethylene foams and protective headgear. Free fall drop tests with a rigid headform on to a flat rigid anvil were conducted. Resultant headform acceleration was measured. Means of the headform acceleration maxima for repeat tests were calculated. Results: Tests on polyethylene foam indicated that an increase in thickness from 10 mm to 16 mm would improve headgear performance. These modifications were incorporated in part into two headgear models: the Albion Headpro and the Canterbury brand Body Armour honeycomb headgear. The headgear tests show that significant reductions in headform acceleration were achieved by increasing the foam density and thickness. Mean headform acceleration maxima for the 16 mm thick modified rugby headgear was about 25% of that of standard headgear for lateral impact 0.3 and 0.4 m drop heights and 27% for the centre front 0.3 m drop tests. At these impacts, the headform acceleration for the modified rugby headgear was below 200 g. Conclusions: Significant improvements in impact energy attenuation performance are possible with small design changes. Whether these are sufficient to reduce the rate or severity of concussion in rugby and Australian rules football can only be shown by formal prospective studies on the field.	Univ New S Wales, Sch Safety Sci, Sydney, NSW 2052, Australia; Univ Melbourne, Melbourne, Vic, Australia	McIntosh, A (corresponding author), Univ New S Wales, Sch Safety Sci, Sydney, NSW 2052, Australia.	a.mcintosh@unsw.edu.au	McCrory, Paul/Q-8688-2019				Allsop D., 1991, P 35 STAPP CAR CRASH; FINCH C, 2000, SPORT HLTH, P35; HIRSCH AE, 1970, P 14 STAPP CAR CRASH, P144; MCINTOSH A, 2000, P 37 STAPP CAR CRASH; McIntosh A, 1995, P 39 STAPP CAR CRASH; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002; McIntosh AS, 2000, BRIT J SPORT MED, V34, P337, DOI 10.1136/bjsm.34.5.337; McIntosh AS, 2001, BRIT J SPORT MED, V35, P167, DOI 10.1136/bjsm.35.3.167; NEWMAN J, 1980, P 24 STAPP CAR CRASH, P701; NUSHOLTZ GS, 1984, P 28 STAPP CAR CRASH, P41	10	35	35	0	22	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674			BRIT J SPORT MED	Br. J. Sports Med.	FEB 1	2004	38	1					46	49		10.1136/bjsm.2002.003103			4	Sport Sciences	Sport Sciences	768JG	WOS:000188539400014	14751945	Green Published, Bronze			2021-06-18	
J	Shah, MK; Al-Adawi, S; Dorvlo, ASS; Burke, DT				Shah, MK; Al-Adawi, S; Dorvlo, ASS; Burke, DT			Functional outcomes following anoxic brain injury: a comparison with traumatic brain injury	BRAIN INJURY			English	Article							CARDIAC-ARREST SURVIVORS; NEUROLOGICAL REHABILITATION; ISCHEMIC COMA; PROGNOSIS	Primary objective: To compare the functional outcomes of patients with anoxic brain injury (ABI) and patients with traumatic brain injury (TBI) following inpatient rehabilitation. Research design: Retrospective chart review. Methods and procedures: Data on 68 patients with brain injury ( 34 with ABI and 34 with TBI) were collected. Main outcomes and results: The ABI and TBI groups were demographically similar, except that patients with ABI were more likely to be married. Both groups significantly improved their function and were similar upon discharge. For the ABI group, there were trends toward a shorter length of stay, increased total FIM efficiency and decreased cost of stay when compared with the TBI group. The patients with ABI tended to be discharged to a sub-acute rehabilitation facility more than those in the TBI group. Conclusions: This study is important because it shows that patients with ABI benefit from inpatient rehabilitation and made significant functional gains comparable to the gains of patients with TBI.	Harvard Univ, Sch Med, Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Boston, MA USA; Sultan Qaboos Univ, Coll Med, Muscat, Oman; Sultan Qaboos Univ, Coll Sci, Dept Math & Stat, Muscat, Oman	Shah, MK (corresponding author), 9262 Forest Lane,Suite 101, Dallas, TX 75243 USA.		Al-Adawi, Samir/A-9663-2016	Al-Adawi, Samir/0000-0002-9858-5582			BEDELL SE, 1983, NEW ENGL J MED, V309, P569, DOI 10.1056/NEJM198309083091001; Caine D, 2000, J INT NEUROPSYCH SOC, V6, P86, DOI 10.1017/S1355617700611116; EDGREN E, 1994, LANCET, V343, P1055, DOI 10.1016/S0140-6736(94)90179-1; Fertl E, 2000, RESUSCITATION, V47, P231, DOI 10.1016/S0300-9572(00)00239-2; Graves JR, 1997, RESUSCITATION, V35, P117; GROSWASSER Z, 1989, ARCH PHYS MED REHAB, V70, P186; LEVY DE, 1985, JAMA-J AM MED ASSOC, V253, P1420, DOI 10.1001/jama.253.10.1420; Ornato JP, 2001, RESUSCITATION, V48, P117, DOI 10.1016/S0300-9572(00)00255-0; Pusswald G, 2000, RESUSCITATION, V47, P241, DOI 10.1016/S0300-9572(00)00240-9; SAZBON L, 1993, J NEUROL NEUROSUR PS, V56, P407, DOI 10.1136/jnnp.56.4.407; Schmidt JG, 1997, J NEUROL REHABIL, V11, P189; SYNDER BD, 1977, NEUROLOGY, V27, P807; Zandbergen EGJ, 1998, LANCET, V352, P1808, DOI 10.1016/S0140-6736(98)04076-8	13	35	35	0	2	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	FEB	2004	18	2					111	117		10.1080/0269905031000149551			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	751DR	WOS:000187038000001	14660224				2021-06-18	
J	Hanten, G; Dennis, M; Zhang, LF; Barnes, M; Roberson, G; Archibald, J; Song, J; Levin, HS				Hanten, G; Dennis, M; Zhang, LF; Barnes, M; Roberson, G; Archibald, J; Song, J; Levin, HS			Childhood head injury and metacognitive processes in language and memory	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; VERBAL REHEARSAL; WORKING-MEMORY; CHILDREN; COMPREHENSION; AWARENESS; RECALL	We studied the metacognitive functioning of children with severe and mild traumatic brain injury (TBI) and typically developing children. To test metacognition for memory, children were tested on a modified Judgment of Learning task. We found that children with severe TBI were impaired in their ability to predict recall of specific items prior to study-recall trials, but were unimpaired in predicting recall on a delayed test when the judgment was made after study-recall trials. Metacognitive knowledge impairment for memorial abilities was also demonstrated in children with severe TBI by poor estimation of memory span and exaggerated overconfidence in performance. To test metacognition within the language domain, we gave children a sentence anomaly detection and repair task in which spoken sentences were monitored for semantic anomalies. Children with severe TBI were impaired on the detection of semantic anomalies, especially under conditions of high memory load. However, metalinguistic knowledge in the form of adequate repairs of anomalous sentences, was preserved. Results are discussed in terms of effects of age at test and injury severity.	Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Hosp Sick Children, Dept Psychol, Toronto, ON M5G 1X8, Canada; Bayer Pharmaceut, Dept Biometry, New Haven, CT USA; Baylor Coll Med, Dept Neurosurg, Cognit Neurosci Lab, Houston, TX 77030 USA; Baylor Coll Med, Dept Psychiat & Behav Sci, Cognit Neurosci Lab, Houston, TX 77030 USA	Hanten, G (corresponding author), Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, 6550 Fannin St,Ste 1144,Box 67, Houston, TX 77030 USA.	ghanten@bcm.tmc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS21889] Funding Source: Medline		ADAMS JH, 1975, HDB CLINICAL NEUROLO, V23, P35; Anderson VA, 2000, BRAIN INJURY, V14, P679; APPEL LF, 1972, CHILD DEV, V43, P1365, DOI 10.2307/1127522; Bigler E, 1990, TRAUMATIC BRAIN INJU, P13; Brown AL, 1978, ADV INSTRUCTIONAL PS, P367; Chapman S. B., 1997, AM J SPEECH-LANG PAT, V6, P66; Dennis M, 1996, DEV NEUROPSYCHOL, V12, P77, DOI 10.1080/87565649609540641; Dennis M., 1995, TRAUMATIC HEAD INJUR, P165; DUFRESNE A, 1989, J EXP CHILD PSYCHOL, V47, P274, DOI 10.1016/0022-0965(89)90033-7; Ewing-Cobbs L, 1998, CHILD NEUROPSYCHOL, V4, P35, DOI 10.1076/chin.4.1.35.3194; FLAVELL JH, 1970, COGNITIVE PSYCHOL, V1, P324, DOI 10.1016/0010-0285(70)90019-8; FLAVELL JH, 1966, CHILD DEV, V37, P283, DOI 10.1111/j.1467-8624.1966.tb05387.x; FLAVELL JH, 1985, DEV PSYCHOL, V21, P207, DOI 10.1037/0012-1649.21.2.207; GARRITY LI, 1975, DEV PSYCHOL, V11, P274, DOI 10.1037/h0076563; Hanten G, 2000, DEV NEUROPSYCHOL, V18, P383, DOI 10.1207/S1532694206Hanten; Hanten G, 1999, DEV NEUROPSYCHOL, V16, P393, DOI 10.1207/S15326942DN1603_23; Hanten G, 2000, J MEM LANG, V43, P335, DOI 10.1006/jmla.2000.2731; HOLCOMB PJ, 1992, DEV NEUROPSYCHOL, V8, P203, DOI 10.1080/87565649209540525; KEENEY TJ, 1967, CHILD DEV, V38, P953, DOI 10.1111/j.1467-8624.1967.tb04373.x; KENNEDY BA, 1976, CHILD DEV, V47, P566, DOI 10.2307/1128824; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; LEONESIO RJ, 1990, J EXP PSYCHOL LEARN, V16, P464, DOI 10.1037/0278-7393.16.3.464; Levin HS, 1996, DEV NEUROPSYCHOL, V12, P17, DOI 10.1080/87565649609540638; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1990, J CLIN EXP NEUROPSYC, V12, P129, DOI 10.1080/01688639008400960; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; LEVIN HS, 1986, J CLIN EXP NEUROPSYC, V8, P643, DOI 10.1080/01688638608405185; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; Liu H, 1997, APPL PSYCHOLINGUIST, V18, P157, DOI 10.1017/S0142716400009954; Martin R.C., 1994, NEUROPSYCHOLOGY, V8, P506, DOI [10.1037/0894-4105.8.4.506, DOI 10.1037/0894-4105.8.4.506]; Mazzoni G, 1998, METACOGNITION AND COGNITIVE NEUROPSYCHOLOGY, pIX; Metcalfe J, 1994, METACOGNITION KNOWIN; MOYNAHAN ED, 1973, CHILD DEV, V44, P238; Nelson T. O., 1992, METACOGNITION CORE R; Rogoff B., 1974, CHILD DEV, V44, P238; Schneider W, 1998, METACOGNITION AND COGNITIVE NEUROPSYCHOLOGY, P1; Schneider W, 2000, COGNITIVE DEV, V15, P115, DOI 10.1016/S0885-2014(00)00024-1; Shallice T., 1990, NEUROPSYCHOLOGICAL I, P11, DOI [10.1017/CBO9780511665547.003, DOI 10.1017/CBO9780511665547.003]; Siegler R. S., 1978, CHILDRENS THINKING W, P3; SUTTER JC, 1990, J SPEECH HEAR RES, V33, P84, DOI 10.1044/jshr.3301.84; Swanson HL, 1996, BRIT J EDUC PSYCHOL, V66, P333, DOI 10.1111/j.2044-8279.1996.tb01201.x; TEASDALE G, 1974, LANCET, V2, P81; TYLER LK, 1981, J VERB LEARN VERB BE, V20, P400, DOI 10.1016/S0022-5371(81)90524-7; WELLMAN HM, 1981, CHILD DEV, V52, P1313, DOI 10.1111/j.1467-8624.1981.tb03182.x; WORDEN PE, 1982, J EDUC PSYCHOL, V74, P341, DOI 10.1037/0022-0663.74.3.341; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78	46	35	35	0	9	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	8756-5641	1532-6942		DEV NEUROPSYCHOL	Dev. Neuropsychol.		2004	25	1-2					85	106		10.1207/s15326942dn2501&2_6			22	Psychology, Developmental; Psychology; Psychology, Experimental	Psychology	774CG	WOS:000188961700006	14984330				2021-06-18	
J	Kuhlow, CJ; Krady, JK; Basu, A; Levison, SW				Kuhlow, CJ; Krady, JK; Basu, A; Levison, SW			Astrocytic ceruloplasmin expression, which is induced by IL-1 beta and by traumatic brain injury, increases in the absence of the IL-1 type 1 receptor	GLIA			English	Article						interleukin 1; traumatic brain injury; ceruloplasmin; oxidative stress; metals; gliosis	NECROSIS-FACTOR-ALPHA; INTERLEUKIN-1-BETA CONVERTING-ENZYME; EXCITOTOXIC NEURONAL DAMAGE; CILIARY NEUROTROPHIC FACTOR; CENTRAL-NERVOUS-SYSTEM; FACTOR MESSENGER-RNA; NF-KAPPA-B; GENE-EXPRESSION; RAT-BRAIN; NEURODEGENERATIVE DISORDERS	IL-1alpha and IL-1beta are induced immediately after insults to the brain, and signaling through the type 1 IL-1 receptor is essential for a normal microglial and astroglial response to injury. To better understand which genes are induced in astrocytes by IL-1beta, we used the unbiased technique of differential display to analyze mouse astroglial gene expression after IL-1beta treatment. Two novel genes were induced, as well as the gene for ceruloplasmin, a ferroxidase with antioxidant properties. Ceruloplasmin was analyzed further by Northern and Western blot. RNA and protein levels of ceruloplasmin were increased when astrocytes were treated with IL-1beta. To determine whether the IL-1 type 1 receptor (IL-1R1) is essential for the injury-induced expression of ceruloplasmin, a Western blot analysis was performed after a traumatic brain injury on mice that were IL-1R1-deficient. Ceruloplasmin increased significantly above controls after injury; however, injury-induced levels of ceruloplasmin were lower in IL-1R1-deficient (2.7-fold increase) than in the wild-type animals (3.5-fold increase). These data indicate that while IL-1R1 deletion has a slight effect on ceruloplasmin expression, it is not essential for either the basal or the induced expression of ceruloplasmin in vivo. Since ceruloplasmin buffers free copper, oxidizes ferrous iron, and catalyzes the dismutation of free radicals, increased levels of ceruloplasmin likely protect neurons and glia from sustaining damage after injury. Furthermore, as the lL-1R1 has been proposed to be a target for achieving neuroprotection after injury, these data suggest that the protection afforded by ceruloplasmin will be retained even when the lL-1R1 is antagonized. (C) 2003 Wiley-Liss, Inc.	Penn State Coll Med, Dept Neurosci & Anat, Hershey, PA 17033 USA	Levison, SW (corresponding author), Penn State Coll Med, Dept Neurosci & Anat, H109,POB 850, Hershey, PA 17033 USA.		Levison, Steven W./Q-6903-2019	Levison, Steven W./0000-0002-1264-7309; Basu, Anirban/0000-0002-5200-2054			Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Albrecht PJ, 2002, EXP NEUROL, V173, P46, DOI 10.1006/exnr.2001.7834; Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; ALOISI F, 1992, J IMMUNOL, V149, P2358; ARAUJO DM, 1992, J NEUROSCI, V12, P1668; BANDTLOW CE, 1990, J CELL BIOL, V111, P1701, DOI 10.1083/jcb.111.4.1701; BARTLETT PF, 1980, BRAIN RES, V204, P339; Basu A, 2002, J NEUROSCI, V22, P6071; BAUER J, 1993, J NEUROIMMUNOL, V48, P13, DOI 10.1016/0165-5728(93)90053-2; BENVENISTE EN, 1990, J NEUROIMMUNOL, V30, P201, DOI 10.1016/0165-5728(90)90104-U; Boutin H, 2001, J NEUROSCI, V21, P5528; Chang JW, 2001, NEUROCHEM INT, V39, P349, DOI 10.1016/S0197-0186(01)00042-0; CHUNG IY, 1990, J IMMUNOL, V144, P2999; CONNOR JR, 1993, NEUROSCI LETT, V159, P88, DOI 10.1016/0304-3940(93)90805-U; DACUNHA A, 1992, J NEUROIMMUNOL, V36, P157; DECKERTSCHLUTER M, 1992, J NEUROL SCI, V113, P50, DOI 10.1016/0022-510X(92)90264-L; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; Friedlander RM, 1997, J EXP MED, V185, P933, DOI 10.1084/jem.185.5.933; Friedman WJ, 1996, J BIOL CHEM, V271, P31115, DOI 10.1074/jbc.271.49.31115; GADIENT RA, 1990, NEUROSCI LETT, V117, P335, DOI 10.1016/0304-3940(90)90687-5; GELMAN BB, 1995, J NEUROPATH EXP NEUR, V54, P477, DOI 10.1097/00005072-199507000-00001; GERLACH M, 1994, J NEUROCHEM, V63, P793, DOI 10.1046/j.1471-4159.1994.63030793.x; GIULIAN D, 1988, J NEUROSCI, V8, P2485; GOLDSTEIN E, 1979, ARCH ENVIRON HEALTH, V34, P424, DOI 10.1080/00039896.1979.10667444; GOTZ ME, 1994, PHARMACOL THERAPEUT, V63, P37, DOI 10.1016/0163-7258(94)90055-8; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; HARRIS ZL, 1995, P NATL ACAD SCI USA, V92, P2539, DOI 10.1073/pnas.92.7.2539; HARTUNG HP, 1989, BRAIN RES, V489, P113, DOI 10.1016/0006-8993(89)90013-9; Hedtjarn M, 2002, J NEUROSCI, V22, P5910; Herx LM, 2000, J IMMUNOL, V165, P2232, DOI 10.4049/jimmunol.165.4.2232; Herx LM, 2001, J NEUROPATH EXP NEUR, V60, P961, DOI 10.1093/jnen/60.10.961; HOFMAN FM, 1986, J IMMUNOL, V136, P3239; Jacobson D R, 1991, PCR Methods Appl, V1, P146; JENNER P, 1994, LANCET, V344, P796, DOI 10.1016/S0140-6736(94)92347-7; Klomp LWJ, 1996, J CLIN INVEST, V98, P207, DOI 10.1172/JCI118768; LEE SC, 1995, J NEUROCHEM, V64, P1800; Legos JJ, 2000, NEUROSCI LETT, V282, P189, DOI 10.1016/S0304-3940(00)00907-1; Levison S., 1991, CULTURING NERVE CELL, P309; Liu XH, 1999, J CEREBR BLOOD F MET, V19, P1099, DOI 10.1097/00004647-199910000-00006; Loddick SA, 1996, J CEREBR BLOOD F MET, V16, P932, DOI 10.1097/00004647-199609000-00017; Loeffler DA, 1996, BRAIN RES, V738, P265, DOI 10.1016/S0006-8993(96)00782-2; Martinez Oscar J., 1994, GLOBAL BOUNDARIES WO, V1, P1, DOI [10.1163/9789401204774_002, DOI 10.4324/9780203211960]; Mason JL, 2001, J NEUROSCI, V21, P7046, DOI 10.1523/JNEUROSCI.21-18-07046.2001; McGuinness MC, 1997, J NEUROIMMUNOL, V75, P174, DOI 10.1016/S0165-5728(97)00020-9; MINAMI M, 1992, J NEUROCHEM, V58, P390, DOI 10.1111/j.1471-4159.1992.tb09324.x; MIYAJIMA H, 1987, NEUROLOGY, V37, P761, DOI 10.1212/WNL.37.5.761; MORELL AG, 1958, SCIENCE, V127, P588, DOI 10.1126/science.127.3298.588-a; NORRIS JG, 1994, J IMMUNOL, V152, P841; Patel BN, 1997, J BIOL CHEM, V272, P20185, DOI 10.1074/jbc.272.32.20185; Qian ZM, 1998, BRAIN RES REV, V27, P257, DOI 10.1016/S0165-0173(98)00012-5; RELTON JK, 1992, BRAIN RES BULL, V29, P243, DOI 10.1016/0361-9230(92)90033-T; ROESER HP, 1970, J CLIN INVEST, V49, P2408, DOI 10.1172/JCI106460; Rothwell NJ, 2000, TRENDS NEUROSCI, V23, P618, DOI 10.1016/S0166-2236(00)01661-1; Salzer JL, 1998, J NEUROSCI RES, V54, P147, DOI 10.1002/(SICI)1097-4547(19981015)54:2<147::AID-JNR3>3.3.CO;2-Z; Schielke GP, 1998, J CEREBR BLOOD F MET, V18, P180, DOI 10.1097/00004647-199802000-00009; SPARACIO SM, 1992, J NEUROIMMUNOL, V39, P231, DOI 10.1016/0165-5728(92)90257-L; TAKAHASHI N, 1984, P NATL ACAD SCI-BIOL, V81, P390, DOI 10.1073/pnas.81.2.390; YAMASAKI Y, 1995, STROKE, V26, P676, DOI 10.1161/01.STR.26.4.676	59	35	35	0	3	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0894-1491			GLIA	Glia	OCT	2003	44	1					76	84		10.1002/glia.10273			9	Neurosciences	Neurosciences & Neurology	723QF	WOS:000185442500008	12951659				2021-06-18	
J	Peerdeman, SM; Girbes, ARJ; Polderman, KH; Vandertop, WP				Peerdeman, SM; Girbes, ARJ; Polderman, KH; Vandertop, WP			Changes in cerebral interstitial glycerol concentration in head-injured patients; correlation with secondary events	INTENSIVE CARE MEDICINE			English	Article						head injury; microdialysis; glycerol; outcome	MEMBRANE PHOSPHOLIPID DEGRADATION; SUBARACHNOID HEMORRHAGE; INTRACEREBRAL MICRODIALYSIS; HUMAN BRAIN; MARKER; TOOL	Objective. To investigate the association between the occurrence of secondary events, clinical outcome and the interstitial glycerol levels as measured with cerebral microdialysis. Design. All patients received a ventriculostomy, a Camino pressure sensor and a CMA 70 microdialysis catheter. Intracranial pressure (ICP), cerebral perfusion pressure (CPP), blood pressure and arterial oxygen saturation (SaO(2)) were continuously monitored. Hourly microdialysis samples were collected and glycerol concentrations analyzed on-line. Glasgow Coma Score (GCS) scoring, blood gas and other laboratory analyses or investigations followed the routine of the intensive care unit. The Glasgow Outcome Scale (GOS) was assessed 6 months after injury. Setting. Intensive Care Unit and Department of Neurosurgery, VU University Hospital. Patients. Fifteen consecutive patients with severe traumatic brain injury and a GCS of 8 or less. Results. No association was found between low CPP, high ICP, low PaCO2, low SaO(2) or rise in temperature and the level of interstitial glycerol. In patients with a favorable outcome, the glycerol concentration never reached a level above 150 mumol/l, whereas a peak glycerol level above 150 mumol/l had a positive predictive value of 100% for an unfavorable outcome. The average of the area under the curve during the first 24 h of monitoring was significantly higher in the group with an unfavorable outcome (Kolmogorov-Smirnov test, p=0.044). Conclusion. Measuring interstitial glycerol for early detection of secondary adverse events, which possibly lead to secondary brain damage, does not seem useful. A peak level of interstitial glycerol above 150 mumol/l has a positive predictive value of 100% for an unfavorable outcome and hence indicates the severity of the parenchymal damage.	Vrije Univ Amsterdam Med Ctr, Dept Neurosurg, NL-1007 MB Amsterdam, Netherlands; Vrije Univ Amsterdam Med Ctr, Dept Intens Care, NL-1007 MB Amsterdam, Netherlands	Peerdeman, SM (corresponding author), Vrije Univ Amsterdam Med Ctr, Dept Neurosurg, POB 7057, NL-1007 MB Amsterdam, Netherlands.	sm.peerdeman@vumc.nl	Vandertop, William P./K-9288-2018; Polderman, Kees H/K-3623-2012				ANDERSON DK, 1994, NEUROBIOLOGY CENTRAL, P131; BAZAN NG, 1970, LIFE SCI, V9, P501, DOI 10.1016/0024-3205(70)90205-5; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Frykholm P, 2001, J NEUROL NEUROSUR PS, V71, P455, DOI 10.1136/jnnp.71.4.455; HILLERED L, 1990, ACTA NEUROCHIR, V102, P91, DOI 10.1007/BF01405420; Hillered L, 1998, J NEUROL NEUROSUR PS, V64, P486, DOI 10.1136/jnnp.64.4.486; Marklund N, 1997, NEUROREPORT, V8, P1457, DOI 10.1097/00001756-199704140-00026; Nilsson OG, 1999, NEUROSURGERY, V45, P1176, DOI 10.1097/00006123-199911000-00032; Peerdeman SM, 2000, INTENS CARE MED, V26, P662, DOI 10.1007/s001340051230; Polderman KH, 2002, INTENS CARE MED, V28, P1563, DOI 10.1007/s00134-002-1511-3; Polderman KH, 2001, J NEUROSURG, V94, P697, DOI 10.3171/jns.2001.94.5.0697; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Sarrafzadeh AS, 2002, CRIT CARE MED, V30, P1062, DOI 10.1097/00003246-200205000-00018; Schulz MK, 2000, J NEUROSURG, V93, P808, DOI 10.3171/jns.2000.93.5.0808; SIESJO BK, 1992, ADV EXP MED BIOL, V318, P41	16	35	35	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	OCT	2003	29	10					1825	1828		10.1007/s00134-003-1850-8			4	Critical Care Medicine	General & Internal Medicine	732AJ	WOS:000185918400036	12827237				2021-06-18	
J	Blostein, P; Jones, SJ				Blostein, P; Jones, SJ			Identification and evaluation of patients with mild traumatic brain injury: Results of a national survey of level I trauma centers	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						mild traumatic brain injury; brain injury; cognitive deficits	MINOR HEAD-INJURIES; UNITED-STATES; MANAGEMENT; HOSPITALIZATION; CONCUSSION; GUIDELINES	Background: Mild traumatic brain injury (MTBI), alone or in combination with other injuries, is frequently present in trauma patients requiring hospital admission. A survey was conducted to characterize the current practices of identification and management of patients with MTBI at Level I trauma centers in the United States. Methods. Surveys were mailed to trauma program managers at 68 verified Level I trauma centers. Results: Thirty-five (51.4%) centers responded, representing 24 states. Multiple terms are used synonymously with MTBI, and less than half (45%) of centers formally evaluate all trauma patients with MTBI. Patients identified with MTBI discharged from the emergency department are referred for further evaluation at only 34% of centers. There is no consistent practice for determining which hospitalized patients with MTBI are formally evaluated, who performs the evaluations, or which evaluation tool(s) are used. Patients with MTBI and cognitive deficits are referred to a variety of specialists after discharge. Conclusion: There is currently no standard practice for defining, evaluating, or managing MTBI at Level I trauma centers. A consistent definition of MTBI and its management could promote recognition of MTBI; facilitate data collection, analysis, and comparison; and provide guidelines for activity modification during recovery.	Bronson Methodist Hosp, Trauma Surg Serv, Kalamazoo, MI 49007 USA; Bronson Methodist Hosp, Rehabil Serv, Kalamazoo, MI 49007 USA	Blostein, P (corresponding author), Bronson Methodist Hosp, Trauma Surg Serv, 601 John St, Kalamazoo, MI 49007 USA.						ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Blostein PA, 1997, J NEUROTRAUM, V14, P171, DOI 10.1089/neu.1997.14.171; BOHNEN N, 1992, NEUROSURGERY, V30, P692; Chambers J, 1996, J TRAUMA, V41, P976, DOI 10.1097/00005373-199612000-00006; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; Cushman JG, 2001, J TRAUMA, V51, P1016, DOI 10.1097/00005373-200111000-00034; DENTON GL, 1999, BRAINLASH MAXIMIZE Y; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dunham CM, 1996, J TRAUMA, V41, P679, DOI 10.1097/00005373-199610000-00014; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; KURTZKE JF, 1993, CLIN NEUROLOGY, P111; Lawler KA, 1996, J HEAD TRAUMA REHAB, V11, P18, DOI 10.1097/00001199-199612000-00005; Levin HS, 1996, NEUROTRAUMA, P749; LIVINGSTON DH, 1991, J TRAUMA, V31, P483, DOI 10.1097/00005373-199104000-00006; Miller EC, 1996, ANN EMERG MED, V27, P290, DOI 10.1016/S0196-0644(96)70261-5; MINDERHOUD JM, 1980, CLIN NEUROL NEUROSUR, V82, P127, DOI 10.1016/0303-8467(80)90007-4; MITTENBERG W, 1994, BRAIN INJURY, V8, P429, DOI 10.3109/02699059409150994; OSBORNE CL, 1998, OVER HEAD DOCTORS OW; Owings JT, 1998, ARCH SURG-CHICAGO, V133, P941, DOI 10.1001/archsurg.133.9.941; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; Sosin DM, 1996, BRAIN INJURY, V10, P47; STEIN SC, 1992, J TRAUMA, V33, P11, DOI 10.1097/00005373-199207000-00003; STEIN SC, 1996, NEUROTRAUMA, P755; STOLER DR, 1998, COPING MILD TRAUMATI; Swanson Kara L., 1999, ILL CARRY FORK RECOV; TAHERI PA, 1993, ARCH SURG-CHICAGO, V128, P289; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954	32	35	35	1	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	SEP	2003	55	3					450	453		10.1097/01.TA.0000038545.24879.4D			4	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	721DZ	WOS:000185302900012	14501885				2021-06-18	
J	Piper, I; Citerio, G; Chambers, I; Contant, C; Enblad, P; Fiddes, H; Howells, T; Kiening, K; Nilsson, P; Yau, YH				Piper, I; Citerio, G; Chambers, I; Contant, C; Enblad, P; Fiddes, H; Howells, T; Kiening, K; Nilsson, P; Yau, YH		BrainIT Grp	The BrainIT group: concept and core dataset definition	ACTA NEUROCHIRURGICA			English	Article						head injury; multi-centre network; health technology assessment	HEAD-INJURED PATIENTS; INTENSIVE-CARE; SECONDARY INSULTS; UNITED-KINGDOM; MANAGEMENT; CONSORTIUM; ADULTS	Introduction. An open collaborative international network has been established which aims to improve inter-centre standards for collection of high-resolution, neurointensive care data on patients with traumatic brain injury. The group is also working towards the creation of an open access, detailed and validated database that will be useful for post-hoc hypothesis testing. In Part A, the underlying concept, the group coordination structure, membership guidelines and database access and publication criteria are described. Secondly, in part B, we describe a set of meetings funded by the EEC that allowed us to define a "Core Dataset" and we present the results of a feasibility exercise for collection of this core dataset. Methods. Four group meetings funded by the EEC have enabled definition of a "Core Dataset" to be collected from all centres regardless of specific project aim. A paper based pilot collection of data was conducted to determine the feasibility for collection of the core dataset. Specially designed forms to collect the core dataset demographic and clinical information as well as sample the time-series data elements were distributed by both email and standard mail to 22 BrainIT centres. A deadline of two months was set to receive completed forms back from centres. A pilot data collection of minute by minute physiological monitoring data was also performed. Findings. A core-dataset was defined and can be downloaded from the BrainIT web-site (go to "Core dataset" link at: www.brainit.org). Eighteen centres (82%) returned completed forms by the set deadline. Overall the feasibility for collection of the core data elements was high with only 10 of the 64 questions (16%) showing missing data. Of those 10 fields with missing data, the average number of centres not responding was 12% and the median 6%. An SQL database to hold the data has been designed and is being tested. Software tools for collection of the core dataset have been developed. Ethics approval has been granted for collection of multi-centre data as part of a pilot data collection study. Interpretation. The BrainIT network provides a more standardised and higher resolution data collection mechanism for research groups, organisations and the device industry to conduct multi-centre trials of new health care technology in patients with traumatic brain injury.	So Gen Hosp, Inst Neurol Sci, Dept Clin Phys, Glasgow G51 4TF, Lanark, Scotland; Newcastle Gen Hosp, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England; Osped San Gerardo, Monza, Italy; Queen Elizabeth Hosp, Birmingham B15 2TH, W Midlands, England; Addenbrookes Hosp, Cambridge, England; Univ Rotterdam Hosp, Rotterdam, Netherlands; Cattedra Anestesiol Novara, Novara, Italy; Univ Uppsala Hosp, Uppsala, Sweden; Southampton Gen Hosp, Southampton SO9 4XY, Hants, England; Univ Hosp Brno, Brno, Czech Republic; Rigshosp, DK-2100 Copenhagen, Denmark; Catholic Univ Louvain, Hosp Gasthuisberg, B-3000 Louvain, Belgium; SF Treime Hosp, Iasi, Romania; Vilnius Univ Hosp, Vilnius, Lithuania; Univ Kliniken Saarlandes, Homburg, Germany; Univ Heidelberg, D-6900 Heidelberg, Germany; Hop Gabriel Montpied, Clermont Ferrand, France; Hosp 12 Octubre, E-28041 Madrid, Spain; Osped Molinette, Turin, Italy; Univ Hosp Leipzig, Leipzig, Germany; Univ Lund Hosp, S-22185 Lund, Sweden; Kaunas Med Univ Hosp, Kaunas, Lithuania; Sahlgrens Univ Hosp, S-41345 Gothenburg, Sweden; Valle Hebron Univ Hosp Barcelona, Barcelona, Spain; Terapia Intens Neurosci, Milan, Italy; Univ Spital Zurich, Zurich, Switzerland; Univ Hosp Mannheim, Mannheim, Germany; Natl Hosp, London WC1N 3BG, England; Western Gen Hosp, Edinburgh EH4 2XU, Midlothian, Scotland; Hosp Clin Barcelona, UCI Quirurg, Barcelona, Spain	Piper, I (corresponding author), So Gen Hosp, Inst Neurol Sci, Dept Clin Phys, 1345 Govan Rd, Glasgow G51 4TF, Lanark, Scotland.		Citerio, Giuseppe/B-1839-2015	Citerio, Giuseppe/0000-0002-5374-3161			*AM ASS NEUR SURG, 1995, GUID MAN HEAD INJ; Berkowitz Monroe, 1993, Journal of Emergency Medicine, V11, P63; BOUMA GJ, 1990, J NEUROSURG, V73, P368, DOI 10.3171/jns.1990.73.3.0368; Chambers IR, 2000, BRIT J NEUROSURG, V14, P424; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; CORRIE J, 1993, BRIT J INT CARE, V3, P225; *CPP, HYDR FLUID COL; GABE IT, 1972, ACTA PHYSL SCAND, V19, P306; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; Jeevaratnam DR, 1996, BRIT MED J, V312, P944; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MARMAROU A, 1991, J NEUROSURG S, V75, P59; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; McGraw CP, 1989, INTRACRANIAL PRESSUR, P839; McKeating EG, 1998, BRIT J NEUROSURG, V12, P7; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; PIPER IR, 1991, BR J INTENS CARE, V1, P73; ROBERTSON CS, 1997, P 10 INT S INTR PRES, P3; Robertson N, 2002, SIMULAT PRACT THEORY, V9, P349, DOI 10.1016/S0928-4869(01)00055-6; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; *SOC BRIT NEUR SUR, 1998, B J NEUROSURG, V14; Teasdale GM, 1997, ACTA NEUROCHIR, V139, P797, DOI 10.1007/BF01411397	24	35	35	0	1	SPRINGER-VERLAG WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.	AUG	2003	145	8					615	629		10.1007/s00701-003-0066-6			15	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	719WL	WOS:000185228000003	14520540				2021-06-18	
J	Braverman, ER; Blum, K				Braverman, ER; Blum, K			P300 (latency) event-related potential: An accurate predictor of memory impairment	CLINICAL ELECTROENCEPHALOGRAPHY			English	Article; Proceedings Paper	Conference of the American-Academy-of-Anti-Aging-Medicine	DEC 05-08, 2002	LAS VEGAS, NV	Amer Acad Anti Aging Med		aging; Alzheimer's disease; brain health; memory loss; mini-mental status exam; p300; QEEG; Wechsler memory scale	MINI-MENTAL-STATE; ACADEMY-OF-NEUROLOGY; CLINICAL-NEUROPHYSIOLOGY-SOCIETY; OBSESSIVE-COMPULSIVE DISORDER; MILD ALZHEIMERS-DISEASE; TRAUMATIC BRAIN INJURY; RECEPTOR A1 ALLELE; AUDITORY P300; PARKINSONS-DISEASE; COGNITIVE FUNCTION	To determine if P300 latency changes precede and correlate with memory and mental status, patients (N=1506 aged 20-100 years) who received medical and psychiatric diagnoses (from 1997 to 2002), were assessed for P300 (N=1496), WMS-III (N=694), and MMSE (N=456). Patient and control groups included, a) normal WMS-111 on all 4 subscales (N=36), b) normal WMS-111 and MMSE (N=189) with subjective memory/mental status complaints, and c) medical patients with normal WMS-111 and no memory complaints (N=205), and d) P300 control group without medical, psychiatric or memory problems for ROC. Patients with impaired/borderline memory had a prolonged P300 latency (P<0.02) compared to age matched non-impaired controls; in patients with normal WMS-III/MMSE, with subjective mild memory/mental status impairment, P300 latency was prolonged compared to controls (P=0.0004). The P300 latency increased by 0.72ms per year (P=7.9x10(-65)) and voltage decreased by 0.03dV per year (P=6.7x10(-10)), and both parameters were linearly correlated with the age of the subjects. Male subjects had an average voltage of 6.1 dV and female 6.8 dV(P=0.00009). Statistically, prolonged latency began at age range 41-50 (P=0.0002); reduced P300 volt age began at age range 51-60 (P=0.003). WMS-111 memory decline for all measures began in females at age range 61 70 (P value at least=0.02) and for males at age range 61 80 (P=0.02). Prolonged P300 latency (P<0.0001) and memory impairment (at least <0.02) were greater for females than males. MMSE memory decline, male and female, began at age range 81-90 (P value of at least 0.00007). In our logistic regression model P300 latency was more predictive of WMS-111 impairment than MMSE >24. In patients whose WMS-III score is impaired less than or equal to69, or borderline less than or equal to79 (P at least =0.004), a P300 latency more prolonged than the norm (greater than or equal to300 + 30 + Age) identifies these patients, whereas a MMSE >24 failed. With the ROC curve, we confirmed that P300 latency could accurately identify borderline/impaired memory.	Path Med Res Fdn, New York, NY 10016 USA; Univ N Texas, Dept Sci Biol, Denton, TX USA	Braverman, ER (corresponding author), Path Med Res Fdn, 185 Madison Ave,6th Floor, New York, NY 10016 USA.	Pathmedical@aol.com					Alberti A, 2001, HEADACHE, V41, P579, DOI 10.1046/j.1526-4610.2001.041006579.x; Ament P A, 1995, J Spinal Cord Med, V18, P208; Aminoff JC, 2001, J CLIN NEUROPHYSIOL, V18, P372, DOI 10.1097/00004691-200107000-00009; Anderer P, 1998, NEUROPSYCHOBIOLOGY, V37, P20, DOI 10.1159/000026472; Anokhin AP, 2000, PSYCHOPHARMACOLOGY, V149, P409, DOI 10.1007/s002130000387; [Anonymous], 1991, Am J Psychiatry, V148, P961; Attias J, 1996, BIOL PSYCHIAT, V40, P373, DOI 10.1016/0006-3223(95)00419-X; Bandini F, 2002, J NEURAL TRANSM, V109, P41, DOI 10.1007/s702-002-8235-5; BARAJAS JJ, 1991, ACTA OTO-LARYNGOL, P157; Barrett G, 1999, EEG CL N SU, V50, P469; Bashore TR, 2002, PSYCHOL BULL, V128, P151, DOI 10.1037/0033-2909.128.1.151; Bauer LO, 1999, BIOL PSYCHIAT, V46, P263, DOI 10.1016/S0006-3223(98)00335-7; Bauer LO, 2001, J STUD ALCOHOL, V62, P571, DOI 10.15288/jsa.2001.62.571; BLACKER D, 2000, COMPREHENSIVE TXB PS, V1, P776; BLEECKER ML, 1988, NEUROLOGY, V38, P1565, DOI 10.1212/WNL.38.10.1565; BLOM JL, 1982, ELECTROEN CLIN NEURO, V54, P591, DOI 10.1016/0013-4694(82)90046-3; BLUM K, 1994, PHARMACOGENETICS, V4, P313, DOI 10.1097/00008571-199412000-00004; BodisWollner I, 1997, CLIN ELECTROENCEPHAL, V28, P143, DOI 10.1177/155005949702800305; BOWSER A, 2002, CNS NEWS, V5, P1; Braverman ER, 1996, CLIN ELECTROENCEPHAL, V27, P5, DOI 10.1177/1550059496027S0402; Braverman ER, 2001, MOL PSYCHIATR, V6, pS5; BROWN WS, 1991, NEUROPSYCHOLOGIA, V29, P35, DOI 10.1016/0028-3932(91)90092-M; BUTLER RW, 1995, COMPREHENSIVE TXB PS, V1, P568; CAINE ED, 2000, COMPREHENSIVE TXB PS, V1, P894; Casey BJ, 2002, SCIENCE, V296, P1408, DOI 10.1126/science.1072684; Clark CR, 1996, BIOL PSYCHIAT, V39, P845; Coburn KL, 2003, J NEUROPSYCH CLIN N, V15, P175, DOI 10.1176/appi.neuropsych.15.2.175; d'Ardhuy XL, 1999, NEUROPSYCHOBIOLOGY, V40, P207, DOI 10.1159/000026621; De Jager CA, 2002, PSYCHOL MED, V32, P483, DOI 10.1017/S003329170200524X; DeFrance JF, 1996, INT J NEUROSCI, V86, P119, DOI 10.3109/00207459608986704; deGroot CM, 1997, CLIN ELECTROENCEPHAL, V28, P148, DOI 10.1177/155005949702800306; Deguchi K, 2001, J NEUROL SCI, V190, P61, DOI 10.1016/S0022-510X(01)00588-3; Derrer DS, 2001, J GERIATR PSYCH NEUR, V14, P1, DOI 10.1177/089198870101400102; DETOLEDOMORRELL L, 1991, ARCH NEUROL-CHICAGO, V48, P605, DOI 10.1001/archneur.1991.00530180061018; DIERKS T, 1994, PHARMACOPSYCHIATRY, V27, P72, DOI 10.1055/s-2007-1014282; DOLLINS AB, 1995, PHYSIOL BEHAV, V57, P223, DOI 10.1016/0031-9384(94)00278-D; Drake M E Jr, 1996, Electromyogr Clin Neurophysiol, V36, P457; DUFFY FH, 1994, CLIN ELECTROENCEPHAL, V25, pR6, DOI 10.1177/155005949402500403; Dufouil C, 2000, NEUROLOGY, V55, P1609, DOI 10.1212/WNL.55.11.1609; Enoch MA, 2001, ALCOHOL CLIN EXP RES, V25, P1293; Farrag AF, 2002, DEMENT GERIATR COGN, V13, P193, DOI 10.1159/000048652; Folmer RL, 1997, BRAIN LANG, V56, P306, DOI 10.1006/brln.1997.1828; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fontani G, 2000, NEUROPSYCHOBIOLOGY, V41, P158, DOI 10.1159/000026649; Ford JM, 2001, BIOL PSYCHIAT, V49, P848, DOI 10.1016/S0006-3223(00)01051-9; FOWLER B, 1993, AVIAT SPACE ENVIR MD, V64, P493; Frodl T, 2002, INT J PSYCHOPHYSIOL, V43, P237, DOI 10.1016/S0167-8760(01)00182-9; Frodl T, 2000, BRAIN TOPOGR, V13, P3, DOI 10.1023/A:1007831017318; Frodl-Bauch T, 1999, NEUROPSYCHOBIOLOGY, V40, P86, DOI 10.1159/000026603; Gaeta H, 2001, PSYCHOL AGING, V16, P55, DOI 10.1037//0882-7974.16.1.55; Gaetz M, 2000, BRAIN INJURY, V14, P815; Geerlings MI, 1999, AM J PSYCHIAT, V156, P531; GEISLER MW, 1992, PSYCHOPHYSIOLOGY, V29, P76, DOI 10.1111/j.1469-8986.1992.tb02017.x; Giger-Mateeva VI, 2000, METAB BRAIN DIS, V15, P179, DOI 10.1023/A:1011159624831; Glass I, 1998, CLIN ELECTROENCEPHAL, V29, P19, DOI 10.1177/155005949802900109; Goldman WP, 2001, ALZ DIS ASSOC DIS, V15, P72, DOI 10.1097/00002093-200104000-00006; Golob EJ, 2002, CLIN NEUROPHYSIOL, V113, P151, DOI 10.1016/S1388-2457(01)00713-1; Grigoletto F, 1999, NEUROLOGY, V53, P315, DOI 10.1212/WNL.53.2.315; Haaland KY, 2003, J INT NEUROPSYCH SOC, V9, P89, DOI 10.1017/S1355617703910101; HAMMOND EJ, 1987, NEUROLOGY, V37, P346, DOI 10.1212/WNL.37.2.346; Hansenne M, 2000, EUR PSYCHIAT, V15, P370, DOI 10.1016/S0924-9338(00)00505-8; HANSENNE M, 1995, EVOKED POTENTIAL, V96, P194, DOI 10.1016/0168-5597(94)00317-8; Hansenne M, 1999, EUR PSYCHIAT, V14, P143, DOI 10.1016/S0924-9338(99)80732-9; Hayakawa T, 2000, PSYCHIAT CLIN NEUROS, V54, P319, DOI 10.1046/j.1440-1819.2000.00695.x; HENDERSON AS, 2000, COMPREHENSIVE TXB PS, V2, P2990; Henderson RM, 2000, ACTA PAEDIATR, V89, P52, DOI 10.1080/080352500750029068; HENDERSON S, 1995, COMPREHENSIVE TXB PS, V2, P2514; Hill SY, 2000, BIOL PSYCHIAT, V48, P265, DOI 10.1016/S0006-3223(00)00841-6; Hill SY, 1999, BIOL PSYCHIAT, V46, P970, DOI 10.1016/S0006-3223(99)00032-3; Hill SY, 1998, BIOL PSYCHIAT, V43, P40, DOI 10.1016/S0006-3223(97)00203-5; Hill SY, 1999, BIOL PSYCHIAT, V45, P346, DOI 10.1016/S0006-3223(97)00525-8; Himani A, 1999, Indian J Physiol Pharmacol, V43, P367; Hoffman DA, 1999, J NEUROPSYCH CLIN N, V11, P401, DOI 10.1176/jnp.11.3.401; HOLMES TH, 1967, J PSYCHOSOM RES, V11, P213, DOI 10.1016/0022-3999(67)90010-4; HOLSCHNEIDER DP, 2000, TXB GERIATRIC NEUROP, P293; Hughes JR, 1999, J NEUROPSYCH CLIN N, V11, P190, DOI 10.1176/jnp.11.2.190; Idiazabal MA, 2002, REV NEUROLOGIA, V34, P301, DOI 10.33588/rn.3404.2000501; Javitt DC, 1995, EEG CL N SU, P161; Jing H, 2001, J NEUROL, V248, P184, DOI 10.1007/s004150170224; JING H, 2000, CLIN NEUROPHYSIOL, V38, P109; Justus AN, 2001, ALCOHOL CLIN EXP RES, V25, P1457, DOI 10.1111/j.1530-0277.2001.tb02147.x; Kalayam B, 1998, AM J PSYCHIAT, V155, P425, DOI 10.1176/ajp.155.3.425; Kazis A, 1996, NEUROPHYSIOL CLIN, V26, P75, DOI 10.1016/0987-7053(96)83148-0; Kiehl KA, 1999, BIOL PSYCHIAT, V45, P1498, DOI 10.1016/S0006-3223(98)00193-0; Kilo J, 2001, ANN THORAC SURG, V72, P1926, DOI 10.1016/S0003-4975(01)03199-X; Kilpelainen R, 1999, PSYCHOPHYSIOLOGY, V36, P343, DOI 10.1017/S0048577299981337; Kilpelainen R, 1999, NEUROREPORT, V10, P3405, DOI 10.1097/00001756-199911080-00027; KONISHI T, 1995, PEDIATR NEUROL, V12, P132, DOI 10.1016/0887-8994(95)00001-V; Korpelainen JT, 2000, ACTA NEUROL SCAND, V101, P202, DOI 10.1034/j.1600-0404.2000.101003202.x; Kotchoubey B, 2001, NEUROSCI LETT, V301, P37, DOI 10.1016/S0304-3940(01)01600-7; KUKULL WA, 1994, J CLIN EPIDEMIOL, V47, P1061, DOI 10.1016/0895-4356(94)90122-8; KURITA A, 1995, ACTA NEUROL SCAND, V92, P319; LACADENA CG, 1996, GAC MED MEX, V3, P267; Lagopoulos J, 1998, NEUROL RES, V20, P5; Legrain V, 2001, REV NEUROL-FRANCE, V157, P365; Lindgren M, 1997, J CLIN EXP NEUROPSYC, V19, P772, DOI 10.1080/01688639708403759; Lorberboym M, 2002, J TRAUMA, V52, P521, DOI 10.1097/00005373-200203000-00017; LYONS WL, 2002, GERIATRIC MED, V41, P55; Makatura TJ, 1999, BRAIN INJURY, V13, P355; Mannan MR, 2001, PSYCHIAT CLIN NEUROS, V55, P451, DOI 10.1046/j.1440-1819.2001.00889.x; Mathalon DH, 2000, BIOL PSYCHIAT, V47, P434, DOI 10.1016/S0006-3223(99)00277-2; MAZZOTTA G, 1995, HEADACHE, V35, P210, DOI 10.1111/j.1526-4610.1995.hed3504210.x; MCCARLEY RW, 1991, SCHIZOPHR RES, V4, P209, DOI 10.1016/0920-9964(91)90034-O; McEvoy LK, 2001, COGNITIVE BRAIN RES, V11, P363, DOI 10.1016/S0926-6410(01)00009-X; Mecklinger A, 1998, BRAIN, V121, P1919, DOI 10.1093/brain/121.10.1919; Meyer JS, 2001, INT J GERIATR PSYCH, V16, P430, DOI 10.1002/gps.359; MOCHIZUKI M, 1996, CLIN ELECTROENCEPHAL, V29, P1; Mochizuki Y, 2001, J CLIN NEUROSCI, V8, P407, DOI 10.1054/jocn.2000.0850; Mutschler V, 1996, NEUROPHYSIOL CLIN, V26, P158, DOI 10.1016/0987-7053(96)89626-2; Naganuma Y, 1997, BRAIN DEV-JPN, V19, P117, DOI 10.1016/S0387-7604(96)00489-5; Nakano Yoko, 2000, Hiroshima Journal of Medical Sciences, V49, P37; Naumann A, 2001, NEUROREPORT, V12, P2807, DOI 10.1097/00001756-200109170-00011; NESHIGE R, 1988, J NEUROL NEUROSUR PS, V51, P1120, DOI 10.1136/jnnp.51.9.1120; NOBLE EP, 1994, AM J HUM GENET, V54, P658; Nuwer M, 1997, NEUROLOGY, V49, P277, DOI 10.1212/WNL.49.1.277; OSTERWEIL D, 1992, J AM GERIATR SOC, V40, P325, DOI 10.1111/j.1532-5415.1992.tb02130.x; Perry RJ, 2000, DEMENT GERIATR COGN, V11, P342, DOI 10.1159/000017264; Perry RJ, 2000, NEUROPSYCHOLOGIA, V38, P252, DOI 10.1016/S0028-3932(99)00079-2; PEWERSELL RC, 1999, ARCH NEUROL-CHICAGO, V56, P303; PFEFFERBAUM A, 1984, ELECTROEN CLIN NEURO, V59, P85, DOI 10.1016/0168-5597(84)90026-1; Pimenta MG, 1999, AVIAT SPACE ENVIR MD, V70, pA107; Polich J, 2000, INT J PSYCHOPHYSIOL, V38, P97, DOI 10.1016/S0167-8760(00)00133-1; POLICH J, 1991, ELECTROEN CLIN NEURO, P304; POLICH J, 1995, BIOL PSYCHOL, V41, P103, DOI 10.1016/0301-0511(95)05130-9; POLICH J, 1995, J CLIN NEUROPHYSIOL, V12, P186, DOI 10.1097/00004691-199503000-00009; Polich J, 1999, EEG CL N SU, V50, P281; Portin R, 2000, SCAND J PSYCHOL, V41, P31, DOI 10.1111/1467-9450.00168; Prabhakar S, 2000, NEUROL INDIA, V48, P239; RATCLIFF G, 2000, TXB GERIATRIC NEUROP, P174; RAY PG, 1992, J CLIN PSYCHOPHARM, V12, P415; Reeves RR, 1999, CLIN ELECTROENCEPHAL, V30, P122, DOI 10.1177/155005949903000310; REILLY EL, 2000, COMPREHENSIVE TXB PS, V1, P152; RODIN E, 1999, ELECTROENCEPHALOGRAP, P1207; Salamat M T, 1999, J Am Acad Audiol, V10, P379; Sangal RB, 1996, BIOL PSYCHIAT, V39, P305, DOI 10.1016/0006-3223(95)00447-5; Sangal RB, 1998, CLIN ELECTROENCEPHAL, V29, P1, DOI 10.1177/155005949802900105; Sangal RB, 1996, CLIN ELECTROENCEPHAL, V27, P46, DOI 10.1177/155005949602700108; Sangal RB, 1997, CLIN ELECTROENCEPHAL, V28, P16, DOI 10.1177/155005949702800104; Sanz M, 2001, PSYCHIAT RES, V101, P75, DOI 10.1016/S0165-1781(00)00250-X; Saxena N, 2001, J GASTROEN HEPATOL, V16, P322, DOI 10.1046/j.1440-1746.2001.02388.x; SEMLITSCH HV, 1993, INT CLIN PSYCHOPHARM, V8, P155, DOI 10.1097/00004850-199300830-00004; SHAW TG, 1984, NEUROLOGY, V34, P855, DOI 10.1212/WNL.34.7.855; SOLLIWAY BM, 1994, ELECTROENCEPHALOGR C, V92, P422; SOUZA VBN, 1995, BIOL PSYCHIAT, V37, P300, DOI 10.1016/0006-3223(94)00131-L; SUTTON S, 1965, SCIENCE, V150, P1187, DOI 10.1126/science.150.3700.1187; Tachibana H, 1999, J NEUROL SCI, V168, P52, DOI 10.1016/S0022-510X(99)00182-3; Tasman A, 1999, BIOL PSYCHIAT, V45, P1516, DOI 10.1016/S0006-3223(98)00196-6; Thatcher RW, 1999, CLIN ELECTROENCEPHAL, V30, P94, DOI 10.1177/155005949903000304; Thomas A, 2001, CLIN NEUROPHARMACOL, V24, P31, DOI 10.1097/00002826-200101000-00007; TREIMAN DM, 1990, EPILEPSY RES, V5, P49, DOI 10.1016/0920-1211(90)90065-4; Tulsky DS, 2001, J INT NEUROPSYCH SOC, V7, P860, DOI 10.1017/S1355617701777089; van Gorp WG, 1999, J CLIN EXP NEUROPSYC, V21, P29, DOI 10.1076/jcen.21.1.29.939; von Bierbrauer A, 1998, ACTA NEUROL BELG, V98, P21; Winker MA, 2002, JAMA-J AM MED ASSOC, V287, P1326, DOI 10.1001/jama.287.10.1326; Yagi Y, 1999, EUR J APPL PHYSIOL O, V80, P402, DOI 10.1007/s004210050611; Zhu JJ, 2001, J INT NEUROPSYCH SOC, V7, P862, DOI 10.1017/S1355617701777090	156	35	39	0	5	EEG & CLINICAL NEUROSCIENCE SOC (E C N S)	WHEATON	805 W LIBERTY DR, PO BOX 725, WHEATON, IL 60187 USA	0009-9155			CLIN ELECTROENCEPHAL	Clin. Electroencephalogr.	JUL	2003	34	3					124	139		10.1177/155005940303400306			16	Engineering, Biomedical; Clinical Neurology	Engineering; Neurosciences & Neurology	706WN	WOS:000184478200004	14521274				2021-06-18	
J	Boone, KB; Lu, P				Boone, KB; Lu, P			Noncredible cognitive performance in the context of severe brain injury	CLINICAL NEUROPSYCHOLOGIST			English	Article							HEAD-INJURY; MMPI-2; SENSITIVITY	In two litigating patients with histories of severe brain injury (i.e., coma greater than or equal to2 days and residual brain imaging abnormalities), noncredible cognitive symptomatology was demonstrated by: (1) "failed" performance on multiple cognitive "effort" tests, (2) noncredible performance on standard neuropsychological instruments, (3) questionable validity of personality inventory profiles, and (4) marked inconsistency in test performance across testing evaluations or marked inconsistency between test scores and activities of daily living documented through surveillance videotapes. Some patients with severe traumatic brain injury show substantial, if not full recovery, and in a litigating context, may feign cognitive symptoms. These cases indicate that tests to verify cognitive effort should be routinely administered to all patients in litigation or who have other motive to feign symptoms, not just patients with mild or questionable brain injury.	Harbor UCLA Med Ctr, Dept Psychiat, ABPP ABCN, Torrance, CA 90509 USA	Boone, KB (corresponding author), Harbor UCLA Med Ctr, Dept Psychiat, ABPP ABCN, Box 495,1000 W Carson St,F-9, Torrance, CA 90509 USA.	kboone@rei.edu					ANDRIKOPOULOS J, 1998, 26 ANN M INT NEUR SO; Boone K., 2002, B TEST MANUAL; Boone KB, 2002, ARCH CLIN NEUROPSYCH, V17, P625, DOI 10.1016/S0887-6177(01)00166-4; Boone KB, 2002, J CLIN EXP NEUROPSYC, V24, P561, DOI 10.1076/jcen.24.5.561.1004; CONZEN M, 1992, Brain Injury, V6, P45, DOI 10.3109/02699059209008121; CRAWFORD JR, 1988, BRIT J PSYCHIAT, V153, P178, DOI 10.1192/bjp.153.2.178; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Greiffenstein M F, 1996, J Int Neuropsychol Soc, V2, P477; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greiffenstein MF, 1996, ARCH CLIN NEUROPSYCH, V11, P283, DOI 10.1016/0887-6177(95)00038-0; GREIFFENSTEIN MF, 1995, CLIN NEUROPSYCHOL, V9, P230, DOI 10.1080/13854049508400485; HEATON RK, 1978, J CONSULT CLIN PSYCH, V46, P892, DOI 10.1037/0022-006X.46.5.892; Hoofien D, 2001, BRAIN INJURY, V15, P189; Iverson G.L., 1994, ASSESSMENT, V1, P323, DOI [DOI 10.1177/1073191, https://doi.org/10.1177/107319119400100401, DOI 10.1177/107319119400100401]; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Larrabee GJ, 1998, CLIN NEUROPSYCHOL, V12, P179, DOI 10.1076/clin.12.2.179.2008; LEESHALEY PR, 1991, PSYCHOL REP, V68, P203, DOI 10.2466/PR0.68.1.203-210; LEVATI A, 1982, J NEUROSURG, V57, P779, DOI 10.3171/jns.1982.57.6.0779; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; LU P, 2003, 31 ANN M INT NEUR SO; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; MILLIS SR, 1992, CLIN NEUROPSYCHOL, V6, P406; PALMER BW, 1995, CLIN NEUROPSYCHOL, V9, P68, DOI 10.1080/13854049508402060; Rawling P, 1990, NEUROPSYCHOLOGY, V4, P223, DOI 10.1037/0894-4105.4.4.223; Sherer M, 2000, J HEAD TRAUMA REHAB, V15, P767, DOI 10.1097/00001199-200004000-00002; Sherer M, 2002, CLIN NEUROPSYCHOL, V16, P157, DOI 10.1076/clin.16.2.157.13238; Sherman DS, 2002, CLIN NEUROPSYCHOL, V16, P242, DOI 10.1076/clin.16.3.242.13860; Strauss E, 2002, ARCH CLIN NEUROPSYCH, V17, P423, DOI 10.1016/S0887-6177(01)00126-3; TRUEBLOOD W, 1993, J CLIN EXP NEUROPSYC, V15, P578, DOI 10.1080/01688639308402580; Vickery CD, 2001, ARCH CLIN NEUROPSYCH, V16, P45, DOI 10.1016/S0887-6177(99)00058-X; Willis SC., 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI [10.1037/1040-3590.3.2.175, DOI 10.1037/1040-3590.3.2.175]; YOUNGJOHN JR, 1995, CLIN NEUROPSYCHOL, V9, P112, DOI 10.1080/13854049508401593	34	35	35	0	1	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	MAY	2003	17	2					244	254		10.1076/clin.17.2.244.16497			11	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	734PF	WOS:000186065200014	13680432				2021-06-18	
J	Farmer, JE; Clark, MJ; Sherman, AK				Farmer, JE; Clark, MJ; Sherman, AK			Rural versus urban social support seeking as a moderating variable in traumatic brain injury outcome	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						community integration; rural; traumatic brain injury	QUALITY-OF-LIFE; DISCOURSE ABILITIES; DEPRESSION; INDIVIDUALS; INTEGRATION; ADJUSTMENT; IMPAIRMENT; COMPETENCE	Objective: To investigate personal beliefs about seeking social support following traumatic brain injury (TBI) and the relationship of these appraisals to demographic and injury variables, social integration, and quality of life ratings. Setting: The central region of a Midwest state. Participants: Fifty-six adults with TBI who were more than 6 months postinjury and living in the community. Main outcome measures: The Hesitation Scale, a 20-item survey that assesses reasons that people might hesitate to reach out to others in the community, and portions of the Living Life After Traumatic Brain Injury Scale. Results: Negative attitudes and beliefs about seeking social support were significantly related to lower perceptions of social support, lower ratings of quality of life, longer time since injury, being divorced or separated, and living in an urban area. Predictors of higher quality of fife ratings included more positive appraisals about seeking social support, living in a rural area, and the ability to engage in productive activity. Conclusions: Positive outcomes after TBI appear to be moderated by living in a rural area, which is associated with more openness to seeking social supports and contributes to better quality of life.	Univ Missouri, Columbia Sch Hlth Profess, Dept Hlth Psychol, Columbia, MO 65212 USA	Farmer, JE (corresponding author), Univ Missouri, Columbia Sch Hlth Profess, Dept Hlth Psychol, DCO46-46,1 Hosp Dr, Columbia, MO 65212 USA.	farmerje@health.missouri.edu					ABRAMSON LY, 1978, J ABNORM PSYCHOL, V87, P49, DOI 10.1037/0021-843X.87.1.49; Andrews F. M., 1976, SOCIAL INDICATORS WE; Beck A. T., 1967, DEPRESSION CLIN EXPT; BIGELOW DA, 1990, PSYCHOSOC REHABIL, V14, P94; BOAKE C, 1991, COGNITIVE REHABILITA, P181; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; Centers for Disease Control and Prevention, 1998, BEH RISK FACT SURV S; Chwalisz K, 2000, HANDBOOK OF REHABILITATION PSYCHOLOGY, P537, DOI 10.1037/10361-025; COELHO CA, 1995, BRAIN INJURY, V9, P471, DOI 10.3109/02699059509008206; Condeluci A, 1999, Top Health Inf Manage, V19, P40; *CRAIG RES DEP, 2001, CRAIG HOSP INV ENV F; DUNST CJ, 1994, SUPPORTING STRENGTHE, P152; FINSET A, 1995, BRAIN INJURY, V9, P141, DOI 10.3109/02699059509008187; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; GODFREY HPD, 1989, PSYCHOL MED, V19, P175, DOI 10.1017/S0033291700011120; GomezHernandez R, 1997, ARCH PHYS MED REHAB, V78, P1321, DOI 10.1016/S0003-9993(97)90304-X; Gottlieb B., 2000, SOCIAL SUPPORT MEASU, P195, DOI DOI 10.1093/MED:PSYCH/9780195126709.003.0006; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; Johnson M, 1998, GENERATIONS, V22, P4; Johnstone B, 2002, J RURAL HEALTH, V18, P109, DOI 10.1111/j.1748-0361.2002.tb00882.x; JOHNSTONE B, IN PRESS NEUROREHAB; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; KALPAKJIAN CZ, 2001, ANN M AM PSYCH ASS A; Karlovits T, 1999, BRAIN INJURY, V13, P845; Kendall E, 1997, J HEAD TRAUMA REHAB, V12, P68, DOI 10.1097/00001199-199706000-00007; Kozloff R, 1987, J HEAD TRAUMA REHAB, V2, P14, DOI DOI 10.1097/00001199-198709000-00004; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Lazarus R.S., 1984, STRESS APPRAISAL COP; LEZAK MD, 1988, J LEARN DISABIL, V21, P456, DOI 10.1177/002221948802100802; MARSH NV, 1991, J CLIN EXP NEUROPSYC, V13, P729, DOI 10.1080/01688639108401086; McKinlay W, 1999, REHABILITATION ADULT, V3, P74; MOORE AD, 1995, BRAIN INJURY, V9, P109, DOI 10.3109/02699059509008185; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; *MT SIN MED CTR DE, 1999, LIV LIF TBI SURV MAN; NEWTON A, 1985, BRIT J CLIN PSYCHOL, V24, P225, DOI 10.1111/j.2044-8260.1985.tb00655.x; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; OBRIEN J, 1992, NATURAL SUPPORTS SCH, P17; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; Prigatano GP, 1999, REHABILITATION ADULT, P271; Reis H. T., 2000, SOCIAL SUPPORT MEASU, P136, DOI [DOI 10.1093/MED:PSYCH/9780195126709.003.0005, 10.1093/med:psych/9780195126709.003.0005]; Schaefer JA, 1998, LEA SER PER CLIN PSY, P99; SCHOOTMAN M, 1999, BRAIN INJURY, V13, P70; Schopp LH, 2000, J TELEMED TELECARE, V6, P146, DOI 10.1258/1357633001934474; Snow P, 1998, BRAIN INJURY, V12, P911, DOI 10.1080/026990598121981; Stroebe W, 1996, SOCIAL PSYCHOL HDB B, P597; Tate RL, 1999, PSYCHOL MED, V29, P713, DOI 10.1017/S0033291799008466; Taylor SE, 2000, AM PSYCHOL, V55, P99, DOI 10.1037//0003-066X.55.1.99; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Van Horn K R, 1992, Brain Inj, V6, P15, DOI 10.3109/02699059209008118; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; World Health Organization, 2001, INT CLASS FUNCT DIS	52	35	35	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2003	18	2					116	127		10.1097/00001199-200303000-00003			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	663DU	WOS:000181991600003	12802221				2021-06-18	
J	Nassogne, MC; Sharrard, M; Hertz-Pannier, L; Armengaud, D; Touati, G; Delonlay-Debeney, P; Zerah, M; Brunelle, F; Saudubray, JM				Nassogne, MC; Sharrard, M; Hertz-Pannier, L; Armengaud, D; Touati, G; Delonlay-Debeney, P; Zerah, M; Brunelle, F; Saudubray, JM			Massive subdural haematomas in Menkes disease mimicking shaken baby syndrome	CHILDS NERVOUS SYSTEM			English	Article						brain diseases; inborn; metabolic; intracranial haemorrhage; traumatic		Introduction: Menkes disease is an X-linked inherited disorder of intestinal copper absorption resulting in copper deficiency. Cardinal features include hair abnormalities, facial dysmorphism, severe neurological impairment, hypothermia, arterial anomalies, bone abnormalities and a fatal outcome. Case report: We present a case of Menkes disease complicated by progressive macrocephaly following the development of massive subdural haematomas. These lesions associated with femoral metaphyseal spurs could be confused with nonaccidental injury such as that seen in the shaken baby syndrome. Discussion: This case emphasises that Menkes disease, like glutaric aciduria type 1, should be included in the differential diagnosis of unexplained subdural haematomas and neurological deficits in infants.	Hop Necker Enfants Malad, Serv Malad Metab Neurol & Genet, Paris, France; Clin Univ St Luc, Serv Neurol Pediat, B-1200 Brussels, Belgium	Nassogne, MC (corresponding author), Hop Necker Enfants Malad, Serv Malad Metab Neurol & Genet, Paris, France.		ZERAH, Michel/E-6473-2012	Nassogne, Marie-Cecile/0000-0001-6936-1611; Hertz-Pannier, Lucie/0000-0003-4952-7009			ADAMS PC, 1974, RADIOLOGY, V112, P401, DOI 10.1148/112.2.401; Baric I, 1998, J INHERIT METAB DIS, V21, P326, DOI 10.1023/A:1005390105171; DANKS DM, 1995, METABOLIC MOL BASES, V2, P2211; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; Kodama K, 1999, PEDIATR INT, V41, P430, DOI 10.1046/j.1442-200x.1999.01091.x; MENKES JH, 1962, PEDIATRICS, V29, P764	6	35	37	0	1	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0256-7040			CHILD NERV SYST	Childs Nerv. Syst.	DEC	2002	18	12					729	731		10.1007/s00381-002-0630-z			3	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	629HR	WOS:000180044700016	12483361				2021-06-18	
J	Stein, TD; Fedynyshyn, JP; Kalil, RE				Stein, TD; Fedynyshyn, JP; Kalil, RE			Circulating autoantibodies recognize and bind dying neurons following injury to the brain	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						autoimmunity; blood-brain barrier; cortical lesion; immunoglobulins; neural cell death	CENTRAL-NERVOUS-SYSTEM; LIPID-PEROXIDATION; MULTIPLE-SCLEROSIS; CEREBRAL-ISCHEMIA; SPINAL-CORD; RAT-BRAIN; PHAGOCYTOSIS; BLOOD; IGG; DEATH	While it is known that autoimmune cells can protect against cell damage following traumatic injury of the brain, the role of autoantibodies in brain injury is less clear. Here we present evidence in adult rats that following a cortical lesion of the brain, circulating IgG autoantibodies bind to dying neurons in the vicinity of the lesion. At intervals that ranged from 4 h to 7 days after making a unilateral lesion of visual cortex, we observed neurons near the lesion that were immunopositive for rat IgG. Many of these IgG-positive neurons were in advanced stages of degeneration. The magnitude of the immunostaining observed was directly proportional to the percent reactivity to rat IgG of the antibodies that were used. Preadsorption of the antibodies with rat serum eliminated the immunostaining. In addition, immunostaining for serum albumin in sections through the cortical lesion was negative, supporting the conclusion that the positive staining for IgG does not result from the passive diffusion of serum proteins into injured cells. Instead, the evidence presented here strongly suggests that naturally occurring IgG autoantibodies bind specifically to dying neurons in the injured brain. We propose that this autoantibody binding may participate in the phagocytosis and removal of injured neurons.	Univ Wisconsin, Sch Med, Dept Ophthalmol & Visual Sci, Madison, WI 53706 USA; Univ Wisconsin, Neurosci Training Program, Madison, WI 53706 USA	Kalil, RE (corresponding author), Univ Wisconsin, Sch Med, Dept Ophthalmol & Visual Sci, 1300 Univ Ave,173 Med Sci Bldg, Madison, WI 53706 USA.			Stein, Thor/0000-0001-6954-4477	NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32 GM008692] Funding Source: Medline; CSRD VA [I01 CX001038] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008692] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01CX001038] Funding Source: NIH RePORTER; VAUS Department of Veterans Affairs [5I01CX001038-04] Funding Source: Federal RePORTER		AANDERUD S, 1983, INT ARCH ALLER A IMM, V70, P40, DOI 10.1159/000233271; ABERCROMBIE M, 1946, ANAT REC, V94, P239, DOI 10.1002/ar.1090940210; Agarwala S, 1998, J COMP NEUROL, V392, P252, DOI 10.1002/(SICI)1096-9861(19980309)392:2<252::AID-CNE7>3.0.CO;2-1; AIHARA N, 1994, J COMP NEUROL, V342, P481, DOI 10.1002/cne.903420402; Albayrak S, 1997, ACTA NEUROPATHOL, V94, P158, DOI 10.1007/s004010050688; ANDERSON DK, 1994, NEUROBIOLOGY CENTRAL, P131; Asakura K, 1998, MULT SCLER, V4, P217, DOI 10.1191/135245898678909222; AVRAMEAS S, 1991, IMMUNOL TODAY, V12, P154; BALOYANNIS SJ, 1979, J NEUROPATH EXP NEUR, V38, P519, DOI 10.1097/00005072-197909000-00006; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; BERNEMAN A, 1992, EUR J IMMUNOL, V22, P625, DOI 10.1002/eji.1830220303; BERNSTEIN JJ, 1987, BRAIN RES, V426, P112, DOI 10.1016/0006-8993(87)90430-6; BRIGHTMA.MW, 1970, J NEUROL SCI, V10, P215, DOI 10.1016/0022-510X(70)90151-6; BROADWELL RD, 1976, J COMP NEUROL, V166, P257, DOI 10.1002/cne.901660302; Butler MH, 2000, NEURON, V26, P307, DOI 10.1016/S0896-6273(00)81165-4; Cover CC, 1996, LIFE SCI, V58, P655, DOI 10.1016/0024-3205(95)02334-8; Davidson A, 2001, NEW ENGL J MED, V345, P340, DOI 10.1056/NEJM200108023450506; DEMEDIUK P, 1985, P NATL ACAD SCI USA, V82, P7071, DOI 10.1073/pnas.82.20.7071; Denecker G, 2000, FEBS LETT, V465, P47, DOI 10.1016/S0014-5793(99)01702-0; Genain CP, 1999, NAT MED, V5, P170, DOI 10.1038/5532; Goldrath AW, 1999, NATURE, V402, P255, DOI 10.1038/35005508; GRABAR P, 1975, CLIN IMMUNOL IMMUNOP, V4, P453, DOI 10.1016/0090-1229(75)90087-2; Hanisch UK, 1996, SYNAPSE, V24, P104, DOI 10.1002/(SICI)1098-2396(199610)24:2<104::AID-SYN2>3.0.CO;2-J; HINTNER H, 1987, J INVEST DERMATOL, V88, P176, DOI 10.1111/1523-1747.ep12525322; Islekel H, 1999, BRAIN RES, V843, P18, DOI 10.1016/S0006-8993(99)01845-4; Janeway CAJ., 2001, IMMUNOBIOLOGY IMMUNE, V5; Kalil R. E., 1996, Society for Neuroscience Abstracts, V22, P305; Kalil R. E., 1998, Society for Neuroscience Abstracts, V24, P1303; KAY MMB, 1994, ANN NY ACAD SCI, V719, P419, DOI 10.1111/j.1749-6632.1994.tb56847.x; KAY MMB, 1981, NATURE, V289, P491, DOI 10.1038/289491a0; Keller JN, 1998, REV NEUROSCIENCE, V9, P105; KERGONOU JF, 1988, BIOCHEM INT, V16, P835; KHANSARI N, 1983, CELL IMMUNOL, V78, P114, DOI 10.1016/0008-8749(83)90264-2; LAURSEN H, 1993, ACTA NEUROPATHOL, V86, P378, DOI 10.1007/BF00369451; Ling C., 1999, Society for Neuroscience Abstracts, V25, P759; Ling C., 1998, Society for Neuroscience Abstracts, V24, P1304; LUTZ HU, 1987, P NATL ACAD SCI USA, V84, P7368, DOI 10.1073/pnas.84.21.7368; MAEDA M, 1992, ACTA NEUROPATHOL, V84, P59, DOI 10.1007/BF00427216; MARTIN SE, 1975, P NATL ACAD SCI USA, V72, P1036, DOI 10.1073/pnas.72.3.1036; Moalem G, 1999, NAT MED, V5, P49, DOI 10.1038/4734; MRINI A, 1995, J HISTOCHEM CYTOCHEM, V43, P1285, DOI 10.1177/43.12.8537644; PERL A, 1982, ACTA PHYSIOL HUNG, V60, P53; Petersen A, 2000, BRAIN RES, V857, P20, DOI 10.1016/S0006-8993(99)02320-3; Platt N, 1998, TRENDS CELL BIOL, V8, P365, DOI 10.1016/S0962-8924(98)01329-4; Remmers M, 1999, BRAIN RES, V827, P237, DOI 10.1016/S0006-8993(99)01304-9; Roitt I, 1998, IMMUNOLOGY; SCHMIDTKASTNER R, 1993, J NEUROSCI METH, V46, P121, DOI 10.1016/0165-0270(93)90147-J; Soares HD, 1995, J NEUROSCI, V15, P8223; UCHIDA K, 1992, P NATL ACAD SCI USA, V89, P4544, DOI 10.1073/pnas.89.10.4544; ULVESTAD E, 1994, J NEUROPATH EXP NEUR, V53, P27, DOI 10.1097/00005072-199401000-00004; Upender M. B., 1996, Society for Neuroscience Abstracts, V22, P1202; Upender MB, 1997, J COMP NEUROL, V384, P271; van Noort JM, 2000, J NEUROIMMUNOL, V105, P46, DOI 10.1016/S0165-5728(00)00181-8; Vercammen D, 1998, J EXP MED, V188, P919, DOI 10.1084/jem.188.5.919; Yahya MD, 1996, J AUTOIMMUN, V9, P3, DOI 10.1006/jaut.1996.0002; Yoles E, 2001, J NEUROSCI, V21, P3740, DOI 10.1523/JNEUROSCI.21-11-03740.2001; Yuki N, 1999, JPN J INFECT DIS, V52, P99	57	35	38	0	1	AMER ASSN NEUROPATHOLOGISTS INC	LAWRENCE	1041 NEW HAMPSHIRE ST, LAWRENCE, KS 66044 USA	0022-3069			J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	DEC	2002	61	12					1100	1108		10.1093/jnen/61.12.1100			9	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	624LY	WOS:000179762200009	12484573	Bronze			2021-06-18	
J	Yun, SJ; Kim, MO; Kim, SO; Park, J; Kwon, YK; Kim, IS; Lee, EH				Yun, SJ; Kim, MO; Kim, SO; Park, J; Kwon, YK; Kim, IS; Lee, EH			Induction of TGF-beta-inducible gene-h3 (beta ig-h3) by TGF-beta 1 in astrocytes: implications for astrocyte response to brain injury	MOLECULAR BRAIN RESEARCH			English	Article						astrocyte; beta ig-h3; brain injury; gliosis; TGF-beta 1; wound healing	GROWTH-FACTOR-BETA; CENTRAL-NERVOUS-SYSTEM; 5Q31-LINKED CORNEAL DYSTROPHIES; TRANSFORMING GROWTH-FACTOR-BETA-1; REACTIVE ASTROCYTES; MESSENGER-RNA; RAT-BRAIN; EXTRACELLULAR-MATRIX; SEQUENCE-ANALYSIS; CELL-ADHESION	Transforming growth factor (TGF)-beta-inducible gene-h3 (betaig-h3) product is a secreted protein that is induced by TGF-beta in several cell types and implicated in various tissue pathologies. The aims of this study were to determine the effect of TGF-beta1 on betaig-h3 expression in cultured astrocytes and to examine whether betaig-h3 is expressed in the brain after traumatic injury. The results showed that betaig-h3 mRNA and protein increased in response to TGF-beta1 in U87 human astrocytoma cells and mouse cortical astrocytes. Treatment with other cytokines, including tumor necrosis factor-alpha and fibroblast growth factor-2, did not enhance the expression of betaig-h3 in astrocytes. betaig-h3 was significantly expressed in reactive astrocytes at the site of a stab wound in the cerebral cortex of adult rats. These results provide an insight into understanding a novel role for betaig-h3 protein in the response of astrocytes to brain injury. (C) 2002 Elsevier Science B.V. All rights reserved.	Kyung Hee Univ, Grad Sch EW Med Sci, Yongin 449701, South Korea; Kyung Hee Univ, Dept Biol, Seoul, South Korea; Kyungpook Natl Univ, Sch Med, Dept Biochem, Taegu 702701, South Korea; Kyungpook Natl Univ, Cell & Matrix Natl Res Lab, Taegu 702701, South Korea	Lee, EH (corresponding author), Kyung Hee Univ, Grad Sch EW Med Sci, Yongin 449701, South Korea.	ehwang@khu.ac.kr	김, 인산/I-8988-2014; Park, Ji-Ho/AAI-8644-2020	Park, Ji-Ho/0000-0001-9722-8463; hwang, hwang-eunju/0000-0002-5569-0067			Asher RA, 2000, J NEUROSCI, V20, P2427; Bae JS, 2002, BIOCHEM BIOPH RES CO, V294, P940, DOI 10.1016/S0006-291X(02)00576-4; BAGHDASSARIAN D, 1993, GLIA, V7, P193, DOI 10.1002/glia.440070302; Billings PC, 2002, J BIOL CHEM, V277, P28003, DOI 10.1074/jbc.M106837200; Billings PC, 2000, AM J RESP CELL MOL, V22, P352, DOI 10.1165/ajrcmb.22.3.3732; BORDER WA, 1992, J CLIN INVEST, V90, P1, DOI 10.1172/JCI115821; Bottner M, 2000, J NEUROCHEM, V75, P2227, DOI 10.1046/j.1471-4159.2000.0752227.x; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; ESCRIBANO J, 1994, J CELL PHYSIOL, V160, P511, DOI 10.1002/jcp.1041600314; FAISSNER A, 1990, NEURON, V5, P627, DOI 10.1016/0896-6273(90)90217-4; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Flanders KC, 1998, PROG NEUROBIOL, V54, P71, DOI 10.1016/S0301-0082(97)00066-X; Gilbert RE, 1998, KIDNEY INT, V54, P1052, DOI 10.1046/j.1523-1755.1998.00081.x; Hashimoto K, 1997, BBA-MOL CELL RES, V1355, P303, DOI 10.1016/S0167-4889(96)00147-4; Kawasaki S, 1999, AM J OPHTHALMOL, V127, P456, DOI 10.1016/S0002-9394(98)00360-2; KIEFER R, 1995, INT J DEV NEUROSCI, V13, P331; Kim JE, 2000, J CELL BIOCHEM, V77, P169, DOI 10.1002/(SICI)1097-4644(20000501)77:2<169::AID-JCB1>3.0.CO;2-L; Kim JE, 2000, J BIOL CHEM, V275, P30907, DOI 10.1074/jbc.M002752200; Knuckey NW, 1996, MOL BRAIN RES, V40, P1; LEBARON RG, 1995, J INVEST DERMATOL, V104, P844, DOI 10.1111/1523-1747.ep12607024; Lee EH, 2000, INVEST OPHTH VIS SCI, V41, P1840; LOGAN A, 1994, EUR J NEUROSCI, V6, P355, DOI 10.1111/j.1460-9568.1994.tb00278.x; Logan A, 1999, EXP NEUROL, V159, P504, DOI 10.1006/exnr.1999.7180; Logan A, 1999, EUR J NEUROSCI, V11, P2367, DOI 10.1046/j.1460-9568.1999.00654.x; LOGAN A, 1992, BRAIN RES, V587, P216, DOI 10.1016/0006-8993(92)91000-5; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; McGraw J, 2001, J NEUROSCI RES, V63, P109, DOI 10.1002/1097-4547(20010115)63:2<109::AID-JNR1002>3.0.CO;2-J; McKeon RJ, 1999, J NEUROSCI, V19, P10778; McTigue DM, 2000, EXP NEUROL, V163, P220, DOI 10.1006/exnr.2000.7372; MORGAN TE, 1993, EXP NEUROL, V120, P291, DOI 10.1006/exnr.1993.1063; Morganti-Kossmann MC, 1999, J NEUROTRAUM, V16, P617, DOI 10.1089/neu.1999.16.617; Munier FL, 1997, NAT GENET, V15, P247, DOI 10.1038/ng0397-247; OBrien ER, 1996, ARTERIOSCL THROM VAS, V16, P576, DOI 10.1161/01.ATV.16.4.576; Ohno S, 1999, BBA-MOL CELL RES, V1451, P196, DOI 10.1016/S0167-4889(99)00093-2; PASINETTI GM, 1993, NEUROSCIENCE, V54, P893, DOI 10.1016/0306-4522(93)90583-2; Pratt Bruce M., 1997, Cytokine and Growth Factor Reviews, V8, P267, DOI 10.1016/S1359-6101(97)00018-X; Rawe IM, 1997, INVEST OPHTH VIS SCI, V38, P893; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; SANES JR, 1989, ANNU REV NEUROSCI, V12, P491, DOI 10.1146/annurev.ne.12.030189.002423; Schorderet DF, 2000, BIOCHEM BIOPH RES CO, V274, P267, DOI 10.1006/bbrc.2000.3116; SKONIER J, 1994, DNA CELL BIOL, V13, P571, DOI 10.1089/dna.1994.13.571; SKONIER J, 1992, DNA CELL BIOL, V11, P511, DOI 10.1089/dna.1992.11.511; Smith GM, 1997, J NEUROSCI, V17, P9624; Srivastava OP, 1999, CURR EYE RES, V19, P348, DOI 10.1076/ceyr.19.4.348.5303; Streeten BW, 1999, ARCH OPHTHALMOL-CHIC, V117, P67; Tsujimoto H, 1999, MOL CARCINOGEN, V26, P298, DOI 10.1002/(SICI)1098-2744(199912)26:4<298::AID-MC8>3.0.CO;2-M; UNSICKER K, 1991, NEUROSCIENCE, V44, P613, DOI 10.1016/0306-4522(91)90082-Y; VANDERWAL EA, 1993, NEUROREPORT, V4, P69, DOI 10.1097/00001756-199301000-00018; Vawter MP, 1996, EXP NEUROL, V142, P313, DOI 10.1006/exnr.1996.0200; ZINN K, 1988, CELL, V53, P577, DOI 10.1016/0092-8674(88)90574-0	50	35	38	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0169-328X			MOL BRAIN RES	Mol. Brain Res.	OCT 30	2002	107	1					57	64	PII S0169-328X(02)00447-3	10.1016/S0169-328X(02)00447-3			8	Neurosciences	Neurosciences & Neurology	619AH	WOS:000179450500008	12414124				2021-06-18	
J	Koh, JO; Watkinson, EJ				Koh, JO; Watkinson, EJ			Video analysis of blows to the head and face at the 1999 World Taekwondo Championships	JOURNAL OF SPORTS MEDICINE AND PHYSICAL FITNESS			English	Article						video analysis; brain injuries, diagnosis; brain injiuries, prevention and control; exercise	INJURIES; CONCUSSION	Background. Limited research has been done on head blows that may result in mild traumatic brain injury in Taekwondo. The purpose of this study was to investigate the fighting conditions under which blows to the head commonly take place, with a view to determining the typical conditions under which injury may occur. Methods. Experimental design: videotape analysis (retrospective). Setting: the semi-final and final matches (a total of 48 matches) at the 14(th) World Taekwondo Championships in 1999. Participants: 64 athletes (32 females and 32 males) who won elimination-round matches (out of 563 competitors), aged 15 to 38 years. Measures: frequency, mechanism of head blows, characteristics of situations leading up to and following head blows, frequency of multiple impacts. Results. A total of 35 incidents of head blow occurred (365 blows per 1,000 athlete exposures). All of these head blows were associated with a direct head or face contact and frequently involved: a closed sparring stance, shorter athletes, axe or roundhouse type kicks, attacker's offensive kick, and head-blow-receiver's offensive action with absence of a blocking skill. Conclusions. To prevent possible brain injury resulting from direct head blows, updated safety education, a complete understanding of concussion for athletes, coaches, and referees, and a rule change in competition Taekwondo are recommended.	Univ Alberta, Fac Phys Educ & Recreat, Edmonton, AB T6G 2H9, Canada	Koh, JO (corresponding author), Univ Alberta, Fac Phys Educ & Recreat, Edmonton, AB T6G 2H9, Canada.			Koh, Jae Ok/0000-0002-3639-0739			Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Barth JT., 1989, MILD HEAD INJURY, P257; CHUANG TY, 1992, J BIOMECH ENG-T ASME, V114, P346, DOI 10.1115/1.2891394; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Koh JO, 2001, INT J APPL SPORTS SC, V13, P33; LLOYD LE, 1987, TEX MED, V83, P30; MASTER EJT, 2000, PHYSICIAN SPORTSMED, V28, P87; Pieter W, 1998, J ROY SOC HEALTH, V118, P272, DOI 10.1177/146642409811800512; Pieter W, 1999, J SPORT MED PHYS FIT, V39, P147; Pieter W., 1994, Journal of Sports Traumatology and Related Research, V16, P49; Pieter W, 1995, J HUM MOVEMENT STUD, V28, P1; SERINA ER, 1991, J BIOMECH, V24, P951, DOI 10.1016/0021-9290(91)90173-K; Siana J E, 1986, Br J Sports Med, V20, P165; Sung N.J., 1987, US TAEKWONDO J, V6, P10	14	35	35	0	3	EDIZIONI MINERVA MEDICA	TURIN	CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY	0022-4707			J SPORT MED PHYS FIT	J. Sports Med. Phys. Fit.	SEP	2002	42	3					348	353					6	Sport Sciences	Sport Sciences	602TD	WOS:000178519800014	12094126				2021-06-18	
J	Williams, WH; Evans, JJ; Wilson, BA; Needham, P				Williams, WH; Evans, JJ; Wilson, BA; Needham, P			Prevalence of post-traumatic stress disorder symptoms after severe traumatic brain injury in a representative community sample	BRAIN INJURY			English	Article							EVENT SCALE; HEAD-INJURY; DEPRESSION; IMPACT	Primary objective: In this study, the authors investigated the prevalence of symptoms of post-traumatic stress disorder (PTSD) in a community sample of 66 survivors of severe traumatic brain injury (TBI). Research design, method and procedures: A representative sample of survivors of TBI were selected on the basis of having suffered significant disturbance in consciousness following their trauma event in the form of coma and/or post-traumatic amnesia. Neuropsychological testing confirmed that participants had suffered cognitive deficits consistent with severe brain injury. Participants were administered the Impact of Events inventory for symptoms of PTSD. Main outcomes and results: The authors found a prevalence rate of 18% for moderate-to-severe PTSD symptoms. Conclusions: PTSD symptoms are common following severe TBI. Further research is needed to establish protective and predictive factors for PTSD in TBI groups.	Univ Exeter, Washington Singer Labs, Sch Psychol, Exeter, Devon, England; Prince Wales Hosp, Oliver Zangwill Ctr Neuropsychol Rehabil, Ely, England; Cognit & Brain Sci Unit, Cambridge, England	Williams, WH (corresponding author), Univ Exeter, Washington Singer Labs, Sch Psychol, Exeter, Devon, England.	w.h.williams@exeter.ac.uk		williams, huw/0000-0003-0670-2620			Baddeley A.D., 1992, SPEED CAPACITY LANGU; Bond M. R., 1990, REHABILITATION ADULT, P179; Bowen A, 1998, BRAIN INJURY, V12, P177, DOI 10.1080/026990598122656; Brewin CR, 1996, PSYCHOL REV, V103, P670, DOI 10.1037/0033-295X.103.4.670; Briere J, 1998, ASSESSMENT, V5, P171, DOI 10.1177/107319119800500207; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Bryant RA, 2000, BRAIN INJURY, V14, P175, DOI 10.1080/026990500120826; CORNEIL W, 1999, J OCCUP HEALTH, V4, P1; GARSKE GG, 1992, REHABIL COUNS BULL, V36, P44; Hickling EJ, 1998, BRAIN INJURY, V12, P265, DOI 10.1080/026990598122566; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; King NS, 1997, J NEUROL NEUROSUR PS, V62, P82, DOI 10.1136/jnnp.62.1.82; Markowitsch HJ, 1998, NEUROCASE, V4, P429, DOI 10.1080/13554799808410636; McKenna P.W.E., 1983, GRADED NAMING TEST; McMillan TM, 1996, BRAIN INJURY, V10, P749, DOI 10.1080/026990596124016; McMillan TM, 2001, BRAIN INJURY, V15, P39, DOI 10.1080/02699050150209110; McNeil J E, 1996, Cogn Neuropsychiatry, V1, P239, DOI 10.1080/135468096396532; Ohry A, 1996, BRAIN INJURY, V10, P687, DOI 10.1080/026990596124106; Ownsworth TL, 1998, BRAIN INJURY, V12, P735, DOI 10.1080/026990598122133; Raven J.C., 1947, RAVENS PROGR MATRICE; RICHARDSON JTE, 1990, CLIN NEUROPSYCHOLOGI; Robertson I. H., 1994, TEST EVERYDAY ATTENT; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; TURNER S, 1998, MEASURES POST TRAUMA; WATSON CG, 1991, J CLIN PSYCHOL, V47, P179, DOI 10.1002/1097-4679(199103)47:2<179::AID-JCLP2270470202>3.0.CO;2-P; Williams WH, 1999, NEUROPSYCHOL REHABIL, V9, P421, DOI 10.1080/096020199389482; Wilson, 1991, NATL ADULT READING T; Wilson B. A., 1985, RIVERMEAD BEHAV MEMO	29	35	35	0	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	AUG	2002	16	8					673	679		10.1080/02699050210128861			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	583GP	WOS:000177399100003	12167192				2021-06-18	
J	Adler, DE; Milhorat, TH				Adler, DE; Milhorat, TH			The tentorial notch: anatomical variation, morphometric analysis, and classification in 100 human autopsy cases	JOURNAL OF NEUROSURGERY			English	Article						tentorium cerebelli; oculomotor nerve; brainstem; brain herniation; brain concussion; morphometric study	MINOR HEAD-INJURY; CONCUSSION	Object. Variations in the structure of the tentorial notch may influence the degree of brainstem distortion in transtentorial herniation, concussion, and acceleration-deceleration injuries. The authors examined the anatomical relationships of the mesencephalon, cerebellum, and oculomotor nerves to the dimensions of the tentorial aperture. On the basis of numerical data collected from this study, the authors have developed the first classification system of the tentorial notch and present new neuroanatomical observations pertaining to the subarachnoid third cranial nerve and the brainstem. Methods. The mesencephalon was sectioned at the level of the tentorial edge in 100 human autopsy cases (specimens from 23 female and 77 male cadavers with a mean age, at time of death of 42.5 years [range 18-80 years]). The following measurements were determined: 1) anterior notch width, the width of the tentorial notch in the axial plane through the posterior aspect of the dorsum sellae; 2) maximum notch width (MNW), the maximum width of the notch in the axial plane; 3) notch length (NL), the length of the tentorial notch from the superoposterior edge of the dorsum sellae to the apex of the notch; 4) posterior tentorial length, the shortest distance between the apex of the notch and the most anterior part of the confluence of the sinuses; 5) interpedunculoclival (IC) distance, the distance from the interpeduncular fossa to the superoposterior edge of the dorsum sellae; 6) apicotectal (AT) distance, the distance from the tectum in the median plane to a perpendicular line dropped from the apex of the tentorial notch to the cerebellum; 7) cisternal third nerve distance, the distance covered by the cisternal portion of the third cranial nerve; and 8) inter-third nerve angle, the angle between the two third cranial nerves. The quartile distribution technique was applied to all measurements. Mean values are presented as the means +/- standard deviations. Quartile groups defined by NL (mean 57.7 +/- 5.6 mm) were labeled long, short, and midrange, and those defined by MNW (mean 29.6 +/- 3 mm) were labeled wide, narrow, and midrange. Combining these groups into a matrix formation resulted in the classification of the tentorial notch into the following eight types: 1) narrow (15% of specimens); 2) wide (12% of specimens); 3) short (8% of specimens); 4) long (15% of specimens); 5) typical (24% of specimens); 6) large (9% of specimens); 7) small (10% of specimens); and 8) mixed (7% of specimens). The IC distance (mean 20.4 +/- 3.2 mm) was used to characterize brainstem position as prefixed (28% of specimens), postfixed (36% of specimens), or midposition (36% of specimens). The IC distance was correlated with the left and right cisternal third nerve distances (means 26.7 +/- 2.9 mm and 26.1 +/- 3.2 mm, respectively) and the inter-third nerve angle (mean 57.3 +/- 7.3degrees). The exposed cerebellar parenchyma within the notch, the relationship between the brainstem and tentorial edge, and the brainstem position varied considerably among individuals. The cisternal third nerve distance, its trajectory, and its anatomical relation to the skull base also varied widely. Two anatomically distinct segments of the subarachnoid third cranial nerves were characterized with respect to the skull base as suspended and supported segments. Conclusions. The authors present a new classification system for the tentorial aperture to help explain variations in herniation syndromes in patients with otherwise similar intracranial pathological conditions, and responses to concussive and acceleration-deceleration injuries. The authors present observations not previously described regarding the position of the brainstem within the tentorial aperture and the cisternal portion of the third cranial nerves. A significant statistical correlation was discovered among specific morphometric parameters of the tentorial notch, brainstem, and oculomotor nerves. These findings may have neurosurgical implications in clinical situations that cause brainstem distortion. Additionally, this analysis provides baseline data for interpreting magnetic resonance and computerized tomography images of the tentorial notch and its regional anatomy.	Legacy Hlth Syst, Dept Neurosurg, Portland, OR USA; Dept Oregon State Police, Med Examiner Div, State Med Examiners Off, Portland, OR USA; SUNY Hlth Sci Ctr, Dept Neurosurg, Brooklyn, NY 11203 USA; Kings Cty Hosp, Off Chief Med Examiner, Brooklyn, NY USA	Adler, DE (corresponding author), Legacy Neurol Sci Ctr, 1040 NW 22nd Ave,Suite 200, Portland, OR 97210 USA.	DAdler@lhs.org					BAKAY L, 1977, J NEUROSURG, V47, P525, DOI 10.3171/jns.1977.47.4.0525; BROWN WJ, 1972, AM J PATHOL, V67, P41; BULL JWD, 1969, P ROY SOC MED, V62, P1301, DOI 10.1177/003591576906201242; CORSELLIS JAN, 1958, J NEUROL NEUROSUR PS, V21, P279, DOI 10.1136/jnnp.21.4.279; ECKER A, 1948, J NEUROSURG, V5, P51, DOI 10.3171/jns.1948.5.1.0051; FOLTZ EL, 1953, J NEUROSURG, V10, P342, DOI 10.3171/jns.1953.10.4.0342; FREEDMAN H, 1952, J NEUROSURG, V9, P52, DOI 10.3171/jns.1952.9.1.0052; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GROAT RA, 1945, J NEUROSURG, V2, P26, DOI 10.3171/jns.1945.2.1.0026; JANE JA, 1985, J NEUROSURG, V62, P96, DOI 10.3171/jns.1985.62.1.0096; Jefferson G, 1938, ARCH NEURO PSYCHIATR, V40, P857, DOI 10.1001/archneurpsyc.1938.02270110011001; Kernohan JW, 1929, ARCH NEURO PSYCHIATR, V21, P274, DOI 10.1001/archneurpsyc.1929.02210200030004; KLINTWORTH GK, 1968, ANAT RECORD, V160, P635, DOI 10.1002/ar.1091600312; LEBEAU J, 1938, OEDEME CERVEAU SON R; Meyer A, 1920, ARCH NEURO PSYCHIATR, V4, P387, DOI 10.1001/archneurpsyc.1920.02180220036003; MUNRO D, 1950, T AM NEUROL ASSOC, P62; POVLISHOCK JT, 1979, ACTA NEUROPATHOL, V47, P1, DOI 10.1007/BF00698266; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Reid WL, 1939, J AMER MED ASSOC, V112, P2030, DOI 10.1001/jama.1939.02800200028008; Reid WL, 1940, SURGERY, V8, P756; SCHEINKER M, 1945, ARCH NEURO PSYCHIATR, V53, P289; Schwarz GA, 1941, ARCH NEURO PSYCHIATR, V46, P297, DOI 10.1001/archneurpsyc.1941.02280200103005; SUNDERLAND S, 1958, BRIT J SURG, V45, P422, DOI 10.1002/bjs.18004519306; Vincent C, 1936, REV NEUROL-FRANCE, V65, P536; Ward A A Jr, 1964, Clin Neurosurg, V12, P95; WINDLE W. F., 1944, TRANS AMER NEUROL ASSOC, V70, P117; Windle W. F., 1944, SURG GYNECOL AND OBSTET, V79, P561	27	35	40	1	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUN	2002	96	6					1103	1112		10.3171/jns.2002.96.6.1103			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	559LD	WOS:000176026900027	12066913				2021-06-18	
J	Schneider, G; Fries, P; Wagner-Jochem, D; Thome, D; Laurer, H; Kramann, B; Mautes, A; Hagen, T				Schneider, G; Fries, P; Wagner-Jochem, D; Thome, D; Laurer, H; Kramann, B; Mautes, A; Hagen, T			Pathophysiological changes after traumatic brain injury: comparison of two experimental animal models by means of MRI	MAGNETIC RESONANCE MATERIALS IN PHYSICS BIOLOGY AND MEDICINE			English	Article						traumatic brain injury; experimental animal model; MRI; pathophysiology	CEREBRAL BLOOD-FLOW; TIME-COURSE; RATS; EDEMA	In an experimental study MRI was used to compare the pathophysiological changes of brain tissue after lateral fluid percussion injury (FPI) versus cold injury (CI) as models of traumatic brain injury (TBI), Two groups of Sprague-Dawley rats (n = 23) were subjected to mild FPI, respectively, Cl localized over the right parietal cortex. MRI was performed at different time points including T1w, T2w and T1w-CE (Gd-DTPA 0.2 mmol/kg BW) sequences as well as perfusion-weighted imaging with calculation of regional cerebral blood volume (rCBV) and regional cerebral blood flow (rCBF). T2w and T1w-CE images showed hyperintense areas in the traumatised cortex demonstrating brain edema and blood-brain barrier (BBB)-breakdown increasing up to 12 h. Perfusion-weighted imaging demonstrated a significant decrease of rCBV and rCBF in the ipsilateral cortex of CI animals compared with the contralateral hemisphere, In contrast, rats of the FPI group showed only slight differences in rCBF and rCBV comparing the left and right cortex. The results of our study confirm that both mild FPI and CI produced focal brain edema with concomitant breakdown of the BBB as a model of TBI. Since differences regarding perfusion are much more pronounced in CI our results suggest that, this model more likely seems to reflect pathophysiological changes of brain ischemia, whereas FPI seems to be better suited to model the pathophysiological characteristics of TBI. (C) 2002 Elsevier Science B.V. All rights reserved.	Univ Hosp, Dept Diagnost Radiol, D-66421 Homburg, Germany; Univ Hosp, Neurosurg Res Lab, D-66421 Homburg, Germany; Univ Hosp, Dept Neuroradiol, D-66421 Homburg, Germany	Schneider, G (corresponding author), Univ Hosp, Dept Diagnost Radiol, Gebaude 49, D-66421 Homburg, Germany.	ragsne@uniklinik-saarland.de					Assaf Y, 1997, MAGN RESON IMAGING, V15, P77, DOI 10.1016/S0730-725X(96)00246-9; Baethmann A, 1997, ZBL NEUROCHIR, V58, P20; Bareyre F, 1997, J NEUROTRAUM, V14, P839, DOI 10.1089/neu.1997.14.839; Dietrich WD, 1998, NEUROSURGERY, V43, P585, DOI 10.1097/00006123-199809000-00105; EDELMAN RR, 1990, RADIOLOGY, V176, P211, DOI 10.1148/radiology.176.1.2353094; EVERETT NB, 1956, CIRC RES, V4, P419, DOI 10.1161/01.RES.4.4.419; FUKUDA K, 1995, J NEUROTRAUM, V12, P315, DOI 10.1089/neu.1995.12.315; HAASE A, 1986, J MAGN RESON, V67, P258, DOI 10.1016/0022-2364(86)90433-6; Hagen T, 1999, J COMPUT ASSIST TOMO, V23, P257, DOI 10.1097/00004728-199903000-00015; HENNIG J, 1986, MAGNET RESON MED, V3, P823, DOI 10.1002/mrm.1910030602; Hermann DM, 1999, NEUROREPORT, V10, P759, DOI 10.1097/00001756-199903170-00018; KUCHIWAKI H, 1990, ACT NEUR S, V51, P77; Laurer HL, 1999, CURR OPIN NEUROL, V12, P715, DOI 10.1097/00019052-199912000-00010; MATTHAEI D, 1986, Magnetic Resonance Imaging, V4, P381, DOI 10.1016/0730-725X(86)90043-3; MCINTOSH TK, 1990, ACT NEUR S, V51, P263; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; PAPPIUS HM, 1981, ANN NEUROL, V9, P484, DOI 10.1002/ana.410090511; SCHNEIDER GH, 1994, ACTA NEUROCHIR, P437; SCHNEIDER GH, 1994, ACTA NEUROCHIR, P516	19	35	35	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0968-5243	1352-8661		MAGN RESON MATER PHY	Magn. Reson. Mat. Phys. Biol. Med.	JUN	2002	14	3					233	241	PII S1352-8661(02)00068-6	10.1016/S1352-8661(02)00068-6			9	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	578PD	WOS:000177126100003	12098566				2021-06-18	
J	Festoff, BW; SantaCruz, K; Arnold, PM; Sebastian, CT; Davies, PJA; Citron, BA				Festoff, BW; SantaCruz, K; Arnold, PM; Sebastian, CT; Davies, PJA; Citron, BA			Injury-induced 'switch' from GTP-regulated to novel GTP-independent isoform of tissue transglutaminase in the rat spinal cord	JOURNAL OF NEUROCHEMISTRY			English	Article						apoptosis; cross-linking; GTPase; motoneurons; spinal cord; transglutaminase	TUMOR-NECROSIS-FACTOR; INDUCED CROSS-LINKING; KAPPA-B ACTIVATION; ALZHEIMERS-DISEASE; MESSENGER-RNA; UP-REGULATION; CELL-DEATH; INTRANUCLEAR INCLUSIONS; NEURONAL DEGENERATION; GENE-EXPRESSION	We recently found that alternative transcripts of tissue transglutaminase (tTG or TG2) were present in hippocampal brain regions of Alzheimer's disease (AD), but not in control, non-demented, age-matched brains. Since antecedent non-severe trauma has been implicated in AD and other neurodegenerative diseases, such as Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS), we were interested in whether alternative transcripts might be detected in a model of neurotrauma, controlled-contusion spinal cord injury (SCI) in the rat. Implicated in diverse roles from growth and differentiation to apoptotic cell death, only bifunctional tTG, of the nine member TG family, has dual catalytic activities: guanine trinucleotide (GTP) hydrolyzing activity (GTPase), as well as protein cross-linking. These functions imply two physiological functions: programmed cell life and death. These may have profound roles in the nervous system since studies in cultured astrocytes found tTG short (S) mRNA transcripts induced by treatment with injury-related cytokines. In the developing rat spinal cord, tTG activity is concentrated in ventral horn alpha motoneurons, but neither studies of spinal cord tTG gene expression, nor evaluation of the GTP-regulated isoforms in tissues, have been reported. We now report increased tTG protein and gene expression occurring rapidly after SCI. In parallel, novel appearance of a second, short form transcript, in addition to the normal long (L) isoform, occurs by 8 h of injury. Up-regulation of tTG message and activity following neural injury. with appearance of a truncated GTP-unregulated S form, may represent new approaches to drug targets in neurotrauma.	Univ Kansas, Med Ctr, Dept Vet Affairs Med Ctr, Neurobiol Res Lab, Kansas City, MO 64128 USA; Univ Kansas, Med Ctr, Dept Neurol, Kansas City, MO 64128 USA; Univ Kansas, Med Ctr, Dept Pharmacol Toxicol & Therapeut, Kansas City, MO 64128 USA; Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Kansas City, MO 64128 USA; Univ Kansas, Med Ctr, Dept Surg Neurosurg, Kansas City, MO 64128 USA; Univ Texas, Med Ctr, Dept Integrat Biol Pharmacol & Physiol, Houston, TX USA	Festoff, BW (corresponding author), Univ Kansas, Med Ctr, Dept Vet Affairs Med Ctr, Neurobiol Res Lab 151, 4801 Linwood Blvd, Kansas City, MO 64128 USA.	bfestoff@kumc.edu					Aeschlimann D, 1998, J BIOL CHEM, V273, P3452, DOI 10.1074/jbc.273.6.3452; AESCHLIMANN D, 1991, J BIOL CHEM, V266, P15308; Appelt DM, 1996, J HISTOCHEM CYTOCHEM, V44, P1421, DOI 10.1177/44.12.8985134; Bethea JR, 1998, J NEUROSCI, V18, P3251; CARIELLO L, 1994, BIOCHEM BIOPH RES CO, V205, P565, DOI 10.1006/bbrc.1994.2702; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Citron BA, 2000, EXP NEUROL, V166, P213, DOI 10.1006/exnr.2000.7523; Citron BA, 2001, J BIOL CHEM, V276, P3295, DOI 10.1074/jbc.M004776200; Citron BA, 2000, NEUROCHEM INT, V37, P337, DOI 10.1016/S0197-0186(00)00044-9; Citron BA, 2000, J NEUROTRAUM, V17, P1191, DOI 10.1089/neu.2000.17.1191; Cooper AJL, 1999, J NEUROCHEM, V72, P889, DOI 10.1046/j.1471-4159.1999.0720889.x; Crowe M. J., 1995, Society for Neuroscience Abstracts, V21, P232; EITAN S, 1994, SCIENCE, V264, P1764, DOI 10.1126/science.7911602; ELALAOUI S, 1991, INT J CANCER, V48, P221; Farlow DN, 2000, J CELL BIOCHEM, V80, P171; Feng JF, 1999, BIOCHEMISTRY-US, V38, P10743, DOI 10.1021/bi9905009; FRAIJ BM, 1992, J BIOL CHEM, V267, P22616; Fraij BM, 1996, BIOCHEM BIOPH RES CO, V218, P45, DOI 10.1006/bbrc.1996.0009; Fujita K, 1998, NEUROCHEM RES, V23, P557, DOI 10.1023/A:1022442904179; Fujita K, 1995, NEUROCHEM RES, V20, P1195, DOI 10.1007/BF00995383; Gentile V, 1998, ARCH BIOCHEM BIOPHYS, V352, P314, DOI 10.1006/abbi.1998.0592; GILAD GM, 1985, J NEUROCHEM, V44, P1385, DOI 10.1111/j.1471-4159.1985.tb08774.x; Gill LS, 1998, BRAIN RES, V788, P95, DOI 10.1016/S0006-8993(97)01526-6; GREENBERG CS, 1991, FASEB J, V5, P3071; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; Holmes FE, 1996, NEUROSCI LETT, V213, P185; HWANG KC, 1995, J BIOL CHEM, V270, P27058, DOI 10.1074/jbc.270.45.27058; Iismaa SE, 2000, J BIOL CHEM, V275, P18259, DOI 10.1074/jbc.M000583200; Iismaa SE, 1997, BIOCHEMISTRY-US, V36, P11655, DOI 10.1021/bi970545e; Im MJ, 1997, CELL SIGNAL, V9, P477, DOI 10.1016/S0898-6568(97)00049-1; Johnson GVW, 1997, BRAIN RES, V751, P323, DOI 10.1016/S0006-8993(96)01431-X; Kahlem P, 1996, P NATL ACAD SCI USA, V93, P14580, DOI 10.1073/pnas.93.25.14580; Kahlem P, 1998, MOL CELL, V1, P595, DOI 10.1016/S1097-2765(00)80059-3; Kim SY, 1999, J BIOL CHEM, V274, P30715, DOI 10.1074/jbc.274.43.30715; Kim TW, 1998, NEURON, V21, P657, DOI 10.1016/S0896-6273(00)80581-4; Kuncio GS, 1998, AM J PHYSIOL-GASTR L, V274, pG240; LEE KN, 1993, BIOCHIM BIOPHYS ACTA, V1202, P1, DOI 10.1016/0167-4838(93)90055-V; LEE KN, 1989, BIOCHEM BIOPH RES CO, V162, P1370, DOI 10.1016/0006-291X(89)90825-5; Liu XZ, 1997, J NEUROSCI, V17, P5395; Lorand L, 1996, P NATL ACAD SCI USA, V93, P14310, DOI 10.1073/pnas.93.25.14310; Melino G, 2000, CELL MOL LIFE SCI, V57, P612, DOI 10.1007/PL00000723; Melino G, 1998, FEBS LETT, V430, P59, DOI 10.1016/S0014-5793(98)00521-3; Mey J, 2001, Z NATURFORSCH C, V56, P163; Mirza A, 1997, AM J PHYSIOL-GASTR L, V272, pG281; Monsonego A, 1998, FASEB J, V12, P1163; Monsonego A, 1998, J MOL BIOL, V282, P713, DOI 10.1006/jmbi.1998.2052; Monsonego A, 1997, J BIOL CHEM, V272, P3724, DOI 10.1074/jbc.272.6.3724; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; Nicotera P, 1998, CELL CALCIUM, V23, P173, DOI 10.1016/S0143-4160(98)90116-6; Norlund MA, 1999, BRAIN RES, V851, P154, DOI 10.1016/S0006-8993(99)02179-4; Pabbathi VK, 1997, BRAIN RES, V760, P22, DOI 10.1016/S0006-8993(97)00272-2; Pan WH, 1999, J NEUROSCI, V19, P3649; PERRY MJM, 1993, INT J DEV NEUROSCI, V11, P325, DOI 10.1016/0736-5748(93)90004-W; Piredda L, 1999, FASEB J, V13, P355; Raghunath M, 1996, J CLIN INVEST, V98, P1174, DOI 10.1172/JCI118901; Ritter SJ, 1998, J BIOL CHEM, V273, P12798, DOI 10.1074/jbc.273.21.12798; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Sisodia SS, 1998, CELL, V95, P1, DOI 10.1016/S0092-8674(00)81743-2; Streit WJ, 1998, EXP NEUROL, V152, P74, DOI 10.1006/exnr.1998.6835; SWINGLER S, 1994, BIOCHEM BIOPH RES CO, V203, P623, DOI 10.1006/bbrc.1994.2228; Tan J, 2000, J NEUROSCI, V20, P7587; TETZLAFF W, 1988, BRAIN RES, V445, P142, DOI 10.1016/0006-8993(88)91083-9; UPCHURCH HF, 1991, J CELL PHYSIOL, V149, P375, DOI 10.1002/jcp.1041490304; Wang CX, 1996, J NEUROIMMUNOL, V69, P151; Xu J, 1998, MOL BRAIN RES, V59, P135, DOI 10.1016/S0169-328X(98)00142-9; Yong C, 1998, J NEUROTRAUM, V15, P459, DOI 10.1089/neu.1998.15.459; Zemaitaitis MO, 2000, J NEUROPATH EXP NEUR, V59, P983, DOI 10.1093/jnen/59.11.983; Zhang HF, 1998, HUM PATHOL, V29, P965, DOI 10.1016/S0046-8177(98)90202-7; Zhang SR, 1996, INVEST OPHTH VIS SCI, V37, P1793; Zhang W, 1997, LIFE SCI, V60, P2323, DOI 10.1016/S0024-3205(97)00288-9; Zhang-Gouillon ZQ, 1998, HEPATOLOGY, V27, P116, DOI 10.1002/hep.510270119	72	35	35	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	MAY	2002	81	4					708	718		10.1046/j.1471-4159.2002.00850.x			11	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	549YL	WOS:000175475100005	12065630				2021-06-18	
J	Nielsen, AS; Mortensen, PB; O'Callaghan, E; Mors, O; Ewald, H				Nielsen, AS; Mortensen, PB; O'Callaghan, E; Mors, O; Ewald, H			Is head injury a risk factor for schizophrenia?	SCHIZOPHRENIA RESEARCH			English	Article						head injury; schizophrenia; concussion	FIRST-EPISODE SCHIZOPHRENIA; PSYCHOSIS; REGISTER; TRAUMA	Background: The few studies that have examined whether head injury is a risk factor for later schizophrenia have had important methodological problems. Method: We examined the rates of head injury among 8288 persons in the 15 years up to their first admission with schizophrenia and compared them with 82880 age- and gender-matched controls. We used hospitalization for concussion or severe head injury as a definition of head injury. We controlled for any generally altered accident proneness prior to schizophrenia by also comparing the groups with respect to exposition to fractures not involving the skull or spine. Results: Males with schizophrenia had significantly reduced exposure to concussion (OR = 0.864, p = 0.024), whereas females had significantly increased exposure (OR = 1.322, p = 0.025). No differences were found as regards severe head injury. Males had significantly reduced risk of other fractures (OR = 0.616, p < 0.0001). whereas the risk in females did not differ from controls (OR = 1.154 p = 0.189). After adjusting head injury with the risk for other fractures, both concussion and severe head injury were significantly increased in males (OR = 1.501, p < 0.001 and OR = 1.516, p < 0,001, respectively) but not in females (OR = 1. 15, p = 0.413 and OR = 0.819. p = 0.442, respectively). Conclusion: Our results do not exclude that for males. head injury may contribute to the risk for schizophrenia in a limited number of cases. This relation may also exist for females. but it is paralleled by an increased liability to traumas in general. Premorbid general accident proneness requires consideration when studying this association. (C) 2002 Elsevier Science B.V. All rights reserved.	Univ Aarhus, Natl Ctr Register Based Res, DK-8000 Aarhus C, Denmark; Psychiat Hosp Aarhus, Inst Basic Psychiat Res, Dept Psychiat Demog, DK-8240 Risskov, Denmark; Cluain Mhuire Family Care, Dublin, Ireland; Psychiat Hosp Aarhus, Dept Biol Psychiat, DK-8240 Risskov, Denmark	Mortensen, PB (corresponding author), Univ Aarhus, Natl Ctr Register Based Res, Taasingegade 1, DK-8000 Aarhus C, Denmark.		Mortensen, Preben B/D-2358-2015	Mortensen, Preben B/0000-0002-5230-9865; Mors, Ole/0000-0002-5660-0393			ACHTE K, 1991, PSYCHOPATHOLOGY, V24, P309, DOI 10.1159/000284731; AITA JA, 1948, AM J PSYCHIAT, V105, P161, DOI 10.1176/ajp.105.3.161; Andersen TF, 1999, DAN MED BULL, V46, P263; BALDWIN JA, 1978, BRIT J PSYCHIAT, V133, P445, DOI 10.1192/bjp.133.5.445; Clayton DH M, 1993, STAT MODELS EPIDEMIO; DAVISON D, 1969, SPECIAL PUBLICATION, V4, P113; Deb S, 1999, AM J PSYCHIAT, V156, P374; FLANDERS WD, 1986, AM J EPIDEMIOL, V124, P684, DOI 10.1093/oxfordjournals.aje.a114442; GREENLAND S, 1982, AM J EPIDEMIOL, V116, P547, DOI 10.1093/oxfordjournals.aje.a113439; GUREJE O, 1994, AM J PSYCHIAT, V151, P368; HAAS GL, 1992, SCHIZOPHRENIA BULL, V18, P373, DOI 10.1093/schbul/18.3.373; JOHANSSON E, 1958, ACTA PSYCHIAT SCAND, V125, P33; Larsen TK, 1996, SCHIZOPHRENIA BULL, V22, P241, DOI 10.1093/schbul/22.2.241; Larsen TK, 1996, SCHIZOPHRENIA BULL, V22, P257, DOI 10.1093/schbul/22.2.257; LEWIN W, 1979, BRIT MED J, V2, P1533, DOI 10.1136/bmj.2.6204.1533; LISHMAN WA, 1968, BRIT J PSYCHIAT, V114, P373, DOI 10.1192/bjp.114.509.373; MunkJorgensen P, 1997, DAN MED BULL, V44, P82; MUNKJORGENSEN P, 1995, THESIS AARHUS; NASRALLAH HA, 1981, PSYCHOSOMATICS, V22, P359; NEUSTADT R, 1931, DTSCH Z GESAMTE GERI, V18, P1; OCALLAGHAN E, 1988, BRIT J PSYCHIAT, V153, P394, DOI 10.1192/bjp.153.3.394; Siegel E, 1970, Psychiatr Neurol Med Psychol (Leipz), V22, P345; *SUNDH, 1986, KLASS SYGD, P8; *WHO, 1967, INT CLASS DIS MAN IN; WILCOX JA, 1987, PSYCHIAT RES, V21, P303, DOI 10.1016/0165-1781(87)90013-8; Yung AR, 1996, AUST NZ J PSYCHIAT, V30, P587, DOI 10.3109/00048679609062654	26	35	36	0	12	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0920-9964			SCHIZOPHR RES	Schizophr. Res.	MAY 1	2002	55	1-2					93	98	PII S0920-9964(01)00205-5	10.1016/S0920-9964(01)00205-5			6	Psychiatry	Psychiatry	546ZQ	WOS:000175307500011	11955968				2021-06-18	
J	Wiedemayer, H; Triesch, K; Schafer, H; Stolke, D				Wiedemayer, H; Triesch, K; Schafer, H; Stolke, D			Early seizures following non-penetrating traumatic brain injury in adults: risk factors and clinical significance	BRAIN INJURY			English	Article							POSTTRAUMATIC SEIZURES; CHILDREN	Background: In the literature dissenting data are obtained about risk factors for early post-traumatic seizures and their impact on outcome. This study was conducted to obtain more information about the clinical significance of early seizures and their possible impact on the treatment of traumatic brain injury. Methods and results: A consecutive series of 1868 adult patients with head injury were analysed retrospectively. Demographic data of the patients, characteristics of the injury, and findings on CT scan were recorded. Risk factors for early post-traumatic seizures were identified using univariate statistics. A multivariate logistic regression was performed to look for interaction of different variables. The impact of early post-traumatic seizures on outcome was examined in an analogous way. Chronic alcohol abuse, subdural haematoma and brain contusion were identified as independent risk factors for early post-traumatic seizures. A significant association of early post-traumatic seizures with an unfavourable outcome was observed, but this effect was small compared to other variables. Conclusions: Early post-traumatic seizures appear to be an acute reaction of the brain to cortical damage with little independent impact on the management of head injury.	Univ Essen Gesamthsch, Sch Med, Dept Neurosurg, Essen, Germany	Wiedemayer, H (corresponding author), Univ Essen Gesamthsch Klinikum, Neurochirurg Klin, Hufelandstr 55, D-45122 Essen, Germany.	helmut.wiedemayer@uni-essen.de					ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; BAUMHACKL U, 1994, EUROPEAN NEUROLOGY S, V1, P71; Dalmady-Israel Christina, 1993, Brain Injury, V7, P263, DOI 10.3109/02699059309029679; De Santis A, 1992, Acta Neurochir Suppl (Wien), V55, P64; DESAI BT, 1983, EPILEPSIA, V24, P289, DOI 10.1111/j.1528-1157.1983.tb04892.x; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1974, ARCH NEUROL-CHICAGO, V30, P394, DOI 10.1001/archneur.1974.00490350052008; Kollevold T, 1978, J Oslo City Hosp, V28, P77; KOLLEVOLD T, 1979, J OWLO CITY HOSP, V29, P36; LEE ST, 1992, J NEUROSURG, V76, P435, DOI 10.3171/jns.1992.76.3.0435; Lee ST, 1995, ACTA NEUROCHIR, V137, P151, DOI 10.1007/BF02187187; Lee ST, 1997, CAN J NEUROL SCI, V24, P40, DOI 10.1017/S0317167100021077; LEWIS RJ, 1993, ANN EMERG MED, V22, P1114, DOI 10.1016/S0196-0644(05)80974-6; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; MAUGUIERE F, 1979, REV EEG NEUROPHYSIOL, V9, P149, DOI 10.1016/S0370-4475(79)80069-6; Ong LC, 1996, J PAEDIATR CHILD H, V32, P173, DOI 10.1111/j.1440-1754.1996.tb00917.x; RUTHERFORD WH, 1977, LANCET, V1, P1021; SAZBON L, 1990, J NEUROSURG, V72, P75, DOI 10.3171/jns.1990.72.1.0075; Schutze M, 1999, ZBL NEUROCHIR, V60, P163; TEASDALE G, 1974, LANCET, V2, P81; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37	23	35	36	0	2	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	APR	2002	16	4					323	330		10.1080/02699050110102077			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	541CM	WOS:000174967700004	11953003				2021-06-18	
J	Butterwick, DJ; Hagel, B; Nelson, DS; LeFave, MR; Meeuwisse, WH				Butterwick, DJ; Hagel, B; Nelson, DS; LeFave, MR; Meeuwisse, WH			Epidemiologic analysis of injury in five years of Canadian professional rodeo	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article								Longitudinal studies of rodeo injuries are rare. We prospectively investigated injuries in professional rodeo in Canada over a 5-year period. Our specific interests included injury incidence density in specific rodeo events, risk factors such as past injury, and the incidence of head injury. Of 323 professional rodeos from 1995 through 1999, 63 rodeos provided a convenience sample. These rodeos were selected because the Canadian Professional Rodeo Sport Medicine Team was in attendance at these events, thus providing both competitor health care and data collection. Four hundred fifty-one injuries were reported during 30,564 competitor-exposures. The greatest injury frequency and injury incidence density were in the rough stock events (bull riding, bareback riding, and saddle bronc). Bull riding accounted for the greatest injury frequency (141) and incidence density (32.2 injuries per 1000 competitor-exposures). Bull riding had a relative injury risk of 1.32 when compared with bareback riding; bareback riding had a relative injury risk of 1.39 when compared with saddle bronc riding. Concussions accounted for 8.6% of all reported injuries. Concussions and other head injuries (65) were second only to knee injuries (76) in frequency of injury to specific body parts. This concussion frequency is higher than has previously been reported.	Univ Calgary, Fac Kinesiol, Sport Med Ctr, Calgary, AB T2N 1N4, Canada; Mt Royal Coll, Calgary, AB, Canada; McGill Univ, Montreal, PQ, Canada	Butterwick, DJ (corresponding author), Univ Calgary, Fac Kinesiol, Sport Med Ctr, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.		Hagel, Brent/AAK-3319-2020				Brandenburg MA, 1998, ANN EMERG MED, V32, P118, DOI 10.1016/S0196-0644(98)70123-4; Butterwick DJ, 1996, CLIN J SPORT MED, V6, P171, DOI 10.1097/00042752-199607000-00006; GRIFFIN R, 1987, PHYSICIAN SPORTSMED, V15, P104, DOI 10.1080/00913847.1987.11709284; Griffin R, 1983, Phys Sportsmed, V11, P110, DOI 10.1080/00913847.1983.11708608; HARVEY J, 1995, SPORTS MED UPDATE, V10, P1; MEYERS MC, 1990, AM J SPORT MED, V18, P87, DOI 10.1177/036354659001800114; NEBERGALL R, 1996, EPIDEMIOLOGY SPORTS, P350; SEAGER SB, 1981, ANN EMERG MED, V10, P252, DOI 10.1016/S0196-0644(81)80050-9; Slawski D P, 1997, Am J Orthop (Belle Mead NJ), V26, P794; STOCK C, 2000, CALGARY HERALD  0529, pC16; TRIPP HF, 1995, MIL MED, V160, P422; Warren WL, 1998, CLIN SPORT MED, V17, P13, DOI 10.1016/S0278-5919(05)70057-0; 1996, MMWR MORB MORTAL WKL, V45, P796	13	35	35	0	3	AMER ORTHOPAEDIC SOC SPORT MED	WALTHAM	230 CALVARY STREET, WALTHAM, MA 02154 USA	0363-5465			AM J SPORT MED	Am. J. Sports Med.	MAR-APR	2002	30	2					193	198		10.1177/03635465020300020801			6	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	533FV	WOS:000174519500008	11912087				2021-06-18	
J	Hofman, PAM; Verhey, FRJ; Wilmink, JT; Rozendaal, N; Jolles, J				Hofman, PAM; Verhey, FRJ; Wilmink, JT; Rozendaal, N; Jolles, J			Brain lesions in patients visiting a memory clinic with postconcussional sequelae after mild to moderate brain injury	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							CLOSED-HEAD-INJURY; MAGNETIZATION-TRANSFER; MULTIPLE-SCLEROSIS; HISTOPATHOLOGIC CORRELATION; CEREBRAL CONCUSSION; MICROSCOPIC DISEASE; WHITE-MATTER; MR; DEGENERATION; PERFORMANCE	Postconcussional disorder after a relatively mild head injury is common. Although a partial organic etiology is presumed, little imaging evidence exists for this assumption, In this study, patients with mild to moderate brain injury (median Glasgow Coma Scale score of 14) had more parenchymal brain lesions than control subjects (P = 0.02). Additionally, the authors investigated the potential of quantifying brain injury by the magnetization transfer ratio (MTR). The curve amplitude of the MTR histogram was used as a measure of normal white matter. Patients had a lower curve amplitude than control subjects (P = 0.008). This study provides evidence of persistent traumatic brain alterations in patients who sustained a relatively mild traumatic brain injury.	Univ Hosp Maastricht, Dept Radiol, NL-6200 AZ Maastricht, Netherlands; Univ Hosp Maastricht, Dept Psychiat & Neuropsychol, NL-6200 AZ Maastricht, Netherlands	Hofman, PAM (corresponding author), Univ Hosp Maastricht, Dept Radiol, POB 5800, NL-6200 AZ Maastricht, Netherlands.	pho@rdia.azm.nl					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; BAKAY L, 1977, J NEUROSURG, V47, P525, DOI 10.3171/jns.1977.47.4.0525; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Binder LM, 1996, AM J PSYCHIAT, V153, P7; BOHNEN N, 1993, NEUROPSY NEUROPSY BE, V6, P193; BOHNEN N, 1992, NEUROSURGERY, V30, P692; BOORSTEIN JM, 1994, RADIOLOGY, V191, P799, DOI 10.1148/radiology.191.3.8184068; BRAND N, 1985, J GEN PSYCHOL, V112, P201, DOI 10.1080/00221309.1985.9711004; BRAND N, 1987, PSYCHOL MED, V17, P145, DOI 10.1017/S0033291700013040; BROWN SJ, 1994, J NEUROPSYCH CLIN N, V6, P15; DOUSSET V, 1992, RADIOLOGY, V182, P483, DOI 10.1148/radiology.182.2.1732968; FORSEN S, 1963, J CHEM PHYS, V39, P2892, DOI 10.1063/1.1734121; Gean A, 1994, IMAGING HEAD TRAUMA; HAJNAL JV, 1992, J COMPUT ASSIST TOMO, V16, P7, DOI 10.1097/00004728-199201000-00003; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HESSELINK JR, 1988, AM J ROENTGENOL, V150, P1133; Hofman PAM, 2000, J NEUROL NEUROSUR PS, V68, P416, DOI 10.1136/jnnp.68.4.416; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Hofman PAM, 1999, MAGN RESON MED, V42, P803, DOI 10.1002/(SICI)1522-2594(199910)42:4<803::AID-MRM24>3.3.CO;2-6; HOUX P, 1991, COGNITIVE AGING HLTH; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Jacobs A, 1996, J NUCL MED, V37, P1605; JANE JA, 1985, J NEUROSURG, V62, P96, DOI 10.3171/jns.1985.62.1.0096; Kimura H, 1996, J COMPUT ASSIST TOMO, V20, P540, DOI 10.1097/00004728-199607000-00007; Klein M, 1996, J NERV MENT DIS, V184, P459, DOI 10.1097/00005053-199608000-00002; KLEIN M, 1997, THESIS MAASTRICHT U; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; KRUGER J, 1991, NERVENARZT, V62, P226; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LEXA FJ, 1994, AM J NEURORADIOL, V15, P201; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; LOEVNER LA, 1995, RADIOLOGY, V196, P511, DOI 10.1148/radiology.196.2.7617869; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; MIDDELBOE T, 1992, J PERS DISORD, V6, P246, DOI 10.1521/pedi.1992.6.3.246; MILLER JD, 1993, J NEUROL NEUROSUR PS, V56, P440, DOI 10.1136/jnnp.56.5.440; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; ORRISON WW, 1994, AM J NEURORADIOL, V15, P351; SCHELTENS P, 1993, J NEUROL SCI, V114, P7, DOI 10.1016/0022-510X(93)90041-V; TEASDALE G, 1974, LANCET, V2, P81; vanBoxtel MPJ, 1996, EXP AGING RES, V22, P363, DOI 10.1080/03610739608254017; vanBuchem MA, 1996, MAGN RESON MED, V36, P632, DOI 10.1002/mrm.1910360420; Verhage F, 1964, INTELLIGENTIE LEEFTI; VERHEY FRJ, 1993, J NEUROPSYCH CLIN N, V5, P78; Wilmink JT, 1997, NEURORADIOLOGY, V39, P589, DOI 10.1007/s002340050473; WOLFF SD, 1989, MAGNET RESON MED, V10, P135, DOI 10.1002/mrm.1910100113; WOLFF SD, 1994, RADIOLOGY, V192, P593, DOI 10.1148/radiology.192.3.8058919; YOKOTA H, 1991, J TRAUMA, V31, P351, DOI 10.1097/00005373-199103000-00007	54	35	35	0	2	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	0895-0172	1545-7222		J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	SPR	2002	14	2					176	184		10.1176/appi.neuropsych.14.2.176			9	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	555JB	WOS:000175790000007	11983792				2021-06-18	
J	Garnett, MR; Cadoux-Hudson, TAD; Styles, P				Garnett, MR; Cadoux-Hudson, TAD; Styles, P			How useful is magnetic resonance imaging in predicting severity and outcome in traumatic brain injury?	CURRENT OPINION IN NEUROLOGY			English	Article							CLOSED-HEAD-INJURY; SPECTROSCOPY; DIFFUSION; MILD; MRI; LESIONS	Major advances have been made in the ever-expanding field of magnetic resonance imaging and related technologies, such as magnetic resonance spectroscopy, haemodynamic and functional imaging. Although these magnetic resonance modalities are of great research interest, it is still questionable as to how useful these investigations are in the clinical setting. All of these modalities strive to define a few variables that might dominate the heterogeneous but common aetiopathology of traumatic brain injury. Recent studies have found that the use of various magnetic resonance imaging techniques at early and delayed time points can provide useful information with regard to the severity and clinical outcome of patients following traumatic brain injury. These new observations offer opportunities for improved clinical management in such patients. Curr Opin Neurol 14:753-757. (C) 2001 Lippincott Williams Wilkins.	Radcliffe Infirm, Dept Neurosurg, Oxford OX2 9DL, England; Univ Oxford, Dept Biochem, MRC, Biochem & Clin Magnet Resonance Unit, Oxford OX1 3QU, England	Cadoux-Hudson, TAD (corresponding author), Radcliffe Infirm, Dept Neurosurg, Oxford OX2 9DL, England.						Ashwal S, 2000, PEDIATR NEUROL, V23, P114, DOI 10.1016/S0887-8994(00)00176-4; Assaf Y, 1999, J NEUROTRAUM, V16, P1165, DOI 10.1089/neu.1999.16.1165; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Bruce DA, 2000, CHILD NERV SYST, V16, P755, DOI 10.1007/PL00013720; CADOUXHUDSON TAD, 1998, P INT SOC MAGN RES M, P1383; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Condon B, 1998, J NEUROTRAUM, V15, P563, DOI 10.1089/neu.1998.15.563; Di Stefano G, 2000, J NEUROL NEUROSUR PS, V69, P210, DOI 10.1136/jnnp.69.2.210; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Garnett MR, 2001, J NEUROTRAUM, V18, P585, DOI 10.1089/089771501750291828; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Garnett MR, 2001, J NEUROTRAUM, V18, P231, DOI 10.1089/08977150151070838; Grados MA, 2001, J NEUROL NEUROSUR PS, V70, P350, DOI 10.1136/jnnp.70.3.350; Heath DL, 1996, BRAIN RES, V738, P150, DOI 10.1016/0006-8993(96)00957-2; Henry-Feugeas MC, 2000, BRAIN INJURY, V14, P597; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Jones DK, 2000, NEUROSURGERY, V47, P306, DOI 10.1097/00006123-200008000-00008; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; Kuzma BB, 2000, SURG NEUROL, V53, P400; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; Shibata Y, 2000, CLIN NEUROL NEUROSUR, V102, P124, DOI 10.1016/S0303-8467(00)00095-0; Sinson G, 2001, AM J NEURORADIOL, V22, P143; Smith DH, 1998, J NEUROTRAUM, V15, P665, DOI 10.1089/neu.1998.15.665; Takanashi Y, 2000, J NEUROTRAUM, V17, P359, DOI 10.1089/neu.2000.17.359; Takayama H, 2000, CLIN NEUROL NEUROSUR, V102, P135, DOI 10.1016/S0303-8467(00)00079-2; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; van der Naalt J, 2000, BRAIN INJURY, V14, P781; Vinjamuri S, 2000, NUCL MED COMMUN, V21, P645, DOI 10.1097/00006231-200007000-00008	31	35	37	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1350-7540			CURR OPIN NEUROL	Curr. Opin. Neurol.	DEC	2001	14	6					753	757		10.1097/00019052-200112000-00012			5	Clinical Neurology; Neurosciences	Neurosciences & Neurology	510NG	WOS:000173213700012	11723384				2021-06-18	
J	Hutchison, JS; Derrane, RE; Johnston, DL; Gendron, N; Barnes, D; Fliss, H; King, WJ; Rasquinha, I; MacManus, J; Robertson, GS; MacKenzie, AE				Hutchison, JS; Derrane, RE; Johnston, DL; Gendron, N; Barnes, D; Fliss, H; King, WJ; Rasquinha, I; MacManus, J; Robertson, GS; MacKenzie, AE			Neuronal apoptosis inhibitory protein expression after traumatic brain injury in the mouse	JOURNAL OF NEUROTRAUMA			English	Article						apoptosis; caspase; microglia; neuronal apoptosis inhibitor protein (NAIP); tumor necrosis factor-alpha (TNF alpha); immunofluorescence; Western blot	NECROSIS-FACTOR-ALPHA; PROGRAMMED CELL-DEATH; SPINAL-CORD INJURY; CLOSED-HEAD INJURY; DNA FRAGMENTATION; POLY(ADP-RIBOSE) POLYMERASE; COGNITIVE DEFICITS; RAT-BRAIN; TNF-ALPHA; IN-VIVO	Apoptosis of brain cells is triggered by traumatic brain injury (TBI) and is blocked by caspase inhibitors. The neuronal apoptosis inhibitor protein (NAIP), which has been shown to inhibit apoptosis by both caspase-dependant and caspase-independent mechanisms, is neuroprotective in rat models of cerebral ischemia and axotomy. In order to gain a better appreciation of CNS apoptosis following head injury in general and the possible involvement of NAIP specifically, we have configured a mouse model of TBI. In addition to demonstrating apoptosis, the spatiotemporal expression or levels of a number of proteins with apoptosis modulating effects have been determined. Apoptosis of neurons and oligodendrocytes following TBI was observed in brain sections which were triple-stained with in situ end labeling, bisbenzimide and immunofluorescent stain for neuron specific nuclear protein and myelin-associated glycoprotein, respectively. Further evidence for apoptosis following TBI in this model was obtained in brain samples using ligation-mediated PCR amplification of DNA fragments and gel electrophoresis. The temporal profile of apoptosis was similar to the temporal profile of microglial activation determined by CD11b staining and TNF alpha expression induced by TBI. NAIP staining in sections of cerebral cortex and subcortical white matter increased at 6 h and decreased towards control levels at 24 h post-TBI. Temporal changes in the expression of NAIP were also observed using Western blot analysis of brain samples removed from injured cortex and sub-cortical white matter. At the time that NAIP expression decreased markedly (24 h post-TBI), procaspase-3 levels also decreased, PARP cleavage increased, and the highest levels of apoptosis were observed. These findings have implications in our understanding of traumatically induced programmed cell death and may be useful in the configuration of therapies for this common injury state.	Univ Ottawa, Fac Med, Dept Pediat, Div Pediat Intens Care, Ottawa, ON, Canada; Univ Ottawa, Fac Med, Dept Cellular & Mol Med, Ottawa, ON, Canada; Childrens Hosp Eastern Ontario, Inst Res, Genet Mol Lab, Ottawa, ON K1H 8L1, Canada; Univ Ottawa, Fac Med, Dept Pediat, Ottawa, ON, Canada; Natl Res Council Canada, Inst Biol Sci, Apoptosis Res Grp, Ottawa, ON, Canada; Univ Ottawa, Fac Med, Dept Biochem, Ottawa, ON, Canada	Hutchison, JS (corresponding author), Univ Ottawa, Fac Med, Dept Pediat, Div Pediat Intens Care, Ottawa, ON, Canada.		Fliss, Henry/ABG-2561-2020				ALTHAUS JS, 1993, MOL CHEM NEUROPATHOL, V20, P147, DOI 10.1007/BF02815368; ANSARI B, 1993, J PATHOL, V170, P1, DOI 10.1002/path.1711700102; Beer R, 2000, J CEREBR BLOOD F MET, V20, P669, DOI 10.1097/00004647-200004000-00004; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Clark D, 1999, IEEE INTERNET COMPUT, V3, P13; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1997, J NEUROSCI, V17, P9172; Clark RSB, 2000, J PEDIATR-US, V137, P197, DOI 10.1067/mpd.2000.106903; Conti AC, 1998, J NEUROSCI, V18, P5663; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Diez E, 2000, J IMMUNOL, V164, P1470, DOI 10.4049/jimmunol.164.3.1470; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Gourin CG, 1997, J TRAUMA, V42, P1101, DOI 10.1097/00005373-199706000-00020; GRASLKRAUPP B, 1995, HEPATOLOGY, V21, P1465, DOI 10.1016/0270-9139(95)90071-3; HALL ED, 1985, J NEUROSURG, V62, P882, DOI 10.3171/jns.1985.62.6.0882; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; HILL IE, 1995, BRAIN RES, V676, P398, DOI 10.1016/0006-8993(95)00145-G; Holcik M, 2000, P NATL ACAD SCI USA, V97, P2286, DOI 10.1073/pnas.040469797; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Kreider BQ, 1996, J NEUROSCI RES, V44, P459; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; LINNIK MD, 1993, STROKE, V24, P2002, DOI 10.1161/01.STR.24.12.2002; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; LIU MY, 1995, J FORMOS MED ASSOC, V94, P386; Liu XZ, 1997, J NEUROSCI, V17, P5395; MACMANUS JP, 1995, J CEREBR BLOOD F MET, V15, P728, DOI 10.1038/jcbfm.1995.93; MacManus JP, 1999, J CEREBR BLOOD F MET, V19, P502, DOI 10.1097/00004647-199905000-00004; MACMANUS JP, 1993, NEUROSCI LETT, V164, P89, DOI 10.1016/0304-3940(93)90864-H; MACMANUS JP, 1994, NEUROREPORT, V5, P493, DOI 10.1097/00001756-199401120-00031; Mercer EA, 2000, EMBO J, V19, P3597, DOI 10.1093/emboj/19.14.3597; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; O'Dell DM, 2000, J NEUROSCI, V20, P4821; Oliver FJ, 1998, J BIOL CHEM, V273, P33533, DOI 10.1074/jbc.273.50.33533; Perrelet D, 2000, EUR J NEUROSCI, V12, P2059, DOI 10.1046/j.1460-9568.2000.00098.x; Pravdenkova SV, 1996, BRAIN RES, V729, P151, DOI 10.1016/0006-8993(96)00222-3; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; RINK A, 1995, AM J PATHOL, V147, P1575; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Shah GM, 1995, ANAL BIOCHEM, V232, P251, DOI 10.1006/abio.1995.0016; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; Westmoreland SV, 1996, J NEUROVIROL, V2, P118, DOI 10.3109/13550289609146545; Xu DG, 1997, NAT MED, V3, P997, DOI 10.1038/nm0997-997; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yaraghi Z, 1998, GENOMICS, V51, P107, DOI 10.1006/geno.1998.5378; Ye P, 1999, ENDOCRINOLOGY, V140, P3063, DOI 10.1210/en.140.7.3063	50	35	36	0	4	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	DEC	2001	18	12					1333	1347		10.1089/08977150152725632			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	504RE	WOS:000172869000004	11780864				2021-06-18	
J	Borgens, RB				Borgens, RB			Cellular engineering: Molecular repair of membranes to rescue cells of the damaged nervous system	NEUROSURGERY			English	Article						neurotrauma; poloxamers; polyethylene glycol; spinal cord injury	SPINAL-CORD-INJURY; APPLIED ELECTRIC-FIELDS; CONTROLLED-TRIAL; GUINEA-PIGS; RECOVERY; FUSION; HYBRIDIZATION; HEMISECTION; CONDUCTION; MODEL	PURPOSE: The acute administration of hydrophilic polymers (polyethylene glycol) can immediately seal nerve membranes, preventing their continuing dissolution and secondary axotomy. Polymer application can even be used to reconnect, or fuse, the proximal and distal segments of severed axons in completely transected adult mammalian spinal cord. CONCEPT: The sealing or fusion of damaged nerve membranes leads to a very rapid (minutes or hours) recovery of excitability in severely damaged nerve fibers, observed as a rapid return of nerve impulse conduction in vitro, as well as an in vivo recovery of spinal cord conduction and behavioral loss in spinal cord-injured adult guinea pigs. RATIONALE: Surfactant application produces a rapid repair of membrane breaches through mechanisms of interaction between the polymers and the aqueous phase of damaged membranes, and their ability to insert into, or seal, the hydrophobic core of the axolemma exposed by mechanical damage. DISCUSSION: This new technology applied to severe neurotrauma offers a clinically safe and practical means to rescue significant populations of spinal cord nerve fibers within 8 hours after damage-preventing their continued dissolution and secondary axotomy by secondary injury mechanisms. Application of this novel technology to other injuries to the peripheral and central nervous system is discussed, as well as a general application to soft tissue trauma.	Purdue Univ, Sch Vet Med, Ctr Paralysis Res, Dept Basic Med Sci,Inst Appl Neurol, W Lafayette, IN 47907 USA	Borgens, RB (corresponding author), Purdue Univ, Sch Vet Med, Ctr Paralysis Res, Dept Basic Med Sci,Inst Appl Neurol, 1244 VCPR, W Lafayette, IN 47907 USA.	CPR@vet.purdue.edu					Bisby Mark A., 1995, P553; BLIGHT AR, 1991, J NEUROL SCI, V103, P156, DOI 10.1016/0022-510X(91)90159-5; BLIGHT AR, 1990, J COMP NEUROL, V296, P614, DOI 10.1002/cne.902960408; BLIGHT AR, 1993, ADV NEUROL, V59, P91; Borgens R B, 1988, Adv Neurol, V47, P51; Borgens RB, 2000, FASEB J, V14, P27; Borgens RB, 1999, J NEUROTRAUM, V16, P639, DOI 10.1089/neu.1999.16.639; BORGENS RB, 1980, P NATL ACAD SCI-BIOL, V77, P1209, DOI 10.1073/pnas.77.2.1209; BORGENS RB, 1986, J COMP NEUROL, V250, P157, DOI 10.1002/cne.902500203; BORGENS RB, 1987, SCIENCE, V238, P366, DOI 10.1126/science.3659920; BORGENS RB, 1993, RESTOR NEUROL NEUROS, V5, P305, DOI 10.3233/RNN-1993-55601; BORGENS RB, 1990, J COMP NEUROL, V296, P634, DOI 10.1002/cne.902960409; BORGENS RB, 1989, ELECT FIELDS VERTEBR, P71; BORGENS RB, 1992, SPINAL CORD DYSFUNCT, V3, P110; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; Carafoli E., 1976, S SOC EXP BIOL, V30, P89; DAVIDSON RL, 1976, SOMAT CELL GENET, V2, P165, DOI 10.1007/BF01542629; DAVIDSON RL, 1976, SOMAT CELL GENET, V2, P271, DOI 10.1007/BF01538965; GEISLER FH, 1991, NEW ENGL J MED, V324, P1829, DOI 10.1056/NEJM199106273242601; Hannig J, 1999, INT J RADIAT BIOL, V75, P379, DOI 10.1080/095530099140555; Honmou Osamu, 1995, P480; JOHNSON AJ, 1971, BRIT J HAEMATOL, V21, P21, DOI 10.1111/j.1365-2141.1971.tb03414.x; KRAUSE TL, 1990, P NATL ACAD SCI USA, V87, P1471, DOI 10.1073/pnas.87.4.1471; Lee J, 1997, BIOCHEMISTRY-US, V36, P6251, DOI 10.1021/bi970404c; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; LEE RC, 1992, P NATL ACAD SCI USA, V89, P4524, DOI 10.1073/pnas.89.10.4524; LENTZ BR, 1994, CHEM PHYS LIPIDS, V73, P91, DOI 10.1016/0009-3084(94)90176-7; MALMGREN L, 1977, J HISTOCHEM CYTOCHEM, V25, P1280, DOI 10.1177/25.11.915248; Marks Jeremy D., 2001, FASEB Journal, V15, P1107; Maxwell WL, 1997, J NEUROTRAUM, V14, P603, DOI 10.1089/neu.1997.14.603; Maxwell WL, 1996, MICROSC RES TECHNIQ, V34, P522, DOI 10.1002/(SICI)1097-0029(19960815)34:6<522::AID-JEMT4>3.0.CO;2-L; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; Merchant FA, 1998, J SURG RES, V74, P131, DOI 10.1006/jsre.1997.5252; NAKAJIMA N, 1994, J BIOMAT SCI-POLYM E, V6, P751, DOI 10.1163/156856295X00139; OLAGUE PH, 1980, P NATL ACAD SCI-BIOL, V77, P1701, DOI 10.1073/pnas.77.3.1701; PADANLAM JT, 1994, ANN NY ACAD SCI, V92, P111; PALMER JS, 1988, J UROLOGY, V159, P2136; SCHMOLKA IR, 1994, ANN NY ACAD SCI, V720, P92, DOI 10.1111/j.1749-6632.1994.tb30437.x; Sharma V, 1996, BIOPHYS J, V71, P3229, DOI 10.1016/S0006-3495(96)79516-4; Shi R, 1999, J NEUROPHYSIOL, V81, P2406; Shi R, 1997, NEUROSCIENCE, V77, P553, DOI 10.1016/S0306-4522(96)00477-0; Shi R, 2000, J NEUROCYTOL, V29, P633, DOI 10.1023/A:1010879219775; Shi R, 1996, J NEUROPHYSIOL, V76, P1572; Shi RY, 1999, J NEUROTRAUM, V16, P727, DOI 10.1089/neu.1999.16.727; STYS PK, 1990, P NATL ACAD SCI USA, V87, P4212, DOI 10.1073/pnas.87.11.4212; THERIAULT E, 1988, J NEUROPHYSIOL, V60, P446; Working PK, 1997, ACS SYM SER, V680, P45; Young Wise, 1993, Journal of Emergency Medicine, V11, P13	48	35	37	0	8	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	AUG	2001	49	2					370	378		10.1097/00006123-200108000-00021			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	457MQ	WOS:000170141700065	11504113				2021-06-18	
J	Weise, J; Isenmann, S; Bahr, M				Weise, J; Isenmann, S; Bahr, M			Increased expression and activation of poly(ADP-ribose) polymerase (PARP) contribute to retinal ganglion cell death following rat optic nerve transection	CELL DEATH AND DIFFERENTIATION			English	Article						PARP; retinal ganglion cell death; optic nerve transection; neuroprotection; 3-aminobenzamide; necrosis	NITRIC-OXIDE SYNTHASE; ISCHEMIA-REPERFUSION INJURY; IN-VIVO; NEUROTROPHIC FACTOR; ADULT-RATS; CEREBRAL-ISCHEMIA; ENDOTHELIAL-CELLS; NUCLEAR PROTEINS; FOCAL ISCHEMIA; UP-REGULATION	Excessive activation of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) by free-radical damaged DNA mediates necrotic cell death in injury models of cerebral ischemia-reperfusion and excitotoxicity. We recently reported that secondary retinal ganglion cell (RGC) death following rat optic nerve (ON) transection is mainly apoptotic and can significantly but not entirely be blocked by caspase inhibition. In the present study, we demonstrate transient, RGC specific PARP activation and increased retinal PARP expression early after ON axotomy. In addition, intravitreal injections of 3-aminobenzamide blocked PARP activation in RGCs and resulted in an increased number of surviving RGCs when compared to control animals 14 days after ON transection. These data indicate that secondary degeneration of a subset of axotomized RGCs results from a necrotic-type cell death mediated by PARP activation and increased PARP expression. Furthermore, PARP inhibition may constitute a relevant strategy for clinical treatment of traumatic brain injury.	Univ Gottingen, Sch Med, Dept Neurol, D-37075 Gottingen, Germany; Univ Tubingen, Dept Neurol, Sch Med, D-72076 Tubingen, Germany	Weise, J (corresponding author), Univ Gottingen, Sch Med, Dept Neurol, Robert Koch Str 40, D-37075 Gottingen, Germany.		Baehr, Mathias/K-2188-2014; Isenmann, Stefan/AAJ-3788-2020				BERKELAAR M, 1994, J NEUROSCI, V14, P4368, DOI 10.1523/jneurosci.14-07-04368.1994; Bien A, 1999, J NEUROTRAUM, V16, P153, DOI 10.1089/neu.1999.16.153; Chatterjee PK, 2000, FASEB J, V14, P641; CHOI DW, 1995, TRENDS NEUROSCI, V18, P58; COSI C, 1994, J NEUROSCI RES, V39, P38, DOI 10.1002/jnr.490390106; Cosi C, 1996, BRAIN RES, V729, P264, DOI 10.1016/S0006-8993(96)00571-9; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Endres M, 1998, NEUROSCI LETT, V248, P41, DOI 10.1016/S0304-3940(98)00224-9; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; ESCHWEILER GW, 1993, J NEUROL SCI, V116, P34, DOI 10.1016/0022-510X(93)90086-E; GAAL JC, 1987, TRENDS BIOCHEM SCI, V12, P129, DOI 10.1016/0968-0004(87)90061-2; IKAI K, 1980, J HISTOCHEM CYTOCHEM, V28, P670, DOI 10.1177/28.7.6993553; Isenmann S, 1997, EUR J NEUROSCI, V9, P1763, DOI 10.1111/j.1460-9568.1997.tb01534.x; Kermer P, 1999, EXP NEUROL, V158, P202, DOI 10.1006/exnr.1999.7094; Kermer P, 1999, FEBS LETT, V453, P361, DOI 10.1016/S0014-5793(99)00747-4; Kermer P, 1998, J NEUROSCI, V18, P4656; Klocker N, 1997, NEUROREPORT, V8, P3439; Klocker N, 1998, J NEUROSCI, V18, P1038; Klocker N, 1999, J NEUROSCI, V19, P8517; Klocker N, 2000, J NEUROSCI, V20, P6962, DOI 10.1523/JNEUROSCI.20-18-06962.2000; Kreutz MR, 1998, J NEUROSCI, V18, P8278; LAMM TT, 1997, RES COMMUN MOL PATH, V95, P241; Leist M, 1997, BIOCHEM BIOPH RES CO, V233, P518, DOI 10.1006/bbrc.1997.6491; LINDAHL T, 1995, TRENDS BIOCHEM SCI, V20, P405, DOI 10.1016/S0968-0004(00)89089-1; Love S, 1999, BRAIN, V122, P247, DOI 10.1093/brain/122.2.247; MEY J, 1993, BRAIN RES, V602, P304, DOI 10.1016/0006-8993(93)90695-J; Nagayama T, 2000, J NEUROCHEM, V74, P1636, DOI 10.1046/j.1471-4159.2000.0741636.x; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; RADONS J, 1994, BIOCHEM BIOPH RES CO, V199, P1270, DOI 10.1006/bbrc.1994.1368; RusselakisCarneiro M, 1996, J NEUROCYTOL, V25, P393, DOI 10.1007/BF02284810; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; Simbulan-Rosenthal CM, 1998, J BIOL CHEM, V273, P13703, DOI 10.1074/jbc.273.22.13703; Szabo C, 1998, TRENDS PHARMACOL SCI, V19, P287, DOI 10.1016/S0165-6147(98)01193-6; Takahashi K, 1997, J CEREBR BLOOD F MET, V17, P1137, DOI 10.1097/00004647-199711000-00001; Takahashi K, 1999, BRAIN RES, V829, P46, DOI 10.1016/S0006-8993(99)01335-9; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Thiemermann C, 1997, P NATL ACAD SCI USA, V94, P679, DOI 10.1073/pnas.94.2.679; THIES RL, 1991, ARCH BIOCHEM BIOPHYS, V286, P353, DOI 10.1016/0003-9861(91)90051-J; Tokime T, 1998, J CEREBR BLOOD F MET, V18, P991; VILLEGASPEREZ MP, 1993, J NEUROBIOL, V24, P23, DOI 10.1002/neu.480240103; Wagenknecht B, 1998, CELL DEATH DIFFER, V5, P894, DOI 10.1038/sj.cdd.4400435; Walisser JA, 1999, EXP CELL RES, V251, P401, DOI 10.1006/excr.1999.4589; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; Weise J, 2000, NEUROBIOL DIS, V7, P212, DOI 10.1006/nbdi.2000.0285; Yoles E, 1998, ARCH OPHTHALMOL-CHIC, V116, P906, DOI 10.1001/archopht.116.7.906; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500	49	35	39	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	1350-9047			CELL DEATH DIFFER	Cell Death Differ.	AUG	2001	8	8					801	807		10.1038/sj.cdd.4400872			7	Biochemistry & Molecular Biology; Cell Biology	Biochemistry & Molecular Biology; Cell Biology	454YN	WOS:000169999500005	11526433	Bronze			2021-06-18	
J	Powell, JW				Powell, JW			Cerebral concussion: Causes, effects, and risks in sports	JOURNAL OF ATHLETIC TRAINING			English	Article						mild traumatic brain injury; head injury; injury prevention	TRAUMATIC BRAIN INJURY; HEAD-INJURY; GUIDELINES	Objective: To characterize the causes, effects, and risks associated with concussion in sports. Background. Concussion is an injury associated with sports and is most often identified with boxing, football, ice hockey, and the martial arts. In addition, recent research has shown that concussion occurs in many different sports. In the decade of the 1990s, concussion became a primary issue for discussion among the media, sports sponsors, sports medicine professionals, and athletes. Description: Concussion is an injury that results from a wide variety of mechanisms and has numerous signs and symptoms that are common to different types of injury. Continued improvement in prevention and management strategies for concussion requires a strong body of research from a variety of different disciplines. It is essential that research efforts focus on both prevention and management and that researchers and clinicians work closely toward their common goals. Conclusions/Recommendations: Until the research community is able to provide sound recommendations for the prevention and management of the concussion, the care of the injured player falls squarely on the clinician. It is important for sports medicine professionals to continue to stay up to date on the advances in understanding concussions and how to care individually for each player who sustains a concussion.	Michigan State Univ, E Lansing, MI 48824 USA	Powell, JW (corresponding author), Michigan State Univ, 40 IM Sports Circle, E Lansing, MI 48824 USA.						BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; CANTU RC, 1991, ADOLESC MED, V2, P141; *COL MED SOC, 1991, GUID MAN CONC SPORTS; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P2283, DOI 10.1001/jama.282.24.2283; Committee on Head Injury Nomenclature of Congress of Neurological Surgeons, 1966, CLIN NEUROSURG, V12, P386; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Gronwall D, 1986, J HEAD TRAUMA REHAB, V1, P53, DOI DOI 10.1097/00001199-198606000-00009; HADDON W, 1972, J TRAUM, V12, P193, DOI 10.1097/00005373-197203000-00002; Jordan B. D., 1991, P MILD BRAIN INJ SPO, P43; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P74, DOI DOI 10.1097/00001199-199309000-00009; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P581; Kelly JP, 1999, JAMA-J AM MED ASSOC, V282, P989, DOI 10.1001/jama.282.10.989; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lowrance WW, 1976, ACCEPTABLE RISK; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; *NAT ATHL TRAIN AS, 1994, P MILD BRAIN INJ SPO, P2; *NAT FED STAT HIGH, 1996, 1996 HIGH SCH ATHL P, P97; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001	21	35	38	0	15	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050			J ATHL TRAINING	J. Athl. Train.	JUL-SEP	2001	36	3					307	311					5	Sport Sciences	Sport Sciences	557NC	WOS:000175913800015	12937501				2021-06-18	
J	Richards, HK; Simac, S; Piechnik, S; Pickard, JD				Richards, HK; Simac, S; Piechnik, S; Pickard, JD			Uncoupling of cerebral blood flow and metabolism after cerebral contusion in the rat	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						head injury; LCBF; LCGU	TRAUMATIC BRAIN INJURY; AUTORADIOGRAPHIC DETERMINATION; GLUCOSE-UTILIZATION	Positron emission tomography scans of patients with head injuries often show discrete areas of increased F-18- fluorodeoxyglucose uptake ("hot spots") when performed hours to days after the initial ictus. Using quantitative autoradiographic methods, the authors have investigated whether cerebral blood flow and glucose metabolism are uncoupled 2 hours after controlled head injury in an animal model, and whether any "hot spots" are accompanied by changes in cerebral glucose concentration. Experiments were performed on 18 anesthetized, ventilated (1.5% halothane in 2:1 nitrous oxide:oxygen) Sprague-Dawley rats weighing 300 to 330 g. A burr hole was made over the left parietal cortex, and all animals received a piston impact on the intact dura (2 mm in diameter, 2.0 m/sec, 2 mm in depth). All animals remained anesthetized and ventilated for a further 2 hours, after which quantitative autoradiography was used to determine either (1) local cerebral blood flow (LCBF) using C-14-iodoantipyrine, (2) local cerebral glucose utilization (LCGU) using C-14-deoxyglucose, or (3) local cerebral glucose content (LCGC) using C-14-methylglucose. Local CBF, LCGU, and LCGC were measured in five regions adjacent to the contusion, and values then were normalized on the contralateral cortex. Normalized LCBF, LCGU, or LCGC varied in parallel in ipsilateral cortex (no change) and in the ischemic core of the contusion (reduced). However, there were marked changes in the patterns observed in the boundary zone (within 1 mm of the contusion). In all six rats used for LCGU measurement, there were discrete areas of high metabolism, whereas in all six rats used for LCBF measurement, flow was universally depressed in the boundary zone. Of the six rats used for LCGC determination, there was a discrete area of high signal in only one. The authors conclude that there are discrete areas of uncoupling of cerebral blood flow and metabolism after head injury within 2 hours of cerebral contusion in the rat that cannot be explained by changes in cerebral glucose content in the majority of animals.	Addenbrookes Hosp, Acad Neurosurg Unit, Cambridge CB2 2QQ, England; Addenbrookes Hosp, Cambridge Ctr Brain Repair, Cambridge CB2 2QQ, England	Richards, HK (corresponding author), Addenbrookes Hosp, Acad Neurosurg Unit, Box 167, Cambridge CB2 2QQ, England.			Piechnik, Stefan K./0000-0002-0268-5221			Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BERGSNEIDER M, 1999, J CEREB BLOOD FLO S1, V19, pS360; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859; GJEDDE A, 1983, J CEREBR BLOOD F MET, V3, P303, DOI 10.1038/jcbfm.1983.45; KELLY PAT, 1992, NEUROSCIENCE, V48, P417, DOI 10.1016/0306-4522(92)90501-R; MENON DK, 1999, J CEREB BLOOD FLO S1, V19, pS372; Moore AH, 2000, J CEREBR BLOOD F MET, V20, P1492, DOI 10.1097/00004647-200010000-00011; SAKURADA O, 1978, AM J PHYSIOL, V234, P59; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	10	35	35	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JUL	2001	21	7					779	781		10.1097/00004647-200107000-00002			3	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	448WV	WOS:000169653700002	11435789	Bronze			2021-06-18	
J	Pineda, JA; Aono, M; Sheng, HX; Lynch, J; Wellons, JC; Laskowitz, DT; Pearlstein, RD; Bowler, R; Crapo, J; Warner, DS				Pineda, JA; Aono, M; Sheng, HX; Lynch, J; Wellons, JC; Laskowitz, DT; Pearlstein, RD; Bowler, R; Crapo, J; Warner, DS			Extracellular superoxide dismutase overexpression improves behavioral outcome from closed head injury in the mouse	JOURNAL OF NEUROTRAUMA			English	Article						behavior; brain; extracellular superoxide dismutase; histology; mouse; trauma	FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN INJURY; HEPARIN-BINDING DOMAIN; HUMAN CELL-LINES; OXIDATIVE STRESS; TRANSGENIC MICE; NITRIC-OXIDE; INCREASED RESISTANCE; GENERATION; RAT	Oxidative stress is known to play an important role in the response of brain to traumatic insults. We tested the hypothesis that increased extracellular superoxide dismutase (EC-SOD) expression can reduce injury in a mouse model of closed head injury. Neurologic, cognitive, and histologic outcomes were compared between transgenic mice exhibiting a fivefold increase in EC-SOD activity and wild-type littermate controls. Severe or moderate transcranial impact was induced in anesthetized and physiologically controlled animals. After severe impact, transgenic mice had better neurological outcome at 24 hr postinjury (p = 0.038), Brain water content was increased, but there was no difference between groups. Moderate impact resulted in predominantly mild neurologic deficits in both groups at both 24 hr and 14 days postinjury, Morris water maze performance, testing cognitive function at 14-17 days after trauma, was better in EC-SOD overexpressors (p = 0.018), No differences were observed between groups for histologic damage in hippocampal CA1 and CA3, We conclude that EC-SOD has a beneficial effect on behavioral outcome after both severe and moderate closed head injury in mice. Because EC-SOD is believed to be predominantly located in the extracellular space, these data implicate an adverse effect of extracellular superoxide anion on outcome from closed head injury.	Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Div Pediat Crit Care, Durham, NC 27710 USA; Natl Jewish Med & Res Ctr, Dept Med, Denver, CO USA	Warner, DS (corresponding author), Duke Univ, Med Ctr, Dept Anesthesiol, Box 3094, Durham, NC 27710 USA.	warne002@mc.duke.edu	Bowler, Russell P/J-8283-2015; Pineda, Jose/W-2806-2019	Bowler, Russell P/0000-0003-4651-363X; 	NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [P01 HL 31992] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS38944] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [P01HL031992] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038944] Funding Source: NIH RePORTER		BIAGAS KV, 1992, J NEUROTRAUM, V9, P363, DOI 10.1089/neu.1992.9.363; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Crow JP, 1996, ADV EXP MED BIOL, V387, P147; Enghild JJ, 1999, J BIOL CHEM, V274, P14818, DOI 10.1074/jbc.274.21.14818; Fox GB, 1999, J NEUROTRAUM, V16, P377, DOI 10.1089/neu.1999.16.377; GARDNER PR, 1992, J BIOL CHEM, V267, P8757; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HALL ED, 1999, ANN NY ACAD SCI, V860, P462; Hannay HJ, 1999, J NEUROTRAUM, V16, P1103, DOI 10.1089/neu.1999.16.1103; HOFFSTEIN ST, 1985, INFLAMMATION, V9, P425, DOI 10.1007/BF00916342; KINNULA VL, 1995, LAB INVEST, V73, P3; Koelfen W, 1997, EUR J PEDIATR, V156, P230, DOI 10.1007/s004310050590; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; KONTOS HA, 1989, CHEM-BIOL INTERACT, V72, P229, DOI 10.1016/0009-2797(89)90001-X; Levin ED, 1998, BEHAV GENET, V28, P381, DOI 10.1023/A:1021673703129; Lipton SA, 1996, TRENDS PHARMACOL SCI, V17, P186, DOI 10.1016/0165-6147(96)20028-8; MARKLUND S, 1980, ACTA PHYSIOL SCAND, P19; MARKLUND SL, 1990, BIOCHEM J, V266, P213, DOI 10.1042/bj2660213; MARKLUND SL, 1984, J CLIN INVEST, V74, P1398, DOI 10.1172/JCI111550; McIntosh TK, 1996, LAB INVEST, V74, P315; Mikawa S, 1996, J NEUROSURG, V85, P885, DOI 10.3171/jns.1996.85.5.0885; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Murakami K, 1998, J NEUROSCI, V18, P205; Murakami K, 1997, STROKE, V28, P1797, DOI 10.1161/01.STR.28.9.1797; OURY TD, 1993, J BIOL CHEM, V268, P15394; Oury TD, 1999, BRAIN RES, V850, P96, DOI 10.1016/S0006-8993(99)02103-4; OURY TD, 1992, P NATL ACAD SCI USA, V89, P9715, DOI 10.1073/pnas.89.20.9715; SANDSTROM J, 1992, J BIOL CHEM, V267, P18205; Sankarapandi S, 1998, ARCH BIOCHEM BIOPHYS, V353, P312, DOI 10.1006/abbi.1998.0658; Sheng H, 1999, NEUROSCIENCE, V88, P185, DOI 10.1016/S0306-4522(98)00208-5; Sheng H, 2000, EXP NEUROL, V163, P392, DOI 10.1006/exnr.2000.7363; Sheng HX, 1999, NEUROSCI LETT, V267, P13, DOI 10.1016/S0304-3940(99)00316-X; Shohami E, 1999, J NEUROTRAUM, V16, P365, DOI 10.1089/neu.1999.16.365; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; SINSON G, 1995, J NEUROCHEM, V65, P2209; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Teasdale GM, 1998, NEUROSURGERY, V43, P723, DOI 10.1097/00006123-199810000-00001; Thiels E, 2000, J NEUROSCI, V20, P7631; YANG GY, 1994, STROKE, V25, P165, DOI 10.1161/01.STR.25.1.165	39	35	36	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2001	18	6					625	634		10.1089/089771501750291864			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	445ZQ	WOS:000169488800006	11437085				2021-06-18	
J	Schoenberger, NE; Shiflett, SC; Esty, ML; Ochs, L; Matheis, RJ				Schoenberger, NE; Shiflett, SC; Esty, ML; Ochs, L; Matheis, RJ			Flexyx neurotherapy system in the treatment of traumatic brain injury: An initial evaluation	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						alternative medicine; biofeedback; brain injuries; neurotherapy	EEG BIOFEEDBACK; DISORDERS	Objective: To conduct a preliminary experimental evaluation of the potential efficacy of Flexyx Neurotherapy System (FNS), an innovative electroencephalography (EEG)-based therapy used clinically in the treatment of traumatic brain injury (TBI). Participants: Twelve people aged 21 to 53 who had experienced mild to moderately severe closed head injury at least 12 months previously and who reported substantial cognitive difficulties after injury which interfered with their functioning. Design: Participants were randomly assigned to an immediate treatment group or a wait-list control group and received 25 sessions of FNS treatment. They were assessed at pretreatment, posttreatment, and follow-up with standardized neuropsychological and mood measures. Results: Comparison of the two groups on outcome measures indicated improvement after treatment for participants' reports of depression, fatigue, and other problematic symptoms, as well as for some measures of cognitive functioning. Most participants experienced meaningful improvement in occupational and social functioning. Conclusion: On the basis of these results, FNS appears to be a promising new therapy for TBI and merits more extensive evaluation.	Kessler Med Rehabil Res & Educ Corp, W Orange, NJ USA; Beth Israel Med Ctr, Ctr Hlth & Healing, New York, NY 10003 USA; Neurotherapy Ctr Washington, Chevy Chase, MD USA; Flexyx LLC, Walnut Creek, CA USA	Schoenberger, NE (corresponding author), POB 18082, Memphis, TN 38181 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U24HD032994] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U24 HD32994] Funding Source: Medline		Alhambra M. A., 1995, J NEUROTHERAPY, V1, P39; AYERS ME, 1987, NATL HEAD INJURY SYL, P380; BYERS AP, 1995, J NEUROTHERAPY, V1, P22, DOI DOI 10.1300/J184V01N01_; Carter J. L., 1993, TEXAS RES, V4, P65; Derogatis L.R, 1994, SYMPTOM CHECKLIST 90; DULEY JF, 1993, CLIN NEUROPSYCHOL, V7, P29, DOI DOI 10.1080/13854049308401885; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Hoffman D. A., 1995, J NEUROTHERAPY, V1, P14, DOI [10.1300/ J184v01n01_03, DOI 10.1300/J184V01N01_03]; Kumano H, 1996, BIOFEEDBACK SELF-REG, V21, P323, DOI 10.1007/BF02214432; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Linden M, 1996, BIOFEEDBACK SELF-REG, V21, P35, DOI 10.1007/BF02214148; LUBAR JF, 1995, BIOFEEDBACK SELF-REG, V20, P83, DOI 10.1007/BF01712768; LUBAR JF, 1991, BIOFEEDBACK SELF-REG, V16, P201, DOI 10.1007/BF01000016; LUBAR JO, 1984, BIOFEEDBACK SELF-REG, V9, P1, DOI 10.1007/BF00998842; McDowell I, 1996, MEASURING HLTH GUIDE; OCHS L, 1994, EEG DRIV STIM MILD H; OCHS L, 1994, EEG DRIV STIM HET HE; Packard RC, 1997, HEADACHE Q-CURR TREA, V8, P348; Patrick G. J., 2008, J NEUROTHERAPY, V1, P27, DOI [10.1300/J184v01n04_04, DOI 10.1300/J184V01N04_04]; Rossiter D.T.R., 1995, J NEUROTHERAPY, V1, P48, DOI DOI 10.1300/J184V01N01_; Shapiro D M, 1990, Arch Clin Neuropsychol, V5, P405, DOI 10.1016/0887-6177(90)90018-K; SMETS EMA, 1995, J PSYCHOSOM RES, V39, P315, DOI 10.1016/0022-3999(94)00125-O; Thatcher RW, 2000, CLIN ELECTROENCEPHAL, V31, P38, DOI 10.1177/155005940003100110; THATCHER RW, 1989, ELECTROEN CLIN NEURO, V73, P94, DOI 10.1016/0013-4694(89)90188-0; WALTER VJ, 1949, ELECTROEN CLIN NEURO, V1, P57, DOI 10.1016/0013-4694(49)90011-5; WILSON BA, 1990, TRAUMATIC BRAIN INJU, P121	26	35	35	0	7	ASPEN PUBL INC	GAITHERSBURG	200 ORCHARD RIDGE DR, STE 200, GAITHERSBURG, MD 20878 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUN	2001	16	3					260	274		10.1097/00001199-200106000-00005			15	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	442YY	WOS:000169313600005	11346448				2021-06-18	
J	Zwienenberg, M; Gong, QZ; Berman, RF; Muizelaar, JP; Lyeth, BG				Zwienenberg, M; Gong, QZ; Berman, RF; Muizelaar, JP; Lyeth, BG			The effect of groups II and III metabotropic glutamate receptor activation on neuronal injury in a rodent model of traumatic brain injury	NEUROSURGERY			English	Article						fluoro-jade; metabotropic glutamate receptor; rat; traumatic brain injury	AGONIST DCG-IV; FLUORO-JADE; CORTICAL-NEURONS; AMINO-ACIDS; RAT-BRAIN; DEGENERATION; HIPPOCAMPUS; SUBTYPES; POTENT; DEATH	OBJECTIVE: The role of metabotropic glutamate receptor activation after traumatic brain injury (TBI) is not well understood. In vitro studies suggest that activation of Groups II and III metabotropic glutamate receptors may provide some degree of neuroprotection and may be potential targets for the development of therapeutic strategies. Thus, we examined the effects of Group II and Group III selective agonists on neuronal degeneration after in vivo TBI. METHODS: fifty male Sprague-Dawley rats were subjected to lateral fluid percussion brain injury immediately followed by an intracranial injection of 2-(2',3')-dicarboxycyclopropylglycine (DCG-IV) (Group II) or (R,S)-4-phosphonophenylglycine (Group III) in the CA2 and CA3 areas of the hippocampus. DCG-IV was injected at doses of 20 fmol, 100 fmol, and 500 fmol, and (R,S)-4-phosphonophenylglycine was injected at 8 nmol, 40 nmol, and 200 nmol. Vehicle injection control groups were used for comparison with each drug group. All animals were killed 24 hours after TBI was induced. Four 50-mum brain sections were obtained from each animal and stained for degenerating neurons with the fluorochrome Fluoro-Jade. Two independent, blinded investigators counted the number of degenerating (Fluoro-Jade-positive) neurons in the CA2 and CA3 areas of the hippocampus of each brain section. RESULTS: Compared with vehicle, the 500-fmol dose of DCG-IV significantly reduced the number of Fluoro-Jade-positive degenerating neurons (P < 0.001). Lower doses of DCG-IV were associated with a decreased but not statistically significant number of Fluoro-Jade-positive neurons. In contrast, (R,S)-4-phosphonophenylglycine had no significant effect on the number of degenerating neurons. CONCLUSION: Administration of selective Group II metabotropic glutamate receptor agonists protects neurons against in vive TBI. These receptors may thus be a promising target for future neuroprotective drugs.	Univ Calif Davis, Dept Neurol Surg, Davis, CA 95616 USA	Lyeth, BG (corresponding author), Univ Calif Davis, Dept Neurol Surg, 1 Shields Ave, Davis, CA 95616 USA.			Lyeth, Bruce/0000-0003-4811-1474	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS029995] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 29995] Funding Source: Medline		Allen JW, 1999, J PHARMACOL EXP THER, V290, P112; Blumcke I, 1996, BRAIN RES, V736, P217; Brabet I, 1998, NEUROPHARMACOLOGY, V37, P1043, DOI 10.1016/S0028-3908(98)00091-4; Bradley SR, 1996, J NEUROSCI, V16, P2044; BRUNO V, 1995, EUR J NEUROSCI, V7, P1906, DOI 10.1111/j.1460-9568.1995.tb00712.x; BRUNO V, 1994, EUR J PHARMACOL, V256, P109, DOI 10.1016/0014-2999(94)90624-6; Buisson A, 1996, EUR J NEUROSCI, V8, P138, DOI 10.1111/j.1460-9568.1996.tb01174.x; BUISSON A, 1995, NEUROPHARMACOLOGY, V34, P1081, DOI 10.1016/0028-3908(95)00073-F; Bullock MR, 1999, NEUROSURGERY, V45, P207, DOI 10.1097/00006123-199908000-00001; Cartmell J, 1998, BRIT J PHARMACOL, V123, P497, DOI 10.1038/sj.bjp.0701647; Collins J G, 1990, Vital Health Stat 10, P1; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Faden AI, 1996, PHARMACOL TOXICOL, V78, P12, DOI 10.1111/j.1600-0773.1996.tb00173.x; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Faden AI, 1997, J NEUROTRAUM, V14, P885, DOI 10.1089/neu.1997.14.885; Gasparini F, 1999, J PHARMACOL EXP THER, V289, P1678; Glaum S. R., 1994, METABOTROPIC GLUTAMA, P147; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; HALLAM TM, 1999, J NEUROTRAUM, V16, P1000; HAYASHI Y, 1993, NATURE, V366, P687, DOI 10.1038/366687a0; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HICKS RR, 1994, BRAIN RES, V655, P91, DOI 10.1016/0006-8993(94)91601-2; Johnson BG, 1999, NEUROPHARMACOLOGY, V38, P1519, DOI 10.1016/S0028-3908(99)00053-2; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; Kokaia Z, 1998, EXP NEUROL, V154, P289, DOI 10.1006/exnr.1998.6888; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; Miyamoto M, 1997, NEUROSCIENCE, V77, P131, DOI 10.1016/S0306-4522(96)00442-3; Monn JA, 1997, J MED CHEM, V40, P528, DOI 10.1021/jm9606756; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; OHISHI H, 1995, J COMP NEUROL, V360, P555, DOI 10.1002/cne.903600402; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Petralia RS, 1996, NEUROSCIENCE, V71, P949, DOI 10.1016/0306-4522(95)00533-1; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; Poirier JL, 2000, NEUROSCIENCE, V97, P59, DOI 10.1016/S0306-4522(00)00026-9; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schmued LC, 2000, TOXICOL PATHOL, V28, P91, DOI 10.1177/019262330002800111; Schoepp DD, 1999, NEUROPHARMACOLOGY, V38, P1431, DOI 10.1016/S0028-3908(99)00092-1; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; TROMBLEY PQ, 1992, J NEUROSCI, V12, P2043; WILSCH VW, 1994, EUR J PHARMACOL, V262, P287, DOI 10.1016/0014-2999(94)90743-9	46	35	36	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	MAY	2001	48	5					1119	1126		10.1097/00006123-200105000-00031			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	424GB	WOS:000168223000078	11334279				2021-06-18	
J	Bara, BG; Cutica, I; Tirassa, M				Bara, BG; Cutica, I; Tirassa, M			Neuropragmatics: Extralinguistic communication after closed head injury	BRAIN AND LANGUAGE			English	Article						neuropragmatics; closed head injury; intentional communication; extralinguistic communication	LANGUAGE; DISCOURSE; ABILITY	This work is concerned with the decay of communicative abilities after head trauma. A protocol composed of 16 videotaped scenes was devised in order to investigate the comprehension of several types of communicative actions realized with extralinguistic means, like pointing or clapping. The protocol was administered to 30 closed-head-injured individuals. The results showed that performance decreased from simple standard acts to complex standard acts, deceits, and ironies. The subjects' performance was worse with the scenes reproducing failing, rather than successful, communicative actions. The results are compared with those we previously obtained with a linguistic protocol. A theory of the cognitive processes underlying intentional communication is outlined and used to explain the results. (C) 2001 Academic Press.	Univ Turin, Ctr Cognit Sci, I-10123 Turin, Italy	Bara, BG (corresponding author), Univ Turin, Ctr Cognit Sci, Via Lagrange 3, I-10123 Turin, Italy.	bara@psych.unito.it		CUTICA, ILARIA/0000-0003-2749-0719			AIRENTI G, 1993, COGNITIVE SCI, V17, P197, DOI 10.1016/0364-0213(93)90011-V; AIRENTI G, 1993, J PRAGMATICS, V20, P303, DOI 10.1016/0378-2166(93)90055-T; Austin John L, 1962, DO THINGS WORDS, Vsecond; Bara BG, 2000, BRAIN COGNITION, V43, P21; Bara BG, 1997, BRAIN LANG, V59, P7, DOI 10.1006/brln.1997.1812; Bara BG, 1999, PROCEEDINGS OF THE TWENTY FIRST ANNUAL CONFERENCE OF THE COGNITIVE SCIENCE SOCIETY, P55; BARA BG, 2000, IN PRESS BRAIN LANGU; Bara BG, 1999, P 3 EUR C COGN SCI E; Caplan D., 1992, LANGUAGE STRUCTURE P; Clark H. H., 1996, USING LANGUAGE; COLOMBETTI M, 1993, ARTIF INTELL, V62, P341, DOI 10.1016/0004-3702(93)90082-M; Ehrlich J, 1989, Brain Inj, V3, P193, DOI 10.3109/02699058909004552; FEYEREISEN P, 1982, BRAIN LANG, V16, P191, DOI 10.1016/0093-934X(82)90083-9; Foldi N.S., 1983, LANGUAGE FUNCTIONS B; Grice H.P, 1989, STUDIES WAY WORDS; HOLLAND AL, 1982, J SPEECH HEAR DISORD, V47, P50, DOI 10.1044/jshd.4701.50; JOANETTE Y, 1991, DISCOURSE ABILITY BR; MCDONALD S, 1993, COGNITIVE NEUROPSYCH, V10, P297, DOI 10.1080/02643299308253466; MCDONALD S, 1992, APPL PSYCHOLINGUIST, V13, P295, DOI 10.1017/S0142716400005658; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; PAGE EB, 1963, J AM STAT ASSOC, V58, P216, DOI 10.2307/2282965; PETITTO LA, 1987, COGNITION, V27, P1, DOI 10.1016/0010-0277(87)90034-5; Poizner H., 1987, WHAT HANDS REVEAL BR; REITER R, 1980, ARTIF INTELL, V13, P81, DOI 10.1016/0004-3702(80)90014-4; Searle J., 1979, EXPRESSION MEANING; Searle J. R., 1969, SPEECH ACTS ESSAY PH, V626; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SHERRATT SM, 1990, APHASIOLOGY, V4, P539, DOI 10.1080/02687039008248506; Sperber D., 1986, RELEVANCE COMMUNICAT; STEMMER B, 1994, BRAIN LANG, V46, P565, DOI 10.1006/brln.1994.1031; Tirassa M, 1999, BRAIN LANG, V68, P419, DOI 10.1006/brln.1999.2121; TIRASSA M, 1997, P 2 EUR C COGN SCI E, P103; WYCKOFF LH, 1984, THESIS U FLORIDA	33	35	35	1	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0093-934X	1090-2155		BRAIN LANG	Brain Lang.	APR	2001	77	1					72	94		10.1006/brln.2000.2430			23	Audiology & Speech-Language Pathology; Linguistics; Neurosciences; Psychology, Experimental	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Psychology	416BP	WOS:000167760100006	11247657	Green Accepted			2021-06-18	
J	Morris, KC				Morris, KC			Psychological distress in carers of head injured individuals: the provision of written information	BRAIN INJURY			English	Article							TRAUMATIC BRAIN INJURY; FAMILY NEEDS; FOLLOW-UP; RELATIVES; CAREGIVERS; QUESTIONNAIRE; HEALTH; STRESS; SCALE	Since the early 1970s, researchers have expressed concern about the emotional well- being of family members after traumatic brain injury (TBI), and it is now widely acknowledged that TBI has longterm effects on the patient and relatives alike. Researchers have found a substantial number of relatives caring for head injured patients to show significant levels of anxiety and depression, and have emphasized the need for information for relatives on the prognosis of head injury. There are, however, very few studies that have investigated the usefulness of giving literature to relatives. Using a longitudinal, mixed variable, within- and between- subject design, the present study investigated the effect of an information booklet on levels of distress in a group of 34 carers of individuals with TBI. These results are discussed, and the proposal made that an information booklet such as the one used in the present study should become an integral part of the discharge procedure for relatives of individuals who have sustained a head injury.	Tayside Area Clin Psychol Dept, Dundee, Scotland	Morris, KC (corresponding author), Tayside Area Clin Psychol Dept, Wedderburn House, Dundee, Scotland.						ALLEN K, 1994, REHABIL PSYCHOL, V39, P29, DOI 10.1037/h0080313; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; BRUMFITT S, 1994, APHASIOLOGY, V8, P583, DOI 10.1080/02687039408248683; Eisner J, 1989, Brain Inj, V3, P79, DOI 10.3109/02699058909008078; ELLIS DA, 1979, BRIT MED J, V1, P456, DOI 10.1136/bmj.1.6161.456; Frosch S, 1997, BRAIN INJURY, V11, P891; GENTLEMAN D, 1996, EUR J NEUROL S2, V3, P52; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; GRONWALL D, 1997, HEAD INJURY FACTS GU; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; Junque C, 1997, BRAIN INJURY, V11, P251, DOI 10.1080/026990597123557; KREUTZER JS, 1994, J HEAD TRAUMA REHAB, V9, P104, DOI 10.1097/00001199-199409000-00009; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; LEAF LE, 1993, BRAIN INJURY, V7, P543, DOI 10.3109/02699059309008182; Leathem J, 1996, BRAIN INJURY, V10, P27; LEY P, 1990, COMMUNICATING PATIEN; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; Livingston M G, 1987, Brain Inj, V1, P33, DOI 10.3109/02699058709034442; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; LIVINGSTON MG, 1986, BRIT MED J, V293, P742, DOI 10.1136/bmj.293.6549.742; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MCKINLAY WW, 1990, QUESTIONNAIRE RELATI; MERRITT KL, 1990, PSYCHOL REP, V67, P129, DOI 10.2466/PR0.67.5.129-130; NOVACK TA, 1991, J HEAD TRAUMA REHAB, V6, P69, DOI DOI 10.1097/00001199-199112000-00014; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; ODDY M, 1995, TRAUMATIC BRAIN INJU, P167; Panting A., 1972, REHABILITATION, V38, P33; PEARLIN LI, 1990, GERONTOLOGIST, V30, P583, DOI 10.1093/geront/30.5.583; PONSFORD J, 1996, TRAUMATIC BRAIN INJU; ROSE FD, 1996, BRAIN INJURY IMPROVE; Sander AM, 1997, BRAIN INJURY, V11, P235, DOI 10.1080/026990597123548; Serio CD, 1997, BRAIN INJURY, V11, P1, DOI 10.1080/026990597123764; SERIO CD, 1995, J HEAD TRAUMA REHAB, V10, P32, DOI 10.1097/00001199-199504000-00005; SINGER GHS, 1994, J HEAD TRAUMA REHAB, V9, P38, DOI DOI 10.1097/00001199-199412000-00006; TEASDALE G, 1974, LANCET, V2, P81; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Toner H, 1987, BRIT J CLIN SOCIAL P, V5, P24; TURVEY T, 1985, NEW DEV CLIN PSYCHOL, P234; WALLACE LM, 1986, BRIT J CLIN PSYCHOL, V25, P111, DOI 10.1111/j.2044-8260.1986.tb00679.x; Wiles R, 1998, J ADV NURS, V28, P794, DOI 10.1046/j.1365-2648.1998.00709.x; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	42	35	37	1	5	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	MAR	2001	15	3					239	254		10.1080/02699050010004068			16	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	407ZM	WOS:000167302100004	11260772				2021-06-18	
J	Feeney, TJ; Ylvisaker, M; Rosen, BH; Greene, P				Feeney, TJ; Ylvisaker, M; Rosen, BH; Greene, P			Community supports for individuals with challenging behavior after brain injury: An analysis of the New York State Behavioral Resource Project	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						behavioral challenges; behavior disorders; behavior impairment; cost-benefit analysis; HCBS-TBI Waiver; positive person-centered behavioral supports		Objective: To articulate a framework for supporting individuals with behavioral challenges following brain injury. to describe a state-funded clinical intervention program established to provide community support to individuals with challenging behaviors following brain injury using such a framework, to present data from which it can be concluded that such a program is cost-effective. and to offer policy recommendations. Design: Retrospective analysis of cost data and living arrangements for individuals with behavioral challenges served for a period of 3-4 years through the New York State Home and Community-Based Services Traumatic Brain Injury (HCBS-TBI) Waiver program and the State Behavioral Resource Project. Subjects: 80 individuals with TBI and severe behavioral challenges that included criminal behavior, physical threats, assault and physical aggression, sexually inappropriate behavior. substance abuse, refusal to participate in intervention programs, and psychiatric disturbances, all of whom were at least 2 years postinjury ((X) over bar = 7.33 years postinjury). Results: The majority of individuals (82% of the 1996 cohort; 89% of the 1997 cohort) with challenging behaviors were living successfully in their home communities 3-4 years after the initiation of behavioral supports. In addition, the costs of serving these individuals decreased in the first year of community integration and for that last year that a cost analysis was completed. Conclusions: Many individuals with behavioral impairments can be supported successfully in community settings, so long as those supports are flexibly implemented to meet the changing needs of those individuals. Moreover, even with intensive supports, it is cost-effective to serve this population in the community.	Wildwood Traumat Brain Injury Behav Resource Proj, Schenectady, NY USA; Coll St Rose, Albany, NY USA; New York State Dept Hlth, Off Continuing Care, Delmar, NY USA	Feeney, TJ (corresponding author), Wildwood Inst, 219 Liberty St, Schenectady, NY 12305 USA.	tfeeney@wildwood.edu					ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; Alderman N, 1996, NEUROPSYCHOL REHABIL, V6, P161, DOI 10.1080/713755505; Anderson, 1989, TRANSFER COGNITIVE S; BAER D, 1981, PLAN GEN; BASSUK EL, 1984, AM J PSYCHIAT, V141, P1546; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; Carr E.G., 1999, POSITIVE BEHAV SUPPO; Damasio A., 1994, DESCARTESERROR EMOTI; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Fairweather G.W, 1969, COMMUNITY LIFE MENTA; FEENEY T, 1997, STUDENTS ACQUIRED BR, P229; FEENEY TJ, 1995, J HEAD TRAUMA REHAB, V10, P67; GARCIA J, 1994, REHABIL ED, V8, P259; HAMMELL KRW, 1994, INT J REHABIL RES, V17, P319; JACOBS HE, 1993, BEHAV ANAL GUIDELINE; Levine B, 2000, MEMORY, CONSCIOUSNESS, AND THE BRAIN, P200; Levine B, 1999, NEUROCASE, V5, P263, DOI 10.1080/13554799908402731; LIVINGSTON M, 1988, J HEAD TRAUMA REHAB, V3, P6, DOI DOI 10.1097/00001199-198812000-00004; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; MITCHLEY N, 1996, CLIN REHABIL, V10, P3; ROLLS ET, 1994, J NEUROL NEUROSUR PS, V57, P1518, DOI 10.1136/jnnp.57.12.1518; SIERT L, 2000, BRAIN INJ SOURCE, V4, P24; Thomsen I V, 1987, Brain Inj, V1, P131, DOI 10.3109/02699058709034452; Vygotsky L. S., 1978, MIND SOC DEV HIGHER; Ylvisaker M, 2000, APHASIOLOGY, V14, P407, DOI 10.1080/026870300401432; Ylvisaker M., 1999, CLIN PRACTICE MANAGE, P117; Ylvisaker M., 1998, TRAUMATIC BRAIN INJU, P429; Ylvisaker M., 1998, COLLABORATIVE BRAIN; YLVISAKER M, IN PRESS LANGUAGE IN; Ylvisaker M, 2000, BRAIN IMPAIR, V1, P12, DOI DOI 10.1375/BRIM.1.1.12; YLVISAKER M, 1998, TRAUMATIC BRAIN INJU, P271; Ylvisaker Mark, 1996, Seminars in Speech and Language, V17, P217, DOI 10.1055/s-2008-1064100	32	35	38	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	FEB	2001	16	1					61	75		10.1097/00001199-200102000-00008			15	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	403ZC	WOS:000167072100010	11277851				2021-06-18	
J	Togher, L				Togher, L			Discourse sampling in the 21st century	JOURNAL OF COMMUNICATION DISORDERS			English	Article						discourse; neurogenic communication disorder; linguistics; brain damage; functional therapy	CLOSED HEAD-INJURY; NARRATIVE DISCOURSE; INFORMATION; CHILDREN; ABILITY	This paper examines the importance of evaluating discourse in individuals with a neurogenic language disorder. Discourse analysis is acknowledged as an important tool for speech-language pathologists, although it is often not the assessment tool of choice due to its apparent time-consuming nature and the overwhelming number of options available. The wide range of analyses available to clinicians such as the number of T-units and total words produced or Pragmatic Protocol checklists make it difficult to choose assessment measures. Even more difficult is the decision of where to direct treatment efforts. This paper aims to show that there are a number of levels of discourse analysis available to clinicians and that it is possible to sample a number of different genres in a clinical setting. The significance of the communication partner's contribution is discussed, particularly with regard to the limitations of the therapeutic interaction and the need to assess clients with a range of communication partners. The discourse opportunities we make available to people with communication problems will influence what is possible for them. To achieve this, the benefits of a theory of linguistic analysis, namely, Systemic Functional Linguistics (SFL) [Halliday, M. A. K. (1994). An introduction to functional grammar (2nd ed.). London: Edward Arnold.] will be explored. (C) 2001 Elsevier Science Inc. All rights reserved.	Univ Sydney, Fac Hlth Sci, Sch Commun Sci & Disorders, Sydney, NSW 2141, Australia	Togher, L (corresponding author), Univ Sydney, Fac Hlth Sci, Sch Commun Sci & Disorders, POB 170, Sydney, NSW 2141, Australia.	l.tougher@cchs.usyd.edu.au	Togher, Leanne/AAC-7083-2019	Togher, Leanne/0000-0002-4518-6748			AMRTIN J, 2000, EVALUATION TEXT, P142; Armstrong E., 1993, APHASIA TREATMENT WO, P263; Atkinson J. M., 1984, STRUCTURES SOCIAL AC; Berry M., 1981, STUDIES DISCOURSE AN, P120; Bloom R. L., 1994, DISCOURSE ANAL APPL; Boles L, 1998, APHASIOLOGY, V12, P547, DOI 10.1080/02687039808249557; BROWNELL HH, 1993, NARRATIVE DISCOURSE; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; Cherney L.R., 1998, ANAL DISCOURSE COMMU; COELHO C A, 1991, Brain Injury, V5, P381, DOI 10.3109/02699059109008111; COELHO CA, 1995, BRAIN INJURY, V9, P471, DOI 10.3109/02699059509008206; EGGINS S, 1997, ANAL CASUAL CONSERVA; Eggins S, 1994, INTRO SYSTEMIC FUNCT; Ehrlich J, 1989, Brain Inj, V3, P193, DOI 10.3109/02699058909004552; Enderby P, 1997, THERAPY OUTCOME MEAS; Fairclough N., 1992, DISCOURSE SOCIAL CHA; FERGUSON A, 1994, APHASIOLOGY, V8, P143, DOI 10.1080/02687039408248647; FERGUSON A, 1998, COMMUNICATION; FERGUSON A, 1998, SPEECH PATH AUSTR NA; FRATTALI C, 1997, MEASURING OUTCOMES S; GALLARD L, UNPUB MAKING MOST ME; GEROT L, 1994, MAKING SENSE FUNCTIO; GLOSSER G, 1991, BRAIN LANG, V40, P67, DOI 10.1016/0093-934X(91)90117-J; Halliday M., 1994, INTRO FUNCTIONAL GRA, V3rd; Halliday M. A. K., 1985, INTRO FUNCTIONAL GRA; HARTLEY L L, 1991, Brain Injury, V5, P267, DOI 10.3109/02699059109008097; HYMES Dell, 1974, FDN SOCIOLINGUISTICS; Joanette Y., 1990, DISCOURSE ABILITY BR; LILES BZ, 1989, J SPEECH HEAR DISORD, V54, P356, DOI 10.1044/jshd.5403.356; LILES BZ, 1995, J SPEECH HEAR RES, V38, P415, DOI 10.1044/jshr.3802.415; Martin J. R., 1992, ENGLISH TEXT SYSTEM; Martin James R., 1997, WORKING FUNCTIONAL G; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; MENTIS M, 1991, J SPEECH HEAR RES, V34, P583, DOI 10.1044/jshr.3403.583; MILTON SB, 1984, CLIN APHASIOLOGY C P, P114; MORTENSEN L, 1992, J NEUROLINGUIST, V7, P309, DOI 10.1016/0911-6044(92)90021-N; Penn C, 1988, Brain Inj, V2, P3, DOI 10.3109/02699058809150928; Perkins M. R., 1995, CASE STUDIES CLIN LI, P293; Poynton C., 1985, LANGUAGE GENDER MAKI; Prigatano G. P., 1985, LANG SCI, V7, P217, DOI [10.1016/S0388-0001(85)80020-6, DOI 10.1016/S0388-0001(85)80020-6]; PRUTTING CA, 1987, J SPEECH HEAR DISORD, V52, P105, DOI 10.1044/jshd.5202.105; ROTHERY J, 1994, EXPLORING LIT SCH EN; SLADE D, 1994, AUSTR REV APPL LIN S, P47; Thompson G., 1996, INTRO FUNCTIONAL GRA; THOMSON J, 1997, SPEECH PATH AUSTR NA; Togher L, 1997, BRAIN INJURY, V11, P169, DOI 10.1080/026990597123629; Togher L, 1999, APHASIOLOGY, V13, P709, DOI 10.1080/026870399401821; Togher L, 1998, APHASIOLOGY, V12, P755, DOI 10.1080/02687039808249571; Togher L, 1997, APHASIOLOGY, V11, P491, DOI 10.1080/02687039708248486; Togher L, 1996, DISABIL REHABIL, V18, P559, DOI 10.3109/09638289609166317; Togher L, 2000, APHASIOLOGY, V14, P365, DOI 10.1080/026870300401414; TOGHER L, 1999, BRAIN DAM B, P113; ULATOWSKA HK, 1981, BRAIN LANG, V13, P345, DOI 10.1016/0093-934X(81)90100-0; VENTOLA E, 1979, J PRAGMATICS, V3, P267, DOI 10.1016/0378-2166(79)90034-1; Ventola E., 1987, STRUCTURE SOCIAL INT; WECKERT C, UNPUB MAKING MOST ME; Wirz SL, 1990, REVISED EDINBURGH FU	58	35	36	0	16	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0021-9924	1873-7994		J COMMUN DISORD	J. Commun. Disord.	JAN-APR	2001	34	1-2					131	150		10.1016/S0021-9924(00)00045-9			20	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	416PZ	WOS:000167790500009	11322564				2021-06-18	
J	Kaipio, ML; Cheour, M; Ceponiene, R; Ohman, J; Alku, P; Naatanen, R				Kaipio, ML; Cheour, M; Ceponiene, R; Ohman, J; Alku, P; Naatanen, R			Increased distractibility in closed head injury as revealed by event-related potentials	NEUROREPORT			English	Article						attention; audition; closed head injury; distractibility; event-related brain potential (ERP); mismatch negativity (MMN); P3a	PHONEME REPRESENTATIONS; AUDITORY-CORTEX; FRONTAL-CORTEX; BRAIN; STIMULI; LESIONS	The present study demonstrates that event-related potentials (ERPs) may be used to reveal increased distractibility as a physiologically measurable condition after chronic closed head injury (CHI). ERPs were recorded from 17 chronic CHI subjects and from 17 healthy age-matched controls. Auditory stimuli consisted of variants of vowel /(o) over bar/ (standards) occasionally replaced by an /(e) over bar/ vowel (deviant). Subjects were instructed to ignore auditory stimuli while watching a silent movie. In the constant-standard condition, the vowel /(o) over bar/ served as the standard and vowel /(e) over bar/ as the deviant. In the roving-standard condition, four variants of the vowel /(o) over bar/ were randomly used as standards in the same stimulus block. None of the stimuli were prototypes in the subjects' mother tongues. Deviant stimuli elicited significant MMNs in both groups in both conditions, which were significantly smaller in the roving-standard than in the constant-standard condition. CHI victims showed significantly larger P3a amplitudes than controls in both conditions, apparently reflecting their enhanced involuntary sifting of attention and thus their increased distractibility. NeuroReport 11:1463-1468 (C) 2000 Lippincott Williams & Wilkins.	Univ Helsinki, Dept Psychol, Cognit Brain Res Unit, FIN-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, Dept Neurosurg, SF-00260 Helsinki, Finland; Aalto Univ, Acoust Lab, FIN-02015 Helsinki, Finland	Kaipio, ML (corresponding author), Univ Helsinki, Dept Psychol, Cognit Brain Res Unit, POB 13, FIN-00014 Helsinki, Finland.		Hari, Riitta K/J-1880-2012; Alku, Paavo/E-2400-2012	Hari, Riitta K/0000-0002-3142-2703; Alku, Paavo/0000-0002-8173-9418; Ohman, Juha/0000-0002-6592-1367			Alain C, 1998, BRAIN RES, V812, P23, DOI 10.1016/S0006-8993(98)00851-8; Alho K, 1998, PSYCHOPHYSIOLOGY, V35, P211, DOI 10.1017/S004857729800211X; ALHO K, 1994, ELECTROEN CLIN NEURO, V91, P353, DOI 10.1016/0013-4694(94)00173-1; Alku P, 1999, CLIN NEUROPHYSIOL, V110, P1329, DOI 10.1016/S1388-2457(99)00088-7; BAUDENA P, 1995, ELECTROEN CLIN NEURO, V94, P251, DOI 10.1016/0013-4694(95)98476-O; Campbell K. B., 1995, HDB NEUROPSYCHOLOGY, V10, P269; Cheour M, 1998, NAT NEUROSCI, V1, P351, DOI 10.1038/1561; Damasio A., 1994, DESCARTESERROR EMOTI; GIARD MH, 1990, PSYCHOPHYSIOLOGY, V27, P627, DOI 10.1111/j.1469-8986.1990.tb03184.x; Kaipio ML, 1999, NEUROREPORT, V10, P2125, DOI 10.1097/00001756-199907130-00024; KNIGHT RT, 1984, ELECTROEN CLIN NEURO, V59, P9, DOI 10.1016/0168-5597(84)90016-9; Levanen S, 1996, CEREB CORTEX, V6, P288, DOI 10.1093/cercor/6.2.288; LEVIN HS, 1990, NEUROBEHAVIOURAL SEQUELAE OF TRAUMATIC BRAIN INJURY, P89; Naatanen R, 1997, NATURE, V385, P432, DOI 10.1038/385432a0; NAATANEN R, 1995, HDB NEUROPSYCHOLOGY, V10, P75; Naatanen R., 1992, ATTENTION BRAIN FUNC; NELSON C, 1993, J EXP NEUROPSYCHOLOG, V19, P909; PAAVILAINEN P, 1991, ELECTROEN CLIN NEURO, V78, P466, DOI 10.1016/0013-4694(91)90064-B; Pearl GS, 1998, CLIN LAB MED, V18, P39; Picton T.W., 1988, HUMAN EVENT RELATED, VVolume 1, P361; Scherg M, 1989, J Cogn Neurosci, V1, P336, DOI 10.1162/jocn.1989.1.4.336; Solbakk AK, 1999, PSYCHOPHYSIOLOGY, V36, P802; Van Zomeren A. H., 1984, CLOSED HEAD INJURY P, P74; VANZOMEREN AH, 1994, CLIN NEUROPSYCHOLOGY, P63; Zampolini M, 1997, EUR J NEUROL, V4, P246, DOI 10.1111/j.1468-1331.1997.tb00343.x	25	35	35	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0959-4965	1473-558X		NEUROREPORT	Neuroreport	MAY 15	2000	11	7					1463	1468					6	Neurosciences	Neurosciences & Neurology	316WN	WOS:000087191200022	10841358				2021-06-18	
J	Stout, CE; Yorkston, KM; Pimentel, JI				Stout, CE; Yorkston, KM; Pimentel, JI			Discourse production following mild, moderate, and severe traumatic brain injury: A comparison of two tasks	JOURNAL OF MEDICAL SPEECH-LANGUAGE PATHOLOGY			English	Article							ADULTS; DEFICITS	The purpose of this study was to examine discourse production in adults with traumatic brain injury (TBI) using a picture description and a story retelling task. Our questions were: (1) do individuals with TBI perform differently from educationally compatible controls, and (2) what is the relationship between severity of initial injury and performance on these tasks? Ninety-four individuals with mild, moderate, or severe TBI and 38 control subjects participated. All subjects with TBI had been referred to speech pathology for treatment, but none had yet returned to his or her former employment. The samples were analyzed on a variety of measures that reflect quantity and efficiency of production. Results suggested some task differences that may be associated with varying cognitive demands. For the picture description task, subjects with TBI spoke more slowly, communicated content at a slower rate, and produced longer mazes than did control subjects. On the other hand, stories produced by individuals with TBI were shorter and contained less content than those produced by controls. There was Little relationship between the severity of the initial injury and performance on a variety of measures of spoken discourse. Implications are discussed for the diagnostic, prognostic, and treatment challenges in this population.	Oklahoma State Univ, Dept Commun Sci & Disorders, Stillwater, OK 74078 USA; Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; Eastern Washington Univ, Dept Commun Disorders, Cheney, WA 99004 USA	Stout, CE (corresponding author), Oklahoma State Univ, Dept Commun Sci & Disorders, 120 Hanner Hall, Stillwater, OK 74078 USA.						Biddle KR, 1996, J COMMUN DISORD, V29, P447, DOI 10.1016/0021-9924(95)00038-0; CHERNEY LR, 1998, ANAL DISCOURSE COMMU, P1; COELHO CA, 1991, ARCH PHYS MED REHAB, V72, P465; COELHO CA, 1995, APHASIOLOGY, V9, P409, DOI 10.1080/02687039508248707; EHRLICH JS, 1988, J COMMUN DISORD, V21, P1, DOI 10.1016/0021-9924(88)90006-8; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; Goodglass H., 1983, ASSESSMENT APHASIA R; Hagen C, 1984, LANGUAGE DISORDERS A, P245; Hagen C., 1979, LEVELS COGNITIVE FUN; HARTLEY L L, 1991, Brain Injury, V5, P267, DOI 10.3109/02699059109008097; Hinchliffe FJ, 1998, BRAIN INJURY, V12, P109, DOI 10.1080/026990598122746; HUNT KW, 1970, MONOGR SOC RES CHILD, V35, P1; LILES BZ, 1989, J SPEECH HEAR DISORD, V54, P356, DOI 10.1044/jshd.5403.356; Loban W. D., 1976, LANGUAGE DEV KINDERG; MACLAY H, 1959, WORD, V15, P19, DOI 10.1080/00437956.1959.11659682; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; REEVES J, 1985, FABLES AESOP, P30; SNOW P, 1995, APHASIOLOGY, V9, P365, DOI 10.1080/02687039508248210; Snow P, 1997, BRAIN INJURY, V11, P409; UOMOTO JM, 1990, COMMUNICATION DISORD; YORKSTON KM, 1980, J SPEECH HEAR DISORD, V45, P27, DOI 10.1044/jshd.4501.27	21	35	35	1	10	SINGULAR PUBLISHING GROUP INC	SAN DIEGO	401 WEST A ST, STE 325, SAN DIEGO, CA 92101-7904 USA	1065-1438			J MED SPEECH-LANG PA	J. Med. Speech-Lang. Pathol.	MAR	2000	8	1					15	25					11	Audiology & Speech-Language Pathology; Clinical Neurology	Audiology & Speech-Language Pathology; Neurosciences & Neurology	290LH	WOS:000085677400003					2021-06-18	
J	Pepe, JL; Barba, CA				Pepe, JL; Barba, CA			The metabolic response to acute traumatic brain injury and implications for nutritional support	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						alimentation; metabolic response; nutrition; severe brain injury	SEVERE HEAD-INJURY; PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; TOTAL PARENTERAL-NUTRITION; CRITICALLY ILL PATIENTS; ENTERAL NUTRITION; PLACEMENT; GASTROPARESIS; COMPLICATIONS; CISAPRIDE; GLUCOSE	An overview of the metabolic response to acute traumatic brain injury is presented. The consequences of hypermetabolism hypercatabolism, and an altered immune function are discussed. Once a person with acute traumatic brain injury; develops this hyperdynamic state, the resultant excessive protein breakdown ensues. This can lead to malnutrition. The feeding methods used to prevent malnutrition are discussed, along with the proper alimentation to provide to diminish the hyperdynamic state and improve immune function.	St Francis Hosp & Med Ctr, Hartford, CT 06105 USA; Univ Connecticut, Hartford, CT 06112 USA	Pepe, JL (corresponding author), St Francis Hosp & Med Ctr, 114 Woodland St, Hartford, CT 06105 USA.						Akkersdijk WL, 1998, INJURY, V29, P11, DOI 10.1016/S0020-1383(97)00108-3; ALEXANDER JW, 1980, ANN SURG, V192, P505, DOI 10.1097/00000658-198010000-00009; Altmayer T, 1996, ARCH PHYS MED REHAB, V77, P1093, DOI 10.1016/S0003-9993(96)90075-1; ANTONACCI A, 1984, INFECT SURG, V3, P590; Berger WL, 1996, GASTROINTEST ENDOSC, V43, P63, DOI 10.1016/S0016-5107(06)80085-4; BIVINS BA, 1986, J TRAUMA, V26, P980, DOI 10.1097/00005373-198611000-00004; BORZOTTA AP, 1994, J TRAUMA, V37, P459, DOI 10.1097/00005373-199409000-00022; CHANDRA RK, 1979, ACTA PAEDIATR SCAND, V68, P137, DOI 10.1111/j.1651-2227.1979.tb04975.x; CHIOLERO R, 1989, JPEN-PARENTER ENTER, V13, P5, DOI 10.1177/014860718901300105; CHIOLERO RL, 1989, CRIT CARE MED, V17, P328, DOI 10.1097/00003246-198904000-00006; Choudhry U, 1996, GASTROINTEST ENDOSC, V44, P164, DOI 10.1016/S0016-5107(96)70134-7; CLIFTON CL, 1991, NEUROSURGERY, V8, P10; CLIFTON GL, 1986, J NEUROSURG, V64, P895, DOI 10.3171/jns.1986.64.6.0895; DAMELIO LF, 1994, AM SURGEON, V60, P180; DEUTSCHMAN CS, 1987, J NEUROSURG, V66, P388, DOI 10.3171/jns.1987.66.3.0388; DEUTSCHMAN CS, 1986, J NEUROSURG, V64, P89, DOI 10.3171/jns.1986.64.1.0089; DISARIO JA, 1990, GASTROINTEST ENDOSC, V36, P257, DOI 10.1016/S0016-5107(90)71018-8; DREW JH, 1947, J NEUROSURG, V4, P7, DOI 10.3171/jns.1947.4.1.0007; FORD E G, 1987, Current Surgery, V44, P311; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; HADLEY MN, 1986, NEUROSURGERY, V19, P367, DOI 10.1097/00006123-198609000-00006; HAIDER W, 1975, EUR J INTEN CARE MED, V1, P19, DOI 10.1007/BF00735865; Harbrecht BG, 1998, AM J SURG, V176, P311, DOI 10.1016/S0002-9610(98)00206-2; HELLING TS, 1988, J TRAUMA, V28, P1575, DOI 10.1097/00005373-198811000-00009; INOUE M, 1991, J CEREBR BLOOD F MET, V11, P242, DOI 10.1038/jcbfm.1991.56; JACKSON MD, 1989, ARCH PHYS MED REHAB, V70, P553; KADAKIA SC, 1992, AM J SURG, V64, P114; KIRBY DF, 1991, JPEN-PARENTER ENTER, V15, P298, DOI 10.1177/0148607191015003298; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; KUDSK KA, 1994, ARCH SURG-CHICAGO, V129, P66; Langmore SE, 1998, DYSPHAGIA, V13, P69, DOI 10.1007/PL00009559; MARIE C, 1991, CEREBROVAS BRAIN MET, V3, P29; McCarter TL, 1998, AM J GASTROENTEROL, V93, P419, DOI 10.1111/j.1572-0241.1998.00419.x; MCCLAIN CJ, 1986, J NEUROSURG, V64, P224, DOI 10.3171/jns.1986.64.2.0224; MILLER C H, 1991, Neurological Research, V13, P117; MOORE FA, 1989, J TRAUMA, V29, P916, DOI 10.1097/00005373-198907000-00003; NORTON JA, 1988, J NEUROSURG, V68, P62, DOI 10.3171/jns.1988.68.1.0062; Ott L, 1990, Nutr Clin Pract, V5, P68, DOI 10.1177/011542659000500268; OTT L, 1989, NUTRITION, V5, P75; PETERSEN SR, 1993, J TRAUMA, V34, P653, DOI 10.1097/00005373-199305000-00007; PETERSON VM, 1988, SURGERY, V104, P199; QUATTROCCHI K B, 1990, Journal of Neurotrauma, V7, P77, DOI 10.1089/neu.1990.7.77; QUATTROCCHI KB, 1991, J NEUROSURG, V75, P766, DOI 10.3171/jns.1991.75.5.0766; Rabeneck L, 1996, J GEN INTERN MED, V11, P287, DOI 10.1007/BF02598270; RAPP RP, 1983, J NEUROSURG, V58, P906, DOI 10.3171/jns.1983.58.6.0906; Reed RL, 1998, J TRAUMA, V45, P388, DOI 10.1097/00005373-199808000-00034; ROBERTSON CS, 1991, J LAB CLIN MED, V118, P205; ROBERTSON CS, 1984, NEUROSURGERY, V15, P307, DOI 10.1227/00006123-198409000-00003; ROBERTSON CS, 1985, J NEUROSURG, V63, P714, DOI 10.3171/jns.1985.63.5.0714; SAXE JM, 1994, J TRAUMA, V37, P581, DOI 10.1097/00005373-199410000-00010; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; SIEBER FE, 1992, CRIT CARE MED, V20, P104, DOI 10.1097/00003246-199201000-00022; Spain DA, 1995, J TRAUMA, V39, P1100, DOI 10.1097/00005373-199512000-00015; SPAPEN HD, 1995, CRIT CARE MED, V23, P481, DOI 10.1097/00003246-199503000-00011; STRONG RM, 1992, JPEN-PARENTER ENTER, V16, P59, DOI 10.1177/014860719201600159; SUNDERLAND PM, 1992, NEUROSURGERY, V31, P246, DOI 10.1227/00006123-199208000-00009; TWYMAN D, 1985, JPEN-PARENTER ENTER, V9, P679, DOI 10.1177/0148607185009006679; VANWAY CW, 1991, SURG CLIN N AM, V71, P537; Weekes Elizabeth, 1996, Journal of Parenteral and Enteral Nutrition, V20, P31, DOI 10.1177/014860719602000131; WEISSMAN C, 1986, ANESTHESIOLOGY, V64, P673, DOI 10.1097/00000542-198606000-00001; WOLF DC, 1992, AM J GASTROENTEROL, V87, P1278; Yorkston KM, 1989, J HEAD TRAUMA REHAB, V4, P1; Young B, 1991, Neurosurg Clin N Am, V2, P301; Young B, 1996, J NEUROTRAUM, V13, P25, DOI 10.1089/neu.1996.13.25; YOUNG B, 1987, J NEUROSURG, V67, P76, DOI 10.3171/jns.1987.67.1.0076; YOUNG B, 1992, J NEUROTRAUM, V9, pS375; YOUNG B, 1987, J NEUROSURG, V67, P668, DOI 10.3171/jns.1987.67.5.0668; YOUNG B, 1989, ANN SURG, V210, P466, DOI 10.1097/00000658-198910000-00007	68	35	36	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	OCT	1999	14	5					462	474		10.1097/00001199-199910000-00007			13	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	245MW	WOS:000083113600007	10653942				2021-06-18	
J	Hamilton, BB; Deutsch, A; Russell, C; Fiedler, RC; Granger, CV				Hamilton, BB; Deutsch, A; Russell, C; Fiedler, RC; Granger, CV			Relation of disability costs to function: Spinal cord injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							TRAUMATIC BRAIN INJURY; INDEPENDENCE MEASURE FIM; ASSESSMENT SCALES; UNITED-STATES; AGREEMENT; STROKE; PERFORMANCE; RELIABILITY; PREVALENCE; STABILITY	Objective: This study evaluated the validity of the Functional Independence Measure (FIM(TM) instrument) in predicting (1) the number of minutes of daily assistance provided, (2) the cost of durable goods currently used, and (3) the number of paid helper hours provided daily to persons with spinal cord injury living in the community. Design: A cross-sectional study. Subjects: One hundred nine persons with spinal cord injury who were a median 6 years postdischarge from initial medical rehabilitation. Results: A significant inverse linear relationship was observed between FIM scores and the square root values of the three cost-related measures. The FIM-18 and the FIM motor scores were the best single predictors of the square root of minutes of assistance (paid and/or unpaid) per day, explaining 85% of variance. The FIM motor measure was the best single predictor of square root of cost of durable goods, explaining 29% of variance. The Self-Care, FIM motor, and FIM-ls scores equally predicted square root of hours of paid help per day, explaining 58% of variance. Conclusion: The findings indicate FIM-related scores pre diet the amount of assistance needed and certain costs for persons with spinal cord injury disability. (C) 1999 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	SUNY Buffalo, Dept Rehabil Med, Ctr Funct Assessment Res, Buffalo, NY 14214 USA; Duke Univ, Med Ctr, Div Geriatr, Durham, NC USA; Youville Coll, Div Rehabil Sci, Buffalo, NY USA	Granger, CV (corresponding author), SUNY Buffalo, Dept Rehabil Med, Ctr Funct Assessment Res, 232 Parker Hall,3435 Main St, Buffalo, NY 14214 USA.						BERKOWITZ M, EC CONSEQUENCES TRAU; Chau N, 1994, Disabil Rehabil, V16, P63; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P828, DOI 10.1016/S0003-9993(97)90195-7; DISCALA C, 1992, AM J PHYS MED REHAB, V71, P145, DOI 10.1097/00002060-199206000-00004; DISLER PB, 1993, ARCH PHYS MED REHAB, V74, P139; DODDS TA, 1993, ARCH PHYS MED REHAB, V74, P531, DOI 10.1016/0003-9993(93)90119-U; Fiedler R.C., 1996, FUNCTIONAL EVALUATIO, P75; FISHER WP, 1995, ARCH PHYS MED REHAB, V76, P113, DOI 10.1016/S0003-9993(95)80020-4; FORTINSKY RH, 1981, MED CARE, V19, P489, DOI 10.1097/00005650-198105000-00002; Fricke J., 1993, AUST OCCUP THER J, V40, P7; Fuhrer MJ, 1987, REHABILITATION OUTCO, P137; Go Bette K., 1995, P21; GRANGER CV, 1993, ARCH PHYS MED REHAB, V74, P133; GRANGER CV, 1990, ARCH PHYS MED REHAB, V71, P870; GRANGER CV, 1993, AM J PHYS MED REHAB, V72, P84, DOI 10.1097/00002060-199304000-00005; GRANGER CV, 1995, AM J PHYS MED REHAB, V74, P107; Granger CV, 1986, TOP GERIATR REHABIL, V1, P59, DOI 10.1097/00013614-198604000-00007; Hall KM., 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199308020-00008, 10.1097/00001199-199308020-00008]; HAMILTON BB, 1994, SCAND J REHABIL MED, V26, P115; HAMILTON BB, 1997, H133G90157 STAT U NY; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; Heinemann AW, 1994, TOP STROKE REHABIL, V1, P1; Hoffman C, 1996, JAMA-J AM MED ASSOC, V276, P1473, DOI 10.1001/jama.276.18.1473; Jaworski DM, 1994, REHABIL NURS RES, V3, P141; KIDD D, 1995, DISABIL REHABIL, V17, P10, DOI 10.3109/09638289509166622; LAPLANTE MP, 1996, DISABILITY STAT REHA; LASFARGUES JE, 1995, PARAPLEGIA, V33, P62, DOI 10.1038/sc.1995.16; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; Manton KG, 1997, P NATL ACAD SCI USA, V94, P2593, DOI 10.1073/pnas.94.6.2593; MCNEIL JM, 1993, P7033 US BUR CENS; OTTENBACHER KJ, 1994, ARCH PHYS MED REHAB, V75, P1297; ROTH E, 1990, CLIN REHABIL, V4, P277, DOI DOI 10.1177/026921559000400405; SEGAL ME, 1993, PARAPLEGIA, V31, P622, DOI 10.1038/sc.1993.101; Segal ME, 1996, AM J PHYS MED REHAB, V75, P208, DOI 10.1097/00002060-199605000-00013; SEGAL ME, 1994, STROKE, V25, P2391, DOI 10.1161/01.STR.25.12.2391; Smith PM, 1996, ARCH PHYS MED REHAB, V77, P431, DOI 10.1016/S0003-9993(96)90029-5; Stineman MG, 1996, AM J PHYS MED REHAB, V75, P68, DOI 10.1097/00002060-199601000-00018; WATSON AH, 1995, AM J OCCUP THER, V49, P229, DOI 10.5014/ajot.49.3.229; World Health Organization, 1980, INT CLASS IMP DIS HA	39	35	35	0	8	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	1999	80	4					385	391		10.1016/S0003-9993(99)90274-5			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	184TG	WOS:000079629100005	10206599				2021-06-18	
J	Stancin, T; Taylor, HG; Thompson, GH; Wade, S; Drotar, D; Yeates, KO				Stancin, T; Taylor, HG; Thompson, GH; Wade, S; Drotar, D; Yeates, KO			Acute psychosocial impact of pediatric orthopedic trauma with and without accompanying brain injuries	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	Annual Meeting of the Society-for-Behavioral-Pediatrics	SEP   18, 1995	PHILADELPHIA, PENNSYLVANIA	Soc Behavioral Pediat		psychosocial; injuries; fractures; family	ACQUIRED LIMB DEFICIENCIES; FAMILY ASSESSMENT DEVICE; HEAD-INJURY; SEVERITY SCALE; CHILDREN; RELIABILITY; MORBIDITY; VALIDITY	Background: The acute psychosocial effects of orthopedic injuries on children and their families are poorly understood. Previous studies have relied on retrospective reports or failed to take into account accompanying brain injuries. The purpose of the present study was to examine prospectively the psychosocial impact of pediatric orthopedic traumatic fractures with and without accompanying brain injuries. Methods: Participants were 108 children 6 to 12 years old with orthopedic injuries requiring hospitalization: group 1 (n = 80) had fractures only, group 2 (n = 28) also had moderate or severe brain injuries. Using standardized measures and parent interviews, we obtained preinjury estimates of family functioning and child behavior problems and postinjury measures of parental distress, family stresses, and child behavior. Results: Parents reported significant clinical distress (35% in group 1, 57% in group 2), family burdens (group 2 > group 1), and child behavioral changes (41% in group 1, 89% in group 2), Multiple regression analyses indicated that preinjury family status and brain injuries predicted postinjury parental and family distress. Conclusion: Pediatric orthopedic injuries have greater social effects on children with accompanying brain injuries and poorer preinjury family functioning.	Case Western Reserve Univ, Sch Med, Cleveland, OH USA; Ohio State Univ, Sch Med, Columbus, OH 43210 USA	Stancin, T (corresponding author), Case Western Reserve Univ, Metrohlth Med Ctr, Dept Pediat, 2500 MetroHealth Dr, Cleveland, OH 44109 USA.		Stancin, Terry/L-7993-2019; Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892			Achenbach T. M., 1991, MANUAL CHILD BEHAV C; BASSON MD, 1991, J TRAUMA, V31, P1363, DOI 10.1097/00005373-199110000-00008; Bishop DS, 1988, J HEAD TRAUMA REHAB, V3, P16; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; BYLES J, 1988, FAM PROCESS, V27, P97, DOI 10.1111/j.1545-5300.1988.00097.x; Christoffel KK, 1996, PEDIATRICS, V97, P33; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; DISCALA C, 1991, ARCH PHYS MED REHAB, V72, P662; EISEN M, 1980, RAND CORP PUBL; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; FLETCHER JM, 1988, HDB PEDIATRIC PSYCHO, P258; FREEMAN HE, 1986, HLTH AFFAIRS     SPR, P6; GALLAGHER SS, 1984, AM J PUBLIC HEALTH, V74, P1340, DOI 10.2105/AJPH.74.12.1340; GREENSPAN AI, 1994, PEDIATRICS, V94, P425; HARRIS BH, 1989, J PEDIATR SURG, V24, P103, DOI 10.1016/S0022-3468(89)80311-2; HENKER FO, 1979, PSYCHOSOMATICS, V20, P812; KASHANI JH, 1981, BRIT J PSYCHIAT, V138, P21, DOI 10.1192/bjp.138.1.21; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; LANGLEY J, 1983, Journal of Pediatric Psychology, V8, P181, DOI 10.1093/jpepsy/8.2.181; LODER RT, 1995, J PEDIATR ORTHOPED, V15, P41, DOI 10.1097/01241398-199501000-00010; MARCUS IM, 1986, TRAUMA CHILDREN, P245; MAYER T, 1980, J PEDIATR SURG, V15, P719, DOI 10.1016/S0022-3468(80)80271-5; MAYER T, 1984, J TRAUMA, V24, P31, DOI 10.1097/00005373-198401000-00004; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; MOOS R, 1988, LIFE STRESSORS SOCIA; *NAT CTR HLTH STAT, 1980, NAT HLTH SURV SER, V10, P139; PRUGH DG, 1980, ADV BEHAV PEDIAT, V1, P181; RIVARA JB, 1994, PEDIATR ANN, V23, P38, DOI 10.3928/0090-4481-19940101-09; Shindi J, 1983, Int J Soc Psychiatry, V29, P292, DOI 10.1177/002076408302900409; Stein R, 1985, PACTS PAPERS AECOM T; STEVENS G, 1981, SOC SCI RES, V10, P364, DOI 10.1016/0049-089X(81)90011-9; STEVENSONHINDE J, 1995, FAM PROCESS, V34, P337, DOI 10.1111/j.1545-5300.1995.00337.x; Suhr M A, 1986, Adv Psychosom Med, V16, P31; Taylor H.G., 1995, TRAUMATIC HEAD INJUR, P188; THOMPSON GH, 1983, J PEDIATR ORTHOPED, V3, P443, DOI 10.1097/01241398-198309000-00005; VARNI JW, 1989, J DEV BEHAV PEDIATR, V10, P13; VARNI JW, 1989, J PEDIATR PSYCHOL, V14, P515, DOI 10.1093/jpepsy/14.4.515; VARNI JW, 1989, PEDIATRICS, V84, P320; WADE S, 1995, J PEDIATR PSYCHOL, V20, P737, DOI 10.1093/jpepsy/20.6.737; Wade SL, 1996, J LEARN DISABIL, V29, P652, DOI 10.1177/002221949602900609	41	35	35	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	1998	45	6					1031	1038		10.1097/00005373-199812000-00010			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	151DF	WOS:000077704900009	9867044				2021-06-18	
J	McGuire, LM; Burright, RG; Williams, R; Donovick, PJ				McGuire, LM; Burright, RG; Williams, R; Donovick, PJ			Prevalence of traumatic brain injury in psychiatric and non-psychiatric subjects	BRAIN INJURY			English	Article							HEAD-INJURY	Traumatic brain injury (TBI) and its sequelae may impact the expression and treatment of psychiatric disorders. The prevalence of TBI in psychiatric patients is unknown and investigations in the general population are limited. This study examined the prevalence of TBI with loss of consciousness in mental health setting patients (n = 231), general hospital and university staff and students (n = 534) and non-psychiatric medical clinical patients (n = 59). The Traumatic Brain Injury Questionnaire was used to assess TBI. A greater percentage of psychiatric patients reported TBI than medical patients or staff and students. Traumatic brain injuries were typically mild-moderate, medical assistance was frequently sought and use of alcohol and drugs was reported in a minority of TBI incidents. Multiple injuries were most common in psychiatric patients. The percentage of medical patients and staff and students reporting TBI was similar to previous research. The greater percentage of psychiatric patients reporting TBI indicates the need to assess TBI in this population. The role of TBI in the emergence, expression and treatment outcome of psychiatric disorders and the risk factors that leave psychiatric patients vulnerable to TBI should be further examined.	SUNY Binghamton, Dept Psychol, Environm Neuropsychol Lab, Binghamton, NY 13902 USA; SUNY Coll Potsdam, Dept Psychol, Potsdam, Germany; United Hlth Serv Hosp, Div Behav Hlth, Neuropsychol Unit, Johnson City, NY USA	McGuire, LM (corresponding author), SUNY Binghamton, Dept Psychol, Environm Neuropsychol Lab, Binghamton, NY 13902 USA.						Burg JS, 1996, J CLIN PSYCHOL MED S, V3, P243, DOI 10.1007/BF01993910; CROVITZ HF, 1992, CORTEX, V28, P509, DOI 10.1016/S0010-9452(13)80160-8; HOLMES CB, 1991, PERCEPT MOTOR SKILL, V73, P497, DOI 10.2466/PMS.73.5.497-498; Kraus Jess F., 1994, P3; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; SEGALOWITZ SJ, 1995, J LEARN DISABIL, V28, P309, DOI 10.1177/002221949502800507; Silver JM., 1994, NEUROPSYCHIATRY TRAU; SOLOMON DA, 1992, NEUROPSYCHOL REV, V3, P249, DOI 10.1007/BF01109050; Sparadeo F. R., 1990, J HEAD TRAUMA REHAB, V5, P1, DOI DOI 10.1097/00001199-199009000-00004	9	35	36	0	1	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAR	1998	12	3					207	214		10.1080/026990598122683			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	ZA456	WOS:000072365100004	9547951				2021-06-18	
J	Hoane, MR; Irish, SL; Marks, BB; Barth, TM				Hoane, MR; Irish, SL; Marks, BB; Barth, TM			Preoperative regimens of magnesium facilitate recovery of function and prevent subcortical atrophy following lesions of the rat sensorimotor cortex	BRAIN RESEARCH BULLETIN			English	Article						sensorimotor function; secondary brain injury; glutamate neurotoxicity; striatum; magnesium chloride; behavior	CEREBRAL-ARTERY OCCLUSION; TRAUMATIC BRAIN INJURY; MOUSE CENTRAL NEURONS; GLUTAMATE NEUROTOXICITY; CORTICAL DAMAGE; RESPONSES; ISCHEMIA; CULTURE; DISEASE; MOTOR	Following brain injury, there is a reduction of intra- and extracellular levels of magnesium (Mg++), which may contribute to the severity of the lesion-induced behavioral impairments. Injections of magnesium prior to or after brain injury attenuate these behavioral impairments. The present study extends these findings by manipulating the number of injections and the time period between the injections and the time of injury, Rats were given either two or five daily preoperative injections of MgCl2 (1 mmol/kg, ip), or saline (1 ml/kg, ip) with the final injection given 24 h prior to electrolytic lesions of the somatic sensorimotor cortex (SMC). Following SMC lesions the rats exhibited contralateral deficits in forelimb placing and locomotor placing. Rats treated with either two or five preoperative injections of MgCl2 showed a reduction in the initial magnitude of the contralateral deficits and an accelerated rate of recovery compared to saline-treated rats. In addition, analysis of striatal atrophy revealed that MgCl2 treatment prevented atrophy in the ipsilateral posterior striatum compared to rats treated with saline. These data suggest that preoperative injections of MgCl2 produce facilitation of sensorimotor recovery and reduce subcortical atrophy. Moreover, to observe the beneficial effects of MgCl2, the timing of injections need not be tied to the period immediately around the brain injury. The present data may indicate that daily supplements of magnesium may partially protect against some of the deleterious effects of brain injury. (C) 1998 Elsevier Science Inc.	Texas Christian Univ, Dept Psychol, Ft Worth, TX 76129 USA; Texas Christian Univ, Program Neurosci, Ft Worth, TX 76129 USA	Hoane, MR (corresponding author), Cytotherapeutics, 701 George Washington Highway, Lincoln, RI 02865 USA.			Hoane, Michael/0000-0001-7779-2657			Aikawa J.W., 1981, MAGNESIUM ITS BIOL S, P21; ALTURA B M, 1985, Magnesium, V4, P245; ASCHER P, 1988, J PHYSIOL-LONDON, V399, P247; Bara M, 1984, MAGNESIUM, V3, P212; BARKER ES, 1959, J CLIN INVEST, V38, P1733, DOI 10.1172/JCI103952; BARTH TM, 1990, STROKE, V21, P153; BARTH TM, 1990, J NEUROSCI, V10, P3449; BARTH TM, 1990, BEHAV BRAIN RES, V39, P73, DOI 10.1016/0166-4328(90)90122-U; BASHIR Y, 1993, AM J CARDIOL, V72, P1156, DOI 10.1016/0002-9149(93)90986-M; CHOI DW, 1987, J NEUROSCI, V7, P369; CHOI DW, 1987, J NEUROSCI, V7, P357; DONOGHUE JP, 1982, J COMP NEUROL, V212, P76, DOI 10.1002/cne.902120106; EBEL H, 1980, J CLIN CHEM CLIN BIO, V18, P257; Feldman Z, 1996, J NEUROSURG, V85, P131, DOI 10.3171/jns.1996.85.1.0131; GARFINKEL L, 1985, Magnesium, V4, P60; GLOBUS MYT, 1988, J NEUROCHEM, V51, P1455, DOI 10.1111/j.1471-4159.1988.tb01111.x; GUNTHER T, 1986, MAGNESIUM, V5, P53; HALL RD, 1974, BRAIN RES, V66, P23, DOI 10.1016/0006-8993(74)90076-6; HARA H, 1993, BRAIN RES, V618, P251, DOI 10.1016/0006-8993(93)91273-U; Hoane M. R., 1995, Society for Neuroscience Abstracts, V21, P172; Hoane M. R., 1994, Society for Neuroscience Abstracts, V20, P1430; Hoane MR, 1997, RESTOR NEUROL NEUROS, V11, P71, DOI 10.3233/RNN-1997-111208; HOANE MR, 1996, J NEUROTRAUM, V13, P610; HOFFMAN SW, 1994, J NEUROTRAUM, V11, P417, DOI 10.1089/neu.1994.11.417; IZUMI Y, 1991, J CEREBR BLOOD F MET, V11, P1025, DOI 10.1038/jcbfm.1991.170; JONES TA, 1992, BEHAV BRAIN RES, V51, P1, DOI 10.1016/S0166-4328(05)80306-7; Lasserre Bertrand, 1994, Magnesium Research, V7, P145; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; SAPONJIC RM, 1995, RESTOR NEUROL NEUROS, V8, P205, DOI 10.3233/RNN-1995-8406; SCHALLERT T, 1990, STROKE, V21, P143; Sjostrom I, 1994, SOC NEUR ABST, V20, P181; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Tramer MR, 1996, ANESTHESIOLOGY, V84, P340, DOI 10.1097/00000542-199602000-00011; TSUDA T, 1991, NEUROSCIENCE, V44, P335, DOI 10.1016/0306-4522(91)90058-V; VACANTI FX, 1984, STROKE, V15, P695, DOI 10.1161/01.STR.15.4.695; Vink R, 1990, Magnes Res, V3, P163; VINK R, 1987, BIOCHEM BIOPH RES CO, V149, P594, DOI 10.1016/0006-291X(87)90409-8; VINK R, 1988, J BIOL CHEM, V263, P757; WATKINS JC, 1981, ANNU REV PHARMACOL, V21, P165, DOI 10.1146/annurev.pa.21.040181.001121	43	35	35	0	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0361-9230	1873-2747		BRAIN RES BULL	Brain Res. Bull.		1998	45	1					45	51		10.1016/S0361-9230(97)00288-8			7	Neurosciences	Neurosciences & Neurology	YM060	WOS:000071023900008	9434201				2021-06-18	
J	Wicky, S; Capasso, P; Meuli, R; Fischer, A; von Segesser, L; Schnyder, P				Wicky, S; Capasso, P; Meuli, R; Fischer, A; von Segesser, L; Schnyder, P			Spiral CT aortography: an efficient technique for the diagnosis of traumatic aortic injury	EUROPEAN RADIOLOGY			English	Article						thoracic aorta; trauma; aorta rupture; spiral CT; angiography	OSSEOUS PINCH; HELICAL CT; RUPTURE; CHEST; MECHANISM	The objective of this study was to assess the efficiency of spiral CT (SCT) aortography for diagnosing acute aortic lesions in blunt thoracic trauma patients. Between October 1992 and June 1997, 487 SCT scans of the chest were performed on blunt thoracic trauma patients. To assess aortic injury, the following SCT criteria were considered: hemomediastinum, peri-aortic hematoma, irregular aspect of the aortic wall, aortic pseudodiverticulum, intimal flap and traumatic dissection. Aortic injury was diagnosed on 14 SCT examinations (2.9 %), five of the patients having had an additional digital aortography that confirmed the aortic trauma. Twelve subjects underwent surgical repair of the thoracic aorta, which in all but one case confirmed the aortic injury. Two patients died before surgery from severe brain lesions. The aortic blunt lesions were confirmed at autopsy. According to the follow-up of the other 473 patients, we are aware of no false-negative SCT examination. Our Limited series shows a sensitivity of 100% and specificity of 99.8 % of SCT aortography in the diagnosis of aortic injury. It is concluded that SCT aortagraphy is an accurate diagnostic method for the assessment of aortic injury in blunt thoracic trauma patients.	CHU Vaudois, Dept Radiol & Intervent Radiol, CH-1011 Lausanne, Switzerland; CHU Vaudois, Dept Cardiovasc Surg, CH-1011 Lausanne, Switzerland	Schnyder, P (corresponding author), CHU Vaudois, Dept Radiol & Intervent Radiol, CH-1011 Lausanne, Switzerland.						BESSON A, 1983, COLOR ATLAS CHEST TR, V2, P127; COHEN AM, 1992, AM J ROENTGENOL, V159, P271, DOI 10.2214/ajr.159.2.1632338; CRASS JR, 1990, RADIOLOGY, V176, P645, DOI 10.1148/radiology.176.3.2389022; ECKERT WG, 1977, FORENSIC MED STUDY T, V2, P853; FISHER RG, 1994, AM J ROENTGENOL, V162, P1047, DOI 10.2214/ajr.162.5.8165979; Gavant ML, 1996, AM J ROENTGENOL, V166, P955, DOI 10.2214/ajr.166.4.8610581; GAVANT ML, 1995, RADIOLOGY, V197, P125, DOI 10.1148/radiology.197.1.7568809; MILLER FB, 1989, SURGERY, V106, P596; MIRVIS SE, 1987, RADIOLOGY, V163, P487, DOI 10.1148/radiology.163.2.3562831; MIRVIS SE, 1994, EMERG RADIOL, V1, P24; MIRVIS SE, 1997, EUR RADIOL S, V7, pS278; MORGAN PW, 1992, RADIOLOGY, V182, P661, DOI 10.1148/radiology.182.3.1535878; PARMLEY LF, 1958, CIRCULATION, V17, P1086, DOI 10.1161/01.CIR.17.6.1086; RAPTOPOULOS V, 1992, RADIOLOGY, V182, P667, DOI 10.1148/radiology.182.3.1535879; SANDOR F, 1967, THORAX, V22, P43, DOI 10.1136/thx.22.1.43; Schnyder P, 1996, J THORAC IMAG, V11, P39, DOI 10.1097/00005382-199601110-00003; ZEHNDER MAX A., 1956, ANGIOLOGY, V7, P252, DOI 10.1177/000331975600700306	17	35	35	0	1	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0938-7994			EUR RADIOL	Eur. Radiol.		1998	8	5					828	833		10.1007/s003300050480			6	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	ZT363	WOS:000074077600022	9601973				2021-06-18	
J	Eng, DL; Lee, YL; Lal, PG				Eng, DL; Lee, YL; Lal, PG			Expression of glutamate uptake transporters after dibutyryl cyclic AMP differentiation and traumatic injury in cultured astrocytes	BRAIN RESEARCH			English	Article						cell injury; astrocyte; glutamate; uptake; transporter	AMINO-ACID TRANSPORTER; RAT-BRAIN; HIGH-AFFINITY; NEUROTRANSMITTER TRANSPORTERS; ASPARTATE TRANSPORTER; MESSENGER-RNA; CLONING; CELLS	Our findings indicate that differentiation of primary astrocytes by dibutyryl cyclic adenosine monophosphate (dBcAMP) and scratch injury together resulted in increased glutamate transporter gene expression. Confluent primary cultures were prepared from cerebral cortex of normal new born rat pups. The primary cultures were then divided into four groups each: control and scratch-injured, and dBcAMP-treated control and scratch-injured cultures. Total RNA was extracted at 0, 1, 2, 4, and 7 days after injury. Expression of the electrogenic glutamate transporters, GLAST, GLT-1, and EAAC-1, was quantitated by the reverse transcriptase-polymerase chain reaction method (RT-PCR) and slot blot hybridization followed by densitometric scanning. Triplicate cultures were analyzed for each time-point. Our studies indicate that all these astrocyte cultures expressed the two glial transporters, GLAST and GLT-1, while none of the cultures expressed the neuronal transporter, EAAC-1. The expression of the two transporters in the dBcAMP-treated primary cultures were markedly increased from the non-treated cultures. The dBcAMP-treated cultures had 2- to 4-times increase in levels of GLAST and GLT-1-mRNA expression both before and after scratch injury, as compared to untreated non-injured and injured primary cultures. All of the cultures expressed GLAST in greater proportion than GLT-1. (C) 1997 Elsevier Science B.V.	Vet Affairs Palo Alto Hlth Care Syst, Med Res Serv, Palo Alto, CA 94304 USA	Eng, DL (corresponding author), Vet Affairs Palo Alto Hlth Care Syst, Med Res Serv, 3801 Miranda Ave, Palo Alto, CA 94304 USA.						AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; ARRIZA JL, 1993, J BIOL CHEM, V268, P15329; BALCAR VJ, 1972, J NEUROCHEM, V19, P2657, DOI 10.1111/j.1471-4159.1972.tb01325.x; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK JA, 1993, BIOESSAYS, V15, P323, DOI 10.1002/bies.950150506; CLEMENTS JD, 1992, SCIENCE, V258, P1498, DOI 10.1126/science.1359647; DREJER J, 1982, EXP BRAIN RES, V47, P259; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; FLOTT B, 1991, GLIA, V4, P293, DOI 10.1002/glia.440040307; KAKU DA, 1993, SCIENCE, V260, P1516, DOI 10.1126/science.8389056; KANAI Y, 1993, TRENDS NEUROSCI, V16, P365, DOI 10.1016/0166-2236(93)90094-3; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KONDO K, 1995, NEUROSCI LETT, V188, P140, DOI 10.1016/0304-3940(95)11408-O; LEHRE KP, 1995, J NEUROSCI, V15, P1835; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MENNERICK S, 1994, NATURE, V368, P59, DOI 10.1038/368059a0; MURPHY GM, 1993, J NEUROSCI RES, V35, P643, DOI 10.1002/jnr.490350607; OTORI Y, 1994, MOL BRAIN RES, V27, P310, DOI 10.1016/0169-328X(94)90014-0; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; RONG H, 1993, BRAIN RES, V618, P346, DOI 10.1016/0006-8993(93)91289-5; ROSENBERG PA, 1992, J NEUROSCI, V12, P56; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; ROTHSTEIN JD, 1994, NEURON, V13, P713, DOI 10.1016/0896-6273(94)90038-8; SCHOUSBOE A, 1977, J NEUROCHEM, V29, P999, DOI 10.1111/j.1471-4159.1977.tb06503.x; SHER PK, 1990, GLIA, V3, P350, DOI 10.1002/glia.440030506; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; TONG G, 1994, NEURON, V13, P1195, DOI 10.1016/0896-6273(94)90057-4; YU ACH, 1993, J NEUROSCI RES, V34, P295, DOI 10.1002/jnr.490340306; YU ACH, 1991, J NEUROSCI RES, V30, P72, DOI 10.1002/jnr.490300109; Zerangue N, 1996, NATURE, V383, P634, DOI 10.1038/383634a0	31	35	36	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	DEC 5	1997	778	1					215	221		10.1016/S0006-8993(97)01093-7			7	Neurosciences	Neurosciences & Neurology	YP069	WOS:000071238100024	9462894				2021-06-18	
J	Viano, D; vonHolst, H; Gordon, E				Viano, D; vonHolst, H; Gordon, E			Serious brain injury from traffic-related causes: Priorities for primary prevention	ACCIDENT ANALYSIS AND PREVENTION			English	Article						disability; epidemiology; head injury; traffic crashes; traumatic brain injury	HEAD-INJURY	This study evaluated the incidence and outcome of serious brain injury from traffic-related causes in 695 patients admitted to the Department of Neurosurgery at Karolinska Hospital during 1981-1992. A total of 37.3% of patients were car occupants, 28.1% pedestrians, 12.9% bicyclists, 12.2% car-bicycle/car-moped and 9.5% motorcycle riders. The dominating injury was brain contusion (61.6%) verified with computerized tomography. The level of consciousness was evaluated by the Glasgow Coma Scale (GCS) and outcome by the Glasgow Outcome Scale (GOS) at discharge and 6-36 months thereafter. The final outcome was 67.5% good recovery (GOS 4-5), 11.5% severely disabled (GOS 2-3) and 21.0% GOS 1 or brain dead. Patients with GOS <4 (32.5%) were severely disabled and motivate priorities for injury prevention. Car occupants represent 40.7% of the total, followed by pedestrians at 33.6% and bicyclists at 18.2%. Much remains to be done in the primary prevention of disabling brain injury to car occupants and pedestrians. In order to achieve a more-effective primary prevention, future research should be directed toward biomechanical aspects of brain contusion as a dominating brain injury. (C) 1997 Elsevier Science Ltd.	KAROLINSKA HOSP,DEPT NEUROSURG,S-10401 STOCKHOLM,SWEDEN; ROYAL INST TECHNOL,DEPT LIGHTWEIGHT STRUCT,S-10044 STOCKHOLM,SWEDEN; KAROLINSKA HOSP,DEPT ANESTHESIOL,S-10401 STOCKHOLM,SWEDEN							GORDON E, 1995, J NEUROSURG ANESTH, V7, P235, DOI 10.1097/00008506-199510000-00001; GRAHAM J, 1992, 3 NAT INJ CONTR C US; JENNETT B, 1975, LANCET, V1, P480; KRAUS JF, 1991, NEUROEPIDEMIOLOGY TR, P333; Kraus JF, 1993, HEAD INJURY, P1; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; TEASDALE G, 1974, LANCET, V2, P81; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509	9	35	41	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0001-4575			ACCIDENT ANAL PREV	Accid. Anal. Prev.	NOV	1997	29	6					811	816		10.1016/S0001-4575(97)00050-X			6	Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation	Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation	YD872	WOS:A1997YD87200012	9370017				2021-06-18	
J	Duke, BJ; Ryu, RK; Brega, KE; Coldwell, DM				Duke, BJ; Ryu, RK; Brega, KE; Coldwell, DM			Traumatic bilateral jugular vein thrombosis: Case report and review of the literature	NEUROSURGERY			English	Article						injury; jugular vein; stent; thrombosis	PSEUDOTUMOR CEREBRI; SINUS THROMBOSIS	OBJECTIVE AND IMPORTANCE: Thrombosis of the internal jugular vein (IJV) with associated elevated intracranial pressure (ICP) is a rare complication of central venous catheterization but has not been reported as a result of blunt trauma. CLINICAL PRESENTATION: An 18-year-old male patient was observed to be obtunded after an assault, The initial examination was remarkable for somnolence, bruising of the anterior neck, and diffuse, edematous swelling of the face and scalp, The results of computed tomography of the brain were normal. An angiogram obtained on the 2nd hospital day to rule out carotid injury revealed bilateral IJV thromboses to the cranial base. An ICP monitor was placed with an opening pressure of 33 mm Hg. The central venous pressure was measured to be 9 mm Hg. A catheter was passed through the left IJV thrombus and into the sigmoid sinus, where the pressure was 17 mm Hg, INTERVENTION: An intravascular stent was deployed in the left IJV. ICP rapidly normalized. A regimen of coumadin was administered to the patient for 6 weeks, at which time the stent remained patent. CONCLUSION: We conclude that traumatic jugular vein thrombosis can be associated with significant elevation in ICP and that treatment with an endovascular stent can affect the rapid correction of intracranial hypertension in patients who are candidates for anticoagulation.	UNIV COLORADO,HLTH SCI CTR,DIV NEUROSURG,DENVER,CO; UNIV COLORADO,HLTH SCI CTR,DEPT RADIOL,DENVER,CO 80262; DENVER HLTH MED CTR,DENVER,CO							AGMED N, 1976, MED J AUSTRALIA, V1, P217; CHOWDHURY K, 1990, HEAD NECK-J SCI SPEC, V12, P168, DOI 10.1002/hed.2880120214; COHEN JP, 1985, LARYNGOSCOPE, V95, P1478; DEBRUIJN NP, 1981, ANESTH ANALG, V60, P448; DUNSKER SB, 1970, ARCH NEUROL-CHICAGO, V23, P120, DOI 10.1001/archneur.1970.00480260026004; EMERSON TE, 1975, CEREBRAL CIRCULATION, P10; FITZHUGH GS, 1966, LARYNGOSCOPE, V76, P893; GOODMAN C, 1917, ANN OTO RHINOL LARYN, V26, P527; GUTTERIDGE IF, 1987, STROKE, V18, P808, DOI 10.1161/01.STR.18.4.808; KAPLAN RE, 1985, J PEDIATR-US, V107, P266; KOTANI J, 1992, BRIT J ORAL MAX SURG, V30, P171, DOI 10.1016/0266-4356(92)90151-8; LAM BL, 1992, OPHTHALMOLOGY, V99, P706; Long JW, 1912, SURG GYNECOL OBSTET, V14, P86; MARKS MP, 1994, RADIOLOGY, V191, P441, DOI 10.1148/radiology.191.2.8153318; MARR WG, 1965, AM J OPHTHALMOL, V51, P605; MOFIT HM, 1958, ARCH SURG-CHICAGO, V76, P713; MULLER KM, 1976, DEUT MED WOCHENSCHR, V101, P411; OTUAMA LA, 1973, LANCET, V2, P1101; RAISANEN H, 1979, NEW TESTAMENT STUD, V26, P101, DOI 10.1017/S0028688500008699; SAXENA VK, 1976, JAMA-J AM MED ASSOC, V235, P2124, DOI 10.1001/jama.235.19.2124; SEGAL J, 1993, NEUROSURGERY, V32, P468, DOI 10.1227/00006123-199303000-00023; STEPHENS PH, 1991, BRIT J ANAESTH, V67, P476, DOI 10.1093/bja/67.4.476; TOBIN HA, 1972, LARYNGOSCOPE, V82, P817, DOI 10.1288/00005537-197205000-00007; TOUNG TJK, 1988, ANESTHESIOLOGY, V68, P53, DOI 10.1097/00000542-198801000-00009	24	35	37	0	2	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	SEP	1997	41	3					680	683		10.1097/00006123-199709000-00036			4	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	XU972	WOS:A1997XU97200101	9310989				2021-06-18	
J	Cobbs, CS; Fenoy, A; Bredt, DS; Noble, LJ				Cobbs, CS; Fenoy, A; Bredt, DS; Noble, LJ			Expression of nitric oxide synthase in the cerebral microvasculature after traumatic brain injury in the rat	BRAIN RESEARCH			English	Article						traumatic brain injury; endothelial nitric oxide synthase; NADPHd	BLOOD-FLOW; BARRIER; AUTOREGULATION; INHIBITION; MECHANISMS; BREAKDOWN; PROTEIN	Reduced nicotinamide adenine dinucleotide phosphate-diaphorase (NADPHd) histochemistry and nitric oxide synthase (NOS) immunocytochemistry were performed on sections of brain after moderate traumatic brain injury. There was a pronounced increase in NADPHd reactivity and an induction of the endothelial NOS (eNOS) isoform in microvessels surrounding the cortical contusion by 24 h post-injury. This altered microvascular state may contribute to barrier breakdown and hyperemia which characterize traumatic brain injury.	SAN FRANCISCO GEN HOSP,DEPT NEUROSURG,SAN FRANCISCO,CA 94110; UNIV CALIF SAN FRANCISCO,DEPT NEUROSURG,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS014543, P50NS014543] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS14543] Funding Source: Medline		BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; CHI OZ, 1994, PHARMACOLOGY, V48, P367, DOI 10.1159/000139202; FARACI FM, 1993, CIRC RES, V72, P476, DOI 10.1161/01.RES.72.2.476; JANIGRO D, 1994, CIRC RES, V75, P528, DOI 10.1161/01.RES.75.3.528; KOBARI M, 1994, BRAIN RES, V667, P255, DOI 10.1016/0006-8993(94)91503-2; LYNCH DR, 1994, CURR OPIN NEUROL, V7, P510, DOI 10.1097/00019052-199412000-00007; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; TALMAN WT, 1995, BRAIN RES, V672, P48, DOI 10.1016/0006-8993(94)01381-Q; TANNO H, 1993, J CEREBR BLOOD F MET, V13, P116, DOI 10.1038/jcbfm.1993.14; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; WEIMER G, 1994, BRAIN RES, V638, P261	11	35	35	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	MAR 21	1997	751	2					336	338		10.1016/S0006-8993(96)01429-1			3	Neurosciences	Neurosciences & Neurology	WQ807	WOS:A1997WQ80700021	9099824				2021-06-18	
J	Sander, AM; Witol, AD; Kreutzer, JS				Sander, AM; Witol, AD; Kreutzer, JS			Alcohol use after traumatic brain injury: Concordance of patients' and relatives' reports	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							SELF-REPORTS; FOLLOW-UP; DRINKING; VALIDITY	Objective: To investigate bias and concurrent validity of patients' alcohol use reports by examining concordance with relatives' reports. Design: Using a quasiexperimental static group comparison design, alcohol use was examined at 1 year after injury. Chi-square analyses, t tests, and a Fisher exact probability test were conducted to investigate the relationship between patients' and caregivers' reports on measures of alcohol use. Setting: Medical center outpatient clinic Participants: 175 adult patients with traumatic brain injury and 175 family informants. Inclusion criteria were: patient older than 18 years of age and completion of self-report and family member versions of questionnaires. The full range of brain injury severity was represented. Main Outcome Measures: Quantity-Frequency-Variability Index (QFVI; Cahalan and Cisin, 1968); Brief Michigan Alcohol Screening Test (B-MAST; Porkorny et al, 1972). Results: A high rate of concordance, typically greater than 90%, was noted between patients' and relatives' reports on each of the alcohol use measures. Chi-square analyses revealed no significant differences (p > .05) between patients' and relatives' reports for the QFVI or the B-MAST. Inspection of the data found lesser rates of agreement for persons with severe injuries. Chi-square analyses revealed no differences based on family members' relationship to patients or whether they lived together or apart. However, a Fisher exact probability test (p < .03) for the QFVI indicated higher agreement rates for spouses relative to parents. Conclusions: The results do not support the hypothesis that patients underreport drinking and that their reports are inconsistent with those of caregivers. The high levels of concordance are consistent with those found in similar research studies involving alcoholic populations. Results suggest that patients' reports should be given higher credibility and should not be routinely dismissed in favor of information provided by families. However, more caution is necessary when collecting information from persons with severe injury. (C) 1997 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT REHABIL MED,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DIV NEUROL SURG,RICHMOND,VA 23298							Brooks N, 1989, Brain Inj, V3, P235, DOI 10.3109/02699058909029638; CAHALAN D, 1968, Q J STUD ALCOHOL, V29, P642; CAHALAN D, 1968, Q J STUD ALCOHOL, V29, P130; CAVALLO M M, 1992, Brain Injury, V6, P327, DOI 10.3109/02699059209034947; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Crosson B., 1989, J HEAD TRAUMA REHAB, V4, P46, DOI [10.1097/00001199-198909000-00008, DOI 10.1097/00001199-198909000-00008]; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; HEINEMANN AW, 1988, ARCH PHYS MED REHAB, V69, P619; HESSELBROCK M, 1983, INT J ADDICT, V18, P593, DOI 10.3109/10826088309027359; HOFFMANN NG, 1994, ALCOHOL CLIN EXP RES, V18, P231, DOI 10.1111/j.1530-0277.1994.tb00006.x; Kreutzer J., 1987, GEN HLTH HIST QUESTI; KREUTZER J S, 1991, Brain Injury, V5, P177, DOI 10.3109/02699059109008088; Kreutzer J.S., 1990, COMMUNITY INTEGR TRA, P249; KREUTZER JS, 1990, J HEAD TRAUMA REHAB, V5, P9, DOI DOI 10.1097/00001199-199009000-00005; MAISTO SA, 1979, J CONSULT CLIN PSYCH, V47, P106, DOI 10.1037/0022-006X.47.1.106; OFARRELL TJ, 1984, BEHAV ASSESS, V6, P263; POLICH JM, 1982, ADDICT BEHAV, V7, P123, DOI 10.1016/0306-4603(82)90037-5; PORKORNY AD, 1972, AM J PSYCHIAT, V129, P342; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; *SECR HLTH HUM SER, 1987, 6 SPEC REP US C ALC; Siegel S., 1956, NONPARAMETRIC STAT B; SKINNER H, 1982, J STUD ALCOHOL, V40, P502; Sparadeo F. R., 1989, J HEAD TRAUMA REHAB, V4, P75, DOI DOI 10.1097/00001199-198903000-00010; Sparadeo F. R., 1990, J HEAD TRAUMA REHAB, V5, P1, DOI DOI 10.1097/00001199-199009000-00004; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; WILKINSON DA, 1987, NEUROPSYCHOLOGY ALCO, P76; *WISC DEP HLTH SOC, 1985, ALC PERS DIS PREL RE; ZUNG BJ, 1975, J STUD ALCOHOL, V36, P127, DOI 10.15288/jsa.1975.36.127	29	35	35	0	3	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	1997	78	2					138	142		10.1016/S0003-9993(97)90254-9			5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	WH072	WOS:A1997WH07200005	9041893				2021-06-18	
J	Perri, BR; Smith, DH; Murai, H; Sinson, G; Saatman, KE; Raghupathi, R; Bartus, RT; McIntosh, TK				Perri, BR; Smith, DH; Murai, H; Sinson, G; Saatman, KE; Raghupathi, R; Bartus, RT; McIntosh, TK			Metabolic quantification of lesion volume following experimental traumatic brain injury in the rat	JOURNAL OF NEUROTRAUMA			English	Article						brain injury; histopathology; lateral fluid-percussion; lesion volume; metabolism; TTC	FOCAL CEREBRAL-ISCHEMIA; BLOOD-FLOW; CALPAIN INHIBITOR; ARTERY OCCLUSION; DAMAGE; EDEMA; CHLORIDE; MODEL; (S)-EMOPAMIL; REDUCTION	A reliable and rapid method for quantifying lesion volume following traumatic brain injury (TBI) has vast potential in brain injury research. Staining with 2,3,5-triphenyltetrazolium chloride (TTC) provides for demarcation of damaged or infarcted tissue from normal, viable cerebral tissue, in which a red formazan product is formed by reduction during cellular respiration of mitochondrial dehydrogenase enzymes. The present study evaluated the use of TTC staining to quantify the cortical lesion volume in rats undergoing fluid-percussion (FP) brain injury. Male Sprague-Dawley rats (350-450 g, n = 27) were anesthetized (sodium pentobarbital, 60 mg/kg, ip) and subjected to lateral FP brain injury of mild (1.1-1.3 atm, n = 5), moderate (2.0-2.3 atm, n = 9), or high (2.4-2.6 atm, n = 8) severity, while sham (noninjured) animals (n = 5) were anesthetized and surgically prepared without injury. Forty-eight hours after injury animals were sacrificed, brains were stained with TTC, and lesion volumes were calculated. A highly significant correlation was found between cerebral cortical lesion volume (mm(3)) and severity of brain injury (r = 0.85; p < 0.0001). The mean (+/- SD) lesion volumes were 12.1 (+/- 4.5) mm(3) following mild injury, 33.8 (+/- 8.6) mm(3) following moderate injury, and 45.1 (+/- 14.0) mm(3) following severe injury. A significant difference was observed between all injury groups using a t test with Bonferroni correction (p < 0.05). These results suggest that the TTC staining technique is a useful, rapid, and reproducible method for quantification of lesion volume following lateral FP brain injury.	UNIV PENN,DIV NEUROSURG,PHILADELPHIA,PA 19104; ALKERMES INC,CAMBRIDGE,MA 02139			smith, douglas/A-1321-2007		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS026818] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG012527] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01-AG12527] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS26818, R01-NS08803] Funding Source: Medline		BARTUS RT, 1994, J CEREBR BLOOD F MET, V14, P537, DOI 10.1038/jcbfm.1994.67; BARTUS RT, 1994, STROKE, V25, P2265, DOI 10.1161/01.STR.25.11.2265; BEDERSON JB, 1986, STROKE, V17, P1304, DOI 10.1161/01.STR.17.6.1304; BOSE B, 1988, STROKE, V19, P28, DOI 10.1161/01.STR.19.1.28; CLARK RK, 1993, BRAIN RES BULL, V31, P565, DOI 10.1016/0361-9230(93)90124-T; COLE DJ, 1990, ACTA NEUROPATHOL, V80, P152, DOI 10.1007/BF00308918; COLE DJ, 1993, CAN J NEUROL SCI, V20, P30, DOI 10.1017/S0317167100047363; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; ELGER B, 1994, EUR J PHARMACOL, V254, P65, DOI 10.1016/0014-2999(94)90371-9; FADEN AI, 1993, J NEUROTRAUM, V10, P91, DOI 10.1089/neu.1993.10.91; HEINEL LA, 1994, BRAIN RES BULL, V34, P137, DOI 10.1016/0361-9230(94)90010-8; Hill SJ, 1996, J NEUROPATH EXP NEUR, V55, P1221, DOI 10.1097/00005072-199612000-00005; HOVDA DA, 1992, J NEUROTRAUMA, V9, P547; ISAYAMA K, 1991, STROKE, V22, P1394, DOI 10.1161/01.STR.22.11.1394; KIYOTA Y, 1993, EXP BRAIN RES, V95, P388; LISZCZAK TM, 1984, ACTA NEUROPATHOL, V65, P150, DOI 10.1007/BF00690469; MARINOV M, 1991, Neurological Research, V13, P77; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MEMEZAWA H, 1992, EXP BRAIN RES, V89, P67; MINEMATSU K, 1992, NEUROLOGY, V42, P235, DOI 10.1212/WNL.42.1.235; OKIYAMA K, 1992, J NEUROSURG, V77, P607, DOI 10.3171/jns.1992.77.4.0607; OKIYAMA K, 1994, J NEUROTRAUM, V11, P83, DOI 10.1089/neu.1994.11.83; PARK CK, 1988, NEUROPATH APPL NEURO, V14, P289, DOI 10.1111/j.1365-2990.1988.tb00889.x; PITTS L, 1990, HDB CLIN NEUROLOGY, P65; RANJAN A, 1993, ACTA NEUROCHIR, V123, P87, DOI 10.1007/BF01476291; SAEED D, 1993, PEDIATR NEUROL, V9, P263, DOI 10.1016/0887-8994(93)90061-G; Smith D. H., 1994, Society for Neuroscience Abstracts, V20, P424; SMITH DH, 1993, J NEUROSCI, V13, P5383; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; Soares HD, 1995, J NEUROSCI, V15, P8223; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; TOULMOND S, 1993, BRAIN RES, V620, P32, DOI 10.1016/0006-8993(93)90267-Q; VINK R, 1994, J NEUROTRAUM, V11, P265, DOI 10.1089/neu.1994.11.265; VINK R, 1994, NEUROBIOLOGY CNS TRA, P68; Vink R, 1990, J NEUROTRAUM, V7, P21, DOI 10.1089/neu.1990.7.21; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	42	35	36	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	JAN	1997	14	1					15	22		10.1089/neu.1997.14.15			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	WK032	WOS:A1997WK03200002	9048307				2021-06-18	
J	Thatcher, RW; Camacho, M; Salazar, A; Linden, C; Biver, C; Clarke, L				Thatcher, RW; Camacho, M; Salazar, A; Linden, C; Biver, C; Clarke, L			Quantitative MRI of the gray-white matter distribution in traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						quantitative MRI; pixel intensity change; traumatic brain injury	MAGNETIC-RESONANCE IMAGES; DIFFUSE AXONAL INJURY; HEAD-INJURY	Quantitative analyses were performed on magnetic resonance images (MRIs) obtained from the brains of 31 traumatic brain-injured (TBI) patients and 25 normal control subjects. The quantitative analyses involved comparisons of the shapes of proton density gray scale pixel histograms obtained from both 3-mm and 5-mm slice thickness. Image segmentation was accomplished by a multispectral fuzzy C-means and/or k-nearest-neighbor (kNN) algorithms and manual classification was used to label segmented classes into CSF, white matter, gray matter, and other. Shape descriptors were derived from the pixel intensity histograms of the combined gray matter and white matter classes for each MRI slice. Statistical analyses revealed significant differences in pixel intensity distributions between TBI and control subjects. Normal control subjects tended to exhibit bimodal gray matter-white matter histograms, whereas, TBI patients tended to exhibit unimodal gray matter-white matter histograms. In the control subjects the pixels intermediate in intensity between gray and white matter were located primarily at the border between the gray and white matter, whereas TBI patients exhibited a thickening of the number of intermediate pixels at the border as well as an increase in intermediate pixels in the middle of the gray and white matter. The greater the severity of TBI, then the larger the number of intermediate intensity pixels within and between gray and white matter. Further analyses demonstrated shifts in magnetic resonance relaxation times in gray and white matter in TBI patients, which suggested that the tendency toward unimodality in TBI patients represents a pathological reduction in brain differentiation due to measurable biophysical change.	UNIV S FLORIDA,COLL MED,DEPT NEUROL,TAMPA,FL 33612; UNIV S FLORIDA,COLL MED,DEPT RADIOL,TAMPA,FL 33612; DEF & VET HEAD INJURY PROGRAM,WASHINGTON,DC	Thatcher, RW (corresponding author), VET ADM MED CTR,RES & DEV SERV 151,BAY PINES,FL 33744, USA.						ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P257; BENES FM, 1977, BRAIN RES, V122, P1, DOI 10.1016/0006-8993(77)90658-8; BENSAID AM, 1994, P SOC PHOTO-OPT INS, V2167, P454, DOI 10.1117/12.175079; BEZDEK JC, 1993, MED PHYS, V20, P100; BIGLER ED, 1996, NEUROPSYCHOLOGY, V10, P33; BOTTOMLEY PA, 1984, MED PHYS, V11, P425, DOI 10.1118/1.595535; BRANDT ME, 1994, COMPUT MED IMAG GRAP, V18, P25, DOI 10.1016/0895-6111(94)90058-2; CLARKE LP, 1995, MAGN RESON IMAGING, V13, P343, DOI 10.1016/0730-725X(94)00124-L; ELSTER AD, 1988, J COMPUT ASSIST TOMO, V12, P130, DOI 10.1097/00004728-198801000-00025; Frankowski RF, 1985, CENTRAL NERVOUS SYST, P33; GALE SD, 1994, NEUROPSY NEUROPSY BE, V7, P160; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENNARELLI TA, 1986, J HEAD TRAUMA REHAB, V1, P23; Gentry L.R., 1990, MAGNETIC RESONANCE I, P439; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1994, RADIOLOGY, V191, P1; GROSWASSER Z, 1987, SURG NEUROL, V27, P331, DOI 10.1016/0090-3019(87)90007-3; HALL LO, 1992, IEEE T NEURAL NETWOR, V3, P672, DOI 10.1109/72.159057; Holbourn AHS, 1943, LANCET, V2, P438; HOLBOURN AHS, 1945, BRIT MED BULL, V3, P147, DOI 10.1093/oxfordjournals.bmb.a071895; Johnson SC, 1994, NEUROPSYCHOLOGY, V8, P307, DOI DOI 10.1037/0894-4105.8.3.301; KWENTUS JA, 1985, PSYCHOSOMATICS, V26, P8, DOI 10.1016/S0033-3182(85)72900-3; Povlishock J T, 1985, Cent Nerv Syst Trauma, V2, P285; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; POVLISHOCK JT, 1986, ACTA NEUROPATHOL, V70, P53, DOI 10.1007/BF00689514; POVLISHOCK JT, 1989, MILD HEAD INJURY, P37; PRAYER LM, 1994, MAGNETIC RESONANCE N, P441; PRIGATANO GP, 1987, BARROW NEUROL I Q, V3, P18; SAVITZKY A, 1964, ANAL CHEM, V36, P1627, DOI 10.1021/ac60214a047; STREIT WJ, 1995, SCI AM, V273, P54, DOI 10.1038/scientificamerican1195-54; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRICH SJ, 1961, LANCET, V2, P443; THOMAS LB, 1995, NEUROSCIENTIST, V1, P142; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37	36	35	36	0	2	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	JAN	1997	14	1					1	14		10.1089/neu.1997.14.1			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	WK032	WOS:A1997WK03200001	9048306				2021-06-18	
J	Uchikawa, O; Fukatsu, K; Suno, M; Aono, T; Doi, T				Uchikawa, O; Fukatsu, K; Suno, M; Aono, T; Doi, T			In vivo biological activity of antioxidative aminothiazole derivatives	CHEMICAL & PHARMACEUTICAL BULLETIN			English	Article						thiazoloazepine; thiazolopyridine; iron(II) chloride intrathecal injection; antioxidant; central nervous system	CENTRAL-NERVOUS-SYSTEM; LIPID-PEROXIDATION; RAT-BRAIN; IRON; INHIBITOR; INJECTION; ISCHEMIA; TRAUMA; CORTEX; ASSAY	For the development of novel antioxidants having therapeutic utility, a new series of condensed 4- and 5-aminothiazole derivatives has been synthesized using simple methods. Condensed 4-aminothiazoles were prepared by the reaction of alpha-bromolactans a;with thioamides in ethanol and 5-aminothiazole derivatives were obtained by the treatment of 3-(acylamino)lactams with a thiating agent such as phosphorus pentasulfide and Lawesson's reagent in pyridine. In vitro assay of the condensed 5-aminothiazole derivatives showed them to be potent inhibitors of lipid peroxidation. In order to evaluate these compounds in an in vivo system, we devised a simple and reproducible method in which the inhibition of characteristic behaviors induced by spinal injection of FeCl2 was expressed numerically. Compounds having strong in vitro activity protected the central nervous system from injury caused by iron-dependent lipid peroxidation. The results suggest that the in vivo assay developed in this study should be useful as a screening method for antioxidants and also that condensed 5-aminothiazole derivatives are promising candidates for the treatment of traumatic and ischemic injury of the central nervous system.	TAKEDA CHEM IND LTD, DIV PHARMACEUT RES, PHARMACEUT RES LABS 3, YODOGAWA KU, OSAKA 532, JAPAN; TAKEDA CHEM IND LTD, DIV DISCOVERY RES, RES RES, TSUKUBA, IBARAKI 30042, JAPAN	Uchikawa, O (corresponding author), TAKEDA CHEM IND LTD, DIV PHARMACEUT RES, PHARMACEUT RES LABS 1, YODOGAWA KU, OSAKA 532, JAPAN.						BLADEFONT A, 1980, TETRAHEDRON LETT, P2443; BOYER SK, 1988, HELV CHIM ACTA, V71, P337, DOI 10.1002/hlca.19880710205; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; COLOMBO JA, 1975, BRAIN RES, V96, P88; DOI T, 1987, EUR J PHARMACOL, V137, P227, DOI 10.1016/0014-2999(87)90226-3; HALL ED, 1991, J PHARMACOL EXP THER, V258, P688; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; HARRISON SC, 1994, BRAIN RES, V639, P102; JACOBSEN EJ, 1992, J MED CHEM, V35, P4464, DOI 10.1021/jm00101a025; NAGASAWA HT, 1971, J MED CHEM, V14, P501, DOI 10.1021/jm00288a010; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; PAPPALARDO G, 1966, FARMACO-ED SCI, V21, P740; PELLEGATA R, 1978, SYNTHESIS-STUTTGART, P614; SAUNDERS RD, 1987, J NEUROCHEM, V49, P24, DOI 10.1111/j.1471-4159.1987.tb03388.x; STOCKS J, 1974, CLIN SCI MOL MED, V47, P215, DOI 10.1042/cs0470215; SUBBARAO KV, 1990, J NEUROSCI RES, V26, P224, DOI 10.1002/jnr.490260212; THORSETT ED, 1986, J MED CHEM, V29, P251, DOI 10.1021/jm00152a014; UCHIKAWA O, 1994, J HETEROCYCLIC CHEM, V31, P1545, DOI 10.1002/jhet.5570310645; UCHIKAWA O, 1994, J HETEROCYCLIC CHEM, V31, P877, DOI 10.1002/jhet.5570310432; WILLMORE LJ, 1983, BRAIN RES, V277, P393, DOI 10.1016/0006-8993(83)90954-X; WILLMORE LJ, 1978, BRAIN RES, V152, P406, DOI 10.1016/0006-8993(78)90273-1; WILLMORE LJ, 1978, SCIENCE, V200, P1501, DOI 10.1126/science.96527; WILLMORE LJ, 1984, EXP NEUROL, V83, P62, DOI 10.1016/0014-4886(84)90046-3; WINEMAN RJ, 1958, J AM CHEM SOC, V80, P6233, DOI 10.1021/ja01556a019; WINTER W, 1983, LIEBIGS ANN CHEM, P2021	25	35	37	1	5	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0009-2363			CHEM PHARM BULL	Chem. Pharm. Bull.	NOV	1996	44	11					2070	2077					8	Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Pharmacology & Pharmacy; Chemistry	VV313	WOS:A1996VV31300013	8945772				2021-06-18	
J	Gates, MA; Laywell, ED; Fillmore, H; Steindler, DA				Gates, MA; Laywell, ED; Fillmore, H; Steindler, DA			Astrocytes and extracellular matrix following intracerebral transplantation of embryonic ventral mesencephalon or lateral ganglionic eminence	NEUROSCIENCE			English	Article						brain grafts; glia; tenascin; chondroitin sulfate proteoglycans; dopaminergic neurons	CHONDROITIN SULFATE PROTEOGLYCAN; FETAL STRIATAL PRIMORDIA; CENTRAL-NERVOUS-SYSTEM; ADULT-RAT-BRAIN; NEURITE OUTGROWTH; SPINAL-CORD; RADIAL GLIA; INHIBITORY MOLECULES; CNS INJURY; MONOCLONAL-ANTIBODY	Transplantation of embryonic neurons to the adult mammalian central nervous system (CNS) offers the possibility of re-establishing neural functions lost after traumatic injuries or neurodegenerative disease. In the adult CNS, however, transplanted neurons and their growing neurites can become confined to the graft region, and there may also be a relative paucity of afferents innervating grafted neurons. Because glia may influence the development and regeneration of CNS neurons, the present study has characterized the distribution of astrocytes and developmentally regulated glycoconjugates (chondroitin-6-sulfate proteoglycan and tenascin) within regions of the embryonic mouse CNS used as donor tissues, and in and around these grafts to the adult striatum and substantia nigra. Both chondroitin-6-sulfate proteoglycan and tenascin are present in the embryonic ventral mesencephalon (in association with radial glia and their endfeet, and glial boundaries that cordon off the ventral mesencephalon dopamine neuron migratory zone) and lateral ganglionic eminence before transplantation, and they are conserved within grafts of these tissues to the adult mouse. Neostriatal grafts exhibit a heterogeneous pattern of astrocyte and extracellular matrix molecule distribution, unlike ventral mesencephalon grafts, which are rather homogeneous. There is evidence to suggest that, in addition to variation in astroglial/extracellular matrix immunostaining within different compartments in striatal grafts to either adult striatum or substantia nigra, there are also boundaries between these compartments that are rich in glial fibrillary acidic protein/extracellular matrix components. Substantia nigra grafts, with cells immunoreactive for tyrosine hydroxylase, are also rich in immature astroglia (RC-2-immunopositive), and as the astroglia mature (to glial fibrillary acidic protein-positive) over time the expression of chondroitin-6-sulfate proteoglycan and tenascin is also reduced. These same extracellular matrix constituents, however, are only slightly up-regulated in an area of the adult host which surrounds the grafted tissue. Glial scar components exhibit no obvious differences between grafts from different sources to homotopic (e.g., striatum to striatum) or heterotopic (e.g., substantia nigra to striatum) sites, and likewise grafts of non-synaptically associated structures (e.g., cerebellum to striatum), needle lesions or vehicle injections all yield astroglial/extracellular matrix scars in the host that are indistinguishable. Studies utilizing the ROSA-26 transgenic (beta-galactosidase-positive) mouse as a host for non-5-bromo-4-chloro-3-indolyl-beta-d-galactopyranoside-labeled grafts indicate that the early astroglial/extracellular matrix response to the graft is derived from the surrounding host structures. Furthermore, biochemical analysis of one of the ''boundary molecules'', tenascin, from the developing ventral mesencephalon versus adult striatal lesions, suggests that different forms of the molecule predominate in the embryonic versus lesioned adult brain. Such differences in the nature and distribution of astroglia and developmentally regulated extracellular matrix molecules between donor and host regions may affect the growth and differentiation of transplanted neurons. The present study suggests that transplanted neurons and their processes may flourish within graft versus host regions, in part due to a confining glial scar, but also because the extracellular milieu within the graft site remains more representative of the developmental environment from which the donor neurons were obtained [Gates M. A., et at. (1994) Sec. Neurosci Abstr. 20, 471]. Copyright (C) 1996 IBRO. Published by Elsevier Science Ltd.	UNIV TENNESSEE, COLL MED, DEPT ANAT & NEUROBIOL, MEMPHIS, TN 38163 USA			Steindler, Dennis/AAJ-5811-2020		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS29225] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS029225] Funding Source: NIH RePORTER		ARD MD, 1991, ANN NY ACAD SCI, V633, P566; AVNUR Z, 1984, CELL, V38, P811, DOI 10.1016/0092-8674(84)90276-9; AZMITIA EC, 1983, NEUROSCI LETT, V38, P145, DOI 10.1016/0304-3940(83)90031-9; BAKAY RAE, 1993, ACTA NEUROCHIR, P8; BARTSCH S, 1992, J NEUROSCI, V12, P736; BICKNESE AR, 1994, J NEUROSCI, V14, P3500; BIGNAMI A, 1972, BRAIN RES, V43, P429, DOI 10.1016/0006-8993(72)90398-8; BJORKLUND A, 1983, ACTA PHYSIOL SCAND, P1; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; BREEZE RE, 1995, NEUROSURGERY, V36, P1044, DOI 10.1227/00006123-199505000-00027; BREGMAN BS, 1993, EXP NEUROL, V123, P3, DOI 10.1006/exnr.1993.1136; BRITTIS PA, 1992, SCIENCE, V255, P733, DOI 10.1126/science.1738848; BRODKEY JA, 1993, EXP NEUROL, V123, P251, DOI 10.1006/exnr.1993.1158; CRANDALL JE, 1990, DEV BRAIN RES, V55, P87, DOI 10.1016/0165-3806(90)90108-B; CULICAN SM, 1990, J NEUROSCI, V10, P684; DAVIES SJA, 1994, J NEUROSCI, V14, P1596; DOUCET G, 1990, EUR J NEUROSCI, V2, P279, DOI 10.1111/j.1460-9568.1990.tb00419.x; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; EDWARDS MA, 1990, NEUROSCIENCE, V36, P121, DOI 10.1016/0306-4522(90)90356-9; FAISSNER A, 1995, GLIA, V13, P233, DOI 10.1002/glia.440130402; FAISSNER A, 1994, J CELL BIOL, V126, P783, DOI 10.1083/jcb.126.3.783; FAISSNER A, 1990, NEURON, V5, P627, DOI 10.1016/0896-6273(90)90217-4; FAISSNER A, 1988, DIFFERENTIATION, V37, P104, DOI 10.1111/j.1432-0436.1988.tb00802.x; Faissner A, 1993, Perspect Dev Neurobiol, V1, P155; FAWCETT JW, 1989, DEV BIOL, V135, P449, DOI 10.1016/0012-1606(89)90193-0; FISHER LJ, 1994, FASEB J, V8, P489; FISHER LJ, 1993, PHYSIOL REV, V73, P583; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; Gates M. A., 1994, Society for Neuroscience Abstracts, V20, P471; GATES MA, 1995, J COMP NEUROL, V361, P249, DOI 10.1002/cne.903610205; GATES MA, 1993, J CHEM NEUROANAT, V6, P179, DOI 10.1016/0891-0618(93)90040-B; GRAYBIEL AM, 1990, PROG BRAIN RES, V82, P401; GRAYBIEL AM, 1989, J NEUROSCI, V9, P3250; GROVES AK, 1993, DEV BIOL, V159, P87, DOI 10.1006/dbio.1993.1223; GURDON JB, 1994, NATURE, V371, P487, DOI 10.1038/371487a0; HALLAS BH, 1980, AM J ANAT, V158, P147, DOI 10.1002/aja.1001580205; HATTEN ME, 1991, GLIA, V4, P233, DOI 10.1002/glia.440040215; HYNES M, 1995, CELL, V80, P95, DOI 10.1016/0092-8674(95)90454-9; KRUSE J, 1985, NATURE, V316, P146, DOI 10.1038/316146a0; LANDIS DMD, 1994, ANNU REV NEUROSCI, V17, P133, DOI 10.1146/annurev.ne.17.030194.001025; LAYWELL ED, 1991, ANN NY ACAD SCI, V633, P122; LAYWELL ED, 1992, P NATL ACAD SCI USA, V89, P2634, DOI 10.1073/pnas.89.7.2634; LINDSAY RM, 1979, NATURE, V282, P80, DOI 10.1038/282080a0; LOCHTER A, 1991, J CELL BIOL, V113, P1159, DOI 10.1083/jcb.113.5.1159; LUND RD, 1976, SCIENCE, V193, P582, DOI 10.1126/science.959815; MANSOUR H, 1990, J NEUROSCI RES, V25, P300, DOI 10.1002/jnr.490250306; MAXWELL WL, 1990, PHILOS T R SOC B, V328, P501, DOI 10.1098/rstb.1990.0122; MCKEON RJ, 1991, J NEUROSCI, V11, P3398; MISSON JP, 1988, DEV BRAIN RES, V44, P95, DOI 10.1016/0165-3806(88)90121-6; NAGAO M, 1993, NEUROSCI LETT, V156, P47, DOI 10.1016/0304-3940(93)90436-O; Nieto-Sampedro M, 1988, PHARM APPROACHES TRE, P301; NIETOSAMPEDRO M, 1984, P NATL ACAD SCI-BIOL, V81, P6250, DOI 10.1073/pnas.81.19.6250; NIKKAH G, 1994, THESIS LUND SWEDEN; NIKKHAH G, 1994, BRAIN RES, V633, P133, DOI 10.1016/0006-8993(94)91532-6; NORENBERG MD, 1994, J NEUROPATH EXP NEUR, V53, P213, DOI 10.1097/00005072-199405000-00001; OBRIEN TF, 1992, DEV BRAIN RES, V65, P259, DOI 10.1016/0165-3806(92)90187-2; OBRIEN TF, 1995, CELLULAR MOL MECH ST, P21; PAINO CL, 1994, J NEUROCYTOL, V23, P433, DOI 10.1007/BF01207115; Reier P J, 1988, Adv Neurol, V47, P87; ROBSON JA, 1994, J COMP NEUROL, V340, P349, DOI 10.1002/cne.903400306; RUDGE JS, 1990, J NEUROSCI, V10, P3594; SAJIN B, 1994, PERSPECT DEV NEUROBI, V2, P275; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; SCHWAB ME, 1993, ANNU REV NEUROSCI, V16, P565, DOI 10.1146/annurev.ne.16.030193.003025; SHULTS CW, 1990, NEUROSCIENCE, V38, P427, DOI 10.1016/0306-4522(90)90039-7; SMITH GM, 1986, J COMP NEUROL, V251, P23, DOI 10.1002/cne.902510103; SNOW DM, 1990, DEV BIOL, V138, P359, DOI 10.1016/0012-1606(90)90203-U; SNOW DM, 1990, EXP NEUROL, V109, P111, DOI 10.1016/S0014-4886(05)80013-5; STEINDLER DA, 1989, DEV BIOL, V131, P243, DOI 10.1016/S0012-1606(89)80056-9; STEINDLER DA, 1993, ANNU REV NEUROSCI, V16, P445, DOI 10.1146/annurev.ne.16.030193.002305; STEINDLER DA, 1988, J COMP NEUROL, V267, P357, DOI 10.1002/cne.902670306; STEINDLER DA, 1995, J NEUROSCI, V15, P1971; STEINDLER DA, 1990, EXP NEUROL, V109, P35, DOI 10.1016/S0014-4886(05)80007-X; STEINDLER DA, 1989, COMMENTS DEV NEUROBI, V1, P29; STENEVI U, 1976, BRAIN RES, V114, P1, DOI 10.1016/0006-8993(76)91003-9; THOMAS LB, 1995, NEUROSCIENTIST, V1, P142; TRIMMER PA, 1990, J COMP NEUROL, V296, P359, DOI 10.1002/cne.902960303; WALKER PD, 1987, BRAIN RES, V425, P34, DOI 10.1016/0006-8993(87)90480-X; XU ZC, 1992, NEUROSCIENCE, V48, P95, DOI 10.1016/0306-4522(92)90341-X; ZHOU FC, 1989, NEUROSCIENCE, V30, P19, DOI 10.1016/0306-4522(89)90350-3; ZHOU FC, 1987, J NEUROSCI RES, V17, P235, DOI 10.1002/jnr.490170306; ZHOU HF, 1990, J COMP NEUROL, V292, P320, DOI 10.1002/cne.902920213	82	35	37	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	SEP	1996	74	2					579	597		10.1016/0306-4522(96)00146-7			19	Neurosciences	Neurosciences & Neurology	VC755	WOS:A1996VC75500026	8865207				2021-06-18	
J	Hux, K; Walker, M; Sanger, DD				Hux, K; Walker, M; Sanger, DD			Traumatic brain injury: Knowledge and self-perceptions of school speech-language pathologists	LANGUAGE SPEECH AND HEARING SERVICES IN SCHOOLS			English	Article						traumatic brain injury; service delivery; cognitive-communication deficits	CLOSED HEAD-INJURY; VERBAL IMPAIRMENT	School-based speech-language pathologists from 10 states, responded to a survey concerning their readiness to provide services to students with traumatic brain injuries (TBIs). Survey responses provided a means of exploring speech-language pathologists' knowledge of TBI and facilitated recognition of accurate and inaccurate conceptions held by school-based speech-language pathologists concerning the characteristics and behaviors, criteria for identification and verification, and procedures for the assessment, treatment, and reintegration of students with TBI. Findings indicated that training had a positive effect on speech-language pathologists' knowledge of assessment, treatment, and overall management of students with TBI; however, a large percentage of school-based speech-language pathologists remain uncertain about providing services to students with TBI even after receiving specific TBI training. Furthermore, school-based speech-language pathologists continue to hold many misconceptions concerning TBI and its consequences.		Hux, K (corresponding author), UNIV NEBRASKA, 318 BARKLEY MEM CTR, LINCOLN, NE 68583 USA.		Hux, Karen/AAQ-2078-2020				ADAMOVICH BB, 1990, REHABILITATION ADULT, P374; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; BLOSSER JL, 1989, TOP LANG DISORD, V9, P67, DOI 10.1097/00011363-198903000-00007; Blosser JL, 1991, J HEAD TRAUMA REHAB, V6, P73; BROOKS DN, 1980, J NEUROL NEUROSUR PS, V43, P529, DOI 10.1136/jnnp.43.6.529; CARTER S, 1993, OFF SPECIAL ED REHAB; Caveness W F, 1979, Adv Neurol, V22, P1; Cohen SB, 1985, HEAD INJURY REHABILI, P383; Colson S. E, 1992, INTERV SCH CLIN, V27, P198; DePompei R, 1987, LANG SPEECH HEAR SER, V18, P292, DOI 10.1044/0161-1461.1804.292; GOLDSTEIN FC, 1987, J LEARN DISABIL, V20, P518, DOI 10.1177/002221948702000903; GROHER ME, 1990, REHABILITATION ADULT, P148; Hagen C, 1981, TOP LANG DIS, V1, P73; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; MILLER JD, 1990, REHABILITATION ADULT, P236; Mira M. P., 1992, TRAUMATIC BRAIN INJU; Russell N, 1993, LANG SPEECH HEAR SER, V24, P67; SARNO MT, 1986, ARCH PHYS MED REHAB, V67, P400; SARNO MT, 1980, J NERV MENT DIS, V168, P685, DOI 10.1097/00005053-198011000-00008; SAVAGE RC, 1991, J HEAD TRAUMA REHAB, V6, P1; TELZROW CF, 1990, TRAUMATIC BRAIN INJU, P251; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; YLVISAKER M, 1994, ED DIMENSIONS ACQUIR, P35; Ylvisaker M., 1986, J HEAD TRAUMA REHAB, V1, P48; YLVISAKER MA, 1991, CLIN CONNECTION, V5, P1; 1992, FED REGISTER, V57, P44794; 1990, AM J DISEASE CONTROL, V144, P627	30	35	35	0	5	AMER SPEECH-LANGUAGE-HEARING ASSOC	ROCKVILLE	2200 RESEARCH BLVD, #271, ROCKVILLE, MD 20850-3289 USA	0161-1461	1558-9129		LANG SPEECH HEAR SER	Lang. Speech Hear. Serv. Sch.	APR	1996	27	2					171	184		10.1044/0161-1461.2702.171			14	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	UE675	WOS:A1996UE67500008					2021-06-18	
J	Boake, C; High, WM				Boake, C; High, WM			Functional outcome from traumatic brain injury - Unidimensional or multidimensional?	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						brain injury; head injury; functional assessment outcome assessment; quality of life; rehabilitation	HEAD-INJURY; DISABILITY; SCALE	This study compared multidimensional and unidimensional measures of functional outcome from traumatic brain injury in a referred sample of 67 persons with moderate to severe traumatic brain injury who resided in the community or in a nonhospital facility. Four outcome indicators (independence in self-care, independence in travel, paid employment, and friendship) were correlated with the patients' ratings on two unidimensional outcome measures, the Disability Rating Scale (DRS) and Glasgow Outcome Scale (COS), and on a multidimensional outcome measure, the Craig Handicap Assessment and Reporting Technique (CHART). The results showed that the CHART Occupation and Social Integration scales were associated with different outcome indicators, controlling for overall outcome as measured by the DRS and COS. DRS and GOS ratings were associated more strongly with the self-care and travel indicators than with the employment or friendship indicators. The results support a multidimensional model of functional outcome from brain injury, suggest that the CHART may measure some outcome dimensions more specifically than do the DRS and COS, and point to limitations of unidimensional outcome scales.	UNIV TEXAS,SCH MED,DEPT PHYS MED & REHABIL,HOUSTON,TX; INST REHABIL & RES,HOUSTON,TX; BAYLOR COLL MED,DEPT PHYS MED & REHABIL,HOUSTON,TX 77030							[Anonymous], 1980, INT CLASSIFICATION I; CLIFTON GL, 1992, NEUROSURGERY, V31, P975, DOI 10.1227/00006123-199211000-00028; Condeluci A., 1992, J HEAD TRAUMA REHAB, V7, P37; DILLER L, 1987, REHABILITATION OUTCO, P209; DODDARD D, 1988, J NEUROL NEUROSUR PS, V51, P833; Fuhrer MJ, 1987, REHABILITATION OUTCO, P137; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; JONES ML, 1991, CASE MANAGER     JAN, P44; Kraus JF, 1993, HEAD INJURY, P1; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; WADE DT, 1993, MEASUREMENT NEUROLOG; WHITENECK G, 1988, GUIDE USE CHART CRAI; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009	17	35	35	0	1	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	MAR-APR	1996	75	2					105	113		10.1097/00002060-199603000-00005			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	UF391	WOS:A1996UF39100005	8630190				2021-06-18	
J	Massagli, TL; Jaffe, KM; Fay, GC; Polissar, NL; Liao, SQ; Rivara, JB				Massagli, TL; Jaffe, KM; Fay, GC; Polissar, NL; Liao, SQ; Rivara, JB			Neurobehavioral sequelae of severe pediatric traumatic brain injury: A cohort study	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							SEVERE HEAD-INJURY; CHILDREN; ADOLESCENTS; RECOVERY; MEMORY	Objectives: To determine: (1) the magnitude of neurobehavioral deficits following severe traumatic brain injury (TBI) in children, 3 weeks and 1 year after resolution of post-traumatic amnesia (PTA); (2) the relationship between deficits and injury severity; (3) the performance of cases compared to population norms versus individually matched controls. Design: Prospective cohort study. Setting: Two regional university medical centers, Participants: Cases were 30 children 6 to 15 years old with severe TBI, measured by initial Glasgow Coma Scale (GCS) score and days to reach a GCS score of 15. Controls were individually matched for age, gender, and premorbid academic achievement. Main Outcome Measures: Subjects received the same neurobehavioral tests three weeks and one year after resolution of PTA, Outcomes included individual test scores and variables summarizing results in eight domains. Correlations were calculated between deficits, expressed as case-control differences, and injury severity. Results: Cases showed substantial deficits and performed significantly more poorly than controls at both initial and 1-year testing. At initial testing, cases had an overall score two standard deviations below controls, At I-year testing their overall score was one standard deviation below controls. Greater impairment was found in those who reached a GCS score of 15 after 1 month or who had an initial GCS of 3 to 5. The proportion of cases with deficits and the magnitude of deficits at both testing times was underestimated by using population norms instead of controls. Conclusions: Severe TBI results in significant, persistent deficits related to the level of severity, Comparisons with population norms instead of controls underestimates deficits. (C) 1996 by the American Congress of Rehabilitation Medicine	CHILDRENS HOSP & MED CTR,DEPT PEDIAT,SEATTLE,WA 98105; CHILDRENS HOSP & MED CTR,DEPT NEUROL SURG,SEATTLE,WA 98105; UNIV WASHINGTON,DEPT REHABIL MED,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT PEDIAT,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT NEUROL SURG,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOSTAT,SEATTLE,WA 98195; UNIV WASHINGTON,SCH SOCIAL WORK,SEATTLE,WA 98195; STAT & EPIDEMIOL RES CORP,SEATTLE,WA; NORTHWEST HOSP,SEATTLE,WA	Massagli, TL (corresponding author), CHILDRENS HOSP & MED CTR,DEPT REHABIL MED,CH-71,POB 5371,SEATTLE,WA 98105, USA.						BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BRINK JD, 1980, J PEDIATR-US, V97, P721, DOI 10.1016/S0022-3476(80)80253-8; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Bruininks R.H., 1984, SCALES INDEPENDENT B; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHADWICK O, 1984, J CLIN NEUROPSYCHOL, V6, P269; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; DELIS DC, 1989, CALIFORNIA VERBAL LE; DeMyer W, 1980, TECHNIQUE NEUROLOGIC; DIKMEN SS, 1991, JAMA-J AM MED ASSOC, V265, P1271, DOI 10.1001/jama.265.10.1271; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FAY GC, 1993, ARCH PHYS MED REHAB, V74, P895; GOTTFRIED AW, 1985, MERRILL PALMER QUART, V31, P85; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P681, DOI 10.1016/0003-9993(93)90024-5; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; Jastak S, 1984, WIDE RANGE ACHIEVEME; JENNET B, 1979, ADV NEUROLOGY, V22; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; Levin H., 1979, J PEDIATR PSYCHOL, V4, P389, DOI DOI 10.1093/JPEPSY/4.4.389; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; MCDONALD CM, 1994, ARCH PHYS MED REHAB, V75, P328, DOI 10.1016/0003-9993(94)90038-8; Reitan R, 1974, CLIN NEUROPSYCHOLOGY; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; Snedecor G.W., 1967, STATISTICAL METHODS; Wechsler D., 1974, MANUAL WECHSLER INTE; WINOGRON HW, 1984, J CLIN NEUROPSYCHOL, V6, P269, DOI 10.1080/01688638408401218	32	35	35	0	6	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAR	1996	77	3					223	231		10.1016/S0003-9993(96)90102-1			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	TZ874	WOS:A1996TZ87400003	8600862				2021-06-18	
J	ALEXIS, NE; DIETRICH, WD; GREEN, EJ; PRADO, R; WATSON, BD				ALEXIS, NE; DIETRICH, WD; GREEN, EJ; PRADO, R; WATSON, BD			NONOCCLUSIVE COMMON CAROTID-ARTERY THROMBOSIS IN THE RAT RESULTS IN REVERSIBLE SENSORIMOTOR AND COGNITIVE-BEHAVIORAL DEFICITS	STROKE			English	Article						BEHAVIOR, ANIMAL; CEREBRAL ISCHEMIA; COGNITION; STROKE; RATS	MIDDLE CEREBRAL-ARTERY; TRAUMATIC BRAIN INJURY; DOPPLER ULTRASOUND; CORTEX INJURY; RECOVERY; CONSEQUENCES; INFARCTION; OCCLUSION; STROKE; MODEL	Background and Purpose Microemboli released during transient ischemic attack, stroke, and cardiac surgery are thought to cause a variety of functional deficits in humans. The purpose of this study was to characterize the type and extent of neurobehavioral deficits present after photochemically induced common carotid artery thrombosis (CCAT), a thromboembolic model of stroke in the rat that results In shower. Methods Thirty-two male Wistar rats were assigned to four groups 1 (n=8) and 3 (n=8) were long-term (6-week survival) and short-term (2-week survival) experimental groups subjected to right CCAT with the use of the photochemical technique. Groups 2 (n=8) and 4 (n=8) served as sham-operated controls for each experimental group. A battery of behavioral tests was applied daily beginning 24 hours after thrombosis; this consisted of elicited forelimb placing, postural reflex, beam balance, beam walking, and open Field activity. Cognitive testing with a water maze task was performed on post-CCAT days 30 to 33 fur groups 1 and 2 and on post-CCAT day 2 for groups 3 and 4. Ten-micrometer coronal brain sections were stained with hematoxylin and eosin, and infarct location and frequency were determined. Results Significant sensorimotor deficits were observed; which recovered within 2 weeks after CCAT. The data that follow are derived by combining the two experimental groups and comparing these with the two sham groups. The following tests showed significant effects after CCAT: contralateral elicited forelimb placing, ipsilateral elicited forelimb placing, beam balance, and beam walking score. Cognitive dysfunction was seen acutely (group 3 animals) at 2 days after CCAT; Morris water maze length and latency to target were significantly greater in the experimental group. No deficits were seen in postural reflex, open field activity, or delayed cognitive testing. Histopathological assessment revealed small infarcts in 11 of 16 thrombosed rats. However, a strong relationship between neurobehavioral deficits and infarct location was not consistently demonstrated. Conclusions CCAT produces consistent sensorimotor and cognitive behavioral deficits that recover within 2 weeks of injury. Behavioral outcome was not necessarily associated with overt histopathological damage, suggesting that reversible injury mechanisms, both vascular and neuronal, may be partly responsible for the temporary loss of function. These data strengthen the role of CCAT as a clinically relevant model of thromboembolic stroke.	UNIV MIAMI,DEPT PSYCHOL,CORAL GABLES,FL 33124; UNIV MIAMI,SCH MED,DEPT NEUROL,CEREBRAL VASC DIS RES CTR,CORAL GABLES,FL 33124					NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-05820, NS-23244, NS-27127] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027127, R01NS023244, P50NS005820, P01NS005820] Funding Source: NIH RePORTER		ATTELLA MJ, 1992, BEHAV NEURAL BIOL, V57, P157, DOI 10.1016/0163-1047(92)90665-Q; BARBUT D, 1994, STROKE, V25, P2398, DOI 10.1161/01.STR.25.12.2398; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Betz A. Lorris, 1994, P681; BLAUTH CI, 1988, J THORAC CARDIOV SUR, V95, P668; Brierley JB, 1984, GREENFIELDS NEUROPAT, P125; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; COLBOURNE F, 1994, BRAIN RES, V654, P265, DOI 10.1016/0006-8993(94)90488-X; COYLE P, 1992, STROKE, V23, P697; DERYCK M, 1992, BRAIN RES, V573, P44; DIETRICH WD, 1994, PHARMACOLOGY OF CEREBRAL ISCHEMIA 1994, P565; DIETRICH WD, 1995, STROKE, V26, P111, DOI 10.1161/01.STR.26.1.111; DIETRICH WD, 1993, J NEUROPATH EXP NEUR, V52, P351, DOI 10.1097/00005072-199307000-00002; DIETRICH WD, 1991, J CEREBR BLOOD F MET, V11, P957, DOI 10.1038/jcbfm.1991.161; DIETRICH WD, 1993, STROKE, V24, P1534, DOI 10.1161/01.STR.24.10.1534; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FUTRELL N, 1988, ANN NEUROL, V23, P251, DOI 10.1002/ana.410230307; FUTRELL N, 1993, STROKE, V24, P1983, DOI 10.1161/01.STR.24.12.1983; GAROFALO L, 1992, PHYSIOL BEHAV, V52, P971, DOI 10.1016/0031-9384(92)90379-G; GOLDSTEIN LB, 1990, BEHAV NEUROSCI, V104, P318; GRABOWSKI M, 1993, STROKE, V24, P83; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HENNERICI MG, 1993, STROKE, V24, P637, DOI 10.1161/01.STR.24.5.637; HURWITZ BE, 1991, STROKE, V22, P648, DOI 10.1161/01.STR.22.5.648; JARRARD LE, 1973, PSYCHOL BULL, V79, P1, DOI 10.1037/h0033792; JASPERS RMA, 1990, NEUROSCI LETT, V117, P149, DOI 10.1016/0304-3940(90)90135-V; JOHANSSON BB, 1994, BRAIN PATHOL, V4, P85; KIMBLE DP, 1963, J COMP PHYSIOL PSYCH, V56, P273, DOI 10.1037/h0048903; KOTILA M, 1984, STROKE, V15, P1039, DOI 10.1161/01.STR.15.6.1039; LYDEN PD, 1992, EXP NEUROL, V116, P122, DOI 10.1016/0014-4886(92)90160-R; MARKGRAF CG, 1994, STROKE, V25, P153, DOI 10.1161/01.STR.25.1.153; MARKGRAF CG, 1992, BRAIN RES, V575, P238, DOI 10.1016/0006-8993(92)90085-N; MILESON BE, 1991, NEUROSCI LETT, V128, P71, DOI 10.1016/0304-3940(91)90762-I; PADAYACHEE TS, 1987, ANN THORAC SURG, V44, P298, DOI 10.1016/S0003-4975(10)62077-2; PUGSLEY W, 1994, STROKE, V25, P1393, DOI 10.1161/01.STR.25.7.1393; ROBINSON RG, 1979, SCIENCE, V205, P707, DOI 10.1126/science.462179; RUSSELL D, 1991, STROKE, V22, P253, DOI 10.1161/01.STR.22.2.253; SCHVIER FJ, 1978, ARCH NEUROL-CHICAGO, V35, P264; SKILBECK CE, 1983, J NEUROL NEUROSUR PS, V46, P5, DOI 10.1136/jnnp.46.1.5; SPENCER MP, 1990, STROKE, V21, P415, DOI 10.1161/01.STR.21.3.415; TEGELER CH, 1991, J NEUROIMAGING, V1, P61; WATSON BD, 1987, J NEUROSURG, V66, P748, DOI 10.3171/jns.1987.66.5.0748; WESTER P, 1992, ROLE OF NEUROTRANSMITTERS IN BRAIN INJURY, P153; WESTER P, 1992, STROKE, V23, P870, DOI 10.1161/01.STR.23.6.870; Zilles K., 1985, CORTEX RAT; 1986, ARCH NEUROL-CHICAGO, V43, P71	46	35	37	0	7	AMER HEART ASSOC	DALLAS	7272 GREENVILLE AVENUE, DALLAS, TX 75231-4596	0039-2499			STROKE	Stroke	DEC	1995	26	12					2338	2346		10.1161/01.STR.26.12.2338			9	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	TH075	WOS:A1995TH07500029	7491661				2021-06-18	
J	KRAUSS, JK; WAKHLOO, AK; NOBBE, F; TRANKLE, R; MUNDINGER, F; SEEGER, W				KRAUSS, JK; WAKHLOO, AK; NOBBE, F; TRANKLE, R; MUNDINGER, F; SEEGER, W			LESIONS OF DENTATOTHALAMIC PATHWAYS IN SEVERE POSTTRAUMATIC TREMOR	NEUROLOGICAL RESEARCH			English	Article						HEAD INJURY; MAGNETIC RESONANCE IMAGING; MOVEMENT DISORDER; OUTCOME; TREMOR	POSTTRAUMATIC CEREBELLAR SYNDROME; DIFFUSE AXONAL INJURY; HEAD-INJURY; STEREOTAXIC SURGERY; MOVEMENT-DISORDERS; MR; BRAIN; THALAMOTOMY; FERRITIN; IRON	The present study investigates evidence of dentatothalamic pathway lesions in nineteen patients with severe kinetic post-traumatic tremor retrospectively by magnetic resonance imaging (MRI). Kinetic tremor is thought to be characteristic of lesions of the cerebellar outflow While this hypothesis is supported by experimental data, neuropathological and neuroradiological findings have been limited. The appendicular tremors were unilateral in 13 patients and bilateral in 6, accounting for 25 instances of tremor. The tremor developed after severe head trauma in 18 patients. These patients had evidence of diffuse axonal injury on MRI. Postural and kinetic tremor was present in all patients, and was accompanied by tremor also present at rest in 14 instances. Multiplanar MRI studies were performed on a high-field MRI system operating at 2.0 T in 13 patients and on intermediate-field strength MRI systems in 6 patients according to a standardized protocol. To detect small deposits of hemosiderin after post-traumatic lesions, the protocol included a heavily T2-weighted spin-echo pulse sequence. Lesions of the dentatothalamic pathways were found in 22 instances. The lesions were classified into different types according to their distribution. A lesion of the dentate nucleus ipsilateral to the tremor (type I) was found in one instance (4%), lesions involving the ipsilateral predecussational dentatothalamic pathway (type II and III) were found in 14 instances (56%), and lesions involving the contralateral post-decussational course (type IV) in 7 instances (28%). One patient with a mild head trauma had a lesion of the contralateral thalamus. The lesions appeared as hypointense, hyperintense or mixed. Two of three patients with a parkinsonian-like rest tremor had type IV lesions involving the substantia nigra. The nosological concepts of tremors are discussed. 'Midbrain' tremor may have distinct pathoanatomical lesion sites.	UNIV FREIBURG,DEPT NEUROSURG,FREIBURG,GERMANY; UNIV FREIBURG,NEURORADIOL SECT,FREIBURG,GERMANY; ST JOSEFS HOSP,DEPT FUNCT & STEREOTACT NEUROSURG,FREIBURG,GERMANY							ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ANDREW J, 1982, J NEUROL NEUROSUR PS, V45, P815, DOI 10.1136/jnnp.45.9.815; BIRG W, 1982, APPL NEUROPHYSIOL, V45, P387; BIZZI A, 1990, RADIOLOGY, V177, P59, DOI 10.1148/radiology.177.1.2399339; BROGGI G, 1993, MOVEMENT DISORD, V8, P206, DOI 10.1002/mds.870080217; BULLARD DE, 1984, J NEUROSURG, V61, P316, DOI 10.3171/jns.1984.61.2.0316; BUZSAKI G, 1990, NEUROSCIENCE, V36, P1, DOI 10.1016/0306-4522(90)90345-5; CARPENTER MB, 1956, J COMP NEUROL, V105, P195, DOI 10.1002/cne.901050204; CARREA RME, 1955, J COMP NEUROL, V102, P151, DOI 10.1002/cne.901020108; CHEN JC, 1989, RADIOLOGY, V173, P521, DOI 10.1148/radiology.173.2.2798884; COOPER IS, 1960, NEW ENGL J MED, V263, P441, DOI 10.1056/NEJM196009012630905; DECARO R, 1993, 2ND INT NEUR S GLASG, P38; DIENER HC, 1992, MOVEMENT DISORD, V7, P95, DOI 10.1002/mds.870070202; Fahn S, 1986, MOVEMENT DISORD, V1, P299; FERBERT A, 1993, MOVEMENT DISORD, V8, P179, DOI 10.1002/mds.870080211; FERRIER O, 1894, PHILOS T ROY SOC LON, V185, P719; FRIEDMAN JH, 1992, MOVEMENT DISORD, V7, P281, DOI 10.1002/mds.870070315; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GERSTENBRAND F, 1970, INT J NEUROL, V7, P271; GILMAN S, 1976, BRAIN, V99, P311, DOI 10.1093/brain/99.2.311; GOLDMAN MS, 1992, J NEUROSURG, V77, P223, DOI 10.3171/jns.1992.77.2.0223; HADLEY MDM, 1993, 2ND INT NEUR S GLASG, P180; HAGGARD P, 1995, J NEUROL NEUROSUR PS, V58, P433, DOI 10.1136/jnnp.58.4.433; HALLETT M, 1986, HDB CLIN NEUROLOGY, V49, P583; HARDY PA, 1989, MAGN RESON IMAGING, V12, P25; HENNIG J, 1986, MAGNET RESON MED, V3, P823, DOI 10.1002/mrm.1910030602; HORSTINK MWI, 1991, J NEUROL NEUROSUR PS, V55, P632; Huhn B, 1970, Nervenarzt, V41, P326; IWADATE Y, 1989, Neurosurgical Review, V12, P500, DOI 10.1007/BF01790695; JANKOVIC J, 1980, ANN INTERN MED, V93, P460, DOI 10.7326/0003-4819-93-3-460; JANKOVIC J, 1994, NEUROLOGY, V44, P2006, DOI 10.1212/WNL.44.11.2006; JELLINGER K, 1970, J NEUROL SCI, V10, P51, DOI 10.1016/0022-510X(70)90091-2; JOHNSON SLJ, 1992, ARCH DIS CHILD, V67, P227, DOI 10.1136/adc.67.2.227; KOLLER WC, 1989, MOVEMENT DISORD, V4, P20, DOI 10.1002/mds.870040106; KRAUSS JK, 1994, J NEUROSURG, V80, P810, DOI 10.3171/jns.1994.80.5.0810; KRAUSS JK, 1992, MOVEMENT DISORD, V7, P263, DOI 10.1002/mds.870070313; KREMER M, 1947, J NEUROL NEUROSUR PS, V10, P49, DOI 10.1136/jnnp.10.2.49; LEVIN HS, 1990, J NEUROSURG, V73, P77, DOI 10.3171/jns.1990.73.1.0077; Marks Paul V., 1993, Stereotactic and Functional Neurosurgery, V60, P157, DOI 10.1159/000100605; Marsden C.D., 1984, MOVEMENT DISORDERS T, P37; METTLER FA, 1966, ARCH NEUROL-CHICAGO, V15, P241, DOI 10.1001/archneur.1966.00470150019004; MUNDINGER F, 1963, Fortschr Neurol Psychiatr Grenzgeb, V31, P69; MUNDINGER F, 1965, CONFIN NEUROL, V26, P222; MUNDINGER F, 1963, Fortschr Neurol Psychiatr Grenzgeb, V31, P1; NAKAMURA R, 1993, MOVEMENT DISORD, V8, P209, DOI 10.1002/mds.870080218; OBESO JA, 1983, J NEUROL NEUROSUR PS, V46, P788, DOI 10.1136/jnnp.46.8.788; OHYE C, 1988, BEHAV BRAIN RES, V28, P241, DOI 10.1016/0166-4328(88)90102-7; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; POIRIER LJ, 1960, J NEUROPHYSIOL, V23, P534; ROSENBLUM WI, 1981, NEUROSURGERY, V9, P61; SABRA AF, 1984, NEUROLOGY, V34, P151, DOI 10.1212/WNL.34.2.151; SAMIE MR, 1990, NEUROLOGY, V40, P62, DOI 10.1212/WNL.40.1.62; SANDYK R, 1989, INT J NEUROSCI, V47, P301, DOI 10.3109/00207458908987443; SOLOMON DH, 1994, NEUROLOGY, V44, P810, DOI 10.1212/WNL.44.5.810; STRICH SJ, 1969, LATE EFFECTS HEAD IN, P501; Tomlinson B, 1970, J CLIN PATHOL S4, V23, P154; Walker AE, 1937, BRAIN, V60, P329, DOI 10.1093/brain/60.3.329; Walker AE, 1982, STEREOTAXY HUMAN BRA, P181; WILBERGER JE, 1987, NEUROSURGERY, V20, P571, DOI 10.1227/00006123-198704000-00011	62	35	36	0	1	FOREFRONT PUBL GROUP	LONDON	MONOMARK HOUSE 27 OLD GLOUCESTER STREET, LONDON, ENGLAND WC1N 3XX	0161-6412			NEUROL RES	Neurol. Res.	DEC	1995	17	6					409	416		10.1080/01616412.1995.11740353			8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	TJ818	WOS:A1995TJ81800002	8622792				2021-06-18	
J	STALLINGS, G; BOAKE, C; SHERER, M				STALLINGS, G; BOAKE, C; SHERER, M			COMPARISON OF THE CALIFORNIA VERBAL-LEARNING TEST AND THE REY AUDITORY VERBAL-LEARNING TEST IN HEAD-INJURED PATIENTS	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							MEMORY; FORM	Performances of moderate and severe closed-head-injury patients were compared on the California Verbal Learning Test (CVLT) and Rey Auditory Verbal Learning Test (RAVLT). Results showed that raw scores were highly correlated between tests. There were no significant between-test differences in mean raw scores. However, standard scores calculated from existing CVLT and RAVLT norms were significantly lower on the CVLT than on the RAVLT. Furthermore, there were differences between the various RAVLT norm sets. The results indicate that although the CVLT and RAVLT measure similar cognitive processes in closed-head-injury patients, there are major discrepancies in test interpretation using existing norms. Test and norm set selection significantly influence the likelihood of a patient being classified as memory-impaired.	UNIV TEXAS,SCH MED,HOUSTON,TX; BAYLOR COLL MED,HOUSTON,TX	STALLINGS, G (corresponding author), UNIV HOUSTON,DEPT PSYCHOL,4800 CALHOUN,HOUSTON,TX 77204, USA.						BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; BUSCHKE H, 1973, J VERB LEARN VERB BE, V12, P543, DOI 10.1016/S0022-5371(73)80034-9; CRAWFORD JR, 1989, J CLIN EXP NEUROPSYC, V11, P975, DOI 10.1080/01688638908400950; CROSSEN JR, 1994, J CLIN EXP NEUROPSYC, V16, P190, DOI 10.1080/01688639408402630; CROSSON B, 1988, J CLIN EXP NEUROPSYC, V10, P754, DOI 10.1080/01688638808402812; DELIS D, 1987, CALIFORNIA VERBAL LE; Geffen Gina, 1990, Clin Neuropsychol, V4, P45, DOI 10.1080/13854049008401496; Ivnik R. J., 1990, PSYCHOL ASSESSMENT J, V2, P304, DOI [10.1037/1040-3590.2.3.304, DOI 10.1037/1040-3590.2.3.304]; LEVIN HS, 1986, J CLIN EXP NEUROPSYC, V8, P643, DOI 10.1080/01688638608405185; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; MACARTNEYFILGAT.MS, 1988, ARCH CLIN NEUROPSYCH, V3, P121; Rey A, 1964, LEXAMEN CLIN PSYCHOL; RYAN JJ, 1986, J CLIN EXP NEUROPSYC, V8, P611, DOI 10.1080/01688638608405179; SAVAGE RM, 1992, ARCH CLIN NEUROPSYCH, V7, P407, DOI 10.1016/0887-6177(92)90153-E; Schear J.M., 1989, CLIN NEUROPSYCHOL, V3, P162; SPRREN O, 1991, COMPENDIUM NEUROPSYC; TEASDALE G, 1974, LANCET, V1, P81; WIENS AN, 1994, CLIN NEUROPSYCHOL, V8, P75, DOI 10.1080/13854049408401545; WIENS AN, 1988, CLIN NEUROPSYCHOL, V2, P67, DOI DOI 10.1080/13854048808520087	21	35	36	0	7	SWETS ZEITLINGER BV	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	OCT	1995	17	5					706	712		10.1080/01688639508405160			7	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	TD240	WOS:A1995TD24000006	8557811				2021-06-18	
J	PERSINGER, MA				PERSINGER, MA			SENSE OF A PRESENCE AND SUICIDAL IDEATION FOLLOWING TRAUMATIC BRAIN INJURY - INDICATIONS OF RIGHT-HEMISPHERIC INTRUSIONS FROM NEUROPSYCHOLOGICAL PROFILES	PSYCHOLOGICAL REPORTS			English	Article							TEMPORAL-LOBE EPILEPSY; MYSTICAL EXPERIENCES; SELF	50 patients who had sustained a traumatic brain injury were given complete neuropsychological assessments between 0.5 and 4.0 years after the incident; 62% of these patients reported that episodes of a ''sensed presence'' (left side: 71%; right side: 19%; both: 10%) had occurred. Sensed presences along the left side were primarily (82%) associated with anxiety or fear while those which occurred along the right side were more pleasant (83%). The neuropsychological profiles of patients who reported these experiences suggested elevated complex partial epileptic-like signs and a pattern of mild dysfunction within the right prefrontal and temporoparietal lobes which would promote brief hypermetabolic periods within the latter region. Patients who displayed this profile in conjunction with fragmentation of the self-concept and concomitantly lowered left-hemispheric linguistic functions reported more frequent suicidal impulses. The results are compatible with the hypothesis that the ''sense of a presence'' is an intrusion of the right-hemispheric homologue of the sense of self into left-hemispheric awareness.		PERSINGER, MA (corresponding author), LAURENTIAN UNIV,DEPT PSYCHOL,CLIN NEUROPSYCHOL LAB,RAMSEY LAKE RD,SUDBURY,ON P3E 2C6,CANADA.						ARDILA A, 1988, EPILEPSIA, V29, P188, DOI 10.1111/j.1528-1157.1988.tb04417.x; BEKENSTEIN JW, 1993, SCIENCE, V259, P97, DOI 10.1126/science.8093417; Critchley M, 1953, PARIETAL LOBES; Edelman G., 1989, REMEMBERED PRESENT B; GLOOR P, 1982, ANN NEUROL, V12, P129, DOI 10.1002/ana.410120203; HULL CL, 1952, BEHAVIOR SYSTEM; JIBIKI I, 1994, NEUROSCI BIOBEHAV R, V18, P281, DOI 10.1016/0149-7634(94)90030-2; Kolb B., 1990, FUNDAMENTALS HUMAN N; Maclean P. D., 1990, TRIUNE BRAIN EVOLUTI; Miller L., 1993, PSYCHOTHERAPY BRAIN; Persinger M. A., 1987, NEUROPSYCHOLOGICAL B; PERSINGER MA, 1993, PERCEPT MOTOR SKILL, V76, P915, DOI 10.2466/pms.1993.76.3.915; PERSINGER MA, 1983, PERCEPT MOTOR SKILL, V57, P1255, DOI 10.2466/pms.1983.57.3f.1255; PERSINGER MA, 1993, PSYCHOL REP, V72, P1059, DOI 10.2466/pr0.1993.72.3c.1059; PERSINGER MA, UNPUB HYPERPERFUSION; PHELPS ME, 1985, SCIENCE, V228, P799, DOI 10.1126/science.2860723; Prigatano GP., 1988, J HEAD TRAUMA REHAB, V3, P45; Reitan RM., 1985, HALSTEAD REITAN NEUR; RICHARDS P, 1992, PERCEPT MOTOR SKILL, V74, P1027, DOI 10.2466/PMS.74.4.1027-1030; Roberts RJ, 1990, NEUROPSYCHOLOGY, V4, P65; ROBERTS RJ, 1990, J CLIN EXP NEUROPSYC, V12, P448, DOI 10.1080/01688639008400992; SABOURIN L, 1987, PERCEPT MOTOR SKILL, V64, P309, DOI 10.2466/pms.1987.64.1.309; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002	23	35	37	0	3	PSYCHOLOGICAL REPORTS	MISSOULA	P O BOX 9229, MISSOULA, MT 59807	0033-2941			PSYCHOL REP	Psychol. Rep.	DEC	1994	75	3	1				1059	1070		10.2466/pr0.1994.75.3.1059			12	Psychology, Multidisciplinary	Psychology	PX548	WOS:A1994PX54800001	7892368				2021-06-18	
J	PIERCE, JES; SMITH, DH; EISON, MS; MCINTOSH, TK				PIERCE, JES; SMITH, DH; EISON, MS; MCINTOSH, TK			THE NOOTROPIC COMPOUND BMY-21502 IMPROVES SPATIAL-LEARNING ABILITY IN BRAIN-INJURED RATS	BRAIN RESEARCH			English	Article						FLUID-PERCUSSION BRAIN INJURY; COGNITIVE ENHANCER; NOOTROPIC DRUG; MORRIS WATER MAZE (MWM)	LONG-TERM POTENTIATION; FLUID-PERCUSSION MODEL; ASPARTATE RECEPTOR ANTAGONIST; RABBIT FOLLOWING STIMULATION; HEAD-INJURY; SYNAPTIC TRANSMISSION; LASTING POTENTIATION; SELECTIVE IMPAIRMENT; GLUCOSE-UTILIZATION; MEMORY IMPAIRMENT	Although long-lasting cognitive dysfunction often follows clinical traumatic brain injury (TBI), few pharmacologic regimens have been developed to treat post-traumatic cognitive deficits. We have previously shown that, in the rat, experimental lateral fluid-percussion (FP) brain injury induces a profound impairment in retrograde memory. In the present study, we characterized alterations in the ability of rats to learn a novel task following lateral FP brain injury and examined the potential modulatory effects of the nootropic cognitive enhancer BMY-21502 on post-injury learning. Male Sprague-Dawley rats were subjected to lateral (parasagittal) FP brain injury of moderate severity (2.4 atm) or sham surgery (no injury). On days 7 and 8 post-injury, animals were tested in a Morris water maze for their ability to learn to navigate to a submerged, invisible platform using external visual cues. BMY-21502 (10 mg/kg) or vehicle was administered 30 min prior to the first trial on both days. A highly significant (P < 0.001) impairment in post-injury learning was observed in vehicle-treated brain-injured animals compared with vehicle-treated sham animals. Injured animals treated with BMY-21502 at one week post-injury showed significant (P < 0.05) improvement in post-injury learning ability compared to injured animals treated with vehicle. Paradoxically, in uninjured control animals BMY-21502 treatment appeared to worsen learning scores. The results of this study indicate that BMY-21502 may be useful for attenuating the dysfunction in learning ability that occurs following TBI.	UNIV CONNECTICUT, CTR HLTH, CTR NEUROL SCI, FARMINGTON, CT 06030 USA; BRISTOL MYERS SQUIBB CO, CNS DRUG DISCOVERY, PHARMACEUT RES INST, WALLINGFORD, CT 06492 USA	PIERCE, JES (corresponding author), UNIV PENN, DIV NEUROSURG, 105 HAYDEN HALL, 240 S 33RD ST, PHILADELPHIA, PA 19104 USA.		smith, douglas/A-1321-2007		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS026818, R55NS026818] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS26818] Funding Source: Medline		BARTUS RT, 1981, AGING-US, V17, P209; BERARDI A, 1991, Society for Neuroscience Abstracts, V17, P698; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P357, DOI 10.1113/jphysiol.1973.sp010274; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; BROOKS DN, 1972, J NERV MENT DIS, V155, P350; BROWN TH, 1988, SCIENCE, V242, P724, DOI 10.1126/science.2903551; BUCZEK M, 1991, J CEREBR BLOOD F MET, V11, P845, DOI 10.1038/jcbfm.1991.144; CHOI DW, 1987, J NEUROSCI, V7, P357; COLLINGRIDGE GL, 1987, TRENDS NEUROSCI, V10, P288, DOI 10.1016/0166-2236(87)90175-5; COPANI A, 1992, J NEUROCHEM, V58, P1199, DOI 10.1111/j.1471-4159.1992.tb11329.x; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; COTMAN CW, 1987, TRENDS NEUROSCI, V10, P273, DOI 10.1016/0166-2236(87)90172-X; DAVIS S, 1992, J NEUROSCI, V12, P21; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DOUGLAS RJ, 1967, PSYCHOL BULL, V67, P416, DOI 10.1037/h0024599; Dworetzky S. I., 1992, Society for Neuroscience Abstracts, V18, P1154; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FERRIS SH, 1982, ALZHEIMERS DISEASE R, P475; FITTEN LJ, 1990, PHARMACOL BIOCHEM BE, V35, P553; GASQUOINE P G, 1991, Brain Injury, V5, P169, DOI 10.3109/02699059109008087; GRIBKOFF VK, 1990, NEUROPHARMACOLOGY, V29, P1001, DOI 10.1016/0028-3908(90)90105-Z; GRIBKOFF VK, 1989, ALZHEIMERS DISEASE A, P709; GRONWALL D, 1974, LANCET, V2, P605; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HICKS RR, IN PRESS J NEUROTRAU; ITO I, 1990, J PHYSIOL-LONDON, V424, P533, DOI 10.1113/jphysiol.1990.sp018081; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; KREPS M H, 1991, Society for Neuroscience Abstracts, V17, P874; LAL H, 1991, Society for Neuroscience Abstracts, V17, P1235; LEVIN HS, 1976, CORTEX, V12, P175, DOI 10.1016/S0010-9452(76)80021-4; LINDGREN S, 1969, ACTA PHYSIOL SCAND, V76, P340, DOI 10.1111/j.1748-1716.1969.tb04477.x; LINDNER MD, 1992, PSYCHOPHARMACOLOGY, V107, P485, DOI 10.1007/BF02245260; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MCINTOSH T, 1989, Society for Neuroscience Abstracts, V15, P132; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MCINTOSH TK, 1992, FIDIA RES F S SERIES, V9, P247; MCLEAN A JR, 1991, Brain Injury, V5, P375, DOI 10.3109/02699059109008110; MEANS L W, 1990, Society for Neuroscience Abstracts, V16, P1331; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; Miyazaki S, 1989, INTRACRANIAL PRESSUR, P651; MONAGHAN DT, 1985, J NEUROSCI, V5, P2909; MONAGHAN DT, 1983, NATURE, V306, P176, DOI 10.1038/306176a0; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MORRIS RGM, 1989, J NEUROSCI, V9, P3040; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; OKIYAMA K, 1992, J NEUROSURG, V77, P607, DOI 10.3171/jns.1992.77.4.0607; OLPE HR, 1982, EUR J PHARMACOL, V80, P415, DOI 10.1016/0014-2999(82)90088-7; OLTON DS, 1978, BRAIN RES, V139, P295, DOI 10.1016/0006-8993(78)90930-7; PITTS LH, 1990, HDB CLIN NEUROLOGY, V13, P65; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RUTHERFORD WH, 1977, LANCET, V1, P1; SATOH M, 1986, NEUROSCI LETT, V68, P216, DOI 10.1016/0304-3940(86)90145-X; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; Smith D. H., 1992, Society for Neuroscience Abstracts, V18, P170; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SQUIRE LR, 1992, P NATL ACAD SCI USA, V89, P1837, DOI 10.1073/pnas.89.5.1837; SQUIRE LR, 1986, SCIENCE, V232, P1612, DOI 10.1126/science.3086978; STAUBLI U, 1992, HIPPOCAMPUS, V2, P49, DOI 10.1002/hipo.450020107; STEGINK AJ, 1972, ARZNEI-FORSCHUNG, V22, P975; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; TEYLER TJ, 1984, BRAIN RES REV, V7, P15, DOI 10.1016/0165-0173(84)90027-4; TOCCO G, 1992, BRAIN RES, V573, P228, DOI 10.1016/0006-8993(92)90767-4; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	72	35	35	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	OCT 8	1993	624	1-2					199	208		10.1016/0006-8993(93)90078-2			10	Neurosciences	Neurosciences & Neurology	MA059	WOS:A1993MA05900026	8252392				2021-06-18	
J	KRIEL, RL; KRACH, LE; JONESSAETE, C				KRIEL, RL; KRACH, LE; JONESSAETE, C			OUTCOME OF CHILDREN WITH PROLONGED UNCONSCIOUSNESS AND VEGETATIVE STATES	PEDIATRIC NEUROLOGY			English	Article							CLOSED-HEAD-INJURY; COMA	The outcomes of 60 children unconscious for 90 days or longer following acquired brain injury are reported. Eight children who died had remained in persistent vegetative states. As expected, most neurologic improvement occurred within the first year after injury, although some delayed improvements were observed. Outcomes were strongly correlated with causes of brain injury. Better cognitive and motor function was observed with nonanoxic injuries. No child in this report with anoxic brain injury regained functional cognitive or motor skills, although 3 became socially responsive. The remarkable contrast with adults following acquired brain injury is the significantly longer survival of children. The only children who died had remained in persistent vegetative states.	HENNEPIN CTY MED CTR,DEPT PEDIAT,MINNEAPOLIS,MN 55415; GILLETTE CHILDRENS HOSP,DEPT PEDIAT NEUROL,ST PAUL,MN 55101; GILLETTE CHILDRENS HOSP,DEPT REHABIL,ST PAUL,MN 55101	KRIEL, RL (corresponding author), HENNEPIN CTY MED CTR,DEPT NEUROL,867-B,701 PK AVE S,MINNEAPOLIS,MN 55415, USA.						[Anonymous], 1989, NEUROLOGY, V39, P125; ASHWAL S, 1992, ANN NEUROL, V32, P454; BRAAKMAN R, 1988, ACTA NEUROCHIR, V95, P49, DOI 10.1007/BF01793082; COLE G, 1984, BRIT MED J, V289, P1620, DOI 10.1136/bmj.289.6458.1620-c; EYMAN RK, 1990, NEW ENGL J MED, V323, P584, DOI 10.1056/NEJM199008303230906; GILLIES JD, 1980, DEV MED CHILD NEUROL, V22, P642; HIGASHI K, 1977, J NEUROL NEUROSUR PS, V40, P876, DOI 10.1136/jnnp.40.9.876; HIGASHI K, 1981, J NEUROL NEUROSUR PS, V44, P552, DOI 10.1136/jnnp.44.6.552; JOHNSTON RB, 1980, DEV MED CHILD NEUROL, V22, P3; JORDAN F M, 1990, Brain Injury, V4, P101, DOI 10.3109/02699059009026154; KRIEL RL, 1988, ARCH PHYS MED REHAB, V69, P678; LEVIN HS, 1991, ARCH NEUROL-CHICAGO, V48, P580, DOI 10.1001/archneur.1991.00530180032013; LUYENDIJK W, 1992, CLIN NEUROL NEUROSUR, V94, pS113; MAHONEY WJ, 1983, PEDIATRICS, V71, P756; MARGOLIS LH, 1980, PEDIATRICS, V665, P477; 1990, JAMA-J AM MED ASSOC, V263, P426	16	35	35	0	2	ELSEVIER SCIENCE INC	NEW YORK	655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010	0887-8994			PEDIATR NEUROL	Pediatr. Neurol.	SEP-OCT	1993	9	5					362	368		10.1016/0887-8994(93)90104-K			7	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	MC808	WOS:A1993MC80800004	8292210				2021-06-18	
J	MICHAUD, LJ; RIVARA, FP; JAFFE, KM; FAY, G; DAILEY, JL				MICHAUD, LJ; RIVARA, FP; JAFFE, KM; FAY, G; DAILEY, JL			TRAUMATIC BRAIN INJURY AS A RISK FACTOR FOR BEHAVIORAL-DISORDER IN CHILDREN	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						BRAIN INJURIES; CHILD BEHAVIOR DISORDERS; CHILDREN; HEAD INJURIES; TRAUMA	CLOSED HEAD-INJURY; PSYCHOLOGICAL SEQUELAE; FOLLOW-UP; CHILDHOOD; ADOLESCENTS; DAMAGE; MOTOR		CHILDRENS HOSP MED CTR,HARBORVIEW INJURY PREVENT & RES CTR,DEPT REHABIL MED,SEATTLE,WA; OFF SUPERINTENDENT PUBL INSTRUCT,OLYMPIA,WA; CHILDRENS HOSP MED CTR,HARBORVIEW INJURY PREVENT & RES CTR,DEPT PEDIAT,SEATTLE,WA; CHILDRENS HOSP MED CTR,HARBORVIEW INJURY PREVENT & RES CTR,DEPT EPIDEMIOL,SEATTLE,WA; CHILDRENS HOSP MED CTR,HARBORVIEW INJURY PREVENT & RES CTR,DEPT NEURODIAGNOST,SEATTLE,WA; UNIV WASHINGTON,SEATTLE,WA 98195					PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR002570-04] Funding Source: Medline		BAKER SP, 1984, INJURY FACT BOOK, P24; BIJUR PE, 1986, AM J DIS CHILD, V140, P487, DOI 10.1001/archpedi.1986.02140190097036; BLACK P, 1969, LATE EFFECTS HEAD IN, P142; BOLL TJ, 1983, J CLIN CHILD PSYCHOL, V12, P74, DOI 10.1080/15374418309533114; BRINK JD, 1970, DEV MED CHILD NEUROL, V12, P565; BROUILLET FB, 1988, STATE WASHINGTON RUL, V1, pC392; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; CASEY R, 1986, PEDIATRICS, V78, P497; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHADWICK O, 1985, DEV MED CHILD NEUROL, V27, P72; CHADWICK O, 1981, J CHILD PSYCHOL PSYC, V22, P117, DOI 10.1111/j.1469-7610.1981.tb00538.x; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; Cohen S. B., 1986, J HEAD TRAUMA REHAB, V1, P22; CRAFT AW, 1972, BMJ-BRIT MED J, V4, P200, DOI 10.1136/bmj.4.5834.200; DAVIDSON LL, 1988, PEDIATRICS, V82, P644; DERSHEWITZ RA, 1983, PEDIATRICS, V72, P602; DILLON H, 1961, JAMA-J AM MED ASSOC, V175, P86, DOI 10.1001/jama.1961.03040020012003; EWINGCOBBS L, 1986, J HEAD TRAUMA REHAB, V1, P57; FILLEY CM, 1987, ARCH NEUROL-CHICAGO, V44, P194, DOI 10.1001/archneur.1987.00520140058018; Goldstein FC, 1985, DEV NEUROPSYCHOL, V1, P195, DOI 10.1080/87565648509540310; GULBRANDSEN GB, 1984, J CLIN NEUROPSYCHOL, V6, P257, DOI 10.1080/01688638408401217; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; JACOBSON MS, 1986, PEDIATRICS, V77, P236; JANE JA, 1985, J NEUROSURG, V62, P96, DOI 10.3171/jns.1985.62.1.0096; Jennett B, 1978, Practitioner, V221, P77; KLONOFF H, 1971, AM J PUBLIC HEALTH N, V61, P2405, DOI 10.2105/AJPH.61.12.2405; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; LANGLEY J, 1983, Journal of Pediatric Psychology, V8, P181, DOI 10.1093/jpepsy/8.2.181; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1979, CHILD BRAIN, V5, P281; LEZAK MD, 1978, AM J PHYS MED REHAB, V57, P9; MAHONEY WJ, 1983, PEDIATRICS, V71, P756; MATHENY AP, 1971, J PEDIATR-US, V79, P122, DOI 10.1016/S0022-3476(71)80071-9; MCGUIRE TL, 1986, J HEAD TRAUMA REHAB, V1, P1; MCLEAN A, 1984, NEUROSURGERY, V14, P393, DOI 10.1227/00006123-198404000-00001; NORUSIS MJ, 1986, SPSS PC PLUS IBM PC; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; REEVE R, 1978, BEHAVIOR EXCEPTIONAL, P123; RIVARA FP, 1984, DEV MED CHILD NEUROL, V26, P81; Rothman K. J., 1986, MODERN EPIDEMIOLOGY; Rothman KJ, 1982, EPIDEMIOLOGIC ANAL P; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; RUTTER M, 1981, AM J PSYCHIAT, V138, P1533; RUTTER M, 1980, PSYCHOL MED, V10, P633, DOI 10.1017/S0033291700054933; SHAFFER D, 1980, J AM ACAD CHILD PSY, V19, P592, DOI 10.1016/S0002-7138(09)60964-X; SINGER HS, 1978, PEDIATRICS, V62, P819; SPIVACK MP, 1986, J HEAD TRQAUMA REHAB, V1, P41	47	35	35	0	7	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	1993	74	4					368	375					8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	KX398	WOS:A1993KX39800005	8466417				2021-06-18	
J	HASHIMOTO, T; NAKAMURA, N; RICHARD, KE; FROWEIN, RA				HASHIMOTO, T; NAKAMURA, N; RICHARD, KE; FROWEIN, RA			PRIMARY BRAIN-STEM LESIONS CAUSED BY CLOSED-HEAD INJURIES	NEUROSURGICAL REVIEW			English	Article						DIFFUSE AXONAL INJURY; HEAD INJURY; PRIMARY BRAIN STEM INJURY; SHEARING INJURY		Traumatic lesions of the brain stem are of two types: primary, which are considered to be caused at the moment of impact, and secondary, associated with supratentorial mass lesion. Of the 239 patients with a serious head injury who showed a severe disturbance of consciousness upon admisision and who had CT scan carried out immediately, 21 cases were considered to have a primary brain stem lesion with initial CT scan. A primary brain stem lesion was found in 21 of 239 (8.8%) of patients with serious head injury. Their injuries were caused primarily by traffic accidents. Sixteen of the 21 cases showed not only brain stem lesions but also other brain injuries such as cerebral contusion of the white and gray matter, callosal injury, intraventricular hemorrhage, and subarachnoid hemorrhage, which are considered to be caused by a diffuse shearing injury. Five cases who showed a single injury to the brain stem with no other brain lesions were considered to have a pure brain stem lesion. Primary brain stem lesions were observed on the dorsal side of the midbrain, where they can be differentiated from secondary brain stem lesions. These lesions are considered to result from the shearing mechanism in and around the brain stem very close to the tentorial edge, or to an injury of the lower brain stem by hyperextension of the cervical vertebrae. The prognosis of patients with a primary brain stem lesion was usually unfavorable, except in those with a single brain stem lesion.	UNIV COLOGNE, FAC MED, DEPT NEUROSURG, W-5000 COLOGNE 41, GERMANY	HASHIMOTO, T (corresponding author), JIKEI UNIV SCH MED, DEPT NEUROSURG, 3-25-8 NISHI SHINBASHI, MINATO KU, TOKYO 105, JAPAN.						Abe T, 1979, No Shinkei Geka, V7, P345; ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1982, ADV NEUROPATHOLOGY, V2; BRITT RH, 1980, NEUROSURGERY, V6, P623, DOI 10.1227/00006123-198006000-00002; CLIFTON GL, 1981, NEUROSURGERY, V8, P309, DOI 10.1227/00006123-198103000-00002; COOPER PR, 1979, NEUROSURGERY, V4, P115, DOI 10.1227/00006123-197902000-00002; CROMPTON MR, 1971, LANCET, V1, P669; DIRNHOFER R, 1977, RECHTSMEDIZIN, V79, P25; FRENCH BN, 1977, SURG NEUROL, V7, P171; FROWEIN RA, 1976, ACTA NEUROCHIR, V34, P5, DOI 10.1007/BF01405858; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Huhn B, 1970, Nervenarzt, V41, P326; KOBAYASHI S, 1980, Neurological Surgery, V8, P1165; LINDENBERG R, 1970, ARCH PATHOL, V90, P509; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; Mayer E T, 1969, Radiologe, V9, P16; MITCHELL DE, 1973, LANCET, V2, P215; NAKAJIMA S, 1980, JIKEIKAI MED J, V95, P529; NAKAMURA N, 1985, HEAD INJURY; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; PILZ P, 1982, J NEUROL NEUROSUR PS, V45, P422, DOI 10.1136/jnnp.45.5.422; ROSENBLUM WI, 1981, NEUROSURGERY, V9, P613, DOI 10.1227/00006123-198112000-00001; SAEKI N, 1985, Neurologia Medico-Chirurgica, V25, P939, DOI 10.2176/nmc.25.939; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRICH SJ, 1969, LATE EFFECT HEAD INJ; Tomlinson B E, 1970, J Clin Pathol Suppl (R Coll Pathol), V4, P154; TSAI FY, 1980, AM J NEURORADIOL, V1, P23; ZIMMERMAN RA, 1978, AM J ROENTGENOL, V131, P27, DOI 10.2214/ajr.131.1.27; ZUCCARELLO M, 1983, ACTA NEUROCHIR, V67, P103, DOI 10.1007/BF01401670	29	35	35	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0344-5607	1437-2320		NEUROSURG REV	Neurosurg. Rev.		1993	16	4					291	298		10.1007/BF00383839			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	MR330	WOS:A1993MR33000006	8127442				2021-06-18	
J	JACOBSEN, EJ; VANDOORNIK, FJ; AYER, DE; BELONGA, KL; BRAUGHLER, JM; HALL, ED; HOUSER, DJ				JACOBSEN, EJ; VANDOORNIK, FJ; AYER, DE; BELONGA, KL; BRAUGHLER, JM; HALL, ED; HOUSER, DJ			2-(AMINOMETHYL)CHROMANS THAT INHIBIT IRON-DEPENDENT LIPID-PEROXIDATION AND PROTECT AGAINST CENTRAL-NERVOUS-SYSTEM TRAUMA AND ISCHEMIA	JOURNAL OF MEDICINAL CHEMISTRY			English	Article							SPINAL-CORD INJURY; EXPERIMENTAL BRAIN INJURY; VITAMIN-E; CEREBRAL-ISCHEMIA; ALPHA-TOCOPHEROL; OXYGEN RADICALS; 21-AMINOSTEROID U74006F; GLOBAL-ISCHEMIA; HUMAN-DISEASE; RAT-BRAIN	A series of 2-(aminomethyl)chromans was developed as potent inhibitors of iron-dependent lipid peroxidation. Compounds within this class are extremely effective at inhibiting lipid peroxidation with IC50's as low as 0.2 muM. Selected members were found to enhance early neurological recovery and survival in a mouse head injury model. In this assay, improvement in the 1-h post-head-injury neurological status (grip test score) by as much as 230 % of control was observed. One of the most efficacious compounds (35) was evaluated in two models of cerebral ischemia where significant neuroprotection was observed. These results provide further support for the importance of cerebroprotective antioxidants for the treatment of traumatic and ischemic injury as well as additional evidence for the role of oxygen radicals in postischemic brain damage.	UPJOHN CO,CHEM RES PREPARAT,KALAMAZOO,MI 49001; UPJOHN CO,CNS RES,KALAMAZOO,MI 49001	JACOBSEN, EJ (corresponding author), UPJOHN CO,MED CHEM RES,7246-209-719,301 HENRIETTA ST,KALAMAZOO,MI 49001, USA.		Hall, Edward D/F-8930-2013				Anderson D.K., 1983, NEUROCHEM PATHOL, V1, P249; ANDERSON DK, 1988, J NEUROSURG, V69, P562, DOI 10.3171/jns.1988.69.4.0562; ARDELT BK, 1989, TOXICOLOGY, V56, P147, DOI 10.1016/0300-483X(89)90129-7; Asano T, 1980, CEREBRAL ARTERIAL SP, P190; BOLKENIUS FN, 1991, FREE RADICAL RES COM, V14, P363, DOI 10.3109/10715769109093425; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; BRAUGHLER J M, 1989, Drugs of the Future, V14, P143; BRAUGHLER JM, 1986, J BIOL CHEM, V261, P282; BRAUGHLER JM, 1988, BIOCHEM PHARMACOL, V37, P3853, DOI 10.1016/0006-2952(88)90066-4; BRAUGHLER JM, 1987, J BIOL CHEM, V262, P10438; BRAUGHLER JM, 1988, J PHARMACOL EXP THER, V244, P423; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; BURTON GW, 1986, ACCOUNTS CHEM RES, V19, P194, DOI 10.1021/ar00127a001; BURTON GW, 1981, J AM CHEM SOC, V103, P6472, DOI 10.1021/ja00411a035; COHEN G, 1982, PATHOLOGY OXYGEN, P115; COHEN N, 1982, SYNTHETIC COMMUN, V12, P57, DOI 10.1080/00397918208080067; CRAW MT, 1985, REV CHEM INTERMED, V6, P1, DOI 10.1007/BF03155990; CROSS CE, 1987, ANN INTERN MED, V107, P526, DOI 10.7326/0003-4819-107-4-526; DEMOPOULOS HB, 1982, CAN J PHYSIOL PHARM, V60, P1415, DOI 10.1139/y82-210; FANTONE JC, 1982, AM J PATHOL, V107, P397; FLOYD RA, 1982, FREE RADICALS CANCER; FUJIMOTO S, 1984, SURG NEUROL, V22, P449, DOI 10.1016/0090-3019(84)90301-X; GIROTTI AW, 1984, J BIOL CHEM, V259, P1744; Hall E., 1989, J CEREB BLOOD FLO S1, V19, pS561; Hall E D, 1987, Acta Anaesthesiol Belg, V38, P421; Hall E D, 1986, Cent Nerv Syst Trauma, V3, P281; HALL ED, 1982, INT REV NEUROBIOL, V23, P165, DOI 10.1016/S0074-7742(08)60625-X; HALL ED, 1982, SURG NEUROL, V18, P320, DOI 10.1016/0090-3019(82)90140-9; HALL ED, 1988, J NEUROSURG, V68, P462, DOI 10.3171/jns.1988.68.3.0462; HALL ED, 1985, J NEUROSURG, V62, P882, DOI 10.3171/jns.1985.62.6.0882; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; HALL ED, 1990, STROKE, V21, P83; HALL ED, 1988, STROKE, V19, P997, DOI 10.1161/01.STR.19.8.997; HALL ED, 1988, EXP NEUROL, V102, P244, DOI 10.1016/0014-4886(88)90100-8; HALL ED, 1982, J NEUROSURG, V57, P247, DOI 10.3171/jns.1982.57.2.0247; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; HALL ED, 1991, J PHARMACOL EXP THER, V258, P688; HALL ED, Patent No. 78517; HALLIWELL B, 1985, TRENDS NEUROSCI, V8, P22, DOI 10.1016/0166-2236(85)90010-4; HARMAN D, 1982, FREE RADICAL BIO MED, V5, P255; HARRIS RJ, 1981, J CEREBR BLOOD F MET, V1, P203, DOI 10.1038/jcbfm.1981.21; JACOBSEN EJ, 1990, J MED CHEM, V33, P1145, DOI 10.1021/jm00166a010; KANAMARU K, 1991, J NEUROSURG, V74, P454, DOI 10.3171/jns.1991.74.3.0454; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; KURRARY, Patent No. 202580; MAKER HS, 1981, J NEUROCHEM, V36, P589, DOI 10.1111/j.1471-4159.1981.tb01631.x; McBrien D. C. H., 1982, FREE RADICALS LIPID; McCall J M, 1987, Acta Anaesthesiol Belg, V38, P417; MCCAY PB, 1985, ANNU REV NUTR, V5, P323, DOI 10.1146/annurev.nu.05.070185.001543; MCCORD JM, 1968, J BIOL CHEM, V243, P5753; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; MUKAI K, 1982, CHEM PHYS LIPIDS, V30, P337, DOI 10.1016/0009-3084(82)90027-5; NISHIKIMI M, 1975, ARCH BIOCHEM BIOPHYS, V170, P684, DOI 10.1016/0003-9861(75)90165-4; OBRIEN PJ, 1969, CAN J BIOCHEM CELL B, V47, P485, DOI 10.1139/o69-076; PIETTE LH, 1983, OXYGEN RADICALS CHEM, P137; Pryor W.A., 1984, FREE RADICALS MOL BI, P13; Sano K, 1980, Neurol Res, V2, P253; SAUNDERS RD, 1987, J NEUROCHEM, V49, P24, DOI 10.1111/j.1471-4159.1987.tb03388.x; SCHUDEL P, 1972, VITAMINS, P168; SCOTT J, 1977, Patent No. 4003919; SCOTT JW, 1974, J AM OIL CHEM SOC, V51, P200, DOI 10.1007/BF02632894; SCOTT ML, 1978, FAT SOLUBLE VITAMINS, P133; SLIVKA A, 1985, J BIOL CHEM, V260, P5466; SOUTHORN PA, 1988, MAYO CLIN PROC, V63, P390, DOI 10.1016/S0025-6196(12)64862-9; STEINKE DE, 1989, NEUROSURGERY, V24, P179, DOI 10.1227/00006123-198902000-00005; TAYLOR MJ, 1981, J AM OIL CHEM SOC, V58, P622, DOI 10.1007/BF02672378; THOMAS CE, 1985, J BIOL CHEM, V260, P3275; WATSON BD, 1984, J NEUROCHEM, V42, P268, DOI 10.1111/j.1471-4159.1984.tb09728.x; WAUQUIER A, 1981, ARCH INT PHARMACOD T, V249, P330; YAMAMOTO M, 1983, STROKE, V14, P977, DOI 10.1161/01.STR.14.6.977; YAMAMOTO S, 1983, PROSTAGLANDINS RELAT, P171	71	35	36	1	3	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036	0022-2623			J MED CHEM	J. Med. Chem.	NOV 13	1992	35	23					4464	4472		10.1021/jm00101a025			9	Chemistry, Medicinal	Pharmacology & Pharmacy	JY974	WOS:A1992JY97400025	1447746				2021-06-18	
J	SCHMITTEREDGECOMBE, ME; MARKS, W; FAHY, JF; LONG, CJ				SCHMITTEREDGECOMBE, ME; MARKS, W; FAHY, JF; LONG, CJ			EFFECTS OF SEVERE CLOSED-HEAD INJURY ON 3 STAGES OF INFORMATION-PROCESSING	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							REACTION-TIME; MEMORY; TASK; PERFORMANCE; SPEED; P300	The present study investigated the loci of the information-processing delay that characteristically follows severe closed-head injury (CHI). Sternberg's additive-factors logic was used to determine the effects of severe CHI on the central information-processing stages of stimulus encoding, memory comparison, and decision-making/response-selection. The task variables used to define the stages operationally were stimulus quality, memory set size, and stimulus-response compatibility. Twenty subjects who had sustained a severe CHI more than 18 months earlier and 20 matched control subjects completed a stimulus encoding by response selection task in Experiment 1, and a Sternberg high-speed memory scanning task in Experiment 2. The CHI group performed the stimulus encoding and decision-making/response-selection stages of processing significantly slower than did the control group. However, no significant group differences were found on the memory comparison stage, suggesting that memory comparison processes may be relatively intact in long-term patients with severe head trauma. The results are discussed in relation to a global and a late-specificity hypothesis of central processing deficits following severe CHI. The possibility that cognitive processes demanding less attention may be more resilient to injury is also considered.		SCHMITTEREDGECOMBE, ME (corresponding author), MEMPHIS STATE UNIV, DEPT PSYCHOL, MEMPHIS, TN 38152 USA.						ANDERS TR, 1973, DEV PSYCHOL, V9, P411, DOI 10.1037/h0034930; BADDELEY A, 1987, NEUROBEHAVIORAL RECO, P295; Baddeley A.D, 1976, PSYCHOL MEMORY; Bashore T.R., 1990, EVENT RELATED BRAIN, P242; BOND MR, 1983, REHABILITATION HEAD, P185; CALLAWAY E, 1983, PSYCHOPHYSIOLOGY, V20, P359, DOI 10.1111/j.1469-8986.1983.tb00915.x; CURRY SH, 1984, ANN NY ACAD SCI, V425, P171, DOI 10.1111/j.1749-6632.1984.tb23529.x; DEACON D, 1991, ELECTROEN CLIN NEURO, V78, P133, DOI 10.1016/0013-4694(91)90113-I; Gronwall D.M., 1974, PSYCHOL EFFECTS CONC; HANNAY H J, 1982, Journal of Clinical Neuropsychology, V4, P117; HARRIS GJ, 1974, J EXP CHILD PSYCHOL, V17, P452, DOI 10.1016/0022-0965(74)90055-1; Haut M W, 1990, Arch Clin Neuropsychol, V5, P299, DOI 10.1016/0887-6177(90)90028-N; Jennett B, 1981, MANAGEMENT HEAD INJU; LOFTUS GR, 1978, MEM COGNITION, V6, P312, DOI 10.3758/BF03197461; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; MAGLIERO A, 1984, PSYCHOPHYSIOLOGY, V21, P171, DOI 10.1111/j.1469-8986.1984.tb00201.x; MANDLEBERG IA, 1975, J NEUROL NEUROSUR PS, V38, P1121, DOI 10.1136/jnnp.38.11.1121; MARKS W, 1989, BEHAV RES METH INSTR, V21, P574, DOI 10.3758/BF03210579; MARSH G R, 1975, Experimental Aging Research, V1, P3, DOI 10.1080/03610737508257942; MCCARTHY G, 1981, SCIENCE, V211, P77, DOI 10.1126/science.7444452; MCCLELLAND JL, 1979, PSYCHOL REV, V86, P287, DOI 10.1037/0033-295X.86.4.287; Miller E, 1970, Cortex, V6, P121; NAVON D, 1979, PSYCHOL REV, V86, P214, DOI 10.1037/0033-295X.86.3.214; PIETERS JPM, 1983, PSYCHOL BULL, V93, P411, DOI 10.1037/0033-2909.93.3.411; Ruesch J, 1944, AM J PSYCHIAT, V100, P480, DOI 10.1176/ajp.100.4.480; Ruesch J, 1944, J NEUROSURG, V1, P243, DOI 10.3171/jns.1944.1.4.0243; RUGG MD, 1988, J NEUROL NEUROSUR PS, V51, P691, DOI 10.1136/jnnp.51.5.691; RUGG MD, 1989, BRAIN, V112, P489, DOI 10.1093/brain/112.2.489; SANDERS AF, 1980, TUTORIALS MOTOR BEHA, P331, DOI DOI 10.1016/S0166-4115(08)61955-X; Sattler J.M., 1988, ASSESSMENT CHILDRENS, V3rd; SCHMITT JC, 1977, AM J PSYCHOL, V90, P565, DOI 10.2307/1421730; SHUM DHK, 1990, J CLIN EXP NEUROPSYC, V12, P247, DOI 10.1080/01688639008400971; SININGER YS, 1989, J SPEECH HEAR RES, V32, P289, DOI 10.1044/jshr.3202.289; STERNBERG S, 1969, AM SCI, V57, P421; STERNBERG S, 1975, Q J EXP PSYCHOL, V27, P1, DOI 10.1080/14640747508400459; Sternberg S, 1969, ACTA PSYCHOL, V30, P276, DOI 10.1016/0001-6918(69)90055-9; STOKX LC, 1986, J CLIN EXP NEUROPSYC, V8, P421, DOI 10.1080/01688638608401332; Van Zomeren A. H., 1981, REACTION TIME ATTENT; Van Zomeren A. H., 1984, CLOSED HEAD INJURY P, P74; VANZOMEREN AH, 1976, CLIN NEUROL NEUROSUR, V79, P81, DOI 10.1016/0303-8467(76)90001-9; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; WILSON RS, 1980, CORTEX, V16, P67, DOI 10.1016/S0010-9452(80)80022-0	42	35	35	0	2	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	SEP	1992	14	5					717	737		10.1080/01688639208402858			21	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	JY191	WOS:A1992JY19100006	1474141				2021-06-18	
J	YING, Z; SCHMID, UD; SCHMID, J; HESS, CW				YING, Z; SCHMID, UD; SCHMID, J; HESS, CW			MOTOR AND SOMATOSENSORY EVOKED-POTENTIALS IN COMA - ANALYSIS AND RELATION TO CLINICAL STATUS AND OUTCOME	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							SEVERE HEAD-INJURY; NITROUS-OXIDE; ELECTRICAL-STIMULATION; MAGNETIC STIMULATION; CEREBRAL-CORTEX; BRAIN; PREDICTION; TRAUMA; SCALE	Central sensory and motor conduction were studied in 23 comatose and three brain-dead patients. Motor evoked potentials (MEPs) to transcranial magnetic (magMEP) and electrical (elMEP) stimulation were recorded from the hypothenar muscle, and somatosensory evoked potentials (SEPs) were recorded after median nerve stimulation. Comparison of clinical with evoked potential (EP) findings revealed: 1) a painful stimulus applied to the skin of the arm lowered excitation threshold to cortical stimulation and was a prerequisite to obtain MEPs in 14 instances; 2) only in brain-dead patients were all EPs abolished simultaneously and bilaterally; 3) MEPS (p less-than-or-equal-to 0-05, chi-2-Test), but not necessarily SEPs (p > 0.1) were preserved in the arms that showed normal motor reaction during clinical examination; 4) no correlation was found between EP findings and the Glasgow Coma Scale (GCS). The results of clinical and EP testing were examined in. the light of the patient's outcome 10 months later: 1) fatal outcome was predicted by a GCS of three (38% of cases, p less-than-or-equal-to 0.05, Fisher's exact test), abolished brainstem- or pupillary reflexes (38%, p less-than-or-equal-to 0.05), the combination of these clinical signs (54%, p less-than-or-equal-to 0.01), bilateral abolition of elMEPs (38%, p less-than-or-equal-to 0.05), magMEPs (38%, p less-than-or-equal-to 0.05), or SEPs (23%, p > 0.1), or a combination of clinical and EP data (85%, p less-than-or-equal-to 0.0005); 2) good outcome was predicted by a GCS of greater-than-or-equal-to 8 only in post-traumatic coma, and EPs did not help to predict quality of survival. It is concluded that EPs may be studied to predict fatal outcome of coma; 1) if this appears impossible on the basis of clinical data alone; 2) if a second indicator is needed to confirm a clinical impression; 3) SEPs may be first evaluated during the acute stage of coma treatment, because they can be recorded in the presence of anaesthetic or relaxant agents; 4) MEP may be studied if outcome prediction remains ambiguous, and if the clinical situation allows for discontinuation of these agents.	BERNE UNIV HOSP,DEPT NEUROL,BERN,SWITZERLAND; BERNE UNIV HOSP,DEPT NEUROSURG,BERN,SWITZERLAND							AMASSIAN VE, 1987, NEUROSURGERY, V20, P74; BARKER AT, 1985, LANCET, V1, P1106; BESSER R, 1988, NEUROSURG REV, V11, P171, DOI 10.1007/BF01794684; BORN J, 1989, ACTA NEUROCHIR WIEN, V91, P1; Braakman R, 1986, Acta Neurochir Suppl (Wien), V36, P112; CANT BR, 1986, ELECTROEN CLIN NEURO, V65, P188, DOI 10.1016/0168-5597(86)90053-5; DATE M, 1991, ELECTROENCEPHALOGR S, V43, P209; DAY BL, 1988, J PHYSL LOND P, V68, P399; GREENBERG RP, 1977, J NEUROSURG, V47, P163, DOI 10.3171/jns.1977.47.2.0163; HACKE W, 1987, EEG-EMG-Z ELEK ELEKT, V18, P173; HESS CW, 1987, J PHYSIOL-LONDON, V388, P397, DOI 10.1113/jphysiol.1987.sp016621; HOULDEN DA, 1990, NEUROSURGERY, V27, P701, DOI 10.1227/00006123-199011000-00006; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1977, LANCET, V1, P878; JUDSON JA, 1990, CRIT CARE MED, V18, P363, DOI 10.1097/00003246-199004000-00003; KOHT A, 1988, ANESTH ANALG, V67, P435; LINDSAY K, 1990, NEUROSURGERY, V26, P278, DOI 10.1227/00006123-199002000-00015; MACDONELL RAL, 1989, ANN NEUROL, V25, P68, DOI 10.1002/ana.410250111; MERTON PA, 1980, NATURE, V285, P227, DOI 10.1038/285227a0; MULLERJENSEN A, 1987, J NEUROL NEUROSUR PS, V50, P389; PATHAK KS, 1989, ANESTHESIOLOGY, V70, P207, DOI 10.1097/00000542-198902000-00005; PLUM F, 1980, DIAGNOSIS STUPOR COM, P313; RIFFEL B, 1989, ANAESTHESIST, V38, P51; RUMPL E, 1988, J CLIN NEUROPHYSIOL, V5, P237, DOI 10.1097/00004691-198807000-00002; SCHMID U, 1991, NEUROSURGERY, V30, P85; SCHMID UD, 1988, J NEUROL NEUROSUR PS, V51, P182, DOI 10.1136/jnnp.51.2.182; SCHMID UD, 1990, J NEUROL NEUROSUR PS, V53, P770, DOI 10.1136/jnnp.53.9.770; TEASDALE G, 1974, LANCET, V2, P81; TUNG H C, 1988, Anesthesiology (Hagerstown), V69, pA313, DOI 10.1097/00000542-198809010-00312; TURNER F, 1988, SPINAL CORD MONITORI, P82; WALSER H, 1986, J NEUROL, V233, P34, DOI 10.1007/BF00313989; ZENTNER J, 1989, NEUROSURGERY, V24, P60, DOI 10.1227/00006123-198901000-00009; ZENTNER J, 1988, EUR ARCH PSY CLIN N, V237, P184, DOI 10.1007/BF00451288; ZENTNER J, 1989, NEUROSURGERY, V24, P253, DOI 10.1227/00006123-198902000-00016	34	35	36	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	JUN	1992	55	6					470	474		10.1136/jnnp.55.6.470			5	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	HZ150	WOS:A1992HZ15000011	1619414	Green Published, Bronze			2021-06-18	
J	GALLYAS, F; ZOLTAY, G; BALAS, I				GALLYAS, F; ZOLTAY, G; BALAS, I			AN IMMEDIATE LIGHT MICROSCOPIC RESPONSE OF NEURONAL SOMATA, DENDRITES AND AXONS TO CONTUSING CONCUSSIVE HEAD-INJURY IN THE RAT	ACTA NEUROPATHOLOGICA			English	Article						CONTUSING CONCUSSIVE HEAD INJURY; INDUCED ARGYROPHILIA; NEURONS; DENDRITES; AXONS	BRAIN; DAMAGE; TRAUMA	Thirty-four rats were killed by transcardial perfusion fixation 1 min after a contusing concussive head injury, and 17 rats 1 day later. From the results obtained with a new silver method demonstrating traumatically damaged neuronal somata, dendrites and axons the following conclusions were drawn: (1) outside the contused territories all features of traumatically induced neuronal argyrophilia are similar to those found in non-contusing concussive head injury, as reported in an accompanying paper; (2) within contused territories the neuronal argyrophilia is abolished by some substance released either from damaged blood vessels or from damaged parenchymal cells, while the neuronal damage otherwise underlying the induction of argyrophilia is present; (3) different phenotypes of neurons are vulnerable to different values of the parameters of the intracranial pressure wave generated by the trauma; (4) some of the neurons may recover from the traumatically induced argyrophilic damage; (5) traumatically induced inundation of neurons with extracellular tracers, as reported by other authors, and somato-dendritic argyrophilia may be different manifestations of one and the same phenomenon; and (6) diffuse primary traumatic axonal injury in human neuropathology may be closely correlated to axonal argyrophilia.		GALLYAS, F (corresponding author), UNIV PECS,DEPT NEUROSURG,RET UTCA 2,H-7623 PECS,HUNGARY.		Gallyas, Ferenc/C-5450-2009				ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1985, CENTRAL NERVOUS SYST, P65; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; ERB DE, 1988, ACTA NEUROPATHOL, V76, P347, DOI 10.1007/BF00686971; GALLYAS F, 1990, ACTA NEUROPATHOL, V79, P620, DOI 10.1007/BF00294239; GALLYAS F, 1992, ACTA NEUROPATHOL, V83, P386, DOI 10.1007/BF00713530; GALLYAS F, 1992, IN PRESS ACTA NEUROP, V83; GRIFFITHS IR, 1974, J NEUROL SCI, V22, P291, DOI 10.1016/0022-510X(74)90002-1; KLATZO IGOR, 1962, ACTA NEUROPATHOLOGICA, V2, P144; MAXWELL WL, 1990, J NEUROCYTOL, V19, P235, DOI 10.1007/BF01217301; PERSSON L, 1976, ACTA NEUROPATHOL, V34, P125, DOI 10.1007/BF00684663; POVLISHOCK JT, 1979, ACTA NEUROPATHOL, V47, P1, DOI 10.1007/BF00698266; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Povlishock JT, 1985, CENTRAL NERVOUS SYST, P443; RINDER L, 1968, ACTA NEUROPATHOL, V11, P183; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; VANDENPOL AN, 1990, J COMP NEUROL, V296, P654, DOI 10.1002/cne.902960410; VANEGAS H, 1978, J COMP NEUROL, V177, P193, DOI 10.1002/cne.901770203	18	35	35	0	1	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010	0001-6322			ACTA NEUROPATHOL	Acta Neuropathol.	MAR	1992	83	4					394	401		10.1007/BF00713531			8	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	HK264	WOS:A1992HK26400010	1374205				2021-06-18	
J	ASHRAF, J; CROCKARD, HA; RANSFORD, AO; STEVENS, JM				ASHRAF, J; CROCKARD, HA; RANSFORD, AO; STEVENS, JM			TRANSORAL DECOMPRESSION AND POSTERIOR STABILIZATION IN MORQUIOS-DISEASE	ARCHIVES OF DISEASE IN CHILDHOOD			English	Article								A 3.5 year old boy with Morquio's disease was referred with a persisting left hemiparesis four months after a fall and was found to have craniocervical junction compression due to atlantoaxial subluxation and significant anterior soft tissue compression. Transient unconsciousness at the time of the fall was probably due to medullary concussion as a result of hyperextension, not a head injury. Spinal cord compression due to atlantoaxial subluxation at the craniovertebral junction is a major cause of disability and death in these patients. Once cervical myelopathy appears, early posterior occipitocervical fusion has been advocated in order to arrest the progression of neurological disability and this is successful in most cases. This conventional approach was considered unsafe because of the significant anterior compression. A combined anterior transoral decompression with posterior fusion to deal with this particularly difficult problem is described.	NATL HOSP NEUROL & NEUROSURG, QUEEN SQ, LONDON WC1N 3BG, ENGLAND; UNIV COLL HOSP LONDON, WC1 LONDON, ENGLAND							Beighton P, 1973, J Bone Joint Surg Br, V55, P478; BETHEM D, 1981, J BONE JOINT SURG AM, V63, P1412, DOI 10.2106/00004623-198163090-00007; Crockard H A, 1988, Clin Neurosurg, V34, P389; CROCKARD HA, 1990, J BONE JOINT SURG BR, V72, P682; EDWARDS MK, 1982, AM J NEURORADIOL, V3, P666; GOLDBERG MJ, 1976, ORTHOP CLIN N AM, V7, P445; GREENBERG AD, 1968, BRAIN, V91, P655, DOI 10.1093/brain/91.4.655; JONES AEP, 1979, ANESTHESIOLOGY, V51, P261, DOI 10.1097/00000542-197909000-00018; KOPITS SE, 1972, J BONE JOINT SURG AM, V54, P1349; KOPITS SE, 1976, CLIN ORTHOP RELAT R, V114, P153; LIPSON SJ, 1977, J BONE JOINT SURG AM, V59, P340, DOI 10.2106/00004623-197759030-00008; MCKUSICK VA, 1972, HERITABLE DISORDERS, P596; MCKUSICK VA, 1983, METABOLIC BASIS INHE, P751; OGDEN JA, 1986, SKELETAL RADIOL, V15, P433, DOI 10.1007/BF00355100; STEVENS JM, 1991, J BONE JOINT SURG BR, V73, P851	15	35	35	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0003-9888	1468-2044		ARCH DIS CHILD	Arch. Dis. Child.	NOV	1991	66	11					1318	1321		10.1136/adc.66.11.1318			4	Pediatrics	Pediatrics	GQ327	WOS:A1991GQ32700015	1755646	Green Published, Bronze			2021-06-18	
J	MARSH, NV; KNIGHT, RG				MARSH, NV; KNIGHT, RG			BEHAVIORAL-ASSESSMENT OF SOCIAL COMPETENCE FOLLOWING SEVERE HEAD-INJURY	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							SKILLS; REHABILITATION; ADJUSTMENT; DISORDERS	Eighteen community-dwelling adults who had suffered a very severe closed-head injury more than 18 months previously and required long-term rehabilitative support were compared with a closely matched control group on a number of behavioral measures of skill during social interaction. Results showed that during social interactions the head-injured patients exhibited impaired communication skills. They appeared disinterested, and thier speech was characterized as lacking in fluency and clarity due to their difficulty in finding appropriate words, use of inappropriate expressions and inability to express ideas clearly. Attempts to find a relationship between the patients' cognitive deficits and their impaired communication skills were unsuccessful. It is suggested that the often reported poor social adjustment of some head-injured patients is in part related to their inappropriate behavior during social interactions. This is particularly manifest in their poor language skills and speech delivery style.	UNIV OTAGO, DUNEDIN, NEW ZEALAND	MARSH, NV (corresponding author), UNIV WAIKATO, DEPT PSYCHOL, PRIVATE BAG 3105, HAMILTON, NEW ZEALAND.		Marsh, Nigel V./F-5433-2019	Marsh, Nigel V./0000-0002-4060-6432			BELLACK AS, 1983, BEHAV RES THER, V21, P29, DOI 10.1016/0005-7967(83)90123-7; Bond M R, 1979, Int Rehabil Med, V1, P155; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; BUSCHKE H, 1973, J VERB LEARN VERB BE, V12, P543, DOI 10.1016/S0022-5371(73)80034-9; Cronbach L.J., 1972, DEPENDABILITY BEHAVI; CURRAN JP, 1984, RADICAL APPROACHES S, P16; DODWELL D, 1988, J NEUROL NEUROSUR PS, V51, P833, DOI 10.1136/jnnp.51.6.833; EAMES P, 1985, J NEUROL NEUROSUR PS, V48, P613, DOI 10.1136/jnnp.48.7.613; EHRLICH JS, 1988, J COMMUN DISORD, V21, P1, DOI 10.1016/0021-9924(88)90006-8; FARRELL AD, 1985, BEHAV ASSESS, V7, P155; FARRELL AD, 1979, J CONSULT CLIN PSYCH, V47, P164; GLOSSER G, 1990, J CLIN EXP NEUROPSYC, V12, P485, DOI 10.1080/01688639008400995; GODFREY HPD, 1989, PSYCHOL MED, V19, P175, DOI 10.1017/S0033291700011120; HAGEN C, 1982, COGNITIVE REHABILITA, P131; Holland A., 1982, CLIN APH P C, P345; HOLLAND BS, 1988, PSYCHOL BULL, V104, P145, DOI 10.1037/0033-2909.104.1.145; HOLM S, 1979, SCAND J STAT, V6, P65; HORTON AM, 1981, PERCEPT MOTOR SKILL, V53, P349, DOI 10.2466/pms.1981.53.2.349; JOHNSON DA, 1987, BRIT J CLIN PSYCHOL, V26, P289, DOI 10.1111/j.2044-8260.1987.tb01362.x; LARZELERE RE, 1977, PSYCHOL BULL, V84, P557, DOI 10.1037/0033-2909.84.3.557; LAWSON MJ, 1989, J CLIN EXP NEUROPSYC, V11, P842, DOI 10.1080/01688638908400939; LEWIS FD, 1988, BEHAV THER, V19, P203, DOI 10.1016/S0005-7894(88)80043-1; Marsh NV, 1990, NEUROPSYCHOLOGY, V4, P13, DOI 10.1037/0894-4105.4.1.13; MARSHALL JC, 1984, J CLIN NEUROPSYCHOL, V6, P65, DOI 10.1080/01688638408401197; MURDOCH BE, 1987, BRAIN LANG, V31, P122, DOI 10.1016/0093-934X(87)90064-2; Nelson H., 1982, NATIONAL ADULT READI; NEWTON A, 1985, BRIT J CLIN PSYCHOL, V24, P225, DOI 10.1111/j.2044-8260.1985.tb00655.x; PASHLER H, 1985, J EXP PSYCHOL HUMAN, V11, P105, DOI 10.1037/0096-1523.11.2.105; POWELL GE, 1980, BRIT J SOC CLIN PSYC, V19, P189, DOI 10.1111/j.2044-8260.1980.tb00947.x; Raven J.C.C.J., 1977, MANUAL RAVENS PROGR; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; SARNO MT, 1988, SCAND J REHABIL MED, P55; SCHLOSS PJ, 1985, APPL RES MENT RETARD, V6, P269, DOI 10.1016/0270-3092(85)90001-3; Stuss D.T., 1986, FRONTAL LOBES; Sunderland A., 1990, CLIN REHABIL, V4, P181, DOI DOI 10.1177/026921559000400301; TURNER SM, 1978, J BEHAV THER EXP PSY, V9, P253, DOI 10.1016/0005-7916(78)90037-X; WALLANDER JL, 1985, BEHAV ASSESS, V7, P137; Wechsler D., 2008, WECHSLER ADULT INTEL; Wiig E. H., 1988, NEUROPSYCHOLOGICAL S, P186; WILSON B, 1987, J CLIN EXP NEUROPSYC, V9, P527, DOI 10.1080/01688638708410767	41	35	35	0	12	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	SEP	1991	13	5					729	740		10.1080/01688639108401086			12	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	GK476	WOS:A1991GK47600008	1955528				2021-06-18	
J	LINDSAY, RM; ALDERSON, RF; FRIEDMAN, B; HYMAN, C; FURTH, ME; MAISONPIERRE, PC; SQUINTO, SP; YANCOPOULOS, GD				LINDSAY, RM; ALDERSON, RF; FRIEDMAN, B; HYMAN, C; FURTH, ME; MAISONPIERRE, PC; SQUINTO, SP; YANCOPOULOS, GD			THE NEUROTROPHIN FAMILY OF NGF-RELATED NEUROTROPHIC FACTORS	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article								The recent molecular cloning of brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3) has established the existence of an NGF-related family of neurotrophic factors - the neurotrophins. Purification and recombinant production of BDNF and NT-3 has allowed the initiation or extension of in vitro studies of the neuronal specificity of each of these factors. We have found that NT-3, like NGF and BDNF, promotes survival and neurite outgrowth from certain populations of sensory neurons. There appear to be both distinct and overlapping specificities of the 3 neurotrophins towards peripheral neurons - sympathetic neurons and subpopulations of neural crest and neural placode-derived sensory neurons. Using cultures of central nervous system neurons, we have recently established that BDNF: (i) promotes the survival and phenotypic differentiation of rat septal cholinergic neurons, a property consistent with the discovery of high levels of BDNF mRNA expression within the hippocampus; (ii) promotes the survival of rat nigral dopaminergic neurons and furthermore protects these neurons from two dopaminergic neurotoxins, 6-hydroxydopamine (6-OHDA) and MPTP. Thus the neurotrophic effects of these factors towards peripheral neurons and neuronal populations known to degenerate in two of the major human neurodegenerative diseases - Alzheimer's and Parkinson's disease - provokes the question of whether neurotrophic factors may have therapeutic potential in halting the progression and ameliorating the symptoms of devastating neurological disorders of the CNS or PNS, or improving regeneration of neurons of CNS or PNS after traumatic injury.		LINDSAY, RM (corresponding author), REGENERON PHARMACEUT INC, 777 OLD SAW MILL RIVER RD, TARRYTOWN, NY 10591 USA.			Ip, Nancy Yuk-Yu/0000-0002-2763-8907			ALDERSON RF, 1990, NEURON, V5, P297, DOI 10.1016/0896-6273(90)90166-D; AUBURGER G, 1987, DEV BIOL, V120, P322, DOI 10.1016/0012-1606(87)90235-1; Barde YA, 1987, PROG BRAIN RES <D>, V71, P185; BARDE YA, 1980, P NATL ACAD SCI-BIOL, V77, P1199, DOI 10.1073/pnas.77.2.1199; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; DAVIES AM, 1986, J NEUROSCI, V6, P1897; ERNFORS P, 1990, P NATL ACAD SCI USA, V87, P5454, DOI 10.1073/pnas.87.14.5454; HARTIKKA J, 1988, J NEUROSCI, V8, P2967; HATANAKA H, 1988, DEV BRAIN RES, V39, P85, DOI 10.1016/0165-3806(88)90069-7; HEFTI F, 1985, NEUROSCIENCE, V14, P55, DOI 10.1016/0306-4522(85)90163-0; HEFTI F, 1986, J NEUROSCI, V6, P2155; HEFTI F, 1989, NEUROBIOL AGING, V10, P515, DOI 10.1016/0197-4580(89)90118-8; HOFER M, 1990, EMBO J, V9, P2459, DOI 10.1002/j.1460-2075.1990.tb07423.x; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; HYMAN C, IN PRESS NATURE; KNUSEL B, 1990, J NEUROSCI, V10, P558; KOLIATSOS VE, 1990, J NEUROSCI, V10, P3801; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LEVIMONTALCINI R, 1968, PHYSIOL REV, V48, P534; LIN LFH, 1989, SCIENCE, V246, P1023, DOI 10.1126/science.2587985; LINDSAY RM, 1985, DEV BIOL, V112, P30, DOI 10.1016/0012-1606(85)90116-2; LINDSAY RM, 1985, DEV BIOL, V112, P319, DOI 10.1016/0012-1606(85)90402-6; LINDSAY RM, 1988, J NEUROSCI, V8, P2394; LINDSAY RM, 1985, J CELL SCI, P115; LINDSAY RM, 1989, NATURE, V337, P362, DOI 10.1038/337362a0; LINDSAY RM, 1988, MAKING NERVOUS SYSTE, P148; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; OTTO D, 1990, J NEUROSCI, V10, P1912; PHILLIPS HS, 1990, SCIENCE, V250, P290, DOI 10.1126/science.1688328; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; SHELTON DL, 1986, P NATL ACAD SCI USA, V83, P2714, DOI 10.1073/pnas.83.8.2714; STOCKLI KA, 1989, NATURE, V342, P920, DOI 10.1038/342920a0; THOENEN H, 1980, PHYSIOL REV, V60, P1284; TUSZYNSKI MH, 1990, J NEUROSCI, V10, P3604; WHITTEMORE SR, 1987, BRAIN RES REV, V12, P439, DOI 10.1016/0165-0173(87)90008-7; WHITTEMORE SR, 1986, P NATL ACAD SCI USA, V83, P817, DOI 10.1073/pnas.83.3.817; WILLIAMS LR, 1986, P NATL ACAD SCI USA, V83, P9231, DOI 10.1073/pnas.83.23.9231; YANCOPOULOS GD, IN PRESS SPR COLD HA; ZIGMOND MJ, 1989, INT REV NEUROBIOL, V31, P1	41	35	35	0	5	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028	1878-3627		RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.	JUL	1991	2	4-6					211	220					10	Neurosciences	Neurosciences & Neurology	FZ024	WOS:A1991FZ02400008	21551605				2021-06-18	
J	GOMEZ, CR; BACKER, RJ; BUCHOLZ, RD				GOMEZ, CR; BACKER, RJ; BUCHOLZ, RD			TRANSCRANIAL DOPPLER ULTRASOUND FOLLOWING CLOSED HEAD-INJURY - VASOSPASM OR VASOPARALYSIS	SURGICAL NEUROLOGY			English	Article						DOPPLER ULTRASOUND; TRAUMA; VASOPARALYSIS	CEREBRAL VASOSPASM; SUBARACHNOID HEMORRHAGE; FLOW VELOCITY; SPASM	Nine patients suffering closed head injury were studied using transcranial Doppler ultrasound recording of the basal cerebral arteries. On admission, six patients had Glasgow Coma Scores of 7 or less, while three had initial scores of 8-10. Eight of the nine patients (82%) developed abnormally high mean velocities (greater-than-or-equal-to-110 cm/s) in one or more vessels. The onset, duration, and amplitude of the altered flow velocities were somewhat different from those that are seen with vasospasm after aneurysmal subarachnoid hemorrhage, which tend to occur later. Cerebral angiography in one of the study patients confirmed the presence of vasospasm. Multivariate regression analysis showed a definite correlation between the velocities recorded, even when abnormally elevated, and concurrent pH and P(CO2) measurements (p = 0.01, R2 = 0.23). Although these results suggest that the cerebral vasculature retains its vasoreactivity following head injury, arguing against vasoparalysis, inconsistencies found in some of the patients lead us to think that both vasospasm and vasoparalysis may occur following head trauma but that they may have different temporal profiles.	ST LOUIS UNIV,MED CTR,DEPT NEUROL,ST LOUIS,MO 63103; ST LOUIS UNIV,MED CTR,DIV NEUROL SURG,ST LOUIS,MO 63103							AASLID R, 1984, J NEUROSURG, V60, P37, DOI 10.3171/jns.1984.60.1.0037; AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; ARNOLDS BJ, 1986, ULTRASOUND MED BIOL, V12, P115, DOI 10.1016/0301-5629(86)90016-5; BISHOP CCR, 1986, STROKE, V17, P913, DOI 10.1161/01.STR.17.5.913; HASSLER W, 1988, J NEUROSURG, V68, P745; MACPHERS.P, 1973, J NEUROL NEUROSUR PS, V36, P1069, DOI 10.1136/jnnp.36.6.1069; MARSHALL LF, 1978, J NEUROSURG, V48, P560, DOI 10.3171/jns.1978.48.4.0560; PASQUALIN A, 1984, NEUROSURGERY, V15, P855, DOI 10.1227/00006123-198412000-00015; ROPPER AH, 1987, NEUROLOGY, V37, P1733, DOI 10.1212/WNL.37.11.1733; SAUNDERS FW, 1988, SURG NEUROL, V29, P401, DOI 10.1016/0090-3019(88)90049-3; SCHNEIDER PA, 1988, STROKE, V19, P589, DOI 10.1161/01.STR.19.5.589; SEILER RW, 1986, J NEUROSURG, V64, P594, DOI 10.3171/jns.1986.64.4.0594; SEKHAR LN, 1988, NEUROSURGERY, V22, P813, DOI 10.1227/00006123-198805000-00002; SUWANWELA C, 1972, J NEUROSURG, V36, P314, DOI 10.3171/jns.1972.36.3.0314; WILKINS RH, 1970, J NEUROSURG, V32, P626, DOI 10.3171/jns.1970.32.6.0626	15	35	35	0	0	ELSEVIER SCIENCE INC	NEW YORK	655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010	0090-3019			SURG NEUROL	Surg. Neurol.	JAN	1991	35	1					30	35		10.1016/0090-3019(91)90198-I			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	EP166	WOS:A1991EP16600005	1983879				2021-06-18	
J	VOLPE, BT; MCDOWELL, FH				VOLPE, BT; MCDOWELL, FH			THE EFFICACY OF COGNITIVE REHABILITATION IN PATIENTS WITH TRAUMATIC BRAIN INJURY	ARCHIVES OF NEUROLOGY			English	Article										VOLPE, BT (corresponding author), CORNELL UNIV,SCH MED,BURKE REHABIL CTR,DEPT NEUROL,785 MAMARONECK AVE,WHITE PLAINS,NY 10605, USA.		volpe, b/U-8409-2019	Volpe, Bruce/0000-0002-1098-1848			ABREU BC, 1987, AM J OCCUP THER, V41, P439, DOI 10.5014/ajot.41.7.439; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ANDERSON DW, 1980, NATIONAL HEAD SPINAL; ASHENASY JJM, 1987, AM J PHYS MED, V66, P315; BACHYRITA P, 1988, PRINCIPLES PRACTICE, pCH10; Balliet R, 1987, Int Rehabil Med, V8, P148; BECKER DP, 1985, CENTRAL NERVOUS SYST; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; CARAMAZZA A, 1984, BRAIN LANG, V21, P9, DOI 10.1016/0093-934X(84)90032-4; CHOI SC, 1983, J NEUROSURG, V59, P294, DOI 10.3171/jns.1983.59.2.0294; COLE JR, 1985, ARCH PHYS MED REHAB, V66, P38; CORRIGAN JD, 1985, ARCH PHYS MED REHAB, V66, P626; Cotman C W, 1988, Adv Neurol, V47, P313; CROSSON B, 1984, J CLIN NEUROPSYCHOL, V6, P287, DOI 10.1080/01688638408401219; DIKMEN S, 1987, J NEUROL NEUROSUR PS, V50, P1613, DOI 10.1136/jnnp.50.12.1613; DILLER L, 1981, J CONSULT CLIN PSYCH, V49, P822, DOI 10.1037/0022-006X.49.6.822; EKBERG K, 1984, SCAND J WORK ENV HEA, V10, P36; Fodor J. A., 1983, MODULARITY MIND; GLISKY EL, 1986, NEUROPSYCHOLOGIA, V24, P313, DOI 10.1016/0028-3932(86)90017-5; GLISKY EL, 1986, J CLIN EXP NEUROPSYC, V8, P282; HAMILL RW, 1987, ANN NEUROL, V21, P438, DOI 10.1002/ana.410210504; Hayden M E, 1986, Adv Psychosom Med, V16, P194; JENNETT B, 1981, CONT NEUROLOGY SERIE, V20, P77; KIRN TF, 1987, JAMA-J AM MED ASSOC, V257, P2400; KIRN TF, 1987, JAMA-J AM MED ASSOC, V257, P3187; KOTSORIS HO, 1987, J NEURO REHAB, V2, P73; LANDAU WM, 1988, ARCH NEUROL-CHICAGO, V45, P371; LEVIN HS, 1987, J NEUROSURG, V66, P716; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; MALEC J, 1983, ARCH PHYS MED REHAB, V64, P436; MARLER JR, 1989, PRINCETON C CEREBRAL, P17; MULLER R, 1956, ARCH NEURO PSYCHIATR, V76, P597; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; RYAN EB, 1986, J LEARN DISABIL, V19, P521, DOI 10.1177/002221948601900902; SCHERZER BP, 1986, ARCH PHYS MED REHAB, V67, P366; WEINBERG J, 1979, ARCH PHYS MED REHAB, V60, P491; Willis S L, 1987, Annu Rev Gerontol Geriatr, V7, P159; 1982, LANCET, V2, P1034	39	35	35	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0003-9942			ARCH NEUROL-CHICAGO	Arch. Neurol.	FEB	1990	47	2					220	222		10.1001/archneur.1990.00530020128026			3	Clinical Neurology	Neurosciences & Neurology	CM306	WOS:A1990CM30600024	2405821				2021-06-18	
J	LAWSON, MJ; RICE, DN				LAWSON, MJ; RICE, DN			EFFECTS OF TRAINING IN USE OF EXECUTIVE STRATEGIES ON A VERBAL MEMORY PROBLEM RESULTING FROM CLOSED HEAD-INJURY	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article									S AUSTRALIAN COLL ADV EDUC,INST STUDY LEARNING DIFFICULTIES,STURT,SA,AUSTRALIA	LAWSON, MJ (corresponding author), FLINDERS UNIV,SCH EDUC,BEDFORD PK,SA 5042,AUSTRALIA.			Lawson, Michael/0000-0002-0175-3683			*AUSTR COUN ED RES, 1972, PROGR ACH TEST READ; BATTIG WF, 1969, J EXPT PSYCHOL MON 2, V80; BINDER L M, 1980, Journal of Clinical Neuropsychology, V2, P71, DOI 10.1080/01688638008403782; BROOKS LR, 1968, CAN J PSYCHOLOGY, V22, P349, DOI 10.1037/h0082775; Brown A. L., 1978, ADV INSTRUCTIONAL PS, V1, P77; BUSCHKE H, 1973, J VERB LEARN VERB BE, V12, P543, DOI 10.1016/S0022-5371(73)80034-9; CAMPIONE JC, 1987, METACOGNITION MOTIVA, P117; CERMAK L S, 1975, Cortex, V11, P163; CERMAK LS, 1982, HUMAN MEMORY AMNESIA; CORVITZ H, 1979, CORTEX, V15, P131; CROSSON B, 1984, J CLIN NEUROPSYCHOL, V6, P287, DOI 10.1080/01688638408401219; DESROSIERS G, 1986, J CLIN EXP NEUROPSYC, V8, P637, DOI 10.1080/01688638608405184; Flavell J H, 1970, Adv Child Dev Behav, V5, P181, DOI 10.1016/S0065-2407(08)60467-X; GASPARRINI B, 1979, Journal of Clinical Neuropsychology, V1, P137, DOI 10.1080/01688637908414447; GIANUTSOS R, 1981, Journal of Clinical Neuropsychology, V3, P143, DOI 10.1080/01688638108403119; GIANUTSOS R, 1979, Journal of Clinical Neuropsychology, V1, P117, DOI 10.1080/01688637908414446; GODFREY HPD, 1987, BRIT J CLIN PSYCHOL, V26, P83, DOI 10.1111/j.2044-8260.1987.tb00735.x; HANNAY HJ, 1985, J CLIN EXP NEUROPSYC, V7, P251, DOI 10.1080/01688638508401258; JONES MK, 1974, NEUROPSYCHOLOGIA, V12, P21, DOI 10.1016/0028-3932(74)90023-2; KEARCOLWELL JJ, 1980, J CLIN PSYCHOL, V36, P782, DOI 10.1002/1097-4679(198007)36:3<782::AID-JCLP2270360334>3.0.CO;2-K; KOVNER R, 1985, J CLIN EXP NEUROPSYC, V7, P395, DOI 10.1080/01688638508401272; Lawson M., 1984, COGNITIVE STRATEGIES, P89; Lawson M. J., 1980, COGNITION DEV INSTRU, P145; LAWSON MJ, 1986, MENTAL RETARDATION L, V14, P2; LAWSON MJ, 1987, COGNITIVE STRATEGY T; MEICHENBAUM DH, 1977, COGNITIVE BEHAVIOR M; PAIVIO A, 1968, J EXPT PSYCHOL MON 2, V76; PARIS SG, 1984, J EDUC PSYCHOL, V76, P1239, DOI 10.1037/0022-0663.76.6.1239; REY A, 1959, EDIITIONS CTR PSYCHO; SCHACTER DL, 1977, CORTEX, V13, P150, DOI 10.1016/S0010-9452(77)80006-3; SCHACTER DL, 1985, J CLIN EXP NEUROPSYC, V7, P79, DOI 10.1080/01688638508401243; WABER DP, 1985, J CLIN EXP NEUROPSYC, V7, P264, DOI 10.1080/01688638508401259; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223; WILSON B, 1982, CORTEX, V18, P581, DOI 10.1016/S0010-9452(82)80055-5	34	35	35	0	3	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	DEC	1989	11	6					842	854		10.1080/01688638908400939			13	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	CC215	WOS:A1989CC21500005	2592526				2021-06-18	
J	RUGG, MD; COWAN, CP; NAGY, ME; MILNER, AD; JACOBSON, I; BROOKS, DN				RUGG, MD; COWAN, CP; NAGY, ME; MILNER, AD; JACOBSON, I; BROOKS, DN			CNV ABNORMALITIES FOLLOWING CLOSED HEAD-INJURY	BRAIN			English	Article									DUNDEE ROYAL INFIRM,DEPT SURG NEUROL,DUNDEE,SCOTLAND; UNIV GLASGOW,DEPT PSYCHOL MED,GLASGOW G12 8QQ,SCOTLAND	RUGG, MD (corresponding author), UNIV ST ANDREWS,DEPT PSYCHOL,MRC,COGNIT NEUROSCI RES GRP,ST ANDREWS KY16 9JU,FIFE,SCOTLAND.						BROOKS DN, 1976, J NEUROL NEUROSUR PS, V39, P593, DOI 10.1136/jnnp.39.6.593; Brooks N., 1984, CLOSED HEAD INJURY P; Curry S H, 1980, Prog Brain Res, V54, P507, DOI 10.1016/S0079-6123(08)61668-4; CURRY SH, 1984, ANN NY ACAD SCI, V425, P171, DOI 10.1111/j.1749-6632.1984.tb23529.x; CURRY SH, 1983, THESIS U BRISTOL; DREWE E A, 1975, Cortex, V11, P8; JENKINS A, 1986, LANCET, V2, P445; KORNHUBE.HH, 1965, PFLUG ARCH GES PHYS, V284, P1, DOI 10.1007/BF00412364; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; Loveless NE, 1979, ORIENTING REFLEX HUM, P77; MCCALLUM WC, 1973, ELECTROEN CLIN NEURO, V35, P449, DOI 10.1016/0013-4694(73)90020-5; MILNER B, 1963, ARCH NEUROL-CHICAGO, V9, P90, DOI 10.1001/archneur.1963.00460070100010; NAATANEN R, 1987, PSYCHOPHYSIOLOGY, V24, P375, DOI 10.1111/j.1469-8986.1987.tb00311.x; RIZZO PA, 1978, ELECTROEN CLIN NEURO, V45, P281, DOI 10.1016/0013-4694(78)90012-3; Rohrbaugh J W, 1986, Electroencephalogr Clin Neurophysiol Suppl, V38, P189; Rohrbaugh JW., 1983, TUTORIALS EVENT RELA, P269, DOI [10.1016/S0166-4115(08)62044-0, DOI 10.1016/S0166-4115(08)62044-0]; ROHRBAUGH JW, 1984, VARIETIES ATTENTION, P323; RUGG MD, 1988, J NEUROL NEUROSUR PS, V51, P691, DOI 10.1136/jnnp.51.5.691; STEPHENSON WA, 1951, ELECTROEN CLIN NEURO, V3, P237, DOI 10.1016/0013-4694(51)90017-X; Stuss D.T., 1986, FRONTAL LOBES; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; Van Zomeren A. H., 1984, CLOSED HEAD INJURY P, P74; VANZOMEREN AH, 1976, CLIN NEUROL NEUROSUR, V79, P81, DOI 10.1016/0303-8467(76)90001-9; VERFAELLIE M, 1987, ARCH NEUROL-CHICAGO, V44, P1265, DOI 10.1001/archneur.1987.00520240045010; WALTER WG, 1964, NATURE, V203, P380, DOI 10.1038/203380a0; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391	27	35	35	0	0	OXFORD UNIV PRESS UNITED KINGDOM	OXFORD	WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP	0006-8950			BRAIN	Brain	APR	1989	112		2				489	506		10.1093/brain/112.2.489			18	Clinical Neurology; Neurosciences	Neurosciences & Neurology	U5295	WOS:A1989U529500011	2706441				2021-06-18	
J	KRIEL, RL; KRACH, LE; SHEEHAN, M				KRIEL, RL; KRACH, LE; SHEEHAN, M			PEDIATRIC CLOSED HEAD-INJURY - OUTCOME FOLLOWING PROLONGED UNCONSCIOUSNESS	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article									GILLETTE CHILDRENS HOSP,DEPT REHABIL,ST PAUL,MN 55101	KRACH, LE (corresponding author), GILLETTE CHILDRENS HOSP,DEPT PEDIAT NEUROL,200 E UNIV AVE,ST PAUL,MN 55101, USA.			Krach, Linda/0000-0002-0993-8199			ARTS WFM, 1985, J NEUROL NEUROSUR PS, V48, P1300, DOI 10.1136/jnnp.48.12.1300; BARTKOWSKI HM, 1986, HEAD TRAUMA REHABIL, V1, P1; BRICOLO A, 1980, J NEUROSURG, V52, P625, DOI 10.3171/jns.1980.52.5.0625; BRINK JD, 1980, J PEDIATR-US, V97, P721, DOI 10.1016/S0022-3476(80)80253-8; BRUCE DA, 1978, J NEUROSURG, V48, P679, DOI 10.3171/jns.1978.48.5.0679; BRUCE DA, 1983, PEDIATRIC HEAD TRAUM, P213; EIBEN CF, 1984, ARCH PHYS MED REHAB, V65, P168; FILLEY CM, 1987, ARCH NEUROL-CHICAGO, V44, P194, DOI 10.1001/archneur.1987.00520140058018; GILLIES JD, 1980, DEV MED CHILD NEUROL, V22, P642; HIGASHI K, 1977, J NEUROL NEUROSUR PS, V40, P876, DOI 10.1136/jnnp.40.9.876; HIGASHI K, 1981, J NEUROL NEUROSUR PS, V44, P552, DOI 10.1136/jnnp.44.6.552; Jennett B, 1981, MANAGEMENT HEAD INJU; JOHNSTON RB, 1980, DEV MED CHILD NEUROL, V22, P3; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; LANGECOSACK H, 1979, NEUROPADIATRIE, V10, P105, DOI 10.1055/s-0028-1085318; MAHONEY WJ, 1983, PEDIATRICS, V71, P756; MAY PG, 1968, DIS NERV SYST, V29, P837; MAYER T, 1981, JAMA-J AM MED ASSOC, V245, P719; NAJENSON T, 1978, SCAND J REHABIL MED, V10, P15; OVERGAARD J, 1973, LANCET, V2, P631; Pagni C A, 1975, J Neurosurg Sci, V19, P120; RAIMONDI AJ, 1984, CHILD BRAIN, V11, P12; SHUTTLEWORTH E, 1983, NEUROLOGY, V33, P372, DOI 10.1212/WNL.33.3.372; STOVER SL, 1976, ARCH PHYS MED REHAB, V57, P201; TANHEHCO J, 1982, ARCH PHYS MED REHAB, V63, P36; TEASDALE G, 1974, LANCET, V2, P81; THIENPRASIT P, 1985, MINN MED, V68, P559	27	35	36	0	1	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	SEP	1988	69	9					678	681					4	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	Q3078	WOS:A1988Q307800005	3421822				2021-06-18	
J	SARNO, MT				SARNO, MT			VERBAL IMPAIRMENT AFTER CLOSED HEAD-INJURY - REPORT OF A REPLICATION STUDY	JOURNAL OF NERVOUS AND MENTAL DISEASE			English	Article										SARNO, MT (corresponding author), NYU MED CTR,DEPT REHABIL MED,NEW YORK,NY 10016, USA.			sarno, martha/0000-0001-7649-8691			Benson D. F., 1967, CORTEX MILANO, V3, P373, DOI [10.1016/S0010-9452(67)80025-X, DOI 10.1016/S0010-9452(67)80025-X]; BOLLER F, 1966, BRAIN, V89, P815, DOI 10.1093/brain/89.4.815; BOLLER F, 1979, AUDITORY COMPREHENSI; GALLAHER AJ, 1979, BRAIN LANG, V7, P34, DOI 10.1016/0093-934X(79)90004-X; GESCHWIND N, 1971, NEW ENGL J MED, V284, P654, DOI 10.1056/NEJM197103252841206; Geschwind N, 1964, Int J Neurol, V4, P207; Geschwind N., 1967, CORTEX, V3, P97, DOI 10.1016/S0010-9452(67)80007-8; HARTJE W, 1973, NEUROPSYCHOLOGIA, V11, P119, DOI 10.1016/0028-3932(73)90072-9; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; MARSHALL JC, 1975, CIBA F S, V34, P245; Orgass B., 1966, CORTEX, V2, P222, DOI [10.1016/S0010-9452(66)80005-9, DOI 10.1016/S0010-9452(66)80005-9]; Sarno M, 1969, FUNCTIONAL COMMUNICA; SARNO MT, 1980, J NERV MENT DIS, V168, P685, DOI 10.1097/00005053-198011000-00008; Spreen O, 1969, NEUROSENSORY CTR COM; TAYLORSARNO M, 1965, ARCH PHYS MED REHABI, V49, P101	15	35	36	0	1	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0022-3018			J NERV MENT DIS	J. Nerv. Ment. Dis.		1984	172	8					475	479		10.1097/00005053-198408000-00006			5	Clinical Neurology; Psychiatry	Neurosciences & Neurology; Psychiatry	TE542	WOS:A1984TE54200006	6747618				2021-06-18	
J	GURDJIAN, ES; LISSNER, HR				GURDJIAN, ES; LISSNER, HR			PHOTOELASTIC CONFIRMATION OF PRESENCE OF SHEARSTRAINS AT CRANIOSPINAL JUNCTION IN CLOSED HEAD INJURY	JOURNAL OF NEUROSURGERY			English	Article																CHASON JL, 1957, J NEUROPATH EXP NEUR, V16, P102, DOI 10.1097/00005072-195701000-00012; Gurdjian ES, 1944, J NEUROSURG, V1, P393, DOI 10.3171/jns.1944.1.6.0393; GURDJIAN ES, 1955, SURG GYNECOL OBSTET, V101, P680; GURDJIAN ES, 1958, HEAD INJURIES MECHAN, P1; HADDAD B. F., 1955, NEUROLOGY, V5, P798; Scott WW, 1940, ARCH NEURO PSYCHIATR, V43, P270, DOI 10.1001/archneurpsyc.1940.02280020078006; WALKER EA, 1944, J NEUROSURG, V1, P103	7	35	36	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.		1961	18	1					58	&		10.3171/jns.1961.18.1.0058			0	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	6057B	WOS:A19616057B00004	13709838				2021-06-18	
J	Smith, DH; Johnson, VE; Trojanowski, JQ; Stewart, W				Smith, Douglas H.; Johnson, Victoria E.; Trojanowski, John Q.; Stewart, William			Chronic traumatic encephalopathy - confusion and controversies	NATURE REVIEWS NEUROLOGY			English	Article							FRONTOTEMPORAL LOBAR DEGENERATION; AMYLOID PROTEIN DEPOSITION; BRAIN-INJURY; HEAD-INJURY; ALZHEIMERS-DISEASE; TDP-43 PROTEINOPATHY; BETA; DEMENTIA; RISK; ACCUMULATION	The term chronic traumatic encephalopathy (CTE) has recently entered public consciousness via media reports and even a Hollywood movie. However, in contrast to general impressions, the incidence of CTE is unknown, the clinical diagnostic criteria have not been agreed upon and the current neuropathological characterization of CTE is acknowledged as preliminary. Additionally, few studies have compared the pathologies of CTE with those of other neurodegenerative disorders or of age-matched controls. Consequently, disagreement continues about the neuropathological aspects that make CTE unique. Furthermore, CTE is widely considered to be a consequence of exposure to repeated head blows, but evidence suggests that a single moderate or severe traumatic brain injury can also induce progressive neuropathological changes. These unresolved aspects of CTE underlie disparate claims about its clinical and pathological features, leading to confusion among the public and health-care professionals alike.	[Smith, Douglas H.; Johnson, Victoria E.] Univ Penn, Perelman Sch Med, Dept Neurosurg, Penn Ctr Brain Injury & Repair, Philadelphia, PA 19104 USA; [Trojanowski, John Q.] Univ Penn, Dept Pathol & Lab Med, Inst Aging, Perelman Sch Med, Philadelphia, PA USA; [Trojanowski, John Q.] Univ Penn, Inst Aging, Philadelphia, PA 19104 USA; [Trojanowski, John Q.] Univ Penn, Ctr Neurodegenerat Dis Res, Perelman Sch Med, Philadelphia, PA 19104 USA; [Stewart, William] Queen Elizabeth Univ Hosp, Dept Neuropathol, Glasgow, Lanark, Scotland; [Stewart, William] Univ Glasgow, Inst Neurosci & Psychol, Glasgow, Lanark, Scotland	Smith, DH (corresponding author), Univ Penn, Perelman Sch Med, Dept Neurosurg, Penn Ctr Brain Injury & Repair, Philadelphia, PA 19104 USA.	smithdou@pennmedicine.upenn.edu		Stewart, William/0000-0003-2199-2582	US National Institute of Neurological Disorders and Stroke of the NIH [R01NS092398, R01NS094003, R01NS038104]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS092398, R01NS038104, R01NS094003] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG010124, P01AG017586] Funding Source: NIH RePORTER	The authors' work is supported by funding from the US National Institute of Neurological Disorders and Stroke of the NIH under award numbers R01NS092398, R01NS094003 and R01NS038104.	BRANDENBURG W, 1954, Virchows Arch Pathol Anat Physiol Klin Med, V325, P680, DOI 10.1007/BF00955101; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Chen-Plotkin AS, 2010, NAT REV NEUROL, V6, P211, DOI 10.1038/nrneurol.2010.18; Cherry JD, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0382-8; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; CRITCHLEY M, 1957, BMJ-BRIT MED J, V1, P357, DOI 10.1136/bmj.1.5015.357; DeKosky ST, 2013, NAT REV NEUROL, V9, P192, DOI 10.1038/nrneurol.2013.36; Drachman DA, 1999, NEW ENGL J MED, V340, P1269, DOI 10.1056/NEJM199904223401609; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Geser F, 2009, J NEUROL, V256, P1205, DOI 10.1007/s00415-009-5069-7; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; GRAHMANN H, 1957, Psychiatr Neurol (Basel), V134, P261; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Hay J, 2016, ANNU REV PATHOL-MECH, V11, P21, DOI 10.1146/annurev-pathol-012615-044116; HOF PR, 1991, ACTA NEUROPATHOL, V82, P321, DOI 10.1007/BF00308819; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2011, ACTA NEUROPATHOL, V122, P715, DOI 10.1007/s00401-011-0909-9; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Johnson VE, 2009, J NEUROTRAUM, V26, P1197, DOI [10.1089/neu.2008.0843, 10.1089/neu.2008-0843]; Josephs KA, 2017, LANCET NEUROL, V16, P917, DOI 10.1016/S1474-4422(17)30284-3; King A, 2010, NEUROPATHOLOGY, V30, P408, DOI 10.1111/j.1440-1789.2009.01085.x; Landesman P., 2015, CONCUSSION; Lehman EJ, 2016, AM J SPORT MED, V44, P2486, DOI 10.1177/0363546516645093; Ling HL, 2017, ACTA NEUROPATHOL, V133, P337, DOI 10.1007/s00401-017-1680-3; Ling HL, 2015, ACTA NEUROPATHOL, V130, P891, DOI 10.1007/s00401-015-1496-y; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; MAWDSLEY C, 1963, LANCET, V2, P795; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mez J, 2017, JAMA-J AM MED ASSOC, V318, P360, DOI 10.1001/jama.2017.8334; Millspaugh J., 1937, US NAVAL MED B, V35, P297; NEUBUERGER KT, 1959, ARCH NEURO PSYCHIATR, V81, P403, DOI 10.1001/archneurpsyc.1959.02340160001001; Neumann M, 2007, ARCH NEUROL-CHICAGO, V64, P1388, DOI 10.1001/archneur.64.10.1388; Neumann M, 2006, SCIENCE, V314, P130, DOI 10.1126/science.1134108; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Nordstrom P, 2014, ANN NEUROL, V75, P374, DOI 10.1002/ana.24101; Nowak LA, 2009, CLIN NEUROPATHOL, V28, P275, DOI 10.2379/NPX0800; Omalu B, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.9.FOCUS11178; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; PAYNE EE, 1968, NEUROCHIRURGIA, V11, P173; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Roberts AH., 1969, BRAIN DAMAGE BOXERS; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Saing T, 2012, J NEUROTRAUM, V29, P1054, DOI 10.1089/neu.2011.1957; Smith C, 2003, NEUROPATH APPL NEURO, V29, P496, DOI 10.1046/j.1365-2990.2003.00488.x; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; SPILLANE J D, 1962, Br Med J, V2, P1205; Stein TD, 2015, ACTA NEUROPATHOL, V130, P21, DOI 10.1007/s00401-015-1435-y; Stewart W, 2016, QJM-INT J MED, V109, P11, DOI 10.1093/qjmed/hcv070; Wang HK, 2012, J NEUROL NEUROSUR PS, V83, P1080, DOI 10.1136/jnnp-2012-302633; Ward J, 2017, NYTIMES; Wilson L, 2017, LANCET NEUROL, V16, P813, DOI 10.1016/S1474-4422(17)30279-X	64	34	34	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1759-4758	1759-4766		NAT REV NEUROL	Nat. Rev. Neurol.	MAR	2019	15	3					179	183		10.1038/s41582-018-0114-8			5	Clinical Neurology	Neurosciences & Neurology	HN8WE	WOS:000460477200011	30664683	Green Accepted			2021-06-18	
J	Majidinia, M; Reiter, RJ; Shakouri, SK; Mohebbi, I; Rastegar, M; Kaviani, M; Darband, SG; Jahanban-Esfahlan, R; Nabavi, SM; Yousefi, B				Majidinia, Maryam; Reiter, Russel J.; Shakouri, Seyed Kazem; Mohebbi, Iraj; Rastegar, Mojgan; Kaviani, Mojtaba; Darband, Saber Ghazizadeh; Jahanban-Esfahlan, Rana; Nabavi, Seyed Mohammad; Yousefi, Bahman			The multiple functions of melatonin in regenerative medicine	AGEING RESEARCH REVIEWS			English	Article						Circadian rhythm; Stem cell; Tissue engineering; Neuroregeneration; Liver regeneration; Kidney regeneration; Bone regeneration; Muscle regeneration	MESENCHYMAL STEM-CELLS; SPINAL-CORD-INJURY; RENAL ISCHEMIA-REPERFUSION; ENDOPLASMIC-RETICULUM STRESS; TRAUMATIC BRAIN-INJURY; OXIDATIVE LIVER-INJURY; SCIATIC-NERVE INJURY; NF-KAPPA-B; SKELETAL-MUSCLE; BONE-GRAFT	Melatonin research has been experiencing hyper growth in the last two decades; this relates to its numerous physiological functions including anti-inflammation, oncostasis, circadian and endocrine rhythm regulation, and its potent antioxidant activity. Recently, a large number of studies have focused on the role of melatonin in the regeneration of cells or tissues after their partial loss. In this review, we discuss the recent findings on the molecular involvement of melatonin in the regeneration of various tissues including the nervous system, liver, bone, kidney, bladder, skin, and muscle, among others.	[Majidinia, Maryam] Urmia Univ Med Sci, Solid Tumor Res Ctr, Orumiyeh, Iran; [Reiter, Russel J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA; [Shakouri, Seyed Kazem] Tabriz Univ Med Sci, Aging Res Inst, Phys Med & Rehabil Res Ctr, Tabriz, Iran; [Mohebbi, Iraj] Urmia Univ Med Sci, Dept Occupat Hlth, Orumiyeh, Iran; [Rastegar, Mojgan] Univ Manitoba, Rady Fac Hlth Sci, Max Rady Coll Med, Regenerat Med Program,Dept Biochem & Med Genet, Winnipeg, MB, Canada; [Kaviani, Mojtaba] Acadia Univ, Sch Nutr & Dietet, Wolfville, NS, Canada; [Darband, Saber Ghazizadeh] Urmia Univ Med Sci, Hlth Technol Dev Ctr, Danesh Pey Hadi Co, Orumiyeh, Iran; [Jahanban-Esfahlan, Rana] Tabriz Univ Med Sci, Drug Appl Res Ctr, Tabriz, Iran; [Jahanban-Esfahlan, Rana] Tabriz Univ Med Sci, Students Res Comm, Tabriz, Iran; [Nabavi, Seyed Mohammad] Baqiyatallah Univ Med Sci, Appl Biotechnol Res Ctr, Tehran, Iran; [Yousefi, Bahman] Tabriz Univ Med Sci, Stem Cell & Regenerat Med Inst, Tabriz, Iran	Yousefi, B (corresponding author), Tabriz Univ Med Sci, Stem Cell & Regenerat Med Inst, Tabriz, Iran.	yousefib@tbzmed.ac.ir	Rastegar, Mojgan/T-9394-2019; Nabavi, Seyed Mohammad/G-5335-2010; majidinia, maryam/V-7187-2019; Mohebbi, Iraj/G-1494-2017; Kaviani, Mohammad Javad/T-9205-2019; Kaviani, Mojtaba/L-4940-2019	Rastegar, Mojgan/0000-0003-3619-6116; Kaviani, Mojtaba/0000-0002-1186-3384; Majidinia, Maryam/0000-0001-9776-5816; Mohebbi, Iraj/0000-0001-9158-5742; Shakouri, Seyed Kazem/0000-0003-3815-4091	Clinical Research Development Unit, Shohada Hospital, Tabriz University of Medical Sciences	The authors would like to thank Clinical Research Development Unit, Shohada Hospital, Tabriz University of Medical Sciences for kind supports.	ABBASOGLU O, 1995, J HEPATOL, V23, P578, DOI 10.1016/0168-8278(95)80065-4; Abdel-Wahab WM, 2012, LIFE SCI J, V9, P1173; Acuna-Castroviejo D, 2014, CELL MOL LIFE SCI, V71, P2997, DOI 10.1007/s00018-014-1579-2; Gonzalez MA, 2012, CELL BIOCHEM FUNCT, V30, P701, DOI 10.1002/cbf.2855; Aktoz T, 2007, RENAL FAILURE, V29, P535, DOI 10.1080/08860220701391738; Albrektsson T, 2001, EUR SPINE J, V10, pS96, DOI 10.1007/s005860100282; Alghasham A. A., 2013, PHARM PHARM, V4, P590; Ambrosio F, 2009, AM J PHYS MED REHAB, V88, P145, DOI 10.1097/PHM.0b013e3181951fc5; Angelini F, 2016, BIOIMPACTS, V6, P14, DOI 10.15171/bi.2016.03; Aranda M, 2010, J PINEAL RES, V49, P78, DOI 10.1111/j.1600-079X.2010.00769.x; Aranda ML, 2016, J PINEAL RES, V60, P360, DOI 10.1111/jpi.12318; ARMSTRONG SM, 1991, MED HYPOTHESES, V34, P300, DOI 10.1016/0306-9877(91)90046-2; Atala A, 2006, CURR OPIN PEDIATR, V18, P167, DOI 10.1097/01.mop.0000193294.94646.be; Atik B, 2011, J SURG RES, V166, P330, DOI 10.1016/j.jss.2009.06.002; Aydin G, 2003, HUM EXP TOXICOL, V22, P383, DOI 10.1191/0960327103ht354oa; Bach AD, 2004, J CELL MOL MED, V8, P413, DOI 10.1111/j.1582-4934.2004.tb00466.x; Back K, 2016, J PINEAL RES, V61, P426, DOI 10.1111/jpi.12364; Bai XZ, 2016, SCI REP-UK, V6, DOI 10.1038/srep32199; Banaei S, 2016, TRAUMA MON, V21, DOI 10.5812/traumamon.23005; Bang OY, 2005, ANN NEUROL, V57, P874, DOI 10.1002/ana.20501; Bauer TW, 2000, CLIN ORTHOP RELAT R, P10; BECKERANDRE M, 1994, J BIOL CHEM, V269, P28531; Belanger K, 2016, MACROMOL BIOSCI, V16, P472, DOI 10.1002/mabi.201500367; Berthiaume F, 2011, ANNU REV CHEM BIOMOL, V2, P403, DOI 10.1146/annurev-chembioeng-061010-114257; Bijonowski BM, 2013, CURR OPIN CHEM ENG, V2, P32, DOI 10.1016/j.coche.2012.12.001; Bliss TM, 2010, NEUROBIOL DIS, V37, P275, DOI 10.1016/j.nbd.2009.10.003; Bonandrini B, 2014, TISSUE ENG PT A, V20, P1486, DOI [10.1089/ten.TEA.2013.0269, 10.1089/ten.tea.2013.0269]; Bostrom Mathias P G, 2005, HSS J, V1, P9, DOI 10.1007/s11420-005-0111-5; Bruck R, 2004, J HEPATOL, V40, P86, DOI 10.1016/S0168-8278(03)00504-X; Calvo JR, 2001, J CELL BIOCHEM, V80, P461, DOI 10.1002/1097-4644(20010315)80:4<461::AID-JCB1000>3.0.CO;2-P; Calvo-Guirado J. L., 2016, CLIN ORAL IMPLANTS R; Calvo-Guirado JL, 2010, J PINEAL RES, V49, P356, DOI 10.1111/j.1600-079X.2010.00801.x; Calvo-Guirado JL, 2015, CLIN ORAL IMPLAN RES, V26, P399, DOI 10.1111/clr.12364; Canaud G, 2015, NEPHROL DIAL TRANSPL, V30, P575, DOI 10.1093/ndt/gfu230; Cao ZW, 2017, J PINEAL RES, V62, DOI 10.1111/jpi.12389; Carloni S, 2016, J PINEAL RES, V61, P370, DOI 10.1111/jpi.12354; Carnovale CE, 2000, J HEPATOL, V32, P798, DOI 10.1016/S0168-8278(00)80249-4; Carretero M, 2009, J PINEAL RES, V47, P192, DOI 10.1111/j.1600-079X.2009.00700.x; Carrillo-Vico A, 2004, FASEB J, V18, P537, DOI 10.1096/fj.03-0694fje; Carrillo-Vico A, 2005, J CLIN ENDOCR METAB, V90, P992, DOI 10.1210/jc.2004-1429; Carrillo-Vico A, 2006, CURR OPIN INVEST DR, V7, P423; Cattin AL, 2016, CURR OPIN NEUROBIOL, V39, P38, DOI 10.1016/j.conb.2016.04.005; Cetinel S, 2005, J UROLOGY, V173, P267, DOI 10.1097/01.ju.0000145891.35810.56; Chalfoun CT, 2006, J CELL MOL MED, V10, P309, DOI 10.1111/j.1582-4934.2006.tb00401.x; Chang HM, 2000, BRAIN RES, V873, P243, DOI 10.1016/S0006-8993(00)02489-6; Chang HM, 2008, J PINEAL RES, V44, P172, DOI 10.1111/j.1600-079X.2007.00505.x; Chang HM, 2014, J PINEAL RES, V56, P322, DOI 10.1111/jpi.12125; Chang YC, 2016, EXP BIOL MED, V241, P1588, DOI 10.1177/1535370216642528; Chang YS, 2016, J UROLOGY, V195, pE375, DOI 10.1016/j.juro.2016.02.1060; Chawla SL, 2008, FLUORIDE, V41, P44; Chen FM, 2010, BIOMATERIALS, V31, P6279, DOI 10.1016/j.biomaterials.2010.04.053; Chen HH, 2014, J PINEAL RES, V57, P16, DOI 10.1111/jpi.12140; Chen YT, 2014, J PINEAL RES, V57, P248, DOI 10.1111/jpi.12164; Cho YA, 2015, J PINEAL RES, V58, P127, DOI 10.1111/jpi.12198; Clafshenkel WP, 2012, J PINEAL RES, V53, P206, DOI 10.1111/j.1600-079X.2012.00989.x; Clavien P, 2007, NEW ENGL J MED, V356, P1545, DOI 10.1056/NEJMra065156; Colman A, 2000, TRENDS BIOTECHNOL, V18, P192, DOI 10.1016/S0167-7799(00)01434-7; Cosovic E., 2017, Veterinaria (Sarajevo), V66, P21; CUNNANE SC, 1979, MED HYPOTHESES, V5, P403, DOI 10.1016/0306-9877(79)90107-5; Dalamagkas K, 2016, MAT SCI ENG C-MATER, V65, P425, DOI 10.1016/j.msec.2016.04.048; Daly W., 2011, J R SOC INTERFACE; Demirbag B, 2011, BIOTECHNOL J, V6, P1437, DOI 10.1002/biot.201100261; Deumens R, 2010, PROG NEUROBIOL, V92, P245, DOI 10.1016/j.pneurobio.2010.10.002; Develioglu H, 2009, DENT MATER J, V28, P396, DOI 10.4012/dmj.28.396; Di Martino Alberto, 2011, Musculoskelet Surg, V95, P69, DOI 10.1007/s12306-011-0097-8; Drobnik Jacek, 1996, Cytobios, V85, P51; Duda GN, 2008, EXERC SPORT SCI REV, V36, P64, DOI 10.1097/JES.0b013e318168eb88; Duffy JF, 2015, SLEEP MED CLIN, V10, P423, DOI 10.1016/j.jsmc.2015.08.002; Duncan AW, 2013, CURR OPIN ORGAN TRAN, V18, P197, DOI 10.1097/MOT.0b013e32835f07e2; Dziedzic K., SEMINARS CELL DEV BI; Ebaid H, 2013, NUTR METAB, V10, DOI 10.1186/1743-7075-10-20; Ehrler DM, 2000, CLIN ORTHOP RELAT R, P38; Ek RO, 2007, NEUROENDOCRINOL LETT, V28, P666; El-Sokkary GH, 2007, TOXICOLOGY, V239, P60, DOI 10.1016/j.tox.2007.06.092; El-Sokkary GH, 2010, ECOTOX ENVIRON SAFE, V73, P456, DOI 10.1016/j.ecoenv.2009.09.014; El-Sokkary GH, 2005, TOXICOLOGY, V213, P25, DOI 10.1016/j.tox.2005.05.003; El-Sokkary H. G., 2009, OPEN NEUROENDOCRINOL, V2, P1; Elkwood AI, 2011, J SPINAL CORD MED, V34, P241, DOI 10.1179/107902611X12972448729521; Esposito E, 2008, J PINEAL RES, V45, P149, DOI 10.1111/j.1600-079X.2008.00569.x; Esposito E, 2009, J PINEAL RES, V46, P79, DOI 10.1111/j.1600-079X.2008.00633.x; Finkemeier CG, 2002, J BONE JOINT SURG AM, V84A, P454, DOI 10.2106/00004623-200203000-00020; Fitch MT, 2008, EXP NEUROL, V209, P294, DOI 10.1016/j.expneurol.2007.05.014; Fortun J, 2009, NEUROSCI LETT, V456, P124, DOI 10.1016/j.neulet.2008.08.092; Fujimoto T, 2000, SPINE, V25, P769, DOI 10.1097/00007632-200004010-00003; FuRong L., 2009, CHINA TROP MED, V9, P2069; Gao YH, 2016, J PINEAL RES, V60, P303, DOI 10.1111/jpi.12311; Garcia-Maurino S, 1998, J NEUROIMMUNOL, V92, P76, DOI 10.1016/S0165-5728(98)00179-9; Garcia-Rubio L, 2005, HUM EXP TOXICOL, V24, P475, DOI 10.1191/0960327105ht548oa; Genovese T, 2005, J PINEAL RES, V38, P198, DOI 10.1111/j.1600-079X.2004.00194.x; Genovese T, 2007, J PINEAL RES, V43, P140, DOI 10.1111/j.1600-079X.2007.00454.x; Giannoudis PV, 2005, INJURY, V36, P20, DOI 10.1016/j.injury.2005.07.029; Gomes KU, 2008, J ORAL MAXIL SURG, V66, P2335, DOI 10.1016/j.joms.2008.06.006; Gomes ME, 2017, TISSUE ENG PART B-RE, V23, P211, DOI [10.1089/ten.teb.2017.0081, 10.1089/ten.TEB.2017.0081]; Gomez-Pinilla PJ, 2008, J PINEAL RES, V44, P416, DOI 10.1111/j.1600-079X.2007.00544.x; Gomez-Pinilla PJ, 2007, J UROLOGY, V177, P1558, DOI 10.1016/j.juro.2006.11.071; Goradel NH, 2015, ADV PHARM BULL, V5, P293, DOI 10.5681/apb.2015.041; Greenwald AS, 2001, J BONE JOINT SURG AM, V83A, P98, DOI 10.2106/00004623-200100022-00007; Gu XS, 2014, BIOMATERIALS, V35, P6143, DOI 10.1016/j.biomaterials.2014.04.064; Gu XS, 2011, PROG NEUROBIOL, V93, P204, DOI 10.1016/j.pneurobio.2010.11.002; Gul S, 2005, SURG NEUROL, V64, P355, DOI 10.1016/j.surneu.2005.03.036; Guo BL, 2014, SCI CHINA CHEM, V57, P490, DOI 10.1007/s11426-014-5086-y; Guo P., 2014, TOXICOL SCI; Guo Y, 2010, BRIT J NEUROSURG, V24, P62, DOI 10.3109/02688690903506077; Harari-Steinberg O, 2011, ORGANOGENESIS, V7, P123, DOI 10.4161/org.7.2.15783; Hardeland R, 2017, MELATONIN HLTH AGING, P209, DOI 10.1007/978-3-319- 63001-4_10; Hardeland R, 2013, J PINEAL RES, V55, P325, DOI 10.1111/jpi.12090; Hevia D, 2015, J PINEAL RES, V58, P234, DOI 10.1111/jpi.12210; Hibaoui Y, 2009, J PINEAL RES, V47, P238, DOI 10.1111/j.1600-079X.2009.00707.x; Hill SM, 2015, ENDOCR-RELAT CANCER, V22, pR183, DOI 10.1530/ERC-15-0030; Hoare TR, 2008, POLYMER, V49, P1993, DOI 10.1016/j.polymer.2008.01.027; Hong Y, 2014, J PINEAL RES, V56, P175, DOI 10.1111/jpi.12110; Hosseinzadeh A, 2016, J PINEAL RES, V61, P411, DOI 10.1111/jpi.12362; Huo XK, 2017, J PINEAL RES, V62, DOI 10.1111/jpi.12390; Itoh T, 2014, HEPATOLOGY, V59, P1617, DOI 10.1002/hep.26753; Jaenisch R., 2015, NUCL CLONING STEM CE; Jahanban-Esfahlan R, 2018, BRIT J PHARMACOL, V175, P3230, DOI 10.1111/bph.13898; Jana S, 2016, ADV MATER, V28, P10588, DOI 10.1002/adma.201600240; Janicki P, 2011, INJURY, V42, pS77, DOI 10.1016/j.injury.2011.06.014; Jiang X, 2010, EXP NEUROL, V223, P86, DOI 10.1016/j.expneurol.2009.09.009; Johnson EO, 2008, INJURY, V39, pS37, DOI 10.1016/j.injury.2008.06.015; Johnson EO, 2008, INJURY, V39, pS30, DOI 10.1016/j.injury.2008.05.018; Jou MJ, 2004, J PINEAL RES, V37, P55, DOI 10.1111/j.1600-079X.2004.00140.x; Jung KH, 2009, J PINEAL RES, V47, P173, DOI 10.1111/j.1600-079X.2009.00698.x; Kandemir YB, 2015, FOLIA MORPHOL, V74, P283, DOI 10.5603/FM.2015.0043; Kaplan S, 2011, MICROSURG, V31, P306, DOI 10.1002/micr.20876; Kaptanoglu E, 2000, J NEUROSURG, V93, P77, DOI 10.3171/spi.2000.93.1.0077; Karimaian A, 2017, DNA REPAIR, V51, P14, DOI 10.1016/j.dnarep.2017.01.003; KAUFMANN PM, 1994, TRANSPL P, V26, P3343; Kaya Y, 2013, J CHEM NEUROANAT, V53, P18, DOI 10.1016/j.jchemneu.2013.08.002; Kaya Y, 2013, CHILD NERV SYST, V29, P389, DOI 10.1007/s00381-012-1936-0; Keating JF, 2001, J BONE JOINT SURG BR, V83B, P3, DOI 10.1302/0301-620X.83B1.11952; Keeffe EB, 2001, GASTROENTEROLOGY, V120, P749, DOI 10.1053/gast.2001.22583; Kelestemur T, 2016, NEUROSCI LETT, V612, P92, DOI 10.1016/j.neulet.2015.11.043; Kode JA, 2009, CYTOTHERAPY, V11, P377, DOI 10.1080/14653240903080367; Koh CJ, 2004, J AM SOC NEPHROL, V15, P1113, DOI 10.1097/01.ASN.0000119683.59068.F0; Kokaia Z, 2012, NAT NEUROSCI, V15, P1078, DOI 10.1038/nn.3163; Koyama H, 2002, J BONE MINER RES, V17, P1219, DOI 10.1359/jbmr.2002.17.7.1219; Kramann R, 2015, NEPHROL DIAL TRANSPL, V30, P903, DOI 10.1093/ndt/gfu281; Krityakiarana W, 2016, J NEUROSCI RES, V94, P1451, DOI 10.1002/jnr.23930; Kumar A, 2012, IN VITRO CELL DEV-AN, V48, P625, DOI 10.1007/s11626-012-9556-2; Kunak ZI, 2012, J SURG RES, V175, pE17, DOI 10.1016/j.jss.2011.11.002; Kuraitis D, 2012, BIOMATERIALS, V33, P428, DOI 10.1016/j.biomaterials.2011.09.078; Kurcer Z, 2007, J PINEAL RES, V43, P42, DOI 10.1111/j.1600-079X.2007.00441.x; Kus I, 2005, CELL BIOCHEM FUNCT, V23, P169, DOI 10.1002/cbf.1136; Kwon YJ, 2015, CLIN MOL HEPATOL, V21, P7, DOI 10.3350/cmh.2015.21.1.7; Lacoste B, 2015, J PINEAL RES, V58, P397, DOI 10.1111/jpi.12224; Lad SP, 2010, NEUROSURGERY, V66, P953, DOI 10.1227/01.NEU.0000368545.83463.91; Laliena A, 2012, J PINEAL RES, V53, P270, DOI 10.1111/j.1600-079X.2012.00995.x; Lardone PJ, 2011, J PINEAL RES, V51, P454, DOI 10.1111/j.1600-079X.2011.00909.x; Lee MS, 2017, J PINEAL RES, V62, DOI 10.1111/jpi.12372; Lee SJ, 2014, J PINEAL RES, V57, P393, DOI 10.1111/jpi.12179; Lee Seunghoon, 2012, Lab Anim Res, V28, P47, DOI 10.5625/lar.2012.28.1.47; Lepper C, 2011, DEVELOPMENT, V138, P3639, DOI 10.1242/dev.067595; Lerou PH, 2005, BLOOD REV, V19, P321, DOI 10.1016/j.blre.2005.01.005; Liang R, 2009, J PINEAL RES, V46, P8, DOI 10.1111/j.1600-079X.2008.00596.x; Lin C, 2016, J PINEAL RES, V61, P177, DOI 10.1111/jpi.12337; Lin MY, 2013, HAND CLIN, V29, P331, DOI 10.1016/j.hcl.2013.04.003; Liu JB, 2004, CHINESE MED J-PEKING, V117, P571; Loi P, 2016, TRENDS BIOTECHNOL, V34, P791, DOI 10.1016/j.tibtech.2016.03.008; Luchetti F, 2014, J PINEAL RES, V56, P382, DOI 10.1111/jpi.12133; Luchetti F, 2010, FASEB J, V24, P3603, DOI 10.1096/fj.10-154450; Calvo-Guirado JL, 2015, CLIN ORAL IMPLAN RES, V26, P1421, DOI 10.1111/clr.12472; Calvo-Guirado JL, 2010, J PINEAL RES, V48, P194, DOI 10.1111/j.1600-079X.2009.00743.x; Calvo-Guirado JL, 2009, J PINEAL RES, V47, P164, DOI 10.1111/j.1600-079X.2009.00696.x; Mackinnon SE, 2001, PLAST RECONSTR SURG, V107, P1419, DOI 10.1097/00006534-200105000-00016; Mahieu S, 2009, TOXICOL LETT, V190, P9, DOI 10.1016/j.toxlet.2009.06.852; Majidinia M, 2018, J CELL PHYSIOL, V233, P5598, DOI 10.1002/jcp.26265; Majidinia M, 2018, J CELL PHYSIOL, V233, P2937, DOI 10.1002/jcp.26042; Majidinia M, 2017, J PINEAL RES, V63, DOI 10.1111/jpi.12416; Majidinia M, 2017, CHEM BIOL DRUG DES, V89, P309, DOI 10.1111/cbdd.12893; Majidinia M, 2016, DNA REPAIR, V47, P1, DOI 10.1016/j.dnarep.2016.09.003; Malafaya PB, 2007, ADV DRUG DELIVER REV, V59, P207, DOI 10.1016/j.addr.2007.03.012; Maldonado MD, 2007, J PINEAL RES, V42, P1, DOI 10.1111/j.1600-079X.2006.00376.x; Maria S, 2014, J PINEAL RES, V56, P115, DOI 10.1111/jpi.12116; Markus RP, 2013, INT J MOL SCI, V14, P10979, DOI 10.3390/ijms140610979; Pereira-Junior OCM, 2007, J BIOMATER APPL, V21, P283, DOI 10.1177/0885328206063526; Mayo J.C., 2017, J PINEAL RES, V62; Mayo JC, 2002, CELL MOL LIFE SCI, V59, P1706, DOI 10.1007/PL00012498; McKay WF, 2017, GOOGLE PATENTS; Mehanna RA, 2017, INT J CLIN EXP MED, V10, P1490; Meki ARMA, 2004, TOXICON, V43, P93, DOI 10.1016/j.toxicon.2003.10.026; Meki ARMA, 2001, NEUROENDOCRINOL LETT, V22, P417; Meki ARMA, 2001, COMP BIOCHEM PHYS C, V130, P305, DOI 10.1016/S1532-0456(01)00248-4; Menovsky T, 2001, J NEUROSURG, V95, P694, DOI 10.3171/jns.2001.95.4.0694; Mias C, 2008, STEM CELLS, V26, P1749, DOI 10.1634/stemcells.2007-1000; Mohammadian M, 2013, ADV PHARM BULL, V3, P433, DOI 10.5681/apb.2013.070; Moore KA, 2006, SCIENCE, V311, P1880, DOI 10.1126/science.1110542; Morsy FA, 2006, INT J TOXICOL, V25, P523, DOI 10.1080/10915810600961648; Moshiri A., 2012, HARD TISSUE, V1, P11, DOI [10.13172/2050-2303-1-2-291., DOI 10.13172/2050-2303-1-2-291]; Muir D, 2010, EXP NEUROL, V223, P102, DOI 10.1016/j.expneurol.2009.05.038; Murphy MB, 2013, EXP MOL MED, V45, DOI 10.1038/emm.2013.94; Najafi M, 2014, J DIABETES METAB DIS, V13, DOI 10.1186/s40200-014-0106-1; Nakade O, 1999, J PINEAL RES, V27, P106, DOI 10.1111/j.1600-079X.1999.tb00603.x; Nava M, 2000, AM J PHYSIOL-RENAL, V279, pF910; Nomiya M, 2013, BJU INT, V112, pE221, DOI 10.1111/j.1464-410X.2012.11746.x; Odaci E, 2009, INT REV NEUROBIOL, V87, P317, DOI 10.1016/S0074-7742(09)87016-5; Oguz E, 2015, RENAL FAILURE, V37, P318, DOI 10.3109/0886022X.2014.991263; Ohta Y, 2004, J PINEAL RES, V36, P10, DOI 10.1046/j.1600-079X.2003.00091.x; Ohta Y, 2001, J PINEAL RES, V31, P370, DOI 10.1034/j.1600-079X.2001.310413.x; Ohta Y, 2000, J PINEAL RES, V28, P119, DOI 10.1034/j.1600-079X.2001.280208.x; Ohta Y, 2000, J PINEAL RES, V29, P15, DOI 10.1034/j.1600-079X.2000.290103.x; Okamoto M, 2013, PROG POLYM SCI, V38, P1487, DOI 10.1016/j.progpolymsci.2013.06.001; Oner J, 2008, ANAT REC, V291, P448, DOI 10.1002/ar.20659; Orive G, 2009, NAT REV NEUROSCI, V10, P682, DOI 10.1038/nrn2685; Orlando G, 2013, BIOMATERIALS, V34, P5915, DOI 10.1016/j.biomaterials.2013.04.033; Orlando G, 2012, ANN SURG, V256, P363, DOI 10.1097/SLA.0b013e31825a02ab; Oryan A, 2012, CELL TISSUE BANK, V13, P639, DOI 10.1007/s10561-011-9285-x; Oryan A, 2013, HARD TISSUE, V2, P13; Oryan A, 2012, J TISSUE VIABILITY, V21, P88, DOI 10.1016/j.jtv.2012.06.002; Pakulska MM, 2012, BIOMED MATER, V7, DOI 10.1088/1748-6041/7/2/024101; Pandi-Perumal SR, 2013, NEUROTOX RES, V23, P267, DOI 10.1007/s12640-012-9337-4; Panseri S, 2008, BMC BIOTECHNOL, V8, DOI 10.1186/1472-6750-8-39; Paradies G, 2017, CELL MOL LIFE SCI, V74, P3897, DOI 10.1007/s00018-017-2619-5; Parikh S N, 2002, J Postgrad Med, V48, P142; Park KH, 2011, J PINEAL RES, V51, P187, DOI 10.1111/j.1600-079X.2011.00875.x; Patschan D, 2012, AM J PHYSIOL-RENAL, V302, pF1305, DOI 10.1152/ajprenal.00445.2011; Peyrot F, 2008, J PINEAL RES, V45, P235, DOI 10.1111/j.1600-079X.2008.00580.x; Ramirez-Fernandez MP, 2013, CLIN ORAL INVEST, V17, P147, DOI 10.1007/s00784-012-0684-6; Ping ZC, 2017, ACTA BIOMATER, V51, P513, DOI 10.1016/j.actbio.2017.01.034; Place ES, 2009, NAT MATER, V8, P457, DOI [10.1038/NMAT2441, 10.1038/nmat2441]; Pugazhenthi K, 2008, J PINEAL RES, V44, P387, DOI 10.1111/j.1600-079X.2007.00541.x; Qiu TT, 2016, INT J CLIN EXP MED, V9, P8014; Quertainmont R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039500; Radio NM, 2006, J PINEAL RES, V40, P332, DOI 10.1111/j.1600-079X.2006.00318.x; Raggi Chiara, 2012, Muscles Ligaments Tendons J, V2, P239; Rajaram A, 2012, TISSUE ENG PART B-RE, V18, P454, DOI [10.1089/ten.teb.2012.0006, 10.1089/ten.TEB.2012.0006]; Ramirez-Garcia G, 2015, ELECTROCHIM ACTA, V166, P88, DOI 10.1016/j.electacta.2015.03.063; Ramis MR, 2015, CURR MED CHEM, V22, P2690, DOI 10.2174/0929867322666150619104143; Ramis MR, 2015, MECH AGEING DEV, V146, P28, DOI 10.1016/j.mad.2015.03.008; Rateb EE, 2017, EXCLI J, V16, P138, DOI 10.17179/excli2016-763; Reiter R., 2007, ADV MED SCI, V52, P52; Reiter RJ, 2002, J PHARM PHARMACOL, V54, P1299, DOI 10.1211/002235702760345374; REITER RJ, 1969, NEUROENDOCRINOLOGY, V5, P219, DOI 10.1159/000121862; Reiter RJ, 2000, ANN NY ACAD SCI, V917, P376; Reiter RJ, 2017, HEALTHY AGEING LONG, V7, P1, DOI 10.1007/978-3-319-64543-8_1; Reiter RJ, 2016, J PINEAL RES, V61, P253, DOI 10.1111/jpi.12360; Reiter RJ, 2014, PHYSIOLOGY, V29, P325, DOI 10.1152/physiol.00011.2014; Reiter RJ, 2010, PROG BRAIN RES, V181, P127, DOI 10.1016/S0079-6123(08)81008-4; Reule S, 2011, ORGANOGENESIS, V7, P135, DOI 10.4161/org.7.2.16285; Ringe J, 2002, NATURWISSENSCHAFTEN, V89, P338, DOI 10.1007/s00114-002-0344-9; Rodriguez C, 2004, J PINEAL RES, V36, P1, DOI 10.1046/j.1600-079X.2003.00092.x; Rodriguez MI, 2007, FREE RADICAL RES, V41, P15, DOI 10.1080/10715760600936359; Rogerio F, 2002, BRAIN RES, V926, P33, DOI 10.1016/S0006-8993(01)03286-3; Romagnani P, 2013, NAT REV NEPHROL, V9, P137, DOI 10.1038/nrneph.2012.290; Romero A, 2014, J PINEAL RES, V56, P343, DOI 10.1111/jpi.12132; Ross EA, 2012, ORGANOGENESIS, V8, P49, DOI 10.4161/org.20209; Ross EA, 2009, J AM SOC NEPHROL, V20, P2338, DOI 10.1681/ASN.2008111196; Sagmanligil H. O., 2006, ARCH TOXICOL, V80, P362; Sainz RM, 2003, CELL MOL LIFE SCI, V60, P1407, DOI 10.1007/s00018-003-2319-1; Salucci S, 2016, MICROSC RES TECHNIQ, V79, P532, DOI 10.1002/jemt.22663; Samantaray S, 2008, J PINEAL RES, V44, P348, DOI 10.1111/j.1600-079X.2007.00534.x; Samantaray S, 2009, J PINEAL RES, V47, P134, DOI 10.1111/j.1600-079X.2009.00703.x; Sato M, 2011, J BIOSCI BIOENG, V112, P273, DOI 10.1016/j.jbiosc.2011.05.007; Satomura K, 2007, J PINEAL RES, V42, P231, DOI 10.1111/j.1600-079X.2006.00410.x; Sayan H, 2004, J PINEAL RES, V37, P143, DOI 10.1111/j.1600-079X.2004.00145.x; Scheer FAJL, 2006, SPINAL CORD, V44, P78, DOI 10.1038/sj.sc.3101784; Schiaffino S, 2017, FEBS J, V284, P517, DOI 10.1111/febs.13827; Schmidt CE, 2003, ANNU REV BIOMED ENG, V5, P293, DOI 10.1146/annurev.bioeng.5.011303.120731; Seidlits S. K., 2008, NANOSTRUCTURED SCAFF; Sethi S, 2010, J PINEAL RES, V49, P222, DOI 10.1111/j.1600-079X.2010.00784.x; Sharfuddin AA, 2011, NAT REV NEPHROL, V7, P189, DOI 10.1038/nrneph.2011.16; Sharma S, 2013, ARH HIG RADA TOKSIKO, V64, P219, DOI 10.2478/10004-1254-64-2013-2248; Shino H, 2016, MED ORAL PATOL ORAL, V21, pE122, DOI 10.4317/medoral.20904; Shoichet Molly S., 2008, P221; Shokouhi G, 2008, CHILD NERV SYST, V24, P111, DOI 10.1007/s00381-007-0366-x; Sidhu S, 2010, EUR J PHARMACOL, V628, P282, DOI 10.1016/j.ejphar.2009.11.058; Son JH, 2017, LASER MED SCI, V32, P533, DOI 10.1007/s10103-017-2145-6; Son JH, 2014, J PINEAL RES, V57, P385, DOI 10.1111/jpi.12177; Song JJ, 2013, NAT MED, V19, P646, DOI 10.1038/nm.3154; Song J, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/854359; Stavisky RC, 2005, NEUROSCI LETT, V376, P98, DOI 10.1016/j.neulet.2004.11.033; STEINHILBER D, 1995, J BIOL CHEM, V270, P7037, DOI 10.1074/jbc.270.13.7037; Stratos I, 2012, J PINEAL RES, V52, P62, DOI 10.1111/j.1600-079X.2011.00919.x; Sullivan DC, 2012, BIOMATERIALS, V33, P7756, DOI 10.1016/j.biomaterials.2012.07.023; Sutken E, 2007, INT J TOXICOL, V26, P81, DOI 10.1080/10915810601122893; Tabar V, 2014, NAT REV GENET, V15, P82, DOI 10.1038/nrg3563; Takahashi H, 2016, ADV HEALTHC MATER, V5, P1931, DOI 10.1002/adhm.201600197; Takebe T, 2013, NATURE, V499, P481, DOI 10.1038/nature12271; Tam RY, 2014, NEUROPSYCHOPHARMACOL, V39, P169, DOI 10.1038/npp.2013.237; Tan DX, 2016, J PINEAL RES, V61, P27, DOI 10.1111/jpi.12336; Tan DX, 2013, J PINEAL RES, V54, P127, DOI 10.1111/jpi.12026; Tan DX, 2003, EXPERT OPIN THER PAT, V13, P1513, DOI 10.1517/eotp.13.10.1513.22913; Tas U, 2011, TOXICOL IND HEALTH, V27, P465, DOI 10.1177/0748233710389853; Taskiran D, 2000, INT J NEUROSCI, V104, P63, DOI 10.3109/00207450009035009; Taub R, 2004, NAT REV MOL CELL BIO, V5, P836, DOI 10.1038/nrm1489; Teixeira CFP, 2003, MUSCLE NERVE, V28, P449, DOI 10.1002/mus.10453; Topsakal C, 2003, SPINE, V28, P1643, DOI 10.1097/00007632-200308010-00004; Tripathi DN, 2010, J PINEAL RES, V48, P324, DOI 10.1111/j.1600-079X.2010.00756.x; Turgut M, 2005, J PINEAL RES, V38, P284, DOI 10.1111/j.1600-079X.2004.00205.x; Turgut M, 2005, ACTA NEUROCHIR, V147, P67, DOI 10.1007/s00701-004-0426-x; Turgut M, 2006, J CLIN NEUROSCI, V13, P753, DOI 10.1016/j.jocn.2005.07.019; Uygun BE, 2010, NAT MED, V16, P814, DOI 10.1038/nm.2170; Uygur R, 2016, TOXICOL IND HEALTH, V32, P848, DOI 10.1177/0748233713512891; Uzarski JS, 2014, CURR OPIN NEPHROL HY, V23, P399, DOI 10.1097/01.mnh.0000447019.66970.ea; Venegas C, 2012, J PINEAL RES, V52, P217, DOI 10.1111/j.1600-079X.2011.00931.x; Vogelstein B, 2002, SCIENCE, V295, P1237, DOI 10.1126/science.1070247; Wang L, 2017, J PINEAL RES, V63, DOI 10.1111/jpi.12429; Wang WZ, 2005, J PINEAL RES, V39, P57, DOI 10.1111/j.1600-079X.2005.00215.x; WEICHSELBAUM R, 1975, NATURE, V254, P349, DOI 10.1038/254349a0; White RE, 2008, RESTOR NEUROL NEUROS, V26, P197; Willerth SM, 2011, STEM CELL RES THER, V2, DOI 10.1186/scrt58; Witt-Enderby PA, 2012, J PINEAL RES, V53, P374, DOI 10.1111/j.1600-079X.2012.01007.x; Wobma H, 2016, TISSUE ENG PART B-RE, V22, P101, DOI [10.1089/ten.TEB.2015.0535, 10.1089/ten.teb.2015.0535]; Wright LS, 2003, J NEUROCHEM, V86, P179, DOI 10.1046/j.1471-4159.2003.01826.x; Wu QB, 2014, J MOL NEUROSCI, V54, P714, DOI 10.1007/s12031-014-0430-4; Yang F, 2017, J PINEAL RES, V63, DOI 10.1111/jpi.12422; Yanilmaz M, 2015, J CRANIOFAC SURG, V26, P667, DOI 10.1097/SCS.0000000000001503; Yildirim ME, 2016, CENT EUR J UROL, V69, P225, DOI 10.5173/ceju.2016.770; Yoe YM, 2011, BRAIN RES, V1385, P1, DOI 10.1016/j.brainres.2011.02.047; Yousefi B, 2014, BIOL TRACE ELEM RES, V158, P276, DOI 10.1007/s12011-014-9956-0; Yousefi B, 2012, BIOIMPACTS, V2, P145, DOI 10.5681/bi.2012.019; Zandstra PW, 2001, ANNU REV BIOMED ENG, V3, P275, DOI 10.1146/annurev.bioeng.3.1.275; Zaouali MA, 2013, J PINEAL RES, V55, P65, DOI 10.1111/jpi.12051; Zeitzer JM, 2000, J CLIN ENDOCR METAB, V85, P2189, DOI 10.1210/jc.85.6.2189; Zencirci SG, 2010, J NEUROSCI METH, V191, P277, DOI 10.1016/j.jneumeth.2010.07.008; Zhang HM, 2014, J PINEAL RES, V57, P131, DOI 10.1111/jpi.12162; Zhang JJ, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040673; Zhang LM, 2010, J PINEAL RES, V49, P364, DOI 10.1111/j.1600-079X.2010.00803.x; Zhang S, 2017, PHARMACOL RES, V117, P252, DOI 10.1016/j.phrs.2016.12.035; Zhao J, 2015, AM J PHYSIOL-RENAL, V308, pF1474, DOI 10.1152/ajprenal.00512.2014; Zheng BL, 2017, SAUDI PHARM J, V25, P570, DOI 10.1016/j.jsps.2017.04.025; Zhu FM, 2017, AM J TRANSL RES, V9, P1694; Zimmermann G, 2011, INJURY, V42, pS16, DOI 10.1016/j.injury.2011.06.199; Zochodne DW, 2012, J PERIPHER NERV SYST, V17, P1, DOI 10.1111/j.1529-8027.2012.00378.x; Zupancic D, 2008, J PINEAL RES, V44, P299, DOI 10.1111/j.1600-079X.2007.00530.x; Zupancic D, 2009, VIRCHOWS ARCH, V454, P657, DOI 10.1007/s00428-009-0765-3	326	34	36	2	32	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1568-1637	1872-9649		AGEING RES REV	Ageing Res. Rev.	AUG	2018	45						33	52		10.1016/j.arr.2018.04.003			20	Cell Biology; Geriatrics & Gerontology	Cell Biology; Geriatrics & Gerontology	GO8YU	WOS:000440390000004	29630951				2021-06-18	
J	Curley, WH; Forgacs, PB; Voss, HU; Conte, MM; Schiff, ND				Curley, William H.; Forgacs, Peter B.; Voss, Henning U.; Conte, Mary M.; Schiff, Nicholas D.			Characterization of EEG signals revealing covert cognition in the injured brain	BRAIN			English	Article						arousal; brain-computer interface (BCI); consciousness; electroencephalography (EEG); traumatic brain injury (TBI)	FALSE DISCOVERY RATE; VEGETATIVE STATE; BEDSIDE DETECTION; FUNCTIONAL MRI; DISORDERS; CONSCIOUSNESS; AWARENESS; STIMULATION; PARADIGM; DYNAMICS	Patients with severe brain injury are difficult to assess and frequently subject to misdiagnosis. 'Cognitive motor dissociation' is a term used to describe a subset of such patients with preserved cognition as detected with neuroimaging methods but not evident in behavioural assessments. Unlike the locked-in state, cognitive motor dissociation after severe brain injury is prominently marked by concomitant injuries across the cerebrum in addition to limited or no motoric function. In the present study, we sought to characterize the EEG signals used as indicators of cognition in patients with disorders of consciousness and examine their reliability for potential future use to re-establish communication. We compared EEG-based assessments to the results of using similar methods with functional MRI. Using power spectral density analysis to detect EEG evidence of task performance (Two Group Test, P40.05, with false discovery rate correction), we found evidence of the capacity to follow commands in 21 of 28 patients with severe brain injury and all 15 healthy individuals studied. We found substantial variability in the temporal and spatial characteristics of significant EEG signals among the patients in contrast to only modest variation in these domains across healthy controls; the majority of healthy controls showed suppression of either 8-12Hz 'alpha' or 13-40Hz 'beta' power during task performance, or both. Nine of the 21 patients with EEG evidence of command-following also demonstrated functional MRI evidence of command-following. Nine of the patients with command-following capacity demonstrated by EEG showed no behavioural evidence of a communication channel as detected by a standardized behavioural assessment, the Coma Recovery Scale - Revised. We further examined the potential contributions of fluctuations in arousal that appeared to co-vary with some patients' ability to reliably generate EEG signals in response to command. Five of nine patients with statistically indeterminate responses to one task tested showed a positive response after accounting for variations in overall background state (as visualized in the qualitative shape of the power spectrum) and grouping of trial runs with similar background state characteristics. Our findings reveal signal variations of EEG responses in patients with severe brain injuries and provide insight into the underlying physiology of cognitive motor dissociation. These results can help guide future efforts aimed at re-establishment of communication in such patients who will need customization for brain-computer interfaces.	[Curley, William H.] Harvard Med Sch, Boston, MA USA; [Forgacs, Peter B.; Conte, Mary M.; Schiff, Nicholas D.] Weill Cornell Med, Feil Family Brain & Mind Res Inst, 1300 York Ave,Room F610, New York, NY 10065 USA; [Forgacs, Peter B.; Schiff, Nicholas D.] Weill Cornell Med, Dept Neurol, New York, NY USA; [Forgacs, Peter B.; Schiff, Nicholas D.] Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA; [Voss, Henning U.] Weill Cornell Med, Dept Radiol, New York, NY USA; [Voss, Henning U.] Weill Cornell Med, Citigrp Biomed Imaging Ctr, New York, NY USA	Schiff, ND (corresponding author), Weill Cornell Med, Feil Family Brain & Mind Res Inst, 1300 York Ave,Room F610, New York, NY 10065 USA.	nds2001@med.cornell.edu	Voss, Henning/C-2194-2009	Voss, Henning/0000-0003-2811-2074; Curley, William/0000-0002-0393-4998	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HD51912]; James S. McDonnell Foundation; Jerold B. Katz Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD051912] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR002384, UL1TR000043, UL1TR000457] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS096222] Funding Source: NIH RePORTER	This study was supported by NIH HD51912, the James S. McDonnell Foundation, and the Jerold B. Katz Foundation.	Adapa R, 2012, 18 ANN M ORG HUM BRA; Allison JD, 2000, NEUROLOGY, V54, P135, DOI 10.1212/WNL.54.1.135; Bai O, 2008, J NEURAL ENG, V5, P24, DOI 10.1088/1741-2560/5/1/003; Bardin JC, 2012, ARCH NEUROL-CHICAGO, V69, P176, DOI 10.1001/archneurol.2011.892; Bardin JC, 2011, BRAIN, V134, P769, DOI 10.1093/brain/awr005; Benjamini Y, 2001, ANN STAT, V29, P1165; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bokil H, 2010, J NEUROSCI METH, V192, P146, DOI 10.1016/j.jneumeth.2010.06.020; Boly M, 2007, NEUROIMAGE, V36, P979, DOI 10.1016/j.neuroimage.2007.02.047; Casali AG, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006294; Chaudhary U, 2017, PLOS BIOL, V15, DOI 10.1371/journal.pbio.1002593; Cruse D, 2011, LANCET, V378, P2088, DOI 10.1016/S0140-6736(11)61224-5; Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009; Edlow BL, 2017, BRAIN, V140, P2399, DOI 10.1093/brain/awx176; Fernandez-Espejo D, 2015, JAMA NEUROL, V72, P1442, DOI 10.1001/jamaneurol.2015.2614; Fins JJ., 2015, RIGHTS COME MIND BRA; Fins JJ, 2016, SCI AM MIND, P44; Fins JJ, 2007, NEUROLOGY, V68, P304, DOI 10.1212/01.wnl.0000252376.43779.96; Forgacs PB, 2014, ANN NEUROL, V76, P869, DOI 10.1002/ana.24283; Fridman EA, 2014, P NATL ACAD SCI USA, V111, P6473, DOI 10.1073/pnas.1320969111; Friston K.J., 2008, STAT PARAMETRIC MAPP; Giacino JT, 2014, NAT REV NEUROL, V10, P99, DOI 10.1038/nrneurol.2013.279; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Gibson RM, 2016, ANN NEUROL, V80, P412, DOI 10.1002/ana.24726; Gibson RM, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00950; Gill-Thwaites H, 2006, BRAIN INJURY, V20, P1321, DOI 10.1080/02699050601081802; Goldfine AM, 2013, LANCET, V381, P289, DOI 10.1016/S0140-6736(13)60125-7; Goldfine AM, 2011, CLIN NEUROPHYSIOL, V122, P2157, DOI 10.1016/j.clinph.2011.03.022; Hauger SL, 2015, BEHAV NEUROL, V2015, DOI 10.1155/2015/145913; HJORTH B, 1975, ELECTROEN CLIN NEURO, V39, P526, DOI 10.1016/0013-4694(75)90056-5; Hjorth B, 1980, AM J EEG TECHNOL, V20, P121; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; Laureys S, 2012, NEUROIMAGE, V61, P478, DOI 10.1016/j.neuroimage.2011.12.041; Liu YD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023839; Lule D, 2013, CLIN NEUROPHYSIOL, V124, P101, DOI 10.1016/j.clinph.2012.04.030; Mazziotta J, 2001, PHILOS T R SOC B, V356, P1293, DOI 10.1098/rstb.2001.0915; Monti MM, 2010, NEW ENGL J MED, V362, P579, DOI 10.1056/NEJMoa0905370; Moreno DR, 2010, NEUROLOGY, V75, P1871, DOI 10.1212/WNL.0b013e3181feb259; Owen AM, 2007, SCIENCE, V315, DOI 10.1126/science.1135583; Owen AM, 2006, SCIENCE, V313, P1402, DOI 10.1126/science.1130197; Percival DB, 1993, SPECTRAL ANAL PHYS A; Pfurtscheller G, 1999, CLIN NEUROPHYSIOL, V110, P1842, DOI 10.1016/S1388-2457(99)00141-8; Pfurtscheller G, 1997, NEUROSCI LETT, V239, P65, DOI 10.1016/S0304-3940(97)00889-6; Pignat JM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156882; Pokorny C, 2013, ARTIF INTELL MED, V59, P81, DOI 10.1016/j.artmed.2013.07.003; Schiff ND, 2007, NATURE, V448, P600, DOI 10.1038/nature06041; Schiff ND, 2016, J NEURAL TRANSM, V123, P797, DOI 10.1007/s00702-016-1547-0; Schiff ND, 2015, JAMA NEUROL, V72, P1413, DOI 10.1001/jamaneurol.2015.2899; Schiff ND, 2014, CURR OPIN NEUROBIOL, V25, P7, DOI 10.1016/j.conb.2013.10.007; Schiff ND, 2010, TRENDS NEUROSCI, V33, P1, DOI 10.1016/j.tins.2009.11.002; Schnakers C, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-35; Stender J, 2016, CURR BIOL, V26, P1494, DOI 10.1016/j.cub.2016.04.024; Stender J, 2014, LANCET, V384, P514, DOI 10.1016/S0140-6736(14)60042-8; Thengone DJ, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf6113; THICKBROOM GW, 1984, ELECTROEN CLIN NEURO, V59, P279, DOI 10.1016/0168-5597(84)90045-5; THOMSON DJ, 1982, P IEEE, V70, P1055, DOI 10.1109/PROC.1982.12433; Wannez S, 2017, ANN NEUROL, V81, P883, DOI 10.1002/ana.24962; Williams ST, 2013, ELIFE, V2, DOI 10.7554/eLife.01157	58	34	34	2	18	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	MAY	2018	141		5				1404	1421		10.1093/brain/awy070			18	Clinical Neurology; Neurosciences	Neurosciences & Neurology	GF7VS	WOS:000432177000023	29562312	Green Published, Bronze			2021-06-18	
J	Zeiler, FA; Donnelly, J; Smielewski, P; Menon, DK; Hutchinson, PJ; Czosnyka, M				Zeiler, Frederick A.; Donnelly, Joseph; Smielewski, Peter; Menon, David K.; Hutchinson, Peter J.; Czosnyka, Marek			Critical Thresholds of Intracranial Pressure-Derived Continuous Cerebrovascular Reactivity Indices for Outcome Prediction in Noncraniectomized Patients with Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						autoregulation; ICP index; outcome; thresholds	CEREBRAL PERFUSION-PRESSURE; BLOOD-FLOW; AUTOREGULATION	The aim of the study was to compare intracranial pressure (ICP)-derived cerebrovascular reactivity indices in their ability to predict six-month outcome, and to determine/compare critical thresholds related to outcome for each index in adult noncraniectomized traumatic brain injury (TBI). Using a retrospective cohort of nondecompressive craniectomy (non-DC) patients with TBI, we performed univariate and multi-variate binary logistic regression outcome analysis of: pressure reactivity index (PRx), pulse amplitude index (PAx), and a newly described index (RAC) calculated as the regression coefficient between ICP waveform amplitude and cerebral perfusion pressure (CPP). Finally, we performed sequential chi-square threshold analysis for each index as it related to six-month binary outcomes. Outcome was assessed via dichotomized Glasgow Outcome Scores (GOS): (A) favorable (GOS 4 or 5) versus unfavorable (GOS 3 or less), (B) alive versus dead. There were 358 non-DC patients with TBI included in all aspects of the analysis. In an analysis of the entire recording period for all patients using univariate binary logistic regression, the areas under the curves (AUCs) for favorable versus unfavorable outcome were: PRx (0.573, p<0.0001), PAx (0.606, p<0.0001), and RAC (0.655, p<0.0001). Similarly, the AUCs for alive versus dead outcome were: PRx (0.651, p<0.0001), PAx (0.705, p<0.0001), and RAC (0.722, p<0.0001). RAC displayed superior AUC statistics compared with PRx and PAx, using both univariate and multi-variate regression. RAC displayed more stable critical thresholds related to six-month outcomes. Thresholds for both favorable versus unfavorable and alive versus dead outcomes for PRx, PAx, and RAC across the entire recording period were: +0.35 and +0.35, 0 and +0.25, -0.10 and -0.05, respectively. In non-DC patients with TBI, RAC appears to be superior to PRx and PAx in six-month outcome prediction, using both univariate and multi-variate logistic regression. Further, RAC displayed more stable critical thresholds associated with binary outcomes at six months. Further analysis of RAC in TBI is required.	[Zeiler, Frederick A.; Menon, David K.] Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Cambridge, England; [Zeiler, Frederick A.] Univ Manitoba, Dept Surg, Rady Fac Hlth Sci, Winnipeg, MB, Canada; [Zeiler, Frederick A.] Univ Manitoba, Rady Fac Hlth Sci, Clinician Investigator Program, Winnipeg, MB, Canada; [Donnelly, Joseph; Smielewski, Peter; Hutchinson, Peter J.; Czosnyka, Marek] Univ Cambridge, Addenbrookes Hosp, Div Neurosurg, Dept Clin Neurosci,Brain Phys Lab, Cambridge, England; [Czosnyka, Marek] Warsaw Univ Technol, Inst Elect Syst, Warsaw, Poland	Zeiler, FA (corresponding author), Univ Manitoba, Dept Surg, Rady Fac Hlth Sci, Winnipeg, MB, Canada.	umzeiler@myumanitoba.ca	Donnelly, Joseph/E-9235-2018; Donnelly, Joseph/N-6803-2019	Donnelly, Joseph/0000-0002-6502-8069; Donnelly, Joseph/0000-0002-6502-8069; czosnyka, marek/0000-0003-2446-8006; Zeiler, Frederick/0000-0003-1737-0510	Cambridge Commonwealth Trust Scholarship; Royal College of Surgeons of Canada-Harry S. Morton Travelling Fellowship in Surgery; University of Manitoba Clinician Investigator Program; R. Samuel McLaughlin Research and Education Award; Manitoba Medical Service Foundation; University of Manitoba Faculty of Medicine Dean's Fellowship Fund; Woolf Fisher Scholarship (New Zealand); National Institute for Healthcare Research (NIHR, UK) through the Acute Brain Injury and Repair theme of the Cambridge NIHR Biomedical Research Centre; NIHRNational Institute for Health Research (NIHR); European Union Framework Program 7 grant (CENTER-TBI) [602150]; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G1002277] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NIHR-RP-R3-12-013, NF-SI-0512-10090] Funding Source: researchfish	This work was made possible through salary support through the Cambridge Commonwealth Trust Scholarship, the Royal College of Surgeons of Canada-Harry S. Morton Travelling Fellowship in Surgery, the University of Manitoba Clinician Investigator Program, R. Samuel McLaughlin Research and Education Award, the Manitoba Medical Service Foundation, and the University of Manitoba Faculty of Medicine Dean's Fellowship Fund.; JD is supported by a Woolf Fisher Scholarship (New Zealand).; These studies were supported by National Institute for Healthcare Research (NIHR, UK) through the Acute Brain Injury and Repair theme of the Cambridge NIHR Biomedical Research Centre, an NIHR Senior Investigator Award to DKM, and an NIHR Research Professorship to PJAH. Authors were also supported by a European Union Framework Program 7 grant (CENTER-TBI; Grant Agreement No. 602150)	Aries MJH, 2012, NEUROCRIT CARE, V17, P67, DOI 10.1007/s12028-012-9687-z; Brady KM, 2008, STROKE, V39, P2531, DOI 10.1161/STROKEAHA.108.514877; Budohoski KP, 2012, NEUROSURGERY, V71, P652, DOI 10.1227/NEU.0b013e318260feb1; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Czosnyka M, 2014, NEUROCRIT CARE, V21, P95, DOI 10.1007/s12028-014-0046-0; LASSEN NA, 1959, PHYSIOL REV, V39, P183; Le Roux P, 2014, NEUROCRIT CARE, V21, P1, DOI 10.1007/s12028-014-0041-5; Needham E, 2017, J NEUROTRAUM, V34, P963, DOI 10.1089/neu.2016.4450; Sorrentino E, 2012, NEUROCRIT CARE, V16, P258, DOI 10.1007/s12028-011-9630-8; Sorrentino E, 2011, NEUROCRIT CARE, V14, P188, DOI 10.1007/s12028-010-9492-5; Timofeev I, 2008, J NEUROSURG, V108, P66, DOI 10.3171/JNS/2008/108/01/0066; Zeiler F.A., 2017, J NEUROTRAUM, DOI DOI 10.1089/neu.2017.5364; Zeiler FA, 2017, J NEUROTRAUM, V34, P3070, DOI 10.1089/neu.2017.5129; Zweifel C, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E2	14	34	34	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2018	35	10					1107	1115		10.1089/neu.2017.5472			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	GF8DL	WOS:000432198500001	29241396				2021-06-18	
J	Asken, BM; Snyder, AR; Clugston, JR; Gaynor, LS; Sullan, MJ; Bauer, RM				Asken, Breton M.; Snyder, Aliyah R.; Clugston, James R.; Gaynor, Leslie S.; Sullan, Molly J.; Bauer, Russell M.			Concussion-Like Symptom Reporting in Non-Concussed Collegiate Athletes	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						SCAT3; Post-Concussion Scale; Post-concussion syndrome; College; Brain injury; Athlete	SPORTS-RELATED CONCUSSION; MILD HEAD-INJURY; POSTCONCUSSION SYNDROME; HIGH-SCHOOL; BASE-LINE; NEUROCOGNITIVE PERFORMANCE; EXPECTATION; PREDICTORS; DEPRESSION; RECOVERY	Objective: Non-concussed individuals may report a variety of concussion-like symptoms even in the absence of a diagnosed brain injury. Previous studies described concussion-like symptom reporting in adolescent athletes. This study provides complementary data on concussion-like symptoms in collegiate athletes. Methods: We analyzed baseline symptom scales from 738 collegiate athletes (452 men and 286 women) who completed either the Sport Concussion Assessment Tool, 3 Symptom Evaluation (S3SE; n = 377) or the Post-Concussion Scale (PCS; n = 361) and determined if subjects met criteria for diagnosis of International Classification of Diseases 10th Revision (ICD-10) postconcussional syndrome. Symptoms were grouped as somatic, cognitive, emotional, or sleep-related. We analyzed associations with medical history factors using chi-square analyses, and examined recovery time of a subset of concussed athletes based on baseline symptomatology (n = 117) with independent samples t-test. Results: Across all athletes, 120 (16.3%) reported baseline symptoms meeting criteria for ICD-10 postconcussional syndrome. Women were 1.7 times more likely to meet these criteria (21.7% vs. 12.8%, p = .002). Athletes completing the S3SE were 1.5 times more likely to meet criteria than those completing the PCS (p = .011). Previously diagnosed psychiatric disorder was significantly associated with emotional domain symptom reporting, and attention deficit-hyperactivity disorder diagnosis was associated with cognitive domain symptom reporting. On average, athletes meeting ICD-10 postconcussional syndrome criteria at baseline experienced longer recovery from concussion (t[115] = 2.35, p = .020). Conclusions: Non-concussed collegiate athletes report concussion-like symptoms at a clinically significant rate. Pre-injury medical history and reporting rates of concussion-like symptoms may explain variance in post-concussion symptom expression. Measured incidence of baseline postconcussional syndrome may, in part, depend on the symptom report measure that is used.	[Asken, Breton M.; Snyder, Aliyah R.; Gaynor, Leslie S.; Sullan, Molly J.; Bauer, Russell M.] Univ Florida, Hlth Sci Ctr, Dept Clin & Hlth Psychol, POB 100165, Gainesville, FL 32610 USA; [Clugston, James R.] Univ Florida, Dept Community Hlth & Family Med, Univ Athlet Assoc, Gainesville, FL 32610 USA	Asken, BM (corresponding author), Univ Florida, Dept Clin & Hlth Psychol, Gainesville, FL 32610 USA.	basken8@phhp.ufl.edu	Snyder, Aliyah/AAT-6250-2020	Clugston, James/0000-0002-2103-1039; Snyder, Aliyah/0000-0003-1185-7424; Asken, Breton/0000-0001-8419-142X	Grand Alliance Concussion Assessment, Research, and Education (CARE) Consortium - National Collegiate Athletic Association (NCAA); Department of Defense (DOD)United States Department of Defense; U.S. Army Medical Research Acquisition Activity, Chandler Street, Ford Detrick MD; Office of the Assistant Secretary of Defense for Health Affairs through the Psychological Health and Traumatic Brain Injury Program [W81XWH-14-2-0151]	Data collection for this project was supported, in part, with support from the Grand Alliance Concussion Assessment, Research, and Education (CARE) Consortium, funded in part by the National Collegiate Athletic Association (NCAA) and the Department of Defense (DOD). The U.S. Army Medical Research Acquisition Activity, 820 Chandler Street, Ford Detrick MD 21702-5014 is the awarding and administering acquisition office. This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs through the Psychological Health and Traumatic Brain Injury Program under Award No. W81XWH-14-2-0151. Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the Department of Defense (DHP funds).	American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, DOI [10.1176/appi.books.9780890425596., DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]; Asken BM, 2017, CLIN NEUROPSYCHOL, V31, P138, DOI 10.1080/13854046.2016.1246672; Asken BM, 2016, J ATHL TRAINING, V51, P329, DOI 10.4085/1062-6050-51.5.02; Beck AT., 1996, BECK DEPRESSION INVE, V2; Blom G., 1958, STAT ESTIMATES TRANS; Brooks A., 2014, BRIT J SPORT MED, V48, P573, DOI DOI 10.1136/BJSPORTS-2014-093494.38; Concussion in Sport Group, 2013, BRIT J SPORT MED, V47, P259; Covassin T, 2013, AM J SPORT MED, V41, P2885, DOI 10.1177/0363546513499230; Covassin T, 2012, CLIN J SPORT MED, V22, P98, DOI 10.1097/JSM.0b013e31823403d2; Daneshvar DH, 2011, PHYS MED REH CLIN N, V22, P683, DOI 10.1016/j.pmr.2011.08.009; Dean PJA, 2012, BRAIN INJURY, V26, P14, DOI 10.3109/02699052.2011.635354; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; Ferguson RJ, 1999, NEUROPSYCHOLOGY, V13, P582, DOI 10.1037/0894-4105.13.4.582; FOX DD, 1995, CLIN NEUROPSYCHOL, V9, P89, DOI 10.1080/13854049508402064; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Iverson GL, 2015, JAMA PEDIATR, V169, P1132, DOI 10.1001/jamapediatrics.2015.2374; Jotwani V, 2010, CURR SPORT MED REP, V9, P21, DOI 10.1249/JSR.0b013e3181ccb55e; Joyce AS, 2015, MED SCI SPORT EXER, V47, P1119, DOI 10.1249/MSS.0000000000000534; Kontos AP, 2012, AM J SPORT MED, V40, P2375, DOI 10.1177/0363546512455400; Lange RT, 2011, J HEAD TRAUMA REHAB, V26, P127, DOI 10.1097/HTR.0b013e3181e4622a; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2015, BRAIN INJURY, V29, P276, DOI 10.3109/02699052.2014.965216; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; Merritt VC, 2015, DEV NEUROPSYCHOL, V40, P45, DOI 10.1080/87565641.2014.979928; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Morgan CD, 2015, J NEUROSURG-PEDIATR, V15, P589, DOI 10.3171/2014.10.PEDS14356; Nelson LD, 2016, NEUROLOGY, V86, P1856, DOI 10.1212/WNL.0000000000002679; Putukian M, 2003, CLIN SPORT MED, V22, P617, DOI 10.1016/S0278-5919(02)00100-X; Register-Mihalik JK, 2009, SPORTS HEALTH, V1, P61, DOI 10.1177/1941738108325920; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Spielberger CD, 1983, STATE TRAIT ANXIETY; Waljas M, 2015, J NEUROTRAUM, V32, P534, DOI 10.1089/neu.2014.3339; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3; World Health Organization, 1992, ICD 10 CLASS MENT BE; Zimmer A, 2015, APPL NEUROPSYCH-ADUL, V22, P132, DOI 10.1080/23279095.2013.867265	44	34	34	0	12	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	DEC	2017	32	8					963	971		10.1093/arclin/acx018			9	Psychology, Clinical; Psychology	Psychology	FN7AS	WOS:000416170000005	28334382	Bronze			2021-06-18	
J	Hill, RL; Singh, IN; Wang, JA; Hall, ED				Hill, Rachel L.; Singh, Indrapal N.; Wang, Juan A.; Hall, Edward D.			Time courses of post-injury mitochondrial oxidative damage and respiratory dysfunction and neuronal cytoskeletal degradation in a rat model of focal traumatic brain injury	NEUROCHEMISTRY INTERNATIONAL			English	Article						Traumatic brain injury; Mitochondria; Peroxynitrite 4-hydroxynonenal; Acrolein; Calpain	CONTROLLED CORTICAL IMPACT; LATERAL FLUID PERCUSSION; CYCLOSPORINE-A ANALOG; LIPID-PEROXIDATION; NITRIC-OXIDE; CELL-DEATH; ANTIOXIDANT THERAPIES; HIPPOCAMPAL-NEURONS; MOUSE MODEL; CALPAIN-I	Traumatic brain injury (TBI) results in rapid reactive oxygen species (ROS) production and oxidative damage to essential brain cellular components leading to neuronal dysfunction and cell death. It is increasingly appreciated that a major player in TBI-induced oxidative damage is the reactive nitrogen species (RNS) peroxynitrite (PN) which is produced in large part in injured brain mitochondria. Once formed, PN decomposes into highly reactive free radicals that trigger membrane lipid peroxidation (LP) of polyunsaturated fatty acids (e.g. arachidonic acid) and protein nitration (3-nitrotyrosine, 3-NT) in mitochondria and other cellular membranes causing various functional impairments to mitochondrial oxidative phosphorylation and calcium (Ca2+) buffering capacity. The LP also results in the formation of neurotoxic reactive aldehyde byproducts including 4-hydroxynonenal (4-HNE) and propenal (acrolein) which exacerbates ROS/RNS production and oxidative protein damage in the injured brain. Ultimately, this results in intracellular Ca2+ overload that activates proteolytic degradation of alpha-spectrin, a neuronal cytoskeletal protein. Therefore, the aim of this study was to establish the temporal evolution of mitochondrial dysfunction, oxidative damage and cytoskeletal degradation in the brain following a severe controlled cortical impact (CCI) TBI in young male adult rats. In mitochondria isolated from an 8 mm diameter cortical punch including the 5 mm wide impact site and their respiratory function studied ex vivo, we observed an initial decrease in complex I and II mitochondrial bioenergetics within 3 h (h). For complex I bioenergetics, this partially recovered by 12-16 h, whereas for complex II respiration the recovery was complete by 12 h. During the first 24 h, there was no evidence of an injury-induced increase in LP or protein nitration in mitochondrial or cellular homogenates. However, beginning at 24 h, there was a gradual secondary decline in complex I and II respiration that peaked at 72 h. post-TBI that coincided with progressive peroxidation of mitochondrial and cellular lipids, protein nitration and protein modification by 4-HNE and acrolein. The oxidative damage and respiratory failure paralleled an increase in Ca2+-induced proteolytic degradation of the neuronal cytoskeletal protein alpha-spectrin indicating a failure of intracellular Ca2+ homeostasis. These findings of a surprisingly delayed peak in secondary injury, suggest that the therapeutic window and needed treatment duration for certain antioxidant treatment strategies following CCI-TBI in rodents may be longer than previously believed. (C) 2017 Elsevier Ltd. All rights reserved.	[Hill, Rachel L.; Singh, Indrapal N.; Wang, Juan A.; Hall, Edward D.] Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr SCoBIRC, 741 S Limestone St, Lexington, KY 40536 USA; [Singh, Indrapal N.; Hall, Edward D.] Univ Kentucky, Coll Med, Dept Neurosci, 741 S Limestone St, Lexington, KY 40536 USA	Hall, ED (corresponding author), Univ Kentucky, Med Ctr, Spinal Cord & Brain Injury Res Ctr SCoBIRC, 741 S Limestone St, Lexington, KY 40536 USA.	edhall@uky.edu	Hall, Edward D/F-8930-2013		National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5R01 NS083405, 5R01 NS084857, 5P30 NS051220]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS083405, P30NS051220, T32NS077889, R01NS084857] Funding Source: NIH RePORTER	This work was supported by the following grants from the National Institute of Neurological Disorders and Stroke: 5R01 NS083405, 5R01 NS084857 and 5P30 NS051220.	Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; Carroll RT, 2000, CHEM RES TOXICOL, V13, P294, DOI 10.1021/tx990159t; Deng Y, 2007, EXP NEUROL, V205, P154, DOI 10.1016/j.expneurol.2007.01.023; Deng-Bryant Y, 2008, J CEREBR BLOOD F MET, V28, P1114, DOI 10.1038/jcbfm.2008.10; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Facecchia K., 2011, J TOXICOL, V2011, P1; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Glancy B, 2012, BIOCHEMISTRY-US, V51, P2959, DOI 10.1021/bi2018909; Griffiths EJ, 2009, BBA-BIOENERGETICS, V1787, P1324, DOI 10.1016/j.bbabio.2009.01.019; Hall ED, 1997, J PHARMACOL EXP THER, V281, P895; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; HALL ED, 1991, J PHARMACOL EXP THER, V258, P688; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Halliwell B., 2008, FREE RADICALS BIOL M; Hamann K, 2008, J NEUROCHEM, V107, P712, DOI 10.1111/j.1471-4159.2008.05622.x; Kehrer JP, 2000, TOXICOL SCI, V57, P6, DOI 10.1093/toxsci/57.1.6; Kupina NC, 2002, J CEREBR BLOOD F MET, V22, P1212; Kuznetsov AV, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00082; Lai J C, 1979, Methods Enzymol, V55, P51; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Llorente-Folch I, 2013, J NEUROSCI, V33, P13957, DOI 10.1523/JNEUROSCI.0929-13.2013; Mbye LH, 2008, EXP NEUROL, V209, P243, DOI 10.1016/j.expneurol.2007.09.025; Mbye LH, 2009, J CEREBR BLOOD F MET, V29, P87, DOI 10.1038/jcbfm.2008.93; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391; Miller DM, 2015, EXP NEUROL, V264, P103, DOI 10.1016/j.expneurol.2014.11.008; Mustafa AG, 2011, J NEUROCHEM, V117, P579, DOI 10.1111/j.1471-4159.2011.07228.x; Mustafa AG, 2010, J NEUROCHEM, V114, P271, DOI 10.1111/j.1471-4159.2010.06749.x; Nicholls DG, 2000, PHYSIOL REV, V80, P315; Nobre HV, 2009, OXID MED CELL LONGEV, V2, P130, DOI 10.4161/oxim.2.3.8488; Osteen CL, 2004, NEUROSCIENCE, V128, P305, DOI 10.1016/j.neuroscience.2004.06.034; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; Pandya Jignesh D, 2013, Front Neuroenergetics, V5, P10, DOI 10.3389/fnene.2013.00010; Petersen DR, 2004, FREE RADICAL BIO MED, V37, P937, DOI 10.1016/j.freeradbiomed.2004.06.012; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; Radi R, 2001, FREE RADICAL BIO MED, V30, P463, DOI 10.1016/S0891-5849(00)00373-7; Radi R, 2002, FREE RADICAL BIO MED, V33, P1451, DOI 10.1016/S0891-5849(02)01111-5; Radi R, 2002, BIOL CHEM, V383, P401, DOI 10.1515/BC.2002.044; Radi R, 2004, P NATL ACAD SCI USA, V101, P4003, DOI 10.1073/pnas.0307446101; Ringger NC, 2004, J NEUROTRAUM, V21, P1443, DOI 10.1089/neu.2004.21.1443; Robertson CL, 2004, J BIOENERG BIOMEMBR, V36, P363, DOI 10.1023/B:JOBB.0000041769.06954.e4; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Shi RY, 2011, MOL NUTR FOOD RES, V55, P1320, DOI 10.1002/mnfr.201100217; SIMAN R, 1989, J NEUROSCI, V9, P1579; SIMAN R, 1984, P NATL ACAD SCI-BIOL, V81, P3572, DOI 10.1073/pnas.81.11.3572; Singh IN, 2007, J NEUROSCI RES, V85, P2216, DOI 10.1002/jnr.21360; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Singh IN, 2013, J CEREBR BLOOD F MET, V33, P593, DOI 10.1038/jcbfm.2012.211; Sullivan PG, 2011, J NEUROTRAUM, V28, P311, DOI 10.1089/neu.2010.1646; Sullivan PG, 2004, J COMP NEUROL, V474, P524, DOI 10.1002/cne.20130; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Sullivan PG, 2003, ANN NEUROL, V53, P711, DOI 10.1002/ana.10543; Sun DA, 2008, EUR J NEUROSCI, V27, P1659, DOI 10.1111/j.1460-9568.2008.06156.x; Tobaben S, 2011, CELL DEATH DIFFER, V18, P282, DOI 10.1038/cdd.2010.92; Ucal M, 2017, J NEUROTRAUM, V34, P475, DOI 10.1089/neu.2016.4411; Vespa PM, 2007, CRIT CARE MED, V35, P1153, DOI 10.1097/01.CCM.0000259466.66310.4F; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Weber JT, 2004, CURR NEUROVASC RES, V1, P151, DOI 10.2174/1567202043480134; Wu HM, 2013, J NEUROTRAUM, V30, P352, DOI 10.1089/neu.2012.2610; Xiong Y, 1997, J NEUROTRAUM, V14, P907, DOI 10.1089/neu.1997.14.907; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yan XX, 2012, CURR GERIATR REP, V1, P85, DOI 10.1007/s13670-012-0009-2; Zhang ZQ, 2009, APOPTOSIS, V14, P1289, DOI 10.1007/s10495-009-0405-z	64	34	35	0	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0197-0186	1872-9754		NEUROCHEM INT	Neurochem. Int.	DEC	2017	111				SI		45	56		10.1016/j.neuint.2017.03.015			12	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	FR3OS	WOS:000418976600006	28342966	Green Accepted			2021-06-18	
J	Hyman, SA; Shotwell, MS; Michaels, DR; Han, X; Card, EB; Morse, JL; Weinger, MB				Hyman, Steve Alan; Shotwell, Matthew S.; Michaels, Damon R.; Han, Xue; Card, Elizabeth Borg; Morse, Jennifer L.; Weinger, Matthew B.			A Survey Evaluating Burnout, Health Status, Depression, Reported Alcohol and Substance Use, and Social Support of Anesthesiologists	ANESTHESIA AND ANALGESIA			English	Article							MIDDLE-CEREBRAL-ARTERY; TRAUMATIC BRAIN-INJURY; ACUTE SUBDURAL HEMATOMAS; ACUTE ISCHEMIC-STROKE; SEVERE HEAD-INJURY; DECOMPRESSIVE CRANIECTOMY; INTRACRANIAL-PRESSURE; PERFUSION-PRESSURE; MALIGNANT INFARCTION; TERRITORY INFARCTION	BACKGROUND: Burnout affects all medical specialists, and concern about it has become common in today's health care environment. The gold standard of burnout measurement in health care professionals is the Maslach Burnout Inventory-Human Services Survey (MBI-HSS), which measures emotional exhaustion, depersonalization (DP), and personal accomplishment. Besides affecting work quality, burnout is thought to affect health problems, mental health issues, and substance use negatively, although confirmatory data are lacking. This study evaluates some of these effects. METHODS: In 2011, the American Society of Anesthesiologists and the journal Anesthesiology cosponsored a webinar on burnout. As part of the webinar experience, we included access to a survey using MBI-HSS, 12-item Short Form Health Survey (SF-12), Social Support and Personal Coping (SSPC-14) survey, and substance use questions. Results were summarized using sample statistics, including mean, standard deviation, count, proportion, and 95% confidence intervals. Adjusted linear regression methods examined associations between burnout and substance use, SF-12, SSPC-14, and respondent demographics. RESULTS: Two hundred twenty-one respondents began the survey, and 170 (76.9%) completed all questions. There were 266 registrants total (31 registrants for the live webinar and 235 for the archive event), yielding an 83% response rate. Among respondents providing job titles, 206 (98.6%) were physicians and 2 (0.96%) were registered nurses. The frequency of high-risk responses ranged from 26% to 59% across the 3 MBI-HSS categories, but only about 15% had unfavorable scores in all 3. Mean mental composite score of the SF-12 was 1 standard deviation below normative values and was significantly associated with all MBI-HSS components. With SSPC-14, respondents scored better in work satisfaction and professional support than in personal support and workload. Males scored worse on DP and personal accomplishment and, relative to attending physicians, residents scored worse on DP. There was no significant association between MBI-HSS and substance use. CONCLUSIONS: Many anesthesiologists exhibit some high-risk burnout characteristics, and these are associated with lower mental health scores. Personal and professional support were associated with less emotional exhaustion, but overall burnout scores were associated with work satisfaction and professional support. Respondents were generally economically satisfied but also felt less in control at work and that their job kept them from friends and family. The association between burnout and substance use may not be as strong as previously believed. Additional work, perhaps with other survey instruments, is needed to confirm our results.	[Hyman, Steve Alan; Michaels, Damon R.; Weinger, Matthew B.] Vanderbilt Univ, Sch Med, Dept Anesthesiol, Nashville, TN 37212 USA; [Shotwell, Matthew S.; Morse, Jennifer L.] Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37212 USA; Vanderbilt Univ, Med Ctr, Nashville, TN USA; [Han, Xue] Fred Hutchinson Canc Res Ctr, Stat Ctr HIV AIDS Res & Prevent, 1124 Columbia St, Seattle, WA 98104 USA; [Card, Elizabeth Borg] Vanderbilt Univ, Med Ctr, Dept Nursing Res, Vanderbilt Nursing, Nashville, TN USA; [Weinger, Matthew B.] Vanderbilt Univ, Sch Med, Dept Biomed Informat, Nashville, TN 37212 USA; [Weinger, Matthew B.] Vanderbilt Univ, Sch Med, Dept Med Educ, Nashville, TN 37212 USA; [Weinger, Matthew B.] VA Tennessee Valley Healthcare Syst, Geriatr Res Educ & Clin Ctr, Nashville, TN USA	Hyman, SA (corresponding author), Vanderbilt Univ, Dept Anesthesiol, Med Ctr, 1301 Med Ctr Dr, Nashville, TN 37205 USA.	steve.hyman@vanderbilt.edu			Vanderbilt Institute for Clinical and Translational Research (VICTR) [VR8248]	Vanderbilt Institute for Clinical and Translational Research (VICTR, #VR8248).	Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Ahmed AI, 2010, NEUROCRIT CARE, V13, P393, DOI 10.1007/s12028-010-9420-8; Alotaibi NM, 2017, J NEUROSURG; Andrews PJD, 2015, NEW ENGL J MED, V373, P2403, DOI 10.1056/NEJMoa1507581; Poca MA, 2010, J NEUROSURG, V112, P648, DOI 10.3171/2009.7.JNS081677; Badri S, 2012, INTENS CARE MED, V38, P1800, DOI 10.1007/s00134-012-2655-4; Balami JS, 2012, LANCET NEUROL, V11, P101, DOI 10.1016/S1474-4422(11)70264-2; Balestreri M, 2006, NEUROCRIT CARE, V4, P8, DOI 10.1385/NCC:4:1:008; Bender A, 2013, BRAIN INJURY, V27, P1073, DOI 10.3109/02699052.2013.794972; Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Chambers IR, 2001, J NEUROSURG, V94, P412, DOI 10.3171/jns.2001.94.3.0412; Chang JJJ, 2009, CRIT CARE MED, V37, P283, DOI 10.1097/CCM.0b013e318192fbd7; Chesnut RM, 2016, NEW ENGL J MED, V375, P2403, DOI 10.1056/NEJMc1613479; Chesnut RM, 2013, INTENS CARE MED, V39, P771, DOI 10.1007/s00134-013-2852-9; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Cooper DJ, 2011, NEW ENGL J MED, V365, P376; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Cossu G, 2016, MINERVA ANESTESIOL, V82, P684; Cruz-Flores S, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003435.pub2; Cushing H, 1908, ANN SURG, V47, P641, DOI 10.1097/00000658-190805000-00001; Farahvar A, 2011, J NEUROSURG, V114, P1471, DOI 10.3171/2010.11.JNS101116; Ferro JM, 2011, STROKE, V42, P2825, DOI 10.1161/STROKEAHA.111.615393; Fung C, 2012, STROKE, V43, P3207, DOI 10.1161/STROKEAHA.112.666537; Grindlinger GA, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-3251-9; Gupta R, 2004, STROKE, V35, P539, DOI 10.1161/01.STR.0000109772.64650.18; Heiss WD, 2016, CEREBROVASC DIS, V41, P1, DOI 10.1159/000441627; Hill CS, 2012, BRIT J NEUROSURG, V26, P832, DOI 10.3109/02688697.2012.692839; Hofmeijer J, 2009, LANCET NEUROL, V8, P326, DOI 10.1016/S1474-4422(09)70047-X; Honeybul S, 2017, J CRIT CARE, V39, P185, DOI 10.1016/j.jcrc.2017.03.006; Honeybul S, 2013, BRAIN INJURY, V27, P979, DOI 10.3109/02699052.2013.794974; Honeybul S, 2016, J NEUROSURG, V125, P775, DOI 10.3171/2016.3.JNS1683; Honeybul S, 2013, J NEUROSURG, V119, P1566, DOI 10.3171/2013.8.JNS13857; Hutchinson PJ, 2016, NEW ENGL J MED, V375, P1119, DOI 10.1056/NEJMoa1605215; Huttner HB, 2009, LANCET NEUROL, V8, P949, DOI 10.1016/S1474-4422(09)70224-8; Jauch EC, 2013, STROKE, V44, P870, DOI 10.1161/STR.0b013e318284056a; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Juttler E, 2014, NEW ENGL J MED, V370, P1091, DOI 10.1056/NEJMoa1311367; Juttler E, 2007, STROKE, V38, P2518, DOI 10.1161/STROKEAHA.107.485649; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kirkman MA, 2014, BRIT J ANAESTH, V112, P35, DOI 10.1093/bja/aet418; Kirkman Matthew A, 2016, Anesthesiol Clin, V34, P511, DOI 10.1016/j.anclin.2016.04.005; Kirkman MA, 2014, INTENS CARE MED, V40, P640, DOI 10.1007/s00134-014-3266-z; Kolias AG, 2016, BRIT J NEUROSURG, V30, P246, DOI 10.3109/02688697.2016.1159655; Kolias AG, 2013, NAT REV NEUROL, V9, P405, DOI 10.1038/nrneurol.2013.106; Kolias AG, 2012, ACTA NEUROCHIR, V154, P1563, DOI 10.1007/s00701-012-1349-6; Kurland DB, 2015, NEUROCRIT CARE, V23, P292, DOI 10.1007/s12028-015-0144-7; Larach DR, 2009, NEUROCRIT CARE, V11, P106, DOI 10.1007/s12028-008-9180-x; Lazaridis C, 2012, NEUROCRIT CARE, V16, P478, DOI 10.1007/s12028-012-9685-1; Li LM, 2012, ACTA NEUROCHIR, V154, P1555, DOI 10.1007/s00701-012-1428-8; Lu XC, 2014, SCI REP-UK, V4, DOI 10.1038/srep07070; Maas AIR, 2013, LANCET NEUROL, V12, P1200, DOI 10.1016/S1474-4422(13)70234-5; Makarenko S, 2016, J CLIN NEUROSCI, V26, P8, DOI 10.1016/j.jocn.2015.05.065; McGinn MJ, 2016, NEUROSURG CLIN N AM, V27, P397, DOI 10.1016/j.nec.2016.06.002; Muehlschlegel S, 2015, NEUROCRIT CARE, V23, P127, DOI 10.1007/s12028-014-0097-2; Neugebauer H, 2014, NEUROCRIT CARE, V21, P27, DOI 10.1007/s12028-014-9956-0; Oddo M, 2011, NEUROSURGERY, V69, P1037, DOI 10.1227/NEU.0b013e3182287ca7; Perez-Bovet J, 2012, ACTA NEUROCHIR, V154, P1717, DOI 10.1007/s00701-012-1323-3; Pizzi MA, 2016, J STROKE CEREBROVASC, V25, P2312, DOI 10.1016/j.jstrokecerebrovasdis.2016.05.025; QIZILBASH N, 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000064; Qureshi AI, 2003, CRIT CARE MED, V31, P272, DOI 10.1097/00003246-200301000-00043; Rahme R, 2012, J NEUROSURG, V117, P749, DOI 10.3171/2012.6.JNS111140; Roberts I, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000033.pub2; Romero CM, 2011, NEW ENGL J MED, V365, P373, DOI 10.1056/NEJMc1106421; Roozenbeek B, 2011, CRIT CARE, V15, DOI 10.1186/cc10240; Ropper AH, 2012, NEW ENGL J MED, V367, P746, DOI 10.1056/NEJMct1206321; Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2; Sahuquillo J, 2013, CURR OPIN CRIT CARE, V19, P101, DOI 10.1097/MCC.0b013e32835eba1a; Saposnik G, 2011, STROKE, V42, P1158, DOI 10.1161/STR.0b013e31820a8364; Schuss P, 2013, J NEUROL, V260, P2149, DOI 10.1007/s00415-013-6950-y; Servadei F, 2011, NEW ENGL J MED, V364, P1558, DOI 10.1056/NEJMe1102998; Stocchetti N, 2008, INTENS CARE MED, V34, P461, DOI 10.1007/s00134-007-0948-9; Stocchetti N, 2014, ACTA NEUROCHIR, V156, P1615, DOI 10.1007/s00701-014-2127-4; Stocchetti N, 2014, NEW ENGL J MED, V370, P2121, DOI 10.1056/NEJMra1208708; Tahir Rizwan A, 2016, Surg Neurol Int, V7, pS381, DOI 10.4103/2152-7806.183492; Torbey MT, 2015, NEUROCRIT CARE, V22, P146, DOI 10.1007/s12028-014-0085-6; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vahedi K, 2007, STROKE, V38, P2506, DOI 10.1161/STROKEAHA.107.485235; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; Vinciguerra L, 2017, NEUROCRIT CARE, V27, P122, DOI 10.1007/s12028-016-0361-8; Weil AG, 2011, CAN J NEUROL SCI, V38, P434, DOI 10.1017/S0317167100011835; Whitfield PC, 2001, BRIT J NEUROSURG, V15, P500, DOI 10.1080/02688690120105110; Wilson MH, 2016, J CEREBR BLOOD F MET, V36, P1338, DOI 10.1177/0271678X16648711; Yang MH, 2015, SURG-J R COLL SURG E, V13, P230, DOI 10.1016/j.surge.2014.12.002; Yuan Q, 2015, J NEUROSURG, V122, P574, DOI 10.3171/2014.10.JNS1460	85	34	34	0	26	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	DEC	2017	125	6					2009	2018		10.1213/ANE.0000000000002298			10	Anesthesiology	Anesthesiology	FQ8BK	WOS:000418587700027	28991114	Bronze			2021-06-18	
J	Yang, JZ; Comstock, RD; Yi, HG; Harvey, HH; Xun, PC				Yang, Jingzhen; Comstock, R. Dawn; Yi, Honggang; Harvey, Hosea H.; Xun, Pengcheng			New and Recurrent Concussions in High-School Athletes Before and After Traumatic Brain Injury Laws, 2005-2016	AMERICAN JOURNAL OF PUBLIC HEALTH			English	Article							PROFESSIONAL FOOTBALL PLAYERS; UNITED-STATES; SPORTS; EDUCATION; SYMPTOMS; ENCEPHALOPATHY; EPIDEMIOLOGY; LEGISLATION; CHILDREN; COACHES	Objectives. To examine the trends of new and recurrent sports-related concussions in high-school athletes before and after youth sports traumatic brain injury laws. Methods. We used an interrupted time-series design and analyzed the concussion data (2005-2016) from High School Reporting Injury Online. We examined the trends of new or recurrent concussion rates among US representative high-school athletes participating in 9 sports across prelaw, immediate-postlaw, and postlaw periods by using general linear models. We defined 1 athlete exposure as attending 1 competition or practice. Results. We included a total of 8043 reported concussions (88.7% new, 11.3% recurrent). The average annual concussion rate was 39.8 per 100 000 athlete exposures. We observed significantly increased trends of reported new and recurrent concussions from the prelaw, through immediate-postlaw, into the postlaw period. However, the recurrent concussion rate showed a significant decline 2.6 years after the laws went into effect. Football exhibited different trends compared with other boys' sports and girls' sports. Conclusions. Observed trends of increased concussion rates are likely attributable to increased identification and reporting. Additional research is needed to evaluate intended long-term impact of traumatic brain injury laws.	[Yang, Jingzhen] Ohio State Univ, Nationwide Childrens Hosp, Res Inst, Ctr Injury Res & Policy, Columbus, OH 43210 USA; [Yang, Jingzhen] Ohio State Univ, Coll Med, Dept Pediat, Columbus, OH 43210 USA; [Yang, Jingzhen] Ohio State Univ, Coll Publ Hlth, Dept Epidemiol, Columbus, OH 43210 USA; [Comstock, R. Dawn] Univ Colorado Anschutz, Colorado Sch Publ Hlth, Dept Epidemiol, Aurora, CO USA; [Comstock, R. Dawn] Univ Colorado Anschutz, Sch Med, Dept Pediat, Emergency Med, Aurora, CO USA; [Yi, Honggang] Nanjing Med Univ, Nationwide Childrens Hosp, Res Inst, Ctr Injury Res & Policy, Nanjing, Jiangsu, Peoples R China; [Yi, Honggang] Nanjing Med Univ, Sch Publ Hlth, Dept Biostat, Nanjing, Jiangsu, Peoples R China; [Harvey, Hosea H.] Temple Univ, Beasley Sch Law, Philadelphia, PA 19122 USA; [Xun, Pengcheng] Indiana Univ, Sch Publ Hlth Bloomington, Dept Epidemiol & Biostat, Bloomington, IN USA	Yang, JZ (corresponding author), Ohio State Univ, Coll Med, Dept Pediat, Ctr Injury Res & Policy,Res Inst,Nationwide Child, 700 Childrens Dr,RB3-WB5403, Columbus, OH 43205 USA.	ginger.yang@nationwidechildrens.org	pengcheng, xun/D-3411-2013	pengcheng, xun/0000-0002-6245-4505	Robert Wood Johnson FoundationRobert Wood Johnson Foundation (RWJF) [30822]	This research work was supported by the Robert Wood Johnson Foundation (grant 30822).	[Anonymous], 2013, GET HEADS CONC SPORT; Baugh CM, 2014, J LAW MED ETHICS, V42, P297, DOI 10.1111/jlme.12147; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Bompadre V, 2014, J ATHL TRAINING, V49, P486, DOI 10.4085/1062-6050-49.3.30; Bryan MA, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2015-4635; Castile L, 2012, BRIT J SPORT MED, V46, P603, DOI 10.1136/bjsports-2011-090115; Chrisman SP, 2014, AM J SPORT MED, V42, P1190, DOI 10.1177/0363546513519073; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Esquivel A, 2013, SPORTS HEALTH, V5, P258, DOI 10.1177/1941738113476850; Gibson TB, 2015, JAMA PEDIATR, V169, P163, DOI 10.1001/jamapediatrics.2014.2320; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Harvey HH, 2015, J LAW MED ETHICS, V43, P87, DOI 10.1111/jlme.12225; Harvey Hosea H, 2014, Yale J Health Policy Law Ethics, V14, P66; Harvey HH, 2013, AM J PUBLIC HEALTH, V103, P1249, DOI 10.2105/AJPH.2012.301107; LawAtlas, POL SURV PORT PUBL H; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Lowrey Kerri McGowan, 2016, J Health Care Law Policy, V19, P99; Lowrey KM, 2014, J LAW MED ETHICS, V42, P290, DOI 10.1111/jlme.12146; Lowrey KM, 2014, J BUSINESS TECH L, V10, P61; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Mez J, 2017, JAMA-J AM MED ASSOC, V318, P360, DOI 10.1001/jama.2017.8334; National Center for Injury Prevention and Control, 2013, IMPL RET PLAY LEARN; Program for Injury Prevention Education & Research (PIPER), HIGH SCH RIO REP FOR; Rechel JA, 2008, J ATHL TRAINING, V43, P197, DOI 10.4085/1062-6050-43.2.197; Rivara FP, 2014, AM J SPORT MED, V42, P1197, DOI 10.1177/0363546514521774; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; Tomei KL, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.9.FOCUS12280; Trojian Thomas, 2015, Inj Epidemiol, V2, P2	33	34	34	1	12	AMER PUBLIC HEALTH ASSOC INC	WASHINGTON	800 I STREET, NW, WASHINGTON, DC 20001-3710 USA	0090-0036	1541-0048		AM J PUBLIC HEALTH	Am. J. Public Health	DEC	2017	107	12					1916	1922		10.2105/AJPH.2017.304056			7	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	FR7HU	WOS:000419239300040	29048967	Green Published			2021-06-18	
J	Fann, JR; Bombardier, CH; Temkin, N; Esselman, P; Warms, C; Barber, J; Dikmen, S				Fann, Jesse R.; Bombardier, Charles H.; Temkin, Nancy; Esselman, Peter; Warms, Catherine; Barber, Jason; Dikmen, Sureyya			Sertraline for Major Depression During the Year Following Traumatic Brain Injury: A Randomized Controlled Trial	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						antidepressant; clinical trial; depression; head injury; placebo; quality of life; traumatic brain injury; treatment	COGNITIVE-BEHAVIORAL THERAPY; RATING-SCALE; 1ST YEAR; SEVERITY; SYMPTOMS; ANXIETY; REHABILITATION; METAANALYSIS; DISABILITY; DISORDERS	Objective: Major depressive disorder (MDD) is common and associated with impaired functioning after traumatic brain injury (TBI). Few placebo-controlled antidepressant trials exist in this population. We evaluated the efficacy and tolerability of sertraline for MDD within 1 year of sustaining a TBI. Setting: Level I trauma center. Participants: Adults with MDD within 1 year of hospitalization for complicated mild to severe TBI. Design: Randomized, double-blind, placebo-controlled trial. Main Measures: Twelve-week treatment response on the 17-item Hamilton Depression Rating Scale. We also assessed symptom improvement and remission. Results: We randomized 62 participants: 32% sustained a severe TBI, 68% had significant anxiety, 63% had a history of prior MDD, and 69% had a history of alcohol or drug dependence. Depression significantly improved from baseline to 12 weeks in both treatment groups (P < .001). There were no significant differences between the sertraline and placebo groups over 12 weeks on depression severity, response, or remission. The sertraline group had significant improvement on speed of information processing compared with the placebo group (P < .006). Conclusion: Sertraline monotherapy was not superior to placebo for MDD in people with post-acute complicated mild to severe TBI. Research is needed on the effectiveness of interventions that also address the significant psychosocial needs of this population.	[Fann, Jesse R.; Dikmen, Sureyya] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Box 356560,1959 NE Pacific St, Seattle, WA 98195 USA; [Fann, Jesse R.; Bombardier, Charles H.; Esselman, Peter; Warms, Catherine; Dikmen, Sureyya] Univ Washington, Sch Med, Dept Rehabil Med, Seattle, WA 98195 USA; [Temkin, Nancy; Barber, Jason] Univ Washington, Sch Med, Dept Neurol Surg, Seattle, WA 98195 USA	Fann, JR (corresponding author), Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Box 356560,1959 NE Pacific St, Seattle, WA 98195 USA.	fann@uw.edu			National Center for Medical Rehabilitation Research; National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01HD39415]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD039415] Funding Source: NIH RePORTER	This work was supported by the National Center for Medical Rehabilitation Research, the National Institute of Child Health and Human Development, and National Institutes of Health grant R01HD39415. Pfizer supplied masked sertraline and placebo for the controlled trial. The authors thank Erika Pelzer, BS, University of Washington School of Medicine, who provided expert assistance and oversight in data collection efforts.	AMADOBOCCARA I, 1995, NEUROSCI BIOBEHAV R, V19, P479, DOI 10.1016/0149-7634(94)00068-C; Ashman TA, 2009, ARCH PHYS MED REHAB, V90, P733, DOI 10.1016/j.apmr.2008.11.005; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Banos JH, 2010, J HEAD TRAUMA REHAB, V25, P357, DOI 10.1097/HTR.0b013e3181d6c715; Barker-Collo S, 2013, BRAIN INJURY, V27, P1124, DOI 10.3109/02699052.2013.801513; Baune BT, 2014, PSYCHIAT RES, V219, P25, DOI 10.1016/j.psychres.2014.05.013; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bombardier CH, 2009, J HEAD TRAUMA REHAB, V24, P230, DOI 10.1097/HTR.0b013e3181ad65f0; Centers for Disease Control and Prevention, 2015, C TRAUM BRAIN INJ US; Cleeland C. S., 1994, Annals Academy of Medicine Singapore, V23, P129; Derogatis L R, 1974, Mod Probl Pharmacopsychiatry, V7, P79; Dyer JR, 2016, J HEAD TRAUMA REHAB, V31, P225, DOI 10.1097/HTR.0000000000000177; Entsuah R, 2002, J PSYCHIATR RES, V36, P437, DOI 10.1016/S0022-3956(02)00024-9; Fann JR, 2015, J NEUROTRAUM, V32, P45, DOI 10.1089/neu.2014.3423; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; Fann JR, 2009, J HEAD TRAUMA REHAB, V24, P272, DOI 10.1097/HTR.0b013e3181a66342; Fann JR, 2005, J HEAD TRAUMA REHAB, V20, P501, DOI 10.1097/00001199-200511000-00003; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; Fann JR, 2000, J NEUROPSYCH CLIN N, V12, P226, DOI 10.1176/appi.neuropsych.12.2.226; Faries D, 2000, J PSYCHIAT RES, V34, P3, DOI 10.1016/S0022-3956(99)00037-0; First Michael B, 2001, USERS GUIDE STRUCTUR; Fournier JC, 2010, JAMA-J AM MED ASSOC, V303, P47, DOI 10.1001/jama.2009.1943; GIBBONS RD, 1993, ARCH GEN PSYCHIAT, V50, P739; Guillamondegui OD, 2011, TRAUMATIC BRAIN INJU; Guy W., 1976, ECDEU ASSESSMENT MAN, P218; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HAMILTON M, 1959, BRIT J MED PSYCHOL, V32, P50, DOI 10.1111/j.2044-8341.1959.tb00467.x; Hammond FM, 2015, ARCH PHYS MED REHAB, V96, pS256, DOI 10.1016/j.apmr.2015.01.025; Hart T, 2016, ARCH PHYS MED REHAB, V97, P701, DOI 10.1016/j.apmr.2015.08.436; HOLM S, 1979, SCAND J STAT, V6, P65; Iosifescu DV, 2007, PSYCHIAT CLIN N AM, V30, P77, DOI 10.1016/j.psc.2006.12.008; Jorge RE, 2016, JAMA PSYCHIAT, V73, P1041, DOI 10.1001/jamapsychiatry.2016.2189; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Lee H, 2005, HUM PSYCHOPHARM CLIN, V20, P97, DOI 10.1002/hup.668; MAIER W, 1985, PHARMACOPSYCHIATRY, V18, P114, DOI 10.1055/s-2007-1017335; Maiuro R. D., 1987, J INTERPERS VIOLENCE, V2, P166, DOI DOI 10.1177/088626087002002003; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; Novack TA, 2009, J NEUROTRAUM, V26, P1921, DOI 10.1089/neu.2009.0895; Ponsford J, 2016, PSYCHOL MED, V46, P1079, DOI 10.1017/S0033291715002640; Previc FH, 1999, BRAIN COGNITION, V41, P299, DOI 10.1006/brcg.1999.1129; Ricker, 1994, Assessment, V1, P47, DOI 10.1177/1073191194001001007; Ruhe HG, 2005, COMPR PSYCHIAT, V46, P417, DOI 10.1016/j.comppsych.2005.03.001; Sheehan DV, 1996, INT CLIN PSYCHOPHARM, V11, P89, DOI 10.1097/00004850-199606003-00015; Turner-Stokes L, 2002, CLIN REHABIL, V16, P261, DOI 10.1191/0269215502cr489oa; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WILLIAMS JBW, 1988, ARCH GEN PSYCHIAT, V45, P742; Yengo-Kahn AM, 2015, PHYSICIAN SPORTSMED, V43, P227, DOI 10.1080/00913847.2015.1071638	50	34	34	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2017	32	5					332	342		10.1097/HTR.0000000000000322			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	FG2DW	WOS:000409893800013	28520672	Green Accepted			2021-06-18	
J	Kim, SY; Senatorov, VV; Morrissey, CS; Lippmann, K; Vazquez, O; Milikovsky, DZ; Gu, F; Parada, I; Prince, DA; Becker, AJ; Heinemann, U; Friedman, A; Kaufer, D				Kim, Soo Young; Senatorov, Vladimir V., Jr.; Morrissey, Christapher S.; Lippmann, Kristina; Vazquez, Oscar; Milikovsky, Dan Z.; Gu, Feng; Parada, Isabel; Prince, David A.; Becker, Albert J.; Heinemann, Uwe; Friedman, Alon; Kaufer, Daniela			TGF beta signaling is associated with changes in inflammatory gene expression and perineuronal net degradation around inhibitory neurons following various neurological insults	SCIENTIFIC REPORTS			English	Article							BLOOD-BRAIN-BARRIER; INJURED EPILEPTOGENIC NEOCORTEX; MARKED NEUROPROTECTIVE EFFICACY; FAST-SPIKING INTERNEURONS; ACUTE ISCHEMIC-STROKE; EXTRACELLULAR-MATRIX; TRANSFORMING GROWTH-FACTOR-BETA-1; ACQUIRED EPILEPSY; ALBUMIN THERAPY; VISUAL-CORTEX	Brain damage due to stroke or traumatic brain injury (TBI), both leading causes of serious long-term disability, often leads to the development of epilepsy. Patients who develop post-injury epilepsy tend to have poor functional outcomes. Emerging evidence highlights a potential role for blood-brain barrier (BBB) dysfunction in the development of post-injury epilepsy. However, common mechanisms underlying the pathological hyperexcitability are largely unknown. Here, we show that comparative transcriptome analyses predict remodeling of extracellular matrix (ECM) as a common response to different types of injuries. ECM-related transcriptional changes were induced by the serum protein albumin via TGF beta signaling in primary astrocytes. In accordance with transcriptional responses, we found persistent degradation of protective ECM structures called perineuronal nets (PNNs) around fast-spiking inhibitory interneurons, in a rat model of TBI as well as in brains of human epileptic patients. Exposure of a naive brain to albumin was sufficient to induce the transcriptional and translational upregulation of molecules related to ECM remodeling and the persistent breakdown of PNNs around fast-spiking inhibitory interneurons, which was contingent on TGF beta signaling activation. Our findings provide insights on how albumin extravasation that occurs upon BBB dysfunction in various brain injuries can predispose neural circuitry to the development of chronic inhibition deficits.	[Kim, Soo Young; Morrissey, Christapher S.; Kaufer, Daniela] Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA; [Senatorov, Vladimir V., Jr.; Vazquez, Oscar; Kaufer, Daniela] Univ Calif Berkeley, Helen Wills Neurosci Inst, Berkeley, CA 94720 USA; [Lippmann, Kristina; Heinemann, Uwe] Charite Univ Med Berlin, Inst Neurophysiol, D-10117 Berlin, Germany; [Milikovsky, Dan Z.; Friedman, Alon] Ben Gurion Univ Negev, Zlotowski Ctr Neurosci, Dept Cognit & Brain Sci, IL-84105 Beer Sheva, Israel; [Milikovsky, Dan Z.; Friedman, Alon] Ben Gurion Univ Negev, Zlotowski Ctr Neurosci, Dept Physiol, IL-84105 Beer Sheva, Israel; [Milikovsky, Dan Z.; Friedman, Alon] Ben Gurion Univ Negev, Zlotowski Ctr Neurosci, Dept Cell Biol, IL-84105 Beer Sheva, Israel; [Gu, Feng; Parada, Isabel; Prince, David A.] Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA; [Becker, Albert J.] Univ Bonn, Med Ctr, Dept Neuropathol, D-53105 Bonn, Germany; [Friedman, Alon] Dalhousie Univ, Dept Med Neurosci, Halifax, NS B3H 4R2, Canada; [Kaufer, Daniela] Canadian Inst Adv Res CIFAR, Program Child & Brain Dev, Toronto, ON M5G 1Z8, Canada; [Lippmann, Kristina] Univ Leipzig, Carl Ludwig Inst Physiol, D-04315 Leipzig, Germany	Kim, SY; Kaufer, D (corresponding author), Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA.; Kaufer, D (corresponding author), Univ Calif Berkeley, Helen Wills Neurosci Inst, Berkeley, CA 94720 USA.; Kaufer, D (corresponding author), Canadian Inst Adv Res CIFAR, Program Child & Brain Dev, Toronto, ON M5G 1Z8, Canada.	sooykim29@gmail.com; danielak@berkeley.edu	Kim, Soo Young/K-2083-2012; Lippmann, Kristina/AAA-6709-2019; Becker, Albert J/F-6248-2012	Kim, Soo Young/0000-0002-2111-4619; Milikovsky, Dan Z/0000-0002-4826-5273; Lippmann, Kristina/0000-0001-7719-0437	NARSAD Young Investigator Grant Award; Siebel Stem Cell Postdoctoral Fellowship; US National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS 39579, NS 082644, NS 090076, T32-AG00266, 2R56NS066005-05A1]; CURE (Citizens United for Research in Epilepsy) Prevention of Acquired Epilepsies Grant Award; German Research Foundation Grant Cluster of Excellence [DFG-EXC257 NeuroCure, DFG-HE1128/18-1, GRK 1123]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [T32AG000266] Funding Source: NIH RePORTER	We wish to dedicate this paper in memory of our co-author, Dr. Uwe Heinemann, who passed away during the work on this manuscript. Uwe was a role model, a wonderful colleague and a dear friend to us. We thank Dr. Yunyong Ma, Delina T. Meharenna, and Min-Sun Jun for technical assistance, Dr. Justin Y. Choi in the Functional Genomics Lab at UC Berkeley for the help with microarray analysis, and Dr. DeAnna L. Adkins for helpful comments on the manuscript. This work is supported by NARSAD Young Investigator Grant Award and Siebel Stem Cell Postdoctoral Fellowship (to S.Y.K.), the US National Institutes of Health grant NS 39579, NS 082644, and NS 090076 (to D.A.P.), T32-AG00266 (to C.S.M.), 2R56NS066005-05A1 (to D.K.), CURE (Citizens United for Research in Epilepsy) Prevention of Acquired Epilepsies Grant Award (to A.F. and D.K.), and the German Research Foundation Grant Cluster of Excellence DFG-EXC257 NeuroCure (to U.H.), DFG-HE1128/18-1 (to U.H. and A.F.), and GRK 1123 (K.L.).	Abbott NJ, 2002, J ANAT, V200, P629, DOI 10.1046/j.1469-7580.2002.00064.x; Akhurst RJ, 2012, NAT REV DRUG DISCOV, V11, P790, DOI 10.1038/nrd3810; Asher RA, 2000, J NEUROSCI, V20, P2427; Balami JS, 2011, LANCET NEUROL, V10, P357, DOI 10.1016/S1474-4422(10)70313-6; Bar-Klein G, 2014, ANN NEUROL, V75, P864, DOI 10.1002/ana.24147; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Belayev L, 1998, STROKE, V29, P2587, DOI 10.1161/01.STR.29.12.2587; Belayev L, 2001, STROKE, V32, P553, DOI 10.1161/01.STR.32.2.553; Beurdeley M, 2012, J NEUROSCI, V32, P9429, DOI 10.1523/JNEUROSCI.0394-12.2012; Bien CG, 2007, NEUROLOGY, V69, P1236, DOI 10.1212/01.wnl.0000276946.08412.ef; BRUCKNER G, 1993, GLIA, V8, P183, DOI 10.1002/glia.440080306; BUZSAKI G, 1995, CURR OPIN NEUROBIOL, V5, P504, DOI 10.1016/0959-4388(95)80012-3; Cabungcal JH, 2013, P NATL ACAD SCI USA, V110, P9130, DOI 10.1073/pnas.1300454110; Cacheaux LP, 2009, J NEUROSCI, V29, P8927, DOI 10.1523/JNEUROSCI.0430-09.2009; Cammarota M, 2013, J PHYSIOL-LONDON, V591, P807, DOI 10.1113/jphysiol.2012.238154; Cekanaviciute E, 2014, GLIA, V62, P1227, DOI 10.1002/glia.22675; Cohn RD, 2007, NAT MED, V13, P204, DOI 10.1038/nm1536; Czuwara-Ladykowska J, 2002, J BIOL CHEM, V277, P20399, DOI 10.1074/jbc.M200206200; Davies M, 2005, J CELL BIOCHEM, V95, P918, DOI 10.1002/jcb.20458; Deller T, 1997, NEUROSCIENCE, V81, P829, DOI 10.1016/S0306-4522(97)00194-2; Dityatev A, 2010, TRENDS NEUROSCI, V33, P503, DOI 10.1016/j.tins.2010.08.003; Fauser S, 2004, ACTA NEUROPATHOL, V108, P272, DOI 10.1007/s00401-004-0889-0; Gaudet AD, 2014, EXP NEUROL, V258, P24, DOI 10.1016/j.expneurol.2013.11.020; Geirsson A, 2012, CIRCULATION, V126, pS189, DOI 10.1161/CIRCULATIONAHA.111.082610; Geissler M, 2013, J NEUROSCI, V33, P7742, DOI 10.1523/JNEUROSCI.3275-12.2013; Gliem M, 2012, ANN NEUROL, V71, P743, DOI 10.1002/ana.23529; Hametner S, 2013, ANN NEUROL, V74, P848, DOI 10.1002/ana.23974; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Hensch TK, 2005, NAT REV NEUROSCI, V6, P877, DOI 10.1038/nrn1787; Hsieh T. H., 2016, CEREB CORTEX; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Ivens S, 2007, BRAIN, V130, P535, DOI 10.1093/brain/awl317; Jin XM, 2011, CEREB CORTEX, V21, P1094, DOI 10.1093/cercor/bhq181; Kann O, 2011, BRAIN, V134, P345, DOI 10.1093/brain/awq333; Kim HT, 2015, CELL REP, V13, P990, DOI 10.1016/j.celrep.2015.09.075; Kim S. Y., 2016, J NEUROSCIENCE RES; Kim SY, 2016, J NEUROSCI RES, V94, P794, DOI 10.1002/jnr.23758; Kim SY, 2012, EPILEPSIA, V53, P37, DOI 10.1111/j.1528-1167.2012.03701.x; Kyriakis JM, 2001, PHYSIOL REV, V81, P807; Lapilover EG, 2012, NEUROBIOL DIS, V48, P495, DOI 10.1016/j.nbd.2012.06.024; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Librizzi L, 2012, ANN NEUROL, V72, P82, DOI 10.1002/ana.23567; Lippmann K., 2016, J CEREBRAL BLOOD FLO; Ma YY, 2012, NEUROBIOL DIS, V47, P102, DOI 10.1016/j.nbd.2012.03.027; Martin RH, 2016, STROKE, V47, P2355, DOI 10.1161/STROKEAHA.116.012825; McFarland BC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078728; McMillin M. A., 2015, LAB INVEST; Mercado-Gomez O, 2014, EPILEPSY RES, V108, P1694, DOI 10.1016/j.eplepsyres.2014.09.019; Montagne A, 2015, NEURON, V85, P296, DOI 10.1016/j.neuron.2014.12.032; Okamoto M, 2003, EXP NEUROL, V184, P179, DOI 10.1016/S0014-4886(03)00251-6; Pollock E, 2014, NEUROBIOL DIS, V70, P21, DOI 10.1016/j.nbd.2014.06.003; PREHN JHM, 1993, J CEREBR BLOOD F MET, V13, P521, DOI 10.1038/jcbfm.1993.67; Raabe A, 2012, EPILEPSIA, V53, P539, DOI 10.1111/j.1528-1167.2012.03405.x; Rankin- Gee E. K., 2015, EPILEPSIA; Rhodes DR, 2004, P NATL ACAD SCI USA, V101, P9309, DOI 10.1073/pnas.0401994101; Rossi S, 2011, BRAIN BEHAV IMMUN, V25, P947, DOI 10.1016/j.bbi.2010.10.004; Salar S, 2016, NEUROBIOL DIS, V91, P155, DOI 10.1016/j.nbd.2016.03.008; Schachtrup C, 2010, J NEUROSCI, V30, P5843, DOI 10.1523/JNEUROSCI.0137-10.2010; Seiffert E, 2004, J NEUROSCI, V24, P7829, DOI 10.1523/JNEUROSCI.1751-04.2004; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Sorg BA, 2016, J NEUROSCI, V36, P11459, DOI 10.1523/JNEUROSCI.2351-16.2016; Sorokin L, 2010, NAT REV IMMUNOL, V10, P712, DOI 10.1038/nri2852; Sugiyama S, 2008, CELL, V134, P508, DOI 10.1016/j.cell.2008.05.054; Town T, 2008, NAT MED, V14, P681, DOI 10.1038/nm1781; Upchurch K, 2010, SEIZURE-EUR J EPILEP, V19, P120, DOI 10.1016/j.seizure.2009.11.006; Verret L, 2012, CELL, V149, P708, DOI 10.1016/j.cell.2012.02.046; Wegner F, 2003, EXP NEUROL, V184, P705, DOI 10.1016/S0014-4886(03)00313-3; Weissberg I, 2015, NEUROBIOL DIS, V78, P115, DOI 10.1016/j.nbd.2015.02.029; Wilczynski GM, 2008, J CELL BIOL, V180, P1021, DOI 10.1083/jcb.200708213; Wu M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155730; WYSSCORAY T, 1995, AM J PATHOL, V147, P53; Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818; Yu Q, 2000, GENE DEV, V14, P163; Yutsudo N., 2015, EXP NEUROL; Zlokovic BV, 2008, NEURON, V57, P178, DOI 10.1016/j.neuron.2008.01.003	75	34	34	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	AUG 9	2017	7								7711	10.1038/s41598-017-07394-3			14	Multidisciplinary Sciences	Science & Technology - Other Topics	FD1KC	WOS:000407295200010	28794441	DOAJ Gold, Green Published			2021-06-18	
J	Esnault, P; Cardinale, M; Boret, H; D'Aranda, E; Montcriol, A; Bordes, J; Prunet, B; Joubert, C; Dagain, A; Goutorbe, P; Kaiser, E; Meaudre, E				Esnault, Pierre; Cardinale, Mickael; Boret, Henry; D'Aranda, Erwan; Montcriol, Ambroise; Bordes, Julien; Prunet, Bertrand; Joubert, Christophe; Dagain, Arnaud; Goutorbe, Philippe; Kaiser, Eric; Meaudre, Eric			Blunt cerebrovascular injuries in severe traumatic brain injury: incidence, risk factors, and evolution	JOURNAL OF NEUROSURGERY			English	Article						blunt cerebrovascular injury; traumatic brain injury; cervical artery dissection; anticoagulation therapy	CAROTID ARTERIAL INJURIES; COMPUTED-TOMOGRAPHY; SCREENING CRITERIA; EARLY-DIAGNOSIS; ANTICOAGULATION; DISSECTIONS	OBJECTIVE Blunt cerebrovascular injuries (BCVIs) affect approximately 1% of patients with blunt trauma. An antithrombotic or anticoagulation therapy is recommended to prevent the occurrence or recurrence of neurovascular events. This treatment has to be carefully considered after severe traumatic brain injury (TBI), due to the risk of intracranial hemorrhage expansion. Thus, the physician in charge of the patient is confronted with a hemorrhagic and ischemic risk. The main objective of this study was to determine the incidence of BCVI after severe TBI. METHODS The authors conducted a prospective, observational, single-center study including all patients with severe TBI admitted in the trauma center. Diagnosis of BCVI was performed using a 64-channel multidetector CT. Characteristics of the patients, CT scan results, and outcomes were collected. A multivariate logistic regression model was developed to determine the risk factors of BCVI. Patients in whom BCVI was diagnosed were treated with systemic anticoagulation. RESULTS In total, 228 patients with severe TBI who were treated over a period of 7 years were included. The incidence of BCVI was 9.2%. The main risk factors were as follows: motorcycle crash (OR 8.2, 95% CI 1.9-34.8), fracture involving the carotid canal (OR 11.7, 95% CI 1.7-80.9), cervical spine injury (OR 13.5, 95% CI 3.1-59.4), thoracic trauma (OR 7.3, 95% CI 1.1-51.2), and hepatic lesion (OR 13.3, 95% CI 2.1-84.5). Among survivors, 82% of patients with BCVI received systemic anticoagulation therapy, beginning at a median of Day 1.5. The overall stroke rate was 19%. One patient had an intracranial hemorrhagic complication. CONCLUSIONS Blunt cerebrovascular injuries are frequent after severe TBI (incidence 9.2%). The main risk factors are high-velocity lesions and injuries near cervical arteries.	[Esnault, Pierre; Cardinale, Mickael; Boret, Henry; D'Aranda, Erwan; Montcriol, Ambroise; Bordes, Julien; Prunet, Bertrand; Goutorbe, Philippe; Kaiser, Eric; Meaudre, Eric] St Anne Mil Hosp, Intens Care Unit, Toulon, France; [Joubert, Christophe; Dagain, Arnaud] St Anne Mil Hosp, Dept Neurosurg, Toulon, France; [Dagain, Arnaud; Kaiser, Eric; Meaudre, Eric] Ecole Val de Grace, French Mil Hlth Serv, Acad Unit, Paris, France	Esnault, P (corresponding author), Hop Instruct Armees St Anne, Serv Reanimat Brules, Blvd St Anne, F-83000 Toulon, France.	pierre.esnault@gmail.com	Esnault, Pierre/AAN-5792-2020; Joubert, Christophe/AAU-4807-2020	dagain, arnaud/0000-0001-8416-1976			Abdel-Aziz H, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0814-z; Arthurs ZM, 2008, INJURY, V39, P1232, DOI 10.1016/j.injury.2008.02.042; Bauer D, 2008, J NEUROTRAUM, V25, P276; Bauer Derek, 2015, Semin Neurol, V35, pe14, DOI 10.1055/s-0035-1549095; Berne JD, 2001, J AM COLL SURGEONS, V192, P314, DOI 10.1016/S1072-7515(01)00772-4; Berne JD, 2010, J VASC SURG, V51, P57, DOI 10.1016/j.jvs.2009.08.071; Biffl WL, 1998, ANN SURG, V228, P462, DOI 10.1097/00000658-199810000-00003; Biffl WL, 2000, ANN SURG, V231, P672, DOI 10.1097/00000658-200005000-00007; Biffl WL, 1999, J TRAUMA, V47, P845, DOI 10.1097/00005373-199911000-00004; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS87; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS7; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Bratton SL, 2008, J NEUROTRAUM, V25, P276; Bratton SL, 2007, J NEUROTRAUMA S1, V24, P555, DOI DOI 10.1089/NEU.2007.9988; Bromberg WJ, 2010, J TRAUMA, V68, P471, DOI 10.1097/TA.0b013e3181cb43da; Burlew CC, 2011, SURG CLIN N AM, V91, P217, DOI 10.1016/j.suc.2010.10.004; Burlew CC, 2010, CURR OPIN CRIT CARE, V16, P587, DOI 10.1097/MCC.0b013e32833ee8b4; Callcut RA, 2012, J TRAUMA ACUTE CARE, V72, P338, DOI 10.1097/TA.0b013e318243d978; Cothren CC, 2009, ARCH SURG-CHICAGO, V144, P685, DOI 10.1001/archsurg.2009.111; Cothren CC, 2004, ARCH SURG-CHICAGO, V139, P540, DOI 10.1001/archsurg.139.5.540; Debette S, 2009, LANCET NEUROL, V8, P668, DOI 10.1016/S1474-4422(09)70084-5; DiCocco JM, 2011, ANN SURG, V253, P444, DOI 10.1097/SLA.0b013e31820d946b; Fabian TC, 1996, ANN SURG, V223, P513, DOI 10.1097/00000658-199605000-00007; Fleck SK, 2011, NEUROSURGERY, V69, P615, DOI 10.1227/NEU.0b013e31821a8701; Franz RW, 2012, J AM COLL SURGEONS, V214, P313, DOI 10.1016/j.jamcollsurg.2011.11.012; Fusco MR, 2011, NEUROSURGERY, V68, P517, DOI 10.1227/NEU.0b013e3181fe2fda; Jacobson LE, 2015, WORLD J EMERG SURG, V10, DOI 10.1186/s13017-015-0040-7; Markus HS, 2015, LANCET NEUROL, V14, P361, DOI 10.1016/S1474-4422(15)70018-9; Mayberry JC, 2004, ARCH SURG-CHICAGO, V139, P609, DOI 10.1001/archsurg.139.6.609; McKinney A, 2007, EUR J RADIOL, V62, P385, DOI 10.1016/j.ejrad.2007.01.008; Miller PR, 2002, ANN SURG, V236, P386, DOI 10.1097/00000658-200209000-00015; Mundinger GS, 2013, J ORAL MAXIL SURG, V71, P2092, DOI 10.1016/j.joms.2013.07.005; Paulus EM, 2014, J TRAUMA ACUTE CARE, V76, P279, DOI 10.1097/TA.0000000000000101; Sliker CW, 2008, RADIOGRAPHICS, V28, P1689, DOI 10.1148/rg.286085521; Stein DM, 2009, J TRAUMA, V66, P132, DOI 10.1097/TA.0b013e318142d146	35	34	36	0	7	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUL	2017	127	1					16	22		10.3171/2016.4.JNS152600			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	EY6JB	WOS:000404087500003	27471889				2021-06-18	
J	Howell, DR; Osternig, LR; Chou, LS				Howell, David R.; Osternig, Louis R.; Chou, Li-Shan			Single-task and dual-task tandem gait test performance after concussion	JOURNAL OF SCIENCE AND MEDICINE IN SPORT			English	Article						Tandem gait; Locomotion; Balance; Concussion; Mild traumatic brain injury; Dual-task	SPORT-RELATED CONCUSSION; ERROR SCORING SYSTEM; EXECUTIVE FUNCTION; POSTURAL CONTROL; BALANCE CONTROL; ADOLESCENTS; ATTENTION	Objectives: To compare single-task and dual-task tandem gait test performance between athletes after concussion with controls on observer-timed, spatio-temporal, and center-of-mass (COM) balance control measurements. Design: Ten participants (19.0 +/- 5.5 years) were prospectively identified and completed a tandem gait test protocol within 72 h of concussion and again 1 week, 2 weeks, 1 month, and 2 months post-injury. Seven uninjured controls (20.0 +/- 4.5 years) completed the same protocol in similar time increments. Methods: Tandem gait test trials were performed with (dual-task) and without (single-task) concurrently performing a cognitive test as whole-body motion analysis was performed. Outcome variables included test completion time, average tandem gait velocity, cadence, and whole-body COM frontal plane displacement. Results: Concussion participants took significantly longer to complete the dual-task tandem gait test than controls throughout the first 2 weeks post-injury (mean time = 16.4 [95% CI: 13.4-19.4] vs. 10.1 [95% CI: 6.4-13.7] seconds; p = 0.03). Single-task tandem gait times were significantly lower 72 h post-injury (p = 0.04). Dual-task cadence was significantly lower for concussion participants than controls (89.5 [95% CI: 68.6-110.4] vs. 127.0 [95% CI: 97.4-156.6] steps/minute; p = 0.04). Moderately-high to high correlations between tandem gait test time and whole-body COM medial-lateral displacement were detected at each time point during dual-task gait (r(s) = 0.70-0.93; p = 0.03-0.001). Conclusions: Adding a cognitive task during the tandem gait test resulted in longer detectable deficits post-concussion compared to the traditional single-task tandem gait test. As a clinical tool to assess dynamic motor function, tandem gait may assist with return to sport decisions after concussion. (C) 2017 Sports Medicine Australia. Published by Elsevier Ltd. All rights reserved.	[Howell, David R.] Micheli Ctr Sports Injury Prevent, Waltham, MA USA; [Howell, David R.] Boston Childrens Hosp, Dept Orthopaed, Div Sports Med, Boston, MA USA; [Howell, David R.] Boston Childrens Hosp, Brain Injury Ctr, Boston, MA USA; [Osternig, Louis R.; Chou, Li-Shan] Univ Oregon, Dept Human Physiol, Mot Anal Lab, Eugene, OR 97403 USA	Chou, LS (corresponding author), Univ Oregon, Dept Human Physiol, Mot Anal Lab, Eugene, OR 97403 USA.	chou@uoregon.edu		Chou, Li-Shan/0000-0002-2777-7034	Department of Defense-TATRC Award [W81XWH-11-1-0717]; Eugene and Clarissa Evonuk Memorial Graduate Fellowship in Environmental, Cardiovascular, or Stress Physiology	Funding for the data collection of this work was supported by the Department of Defense-TATRC Award (W81XWH-11-1-0717), and the Eugene and Clarissa Evonuk Memorial Graduate Fellowship in Environmental, Cardiovascular, or Stress Physiology. The authors would also like to acknowledge Mr. Quinn Peterson, Mr. Michael Kado, Ms. Madison Murray, and Ms. Rachel Klas for their assistance with data collection.	Bell DR, 2011, SPORTS HEALTH, V3, P287, DOI 10.1177/1941738111403122; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Broglio SP, 2009, J ATHL TRAINING, V44, P497, DOI 10.4085/1062-6050-44.5.497; Brown HJ, 2014, MED SCI SPORT EXER, V46, P1610, DOI 10.1249/MSS.0000000000000263; Davis GA, 2009, BRIT J SPORT MED, V43, pI36, DOI 10.1136/bjsm.2009.058123; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; Hahn ME, 2003, CLIN BIOMECH, V18, P737, DOI 10.1016/S0268-0033(03)00139-6; Hanninen T, 2016, J SCI MED SPORT, V19, P636, DOI 10.1016/j.jsams.2015.08.005; Howell D, 2013, MED SCI SPORT EXER, V45, P1030, DOI 10.1249/MSS.0b013e3182814595; Howell DR, 2015, MED SCI SPORT EXER, V47, P673, DOI 10.1249/MSS.0000000000000462; Howell DR, 2014, EXP BRAIN RES, V232, P1773, DOI 10.1007/s00221-014-3869-1; Howell DR, 2013, ARCH PHYS MED REHAB, V94, P1513, DOI 10.1016/j.apmr.2013.04.015; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; Register-Mihalik JK, 2013, NEUROPSYCHOL REV, V23, P300, DOI 10.1007/s11065-013-9238-1; Sambasivan K, 2015, J PEDIATR REHAB MED, V8, P335, DOI 10.3233/PRM-150351; Schneiders AG, 2010, J SCI MED SPORT, V13, P196, DOI 10.1016/j.jsams.2009.05.004; Shumway-Cook A, 2000, J GERONTOL A-BIOL, V55, pM10; Sosnoff JJ, 2008, EXP BRAIN RES, V187, P563, DOI 10.1007/s00221-008-1324-x; Winter D. A., 2009, BIOMECHANICS MOTOR C, P86, DOI 10.1002/9780470549148; WOLTRING HJ, 1986, ADV ENG SOFTW WORKST, V8, P104, DOI 10.1016/0141-1195(86)90098-7; Yogev-Seligmann G, 2008, MOVEMENT DISORD, V23, P329, DOI 10.1002/mds.21720; Zhu WM, 2012, J SPORT HEALTH SCI, V1, P9, DOI 10.1016/j.jshs.2012.02.002; Zimmer A, 2015, APPL NEUROPSYCH-ADUL, V22, P132, DOI 10.1080/23279095.2013.867265	23	34	34	0	14	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1440-2440	1878-1861		J SCI MED SPORT	J. Sci. Med. Sport	JUL	2017	20	7					622	626		10.1016/j.jsams.2016.11.020			5	Sport Sciences	Sport Sciences	FA2FI	WOS:000405255800003	28169147				2021-06-18	
J	Shilpa, BM; Bhagya, V; Harish, G; Bharath, MMS; Rao, BSS				Shilpa, B. M.; Bhagya, V; Harish, G.; Bharath, Srinivas M. M.; Rao, Shankaranarayana B. S.			Environmental enrichment ameliorates chronic immobilisation stress-induced spatial learning deficits and restores the expression of BDNF, VEGF, GFAP and glucocorticoid receptors	PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY			English	Article						Enriched environment; Chronic immobilisation stress; Hippocampus; Amygdalar complex; Depression; Neurotrophic factors; Glucocorticoid receptors; Structural plasticity	ENDOTHELIAL GROWTH-FACTOR; FIBRILLARY ACIDIC PROTEIN; HIPPOCAMPAL CELL-PROLIFERATION; NEUROTROPHIC FACTOR EXPRESSION; INDUCED COGNITIVE DEFICITS; ANTERIOR CINGULATE CORTEX; DEPRESSION-LIKE BEHAVIOR; TRAUMATIC BRAIN-INJURY; RAT MODEL; PREFRONTAL CORTEX	Severe and prolonged stress is the main environmental factor that precipitates depression, anxiety and cognitive dysfunctions. On the other hand, exposure to environmental enrichment (EE) has been shown to induce progressive plasticity in the brain and improve learning and memory in various neurological and psychiatric disorders. It is not known whether exposure to enriched environment could ameliorate chronic immobilisation stress-induced cognitive deficits and altered molecular markers. Hence, in the present study we aimed to evaluate the effect of enriched environment on chronic immobilisation stress (CIS) associated changes in spatial learning and memory, behavioural measures of anxiety, depression and molecular markers as well as structural alterations. Male Wistar rats were subjected to chronic immobilisation stress for 2 h/day/10 days followed by 2 weeks of exposure to EE. CIS resulted in weight loss, anhedonia, increased immobility, spatial learning and memory impairment, enhanced anxiety, and reduced expression of BDNF, VEGF, GFAP and glucocorticoid receptors (GR) in discrete brain regions. Interestingly, stressed rats exposed to enrichment ameliorated behavioural depression, spatial learning and memory impairment and reduced anxiety behaviour. In addition, EE restored BDNF, VEGF, GFAP and GR expression and normalized hypotrophy of dentate gyrus and hippocampus in CIS rats. In contrast, EE did not restore hypertrophy of the amygdalar complex. Thus, EE ameliorates stress-induced cognitive deficits by modulating the neurotrophic factors, astrocytes and glucocorticoid receptors in the hippocampus, frontal cortex and amygdala. (C) 2017 Elsevier Inc. All rights reserved.	[Shilpa, B. M.; Bhagya, V; Rao, Shankaranarayana B. S.] Natl Inst Mental Hlth & Neurosci, Dept Neurophysiol, Hosur Rd,PB 2900, Bengaluru 560029, India; [Harish, G.; Bharath, Srinivas M. M.] Natl Inst Mental Hlth & Neurosci, Dept Neurochem, Hosur Rd, Bengaluru 560029, India	Rao, BSS (corresponding author), Natl Inst Mental Hlth & Neurosci, Dept Neurophysiol, Hosur Rd,PB 2900, Bengaluru 560029, India.	bssrao.nimhans@gmail.com	Rao, Bhagya Venkanna/AAY-7370-2020	Rao, Bhagya Venkanna/0000-0003-0664-0335; Shankaranarayana Rao, BS/0000-0002-8323-8211			Alwis DS, 2014, FRONT SYST NEUROSCI, V8, DOI 10.3389/fnsys.2014.00156; Angelucci F, 2000, NEUROREPORT, V11, P1369, DOI 10.1097/00001756-200004270-00044; Anuradha H, 2008, J NEURAL TRANSM, V115, P35, DOI 10.1007/s00702-007-0821-6; Arango-Lievano M, 2015, P NATL ACAD SCI USA, V112, P15737, DOI 10.1073/pnas.1509045112; Baroncelli L, 2010, CELL DEATH DIFFER, V17, P1092, DOI 10.1038/cdd.2009.193; Baykara B, 2012, TURK NEUROSURG, V22, P604, DOI 10.5137/1019-5149.JTN.5633-11.1; Beauquis J, 2013, EXP NEUROL, V239, P28, DOI 10.1016/j.expneurol.2012.09.009; Beauquis J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013993; Benes FM, 2001, BIOL PSYCHIAT, V50, P395, DOI 10.1016/S0006-3223(01)01084-8; Bergstrom A, 2008, BRAIN RES, V1196, P41, DOI 10.1016/j.brainres.2007.12.025; Bhagya V, 2008, BEHAV BRAIN RES, V187, P190, DOI 10.1016/j.bbr.2007.08.020; Bhagya V, 2016, INDIAN J PHARMACOL, V48, P687, DOI 10.4103/0253-7613.194853; Bhagya V, 2015, J NEUROSCI RES, V93, P104, DOI 10.1002/jnr.23473; Bhagya V, 2011, PSYCHOPHARMACOLOGY, V214, P477, DOI 10.1007/s00213-010-2054-x; Bhagya VR, 2017, J NEUROSCI RES, V95, P1602, DOI 10.1002/jnr.23992; Bindu B, 2007, NEUROSCIENCE, V144, P412, DOI 10.1016/j.neuroscience.2006.09.057; Cao L, 2004, NAT GENET, V36, P827, DOI 10.1038/ng1395; Cao WY, 2014, BEHAV BRAIN RES, V265, P76, DOI 10.1016/j.bbr.2014.02.022; Chana G, 2003, BIOL PSYCHIAT, V53, P1086, DOI 10.1016/S0006-3223(03)00114-8; Chandana R, 2009, INDIAN J MED RES, V129, P189; Conrad CD, 1999, BEHAV NEUROSCI, V113, P902, DOI 10.1037/0735-7044.113.5.902; Cotter D, 2002, CEREB CORTEX, V12, P386, DOI 10.1093/cercor/12.4.386; Dhanushkodi A, 2008, NEUROSCI BIOBEHAV R, V32, P657, DOI 10.1016/j.neubiorev.2007.10.004; Dinan TG, 2005, EUR PSYCHIAT, V20, pS326, DOI 10.1016/S0924-9338(05)80184-1; Duman Ronald S, 2009, Dialogues Clin Neurosci, V11, P239; Duman RS, 2005, NEUROBIOL AGING, V26, pS88, DOI 10.1016/j.neurobiolaging.2005.08.018; Ehninger D, 2003, CEREB CORTEX, V13, P845, DOI 10.1093/cercor/13.8.845; Elfving B, 2010, NEUROSCI LETT, V474, P13, DOI 10.1016/j.neulet.2010.02.063; Fernandez-Teruel A, 2002, PHARMACOL BIOCHEM BE, V73, P233, DOI 10.1016/S0091-3057(02)00787-6; Fournier NM, 2012, BEHAV BRAIN RES, V227, P440, DOI 10.1016/j.bbr.2011.04.022; Frodl T, 2002, BIOL PSYCHIAT, V51, P708, DOI 10.1016/S0006-3223(01)01359-2; Frodl T, 2013, NEUROBIOL DIS, V52, P24, DOI 10.1016/j.nbd.2012.03.012; Givalois L, 2004, MOL CELL NEUROSCI, V27, P280, DOI 10.1016/j.mcn.2004.07.002; Gormanns P, 2011, J PSYCHIATR RES, V45, P973, DOI 10.1016/j.jpsychires.2010.12.010; Gosselin RD, 2009, NEUROSCIENCE, V159, P915, DOI 10.1016/j.neuroscience.2008.10.018; Govindarajan A, 2006, P NATL ACAD SCI USA, V103, P13208, DOI 10.1073/pnas.0605180103; Grassi-Oliveira R, 2008, BIOL PSYCHIAT, V64, P281, DOI 10.1016/j.biopsych.2008.02.023; Harish G, 2011, BIOPRESERV BIOBANK, V9, P379, DOI 10.1089/bio.2011.0033; Hegde P, 2008, NEUROSCIENCE, V153, P20, DOI 10.1016/j.neuroscience.2008.01.042; Heine VM, 2005, EUR J NEUROSCI, V21, P1304, DOI 10.1111/j.1460-9568.2005.03951.x; Hendriksen H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011943; Huang YF, 2012, J BIOL CHEM, V287, P40938, DOI 10.1074/jbc.M112.392076; Jaeger J, 2006, PSYCHIAT RES, V145, P39, DOI 10.1016/j.psychres.2005.11.011; Jha S, 2011, TRANSL PSYCHIAT, V1, DOI 10.1038/tp.2011.33; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Karege F, 2005, BIOL PSYCHIAT, V57, P1068, DOI 10.1016/j.biopsych.2005.01.008; Karege F, 2002, PSYCHIAT RES, V109, P143, DOI 10.1016/S0165-1781(02)00005-7; Karl A, 2006, NEUROSCI BIOBEHAV R, V30, P1004, DOI 10.1016/j.neubiorev.2006.03.004; Kendler KS, 1999, AM J PSYCHIAT, V156, P837, DOI 10.1176/ajp.156.6.837; Kim KS, 2006, J NEUROSCI RES, V83, P497, DOI 10.1002/jnr.20754; Kiuchi T, 2012, NEUROSCIENCE, V207, P208, DOI 10.1016/j.neuroscience.2012.01.023; Koehl M, 2002, NEUROTOX RES, V4, P281, DOI 10.1080/1029842021000010866; Kovesdi E, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00042; Lakshminarasimhan H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030481; Lambert WM, 2013, MOL CELL BIOL, V33, P3700, DOI 10.1128/MCB.00150-13; Li H, 2013, COMMUNITY MENT HLT J, V49, P419, DOI 10.1007/s10597-012-9567-1; Mahati K, 2016, NEUROBIOL LEARN MEM, V134, P379, DOI 10.1016/j.nlm.2016.08.017; Malik R, 2012, J NEUROPHYSIOL, V107, P1366, DOI 10.1152/jn.01009.2011; McCloskey DP, 2005, J NEUROSCI, V25, P8889, DOI 10.1523/JNEUROSCI.2577-05.2005; Miguel-Hidalgo JJ, 2000, BIOL PSYCHIAT, V48, P861, DOI 10.1016/S0006-3223(00)00999-9; Minelli A, 2011, PROG NEURO-PSYCHOPH, V35, P1322, DOI 10.1016/j.pnpbp.2011.04.013; Mitra R, 2005, P NATL ACAD SCI USA, V102, P9371, DOI 10.1073/pnas.0504011102; Mitra R, 2006, PHYSIOL BEHAV, V89, P123, DOI 10.1016/j.physbeh.2006.05.047; Morley-Fletcher S, 2003, EUR J NEUROSCI, V18, P3367, DOI 10.1111/j.1460-9568.2003.03070.x; Naert G, 2011, MOL CELL NEUROSCI, V46, P55, DOI 10.1016/j.mcn.2010.08.006; Naismith SL, 2007, BMC PSYCHIATRY, V7, DOI 10.1186/1471-244X-7-32; Novkovic T, 2015, HIPPOCAMPUS, V25, P1, DOI 10.1002/hipo.22342; Nowacka MM, 2012, NEUROPEPTIDES, V46, P1, DOI 10.1016/j.npep.2011.05.005; Nowakowska E, 2014, PHARMACOL REP, V66, P404, DOI 10.1016/j.pharep.2013.12.008; Pang TYC, 2013, NEUROPHARMACOLOGY, V64, P515, DOI 10.1016/j.neuropharm.2012.06.029; PAPP M, 1991, PSYCHOPHARMACOLOGY, V104, P255, DOI 10.1007/BF02244188; Park HJ, 2015, ARCH PHARM RES, V38, P1204, DOI 10.1007/s12272-015-0548-0; Paxinos G., 2005, RAT BRAIN STEREOTAXI; Pizarro JM, 2004, BRAIN RES, V1025, P10, DOI 10.1016/j.brainres.2004.06.085; PORSOLT RD, 1978, EUR J PHARMACOL, V47, P379, DOI 10.1016/0014-2999(78)90118-8; Radecki DT, 2005, HIPPOCAMPUS, V15, P246, DOI 10.1002/hipo.20048; Ramkumar K, 2008, NEUROCHEM RES, V33, P1651, DOI 10.1007/s11064-007-9511-x; Ravenelle R, 2014, NEUROSCIENCE, V270, P76, DOI 10.1016/j.neuroscience.2014.03.060; Reichardt HM, 2000, MOL CELL BIOL, V20, P9009, DOI 10.1128/MCB.20.23.9009-9017.2000; Richter SH, 2013, BEHAV BRAIN RES, V252, P287, DOI 10.1016/j.bbr.2013.06.021; Roceri M, 2002, MOL PSYCHIATR, V7, P609, DOI 10.1038/sj.mp.4001036; Roohafza HR, 2014, J RES MED SCI, V19, P944; Rubinow MJ, 2009, J COMP NEUROL, V512, P717, DOI 10.1002/cne.21924; Salmaso N, 2012, J NEUROSCI, V32, P8930, DOI 10.1523/JNEUROSCI.1398-12.2012; Sampedro-Piquero P, 2014, NEUROBIOL LEARN MEM, V114, P16, DOI 10.1016/j.nlm.2014.04.002; SAPOLSKY RM, 1984, ENDOCRINOLOGY, V114, P287, DOI 10.1210/endo-114-1-287; Schmidt HD, 2007, BEHAV PHARMACOL, V18, P391, DOI 10.1097/FBP.0b013e3282ee2aa8; Sheline YI, 2000, BIOL PSYCHIAT, V48, P791, DOI 10.1016/S0006-3223(00)00994-X; Sheline YI, 1996, P NATL ACAD SCI USA, V93, P3908, DOI 10.1073/pnas.93.9.3908; Sloan SA, 2014, CURR OPIN NEUROBIOL, V27, P75, DOI 10.1016/j.conb.2014.03.005; Srikumar BN, 2007, PSYCHOPHARMACOLOGY, V193, P363, DOI 10.1007/s00213-007-0801-4; Stockmeier Craig A, 2004, Dialogues Clin Neurosci, V6, P185; Storkebaum E, 2004, BIOESSAYS, V26, P943, DOI 10.1002/bies.20092; Sun FY, 2005, J NEUROSCI RES, V79, P180, DOI 10.1002/jnr.20321; Suvrathan A, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0151; Taliaz D, 2010, MOL PSYCHIATR, V15, P80, DOI 10.1038/mp.2009.67; Tapia-Arancibia L, 2004, FRONT NEUROENDOCRIN, V25, P77, DOI 10.1016/j.yfrne.2004.04.001; Uysal N, 2012, NEUROSCI LETT, V514, P141, DOI 10.1016/j.neulet.2012.02.049; van Praag H, 1999, P NATL ACAD SCI USA, V96, P13427, DOI 10.1073/pnas.96.23.13427; van Praag H, 1999, NAT NEUROSCI, V2, P266; Veena J, 2009, NEUROSCI LETT, V455, P178, DOI 10.1016/j.neulet.2009.03.059; Veena J, 2009, J NEUROSCI RES, V87, P831, DOI 10.1002/jnr.21907; von Gunten A, 2000, J NEUROPSYCH CLIN N, V12, P493, DOI 10.1176/appi.neuropsych.12.4.493; Vyas A, 2004, BEHAV NEUROSCI, V118, P1450, DOI 10.1037/0735-7044.118.6.1450; Vyas A, 2004, NEUROSCIENCE, V128, P667, DOI 10.1016/j.neuroscience.2004.07.013; Vyas A, 2002, J NEUROSCI, V22, P6810; Warner-Schmidt JL, 2007, P NATL ACAD SCI USA, V104, P4647, DOI 10.1073/pnas.0610282104; Wislowska-Stanek A, 2013, NEUROSCI LETT, V533, P17, DOI 10.1016/j.neulet.2012.11.012; Xu ZW, 2009, EUR NEUROPSYCHOPHARM, V19, P868, DOI 10.1016/j.euroneuro.2009.07.004; Yehuda R., 2012, DEPRESS RES TREAT, V2012; Yulug B, 2009, J NEUROPSYCH CLIN N, V21, P471, DOI 10.1176/appi.neuropsych.21.4.471; Zanca RM, 2015, FRONT BEHAV NEUROSCI, V9, DOI 10.3389/fnbeh.2015.00303; Zhang L, 2013, PHARMACOL BIOCHEM BE, V103, P693, DOI 10.1016/j.pbb.2012.12.023; Zhang L, 2011, CURR NEUROVASC RES, V8, P286, DOI 10.2174/156720211798121025	114	34	38	0	12	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0278-5846	1878-4216		PROG NEURO-PSYCHOPH	Prog. Neuro-Psychopharmacol. Biol. Psychiatry	JUN 2	2017	76						88	100		10.1016/j.pnpbp.2017.02.025			13	Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	EY9LR	WOS:000404320600011	28288856				2021-06-18	
J	Orendorff, R; Peck, AJ; Zheng, B; Shirazi, SN; Ferguson, RM; Khandhar, AP; Kemp, SJ; Goodwill, P; Krishnan, KM; Brooks, GA; Kaufer, D; Conolly, S				Orendorff, Ryan; Peck, Austin J.; Zheng, Bo; Shirazi, Shawn N.; Ferguson, R. Matthew; Khandhar, Amit P.; Kemp, Scott J.; Goodwill, Patrick; Krishnan, Kannan M.; Brooks, George A.; Kaufer, Daniela; Conolly, Steven			First in vivo traumatic brain injury imaging via magnetic particle imaging	PHYSICS IN MEDICINE AND BIOLOGY			English	Article						traumatic brain injury; magnetic particle imaging; iron nanoparticles; tracer imaging	INTERSTITIAL FLUID; CLEARANCE; BIODISTRIBUTION; NANOPARTICLES; SYSTEM; IMPACT; MRI	Emergency room visits due to traumatic brain injury (TBI) is common, but classifying the severity of the injury remains an open challenge. Some subjective methods such as the Glasgow Coma Scale attempt to classify traumatic brain injuries, as well as some imaging based modalities such as computed tomography and magnetic resonance imaging. However, to date it is still difficult to detect and monitor mild to moderate injuries. In this report, we demonstrate that the magnetic particle imaging (MPI) modality can be applied to imaging TBI events with excellent contrast. MPI can monitor injected iron nanoparticles over long time scales without signal loss, allowing researchers and clinicians to monitor the change in blood pools as the wound heals.	[Orendorff, Ryan; Zheng, Bo; Conolly, Steven] Univ Calif Berkeley, Dept Bioengn, Berkeley, CA 94720 USA; [Peck, Austin J.; Shirazi, Shawn N.; Brooks, George A.; Kaufer, Daniela] Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA; [Ferguson, R. Matthew; Khandhar, Amit P.; Kemp, Scott J.; Krishnan, Kannan M.] LodeSpin Labs LLC, Seattle, WA USA; [Goodwill, Patrick] Magnet Insight Inc, Alameda, CA USA; [Krishnan, Kannan M.] Univ Washington, Dept Mat Sci & Engn, Seattle, WA 98195 USA; [Conolly, Steven] Univ Calif Berkeley, Dept Elect Engn & Comp Sci, Berkeley, CA 94720 USA	Conolly, S (corresponding author), Univ Calif Berkeley, Dept Bioengn, Berkeley, CA 94720 USA.; Conolly, S (corresponding author), Univ Calif Berkeley, Dept Elect Engn & Comp Sci, Berkeley, CA 94720 USA.	sconolly@berkeley.edu		Goodwill, Patrick/0000-0003-4240-1956; Khandhar, Amit/0000-0003-4049-1855	Keck FoundationW.M. Keck Foundation [009323]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R01EB019458, 1R24MH106053, 2R42EB013520-02A1]; UC DiscoveryUniversity of California System; NSF GRFPNational Science Foundation (NSF)NSF - Office of the Director (OD); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R42EB013520, R01EB019458] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R24MH106053] Funding Source: NIH RePORTER	We are grateful for funding support from the Keck Foundation Grant 009323, NIH 1R01EB019458, NIH 1R24MH106053, and a UC Discovery Grant. LodeSpin Labs is also grateful for NIH 2R42EB013520-02A1. Ryan Orendorff would like to thank the NSF GRFP for funding support.	Albert-Weissenberger Christiane, 2010, Exp Transl Stroke Med, V2, P16, DOI 10.1186/2040-7378-2-16; Aspelund A, 2015, J EXP MED, V212, P991, DOI 10.1084/jem.20142290; BRADBURY MWB, 1981, AM J PHYSIOL, V240, pF329; Ferguson RM, 2015, IEEE T MED IMAGING, V34, P1077, DOI 10.1109/TMI.2014.2375065; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Gleich B, 2005, NATURE, V435, P1214, DOI 10.1038/nature03808; Goodwill PW, 2011, IEEE T MED IMAGING, V30, P1581, DOI 10.1109/TMI.2011.2125982; Goodwill PW, 2010, IEEE T MED IMAGING, V29, P1851, DOI 10.1109/TMI.2010.2052284; Jain TK, 2008, MOL PHARMACEUT, V5, P316, DOI 10.1021/mp7001285; Kemp SJ, 2016, RSC ADV, V6, P77452, DOI 10.1039/c6ra12072e; Keselman P, 2016, WORLD MOL IM C; Konkle JJ, 2013, BIOMED ENG-BIOMED TE, V58, P565, DOI 10.1515/bmt-2012-0062; Konkle JJ, 2013, IEEE T MED IMAGING, V32, P338, DOI 10.1109/TMI.2012.2227121; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lee Bruce, 2005, NeuroRx, V2, P372; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; Longmire M, 2008, NANOMEDICINE-UK, V3, P703, DOI 10.2217/17435889.3.5.703; Louveau A, 2015, NATURE, V523, P337, DOI 10.1038/nature14432; Lu K, 2013, IEEE T MED IMAGING, V32, P1565, DOI 10.1109/TMI.2013.2257177; Lu M, 2010, AM J HEMATOL, V85, P315, DOI 10.1002/ajh.21656; Mathieu E, 2013, FLUIDS BARRIERS CNS, V10, DOI 10.1186/2045-8118-10-35; Reimer P, 2003, EUR RADIOL, V13, P1266, DOI 10.1007/s00330-002-1721-7; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Saritas EU, 2013, J MAGN RESON, V229, P116, DOI 10.1016/j.jmr.2012.11.029; Stacul F, 2011, EUR RADIOL, V21, P2527, DOI 10.1007/s00330-011-2225-0; TEASDALE G, 1974, LANCET, V2, P81; Yu E., 2016, WORLD MOL IM C; Zheng B, 2016, THERANOSTICS, V6, P291, DOI 10.7150/thno.13728; Zheng B, 2015, SCI REP-UK, V5, DOI 10.1038/srep14055	31	34	36	0	15	IOP PUBLISHING LTD	BRISTOL	TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND	0031-9155	1361-6560		PHYS MED BIOL	Phys. Med. Biol.	MAY 7	2017	62	9					3501	3509		10.1088/1361-6560/aa52ad			9	Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging	Engineering; Radiology, Nuclear Medicine & Medical Imaging	ES0JL	WOS:000399212500007	28378708	Green Accepted			2021-06-18	
J	Stacey, A; Lucas, S; Dikmen, S; Temkin, N; Bell, KR; Brown, A; Brunner, R; Diaz-Arrastia, R; Watanabe, TK; Weintraub, A; Hoffman, JM				Stacey, Arthur; Lucas, Sylvia; Dikmen, Sureyya; Temkin, Nancy; Bell, Kathleen R.; Brown, Allen; Brunner, Robert; Diaz-Arrastia, Ramon; Watanabe, Thomas K.; Weintraub, Alan; Hoffman, Jeanne M.			Natural History of Headache Five Years after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						headache; post-traumatic headache; secondary headache; TBI	CHRONIC POSTTRAUMATIC HEADACHE; MILITARY PERSONNEL; CHRONIC PAIN; PREVALENCE; IMPACT; VETERANS; PERSIST; SLEEP; RATES; IRAQ	Headache is one of the most frequently reported symptoms following traumatic brain injury (TBI). Little is known about how these headaches change over time. We describe the natural history of headache in individuals with moderate to severe TBI over 5 years after injury. A total of 316 patients were prospectively enrolled and followed at 3, 6, 12, and 60 months after injury. Individuals were 72% male, 73% white, and 55% injured in motor vehicle crashes, with an average age of 42. Pre-injury headache was reported in 17% of individuals. New or worse headache prevalence remained consistent with at least 33% at all time points. Incidence was > 17% at all time points with first report of new or worse headache in 20% of participants at 60 months. Disability related to headache was high, with average headache pain (on 0-10 scale) ranging from 5.5 at baseline to 5.7 at 60 months post-injury, and reports of substantial impact on daily life across all time points. More than half of classifiable headaches matched the profile of migraine or probable migraine. Headache is a substantial problem after TBI. Results suggest that ongoing assessment and treatment of headache after TBI is needed, as this symptom may be a problem up to 5 years post-injury.	[Stacey, Arthur; Lucas, Sylvia; Dikmen, Sureyya; Temkin, Nancy; Hoffman, Jeanne M.] Univ Washington, Med Ctr, Dept Rehabil Med, Seattle, WA 98195 USA; [Lucas, Sylvia] Univ Washington, Dept Neurol, Seattle, WA 98195 USA; [Lucas, Sylvia; Dikmen, Sureyya; Temkin, Nancy] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Dikmen, Sureyya] Univ Washington, Dept Psychiat & Behav Med, Seattle, WA 98195 USA; [Temkin, Nancy] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Bell, Kathleen R.] UT Southwestern, Dept Phys Med & Rehabil, Dallas, TX USA; [Brown, Allen] Mayo Clin, Dept Phys Med & Rehabil, Rochester, MN USA; [Brunner, Robert] Univ Alabama Birmingham, UAB Spain Rehabil Ctr, Dept Phys Med & Rehabil, Birmingham, AL USA; [Diaz-Arrastia, Ramon] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Watanabe, Thomas K.] Einstein Med Ctr, MossRehab Elkins Pk, Elkins Pk, PA USA; [Weintraub, Alan] Craig Hosp, CNS Med Grp, Englewood, CO USA	Hoffman, JM (corresponding author), Univ Washington, Dept Rehabil Med, Box 356490, Seattle, WA 98195 USA.	jeanneh@uw.edu		Bell, Kathleen/0000-0002-0928-2046; Diaz-Arrastia, Ramon/0000-0001-6051-3594	National Institute on Disability, Independent Living, and Rehabilitation ResearchUnited States Department of Health & Human Services	Arthur Stacey has nothing to disclose. Sylvia Lucas has received a grant from the National Institute of Disability, Independent Living, and Rehabilitation Research during the conduct of the study; grants from Amgen and Allergan; and consultation fee from Lilly, outside the submitted work. Sureyya Dikmen received a grant from the National Institute on Disability, Independent Living, and Rehabilitation Research during the conduct of the study. Nancy Temkin received a grant from the National Institute on Disability, Independent Living, and Rehabilitation Research during the conduct of the study; and personal fees from Novartis, Celgene, Sage, TauRx, and other drug companies for participation on DSMBs outside the submitted work. Kathleen R. Bell received a grant from the National Institute on Disability, Independent Living, and Rehabilitation Research during the conduct of the study. Allen Brown received a grant from the National Institute on Disability, Independent Living, and Rehabilitation Research during the conduct of the study. Robert Brunner received a grant from the National Institute on Disability, Independent Living, and Rehabilitation Research during the conduct of the study. Ramon Diaz-Arrastia has nothing to disclose. Thomas K. Watanabe received a grant from National Institute on Disability, Independent Living, and Rehabilitation Research during the conduct of the study. Alan Weintraub received a grant from the National Institute on Disability, Independent Living, and Rehabilitation Research during the conduct of the study. Jeanne M. Hoffman received a grant from the National Institute on Disability, Independent Living, and Rehabilitation Research during the conduct of the study.	Baandrup L, 2005, CEPHALALGIA, V25, P132, DOI 10.1111/j.1468-2982.2004.00818.x; Bekkelund SI, 2003, HEADACHE, V43, P59, DOI 10.1046/j.1526-4610.2003.03010.x; Bettucci D, 1998, ITAL J NEUROL SCI, V19, P20, DOI 10.1007/BF03028807; Brown AW, 2015, PM&R, V7, P3, DOI 10.1016/j.pmrj.2014.06.016; Couch JR, 2016, HEADACHE, V56, P1004, DOI 10.1111/head.12837; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; Finkel AG, 2012, HEADACHE, V52, P957, DOI 10.1111/j.1526-4610.2012.02167.x; Fogelberg DJ, 2012, ARCH PHYS MED REHAB, V93, P1313, DOI 10.1016/j.apmr.2012.04.031; Haas DC, 1996, CEPHALALGIA, V16, P486, DOI 10.1046/j.1468-2982.1996.1607486.x; Hay JR, 2015, J NEUROPATH EXP NEUR, V74, P1147, DOI [10.1093/jnen/74.12.1147, 10.1097/NEN.0000000000000261]; JENSEN OK, 1990, CEPHALALGIA, V10, P285, DOI 10.1046/j.1468-2982.1990.1006285.x; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kenney K, 2016, EXP NEUROL, V275, P353, DOI 10.1016/j.expneurol.2015.05.019; Kosinski M, 2003, QUAL LIFE RES, V12, P963, DOI 10.1023/A:1026119331193; Lerman B, 2011, J NEUROTRAUM, V28, pA16; Lew HL, 2006, AM J PHYS MED REHAB, V85, P619, DOI 10.1097/01.phm.0000223235.09931.c0; Loane DJ, 2016, EXP NEUROL, V275, P316, DOI 10.1016/j.expneurol.2015.08.018; Lucas S, 2012, CEPHALALGIA, V32, P600, DOI 10.1177/0333102412445224; Nakase-Richardson R, 2013, ARCH PHYS MED REHAB, V94, P875, DOI 10.1016/j.apmr.2013.01.001; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Packard Russell C, 2005, Curr Pain Headache Rep, V9, P59, DOI 10.1007/s11916-005-0076-6; Ponsford JL, 2014, J NEUROTRAUM, V31, P64, DOI 10.1089/neu.2013.2997; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; Smitherman TA, 2013, HEADACHE, V53, P427, DOI 10.1111/head.12074; Theeler B, 2013, HEADACHE, V53, P881, DOI 10.1111/head.12123; Theeler BJ, 2012, CURR TREAT OPTION NE, V14, P36, DOI 10.1007/s11940-011-0157-2; Torelli P, 2004, CEPHALALGIA, V24, P29, DOI 10.1111/j.1468-2982.2004.00633.x; UOMOTO JM, 1993, ARCH PHYS MED REHAB, V74, P61; Walker WC, 2005, ARCH PHYS MED REHAB, V86, P1793, DOI 10.1016/j.apmr.2004.12.042	29	34	34	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2017	34	8					1558	1564		10.1089/neu.2016.4721			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	ES1ZM	WOS:000399325500007	27927072				2021-06-18	
J	Amorini, AM; Lazzarino, G; Di Pietro, V; Signoretti, S; Lazzarino, G; Belli, A; Tavazzi, B				Amorini, Angela Maria; Lazzarino, Giacomo; Di Pietro, Valentina; Signoretti, Stefano; Lazzarino, Giuseppe; Belli, Antonio; Tavazzi, Barbara			Severity of experimental traumatic brain injury modulates changes in concentrations of cerebral free amino acids	JOURNAL OF CELLULAR AND MOLECULAR MEDICINE			English	Article						cerebral free amino acids; excitotoxicity; high performance liquid chromatography; methyl-cycle; N-acetylaspartate; mild traumatic brain injury; severe traumatic brain injury	N-ACETYLASPARTATE; CEREBROSPINAL-FLUID; RAT-BRAIN; MASS-SPECTROMETRY; METABOLIC-CHANGES; CANAVANS-DISEASE; TEMPORAL WINDOW; INBORN-ERRORS; FATTY-ACIDS; MOUSE MODEL	In this study, concentrations of free amino acids (FAA) and amino group containing compounds (AGCC) following graded diffuse traumatic brain injury (mild TBI, mTBI; severe TBI, sTBI) were evaluated. After 6, 12, 24, 48 and 120 hr aspartate (Asp), glutamate (Glu), asparagine (Asn), serine (Ser), glutamine (Gln), histidine (His), glycine (Gly), threonine (Thr), citrulline (Cit), arginine (Arg), alanine (Ala), taurine (Tau), caminobutyrate (GABA), tyrosine (Tyr), S-adenosylhomocysteine (SAH), L-cystathionine (L-Cystat), valine (Val), methionine (Met), tryptophane (Trp), phenylalanine (Phe), isoleucine (Ile), leucine (Leu), ornithine (Orn), lysine (Lys), plus N-acetylaspartate (NAA) were determined in whole brain extracts (n = 6 rats at each time for both TBI levels). Sham-operated animals (n = 6) were used as controls. Results demonstrated that mTBI caused modest, transient changes in NAA, Asp, GABA, Gly, Arg. Following sTBI, animals showed profound, long-lasting modifications of Glu, Gln, NAA, Asp, GABA, Ser, Gly, Ala, Arg, Citr, Tau, Met, SAH, L-Cystat, Tyr and Phe. Increase in Glu and Gln, depletion of NAA and Asp increase, suggested a link between NAA hydrolysis and excitotoxicity after sTBI. Additionally, sTBI rats showed net imbalances of the Glu-Gln/GABA cycle between neurons and astrocytes, and of the methyl-cycle (demonstrated by decrease in Met, and increase in SAH and L-Cystat), throughout the post-injury period. Besides evidencing new potential targets for novel pharmacological treatments, these results suggest that the force acting on the brain tissue at the time of the impact is the main determinant of the reactions ignited and involving amino acid metabolism.	[Amorini, Angela Maria; Lazzarino, Giacomo; Tavazzi, Barbara] Univ Cattolica Sacro Cuore, Inst Biochem & Clin Biochem, Rome, Italy; [Di Pietro, Valentina; Belli, Antonio] Univ Birmingham, Coll Med & Dent Sci, Sch Clin & Expt Med, Neurosci & Ophthalmol Grp, Birmingham, W Midlands, England; [Signoretti, Stefano] San Camillo Hosp, Dept Neurosci Head & Neck Surg, Div Neurosurg, Rome, Italy; [Lazzarino, Giuseppe] Univ Catania, Dept Biomed & Biotechnol Sci, Div Med Biochem, Catania, Italy; [Belli, Antonio] Queen Elizabeth Hosp, Natl Inst Hlth Res Surg Reconstruct, Birmingham B15 2TH, W Midlands, England; [Belli, Antonio] Queen Elizabeth Hosp, Microbiol Res Ctr, Birmingham B15 2TH, W Midlands, England	Lazzarino, G (corresponding author), Univ Catania, Dept Biomed & Biotechnol Sci, Div Med Biochem, Catania, Italy.	lazzarig@unict.it	Belli, Antonio/I-3799-2015; Signoretti, stefano/AAL-5631-2020; TAVAZZI, BARBARA/AAB-9830-2019; lazzarino, giuseppe/K-2277-2015	Belli, Antonio/0000-0002-3211-9933; Signoretti, stefano/0000-0002-8086-1622; TAVAZZI, BARBARA/0000-0001-8743-0895; Lazzarino, Giacomo/0000-0003-1639-0966; AMORINI, Angela Maria/0000-0003-3525-9955; lazzarino, giuseppe/0000-0002-5917-7279	Catholic University of Rome the University of Catania; University of Birmingham	This work has been funded in part by research funds of the Catholic University of Rome (BT) the University of Catania (Giuseppe L) and the University of Birmingham (AB).	Amorini AM, 2012, MOL CELL BIOCHEM, V359, P205, DOI 10.1007/s11010-011-1015-y; Amorini AM, 2016, BBA-MOL BASIS DIS, V1862, P679, DOI 10.1016/j.bbadis.2016.01.023; Balan IS, 2013, J NEUROTRAUM, V30, P367, DOI 10.1089/neu.2012.2339; Bame M, 2014, BBA-MOL BASIS DIS, V1842, P79, DOI 10.1016/j.bbadis.2013.10.004; Bartnik-Olson BL, 2010, J NEUROTRAUM, V27, P2191, DOI 10.1089/neu.2010.1508; Baslow MH, 2013, BIOCHIMIE, V95, P946, DOI 10.1016/j.biochi.2012.10.023; Baslow MH, 2002, NEUROCHEM INT, V40, P295, DOI 10.1016/S0197-0186(01)00095-X; Baslow MH, 2010, AMINO ACIDS, V39, P1139, DOI 10.1007/s00726-010-0656-6; BAZAN NG, 1971, J NEUROCHEM, V18, P1379, DOI 10.1111/j.1471-4159.1971.tb00002.x; Bouzat P, 2014, INTENS CARE MED, V40, P412, DOI 10.1007/s00134-013-3203-6; Cai XJ, 2015, MOL MED REP, V11, P1715, DOI 10.3892/mmr.2014.2947; Cao Y, 2016, BMC NEUROSCI, V17, DOI 10.1186/s12868-016-0251-1; Chamoun R, 2010, J NEUROSURG, V113, P564, DOI 10.3171/2009.12.JNS09689; Chan CY, 2013, ADV EXP MED BIOL, V775, P45, DOI 10.1007/978-1-4614-6130-2_4; Chen X, 2014, J NEUROL SCI, V342, P93, DOI 10.1016/j.jns.2014.04.032; Choe KY, 2012, J NEUROSCI, V32, P12518, DOI 10.1523/JNEUROSCI.1380-12.2012; Clark JF, 2006, MED HYPOTHESES, V67, P506, DOI 10.1016/j.mehy.2006.02.047; Cooper AJL, 2016, BIOMOLECULES, V6, DOI 10.3390/biom6020016; Dash PK, 2016, FRONT SYST NEUROSCI, V10, DOI 10.3389/fnsys.2016.00036; De Simone R, 2013, BBA-MOL BASIS DIS, V1832, P650, DOI 10.1016/j.bbadis.2013.02.001; Di Pietro V, 2014, MOL MED, V20, P147, DOI 10.2119/molmed.2013.00153; Di Pietro V, 2014, FREE RADICAL BIO MED, V69, P258, DOI 10.1016/j.freeradbiomed.2014.01.032; Di Pietro V, 2010, J NEUROTRAUM, V27, P349, DOI 10.1089/neu.2009.1095; ERECINSKA M, 1984, BRAIN RES, V304, P9, DOI 10.1016/0006-8993(84)90857-6; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Gu F, 2015, CURR OPIN CLIN NUTR, V18, P89, DOI 10.1097/MCO.0000000000000134; Guerriero RM, 2015, CURR NEUROL NEUROSCI, V15, DOI 10.1007/s11910-015-0545-1; Gundersen V, 2015, PHYSIOL REV, V95, P695, DOI 10.1152/physrev.00024.2014; Hill CS, 2016, TRENDS NEUROSCI, V39, P311, DOI 10.1016/j.tins.2016.03.002; Hui H, 2016, NEUROCHEM INT, V94, P23, DOI 10.1016/j.neuint.2016.02.002; Kinoshita K, 2016, J INTENSIVE CARE, V4, DOI 10.1186/s40560-016-0138-3; Larner SF, 2006, J NEUROTRAUM, V23, P807, DOI 10.1089/neu.2006.23.807; Lazzarino G, 2003, ANAL BIOCHEM, V322, P51, DOI 10.1016/j.ab.2003.07.013; LAZZARINO G, 1989, ANAL BIOCHEM, V181, P239, DOI 10.1016/0003-2697(89)90236-4; Madhavarao CN, 2005, P NATL ACAD SCI USA, V102, P5221, DOI 10.1073/pnas.0409184102; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Meunier CNJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151233; Oenarto J, 2014, ARCH BIOCHEM BIOPHYS, V560, P59, DOI 10.1016/j.abb.2014.06.024; Olsen GM, 2015, NEUROCHEM INT, V88, P47, DOI 10.1016/j.neuint.2014.11.006; Omalu B, 2014, PROG NEUROL SURG, V28, P38, DOI 10.1159/000358761; Panzaa F, 2009, J ALZHEIMERS DIS, V16, P467, DOI 10.3233/JAD-2009-1012; Pascual JM, 2007, J NEUROTRAUM, V24, P944, DOI 10.1089/neu.2006.0190; Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X; Perez-Neri I, 2007, J CHROMATOGR B, V851, P250, DOI 10.1016/j.jchromb.2006.10.047; Pu BF, 2015, MOL MED REP, V12, P3704, DOI 10.3892/mmr.2015.3830; Purins K, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00064; Quintard H, 2015, NEUROCRIT CARE, V22, P243, DOI 10.1007/s12028-014-0062-0; Rae C, 2012, NEUROCHEM RES, V37, P2541, DOI 10.1007/s11064-012-0847-5; Reinert M, 2000, ACTA NEUROCHIR SUPPL, V76, P439; Schneider BL, 2016, J NEUROTRAUM, V33, P1614, DOI 10.1089/neu.2015.4190; Seki Y, 2005, NEUROCHEM RES, V30, P123, DOI 10.1007/s11064-004-9693-4; Sekine A, 2015, SPRINGERPLUS, V4, DOI 10.1186/s40064-015-0826-9; Shin SS, 2015, J NEUROTRAUM, V32, P1429, DOI 10.1089/neu.2014.3445; Shnitko TA, 2016, PSYCHOPHARMACOLOGY, V233, P2045, DOI 10.1007/s00213-016-4259-0; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Signoretti S, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10183; SINGH AK, 1988, J CHROMATOGR-BIOMED, V425, P245, DOI 10.1016/0378-4347(88)80029-X; Singhal NK, 2015, J NEUROSCI, V35, P15170, DOI 10.1523/JNEUROSCI.4349-14.2015; Song Y, 2008, NEUROSCI LETT, V445, P53, DOI 10.1016/j.neulet.2008.08.058; Stover JF, 2000, BRAIN RES, V875, P51, DOI 10.1016/S0006-8993(00)02597-X; Stover JF, 1999, J NEUROTRAUM, V16, P135, DOI 10.1089/neu.1999.16.135; Suchy J, 2010, NEUROMOL MED, V12, P86, DOI 10.1007/s12017-009-8089-7; Surendran S, 2003, J CHILD NEUROL, V18, P611, DOI 10.1177/08830738030180090701; Surendran S, 2003, BRAIN RES BULL, V61, P427, DOI 10.1016/S0361-9230(03)00158-8; Tavazzi B, 2005, CLIN BIOCHEM, V38, P997, DOI 10.1016/j.clinbiochem.2005.08.002; Tavazzi B, 2005, NEUROSURGERY, V56, P582, DOI 10.1227/01.NEU.0000156715.04900.E6; Tavazzi B, 2007, NEUROSURGERY, V61, P390, DOI 10.1227/01.NEU.0000255525.34956.3F; Titus DJ, 2013, J NEUROSCI, V33, P5216, DOI 10.1523/JNEUROSCI.5133-12.2013; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Vagnozzi R, 2013, J HEAD TRAUMA REHAB, V28, P284, DOI 10.1097/HTR.0b013e3182795045; Vitvitsky V, 2011, J BIOL CHEM, V286, P32002, DOI 10.1074/jbc.M111.253344; WALLWORK JC, 1983, J NUTR, V113, P47; Pinto MCX, 2015, NEUROPHARMACOLOGY, V89, P274, DOI 10.1016/j.neuropharm.2014.10.003; Zhuo JC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136151	74	34	34	2	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1582-4934			J CELL MOL MED	J. Cell. Mol. Med.	MAR	2017	21	3					530	542		10.1111/jcmm.12998			13	Cell Biology; Medicine, Research & Experimental	Cell Biology; Research & Experimental Medicine	EP5KP	WOS:000397417700011	27696676	DOAJ Gold, Green Published			2021-06-18	
J	Sufrinko, AM; Mucha, A; Covassin, T; Marchetti, G; Elbin, RJ; Collins, MW; Kontos, AP				Sufrinko, Alicia M.; Mucha, Anne; Covassin, Tracey; Marchetti, Greg; Elbin, R. J.; Collins, Michael W.; Kontos, Anthony P.			Sex Differences in Vestibular/Ocular and Neurocognitive Outcomes After Sport-Related Concussion	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; adolescents; vestibular; ocular; sex differences	POSTURAL STABILITY; NEUROPSYCHOLOGICAL DEFICITS; HIGH-SCHOOL; BASE-LINE; SYMPTOMS; MANAGEMENT; BALANCE; SUSCEPTIBILITY; SPECIFICITY; SENSITIVITY	Objective:To examine sex differences in vestibular and oculomotor symptoms and impairment in athletes with sport-related concussion (SRC). The secondary purpose was to replicate previously reported sex differences in total concussion symptoms, and performance on neurocognitive and balance testing.Design:Prospective cross-sectional study of consecutively enrolled clinic patients within 21 days of a SRC.Setting:Specialty Concussion Clinic.Participants:Included male (n = 36) and female (n = 28) athletes ages 9 to 18 years.Interventions:Vestibular symptoms and impairment was measured with the Vestibular/Ocular Motor Screening (VOMS). Participants completed the Immediate Post-concussion Assessment and Cognitive Test (ImPACT), Post-concussion Symptom Scale (PCSS), and Balance Error Scoring System (BESS).Main Outcomes Measures:Sex differences on clinical measures.Results:Females had higher PCSS scores (P = 0.01) and greater VOMS vestibular ocular reflex (VOR) score (P = 0.01) compared with males. There were no sex differences on BESS or ImPACT. Total PCSS scores together with female sex accounted for 45% of the variance in VOR scores.Conclusions:Findings suggest higher VOR scores after SRC in female compared with male athletes. Findings did not extend to other components of the VOMS tool suggesting that sex differences may be specific to certain types of vestibular impairment after SRC. Additional research on the clinical significance of the current findings is needed.	[Sufrinko, Alicia M.; Collins, Michael W.; Kontos, Anthony P.] Univ Pittsburgh, Sch Med, Dept Orthopaed Surg, Pittsburgh, PA 15261 USA; [Mucha, Anne] UPMC, Centers Rehabil Serv, Pittsburgh, PA USA; [Covassin, Tracey] Michigan State Univ, Dept Kinesiol, E Lansing, MI 48824 USA; [Marchetti, Greg] Duquesne Univ, Dept Phys Therapy, Pittsburgh, PA 15219 USA; [Elbin, R. J.] Univ Arkansas, Dept Hlth Human Performance & Recreat, Fayetteville, AR 72701 USA	Kontos, AP (corresponding author), UPMC Ctr Sports Med, 3200 South Water St, Pittsburgh, PA 15203 USA.	akontos@pitt.edu		Kontos, Anthony/0000-0002-3749-4310	University of Pittsburgh from the National Institute on Deafness and Other Communication Disorders [1K01DC012332-01A1]; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [K01DC012332] Funding Source: NIH RePORTER	Supported in part by a grant to the University of Pittsburgh from the National Institute on Deafness and Other Communication Disorders (1K01DC012332-01A1).	Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Berz K, 2013, PHYSICIAN SPORTSMED, V41, P58, DOI 10.3810/psm.2013.05.2015; Black FO, 2002, AM J OBSTET GYNECOL, V186, pS204, DOI 10.1067/mob.2002.122602; Broglio SP, 2015, CLIN SPORT MED, V34, P213, DOI 10.1016/j.csm.2014.12.005; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Buse DC, 2013, HEADACHE, V53, P1278, DOI 10.1111/head.12150; Collins MW, 2014, KNEE SURG SPORT TR A, V22, P235, DOI 10.1007/s00167-013-2791-6; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Corwin DJ, 2015, J PEDIATR-US, V166, P1221, DOI 10.1016/j.jpeds.2015.01.039; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2013, SPORT PSYCHOL, V27, P372, DOI 10.1123/tsp.27.4.372; Covassin T, 2013, AM J SPORT MED, V41, P2890, DOI 10.1177/0363546513509962; Covassin T, 2013, TRANSL STROKE RES, V4, P420, DOI 10.1007/s12975-012-0228-z; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; De Bellis MD, 2001, CEREB CORTEX, V11, P552, DOI 10.1093/cercor/11.6.552; Dougan BK, 2014, J INT NEUROPSYCH SOC, V20, P81, DOI 10.1017/S1355617713001288; Ferrari S, 2014, PSYCHOSOMATICS, V55, P280, DOI 10.1016/j.psym.2013.02.005; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Furman JM, 2010, CURR OPIN OTOLARYNGO, V18, P386, DOI 10.1097/MOO.0b013e32833ce5a6; Guskiewicz KM, 2011, CLIN SPORT MED, V30, P89, DOI 10.1016/j.csm.2010.09.004; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Hammar ML, 1996, OBSTET GYNECOL, V88, P955; Helm MR, 2005, HEADACHE, V45, P332, DOI 10.1111/j.1526-4610.2005.05070.x; Hormones Haybach P., 2006, HORMONES, V3, P6; Jokerst MD, 1999, AVIAT SPACE ENVIR MD, V70, P962; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lee AJY, 2007, J APPL BIOMECH, V23, P173, DOI 10.1123/jab.23.3.173; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mickle KJ, 2011, J SCI MED SPORT, V14, P243, DOI 10.1016/j.jsams.2010.11.002; Monzani D, 2001, J PSYCHOSOM RES, V50, P319, DOI 10.1016/S0022-3999(01)00208-2; Mucha A, 2014, AM J SPORT MED, V42, P2479, DOI 10.1177/0363546514543775; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; von Brevern M, 2014, VESTIBULAR MIGRAINE, P83; Zhou GW, 2015, OTOLARYNG HEAD NECK, V152, P1133, DOI 10.1177/0194599815576720; Zuckerman SL, 2014, J NEUROSURG-PEDIATR, V13, P72, DOI 10.3171/2013.9.PEDS13257	36	34	34	2	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	MAR	2017	27	2					133	138		10.1097/JSM.0000000000000324			6	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	EM8PJ	WOS:000395573100007	27379660	Green Accepted			2021-06-18	
J	Cottle, JE; Hall, EE; Patel, K; Barnes, KP; Ketcham, CJ				Cottle, Jordan E.; Hall, Eric E.; Patel, Kirtida; Barnes, Kenneth P.; Ketcham, Caroline J.			Concussion Baseline Testing: Preexisting Factors, Symptoms, and Neurocognitive Performance	JOURNAL OF ATHLETIC TRAINING			English	Article						neurocognitive testing; ImPACT; return to play	TEST-RETEST RELIABILITY; SPORT CONCUSSION; UNITED-STATES; HIGH-SCHOOL; IMPACT; PREVALENCE; DEPRESSION; MIGRAINE; SCORES; ADHD	Context: Neurocognitive test scores are often considered an important aspect of concussion management. To best use these data, clinicians must understand potential factors that may influence baseline performance on these tests. Objective: To determine preexisting factors that may influence performance on the Immediate Post-Concussion Assessment and Cognitive Test (ImPACT). Design: Cross-sectional study. Setting: Research laboratory. Patients or Other Participants: A total of 486 National Collegiate Athletic Association Division I collegiate student-athletes. Main Outcome Measure(s): To determine neurocognitive functioning and total symptom score at baseline, ImPACT was administered. Outcomes were verbal memory, visual memory, visual motor speed, reaction time, and total symptom score. A self-report demographic section at the beginning of ImPACT was used to gather information concerning previous treatment for headaches, migraines, and psychiatric conditions; diagnosis of attention-deficit/hyperactivity disorder; and exposure to previous strenuous exercise. We conducted multivariate analyses of variance to determine if the ImPACT composite and total symptom scores differed according to preexisting factors (P < .0083). Results: Sex showed an effect on verbal memory (P = .001), visual motor speed (P < .001), and reaction time (P = .006), with women performing better than men. A previous diagnosis of attention-deficit/hyperactivity disorder affected visual motor speed (P = .008). Previous treatment for headaches (P < .001), migraines (P = .001), a psychiatric condition (P < .001), or a diagnosis ofattention-deficit/hyperactivity disorder (P < .001) all showed effects on the total symptom score. Strenuous exercise did not affect neurocogntive performance or total symptom score. Conclusions: Based on our findings and the previous literature, we suggest that many preexisting factors influence baseline neurocognitive data. Baseline testing is an important aspect of concussion management. Sports medicine professionals should be cognizant of these factors when developing concussion-management protocols.	[Cottle, Jordan E.; Hall, Eric E.; Ketcham, Caroline J.] Elon Univ, Dept Exercise Sci, 2525 Campus Box, Elon, NC 27244 USA; [Patel, Kirtida] Elon Univ, Dept Athlet, Elon, NC USA; [Barnes, Kenneth P.] Greensboro Orthopaed, Greensboro, NC USA	Hall, EE (corresponding author), Elon Univ, Dept Exercise Sci, 2525 Campus Box, Elon, NC 27244 USA.	ehall@elon.edu		Ketcham, Caroline/0000-0002-6713-130X	American Medical Society for Sports Medicine	This research was supported by a grant from the American Medical Society for Sports Medicine (K.P.B., E.E.H., coinvestigators).	Bailey CM, 2010, CLIN J SPORT MED, V20, P272, DOI 10.1097/JSM.0b013e3181e8f8d8; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Brown CN, 2007, J ATHL TRAINING, V42, P515; Chang YK, 2012, BRAIN RES, V1453, P87, DOI 10.1016/j.brainres.2012.02.068; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2012, CLIN J SPORT MED, V22, P98, DOI 10.1097/JSM.0b013e31823403d2; Covassin T, 2010, J NEUROL NEUROSUR PS, V81, P597, DOI 10.1136/jnnp.2009.193797; DeMars C. E., 2013, RES PRACTICE ASSESSM, V8, P69; Doose-Grunefeld S, 2015, FRONT INTEGR NEUROSC, V9, DOI 10.3389/fnint.2015.00003; Ebell MH, 2004, AM FAM PHYSICIAN, V69, P548; Elbin RJ, 2013, ARCH CLIN NEUROPSYCH, V28, P476, DOI 10.1093/arclin/act024; Elbin RJ, 2011, AM J SPORT MED, V39, P2319, DOI 10.1177/0363546511417173; Gil-Gouveia R, 2016, PAIN PHYSICIAN, V19, pE137; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Kessler RC, 2006, AM J PSYCHIAT, V163, P716, DOI 10.1176/appi.ajp.163.4.716; Littleton AC, 2015, ARCH CLIN NEUROPSYCH, V30, P683, DOI 10.1093/arclin/acv043; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Moser RS, 2011, AM J SPORT MED, V39, P2325, DOI 10.1177/0363546511417114; Mrazik M, 2013, J ATHL TRAINING, V48, P654, DOI 10.4085/1062-6050-48.3.19; Register-Mihalik J, 2007, CLIN J SPORT MED, V17, P282, DOI 10.1097/JSM.0b013e31804ca68a; Schatz P, 2013, ARCH CLIN NEUROPSYCH, V28, P236, DOI 10.1093/arclin/act009; Schatz P, 2012, J ATHL TRAINING, V47, P289, DOI 10.4085/1062-6050-47.3.14; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Schmidt JD, 2012, MED SCI SPORT EXER, V44, P1621, DOI 10.1249/MSS.0b013e318258a9fb; Smitherman TA, 2013, HEADACHE, V53, P427, DOI 10.1111/head.12074; Solomon GS, 2008, ARCH CLIN NEUROPSYCH, V23, P563, DOI 10.1016/j.acn.2008.05.008; Substance Abuse and Mental Health Services Administration, RES 2013 NAT SURV DR; Zuckerman SL, 2013, J NEUROSURG-PEDIATR, V12, P103, DOI 10.3171/2013.5.PEDS12524	29	34	34	0	8	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	FEB	2017	52	2					77	81		10.4085/1062-6050-51.12.21			5	Sport Sciences	Sport Sciences	EP2IW	WOS:000397207600001	28071936	Green Published, Bronze			2021-06-18	
J	Menzel, L; Kleber, L; Friedrich, C; Hummel, R; Dangel, L; Winter, J; Schmitz, K; Tegeder, I; Schafer, MKE				Menzel, Lutz; Kleber, Lisa; Friedrich, Carina; Hummel, Regina; Dangel, Larissa; Winter, Jennifer; Schmitz, Katja; Tegeder, Irmgard; Schaefer, Michael K. E.			Progranulin Protects Against Exaggerated Axonal Injury and Astrogliosis Following Traumatic Brain Injury	GLIA			English	Article						traumatic brain injury; progranulin; astrocytes; TNF alpha; neuroinflammation	ACTIVATED MICROGLIA; PATHOLOGICAL CONDITIONS; ASTROCYTE ACTIVATION; TNF RECEPTORS; GROWTH-FACTOR; WHITE-MATTER; EXPRESSION; MUTATIONS; INFLAMMATION; RESPONSES	In response to traumatic brain injury (TBI) microglia/macrophages and astrocytes release inflammatory mediators with dual effects on secondary brain damage progression. The neurotrophic and anti-inflammatory glycoprotein progranulin (PGRN) attenuates neuronal damage and microglia/macrophage activation in brain injury but mechanisms are still elusive. Here, we studied histopathology, neurology and gene expression of inflammatory markers in PGRN-deficient mice (Grn(-/-)) 24 h and 5 days after experimental TBI. Grn(-/-) mice displayed increased perilesional axonal injury even though the overall brain tissue loss and neurological consequences were similar to wild-type mice. Brain inflammation was elevated in Grn(-/-) mice as reflected by increased transcription of pro-inflammatory cytokines TNF alpha, IL-1, IL-6, and decreased transcription of the anti-inflammatory cytokine IL-10. However, numbers of Iba1(+) microglia/macrophages and immigrated CD45(+) leukocytes were similar at perilesional sites while determination of IgG extravasation suggested stronger impairment of blood brain barrier integrity in Grn(-/-) compared to wild-type mice. Most strikingly, Grn(-/-) mice displayed exaggerated astrogliosis 5 days after TBI as demonstrated by anti-GFAP immunohistochemistry and immunoblot. GFAP(+) astrocytes at perilesional sites were immunolabelled for iNOS and TNF alpha suggesting that pro-inflammatory activation of astrocytes was attenuated by PGRN. Accordingly, recombinant PGRN (rPGRN) attenuated LPS- and cytokine-evoked iNOS and TNF alpha mRNA expression in cultured astrocytes. Moreover, intracerebroventricular administration of rPGRN immediately before trauma reduced brain damage and neurological deficits, and restored normal levels of cytokine transcription, axonal injury and astrogliosis 5 days after TBI in Grn(-/-) mice. Our results show that endogenous and recombinant PGRN limit axonal injury and astrogliosis and suggest therapeutic potential of PGRN in TBI.	[Menzel, Lutz; Kleber, Lisa; Friedrich, Carina; Hummel, Regina; Dangel, Larissa; Schaefer, Michael K. E.] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Anesthesiol, Mainz, Germany; [Winter, Jennifer] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Inst Human Genet, Mainz, Germany; [Winter, Jennifer; Schaefer, Michael K. E.] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Focus Program Translat Neurosci FTN, Mainz, Germany; [Schmitz, Katja; Tegeder, Irmgard] Goethe Univ Hosp, Clin Pharmacol, Frankfurt, Germany	Schafer, MKE (corresponding author), Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Anesthesiol, Langenbeckstr 1,Bld 505, Mainz, Germany.; Schafer, MKE (corresponding author), Johannes Gutenberg Univ Mainz, Univ Med Ctr, Focus Program Translat Neurosci, Langenbeckstr 1,Bld 505, Mainz, Germany.	michael.schaefer@unimedizin-mainz.de	Tegeder, Irmgard/AAM-2246-2020	Tegeder, Irmgard/0000-0001-7524-8025; Menzel, Lutz/0000-0002-3816-6255	Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [CRC1080]	The autors gratefully acknowledge the technical assistance of Wiesia Bobkiewicz and Tobias Hirnet (Department of Anesthesiology, UMC Mainz, Germany) and Annett Haussler (Clinical Pharmacology, Goethe-University Hospital, Frankfurt, Germany). This study was supported by the Deutsche Forschungsgemeinschaft (CRC1080, project B6 to M.K.E.S. and project A9 to I.T.).	Abudara V, 2015, GLIA, V63, P795, DOI 10.1002/glia.22785; Almeida S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026454; Alvarez JI, 2013, GLIA, V61, P1939, DOI 10.1002/glia.22575; Anderson MA, 2016, NATURE, V532, P195, DOI 10.1038/nature17623; Baker CA, 2003, P NATL ACAD SCI USA, V100, P675, DOI 10.1073/pnas.0237313100; Baker M, 2006, NATURE, V442, P916, DOI 10.1038/nature05016; Bezzi P, 2001, NAT NEUROSCI, V4, P702, DOI 10.1038/89490; Brambilla R, 2009, J NEUROCHEM, V110, P765, DOI 10.1111/j.1471-4159.2009.06190.x; Burda JE, 2016, EXP NEUROL, V275, P305, DOI 10.1016/j.expneurol.2015.03.020; Byrnes KR, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-130; Caesar M, 2014, GLIA, V62, P1075, DOI 10.1002/glia.22663; Chen X, 2013, J NEUROSCI, V33, P9202, DOI 10.1523/JNEUROSCI.5336-12.2013; Cheong CU, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/620837; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; Cruts M, 2006, NATURE, V442, P920, DOI 10.1038/nature05017; de Munain AL, 2008, BIOL PSYCHIAT, V63, P946, DOI 10.1016/j.biopsych.2007.08.015; DiLeonardi AM, 2012, J NEUROPATH EXP NEUR, V71, P959, DOI 10.1097/NEN.0b013e31826f5876; Etemadi N, 2013, IMMUNOL CELL BIOL, V91, P661, DOI 10.1038/icb.2013.53; Filiano AJ, 2013, J NEUROSCI, V33, P5352, DOI 10.1523/JNEUROSCI.6103-11.2013; Gass J, 2006, HUM MOL GENET, V15, P2988, DOI 10.1093/hmg/ddl241; He ZH, 2003, J MOL MED-JMM, V81, P600, DOI 10.1007/s00109-003-0474-3; Hennessy E, 2015, J NEUROSCI, V35, P8411, DOI 10.1523/JNEUROSCI.2745-14.2015; Hsieh CL, 2013, EUR J IMMUNOL, V43, P2010, DOI 10.1002/eji.201243084; Hu FH, 2010, NEURON, V68, P654, DOI 10.1016/j.neuron.2010.09.034; Huang CS, 2016, GLIA, V64, P507, DOI 10.1002/glia.22944; Jackman K, 2013, J NEUROSCI, V33, P19579, DOI 10.1523/JNEUROSCI.4318-13.2013; Jin X, 2016, J BIOCH, V8; Kanazawa M, 2015, BRAIN, V138, P1932, DOI 10.1093/brain/awv079; Karve IP, 2016, BRIT J PHARMACOL, V173, P692, DOI 10.1111/bph.13125; Kim JY, 2010, NAT NEUROSCI, V13, P180, DOI 10.1038/nn.2471; Kou ZF, 2014, GLIA, V62, P1831, DOI 10.1002/glia.22690; LEE SC, 1993, J NEUROIMMUNOL, V46, P19, DOI 10.1016/0165-5728(93)90229-R; Li BL, 2003, MOL BRAIN RES, V111, P155, DOI 10.1016/S0169-328X(03)00025-1; Li B, 2015, CRIT CARE MED, V43, pE304, DOI 10.1097/CCM.0000000000001096; Lim HY, 2012, J CELL MOL MED, V16, P708, DOI 10.1111/j.1582-4934.2011.01350.x; Liu W, 2011, LIFE SCI, V89, P141, DOI 10.1016/j.lfs.2011.05.011; Liu Z, 2015, PROG NEUROBIOL, V9, P30001; Loane DJ, 2016, EXP NEUROL, V275, P316, DOI 10.1016/j.expneurol.2015.08.018; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Malaspina A, 2001, J NEUROCHEM, V77, P132, DOI 10.1046/j.1471-4159.2001.t01-1-00231.x; Martens LH, 2012, J CLIN INVEST, V122, P3955, DOI 10.1172/JCI63113; Medina S, 2002, FREE RADICAL RES, V36, P1179, DOI 10.1080/107157602100006445; Milani D, 2003, J NEUROCHEM, V86, P126, DOI 10.1046/j.1471-4159.2003.01805.x; Norden DM, 2014, GLIA, V62, P881, DOI 10.1002/glia.22647; Pekny M, 2005, GLIA, V50, P427, DOI 10.1002/glia.20207; Pekny M, 2014, NEUROSCI LETT, V565, P30, DOI 10.1016/j.neulet.2013.12.071; Perry DC, 2013, JAMA NEUROL, V70, P774, DOI 10.1001/2013.jamaneurol.393; Petkau TL, 2016, NEUROSCIENCE, V315, P175, DOI 10.1016/j.neuroscience.2015.12.006; Petzold A, 2005, J NEUROL SCI, V233, P183, DOI 10.1016/j.jns.2005.03.015; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Phulwani NK, 2008, J IMMUNOL, V181, P3841, DOI 10.4049/jimmunol.181.6.3841; Pitt D, 2000, NAT MED, V6, P67, DOI 10.1038/71555; Raposo C, 2014, GLIA, V62, P1895, DOI 10.1002/glia.22676; Schafer M, 2014, CELL TISSUE RES, V357, P395, DOI 10.1007/s00441-014-1807-y; Schaible EV, 2014, J NEUROCHEM, V129, P940, DOI 10.1111/jnc.12708; Schaible EV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071056; Schildge S, 2013, JOVE-J VIS EXP, DOI 10.3791/50079; Smith KR, 2012, AM J HUM GENET, V90, P1102, DOI 10.1016/j.ajhg.2012.04.021; Sofroniew MV, 2015, NAT REV NEUROSCI, V16, P249, DOI 10.1038/nrn3898; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Tanaka Y, 2013, NEUROSCIENCE, V250, P8, DOI 10.1016/j.neuroscience.2013.06.049; Tanaka Y, 2013, NEUROSCIENCE, V231, P49, DOI 10.1016/j.neuroscience.2012.11.032; Tanaka Y, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/s40478-014-0078-x; Tang W, 2011, SCIENCE, V332, P478, DOI 10.1126/science.1199214; Thal SC, 2008, J NEUROTRAUM, V25, P785, DOI 10.1089/neu.2007.0497; Tian QY, 2014, METHODS MOL BIOL, V1155, P163, DOI 10.1007/978-1-4939-0669-7_14; Timaru-Kast R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043829; Tobinick E, 2012, CNS DRUGS, V26, P1051, DOI 10.1007/s40263-012-0013-2; Toklu HZ, 2015, OXIDATIVE STRESS BRA; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; Tuttolomondo A, 2014, DRUG DES DEV THER, V8, P2221, DOI 10.2147/DDDT.S67655; Van Damme P, 2008, J CELL BIOL, V181, P37, DOI 10.1083/jcb.200712039; Vercellino M, 2011, MULT SCLER J, V17, P1194, DOI 10.1177/1352458511406164; Villapol S, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00082; Wang BC, 2015, PROTEIN CELL, V6, P792, DOI 10.1007/s13238-015-0213-x; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Wang XK, 2003, MOL PHARMACOL, V64, P833, DOI 10.1124/mol.64.4.833; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wes PD, 2016, GLIA; Wilson CM, 2009, INT J RADIAT ONCOL, V74, P934, DOI 10.1016/j.ijrobp.2009.02.035; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Yin FF, 2010, J EXP MED, V207, P117, DOI 10.1084/jem.20091568; Zamanian JL, 2012, J NEUROSCI, V32, P6391, DOI 10.1523/JNEUROSCI.6221-11.2012; Zhao YP, 2013, BIOMATERIALS, V34, P6412, DOI 10.1016/j.biomaterials.2013.05.030; Zhu SS, 2013, BRAIN RES, V1530, P54, DOI 10.1016/j.brainres.2013.07.023	86	34	34	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	FEB	2017	65	2					278	292		10.1002/glia.23091			15	Neurosciences	Neurosciences & Neurology	EK1ER	WOS:000393669100005	27778404				2021-06-18	
J	Feng, Y; Gao, JL; Cui, Y; Li, MH; Li, R; Cui, CM; Cui, JZ				Feng, Yan; Gao, Junling; Cui, Ying; Li, Minghang; Li, Ran; Cui, Changmeng; Cui, Jianzhong			Neuroprotective Effects of Resatorvid Against Traumatic Brain Injury in Rat: Involvement of Neuronal Autophagy and TLR4 Signaling Pathway	CELLULAR AND MOLECULAR NEUROBIOLOGY			English	Article						Toll-like receptor 4 (TLR4); Resatorvid (TAK-242); Traumatic brain injury (TBI); Autophagy; Neuroinflammation	TOLL-LIKE RECEPTORS; CELL-DEATH; CEREBRAL EDEMA; TAK-242; ANTAGONIST; INHIBITOR; INFLAMMATION; CONTRIBUTES; MECHANISM; DEFICITS	Accumulating evidence indicates that autophagy and inflammatory responses contributes to secondary brain injury after traumatic brain injury (TBI), and toll-like receptor 4 (TLR4) is considered to involvement of this cascade and plays an important role. The present study was designed to determine the hypothesis that administration of resatorvid (TAK-242), a TLR4 antagonist, might provide a neuroprotective effect by inhibit TLR4-mediated pathway in a TBI rat model. Rat subjected to controlled cortical impact injury were injected with TAK-242 (0.5 mg/kg, i.v. injected) 10 min prior to injury. The results demonstrated that TAK-242 treatment significantly attenuated TBI-induced neurons loss, brain edema, and neurobehavioral impairment in rats. Immunoblotting analysis showed that TAK-242 treatment reduced TBI-induced TLR4, Beclin 1, and LC3-II levels, and maintained p62 levels at 24 h. Double immunolabeling demonstrated that LC3 dots co-localized with the hippocampus pyramidal neurons, and TLR4 was localized with the hippocampus neurons and astrocytes. In addition, the expression of TLR4 downstream signaling molecules, including MyD88, TRIF, NF-kappa B, TNF-alpha, and IL-1 beta, was significantly downregulated in hippocampus tissue by Western blot analysis. In conclusion, our findings indicate that pre-injury treatment with TAK-242 could inhibit neuronal autophagy and neuroinflammation responses in the hippocampus in a rat model of TBI. The neuroprotective effects of TAK-242 may be related to modulation of the TLR4-MyD88/TRIF-NF-kappa B signaling pathway. Furthermore, the study also suggests that TAK-242, an attractive potential drug, may be a promising drug candidate for TBI.	[Feng, Yan; Cui, Changmeng; Cui, Jianzhong] Hebei Med Univ, Dept Surg, 361 East Zhongshan Rd, Shijiazhuang 050017, Peoples R China; [Feng, Yan] Hebei Med Univ, Dept Neurosurg, Hosp 2, Shijiazhuang 050000, Hebei, Peoples R China; [Gao, Junling; Li, Minghang; Li, Ran] North China Univ Sci & Technol, Sch Basic Med Sci, Tangshan, Peoples R China; [Cui, Ying; Cui, Jianzhong] Tangshan Workers Hosp, Dept Neurosurg, Tangshan 063000, Hebei, Peoples R China	Cui, JZ (corresponding author), Hebei Med Univ, Dept Surg, 361 East Zhongshan Rd, Shijiazhuang 050017, Peoples R China.; Cui, JZ (corresponding author), Tangshan Workers Hosp, Dept Neurosurg, Tangshan 063000, Hebei, Peoples R China.	jzhcuidr2001@163.com		Gao, Junling/0000-0001-5267-5884	Natural Science Foundation of Hebei ProvinceNatural Science Foundation of Hebei Province [H2014105079]	The present study was supported by a grant from the Natural Science Foundation of Hebei Province (Grant No. H2014105079).	Ahmad A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057208; Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Bao HJ, 2015, NEUROCHEM RES, V40, P89, DOI 10.1007/s11064-014-1469-x; Bierbach B, 2008, STROKE, V39, P213, DOI 10.1161/STROKEAHA.107.496620; Blander JM, 2004, SCIENCE, V304, P1014, DOI 10.1126/science.1096158; Bredesen DE, 2006, NATURE, V443, P796, DOI 10.1038/nature05293; Bursch W, 2000, J CELL SCI, V113, P1189; Chen CC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030294; Chen SF, 2008, BRIT J PHARMACOL, V155, P1279, DOI 10.1038/bjp.2008.345; Clark RSB, 2008, AUTOPHAGY, V4, P88, DOI 10.4161/auto.5173; Cui CM, 2014, NEUROL SCI, V35, P695, DOI 10.1007/s10072-013-1585-4; Delgado MA, 2009, CELL DEATH DIFFER, V16, P976, DOI 10.1038/cdd.2009.40; Delgado MA, 2008, EMBO J, V27, P1110, DOI 10.1038/emboj.2008.31; Erlich S, 2007, NEUROBIOL DIS, V26, P86, DOI 10.1016/j.nbd.2006.12.003; Fang H, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-27; Garate I, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-8; Hanamsagar R, 2012, TRENDS IMMUNOL, V33, P333, DOI 10.1016/j.it.2012.03.001; Hu YC, 2014, INFLAMM RES, V63, P109, DOI 10.1007/s00011-013-0677-1; Hua F, 2015, J CEREBR BLOOD F MET, V35, P536, DOI 10.1038/jcbfm.2014.240; Ichimura Y, 2008, J BIOL CHEM, V283, P22847, DOI 10.1074/jbc.M802182200; Kim HM, 2007, CELL, V130, P906, DOI 10.1016/j.cell.2007.08.002; Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Komatsu M, 2007, P NATL ACAD SCI USA, V104, P14489, DOI 10.1073/pnas.0701311104; Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723; Kong Y, 2011, INT IMMUNOPHARMACOL, V11, P1407, DOI 10.1016/j.intimp.2011.04.025; Lai YC, 2008, J CEREBR BLOOD F MET, V28, P540, DOI 10.1038/sj.jcbfm.9600551; Laird MD, 2014, GLIA, V62, P26, DOI 10.1002/glia.22581; Li GZ, 2011, BRAIN RES, V1396, P96, DOI 10.1016/j.brainres.2011.04.014; Li HY, 2012, CHINESE MED J-PEKING, V125, P1586, DOI 10.3760/cma.j.issn.0366-6999.2012.09.012; Lipinski MM, 2015, ANTIOXID REDOX SIGN, V23, P565, DOI 10.1089/ars.2015.6306; Liu HG, 2010, SLEEP MED, V11, P205, DOI 10.1016/j.sleep.2009.05.015; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Lu J, 2009, FRONT BIOSCI-LANDMRK, V14, P3795, DOI 10.2735/3489; Lucas K, 2013, MOL NEUROBIOL, V48, P190, DOI 10.1007/s12035-013-8425-7; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Mao SS, 2012, J NEUROTRAUM, V29, P1941, DOI 10.1089/neu.2011.2244; Matsunaga N, 2011, MOL PHARMACOL, V79, P34, DOI 10.1124/mol.110.068064; McCray BA, 2008, NEUROSIGNALS, V16, P75, DOI 10.1159/000109761; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Rice TW, 2010, CRIT CARE MED, V38, P1685, DOI 10.1097/CCM.0b013e3181e7c5c9; Sarkar C, 2014, AUTOPHAGY, V10, P2208, DOI 10.4161/15548627.2014.981787; Schmid D, 2007, IMMUNITY, V27, P11, DOI 10.1016/j.immuni.2007.07.004; Shi RY, 2012, CNS NEUROSCI THER, V18, P250, DOI 10.1111/j.1755-5949.2012.00295.x; Simao F, 2012, EUR J NEUROSCI, V36, P2899, DOI 10.1111/j.1460-9568.2012.08229.x; Song SX, 2013, MOL MED REP, V7, P327, DOI 10.3892/mmr.2012.1147; Sun LQ, 2014, MOL MED REP, V9, P77, DOI 10.3892/mmr.2013.1787; Tolias Christos M, 2004, NeuroRx, V1, P71, DOI 10.1602/neurorx.1.1.71; Wang YC, 2013, STROKE, V44, P2545, DOI 10.1161/STROKEAHA.113.001038; Watts LT, 2013, J NEUROTRAUM, V30, P55, DOI 10.1089/neu.2012.2488; Wu FX, 2010, INT J MED SCI, V7, P251; Xu Y, 2007, IMMUNITY, V27, P135, DOI 10.1016/j.immuni.2007.05.022; Zhang D, 2013, NEUROSCIENCE, V238, P209, DOI 10.1016/j.neuroscience.2013.02.022; Zhang DD, 2014, NEUROCHEM INT, V75, P11, DOI 10.1016/j.neuint.2014.05.003; Zhu HT, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-59	57	34	35	2	15	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0272-4340	1573-6830		CELL MOL NEUROBIOL	Cell. Mol. Neurobiol.	JAN	2017	37	1					155	168		10.1007/s10571-016-0356-1			14	Cell Biology; Neurosciences	Cell Biology; Neurosciences & Neurology	EI3QU	WOS:000392407200016	26961544				2021-06-18	
J	Mac Donald, CL; Barber, J; Andre, J; Evans, N; Panks, C; Sun, S; Zalewski, K; Sanders, RE; Temkin, N				Mac Donald, Christine L.; Barber, Jason; Andre, Jalal; Evans, Nicole; Panks, Chris; Sun, Samantha; Zalewski, Kody; Sanders, R. Elizabeth; Temkin, Nancy			5-Year imaging sequelae of concussive blast injury and relation to early clinical outcome	NEUROIMAGE-CLINICAL			English	Article						Diffusion tensor imaging; Concussion; Neurodegeneration; Traumatic brain injury	TRAUMATIC BRAIN-INJURY; WHITE-MATTER ABNORMALITIES; POSTTRAUMATIC-STRESS-DISORDER; US MILITARY PERSONNEL; DIFFUSE AXONAL INJURY; ROBUST ESTIMATION; IRAQI FREEDOM; MOUSE MODEL; TENSOR; MILD	Current imaging diagnostic techniques are often insensitive to the underlying pathological changes following mild traumatic brain injury (TBI) or concussion so much so that the explicit definition of these uncomplicated mild brain injuries includes the absence of radiological findings. In the US military, this is complicated by the natural tendency of service members to down play symptoms for fear of removal from their unit particularly in combat making it challenging for clinicians to definitively diagnose and determine course of treatment. Questions remain regarding the long-term impact of these war-time brain injuries. The objective of the current study was to evaluate the long-term imaging sequelae of blast concussion in active-duty US military and leverage previous longitudinal data collected in these same patients to identify predictors of sustained DTI signal change indicative of chronic neurodegeneration. In total, 50 blast TBI and 44 combat-deployed controls were evaluated at this 5-year follow up by advanced neuroimaging techniques including diffusion tensor imaging and quantitative volumetry. While cross-sectional analysis of regions of white matter on DTI images did not reveal significant differences across groups after statistical correction, an approach flexible to the heterogeneity of brain injury at the single-subject level identified 74% of the concussive blast TBI cohort to have reductions in fractional anisotropy indicative of chronic brain injury. Logistic regression leveraging clinical and demographic data collected in the acute/sub-acute and 1-year follow up to determine predictors of these long-term imaging changes determined that brain injury diagnosis, older age, verbal memory and verbal fluency best predicted the presence of DTI abnormalities 5 years post injury with an AUC of 0.78 indicating good prediction strength. These results provide supporting evidence for the evolution not resolution of this brain injury pathology, adding to the growing body of literature describing imaging signatures of chronic neurodegeneration even after mild TBI and concussion. (C) 2017 The Author(s). Published by Elsevier Inc.	[Mac Donald, Christine L.; Barber, Jason; Evans, Nicole; Panks, Chris; Sun, Samantha; Zalewski, Kody; Temkin, Nancy] Univ Washington, Dept Neurol Surg, 352 9th Ave,Box 959924, Seattle, WA 98104 USA; [Andre, Jalal] Univ Washington, Dept Radiol, Seattle, WA 98195 USA; [Sanders, R. Elizabeth] Univ Washington, Dept Internal Med, Seattle, WA 98195 USA; [Temkin, Nancy] Univ Washington, Dept Biostat, Seattle, WA 98195 USA	Mac Donald, CL (corresponding author), Univ Washington, Dept Neurol Surg, 352 9th Ave,Box 959924, Seattle, WA 98104 USA.	cmacd@uw.edu		Temkin, Nancy/0000-0002-6392-5292; Andre, Jalal/0000-0002-0896-183X; Sun, Samantha/0000-0002-5971-066X	Department of Defense through Chronic Effects of Neurotrauma Consortium [W81XWH-13-2-0095]; NIH RO1 from NINDS [1R01NS091618-01]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS091618] Funding Source: NIH RePORTER	Support for this study was provided by a Department of Defense grant through the Chronic Effects of Neurotrauma Consortium (W81XWH-13-2-0095) and by an NIH RO1 grant from NINDS (1R01NS091618-01).	Adam O, 2015, NEUROLOGY, V85, P219, DOI 10.1212/WNL.0000000000001758; Akaike H, 1973, P 2 INTERNTERNATIONA, P267, DOI 10.1007/978-1-4612-1694-0; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; BASSER PJ, 1994, J MAGN RESON SER B, V103, P247, DOI 10.1006/jmrb.1994.1037; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bazarian JJ, 2013, J HEAD TRAUMA REHAB, V28, P1, DOI 10.1097/HTR.0b013e318256d3d3; Bennett RE, 2012, NEUROSCI LETT, V513, P160, DOI 10.1016/j.neulet.2012.02.024; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Brody DL, 2015, MOL CELL NEUROSCI, V66, P91, DOI 10.1016/j.mcn.2015.02.005; Casscells SW, 2007, TRAUMATIC BRAIN INJU; Chang LC, 2005, MAGN RESON MED, V53, P1088, DOI 10.1002/mrm.20426; Chang LC, 2012, MAGN RESON MED, V68, P1654, DOI 10.1002/mrm.24173; DVBIC, 2016, DOD WORLDW TBI NUMB; Farbota KD, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00160; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Han K, 2014, NEUROIMAGE, V84, P76, DOI 10.1016/j.neuroimage.2013.08.017; Hayes JP, 2015, NEUROIMAGE-CLIN, V8, P148, DOI 10.1016/j.nicl.2015.04.001; HOLM S, 1979, SCAND J STAT, V6, P65; Hoy AR, 2014, NEUROIMAGE, V103, P323, DOI 10.1016/j.neuroimage.2014.09.053; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Irfanoglu MO, 2015, NEUROIMAGE, V106, P284, DOI 10.1016/j.neuroimage.2014.11.042; Jorge RE, 2012, AM J PSYCHIAT, V169, P1284, DOI 10.1176/appi.ajp.2012.12050600; Koay CG, 2006, J MAGN RESON, V182, P115, DOI 10.1016/j.jmr.2006.06.020; Koay CG, 2009, J MAGN RESON, V197, P108, DOI 10.1016/j.jmr.2008.11.015; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Lingsma HF, 2015, J NEUROTRAUM, V32, P83, DOI 10.1089/neu.2014.3384; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055823; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Mac Donald CL, 2015, BRAIN, V138, P1314, DOI 10.1093/brain/awv038; Mac Donald CL, 2014, JAMA NEUROL, V71, P994, DOI 10.1001/jamaneurol.2014.1114; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Mac Donald CL, 2016, J NEUROTRAUMA; MacDonald Christine L, 2014, J Neurotrauma, V31, P889, DOI 10.1089/neu.2013.3173; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Mangin JF, 2002, MED IMAGE ANAL, V6, P191, DOI 10.1016/S1361-8415(02)00079-8; Matthews SC, 2012, PSYCHIAT RES-NEUROIM, V204, P149, DOI 10.1016/j.pscychresns.2012.04.018; Miller DR, 2016, HUM BRAIN MAPP, V37, P220, DOI 10.1002/hbm.23022; Morey RA, 2013, HUM BRAIN MAPP, V34, P2986, DOI 10.1002/hbm.22117; Morey RA, 2012, ARCH GEN PSYCHIAT, V69, P1169, DOI 10.1001/archgenpsychiatry.2012.50; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Oishi K., 2011, MRI ATLAS HUMAN WHIT; Oishi K, 2009, NEUROIMAGE, V46, P486, DOI 10.1016/j.neuroimage.2009.01.002; Pierpaoli C, 1996, RADIOLOGY, V201, P637, DOI 10.1148/radiology.201.3.8939209; Pierpaoli C., 2010, INT SOC MAGN RES MED; Pierpaoli C, 2010, P ISMRM 18 ANN M, P1597; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rohde GK, 2005, NEUROIMAGE, V26, P673, DOI 10.1016/j.neuroimage.2005.02.023; Rohde GK, 2004, MAGN RESON MED, V51, P103, DOI 10.1002/mrm.10677; Sorg SF, 2014, J HEAD TRAUMA REHAB, V29, P21, DOI 10.1097/HTR.0b013e31828a1aa4; Taber KH, 2015, J HEAD TRAUMA REHAB, V30, pE15, DOI 10.1097/HTR.0000000000000030; Thomas C, 2014, P NATL ACAD SCI USA, V111, P16574, DOI 10.1073/pnas.1405672111; Trotter BB, 2015, BRAIN, V138, P2278, DOI 10.1093/brain/awv139; Vittinghoff E, 2007, AM J EPIDEMIOL, V165, P710, DOI 10.1093/aje/kwk052; Ware JB, 2016, RADIOLOGY, V280, P212, DOI 10.1148/radiol.2016151013; Wu M, 2008, LECT NOTES COMPUT SC, V5242, P321, DOI 10.1007/978-3-540-85990-1_39; Yeh PH, 2014, HUM BRAIN MAPP, V35, P2652, DOI 10.1002/hbm.22358; Zhang YJ, 2010, NEUROIMAGE, V52, P1289, DOI 10.1016/j.neuroimage.2010.05.049	60	34	34	0	6	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	2213-1582			NEUROIMAGE-CLIN	NeuroImage-Clin.		2017	14						371	378		10.1016/j.nicl.2017.02.005			8	Neuroimaging	Neurosciences & Neurology	FB2OY	WOS:000405984300040	28243574	DOAJ Gold, Green Published			2021-06-18	
J	Bombardier, CH; Hoekstra, T; Dikmen, S; Fann, JR				Bombardier, Charles H.; Hoekstra, Trynke; Dikmen, Sureyya; Fann, Jesse R.			Depression Trajectories during the First Year after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						depression; prognosis; substance abuse; trajectories; traumatic brain injury	SCHEDULED TELEPHONE INTERVENTION; RANDOMIZED CONTROLLED-TRIAL; PSYCHIATRIC-DISORDERS; MAJOR DEPRESSION; SUICIDAL IDEATION; AXIS-I; SYMPTOMS; SEVERITY; MODERATE; RESILIENCE	Major depression is prevalent after traumatic brain injury (TBI) and associated with poor outcomes. Little is known about the course of depression after TBI. Participants were 559 consecutively admitted patients with mild to severe TBI recruited from inpatient units at Harborview Medical Center, a Level I trauma center in Seattle, WA. Participants were assessed with the Patient Health Questionnaire-9 (PHQ-9) depression measure at months 1-6, 8, 10, and 12 post-injury. We used linear latent class growth mixture modeling (LCGMM) of PHQ-9 total scores to identify homogeneous subgroups with distinct longitudinal trajectories. A four-class LCGMM had good fit indices and clinical interpretability. Trajectory groups were: low depression (70.1%), delayed depression (13.2%), depression recovery (10.4%), and persistent depression (6.3%). Multinomial logistic regression analyses were used to distinguish trajectory classes based on baseline demographic, psychiatric history, and clinical variables. Relative to the low depression group, the other three groups were consistently more likely to have a pre-injury history of other mental health disorders or major depressive disorder, a positive toxicology screen for cocaine or amphetamines at the time of injury, and a history of alcohol dependence. They were less likely to be on Medicare versus commercial insurance. Trajectories based on LCGMM are an empirical and clinically meaningful way to characterize distinct courses of depression after TBI. When combined with baseline predictors, this line of research may improve our ability to predict prognosis and target groups who may benefit from treatment or secondary prevention efforts (e.g., proactive telephone counseling).	[Bombardier, Charles H.; Dikmen, Sureyya] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Hoekstra, Trynke] Vrije Univ Amsterdam, Med Ctr, Dept Hlth Sci, Fac Earth & Life Sci, Amsterdam, Netherlands; [Hoekstra, Trynke] Vrije Univ Amsterdam, Med Ctr, Dept Epidemiol & Biostat, EMGO Inst Hlth & Care Res, Amsterdam, Netherlands; [Fann, Jesse R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA	Bombardier, CH (corresponding author), Univ Washington, Dept Rehabil Med, Harborview Med Ctr, Box 359612,325 9th Ave, Seattle, WA 98104 USA.	chb@uw.edu	Hoekstra, Trynke/AAG-5901-2020	Hoekstra, Trynke/0000-0002-0535-0056	National Center for Medical Rehabilitation Research, the National Institute of Child Health and Human Development, and National Institutes of Health [R01HD39415]	This work was supported by the National Center for Medical Rehabilitation Research, the National Institute of Child Health and Human Development, and National Institutes of Health grant R01HD39415 to Drs. Bombardier and Fann (co-principal investigators). Pfizer supplied masked sertraline and placebo for the controlled trial. The funding sources had no role in the design and conduct of the study; in the collection, analysis, and interpretation of the data; or in the preparation, review, or approval of the article.	Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; Ashman TA, 2009, ARCH PHYS MED REHAB, V90, P733, DOI 10.1016/j.apmr.2008.11.005; Asparouhov T, 2014, STRUCT EQU MODELING, V21, P329, DOI 10.1080/10705511.2014.915181; Bay E, 2008, BRAIN INJURY, V22, P233, DOI 10.1080/02699050801953073; Bay E, 2009, J NEUROSCI NURS, V41, P298, DOI 10.1097/JNN.0b013e3181b6be81; Bell KR, 2011, ARCH PHYS MED REHAB, V92, P1552, DOI 10.1016/j.apmr.2011.05.018; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bombardier CH, 2009, J HEAD TRAUMA REHAB, V24, P230, DOI 10.1097/HTR.0b013e3181ad65f0; Bonanno GA, 2012, REHABIL PSYCHOL, V57, P236, DOI 10.1037/a0029256; Bonanno GA, 2011, ANNU REV CLIN PSYCHO, V7, P511, DOI 10.1146/annurev-clinpsy-032210-104526; Cook KF, 2011, ARCH PHYS MED REHAB, V92, P818, DOI 10.1016/j.apmr.2010.12.008; Corrigan JD, 2013, ARCH PHYS MED REHAB, V94, P1199, DOI 10.1016/j.apmr.2013.01.023; DeRoon-Cassini TA, 2010, REHABIL PSYCHOL, V55, P1, DOI 10.1037/a0018601; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; DOBSON KS, 1986, COGNITIVE THER RES, V10, P13, DOI 10.1007/BF01173379; Duncan T. E., 1999, INTRO LATENT VARIABL; ESSELMAN PC, 1995, BRAIN INJURY, V9, P417, DOI 10.3109/02699059509005782; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; Fann JR, 2015, J NEUROTRAUM, V32, P45, DOI 10.1089/neu.2014.3423; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; Fann JR, 2005, J HEAD TRAUMA REHAB, V20, P501, DOI 10.1097/00001199-200511000-00003; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Fava M, 2000, NEURON, V28, P335, DOI 10.1016/S0896-6273(00)00112-4; GomezHernandez R, 1997, ARCH PHYS MED REHAB, V78, P1321, DOI 10.1016/S0003-9993(97)90304-X; Gould KR, 2011, PSYCHOL MED, V41, P2099, DOI 10.1017/S003329171100033X; Gould KR, 2011, J NEUROTRAUM, V28, P1155, DOI 10.1089/neu.2010.1528; Grauwmeijer E, 2012, ARCH PHYS MED REHAB, V93, P993, DOI 10.1016/j.apmr.2012.01.018; Hart T, 2014, J NEUROTRAUM, V31, P610, DOI 10.1089/neu.2013.3041; Hart T, 2011, ARCH PHYS MED REHAB, V92, P1211, DOI 10.1016/j.apmr.2011.03.005; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Hoekstra T., 2013, APPL LATENT CLASS MO; Hoekstra T, 2011, LONGITUD LIFE COURSE, V2, P319; Hoffman JM, 2010, PM&R, V2, P911, DOI 10.1016/j.pmrj.2010.06.008; Hoofien D, 2001, BRAIN INJURY, V15, P189; JAGGER J, 1984, NEUROSURGERY, V15, P303, DOI 10.1227/00006123-198409000-00002; Jakubovski E, 2014, J CLIN PSYCHIAT, V75, P738, DOI 10.4088/JCP.13m08727; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; Jung T, 2008, SOC PERSONAL PSYCHOL, V2, P302, DOI 10.1111/j.1751-9004.2007.00054.x; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; KIERNAN RJ, 1987, ANN INTERN MED, V107, P481, DOI 10.7326/0003-4819-107-4-481; Kishi Y, 2001, PSYCHOSOMATICS, V42, P382, DOI 10.1176/appi.psy.42.5.382; Koponen S, 2006, PSYCHIAT RES-NEUROIM, V146, P263, DOI 10.1016/j.pscychresns.2005.05.015; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; LEWINSOHN PM, 1973, J CONSULT CLIN PSYCH, V41, P261, DOI 10.1037/h0035142; Mackelprang JL, 2014, AM J PUBLIC HEALTH, V104, pE100, DOI 10.2105/AJPH.2013.301794; Malec JF, 2010, ARCH PHYS MED REHAB, V91, P1087, DOI 10.1016/j.apmr.2010.04.002; Muthen B, 2000, ALCOHOL CLIN EXP RES, V24, P882, DOI 10.1111/j.1530-0277.2000.tb02070.x; Muthen B, 2006, INFANT CHILD DEV, V15, P623, DOI 10.1002/icd.482; Muthen L. K., 2012, MPLUS USERS GUIDE, V7th; Nagin DS, 2010, ANNU REV CLIN PSYCHO, V6, P109, DOI 10.1146/annurev.clinpsy.121208.131413; Novack TA, 2009, J NEUROTRAUM, V26, P1921, DOI 10.1089/neu.2009.0895; Nylund KL, 2007, STRUCT EQU MODELING, V14, P535, DOI 10.1080/10705510701575396; Rapoport MJ, 2006, J AFFECT DISORDERS, V92, P273, DOI 10.1016/j.jad.2005.05.022; RIMEL RW, 1979, JACEP-J AM COLL EMER, V8, P64, DOI 10.1016/S0361-1124(79)80039-8; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; SCHWARZ G, 1978, ANN STAT, V6, P461, DOI 10.1214/aos/1176344136; Sigurdardottir S, 2014, BRAIN INJURY, V28, P1542, DOI 10.3109/02699052.2014.934285; Sullivan-Singh SJ, 2014, ARCH PHYS MED REHAB, V95, P1100, DOI 10.1016/j.apmr.2014.02.001; Tsaousides T, 2011, J HEAD TRAUMA REHAB, V26, P265, DOI 10.1097/HTR.0b013e3182225271; van Leeuwen CM, 2011, ARCH PHYS MED REHAB, V92, P207, DOI 10.1016/j.apmr.2010.10.011; van Loo HM, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-156; Vermunt JK, 2010, POLIT ANAL, V18, P450, DOI 10.1093/pan/mpq025; Wagner AK, 2010, EUR J PHYS REHAB MED, V46, P549; Whelan-Goodinson R, 2010, J HEAD TRAUMA REHAB, V25, P320, DOI 10.1097/HTR.0b013e3181c8f8e7; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; Young AS, 2001, ARCH GEN PSYCHIAT, V58, P55, DOI 10.1001/archpsyc.58.1.55	71	34	34	0	48	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC 1	2016	33	23					2115	2124		10.1089/neu.2015.4349			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	ED2JG	WOS:000388669800007	26979826	Green Published			2021-06-18	
J	Woods, AJ; Porges, EC; Bryant, VE; Seider, T; Gongvatana, A; Kahler, CW; de la Monte, S; Monti, PM; Cohen, RA				Woods, Adam J.; Porges, Eric C.; Bryant, Vaughn E.; Seider, Talia; Gongvatana, Assawin; Kahler, Christopher W.; de la Monte, Suzanne; Monti, Peter M.; Cohen, Ronald A.			Current Heavy Alcohol Consumption is Associated with Greater Cognitive Impairment in Older Adults	ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH			English	Article						Alcohol Consumption; Alcohol Dependence; Cognitive Aging; EtOH; Cognitive Impairment	TRAUMATIC BRAIN-INJURY; DEMENTIA; DRINKING; ETHANOL; ABUSE; AGE; ADOLESCENT; DISORDERS; DEFICITS; OUTCOMES	BackgroundThe acute consumption of excessive quantities of alcohol causes well-recognized neurophysiological and cognitive alterations. As people reach advanced age, they are more prone to cognitive decline. To date, the interaction of current heavy alcohol (ethanol [EtOH]) consumption and aging remains unclear. This study tested the hypothesis that negative consequences of current heavy alcohol consumption on neurocognitive function are worse with advanced age. Further, we evaluated the relations between lifetime history of alcohol dependence and neurocognitive function MethodsSixty-six participants underwent a comprehensive neurocognitive battery. Current heavy EtOH drinkers were classified using National Institute on Alcohol Abuse and Alcoholism criteria (EtOH heavy, n=21) based on the Timeline follow-back and a structured clinical interview and compared to nondrinkers, and moderate drinkers (EtOH low, n=45). Of the total population, 53.3% had a lifetime history of alcohol dependence. Neurocognitive data were grouped and analyzed relative to global and domain scores assessing: global cognitive function, attention/executive function, learning, memory, motor function, verbal function, and speed of processing. ResultsHeavy current EtOH consumption in older adults was associated with poorer global cognitive function, learning, memory, and motor function (ps<0.05). Furthermore, lifetime history of alcohol dependence was associated with poorer function in the same neurocognitive domains, in addition to the attention/executive domain, irrespective of age (ps<0.05). ConclusionsThese data suggest that while heavy current alcohol consumption is associated with significant impairment in a number of neurocognitive domains, history of alcohol dependence, even in the absence of heavy current alcohol use, is associated with lasting negative consequences for neurocognitive function.	[Woods, Adam J.; Porges, Eric C.; Bryant, Vaughn E.; Seider, Talia; Cohen, Ronald A.] Univ Florida, Dept Aging & Geriatr Res, Inst Aging, Ctr Cognit Aging & Memory CAM, Gainesville, FL 32610 USA; [Gongvatana, Assawin] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA; [Kahler, Christopher W.; Monti, Peter M.] Brown Univ, Ctr Alcohol & Addict Studies, Sch Publ Hlth, Dept Behav & Social Sci, Providence, RI 02912 USA; Brown Univ, ARCH, Sch Publ Hlth, Providence, RI 02912 USA; [de la Monte, Suzanne] Brown Univ, Dept Pathol & Lab Med, Dept Neurosurg, Providence, RI 02912 USA	Woods, AJ (corresponding author), Univ Florida, Cognit Aging & Memory Clin Translat Res Program, Inst Aging, Dept Aging & Geriatr Res, 2004 Mowry Rd, Gainesville, FL 32610 USA.	ajwoods@ufl.edu	de la monte, suzanne/L-7670-2019	de la monte, suzanne/0000-0001-5886-2306; Gongvatana, Assawin/0000-0001-6102-6384; Woods, Adam/0000-0002-0786-0236	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [KL2TR001429] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG028740] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [P01AA019072, F31AA024060] Funding Source: NIH RePORTER; NCATS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [KL2 TR001429] Funding Source: Medline; NIAAA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [P01 AA019072, F31 AA024060] Funding Source: Medline; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30 AG028740] Funding Source: Medline		Alexander S, 2004, J NEUROTRAUM, V21, P575, DOI 10.1089/089771504774129900; Benedict R., 1997, BRIEF VISUOSPATIAL M; Benedict RHB, 1998, CLIN NEUROPSYCHOL, V12, P43, DOI 10.1076/clin.12.1.43.1726; Benedict RHB., 1991, HOPKINS VERBAL LEARN; Benton A., 1994, MULTILINGUAL APHASIA; Carey CL, 2004, CLIN NEUROPSYCHOL, V18, P234, DOI 10.1080/13854040490501448; Carey CL, 2004, J CLIN EXP NEUROPSYC, V26, P307, DOI 10.1080/13803390490510031; Downer B, 2015, AM J ALZHEIMERS DIS, V30, P364, DOI 10.1177/1533317514549411; DRAKE AI, 1995, J STUD ALCOHOL, V56, P104, DOI 10.15288/jsa.1995.56.104; Draper B, 2011, AUST NZ J PSYCHIAT, V45, P985, DOI 10.3109/00048674.2011.610297; Durazzo TC, 2013, ALCOHOL CLIN EXP RES, V37, P1794, DOI 10.1111/acer.12140; Fals-Stewart W, 2000, J CONSULT CLIN PSYCH, V68, P134, DOI 10.1037/0022-006X.68.1.134; Friend KB, 2005, ADDICT BEHAV, V30, P193, DOI 10.1016/j.addbeh.2004.04.020; GOLDBERG RJ, 1994, CIRCULATION, V89, P651, DOI 10.1161/01.CIR.89.2.651; Golden C., 1978, STROOP COLOR WORD TE; Green A, 2010, ALCOHOL CLIN EXP RES, V34, P443, DOI 10.1111/j.1530-0277.2009.01108.x; Haorah J, 2005, J LEUKOCYTE BIOL, V78, P1223, DOI 10.1189/jlb.0605340; Houston RJ, 2014, ADDICT BEHAV, V39, P345, DOI 10.1016/j.addbeh.2013.09.032; Kellogg SH, 2003, DRUG ALCOHOL DEPEN, V69, P137, DOI 10.1016/S0376-8716(02)00308-3; Kist N, 2014, INT PSYCHOGERIATR, V26, P1863, DOI 10.1017/S1041610214000878; Klove H., 1963, GROOVED PEGBOARD; Marksteiner J, 2002, Wien Med Wochenschr, V152, P98, DOI 10.1046/j.1563-258x.2002.01132.x; Meyer JS, 1998, EUR NEUROL, V39, P7, DOI 10.1159/000052064; MOLINA JA, 1994, ACTA NEUROL SCAND, V89, P384; O'Dell KM, 2012, J HEAD TRAUMA REHAB, V27, P361, DOI 10.1097/HTR.0b013e318266735c; Panza F, 2009, J ALZHEIMERS DIS, V17, P7, DOI 10.3233/JAD-2009-1009; Reitan R. M, 1992, TRAIL MAKING TEST; RIEGE WH, 1981, ALCOHOL CLIN EXP RES, V5, P378, DOI 10.1111/j.1530-0277.1981.tb04920.x; Schuckit MA, 2009, LANCET, V373, P492, DOI 10.1016/S0140-6736(09)60009-X; Shih CL, 2001, ALCOHOL CLIN EXP RES, V25, P612, DOI 10.1097/00000374-200104000-00020; Snow WM, 2009, AGE AGEING, V38, P206, DOI 10.1093/ageing/afn284; Solfrizzi V, 2007, NEUROLOGY, V68, P1790, DOI 10.1212/01.wnl.0000262035.87304.89; SOLOMON DA, 1992, NEUROPSYCHOL REV, V3, P249, DOI 10.1007/BF01109050; SPIRDUSO WW, 1989, PSYCHOPHARMACOLOGY, V97, P413, DOI 10.1007/BF00439461; Squeglia LM, 2014, ALCOHOL CLIN EXP RES, V38, P2509, DOI 10.1111/acer.12531; Squeglia LM, 2009, PSYCHOL ADDICT BEHAV, V23, P715, DOI 10.1037/a0016516; Sullivan EV, 2010, ALCOHOL RES HEALTH, V33, P127; Sullivan EV, 2002, NEUROPSYCHOLOGY, V16, P74, DOI 10.1037//0894-4105.16.1.74; Tyas SL, 2001, ALCOHOL RES HEALTH, V25, P299; Vinod KY, 2005, LIFE SCI, V77, P1569, DOI 10.1016/j.lfs.2005.05.041; Webb B, 1997, ALCOHOL CLIN EXP RES, V21, P1643, DOI 10.1111/j.1530-0277.1997.tb04502.x; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wilde EA, 2004, J NEUROTRAUM, V21, P137, DOI 10.1089/089771504322778604; Wilhelm CJ, 2015, BRAIN RES, V1601, P102, DOI 10.1016/j.brainres.2015.01.002; Woods AJ, 2013, J NUTR HEALTH AGING, V17, P741, DOI 10.1007/s12603-013-0398-8; Woods AJ, 2012, NEUROCASE, V18, P115, DOI 10.1080/13554794.2011.568498; Woods AJ, 2011, PM&R, V3, P426, DOI 10.1016/j.pmrj.2011.02.018	47	34	34	0	27	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0145-6008	1530-0277		ALCOHOL CLIN EXP RES	Alcoholism (NY)	NOV	2016	40	11					2435	2444		10.1111/acer.13211			10	Substance Abuse	Substance Abuse	EA8VT	WOS:000386918400023	27658235	Green Accepted			2021-06-18	
J	Bernard, CO; Ponsford, JA; McKinlay, A; McKenzie, D; Krieser, D				Bernard, Coco O.; Ponsford, Jennie A.; McKinlay, Audrey; McKenzie, Dean; Krieser, David			Predictors of Post-concussive Symptoms in Young Children: Injury versus Non-injury Related Factors	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Mild traumatic brain injury; Concussion; Post concussive symptoms; Child; Predictors; Child; Pediatric; Behavior	TRAUMATIC-BRAIN-INJURY; MILD HEAD-INJURY; POSTCONCUSSIVE SYMPTOMS; PSYCHOSOCIAL OUTCOMES; EMERGENCY-DEPARTMENT; PEDIATRIC CONCUSSION; ADOLESCENTS; CHILDHOOD; RECOVERY; IDENTIFICATION	Objectives: A notable minority of children will experience persistent post-concussive symptoms (PCS) following mild traumatic brain injury (mTBI), likely maintained by a combination of injury and non-injury related factors. Adopting a prospective longitudinal design, this study aimed to investigate the relative influence of child, family, and injury factors on both acute and persistent PCS in young children. Methods: Participants were 101 children aged 2-12 who presented to an Emergency Department, with either mTBI or minor bodily trauma (control). PCS were assessed at time of injury, 1 week, and 1, 2, and 3 months post-injury. Predictors included injury and demographic variables, premorbid child behavior, sleep hygiene, and parental stress. Random effects ordinal logistic regression models were used to analyze the relative influence of these predictors on PCS at early (acute - 1 week) and late (1-3 month) post-injury phases. Results: Presence of mTBI was a stronger predictor of PCS in the early [odds ratio (OR)=18.2] compared with late (OR=7.3) post-injury phase. Older age at injury and pre-existing learning difficulties were significant predictors of PCS beyond 1 month post-injury. Family factors, including higher levels of parental stress, higher socio-economic status, and being of Anglo-Saxon descent, consistently predicted greater PCS. Conclusions: Injury characteristics were significantly associated with PCS for 3 months following mTBI but the association weakened over time. On the other hand, pre-existing child and family factors displayed an increasingly strong association with PCS over time. Follow-up for these at-risk children which also addresses family stress may minimize longer-term complications.	[Bernard, Coco O.; Ponsford, Jennie A.] Monash Univ, Sch Psychol Sci, Melbourne, Vic, Australia; [McKinlay, Audrey] Univ Melbourne, Melbourne Sch Psychol Sci, Melbourne, Vic 3010, Australia; [McKenzie, Dean] Epworth HealthCare, Melbourne, Vic, Australia; [McKenzie, Dean] Sch Publ Hlth & Prevent Med, Melbourne, Vic, Australia; [Krieser, David] Sunshine Hosp, Emergency Dept, Melbourne, Vic, Australia	Bernard, CO (corresponding author), Monash Univ, Sch Psychol Sci, Clin Neuropsychol, Clayton, Vic 3800, Australia.	coco.bernard@monash.edu	Krieser, David/AAA-1370-2021	Krieser, David/0000-0002-7173-6993; McKinlay, Audrey/0000-0001-9846-8514	Monash University Doctoral Research Fund; Jack Brockoff Foundation	Coco O. Bernard and Jennie A. Ponsford, School of Psychological Sciences, Monash University, Melbourne, Australia; Audrey McKinlay, Melbourne School of Psychological Sciences, The University of Melbourne, Melbourne, Australia; Dean McKenzie, Epworth HealthCare and School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia; David Krieser, Sunshine Hospital Emergency Department, Melbourne, Australia. The authors have indicated that they have no financial relationships relevant to this article, potential conflicts of interest, to disclose. Research funding was awarded to Professor Jennie A. Ponsford and Dr. Audrey McKinlay by the Jack Brockoff Foundation, and to Coco O. Bernard from the Monash University Doctoral Research Fund. This research was conducted as part of Coco O. Bernard's Doctoral Thesis (Doctorate of Clinical Neuropsychology).	Abidin R., 1983, PARENTAL STRESS INDE; Anderson V, 2001, J CLIN EXP NEUROPSYC, V23, P705, DOI 10.1076/jcen.23.6.705.1015; Anderson V., 1997, J INT NEUROPSYCH SOC, V3, P553; Anderson V, 2012, PEDIATRICS, V129, pE254, DOI 10.1542/peds.2011-0311; Araujo GC, 2014, CLIN NEUROPSYCHOL, V28, P786, DOI 10.1080/13854046.2014.896415; Ayr LK, 2009, J INT NEUROPSYCH SOC, V15, P19, DOI 10.1017/S1355617708090188; Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Babikian T, 2013, J INT NEUROPSYCH SOC, V19, P145, DOI 10.1017/S135561771200104X; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Bracken BA, 2004, CLIN ASSESSMENT BEHA; Brooks BL, 2014, ARCH CLIN NEUROPSYCH, V29, P186, DOI 10.1093/arclin/act083; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Chan LG, 2015, J HEAD TRAUMA REHAB, V30, pE67, DOI 10.1097/HTR.0000000000000119; Connery AK, 2016, CLIN NEUROPSYCHOL, V30, P579, DOI 10.1080/13854046.2016.1177596; CRONBACH LJ, 1951, PSYCHOMETRIKA, V16, P297; Crowe LM, 2012, J PEDIATR PSYCHOL, V37, P745, DOI 10.1093/jpepsy/jss070; Gagnon I, 2005, J HEAD TRAUMA REHAB, V20, P436, DOI 10.1097/00001199-200509000-00005; Ganesalingam K, 2008, J PEDIATR PSYCHOL, V33, P621, DOI 10.1093/jpepsy/jsm133; GIBBONS RD, 1993, ARCH GEN PSYCHIAT, V50, P739; Gioia GA, 2009, BRIT J SPORT MED, V43, pI13, DOI 10.1136/bjsm.2009.058255; Gioia GA, 2008, J HEAD TRAUMA REHAB, V23, P230, DOI 10.1097/01.HTR.0000327255.38881.ca; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Goodlin-Jones BL, 2008, J DEV BEHAV PEDIATR, V29, P82, DOI 10.1097/DBP.0b013e318163c39a; Gronwall D, 1997, J Int Neuropsychol Soc, V3, P592; Grubenhoff JA, 2016, J PEDIATR-US, V174, P27, DOI 10.1016/j.jpeds.2016.03.027; Guo S., 2015, PROPENSITY SCORE ANA, V2nd; Hajek CA, 2011, CHILD NEUROPSYCHOL, V17, P17, DOI 10.1080/09297049.2010.495058; Hosmer DW., 2013, APPL LOGISTIC REGRES, V3rd ed.; Keenan HT, 2006, PEDIATRICS, V117, P1291, DOI 10.1542/peds.2005-1883; Kirkwood MW, 2008, CLIN NEUROPSYCHOL, V22, P769, DOI 10.1080/13854040701543700; Kirkwood MW, 2014, PEDIATRICS, V133, P643, DOI 10.1542/peds.2013-3195; Koepsell TD, 2011, PEDIATRICS, V128, P946, DOI 10.1542/peds.2010-2259; Kolb B, 1999, CAN J EXP PSYCHOL, V53, P62, DOI 10.1037/h0087300; Kolb B, 2012, DEV PSYCHOBIOL, V54, P311, DOI 10.1002/dev.20515; Kraus J, 2009, J HEAD TRAUMA REHAB, V24, P344, DOI 10.1097/HTR.0b013e3181ae35fd; Lloyd J, 2015, BRAIN INJURY, V29, P539, DOI 10.3109/02699052.2014.1002003; MacFarlane MP, 2015, BRAIN INJURY, V29, P139, DOI 10.3109/02699052.2014.965208; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; McKinlay A, 2014, J HEAD TRAUMA REHAB, V29, P233, DOI 10.1097/HTR.0b013e3182a2dd7f; McNally KA, 2013, NEUROPSYCHOLOGY, V27, P1, DOI 10.1037/a0031370; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; Nelson LD, 2016, NEUROLOGY, V86, P1856, DOI 10.1212/WNL.0000000000002679; ODDY M, 1993, NEUROPSYCHOL REHABIL, V3, P301, DOI 10.1080/09602019308401444; Olsson KA, 2013, BRAIN INJURY, V27, P145, DOI 10.3109/02699052.2012.729286; Osberg JS, 1996, PEDIATRICS, V98, P890; Owens JA, 2000, SLEEP, V23, P1043; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Prigatano GP, 2007, BRAIN INJURY, V21, P721, DOI 10.1080/02699050701481605; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; Sady MD, 2014, ARCH CLIN NEUROPSYCH, V29, P348, DOI 10.1093/arclin/acu014; Saltapidas H, 2007, J HEAD TRAUMA REHAB, V22, P132, DOI 10.1097/01.HTR.0000265101.75177.8d; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; Scott C, 2015, NEUROPSYCHOLOGY, V29, P501, DOI 10.1037/neu0000074; Shores EA, 2008, J NEUROL NEUROSUR PS, V79, P1100, DOI 10.1136/jnnp.2007.132571; Stavinoha PL, 2012, PEDIATRIC AND ADOLESCENT CONCUSSION: DIAGNOSIS, MANAGEMENT AND OUTCOMES, P135, DOI 10.1007/978-0-387-89545-1_11; Tabachnick B.G., 2013, USING MULTIVARIATE S; Taylor H., 1995, RECOVERY TRAUMATIC B, P188; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; Theadom A, 2015, SLEEP MED, V16, P926, DOI 10.1016/j.sleep.2015.04.013; Melo JRT, 2010, ARQ NEURO-PSIQUIAT, V68, P381, DOI 10.1590/S0004-282X2010000300010; Wade SL, 2006, J PEDIATR PSYCHOL, V31, P1072, DOI 10.1093/jpepsy/jsj077; Wade SL, 2011, DEV PSYCHOL, V47, P119, DOI 10.1037/a0021028; Whelan-Goodinson R, 2010, J HEAD TRAUMA REHAB, V25, P320, DOI 10.1097/HTR.0b013e3181c8f8e7; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Winkler R, 2015, J HEAD TRAUMA REHAB, V30, P324, DOI 10.1097/HTR.0000000000000114; Woodrome SE, 2011, J INT NEUROPSYCH SOC, V17, P317, DOI 10.1017/S1355617710001700; Yeates KO, 2012, INT J DEV NEUROSCI, V30, P231, DOI 10.1016/j.ijdevneu.2011.05.008; Yeates KO, 2010, NEUROPSYCHOLOGY, V24, P345, DOI 10.1037/a0018387; Yeates KO, 2002, J PEDIATR PSYCHOL, V27, P393, DOI 10.1093/jpepsy/27.4.393; Yeates KO, 2001, J PEDIATR PSYCHOL, V26, P79, DOI 10.1093/jpepsy/26.2.79; Zemek R, 2016, JAMA-J AM MED ASSOC, V315, P1014, DOI 10.1001/jama.2016.1203; Zemek RL, 2013, JAMA PEDIATR, V167, P259, DOI 10.1001/2013.jamapediatrics.216	79	34	34	0	18	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	SEP	2016	22	8					793	803		10.1017/S1355617716000709			11	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	DX4BU	WOS:000384324800001	27619107				2021-06-18	
J	Di Battista, AP; Rizoli, SB; Lejnieks, B; Min, A; Shiu, MY; Peng, HT; Baker, AJ; Hutchison, MG; Churchill, N; Inaba, K; Nascimento, BB; Manoel, ALD; Beckett, A; Rhind, SG				Di Battista, Alex P.; Rizoli, Sandro B.; Lejnieks, Brandon; Min, Arimie; Shiu, Maria Y.; Peng, Henry T.; Baker, Andrew J.; Hutchison, Michael G.; Churchill, Nathan; Inaba, Kenji; Nascimento, Bartolomeu B.; Manoel, Airton Leonardo de Oliveira; Beckett, Andrew; Rhind, Shawn G.			SYMPATHOADRENAL ACTIVATION IS ASSOCIATED WITH ACUTE TRAUMATIC COAGULOPATHY AND ENDOTHELIOPATHY IN ISOLATED BRAIN INJURY	SHOCK			English	Article						Catecholamines; D-dimer; hemostasis; norepinephrine; syndecan-1; thrombin-activatable fibrinolysis inhibitor; thrombomodulin; tissue factor pathway inhibitor; tissue plasminogen activator; vascular adhesion protein-1	DISSEMINATED INTRAVASCULAR COAGULATION; PARTIAL THROMBOPLASTIN TIME; HEAD-INJURY; GLYCOCALYX DEGRADATION; HYPERCOAGULABLE STATE; PROTHROMBIN TIME; SEVERE SEPSIS; IN-VIVO; DAMAGE; INFLAMMATION	Background: Acute coagulopathy after traumatic brain injury (TBI) involves a complex multifactorial hemostatic response that is poorly characterized. Objectives: To examine early posttraumatic alterations in coagulofibrinolytic, endothelial, and inflammatory blood biomarkers in relation to sympathetic nervous system (SNS) activation and 6-month patient outcomes, using multivariate partial least-squares (PLS) analysis. Patients and Methods: A multicenter observational study of 159 adult isolated TBI patients admitted to the emergency department at an urban level I trauma center, was performed. Plasma concentrations of 6 coagulofibrinolytic, 10 vascular endothelial, 19 inflammatory, and 2 catecholamine biomarkers were measured by immunoassay on admission and 24 h postinjury. Neurological outcome at 6 months was assessed using the Extended Glasgow Outcome Scale. PLS-discriminant analysis was used to identify salient biomarker contributions to unfavorable outcome, whereas PLS regression analysis was used to evaluate the covariance between SNS correlates (catecholamines) and biomarkers of coagulopathy, endotheliopathy, and inflammation. Results: Biomarker profiles in patients with an unfavorable outcome displayed procoagulation, hyperfibrinolysis, glycocalyx and endothelial damage, vasculature activation, and inflammation. A strong covariant relationship was evident between catecholamines and biomarkers of coagulopathy, endotheliopathy, and inflammation at both admission and 24 h postinjury. Conclusions: Biomarkers of coagulopathy and endotheliopathy are associated with poor outcome after TBI. Catecholamine levels were highly correlated with endotheliopathy and coagulopathy markers within the first 24 h after injury. Further research is warranted to characterize the pathogenic role of SNS-mediated hemostatic alterations in isolated TBI.	[Di Battista, Alex P.; Shiu, Maria Y.; Peng, Henry T.; Rhind, Shawn G.] Toronto Res Ctr, Def Res & Dev Canada, Toronto, ON, Canada; [Di Battista, Alex P.; Rizoli, Sandro B.; Baker, Andrew J.] Univ Toronto, Inst Med Sci, Toronto, ON, Canada; [Rizoli, Sandro B.; Lejnieks, Brandon; Min, Arimie; Baker, Andrew J.; Manoel, Airton Leonardo de Oliveira] St Michaels Hosp, Li Ka Shing Knowledge Inst, Keenan Res Ctr, Toronto, ON, Canada; [Rizoli, Sandro B.; Baker, Andrew J.] Univ Toronto, St Michaels Hosp, Dept Crit Care, Toronto, ON, Canada; [Rizoli, Sandro B.; Baker, Andrew J.] Univ Toronto, St Michaels Hosp, Dept Anesthesia & Surg, Toronto, ON, Canada; [Hutchison, Michael G.; Rhind, Shawn G.] Univ Toronto, Fac Kinesiol & Phys Educ, Toronto, ON, Canada; [Hutchison, Michael G.; Churchill, Nathan] St Michaels Hosp, Keenan Res Ctr Biomed Sci, Toronto, ON, Canada; [Inaba, Kenji] Univ Southern Calif, Div Trauma & Crit Care, Los Angeles, CA USA; [Inaba, Kenji] LA Cty & USC Med Ctr, Los Angeles, CA USA; [Nascimento, Bartolomeu B.] Univ Toronto, Dept Surg, Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada; [Beckett, Andrew] 1 Canadian Field Hosp, Canadian Forces Hlth Serv, Petawawa, ON, Canada; [Beckett, Andrew] McGill Univ, Ctr Hlth, Trauma Program, Montreal, PQ, Canada	Di Battista, AP (corresponding author), Toronto Res Ctr, Def Res & Dev Canada, Toronto, ON, Canada.	dibattista.alex@gmail.com	de Oliveira Manoel, Airton Leonardo/C-4724-2018; INABA, KENJI/AAC-8532-2020	de Oliveira Manoel, Airton Leonardo/0000-0002-9593-1013; Rhind, Shawn/0000-0003-2300-0620; Di Battista, Alex/0000-0002-3325-6833			Abdelmalik PA, 2016, NEUROCRIT CARE, V24, P361, DOI 10.1007/s12028-015-0191-0; Bishop CM, 2006, INFORM SCI STAT, V1, P738; Brown JB, 2012, J TRAUMA ACUTE CARE, V73, P1395, DOI 10.1097/TA.0b013e31825b9f05; Canonico B, 2010, CYTOM PART B-CLIN CY, V78B, P267, DOI 10.1002/cyto.b.20510; Cap A, 2015, ANAESTHESIA, V70, DOI 10.1111/anae.12914; Cap AP, 2011, J TRAUMA, V71, pS78, DOI 10.1097/TA.0b013e3182218cd8; Chignalia AZ, 2016, SHOCK, V45, P338, DOI 10.1097/SHK.0000000000000513; Choudhry MA, 2007, INJURY, V38, P1382, DOI 10.1016/j.injury.2007.09.027; Conway EM, 2012, SEMIN IMMUNOPATHOL, V34, P107, DOI 10.1007/s00281-011-0282-8; Davenport RA, 2016, CURR OPIN ANESTHESIO, V29, P212, DOI 10.1097/ACO.0000000000000295; Manoel ALD, 2015, NEUROCRIT CARE, V22, P34, DOI 10.1007/s12028-014-0026-4; Di Battista AP, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0500-3; Di Battista AP, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00110; Dobson GP, 2015, J TRAUMA ACUTE CARE, V79, P301, DOI 10.1097/TA.0000000000000729; Epstein DS, 2014, INJURY, V45, P819, DOI 10.1016/j.injury.2014.01.011; Flierl MA, 2008, MOL MED, V14, P195, DOI 10.2119/2007-00105.Flierl; Gando S, 2013, J THROMB HAEMOST, V11, P826, DOI 10.1111/jth.12190; Gando S, 1999, J TRAUMA, V46, P1070, DOI 10.1097/00005373-199906000-00018; Garber BG, 2014, BMC PSYCHIATRY, V14, DOI 10.1186/s12888-014-0325-5; Genet GF, 2013, J NEUROTRAUM, V30, P301, DOI 10.1089/neu.2012.2612; GOODNIGHT SH, 1974, NEW ENGL J MED, V290, P1043, DOI 10.1056/NEJM197405092901903; Armitage EG, 2015, ELECTROPHORESIS, V36, P3050, DOI 10.1002/elps.201500352; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; Hemker HC, 2004, CURR OPIN HEMATOL, V11, P170, DOI 10.1097/01.moh.0000130314.33410.d7; ISHII H, 1991, THROMB HAEMOSTASIS, V65, P618; Johansson PI, 2010, MED HYPOTHESES, V75, P564, DOI 10.1016/j.mehy.2010.07.031; Johansson PI, 2014, J CRIT CARE, V29, P327, DOI 10.1016/j.jcrc.2013.10.028; Johansson PI, 2011, CRIT CARE, V15, DOI 10.1186/cc10553; Johansson PI, 2011, ANN SURG, V254, P194, DOI 10.1097/SLA.0b013e318226113d; Johansson PI, 2012, J TRAUMA ACUTE CARE, V72, P428, DOI 10.1097/TA.0b013e31821e0f93; Joseph B, 2014, J TRAUMA ACUTE CARE, V76, P121, DOI 10.1097/TA.0b013e3182a9cc95; Kunio NR, 2012, AM J SURG, V203, P584, DOI 10.1016/j.amjsurg.2011.12.011; Levi M, 2010, CRIT CARE MED, V38, pS26, DOI 10.1097/CCM.0b013e3181c98d21; Maegele M, 2013, TRANSFUSION, V53, p28S, DOI 10.1111/trf.12033; Nekludov M, 2007, J NEUROTRAUM, V24, P174, DOI 10.1089/neu.2006.0173; Nieuwdorp M, 2006, DIABETES, V55, P480, DOI 10.2337/diabetes.55.02.06.db05-1103; Ostrowski SR, 2015, J CRIT CARE, V30, P90, DOI 10.1016/j.jcrc.2014.10.006; Ostrowski SR, 2013, J CRIT CARE, V28, P586, DOI 10.1016/j.jcrc.2013.04.010; Ostrowski SR, 2013, CRIT CARE, V17, DOI 10.1186/cc12532; Ostrowski SR, 2012, J TRAUMA ACUTE CARE, V73, P60, DOI 10.1097/TA.0b013e31825b5c10; Ostrowski SR, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0918-5; Pannell D, 2011, J TRAUMA, V71, pS401, DOI 10.1097/TA.0b013e318232e53f; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Park MS, 2009, J TRAUMA, V67, P266, DOI 10.1097/TA.0b013e3181ae6f1c; Reid MW, 2015, MOL CELL NEUROSCI, V66, P123, DOI 10.1016/j.mcn.2015.03.014; Schafer AI, 2007, CARDIOVASCULAR MED, VIII, P2423; Schreiber M, 2009, J TRAUMA, V67, P275; Schrieber M, 2007, J TRAUMA, V63, P1261; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; Tien Homer, 2015, Can J Surg, V58, pS91; Tien HCN, 2010, AM J PREV MED, V38, P331, DOI 10.1016/j.amepre.2009.12.012; van der Poll T, 2011, CURR OPIN INFECT DIS, V24, P273, DOI 10.1097/QCO.0b013e328344c078; Versteeg HH, 2013, PHYSIOL REV, V93, P327, DOI 10.1152/physrev.00016.2011; von Kanel R, 2000, EUR J HAEMATOL, V65, P357, DOI 10.1034/j.1600-0609.2000.065006357.x; Wafaisade A, 2010, NEUROCRIT CARE, V12, P211, DOI 10.1007/s12028-009-9281-1; White NJ, 2015, J THROMB HAEMOST, V13, P978, DOI 10.1111/jth.12919; Wold S, 2001, CHEMOMETR INTELL LAB, V58, P109, DOI 10.1016/S0169-7439(01)00155-1; Xu L, 2015, BLOOD COAGUL FIBRIN, V26, P152, DOI 10.1097/MBC.0000000000000211; Yokota H, 2002, J NEUROTRAUM, V19, P1007, DOI 10.1089/089771502760341929	60	34	34	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1073-2322	1540-0514		SHOCK	Shock	SEP	2016	46	3		1			96	103		10.1097/SHK.0000000000000642			8	Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease	General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology	DX3HG	WOS:000384263600014	27206278	Green Published			2021-06-18	
J	Titus, DJ; Wilson, NM; Freund, JE; Carballosa, MM; Sikah, KE; Furones, C; Dietrich, WD; Gurney, ME; Atkins, CM				Titus, David J.; Wilson, Nicole M.; Freund, Julie E.; Carballosa, Melissa M.; Sikah, Kevin E.; Furones, Concepcion; Dietrich, W. Dalton; Gurney, Mark E.; Atkins, Coleen M.			Chronic Cognitive Dysfunction after Traumatic Brain Injury Is Improved with a Phosphodiesterase 4B Inhibitor	JOURNAL OF NEUROSCIENCE			English	Article						cAMP; cognition; learning; long-term potentiation; phosphodiesterase; traumatic brain injury	NECROSIS-FACTOR-ALPHA; WORKING-MEMORY DYSFUNCTION; FLUID PERCUSSION INJURY; LONG-TERM POTENTIATION; A-META-ANALYSIS; RAT-BRAIN; ALZHEIMERS-DISEASE; PDE4 INHIBITORS; MICE DEFICIENT; MESSENGER-RNAS	Learning and memory impairments are common in traumatic brain injury (TBI) survivors. However, there are no effective treatments to improve TBI-induced learning and memory impairments. TBI results in decreased cAMP signaling and reduced cAMP-response-element binding protein (CREB) activation, a critical pathway involved in learning and memory. TBI also acutely upregulates phosphodiesterase 4B2 (PDE4B2), which terminates cAMP signaling by hydrolyzing cAMP. We hypothesized that a subtype-selective PDE4B inhibitor could reverse the learning deficits induced by TBI. To test this hypothesis, adult male Sprague-Dawley rats received sham surgery or moderate parasagittal fluid-percussion brain injury. At 3 months postsurgery, animals were administered a selective PDE4B inhibitor or vehicle before cue and contextual fear conditioning, water maze training and a spatial working memory task. Treatment with the PDE4B inhibitor significantly reversed the TBI-induced deficits in cue and contextual fear conditioning and water maze retention. To further understand the underlying mechanisms of these memory impairments, we examined hippocampal long-term potentiation (LTP). TBI resulted in a significant reduction in basal synaptic transmission and impaired expression of LTP. Treatment with the PDE4B inhibitor significantly reduced the deficits in basal synaptic transmission and rescued LTP expression. The PDE4B inhibitor reduced tumor necrosis factor-alpha levels and increased phosphorylated CREB levels after TBI, suggesting that this drug inhibited molecular pathways in the brain known to be regulated by PDE4B. These results suggest that a subtype-selective PDE4B inhibitor is a potential therapeutic to reverse chronic learning and memory dysfunction and deficits in hippocampal synaptic plasticity following TBI.	[Titus, David J.; Wilson, Nicole M.; Freund, Julie E.; Carballosa, Melissa M.; Sikah, Kevin E.; Furones, Concepcion; Dietrich, W. Dalton; Atkins, Coleen M.] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami Project Cure Paralysis, Miami, FL 33136 USA; [Gurney, Mark E.] Tetra Discovery Partners, Grand Rapids, MI 49503 USA	Atkins, CM (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol Surg, 1095 Northwest 14 Terrace, Miami, FL 33136 USA.	catkins@med.miami.edu			National Institutes of Health/National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS069721, R01 NS056072, F31 NS089351]; Miami Project to Cure Paralysis; National Institutes of Health/National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R44 MH091791]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R44MH091791] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS069721, R25NS083064, R41NS090666, F31NS089351, R01NS056072] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health/National Institute of Neurological Disorders and Stroke R01 NS069721 to C.M.A., R01 NS056072 to C.M.A. and W.D.D., F31 NS089351 to N.M.W., and The Miami Project to Cure Paralysis. M.E.G. acknowledges support by the National Institutes of Health/National Institute of Mental Health R44 MH091791. We thank Jonathan Mendoza, Rosmery Santos, and David Sequeira for technical support, and Dr Xuesheng Mo for synthesis of A33.	Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053376; Ahmed T, 2005, BRAIN RES, V1041, P212, DOI 10.1016/j.brainres.2005.02.023; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Atkins CM, 2012, J NEUROSCI RES, V90, P1861, DOI 10.1002/jnr.23069; Atkins CM, 2007, EXP NEUROL, V208, P145, DOI 10.1016/j.expneurol.2007.08.011; Atkins CM, 2013, NEUROSCI LETT, V532, P1, DOI 10.1016/j.neulet.2012.10.019; Atkins CM, 2010, EUR J NEUROSCI, V32, P1912, DOI 10.1111/j.1460-9568.2010.07467.x; Atkins CM, 2009, NEUROSCI LETT, V459, P52, DOI 10.1016/j.neulet.2009.04.064; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Burgin AB, 2010, NAT BIOTECHNOL, V28, P63, DOI 10.1038/nbt.1598; Cherry JA, 1999, J COMP NEUROL, V407, P287; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Clapcote SJ, 2007, NEURON, V54, P387, DOI 10.1016/j.neuron.2007.04.015; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fox D, 2014, CELL SIGNAL, V26, P657, DOI 10.1016/j.cellsig.2013.12.003; Garcia-Osta A, 2012, ACS CHEM NEUROSCI, V3, P832, DOI 10.1021/cn3000907; Glushakova OY, 2014, J NEUROTRAUM, V31, P1180, DOI 10.1089/neu.2013.3080; Hansen RT, 2014, PSYCHOPHARMACOLOGY, V231, P2941, DOI 10.1007/s00213-014-3480-y; Hoskison MM, 2009, NEUROSCIENCE, V159, P483, DOI 10.1016/j.neuroscience.2008.12.050; Houslay MD, 2005, DRUG DISCOV TODAY, V10, P1503, DOI 10.1016/S1359-6446(05)03622-6; Jin SLC, 2005, J IMMUNOL, V175, P1523, DOI 10.4049/jimmunol.175.3.1523; Jin SLC, 2002, P NATL ACAD SCI USA, V99, P7628, DOI 10.1073/pnas.122041599; Johansson EM, 2012, NEUROSCI LETT, V525, P1, DOI 10.1016/j.neulet.2012.07.050; Kabadi SV, 2014, J CEREBR BLOOD F MET, V34, P502, DOI 10.1038/jcbfm.2013.228; Klann E, 1998, J BIOL CHEM, V273, P4516, DOI 10.1074/jbc.273.8.4516; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Lakics V, 2010, NEUROPHARMACOLOGY, V59, P367, DOI 10.1016/j.neuropharm.2010.05.004; Lew HL, 2006, J REHABIL RES DEV, V43, pVII, DOI 10.1682/JRRD.2006.05.0054; Li YF, 2011, J NEUROSCI, V31, P172, DOI 10.1523/JNEUROSCI.5236-10.2011; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Lotocki G, 2006, EUR J NEUROSCI, V24, P2283, DOI 10.1111/j.1460-9568.2006.05123.x; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McConeghy KW, 2012, CNS DRUGS, V26, P613, DOI 10.2165/11634020-000000000-00000; McDonnell MN, 2011, ARCH PHYS MED REHAB, V92, P1044, DOI 10.1016/j.apmr.2011.01.021; McGirr A, 2016, NEUROPSYCHOPHARMACOL, V41, P1080, DOI 10.1038/npp.2015.240; Naganuma K, 2009, BIOORG MED CHEM LETT, V19, P3174, DOI 10.1016/j.bmcl.2009.04.121; Oliva AA, 2012, J NEUROCHEM, V123, P1019, DOI 10.1111/jnc.12049; Ferreira APO, 2013, NEUROCHEM INT, V63, P583, DOI 10.1016/j.neuint.2013.09.012; Perez-Torres S, 2000, J CHEM NEUROANAT, V20, P349, DOI 10.1016/S0891-0618(00)00097-1; Potts MB, 2009, J NEUROSCI RES, V87, P1848, DOI 10.1002/jnr.21996; Press NJ, 2009, PROGR MED CHEM, V47, P37, DOI 10.1016/S0079-6468(08)00202-6; Reyes-Irisarri E, 2008, SYNAPSE, V62, P74, DOI 10.1002/syn.20459; Robichaud A, 2002, BRIT J PHARMACOL, V135, P113, DOI 10.1038/sj.bjp.0704457; Robichaud A, 2001, NEUROPHARMACOLOGY, V40, P262, DOI 10.1016/S0028-3908(00)00142-8; Rohling ML, 2009, NEUROPSYCHOLOGY, V23, P20, DOI 10.1037/a0013659; Rudy JW, 1999, BEHAV NEUROSCI, V113, P867, DOI 10.1037/0735-7044.113.5.867; Rutten K, 2008, EUR J NEUROSCI, V28, P625, DOI 10.1111/j.1460-9568.2008.06349.x; Rutten K, 2011, NEUROPHARMACOLOGY, V61, P138, DOI 10.1016/j.neuropharm.2011.03.020; Sakurai H, 2013, GERIATR GERONTOL INT, V13, P90, DOI 10.1111/j.1447-0594.2012.00866.x; Schaefer TL, 2012, GENES BRAIN BEHAV, V11, P614, DOI 10.1111/j.1601-183X.2012.00796.x; Schwam EM, 2014, CURR ALZHEIMER RES, V11, P413, DOI 10.2174/1567205011666140505100858; Serra-Grabulosa JM, 2005, J NEUROL NEUROSUR PS, V76, P129, DOI 10.1136/jnnp.2004.027631; Shim YS, 2014, INT J IMPOT RES, V26, P76, DOI 10.1038/ijir.2013.38; Shojo H, 2010, NEUROSCIENCE, V171, P1273, DOI 10.1016/j.neuroscience.2010.10.018; Siuciak JA, 2008, PSYCHOPHARMACOLOGY, V197, P115, DOI 10.1007/s00213-007-1014-6; Smith C, 2013, NEUROPATH APPL NEURO, V39, P654, DOI 10.1111/nan.12008; Su Y, 2014, NEUROSCIENCE, V266, P56, DOI 10.1016/j.neuroscience.2014.02.006; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Titus DJ, 2013, NEUROSCIENCE, V231, P182, DOI 10.1016/j.neuroscience.2012.12.002; Titus DJ, 2013, J NEUROSCI, V33, P5216, DOI 10.1523/JNEUROSCI.5133-12.2013; Tsai MC, 2015, J NEUROIMMUNE PHARM, V10, P45, DOI 10.1007/s11481-014-9570-0; Urrea C, 2007, RESTOR NEUROL NEUROS, V25, P65; Vitarbo EA, 2004, NEUROSURGERY, V55, P416, DOI 10.1227/01.NEU.0000130036.52521.2C; Wheaton P, 2011, J CLIN PSYCHOPHARM, V31, P745, DOI 10.1097/JCP.0b013e318235f4ac; Wheaton P, 2009, J CLIN PSYCHOPHARM, V29, P468, DOI 10.1097/JCP.0b013e3181b66f04; Wilson NM, 2016, FRONT SYST NEUROSCI, V10, DOI 10.3389/fnsys.2016.00005; YAKOVLEV AG, 1994, MOL CHEM NEUROPATHOL, V23, P179, DOI 10.1007/BF02815410; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac; Zhang HT, 2008, NEUROPSYCHOPHARMACOL, V33, P1611, DOI 10.1038/sj.npp.1301537	72	34	34	0	7	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JUL 6	2016	36	27					7095	7108		10.1523/JNEUROSCI.3212-15.2016			14	Neurosciences	Neurosciences & Neurology	DQ2GX	WOS:000379021800004	27383587	Green Published, Bronze			2021-06-18	
J	Hue, CD; Cho, FS; Cao, S; Nicholls, RE; Vogel, EW; Sibindi, C; Arancio, O; Bass, CRD; Meaney, DF; Morrison, B				Hue, Christopher D.; Cho, Frances S.; Cao, Siqi; Nicholls, Russell E.; Vogel, Edward W., III; Sibindi, Cosmas; Arancio, Ottavio; Bass, Cameron R.Dale; Meaney, David F.; Morrison, Barclay, III			Time Course and Size of Blood Brain Barrier Opening in a Mouse Model of Blast-Induced Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						blast injury; blood brain barrier; dextran; shock tube; traumatic brain injury	RAT MODEL; INFLAMMATION; DISRUPTION; EXPOSURE; RECOVERY; OVERPRESSURE; EXPRESSION; MICROGLIA; STRESS; RANGE	An increasing number of studies have reported blood brain barrier (BBB) dysfunction after blast-induced traumatic brain injury (bTBI). Despite this evidence, there is limited quantitative understanding of the extent of BBB opening and the time course of damage after blast injury. In addition, many studies do not report kinematic parameters of head motion, making it difficult to separate contributions of primary and tertiary blast-loading. Detailed characterization of blast-induced BBB damage may hold important implications for serum constituents that may potentially cross the compromised barrier and contribute to neurotoxicity, neuroinflammation, and persistent neurologic deficits. Using an in vivo bTBI model, systemic administration of sodium fluorescein (NaFl; 376 Da), Evans blue (EB; 69 kDa when bound to serum albumin), and dextrans (3-500 kDa) was used to estimate the pore size of BBB opening and the time required for recovery. Exposure to blast with 272 +/- 6 kPa peak overpressure, 0.69 +/- 0.01 ms duration, and 65 +/- 1 kPa*ms impulse resulted in significant acute extravasation of NaFl, 3 kDa dextran, and EB. However, there was no significant acute extravasation of 70 kDa or 500 kDa dextrans, and minimal to no extravasation of NaFl, dextrans, or EB 1 day after exposure. This study presents a detailed analysis of the time course and pore size of BBB opening after bTBI, supported by a characterization of kinematic parameters associated with blast-induced head motion.	[Hue, Christopher D.; Cho, Frances S.; Cao, Siqi; Vogel, Edward W., III; Sibindi, Cosmas; Morrison, Barclay, III] Columbia Univ, Dept Biomed Engn, 351 Engn Terrace,MC8904,1210 Amsterdam Ave, New York, NY 10027 USA; [Nicholls, Russell E.; Arancio, Ottavio] Columbia Univ, Taub Inst Res Alzheimers Dis & Aging Brain, New York, NY 10027 USA; [Bass, Cameron R.Dale] Duke Univ, Dept Biomed Engn, Durham, NC 27706 USA; [Meaney, David F.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA	Morrison, B (corresponding author), Columbia Univ, Dept Biomed Engn, 351 Engn Terrace,MC8904,1210 Amsterdam Ave, New York, NY 10027 USA.	bm2119@columbia.edu	Morrison, Barclay/B-7132-2008; arancio, ottavio/AAB-7959-2019	Morrison, Barclay/0000-0001-7676-0864; Meaney, David/0000-0002-0954-4122; arancio, ottavio/0000-0001-6335-164X; , Siqi/0000-0001-9779-4174			Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; Adams J H, 1981, Acta Neuropathol Suppl, V7, P26; Algattas H, 2014, INT J MOL SCI, V15, P309, DOI 10.3390/ijms15010309; Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; Arun P, 2013, NEUROSCI LETT, V552, P87, DOI 10.1016/j.neulet.2013.07.047; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Bass CR, 2008, J TRAUMA, V65, P604, DOI 10.1097/TA.0b013e3181454ab4; Beamer M, 2016, EXP NEUROL, V283, P16, DOI 10.1016/j.expneurol.2016.05.025; Chavko M, 2006, J TRAUMA, V61, P933, DOI 10.1097/01.ta.0000233742.75450.47; Chen H, 2014, J CEREBR BLOOD F MET, V34, P1197, DOI 10.1038/jcbfm.2014.71; Chen Y, 2013, J NEUROPSYCH CLIN N, V25, P103, DOI 10.1176/appi.neuropsych.12030058; Chen Y, 2011, BRAIN INJURY, V25, P641, DOI 10.3109/02699052.2011.580313; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Choi JJ, 2010, ULTRASOUND MED BIOL, V36, P58, DOI 10.1016/j.ultrasmedbio.2009.08.006; Davidsson Johan, 2011, Front Neurol, V2, P41, DOI 10.3389/fneur.2011.00041; Duckworth Josh L, 2013, Pathophysiology, V20, P23, DOI 10.1016/j.pathophys.2012.03.001; Effgen GB, 2014, J NEUROTRAUM, V31, P1202, DOI 10.1089/neu.2013.3227; ENTERS EK, 1992, BRAIN RES, V576, P271; Fijalkowski RJ, 2007, J NEUROTRAUM, V24, P1387, DOI 10.1089/neu.2007.0268; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; Gennarelli T A, 1981, Acta Neuropathol Suppl, V7, P23; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Glushakova OY, 2014, J NEUROTRAUM, V31, P1180, DOI 10.1089/neu.2013.3080; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Gullotti DM, 2014, J BIOMECH ENG-T ASME, V136, DOI 10.1115/1.4027873; Gutierrez E, 2001, J NEUROTRAUM, V18, P247, DOI 10.1089/08977150151070874; Hue CD, 2015, J CEREBR BLOOD F MET, V35, P1191, DOI 10.1038/jcbfm.2015.38; Hue CD, 2014, J NEUROTRAUM, V31, P951, DOI 10.1089/neu.2013.3149; Hue CD, 2013, J NEUROTRAUM, V30, P1652, DOI 10.1089/neu.2012.2773; KAUR C, 1995, NEUROPATH APPL NEURO, V21, P369, DOI 10.1111/j.1365-2990.1995.tb01073.x; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Logsdon AF, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00421; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Lozano D, 2015, NEUROPSYCH DIS TREAT, V11, P97, DOI 10.2147/NDT.S65815; Lucke-Wold BP, 2015, MOL NEUROBIOL, V52, P1119, DOI 10.1007/s12035-014-8902-7; Magnuson J, 2012, CURR NEUROL NEUROSCI, V12, P570, DOI 10.1007/s11910-012-0303-6; MAXWELL WL, 1992, ACTA NEUROPATHOL, V84, P289; Panzer Matthew B, 2012, Front Neurol, V3, P46, DOI 10.3389/fneur.2012.00046; Patel TP, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00349; Raghupathi R, 2002, J NEUROTRAUM, V19, P843, DOI 10.1089/08977150260190438; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Skotak M, 2013, J NEUROTRAUM, V30, P1147, DOI 10.1089/neu.2012.2652; Stemper BD, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00031; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; VandeVord PJ, 2012, ANN BIOMED ENG, V40, P227, DOI 10.1007/s10439-011-0420-4; VIEIRA P, 1988, EUR J IMMUNOL, V18, P313, DOI 10.1002/eji.1830180221; Wang Y, 2011, J NEUROTRAUM, V28, P2171, DOI 10.1089/neu.2011.1990; WOLMAN M, 1981, ACTA NEUROPATHOL, V54, P55, DOI 10.1007/BF00691332; Wu JF, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-169; Yen LF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068595; Yeoh S, 2013, ANN BIOMED ENG, V41, P2206, DOI 10.1007/s10439-013-0805-7	52	34	35	0	14	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL 1	2016	33	13					1202	+		10.1089/neu.2015.4067			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	DP2QY	WOS:000378336200386	26414212				2021-06-18	
J	Harris, NG; Verley, DR; Gutman, BA; Sutton, RL				Harris, N. G.; Verley, D. R.; Gutman, B. A.; Sutton, R. L.			Bi-directional changes in fractional anisotropy after experiment TBI: Disorganization and reorganization?	NEUROIMAGE			English	Article						Plasticity; Structural reorganization; Connectivity; Controlled cortical impact; Rat; Imaging; MRI	TRAUMATIC BRAIN-INJURY; CONTROLLED CORTICAL IMPACT; DIFFUSION TENSOR MRI; AXONAL INJURY; MOUSE MODEL; MILD; ROBUST; MICE; RAT; NEURODEGENERATION	The current dogma to explain the extent of injury-related changes following rodent controlled cortical impact (CCI) injury is a focal injury with limited axonal pathology. However, there is in fact good, published histologic evidence to suggest that axonal injury is far more widespread in this model than generally thought. One possibility that might help to explain this is the often-used region-of-interest data analysis approach taken by experimental traumatic brain injury (TBI) diffusion tensor imaging (DTI) or histologic studies that might miss more widespread damage, when compared to the whole brain, statistically robust method of tract-based analysis used more routinely in clinical research. To determine the extent of DTI changes in this model, we acquired in vivo DTI data before and at 1 and 4 weeks after CCI injury in 17 adult male rats and analyzed parametric maps of fractional anisotropy (FA), axial, radial, and mean diffusivity (AD, RD, MD), tensor mode (MO), and fiber tract density (FTD) using tract-based spatial statistics. Contusion volume was used as a surrogate marker of injury severity and as a covariate for investigating severity dependence of the data. Mean fiber tract length was also computed from seeds in the cortical spinal tract regions. In parallel experiments (n = 3-5/group), we investigated corpus callosum neurofilaments and demyelination using immunohistochemistry (IHC) at 3 days and 6 weeks, callosal tract patency using dual-label retrograde tract tracing at 5 weeks, and the contribution of gliosis to DTI parameter maps using GFAP IHC at 4 weeks post-injury. The data show widespread ipsilateral regions of significantly reduced FA at 1 week post-injury, driven by temporally changing values of AD, RD, and MD that persist to 4 weeks. Demyelination, retrograde label tract loss, and reductions in MO (tract degeneration) and FTD were shown to underpin these data. Significant FA increases occurred in subcortical and corticospinal tract regions that were spatially distinct from regions of FA decrease, grossly affected gliotic areas, and MO changes. However, there was good spatial correspondence between regions of increased FA and areas of increased FTD and mean fiber length. We discuss these widespread changes in DTI parameters in terms of axonal degeneration and potential reorganization, with reference to a resting state fMRI companion paper (Harris et al., 2016, Exp. Neurol. 227: 124-138) that demonstrated altered functional connectivity data acquired from the same rats used in this study. (C) 2016 Elsevier Inc. All rights reserved.	[Harris, N. G.; Verley, D. R.; Sutton, R. L.] Univ Calif Los Angeles, UCLA Brain Injury Res Ctr, Dept Neurosurg, Los Angeles, CA USA; [Gutman, B. A.] Univ So Calif, Dept Neurol, Imaging Genet Ctr, Keck USC Sch Med,Inst Neuroimaging & Informat, Los Angeles, CA USA	Harris, NG (corresponding author), Univ Calif Los Angeles, UCLA Brain Injury Res Ctr, Dept Neurosurg, Los Angeles, CA USA.; Harris, NG (corresponding author), UCLA, Dept Neurosurg, David Geffen Sch Med, 300 Stein Plaza,Ste 535,Box 956901, Los Angeles, CA 90095 USA.	ngharris@mednet.ucla.edu	; Verley, Derek/J-4550-2015	Gutman, Boris/0000-0001-5388-897X; Verley, Derek/0000-0002-2670-6568; Harris, Neil/0000-0002-1965-6750	UCLA Brain Injury Research Center; NIH NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS091222, NS27544]; MRI Core of the Semel Institute of Neuroscience at UCLA; Intellectual Development and Disabilities Research Center from the Eunice Kennedy Shriver National Institute of Child Health and Human Development [U54HD087101-01]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U54HD087101] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS091222, R01NS027544] Funding Source: NIH RePORTER	Funding source: UCLA Brain Injury Research Center; NIH NINDS NS091222 and NS27544. The project described was also supported in part by the MRI Core of the Semel Institute of Neuroscience at UCLA, which is supported by the Intellectual Development and Disabilities Research Center grant number U54HD087101-01 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Eunice Kennedy Shriver National Institute of Child Health and Human Development or the National Institutes of Health. NGH is a fellow of The Center for Neuroskills, Bakersfield, California.	Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Behrens TEJ, 2007, NEUROIMAGE, V34, P144, DOI 10.1016/j.neuroimage.2006.09.018; Behrens TEJ, 2003, MAGN RESON MED, V50, P1077, DOI 10.1002/mrm.10609; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Budde MD, 2009, J NEUROSCI, V29, P2805, DOI 10.1523/JNEUROSCI.4605-08.2009; Caeyenberghs K, 2010, HUM BRAIN MAPP, V31, P992, DOI 10.1002/hbm.20911; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Chen S., 2002, J NEUROTRAUM, V19, P1300; Chen SF, 2004, J CEREBR BLOOD F MET, V24, P1025, DOI 10.1097/01.WCB.0000129415.34520.47; Chiang CW, 2014, NEUROIMAGE, V101, P310, DOI 10.1016/j.neuroimage.2014.06.064; Choe AS, 2012, NMR BIOMED, V25, P900, DOI 10.1002/nbm.1810; Christman CW, 1997, ACTA NEUROPATHOL, V94, P329, DOI 10.1007/s004010050715; Crum WR, 2013, J NEUROSCI METH, V218, P170, DOI 10.1016/j.jneumeth.2013.05.009; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Dennis EL, 2015, J NEUROSCI, V35, P10202, DOI 10.1523/JNEUROSCI.1595-15.2015; Douaud G, 2009, NEUROIMAGE, V46, P958, DOI 10.1016/j.neuroimage.2009.03.044; Ennis DB, 2006, MAGN RESON MED, V55, P136, DOI 10.1002/mrm.20741; Haberg A.K., 2014, J NEUROSCI RES; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Harris NG, 2016, EXP NEUROL, V277, P124, DOI 10.1016/j.expneurol.2015.12.020; Harris N, 2009, J NEUROTRAUM, V26, pA37; Harris NG, 2013, J NEUROTRAUM, V30, P1137, DOI 10.1089/neu.2012.2785; Harris NG, 2012, J NEUROTRAUM, V29, P1469, DOI 10.1089/neu.2011.2161; Harris NG, 2010, J NEUROTRAUM, V27, P1971, DOI 10.1089/neu.2010.1470; Harris NG, 2010, J NEUROPATH EXP NEUR, V69, P139, DOI 10.1097/NEN.0b013e3181cb5bee; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; Jenkinson M, 2001, MED IMAGE ANAL, V5, P143, DOI 10.1016/S1361-8415(01)00036-6; Johnstone VPA, 2015, J NEUROTRAUM, V32, P1333, DOI 10.1089/neu.2014.3785; Kindlmann G, 2007, IEEE T MED IMAGING, V26, P1483, DOI 10.1109/TMI.2007.907277; Laitinen T, 2015, FRONT NEUROSCI-SWITZ, V9, DOI [10.3389/fnins.7015.00128, 10.3389/fnins.2015.00128]; Laitinen T, 2010, NEUROIMAGE, V51, P521, DOI 10.1016/j.neuroimage.2010.02.077; Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073; Lipton ML, 2012, BRAIN IMAGING BEHAV, V6, P329, DOI 10.1007/s11682-012-9175-2; Lo C, 2009, J COMPUT ASSIST TOMO, V33, P293, DOI 10.1097/RCT.0b013e31817579d1; Long JA, 2015, J NEUROTRAUM, V32, P598, DOI 10.1089/neu.2014.3563; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Matthews MA, 1998, BRAIN RES, V794, P1, DOI 10.1016/S0006-8993(98)00107-3; Mayer A.R., 2010, NEUROLOGY; Mayer AR, 2015, J NEUROTRAUM, V32, P723, DOI 10.1089/neu.2014.3534; Messe A., 2010, HUM BRAIN MAPP; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; Onyszchuk G, 2009, NEUROSCI LETT, V452, P204, DOI 10.1016/j.neulet.2009.01.049; PAXINOS G, 1997, RAT BRAIN STEREOTAXI; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Rulseh AM, 2013, J MAGN RESON IMAGING, V38, P1103, DOI 10.1002/jmri.24065; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Schlegel AA, 2012, J COGNITIVE NEUROSCI, V24, P1664, DOI 10.1162/jocn_a_00240; Scholz J, 2015, NEUROIMAGE, V107, P182, DOI 10.1016/j.neuroimage.2014.12.003; Scholz J, 2009, NAT NEUROSCI, V12, P1370, DOI 10.1038/nn.2412; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Sierra A, 2011, BRAIN STRUCT FUNCT, V216, P123, DOI 10.1007/s00429-010-0299-0; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Valdes-Hernandez Pedro Antonio, 2011, Front Neuroinform, V5, P26, DOI 10.3389/fninf.2011.00026; Vos SB, 2011, NEUROIMAGE, V55, P1566, DOI 10.1016/j.neuroimage.2011.01.048; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Winkler AM, 2014, NEUROIMAGE, V92, P381, DOI 10.1016/j.neuroimage.2014.01.060; Xu S, 2011, J NEUROTRAUM, V28, P2091, DOI 10.1089/neu.2010.1739; Yushkevich PA, 2006, NEUROIMAGE, V31, P1116, DOI 10.1016/j.neuroimage.2006.01.015; Zheng X, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00229; Zhuo JC, 2012, NEUROIMAGE, V59, P467, DOI 10.1016/j.neuroimage.2011.07.050	65	34	34	1	5	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	JUN	2016	133						129	143		10.1016/j.neuroimage.2016.03.012			15	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	DN4PB	WOS:000377048600012	26975556	Green Accepted			2021-06-18	
J	Morganti, JM; Riparip, LK; Chou, A; Liu, S; Gupta, N; Rosi, S				Morganti, Josh M.; Riparip, Lara-Kirstie; Chou, Austin; Liu, Sharon; Gupta, Nalin; Rosi, Susanna			Age exacerbates the CCR2/5-mediated neuroinflammatory response to traumatic brain injury	JOURNAL OF NEUROINFLAMMATION			English	Article						Microglia; Macrophage; CCR2; Chemokine; Antagonist; Aging; Neurotrauma	MONOCYTE CHEMOATTRACTANT PROTEIN-1; NADPH OXIDASE; ALTERNATIVE ACTIVATION; SPINAL-CORD; MICROGLIA; RECRUITMENT; NEUROTOXICITY; FRACTALKINE; CHEMOKINES; RECOVERY	Background: Traumatic brain injury (TBI) is a major risk factor for the development of multiple neurodegenerative diseases, including Alzheimer's disease (AD) and numerous recent reports document the development of dementia after TBI. Age is a significant factor in both the risk of and the incidence of acquired brain injury. TBI-induced inflammatory response is associated with activation of brain resident microglia and accumulation of infiltrating monocytes, which plays a pivotal role in chronic neurodegeneration and loss of neurological function after TBI. Despite the extensive clinical evidence implicating neuroinflammation with the TBI-related sequelae, the specific role of these different myeloid cells and the influence of age on TBI-initiated innate immune response remain unknown and poorly studied. Methods: We used gene profiling and pathway analysis to define the effect of age on inflammatory response at the time of injury. The recruitment of peripheral CCR2(+) macrophages was delineated using the CX3CR1(GFP/+)CCR2(RFP/+) reporter mouse. These responses were examined in the context of CCR2/5 antagonism using cenicriviroc. Results: Unsupervised gene clustering and pathway analysis revealed that age predisposes exacerbated inflammatory response related to the recruitment and activation of peripheral monocytes to the injured brain. Using a unique reporter animal model able to discriminate resident versus peripherally derived myeloid cells, we demonstrate that in the aged brain, there is an increased accumulation of peripherally derived CCR2(+) macrophages after TBI compared to young animals. Exaggerated recruitment of this population of cells was associated with an augmented inflammatory response in the aged TBI animals. Targeting this cellular response with cenicriviroc, a dual CCR2/5 antagonist, significantly ameliorated injury-induced sequelae in the aged TBI animals. Conclusions: Importantly, these findings demonstrate that peripheral monocytes play a non-redundant and contributing role to the etiology of trauma-induced inflammatory sequelae in the aged brain.	[Morganti, Josh M.; Riparip, Lara-Kirstie; Chou, Austin; Rosi, Susanna] Univ Calif San Francisco, Brain & Spinal Injury Ctr, 1001 Potrero Ave,Bldg 1,Room 101, San Francisco, CA 94110 USA; [Morganti, Josh M.; Rosi, Susanna] Univ Calif San Francisco, Dept Phys Therapy & Rehabil Sci, San Francisco, CA 94143 USA; [Chou, Austin; Rosi, Susanna] Univ Calif San Francisco, Grad Program Neurosci, San Francisco, CA 94143 USA; [Liu, Sharon; Gupta, Nalin; Rosi, Susanna] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA; [Gupta, Nalin] Univ Calif San Francisco, Dept Pediat, San Francisco, CA USA	Rosi, S (corresponding author), Univ Calif San Francisco, Brain & Spinal Injury Ctr, 1001 Potrero Ave,Bldg 1,Room 101, San Francisco, CA 94110 USA.; Rosi, S (corresponding author), Univ Calif San Francisco, Dept Phys Therapy & Rehabil Sci, San Francisco, CA 94143 USA.; Rosi, S (corresponding author), Univ Calif San Francisco, Grad Program Neurosci, San Francisco, CA 94143 USA.; Rosi, S (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA.	susanna.rosi@ucsf.edu	Morganti, Josh/AAL-9727-2020	Morganti, Josh/0000-0002-4183-0049; Chou, Austin/0000-0003-4328-5811	National Institute Of Neurological Disorders And StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); National Institute on Aging of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [F32NS090805, R21NS087458, R21AG042016]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS087458, F32NS090805] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R21AG042016] Funding Source: NIH RePORTER	Research reported in this publication was supported by the National Institute Of Neurological Disorders And Stroke and National Institute on Aging of the National Institutes of Health under award numbers F32NS090805 (J.M.M.), R21NS087458 (S.R.); R21AG042016 (S.R.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Auffray C, 2007, SCIENCE, V317, P666, DOI 10.1126/science.1142883; Bachstetter AD, 2011, NEUROBIOL AGING, V32, P2030, DOI 10.1016/j.neurobiolaging.2009.11.022; Balboa L, 2011, J LEUKOCYTE BIOL, V90, P69, DOI 10.1189/jlb.1010577; Blanpain C, 1999, BLOOD, V94, P1899; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Cardona AE, 2006, NAT PROTOC, V1, P1947, DOI 10.1038/nprot.2006.327; Cardona AE, 2006, NAT NEUROSCI, V9, P917, DOI 10.1038/nn1715; Deshmane SL, 2009, J INTERF CYTOK RES, V29, P313, DOI 10.1089/jir.2008.0027; Donnelly DJ, 2011, J NEUROSCI, V31, P9910, DOI 10.1523/JNEUROSCI.2114-11.2011; El Khoury J, 2007, NAT MED, V13, P432, DOI 10.1038/nm1555; Giunta B, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-185; Gyoneva S, 2015, TRENDS PHARMACOL SCI, V36, P471, DOI 10.1016/j.tips.2015.04.003; Hernandes MS, 2012, CURR NEUROPHARMACOL, V10, P321, DOI 10.2174/157015912804143540; Hernandez-Ontiveros DG, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00030; Hickman SE, 2013, NAT NEUROSCI, V16, P1896, DOI 10.1038/nn.3554; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Inadera H, 1999, J INTERF CYTOK RES, V19, P1179, DOI 10.1089/107999099313127; Jellinger KA, 2004, J NEUROL NEUROSUR PS, V75, P511; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Lee DC, 2013, NEUROBIOL AGING, V34, P1610, DOI 10.1016/j.neurobiolaging.2012.12.014; Limatola C, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00229; Loane DJ, 2013, J NEUROTRAUM, V30, P403, DOI 10.1089/neu.2012.2589; Mildner A, 2009, BRAIN, V132, P2487, DOI 10.1093/brain/awp144; Morganti JM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148001; Morganti JM, 2015, J NEUROSCI, V35, P748, DOI 10.1523/JNEUROSCI.2405-14.2015; Morganti JM, 2012, J NEUROSCI, V32, P14592, DOI 10.1523/JNEUROSCI.0539-12.2012; Mueller A, 2002, BLOOD, V99, P785, DOI 10.1182/blood.V99.3.785; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Norden DM, 2013, NEUROPATH APPL NEURO, V39, P19, DOI 10.1111/j.1365-2990.2012.01306.x; Norden DM, 2015, NEUROPHARMACOLOGY, V96, P29, DOI 10.1016/j.neuropharm.2014.10.028; Saederup N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013693; Schonberger M, 2009, J NEUROTRAUM, V26, P2157, DOI 10.1089/neu.2009.0939; Shechter R, 2013, IMMUNITY, V38, P555, DOI 10.1016/j.immuni.2013.02.012; Stefini R, 2008, J NEUROSURG, V108, P958, DOI 10.3171/JNS/2008/108/5/0958; Stocchetti N, 2012, J NEUROTRAUM, V29, P1119, DOI 10.1089/neu.2011.1995; Takahashi M, 2009, J IMMUNOL, V183, P3463, DOI 10.4049/jimmunol.0802812; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Wu DC, 2003, P NATL ACAD SCI USA, V100, P6145, DOI 10.1073/pnas.0937239100; Wynn TA, 2013, NATURE, V496, P445, DOI 10.1038/nature12034; Yamasaki R, 2014, J EXP MED, V211, P1533, DOI 10.1084/jem.20132477; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	43	34	35	0	8	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1742-2094		J NEUROINFLAMM	J. Neuroinflamm.	APR 18	2016	13								80	10.1186/s12974-016-0547-1			12	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	DJ5YB	WOS:000374285600002	27090212	DOAJ Gold, Green Published			2021-06-18	
J	Riedy, G; Senseney, JS; Liu, W; Ollinger, J; Sham, E; Krapiva, P; Patel, JB; Smith, A; Yeh, PH; Graner, J; Nathan, D; Caban, J; French, LM; Harper, J; Eskay, V; Morissette, J; Oakes, TR				Riedy, Gerard; Senseney, Justin S.; Liu, Wei; Ollinger, John; Sham, Elyssa; Krapiva, Pavel; Patel, Jigar B.; Smith, Alice; Yeh, Ping-Hong; Graner, John; Nathan, Dominic; Caban, Jesus; French, Louis M.; Harper, Jamie; Eskay, Victoria; Morissette, John; Oakes, Terrence R.			Findings from Structural MR Imaging in Military Traumatic Brain Injury	RADIOLOGY			English	Article							WHITE-MATTER LESIONS; POSTTRAUMATIC-STRESS-DISORDER; DIFFUSE AXONAL INJURY; COMMON DATA ELEMENTS; MILD HEAD-INJURY; SERVICE MEMBERS; BLAST; SYMPTOMS; TBI; HYPERINTENSITIES	Purpose: To describe the initial neuroradiology findings in a cohort of military service members with primarily chronic mild traumatic brain injury (TBI) from blast by using an integrated magnetic resonance (MR) imaging protocol. Materials and Methods: This study was approved by the Walter Reed National Military Medical Center institutional review board and is compliant with HIPAA guidelines. All participants were military service members or dependents recruited between August 2009 and August 2014. There were 834 participants with a history of TBI and 42 participants in a control group without TBI (not explicitly age-and sex-matched). MR examinations were performed at 3 T primarily with three-dimensional volume imaging at smaller than 1 mm(3) voxels for the structural portion of the examination. The structural portion of this examination, including T1-weighted, T2-weighted, before and after contrast agent administrtion T2 fluid attenuation inversion recovery, and susceptibility-weighted images, was evaluated by neuroradiologists by using a modified version of the neuroradiology TBI common data elements (CDEs). Incident odds ratios (ORs) between the TBI participants and a comparison group without TBI were calculated. Results: The 834 participants were diagnosed with predominantly chronic (mean, 1381 days; median, 888 days after injury) and mild (92% [768 of 834]) TBI. Of these participants, 84.2% (688 of 817) reported one or more blast-related incident and 63.0% (515 of 817) reported loss of consciousness at the time of injury. The presence of white matter T2-weighted hyperintense areas was the most common pathologic finding, observed in 51.8% (432 of 834; OR, 1.75) of TBI participants. Cerebral microhemorrhages were observed in a small percentage of participants (7.2% [60 of 834]; OR, 6.64) and showed increased incidence with TBI severity (P < .001, moderate and severe vs mild). T2-weighted hyperintense areas and microhemorrhages did not collocate by visual inspection. Pituitary abnormalities were identified in a large proportion (29.0% [242 of 834]; OR, 16.8) of TBI participants. Conclusion: Blast-related injury and loss of consciousness is common in military TBI. Structural MR imaging demonstrates a high incidence of white matter T2-weighted hyperintense areas and pituitary abnormalities, with a low incidence of microhemorrhage in the chronic phase. (C) RSNA, 2015	[Riedy, Gerard; Senseney, Justin S.; Liu, Wei; Ollinger, John; Sham, Elyssa; Yeh, Ping-Hong; Graner, John; Nathan, Dominic; Caban, Jesus; Harper, Jamie; Eskay, Victoria; Morissette, John; Oakes, Terrence R.] NCNC, Bethesda, MD USA; [Riedy, Gerard; Senseney, Justin S.; Liu, Wei; Ollinger, John; Sham, Elyssa; Yeh, Ping-Hong; Graner, John; Nathan, Dominic; Caban, Jesus; French, Louis M.; Eskay, Victoria; Morissette, John; Oakes, Terrence R.] NICoE, 4860 S Palmer Rd, Bethesda, MD 20889 USA; [Riedy, Gerard; French, Louis M.] Ctr Neurosci & Regenerat Med, Bethesda, MD USA; [Riedy, Gerard; Smith, Alice; French, Louis M.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; [Yeh, Ping-Hong] Henry M Jackson Fdn Adv Mil Med, Bethesda, MD USA; [Krapiva, Pavel; French, Louis M.] WRNMMC, Bethesda, MD USA; [Patel, Jigar B.] VAMHCS, Baltimore, MD USA	Riedy, G (corresponding author), NCNC, Bethesda, MD USA.; Riedy, G (corresponding author), NICoE, 4860 S Palmer Rd, Bethesda, MD 20889 USA.; Riedy, G (corresponding author), Ctr Neurosci & Regenerat Med, Bethesda, MD USA.; Riedy, G (corresponding author), Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA.	griedy1@gmail.com	french, louis/AAB-2083-2020	Patel, Jigar/0000-0002-2343-9142; french, louis/0000-0002-9451-0604	Congressionally Directed Medical Research ProgramUnited States Department of Defense [PT074437, 13129004]; Center for Neuroscience and Regenerative MedicineUnited States Department of Defense [300606]	Supported by the Congressionally Directed Medical Research Program (grants PT074437 and 13129004) and Center for Neuroscience and Regenerative Medicine (grant 300606).	Agresti A, 2007, INTRO CATEGORICAL DA, P21; Aradi M, 2013, HEADACHE, V53, P752, DOI 10.1111/head.12013; Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; Assareh A, 2011, CNS NEUROSCI THER, V17, P525, DOI 10.1111/j.1755-5949.2010.00181.x; Barkhof F, 2002, CEREBROVASC DIS, V13, P21, DOI 10.1159/000049146; Bazarian JJ, 2013, J HEAD TRAUMA REHAB, V28, P1, DOI 10.1097/HTR.0b013e318256d3d3; Belanger HG, 2011, CLIN NEUROPSYCHOL, V25, P702, DOI 10.1080/13854046.2011.566892; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Benson RR, 2012, NEUROREHABILITATION, V31, P261, DOI 10.3233/NRE-2012-0795; Benzinger TLS, 2009, J NEUROTRAUM, V26, P2127, DOI 10.1089/neu.2009-0885; Clark ME, 2009, PAIN MED, V10, P447, DOI 10.1111/j.1526-4637.2009.00590.x; de la Plata CM, 2007, J NEUROTRAUM, V24, P591, DOI 10.1089/neu.2006.0214; Debette S, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c3666; Defense and Veterans Brain Injury Center, 2015, DOD WORLDW NUMB TBI; Duhaime AC, 2010, ARCH PHYS MED REHAB, V91, P1661, DOI 10.1016/j.apmr.2010.07.238; Erten-Lyons D, 2013, NEUROLOGY, V81, P977, DOI 10.1212/WNL.0b013e3182a43e45; French LM, 2010, ANN NY ACAD SCI, V1208, P38, DOI 10.1111/j.1749-6632.2010.05696.x; Galluzzi S, 2008, J NEUROL SCI, V273, P3, DOI 10.1016/j.jns.2008.06.023; Guerrero AF, 2010, MIL MED, V175, P574, DOI 10.7205/MILMED-D-09-00189; Haacke EM, 2010, J MAGN RESON IMAGING, V32, P516, DOI 10.1002/jmri.22259; Haacke EM, 2004, MAGN RESON MED, V52, P612, DOI 10.1002/mrm.20198; Higgins JP, 2010, STAT METHODS GROUP C, P1; Kennedy JE, 2010, NEUROREHABILITATION, V26, P223, DOI 10.3233/NRE-2010-0558; Kim SC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102229; Kochunov P, 2008, HUM BRAIN MAPP, V29, P36, DOI 10.1002/hbm.20369; Lange RT, 2012, J INT NEUROPSYCH SOC, V18, P595, DOI 10.1017/S1355617712000239; Lew HL, 2009, J REHABIL RES DEV, V46, P819, DOI 10.1682/JRRD.2008.09.0129; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Liu W, 2016, RADIOLOGY, V278, P536, DOI 10.1148/radiol.2015150160; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Pagano M, 2000, PRINCIPLES BIOSTATIS, P151; Peleg K, 2003, AM J EMERG MED, V21, P258, DOI 10.1016/S0735-6757(03)00043-3; Reid MW, 2014, J NEUROTRAUM, V31, P1899, DOI 10.1089/neu.2014.3455; Rothman MS, 2007, J NEUROPSYCH CLIN N, V19, P363, DOI 10.1176/appi.neuropsych.19.4.363; Sahraian MA, 2010, CLIN NEUROL NEUROSUR, V112, P609, DOI 10.1016/j.clineuro.2010.03.022; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; The Management of Concussion/mTBI Working Group, 2009, VA DOD CLIN PRACT GU; Theeler B, 2013, HEADACHE, V53, P881, DOI 10.1111/head.12123; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Wilkinson Charles W, 2012, Front Neurol, V3, P11, DOI 10.3389/fneur.2012.00011; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783	44	34	34	0	11	RADIOLOGICAL SOC NORTH AMERICA	OAK BROOK	820 JORIE BLVD, OAK BROOK, IL 60523 USA	0033-8419			RADIOLOGY	Radiology	APR	2016	279	1					207	215		10.1148/radiol.2015150438			9	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	DP7WK	WOS:000378709700020	26669604	Bronze			2021-06-18	
J	Sukumari-Ramesh, S; Alleyne, CH; Dhandapani, KM				Sukumari-Ramesh, Sangeetha; Alleyne, Cargill H., Jr.; Dhandapani, Krishnan M.			The Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) Confers Acute Neuroprotection After Intracerebral Hemorrhage in Mice	TRANSLATIONAL STROKE RESEARCH			English	Article						Microglial activation; Stroke; Gliosis	TRAUMATIC BRAIN-INJURY; T-CELL LYMPHOMA; NF-KAPPA-B; HEME OXYGENASE; GENE-EXPRESSION; TIME-COURSE; VORINOSTAT; EDEMA; TRANSCRIPTION; INFLAMMATION	Spontaneous intracerebral hemorrhage (ICH) is a stroke subtype with no effective treatment. Though ICH is known to induce severe neurological damage, the molecular mechanisms of neurological injury after ICH remain largely unclear. Given the emerging role of epigenetic mechanisms in neurodegeneration, the present study evaluated whether suberoylanilide hydroxamic acid (SAHA: vorinostat), a clinically well-tolerated pan-histone deacetylase inhibitor (HDACi), would attenuate neurological injury and improve functional outcomes in a preclinical model of ICH. Mice were administered with SAHA or vehicle after an induction of ICH and acute neuronal death, glial activation, and neurological outcomes were assessed. SAHA-treated mice exhibited less neurodegeneration with concomitant improvement in neurological outcomes than vehicle-treated mice. Furthermore, SAHA downregulated glial activation and the expression of heme oxygenase-1, a stress-inducible enzyme that plays critical roles in neurological damage after ICH. Altogether, the data strongly suggest the role of epigenetic mechanisms in inducing neurological injury after ICH and raise the possible clinical utility of SAHA for therapeutic intervention after ICH.	[Sukumari-Ramesh, Sangeetha; Alleyne, Cargill H., Jr.; Dhandapani, Krishnan M.] Georgia Regents Univ, Dept Neurosurg, 1120 15th St CA1010, Augusta, GA 30912 USA	Sukumari-Ramesh, S (corresponding author), Georgia Regents Univ, Dept Neurosurg, 1120 15th St CA1010, Augusta, GA 30912 USA.	sramesh@gru.edu		Dhandapani, Krishnan/0000-0001-7044-1117	American Heart AssociationAmerican Heart Association [14SDG18730034]; National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS065172, R21NS075774]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS065172, R21NS075774] Funding Source: NIH RePORTER	This work was supported by grants from the American Heart Association (14SDG18730034 to SSR) and National Institute of Health (R01NS065172, R21NS075774 to KMD).	Abraham NG, 2008, PHARMACOL REV, V60, P79, DOI 10.1124/pr.107.07104; Aronowski J, 2005, NEUROL RES, V27, P268, DOI 10.1179/016164105X25225; Babu R, 2012, NEUROSURG FOCUS, V32, DOI 10.3171/2012.1.FOCUS11366; Baltan S, 2011, TRANSL STROKE RES, V2, P411, DOI 10.1007/s12975-011-0087-z; Bode KA, 2007, IMMUNOLOGY, V122, P596, DOI 10.1111/j.1365-2567.2007.02678.x; Boutillier AL, 2003, J NEUROCHEM, V84, P814, DOI 10.1046/j.1471-4159.2003.01581.x; Chen M, 2007, J NEUROCHEM, V103, P2015, DOI 10.1111/j.1471-4159.2007.04885.x; Choo QY, 2010, RHEUMATOLOGY, V49, P1447, DOI 10.1093/rheumatology/keq108; Ciccone A, 2008, NEUROL SCI, V29, pS256, DOI 10.1007/s10072-008-0955-9; Duvic M, 2007, BLOOD, V109, P31, DOI 10.1182/blood-2006-06-025999; Faraco G, 2006, MOL PHARMACOL, V70, P1876, DOI 10.1124/mol.106.027912; Faraco G, 2009, NEUROBIOL DIS, V36, P269, DOI 10.1016/j.nbd.2009.07.019; Glozak MA, 2005, GENE, V363, P15, DOI 10.1016/j.gene.2005.09.010; Hockly E, 2003, P NATL ACAD SCI USA, V100, P2041, DOI 10.1073/pnas.0437870100; Kazantsev AG, 2008, NAT REV DRUG DISCOV, V7, P854, DOI 10.1038/nrd2681; Keep RF, 2012, LANCET NEUROL, V11, P720, DOI 10.1016/S1474-4422(12)70104-7; King MD, 2011, J NEUROSURG, V115, P116, DOI 10.3171/2011.2.JNS10784; Kirschbaum M, 2011, J CLIN ONCOL, V29, P1198, DOI 10.1200/JCO.2010.32.1398; Koeppen AH, 2004, J NEUROPATH EXP NEUR, V63, P587, DOI 10.1093/jnen/63.6.587; Laird MD, 2010, J NEUROCHEM, V113, P637, DOI 10.1111/j.1471-4159.2010.06630.x; Leoni F, 2002, P NATL ACAD SCI USA, V99, P2995, DOI 10.1073/pnas.052702999; Lin S, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-46; Liu DZ, 2012, SCI WORLD J, DOI 10.1100/2012/491737; Lu J, 2013, P NATL ACAD SCI USA, V110, P10747, DOI 10.1073/pnas.1308950110; Mann BS, 2007, ONCOLOGIST, V12, P1247, DOI 10.1634/theoncologist.12-10-1247; Manno Edward M, 2012, Continuum (Minneap Minn), V18, P598, DOI 10.1212/01.CON.0000415430.99394.3e; Morgenstern LB, 2010, STROKE, V41, P2108, DOI 10.1161/STR.0b013e3181ec611b; Munster PN, 2011, BRIT J CANCER, V104, P1828, DOI 10.1038/bjc.2011.156; Perry VH, 2010, NAT REV NEUROL, V6, P193, DOI 10.1038/nrneurol.2010.17; Ramalingam SS, 2010, J CLIN ONCOL, V28, P56, DOI 10.1200/JCO.2009.24.9094; Ribo M, 2006, CURR NEUROL NEUROSCI, V6, P17, DOI 10.1007/s11910-996-0004-0; Rouaux C, 2003, EMBO J, V22, P6537, DOI 10.1093/emboj/cdg615; Ryu H, 2003, P NATL ACAD SCI USA, V100, P4281, DOI 10.1073/pnas.0737363100; Sansing LH, 2011, ANN NEUROL, V70, P646, DOI 10.1002/ana.22528; Sukumari-Ramesh S, 2012, J NEUROTRAUM, V29, P2798, DOI 10.1089/neu.2011.2243; Verdone L, 2005, BIOCHEM CELL BIOL, V83, P344, DOI 10.1139/o05-041; Wagner KR, 1996, STROKE, V27, P490, DOI 10.1161/01.STR.27.3.490; Wang JA, 2007, BRAIN, V130, P1643, DOI 10.1093/brain/awm095; Wang JA, 2010, PROG NEUROBIOL, V92, P463, DOI 10.1016/j.pneurobio.2010.08.001; Wu H, 2012, NEUROBIOL DIS, V45, P388, DOI 10.1016/j.nbd.2011.08.028; Wu H, 2011, J CEREBR BLOOD F MET, V31, P1243, DOI 10.1038/jcbfm.2010.209; Xue MZ, 2000, NEUROSCI LETT, V283, P230, DOI 10.1016/S0304-3940(00)00971-X; YANG GY, 1994, J NEUROSURG, V81, P93, DOI 10.3171/jns.1994.81.1.0093; Ziesche E, 2013, NUCLEIC ACIDS RES, V41, P90, DOI 10.1093/nar/gks916	44	34	34	1	6	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1868-4483	1868-601X		TRANSL STROKE RES	Transl. Stroke Res.	APR	2016	7	2					141	148		10.1007/s12975-015-0421-y			8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	DF5XJ	WOS:000371425900008	26338677				2021-06-18	
J	Wrocklage, KM; Schweinsburg, BC; Krystal, JH; Trejo, M; Roy, A; Weisser, V; Moore, TM; Southwick, SM; Scott, JC				Wrocklage, Kristen M.; Schweinsburg, Brian C.; Krystal, John H.; Trejo, Marcia; Roy, Alicia; Weisser, Valerie; Moore, Tyler M.; Southwick, Steven M.; Scott, J. Cobb			Neuropsychological Functioning in Veterans with Posttraumatic Stress Disorder: Associations with Performance Validity, Comorbidities, and Functional Outcomes	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Posttraumatic stress disorder; Neuropsychology; Cognitive abilities; Memory; Executive functions; Quality of life; Occupational functioning	TRAUMATIC BRAIN-INJURY; COMBAT EXPOSURE; VERBAL MEMORY; PTSD; HEALTH; ATTENTION; SYMPTOMS; DEFICITS; COGNITION; SCHIZOPHRENIA	Objectives: Numerous studies have shown that individuals with posttraumatic stress disorder (PTSD) display reduced performances on neuropsychological tests, although most prior research has not adequately accounted for comorbidities or performance validity concerns that are common in this population and could partially account for the observed neurocognitive findings. Moreover, few studies have examined the functional implications of neuropsychological results in PTSD. Methods: We examined neuropsychological functioning in 44 veterans with PTSD and 40 veteran trauma comparison (TC) participants with combat exposure and no PTSD. Results: After excluding four veterans with PTSD for performance validity concerns, multivariate analyses of variance by neurocognitive domain revealed significantly worse performance by the PTSD group in the domains of speed of information processing (p = .035) and executive functions (p = .017), but no group differences in attention/working memory, verbal/language functioning, visuoconstruction, or episodic memory. Group differences by PTSD status were still present after covarying for depression, a history of head injuries, and substance use disorders. Executive functioning performance was associated with poorer self-reported occupational functioning and physical health-related quality of life, while speed of information processing performance was associated with poorer physical health-related quality of life. Discussion: These results are generally consistent with a fronto-limbic conceptualization of PTSD-associated neuropsychological dysfunction and show that cognitive functioning may be associated with critical functional outcomes. Taken together, results suggest that consideration of neurocognitive functioning may enhance the clinical management of individuals with PTSD.	[Wrocklage, Kristen M.; Schweinsburg, Brian C.; Krystal, John H.; Trejo, Marcia; Roy, Alicia; Weisser, Valerie; Southwick, Steven M.] Natl Ctr PTSD, Clin Neurosci Div, West Haven, CT USA; [Wrocklage, Kristen M.; Schweinsburg, Brian C.; Krystal, John H.; Trejo, Marcia; Roy, Alicia; Weisser, Valerie; Southwick, Steven M.] VA Connecticut Healthcare Syst, West Haven, CT USA; [Schweinsburg, Brian C.; Krystal, John H.; Roy, Alicia; Southwick, Steven M.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA; [Krystal, John H.] Yale Univ, Sch Med, Dept Neurobiol, New Haven, CT USA; [Krystal, John H.] Yale New Haven Med Ctr, Psychiat Serv, 20 York St, New Haven, CT 06504 USA; [Moore, Tyler M.; Scott, J. Cobb] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA; [Scott, J. Cobb] Philadelphia VA Med Ctr, Mental Illness Res Educ & Clin Ctr VISN4, Philadelphia, PA 19104 USA	Scott, JC (corresponding author), Philadelphia VA Med Ctr, MIRECC 116, 3900 Woodland Ave, Philadelphia, PA 19104 USA.	scott1@upenn.edu		Moore, Tyler/0000-0002-1384-0151; Scott, J. Cobb/0000-0001-6538-9043	Department of Veterans Affairs Career Development AwardUS Department of Veterans Affairs [IK2CX000772]; National Center for PTSD (NCPTSD); National Center for Advancing Translational Science [1UH2TR000960-01]; Department of Veterans Affairs (NCPTSD)US Department of Veterans Affairs; National Institute on Alcohol Abuse and AlcoholismUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [P50AA12870, M01RR00125]; Yale Center for Clinical Investigation [UL1 RR024139]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UH2TR000960] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000125, UL1RR024139] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [P50AA012870] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [IK2CX000772] Funding Source: NIH RePORTER	This work was supported by a Department of Veterans Affairs Career Development Award (IK2CX000772) to Dr. Scott, as well as the National Center for PTSD (NCPTSD). Dr. Krystal's participation was supported by the National Center for Advancing Translational Science (1UH2TR000960-01), the Department of Veterans Affairs (NCPTSD), the National Institute on Alcohol Abuse and Alcoholism (P50AA12870, M01RR00125), and the Yale Center for Clinical Investigation (UL1 RR024139). Portions of this research were presented at the 2014 Annual Meeting of the American Psychological Association (APA). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs. The authors declare no conflicts of interest.	Alonso J, 2004, ACTA PSYCHIAT SCAND, V109, P38; American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, DOI [10.1176/appi.books.9780890425596., DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]; Andreou C, 2013, CURR OPIN PSYCHIATR, V26, P54, DOI 10.1097/YCO.0b013e32835a2acf; Antshel K. M., 2014, J ATTENTION DISORDER; Antshel KM, 2013, J CLIN PSYCHIAT, V74, pE197, DOI 10.4088/JCP.12m07698; Asmundson GJG, 2004, J TRAUMA STRESS, V17, P467, DOI 10.1007/s10960-004-5795-7; Aupperle RL, 2012, NEUROPHARMACOLOGY, V62, P686, DOI 10.1016/j.neuropharm.2011.02.008; Barker MJ, 2005, J INT NEUROPSYCH SOC, V11, P281, DOI 10.1017/S1355617705050332; Barker MJ, 2004, ARCH CLIN NEUROPSYCH, V19, P437, DOI 10.1016/S0887-6177(03)00096-9; Barrash J, 2007, MIL MED, V172, P697, DOI 10.7205/MILMED.172.7.697; Beck A. T., 1996, BECK DEPRESSION INVE; Berndt ER, 2000, HEALTH AFFAIR, V19, P244, DOI 10.1377/hlthaff.19.4.244; Berry D.T., 1991, CLIN NEUROPSYCHOL, V5, P143, DOI [10.1080/13854049108403298, DOI 10.1080/13854049108403298, https://doi.org/10.1080/13854049108403298]; Bigler ED, 2013, CLIN NEUROPSYCHOL, V27, P176, DOI 10.1080/13854046.2012.693950; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Boyle Eleanor, 2014, Arch Phys Med Rehabil, V95, pS230, DOI 10.1016/j.apmr.2013.08.297; Bremner JD, 1995, PSYCHIAT RES, V59, P97; Breslau N, 2006, ARCH GEN PSYCHIAT, V63, P1238, DOI 10.1001/archpsyc.63.11.1238; Brewin CR, 2007, J ABNORM PSYCHOL, V116, P448, DOI 10.1037/0021-843X.116.3.448; Burriss L, 2008, DEPRESS ANXIETY, V25, P149, DOI 10.1002/da.20291; Bustamante V, 2001, J TRAUMA STRESS, V14, P791, DOI 10.1023/A:1013050423901; Casada JH, 2005, J NERV MENT DIS, V193, P102, DOI 10.1097/01.nmd.0000152809.20938.37; Cohen BE, 2013, J CLIN PSYCHIAT, V74, P1063, DOI 10.4088/JCP.12m08291; Conners C., 2000, CONNERS CONTINUOUS P; Crowell TA, 2002, CLIN NEUROPSYCHOL, V16, P310, DOI 10.1076/clin.16.3.310.13851; Danckwerts A, 2003, NEUROPSYCHOL REV, V13, P221, DOI 10.1023/B:NERV.0000009485.76839.b7; Daniels JK, 2010, J PSYCHIATR NEUROSCI, V35, P258, DOI 10.1503/jpn.090010; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Delis DC, 2000, CALIFORNIA VERBAL LE; Demakis GJ, 2008, CLIN NEUROPSYCHOL, V22, P879, DOI 10.1080/13854040701564482; Denning JH, 2012, ARCH CLIN NEUROPSYCH, V27, P417, DOI 10.1093/arclin/acs044; ERRICO AL, 1990, PSYCHOL ASSESSMENT, V2, P45, DOI DOI 10.1037/1040-3590.2.1.45; First MB., 2002, STRUCTURED CLIN INTE; Flaks MK, 2014, J PSYCHIATR RES, V48, P32, DOI 10.1016/j.jpsychires.2013.10.009; French L., 2008, J SPEC OPER MED, V8, P68; Geuze E, 2009, DEPRESS ANXIETY, V26, P7, DOI 10.1002/da.20476; Gilbertson MW, 2006, J ABNORM PSYCHOL, V115, P484, DOI 10.1037/0021-843X.115.3.484; Golier JA, 2006, ANN NY ACAD SCI, V1071, P54, DOI 10.1196/annals.1364.006; Harrington KM, 2012, COMPR PSYCHIAT, V53, P679, DOI 10.1016/j.comppsych.2011.12.001; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Hinkin CH, 2004, AIDS, V18, pS19, DOI 10.1097/00002030-200418001-00004; HISCOCK M, 1989, J CLIN EXP NEUROPSYC, V11, P967, DOI 10.1080/01688638908400949; Hoge CW, 2007, AM J PSYCHIAT, V164, P150, DOI 10.1176/appi.ajp.164.1.150; Horner MD, 2002, NEUROPSYCHOL REV, V12, P15, DOI 10.1023/A:1015439106231; Horner MD, 2013, CNS SPECTRUMS, V18, P90, DOI 10.1017/S1092852912000909; Jelinek L, 2006, J CLIN EXP NEUROPSYC, V28, P940, DOI 10.1080/13803390591004347; Jones D, 2001, J Ambul Care Manage, V24, P68; Jovanovski D, 2005, J CLIN EXP NEUROPSYC, V27, P189, DOI 10.1080/13803390490515694; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kazis L. E., 2008, VETERANS RAND UNPUB; Keane T.M., 1989, PSYCHOL ASSESSMENT J, V1, P53, DOI DOI 10.1037/1040-3590.1.1.53; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; Kessler RC, 2004, J OCCUP ENVIRON MED, V46, pS23, DOI 10.1097/01.jom.0000126683.75201.c5; Marcotte TA, 2008, ARCH PHYS MED REHAB, V89, P1753, DOI 10.1016/j.apmr.2007.12.049; Marx BP, 2009, J INT NEUROPSYCH SOC, V15, P840, DOI 10.1017/S1355617709990488; McAllister TW, 2010, ANN NY ACAD SCI, V1208, P46, DOI 10.1111/j.1749-6632.2010.05720.x; McGurk SR, 2006, ADM POLICY MENT HLTH, V33, P598, DOI 10.1007/s10488-006-0070-2; MCNALLY RJ, 1995, AM J PSYCHIAT, V152, P936; Meyers J., 1995, REY COMPLEX FIGURE T; Mohamed S, 2008, AM J PSYCHIAT, V165, P978, DOI 10.1176/appi.ajp.2008.07111713; Nijdam MJ, 2015, J CLIN PSYCHIAT, V76, pE1023, DOI 10.4088/JCP.14m09438; O'Bryant SE, 2008, APPL NEUROPSYCHOL, V15, P113, DOI 10.1080/09084280802083921; Olff M, 2014, NEUROBIOL LEARN MEM, V112, P114, DOI 10.1016/j.nlm.2014.01.003; Parslow RA, 2007, AM J PSYCHIAT, V164, P509, DOI 10.1176/appi.ajp.164.3.509; Pietrzak RH, 2012, AM J GERIAT PSYCHIAT, V20, P380, DOI 10.1097/JGP.0b013e31820d92e7; Pirogovsky E, 2012, J INT NEUROPSYCH SOC, V18, P986, DOI 10.1017/S1355617712000781; Richardson-Vejlgaard R, 2009, PSYCHIAT RES, V169, P70, DOI 10.1016/j.psychres.2008.06.018; Roca V, 2001, AM J PSYCHIAT, V158, P1738, DOI 10.1176/appi.ajp.158.10.1738-a; Rohling ML, 2012, CLIN NEUROPSYCHOL, V26, P197, DOI 10.1080/13854046.2011.647085; Rourke S.B., 2009, NEUROPSYCHOLOGICAL A, P398; Samuelson KW, 2006, NEUROPSYCHOLOGY, V20, P716, DOI 10.1037/0894-4105.20.6.716; Scherrer JF, 2008, COMPR PSYCHIAT, V49, P297, DOI 10.1016/j.comppsych.2007.11.001; Schnittker J, 2005, SOC SCI RES, V34, P821, DOI 10.1016/j.ssresearch.2005.01.003; Schroeder RW, 2011, CLIN NEUROPSYCHOL, V25, P437, DOI 10.1080/13854046.2011.556668; Schuitevoerder S, 2013, J ANXIETY DISORD, V27, P550, DOI 10.1016/j.janxdis.2013.01.001; Scott JC, 2007, NEUROPSYCHOL REV, V17, P275, DOI 10.1007/s11065-007-9031-0; Scott JC, 2015, PSYCHOL BULL, V141, P105, DOI 10.1037/a0038039; Selim A, 2009, QUAL LIFE RES, V18, P43, DOI 10.1007/s11136-008-9418-2; Shucard JL, 2008, BIOL PSYCHOL, V79, P223, DOI 10.1016/j.biopsycho.2008.05.005; Tas C, 2013, COMPR PSYCHIAT, V54, P262, DOI 10.1016/j.comppsych.2012.08.001; Tombaugh TN, 1996, TEST MEMORY MALINGER; Twamley EW, 2004, PSYCHIAT RES, V126, P265, DOI 10.1016/j.psychres.2004.01.008; Vasterling J.J., 2005, NEUROPSYCHOLOGY PTSD, P178; Vasterling JJ, 2012, BRIT J PSYCHIAT, V201, P186, DOI 10.1192/bjp.bp.111.096461; Vasterling JJ, 2002, NEUROPSYCHOLOGY, V16, P5, DOI 10.1037//0894-4105.16.1.5; Vasterling JJ, 1998, NEUROPSYCHOLOGY, V12, P125, DOI 10.1037/0894-4105.12.1.125; Wechsler D., 2001, WECHSLER TEST ADULT; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th ed; Wild J, 2008, BRIT J PSYCHIAT, V193, P254, DOI 10.1192/bjp.bp.107.045922; Wisdom NM, 2014, CLIN NEUROPSYCHOL, V28, P128, DOI 10.1080/13854046.2013.863977; Woods SP, 2003, CLIN NEUROPSYCHOL, V17, P383, DOI 10.1076/clin.17.3.383.18079; Woods SP, 2008, COGN BEHAV NEUROL, V21, P28, DOI 10.1097/WNN.0b013e3181684414	92	34	36	0	20	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	APR	2016	22	4					399	411		10.1017/S1355617716000059			13	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	DI1ZK	WOS:000373295300003	26892753				2021-06-18	
J	Bodien, YG; Carlowicz, CA; Chatelle, C; Giacino, JT				Bodien, Yelena G.; Carlowicz, Cecilia A.; Chatelle, Camille; Giacino, Joseph T.			Sensitivity and Specificity of the Coma Recovery Scale-Revised Total Score in Detection of Conscious Awareness	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Consciousness disorders; Rehabilitation; Sensitivity and specificity	STATE; DISORDERS	Objective: To describe the sensitivity and specificity of Coma Recovery Scale-Revised (CRS-R) total scores in detecting conscious awareness. Design: Data were retrospectively extracted from the medical records of patients enrolled in a specialized disorders of consciousness (DOC) program. Sensitivity and specificity analyses were completed using CRS-R derived diagnoses of minimally conscious state (MCS) or emerged from minimally conscious state (EMCS) as the reference standard for conscious awareness and the total CRS-R score as the test criterion. A receiver operating characteristic curve was constructed to demonstrate the optimal CRS-R total cutoff score for maximizing sensitivity and specificity. Setting: Specialized DOC program. Participants: Patients enrolled in the DOC program (N=252, 157 men; mean age, 49y; mean time from injury, 48d; traumatic etiology, n=127; nontraumatic etiology, n=125; diagnosis of coma or vegetative state, n=70; diagnosis of MCS or EMCS, n=182). Interventions: Not applicable. Main Outcome Measures: Sensitivity and specificity of CRS-R total scores in detecting conscious awareness. Results: A CRS-R total score of 10 or higher yielded a sensitivity of .78 for correct identification of patients in MCS or EMCS, and a specificity of 1.00 for correct identification of patients who did not meet criteria for either of these diagnoses (ie, were diagnosed with vegetative state or coma). The area under the curve in the receiver operating characteristic curve analysis is .98. Conclusions: A total CRS-R score of 10 or higher provides strong evidence of conscious awareness but resulted in a false-negative diagnostic error in 22% of patients who demonstrated conscious awareness based on CRS-R diagnostic criteria. A cutoff score of 8 provides the best balance between sensitivity and specificity, accurately classifying 93% of cases. The optimal total score cutoff will vary depending on the user's objective. (C) 2016 by the American Congress of Rehabilitation Medicine	[Bodien, Yelena G.; Carlowicz, Cecilia A.; Chatelle, Camille; Giacino, Joseph T.] Harvard Univ, Sch Med, Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Charlestown, MA USA	Bodien, YG (corresponding author), 300 First Ave 3122, Charlestown, MA 02129 USA.	ybodien@partners.org	Giacino, Joseph/AAF-1952-2021	Giacino, Joseph/0000-0002-7916-9698; Bodien, Yelena/0000-0003-4858-2903; Chatelle, Camille/0000-0002-7526-2107	National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR)United States Department of Health & Human Services [90DP0039-01-00]; James S. McDonnell Foundation; Harvard Catalyst \ the Harvard Clinical and Translational Science Center (National Center for Research Resources); Harvard University; Harvard Catalyst \ the Harvard Clinical and Translational Science Center (National Center for Advancing Translational Sciences, National Institutes of Health) [UL1 TR001102]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001102] Funding Source: NIH RePORTER; NATIONAL CENTER FOR CHRONIC DISEASE PREV AND HEALTH PROMOUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [U48DP000039] Funding Source: NIH RePORTER	The contents of this report were developed under a grant from the National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR; grant no. 90DP0039-01-00). NIDILRR is a center within the Administration for Community Living (ACL), Department of Health and Human Services (HITS). Additional support was provided by the James S. McDonnell Foundation, Harvard Catalyst vertical bar the Harvard Clinical and Translational Science Center (National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health award no UL1 TR001102), and financial contributions from Harvard University and its affiliated academic health care centers. The content is solely the responsibility of the authors and does not necessarily represent the official views of NIDILRR, ACL, HI'S, National Institutes of Health, the James S. McDonnell Foundation, Harvard Catalyst, or Harvard University and its affiliated academic health care centers, and you should not assume endorsement by the Federal Government.	ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Bagnato S, 2015, CLIN NEUROPHYSIOL, V126, P959, DOI 10.1016/j.clinph.2014.08.005; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; GIACINO JT, 1991, ARCH PHYS MED REHAB, V72, P897, DOI 10.1016/0003-9993(91)90008-7; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Lammi MH, 2005, ARCH PHYS MED REHAB, V86, P746, DOI 10.1016/j.apmr.2004.11.004; Margetis K, 2014, NEUROMODULATION, V17, P699, DOI 10.1111/ner.12147; Moreno DR, 2010, NEUROLOGY, V75, P1871, DOI 10.1212/WNL.0b013e3181feb259; Schnakers C, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-35	9	34	35	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAR	2016	97	3					490	492		10.1016/j.apmr.2015.08.422			3	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	DG1TJ	WOS:000371850100017	26342571	Green Accepted			2021-06-18	
J	Decq, P; Gault, N; Blandeau, M; Kerdraon, T; Berkal, M; ElHelou, A; Dusfour, B; Peyrin, JC				Decq, Philippe; Gault, Nathalie; Blandeau, Mathias; Kerdraon, Tristan; Berkal, Miassa; ElHelou, Amine; Dusfour, Bernard; Peyrin, Jean-Claude			Long-term consequences of recurrent sports concussion	ACTA NEUROCHIRURGICA			English	Article						Concussion; Rugby; Depression; Cognitive disorder; Headache	CHRONIC TRAUMATIC ENCEPHALOPATHY; MODIFIED TELEPHONE INTERVIEW; INTERNATIONAL-CONFERENCE; HIGH-SCHOOL; AGREEMENT STATEMENT; CONSENSUS STATEMENT; ALZHEIMERS-DISEASE; TICS-M; FOOTBALL; EPIDEMIOLOGY	Recurrent concussions are suspected to promote the development of long-term neurological disorders. The study was designed to assess the prevalence of major depressive disorder, mild cognitive disorders and headache in a population of retired high-level sportsmen and rugby players and to study the link between scores evaluating these disorders and the number of reported concussions (RCs). A total of 239 retired rugby players (RRPs) and 138 other retired sportsmen (ORSs) who had reached the French national or international championship level between 1985 and 1990 filled in a self-administered questionnaire describing their sociodemographic data, comorbidities and reported history of RC. A phone interview was then conducted using validated questionnaires for the detection of major depressive disorder (PHQ-9), mild cognitive disorders (F-TICS-m) and headache (HIT-6). RRPs reported a higher number of RCs than ORSs (p < 0.001). A higher rate of major depressive disorder (PHQ-9 score > 9) was observed among RRPs compared to ORSs (9% versus 6%) (p = 0.04), and the PHQ-9 score increased with the number of RCs regardless of the type of sport (p = 0.026). A higher rate of mild cognitive disorders (TICS-m score a parts per thousand currency sign30) was observed in RRPs compared to ORSs (57% versus 40%, p = 0.005), but no association was found with the number of RC. The HIT-6 score increased with the number of RCs (p = 0.019) More than 20 years after the end of their career, RRPs present higher rates of depression and lower F-TICS-m scores in favor of mild cognitive impairment compared with ORSs. PHQ-9 and HIT-6 scores were significantly associated with the number of RCs.	[Decq, Philippe; Blandeau, Mathias; Kerdraon, Tristan; Berkal, Miassa] Arts & Metiers ParisTech, Georges Charpak Human Biomecan Inst, Paris, France; [Gault, Nathalie] Beaujon Hosp, AP HP, Epidemiol & Clin Res Dept, Clichy, France; [Decq, Philippe; Blandeau, Mathias; Kerdraon, Tristan; Berkal, Miassa] Beaujon Hosp, AP HP, Dept Neurosurg, Clichy, France; [ElHelou, Amine] Inst Cerveau & Moelle Epiniere, Paris, France; [Dusfour, Bernard] Ligue Natl Rugby, Paris, France; [Peyrin, Jean-Claude] Federat Francaise Rugby, Marcoussis, France; [Decq, Philippe] Rene Diderot Paris 7 Med Univ, Paris, France	Decq, P (corresponding author), Arts & Metiers ParisTech, Georges Charpak Human Biomecan Inst, Paris, France.; Decq, P (corresponding author), Beaujon Hosp, AP HP, Dept Neurosurg, Clichy, France.; Decq, P (corresponding author), Rene Diderot Paris 7 Med Univ, Paris, France.	philippe.decq@aphp.fr	GAULT, Nathalie/Y-9693-2019; Helou, Amine El/AAN-6827-2020	GAULT, Nathalie/0000-0002-9913-9760; Blandeau, Mathias/0000-0002-7727-7580	Federation Francaise de Rugby (FFR); la Ligue Nationale de Rugby (LNR)	The Federation Francaise de Rugby (FFR) and la Ligue Nationale de Rugby (LNR) provided financial support in the form of research technician funding. The sponsor had no role in the design or conduct of this research.	Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Cantu RC, 2007, NEUROSURGERY, V61, P223, DOI 10.1227/01.NEU.0000255514.73967.90; Carney N, 2014, NEUROSURGERY, V75, pS3, DOI 10.1227/NEU.0000000000000433; Cook SE, 2009, J GERIATR PSYCH NEUR, V22, P103, DOI 10.1177/0891988708328214; Critchley M, 1949, PUNCH DRUNK SYNDROME; Decq P, 2011, J TRAUMATOLOGIE SPOR, V28, P227; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gonzalez HM, 2010, J PSYCHIATR RES, V44, P1043, DOI 10.1016/j.jpsychires.2010.03.017; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hollis SJ, 2012, BRIT J SPORT MED, V46, P735, DOI 10.1136/bjsm.2011.085332; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kemp SPT, 2008, CLIN J SPORT MED, V18, P227, DOI 10.1097/JSM.0b013e31816a1c9a; King D, 2015, AM J SPORT MED, V43, P614, DOI 10.1177/0363546514560876; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Lacoste L, 2009, NEUROLOGIE PSYCHIAT, V9, P17, DOI DOI 10.1016/J.NPG.2008.06.009; Laker SR, 2011, PM&R, V3, pS354, DOI 10.1016/j.pmrj.2011.07.017; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; Martin M, 2004, J CLIN EPIDEMIOL, V57, P1271, DOI 10.1016/j.jclinepi.2004.05.004; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2013, BRIT J SPORT MED, V47, P327, DOI 10.1136/bjsports-2013-092248; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory P, 2009, PHYSICIAN SPORTSMED, V37, P141, DOI 10.3810/psm.2009.06.1721; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Merritt VC, 2015, J CLIN EXP NEUROPSYC, V37, P265, DOI 10.1080/13803395.2015.1004303; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Rothman KJ, 2008, MODERN EPIDEMIOLOGY; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Seifert TD, 2013, HEADACHE, V53, P726, DOI 10.1111/head.12087; Thomas Anterion C, 2001, REV NEUROL, V157, P1377; Torelli P, 2004, CEPHALALGIA, V24, P29, DOI 10.1111/j.1468-2982.2004.00633.x; Torres Daniel M, 2013, Neurol Clin Pract, V3, P279; Vercambre MN, 2010, INT J GERIATR PSYCH, V25, P1142, DOI 10.1002/gps.2447; Yang M, 2011, CEPHALALGIA, V31, P357, DOI 10.1177/0333102410379890; Zuithoff NPA, 2010, BMC FAM PRACT, V11, DOI 10.1186/1471-2296-11-98	40	34	34	0	51	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	FEB	2016	158	2					289	300		10.1007/s00701-015-2681-4			12	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	DB6DK	WOS:000368603400012	26711286	Green Published			2021-06-18	
J	Tang, Q; Song, PP; Li, JJ; Kong, FL; Sun, L; Xu, LZ				Tang, Qi; Song, Peipei; Li, Jiajia; Kong, Fanlei; Sun, Long; Xu, Lingzhong			Control of antibiotic resistance in China must not be delayed: The current state of resistance and policy suggestions for the government, medical facilities, and patients	BIOSCIENCE TRENDS			English	Article						Antibiotic resistance; antibiotic misuse; China	SURGICAL SITE INFECTIONS; MULTIDISCIPLINARY TEAM; CDC DEFINITIONS; ANTIBACTERIAL; BURDEN	Antibiotics are medicines used to prevent and treat bacterial infections. Antibiotic resistance occurs when bacteria change in response to the use of these medicines. Antibiotic resistance is rising to dangerously high levels in all parts of the world, leading to higher medical costs, prolonged hospital stays, and increased mortality. In the European Union alone, drug-resistant bacteria are estimated to cause 25,000 deaths and cost more than US$1.5 billion every year in healthcare expenses and productivity losses. The problems of antibiotic misuse and antibiotic resistance are quite serious in China. In 2015, results of a study by the State Key Laboratory of Organic Geochemistry, Guangzhou Institute of Geochemistry, Chinese Academy of Sciences indicated that the total antibiotic usage in China in 2013 was approximately 162,000 tons, including human use (48%) and use in animals (52%). This amount accounted for about half of the antibiotic usage worldwide. The per-capita use of antibiotics in China is more than 5 times that in Europe and the United States. These data mean that China is one of the world's leading countries with serious problems in terms of antibiotic misuse and antibiotic resistance. The current article analyzes the current state and harms of antibiotic misuse and causes of antibiotic resistance in China. The Government needs to pay close attention to the issue of antibiotic resistance in China and formulate a strategy at the national level. Thus, the following suggestions are offered: i) The Chinese Government should implement policies that promote antibiotic research and development; ii) Medical facilities in China should create multidisciplinary teams (MDTs) and encourage early action by MDTs to control the spread of multi-drug-resistant bacteria (MDRB); iii) An intervention in the form of health education should target patients and accompanying family members (AFM) in China. In other words, antibiotic resistance is not a personal problem but an urgent public health problem. Without urgent action, China is heading for a post-antibiotic era in which common infections and minor injuries can once again kill. Therefore, the aforementioned proposals have been offered with the hope that policy suggestions help to limit the phenomenon of antibiotic misuse and antibiotic resistance in China.	[Tang, Qi; Li, Jiajia; Kong, Fanlei; Sun, Long; Xu, Lingzhong] Shandong Univ, Sch Publ Hlth, Dept Social Med & Med Serv Management, Box 110,44 Wenhuaxi Rd, Jinan 250012, Shandong, Peoples R China; [Song, Peipei] Univ Tokyo, Grad Sch Frontier Sci, Kashiwa, Chiba, Japan	Xu, LZ (corresponding author), Shandong Univ, Sch Publ Hlth, Dept Social Med & Med Serv Management, Box 110,44 Wenhuaxi Rd, Jinan 250012, Shandong, Peoples R China.	lzxu@sdu.edu.cn		Sun, Long/0000-0002-3070-8427			Ai RT, 2012, GUIDE CHINA MED, V10, P284; Ameh EA, 2009, SURG INFECT, V10, P105, DOI 10.1089/sur.2007.082; [Anonymous], 2015, CHINA HLTH FAMILY PL; Boltz MM, 2011, SURGERY, V150, P934, DOI 10.1016/j.surg.2011.04.006; Brown ED, 2013, CAN J MICROBIOL, V59, P153, DOI 10.1139/cjm-2013-0089; Dramowski A, 2015, PAEDIATR INT CHILD H, V35, P265, DOI 10.1179/2046905515Y.0000000029; Edwards JR, 2008, AM J INFECT CONTROL, V36, P609, DOI 10.1016/j.ajic.2008.08.001; Fankam AG, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906-015-0726-0; Feng Fing-jing, 2014, Zhongguo Kangshengsu Zazhi, V39, P14; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; Gu JF, 2010, P 2010 CHIN PHARM C; Hoque R, 2015, THER CLIN RISK MANAG, V11, P1177, DOI 10.2147/TCRM.S90110; HORAN TC, 1992, INFECT CONT HOSP EP, V13, P606; Juayang AC, 2015, INT J BACTERIOL, V2015; Kirby T, 2015, LANCET INFECT DIS, V15, P271, DOI 10.1016/S1473-3099(15)70072-1; Li FC, 2014, CHINESE J CLIN RATIO, V26, P175; Li XP, 2005, MED PHILOS, V26, P20; Magedanz L, 2012, INT J CLIN PHARM-NET, V34, P290, DOI 10.1007/s11096-012-9621-7; Morrison KD, 2016, SCI REP-UK, V6, DOI 10.1038/srep19043; National Health and Family Planning Commission, 2015, REP MON BACT DRUG RE; Rawson TM, 2015, J VASC SURG, V62, P1686, DOI 10.1016/j.jvs.2015.07.081; [宋丹妮 SONG Danni], 2005, [广东微量元素科学, Guangdong Weiliang Yuansu Kexue], V12, P64; [王丹 Wang Dan], 2014, [科学通报, Chinese Science Bulletin], V59, P743; Wang XL, 2012, CHINESE J PHARMACOEP, V10, P491; Wang YP, 2008, CHINESE J ANTIBIOTIC, V9, P519; WHO-World Health Organization, 2015, WORLDW COUNTR SIT AN; World Health Organization, 2015, FACT SHEET ANT RES; World Health Organization, 2015, WHO MULT SURV REV WI; Yang ZY, 2011, HLTH NEWS, V01, P03008; [张梦 Zhang Meng], 2016, [中国新药杂志, Chinese Journal New Drugs], V25, P13; Zhang QQ, 2015, ENVIRON SCI TECHNOL, V49, P6772, DOI 10.1021/acs.est.5b00729; [邹英 ZOU Ying], 2006, [第三军医大学学报, Acta Academiae Medicinae Militaris Tertiae], V28, P724	32	34	35	3	28	IRCA-BSSA	TOKYO	PEARL CITY KOISHIKAWA 603, 2-4-5 KASUGA, BUNKYO-KU, TOKYO, 112-0003, JAPAN	1881-7815	1881-7823		BIOSCI TRENDS	BioSci. Trends	FEB	2016	10	1					1	6		10.5582/bst.2016.01034			6	Biology	Life Sciences & Biomedicine - Other Topics	DG1GM	WOS:000371814100001	26961210	Bronze			2021-06-18	
J	Gardner, RC; Hess, CP; Brus-Ramer, M; Possin, KL; Cohn-Sheehy, BI; Kramer, JH; Berger, MS; Yaffe, K; Miller, B; Rabinovici, GD				Gardner, Raquel C.; Hess, Christopher P.; Brus-Ramer, Marcel; Possin, Katherine L.; Cohn-Sheehy, Brendan I.; Kramer, Joel H.; Berger, Mitchel S.; Yaffe, Kristine; Miller, Bruce; Rabinovici, Gil D.			Cavum Septum Pellucidum in Retired American Pro-Football Players	JOURNAL OF NEUROTRAUMA			English	Article						concussion; magnetic resonance imaging; septum pellucidum; traumatic brain injury	TRAUMATIC BRAIN-INJURY; ENCEPHALOPATHY; DEMENTIA; DISEASE; BOXERS; MRI	Previous studies report that cavum septum pellucidum (CSP) is frequent among athletes with a history of repeated traumatic brain injury (TBI), such as boxers. Few studies of CSP in athletes, however, have assessed detailed features of the septum pellucidum in a case-control fashion. This is important because prevalence of CSP in the general population varies widely (2% to 85%) between studies. Further, rates of CSP among American pro-football players have not been described previously. We sought to characterize MRI features of the septum pellucidum in a series of retired pro-football players with a history of repeated concussive/subconcussive head traumas compared with controls. We retrospectively assessed retired American pro-football players presenting to our memory clinic with cognitive/behavioral symptoms in whom structural MRI was available with slice thickness 2mm (n=17). Each player was matched to a memory clinic control patient with no history of TBI. Scans were interpreted by raters blinded to clinical information and TBI/football history, who measured CSP grade (0-absent, 1-equivocal, 2-mild, 3-moderate, 4-severe) and length according to a standard protocol. Sixteen of 17 (94%) players had a CSP graded 2 compared with 3 of 17 (18%) controls. CSP was significantly higher grade (p<0.001) and longer in players than controls (mean length +/- standard deviation: 10.6mm +/- 5.4 vs. 1.1mm +/- 1.3, p<0.001). Among patients presenting to a memory clinic, long high-grade CSP was more frequent in retired pro-football players compared with patients without a history of TBI.	[Gardner, Raquel C.; Possin, Katherine L.; Cohn-Sheehy, Brendan I.; Kramer, Joel H.; Miller, Bruce; Rabinovici, Gil D.] Univ Calif San Francisco, Dept Neurol, Memory & Aging Ctr, San Francisco, CA 94121 USA; [Gardner, Raquel C.; Yaffe, Kristine] San Francisco VA Med Ctr, Dept Vet Affairs, San Francisco, CA USA; [Hess, Christopher P.; Brus-Ramer, Marcel] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94121 USA; [Berger, Mitchel S.] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94121 USA; [Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94121 USA; [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA	Gardner, RC (corresponding author), Univ Calif San Francisco, Dept Neurol, 4150 Clement St,Neurol Box 127, San Francisco, CA 94121 USA.	raquel.gardner@ucsf.edu	Rabinovici, Gil/AAA-2495-2020; Brus-Ramer, Marcel/AAQ-8858-2020	Gardner, Raquel C./0000-0003-4028-440X	Department of Veterans Affairs Advanced Fellowship in Mental Illness Research/Treatment; UCSF Pepper Center Research Career Development Core; NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K24-AG031155, R01-AG045611, K23-AG037566]; Alzheimer's AssociationAlzheimer's Association; Avid Radiopharmaceuticals; John Douglas French Alzheimer's Foundation; Hellman Family Foundation; Tau Consortium; UCSF ADRC [P50 AG023501]; State Center grants; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG023501, R01AG045611, P01AG019724, P30AG044281, K23AG037566, K24AG031155] Funding Source: NIH RePORTER	We thank our patients and their families for contributing to research on TBI. We acknowledge administrative and technical support from Trishna Subas and Shirley Reeder. Funding: Department of Veterans Affairs Advanced Fellowship in Mental Illness Research/Treatment (RCG); UCSF Pepper Center Research Career Development Core (RCG); NIA K24-AG031155 (KY), NIA R01-AG045611 (GDR), Alzheimer's Association (GDR), Avid Radiopharmaceuticals (GDR), John Douglas French Alzheimer's Foundation (GDR), Hellman Family Foundation (GDR), Tau Consortium (GDR), UCSF ADRC (P50 AG023501) (GDR, BM), and State Center grants (BM), NIA K23-AG037566 (KP).	Bodensteiner JB, 1997, SPORTS MED, V24, P361, DOI 10.2165/00007256-199724060-00002; BOGDANOFF B, 1989, NEUROLOGY, V39, P991, DOI 10.1212/WNL.39.7.991; Born CM, 2004, EUR ARCH PSY CLIN N, V254, P295, DOI 10.1007/s00406-004-0496-z; Cabanis E A, 1986, Acta Radiol Suppl, V369, P365; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Hwang J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078590; MAWDSLEY C, 1963, LANCET, V2, P795; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Orrison WW, 2009, J NEUROTRAUM, V26, P689, DOI 10.1089/neu.2008.0636; Pittella JEH, 2005, SURG NEUROL, V63, P30, DOI 10.1016/j.surneu.2004.09.012; Raybaud C, 2010, NEURORADIOLOGY, V52, P447, DOI 10.1007/s00234-010-0696-3; Rosset A, 2004, J DIGIT IMAGING, V17, P205, DOI 10.1007/s10278-004-1014-6; Silk T, 2013, PSYCHIAT RES-NEUROIM, V213, P186, DOI 10.1016/j.pscychresns.2013.03.001; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Zimmerman RD, 1993, MED ASPECTS BOXING, P188	15	34	34	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 1	2016	33	1					157	161		10.1089/neu.2014.3805			5	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CZ4EW	WOS:000367057200018	25970145	Green Published			2021-06-18	
J	Newcombe, VFJ; Correia, MM; Ledig, C; Abate, MG; Outtrim, JG; Chatfield, D; Geeraerts, T; Manktelow, AE; Garyfallidis, E; Pickard, JD; Sahakian, BJ; Hutchinson, PJA; Rueckert, D; Coles, JP; Williams, GB; Menon, DK				Newcombe, Virginia F. J.; Correia, Marta M.; Ledig, Christian; Abate, Maria G.; Outtrim, Joanne G.; Chatfield, Doris; Geeraerts, Thomas; Manktelow, Anne E.; Garyfallidis, Eleftherios; Pickard, John D.; Sahakian, Barbara J.; Hutchinson, Peter J. A.; Rueckert, Daniel; Coles, Jonathan P.; Williams, Guy B.; Menon, David K.			Dynamic Changes in White Matter Abnormalities Correlate With Late Improvement and Deterioration Following TBI: A Diffusion Tensor Imaging Study	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						traumatic brain injury; magnetic resonance imaging; diffusion tensor imaging	TRAUMATIC BRAIN-INJURY; HEAD-INJURY; AXONAL INJURY; INTEGRITY; SEVERITY; RAT; MRI; DYSFUNCTION; TOMOGRAPHY; ACTIVATION	Objective. Traumatic brain injury (TBI) is not a single insult with monophasic resolution, but a chronic disease, with dynamic processes that remain active for years. We aimed to assess patient trajectories over the entire disease narrative, from ictus to late outcome. Methods. Twelve patients with moderate-to-severe TBI underwent magnetic resonance imaging in the acute phase (within 1 week of injury) and twice in the chronic phase of injury (median 7 and 21 months), with some undergoing imaging at up to 2 additional time points. Longitudinal imaging changes were assessed using structural volumetry, deterministic tractography, voxel-based diffusion tensor analysis, and region of interest analyses (including corpus callosum, parasagittal white matter, and thalamus). Imaging changes were related to behavior. Results. Changes in structural volumes, fractional anisotropy, and mean diffusivity continued for months to years postictus. Changes in diffusion tensor imaging were driven by increases in both axial and radial diffusivity except for the earliest time point, and were associated with changes in reaction time and performance in a visual memory and learning task (paired associates learning). Dynamic structural changes after TBI can be detected using diffusion tensor imaging and could explain changes in behavior. Conclusions. These data can provide further insight into early and late pathophysiology, and begin to provide a framework that allows magnetic resonance imaging to be used as an imaging biomarker of therapy response. Knowledge of the temporal pattern of changes in TBI patient populations also provides a contextual framework for assessing imaging changes in individuals at any given time point.	[Newcombe, Virginia F. J.; Correia, Marta M.; Abate, Maria G.; Outtrim, Joanne G.; Chatfield, Doris; Geeraerts, Thomas; Manktelow, Anne E.; Pickard, John D.; Sahakian, Barbara J.; Hutchinson, Peter J. A.; Coles, Jonathan P.; Williams, Guy B.; Menon, David K.] Univ Cambridge, Cambridge CB2 2QQ, England; [Ledig, Christian; Rueckert, Daniel] Univ London Imperial Coll Sci Technol & Med, London, England; [Abate, Maria G.] Gerardo Hosp, Milan, Italy; [Geeraerts, Thomas] Univ Hosp Toulouse, Toulouse, France; [Garyfallidis, Eleftherios] Univ Sherbrooke, Sherbrooke, PQ J1K 2R1, Canada	Newcombe, VFJ (corresponding author), Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Box 93,Hills Rd, Cambridge CB2 2QQ, England.	vfjn2@cam.ac.uk	Sahakian, Barbara/AAW-1198-2020	Sahakian, Barbara/0000-0001-7352-1745; Newcombe, Virginia/0000-0001-6044-9035; Hutchinson, Peter/0000-0002-2796-1835; Ledig, Christian/0000-0003-4862-3138	Medical Research Council (UK)UK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G9439390 ID 65883]; UK National Institute of Health Research Biomedical Research Centre at CambridgeNational Institute for Health Research (NIHR); Technology Platform - UK Department of Health; Health Foundation/Academy of Medical Sciences Clinician Scientist Fellowship; Societe Francaise d'Anesthesie et de Reanimation (SFAR); National Institute for Health Research Professorship; NIHR Senior Investigator Award; FP7 grant from the European Commission; Academy of Medical Sciences (AMS)Academy of Medical Sciences (AMS) [AMS-CSF4-Newcombe] Funding Source: researchfish; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G1002277, G0600986, G0601025, G0001354, G1000183B, G0001237, G9439390, G0001354B] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0512-10090, NIHR-RP-R3-12-013, ACF-2009-14-007, NF-SI-0508-10327] Funding Source: researchfish	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by a Medical Research Council (UK) Program Grant (Acute brain injury: heterogeneity of mechanisms, therapeutic targets and outcome effects [G9439390 ID 65883]), the UK National Institute of Health Research Biomedical Research Centre at Cambridge, and the Technology Platform funding provided by the UK Department of Health. VFJN is supported by a Health Foundation/Academy of Medical Sciences Clinician Scientist Fellowship. TG was supported by the Societe Francaise d'Anesthesie et de Reanimation (SFAR). PJAH is supported by a National Institute for Health Research Professorship. DKM is supported by an NIHR Senior Investigator Award and by an FP7 grant from the European Commission.	Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; Dinkel J, 2014, AM J NEURORADIOL, V35, P23, DOI 10.3174/ajnr.A3616; Farbota KD, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00160; Garyfallidis E, 2012, FRONT NEUROSCI-SWITZ, V6, DOI 10.3389/fnins.2012.00175; Greenberg G, 2008, ARCH PHYS MED REHAB, V89, pS45, DOI 10.1016/j.apmr.2008.08.211; GREENSPAN L, 1985, J TRAUMA, V25, P60, DOI 10.1097/00005373-198501000-00010; Heck RH, 2014, QUANT METH SER, P1; Hedman AM, 2012, HUM BRAIN MAPP, V33, P1987, DOI 10.1002/hbm.21334; Hellyer PJ, 2013, ANN NEUROL, V73, P489, DOI 10.1002/ana.23824; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; JENNETT B, 1975, LANCET, V1, P480; Kawai N, 2010, J NEUROTRAUM, V27, P2131, DOI 10.1089/neu.2010.1464; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Laitinen T, 2010, NEUROIMAGE, V51, P521, DOI 10.1016/j.neuroimage.2010.02.077; Ledig C, 2014, IEEE 11 INT S BIOM I; Ledig C, 2015, MED IMAGE ANAL, V21, P40, DOI 10.1016/j.media.2014.12.003; Leung KK, 2012, NEUROIMAGE, V59, P3995, DOI 10.1016/j.neuroimage.2011.10.068; Little DM, 2010, NEUROLOGY, V74, P558, DOI 10.1212/WNL.0b013e3181cff5d5; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Marcus DS, 2007, J COGNITIVE NEUROSCI, V19, P1498, DOI 10.1162/jocn.2007.19.9.1498; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Maxwell WL, 2010, BRAIN, V133, P139, DOI 10.1093/brain/awp264; Modat M, 2010, COMPUT METH PROG BIO, V98, P278, DOI 10.1016/j.cmpb.2009.09.002; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Newcombe V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019214; Newcombe VFJ, 2013, J CEREBR BLOOD F MET, V33, P855, DOI 10.1038/jcbfm.2013.11; Newcombe VFJ, 2008, ACTA NEUROCHIR SUPPL, V102, P247, DOI 10.1007/978-3-211-85578-2_47; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Puig J, 2013, STROKE, V44, P1162, DOI 10.1161/STROKEAHA.111.678110; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rueckert D, 1999, IEEE T MED IMAGING, V18, P712, DOI 10.1109/42.796284; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Salmond CH, 2005, BRAIN, V128, P189, DOI 10.1093/brain/awh352; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Spitz G, 2013, BRAIN TOPOGR, V26, P648, DOI 10.1007/s10548-013-0283-0; Tustison NJ, 2010, IEEE T MED IMAGING, V29, P1310, DOI 10.1109/TMI.2010.2046908; WAGNER DP, 1984, MED DECIS MAKING, V4, P297, DOI 10.1177/0272989X8400400305; Walker KR, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00029; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246; Wilson S, 2004, J NEUROTRAUM, V21, P239, DOI 10.1089/089771504322972031; Worsley KJ, 1996, HUM BRAIN MAPP, V4, P58, DOI 10.1002/(SICI)1097-0193(1996)4:1<58::AID-HBM4>3.0.CO;2-O; Xu S, 2011, J NEUROTRAUM, V28, P2091, DOI 10.1089/neu.2010.1739	48	34	35	0	13	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1545-9683	1552-6844		NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair	JAN	2016	30	1					49	62		10.1177/1545968315584004			14	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	CZ5VH	WOS:000367169900005	25921349				2021-06-18	
J	Tweedie, D; Rachrnany, L; Rubovitch, V; Li, YZ; Holloway, HW; Lehrmann, E; Zhang, YQ; Becker, KG; Perez, E; Hoffer, BJ; Pick, CG; Greig, NH				Tweedie, David; Rachrnany, Lital; Rubovitch, Vardit; Li, Yazhou; Holloway, Harold W.; Lehrmann, Elin; Zhang, Yongqing; Becker, Kevin G.; Perez, Evelyn; Hoffer, Barry J.; Pick, Chaim G.; Greig, Nigel H.			Blast traumatic brain injury-induced cognitive deficits are attenuated by preinjury or postinjury treatment with the glucagon-like peptide-1 receptor agonist, exendin-4	ALZHEIMERS & DEMENTIA			English	Article						Exendin-4; Blast injury; Traumatic brain injury; Neurodegeneration; Alzheimer's disease; Parkinson's disease; Behavioral deficits; Gene expression; Glucagon-like peptide-1	DEPENDENT INSULINOTROPIC POLYPEPTIDE; REVERSES BEHAVIORAL IMPAIRMENTS; GENE-EXPRESSION; CELL-DEATH; TNF-ALPHA; DRUG CANDIDATES; INCREASED RISK; HEAD-INJURY; DEMENTIA; MECHANISMS	Introduction: Blast traumatic brain injury (B-TBI) affects military and civilian personnel. Presently, there are no approved drugs for blast brain injury. Methods: Exendin-4 (Ex-4), administered subcutaneously, was evaluated as a pretreatment (48 hours) and postinjury treatment (2 hours) on neurodegeneration, behaviors, and gene expressions in a marine open field model of blast injury. Results: B-TBI induced neurodegeneration, changes in cognition, and genes expressions linked to dementia disorders. Ex-4, administered preinjury or postinjury, ameliorated B-TBI induced neurodegeneration at 72 hours, memory deficits from days 7-14, and attenuated genes regulated by blast at day 14 postinjury. Discussion: The present data suggest shared pathologic processes between concussive and B-TBI, with end points amenable to beneficial therapeutic manipulation by Ex-4. B-TBI induced dementia-related gene pathways and cognitive deficits in mice somewhat parallel epidemiologic studies of Barnes et al. who identified a greater risk in US military veterans who experienced diverse TBIs, for dementia in later life. Published by Elsevier Inc. on behalf of the Alzheimer's Association.	[Tweedie, David; Li, Yazhou; Holloway, Harold W.; Greig, Nigel H.] NIA, Translat Gerontol Branch, Intramural Res Program, NIH, Baltimore, MD 21224 USA; [Rachrnany, Lital; Rubovitch, Vardit; Pick, Chaim G.] Tel Aviv Univ, Sackler Sch Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel; [Lehrmann, Elin; Zhang, Yongqing; Becker, Kevin G.] NIA, Genet Lab, Intramural Res Program, NIH, Baltimore, MD 21224 USA; [Perez, Evelyn] NIA, Lab Behav Neurosci, Intramural Res Program, NIH, Baltimore, MD 21224 USA; [Hoffer, Barry J.] Case Western Reserve Univ, Sch Med, Dept Neurosurg, Cleveland, OH USA; [Hoffer, Barry J.] Taipei Med Univ, Grad Program Neuroregenerat, Taipei, Taiwan; [Pick, Chaim G.] Tel Aviv Univ, Sagol Sch Neurosci, IL-69978 Tel Aviv, Israel	Tweedie, D (corresponding author), NIA, Translat Gerontol Branch, Intramural Res Program, NIH, Baltimore, MD 21224 USA.	tweedieda@grc.nia.nih.gov		Lehrmann, Elin/0000-0002-9869-9475	Intramural Research Program of the National Institute on Aging, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG000333-07]; Sackler School of Medicine, Tel Aviv University; Israel Science FoundationIsrael Science Foundation [108/09]; Joseph Sagol Fellowship; National Science Council TaiwanMinistry of Science and Technology, Taiwan [NSC101-2632-B-038-001-MY3]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [ZIAAG000333, ZICAG000616] Funding Source: NIH RePORTER	This research was supported in part by (1) the Intramural Research Program of the National Institute on Aging, National Institutes of Health, grant AG000333-07; (2) the Sackler School of Medicine, Tel Aviv University; (3) a grant from the Israel Science Foundation, grant number 108/09; (4) the Joseph Sagol Fellowship, and (5) the National Science Council Taiwan, grant NSC101-2632-B-038-001-MY3.	Abner EL, 2014, DEMENT GERIATR COGN, V37, P294, DOI 10.1159/000355478; Aviles-Olmos I, 2014, J PARKINSON DIS, V4, P337, DOI 10.3233/JPD-140364; Aviles-Olmos I, 2013, J CLIN INVEST, V123, P2730, DOI 10.1172/JCI68295; Baratz R, 2011, J NEUROCHEM, V118, P1032, DOI 10.1111/j.1471-4159.2011.07377.x; Baratz R, 2010, J NEUROTRAUM, V27, P555, DOI 10.1089/neu.2009.0891; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Barnes DE, 2014, NEUROLOGY, V83, P312, DOI 10.1212/WNL.0000000000000616; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Brandt-Bohne U, 2007, BIOCHEM J, V401, P447, DOI 10.1042/BJ20060691; Campbell JE, 2013, CELL METAB, V17, P819, DOI 10.1016/j.cmet.2013.04.008; Chen Y, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00117; CHOI DW, 1987, J NEUROSCI, V7, P357; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; Czibere L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023604; Dams-O'Connor K, 2013, J NEUROL NEUROSUR PS, V84, P177, DOI 10.1136/jnnp-2012-303938; Daneshvar DH, 2011, PHYS MED REH CLIN N, V22, P683, DOI 10.1016/j.pmr.2011.08.009; Darsalia V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103114; Dong SZ, 2007, EUR J NEUROSCI, V26, P101, DOI 10.1111/j.1460-9568.2007.05641.x; Duarte AI, 2013, BBA-MOL BASIS DIS, V1832, P527, DOI 10.1016/j.bbadis.2013.01.008; Eakin K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082016; Faivre E, 2011, J NEUROPHYSIOL, V105, P1574, DOI 10.1152/jn.00866.2010; Finkel MF, 2006, J NEUROL SCI, V249, P63, DOI 10.1016/j.jns.2006.06.005; Frankola KA, 2011, CNS NEUROL DISORD-DR, V10, P391; Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668; Gitton Y, 2002, NATURE, V420, P586, DOI 10.1038/nature01178; Goel MD, 2012, DEFENCE SCI J, V62, P300, DOI 10.14429/dsj.62.1149; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Greig NH, 2004, ANN NY ACAD SCI, V1035, P290, DOI 10.1196/annals.1332.018; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Hayashi K, 2006, J NEUROCHEM, V99, P237, DOI 10.1111/j.1471-4159.2006.04113.x; Holscher C, 2012, CNS DRUGS, V26, P871, DOI 10.2165/11635890-000000000-00000; Hoffer ME, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054163; Holscher Christian, 2010, Recent Pat CNS Drug Discov, V5, P109; Hosek J., 2011, IS DEPLOYMENT IRAQ A; Jones SAV, 2014, BRIT J SPORT MED, V48, P159, DOI 10.1136/bjsports-2013-092758; Kim SY, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-144; Kochanek PM, 2013, J NEUROTRAUM, V30, P920, DOI 10.1089/neu.2013.2862; Lee YK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062422; Li YZ, 2015, J NEUROCHEM, V135, P1203, DOI 10.1111/jnc.13169; Li YZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032008; Li YZ, 2010, J ALZHEIMERS DIS, V19, P1205, DOI 10.3233/JAD-2010-1314; Lippa SM, 2010, J INT NEUROPSYCH SOC, V16, P856, DOI 10.1017/S1355617710000743; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; Mattson MP, 2006, NAT REV NEUROSCI, V7, P278, DOI 10.1038/nrn1886; Mccoy MK, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-45; Mirza Z, 2014, CNS NEUROL DISORD-DR, V13, P501, DOI 10.2174/18715273113126660154; Miu J, 2008, INFECT IMMUN, V76, P1812, DOI 10.1128/IAI.01650-07; Morrison RS, 2003, NEUROCHEM RES, V28, P15, DOI 10.1023/A:1021687810103; Nordstrom P, 2014, ANN NEUROL, V75, P374, DOI 10.1002/ana.24101; Nyberg J, 2007, J NEUROSCI RES, V85, P2099, DOI 10.1002/jnr.21349; Perry T, 2003, TRENDS PHARMACOL SCI, V24, P377, DOI 10.1016/S0165-6147(03)00160-3; Perry T, 2007, EXP NEUROL, V203, P293, DOI 10.1016/j.expneurol.2006.09.028; Perry T, 2002, J ALZHEIMERS DIS, V4, P487; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Poulain FE, 2007, MOL CELL NEUROSCI, V34, P137, DOI 10.1016/j.mcn.2006.10.012; Pun Pamela B L, 2011, Front Neurol, V2, P19, DOI 10.3389/fneur.2011.00019; Rachmany L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079837; Rachmany L, 2013, AGE, V35, P1621, DOI 10.1007/s11357-012-9464-0; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Rappaport N, 2013, DATABASE-OXFORD, DOI 10.1093/database/bat018; Risling M, 2011, NEUROIMAGE, V54, pS89, DOI 10.1016/j.neuroimage.2010.05.031; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Rubovitch V, 2010, NEUROBIOL DIS, V38, P299, DOI 10.1016/j.nbd.2010.01.021; Salcedo I, 2012, BRIT J PHARMACOL, V166, P1586, DOI 10.1111/j.1476-5381.2012.01971.x; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Seichepine DR, 2013, J NEUROTRAUM, V30, P1299, DOI 10.1089/neu.2012.2690; Stamm JM, 2015, NEUROLOGY, V84, P1114, DOI 10.1212/WNL.0000000000001358; Sundstrom A, 2007, INT PSYCHOGERIATR, V19, P159, DOI 10.1017/S1041610206003498; Tashlykov V, 2009, J MOL NEUROSCI, V37, P16, DOI 10.1007/s12031-008-9094-2; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Tweedie D, 2007, CURR ALZHEIMER RES, V4, P378, DOI 10.2174/156720507781788873; Tweedie D, 2007, J NEUROSCI RES, V85, P805, DOI 10.1002/jnr.21160; Tweedie D, 2013, NEUROBIOL DIS, V54, P1, DOI 10.1016/j.nbd.2013.02.006; Tweedie D, 2013, EXP NEUROL, V239, P170, DOI 10.1016/j.expneurol.2012.10.001; Valiyaveettil M, 2013, CHEM-BIOL INTERACT, V203, P371, DOI 10.1016/j.cbi.2012.10.022; Valiyaveettil M, 2012, J REHABIL RES DEV, V49, P1153, DOI 10.1682/JRRD.2011.09.0182; Wang HK, 2012, J NEUROL NEUROSUR PS, V83, P1080, DOI 10.1136/jnnp-2012-302633; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Yamada K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008596	80	34	36	1	13	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1552-5260	1552-5279		ALZHEIMERS DEMENT	Alzheimers. Dement.	JAN	2016	12	1					34	48		10.1016/j.jalz.2015.07.489			15	Clinical Neurology	Neurosciences & Neurology	DC1HU	WOS:000368968200005	26327236	Green Accepted			2021-06-18	
J	Ahmadzadeh, H; Smith, DH; Shenoy, VB				Ahmadzadeh, Hossein; Smith, Douglas H.; Shenoy, Vivek B.			Mechanical Effects of Dynamic Binding between Tau Proteins on Microtubules during Axonal Injury	BIOPHYSICAL JOURNAL			English	Article							BRAIN-INJURY; DEFORMATION; TRANSPORT; STRAIN; DAMAGE; BIOMECHANICS; ORGANIZATION; DENDRITES; BREAKING; SINGLE	The viscoelastic nature of axons plays a key role in their selective vulnerability to damage in traumatic brain injury (TBI). Experimental studies have shown that although axons can tolerate 100% strain under slow loading rates, even strain as small as 5% can rupture microtubules (MTs) during the fast loading velocities relevant to TBI. Here, we developed a computational model to examine rate-dependent behavior related to dynamic interactions between MTs and the MT-associated protein tau under varying strains and strain rates. In the model, inverted pairs of tau proteins can dynamically cross-link parallel MTs via the respective MT-binding domain of each tau. The model also incorporates realistic thermodynamic breaking and reformation of the bonds between the connected tau proteins as they respond to mechanical stretch. With simulated stretch of the axon, the model shows that despite the highly dynamic nature of binding and unbinding events, under fast loading rates relevant to TBI, large tensile forces can be transmitted to the MTs that can lead to mechanical rupture of the MT cylinder, in agreement with experimental observations and as inferred in human TBI. In contrast, at slow loading rates, the progressive breaking and reformation of the bonds between the tau proteins facilitate the extension of axons up to similar to 100% strain without any microstructural damage. The model also predicts that under fast loading rates, individual MTs detach from MT bundles via sequential breaking of the tau-tau bonds. Finally, the model demonstrates that longer MTs are more susceptible to mechanical rupture, whereas short MTs are more prone to detachment from the MT bundle, leading to disintegration of the axonal MT ultrastructure. Notably, the predictions from the model are in excellent agreement with the findings of the recent in vitro mechanical testing of micropatterned neuronal cultures.	[Ahmadzadeh, Hossein; Shenoy, Vivek B.] Univ Penn, Dept Mat Sci & Engn, Philadelphia, PA 19104 USA; [Smith, Douglas H.] Univ Penn, Penn Ctr Brain Injury & Repair, Philadelphia, PA 19104 USA; [Smith, Douglas H.] Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA	Shenoy, VB (corresponding author), Univ Penn, Dept Mat Sci & Engn, 3231 Walnut St, Philadelphia, PA 19104 USA.	vshenoy@seas.upenn.edu			National Institute of Biomedical Imaging and Bioengineering of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB017753]; U.S. National Science FoundationNational Science Foundation (NSF) [CMMI-1312392]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-N5038104, R01 NS092389, P01-NS056202]; U.S. Department of DefenseUnited States Department of Defense [PT110785]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB017753] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS056202, R01NS038104] Funding Source: NIH RePORTER	This study was supported by the National Institute of Biomedical Imaging and Bioengineering of the National Institutes of Health under award number R01EB017753, and by U.S. National Science Foundation grant CMMI-1312392 (to V.B.S.), National Institutes of Health grants R01-N5038104, R01 NS092389, and P01-NS056202, and U.S. Department of Defense grant PT110785 (to D.H.S.).	AAMODT EJ, 1986, J CELL BIOL, V103, P23, DOI 10.1083/jcb.103.1.23; Ackbarow T, 2007, P NATL ACAD SCI USA, V104, P16410, DOI 10.1073/pnas.0705759104; Ackbarow T, 2009, J PHYS-CONDENS MAT, V21, DOI 10.1088/0953-8984/21/3/035111; Ahmadzadeh H, 2014, BIOPHYS J, V106, P1123, DOI 10.1016/j.bpj.2014.01.024; Baas PW, 2004, J NEUROBIOL, V58, P3, DOI 10.1002/neu.10281; Baas PW, 2005, TRENDS CELL BIOL, V15, P518, DOI 10.1016/j.tcb.2005.08.004; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bayly PV, 2005, J NEUROTRAUM, V22, P845, DOI 10.1089/neu.2005.22.845; BELL GI, 1978, SCIENCE, V200, P618, DOI 10.1126/science.347575; Brady S., 2005, BASIC NEUROCHEMISTRY; BRAY D, 1981, J NEUROCYTOL, V10, P589, DOI 10.1007/BF01262592; CHEN J, 1992, NATURE, V360, P674, DOI 10.1038/360674a0; Chen XH, 1999, J NEUROPATH EXP NEUR, V58, P588, DOI 10.1097/00005072-199906000-00003; Cloots RJH, 2013, BIOMECH MODEL MECHAN, V12, P137, DOI 10.1007/s10237-012-0387-6; Conde C, 2009, NAT REV NEUROSCI, V10, P319, DOI 10.1038/nrn2631; DENNERLL TJ, 1989, J CELL BIOL, V109, P3073, DOI 10.1083/jcb.109.6.3073; DiLeonardi AM, 2009, BRAIN RES, V1263, P174, DOI 10.1016/j.brainres.2009.01.021; Dolle JP, 2013, LAB CHIP, V13, P432, DOI 10.1039/c2lc41063j; DRECHSEL DN, 1992, MOL BIOL CELL, V3, P1141; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Feng Y, 2010, J R SOC INTERFACE, V7, P1677, DOI 10.1098/rsif.2010.0210; Fournier AJ, 2014, FASEB J, V28, P5277, DOI 10.1096/fj.14-251942; Giordano Chiara, 2014, Stapp Car Crash J, V58, P29; Hammarlund M, 2007, J CELL BIOL, V176, P269, DOI 10.1083/jcb.200611117; Hinrichs MH, 2012, J BIOL CHEM, V287, P38559, DOI 10.1074/jbc.M112.369785; HIROKAWA N, 1988, J CELL BIOL, V107, P1449, DOI 10.1083/jcb.107.4.1449; HIROKAWA N, 1982, J CELL BIOL, V94, P129, DOI 10.1083/jcb.94.1.129; Jerusalem A, 2014, BIOMECH MODEL MECHAN, V13, P883, DOI 10.1007/s10237-013-0543-7; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Konzack S, 2007, J NEUROSCI, V27, P9916, DOI 10.1523/JNEUROSCI.0927-07.2007; Kuznetsov IA, 2015, MATH MED BIOL, V32, P263, DOI 10.1093/imammb/dqu003; LEWIS SA, 1989, NATURE, V342, P498, DOI 10.1038/342498a0; Makrides V, 2004, P NATL ACAD SCI USA, V101, P6746, DOI 10.1073/pnas.0400992101; McVicker DP, 2014, CYTOSKELETON, V71, P184, DOI 10.1002/cm.21163; Meaney DF, 2011, CLIN SPORT MED, V30, P19, DOI 10.1016/j.csm.2010.08.009; Morris M, 2011, NEURON, V70, P410, DOI 10.1016/j.neuron.2011.04.009; Ouyang H, 2013, J BIOL ENG, V7, DOI 10.1186/1754-1611-7-21; Phillips R., 2012, PHYS BIOL CELL; Qiang L, 2006, J NEUROSCI, V26, P3120, DOI 10.1523/JNEUROSCI.5392-05.2006; Rajagopalan J, 2010, BIOPHYS J, V99, P3208, DOI 10.1016/j.bpj.2010.09.029; Rosenberg KJ, 2008, P NATL ACAD SCI USA, V105, P7445, DOI 10.1073/pnas.0802036105; Ross JL, 2004, P NATL ACAD SCI USA, V101, P12910, DOI 10.1073/pnas.0402928101; Sabet AA, 2008, J BIOMECH, V41, P307, DOI 10.1016/j.jbiomech.2007.09.016; Scholz T, 2014, CELL MOL LIFE SCI, V71, P3139, DOI 10.1007/s00018-014-1610-7; Sendek A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104965; Shahpasand K, 2012, J NEUROSCI, V32, P2430, DOI 10.1523/JNEUROSCI.5927-11.2012; Siedler DG, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00429; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Smith DH, 1999, J NEUROSCI, V19, P4263; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Suresh S, 2007, ACTA BIOMATER, V3, P413, DOI 10.1016/j.actbio.2007.04.002; Tamura A, 2007, STAPP CAR CRASH JO, V51, P139; Tang-Schomer MD, 2012, EXP NEUROL, V233, P364, DOI 10.1016/j.expneurol.2011.10.030; Tang-Schomer MD, 2010, FASEB J, V24, P1401, DOI 10.1096/fj.09-142844; Wegmann S, 2011, J BIOL CHEM, V286, P20512, DOI 10.1074/jbc.M111.237875; Wright RM, 2013, J NEUROTRAUM, V30, P102, DOI 10.1089/neu.2012.2418; Xu K, 2013, SCIENCE, V339, P452, DOI 10.1126/science.1232251; Yuen TJ, 2009, J NEUROSCI RES, V87, P3620, DOI 10.1002/jnr.22161	59	34	35	1	25	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0006-3495	1542-0086		BIOPHYS J	Biophys. J.	DEC 1	2015	109	11					2328	2337		10.1016/j.bpj.2015.09.010			10	Biophysics	Biophysics	CX8CG	WOS:000365929500013	26636944	Green Published, Bronze			2021-06-18	
J	Varsos, GV; Werndle, MC; Czosnyka, ZH; Smielewski, P; Kolias, AG; Phang, I; Saadoun, S; Bell, BA; Zoumprouli, A; Papadopoulos, MC; Czosnyka, M				Varsos, Georgios V.; Werndle, Melissa C.; Czosnyka, Zofia H.; Smielewski, Peter; Kolias, Angelos G.; Phang, Isaac; Saadoun, Samira; Bell, B. Anthony; Zoumprouli, Argyro; Papadopoulos, Marios C.; Czosnyka, Marek			Intraspinal pressure and spinal cord perfusion pressure after spinal cord injury: an observational study	JOURNAL OF NEUROSURGERY-SPINE			English	Article						intraspinal pressure; spinal cord injury; biophysics; observation	INTRACRANIAL-PRESSURE; WAVE-FORM; OUTFLOW; ICP; CSF	OBJECT In contrast to intracranial pressure (ICP) in traumatic brain injury (TBI), intraspinal pressure (ISP) after traumatic spinal cord injury (TSCI) has not received the same attention in terms of waveform analysis. Based on a recently introduced technique for continuous monitoring of ISP, here the morphological characteristics of ISP are observationally described. It was hypothesized that the waveform analysis method used to assess ICP could be similarly applied to ISP. METHODS Data included continuous recordings of ISP and arterial blood pressure (ABP) in 18 patients with severe TSCI. RESULTS The morphology of the ISP pulse waveform resembled the ICP waveform shape and was composed of 3 peaks representing percussion, tidal, and dicrotic waves. Spectral analysis demonstrated the presence of slow, respiratory, and pulse waves at different frequencies. The pulse amplitude of ISP was proportional to the mean ISP, suggesting a similar exponential pressure-volume relationship as in the intracerebral space. The interaction between the slow waves of ISP and ABP is capable of characterizing the spinal autoregulatory capacity. CONCLUSIONS This preliminary observational study confirms morphological and spectral similarities between ISP in TSCI and ICP. Therefore, the known methods used for ICP waveform analysis could be transferred to ISP analysis and, upon verification, potentially used for monitoring TSCI patients.	[Varsos, Georgios V.; Czosnyka, Zofia H.; Smielewski, Peter; Kolias, Angelos G.; Czosnyka, Marek] Univ Cambridge, Addenbrookes Hosp, Dept Clin Neurosci, Div Neurosurg, Cambridge CB3 0BN, England; [Werndle, Melissa C.; Phang, Isaac; Saadoun, Samira; Bell, B. Anthony; Papadopoulos, Marios C.] St Georges Univ London, Acad Neurosurg Unit, London, England; [Zoumprouli, Argyro] St George Hosp, Dept Anaesthesia, London, England; [Czosnyka, Marek] Warsaw Univ Technol, Inst Elect Syst, Warsaw, Poland	Varsos, GV (corresponding author), Univ Cambridge, St Edmunds Coll, Cambridge CB3 0BN, England.	gv249@cam.ac.uk		czosnyka, marek/0000-0003-2446-8006; Kolias, Angelos/0000-0003-3992-0587; Saadoun, Samira/0000-0002-5480-5678; Zoumprouli, Argyro/0000-0003-0890-690X; Papadopoulos, Marios/0000-0001-9174-4176; Smielewski, Peter/0000-0001-5096-3938	A.G. Leventis Foundation Scholarship; St. Edmund's College, Cambridge, United Kingdom; Royal College of Surgeons of England Research Fellowship; National Institute for Health Research (NIHR) Academic Clinical FellowshipNational Institute for Health Research (NIHR); Raymond and Beverly Sackler Studentship; UK Spinal Cord Injuries Research Network (UKSCIRN); Neurosciences Research Foundation; UKSCIRN; Guthy Jackson Charitable Foundation; Wings for Life Spinal Cord Research Foundation; NIHR Cambridge Biomedical Center; Cambridge Enterprise, Cambridge, United Kingdom	Mr. Varsos is supported by an A.G. Leventis Foundation Scholarship and a Charter Studentship from St. Edmund's College, Cambridge, United Kingdom. Dr. Kolias is supported by a Royal College of Surgeons of England Research Fellowship, a National Institute for Health Research (NIHR) Academic Clinical Fellowship, and a Raymond and Beverly Sackler Studentship. Dr. Werndle is supported by the UK Spinal Cord Injuries Research Network (UKSCIRN), a Royal College of Surgeons of England Research Fellowship, and the Housham Fellowship from the Neurosciences Research Foundation. Dr. Papadopoulos is supported by the UKSCIRN and the Guthy Jackson Charitable Foundation, and is also funded by the Wings for Life Spinal Cord Research Foundation. Dr. Czosnyka is supported by NIHR Cambridge Biomedical Center. Drs. Czosnyka and Smielewski have a financial interest in a fraction of the licensing fee for ICM+Software, which is licensed by Cambridge Enterprise, Cambridge, United Kingdom, and used in this study.	Aries MJH, 2012, CRIT CARE MED, V40, P2456, DOI 10.1097/CCM.0b013e3182514eb6; AVEZAAT CJJ, 1979, J NEUROL NEUROSUR PS, V42, P687, DOI 10.1136/jnnp.42.8.687; Balestreri M, 2004, ACTA NEUROCHIR, V146, P131, DOI 10.1007/s00701-003-0187-y; BORGESEN SE, 1982, BRAIN, V105, P65, DOI 10.1093/brain/105.1.65; CARDOSO ER, 1983, J NEUROSURG, V59, P817, DOI 10.3171/jns.1983.59.5.0817; Carrera E, 2010, J NEUROTRAUM, V27, P317, DOI 10.1089/neu.2009.0951; Czosnyka M, 2006, ACTA NEUROCHIR SUPPL, V96, P114; Czosnyka M, 2004, J NEUROL NEUROSUR PS, V75, P813, DOI 10.1136/jnnp.2003.033126; CZOSNYKA M, 1994, ACTA NEUROCHIR, V126, P113, DOI 10.1007/BF01476419; Czosnyka M, 1999, J NEUROSURG, V90, P752, DOI 10.3171/jns.1999.90.4.0752; Czosnyka M, 1996, ACTA NEUROCHIR, V138, P531, DOI 10.1007/BF01411173; Czosnyka Marek, 2007, Neurosurg Focus, V22, pE10; DAVSON H, 1970, Brain Behavior and Evolution, V93, P665, DOI 10.1093/brain/93.4.665; GOBIET W, 1975, ACTA NEUROCHIR, V32, P13, DOI 10.1007/BF01405899; Howells T, 2012, INTENS CARE MED, V38, P1061, DOI 10.1007/s00134-012-2571-7; Kolias Angelos G, 2013, Pract Neurol, V13, P228, DOI 10.1136/practneurol-2012-000268; LOFGREN J, 1973, ACTA NEUROL SCAND, V49, P557; LUNDBERG N, 1960, Acta Psychiatr Scand Suppl, V36, P1; MARMAROU A, 1975, J NEUROSURG, V43, P523, DOI 10.3171/jns.1975.43.5.0523; MARMAROU A, 1987, J NEUROSURG, V66, P883, DOI 10.3171/jns.1987.66.6.0883; Miller J D, 1972, Prog Brain Res, V35, P411; Pearce JMS, 2006, J NEUROL NEUROSUR PS, V77, P728, DOI 10.1136/jnnp.2005.083618; RYDER HW, 1953, J LAB CLIN MED, V41, P428; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Werndle MC, 2014, CRIT CARE MED, V42, P646, DOI 10.1097/CCM.0000000000000028	25	34	35	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1547-5654	1547-5646		J NEUROSURG-SPINE	J. Neurosurg.-Spine	DEC	2015	23	6					763	771		10.3171/2015.3.SPINE14870			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	CX0FI	WOS:000365371900012	26273764	Bronze			2021-06-18	
J	Qin, YB; Chen, ZS; Han, XL; Wu, HH; Yu, Y; Wu, J; Liu, S; Hou, YN				Qin, Yabin; Chen, Zesha; Han, Xiaolei; Wu, Honghai; Yu, Yang; Wu, Jie; Liu, Sha; Hou, Yanning			Progesterone attenuates A beta(25-35)-induced neuronal toxicity via JNK inactivation and progesterone receptor membrane component 1-dependent inhibition of mitochondrial apoptotic pathway	JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY			English	Article						beta-Amyloid progesterone apoptosis PGRMC1 JNK	TRAUMATIC BRAIN-INJURY; SPINAL-CORD; UP-REGULATION; NEUROTROPHIC FACTOR; CELL-DEATH; IN-VIVO; EXPRESSION; ALLOPREGNANOLONE; PROTECTION; PEPTIDE	Progesterone, which acts as a neurosteroid in nervous system, has been shown to have neuroprotective effects in different experiments in vitro and in vivo. Our previous study demonstrates that progesterone exerts neuroprotections in Alzheimer's disease-like rats. Present study attempted to evaluate the protective effects of progesterone on A beta-treated neurons and potential mechanisms involved in neuroprotection. Results showed that treatment with progesterone protected primary cultured rat cortical neurons against A beta(25-35)-induced apoptosis. Furthermore, we observed that progesterone alleviated mitochondrial dysfunction by rescuing mitochondrial membrane potential under A beta challenge. Moreover, progesterone could also attenuate Bax/Bcl-2 proteins ratio upregulation and inhibit the activation of caspase-3 in A beta-treated neurons. These indicate that progesterone attenuates A beta(25-35)-induced neuronal toxicity by inhibiting mitochondria-associated apoptotic pathway. Both classic progesterone receptors (classic PR) and progesterone receptor membrane component 1 (PGRMC1), a special progesterone membrane receptor, are broadly expressed throughout the brain. The protective effect of progesterone was partially abolished by PGRMC1 inhibitor AG205 rather than classic PR antagonist RU486 in this study. Additionally, progesterone protected neurons by inhibiting A beta-induced activation of JNK, which was an upstream signaling component in A beta-induced mitochondria-associated apoptotic pathway. But this process was independent of PGRMC1. Taken together, these results suggest that progesterone exerts a protective effect against A beta(25-35)-induced insults at least in part by two complementary pathways: (1) progesterone receptor membrane component 1-dependent inhibition of mitochondrial apoptotic pathway, and (2) blocking A beta-induced JNK activation. The present study provides new insights into the mechanism by which progesterone brings neuroprotection. This article is part of a Special Issue entitled 'Steroids 82 Nervous System'. (C) 2015 Elsevier Ltd. All rights reserved.	[Qin, Yabin; Chen, Zesha; Wu, Jie; Liu, Sha; Hou, Yanning] Hebei Med Univ, Shijiazhuang 050017, Hebei Province, Peoples R China; [Han, Xiaolei; Wu, Honghai; Yu, Yang] Bethune Int Peace Hosp Chinese PLA, Dept Pharm, Shijiazhuang 050082, Hebei Province, Peoples R China	Hou, YN (corresponding author), Bethune Int Peace Hosp Chinese PLA, Dept Pharm, Shijiazhuang 050082, Hebei Province, Peoples R China.	biph2011@163.com		Hou, Yanning/0000-0001-7405-5643			Afrazi S, 2014, J STEROID BIOCHEM, V139, P98, DOI 10.1016/j.jsbmb.2013.10.010; BAULIEU EE, 1991, BIOL CELL, V71, P3, DOI 10.1016/0248-4900(91)90045-O; Borowicz K.K., 2011, FRONT ENDOCRINOL, V2, P89; Carroll JC, 2010, ENDOCRINOLOGY, V151, P2713, DOI 10.1210/en.2009-1487; Cha MY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034929; Chan WH, 2007, BIOCHEM J, V404, P317, DOI 10.1042/BJ20061875; Clement ME, 2006, BIOCHEM BIOPH RES CO, V342, P206, DOI 10.1016/j.bbrc.2006.01.137; Compagnone NA, 2008, J STEROID BIOCHEM, V109, P307, DOI 10.1016/j.jsbmb.2008.03.022; Cooke PS, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00108; Deniselle MCG, 2002, J STEROID BIOCHEM, V83, P199, DOI 10.1016/S0960-0760(02)00262-5; Espinosa-Garcia C, 2014, BRAIN RES, V1545, P23, DOI 10.1016/j.brainres.2013.11.030; Coronel MF, 2011, PAIN MED, V12, P1249, DOI 10.1111/j.1526-4637.2011.01178.x; Frye CA, 2008, NEUROBIOL LEARN MEM, V89, P17, DOI 10.1016/j.nlm.2007.09.008; Deniselle MCG, 2012, J NEUROCHEM, V122, P185, DOI 10.1111/j.1471-4159.2012.07753.x; Gonzalez SL, 2005, J STEROID BIOCHEM, V94, P143, DOI 10.1016/j.jsbmb.2005.01.016; Guennoun R, 2008, BRAIN RES REV, V57, P493, DOI 10.1016/j.brainresrev.2007.05.009; Guennoun R, 2015, J STEROID BIOCHEM, V146, P48, DOI 10.1016/j.jsbmb.2014.09.001; Harris MH, 2000, CELL DEATH DIFFER, V7, P1182, DOI 10.1038/sj.cdd.4400781; Hroudova J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/175062; Intlekofer KA, 2011, NEUROSCIENCE, V172, P55, DOI 10.1016/j.neuroscience.2010.10.051; Ishihara Y, 2013, J STEROID BIOCHEM, V135, P1, DOI 10.1016/j.jsbmb.2012.12.013; Kaur P, 2007, J NEUROSCI RES, V85, P2441, DOI 10.1002/jnr.21370; Keil U, 2004, J BIOL CHEM, V279, P50310, DOI 10.1074/jbc.M405600200; Lazcano Z., 2014, SYNAPSE, V41, P126; Li JL, 2013, BASIC CLIN PHARMACOL, V113, P411, DOI 10.1111/bcpt.12124; Liu R, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-105; Liu S, 2013, NEURAL REGEN RES, V8, P2800, DOI 10.3969/j.issn.1673-5374.2013.30.002; Lopez V, 2009, J COMP NEUROL, V512, P124, DOI 10.1002/cne.21883; Ma SB, 2014, CELL DEATH DIFFER, V21, P1925, DOI 10.1038/cdd.2014.119; Nilsen J, 2006, GYNECOL ENDOCRINOL, V22, P355, DOI 10.1080/09513590600863337; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Paradis E, 1996, J NEUROSCI, V16, P7533; Pascual JL, 2013, AM J SURG, V206, P840, DOI 10.1016/j.amjsurg.2013.07.016; Peluso JJ, 2006, ENDOCRINOLOGY, V147, P3133, DOI 10.1210/en.2006-0114; Peluso JJ, 2005, BIOL REPROD, V73, P261, DOI 10.1095/biolreprod.105.041061; Peluso JJ, 2008, ENDOCRINOLOGY, V149, P534, DOI 10.1210/en.2007-1050; Peluso JJ, 2009, J CLIN ENDOCR METAB, V94, P2644, DOI 10.1210/jc.2009-0147; Petersen S., 2013, FRONT NEUROSCI, V7, P489; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.ne.17.030194.002421; Singh M, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00159; Singh M, 2013, HORM BEHAV, V63, P284, DOI 10.1016/j.yhbeh.2012.06.003; Stein DG, 2011, NEUROSCIENCE, V191, P101, DOI 10.1016/j.neuroscience.2011.04.013; Stein DG, 2013, HORM BEHAV, V63, P291, DOI 10.1016/j.yhbeh.2012.05.004; Sun QR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098866; Troy CM, 2001, J NEUROCHEM, V77, P157, DOI 10.1046/j.1471-4159.2001.t01-1-00218.x; Xilouri M, 2006, EUR J NEUROSCI, V23, P43, DOI 10.1111/j.1460-9568.2005.04548.x; Yan JP, 2013, J ETHNOPHARMACOL, V147, P456, DOI 10.1016/j.jep.2013.03.039; Yao MZ, 2007, J NEUROSCI, V27, P1422, DOI 10.1523/JNEUROSCI.2382-06.2007; Yousuf S, 2014, PSYCHOPHARMACOLOGY, V231, P3313, DOI 10.1007/s00213-014-3556-8; Zhang L, 2010, NEUROCHEM INT, V57, P547, DOI 10.1016/j.neuint.2010.06.021; Zhao X.D., 2008, J SURG RES, V171, pe47	51	34	37	2	12	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0960-0760			J STEROID BIOCHEM	J. Steroid Biochem. Mol. Biol.	NOV	2015	154						302	311		10.1016/j.jsbmb.2015.01.002			10	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Biochemistry & Molecular Biology; Endocrinology & Metabolism	CV4QI	WOS:000364251200034	25576906				2021-06-18	
J	Fride, Y; Adamit, T; Maeir, A; Ben Assayag, E; Bornstein, NM; Korczyn, AD; Katz, N				Fride, Y.; Adamit, T.; Maeir, A.; Ben Assayag, E.; Bornstein, N. M.; Korczyn, A. D.; Katz, N.			What are the correlates of cognition and participation to return to work after first ever mild stroke?	TOPICS IN STROKE REHABILITATION			English	Article						Mild stroke; work; RTW; Cognition; Executive function; Participation; Quality of life	QUALITY-OF-LIFE; TRAUMATIC BRAIN-INJURY; TO-MODERATE STROKE; IMPACT SCALE; HEALTH; REHABILITATION; VALIDITY; CONSEQUENCES; DETERMINANTS; RELIABILITY	Background: The percentage of working age people with mild stroke has risen. Evidence indicates that even mild stroke impact cognition, executive functioning, and daily functioning, consequently affecting participation, quality of life (QoL) and return to work (RTW). Objectives: (1) Compare cognition, participation and QoL between people 3 months post-mild stroke who RTW and those who did not; and (2) To determine the correlates of these variables to RTW of participants 3 months post-stroke. Methods: We visited at home 163 stroke survivors (117 men, 46 women) 3 months post-mild stroke ranging from 50 to 89 years. Participants who returned to work (n=114) and those who did not (n=49). Data collection at home included measures for cognitive status (MoCA), executive functions (EFPT, DEX), depression (GDS), participation (RNL), and QoL (SIS recovery). Results: Significant differences were found between RTW participants and those who did not RTW in measures of cognition, depression, participation and QoL (t=2.36 to -5.62, P<0.022-0.001). No difference was found on age or gender. Stepwise regression showed that significant correlates of RTW were participation (RNL), executive functions (EFPT), and QoL (SIS recovery). Conclusions: To enable RTW after mild stroke, participation, executive functions and QoL must be considered in planning interventions.	[Fride, Y.; Adamit, T.; Maeir, A.] Hebrew Univ Jerusalem, Sch Occupat Therapy, IL-91905 Jerusalem, Israel; [Ben Assayag, E.; Bornstein, N. M.] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, IL-69978 Tel Aviv, Israel; [Korczyn, A. D.] Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel; [Katz, N.] Ono Acad Coll, Res Inst Hlth & Med Profess, Qiryat Ono, Israel	Katz, N (corresponding author), Ono Acad Coll, Res Inst Hlth & Med Profess, Qiryat Ono, Israel.	Noomi.katz@ono.ac.il	Korczyn, Amos D/C-3461-2017	Korczyn, Amos D/0000-0003-0125-2579			Adamit T, 2015, DISABIL REHABIL, V37, P667, DOI 10.3109/09638288.2014.923523; Adams HP, 1999, NEUROLOGY, V53, P126, DOI 10.1212/WNL.53.1.126; [Anonymous], 1988, J CLIN EPIDEMIOL, V41, P105, DOI 10.1016/0895-4356(88)90084-4; Baum CM, 2008, AM J OCCUP THER, V62, P446, DOI 10.5014/ajot.62.4.446; Ben Assayag E, 2012, INT J STROKE, V7, P341, DOI 10.1111/j.1747-4949.2011.00652.x; Brenner MH., 2002, UNEMPLOYMENT EMPLOYM; Busch MA, 2009, J NEUROL NEUROSUR PS, V80, P888, DOI 10.1136/jnnp.2008.163295; Carlsson GE, 2004, DISABIL REHABIL, V26, P1373, DOI 10.1080/09638280400000211; Carlsson GE, 2009, DISABIL REHABIL, V31, P773, DOI 10.1080/09638280802638857; Corr S., 2003, BRIT J OCCUPATIONAL, V66, P186, DOI DOI 10.1177/030802260306600502; Cumming TB, 2013, INT J STROKE, V8, P38, DOI 10.1111/j.1747-4949.2012.00972.x; Duncan PW, 1999, STROKE, V30, P2131, DOI 10.1161/01.STR.30.10.2131; Edwards Dorothy F, 2006, J Stroke Cerebrovasc Dis, V15, P151, DOI 10.1016/j.jstrokecerebrovasdis.2006.04.001; Evans JJ, 1997, PSYCHOL MED, V27, P635, DOI 10.1017/S0033291797004790; Frey B., 2002, HAPPINESS EC EC I AF; Gallo WT, 2000, J GERONTOL B-PSYCHOL, V55, pS131, DOI 10.1093/geronb/55.3.S131; Hofgren C, 2010, WORK, V36, P431, DOI 10.3233/WOR-2010-1039; Hommel M, 2009, J NEUROL NEUROSUR PS, V80, P876, DOI 10.1136/jnnp.2008.169672; Ingles JL, 1999, ARCH PHYS MED REHAB, V80, P173, DOI 10.1016/S0003-9993(99)90116-8; Jaillard A, 2010, CEREBROVASC DIS, V29, P415, DOI 10.1159/000289344; Jaillard A, 2009, STROKE, V40, P2473, DOI 10.1161/STROKEAHA.108.541144; Johansson Ann, 2007, Occup Ther Int, V14, P170, DOI 10.1002/oti.232; Kissela BM, 2012, NEUROLOGY, V79, P1781, DOI 10.1212/WNL.0b013e318270401d; Lai SM, 2003, STROKE, V34, P488, DOI 10.1161/01.STR.0000054162.94998.C0; Lai SM, 2002, STROKE, V33, P1840, DOI 10.1161/01.STR.0000019289.15440.F2; Lindstrom B, 2009, J REHABIL MED, V41, P714, DOI 10.2340/16501977-0423; Lindstrom M, 2005, OCCUP MED-OXFORD, V55, P568, DOI 10.1093/occmed/kqi122; Mansueti L, 2008, AGING NEUROPSYCHOL C, V15, P545, DOI 10.1080/13825580701858216; Mayo NE, 2002, ARCH PHYS MED REHAB, V83, P1035, DOI 10.1053/apmr.2002.33984; Medin J, 2006, DISABIL REHABIL, V28, P1051, DOI 10.1080/09638280500494819; Mendis S, 2013, INT J STROKE, V8, P3, DOI 10.1111/j.1747-4949.2012.00969.x; Muren MA, 2008, TOP STROKE REHABIL, V15, P51, DOI 10.1310/tsr1501-51; Muus I, 2010, SCAND J CARING SCI, V24, P211, DOI 10.1111/j.1471-6712.2009.00705.x; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; Nichols-Larsen DS, 2005, STROKE, V36, P1480, DOI 10.1161/01.STR.0000170706.13595.4f; Nolin P, 2006, J HEAD TRAUMA REHAB, V21, P514, DOI 10.1097/00001199-200611000-00006; O'Brien AN, 2010, WORK, V36, P441, DOI 10.3233/WOR-2010-1047; Ownsworth T, 2008, DISABIL REHABIL, V30, P531, DOI 10.1080/09638280701355694; RANKIN J, 1957, Scott Med J, V2, P200; Rochette A, 2007, TOP STROKE REHABIL, V14, P59, DOI 10.1310/tsr1403-59; Rosamond W, 2008, CIRCULATION, V117, pE25, DOI 10.1161/CIRCULATIONAHA.107.187998; Roth EJ, 2014, TOP STROKE REHABIL, V21, pS75, DOI 10.1310/tsr21S1-S75; Saeki S, 2010, J REHABIL MED, V42, P254, DOI 10.2340/16501977-0503; Schmidt WP, 2004, J AM GERIATR SOC, V52, P1045, DOI 10.1111/j.1532-5415.2004.52300.x; Shopin L, 2013, DEMENT GERIATR COGN, V36, P36, DOI 10.1159/000350035; SMITH NR, 1986, AM J OCCUP THER, V40, P278, DOI 10.5014/ajot.40.4.278; Smith T, 2007, CAN J PSYCHIAT, V52, P329, DOI 10.1177/070674370705200508; Srikanth VK, 2003, STROKE, V34, P1136, DOI 10.1161/01.STR.0000069161.35736.39; Stark SL, 2005, ARCH PHYS MED REHAB, V86, P344, DOI 10.1016/j.apmr.2004.03.020; Tanaka H, 2011, ARCH PHYS MED REHAB, V92, P743, DOI 10.1016/j.apmr.2010.12.009; Tellier M, 2009, TOP STROKE REHABIL, V16, P454, DOI 10.1310/tsr1606-454; Vestling M, 2003, J REHABIL MED, V35, P127, DOI 10.1080/16501970310010475; Waddell G., 2006, IS WORK GOOD YOUR HL; Walker WC, 2006, ARCH PHYS MED REHAB, V87, P1576, DOI 10.1016/j.apmr.2006.08.335; Wilkinson R, 2003, SOCIAL DETERMINANTS; Wilson AB, 1997, METHODOLOGY FRONTAL, P239; Wolf TJ, 2009, AM J OCCUP THER, V63, P621, DOI 10.5014/ajot.63.5.621; WOLFE CDA, 1991, STROKE, V22, P1242, DOI 10.1161/01.STR.22.10.1242; WOODDAUPHINEE SL, 1988, ARCH PHYS MED REHAB, V69, P583; World Health Organization, 2001, INT CLASS FUNCT DIS; Wozniak MA, 1999, STROKE, V30, P2568, DOI 10.1161/01.STR.30.12.2568; Wright J., FUNCTIONAL INDEPENDE; YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4	63	34	37	1	16	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1074-9357	1945-5119		TOP STROKE REHABIL	Top. Stroke Rehabil.	OCT	2015	22	5					317	325		10.1179/1074935714Z.0000000013			9	Rehabilitation	Rehabilitation	CT5HA	WOS:000362838400001	26461878				2021-06-18	
J	Graves, JM; Rivara, FP; Vavilala, MS				Graves, Janessa M.; Rivara, Frederick P.; Vavilala, Monica S.			Health Care Costs 1 Year After Pediatric Traumatic Brain Injury	AMERICAN JOURNAL OF PUBLIC HEALTH			English	Article							ABUSIVE HEAD TRAUMA; UNITED-STATES; OUTCOMES; CHILDREN; ADOLESCENTS; DISABILITY; MORTALITY; MODELS	Objectives. This study sought to estimate total health care costs for mild, moderate, and severe pediatric traumatic brain injury (TBI) and to compare individual- and population-level costs across levels of TBI severity. Methods. Using 2007 to 2010 MarketScan Commercial Claims and Encounters data, we estimated total quarterly health care costs 1 year after TBI among enrollees (aged < 18 years). We compared costs across levels of TBI severity using generalized linear models. Results. Mild TBI accounted for 96.6% of the 319 103 enrollees with TBI; moderate and severe TBI accounted for 1.7% and 1.6%, respectively. Adjusted individual health care costs for moderate and severe TBI were significantly higher than mild TBI in the year after injury (P < .01). At the population level, moderate and severe TBI costs were 88% and 75% less than mild TBI, respectively. Conclusions. Individually, moderate and severe TBI initially generated costs that were markedly higher than those of mild TBI. At the population level, costs following mild TBI far exceeded those of more severe cases, a result of the extremely high population burden of mild TBI.	[Graves, Janessa M.; Rivara, Frederick P.; Vavilala, Monica S.] Harborview Injury & Res Ctr HIPRC, Seattle, WA USA; [Graves, Janessa M.] Washington State Univ Spokane, Coll Nursing, Spokane, WA 99210 USA; [Rivara, Frederick P.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; [Rivara, Frederick P.; Vavilala, Monica S.] Univ Washington, Dept Pediat, Seattle, WA 98195 USA; [Vavilala, Monica S.] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA	Graves, JM (corresponding author), Washington State Univ Spokane, Coll Nursing, POB 1495, Spokane, WA 99210 USA.	janessa.graves@wsu.edu	Graves, Janessa M./J-2596-2019	Graves, Janessa M./0000-0002-7659-2634	National Institute of Neurologic Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS072308-03]; HIPRC; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS072308] Funding Source: NIH RePORTER	The study was supported by funding from the National Institute of Neurologic Disorders and Stroke (grant R01 NS072308-03 to M. S. V.) and the HIPRC.	[Anonymous], CONS PRIC IND INFL C; Blough DK, 1999, J HEALTH ECON, V18, P153, DOI 10.1016/S0167-6296(98)00032-0; Blume HK, 2012, PEDIATRICS, V129, pE31, DOI 10.1542/peds.2011-1742; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Brener I, 2004, J HEAD TRAUMA REHAB, V19, P405, DOI 10.1097/00001199-200409000-00005; Clark DE OT, 2010, ICDPIC STATA MODULE; Diehr P, 1999, ANNU REV PUBL HEALTH, V20, P125, DOI 10.1146/annurev.publhealth.20.1.125; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Greene NH, 2015, INJ PREV; Hansen LG, HLTH RES DATA REAL W; Hu JH, 2013, J NEUROTRAUM, V30, P1755, DOI 10.1089/neu.2013.2857; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P681, DOI 10.1016/0003-9993(93)90024-5; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Leibson CL, 2012, J NEUROTRAUM, V29, P2038, DOI 10.1089/neu.2010.1713; Manning WG, 2001, J HEALTH ECON, V20, P461, DOI 10.1016/S0167-6296(01)00086-8; Manning WG, 2005, J HEALTH ECON, V24, P465, DOI 10.1016/j.jhealeco.2004.09.011; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Miller TR, 2014, PEDIATRICS, V134, pE1545, DOI 10.1542/peds.2014-1385; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; O'Connor SS, 2012, J TRAUMA STRESS, V25, P264, DOI 10.1002/jts.21704; Peterson C, 2014, PEDIATRICS, V134, P91, DOI 10.1542/peds.2014-0117; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Rivara FP, 2012, AM J PUBLIC HEALTH, V102, P2074, DOI 10.2105/AJPH.2012.300696; Rockhill CM, 2010, BRAIN INJURY, V24, P1051, DOI 10.3109/02699052.2010.494586; Sanchez AI, 2012, J HEAD TRAUMA REHAB, V27, P159, DOI 10.1097/HTR.0b013e3182074c41; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Schootman M, 2003, BRAIN INJURY, V17, P983, DOI 10.1080/0269905031000110427; Shi JX, 2009, BRAIN INJURY, V23, P602, DOI 10.1080/02699050903014907; Truven Health Analytics, MARKETSCAN STUD ABBR	30	34	35	0	4	AMER PUBLIC HEALTH ASSOC INC	WASHINGTON	800 I STREET, NW, WASHINGTON, DC 20001-3710 USA	0090-0036	1541-0048		AM J PUBLIC HEALTH	Am. J. Public Health	OCT	2015	105	10					E35	E41		10.2105/AJPH.2015.302744			7	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	CZ9UC	WOS:000367441500013	26270293	Green Published			2021-06-18	
J	Gardner, AJ; Iverson, GL; Quinn, TN; Makdissi, M; Levi, CR; Shultz, SR; Wright, DK; Stanwell, P				Gardner, Andrew J.; Iverson, Grant L.; Quinn, Tanya N.; Makdissi, Michael; Levi, Christopher R.; Shultz, Sandy R.; Wright, David K.; Stanwell, Peter			A preliminary video analysis of concussion in the National Rugby League	BRAIN INJURY			English	Article						Athletes; brain concussion; epidemiology; injury surveillance	INCIDENT ANALYSIS; PROFESSIONAL FOOTBALL; INJURY; MATCH; SITUATIONS; NHL	Primary objective: To conduct the first video analysis of concussion in the Australian National Rugby League (NRL) and describe player and injury characteristics, situational factors and time to return to play. Research design: Descriptive, observational case series. Methods and procedures: Video analysis of 20 medically diagnosed concussions for three consenting clubs during the 2013 NRL season. Main outcome and results: Most concussions (83%) occurred during a high tackle, and all injured ball carriers were hit high. Loss of consciousness was observed in 30% of cases. Common observable signs of injury included clutching of the head, balance problems or wobbly legs and a blank or vacant state. There were no post-concussive seizures. All players with loss of consciousness were removed from play. However, only half of the total sample was removed from play and one athlete who was removed returned to play in the same match. Of the players who were removed from play, the large majority returned the following week. Illegal play accounted for 25% of all concussions. Conclusions: Video analysis may be a useful method to study the incidence, mechanism and management of concussion in sports such as Rugby League. Future studies may include larger numbers to validate this preliminary data and may also investigate other levels of play and age ranges.	[Gardner, Andrew J.; Levi, Christopher R.] Univ Newcastle, Sch Med & Publ Hlth, Ctr Translat Neurosci & Mental Hlth, Callaghan, NSW 2308, Australia; [Iverson, Grant L.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA; [Iverson, Grant L.] Harvard Univ, Sch Med, Spaulding Rehabil Hosp, Boston, MA USA; [Iverson, Grant L.] MGHfC Sports Concuss Program, Boston, MA USA; [Iverson, Grant L.] Red Sox Fdn, Boston, MA USA; [Iverson, Grant L.] Massachusetts Gen Hosp, Home Base Program, Boston, MA 02114 USA; [Quinn, Tanya N.] Univ Newcastle, Dept Psychol, Callaghan, NSW 2308, Australia; [Makdissi, Michael] Melbourne Brain Ctr, Florey Inst Neurosci & Mental Hlth, Heidelberg, Vic, Australia; [Makdissi, Michael] Federat Univ, Australian Ctr Res Injury Sport & Its Prevent, Ballarat, Vic, Australia; [Shultz, Sandy R.] Univ Melbourne, Royal Melbourne Hosp, Dept Med, Parkville, Vic, Australia; [Wright, David K.] Univ Melbourne, Dept Anat & Neurosci, Parkville, Vic 3052, Australia; [Stanwell, Peter] Univ Newcastle, Fac Hlth, Sch Hlth Sci, Ctr Translat Neurosci & Mental Hlth, Callaghan, NSW 2308, Australia	Gardner, AJ (corresponding author), Calvary Mater Hosp, Ctr Translat Neurosci & Mental Hlth, Level 5,McAuley Bldg, Waratah, NSW 2298, Australia.	andrew.gardner@neurogard.com.au	Stanwell, Peter/F-9136-2012; Gardner, Andrew/J-5162-2013	Stanwell, Peter/0000-0002-4780-0393; Levi, Christopher/0000-0002-9474-796X; Wright, David/0000-0002-7535-8651; Iverson, Grant/0000-0001-7348-9570	New South Wales Sporting Injuries Committee-Sports Research & Injury Prevention Scheme Grant; Brain Foundation, Australia-Brain Injury Award; Hunter Medical Research Institute; Mooney-Reed Charitable Foundation	Andrew J. Gardner, Peter Stanwell and Christopher R. Levi have been funded to conduct research into concussion in rugby league through a New South Wales Sporting Injuries Committee-Sports Research & Injury Prevention Scheme Grant, and a Brain Foundation, Australia-Brain Injury Award. Andrew J. Gardner acknowledges sport concussion research fellowship funding from Jennie Thomas, Life Governor of the Hunter Medical Research Institute. Grant L. Iverson acknowledges sport concussion research funding from the Mooney-Reed Charitable Foundation.	Andersen TE, 2003, BRIT J SPORT MED, V37, P226, DOI 10.1136/bjsm.37.3.226; Arnason A, 2004, AM J SPORT MED, V32, P1459, DOI 10.1177/0363546504262973; Bjorneboe J, 2014, BRIT J SPORT MED, V48, P774, DOI 10.1136/bjsports-2012-091856; Gabbett TJ, 2005, J STRENGTH COND RES, V19, P749; Gabbett TJ, 2004, BRIT J SPORT MED, V38, P743, DOI 10.1136/bjsm.2003.008391; Gabbett TJ, 2004, J SPORT SCI, V22, P409, DOI 10.1080/02640410310001641638; Gardner A, 2015, BRIT J SPORT MED, V49, P495, DOI 10.1136/bjsports-2013-093102; Hoskins W, 2006, J SCI MED SPORT, V9, P46, DOI 10.1016/j.jsams.2006.03.013; Hutchison MG, 2015, BRIT J SPORT MED, V49, P552, DOI 10.1136/bjsports-2013-092235; Hutchison MG, 2015, BRIT J SPORT MED, V49, P547, DOI 10.1136/bjsports-2013-092234; King DA, 2006, J SCI MED SPORT, V9, P110, DOI 10.1016/j.jsams.2005.09.001; King DA, 2010, SPORTS MED, V40, P163, DOI 10.2165/11319740-000000000-00000; Koh JO, 2004, BRAIN INJURY, V18, P1287, DOI 10.1080/02699050410001719907; Lincoln AE, 2013, AM J SPORT MED, V41, P756, DOI 10.1177/0363546513476265; Miele VJ, 2007, NEUROSURGERY, V60, P307, DOI 10.1227/01.NEU.0000249247.48299.5B	15	34	35	0	21	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	SEP	2015	29	10					1182	1185		10.3109/02699052.2015.1034179			4	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	CR3UK	WOS:000361258400006	26083052				2021-06-18	
J	Johnstone, VPA; Wright, DK; Wong, K; O'Brien, TJ; Rajan, R; Shultz, SR				Johnstone, Victoria P. A.; Wright, David K.; Wong, Kendrew; O'Brien, Terence J.; Rajan, Ramesh; Shultz, Sandy R.			Experimental Traumatic Brain Injury Results in Long-Term Recovery of Functional Responsiveness in Sensory Cortex but Persisting Structural Changes and Sensorimotor, Cognitive, and Emotional Deficits	JOURNAL OF NEUROTRAUMA			English	Article						DTI; MRI; barrel cortex; tractography; electrophysiology	RAT BARREL CORTEX; FLUID PERCUSSION INJURY; WHISKER VIBRATION; WHITE-MATTER; ANIMAL-MODEL; MILD; NEUROINFLAMMATION; TRACTOGRAPHY; IMPAIRMENTS; BEHAVIOR	Traumatic brain injury (TBI) is a leading cause of death worldwide. In recent studies, we have shown that experimental TBI caused an immediate (24-h post) suppression of neuronal processing, especially in supragranular cortical layers. We now examine the long-term effects of experimental TBI on the sensory cortex and how these changes may contribute to a range of TBI morbidities. Adult male Sprague-Dawley rats received either a moderate lateral fluid percussion injury (n=14) or a sham surgery (n=12) and 12 weeks of recovery before behavioral assessment, magnetic resonance imaging, and electrophysiological recordings from the barrel cortex. TBI rats demonstrated sensorimotor deficits, cognitive impairments, and anxiety-like behavior, and this was associated with significant atrophy of the barrel cortex and other brain structures. Extracellular recordings from ipsilateral barrel cortex revealed normal neuronal responsiveness and diffusion tensor MRI showed increased fractional anisotropy, axial diffusivity, and tract density within this region. These findings suggest that long-term recovery of neuronal responsiveness is owing to structural reorganization within this region. Therefore, it is likely that long-term structural and functional changes within sensory cortex post-TBI may allow for recovery of neuronal responsiveness, but that this recovery does not remediate all behavioral deficits.	[Johnstone, Victoria P. A.; Rajan, Ramesh] Monash Univ, Dept Physiol, Clayton, Vic 3168, Australia; [Wright, David K.] Univ Melbourne, Anat & Neurosci, Parkville, Vic 3052, Australia; [Wright, David K.] Florey Inst Neurosci & Mental Hlth, Parkville, Vic, Australia; [Wong, Kendrew; O'Brien, Terence J.; Shultz, Sandy R.] Univ Melbourne, Melbourne Brain Ctr, Royal Melbourne Hosp, Dept Med, Parkville, Vic 3052, Australia	Johnstone, VPA (corresponding author), Univ Western Australia, Sch Anat Physiol & Human Biol, Mailbag M311, Crawley, WA 6009, Australia.	vicky.johnstone@uwa.edu.au; sshultz@unimelb.edu.au	rajan, ramesh/L-4842-2019; Johnstone, Victoria/B-5083-2015	Johnstone, Victoria/0000-0001-9885-3607; Wright, David/0000-0002-7535-8651; Rajan, Ramesh/0000-0001-9862-0520; O'Brien, Terence/0000-0002-7198-8621	NHMRCNational Health and Medical Research Council of Australia; Victorian Transport Accident Commission; Royal Melbourne Hospital Neuroscience Foundation; Canadian Institute of Health ResearchCanadian Institutes of Health Research (CIHR)	The authors acknowledge the facilities as well as the scientific and technical assistance of the National Imaging Facility at the Florey Institute of Neuroscience and Mental Health (Parkville, VIC, Australia). This work was supported by grants to T.O. and S.S. from the NHMRC, the Victorian Transport Accident Commission, the Royal Melbourne Hospital Neuroscience Foundation, and the Canadian Institute of Health Research.	Alwis DS, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00124; Alwis DS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052169; Arabzadeh E, 2004, J NEUROSCI, V24, P6011, DOI 10.1523/JNEUROSCI.1389-04.2004; Arabzadeh E, 2003, J NEUROSCI, V23, P9146; Arciniegas David B., 2002, Curr Treat Options Neurol, V4, P43, DOI 10.1007/s11940-002-0004-6; Bao F, 2012, J NEUROTRAUM, V29, P2375, DOI 10.1089/neu.2012.2408; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Carmichael ST, 2002, J NEUROSCI, V22, P6062; Davis AS, 2010, APPL NEUROPSYCHOL, V17, P104, DOI 10.1080/09084281003708951; Debert CT, 2012, J NEUROL PHYS THER, V36, P58, DOI 10.1097/NPT.0b013e318254bd4f; DIETRICH WD, 1994, J NEUROTRAUM, V11, P629, DOI 10.1089/neu.1994.11.629; Ding GL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061241; Farquharson S, 2013, J NEUROSURG, V118, P1367, DOI 10.3171/2013.2.JNS121294; Galvin J, 2009, AM J OCCUP THER, V63, P701, DOI 10.5014/ajot.63.6.701; Gao PH, 2001, J NEUROSCI, V21, P5374, DOI 10.1523/JNEUROSCI.21-14-05374.2001; Gould KR, 2011, PSYCHOL MED, V41, P2099, DOI 10.1017/S003329171100033X; Graham DI, 2000, ACTA NEUROPATHOL, V99, P117, DOI 10.1007/PL00007414; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; Harrison TC, 2013, STROKE, V44, P2300, DOI 10.1161/STROKEAHA.113.001272; Hartmann MJ, 2003, J NEUROSCI, V23, P6510; HENNIG J, 1986, MAGNET RESON MED, V3, P823, DOI 10.1002/mrm.1910030602; Hylin MJ, 2013, J NEUROTRAUM, V30, P702, DOI 10.1089/neu.2012.2630; Iwamoto Y, 1997, NEUROSURGERY, V40, P163, DOI 10.1097/00006123-199701000-00036; Johnstone VPA, 2014, J NEUROTRAUM, V31, P1881, DOI 10.1089/neu.2014.3343; Johnstone VPA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063454; Jones NC, 2008, J NEUROTRAUM, V25, P1367, DOI 10.1089/neu.2008.0641; Lew HL, 2009, J REHABIL RES DEV, V46, P819, DOI 10.1682/JRRD.2008.09.0129; Liu YR, 2010, J NUCL MED, V51, P1788, DOI 10.2967/jnumed.110.078626; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; Markram H, 2004, NAT REV NEUROSCI, V5, P793, DOI 10.1038/nrn1519; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Pandey DK, 2009, BEHAV BRAIN RES, V205, P436, DOI 10.1016/j.bbr.2009.07.027; Paxinos G., 2007, RAT BRAIN STEREOTAXI, V6th, P456; Petersen C. C. H., 2009, ENCY NEUROSCIENCE, P41; Pinto DJ, 2000, J NEUROPHYSIOL, V83, P1158; Rajan R, 2007, EUR J NEUROSCI, V25, P2383, DOI 10.1111/j.1460-9568.2007.05481.x; Rajan R, 2006, J NEUROSCI METH, V157, P103, DOI 10.1016/j.jneumeth.2006.04.008; Ritt JT, 2008, NEURON, V57, P599, DOI 10.1016/j.neuron.2007.12.024; Schwarzbold ML, 2010, J NEUROTRAUM, V27, P1883, DOI 10.1089/neu.2010.1318; Shultz SR, 2014, J NEUROTRAUM, V31, P976, DOI 10.1089/neu.2013.3106; Shultz SR, 2013, EPILEPSIA, V54, P1240, DOI 10.1111/epi.12223; Shultz SR, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-26; Shultz SR, 2012, BEHAV BRAIN RES, V229, P145, DOI 10.1016/j.bbr.2011.12.015; Shultz SR, 2012, J NEUROTRAUM, V29, P281, DOI 10.1089/neu.2011.2123; Shultz SR, 2011, BEHAV BRAIN RES, V224, P326, DOI 10.1016/j.bbr.2011.06.012; SMITH ML, 1984, ACTA NEUROPATHOL, V64, P319, DOI 10.1007/BF00690397; STEJSKAL EO, 1965, J CHEM PHYS, V42, P288, DOI 10.1063/1.1695690; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Tournier JD, 2013, NMR BIOMED, V26, P1775, DOI 10.1002/nbm.3017; Vorhees CV, 2006, NAT PROTOC, V1, P848, DOI 10.1038/nprot.2006.116; Walf AA, 2007, NAT PROTOC, V2, P322, DOI 10.1038/nprot.2007.44; Washington PM, 2012, J NEUROTRAUM, V29, P2283, DOI 10.1089/neu.2012.2456; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; Yan EB, 2013, NEUROSCIENCE, V248, P17, DOI 10.1016/j.neuroscience.2013.05.045	54	34	35	0	20	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP 1	2015	32	17					1333	1346		10.1089/neu.2014.3785			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CP0KP	WOS:000359564500007	25739059				2021-06-18	
J	Taylor, AM; Nigrovic, LE; Saillant, ML; Trudell, EK; Proctor, MR; Modest, JR; Vernacchio, L				Taylor, Alex M.; Nigrovic, Lise E.; Saillant, Meredith L.; Trudell, Emily K.; Proctor, Mark R.; Modest, Jonathan R.; Vernacchio, Louis			Trends in Ambulatory Care for Children with Concussion and Minor Head Injury from Eastern Massachusetts between 2007 and 2013	JOURNAL OF PEDIATRICS			English	Article							TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL; EMERGENCY-DEPARTMENTS; MANAGEMENT; SPORT; EPIDEMIOLOGY; VISITS; IMPACT; KNOWLEDGE; PATIENT	Objective To characterize trends in health care utilization and costs for children diagnosed with concussion or minor head injury within a large pediatric primary-care association. Study design We conducted a retrospective cohort analysis from 2007 through 2013 examining all outpatient medical claims related to concussion and minor head injury from 4 commercial insurance companies for children 6-21 years of age who were patients within a large pediatric independent practice association located throughout eastern Massachusetts. Results Health care visits for concussion and minor head injury increased more than 4-fold during the study period, with primary-care and specialty clinics experiencing the greatest increases in the rate of visits while emergency department visits increased comparatively less. These increases were accounted for by both the proportion of children diagnosed with concussion or minor head injury (1.3% of all children in 2007 vs 3.3% in 2013) and the number of encounters per diagnosed patient (1.0 encounters per patient in 2007 vs 1.7 in 2013). Although the overall population costs devoted to care for concussion or minor head injury increased 34%, the cost per individual diagnosed child decreased 31%. Conclusions Over the past 7 years, health care encounters for children diagnosed with concussion or minor head injury increased substantially in eastern Massachusetts. Care for these injuries increasingly shifted from the emergency department to primary-care and specialty providers.	[Taylor, Alex M.] Boston Childrens Hosp, Dept Neurol, Boston, MA 02115 USA; [Taylor, Alex M.] Boston Childrens Hosp, Dept Psychiat, Boston, MA 02115 USA; [Nigrovic, Lise E.] Boston Childrens Hosp, Div Emergency Med, Boston, MA 02115 USA; [Saillant, Meredith L.; Trudell, Emily K.; Modest, Jonathan R.; Vernacchio, Louis] Pediat Phys Org Childrens, Boston, MA USA; [Proctor, Mark R.] Boston Childrens Hosp, Dept Neurosurg, Boston, MA 02115 USA; [Vernacchio, Louis] Boston Childrens Hosp, Div Gen Pediat, Boston, MA 02115 USA	Taylor, AM (corresponding author), Boston Childrens Hosp, Dept Neurol, BCH 3124,300 Longwood Ave, Boston, MA 02115 USA.	alex.taylor@childrens.harvard.edu		Correa, Emily/0000-0003-1985-405X; Vernacchio, Louis/0000-0002-2012-5404; Nigrovic, Lise/0000-0002-6369-3997	Provider-Payor Quality Initiative at Boston Children's Hospital [76315]	Supported in part by the Provider-Payor Quality Initiative at Boston Children's Hospital (76315). The authors declare no conflicts of interest.	[Anonymous], 2013, IRW BROH RES SPORTS; Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Brenner DJ, 2001, AM J ROENTGENOL, V176, P289, DOI 10.2214/ajr.176.2.1760289; Carl RL, 2014, CLIN PEDIATR, V53, P689, DOI 10.1177/0009922814526979; Centers for Disease Control and Prevention, HEADS UP; Colvin JD, 2013, ARCH DIS CHILD, V98, P934, DOI 10.1136/archdischild-2012-303588; Echemendia RJ, 2013, BRIT J SPORT MED, V47, P294, DOI 10.1136/bjsports-2013-092186; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Forrest CB, 2006, MED DECIS MAKING, V26, P76, DOI 10.1177/0272989X05284110; Gerberding JL, 2003, REP C MILD TRAUM BRA; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Hotz RL, 2013, WALL ST J; Kinnaman KA, 2014, PEDIATR EMERG CARE, V30, P1; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LeBlanc CMA, 2000, PEDIATRICS, V106, P1524, DOI 10.1542/peds.106.6.1524; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Mackenzie B, 2015, PEDIATR EMERG CARE, V31, P25, DOI 10.1097/PEC.0000000000000325; Macur Juliet, 2014, NY TIMES; Mannix R, 2013, NEUROSURGERY, V73, P129, DOI 10.1227/01.neu.0000429846.14579.41; Marin JR, 2014, JAMA-J AM MED ASSOC, V311, P1917, DOI 10.1001/jama.2014.3979; Massachusetts Department of Public Health, 2010, HEAD INJ CONC EXTR A; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meehan WP, 2012, PEDIATRICS, V129, P38, DOI 10.1542/peds.2011-1972; Meehan WP, 2011, AM J SPORT MED, V39, P2304, DOI 10.1177/0363546511423503; Meehan WP, 2010, J PEDIATR-US, V157, P889, DOI 10.1016/j.jpeds.2010.06.040; National federation of state high school associations, 2013, NFHS HDB, V2013-14; Pearce MS, 2012, LANCET, V380, P499, DOI 10.1016/S0140-6736(12)60815-0; Ray KN, 2014, PEDIATRICS, V133, P1061, DOI 10.1542/peds.2013-3466; Resch JE, 2013, NEUROPSYCHOL REV, V23, P335, DOI 10.1007/s11065-013-9242-5; Rosenthal JA, 2014, AM J SPORT MED, V42, P1710, DOI 10.1177/0363546514530091; US Department of Labor, CONS PRIC IND; Wilkins SA, 2014, J NEUROSURG-PEDIATR, V13, P82, DOI 10.3171/2013.10.PEDS13241; Yeates KO, 2012, ARCH PEDIAT ADOL MED, V166, P615, DOI 10.1001/archpediatrics.2011.1082; Zonfrillo MR, 2012, PEDIATRICS, V130, P1120, DOI 10.1542/peds.2012-1431	38	34	34	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0022-3476	1097-6833		J PEDIATR-US	J. Pediatr.	SEP	2015	167	3					738	744		10.1016/j.jpeds.2015.05.036			7	Pediatrics	Pediatrics	CU4ZI	WOS:000363540200047	26116471				2021-06-18	
J	Allison, MA; Kang, YS; Maltese, MR; Bolte, JH; Arbogast, KB				Allison, Mari A.; Kang, Yun Seok; Maltese, Matthew R.; Bolte, John H.; Arbogast, Kristy B.			Measurement of Hybrid III Head Impact Kinematics Using an Accelerometer and Gyroscope System in Ice Hockey Helmets	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						mTBI; Concussion; Head injury; Head acceleration; Head impact biomechanics; Impact monitoring; Helmet sensors	COLLEGIATE FOOTBALL PLAYERS; TRAUMATIC BRAIN-INJURIES; BIOMECHANICS; MILD; VALIDATION	Helmet-based instrumentation is used to study the biomechanics of concussion. The most extensively used systems estimate rotational acceleration from linear acceleration, but new instrumentation measures rotational velocity using gyroscopes, potentially reducing error. This study compared kinematics from an accelerometer and gyroscope-containing system to reference measures. A Hybrid III (HIII) adult male anthropometric test device head and neck was fit with two helmet brands, each instrumented with gForce Tracker (GFT) sensor systems in four locations. Helmets were impacted at various speeds and directions. Regression relationships between GFT-measured and reference peak kinematics were quantified, and influence of impact direction, sensor location, and helmet brand was evaluated. The relationship between the sensor output and the reference acceleration/velocity experienced by the head was strong. Coefficients of determination for data stratified by individual impact directions ranged from 0.77 to 0.99 for peak linear acceleration and from 0.78 to 1.0 for peak rotational velocity. For the data from all impact directions combined, coefficients of determination ranged from 0.60 to 0.80 for peak resultant linear acceleration and 0.83 to 0.91 for peak resultant rotational velocity. As expected, raw peak resultant linear acceleration measures exhibited large percent differences from reference measures. Adjustment using regressions resulted in average absolute errors of 10-15% if regression adjustments were done by impact direction or 25-40% if regressions incorporating data from all impact directions were used. Average absolute percent differences in raw peak resultant rotational velocity were much lower, around 10-15%. It is important to define system accuracy for a particular helmet brand, sensor location, and impact direction in order to interpret real-world data.	[Allison, Mari A.; Arbogast, Kristy B.] Childrens Hosp Philadelphia, Ctr Injury Res & Prevent, Philadelphia, PA 19104 USA; [Allison, Mari A.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; [Kang, Yun Seok; Bolte, John H.] Ohio State Univ, Injury Biomech Res Ctr, Columbus, OH 43210 USA; [Maltese, Matthew R.] Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care Med, Philadelphia, PA 19104 USA; [Maltese, Matthew R.; Arbogast, Kristy B.] Univ Penn, Dept Pediat, Philadelphia, PA 19104 USA	Arbogast, KB (corresponding author), Childrens Hosp Philadelphia, Ctr Injury Res & Prevent, 3535 Market St Suite 1150, Philadelphia, PA 19104 USA.	maall@seas.upenn.edu; arbogast@email.chop.edu	Bolte, John/AAK-9695-2021	Arbogast, Kristy/0000-0002-1694-4562; Bolte, John/0000-0001-9894-4998	National Science Foundation Graduate Research FellowshipNational Science Foundation (NSF); Fundamental Research Supplement, the Center for Child Injury Prevention Studies; National Highway Traffic Safety Administration; Toyota Collaborative Safety Research Center; SAFER Vehicle and Traffic Safety Centre	This study was supported by a National Science Foundation Graduate Research Fellowship and Fundamental Research Supplement, the Center for Child Injury Prevention Studies, particularly the National Highway Traffic Safety Administration and Toyota Collaborative Safety Research Center, and the SAFER Vehicle and Traffic Safety Centre. The sensors were provided free of charge by GForceTracker Inc and there is no financial relationship between the authors, Children's Hospital of Philadelphia, and GForceTracker Inc. Dr. Arbogast serves as a consultant for the National Football League Players Association (NFLPA) on head injury biomechanics topics unrelated to this manuscript.	Allison MA, 2014, MED SCI SPORT EXER, V46, P115, DOI 10.1249/MSS.0b013e3182a32d0d; Brainard LL, 2012, MED SCI SPORT EXER, V44, P297, DOI 10.1249/MSS.0b013e31822b0ab4; Browne KD, 2011, J NEUROTRAUM, V28, P1747, DOI 10.1089/neu.2011.1913; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Faul M., 2010, TRAUMATIC BRAIN INJU, P7; Funk J R, 2007, Annu Proc Assoc Adv Automot Med, V51, P343; Funk JR, 2012, ANN BIOMED ENG, V40, P79, DOI 10.1007/s10439-011-0400-8; Gennarelli T.A., 1972, 720970 SAE, DOI [10.4271/720970, DOI 10.4271/720970]; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Guskiewicz KM, 2011, EXERC SPORT SCI REV, V39, P4, DOI 10.1097/JES.0b013e318201f53e; Jadischke R, 2013, J BIOMECH, V46, P2310, DOI 10.1016/j.jbiomech.2013.05.030; Konrad C, 2011, PSYCHOL MED, V41, P1197, DOI 10.1017/S0033291710001728; Meaney DF, 1993, ASME CRASHWORTHINESS, V25, P169; Mihalik JP, 2008, P I MECH ENG P-J SPO, V222, P45, DOI 10.1243/17543371JSET4; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Mihalik JP, 2012, ANN BIOMED ENG, V40, P141, DOI 10.1007/s10439-011-0405-3; Mihalik JP, 2011, CLIN J SPORT MED, V21, P416, DOI 10.1097/JSM.0B013E31822C8A5C; Mihalik JP, 2010, MED SCI SPORT EXER, V42, P1431, DOI 10.1249/MSS.0b013e3181d2521a; National Center for Injury Prevention and Control (U.S.), 2003, REP C MILD TRAUM BRA, P26; Ocwieja KE, 2012, ANN BIOMED ENG, V40, P90, DOI 10.1007/s10439-011-0401-7; PADGAONKAR AJ, 1975, J APPL MECH-T ASME, V42, P552, DOI 10.1115/1.3423640; Reed N, 2010, INT J SPORTS MED, V31, P826, DOI 10.1055/s-0030-1263103; Rowson S, 2011, ANN BIOMED ENG, V39, P2130, DOI 10.1007/s10439-011-0322-5; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; Stojsih S, 2010, BRIT J SPORT MED, V44, P725, DOI 10.1136/bjsm.2008.052845; Takhounts Erik G, 2013, Stapp Car Crash J, V57, P243; Takhounts EG, 2008, STAPP CAR C, V52, P1; USA Hockey, EQ SIZ GUID	28	34	34	0	19	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	AUG	2015	43	8					1896	1906		10.1007/s10439-014-1197-z			11	Engineering, Biomedical	Engineering	CN2KM	WOS:000358249800016	25476162				2021-06-18	
J	Diamond, ML; Ritter, AC; Jackson, EK; Conley, YP; Kochanek, PM; Boison, D; Wagner, AK				Diamond, Matthew L.; Ritter, Anne C.; Jackson, Edwin K.; Conley, Yvette P.; Kochanek, Patrick M.; Boison, Detlev; Wagner, Amy K.			Genetic variation in the adenosine regulatory cycle is associated with posttraumatic epilepsy development	EPILEPSIA			English	Article						Traumatic brain injury; Posttraumatic epilepsy; Epileptogenesis; Genetics; Adenosine; Rehabilomics	TRAUMATIC BRAIN-INJURY; RISK-FACTORS; KINASE; SEIZURES; ASTROGLIOSIS; METHYLATION; OVEREXPRESSION; ASTROCYTES; PREVENTION; RELEASE	ObjectiveDetermine if genetic variation in enzymes/transporters influencing extracellular adenosine homeostasis, including adenosine kinase (ADK), [ecto-5-nucleotidase (NT5E), cluster of differentiation 73 (CD73)], and equilibrative nucleoside transporter type-1 (ENT-1), is significantly associated with epileptogenesis and posttraumatic epilepsy (PTE) risk, as indicated by time to first seizure analyses. MethodsNine ADK, three CD73, and two ENT-1 tagging single nucleotide polymorphisms (SNPs) were genotyped in 162 white adults with moderate/severe traumatic brain injury (TBI) and no history of premorbid seizures. Kaplan-Meier models were used to screen for genetic differences in time to first seizure occurring >1week post-TBI. SNPs remaining significant after correction for multiple comparisons were examined using Cox proportional hazards analyses, adjusting for subdural hematoma, injury severity score, and isolated TBI status. SNPs significant in multivariate models were then entered simultaneously into an adjusted Cox model. ResultsComparing Kaplan-Meier curves, rs11001109 (ADK) rare allele homozygosity and rs9444348 (NT5E) heterozygosity were significantly associated with shorter time to first seizure and an increased seizure rate 3years post-TBI. Multivariate Cox proportional hazard models showed that these genotypes remained significantly associated with increased PTE hazard up to 3years post-TBI after controlling for variables of interest (rs11001109: hazard ratio (HR) 4.47, 95% confidence interval (CI) 1.27-15.77, p=0.020; rs9444348: HR 2.95, 95% CI 1.19-7.31, p=0.019) . SignificanceGenetic variation in ADK and NT5E may help explain variability in time to first seizure and PTE risk, independent of previously identified risk factors, after TBI. Once validated, identifying genetic variation in adenosine regulatory pathways relating to epileptogenesis and PTE may facilitate exploration of therapeutic targets and pharmacotherapy development.	[Diamond, Matthew L.; Ritter, Anne C.; Wagner, Amy K.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; [Jackson, Edwin K.] Univ Pittsburgh, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15213 USA; [Conley, Yvette P.] Univ Pittsburgh, Dept Hlth Promot & Human Genet, Pittsburgh, PA 15213 USA; [Kochanek, Patrick M.] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15213 USA; [Conley, Yvette P.; Kochanek, Patrick M.; Wagner, Amy K.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; [Boison, Detlev] Legacy Res Inst, RS Dow Neurobiol Labs, Portland, OR USA; [Wagner, Amy K.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15213 USA	Wagner, AK (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, Res, 3471 Fifth Ave,Suite 202, Pittsburgh, PA 15213 USA.	wagnerak@upmc.edu	Boison, Detlev/ABE-6302-2020	Conley, Yvette/0000-0002-1784-6067; Boison, Detlev/0000-0002-7740-5781; Jackson, Edwin/0000-0002-8101-6009	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NR013342]; DODUnited States Department of Defense [W81XWH-12-1-0283];  [NIH-R01HD048162];  [DODW81XWH-071-0701];  [NIH-R01NS087978]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048162] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000005] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS087978] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01NR013342] Funding Source: NIH RePORTER	This work was supported by NIH-R01HD048162, DODW81XWH-071-0701, NIH R01NR013342, DOD W81XWH-12-1-0283, and NIH-R01NS087978. Thanks to Sandra Deslouche for support with genotyping and Dr. Candice Kammerer for statistical genetic guidance, and the subjects and their families for their generous participation. Thanks to the UPMC Trauma Registry for assisting with some elements of data collection.	Aronica E, 2011, EPILEPSIA, V52, P1645, DOI 10.1111/j.1528-1167.2011.03115.x; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Bjursell MK, 2011, AM J HUM GENET, V89, P507, DOI 10.1016/j.ajhg.2011.09.004; Boison D, 2013, PHARMACOL REV, V65, P906, DOI 10.1124/pr.112.006361; Boison D, 2012, GLIA, V60, P1234, DOI 10.1002/glia.22285; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Chu S, 2014, PURINERG SIGNAL, V10, P603, DOI 10.1007/s11302-014-9421-8; Cunha Rodrigo A, 2005, Purinergic Signal, V1, P111, DOI 10.1007/s11302-005-0649-1; Diamond ML, 2014, EPILEPSIA, V55, P1109, DOI 10.1111/epi.12628; Diogenes MJ, 2014, CEREB CORTEX, V24, P67, DOI 10.1093/cercor/bhs284; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; Fedele DE, 2005, BRAIN, V128, P2383, DOI 10.1093/brain/awh555; Fedele DE, 2006, EXP NEUROL, V200, P184, DOI 10.1016/j.expneurol.2006.02.133; Fisher RS, 2014, EPILEPSIA, V55, P475, DOI 10.1111/epi.12550; Gao WM, 2006, BRAIN RES, V1070, P31, DOI 10.1016/j.brainres.2005.11.038; Gennarelli TA, 2006, INJURY, V37, P1083, DOI 10.1016/j.injury.2006.07.009; Gomes CV, 2011, BBA-BIOMEMBRANES, V1808, P1380, DOI 10.1016/j.bbamem.2010.12.001; Gouder N, 2004, J NEUROSCI, V24, P692, DOI 10.1523/JNEUROSCI.4781-03.2004; Ke RH, 2009, NEUROSCI RES, V65, P280, DOI 10.1016/j.neures.2009.08.002; Knapp K, 2012, STRUCTURE, V20, P2161, DOI 10.1016/j.str.2012.10.001; Kobow K, 2011, EPILEPSIA, V52, P15, DOI 10.1111/j.1528-1167.2011.03145.x; Kochanek PM, 2006, J CEREBR BLOOD F MET, V26, P565, DOI 10.1038/sj.jcbfm.9600218; Kolakowsky-Hayner SA, 2013, BRAIN INJURY, V27, P578, DOI 10.3109/02699052.2013.765595; Kumar RG, 2015, BRAIN BEHAV IMMUN, V45, P253, DOI 10.1016/j.bbi.2014.12.021; Li J, 2005, HEREDITY, V95, P221, DOI 10.1038/sj.hdy.6800717; Li TF, 2008, J CLIN INVEST, V118, P571, DOI 10.1172/JCI33737; Li TF, 2012, GLIA, V60, P83, DOI 10.1002/glia.21250; Lo Nigro C, 2012, BRIT J CANCER, V107, P75, DOI 10.1038/bjc.2012.212; Lovatt D, 2012, P NATL ACAD SCI USA, V109, P6265, DOI 10.1073/pnas.1120997109; Maegele M, 2007, INFLAMM RES, V56, P318, DOI 10.1007/s00011-007-6141-3; McGraw J, 2001, J NEUROSCI RES, V63, P109, DOI 10.1002/1097-4547(20010115)63:2<109::AID-JNR1002>3.0.CO;2-J; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Parkinson FE, 2004, J NEUROCHEM, V88, P1305, DOI 10.1046/j.1471-4159.2003.02266.x; Pascual O, 2005, SCIENCE, V310, P113, DOI 10.1126/science.1116916; Robel S, 2015, J NEUROSCI, V35, P3330, DOI 10.1523/JNEUROSCI.1574-14.2015; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Schumacher MA, 2000, J MOL BIOL, V298, P875, DOI 10.1006/jmbi.2000.3753; Strater Norbert, 2006, Purinergic Signal, V2, P343, DOI 10.1007/s11302-006-9000-8; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 2003, EPILEPSIA, V44, P18, DOI 10.1046/j.1528-1157.44.s10.6.x; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Wagner Amy K, 2013, Pathophysiology, V20, P39, DOI 10.1016/j.pathophys.2012.02.007; Wagner AK, 2010, EPILEPSY RES, V90, P259, DOI 10.1016/j.eplepsyres.2010.06.001; Wiesner JB, 1999, J PHARMACOL EXP THER, V289, P1669; Williams-Karnesky RL, 2013, J CLIN INVEST, V123, P3552, DOI 10.1172/JCI65636	46	34	36	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0013-9580	1528-1167		EPILEPSIA	Epilepsia	AUG	2015	56	8					1198	1206		10.1111/epi.13044			9	Clinical Neurology	Neurosciences & Neurology	CO2AX	WOS:000358958700005	26040919	Green Accepted, Bronze			2021-06-18	
J	Adam, O; Mac Donald, CL; Rivet, D; Ritter, J; May, T; Barefield, M; Duckworth, J; LaBarge, D; Asher, D; Drinkwine, B; Woods, Y; Connor, M; Brody, DL				Adam, Octavian; Mac Donald, Christine L.; Rivet, Dennis; Ritter, John; May, Todd; Barefield, Maria; Duckworth, Josh; LaBarge, Donald; Asher, Dean; Drinkwine, Benjamin; Woods, Yvette; Connor, Michael; Brody, David L.			Clinical and imaging assessment of acute combat mild traumatic brain injury in Afghanistan	NEUROLOGY			English	Article							AMYLOID PRECURSOR PROTEIN; HEAD-INJURY; AXONAL INJURY; MILITARY PERSONNEL; CONCUSSION; BLAST; DEPRESSION; SPORTS; PERFORMANCE; MANAGEMENT	Objective: To evaluate whether diffusion tensor imaging (DTI) will noninvasively reveal white matter changes not present on conventional MRI in acute blast-related mild traumatic brain injury (mTBI) and to determine correlations with clinical measures and recovery. Methods: Prospective observational study of 95 US military service members with mTBI enrolled within 7 days from injury in Afghanistan and 101 healthy controls. Assessments included Rivermead Post-Concussion Symptoms Questionnaire (RPCSQ), Post-Traumatic Stress Disorder Checklist Military (PCLM), Beck Depression Inventory (BDI), Balance Error Scoring System (BESS), Automated Neuropsychological Assessment Metrics (ANAM), conventional MRI, and DTI. Results: Significantly greater impairment was observed in participants with mTBI vs controls: RPCSQ (19.7 +/- 12.9 vs 3.6 +/- 7.1, p < 0.001), PCLM (32 +/- 13.2 vs 20.9 +/- 7.1, p < 0.001), BDI (7.4 +/- 6.8 vs 2.5 +/- 4.9, p < 0.001), and BESS (18.2 +/- 8.4 vs 15.1 +/- 8.3, p = 0.01). The largest effect size in ANAM performance decline was in simple reaction time (mTBI 74.5 +/- 148.4 vs control -11 +/- 46.6 milliseconds, p < 0.001). Fractional anisotropy was significantly reduced in mTBI compared with controls in the right superior longitudinal fasciculus (0.393 +/- 0.022 vs 0.405 +/- 0.023, p < 0.001). No abnormalities were detected with conventional MRI. Time to return to duty correlated with RPCSQ (r = 0.53, p < 0.001), ANAM simple reaction time decline (r = 0.49, p < 0.0001), PCLM (r = 0.47, p < 0.0001), and BDI (r = 0.36 p = 0.0005). Conclusions: Somatic, behavioral, and cognitive symptoms and performance deficits are substantially elevated in acute blast-related mTBI. Postconcussive symptoms and performance on measures of posttraumatic stress disorder, depression, and neurocognitive performance at initial presentation correlate with return-to-duty time. Although changes in fractional anisotropy are uncommon and subtle, DTI is more sensitive than conventional MRI in imaging white matter integrity in blast-related mTBI acutely.	[Adam, Octavian] Naval Med Ctr Portsmouth, Div Neurol, Portsmouth, VA USA; [Rivet, Dennis] Naval Med Ctr Portsmouth, Dept Neurol Surg, Portsmouth, VA USA; [LaBarge, Donald] Naval Med Ctr Portsmouth, Dept Radiol, Portsmouth, VA USA; [Mac Donald, Christine L.; Brody, David L.] Washington Univ, Dept Neurol, St Louis, MO USA; [Rivet, Dennis] Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA 23284 USA; [Ritter, John] San Antonio Mil Med Ctr, Dept Radiol, San Antonio, TX USA; [Woods, Yvette] San Antonio Mil Med Ctr, Dept Orthoped & Rehabil, Occupat Therapy Serv, San Antonio, TX USA; [May, Todd] Naval Hosp, Dept Sports Med, Camp Pendleton, CA USA; [Barefield, Maria] Naval Hosp Jacksonville, Dept Occupat Therapy, Jacksonville, FL USA; [Duckworth, Josh] San Diego Naval Med Ctr, Dept Neurol, San Diego, CA USA; [Asher, Dean; Drinkwine, Benjamin] San Diego Naval Med Ctr, Dept Radiol, San Diego, CA USA; [Connor, Michael] Naval Air Stn Jacksonville, Branch Hlth Clin, Jacksonville, FL USA	Adam, O (corresponding author), Berkshire Med Ctr, Dept Neurol, Pittsfield, MA 01201 USA.	oadam@bhs1.org	Ritter, John/AAG-8899-2020		Congressionally Directed Medical Research ProgramUnited States Department of Defense	Grant funding was provided by the Congressionally Directed Medical Research Program (D. Brody). The funding agency did not take part in and in no way influenced the research design, data collection, data analysis, interpretation of data, or preparation of the manuscript.	BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Cantu RC, 1998, CLIN SPORT MED, V17, P45, DOI 10.1016/S0278-5919(05)70060-0; Cernich A, 2007, ARCH CLIN NEUROPSYCH, V22, pS101, DOI 10.1016/j.acn.2006.10.008; Coldren RL, 2012, MIL MED, V177, P179, DOI 10.7205/MILMED-D-11-00278; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Geary EK, 2010, J INT NEUROPSYCH SOC, V16, P506, DOI 10.1017/S135561771000010X; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Harmon KG, 1999, AM FAM PHYSICIAN, V60, P887; Hayward P, 2008, LANCET NEUROL, V7, P200, DOI 10.1016/S1474-4422(08)70032-2; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Homaifar BY, 2009, ARCH PHYS MED REHAB, V90, P652, DOI 10.1016/j.apmr.2008.10.028; Keane T.M., 1989, PSYCHOL ASSESSMENT J, V1, P53, DOI DOI 10.1037/1040-3590.1.1.53; Kelly JP, 1997, NEUROLOGY, V48, P581; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055823; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Mac Donald CL, 2015, BRAIN, V138, P1314, DOI 10.1093/brain/awv038; Mac Donald CL, 2014, JAMA NEUROL, V71, P994, DOI 10.1001/jamaneurol.2014.1114; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Matthews SC, 2011, NEUROIMAGE, V54, pS69, DOI 10.1016/j.neuroimage.2010.04.269; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Mori S, 2009, CURR OPIN NEUROL, V22, P362, DOI 10.1097/WCO.0b013e32832d954b; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Pierpaoli C, 1996, RADIOLOGY, V201, P637, DOI 10.1148/radiology.201.3.8939209; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; Sotiropoulos SN, 2013, NEUROIMAGE, V80, P125, DOI 10.1016/j.neuroimage.2013.05.057; Tate CM, 2013, J NEUROTRAUM, V30, P1620, DOI 10.1089/neu.2012.2683; Tombough T., 1996, TEST MEMORY MALINGER; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Yeager DE, 2007, GEN HOSP PSYCHIAT, V29, P294, DOI 10.1016/j.genhosppsych.2007.03.004; Zhang YJ, 2010, NEUROIMAGE, V52, P1289, DOI 10.1016/j.neuroimage.2010.05.049	38	34	36	0	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	JUL 21	2015	85	3					219	227		10.1212/WNL.0000000000001758			9	Clinical Neurology	Neurosciences & Neurology	CN1GR	WOS:000358167100004	26109715	Green Published			2021-06-18	
J	Ilie, G; Adlaf, EM; Mann, RE; Ialomiteanu, A; Hamilton, H; Rehm, J; Asbridge, M; Cusimano, MD				Ilie, Gabriela; Adlaf, Edward M.; Mann, Robert E.; Ialomiteanu, Anca; Hamilton, Hayley; Rehm, Juergen; Asbridge, Mark; Cusimano, Michael D.			Associations between a History of Traumatic Brain Injuries and Current Cigarette Smoking, Substance Use, and Elevated Psychological Distress in a Population Sample of Canadian Adults	JOURNAL OF NEUROTRAUMA			English	Article						adults; psychological distress; substance use; traumatic brain injury	UNITED-STATES; ALCOHOL; ABUSE; WORK	This study describes the prevalence of reported history of traumatic brain injury (TBI) and its association with reports of current substance use, cigarette smoking, and psychological distress among Canadian adults in a population sample. A cross-sectional sample of 1999 Ontario adults 18-93 years of age were surveyed by telephone in 2011 as part of the Center for Addiction and Mental Health's ongoing representative survey of adult mental health and substance use in Ontario, Canada. Loss of consciousness for at least 5min or at least one overnight hospitalization resulting from symptoms associated with the TBI injury represented minimum criteria for TBI. An estimated 16.8% (95% confidence interval, 14.8, 19.0) of adults reported a TBI in their lifetime. Men had higher prevalence of TBI than women. Adults who reported a history of TBI had higher odds of reported past-year daily smoking (adjusted odds ratio [AOR]=2.15), using cannabis (AOR=2.80) and nonmedical opioids (AOR=2.90), as well as screened significantly for recent elevated psychological distress (AOR=1.97) in the past few weeks, compared to adults without a history of TBI. Co-occurrence of a history of TBI with current elevated psychological distress and substance use warrants vigilance among medical practitioners to assess the possibility of a history of TBI during reviews of the history leading to the occurrence of these conditions.	[Ilie, Gabriela; Cusimano, Michael D.] St Michaels Hosp, Injury Prevent Res Off, Toronto, ON M5B 1W8, Canada; [Adlaf, Edward M.; Mann, Robert E.; Ialomiteanu, Anca; Hamilton, Hayley; Rehm, Juergen] Ctr Addict & Mental Hlth, Social & Epidemiol Res, Toronto, ON, Canada; [Asbridge, Mark] Dalhousie Univ, Dept Community Hlth & Epidemiol, Halifax, NS, Canada; [Ilie, Gabriela; Cusimano, Michael D.] Univ Toronto, Div Neurosurg, Toronto, ON, Canada	Ilie, G (corresponding author), St Michaels Hosp, Div Neurosurg, 30 Bond St, Toronto, ON M5B 1W8, Canada.	ilieg@smh.ca	Cusimano, Michael/X-4059-2019; Ilie, Gabriela/AAM-9122-2021	Cusimano, Michael/0000-0002-9989-0650	Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR) [TIR103946]; Ontario Neurotrauma Foundation; AUTO21, a member of the Networks of Centers of Excellence (NCE) - Natural Sciences and Engineering Research Council (NSERC); CIHRCanadian Institutes of Health Research (CIHR); Social Sciences and Humanities Research Council (SSHRC)Social Sciences and Humanities Research Council of Canada (SSHRC); Industry Canada; Ontario Ministry of Health and Long-Term CareMinistry of Health and Long-Term Care, Ontario	This work was financially supported by a Team Grant (TIR103946) from Canadian Institutes of Health Research (CIHR) and by funds from the Ontario Neurotrauma Foundation. Additional funding was obtained from a grant from AUTO21, a member of the Networks of Centers of Excellence (NCE) program that is administered and funded by the Natural Sciences and Engineering Research Council (NSERC), the CIHR, and the Social Sciences and Humanities Research Council (SSHRC), in partnership with Industry Canada. R.M., H.H., and J.R. also acknowledge ongoing funding support from the Ontario Ministry of Health and Long-Term Care.	Andelic N, 2013, LANCET NEUROL, V12, P28, DOI 10.1016/S1474-4422(12)70294-6; Anstey KJ, 2004, J CLIN EPIDEMIOL, V57, P1202, DOI 10.1016/j.jclinepi.2003.11.011; Billette J. M., 2013, HLTH GLANCE INJURIES; Butterworth P, 2004, J CLIN EPIDEMIOL, V57, P742, DOI 10.1016/j.jclinepi.2003.10.015; Cherpitel CJ, 2007, DRUG ALCOHOL REV, V26, P201, DOI 10.1080/09595230601146686; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Dean PJA, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00030; Dooley JJ, 2008, BRAIN INJURY, V22, P836, DOI 10.1080/02699050802425444; ESSELMAN PC, 1995, BRAIN INJURY, V9, P417, DOI 10.3109/02699059509005782; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Frances A, 2000, DSM 4 CLASSIFICATION; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Goldberg DP, 1997, PSYCHOL MED, V27, P191, DOI 10.1017/S0033291796004242; Gustavsson A, 2011, EUR NEUROPSYCHOPHARM, V21, P718, DOI 10.1016/j.euroneuro.2011.08.008; Horner MD, 2005, J INT NEUROPSYCH SOC, V11, P322, DOI 10.1017/S135561770505037X; Ialomiteanu A. R., 2011, CAMH RES DOCUMENT SE, V35; Ilie G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094936; Ilie G, 2013, JAMA-J AM MED ASSOC, V309, P2550, DOI 10.1001/jama.2013.6750; Institute of Medicine of the National Academies, 2013, COMM SPORTS REL CONC; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Rusnak M, 2013, NAT REV NEUROL, V9, P186, DOI 10.1038/nrneurol.2013.38; Tait RJ, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-171; Topolovec-Vranic Jane, 2014, CMAJ Open, V2, pE69, DOI 10.9778/cmajo.20130046; Wehman P, 2005, J HEAD TRAUMA REHAB, V20, P115, DOI 10.1097/00001199-200503000-00001; Wright DW, 2013, MMWR-MORBID MORTAL W, V62, P549; Yasuda S, 2001, AM J PHYS MED REHAB, V80, P852, DOI 10.1097/00002060-200111000-00011	30	34	34	1	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL 15	2015	32	14					1130	1134		10.1089/neu.2014.3619			5	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CV0TB	WOS:000363965000012	25496189	Green Published, Green Accepted			2021-06-18	
J	Mychasiuk, R; Hehar, H; Esser, MJ				Mychasiuk, Richelle; Hehar, Harleen; Esser, Michael J.			A mild traumatic brain injury (mTBI) induces secondary attention-deficit hyperactivity disorder-like symptomology in young rats	BEHAVIOURAL BRAIN RESEARCH			English	Article						Go/No-Go; Executive function; Impulsive; Secondary ADHD; Weight-drop	PROBLEM-SOLVING SKILLS; REACTION-TIME-TASK; DEFICIT/HYPERACTIVITY DISORDER; EXECUTIVE FUNCTION; INHIBITORY CONTROL; SEX-DIFFERENCES; HEAD-INJURY; SHORT-TERM; CONCUSSION; CHILDREN	Although attention-deficit hyperactivity disorder (ADHD) is commonly reported after moderate and severe traumatic brain injury (TBI), research is struggling to find a strong link between mild TBI or concussion and ADHD. Epidemiological studies often generate conflicting results which may be related to the difficulty identifying the lingering symptoms of mTBI, the lack of baseline knowledge and the possible exacerbation of pre-existing ADHD symptomology, and/or differential diagnostic criteria for secondary ADHD. The purpose of this study was to determine if a mild TBI/concussion in the juvenile period (postnatal day 30) could induce ADHD-like symptoms in young rodents. Using the Go/No-Go paradigm of the 5-choice serial reaction task, sustained attention, impulsivity, and response inhibition was measured. The open field was also used to measure activity levels at two time points. Animals that experienced an mTBI in the juvenile period exhibited ADHD symptomology, with sex-differences present on one of the tasks. Significant deficits were identified in sustained attention, response inhibition, and impulsivity. Immediately after the mTBI, all rats were hypoactive in the open field, and while male animals exhibited a trend toward hyperactivity in the long-term, females continued to trend toward hypoactivity for the duration of the experiment. These findings provide a unique platform upon which preventative and therapeutic strategies can be implemented and tested in an effort to improve ADHD-like symptoms following mTBI. (C) 2015 Elsevier B.V. All rights reserved.	[Mychasiuk, Richelle; Hehar, Harleen; Esser, Michael J.] Univ Calgary, Alberta Childrens Hosp, Res Inst, Calgary, AB T2N 1N4, Canada	Mychasiuk, R (corresponding author), Univ Calgary, Alberta Childrens Hosp, Res Inst, Room 274,Heritage Med Res Bldg,3330 Hosp Dr NW, Calgary, AB T2N 1N4, Canada.	rmmychas@ucalgary.ca			Alberta Children's Hospital Research Institute; Alberta Children's Hospital Foundation; Canadian Institute for Health ResearchCanadian Institutes of Health Research (CIHR); Markin USRP for Health and Wellness	The authors would like to thank Irene Ma, Simon Spanswick, and Rose Tobias for their technical assistance. They would also like to thank the Alberta Children's Hospital Research Institute, the Alberta Children's Hospital Foundation, the Canadian Institute for Health Research, and the Markin USRP for Health and Wellness, for their financial contributions.	American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, DOI [10.1176/appi.books.9780890425596., DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]; Bari A, 2008, NAT PROTOC, V3, P759, DOI 10.1038/nprot.2008.41; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Blakemore SJ, 2006, J CHILD PSYCHOL PSYC, V47, P296, DOI 10.1111/j.1469-7610.2006.01611.x; Brooks J, 1999, J TRAUMA, V46, P159, DOI 10.1097/00005373-199901000-00027; Castellanos FX, 2006, TRENDS COGN SCI, V10, P117, DOI 10.1016/j.tics.2006.01.011; Catroppa C, 2003, DEV NEUROPSYCHOL, V23, P359, DOI 10.1207/S15326942DN2303_3; Centers for Disease Control and Prevention, 2014, ATT DEF HYP DIS ADHD; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Chudasama Y, 2003, BEHAV BRAIN RES, V146, P105, DOI 10.1016/j.bbr.2003.09.020; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Dalley JW, 2011, NEURON, V69, P680, DOI 10.1016/j.neuron.2011.01.020; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Ganesalingam K, 2007, J NEUROPSYCHOL, V1, P149, DOI 10.1348/174866407X185300; Ginstfeldt T, 2010, BRAIN INJURY, V24, P1123, DOI 10.3109/02699052.2010.506853; Golmirzaei J, 2013, INT J PEDIAT, V2013, DOI 10.1155/2013/953103; Hooper SR, 2004, NEUROREHABILITATION, V19, P175; Howell D, 2013, MED SCI SPORT EXER, V45, P1030, DOI 10.1249/MSS.0b013e3182814595; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; Keenan HT, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1984; Kolb B., 2008, FUNDAMENTALS HUMAN N; Konrad KN, 2000, BRAIN INJURY, V14, P859; Levin H, 2007, J DEV BEHAV PEDIATR, V28, P108, DOI 10.1097/01.DBP.0000267559.26576.cd; Malojcic B, 2008, J NEUROTRAUM, V25, P30, DOI 10.1089/neu.2007.0384; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1041, DOI 10.1097/01.chi.0000173292.05817.f8; Max JE, 1998, BRAIN INJURY, V12, P41; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mychasiuk R, 2014, BEHAV BRAIN RES, V259, P284, DOI 10.1016/j.bbr.2013.10.048; Mychasiuk R, 2014, J NEUROTRAUM, V31, P749, DOI 10.1089/neu.2013.3132; Pellis SM, 2010, AM J PLAY, V2, P278; Pinto PS, 2012, J NEUROIMAGING, V22, pe18, DOI 10.1111/j.1552-6569.2011.00690.x; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Sagvolden T, 2005, BIOL PSYCHIAT, V57, P1239, DOI 10.1016/j.biopsych.2005.02.002; Sarter M, 2001, BRAIN RES REV, V35, P146, DOI 10.1016/S0165-0173(01)00044-3; Schallert T., 2002, PHARM CEREBRAL ISCHE, P201; Sinopoli KJ, 2012, INT J DEV NEUROSCI, V30, P207, DOI 10.1016/j.ijdevneu.2011.08.006; Sinopoli KJ, 2011, J CLIN EXP NEUROPSYC, V33, P805, DOI 10.1080/13803395.2011.562864; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; White RD, 2014, SPORTS HEALTH, V6, P149, DOI 10.1177/1941738113484679; Willcutt EG, 2005, BIOL PSYCHIAT, V57, P1336, DOI 10.1016/j.biopsych.2005.02.006; Wodka EL, 2007, J CLIN EXP NEUROPSYC, V29, P345, DOI 10.1080/13803390600678046; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Zang YF, 2005, BRAIN DEV-JPN, V27, P544, DOI 10.1016/j.braindev.2004.11.009	44	34	35	0	14	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	JUN 1	2015	286						285	292		10.1016/j.bbr.2015.03.010			8	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	CG8XS	WOS:000353599600038	25771208				2021-06-18	
J	van Zellem, L; Buysse, C; Madderom, M; Legerstee, JS; Aarsen, F; Tibboel, D; Utens, EM				van Zellem, Lennart; Buysse, Corinne; Madderom, Marlous; Legerstee, Jeroen S.; Aarsen, Femke; Tibboel, Dick; Utens, Elisabeth M.			Long-term neuropsychological outcomes in children and adolescents after cardiac arrest	INTENSIVE CARE MEDICINE			English	Article						Heart arrest; Follow-up studies; Neuropsychology; Pediatric; Cognition	TRAUMATIC BRAIN-INJURY; COGNITIVE FUNCTION; EXECUTIVE FUNCTION; FOLLOW-UP; ENCEPHALOPATHY; RESUSCITATION; MULTICENTER; IMPAIRMENT; SURVIVORS; RECOVERY	Research into neuropsychological functioning of survivors of cardiac arrest (CA) in childhood is scarce. We sought to assess long-term neuropsychological functioning in children and adolescents surviving CA. Neuropsychological follow-up study involving all consecutive children surviving CA between January 2002 and December 2011. Intelligence (IQ), language, attention, memory, visual-spatial, and executive functioning were assessed with internationally validated, neuropsychological tests and questionnaires. Scores were compared with Dutch normative data. Of 107 eligible children, 47 who visited the outpatient clinic (median follow-up interval: 5.6 years) were analyzed. Fifty-five percent had an in-hospital CA, 86 % a non-shockable rhythm, and 49 % a respiratory-related etiology. CA survivors scored significantly worse on full-scale IQ (), verbal IQ (), performance IQ (), verbal comprehension index (), perceptual organization index (), and processing speed index (), than the norm population (mean IQ = 100). On neuropsychological tests, compared with norms, respectively adjusted for IQ, significantly worse scores were found on visual memory, significantly better on verbal memory (recognition), and comparable outcomes on visual-motor integration, attention, other measures of verbal memory, and executive functioning. On questionnaires, parents reported better executive functioning than the norm, but teachers reported more problems in planning/organizing skills. Long-term neuropsychological assessment of CA survivors showed significant weaknesses, but also relatively intact functioning. As deficits in IQ, memory and executive functioning have significant impact on the child, long-term follow-up and neuropsychological support of CA survivors is warranted.	[van Zellem, Lennart; Buysse, Corinne; Madderom, Marlous; Aarsen, Femke; Tibboel, Dick] Erasmus MC Sophia Childrens Hosp, Intens Care, NL-3015 CN Rotterdam, Netherlands; [van Zellem, Lennart; Buysse, Corinne; Madderom, Marlous; Aarsen, Femke; Tibboel, Dick] Erasmus MC Sophia Childrens Hosp, Dept Pediat Surg, NL-3015 CN Rotterdam, Netherlands; [Madderom, Marlous; Legerstee, Jeroen S.; Aarsen, Femke; Utens, Elisabeth M.] Erasmus MC Sophia Childrens Hosp, Dept Child & Adolescent Psychiat Psychol, NL-3015 CN Rotterdam, Netherlands	Buysse, C (corresponding author), Erasmus MC Sophia Childrens Hosp, Intens Care, Wytemaweg 80, NL-3015 CN Rotterdam, Netherlands.	c.buysse@erasmusmc.nl					Aarsen FK, 2006, CANCER-AM CANCER SOC, V106, P396, DOI 10.1002/cncr.21612; Amicuzi I, 2005, BRAIN INJURY, V19, P371, DOI 10.1080/02699050400004286; Anderson V, 2012, PEDIATRICS, V129, pE254, DOI 10.1542/peds.2011-0311; Antonelli M, 2012, INTENS CARE MED, V38, P542, DOI 10.1007/s00134-012-2508-1; Beery K.E., 2004, BEERY BUKTENICA DEV, V5th; Cassidy AR, 2015, J INT NEUROPSYCH SOC, V21, P34, DOI 10.1017/S1355617714001027; Chiang MC, 2009, J NEUROSCI, V29, P2212, DOI 10.1523/JNEUROSCI.4184-08.2009; Donoghue AJ, 2005, ANN EMERG MED, V46, P512, DOI 10.1016/j.annemergmed.2005.05.028; Dunn L. M., 2005, PEABODY PICTURE VOCA; Gonzalez FF, 2006, ARCH DIS CHILD-FETAL, V91, pF454, DOI 10.1136/adc.2005.092445; Grubb NR, 2000, STROKE, V31, P1509, DOI 10.1161/01.STR.31.7.1509; Harukuni I, 2006, NEUROL CLIN, V24, P1, DOI 10.1016/j.ncl.2005.10.004; Hendriksen J., 2009, WPPSI 3 NL WECHSLER; Kok TB, 2009, TIJDSCHRIFT NEUROPSY, V4, P42; Kort W., 2005, WISC 3 NL WECHSLER I; Lopez-Herce J, 2013, INTENS CARE MED, V39, P309, DOI 10.1007/s00134-012-2709-7; Madderom MJ, 2013, INTENS CARE MED, V39, P1584, DOI 10.1007/s00134-013-2973-1; Manly T., 1999, TEST EVERYDAY ATTENT; Marlow N, 2005, ARCH DIS CHILD-FETAL, V90, pF380, DOI 10.1136/adc.2004.067520; Maryniak A, 2008, RESUSCITATION, V77, P46, DOI 10.1016/j.resuscitation.2007.10.024; McAuley T, 2010, J INT NEUROPSYCH SOC, V16, P495, DOI 10.1017/S1355617710000093; Michiels EA, 2013, PEDIATR CRIT CARE ME, V14, P755, DOI 10.1097/PCC.0b013e31829763e2; Middleton J.A., 2001, ADV PSYCHIAT TREATME, V7, P257, DOI [10.1192/apt.7.4.257, DOI 10.1192/APT.7.4.257]; MORRIS RD, 1993, J LEARN DISABIL, V26, P46, DOI 10.1177/002221949302600105; Opic P, 2013, IMPACT CONGENITAL HE; Oualha M, 2013, INTENS CARE MED, V39, P1306, DOI 10.1007/s00134-013-2930-z; Rey A, 1964, EXAMEN CLIN PSYCHOL; Schmand B, 2005, NORMEN STROOP KLEURW; Schmand B, 2012, NORMEN 15 WOORDENTES; Sesma HW, 2008, PEDIATRICS, V121, pE1686, DOI 10.1542/peds.2007-2461; Smidts D.P., 2009, BRIEF EXECUTIEVE FUN; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Suominen PK, 2014, RESUSCITATION, V85, P1059, DOI 10.1016/j.resuscitation.2014.03.307; Suominen PK, 2012, SCAND J TRAUMA RESUS, V20, DOI 10.1186/1757-7241-20-55; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; The Netherlands Institute for Social Research (Sociaal en Cultureel Planbureau), 2012, RANG NAAR SOC STAT P; Topjian AA, 2009, CURR OPIN CRIT CARE, V15, P203, DOI 10.1097/MCC.0b013e32832931e1; Vermunt LCAC, 2009, BRIT J CLIN PSYCHOL, V48, P195, DOI 10.1348/014466508X391094; Wechsler D., 2012, WECHSLER ADULT INTEL, V4; Wernovsky G, 2006, CARDIOL YOUNG, V16, P92, DOI 10.1017/S1047951105002398	40	34	34	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	JUN	2015	41	6					1057	1066		10.1007/s00134-015-3789-y			10	Critical Care Medicine	General & Internal Medicine	CL2UO	WOS:000356801200010	25894622	Other Gold, Green Published			2021-06-18	
J	List, J; Ott, S; Bukowski, M; Lindenberg, R; Floel, A				List, Jonathan; Ott, Stefanie; Bukowski, Martin; Lindenberg, Robert; Floeel, Agnes			Cognitive function and brain structure after recurrent mild traumatic brain injuries in young-to-middle-aged adults	FRONTIERS IN HUMAN NEUROSCIENCE			English	Article						concussion; cortical thickness; MRI; cognition; traumatic brain injury	HUMAN CEREBRAL-CORTEX; ALZHEIMERS-DISEASE; FOOTBALL PLAYERS; CONCUSSION; DEMENTIA; ENCEPHALOPATHY; COLLEGIATE; HISTORY; MRI; ABNORMALITIES	Recurrent mild traumatic brain injuries (mTBIs) are regarded as an independent risk factor for developing dementia in later life. We here aimed to evaluate associations between recurrent mTBIs, cognition, and gray matter volume and microstructure as revealed by structural magnetic resonance imaging (MRI) in the chronic phase after mTBIs in young adulthood. We enrolled 20 young-to-middle-aged subjects, who reported two or more sports-related mTBIs, with the last mTBI > 6 months prior to study enrolment (mTBI group), and 21 age-, sex- and education matched controls with no history of mTBI (control group). All participants received comprehensive neuropsychological testing, and high resolution T1-weighted and diffusion tensor MRI in order to assess cortical thickness (CT) and microstructure, hippocampal volume, and ventricle size. Compared to the control group, subjects of the mTBI group presented with lower CT within the right temporal lobe and left insula using an a priori region of interest approach. Higher number of mTBIs was associated with lower CT in bilateral insula, right middle temporal gyrus and right entorhinal area. Our results suggest persistent detrimental effects of recurrent mTBIs on CT already in young-to-middle-aged adults. If additional structural deterioration occurs during aging, subtle neuropsychological decline may progress to clinically overt dementia earlier than in age-matched controls, a hypothesis to be assessed in future prospective trials.	[List, Jonathan; Ott, Stefanie; Bukowski, Martin; Lindenberg, Robert; Floeel, Agnes] Charite, Dept Neurol, D-10117 Berlin, Germany; [Lindenberg, Robert; Floeel, Agnes] Charite, Ctr Stroke Res Berlin, D-10117 Berlin, Germany; [Floeel, Agnes] Charite, NeuroCure Cluster Excellence, D-10117 Berlin, Germany	List, J (corresponding author), Charite, Dept Neurol, Charitepl 1, D-10117 Berlin, Germany.	jonathan.list@charite.de; agnes.floeel@charite.de	Meijer, Anna/K-5118-2016; Floel, Agnes/A-9426-2017		Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [F1-379-8/1, 379-10/1, 379-11/1, DFG-Exc-257]; Bundesministerium fur Bildung und ForschungFederal Ministry of Education & Research (BMBF) [FKZ0315673A, 01EO0801, 01GY1144]; Else-Kroner Fresenius Stiftung [2011_119]; Charite Universitatsmedizin Berlin; Berlin Institute of Health	This work was supported by grants from the Deutsche Forschungsgemeinschaft (AF: F1-379-8/1; 379-10/1; 379-11/1; DFG-Exc-257), Bundesministerium fur Bildung und Forschung (AF: FKZ0315673A; 01EO0801; 01GY1144) and Else-Kroner Fresenius Stiftung (RL: 2011_119). JL is participant in the Charite Clinical Scientist Program funded by the Charite Universitatsmedizin Berlin and the Berlin Institute of Health.	Albert Marilyn, 2008, Handb Clin Neurol, V88, P511, DOI 10.1016/S0072-9752(07)88027-4; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Bigler ED, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00395; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; Craig AD, 2009, NAT REV NEUROSCI, V10, P59, DOI 10.1038/nrn2555; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2012, CEREB CORTEX, V22, P112, DOI 10.1093/cercor/bhr096; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; Dickerson BC, 2009, CEREB CORTEX, V19, P497, DOI 10.1093/cercor/bhn113; Fischl B, 2001, IEEE T MED IMAGING, V20, P70, DOI 10.1109/42.906426; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Fischl B, 2000, P NATL ACAD SCI USA, V97, P11050, DOI 10.1073/pnas.200033797; Fjell AM, 2014, CEREB CORTEX, V24, P919, DOI 10.1093/cercor/bhs379; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hagler DJ, 2006, NEUROIMAGE, V33, P1093, DOI 10.1016/j.neuroimage.2006.07.036; Helmstaedter C., 2001, VLMT VERBALER LERN U; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Juottonen K, 1998, NEUROBIOL AGING, V19, P15, DOI 10.1016/S0197-4580(98)00007-4; Keightley ML, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00139; Kelly JP, 1997, NEUROLOGY, V48, P581; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Ling JM, 2013, NEUROLOGY, V81, P2121, DOI 10.1212/01.wnl.0000437302.36064.b1; Lucke-Wold BP, 2014, J NEUROTRAUM, V31, P1129, DOI 10.1089/neu.2013.3303; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mielke MM, 2014, NEUROLOGY, V82, P70, DOI 10.1212/01.wnl.0000438229.56094.54; Monti JM, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00041; Moretti L, 2012, LANCET NEUROL, V11, P1103, DOI 10.1016/S1474-4422(12)70226-0; Nestor SM, 2008, BRAIN, V131, P2443, DOI 10.1093/brain/awn146; Pressley JC, 2003, J CLIN EPIDEMIOL, V56, P896, DOI 10.1016/S0895-4356(03)00133-1; Rodgers KM, 2012, J NEUROTRAUM, V29, P1886, DOI 10.1089/neu.2011.2273; Segonne F, 2004, NEUROIMAGE, V22, P1060, DOI 10.1016/j.neuroimage.2004.03.032; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Shumskaya E, 2012, NEUROLOGY, V79, P175, DOI 10.1212/WNL.0b013e31825f04fb; Singh R, 2014, JAMA-J AM MED ASSOC, V311, P1883, DOI 10.1001/jama.2014.3313; Sled JG, 1998, IEEE T MED IMAGING, V17, P87, DOI 10.1109/42.668698; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Strain J, 2013, NEUROLOGY, V81, P25, DOI 10.1212/WNL.0b013e318299ccf8; Tremblay S, 2014, CLIN NEUROPHYSIOL, V125, P1371, DOI 10.1016/j.clinph.2013.11.040; Tremblay S, 2014, BRAIN, V137, P2997, DOI 10.1093/brain/awu236; Tremblay S, 2013, CEREB CORTEX, V23, P1159, DOI 10.1093/cercor/bhs102; Walker KR, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00029; Williams WH, 2010, J NEUROL NEUROSUR PS, V81, P1116, DOI 10.1136/jnnp.2008.171298; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9	51	34	34	0	25	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5161			FRONT HUM NEUROSCI	Front. Hum. Neurosci.	MAY 21	2015	9								228	10.3389/fnhum.2015.00228			9	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	CK2TA	WOS:000356064200001	26052275	DOAJ Gold, Green Published			2021-06-18	
J	Brody, DL; Benetatos, J; Bennett, RE; Klemenhagen, KC; Mac Donald, CL				Brody, David L.; Benetatos, Joseph; Bennett, Rachel E.; Klemenhagen, Kristen C.; Mac Donald, Christine L.			The pathophysiology of repetitive concussive traumatic brain injury in experimental models; new developments and open questions	MOLECULAR AND CELLULAR NEUROSCIENCE			English	Article						Concussion; Traumatic brain injury; Traumatic axonal injury; Amyloid-beta; Tau; Microglia; Depression; Social behavior; Mouse; Sertraline	AMYLOID PROTEIN DEPOSITION; AXONAL INJURY; MOUSE MODEL; ALZHEIMERS-DISEASE; DENDRITIC SPINES; TAU OLIGOMERS; COGNITIVE IMPAIRMENT; PRECURSOR PROTEIN; HEAD-INJURY; RAT MODEL	In recent years, there has been an increasing interest in the pathophysiology of repetitive concussive traumatic brain injury (rcTBI) in large part due to the association with dramatic cases of progressive neurological deterioration in professional athletes, military personnel, and others. However, our understanding of the pathophysiology of rcTBI is less advanced than for more severe brain injuries. Most prominently, the mechanisms underlying traumatic axonal injury, microglial activation, amyloid-beta accumulation, and progressive tau pathology are not yet known. In addition, the role of injury to dendritic spine cytoskeletal structures, vascular reactivity impairments, and microthrombi are intriguing and subjects of ongoing inquiry. Methods for quantitative analysis of axonal injury, dendritic injury, and synaptic loss need to be refined for the field to move forward in a rigorous fashion. We and others are attempting to develop translational approaches to assess these specific pathophysiological events in both animals and humans to facilitate clinically relevant pharmacodynamic assessments of candidate therapeutics. In this article, we review and discuss several of the recent experimental results from our lab and others. We include new initial data describing the difficulty in modeling progressive tau pathology in experimental rcTBI, and results demonstrating that sertraline can alleviate social interaction deficits and depressive-like behaviors following experimental rcTBI plus foot shock stress. Furthermore, we propose a discrete set of open, experimentally tractable questions that may serve as a framework for future investigations. In addition, we also raise several important questions that are less experimentally tractable at this time, in hopes that they may stimulate future methodological developments to address them. This article is part of a Special Issue entitled "Traumatic Brain Injury". (C) 2015 Elsevier Inc All rights reserved.	[Brody, David L.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; Hope Ctr Neurol Disorders, St Louis, MO USA	Brody, DL (corresponding author), Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA.	brodyd@neuro.wustl.edu	Bennett, Rachel/AAU-6949-2020		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS065069] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS065069] Funding Source: Medline		Aguzzi A, 2013, SCIENCE, V339, P156, DOI 10.1126/science.1227901; Andorfer C, 2003, J NEUROCHEM, V86, P582, DOI 10.1046/j.1471-4159.2003.01879.x; Benilova I, 2012, NAT NEUROSCI, V15, P349, DOI 10.1038/nn.3028; Bennett RE, 2014, J NEUROTRAUM, V31, P1647, DOI 10.1089/neu.2013.3320; Bennett RE, 2012, NEUROSCI LETT, V513, P160, DOI 10.1016/j.neulet.2012.02.024; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Campbell JN, 2012, J NEUROTRAUM, V29, P201, DOI 10.1089/neu.2011.1761; Cheng JS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115765; Conte V, 2004, J NEUROCHEM, V90, P758, DOI 10.1111/j.1471-4159.2004.02560.x; Coughlin JM, 2015, NEUROBIOL DIS, V74, P58, DOI 10.1016/j.nbd.2014.10.019; Creeley CE, 2004, ACAD EMERG MED, V11, P809, DOI 10.1197/j.aem.2004.03.006; Dardiotis E, 2014, J NEUROTRAUM, V31, P1920, DOI 10.1089/neu.2014.3347; DeFord SM, 2002, J NEUROTRAUM, V19, P427, DOI 10.1089/08977150252932389; Elder GA, 2012, J NEUROTRAUM, V29, P2564, DOI 10.1089/neu.2012.2510; Esparza TJ, 2013, ANN NEUROL, V73, P104, DOI 10.1002/ana.23748; Friess SH, 2009, J NEUROTRAUM, V26, P1111, DOI [10.1089/neu.2008.0845, 10.1089/neu.2008-0845]; Gan WB, 2000, NEURON, V27, P219, DOI 10.1016/S0896-6273(00)00031-3; Gao X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024566; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Hailer NP, 2008, PROG NEUROBIOL, V84, P211, DOI 10.1016/j.pneurobio.2007.12.001; Hawkins BE, 2013, J BIOL CHEM, V288, P17042, DOI 10.1074/jbc.M113.472746; Hoskison MM, 2009, NEUROSCIENCE, V159, P483, DOI 10.1016/j.neuroscience.2008.12.050; Iliff JJ, 2014, J NEUROSCI, V34, P16180, DOI 10.1523/JNEUROSCI.3020-14.2014; Kanayama G, 1996, METHOD FIND EXP CLIN, V18, P105; Kleffner I, 2008, STROKE, V39, P1333, DOI 10.1161/STROKEAHA.107.500785; Klemenhagen KC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074510; Koffie RM, 2012, BRAIN, V135, P2155, DOI 10.1093/brain/aws127; Koffie RM, 2009, P NATL ACAD SCI USA, V106, P4012, DOI 10.1073/pnas.0811698106; Lasagna-Reeves CA, 2011, CURR ALZHEIMER RES, V8, P659; Lasagna-Reeves CA, 2012, SCI REP-UK, V2, DOI 10.1038/srep00700; Lasagna-Reeves CA, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-39; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Mac Donald CL, 2014, JAMA NEUROL, V71, P994, DOI 10.1001/jamaneurol.2014.1114; MacDonald Christine L, 2014, J Neurotrauma, V31, P889, DOI 10.1089/neu.2013.3173; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meehan WP, 2012, NEUROSURGERY, V71, P885, DOI 10.1227/NEU.0b013e318265a439; Micheva KD, 2007, NEURON, V55, P25, DOI 10.1016/j.neuron.2007.06.014; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Ojo JO, 2013, J NEUROPATH EXP NEUR, V72, P137, DOI 10.1097/NEN.0b013e3182814cdf; Opdal SH, 2010, PEDIATR RES, V68, P48, DOI [10.1203/PDR.0b013e3181df4e7c, 10.1203/00006450-201011001-00091]; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Perry VH, 2010, ACTA NEUROPATHOL, V120, P277, DOI 10.1007/s00401-010-0722-x; Petraglia Anthony L, 2014, Surg Neurol Int, V5, P184, DOI 10.4103/2152-7806.147566; Petraglia AL, 2014, J NEUROTRAUM, V31, P1211, DOI 10.1089/neu.2013.3255; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Sala C, 2014, PHYSIOL REV, V94, P141, DOI 10.1152/physrev.00012.2013; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Smith C, 2013, NEUROPATH APPL NEURO, V39, P654, DOI 10.1111/nan.12008; Smith C, 2013, NEUROPATH APPL NEURO, V39, P35, DOI 10.1111/nan.12006; Sorani MD, 2008, HUM MOL GENET, V17, P2379, DOI 10.1093/hmg/ddn138; Sword J, 2013, BRAIN, V136, P1446, DOI 10.1093/brain/awt026; Tran HT, 2012, J NEUROPATH EXP NEUR, V71, P116, DOI 10.1097/NEN.0b013e3182456aed; Tran HT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025475; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Winston CN, 2013, J NEUROTRAUM, V30, P1966, DOI 10.1089/neu.2013.2960	63	34	35	0	11	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1044-7431	1095-9327		MOL CELL NEUROSCI	Mol. Cell. Neurosci.	MAY	2015	66		B		SI		91	98		10.1016/j.mcn.2015.02.005			8	Neurosciences	Neurosciences & Neurology	CK7FT	WOS:000356398900004	25684677	Green Accepted			2021-06-18	
J	Goddeyne, C; Nichols, J; Wu, C; Anderson, T				Goddeyne, Corey; Nichols, Joshua; Wu, Chen; Anderson, Trent			Repetitive mild traumatic brain injury induces ventriculomegaly and cortical thinning in juvenile rats	JOURNAL OF NEUROPHYSIOLOGY			English	Article						concussion; electrophysiology; MRI; pediatrics; traumatic brain injury	COLLEGIATE FOOTBALL PLAYERS; SPORT-RELATED CONCUSSION; LONG-TERM; MOTOR CORTEX; HEAD-INJURY; HIGH-SCHOOL; PROFESSIONAL FOOTBALL; ANIMAL-MODELS; MOUSE MODEL; NEUROPSYCHOLOGICAL OUTCOMES	Traumatic brain injury (TBI) most frequently occurs in pediatric patients and remains a leading cause of childhood death and disability. Mild TBI (mTBI) accounts for nearly 75% of all TBI cases, yet its neuropathophysiology is still poorly understood. While even a single mTBI injury can lead to persistent deficits, repeat injuries increase the severity and duration of both acute symptoms and long-term deficits. In this study, to model pediatric repetitive mTBI (rmTBI) we subjected unrestrained juvenile animals (postnatal day 20) to repeat weight-drop impacts. Animals were anesthetized and subjected to sham injury or rmTBI once per day for 5 days. Magnetic resonance imaging (MRI) performed 14 days after injury revealed marked cortical atrophy and ventriculomegaly in rmTBI animals. Specifically, beneath the impact zone the thickness of the cortex was reduced by up to 46% and the area of the ventricles increased by up to 970%. Immunostaining with the neuron-specific marker NeuN revealed an overall loss of neurons within the motor cortex but no change in neuronal density. Examination of intrinsic and synaptic properties of layer II/III pyramidal neurons revealed no significant difference between sham-injured and rmTBI animals at rest or under convulsant challenge with the potassium channel blocker 4-aminopyridine. Overall, our findings indicate that the neuropathological changes reported after pediatric rmTBI can be effectively modeled by repeat weight drop in juvenile animals. Developing a better understanding of how rmTBI alters the pediatric brain may help improve patient care and direct "return to game" decision making in adolescents.	[Goddeyne, Corey; Nichols, Joshua; Wu, Chen; Anderson, Trent] Univ Arizona, Coll Med Phoenix, Phoenix, AZ 85004 USA; [Goddeyne, Corey; Nichols, Joshua] Arizona State Univ, Sch Life Sci, Tempe, AZ USA	Anderson, T (corresponding author), Univ Arizona, Coll Med Phoenix, 425 N 5th St, Phoenix, AZ 85004 USA.	andersot@email.arizona.edu			University of Arizona College of Medicine-Phoenix; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS087031] Funding Source: NIH RePORTER	Support for this project was provided by the University of Arizona College of Medicine-Phoenix.	Adelson PD, 1999, EXP TOXICOL PATHOL, V51, P130; Akbik FV, 2013, NEURON, V77, P859, DOI 10.1016/j.neuron.2012.12.027; Allen GV, 2000, NEUROSCIENCE, V99, P93, DOI 10.1016/S0306-4522(00)00185-8; Anderson TR, 2005, J NEUROPHYSIOL, V93, P963, DOI 10.1152/jn.00654.2004; Anderson TR, 2010, J PHYSIOL-LONDON, V588, P4401, DOI 10.1113/jphysiol.2010.191858; Angoa-Perez M, 2014, J NEUROCHEM, V129, P916, DOI 10.1111/jnc.12690; Arciniegas David B, 2005, Neuropsychiatr Dis Treat, V1, P311; Baki SGA, 2009, BRAIN RES, V1280, P98, DOI 10.1016/j.brainres.2009.05.034; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P737, DOI 10.1249/MSS.0b013e3182792ed7; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Boudkkazi S, 2011, J PHYSIOL-LONDON, V589, P1117, DOI 10.1113/jphysiol.2010.199653; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; BUCKLE PJ, 1982, J PHYSIOL-LONDON, V326, P109, DOI 10.1113/jphysiol.1982.sp014180; Bush PC, 1999, J NEUROPHYSIOL, V82, P1748; Cantu D, 2014, CEREB CORTEX, DOI [10.1093/cercor/bhu041, DOI 10.1093/CERC0R/BHU041]; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; CHUGANI HT, 1987, ANN NEUROL, V22, P487, DOI 10.1002/ana.410220408; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; CONNORS BW, 1982, J NEUROPHYSIOL, V48, P1302; Covassin T, 2008, J ATHL TRAINING, V43, P119, DOI 10.4085/1062-6050-43.2.119; Creeley CE, 2004, ACAD EMERG MED, V11, P809, DOI 10.1197/j.aem.2004.03.006; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2012, CEREB CORTEX, V22, P112, DOI 10.1093/cercor/bhr096; De Beaumont L, 2011, J ATHL TRAINING, V46, P234; Douglas RJ, 2004, ANNU REV NEUROSCI, V27, P419, DOI 10.1146/annurev.neuro.27.070203.144152; Duhaime AC, 2012, J NEUROSURG, V117, P1092, DOI 10.3171/2012.8.JNS112298; Eisenberg MA, 2013, PEDIATRICS, V132, P8, DOI 10.1542/peds.2013-0432; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Faul M, 2010, TRAUMATIC BRAIN INJU; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; FRIEDMAN WJ, 1991, EUR J NEUROSCI, V3, P688, DOI 10.1111/j.1460-9568.1991.tb00854.x; Friess SH, 2009, J NEUROTRAUM, V26, P1111, DOI [10.1089/neu.2008.0845, 10.1089/neu.2008-0845]; Gao XA, 2011, J NEUROPATH EXP NEUR, V70, P183, DOI 10.1097/NEN.0b013e31820c6878; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; GENNARELLI TA, 1982, J TRAUMA, V22, P680, DOI 10.1097/00005373-198208000-00005; Giza CC, 2006, INDIAN J NEUROTRAUM, V3, P19; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Gregg CT, 2001, EXPTL BIOL REV, P1; Grutzendler J, 2002, NATURE, V420, P812, DOI 10.1038/nature01276; GUATTEO E, 1994, NEUROSCI LETT, V175, P117, DOI 10.1016/0304-3940(94)91093-6; Guskiewicz KM, 2011, CLIN SPORT MED, V30, P89, DOI 10.1016/j.csm.2010.09.004; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Higgs MH, 2011, J PHYSIOL-LONDON, V589, P5125, DOI 10.1113/jphysiol.2011.216721; Holbourn AHS, 1943, LANCET, V2, P438; Huh JW, 2007, J NEUROTRAUM, V24, P15, DOI 10.1089/neu.2006.0072; INSEL TR, 1990, NEUROSCIENCE, V35, P31, DOI 10.1016/0306-4522(90)90117-M; Iremonger KJ, 2006, J NEUROPHYSIOL, V96, P613, DOI 10.1152/jn.00105.2006; Kamper JE, 2013, EXP NEUROL, V250, P8, DOI 10.1016/j.expneurol.2013.09.016; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Khurana VG, 2012, J CLIN NEUROSCI, V19, P1, DOI 10.1016/j.jocn.2011.08.002; Klein M, 1996, J NERV MENT DIS, V184, P459, DOI 10.1097/00005053-199608000-00002; Kolb B, 2007, J CEREBR BLOOD F MET, V27, P983, DOI 10.1038/sj.jcbfm.9600402; Kolb Bryan, 2011, J Can Acad Child Adolesc Psychiatry, V20, P265; Konrad C, 2011, PSYCHOL MED, V41, P1197, DOI 10.1017/S0033291710001728; Kontos AP, 2013, J PEDIATR-US, V163, P717, DOI 10.1016/j.jpeds.2013.04.011; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Li HL, 2011, J NEUROPHYSIOL, V105, P1963, DOI 10.1152/jn.01104.2010; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; MacGregor AJ, 2011, J REHABIL RES DEV, V48, P1269, DOI 10.1682/JRRD.2011.01.0013; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Maxwell WL, 2012, INT J DEV NEUROSCI, V30, P167, DOI 10.1016/j.ijdevneu.2011.12.008; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meaney DF, 2011, CLIN SPORT MED, V30, P19, DOI 10.1016/j.csm.2010.08.009; MILLER H, 1966, P ROY SOC MED, V59, P257, DOI 10.1177/003591576605900327; Miller NR, 2014, BRAIN INJURY, V28, P1270, DOI 10.3109/02699052.2014.915987; Minino AM, 2006, NATL VITAL STAT REP, V54, P1; Morey RA, 2013, HUM BRAIN MAPP, V34, P2986, DOI 10.1002/hbm.22117; Mychasiuk R, 2014, J NEUROTRAUM, V31, P749, DOI 10.1089/neu.2013.3132; Nichols J, 2015, CNS NEUROSCI THER, V21, P193, DOI 10.1111/cns.12351; Omalu Bennet I, 2010, J Forensic Nurs, V6, P130, DOI 10.1111/j.1939-3938.2010.01078.x; Omalu Bennet I, 2010, J Forensic Nurs, V6, P40, DOI 10.1111/j.1939-3938.2009.01064.x; Ommaya AK, 1967, 11 STAPP CAR CRASH C, P73; Panzer MB, 2014, EXP NEUROL, V261, P120, DOI 10.1016/j.expneurol.2014.07.002; Paxinos G., 2007, RAT BRAIN STEREOTAXI, V6th ed.; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Petchprapai Nutthita, 2007, J Neurosci Nurs, V39, P260; Petraglia AL, 2014, J NEUROTRAUM, V31, P1211, DOI 10.1089/neu.2013.3255; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Prince D A, 1986, Adv Neurol, V44, P275; Prinz A, 2013, EXP NEUROL, V248, P236, DOI 10.1016/j.expneurol.2013.06.015; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Selemon LD, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2013.7; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Shu YS, 2007, P NATL ACAD SCI USA, V104, P11453, DOI 10.1073/pnas.0702041104; Slobounov S, 2007, NEUROSURGERY, V61, P338, DOI 10.1227/01.NEU.0000280001.03578.FF; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Sun QQ, 2006, J NEUROSCI, V26, P1219, DOI 10.1523/JNEUROSCI.4727-04.2006; Tremblay S, 2014, CLIN NEUROPHYSIOL, V125, P1371, DOI 10.1016/j.clinph.2013.11.040; Tremblay S, 2011, J NEUROTRAUM, V28, P493, DOI 10.1089/neu.2010.1615; Tremblay S, 2013, CEREB CORTEX, V23, P1159, DOI 10.1093/cercor/bhs102; van Zundert B, 2012, J CELL BIOCHEM, V113, P3301, DOI 10.1002/jcb.24234; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Vasterling JJ, 2012, BRIT J PSYCHIAT, V201, P186, DOI 10.1192/bjp.bp.111.096461; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Wang X, 2015, J NEUROTRAUM, V32, P455, DOI 10.1089/neu.2014.3492; WILLMORE LJ, 1990, EPILEPSIA, V31, pS67, DOI 10.1111/j.1528-1157.1990.tb05861.x; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yang L, 2007, J NEUROPHYSIOL, V97, P178, DOI 10.1152/jn.01374.2005; Yuh Esther L, 2014, Neurosurgery, V75 Suppl 4, pS50, DOI 10.1227/NEU.0000000000000491; Zecharia AY, 2012, J NEUROSCI, V32, P13062, DOI 10.1523/JNEUROSCI.2931-12.2012; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA	112	34	34	1	18	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-3077	1522-1598		J NEUROPHYSIOL	J. Neurophysiol.	MAY 1	2015	113	9					3268	3280		10.1152/jn.00970.2014			13	Neurosciences; Physiology	Neurosciences & Neurology; Physiology	CL1LM	WOS:000356704800022	25695652	Green Published			2021-06-18	
J	Gu, XH; Wei, ZZ; Espinera, A; Lee, JH; Ji, XY; Wei, L; Dix, TA; Yu, SP				Gu, Xiaohuan; Wei, Zheng Zachory; Espinera, Alyssa; Lee, Jin Hwan; Ji, Xiaoya; Wei, Ling; Dix, Thomas A.; Yu, Shan Ping			Pharmacologically induced hypothermia attenuates traumatic brain injury in neonatal rats	EXPERIMENTAL NEUROLOGY			English	Article						Drug-induced hypothermia; Neonates; Traumatic brain injury; Cell death; Brain protection; Functional recovery	FOCAL CEREBRAL-ISCHEMIA; THERAPEUTIC HYPOTHERMIA; MILD HYPOTHERMIA; NEUROPROTECTION; MODEL; INDUCTION; ERYTHROPOIETIN; SEIZURES; BENEFIT; STATE	Neonatal brain trauma is linked to higher risks of mortality and neurological disability. The use of mild to moderate hypothermia has shown promising potential against brain injuries induced by stroke and traumatic brain injury (TBI) in various experimental models and in clinical trials. Conventional methods of physical cooling, however, are difficult to use in acute treatments and in induction of regulated hypothermia. In addition, general anesthesia is usually required to mitigate the negative effects of shivering during physical cooling. Our recent investigations demonstrate the potential therapeutic benefits of pharmacologically induced hypothermia (PIH) using the neurotensin receptor (NTR) agonist HPI201 (formerly known as ABS201) in stroke and TBI models of adult rodents. The present investigation explored the brain protective effects of HPI201 in a P14 rat pediatric model of TBI induced by controlled cortical impact. When administered via intraperitoneal (i.p.) injection, HPI201 induced dose-dependent reduction of body and brain temperature. A 6-h hypothermic treatment providing an overall 2-3 degrees C reduction of brain and body temperature, showed significant effect of attenuating the contusion volume versus TBI controls. Attenuation occurs whether hypothermia is initiated 15 min or 2 h after TBI. No shivering response was seen in HPI201-treated animals. HPI201 treatment also reduced TUNEL-positive and TUNEL/NeuN-colabeled cells in the contusion area and pen-injury regions. TBI-induced blood-brain barrier damage was attenuated by HPI201 treatment, evaluated using the Evans Blue assay. HPI201 significantly decreased MMP-9 levels and caspase-3 activation, both of which are pro-apototic, while it increased antiapoptotic Bcl-2 gene expression in the pen-contusion region. In addition, HPI201 prevented the up-regulation of pro-inflammatory tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1 beta) and IL-6. In sensorimotor activity assessments, rats in the HPI201 treated group exhibited improved functional recovery after TBI versus controls. These data support that PIH therapy using our NTR agonist is effective in reducing neuronal and BBB damage, attenuating inflammatory response and detrimental cellular signaling, and promoting functional recovery after TEL in the developing brain, supporting its potential for further evaluation towards clinical development. (C) 2015 Elsevier Inc. All rights reserved.	[Gu, Xiaohuan; Wei, Zheng Zachory; Espinera, Alyssa; Lee, Jin Hwan; Ji, Xiaoya; Wei, Ling; Yu, Shan Ping] Emory Univ, Sch Med, Dept Anesthesiol, Atlanta, GA 30322 USA; [Wei, Zheng Zachory; Yu, Shan Ping] Atlanta VA Med Ctr, Ctr Visual & Neurocognit Rehabil, Decatur, GA 30033 USA; [Wei, Ling] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA; [Dix, Thomas A.] Med Univ S Carolina, Dept Drug Discovery Biomed Sci, Charleston, SC 29425 USA; [Dix, Thomas A.] JT Pharmaceut Inc, Mt Pleasant, SC 29464 USA	Yu, SP (corresponding author), Emory Univ, Sch Med, Dept Anesthesiol, 101 Woodruff Circle,WMB 620, Atlanta, GA 30322 USA.	spyu@emory.edu	Wei, Zheng Zachory/I-2109-2019	Wei, Zheng Zachory/0000-0001-7682-9286	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS045810, R41NS073378, NS057255, NS075338]; AHA Established Investigator AwardAmerican Heart Association [0840110N]; VA national merit grant; O. Wayne Rolling's Endowed Chair fund;  [12GRNT12060222]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS057255, R01NS045810, R41NS073378, R01NS085568, R21NS075338] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX000666] Funding Source: NIH RePORTER	This work was supported by NIH grants (NS045810 to SPY, R41NS073378 to SPY and TAD, NS057255 and NS075338 to LW), AHA Established Investigator Award (0840110N to LW), a Grant-in-Aid award (12GRNT12060222 to SPY) and a VA national merit grant (SPY). It was also supported by the O. Wayne Rolling's Endowed Chair fund to SPY.	Adelson PD, 2013, LANCET NEUROL, V12, P546, DOI 10.1016/S1474-4422(13)70077-2; Ahmad FU, 2014, WORLD NEUROSURG, V82, P207, DOI 10.1016/j.wneu.2013.01.008; Alexander ML, 2012, DEV NEUROSCI-BASEL, V34, P515, DOI 10.1159/000345645; Chang I, 2013, J CLIN INVEST, V123, P2643, DOI 10.1172/JCI66735; Chen J, 2013, STROKE, V44, P260, DOI 10.1161/STROKEAHA.112.675462; Choe MC, 2012, CURR OPIN PEDIATR, V24, P689, DOI 10.1097/MOP.0b013e32835a1a44; Choi KE, 2012, FASEB J, V26, P2799, DOI 10.1096/fj.11-201822; D'Ambrosio R, 2013, ANN NEUROL, V73, P199, DOI 10.1002/ana.23764; Egginton S, 2013, J EXP BIOL, V216, P2140, DOI 10.1242/jeb.079160; Fan XY, 2013, PEDIATR RES, V73, P18, DOI 10.1038/pr.2012.139; Finnie JW, 2012, AUST VET J, V90, P301, DOI 10.1111/j.1751-0813.2012.00955.x; Fugate JE, 2013, NEUROLOGY, V81, P40, DOI 10.1212/WNL.0b013e318297ee7e; Garfinkle J, 2013, EUR J PAEDIATR NEURO, V17, P492, DOI 10.1016/j.ejpn.2013.03.006; Georgiou AP, 2013, BRIT J ANAESTH, V110, P357, DOI 10.1093/bja/aes500; Gong P, 2013, J CEREBR BLOOD F MET, V33, P928, DOI 10.1038/jcbfm.2013.33; Groger M, 2013, CRIT CARE MED, V41, pE105, DOI 10.1097/CCM.0b013e31827c0b1f; Harris B, 2012, HEALTH TECHNOL ASSES, V16, P1, DOI 10.3310/hta16450; Inoue S, 2013, J THORAC CARDIOV SUR, V146, P696, DOI 10.1016/j.jtcvs.2012.11.040; Jacobs SE, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003311.pub3; Jia F, 2014, J NEUROTRAUM, V31, P387, DOI 10.1089/neu.2008.0814; Katz LM, 2012, THER HYPOTHERMIA TEM, V2, P61, DOI 10.1089/ther.2012.0011; Kim JH, 2013, CURR PROTEIN PEPT SC, V14, P51; Kuboi T, 2013, PEDIATR INT, V55, pE23, DOI 10.1111/j.1442-200X.2012.03730.x; Lee JH, 2014, J NEUROTRAUM, V31, P1417, DOI 10.1089/neu.2013.3251; Li WL, 2013, NEUROSCIENCE, V244, P16, DOI 10.1016/j.neuroscience.2013.03.045; Maier CM, 2001, J NEUROSURG, V94, P90, DOI 10.3171/jns.2001.94.1.0090; Matsui T, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/436263; Mohr J, 2013, J TRAUMA ACUTE CARE, V74, P1014, DOI 10.1097/TA.0b013e3182826edd; Motamedi GK, 2013, EPILEPSIA, V54, P959, DOI 10.1111/epi.12144; Muzzi M, 2013, J CEREBR BLOOD F MET, V33, P183, DOI 10.1038/jcbfm.2012.157; Rey-Funes M, 2013, INVEST OPHTH VIS SCI, V54, P2836, DOI 10.1167/iovs.12-11198; See K C, 2012, Med J Malaysia, V67, P265; Seo M, 2012, ELECTROPHORESIS, V33, P3835, DOI 10.1002/elps.201200331; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; Sheng SP, 2012, ANESTHESIOLOGY, V117, P1262, DOI 10.1097/ALN.0b013e3182746b81; Srinivasakumar P, 2013, J PEDIATR-US, V163, P465, DOI 10.1016/j.jpeds.2013.01.041; Testori C, 2013, RESUSCITATION, V84, P1051, DOI 10.1016/j.resuscitation.2013.03.013; Tupone D, 2013, AUTON NEUROSCI-BASIC, V176, P1, DOI 10.1016/j.autneu.2013.02.004; Wei S, 2013, NEUROSCIENCE, V252, P489, DOI 10.1016/j.neuroscience.2013.07.052; Wu TC, 2013, LANCET NEUROL, V12, P275, DOI 10.1016/S1474-4422(13)70013-9; Zgavc T, 2013, BRAIN RES, V1501, P81, DOI 10.1016/j.brainres.2013.01.034; Zhang MJ, 2013, CNS NEUROL DISORD-DR, V12, P371, DOI 10.2174/1871527311312030010; Zhao H, 2013, AM J TRANSPLANT, V13, P2006, DOI 10.1111/ajt.12293	43	34	35	0	16	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	MAY	2015	267						135	142		10.1016/j.expneurol.2015.02.029			8	Neurosciences	Neurosciences & Neurology	CH1AZ	WOS:000353754800014	25725354	Green Accepted			2021-06-18	
J	Pandya, JD; Grondin, R; Yonutas, HM; Haghnazar, H; Gash, DM; Zhang, ZM; Sullivan, PG				Pandya, Jignesh D.; Grondin, Richard; Yonutas, Heather M.; Haghnazar, Hamed; Gash, Don M.; Zhang, Zhiming; Sullivan, Patrick G.			Decreased mitochondrial bioenergetics and calcium buffering capacity in the basal ganglia correlates with motor deficits in a nonhuman primate model of aging	NEUROBIOLOGY OF AGING			English	Article						Aging; Alzheimer's disease; Brain; Calcium buffering; Mitochondria; Mitochondrial permeability transition pore; Pyruvate dehydrogenase complex enzyme activity; Parkinsonism; Parkinson's disease; Respiration; Rhesus monkeys	TRAUMATIC BRAIN-INJURY; FREE-RADICAL THEORY; AGE-RELATED-CHANGES; SPINAL-CORD; DOPAMINERGIC-NEURONS; OXIDATIVE STRESS; NEURODEGENERATIVE DISORDERS; RESPIRATORY-CHAIN; COGNITIVE DECLINE; PROCESSING SPEED	Altered mitochondrial function in the basal ganglia has been hypothesized to underlie cellular senescence and promote age-related motor decline. We tested this hypothesis in a nonhuman primate model of human aging. Six young (6-8 years old) and 6 aged (20-25 years old) female Rhesus monkeys (Macaca mulatta) were behaviorally characterized from standardized video records. Additionally, we measured mitochondrial bioenergetics along with calcium buffering capacity in the substantia nigra and putamen (PUT) from both age groups. Our results demonstrate that the aged animals had significantly reduced locomotor activity and movement speed compared with younger animals. Moreover, aged monkeys had significantly reduced ATP synthesis capacity (in substantia nigra and PUT), reduced pyruvate dehydrogenase activity (in PUT), and reduced calcium buffering capacity (in PUT) compared with younger animals. Furthermore, this age-related decline in mitochondrial function in the basal ganglia correlated with decline in motor function. Overall, our results suggest that drug therapies designed to enhance altered mitochondrial function may help improve motor deficits in the elderly. (C) 2015 Elsevier Inc. All rights reserved.	[Pandya, Jignesh D.; Yonutas, Heather M.; Sullivan, Patrick G.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Chandler Coll Med, Lexington, KY 40536 USA; [Pandya, Jignesh D.; Grondin, Richard; Yonutas, Heather M.; Haghnazar, Hamed; Gash, Don M.; Zhang, Zhiming; Sullivan, Patrick G.] Univ Kentucky, Dept Anat & Neurobiol, Chandler Coll Med, Lexington, KY 40536 USA	Sullivan, PG (corresponding author), Univ Kentucky, Dept Anat & Neurobiol, Chandler Coll Med, 475 BBSRB,741 S Limestone St, Lexington, KY 40536 USA.	patsull@uky.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS 48191]; Kentucky Spinal Cord and Head Injury Research Trust (KSCHIRT) chair endowment funds; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS048191] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health grant NS 48191 and Kentucky Spinal Cord and Head Injury Research Trust (KSCHIRT) chair endowment funds (to PGS).	Alexeyev MF, 2009, FEBS J, V276, P5768, DOI 10.1111/j.1742-4658.2009.07269.x; Allum JHJ, 2002, J PHYSIOL-LONDON, V542, P643, DOI 10.1113/jphysiol.2001.015644; Andersen AH, 1999, BRAIN RES, V829, P90, DOI 10.1016/S0006-8993(99)01343-8; Avery MA, 2012, CURR BIOL, V22, P596, DOI 10.1016/j.cub.2012.02.043; BACHEVALIER J, 1991, NEUROBIOL AGING, V12, P99, DOI 10.1016/0197-4580(91)90048-O; Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001; BANNON MJ, 1992, P NATL ACAD SCI USA, V89, P7095, DOI 10.1073/pnas.89.15.7095; Bishop NA, 2010, NATURE, V464, P529, DOI 10.1038/nature08983; Bjorklund A, 2010, PROG BRAIN RES, V184, P133, DOI 10.1016/S0079-6123(10)84007-5; Blalock EM, 2010, J NEUROSCI, V30, P6058, DOI 10.1523/JNEUROSCI.3956-09.2010; BOWLING AC, 1993, J NEUROCHEM, V60, P1964, DOI 10.1111/j.1471-4159.1993.tb13430.x; BOWLING AC, 1995, LIFE SCI, V56, P1151, DOI 10.1016/0024-3205(95)00055-B; Brody H., 1975, CLIN MORPHOLOGIC NEU, p[221, xi]; Brown MR, 2004, J NEUROSCI METH, V137, P299, DOI 10.1016/j.jneumeth.2004.02.028; Brown MR, 2006, J BIOL CHEM, V281, P11658, DOI 10.1074/jbc.M510303200; Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8; Calabrese V, 2004, IN VIVO, V18, P245; Capitanio JP, 2008, LANCET, V371, P1126, DOI 10.1016/S0140-6736(08)60489-4; Carafoli E, 2001, CRIT REV BIOCHEM MOL, V36, P107, DOI 10.1080/20014091074183; Cass WA, 2007, NEUROBIOL AGING, V28, P258, DOI 10.1016/j.neurobiolaging.2005.12.010; CHAGNON P, 1995, NEUROREPORT, V6, P711, DOI 10.1097/00001756-199503270-00002; Chalmers S, 2003, J BIOL CHEM, V278, P19062, DOI 10.1074/jbc.M212661200; Chan CS, 2007, NATURE, V447, P1081, DOI 10.1038/nature05865; Collier TJ, 2011, NAT REV NEUROSCI, V12, P359, DOI 10.1038/nrn3039; Curtis RG, 2015, AGING NEUROPSYCHOL C, V22, P42, DOI 10.1080/13825585.2014.888392; DENTON RM, 1988, J CARDIOVASC PHARM, V12, pS69; Duchen MR, 2004, DIABETES, V53, pS96, DOI 10.2337/diabetes.53.2007.S96; DUGAN LL, 1995, J NEUROSCI, V15, P6377; DYKENS JA, 1994, J NEUROCHEM, V63, P584; Ekstrand MI, 2007, P NATL ACAD SCI USA, V104, P1325, DOI 10.1073/pnas.0605208103; Emborg ME, 2007, ILAR J, V48, P339, DOI 10.1093/ilar.48.4.339; Emborg ME, 1998, J COMP NEUROL, V401, P253; Erickson KI, 2010, J NEUROSCI, V30, P5368, DOI 10.1523/JNEUROSCI.6251-09.2010; Fields RD, 2010, SCIENCE, V330, P768, DOI 10.1126/science.1199139; Fjell AM, 2010, REV NEUROSCIENCE, V21, P187, DOI 10.1515/revneuro.2010.21.3.187; Freeman WM, 2009, NEUROSCIENCE, V159, P183, DOI 10.1016/j.neuroscience.2008.12.004; Gash DM, 2008, ANN NEUROL, V63, P184, DOI 10.1002/ana.21288; Gavilan MP, 2006, NEUROBIOL AGING, V27, P973, DOI 10.1016/j.neurobiolaging.2005.05.010; Geddes JW, 2009, EXP NEUROL, V218, P169, DOI 10.1016/j.expneurol.2009.05.011; GERHARDT GA, 1995, NEUROBIOL AGING, V16, P939, DOI 10.1016/0197-4580(95)02013-6; Gerhardt GA, 2002, J NEUROCHEM, V80, P168, DOI 10.1046/j.0022-3042.2001.00684.x; Glisky EL, 2007, BRAIN AGING MODELS M; Glover A, 2014, BMC GERIATR, V14, DOI 10.1186/1471-2318-14-43; GRACE AA, 1983, NEUROSCIENCE, V10, P317, DOI 10.1016/0306-4522(83)90136-7; Gunter TE, 2004, FEBS LETT, V567, P96, DOI 10.1016/j.febslet.2004.03.071; Guzman JN, 2010, NATURE, V468, P696, DOI 10.1038/nature09536; Guzman JN, 2009, J NEUROSCI, V29, P11011, DOI 10.1523/JNEUROSCI.2519-09.2009; HANSFORD RG, 1978, BIOCHEM J, V170, P285, DOI 10.1042/bj1700285; HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; HARMAN D, 1994, ANN NY ACAD SCI, V717, P1, DOI 10.1111/j.1749-6632.1994.tb12069.x; HARMAN D, 1992, MUTAT RES, V275, P257, DOI 10.1016/0921-8734(92)90030-S; Harman D., 1955, AGING THEORY BASED F; Harman D, 2006, ANN NY ACAD SCI, V1067, P454, DOI 10.1196/annals.1354.065; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.bi.54.070185.005055; Head E, 2009, EXP NEUROL, V220, P171, DOI 10.1016/j.expneurol.2009.08.014; Hedden T, 2004, NAT REV NEUROSCI, V5, P87, DOI 10.1038/nrn1323; IRWIN I, 1994, NEURODEGENERATION, V3, P251; Jemmerson R, 2005, ANTIOXID REDOX SIGN, V7, P1158, DOI 10.1089/ars.2005.7.1158; Jin KL, 2010, AGING DIS, V1, P72; Kann O, 2007, AM J PHYSIOL-CELL PH, V292, pC641, DOI 10.1152/ajpcell.00222.2006; Kelly DP, 2011, NATURE, V470, P342, DOI 10.1038/nature09896; Khaliq ZM, 2010, J NEUROSCI, V30, P7401, DOI 10.1523/JNEUROSCI.0143-10.2010; KING FA, 1988, SCIENCE, V240, P1475, DOI 10.1126/science.3287624; Kraytsberg Y, 2006, NAT GENET, V38, P518, DOI 10.1038/ng1778; MANN VM, 1992, BRAIN, V115, P333, DOI 10.1093/brain/115.2.333; Mattson MP, 2002, PHYSIOL REV, V82, P637, DOI 10.1152/physrev.00004.2002; MEDVEDEV ZA, 1990, BIOL REV, V65, P375, DOI 10.1111/j.1469-185X.1990.tb01428.x; MIZUNO Y, 1989, BIOCHEM BIOPH RES CO, V163, P1450, DOI 10.1016/0006-291X(89)91141-8; Mosharov EV, 2009, NEURON, V62, P218, DOI 10.1016/j.neuron.2009.01.033; Navarro A, 2004, AM J PHYSIOL-REG I, V287, pR1244, DOI 10.1152/ajpregu.00226.2004; Navarro A, 2007, AM J PHYSIOL-CELL PH, V292, pC670, DOI 10.1152/ajpcell.00213.2006; Nicholls DG, 2004, J BIOENERG BIOMEMBR, V36, P277, DOI 10.1023/B:JOBB.0000041753.52832.f3; Nilsson J, 2014, J INT NEUROPSYCH SOC, V20, P262, DOI 10.1017/S1355617713001458; OVADIA A, 1995, NEUROBIOL AGING, V16, P931, DOI 10.1016/0197-4580(95)02012-8; Pandya JD, 2007, J NEUROTRAUM, V24, P798, DOI 10.1089/neu.2006.3673; Pandya Jignesh D, 2013, Front Neuroenergetics, V5, P10, DOI 10.3389/fnene.2013.00010; Pandya JD, 2011, BRAIN RES, V1384, P151, DOI 10.1016/j.brainres.2011.01.102; Pandya JD, 2009, EXP NEUROL, V218, P381, DOI 10.1016/j.expneurol.2009.05.023; PARADIES G, 1991, BIOCHIM BIOPHYS ACTA, V1070, P180, DOI 10.1016/0005-2736(91)90161-Z; Parihar MS, 2007, AM J PHYSIOL-CELL PH, V292, pC8, DOI 10.1152/ajpcell.00232.2006; Patel SP, 2009, J NEUROSCI RES, V87, P130, DOI 10.1002/jnr.21814; Pawlowski TL, 2009, BRAIN RES, V1256, P101, DOI 10.1016/j.brainres.2008.12.039; Poon HF, 2006, NEUROBIOL AGING, V27, P1020, DOI 10.1016/j.neurobiolaging.2005.05.014; Puopolo M, 2007, J NEUROSCI, V27, P645, DOI 10.1523/JNEUROSCI.4341-06.2007; Readnower RD, 2011, INT J ALZHEIMERS DIS, V2011, P1; Rowe WB, 2007, J NEUROSCI, V27, P3098, DOI 10.1523/JNEUROSCI.4163-06.2007; Serper M, 2014, HEALTH SERV RES, V49, P1249, DOI 10.1111/1475-6773.12154; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; Silver I, 1998, ADV EXP MED BIOL, V454, P7; Sinnegger-Brauns MJ, 2009, MOL PHARMACOL, V75, P407, DOI 10.1124/mol.108.049981; Sonntag WE, 1999, J GERONTOL A-BIOL, V54, pB521, DOI 10.1093/gerona/54.12.B521; SOONG NW, 1992, NAT GENET, V2, P318; Starkov AA, 2004, J NEUROSCI, V24, P7779, DOI 10.1523/JNEUROSCI.1899-04.2004; Sullivan PG, 2007, J NEUROTRAUM, V24, P991, DOI 10.1089/neu.2006.0242; Sullivan PG, 2005, PROG NEURO-PSYCHOPH, V29, P407, DOI 10.1016/j.pnpbp.2004.12.007; Sullivan PG, 2004, J COMP NEUROL, V474, P524, DOI 10.1002/cne.20130; Sullivan PG, 2003, ANN NEUROL, V53, P711, DOI 10.1002/ana.10543; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Surmeier DJ, 2011, NEUROSCIENCE, V198, P221, DOI 10.1016/j.neuroscience.2011.08.045; Surmeier DJ, 2007, LANCET NEUROL, V6, P933, DOI 10.1016/S1474-4422(07)70246-6; Swerdlow RH, 1996, ANN NEUROL, V40, P663, DOI 10.1002/ana.410400417; Territo PR, 2000, AM J PHYSIOL-CELL PH, V278, pC423; Uusi-Rasi K, 2012, BMC GERIATR, V12, DOI 10.1186/1471-2318-12-12; VanGuilder HD, 2011, FRONT AGING NEUROSCI, V3, DOI 10.3389/fnagi.2011.00008; Vina J, 2007, IUBMB LIFE, V59, P249, DOI 10.1080/15216540601178067; W.H. Organisation N.I.o. Aging N.I.o. Health U.S.D.o.H.a.H. Services, 2011, GLOB HLTH AG; Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751; WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953; Walton A, 2006, NEUROBIOL AGING, V27, P1477, DOI 10.1016/j.neurobiolaging.2005.08.003; WAN B, 1989, J BIOL CHEM, V264, P13430; Weinert BT, 2003, J APPL PHYSIOL, V95, P1706, DOI 10.1152/japplphysiol.00288.2003; Welmer AK, 2014, J GERONTOL A-BIOL, V69, P1503, DOI 10.1093/gerona/glu047; Wharton D., 1967, METHODS ENZYMOL, V10, P245, DOI [10.1016/0076-6879(67)10048-7, DOI 10.1016/0076-6879(67)10048-7]; Wilson CJ, 2000, J NEUROPHYSIOL, V83, P3084; Wolfgang MJ, 2002, TRENDS BIOTECHNOL, V20, P479, DOI 10.1016/S0167-7799(02)02052-8; Yonutas HM, 2015, J BIOENERG BIOMEMBR, V47, P149, DOI 10.1007/s10863-014-9593-5; Zhang ZM, 2000, J GERONTOL A-BIOL, V55, pB473, DOI 10.1093/gerona/55.10.B473	118	34	36	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0197-4580	1558-1497		NEUROBIOL AGING	Neurobiol. Aging	MAY	2015	36	5					1903	1913		10.1016/j.neurobiolaging.2015.01.018			11	Geriatrics & Gerontology; Neurosciences	Geriatrics & Gerontology; Neurosciences & Neurology	CI9PA	WOS:000355100900012	25726361				2021-06-18	
J	Struzyna, LA; Harris, JP; Katiyar, KS; Chen, HI; Cullen, DK				Struzyna, Laura A.; Harris, James P.; Katiyar, Kritika S.; Chen, H. Isaac; Cullen, D. Kacy			Restoring nervous system structure and function using tissue engineered living scaffolds	NEURAL REGENERATION RESEARCH			English	Article						living scaffolds; neural tissue engineering; cell transplant; biomaterials; regeneration; neurotrauma; neurodegeneration; axon pathfinding; cell migration	LONG-TERM SURVIVAL; SPINAL-CORD INJURY; NEURAL STEM-CELLS; IN-VITRO; NEUROTROPHIC FACTORS; CHONDROITINASE ABC; AXON REGENERATION; GROWTH CONES; NEURONS; RECOVERY	Neural tissue engineering is premised on the integration of engineered living tissue with the host nervous system to directly restore lost function or to augment regenerative capacity following nervous system injury or neurodegenerative disease. Disconnection of axon pathways - the long-distance fibers connecting specialized regions of the central nervous system or relaying peripheral signals - is a common feature of many neurological disorders and injury. However, functional axonal regeneration rarely occurs due to extreme distances to targets, absence of directed guidance, and the presence of inhibitory factors in the central nervous system, resulting in devastating effects on cognitive and sensorimotor function. To address this need, we are pursuing multiple strategies using tissue engineered "living scaffolds", which are preformed three-dimensional constructs consisting of living neural cells in a defined, often anisotropic architecture. Living scaffolds are designed to restore function by serving as a living labeled pathway for targeted axonal regeneration - mimicking key developmental mechanisms- or by restoring lost neural circuitry via direct replacement of neurons and axonal tracts. We are currently utilizing preformed living scaffolds consisting of neuronal clusters spanned by long axonal tracts as regenerative bridges to facilitate long-distance axonal regeneration and for targeted neurosurgical reconstruction of local circuits in the brain. Although there are formidable challenges in preclinical and clinical advancement, these living tissue engineered constructs represent a promising strategy to facilitate nervous system repair and functional recovery.	[Struzyna, Laura A.; Harris, James P.; Katiyar, Kritika S.; Chen, H. Isaac; Cullen, D. Kacy] Univ Penn, Dept Neurosurg, Perelman Sch Med, Ctr Brain Injury & Repair, Philadelphia, PA 19104 USA; [Struzyna, Laura A.; Harris, James P.; Chen, H. Isaac; Cullen, D. Kacy] Philadelphia Vet Affairs Med Ctr, Ctr Neurotrauma Neurodegenerat & Restorat, Philadelphia, PA USA; [Katiyar, Kritika S.] Drexel Univ, Sch Biomed Engn, Philadelphia, PA 19104 USA	Cullen, DK (corresponding author), Univ Penn, Dept Neurosurg, Perelman Sch Med, Ctr Brain Injury & Repair, Philadelphia, PA 19104 USA.	dkacy@mail.med.upenn.edu		Harris, James/0000-0002-8458-5434	U.S. Army Medical Research and Materiel Command through the Joint Warfighter Medical Research Program [W81XWH-13-13207004]; Axonia Medical, Inc.; Department of Veterans Affairs (RRD Merit Review)US Department of Veterans Affairs [B1097-I]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NINDS T32-NS043126]; Penn Medicine Neuroscience Center; National Science FoundationNational Science Foundation (NSF) [DGE-1321851]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F31NS090746, T32NS043126] Funding Source: NIH RePORTER	This work was made possible due to financial support provided by the U.S. Army Medical Research and Materiel Command through the Joint Warfighter Medical Research Program (#W81XWH-13-13207004); Axonia Medical, Inc.; Department of Veterans Affairs (RR&D Merit Review #B1097-I); National Institutes of Health (NINDS T32-NS043126); Penn Medicine Neuroscience Center; and the National Science Foundation (Graduate Research Fellowship DGE-1321851).	Apel PJ, 2010, MUSCLE NERVE, V41, P335, DOI 10.1002/mus.21485; Barker Roger A, 2004, NeuroRx, V1, P472, DOI 10.1007/BF03206631; Borisoff JF, 2003, MOL CELL NEUROSCI, V22, P405, DOI 10.1016/S1044-7431(02)00032-5; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Bryson JB, 2014, SCIENCE, V344, P94, DOI 10.1126/science.1248523; Burnett Mark G, 2004, Neurosurg Focus, V16, pE1, DOI 10.3171/foc.2004.16.5.2; Chan BP, 2008, EUR SPINE J, V17, pS467, DOI 10.1007/s00586-008-0745-3; Colicos MA, 2006, J EXP BIOL, V209, P2312, DOI 10.1242/jeb.02163; Cristofanilli M, 2011, STEM CELLS DEV, V20, P2065, DOI 10.1089/scd.2010.0547; Cullen DK, 2007, J NEUROSCI RES, V85, P3642, DOI 10.1002/jnr.21434; Cullen DK, 2007, J NEURAL ENG, V4, P159, DOI 10.1088/1741-2560/4/2/015; Cullen DK, 2007, ANN BIOMED ENG, V35, P835, DOI 10.1007/s10439-007-9292-z; Cullen DK, 2012, TISSUE ENG PT A, V18, P2280, DOI [10.1089/ten.tea.2011.0534, 10.1089/ten.TEA.2011.0534]; Cullen D. Kacy, 2011, Critical Reviews in Biomedical Engineering, V39, P201; Cullen D. Kacy, 2011, Critical Reviews in Biomedical Engineering, V39, P241; Dayawansa S, 2014, NEUROL RES, V36, P1020, DOI 10.1179/1743132814Y.0000000386; Eberli D, 2006, METHOD ENZYMOL, V420, P287, DOI 10.1016/S0076-6879(06)20013-2; Faroni A, 2013, INT REV NEUROBIOL, V108, P121, DOI 10.1016/B978-0-12-410499-0.00005-8; Filous AR, 2010, DEV NEUROBIOL, V70, P826, DOI 10.1002/dneu.20820; Fine EG, 2002, EUR J NEUROSCI, V15, P589, DOI 10.1046/j.1460-9568.2002.01892.x; Fitch MT, 2008, EXP NEUROL, V209, P294, DOI 10.1016/j.expneurol.2007.05.014; Fouad K, 2005, J NEUROSCI, V25, P1169, DOI 10.1523/JNEUROSCI.3562-04.2005; Ganguly K, 2013, NEURON, V80, P729, DOI 10.1016/j.neuron.2013.10.028; Hu BY, 2010, P NATL ACAD SCI USA, V107, P4335, DOI 10.1073/pnas.0910012107; Huang JH, 2009, TISSUE ENG PT A, V15, P1677, DOI 10.1089/ten.tea.2008.0294; Iwata A, 2006, TISSUE ENG, V12, P101, DOI 10.1089/ten.2006.12.101; JACOBS JR, 1989, J NEUROSCI, V9, P2402; Jain A, 2004, J NEUROSCI RES, V77, P299, DOI 10.1002/jnr.20161; Kandel E.R., 2013, PRINCIPLES NEURAL SC; Kim SU, 2009, J NEUROSCI RES, V87, P2183, DOI 10.1002/jnr.22054; Korecka JA, 2007, REGEN MED, V2, P425, DOI 10.2217/17460751.2.4.425; Liu K, 2010, NAT NEUROSCI, V13, P1075, DOI 10.1038/nn.2603; Madduri S, 2010, BIOMATERIALS, V31, P8402, DOI 10.1016/j.biomaterials.2010.07.052; Mingorance A, 2006, FASEB J, V20, P491, DOI 10.1096/fj.05-5121fje; Moore MJ, 2006, BIOMATERIALS, V27, P419, DOI 10.1016/j.biomaterials.2005.07.045; Park KI, 2002, NAT BIOTECHNOL, V20, P1111, DOI 10.1038/nbt751; Pfister BJ, 2004, J NEUROSCI, V24, P7978, DOI 10.1523/JNEUROSCI.1974-04.2004; Pfister Bryan J., 2011, Critical Reviews in Biomedical Engineering, V39, P81; Pina-Crespo JC, 2012, J NEUROSCI, V32, P15837, DOI 10.1523/JNEUROSCI.3735-12.2012; RAPER JA, 1983, J NEUROSCI, V3, P31; Raper J, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001933; Rosenstein JM, 2010, ORGANOGENESIS, V6, P107, DOI 10.4161/org.6.2.11687; Sepp KJ, 2001, DEV BIOL, V238, P47, DOI 10.1006/dbio.2001.0411; Shein-Idelson Mark, 2011, Front Neuroeng, V4, P10, DOI 10.3389/fneng.2011.00010; Smeal RM, 2005, ANN BIOMED ENG, V33, P376, DOI 10.1007/s10439-005-1740-z; Smith DH, 2001, TISSUE ENG, V7, P131, DOI 10.1089/107632701300062714; Smith DH, 2009, PROG NEUROBIOL, V89, P231, DOI 10.1016/j.pneurobio.2009.07.006; Struzyna LA, 2013, RESTORING BRAIN CIRC; Struzyna LA, 2014, CURR OPIN SOLID ST M, V18, P308, DOI 10.1016/j.cossms.2014.07.004; Tang XQ, 2007, J NEUROSCI, V27, P6068, DOI 10.1523/JNEUROSCI.1442-07.2007; Teng YD, 2002, P NATL ACAD SCI USA, V99, P3024, DOI 10.1073/pnas.052678899; Thorne RG, 2001, CLIN PHARMACOKINET, V40, P907, DOI 10.2165/00003088-200140120-00003; Tornero D, 2013, BRAIN, V136, P3561, DOI 10.1093/brain/awt278; Tsai EC, 2004, J NEUROTRAUM, V21, P789, DOI 10.1089/0897715041269687; Varier S, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1001044; Wang S, 2013, CELL STEM CELL, V12, P252, DOI 10.1016/j.stem.2012.12.002; Weick JP, 2010, STEM CELLS, V28, P2008, DOI 10.1002/stem.514; Wernig M, 2004, J NEUROSCI, V24, P5258, DOI 10.1523/JNEUROSCI.0428-04.200; Xu G, 2004, NEUROREPORT, V15, P2167, DOI 10.1097/00001756-200410050-00004; Yan QJ, 2012, BIOMED ENG ONLINE, V11, DOI 10.1186/1475-925X-11-36; Yip PK, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000399	61	34	37	1	22	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	1673-5374	1876-7958		NEURAL REGEN RES	Neural Regen. Res.	MAY	2015	10	5					679	685		10.4103/1673-5374.156943			7	Cell Biology; Neurosciences	Cell Biology; Neurosciences & Neurology	CK1JU	WOS:000355964400002	26109930	DOAJ Gold, Green Published			2021-06-18	
J	Fournier, CN; Gearing, M; Upadhyayula, SR; Klein, M; Glass, JD				Fournier, Christina N.; Gearing, Marla; Upadhyayula, Saila R.; Klein, Mitch; Glass, Jonathan D.			Head injury does not alter disease progression or neuropathologic outcomes in ALS	NEUROLOGY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; CHRONIC TRAUMATIC ENCEPHALOPATHY; MOTOR-NEURON DISEASE; TDP-43 PROTEINOPATHY; SURVIVAL; RILUZOLE; RISK; DIAGNOSIS; FOOTBALL	Objectives:To study the effects of head injury on disease progression and on neuropathologic outcomes in amyotrophic lateral sclerosis (ALS).Methods:Patients with ALS were surveyed to obtain head injury history, and medical records were reviewed. Linear regression was performed to determine if head injury was a predictor for mean monthly decline of Amyotrophic Lateral Sclerosis Functional Rating Scale-revised (ALSFRS-R), while controlling for confounders. Head injury history was obtained from family members of ALS autopsy cases. The frequency of tau proteinopathy, brain TDP-43 inclusions, and pathologic findings of Alzheimer disease (AD) were examined in ALS cases with head injury compared to cases without. Logistic regression was performed with each neuropathologic diagnosis as an outcome measure and head injury as a predictor variable.Results:No difference was seen in rate of decline of the ALSFRS-R between patients with head injury (n = 24) and without (n = 76), with mean monthly decline of -0.9 for both groups (p = 0.18). Of 47 ALS autopsy cases (n = 9 with head injury, n = 38 without), no significant differences were seen in the frequency of tau proteinopathy (11% with head injury; 24% without), TDP-43 in the brain (44% with head injury; 45% without), or AD pathology (33% with head injury; 26% without). Independent logistic regression models showed head injury was not a predictor of tau pathology (p = 0.42) or TDP-43 in the brain (p = 0.99).Conclusions:Head injury was not associated with faster disease progression in ALS and did not result in a specific neuropathologic phenotype. The tau pathology described with chronic traumatic encephalopathy was found in ALS autopsy cases both with and without head injury.	[Fournier, Christina N.; Gearing, Marla; Upadhyayula, Saila R.; Glass, Jonathan D.] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA; [Gearing, Marla; Glass, Jonathan D.] Emory Univ, Sch Med, Dept Pathol, Atlanta, GA 30322 USA; [Klein, Mitch] Emory Univ, Sch Med, Dept Environm Hlth, Atlanta, GA USA	Fournier, CN (corresponding author), Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA.	christina.nicole.fournier@emory.edu			National Center for Advancing Translational Sciences of the NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000454]; National Institute of AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50 AG025688-03]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000454] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG025688] Funding Source: NIH RePORTER	Supported in part by the National Center for Advancing Translational Sciences of the NIH under award number UL1TR000454. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Supported in part by a grant from the National Institute of Aging P50 AG025688-03.	Appel SH, 2010, MUSCLE NERVE, V42, P851, DOI 10.1002/mus.21939; Armon C, 2012, AMYOTROPH LATERAL SC, V13, P351, DOI 10.3109/17482968.2012.660954; Armon C, 2011, J NEUROPATH EXP NEUR, V70, P97, DOI 10.1097/01.JNEN.0000392910.86750.32; Bedlack RS, 2011, J NEUROPATH EXP NEUR, V70, P96, DOI 10.1097/NEN.0b013e318204782b; BROOKS BR, 1994, J NEUROL SCI, V124, P96, DOI 10.1016/0022-510X(94)90191-0; Cedarbaum JM, 1999, J NEUROL SCI, V169, P13, DOI 10.1016/S0022-510X(99)00210-5; Chen HL, 2007, AM J EPIDEMIOL, V166, P810, DOI 10.1093/aje/kwm153; de Jong SW, 2012, AM J EPIDEMIOL, V176, P233, DOI 10.1093/aje/kws015; Georgoulopoulou E, 2013, AMYOTROPH LAT SCL FR, V14, P338, DOI 10.3109/21678421.2013.763281; Huisman MHB, 2013, J NEUROL NEUROSUR PS, V84, P976, DOI 10.1136/jnnp-2012-304724; Kimura F, 2006, NEUROLOGY, V66, P265, DOI 10.1212/01.wnl.0000194316.91908.8a; Lacomblez L, 1996, NEUROLOGY, V47, pS242, DOI 10.1212/WNL.47.6_Suppl_4.242S; Lee CTC, 2013, J EPIDEMIOL, V23, P35, DOI 10.2188/jea.JE20120119; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; Peters TL, 2013, AMYOTROPH LAT SCL FR, V14, P267, DOI 10.3109/21678421.2012.754043; Picard M, 1991, HELPS TBI SCREENING; Qureshi M, 2009, AMYOTROPH LATERAL SC, V10, P324, DOI 10.3109/17482960903009054; Savica R, 2012, MAYO CLIN PROC, V87, P335, DOI 10.1016/j.mayocp.2011.12.016; Schmidt S, 2010, J NEUROL SCI, V291, P22, DOI 10.1016/j.jns.2010.01.011; Traxinger Kim, 2013, Neurol Clin Pract, V3, P313; Turner MR, 2010, J NEUROL SCI, V288, P45, DOI 10.1016/j.jns.2009.10.010; Weisskopf MG, 2005, NEUROLOGY, V64, P32, DOI 10.1212/01.WNL.0000148649.17706.D9	25	34	34	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	APR 28	2015	84	17					1788	1795		10.1212/WNL.0000000000001522			8	Clinical Neurology	Neurosciences & Neurology	CH5GB	WOS:000354062200017	25832660	Green Published			2021-06-18	
J	Walker, WC; Cifu, DX; Hudak, AM; Goldberg, G; Kunz, RD; Sima, AP				Walker, William C.; Cifu, David X.; Hudak, Anne M.; Goldberg, Gary; Kunz, Richard D.; Sima, Adam P.			Structured Interview for Mild Traumatic Brain Injury after Military Blast: Inter-Rater Agreement and Development of Diagnostic Algorithm	JOURNAL OF NEUROTRAUMA			English	Article						assessment tools; epidemiology; adult brain injury; traumatic brain injury; concussion; military injury	OPERATION ENDURING FREEDOM; IRAQI FREEDOM; TBI IDENTIFICATION; STRESS-DISORDER; UNITED-STATES; VETERANS; CONCUSSION; VALIDITY; RELIABILITY; DEPLOYMENT	The existing gold standard for diagnosing a suspected previous mild traumatic brain injury (mTBI) is clinical interview. But it is prone to bias, especially for parsing the physical versus psychological effects of traumatic combat events, and its inter-rater reliability is unknown. Several standardized TBI interview instruments have been developed for research use but have similar limitations. Therefore, we developed the Virginia Commonwealth University (VCU) retrospective concussion diagnostic interview, blast version (VCU rCDI-B), and undertook this cross-sectional study aiming to 1) measure agreement among clinicians' mTBI diagnosis ratings, 2) using clinician consensus develop a fully structured diagnostic algorithm, and 3) assess accuracy of this algorithm in a separate sample. Two samples (n=66; n=37) of individuals within 2 years of experiencing blast effects during military deployment underwent semistructured interview regarding their worst blast experience. Five highly trained TBI physicians independently reviewed and interpreted the interview content and gave blinded ratings of whether or not the experience was probably an mTBI. Paired inter-rater reliability was extremely variable, with kappa ranging from 0.194 to 0.825. In sample 1, the physician consensus prevalence of probable mTBI was 84%. Using these diagnosis ratings, an algorithm was developed and refined from the fully structured portion of the VCU rCDI-B. The final algorithm considered certain symptom patterns more specific for mTBI than others. For example, an isolated symptom of "saw stars" was deemed sufficient to indicate mTBI, whereas an isolated symptom of "dazed" was not. The accuracy of this algorithm, when applied against the actual physician consensus in sample 2, was almost perfect (correctly classified=97%; Cohen's kappa=0.91). In conclusion, we found that highly trained clinicians often disagree on historical blast-related mTBI determinations. A fully structured interview algorithm was developed from their consensus diagnosis that may serve to enhance diagnostic standardization for clinical research in this population.	[Walker, William C.; Cifu, David X.; Hudak, Anne M.; Goldberg, Gary; Kunz, Richard D.] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA 23298 USA; [Walker, William C.; Cifu, David X.; Hudak, Anne M.; Goldberg, Gary] HH McGuire Vet Affairs Med Ctr, Richmond, VA USA; [Sima, Adam P.] Virginia Commonwealth Univ, Dept Biostat, Richmond, VA 23298 USA	Walker, WC (corresponding author), Virginia Commonwealth Univ, Dept Phys Med & Rehabil, MCV Box 677, Richmond, VA 23298 USA.	wwalker@mcvh-vcu.edu		Sima, Adam/0000-0001-8426-9987; Cifu, David/0000-0003-1600-9387	US Army Medical Research & Material Command, Congressionally Directed Medical Research Program (CDMRP) [W91ZSQ8118N6200001]; Epidemiological Study of Mild Traumatic Brain Injury Sequelae Caused by Blast Exposure during Operations Iraq Freedom and Enduring Freedom	This study was supported by a grant from US Army Medical Research & Material Command, Congressionally Directed Medical Research Program (CDMRP; grant no.: W91ZSQ8118N6200001); Epidemiological Study of Mild Traumatic Brain Injury Sequelae Caused by Blast Exposure during Operations Iraq Freedom and Enduring Freedom.	Bazarian JJ, 2001, ACAD EMERG MED, V8, P788, DOI 10.1111/j.1553-2712.2001.tb00208.x; Brown LD, 2001, STAT SCI, V16, P101, DOI 10.1214/ss/1009213286; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; Capehart B, 2012, J REHABIL RES DEV, V49, P789, DOI 10.1682/JRRD.2011.10.0185; Carlson KF, 2013, BRAIN INJURY, V27, P640, DOI 10.3109/02699052.2013.771795; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P315, DOI 10.1097/01.HTR.0000300226.67748.3e; Crewson PE, 2005, AM J ROENTGENOL, V184, P1391, DOI 10.2214/ajr.184.5.01841391; Diamond PM, 2007, J HEAD TRAUMA REHAB, V22, P330, DOI 10.1097/01.HTR.0000300228.05867.5c; Donnelly KT, 2011, J HEAD TRAUMA REHAB, V26, P439, DOI 10.1097/HTR.0b013e3182005de3; Evans CT, 2013, PM&R, V5, P210, DOI 10.1016/j.pmrj.2012.12.004; First MB., 2002, STRUCTURED CLIN INTE; Fortier CB, 2014, J HEAD TRAUMA REHAB, V29, P89, DOI 10.1097/HTR.0b013e3182865859; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Harvey AG, 2002, PSYCHOL BULL, V128, P886, DOI 10.1037//0033-2909.128.6.886; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Lew HL, 2008, J REHABIL RES DEV, V45, pXI, DOI 10.1682/JRRD.2008.05.0064; McCrea M, 2001, CLIN J SPORT MED, V11, P176, DOI 10.1097/00042752-200107000-00008; Meyer KS, 2010, PSYCHIAT CLIN N AM, V33, P783, DOI 10.1016/j.psc.2010.08.007; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Powell JM, 2008, ARCH PHYS MED REHAB, V89, P1550, DOI 10.1016/j.apmr.2007.12.035; ROBINS LN, 1988, ARCH GEN PSYCHIAT, V45, P1069; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Scholten JD, 2012, BRAIN INJURY, V26, P1177, DOI 10.3109/02699052.2012.661914; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Sundin J, 2010, PSYCHOL MED, V40, P367, DOI 10.1017/S0033291709990791; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Vanderploeg RD, 2012, J REHABIL RES DEV, V49, P545, DOI 10.1682/JRRD.2011.04.0069; Walker WC, 2013, J HEAD TRAUMA REHAB, V28, P68, DOI 10.1097/HTR.0b013e318255dfd0	37	34	34	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR 1	2015	32	7					464	473		10.1089/neu.2014.3433			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CE4YV	WOS:000351837400006	25264909				2021-06-18	
J	Kerr, ZY; Mihalik, JP; Guskiewicz, KM; Rosamond, WD; Evenson, KR; Marshall, SW				Kerr, Zachary Y.; Mihalik, Jason P.; Guskiewicz, Kevin M.; Rosamond, Wayne D.; Evenson, Kelly R.; Marshall, Stephen W.			Agreement Between Athlete-Recalled and Clinically Documented Concussion Histories in Former Collegiate Athletes	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						concussion; injury; epidemiology; traumatic brain injury; concurrent validity	RECURRENT CONCUSSION; FOOTBALL PLAYERS; EPIDEMIOLOGY; ASSOCIATION; DEPRESSION; MANAGEMENT; STATEMENT; DIAGNOSIS; KNOWLEDGE; SYMPTOMS	Background: Athlete-recalled and clinically documented concussion histories have been used in research on former athletes, but both have limitations. Comparisons of these 2 types of concussion histories are needed to improve the accuracy of estimates of concussion history for future research and clinical care. Purpose: To estimate the agreement between athlete-recalled and clinically documented concussion histories during college and to explore reasons for differences. Study: Cohort study (diagnosis); Level of evidence, 3. Methods: Athlete-recalled concussion histories were provided by a convenience sample of 130 former collegiate athletes using an online questionnaire, and they were individually linked to previously collected clinical data that tracked medically diagnosed concussions at the host institution from 1996 to 2012. The intraclass correlation coefficient (ICC2,1) was used to assess agreement between athlete-recalled and clinically documented concussion histories. Descriptive analyses were performed to assess reasons for disagreement. Results: Agreement between athlete-recalled and clinically documented concussion histories was low (ICC2,1 = 0.21; 95% confidence interval, 0.05-0.37), but it was higher for women (ICC2,1 = 0.65; 95% confidence interval, 0.44-0.79) and for athletes playing more recently (2005-2012; ICC2,1 = 0.39; 95% confidence interval, 0.01-0.67). Of the 53 athletes who self-reported college sports-related concussions, 40% believed that they sustained impacts that should have been diagnosed as concussions but were undetected, and 21% admitted nondisclosure of suspected concussions. Common reasons for nondisclosure included the following: did not think injury was serious enough (91%), did not know it was a concussion (73%), and did not want to leave the game/practice (73%). Conclusion: Given the low agreement between athlete-recalled and clinically documented concussion histories, methodologic research is needed to improve the quality of tools used to assess concussion histories in former athletes.	[Kerr, Zachary Y.; Mihalik, Jason P.; Guskiewicz, Kevin M.; Rosamond, Wayne D.; Evenson, Kelly R.; Marshall, Stephen W.] Univ N Carolina, Chapel Hill, NC USA	Kerr, ZY (corresponding author), Datalys Ctr Sports Injury Res & Prevent, NCAA Injury Surveillance Program, 401 West Michigan St,Suite 500, Indianapolis, IN 46202 USA.	zkerr@datalyscenter.org		Mihalik, Jason/0000-0001-6085-8322; Kerr, Zachary/0000-0003-1423-1259; Evenson, Kelly/0000-0002-3720-5830; Guskiewicz, Kevin/0000-0002-8682-2130	National Center for Injury Prevention and ControlUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA; Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49-CE001495]	The Matthew A. Gfeller Sport-Related Traumatic Brain Injury Research and the Center for the Study of Retired Athletes are funded by private donations and various grant-funding agencies interested in understanding the current and late-life consequences and benefits of sports participation. The Injury Prevention Research Center is partially supported by the National Center for Injury Prevention and Control to facilitate research that increases knowledge of the consequences of injuries and opportunities for injury prevention. S.W.M. is partly supported by grant R49-CE001495 from the Centers for Disease Control and Prevention to the University of North Carolina Injury Prevention Research Center.	[Anonymous], ATHL TRAIN FILL NEC; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bandura A., 1986, SOCIAL FDN THOUGHT A; BARTKO JJ, 1966, PSYCHOL REP, V19, P3, DOI 10.2466/pr0.1966.19.1.3; Broglio SP, 2010, J SPORT SCI MED, V9, P418; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Didehbani N, 2013, ARCH CLIN NEUROPSYCH, V28, P418, DOI 10.1093/arclin/act028; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kerr ZY, 2014, BRAIN INJURY, V28, P1009, DOI 10.3109/02699052.2014.904049; Kerr ZY, 2013, AM J PREV MED, V44, P8, DOI 10.1016/j.amepre.2012.09.058; Kerr ZY, 2012, AM J SPORT MED, V40, P2206, DOI 10.1177/0363546512456193; Kerr ZY, 2012, MED SCI SPORT EXER, V44, P377, DOI 10.1249/MSS.0b013e31823240f2; Kroshus E, 2014, BRIT J SPORT MED, V48, P135, DOI 10.1136/bjsports-2013-092498; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Leddy JJ, 2015, CLIN J SPORT MED, V25, P237, DOI 10.1097/JSM.0000000000000128; Llewellyn T, 2014, CLIN J SPORT MED, V24, P76, DOI 10.1097/01.jsm.0000432853.77520.3d; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory Paul, 2009, J Athl Train, V44, P434, DOI 10.4085/1062-6050-44.4.434; Mueller FO, 2012, PREVENTING SUDDEN DE, P1; Register-Mihalik JK, 2013, J ATHL TRAINING, V48, P645, DOI 10.4085/1062-6050-48.3.20; Torres Daniel M, 2013, Neurol Clin Pract, V3, P279	28	34	34	0	20	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	MAR	2015	43	3					606	613		10.1177/0363546514562180			8	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	CC6JP	WOS:000350471500013	25560539				2021-06-18	
J	Yerry, JA; Kuehn, D; Finkel, AG				Yerry, Juanita A.; Kuehn, Devon; Finkel, Alan G.			Onabotulinum Toxin A for the Treatment of Headache in Service Members With a History of Mild Traumatic Brain Injury: A Cohort Study	HEADACHE			English	Article						traumatic brain injury; botulinum toxin; military; headache; migraine; chronic migraine	CHRONIC POSTTRAUMATIC HEADACHES; BOTULINUM TOXIN; CHRONIC MIGRAINE; DOUBLE-BLIND; US SOLDIERS; PROPHYLACTIC TREATMENT; CERVICOGENIC HEADACHE; INTERNATIONAL BURDEN; STRESS-DISORDER; PREVALENCE	ObjectivePost-traumatic headache (PTH) of the migraine type is a common complication of mild traumatic brain injury (including blast injuries) in active duty service members. Persistent and near-daily headache occur. Usual preventive medications may have unacceptable side effects. Anecdotal reports suggest that onabotulinum toxin A (OBA) might be an effective treatment in these patients. MethodsThis study is a real-time retrospective consecutive case series of all patients treated with OBA at the Concussion Care Clinic of Womack Army Medical Center, Ft. Bragg, NC, between August 2008 and August 2012. Clinical treatment and pharmacy records were corroborated with the electronic medical records in the Armed Forces Health Longitudinal Technology Application to determine demographics, current headache and treatment characteristics, and clinical and occupational outcomes. ResultsSixty-four subjects (63 male) with mean age of 31.3 +/- 7.5 (range 20-59) years were evaluated and treated. Blast injuries were most common (n=36; 56.3%) and 7 patients (11%) reported a prior history of headache. Most patients (36; 56.3%) described more than 1 headache type and 48 (75%) patients had continuous pain. The most prevalent treating diagnosis was mixed continuous headache with migraine features on more than 15 days per month (n=26; 40.6%). The mean time from injury to the first injections was 10.8 +/- 21.9 (1-96) months. Forty (62.5%) patients received the Food and Drug Administration-approved chronic migraine injection protocol. Forty-one (64%) patients reported being better. Two patients discontinued for side effects. Twenty-seven (41%) remained on active duty. ConclusionsWe demonstrate that active duty military patients with headaches related to concussions may benefit from treatment with OBA. Further studies are indicated.	[Yerry, Juanita A.; Kuehn, Devon; Finkel, Alan G.] Womack Army Med Ctr, Dept Brain Injury Med, Ft Bragg, NC USA; [Finkel, Alan G.] Def & Vet Brain Injury Ctr, Silver Spring, MD USA; [Finkel, Alan G.] Carolina Headache Inst, Chapel Hill, NC USA	Finkel, AG (corresponding author), Carolina Headache Inst, Headache Med, 6114 Fayetteville Rd, Durham, NC 27713 USA.	finkela@chi09.com			Defense and Veteran Brain Injury Centers	One of the authors (AF) received salary support from the Defense and Veteran Brain Injury Centers in the conduct of this study and preparation of the manuscript. The views expressed herein are those of the presenters and do not reflect the official policy of the Department of the Army, Department of Defense, or the U.S. Government.	Afari N, 2009, HEADACHE, V49, P1267, DOI 10.1111/j.1526-4610.2009.01517.x; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; [Anonymous], 2013, MSMR, V20, P9; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; Baandrup L, 2005, CEPHALALGIA, V25, P132, DOI 10.1111/j.1468-2982.2004.00818.x; Becker WJ, 2011, CEPHALALGIA, V31, P979, DOI 10.1177/0333102411410086; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Belanger HG, 2011, CLIN NEUROPSYCHOL, V1, P1; Bloudek LM, 2012, J HEADACHE PAIN, V13, P361, DOI 10.1007/s10194-012-0460-7; Blumenfeld AM, 2011, CEPHALALGIA, V31, P301, DOI 10.1177/0333102410381145; Bryan CJ, 2011, HEADACHE, V51, P945, DOI 10.1111/j.1526-4610.2011.01887.x; Burstein R, 2000, BRAIN, V123, P1703, DOI 10.1093/brain/123.8.1703; Christensen J, 2009, LANCET, V373, P1105, DOI 10.1016/S0140-6736(09)60214-2; Cohen SP, 2012, CEPHALALGIA, V32, P94, DOI 10.1177/0333102411422382; Couch JR, 2007, NEUROLOGY, V69, P1169, DOI 10.1212/01.wnl.0000276985.07981.0a; Diener HC, 2010, CEPHALALGIA, V30, P804, DOI 10.1177/0333102410364677; Diener HC, 2012, NAT REV NEUROL, V8, P162, DOI 10.1038/nrneurol.2012.13; Dusitanond P, 2008, HEADACHE, V48, P1379, DOI 10.1111/j.1526-4610.2008.01245.x; Emanuelson I, 2009, BRAIN INJURY, V23, P612, DOI 10.1080/02699050902973913; Erickson JC, 2011, HEADACHE, V51, P932, DOI 10.1111/j.1526-4610.2011.01909.x; Eross EJ, 2005, HEADACHE, V45, P308, DOI 10.1111/j.1526-4610.2005.05067.x; Ferguson PL, 2010, EPILEPSIA, V51, P891, DOI 10.1111/j.1528-1167.2009.02384.x; Finkel AG, 2012, HEADACHE, V52, P957, DOI 10.1111/j.1526-4610.2012.02167.x; Finkel AG, 2011, HEADACHE, V51, P1565, DOI 10.1111/j.1526-4610.2011.02021.x; Haas DC, 1996, CEPHALALGIA, V16, P486, DOI 10.1046/j.1468-2982.1996.1607486.x; Halbauer JD, 2009, J REHABIL RES DEV, V46, P757, DOI 10.1682/JRRD.2008.08.0119; He MW, 2009, CHINESE MED J-PEKING, V122, P427, DOI 10.3760/cma.j.issn.0366-6999.2009.04.0013; Hoffman JM, 2011, J NEUROTRAUM, V28, P1719, DOI 10.1089/neu.2011.1914; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2011, NEW ENGL J MED, V365, P860, DOI 10.1056/NEJMc1107891; Hoge CW, 2010, ARCH PHYS MED REHAB, V91, P963, DOI 10.1016/j.apmr.2010.02.005; International Headache Society, 2004, CEPHALALGIA S1, V24, P86; Kapural Leonardo, 2007, Pain Pract, V7, P337, DOI 10.1111/j.1533-2500.2007.00150.x; Kosaras B, 2009, J COMP NEUROL, V515, P331, DOI 10.1002/cne.22049; Larson GE, 2008, AM J EPIDEMIOL, V167, P1269, DOI 10.1093/aje/kwn084; Linde M, 2011, CEPHALALGIA, V31, P797, DOI 10.1177/0333102411398402; Lippert-Gruner M, 2012, NEUROL NEUROCHIR POL, V46, P591, DOI 10.5114/ninp.2012.32109; Lucas S, 2014, CEPHALALGIA, V34, P93, DOI 10.1177/0333102413499645; Lucas S, 2012, CEPHALALGIA, V32, P600, DOI 10.1177/0333102412445224; Lucas S, 2011, PM&R, V3, pS406, DOI 10.1016/j.pmrj.2011.07.016; Mathew NT, 2008, HEADACHE, V48, P442, DOI 10.1111/j.1526-4610.2007.00960.x; Mathew NT, 2005, HEADACHE, V45, P293, DOI 10.1111/j.1526-4610.2005.05066.x; McCauley SR, 2013, J NEUROTRAUM, V30, P642, DOI 10.1089/neu.2012.2393; Moon J, 2010, CEPHALALGIA, V30, P1527, DOI 10.1177/0333102410368445; Neely ET, 2009, HEADACHE, V49, P1089, DOI 10.1111/j.1526-4610.2009.001460.x; Negro A, 2011, EUR REV MED PHARMACO, V15, P1401; Patil VK, 2011, HEADACHE, V51, P1112, DOI 10.1111/j.1526-4610.2011.01946.x; Rapp PE, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00091; Rosenthal JF, 2013, HEADACHE, V53, P1564, DOI 10.1111/head.12200; Ruff RL, 2008, J REHABIL RES DEV, V45, P941, DOI 10.1682/JRRD.2008.02.0028; Ryan NP, 2014, J NEUROTRAUM, V31, P649, DOI 10.1089/neu.2013.3153; Scher AI, 2011, 63 ANN M AM AC NEUR; Scher AI, 2014, CEPHALALGIA, V34, P83, DOI 10.1177/0333102413499644; Sela-Kaufman M, 2013, J CLIN EXP NEUROPSYC, V35, P584, DOI 10.1080/13803395.2013.799123; Serrano D, 2013, VALUE HEALTH, V16, P31, DOI 10.1016/j.jval.2012.08.2212; Silberstein SD, 2006, CEPHALALGIA, V26, P790, DOI 10.1111/j.1468-2982.2006.01114.x; Smitherman TA, 2013, HEADACHE, V53, P427, DOI 10.1111/head.12074; Sycha T, 2004, J NEUROL, V251, P19, DOI 10.1007/s00415-004-1106-8; Theeler B, 2013, HEADACHE, V53, P881, DOI 10.1111/head.12123; Theeler BJ, 2008, HEADACHE, V48, P876, DOI 10.1111/j.1526-4610.2008.01159.x; Theeler BJ, 2012, CEPHALALGIA, V32, P589, DOI 10.1177/0333102412445220; Theeler BJ, 2010, HEADACHE, V50, P1262, DOI 10.1111/j.1526-4610.2010.01700.x; Theeler BJ, 2009, HEADACHE, V49, P529, DOI 10.1111/j.1526-4610.2009.01345.x; Thomas JL, 2010, ARCH GEN PSYCHIAT, V67, P614, DOI 10.1001/archgenpsychiatry.2010.54; Torelli P, 2004, CEPHALALGIA, V24, P29, DOI 10.1111/j.1468-2982.2004.00633.x; Vargas BB, 2009, CURR PAIN HEADACHE R, V13, P64, DOI 10.1007/s11916-009-0013-1; Walker WC, 2013, CEPHALALGIA, V33, P998, DOI 10.1177/0333102413482197; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f; Wilson J, 2009, AM J EPIDEMIOL, V169, P1362, DOI 10.1093/aje/kwp044; Yamazaki Y, 2011, J HEADACHE PAIN, V12, P661, DOI 10.1007/s10194-011-0382-9; Zatzick DF, 2010, ARCH GEN PSYCHIAT, V67, P1291, DOI 10.1001/archgenpsychiatry.2010.158	71	34	34	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0017-8748	1526-4610		HEADACHE	Headache	MAR	2015	55	3					395	406		10.1111/head.12495			12	Clinical Neurology	Neurosciences & Neurology	CD6AS	WOS:000351171200004	25644249				2021-06-18	
J	Downar, J; You, JJ; Bagshaw, SM; Golan, E; Lamontagne, F; Burns, K; Sridhar, SK; Seely, A; Meade, MO; Fox-Robichaud, A; Cook, D; Turgeon, AF; Dodek, P; Xiong, W; Fowler, R				Downar, James; You, John J.; Bagshaw, Sean M.; Golan, Eyal; Lamontagne, Francois; Burns, Karen; Sridhar, S. Kavita; Seely, Andrew; Meade, Maureen O.; Fox-Robichaud, Alison; Cook, Deborah; Turgeon, Alexis F.; Dodek, Peter; Xiong, Wei; Fowler, Rob		Canadian Critical Care Trials Grp	Nonbeneficial Treatment Canada: Definitions, Causes, and Potential Solutions From the Perspective of Healthcare Practitioners	CRITICAL CARE MEDICINE			English	Article						attitude of health personnel; communication; decision making; ethics; medical; medical staff; hospital/ethics/legislation; and jurisprudence; medical futility; nursing staff; hospital/ethics/legislation; and jurisprudence	TRAUMATIC BRAIN-INJURY; EARLY PALLIATIVE CARE; OF-LIFE CARE; INTENSIVE-CARE; MEDICAL FUTILITY; COMMUNICATION-SKILLS; DECISION-MAKING; END; UNIT; PERCEPTIONS	Objective: Many healthcare workers are concerned about the provision of nonbeneficial treatment in the acute care setting. We sought to explore the perceptions of acute care practitioners to determine whether they perceived nonbeneficial treatment to be a problem, to generate an acceptable definition of nonbeneficial treatment, to learn about their perceptions of the impact and causes of nonbeneficial treatment, and the ways that they feel could reduce or resolve nonbeneficial treatment. Design: National, bilingual, cross-sectional survey of a convenience sample of nursing and medical staff who provide direct patient care in acute medical wards or ICUs in Canada. Main Results: We received 688 responses (response rate 61%) from 11 sites. Seventy-four percent of respondents were nurses. Eighty-two percent of respondents believe that our current means of resolving nonbeneficial treatment are inadequate. The most acceptable definitions of nonbeneficial treatment were "advanced curative/life-prolonging treatments that would almost certainly result in a quality of life that the patient has previously stated that he/she would not want" (88% agreement) and "advanced curative/life-prolonging treatments that are not consistent with the goals of care (as indicated by the patient)" (83% agreement). Respondents most commonly believed that nonbeneficial treatment was caused by substitute decision makers who do not understand the limitations of treatment, or who cannot accept a poor prognosis (90% agreement for each cause), and 52% believed that nonbeneficial treatment was "often" or "always" continued until the patient died or was discharged from hospital. Respondents believed that nonbeneficial treatment was a common problem with a negative impact on all stakeholders (>80%) and perceived that improved advance care planning and communication training would be the most effective (92% and 88%, respectively) and morally acceptable (95% and 92%, respectively) means to resolve the problem of nonbeneficial treatment. Conclusions: Canadian nurses and physicians perceive that our current means of resolving nonbeneficial treatment are inadequate, and that we need to adopt new techniques of resolving nonbeneficial treatment. The most promising strategies to reduce nonbeneficial treatment are felt to be improved advance care planning and communication training for healthcare professionals.	[Downar, James; Golan, Eyal] Univ Toronto, Dept Med, Div Crit Care, Toronto, ON, Canada; [Downar, James] Univ Toronto, Dept Med, Div Palliat Care, Toronto, ON, Canada; [You, John J.; Meade, Maureen O.; Fox-Robichaud, Alison; Cook, Deborah] McMaster Univ, Dept Med, Hamilton, ON, Canada; [You, John J.; Meade, Maureen O.; Cook, Deborah] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; [Bagshaw, Sean M.] Univ Alberta, Fac Med & Dent, Div Crit Care Med, Edmonton, AB, Canada; [Lamontagne, Francois] Univ Sherbrooke, Ctr Rech Etienne Le Bel, Sherbrooke, PQ J1K 2R1, Canada; [Burns, Karen] Univ Toronto, Interdept Div Crit Care, Toronto, ON, Canada; [Burns, Karen] St Michaels Hosp, Keenan Res Ctr, Toronto, ON M5B 1W8, Canada; [Burns, Karen] St Michaels Hosp, Li KaShing Knowledge Inst, Toronto, ON M5B 1W8, Canada; [Sridhar, S. Kavita] Lakeridge Hlth, Dept Emergency Med & Crit Care, Oshawa, ON, Canada; [Seely, Andrew] Univ Ottawa, Fac Med & Dent, Dept Surg, Ottawa, ON, Canada; [Seely, Andrew] Univ Ottawa, Dept Crit Care Med, Fac Med & Dent, Ottawa, ON, Canada; [Turgeon, Alexis F.] Univ Laval, Dept Anesthesiol, Div Crit Care, Quebec City, PQ, Canada; [Turgeon, Alexis F.] Univ Laval, Ctr Hosp Univ CHU Quebec, CHU Quebec, Hop Enfant Jesus,Res Ctr, Quebec City, PQ, Canada; [Dodek, Peter] St Pauls Hosp, Div Crit Care Med, Vancouver, BC V6Z 1Y6, Canada; [Dodek, Peter] St Pauls Hosp, Ctr Hlth Evaluat & Outcome Sci, Vancouver, BC V6Z 1Y6, Canada; [Dodek, Peter] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; [Xiong, Wei] Sunnybrook Med Ctr, Toronto, ON, Canada; [Fowler, Rob] Univ Toronto, Dept Med, Interdept Div Crit Care, Toronto, ON, Canada	Downar, J (corresponding author), 200 Elizabeth St 9N-926, Toronto, ON M5G 2C4, Canada.	james.downar@utoronto.ca	Golan, Eyal/D-3086-2014	Golan, Eyal/0000-0002-2904-9321	Research Early Career Award from Hamilton Health Sciences; Clinical Investigator Award from Alberta Innovates-Health Solutions; Canada Research Chair in Critical Care Nephrology; Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR); Research Career Award from the Fonds de la Recherche du Quebec-Sante; CIHR (HALO translational study)Canadian Institutes of Health Research (CIHR); Heart and Stroke Foundation Career Scientist Award; Department of Medicine Integrating Challenge Fund, University of Toronto	Dr. John You is supported by a Research Early Career Award from Hamilton Health Sciences. Dr. Sean M. Baghsaw is support by a Clinical Investigator Award from Alberta Innovates-Health Solutions and a Canada Research Chair in Critical Care Nephrology. Dr. Karen Burns holds a Clinician Scientist-Phase 2 Award from the Canadian Institutes of Health Research (CIHR). Dr. Alexis Turgeon is supported by a Research Career Award from the Fonds de la Recherche du Quebec-Sante. Dr. Deborah Cook holds a Research Chair of the Canadian Institutes of Health Research. Dr. Bagshaw consulted and lectured for Gambro. Dr. Fox-Robichaud received support for travel from rCPSC (Examination Chair, Member Speciaty Committee, Member Assessment Committee). Her institution received grant support from CIHR (HALO translational study) and received support for development of educational presentations from SimOne/CPSI (Sepsis Education). Dr. Rob Fowler is supported by a Heart and Stroke Foundation Career Scientist Award. Dr. Fowler received grant support from the Department of Medicine Integrating Challenge Fund, University of Toronto. The remaining authors have disclosed that they do not have any potential conflicts of interest.	Angus DC, 2004, CRIT CARE MED, V32, P638, DOI 10.1097/01.CCM.0000114816.62331.08; BRODY BA, 1995, J MED PHILOS, V20, P123, DOI 10.1093/jmp/20.2.123; Burns KEA, 2008, CAN MED ASSOC J, V179, P245, DOI 10.1503/cmaj.080372; Canadian Institute for Health Information, 2007, HLTH CAR US END LIF; Chidwick Paula, 2011, Healthc Q, V14, P69; Choong K, 2010, CLIN INVEST MED, V33, pE240; Cribb R, 2010, TORONTO STAR    0904; Detering KM, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c1345; Downer J, 2012, CRIT CARE MED, V40, P1814, DOI 10.1097/CCM.0b013e31824e0fb7; Ferrand E, 2003, AM J RESP CRIT CARE, V167, P1310, DOI 10.1164/rccm.200207-752OC; Fine RL, 2003, ANN INTERN MED, V138, P743, DOI 10.7326/0003-4819-138-9-200305060-00011; Gabbay E, 2010, J GEN INTERN MED, V25, P1083, DOI 10.1007/s11606-010-1445-3; Gordon GH, 2000, PATIENT EDUC COUNS, V40, P59, DOI 10.1016/S0738-3991(99)00069-5; Greer JA, 2012, J CLIN ONCOL, V30, P394, DOI 10.1200/JCO.2011.35.7996; Griffith L, 2004, INTENS CARE MED, V30, P1783, DOI 10.1007/s00134-004-2360-z; Hamric AB, 2007, CRIT CARE MED, V35, P422, DOI 10.1097/01.CCM.0000254722.50608.2D; Helft PR, 2000, NEW ENGL J MED, V343, P293, DOI 10.1056/NEJM200007273430411; Henry MS, 2006, J MED ETHICS, V32, P321, DOI 10.1136/jme.2005.013987; Heyland DK, 2006, CHEST, V130, P419, DOI 10.1378/chest.130.2.419; Heyland DK, 2013, JAMA INTERN MED, V173, P778, DOI 10.1001/jamainternmed.2013.180; Ho TH, 2011, J CLIN ONCOL, V29, P1587, DOI 10.1200/JCO.2010.31.9897; Huynh TN, 2013, JAMA INTERN MED, V173, P1887, DOI 10.1001/jamainternmed.2013.10261; Johnson SK, 2011, AM J RESP CRIT CARE, V183, P915, DOI 10.1164/rccm.201008-1214OC; Knickle K, 2012, CRIT CARE, V16, DOI [10.1186/cc11141, 10.1186/CC11141]; Lienard A, 2010, BRIT J CANCER, V103, P171, DOI 10.1038/sj.bjc.6605749; Nappa U, 2011, ANN ONCOL, V22, P2375, DOI 10.1093/annonc/mdq778; Palda VA, 2005, J CRIT CARE, V20, P207, DOI 10.1016/j.jcrc.2005.05.006; Piers RD, 2012, J AM MED DIR ASSOC, V13, DOI 10.1016/j.jamda.2010.12.014; Piers RD, 2011, JAMA-J AM MED ASSOC, V306, P2694, DOI 10.1001/jama.2011.1888; Poncet MC, 2007, AM J RESP CRIT CARE, V175, P698, DOI 10.1164/rccm.200606-806OC; Pope TM, 2007, TENESSEE LAW REV, V75, P80; Quill TE, 2011, JAMA-J AM MED ASSOC, V306, P1483, DOI 10.1001/jama.2011.1413; Rodriguez KL, 2006, J MED ETHICS, V32, P444, DOI 10.1136/jme.2005.014118; Schneiderman LJ, 1996, ANN INTERN MED, V125, P669, DOI 10.7326/0003-4819-125-8-199610150-00007; SCHNEIDERMAN LJ, 1990, ANN INTERN MED, V112, P949, DOI 10.7326/0003-4819-112-12-949; Seely AJE, 2013, PERSPECT BIOL MED, V56, P65, DOI 10.1353/pbm.2013.0009; Sibbald R, 2007, CAN MED ASSOC J, V177, P1201, DOI 10.1503/cmaj.070144; Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678; Teno JM, 2002, J AM GERIATR SOC, V50, P496, DOI 10.1046/j.1532-5415.2002.50116.x; Truog RD, 2008, CRIT CARE MED, V36, P953, DOI 10.1097/CCM.0B013E3181659096; Truog RD, 2009, CHEST, V136, P968, DOI 10.1378/chest.09-1269; Turgeon AF, 2013, CRIT CARE MED, V41, P1086, DOI 10.1097/CCM.0b013e318275d046; Turgeon AF, 2011, CAN MED ASSOC J, V183, P1581, DOI 10.1503/cmaj.101786; Tversky A, 1973, COGNITIVE PSYCHOL, V5, P27; Vincent JL, 1999, CRIT CARE MED, V27, P1626, DOI 10.1097/00003246-199908000-00042; White DB, 2004, CRIT CARE CLIN, V20, P329, DOI 10.1016/j.ccc.2004.03.003; White DB, 2012, JAMA-J AM MED ASSOC, V307, P151, DOI 10.1001/jama.2011.1990; White DB, 2009, AM J RESP CRIT CARE, V180, P320, DOI 10.1164/rccm.200811-1776OC; Wilkinson DJC, 2011, CURR OPIN ANESTHESIO, V24, P160, DOI 10.1097/ACO.0b013e328343c5af; Wright AA, 2008, JAMA-J AM MED ASSOC, V300, P1665, DOI 10.1001/jama.300.14.1665; Yourman LC, 2012, JAMA-J AM MED ASSOC, V307, P182, DOI 10.1001/jama.2011.1966; Zier LS, 2009, CHEST, V136, P110, DOI 10.1378/chest.08-2753	52	34	34	1	26	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	FEB	2015	43	2					270	281		10.1097/CCM.0000000000000704			12	Critical Care Medicine	General & Internal Medicine	AZ2YX	WOS:000348096200003	25377017				2021-06-18	
J	Heidari, K; Asadollahi, S; Jamshidian, M; Abrishamchi, SN; Nouroozi, M				Heidari, Kamran; Asadollahi, Shadi; Jamshidian, Morteza; Abrishamchi, Shohreh Nasiri; Nouroozi, Mahdi			Prediction of neuropsychological outcome after mild traumatic brain injury using clinical parameters, serum S100B protein and findings on computed tomography	BRAIN INJURY			English	Article						Computed tomography; outcome; post-concussion syndrome; prognosis; S100 protein; traumatic brain injury	MINOR HEAD-INJURY; NEURON-SPECIFIC ENOLASE; POST-CONCUSSION SYMPTOMS; NEW-ORLEANS CRITERIA; BIOCHEMICAL MARKERS; S-100B PROTEIN; DAMAGE; MANAGEMENT; RULE	Primary objective: To identify if demographics, clinical and computed tomographic (CT) characteristics at first presentation and S100B concentrations at 3 and 6 hours after mild traumatic brain injury (MTBI) predict the development of post-concussion syndrome (PCS) after 1 month. Research design and methods: All consecutive MTBI patients (Glasgow Coma Scale [GCS] score 13-15) admitted to the Emergency Department aged older than 15 were included in this prospective, observational study. Outcome was assessed using a Rivermead Post-Concussion Symptoms Questionnaire to identify the patients with and without PCS 1 month after the injury. Main outcomes and results: A total of 176 patients with isolated MTBI were included in the study. After multivariate analysis of the demographics, clinical variables, and CT abnormalities, headache (OR = 2.09, 95% CI = 1.04-4.21, p = 0.038), seizure (OR = 5.64, 95% CI = 1.55-20.54, p = 0.009), the presence of subarachnoid haemorrhage on CT (OR = 3.67, 95% CI = 1.46-9.24, p = 0.006) and 6-hour S100B concentration (OR = 2.22, 95% CI = 1.15-4.28, p = 0.017) were independently significant predictors of the outcome. Conclusions: Outcome prediction using baseline characteristics (post-traumatic headache and seizure), CT and laboratory findings (6-hour S100B) were valuable factors for identification of the individual MTBI patient at risk for developing PCS 1 month after the injury.	[Heidari, Kamran] Shahid Beheshti Univ Med Sci, Loghman Hakim Hosp, Dept Emergency Med, Tehran, Iran; [Asadollahi, Shadi] Shahid Beheshti Univ Med Sci, Sch Med, Tehran, Iran; [Jamshidian, Morteza; Abrishamchi, Shohreh Nasiri; Nouroozi, Mahdi] Shahid Beheshti Univ Med Sci, Imam Hossein Hosp, Dept Emergency Med, Tehran, Iran	Asadollahi, S (corresponding author), Shahid Beheshti Univ Med Sci, Sch Med, Daneshju Blv,Chamran Hwy, Tehran, Iran.	asadollahi.shadi@yahoo.com			Sina Trauma; Sina Trauma and Surgery Research Center, Tehran University of Medical Sciences, Tehran (Iran)Tehran University of Medical Sciences	The authors thank the people who took part in this study. The study was financially supported by a grant from Sina Trauma and Surgery Research Center, Tehran University of Medical Sciences, Tehran (Iran).	*AM PSYCH ASS, 1994, DIAGN STAT MAN MENT, P704; [Anonymous], 1999, JAMA, V282, P974; Biberthaler P, 2006, SHOCK, V25, P446, DOI 10.1097/01.shk.0000209534.61058.35; Biberthaler P, 2002, EUR J MED RES, V7, P164; Biberthaler P, 2001, WORLD J SURG, V25, P93, DOI 10.1007/s002680020370; BORCZUK P, 1995, ANN EMERG MED, V25, P731, DOI 10.1016/S0196-0644(95)70199-0; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x; Egea-Guerrero JJ, 2012, BRAIN INJURY, V26, P76, DOI 10.3109/02699052.2011.635360; Fleminger S, 2005, BRIT MED J, V331, P1419, DOI 10.1136/bmj.331.7530.1419; HARDEMARK HG, 1989, J NEUROSURG, V71, P727, DOI 10.3171/jns.1989.71.5.0727; Heizmann CW, 2007, FRONTIERS BIOSCIENCE, V7, P1356; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; Ingebrigtsen T, 1997, J CLIN NEUROSCI, V4, P29, DOI 10.1016/S0967-5868(97)90007-2; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; KRAUS JF, 1996, NEUROTRAUMA, P13; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; Meerhoff S R, 2000, Ned Tijdschr Geneeskd, V144, P1915; MURRAY LS, 1993, LANCET, V341, P1487, DOI 10.1016/0140-6736(93)90631-P; Perel P, 2007, J EVAL CLIN PRACT, V13, P464, DOI 10.1111/j.1365-2753.2006.00713.x; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; Savola O, 2005, EUROPEAN J NEUROLOGY, V10, P175; Sharma R, 2012, CURR NEUROL NEUROSCI, V12, P560, DOI 10.1007/s11910-012-0301-8; SKOGSEID IM, 1992, ACTA NEUROCHIR, V115, P106, DOI 10.1007/BF01406367; Smits M, 2005, JAMA-J AM MED ASSOC, V294, P1519, DOI 10.1001/jama.294.12.1519; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Stranjalis G, 2004, J NEUROTRAUM, V21, P1070, DOI 10.1089/0897715041651088; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Townend WJ, 2002, J NEUROL NEUROSUR PS, V73, P542, DOI 10.1136/jnnp.73.5.542; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Waterloo K, 1997, ACTA NEUROCHIR, V139, P26, DOI 10.1007/BF01850864; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026; Zongo D, 2012, ANN EMERG MED, V59, P209, DOI 10.1016/j.annemergmed.2011.07.027	40	34	34	1	17	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2015	29	1					33	40		10.3109/02699052.2014.948068			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AW1WC	WOS:000346078000005	25207823				2021-06-18	
J	Khan, M; Dhammu, TS; Matsuda, F; Baarine, M; Dhindsa, TS; Singh, I; Singh, AK				Khan, Mushfiquddin; Dhammu, Tajinder S.; Matsuda, Fumiyo; Baarine, Mauhammad; Dhindsa, Tejbir Singh; Singh, Inderjit; Singh, Avtar K.			Promoting endothelial function by S-nitrosoglutathione through the HIF-1 alpha/VEGF pathway stimulates neurorepair and functional recovery following experimental stroke in rats	DRUG DESIGN DEVELOPMENT AND THERAPY			English	Article						GSNO; IR; HIF-1 alpha; VEGF; motor function; subtle behavior; neuroprotection; neurorepair; angiogenesis; S-nitrosylation; stroke	TRAUMATIC BRAIN-INJURY; INDUCIBLE FACTOR-I; NITRIC-OXIDE DONORS; CEREBRAL-ISCHEMIA; LIQUID-CHROMATOGRAPHY; COGNITIVE IMPAIRMENT; NEUROVASCULAR UNIT; PROTECTS BRAIN; CELL MIGRATION; HEART-DISEASE	Background: For stroke patients, stimulating neurorepair mechanisms is necessary to reduce morbidity and disability. Our previous studies on brain and spinal cord trauma show that exogenous treatment with the S-nitrosylating agent S-nitrosoglutathione (GSNO) - a nitric oxide and glutathione metabolite of the human body - stimulates neurorepair and aids functional recovery. Using a rat model of cerebral ischemia and reperfusion (IR) in this study, we tested the hypothesis that GSNO invokes the neurorepair process and improves neurobehavioral functions through the angiogenic HIF-1 alpha/VEGF pathway. Methods: Stroke was induced by middle cerebral artery occlusion for 60 minutes followed by reperfusion in adult male rats. The injured animals were treated with saline (IR group, n=7), GSNO (0.25 mg/kg, GSNO group, n=7), and GSNO plus the HIF-1 alpha inhibitor 2-methoxyestradiol (2-ME) (0.25 mg/kg GSNO + 5.0 mg/kg 2-ME, GSNO + 2-ME group, n=7). The groups were studied for either 7 or 14 days to determine neurorepair mediators and functional recovery. Brain capillary endothelial cells were used to show that GSNO promotes angiogenesis and that GSNO-mediated induction of VEGF and the stimulation of angiogenesis are dependent on HIF-1 alpha activity. Results: IR injury increased the expression of neurorepair mediators HIF-1 alpha, VEGF, and PECAM-1 and vessel markers to a limited degree that correlate well with significantly compromised neurobehavioral functions compared with sham animals. GSNO treatment of IR not only remarkably enhanced further the expression of HIF-1 alpha, VEGF, and PECAM-1 but also improved functioning compared with IR. The GSNO group also had a higher degree of vessel density than the IR group. Increased expression of VEGF and the degree of tube formation (angiogenesis) by GSNO were reduced after the inhibition of HIF-1 alpha by 2-ME in an endothelial cell culture model. 2-ME treatment of the GSNO group also blocked not only GSNO's effect of reduced infarct volume, decreased neuronal loss, and enhanced expression of PECAM-1 (P<0.001), but also its improvement of motor and neurological functions (P<0.001). Conclusion: GSNO stimulates the process of neurorepair, promotes angiogenesis, and aids functional recovery through the HIF-1 alpha-dependent pathway, showing therapeutic and translational promise for stroke.	[Khan, Mushfiquddin; Dhammu, Tajinder S.; Matsuda, Fumiyo; Dhindsa, Tejbir Singh; Singh, Inderjit] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA; [Matsuda, Fumiyo] Kagoshima Univ, Sch Hlth Sci, Kagoshima 890, Japan; [Baarine, Mauhammad; Singh, Avtar K.] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA; [Singh, Avtar K.] Ralph H Johnson VA Med Ctr, Charleston, SC USA	Singh, AK (corresponding author), Med Univ S Carolina, Dept Pathol & Lab Med, 513 Childrens Res Inst,173 Ashley Ave, Charleston, SC 29425 USA.	khanm@musc.edu; singha@musc.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS-72511]; VA merit awardUS Department of Veterans Affairs [BX001062]; NIH from the Extramural Research Facilities Program of the National Center for Research ResourcesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [C06 RR018823, C06 RR015455]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [C06RR018823, C06RR015455] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS072511] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01BX001062] Funding Source: NIH RePORTER	This work was supported by grants from NIH (NS-72511) and VA merit award (BX001062). This work was also supported by the NIH, Grants C06 RR018823 and No C06 RR015455 from the Extramural Research Facilities Program of the National Center for Research Resources. We thank Ms Joyce Bryan and Ms Terry Hope for their technical help and secretarial assistance. We are grateful to Dr Harutoshi Sakakima and Dr Yoshihiro Yoshida for their valuable input. We also acknowledge Dr Tom Smith and Dr Lisa Kerr from the MUSC Writing Center for their valuable editing of the manuscript.	Aggarwal A, J NEUROCHEM; Bauer AT, 2010, J CEREBR BLOOD F MET, V30, P837, DOI 10.1038/jcbfm.2009.248; BORLONGAN CV, 1995, J NEUROSCI, V15, P5372; Bove PF, 2008, J BIOL CHEM, V283, P17919, DOI 10.1074/jbc.M709914200; Bryan NS, 2004, P NATL ACAD SCI USA, V101, P4308, DOI 10.1073/pnas.0306706101; Carver DJ, 2007, AM J RESP CELL MOL, V37, P255, DOI 10.1165/rcmb.2006-0289SM; Chen JL, 2007, ANN NEUROL, V62, P49, DOI 10.1002/ana.21160; Chen JL, 2003, ANN NEUROL, V53, P743, DOI 10.1002/ana.10555; Chen QM, 2013, J APPL PHYSIOL, V114, P752, DOI 10.1152/japplphysiol.01302.2012; Chou PCT, 2011, J MAGN RESON IMAGING, V33, P1301, DOI 10.1002/jmri.22574; Cramer SC, 2008, ANN NEUROL, V63, P549, DOI 10.1002/ana.21412; Cramer SC, 2008, ANN NEUROL, V63, P272, DOI 10.1002/ana.21393; Harten SK, 2010, ANTIOXID REDOX SIGN, V12, P459, DOI 10.1089/ars.2009.2870; He P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088143; Heiss C, 2006, J AM COLL CARDIOL, V47, P573, DOI 10.1016/j.jacc.2005.06.089; Hess DT, 2012, J BIOL CHEM, V287, P4411, DOI 10.1074/jbc.R111.285742; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jatana M, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-12; Ju TC, 2005, FREE RADICAL BIO MED, V38, P938, DOI 10.1016/j.freeradbiomed.2004.12.019; Kasivisvanathan V, 2011, CURR VASC PHARMACOL, V9, P333, DOI 10.2174/157016111795495602; Kawasaki K, 2003, MOL CELL BIOL, V23, P5726, DOI 10.1128/MCB.23.16.5726-5737.2003; Ke QD, 2006, MOL PHARMACOL, V70, P1469, DOI 10.1124/mol.106.027029; Ke XJ, 2013, J HUAZHONG U SCI-MED, V33, P433, DOI 10.1007/s11596-013-1137-4; Khan M, 2005, J CEREBR BLOOD F MET, V25, P177, DOI 10.1038/sj.jcbfm.9600012; Khan M, 2006, NITRIC OXIDE-BIOL CH, V15, P114, DOI 10.1016/j.niox.2006.01.008; Khan M, 2012, J NEUROCHEM, V123, P86, DOI 10.1111/j.1471-4159.2012.07947.x; Khan M, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-78; Khan M, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-32; Kimura H, 2002, BIOCHEM BIOPH RES CO, V296, P976, DOI 10.1016/S0006-291X(02)02029-6; Kluge I, 1997, J NEUROCHEM, V69, P2599; KONOREV EA, 1995, J PHARMACOL EXP THER, V274, P200; Lee CHZ, 2007, STROKE, V38, P2563, DOI 10.1161/STROKEAHA.106.481515; Lee CZ, 2009, STROKE, V40, P2879, DOI 10.1161/STROKEAHA.109.552059; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Lima B, 2009, P NATL ACAD SCI USA, V106, P6297, DOI 10.1073/pnas.0901043106; Liu DH, 2013, NEUROSCIENCE, V229, P36, DOI 10.1016/j.neuroscience.2012.10.055; Lok J, 2007, NEUROCHEM RES, V32, P2032, DOI 10.1007/s11064-007-9342-9; Mahmood A, 2008, J NEUROTRAUM, V25, P1441, DOI 10.1089/neu.2007.0495; Maki T, 2013, CNS NEUROL DISORD-DR, V12, P302, DOI 10.2174/1871527311312030004; Matsuda F, 2011, ACTA PHYSIOL, V201, P275, DOI [10.1111/j.1748-1716.2010.02174.x, 10.1111/j.1748-1708.2010.02174.x]; Matsumoto A, 2011, NITRIC OXIDE-BIOL CH, V25, P102, DOI 10.1016/j.niox.2011.02.006; Metzen E, 2003, MOL BIOL CELL, V14, P3470, DOI 10.1091/mbc.E02-12-0791; MONTESANO R, 1990, CELL, V62, P435, DOI 10.1016/0092-8674(90)90009-4; Monville C, 2006, J NEUROSCI METH, V158, P219, DOI 10.1016/j.jneumeth.2006.06.001; Mooberry SL, 2003, DRUG RESIST UPDATE, V6, P355, DOI 10.1016/j.drup.2003.10.001; Moskowitz MA, 2010, NEURON, V67, P181, DOI 10.1016/j.neuron.2010.07.002; Mozaffarian D, 2015, CIRCULATION, V131, pE29, DOI [10.1161/01.cir.0000441139.02102.80, 10.1161/CIR.0000000000000152, 10.1161/CIR.0b013e31828124ad]; Palmer LA, 2000, MOL PHARMACOL, V58, P1197; Pluta RM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014504; Prasad R, 2007, GLIA, V55, P65, DOI 10.1002/glia.20436; RADOMSKI MW, 1992, BRIT J PHARMACOL, V107, P745, DOI 10.1111/j.1476-5381.1992.tb14517.x; Rashid Parveen A, 2003, J Stroke Cerebrovasc Dis, V12, P82, DOI 10.1053/jscd.2003.9; Rassaf T, 2006, EUR HEART J, V27, P1699, DOI 10.1093/eurheartj/ehl096; Rauhala P, 1996, SYNAPSE, V23, P58, DOI 10.1002/(SICI)1098-2396(199605)23:1<58::AID-SYN7>3.0.CO;2-G; Roberts BW, 2013, SHOCK, V39, P229, DOI 10.1097/SHK.0b013e31827f565b; Rosamond W, 2008, CIRCULATION, V117, pE25, DOI 10.1161/CIRCULATIONAHA.107.187998; Sakakima H, 2012, RESTOR NEUROL NEUROS, V30, P383, DOI 10.3233/RNN-2012-110209; Savidge TC, 2007, GASTROENTEROLOGY, V132, P1344, DOI 10.1053/j.gastro.2007.01.051; Schonhoff CM, 2006, P NATL ACAD SCI USA, V103, P2404, DOI 10.1073/pnas.0507243103; Singh SP, 1996, P NATL ACAD SCI USA, V93, P14428, DOI 10.1073/pnas.93.25.14428; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Teng H, 2008, J CEREBR BLOOD F MET, V28, P764, DOI 10.1038/sj.jcbfm.9600573; Terpolilli NA, 2012, J CEREBR BLOOD F MET, V32, P1332, DOI 10.1038/jcbfm.2012.12; Tsikas D, 1999, ANAL BIOCHEM, V273, P32, DOI 10.1006/abio.1999.4209; Valable S, 2005, J CEREBR BLOOD F MET, V25, P1491, DOI 10.1038/sj.jcbfm.9600148; Wang ZF, 2012, STROKE, V43, P2430, DOI 10.1161/STROKEAHA.112.652545; Wei L, 2001, STROKE, V32, P2179, DOI 10.1161/hs0901.094282; Wellman TL, 2003, FASEB J, V17, P379, DOI 10.1096/fj.03-0143fje; Won JS, 2013, J ALZHEIMERS DIS, V34, P621, DOI 10.3233/JAD-121786; Yasinska IM, 2003, FEBS LETT, V549, P105, DOI 10.1016/S0014-5793(03)00807-X; Yin XH, 2013, NEUROSCIENCE, V248, P290, DOI 10.1016/j.neuroscience.2013.06.012; Zhang RL, 2013, EXPERT OPIN INV DRUG, V22, P843, DOI 10.1517/13543784.2013.793672; Zhang ZY, 2014, FREE RADICAL BIO MED, V68, P8, DOI 10.1016/j.freeradbiomed.2013.11.007; Zhou DC, 2008, NEUROL RES, V30, P268, DOI 10.1179/016164107X229920; Zhu YJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093334	76	34	34	0	10	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1177-8881			DRUG DES DEV THER	Drug Des. Dev. Ther.		2015	9						2233	2247		10.2147/DDDT.S77115			15	Chemistry, Medicinal; Pharmacology & Pharmacy	Pharmacology & Pharmacy	CG1SN	WOS:000353054400001	25945035	DOAJ Gold, Green Published			2021-06-18	
J	Olabarrieta-Landa, L; Rivera, D; Galarza-del-Angel, J; Garza, MT; Saracho, CP; Rodriguez, W; Chavez-Oliveros, M; Rabago, B; Leibach, G; Schebela, S; Martinez, C; Luna, M; Longoni, M; Ocampo-Barba, N; Rodriguez, G; Aliaga, A; Esenarro, L; de la Cadena, CG; Perrin, PB; Arango-Lasprilla, JC				Olabarrieta-Landa, L.; Rivera, D.; Galarza-del-Angel, J.; Garza, M. T.; Saracho, C. P.; Rodriguez, W.; Chavez-Oliveros, M.; Rabago, B.; Leibach, G.; Schebela, S.; Martinez, C.; Luna, M.; Longoni, M.; Ocampo-Barba, N.; Rodriguez, G.; Aliaga, A.; Esenarro, L.; Garcia de la Cadena, C.; Perrin, P. B.; Arango-Lasprilla, J. C.			Verbal Fluency Tests: Normative data for the Latin American Spanish speaking adult population	NEUROREHABILITATION			English	Article						Normative data; semantic verbal fluency test; phonological verbal fluency test; Latin America; executive functions	TRAUMATIC BRAIN-INJURY; WORD-ASSOCIATION TEST; CATEGORY FLUENCY; NEUROPSYCHOLOGICAL TESTS; COGNITIVE IMPAIRMENT; MULTIPLE-SCLEROSIS; NORMS; AGE; EDUCATION; PERFORMANCE	OBJECTIVE: To generate normative data for theVerbal Fluency Tests across 11 countries in Latin America, with country-specific adjustments for gender, age, and education, where appropriate. METHOD: The sample consisted of 3,977 healthy adults who were recruited from Argentina, Bolivia, Chile, Cuba, El Salvador, Guatemala, Honduras, Mexico, Paraguay, Peru, and, Puerto Rico. Each subject was administered the Verbal Fluency Test as part of a larger neuropsychological battery. A standardized five-step statistical procedure was used to generate the norms. RESULTS: The final multiple linear regression models for the letter F explained 8-30% of the variance, 7-32% for letter A, 8-32% for the letter S, and 16-43% for the animal category in Verbal Fluency Test scores. Although t-tests showed significant differences between men and women on the Verbal Fluency Test, they did not have an effect size larger than 0.3. As a result, gender-adjusted norms were not generated. CONCLUSIONS: This is the first normative multicenter study conducted in Latin America aiming to create norms for the Verbal Fluency Test; this study will have important outcomes for the future of neuropsychology in the region.	[Olabarrieta-Landa, L.; Rivera, D.; Arango-Lasprilla, J. C.] Univ Deusto, Fac Psychol & Educ, Bilbao, Spain; [Galarza-del-Angel, J.] Univ Autonoma Baja California, Mexicali 21100, Baja California, Mexico; [Garza, M. T.] Univ Autonoma Nuevo Leon, Fac Psicol, Monterrey, Mexico; [Saracho, C. P.] CETYS Univ, Mexicali, Baja California, Mexico; [Rodriguez, W.] Ponce Hlth Sci Univ, Ponce, Puerto Rico, Spain; [Chavez-Oliveros, M.] Inst Nacl Neurol & Neurocirugia MVS, Mexico City, DF, Mexico; [Rabago, B.] Inst Vocac Enrique Diaz Leon, Guadalajara, Mexico; [Leibach, G.; Perrin, P. B.] Virginia Commonwealth Univ, Dept Psychol, Richmond, VA 23284 USA; [Schebela, S.] Inst Prevenc Social, Asuncion, Paraguay; [Martinez, C.] Univ Nacl Autonoma Honduras, Dept Med Rehabilitac, Tegucigalpa, Honduras; [Luna, M.] Univ Dr Jose Matias Delgado, San Salvador, El Salvador; [Longoni, M.] Clin Rehabilitac Las Araucarias, Buenos Aires, DF, Argentina; [Ocampo-Barba, N.] Fdn Horizontes, Santa Cruz, Bolivia; [Rodriguez, G.] Univ Camaguey Ignacio Agramonte Loynaz, Camaguey, Cuba; [Aliaga, A.] Minist Justicia, Serv Med Legal, Santiago, Chile; [Esenarro, L.] Inst Neuropsicol & Demencias, Lima, Peru; [Garcia de la Cadena, C.] Univ Valle Guatemala, Dept Psicol, Guatemala City, Guatemala; [Arango-Lasprilla, J. C.] Ikerbasque, Basque Fdn Sci, E-48011 Bilbao, Spain	Arango-Lasprilla, JC (corresponding author), Univ Deusto, Basque Fdn Sci, Ikerbasque, Dept Psychol, Bilbao, Spain.	jcarango@deusto.es	Landa, Laiene Olabarrieta/V-6207-2017; Rivera, Diego/U-8872-2017; Rabago, Brenda/AAF-6231-2021; Oliveros, Mireya Chavez -/AAU-3898-2020	Landa, Laiene Olabarrieta/0000-0002-8305-8720; Rivera, Diego/0000-0001-7477-1893; Oliveros, Mireya Chavez -/0000-0002-1064-2096; Galarza-del-Angel, Javier/0000-0001-5865-5198; Esenarro, Loida/0000-0002-9978-0072			Acevedo A, 2000, J INT NEUROPSYCH SOC, V6, P760, DOI 10.1017/S1355617700677032; Anderson VA, 2001, DEV NEUROPSYCHOL, V20, P385, DOI 10.1207/S15326942DN2001_5; Anhoque CF, 2013, ARQ NEURO-PSIQUIAT, V71, P74, DOI 10.1590/S0004-282X2013005000004; Baldo JV, 1998, NEUROPSYCHOLOGY, V12, P259, DOI 10.1037/0894-4105.12.2.259; Barr WB, 2003, ARCH CLIN NEUROPSYCH, V18, P91, DOI 10.1016/S0887-6177(01)00185-8; Benton A, 1989, CLIN NEUROPSYCHOL, V3, P375, DOI DOI 10.1080/13854048908401486; Brissart H, 2013, NEUROCASE, V19, P553, DOI 10.1080/13554794.2012.701644; Cabeza R, 2000, J COGNITIVE NEUROSCI, V12, P1, DOI 10.1162/08989290051137585; Costafreda SG, 2011, BMC PSYCHIATRY, V11, DOI 10.1186/1471-244X-11-18; da Silva CG, 2004, J CLIN EXP NEUROPSYC, V26, P266, DOI 10.1076/jcen.26.2.266.28089; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Diaz-Asper CM, 2004, J INT NEUROPSYCH SOC, V10, P82; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gladsjo JA, 1999, ASSESSMENT, V6, P147, DOI 10.1177/107319119900600204; Guardia-Olmos J, 2015, NEUROREHABILITATION, V37, P493, DOI 10.3233/NRE-151277; HALPERIN JM, 1989, J CLIN EXP NEUROPSYC, V11, P518, DOI 10.1080/01688638908400910; Heaton RK, 2004, REVISED COMPREHENSIV; HELLER RB, 1993, PSYCHOL AGING, V8, P443, DOI 10.1037/0882-7974.8.3.443; Henry JD, 2004, NEUROPSYCHOLOGY, V18, P621, DOI 10.1037/0894-4105.18.4.621; Henry JD, 2004, J INT NEUROPSYCH SOC, V10, P608, DOI 10.1017/S1355617704104141; Henry Julie D, 2005, Cogn Neuropsychiatry, V10, P1, DOI 10.1080/13546800344000309; Indefrey P., 2000, NEW COGNITIVE NEUROS, P845; Ivnik RJ, 1996, CLIN NEUROPSYCHOL, V10, P262, DOI 10.1080/13854049608406689; Moreno-Martinez FJ, 2010, APHASIOLOGY, V24, P1389, DOI 10.1080/02687030903515370; Johnson-Selfridge M, 2001, SCHIZOPHRENIA BULL, V27, P305, DOI 10.1093/oxfordjournals.schbul.a006876; Khalil MS, 2010, J CLIN EXP NEUROPSYC, V32, P1028, DOI 10.1080/13803391003672305; Kosmidis MH, 2004, J INT NEUROPSYCH SOC, V10, P164, DOI 10.1017/S1355617704102014; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Loonstra A S, 2001, Appl Neuropsychol, V8, P161, DOI 10.1207/S15324826AN0803_5; Lucas JA, 1998, J CLIN EXP NEUROPSYC, V20, P194, DOI 10.1076/jcen.20.2.194.1173; MAHONEY F I, 1965, Md State Med J, V14, P61; March EG, 2006, J CLIN EXP NEUROPSYC, V28, P549, DOI 10.1080/13803390590949502; McGraw P, 2001, NEUROIMAG CLIN N AM, V11, P343; Mitrushina M., 2005, HDB NORMATIVE DATA N; PASQUIER F, 1995, J NEUROL NEUROSUR PS, V58, P81, DOI 10.1136/jnnp.58.1.81; Price SE, 2012, NEUROPSYCHOLOGY, V26, P490, DOI 10.1037/a0028567; Randolph C., 1993, NEUROPSYCHOLOGY, V7, P82, DOI [10.1037/0894-4105.7.1.82, DOI 10.1037/0894-4105.7.1.82]; Raskin SA, 1996, NEUROPSYCHOLOGY, V10, P416, DOI 10.1037/0894-4105.10.3.416; Ravdin LD, 2003, CLIN NEUROPSYCHOL, V17, P195, DOI 10.1076/clin.17.2.195.16500; Gouveia PAR, 2007, BRAIN COGNITION, V63, P240, DOI 10.1016/j.bandc.2006.09.001; Ruff RM, 1996, ARCH CLIN NEUROPSYCH, V11, P329, DOI 10.1016/0887-6177(95)00033-X; Sauzeon H, 2004, BRAIN LANG, V89, P192, DOI 10.1016/S0093-934X(03)00367-5; Steinberg BA, 2005, CLIN NEUROPSYCHOL, V19, P329, DOI 10.1080/13854040590945210; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Stricks L, 1998, J INT NEUROPSYCH SOC, V4, P311, DOI 10.1017/S1355617798003117; Tallberg IM, 2008, SCAND J PSYCHOL, V49, P479, DOI 10.1111/j.1467-9450.2008.00653.x; Till C, 2013, NEUROPSYCHOLOGY, V27, P210, DOI 10.1037/a0031665; Ting SKS, 2013, CLIN NEUROL NEUROSUR, V115, P1049, DOI 10.1016/j.clineuro.2012.10.030; Tombaugh TN, 1999, ARCH CLIN NEUROPSYCH, V14, P167, DOI 10.1016/S0887-6177(97)00095-4; Troyer AK, 2000, J CLIN EXP NEUROPSYC, V22, P370, DOI 10.1076/1380-3395(200006)22:3;1-V;FT370; Van Breukelen GJP, 2005, PSYCHOL ASSESSMENT, V17, P336, DOI 10.1037/1040-3590.17.3.336; Van der Elst W, 2006, J INT NEUROPSYCH SOC, V12, P80, DOI 10.1017/S1355617706060115; Van Der Elst W, 2007, PSYCHOL MED, V37, P1335, DOI 10.1017/S0033291707000360; Weber N, 2012, J NEUROL NEUROSUR PS, V83, pA36, DOI 10.1136/jnnp-2012-303524.114; Wysokinski A, 2010, ARCH MED SCI, V6, P438, DOI 10.5114/aoms.2010.14268	55	34	37	0	20	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2015	37	4					515	561		10.3233/NRE-151279			47	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	DA0XY	WOS:000367522100004	26639930	Bronze			2021-06-18	
J	Billeter, AT; Hellmann, J; Roberts, H; Druen, D; Gardner, SA; Sarojini, H; Galandiuk, S; Chien, SF; Bhatnagar, A; Spite, M; Polk, HC				Billeter, Adrian T.; Hellmann, Jason; Roberts, Henry; Druen, Devin; Gardner, Sarah A.; Sarojini, Harshini; Galandiuk, Susan; Chien, Sufan; Bhatnagar, Aruni; Spite, Matthew; Polk, Hiram C., Jr.			MicroRNA-155 potentiates the inflammatory response in hypothermia by suppressing IL-10 production	FASEB JOURNAL			English	Article						sepsis; peritonitis; cold exposure	RANDOMIZED CLINICAL-TRIAL; TRAUMATIC BRAIN-INJURY; NF-KAPPA-B; THERAPEUTIC HYPOTHERMIA; INTRAOPERATIVE HYPOTHERMIA; PERIOPERATIVE HYPOTHERMIA; DENDRITIC CELLS; WOUND-INFECTION; IN-VIVO; MIR-155	Therapeutic hypothermia is commonly used to improve neurological outcomes in patients after cardiac arrest. However, therapeutic hypothermia increases sepsis risk and unintentional hypothermia in surgical patients increases infectious complications. Nonetheless, the molecular mechanisms by which hypothermia dysregulates innate immunity are incompletely understood. We found that exposure of human monocytes to cold (32 degrees C) potentiated LPS-induced production of TNF and IL-6, while blunting IL-10 production. This dysregulation was associated with increased expression of microRNA-155 (miR-155), which potentiates Toll-like receptor (TLR) signaling by negatively regulating Ship1 and Socs1. Indeed, Ship1 and Socs1 were suppressed at 32 degrees C and miR-155 antagomirs increased Ship1 and Socs1 and reversed the alterations in cytokine production in cold-exposed monocytes. In contrast, miR-155 mimics phenocopied the effects of cold exposure, reducing Ship1 and Socs1 and altering TNF and IL-10 production. In a murine model of LPS-induced peritonitis, cold exposure potentiated hypothermia and decreased survival (10 vs. 50%; P < 0.05), effects that were associated with increased miR-155, suppression of Ship1 and Socs1, and alterations in TNF and IL-10. Importantly, miR-155-deficiency reduced hypothermia and improved survival (78 vs. 32%, P < 0.05), which was associated with increased Ship1, Socs1, and IL-10. These results establish a causal role of miR-155 in the dysregulation of the inflammatory response to hypothermia.	[Billeter, Adrian T.; Roberts, Henry; Druen, Devin; Gardner, Sarah A.; Sarojini, Harshini; Galandiuk, Susan; Chien, Sufan; Polk, Hiram C., Jr.] Univ Louisville, Sch Med, Dept Surg, Price Inst Surg Res, Louisville, KY 40292 USA; [Hellmann, Jason; Bhatnagar, Aruni; Spite, Matthew] Univ Louisville, Sch Med, Diabet & Obes Ctr, Inst Mol Cardiol, Louisville, KY 40292 USA	Billeter, AT (corresponding author), Univ Louisville, Sch Med, Dept Surg, Price Inst Surg Res, Louisville, KY 40292 USA.	adrianbilleter@bluewin.ch; mspite@partners.org	Billeter, Adrian/O-2185-2019; Sarojini, Harshini/AAD-4870-2019; Hellmann, Jason/B-9360-2012	Sarojini, Harshini/0000-0002-3103-9712; Billeter, Adrian/0000-0001-8724-4793	Price Trust Fund; Joint Royal College of Surgeons of Edinburgh (RCSEd)/James and Emmeline Ferguson Research Fellowship Trust; U. S. National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HL-106173, GM-103492, HL-116186]; Joint RCSEd/James and Emmeline Ferguson Research Fellowship; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL106173, F32HL116186] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20GM103492] Funding Source: NIH RePORTER	The authors thank Donald E. Fry for insight, advice, and productive discussions and Dr. James McCracken for help with the FACS analysis of the peritoneal exudate cells. This work was funded by the Price Trust Fund, by the Joint Royal College of Surgeons of Edinburgh (RCSEd)/James and Emmeline Ferguson Research Fellowship Trust and by U. S. National Institutes of Health grants HL-106173 (to M. S.) and GM-103492 (to M. S. and A. B.). A. T. B. holds the Joint RCSEd/James and Emmeline Ferguson Research Fellowship and currently works at the Department of Surgery at the University of Heidelberg (Heidelberg, Germany). J.H. is the recipient of a National Research Service Award from the U. S. National Institutes of Health (grant HL-116186). The funding sources had no role in the production of the manuscript.	Ahmad FU, 2014, WORLD NEUROSURG, V82, P207, DOI 10.1016/j.wneu.2013.01.008; Ajuebor MN, 1999, J IMMUNOL, V162, P1685; AKRIOTIS V, 1985, J LEUKOCYTE BIOL, V37, P51; Ariel A, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00004; Arons MM, 1999, CRIT CARE MED, V27, P699, DOI 10.1097/00003246-199904000-00020; Arrich J, 2012, COCHRANE DB SYST REV, V4, P9; Bannenberg GL, 2005, J IMMUNOL, V174, P4345, DOI 10.4049/jimmunol.174.7.4345; Beilman GJ, 2009, ANN SURG, V249, P845, DOI 10.1097/SLA.0b013e3181a41f6f; Billeter AT, 2014, SURGERY, V156, P1245, DOI 10.1016/j.surg.2014.04.024; Billeter AT, 2012, SURGERY, V151, P1, DOI 10.1016/j.surg.2011.08.006; Ghosn EEB, 2010, P NATL ACAD SCI USA, V107, P2568, DOI 10.1073/pnas.0915000107; Brock M, 2014, EUR HEART J, V35, P3203, DOI 10.1093/eurheartj/ehs060; Bukur M, 2012, J SURG RES, V175, P24, DOI 10.1016/j.jss.2011.07.003; Care A, 2007, NAT MED, V13, P613, DOI 10.1038/nm1582; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Ceppi M, 2009, P NATL ACAD SCI USA, V106, P2735, DOI 10.1073/pnas.0811073106; Clark N, 2007, FASEB J, V21, P3747, DOI 10.1096/fj.06-7460com; Cremer TJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008508; Fairchild KD, 2005, AM J PHYSIOL-CELL PH, V289, pC1114, DOI 10.1152/ajpcell.00152.2005; Fairchild KD, 2004, AM J PHYSIOL-CELL PH, V287, pC422, DOI 10.1152/ajpcell.00507.2003; Fairchild KD, 2000, J INTERF CYTOK RES, V20, P1049, DOI 10.1089/107999000750053708; Fernandes ES, 2012, J IMMUNOL, V188, P5741, DOI 10.4049/jimmunol.1102147; Flores-Maldonado A, 2001, ARCH MED RES, V32, P227, DOI 10.1016/S0188-4409(01)00272-7; Frank SM, 1997, JAMA-J AM MED ASSOC, V277, P1127, DOI 10.1001/jama.277.14.1127; Fries M, 2009, J CRIT CARE, V24, P453, DOI 10.1016/j.jcrc.2008.10.012; Geurts M, 2014, CRIT CARE MED, V42, P231, DOI 10.1097/CCM.0b013e3182a276e8; Goldszmid RS, 2012, IMMUNITY, V36, P1047, DOI 10.1016/j.immuni.2012.03.026; Hammarfjord O, 2010, J LEUKOCYTE BIOL, V88, P747, DOI 10.1189/jlb.0310155; Hou J, 2009, J IMMUNOL, V183, P2150, DOI 10.4049/jimmunol.0900707; Inaba K, 2012, J TRAUMA ACUTE CARE, V73, P1478, DOI 10.1097/TA.0b013e3182781db3; Jenkins SJ, 2011, SCIENCE, V332, P1284, DOI 10.1126/science.1204351; Jiang SY, 2013, CRIT CARE, V17, DOI 10.1186/cc12559; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Kurowska-Stolarska M, 2011, P NATL ACAD SCI USA, V108, P11193, DOI 10.1073/pnas.1019536108; Kurz A, 1996, NEW ENGL J MED, V334, P1209, DOI 10.1056/NEJM199605093341901; Li RC, 2013, CIRC RES, V112, P601, DOI 10.1161/CIRCRESAHA.112.300806; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Matsui T, 2014, NEUROCRIT CARE, V20, P301, DOI 10.1007/s12028-013-9911-5; McCoy CE, 2010, J BIOL CHEM, V285, P20492, DOI 10.1074/jbc.M110.102111; Meybohm P, 2010, CRIT CARE, V14, DOI 10.1186/cc8879; Monk CE, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013669; Mourvillier B, 2013, JAMA-J AM MED ASSOC, V310, P2174, DOI 10.1001/jama.2013.280506; O'Connell RM, 2007, P NATL ACAD SCI USA, V104, P1604, DOI 10.1073/pnas.0610731104; O'Connell RM, 2009, P NATL ACAD SCI USA, V106, P7113, DOI 10.1073/pnas.0902636106; O'Neill LA, 2011, NAT REV IMMUNOL, V11, P163, DOI 10.1038/nri2957; Perbet S, 2011, AM J RESP CRIT CARE, V184, P1048, DOI 10.1164/rccm.201102-0331OC; Pu J, 2012, BIOCHEM BIOPH RES CO, V428, P210, DOI 10.1016/j.bbrc.2012.09.126; Schif-Zuck S, 2011, EUR J IMMUNOL, V41, P366, DOI 10.1002/eji.201040801; Seamon MJ, 2012, ANN SURG, V255, P789, DOI 10.1097/SLA.0b013e31824b7e35; Sheedy FJ, 2010, NAT IMMUNOL, V11, P141, DOI 10.1038/ni.1828; Tian DH, 2013, ANN CARDIOTHORAC SUR, V2, P148, DOI 10.3978/j.issn.2225-319X.2013.03.13; Tili E, 2007, J IMMUNOL, V179, P5082, DOI 10.4049/jimmunol.179.8.5082; Trotta R, 2012, BLOOD, V119, P3478, DOI 10.1182/blood-2011-12-398099; Truettner JS, 2013, BRAIN RES, V1533, P122, DOI 10.1016/j.brainres.2013.08.011; Truettner JS, 2011, J CEREBR BLOOD F MET, V31, P1897, DOI 10.1038/jcbfm.2011.33; van Der Poll Tom, 1997, Clin Microbiol Infect, V3, P605, DOI 10.1111/j.1469-0691.1997.tb00465.x; Wang P, 2010, J IMMUNOL, V185, P6226, DOI 10.4049/jimmunol.1000491; Wenisch C, 1996, ANESTH ANALG, V82, P810, DOI 10.1097/00000539-199604000-00023; Xiao HY, 2005, CRIT CARE MED, V33, P161, DOI 10.1097/01.CCM.0000151049.19253.54; Zhu QY, 2010, J IMMUNOL, V185, P7435, DOI 10.4049/jimmunol.1000798	60	34	40	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2014	28	12					5322	5336		10.1096/fj.14-258335			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AU9EN	WOS:000345894500026	25231976	Green Published			2021-06-18	
J	Hofler, J; Unterberger, I; Dobesberger, J; Kuchukhidze, G; Walser, G; Trinka, E				Hoefler, Julia; Unterberger, Iris; Dobesberger, Judith; Kuchukhidze, Giorgi; Walser, Gerald; Trinka, Eugen			Seizure outcome in 175 patients with juvenile myoclonic epilepsy - A long-term observational study	EPILEPSY RESEARCH			English	Article						Juvenile myoclonic epilepsy; Seizure-freedom; Generalized epilepsy; Prognosis	PSYCHIATRIC COMORBIDITY; ANTIEPILEPTIC DRUGS; POLYCYSTIC OVARIES; VALPROATE; PROGNOSIS; PHOTOSENSITIVITY; POPULATION; RESISTANCE; DISORDERS; WOMEN	Introduction: Juvenile myoclonic epilepsy (JME) is a genetic generalized epilepsy syndrome. Under appropriate antiepileptic drugs (AED) up to 85% of patients become seizure-free, but many may have a relapse after AED withdrawal. Methods: We retrospectively studied 242 patients with JME at the Department of Neurology, Medical University Innsbruck, Austria (1975-2006). We analyzed age at seizure onset, age at last follow up, seizure types, photosensitivity, seizure outcome and neuroimaging findings; inclusion criterion was a medical treatment period of >2 years; exclusion criteria were traumatic or infectious brain injury before the onset of JME and/or gross structural pathology on neuroimaging. Results: We identified 175 patients (111 women) with a median age at seizure onset of 15 years, (range 3-46) and a median age at follow-up (FU) of 38 years (range 14-87; median FU 8 years, range 2-38). Fourteen percent showed (24/175) photosensitivity on routine EEG. Seizure outcome: 62% (109/175) were seizure-free of myoclonic seizures (MS), generalized tonic clonic seizures (GTCS) and absence seizures (AS) for >1 year, and 53% (94/175) for >2 years, including 16 patients (9%) without AEDs. Thirty-one percent (54/175) were seizure-free between 2and 5 years, 15% (26/175) between 6 and 10, and 8% (14/175) >10 years; 38% (66/175) were not seizure-free. Not seizure-free patients had more often MS, AS and GTCS within the first year of epilepsy than those who were seizure-free at last FU (11% vs. 3%, Chi(2) =4.679, df = 1, p = 0.043). Seizure-free patients had more often M GTCS as last seizure types in the year before becoming seizure-free (37% vs. 15%, p = 0.003), whereas in not seizure-free group MS only and GTCS only persisted. Conclusions: JME does not always need lifelong treatment, as a substantial minority of patients remain seizure-free without AEDs. AS, MS and GTCS at onset of the disease are indicators of poor long-term seizure control. (C) 2014 The Authors. Published by Elsevier B.V.	[Hoefler, Julia; Dobesberger, Judith; Kuchukhidze, Giorgi; Trinka, Eugen] Paracelsus Med Univ Salzburg, Dept Neurol, Christian Doppler Klin, Salzburg, Austria; [Hoefler, Julia; Unterberger, Iris; Dobesberger, Judith; Kuchukhidze, Giorgi; Walser, Gerald; Trinka, Eugen] Med Univ Innsbruck, Dept Neurol, A-6020 Innsbruck, Austria	Trinka, E (corresponding author), Paracelsus Med Univ, Univ Klin Neurol, Christian Doppler Klin, Ignaz Harrer Str 79, A-5020 Salzburg, Austria.	E.Trinka@salk.at		Trinka, Eugen/0000-0002-5950-2692; Kuchukhidze, Giorgi/0000-0001-6899-8506	UCBUCB Pharma SA; Biogen-IdecBiogen; Sanofi-AventisSanofi-Aventis; FWFAustrian Science Fund (FWF) [KLI12-B00]; Jubilaumsfond der Oster-reichischen Nationalbank [14201]; Red Bull; EisaiEisai Co Ltd; Ever Neuropharma; Biogen IdecBiogen; Medtronics; BialBial Group	E. Trinka has acted as a paid consultant to Eisai, Ever Neuropharma, Biogen Idec, Medtronics, Bial, and UCB. He has received research funding from UCB, Biogen-Idec, Sanofi-Aventis, FWF (KLI12-B00), Jubilaumsfond der Oster-reichischen Nationalbank (14201) and Red Bull. He has received speakers' honoraria from Bial, Eisai, GL Lannacher, Glaxo Smith Kline, Bohringer, Viropharma, Actavis and UCB.	[Anonymous], 1989, EPILEPSIA, V30, P389, DOI 10.1111/j.1528-1157.1989.tb05316.x; Appleton R, 2000, SEIZURE-EUR J EPILEP, V9, P108, DOI 10.1053/seiz.1999.0376; Baykan B, 2008, NEUROLOGY, V70, P2123, DOI 10.1212/01.wnl.0000313148.34629.1d; Camfield CS, 2009, NEUROLOGY, V73, P1041, DOI 10.1212/WNL.0b013e3181b9c86f; Canevini M P, 1992, Seizure, V1, P291, DOI 10.1016/1059-1311(92)90039-4; Chakravarty A, 2007, SEIZURE-EUR J EPILEP, V16, P134, DOI 10.1016/j.seizure.2006.10.012; de Araujo GM, 2008, EPILEPSY BEHAV, V13, P196, DOI 10.1016/j.yebeh.2008.01.008; Delgado-Escueta A. V., 1997, TREATMENT EPILEPSY P, P484; DELGADOESCUETA AV, 1984, NEUROLOGY, V34, P285, DOI 10.1212/WNL.34.3.285; DREIFUSS FE, 1989, EPILEPSIA, V30, pS1, DOI 10.1111/j.1528-1157.1989.tb05832.x; Geithner J, 2012, EPILEPSIA, V53, P1379, DOI 10.1111/j.1528-1167.2012.03526.x; Gelisse P, 2001, J NEUROL NEUROSUR PS, V70, P240, DOI 10.1136/jnnp.70.2.240; Gelisse P, 2007, EPILEPSIA, V48, P1032, DOI 10.1111/j.1528-1167.2007.01009_4.x; Genton P, 2001, EPILEPSIA, V42, P295, DOI 10.1046/j.1528-1157.2001.28899.x; GRUNEWALD RA, 1993, ARCH NEUROL-CHICAGO, V50, P594, DOI 10.1001/archneur.1993.00540060034013; Guaranha MSB, 2011, SEIZURE-EUR J EPILEP, V20, P42, DOI 10.1016/j.seizure.2010.10.004; Hirsch E, 2003, ACTA NEUROL SCAND, V108, P23, DOI 10.1034/j.1600-0404.108.s180.4.x; ISOJARVI JIT, 1993, NEW ENGL J MED, V329, P1383, DOI 10.1056/NEJM199311043291904; Jain S, 1997, ACTA NEUROL SCAND, V95, P263, DOI 10.1111/j.1600-0404.1997.tb00207.x; JANZ D, 1985, ACTA NEUROL SCAND, V72, P449; Janz D., 1969, DIE EPILEPSIEN; Janz D, 1957, DTSCH Z NERVENHEILK, V176, P346, DOI [DOI 10.1007/BF00242439, 10.1007/BF00242439]; Kasteleijn-Nolst Trenite D G, 1989, Acta Neurol Scand Suppl, V125, P3; Kleveland G, 1998, SEIZURE-EUR J EPILEP, V7, P31, DOI 10.1016/S1059-1311(98)90005-X; Labate A, 2007, EPILEPSY RES, V77, P17, DOI 10.1016/j.eplepsyres.2007.07.010; Luef G, 2002, J NEUROL, V249, P835, DOI 10.1007/S00415-002-0731-3; Luef GJ, 2004, ANN NEUROL, V55, P729, DOI 10.1002/ana.20074; Martinez-Juarez IE, 2006, BRAIN, V129, P1269, DOI 10.1093/brain/awl048; Meador Kimford J, 2008, Epilepsy Curr, V8, P90, DOI 10.1111/j.1535-7511.2008.00250.x; PANAYIOTOPOULOS CP, 1994, EPILEPSIA, V35, P285, DOI 10.1111/j.1528-1157.1994.tb02432.x; PENRY JK, 1989, EPILEPSIA, V30, pS19, DOI 10.1111/j.1528-1157.1989.tb05833.x; Perini GI, 1996, J NEUROL NEUROSUR PS, V61, P601, DOI 10.1136/jnnp.61.6.601; Rinnerthaler M, 2005, EPILEPSIA, V46, P320, DOI 10.1111/j.0013-9580.2005.36204.x; SCOLLOLAVIZZARI G, 1974, EUR NEUROL, V11, P1, DOI 10.1159/000114301; Senf P, 2013, NEUROLOGY, V81, P2128, DOI 10.1212/01.wnl.0000437303.36064.f8; SHINNAR S, 1994, ANN NEUROL, V35, P534, DOI 10.1002/ana.410350506; Teich M, 2004, EPILEPSIA, V45, P187, DOI 10.1111/j.0013-9580.2004.28302.x; Trenite DGAKN, 2013, EPILEPSY BEHAV, V28, pS25, DOI 10.1016/j.yebeh.2012.11.045; Trinka E, 2006, EPILEPSIA, V47, P2086, DOI 10.1111/j.1528-1167.2006.00828.x	39	34	34	0	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0920-1211	1872-6844		EPILEPSY RES	Epilepsy Res.	DEC	2014	108	10					1817	1824		10.1016/j.eplepsyres.2014.09.008			8	Clinical Neurology	Neurosciences & Neurology	AY3RP	WOS:000347500600016	25443450	Other Gold			2021-06-18	
J	Jeon, SB; Choi, HA; Badjatia, N; Schmidt, JM; Lantigua, H; Claassen, J; Connolly, ES; Mayer, SA; Lee, K				Jeon, Sang-Beom; Choi, H. Alex; Badjatia, Neeraj; Schmidt, J. Michael; Lantigua, Hector; Claassen, Jan; Connolly, E. Sander; Mayer, Stephan A.; Lee, Kiwon			Hyperoxia may be related to delayed cerebral ischemia and poor outcome after subarachnoid haemorrhage	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							TRAUMATIC BRAIN-INJURY; OXYGEN-THERAPY; OXIDATIVE STRESS; HEAD-INJURY; BLOOD-FLOW; VASOSPASM; STROKE; ASSOCIATION; REPERFUSION; MORTALITY	Objective To determine the association between exposure to hyperoxia and the risk of delayed cerebral ischaemia (DCI) after subarachnoid haemorrhage (SAH). Methods We analysed data from a single centre, prospective, observational cohort database. Patient inclusion criteria were age >= 18 years, aneurysmal SAH, endotracheal intubation with mechanical ventilation, and arterial partial pressure of oxygen (PaO2) measurements. Hyperoxia was defined as the highest quartile of an area under the curve of PaO2, until the development of DCI (PaO2 >= 173 mm Hg). Poor outcome was defined as modified Rankin Scale 4-6 at 3 months after SAH. Results Of 252 patients, there were no differences in baseline characteristics between the hyperoxia and control group. Ninety-seven (38.5%) patients developed DCI. The hyperoxia group had a higher incidence of DCI (p<0.001) and poor outcome (p=0.087). After adjusting for modified Fisher scale, rebleeding, global cerebral oedema, intracranial pressure crisis, pneumonia and sepsis, hyperoxia was independently associated with DCI (OR, 3.16; 95% CI 1.69 to 5.92; p<0.001). After adjusting for age, Hunt-Hess grade, aneurysm size, Acute Physiology and Chronic Health Evaluation II score, rebleeding, pneumonia and sepsis, hyperoxia was independently associated with poor outcome (OR, 2.30; 95% CI 1.03 to 5.12; p=0.042). Conclusions In SAH patients, exposure to hyperoxia was associated with DCI. Our findings suggest that exposure to excess oxygen after SAH may represent a modifiable factor for morbidity and mortality in this population.	[Jeon, Sang-Beom] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Neurol, Seoul, South Korea; [Jeon, Sang-Beom; Choi, H. Alex; Lee, Kiwon] Univ Texas Med Sch Houston, Dept Neurol, Houston, TX 77030 USA; [Jeon, Sang-Beom; Choi, H. Alex; Lee, Kiwon] Univ Texas Med Sch Houston, Dept Neurosurg, Houston, TX 77030 USA; [Jeon, Sang-Beom; Choi, H. Alex; Badjatia, Neeraj; Schmidt, J. Michael; Lantigua, Hector; Claassen, Jan; Mayer, Stephan A.; Lee, Kiwon] Columbia Univ Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA; [Badjatia, Neeraj] Univ Maryland, Sch Med, Dept Neurol, Baltimore, MD 21201 USA; [Connolly, E. Sander] Columbia Univ Coll Phys & Surg, Dept Neurosurg, New York, NY 10032 USA	Lee, K (corresponding author), Univ Texas Med Sch Houston, Dept Neurol, 6431 Fannin St,MSB 7-152, Houston, TX 77030 USA.	Kiwon.Lee@uth.tmc.edu	Claassen, Jan/AAA-5451-2020	Schmidt, J. Michael/0000-0001-8141-2944; Jeon, Sang-Beom/0000-0003-0735-5499			BALENTINE JD, 1966, NEW ENGL J MED, V275, P1038, DOI 10.1056/NEJM196611102751903; Barazzone C, 1996, J CLIN INVEST, V98, P2666, DOI 10.1172/JCI119089; Becker LB, 2004, CARDIOVASC RES, V61, P461, DOI 10.1016/j.cardiores.2003.10.025; Brenner M, 2012, ARCH SURG-CHICAGO, V147, P1042, DOI 10.1001/archsurg.2012.1560; Buonocore G, 2010, SEMIN FETAL NEONAT M, V15, P186, DOI 10.1016/j.siny.2010.04.003; Calzia E, 2010, CRIT CARE MED, V38, pS559, DOI 10.1097/CCM.0b013e3181f1fe70; Claassen J, 2002, STROKE, V33, P1225, DOI 10.1161/01.STR.0000015624.29071.1F; Claassen J, 2001, STROKE, V32, P2012, DOI 10.1161/hs0901.095677; Davis DP, 2009, J NEUROTRAUM, V26, P2217, DOI 10.1089/neu.2009.0940; de Graaff AE, 2011, INTENS CARE MED, V37, P46, DOI 10.1007/s00134-010-2025-z; Floyd TF, 2003, J APPL PHYSIOL, V95, P2453, DOI 10.1152/japplphysiol.00303.2003; Frontera JA, 2009, STROKE, V40, P1963, DOI 10.1161/STROKEAHA.108.544700; GRIFFITH DE, 1992, CHEST, V101, P392, DOI 10.1378/chest.101.2.392; Hazelton JL, 2010, J NEUROTRAUM, V27, P753, DOI 10.1089/neu.2009.1186; JACKSON RM, 1985, CHEST, V88, P900, DOI 10.1378/chest.88.6.900; KASSELL NF, 1982, NEUROSURGERY, V11, P337, DOI 10.1227/00006123-198209000-00001; Kilgannon JH, 2010, JAMA-J AM MED ASSOC, V303, P2165, DOI 10.1001/jama.2010.707; Ko SB, 2011, STROKE, V42, P3087, DOI 10.1161/STROKEAHA.111.623165; Leng LZ, 2011, ARCH NEUROL-CHICAGO, V68, P31, DOI 10.1001/archneurol.2010.226; Lord AS, 2012, NEUROLOGY, V78, P31, DOI 10.1212/WNL.0b013e31823ed0a4; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; Nakanishi H, 2009, BEHAV BRAIN RES, V201, P1, DOI 10.1016/j.bbr.2009.02.001; Pancioli AM, 2004, STROKE PATHOPHYSIOLO, P905; Quinlan GJ, 1997, AM J RESP CRIT CARE, V155, P479, DOI 10.1164/ajrccm.155.2.9032182; Robertson CL, 2009, EXP NEUROL, V218, P371, DOI 10.1016/j.expneurol.2009.04.030; Rousseau A, 2005, ACTA PHYSIOL SCAND, V183, P231, DOI 10.1111/j.1365-201X.2005.01405.x; Singhal AB, 2005, STROKE, V36, P797, DOI 10.1161/01.STR.0000158914.66827.2e; Singhal AB, 2007, STROKE, V38, P2851, DOI 10.1161/STROKEAHA.107.487280; Singhal AB, 2006, INT J STROKE, V1, P191, DOI 10.1111/j.1747-4949.2006.00058.x; Starke RM, 2013, CURR NEUROVASC RES, V10, P247, DOI 10.2174/15672026113109990003; Tolias CM, 2004, J NEUROSURG, V101, P435, DOI 10.3171/jns.2004.101.3.0435; Wartenberg KE, 2006, CRIT CARE MED, V34, P617, DOI 10.1097/01.CCM.0000201903.46435.35; Watson NA, 2000, EUR J ANAESTH, V17, P152, DOI 10.1046/j.1365-2346.2000.00640.x	33	34	38	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	DEC	2014	85	12					1301	1307		10.1136/jnnp-2013-307314			7	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	AT9XF	WOS:000345276400005	24860138	Bronze			2021-06-18	
J	Mychasiuk, R; Farran, A; Angoa-Perez, M; Briggs, D; Kuhn, D; Esser, MJ				Mychasiuk, Richelle; Farran, Allyson; Angoa-Perez, Mariana; Briggs, Denise; Kuhn, Donald; Esser, Michael J.			A Novel Model of Mild Traumatic Brain Injury for Juvenile Rats	JOVE-JOURNAL OF VISUALIZED EXPERIMENTS			English	Article						Neuroscience; Issue 94; Childhood; Concussion; Repetitive Brain Injury; Rodent; Translational Research		Despite growing evidence that childhood represents a major risk period for mild traumatic brain injury (mTBI) from sports-related concussions, motor vehicle accidents, and falls, a reliable animal model of mTBI had previously not been developed for this important aspect of development. The modified weight-drop technique employs a glancing impact to the head of a freely moving rodent transmitting acceleration, deceleration, and rotational forces upon the brain. When applied to juvenile rats, this modified weight-drop technique induced clinically relevant behavioural outcomes that were representative of post-concussion symptomology. The technique is a rapidly applied procedure with an extremely low mortality rate, rendering it ideal for high-throughput studies of therapeutics. In addition, because the procedure involves a mild injury to a closed head, it can easily be used for studies of repetitive brain injury. Owing to the simplistic nature of this technique, and the clinically relevant biomechanics of the injury pathophysiology, the modified weight-drop technique provides researchers with a reliable model of mTBI that can be used in a wide variety of behavioural, molecular, and genetic studies.	[Mychasiuk, Richelle; Farran, Allyson; Esser, Michael J.] Univ Calgary, Alberta Childrens Hosp, Res Inst, Calgary, AB T2N 1N4, Canada; [Angoa-Perez, Mariana; Briggs, Denise; Kuhn, Donald] Wayne State Univ, Sch Med, Dept Psychiat & Behav Neurosci, Detroit, MI 48202 USA; [Angoa-Perez, Mariana; Briggs, Denise; Kuhn, Donald] John D Dingell VA Med Ctr, Detroit, MI USA	Mychasiuk, R (corresponding author), Univ Calgary, Alberta Childrens Hosp, Res Inst, Calgary, AB T2N 1N4, Canada.	r.mychasiuk@uleth.ca		Briggs, Denise/0000-0002-4824-3947	Department of Pediatrics at the University of Calgary; Alberta Children's Hospital Foundation (ACHF); Alberta Children's Hospital Research Institute (ACHRI); ACHF; Veterans AffairsUS Department of Veterans Affairs [IK6RX002419] Funding Source: NIH RePORTER	The authors would like to thank Irene Ma, Rose Tobais, and Jong Rho for their technical assistance. Funding was provided to MJE by the Department of Pediatrics at the University of Calgary, the Alberta Children's Hospital Foundation (ACHF) and the Alberta Children's Hospital Research Institute (ACHRI). The Postdoctoral fellowship for RM was provided by ACHF.	Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA, P1; DeWitt DS, 2013, J NEUROTRAUM, V30, P688, DOI 10.1089/neu.2012.2349; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Mychasiuk R, 2014, BEHAV BRAIN RES, V259, P284, DOI 10.1016/j.bbr.2013.10.048; Mychasiuk R., 2014, J NEUROTRAUMA, V31; Schallert T, 2002, PHARM CEREBRAL ISCHE; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Zhang Z, 2010, METHODS MOL BIOL	10	34	36	0	7	JOURNAL OF VISUALIZED EXPERIMENTS	CAMBRIDGE	1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA	1940-087X			JOVE-J VIS EXP	J. Vis. Exp.	DEC	2014		94							e51820	10.3791/51820			7	Multidisciplinary Sciences	Science & Technology - Other Topics	CB1AE	WOS:000349358000007	25548960	Bronze, Green Published			2021-06-18	
J	Theadom, A; Starkey, NJ; Dowell, T; Hume, PA; Kahan, M; McPherson, K; Feigin, V				Theadom, Alice; Starkey, Nicola J.; Dowell, Tony; Hume, Patria A.; Kahan, Michael; McPherson, Kathryn; Feigin, Valery		BIONIC Res Grp	Sports-related brain injury in the general population: An epidemiological study	JOURNAL OF SCIENCE AND MEDICINE IN SPORT			English	Article						Brain injury; Incidence; Concussion; Epidemiology; Sport and recreation; Population-based	HEAD-INJURY; RECURRENT CONCUSSION; NEW-ZEALAND; SEVERITY; OUTCOMES; TRENDS; RISK	Objectives: To determine the incidence, nature and severity of all sports-related brain injuries in the general population. Design: Population-based epidemiological incidence study. Methods: Data on all traumatic brain injury events sustained during a sports-related activity were extracted from a dataset of all new traumatic brain injury cases (both fatal and non-fatal), identified over a one-year period in the Hamilton and Waikato districts of New Zealand. Prospective and retrospective case ascertainment methods from multiple sources were used. All age groups and levels of traumatic brain injury severity were included. Details of the registering injuries and recurrent injuries sustained over the subsequent year were obtained through medical/accident records and assessment interviews with participants. Results: Of 1369 incident traumatic brain injury cases, 291 were identified as being sustained during a sports-related activity (21% of all traumatic brain injuries) equating to an incidence rate of 170 per 100,000 of the general population. Recurrent injuries occurred more frequently in adults (11%) than children (5%). Of the sports-related injuries 46% were classified as mild with a high risk of complications. Injuries were most frequently sustained during rugby, cycling and equestrian activities. It was revealed that up to 19% of traumatic brain injuries were not recorded in medical notes. Conclusions: Given the high incidence of new and recurrent traumatic brain injury and the high risk of complications following injury, further sport specific injury prevention strategies are urgently needed to reduce the impact of traumatic brain injury and facilitate safer engagement in sports activities. The high levels of 'missed' traumatic brain injuries, highlights the importance in raising awareness of traumatic brain injury during sports-related activity in the general population. (C) 2014 Sports Medicine Australia. Published by Elsevier Ltd. All rights reserved.	[Theadom, Alice; Feigin, Valery] Auckland Univ Technol, Fac Hlth & Environm Sci, Natl Inst Stroke & Appl Neurosci, Auckland, New Zealand; [Starkey, Nicola J.] Univ Waikato, Sch Psychol, Hamilton, New Zealand; [Dowell, Tony] Univ Otago, Wellington Sch Med & Hlth Sci, Dunedin, New Zealand; [Hume, Patria A.] Auckland Univ Technol, Fac Hlth & Environm Studies, Sports Performance Res Inst New Zealand, Auckland, New Zealand; [Kahan, Michael] Waikato Occupat Serv Ltd, Hamilton, New Zealand; [McPherson, Kathryn] Auckland Univ Technol, Fac Hlth & Environm Studies, Person Centred Res Ctr, Auckland, New Zealand	Theadom, A (corresponding author), Auckland Univ Technol, Fac Hlth & Environm Sci, Natl Inst Stroke & Appl Neurosci, Auckland, New Zealand.	alice.theadom@aut.ac.nz	Starkey, Nicola/AAJ-3795-2020; Feigin, Valery/AAF-2313-2019; Hume, Patria/AAN-5514-2021	Starkey, Nicola/0000-0002-4370-8186; Hume, Patria/0000-0003-1847-8128; Ameratunga, Shanthi/0000-0001-8042-2251; Barber, P Alan/0000-0003-2469-9023; Te Ao, Braden/0000-0002-1050-200X; Theadom, Alice/0000-0003-0351-6216; Feigin, Valery L./0000-0002-6372-1740; McPherson, Kathryn/0000-0003-1240-8882; McPherson, Kath/0000-0003-0487-8497	Health Research Council of New ZealandHealth Research Council of New Zealand [HRC 09/063A]	The authors declare that there are no competing interests associated with the research contained within this manuscript. The BIONIC study was funded by the Health Research Council of New Zealand (HRC 09/063A).	Barker-Collo SL, 2009, NEUROEPIDEMIOLOGY, V32, P32, DOI 10.1159/000170090; Bazarian JJ, 2009, J HEAD TRAUMA REHAB, V24, P439, DOI 10.1097/HTR.0b013e3181c15600; Beck AJ, 2011, BR J SPORTS MED, V45; Burt CW, 2001, ANN EMERG MED, V37, P301, DOI 10.1067/mem.2001.111707; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Harris AW, 2012, J SCI MED SPORT, V15, P298, DOI 10.1016/j.jsams.2011.12.005; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; King D, 2010, NZJ SPORTS MED, V37, P56; Kolt GS, 2013, J SCI MED SPORT, V16, P87, DOI 10.1016/j.jsams.2013.01.003; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; McCrory P, 2013, PM&R, V5, P255, DOI 10.1016/j.pmrj.2013.02.012; Pakzad-Vaezi K, 2011, PAED CHILD HEALT-CAN, V16, P217, DOI 10.1093/pch/16.4.217; Penedo FJ, 2005, CURR OPIN PSYCHIATR, V18, P189, DOI 10.1097/00001504-200503000-00013; Ponsford J, 2004, BRAIN INJURY, V18, P603, DOI 10.1080/02699050310001646152; Safaz I, 2008, BRAIN INJURY, V22, P733, DOI 10.1080/02699050802304714; Sahler CS, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/659652; Selassie AW, 2013, ANN EPIDEMIOL, V23, P750, DOI 10.1016/j.annepidem.2013.07.022; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; Sport and Recreation New Zealand, 2009, SPORT RECR PART LEV; Sport New Zealand, 2012, SPORT RECR YOUNG NZ; Statistics New Zealand, 2006, NZ CENS 2006 STAT NZ; TEASDALE G, 1974, LANCET, V2, P81; Theadom A, 2012, NEUROEPIDEMIOLOGY, V38, P18, DOI 10.1159/000334746; VANMECHELEN W, 1992, SPORTS MED, V14, P82, DOI 10.2165/00007256-199214020-00002	30	34	34	1	28	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1440-2440	1878-1861		J SCI MED SPORT	J. Sci. Med. Sport	NOV	2014	17	6					591	596		10.1016/j.jsams.2014.02.001			6	Sport Sciences	Sport Sciences	AT3PA	WOS:000344845200006	24602688	Green Accepted			2021-06-18	
J	Jean, A; Nyein, MK; Zheng, JQ; Moore, DF; Joannopoulos, JD; Radovitzky, R				Jean, Aurelie; Nyein, Michelle K.; Zheng, James Q.; Moore, David F.; Joannopoulos, John D.; Radovitzky, Raul			An animal-to-human scaling law for blast-induced traumatic brain injury risk assessment	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						interspecies scaling; injury risk criteria; transfer function; TBI	VIRTUAL TEST FACILITY; DYNAMIC-RESPONSE; HEAD; BIOMECHANICS; SIMULATION; MODEL; EXPOSURE; SHOCK; RATS; IRAQ	Despite recent efforts to understand blast effects on the human brain, there are still no widely accepted injury criteria for humans. Recent animal studies have resulted in important advances in the understanding of brain injury due to intense dynamic loads. However, the applicability of animal brain injury results to humans remains uncertain. Here, we use advanced computational models to derive a scaling law relating blast wave intensity to the mechanical response of brain tissue across species. Detailed simulations of blast effects on the brain are conducted for different mammals using image-based biofidelic models. The intensity of the stress waves computed for different external blast conditions is compared across species. It is found that mass scaling, which successfully estimates blast tolerance of the thorax, fails to capture the brain mechanical response to blast across mammals. Instead, we show that an appropriate scaling variable must account for the mass of protective tissues relative to the brain, as well as their acoustic impedance. Peak stresses transmitted to the brain tissue by the blast are then shown to be a power function of the scaling parameter for a range of blast conditions relevant to TBI. In particular, it is found that human brain vulnerability to blast is higher than for any other mammalian species, which is in distinct contrast to previously proposed scaling laws based on body or brain mass. An application of the scaling law to recent experiments on rabbits furnishes the first physics-based injury estimate for blast-induced TBI in humans.	[Jean, Aurelie; Nyein, Michelle K.; Moore, David F.; Joannopoulos, John D.; Radovitzky, Raul] MIT, Inst Soldier Nanotechnol, Cambridge, MA 02139 USA; [Jean, Aurelie; Nyein, Michelle K.; Radovitzky, Raul] MIT, Dept Aeronaut & Astronaut, Cambridge, MA 02139 USA; [Joannopoulos, John D.] MIT, Dept Phys, Cambridge, MA 02139 USA; [Zheng, James Q.] US Army, Program Execut Off Soldier, Ft Belvoir, VA 22060 USA	Jean, A (corresponding author), MIT, Inst Soldier Nanotechnol, Cambridge, MA 02139 USA.	ajean@mit.edu; joannop@mit.edu	Radovitzky, Raul A/A-5353-2009	Radovitzky, Raul A/0000-0001-6339-2708	US Army through the Institute for Soldier Nanotechnologies [DAAD-19-02-D-0002]	This work was supported by the US Army through the Institute for Soldier Nanotechnologies under Contract DAAD-19-02-D-0002.	ALBERIUS P, 1987, ARCH ORAL BIOL, V32, P637, DOI 10.1016/0003-9969(87)90037-9; ANSYS, 2012, ANSYS AC RES REL 15; Bass CR, 2008, J TRAUMA, V65, P604, DOI 10.1097/TA.0b013e3181454ab4; Bass CR, 2012, ANN BIOMED ENG, V40, P185, DOI 10.1007/s10439-011-0424-0; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI 10.1089/neu.2009-0898; Belingardi G., 2005, P 19 INT TECHN C ENH, P1; Bochicchio GV, 2008, AM SURGEON, V74, P267; BOWEN IG, 1968, ANN NY ACAD SCI, V152, P122, DOI 10.1111/j.1749-6632.1968.tb11971.x; Chafi MS, 2010, ANN BIOMED ENG, V38, P490, DOI 10.1007/s10439-009-9813-z; CRILE GEORGE, 1940, OHIO JOUR SCI, V40, P219; Cummings J, 2002, J SUPERCOMPUT, V23, P39, DOI 10.1023/A:1015733102520; Deiterding R, 2006, ENG COMPUT-GERMANY, V22, P325, DOI 10.1007/s00366-006-0043-9; *DVBIC, 2010, TBI NUMB DEP DEF NUM; El Sayed T, 2008, COMPUT METHOD APPL M, V197, P4692, DOI 10.1016/j.cma.2008.06.006; Eskridge SL, 2012, INJURY, V43, P1678, DOI 10.1016/j.injury.2012.05.027; Fang QQ, 2009, 2009 IEEE INTERNATIONAL SYMPOSIUM ON BIOMEDICAL IMAGING: FROM NANO TO MACRO, VOLS 1 AND 2, P1142, DOI 10.1109/ISBI.2009.5193259; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; Gibson LJ, 2006, J ZOOL, V270, P462, DOI 10.1111/j.1469-7998.2006.00166.x; Gilchrist MD, 2001, INT J CRASHWORTHINES, V6, P253, DOI 10.1533/cras.2001.0176; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Gong SW, 2008, COMPUT STRUCT, V86, P758, DOI 10.1016/j.compstruc.2007.06.003; Hansen CD, 2005, VISUALIZATION HDB; Hicks RR, 2010, J TRAUMA, V68, P1257, DOI 10.1097/TA.0b013e3181d8956d; Ho J, 2007, J BIOMECH, V40, P3006, DOI 10.1016/j.jbiomech.2007.02.011; Horgan TJ, 2004, INT J CRASHWORTHINES, V9, P401, DOI 10.1533/ijcr.2004.0299; Kleiven S, 2002, J BIOMECH, V35, P153, DOI 10.1016/S0021-9290(01)00202-0; Kleiven Svein, 2002, Stapp Car Crash J, V46, P123; Leonardi AD, 2012, J BIOMECH, V45, P2595, DOI 10.1016/j.jbiomech.2012.08.024; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Magnuson J, 2012, CURR NEUROL NEUROSCI, V12, P570, DOI 10.1007/s11910-012-0303-6; Moore DF, 2009, NEUROIMAGE, V47, pT10, DOI 10.1016/j.neuroimage.2009.02.019; Moore DF, 2012, TRAUMATIC BRAIN INJU, P1; Nishimoto T, 1998, J BIOMECH ENG-T ASME, V120, P140, DOI 10.1115/1.2834294; Nyein MK, 2010, P NATL ACAD SCI USA, V107, P20703, DOI 10.1073/pnas.1014786107; Okhotsimskii DE, 1957, T MAT I STEKLOVA, V50, P1; Panzer MB, 2012, ANN BIOMED ENG, V40, P1530, DOI 10.1007/s10439-012-0519-2; Prevost TP, 2011, ACTA BIOMATER, V7, P83, DOI 10.1016/j.actbio.2010.06.035; Rafaels K, 2011, J NEUROTRAUM, V28, P2319, DOI 10.1089/neu.2009.1207; Rafaels KA, 2010, J TRAUMA, V69, P368, DOI 10.1097/TA.0b013e3181e88122; Raul JS, 2006, INT J LEGAL MED, V120, P212, DOI 10.1007/s00414-005-0018-1; RUAN JS, 1994, J BIOMECH ENG-T ASME, V116, P44, DOI 10.1115/1.2895703; Shridharani Jay K, 2012, Front Neurol, V3, P70, DOI 10.3389/fneur.2012.00070; Sundaramurthy A, 2012, J NEUROTRAUM, V29, P2352, DOI 10.1089/neu.2012.2413; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Taylor PA, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3118765; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Willinger R, 2003, INT J CRASHWORTHINES, V8, P605, DOI 10.1533/cras.8.6.605.19261; Wood GW, 2013, P INT RES COUNC BIOM, P549; Zhang L, 2001, Stapp Car Crash J, V45, P369; Zhang L, 2011, HFM 207 SURVEY BLAST, P33; Zhang LY, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00088; Zhang LY, 2001, J NEUROTRAUM, V18, P21, DOI 10.1089/089771501750055749; Zhu F, 2013, J MECH MED BIOL, V13, DOI 10.1142/S0219519413500656	55	34	35	1	19	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	OCT 28	2014	111	43					15310	15315		10.1073/pnas.1415743111			6	Multidisciplinary Sciences	Science & Technology - Other Topics	AR6ZL	WOS:000343729500029	25267617	Green Published, Bronze			2021-06-18	
J	Gupta, A; Ip, IK; Raja, AS; Andruchow, JE; Sodickson, A; Khorasani, R				Gupta, Anurag; Ip, Ivan K.; Raja, Ali S.; Andruchow, James E.; Sodickson, Aaron; Khorasani, Ramin			Effect of clinical decision support on documented guideline adherence for head CT in emergency department patients with mild traumatic brain injury	JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION			English	Article							NEW-ORLEANS CRITERIA; COMPUTED-TOMOGRAPHY; RADIATION-EXPOSURE; MEANINGFUL USE; RULE; QUALITY; INFORMATION; RADIOLOGY; OUTCOMES; ENTRY	Imaging utilization in emergency departments (EDs) has increased significantly. More than half of the 1.2 million patients with mild traumatic brain injury (MTBI) presenting to US EDs receive head CT. While evidence-based guidelines can help emergency clinicians decide whether to obtain head CT in these patients, adoption of these guidelines has been highly variable. Promulgation of imaging efficiency guidelines by the National Quality Forum has intensified the need for performance reporting, but measuring adherence to these imaging guidelines currently requires labor-intensive and potentially inaccurate manual chart review. We implemented clinical decision support (CDS) based on published evidence to guide emergency clinicians towards appropriate head CT use in patients with MTBI and automated data capture needed for unambiguous guideline adherence metrics. Implementation of the CDS was associated with a 56% relative increase in documented adherence to evidence-based guidelines for imaging in ED patients with MTBI.	[Gupta, Anurag; Ip, Ivan K.; Raja, Ali S.; Andruchow, James E.; Sodickson, Aaron; Khorasani, Ramin] Brigham & Womens Hosp, Ctr Evidence Based Imaging, Brookline, MA 02445 USA; [Gupta, Anurag; Ip, Ivan K.; Raja, Ali S.; Andruchow, James E.; Sodickson, Aaron; Khorasani, Ramin] Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA; [Gupta, Anurag; Raja, Ali S.; Andruchow, James E.] Brigham & Womens Hosp, Dept Emergency Med, Boston, MA 02115 USA; [Gupta, Anurag; Ip, Ivan K.; Raja, Ali S.; Sodickson, Aaron; Khorasani, Ramin] Harvard Univ, Sch Med, Boston, MA USA; [Ip, Ivan K.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA	Gupta, A (corresponding author), Brigham & Womens Hosp, Ctr Evidence Based Imaging, 20 Kent St,2nd Floor, Brookline, MA 02445 USA.	agupta15@partners.org	Raja, Ali S./AAE-5103-2019; Khorasani, Ramin/AAM-8526-2021	Gupta, Anurag/0000-0003-1566-1656; Sodickson, Aaron/0000-0003-1275-681X	National Library of MedicineUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM) [T15LM007092]; National Institute of Biomedical Imaging and BioengineeringUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [1UC4EB012952-01]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [UC4EB012952] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM) [T15LM007092] Funding Source: NIH RePORTER	This study was funded in part by Grant T15LM007092 from the National Library of Medicine and by Grant 1UC4EB012952-01 from the National Institute of Biomedical Imaging and Bioengineering.	Blumenthal D, 2010, NEW ENGL J MED, V362, P382, DOI 10.1056/NEJMp0912825; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Congress of Rehabilitation Medicine Head Injury Interdisciplinary American Special Interest Group, 1993, J HEAD TRAUMA REHAB, V8, P86; De Haan GG, 2008, IMAGING MINOR HEAD I, V146, P55; Eagles D, 2008, ACAD EMERG MED, V15, P1256, DOI 10.1111/j.1553-2712.2008.00265.x; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Federal Register, 2012, HLTH INF TECHN STAND, V77, P54163; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; Gupta A, 2014, J AM MED INFORM ASSN, V21, P23, DOI 10.1136/amiajnl-2013-001617; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Hedner C, 2013, ACAD RADIOL, V20, P1115, DOI 10.1016/j.acra.2013.05.010; Hunt DL, 1998, JAMA-J AM MED ASSOC, V280, P1339, DOI 10.1001/jama.280.15.1339; Ip IK, 2012, J AM COLL RADIOL, V9, P129, DOI 10.1016/j.jacr.2011.10.010; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; Jha AK, 2010, JAMA-J AM MED ASSOC, V304, P1709, DOI 10.1001/jama.2010.1497; Larson DB, 2011, RADIOLOGY, V258, P164, DOI 10.1148/radiol.10100640; Linder JA, 2012, J AM MED INFORM ASSN, V19, P1019, DOI [10.1136/amiajnl-2011-000788, 10.1136/amiajnl-2011-00078]; Lugtenberg M, 2009, QUAL SAF HEALTH CARE, V18, P385, DOI 10.1136/qshc.2008.028043; Mannix R, 2013, NEUROSURGERY, V73, P129, DOI 10.1227/01.neu.0000429846.14579.41; NQF, NAT VOL CONS STAND I; Raja AS, 2012, RADIOLOGY, V262, P468, DOI 10.1148/radiol.11110951; Rosenbloom ST, 2011, J AM MED INFORM ASSN, V18, P181, DOI 10.1136/jamia.2010.007237; Schuur JD, 2012, ANN EMERG MED, V60, P280, DOI 10.1016/j.annemergmed.2011.12.025; Shinagare A, 2013, AJR AM J RO IN PRESS; Smits M, 2005, JAMA-J AM MED ASSOC, V294, P1519, DOI 10.1001/jama.294.12.1519; Sodickson A, 2009, RADIOLOGY, V251, P175, DOI 10.1148/radiol.2511081296; Sox HC, 2012, ANN EMERG MED, V60, P291, DOI 10.1016/j.annemergmed.2012.05.032; Stiell IG, 2007, ACAD EMERG MED, V14, P955, DOI 10.1197/j.aem.2007.06.039; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; TEASDALE G, 1974, LANCET, V2, P81; Tierney WM, 2001, INT J MED INFORM, V62, P1, DOI 10.1016/S1386-5056(01)00127-7	32	34	34	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1067-5027	1527-974X		J AM MED INFORM ASSN	J. Am. Med. Inf. Assoc.	OCT	2014	21	E2					E347	E351		10.1136/amiajnl-2013-002536			5	Computer Science, Information Systems; Computer Science, Interdisciplinary Applications; Health Care Sciences & Services; Information Science & Library Science; Medical Informatics	Computer Science; Health Care Sciences & Services; Information Science & Library Science; Medical Informatics	AP1UV	WOS:000341858100024	24534635	Green Published, Bronze			2021-06-18	
J	Christen, T; Bouzat, P; Pannetier, N; Coquery, N; Moisan, A; Lemasson, B; Thomas, S; Grillon, E; Detante, O; Remy, C; Payen, JF; Barbier, EL				Christen, Thomas; Bouzat, Pierre; Pannetier, Nicolas; Coquery, Nicolas; Moisan, Anaick; Lemasson, Benjamin; Thomas, Sebastien; Grillon, Emmanuelle; Detante, Olivier; Remy, Chantal; Payen, Jean-Francois; Barbier, Emmanuel Luc			Tissue oxygen saturation mapping with magnetic resonance imaging	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						brain; MRI; oxygenation; stroke; trauma; tumor	CEREBRAL BLOOD-VOLUME; TRAUMATIC BRAIN-INJURY; EXTRACTION FRACTION; VESSEL SIZE; SUSCEPTIBILITY; HYPOXIA; MODEL; MRI; FERUMOXYTOL; PARAMETERS	A quantitative estimate of cerebral blood oxygen saturation is of critical importance in the investigation of cerebrovascular disease. While positron emission tomography can Map in viva the oxygen level in blood, it has limited availability and requires ionizing radiation. Magnetic resonance imaging (MRI) offers an alternative through the blood oxygen level-dependent contrast. Here, we describe an in vivo and non-invasive approach to map brain tissue oxygen saturation (StO(2)) with high spatial resolution. StO(2) obtained with MRI correlated well with results from blood gas analyses for various oxygen and hematocrit challenges. In a stroke model, the hypoxic areas delineated in vivo by MRI spatially matched those observed ex vivo by pimonidazole staining. In a model of diffuse traumatic brain injury, MRI was able to-detect even a reduction in StO(2) that was too small to be detected by histology. In a F98 glioma model, MRI was able to map oxygenation heterogeneity. Thus, the MRI technique may improve our understanding of the pathophysiology of several brain diseases involving impaired oxygenation.	[Christen, Thomas; Bouzat, Pierre; Pannetier, Nicolas; Coquery, Nicolas; Moisan, Anaick; Lemasson, Benjamin; Thomas, Sebastien; Detante, Olivier; Remy, Chantal; Payen, Jean-Francois; Barbier, Emmanuel Luc] INSERM, U836, Grenoble, France; [Christen, Thomas; Bouzat, Pierre; Pannetier, Nicolas; Coquery, Nicolas; Moisan, Anaick; Lemasson, Benjamin; Thomas, Sebastien; Detante, Olivier; Remy, Chantal; Payen, Jean-Francois; Barbier, Emmanuel Luc] Univ Grenoble Alpes, Grenoble Inst Neurosci, Grenoble, France; [Bouzat, Pierre; Thomas, Sebastien; Payen, Jean-Francois] CHU Grenoble, Pole Anesthesie Reanimat, F-38043 Grenoble, France; [Grillon, Emmanuelle] INSERM, US 017, Grenoble, France; [Grillon, Emmanuelle] Univ Grenoble Alpes, IRMaGe, Grenoble, France; [Grillon, Emmanuelle] CHU Grenoble, IRMaGe, F-38043 Grenoble, France; [Grillon, Emmanuelle] CNRS, UMS 3552, Grenoble, France; [Detante, Olivier] CHU Grenoble, Serv Neurol, F-38043 Grenoble, France	Barbier, EL (corresponding author), Grenoble Inst Neurosci, U836, Team 5, UJF Site Sante,BP 170, F-38042 Grenoble 9, France.	emmanuel.barbier@ujf-grenoble.fr	Moisan, Anaick/P-4838-2014; christen, thomas/O-4482-2018; Bouzat, Pierre/L-6881-2014; Payen, Jean-Francois/L-6667-2014; Lemasson, Benjamin/L-1608-2014; Remy, Chantal/L-9459-2014; Barbier, Emmanuel/E-6302-2011; coquery, nicolas/N-9206-2019; Lemasson, Benjamin/AAC-4092-2019; Detante, Olivier/M-1737-2014; Bouzat, Pierre/AAC-4105-2019	Moisan, Anaick/0000-0002-6680-8593; Lemasson, Benjamin/0000-0003-0446-3531; Barbier, Emmanuel/0000-0002-4952-1240; Lemasson, Benjamin/0000-0003-0446-3531; Bouzat, Pierre/0000-0003-4667-6738; Pannetier, Nicolas/0000-0002-0744-5155	ANR Imoxy programFrench National Research Agency (ANR) [2011-BSV5-004]; Lyon Biopole; 'Fondation Gueules Cassees'; 'fondation ARC pour la recherche sur le cancer'	Financial support for this project was provided by ANR Imoxy program 2011-BSV5-004, Lyon Biopole, 'Fondation Gueules Cassees', and 'fondation ARC pour la recherche sur le cancer'.	An HY, 2009, STROKE, V40, P2165, DOI 10.1161/STROKEAHA.108.540864; An HY, 2002, MAGNET RESON MED, V47, P958, DOI 10.1002/mrm.10148; An HY, 2000, J CEREBR BLOOD F MET, V20, P1225, DOI 10.1097/00004647-200008000-00008; BANDETTINI PA, 1995, INT J IMAG SYST TECH, V6, P133, DOI 10.1002/ima.1850060203; Barcroft J, 1910, J PHYSIOL-LONDON, V39, P411; BENDA P, 1971, J NEUROSURG, V34, P310, DOI 10.3171/jns.1971.34.3.0310; Beynon C, 2012, J NEUROTRAUM, V29, P2109, DOI 10.1089/neu.2012.2365; Bouzat P, 2013, CRIT CARE MED, V41, P1316, DOI 10.1097/CCM.0b013e31827ca64e; Brauer-Krisch E, 2009, REV SCI INSTRUM, V80, DOI 10.1063/1.3170035; Christen T, 2013, MAGN RESON MED, V70, P705, DOI 10.1002/mrm.24500; Christen T, 2012, MAGN RESON MED, V67, P1458, DOI 10.1002/mrm.23094; Christen T, 2011, NMR BIOMED, V24, P393, DOI 10.1002/nbm.1603; Emblem KE, 2013, NAT MED, V19, P1178, DOI 10.1038/nm.3289; FRACKOWIAK RSJ, 1980, J COMPUT ASSIST TOMO, V4, P727, DOI 10.1097/00004728-198012000-00001; GROSS MW, 1995, INT J CANCER, V61, P567, DOI 10.1002/ijc.2910610422; GRUBB RL, 1973, ARCH NEUROL-CHICAGO, V28, P38, DOI 10.1001/archneur.1973.00490190056006; HALL FG, 1966, J APPL PHYSIOL, V21, P375; He X, 2008, MAGN RESON MED, V60, P882, DOI 10.1002/mrm.21719; He X, 2007, MAGN RESON MED, V57, P115, DOI 10.1002/mrm.21108; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Heiss WD, 2010, INT J STROKE, V5, P290, DOI 10.1111/j.1747-4949.2010.00444.x; Jensen-Kondering U, 2012, STROKE, V43, P2264, DOI 10.1161/STROKEAHA.111.632455; Joyeux-Faure M, 2005, J APPL PHYSIOL, V98, P1691, DOI 10.1152/japplphysiol.01146.2004; Klassen LM, 2007, BIOPHYS J, V92, P1014, DOI 10.1529/biophysj.106.087965; Kurth CD, 2002, J CEREBR BLOOD F MET, V22, P335, DOI 10.1097/00004647-200203000-00011; Lee J, 2012, NEUROIMAGE, V59, P3967, DOI 10.1016/j.neuroimage.2011.10.076; Lemasson B, 2011, NMR BIOMED, V24, P473, DOI 10.1002/nbm.1611; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Marques JP, 2005, CONCEPT MAGN RESON B, V25B, P65, DOI 10.1002/cmr.b.20034; OGAWA S, 1990, P NATL ACAD SCI USA, V87, P9868, DOI 10.1073/pnas.87.24.9868; Pittman RN., 2011, REGULATION TISSUE OX; Spees WM, 2001, MAGN RESON MED, V45, P533, DOI 10.1002/mrm.1072; Tropres I, 2001, MAGN RESON MED, V45, P397, DOI 10.1002/1522-2594(200103)45:3<397::AID-MRM1052>3.0.CO;2-3; Valable S, 2008, NMR BIOMED, V21, P1043, DOI 10.1002/nbm.1278; Varallyay CG, 2013, J CEREBR BLOOD F MET, V33, P780, DOI 10.1038/jcbfm.2013.36; Watzman HM, 2000, ANESTHESIOLOGY, V93, P947, DOI 10.1097/00000542-200010000-00012; Wintermark M, 2005, STROKE, V36, pE83, DOI 10.1161/01.STR.0000177884.72657.8b; Yablonskiy DA, 2013, NMR BIOMED, V26, P963, DOI 10.1002/nbm.2839	39	34	34	0	25	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	SEP	2014	34	9					1550	1557		10.1038/jcbfm.2014.116			8	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	AO4WT	WOS:000341342800016	25005878	Green Published, Bronze			2021-06-18	
J	Bere, T; Florenes, TW; Krosshaug, T; Haugen, P; Svandal, I; Nordsletten, L; Bahr, R				Bere, T.; Florenes, T. W.; Krosshaug, T.; Haugen, P.; Svandal, I.; Nordsletten, L.; Bahr, R.			A systematic video analysis of 69 injury cases in World Cup alpine skiing	SCANDINAVIAN JOURNAL OF MEDICINE & SCIENCE IN SPORTS			English	Article						Alpine ski racing; injuries; mechanisms; World Cup skier; video recordings	CRUCIATE LIGAMENT INJURY; PREVENTION; MECHANISMS; SKIERS; SPORT; CONCUSSION; ETIOLOGY; SHOULDER; RISK	We have limited insight into how injuries occur in professional ski racing. The aim of this study was to describe the injury situations in World Cup alpine skiing. Injuries reported through the International Ski Federation Injury Surveillance System for three consecutive World Cup seasons (2006-2009) were obtained on video. In total, 69 injuries and 124 runs of matched controls were analysed by five experts to evaluate the skiing situation, skier behavior, as well as piste-related factors. A chi-square test (95% CI, P <= 0.05) was used to examine whether there was a difference between course sections regarding where the injury situation occurred. The skier was most frequently turning (n = 55) or landing from a jump (n = 13) at the time of injury. Most of the injuries to the head and upper body (96%) resulted from crashes, while the majority of knee injuries (83%) occurred while the skier was still skiing. Gate contact contributed to 30% of the injuries, while 9% occurred at contact with safety nets/material. Almost half of the injuries (46%) occurred in the final fourth of the course. A particular concern was the high contribution of inappropriate gate contact and the high-energy impacts to the body when crashing.	[Bere, T.; Florenes, T. W.; Krosshaug, T.; Nordsletten, L.; Bahr, R.] Norwegian Sch Sport Sci, Oslo Sports Trauma Res Ctr, Dept Sports Med, N-0806 Oslo, Norway; [Haugen, P.] Norwegian Sch Sport Sci, Dept Phys Performance, N-0806 Oslo, Norway; [Svandal, I.] Norwegian Ski Federat, Norwegian Alpine Ski Team, Oslo, Norway	Bere, T (corresponding author), Norwegian Sch Sport Sci, Oslo Sports Trauma Res Ctr, Dept Sports Med, PB 4014 Ulleval Stad, N-0806 Oslo, Norway.	tone.bere@nih.no		Bahr, Roald/0000-0001-5725-4237	Royal Norwegian Ministry of Culture; South-Eastern Norway Regional Health Authority; International Olympic Committee; Norwegian Olympic Committee & Confederation of Sport; Norsk Tipping AS; International Ski Federation; DJO	The Oslo Sports Trauma Research Center has been established at the Norwegian School of Sport Sciences through generous grants from the Royal Norwegian Ministry of Culture, the South-Eastern Norway Regional Health Authority, the International Olympic Committee, the Norwegian Olympic Committee & Confederation of Sport, and Norsk Tipping AS. The FIS Injury Surveillance System is supported by the International Ski Federation and was established through a grant from DJO. We would like to thank the International Ski Federation staff and officials for all practical support in collecting the injury data, as well as Anna Banach and Infront Sports & Media for help with video capture and editing.	Ackery A, 2007, INJURY PREV, V13, P368, DOI 10.1136/ip.2007.017285; Bahr R, 2005, BRIT J SPORT MED, V39, P324, DOI 10.1136/bjsm.2005.018341; Benson BW, 2009, BRIT J SPORT MED, V43, pI56, DOI 10.1136/bjsm.2009.058271; Bere T, 2011, BRIT J SPORT MED, V45, P1294, DOI 10.1136/bjsports-2011-090517; Bere T, 2011, AM J SPORT MED, V39, P1421, DOI 10.1177/0363546511405147; Boden Barry P, 2005, Curr Sports Med Rep, V4, P45; Boutin RD, 2005, SEMIN MUSCULOSKEL R, V9, P360, DOI 10.1055/s-2005-923380; Chuter GSJ, 2009, INJURY, V40, P652, DOI 10.1016/j.injury.2009.01.107; Dainese, 2012, D AIR PROT; Ekeland A, 1985, ASTM STP, P293; ENGKVIST O, 1982, INT J SPORTS MED, V3, P50, DOI 10.1055/s-2008-1026063; ETTLINGER CF, 1995, AM J SPORT MED, V23, P531, DOI 10.1177/036354659502300503; Fischer J F, 1994, Acta Orthop Belg, V60, P194; Florenes TW, 2012, SCAND J MED SCI SPOR, V22, P58, DOI 10.1111/j.1600-0838.2010.01147.x; Florenes TW, 2011, SCAND J MED SCI SPOR, V21, P196, DOI 10.1111/j.1600-0838.2009.01048.x; Florenes TW, 2009, BRIT J SPORT MED, V43, P973, DOI 10.1136/bjsm.2009.068759; Hunter RE, 1999, AM J SPORT MED, V27, P381, DOI 10.1177/03635465990270032101; Johnson RJ, 1997, AM SOC TEST MATER, V1289, P37, DOI 10.1520/STP18287S; Kocher MS, 1998, SPORTS MED, V25, P201, DOI 10.2165/00007256-199825030-00006; Koehle MS, 2002, SPORTS MED, V32, P785, DOI 10.2165/00007256-200232120-00003; Krosshaug T, 2005, BRIT J SPORT MED, V39, P330, DOI 10.1136/bjsm.2005.018358; MARGREITER R, 1976, ORTHOP CLIN N AM, V7, P51; McCall D, 2009, BRIT J SPORT MED, V43, P987, DOI 10.1136/bjsm.2009.068767; McCrory P, 2009, PHYSICIAN SPORTSMED, V37, P141, DOI 10.3810/psm.2009.06.1721; McIntosh AS, 2011, BRIT J SPORT MED, V45, P1258, DOI 10.1136/bjsports-2011-090509; Meeuwisse WH, 2009, CLIN J SPORT MED, V19, P1, DOI 10.1097/JSM.0b013e3181979c1d; Natri A, 1999, SPORTS MED, V28, P35, DOI 10.2165/00007256-199928010-00004; Raas E., 1982, SKI TRAUMA SKIING SA, P202; Ruedl G, 2009, KNEE SURG SPORT TR A, V17, P1393, DOI 10.1007/s00167-009-0860-7; The International Ski Federation (FIS), 2011, INT SKI COMP RUL ICR; The International Ski Federation (FIS), 2011, FIS SPEC FLEX POL; The International Ski Federation (FIS), 2011, FIS SPEC COMP EQ COM; The International Ski Federation (FIS), 2011, FIS SP REL PAN 2012; The International Ski Federation (FIS), 2011, FIS SAF MAT; The International Ski Federation (FIS), 2011, FIS SPEC WORLD CUP R; VANMECHELEN W, 1992, SPORTS MED, V14, P82, DOI 10.2165/00007256-199214020-00002	36	34	35	2	33	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0905-7188	1600-0838		SCAND J MED SCI SPOR	Scand. J. Med. Sci. Sports	AUG	2014	24	4					667	677		10.1111/sms.12038			11	Sport Sciences	Sport Sciences	AM2YF	WOS:000339716800020	23301907				2021-06-18	
J	Jerusalem, A; Garcia-Grajales, JA; Merchan-Perez, A; Pena, JM				Jerusalem, Antoine; Garcia-Grajales, Julian A.; Merchan-Perez, Angel; Pena, Jose M.			A computational model coupling mechanics and electrophysiology in spinal cord injury	BIOMECHANICS AND MODELING IN MECHANOBIOLOGY			English	Article						Computational model; Axon; Electrophysiology; Mechanics; Spinal cord injury	WHITE-MATTER; MYELIN; AXONS; CONDUCTION; ELONGATION; CHANNELS; DEFICITS	Traumatic brain injury and spinal cord injury have recently been put under the spotlight as major causes of death and disability in the developed world. Despite the important ongoing experimental and modeling campaigns aimed at understanding the mechanics of tissue and cell damage typically observed in such events, the differentiated roles of strain, stress and their corresponding loading rates on the damage level itself remain unclear. More specifically, the direct relations between brain and spinal cord tissue or cell damage, and electrophysiological functions are still to be unraveled. Whereas mechanical modeling efforts are focusing mainly on stress distribution and mechanistic-based damage criteria, simulated function-based damage criteria are still missing. Here, we propose a new multiscale model of myelinated axon associating electrophysiological impairment to structural damage as a function of strain and strain rate. This multiscale approach provides a new framework for damage evaluation directly relating neuron mechanics and electrophysiological properties, thus providing a link between mechanical trauma and subsequent functional deficits.	[Jerusalem, Antoine] Univ Oxford, Dept Engn Sci, Oxford OX1 3PJ, England; [Garcia-Grajales, Julian A.] Univ Politecn Madrid, Madrid, Spain; [Garcia-Grajales, Julian A.] IMDEA Mat Inst, Madrid, Spain; [Merchan-Perez, Angel] Univ Politecn Madrid, Lab Circuitos Cort, Ctr Tecnol Biomed, Madrid, Spain; [Merchan-Perez, Angel; Pena, Jose M.] Univ Politecn Madrid, DATSI, Madrid, Spain	Jerusalem, A (corresponding author), Univ Oxford, Dept Engn Sci, Parks Rd, Oxford OX1 3PJ, England.	antoine.jerusalem@eng.ox.ac.uk	Merchan-Perez, Angel/D-7417-2014; Merchan-Perez, Angel/AAY-8947-2020	Merchan-Perez, Angel/0000-0002-7228-5821; Merchan-Perez, Angel/0000-0002-7228-5821; Jerusalem, Antoine/0000-0001-5026-8038	European Research Council under the European UnionEuropean Research Council (ERC) [306587]; Spanish Ministry of ScienceSpanish Government [TIN2010-21289-C02-02]; Cajal Blue Brain Project, the Spanish partner of the Blue Brain Project	The research leading to these results has received funding from the European Research Council under the European Union's Seventh Framework Programme (FP72007-2013)/ERC Grant Agreement No. 306587, from the Spanish Ministry of Science (TIN2010-21289-C02-02), and the Cajal Blue Brain Project, the Spanish partner of the Blue Brain Project. The authors gratefully acknowledge the computer resources, technical expertise and assistance provided by the Supercomputing and Visualization Center of Madrid (CeSViMa).	Alford PW, 2011, P NATL ACAD SCI USA, V108, P12705, DOI 10.1073/pnas.1105860108; Babbs CF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067767; Boucher PA, 2012, J COMPUT NEUROSCI, V33, P301, DOI 10.1007/s10827-012-0387-7; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chomiak T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007754; Cloots RJH, 2013, BIOMECH MODEL MECHAN, V12, P137, DOI 10.1007/s10237-012-0387-6; Cloots RJH, 2011, THESIS EINDHOVEN U T; Coggan JS, 2010, P NATL ACAD SCI USA, V107, P20602, DOI 10.1073/pnas.1013798107; Connell S, 2011, J NEUROTRAUM, V28, P1229, DOI 10.1089/neu.2011.1832; D'Ambrosio R, 1999, J NEUROSCI, V19, P8152; DENNERLL TJ, 1989, J CELL BIOL, V109, P3073, DOI 10.1083/jcb.109.6.3073; Garcia JA, 2012, CMES-COMP MODEL ENG, V87, P411; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Gupta RS, 2013, FRONT MICROBIOL, V4, DOI 10.3389/fmicb.2013.00217; Hains BC, 2004, EXP NEUROL, V188, P365, DOI 10.1016/j.expneurol.2004.04.001; Hicks RR, 2010, J TRAUMA, V68, P1257, DOI 10.1097/TA.0b013e3181d8956d; HILDEBRAND C, 1978, J NEUROL SCI, V38, P421, DOI 10.1016/0022-510X(78)90147-8; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; Hui OY, 2008, J NEUROTRAUM, V25, P19, DOI 10.1089/neu.2007.0340; IBRAHIM M, 1995, J NEUROL SCI, V133, P119, DOI 10.1016/0022-510X(95)00174-Z; Ichimura H, 2005, J ORTHOP SCI, V10, P214, DOI 10.1007/s00776-004-0870-8; JACOBS JM, 1969, J ANAT, V105, P295; Jensen TH, 2011, NEUROIMAGE, V57, P124, DOI 10.1016/j.neuroimage.2011.04.013; Jerusalem A, 2012, ACTA BIOMATER, V8, P3360, DOI 10.1016/j.actbio.2012.04.039; Koch Christof, 1999, P1; Markin VS, 1999, BIOPHYS J, V76, P2852, DOI 10.1016/S0006-3495(99)77439-4; Moore DF, 2009, NEUROIMAGE, V47, pT10, DOI 10.1016/j.neuroimage.2009.02.019; Nyein MK, 2010, P NATL ACAD SCI USA, V107, P20703, DOI 10.1073/pnas.1014786107; OCHS S, 1994, NEUROSCIENCE, V61, P361, DOI 10.1016/0306-4522(94)90237-2; Ouyang H, 2010, J NEUROTRAUM, V27, P1109, DOI 10.1089/neu.2010.1271; Park E, 2013, NEUROBIOL DIS, V52, P150, DOI 10.1016/j.nbd.2012.12.002; Peter SJ, 2012, BIOPHYS J, V102, P749, DOI 10.1016/j.bpj.2011.11.4024; Shi R, 2002, NEUROSCIENCE, V110, P765, DOI 10.1016/S0306-4522(01)00596-6; Shi R, 2006, J NEUROPHYSIOL, V95, P3384, DOI 10.1152/jn.00350.2005; Shreiber DI, 2009, BIOMECH MODEL MECHAN, V8, P311, DOI 10.1007/s10237-008-0137-y; Volman V, 2013, NEURAL COMPUT, V25, P2646, DOI 10.1162/NECO_a_00491; Wang JA, 2009, AM J PHYSIOL-CELL PH, V297, pC823, DOI 10.1152/ajpcell.00505.2008; WAXMAN SG, 1978, J NEUROL NEUROSUR PS, V41, P408, DOI 10.1136/jnnp.41.5.408; Wu L, 2013, ENG FRACT MECH, V104, P162, DOI 10.1016/j.engfracmech.2013.03.018	39	34	35	0	16	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1617-7959	1617-7940		BIOMECH MODEL MECHAN	Biomech. Model. Mechanobiol.	AUG	2014	13	4					883	896		10.1007/s10237-013-0543-7			14	Biophysics; Engineering, Biomedical	Biophysics; Engineering	AL5EN	WOS:000339156400015	24337934	Green Accepted			2021-06-18	
J	Pandit, V; Patel, N; Rhee, P; Kulvatunyou, N; Aziz, H; Green, DJ; O'Keeffe, T; Zangbar, B; Tang, A; Gries, L; Friese, RS; Joseph, B				Pandit, Viraj; Patel, Nikita; Rhee, Peter; Kulvatunyou, Narong; Aziz, Hassan; Green, Donald J.; O'Keeffe, Terence; Zangbar, Bardiya; Tang, Andrew; Gries, Lynn; Friese, Randall S.; Joseph, Bellal			Effect of alcohol in traumatic brain injury: is it really protective?	JOURNAL OF SURGICAL RESEARCH			English	Article						Alcohol intoxication; Severe traumatic brain injury; Mortality; Complications; National trauma data bank	HEAD-INJURY; ETHANOL INTOXICATION; MORTALITY; CYTOKINES; SURVIVAL; MODERATE; RATS	Background: Studies have proposed a neuroprotective role for alcohol (ETOH) in traumatic brain injury (TBI). We hypothesized that ETOH intoxication is associated with mortality in patients with severe TBI. Methods: Version 7.2 of the National Trauma Data Bank (2007-2010) was queried for all patients with isolated blunt severe TBI (Head Abbreviated Injury Score >= 4) and blood ETOH levels recorded on admission. Primary outcome measure was mortality. Multivariate logistic regression analysis was performed to assess factors predicting mortality and in-hospital complications. Results: A total of 23,983 patients with severe TBI were evaluated of which 22.8% (n=5461) patients tested positive for ETOH intoxication. ETOH-positive patients were more likely to have in-hospital complications (P=0.001) and have a higher mortality rate (P=0.01). ETOH intoxication was an independent predictor for mortality (odds ratio: 1.2, 95% confidence interval: 1.1-2.1, P=0.01) and development of in-hospital complications (odds ratio: 1.3, 95% confidence interval: 1.1-2.8, P=0.009) in patients with isolated severe TBI. Conclusions: ETOH intoxication is an independent predictor for mortality in patients with severe TBI patients and is associated with higher complication rates. Our results from the National Trauma Data Standards differ from those previously reported. The proposed neuroprotective role of ETOH needs further clarification. (C) 2014 Elsevier Inc. All rights reserved.	[Pandit, Viraj; Patel, Nikita; Rhee, Peter; Kulvatunyou, Narong; Aziz, Hassan; Green, Donald J.; O'Keeffe, Terence; Zangbar, Bardiya; Tang, Andrew; Gries, Lynn; Friese, Randall S.; Joseph, Bellal] Univ Arizona, Dept Surg, Div Trauma Crit Care Emergency Surg & Burns, Tucson, AZ 85724 USA	Joseph, B (corresponding author), Univ Arizona, Dept Surg, Div Trauma Crit Care & Emergency Surg, 1501 N Campbell Ave,Room 5411,POB 245063, Tucson, AZ 85724 USA.	bjoseph@surgery.arizona.edu	Zangbar, Bardiya/K-7147-2014	Zangbar, Bardiya/0000-0003-1215-1693			CDC, 2012, INJ PREV CONTR TRAUM; CDC, 2012, TRAUM BRAIN INJ US; Cebere A, 2003, NEUROCHEM RES, V28, P1193, DOI 10.1023/A:1024228412198; Centers for Disease Control, 2013, INJ PREV CONTR MOT V; Chen CM, 2012, J STUD ALCOHOL DRUGS, V73, P531, DOI 10.15288/jsad.2012.73.531; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Cunningham RM, 2002, ALCOHOL ALCOHOLISM, V37, P236, DOI 10.1093/alcalc/37.3.236; Goodman MD, 2013, J SURG RES, V184, P1053, DOI 10.1016/j.jss.2013.04.058; Gottesfeld Z, 2002, J NEUROTRAUM, V19, P317, DOI 10.1089/089771502753594882; Greiffenstein P, 2007, ALCOHOL CLIN EXP RES, V31, P704, DOI 10.1111/j.1530-0277.2007.00355.x; Hadjibashi AA, 2012, J SURG RES, V173, P212, DOI 10.1016/j.jss.2011.05.029; Janis GC, 1998, ALCOHOL CLIN EXP RES, V22, P2055, DOI 10.1097/00000374-199812000-00023; Johnston JJE, 2004, EMERG MED J, V21, P185, DOI 10.1136/emj.2003.006130; Kelly DF, 2000, J NEUROTRAUM, V17, P261, DOI 10.1089/neu.2000.17.261; Lustenberger T, 2011, J NEUROTRAUM, V28, P1699, DOI 10.1089/neu.2011.1866; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; Martin TR, 1999, CHEST, V116, p2S, DOI 10.1378/chest.116.suppl_1.2S; Nelson Steve, 1992, ALCOHOL HEALTH RES W, V16, P73; Opreanu RC, 2010, J AM COLL SURGEONS, V210, P997, DOI 10.1016/j.jamcollsurg.2010.01.036; Salim A, 2009, J TRAUMA, V67, P697, DOI 10.1097/TA.0b013e3181b5dcf2; Salim A, 2009, ARCH SURG-CHICAGO, V144, P865, DOI 10.1001/archsurg.2009.158; Shahin H, 2012, J TRAUMA, V14, P233; Shahin H, 2010, J TRAUMA, V69, P1176, DOI 10.1097/TA.0b013e3181edbd47; Shandro JR, 2009, J TRAUMA, V66, P1584, DOI 10.1097/TA.0b013e318182af96; Talving P, 2010, J TRAUMA, V68, P357, DOI 10.1097/TA.0b013e3181bb80bf; Tureci E, 2004, NEUROL RES, V26, P108, DOI 10.1179/016164104225013699	26	34	34	0	5	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804	1095-8673		J SURG RES	J. Surg. Res.	AUG	2014	190	2					634	639		10.1016/j.jss.2014.04.039			6	Surgery	Surgery	AM4DD	WOS:000339801800038	24857283				2021-06-18	
J	Grauwmeijer, E; Heijenbrok-Kal, MH; Ribbers, GM				Grauwmeijer, Erik; Heijenbrok-Kal, Majanka H.; Ribbers, Gerard M.			Health-Related Quality of Life 3 Years After Moderate to Severe Traumatic Brain Injury: A Prospective Cohort Study	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries traumatic; Prospective studies; Quality of life; Rehabilitation	FUNCTIONAL ASSESSMENT MEASURE; HEAD-INJURY; INTERRATER RELIABILITY; 1ST YEAR; SF-36; REHABILITATION; CLASSIFICATION; SATISFACTION; INDIVIDUALS; DISABILITY	Objectives: To evaluate the time course of health-related quality of life (HRQoL) after moderate to severe traumatic brain injury (TBI) and to identify its predictors. Design: Prospective cohort study with follow-up measurements at 3, 6, 12, 18, 24, and 36 months after TBI. Setting: Patients. with moderate to severe TBI discharged from 3 level-1 trauma centers. Participants: Patients (N=97, 72% men) with a mean age +/- SD of 32.8+/-13.0 years (range, 18-65y), hospitalized with moderate (23%) or severe (77%) TBI. Interventions: Not applicable. Main Outcome Measures: HRQoL was measured with the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36), functional outcomes with the Glasgow Outcome Scale (GOS), Barthel Index, FIM, and Functional Assessment Measure, and mood with the Wimbledon Self-Report Scale. Results: The SF-36 domains showed significant improvement over time for Physical Functioning (P<.001), Role Physical (P<.001), Bodily Pain (P<.001), Social Functioning (P<.001), and Role Emotional (P=.024), but not for General Health (P=.263), Vitality (P=.530), and Mental Health (P=.138). Over time there was significant improvement in the Physical Component Summary (PCS) score, whereas the Mental Component Summary (MCS) score remained stable. At 3-year follow-up, HRQoL of patients with TBI was the same as that in the Dutch normative population. Time after TBI, hospital length of stay (LOS), FTM, and GOS were independent predictors of the PCS, whereas LOS and mood were predictors of the MCS. Conclusions: After TBI, the physical component of HRQoL showed significant improvement over time, whereas the mental component remained stable. Problems of disease awareness seem to Play a role in self-reported mental HRQoL. After TBI, mood status is a better predictor of the mental component of BRQoL than functional outcome, implying that mood should be closely monitored during and after rehabilitation. (C) 2014 by the American Congress of Rehabilitation Medicine	Erasmus Univ, Rijndam Rehabil Ctr, Med Ctr, Rotterdam, Netherlands; Erasmus Univ, Dept Rehabil Med, Med Ctr, Rotterdam, Netherlands	Grauwmeijer, E (corresponding author), Rotterdam Neurorehabil Res RoNeRes, Rijndam Rehabil Ctr, POB 23181, NL-3001 KD Rotterdam, Netherlands.	egrauwmeijer@rijndam.nl	Ribbers, Gerard M/C-1454-2014; Ribbers, Gerard/N-3623-2019	Ribbers, Gerard M/0000-0002-6114-349X; Heijenbrok-Kal, Majanka H./0000-0002-2982-4404	Netherlands Organisation for Health Research and DevelopmentNetherlands Organization for Health Research and Development [1435.0020]	Supported by the Netherlands Organisation for Health Research and Development (project no. 1435.0020).	Aaronson NK, 1998, J CLIN EPIDEMIOL, V51, P1055, DOI 10.1016/S0895-4356(98)00097-3; Andelic N, 2009, ACTA NEUROL SCAND, V120, P16, DOI 10.1111/j.1600-0404.2008.01116.x; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; Carlozzi NE, 2011, ARCH PHYS MED REHAB, V92, pS52, DOI 10.1016/j.apmr.2010.12.046; Cieza A, 2005, QUAL LIFE RES, V14, P1225, DOI 10.1007/s11136-004-4773-0; Collin C, 1988, Int Disabil Stud, V10, P61; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Coughlan AK, 1988, CLIN REHABIL, V2, P207, DOI DOI 10.1177/026921558800200305; Diaz AP, 2012, J NEUROTRAUM, V29, P1029, DOI 10.1089/neu.2011.2089; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; Donaghy S, 1998, ARCH PHYS MED REHAB, V79, P1231, DOI 10.1016/S0003-9993(98)90267-2; Emanuelson I, 2003, ACTA NEUROL SCAND, V108, P332, DOI 10.1034/j.1600-0404.2003.00155.x; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Forslund MV, 2013, ACTA NEUROL SCAND, V128, P220, DOI 10.1111/ane.12130; Grauwmeijer E, 2012, ARCH PHYS MED REHAB, V93, P993, DOI 10.1016/j.apmr.2012.01.018; Guilfoyle MR, 2010, J NEUROTRAUM, V27, P2173, DOI 10.1089/neu.2010.1353; Hart T, 2011, ARCH PHYS MED REHAB, V92, P1211, DOI 10.1016/j.apmr.2011.03.005; Hawley CA, 1999, J NEUROL NEUROSUR PS, V67, P749, DOI 10.1136/jnnp.67.6.749; Hawthorne G, 2009, J NEUROTRAUM, V26, P1623, DOI [10.1089/neu.2008.0735, 10.1089/neu.2008-0735]; Heitger MH, 2007, J REHABIL MED, V39, P612, DOI 10.2340/16501977-0100; Jacobsson LJ, 2010, BRAIN INJURY, V24, P1075, DOI 10.3109/02699052.2010.494590; JENNETT B, 1975, LANCET, V1, P480; Lin MR, 2010, ARCH PHYS MED REHAB, V91, P474, DOI 10.1016/j.apmr.2009.10.031; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MAHONEY F I, 1965, Md State Med J, V14, P61; Mailhan L, 2005, BRAIN INJURY, V19, P227, DOI 10.1080/02699050410001720149; McCarthy ML, 2006, ARCH PHYS MED REHAB, V87, P953, DOI 10.1016/j.apmr.2006.03.007; McPherson KM, 1996, DISABIL REHABIL, V18, P341, DOI 10.3109/09638289609165892; Pagulayan KF, 2006, ARCH PHYS MED REHAB, V87, P611, DOI 10.1016/j.apmr.2006.01.018; Ribbers GM, 2007, J HEAD TRAUMA REHAB, V22, P234, DOI 10.1097/01.HTR.0000281839.07968.32; Stancin T, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e34; Stineman MG, 1996, ARCH PHYS MED REHAB, V77, P1101, DOI 10.1016/S0003-9993(96)90130-6; Truelle JL, 2010, BRAIN INJURY, V24, P1272, DOI 10.3109/02699052.2010.506865; Turner-Stokes L, 1999, CLIN REHABIL, V13, P277, DOI 10.1191/026921599676896799; Van Baalen B, 2008, BRAIN INJURY, V22, P25, DOI 10.1080/02699050701810662; Van Baalen B, 2003, DISABIL REHABIL, V25, P9, DOI 10.1080/713813430; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Ware JE., 1993, SF 36 HLTH SURVEY MA; Ware JE., 1994, SF 36 PHYS MENTAL HL, V1st; Willemse-Van Son AHP, 2009, J REHABIL MED, V41, P521, DOI 10.2340/16501977-0377; World Health Organization, 2002, INT CLASS FUNCT DIS	41	34	36	0	19	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUL	2014	95	7					1268	1276		10.1016/j.apmr.2014.02.002			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	AK5QA	WOS:000338479700007	24561059				2021-06-18	
J	Launey, Y; Nesseler, N; Le Maguet, P; Malledant, Y; Seguin, P				Launey, Yoann; Nesseler, Nicolas; Le Maguet, Pascale; Malledant, Yannick; Seguin, Philippe			Effect of Osmotherapy on Optic Nerve Sheath Diameter in Patients with Increased Intracranial Pressure	JOURNAL OF NEUROTRAUMA			English	Article						intracranial hypertension; adult brain injury; optic nerve sheath diameter; osmotherapy	TRANSORBITAL SONOGRAPHIC EVALUATION; OCULAR SONOGRAPHY; ULTRASOUND; HYPERTENSION; ULTRASONOGRAPHY; FUNDAMENTALS; MANAGEMENT; EXPANSION; ACCURACY	The measurement of ocular nerve sheath diameter (ONSD) via ocular ultrasound scanning is a recent non-invasive method for intracranial pressure (ICP) assessment. Few clinical studies have assessed ONSD variations during osmotherapy for the treatment of sustained increased ICP episodes. The aim of our study was to determine the rate of ONSD variation after mannitol administration for increased ICP episodes. We consecutively included in a prospective, observational study, the patients who had severe acute brain injury and monitored with an invasive ICP monitor. For each episode of sustained elevated ICP, the ONSD was measured in the right and left eye with a 7.5-MHz echography probe, and the mean value was reported. Simultaneously, ICP and cerebral perfusion pressure (CPP) were recorded. All measurements were performed just before and 20 minutes following a 20% mannitol infusion. Data were expressed as medians and interquartile ranges. Thirteen patients were included and analysed (traumatic brain injury, n=10; subarachnoid haemorrhage, n=3). The median value of the mannitol dose infused was 0.54 g/kg (0.49-0.80 g/kg). In all cases, the ONSD was greater than 5.8 mm before osmotherapy. The ONSD significantly decreased after mannitol infusion from 6.3 (6.1-6.7) to 5. mm (5.5-6.3) (p=0.0007). Concomitantly, the intracranial pressure decreased from 35 (32-41) to 25 (22-29) mmHg (p=0.001) and the CPP increased from 47 (50-60) to 66 (59-69) mmHg (p=0.003). The variations of ONSD appear to be an interesting parameter to evaluate the efficacy of osmotherapy for elevated ICP episodes in patients with acute brain injury.	[Launey, Yoann; Nesseler, Nicolas; Le Maguet, Pascale; Malledant, Yannick; Seguin, Philippe] Hop Pontchaillou, CHU Rennes, Dept Anesthesie Reanimat, F-35033 Rennes, France; [Launey, Yoann; Nesseler, Nicolas; Malledant, Yannick; Seguin, Philippe] INSERM, U991, Rennes, France; [Launey, Yoann; Nesseler, Nicolas; Malledant, Yannick; Seguin, Philippe] Univ Rennes 1, Rennes, France	Launey, Y (corresponding author), Hop Pontchaillou, CHU Rennes, Dept Anesthesie Reanimat, 2 Rue Henri Le Guilloux, F-35033 Rennes, France.	yoann.launey@chu-rennes.fr	Seguin, Philippe/P-9487-2019; Launey, Yoann/AAN-7176-2020	Seguin, Philippe/0000-0002-7774-4257; Launey, Yoann/0000-0001-9105-8862; Malledant, yannick/0000-0001-6680-5184			BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Blaivas M, 2003, ACAD EMERG MED, V10, P376, DOI 10.1197/aemj.10.4.376; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Brain Trauma Foundation American Association of Neurological Surgeons Congress of Neurological Surgeons, 2007, J NEUROTRAUM, V24, pS45, DOI DOI 10.1089/NEU.2007.9989; Connolly ES, 2012, STROKE, V43, P1711, DOI 10.1161/STR.0b013e3182587839; Dubourg J, 2011, ACTA ANAESTH SCAND, V55, P899, DOI 10.1111/j.1399-6576.2011.02468.x; Dubourg J, 2012, J NEUROSURG-PEDIATR, V9, P570, DOI 10.3171/2011.10.PEDS11458; Dubourg J, 2011, INTENS CARE MED, V37, P1059, DOI 10.1007/s00134-011-2224-2; Geeraerts T, 2008, INTENS CARE MED, V34, P2062, DOI 10.1007/s00134-008-1149-x; Geeraerts T, 2007, INTENS CARE MED, V33, P1704, DOI 10.1007/s00134-007-0797-6; Geeraerts T, 2008, CRIT CARE, V12, DOI 10.1186/cc6893; Hansen HC, 2011, ACTA OPHTHALMOL, V89, pE528, DOI 10.1111/j.1755-3768.2011.02159.x; Hansen HC, 1997, J NEUROSURG, V87, P34, DOI 10.3171/jns.1997.87.1.0034; Hansen HC, 1996, SURG RADIOL ANAT, V18, P323, DOI 10.1007/BF01627611; Helmke K, 1996, PEDIATR RADIOL, V26, P706, DOI 10.1007/BF01383384; Helmke K, 1996, PEDIATR RADIOL, V26, P701, DOI 10.1007/BF01383383; LIU D, 1993, AM J OPHTHALMOL, V116, P548, DOI 10.1016/S0002-9394(14)73195-2; MARSHALL LF, 1979, J NEUROSURG, V50, P26, DOI 10.3171/jns.1979.50.1.0026; Moretti R, 2009, J NEUROSURG ANESTH, V21, P16, DOI 10.1097/ANA.0b013e318185996a; Newman WD, 2002, BRIT J OPHTHALMOL, V86, P1109, DOI 10.1136/bjo.86.10.1109; Ract C, 2007, INTENS CARE MED, V33, P645, DOI 10.1007/s00134-007-0558-6; Rajajee V, 2012, CRIT CARE, V16, DOI [10.1186/cc11336, 10.1186/CC11336]; Regillo C. D., 1999, OPHTHALMOLOGY; Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138; Soldatos T, 2009, EMERG MED J, V26, P630, DOI 10.1136/emj.2008.058453; Soldatos T, 2008, CRIT CARE, V12, DOI 10.1186/cc6897; Wakai A, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001049.pub5; Young Jeanne, 2006, Intensive Crit Care Nurs, V22, P32, DOI 10.1016/j.iccn.2005.04.004	28	34	39	1	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY 15	2014	31	10					984	988		10.1089/neu.2012.2829			5	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AH1ES	WOS:000335863200010	24372319				2021-06-18	
J	Garcia-Ovejero, D; Gonzalez, S; Paniagua-Torija, B; Lima, A; Molina-Holgado, E; De Nicola, AF; Labombarda, F				Garcia-Ovejero, Daniel; Gonzalez, Susana; Paniagua-Torija, Beatriz; Lima, Analia; Molina-Holgado, Eduardo; De Nicola, Alejandro F.; Labombarda, Florencia			Progesterone Reduces Secondary Damage, Preserves White Matter, and Improves Locomotor Outcome after Spinal Cord Contusion	JOURNAL OF NEUROTRAUMA			English	Article						oligodendrocytes; spinal cord injury; spare white matter; progesterone; CatWalk	TRAUMATIC BRAIN-INJURY; FUNCTIONAL RECOVERY; GAIT ANALYSIS; SCIATIC-NERVE; RAT; OLIGODENDROCYTE; MOTOR; EXPRESSION; INCREASES; NEURONS	Progesterone is an anti-inflammatory and promyelinating agent after spinal cord injury, but its effectiveness on functional recovery is still controversial. In the current study, we tested the effects of chronic progesterone administration on tissue preservation and functional recovery in a clinically relevant model of spinal cord lesion (thoracic contusion). Using magnetic resonance imaging, we observed that progesterone reduced both volume and rostrocaudal extension of the lesion at 60 days post-injury. In addition, progesterone increased the number of total mature oligodendrocytes, myelin basic protein immunoreactivity, and the number of axonal profiles at the epicenter of the lesion. Further, progesterone treatment significantly improved motor outcome as assessed using the Basso-Bresnahan-Beattie scale for locomotion and CatWalk gait analysis. These data suggest that progesterone could be considered a promising therapeutical candidate for spinal cord injury.	[Garcia-Ovejero, Daniel; Paniagua-Torija, Beatriz; Molina-Holgado, Eduardo] Hosp Nacl Paraplej, Lab Neuroinflamac, Toledo, Spain; [Gonzalez, Susana] Inst Biol & Med Expt, Lab Nocicepc & Dolor Neuropat, RA-1428 Buenos Aires, DF, Argentina; [Lima, Analia; De Nicola, Alejandro F.; Labombarda, Florencia] Inst Biol & Med Expt, Lab Bioquim Neuroendocrina, RA-1428 Buenos Aires, DF, Argentina; [Gonzalez, Susana; De Nicola, Alejandro F.; Labombarda, Florencia] Univ Buenos Aires, Dept Human Biochem, Sch Med, Buenos Aires, DF, Argentina	Labombarda, F (corresponding author), Inst Biol & Med Expt CONICET, Lab Bioquim Neuroendocrina, Vuelta Obligado 2490, RA-1428 Buenos Aires, DF, Argentina.	florlabombarda@gmail.com	Garcia-Ovejero, Daniel/H-9090-2019; Molina-Holgado, Eduardo/C-2714-2008	Garcia-Ovejero, Daniel/0000-0002-7479-5104; Molina-Holgado, Eduardo/0000-0001-6693-1682	University of Buenos AiresUniversity of Buenos Aires [UBACyT 2011-2014: 20020100200053, UBACyT 2011-2014: 20020100100089]; Wings for Life Foundation	We thank Dr. Angel Arevalo-Martin for his generous assistance with MRI interpretation and his contribution to the development of some quantification procedures. We also are grateful to Dr. Jorge Collazos-Castro for his selfless help and generosity in sharing his knowledge. We thank Javier Mazario for his generous assistance with thermical and mechanical sensitivity tests. We thank Marien Fernandez, David Castejon, and Palmira Villa (CAI de Resonancia Magnetica, Instituto Pluridisciplinar, Universidad Complutense de Madrid) for technical assistance with the MRI. This work was supported by the University of Buenos Aires (UBACyT 2011-2014: 20020100200053 - / UBACyT 2011-2014: 20020100100089). B. Paniagua was partially funded by Wings for Life Foundation.	Alsina B, 2001, NAT NEUROSCI, V4, P1093, DOI 10.1038/nn735; Ambrozaitis Kazys Vytautas, 2006, Medicina (Kaunas), V42, P255; Arevalo-Martin A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049057; Arevalo-Martin A, 2010, NEUROBIOL DIS, V38, P304, DOI 10.1016/j.nbd.2010.02.002; Azcoitia I, 2003, NEUROBIOL AGING, V24, P853, DOI 10.1016/S0197-4580(02)00234-8; Ballermann M, 2006, EUR J NEUROSCI, V23, P1988, DOI 10.1111/j.1460-9568.2006.04726.x; Bareyre FM, 2004, NAT NEUROSCI, V7, P269, DOI 10.1038/nn1195; Barriere G, 2008, J NEUROSCI, V28, P3976, DOI 10.1523/JNEUROSCI.5692-07.2008; Basso DM, 2004, J NEUROTRAUM, V21, P395, DOI 10.1089/089771504323004548; Basso DM, 2002, RESTOR NEUROL NEUROS, V20, P189; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Basso DM, 2000, PHYS THER, V80, P808, DOI 10.1093/ptj/80.8.808; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; Beattie MS, 2000, J NEUROTRAUM, V17, P915, DOI 10.1089/neu.2000.17.915; Ben Borgens R, 2012, Q REV BIOL, V87, P89, DOI 10.1086/665457; Bodley R, 2002, EUR J RADIOL, V42, P135, DOI 10.1016/S0720-048X(02)00046-3; BRACKEN MB, 1990, MED J AUSTRALIA, V153, P368, DOI 10.5694/j.1326-5377.1990.tb136976.x; Bracken MB, 1997, JAMA-J AM MED ASSOC, V277, P1597, DOI 10.1001/jama.277.20.1597; BRESNAHAN JC, 1987, EXP NEUROL, V95, P548, DOI 10.1016/0014-4886(87)90299-8; Cadotte DW, 2011, CLIN ORTHOP RELAT R, V469, P732, DOI 10.1007/s11999-010-1674-0; Ciriza I, 2004, J NEUROENDOCRINOL, V16, P58, DOI 10.1111/j.1365-2826.2004.01121.x; Ciriza I, 2006, J NEUROBIOL, V66, P916, DOI 10.1002/neu.20293; Clarac F, 2008, BRAIN RES REV, V57, P13, DOI 10.1016/j.brainresrev.2007.07.015; Coleman MP, 2002, TRENDS NEUROSCI, V25, P532, DOI 10.1016/S0166-2236(02)02255-5; Cutler SM, 2007, J NEUROTRAUM, V24, P1475, DOI 10.1089/neu.2007.0294; De Nicola AF, 2009, FRONT NEUROENDOCRIN, V30, P173, DOI 10.1016/j.yfrne.2009.03.001; Deumens R, 2006, EXP NEUROL, V200, P89, DOI 10.1016/j.expneurol.2006.01.030; Deumens R, 2007, J NEUROSCI METH, V164, P120, DOI 10.1016/j.jneumeth.2007.04.009; Dolan S, 2007, EUR J PAIN, V11, P644, DOI 10.1016/j.ejpain.2006.10.002; Fee DB, 2007, BRAIN RES, V1137, P146, DOI 10.1016/j.brainres.2006.12.024; FEHLINGS MG, 1995, EXP NEUROL, V132, P220, DOI 10.1016/0014-4886(95)90027-6; Flygt J, 2013, EUR J NEUROSCI, V38, P2153, DOI 10.1111/ejn.12179; Gago N, 2001, GLIA, V36, P295, DOI 10.1002/glia.1117; Garay L, 2011, NEUROSCIENCE, V192, P588, DOI 10.1016/j.neuroscience.2011.06.065; Garay LI, 2012, NEUROSCIENCE, V226, P40, DOI 10.1016/j.neuroscience.2012.09.032; Garcia-Ovejero D, 2013, J COMP NEUROL, V521, P233, DOI 10.1002/cne.23184; Ghoumari AM, 2005, NEUROSCIENCE, V135, P47, DOI 10.1016/j.neuroscience.2005.05.023; Giatti S, 2012, J NEUROENDOCRINOL, V24, P851, DOI 10.1111/j.1365-2826.2012.02284.x; GOLDBERG AL, 1990, CLIN IMAG, V14, P11, DOI 10.1016/0899-7071(90)90111-N; Gonzalez SL, 2004, NEUROSCIENCE, V125, P605, DOI 10.1016/j.neuroscience.2004.02.024; Grossman KJ, 2004, BRAIN RES, V1008, P29, DOI 10.1016/j.brainres.2004.02.022; Guertin PA, 2009, BRAIN RES REV, V62, P45, DOI 10.1016/j.brainresrev.2009.08.002; Guo QM, 2006, EXP NEUROL, V198, P469, DOI 10.1016/j.expneurol.2005.12.013; Hamers FPT, 2006, J NEUROTRAUM, V23, P537, DOI 10.1089/neu.2006.23.537; Hamers FPT, 2001, J NEUROTRAUM, V18, P187, DOI 10.1089/08977150150502613; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; Hendriks WTJ, 2006, J NEUROTRAUM, V23, P18, DOI 10.1089/neu.2006.23.18; Huang WL, 2007, BRAIN, V130, P3004, DOI 10.1093/brain/awm223; Joosten EAJ, 2004, J NEUROSCI RES, V77, P127, DOI 10.1002/jnr.20088; Kloos AD, 2005, EXP NEUROL, V191, P251, DOI 10.1016/j.expneurol.2004.09.016; Koopmans GC, 2006, EUR J NEUROSCI, V23, P1035, DOI 10.1111/j.1460-9568.2006.04627.x; Koopmans GC, 2005, J NEUROTRAUM, V22, P214, DOI 10.1089/neu.2005.22.214; Kwon BK, 2011, J NEUROTRAUM, V28, P1545, DOI 10.1089/neu.2009.1149; Labombarda F, 2006, ENDOCRINOLOGY, V147, P1847, DOI 10.1210/en.2005-0955; Labombarda F, 2006, J NEUROTRAUM, V23, P181, DOI 10.1089/neu.2006.23.181; Labombarda F, 2002, J NEUROTRAUM, V19, P343, DOI 10.1089/089771502753594918; Labombarda F, 2011, EXP NEUROL, V231, P135, DOI 10.1016/j.expneurol.2011.06.001; Labombarda F, 2009, GLIA, V57, P884, DOI 10.1002/glia.20814; Lambert JJ, 2003, PROG NEUROBIOL, V71, P67, DOI 10.1016/j.pneurobio.2003.09.001; Lammertse DP, 2013, SPINAL CORD, V51, P2, DOI 10.1038/sc.2012.137; Lankhorst AJ, 2001, J NEUROTRAUM, V18, P203, DOI 10.1089/08977150150502622; Leonelli E, 2006, J MOL NEUROSCI, V28, P65, DOI 10.1385/JMN:28:1:65; Ma MH, 2001, EXP NEUROL, V169, P239, DOI 10.1006/exnr.2001.7679; Magnuson DSK, 1999, EXP NEUROL, V156, P191, DOI 10.1006/exnr.1999.7016; Nguyen T, 2009, J NEUROSCI, V29, P630, DOI 10.1523/JNEUROSCI.5204-08.2009; Obata K, 2004, J NEUROSCI, V24, P10211, DOI 10.1523/JNEUROSCI.3388-04.2004; Parashari UC, 2011, J CRANIOVERTEBRAL JU, V2, P17, DOI 10.4103/0974-8237.85309; PEARSON KG, 1991, J NEUROPHYSIOL, V66, P1874; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Rabchevsky AG, 2007, GLIA, V55, P831, DOI 10.1002/glia.20508; Rabchevsky AG, 2011, PHARMACOL THERAPEUT, V132, P15, DOI 10.1016/j.pharmthera.2011.05.001; Raineteau O, 2002, EUR J NEUROSCI, V16, P1761, DOI 10.1046/j.1460-9568.2002.02243.x; Reier PJ, 2002, PROG BRAIN RES, V137, P49; Robertson CL, 2006, EXP NEUROL, V197, P235, DOI 10.1016/j.expneurol.2005.09.014; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099; Schmitz C, 2005, NEUROSCIENCE, V130, P813, DOI 10.1016/j.neuroscience.2004.08.050; Schucht P, 2002, EXP NEUROL, V176, P143, DOI 10.1006/exnr.2002.7909; Schumacher M, 2012, FRONT NEUROSCI-SWITZ, V6, DOI 10.3389/fnins.2012.00010; Singh A, 2011, NEUROREHAB NEURAL RE, V25, P24, DOI 10.1177/1545968310378510; Stein DG, 2011, NEUROSCIENCE, V191, P101, DOI 10.1016/j.neuroscience.2011.04.013; Stein DG, 2008, BRAIN RES REV, V57, P386, DOI 10.1016/j.brainresrev.2007.06.012; Stirling DP, 2004, J NEUROSCI, V24, P2182, DOI 10.1523/JNEUROSCI.5275-03.2004; Thomas AJ, 1999, SPINE, V24, P2134, DOI 10.1097/00007632-199910150-00013; Van Meeteren NLU, 2003, J NEUROTRAUM, V20, P1029, DOI 10.1089/089771503770195876; Vlamings R, 2007, NEUROSCIENCE, V148, P815, DOI 10.1016/j.neuroscience.2007.06.043; Vrinten DH, 2003, PAIN, V102, P203, DOI 10.1016/S0304-3959(02)00382-2; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887	89	34	35	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY 1	2014	31	9					857	871		10.1089/neu.2013.3162			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AF6TQ	WOS:000334847900007	24460450	Green Published			2021-06-18	
J	Su, SH; Xu, W; Li, M; Zhang, L; Wu, YF; Yu, F; Hai, J				Su, Shao-Hua; Xu, Wei; Li, Ming; Zhang, Lin; Wu, Yi-Fang; Yu, Fei; Hai, Jian			Elevated C-reactive protein levels may be a predictor of persistent unfavourable symptoms in patients with mild traumatic brain injury: A preliminary study	BRAIN BEHAVIOR AND IMMUNITY			English	Article						Mild traumatic brain injury; High-sensitivity C-reactive protein; Postconcussion syndrome; Depression; Anxiety; Cognitive impairment	INFLAMMATORY RESPONSE SYNDROME; COGNITIVE IMPAIRMENT; SUBARACHNOID HEMORRHAGE; POSTCONCUSSION SYNDROME; CLINICAL-PRACTICE; HEAD-INJURY; DEPRESSION; DISEASE; ADULTS; QUESTIONNAIRE	The pathogenesis of persistent unfavourable outcomes following mild traumatic brain injury (mTBI) are not fully understood. Low-grade systemic inflammation might contribute to the development of persistent unfavourable outcomes in patients with mTBI. We used plasma high-sensitivity C-reactive protein (CRP) levels as the biomarker of systemic inflammation to investigate whether elevated CRP levels were associated with persistent adverse outcomes in these patients. A total of 213 consecutive patients with mTBI were identified in our study. Plasma high-sensitivity CRP levels were measured at baseline, 1 month, 2 months and 3 months after initial traumatic brain injury. The study endpoints included persistent postconcussion syndrome (PCS), persistent psychological problems (depression and anxiety), persistent physiological problems (frequent headache, nausea, insomnia, dizziness and fatigue) and persistent cognitive impairment, which were screened by International Classification of Diseases (ICD-10), diagnostic and statistical manual of mental disorders (DSM-IV), Beck anxiety inventory (BAI), Beck depression inventory (BDI) and montreal cognitive assessment (MoCA) 3 months post-injury. The associations between baseline CRP levels and persistent unfavourable outcomes were estimated from multiple regression models adjusting for various confounding covariates. Elevated baseline CRP levels were associated with a significant increase in the incidence of persistent PCS (odds ratio [OR], 2.719; 95% confidence interval [CI], 1.609-4.594; p = 0.000), persistent psychological problems (OR, 1.535; 95% CI, 1.063-2.216; p = 0.022), and persistent cognitive impairment (OR, 1.687; 95% CI, 1.135-2.507; p = 0.010). However, elevated CRP levels were not associated with persistent physiological problems (OR, 1.330; 95% CI, 0.905-1.956; p = 0.146). Furthermore, three adjusted models did not essentially affect the OR of elevated CRP levels for these persistent unfavourable outcomes. Among patients with mTBI, baseline elevated CRP levels may be an independent predictor of persistent persistent PCS, psychological problems and cognitive impairment. (C) 2014 Elsevier Inc. All rights reserved.	[Su, Shao-Hua; Wu, Yi-Fang; Yu, Fei; Hai, Jian] Tongji Univ, Sch Med, Tongji Hosp, Dept Neurosurg, Shanghai 200065, Peoples R China; [Xu, Wei] Shanghai Changning Cent Hosp, Dept Trauma Ctr, Shanghai 200036, Peoples R China; [Li, Ming] Shanghai Jiao Tong Univ, Sch Med, Dept Emergency, Xinhua Hosp, Shanghai 200092, Peoples R China; [Zhang, Lin] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 6, Dept Neurosurg, Shanghai 200003, Peoples R China	Su, SH (corresponding author), Tongji Univ, Sch Med, Tongji Hosp, Dept Neurosurg, 389 Xincun Rd, Shanghai 200065, Peoples R China.	sushdoc@sohu.com; haijiandoc@163.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30772233, 81071063, 81271212]	This work was supported by the National Natural Science Foundation of China (Grant Nos: 30772233, 81071063 and 81271212 to J. Hai).	Allin KH, 2009, J CLIN ONCOL, V27, P2217, DOI 10.1200/JCO.2008.19.8440; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Arfanakis K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073107; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Black S, 2004, J BIOL CHEM, V279, P48487, DOI 10.1074/jbc.R400025200; Briones T. L., 2013, BRAIN BEHAV IMMUN, VS0889-1591, P00409; Capuron L, 2011, PHARMACOL THERAPEUT, V130, P226, DOI 10.1016/j.pharmthera.2011.01.014; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Dernellis J, 2004, EUR HEART J, V25, P1100, DOI 10.1016/j.ehj.2004.04.025; Dickerson F, 2012, SCHIZOPHR RES, V134, P83, DOI 10.1016/j.schres.2011.10.003; Evans RW, 2010, HEADACHE, V50, P716, DOI 10.1111/j.1526-4610.2010.01645.x; Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607; Grossman EJ, 2013, AM J NEURORADIOL, V34, P951, DOI 10.3174/ajnr.A3358; Haroon E, 2012, NEUROPSYCHOPHARMACOL, V37, P137, DOI 10.1038/npp.2011.205; Hergenroeder G, 2008, J NEUROTRAUM, V25, P79, DOI 10.1089/neu.2007.0386; Jorge RE, 2012, AM J PSYCHIAT, V169, P1284, DOI 10.1176/appi.ajp.2012.12050600; King NS, 2011, BRAIN INJURY, V25, P462, DOI 10.3109/02699052.2011.558042; Kirsch NL, 2010, ARCH PHYS MED REHAB, V91, P35, DOI 10.1016/j.apmr.2009.09.019; LAWSON LJ, 1990, NEUROSCIENCE, V39, P151, DOI 10.1016/0306-4522(90)90229-W; Lindqvist D, 2013, BRAIN BEHAV IMMUN, V33, P183, DOI 10.1016/j.bbi.2013.07.007; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Marshall S, 2012, CAN FAM PHYSICIAN, V58, P257; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Miller AH, 2009, BIOL PSYCHIAT, V65, P732, DOI 10.1016/j.biopsych.2008.11.029; Murray KN, 2013, MOL CELL NEUROSCI, V53, P14, DOI 10.1016/j.mcn.2012.09.004; Mustafa T, 2013, ADV PHARMACOL, V68, P445, DOI 10.1016/B978-0-12-411512-5.00021-X; Musunuru K, 2008, NAT CLIN PRACT CARD, V5, P621, DOI 10.1038/ncpcardio1322; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; Nazmi A, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-212; Nolin P, 2006, J HEAD TRAUMA REHAB, V21, P514, DOI 10.1097/00001199-200611000-00006; Paniak C, 2002, ARCH CLIN NEUROPSYCH, V17, P319, DOI 10.1016/S0887-6177(01)00115-9; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Prigatano GP, 2011, CURR OPIN PSYCHIATR, V24, P243, DOI 10.1097/YCO.0b013e328344698b; Qin LY, 2007, GLIA, V55, P453, DOI 10.1002/glia.20467; Raison CL, 2011, CURR PSYCHIAT REP, V13, P467, DOI 10.1007/s11920-011-0232-0; Reuben A., 2013, EMERG MED J; Shaaban R, 2006, RESP MED, V100, P2112, DOI 10.1016/j.rmed.2006.03.027; Shacham Y, 2013, J CARDIOL, V2013; SHEK DTL, 1990, J CLIN PSYCHOL, V46, P35, DOI 10.1002/1097-4679(199001)46:1<35::AID-JCLP2270460106>3.0.CO;2-W; Silverberg ND, 2011, NEUROREHABILITATION, V29, P317, DOI 10.3233/NRE-2011-0708; Tam AKH, 2010, NEUROCRIT CARE, V13, P182, DOI 10.1007/s12028-010-9402-x; Tiainen M., 2013, INT J STROKE; Visser M, 1999, JAMA-J AM MED ASSOC, V282, P2131, DOI 10.1001/jama.282.22.2131; Wium-Andersen MK, 2013, JAMA PSYCHIAT, V70, P176, DOI 10.1001/2013.jamapsychiatry.102; Wood R. L., 2013, J HEAD TRAUMA REHABI; World Health Organization, 1992, ICD 10 INT STAT CLAS; Wortzel H., 2013, BEHAV SCI LAW; Wu SFV, 2011, INT J NURS STUD, V48, P1376, DOI 10.1016/j.ijnurstu.2011.04.008; Yamada A, 2009, J NEUROCHEM, V110, P791, DOI 10.1111/j.1471-4159.2009.06175.x; Yang SH, 2013, J SURG RES, V184, P981, DOI 10.1016/j.jss.2013.03.075; Yoshimoto Y, 2001, STROKE, V32, P1989, DOI 10.1161/hs0901.095646; [张立秀 Zhang Lixiu], 2008, [中国心理卫生杂志, Chinese Mental Health Journal], V22, P123	53	34	37	0	16	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1591	1090-2139		BRAIN BEHAV IMMUN	Brain Behav. Immun.	MAY	2014	38						111	117		10.1016/j.bbi.2014.01.009			7	Immunology; Neurosciences; Psychiatry	Immunology; Neurosciences & Neurology; Psychiatry	AF8RU	WOS:000334984100012	24456846				2021-06-18	
J	Zonfrillo, MR; Durbin, DR; Koepsell, TD; Wang, J; Temkin, NR; Dorsch, AM; Vavilala, MS; Jaffe, KM; Rivara, FP				Zonfrillo, Mark R.; Durbin, Dennis R.; Koepsell, Thomas D.; Wang, Jin; Temkin, Nancy R.; Dorsch, Andrea M.; Vavilala, Monica S.; Jaffe, Kenneth M.; Rivara, Frederick P.			Prevalence of and Risk Factors for Poor Functioning after Isolated Mild Traumatic Brain Injury in Children	JOURNAL OF NEUROTRAUMA			English	Article						outcome measures; epidemiology; pediatric brain injury; prospective study	QUALITY-OF-LIFE; OUTCOMES; RELIABILITY; VALIDITY; PEDSQL(TM)-4.0	This study aimed to determine the prevalence and predictors of poor 3 and 12 month quality of life outcomes in a cohort of pediatric patients with isolated mild TBI. We conducted a prospective cohort study of children and adolescents <18 years of age treated for an isolated mild TBI, defined as "no radiographically apparent intracranial injury" or "an isolated skull fracture, and no other clinically significant non-brain injuries." The main outcome measure was the change in quality of life from baseline at 3 and 12 months following injury, as measured by the Pediatric Quality of Life index (PedsQL). Poor functioning was defined as a decrease in total PedsQL score of >15 points between baseline and follow-up scores (at 3 and 12 months). Of the 329 patients who met inclusion criteria, 11.3% (95% CI 8.3-15.3%) at 3 months and 12.9% (95% CI 9.6-17.2%) at 12 months following injury had relatively poor functioning. Significant predictors of poor functioning included less parental education, Hispanic ethnicity (at 3 months following injury, but not at 12 months); low household income (at 3 and 12 months), and Medicaid insurance (at 12 months only). Children and adolescents sustaining a mild TBI who are socioeconomically disadvantaged may require additional intervention to mitigate the effects of mild TBI on their functioning.	[Zonfrillo, Mark R.; Durbin, Dennis R.] Childrens Hosp Philadelphia, Ctr Injury Res & Prevent, Philadelphia, PA 19104 USA; [Zonfrillo, Mark R.; Durbin, Dennis R.] Childrens Hosp Philadelphia, Div Emergency Med, Philadelphia, PA 19104 USA; [Zonfrillo, Mark R.; Durbin, Dennis R.] Univ Penn, Dept Pediat, Philadelphia, PA 19104 USA; [Zonfrillo, Mark R.; Durbin, Dennis R.] Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; [Koepsell, Thomas D.; Rivara, Frederick P.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; [Temkin, Nancy R.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Wang, Jin; Vavilala, Monica S.; Jaffe, Kenneth M.; Rivara, Frederick P.] Univ Washington, Dept Pediat, Seattle, WA 98195 USA; [Temkin, Nancy R.] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Dorsch, Andrea M.; Jaffe, Kenneth M.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Vavilala, Monica S.] Univ Washington, Dept Anesthesiol, Seattle, WA 98195 USA; [Koepsell, Thomas D.; Wang, Jin; Vavilala, Monica S.; Jaffe, Kenneth M.; Rivara, Frederick P.] Univ Washington, Harborview Injury Prevent & Res Ctr, Seattle, WA 98195 USA	Zonfrillo, MR (corresponding author), Childrens Hosp Philadelphia, Div Emergency Med, 34th & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	zonfrillo@email.chop.edu	Zonfrillo, Mark R./H-9403-2017	Zonfrillo, Mark R./0000-0002-0610-9563	National Center for Injury Prevention and Control, CDCUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49 CE 001021]; Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [1K08HD073241-02]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08HD073241] Funding Source: NIH RePORTER; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE001021] Funding Source: NIH RePORTER	This project was supported by the National Center for Injury Prevention and Control, CDC grant R49 CE 001021, and by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health (NIH) grant 1K08HD073241-02. The CDC and the NIH had no role in the design or conduct of the study; collection, management, analysis, or interpretation of the data; or preparation, review, or approval of the manuscript.	Association for the Advancement of Automotive Medicine, 2008, ABBR INJ SCAL 2005; Babikian T, 2011, J INT NEUROPSYCH SOC, V17, P886, DOI 10.1017/S1355617711000907; Blume HK, 2012, PEDIATRICS, V129, pE31, DOI 10.1542/peds.2011-1742; Carroll Christopher P, 2010, Ann Adv Automot Med, V54, P233; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Centers for Disease Control and Prevention, 2003, C MILD TRAUM BRAIN I; Centers for Disease Control and Prevention National Centers for Injury Prevention and Control, CONC MILD TBI; Haider AH, 2007, J TRAUMA, V62, P1259, DOI 10.1097/TA.0b013e31803c760e; Hakmeh W, 2010, ACAD EMERG MED, V17, P809, DOI 10.1111/j.1553-2712.2010.00819.x; Huang IC, 2009, VALUE HEALTH, V12, P773, DOI 10.1111/j.1524-4733.2008.00487.x; Keenan HT, 2006, PEDIATRICS, V117, P1291, DOI 10.1542/peds.2005-1883; Keenan HT, 2006, PEDIATRICS, V117, P317, DOI 10.1542/peds.2005-0979; Koepsell TD, 2011, PEDIATRICS, V128, P946, DOI 10.1542/peds.2010-2259; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Marr AL., 2004, CENTRAL NERVOUS SYST; McCarthy ML, 2007, J TRAUMA, V63, pS122, DOI 10.1097/TA.0b013e31815accdf; McCarthy ML, 2006, ARCH PEDIAT ADOL MED, V160, P252, DOI 10.1001/archpedi.160.3.252; McCarthy ML, 2005, ARCH PHYS MED REHAB, V86, P1901, DOI 10.1016/j.apmr.2005.03.026; McKinlay A, 2010, CHILD CARE HLTH DEV, V36, P3, DOI 10.1111/j.1365-2214.2009.01006.x; Rivara FP, 2011, PEDIATRICS, V128, pE1129, DOI 10.1542/peds.2011-0840; Sroufe NS, 2010, PEDIATRICS, V125, pE1331, DOI 10.1542/peds.2008-2364; Steinberg Alan M, 2004, Curr Psychiatry Rep, V6, P96, DOI 10.1007/s11920-004-0048-2; Tham SW, 2012, J NEUROTRAUM, V29, P154, DOI 10.1089/neu.2011.2126; Varni JW, 2003, AMBUL PEDIATR, V3, P329, DOI 10.1367/1539-4409(2003)003<0329:TPAAPP>2.0.CO;2; Varni JW, 2001, MED CARE, V39, P800, DOI 10.1097/00005650-200108000-00006; Yeates KO, 2012, ARCH PEDIAT ADOL MED, V166, P615, DOI 10.1001/archpediatrics.2011.1082; Zonfrillo M. R., 2012, PEDIATRICS, V52, P397	27	34	34	0	15	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR 15	2014	31	8					722	727		10.1089/neu.2013.3088			6	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AD7PX	WOS:000333457200003	24294826	Green Published			2021-06-18	
J	Du, W; Yang, J; Powis, B; Zheng, XY; Ozanne-Smith, J; Bilston, L; He, JL; Ma, T; Wang, XF; Wu, M				Du, Wei; Yang, Jie; Powis, Brent; Zheng, Xiaoying; Ozanne-Smith, Joan; Bilston, Lynne; He, JingLin; Ma, Ting; Wang, Xiaofei; Wu, Ming			Epidemiological profile of hospitalised injuries among electric bicycle riders admitted to a rural hospital in Suzhou: a cross-sectional study	INJURY PREVENTION			English	Article							CHINA	Police reports indicate an increasing burden of electric bike (E-bike) casualties in China; however, hospitalised injury data have not been reported. The aim of the present work was to describe hospitalised injury patterns for E-bikers involved in road crashes and explore injury risk disparities among them. For the period October 2010 to April 2011, this cross-sectional study retrospectively collected information for hospitalised E-bikers involved in road crashes from hospital records, in Suzhou China, using the International Classification of Diseases, 10th revision (ICD-10) injury diagnosis codes. Injury nature and body region were further categorised using ICD-10 codes. Multivariate logistic regression was used to assess the risk of specific injury types. We found that hospitalised E-biker injuries (n=323) accounted for 57.2% of road traffic hospitalisations over the 6-month study period. The average age, length of stay and hospitalisation cost were 43.8years, 10.0days and yen8229 (US$1286), respectively. Fractures and head injuries were common. The odds of traumatic brain injuries were significantly elevated for night-time E-bike crashes and incidents other than colliding with motor vehicles. These findings confirm E-bike injuries as an important population health problem and identify elevated injury odds in different E-biker groups. Future injury prevention initiatives should include encouraging helmet use among E-bikers.	[Du, Wei; Zheng, Xiaoying] Peking Univ, Inst Populat Res, Beijing 100871, Peoples R China; [Du, Wei; Bilston, Lynne] Univ New S Wales, Neurosci Res Australia, Randwick, NSW, Australia; [Yang, Jie; Wu, Ming] Jiangsu Prov Ctr Dis Control, Nanjing, Jiangsu, Peoples R China; [Powis, Brent] Int Med Univ, Sch Postgrad Studies & Res, Kuala Lumpur 57000, Malaysia; [Ozanne-Smith, Joan] Monash Univ, Dept Forens Med, Melbourne, Vic 3004, Australia; [He, JingLin] World Hlth Org Beijing Off, Beijing, Peoples R China; [Ma, Ting; Wang, Xiaofei] Third Municipal Hosp Zhangjiagang, Suzhou, Peoples R China	Du, W (corresponding author), Peking Univ, Inst Populat Res WHO Collaborating Ctr Reprod Hlt, Beijing 100871, Peoples R China.	kelvindu@gmail.com; jswuming@vip.sina.com	Bilston, Lynne E/C-9665-2011; Du, Wei/H-5376-2012	Bilston, Lynne E/0000-0001-8250-9019; Du, Wei/0000-0003-3622-2265	Bloomberg Philanthropies as part of the Road Safety in 10 Countries Project in China	This project received funding support from Bloomberg Philanthropies as part of the Road Safety in 10 Countries Project in China.	Barros Aluísio J. D., 2003, Cad. Saúde Pública, V19, P979, DOI 10.1590/S0102-311X2003000400021; China National People's Congress, 2004, LAW PEOPL REP CHIN R; Duan L, 2010, J PUBLIC HLTH PREVEN, V21, P10; Feng ZY, 2010, INJURY PREV, V16, DOI 10.1136/ip.2009.024646; Horan JM, 2003, EPIDEMIOL REV, V25, P24, DOI 10.1093/epirev/mxg010; Hu GQ, 2011, B WORLD HEALTH ORGAN, V89, P41, DOI 10.2471/BLT.10.080317; Hurst D., 2010, ELECT 2 WHEEL VEHICL; Larson K, 2012, TRAFFIC INJ PREV, V13, P3, DOI 10.1080/15389588.2012.671737; Liu BC, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004333.pub3; Murray CJL, 2012, LANCET, V380, P2197, DOI 10.1016/S0140-6736(12)61689-4; Peden M, WORLD REPORT ON ROAD; Research In China, 2011, IND REP EL BIC CHIN; Thompson DC, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001855; Wang SY, 2008, LANCET, V372, P1765, DOI 10.1016/S0140-6736(08)61367-7; Weinert J, 2007, TRANSPORTATION, V34, P301, DOI 10.1007/s11116-007-9118-8; WHO, 2011, GLOB PLAN DEC ACT RO; World Health Organization, 2004, WORLD REPORT ROAD TR; Wu C, 2012, TRANSPORTATION RES R; Yang CJ, 2010, TECHNOL FORECAST SOC, V77, P831, DOI 10.1016/j.techfore.2010.01.010	19	34	38	3	34	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1353-8047	1475-5785		INJURY PREV	Inj. Prev.	APR	2014	20	2					128	133		10.1136/injuryprev-2012-040618			6	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	AD2AJ	WOS:000333034500010	23728530				2021-06-18	
J	Estraneo, A; Moretta, P; Loreto, V; Santoro, L; Trojano, L				Estraneo, Anna; Moretta, Pasquale; Loreto, Vincenzo; Santoro, Lucio; Trojano, Luigi			Clinical and Neuropsychological Long-Term Outcomes After Late Recovery of Responsiveness: A Case Series	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Outcome assessment (health care); Persistent vegetative state; Rehabilitation	MINIMALLY CONSCIOUS STATE; TRAUMATIC BRAIN-INJURY; VEGETATIVE STATE; FOLLOW-UP; UNRESPONSIVE WAKEFULNESS; COGNITIVE REHABILITATION; DISORDERS; SCALE; COMA; PROGRAM	Objective: To report clinical conditions and neuropsychological functioning of patients with late recovery of responsiveness at least 5 years after injury. Design: Patient series. Setting: Patients discharged from an inpatient rehabilitation unit. Participants: Patients (N=13) who recovered from a vegetative state 1 year after severe traumatic brain injury or 6 months after nontraumatic brain injury. Interventions: Not applicable. Main Outcome Measures: Coma Recovery Scale-Revised, Disability Rating Scale, and FIM. For patients who recovered full consciousness, neuropsychological tests specifically adapted for patients with very severe disabilities were used. Results: After regaining responsiveness, 2 patients died because of severe clinical complications. Among the remaining 11 patients, 5 were still in a minimally conscious state at their last. assessment, but 4 of them had recovered some complex behavioral responses to the environment (eg, they could follow simple commands, albeit inconsistently). Six patients had emerged from a minimally conscious state at the last evaluation. Severe functional disability was present in both patients who were conscious and patients who were minimally conscious. No patient was autonomous in common daily life activities or in transfers. All patients who were conscious showed variable cognitive impairments, and some of them also developed behavioral and psychological symptoms. However, such disturbances did not impede the patients' interaction with relatives and caregivers. Conclusions: This study provides systematic data about the course of the disease in a cohort of patients that was previously considered as exceptional. Patients with late recovery show a variable degree of functional recovery, although they experience marked residual motor and cognitive disabilities. The present findings contribute to enhance the understanding of the course of the disease in patients with late recovery. and might help clinicians optimize the levels of care and provide the patients' families with correct information. (C) 2014 by the American Congress of Rehabilitation Medicine	[Estraneo, Anna; Moretta, Pasquale; Loreto, Vincenzo] Salvatore Maugeri Fdn, IRCCS, Sci Inst Telese Terme, Telese Terme, Italy; [Santoro, Lucio] Univ Naples Federico II, Dept Neurol Sci, Naples, Italy; [Trojano, Luigi] Univ Naples 2, Dept Psychol, Neuropsychol Lab, I-81100 Caserta, Italy	Trojano, L (corresponding author), Univ Naples 2, Dept Psychol, Viale Ellitt 31, I-81100 Caserta, Italy.	luigi.trojano@unina2.it	Moretta, Pasquale/AAE-5162-2021; Trojano, Luigi/F-2396-2016	Moretta, Pasquale/0000-0003-2244-254X; Trojano, Luigi/0000-0002-0328-9642; Santoro, Lucio/0000-0001-9507-2303	Salvatore Maugeri Foundation	Supported by the Salvatore Maugeri Foundation.	ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Avesani R, 2006, BRAIN INJURY, V20, P333, DOI 10.1080/02699050500487605; Bernat JL, 2006, LANCET, V367, P1181, DOI 10.1016/S0140-6736(06)68508-5; Bruno MA, 2011, J NEUROL, V258, P1373, DOI 10.1007/s00415-011-6114-x; DEVOLDER AG, 1994, ACTA NEUROL BELG, V94, P183; Eilander HJ, 2005, BRAIN INJURY, V19, P425, DOI 10.1080/02699050400025299; Elliott L, 2005, NEUROPSYCHOL REHABIL, V15, P480, DOI 10.1080/09602010443000506; Estraneo A, 2010, NEUROLOGY, V75, P239, DOI 10.1212/WNL.0b013e3181e8e8cc; Estraneo A, 2013, NEUROLOGY, V80, P464, DOI 10.1212/WNL.0b013e31827f0f31; Fischer C, 2010, CLIN NEUROPHYSIOL, V121, P1032, DOI 10.1016/j.clinph.2010.02.005; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Gray DS, 2000, BRAIN INJURY, V14, P1003, DOI 10.1080/02699050050191940; Hirschberg R, 2011, NEUROL CLIN, V29, P773, DOI 10.1016/j.ncl.2011.07.009; Katz DI, 2009, PROG BRAIN RES, V177, P73, DOI 10.1016/S0079-6123(09)17707-5; Lammi MH, 2005, ARCH PHYS MED REHAB, V86, P746, DOI 10.1016/j.apmr.2004.11.004; Laureys S, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-68; Lombardi F, 2007, FUNCT NEUROL, V22, P47; Luaute J, 2010, NEUROLOGY, V75, P246, DOI 10.1212/WNL.0b013e3181e8e8df; MACKAY LE, 1992, ARCH PHYS MED REHAB, V73, P635; Nakase-Richardson R, 2012, J NEUROTRAUM, V29, P59, DOI 10.1089/neu.2011.1829; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Sancisi E, 2009, BRAIN INJURY, V23, P163, DOI 10.1080/02699050802660446; Schnakers C, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-35; Trojano L, 2011, FUNCT NEUROL, V26, P55; Trojano L, 2010, ARCH PHYS MED REHAB, V91, P498, DOI 10.1016/j.apmr.2009.10.033; *UNIF DATA SYST ME, 1992, RICERCHE RIABILITAZI, V2, pS1; Voss HU, 2006, J CLIN INVEST, V116, P2005, DOI 10.1172/JCI27021	28	34	34	0	8	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	2014	95	4					711	716		10.1016/j.apmr.2013.11.004			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	AF3YJ	WOS:000334648300019	24275063				2021-06-18	
J	Rosenthal, G; Furmanov, A; Itshayek, E; Shoshan, Y; Singh, V				Rosenthal, Guy; Furmanov, Alex; Itshayek, Eyal; Shoshan, Yigal; Singh, Vineeta			Assessment of a noninvasive cerebral oxygenation monitor in patients with severe traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						brain oxygenation; non-invasive monitor; jugular bulb venous monitor; severe traumatic brain injury	CALCULATING CORRELATION-COEFFICIENTS; TISSUE OXYGEN; INSPIRED OXYGEN; SWINE MODEL; BLOOD-FLOW; HYPEROXIA; TENSION; AUTOREGULATION; RESUSCITATION; METABOLISM	Object. Development of a noninvasive monitor to assess cerebral oxygenation has long been a goal in neurocritical care. The authors evaluated the feasibility and utility of a noninvasive cerebral oxygenation monitor, the CerOx 3110, which uses near-infrared spectroscopy and ultrasound to measure regional cerebral tissue oxygenation in patients with severe traumatic brain injury (TBI), and compared measurements obtained using this device to those obtained using invasive cerebral monitoring. Methods. Patients with severe TBI admitted to the intensive care unit at Hadassah-Hebrew University Hospital requiring intracranial pressure (ICP) monitoring and advanced neuromonitoring were included in this study. The authors assessed 18 patients with severe TBI using the CerOx monitor and invasive advanced cerebral monitors. Results. The mean age of the patients was 45.3 +/- 23.7 years and the median Glasgow Coma Scale score on admission was 5 (interquartile range 3-7). Eight patients underwent unilateral decompressive hemicraniectomy and 1 patient underwent craniotomy. Sixteen patients underwent insertion of a jugular bulb venous catheter, and 18 patients underwent insertion of a Licox brain tissue oxygen monitor. The authors found a strong correlation (r = 0.60, p < 0.001) between the jugular bulb venous saturation from the venous blood gas and the CerOx measure of regional cerebral tissue saturation on the side ipsilateral to the catheter. A multivariate analysis revealed that among the physiological parameters of mean arterial blood pressure, ICP, brain tissue oxygen tension, and CerOx measurements on the ipsilateral and contralateral sides, only ipsilateral CerOx measurements were significantly correlated to jugular bulb venous saturation (p < 0.001). Conclusions. Measuring regional cerebral tissue oxygenation with the CerOx monitor in a noninvasive manner is feasible in patients with severe TBI in the neurointensive care unit. The correlation between the CerOx measurements and the jugular bulb venous measurements of oxygen saturation indicate that the CerOx may be able to provide an estimation of cerebral oxygenation status in a noninvasive manner.	[Rosenthal, Guy; Furmanov, Alex; Itshayek, Eyal; Shoshan, Yigal] Hadassah Hebrew Univ Med Ctr, Dept Neurosurg, IL-91120 Jerusalem, Israel; [Singh, Vineeta] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA	Rosenthal, G (corresponding author), Hadassah Hebrew Univ Med Ctr, Dept Neurosurg, POB 12000, IL-91120 Jerusalem, Israel.	rosenthalg@hadassah.org.il		singh, vineeta/0000-0003-3470-3532	Ornim Medical Ltd.	This work was supported by a grant from Ornim Medical Ltd. None of the authors has any financial interest in the company or the device.	BLAND JM, 1995, BRIT MED J, V310, P446, DOI 10.1136/bmj.310.6977.446; BLAND JM, 1995, BRIT MED J, V310, P633, DOI 10.1136/bmj.310.6980.633; Bratton SL, 2008, J NEUROTRAUM, V25, P276; Bullock AR, 2006, NEUROSURGERY, V58, pVI; Feldman Z, 1997, CRIT CARE CLIN, V13, P51, DOI 10.1016/S0749-0704(05)70296-7; Friess SH, 2011, NEUROSURGERY, V69, P1139, DOI 10.1227/NEU.0b013e3182284aa1; Gopinath SP, 1999, CRIT CARE MED, V27, P2337, DOI 10.1097/00003246-199911000-00003; Gupta AK, 1999, ANESTH ANALG, V88, P549, DOI 10.1097/00000539-199903000-00016; Hemphill JC, 2001, NEUROSURGERY, V48, P377, DOI 10.1097/00006123-200102000-00028; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; Longhi L, 2002, ACT NEUR S, V81, P315; Marion DW, 2006, NEUROSURGERY, V58, P655; McLeod AD, 2003, ANESTH ANALG, V97, P851, DOI 10.1213/01.ANE.0000072541.57132.BA; Menzel M, 1999, J NEUROSURG ANESTH, V11, P240, DOI 10.1097/00008506-199910000-00003; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; Oddo M, 2010, NEUROSURGERY, V67, P338, DOI 10.1227/01.NEU.0000371979.48809.D9; RACHELI N, 2012, P SPIE, V8223; Reinert M, 2003, ACTA NEUROCHIR, V145, P341, DOI 10.1007/s00701-003-0027-0; Ron A, 2013, PROC SPIE, V8583, DOI 10.1117/12.2003528; Rosenthal G, 2008, CRIT CARE MED, V36, P1917, DOI 10.1097/CCM.0b013e3181743d77; Rosenthal G, 2008, J NEUROSURG, V108, P575, DOI 10.3171/JNS/2008/108/3/0575; Rosenthal G, 2008, J NEUROSURG, V108, P59, DOI 10.3171/JNS/2008/108/01/0059; Rosenthal G, 2011, J NEUROSURG, V114, P62, DOI 10.3171/2010.6.JNS091360; Scheufler KM, 2002, ANESTH ANALG, V95, P1042, DOI 10.1097/00000539-200210000-00046; Stocchetti N, 1991, Minerva Anestesiol, V57, P319; Teranishi K, 2012, INJURY, V43, P585, DOI 10.1016/j.injury.2010.09.042	26	34	35	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	APR	2014	120	4					901	907		10.3171/2013.12.JNS131089			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	AD7IZ	WOS:000333438800015	24484228				2021-06-18	
J	Lu, Q; Gao, L; Huang, LJ; Ruan, LH; Yang, JJ; Huang, WL; Li, ZX; Zhang, YL; Jin, KL; Zhuge, QC				Lu, Qin; Gao, Lu; Huang, Lijie; Ruan, Linhui; Yang, Jianjing; Huang, Weilong; Li, Zhenxing; Zhang, Yongliang; Jin, Kunlin; Zhuge, Qichuan			Inhibition of mammalian target of rapamycin improves neurobehavioral deficit and modulates immune response after intracerebral hemorrhage in rat	JOURNAL OF NEUROINFLAMMATION			English	Article						ICH; mTOR; Rapamycin; Outcome; Immune response	REGULATORY T-CELLS; ISCHEMIC-STROKE; GROWTH-FACTOR; MECHANISMS; PROTEIN; KINASE; INJURY; NEUROPROTECTION; ANGIOGENESIS; MICROGLIA	Background: Mammalian target of rapamycin (mTOR), a serine/threonine kinase, regulates many processes, including cell growth and the immune response. mTOR is also dysregulated in several neurological diseases, such as traumatic brain injury (TBI), stroke, and neurodegenerative disease. However, the role of mTOR in intracerebral hemorrhage (ICH) remains unexplored. The aims of our study were to determine whether inhibiting mTOR signaling could affect the outcome after ICH and to investigate the possible underlying mechanism. Methods: A rat ICH model was induced by intracerebral injection of collagenase IV into the striatum, and mTOR activation was inhibited by administration of rapamycin. mTOR signaling activation was determined by western blotting. Neurobehavioral deficit after ICH was determined by a set of modified Neurological Severity Scores (mNSS). The levels of CD4+CD25+Foxp3+ regulatory T cells (Tregs) and cytokines were examined using flow cytometry and ELISA, respectively. Results: Our results demonstrated thatmTOR signaling was activated 30 minutes and returned to its basal level 1 day after ICH. Increased p-mTOR, which mean that mTOR signaling was activated, was predominantly located around the hematoma. Rapamycin treatment significantly improved the neurobehavioral deficit after ICH, increased the number of Tregs, increased levels of interleukin-10 and transforming growth factor-beta and reduced interferon-gamma both in peripheral blood and brain. Conclusions: Our study suggests that mTOR improves ICH outcome and modulates immune response after ICH.	[Lu, Qin; Gao, Lu; Huang, Lijie; Ruan, Linhui; Yang, Jianjing; Huang, Weilong; Li, Zhenxing; Zhang, Yongliang; Zhuge, Qichuan] Wenzhou Med Univ, Affiliated Hosp 1, Dept Neurosurg, Wenzhou, Zhejiang, Peoples R China; [Lu, Qin; Gao, Lu; Huang, Lijie; Ruan, Linhui; Yang, Jianjing; Huang, Weilong; Li, Zhenxing; Zhuge, Qichuan] Wenzhou Med Univ, Zhejiang Prov Key Lab Aging & Neurol Dis, Wenzhou, Zhejiang, Peoples R China; [Jin, Kunlin] Univ North Texas Hlth Sci Ctr Ft Worth, Dept Pharmacol & Neurosci, Inst Aging & Alzheimers Dis Res, Ft Worth, TX USA	Zhuge, QC (corresponding author), Wenzhou Med Univ, Affiliated Hosp 1, Dept Neurosurg, Wenzhou, Zhejiang, Peoples R China.	zhugeqichuan@vip.163.com		Lu, Qin/0000-0001-8211-6127	National Natural Science foundation of ChinaNational Natural Science Foundation of China (NSFC) [81171088]	The study was supported by a grant from the National Natural Science foundation of China (No. 81171088). We are grateful to Professor Dong-Ming Su (University of North Texas Health Science Center, USA) for critical suggestions on the experiments.	An WL, 2003, AM J PATHOL, V163, P591, DOI 10.1016/S0002-9440(10)63687-5; Battaglia M, 2005, BLOOD, V105, P4743, DOI 10.1182/blood-2004-10-3932; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Carloni S, 2008, NEUROBIOL DIS, V32, P329, DOI 10.1016/j.nbd.2008.07.022; Castilho RM, 2009, CELL STEM CELL, V5, P279, DOI 10.1016/j.stem.2009.06.017; Chen SY, 2007, J CEREBR BLOOD F MET, V27, P939, DOI 10.1038/sj.jcbfm.9600393; Deinsberger W, 1996, NEUROL RES, V18, P475; Dello Russo C, 2009, BIOCHEM PHARMACOL, V78, P1242, DOI 10.1016/j.bcp.2009.06.097; Erlich S, 2007, NEUROBIOL DIS, V26, P86, DOI 10.1016/j.nbd.2006.12.003; Gaengel K, 2009, ARTERIOSCL THROM VAS, V29, P630, DOI 10.1161/ATVBAHA.107.161521; Gelderblom M, 2009, STROKE, V40, P1849, DOI 10.1161/STROKEAHA.108.534503; Gliem M, 2012, ANN NEUROL, V71, P743, DOI 10.1002/ana.23529; Harris Thurl E, 2003, Sci STKE, V2003, pre15; Hartlage-Rubsamen M, 1999, J NEUROSCI RES, V57, P388, DOI 10.1002/(SICI)1097-4547(19990801)57:3<388::AID-JNR11>3.0.CO;2-2; Inagawa T, 2002, NEUROSURG REV, V25, P237, DOI 10.1007/s10143-002-0222-0; Ingall Timothy, 2004, J Insur Med, V36, P143; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Josefowicz SZ, 2009, IMMUNITY, V30, P616, DOI 10.1016/j.immuni.2009.04.009; Kopf H, 2007, INT IMMUNOPHARMACOL, V7, P1819, DOI 10.1016/j.intimp.2007.08.027; Krupinski J, 1997, STROKE, V28, P564, DOI 10.1161/01.STR.28.3.564; Krupinski J, 1996, STROKE, V27, P852, DOI 10.1161/01.STR.27.5.852; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; Leker RR, 2009, NEUROSCIENCE, V163, P233, DOI 10.1016/j.neuroscience.2009.05.050; Liesz A, 2009, NAT MED, V15, P192, DOI 10.1038/nm.1927; Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672; Malagelada C, 2010, J NEUROSCI, V30, P1166, DOI 10.1523/JNEUROSCI.3944-09.2010; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; Meyuhas O, 2000, EUR J BIOCHEM, V267, P6321, DOI 10.1046/j.1432-1327.2000.01719.x; O'Garra A, 2004, NAT MED, V10, P801, DOI 10.1038/nm0804-801; Pan TH, 2008, NEUROBIOL DIS, V32, P16, DOI 10.1016/j.nbd.2008.06.003; Perera MN, 2006, J CLIN NEUROSCI, V13, P1, DOI 10.1016/j.jocn.2005.07.005; Popko B, 1997, MOL NEUROBIOL, V14, P19, DOI 10.1007/BF02740619; Powell JD, 2012, ANNU REV IMMUNOL, V30, P39, DOI 10.1146/annurev-immunol-020711-075024; Qureshi AI, 2001, NEW ENGL J MED, V344, P1450, DOI 10.1056/NEJM200105103441907; Radimerski T, 2002, NAT CELL BIOL, V4, P251, DOI 10.1038/ncb763; ROSENBERG GA, 1990, STROKE, V21, P801, DOI 10.1161/01.STR.21.5.801; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; Schallert T, 1997, ADV NEUROL, V73, P229; Sharma S, 2011, BRAIN RES, V1373, P189, DOI 10.1016/j.brainres.2010.11.096; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; Strle K, 2001, CRIT REV IMMUNOL, V21, P427; Suri-Payer E, 2006, SPRINGER SEMIN IMMUN, V28, P3, DOI 10.1007/s00281-006-0021-8; Wang J, 2005, NEUROCRIT CARE, V3, P77, DOI 10.1385/NCC:3:1:077; Wang J, 2007, J CEREBR BLOOD F MET, V27, P894, DOI 10.1038/sj.jcbfm.9600403; Wang Q, 2007, J NEUROIMMUNOL, V184, P53, DOI 10.1016/j.jneuroim.2006.11.014; Xi GH, 2006, LANCET NEUROL, V5, P53, DOI 10.1016/S1474-4422(05)70283-0; Zeng LH, 2009, J NEUROSCI, V29, P6964, DOI 10.1523/JNEUROSCI.0066-09.2009; Zhang WG, 2012, EXP NEUROL, V233, P799, DOI 10.1016/j.expneurol.2011.11.046; Zhou L, 2009, IMMUNITY, V30, P646, DOI 10.1016/j.immuni.2009.05.001	49	34	40	0	13	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1742-2094		J NEUROINFLAMM	J. Neuroinflamm.	MAR 6	2014	11								44	10.1186/1742-2094-11-44			13	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	AD4ST	WOS:000333241500001	24602288	DOAJ Gold, Green Published			2021-06-18	
J	Silver, CH				Silver, Cheryl H.			Sources of data about children's executive functioning: Review and commentary	CHILD NEUROPSYCHOLOGY			English	Article						Child; Assessment; Executive function; Ecological validity; Parent report	BEHAVIOR RATING INVENTORY; PERFORMANCE-BASED MEASURES; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; CROSS-INFORMANT CORRELATIONS; TRAUMATIC BRAIN-INJURY; FUNCTION DEFICITS; PARENT RATINGS; YOUNG-CHILDREN; VALIDITY; ADOLESCENTS	Accurate measurement of a child's executive functioning (EF) is important for diagnosis, description of functional impairment, and treatment planning. EF assessment typically consists of administration of a battery of performance-based tests involving abilities such as attention, inhibition, reasoning, planning, and mental flexibility. In recent years, observer (e.g., parent) rating scales have been added to the typical EF battery. However, research has revealed that performance-based tests and parent rating scales are not highly correlated. In other words, level of impairment indicated by one source of data often does not match level of impairment indicated by the other source of data. This disagreement places the clinician in a difficult situation when attempting to interpret evaluation results. The profession of pediatric neuropsychology needs to provide guidance about handling this disagreement. Using the current assessment tools, specific EF subdomains may need to be examined systematically to identify precisely where the disagreements lie. Perhaps the relative validity of the two data sources can be determined, and decisions can be made about what to emphasize and what/when to interpret cautiously. Alternatively, perhaps the goal should be to develop and/or refine measurement tools to increase agreement in order to improve accuracy and validity of test interpretation. At this time, the results of performance-based tests and rating scales of EF are being used together but are not being integrated. Evidence-based practice requires that more work be done to enhance the use of these two sources of data.	Univ Texas SW Med Ctr Dallas, Dept Rehabil Counseling, Dallas, TX 75390 USA	Silver, CH (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Rehabil Counseling, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	cheryl.silver@utsouthwestern.edu					Achenbach TM, 2006, CURR DIR PSYCHOL SCI, V15, P94, DOI 10.1111/j.0963-7214.2006.00414.x; ACHENBACH TM, 1987, PSYCHOL BULL, V101, P213, DOI 10.1037/0033-2909.101.2.213; Anderson P, 2000, NEW LEFT REV, P5; Anderson V, 2005, BRAIN INJURY, V19, P459, DOI 10.1080/02699050400004823; Anderson VA, 2002, CHILD NEUROPSYCHOL, V8, P231, DOI 10.1076/chin.8.4.231.13509; Anderson V, 2010, STUD NEUROPSYCHOL NE, P123; Archibald SJ, 1999, CHILD NEUROPSYCHOL, V5, P115, DOI 10.1076/chin.5.2.115.3167; Barkley RA, 1997, PSYCHOL BULL, V121, P65, DOI 10.1037/0033-2909.121.1.65; Barkley RA, 2010, ARCH CLIN NEUROPSYCH, V25, P157, DOI 10.1093/arclin/acq014; Baron I., 2004, NEUROPSYCHOLOGICAL E; Bernstein JH., 1996, DEV SCORING SYSTEM R; Bodnar LE, 2007, CHILD NEUROPSYCHOL, V13, P345, DOI 10.1080/09297040600899867; Bodnarchuk JL, 2004, J APPL DEV PSYCHOL, V25, P481, DOI 10.1016/j.appdev.2004.06.005; Burden V., 2003, BEHAV ASSESSMENT DYS; Cambridge Cognition, 1996, CAMBR NEUR TEST AUT; Chaytor N, 2006, ARCH CLIN NEUROPSYCH, V21, P217, DOI 10.1016/j.acn.2005.12.002; Cripe L., 1996, ECOLOGICAL VALIDITY, P171; De Los Reyes A, 2005, PSYCHOL BULL, V131, P483, DOI 10.1037/0033-2909.131.4.483; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Denckla M.B., 1996, ATTENTION MEMORY EXE, P263; Denckla MB, 2002, CHILD NEUROPSYCHOL, V8, P304, DOI 10.1076/chin.8.4.304.13512; Donders J, 2002, CHILD NEUROPSYCHOL, V8, P229, DOI 10.1076/chin.8.4.229.13508; Duhig AM, 2000, CLIN PSYCHOL-SCI PR, V7, P435, DOI 10.1093/clipsy/7.4.435; Espy KA, 2004, CLIN NEUROPSYCHOL, V18, P411, DOI 10.1080/138540409052416; Espy KA, 2006, PSYCHOL ASSESSMENT, V18, P373, DOI 10.1037/1040-3590.18.4.373; Franzen M.D., 1996, ECOLOGICAL VALIDITY, P91; Ganesalingam K, 2011, NEUROPSYCHOLOGY, V25, P466, DOI 10.1037/a0022768; Gioia G.A., 2000, BEHAV RATING INVENTO; Gioia GA, 2002, CHILD NEUROPSYCHOL, V8, P249, DOI 10.1076/chin.8.4.249.13513; Gioia GA, 2002, CHILD NEUROPSYCHOL, V8, P121, DOI 10.1076/chin.8.2.121.8727; Gioia GA, 2010, J HEAD TRAUMA REHAB, V25, P433, DOI 10.1097/HTR.0b013e3181fbc272; Glickman M., 2002, THESIS U TEXAS DALLA; Goulden LG, 2009, J PSYCHOEDUC ASSESS, V27, P439, DOI 10.1177/0734282909335574; Happe F, 2006, BRAIN COGNITION, V61, P25, DOI 10.1016/j.bandc.2006.03.004; Heaton R., 1993, WISCONSIN CARD SORTI; Joyner K. B., 2008, THESIS U TEXAS DALLA; Joyner KB, 2009, J PSYCHOEDUC ASSESS, V27, P452, DOI 10.1177/0734282909333945; Kerns KA, 2000, J INT NEUROPSYCH SOC, V6, P62, DOI 10.1017/S1355617700611074; Kodituwakku PW, 2001, NEUROPSYCHOLOGIA, V39, P699, DOI 10.1016/S0028-3932(01)00002-1; KOLKO DJ, 1993, J CHILD PSYCHOL PSYC, V34, P991, DOI 10.1111/j.1469-7610.1993.tb01103.x; Korkman M., 2007, NEPSY 2; Korkman M, 1998, NEPSY DEV NEUROPSYCH; KRIKORIAN R, 1994, J CLIN EXP NEUROPSYC, V16, P840, DOI 10.1080/01688639408402697; Llorente AM., 2003, CHILDRENS COLOR TRAI; Mahone EM, 2009, J INT NEUROPSYCH SOC, V15, P31, DOI 10.1017/S1355617708090164; Mahone EM, 2002, CHILD NEUROPSYCHOL, V8, P258, DOI 10.1076/chin.8.4.258.13510; Mahone EM, 2002, ARCH CLIN NEUROPSYCH, V17, P643, DOI 10.1016/S0887-6177(01)00168-8; Maillard-Wermelinger A, 2009, DEV NEUROREHABIL, V12, P330, DOI 10.3109/17518420903087251; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; McAuley T, 2010, J INT NEUROPSYCH SOC, V16, P495, DOI 10.1017/S1355617710000093; Molho C. E., 1996, THESIS U TEXAS DALLA; Muller U, 2012, CLIN NEUROPSYCHOL, V26, P271, DOI 10.1080/13854046.2011.645558; Oberg E, 2011, CHILD NEUROPSYCHOL, V17, P521, DOI 10.1080/09297049.2011.555760; Parrish J, 2007, DEV MED CHILD NEUROL, V49, P412, DOI 10.1111/j.1469-8749.2007.00412.x; Rasmussen C, 2009, CHILD NEUROPSYCHOL, V15, P201, DOI 10.1080/09297040802385400; Reitan R.M., 1992, NEUROPSYCHOLOGICAL E; RICHTERS JE, 1992, PSYCHOL BULL, V112, P485, DOI 10.1037/0033-2909.112.3.485; RUFF R, 2001, ANN M NAT AC NEUR SA; Sbordone R. J., 1996, ECOLOGICAL VALIDITY, P15; Semrud-Clikeman M, 2010, J AUTISM DEV DISORD, V40, P1017, DOI 10.1007/s10803-010-0951-9; Shiffman S, 2008, ANNU REV CLIN PSYCHO, V4, P1, DOI 10.1146/annurev.clinpsy.3.022806.091415; Silver C. H., 1993, CHILDRENS EXECUTIVE; Smith SR, 2007, J PSYCHOEDUC ASSESS, V25, P139, DOI 10.1177/0734282906296233; Taylor HG, 2004, J INT NEUROPSYCH SOC, V10, P987, DOI 10.1017/S1355617704107078; Toplak ME, 2009, CHILD NEUROPSYCHOL, V15, P53, DOI 10.1080/09297040802070929; Treutler CM, 2003, J ABNORM CHILD PSYCH, V31, P13, DOI 10.1023/A:1021765114434; Vriezen ER, 2002, CHILD NEUROPSYCHOL, V8, P296, DOI 10.1076/chin.8.4.296.13505; Youngstrom E, 2000, J CONSULT CLIN PSYCH, V68, P1038, DOI 10.1037/0022-006X.68.6.1038	68	34	35	0	51	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0929-7049	1744-4136		CHILD NEUROPSYCHOL	Child Neuropsychol.	JAN 2	2014	20	1					1	13		10.1080/09297049.2012.727793			13	Clinical Neurology	Neurosciences & Neurology	259FM	WOS:000327512800001	23030631				2021-06-18	
J	Cantor, J; Ashman, T; Dams-O'Connor, K; Dijkers, MP; Gordon, W; Spielman, L; Tsaousides, T; Allen, H; Nguyen, M; Oswald, J				Cantor, Joshua; Ashman, Teresa; Dams-O'Connor, Kristen; Dijkers, Marcel P.; Gordon, Wayne; Spielman, Lisa; Tsaousides, Theodore; Allen, Hafina; Michael Nguyen; Oswald, Jennifer			Evaluation of the Short-Term Executive Plus Intervention for Executive Dysfunction After Traumatic Brain Injury: A Randomized Controlled Trial With Minimization	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Brain injury; chronic; Cognition disorders; Cognitive therapy; Rehabilitation	PROBLEM-SOLVING DEFICITS; OF-THE-LITERATURE; COGNITIVE REHABILITATION; NEUROPSYCHOLOGIC REHABILITATION; VALIDATION; MANAGEMENT; INDIVIDUALS; ATTENTION; BEHAVIOR; REMEDIATION	Objective: To determine whether the Short-Term Executive Plus (STEP) cognitive rehabilitation program improves executive dysfunction after traumatic brain injury (TBI). Design: Randomized, waitlist controlled trial with minimization and blinded outcome assessment. Setting: Community. Participants: Participants with TBI and executive dysfunction (N=98; TBI severity 50% moderate/severe; mean time since injury +/- SD, 12 +/- 14y; mean age +/- SD, 45 +/- 14y; 62% women; 76% white). Intervention: STEP program: 12 weeks (9h/wk) of group training in problem solving and emotional regulation and individual sessions of attention and compensatory strategies training. Main Outcome Measures: Factor analysis was used to create a composite executive function measure using the Problem Solving Inventory, Frontal Systems Behavior Scale, Behavioral Assessment of the Dysexecutive Syndrome, and Self-Awareness of Deficits Interview. Emotional regulation was assessed with the Difficulties in Emotion Regulation Scale. The primary attention measure was the Attention Rating and Monitoring Scale. Secondary measures included neuropsychological measures of executive function, attention, and memory and measures of affective distress, self-efficacy, social participation, and quality of life. Results: Intention-to-treat mixed-effects analyses revealed significant treatment effects for the composite executive function measure (P =.008) and the Frontal Systems Behavior Scale (P=.049) and Problem Solving Inventory (P =.016). We found no between-group differences on the neuropsychological measures or on measures of attention, emotional regulation, self-awareness, affective distress, self-efficacy, participation, or quality of life. Conclusions: The STEP program is efficacious in improving self-reported post-TBI executive function and problem solving. Further research is needed to identify the roles of the different components of the intervention and its effectiveness with different TBI populations. Archives of Physical Medicine and Rehabilitation 2014;95:1-9 (c) 2014 by the American Congress of Rehabilitation Medicine	[Cantor, Joshua; Ashman, Teresa; Dams-O'Connor, Kristen; Dijkers, Marcel P.; Gordon, Wayne; Spielman, Lisa; Tsaousides, Theodore; Allen, Hafina; Michael Nguyen; Oswald, Jennifer] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA	Gordon, W (corresponding author), Icahn Sch Med Mt Sinai, Dept Rehabil Med, 3 East 101 St,Rm 118, New York, NY 10029 USA.	Wayne.gordon@mountsinai.org		Dijkers, Marcel/0000-0002-8362-5596	Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [1R49CE001171-01]; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE001171] Funding Source: NIH RePORTER	Supported by the Centers for Disease Control and Prevention (grant no. 1R49CE001171-01).	Andrews F. M., 1976, SOCIAL INDICATORS WE; Anson K, 2006, BRAIN INJURY, V20, P167, DOI 10.1080/02699050500442956; Beck A. T., 1996, BECK DEPRESSION INVE, VII; Beck J.S., 2011, COGNITIVE BEHAV THER; BECT AT, 1976, COGNITIVE THERAPY EM; Benton A, 1989, MULTILINGUAL APHASIA; BENYISHAY Y, 1985, SEMIN NEUROL, V5, P252, DOI 10.1055/s-2008-1041522; Braden C, 2010, BRAIN INJURY, V24, P1298, DOI 10.3109/02699052.2010.506859; Brandt J., 1998, HOPKINS VERBAL LEARN; Brown M, 2004, J HEAD TRAUMA REHAB, V19, P459, DOI 10.1097/00001199-200411000-00004; Bufkin JL, 2005, TRAUMA VIOLENCE ABUS, V6, P176, DOI 10.1177/1524838005275089; Canadian Academy of Psychosomatic Medicine, AID CAP EV ACE ADM; Cicerone KD, 2002, BRAIN INJURY, V16, P185, DOI 10.1080/02699050110103959; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone K, 2006, J COGNITIVE NEUROSCI, V18, P1212, DOI 10.1162/jocn.2006.18.7.1212; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Cicerone KD, 2008, ARCH PHYS MED REHAB, V89, P2239, DOI 10.1016/j.apmr.2008.06.017; Conners C., 2000, CONNERS CONTINUOUS P; D'Zurilla T. J., 1988, HDB COGNITIVE BEHAV; Dahlberg CA, 2007, ARCH PHYS MED REHAB, V88, P1561, DOI 10.1016/j.apmr.2007.07.033; Dams-O'Connor K, 2010, PSYCHIAT CLIN N AM, V33, P893, DOI 10.1016/j.psc.2010.08.002; Diggle P., 2002, ANAL LONGITUDINAL DA; DZURILLA TJ, 1971, J ABNORM PSYCHOL, V78, P107, DOI 10.1037/h0031360; First M., 1997, USER GUIDE STRUCTURE; Gagne RM., 1965, CONDITIONS LEARNING, V1st; Golden C., 1978, STROOP COLOR WORD TE; Goodglass H., 1983, BOSTON DIAGNOSTIC AP; Gordon WA, 2006, J HEAD TRAUMA REHAB, V21, P156, DOI 10.1097/00001199-200603000-00008; Grant M, 2012, NEUROPSYCHOL REHABIL, V22, P852, DOI 10.1080/09602011.2012.693455; Gratz KL, 2004, J PSYCHOPATHOL BEHAV, V26, P41, DOI 10.1023/B:JOBA.0000007455.08539.94; Halbauer JD, 2009, J REHABIL RES DEV, V46, P757, DOI 10.1682/JRRD.2008.08.0119; Hawley LA, 2010, BRAIN INJURY, V24, P1292, DOI 10.3109/02699052.2010.506866; Heaton R., 1993, WISCONSIN CARD SORTI; HEPPNER PP, 1982, J COUNS PSYCHOL, V29, P66, DOI 10.1037/0022-0167.29.1.66; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kennedy MRT, 2008, NEUROPSYCHOL REHABIL, V18, P257, DOI 10.1080/09602010701748644; Kurowski BG, 2013, ARCH PHYS MED REHAB, V94, P543, DOI 10.1016/j.apmr.2012.10.029; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Luria A. R., 1966, HIGHER CORTICAL FUNC; Luria A. R., 1963, RESTORATION FUNCTION; Mai N, 1991, NEUROPSYCHOL REHABIL, V1, P45, DOI DOI 10.1080/09602019108401379; Malloy PF, 2001, FRONTAL SYSTEMS BEHA; Man DWK, 2006, NEUROREHABILITATION, V21, P205; McDonald BC, 2002, NEUROREHABILITATION, V17, P333; Ownsworth TL, 1999, BRAIN INJURY, V13, P605, DOI 10.1080/026990599121340; Palmese CA, 2000, BRAIN INJURY, V14, P535; PETERSON LR, 1959, J EXP PSYCHOL, V58, P193, DOI 10.1037/h0049234; Rand D, 2009, NEUROPSYCHOL REHABIL, V19, P583, DOI 10.1080/09602010802469074; Raspelli S, 2011, STUD HEALTH TECHNOL, V167, P92, DOI 10.3233/978-1-60750-766-6-92; Rath JF, 2003, NEUROPSYCHOL REHABIL, V13, P461, DOI 10.1080/09602010343000039; Rath JF, 2000, J HEAD TRAUMA REHAB, V15, P724, DOI 10.1097/00001199-200002000-00010; Reitan RM., 1985, HALSTEAD REITAN NEUR; Renison B, 2012, J INT NEUROPSYCH SOC, V18, P440, DOI 10.1017/S1355617711001883; Rohling ML, 2012, CLIN NEUROPSYCHOL, V26, P197, DOI 10.1080/13854046.2011.647085; Scott NW, 2002, CONTROL CLIN TRIALS, V23, P662, DOI 10.1016/S0197-2456(02)00242-8; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SHALLICE T, 1981, BRIT MED BULL, V37, P187, DOI 10.1093/oxfordjournals.bmb.a071699; Simmond M, 2003, BRAIN INJURY, V17, P325, DOI 10.1080/0269905021000013219; Smith A., 1993, SYMBOL DIGIT MODALIT; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; Sohlberg MM, 2001, ATTENTION PROCESS TR; Solberg MM, 2003, J MED SPEECH LANG PA, V11; Spielberger C.D., 1970, STATE TRAIT ANXIETY; Spreen O., 1998, COMPENDIUM NEUROPSYC; Stuss D.T., 1986, FRONTAL LOBES; Stuss DT, 1995, ANN NY ACAD SCI, V769, P191, DOI 10.1111/j.1749-6632.1995.tb38140.x; Tennant A, 2007, DISABIL REHABIL, V29, P1583, DOI 10.1080/09638280701618828; Vas AK, 2011, J HEAD TRAUMA REHAB, V26, P224, DOI 10.1097/HTR.0b013e318218dd3d; Wade SL, 2012, HEALTH PSYCHOL, V31, P767, DOI 10.1037/a0028440; Wade SL, 2011, PEDIATRICS, V128, pE947, DOI 10.1542/peds.2010-3721; Walker AJ, 2010, BRAIN INJURY, V24, P517, DOI 10.3109/02699051003601721; Wechsler, 1997, WAIS 3 WMS 3 TECHNIC; Wetzel L, 1991, SHORT CATEGORY BOOKL; Whyte J, 2003, AM J PHYS MED REHAB, V82, P639, DOI 10.1097/01.PHM.0000078200.61840.2D; Woodcock R, 2001, TESTS COGNITIVE ABIL	77	34	34	2	35	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JAN	2014	95	1					1	9		10.1016/j.apmr.2013.08.005			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	289KI	WOS:000329681000001	23988395				2021-06-18	
J	O'Keeffe, F; Liegeois, F; Eve, M; Ganesan, V; King, J; Murphy, T				O'Keeffe, Fiadhnait; Liegeois, Frederique; Eve, Megan; Ganesan, Vijeya; King, John; Murphy, Tara			Neuropsychological and neurobehavioral outcome following childhood arterial ischemic stroke: Attention deficits, emotional dysregulation, and executive dysfunction	CHILD NEUROPSYCHOLOGY			English	Article						Childhood arterial ischemic stroke; Neuropsychology; Neurobehavior; Attention; Executive function; Emotional regulation	TRAUMATIC BRAIN-INJURY; QUALITY-OF-LIFE; PEDIATRIC STROKE; CHILDREN; LESION; PLASTICITY; AGE; VULNERABILITY; REMEDIATION; LANGUAGE	Objectives. To investigate neuropsychological and neurobehavioral outcome in children with arterial ischemic stroke (AIS).Background. Childhood stroke can have consequences on motor, cognitive, and behavioral development. We present a cross-sectional study of neuropsychological and neurobehavioral outcome at least one year poststroke in a uniquely homogeneous sample of children who had experienced AIS.Method. Forty-nine children with AIS aged 6 to 18 years were recruited from a specialist clinic. Neuropsychological measures of intelligence, reading comprehension, attention, and executive function were administered. A triangulation of data collection included questionnaires completed by the children, their parents, and teachers, rating behavior, executive functions, and emotions.Key Findings. Focal neuropsychological vulnerabilities in attention (response inhibition and dual attention) and executive function were found, beyond general intellectual functioning, irrespective of hemispheric side of stroke. Difficulties with emotional and behavioral regulation were also found. Consistent with an early plasticity hypothesis, earlier age of stroke was associated with better performance on measures of executive function.Conclusions. A significant proportion of children poststroke are at long-term risk of difficulties with emotional regulation, executive function, and attention. Data also suggest that executive functions are represented in widespread networks in the developing brain and are vulnerable to unilateral injury.	[O'Keeffe, Fiadhnait; King, John] UCL, Res Dept Clin Educ & Hlth Psychol, London WC1E 6BT, England; [Liegeois, Frederique; Ganesan, Vijeya] UCL, Inst Child Hlth, London WC1E 6BT, England; [Eve, Megan; Murphy, Tara] Great Ormond St Hosp Children NHS Fdn Trust, Dept Clin Neuropsychol, London, England	O'Keeffe, F (corresponding author), UCL, Dept Clin Educ & Hlth Psychol, Gower St, London WC1E 6BT, England.	fiokeeffe@gmail.com	king, john/G-3570-2011	Liegeois, Frederique/0000-0002-8640-6217	University of London Central Research Fund; Graduate School University College London; Research Department of Clinical, Educational and Health Psychology University College London	Special appreciation to all the children, parents, and their teachers without whose generous participation this research would not have been possible. This research was partially funded by The University of London Central Research Fund, the Graduate School University College London, and The Research Department of Clinical, Educational and Health Psychology University College London to the first author (F. O'Keeffe). No conflict of interest exists.	Allman C, 2013, CHILD NEUROPSYCHOL, V19, P97, DOI 10.1080/09297049.2011.639756; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2011, BRAIN, V134, P2197, DOI 10.1093/brain/awr103; Anderson V, 2010, NEUROPSYCHOLOGIA, V48, P2041, DOI 10.1016/j.neuropsychologia.2010.03.025; Anderson V, 2009, BRAIN, V132, P45, DOI 10.1093/brain/awn293; Ballantyne AO, 2008, BRAIN, V131, P2975, DOI 10.1093/brain/awn176; Blakemore SJ, 2006, J CHILD PSYCHOL PSYC, V47, P296, DOI 10.1111/j.1469-7610.2006.01611.x; Block GW, 1999, CHILD NEUROPSYCHOL, V5, P81, DOI 10.1076/chin.5.2.81.3169; Butler RW, 2002, J INT NEUROPSYCH SOC, V8, P115, DOI 10.1017/S1355617701020112; Cnossen MH, 2010, DEV MED CHILD NEUROL, V52, P394, DOI 10.1111/j.1469-8749.2009.03580.x; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Everts R, 2008, CHILD NEUROPSYCHOL, V14, P323, DOI 10.1080/09297040701792383; Galbiati S, 2009, NEUROPSYCHOLOGY, V23, P40, DOI 10.1037/a0013409; Ganesan V, 2000, DEV MED CHILD NEUROL, V42, P455, DOI 10.1017/S0012162200000852; Gioia G.A., 2000, BEHAV RATING INVENTO; Gogtay N, 2004, P NATL ACAD SCI USA, V101, P8174, DOI 10.1073/pnas.0402680101; Goodman R, 1997, J CHILD PSYCHOL PSYC, V38, P581, DOI 10.1111/j.1469-7610.1997.tb01545.x; Jordan LC, 2006, NEUROLOGIST, V12, P94, DOI 10.1097/01.nrl.0000195826.72179.0b; Laatsch L, 2007, J HEAD TRAUMA REHAB, V22, P248, DOI 10.1097/01.HTR.0000281841.92720.0a; Long B, 2011, DEV NEUROPSYCHOL, V36, P971, DOI 10.1080/87565641.2011.581537; Long B, 2011, J CHILD NEUROL, V26, P279, DOI 10.1177/0883073810380049; Manly T., 1998, TEST EVERYDAY ATTENT; Marcantuono JT, 2008, NEUROREHABILITATION, V23, P457; Max JE, 2004, J INT NEUROPSYCH SOC, V10, P976, DOI 10.1017/S1355617704107066; Max JE, 2004, J INT NEUROPSYCH SOC, V10, P698, DOI 10.1017/S1355617704105092; Max JE, 2003, J INT NEUROPSYCH SOC, V9, P815, DOI 10.1017/S1355617703960012; Max JE, 2002, J AM ACAD CHILD PSY, V41, P555, DOI 10.1097/00004583-200205000-00013; Max JE, 2010, J NEUROPSYCH CLIN N, V22, P30, DOI 10.1176/appi.neuropsych.22.1.30; Norwood S, 2007, VULNERABLE CHILD YOU, V2, P89, DOI 10.1080/17450120701403136; O'Keeffe F, 2012, BRAIN INJURY, V26, P1072, DOI 10.3109/02699052.2012.661117; *OFF NAT STAT, 2005, NAT STAT SOC EC CLAS; Pavlovic J, 2006, NEUROPEDIATRICS, V37, P13, DOI 10.1055/s-2006-923932; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Ross KA, 2011, DEV MED CHILD NEUROL, V53, P692, DOI 10.1111/j.1469-8749.2011.03976.x; Royal College of Physicians London. Pediatric Stroke Working Group, 2004, STROK CHILDH CLIN GU; Schatz J, 1999, CHILD NEUROPSYCHOL, V5, P92, DOI 10.1076/chin.5.2.92.3170; Schatz J, 2004, NEUROPSYCHOLOGY, V18, P340, DOI 10.1037/0894-4105.18.2.340; Shaw P, 2008, J NEUROSCI, V28, P3586, DOI 10.1523/JNEUROSCI.5309-07.2008; Steinlin M, 2004, EUR J PEDIATR, V163, P245, DOI 10.1007/s00431-003-1357-x; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Van't Hooft I, 2005, BRAIN INJURY, V19, P511, DOI 10.1080/02699050400025224; Wechsler D, 2005, WECHSLER INDIVIDUAL; Wechsler D., 2011, WECHLSER ABBREVIATED; Wechsler D., 2004, WECHSLER INTELLIGENC; Wechsler D., 1991, WECHSLER INTELLIGENC; Wechsler D, 1997, WAIS 3 ADM SCORING M; Westmacott R, 2010, DEV MED CHILD NEUROL, V52, P386, DOI 10.1111/j.1469-8749.2009.03403.x; White DA, 2000, J CLIN EXP NEUROPSYC, V22, P257, DOI 10.1076/1380-3395(200004)22:2;1-1;FT257; Williams TS, 2012, DEV MED CHILD NEUROL, V54, P30, DOI 10.1111/j.1469-8749.2011.04144.x	49	34	34	1	23	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0929-7049	1744-4136		CHILD NEUROPSYCHOL	Child Neuropsychol.		2014	20	5					557	582		10.1080/09297049.2013.832740			26	Clinical Neurology	Neurosciences & Neurology	AJ8QE	WOS:000337970600005	24028185	Green Published			2021-06-18	
J	Silverberg, JI; Joks, R; Durkin, HG				Silverberg, J. I.; Joks, R.; Durkin, H. G.			Allergic disease is associated with epilepsy in childhood: a US population-based study	ALLERGY			English	Article						asthma; eczema; food allergies; obesity; seizure disorders	BODY-MASS INDEX; SERUM IMMUNOGLOBULIN-E; PSYCHOLOGICAL DISTRESS; ATOPIC-DERMATITIS; NATIONAL-HEALTH; ASTHMA SEVERITY; UNITED-STATES; OBESITY; VALIDATION; ECZEMA	BackgroundPrevious studies using animal models suggest an association between allergic disease and epilepsy. We sought to determine whether allergic disease is associated with epilepsy in children. MethodsWe used the 2007-2008 National Survey of Children's Health, a US population-based study of 91642 children aged 0-17years to determine the association between the prevalence of epilepsy and allergic disease, including asthma, atopic dermatitis (AD)/eczema, hay fever, and food allergies. Multivariate logistic regression models were constructed that controlled for confounding variables. ResultsThe US lifetime prevalence of childhood epilepsy was 1.03% and was significantly associated with older age, male sex, lower household income, family structure and history of brain injury or concussion. Children with 1 allergic disease had more epilepsy in their lifetime than nonallergic children (logistic regression, adjusted odds ratio [95% confidence interval]=1.79 [1.37-2.33]). Lifetime prevalence (2.30 [1.50-3.52]) and one-year prevalence of asthma (2.00 [1.41-2.84]), AD/eczema (1.73 [1.17-2.56]), hay fever (1.93 [1.41-2.65]) and food allergies (2.69 [1.38-4.01]) were associated with increased odds of ever being diagnosed with epilepsy. Similar results were found for current history of epilepsy. Severe AD/eczema (23.89 [1.34-11.32]) and hay fever (2.46 [1.11-5.41]) were associated with even higher odds of epilepsy compared with mild/moderate disease. As the number of allergic diseases increased, so did the odds of lifetime history and current history of epilepsy. ConclusionsThe US prevalence of epilepsy is associated with allergic diseases in children. Further studies are needed to determine whether allergic inflammation contributes toward epileptogenesis.	[Silverberg, J. I.] Northwestern Univ, Dept Dermatol, Chicago, IL 60611 USA; [Silverberg, J. I.] Northwestern Univ, Dept Prevent Med, Chicago, IL 60611 USA; [Silverberg, J. I.] Northwestern Univ, Dept Med Social Sci, Chicago, IL 60611 USA; [Silverberg, J. I.] Beth Israel Deaconess Med Ctr, Dept Dermatol, New York, NY 10003 USA; [Silverberg, J. I.] St Lukes Roosevelt Hosp, New York, NY USA; [Joks, R.; Durkin, H. G.] Suny Downstate Med Ctr, Ctr Allergy & Asthma Res, Brooklyn, NY 11203 USA; [Joks, R.] Suny Downstate Med Ctr, Dept Med, Brooklyn, NY 11203 USA; [Joks, R.] Suny Downstate Med Ctr, Dept Allergy, Brooklyn, NY 11203 USA; [Joks, R.] Suny Downstate Med Ctr, Dept Immunol, Brooklyn, NY 11203 USA; [Durkin, H. G.] Suny Downstate Med Ctr, Dept Pathol, Brooklyn, NY 11203 USA	Silverberg, JI (corresponding author), Northwestern Univ, Dept Dermatol, Suite 1400,680 Lakeshore Dr, Chicago, IL 60611 USA.	JonathanISilverberg@Gmail.com		Silverberg, Jonathan/0000-0003-3686-7805			Akinbami LJ, 2009, OBESITY, V17, P1574, DOI 10.1038/oby.2009.1; Arif AA, 2010, J ASTHMA, V47, P792, DOI 10.3109/02770903.2010.491148; Babu CS, 2009, EPILEPSY RES, V86, P146, DOI 10.1016/j.eplepsyres.2009.05.015; Barr J, 1998, CLIN NEUROL NEUROSUR, V100, P196, DOI 10.1016/S0303-8467(98)00040-7; Brooks DR, 2012, EPILEPSY BEHAV, V23, P57, DOI 10.1016/j.yebeh.2011.11.002; Busi LE, 2012, PEDIATR PULM, V47, P1, DOI 10.1002/ppul.21500; Chen Y, 2006, CHEST, V130, P890, DOI 10.1378/chest.130.3.890; Chen Y, 2010, INT ARCH ALLERGY IMM, V153, P372, DOI 10.1159/000316348; Delclos GL, 2006, OCCUP ENVIRON MED, V63, P173, DOI 10.1136/oem.2005.021634; Elliott JO, 2008, EPILEPSY BEHAV, V12, P434, DOI 10.1016/j.yebeh.2007.12.001; Emerson RM, 2000, BRIT J DERMATOL, V142, P288, DOI 10.1046/j.1365-2133.2000.03300.x; Fasmer OB, 2011, BMC PSYCHIATRY, V11, DOI 10.1186/1471-244X-11-128; Figueroa-Munoz JI, 2001, THORAX, V56, P133, DOI 10.1136/thorax.56.2.133; Fitzpatrick S, 2012, CLIN EXP ALLERGY, V42, P747, DOI 10.1111/j.1365-2222.2011.03863.x; Grammer LC, 2010, J ASTHMA, V47, P491, DOI 10.3109/02770901003801980; Hashizume H, 2006, CURR OPIN ALLERGY CL, V6, P335, DOI 10.1097/01.all.0000244793.03239.40; Housman TS, 2002, BRIT J DERMATOL, V147, P1192, DOI 10.1046/j.1365-2133.2002.05031.x; Kiguchi N, 2009, BIOCHEM BIOPH RES CO, V384, P311, DOI 10.1016/j.bbrc.2009.04.121; Kobau R, 2004, EPILEPSY BEHAV, V5, P358, DOI 10.1016/j.yebeh.2004.02.007; Lavoie KL, 2006, RESP MED, V100, P648, DOI 10.1016/j.rmed.2005.08.001; Lord GM, 2002, J LEUKOCYTE BIOL, V72, P330; Magin PJ, 2011, INT J DERMATOL, V50, P1486, DOI 10.1111/j.1365-4632.2011.04883.x; Mai XM, 2003, ACTA PAEDIATR, V92, P1144, DOI 10.1080/08035250310005666; Martin-Romero C, 2000, CELL IMMUNOL, V199, P15, DOI 10.1006/cimm.1999.1594; Mokran V, 1997, Bratisl Lek Listy, V98, P229; Mosen DM, 2008, J ALLERGY CLIN IMMUN, V122, P507, DOI 10.1016/j.jaci.2008.06.024; Murray CS, 2011, CLIN EXP ALLERGY, V41, P78, DOI 10.1111/j.1365-2222.2010.03598.x; Rausch ME, 2008, INT J OBESITY, V32, P451, DOI 10.1038/sj.ijo.0803744; Scahill L, 1997, J Child Adolesc Psychiatr Nurs, V10, P36, DOI 10.1111/j.1744-6171.1997.tb00279.x; Schmitt J, 2009, JAMA-J AM MED ASSOC, V301, P724, DOI 10.1001/jama.2009.136; SENTHILSELVAN A, 1993, J ASTHMA, V30, P185, DOI 10.3109/02770909309054516; Shaw TE, 2011, J INVEST DERMATOL, V131, P67, DOI 10.1038/jid.2010.251; Silverberg J, 2010, BRAIN BEHAV IMMUN, V24, P263, DOI 10.1016/j.bbi.2009.10.006; Silverberg JI, 2008, J ALLERGY CLIN IMMUN, V121, pS117, DOI 10.1016/j.jaci.2007.12.464; Silverberg JI, 2012, BRIT J DERMATOL, V166, P498, DOI 10.1111/j.1365-2133.2011.10694.x; Silverberg JI, 2011, J ALLERGY CLIN IMMUN, V127, P1180, DOI 10.1016/j.jaci.2011.01.063; Strine TW, 2005, EPILEPSIA, V46, P1133, DOI 10.1111/j.1528-1167.2005.01605.x; SUSITAIVAL P, 1995, SCAND J WORK ENV HEA, V21, P30, DOI 10.5271/sjweh.5; Tai A, 2009, J ASTHMA, V46, P362, DOI 10.1080/02770900902759260; Van Lieshout RJ, 2012, CHEM IMMUNOL ALLERGY, V98, P1, DOI 10.1159/000336493; Vieira VJ, 2005, AM J CLIN NUTR, V82, P504; Visness CM, 2009, J ALLERGY CLIN IMMUN, V123, P1163, DOI 10.1016/j.jaci.2008.12.1126; von Mutius E, 2001, THORAX, V56, P835, DOI 10.1136/thorax.56.11.835; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Yaghmaie P, 2013, J ALLERGY CLIN IMMUN, V131, P428, DOI 10.1016/j.jaci.2012.10.041; Yang YW, 2010, ALLERGY, V65, P801, DOI 10.1111/j.1398-9995.2009.02249.x	46	34	37	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0105-4538	1398-9995		ALLERGY	Allergy	JAN	2014	69	1			SI		95	103		10.1111/all.12319			9	Allergy; Immunology	Allergy; Immunology	291BB	WOS:000329801500011	24251558				2021-06-18	
J	Egea-Guerrero, JJ; Murillo-Cabezas, F; Gordillo-Escobar, E; Rodriguez-Rodriguez, A; Enamorado-Enamorado, J; Revuelto-Rey, J; Pacheco-Sanchez, M; Leon-Justel, A; Dominguez-Roldan, JM; Vilches-Arenas, A				Egea-Guerrero, Juan J.; Murillo-Cabezas, Francisco; Gordillo-Escobar, Elena; Rodriguez-Rodriguez, Ana; Enamorado-Enamorado, Judy; Revuelto-Rey, Jaume; Pacheco-Sanchez, Maria; Leon-Justel, Antonio; Dominguez-Roldan, Jose M.; Vilches-Arenas, Angel			S100B Protein May Detect Brain Death Development after Severe Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						BD; biomarkers; S100B protein; TBI	SEVERE HEAD-INJURY; SERUM S-100B PROTEIN; INTRACRANIAL-PRESSURE; S100-BETA PROTEIN; TISSUE OXYGENATION; EARLY PREDICTOR; MARKER; ACTIVATION; EXPRESSION; MORTALITY	Despite improvements in the process of organ donation and transplants, the number of organ donors is progressively declining in developed countries. Therefore, the early detection of patients at risk for brain death (BD) is a priority for transplant teams seeking more efficient identification of potential donors. In the extensive literature on S100B as a biomarker for traumatic brain injury (TBI), no evidence appears to exist on its prognostic capacity as a predictor of BD after severe TBI. The objective of this study is to assess the value of including acute S100B levels in standard clinical data as an early screening tool for BD after severe TBI. This prospective study included patients with severe TBI (Glasgow Coma Scale score [GCS] 8) admitted to our Neurocritical Care Unit over a 30 month period. We collected the following clinical variables: age, gender, GCS score, pupillary alterations at admission, hypotension and pre-hospital desaturation, CT scan results, isolated TBI or other related injuries, Injury Severity Score (ISS), serum S100B levels at admission and 24h post-admission, and a final diagnosis regarding BD. Of the 140 patients studied, 11.4% developed BD and showed significantly higher S100B concentrations (p<0.001). Multivariate analysis showed that bilateral unresponsive mydriasis at admission and serum S100B at 24h post-admission had odds ratios (ORs) of 21.35 (p=0.005) and 4.9 (p=0.010), respectively. The same analysis on patients with photomotor reflex in one pupil at admission left only the 24h S100B sample in the model (OR=15.5; p=0.009). Receiver operating characteristics (ROC) curve analysis on this group showed the highest area under the curve (AUC) (0.86; p=0.001) for 24h S100B determinations. The cut off was set at 0.372g/L (85.7% sensitivity, 79.3% specificity, positive predictive value [PPV]=18.7% and negative predictive value [NPV]=98.9%). This study shows that pupillary responsiveness at admission, as well as 24h serum S100B levels, could serve as screening tools for the early detection of patients at risk for BD after severe TBI.	[Egea-Guerrero, Juan J.; Murillo-Cabezas, Francisco; Gordillo-Escobar, Elena; Enamorado-Enamorado, Judy; Revuelto-Rey, Jaume; Pacheco-Sanchez, Maria; Dominguez-Roldan, Jose M.] Univ Seville, NeuroCrit Care Unit, Seville, Spain; [Rodriguez-Rodriguez, Ana; Leon-Justel, Antonio] Univ Seville, Dept Clin Biochem, Virgen del Rocio Univ Hosp, Seville, Spain; [Vilches-Arenas, Angel] Univ Seville, CSIC, IBIS, Dept Prevent Med & Publ Hlth, Seville, Spain	Egea-Guerrero, JJ (corresponding author), Univ Seville, CSIC, IBIS, NeuroCrit Care Unit,Virgen del Rocio Univ Hosp, Avda Manuel Siurot S-N,PC 41013, Seville, Spain.	juanjoegea@hotmail.com	Rodriguez-Rodriguez, Ana/F-4718-2016; Vilches-Arenas, Angel/C-1167-2015; Dominguez-Roldan, Jose-Maria/M-1728-2016; IBIS, NEUROCRITICOS/C-1805-2016; Murillo-Cabezas, Francisco/AAO-3348-2021; IBIS, NEUROINMUNO/O-9306-2015; Egea-Guerrero, Juan Jose/P-5080-2014	Rodriguez-Rodriguez, Ana/0000-0002-6854-9695; Vilches-Arenas, Angel/0000-0003-2197-3760; Dominguez-Roldan, Jose-Maria/0000-0003-1933-1478; Revuelto-Rey, Jaume/0000-0001-8350-9555; Egea-Guerrero, Juan Jose/0000-0002-4166-313X	Junta de Andalucia Health Department [S0430]; Roche Diagnostics, Mannheim, Germany [S100B]	This research was made possible by funding from the Junta de Andalucia Health Department 2010 Grant Fund (cod. S0430), and through the generous donation of Protein S100B Electrochemiluminescence Assay Kits from Roche Diagnostics, Mannheim, Germany. We thank the nursing staff at the Virgen del Rocio University Hospital for their collaboration with blood sample extractions related to this study.	*AM EL SOC, 1994, J CLIN NEUROPHYSIOL, V11, P10; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; [Anonymous], 2007, J NEUROTRAUMA S1, V24, pS1, DOI DOI 10.1089/NEU.2006.0209; Bloomfield SM, 2007, NEUROCRIT CARE, V6, P121, DOI 10.1007/s12028-007-0008-x; Bohmer AE, 2011, NEUROSURGERY, V68, P1624, DOI 10.1227/NEU.0b013e318214a81f; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; da Rocha AB, 2006, CLIN CHEM LAB MED, V44, P1234, DOI 10.1515/CCLM.2006.218; Dimopoulou I, 2003, NEUROLOGY, V60, P947, DOI 10.1212/01.WNL.0000049931.77887.7F; Dominguez-Roldan JM, 2009, MED INTENSIVA, V33, P434, DOI 10.1016/j.medin.2009.03.008; Dominguez-Roldan J.M., 2010, INTENS CARE MED, V36, P205; Dominguez-Roldan J.M., 1994, REV ESPANOLA TRASPLA, V3, P30; Dominguez-Roldan J.M., 1999, TRANSPL P, V31, P2957; Egea-Guerrero JJ, 2012, TRANSPL P, V44, P2050, DOI 10.1016/j.transproceed.2012.07.070; Egea-Guerrero JJ, 2012, NEUROLOGIA, V27, P377, DOI 10.1016/j.nrl.2011.07.013; Egea-Guerrero JJ, 2012, BRAIN INJURY, V26, P76, DOI 10.3109/02699052.2011.635360; Escudero D, 2009, MED INTENSIVA, V33, P185, DOI 10.1016/S0210-5691(09)71215-X; Figaji AA, 2010, NEUROCRIT CARE, V12, P56, DOI 10.1007/s12028-009-9298-5; Haddad S, 2011, ANAESTH INTENS CARE, V39, P1043, DOI 10.1177/0310057X1103900610; Iznerowicz A, 2011, TRANSPL P, V43, P2887, DOI 10.1016/j.transproceed.2011.08.013; JENSEN R, 1985, J NEUROCHEM, V45, P700, DOI 10.1111/j.1471-4159.1985.tb04048.x; Egea-Guerrero JJ, 2011, NEUROLOGY, V76, P489, DOI 10.1212/WNL.0b013e3181fe77fa; Kompanje EJO, 2011, TRANSPLANTATION, V91, P1177, DOI 10.1097/TP.0b013e3182180567; Korfias S, 2006, BRAIN INJURY, V20, P867, DOI 10.1080/02699050600832395; Koudstaal LG, 2008, TRANSPLANTATION, V86, P148, DOI 10.1097/TP.0b013e31817ba53a; Leal-Noval SR, 2010, INTENS CARE MED, V36, P1309, DOI 10.1007/s00134-010-1920-7; Marin-Caballos A, 2005, CRIT CARE, V9, pR670, DOI 10.1186/cc3822; Marin-Caballos AJ, 2008, MED INTENSIVA, V32, P81, DOI 10.1016/S0210-5691(08)70912-4; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Meers C, 2009, TRANSPL P, V41, P572, DOI 10.1016/j.transproceed.2008.12.029; Murillo-Cabezas F, 2010, BRAIN INJURY, V24, P609, DOI 10.3109/02699051003652823; Mussack T, 2002, CRIT CARE MED, V30, P2669, DOI 10.1097/00003246-200212000-00010; Nijboer WN, 2004, TRANSPLANTATION, V78, P978, DOI 10.1097/01.TP.0000135565.49535.60; Pelinka LE, 2003, BRIT J ANAESTH, V91, P595, DOI 10.1093/bja/aeg225; Petzold A, 2002, CRIT CARE MED, V30, P2705, DOI 10.1097/00003246-200212000-00015; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; R Donato, 2010, CARDIOVASC PSYCHIAT, V92, P87; Raabe A, 2000, NEUROSURG REV, V23, P136, DOI 10.1007/PL00011944; Raabe A, 1999, J NEUROSURG, V91, P875, DOI 10.3171/jns.1999.91.5.0875; Rainey T, 2009, RESUSCITATION, V80, P341, DOI 10.1016/j.resuscitation.2008.11.021; Regner A, 2001, NEUROREPORT, V12, P691, DOI 10.1097/00001756-200103260-00015; Rodriguez-Rodriguez A, 2012, CLIN CHIM ACTA, V414, P228, DOI 10.1016/j.cca.2012.09.025; Salim A, 2011, J TRAUMA, V71, P733, DOI 10.1097/TA.0b013e31820500e6; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; Siminoff L.A., 2011, JAMA-J AM MED ASSOC, V1, P71; van der Hoeven JAB, 2000, ANN SURG, V232, P804, DOI 10.1097/00000658-200012000-00009; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Wijdicks EFM, 2001, NEW ENGL J MED, V344, P1215, DOI 10.1056/NEJM200104193441606; Wilhelm MJ, 2000, CIRCULATION, V102, P2426, DOI 10.1161/01.CIR.102.19.2426	49	34	36	0	16	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT 15	2013	30	20					1762	1769		10.1089/neu.2012.2606			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	232JW	WOS:000325491000009	23710646	Green Published			2021-06-18	
J	Dawson, DR; Binns, MA; Hunt, A; Lemsky, C; Polatajko, HJ				Dawson, Deirdre R.; Binns, Malcolm A.; Hunt, Anne; Lemsky, Carolyn; Polatajko, Helene J.			Occupation-Based Strategy Training for Adults With Traumatic Brain Injury: A Pilot Study	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Cognition therapy; Executive function; Rehabilitation; Rehabilitation outcome	COGNITIVE REHABILITATION	Objective: To evaluate, before undertaking a larger trial, feasibility of the study processes to determine the effectiveness of occupation-based strategy training for producing changes on trained real-world behaviors, and to determine whether far transfer of training effects to measures of real-world impact, including participation in everyday life, could be achieved. Design: Partially randomized controlled trial with pre- and postintervention assessments done by assessors masked to the treatment arm. Setting: Testing occurred at a research institute, interventions at participants' homes. Participants: People (N=13) with chronic traumatic brain injury (TBI), 7 in the experimental group (mean age, 42.6y; mean time post-TBI, 9.8y; 4 men) and 6 in the control arm (mean age, 40.5y; mean time post-TBI, 10.8y; 3 men), were assessed immediately before and after the intervention phase. Intervention: Occupation-based strategy training, an adapted version of the Cognitive Orientation to daily Occupational Performance (CO-OP), was provided in two 1-hour sessions per week for 10 weeks. Main Outcome Measures: Canadian Occupational Performance Measure, Dysexecutive Questionnaire, Mayo-Portland Adaptability Inventory-4 Participation Index, and Assessment of Motor and Process Skills. Results: The study processes (testing and intervention) were acceptable to all participants. Evidence of far transfer was found as the experimental group improved significantly more than the control group on performance and satisfaction with performance ratings on untrained goals (P<05), and reported increased levels of participation (P<.01). Conclusions: Findings must be interpreted with caution since the sample is small and comparisons are made with a no-treatment control. Nevertheless, they suggest that the training is feasible and a larger trial warranted. (c) 2013 by the American Congress of Rehabilitation Medicine	[Dawson, Deirdre R.; Binns, Malcolm A.] Baycrest, RRI, Toronto, ON M6A 2E1, Canada; [Dawson, Deirdre R.; Polatajko, Helene J.] Univ Toronto, Dept Occupat Sci & Occupat Therapy, Toronto, ON, Canada; [Dawson, Deirdre R.; Hunt, Anne; Polatajko, Helene J.] Univ Toronto, Grad Dept Rehabil Sci, Toronto, ON, Canada; [Lemsky, Carolyn] Community Head Injury Resource Serv, West Toronto, ON, Canada	Dawson, DR (corresponding author), Baycrest, RRI, 3560 Bathurst St, Toronto, ON M6A 2E1, Canada.	ddawson@research.baycrest.org	Binns, Malcolm/AAQ-9195-2020; Dawson, Deirdre R/I-8882-2014	Binns, Malcolm/0000-0001-9998-6612; Dawson, Deirdre R/0000-0001-7517-6121	Ontario Neurotrauma Foundation; Quebec Rehabilitation Research Network [2005-ABI-POP-363, 2007-ONF-REPAR-582]	Supported by the Ontario Neurotrauma Foundation and the Quebec Rehabilitation Research Network (grant nos. 2005-ABI-POP-363, 2007-ONF-REPAR-582).	Burgess P. W., 1996, BEHAV ASSESSMENT DYS; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Dawson DR, 2009, CAN J OCCUP THER, V76, P115, DOI 10.1177/000841740907600209; Fisher A. G., 2010, ASSESSMENT MOTOR PRO, V1; Haskins EC, 2012, COGNITIVE REHABILITA; Kuipers P., 2004, BRAIN IMPAIR, V5, P30, DOI DOI 10.1375/BRIM.5.1.30.35404; Law M, 1991, CANADIAN OCCUPATIONA; Malec JF, 2004, ARCH PHYS MED REHAB, V85, P1989, DOI 10.1016/j.apmr.2004.01.032; Polatajko H. J., 2004, ENABLING OCCUPATION; Sidani S, ADV DESIGNS METHODS; Simons J.S., 2005, EFFECTIVENESS REHABI, V211, DOI [10.1093/acprof:oso/9780198526544.003.0018, DOI 10.1093/ACPROF:OSO/9780198526544.001.0001]; Skidmore ER, 2011, NEUROPSYCHOL REHABIL, V21, P208, DOI 10.1080/09602011.2011.552559; van Heugten C, 2012, NEUROPSYCHOL REHABIL, V22, P653, DOI 10.1080/09602011.2012.680891; Zelinski EM, 2009, RESTOR NEUROL NEUROS, V27, P455, DOI 10.3233/RNN-2009-0495	15	34	35	2	32	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	2013	94	10					1959	1963		10.1016/j.apmr.2013.05.021			5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	231TU	WOS:000325442100014	23796683				2021-06-18	
J	Wu, A; Ying, Z; Gomez-Pinilla, F				Wu, A.; Ying, Z.; Gomez-Pinilla, F.			EXERCISE FACILITATES THE ACTION OF DIETARY DHA ON FUNCTIONAL RECOVERY AFTER BRAIN TRAUMA	NEUROSCIENCE			English	Article						DHA; exercise; BDNF; omega-3 fatty acids; cognition	ALPHA-LINOLENIC ACID; DOCOSAHEXAENOIC ACID; MEMBRANE HOMEOSTASIS; SYNAPTIC PLASTICITY; FATTY-ACIDS; PROTEIN; INJURY; SUPPLEMENTATION; DAMAGE; BDNF	The abilities of docosahexaenoic acid (DHA) and exercise to counteract cognitive decay after traumatic brain injury (TBI) is getting increasing recognition; however, the possibility that these actions can be complementary remains just as an intriguing possibility. Here we have examined the likelihood that the combination of diet and exercise has the added potential to facilitate functional recovery following TBI. Rats received mild fluid percussion injury (mFPI) or sham injury and then were maintained on a diet high in DHA (1.2% DHA) with or without voluntary exercise for 12 days. We found that FPI reduced DHA content in the brain, which was accompanied by increased levels of lipid peroxidation assessed using 4-hydroxy-2-hexenal (4-HHE). FPI reduced the enzymes acyl-CoA oxidase 1 (Acox1) and 17 beta-hydroxysteroid dehydrogenase type 4 (17 beta-HSD4), and the calcium-independent phospholipases A2 (iPLA(2)), which are involved in metabolism of membrane phospholipids. FPI reduced levels of syntaxin-3 (STX-3), involved in the action of membrane DHA on synaptic membrane expansion, and also reduced brain-derived neurotrophic factor (BDNF) signaling through its tyrosine kinase B (TrkB) receptor. These effects of FPI were optimally counteracted by the combination of DHA and exercise. Our results support the possibility that the complementary action of exercise is exerted on restoring membrane homeostasis after TBI, which is necessary for supporting synaptic plasticity and cognition. It is our contention that strategies that take advantage of the combined applications of diet and exercise may have additional effects to the injured brain. (C) 2013 IBRO. Published by Elsevier Ltd. All rights reserved.	[Wu, A.; Ying, Z.; Gomez-Pinilla, F.] Univ Calif Los Angeles, Dept Integrat Biol & Physiol, Los Angeles, CA 90095 USA; [Gomez-Pinilla, F.] Univ Calif Los Angeles, Dept Neurosurg, Brain Injury Res Ctr, Los Angeles, CA 90095 USA	Gomez-Pinilla, F (corresponding author), Univ Calif Los Angeles, Dept Integrat Biol & Physiol, 621 Charles E Young Dr, Los Angeles, CA 90095 USA.	agwu@ucla.edu; lying@physci.ucla.edu; fgomezpi@ucla.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS50465]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS050465] Funding Source: NIH RePORTER	This study was supported by NIH award NS50465.	Adasme T, 2011, P NATL ACAD SCI USA, V108, P3029, DOI 10.1073/pnas.1013580108; Allyson J, 2012, NEURAL PLAST, V2012, DOI 10.1155/2012/569149; Amen DG, 2011, J PSYCHOACTIVE DRUGS, V43, P1, DOI 10.1080/02791072.2011.566489; Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Astarita G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012538; Biegon A, 2004, CURR PHARM DESIGN, V10, P2177, DOI 10.2174/1381612043384196; Bigford GE, 2009, J NEUROTRAUM, V26, P703, DOI 10.1089/neu.2008.0783; Burdge GC, 2005, REPROD NUTR DEV, V45, P581, DOI 10.1051/rnd:2005047; Calder PC, 2012, J NUTR, V142, p592S, DOI 10.3945/jn.111.155259; Calder PC, 2009, POSTGRAD MED, V121, P148, DOI 10.3810/pgm.2009.11.2083; Cansev M, 2007, NEUROSCIENCE, V148, P421, DOI 10.1016/j.neuroscience.2007.06.016; Chytrova G, 2010, BRAIN RES, V1341, P32, DOI 10.1016/j.brainres.2009.05.018; Crawford MA, 2009, ANN NUTR METAB, V55, P202, DOI 10.1159/000229003; Darios F, 2006, NATURE, V440, P813, DOI 10.1038/nature04598; Ferdinandusse S, 2001, J LIPID RES, V42, P1987; Griesbach GS, 2007, J NEUROTRAUM, V24, P1161, DOI 10.1089/neu.2006.0255; Huyghe S, 2006, ENDOCRINOLOGY, V147, P2228, DOI 10.1210/en.2005-1571; Igarashi M, 2007, J LIPID RES, V48, P1150, DOI 10.1194/jlr.M600549-JLR200; Joseph MS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041288; Kim HY, 2007, J BIOL CHEM, V282, P18661, DOI 10.1074/jbc.R700015200; Long EK, 2008, J NEUROCHEM, V105, P714, DOI 10.1111/j.1471-4159.2007.05175.x; Lukiw WJ, 2008, J NUTR, V138, P2510, DOI 10.3945/jn.108.096016; Lukiw WJ, 2005, J CLIN INVEST, V115, P2774, DOI 10.1172/JCI25420; Marszalek JR, 2005, ANNU REV CELL DEV BI, V21, P633, DOI 10.1146/annurev.cellbio.21.122303.120624; Menzies KJ, 2013, J BIOL CHEM, V288, P6968, DOI 10.1074/jbc.M112.431155; Merenda A, 2008, J NEUROTRAUM, V25, P527, DOI 10.1089/neu.2007.0359; Minichiello L, 2009, NAT REV NEUROSCI, V10, P850, DOI 10.1038/nrn2738; Nagahara AH, 2011, NAT REV DRUG DISCOV, V10, P209, DOI 10.1038/nrd3366; Sajikumar S, 2011, P NATL ACAD SCI USA, V108, P2551, DOI 10.1073/pnas.1016849108; Schaeffer EL, 2009, PSYCHOPHARMACOLOGY, V202, P37, DOI 10.1007/s00213-008-1351-0; Sharma S, 2010, EXP NEUROL, V226, P191, DOI 10.1016/j.expneurol.2010.08.027; Stillwell W, 2005, REPROD NUTR DEV, V45, P559, DOI 10.1051/rnd:2005046; Su HM, 2001, J BIOL CHEM, V276, P38115; Tanaka JI, 2008, SCIENCE, V319, P1683, DOI 10.1126/science.1152864; Vaynman S, 2007, NEUROSCIENCE, V144, P825, DOI 10.1016/j.neuroscience.2006.10.005; Wu A, 2008, NEUROSCIENCE, V155, P751, DOI 10.1016/j.neuroscience.2008.05.061; Wu A, 2004, J NEUROTRAUM, V21, P1457, DOI 10.1089/neu.2004.21.1457; Wu A, 2003, NEUROSCIENCE, V119, P365, DOI 10.1016/S0306-4522(03)00154-4; Wu AG, 2011, J NEUROTRAUM, V28, P2113, DOI 10.1089/neu.2011.1872	39	34	34	0	21	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	SEP 17	2013	248						655	663		10.1016/j.neuroscience.2013.06.041			9	Neurosciences	Neurosciences & Neurology	299UV	WOS:000330422100058	23811071	Green Accepted			2021-06-18	
J	Arnett, AB; Peterson, RL; Kirkwood, MW; Taylor, HG; Stancin, T; Brown, TM; Wade, SL				Arnett, Anne B.; Peterson, Robin L.; Kirkwood, Michael W.; Taylor, H. Gerry; Stancin, Terry; Brown, Tanya M.; Wade, Shari L.			Behavioral and Cognitive Predictors of Educational Outcomes in Pediatric Traumatic Brain Injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Executive function; Neuropsychology; Adolescent; Language; Special education; Brain concussion	EXECUTIVE FUNCTION DEFICITS; ACADEMIC-ACHIEVEMENT; YOUNG-CHILDREN; HEAD-INJURY; TERM; RECOVERY; ADOLESCENTS; CHILDHOOD; PLACEMENT; RATINGS	Research reveals mixed results regarding the utility of standardized cognitive and academic tests to predict educational outcomes in youth following a traumatic brain injury (TBI). Yet, deficits in everyday school-based outcomes are prevalent after pediatric TBI. The current study used path modeling to test the hypothesis that parent ratings of adolescents' daily behaviors associated with executive functioning (EF) would predict long-term functional educational outcomes following pediatric TBI, even when injury severity and patient demographics were included in the model. Furthermore, we contrasted the predictive strength of the EF behavioral ratings with that of a common measure of verbal memory. A total of 132 adolescents who were hospitalized for moderate to severe TBI were recruited to participate in a randomized clinical intervention trial. EF ratings and verbal memory were measured within 6 months of the injury; functional educational outcomes were measured 12 months later. EF ratings and verbal memory added to injury severity in predicting educational competence post injury but did not predict post-injury initiation of special education. The results demonstrated that measurement of EF behaviors is an important research and clinical tool for prediction of functional outcomes in pediatric TBI.	[Arnett, Anne B.; Peterson, Robin L.; Kirkwood, Michael W.] Childrens Hosp Colorado, Dept Phys Med & Rehabil, Aurora, CO USA; [Arnett, Anne B.; Peterson, Robin L.; Kirkwood, Michael W.] Univ Colorado Denver, Sch Med, Aurora, CO USA; [Arnett, Anne B.; Peterson, Robin L.] Univ Denver, Dept Child Clin Psychol, Denver, CO USA; [Taylor, H. Gerry] Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; [Taylor, H. Gerry] Univ Hosp Cleveland, Case Med Ctr, Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA; [Stancin, Terry] MetroHealth Med Ctr, Dept Psychiat, Cleveland, OH USA; [Stancin, Terry] Case Western Reserve Univ, Cleveland, OH 44106 USA; [Brown, Tanya M.] Mayo Clin, Dept Psychiat & Psychol, Rochester, MN USA; [Wade, Shari L.] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Cincinnati, OH 45229 USA; [Wade, Shari L.] Univ Cincinnati, Coll Med, Cincinnati, OH USA	Arnett, AB (corresponding author), Childrens Hosp Colorado Rehabil Med, 13123 E 16th Ave,B285, Aurora, CO 80045 USA.	arnett.anne@gmail.com	Stancin, Terry/L-7993-2019	Arnett, Anne/0000-0003-1342-0488	NIH from the National Institute of Mental Health [R01-MH073764]; Colorado Traumatic Brain Injury Trust Fund Research Program, Colorado Department of Human Services, Division of Vocational Rehabilitation, Traumatic Brain Injury Program; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH073764] Funding Source: NIH RePORTER	The authors thank Robert Blaha, Elizabeth Hagesfeld, Michelle Jacobs, Daniel Maier, and Nina Fox in data collection and entry, Amy Cassedy in data management, and John Stullenberger in Website support. We also thank the therapists JoAnne Carey, PsyD, Britt Nielsen, PsyD, and Brad Jackson, PhD. Conflicts of Interest and Sources of Funding: This work was supported in part by (1) NIH grant R01-MH073764 from the National Institute of Mental Health; and (2) a grant from the Colorado Traumatic Brain Injury Trust Fund Research Program, Colorado Department of Human Services, Division of Vocational Rehabilitation, Traumatic Brain Injury Program. We certify that no party having a direct interest in the results of the research supporting this article has or will confer a benefit on us or on any organization with which we are associated AND, if applicable, we certify that all financial and material support for this research (e.g., NIH or NHS grants) and work are clearly identified in the title page of the manuscript. This clinical trial was registered with clinicaltrials.gov, assigned identifier: NCT00409448. The authors acknowledge that the information in this manuscript and the manuscript itself has never been published either electronically or in print.	Achenbach T., 2001, CHILD BEHAV CHECKLIS; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Barrett P, 2007, PERS INDIV DIFFER, V42, P815, DOI 10.1016/j.paid.2006.09.018; Biederman J, 2004, J CONSULT CLIN PSYCH, V72, P757, DOI 10.1037/0022-006X.72.5.757; Delis D. C., 2000, CVLT 2 CALIFORNIA VE; Delis D.C., 1994, CVLT C CALIFORNIA VE; Dennis M, 2001, J INT NEUROPSYCH SOC, V7, P683, DOI 10.1017/S1355617701766040; DONDERS J, 1994, J SCHOOL PSYCHOL, V32, P53, DOI 10.1016/0022-4405(94)90028-0; Ewing-Cobbs L, 1998, J CLIN EXP NEUROPSYC, V20, P769, DOI 10.1076/jcen.20.6.769.1109; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Ganesalingam K, 2011, NEUROPSYCHOLOGY, V25, P466, DOI 10.1037/a0022768; Gioia G. A., 2000, BRIEF BEHAV RATING I; Goldstrohm SL, 2005, ARCH CLIN NEUROPSYCH, V20, P675, DOI 10.1016/j.acn.2005.02.005; Horneman G, 2009, BRAIN INJURY, V23, P907, DOI 10.1080/02699050903283239; Johnson CP, 2011, J INT NEUROPSYCH SOC, V17, P663, DOI 10.1017/S1355617711000464; Kinsella G J, 1997, J Int Neuropsychol Soc, V3, P608; Kline R.B., 2005, PRINCIPLES PRACTICE, V2nd; Levin HS, 2005, PEDIATR NEUROL, V33, P79, DOI 10.1016/j.pediatrneurol.2005.02.002; Mahone EM, 2002, CHILD NEUROPSYCHOL, V8, P258, DOI 10.1076/chin.8.4.258.13510; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; METHUEN LK, 1998, MPLUS USERS GUIDE; Miller LJ, 2003, REHABIL PSYCHOL, V48, P237, DOI 10.1037/0090-5550.48.4.237; Moos R, 1994, LIFE STRESSORS SOCIA; Muscara F, 2008, J NEUROPSYCHOL, V2, P445, DOI 10.1348/174866407X250820; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; Rassovsky Y, 2006, J CLIN EXP NEUROPSYC, V28, P567, DOI 10.1080/13803390500434466; REYNOLDS CR, 1998, BEHAV ASSESSMENT SYS; Ryu WHA, 2010, INT J REHABIL RES, V33, P84, DOI 10.1097/MRR.0b013e32832e6b4b; Savage Ronald C, 2005, Pediatr Rehabil, V8, P92; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor HG, 2008, J INT NEUROPSYCH SOC, V14, P734, DOI 10.1017/S1355617708081150; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Toplak ME, 2013, J CHILD PSYCHOL PSYC, V54, P131, DOI 10.1111/jcpp.12001; Wade SL, 2010, J HEAD TRAUMA REHAB, V25, P409, DOI 10.1097/HTR.0b013e3181fb900d; Wade SL, 2013, J HEAD TRAUMA REHABI; Yeates KO, 2005, J AM ACAD CHILD PSY, V44, P574, DOI 10.1097/01.chi.0000159947.50523.64	38	34	34	2	47	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	SEP	2013	19	8					881	889		10.1017/S1355617713000635			9	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	209AQ	WOS:000323725800005	23790158	Green Accepted			2021-06-18	
J	Soberg, HL; Roe, C; Anke, A; Arango-Lasprilla, JC; Skandsen, T; Sveen, U; von Steinbuchel, N; Andelic, N				Soberg, Helene L.; Roe, Cecilie; Anke, Audny; Carlos Arango-Lasprilla, Juan; Skandsen, Toril; Sveen, Unni; von Steinbuechel, Nicole; Andelic, Nada			HEALTH-RELATED QUALITY OF LIFE 12 MONTHS AFTER SEVERE TRAUMATIC BRAIN INJURY: A PROSPECTIVE NATIONWIDE COHORT STUDY	JOURNAL OF REHABILITATION MEDICINE			English	Article						traumatic brain injury; quality of life; depression; rehabilitation; outcome assessment	POST-CONCUSSION SYMPTOMS; HEAD-INJURY; MULTIPLE INJURIES; SCALE; PREVALENCE; DISORDERS; MODERATE; QOLIBRI; CLASSIFICATION; SATISFACTION	Objective: To assess health-related quality of life in individuals with severe traumatic brain injury at 12 months post-injury, applying the Quality of Life after Brain Injury (QOLIBRI) instrument, and to study the relationship between injury-related factors, post-injury functioning and health-related quality of life. Design/subjects: The study is part of a prospective, Norwegian multicentre study of adults (>= 16 years old) with severe traumatic brain injury, as defined by a Glasgow Coma Scale score of 3-8 during the first 24 h post-injury. A total of 126 patients were included. Methods: Socio-demographic data and injury severity variables were collected. Functioning at 3 and 12 months was assessed with the Glasgow Outcome Scale Extended (GOSE), the Functional Independence Measure (FIM), the Rivermead Post-concussion Questionnaire (RPQ), and the Hospital Anxiety and Depression Scale (HADS). Hierarchical regression analysis was applied. Results: Mean QOLIBRI score was 68.5 (standard deviation =18.8). Predictors of the QOLIBRI in the final regression model were: employment status (p=0.05), GOSE (p=0.05), RPQ (p<0.001) and RADS (p<0.001). The adjusted R-2 showed that the model explained 64.0% of the variance in the QOLIBRI score. Conclusion: Symptom pressure and global functioning in the sub-acute phase of traumatic brain injury and psychological distress in the post-acute phase are important for health-related quality of life at 12 months post-injury. These domains should be the focus in rehabilitation aiming to improve health-related quality of life in patients with severe traumatic brain injury.	[Soberg, Helene L.; Roe, Cecilie; Sveen, Unni; Andelic, Nada] Oslo Univ Hosp, Dept Phys Med & Rehabil, Ulleval, Norway; [Roe, Cecilie] Univ Oslo, Fac Med, Oslo, Norway; [Anke, Audny] Univ Tromso, Inst Clin Med, Fac Hlth Sci, Tromso, Norway; [Carlos Arango-Lasprilla, Juan] Univ Deusto Bilbao, Basque Fdn Sci, IKERBASQUE, Bilbao, Spain; [Skandsen, Toril] Norwegian Univ Sci & Technol NTNU, Fac Med, Dept Neurosci, Trondheim, Norway; [Skandsen, Toril] Univ Trondheim Hosp, St Olavs Hosp, Dept Phys Med & Rehabil, Trondheim, Norway; [Sveen, Unni] Oslo & Akershus Univ, Coll Appl Sci, Oslo, Norway; [von Steinbuechel, Nicole] Univ Gottingen, Dept Med Psychol & Med Sociol, Gottingen, Germany	Soberg, HL (corresponding author), Ullevaal Univ Hosp, Dept Phys Med & Rehabil, NO-0407 Oslo, Norway.	h.l.soberg@medisin.uio.no	Skandsen, Toril/P-6767-2014	Skandsen, Toril/0000-0001-5495-9338; Anke, Audny/0000-0002-2491-2560; Andelic, Nada/0000-0002-3719-4406	Norwegian Research CouncilResearch Council of NorwayEuropean Commission	We thank the Trauma Registry at Oslo University Hospital and Haukeland University Hospital for providing data regarding injury severity. We also thank Tone Jerstad, neuroradiologist for her effort in analysing the majority of CT scans and providing the Rotterdam scores. This multicentre study was funded by the Norwegian Research Council.	Ahmadi SA, 2010, BRAIN INJURY, V24, P1539, DOI 10.3109/02699052.2010.523049; Andelic N, 2012, NEUROEPIDEMIOLOGY, V38, P259, DOI 10.1159/000338032; Andelic N, 2009, ACTA NEUROL SCAND, V120, P16, DOI 10.1111/j.1600-0404.2008.01116.x; Andelic N, 2010, DISABIL REHABIL, V32, P1122, DOI 10.3109/09638280903410722; Arango-Lasprilla JC, 2009, NEUROREHABILITATION, V24, P5, DOI 10.3233/NRE-2009-0449; Ayuso-Mateos JL, 2001, BRIT J PSYCHIAT, V179, P308, DOI 10.1192/bjp.179.4.308; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bullinger M, 2002, RESTOR NEUROL NEUROS, V20, P111; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; De Silva MJ, 2009, INT J EPIDEMIOL, V38, P452, DOI 10.1093/ije/dyn189; Diaz AP, 2012, J NEUROTRAUM, V29, P1029, DOI 10.1089/neu.2011.2089; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; Englander J, 2010, BRAIN INJURY, V24, P1379, DOI 10.3109/02699052.2010.523041; Ewing-Cobbs Linda, 2002, Semin Pediatr Neurol, V9, P209, DOI 10.1053/spen.2002.35502; Hawthorne G, 2011, J CLIN NEUROSCI, V18, P197, DOI 10.1016/j.jocn.2010.06.015; Jacobsson LJ, 2010, BRAIN INJURY, V24, P1075, DOI 10.3109/02699052.2010.494590; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Koskinen S, 2011, DISABIL REHABIL, V33, P2464, DOI 10.3109/09638288.2011.574776; Lehtonen S, 2005, BRAIN INJURY, V19, P239, DOI 10.1080/0269905040004310; Levack WMM, 2010, DISABIL REHABIL, V32, P986, DOI 10.3109/09638281003775394; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Mathias JL, 2012, SLEEP MED, V13, P898, DOI 10.1016/j.sleep.2012.04.006; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Nichol AD, 2011, INJURY, V42, P281, DOI 10.1016/j.injury.2010.11.047; Safaz I, 2008, BRAIN INJURY, V22, P733, DOI 10.1080/02699050802304714; Sasse N, 2012, J HEAD TRAUMA REHABI; Schonberger M, 2010, PSYCHIAT RES, V179, P342, DOI 10.1016/j.psychres.2009.07.003; Seeley HM, 2009, BRIT J NEUROSURG, V23, P530, DOI 10.1080/02688690903078874; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Steel J, 2010, J TRAUMA, V69, P523, DOI 10.1097/TA.0b013e3181e90c24; TEASDALE G, 1974, LANCET, V2, P81; The Association for the Advancement of Automotive Medicine, 2008, ABBR INJ SCAL AIS 20; Truelle JL, 2010, BRAIN INJURY, V24, P1272, DOI 10.3109/02699052.2010.506865; Uniform Data System for Medical Rehabilitation, 1996, GUID UN DAT SET MED; Vakil E, 2005, J CLIN EXP NEUROPSYC, V27, P977, DOI 10.1080/13803390490919245; von Steinbuchel N, 2010, J NEUROTRAUM, V27, P1167, DOI 10.1089/neu.2009.1076; von Steinbuchel N, 2010, J NEUROTRAUM, V27, P1157, DOI 10.1089/neu.2009.1077; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Zigmond AS, 1983, PSYCHIAT SCAND, V76, P361, DOI DOI 10.1111/J.1600-0447.1983.TB09716.X	41	34	34	0	10	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	SEP	2013	45	8					785	791		10.2340/16501977-1158			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	243ZS	WOS:000326357500014	24002315	DOAJ Gold, Green Published			2021-06-18	
J	Chang, JC; Brennan, KC; He, DD; Huang, HX; Miura, RM; Wilson, PL; Wylie, JJ				Chang, Joshua C.; Brennan, Kevin C.; He, Dongdong; Huang, Huaxiong; Miura, Robert M.; Wilson, Phillip L.; Wylie, Jonathan J.			A Mathematical Model of the Metabolic and Perfusion Effects on Cortical Spreading Depression	PLOS ONE			English	Article							CEREBRAL-ARTERIES; BLOOD-FLOW; MECHANISMS; POTASSIUM; ASTROCYTES; DIFFUSION; ISCHEMIA; NEURONS; VOLUME; OXYGEN	Cortical spreading depression (CSD) is a slow-moving ionic and metabolic disturbance that propagates in cortical brain tissue. In addition to massive cellular depolarizations, CSD also involves significant changes in perfusion and metabolism-aspects of CSD that had not been modeled and are important to traumatic brain injury, subarachnoid hemorrhage, stroke, and migraine. In this study, we develop a mathematical model for CSD where we focus on modeling the features essential to understanding the implications of neurovascular coupling during CSD. In our model, the sodium-potassium-ATPase, mainly responsible for ionic homeostasis and active during CSD, operates at a rate that is dependent on the supply of oxygen. The supply of oxygen is determined by modeling blood flow through a lumped vascular tree with an effective local vessel radius that is controlled by the extracellular potassium concentration. We show that during CSD, the metabolic demands of the cortex exceed the physiological limits placed on oxygen delivery, regardless of vascular constriction or dilation. However, vasoconstriction and vasodilation play important roles in the propagation of CSD and its recovery. Our model replicates the qualitative and quantitative behavior of CSD-vasoconstriction, oxygen depletion, extracellular potassium elevation, prolonged depolarization-found in experimental studies. We predict faster, longer duration CSD in vivo than in vitro due to the contribution of the vasculature. Our results also help explain some of the variability of CSD between species and even within the same animal. These results have clinical and translational implications, as they allow for more precise in vitro, in vivo, and in silico exploration of a phenomenon broadly relevant to neurological disease.	[Chang, Joshua C.] Ohio State Univ, Math Biosci Inst, Columbus, OH 43210 USA; [Brennan, Kevin C.] Univ Utah, Dept Neurol, Salt Lake City, UT USA; [He, Dongdong] City Univ Hong Kong, Dept Math, Kowloon Tong, Hong Kong, Peoples R China; [Huang, Huaxiong] York Univ, Dept Math & Stat, Toronto, ON M3J 2R7, Canada; [Miura, Robert M.] New Jersey Inst Technol, Dept Math Sci, Newark, NJ 07102 USA; [Miura, Robert M.] New Jersey Inst Technol, Ctr Appl Math & Stat, Newark, NJ 07102 USA; [Wilson, Phillip L.] Univ Canterbury, Dept Math & Stat, Christchurch 1, New Zealand; [Wylie, Jonathan J.] City Univ Hong Kong, Dept Math, Kowloon Tong, Hong Kong, Peoples R China	Chang, JC (corresponding author), Ohio State Univ, Math Biosci Inst, Columbus, OH 43210 USA.	chang.1166@mbi.osu.edu		Brennan, K.C./0000-0003-4193-5841; Chang, Joshua/0000-0001-9690-9179; WYLIE, Jonathan James/0000-0001-8314-9764	National Institute of General Medical SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008185]; Army Research Office [58386MA]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NINDS NS059072, NS070084]; Department of DefenseUnited States Department of Defense [CDMRP PR100060]; Natural Sciences and Engineering Research Council of CanadaNatural Sciences and Engineering Research Council of Canada (NSERC)CGIAR; Mathematics in Technology and Complex Systems; National Science FoundationNational Science Foundation (NSF) [DMS-1022848, 0635561]; Research Grants Council of the Hong Kong Special Administrative Region, ChinaHong Kong Research Grants Council [CityU 104211]; Direct For Mathematical & Physical ScienNational Science Foundation (NSF)NSF - Directorate for Mathematical & Physical Sciences (MPS) [1022848] Funding Source: National Science Foundation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008185] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS059072, R21NS070084] Funding Source: NIH RePORTER	The authors thank grant number T32GM008185 from the National Institute of General Medical Sciences and grant number 58386MA from the Army Research Office (JCC); the National Institutes of Health (NINDS NS059072 and NS070084) and the Department of Defense (CDMRP PR100060) (KCB); the Natural Sciences and Engineering Research Council of Canada and the Mathematics in Technology and Complex Systems (HH), the National Science Foundation through grant DMS-1022848 (RMM, HH, JJW), and agreement No. 0635561 (JCC), and the Research Grants Council of the Hong Kong Special Administrative Region, China, CityU 104211 (JJW). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andrew RD, 2007, CEREB CORTEX, V17, P787, DOI 10.1093/cercor/bhk032; Aperia A, 2001, Curr Hypertens Rep, V3, P165, DOI 10.1007/s11906-001-0032-8; Attwell D, 2010, NATURE, V468, P232, DOI 10.1038/nature09613; Bennett MR, 2008, BIOPHYS J, V95, P5648, DOI 10.1529/biophysj.108.137190; Brennan KC, 2010, CURR OPIN NEUROL, V23, P266, DOI 10.1097/WCO.0b013e32833821c1; Bures J, 1974, MECH APPL LEAOS SPRE; Busija DW, 2008, PROG NEUROBIOL, V86, P379, DOI 10.1016/j.pneurobio.2008.09.008; Chang JC, 2010, BRAIN, V133, P996, DOI 10.1093/brain/awp338; Charles A, 2009, CEPHALALGIA, V29, P1115, DOI 10.1111/j.1468-2982.2009.01983.x; Chih CP, 2003, J CEREBR BLOOD F MET, V23, P1263, DOI 10.1097/01.WCB.0000081369.51727.6F; Dirnagl U, 2010, J CEREBR BLOOD F MET, V30, P1, DOI 10.1038/jcbfm.2009.252; Dreier JP, 2011, NAT MED, V17, P439, DOI 10.1038/nm.2333; Dreier JP, 2009, BRAIN, V132, P1866, DOI 10.1093/brain/awp102; Farr H, 2011, J THEOR BIOL, V286, P13, DOI 10.1016/j.jtbi.2011.07.006; Filosa JA, 2004, CIRC RES, V95, pE73, DOI 10.1161/01.RES.0000148636.60732.2e; Gordon GRJ, 2008, NATURE, V456, P745, DOI 10.1038/nature07525; Hadjikhani N, 2001, P NATL ACAD SCI USA, V98, P4687, DOI 10.1073/pnas.071582498; Hansen A, 2008, ACTA PHYSL SCANDINAV, V113, P437; HANSEN AJ, 1988, NEUROCHEM PATHOL, V9, P195; HEINEMANN U, 1977, BRAIN RES, V120, P231, DOI 10.1016/0006-8993(77)90903-9; Kager H, 2000, J NEUROPHYSIOL, V84, P495; Kager H, 2002, J NEUROPHYSIOL, V88, P2700, DOI 10.1152/jn.00237.2002; Keener J., 2009, MATH PHYSL; Klein J, 2003, PRINCIPLES CEREBRAL, P291; Knot HJ, 1996, J PHYSIOL-LONDON, V492, P419, DOI 10.1113/jphysiol.1996.sp021318; KRAIG RP, 2002, CEREBROVASC DIS, P142; Lashley KS, 1941, ARCH NEURO PSYCHIATR, V46, P331, DOI 10.1001/archneurpsyc.1941.02280200137007; Laughlin SB, 1998, NAT NEUROSCI, V1, P36, DOI 10.1038/236; Leao AAP, 1944, J NEUROPHYSIOL, V7, P359; Mazel T, 2002, PHYSIOL RES, V51, pS85; MCCARRON JG, 1990, AM J PHYSIOL, V259, pH902; NICHOLSON C, 1981, J PHYSIOL-LONDON, V321, P225, DOI 10.1113/jphysiol.1981.sp013981; Nicholson C, 2001, REP PROG PHYS, V64, P815, DOI 10.1088/0034-4885/64/7/202; Piilgaard H, 2009, J CEREBR BLOOD F MET, V29, P1517, DOI 10.1038/jcbfm.2009.73; Sakadzic S, 2009, APPL OPTICS, V48, pD169, DOI 10.1364/AO.48.00D169; Shapiro BE, 2001, J COMPUT NEUROSCI, V10, P99, DOI 10.1023/A:1008924227961; Somjen GG, 2008, J COMPUT NEUROSCI, V25, P349, DOI 10.1007/s10827-008-0083-9; Somjen GG, 2001, PHYSIOL REV, V81, P1065; SOMJEN GG, 1975, ANNU REV PHYSIOL, V37, P163, DOI 10.1146/annurev.ph.37.030175.001115; Sukhotinsky I, 2008, J CEREBR BLOOD F MET, V28, P1369, DOI 10.1038/jcbfm.2008.35; Sukhotinsky I, 2011, CEPHALALGIA, V31, P1601, DOI 10.1177/0333102411425865; Takano T, 2007, NAT NEUROSCI, V10, P754, DOI 10.1038/nn1902; Tfelt-Hansen PC, 2010, CEPHALALGIA, V30, P780, DOI 10.1111/j.1468-2982.2009.02015.x; TUCKWELL HC, 1978, BIOPHYS J, V23, P257, DOI 10.1016/S0006-3495(78)85447-2; Walz W, 2000, NEUROCHEM INT, V36, P291, DOI 10.1016/S0197-0186(99)00137-0; Yao W, 2011, B MATH BIOL, V73, P2773, DOI 10.1007/s11538-011-9647-3; Zamir M., 2000, PHYS PULSATILE FLOW	47	34	34	1	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 14	2013	8	8							e70469	10.1371/journal.pone.0070469			9	Multidisciplinary Sciences	Science & Technology - Other Topics	202MQ	WOS:000323221500016	23967075	DOAJ Gold, Green Published			2021-06-18	
J	Kawai, N; Kawanishi, M; Kudomi, N; Maeda, Y; Yamamoto, Y; Nishiyama, Y; Tamiya, T				Kawai, Nobuyuki; Kawanishi, Masahiko; Kudomi, Nobuyuki; Maeda, Yukito; Yamamoto, Yuka; Nishiyama, Yoshihiro; Tamiya, Takashi			Detection of brain amyloid beta deposition in patients with neuropsychological impairment after traumatic brain injury: PET evaluation using Pittsburgh Compound-B	BRAIN INJURY			English	Article						Amyloid beta (beta); neuropsychological impairment; Pittsburgh Compound B; positron emission tomography; traumatic brain injury	POSITRON-EMISSION-TOMOGRAPHY; ALZHEIMERS-DISEASE; APOLIPOPROTEIN-E; HEAD-INJURY; SENILE PLAQUES; AXONAL INJURY; RISK-FACTOR; ACCUMULATION; ASSOCIATION; CEREBELLUM	Objective: Traumatic brain injury (TBI) is an epigenetic risk factor for Alzheimer's disease (AD) and amyloid beta (A beta) deposition is observed histopathologically in the traumatized brain. This study was conducted to detect cerebral Ab deposition using amyloid positron emission tomography (PET) in patients with neuropsychological impairment after TBI. Methods: Twelve patients with post-traumatic neuropsychological impairment (11 men and one woman, age range = 21-78 years) were examined using Pittsburgh Compound B (C-11-PIB) PET at the chronic stage after TBI (range 5-129 months). Results: C-11-PIB was positive in three patients and negative in the other nine patients. There was no correlation between C-11-PIB deposition and the severity of injury; initial CT findings; elapsed time from the injury; and neuropsychological test scores. Conclusions: The absence of A beta deposition in many patients with chronic neuropsychological impairment after TBI does not support the premise that A beta pathology progresses over time in the traumatized brain. Early and sequential C-11-PIB PET examination may clarify the time course of A beta deposition in the traumatized brain and the relationship between traumatic brain insult and subsequent neuropsychological impairment.	[Kawai, Nobuyuki; Kawanishi, Masahiko; Tamiya, Takashi] Kagawa Univ, Dept Neurol Surg, Fac Med, Kagawa 7610793, Japan; [Kudomi, Nobuyuki] Kagawa Univ, Dept Med Phys, Fac Med, Kagawa 7610793, Japan; [Maeda, Yukito] Kagawa Univ Hosp, Dept Clin Radiol, Kagawa, Japan; [Yamamoto, Yuka; Nishiyama, Yoshihiro] Kagawa Univ, Dept Radiol, Fac Med, Kagawa 7610793, Japan	Kawai, N (corresponding author), Kagawa Univ, Dept Neurol Surg, Fac Med, 1750-1 Miki Cho, Kagawa 7610793, Japan.	nobu@med.kagawa-u.ac.jp			Japan Society for the Promotion of ScienceMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science; General Insurance Association of Japan	This work was supported in parts by grants from the Grant-in-Aid for Scientific Research (C) from the Japan Society for the Promotion of Science and the General Insurance Association of Japan. The authors report no conflicts of interests.	Bacskai BJ, 2007, ARCH NEUROL-CHICAGO, V64, P431, DOI 10.1001/archneur.64.3.431; Berger E, 1999, RESTOR NEUROL NEUROS, V14, P93; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Ikonomovic MD, 2008, BRAIN, V131, P1630, DOI 10.1093/brain/awn016; JOACHIM CL, 1989, AM J PATHOL, V135, P309; Kadir A, 2011, BRAIN, V134, P301, DOI 10.1093/brain/awq349; Kawai N, 2010, J NEUROTRAUM, V27, P2131, DOI 10.1089/neu.2010.1464; Kim J, 2009, NEURON, V63, P287, DOI 10.1016/j.neuron.2009.06.026; Klunk WE, 2004, ANN NEUROL, V55, P306, DOI 10.1002/ana.20009; Kraus J, 2000, HEAD INJURY, P1; Luukinen H, 1999, NEUROLOGY, V52, P557, DOI 10.1212/WNL.52.3.557; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; Lyketsos CG, 2002, JAMA-J AM MED ASSOC, V288, P1475, DOI 10.1001/jama.288.12.1475; Magnoni S, 2010, ARCH NEUROL-CHICAGO, V67, P1068, DOI 10.1001/archneurol.2010.214; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Mormino EC, 2012, NEUROIMAGE, V59, P1152, DOI 10.1016/j.neuroimage.2011.07.098; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; YAMAGUCHI H, 1989, ACTA NEUROPATHOL, V77, P314, DOI 10.1007/BF00687584; Yaqub M, 2008, NEUROIMAGE, V42, P76, DOI 10.1016/j.neuroimage.2008.04.251	31	34	34	0	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	AUG	2013	27	9					1026	1031		10.3109/02699052.2013.794963			6	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	180HZ	WOS:000321586100006	23662609				2021-06-18	
J	Bernick, C; Banks, S; Phillips, M; Lowe, M; Shin, W; Obuchowski, N; Jones, S; Modic, M				Bernick, Charles; Banks, Sarah; Phillips, Michael; Lowe, Mark; Shin, Wanyong; Obuchowski, Nancy; Jones, Stephen; Modic, Michael			Professional Fighters Brain Health Study: Rationale and Methods	AMERICAN JOURNAL OF EPIDEMIOLOGY			English	Article						boxing; chronic traumatic encephalopathy; mixed martial arts; traumatic brain injury	CHRONIC TRAUMATIC ENCEPHALOPATHY; INJURY; CONCUSSION; EDUCATION	Repetitive head trauma is a risk factor for Alzheimer's disease and is the primary cause of chronic traumatic encephalopathy. However, little is known about the natural history of, and risk factors for, chronic traumatic encephalopathy or about means of early detection and intervention. The Professional Fighters Brain Health Study is a longitudinal study of active professional fighters (boxers and mixed martial artists), retired professional fighters, and controls matched for age and level of education. The main objective of the Professional Fighters Brain Health Study is to determine the relationships between measures of head trauma exposure and other potential modifiers and changes in brain imaging and neurological and behavioral function over time. The study is designed to extend over 5 years, and we anticipate enrollment of more than 400 boxers and mixed martial artists. Participants will undergo annual evaluations that include 3-tesla magnetic resonance imaging scanning, computerized cognitive assessments, speech analysis, surveys of mood and impulsivity, and blood sampling for genotyping and exploratory biomarker studies. Statistical models will be developed and validated to predict early and progressive changes in brain structure and function. A composite fight exposure index, developed as a summary measure of cumulative traumatic exposure, shows promise as a predictor of brain volumes and cognitive function.	[Bernick, Charles; Banks, Sarah] Cleveland Clin, Lou Ruvo Ctr Brain Hlth, Las Vegas, NV 89106 USA; [Phillips, Michael; Lowe, Mark; Shin, Wanyong; Obuchowski, Nancy; Jones, Stephen; Modic, Michael] Cleveland Clin, Dept Diagnost Radiol, Cleveland, OH 44106 USA; [Phillips, Michael; Lowe, Mark; Jones, Stephen] Cleveland Clin, Mellen Ctr Multiple Sclerosis, Cleveland, OH 44106 USA; [Obuchowski, Nancy] Cleveland Clin, Cleveland, OH 44106 USA	Bernick, C (corresponding author), Cleveland Clin, Lou Ruvo Ctr Brain Hlth, 888 West Bonneville Ave, Las Vegas, NV 89106 USA.	bernicc@ccf.org		Banks, Sarah/0000-0001-7536-2370	Lincy Foundation	Funding for this study was provided by the Lincy Foundation.	Bazarian JJ, 2009, J HEAD TRAUMA REHAB, V24, P439, DOI 10.1097/HTR.0b013e3181c15600; Bright P, 2002, J INT NEUROPSYCH SOC, V8, P847, DOI 10.1017/S1355617702860131; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Heilbronner RL, 2009, ARCH CLIN NEUROPSYCH, V24, P11, DOI 10.1093/arclin/acp005; Ikonomovic MD, 2008, BRAIN, V131, P1630, DOI 10.1093/brain/awn016; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Jordan BD, 1996, PHYSICIAN SPORTSMED, V24, P87, DOI 10.3810/psm.1996.05.1358; Kirsch W, 2009, J ALZHEIMERS DIS, V17, P599, DOI 10.3233/JAD-2009-1073; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; LEVIN HS, 1987, J NEUROSURG, V67, P657, DOI 10.3171/jns.1987.67.5.0657; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; MENDEZ MF, 1995, INT J PSYCHIAT MED, V25, P249, DOI 10.2190/CUMK-THT1-X98M-WB4C; Moseley IF, 2000, NEURORADIOLOGY, V42, P1, DOI 10.1007/s002340050001; Navarro RR, 2011, CURR SPORT MED REP, V10, P27, DOI 10.1249/JSR.0b013e318205e072; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Omalu BI, 2010, AM J FOREN MED PATH, V31, P130, DOI 10.1097/PAF.0b013e3181ca7f35; Orrison WW, 2009, J NEUROTRAUM, V26, P689, DOI 10.1089/neu.2008.0636; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Roberts AH., 1969, BRAIN DAMAGE BOXERS; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Solomon GS, 2011, CLIN SPORT MED, V30, P165, DOI 10.1016/j.csm.2010.09.002; Stanford MS, 2009, PERS INDIV DIFFER, V47, P385, DOI 10.1016/j.paid.2009.04.008; Tombaugh TN, 1999, ARCH CLIN NEUROPSYCH, V14, P167, DOI 10.1016/S0887-6177(97)00095-4; Van Den Heuvel C, 2007, PROG BRAIN RES, V161, P303, DOI 10.1016/S0079-6123(06)61021-2; Weiner MF, 2011, INT PSYCHOGERIATR, V23, P1602, DOI 10.1017/S1041610211000767; Zazryn T, 2007, SPORTS MED, V37, P467; Zhang L, 2006, AM J NEURORADIOL, V27, P2000	29	34	34	0	50	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9262	1476-6256		AM J EPIDEMIOL	Am. J. Epidemiol.	JUL 15	2013	178	2					280	286		10.1093/aje/kws456			7	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	186DD	WOS:000322021300014	23735309	Bronze			2021-06-18	
J	Downing, MG; Stolwyk, R; Ponsford, JL				Downing, Marina G.; Stolwyk, Rene; Ponsford, Jennie L.			Sexual Changes in Individuals With Traumatic Brain Injury: A Control Comparison	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						sexual changes; sexuality; Sexuality Questionnaire; traumatic brain injury	SELF-ESTEEM; HOSPITAL ANXIETY; DEPRESSION SCALE; BODY-IMAGE; VALIDITY	Background: Previous research has suggested that sexuality is compromised following traumatic brain injury (TBI), but there has been limited comparison with healthy samples. Objectives: The aim of the current study was to compare sexuality in individuals with TBI with that in healthy controls matched for age and gender. In doing this, the current study aimed to characterize those individuals who reported a decrease in sexuality relative to those reporting an increase according to certain demographic and injury variables. Method: A total of 865 participants with predominantly moderate to severe TBI and 142 controls completed the Brain Injury Questionnaire of Sexuality (BIQS), the Hospital Anxiety and Depression Scale, and the Rosenberg Self-Esteem Scale on one occasion. Results: The results indicated that there was a significant difference between participants with TBI and controls on all the BIQS subscales as well as the total score. Age, depression, anxiety, and self-esteem levels significantly differentiated participants with TBI who reported decreased sexuality from those who reported increased sexuality. Participants with TBI attributed sexual changes to various causes-most commonly, fatigue, low confidence, pain, decreased mobility, and feeling unattractive. Conclusions: Further research examining the factors contributing to sexual changes is warranted.	[Downing, Marina G.; Stolwyk, Rene; Ponsford, Jennie L.] Monash Univ, Sch Psychol & Psychiat, Melbourne, Vic 3004, Australia; [Downing, Marina G.; Ponsford, Jennie L.] Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia; [Ponsford, Jennie L.] Natl Trauma Res Inst, Melbourne, Vic, Australia	Ponsford, JL (corresponding author), Monash Univ, Sch Psychol & Psychiat, Clayton, Vic 3800, Australia.	jennie.ponsford@med.monash.edu.au	Downing, Marina/AAX-2380-2020	Downing, Marina/0000-0002-3126-6632	Transport Accident Commission, through the Institute for Safety, Compensation and Recovery Research (ISCRR)	This project is funded by the Transport Accident Commission, through the Institute for Safety, Compensation and Recovery Research (ISCRR).	Anson K, 2006, BRAIN INJURY, V20, P1, DOI 10.1080/02699050500309791; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; Carroll E, 2011, NEUROPSYCHOL REHABIL, V21, P289, DOI 10.1080/09602011.2011.555972; Cooper-Evans S, 2008, NEUROPSYCHOL REHABIL, V18, P607, DOI 10.1080/09602010801948516; Gill CJ, 2011, J HEAD TRAUMA REHAB, V26, P56, DOI 10.1097/HTR.0b013e3182048ee9; GrayLittle B, 1997, PERS SOC PSYCHOL B, V23, P443, DOI 10.1177/0146167297235001; Howes H, 2005, BRAIN INJURY, V19, P135, DOI 10.1080/02699050410001720077; Keppel CC, 2000, NEUROPSYCHOL REHABIL, V10, P15, DOI 10.1080/096020100389273; KOSTELJANETZ M, 1981, ACTA NEUROL SCAND, V63, P169; Kreuter M, 1998, BRAIN INJURY, V12, P349, DOI 10.1080/026990598122494; Kreutzer J S, 1989, Brain Inj, V3, P177, DOI 10.3109/02699058909004550; MILLER BL, 1986, J NEUROL NEUROSUR PS, V49, P867, DOI 10.1136/jnnp.49.8.867; O'CARROLL R E, 1991, Brain Injury, V5, P303, DOI 10.3109/02699059109008100; Ponsford J, 2003, NEUROPSYCHOL REHABIL, V13, P275, DOI 10.1080/09602010244000363; Ponsford JL, 2013, J HEAD TRAUMA REHAB, V28, P195, DOI 10.1097/HTR.0b013e31828b4f7b; Riley GA, 2010, NEUROPSYCHOL REHABIL, V20, P869, DOI 10.1080/09602011.2010.503041; Rosenberg M., 1965, SOC ADOLESCENT SELF, DOI 10.1126/science.148.3671.804; Sandel ME, 1996, BRAIN INJURY, V10, P719, DOI 10.1080/026990596123981; Schonberger M, 2011, J INT NEUROPSYCH SOC, V17, P781, DOI 10.1017/S1355617711000701; Simpson GK, 2011, J HEAD TRAUMA REHAB, V26, P290, DOI 10.1097/HTR.0b013e3182225250; Snaith R.P., 1994, HOSP ANXIETY DEPRESS; Stowyk RJ, 2013, J HEAD TRAUMA REHAB, V28, P164; Whelan-Goodinson R, 2009, J AFFECT DISORDERS, V114, P94, DOI 10.1016/j.jad.2008.06.007; ZENCIUS A, 1990, Brain Injury, V4, P175, DOI 10.3109/02699059009026163	24	34	34	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2013	28	3					171	178		10.1097/HTR.0b013e31828b4f63			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	149PS	WOS:000319334000003	23661068				2021-06-18	
J	Jeter, CB; Hergenroeder, GW; Ward, NH; Moore, AN; Dash, PK				Jeter, Cameron B.; Hergenroeder, Georgene W.; Ward, Norman H., III; Moore, Anthony N.; Dash, Pramod K.			Human Mild Traumatic Brain Injury Decreases Circulating Branched-Chain Amino Acids and Their Metabolite Levels	JOURNAL OF NEUROTRAUMA			English	Article						biomarker; dietary supplementation; intracranial pressure; metabolism; mild traumatic brain injury	CENTRAL-NERVOUS-SYSTEM; CEREBRAL-BLOOD-FLOW; GLUCOSE-UTILIZATION; POSSIBLE LINK; LEUCINE; DOPAMINE; INSULIN; CONSCIOUSNESS; PHENYLALANINE; ISOLEUCINE	The pathophysiology of traumatic brain injury (TBI) is complex and not well understood. Because pathophysiology has ramifications for injury progression and outcome, we sought to identify metabolic cascades that are altered after acute human mild and severe TBI. Because catabolism of branched-chain amino acids (BCAAs; i.e., valine, isoleucine, and leucine) leads to glucose and energy metabolism, and neurotransmitter synthesis and availability, we investigated BCAA metabolites in plasma samples collected within 24 h of injury from mild TBI (Glasgow Coma Scale [GCS] score > 12), severe TBI (GCS <= 8), orthopedic injury, and healthy volunteers. We report decreased levels of all three BCAAs in patients with mild TBI relative to healthy volunteers, while these BCAAs levels in patients with severe TBI were further reduced compared with all groups. Orthopedic patients exhibited reductions in BCAA comparable to those in patients with mild TBI. The decrease in patients with mild and severe TBI persisted for derivatives of BCAA catabolic intermediates. Only plasma levels of methylglutarylcarnitine, a derivative of a leucine metabolite, were increased in patients with severe TBI compared with all other groups. Notably, logistic regression combination of three BCAA metabolites whose levels were changed by 24 h post-injury provided prognostic value (area under the curve = 0.92) in identifying patients with severe TBI in whom elevated intracranial pressure (>= 25mm Hg) developed. These changes suggest alteration of BCAA metabolism after TBI may contribute to decreased energy production and neurotransmitter synthesis and may contribute to TBI pathophysiology. Supplementation of BCAAs and/or their metabolites may reduce TBI pathology and improve outcome.	[Jeter, Cameron B.] Univ Texas Houston, Sch Dent, Dept Diagnost & Biomed Sci, Houston, TX 77225 USA; [Hergenroeder, Georgene W.; Ward, Norman H., III] Univ Texas Houston, Sch Med, Vivian L Smith Dept Neurosurg, Houston, TX 77225 USA; [Moore, Anthony N.; Dash, Pramod K.] Univ Texas Houston, Sch Med, Dept Neurobiol & Anat, Houston, TX 77225 USA	Dash, PK (corresponding author), Univ Texas Houston, Sch Med, Dept Neurobiol & Anat, POB 20708, Houston, TX 77225 USA.	p.dash@uth.tmc.edu	Jeter, Cameron B./AAO-1797-2021	Jeter, Cameron B./0000-0001-5303-5897; Hergenroeder, Georgene/0000-0002-6170-2191	Health Resources and Services AdministrationUnited States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA) [R38OT10585]; Mission Connect/TIRR Foundation; Vivian L. Smith Foundation; Gilson-Longenbaugh Foundation	We would like to thank the nurses at Memorial Hermann Hospital-Texas Medical Center and Elizabeth B. Jones, MD, Toby T. Thomas, MD, and Brad Jacobson, MD, for assistance with recruiting patients. This study was supported by the Health Resources and Services Administration (R38OT10585), Mission Connect/TIRR Foundation, The Vivian L. Smith Foundation, and the Gilson-Longenbaugh Foundation.	American Association for Automotive Medicine, 2001, ABBR INJ SCAL AIS; Aquilani R, 2005, ARCH PHYS MED REHAB, V86, P1729, DOI 10.1016/j.apmr.2005.03.022; Aquilani R, 2008, ARCH PHYS MED REHAB, V89, P1642, DOI 10.1016/j.apmr.2008.02.023; Banks WA, 1998, PEPTIDES, V19, P883, DOI 10.1016/S0196-9781(98)00018-7; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; BERRY HK, 1990, AM J DIS CHILD, V144, P539, DOI 10.1001/archpedi.1990.02150290033020; Brosnan JT, 2006, J NUTR, V136, p207S, DOI 10.1093/jn/136.1.207S; Cole JT, 2010, P NATL ACAD SCI USA, V107, P366, DOI 10.1073/pnas.0910280107; Cousins DA, 2009, BIPOLAR DISORD, V11, P787, DOI 10.1111/j.1399-5618.2009.00760.x; Davis JM, 2000, AM J CLIN NUTR, V72, p573S, DOI 10.1093/ajcn/72.2.573S; de Groot MJ, 2010, MOL GENET METAB, V99, pS86, DOI 10.1016/j.ymgme.2009.10.016; Fernstrom JD, 2005, J NUTR, V135, p1539S, DOI 10.1093/jn/135.6.1539S; FERNSTROM JD, 1990, J NUTR BIOCHEM, V1, P508, DOI 10.1016/0955-2863(90)90033-H; Gijsman HJ, 2002, PSYCHOPHARMACOLOGY, V160, P192, DOI 10.1007/s00213-001-0970-5; Hinzman JM, 2010, J NEUROTRAUM, V27, P889, DOI 10.1089/neu.2009.1238; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; Jeter CB, 2012, J NEUROTRAUM, V29, P119, DOI 10.1089/neu.2011.2029; Jiang XB, 2000, NEUROL MED-CHIR, V40, P16, DOI 10.2176/nmc.40.16; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Mochel F, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000647; Montgomery AJ, 2003, AM J PSYCHIAT, V160, P1887, DOI 10.1176/appi.ajp.160.10.1887; Morris AAM, 2005, J INHERIT METAB DIS, V28, P109, DOI 10.1007/s10545-005-5518-0; Murphy MG, 2007, CHEMOSPHERE, V68, P1692, DOI 10.1016/j.chemosphere.2007.03.049; OBrien RM, 1996, PHYSIOL REV, V76, P1109; PALOVCIK RA, 1984, BRAIN RES, V309, P187, DOI 10.1016/0006-8993(84)91028-X; PARDRIDGE WM, 1986, FASEB J, V45, P2073; Piscopo P, 2011, J NEUROSCI RES, V89, P1276, DOI 10.1002/jnr.22655; Richardson MA, 2003, AM J PSYCHIAT, V160, P1117, DOI 10.1176/appi.ajp.160.6.1117; ROE CR, 1986, J CLIN INVEST, V77, P1391, DOI 10.1172/JCI112446; Sakai R, 2004, J NEUROCHEM, V88, P612, DOI 10.1111/j.1471-4159.2004.02179.x; Scarna A, 2003, BRIT J PSYCHIAT, V182, P210, DOI 10.1192/bjp.182.3.210; Schadewaldt P, 2001, PEDIATR RES, V49, P627, DOI 10.1203/00006450-200105000-00004; SHIBATA S, 1986, PHYSIOL BEHAV, V36, P79, DOI 10.1016/0031-9384(86)90077-6; SMITH QR, 1987, J NEUROCHEM, V49, P1651, DOI 10.1111/j.1471-4159.1987.tb01039.x; TEASDALE G, 1974, LANCET, V2, P81; van Calcar Sandra C, 2007, WMJ, V106, P12; van Os J, 2009, LANCET, V374, P635, DOI 10.1016/S0140-6736(09)60995-8; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; Vuille-Dit-Bille RN, 2012, AMINO ACIDS, V43, P1287, DOI 10.1007/s00726-011-1202-x; Xu G, 1998, J BIOL CHEM, V273, P28178, DOI 10.1074/jbc.273.43.28178; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	42	34	36	1	21	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2013	30	8			SI		671	679		10.1089/neu.2012.2491			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	133PO	WOS:000318151500009	23560894				2021-06-18	
J	Miller, SC; Baktash, SH; Webb, TS; Whitehead, CR; Maynard, C; Wells, TS; Otte, CN; Gore, RK				Miller, Shannon C.; Baktash, Suzanne H.; Webb, Timothy S.; Whitehead, Casserly R.; Maynard, Charles; Wells, Timothy S.; Otte, Clifford N.; Gore, Russel K.			Risk for Addiction-Related Disorders Following Mild Traumatic Brain Injury in a Large Cohort of Active-Duty US Airmen	AMERICAN JOURNAL OF PSYCHIATRY			English	Article							ALCOHOL-USE; SUBSTANCE-ABUSE; DRUG-USE; IRAQ; DEPRESSION; PATTERNS	Objective: Military personnel are at increased risk for traumatic brain injury (TBI) from combat and noncombat exposures. The sequelae of moderate to severe TBI are well described, but little is known regarding long-term performance decrements associated with mild TBI. Furthermore, while alcohol and drug use are well known to increase risk for TBI, little is known regarding the reverse pattern. The authors sought to assess possible associations between mild TBI and addiction-related disorders in active-duty U.S. military personnel. Method: A historical prospective study was conducted using electronically recorded demographic, medical, and military data for more than a half million active-duty U.S. Air Force service members. Cases were identified by ICD-9-CM codes considered by an expert panel to be indicative of mild TBI. Outcomes included ICD-9-CM diagnoses of selected addiction-related disorders. Cox proportional hazards modeling was used to calculate hazard ratios while controlling for varying lengths of follow-up and potential confounding variables. Results: Airmen with mild TBI were at increased risk for certain addiction-related disorders compared with a similarly injured non-mild TBI comparison group. Hazards for alcohol dependence, nicotine dependence, and nondependent abuse of drugs or alcohol were significantly elevated, with a consistent decrease over time. Conclusions: A novel finding of this study was the initial increased risk for addiction-related disorders that decreased with time, thus eroding war fighter performance in a military population. Moreover, these results suggest that mild TBI is distinguished from moderate to severe TBI in terms of timing of the risk, indicating that there is a need for screening and prevention of addiction-related disorders in mild TBI. Screening may be warranted in military troops as well as civilians at both short- and long-term milestones following mild TBI. (Am J Psychiatry 2013; 170:383-390)	[Whitehead, Casserly R.] Vet Affairs Med Ctr, Cincinnati, OH 45267 USA; Univ Cincinnati, Dept Psychiat & Behav Neurosci, Ctr Treatment Res & Educ Addict Disorders, Cincinnati, OH USA; Univ Tennessee, Dept Elect Engn & Comp Sci, Knoxville, TN USA; USAF, Res Lab, Vulnerabil Anal Branch, AFMC Human Performance Wing 711, Wright Patterson AFB, OH 45433 USA; Infoscitex Corp, Waltham, MA USA; VA Puget Sound, Epidemiol Res & Informat Ctr, Seattle, WA USA; Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA	Whitehead, CR (corresponding author), Vet Affairs Med Ctr, Cincinnati, OH 45267 USA.	casserly.whitehead.ctr@wpafb.af.mil	Maynard, Charles/N-3906-2015; Gore, Russell/N-8988-2016	Maynard, Charles/0000-0002-1644-7814; Gore, Russell/0000-0002-8012-1579			American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Armed Forces Health Surveillance Center (AFHSC), 2007, MED SURVEILLANCE MON, V14, P2; Bhattacharjee Y, 2008, SCIENCE, V319, P406, DOI 10.1126/science.319.5862.406; Bombardier CH, 2003, ARCH PHYS MED REHAB, V84, P185, DOI 10.1053/apmr.2003.50002; Bombardier CH, 2006, J NEUROPSYCH CLIN N, V18, P501, DOI 10.1176/appi.neuropsych.18.4.501; Center for Substance Abuse Treatment, 2010, TREAT CLIENTS TRAUM, V9, P2; Collins R, 2012, TRAUMATIC BRAIN INJU, P223; Compton WM, 2011, P C BRIEF WASH DC MA; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P29; Department of Defense, 2007, ACH VIS REP DEP DEF; DIKMEN SS, 1995, ANN EMERG MED, V26, P167, DOI 10.1016/S0196-0644(95)70147-8; Donnemiller E, 2000, EUR J NUCL MED, V27, P1410, DOI 10.1007/s002590000308; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Gawande A, 2004, NEW ENGL J MED, V351, P2471, DOI 10.1056/NEJMp048317; Glenn MB, 2001, BRAIN INJURY, V15, P811, DOI 10.1080/02699050010025777; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hoge CW, 2008, AM J EPIDEMIOL, V168, P1095, DOI 10.1093/aje/kwn261; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Horner MD, 2005, J INT NEUROPSYCH SOC, V11, P322, DOI 10.1017/S135561770505037X; Kersel DA, 2001, BRAIN INJURY, V15, P683, DOI 10.1080/02699050010013662; Kolakowsky-Hayner S, 2002, BRAIN INJURY, V16, P583, DOI 10.1080/02699050110119475; Kreutzer JS, 1996, J HEAD TRAUMA REHAB, V11, P58, DOI 10.1097/00001199-199610000-00006; Kreutzer JS, 1996, J LEARN DISABIL, V29, P643, DOI 10.1177/002221949602900608; KREUTZER JS, 1990, J HEAD TRAUMA REHAB, V5, P9, DOI DOI 10.1097/00001199-199009000-00005; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Ponsford J, 2007, BRAIN INJURY, V21, P1385, DOI 10.1080/02699050701796960; Practice Management Information Corporation, 2006, INT CLASS DIS 9 REV, V1-3; Rogers JM, 2007, BRAIN INJURY, V21, P1321, DOI 10.1080/02699050701765700; Schulte PA, 1996, AM J PUBLIC HEALTH, V86, P1281, DOI 10.2105/AJPH.86.9.1281; Singh JA, 2009, PREV CHRONIC DIS, V6; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Wagner AK, 2005, J NEUROCHEM, V95, P457, DOI 10.1111/j.1471-4159.2005.03382.x; Wells TS, 2010, AM J PUBLIC HEALTH, V100, P90, DOI 10.2105/AJPH.2008.155432	37	34	36	0	21	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	0002-953X	1535-7228		AM J PSYCHIAT	Am. J. Psychiat.	APR	2013	170	4					383	390		10.1176/appi.ajp.2012.12010126			8	Psychiatry	Psychiatry	117AW	WOS:000316925500008	23429886				2021-06-18	
J	Umschweif, G; Alexandrovich, AG; Trembovler, V; Horowitz, M; Shohami, E				Umschweif, Gali; Alexandrovich, Alexander G.; Trembovler, Victoria; Horowitz, Michal; Shohami, Esther			Hypoxia-inducible factor 1 is essential for spontaneous recovery from traumatic brain injury and is a key mediator of heat acclimation induced neuroprotection	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						acriflavine; edema; HIF-1 alpha; hypothermia; preconditioning; traumatic brain injury	FACTOR-I HIF-1; CEREBRAL-ISCHEMIA; FACTOR 1-ALPHA; UP-REGULATION; RAT-BRAIN; EXPRESSION; MICE; PROTEIN; HYPOTHERMIA; BARRIER	Heat acclimation (HA), a well-established preconditioning model, confers neuroprotection in rodent models of traumatic brain injury (TBI). It increases neuroprotective factors, among them is hypoxia-inducible factor 1 alpha (HIF-1 alpha), which is important in the response to postinjury ischemia. However, little is known about the role of HIF-1a in TBI and its contribution to the establishment of the HA protecting phenotype. Therefore, we aimed to explore HIF-1 alpha role in TBI defense mechanisms as well as in HA-induced neuroprotection. Acriflavine was used to inhibit HIF-1 in injured normothermic (NT) or HA mice. After TBI, we evaluated motor function recovery, lesion volume, edema formation, and body temperature as well as HIF-1 downstream transcription targets, such as glucose transporter 1 (GLUT1), vascular endothelial growth factor, and aquaporin 4. We found that HIF-1 inhibition resulted in deterioration of motor function, increased lesion volume, hypothermia, and reduced edema formation. All these parameters were significantly different in the HA mice. Western blot analysis and enzyme-linked immunosorbent assay showed reduced levels of all HIF-1 downstream targets in HA mice, however, only GLUT1 was downregulated in NT mice. We conclude that HIF-1 is a key mediator in both spontaneous recovery and HA-induced neuroprotection after TBI. Journal of Cerebral Blood Flow & Metabolism (2013) 33, 524-531; doi:10.1038/jcbfm.2012.193; published online 2 January 2013	[Umschweif, Gali; Alexandrovich, Alexander G.; Trembovler, Victoria; Shohami, Esther] Hebrew Univ Jerusalem, Dept Pharmacol, IL-91120 Jerusalem, Israel; [Umschweif, Gali; Horowitz, Michal] Hebrew Univ Jerusalem, Environm Physiol Lab, Dept Physiol, IL-91120 Jerusalem, Israel	Horowitz, M (corresponding author), Hebrew Univ Jerusalem, Environm Physiol Lab, POB 12272, IL-91120 Jerusalem, Israel.	m.horowitz@mail.huji.ac.il; esty@cc.huji.ac.il			Professor Jashovam Shani Fund	The authors thank the Hoffman Leadership and Responsibility Program of the Hebrew University and the Professor Jashovam Shani Fund for generous support to GU.	Althaus J, 2006, NEUROCHEM INT, V48, P687, DOI 10.1016/j.neuint.2005.12.008; Argaw AT, 2012, J CLIN INVEST, V122, P2454, DOI 10.1172/JCI60842; Baranova O, 2007, J NEUROSCI, V27, P6320, DOI 10.1523/JNEUROSCI.0449-07.2007; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; BeitYannai E, 1997, J CEREBR BLOOD F MET, V17, P273, DOI 10.1097/00004647-199703000-00004; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Bergeron M, 1999, EUR J NEUROSCI, V11, P4159, DOI 10.1046/j.1460-9568.1999.00845.x; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Choi HA, 2012, NAT REV NEUROL, V8, P214, DOI 10.1038/nrneurol.2012.21; Ding JY, 2009, BRAIN RES, V1268, P125, DOI 10.1016/j.brainres.2009.02.060; Ding JY, 2009, NEUROSCI LETT, V453, P68, DOI 10.1016/j.neulet.2009.01.077; Du F, 2011, EUR J PHARMACOL, V666, P19, DOI 10.1016/j.ejphar.2011.05.018; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Hamlin GP, 2001, J NEUROTRAUM, V18, P1011, DOI 10.1089/08977150152693700; Higashida T, 2011, CURR NEUROVASC RES, V8, P44, DOI 10.2174/156720211794520251; Horowitz M, 2002, COMP BIOCHEM PHYS A, V131, P475, DOI 10.1016/S1095-6433(01)00500-1; Huang RQ, 2010, NEUROSCI LETT, V473, P22, DOI 10.1016/j.neulet.2010.02.011; Lee K, 2009, P NATL ACAD SCI USA, V106, P17910, DOI 10.1073/pnas.0909353106; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; MacAulay N, 2010, NEUROSCIENCE, V168, P941, DOI 10.1016/j.neuroscience.2009.09.016; MAHER F, 1993, J CEREBR BLOOD F MET, V13, P342, DOI 10.1038/jcbfm.1993.43; Maloyan A, 2005, PHYSIOL GENOMICS, V23, P79, DOI 10.1152/physiolgenomics.00279.2004; Moon EJ, 2010, P NATL ACAD SCI USA, V107, P20477, DOI 10.1073/pnas.1006646107; Papadopoulos MC, 2008, PROG BRAIN RES, V170, P589, DOI 10.1016/S0079-6123(08)00446-9; Park E, 2009, J CEREBR BLOOD F MET, V29, P575, DOI 10.1038/jcbfm.2008.151; Pellerin L, 2003, NEUROCHEM INT, V43, P331, DOI 10.1016/S0197-0186(03)00020-2; Rite I, 2008, NEUROCHEM INT, V52, P897, DOI 10.1016/j.neuint.2007.10.004; Saadoun S, 2009, NEUROSCIENCE, V161, P764, DOI 10.1016/j.neuroscience.2009.03.069; Sahuquillo J, 2007, CURR PHARM DESIGN, V13, P2310; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; Shein NA, 2005, J CEREBR BLOOD F MET, V25, P1456, DOI 10.1038/sj.jcbfm.9600142; Shein NA, 2007, BRAIN RES, V1185, P313, DOI 10.1016/j.brainres.2007.09.024; Shein NA, 2007, J NEUROCHEM, V103, P1523, DOI 10.1111/j.1471-4159.2007.04862.x; Singh N, 2012, CELL MOL NEUROBIOL, V32, P491, DOI 10.1007/s10571-012-9803-9; Tanaka T, 2010, AM J PHYSIOL-REG I, V298, pR661, DOI 10.1152/ajpregu.00732.2009; Thomas S, 2000, J NEUROTRAUM, V17, P649, DOI 10.1089/089771500415409; Umschwief G, 2010, J CEREBR BLOOD F MET, V30, P616, DOI 10.1038/jcbfm.2009.234; Valable S, 2005, J CEREBR BLOOD F MET, V25, P1491, DOI 10.1038/sj.jcbfm.9600148; Wong CCL, 2012, J MOL MED, V90, P803, DOI 10.1007/s00109-011-0855-y; Yan JQ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027798; Zhang XM, 2010, J BIOL CHEM, V285, P32869, DOI 10.1074/jbc.M110.135509	42	34	37	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	APR	2013	33	4					524	531		10.1038/jcbfm.2012.193			8	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	117CR	WOS:000316930200008	23281425	Green Published, Bronze			2021-06-18	
J	Cusimano, MD; Cho, N; Amin, K; Shirazi, M; McFaull, SR; Do, MT; Wong, MC; Russell, K				Cusimano, Michael D.; Cho, Newton; Amin, Khizer; Shirazi, Mariam; McFaull, Steven R.; Do, Minh T.; Wong, Matthew C.; Russell, Kelly			Mechanisms of Team-Sport-Related Brain Injuries in Children 5 to 19 Years Old: Opportunities for Prevention	PLOS ONE			English	Article							HEAD-INJURIES; ICE HOCKEY; BODY-CHECKING; SOCCER; EPIDEMIOLOGY; CONCUSSIONS; AGREEMENT; RISK	Background: There is a gap in knowledge about the mechanisms of sports-related brain injuries. The objective of this study was to determine the mechanisms of brain injuries among children and youth participating in team sports. Methods: We conducted a retrospective case series of brain injuries suffered by children participating in team sports. The Canadian Hospitals Injury Reporting and Prevention Program (CHIRPP) database was searched for brain injury cases among 5-19 year-olds playing ice hockey, soccer, American football (football), basketball, baseball, or rugby between 1990 and 2009. Mechanisms of injury were classified as "struck by player,'' "struck by object,'' "struck by sport implement,'' "struck surface,'' and "other.'' A descriptive analysis was performed. Results: There were 12,799 brain injuries related to six team sports (16.2% of all brain injuries registered in CHIRPP). Males represented 81% of injuries and the mean age was 13.2 years. Ice hockey accounted for the greatest number of brain injuries (44.3%), followed by soccer (19.0%) and football (12.9%). In ice hockey, rugby, and basketball, striking another player was the most common injury mechanism. Football, basketball, and soccer also demonstrated high proportions of injuries due to contact with an object (e.g., post) among younger players. In baseball, a common mechanism in the 5-9 year-old group was being hit with a bat as a result of standing too close to the batter (26.1% males, 28.3% females). Interpretation: Many sports-related brain injury mechanisms are preventable. The results suggest that further efforts aimed at universal rule changes, safer playing environments, and the education of coaches, players, and parents should be targeted in maximizing prevention of sport-related brain injury using a multifaceted approach.	[Cusimano, Michael D.; Cho, Newton; Amin, Khizer; Shirazi, Mariam; Wong, Matthew C.; Russell, Kelly] Univ Toronto, St Michaels Hosp, Injury Prevent Res Off, Toronto, ON M5B 1W8, Canada; [Cusimano, Michael D.] Univ Toronto, St Michaels Hosp, Div Neurosurg, Toronto, ON M5B 1W8, Canada; [McFaull, Steven R.; Do, Minh T.] Publ Hlth Agcy Canada, Hlth Surveillance & Epidemiol Div, Ottawa, ON, Canada	Cusimano, MD (corresponding author), Univ Toronto, St Michaels Hosp, Injury Prevent Res Off, Toronto, ON M5B 1W8, Canada.	cusimanom@smh.ca	Cusimano, Michael/X-4059-2019	Cusimano, Michael/0000-0002-9989-0650; Russell, Kelly/0000-0002-9159-9201	Canadian Institute of Health Research Strategic Team Grant in Applied Injury ResearchCanadian Institutes of Health Research (CIHR) [TIR-103946]	This research was supported by Canadian Institute of Health Research Strategic Team Grant in Applied Injury Research #TIR-103946. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. http://www.cihr-irsc.gc.ca/e/193.html	Agresti A, 1998, AM STAT, V52, P119, DOI 10.2307/2685469; Benz B, 1999, RESTOR NEUROL NEUROS, V14, P135; Canadian Fitness & Lifestyle Research Institute, 2011, GETT KIDS ACT 2010 P; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; Cusimano Michael D, 2011, Open Med, V5, pe57; Cusimano MD, 2010, NEUROSURGERY, V67, P1404, DOI 10.1227/NEU.0b013e3181f209f1; Delaney JS, 2006, CLIN J SPORT MED, V16, P162, DOI 10.1097/00042752-200603000-00013; Delaney JS, 2004, CLIN J SPORT MED, V14, P80, DOI 10.1097/00042752-200403000-00005; Emery CA, 2006, AM J SPORT MED, V34, P1960, DOI 10.1177/0363546506290061; Emery CA, 2010, JAMA-J AM MED ASSOC, V303, P2265, DOI 10.1001/jama.2010.755; Emery CA, 2010, INJURY PREV, V16, P113, DOI 10.1136/ip.2009.022764; Giannotti M, 2010, INJURY, V41, P907, DOI 10.1016/j.injury.2009.09.040; Goodman D, 2001, MED SCI SPORT EXER, V33, P2004, DOI 10.1097/00005768-200112000-00005; Hassan A, 2009, CAN J CARDIOL, V25, P207, DOI 10.1016/S0828-282X(09)70062-5; Juhn MS, 2002, CLIN J SPORT MED, V12, P46, DOI 10.1097/00042752-200201000-00014; Kang J., 2012, INT J INJ CONTROL SA, P1; Kelly KD, 2001, CLIN J SPORT MED, V11, P77, DOI 10.1097/00042752-200104000-00003; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Macarthur C, 1997, AM J EPIDEMIOL, V145, P834; Macpherson A, 2006, PEDIATRICS, V117, pE143, DOI 10.1542/peds.2005-1163; Pickett W, 2000, Inj Prev, V6, P9, DOI 10.1136/ip.6.1.9; Statistics Canada, 2010, AGE SEX; Turk EE, 2008, BRIT J SPORT MED, V42, P604, DOI 10.1136/bjsm.2007.038505; Warburton DER, 2006, CAN MED ASSOC J, V174, P801, DOI 10.1503/cmaj.051351	25	34	34	0	44	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 28	2013	8	3							e58868	10.1371/journal.pone.0058868			8	Multidisciplinary Sciences	Science & Technology - Other Topics	121RP	WOS:000317262200007	23555602	DOAJ Gold, Green Published			2021-06-18	
J	Lim, SN; Gladman, SJ; Dyall, SC; Patel, U; Virani, N; Kang, JX; Priestley, JV; Michael-Titus, AT				Lim, Siew-Na; Gladman, Stacy J.; Dyall, Simon C.; Patel, Urva; Virani, Nabeel; Kang, Jing X.; Priestley, John V.; Michael-Titus, Adina T.			Transgenic mice with high endogenous omega-3 fatty acids are protected from spinal cord injury	NEUROBIOLOGY OF DISEASE			English	Article						Transgenic fat-1 mice; Spinal cord injury; Omega-3 fatty acids; Neuroprotection	TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; FATTY-ACIDS; DOCOSAHEXAENOIC ACID; LEUKOCYTE MOBILIZATION; FUNCTIONAL RECOVERY; FAT-1 MICE; RAT; NEUROTOXICITY; METABOLISM	Omega-3 polyunsaturated fatty acids have been shown to have therapeutic potential in a variety of neurological disorders, including acute traumatic injury of the spinal cord. We addressed the question whether the neuroprotective effect of these compounds after spinal cord injury could also be seen when their level is raised in tissues prophylactically, prior to injury. In this study we used transgenic fat-1 mice to examine whether enriching spinal cord tissue in endogenous omega-3 polyunsaturated fatty acids has an effect on the outcome after compression spinal cord injury. The results demonstrate that after thoracic compression spinal cord injury, fat-1 mice display better locomotor recovery compared with the wild-type mice on a high omega-6 diet (high omega-6 polyunsaturated fatty acids in tissues), and wild-type mice on a normal diet (controls). This is associated with a significant increase in neuronal and oligodendrocyte survival and a decrease in non-phosphorylated neurofilament loss. The protection from spinal cord injury in fat-1 mice was also correlated with a reduction in microglia/macrophage activation and in pro-inflammatory mediators. In vitro experiments in dorsal root ganglia primary sensory neurons further demonstrated that a fat-1 tissue background confers robust neuroprotection against a combined mechanical stretch and hypoxic injury. In conclusion, our studies support the hypothesis that a raised omega-3 polyunsaturated fatty acid level and an altered tissue omega-6/omega-3 ratio prior to injury leads to a much improved outcome after spinal cord injury. (C) 2012 Elsevier Inc. All rights reserved.	[Lim, Siew-Na; Gladman, Stacy J.; Dyall, Simon C.; Patel, Urva; Virani, Nabeel; Priestley, John V.; Michael-Titus, Adina T.] Barts & London Queen Marys Sch Med & Dent, Blizard Inst, Ctr Neurosci & Trauma, London, England; [Lim, Siew-Na] Chang Gung Mem Hosp, Dept Neurol, Taipei 10591, Taiwan; [Lim, Siew-Na] Chang Gung Univ, Coll Med, Taipei, Taiwan; [Dyall, Simon C.] Roehampton Univ, Whitelands Coll, Dept Life Sci, London, England; [Kang, Jing X.] Massachusetts Gen Hosp, Dept Med, Lab Lipid Med & Technol, Boston, MA 02114 USA; [Kang, Jing X.] Harvard Univ, Sch Med, Boston, MA 02114 USA	Michael-Titus, AT (corresponding author), Barts & London Queen Marys Sch Med & Dent, Blizard Inst Cell & Mol Sci, Ctr Neurosci & Trauma, 4 Newark St, London, England.	a.t.michael-titus@qmul.ac.uk		Dyall, Simon/0000-0001-7591-4219; Gladman, Stacy/0000-0002-7112-4516	Chang Gung Memorial Hospital, TaiwanChang Gung Memorial Hospital [CMRPG360622]	This work was supported by Chang Gung Memorial Hospital, Taiwan (CMRPG360622). We gratefully acknowledge the assistance of Patrick Pallier, Laura Poddighe and Rasall Choudhury with preparatory staining for the Abercrombie correction.	ABERCROMBIE M, 1946, ANAT REC, V94, P239, DOI 10.1002/ar.1090940210; Basso DM, 2006, J NEUROTRAUM, V23, P635, DOI 10.1089/neu.2006.23.635; Benes FM, 2001, TRENDS NEUROSCI, V24, P11, DOI 10.1016/S0166-2236(00)01660-X; Berquin IM, 2007, J CLIN INVEST, V117, P1866, DOI 10.1172/JCI31494; Bousquet M, 2011, J LIPID RES, V52, P263, DOI 10.1194/jlr.M011692; Campbell SJ, 2003, FASEB J, V17, P1168, DOI 10.1096/fj.02-0757fje; Campbell SJ, 2005, AM J PATHOL, V166, P1487, DOI 10.1016/S0002-9440(10)62365-6; Cao DH, 2004, PHARMACOL BIOCHEM BE, V79, P651, DOI 10.1016/j.pbb.2004.09.016; Coggeshall RE, 1996, J COMP NEUROL, V364, P6, DOI 10.1002/(SICI)1096-9861(19960101)364:1<6::AID-CNE2>3.0.CO;2-9; Davis AEM, 2005, EUR J NEUROSCI, V22, P2441, DOI 10.1111/j.1460-9568.2005.04447.x; Donnelly DJ, 2009, J NEUROSCI METH, V181, P36, DOI 10.1016/j.jneumeth.2009.04.010; Dumont RJ, 2001, CLIN NEUROPHARMACOL, V24, P254, DOI 10.1097/00002826-200109000-00002; Dyall SC, 2007, NEUROBIOL AGING, V28, P424, DOI 10.1016/j.neurobiolaging.2006.01.002; Dyall SC, 2008, NEUROMOL MED, V10, P219, DOI 10.1007/s12017-008-8036-z; Ek CJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012021; FAROOQUI AA, 1991, BRAIN RES REV, V16, P171, DOI 10.1016/0165-0173(91)90004-R; Gladman SJ, 2010, NEUROSCIENCE, V171, P577, DOI 10.1016/j.neuroscience.2010.07.009; Gris D, 2008, EXP NEUROL, V211, P259, DOI 10.1016/j.expneurol.2008.01.033; Grossman SD, 2001, EXP NEUROL, V168, P273, DOI 10.1006/exnr.2001.7628; He CW, 2009, P NATL ACAD SCI USA, V106, P11370, DOI 10.1073/pnas.0904835106; Huang WL, 2007, BRAIN, V130, P3004, DOI 10.1093/brain/awm223; Hudert CA, 2006, P NATL ACAD SCI USA, V103, P11276, DOI 10.1073/pnas.0601280103; Kang JX, 2004, NATURE, V427, P504, DOI 10.1038/427504a; Kaur G, 2010, BRIT J NUTR, V103, P32, DOI 10.1017/S0007114509991334; Kawasaki A, 2002, INVEST OPHTH VIS SCI, V43, P1835; Kelly L, 2011, NEUROBIOL AGING, V32, DOI 10.1016/j.neurobiolaging.2010.04.001; King VR, 2006, J NEUROSCI, V26, P4672, DOI 10.1523/JNEUROSCI.5539-05.2006; LAFONCAZAL M, 1993, NATURE, V364, P535, DOI 10.1038/364535a0; Lim SN, 2010, PROSTAG LEUKOTR ESS, V83, P193, DOI 10.1016/j.plefa.2010.08.003; MANKU MS, 1983, LIPIDS, V18, P906, DOI 10.1007/BF02534572; Marcheselli VL, 2003, J BIOL CHEM, V278, P43807, DOI 10.1074/jbc.M305841200; MURPHY EJ, 1994, MOL CHEM NEUROPATHOL, V23, P13, DOI 10.1007/BF02858504; Okada S, 2004, J NEUROSCI RES, V76, P265, DOI 10.1002/jnr.20044; Pan HC, 2009, J NUTR BIOCHEM, V20, P715, DOI 10.1016/j.jnutbio.2008.06.014; Pearse DD, 2005, J NEUROTRAUM, V22, P680, DOI 10.1089/neu.2005.22.680; Pilitsis JG, 2003, BRAIN RES, V985, P198, DOI 10.1016/S0006-8993(03)03044-0; Popovich P, 2009, NAT MED, V15, P736, DOI 10.1038/nm0709-736; Rice T, 2007, J NEUROPATH EXP NEUR, V66, P184, DOI 10.1097/01.jnen.0000248552.07338.7f; Robins-Steele S, 2012, J NEUROTRAUM, V29, P1586, DOI 10.1089/neu.2011.2005; Schmocker C, 2007, HEPATOLOGY, V45, P864, DOI 10.1002/hep.21626; Sprecher H, 2000, BBA-MOL CELL BIOL L, V1486, P219, DOI 10.1016/S1388-1981(00)00077-9; Tsai MC, 2008, SURG NEUROL, V70, P19, DOI 10.1016/j.surneu.2007.09.033; Ward RE, 2010, J NEUROTRAUM, V27, P1769, DOI 10.1089/neu.2010.1348; Wu A, 2004, J NEUROTRAUM, V21, P1457, DOI 10.1089/neu.2004.21.1457; Wu AG, 2007, J NEUROTRAUM, V24, P1587, DOI 10.1089/neu.2007.0313; Xia SH, 2006, P NATL ACAD SCI USA, V103, P12499, DOI 10.1073/pnas.0605394103	46	34	34	0	22	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961			NEUROBIOL DIS	Neurobiol. Dis.	MAR	2013	51				SI		104	112		10.1016/j.nbd.2012.10.021			9	Neurosciences	Neurosciences & Neurology	085PQ	WOS:000314627100012	23123586				2021-06-18	
J	Bigler, ED; Farrer, TJ; Pertab, JL; James, K; Petrie, JA; Hedges, DW				Bigler, Erin D.; Farrer, Thomas J.; Pertab, Jon L.; James, Kelly; Petrie, Jo Ann; Hedges, Dawson W.			Reaffirmed Limitations of Meta-Analytic Methods in the Study of Mild Traumatic Brain Injury: A Response to Rohling et al.	CLINICAL NEUROPSYCHOLOGIST			English	Article						Mild traumatic brain injury; Meta-analysis limitations; Neuropsychological outcomes	GLASGOW COMA SCALE; MINOR HEAD-INJURY; CEREBRAL ATROPHY; SUICIDAL-BEHAVIOR; FOOTBALL PLAYERS; CONCUSSION; RECOVERY; ADULTS; LONG; POPULATION	In 2009 Pertab, James, and Bigler published a critique of two prior meta-analyses by Binder, Rohling, and Larrabee (1997) and Frencham, Fox, and Maybery (2005) that showed small effect size difference at least 3 months post-injury in individuals who had sustained a mild traumatic brain injury (mTBI). The Binder etal. and Frencham etal. meta-analyses have been widely cited as showing no lasting effect of mTBI. In their critique Pertab etal. (2009) point out many limitations of these two prior meta-analyses, demonstrating that depending on how inclusion/exclusion criteria were defined different meta-analytic findings occur, some supporting the persistence of neuropsychological impairments beyond 3 months. Rohling etal. (2011) have now critiqued Pertab etal. (2009). Herein we respond to the Rolling etal. (2011) critique reaffirming the original findings of Pertab etal. (2009), providing additional details concerning the flaws in prior meta-analytic mTBI studies and the effects on neuropsychological performance.	[Bigler, Erin D.; Farrer, Thomas J.; Pertab, Jon L.; James, Kelly; Petrie, Jo Ann; Hedges, Dawson W.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Bigler, Erin D.; Hedges, Dawson W.] Brigham Young Univ, Ctr Neurosci, Provo, UT 84602 USA; [Bigler, Erin D.] Univ Utah, Dept Psychiat, Salt Lake City, UT USA; [Bigler, Erin D.] Univ Utah, Brain Inst Utah, Salt Lake City, UT USA; [Pertab, Jon L.] Vet Adm Hosp, Salt Lake City, UT USA	Bigler, ED (corresponding author), Brigham Young Univ, Dept Psychol, 1001 SWKT, Provo, UT 84602 USA.	erin_bigler@byu.edu		Farrer, Thomas J./0000-0001-8092-6214			Allen MD, 2011, PSYCHOL INJ LAW, V4, P140, DOI 10.1007/s12207-011-9105-4; ALTERMAN AI, 1985, INT J NEUROSCI, V28, P155, DOI 10.3109/00207458508985386; Aretouli E, 2011, J INT NEUROPSYCH SOC, V17, P277, DOI 10.1017/S1355617710001621; Babikian T, 2011, J INT NEUROPSYCH SOC, V17, P886, DOI 10.1017/S1355617711000907; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; BATCHELOR J, 1995, CLIN NEUROPSYCHOL, V9, P180, DOI 10.1080/13854049508401600; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bernstein DM, 2002, J INT NEUROPSYCH SOC, V8, P673, DOI 10.1017/S1355617702801400; Bigler E.D., 2012, PTSD MILD TRAUMATIC; Bigler ED, 2004, J INT NEUROPSYCH SOC, V10, P794, DOI 10.1017/S1355617704105146; Bigler ED, 2006, AM J PHYS MED REHAB, V85, P793, DOI 10.1097/01.phm.0000237873.26250.e1; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Borenstein M., 2009, INTRO METAANALYSIS; Bornstein R. A., 1993, NEUROPSYCHOLOGY, V7, P228, DOI DOI 10.1037/0894-4105.7.2.228; Browne KD, 2011, J NEUROTRAUM, V28, P1747, DOI 10.1089/neu.2011.1913; Cappa KA, 2011, HEALTH PSYCHOL, V30, P542, DOI 10.1037/a0025220; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Cassidy JD, 2010, J NEUROL NEUROSUR PS, V81, pE12, DOI 10.1136/jnnp.2010.217554.28; Christensen J, 2009, LANCET, V373, P1105, DOI 10.1016/S0140-6736(09)60214-2; Cohen BA, 2007, AM J NEURORADIOL, V28, P907; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Comerford VE, 2002, J CLIN EXP NEUROPSYC, V24, P409, DOI 10.1076/jcen.24.4.409.1044; Contreras R, 2011, BRAIN RES, V1398, P55, DOI 10.1016/j.brainres.2011.05.004; CREMONAMETEYARD SL, 1994, NEUROPSYCHOLOGIA, V32, P649, DOI 10.1016/0028-3932(94)90026-4; Dash PK, 2010, NEUROTHERAPEUTICS, V7, P100, DOI 10.1016/j.nurt.2009.10.019; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Duff K, 2010, ARCH CLIN NEUROPSYCH, V25, P429, DOI 10.1093/arclin/acq045; DURLAK JA, 1995, READING UNDERSTANDIN, P319; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Edlund W, 2004, CLIN PRACTICE GUIDEL; EWING R, 1980, Journal of Clinical Neuropsychology, V2, P147, DOI 10.1080/01688638008403789; Fayol P., 2009, Annals of Physical and Rehabilitation Medicine, V52, P497, DOI 10.1016/j.annrmp.2008.06.003; Ferguson PL, 2010, EPILEPSIA, V51, P891, DOI 10.1111/j.1528-1167.2009.02384.x; FitzGerald DB, 2011, INT J PSYCHOPHYSIOL, V82, P79, DOI 10.1016/j.ijpsycho.2011.02.011; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Gao XA, 2011, J NEUROPATH EXP NEUR, V70, P183, DOI 10.1097/NEN.0b013e31820c6878; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Gavett BE, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt42; Geary EK, 2011, J INT NEUROPSYCH SOC, V17, P709, DOI 10.1017/S1355617711000646; GENTLEMAN D, 1981, BRIT MED J, V283, P408, DOI 10.1136/bmj.283.6288.408; Ghosh A, 2009, BRAIN INJURY, V23, P228, DOI 10.1080/02699050802672789; Glasziou PP, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-23; Goldstein FC, 2001, J INT NEUROPSYCH SOC, V7, P373, DOI 10.1017/S1355617701733115; GRAHAM DI, 2002, GREENFIELDS NEUROPAT, V1; Green Robin, 2010, Neuropsychol Rehabil, V20, P471, DOI 10.1080/09602011003693298; Green W, 2010, J REHABIL RES DEV, V47, P183, DOI 10.1682/JRRD.2009.04.0041; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Hilz MJ, 2011, J NEUROTRAUM, V28, P1727, DOI 10.1089/neu.2010.1497; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Huedo-Medina TB, 2006, PSYCHOL METHODS, V11, P193, DOI 10.1037/1082-989X.11.2.193; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Jennett B, 1997, Int J Trauma Nurs, V3, P114; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Kashluba S, 2008, ARCH PHYS MED REHAB, V89, P904, DOI 10.1016/j.apmr.2007.12.029; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kovesdi E, 2010, ACTA NEUROCHIR, V152, P1, DOI 10.1007/s00701-009-0463-6; Konrad C, 2011, PSYCHOL MED, V41, P1197, DOI 10.1017/S0033291710001728; Kou ZF, 2010, J HEAD TRAUMA REHAB, V25, P267, DOI 10.1097/HTR.0b013e3181e54793; Larson MJ, 2011, INT J PSYCHOPHYSIOL, V82, P69, DOI 10.1016/j.ijpsycho.2011.02.018; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Lipsey M.W., 2001, PRACTICAL META ANAL; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Mangels JA, 2002, NEUROPSYCHOLOGIA, V40, P2369, DOI 10.1016/S0028-3932(02)00084-2; Maruta J, 2010, ANN NY ACAD SCI, V1208, P58, DOI 10.1111/j.1749-6632.2010.05695.x; Mathias JL, 1999, J CLIN EXP NEUROPSYC, V21, P200, DOI 10.1076/jcen.21.2.200.930; Maxwell WL, 2010, BRAIN, V133, P139, DOI 10.1093/brain/awp264; Mayer AR, 2009, HUM BRAIN MAPP, V30, P4152, DOI 10.1002/hbm.20836; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McCrea M, 2010, J HEAD TRAUMA REHAB, V25, P283, DOI 10.1097/HTR.0b013e3181e67923; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McMillan TM, 2011, J NEUROL NEUROSUR PS, V82, P931, DOI 10.1136/jnnp.2010.222232; Meaney DF, 2011, CLIN SPORT MED, V30, P19, DOI 10.1016/j.csm.2010.08.009; Menascu S, 2010, PEDIATR NEUROSURG, V46, P82, DOI 10.1159/000319004; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; MONTGOMERY EA, 1991, PSYCHOL MED, V21, P375, DOI 10.1017/S0033291700020481; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Noguchi K, 2000, AM J NEURORADIOL, V21, P923; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Oquendo MA, 2004, J NERV MENT DIS, V192, P430, DOI 10.1097/01.nmd.0000126706.53615.7b; Ownsworth T, 2004, DISABIL REHABIL, V26, P765, DOI 10.1080/09638280410001696700; Pengel LHM, 2003, BMJ-BRIT MED J, V327, P323, DOI 10.1136/bmj.327.7410.323; Pertab JL, 2009, BRAIN INJURY, V23, P498, DOI 10.1080/02699050902927984; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Pontifex MB, 2009, NEUROPSYCHOLOGIA, V47, P3210, DOI 10.1016/j.neuropsychologia.2009.07.021; Potter DD, 2001, NEUROPSYCHOLOGIA, V39, P1464, DOI 10.1016/S0028-3932(01)00057-4; Reitan RM, 1999, ARCH CLIN NEUROPSYCH, V14, P191, DOI 10.1016/S0887-6177(98)00012-2; Risdall JE, 2011, PHILOS T R SOC B, V366, P241, DOI 10.1098/rstb.2010.0230; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Ruff R.M., 1989, MILD HEAD INJURY, P176; Ruff RM, 2011, NEUROREHABILITATION, V28, P167, DOI 10.3233/NRE-2011-0646; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Segalowitz SJ, 2001, BRAIN COGNITION, V45, P342, DOI 10.1006/brcg.2000.1263; Senn SJ, 2009, BMC MED RES METHODOL, V9, DOI 10.1186/1471-2288-9-10; Sharp DJ, 2011, CURR OPIN NEUROL, V24, P558, DOI 10.1097/WCO.0b013e32834cd523; Sheedy J, 2009, J HEAD TRAUMA REHAB, V24, P333, DOI 10.1097/HTR.0b013e3181aea51f; Sherer M, 2002, CLIN NEUROPSYCHOL, V16, P157, DOI 10.1076/clin.16.2.157.13238; Slobounov S, 2008, CLIN NEUROPHYSIOL, V119, P281, DOI 10.1016/j.clinph.2007.10.006; Stocchetti N, 2008, INTENS CARE MED, V34, P1774, DOI 10.1007/s00134-008-1168-7; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Thomson Reuters, 2012, J CITATION REPORTS; Toledo E, 2012, NEUROSCI BIOBEHAV R, V36, P1510, DOI 10.1016/j.neubiorev.2012.03.007; Trivedi MA, 2007, J NEUROTRAUM, V24, P766, DOI 10.1089/neu.2006.0205; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Viano DC, 2009, NEUROSURGERY, V64, P1162, DOI 10.1227/01.NEU.0000345863.99099.C7; Voller B, 1999, BRAIN INJURY, V13, P821, DOI 10.1080/026990599121214; Wilde EA, 2006, BRAIN INJURY, V20, P695, DOI 10.1080/02699050600744079; Yeo RA, 2011, J NEUROTRAUM, V28, P1, DOI 10.1089/neu.2010.1578; Yurgelun-Todd DA, 2011, J HEAD TRAUMA REHAB, V26, P276, DOI 10.1097/HTR.0b013e31822251dc; Zappala G, 2012, CORTEX, V48, P156, DOI 10.1016/j.cortex.2011.06.020; Zohar O, 2011, ACTA NEUROBIOL EXP, V71, P36	123	34	34	0	12	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	FEB 1	2013	27	2					176	214		10.1080/13854046.2012.693950			39	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	146MH	WOS:000319094700002	23356775				2021-06-18	
J	Darrah, SD; Miller, MA; Ren, DX; Hoh, NZ; Scanlon, JM; Conley, YP; Wagner, AK				Darrah, Shaun D.; Miller, Megan A.; Ren, Dianxu; Hoh, Nichole Z.; Scanlon, Joelle M.; Conley, Yvette P.; Wagner, Amy K.			Genetic variability in glutamic acid decarboxylase genes: Associations with post-traumatic seizures after severe TBI	EPILEPSY RESEARCH			English	Article						Traumatic brain injury; Seizures; GABA; Glutamic acid decarboxylase; Promoter; Single nucleotide polymorphism	TRAUMATIC BRAIN-INJURY; GAMMA-AMINOBUTYRIC-ACID; GABA(A) RECEPTOR; CEREBROSPINAL-FLUID; STATUS EPILEPTICUS; GRANULE CELLS; CLEFT-PALATE; MICE LACKING; RISK-FACTORS; AMINO-ACIDS	Post traumatic seizures (PTS) occur frequently after traumatic brain injury (TBI). Since gamma-amino butyric acid (GABA) neurotransmission is central to excitotoxicity and seizure development across multiple models, we investigated how genetic variability for glutamic acid decarboxylase (GAD) influences risk for PTS. Using both a tagging and functional single nucleotide polymorphism (SNP) approach, we genotyped the GAD1 and GAD2 genes and Linked them with PTS data, regarding time to first seizure, obtained for 257 adult subjects with severe TBI. No significant associations were found for GAD2. In the GAD1 gene, the tagging SNP (tSNP) rs3828275 was associated with an increased risk for PTS occurring <1 wk. The tSNP rs769391and the functional SNP rs3791878 in the GAD1 gene were associated with increased PTS risk occurring 1 wk-6 mo post-injury. Both risk variants conferred an increased susceptibility to PTS compared to subjects with 0-1 risk variant. Also, those with haplotypes having both risk variants had a higher PTS risk 1 wk-6 mo post-injury than those without these haplotypes. Similarly, diplotype analysis showed those with 2 copies of the haplotype containing both risk alleles were at the highest PTS risk. These results implicate genetic variability within the GABA system in modulating the development of PTS. (c) 2012 Elsevier B.V. All rights reserved.	[Darrah, Shaun D.; Miller, Megan A.; Scanlon, Joelle M.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; [Ren, Dianxu; Hoh, Nichole Z.; Conley, Yvette P.] Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15261 USA; [Conley, Yvette P.; Wagner, Amy K.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA	Wagner, AK (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, 3434 5th Ave, Pittsburgh, PA 15260 USA.	Darrah.shaun@medstudent.pitt.edu; mam187@pitt.edu; dir8@pitt.edu; nmzst1@pitt.edu; scanjm2@upmc.edu; yconley@pitt.edu; wagnerak@upmc.edu		Conley, Yvette/0000-0002-1784-6067	DODUnited States Department of Defense [W81XWH-07-1-0701]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NR008424];  [R01HD048162]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048162] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS030318] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01NR008424] Funding Source: NIH RePORTER	This work was supported, in part, by R01HD048162 and DOD W81XWH-07-1-0701 to AKW, NIH R01NR008424, and DOD W81XWH-07-1-0701 to YPC. Thanks to the Brain Trauma Research Center for assistance with some pieces of data collection 5P01NS030318-16. Thanks to Sandra Deslouche for support with genotyping as well as the subjects and their families for their generous participation.	Allen NJ, 2004, PFLUG ARCH EUR J PHY, V449, P132, DOI 10.1007/s00424-004-1318-x; Anderson GD, 2009, EPILEPSY BEHAV, V16, P501, DOI 10.1016/j.yebeh.2009.08.025; Asada H, 1997, P NATL ACAD SCI USA, V94, P6496, DOI 10.1073/pnas.94.12.6496; Bao YH, 2011, J NEUROTRAUM, V28, P35, DOI 10.1089/neu.2010.1383; BU DF, 1994, GENOMICS, V21, P222, DOI 10.1006/geno.1994.1246; BU DF, 1992, P NATL ACAD SCI USA, V89, P2115, DOI 10.1073/pnas.89.6.2115; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Buxbaum JD, 2010, MOL AUTISM, V1, DOI 10.1186/2040-2392-1-6; Cavalleri GL, 2007, EPILEPSIA, V48, P706, DOI 10.1111/j.1528-1167.2007.00977.x; Chen JWY, 2006, LANCET NEUROL, V5, P246, DOI 10.1016/S1474-4422(06)70374-X; Covic M, 2010, HEREDITY, V105, P122, DOI 10.1038/hdy.2010.27; Crestani F, 2000, BRIT J PHARMACOL, V131, P1251, DOI 10.1038/sj.bjp.0703717; DeLorey TM, 1998, J NEUROSCI, V18, P8505; Diaz-Arrastia R, 2003, ARCH NEUROL-CHICAGO, V60, P818, DOI 10.1001/archneur.60.6.818; Du J, 2008, J NEURAL TRANSM, V115, P513, DOI 10.1007/s00702-007-0844-z; Ellenberger C, 2004, AM J VET RES, V65, P1108, DOI 10.2460/ajvr.2004.65.1108; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; Franke B, 2009, HUM GENET, V126, P13, DOI 10.1007/s00439-009-0663-4; Gao WM, 2006, BRAIN RES, V1070, P31, DOI 10.1016/j.brainres.2005.11.038; Haltiner AM, 1997, ARCH PHYS MED REHAB, V78, P835, DOI 10.1016/S0003-9993(97)90196-9; Hasegawa D, 2004, J VET MED SCI, V66, P1555, DOI 10.1292/jvms.66.1555; HAUSER WA, 1991, EPILEPSIA, V32, P429, DOI 10.1111/j.1528-1157.1991.tb04675.x; Homanics GE, 1997, P NATL ACAD SCI USA, V94, P4143, DOI 10.1073/pnas.94.8.4143; Hsu CC, 2000, J BIOL CHEM, V275, P20822, DOI 10.1074/jbc.M001403200; Hung CC, 2005, PHARMACOGENOMICS, V6, P411, DOI 10.1517/14622416.6.4.411; Jamali S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012740; JENNETT B, 1975, LANCET, V1, P480; KANTHAN R, 1995, J NEUROL NEUROSUR PS, V59, P326, DOI 10.1136/jnnp.59.3.326; Kao CF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018696; Kash SF, 1999, P NATL ACAD SCI USA, V96, P1698, DOI 10.1073/pnas.96.4.1698; Kralic JE, 2002, J PHARMACOL EXP THER, V302, P1037, DOI 10.1124/jpet.102.036665; Kuo PH, 2009, DRUG ALCOHOL DEPEN, V101, P80, DOI 10.1016/j.drugalcdep.2008.11.009; Kwan P, 2007, EPILEPSY BEHAV, V11, P112, DOI 10.1016/j.yebeh.2007.04.013; Laje G, 2011, PROG NEURO-PSYCHOPH, V35, P1553, DOI 10.1016/j.pnpbp.2010.11.031; Lambert JJ, 2003, PROG NEUROBIOL, V71, P67, DOI 10.1016/j.pneurobio.2003.09.001; Lin CM, 2009, SURG NEUROL, V72, P50, DOI 10.1016/j.wneu.2009.09.004; Liu SY, 2011, CHIN J TRAUMATOL, V14, P100, DOI 10.3760/cma.j.issn.1008-1275.2011.02.007; MELDRUM BS, 1989, BRIT J CLIN PHARMACO, V27, pS3, DOI 10.1111/j.1365-2125.1989.tb03454.x; Miller MA, 2010, BRAIN INJURY, V24, P1468, DOI 10.3109/02699052.2010.520299; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Ebid AHI, 2007, THER DRUG MONIT, V29, P305; Motsinger AA, 2007, J INFECT DIS, V195, P1737, DOI 10.1086/518247; Muir JK, 1996, J CEREBR BLOOD F MET, V16, P1211, DOI 10.1097/00004647-199611000-00015; NATHAN B, 1994, J BIOL CHEM, V269, P7249; NATHAN B, 1994, BRAIN RES, V642, P297, DOI 10.1016/0006-8993(94)90934-2; National Center for Biotechnology Information U.S. National Library of Medicine, DBSNP SHORT GEN VAR; Neese SL, 2007, BRAIN RES, V1128, P157, DOI 10.1016/j.brainres.2006.09.073; Newton-Cheh C, 2005, MUTAT RES-FUND MOL M, V573, P54, DOI 10.1016/j.mrfmmm.2005.01.006; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; O'Dell DM, 2000, BRAIN RES, V861, P325, DOI 10.1016/S0006-8993(00)02055-2; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Patel AB, 2006, J NEUROCHEM, V97, P385, DOI 10.1111/j.1471-4159.2006.03741.x; Raymont V, 2010, NEUROLOGY, V75, P224, DOI 10.1212/WNL.0b013e3181e8e6d0; Rootsweb, 2012, SOC SEC DEATH IND SS; Rudolph U, 1999, NATURE, V401, P796, DOI 10.1038/44579; Ruegg J, 2008, MOL ENDOCRINOL, V22, P304, DOI 10.1210/me.2007-0128; Ruppel RA, 2001, J PEDIATR-US, V138, P18, DOI 10.1067/mpd.2001.110979; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Scher AI, 2011, J NEUROTRAUM, V28, P1739, DOI 10.1089/neu.2011.1982; SCHWARZER C, 1995, NEUROSCIENCE, V69, P705, DOI 10.1016/0306-4522(95)00348-M; Soghomonian JJ, 1998, TRENDS PHARMACOL SCI, V19, P500, DOI 10.1016/S0165-6147(98)01270-X; Sperk G, 2003, HIPPOCAMPUS, V13, P806, DOI 10.1002/hipo.10133; Sperk G., 2011, HIPPOCAMPUS; Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501; Sur C, 2001, J NEUROSCI, V21, P3409, DOI 10.1523/JNEUROSCI.21-10-03409.2001; Swartz BE, 2006, EPILEPSIA, V47, P1373, DOI 10.1111/j.1528-1167.2006.00602.x; Sweatt JD, 2009, BIOL PSYCHIAT, V65, P191, DOI 10.1016/j.biopsych.2008.09.002; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 2003, EPILEPSIA, V44, P18, DOI 10.1046/j.1528-1157.44.s10.6.x; Treiman DM, 2001, EPILEPSIA, V42, P8, DOI 10.1046/j.1528-1157.2001.042suppl.3008.x; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Wagner AK, 2005, CRIT CARE MED, V33, P407, DOI 10.1097/01.CCM.0000153931.23488.DD; Wagner AK, 2010, EPILEPSY RES, V90, P259, DOI 10.1016/j.eplepsyres.2010.06.001; Waziri A, 2009, ANN NEUROL, V66, P366, DOI 10.1002/ana.21721; Yablon S. A., 2001, PHYS MED REHABIL STA, V15, P301; Yoshida H, 2006, CELL STRUCT FUNCT, V31, P117, DOI 10.1247/csf.06016; Young GB, 1996, NEUROLOGY, V47, P83; Zhang ZY, 2007, NEUROSCI LETT, V429, P1, DOI 10.1016/j.neulet.2007.09.061	78	34	37	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0920-1211	1872-6844		EPILEPSY RES	Epilepsy Res.	FEB	2013	103	2-3					180	194		10.1016/j.eplepsyres.2012.07.006			15	Clinical Neurology	Neurosciences & Neurology	095ZD	WOS:000315372600007	22840783	Green Accepted, Green Published			2021-06-18	
J	Kalamatianos, T; Stavrinou, LC; Koutsarnakis, C; Psachoulia, C; Sakas, DE; Stranjalis, G				Kalamatianos, Theodosis; Stavrinou, Lampis C.; Koutsarnakis, Christos; Psachoulia, Christina; Sakas, Damianos E.; Stranjalis, George			PlGF and sVEGFR-1 in chronic subdural hematoma: implications for hematoma development	JOURNAL OF NEUROSURGERY			English	Article						chronic subdural hematoma; PlGF; sVEGFR-1; angiogenesis; vascular hemorrhagic disorder; traumatic brain injury	PLACENTA GROWTH-FACTOR; ENDOTHELIAL-CELLS; CEREBROSPINAL-FLUID; NATURAL-HISTORY; FINE-STRUCTURE; FACTOR VEGF; FACTOR-I; EXPRESSION; RECURRENCE; ANGIOGENESIS	Object. A considerable body of evidence indicates that inflammation and angiogenesis play a significant role in the development and progression of chronic subdural hematoma (CSDH). While various experimental and clinical studies have implicated placental growth factor (PlGF) in the processes that underpin pathological angiogenesis, no study has thus far investigated its expression in CSDH. The actions of PlGF and its related proangiogenic vascular endothelial growth factor (VEGF) are antagonized by a high-affinity soluble receptor, namely soluble VEGF receptor-1 (sVEGFR-1), and thus the ratio between sVEGFR-1 and angiogenic factors provides an index of angiogenic capacity. Methods. In the present study, using an automated electrochemiluminescence assay, levels of PlGF and sVEGFR-1 were quantified in serum and hematoma fluid obtained in 16 patients with CSDH. Results. Levels of PlGF and sVEGFR-1 were significantly higher in hematoma fluid than in serum (p < 0.0001). In serum, levels of sVEGFR-1 were higher than those of PlGF (p < 0.0001), whereas in hematoma fluid this difference was not apparent. Furthermore, the ratio of sVEGFR-1 to PlGF was significantly lower in hematoma fluid than in serum (p < 0.0001). Conclusions. Given previous evidence indicating a role for PlGF in promoting angiogenesis, inflammatory cell chemotaxis, and stimulation, as well as its ability to amplify VEGF-driven signaling under conditions favoring pathological angiogenesis, enhanced expression of PlGF in hematoma fluid suggests the involvement of this factor in the mechanisms of inflammation and angiogenesis in CSDH. Furthermore, a reduced ratio of sVEGFR-1 to PlGF in hematoma fluid is consistent with the proangiogenic capacity of CSDH. Future studies are warranted to clarify the precise role of PlGF and sVEGFR-1 in CSDH. (http://thejns.org/doi/abs/10.3171/2012.10.JNS12327)	[Kalamatianos, Theodosis; Stavrinou, Lampis C.; Koutsarnakis, Christos; Sakas, Damianos E.; Stranjalis, George] Hellen Ctr Neurosurg Res Prof Petros S Kokkalis, Athens 10675, Greece; [Kalamatianos, Theodosis; Stavrinou, Lampis C.; Koutsarnakis, Christos; Sakas, Damianos E.; Stranjalis, George] Univ Athens, Dept Neurosurg, Athens, Greece; [Psachoulia, Christina] Evangelismos Med Ctr, Dept Biochem, Athens, Greece	Kalamatianos, T (corresponding author), Hellen Ctr Neurosurg Res Prof Petros S Kokkalis, Poutarchou 3, Athens 10675, Greece.	theodosis.kalamatianos@kcl.ac.uk		Kalamatianos, Theodosis/0000-0003-4634-2965			Adini A, 2002, CANCER RES, V62, P2749; Ahmad S, 2011, VASC CELL, V3, DOI 10.1186/2045-824X-3-15; Autiero M, 2003, NAT MED, V9, P936, DOI 10.1038/nm884; Bottomley MJ, 2000, CLIN EXP IMMUNOL, V119, P182, DOI 10.1046/j.1365-2249.2000.01097.x; Cai J, 2003, DIABETES, V52, P2959, DOI 10.2337/diabetes.52.12.2959; Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904; Fischer C, 2008, NAT REV CANCER, V8, P942, DOI 10.1038/nrc2524; Foidart JM, 2009, J REPROD IMMUNOL, V82, P106, DOI 10.1016/j.jri.2009.09.001; Foyouzi N, 2006, INT J GYNECOL OBSTET, V92, P32, DOI 10.1016/j.ijgo.2005.09.004; Frati A, 2004, J NEUROSURG, V100, P24, DOI 10.3171/jns.2004.100.1.0024; FRIEDE RL, 1978, AM J PATHOL, V92, P69; Fujisawa H, 2006, NEUROL MED-CHIR, V46, P333, DOI 10.2176/nmc.46.333; Funai M, 2011, J NEUROTRAUM, V28, P1127, DOI 10.1089/neu.2010.1498; Green CJ, 2001, CANCER RES, V61, P2696; Hattori K, 2002, NAT MED, V8, P841, DOI 10.1038/nm740; Hohenstein A, 2005, J NEUROTRAUM, V22, P518, DOI 10.1089/neu.2005.22.518; Hong HJ, 2009, SURG NEUROL, V71, P161, DOI 10.1016/j.surneu.2008.01.023; Karumanchi SA, 2004, ENDOCRINOLOGY, V145, P4835, DOI 10.1210/en.2004-1028; Khaliq A, 1998, LAB INVEST, V78, P109; Kristof RA, 2008, J NEUROSURG, V108, P275, DOI 10.3171/JNS/2008/108/2/0275; Lee KS, 2004, BRAIN INJURY, V18, P351, DOI 10.1080/02699050310001645801; Luttun A, 2002, NAT MED, V8, P831, DOI 10.1038/nm731; MARKWALDER TM, 1986, ACTA NEUROCHIR, V79, P100, DOI 10.1007/BF01407452; Nakaguchi H, 2001, J NEUROSURG, V95, P256, DOI 10.3171/jns.2001.95.2.0256; Nanko N, 2009, NEUROL MED-CHIR, V49, P379, DOI 10.2176/nmc.49.379; Odorisio T, 2002, J CELL SCI, V115, P2559; Oura H, 2003, BLOOD, V101, P560, DOI 10.1182/blood-2002-05-1516; Pan PX, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471-2121-11-36; Pilarczyk K, 2008, ATHEROSCLEROSIS, V196, P333, DOI 10.1016/j.atherosclerosis.2006.10.038; Roeckl W, 1998, EXP CELL RES, V241, P161, DOI 10.1006/excr.1998.4039; Roncal C, 2010, CARDIOVASC RES, V86, P29, DOI 10.1093/cvr/cvp380; Santarius Thomas, 2010, Clin Neurosurg, V57, P112; SATO S, 1975, J NEUROSURG, V43, P569, DOI 10.3171/jns.1975.43.5.0569; SCHACHENMAYR W, 1978, AM J PATHOL, V92, P53; Schiettecatte J, 2010, CLIN BIOCHEM, V43, P768, DOI 10.1016/j.clinbiochem.2010.02.010; Schoenfeld Jonathan, 2004, Angiogenesis, V7, P143, DOI 10.1007/s10456-004-1677-0; Selvaraj SK, 2003, BLOOD, V102, P1515, DOI 10.1182/blood-2002-11-3423; Shono T, 2001, J CLIN NEUROSCI, V8, P411, DOI 10.1054/jocn.2000.0951; Suzuki K, 1999, J TRAUMA, V46, P532, DOI 10.1097/00005373-199903000-00040; Suzuki M, 1998, ACTA NEUROCHIR, V140, P51, DOI 10.1007/s007010050057; Weigel R, 2001, ACTA NEUROCHIR, V143, P811, DOI 10.1007/s007010170035; Weigel R, 2007, NEUROSURGERY, V61, P788, DOI 10.1227/01.NEU.0000298907.56012.E8; Wu FTH, 2010, J CELL MOL MED, V14, P528, DOI 10.1111/j.1582-4934.2009.00941.x; Yamamoto H, 2003, J NEUROSURG, V98, P1217, DOI 10.3171/jns.2003.98.6.1217; YAMASHIMA T, 1983, J NEUROSURG, V59, P298, DOI 10.3171/jns.1983.59.2.0298; Yonekura H, 1999, J BIOL CHEM, V274, P35172, DOI 10.1074/jbc.274.49.35172; Yoo SA, 2009, ARTHRITIS RHEUM-US, V60, P345, DOI 10.1002/art.24289; Ziche M, 1997, LAB INVEST, V76, P517	48	34	35	0	6	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	FEB	2013	118	2					353	357		10.3171/2012.10.JNS12327			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	076DY	WOS:000313937900019	23140147				2021-06-18	
J	Tang, SS; Wang, XY; Hong, H; Long, Y; Li, YQ; Xiang, GQ; Jiang, LY; Zhang, HT; Liu, LP; Miao, MX; Hu, M; Zhang, TT; Hu, W; Ji, H; Ye, FY				Tang, Su-Su; Wang, Xiao-Yun; Hong, Hao; Long, Yan; Li, Yong-Qi; Xiang, Guo-Qing; Jiang, Li-Ying; Zhang, Han-Ting; Liu, Li-Ping; Miao, Ming-Xing; Hu, Mei; Zhang, Ting-Ting; Hu, Wei; Ji, Hui; Ye, Feng-Ying			Leukotriene D4 induces cognitive impairment through enhancement of CysLT(1)R-mediated amyloid-beta generation in mice	NEUROPHARMACOLOGY			English	Article						Leukotriene D4; Cognition; Cysteinyl leukotriene receptor 1; Amyloid-beta peptides; Alzheimer's disease	FACTOR-KAPPA-B; ACTIVATED PROTEIN-KINASE; TRAUMATIC BRAIN-INJURY; CYSTEINYL-LEUKOTRIENES; MOUSE MODEL; ALZHEIMERS-DISEASE; ASTROCYTE PROLIFERATION; INFLAMMATORY RESPONSE; UP-REGULATION; A-BETA	Amyloid plaques in the extracellular parenchyma mainly consist of amyloid-beta peptides (A beta), one of the pathological hallmarks in Alzheimer's disease (AD). In the present study, we examined neuroinflammation, amyloidogenesis, and memory performance following intracerebral infusions of leukotriene D4 (LTD4) in mice. The results demonstrated that intracerebral infusions of LTD4 (1 ng/mouse) produced memory impairment as determined by Morris water maze test and Y-maze test in mice, and caused the accumulation of A beta 1-40 and A beta 1-42 in the hippocampus and cortex through increased activity of beta- and gamma-secretases accompanied with increased expression of amyloid precursor protein (APP). LTD4 also induced expression of cysteinyl leukotriene receptor 1 (CysLT(1)R) and NF-kappa B p65 in the hippocampus and cortex. Pretreatment with pranlukast (115 ng/mouse, intracerebroventricularly), a CysLT(1)R antagonist, blocked LTD4-induced amyloidogenesis, memory deficits. Pranlukast (0.6 mu M) also prevented LTD4 (20 nM)-induced amyloidogenesis in the cultured neurons in vitro. Moreover, LTD4-induced increases in CysLT(1)R and NF-kappa B p65 in the brain were also attenuated by pranlukast These results suggest that LTD4 increases A beta peptide burden via activation of CysLT(1)R, which further affects APP levels and activity of beta- and gamma-secretases via the NF-kappa B pathway. Our findings identify CysLT(1)R signaling as a novel proinflammatory and proamyloidogenic pathway, and suggest a rationale for development of therapeutics targeting the CysLT(1)R in neuroinflammatory diseases such as AD. (C) 2012 Elsevier Ltd. All rights reserved.	[Tang, Su-Su; Wang, Xiao-Yun; Hong, Hao; Long, Yan; Li, Yong-Qi; Xiang, Guo-Qing; Jiang, Li-Ying; Miao, Ming-Xing; Hu, Mei; Zhang, Ting-Ting; Ji, Hui; Ye, Feng-Ying] China Pharmaceut Univ, Dept Pharmacol, Nanjing 210009, Peoples R China; [Zhang, Han-Ting] W Virginia Univ, Hlth Sci Ctr, Dept Behav Med & Psychiat, Morgantown, WV 26506 USA; [Zhang, Han-Ting] W Virginia Univ, Hlth Sci Ctr, Dept Physiol & Pharmacol, Morgantown, WV 26506 USA; [Liu, Li-Ping; Hu, Wei] Anhui Med Univ, Hosp 2, Dept Pharm, Hefei 230031, Peoples R China	Hong, H (corresponding author), China Pharmaceut Univ, Dept Pharmacol, Nanjing 210009, Peoples R China.	haohongchina@hotmail.com			college graduate research and innovation projects; Jiangsu Province; Natural Science Foundation of Anhui Province, PR ChinaNatural Science Foundation of Anhui Province [1208085MH164]	This work was supported by the college graduate research and innovation projects funded by Jiangsu Province and the Natural Science Foundation of Anhui Province (no. 1208085MH164), PR China.	Back M, 2002, LIFE SCI, V71, P611, DOI 10.1016/S0024-3205(02)01733-2; Bourne KZ, 2007, J NEUROSCI RES, V85, P1194, DOI 10.1002/jnr.21252; Boyce JA, 2008, CURR MOL MED, V8, P335, DOI 10.2174/156652408785160989; Brink C, 2003, PHARMACOL REV, V55, P195, DOI 10.1124/pr.55.1.8; Capra V, 2004, PHARMACOL RES, V50, P1, DOI 10.1016/j.phrs.2003.12.012; Capra V, 2007, MED RES REV, V27, P469, DOI 10.1002/med.20071; Chami L, 2012, J BIOL CHEM, V287, P24573, DOI 10.1074/jbc.M111.333054; Chinnici CM, 2007, NEUROBIOL AGING, V28, P1457, DOI 10.1016/j.neurobiolaging.2006.06.007; Chu J, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-127; Chu J, 2012, MOL NEURODEGENER, V7, DOI 10.1186/1750-1326-7-1; Chu J, 2011, ANN NEUROL, V69, P34, DOI 10.1002/ana.22234; Chu J, 2011, AM J PATHOL, V178, P1762, DOI 10.1016/j.ajpath.2010.12.032; Ciccarelli R, 2004, EUR J NEUROSCI, V20, P1514, DOI 10.1111/j.1460-9568.2004.03613.x; Cuenca-Lopez MD, 2010, REV NEUROLOGIA, V50, P349, DOI 10.33588/rn.5006.2009666; Dahlen SE, 2006, EUR J PHARMACOL, V533, P40, DOI 10.1016/j.ejphar.2005.12.070; Ding Q, 2007, ACTA PHARMACOL SIN, V28, P945, DOI 10.1111/j.1745-7254.2007.00576.x; Evans JF, 2003, PROSTAG LEUKOTR ESS, V69, P117, DOI 10.1016/S0952-3278(03)00072-3; Firuzi O, 2008, FASEB J, V22, P1169, DOI 10.1096/fj.07-9131.com; Giunta B, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-51; Gorelick PB, 2010, ANN NY ACAD SCI, V1207, P155, DOI 10.1111/j.1749-6632.2010.05726.x; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; Guglielmotto M., 2010, NEUROBIOL AGING, V196, pe13; Guo JT, 2002, J NEUROSCI, V22, P5900; Hashimoto K, 2009, INT ARCH ALLERGY IMM, V149, P275, DOI 10.1159/000199724; Heise CE, 2000, J BIOL CHEM, V275, P30531, DOI 10.1074/jbc.M003490200; Hu H, 2005, ACTA PHARMACOL SIN, V26, P685, DOI 10.1111/j.1745-7254.2005.00092.x; Huang XJ, 2008, GLIA, V56, P27, DOI 10.1002/glia.20588; Ikonomovic MD, 2008, J HISTOCHEM CYTOCHEM, V56, P1065, DOI 10.1369/jhc.2008.951855; Im DS, 2009, PROSTAG OTH LIPID M, V89, P53, DOI 10.1016/j.prostaglandins.2009.01.002; Jimenez S, 2008, J NEUROSCI, V28, P11650, DOI 10.1523/JNEUROSCI.3024-08.2008; Kanaoka Y, 2004, J IMMUNOL, V173, P1503, DOI 10.4049/jimmunol.173.3.1503; Kawano T, 2003, J ALLERGY CLIN IMMUN, V112, P369, DOI 10.1067/mai.2003.1636; Kimura R, 2010, J NEUROCHEM, V113, P248, DOI 10.1111/j.1471-4159.2010.06608.x; Krause Daniela L, 2010, Int J Alzheimers Dis, V2010, DOI 10.4061/2010/732806; Lammers CH, 1996, J NEUROCHEM, V66, P147; Lee JW, 2008, J NEUROINFLAMM, V29, P5; Maekawa A, 2008, P NATL ACAD SCI USA, V105, P16695, DOI 10.1073/pnas.0808993105; Manev H, 2011, PROG NEURO-PSYCHOPH, V35, P315, DOI 10.1016/j.pnpbp.2010.07.032; Medeiros R, 2010, BEHAV BRAIN RES, V209, P165, DOI 10.1016/j.bbr.2010.01.040; Montuschi P, 2007, DRUG DISCOV TODAY, V12, P404, DOI 10.1016/j.drudis.2007.03.004; Morris AAM, 1998, LANCET, V352, P1487, DOI 10.1016/S0140-6736(05)60322-4; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Paxinos G., 2003, MOUSE BRAIN STEREOTA; PIOMELLI D, 1994, CRIT REV NEUROBIOL, V8, P65; Polydoro M, 2009, J NEUROSCI, V29, P10741, DOI 10.1523/JNEUROSCI.1065-09.2009; Puccio S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015163; Samuelsson B, 2000, AM J RESP CRIT CARE, V161, pS2, DOI 10.1164/ajrccm.161.supplement_1.ltta-1; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Selkoe DJ, 2002, J CLIN INVEST, V110, P1375, DOI 10.1172/JCI200216783; Singh RK, 2010, PHARMACOLOGY, V85, P336, DOI 10.1159/000312669; Sisodia SS, 2002, NAT REV NEUROSCI, V3, P281, DOI 10.1038/nrn785; Uz T, 1998, FASEB J, V12, P439; Wang C, 2011, INT J NEUROPSYCHOPH, V9, P1; Wang J, 2005, FASEB J, V19, P659, DOI 10.1096/fj.04-3182fje; Wang J, 2007, J CLIN INVEST, V117, P3393, DOI 10.1172/JCI31547; Wang ML, 2006, BIOCHEM BIOPH RES CO, V350, P399, DOI 10.1016/j.bbrc.2006.09.057; Wyss-Coray T, 2006, NAT MED, V12, P1005, DOI 10.1038/nml1484; Yuan YM, 2009, J PHARMACOL SCI, V109, P285, DOI 10.1254/jphs.08321FP; Zhang J, 2006, ACTA PHARMACOL SIN, V27, P1553, DOI 10.1111/j.1745-7254.2006.00458.x; Zhang WP, 2004, NEUROSCI LETT, V363, P247, DOI 10.1016/j.neulet.2004.03.088; Zotova E, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt24	62	34	35	1	32	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	FEB	2013	65						182	192		10.1016/j.neuropharm.2012.08.026			11	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	076CY	WOS:000313935300023	22982445				2021-06-18	
J	Lutkenhoff, ES; McArthur, DL; Hua, X; Thompson, PM; Vespa, PM; Monti, MM				Lutkenhoff, Evan S.; McArthur, David L.; Hua, Xue; Thompson, Paul M.; Vespa, Paul M.; Monti, Martin M.			Thalamic atrophy in antero-medial and dorsal nuclei correlates with six-month outcome after severe brain injury	NEUROIMAGE-CLINICAL			English	Article						Traumatic brain injury; Thalamus; Tensor brain morphometry; Magnetic resonance imaging	MEDIODORSAL NUCLEUS; ALZHEIMERS-DISEASE; PREFRONTAL CORTEX; HIPPOCAMPAL ATROPHY; NEURONAL-ACTIVITY; FLUID-PERCUSSION; GROWTH-PATTERNS; LIMBIC CORTEX; SERIAL MRI; ROBUST	The primary and secondary damage to neural tissue inflicted by traumatic brain injury is a leading cause of death and disability. The secondary processes, in particular, are of great clinical interest because of their potential susceptibility to intervention. We address the dynamics of tissue degeneration in cortico-subcortical circuits after severe brain injury by assessing volume change in individual thalamic nuclei over the first six-months post-injury in a sample of 25 moderate to severe traumatic brain injury patients. Using tensor-based morphometry, we observed significant localized thalamic atrophy over the six-month period in antero-dorsal limbic nuclei as well as in medio-dorsal association nuclei. Importantly, the degree of atrophy in these nuclei was predictive, even after controlling for full-brain volume change, of behavioral outcome at six-months post-injury. Furthermore, employing a data-driven decision tree model, we found that physiological measures, namely the extent of atrophy in the anterior thalamic nucleus, were the most predictive variables of whether patients had regained consciousness by six-months, followed by behavioral measures. Overall, these findings suggest that the secondary non-mechanical degenerative processes triggered by severe brain injury are still ongoing after the first week post-trauma and target specifically antero-medial and dorsal thalamic nuclei. This result therefore offers a potential window of intervention, and a specific target region, in agreement with the view that specific cortico-thalamo-cortical circuits are crucial to the maintenance of large-scale network neural activity and thereby the restoration of cognitive function after severe brain injury. (C) 2013 The Authors. Published by Elsevier Inc.	[Lutkenhoff, Evan S.; Monti, Martin M.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA; [McArthur, David L.; Vespa, Paul M.; Monti, Martin M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, BIRC, Los Angeles, CA 90095 USA; [Hua, Xue; Thompson, Paul M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Lab Neuro Imaging LONI, Los Angeles, CA 90095 USA; [Thompson, Paul M.] Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA 90095 USA; [Vespa, Paul M.] Univ Calif Los Angeles, Dept Neurol, David Geffen Sch Med, Los Angeles, CA 90095 USA	Monti, MM (corresponding author), Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA.	monti@psych.ucla.edu	Thompson, Paul M/C-4194-2018	Thompson, Paul M/0000-0002-4720-8867; Monti, Martin M/0000-0001-5511-3780			Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Ashburner J, 2003, LANCET NEUROL, V2, P79, DOI 10.1016/S1474-4422(03)00304-1; Ashburner J, 2000, NEUROIMAGE, V11, P805, DOI 10.1006/nimg.2000.0582; Ashburner J, 1998, HUM BRAIN MAPP, V6, P348, DOI 10.1002/(SICI)1097-0193(1998)6:5/6<348::AID-HBM4>3.3.CO;2-G; Babikian T, 2005, PEDIATR NEUROL, V33, P184, DOI 10.1016/j.pediatrneurol.2005.03.015; BANERJEE PK, 1994, EPILEPSY RES, V17, P193, DOI 10.1016/0920-1211(94)90050-7; Bekinschtein TA, 2008, J NEUROL NEUROSUR PS, V79, P826, DOI 10.1136/jnnp.2007.132738; Boly M, 2009, HUM BRAIN MAPP, V30, P2393, DOI 10.1002/hbm.20672; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Brefel-Courbon C, 2007, ANN NEUROL, V62, P102, DOI 10.1002/ana.21110; Cachier P, 2000, LECT NOTES COMPUT SC, V1935, P472; Chan HM, 2003, PROC CVPR IEEE, P570; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; Chung MK, 2003, NEUROIMAGE, V18, P198, DOI 10.1016/S1053-8119(02)00017-4; Chung MK, 2001, NEUROIMAGE, V14, P595, DOI 10.1006/nimg.2001.0862; Cipolotti L, 2008, NEUROPSYCHOLOGIA, V46, P2745, DOI 10.1016/j.neuropsychologia.2008.05.009; Dinov Ivo D, 2009, Front Neuroinform, V3, P22, DOI 10.3389/neuro.11.022.2009; Dumont JR, 2012, NEUROSCIENCE, V224, P81, DOI 10.1016/j.neuroscience.2012.08.027; Dupire A, 2013, HIPPOCAMPUS, V23, P392, DOI 10.1002/hipo.22098; Fearing MA, 2008, J CHILD NEUROL, V23, P729, DOI 10.1177/0883073808314159; Fernandez-Espejo D, 2010, J NEUROTRAUM, V27, P1187, DOI 10.1089/neu.2010.1297; Fox NC, 2000, ARCH NEUROL-CHICAGO, V57, P339, DOI 10.1001/archneur.57.3.339; Fox NC, 1996, BRAIN, V119, P2001, DOI 10.1093/brain/119.6.2001; Fox NC, 2001, LANCET, V358, P201, DOI 10.1016/S0140-6736(01)05408-3; Fox NC, 1999, NEUROLOGY, V52, P1687, DOI 10.1212/WNL.52.8.1687; Fox NC, 1997, J MAGN RESON IMAGING, V7, P1069, DOI 10.1002/jmri.1880070620; Freeborough PA, 1997, IEEE T MED IMAGING, V16, P623, DOI 10.1109/42.640753; Freeborough PA, 1996, J COMPUT ASSIST TOMO, V20, P1012, DOI 10.1097/00004728-199611000-00030; Furnkranz J, 1997, MACH LEARN, V27, P139, DOI 10.1023/A:1007329424533; GABRIEL M, 1983, BEHAV NEUROSCI, V97, P675, DOI 10.1037/0735-7044.97.5.675; Ge YL, 2000, RADIOLOGY, V214, P665, DOI 10.1148/radiology.214.3.r00mr30665; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hampstead BM, 2009, CLIN NEUROPSYCHOL, V23, P1232, DOI 10.1080/13854040902936679; HERKENHAM M, 1980, SCIENCE, V207, P532, DOI 10.1126/science.7352263; Hua X, 2011, NEUROIMAGE, V57, P5, DOI 10.1016/j.neuroimage.2011.01.079; Hua X, 2010, NEUROBIOL AGING, V31, P1463, DOI 10.1016/j.neurobiolaging.2010.04.033; Hua X, 2010, NEUROIMAGE, V51, P63, DOI 10.1016/j.neuroimage.2010.01.104; Hua X, 2009, HUM BRAIN MAPP, V30, P209, DOI 10.1002/hbm.20498; Ishwaran H., 2009, ENCY MED DECISION MA, P323; Jank W, 2010, FRONT ARTIF INTEL AP, V218, P137, DOI 10.3233/978-1-60750-633-1-137; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; Jenkinson M, 2001, MED IMAGE ANAL, V5, P143, DOI 10.1016/S1361-8415(01)00036-6; KAISER HF, 1958, PSYCHOMETRIKA, V23, P187, DOI 10.1007/BF02289233; KAITZ SS, 1981, J COMP NEUROL, V195, P527, DOI 10.1002/cne.901950309; Kang EK, 2012, J REHABIL MED, V44, P346, DOI 10.2340/16501977-0947; Kato K, 2008, NEUROL MED-CHIR, V48, P285, DOI 10.2176/nmc.48.285; Klein JC, 2010, NEUROIMAGE, V51, P555, DOI 10.1016/j.neuroimage.2010.02.062; Laureys S, 2005, TRENDS COGN SCI, V9, P556, DOI 10.1016/j.tics.2005.10.010; Laureys S, 2000, LANCET, V355, P1790, DOI 10.1016/S0140-6736(00)02271-6; Lemieux L, 1998, Med Image Anal, V2, P227, DOI 10.1016/S1361-8415(98)80021-2; Leow A, 2005, LECT NOTES COMPUT SC, V3565, P493; Leow A, 2005, NEUROIMAGE, V24, P910, DOI 10.1016/j.neuroimage.2004.09.022; Leow AD, 2007, IEEE T MED IMAGING, V26, P822, DOI 10.1109/TMI.2007.892646; Leow AD, 2009, NEUROIMAGE, V45, P645, DOI 10.1016/j.neuroimage.2009.01.004; Leow AD, 2006, NEUROIMAGE, V31, P627, DOI 10.1016/j.neuroimage.2005.12.013; Lu PH, 2011, J ALZHEIMERS DIS, V23, P433, DOI 10.3233/JAD-2010-101398; MacKenzie EJ, 2000, EPIDEMIOL REV, V22, P112, DOI 10.1093/oxfordjournals.epirev.a018006; Martin LJ, 2001, J COMP NEUROL, V433, P299, DOI 10.1002/cne.1141; Mazziotta J, 2001, PHILOS T R SOC B, V356, P1293, DOI 10.1098/rstb.2001.0915; Mierswa I., 2006, P 12 ACM SIGKDD INT, P935, DOI DOI 10.1145/1150402.1150531; Monti MM, 2012, ANNU REV CLIN PSYCHO, V8, P431, DOI 10.1146/annurev-clinpsy-032511-143050; Murray CJL, 1997, LANCET, V349, P1436, DOI 10.1016/S0140-6736(96)07495-8; Natale JE, 2002, NEUROSCIENCE, V112, P665, DOI 10.1016/S0306-4522(02)00098-2; O'Brien JT, 2001, NEUROLOGY, V56, P1386, DOI 10.1212/WNL.56.10.1386; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; QUINLAN JR, 1987, INT J MAN MACH STUD, V27, P221, DOI 10.1016/S0020-7373(87)80053-6; Rex DE, 2003, NEUROIMAGE, V19, P1033, DOI 10.1016/S1053-8119(03)00185-X; Rey D, 2002, MED IMAGE ANAL, V6, P163, DOI 10.1016/S1361-8415(02)00056-7; ROBERTSON RT, 1981, J COMP NEUROL, V195, P501, DOI 10.1002/cne.901950308; Rokach L, 2005, IEEE T SYST MAN CY C, V35, P476, DOI 10.1109/TSMCC.2004.843247; Rotaru DC, 2005, J COMP NEUROL, V490, P220, DOI 10.1002/cne.20661; Saunders RC, 2005, EXP BRAIN RES, V167, P1, DOI 10.1007/s00221-005-2361-3; Schiff ND, 2007, NATURE, V448, P600, DOI 10.1038/nature06041; Schiff ND, 2008, ANN NY ACAD SCI, V1129, P105, DOI 10.1196/annals.1417.029; Schiff ND, 2010, TRENDS NEUROSCI, V33, P1, DOI 10.1016/j.tins.2009.11.002; Sherman S.M., 2001, EXPLORING THALAMUS; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2002, NEUROIMAGE, V17, P479, DOI 10.1006/nimg.2002.1040; Smith SM, 2001, J COMPUT ASSIST TOMO, V25, P466, DOI 10.1097/00004728-200105000-00022; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; STREET JO, 1988, AM STAT, V42, P152, DOI 10.2307/2684491; Studholme C, 2001, MICCAI, P41; TEASDALE G, 1974, LANCET, V2, P81; Thompson PM, 2000, NATURE, V404, P190, DOI 10.1038/35004593; Van Der Werf YD, 2003, CORTEX, V39, P1047, DOI 10.1016/S0010-9452(08)70877-3; van Groen T, 2002, BEHAV BRAIN RES, V136, P329, DOI 10.1016/S0166-4328(02)00199-7; van Huijzen, 2008, HUMAN CENTRAL NERVOU; Wang L, 2003, NEUROIMAGE, V20, P667, DOI 10.1016/S1053-8119(03)00361-6; Watanabe Y, 2004, J NEUROPHYSIOL, V92, P1738, DOI 10.1152/jn.00994.2003; Watanabe Y, 2012, NEUROSCI BIOBEHAV R, V36, P134, DOI 10.1016/j.neubiorev.2011.05.003; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wilson SL, 1998, LANCET, V352, P485, DOI 10.1016/S0140-6736(05)79220-5; Woods RP, 2003, NEUROIMAGE, V18, P769, DOI 10.1016/S1053-8119(03)00019-3; Yamamoto T, 2013, WORLD NEUROSURG, V80, DOI 10.1016/j.wneu.2012.04.010; Yanovsky Igor, 2008, Conf Comput Vis Pattern Recognit Workshops, V2008, DOI 10.1109/CVPRW.2008.4562988; Yanovsky I, 2009, MED IMAGE ANAL, V13, P679, DOI 10.1016/j.media.2009.06.002; Zhang YY, 2001, IEEE T MED IMAGING, V20, P45, DOI 10.1109/42.906424	100	34	36	0	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	2213-1582			NEUROIMAGE-CLIN	NeuroImage-Clin.		2013	3						396	404		10.1016/j.nicl.2013.09.010			9	Neuroimaging	Neurosciences & Neurology	V37LI	WOS:000209276900043	24273723	DOAJ Gold, Green Published			2021-06-18	
J	Sukumari-Ramesh, S; Alleyne, CH; Dhandapani, KM				Sukumari-Ramesh, Sangeetha; Alleyne, Cargill H., Jr.; Dhandapani, Krishnan M.			Astrocyte-Specific Expression of Survivin after Intracerebral Hemorrhage in Mice: A Possible Role in Reactive Gliosis?	JOURNAL OF NEUROTRAUMA			English	Article						astrogliosis; Inhibitor of Apoptosis protein family; proliferation; repair; stroke	TRAUMATIC BRAIN-INJURY; GLIOBLASTOMA CELLS; BARRIER PROPERTIES; ENDOTHELIAL-CELLS; APOPTOSIS; CANCER; GLIA; STROKE; REPAIR; S100B	Intracerebral hemorrhage (ICH), the most common form of hemorrhagic stroke, accounts for up to 15% of all strokes. Despite maximal surgical intervention and supportive care, ICH is associated with significant morbidity and mortality, in part due to a lack of viable treatment options. Astrogliosis, a key feature of secondary injury that is characterized by glial proliferation, is a poorly-defined process that may produce both beneficial and detrimental outcomes after brain injury. Using a pre-clinical murine model of collagenase-induced ICH, we demonstrate a delayed upregulation of survivin, a key molecule involved in tumor cell proliferation and survival, by 72 h post-ICH. Notably, this increase in survivin expression was prominent in GFAP-positive astrocytes, but absent in neurons. Survivin was not expressed at detectable levels in the striatum of sham-operated mice. The expression of survivin after ICH was temporally and spatially associated with the expression of proliferating cell nuclear antigen (PCNA), an established marker of cellular proliferation. Moreover, the survivin expression was co-localized in proliferating astrocytes as evidenced by triple-label immunohistochemistry. Finally, shRNA-mediated silencing of survivin expression attenuated PCNA expression and reduced cellular proliferation in human glial cells. Together, these data suggest a potentially novel role for survivin in functionally promoting astrocytic proliferation after ICH.	[Sukumari-Ramesh, Sangeetha; Alleyne, Cargill H., Jr.; Dhandapani, Krishnan M.] Georgia Hlth Sci Univ, Dept Neurosurg, Augusta, GA 30912 USA	Sukumari-Ramesh, S (corresponding author), Georgia Hlth Sci Univ, Dept Neurosurg, 1120 15th St, Augusta, GA 30912 USA.	sramesh@georgiahealth.edu		Dhandapani, Krishnan/0000-0001-7044-1117	National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS065172, R21NS075774]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS075774, R01NS065172] Funding Source: NIH RePORTER	This work was supported by grants from the National Institute of Health (R01NS065172, R21NS075774) to KMD.	ABBOTT NJ, 1992, NEUROPATH APPL NEURO, V18, P424, DOI 10.1111/j.1365-2990.1992.tb00808.x; Adida C, 1998, AM J PATHOL, V152, P43; Altieri DC, 1999, LAB INVEST, V79, P1327; Blum R, 2006, MOL CANCER THER, V5, P2337, DOI 10.1158/1535-7163.MCT-06-0193; Broderick JP, 1999, STROKE, V30, P905, DOI 10.1161/01.STR.30.4.905; Busch SA, 2007, CURR OPIN NEUROBIOL, V17, P120, DOI 10.1016/j.conb.2006.09.004; Chakravarti A, 2004, ONCOGENE, V23, P7494, DOI 10.1038/sj.onc.1208049; Clem RJ, 1996, CELL DEATH DIFFER, V3, P9; Das A, 2002, J CANCER RES CLIN, V128, P302, DOI 10.1007/s00432-002-0343-4; Delgado P, 2006, STROKE, V37, P2837, DOI 10.1161/01.STR.0000245085.58807.ad; Dowlatshahi D, 2011, NEUROLOGY, V76, P1238, DOI 10.1212/WNL.0b013e3182143317; Dubrez-Daloz L, 2008, CELL CYCLE, V7, P1036, DOI 10.4161/cc.7.8.5783; Foerch C, 2006, J NEUROL NEUROSUR PS, V77, P181, DOI 10.1136/jnnp.2005.074823; Hayashi Y, 1997, GLIA, V19, P13, DOI 10.1002/(SICI)1098-1136(199701)19:1<13::AID-GLIA2>3.0.CO;2-B; Howard JL, 2008, J TRAUMA, V65, P380, DOI 10.1097/TA.0b013e31817c50d4; Iadecola C, 2004, NAT REV NEUROSCI, V5, P347, DOI 10.1038/nrn1387; James ML, 2009, BIOMARKERS, V14, P388, DOI 10.1080/13547500903015784; JANZER RC, 1987, NATURE, V325, P253, DOI 10.1038/325253a0; Johnson EA, 2004, J NEUROTRAUM, V21, P1183, DOI 10.1089/neu.2004.21.1183; King MD, 2011, J NEUROSURG, V115, P116, DOI 10.3171/2011.2.JNS10784; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; Laird MD, 2010, J NEUROCHEM, V113, P637, DOI 10.1111/j.1471-4159.2010.06630.x; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Mahesh VB, 2006, MOL CELL ENDOCRINOL, V246, P1, DOI 10.1016/j.mce.2005.11.017; Miller LK, 1999, TRENDS CELL BIOL, V9, P323, DOI 10.1016/S0962-8924(99)01609-8; Moon WS, 2003, HUM PATHOL, V34, P1119, DOI 10.1053/j.humpath.2003.07.016; Pfrieger FW, 1997, SCIENCE, V277, P1684, DOI 10.1126/science.277.5332.1684; Qureshi AI, 2001, NEW ENGL J MED, V344, P1450, DOI 10.1056/NEJM200105103441907; Ribo M, 2006, CURR NEUROL NEUROSCI, V6, P17, DOI 10.1007/s11910-996-0004-0; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Rolls A, 2009, NAT REV NEUROSCI, V10, P235, DOI 10.1038/nrn2591; Sofroniew MV, 2005, NEUROSCIENTIST, V11, P400, DOI 10.1177/1073858405278321; Sukumari-Ramesh S, 2011, J NEUROSURG, V114, P1681, DOI 10.3171/2010.12.JNS10588; Sukumari-Ramesh S, 2010, GLIA, V58, P1858, DOI 10.1002/glia.21055; Takano T, 2006, NAT NEUROSCI, V9, P260, DOI 10.1038/nn1623; Ullian EM, 2004, GLIA, V47, P209, DOI 10.1002/glia.20082; Ullian EM, 2001, SCIENCE, V291, P657, DOI 10.1126/science.291.5504.657; Villapol S, 2008, NEUROSCIENCE, V153, P108, DOI 10.1016/j.neuroscience.2008.01.054; Volterra A, 2005, NAT REV NEUROSCI, V6, P626, DOI 10.1038/nrn1722; Wakade C, 2010, J NEUROSURG, V113, P1195, DOI 10.3171/2010.3.JNS091212; Wilson JX, 1997, CAN J PHYSIOL PHARM, V75, P1149, DOI 10.1139/cjpp-75-10-11-1149; Xi GH, 1998, J NEUROSURG, V89, P991, DOI 10.3171/jns.1998.89.6.0991; Xi GH, 1998, STROKE, V29, P2580, DOI 10.1161/01.STR.29.12.2580	43	34	37	0	6	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	DEC	2012	29	18					2798	2804		10.1089/neu.2011.2243			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	050ZE	WOS:000312092800009	22862734	Green Published			2021-06-18	
J	Prichep, LS; Jacquin, A; Filipenko, J; Dastidar, SG; Zabele, S; Vodencarevic, A; Rothman, NS				Prichep, Leslie S.; Jacquin, Arnaud; Filipenko, Julie; Dastidar, Samanwoy Ghosh; Zabele, Stephen; Vodencarevic, Asmir; Rothman, Neil S.			Classification of Traumatic Brain Injury Severity Using Informed Data Reduction in a Series of Binary Classifier Algorithms	IEEE TRANSACTIONS ON NEURAL SYSTEMS AND REHABILITATION ENGINEERING			English	Article						Genetic algorithms (GAs); informed data reduction; multiclass classification; quantitative electroencephalography (QEEG); traumatic brain injury (TBI)	CT HEAD RULE; GENETIC ALGORITHMS; EEG; SPECTROSCOPY; CONCUSSION; DURATION; TOOL; MRI	Assessment of medical disorders is often aided by objective diagnostic tests which can lead to early intervention and appropriate treatment. In the case of brain dysfunction caused by head injury, there is an urgent need for quantitative evaluation methods to aid in acute triage of those subjects who have sustained traumatic brain injury (TBI). Current clinical tools to detect mild TBI (mTBI/concussion) are limited to subjective reports of symptoms and short neurocognitive batteries, offering little objective evidence for clinical decisions; or computed tomography (CT) scans, with radiation-risk, that are most often negative in mTBI. This paper describes a novel methodology for the development of algorithms to provide multi-class classification in a substantial population of brain injured subjects, across a broad age range and representative subpopulations. The method is based on age-regressed quantitative features (linear and nonlinear) extracted from brain electrical activity recorded from a limited montage of scalp electrodes. These features are used as input to a unique "informed data reduction" method, maximizing confidence of prospective validation and minimizing over-fitting. A training set for supervised learning was used, including: "normal control," "concussed," and " structural injury/CT positive (CT+)." The classifier function separating CT+ from the other groups demonstrated a sensitivity of 96% and specificity of 78%; the classifier separating " normal controls" from the other groups demonstrated a sensitivity of 81% and specificity of 74%, suggesting high utility of such classifiers in acute clinical settings. The use of a sequence of classifiers where the desired risk can be stratified further supports clinical utility.	[Prichep, Leslie S.] NYU, Sch Med, Dept Psychiat, Brain Res Labs, New York, NY 10016 USA; [Jacquin, Arnaud; Filipenko, Julie; Dastidar, Samanwoy Ghosh; Rothman, Neil S.] BrainScope Inc, Bethesda, MD 20814 USA; [Zabele, Stephen] BBN, Raytheon, Cambridge, MA 02138 USA; [Vodencarevic, Asmir] Int Grad Sch Dynam Intelligent Syst, D-33102 Paderborn, Germany	Prichep, LS (corresponding author), NYU, Sch Med, Dept Psychiat, Brain Res Labs, New York, NY 10016 USA.	leslie.prichep@nyumc.org; arnaud.jacquin@brain-scope.com; julie.filipenko@brainscope.com; sam.dastidar@brainscope.com; szabele@bbn.com; asmirv@gmail.com; neil.rothman@brainscope.com			BrainScope, Inc., Bethesda, MD, USA	This work was supported by BrainScope, Inc., Bethesda, MD, USA.	Aviyente S, 2011, HUM BRAIN MAPP, V32, P80, DOI 10.1002/hbm.21000; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Cao C, 2008, IEEE T NEUR SYS REH, V16, P327, DOI 10.1109/TNSRE.2008.918422; Coldren RL, 2010, MIL MED, V175, P477, DOI 10.7205/MILMED-D-09-00258; Duda O.R., 2001, PATTERN CLASSIFICATI; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fisch B. J., 1999, FISCH SPEHLMANNS EEG, P3; GASSER T, 1982, ELECTROEN CLIN NEURO, V53, P119, DOI 10.1016/0013-4694(82)90112-2; Ghalenoui H, 2008, PREHOSP DISASTER MED, V23, P558, DOI 10.1017/S1049023X00006415; Harper Paul R, 2005, Health Policy, V71, P315, DOI 10.1016/j.healthpol.2004.05.002; He BYJ, 2010, NEURON, V66, P353, DOI 10.1016/j.neuron.2010.04.020; HIGUCHI T, 1988, PHYSICA D, V31, P277, DOI 10.1016/0167-2789(88)90081-4; Isenhart R., 2012, COMP MED BIOL UNPUB; Jacquin A, 2007, P ANN INT IEEE EMBS, P1928, DOI 10.1109/IEMBS.2007.4352694; JOHN ER, 1988, SCIENCE, V239, P162, DOI 10.1126/science.3336779; JOHN ER, 1980, SCIENCE, V210, P1255, DOI 10.1126/science.7434026; Kahraman S., 2006, J TRAUMA ACUTE CARE, V61; Kalafut MA, 2000, STROKE, V31, P1667, DOI 10.1161/01.STR.31.7.1667; Kessel B, 2007, INJURY, V38, P1065, DOI 10.1016/j.injury.2007.05.009; Kohavi R., 1995, IJCAI-95. Proceedings of the Fourteenth International Joint Conference on Artificial Intelligence, P1137; Kondacs A, 1999, CLIN NEUROPHYSIOL, V110, P1708, DOI 10.1016/S1388-2457(99)00122-4; Langlois J.A., 2006, J HEAD TRAUMA REHABI, V21; Lehmann D, 2005, PSYCHIAT RES-NEUROIM, V138, P141, DOI 10.1016/j.pscychresns.2004.05.007; Leon-Carrion J, 2010, BRAIN INJURY, V24, P1193, DOI 10.3109/02699052.2010.506636; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; Li JL, 2008, BIOSTATISTICS, V9, P566, DOI 10.1093/biostatistics/kxm050; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Malloy P.F., 1998, SEMIN CLIN NEUROPSYC, V3, P186; Mitchell M., 1996, INTRO GENETIC ALGORI; Norman RG, 2000, SLEEP, V23, P901; Oh IS, 2004, IEEE T PATTERN ANAL, V26, P1424, DOI 10.1109/TPAMI.2004.105; Prichep L., 1987, HDB ELECTROENCEPHALO, P449; Prichep LS, 2005, CLIN EEG NEUROSCI, V36, P82, DOI 10.1177/155005940503600207; Prichep LS, 2006, NEUROBIOL AGING, V27, P471, DOI 10.1016/j.neurobiolaging.2005.07.021; Rabinoff M, 2011, Open Med Inform J, V5, P1, DOI 10.2174/1874431101105010001; Raghavendra B. S., 2005, PHYSIOL MEAS, V30, P795; RAUDYS SJ, 1991, IEEE T PATTERN ANAL, V13, P252, DOI 10.1109/34.75512; Raymer ML, 2000, IEEE T EVOLUT COMPUT, V4, P164, DOI 10.1109/4235.850656; Rosso OA, 2001, J NEUROSCI METH, V105, P65, DOI 10.1016/S0165-0270(00)00356-3; Sakkalis V, 2011, COMPUT BIOL MED, V41, P1110, DOI 10.1016/j.compbiomed.2011.06.020; Selesnick I. W., 2002, NEW COMPLEX DIRECTIO, P573; SIEDLECKI W, 1989, PATTERN RECOGN LETT, V10, P335, DOI 10.1016/0167-8655(89)90037-8; Somorjai RL, 2011, J BIOMED INFORM, V44, P775, DOI 10.1016/j.jbi.2011.04.004; Sponheim SR, 2011, NEUROIMAGE, V54, pS21, DOI 10.1016/j.neuroimage.2010.09.007; Stein SC, 2009, ANN EMERG MED, V53, P180, DOI 10.1016/j.annemergmed.2008.01.002; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Suffin S., 2007, J AM PHYS SURG, V12, P104; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Tax DMJ, 2002, INT C PATT RECOG, P124, DOI 10.1109/ICPR.2002.1048253; TEASDALE G, 1974, LANCET, V2, P81; Thakor NV, 2004, ANNU REV BIOMED ENG, V6, P453, DOI 10.1146/annurev.bioeng.5.040202.121601; Thatcher RW, 2005, CLIN EEG NEUROSCI, V36, P116, DOI 10.1177/155005940503600211; Thatcher RW, 1998, NEUROIMAGE, V7, P352, DOI 10.1006/nimg.1998.0330; Thatcher RW, 2005, CLIN NEUROPHYSIOL, V116, P2129, DOI 10.1016/j.clinph.2005.04.026; Thatcher RW, 2001, J NEUROPSYCH CLIN N, V13, P77, DOI 10.1176/appi.neuropsych.13.1.77; THATCHER RW, 1989, ELECTROEN CLIN NEURO, V73, P94, DOI 10.1016/0013-4694(89)90188-0; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; WEINER JM, 1966, BIOMETRICS, V22, P268, DOI 10.2307/2528518; Whithain EM, 2007, CLIN NEUROPHYSIOL, V118, P1877, DOI 10.1016/j.clinph.2007.04.027; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Yang JH, 1998, IEEE INTELL SYST APP, V13, P44, DOI 10.1109/5254.671091	63	34	34	0	12	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	1534-4320	1558-0210		IEEE T NEUR SYS REH	IEEE Trans. Neural Syst. Rehabil. Eng.	NOV	2012	20	6					806	822		10.1109/TNSRE.2012.2206609			17	Engineering, Biomedical; Rehabilitation	Engineering; Rehabilitation	040WW	WOS:000311357400008	22855231				2021-06-18	
J	Kim, J; Whyte, J; Patel, S; Europa, E; Slattery, J; Coslett, HB; Detre, JA				Kim, Junghoon; Whyte, John; Patel, Sunil; Europa, Eduardo; Slattery, John; Coslett, H. Branch; Detre, John A.			A Perfusion fMRI Study of the Neural Correlates of Sustained-Attention and Working-Memory Deficits in Chronic Traumatic Brain Injury	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						traumatic brain injury rehabilitation; cerebral blood flow; arterial spin-labeled fMRI; sustained attention; n-back working-memory task; go/no-go visual reaction time	POSITRON-EMISSION-TOMOGRAPHY; DIFFEOMORPHIC IMAGE REGISTRATION; DIFFUSE AXONAL INJURY; CEREBRAL-BLOOD-FLOW; SEVERE HEAD-INJURY; COGNITIVE REHABILITATION; INATTENTIVE BEHAVIOR; CORTEX; TASK; ACTIVATION	Background. Given that traumatic brain injury (TBI) results in chronic alteration of baseline cerebral perfusion, a perfusion functional MRI (fMRI) method that dissociates resting-and task-related cerebral blood flow (CBF) changes can be useful in noninvasively investigating the neural correlates of cognitive dysfunction and recovery in TBI. Objective. The authors used continuous arterial spin-labeled (ASL) perfusion fMRI to characterize CBF at rest and during sustained-attention and working-memory tasks. Methods. A total of 18 to 21 individuals with moderate to severe TBI and 14 to 18 demographically matched healthy controls completed 3 continuous 6-minute perfusion fMRI scans (resting, visual sustained attention, and 2-back working memory). Results. For both tasks, TBI participants showed worse behavioral performance than controls. Voxelwise neuroimaging analysis of the 2-back task found that group differences in task-induced CBF changes were localized to bilateral superior occipital cortices and the left superior temporal cortex. Whereas controls deactivated these areas during task performance, TBI participants tended to activate these same areas. These regions were among those found to be disproportionately hypoperfused at rest after TBI. For both tasks, the control and TBI groups showed different patterns of correlation between performance and task-related CBF changes. Conclusions. ASL perfusion fMRI demonstrated differences between individuals with TBI and healthy controls in resting perfusion and in task-evoked CBF changes as well as different patterns of performance-activation correlation. These results are consistent with the notion that sensory/attentional modulation deficits contribute to higher cognitive dysfunction in TBI.	[Kim, Junghoon; Whyte, John; Patel, Sunil; Europa, Eduardo; Slattery, John] Moss Rehabil Res Inst, Albert Einstein Healthcare Network, Elkins Pk, PA 19027 USA; [Coslett, H. Branch; Detre, John A.] Univ Penn, Philadelphia, PA 19104 USA	Kim, J (corresponding author), Moss Rehabil Res Inst, Albert Einstein Healthcare Network, 50 Township Line Rd, Elkins Pk, PA 19027 USA.	kimj@einstein.edu	Kim, Junghoon John/I-6702-2019	Kim, Junghoon John/0000-0001-5729-8993; Whyte, John/0000-0002-4381-1474	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R24HD39621, R24HD050836, P30NS045839]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24HD050836, R24HD039621] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS045839] Funding Source: NIH RePORTER	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study is supported by the National Institutes of Health (grant numbers R24HD39621 [to JW], R24HD050836 [to JW; www.ncrrn.org], and P30NS045839 [to JAD]).	Aguirre GK, 1998, NEUROIMAGE, V8, P302, DOI 10.1006/nimg.1998.0367; Aguirre GK, 2002, NEUROIMAGE, V15, P488, DOI 10.1006/nimg.2001.0990; Avants BB, 2008, MED IMAGE ANAL, V12, P26, DOI 10.1016/j.media.2007.06.004; Avants BB, 2006, MED IMAGE ANAL, V10, P397, DOI 10.1016/j.media.2005.03.005; Awh E, 1996, PSYCHOL SCI, V7, P25, DOI 10.1111/j.1467-9280.1996.tb00662.x; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Caeyenberghs K, 2011, NEUROREHAB NEURAL RE, V25, P492, DOI 10.1177/1545968310394870; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Cohen JD, 1997, NATURE, V386, P604, DOI 10.1038/386604a0; Coull JT, 1998, NEUROPSYCHOLOGIA, V36, P1325, DOI 10.1016/S0028-3932(98)00035-9; Denys K, 2004, J NEUROSCI, V24, P2551, DOI 10.1523/JNEUROSCI.3569-03.2004; Detre JA, 2009, CURR OPIN NEUROL, V22, P348, DOI 10.1097/WCO.0b013e32832d9505; Golding EM, 2002, BRAIN RES REV, V38, P377, DOI 10.1016/S0165-0173(02)00141-8; Gusnard DA, 2001, NAT REV NEUROSCI, V2, P685, DOI 10.1038/35094500; Hillary FG, 2007, CLIN NEUROPSYCHOL, V21, P58, DOI 10.1080/13854040601064542; Hillary FG, 2008, J INT NEUROPSYCH SOC, V14, P526, DOI 10.1017/S1355617708080788; Holmes AP, 1998, NEUROIMAGE, V7, pS754, DOI DOI 10.1016/S1053-8119(18)31587-8; Jancke L, 1999, NEUROSCI LETT, V266, P125, DOI 10.1016/S0304-3940(99)00288-8; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Kato T, 2007, J NEUROTRAUM, V24, P919, DOI 10.1089/neu.2006.0203; Kim J, 2005, J INT NEUROPSYCH SOC, V11, P434, DOI 10.1017/S1355617705050563; Kim J, 2008, NEUROIMAGE, V39, P1014, DOI 10.1016/j.neuroimage.2007.10.005; Kim J, 2006, NEUROIMAGE, V31, P376, DOI 10.1016/j.neuroimage.2005.11.035; Kim J, 2010, J NEUROTRAUM, V27, P1399, DOI 10.1089/neu.2009.1215; Kochanek PM, 2002, J NEUROTRAUM, V19, P1029, DOI 10.1089/089771502760341947; Lawrence NS, 2003, J COGNITIVE NEUROSCI, V15, P1028, DOI 10.1162/089892903770007416; Levine B, 2002, J NEUROL NEUROSUR PS, V73, P173, DOI 10.1136/jnnp.73.2.173; Mai J.K., 2004, ATLAS HUMAN BRAIN; Mcallister TW, 2004, BRAIN INJURY, V18, P331, DOI 10.1080/02699050310001617370; Munoz-Cespedes JM, 2005, NEUROPSYCHOL REV, V15, P169, DOI 10.1007/s11065-005-9178-5; Nakashima T, 2007, AM J NEURORADIOL, V28, P236; Owen AM, 2005, HUM BRAIN MAPP, V25, P46, DOI 10.1002/hbm.20131; PARDO JV, 1991, NATURE, V349, P61, DOI 10.1038/349061a0; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; Poghosyan V, 2008, NEURON, V58, P802, DOI 10.1016/j.neuron.2008.04.013; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Sanchez-Carrion R, 2008, J NEUROTRAUM, V25, P479, DOI 10.1089/neu.2007.0417; Scheibel RS, 2007, NEUROREHAB NEURAL RE, V21, P36, DOI 10.1177/1545968306294730; Schroder ML, 1996, J NEUROTRAUM, V13, P17, DOI 10.1089/neu.1996.13.17; Schwartz MF, 2005, ARCH PHYS MED REHAB, V86, P1807, DOI 10.1016/j.apmr.2005.03.009; Slotnick SD, 2003, NEUROIMAGE, V19, P1602, DOI 10.1016/S1053-8119(03)00187-3; Soeda A, 2005, NEURORADIOLOGY, V47, P501, DOI 10.1007/s00234-005-1372-x; Stamatakis EA, 2002, J NUCL MED, V43, P476; Strangman G, 2005, AM J PHYS MED REHAB, V84, P62, DOI 10.1097/01.PHM.0000150787.26860.12; Turner GR, 2008, NEUROLOGY, V71, P812, DOI 10.1212/01.wnl.0000325640.18235.1c; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Van Boven RW, 2009, J REHABIL RES DEV, V46, P717, DOI 10.1682/JRRD.2008.12.0161; Van Essen DC, 2001, VISION RES, V41, P1359, DOI 10.1016/S0042-6989(01)00045-1; Wang JJ, 2005, RADIOLOGY, V235, P218, DOI 10.1148/radiol.2351031663; Wang JJ, 2003, NEUROIMAGE, V19, P1449, DOI 10.1016/S1053-8119(03)00255-6; Whyte J, 2004, AM J PHYS MED REHAB, V83, P401, DOI 10.1097/01.PHM.0000128789.75375.D3; WHYTE J, 1995, NEUROPSYCHOLOGIA, V33, P797, DOI 10.1016/0028-3932(95)00029-3; Whyte J, 2000, J INT NEUROPSYCH SOC, V6, P1, DOI 10.1017/S1355617700611013; WILLIAMS DS, 1992, P NATL ACAD SCI USA, V89, P212, DOI 10.1073/pnas.89.1.212; Wu WC, 2007, MAGN RESON MED, V58, P1020, DOI 10.1002/mrm.21403	56	34	36	1	20	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1545-9683			NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair	SEP	2012	26	7					870	880		10.1177/1545968311434553			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	981MY	WOS:000306973700007	22357634	Green Accepted			2021-06-18	
J	Mondello, S; Palmio, J; Streeter, J; Hayes, RL; Peltola, J; Jeromin, A				Mondello, Stefania; Palmio, Johanna; Streeter, Jackson; Hayes, Ronald L.; Peltola, Jukka; Jeromin, Andreas			Ubiquitin Carboxy-Terminal Hydrolase L1 (UCH-L1) is increased in cerebrospinal fluid and plasma of patients after epileptic seizure	BMC NEUROLOGY			English	Article						Biomarkers; UCH-L1; Epileptic seizures; Neuronal damage	TEMPORAL-LOBE EPILEPSY; NEURON-SPECIFIC ENOLASE; TRAUMATIC BRAIN-INJURY; TONIC-CLONIC SEIZURES; HIPPOCAMPAL SCLEROSIS; RECURRENT SEIZURES; SYNAPTIC REORGANIZATION; S-100 PROTEIN; SERUM; DAMAGE	Background: Clinical and experimental studies have demonstrated that seizures can cause molecular and cellular responses resulting in neuronal damage. At present, there are no valid tests for assessing organic damage to the brain associated with seizure. The aim of this study was to investigate cerebrospinal fluid (CSF) and plasma concentrations of Ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), a sensitive indicator of acute injury to brain neurons, in patients with tonic-clonic or partial secondarily generalized seizures due to various etiologies. Methods: CSF and plasma concentrations of UCH-L1 were assessed in 52 patients within 48 hours after epileptic seizure and in 19 controls using ELISA assays. Results: CSF obtained within 48 hours after seizure or status epilepticus (SE) presented significantly higher levels of UCH-L1 compared to controls (p = 0.008). Plasma UCH-L1 concentrations were negatively correlated with time to sample withdrawal. An analysis conducted using only the first 12 hours post-seizure revealed significant differences between concentrations of UCH-L1 in plasma and controls (p = 0.025). CSF and plasma concentrations were strongly correlated with age in patients with seizure, but not in control patients. Plasma UCH-L1 levels were also significantly higher in patients after recurrent seizures (n = 4) than in those after one or two seizures (p = 0.013 and p = 0.024, respectively). Conclusion: Our results suggest that determining levels of neuronal proteins may provide valuable information on the assessment of brain damage following seizure. These data might allow clinicians to make more accurate therapeutic decisions, to identify patients at risk of progression and, ultimately, to provide new opportunities for monitoring therapy and targeted therapeutic interventions.	[Mondello, Stefania] Banyan Biomarkers Inc, Clin Dept, Alachua, FL 32615 USA; [Palmio, Johanna; Peltola, Jukka] Tampere Univ Hosp, Dept Neurol, FIN-33521 Tampere, Finland	Mondello, S (corresponding author), Banyan Biomarkers Inc, Clin Dept, 113400 Progress Blvd, Alachua, FL 32615 USA.	smondello@banyanbio.com; ajeromin@banyanbio.com	Mondello, Stefania/A-1813-2012	Mondello, Stefania/0000-0002-8587-3614	Banyan Biomarkers, Inc.	Drs. Stefania Mondello and Andreas Jeromin are employees and received salaries from Banyan Biomarkers, Inc. Drs. Streeter and Hayes own stock, receive royalties and salaries from, and are officers of Banyan Biomarkers Inc., and as such may benefit financially as a result of the outcomes of this research or work reported in this publication. Banyan Biomarkers, Inc. filled patent applications based upon the disclosure of this publication. Drs. Palmio and Peltola have no conflicts of interest.	Blyth BJ, 2011, J NEUROTRAUM, V28, P2453, DOI 10.1089/neu.2010.1653; Briellmann RS, 2001, NEUROLOGY, V57, P315, DOI 10.1212/WNL.57.2.315; Brophy GM, 2011, J NEUROTRAUM, V28, P861, DOI 10.1089/neu.2010.1564; Buchet C, 1825, ARCH GEN MED, V9, P510; Buttner T, 1999, J NEUROL, V246, P459, DOI 10.1007/s004150050383; CAVAZOS JE, 1990, BRAIN RES, V527, P1, DOI 10.1016/0006-8993(90)91054-K; CAVAZOS JE, 1994, J NEUROSCI, V14, P3106; Cross DJ, 2007, EPILEPSY RES, V73, P156, DOI 10.1016/j.eplepsyres.2006.09.004; DAM AM, 1980, EPILEPSIA, V21, P617, DOI 10.1111/j.1528-1157.1980.tb04315.x; Douglas-Escobar M, 2010, PEDIATR RES, V68, P531, DOI 10.1203/PDR.0b013e3181f85a03; Fujikawa DG, 2006, STATUS EPILEPTICUS M, V36, P463; Haas KZ, 2001, HIPPOCAMPUS, V11, P615, DOI 10.1002/hipo.1076; Hellsten J, 2005, BIOL PSYCHIAT, V58, P871, DOI 10.1016/j.biopsych.2005.05.023; Henshall DC, 2001, NEUROBIOL DIS, V8, P568, DOI 10.1006/nbdi.2001.0415; Henshall DC, 2003, J NEUROCHEM, V86, P1260, DOI 10.1046/j.1471-4159.2003.01934.x; Holmes GL, 1999, J COMP NEUROL, V404, P537, DOI 10.1002/(SICI)1096-9861(19990222)404:4<537::AID-CNE9>3.0.CO;2-#; Kalviainen R, 1998, NEUROLOGY, V50, P1377, DOI 10.1212/WNL.50.5.1377; Lee SY, 2010, J NEUROL, V257, P1708, DOI 10.1007/s00415-010-5608-2; Lewis SB, 2010, J NEUROSCI RES, V88, P1475, DOI 10.1002/jnr.22323; Liu MC, 2010, EUR J NEUROSCI, V31, P722, DOI 10.1111/j.1460-9568.2010.07097.x; Liu RSN, 2001, NEUROIMAGE, V14, P231, DOI 10.1006/nimg.2001.0773; Liu Z, 1999, NEUROSCIENCE, V92, P1443, DOI 10.1016/S0306-4522(99)00064-0; MATHERN GW, 1995, BRAIN, V118, P105, DOI 10.1093/brain/118.1.105; Mathern GW, 2002, PROG BRAIN RES, V135, P237; MATHERN GW, 1992, DENDRON, V1, P69; Mondello S, NEUROSURGER IN PRESS; Mondello S, 2012, J NEUROTRAUM, V29, P1096, DOI 10.1089/neu.2011.2092; Mondello S, 2011, CRIT CARE, V15, DOI 10.1186/cc10286; O'Regan M E, 1998, Eur J Paediatr Neurol, V2, P193, DOI 10.1016/S1090-3798(98)80019-6; Palmio J, 2001, J NEUROL SCI, V183, P27, DOI 10.1016/S0022-510X(00)00478-0; Palmio J, 2009, SEIZURE-EUR J EPILEP, V18, P474, DOI 10.1016/j.seizure.2009.04.006; Pitkanen A, 2009, EPILEPSY BEHAV, V14, P16, DOI 10.1016/j.yebeh.2008.09.023; Pitkanen A, 2002, LANCET NEUROL, V1, P173, DOI 10.1016/S1474-4422(02)00073-X; QIAO XX, 1993, J NEUROSCI, V13, P4622; Rigau V, 2007, BRAIN, V130, P1942, DOI 10.1093/brain/awm118; Salmenpera T, 2001, EPILEPSY RES, V46, P69, DOI 10.1016/S0920-1211(01)00258-3; Steinhoff BJ, 1999, EPILEPSY RES, V36, P75, DOI 10.1016/S0920-1211(99)00026-1; Suzuki Y, 1999, NEUROLOGY, V53, P1761, DOI 10.1212/WNL.53.8.1761; Tanabe T, 2001, EPILEPSIA, V42, P504, DOI 10.1046/j.1528-1157.2001.30100.x; THOMPSON RJ, 1983, BRAIN RES, V278, P224, DOI 10.1016/0006-8993(83)90241-X; Tumani H, 1999, EPILEPSIA, V40, P713, DOI 10.1111/j.1528-1157.1999.tb00768.x; van Vliet EA, 2007, BRAIN, V130, P521, DOI 10.1093/brain/awl318; VanLandingham KE, 1998, ANN NEUROL, V43, P413, DOI 10.1002/ana.410430403; Yilmazer-Hanke DM, 2000, J NEUROPATH EXP NEUR, V59, P907, DOI 10.1093/jnen/59.10.907	44	34	34	0	12	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1471-2377			BMC NEUROL	BMC Neurol.	AUG 29	2012	12								85	10.1186/1471-2377-12-85			7	Clinical Neurology	Neurosciences & Neurology	038GK	WOS:000311163000001	22931063	DOAJ Gold, Green Published			2021-06-18	
J	Oddy, M; Moir, JF; Fortescue, D; Chadwick, S				Oddy, Michael; Moir, Jane Frances; Fortescue, Deborah; Chadwick, Sarah			The prevalence of traumatic brain injury in the homeless community in a UK city	BRAIN INJURY			English	Article						Prevalence; homeless; traumatic brain injury	ADULTS; HOSTEL	Primary objective: The main aim of the study was to investigate the prevalence of traumatic brain injury in a sample of homeless individuals. Research design: The researchers employed a cross-sectional survey design and contacted 12 organizations providing services for homeless individuals across a city in the UK. Methods and procedures: The sample included 100 homeless participants (75 males and 25 females) who met the inclusion criteria. A matched control group (n = 100) of individuals who were not homeless was also recruited. A questionnaire was administered to all participants to elicit information relating to history of possible traumatic brain injury. Main outcomes and results: Results indicated that a significantly higher number of homeless participants (48%) reported a history of traumatic brain injury than control participants (21%). Of those homeless participants, 90% indicated they had sustained their first traumatic brain injury before they were homeless. Conclusions: These findings suggest that rates of traumatic brain injury are much higher among the homeless population than in the general population and that sustaining a traumatic brain injury may be a risk factor for homelessness.	[Oddy, Michael; Moir, Jane Frances; Chadwick, Sarah] Brain Injury Rehabil Trust, Slinfold RH13 0TP, W Sussex, England; [Oddy, Michael; Fortescue, Deborah] Disabil Trust Fdn, Burgess Hill, W Sussex, England	Oddy, M (corresponding author), Brain Injury Rehabil Trust, 5 Oaks Rd, Slinfold RH13 0TP, W Sussex, England.	michael.oddy@thedtgroup.org			Disabilities Trust Foundation, a constituent of The Disabilities Trust Group	The study was funded by The Disabilities Trust Foundation, a constituent of The Disabilities Trust Group. The authors report no conflict of interest. The authors alone are responsible for the content and writing of the paper.	Backer Thomas Earl, 2007, J Prim Prev, V28, P375, DOI 10.1007/s10935-007-0100-1; Bremner AJ, 1996, BRIT J PSYCHIAT, V169, P434, DOI 10.1192/bjp.169.4.434; Emerson E., 2001, LEARNING DISABILITIE; Gaultieri T, 1991, BRAIN INJURY, V5, P219; Gilchrist G, 2005, EUR J PUBLIC HEALTH, V15, P587, DOI 10.1093/eurpub/cki036; Gonzalez EA, 2001, J NERV MENT DIS, V189, P176, DOI 10.1097/00005053-200103000-00006; Highley JL, 2008, TRAUMATIC BRAIN INJU; Hwang SW, 2008, CAN MED ASSOC J, V179, P779, DOI 10.1503/cmaj.080341; McKinlay A, 2008, BRAIN INJURY, V22, P175, DOI 10.1080/02699050801888824; Oakes PM, 2008, J INTELLECT DISABILI, V12, P325, DOI 10.1177/1744629508100496; Rees S., 2009, MENTAL ILL HLTH ADUL; Silver JM, 1999, NEUROPSYCHIATRY AND MENTAL HEALTH SERVICES, P319; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Slaughter B, 2003, BRAIN INJURY, V17, P731, DOI 10.1080/0269905031000088649; Solliday-McRoy C, 2004, J NERV MENT DIS, V192, P471, DOI 10.1097/01.nmd.0000131962.30547.26; Spence S, 2004, J ROY SOC MED, V97, P375, DOI 10.1258/jrsm.97.8.375; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y	17	34	34	0	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	AUG	2012	26	9					1058	1064		10.3109/02699052.2012.667595			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	971GI	WOS:000306191400002	22571822				2021-06-18	
J	Olsen, AS; Sozda, CN; Cheng, JP; Hoffman, AN; Kline, AE				Olsen, Adam S.; Sozda, Christopher N.; Cheng, Jeffrey P.; Hoffman, Ann N.; Kline, Anthony E.			Traumatic Brain Injury-Induced Cognitive and Histological Deficits Are Attenuated by Delayed and Chronic Treatment with the 5-HT1A-Receptor Agonist Buspirone	JOURNAL OF NEUROTRAUMA			English	Article						behavioral outcome; controlled cortical impact; functional recovery; 5-HT1A-receptor agonist; hippocampus; learning and memory; Morris water maze; traumatic brain injury	5-HT1A RECEPTOR AGONIST; BAY X 3702; NEUROBEHAVIORAL BENEFIT; BEHAVIORAL RECOVERY; TREATMENT REGIMEN; UNITED-STATES; HALOPERIDOL; HIPPOCAMPAL; PERFORMANCE; 8-OH-DPAT	The aim of this study was to evaluate the potential efficacy of the serotonin(1A) (5-HT1A) receptor agonist bus-pirone (BUS) on behavioral and histological outcome after traumatic brain injury (TBI). Ninety-six isoflurane-anesthetized adult male rats were randomized to receive either a controlled cortical impact or sham injury, and then assigned to six TBI and six sham groups receiving one of five doses of BUS (0.01, 0.05, 0.1, 0.3, or 0.5 mg/kg) or saline vehicle (VEH, 1.0 mL/kg). Treatments began 24 h after surgery and were administered intraperitoneally once daily for 3 weeks. Motor function (beam-balance/beam-walk tests) and spatial learning/memory (Morris water maze) were assessed on post-operative days 1-5 and 14-19, respectively. Morphologically intact CA1/CA3 cells and cortical lesion volume were quantified at 3 weeks. No differences were observed among the BUS and VEH sham groups in any end-point measure and thus the data were pooled. Regarding the TBI groups, repeated-measures ANOVAs revealed that the 0.3 mg/kg dose of BUS enhanced cognitive performance relative to VEH and the other BUS doses (p < 0.05), but did not significantly impact motor function. Moreover, the same dose conferred selective histological protection as evidenced by smaller cortical lesions, but not greater CA1/CA3 cell survival. No significant behavioral or histological differences were observed among the other BUS doses versus VEH. These data indicate that BUS has a narrow therapeutic dose response, and that 0.3 mg/kg is optimal for enhancing spatial learning and memory in this model of TBI. BUS may have potential as a novel pharmacotherapy for clinical TBI.	[Olsen, Adam S.; Sozda, Christopher N.; Cheng, Jeffrey P.; Hoffman, Ann N.; Kline, Anthony E.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Ctr Neural Basis Cognit, Pittsburgh, PA 15213 USA	Kline, AE (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, 3471 5th Ave,Suite 201, Pittsburgh, PA 15213 USA.	klineae@upmc.edu		Olsen, Adam/0000-0003-0957-9867; Cheng, Jeffrey/0000-0001-8285-3207	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HD043851, HD046700, NS060005]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R03HD043851, R01HD046700] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS060005] Funding Source: NIH RePORTER	Supported, in part, by National Institutes of Health grants HD043851, HD046700, and NS060005 (to A.E.K.).	Albert PR, 2004, NEUROSCIENTIST, V10, P575, DOI 10.1177/1073858404267382; Alessandri B, 1999, BRAIN RES, V845, P232, DOI 10.1016/S0006-8993(99)01948-4; Bales JW, 2009, NEUROSCI BIOBEHAV R, V33, P981, DOI 10.1016/j.neubiorev.2009.03.011; Banos JH, 2010, J HEAD TRAUMA REHAB, V25, P357, DOI 10.1097/HTR.0b013e3181d6c715; Barnes NM, 1999, NEUROPHARMACOLOGY, V38, P1083, DOI 10.1016/S0028-3908(99)00010-6; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Cheng JP, 2008, BEHAV BRAIN RES, V194, P79, DOI 10.1016/j.bbr.2008.06.025; Cheng JP, 2007, NEUROSCI LETT, V416, P165, DOI 10.1016/j.neulet.2007.02.006; Chew E, 2009, J REHABIL RES DEV, V46, P851, DOI 10.1682/JRRD.2008.09.0120; COOP CF, 1991, NEUROSCIENCE, V40, P169, DOI 10.1016/0306-4522(91)90182-N; De Vry J, 1998, J PHARMACOL EXP THER, V284, P1082; De Vry J, 1998, EUR J PHARMACOL, V357, P1, DOI 10.1016/S0014-2999(98)00503-2; De Vry Jean, 1997, Drugs of the Future, V22, P341; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; Dixon CE, 1997, J NEUROTRAUM, V14, P161, DOI 10.1089/neu.1997.14.161; Faul M.D., 2010, TRAUMATIC BRAIN INJU; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Garcia AN, 2011, PM&R, V3, pS18, DOI 10.1016/j.pmrj.2011.03.017; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Harkany T, 2001, NEUROSCIENCE, V108, P629, DOI 10.1016/S0306-4522(01)00444-4; Hoffman AN, 2008, LIFE SCI, V83, P602, DOI 10.1016/j.lfs.2008.08.007; Horneman G, 2009, BRAIN INJURY, V23, P907, DOI 10.1080/02699050903283239; Kline AE, 2004, J NEUROTRAUM, V21, P175, DOI 10.1089/089771504322778631; Kline AE, 2002, NEUROSCI LETT, V333, P179, DOI 10.1016/S0304-3940(02)01101-1; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Kline AE, 2001, NEUROSCIENCE, V106, P547, DOI 10.1016/S0306-4522(01)00300-1; Kline AE, 2004, J NEUROTRAUM, V21, P1712, DOI 10.1089/0897715042664849; Kline AE, 2007, BEHAV BRAIN RES, V177, P186, DOI 10.1016/j.bbr.2006.11.036; Kline AE, 2007, CRIT CARE MED, V35, P919, DOI 10.1097/01.CCM.0000256722.88854.C0; Kline AE, 2010, J NEUROTRAUM, V27, P2021, DOI 10.1089/neu.2010.1535; Kline AE, 2008, NEUROSCI LETT, V448, P263, DOI 10.1016/j.neulet.2008.10.076; Koen Nastassja, 2011, Dialogues Clin Neurosci, V13, P423; Kokiko ON, 2007, BRAIN INJURY, V21, P259, DOI 10.1080/02699050701209964; KREISS DS, 1992, NEUROPHARMACOLOGY, V31, P1073, DOI 10.1016/0028-3908(92)90110-B; Luttgen M, 2005, NEUROPHARMACOLOGY, V48, P830, DOI 10.1016/j.neuropharm.2005.01.007; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; Matter AM, 2011, NEUROREHAB NEURAL RE, V25, P558, DOI 10.1177/1545968310397206; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; MCMILLEN BA, 1983, J NEUROSCI, V3, P733; Meneses A, 1999, NEUROSCI BIOBEHAV R, V23, P1111, DOI 10.1016/S0149-7634(99)00067-6; Meneses A, 2007, BEHAV BRAIN RES, V184, P81, DOI 10.1016/j.bbr.2007.06.026; Meneses A, 2007, NEUROSCI BIOBEHAV R, V31, P705, DOI 10.1016/j.neubiorev.2007.02.001; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Parton A, 2005, CURR OPIN NEUROL, V18, P675, DOI 10.1097/01.wco.0000189872.54245.13; PREHN JHM, 1993, BRAIN RES, V630, P10, DOI 10.1016/0006-8993(93)90636-2; PREHN JHM, 1991, EUR J PHARMACOL, V203, P213, DOI 10.1016/0014-2999(91)90717-5; Sakaue M, 2000, BRIT J PHARMACOL, V129, P1028, DOI 10.1038/sj.bjp.0703139; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Semkova I, 1998, EUR J PHARMACOL, V359, P251, DOI 10.1016/S0014-2999(98)00634-7; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Sozda CN, 2010, J NEUROTRAUM, V27, P1047, DOI 10.1089/neu.2010.1313; Summers CR, 2009, MT SINAI J MED, V76, P105, DOI 10.1002/msj.20100; SUTTON RL, 1992, RESTOR NEUROL NEUROS, V4, P1, DOI 10.3233/RNN-1992-4101; Temple MD, 1996, BRAIN RES, V741, P246, DOI 10.1016/S0006-8993(96)00940-7; Verbois SL, 2003, NEUROSCIENCE, V119, P1199, DOI 10.1016/S0306-4522(03)00206-9; Wang YG, 2011, J NEUROTRAUM, V28, P259, DOI 10.1089/neu.2010.1648; Wheaton P, 2009, J CLIN PSYCHOPHARM, V29, P468, DOI 10.1097/JCP.0b013e3181b66f04; Wilson MS, 2003, AM J PHYS MED REHAB, V82, P871, DOI 10.1097/01.PHM.0000091982.33232.CB; Wilson MS, 2002, AM J PHYS MED REHAB, V81, P364, DOI 10.1097/00002060-200205000-00009	63	34	36	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2012	29	10					1898	1907		10.1089/neu.2012.2358			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	971YV	WOS:000306244400394	22416854	Green Published			2021-06-18	
J	Elbogen, EB; Johnson, SC; Wagner, HR; Newton, VM; Beckham, JC				Elbogen, Eric B.; Johnson, Sally C.; Wagner, H. Ryan; Newton, Virginia M.; Beckham, Jean C.			Financial Well-Being and Postdeployment Adjustment Among Iraq and Afghanistan War Veterans	MILITARY MEDICINE			English	Article							MENTAL-HEALTH; MILITARY VETERANS; EMPLOYMENT; DISORDERS; BARRIERS; VALIDITY; VIOLENCE; QUALITY; SCALE; MONEY	Research has yet to examine the relationship between financial well-being and community reintegration of veterans. To address this, we analyzed data from n = 1,388 Iraq and Afghanistan War Era Veterans who completed a national survey on postdeployment adjustment. The results indicated that probable major depressive disorder, post-traumatic stress disorder, and traumatic brain injury were associated with financial difficulties. However, regardless of diagnosis, veterans who reported having money to cover basic needs were significantly less likely to have postdeployment adjustment problems such as criminal arrest, homelessness, substance abuse, suicidal behavior, and aggression. Statistical analyses also indicated that poor money management (e.g., incurring significant debt or writing bad checks) was related to maladjustment, even among veterans at higher income levels. Given these findings, efforts;timed at enhancing financial literacy and promoting meaningful employment may have promise to enhance outcomes and improve quality of life among returning veterans.	[Elbogen, Eric B.; Johnson, Sally C.; Newton, Virginia M.] Univ N Carolina, Forens Psychiat Program & Clin, Dept Psychiat, Sch Med, Chapel Hill, NC 27517 USA; [Elbogen, Eric B.; Beckham, Jean C.] Durham VA Med Ctr, VISN Mental Illness Res Educ & Clin Ctr MIRECC 6, Durham, NC 27705 USA; [Wagner, H. Ryan; Beckham, Jean C.] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC 27710 USA	Elbogen, EB (corresponding author), Univ N Carolina, Forens Psychiat Program & Clin, Dept Psychiat, Sch Med, 2218 Nelson Highway, Chapel Hill, NC 27517 USA.				Mid-Atlantic Mental Illness Research, Education and Clinical Center; Office of Research and Development Clinical Science, Department of Veterans AffairsUS Department of Veterans Affairs; National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH080988]; Department of Education, National Institute on Disability and Rehabilitation Research [H133G100145]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH080988] Funding Source: NIH RePORTER	Preparation of this manuscript was supported by the Mid-Atlantic Mental Illness Research, Education and Clinical Center, the Office of Research and Development Clinical Science, Department of Veterans Affairs, the National Institute of Mental Health (R01MH080988), and the Department of Education, National Institute on Disability and Rehabilitation Research (H133G100145).	Agresti A., 1996, INTRO CATEGORICAL DA; Allen SF, 2010, COMMIMITY WORK FAM, V13, P89, DOI 10.1080/13668800903101581; Beckham JC, 2008, MIL MED, V173, P448, DOI 10.7205/MILMED.173.5.448; Black RA, 2008, J NERV MENT DIS, V196, P576, DOI 10.1097/NMD.0b013e31817d0535; Bradley KA, 1998, J GEN INTERN MED, V13, P379, DOI 10.1046/j.1525-1497.1998.00118.x; Commission of Financial Literacy and Education, 2011, COMM FIN LIT ED PROM; Cook JA, 2006, PSYCHIAT SERV, V57, P1391, DOI 10.1176/appi.ps.57.10.1391; Copeland LA, 2009, AM J PUBLIC HEALTH, V99, P871, DOI 10.2105/AJPH.2008.149989; Davidson JRT, 1997, PSYCHOL MED, V27, P153, DOI 10.1017/S0033291796004229; Defense Manpower Data Center, 2010, FY2009 ANN DEM PROF; Dillman D.A., 2009, INTERNET MAIL MIXED; Elbogen EB, 2011, PSYCHIATR REHABIL J, V34, P223, DOI 10.2975/34.3.2011.223.231; FERRANS CE, 1992, RES NURS HEALTH, V15, P29, DOI 10.1002/nur.4770150106; Greenberg GA, 2008, PSYCHIAT SERV, V59, P170, DOI 10.1176/ps.2008.59.2.170; HAMILTON M, 1967, BRIT J SOC CLIN PSYC, V6, P278; Hill RP, 2007, J CONSUM AFF, V41, P29, DOI 10.1111/j.1745-6606.2006.00067.x; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Institute of Medicine, 2010, RET HOM IR AFGH PREL; Iversen A, 2005, EUR J PUBLIC HEALTH, V15, P175, DOI 10.1093/eurpub/cki128; Jenkins R, 2008, PSYCHOL MED, V38, P1485, DOI 10.1017/S0033291707002516; Kertesz SG, 2009, JAMA-J AM MED ASSOC, V301, P1771; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; LEHMAN AF, 1983, ARCH GEN PSYCHIAT, V40, P369; Marmot M, 2001, NEW ENGL J MED, V345, P134, DOI 10.1056/NEJM200107123450210; Marson DC, 2006, SCHIZOPHRENIA BULL, V32, P81, DOI 10.1093/schbul/sbj027; McDonald SD, 2009, J ANXIETY DISORD, V23, P247, DOI 10.1016/j.janxdis.2008.07.007; McFarlane AC, 2009, CURR OPIN PSYCHIATR, V22, P369, DOI 10.1097/YCO.0b013e32832c9064; Pang MF, 2010, INSTR SCI, V38, P659, DOI 10.1007/s11251-009-9094-9; Penk W, 2009, PSYCHIATR REHABIL J, V33, P297, DOI 10.2975/33.4.2010.297.307; PORTER NM, 1992, AM BEHAV SCI, V35, P820, DOI 10.1177/0002764292035006016; Riddle MS, 2008, COMPR PSYCHIAT, V49, P340, DOI 10.1016/j.comppsych.2007.07.007; ROSENHECK R, 1994, AM J PUBLIC HEALTH, V84, P466, DOI 10.2105/AJPH.84.3.466; Rosenheck RA, 2007, PSYCHIAT SERV, V58, P325, DOI 10.1176/appi.ps.58.3.325; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Sayers SL, 2009, J CLIN PSYCHIAT, V70, P163, DOI 10.4088/JCP.07m03863; Siegel CE, 2006, PSYCHIAT SERV, V57, P982, DOI 10.1176/appi.ps.57.7.982; SKINNER HA, 1982, ADDICT BEHAV, V7, P363, DOI 10.1016/0306-4603(82)90005-3; Steadman HJ, 2000, LAW HUMAN BEHAV, V24, P83, DOI 10.1023/A:1005478820425; STRAUS MA, 1979, J MARRIAGE FAM, V41, P75, DOI 10.2307/351733; Strumpel B., 1976, EC MEANS HUMAN NEEDS; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Zivin K, 2011, PSYCHIAT SERV, V62, P35, DOI 10.1176/ps.62.1.pss6201_0035; Zoroya G, 2012, US TODAY        0801	43	34	34	0	30	ASSOC MILITARY SURG US	BETHESDA	9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA	0026-4075			MIL MED	Milit. Med.	JUN	2012	177	6					669	675		10.7205/MILMED-D-11-00388			7	Medicine, General & Internal	General & Internal Medicine	955QP	WOS:000305036300009	22730842	Bronze, Green Accepted			2021-06-18	
J	Magnoni, S; Tedesco, C; Carbonara, M; Pluderi, M; Colombo, A; Stocchetti, N				Magnoni, Sandra; Tedesco, Cecilia; Carbonara, Marco; Pluderi, Mauro; Colombo, Angelo; Stocchetti, Nino			Relationship between systemic glucose and cerebral glucose is preserved in patients with severe traumatic brain injury, but glucose delivery to the brain may become limited when oxidative metabolism is impaired: Implications for glycemic control	CRITICAL CARE MEDICINE			English	Article						brain injury; brain ischemia; glucose; glucose transport; microdialysis; neurochemistry	SUBCUTANEOUS ADIPOSE-TISSUE; LACTATE/PYRUVATE RATIO; COMBINED MICRODIALYSIS; SUBSTRATE DELIVERY; ENERGY-METABOLISM; HEAD-INJURY; BLOOD-FLOW; ISCHEMIA; TRANSPORT; LACTATE	Objective: To clarify the dynamics of glucose delivery to the brain and the effects of changes in blood glucose after severe traumatic brain injury. Design: Retrospective analysis of a prospective observational cohort study. Setting: Neurosurgical intensive care unit of a university hospital. Patients: Seventeen patients with acute traumatic brain injury monitored with cerebral and subcutaneous microdialysis. Interventions: None. Measurements and Main Results: For continuous, accurate systemic monitoring, glucose was measured in the interstitial space of subcutaneous adipose tissue using microdialysis, and 39 specific episodes of spontaneous rises in glucose were identified. During these episodes, there was a significant positive linear relationship between systemic glucose levels and brain glucose concentrations measured by microdialysis (p < .0001). The basal lactate/pyruvate ratio, with a threshold of 25, was adopted to distinguish between disturbed and presumably preserved cerebral oxidative metabolism. Using normal vs. elevated lactate/pyruvate ratio as variable factor, the relationship between brain and systemic glucose during the episodes could be described by two significantly distinct parallel lines (p = .0001), which indicates a strong additive effect of subcutaneous glucose and lactate/pyruvate ratio in determining brain glucose. The line describing the relationship under disturbed metabolic conditions was lower than in presumably intact metabolic conditions, with a significant difference of 0.648 +/- 0.192 mM (p = .002). This let us to accurately predict that in this situation systemic glucose concentrations in the lower range of normality would result in critical brain glucose levels. Conclusions: The linear relationship between systemic and brain glucose in healthy subjects is preserved in traumatic brain-injured patients. As a consequence, in brain tissue where oxidative metabolism is disturbed, brain glucose concentrations might possibly drop below the critical threshold of 0.8 mM to 1.0 mM when there is a reduction in systemic glucose toward the lower limits of the "normal" range. (Crit Care Med 2012; 40:1785-1791)	[Magnoni, Sandra; Tedesco, Cecilia; Carbonara, Marco; Colombo, Angelo; Stocchetti, Nino] Univ Milan, Dept Anesthesia & Intens Care, Milan, Italy; [Pluderi, Mauro] Univ Milan, Dept Neurosurg, Milan, Italy; [Stocchetti, Nino] Univ Milan, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy	Magnoni, S (corresponding author), Univ Milan, Dept Anesthesia & Intens Care, Milan, Italy.	smagnoni@policlinico.mi.it	Carbonara, Marco/N-3793-2015; Stocchetti, Nino/O-7444-2017	Carbonara, Marco/0000-0002-1431-8322; Stocchetti, Nino/0000-0003-3250-6834; Pluderi, Mauro/0000-0002-2981-9277	Fondazione IRCCS Ca Granda-Ospedale Maggiore Policlinico, Milan, Italy	Supported, in part, by the departmental fund of the Fondazione IRCCS Ca Granda-Ospedale Maggiore Policlinico, Milan, Italy.	Belli A, 2008, ACTA NEUROCHIR, V150, P461, DOI 10.1007/s00701-008-1580-3; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BOLINDER J, 1993, LANCET, V342, P1080, DOI 10.1016/0140-6736(93)92063-Y; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Choi IY, 2001, J CEREBR BLOOD F MET, V21, P653, DOI 10.1097/00004647-200106000-00003; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; CRONE C, 1965, J PHYSIOL-LONDON, V181, P103, DOI 10.1113/jphysiol.1965.sp007748; Diaz-Parejo P, 2003, INTENS CARE MED, V29, P544, DOI 10.1007/s00134-003-1669-3; Finfer S, 2009, NEW ENGL J MED, V360, P1283, DOI 10.1056/NEJMoa0810625; Gruetter R, 1998, J NEUROCHEM, V70, P397; GRUETTER R, 1992, P NATL ACAD SCI USA, V89, P1109, DOI 10.1073/pnas.89.3.1109; Hillered L, 2006, CURR OPIN CRIT CARE, V12, P112, DOI 10.1097/01.ccx.0000216576.11439.df; Hlatky R, 2004, J NEUROTRAUM, V21, P894, DOI 10.1089/0897715041526195; Hutchinson PJ, 2002, J CEREBR BLOOD F MET, V22, P735, DOI 10.1097/00004647-200206000-00012; Hutchinson PJA, 1999, ACT NEUR S, V75, P57; Hutchinson PJA, 2000, ACT NEUR S, V76, P431; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; Lonjon M, 2001, NEUROSCI LETT, V304, P21, DOI 10.1016/S0304-3940(01)01739-6; Lourido J, 2002, SCAND J CLIN LAB INV, V62, P285, DOI 10.1080/003655102760145843; LUNDANDERSEN H, 1979, PHYSIOL REV, V59, P305; Marcoux J, 2008, CRIT CARE MED, V36, P2871, DOI 10.1097/CCM.0b013e318186a4a0; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Nielsen JK, 2005, DIABETES, V54, P1635, DOI 10.2337/diabetes.54.6.1635; Oddo M, 2008, CURR OPIN CLIN NUTR, V11, P134, DOI 10.1097/MCO.0b013e3282f37b43; Oddo M, 2008, CRIT CARE MED, V36, P3233, DOI 10.1097/CCM.0b013e31818f4026; Parkin MC, 2005, J CEREBR BLOOD F MET, V25, P402, DOI 10.1038/sj.jcbfm.9600051; Poca MA, 2006, J NEUROTRAUM, V23, P1510, DOI 10.1089/neu.2006.23.1510; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Schlenk F, 2008, INTENS CARE MED, V34, P1200, DOI 10.1007/s00134-008-1044-5; Sehba FA, 2006, NEUROL RES, V28, P381, DOI 10.1179/016164106X114991; Strong AJ, 2008, INTENS CARE MED, V34, P1169, DOI 10.1007/s00134-008-1045-4; Timofeev I, 2011, J NEUROTRAUM, V28, P849, DOI 10.1089/neu.2010.1656; Timofeev I, 2011, BRAIN, V134, P484, DOI 10.1093/brain/awq353; Ungerstedt U, 2004, CURR PHARM DESIGN, V10, P2145, DOI 10.2174/1381612043384105; Vannucci SJ, 1997, GLIA, V21, P2, DOI 10.1002/(SICI)1098-1136(199709)21:1<2::AID-GLIA2>3.0.CO;2-C; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vespa PM, 2007, CRIT CARE MED, V35, P1153, DOI 10.1097/01.CCM.0000259466.66310.4F; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; Zetterling M, 2011, J NEUROSURG, V115, P66, DOI 10.3171/2011.3.JNS10899	40	34	38	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	JUN	2012	40	6					1785	1791		10.1097/CCM.0b013e318246bd45			7	Critical Care Medicine	General & Internal Medicine	946EZ	WOS:000304335600013	22610183				2021-06-18	
J	Betz, J; Zhuo, JC; Roy, A; Shanmuganathan, K; Gullapalli, RP				Betz, Joshua; Zhuo, Jiachen; Roy, Anindya; Shanmuganathan, Kathirkamanthan; Gullapalli, Rao P.			Prognostic Value of Diffusion Tensor Imaging Parameters in Severe Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						diffusion tensor imaging; Glasgow Coma Scale; magnetic resonance imaging; prognosis; severe traumatic brain injury	WHITE-MATTER INJURY; AXONAL INJURY; HEAD-INJURY; CORPUS-CALLOSUM; UNITED-STATES; MILD; MODERATE; ADULTS; SCALE; ABNORMALITIES	Diffusion tensor imaging (DTI) has recently emerged as a useful tool for assessing traumatic brain injury (TBI). In this study, the prognostic value of the relationship between DTI measures and the clinical status of severe TBI patients, both at the time of magnetic resonance imaging (MRI), and their discharge to acute TBI rehabilitation, was assessed. Patients (n = 59) admitted to the trauma center with severe closed head injuries were retrospectively evaluated after approval from the institution's institutional review board, to determine the prognostic value of DTI measures. The relationship of DTI measures, including apparent diffusion coefficient (ADC), fractional anisotropy (FA), axial (lambda(parallel to)) and radial diffusivity (lambda(perpendicular to)) from the whole brain white matter, internal capsule, genu, splenium, and body of the corpus callosum, were compared with neurological status at MRI and at discharge to acute TBI rehabilitation. Whole brain white matter averages of ADC, lambda(parallel to), and lambda(perpendicular to), and their coefficient of variation (CV) were significantly correlated with the Glasgow Coma Scale (GCS) score on the day of MRI. The average lambda(parallel to) was significantly correlated with GCS scores on the day of MRI in all measured brain regions. Outcomes were associated with whole brain white matter averages of ADC and lambda(parallel to), and the CVs of FA, ADC, lambda(parallel to), and lambda(perpendicular to); and the averages and CVs of FA and lambda(parallel to) in all corpus callosum regions. The inclusion of regional and global DTI measures improved the accuracy of prognostic models, when adjusted for admission GCS score and age (p < 0.05). Whole brain white matter and regional DTI measures are sensitive markers of TBI, and correlate with neurological status both at MRI and discharge to rehabilitation. The addition of DTI measures adjusted for age, gender, and admission GCS score significantly improved prognostic models.	[Betz, Joshua; Zhuo, Jiachen; Shanmuganathan, Kathirkamanthan; Gullapalli, Rao P.] Univ Maryland, Sch Med, Dept Diagnost Radiol & Nucl Med, Baltimore, MD 21201 USA; [Betz, Joshua; Zhuo, Jiachen; Gullapalli, Rao P.] Univ Maryland, Sch Med, Magnet Resonance Res Ctr, Baltimore, MD 21201 USA; [Betz, Joshua; Roy, Anindya] Univ Maryland Baltimore Cty, Dept Math & Stat, Baltimore, MD 21228 USA	Gullapalli, RP (corresponding author), Univ Maryland, Sch Med, Dept Diagnost Radiol & Nucl Med, 22 S Greene St, Baltimore, MD 21201 USA.	rgullapalli@umm.edu	See, Kye Yak/A-5118-2011	Betz, Joshua/0000-0003-4488-9799	U.S. Army [W81XWH-08-1-0725]	The authors thank Brigitte Pocta for reviewing the manuscript. This work was partly supported by a grant from the U.S. Army (W81XWH-08-1-0725).	Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Avesani R., 2011, EUR J PHYS REHAB MED, P471; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Gabbe Belinda J, 2003, Emerg Med (Fremantle), V15, P353, DOI 10.1046/j.1442-2026.2003.00474.x; Gill MR, 2004, ANN EMERG MED, V43, P215, DOI 10.1016/S0196-0644(03)00814-X; Greenberg G, 2008, ARCH PHYS MED REHAB, V89, pS45, DOI 10.1016/j.apmr.2008.08.211; Haacke EM, 2010, J MAGN RESON IMAGING, V32, P516, DOI 10.1002/jmri.22259; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Kennedy MRT, 2009, J INT NEUROPSYCH SOC, V15, P130, DOI 10.1017/S1355617708090024; Kornbluth J, 2011, NEUROCRIT CARE, V14, P134, DOI 10.1007/s12028-010-9409-3; Kumar R, 2009, BRAIN INJURY, V23, P675, DOI 10.1080/02699050903014915; Kurca E, 2006, NEURORADIOLOGY, V48, P661, DOI 10.1007/s00234-006-0109-9; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Moppett IK, 2007, BRIT J ANAESTH, V99, P18, DOI 10.1093/bja/aem128; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Newcombe VFJ, 2007, BRIT J NEUROSURG, V21, P340, DOI 10.1080/02688690701400882; Papadakis NG, 2000, MAGN RESON IMAGING, V18, P671, DOI 10.1016/S0730-725X(00)00151-X; Perlbarg V, 2009, HUM BRAIN MAPP, V30, P3924, DOI 10.1002/hbm.20817; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Shanmuganathan K, 2004, AM J NEURORADIOL, V25, P539; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; SOSIN DM, 1989, JAMA-J AM MED ASSOC, V262, P2251, DOI 10.1001/jama.262.16.2251; Stocchetti N, 2004, J NEUROTRAUM, V21, P1131, DOI 10.1089/neu.2004.21.1131; Sugiyama K, 2009, J NEUROTRAUM, V26, P1879, DOI [10.1089/neu.2008.0839, 10.1089/neu.2008-0839]; Teasdale TW, 2005, BRAIN INJURY, V19, P1041, DOI 10.1080/02699050500110397; The Brain Trauma Foundation. The American Association of Neurological Surgeons, 2000, J Neurotrauma, V17, P563, DOI 10.1089/neu.2000.17.563; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Tollard E, 2009, CRIT CARE MED, V37, P1448, DOI 10.1097/CCM.0b013e31819cf050; Vaishnavi S, 2009, PSYCHOSOMATICS, V50, P198, DOI 10.1176/appi.psy.50.3.198; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Xu S, 2011, J NEUROTRAUM, V28, P2091, DOI 10.1089/neu.2010.1739; Zhuo JC, 2012, NEUROIMAGE, V59, P467, DOI 10.1016/j.neuroimage.2011.07.050	52	34	35	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2012	29	7					1292	1305		10.1089/neu.2011.2215			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	933TC	WOS:000303384600002	22364596				2021-06-18	
J	Turner, EL; Perel, P; Clayton, T; Edwards, P; Hernandez, AV; Roberts, I; Shakur, H; Steyerberg, EW				Turner, Elizabeth L.; Perel, Pablo; Clayton, Tim; Edwards, Phil; Hernandez, Adrian V.; Roberts, Ian; Shakur, Haleema; Steyerberg, Ewout W.		CRASH Trial Collaborators	Covariate adjustment increased power in randomized controlled trials: an example in traumatic brain injury	JOURNAL OF CLINICAL EPIDEMIOLOGY			English	Article						Covariate adjustment; Prognostic targeting; Strict selection; Relative sample size; Power in clinical trials; Traumatic brain injury	CLINICAL-TRIALS; STATISTICAL POWER; NEUROPROTECTIVE AGENTS; HEAD-INJURY; SIZE	Objective: We aimed to determine to what extent covariate adjustment could affect power in a randomized controlled trial (RCT) of a heterogeneous population with traumatic brain injury (TBI). Study Design and Setting: We analyzed 14-day mortality in 9,497 participants in the Corticosteroid Randomization After Significant Head Injury (CRASH) RCT of corticosteroid vs. placebo. Adjustment was made using logistic regression for baseline covariates of two validated risk models derived from external data (International Mission on Prognosis and Analysis of Clinical Trials in Traumatic Brain Injury [IMPACT]) and from the CRASH data. The relative sample size (RESS) measure, defined as the ratio of the sample size required by an adjusted analysis to attain the same power as the unadjusted reference analysis, was used to assess the impact of adjustment. Results: Corticosteroid was associated with higher mortality compared with placebo (odds ratio = 1.25, 95% confidence interval = 1.13-1.39). RESS of 0.79 and 0.73 were obtained by adjustment using the IMPACT and CRASH models, respectively, which, for example, implies an increase from 80% to 88% and 91% power, respectively. Conclusion: Moderate gains in power may be obtained using covariate adjustment from logistic regression in heterogeneous conditions such as TBI. Although analyses of RCTs might consider covariate adjustment to improve power, we caution against this approach in the planning of RCTs. (c) 2012 Elsevier Inc. All rights reserved.	[Turner, Elizabeth L.; Perel, Pablo; Clayton, Tim; Edwards, Phil; Roberts, Ian; Shakur, Haleema] Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London WC1E 7HT, England; [Hernandez, Adrian V.] Cleveland Clin, Lerner Res Inst, Dept Quantitat Hlth Sci, Hlth Outcomes & Clin Epidemiol Sect, Cleveland, OH 44195 USA; [Steyerberg, Ewout W.] Erasmus MC, Dept Publ Hlth, Ctr Med Decis Sci, Rotterdam, Netherlands	Turner, EL (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, Keppel St, London WC1E 7HT, England.	elizabeth.tumer@lshtm.ac.uk	Steyerberg, Ewout W/C-1509-2018; Gallardo, Angel Jesus Lacerda/AAZ-9478-2020	Steyerberg, Ewout W/0000-0002-7787-0122; Gallardo, Angel Jesus Lacerda/0000-0001-9171-2000; Hernandez, Adrian V./0000-0002-9999-4003; Edwards, Phil/0000-0003-4431-8822; Clayton, Tim/0000-0002-1266-3288; /0000-0002-2342-301X; Shakur-Still, Haleema/0000-0002-6511-109X	National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS-42691]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042691] Funding Source: NIH RePORTER	The authors wish to thank all CRASH collaborators for their involvement in the trial. Professor Chris Frost provided many helpful comments and advice on an earlier manuscript and the methods. Two reviewers provided helpful comments and references, which greatly improved the final version. Financial support (E.W.S.) was provided by National Institute of Health (NS-42691).	Aberegg Scott K, 2010, Crit Care, V14, pR77, DOI 10.1186/cc8990; Altman DG, 2001, BIOSTATISTICS CLIN T, P122; Austin PC, 2010, J CLIN EPIDEMIOL, V63, P142, DOI 10.1016/j.jclinepi.2009.06.002; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Davison A. C., 2006, CAMBRIDGE SERIES STA; Dickinson K, 2000, BMJ-BRIT MED J, V320, P1308, DOI 10.1136/bmj.320.7245.1308; Ford I, 2002, STAT MED, V21, P2899, DOI 10.1002/sim.1294; GAIL MH, 1984, BIOMETRIKA, V71, P431; Groenwold RHH, 2011, CONTEMP CLIN TRIALS, V32, P399, DOI 10.1016/j.cct.2010.12.011; Halpern SD, 2002, JAMA-J AM MED ASSOC, V288, P358, DOI 10.1001/jama.288.3.358; Hauck WW, 1998, CONTROL CLIN TRIALS, V19, P249, DOI 10.1016/S0197-2456(97)00147-5; Hernandez AV, 2006, J NEUROTRAUM, V23, P1295, DOI 10.1089/neu.2006.23.1295; Hernandez AV, 2004, J CLIN EPIDEMIOL, V57, P454, DOI 10.1016/j.jclinepi.2003.09.014; Maas AIR, 1999, NEUROSURGERY, V44, P1286, DOI 10.1097/00006123-199906000-00076; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Machado SG, 1999, J NEUROTRAUM, V16, P1131, DOI 10.1089/neu.1999.16.1131; Marmarou A, 2007, J NEUROTRAUM, V24, P232; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Pocock S., 1984, CLIN TRIALS PRACTICA; ROBINSON LD, 1991, INT STAT REV, V59, P227, DOI 10.2307/1403444; Roozenbeek B, 2010, CRIT CARE, V14, DOI 10.1186/cc9021; Roozenbeek B, 2009, CRIT CARE MED, V37, P2683, DOI 10.1097/CCM.0b013e3181ab85ec; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Steyerberg ETW, 2004, MED DECIS MAKING, V24, P102, DOI 10.1177/0272989X03262285; Steyerberg EW, 2000, AM HEART J, V139, P745, DOI 10.1016/S0002-8703(00)90001-2; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Weir CJ, 2004, STROKE, V35, P2111, DOI 10.1161/01.STR.0000136556.34438.b3; Zhang PG, 2010, COMMUN STAT-SIMUL C, V39, P1305, DOI 10.1080/03610918.2010.491170	29	34	34	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0895-4356	1878-5921		J CLIN EPIDEMIOL	J. Clin. Epidemiol.	MAY	2012	65	5					474	481		10.1016/j.jclinepi.2011.08.012			8	Health Care Sciences & Services; Public, Environmental & Occupational Health	Health Care Sciences & Services; Public, Environmental & Occupational Health	920ZJ	WOS:000302447500003	22169080	Green Accepted			2021-06-18	
J	Wu, JF; Stoica, BA; Dinizo, M; Pajoohesh-Ganji, A; Piao, CS; Faden, AI				Wu, Junfang; Stoica, Bogdan A.; Dinizo, Michael; Pajoohesh-Ganji, Ahdeah; Piao, Chunshu; Faden, Alan I.			Delayed cell cycle pathway modulation facilitates recovery after spinal cord injury	CELL CYCLE			English	Article						spinal cord injury; cyclin-dependent kinases; cell cycle pathway; flavopiridol; oligodendrocytes; myelination; astrocytes; inflammation; neuron	ADHESION MOLECULE L1; INFLAMMATORY RESPONSE; GLIAL SCAR; AXONAL REGENERATION; NEURONAL DEATH; CLOSE HOMOLOG; BRAIN; RAT; NG2; PROLIFERATION	Traumatic spinal cord injury (SCI) causes tissue loss and associated neurological dysfunction through mechanical damage and secondary biochemical and physiological responses. We have previously described the pathobiological role of cell cycle pathways following rat contusion SCI by examining the effects of early intrathecal cell cycle inhibitor treatment initiation or gene knockout on secondary injury. Here, we delineate changes in cell cycle pathway activation following SCI and examine the effects of delayed (24 h) systemic administration of flavopiridol, an inhibitor of major cyclindependent kinases (CDKs), on functional recovery and histopathology in a rat SCI contusion model. Immunoblot analysis demonstrated a marked upregulation of cell cycle-related proteins, including pRb, cyclin D1, CDK4, E2F1 and PCNA, at various time points following SCI, along with downregulation of the endogenous CDK inhibitor p27. Treatment with flavopiridol reduced induction of cell cycle proteins and increased p27 expression in the injured spinal cord. Functional recovery was significantly improved after SCI from day 7 through day 28. Treatment significantly reduced lesion volume and the number of Iba-1(+) microglia in the preserved tissue and increased the myelinated area of spared white matter as well as the number of CC1(+) oligodendrocytes. Furthermore, flavopiridol attenuated expression of Iba-1 and glactin-3, associated with microglial activation and astrocytic reactivity by reduction of GFAP, NG2 and CHL1 expression. Our current study supports the role of cell cycle activation in the pathophysiology of SCI and, by using a clinically relevant treatment model, provides further support for the therapeutic potential of cell cycle inhibitors in the treatment of human SCI.	[Wu, Junfang; Stoica, Bogdan A.; Dinizo, Michael; Piao, Chunshu; Faden, Alan I.] Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA; [Wu, Junfang; Stoica, Bogdan A.; Dinizo, Michael; Piao, Chunshu; Faden, Alan I.] Univ Maryland, Sch Med, Ctr Shock Trauma & Anesthesiol Res STAR, Baltimore, MD 21201 USA; [Pajoohesh-Ganji, Ahdeah] George Washington Univ, Sch Med, Dept Anat & Regenerat Biol, Washington, DC USA	Wu, JF (corresponding author), Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA.	jwu@anes.umm.edu	STOICA, BOGDAN/H-9782-2013	STOICA, BOGDAN/0000-0002-2501-6434; Pajoohesh-Ganji, Ahdeah/0000-0002-1542-029X	National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NIHNINDS-01, NS054221-03]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS054221] Funding Source: NIH RePORTER	Flavopiridol was provided by the NCI/Aventis. This work was supported by a National Institute of Health contract NIHNINDS-01 (NS054221-03).	Alonso G, 2005, GLIA, V49, P318, DOI 10.1002/glia.20121; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Beck KD, 2010, BRAIN, V133, P433, DOI 10.1093/brain/awp322; BRACKEN MB, 1993, J NEUROSURG, V79, P500, DOI 10.3171/jns.1993.79.4.0500; Butt AM, 2002, J NEUROCYTOL, V31, P551, DOI 10.1023/A:1025751900356; Byrnes KR, 2007, BRAIN, V130, P2977, DOI 10.1093/brain/awm179; Capello E, 1997, ANN NEUROL, V41, P797, DOI 10.1002/ana.410410616; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; Cernak I, 2005, CELL CYCLE, V4, P1286, DOI 10.4161/cc.4.9.1996; Dai Yun, 2004, Curr Oncol Rep, V6, P123, DOI 10.1007/s11912-004-0024-3; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; Di Giovanni S, 2003, ANN NEUROL, V53, P454, DOI 10.1002/ana.10472; Dumont RJ, 2001, CLIN NEUROPHARMACOL, V24, P254, DOI 10.1097/00002826-200109000-00002; Durand B, 1997, EMBO J, V16, P306, DOI 10.1093/emboj/16.2.306; FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175; GALE K, 1985, EXP NEUROL, V88, P123, DOI 10.1016/0014-4886(85)90118-9; Greene LA, 2004, CELL DEATH DIFFER, V11, P49, DOI 10.1038/sj.cdd.4401341; Grossman SD, 2001, EXP NEUROL, V168, P273, DOI 10.1006/exnr.2001.7628; Hagg T, 2006, J NEUROTRAUM, V23, P264, DOI 10.1089/neu.2006.23.263; Herwig S, 1997, EUR J BIOCHEM, V246, P581, DOI 10.1111/j.1432-1033.1997.t01-2-00581.x; Hilton GD, 2008, J CEREBR BLOOD F MET, V28, P1845, DOI 10.1038/jcbfm.2008.75; Jakovcevski I, 2007, J NEUROSCI, V27, P7222, DOI 10.1523/JNEUROSCI.0739-07.2007; Jones LL, 2003, J NEUROSCI, V23, P9276; Kabadi SV, 2012, J CEREBR BLOOD F MET, V32, P137, DOI 10.1038/jcbfm.2011.117; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Lytle JM, 2009, GLIA, V57, P270, DOI 10.1002/glia.20755; Lytle JM, 2006, J NEUROTRAUM, V23, P1726, DOI 10.1089/neu.2006.23.1726; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; Mason KA, 2004, INT J RADIAT ONCOL, V59, P1181, DOI 10.1016/j.ijrobp.2004.03.003; McTigue DM, 2006, J NEUROPATH EXP NEUR, V65, P406, DOI 10.1097/01.jnen.0000218447.32320.52; Morgenstern DA, 2002, PROG BRAIN RES, V137, P313; Nashmi R, 2001, NEUROSCIENCE, V104, P235, DOI 10.1016/S0306-4522(01)00009-4; Newcomb EW, 2004, CELL CYCLE, V3, P230; Nguyen MD, 2003, J NEUROSCI, V23, P2131; Park DS, 2000, J NEUROSCI, V20, P3104, DOI 10.1523/JNEUROSCI.20-09-03104.2000; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Saatman KE, 2010, NEUROTHERAPEUTICS, V7, P31, DOI 10.1016/j.nurt.2009.11.002; Sears RC, 2002, J BIOL CHEM, V277, P11617, DOI 10.1074/jbc.R100063200; Sekhon LHS, 2001, SPINE, V26, pS2, DOI 10.1097/00007632-200112151-00002; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Siman R, 2004, NEUROBIOL DIS, V16, P311, DOI 10.1016/j.nbd.2004.03.016; SIMAN R, 1984, P NATL ACAD SCI-BIOL, V81, P3572, DOI 10.1073/pnas.81.11.3572; Stegmuller J, 2002, J NEUROCYTOL, V31, P497, DOI 10.1023/A:1025743731306; Swanton C, 2004, LANCET ONCOL, V5, P27, DOI 10.1016/S1470-2045(03)01321-4; Tan AM, 2005, J ANAT, V207, P717, DOI 10.1111/j.1469-7580.2005.00452.x; Tator C H, 1996, J Spinal Cord Med, V19, P206; Tator CH, 2002, INJ PREV S4, V8, P33; Tian DS, 2007, BRAIN RES, V1135, P177, DOI 10.1016/j.brainres.2006.11.085; Tian DS, 2006, J NEUROSCI RES, V84, P1053, DOI 10.1002/jnr.20999; Tokumoto YM, 2002, DEV BIOL, V245, P224, DOI 10.1006/dbio.2002.0626; Trotter J, 2010, BRAIN RES REV, V63, P72, DOI 10.1016/j.brainresrev.2009.12.006; Wang W, 2008, J CLIN NEUROSCI, V15, P278, DOI 10.1016/j.jocn.2007.02.004; Wu D, 2005, J NEUROCYTOL, V34, P459, DOI 10.1007/s11068-006-8998-4; Wu JF, 2011, J NEUROSCI RES, V89, P628, DOI 10.1002/jnr.22598; Wu JF, 2011, NEUROTHERAPEUTICS, V8, P221, DOI 10.1007/s13311-011-0028-2; Wu JF, 2010, GLIA, V58, P410, DOI 10.1002/glia.20932; YAKOVLEV AG, 1994, MOL CHEM NEUROPATHOL, V23, P179, DOI 10.1007/BF02815410; Zai LJ, 2005, GLIA, V50, P247, DOI 10.1002/glia.20176; Zhu Z, 2007, GLIA, V55, P546, DOI 10.1002/glia.20476	59	34	35	0	9	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1538-4101	1551-4005		CELL CYCLE	Cell Cycle	MAY 1	2012	11	9					1782	1795		10.4161/cc.20153			14	Cell Biology	Cell Biology	935OL	WOS:000303528500020	22510563	Green Published, Bronze			2021-06-18	
J	Zhang, YL; Chopp, M; Mahmood, A; Meng, YL; Qu, CS; Xiong, Y				Zhang, Yanlu; Chopp, Michael; Mahmood, Asim; Meng, Yuling; Qu, Changsheng; Xiong, Ye			Impact of inhibition of erythropoietin treatment-mediated neurogenesis in the dentate gyrus of the hippocampus on restoration of spatial learning after traumatic brain injury	EXPERIMENTAL NEUROLOGY			English	Article						Astrocytes; Erythropoietin; Microglia; Neurogenesis; Spatial learning; Traumatic brain injury	CONTROLLED CORTICAL IMPACT; MARROW STROMAL CELLS; NEURAL STEM-CELLS; FUNCTIONAL RECOVERY; NEURONAL APOPTOSIS; CA3 REGION; ADULT-RAT; ENHANCES NEUROGENESIS; STRIATAL NEUROGENESIS; COGNITIVE RECOVERY	Our previous study demonstrates that delayed (initiated 24 h post injury) erythropoietin (EPO) therapy for traumatic brain injury (TBI) significantly improves spatial learning. In this study, we investigated the impact of inhibition of EPO treatment-mediated neurogenesis on spatial learning after experimental TBI. Young male Wistar rats (318 +/- 7 g) were subjected to unilateral controlled cortical impact injury. TBI rats received delayed EPO treatment (5000 U/kg in saline) administered intraperitoneally once daily at 1,2, and 3 days post injury and intracerebroventricular (icy) infusion of either a mitotic inhibitor cytosine-b-D-arabinofuranoside or vehicle (saline) for 14 days. Another 2 groups of TBI rats were treated intraperitoneally with saline and infused icy with either a mitotic inhibitor Ara-C or saline for 14 days. Animals receiving sham operation were infused icy with either Ara-C infusion or saline. Bromodeoxyuridine (BrdU) was administered to label dividing cells. Spatial learning was assessed using a modified Morris water maze test. Animals were sacrificed at 35 days after injury and brain sections stained for immunohistochemical analyses. As compared to the saline treatment, immunohistochemical analysis revealed that delayed EPO treatment significantly increased the number of BrdU-positive cells and new neurons co-stained with BrdU and NeuN (mature neuron marker) in the dentate gyrus in TBI rats. EPO treatment improved spatial learning after TBI. Ara-C infusion significantly abolished neurogenesis and spatial learning recovery after TBI and EPO treatment. Both EPO and Ara-C reduced the number of astrocytes and microglia/macrophages in the dentate gyrus after TBI. Our findings are highly suggestive for an important role of EPO-amplified dentate gyrus neurogenesis as one of the mechanisms underlying EPO therapeutic treatments after TBI, strongly indicating that strategies promoting endogenous neurogenesis may hold an important therapeutic potential for treatment of TBI. (C) 2012 Elsevier Inc. All rights reserved.	[Zhang, Yanlu; Mahmood, Asim; Meng, Yuling; Qu, Changsheng; Xiong, Ye] Henry Ford Hlth Syst, Dept Neurosurg, Detroit, MI 48202 USA; [Chopp, Michael] Henry Ford Hlth Syst, Dept Neurol, Detroit, MI 48202 USA; [Chopp, Michael] Oakland Univ, Dept Phys, Rochester, MI 48309 USA	Xiong, Y (corresponding author), Henry Ford Hosp, Dept Neurosurg, E&R Bldg,Room 3096,2799 W Grand Blvd, Detroit, MI 48202 USA.	yxiong1@hfhs.org		Xiong, Ye/0000-0001-9770-6031	NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [RO1 NS62002, PO1 NS023393]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 NS62002, PO1 NS023393]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS062002, P01NS023393] Funding Source: NIH RePORTER	Sources of financial support: NINDS grants RO1 NS62002 (Ye Xiong) and PO1 NS023393 (Michael Chopp).; The authors would like to thank Susan MacPhee-Gray for editorial assistance. This work was supported by NIH grants RO1 NS62002 (yx) and PO1 NS023393 (mc).	Ambrogini P, 2004, BRAIN RES, V1017, P21, DOI 10.1016/j.brainres.2004.05.039; Blaiss CA, 2011, J NEUROSCI, V31, P4906, DOI 10.1523/JNEUROSCI.5265-10.2011; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Castilla-Ortega E, 2011, REV NEUROSCIENCE, V22, P267, DOI 10.1515/RNS.2011.027; Celik M, 2002, P NATL ACAD SCI USA, V99, P2258, DOI 10.1073/pnas.042693799; Cerami A, 2001, SEMIN HEMATOL, V38, P33, DOI 10.1053/shem.2001.27484; Chen H Isaac, 2007, Curr Stem Cell Res Ther, V2, P13; Chen JL, 2005, J CEREBR BLOOD F MET, V25, P281, DOI 10.1038/sj.jcbfm.9600034; Choi SH, 2006, J NEUROSCI METH, V156, P182, DOI 10.1016/j.jneumeth.2006.03.002; Chopp M, 2008, ACTA NEUROCHIR SUPPL, V105, P79; Clausen F, 2005, NEUROSURGERY, V57, P154, DOI 10.1227/01.NEU.0000163412.07546.57; Cotena S, 2008, PANMINERVA MED, V50, P185; Dempsey RJ, 2003, J NEUROSURG, V98, P867, DOI 10.3171/jns.2003.98.4.0867; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Doetsch F, 1999, P NATL ACAD SCI USA, V96, P11619, DOI 10.1073/pnas.96.20.11619; Emery DL, 2005, J NEUROTRAUM, V22, P978, DOI 10.1089/neu.2005.22.978; Esposito MS, 2005, J NEUROSCI, V25, P10074, DOI 10.1523/JNEUROSCI.3114-05.2005; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Gage Fred H., 2010, Keio Journal of Medicine, V59, P79; Gean AD, 2010, NEUROIMAG CLIN N AM, V20, P527, DOI 10.1016/j.nic.2010.08.001; Grasso G, 2006, J NEUROSURG-SPINE, V4, P310, DOI 10.3171/spi.2006.4.4.310; Hastings NB, 1999, J COMP NEUROL, V413, P146, DOI 10.1002/(SICI)1096-9861(19991011)413:1<146::AID-CNE10>3.0.CO;2-B; Im SH, 2010, NEUROSCIENCE, V169, P259, DOI 10.1016/j.neuroscience.2010.04.038; Jain KK, 2008, DRUG DISCOV TODAY, V13, P1082, DOI 10.1016/j.drudis.2008.09.006; Sandoval CJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017689; Koros C, 2007, NEUROTOXICOLOGY, V28, P83, DOI 10.1016/j.neuro.2006.07.016; Laplagne DA, 2006, PLOS BIOL, V4, P2349, DOI 10.1371/journal.pbio.0040409; Leker RR, 2007, STROKE, V38, P153, DOI 10.1161/01.STR.0000252156.65953.a9; Li B, 2010, BRAIN RES, V1327, P91, DOI 10.1016/j.brainres.2010.02.030; Li CQ, 2008, BRAIN RES BULL, V77, P237, DOI 10.1016/j.brainresbull.2008.07.010; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Lu DY, 2001, J NEUROTRAUM, V18, P813, DOI 10.1089/089771501316919175; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Mahmood A, 2007, J NEUROSURG, V107, P392, DOI 10.3171/JNS-07/08/0392; Mahmood A, 2007, NEUROSURGERY, V60, P546, DOI 10.1227/01.NEU.0000255346.25959.99; Marin-Burgin A, 2012, BEHAV BRAIN RES, V227, P391, DOI 10.1016/j.bbr.2011.07.001; Marklund N., 2010, BRIT J PHARMACOL, V164, P1207; Meng YL, 2011, J NEUROSURG, V115, P550, DOI 10.3171/2011.3.JNS101721; Mongiat LA, 2011, EUR J NEUROSCI, V33, P1055, DOI 10.1111/j.1460-9568.2011.07603.x; Mongiat LA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005320; Ning RZ, 2011, BRAIN RES, V1384, P140, DOI 10.1016/j.brainres.2011.01.099; Noguchi Constance Tom, 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000860; Richardson RM, 2007, NEUROSURG CLIN N AM, V18, P169, DOI 10.1016/j.nec.2006.10.007; Richardson RM, 2010, J NEUROSURG, V112, P1125, DOI 10.3171/2009.4.JNS081087; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Schallert Timothy, 2006, NeuroRx, V3, P497, DOI 10.1016/j.nurx.2006.08.001; Schouten JW, 2004, J NEUROTRAUM, V21, P1501, DOI 10.1089/neu.2004.21.1501; Spiers HJ, 2007, NEUROSCIENCE, V149, P7, DOI 10.1016/j.neuroscience.2007.06.056; Stein SC, 2010, J NEUROTRAUM, V27, P1343, DOI 10.1089/neu.2009.1206; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; Sun D, 2007, EXP NEUROL, V204, P264, DOI 10.1016/j.expneurol.2006.11.005; Toni N, 2008, NAT NEUROSCI, V11, P901, DOI 10.1038/nn.2156; Velly L, 2010, PHARMACOL THERAPEUT, V128, P445, DOI 10.1016/j.pharmthera.2010.08.002; Villa P, 2003, J EXP MED, V198, P971, DOI 10.1084/jem.20021067; Wang L, 2004, STROKE, V35, P1732, DOI 10.1161/01.STR.0000132196.49028.a4; Xiong Y, 2011, J NEUROSURG, V114, P102, DOI 10.3171/2010.4.JNS10118; Xiong Y, 2011, J NEUROSURG, V114, P549, DOI 10.3171/2010.10.JNS10925; Xiong Y, 2009, EXPERT OPIN EMERG DR, V14, P67, DOI [10.1517/14728210902769601, 10.1517/14728210902769601 ]; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje; Yau SY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024263; Yoshikawa G, 2010, J NEUROSURG, V113, P835, DOI 10.3171/2010.2.JNS09989; Zhang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011016; Zhang RL, 2004, J CEREBR BLOOD F MET, V24, P441, DOI 10.1097/00004647-200404000-00009; Zhang RL, 2002, STROKE, V33, P2675, DOI 10.1161/01.STR.0000034399.95249.59; Zhang RL, 2004, J NEUROSCI, V24, P5810, DOI 10.1523/JNEUROSCI.1109-04.2004; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033; Zhao CM, 2006, J NEUROSCI, V26, P3, DOI 10.1523/JNEUROSCI.3648-05.2006; Zheng W, 2011, J NEUROTRAUMA	71	34	36	0	8	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	MAY	2012	235	1					336	344		10.1016/j.expneurol.2012.02.015			9	Neurosciences	Neurosciences & Neurology	934FZ	WOS:000303430400035	22414310	Green Accepted			2021-06-18	
J	Nawashiro, H; Wada, K; Nakai, K; Sato, S				Nawashiro, Hiroshi; Wada, Kojiro; Nakai, Kanji; Sato, Shunichi			Focal Increase in Cerebral Blood Flow After Treatment with Near-Infrared Light to the Forehead in a Patient in a Persistent Vegetative State	PHOTOMEDICINE AND LASER SURGERY			English	Article								Objective: This study aimed to quantify the cerebral blood flow (CBF) after bilateral, transcranial near-infrared light-emitting diode (LED) irradiation to the forehead in a patient in a persistent vegetative state following severe head injury. Background data: Positive behavioral improvement has been observed following transcranial near-infrared light therapy in humans with chronic traumatic brain injury and acute stroke. Methods: Single-photon emission computed tomography with N-isopropyl-[123I]p-iodoamphetamine (IMP-SPECT) was performed following a series of LED treatments. Results: IMP-SPECT showed unilateral, left anterior frontal lobe focal increase of 20%, compared to the pre-treatment value for regional CBF (rCBF) for this area, following 146 LED treatments over 73 days from an array of 23 x 850nm LEDs, 13mW each, held 5mm from the skin, 30 min per session, the power density 11.4mW/cm(2); the energy density 20.5 J/cm(2) at the skin. The patient showed some improvement in his neurological condition by moving his left arm/hand to reach the tracheostomy tube, post-LED therapy. Conclusions: Transcranial LED might increase rCBF with some improvement of neurological condition in severely head-injured patients. Further study is warranted.	[Nawashiro, Hiroshi; Wada, Kojiro] Natl Def Med Coll, Dept Neurosurg, Tokorozawa, Saitama 3598513, Japan; [Nakai, Kanji] Natl Def Med Coll, Dept Radiol, Tokorozawa, Saitama 3598513, Japan; [Sato, Shunichi] Natl Def Med Coll Res Inst, Div Biomed Informat Sci, Tokorozawa, Saitama, Japan	Nawashiro, H (corresponding author), Natl Def Med Coll, Dept Neurosurg, 3-2 Namiki, Tokorozawa, Saitama 3598513, Japan.	nawa1957@ndmc.ac.jp					Lampl Y, 2007, STROKE, V38, P1843, DOI 10.1161/STROKEAHA.106.478230; Naeser M.A., 2011, PHOTOMED LA IN PRESS; PODREKA I, 1989, STROKE, V20, P183, DOI 10.1161/01.STR.20.2.183; Schiffer F, 2009, BEHAV BRAIN FUNCT, V5, DOI 10.1186/1744-9081-5-46; Stemer Andrew B, 2010, Curr Cardiol Rep, V12, P29, DOI 10.1007/s11886-009-0071-3; Uozumi Y, 2010, LASER SURG MED, V42, P566, DOI 10.1002/lsm.20938; Zivin JA, 2009, STROKE, V40, P1359, DOI 10.1161/STROKEAHA.109.547547	7	34	35	1	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1549-5418	1557-8550		PHOTOMED LASER SURG	Photomed. Laser Surg.	APR	2012	30	4					231	233		10.1089/pho.2011.3044			3	Surgery	Surgery	925QN	WOS:000302776100007	22047598				2021-06-18	
J	Rockhill, CM; Jaffe, K; Zhou, C; Fan, MY; Katon, W; Fann, JR				Rockhill, Carol Mary; Jaffe, Kenneth; Zhou, Chuan; Fan, Ming-Yu; Katon, Wayne; Fann, Jesse R.			Health Care Costs Associated with Traumatic Brain Injury and Psychiatric Illness in Adults	JOURNAL OF NEUROTRAUMA			English	Article						cost; health care; psychiatry; traumatic brain injury	MEDICAL COSTS; IMPACT; POPULATION; DISORDERS; ADHERENCE; SYMPTOMS; CHILDREN; MODELS	A cohort design was used to determine the contribution of traumatic brain injury (TBI) and psychiatric illness to health care costs for adolescents and adults in the 3 years following mild or moderate-to-severe TBI compared to a matched cohort without TBI, controlling for confounders. In all, 3756 subjects 15 years or older from a large health maintenance organization database were examined. We identified subjects who sustained a TBI in 1993 (n = 939) and selected three control subjects per TBI-exposed subject (n = 2817), matched for age, sex, and enrollment at the time of injury. Unadjusted mean costs in 2009-adjusted dollars were compared using Kruskal-Wallis tests and Mann-Whitney U tests, and adjusted mean costs were compared using gamma regression analyses. Average costs were 76% higher in the 3 years after injury for the mild TBI group, and 5.75 times greater for the moderate-to-severe TBI group compared to controls. The presence of psychiatric illness was associated with more than doubling of total costs for both inpatient and outpatient non-mental health care. Gamma regression analyses confirmed significantly higher costs in patients with TBI or psychiatric illness. A significant interaction between moderate-to-severe TBI and psychiatric illness indicated a 3.39 times greater cost among patients with both exposures compared with those exposed to moderate-to-severe TBI without psychiatric illness. TBI and psychiatric illness were each associated with significant increases in health care costs; those with the combination of moderate-to-severe TBI and psychiatric illness had much higher costs than any other group.	[Rockhill, Carol Mary; Fan, Ming-Yu; Katon, Wayne; Fann, Jesse R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98115 USA; [Jaffe, Kenneth] Childrens Hosp & Med Ctr, Dept Rehabil Med, Seattle, WA 98105 USA; [Zhou, Chuan] Univ Washington, Dept Pediat, Seattle, WA 98115 USA	Rockhill, CM (corresponding author), Univ Washington, Dept Psychiat & Behav Sci, 1959 Pacific Ave NE,Box 359300 W3636, Seattle, WA 98115 USA.	rockhill@uw.edu	MUNOZ, ROSA ANA/H-3964-2018; Zhou, Chuan/AAJ-1935-2020	MUNOZ, ROSA ANA/0000-0002-7504-2163; 	National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia	This research was supported by a grant to the last author from the National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia. The funding organization's role was limited to review of the design of the study. We thank David Rubanowice, B.S., for his computer programming assistance, William Hollingsworth, Ph.D., for guidance regarding cost analyses, and Leighton Chan, M.D., M.P.H., for his expertise with Medicare and rehabilitation service payment policies.	American Medical Rehabilitation Providers Association (AMRPA), 2010, STAT FIELD; Appleton R., 2006, MANAGEMENT BRAIN INJ; Asche CV, 2010, CURR MED RES OPIN, V26, P1843, DOI 10.1185/03007995.2010.488037; Ashman TA, 2006, MT SINAI J MED, V73, P999; Blough DK, 1999, J HEALTH ECON, V18, P153, DOI 10.1016/S0167-6296(98)00032-0; Bombardier C., 2010, JAMA-J AM MED ASSOC, V301, P1938; Brouwer WBF, 2005, BRIT MED J, V331, P446, DOI 10.1136/bmj.331.7514.446; Centers for Disease Control and Prevention, 2010, NAT CTR INJ PREV CON; Ciechanowski PS, 2000, ARCH INTERN MED, V160, P3278, DOI 10.1001/archinte.160.21.3278; COOK RD, 1983, BIOMETRIKA, V70, P1, DOI 10.1093/biomet/70.1.1; Diehr P, 1999, ANNU REV PUBL HEALTH, V20, P125, DOI 10.1146/annurev.publhealth.20.1.125; Dobrez D, 2010, ARCH PHYS MED REHAB, V91, P184, DOI 10.1016/j.apmr.2009.10.020; Dobrez DG, 2004, ARCH PHYS MED REHAB, V85, P1909, DOI 10.1016/j.apmr.2004.06.064; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Gold M., 1996, Cost-Effectiveness in Health and Medicine.; Halpern R, 2011, J MANAGE CARE PHARM, V17, P25, DOI 10.18553/jmcp.2011.17.1.25; Hawthorne G, 2009, J NEUROTRAUM, V26, P1623, DOI [10.1089/neu.2008.0735, 10.1089/neu.2008-0735]; Hessen E, 2007, BRAIN INJURY, V21, P963, DOI 10.1080/02699050701528454; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Katon WJ, 2003, ARCH GEN PSYCHIAT, V60, P897, DOI 10.1001/archpsyc.60.9.897; Lofgren R, 2006, ACAD MED, V81, P713, DOI 10.1097/00001888-200608000-00007; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Manning WG, 2001, J HEALTH ECON, V20, P461, DOI 10.1016/S0167-6296(01)00086-8; Manning WG, 2005, J HEALTH ECON, V24, P465, DOI 10.1016/j.jhealeco.2004.09.011; Massagli TL, 2004, ARCH PHYS MED REHAB, V85, P1428, DOI 10.1016/j.apmr.2003.12.036; Medicare Payment Advisory Commission (MedPAC), 2010, INP REH FAC SERV ASS; National Center for Health Statistics, 1991, NAT CTR HLTH STAT PU; Nolan S, 2005, CRIT CARE NURS Q, V28, P188, DOI 10.1097/00002727-200504000-00010; Ortendahl M, 2002, J CLIN EPIDEMIOL, V55, P843, DOI 10.1016/S0895-4356(02)00447-X; Rockhill CM, 2010, BRAIN INJURY, V24, P1051, DOI 10.3109/02699052.2010.494586; Saunders KW, 1994, PHARMACOEPIDEM DR S, P171; Slomine BS, 2002, BRAIN INJURY, V16, P759, DOI 10.1080/02699050210127286; Smith M.S., 1994, MANAG CARE Q, V2, P21; Thurman DJ., 1995, GUIDELINES SURVEILLA; *US DEP LAB BUR LA, 2006, CONS PRIC IND; Walker EA, 2003, ARCH GEN PSYCHIAT, V60, P369, DOI 10.1001/archpsyc.60.4.369; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Warriner Erin M, 2006, Curr Psychiatry Rep, V8, P73, DOI 10.1007/s11920-006-0083-2; Weiner J P, 1992, HMO Pract, V6, P13	42	34	34	0	6	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	APR	2012	29	6					1038	1046		10.1089/neu.2010.1562			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	927ZL	WOS:000302949100002	22142264				2021-06-18	
J	Zhao, J; Pati, S; Redell, JB; Zhang, M; Moore, AN; Dash, PK				Zhao, Jing; Pati, Shibani; Redell, John B.; Zhang, Min; Moore, Anthony N.; Dash, Pramod K.			Caffeic Acid Phenethyl Ester Protects Blood-Brain Barrier Integrity and Reduces Contusion Volume in Rodent Models of Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						claudin-5; neurovascular function; reactive oxygen species; tight junction; vascular permeability	CONTROLLED CORTICAL IMPACT; FOCAL CEREBRAL-ISCHEMIA; CELL-DEATH MECHANISMS; COGNITIVE DEFICITS; ACUTE-INFLAMMATION; OXIDATIVE STRESS; CHLOROGENIC ACID; MEMORY DEFICITS; MOUSE-BRAIN; HEAD-INJURY	A number of studies have established a deleterious role for inflammatory molecules and reactive oxygen species (ROS) in the pathology of traumatic brain injury (TBI). Caffeic acid phenethyl ester (CAPE) has been shown to exert both antioxidant and anti-inflammatory effects. The primary objective of the present study was to examine if CAPE could be used to reduce some of the pathological consequences of TBI using rodent models. Male Sprague-Dawley rats and C57BL/6 mice were subjected to controlled cortical impact (CCI) injury. Blood-brain barrier (BBB) integrity was assessed by examining claudin-5 expression and the extravasation of Evans blue dye. The effect of post-injury CAPE administration on neurobehavioral function was assessed using vestibulomotor, motor, and two hippocampus-dependent learning and memory tasks. We report that post-TBI administration of CAPE reduces Evans blue extravasation both in rats and mice. This improvement was associated with preservation of the levels of the tight junction protein claudin-5. CAPE treatment did not improve performance in either vestibulomotor/motor function (tested using beam balance and foot-fault tests), or in learning and memory function (tested using the Morris water maze and associative fear memory tasks). However, animals treated with CAPE were found to have significantly less cortical tissue loss than vehicle-treated controls. These findings suggest that CAPE may provide benefit in the treatment of vascular compromise following central nervous system injury.	[Zhao, Jing; Redell, John B.; Zhang, Min; Moore, Anthony N.; Dash, Pramod K.] Univ Texas Med Sch Houston, Dept Neurobiol & Anat, Houston, TX 77225 USA; [Pati, Shibani] Univ Texas Med Sch Houston, Ctr Translat Injury Res, Houston, TX 77225 USA	Dash, PK (corresponding author), Univ Texas Med Sch Houston, Dept Neurobiol & Anat, POB 20708, Houston, TX 77225 USA.	p.dash@uth.tmc.edu		Dash, Pramod/0000-0001-6746-1002	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS049160]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049160] Funding Source: NIH RePORTER	The authors thank Cameron Jeter for her critical reading of the manuscript. The studies were made possible by funds from the NIH (NS049160).	Adelson PD, 1998, ACT NEUR S, V71, P104; Babikian T, 2010, DEV NEUROSCI-BASEL, V32, P431, DOI 10.1159/000320667; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Beauchamp K, 2008, MOL MED, V14, P731, DOI 10.2119/2008-00050.Beauchamp; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Celik S, 2008, MOL CELL BIOCHEM, V312, P39, DOI 10.1007/s11010-008-9719-3; CHAN WS, 1995, ANTICANCER RES, V15, P703; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Dash PK, 2004, J NEUROTRAUM, V21, P1573, DOI 10.1089/neu.2004.21.1573; Dash PK, 2002, NEUROSCIENCE, V114, P755, DOI 10.1016/S0306-4522(02)00277-4; DASH PK, 1995, J NEUROSCI, V15, P2030; Dewitt DS, 2003, J NEUROTRAUM, V20, P795, DOI 10.1089/089771503322385755; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Fan P, 2003, J NEUROTRAUM, V20, P437, DOI 10.1089/089771503765355513; Fedor M, 2010, J NEUROTRAUM, V27, P1605, DOI 10.1089/neu.2010.1370; FESEN MR, 1993, P NATL ACAD SCI USA, V90, P2399, DOI 10.1073/pnas.90.6.2399; Floyd CL, 2007, PROG BRAIN RES, V161, P61, DOI 10.1016/S0079-6123(06)61005-4; Giri BK, 2000, STROKE, V31, P961, DOI 10.1161/01.STR.31.4.961; Giza CC, 2002, J NEUROTRAUM, V19, P387, DOI 10.1089/08977150252932352; Golding EM, 1999, CLIN EXP HYPERTENS, V21, P299, DOI 10.3109/10641969909068668; Hall Edward D., 1993, Journal of Emergency Medicine, V11, P31; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAYES RL, 1994, SEMIN NEUROL, V14, P25, DOI 10.1055/s-2008-1041055; Hayes RL, 2009, METHODS MOL BIOL, V566, P303, DOI 10.1007/978-1-59745-562-6_20; Hicks RR, 2010, J TRAUMA, V68, P1257, DOI 10.1097/TA.0b013e3181d8956d; Hishikawa K, 2005, ARTERIOSCL THROM VAS, V25, P442, DOI 10.1161/01.ATV.0000148404.24271.fc; Honda M, 2006, CELL MOL NEUROBIOL, V26, P109, DOI 10.1007/s10571-006-9028-x; Huh Jimmy W, 2009, Anesthesiol Clin, V27, P213, DOI 10.1016/j.anclin.2009.05.006; Igarashi T, 2001, EXP NEUROL, V172, P332, DOI 10.1006/exnr.2001.7820; Ilhan A, 2004, FREE RADICAL BIO MED, V37, P386, DOI 10.1016/j.freeradbiomed.2004.04.022; Irmak MK, 2003, CELL BIOCHEM FUNCT, V21, P283, DOI 10.1002/cbf.1024; Kalonia Harikesh, 2009, Inflammopharmacology, V17, P211, DOI 10.1007/s10787-009-0012-1; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Khan M, 2007, J NEUROCHEM, V102, P365, DOI 10.1111/j.1471-4159.2007.04526.x; Khan M, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-32; Kochanek AR, 2006, DEV NEUROSCI-BASEL, V28, P410, DOI 10.1159/000094167; KOLB B, 1983, BEHAV NEUROSCI, V97, P13, DOI 10.1037/0735-7044.97.1.13; Kono Y, 1997, BBA-GEN SUBJECTS, V1335, P335, DOI 10.1016/S0304-4165(96)00151-1; KOSHIHARA Y, 1984, BIOCHIM BIOPHYS ACTA, V792, P92; Liao HF, 2003, J AGR FOOD CHEM, V51, P7907, DOI 10.1021/jf034729d; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Lotocki G, 2009, J NEUROTRAUM, V26, P1123, DOI 10.1089/neu.2008.0802; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Margulies S, 2009, J NEUROTRAUM, V26, P925, DOI [10.1089/neu.2008.0794, 10.1089/neu.2008-0794]; Meaney DF, 2011, CLIN SPORT MED, V30, P19, DOI 10.1016/j.csm.2010.08.009; Mechoulam R, 2007, MOL NEUROBIOL, V36, P68, DOI 10.1007/s12035-007-8008-6; Michaluart P, 1999, CANCER RES, V59, P2347; Mirzoeva OK, 1996, PROSTAG LEUKOTR ESS, V55, P441, DOI 10.1016/S0952-3278(96)90129-5; Natarajan K, 1996, P NATL ACAD SCI USA, V93, P9090, DOI 10.1073/pnas.93.17.9090; Orban Z, 2000, NEUROIMMUNOMODULAT, V7, P99, DOI 10.1159/000026427; Orsoilc N, 2005, BIOL PHARM BULL, V28, P1928, DOI 10.1248/bpb.28.1928; Ottens AK, 2010, J NEUROTRAUM, V27, P1837, DOI 10.1089/neu.2010.1374; Park EH, 1999, ARCH PHARM RES, V22, P554, DOI 10.1007/BF02975325; Phillips LL, 2001, RESTOR NEUROL NEUROS, V19, P213; Povlishock J T, 1992, Hum Cell, V5, P345; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Ray SK, 2002, HISTOL HISTOPATHOL, V17, P1137, DOI 10.14670/HH-17.1137; Reeves TM, 2000, J NEUROSCI RES, V60, P370, DOI 10.1002/(SICI)1097-4547(20000501)60:3<370::AID-JNR12>3.3.CO;2-2; Royo NC, 2007, NEUROSCIENCE, V148, P359, DOI 10.1016/j.neuroscience.2007.06.014; Saatman KE, 2010, NEUROTHERAPEUTICS, V7, P31, DOI 10.1016/j.nurt.2009.11.002; Sayeed I, 2009, PROG BRAIN RES, V175, P219, DOI 10.1016/S0079-6123(09)17515-5; Shear DA, 2010, J NEUROTRAUM, V27, P1911, DOI 10.1089/neu.2010.1399; Shellington DK, 2011, CRIT CARE MED, V39, P494, DOI 10.1097/CCM.0b013e318206b1fa; Smith C.M., 2010, NEUROBIOL DIS; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; SONDHEIMER E, 1958, ARCH BIOCHEM BIOPHYS, V74, P131, DOI 10.1016/0003-9861(58)90207-8; Stewart LR, 2001, J NEUROSCI RES, V65, P565, DOI 10.1002/jnr.1186; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; SUDINA GF, 1993, FEBS LETT, V329, P21, DOI 10.1016/0014-5793(93)80184-V; Sullivan PG, 2011, J NEUROTRAUM, V28, P311, DOI 10.1089/neu.2010.1646; Uz T, 1998, FASEB J, V12, P439; Vink R, 2010, NEUROTHERAPEUTICS, V7, P1, DOI 10.1016/j.nurt.2009.12.001; Wei X, 2004, BRAIN, V127, P2629, DOI 10.1093/brain/awh316; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Whalen MJ, 1998, ACT NEUR S, V71, P212; Yakovlev AG, 2001, MOL NEUROBIOL, V24, P131; Yang JQ, 2008, CNS NEUROSCI THER, V14, P10, DOI 10.1111/j.1527-3458.2007.00031.x; Zhang L, 2007, LIFE SCI, V80, P530, DOI 10.1016/j.lfs.2006.09.039; Zhao J, 2007, J NEUROSCI, V27, P10240, DOI 10.1523/JNEUROSCI.1683-07.2007; Zhou Y, 2006, ACTA PHARMACOL SIN, V27, P1103, DOI 10.1111/j.1745-7254.2006.00406.x	84	34	36	1	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2012	29	6					1209	1218		10.1089/neu.2011.1858			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	927ZL	WOS:000302949100021	22150135	Green Published			2021-06-18	
J	Mota, BC; Pereira, L; Souza, MA; Silva, LFA; Magni, DV; Ferreira, APO; Oliveira, MS; Furian, AF; Mazzardo-Martins, L; da Silva, MD; Santos, ARS; Ferreira, J; Fighera, MR; Royes, LFF				Mota, Bibiana Castagna; Pereira, Leticia; Souza, Mauren Assis; Almeida Silva, Luiz Fernando; Magni, Danieli Valnes; Oliveira Ferreira, Ana Paula; Oliveira, Mauro Schneider; Furian, Ana Flavia; Mazzardo-Martins, Leidiane; da Silva, Morgana Duarte; Soares Santos, Adair Roberto; Ferreira, Juliano; Fighera, Michele Rechia; Freire Royes, Luiz Fernando			Exercise Pre-conditioning Reduces Brain Inflammation and Protects against Toxicity Induced by Traumatic Brain Injury: Behavioral and Neurochemical Approach	NEUROTOXICITY RESEARCH			English	Article						Traumatic brain injury; Physical exercise; Inflammation; Na+K+-ATPase	NA+,K+-ATPASE ACTIVITY; HEAD-INJURY; PHYSICAL-ACTIVITY; RAT HIPPOCAMPUS; TNF-ALPHA; MICE; BARRIER; IL-6; EDEMA; INHIBITION	Although the favorable effects of physical exercise in neurorehabilitation after traumatic brain injury (TBI) are well known, detailed pathologic and functional alterations exerted by previous physical exercise on post-traumatic cerebral inflammation have been limited. In the present study, it is showed that fluid percussion brain injury (FPI) induced motor function impairment, followed by increased plasma fluorescein extravasation and cerebral-inflammation characterized by interleukin-1 beta, tumor necrosis factor-alpha (TNF-alpha) increase, and decreased IL-10. In addition, myeloperoxidase (MPO) increase and Na+,K+-ATPase activity inhibition after FPI suggest that the opening of blood-brain barrier (BBB) followed by neurtrophils infiltration and cerebral inflammation may contribute to the failure of selected targets leading to secondary damage. In fact, Pearson's correlation analysis revealed strong correlation of MPO activity increase with Na+,K+-ATPase activity inhibition in sedentary rats. Statistical analysis also revealed that previous running exercise (4 weeks) protected against FPI-induced motor function impairment and fluorescein extravasation. Previous physical training also induced IL-10 increase per se and protected against cerebral IL-1 beta, and TNF-alpha increase and IL-10 decrease induced by FPI. This protocol of physical training was effective against MPO activity increase and Na+,K+-ATPase activity inhibition after FPI. The present protection correlated with MPO activity decrease suggests that the alteration of cerebral inflammatory status profile elicited by previous physical training reduces initial damage and limits long-term secondary degeneration after TBI. This prophylactic effect may facilitate functional recovery in patients suffering from brain injury induced by TBI.	[Mota, Bibiana Castagna; Pereira, Leticia; Souza, Mauren Assis; Almeida Silva, Luiz Fernando; Oliveira Ferreira, Ana Paula; Freire Royes, Luiz Fernando] Univ Fed Santa Maria, Lab Bioquim Exercicio, Dept Metodos & Tecn Desport, Ctr Educ Fis & Desportos, BR-97105900 Santa Maria, RS, Brazil; [Souza, Mauren Assis; Almeida Silva, Luiz Fernando; Magni, Danieli Valnes; Oliveira Ferreira, Ana Paula; Oliveira, Mauro Schneider; Ferreira, Juliano; Fighera, Michele Rechia; Freire Royes, Luiz Fernando] Univ Fed Santa Maria, Programa Posgrad Ciencias Biol Bioquim Toxicol, BR-97105900 Santa Maria, RS, Brazil; [Oliveira, Mauro Schneider; Furian, Ana Flavia] Univ Fed Pampa, BR-97650000 Itaqui, RS, Brazil; [Fighera, Michele Rechia] PUC RS, Hosp Sao Lucas, Serv Neurol, Inst Cerebro, Porto Alegre, RS, Brazil; [Mazzardo-Martins, Leidiane; da Silva, Morgana Duarte; Soares Santos, Adair Roberto] Univ Fed Santa Catarina, Dept Ciencias Fisiol, Ctr Ciencias Biol, Florianopolis, SC, Brazil	Royes, LFF (corresponding author), Univ Fed Santa Maria, Lab Bioquim Exercicio, Dept Metodos & Tecn Desport, Ctr Educ Fis & Desportos, BR-97105900 Santa Maria, RS, Brazil.	nandoroyes@yahoo.com.br	da Silva, Morgana D/D-4942-2015; Fighera, Michele R/J-9576-2014; Ferreira, Juliano/A-9803-2013; Oliveira, Mauro Schneider/G-3437-2012; Souza, Mauren/A-7990-2015; Santos, Adair/C-5565-2013	da Silva, Morgana D/0000-0002-2487-236X; Ferreira, Juliano/0000-0002-9562-0602; Oliveira, Mauro Schneider/0000-0002-5381-1208; Santos, Adair/0000-0002-6435-4698; Almeida Silva, Luiz Fernando/0000-0002-7621-4836			Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; Ang ET, 2007, CURR MED CHEM, V14, P2564, DOI 10.2174/092986707782023280; Arida RM, 2007, PHYSIOL BEHAV, V90, P629, DOI 10.1016/j.physbeh.2006.11.016; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Black PH, 2003, BRAIN BEHAV IMMUN, V17, P350, DOI 10.1016/S0889-1591(03)00048-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cederberg D, 2010, CHILD NERV SYST, V26, P221, DOI 10.1007/s00381-009-1029-x; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; Chow JW, 2010, BRAIN INJURY, V24, P1575, DOI 10.3109/02699052.2010.523053; Costa T, 2010, J NEUROSCI RES, V88, P1329, DOI 10.1002/jnr.22300; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; D'Ambrosio R, 1999, J NEUROSCI, V19, P8152; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; Ding YH, 2006, CURR NEUROVASC RES, V3, P263, DOI 10.2174/156720206778792911; DISHMAN RK, 1988, PHYSIOL BEHAV, V43, P541, DOI 10.1016/0031-9384(88)90206-5; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Endres M, 2003, ANN NEUROL, V54, P582, DOI 10.1002/ana.10722; Erickson KI, 2007, NEUROBIOL AGING, V28, P179, DOI 10.1016/j.neurobiolaging.2005.11.016; FAN L, 1995, MOL BRAIN RES, V30, P125; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Funk JA, 2011, BRAIN BEHAV IMMUN, V25, P1063, DOI 10.1016/j.bbi.2011.03.012; Gobatto CA, 2001, COMP BIOCHEM PHYS A, V130, P21, DOI 10.1016/S1095-6433(01)00362-2; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; HAMM TM, 1990, J NEUROPHYSIOL, V63, P395; HAMMACHER A, 1994, PROTEIN SCI, V3, P2280, DOI 10.1002/pro.5560031213; Ivashkova Y, 2006, J TRAUMA, V61, P879, DOI 10.1097/01.ta.0000234722.98537.01; Jamme I, 1995, NEUROREPORT, V7, P333; Jang SH, 2009, NEUROREHABILITATION, V24, P349, DOI 10.3233/NRE-2009-0489; Juliet PAR, 2008, BRAIN RES, V1210, P230, DOI 10.1016/j.brainres.2008.02.099; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; LEES GJ, 1990, NEUROSCI LETT, V120, P159, DOI 10.1016/0304-3940(90)90027-7; Lenz A, 2007, INJURY, V38, P1336, DOI 10.1016/j.injury.2007.10.003; Lenzlinger PM, 2004, RESTOR NEUROL NEUROS, V22, P73; Li S, 2001, NEUROSCIENCE, V107, P675, DOI 10.1016/S0306-4522(01)00385-2; Lima FD, 2008, BEHAV BRAIN RES, V193, P306, DOI 10.1016/j.bbr.2008.05.013; Lima FD, 2009, BRAIN RES, V1279, P147, DOI 10.1016/j.brainres.2009.04.052; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Marklund N, 2009, NEUROSCIENCE, V163, P540, DOI 10.1016/j.neuroscience.2009.06.042; Marquezi ML, 2003, INT J SPORT NUTR EXE, V13, P65, DOI 10.1123/ijsnem.13.1.65; MATHEW P, 1994, ACTA NEUROCHIR, P428; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Meisel C, 2005, NAT REV NEUROSCI, V6, P775, DOI 10.1038/nrn1765; Nichol KE, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-13; Nimmo AJ, 2004, NEUROPEPTIDES, V38, P40, DOI 10.1016/j.npep.2003.12.003; Oliveira MS, 2009, J NEUROCHEM, V109, P416, DOI 10.1111/j.1471-4159.2009.05961.x; Olsen AL, 2007, ANTIVIR RES, V75, P104, DOI 10.1016/j.antiviral.2006.11.013; Parachikova A, 2008, NEUROBIOL DIS, V30, P121, DOI 10.1016/j.nbd.2007.12.008; Petersen AMW, 2005, J APPL PHYSIOL, V98, P1154, DOI 10.1152/japplphysiol.00164.2004; Potts Mathew B, 2006, NeuroRx, V3, P143; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; SKOU JC, 1992, J BIOENERG BIOMEMBR, V24, P249; Stahel PF, 2000, J NEUROIMMUNOL, V109, P164, DOI 10.1016/S0165-5728(00)00304-0; Steensberg A, 2003, AM J PHYSIOL-ENDOC M, V285, pE433, DOI 10.1152/ajpendo.00074.2003; Steensberg A, 2003, EXERC IMMUNOL REV, V9, P40; SUZUKI K, 1983, ANAL BIOCHEM, V132, P345, DOI 10.1016/0003-2697(83)90019-2; TILG H, 1994, BLOOD, V83, P113; Unterberg AW, 1997, ACT NEUR S, V70, P106; van Praag H, 2005, J NEUROSCI, V25, P8680, DOI 10.1523/JNEUROSCI.1731-05.2005; Venturi L, 2009, J NEUROTRAUM, V26, P1547, DOI [10.1089/neu.2008.0723, 10.1089/neu.2008-0723]; Woods JA, 2005, BRAIN BEHAV IMMUN, V19, P369, DOI 10.1016/j.bbi.2005.04.007; Wyse ATS, 2000, NEUROREPORT, V11, P2331, DOI 10.1097/00001756-200007140-00052; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	63	34	35	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1029-8428	1476-3524		NEUROTOX RES	Neurotox. Res.	FEB	2012	21	2					175	184		10.1007/s12640-011-9257-8			10	Neurosciences	Neurosciences & Neurology	869NK	WOS:000298604700004	21735317				2021-06-18	
J	Torres-Chavez, KE; Sanfins, JM; Clemente-Napimoga, JT; Pelegrini-Da-Silva, A; Parada, CA; Fischer, L; Tambeli, CH				Torres-Chavez, K. E.; Sanfins, J. M.; Clemente-Napimoga, J. T.; Pelegrini-Da-Silva, A.; Parada, C. A.; Fischer, L.; Tambeli, C. H.			Effect of gonadal steroid hormones on formalin-induced temporomandibular joint inflammation	EUROPEAN JOURNAL OF PAIN			English	Article							TRAUMATIC BRAIN-INJURY; ADJUVANT-INDUCED ARTHRITIS; RHEUMATOID-ARTHRITIS; FEMALE RATS; SPINOMEDULLARY JUNCTION; REPLACEMENT THERAPY; TESTOSTERONE REPLACEMENT; OVARIECTOMIZED RATS; OPIOID RECEPTORS; MUSCLE-ACTIVITY	We have recently demonstrated that gonadal steroid hormones decrease formalin-induced temporomandibular joint nociception in rats. Given that the attenuation of inflammation is a potential mechanism underlying this antinociceptive effect, we evaluated the effect of gonadal steroid hormones on formalin-induced temporomandibular joint inflammation. Plasma extravasation, a major sign of acute inflammation, and neutrophil migration, an important event related to tissue injury, were evaluated. Formalin induced significantly lower temporomandibular joint plasma extravasation and neutrophil migration in proestrus females than in males and in diestrus females. Since estradiol serum level is high in proestrus females and low in diestrus females and in males, these findings suggest that the high physiological level of estradiol decreases temporomandibular joint inflammation. Estradiol but not progesterone administration in ovariectomized females significantly decreased formalin-induced plasma extravasation and neutrophil migration, an effect that was blocked by the estrogen receptor antagonist ICI 182780. Plasma extravasation and neutrophil migration were not affected by orchiectomy, but testosterone or estradiol administration in orchidectomized males significantly decreased them. The androgen receptor antagonist flutamide blocked the anti-inflammatory effect of testosterone while ICI 182780 blocked that of estradiol in males. Previous intravenous administration of a nonspecific selectin inhibitor significantly decreased formalin-induced temporomandibular joint nociception and neutrophil migration in males, revealing a potent and positive correlation between temporomandibular joint nociception and inflammation. Taken together, these findings demonstrate a pronounced anti-inflammatory effect of estradiol and testosterone in the temporomandibular joint region and suggest that this effect may mediate, at least in part, the antinociceptive effect of these hormones.	[Torres-Chavez, K. E.; Sanfins, J. M.; Clemente-Napimoga, J. T.; Pelegrini-Da-Silva, A.; Tambeli, C. H.] State Univ Campinas UNICAMP, Piracicaba Dent Sch, Dept Physiol, Sao Paulo, Brazil; [Parada, C. A.; Tambeli, C. H.] State Univ Campinas UNICAMP, Inst Biol, Dept Anat Cell Biol & Physiol & Biophys, Sao Paulo, Brazil; [Fischer, L.] Univ Fed Parana, Dept Physiol, Div Biol Sci, BR-80060000 Curitiba, Parana, Brazil	Tambeli, CH (corresponding author), State Univ Campinas UNICAMP, Piracicaba Dent Sch, Dept Physiol, Sao Paulo, Brazil.	tambeli@fop.unicamp.br	Clemente-Napimoga, Juliana T/E-5163-2013; Tambeli, Claudia/AAQ-4409-2021; Parada, Carlos Amilcar/C-3974-2012	Clemente-Napimoga, Juliana T/0000-0003-1068-3039; 	CAPES (Fundacao Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior)Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES); FAPESP (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo), BrazilFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)	We thank our colleagues, Nadia Cristina Favaro Moreira and Maria Claudia Goncalves de Oliveira for their help with experimental procedures and Carlos Alberto Feliciano for technical assistance. This work was supported by CAPES (Fundacao Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior) and FAPESP (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo), Brazil.	Arthuri MT, 2005, LIFE SCI, V76, P1177, DOI 10.1016/j.lfs.2004.10.019; Badger AM, 1999, J PHARMACOL EXP THER, V291, P1380; Bereiter DA, 2006, PAIN, V126, P175, DOI 10.1016/j.pain.2006.06.030; Bereiter DA, 2001, CELLS TISSUES ORGANS, V169, P226, DOI 10.1159/000047886; Boers M, 2001, ARTHRITIS RHEUM, V44, P2242, DOI 10.1002/1529-0131(200110)44:10<2242::AID-ART386>3.0.CO;2-F; BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; Bruce-Keller AJ, 2000, ENDOCRINOLOGY, V141, P3646, DOI 10.1210/en.141.10.3646; BUTCHER RL, 1974, ENDOCRINOLOGY, V94, P1704, DOI 10.1210/endo-94-6-1704; Cairns BE, 2002, BRAIN RES, V957, P338, DOI 10.1016/S0006-8993(02)03671-5; Campos M, 2003, EUR J PHARMACOL, V471, P149, DOI 10.1016/S0014-2999(03)01822-3; Carlsson G, 1995, EPIDEMIOLOGY TEMPORO, P211; Chaban VV, 2005, J NEUROSCI RES, V81, P31, DOI 10.1002/jnr.20524; Clemente JT, 2004, NEUROSCI LETT, V372, P250, DOI 10.1016/j.neulet.2004.09.048; Cutler SM, 2007, J NEUROTRAUM, V24, P1475, DOI 10.1089/neu.2007.0294; D'Elia HF, 2003, J RHEUMATOL, V30, P1456; DASILVA JAP, 1993, ANN RHEUM DIS, V52, P285, DOI 10.1136/ard.52.4.285; Dong XD, 2007, NEUROSCIENCE, V146, P822, DOI 10.1016/j.neuroscience.2007.01.051; Favaro-Moreira NC, 2009, NEUROSCIENCE, V164, P724, DOI 10.1016/j.neuroscience.2009.08.012; Fiorentino PM, 1999, ARCH ORAL BIOL, V44, P27, DOI 10.1016/S0003-9969(98)00095-8; Fischer L, 2008, J PAIN, V9, P630, DOI 10.1016/j.jpain.2008.02.006; Fischer L, 2007, J PAIN, V8, P437, DOI 10.1016/j.jpain.2006.12.007; Fischer L, 2009, BEHAV NEUROSCI, V123, P1129, DOI 10.1037/a0017063; Flake NM, 2006, AM J PHYSIOL-REG I, V291, pR343, DOI 10.1152/ajpregu.00835.2005; Flake NM, 2005, J NEUROPHYSIOL, V93, P1585, DOI 10.1152/jn.00269.2004; GALLAGHER A, 1993, ENDOCRINOLOGY, V133, P2787, DOI 10.1210/en.133.6.2787; Gordon FT, 1996, HORM BEHAV, V30, P244, DOI 10.1006/hbeh.1996.0029; Green PG, 1999, J NEUROSCI, V19, P4082; Guan GQ, 2005, J STEROID BIOCHEM, V97, P241, DOI 10.1016/j.jsbmb.2005.05.013; HAAS DA, 1992, ARCH ORAL BIOL, V37, P417, DOI 10.1016/0003-9969(92)90026-5; HALL GM, 1994, ANN RHEUM DIS, V53, P112, DOI 10.1136/ard.53.2.112; HANDA RJ, 1994, HORM BEHAV, V28, P464, DOI 10.1006/hbeh.1994.1044; Harbuz MS, 1995, BRIT J RHEUMATOL, V34, P1117; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Ishizuka M, 2004, CLIN SCI, V106, P293, DOI 10.1042/CS20030317; Iwata K, 1999, J NEUROPHYSIOL, V82, P1244; JANSSON L, 1994, J NEUROIMMUNOL, V53, P203, DOI 10.1016/0165-5728(94)90030-2; Jochems C, 2007, ARTHRITIS RHEUM-US, V56, P3261, DOI 10.1002/art.22873; Kang IH, 2004, TOXICOLOGY, V199, P145, DOI 10.1016/j.tox.2004.02.019; Keith JC, 2005, ARTHRITIS RES THER, V7, pR427, DOI 10.1186/ar1692; Klebanoff S.J., 1991, PEROXIDASES CHEM BIO, P1; KLEBANOFF SJ, 1980, ANN INTERN MED, V93, P480, DOI 10.7326/0003-4819-93-3-480; Kramer PR, 2004, ARTHRITIS RHEUM, V50, P1967, DOI 10.1002/art.20309; Lamote I, 2004, J DAIRY SCI, V87, P3340, DOI 10.3168/jds.S0022-0302(04)73470-0; Lee DY, 2002, LIFE SCI, V70, P2047, DOI 10.1016/S0024-3205(01)01534-X; LeResche L, 2005, J OROFAC PAIN, V19, P193; LeResche L, 2003, PAIN, V106, P253, DOI 10.1016/j.pain.2003.06.001; MACDONALD AG, 1994, ANN RHEUM DIS, V53, P54, DOI 10.1136/ard.53.1.54; Malkin CJ, 2004, J CLIN ENDOCR METAB, V89, P3313, DOI 10.1210/jc.2003-031069; Murphy AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005539; Nozawa-Inoue K, 2003, ARCH HISTOL CYTOL, V66, P289, DOI 10.1679/aohc.66.289; Okamoto K, 2003, J NEUROPHYSIOL, V89, P1467, DOI 10.1152/jn.00795.2002; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Roveroni RC, 2001, PAIN, V94, P185, DOI 10.1016/S0304-3959(01)00357-8; RYAN GB, 1977, AM J PATHOL, V86, P183; Tashiro A, 2007, J NEUROPHYSIOL, V98, P3242, DOI 10.1152/jn.00677.2007; Tashiro A, 2009, NEUROSCIENCE, V164, P1805, DOI 10.1016/j.neuroscience.2009.09.067; Tashiro A, 2009, NEUROSCIENCE, V164, P1813, DOI 10.1016/j.neuroscience.2009.09.058; Tiidus PM, 2001, CAN J PHYSIOL PHARM, V79, P400, DOI 10.1139/cjpp-79-5-400; Vegeto E, 2003, P NATL ACAD SCI USA, V100, P9614, DOI 10.1073/pnas.1531957100; Weinstock M, 1998, INT J DEV NEUROSCI, V16, P289, DOI 10.1016/S0736-5748(98)00021-5; Wu YW, 2010, J NEUROSCI, V30, P8710, DOI 10.1523/JNEUROSCI.6323-09.2010; Xing DQ, 2007, AM J PHYSIOL-HEART C, V292, pH2607, DOI 10.1152/ajpheart.01107.2006; YU XM, 1995, PAIN, V60, P143, DOI 10.1016/0304-3959(94)00104-M; ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4	64	34	35	0	4	WILEY PERIODICALS, INC	SAN FRANCISCO	ONE MONTGOMERY ST, SUITE 1200, SAN FRANCISCO, CA 94104 USA	1090-3801			EUR J PAIN	Eur. J. Pain	FEB	2012	16	2					204	216		10.1016/j.ejpain.2011.06.007			13	Anesthesiology; Clinical Neurology; Neurosciences	Anesthesiology; Neurosciences & Neurology	980NU	WOS:000306900900006	22323373	Bronze			2021-06-18	
J	Bryan, C; Hernandez, M				Bryan, Craig; Hernandez, Marie			Magnitudes of Decline on Automated Neuropsychological Assessment Metrics Subtest Scores Relative to Predeployment Baseline Performance Among Service Members Evaluated for Traumatic Brain Injury in Iraq	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						ANAM; military; traumatic brain injury	SPORTS CONCUSSION; AFGHANISTAN; SAMPLE	Objective: Identify the proportion of service members demonstrating declines in Automated Neuropsychological Assessment Metrics (ANAM) scores as part of a traumatic brain injury (TBI) evaluation conducted while deployed to Iraq. Background: Although TBI has been associated with poorer performance on cognitive test in the general population and military combatants, little is known about the proportion of service members demonstrating declines in ANAM scores after TBI. Methods: Military personnel (N = 116) referred to a combat support hospital for TBI evaluation in Iraq underwent a standardized intake evaluation including computerized neurocognitive testing, psychological and physical health questionnaires, a clinical interview, and a physical examination by a physician. Predeployment and postinjury cognitive performance among service members with and without a TBI diagnosis was compared. Results: A significantly larger proportion of patients with TBI demonstrated greater declines in speed across all ANAM subtests compared with patients with no TBI. Differences in accuracy scores among patients with TBI relative to patients without TBI were nonsignificant. Patients with TBI also demonstrated greater than minimal declines on throughput Simple Reaction Time, Procedural Reaction Time, Code Substitution-Learning, and Spatial Memory scores, with no significant differences on Code Substitution-Delayed or Mathematical Processing (MATH). A similar pattern was seen among individuals examined within 72 hours of index injury. Conclusion: Assessment of cognitive impairment following TBI in a combat zone may assist providers in making treatment recommendations for service members with mild TBI.	[Bryan, Craig; Hernandez, Marie] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA	Bryan, C (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, 7550 West IH-10,Ste 1325, San Antonio, TX 78229 USA.	bryanc3@uthscsa.edu		huaxia, li/0000-0001-7346-6600; Bryan, Craig/0000-0002-9714-0733			[Anonymous], 2007, AUT NEUR ASS METR CO; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Bleiberg J, 2000, CLIN NEUROPSYCHOL, V14, P287, DOI 10.1076/1385-4046(200008)14:3;1-P;FT287; Ivins BJ, 2003, J TRAUMA, V55, P617, DOI 10.1097/01.TA.0000052368.97573.D4; Ivins BJ, 2009, J HEAD TRAUMA REHAB, V24, P24, DOI 10.1097/HTR.0b013e3181957042; Kabat MH, 2001, CLIN NEUROPSYCHOL, V15, P498, DOI 10.1076/clin.15.4.498.1882; Reeves DL, 2007, ARCH CLIN NEUROPSYCH, V22, pS15, DOI 10.1016/j.acn.2006.10.013; Reeves DL, 2006, MIL MED, V171, P982, DOI 10.7205/MILMED.171.10.982; Schell T.L., 2008, INVISIBLE WOUNDS WAR, DOI [10.7249/mg720-1ccf.12, DOI 10.7249/MG720-1CCF.12]; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Traumatic Brain Injury (TBI) Task Force, 2008, TRAUM BRAIN INJ TASK; Warden DL, 2001, NEUROLOGY, V57, P524, DOI 10.1212/WNL.57.3.524; Wilken JA, 2003, MULT SCLER, V9, P119, DOI 10.1191/1352458503ms893oa	14	34	34	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2012	27	1					45	54		10.1097/HTR.0b013e318238f146			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	879JV	WOS:000299326400005	22218202				2021-06-18	
J	Falconer, C; Antonucci, SM				Falconer, Carolyn; Antonucci, Sharon M.			Use of semantic feature analysis in group discourse treatment for aphasia: Extension and expansion	APHASIOLOGY			English	Article						Stroke rehabilitation; Lexical retrieval; Connected speech; Discourse; Therapy	CONNECTED SPEECH; WORD RETRIEVAL; ADULTS; THERAPY; STABILITY; SAMPLE	Background: Semantic feature analysis (SFA) is a treatment for lexical retrieval impairment in which participants are cued to provide semantic information about concepts they have difficulty naming, in an effort to facilitate accurate lexical retrieval (Boyle, 2004a). Previous work has provided preliminary evidence that persons with aphasia who participated in SFA-focused group aphasia treatment demonstrate improved lexical retrieval in discourse, with additional improvements observed in either general communication informativeness or efficiency (Antonucci, 2009). Furthermore, results suggested that individuals with differing mechanisms of anomia could derive benefits from participation in SFA-focused group treatment. Aims: The aim of the current study was to investigate further training of SFA in connected speech during group aphasia treatment. This study expanded and extended previous work (Antonucci, 2009), through the addition of participants with more varied aetiologies and severities of aphasia, and through the introduction of home practice. It was hypothesised that lexical retrieval during discourse would improve, as would overall communicative informativeness and/or efficiency. Methods & Procedures: Four individuals with aphasia participated in biweekly group treatment during which SFA was trained through connected speech tasks. Three participants presented with stroke aphasia, while one demonstrated aphasia consequent to traumatic brain injury. Discourse measures included those for overall communicative informativeness and efficiency (Nicholas & Brookshire, 1993) and for word-class-specific lexical retrieval (Mayer & Murray, 2003). Effect sizes were calculated for all discourse measures. Pre-and post-treatment performance on the spontaneous speech portion of theWestern Aphasia Battery-Revised was also analysed relative to discourse measures, to corroborate findings from more frequently repeated probes. Outcomes & Results: All four participants demonstrated improvement to communicative informativeness and/or efficiency in connected speech tasks. Conclusions: Results provide additional support for the hypothesis that SFA administered during group aphasia treatment can be used successfully to facilitate improvement of communicative effectiveness. These results also support previous findings that individuals with differing aetiologies and natures of word retrieval impairment may benefit from participation in the same SFA-focused group aphasia treatment. Future work proceeding from this study may be directed towards differentiating which aspects of the treatment are most effective across participants with varied naming impairment, what is the optimal group composition and size, and towards discerning the most effective methods for facilitating and monitoring home practice.	[Falconer, Carolyn; Antonucci, Sharon M.] NYU, Dept Commun Sci & Disorders, New York, NY 10012 USA	Antonucci, SM (corresponding author), NYU, Dept Commun Sci & Disorders, 665 Broadway,9th Floor, New York, NY 10012 USA.	sma208@nyu.edu	Falconer, Carolyn/AAI-2237-2020				Antonucci SM, 2009, APHASIOLOGY, V23, P854, DOI 10.1080/02687030802634405; Beeson P. M., 2008, METAANALYSES APHASIA; Beeson P. M., 2007, GROUP TREATMENT NEUR, P148; Bernstein-Ellis E., 2007, GROUP TREATMENT NEUR, P71; Boyle M, 2004, AM J SPEECH-LANG PAT, V13, P236, DOI 10.1044/1058-0360(2004/025); Boyle M., 2001, NEUROPHYSIOLOGY NEUR, V11, P23, DOI DOI 10.1044/NNSLD11.2.23; Boyle M., 2004, DISCOURSE TREATMENT; Boyle M., 1995, AM J SPEECH-LANG PAT, V4, P94, DOI DOI 10.1044/1058-0360.0404.94; BROOKSHIRE RH, 1994, J SPEECH HEAR RES, V37, P399, DOI 10.1044/jshr.3702.399; Busk P. L., 1992, SINGLE CASE RES DESI; Clausen NS, 2003, APHASIOLOGY, V17, P625, DOI 10.1080/02687030344000003; Coelho CA, 2000, APHASIOLOGY, V14, P133, DOI 10.1080/026870300401513; Davis GA, 2005, APHASIOLOGY, V19, P21, DOI 10.1080/02687030444000598; Ewing S., 2007, GROUP TREATMENT NEUR, P11; Helm-Estabrooks N., 1989, MELODIC INTONATION T; HELMESTABROOKS N, 2003, NARRATIVE STORY CARD; Howard D., 1992, PYRAMIDS PALM TREES; Kaplan E., 1983, BOSTON NAMING TEST; Katz RC, 1997, J SPEECH LANG HEAR R, V40, P493, DOI 10.1044/jslhr.4003.493; Kertesz A., 2006, W APHASIA BATTERY RE; Larfeuil C, 1997, APHASIOLOGY, V11, P783, DOI 10.1080/02687039708250456; Lowell S., 1995, AM J SPEECH-LANG PAT, V4, P109, DOI DOI 10.1044/1058-0360.0404.109; Mason C, 2011, APHASIOLOGY, V25, P245, DOI 10.1080/02687038.2010.489258; MASSARO M, 1994, CLIN APHASIOL, V22, P245; Mayer JF, 2003, APHASIOLOGY, V17, P481, DOI 10.1080/02687030344000148; MEASSO G, 1993, ACTA NEUROL SCAND, V88, P70; Meinzer M, 2005, STROKE, V36, P1462, DOI 10.1161/01.STR.0000169941.29831.2a; Miller J., 1985, SYSTEMATIC ANAL LANG; NICHOLAS LE, 1993, J SPEECH HEAR RES, V36, P338, DOI 10.1044/jshr.3602.338; Peach RK, 2010, APHASIOLOGY, V24, P971, DOI 10.1080/02687030903058629; Pulvermuller F, 2001, STROKE, V32, P1621, DOI 10.1161/01.STR.32.7.1621; RAVEN J, 1998, COLOURED PROGRESSIVE; Rider JD, 2008, AM J SPEECH-LANG PAT, V17, P161, DOI 10.1044/1058-0360(2008/016); Simmons-Mackie N, 2007, TOP LANG DISORD, V27, P5, DOI 10.1097/00011363-200701000-00003; Wambaugh JL, 2007, J REHABIL RES DEV, V44, P381, DOI 10.1682/JRRD.2006.05.0038	35	34	34	0	32	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0268-7038			APHASIOLOGY	Aphasiology		2012	26	1					64	82		10.1080/02687038.2011.602390			19	Audiology & Speech-Language Pathology; Linguistics; Clinical Neurology; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Rehabilitation	910OI	WOS:000301648700004					2021-06-18	
J	Lehan, T; Arango-Lasprilla, JC; Reyes, CJDL; Quijano, MC				Lehan, Tara; Arango-Lasprilla, Juan Carlos; Reyes, Carlos Jose de los; Quijano, Maria Cristina			The ties that bind: The relationship between caregiver burden and the neuropsychological functioning of TBI survivors	NEUROREHABILITATION			English	Article						Caregivers; burden; traumatic brain injury; neuropsychological functioning; family system	TRAUMATIC BRAIN-INJURY; FAMILY MEMBERS; REHABILITATION; IMPACT; DEPRESSION; HEALTH; ADULTS; SCALE; NEEDS	Advances in medical and assistive technology have increased the likelihood of survival following a traumatic brain injury (TBI). Consequently, families frequently must provide care to individuals with TBI. Because they are rarely prepared for the associated demanding medical needs and financial burden, family caregivers are at risk for physical and emotional problems, which can negatively influence their individual and family functioning. Whereas scholars have examined the influence of survivor functioning on caregiver burden, few have explicitly recognized that caregiver burden also influences survivor functioning. Results of a multivariate linear regression suggest that, in a sample of 51 pairs of TBI survivors and their caregivers living in Colombia, survivors receiving care from a family member who reported a higher level of burden had poorer objective neuropsychological functioning than those receiving care from a family member who reported a lower level of burden, after controlling for survivor education and history of occupational therapy. Therefore, a family-focused approach might maximize intervention effectiveness, especially for Latin American and Hispanic families, which tend to be characterized by a strong sense of familism. The emphasis on family can create problems in a healthcare system that views the individual as the primary unit.	[Lehan, Tara] Northcent Univ, Prescott Valley, AZ USA; [Arango-Lasprilla, Juan Carlos] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA USA; [Reyes, Carlos Jose de los] Univ Norte, Dept Psychol, Barranquilla, Colombia; [Quijano, Maria Cristina] Pontificia Univ Javeriana Cali, Dept Social Sci, Cali, Colombia	Lehan, T (corresponding author), POB 4503, Richmond, VA 23220 USA.	tlehan@ncu.edu	Lehan, Tara/AAO-4793-2020	Quijano Martinez, Maria Cristina/0000-0003-3548-1628			Anderson MI, 2002, BRAIN INJURY, V16, P743, DOI 10.1080/02699050210128906; Baca Zinn M., 1982, HUMBOLDT J SOCIAL RE, V10, P224, DOI DOI 10.1086/493962; Borrell-Carrio F, 2004, ANN FAM MED, V2, P576, DOI 10.1370/afm.245; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Buhse M, 2008, J NEUROSCI NURS, V40, P25, DOI 10.1097/01376517-200802000-00005; Busch RM, 2005, J CLIN EXP NEUROPSYC, V27, P1022, DOI 10.1080/13803390490919263; Carr D, 2010, J MARRIAGE FAM, V72, P743, DOI 10.1111/j.1741-3737.2010.00728.x; Cavallo M.M., 2011, TXB TRAUMATIC BRAIN, P483; Chou K., 2003, AM J MED SCI, V23, P73; Degeneffe CE, 2001, HEALTH SOC WORK, V26, P257, DOI 10.1093/hsw/26.4.257; Dixon T. M., 2005, MED ASPECTS DISABILI, P119; Douglas JM, 1996, BRAIN INJURY, V10, P819, DOI 10.1080/026990596123936; Family Caregiver Alliance, 1998, SEL TRAUM BRAIN INJ; Frosch S, 1997, BRAIN INJURY, V11, P891; Galanti Geri-Ann, 2003, J Transcult Nurs, V14, P180, DOI 10.1177/1043659603014003004; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Gil M, 1996, BRAIN INJURY, V10, P39, DOI 10.1080/026990596124700; GLECKMAN AD, 1995, BRAIN INJURY, V9, P385, DOI 10.3109/02699059509005778; Harris JKJ, 2001, BRAIN INJURY, V15, P223; JACOBS HE, 1989, NEUROPSYCHOLOGICAL T, P297; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; KREUTZER JS, 1992, ARCH PHYS MED REHAB, V73, P771; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; Kreutzer JS, 2001, BRAIN INJURY, V15, P763, DOI 10.1080/02699050010025786; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; LEZAK MD, 1988, J LEARN DISABIL, V21, P456, DOI 10.1177/002221948802100802; LIEBERMAN MA, 1995, GERONTOLOGIST, V35, P94, DOI 10.1093/geront/35.1.94; LIVINGSTON M, 1988, J HEAD TRAUMA REHAB, V3, P6, DOI DOI 10.1097/00001199-198812000-00004; Luna I, 1996, WESTERN J NURS RES, V18, P267, DOI 10.1177/019394599601800304; Machamer J, 2002, J CLIN EXP NEUROPSYC, V24, P420, DOI 10.1076/jcen.24.4.420.1040; Magone C. A., 1993, DEMENTIA, V4, P287; MAITZ EA, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199504000-00003; Marsh NV, 2002, J CLIN EXP NEUROPSYC, V24, P434, DOI 10.1076/jcen.24.4.434.1030; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; Martin-Carrasco M, 2010, AGING MENT HEALTH, V14, P705, DOI 10.1080/13607860903586094; Martin-Carrasco M., 1996, REV GERONTOLOGIA, V6, P338; McKinlay WW, 1988, J HEAD TRAUMA REHAB, p[3, 64]; MILLER B, 1991, J HEALTH SOC BEHAV, V32, P165, DOI 10.2307/2137150; MILLER L, 1993, AM J FAM THER, V21, P111, DOI 10.1080/01926189308250910; Mittelman M, 2005, CURR OPIN PSYCHIATR, V18, P633, DOI 10.1097/01.yco.0000184416.21458.40; MONTGOMERY RJV, 1985, RES AGING, V7, P137, DOI 10.1177/0164027585007001007; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Ostrosky-Solis F, 1997, NEUROPSI EVALUACION; REINHARD SC, 1995, J MARRIAGE FAM, V57, P741, DOI 10.2307/353928; Rivera P, 2007, NEUROREHABILITATION, V22, P3; Riviere S, 2002, INT J GERIATR PSYCH, V17, P950, DOI 10.1002/gps.724; Rolland J. S., 1994, FAMILIES ILLNESS DIS; Rotondi AJ, 2007, J HEAD TRAUMA REHAB, V22, P14, DOI 10.1097/00001199-200701000-00002; Sady MD, 2010, ARCH PHYS MED REHAB, V91, P1542, DOI 10.1016/j.apmr.2010.07.012; Sander AM, 2002, BRAIN INJURY, V16, P649, DOI 10.1080/02699050210128889; SIEGEL K, 1991, CANCER, V68, P1131, DOI 10.1002/1097-0142(19910901)68:5<1131::AID-CNCR2820680541>3.0.CO;2-N; TEASDALE G, 1974, LANCET, V2, P81; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Weihs K., 2002, FAMILIES SYSTEMS HLT, V20, P7, DOI [10.1037/h0089481, DOI 10.1037/H0089481]; Zarit S., 1985, HIDDEN VICTIMS ALZHE	59	34	36	1	19	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135			NEUROREHABILITATION	Neurorehabilitation		2012	30	1					87	95		10.3233/NRE-2011-0730			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	904ZT	WOS:000301240900010	22349845				2021-06-18	
J	Skoglund, K; Enblad, P; Hillered, L; Marklund, N				Skoglund, Karin; Enblad, Per; Hillered, Lars; Marklund, Niklas			The neurological wake-up test increases stress hormone levels in patients with severe traumatic brain injury	CRITICAL CARE MEDICINE			English	Article						ACTH; catecholamines; cerebral perfusion pressure (CPP); cortisol; epinephrine; intracranial pressure (ICP); neurological wake-up test; norepinephrine; propofol; sedation	PITUITARY-ADRENAL AXIS; INTENSIVE-CARE-UNIT; VENTILATOR-ASSOCIATED PNEUMONIA; SENSORIMOTOR CORTEX INJURY; CRITICALLY-ILL PATIENTS; SEVERE HEAD-INJURY; SALIVARY CORTISOL; NOREPINEPHRINE TURNOVER; RAT-BRAIN; STROKE	Objectives: The "neurological wake-up test" is needed to evaluate the level of consciousness in patients with severe traumatic brain injury. However, the neurological wake-up test requires interruption of continuous sedation and may induce a stress response and its use in neurocritical care is controversial. We hypothesized that the neurological wake-up test induces an additional biochemical stress response in patients with severe traumatic brain injury. Patients: Twenty-four patients who received continuous propofol sedation and mechanical ventilation after moderate to severe traumatic brain injury (Glasgow Coma Scale score <= 8; patient age 18-71 yrs old) were analyzed. Exclusion criteria were age <18 yrs old, ongoing pentobarbital infusion, or markedly increased intracranial pressure on interruption of continuous sedation. Design: Single-center prospective study. During postinjury days 1-8, 65 neurological wake-up tests were evaluated. Adrenocorticotrophic hormone, epinephrine, and norepinephrine levels in plasma and cortisol levels in saliva were analyzed at baseline (during continuous intravenous propofol sedation) and during neurological wake-up test. Data are presented using medians and 25th and 75th percentiles. Setting: The study was performed in a university hospital neurocritical care unit. Interventions: None. Measurements and Main Results: At baseline, adrenocorticotrophic hormone and cortisol levels were 10.6 (6.0-19.4) ng/L and 16.0 (10.7-31.8) nmol/L, respectively. Immediately after the neurological wake-up test, adrenocorticotrophic hormone levels increased to 20.5 (11.1-48.4) ng/L (p < .05) and cortisol levels in saliva increased to 24.0 (12.3-42.5) nmol/L (p < .05). The plasma epinephrine and norepinephrine levels increased from a baseline of 0.3 (0.3-0.6) and 1.6 (0.9-2.3) nmol/L, respectively, to 0.75 (0.3-1.4) and 2.8 (1.28-3.58) nmol/L, respectively (both p < .05). Conclusions: The neurological wake-up test induces a biochemical stress response in patients with severe traumatic brain injury. The clinical importance of this stress response remains to be established but should be considered when deciding the frequency and use of the neurological wake-up test during neurocritical care. (Crit Care Med 2012; 40:216-222)	[Skoglund, Karin; Enblad, Per; Hillered, Lars; Marklund, Niklas] Uppsala Univ, Dept Neurosci, Uppsala, Sweden	Skoglund, K (corresponding author), Uppsala Univ, Dept Neurosci, Uppsala, Sweden.	Niklas.Marklund@neurokir.uu.se		Marklund, Niklas/0000-0002-9797-5626; Hillered, Lars/0000-0002-2808-9292	Swedish Research CouncilSwedish Research CouncilEuropean Commission; Laerdal Foundation; Uppsala University	The study was supported by funds from the Swedish Research Council, the Laerdal Foundation, and from Uppsala University.	ASTROM M, 1993, STROKE, V24, P52, DOI 10.1161/01.STR.24.1.52; BARTON RN, 1987, J TRAUMA, V27, P384, DOI 10.1097/00005373-198704000-00007; Bay Esther, 2005, J Neurosci Nurs, V37, P4; Blamoun J, 2009, AM J INFECT CONTROL, V37, P172, DOI 10.1016/j.ajic.2008.05.010; BOHNEN N, 1990, BIOL PSYCHOL, V31, P107, DOI 10.1016/0301-0511(90)90011-K; Bondanelli M, 2005, EUR J ENDOCRINOL, V152, P679, DOI 10.1530/eje.1.01895; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; BOYESON MG, 1992, BRAIN RES BULL, V29, P435, DOI 10.1016/0361-9230(92)90080-H; BOYESON MG, 1990, PHARMACOL BIOCHEM BE, V35, P497, DOI 10.1016/0091-3057(90)90279-Q; BOYESON MG, 1985, EXP NEUROL, V89, P479, DOI 10.1016/0014-4886(85)90107-4; Cernak I, 1999, BRAIN INJURY, V13, P1005; CHROUSOS GP, 1995, NEW ENGL J MED, V332, P1351, DOI 10.1056/NEJM199505183322008; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; CLIFTON GL, 1983, J NEUROSURG, V59, P447, DOI 10.3171/jns.1983.59.3.0447; Cohan P, 2005, CRIT CARE MED, V33, P2358, DOI 10.1097/01.CCM.0000181735.51183.A7; Cooper MS, 2003, NEW ENGL J MED, V348, P727, DOI 10.1056/NEJMra020529; COUCH RM, 1992, ACTA ENDOCRINOL-COP, V127, P115, DOI 10.1530/acta.0.1270115; DAHLGREN N, 1980, BRAIN RES, V184, P143, DOI 10.1016/0006-8993(80)90593-4; Diamond DM, 2000, ANN NY ACAD SCI, V911, P453; Dimopoulou I, 2005, INTENS CARE MED, V31, P1020, DOI 10.1007/s00134-005-2689-y; Dimopoulou I, 2004, INTENS CARE MED, V30, P1051, DOI 10.1007/s00134-004-2257-x; Dimopoulou L, 2004, CRIT CARE MED, V32, P404, DOI 10.1097/01.CCM.0000108885.37811.CA; Dinkel K, 2003, J NEUROCHEM, V84, P705, DOI 10.1046/j.1471-4159.2003.01604.x; Dunn-Meynell AA, 1998, BRAIN RES, V800, P245, DOI 10.1016/S0006-8993(98)00524-1; DUNNMEYNELL A, 1994, BRAIN RES, V660, P88, DOI 10.1016/0006-8993(94)90842-7; Dunser Martin W, 2009, J Intensive Care Med, V24, P293, DOI 10.1177/0885066609340519; Duplessis C, 2010, MIL MED, V175, P340, DOI 10.7205/MILMED-D-09-00166; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; FEIBEL JH, 1977, JAMA-J AM MED ASSOC, V238, P1374, DOI 10.1001/jama.238.13.1374; Fields LB, 2008, J NEUROSCI NURS, V40, P291, DOI 10.1097/01376517-200810000-00007; Gozansky WS, 2005, CLIN ENDOCRINOL, V63, P336, DOI 10.1111/j.1365-2265.2005.02349.x; HAMILL RW, 1987, ANN NEUROL, V21, P438, DOI 10.1002/ana.410210504; Helmy A, 2007, BRIT J ANAESTH, V99, P32, DOI 10.1093/bja/aem139; Huang W, 1999, EUR J PHARMACOL, V366, P127, DOI 10.1016/S0014-2999(98)00929-7; KIRSCHBAUM C, 1994, PSYCHONEUROENDOCRINO, V19, P313, DOI 10.1016/0306-4530(94)90013-2; Koiv L, 1997, ACTA NEUROL SCAND, V96, P52; LANDON J, 1984, P 9 TEN WORKSH 1982, P300; LARSON GM, 1984, AM J SURG, V147, P97, DOI 10.1016/0002-9610(84)90041-2; Larsson CA, 2009, BMC ENDOCR DISORD, V9, DOI 10.1186/1472-6823-9-16; LEVIN BE, 1995, BRAIN RES, V674, P307, DOI 10.1016/0006-8993(95)00032-L; Llompart-Pou JA, 2008, NEUROCRIT CARE, V9, P230, DOI 10.1007/s12028-008-9115-6; Llompart-Pou JA, 2007, J TRAUMA, V62, P1457, DOI 10.1097/01.ta.0000219143.69483.71; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; MACKENZIE ET, 1976, AM J PHYSIOL, V231, P483; Magarinos AM, 1996, J NEUROSCI, V16, P3534; Marklund N, 2004, J INTERN MED, V256, P15, DOI 10.1111/j.1365-2796.2004.01334.x; Mautes AEM, 2001, ACTA NEUROCHIR, V143, P51, DOI 10.1007/s007010170138; McEwen BS, 1999, ANNU REV NEUROSCI, V22, P105, DOI 10.1146/annurev.neuro.22.1.105; MORSE JK, 1992, EXP NEUROL, V118, P47, DOI 10.1016/0014-4886(92)90021-H; OLSSON T, 1990, J INTERN MED, V228, P287, DOI 10.1111/j.1365-2796.1990.tb00233.x; Popovic V, 2004, J ENDOCRINOL INVEST, V27, P1048, DOI 10.1007/BF03345308; Powner DJ, 2006, NEUROCRIT CARE, V5, P61, DOI 10.1385/NCC:5:1:61; Resar R, 2005, JT COMM J QUAL PATIE, V31, P243, DOI 10.1016/S1553-7250(05)31031-2; Rhoney DH, 2001, NEUROL RES, V23, P237, DOI 10.1179/016164101101198398; SAPOLSKY RM, 1985, SCIENCE, V229, P1397, DOI 10.1126/science.4035356; Savaridas T, 2004, INTENS CARE MED, V30, P1479, DOI 10.1007/s00134-004-2306-5; Schell E, 2008, EUR SPINE J, V17, P393, DOI 10.1007/s00586-007-0554-0; Schwarz S, 2003, J NEUROL NEUROSUR PS, V74, P725, DOI 10.1136/jnnp.74.6.725; Skoglund K, 2009, NEUROCRIT CARE, V11, P135, DOI 10.1007/s12028-009-9255-3; SmithSwintosky VL, 1996, J CEREBR BLOOD F MET, V16, P585, DOI 10.1097/00004647-199607000-00008; STARMARK JE, 1988, ACTA NEUROCHIR, V91, P12, DOI 10.1007/BF01400521; TEASDALE G, 1974, LANCET, V2, P81; Tschuor C, 2008, CRIT CARE, V12, DOI 10.1186/cc6931; Tsigos C, 2002, J PSYCHOSOM RES, V53, P865, DOI 10.1016/S0022-3999(02)00429-4; Van den Berghe G, 2000, EUR J ENDOCRINOL, V143, P1, DOI 10.1530/eje.0.1430001; VINING RF, 1987, J STEROID BIOCHEM, V27, P81, DOI 10.1016/0022-4731(87)90297-4; Vyas A, 2002, J NEUROSCI, V22, P6810; Wilson JD, 1998, WILLIAMS TXB ENDOCRI; WOLKOWITZ OM, 1990, AM J PSYCHIAT, V147, P1297; WOOLF PD, 1990, ALCOHOL CLIN EXP RES, V14, P917, DOI 10.1111/j.1530-0277.1990.tb01838.x; WOOLF PD, 1987, J NEUROSURG, V66, P875, DOI 10.3171/jns.1987.66.6.0875; Yamakoshi T, 2009, MED BIOL ENG COMPUT, V47, P449, DOI 10.1007/s11517-009-0447-y; Youngquist P, 2007, JT COMM J QUAL PATIE, V33, P219, DOI 10.1016/S1553-7250(07)33026-2; Zhang Shou-Wen, 2008, Neurosci Bull, V24, P84, DOI 10.1007/s12264-008-0084-8	74	34	35	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	JAN	2012	40	1					216	222		10.1097/CCM.0b013e31822d7dbd			7	Critical Care Medicine	General & Internal Medicine	866KO	WOS:000298379800031	22179339				2021-06-18	
J	Fathi, AR; Pluta, RM; Bakhtian, KD; Qi, M; Lonser, RR				Fathi, Ali Reza; Pluta, Ryszard M.; Bakhtian, Kamran D.; Qi, Meng; Lonser, Russell R.			Reversal of cerebral vasospasm via intravenous sodium nitrite after subarachnoid hemorrhage in primates Laboratory investigation	JOURNAL OF NEUROSURGERY			English	Article						nitric oxide; sodium nitrite; subarachnoid hemorrhage; vasospasm; traumatic brain injury	TRANSLUMINAL BALLOON ANGIOPLASTY; INTRAARTERIAL PAPAVERINE; OXIDE SYNTHASE; ENDOGENOUS INHIBITOR; DOUBLE-BLIND; MODEL; TRIAL; DEOXYHEMOGLOBIN; NITROPRUSSIDE; ASSOCIATION	Object. Subarachnoid hemorrhage (SAH)-induced vasospasm is a significant underlying cause of aneurysm rupture-related morbidity and death. While long-term intravenous infusion of sodium nitrite (NaNO(2)) can prevent cerebral vasospasm after SAH, it is not known if the intravenous administration of this compound can reverse established SAH-induced vasospasm. To determine if the intravenous infusion of NaNO(2) can reverse established vasospasm, the authors infused primates with the compound after SAH-induced vasospasm was established, Methods. Subarachnoid hemorrhage-induced vasospasm was created in 14 cynomolgus macaques via subarachnoid implantation of a 5-ml blood clot. On Day 7 after clot implantation, animals were randomized to either control (saline infusion, 5 monkeys) or treatment groups (intravenous NaNO(2) infusion at 300 mu g/kg/hr for 3 hours 1.7 monkeys) or 8 hours [2 monkeys]). Arteriographic vessel diameter was blindly analyzed to determine the degree of vasospasm before, during, and after treatment. Nitric oxide metabolites (nitrite, nitrate, and S-nitrosothiols) were measured in whole blood and CSF. Results. Moderate-to-severe vasospasm was present in all animals before treatment (control, 36.2% +/- 8.8% [mean +/- SD]; treatment, 45.5% +/- 12.5%; p = 0.9). While saline infusion did not reduce vasospasm, NaNO(2) infusion significantly reduced the degree of vasospasm (26.9% +/- 7.6%; p = 0.008). Reversal of the vasospasm lasted more than 2 hours after cessation of the infusion and could be maintained with a prolonged infusion. Nitrite (peak value, 3.7 +/- 2.1 mu mol/L), nitrate (18.2 +/- 5.3 mu mol/L), and S-nitrosothiols (33.4 +/- 11.4 mu mol/L) increased significantly in whole blood, and nitrite increased significantly in CSF. Conclusions. These findings indicate that the intravenous infusion of NaNO(2) can reverse SAH-induced vasospasm in primates. Further, these findings indicate that a similar treatment paradigm could be useful in reversing cerebral vasospasm after aneurysmal SAH. (DOI: 10.3171/2011.7.JNS11390)	[Fathi, Ali Reza; Pluta, Ryszard M.; Bakhtian, Kamran D.; Qi, Meng; Lonser, Russell R.] Natl Inst Neurol Disorders & Stroke, Surg Neurol Branch, NIH, Bethesda, MD 20892 USA; [Fathi, Ali Reza] Kantonsspital Aarau AG, Dept Neurosurg, Aarau, Switzerland; [Qi, Meng] Nanjing Univ, Dept Neurosurg, Jinling Hosp, Sch Med, Nanjing, Jiangsu, Peoples R China	Lonser, RR (corresponding author), Natl Inst Neurol Disorders & Stroke, Surg Neurol Branch, NIH, Bldg 10,Room 3D20, Bethesda, MD 20892 USA.	lonserr@ninds.nih.gov	QI, Meng/F-2802-2012		National Institute of Neurological Disorders and Stroke at the NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission [PBSKP3-123454]; China Scholarship CouncilChina Scholarship Council [2008619102]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [ZIANS003054] Funding Source: NIH RePORTER	This research was supported by the Intramural Research Program of the National Institute of Neurological Disorders and Stroke at the NIH. Dr. Fathi was supported by a grant from the Swiss National Science Foundation (PBSKP3-123454). Dr. Qi was supported by a scholarship from the China Scholarship Council (Scholarship No. 2008619102).	AASLID R, 1984, J NEUROSURG, V60, P37, DOI 10.3171/jns.1984.60.1.0037; Cosby K, 2003, NAT MED, V9, P1498, DOI 10.1038/nm954; Cross DT, 1998, AM J NEURORADIOL, V19, P1319; Crowley RW, 2011, STROKE, V42, P919, DOI 10.1161/STROKEAHA.110.597005; Dejam A, 2007, CIRCULATION, V116, P1821, DOI 10.1161/CIRCULATIONAHA.107.712133; DOYLE MP, 1981, J BIOL CHEM, V256, P2393; ESPINOSA F, 1984, J NEUROSURG, V60, P1167, DOI 10.3171/jns.1984.60.6.1167; Frontera JA, 2010, NEUROSURGERY, V66, P35, DOI 10.1227/01.NEU.0000359530.04529.07; Giller CA, 1998, NEUROSURGERY, V42, P1076, DOI 10.1097/00006123-199805000-00077; Hoh BL, 2005, NEUROSURG CLIN N AM, V16, P501, DOI 10.1016/j.nec.2005.04.004; Jung CS, 2007, J NEUROSURG, V107, P945, DOI 10.3171/JNS-07/11/0945; Jung CS, 2004, J NEUROSURG, V101, P836, DOI 10.3171/jns.2004.101.5.0836; KASSELL NF, 1984, STROKE, V15, P566, DOI 10.1161/01.STR.15.3.566; Keefer LK, 2003, ANNU REV PHARMACOL, V43, P585, DOI 10.1146/annurev.pharmtox.43.100901.135831; MacArthur PH, 2007, J CHROMATOGR B, V851, P93, DOI 10.1016/j.jchromb.2006.12.012; Macdonald RL, 2008, STROKE, V39, P3015, DOI 10.1161/STROKEAHA.108.519942; MACDONALD RL, 1991, STROKE, V22, P971, DOI 10.1161/01.STR.22.8.971; Park KW, 2002, CAN J ANAESTH, V49, P427, DOI 10.1007/BF03017335; Pluta RM, 2005, JAMA-J AM MED ASSOC, V293, P1477, DOI 10.1001/jama.293.12.1477; Pluta RM, 1996, J NEUROSURG, V84, P648, DOI 10.3171/jns.1996.84.4.0648; Pluta RM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014504; Polin RS, 2000, J NEUROSURG, V92, P284, DOI 10.3171/jns.2000.92.2.0284; Polin RS, 1998, NEUROSURGERY, V42, P1256, DOI 10.1097/00006123-199806000-00031; Raabe A, 2002, NEUROSURGERY, V50, P1006, DOI 10.1097/00006123-200205000-00013; Reinert M, 2004, NEUROL RES, V26, P435, DOI 10.1179/016164104225015976; Rejdak K, 2004, J NEUROL SCI, V219, P71, DOI 10.1016/j.jns.2003.12.011; Thomas JE, 1999, STROKE, V30, P1409, DOI 10.1161/01.STR.30.7.1409; Tierney TS, 2006, NEUROSURGERY, V58, P952, DOI 10.1227/01.NEU.0000210182.48546.8F; Vajkoczy P, 2001, STROKE, V32, P498, DOI 10.1161/01.STR.32.2.498; Vellimana AK, 2011, STROKE, V42, P776, DOI 10.1161/STROKEAHA.110.607200; WEIR B, 1978, J NEUROSURG, V48, P173, DOI 10.3171/jns.1978.48.2.0173; Zwienenberg-Lee M, 2008, STROKE, V39, P1759, DOI 10.1161/STROKEAHA.107.502666	32	34	36	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	DEC	2011	115	6					1213	1220		10.3171/2011.7.JNS11390			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	853UH	WOS:000297450700025	21888479	Green Accepted			2021-06-18	
J	Maung, AA; Schuster, KM; Kaplan, LJ; Maerz, LL; Davis, KA				Maung, Adrian A.; Schuster, Kevin M.; Kaplan, Lewis J.; Maerz, Linda L.; Davis, Kimberly A.			Risk of Venous Thromboembolism After Spinal Cord Injury: Not All Levels Are the Same	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Trauma; Spinal cord injury; Venous thromboembolism; Deep vein thrombosis; Pulmonary embolus	TRAUMA PATIENTS; PULMONARY-EMBOLISM; MAJOR TRAUMA; PREVENTION; COMPLICATIONS; THROMBOSIS; HEPARIN	Background: Venous thromboembolism (VTE), a diagnosis that includes both deep vein thrombosis and pulmonary embolism, is a well-recognized complication following injury. Previous studies have identified multiple risk factors including spinal cord injury (SCI). We hypothesized that the level of SCI also influences the likelihood of VTE. Methods: The National Trauma Data Bank was queried to identify all patients with SCI admitted in 2007 and 2008. Rates of VTE, demographics, admitting comorbidities, in-hospital complications, level of SCI (divided by National Trauma Data Bank into five groups), associated injuries, and outcome variables were abstracted. Multiple regression was used to identify independent risk factors for VTE. Results: During the 2-year period, 18,302 patients were admitted with SCI. The overall rate of VTE was 4.3% but varied significantly depending on the level of SCI injury (chi(2), 44.8; p < 0.05). Patients with high cervical spine (C1-4) injury had a rate VTE of 3.4%, whereas patients with high thoracic spine (T1-6) injury had the highest rate of VTE at 6.3%. The lowest rate of VTE was in patients with lumbar injury (3.2%). There were no significant differences in the preexisting comorbidities or in-hospital complications among the five SCI groups with the exception of pneumonia. In a multiple logistic regression model, the level of SCI was an independent risk factor for VTE as was increasing age, increasing Injury Severity Score, male gender, traumatic brain injury, and chest trauma. Conclusions: The rate of VTE differs with various SCI levels. Patients with high thoracic (T1-6) injury seem to be at the highest risk and patients with high cervical (C1-4) injury at one of the lowest. A higher index of suspicion for VTE should therefore be maintained in patients with a high thoracic SCI. Further studies are required to elucidate the underlying mechanisms.	[Maung, Adrian A.; Schuster, Kevin M.; Kaplan, Lewis J.; Maerz, Linda L.; Davis, Kimberly A.] Yale Univ, Sch Med, Dept Surg, Sect Trauma Surg Crit Care & Surg Emergencies, New Haven, CT 06520 USA	Maung, AA (corresponding author), Yale Univ, Sch Med, Dept Surg, Sect Trauma Surg Crit Care & Surg Emergencies, 330 Cedar St,BB-310, New Haven, CT 06520 USA.	adrian.maung@yale.edu					Azu MC, 2007, AM SURGEON, V73, P1228; BRACH BB, 1977, J TRAUMA, V17, P289, DOI 10.1097/00005373-197704000-00005; Chen D, 1999, ARCH PHYS MED REHAB, V80, P1397, DOI 10.1016/S0003-9993(99)90250-2; Falcone RA, 2008, J PEDIATR SURG, V43, P1858, DOI 10.1016/j.jpedsurg.2008.01.058; GREEN D, 1990, ANN INTERN MED, V113, P571, DOI 10.7326/0003-4819-113-8-571; Jones T, 2005, ARCH PHYS MED REHAB, V86, P2240, DOI 10.1016/j.apmr.2005.07.286; Maxwell RA, 2002, J TRAUMA, V52, P902, DOI 10.1097/00005373-200205000-00013; Merli G, 2003, J TRAUMA, V54, P1116, DOI 10.1097/01.TA.0000066385.10596.71; Montgomery KD, 1996, CLIN ORTHOP RELAT R, P68; MYLLYNEN P, 1985, J TRAUMA, V25, P541, DOI 10.1097/00005373-198506000-00013; OMALLEY KF, 1990, J TRAUMA, V30, P748, DOI 10.1097/00005373-199006000-00018; Paffrath T, 2010, INJURY, V41, P97, DOI 10.1016/j.injury.2009.06.010; Rogers FB, 2002, J TRAUMA, V53, P142, DOI 10.1097/00005373-200207000-00032; SHACKFORD SR, 1990, AM J SURG, V159, P365, DOI 10.1016/S0002-9610(05)81272-3; Sharma OP, 2007, AM SURGEON, V73, P1173; Spinal Cord Injury Thromboprophylaxis Investigators, 2003, J TRAUMA, V54, P1125; WARING WP, 1991, PARAPLEGIA, V29, P8, DOI 10.1038/sc.1991.2	17	34	34	1	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	NOV	2011	71	5					1241	1245		10.1097/TA.0b013e318235ded0			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	849IG	WOS:000297118600031	22071925				2021-06-18	
J	Dockree, PM; Robertson, IH				Dockree, Paul M.; Robertson, Ian H.			Electrophysiological markers of cognitive deficits in traumatic brain injury: A review	INTERNATIONAL JOURNAL OF PSYCHOPHYSIOLOGY			English	Article						Traumatic brain injury; ERP; Spectral EEG; Cognitive impairment	CLOSED-HEAD-INJURY; ANTERIOR CINGULATE CORTEX; INFORMATION-PROCESSING DEFICITS; DIFFUSE AXONAL INJURY; SUSTAINED ATTENTION; RESPONSE-INHIBITION; EXECUTIVE FUNCTIONS; ERP COMPONENTS; SEVERE TBI; AWARENESS	Event-related potentials (ERPs) and oscillatory activity from the human electroencephalogram (EEG) provides a rich source of data that helps elucidate specific processing impairments in TBI patients. This review will focus on some of the central and disabling cognitive deficits in TBI and how broadband ERP markers and the spectral content of the EEG can help explain abnormalities in brain function that impact upon processing speed, sustained attention, performance monitoring, inhibitory control and cognitive flexibility. Physiological signals also provide useful outcome markers in cognitive intervention studies in conjunction with behavioural endpoints. Potential rehabilitation approaches utilising electrophysiological markers of recovery are also discussed. Progress has been made in recent years in defining key pathophysiological mechanisms in the context of sensitive laboratory paradigms. However, aberrant physiological signals need to be understood more clearly in future studies in terms of the neuroanatomical impact of injury, particularly in relation to the most common type of damage in TBI, disrupting extended white matter fibres. (C) 2011 Elsevier B.V. All rights reserved.	[Dockree, Paul M.] Trinity Coll Dublin, Sch Psychol, Dublin, Ireland; Trinity Coll Dublin, Trinity Coll Inst Neurosci, Dublin, Ireland	Dockree, PM (corresponding author), Trinity Coll Dublin, Sch Psychol, Dublin, Ireland.	dockreep@tcd.ie		Robertson, Ian H/0000-0001-8637-561X	Health Research Board, Ireland	This work was supported by a grant from the Health Research Board, Ireland.	Aron AR, 2006, J NEUROSCI, V26, P2424, DOI 10.1523/JNEUROSCI.4682-05.2006; Aron AR, 2004, TRENDS COGN SCI, V8, P170, DOI 10.1016/j.tics.2004.02.010; Bashore TR, 2002, PSYCHOL BULL, V128, P151, DOI 10.1037/0033-2909.128.1.151; Bigler ED, 2010, NEUROLOGY, V74, P626, DOI 10.1212/WNL.0b013e3181d3e43a; Boksem MAS, 2008, BIOL PSYCHOL, V79, P185, DOI 10.1016/j.biopsycho.2008.04.010; CAMPBELL KB, 1990, ELECTROEN CLIN NEURO, P202; Carter CS, 2007, COGN AFFECT BEHAV NE, V7, P367, DOI 10.3758/CABN.7.4.367; Chambers CD, 2006, J COGNITIVE NEUROSCI, V18, P444, DOI 10.1162/jocn.2006.18.3.444; Christoff K, 2009, P NATL ACAD SCI USA, V106, P8719, DOI 10.1073/pnas.0900234106; CREMONAMETEYARD SL, 1994, BRAIN INJURY, V8, P541, DOI 10.3109/02699059409151006; Damasio A.R, 1998, PREFRONTAL CORTEX EX, P103; de Bruijn ERA, 2004, PSYCHOPHARMACOLOGY, V177, P151, DOI 10.1007/s00213-004-1915-6; DEACON D, 1991, J CLIN EXP NEUROPSYC, V13, P639, DOI 10.1080/01688639108401079; Dockree PM, 2006, BRAIN, V129, P128, DOI 10.1093/brain/awh664; Dockree PM, 2006, EXP BRAIN RES, V168, P218, DOI 10.1007/s00221-005-0079-x; Dockree PM, 2005, NEUROIMAGE, V27, P587, DOI 10.1016/j.neuroimage.2005.05.044; Dockree PM, 2004, COGNITIVE BRAIN RES, V20, P403, DOI 10.1016/j.cogbrainres.2004.03.019; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; Falkenstein M, 2000, BIOL PSYCHOL, V51, P87, DOI 10.1016/S0301-0511(99)00031-9; Fassbender C, 2004, COGNITIVE BRAIN RES, V20, P132, DOI 10.1016/j.cogbrainres.2004.02.007; Fassbender C, 2009, EUR J NEUROSCI, V29, P181, DOI 10.1111/j.1460-9568.2008.06557.x; Felmingham KL, 2004, NEUROPSYCHOLOGY, V18, P564, DOI 10.1037/0894-4105.18.3.564; Ferraro FR, 1996, BRAIN COGNITION, V32, P429, DOI 10.1006/brcg.1996.0075; Frank MJ, 2007, COGN AFFECT BEHAV NE, V7, P297, DOI 10.3758/CABN.7.4.297; Franken IHA, 2007, BIOL PSYCHOL, V75, P45, DOI 10.1016/j.biopsycho.2006.11.003; Gaetz M, 2000, BRAIN INJURY, V14, P815; Garavan H, 2002, NEUROIMAGE, V17, P1820, DOI 10.1006/nimg.2002.1326; Ghajar J, 2008, NEUROREHAB NEURAL RE, V22, P217, DOI 10.1177/1545968308315600; HEINZE HJ, 1992, NEUROPSYCHOLOGIA, V30, P495, DOI 10.1016/0028-3932(92)90054-P; Hester R, 2005, NEUROIMAGE, V27, P602, DOI 10.1016/j.neuroimage.2005.04.035; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Holroyd CB, 2002, PSYCHOL REV, V109, P679, DOI [10.1037//0033-295X.109.4.679, 10.1037/0033-295X.109.4.679]; Holroyd CB, 2008, CORTEX, V44, P548, DOI 10.1016/j.cortex.2007.08.013; Iznak EV, 2010, ZH NEVROL PSIKHIATR, V110, P27; Jiang Q, 2010, STROKE, V41, pS112, DOI 10.1161/STROKEAHA.110.595629; KARZMARK P, 1992, Brain Injury, V6, P213, DOI 10.3109/02699059209029662; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; KUTAS M, 1977, SCIENCE, V197, P792, DOI 10.1126/science.887923; Lachapelle J, 2004, VISION RES, V44, P2835, DOI 10.1016/j.visres.2004.06.007; Lachapelle J, 2008, BRAIN INJURY, V22, P265, DOI 10.1080/02699050801938983; Lam C S, 1988, Brain Inj, V2, P235, DOI 10.3109/02699058809150947; Larson MJ, 2007, J INT NEUROPSYCH SOC, V13, P961, DOI 10.1017/S1355617707071305; Larson MJ, 2009, J INT NEUROPSYCH SOC, V15, P927, DOI 10.1017/S1355617709990701; Larson MJ, 2009, NEUROREPORT, V20, P1486, DOI 10.1097/WNR.0b013e32833283fe; Larson MJ, 2009, NEUROPSYCHOLOGY, V23, P433, DOI 10.1037/a0015723; Lavoie ME, 2004, J CLIN EXP NEUROPSYC, V26, P55, DOI 10.1076/jcen.26.1.55.23936; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Levine B, 1998, BRAIN, V121, P1951, DOI 10.1093/brain/121.10.1951; Levine B, 2006, J NEUROTRAUM, V23, P1396, DOI 10.1089/neu.2006.23.1396; Lew HL, 2009, AM J PHYS MED REHAB, V88, P1, DOI 10.1097/PHM.0b013e3181911102; Little DM, 2010, NEUROLOGY, V74, P558, DOI 10.1212/WNL.0b013e3181cff5d5; Lutz A, 2009, J NEUROSCI, V29, P13418, DOI 10.1523/JNEUROSCI.1614-09.2009; Madigan NK, 2000, J HEAD TRAUMA REHAB, V15, P943, DOI 10.1097/00001199-200006000-00007; Marquez de la Plata C.D., 2010, J INT NEUROPSYCH SOC, P1; Mathias JL, 2007, NEUROPSYCHOLOGY, V21, P212, DOI 10.1037/0894-4105.21.2.212; Mathias JL, 2004, J INT NEUROPSYCH SOC, V10, P286, DOI 10.1017/S1355617704102117; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Morton N, 2010, J INT NEUROPSYCH SOC, V16, P1089, DOI 10.1017/S1355617710000925; Nieuwenhuis S, 2001, PSYCHOPHYSIOLOGY, V38, P752, DOI 10.1017/S0048577201001111; O'Connell B.C., 2010, 20 ANN ROTM RES I C; O'Connell RG, 2008, NEUROPSYCHOLOGIA, V46, P1379, DOI 10.1016/j.neuropsychologia.2007.12.018; O'Connell RG, 2007, EUR J NEUROSCI, V25, P2571, DOI 10.1111/j.1460-9568.2007.05477.x; O'Connell RG, 2009, J NEUROSCI, V29, P8604, DOI 10.1523/JNEUROSCI.5967-08.2009; O'Connell RG, 2004, NEUROREPORT, V15, P2535, DOI 10.1097/00001756-200411150-00021; O'Keeffe F, 2007, J INT NEUROPSYCH SOC, V13, P38, DOI 10.1017/S1355617707070075; O'Keeffe FM, 2004, COGNITIVE BRAIN RES, V22, P101, DOI 10.1016/j.cogbrainres.2004.07.012; PARDO JV, 1991, NATURE, V349, P61, DOI 10.1038/349061a0; Perlstein WM, 2006, NEUROPSYCHOLOGIA, V44, P260, DOI 10.1016/j.neuropsychologia.2005.05.009; Pontifex MB, 2009, NEUROPSYCHOLOGIA, V47, P3210, DOI 10.1016/j.neuropsychologia.2009.07.021; Prigatano G., 1986, COGNITIVE DYSFUNCTIO; Reinvang I, 2000, NEUROPSYCHOLOGIA, V38, P995, DOI 10.1016/S0028-3932(99)00153-0; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Roche RAP, 2004, NEUROSCI LETT, V362, P1, DOI 10.1016/j.neulet.2003.11.064; Rolls ET, 2000, CEREB CORTEX, V10, P284, DOI 10.1093/cercor/10.3.284; RUGG MD, 1989, BRAIN, V112, P489, DOI 10.1093/brain/112.2.489; Rule RR, 2002, COGN AFFECT BEHAV NE, V2, P264, DOI 10.3758/CABN.2.3.264; Segalowitz S J, 1997, J Int Neuropsychol Soc, V3, P95; SEGALOWITZ SJ, 1992, J CLIN EXP NEUROPSYC, V14, P545, DOI 10.1080/01688639208402844; Sharma HS, 2010, ANN NY ACAD SCI, V1199, P125, DOI 10.1111/j.1749-6632.2009.05329.x; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; Smallwood J, 2008, J COGNITIVE NEUROSCI, V20, P458, DOI 10.1162/jocn.2008.20037; Smallwood J, 2006, PSYCHOL BULL, V132, P946, DOI 10.1037/0033-2909.132.6.946; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Sonuga-Barke EJS, 2007, NEUROSCI BIOBEHAV R, V31, P977, DOI 10.1016/j.neubiorev.2007.02.005; Stuss DT, 2003, BRAIN, V126, P2363, DOI 10.1093/brain/awg237; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; Trudel TM, 1998, REHABIL PSYCHOL, V43, P267, DOI 10.1037/0090-5550.43.4.267; van Veen V, 2002, J COGNITIVE NEUROSCI, V14, P593, DOI 10.1162/08989290260045837; van Veen V, 2002, PHYSIOL BEHAV, V77, P477, DOI 10.1016/S0031-9384(02)00930-7; Weissman DH, 2006, NAT NEUROSCI, V9, P971, DOI 10.1038/nn1727; Wise K, 2005, BRAIN INJURY, V19, P765, DOI 10.1080/0269905050019977	92	34	35	0	15	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0167-8760	1872-7697		INT J PSYCHOPHYSIOL	Int. J. Psychophysiol.	OCT	2011	82	1			SI		53	60		10.1016/j.ijpsycho.2011.01.004			8	Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental	Psychology; Neurosciences & Neurology; Physiology	859PZ	WOS:000297889600006	21238506				2021-06-18	
J	Zayas, JO; Feliciano, YZ; Hadley, CR; Gomez, AA; Vidal, JA				Zayas, Julio O.; Feliciano, Yara Z.; Hadley, Celene R.; Gomez, Angel A.; Vidal, Jorge A.			Temporal Bone Trauma and the Role of Multidetector CT in the Emergency Department	RADIOGRAPHICS			English	Article							RESOLUTION COMPUTED-TOMOGRAPHY; FACIAL PARALYSIS; MIDDLE-EAR; FRACTURES; COMPLICATIONS; INJURIES; MANAGEMENT; CLASSIFICATION	The temporal bone anatomy is complex, with many critical structures in close association with one another. The temporal bone region comprises cranial nerves V, VI, VII, and VIII; vascular structures such as the internal carotid and middle meningeal arteries; sigmoid sinus; jugular bulb; and sensorineural and membranous structures of the inner ear. Most temporal bone fractures are a result of high-energy blunt head trauma. Multidetector computed tomography (CT) plays a fundamental role in the initial evaluation of patients with polytrauma in the emergency department. Multidetector CT may help identify important structural injuries that may have devastating complications such as sensorineural hearing loss, conductive hearing loss, dizziness and balance dysfunction, perilymphatic fistulas, cerebrospinal fluid leaks, facial nerve paralysis, and vascular injury. Although classifying temporal bone fractures helps physicians understand and predict trauma-associated complications and guide treatment, identifying injury to critical structures is more important for guiding management and determining prognosis than is simply classifying temporal bone fractures into a general category. Many temporal bone fractures and complications may be readily identified and characterized at routine cervical, maxillofacial, and head multidetector CT performed in patients with polytrauma, without the need for dedicated temporal bone multidetector CT. Dedicated temporal bone multidetector CT should be considered when there is a high degree of suspicion for temporal bone fractures and no fractures are identified at head, cervical, or maxillofacial CT. (C) RSNA, 2011 . radiographics.rsna.org	[Zayas, Julio O.; Feliciano, Yara Z.; Hadley, Celene R.; Gomez, Angel A.; Vidal, Jorge A.] Univ Puerto Rico, Dept Radiol Sci, Diagnost Radiol Sect, Puerto Rico Med Ctr, San Juan, PR 00936 USA	Zayas, JO (corresponding author), Univ Puerto Rico, Dept Radiol Sci, Diagnost Radiol Sect, Puerto Rico Med Ctr, Med Sci Campus,Ave Americo Miranda,POB 5067, San Juan, PR 00936 USA.	julio.zayas@upr.edu					AVRAHAMI E, 1988, NEURORADIOLOGY, V30, P166, DOI 10.1007/BF00395619; BELLUCCI RJ, 1983, OTOLARYNG CLIN N AM, V16, P633; Brodie HA, 1997, AM J OTOL, V18, P188; CANNON CR, 1983, ARCH OTOLARYNGOL, V109, P285; Dahiya R, 1999, J TRAUMA, V47, P1079, DOI 10.1097/00005373-199912000-00014; FISCH U, 1974, LARYNGOSCOPE, V84, P2141, DOI 10.1288/00005537-197412000-00005; FISCH U, 1980, J LARYNGOL OTOL, V94, P129, DOI 10.1017/S0022215100088575; GEAN AD, 1994, IMAGING HEAD TRAUMA, P51; GHORAYEB BY, 1992, LARYNGOSCOPE, V102, P129; GRIFFIN JE, 1979, LARYNGOSCOPE, V89, P1432, DOI 10.1002/lary.5540890908; GURDJIAN ES, 1946, SURG GYNECOL OBSTET, V83, P219; HARKER LA, 1974, OTOLARYNG CLIN N AM, V7, P425; HASSO AN, 1988, OTOLARYNG CLIN N AM, V21, P295; Hough JV, 1980, OTOLARYNGOLOGY, V2, P1656; HOUGH JVD, 1968, LARYNGOSCOPE, V78, P899, DOI 10.1288/00005537-196806000-00003; Ishman SL, 2004, LARYNGOSCOPE, V114, P1734, DOI 10.1097/00005537-200410000-00011; Kerman M, 2002, NEUROSURG QUART, V12, P23, DOI 10.1097/00013414-200203000-00003; Kollias SS, 2004, MED RAD DIA IMG, P49; LAMBERT PR, 1984, LARYNGOSCOPE, V94, P1022; Lancaster JL, 1999, J ROY COLL SURG EDIN, V44, P87; Little SC, 2006, ARCH OTOLARYNGOL, V132, P1300, DOI 10.1001/archotol.132.12.1300; MCGOVERN FH, 1968, ARCH OTOLARYNGOL, V88, P536; McHugh HE, 1959, ANN OTOL, V68, P855; Meriot P, 1997, RADIOGRAPHICS, V17, P1445, DOI 10.1148/radiographics.17.6.9397457; Nosan DK, 1997, OTOLARYNG HEAD NECK, V117, P67, DOI 10.1016/S0194-5998(97)70209-2; Patay Z, 1995, RIV NEURORADIOL, V8, P855, DOI 10.1177/197140099500800611; Resnick DK, 1997, NEUROSURGERY, V40, P1177, DOI 10.1097/00006123-199706000-00012; SCHUBIGER O, 1986, NEURORADIOLOGY, V28, P93, DOI 10.1007/BF00327878; Swartz J. D., 1995, HEAD NECK IMAGING, P1425; SWARTZ JD, 1983, RADIOLOGY, V148, P449, DOI 10.1148/radiology.148.2.6867341; Swartz JD, 1997, IMAGING TEMPORAL BON, P318; TRAVIS LW, 1977, J TRAUMA, V17, P761, DOI 10.1097/00005373-197710000-00003; Ulrich K., 1926, ACTA OTO-LARYNGOL, V6, P1; Yanagihara N, 1997, Ear Nose Throat J, V76, P79; Yanagihara N, 1997, ENT-EAR NOSE THROAT, V76, P83	35	34	41	0	5	RADIOLOGICAL SOC NORTH AMERICA	OAK BROOK	820 JORIE BLVD, OAK BROOK, IL 60523 USA	0271-5333			RADIOGRAPHICS	Radiographics	OCT	2011	31	6			SI		1741	1755		10.1148/rg.316115506			15	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	834SU	WOS:000295985200018	21997992	Bronze			2021-06-18	
J	Izzetoglu, K; Ayaz, H; Merzagora, A; Izzetoglu, M; Shewokis, PA; Bunce, SC; Pourrezaei, K; Rosen, A; Onaral, B				Izzetoglu, Kurtulus; Ayaz, Hasan; Merzagora, Anna; Izzetoglu, Meltem; Shewokis, Patricia A.; Bunce, Scott C.; Pourrezaei, Kambiz; Rosen, Arye; Onaral, Banu			THE EVOLUTION OF FIELD DEPLOYABLE fNIR SPECTROSCOPY FROM BENCH TO CLINICAL SETTINGS	JOURNAL OF INNOVATIVE OPTICAL HEALTH SCIENCES			English	Article						Functional near-infrared spectroscopy; fNIR; TBI; anesthesia; BCI; pediatric pain	NEAR-INFRARED SPECTROSCOPY; CEREBRAL-BLOOD; HEMODYNAMIC-RESPONSE; BRAIN ACTIVITY; ACTIVATION; STIMULATION; OXYGENATION; TISSUE; SEVOFLURANE; PROPOFOL	In the late 1980s and early 1990s, Dr. Britton Chance and his colleagues, using picosecond-long laser pulses, spearheaded the development of time-resolved spectroscopy techniques in an effort to obtain quantitative information about the optical characteristics of the tissue. These efforts by Chance and colleagues expedited the translation of near-infrared spectroscopy (NIRS)-based techniques into a neuroimaging modality for various cognitive studies. Beginning in the early 2000s, Dr. Britton Chance guided and steered the collaboration with the Optical Brain Imaging team at Drexel University toward the development and application of a field deployable continuous wave functional near-infrared spectroscopy (fNIR) system as a means to monitor cognitive functions, particularly during attention and working memory tasks as well as for complex tasks such as war games and air traffic control scenarios performed by healthy volunteers under operational conditions. Further, these collaborative efforts led to various clinical applications, including traumatic brain injury, depth of anesthesia monitoring, pediatric pain assessment, and brain-computer interface in neurology. In this paper, we introduce how these collaborative studies have made fNIR an excellent candidate for specified clinical and research applications, including repeated cortical neuroimaging, bedside or home monitoring, the elicitation of a positive effect, and protocols requiring ecological validity. This paper represents a token of our gratitude to Dr. Britton Chance for his influence and leadership. Through this manuscript we show our appreciation by contributing to his commemoration and through our work we will strive to advance the field of optical brain imaging and promote his legacy.	[Izzetoglu, Kurtulus; Ayaz, Hasan; Merzagora, Anna; Izzetoglu, Meltem; Shewokis, Patricia A.; Pourrezaei, Kambiz; Rosen, Arye; Onaral, Banu] Sch Biomed Engn Sci & Hlth Syst, Philadelphia, PA 19104 USA; [Shewokis, Patricia A.] Drexel Univ, Coll Nursing & Hlth Profess, Philadelphia, PA 19104 USA; [Bunce, Scott C.] Penn State Coll Med, Ctr Emerging Neurotechnol & Imaging, Hershey, PA USA; [Bunce, Scott C.] Penn State Coll Med, Dept Psychiat, Hershey, PA USA	Izzetoglu, K (corresponding author), Sch Biomed Engn Sci & Hlth Syst, 3141 Chestnut St, Philadelphia, PA 19104 USA.	ki25@drexel.edu	Shewokis, Patricia A./C-5201-2014; Ayaz, Hasan/A-3274-2008; Izzetoglu, Kurtulus/AAB-6402-2020	Shewokis, Patricia A./0000-0001-9246-9495; Izzetoglu, Kurtulus/0000-0001-5304-7361; Ayaz, Hasan/0000-0001-5514-2741	Defense Advanced Research Projects Agency (DARPA) Augmented Cognition ProgramUnited States Department of DefenseDefense Advanced Research Projects Agency (DARPA); Office of Naval Research (ONR)Office of Naval Research [N00014-02-1-0524, N00014-01-1-0986]; Wallace H. Coulter Foundation; U.S. Army Medical Research Acquisition Activity [W81XWH-08-2-0573]	We acknowledge with thanks Dr. Shoko Nioka for her support and guidance throughout the development of technology; Drs. George Mychaskiw, Harel Rosen, Jay Horrow, Jose Leon-Carrion, and Maria Schultheis for their leadership, support, and guidance during the clinical studies; Ajit Devaraj, Alper Bozkurt, Frank Kepics, Gunay Yurtsever, and Mauricio Rodriguez for their hardware support in helping to develop various fNIR systems. These studies have been sponsored in part by funds from the Defense Advanced Research Projects Agency (DARPA) Augmented Cognition Program and the Office of Naval Research (ONR), under agreement numbers N00014-02-1-0524 and N00014-01-1-0986; Wallace H. Coulter Foundation, U.S. Army Medical Research Acquisition Activity; Cooperative Agreement W81XWH-08-2-0573.	Abdelnour AF, 2009, NEUROIMAGE, V46, P133, DOI 10.1016/j.neuroimage.2009.01.033; ALKIRE MT, 1995, ANESTHESIOLOGY, V82, P393, DOI 10.1097/00000542-199502000-00010; Ang KK, 2010, IEEE IJCNN; Ayaz H., 2010, ADV UNDERSTANDING HU, P21, DOI DOI 10.1201/EBK1439835012-C3; Ayaz H, 2007, 2007 3RD INTERNATIONAL IEEE/EMBS CONFERENCE ON NEURAL ENGINEERING, VOLS 1 AND 2, P342, DOI 10.1109/CNE.2007.369680; Ayaz H, 2011, JOVE-J VIS EXP, DOI 10.3791/3443; Ayaz H, 2012, NEUROIMAGE, V59, P36, DOI 10.1016/j.neuroimage.2011.06.023; Ayaz H, 2009, LECT NOTES ARTIF INT, V5638, P699, DOI 10.1007/978-3-642-02812-0_79; Bartocci M, 2006, PAIN, V122, P109, DOI 10.1016/j.pain.2006.01.015; Bauernfeind G, 2008, BIOMED TECH, V53, P36, DOI 10.1515/BMT.2008.005; Bedforth NM, 2000, ANESTH ANALG, V91, P152, DOI 10.1097/00000539-200007000-00028; Birbaumer N, 2006, CLIN NEUROPHYSIOL, V117, P479, DOI 10.1016/j.clinph.2005.11.002; Boas DA, 2002, OPT EXPRESS, V10, P159, DOI 10.1364/OE.10.000159; Boas DA, 2002, METH NE FRO NEUROSCI, P193; Bozkurt A, 2005, BIOMED ENG ONLINE, V4, DOI 10.1186/1475-925X-4-29; Braver TS, 1997, NEUROIMAGE, V5, P49, DOI 10.1006/nimg.1996.0247; Chance B, 1998, OPT EXPRESS, V2, P411, DOI 10.1364/OE.2.000411; COPE M, 1988, MED BIOL ENG COMPUT, V26, P289, DOI 10.1007/BF02447083; Coyle S, 2004, PHYSIOL MEAS, V25, P815, DOI 10.1088/0967-3334/25/4/003; Coyle SM, 2007, J NEURAL ENG, V4, P219, DOI 10.1088/1741-2560/4/3/007; DELPY DT, 1987, SCAND J CLIN LAB INV, V47, P9; DELPY DT, 1988, PHYS MED BIOL, V33, P1433, DOI 10.1088/0031-9155/33/12/008; Dubroff JG, 2008, SEMIN NEUROL, V28, P548, DOI 10.1055/s-0028-1083698; Eschweiler GW, 2000, PSYCHIAT RES-NEUROIM, V99, P161, DOI 10.1016/S0925-4927(00)00062-7; Fallgatter AJ, 2000, SCHIZOPHRENIA BULL, V26, P913, DOI 10.1093/oxfordjournals.schbul.a033505; FISHKIN JB, 1993, J OPT SOC AM A, V10, P127, DOI 10.1364/JOSAA.10.000127; Heinke W, 2005, CURR OPIN ANESTHESIO, V18, P625, DOI 10.1097/01.aco.0000189879.67092.12; Hock C, 1996, ANN NY ACAD SCI, V777, P22, DOI 10.1111/j.1749-6632.1996.tb34397.x; Hummel P, 2006, SEMIN FETAL NEONAT M, V11, P237, DOI 10.1016/j.siny.2006.02.004; Izzetoglu K, 2004, INT J HUM-COMPUT INT, V17, P211, DOI 10.1207/s15327590ijhc1702_6; Izzetoglu M, 2005, IEEE T NEUR SYS REH, V13, P153, DOI 10.1109/TNSRE.2005.847377; Izzetoglu M., 2010, SOC NEUROSCIEN UNPUB; JOBSIS FF, 1977, SCIENCE, V198, P1264, DOI 10.1126/science.929199; Kaisti KK, 2003, ANESTHESIOLOGY, V99, P603, DOI 10.1097/00000542-200309000-00015; Limongi Tania, 2009, INT J BIOELECTROMAGN, V11, P86; Luu S, 2009, J NEURAL ENG, V6, DOI 10.1088/1741-2560/6/1/016003; Matta BF, 1999, ANESTHESIOLOGY, V91, P677, DOI 10.1097/00000542-199909000-00019; Matthews F., 2008, C P ANN INT C IEEE E, V2008, P4840; McCarthy G, 1997, J NEUROPHYSIOL, V77, P1630; Meek JH, 1998, PEDIATR RES, V43, P840, DOI 10.1203/00006450-199806000-00019; Miezin FM, 2000, NEUROIMAGE, V11, P735, DOI 10.1006/nimg.2000.0568; Millan JDR, 2010, FRONT NEUROSCI-SWITZ, V4, DOI 10.3389/fnins.2010.00161; Obrig H, 1997, ADV EXP MED BIOL, V413, P113; Okada F, 1996, J AFFECT DISORDERS, V37, P13, DOI 10.1016/0165-0327(95)00040-2; OKADA F, 1994, EUR ARCH PSY CLIN N, V244, P17, DOI 10.1007/BF02279807; Oum K., 2010, 2010 2 INT IEEE CONS, P1; PATTERSON MS, 1989, APPL OPTICS, V28, P2331, DOI 10.1364/AO.28.002331; Pitetti RD, 2005, CAN MED ASSOC J, V172, P1699, DOI 10.1503/cmaj.050537; Platek SM, 2005, SCHIZOPHR RES, V73, P125, DOI 10.1016/j.schres.2004.09.024; Power SD, 2010, J NEURAL ENG, V7, DOI 10.1088/1741-2560/7/2/026002; Ranganath S, 2005, PROC SPIE, V5852, P434, DOI 10.1117/12.621536; Ricker JH, 2001, J HEAD TRAUMA REHAB, V16, P191, DOI 10.1097/00001199-200104000-00007; Sakatani K, 1999, J NEUROL NEUROSUR PS, V67, P769, DOI 10.1136/jnnp.67.6.769; Scheibel RS, 2007, NEUROREHAB NEURAL RE, V21, P36, DOI 10.1177/1545968306294730; Sitaram R., 2009, NEURAL NETW; Sitaram R, 2007, NEUROIMAGE, V34, P1416, DOI 10.1016/j.neuroimage.2006.11.005; Strangman G, 2005, AM J PHYS MED REHAB, V84, P62, DOI 10.1097/01.PHM.0000150787.26860.12; Strangman G, 2002, BIOL PSYCHIAT, V52, P679, DOI 10.1016/S0006-3223(02)01550-0; Villringer A, 1997, TRENDS NEUROSCI, V20, P435, DOI 10.1016/S0166-2236(97)01132-6; Watanabe E, 2000, J BIOMED OPT, V5, P287, DOI 10.1117/1.429998; Wolpaw J. R., 2007, J PHYSL 3, V579, P619; Wolpaw JR, 2007, J PHYSIOL-LONDON, V579, P613, DOI 10.1113/jphysiol.2006.125948; Zaramella P, 2001, PEDIATR RES, V49, P213, DOI 10.1203/00006450-200102000-00014	63	34	35	0	7	WORLD SCIENTIFIC PUBL CO PTE LTD	SINGAPORE	5 TOH TUCK LINK, SINGAPORE 596224, SINGAPORE	1793-5458	1793-7205		J INNOV OPT HEAL SCI	J. Innov. Opt. Health Sci.	JUL	2011	4	3					239	250		10.1142/S1793545811001587			12	Optics; Radiology, Nuclear Medicine & Medical Imaging	Optics; Radiology, Nuclear Medicine & Medical Imaging	V27YK	WOS:000208648300006					2021-06-18	
J	Dong, XQ; Yu, WH; Hu, YY; Zhang, ZY; Huang, M				Dong, Xiao-Qiao; Yu, Wen-Hua; Hu, Yue-Yu; Zhang, Zu-Yong; Huang, Man			Oxymatrine reduces neuronal cell apoptosis by inhibiting Toll-like receptor 4/nuclear factor kappa-B-dependent inflammatory responses in traumatic rat brain injury	INFLAMMATION RESEARCH			English	Article						Traumatic brain injury; Oxymatrine; Toll-like receptor 4; Nuclear factor kappa-B; Inflammatory cytokine; Neuronal cell apoptosis	INNATE; MECHANISMS	Objective To investigate the influence of oxymatrine (OMT) on Toll-like receptor 4 (TLR-4)/nuclear factor kappa-B (NF-kappa B)-dependent inflammatory responses and neuronal cell apoptosis after traumatic brain injury (TBI). Materials and methods Wistar rats were given an intraperitoneal injection of 60 or 120 mg/kg OMT after TBI once a day till day 5. Rats were killed by decapitation at hours 2, 6 and 12, and days 1, 2, 3 and 5 after TBI. Gene expressions of TLR-4 and NF-kappa B, concentrations of tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1 beta) and interleukin-6 (IL-6) as well as the number of apoptotic neuronal cells in traumatic rat brain tissues were determined. Results The administration of 120 mg/kg OMT could significantly suppress gene expressions of TLR-4 and NF-kappa B, lessen concentrations of TNF-alpha, IL-1 beta and IL-6, and reduce the number of apoptotic neuronal cells in traumatic rat brain tissues by the Mann-Whitney U test (P < 0.05), but the administration of 60 mg/kg OMT could not (P > 0.05). Conclusion OMT may inhibit TLR4/NF-kappa B-dependent inflammatory responses, and furthermore lessen neuronal cell apoptosis after TBI.	[Dong, Xiao-Qiao; Yu, Wen-Hua; Zhang, Zu-Yong] Nanjing Med Univ, Hangzhou Municipal Peoples Hosp 1, Dept Neurosurg, Hangzhou 310000, Zhejiang, Peoples R China; [Hu, Yue-Yu; Huang, Man] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Intens Care Unit, Coll Med, Hangzhou 310000, Zhejiang, Peoples R China	Dong, XQ (corresponding author), Nanjing Med Univ, Hangzhou Municipal Peoples Hosp 1, Dept Neurosurg, 261 Huansha Rd, Hangzhou 310000, Zhejiang, Peoples R China.	dxqhyy@163.com			Traditional Chinese Medicine Department of Zhejiang Province [2010ZA101]	This work is financially supported by the Traditional Chinese Medicine Department of Zhejiang Province, No. 2010ZA101.	Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Anderson KV, 2000, CURR OPIN IMMUNOL, V12, P13, DOI 10.1016/S0952-7915(99)00045-X; Bermpohl D, 2007, J CEREBR BLOOD F MET, V27, P1806, DOI 10.1038/sj.jcbfm.9600487; Chen G, 2008, ANN CLIN LAB SCI, V38, P65; Chen G, 2009, EXP NEUROL, V216, P398, DOI 10.1016/j.expneurol.2008.12.019; Cui LL, 2011, NEUROL RES, V33, P319, DOI 10.1179/016164110X12759951866876; Fan HG, 2009, MEDIAT INFLAMM, V2009, DOI 10.1155/2009/704706; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Hang CH, 2004, BRAIN RES, V1026, P23, DOI 10.1016/j.brainres.2004.07.090; Hang CH, 2006, BRAIN RES, V1109, P14, DOI 10.1016/j.brainres.2006.06.045; Hong-Li S, 2008, PHYTOTHER RES, V22, P985, DOI 10.1002/ptr.2452; Liu Y, 2009, BRAIN RES, V1268, P174, DOI 10.1016/j.brainres.2009.02.069; Lu J, 2009, FRONT BIOSCI-LANDMRK, V14, P3795, DOI 10.2735/3489; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Wong J, 2005, NEUROCRIT CARE, V3, P177, DOI 10.1385/NCC:3:2:177; Xiang XX, 2002, CHINESE MED J-PEKING, V115, P593; Zeng Z., 1999, J GASTROEN HEPATOL, V14, P5295; Zhao JP, 2008, SURG TODAY, V38, P931, DOI 10.1007/s00595-008-3785-8	22	34	41	0	10	SPRINGER BASEL AG	BASEL	PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND	1023-3830	1420-908X		INFLAMM RES	Inflamm. Res.	JUN	2011	60	6					533	539		10.1007/s00011-010-0300-7			7	Cell Biology; Immunology	Cell Biology; Immunology	765BS	WOS:000290679000004	21190123				2021-06-18	
J	Nishijima, DK; Sena, MJ; Holmes, JF				Nishijima, Daniel K.; Sena, Matthew J.; Holmes, James F.			Identification of Low-Risk Patients With Traumatic Brain Injury and Intracranial Hemorrhage Who Do Not Need Intensive Care Unit Admission	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Intracranial hemorrhage; Traumatic; Brain injuries; Craniocerebral trauma; Triage; Intensive care	COMPUTED-TOMOGRAPHY; STATES; GUIDELINES; UTILITY	Background: Patients with traumatic brain injury (TBI) and traumatic intracranial hemorrhage are frequently admitted to the intensive care unit (ICU) but never require critical care interventions. Improved ICU triage in this patient population can improve resource utilization and decrease health care costs. We sought to identify a low-risk group of patients with TBI who do not require admission to an ICU. Methods: This is a retrospective cohort study of adult patients with TBI and traumatic intracranial hemorrhage. The need for ICU admission was defined as the presence of a critical care intervention. Patients were considered low risk if there was no critical care intervention before hospital admission. Measured outcomes included delayed critical care interventions at 48 hours and during hospitalization, mortality, and emergency surgery. Results: A total of 187 of 320 patients were considered low risk. In the low-risk group, two patients (1.1%; 95% confidence interval [CI], 0.1-3.8) had a delayed critical care intervention within 48 hours of admission and four patients (2.1%; 95% CI, 0.6-5.4) after 48 hours of admission. Two patients (1.1%; 95% CI, 0-3.8) in the low-risk group died. No patients in the low-risk group required neurosurgical intervention. Conclusion: Patients with TBI without a critical care intervention before admission are at low risk for requiring future critical care interventions. Future studies are required to validate if this low-risk criteria can serve as a safe, cost-effective triage tool for ICU admission.	[Sena, Matthew J.] UC Davis Sch Med, Dept Surg, Sacramento, CA USA; [Nishijima, Daniel K.; Holmes, James F.] UC Davis Med Ctr, Dept Emergency Med, UC Davis Sch Med, Sacramento, CA 95817 USA	Nishijima, DK (corresponding author), UC Davis Med Ctr, Dept Emergency Med, UC Davis Sch Med, 2315 Stockton Blvd,PSSB 2100, Sacramento, CA 95817 USA.	daniel.nishijima@ucdmc.ucdavis.edu			NCATS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1 TR000002] Funding Source: Medline; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000002] Funding Source: NIH RePORTER		af Geijerstam JL, 2006, BMJ-BRIT MED J, V333, P465, DOI 10.1136/bmj.38918.669317.4F; Andrews PJD, 2002, J NEUROSURG, V97, P326, DOI 10.3171/jns.2002.97.2.0326; Barker DE, 2006, AM SURGEON, V72, P1166; BONE RC, 1993, CHEST, V104, P1806, DOI 10.1378/chest.104.6.1806; Chalfin DB, 2007, CRIT CARE MED, V35, P1477, DOI 10.1097/01.CCM.0000266585.74905.5A; Cohen DB, 2006, J TRAUMA, V60, P553, DOI 10.1097/01.ta.0000196542.54344.05; COPES WS, 1988, J TRAUMA, V28, P69, DOI 10.1097/00005373-198801000-00010; Egol A, 1999, CRIT CARE MED, V27, P633; Escher M, 2004, BRIT MED J, V329, P425, DOI 10.1136/bmj.329.7463.425; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GROEGER JS, 1993, CRIT CARE MED, V21, P279, DOI 10.1097/00003246-199302000-00022; Hesdorffer DC, 2007, J TRAUMA, V63, P841, DOI 10.1097/TA.0b013e318123fc21; Hesdorffer DC, 2002, J TRAUMA, V52, P1202, DOI 10.1097/00005373-200206000-00031; Hukkelhoven CWPM, 2005, INTENS CARE MED, V31, P799, DOI 10.1007/s00134-005-2628-y; Huynh T, 2006, AM SURGEON, V72, P1162; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; Milbrandt EB, 2008, CRIT CARE MED, V36, P2504, DOI 10.1097/CCM.0b013e318183ef84; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Norlund A, 2006, BMJ-BRIT MED J, V333, P469, DOI 10.1136/bmj.38918.659120.4F; Sifri ZC, 2004, AM J SURG, V187, P338, DOI 10.1016/j.amjsurg.2003.12.015; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Wang MC, 2006, J TRAUMA, V61, P226, DOI 10.1097/01.ta.0000197385.18452.89; Worster A, 2005, ANN EMERG MED, V45, P448, DOI 10.1016/j.annemergmed.2004.11.021	27	34	34	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUN	2011	70	6					E101	E107		10.1097/TA.0b013e3181e88bcb			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	775QR	WOS:000291478500001	20805765	Green Accepted			2021-06-18	
J	Myburgh, J; Bellomo, R; Cass, A; Finfer, S; French, J; Gattas, D; Glass, P; Lee, J; Lipman, J; Liu, B; McArthur, C; McGuinness, S; Rajbhandari, D; Taylor, C; Webb, S				Myburgh, John; Bellomo, Rinaldo; Cass, Alan; Finfer, Simon; French, Julie; Gattas, David; Glass, Parisa; Lee, Joanne; Lipman, Jeffrey; Liu, Bette; McArthur, Colin; McGuinness, Shay; Rajbhandari, Dorrilyn; Taylor, Colman; Webb, Steve		Crystalloid Versus Hydroxyethyl St	The Crystalloid versus Hydroxyethyl Starch Trial: protocol for a multi-centre randomised controlled trial of fluid resuscitation with 6% hydroxyethyl starch (130/0.4) compared to 0.9% sodium chloride (saline) in intensive care patients on mortality	INTENSIVE CARE MEDICINE			English	Article						Hydroxyethyl starch; Fluid therapy; Resuscitation; Colloids; Randomised controlled trials	CRITICALLY-ILL PATIENTS; CARDIAC-SURGERY PATIENTS; SEVERE HEAD-INJURY; RENAL-FUNCTION; ALBUMIN; GELATIN; THERAPY	The intravenous fluid 6% hydroxyethyl starch (130/0.4) (6% HES 130/0.4) is used widely for resuscitation but there is limited information on its efficacy and safety. A large-scale multi-centre randomised controlled trial (CHEST) in critically ill patients is currently underway comparing fluid resuscitation with 6% HES 130/0.4 to 0.9% sodium chloride on 90-day mortality and other clinically relevant outcomes including renal injury. This report describes the study protocol. CHEST will recruit 7,000 patients to concealed, random, parallel assignment of either 6% HES 130/0.4 or 0.9% sodium chloride for all fluid resuscitation needs whilst in the intensive care unit (ICU). The primary outcome will be all-cause mortality at 90 days post-randomisation. Secondary outcomes will include incident renal injury, other organ failures, ICU and hospital mortality, length of ICU stay, quality of life at 6 months, health economic analyses and in patients with traumatic brain injury, functional outcome. Subgroup analyses will be conducted in four predefined subgroups. All analyses will be conducted on an intention-to-treat basis. The study run-in phase has been completed and the main trial commenced in April 2010. CHEST should generate results that will inform and influence prescribing of this commonly used resuscitation fluid.	[Myburgh, John] Univ New S Wales, St George Hosp, George Inst, Sydney, NSW, Australia; [Bellomo, Rinaldo] Univ Melbourne, George Inst, Austin Hosp, Melbourne, Vic 3010, Australia; [Cass, Alan; Liu, Bette; Taylor, Colman] Univ Sydney, George Inst, Sydney, NSW 2006, Australia; [Finfer, Simon] Univ Sydney, George Inst, Royal N Shore Hosp, Sydney, NSW 2006, Australia; [Gattas, David] Royal Prince Alfred Hosp, Sydney, NSW, Australia; [Lipman, Jeffrey] Univ Queensland, Royal Brisbane & Womens Hosp, Brisbane, Qld 4072, Australia; [McArthur, Colin; Webb, Steve] Australian & New Zealand Intens Care Soc Clin Tri, Carlton, Vic, Australia; [McGuinness, Shay] Auckland Cardiovasc Hosp, Auckland, New Zealand	Myburgh, J (corresponding author), George Inst Int Hlth, Crit Care & Trauma Div, Sydney, NSW, Australia.	jmyburgh@george.org.au	Liu, Bette C/A-7581-2013; Lipman, Jeffrey/G-2211-2010; Gattas, David/AAN-9668-2020	Liu, Bette C/0000-0002-0787-5825; Lipman, Jeffrey/0000-0002-5965-9876; Gattas, David/0000-0002-9282-7093; Cass, Alan/0000-0002-3923-3173; Finfer, Simon/0000-0002-2785-5864; Glass, Parisa/0000-0002-1334-7156	Australian National Health and Medical Research CouncilNational Health and Medical Research Council of Australia; New South Wales Department of Health and Fresenius Kabi	The bodies currently funding this study include the Australian National Health and Medical Research Council, New South Wales Department of Health and Fresenius Kabi. The funders had no input into the design of the trial. Fresenius Kabi has provided the blinded study treatment for the conduct of the trial and will manage the warehousing and temperature-controlled distribution of study treatment from the manufacturing plant in Germany to each of the 33 participating centres that are anticipated to be recruiting throughout Australia and New Zealand. All blinded study treatment has been manufactured according to Good Manufacturing Practice requirements as applied to Investigational Medicinal Products. Fresenius Kabi reviewed the protocol to ensure it meets with their regulatory obligations. The funders do not have access to the trial data and all analyses and reports will be conducted independently of the funders.	Antonelli M, 2010, INTENS CARE MED, V36, P412, DOI 10.1007/s00134-010-1770-3; Boldt J, 2008, BRIT J ANAESTH, V100, P457, DOI 10.1093/bja/aen016; Boldt J, 2003, INTENS CARE MED, V29, P763, DOI 10.1007/s00134-003-1702-6; Boldt J, 2007, CRIT CARE MED, V35, P2740, DOI 10.1097/01.CCM.0000288101.02556.DE; Brunkhorst FM, 2008, NEW ENGL J MED, V358, P125, DOI 10.1056/NEJMoa070716; Bunn F, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001319.pub2; Dart AB, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007594.pub2; Fenger-Eriksen C, 2005, ACTA ANAESTH SCAND, V49, P969, DOI 10.1111/j.1399-6576.2005.00714.x; Finfer S, 2004, NEW ENGL J MED, V350, P2247; Finfer S, 2009, NEW ENGL J MED, V360, P1283, DOI 10.1056/NEJMoa0810625; Fluids Study Investigators, 2008, ACTA ANAESTH SCAND, V52, P750, DOI 10.1111/j.1399-6576.2008.01690.x; Jones D, 2010, ANAESTH INTENS CARE, V38, P266, DOI 10.1177/0310057X1003800207; Kellum JA, 2007, CONTRIB NEPHROL, V156, P10; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Mahmood A, 2007, BRIT J SURG, V94, P427, DOI 10.1002/bjs.5726; Martin GS, 2004, AM J RESP CRIT CARE, V170, P1247, DOI 10.1164/rccm.200208-909ST; Miletin MS, 2002, INTENS CARE MED, V28, P917, DOI 10.1007/s00134-002-1337-z; Myburgh J, 2007, NEW ENGL J MED, V357, P874; Neff TA, 2003, ANESTH ANALG, V96, P1453, DOI 10.1213/01.ANE.0000061582.09963.FD; Perel P, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000567.pub3; Schortgen F, 2004, INTENS CARE MED, V30, P2222, DOI 10.1007/s00134-004-2415-1; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; U.S. Food and Drug Administration-FDA, 2003, GUID IND 11; Uchino S, 2005, JAMA-J AM MED ASSOC, V294, P813, DOI 10.1001/jama.294.7.813; Vincent JL, 1998, CRIT CARE MED, V26, P1793, DOI 10.1097/00003246-199811000-00016; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; Zarychanski R, 2008, CLIN INVESTIGATIVE S, V31, pS26	27	34	34	0	11	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	MAY	2011	37	5					816	823		10.1007/s00134-010-2117-9			8	Critical Care Medicine	General & Internal Medicine	747AG	WOS:000289291900013	21308360				2021-06-18	
J	Robertson, CS; Gopinath, SP; Valadka, AB; Van, M; Swank, PR; Goodman, JC				Robertson, Claudia S.; Gopinath, Shankar P.; Valadka, Alex B.; Van, Mai; Swank, Paul R.; Goodman, J. Clay			Variants of the Endothelial Nitric Oxide Gene and Cerebral Blood Flow after Severe Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						CBF autoregulation; cerebral vascular disease; head trauma; vascular reactivity; traumatic brain injury	CORTICAL IMPACT INJURY; SYNTHASE GENE; APOLIPOPROTEIN-E; ISCHEMIC-STROKE; HEAD-INJURY; L-ARGININE; POLYMORPHIC VARIANTS; T-786C POLYMORPHISM; CAROTID-ARTERY; AUTOREGULATION	Experimental studies suggest that nitric oxide produced by endothelial nitric oxide synthase (NOS3) plays a role in maintaining cerebral blood flow (CBF) after traumatic brain injury (TBI). The purpose of this study was to determine if common variants of the NOS3 gene contribute to hypoperfusion after severe TBI. Fifty-one patients with severe TBI were studied. Cerebral hemodynamics, including global CBF by the stable xenon computed tomography (CT) technique, internal carotid artery flow volume (ICA-FVol), and flow velocity in intracranial vessels, were measured within 12 h of injury, and at 48 h after injury. A blood sample was collected for DNA analysis, and genotyping of the following variants of the NOS3 gene was performed: -786T > C, 894G > T, and 27bp VNTR. Cerebral hemodynamics were most closely related to the -786T > C genotype. CBF averaged 57.7 +/- 3.0 mL/100g/min with the normal T/T genotype, 47.0 +/- 2.5 mL/100g/min with the T/C, and 37.3 +/- 8.8 mL/100g/min with the C/C genotype (p = 0.0146). Cerebrovascular resistance followed an inverse pattern with the highest values occurring with the C/C genotype (p = 0.0027). The lowest ICA-FVol of 124 +/- 43mL/min was found at 12 h post-injury in the more injured hemisphere of the patients with the C/C genotype (p = 0.0085). The mortality rate was 20% in patients with the T/T genotype and 17% with the T/C genotype. In contrast, both of the patients with the C/C genotype were dead at 6 months post-injury (p = 0.022). The findings in this study support the importance of NO produced by NOS3 activity in maintaining CBF after TBI, since lower CBF values were found in patients having the -786C allele. The study suggests that a patient's individual genetic makeup may contribute to the brain's response to injury and determine the patient's chances of surviving the injury. The results here will need to be studied in a larger number of patients, but could explain some of the variability in outcome that occurs following severe TBI.	[Robertson, Claudia S.; Gopinath, Shankar P.; Van, Mai] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; [Goodman, J. Clay] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA; [Valadka, Alex B.] Seton Brain & Spine Inst, Austin, TX USA; [Swank, Paul R.] Univ Texas Hlth Sci Ctr Houston, Houston, TX USA	Robertson, CS (corresponding author), Baylor Coll Med, Dept Neurosurg, 1709 Dryden,Suite 750,MS BCM650, Houston, TX 77030 USA.	claudiar@bcm.tmc.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-NS048428]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS048428] Funding Source: NIH RePORTER	This work was funded by National Institutes of Health grant no. R01-NS048428.	AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; Ahn MJ, 2004, J NEUROTRAUM, V21, P1431, DOI 10.1089/neu.2004.21.1431; Asif AR, 2009, J PROTEOME RES, V8, P3161, DOI 10.1021/pr800998k; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; BUCHANAN JE, 1993, BRAIN RES, V610, P248, DOI 10.1016/0006-8993(93)91408-K; Casas JP, 2004, CIRCULATION, V109, P1359, DOI 10.1161/01.CIR.0000121357.76910.A3; Cherian L, 2000, J NEUROPHYSIOL, V83, P2171; Cherian L, 2003, J NEUROTRAUM, V20, P77, DOI 10.1089/08977150360517209; Cherian L, 2003, J PHARMACOL EXP THER, V304, P617, DOI 10.1124/JPET.102.043430; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; FIELD M, 2001, AM ASS NEUR SURG ABS; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Graham DI, 1999, ACT NEUR S, V73, P89; Hlatky R, 2006, NEUROCRIT CARE, V4, P127, DOI 10.1385/NCC:4:2:127; Hlatky R, 2003, J NEUROTRAUM, V20, P995, DOI 10.1089/089771503770195849; Hlatky R, 2002, J NEUROSURG, V97, P1054, DOI 10.3171/jns.2002.97.5.1054; Howard TD, 2005, STROKE, V36, P1848, DOI 10.1161/01.STR.0000177978.97428.53; Johnson VE, 2009, J NEUROTRAUM, V26, P1197, DOI [10.1089/neu.2008.0843, 10.1089/neu.2008-0843]; Khurana VG, 2005, J NEUROSURG, V102, P526, DOI 10.3171/jns.2005.102.3.0526; Kleffner I, 2008, STROKE, V39, P1333, DOI 10.1161/STROKEAHA.107.500785; Ko NU, 2008, STROKE, V39, P1103, DOI 10.1161/STROKEAHA.107.496596; KOBARI M, 1994, BRAIN RES, V667, P255, DOI 10.1016/0006-8993(94)91503-2; Kors EE, 2001, ANN NEUROL, V49, P753, DOI 10.1002/ana.1031; Leeson CPM, 2002, CIRC RES, V90, P1153, DOI 10.1161/01.RES.0000020562.07492.D4; Liaquat I, 2002, J NEUROSURG, V96, P90, DOI 10.3171/jns.2002.96.1.0090; Liberman JN, 2002, NEUROLOGY, V58, P1038, DOI 10.1212/WNL.58.7.1038; Majumdar V, 2010, J ATHEROSCLER THROMB, V17, P45, DOI 10.5551/jat.1560; MARSDEN PA, 1993, J BIOL CHEM, V268, P17478; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Martinez-Lucas P, 2005, INTENS CARE MED, V31, P1168, DOI 10.1007/s00134-005-2715-0; McDonald DM, 2004, PHARMACOGENETICS, V14, P831, DOI 10.1097/00008571-200412000-00006; Miyamoto Y, 2000, HUM MOL GENET, V9, P2629, DOI 10.1093/hmg/9.18.2629; Nasreen S, 2002, ARTERIOSCL THROM VAS, V22, P605, DOI 10.1161/01.ATV.0000013286.60021.FE; Persu A, 2002, HUM MOL GENET, V11, P229, DOI 10.1093/hmg/11.3.229; Reutens DC, 1997, J CEREBR BLOOD F MET, V17, P309, DOI 10.1097/00004647-199703000-00008; Rossi GP, 2003, J AM COLL CARDIOL, V41, P938, DOI 10.1016/S0735-1097(02)03011-5; Sabo T, 2000, NEUROSCIENCE, V101, P879, DOI 10.1016/S0306-4522(00)00438-3; Saidi S, 2010, ACTA NEUROL SCAND, V121, P114, DOI 10.1111/j.1600-0404.2009.01192.x; Savvidou MD, 2001, HYPERTENSION, V38, P1289, DOI 10.1161/hy1201.097305; Smielewski P, 1996, STROKE, V27, P2197, DOI 10.1161/01.STR.27.12.2197; Song J, 2010, INT J MOL MED, V25, P819, DOI 10.3892/ijmm_00000410; Sorani MD, 2008, HUM MUTAT, V29, P1108, DOI 10.1002/humu.20762; Soustiel JF, 2003, STROKE, V34, P1876, DOI 10.1161/01.STR.0000080942.32331.39; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Tanus-Santos JE, 2001, PHARMACOGENETICS, V11, P719, DOI 10.1097/00008571-200111000-00011; Tao HM, 2009, NEUROSCI RES, V64, P311, DOI 10.1016/j.neures.2009.04.001; Tesauro M, 2000, P NATL ACAD SCI USA, V97, P2832, DOI 10.1073/pnas.97.6.2832; TIECKS FP, 1995, STROKE, V26, P1014, DOI 10.1161/01.STR.26.6.1014; Tsukada T, 1998, BIOCHEM BIOPH RES CO, V245, P190, DOI 10.1006/bbrc.1998.8267; Tuzgen S, 2003, NEUROL RES, V25, P31, DOI 10.1179/016164103101201085; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; White RP, 2000, CLIN SCI, V99, P555, DOI 10.1042/CS20000064; Yemisci M, 2009, FREE RADICAL RES, V43, P272, DOI 10.1080/10715760802691489	53	34	37	0	0	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAY	2011	28	5					727	737		10.1089/neu.2010.1476			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	762JI	WOS:000290472100273	21332418	Green Published			2021-06-18	
J	McCauley, SR; Wilde, EA; Bigler, ED; Chu, ZL; Yallampalli, R; Oni, MB; Wu, TC; Ramos, MA; Pedroza, C; Vasquez, AC; Hunter, JV; Levin, HS				McCauley, Stephen R.; Wilde, Elisabeth A.; Bigler, Erin D.; Chu, Zili; Yallampalli, Ragini; Oni, Margaret B.; Wu, Trevor C.; Ramos, Marco A.; Pedroza, Claudia; Vasquez, Ana C.; Hunter, Jill V.; Levin, Harvey S.			Diffusion Tensor Imaging of Incentive Effects in Prospective Memory after Pediatric Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						cingulum bundles; diffusion tensor imaging; event-based prospective memory; incentive; motivation; pediatrics orbitofrontal white matter; traumatic brain injury; uncinate fasciculus	WHITE-MATTER ABNORMALITIES; VISUAL ASSOCIATION CORTEX; ANTERIOR CINGULATE CORTEX; WORKING-MEMORY; TEMPORAL-LOBE; ORBITOFRONTAL CORTEX; PREFRONTAL CORTEX; UNCINATE FASCICULUS; FINANCIAL REWARD; EPISODIC MEMORY	Few studies exist investigating the brain-behavior relations of event-based prospective memory (EB-PM) impairments following traumatic brain injury (TBI). To address this, children with moderate-to-severe TBI performed an EB-PM test with two motivational enhancement conditions and underwent concurrent diffusion tensor imaging (DTI) at 3 months post-injury. Children with orthopedic injuries (OI; n = 37) or moderate-to-severe TBI (n = 40) were contrasted. Significant group differences were found for fractional anisotropy (FA) and apparent diffusion coefficient for orbitofrontal white matter (WM), cingulum bundles, and uncinate fasciculi. The FA of these WM structures in children with TBI significantly correlated with EB-PM performance in the high, but not the low motivation condition. Regression analyses within the TBI group indicated that the FA of the left cingulum bundle (p = 0.003), left orbitofrontal WM (p < 0.02), and left (p < 0.02) and right (p < 0.008) uncinate fasciculi significantly predicted EB-PM performance in the high motivation condition. We infer that the cingulum bundles, orbitofrontal WM, and uncinate fasciculi are important WM structures mediating motivation-based EB-PM responses following moderate-to-severe TBI in children.	[McCauley, Stephen R.] Baylor Coll Med, Cognit Neurosci Lab, Dept Neurol, Houston, TX 77030 USA; [McCauley, Stephen R.; Wilde, Elisabeth A.; Yallampalli, Ragini; Oni, Margaret B.; Ramos, Marco A.; Vasquez, Ana C.; Levin, Harvey S.] Univ Texas Houston, Sch Med, Houston, TX USA; [McCauley, Stephen R.; Levin, Harvey S.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; [Wilde, Elisabeth A.; Chu, Zili; Hunter, Jill V.] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [Levin, Harvey S.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; [McCauley, Stephen R.; Wilde, Elisabeth A.; Levin, Harvey S.] Michael E DeBakey VA Med Ctr, Houston, TX USA; [Bigler, Erin D.; Wu, Trevor C.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Bigler, Erin D.; Wu, Trevor C.] Brigham Young Univ, Ctr Neurosci, Provo, UT 84602 USA; [Bigler, Erin D.] Univ Utah, Dept Psychiat, Salt Lake City, UT USA; [Bigler, Erin D.] Univ Utah, Utah Brain Inst, Salt Lake City, UT USA; [Chu, Zili; Hunter, Jill V.] Texas Childrens Hosp, EB Singleton Dept Diagnost Imaging, Houston, TX 77030 USA; [Pedroza, Claudia] Univ Texas Houston, Sch Med, Ctr Clin Res & Evidence Based Med, Houston, TX USA	McCauley, SR (corresponding author), Baylor Coll Med, Cognit Neurosci Lab, Dept Neurol, 1709 Dryden Rd,Suite 1200, Houston, TX 77030 USA.	mccauley@bcm.edu		Pedroza, Claudia/0000-0003-4235-1282; Ramos, Marco/0000-0002-1649-7547	National Center for Medical Rehabilitation Research [K23 HD-40896]; National Institute Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD040896] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER	This work was supported by the National Center for Medical Rehabilitation Research (grant no. K23 HD-40896 to S. R. M) and the National Institute Neurological Disorders and Stroke (grant no. NS-21889 to H. S. L). The information in this article has never been published before, either electronically or in print. I would like to extend my personal appreciation to Drs. Mark McDaniel and Harvey Levin, who graciously served as mentors on a K-23 mentored patient-oriented research career development award. We also thank the participants and their families for their interest and willingness to take part in this research.	Akitsuki Y, 2003, NEUROIMAGE, V19, P1674, DOI 10.1016/S1053-8119(03)00250-7; Amiez C, 2006, CEREB CORTEX, V16, P1040, DOI 10.1093/cercor/bhj046; Anderson V, 2007, BRAIN INJURY, V21, P1399, DOI 10.1080/02699050701785070; Barbas H, 2007, ANN NY ACAD SCI, V1121, P10, DOI 10.1196/annals.1401.015; Barbas H, 2007, J ANAT, V211, P237, DOI 10.1111/j.1469-7580.2007.00777.x; Bracht T, 2009, PSYCHIAT RES-NEUROIM, V174, P217, DOI 10.1016/j.pscychresns.2009.05.001; BRANDIMONTE MA, 1994, Q J EXP PSYCHOL-A, V47, P565, DOI 10.1080/14640749408401128; Burgel U, 2006, NEUROIMAGE, V29, P1092, DOI 10.1016/j.neuroimage.2005.08.040; Burgess PW, 2001, NEUROPSYCHOLOGIA, V39, P545, DOI 10.1016/S0028-3932(00)00149-4; Burgess PW, 2003, NEUROPSYCHOLOGIA, V41, P906, DOI 10.1016/S0028-3932(02)00327-5; Burianova H, 2010, NEUROIMAGE, V49, P865, DOI 10.1016/j.neuroimage.2009.08.066; Bush G, 2000, TRENDS COGN SCI, V4, P215, DOI 10.1016/S1364-6613(00)01483-2; Bush G, 2002, P NATL ACAD SCI USA, V99, P523, DOI 10.1073/pnas.012470999; Catani M, 2002, NEUROIMAGE, V17, P77, DOI 10.1006/nimg.2002.1136; Catani M, 2008, CORTEX, V44, P1105, DOI 10.1016/j.cortex.2008.05.004; Catroppa C, 2002, BRAIN INJURY, V16, P369, DOI 10.1080/02699050110104444; Catroppa C, 2008, J CHILD NEUROL, V23, P486, DOI 10.1177/0883073807309773; Charlton RA, 2010, CORTEX, V46, P474, DOI 10.1016/j.cortex.2009.07.005; Cheng HD, 2008, BRAIN INJURY, V22, P697, DOI 10.1080/02699050802263035; Clark L, 2009, NEURON, V61, P481, DOI 10.1016/j.neuron.2008.12.031; COCKBURN J, 1995, CORTEX, V31, P87, DOI 10.1016/S0010-9452(13)80107-4; DAUM I, 1994, INT J NEUROSCI, V77, P187, DOI 10.3109/00207459408986030; Daum I, 2000, BEHAV NEUROL, V12, P161, DOI 10.1155/2000/327304; Di Stefano G, 2000, J NEUROL NEUROSUR PS, V69, P210, DOI 10.1136/jnnp.69.2.210; Diehl B, 2008, EPILEPSIA, V49, P1409, DOI 10.1111/j.1528-1167.2008.01596.x; DONDERS J, 1993, BRAIN INJURY, V7, P431, DOI 10.3109/02699059309029686; Donders J, 2002, NEUROPSYCHOLOGY, V16, P491, DOI 10.1037//0894-4105.16.4.491; Driscoll I, 2005, NEUROPSYCHOLOGY, V19, P28, DOI 10.1037/0894-4105.19.1.28; EBELING U, 1992, ACTA NEUROCHIR, V115, P143, DOI 10.1007/BF01406373; Eddington KM, 2009, SOC COGN AFFECT NEUR, V4, P238, DOI 10.1093/scan/nsp016; Einstein G., 1996, PROSPECTIVE MEMORY T, P115; EINSTEIN GO, 1990, J EXP PSYCHOL LEARN, V16, P717, DOI 10.1037/0278-7393.16.4.717; Elliott R, 2003, J NEUROSCI, V23, P303; Eschen A, 2007, INT J PSYCHOPHYSIOL, V64, P259, DOI 10.1016/j.ijpsycho.2006.09.005; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Fang JL, 2009, HUM BRAIN MAPP, V30, P1196, DOI 10.1002/hbm.20583; Fellgiebel A, 2005, NEUROBIOL AGING, V26, P1193, DOI 10.1016/j.neurobiolaging.2004.11.006; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Fortin S, 2002, BRAIN COGNITION, V48, P361, DOI 10.1006/brcg.2001.1378; Fujiwara J, 2009, J NEUROPHYSIOL, V101, P3284, DOI 10.1152/jn.90909.2008; Gazzaley A, 2007, CEREB CORTEX, V17, pI125, DOI 10.1093/cercor/bhm113; Geary EK, 2010, J INT NEUROPSYCH SOC, V16, P506, DOI 10.1017/S135561771000010X; Gilbert Alison M., 2004, Cognitive Affective & Behavioral Neuroscience, V4, P540, DOI 10.3758/CABN.4.4.540; Gilbert SJ, 2009, J EXP PSYCHOL LEARN, V35, P905, DOI 10.1037/a0015535; Greenberg G, 2008, ARCH PHYS MED REHAB, V89, pS45, DOI 10.1016/j.apmr.2008.08.211; Groot YCT, 2002, J INT NEUROPSYCH SOC, V8, P645, DOI 10.1017/S1355617702801321; Guajardo NR, 2000, COGNITIVE DEV, V15, P75, DOI 10.1016/S0885-2014(00)00016-2; Hannon R, 1995, REHABIL PSYCHOL, V40, P289, DOI 10.1037/0090-5550.40.4.289; Harris J. E., 1984, EVERYDAY MEMORY ACTI, P71; Henry JD, 2007, J CLIN EXP NEUROPSYC, V29, P457, DOI 10.1080/13803390600762717; Highley JR, 2002, CEREB CORTEX, V12, P1218, DOI 10.1093/cercor/12.11.1218; Hikosaka K, 2000, CEREB CORTEX, V10, P263, DOI 10.1093/cercor/10.3.263; HOOGENRAAD F, 2002, MULTICENTER EVALUATI; HUPPERT FA, 1993, J CLIN EXP NEUROPSYC, V15, P805, DOI 10.1080/01688639308402597; Kennedy MRT, 2009, J INT NEUROPSYCH SOC, V15, P130, DOI 10.1017/S1355617708090024; Kerns KA, 2001, CHILD NEUROPSYCHOL, V7, P162, DOI 10.1076/chin.7.3.162.8744; Kerns KA, 2000, J INT NEUROPSYCH SOC, V6, P62, DOI 10.1017/S1355617700611074; Kidder DP, 1997, AGING NEUROPSYCHOL C, V4, P93, DOI 10.1080/13825589708256639; Kim JH, 2007, J CLIN NEUROL, V3, P62, DOI 10.3988/jcn.2007.3.1.62; Kinsella G, 1996, BRAIN INJURY, V10, P499, DOI 10.1080/026990596124214; Kirsch P, 2003, NEUROIMAGE, V20, P1086, DOI 10.1016/S1053-8119(03)00381-1; Kliegel M, 2004, BRAIN COGNITION, V56, P43, DOI 10.1016/j.bandc.2004.05.005; Knight RG, 2006, J INT NEUROPSYCH SOC, V12, P8, DOI 10.1017/S1355617706060048; Knight RG, 2005, BRAIN INJURY, V19, P19, DOI 10.1080/02699050410001720022; Ko CH, 2009, J PSYCHIATR RES, V43, P739, DOI 10.1016/j.jpsychires.2008.09.012; Kobayashi Y, 2007, J COMP NEUROL, V502, P810, DOI 10.1002/cne.21346; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Krawczyk DC, 2007, BRAIN RES, V1141, P168, DOI 10.1016/j.brainres.2007.01.052; KVAVILASHVILI L, 1987, BRIT J PSYCHOL, V78, P507, DOI 10.1111/j.2044-8295.1987.tb02265.x; Kvavilashvili L, 2001, DEV PSYCHOL, V37, P418, DOI 10.1037//0012-1649.37.3.418; Lazar M, 2006, AM J NEURORADIOL, V27, P1258; Lee ZI, 2003, AM J PHYS MED REHAB, V82, P556, DOI 10.1097/01.PHM.0000073830.15643.6A; Leube DT, 2008, INT J GERIATR PSYCH, V23, P1114, DOI 10.1002/gps.2036; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; Linke J, 2010, NEUROIMAGE, V49, P2618, DOI 10.1016/j.neuroimage.2009.09.013; LOUDA J, 2007, Z NEUROPSYCHOL, V18, P91; Lowther JL, 2004, ARCH CLIN NEUROPSYCH, V19, P105, DOI 10.1016/S0887-6177(02)00222-6; Mabbott DJ, 2009, BRAIN RES, V1294, P80, DOI 10.1016/j.brainres.2009.07.046; Maddock RJ, 1997, PSYCHIAT RES-NEUROIM, V75, P1, DOI 10.1016/S0925-4927(97)00018-8; Mathias JL, 2005, BRAIN INJURY, V19, P271, DOI 10.1080/02699050400005028; Maujean A., 2003, BRAIN IMPAIR, V4, P135, DOI DOI 10.1375/BRIM.4.2.135.27024; MAYLOR EA, 1990, Q J EXP PSYCHOL-A, V42, P471, DOI 10.1080/14640749008401233; Maylor EA, 2002, MEM COGNITION, V30, P871, DOI 10.3758/BF03195773; McCauley SR, 2004, DEV NEUROPSYCHOL, V25, P5, DOI 10.1207/s15326942dn2501&2_2; MCCAULEY SR, J CLIN EXP IN PRESS; McCauley SR, 2010, DEV NEUROPSYCHOL, V35, P318, DOI 10.1080/87565641003696866; McCauley SR, 2010, CHILD NEUROPSYCHOL, V16, P293, DOI 10.1080/09297041003601470; McCauley SR, 2010, J INT NEUROPSYCH SOC, V16, P335, DOI 10.1017/S135561770999138X; McCauley SR, 2009, NEUROPSYCHOLOGY, V23, P201, DOI 10.1037/a0014192; McCoy AN, 2003, NEURON, V40, P1031, DOI 10.1016/S0896-6273(03)00719-0; McDaniel M A, 1993, Memory, V1, P23, DOI 10.1080/09658219308258223; McDonald CR, 2008, NEUROLOGY, V71, P1869, DOI 10.1212/01.wnl.0000327824.05348.3b; McDonald CR, 2001, NEUROCASE, V7, P407, DOI 10.1076/neur.7.5.407.16250; MEACHAM JA, 1976, PROSPECTIVE REMEMBER; Mori S, 2002, MAGN RESON MED, V47, P215, DOI 10.1002/mrm.10074; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; Nakamura M, 2005, BIOL PSYCHIAT, V58, P468, DOI 10.1016/j.biopsych.2005.04.016; Nestor PG, 2008, NEUROPSYCHOLOGY, V22, P246, DOI 10.1037/0894-4105.22.2.246; Nestor PG, 2004, NEUROPSYCHOLOGY, V18, P629, DOI 10.1037/0894-4105.18.4.629; Netsch T, 2001, EIGHTH IEEE INTERNATIONAL CONFERENCE ON COMPUTER VISION, VOL I, PROCEEDINGS, P718, DOI 10.1109/ICCV.2001.937595; Nielson KA, 2005, NEUROBIOL LEARN MEM, V84, P42, DOI 10.1016/j.nlm.2005.03.004; Nieuwenhuis S, 2005, EUR J NEUROSCI, V21, P3161, DOI 10.1111/j.1460-9568.2005.04152.x; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Nyberg L, 2003, NEUROPSYCHOLOGIA, V41, P371, DOI 10.1016/S0028-3932(02)00168-9; O'Doherty J, 2001, NAT NEUROSCI, V4, P95; Ogai M, 2005, ACTA PSYCHIAT SCAND, V111, P74, DOI 10.1111/j.1600-0447.2004.00395.x; Okuda J, 1998, NEUROSCI LETT, V253, P127, DOI 10.1016/S0304-3940(98)00628-4; Oni MB, 2010, J CHILD NEUROL, V25, P976, DOI 10.1177/0883073809356034; Palmer HM, 2000, BRAIN COGNITION, V44, P103; PAPEZ JW, 1995, J NEUROPSYCH CLIN N, V7, P103; PAUS T, 1993, J NEUROPHYSIOL, V70, P453; Pearson JM, 2009, CURR BIOL, V19, P1532, DOI 10.1016/j.cub.2009.07.048; Pessoa L, 2009, TRENDS COGN SCI, V13, P160, DOI 10.1016/j.tics.2009.01.006; Petrides M, 2007, J NEUROSCI, V27, P11573, DOI 10.1523/JNEUROSCI.2419-07.2007; Pochon JB, 2002, P NATL ACAD SCI USA, V99, P5669, DOI 10.1073/pnas.082111099; Poppenk J, 2010, NEUROIMAGE, V49, P905, DOI 10.1016/j.neuroimage.2009.08.049; Reynolds JR, 2009, CEREB CORTEX, V19, P1208, DOI 10.1093/cercor/bhn164; Riha PD, 2008, NEUROBIOL LEARN MEM, V90, P112, DOI 10.1016/j.nlm.2008.01.011; Risinger RC, 2005, NEUROIMAGE, V26, P1097, DOI 10.1016/j.neuroimage.2005.03.030; Roche NL, 2007, NEUROPSYCHOL REHABIL, V17, P314, DOI 10.1080/09602010600831004; Roche NL, 2002, BRAIN INJURY, V16, P931, DOI 10.1080/02699050210138581; Rolls ET, 2004, BRAIN COGNITION, V55, P11, DOI 10.1016/s0278-2626(03)00277-x; Roman MJ, 1998, J CLIN EXP NEUROPSYC, V20, P245, DOI 10.1076/jcen.20.2.245.1168; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; RUTHER NM, 1993, M SE PSYCH ASS ATL; Salorio CF, 2005, J INT NEUROPSYCH SOC, V11, P686, DOI 10.1017/S1355617705050885; Salthouse TA, 2004, MEM COGNITION, V32, P1133, DOI 10.3758/BF03196887; Sasson E, 2010, NEUROIMAGE, V50, P1231, DOI 10.1016/j.neuroimage.2009.12.079; Scheibel RS, 2009, J NEUROTRAUM, V26, P1447, DOI 10.1089/neu.2008.0736; Schmahmann JD, 2007, BRAIN, V130, P630, DOI 10.1093/brain/awl359; Schultz W, 2004, CURR OPIN NEUROBIOL, V14, P139, DOI 10.1016/j.conb.2004.03.017; Schultz W, 2006, ANNU REV PSYCHOL, V57, P87, DOI 10.1146/annurev.psych.56.091103.070229; Schultz W, 1998, NEUROPHARMACOLOGY, V37, P421, DOI 10.1016/S0028-3908(98)00071-9; Schultz W, 2000, CEREB CORTEX, V10, P272, DOI 10.1093/cercor/10.3.272; Schutter DJLG, 2006, J PSYCHIATR NEUROSCI, V31, P101; SEDAT J, 1990, J NEURORADIOLOGY, V17, P26; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P49, DOI 10.1076/jcen.21.1.49.943; Simoes-Franklin C, 2010, HUM BRAIN MAPP, V31, P458, DOI 10.1002/hbm.20879; Simons JS, 2006, NEUROPSYCHOLOGIA, V44, P1388, DOI 10.1016/j.neuropsychologia.2006.01.005; Singh M, 2010, MAGN RESON IMAGING, V28, P22, DOI 10.1016/j.mri.2009.05.049; Soeda A, 2005, NEURORADIOLOGY, V47, P501, DOI 10.1007/s00234-005-1372-x; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; Staudinger MR, 2009, NEUROIMAGE, V47, P713, DOI 10.1016/j.neuroimage.2009.04.095; Szatkowska I, 2008, NEUROBIOL LEARN MEM, V90, P475, DOI 10.1016/j.nlm.2008.06.001; Szeszko PR, 2008, NEUROPSYCHOPHARMACOL, V33, P976, DOI 10.1038/sj.npp.1301480; Taylor HG, 2004, DEV NEUROPSYCHOL, V25, P199, DOI 10.1207/s15326942dn2501&2_11; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TEASDALE G, 1974, LANCET, V2, P81; Thut G, 1997, NEUROREPORT, V8, P1225, DOI 10.1097/00001756-199703240-00033; Tranel D, 2002, CORTEX, V38, P589, DOI 10.1016/S0010-9452(08)70024-8; UNGERLEIDER LG, 1989, EXP BRAIN RES, V76, P473, DOI 10.1007/BF00248903; VALENSTEIN E, 1987, BRAIN, V110, P1631, DOI 10.1093/brain/110.6.1631; VOINESKOS AN, 2010, NEUROBIOL AGING; Wakana S, 2007, NEUROIMAGE, V36, P630, DOI 10.1016/j.neuroimage.2007.02.049; Wang JJ, 2005, P NATL ACAD SCI USA, V102, P17804, DOI 10.1073/pnas.0503082102; Wang JY, 2008, ARCH NEUROL-CHICAGO, V65, P619, DOI 10.1001/archneur.65.5.619; Ward H, 2004, BRAIN INJURY, V18, P471, DOI 10.1080/02699050310001646107; Ward H, 2007, CHILD NEUROPSYCHOL, V13, P219, DOI 10.1080/09297040600910003; Weisskoff RM, 1996, MAGNET RESON MED, V36, P643, DOI 10.1002/mrm.1910360422; West R, 2001, PSYCHOL AGING, V16, P682, DOI 10.1037//0882-7974.16.4.682; West R, 2005, NEUROPSYCHOLOGIA, V43, P418, DOI 10.1016/j.neuropsychologia.2004.06.012; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wilde EA, 2006, J CHILD NEUROL, V21, P769, DOI 10.1177/08830738060210090201; Wilde EA, 2010, DEV NEUROPSYCHOL, V35, P333, DOI 10.1080/87565641003696940; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Winograd E., 1988, PRACTICAL ASPECTS ME, V1, P348; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Wu TC, 2010, J NEUROTRAUM, V27, P303, DOI 10.1089/neu.2009.1110; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yount R, 2002, J NEUROPSYCH CLIN N, V14, P416, DOI 10.1176/appi.neuropsych.14.4.416; Yung A, 2007, PEDIATR RES, V61, P732, DOI 10.1203/pdr.0b013e31805365db	175	34	35	1	14	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2011	28	4					503	516		10.1089/neu.2010.1555			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	746IW	WOS:000289240200002	21250917	Green Published			2021-06-18	
J	Pedrero-Perez, EJ; de Leon, JMRS; Lozoya-Delgado, P; Llanero-Luque, M; Rojo-Mota, G; Puerta-Garcia, C				Pedrero-Perez, Eduardo J.; de Leon, Jose M. Ruiz-Sanchez; Lozoya-Delgado, Paz; Llanero-Luque, Marcos; Rojo-Mota, Gloria; Puerta-Garcia, Carmen			Prefrontal symptoms assessment: psychometric properties and normative data of the Dysexecutive Questionnaire (DEX) in a sample from the Spanish population	REVISTA DE NEUROLOGIA			Spanish	Article						DEX; Dysexecutive Questionnaire; Dysexecutive syndrome; Prefrontal cortex	FRONTAL-SUBCORTICAL CIRCUITS; TRAUMATIC BRAIN-INJURY; EXECUTIVE FUNCTIONS; ECOLOGICAL VALIDITY; ALZHEIMERS-DISEASE; PARALLEL ANALYSIS; CORTEX; BEHAVIOR; NEUROPSYCHOLOGY; ATTENTION	Introduction. Research on the deficits derived from alterations in the prefrontal circuits has been conducted almost exclusively from a categorical perspective, which differentiates normal from pathological functioning. The functioning of the prefrontal cortex, however, can be seen as a continuous dimension. The Dysexecutive Questionnaire (DEX) was created with the intention of being useful as a qualitative measure of the symptoms of 'dysexecutive syndrome' in day-today life. Aim. To explore the psychometric properties of the self-reported DEX in a broad sample of the non-clinical population with a view to providing interpretations that can be of use in clinical practice. Subjects and methods. The Spanish version of the DEX was administered to 1013 non-clinical individuals living in Madrid, Saragossa, Asturias, Navarre and Seville (380 males and 633 females). Results. The factorial study conducted in parallel reveals the existence of two factors with adequate consistency and internal validity indices: items that explore difficulties in beginning, maintaining and organising behaviour (disorganisation/apathy) and items related with the interruption of behaviour in situations where it is inappropriate (disinhibition/impulsivity). The distribution according to age matches the developmental premises. The following cut-off points are proposed: < 10, optimal functioning; 10-18, sub-optimal functioning within normality; 19-28, moderately dysexecutive functioning that requires identification of the possible causes, and > 28, important degree of dysexecutive disorder that would include severe pathologies. Conclusions. The DEX may be useful as an instrument for detecting subjects with demonstrable brain disorders and those with deficient executive functioning without the presence of any known or identifiable pathology.	[Pedrero-Perez, Eduardo J.; Rojo-Mota, Gloria; Puerta-Garcia, Carmen] Ctr Atenc Drogodependientes CAD 4, Inst Adicc, E-28027 Madrid, Spain; [de Leon, Jose M. Ruiz-Sanchez; Lozoya-Delgado, Paz] Univ Complutense Madrid, Dept Psicol Basica 2, E-28040 Madrid, Spain; [Llanero-Luque, Marcos] Hosp Moraleja, Serv Neurol, Madrid, Spain	Pedrero-Perez, EJ (corresponding author), Ctr Atenc Drogodependientes CAD 4, Inst Adicc, Alcala 527, E-28027 Madrid, Spain.	ejpedrero@yahoo.es	de Leon, Jose Maria Ruiz Sanchez/J-2593-2015; Rojo-Mota, Gloria/P-3916-2016; Pedrero-Perez, Eduardo Jose/P-8127-2015	de Leon, Jose Maria Ruiz Sanchez/0000-0003-2834-0827; Rojo-Mota, Gloria/0000-0003-0358-1181; Pedrero-Perez, Eduardo Jose/0000-0002-3940-5609			Alderman N, 2001, NEUROPSYCHOL REHABIL, V11, P529, DOI 10.1080/09602010042000231; ALEXANDER GE, 1986, ANNU REV NEUROSCI, V9, P357, DOI 10.1146/annurev.ne.09.030186.002041; Amieva H, 2003, BRAIN COGNITION, V53, P129, DOI 10.1016/S0278-2626(03)00094-0; Arnsten AFT, 2009, NAT REV NEUROSCI, V10, P410, DOI 10.1038/nrn2648; Bennett PC, 2005, J INT NEUROPSYCH SOC, V11, P376, DOI 10.1017/S1355617705050423; Blumer D., 1975, PSYCHIAT ASPECTS NEU, P151; Bodenburg S, 2008, J NERV MENT DIS, V196, P75, DOI 10.1097/NMD.0b013e31815faa2b; Burgess P. W., 1997, METHODOLOGY FRONTAL, P81, DOI DOI 10.1024//1016-264X.10.2.123; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Caspi A, 2003, J PERS, V71, P495, DOI 10.1111/1467-6494.7104001; Cederlund M, 2010, RES DEV DISABIL, V31, P287, DOI 10.1016/j.ridd.2009.09.006; Chan RCK, 2008, J NEUROL NEUROSUR PS, V79, P86, DOI 10.1136/jnnp.2007.117184; Chan RCK, 2002, CLIN REHABIL, V16, P900, DOI 10.1191/0269215502cr574oa; Chan RCK, 2001, BRIT J PSYCHOL, V92, P551, DOI 10.1348/000712601162338; Chaytor N, 2007, BRAIN INJURY, V21, P615, DOI 10.1080/02699050701426949; Cullen B, 2005, INT J GERIATR PSYCH, V20, P686, DOI 10.1002/gps.1344; CUMMINGS JL, 1993, ARCH NEUROL-CHICAGO, V50, P873, DOI 10.1001/archneur.1993.00540080076020; Duncan J, 2001, NAT REV NEUROSCI, V2, P820, DOI 10.1038/35097575; Espinosa A, 2009, J INT NEUROPSYCH SOC, V15, P751, DOI 10.1017/S135561770999035X; Garcia-Molina A, 2008, REV NEUROLOGIA, V46, P175, DOI 10.33588/rn.4603.2007196; Garcia-Molina A, 2009, REV NEUROLOGIA, V48, P435, DOI 10.33588/rn.4808.2008265; Gerstorf D, 2008, AGING NEUROPSYCHOL C, V15, P424, DOI 10.1080/13825580701640374; Goldenberg G, 2007, CORTEX, V43, P424, DOI 10.1016/S0010-9452(08)70467-2; Greenop KR, 2010, ALZHEIMER DIS ASS DI; Greenwood PM, 2000, J INT NEUROPSYCH SOC, V6, P705, DOI 10.1017/S1355617700666092; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P333, DOI 10.1097/00001199-200507000-00005; Hayton JC, 2004, ORGAN RES METHODS, V7, P191, DOI 10.1177/1094428104263675; HORN JL, 1965, PSYCHOMETRIKA, V30, P179, DOI 10.1007/BF02289447; Hulette CM, 1998, J NEUROPATH EXP NEUR, V57, P1168, DOI 10.1097/00005072-199812000-00009; Iqbal N, 2009, EPILEPSY BEHAV, V14, P516, DOI 10.1016/j.yebeh.2008.12.025; Larson MJ, 2006, J CLIN EXP NEUROPSYC, V28, P968, DOI 10.1080/13803390600646860; Llanero-Luque M, 2008, REV NEUROLOGIA, V47, P457, DOI 10.33588/rn.4709.2008257; Mathias JL, 2003, APPL NEUROPSYCHOL, V10, P57, DOI 10.1207/S15324826AN1002_01; MEGA MS, 1994, J NEUROPSYCH CLIN N, V6, P358; Mooney B, 2006, APPL NEUROPSYCHOL, V13, P12, DOI 10.1207/s15324826an1301_2; Murphy ME, 2010, EVERYDAY EXECUTIVE F; O'Connor BP, 2000, BEHAV RES METH INS C, V32, P396, DOI 10.3758/BF03200807; Perez EJP, 2009, ADICCIONES, V21, P155, DOI 10.20882/adicciones.243; Pedrero-Perez E.J., 2010, PERSONALITY TRAITS T, P1; RINDFUSS RR, 1991, DEMOGRAPHY, V28, P493, DOI 10.2307/2061419; de Leon JMS, 2010, ADICCIONES, V22, P233, DOI 10.20882/adicciones.184; de Leon JMRS, 2010, REV NEUROLOGIA, V51, P650, DOI 10.33588/rn.5111.2010270; Stuss DT, 2007, PHILOS T R SOC B, V362, P901, DOI 10.1098/rstb.2007.2096; Tirapu-Ustarroz J, 2008, REV NEUROLOGIA, V46, P684, DOI 10.33588/rn.4611.2008119; Tirapu-Ustarroz J, 2008, REV NEUROLOGIA, V46, P742, DOI 10.33588/rn.4612.2008252; Verdejo-Garcia A, 2010, PSICOTHEMA, V22, P227; Walley RM, 2005, J INTELL DISABIL RES, V49, P613, DOI 10.1111/j.1365-2788.2005.00717.x; Wang Y, 2006, ARCH CLIN NEUROPSYCH, V21, P339, DOI 10.1016/j.acn.2006.03.006; West RL, 1996, PSYCHOL BULL, V120, P272, DOI 10.1037/0033-2909.120.2.272; Wilson BA, 1996, BEHAV ASSESSMENT DYS; Wood RL, 2006, ARCH CLIN NEUROPSYCH, V21, P429, DOI 10.1016/j.acn.2005.06.014	51	34	35	0	10	REVISTA DE NEUROLOGIA	BARCELONA	C/O CESAR VIGUERA, EDITOR, APDO 94121, 08080 BARCELONA, SPAIN	0210-0010	1576-6578		REV NEUROLOGIA	Rev. Neurologia	APR 1	2011	52	7					394	404		10.33588/rn.5207.2010731			11	Clinical Neurology	Neurosciences & Neurology	972EP	WOS:000306260300002	21425108				2021-06-18	
J	Lu, KT; Sun, CL; Wo, PYY; Yen, HH; Tang, TH; Ng, MC; Huang, ML; Yang, YL				Lu, Kwok-Tung; Sun, Chien-Lun; Wo, Peter Y. Y.; Yen, Hao-Han; Tang, Tsao-Hao; Ng, Ming-Chong; Huang, Min-Lang; Yang, Yi-Ling			Hippocampal Neurogenesis after Traumatic Brain Injury Is Mediated by Vascular Endothelial Growth Factor Receptor-2 and the Raf/MEK/ERK Cascade	JOURNAL OF NEUROTRAUMA			English	Article						hippocampus; mitogen-activated protein kinase; neurogenesis; rat; traumatic brain injury; vascular endothelial growth factor	STIMULATES NEUROGENESIS; SIGNAL-TRANSDUCTION; DENTATE GYRUS; IN-VITRO; ADULT; VEGF; EDEMA; EXPRESSION; PATHWAY; CELLS	Adult neurogenesis occurs in the subgranular zone of the hippocampal dentate gyrus, and can be modulated by physiological and pathological events. We examined the effect of vascular endothelial growth factor (VEGF), and the correlation between VEGF and the Raf/MEK/ERK cascade in neurogenesis after traumatic brain injury (TBI). The expression of VEGF and the phosphorylation level of Raf/MEK/ERK were analyzed by Western blot, and TBI-induced neurogenesis was determined by immunofluorescence labeling and confocal microscopic detection. Hippocampal VEGF began to increase after 12 h, and reached a peak at day 7. Along with the upregulation of VEGF, neurogenesis in the hippocampus also increased. Administration of the VEGF antisense oligodeoxynucleotide, or the VEGF receptor-2 antagonist SU1498 (10 mu g, ICV), attenuated the phosphorylation of the MAPK cascade proteins and caused a decrease in neurogenesis in the hippocampus. Similarly, administration of the ERK inhibitor PD98059 (500 ng, ICV) also exhibited a suppressive effect on neurogenesis. Our results indicate that VEGF plays an important role in neurogenesis after TBI, and that the process involves VEGF receptor-2 and the Raf/MEK/ERK cascade.	[Sun, Chien-Lun; Wo, Peter Y. Y.; Yen, Hao-Han; Yang, Yi-Ling] Natl Chiayi Univ, Dept Biochem Sci & Technol, Chiayi, Taiwan; [Lu, Kwok-Tung; Tang, Tsao-Hao; Ng, Ming-Chong] Natl Taiwan Normal Univ, Dept Life Sci, Taipei, Taiwan; [Huang, Min-Lang] Natl Chung Cheng Univ, Dept Life Sci, Chiayi, Taiwan	Yang, YL (corresponding author), Natl Chiayi Univ, Dept Biochem Sci & Technol, Chiayi, Taiwan.	ylyang@mail.ncyu.edu.tw			National Science CouncilMinistry of Science and Technology, Taiwan [NSC 97-2320-B-415-006-MY3, NSC 97-2320-B-003-001-MY3]	This work was supported by National Science Council grants NSC 97-2320-B-415-006-MY3 and NSC 97-2320-B-003-001-MY3.	Bellon A, 2010, NEURON, V66, P205, DOI 10.1016/j.neuron.2010.04.006; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909; Galvan V, 2006, MINI-REV MED CHEM, V6, P667, DOI 10.2174/138955706777435742; Galvan V, 2007, CLIN INTERV AGING, V2, P605; Gerstner ER, 2009, NAT REV CLIN ONCOL, V6, P229, DOI 10.1038/nrclinonc.2009.14; Hatakeyama M, 2007, HEART VESSELS, V22, P123, DOI 10.1007/s00380-006-0942-0; Hossain MA, 2004, ANN NEUROL, V55, P660, DOI 10.1002/ana.20065; Huang GJ, 2005, NEUROSCIENCE, V135, P803, DOI 10.1016/j.neuroscience.2005.05.056; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Jin KL, 2006, J NEUROBIOL, V66, P236, DOI 10.1002/neu.20215; Jin KL, 2001, P NATL ACAD SCI USA, V98, P4710, DOI 10.1073/pnas.081011098; Kerbel RS, 2008, NEW ENGL J MED, V358, P2039, DOI 10.1056/NEJMra0706596; Kilic E, 2006, FASEB J, V20, P1185, DOI 10.1096/fj.05-4829fje; Kranich S, 2009, NEUROCHEM INT, V55, P747, DOI 10.1016/j.neuint.2009.07.007; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Lee C, 2010, J NEUROTRAUM, V27, P541, DOI 10.1089/neu.2009.0905; Lichtenwalner RJ, 2006, J CEREBR BLOOD F MET, V26, P1, DOI 10.1038/sj.jcbfm.9600170; Lu KT, 2005, NEUROSCI LETT, V386, P40, DOI 10.1016/j.neulet.2005.05.057; Lu KT, 2008, CRIT CARE MED, V36, P917, DOI 10.1097/CCM.0B013E31816590C4; Lu KT, 2006, EUR J PHARMACOL, V548, P99, DOI 10.1016/j.ejphar.2006.07.048; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MARSHALL LF, 2000, J NEUROTRAUM, V17, P143; Matsuzaki H, 2001, FASEB J, V15, P1218; Miljan EA, 2009, CURR OPIN MOL THER, V11, P394; Parent JM, 2002, ANN NEUROL, V52, P802, DOI 10.1002/ana.10393; Rao MS, 2005, EUR J NEUROSCI, V21, P464, DOI 10.1111/j.1460-9568.2005.03853.x; Richardson RM, 2007, NEUROSURG CLIN N AM, V18, P169, DOI 10.1016/j.nec.2006.10.007; Ristimaki A, 1998, J BIOL CHEM, V273, P8413, DOI 10.1074/jbc.273.14.8413; Salven P, 2002, FASEB J, V16, P1471, DOI 10.1096/fj.02-0134fje; Schanzer A, 2004, BRAIN PATHOL, V14, P237; Shein NA, 2007, J NEUROCHEM, V103, P1523, DOI 10.1111/j.1471-4159.2007.04862.x; Shibuya M, 2006, EXP CELL RES, V312, P549, DOI 10.1016/j.yexcr.2005.11.012; Shioda N, 2009, INT REV NEUROBIOL, V85, P375, DOI 10.1016/S0074-7742(09)85026-5; Shors TJ, 2001, NATURE, V410, P372, DOI 10.1038/35066584; Skold MK, 2005, J NEUROTRAUM, V22, P353, DOI 10.1089/neu.2005.22.353; Sondell M, 2000, EUR J NEUROSCI, V12, P4243, DOI 10.1046/j.0953-816X.2000.01326.x; Sun FY, 2005, J NEUROSCI RES, V79, P180, DOI 10.1002/jnr.20321; Sun YJ, 2006, DEV BIOL, V289, P329, DOI 10.1016/j.ydbio.2005.10.016; Takahashi H, 2005, CLIN SCI, V109, P227, DOI 10.1042/CS20040370; Thau-Zuchman O, 2010, J CEREBR BLOOD F MET, V30, P1008, DOI 10.1038/jcbfm.2009.271; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Watari K, 2008, BIOCHEM BIOPH RES CO, V377, P826, DOI 10.1016/j.bbrc.2008.10.077; Wu HT, 2008, J NEUROTRAUM, V25, P130, DOI 10.1089/neu.2007.0369; Yee KWH, 2002, BLOOD, V100, P2941, DOI 10.1182/blood-2002-02-0531; Zhang ZG, 2002, TRENDS CARDIOVAS MED, V12, P62, DOI 10.1016/S1050-1738(01)00149-9	47	34	41	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2011	28	3					441	450		10.1089/neu.2010.1473			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	734WD	WOS:000288370600009	21091268				2021-06-18	
J	Shellington, DK; Du, LN; Wu, XR; Exo, J; Vagni, V; Ma, L; Janesko-Feldman, K; Clark, RSB; Bayir, H; Dixon, CE; Jenkins, LW; Hsia, CJC; Kochanek, PM				Shellington, David K.; Du, Lina; Wu, Xianren; Exo, Jennifer; Vagni, Vincent; Ma, Li; Janesko-Feldman, Keri; Clark, Robert S. B.; Bayir, Huelya; Dixon, C. Edward; Jenkins, Larry W.; Hsia, Carleton J. C.; Kochanek, Patrick M.			Polynitroxylated pegylated hemoglobin: A novel neuroprotective hemoglobin for acute volume-limited fluid resuscitation after combined traumatic brain injury and hemorrhagic hypotension in mice	CRITICAL CARE MEDICINE			English	Article						head injury; hemoglobin based oxygen carrier; nitroxide; oxidative stress; nitric oxide; polyethylene glycol; hemorrhagic shock; blast injury; polytrauma; blood substitute; polynitroxylation; superoxide	FOCAL CEREBRAL-ISCHEMIA; CORTICAL CELL-CULTURE; OXYGEN CARRIERS; BLOOD SUBSTITUTES; CARBON-MONOXIDE; SWINE MODEL; ALBUMIN; TEMPOL; RATS; SHOCK	Objective: Resuscitation of hemorrhagic hypotension after traumatic brain injury is challenging. A hemoglobin-based oxygen carrier may offer advantages. The novel therapeutic hemoglobin-based oxygen carrier, polynitroxylated pegylated hemoglobin (PNPH), may represent a neuroprotective hemoglobin-based oxygen carrier for traumatic brain injury resuscitation. Hypotheses: 1) PNPH is a unique non-neurotoxic hemoglobin-based oxygen carrier in neuronal culture and is neuroprotective in in vitro neuronal injury models. 2) Resuscitation with PNPH would require less volume to restore mean arterial blood pressure than lactated Ringer's or Hextend and confer neuroprotection in a mouse model of traumatic brain injury plus hemorrhagic hypotension. Design: Prospective randomized, controlled experimental study. Setting: University center. Measurements and Main Results: In rat primary cortical neuron cultures, control bovine hemoglobin was neurotoxic (lactate dehydrogenase release; 3-[4,5-dimethylthiazol-2-yl-]-2,5-diphenyltetrazolium bromide assay) at concentrations from 12.5 to 0.625 mu M, whereas polyethylene glycol-conjugated hemoglobin showed intermediate toxicity. PNPH was not neurotoxic (p < .05 vs. bovine hemoglobin and polyethylene glycol hemoglobin; all concentrations). PNPH conferred neuroprotection in in vitro neuronal injury (glutamate/glycine exposure and neuronal stretch), as assessed via lactate dehydrogenase and 3-[4,5-dimethylthiazol-2- yl-]-2,5-diphenyltetrazolium bromide (all p < .05 vs. control). C57BL6 mice received controlled cortical impact followed by hemorrhagic hypotension (2 mL/100 g, mean arterial blood pressure similar to 35-40 mm Hg) for 90 min. Mice were resuscitated (mean arterial blood pressure >50 mm Hg for 30 min) with lactated Ringer's, Hextend, or PNPH, and then shed blood was reinfused. Mean arterial blood pressures, resuscitation volumes, blood gasses, glucose, and lactate were recorded. Brain sections at 7 days were examined via hematoxylin and eosin and Fluoro-Jade C (identifying dying neurons) staining in CA1 and CA3 hippocampus. Resuscitation with PNPH or Hextend required less volume than lactated Ringer's (both p < .05). PNPH but not Hextend improved mean arterial blood pressure vs. lactated Ringer's (p < .05). Mice resuscitated with PNPH had fewer Fluoro-Jade C positive neurons in CA1 vs. Hextend and lactated Ringer's, and CA3 vs. Hextend (p < .05). Conclusions: PNPH is a novel neuroprotective hemoglobin-based oxygen carrier in vitro and in vivo that may offer unique advantages for traumatic brain injury resuscitation. (Crit Care Med 2011; 39: 494 -505)	[Shellington, David K.; Du, Lina; Wu, Xianren; Exo, Jennifer; Vagni, Vincent; Janesko-Feldman, Keri; Clark, Robert S. B.; Bayir, Huelya; Dixon, C. Edward; Jenkins, Larry W.; Kochanek, Patrick M.] Safar Ctr Resuscitat Res, Pittsburgh, PA USA; [Shellington, David K.; Du, Lina; Clark, Robert S. B.; Bayir, Huelya; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA USA; [Clark, Robert S. B.; Bayir, Huelya; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15261 USA; [Dixon, C. Edward; Jenkins, Larry W.] Univ Pittsburgh, Sch Med, Dept Neurol Surg, Pittsburgh, PA 15261 USA; [Wu, Xianren] Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA 15261 USA; [Ma, Li; Hsia, Carleton J. C.] SynZyme Technol, Irvine, CA USA; [Ma, Li] Georgia So Univ, Dept Phys, Statesboro, GA 30460 USA	Shellington, DK (corresponding author), Safar Ctr Resuscitat Res, Pittsburgh, PA USA.	kochanekpm@ccm.upmc; kochanekpm@ccm.upmc.edu	Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; Shellington, David/0000-0001-6708-6978	U.S. ArmyUnited States Department of Defense [PR054755 W81XWH-06-1-0247]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32HD040686, NS30318]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS030318, P20NS030318, P50NS030318] Funding Source: NIH RePORTER	Supported, in part, by grant PR054755 W81XWH-06-1-0247 from the U.S. Army (PMK), T32HD040686 from the National Institutes of Health (JE, PMK), and NS30318 from the National Institutes of Health (CED).	Abuchowski A, 2009, P 12 INT S BLOOD SUB, P49; AIZENMAN E, 1989, NEURON, V2, P1257, DOI 10.1016/0896-6273(89)90310-3; Alayash AI, 1999, NAT BIOTECHNOL, V17, P545, DOI 10.1038/9849; Beaulieu C, 1998, J CEREBR BLOOD F MET, V18, P1022; BICKELL WH, 1994, NEW ENGL J MED, V331, P1105, DOI 10.1056/NEJM199410273311701; Brennan AM, 2009, NAT NEUROSCI, V12, P857, DOI 10.1038/nn.2334; CHAPMAN KW, 1992, BIOMAT ARTIF CELL IM, V20, P415, DOI 10.3109/10731199209119661; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Chung HT, 2008, METHOD ENZYMOL, V441, P329, DOI 10.1016/S0076-6879(08)01218-4; Deng-Bryant Y, 2008, J CEREBR BLOOD F MET, V28, P1114, DOI 10.1038/jcbfm.2008.10; Dennis AM, 2009, J NEUROTRAUM, V26, P889, DOI 10.1089/neu.2008.0512; DESHPANDE JK, 1987, J CEREBR BLOOD F MET, V7, P89, DOI 10.1038/jcbfm.1987.13; DeWitt DS, 2009, J NEUROTRAUM, V26, P877, DOI 10.1089/neu.2007.0439; Dudkiewicz M, 2008, CRIT CARE MED, V36, P2641, DOI 10.1097/CCM.0b013e3181847af3; Exo JL, 2009, J NEUROTRAUM, V26, P2403, DOI 10.1089/neu.2009.0980; GOLD MS, 1990, ANN SURG, V211, P482, DOI 10.1097/00000658-199004000-00016; Golding EM, 1999, CLIN EXP HYPERTENS, V21, P299, DOI 10.3109/10641969909068668; Hlatky R, 2003, J NEUROTRAUM, V20, P995, DOI 10.1089/089771503770195849; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; Kao LW, 2006, CLIN LAB MED, V26, P99, DOI 10.1016/j.cll.2006.01.005; Kentner R, 2002, J TRAUMA, V53, P968, DOI 10.1097/00005373-200211000-00025; Koehler RC, 2009, P 12 INT S BLOOD SUB, P68; Krishna MC, 1996, J BIOL CHEM, V271, P26018, DOI 10.1074/jbc.271.42.26018; Leker RR, 2002, EXP NEUROL, V176, P355, DOI 10.1006/exnr.2002.7910; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Lui FE, 2008, BIOCHEMISTRY-US, V47, P10773, DOI 10.1021/bi801116k; MOGGIO RA, 1983, CRIT CARE MED, V11, P943, DOI 10.1097/00003246-198312000-00009; Natanson C, 2008, JAMA-J AM MED ASSOC, V299, P2304, DOI 10.1001/jama.299.19.jrv80007; Nelson TJ, 2006, J AM COLL SURGEONS, V202, P418, DOI 10.1016/j.jamcollsurg.2005.11.011; Patel MB, 2006, J TRAUMA, V61, P46, DOI 10.1097/01.ta.0000219730.71206.3a; RAMMING S, 1994, J TRAUMA, V37, P705, DOI 10.1097/00005373-199411000-00003; Regan RF, 1996, J NEUROTRAUM, V13, P223, DOI 10.1089/neu.1996.13.223; Regan RF, 2003, J NEUROTRAUM, V20, P111, DOI 10.1089/08977150360517236; REGAN RF, 1993, NEUROSCI LETT, V153, P219, DOI 10.1016/0304-3940(93)90326-G; Rogers B, 2003, FREE RADICAL BIO MED, V35, P872, DOI 10.1016/S0891-5849(03)00431-3; Rosenthal G, 2008, J NEUROSURG, V108, P575, DOI 10.3171/JNS/2008/108/3/0575; Saetzler RK, 1999, FREE RADICAL BIO MED, V27, P1, DOI 10.1016/S0891-5849(99)00037-4; Spaethling JM, 2008, J NEUROTRAUM, V25, P1207, DOI 10.1089/neu.2008.0532; Statler KD, 2006, J NEUROTRAUM, V23, P97, DOI 10.1089/neu.2006.23.97; Statler KD, 2001, J NEUROTRAUM, V18, P1195, DOI 10.1089/089771501317095232; Stern S, 2009, SHOCK, V31, P64, DOI 10.1097/SHK.0b013e3181778dc3; Whalen MJ, 2000, CRIT CARE MED, V28, P3710, DOI 10.1097/00003246-200011000-00029; Winslow RM, 2005, ARTIF CELL BLOOD SUB, V33, P1, DOI 10.1081/BIO-200046634; Winslow RM, 2008, BBA-PROTEINS PROTEOM, V1784, P1382, DOI 10.1016/j.bbapap.2008.04.032; Yu B, 2008, CIRCULATION, V117, P1982, DOI 10.1161/CIRCULATIONAHA.107.729137; Zhang RL, 1998, FREE RADICAL BIO MED, V24, P332, DOI 10.1016/S0891-5849(97)00267-0; Zhang S, 2000, FREE RADICAL BIO MED, V29, P42, DOI 10.1016/S0891-5849(00)00295-1	47	34	35	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	MAR	2011	39	3					494	505		10.1097/CCM.0b013e318206b1fa			12	Critical Care Medicine	General & Internal Medicine	723BB	WOS:000287480000011	21169820	Green Accepted			2021-06-18	
J	Carlson, KB; Singh, P; Feaster, MM; Ramnarain, A; Pavlides, C; Chen, ZL; Yu, WM; Feltri, ML; Strickland, S				Carlson, Karen B.; Singh, Prabhjot; Feaster, Moses M.; Ramnarain, Anita; Pavlides, Constantine; Chen, Zu-Lin; Yu, Wei-Ming; Feltri, M. Laura; Strickland, Sidney			Mesenchymal Stem Cells Facilitate Axon Sorting, Myelination, and Functional Recovery in Paralyzed Mice Deficient in Schwann Cell-Derived Laminin	GLIA			English	Article						laminin; mesenchymal stem cell; adipose; myelin; schwann cell; sciatic nerve; CMD1A	CONGENITAL MUSCULAR-DYSTROPHY; TRAUMATIC BRAIN-INJURY; ADHESION MOLECULES L1; STROMAL CELLS; NEUROMUSCULAR SYSTEM; CARBOHYDRATE EPITOPE; BASEMENT-MEMBRANES; TRANSGENIC MICE; SCIATIC-NERVE; N-CAM	Peripheral nerve function depends on a regulated process of axon and Schwann cell development. Schwann cells interact with peripheral neurons to sort and ensheath individual axons. Ablation of laminin gamma 1 in the peripheral nervous system (PNS) arrests Schwann cell development prior to radial sorting of axons. Peripheral nerves of laminin-deficient animals are disorganized and hypomyelinated. In this study, sciatic nerves of laminin-deficient mice were treated with syngenic murine adipose-derived stem cells (ADSCs). ADSCs expressed laminin in vitro and in vivo following transplant into mutant sciatic nerves. ADSC-treatment of mutant nerves caused endogenous Schwann cells to differentiate past the point of developmental arrest to sort and myelinate axons. This was shown by (1) functional, (2) ultrastructural, and (3) immunohistochemical analysis. Treatment of laminin-deficient nerves with either soluble laminin or the immortalized laminin-expressing cell line 3T3/L1 did not overcome endogenous Schwann cell developmental arrest. In summary, these results indicate that (1) laminin-deficient Schwann cells can be rescued, (2) a cell-based approach is beneficial in comparison with soluble protein treatment, and (3) mesenchymal stem cells modify sciatic nerve function via trophic effects rather than trans-differentiation in this system. (C) 2010 Wiley-Liss, Inc.	[Carlson, Karen B.; Singh, Prabhjot; Feaster, Moses M.; Ramnarain, Anita; Chen, Zu-Lin; Yu, Wei-Ming; Strickland, Sidney] Rockefeller Univ, Lab Neurobiol & Genet, New York, NY 10065 USA; [Carlson, Karen B.] Weill Cornell New York Hosp, Div Hematol & Oncol, Dept Med, New York, NY USA; [Pavlides, Constantine] Rockefeller Univ, Neuroendocrinol Lab, New York, NY 10065 USA; [Feltri, M. Laura] Ist Sci San Raffaele, Dept Neurol, I-20132 Milan, Italy; [Feltri, M. Laura] Ist Sci San Raffaele, Dept Biol & Technol Res DIBIT, I-20132 Milan, Italy	Strickland, S (corresponding author), Rockefeller Univ, Lab Neurobiol & Genet, 1230 York Ave, New York, NY 10065 USA.	strickland@rockefeller.edu	Feltri, Maria Laura/J-5286-2018	Carlson, Karen-Sue/0000-0003-0418-652X; Strickland, Sidney/0000-0002-3072-9244	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS038472]; Muscular Dystrophy AssociationMuscular Dystrophy Association [MDA4066]; Medical Scientist Training ProgramUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [GM07739]; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; Tri-Institutional/STARR Foundation; F. M. Kirby fellowship for Sensory Neuroscience; Paul and Daisy Soros Fellowship; National Science FoundationNational Science Foundation (NSF); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045630, R01NS038472] Funding Source: NIH RePORTER	Grant sponsor: NIH; Grant number: NS038472; Grant sponsor: Muscular Dystrophy Association; Grant number: MDA4066; Grant sponsor: Medical Scientist Training Program; Grant number: GM07739, Grant sponsor: Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, the Tri-Institutional/STARR Foundation, F. M. Kirby fellowship for Sensory Neuroscience, Paul and Daisy Soros Fellowship, National Science Foundation Graduate Research Fellowship Program.	Amoh Y, 2005, P NATL ACAD SCI USA, V102, P17734, DOI 10.1073/pnas.0508440102; Aumailley M, 2005, MATRIX BIOL, V24, P326, DOI 10.1016/j.matbio.2005.05.006; Chen ZL, 2003, J CELL BIOL, V163, P889, DOI 10.1083/jcb.200307068; Crigler L, 2006, EXP NEUROL, V198, P54, DOI 10.1016/j.expneurol.2005.10.029; Feltri ML, 2005, J PERIPHER NERV SYST, V10, P128, DOI 10.1111/j.1085-9489.2005.0010204.x; Feltri ML, 1999, ANN NY ACAD SCI, V883, P116, DOI 10.1111/j.1749-6632.1999.tb08574.x; Fujimura J, 2005, BIOCHEM BIOPH RES CO, V333, P116, DOI 10.1016/j.bbrc.2005.05.096; Gotherstrom C, 2007, TRANSPLANTATION, V84, pS35, DOI 10.1097/01.tp.0000269200.67707.c8; Haney CA, 1999, J CELL BIOL, V146, P1173, DOI 10.1083/jcb.146.5.1173; Hausman GJ, 1998, J ANIM SCI, V76, P48; Jessen KR, 1997, J ANAT, V191, P501, DOI 10.1046/j.1469-7580.1997.19140501.x; Kuang W, 1998, J CLIN INVEST, V102, P844, DOI 10.1172/JCI3705; Le Blanc K, 2006, CURR OPIN IMMUNOL, V18, P586, DOI 10.1016/j.coi.2006.07.004; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Mahmood A, 2005, NEUROSURGERY, V57, P1026, DOI 10.1227/01.NEU.0000181369.76323.50; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Mahmood A, 2003, NEUROSURGERY, V53, P702; MARTINI R, 1986, J CELL BIOL, V103, P2439, DOI 10.1083/jcb.103.6.2439; Mercuri E, 2001, NEUROMUSCULAR DISORD, V11, P297, DOI 10.1016/S0960-8966(00)00190-5; Miner JH, 2004, DEVELOPMENT, V131, P2247, DOI 10.1242/dev.01112; Mirsky R, 1996, REV NEUROL, V152, P308; Mirsky R, 2001, Prog Brain Res, V132, P3; Mirsky R, 1996, CURR OPIN NEUROBIOL, V6, P89, DOI 10.1016/S0959-4388(96)80013-4; Murray P, 2000, J CELL BIOL, V150, P1215, DOI 10.1083/jcb.150.5.1215; NIEKE J, 1985, DIFFERENTIATION, V30, P141, DOI 10.1111/j.1432-0436.1985.tb00525.x; Niimi T, 1997, MATRIX BIOL, V16, P223, DOI 10.1016/S0945-053X(97)90011-1; Novak A, 2000, GENESIS, V28, P147, DOI 10.1002/1526-968X(200011/12)28:3/4<147::AID-GENE90>3.0.CO;2-G; Patton BL, 2000, MICROSC RES TECHNIQ, V51, P247, DOI 10.1002/1097-0029(20001101)51:3<247::AID-JEMT5>3.0.CO;2-Z; Patton BL, 1997, J CELL BIOL, V139, P1507, DOI 10.1083/jcb.139.6.1507; Pluchino S, 2005, NATURE, V436, P266, DOI 10.1038/nature03889; Puissant N, 2005, BRIT J HAEMATOL, V129, P118, DOI 10.1111/j.1365-2141.2005.05409.x; Schenke-Layland K, 2009, J SURG RES, V153, P217, DOI 10.1016/j.jss.2008.03.019; Smyth N, 1998, ANN NY ACAD SCI, V857, P283, DOI 10.1111/j.1749-6632.1998.tb10133.x; Stewart HJS, 1997, J NEUROBIOL, V33, P914, DOI 10.1002/(SICI)1097-4695(199712)33:7<914::AID-NEU4>3.0.CO;2-B; Sugii S, 2010, P NATL ACAD SCI USA, V107, P3558, DOI 10.1073/pnas.0910172106; Tapp H, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2473; Uziyel Y, 2000, GLIA, V32, P109, DOI 10.1002/1098-1136(200011)32:2<109::AID-GLIA10>3.0.CO;2-1; Xu YF, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-21; Yang LY, 2004, CHINESE MED J-PEKING, V117, P425; Yu WM, 2009, GLIA, V57, P850, DOI 10.1002/glia.20811; Yu WM, 2009, J CELL SCI, V122, P929, DOI 10.1242/jcs.033928; Yu WM, 2005, J NEUROSCI, V25, P4463, DOI 10.1523/JNEUROSCI.5032-04.2005	42	34	36	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	FEB	2011	59	2					267	277		10.1002/glia.21099			11	Neurosciences	Neurosciences & Neurology	707MR	WOS:000286291200009	21125647	Green Accepted			2021-06-18	
J	Shum, D; Fleming, J; Gill, H; Gullo, MJ; Strong, J				Shum, David; Fleming, Jennifer; Gill, Hannah; Gullo, Matthew J.; Strong, Jenny			A RANDOMIZED CONTROLLED TRIAL OF PROSPECTIVE MEMORY REHABILITATION IN ADULTS WITH TRAUMATIC BRAIN INJURY	JOURNAL OF REHABILITATION MEDICINE			English	Article						brain injuries; memory; rehabilitation; awareness	CLOSED-HEAD INJURY; COMPREHENSIVE ASSESSMENT; EXECUTIVE FUNCTIONS; SELF-AWARENESS; PERFORMANCE; REMEDIATION; EVENT; CAPM	Objective: To examine the efficacy of compensatory prospective memory training, preceded by self-awareness training for adults with traumatic brain injury. Design: Randomized controlled trial with 4 intervention groups: (i) self-awareness plus compensatory prospective memory training; (h) self-awareness training plus active control; (iii) active control plus compensatory prospective memory training; and (iv) active control only. Subjects: Forty-five rehabilitation patients with moderate severe traumatic brain injury living in the community. Methods: Four groups of participants completed an 8-session individual intervention programme with pre- and post-assessment by a blind assessor on a standardized test of prospective memory, actual strategy use, relatives' ratings of prospective memory failure, and level of psychosocial reintegration. Results: Larger changes in prospective memory test score and strategy use were found in groups with compensatory prospective memory training compared with those groups without. Conclusion: The results provide evidence that prospective memory can be improved in patients with traumatic brain injury using a compensatory approach in a relatively short duration and low intensity intervention.	[Shum, David; Gullo, Matthew J.] Griffith Univ, Sch Psychol, Brisbane, Qld 4122, Australia; [Shum, David; Gullo, Matthew J.] Griffith Univ, Griffith Hlth Inst, Brisbane, Qld 4122, Australia; [Fleming, Jennifer; Gill, Hannah; Strong, Jenny] Univ Queensland, Sch Hlth & Rehabil Sci, Brisbane, Qld, Australia; [Fleming, Jennifer] Princess Alexandra Hosp, Occupat Therapy Dept, Brisbane, Qld 4102, Australia; [Fleming, Jennifer] Queensland Hlth, Metro S Hlth Dist, Ctr Functioning & Hlth Res, Brisbane, Qld, Australia	Shum, D (corresponding author), Griffith Univ, Sch Psychol, Mt Gravatt Campus,176 Messines Ridge Rd, Brisbane, Qld 4122, Australia.	D.Shum@griffith.edu.au	Fleming, Jennifer M/B-4436-2011; Shum, David/A-3914-2008; Gullo, Hannah/C-5011-2008; Gullo, Matthew/C-3850-2008; Strong, Jenny/F-1211-2010	Shum, David/0000-0002-4810-9262; Gullo, Matthew/0000-0003-3657-5191; Strong, Jenny/0000-0002-9367-8755; GULLO, Hannah/0000-0003-4238-4033	National Health and Medical Research CouncilNational Health and Medical Research Council of Australia [277002]	This project was funded by a National Health and Medical Research Council Project Grant (no: 277002). The authors would like to thank Nadine Roche and the Occupational Therapy staff at the Princess Alexandra Hospital. We thank Professor John O'Gorman for his insightful and useful comments on various versions of this manuscript and Professor Barbara Wilson for making the CAMPROMPT available for the research before it was published.	Chau LT, 2007, NEUROPSYCHOL REHABIL, V17, P707, DOI 10.1080/09602010600923926; Donaghy S, 1998, BRAIN INJURY, V12, P1061, DOI 10.1080/026990598121963; Fish J, 2007, NEUROPSYCHOLOGIA, V45, P1318, DOI 10.1016/j.neuropsychologia.2006.09.015; Fleming J, 2008, J INT NEUROPSYCH SOC, V14, P823, DOI 10.1017/S1355617708080971; Fleming J, 2009, BRAIN IMPAIR, V10, P34, DOI 10.1375/brim.10.1.34; Fleming JM, 2005, BRAIN INJURY, V19, P1, DOI 10.1080/02699050410001720059; GLISKY EL, 1995, NEUROPSYCHOL REHABIL, V5, P299, DOI 10.1080/09602019508401474; Grieve J., 2008, NEUROPSYCHOLOGY OCCU; Groot YCT, 2002, J INT NEUROPSYCH SOC, V8, P645, DOI 10.1017/S1355617702801321; Henry JD, 2007, J CLIN EXP NEUROPSYC, V29, P457, DOI 10.1080/13803390600762717; Kim HJ, 2000, BRAIN INJURY, V14, P187, DOI 10.1080/026990500120844; Kirsch NL, 2004, BRAIN INJURY, V18, P725, DOI 10.1080/02699050310001646161; Kopelman M. D., 1990, AUTOBIOGRAPHICAL MEM; Kvavilashvili L., 1996, PROSPECTIVE MEMORY T, P23; Levine B., 2002, PRINCIPLES FRONTAL L, P51; Martin M, 2003, INT J PSYCHOL, V38, P195, DOI 10.1080/00207590344000123; Mathias JL, 2005, BRAIN INJURY, V19, P271, DOI 10.1080/02699050400005028; McDaniel M. A., 2007, PROSPECTIVE MEMORY O; Ownsworth TL, 1999, BRAIN INJURY, V13, P605, DOI 10.1080/026990599121340; Raskin SA, 1996, J HEAD TRAUMA REHAB, V11, P32, DOI 10.1097/00001199-199606000-00007; Roche NL, 2002, BRAIN INJURY, V16, P931, DOI 10.1080/02699050210138581; Schmitter-Edgecombe M, 2004, BRAIN INJURY, V18, P997, DOI 10.1080/02699050410001719934; Schmitter-Edgecombe M, 2004, NEUROPSYCHOLOGY, V18, P353, DOI 10.1037/0894-4105.18.2.353; SCHMITTEREDGECOMBE M, 1995, J CONSULT CLIN PSYCH, V63, P484; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P49, DOI 10.1076/jcen.21.1.49.943; Shum D., 2002, BRAIN IMPAIR, V3, DOI [https://doi.org/10.1375/brim.3.1.1, DOI 10.1375/BRIM.3.1.1]; SOHLBERG M M, 1992, Brain Injury, V6, P129, DOI 10.3109/02699059209029651; SOHLBERG M M, 1992, Brain Injury, V6, P139, DOI 10.3109/02699059209029652; SOHLBERG MM, 1989, J CLIN EXP NEUROPSYC, V11, P871, DOI 10.1080/01688638908400941; Stuss DT, 2000, PSYCHOL RES-PSYCH FO, V63, P289, DOI 10.1007/s004269900007; Tate R, 1999, J HEAD TRAUMA REHAB, V14, P543, DOI 10.1097/00001199-199912000-00003; van den Broek MD, 2000, BRAIN INJURY, V14, P455; Wechsler D., 1989, WECHSLER ABBREVIATED; Wilson B., 2005, CAMBRIDGE PROSPECTIV; WILSON BA, 2002, HDB MEMORY DISORDERS, P617	35	34	35	0	20	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977			J REHABIL MED	J. Rehabil. Med.	FEB	2011	43	3					216	223		10.2340/16501977-0647			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	721WL	WOS:000287388400006	21305237	DOAJ Gold, Green Published			2021-06-18	
J	Tomura, S; Nawashiro, H; Otani, N; Uozumi, Y; Toyooka, T; Ohsumi, A; Shima, K				Tomura, Satoshi; Nawashiro, Hiroshi; Otani, Naoki; Uozumi, Yoichi; Toyooka, Terushige; Ohsumi, Atsushi; Shima, Katsuji			Effect of Decompressive Craniectomy on Aquaporin-4 Expression after Lateral Fluid Percussion Injury in Rats	JOURNAL OF NEUROTRAUMA			English	Article						aquaporin-4; brain edema; decompressive craniectomy; lateral fluid percussion; traumatic brain injury	TRAUMATIC BRAIN-INJURY; CONTROLLED CORTICAL IMPACT; EDEMA; EPIDEMIOLOGY; HYPERTENSION; DAMAGE; MODEL	Decompressive craniectomy is one therapeutic option for severe traumatic brain injury (TBI), and it has long been used for the treatment of patients with malignant post-traumatic brain edema. A lack of definitive evidence, however, prevents physicians from drawing any conclusions about the effects of decompressive craniectomy for the treatment of TBI. Therefore, the aim of the present study was to investigate the influence of decompressive craniectomy on post-traumatic brain edema formation. The aquaporin-4 (AQP4) water channel is predominantly expressed in astrocytes, and it plays an important role in the regulation of brain water homeostasis. In the present study, we investigated the time course of AQP4 expression and the water content of traumatized cortex following decompressive craniectomy after TBI. Adult male Sprague-Dawley rats (300-400 g) were subjected to lateral fluid percussion injury using the Dragonfly device. The effect of decompressive craniectomy was studied in traumatized rats without craniectomy (closed skull, DC-), and in rats craniectomized immediately after trauma (DC+). AQP4 expression was investigated with a Western blot analysis and immunohistochemistry. Brain edema was measured using the wet weight/dry weight method. At 48 h after TBI, AQP4 expression of the DC- group was significantly increased compared with the DC+ group (p<0.01). In addition, the cortical water content of the DC- group was significantly increased compared to the DC+ group at the same time point (p<0.05). The present results suggest that decompressive craniectomy may affect AQP4 expression and reduce brain edema formation after TBI.	[Tomura, Satoshi; Nawashiro, Hiroshi; Otani, Naoki; Uozumi, Yoichi; Toyooka, Terushige; Ohsumi, Atsushi; Shima, Katsuji] Natl Def Med Coll, Dept Neurosurg, Tokorozawa, Saitama 3598513, Japan	Tomura, S (corresponding author), Natl Def Med Coll, Dept Neurosurg, 3-2 Namiki, Tokorozawa, Saitama 3598513, Japan.	tomura@ndmc.ac.jp		Uozumi, Yoichi/0000-0002-5985-2764			AGRE P, 1993, AM J PHYSIOL, V265, pF463; Arima H, 2003, J BIOL CHEM, V278, P44525, DOI 10.1074/jbc.M304368200; Badaut T, 2002, J CEREBR BLOOD F MET, V22, P367, DOI 10.1097/00004647-200204000-00001; Barzo P, 1997, ACT NEUR S, V70, P119; Bloch Orin, 2007, Neurosurg Focus, V22, pE3; Cooper DJ, 2008, J CRIT CARE, V23, P387, DOI 10.1016/j.jcrc.2007.05.002; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; HATASHITA S, 1985, STROKE, V16, P661, DOI 10.1161/01.STR.16.4.661; Heitsch H, 2000, DRUG NEWS PERSPECT, V13, P213; Hutchinson PJ, 2006, ACTA NEUROCHIR SUPPL, V96, P17; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; Jennett B, 1998, ARCH DIS CHILD, V78, P403, DOI 10.1136/adc.78.5.403; Ke CS, 2001, NEUROSCI LETT, V301, P21, DOI 10.1016/S0304-3940(01)01589-0; Kiening KL, 2002, NEUROSCI LETT, V324, P105, DOI 10.1016/S0304-3940(02)00180-5; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; Kontopoulos V, 2002, ACTA NEUROCHIR, V144, P791, DOI 10.1007/s00701-002-0948-z; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1; Matsushita Y, 2000, J NEUROTRAUM, V17, P143, DOI 10.1089/neu.2000.17.143; MCINTOSH TK, 1990, ACT NEUR S, V51, P263; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Meier U, 2006, ACTA NEUROCHIR SUPPL, V96, P373; Neal CJ, 2007, J NEUROTRAUM, V24, P1609, DOI 10.1089/neu.2007.0301; Nielsen S, 1997, J NEUROSCI, V17, P171; OKIYAMA K, 1995, J NEUROCHEM, V64, P802; Papadopoulos MC, 2004, FASEB J, V18, P1291, DOI 10.1096/fj.04-1723fje; Plesnila N, 2007, PROG BRAIN RES, V161, P393, DOI 10.1016/S0079-6123(06)61028-5; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Shima K, 2003, ACT NEUR S, V86, P17; Sun MC, 2003, J NEUROSURG, V98, P565, DOI 10.3171/jns.2003.98.3.0565; Timofeev I, 2008, J NEUROSURG, V108, P66, DOI 10.3171/JNS/2008/108/01/0066; Umezawa Hitoshi, 1993, Neurologia Medico-Chirurgica, V33, P139, DOI 10.2176/nmc.33.139; Unterberg A, 1990, Adv Neurol, V52, P355; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vakili A, 2005, J CEREBR BLOOD F MET, V25, P1012, DOI 10.1038/sj.jcbfm.9600097; Verkman AS, 2000, AM J PHYSIOL-RENAL, V278, pF13; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	40	34	37	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2011	28	2					237	243		10.1089/neu.2010.1443			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	719UE	WOS:000287234700007	21083433				2021-06-18	
J	Gumera, C; Rauck, B; Wang, YD				Gumera, Christiane; Rauck, Britta; Wang, Yadong			Materials for central nervous system regeneration: bioactive cues	JOURNAL OF MATERIALS CHEMISTRY			English	Article							SPINAL-CORD-INJURY; NEURAL STEM-CELLS; HYALURONIC-ACID HYDROGEL; OLIGODENDROCYTE PROGENITOR CELLS; ELECTRICALLY CONDUCTING POLYMER; TISSUE ENGINEERING APPLICATIONS; IN-VITRO BIOCOMPATIBILITY; NOGO-66 RECEPTOR ANTIBODY; GUIDE NEURITE OUTGROWTH; TRAUMATIC BRAIN-INJURY	Current clinical therapies have limited capacity to restore function in damaged nerves. Regeneration of axons in the injured central nervous system is inhibited by the presence of both physical and mechanical barriers. As such, neural tissue engineering strategies have received considerable attention in recent years. Materials-based approaches offer a way to blend synthetic and biological components in order to generate environments conducive to neural regeneration. While biomaterials themselves can facilitate regeneration simply by providing a substrate for cell growth, incorporation of "bioactive cues''-or molecules which interact with cells to elicit a specific response-has become increasingly necessary in order to promote nerve regeneration. This review attempts to outline the various biomaterials that are promising for central nerve applications, and discusses the array of bioactive cues that are valuable in promoting nerve repair.	[Rauck, Britta; Wang, Yadong] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15219 USA; [Rauck, Britta; Wang, Yadong] Univ Pittsburgh, McGowan Inst, Pittsburgh, PA 15219 USA; [Gumera, Christiane] WL Gore & Associates, Elkton, MD 21922 USA	Wang, YD (corresponding author), Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15219 USA.	cgumera@wlgore.com; yaw20@pitt.edu	Wang, Yadong/AAC-3381-2020; duan, hf/F-9166-2011	Wang, Yadong/0000-0003-2067-382X; 			Ahmed I, 2006, J BIOMED MATER RES A, V76A, P851, DOI 10.1002/jbm.a.30587; Anderson KD, 2004, J NEUROTRAUM, V21, P1371, DOI 10.1089/neu.2004.21.1371; Aramakis VB, 1998, J NEUROSCI, V18, P8485; Armstrong SJ, 2007, TISSUE ENG, V13, P2863, DOI 10.1089/ten.2007.0055; Bamber NI, 2001, EUR J NEUROSCI, V13, P257, DOI 10.1046/j.1460-9568.2001.01387.x; Baumann MD, 2009, J CONTROL RELEASE, V138, P205, DOI 10.1016/j.jconrel.2009.05.009; Baumann N, 2001, PHYSIOL REV, V81, P871; Bechara SL, 2010, BIOMATERIALS, V31, P3492, DOI 10.1016/j.biomaterials.2010.01.084; Belachew S, 2000, EUR J NEUROSCI, V12, P1924, DOI 10.1046/j.1460-9568.2000.00085.x; Belkas JS, 2005, BIOMATERIALS, V26, P1741, DOI 10.1016/j.biomaterials.2004.05.031; BELLAMKONDA R, 1995, J NEUROSCI RES, V41, P501, DOI 10.1002/jnr.490410409; Belluardo N, 2000, BEHAV BRAIN RES, V113, P21, DOI 10.1016/S0166-4328(00)00197-2; Berger F, 1998, J NEUROSCI, V18, P6871; Berkowitz M., 1998, SPINAL CORD INJURY A; Bernardini N, 2004, J NEUROCHEM, V88, P1533, DOI 10.1046/j.1471-4159.2003.02292.x; BIXBY JL, 1991, ANNU REV CELL BIOL, V7, P117, DOI 10.1146/annurev.cellbio.7.1.117; Bonner J, 2001, J NEUROSCI, V21, P9782, DOI 10.1523/JNEUROSCI.21-24-09782.2001; Borgens RB, 1999, NEUROSCIENCE, V91, P251, DOI 10.1016/S0306-4522(98)00584-3; Borgens RB, 1997, EXP NEUROL, V145, P376, DOI 10.1006/exnr.1997.6499; Borkenhagen M, 1998, J BIOMED MATER RES, V40, P392, DOI 10.1002/(SICI)1097-4636(19980603)40:3<392::AID-JBM8>3.0.CO;2-C; Borta A, 2007, J NEUROCHEM, V100, P587, DOI 10.1111/j.1471-4159.2006.04241.x; Bourguignon LYW, 2007, J NEUROCHEM, V101, P1002, DOI 10.1111/j.1471-4159.2007.04485.x; Bracken MB, 1998, J NEUROSURG, V89, P699, DOI 10.3171/jns.1998.89.5.0699; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Bradbury EJ, 2006, NAT REV NEUROSCI, V7, P644, DOI 10.1038/nrn1964; Bryan DJ, 2004, J NEURAL ENG, V1, P91, DOI 10.1088/1741-2560/1/2/004; BYROM D, 1987, TRENDS BIOTECHNOL, V5, P246, DOI 10.1016/0167-7799(87)90100-4; Cai J, 2007, J BIOMED MATER RES A, V83A, P512, DOI 10.1002/jbm.a.31296; Chaudhry N, 2006, EXP NEUROL, V202, P238, DOI 10.1016/j.expneurol.2006.06.001; Chen BK, 2009, J NEUROTRAUM, V26, P1759, DOI [10.1089/neu.2008.0610, 10.1089/neu.2008-0610]; Cheng H, 2007, BIOCHEM BIOPH RES CO, V357, P938, DOI 10.1016/j.bbrc.2007.04.049; Cho Youngnam, 2010, J Biol Eng, V4, P2, DOI 10.1186/1754-1611-4-2; Cho Y, 2010, J EXP BIOL, V213, P1513, DOI 10.1242/jeb.035162; Chvatal SA, 2008, BIOMATERIALS, V29, P1967, DOI 10.1016/j.biomaterials.2008.01.002; Clarke EC, 2009, J BIOMECH, V42, P1397, DOI 10.1016/j.jbiomech.2009.04.008; Collier JH, 2000, J BIOMED MATER RES, V50, P574, DOI 10.1002/(SICI)1097-4636(20000615)50:4<574::AID-JBM13>3.0.CO;2-I; Crompton KE, 2007, BIOMATERIALS, V28, P441, DOI 10.1016/j.biomaterials.2006.08.044; Cui FZ, 2006, J MATER SCI-MATER M, V17, P1393, DOI 10.1007/s10856-006-0615-7; Curtis A, 1997, BIOMATERIALS, V18, P1573, DOI 10.1016/S0142-9612(97)00144-0; De Laporte L, 2009, BIOMATERIALS, V30, P2361, DOI 10.1016/j.biomaterials.2008.12.051; De Sarno P, 2003, J BIOL CHEM, V278, P11086, DOI 10.1074/jbc.M212157200; Deumens R, 2004, NEUROSCIENCE, V125, P591, DOI 10.1016/j.neuroscience.2004.02.010; Dewitt DD, 2009, TISSUE ENG PT A, V15, P2785, DOI [10.1089/ten.tea.2008.0406, 10.1089/ten.TEA.2008.0406]; Dhoot NO, 2004, J BIOMED MATER RES A, V71A, P191, DOI 10.1002/jbm.a.30103; Diaz J, 1997, J NEUROSCI, V17, P4282; Durgam H, 2010, J BIOMAT SCI-POLYM E, V21, P1265, DOI 10.1163/092050609X12481751806330; EDGAR D, 1984, EMBO J, V3, P1463, DOI 10.1002/j.1460-2075.1984.tb01997.x; Filbin MT, 2003, NAT REV NEUROSCI, V4, P703, DOI 10.1038/nrn1195; Fitch MT, 2008, EXP NEUROL, V209, P294, DOI 10.1016/j.expneurol.2007.05.014; Ford MC, 2006, P NATL ACAD SCI USA, V103, P2512, DOI 10.1073/pnas.0506020102; Fu SY, 1997, MOL NEUROBIOL, V14, P67, DOI 10.1007/BF02740621; Fukushima Kazuyuki, 2008, J Med Dent Sci, V55, P71; Gao J, 2006, P NATL ACAD SCI USA, V103, P16681, DOI 10.1073/pnas.0606237103; Goraltchouk A, 2006, J CONTROL RELEASE, V110, P400, DOI 10.1016/j.jconrel.2005.10.019; GRAF J, 1987, BIOCHEMISTRY-US, V26, P6896, DOI 10.1021/bi00396a004; GrandPre T, 2002, NATURE, V417, P547, DOI 10.1038/417547a; GREENBERG ME, 1986, SCIENCE, V234, P80, DOI 10.1126/science.3749894; Gudz TI, 2006, J NEUROSCI, V26, P2458, DOI 10.1523/JNEUROSCI.4054-05.2006; Guimard NK, 2007, PROG POLYM SCI, V32, P876, DOI 10.1016/j.progpolymsci.2007.05.012; Gumera CB, 2007, ADV MATER, V19, P4404, DOI 10.1002/adma.200701747; GUNDERSEN RW, 1987, DEV BIOL, V121, P423, DOI 10.1016/0012-1606(87)90179-5; Gupta D, 2006, BIOMATERIALS, V27, P2370, DOI 10.1016/j.biomaterials.2005.11.015; Hamann MCJ, 2005, EXP NEUROL, V194, P106, DOI 10.1016/j.expneurol.2005.01.030; HATTEN ME, 1990, TRENDS NEUROSCI, V13, P179, DOI 10.1016/0166-2236(90)90044-B; He LM, 2009, TISSUE ENG PART C-ME, V15, P243, DOI 10.1089/ten.tec.2008.0255; He QR, 2009, J MATER SCI-MATER M, V20, P1457, DOI 10.1007/s10856-009-3702-8; Hebb D. O., 1988, NEUROCOMPUTING FDN R, P43; Hejcl A, 2009, J MATER SCI-MATER M, V20, P1571, DOI 10.1007/s10856-009-3714-4; Hejcl A, 2008, J NEUROSURG-SPINE, V8, P67, DOI 10.3171/SPI-08/01/067; Heng JIT, 2007, EUR J NEUROSCI, V26, P537, DOI 10.1111/j.1460-9568.2007.05694.x; Hiramoto T, 2007, NEUROREPORT, V18, P659, DOI 10.1097/WNR.0b013e3280bef9d3; Honig MG, 2002, DEV BIOL, V243, P137, DOI 10.1006/dbio.2001.0556; Horn EM, 2007, J NEUROSURG-SPINE, V6, P133, DOI 10.3171/spi.2007.6.2.133; Horne MK, 2010, STEM CELLS DEV, V19, P843, DOI 10.1089/scd.2009.0158; Hou SP, 2005, J NEUROSCI METH, V148, P60, DOI 10.1016/j.jneumeth.2005.04.016; Hu JG, 2009, J NEUROSCI RES, V87, P2854, DOI 10.1002/jnr.22111; Hubbell JA, 2003, CURR OPIN BIOTECH, V14, P551, DOI 10.1016/j.copbio.2003.09.004; HYNES RO, 1986, J NEUROSCI, V6, P867; Ichikawa N, 2005, BIOCHEMISTRY-US, V44, P5755, DOI 10.1021/bi0476228; Jain A, 2006, BIOMATERIALS, V27, P497, DOI 10.1016/j.biomaterials.2005.07.008; Johnson PJ, 2010, CELL TRANSPLANT, V19, P89, DOI 10.3727/096368909X477273; Johnson PJ, 2009, BIOTECHNOL BIOENG, V104, P1207, DOI 10.1002/bit.22476; Johnson PJ, 2010, J BIOMED MATER RES A, V92A, P152, DOI 10.1002/jbm.a.32343; Ju YE, 2007, BIOMATERIALS, V28, P2097, DOI 10.1016/j.biomaterials.2007.01.008; JUCKER M, 1991, J NEUROSCI RES, V28, P507, DOI 10.1002/jnr.490280407; Kang CE, 2010, J CONTROL RELEASE, V144, P25, DOI 10.1016/j.jconrel.2010.01.029; Kang CE, 2009, TISSUE ENG PT A, V15, P595, DOI 10.1089/ten.tea.2007.0349; Katz JS, 2009, WIRES NANOMED NANOBI, V1, P128, DOI 10.1002/wnan.10; Kenwrick S, 1998, BIOESSAYS, V20, P668, DOI 10.1002/(SICI)1521-1878(199808)20:8<668::AID-BIES10>3.0.CO;2-X; KERNS JM, 1991, NEUROSCIENCE, V40, P93, DOI 10.1016/0306-4522(91)90177-P; Kim DH, 2007, ADV FUNCT MATER, V17, P79, DOI 10.1002/adfm.200500594; Kim H, 2008, BIOTECHNOL PROGR, V24, P932, DOI 10.1021/bp070352a; Kim JW, 2008, MEAS SCI TECHNOL, V19, DOI 10.1088/0957-0233/19/1/017003; Kim YT, 2009, BIOMATERIALS, V30, P2582, DOI 10.1016/j.biomaterials.2008.12.077; King VR, 2010, NEUROSCIENCE, V168, P523, DOI 10.1016/j.neuroscience.2010.03.040; Kirchhoff F, 1996, J NEUROCHEM, V66, P1383; Krewson CE, 1996, J BIOMAT SCI-POLYM E, V8, P103; Krsko P, 2009, BIOMATERIALS, V30, P721, DOI 10.1016/j.biomaterials.2008.10.011; Krych AJ, 2009, ACTA BIOMATER, V5, P2551, DOI 10.1016/j.actbio.2009.03.021; KUHN TB, 1995, NEURON, V14, P275, DOI 10.1016/0896-6273(95)90285-6; Kuhn TB, 1998, J NEUROSCI, V18, P184; Kwon BK, 2007, SPINE, V32, P1164, DOI 10.1097/BRS.0b013e318053ec35; Lee H, 2010, P NATL ACAD SCI USA, V107, P3340, DOI 10.1073/pnas.0905437106; Lee JY, 2009, BIOMATERIALS, V30, P4325, DOI 10.1016/j.biomaterials.2009.04.042; Lee SH, 2009, NEUROL RES, V31, P996, DOI 10.1179/174313209X385626; Leipzig ND, 2009, BIOMATERIALS, V30, P6867, DOI 10.1016/j.biomaterials.2009.09.002; LETOURNEAU PC, 1975, DEV BIOL, V44, P77, DOI 10.1016/0012-1606(75)90378-4; Li XG, 2009, BIOMATERIALS, V30, P4978, DOI 10.1016/j.biomaterials.2009.05.047; Li XG, 2009, BIOMATERIALS, V30, P1121, DOI 10.1016/j.biomaterials.2008.10.063; LIESI P, 1989, FEBS LETT, V244, P141, DOI 10.1016/0014-5793(89)81180-9; LOFBERG J, 1980, DEV BIOL, V75, P148, DOI 10.1016/0012-1606(80)90151-7; LuckenbillEdds L, 1997, BRAIN RES REV, V23, P1, DOI 10.1016/S0165-0173(96)00013-6; Ma J, 2007, BIOMED MATER, V2, P233, DOI 10.1088/1748-6041/2/4/005; Madaghiele M, 2008, J BIOMED MATER RES A, V85A, P757, DOI 10.1002/jbm.a.31517; Maikos JT, 2008, J NEUROTRAUM, V25, P38, DOI 10.1089/neu.2007.0348; MATTSON MP, 1989, BRAIN RES, V478, P337, DOI 10.1016/0006-8993(89)91514-X; MCCOBB DP, 1988, NEURON, V1, P377, DOI 10.1016/0896-6273(88)90187-0; Mckinley M. P., 2006, HUMAN ANATOMY; McTigue DM, 1998, J NEUROSCI, V18, P5354; Meiners S, 2001, J NEUROSCI, V21, P7215, DOI 10.1523/JNEUROSCI.21-18-07215.2001; Mo LH, 2010, BIOMATERIALS, V31, P2184, DOI 10.1016/j.biomaterials.2009.11.078; Moore K, 2006, TISSUE ENG, V12, P267, DOI 10.1089/ten.2006.12.267; Musoke-Zawedde P, 2006, BIOMED MATER, V1, P162, DOI 10.1088/1748-6041/1/3/011; Nguyen L, 2001, CELL TISSUE RES, V305, P187, DOI 10.1007/s004410000343; *NIH NAT I NEUR DI, 2008, SPIN CORD INJ HOP RE; Nisbet DR, 2008, J BIOMAT SCI-POLYM E, V19, P623, DOI 10.1163/156856208784089652; Nisbet DR, 2007, J NEURAL ENG, V4, P35, DOI 10.1088/1741-2560/4/2/004; Nisbet DR, 2009, J BIOMED MATER RES A, V89A, P24, DOI 10.1002/jbm.a.31962; Nisbet DR, 2010, TISSUE ENG PT A, V16, P2833, DOI [10.1089/ten.tea.2009.0677, 10.1089/ten.TEA.2009.0677]; Nisbet DR, 2009, BIOMATERIALS, V30, P4573, DOI 10.1016/j.biomaterials.2009.05.011; Nomura H, 2006, NEUROSURGERY, V59, P183, DOI 10.1227/01.NEU.0000219859.35349.EF; NORRIS CR, 1991, J NEUROSCI, V11, P3481; Novikov LN, 2002, BIOMATERIALS, V23, P3369, DOI 10.1016/S0142-9612(02)00037-6; Novikova LN, 2008, BIOMATERIALS, V29, P1198, DOI 10.1016/j.biomaterials.2007.11.033; Olakowska E, 2010, FOLIA NEUROPATHOL, V48, P231; Olanow CW, 1999, ANNU REV NEUROSCI, V22, P123, DOI 10.1146/annurev.neuro.22.1.123; Olson HE, 2009, TISSUE ENG PT A, V15, P1797, DOI 10.1089/ten.tea.2008.0364; Park J, 2010, J BIOMED MATER RES A, V93A, P1091, DOI 10.1002/jbm.a.32519; Patist CM, 2004, BIOMATERIALS, V25, P1569, DOI 10.1016/S0142-9612(03)00503-9; Pfister LA, 2007, J PERIPHER NERV SYST, V12, P65, DOI 10.1111/j.1529-8027.2007.00125.x; Piantino J, 2006, EXP NEUROL, V201, P359, DOI 10.1016/j.expneurol.2006.04.020; Popolo M, 2004, DEV NEUROSCI-BASEL, V26, P229, DOI 10.1159/000082140; Powell SK, 1997, INT J BIOCHEM CELL B, V29, P401, DOI 10.1016/S1357-2725(96)00110-0; Putney SD, 1998, NAT BIOTECHNOL, V16, P153, DOI 10.1038/nbt0298-153; Ragnarsson KT, 2008, SPINAL CORD, V46, P255, DOI 10.1038/sj.sc.3102091; Ramakers GJA, 1998, DEV BRAIN RES, V108, P205, DOI 10.1016/S0165-3806(98)00050-9; Rauch MF, 2009, EUR J NEUROSCI, V29, P132, DOI 10.1111/j.1460-9568.2008.06567.x; Rivers TJ, 2002, ADV FUNCT MATER, V12, P33, DOI 10.1002/1616-3028(20020101)12:1<33::AID-ADFM33>3.0.CO;2-E; Roerig B, 1997, J NEUROSCI, V17, P8353; Rolls A, 2009, NAT REV NEUROSCI, V10, P235, DOI 10.1038/nrn2591; Rooney GE, 2008, TISSUE ENG PT A, V14, P681, DOI 10.1089/tea.2007.0260; Ruiter GCW, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/FOC.2009.26.2.E5; Runge MB, 2010, BIOMATERIALS, V31, P5916, DOI 10.1016/j.biomaterials.2010.04.012; Saifuddin U, 2003, J BIOMED MATER RES A, V66A, P184, DOI 10.1002/jbm.a.10552; Sakiyama-Elbert SE, 2000, J CONTROL RELEASE, V69, P149, DOI 10.1016/S0168-3659(00)00296-0; Sakiyama-Elbert SE, 2000, J CONTROL RELEASE, V65, P389, DOI 10.1016/S0168-3659(99)00221-7; Sayer FT, 2002, EXP NEUROL, V175, P282, DOI 10.1006/exnr.2002.7901; Schense JC, 2000, NAT BIOTECHNOL, V18, P415; Schmidt CE, 1997, P NATL ACAD SCI USA, V94, P8948, DOI 10.1073/pnas.94.17.8948; Seidlits SK, 2008, NANOMEDICINE-UK, V3, P183, DOI 10.2217/17435889.3.2.183; Seidlits SK, 2010, BIOMATERIALS, V31, P3930, DOI 10.1016/j.biomaterials.2010.01.125; Shen YX, 2010, CELL TRANSPLANT, V19, P147, DOI 10.3727/096368910X492616; Sierpinski P, 2008, BIOMATERIALS, V29, P118, DOI 10.1016/j.biomaterials.2007.08.023; Silva GA, 2004, SCIENCE, V303, P1352, DOI 10.1126/science.1093783; Sorensen A, 2007, BIOMATERIALS, V28, P5498, DOI 10.1016/j.biomaterials.2007.08.034; Spitzer NC, 2006, NATURE, V444, P707, DOI 10.1038/nature05300; Stabenfeldt SE, 2006, J BIOMED MATER RES A, V77A, P718, DOI 10.1002/jbm.a.30638; Stauffer WR, 2006, BIOMATERIALS, V27, P2405, DOI 10.1016/j.biomaterials.2005.10.024; Stichel CC, 1998, CELL TISSUE RES, V294, P1, DOI 10.1007/s004410051151; Stokols S, 2006, BIOMATERIALS, V27, P443, DOI 10.1016/j.biomaterials.2005.06.039; Stokols S, 2006, TISSUE ENG, V12, P2777, DOI 10.1089/ten.2006.12.2777; Straley KS, 2010, J NEUROTRAUM, V27, P1, DOI 10.1089/neu.2009.0948; Suisha F, 1998, INT J PHARM, V172, P27, DOI 10.1016/S0378-5173(98)00157-4; Sundararaghavan HG, 2009, BIOTECHNOL BIOENG, V102, P632, DOI 10.1002/bit.22074; Sundback CA, 2005, BIOMATERIALS, V26, P5454, DOI 10.1016/j.biomaterials.2005.02.004; Suzuki M, 2003, J NEUROSCI RES, V72, P646, DOI 10.1002/jnr.10589; Tan EYM, 2007, PHARM RES-DORDR, V24, P2297, DOI 10.1007/s11095-007-9454-6; Tang X, 2009, J BIOMED MATER RES A, V91A, P166, DOI 10.1002/jbm.a.32212; TASHIRO K, 1989, J BIOL CHEM, V264, P16174; Tata AM, 2003, J NEUROSCI RES, V73, P227, DOI 10.1002/jnr.10650; Tate CC, 2009, J TISSUE ENG REGEN M, V3, P208, DOI 10.1002/term.154; Taylor L, 2006, J NEUROSCI, V26, P9713, DOI 10.1523/JNEUROSCI.0734-06.2006; Taylor SJ, 2006, J CONTROL RELEASE, V116, P204, DOI 10.1016/j.jconrel.2006.07.005; Taylor SJ, 2006, J CONTROL RELEASE, V113, P226, DOI 10.1016/j.jconrel.2006.05.005; Taylor SJ, 2004, J CONTROL RELEASE, V98, P281, DOI 10.1016/j.jconrel.2004.05.003; Thid D, 2008, J BIOMED MATER RES A, V84A, P940, DOI 10.1002/jbm.a.31358; Thonhoff JR, 2008, BRAIN RES, V1187, P42, DOI 10.1016/j.brainres.2007.10.046; Thouas GA, 2008, IEEE ENG MED BIO, P1825, DOI 10.1109/IEMBS.2008.4649534; Thuret S, 2006, NAT REV NEUROSCI, V7, P628, DOI 10.1038/nrn1955; Tian WM, 2005, TISSUE ENG, V11, P513, DOI 10.1089/ten.2005.11.513; Tian WM, 2005, J CONTROL RELEASE, V102, P13, DOI 10.1016/j.jconrel.2004.09.025; Toborek M, 2007, J CELL BIOCHEM, V100, P279, DOI 10.1002/jcb.21013; TODD RD, 1992, BIOL PSYCHIAT, V31, P794, DOI 10.1016/0006-3223(92)90311-M; Tran PA, 2009, ADV DRUG DELIVER REV, V61, P1097, DOI 10.1016/j.addr.2009.07.010; Tysseling-Mattiace VM, 2008, J NEUROSCI, V28, P3814, DOI 10.1523/JNEUROSCI.0143-08.2008; van den Berg MEL, 2010, NEUROEPIDEMIOLOGY, V34, P184, DOI 10.1159/000279335; Van Kampen JM, 2006, J NEUROSCI, V26, P7272, DOI 10.1523/JNEUROSCI.0837-06.2006; Van Kampen JM, 2005, NEUROSCIENCE, V136, P381, DOI 10.1016/j.neuroscience.2005.07.054; Vargas ME, 2007, ANNU REV NEUROSCI, V30, P153, DOI 10.1146/annurev.neuro.30.051606.094354; Vernadakis A, 1996, PROG NEUROBIOL, V49, P185, DOI 10.1016/S0301-0082(96)00012-3; Vu TQ, 2005, BIOMATERIALS, V26, P1895, DOI 10.1016/j.biomaterials.2004.06.007; Wadhwa R, 2006, J CONTROL RELEASE, V110, P531, DOI 10.1016/j.jconrel.2005.10.027; Wan Y, 2004, MACROMOL BIOSCI, V4, P882, DOI 10.1002/mabi.200400044; Wang YD, 2003, J BIOMED MATER RES A, V66A, P192, DOI 10.1002/jbm.a.10534; Wang YC, 2008, BIOMATERIALS, V29, P4546, DOI 10.1016/j.biomaterials.2008.07.050; Wang YF, 2009, J CONTROL RELEASE, V140, P218, DOI 10.1016/j.jconrel.2009.05.025; Webb K, 2001, BIOMATERIALS, V22, P1017, DOI 10.1016/S0142-9612(00)00353-7; Weber RA, 2000, PLAST RECONSTR SURG, V106, P1036, DOI 10.1097/00006534-200010000-00013; Wei YT, 2007, BIOMED MATER, V2, pS142, DOI 10.1088/1748-6041/2/3/S11; Wei YT, 2009, J BIOACT COMPAT POL, V24, P205, DOI 10.1177/0883911509102266; WHITAKERAZMITIA PM, 1990, ANN NY ACAD SCI, V600, P315, DOI 10.1111/j.1749-6632.1990.tb16892.x; Willerth SM, 2008, ADV DRUG DELIVER REV, V60, P263, DOI 10.1016/j.addr.2007.08.028; Willerth SM, 2007, J BIOMED MATER RES A, V80A, P13, DOI 10.1002/jbm.a.30844; Wong DY, 2008, J NEUROTRAUM, V25, P1027, DOI 10.1089/neu.2007.0473; Wong DY, 2007, TISSUE ENG, V13, P2515, DOI 10.1089/ten.2006.0440; Wood MD, 2009, ACTA BIOMATER, V5, P959, DOI 10.1016/j.actbio.2008.11.008; Yang F, 2005, BIOMATERIALS, V26, P2603, DOI 10.1016/j.biomaterials.2004.06.051; Yao L, 2010, J BIOMED MATER RES A, V92A, P484, DOI 10.1002/jbm.a.32359; Yiu G, 2006, NAT REV NEUROSCI, V7, P617, DOI 10.1038/nrn1956; Yoshil S, 2009, J TISSUE ENG REGEN M, V3, P19, DOI 10.1002/term.130; YOUNG SH, 1983, NATURE, V305, P634, DOI 10.1038/305634a0; Yu D, 2009, STEM CELLS, V27, P1212, DOI 10.1002/stem.26; Yu LMY, 2008, J NEUROSCI METH, V171, P253, DOI 10.1016/j.jneumeth.2008.03.023; Yu LMY, 2007, J BIOMED MATER RES A, V82A, P243, DOI 10.1002/jbm.a.31069; Zahir T, 2008, CELL TRANSPLANT, V17, P245, DOI 10.3727/096368908784153887; Zelikin AN, 2002, ANGEW CHEM INT EDIT, V41, P141, DOI 10.1002/1521-3773(20020104)41:1<141::AID-ANIE141>3.0.CO;2-V; ZHENG JQ, 1994, NATURE, V368, P140, DOI 10.1038/368140a0; Zhong YH, 2008, J R SOC INTERFACE, V5, P957, DOI 10.1098/rsif.2008.0071; SPINAL CORD INJURY F	229	34	34	3	69	ROYAL SOC CHEMISTRY	CAMBRIDGE	THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND	0959-9428	1364-5501		J MATER CHEM	J. Mater. Chem.		2011	21	20					7033	7051		10.1039/c0jm04335d			19	Chemistry, Physical; Materials Science, Multidisciplinary	Chemistry; Materials Science	758LV	WOS:000290167200001					2021-06-18	
J	Johnson, EW; Kegel, NE; Collins, MW				Johnson, Eric W.; Kegel, Nathan E.; Collins, Michael W.			Neuropsychological Assessment of Sport-Related Concussion	CLINICS IN SPORTS MEDICINE			English	Article						Neuropsychology; Concussion; mTBI; Sports; Assessment; Management	COMPUTER-BASED ASSESSMENT; TEST-RETEST RELIABILITY; HIGH-SCHOOL; PROFESSIONAL FOOTBALL; SEX-DIFFERENCES; RECOVERY; COLLEGIATE; PERFORMANCE; STATEMENT; SENSITIVITY	Assessment of concussion can be challenging for medical practitioners given the different factors associated with each individual injury. The use of neuropsychological testing provides an objective method in the evaluation and management of concussion. Over the last 20 years it has become increasingly useful in the realm of sports concussion and has been deemed a cornerstone of concussion management by the Concussion in Sport group at the International Symposia on Concussion in Sport. Neuropsychological assessment has evolved to using computer-based neurocognitive testing, which has become increasingly common over the last decade, especially in organized sports. Neuropsychological assessment has also proven to be effective in the detection of differences based on several individual factors, including age, gender, and history of prior concussion. Despite its documented value, neuropsychological assessment should be one of several tools used as part of the concussion assessment/management process.	[Johnson, Eric W.; Kegel, Nathan E.] Univ Pittsburgh, Med Ctr, Sports Concuss Program, Dept Orthopaed Surg, Pittsburgh, PA 15203 USA; [Collins, Michael W.] Univ Pittsburgh, Med Ctr, Dept Orthopaed Surg & Neurol Surg, Pittsburgh, PA 15203 USA	Johnson, EW (corresponding author), Univ Pittsburgh, Med Ctr, Sports Concuss Program, Dept Orthopaed Surg, 3200 S Water St, Pittsburgh, PA 15203 USA.	johnsonew@upmc.edu					Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barth JT., 1989, MILD HEAD INJURY, P257; BARTH JT, 2006, SPORTS NEUROPSYCHOLO; Biagas KV, 1996, J NEUROTRAUM, V13, P189, DOI 10.1089/neu.1996.13.189; Bleiberg Joseph, 2005, Neurosurgery, V56, pE1166; Broglio SP, 2006, BRIT J SPORT MED, V40, P802, DOI 10.1136/bjsm.2006.028019; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; Bruce JM, 2009, NEUROSURGERY, V64, P100, DOI 10.1227/01.NEU.0000336310.47513.C8; Collie A, 2003, BRIT J SPORT MED, V37, P2, DOI 10.1136/bjsm.37.1.2; COLLIE A, 2001, BRIT J SPORT MED, V35, P7; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Erlanger DM, 1999, CONCUSSION RESOLUTIO; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gardner A, 2010, ARCH CLIN NEUROPSYCH, V25, P174, DOI 10.1093/arclin/acq007; Gartland S, 2001, BRIT J SPORT MED, V35, P308, DOI 10.1136/bjsm.35.5.308; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; IVERSON GL, 2009, BR J SPORTS MED S1, V43, P100; Iverson G, 2007, CLIN J SPORT MED, V17, P31; Kraus MF, 2005, BRAIN INJURY, V19, P471, DOI 10.1080/02699050400025059; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Lovell M, 2009, CLIN SPORT MED, V28, P95, DOI 10.1016/j.csm.2008.08.008; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Lovell MR, 1999, SPORTS-RELATED CONCUSSION, P200; LOVELL MR, 2010, 2010 BIG SKY ATHL TR; LOVELL MR, 2000, NEUROLOGIC ATHLETIC, P109; Lovell MR, 2000, IMMEDIATE POSTCONCUS; Lovell MR, 2006, SPORTS NEUROPSYCHOLO, P176; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrea, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI [10.1001/jama.290.19.2556, DOI 10.1001/JAMA.290.19.2556]; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory Paul, 2005, Clin J Sport Med, V15, P48; MCDONALD JW, 1990, BRAIN RES REV, V15, P41, DOI 10.1016/0165-0173(90)90011-C; MCDONALD JW, 1988, BRAIN RES, V459, P200, DOI 10.1016/0006-8993(88)90306-X; McLeod TCV, 2006, J ATHL TRAINING, V41, P399; Mihalik JP, 2005, J NEUROSURG, V102, P850, DOI 10.3171/jns.2005.102.5.0850; PARDINI D, 2004, 2 INT S CONC SPORT P; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Pellman EJ, 2004, NEUROSURGERY, V55, P1290, DOI 10.1227/01.NEU.0000149244.97560.91; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2003, APPL NEUROPSYCHOL, V10, P42, DOI 10.1207/S15324826AN1001_6; Schatz P, 2006, SPORTS NEUROPSYCHOLO, P160; Schatz P, 2006, APPL NEUROPSYCHOL, V13, P151, DOI 10.1207/s15324826an1303_2; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Segalowitz SJ, 2007, NEUROREHABILITATION, V22, P243; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Zillmer E.., 2006, SPORTS NEUROPSYCHOLO, P17	62	34	34	1	26	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-5919	1556-228X		CLIN SPORT MED	Clin. Sports Med.	JAN	2011	30	1					73	+		10.1016/j.csm.2010.08.007			18	Sport Sciences	Sport Sciences	691XR	WOS:000285114800008	21074083				2021-06-18	
J	McDonald, S; Li, S; De Sousa, A; Rushby, J; Dimoska, A; James, C; Tate, RL				McDonald, Skye; Li, Sophie; De Sousa, Arielle; Rushby, Jacqueline; Dimoska, Aneta; James, Charlotte; Tate, Robyn L.			Impaired mimicry response to angry faces following severe traumatic brain injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Emotion; Emotion perception; Electromyography; Traumatic brain injury; Mimicry	EMOTIONAL FACIAL EXPRESSIONS; PERCEPTION DEFICITS; SOCIAL-PERCEPTION; RECOGNITION; BEHAVIOR; AMYGDALA; IMPAIRMENTS; EXPERIENCE; RESONANCE; SADNESS	This study examined whether severe traumatic brain injuries (TBIs) interfere with normal facial mimicry when observing facial expressions. A total of 21 adults with severe TBI and 20 control participants viewed angry and happy facial expressions taken from the Ekman and Friesen (1976) series while facial movement of the corrugator supercilii (brow) and zygomaticus major (cheek) was monitored. Faces were presented both statically and dynamically (gradually morphing from neutral to the final expression). The control group showed increased brow activity to angry expressions and increased cheek activity to happy expressions. This activity was evident as early as 500 ms, consistent with previous research suggesting that facial mimicry commences as an automatic process. The TBI group showed similar activity to happy expressions but no clear response to angry expressions, either early (500-1,000 ms) or over the entire 6-s duration of the displayed image. This was the case for both static and dynamic displays. There was no relationship between facial mimicry and accuracy in identifying (matching) facial expressions for either the TBI or control participants. These results are consistent with the view that ventral frontal structures mediate early responses to angry expressions and that these are frequently compromised as a result of severe TBI. The results did not support the view that simulation (mimicry) facilitates emotion recognition.	[McDonald, Skye] Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia; [Tate, Robyn L.] Univ Sydney, Dept Med, Rehabil Studies Unit, Sydney, NSW 2006, Australia	McDonald, S (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.	s.mcdonald@unsw.edu.au	Rushby, Jacqueline/D-1820-2010; McDonald, Skye/G-4118-2014	Rushby, Jacqueline/0000-0002-5018-638X; McDonald, Skye/0000-0003-0723-6094	National Health & Medical Research Council of AustraliaNational Health and Medical Research Council of Australia	This research was funded with grants from the National Health & Medical Research Council of Australia. We are grateful to the Sydney metropolitan brain injury units-Royal Rehabilitation Centre, Westmead Brain Injury Unit, and Liverpool Brain Injury Unit-who assisted with recruitment. We are particularly grateful to the people with traumatic brain injuries and our control participants who gave willingly of their time to assist this research.	Achaibou A, 2008, NEUROPSYCHOLOGIA, V46, P1104, DOI 10.1016/j.neuropsychologia.2007.10.019; ADELMANN PK, 1989, ANNU REV PSYCHOL, V40, P249, DOI 10.1146/annurev.ps.40.020189.001341; Adolphs R, 2000, J NEUROSCI, V20, P2683; Adolphs R, 2002, CURR OPIN NEUROBIOL, V12, P169, DOI 10.1016/S0959-4388(02)00301-X; Adolphs R, 2004, J COGNITIVE NEUROSCI, V16, P453, DOI 10.1162/089892904322926782; Adolphs R, 1996, J NEUROSCI, V16, P7678; Adolphs R, 1999, PSYCHOL SCI, V10, P167, DOI 10.1111/1467-9280.00126; Adolphs Ralph, 2002, Behav Cogn Neurosci Rev, V1, P21, DOI 10.1177/1534582302001001003; Bailey PE, 2009, PSYCHOL AGING, V24, P224, DOI 10.1037/a0014112; Bavelas J. B., 1986, J PERS SOC PSYCHOL, V51, P1173; Biele C, 2006, EXP BRAIN RES, V171, P1, DOI 10.1007/s00221-005-0254-0; Bigler ED, 2007, NEUROPSYCHOLOGY, V21, P515, DOI 10.1037/0894-4105.21.5.515; Blair RJR, 2000, BRAIN, V123, P1122, DOI 10.1093/brain/123.6.1122; Blair RJR, 1999, BRAIN, V122, P883, DOI 10.1093/brain/122.5.883; Blairy S, 1999, J NONVERBAL BEHAV, V23, P5, DOI 10.1023/A:1021370825283; Bornhofen C, 2008, J INT NEUROPSYCH SOC, V14, P511, DOI 10.1017/S1355617708080703; Broks P, 1998, NEUROPSYCHOLOGIA, V36, P59, DOI 10.1016/S0028-3932(97)00105-X; Buchanan TW, 2004, BEHAV NEUROSCI, V118, P429, DOI 10.1037/0735-7044.118.2.429; BUCK R, 1993, NEUROPSYCHOLOGY, V7, P490, DOI DOI 10.1037/0894-4105.7.4.490; Carr L, 2003, P NATL ACAD SCI USA, V100, P5497, DOI 10.1073/pnas.0935845100; Courville CB, 1945, PATHOLOGY NERVOUS SY; Croker V, 2005, BRAIN INJURY, V19, P787, DOI 10.1080/02699050500110033; Damasio AR, 1998, BRAIN RES REV, V26, P83, DOI 10.1016/S0165-0173(97)00064-7; de Wied M, 2006, J PSYCHIAT RES, V40, P112, DOI 10.1016/j.jpsychires.2005.08.003; Decety J, 2008, DEV PSYCHOPATHOL, V20, P1053, DOI 10.1017/S0954579408000503; Dimberg U, 2000, PSYCHOL SCI, V11, P86, DOI 10.1111/1467-9280.00221; Dimberg U, 2000, PSYCHOPHYSIOLOGY, V37, P693, DOI 10.1017/S0048577200990759; Dimberg U, 1998, SCAND J PSYCHOL, V39, P39, DOI 10.1111/1467-9450.00054; DIMBERG U, 1990, BIOL PSYCHOL, V30, P151, DOI 10.1016/0301-0511(90)90024-Q; Dimberg U, 2007, SCAND J PSYCHOL, V48, P321, DOI 10.1111/j.1467-9450.2007.00586.x; Ekman P., 1976, PICTURES FACIAL AFFE; FADIGA L, 1995, J NEUROPHYSIOL, V73, P2608; Forster KI, 2003, BEHAV RES METH INS C, V35, P116, DOI 10.3758/BF03195503; FRIDLUND AJ, 1986, PSYCHOPHYSIOLOGY, V23, P567, DOI 10.1111/j.1469-8986.1986.tb00676.x; Fujiwara E, 2008, NEUROPSYCHOLOGIA, V46, P461, DOI 10.1016/j.neuropsychologia.2007.08.027; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Goldman AI, 2005, COGNITION, V94, P193, DOI 10.1016/j.cognition.2004.01.005; Green REA, 2004, NEUROPSYCHOLOGIA, V42, P133, DOI 10.1016/j.neuropsychologia.2003.07.005; HADLEY DM, 1988, CLIN RADIOL, V39, P131; Harmer CJ, 2001, NAT NEUROSCI, V4, P17, DOI 10.1038/82854; HAVILAND JM, 1987, DEV PSYCHOL, V23, P97, DOI 10.1037/0012-1649.23.1.97; Hermans EJ, 2009, BIOL PSYCHOL, V80, P348, DOI 10.1016/j.biopsycho.2008.12.002; Hermans EJ, 2006, PSYCHONEUROENDOCRINO, V31, P859, DOI 10.1016/j.psyneuen.2006.04.002; Hess U, 1998, COGNITION EMOTION, V12, P509, DOI 10.1080/026999398379547; Hess U, 2001, INT J PSYCHOPHYSIOL, V40, P129, DOI 10.1016/S0167-8760(00)00161-6; Hoffman M. L., 1984, EMOTIONS COGNITION B, P103; Hopkins MJ, 2002, BRAIN INJURY, V16, P245, DOI 10.1080/02699050110103346; Hornak J, 1996, NEUROPSYCHOLOGIA, V34, P247, DOI 10.1016/0028-3932(95)00106-9; JACKSON HF, 1987, CORTEX, V23, P293, DOI 10.1016/S0010-9452(87)80039-4; Kilts CD, 2003, NEUROIMAGE, V18, P156, DOI 10.1006/nimg.2002.1323; LEVENSON RW, 1990, PSYCHOPHYSIOLOGY, V27, P363, DOI 10.1111/j.1469-8986.1990.tb02330.x; Lovibond SH, 1995, MANUAL DEPRESSION AN; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; McDonald S., 2004, NEUROPSYCHOL REHABIL, V14, P205; McHugo GJ, 1996, MOTIV EMOTION, V20, P85, DOI 10.1007/BF02253867; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; Moody EJ, 2007, EMOTION, V7, P447, DOI 10.1037/1528-3542.7.2.447; Niedenthal PM, 2001, COGNITION EMOTION, V15, P853, DOI 10.1080/02699930143000194; OBRIEN RG, 1985, PSYCHOL BULL, V97, P316, DOI 10.1037/0033-2909.97.2.316; Penn DL, 2000, SCHIZOPHR RES, V46, P217, DOI 10.1016/S0920-9964(00)00005-0; Phillips ML, 2003, BIOL PSYCHIAT, V54, P504, DOI 10.1016/S0006-3223(03)00168-9; Saunders JC, 2006, NEUROPSYCHOLOGY, V20, P224, DOI 10.1037/0894-4105.20.2.224; Smith CA, 1996, MOTIV EMOTION, V20, P237, DOI 10.1007/BF02251888; Sonnby-Borgstrom M, 2002, SCAND J PSYCHOL, V43, P433, DOI 10.1111/1467-9450.00312; Sonnby-Borgstrom M, 2003, J NONVERBAL BEHAV, V27, P3, DOI 10.1023/A:1023608506243; Soussignan R, 2005, NEUROCASE, V11, P114, DOI 10.1080/13554790590922513; Spell LA, 2000, J NONVERBAL BEHAV, V24, P285, DOI 10.1023/A:1006675230193; Sprengelmeyer R, 1996, BRAIN, V119, P1647, DOI 10.1093/brain/119.5.1647; Tabachnick B.G., 1989, USING MULTIVARIATE S; Tassinary L.G., 2000, HDB PSYCHOPHYSIOLOGY, V2nd, P163; TATE RL, 1989, ACTA NEUROL SCAND, V79, P97, DOI 10.1111/j.1600-0404.1989.tb03719.x; Weyers P, 2006, PSYCHOPHYSIOLOGY, V43, P450, DOI 10.1111/j.1469-8986.2006.00451.x; Williams JHG, 2006, NEUROPSYCHOLOGIA, V44, P610, DOI 10.1016/j.neuropsychologia.2005.06.010	74	34	34	0	12	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2011	33	1					17	29	PII 922748270	10.1080/13803391003761967			13	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	714QK	WOS:000286823900003	20526931				2021-06-18	
J	Radford, KA; Lah, S; Say, MJ; Miller, LA				Radford, Kylie A.; Lah, Suncica; Say, Miranda J.; Miller, Laurie A.			Validation of a New Measure of Prospective Memory: The Royal Prince Alfred Prospective Memory Test	CLINICAL NEUROPSYCHOLOGIST			English	Article						Reliability; Sensitivity; Everyday memory; Rehabilitation; Cognition	TRAUMATIC BRAIN-INJURY; EVERYDAY PROSPECTIVE MEMORY; INTENTIONS SCREENING-TEST; SELF-AWARENESS; PERFORMANCE; EVENT; ADULTS; TASKS; TIME; AGE	Prospective memory problems are common in patients with brain injury, but appropriate measures are limited. The reliability and validity of the newly designed Royal Prince Alfred Prospective Memory Test (RPA-ProMem), which has three alternate versions, was investigated in 20 healthy volunteers and 20 neurological patients with everyday prospective memory problems. The RPA-ProMem was found to be easy to score reliably (inter-rater reliability = .90) and its three versions were well matched (delayed alternate-form reliability = .71). Test validity and sensitivity to patient deficits were also supported. This new measure of prospective memory should be particularly useful in situations that require repeated assessments, such as evaluation of rehabilitation efforts.	[Miller, Laurie A.] Royal Prince Alfred Hosp, Neuropsychol Unit, Camperdown, NSW 2050, Australia; [Radford, Kylie A.; Lah, Suncica; Miller, Laurie A.] Univ Sydney, Sch Psychol, Sydney, NSW 2006, Australia; [Say, Miranda J.] Macquarie Univ, Dept Psychol, Sydney, NSW 2109, Australia	Miller, LA (corresponding author), Royal Prince Alfred Hosp, Neuropsychol Unit, Camperdown, NSW 2050, Australia.	lauriem@icn.usyd.edu.au	; Radford, Kylie/D-5338-2011	Miller, Laurie/0000-0001-6329-2969; Lah, Suncica/0000-0003-2282-4812; Radford, Kylie/0000-0001-8095-5314			Adda CC, 2008, NEUROPSYCHOLOGIA, V46, P1954, DOI 10.1016/j.neuropsychologia.2008.01.016; Brooks BM, 2004, BRAIN INJURY, V18, P391, DOI 10.1080/02699050310001619855; Burgess PW, 2001, NEUROPSYCHOLOGIA, V39, P545, DOI 10.1016/S0028-3932(00)00149-4; Burgess PW, 2003, NEUROPSYCHOLOGIA, V41, P906, DOI 10.1016/S0028-3932(02)00327-5; Chau LT, 2007, NEUROPSYCHOL REHABIL, V17, P707, DOI 10.1080/09602010600923926; Cicchetti D.V., 1994, PSYCHOL ASSESS, V6, P284, DOI [10.1037/1040-3590.6.4.284, DOI 10.1037/1040-3590.6.4.284]; Daum I, 2000, BEHAV NEUROL, V12, P161, DOI 10.1155/2000/327304; Ellis JA., 1996, PROSPECTIVE MEMORY T, P1; Fish J, 2007, NEUROPSYCHOLOGIA, V45, P1318, DOI 10.1016/j.neuropsychologia.2006.09.015; Fleming JM, 1996, BRAIN INJURY, V10, P1; Groot YCT, 2002, J INT NEUROPSYCH SOC, V8, P645, DOI 10.1017/S1355617702801321; Hannon R, 1995, REHABIL PSYCHOL, V40, P289, DOI 10.1037/0090-5550.40.4.289; Henry JD, 2004, PSYCHOL AGING, V19, P27, DOI 10.1037/0882-7974.19.1.27; Howell D.C., 2007, STAT METHODS PSYCHOL, V6th ed.; Kinsella G, 1996, BRAIN INJURY, V10, P499, DOI 10.1080/026990596124214; Knight RG, 2005, BRAIN INJURY, V19, P19, DOI 10.1080/02699050410001720022; Marsh RL, 1998, MEM COGNITION, V26, P633, DOI 10.3758/BF03211383; Mateer C.A., 1987, J HEAD TRAUMA REHAB, V2, P74, DOI [10.1097/00001199-198709000-00009, DOI 10.1097/00001199-198709000-00009]; Mathias JL, 2005, BRAIN INJURY, V19, P271, DOI 10.1080/02699050400005028; McDaniel MA, 1999, NEUROPSYCHOLOGY, V13, P103, DOI 10.1037/0894-4105.13.1.103; Palmer HM, 2000, BRAIN COGNITION, V44, P103; Portney L., 2015, FDN CLIN RES APPL PR, V3rd ed.; RASKIN S, 2000, MEMORY INTENTI UNPUB; Raskin S, 2004, J INT NEUROPSYCHO S1, V10, P110, DOI DOI 10.1017/S1355617704040019; Raskin SA, 2009, BRAIN IMPAIR, V10, P23, DOI 10.1375/brim.10.1.23; Rendell PG, 2000, APPL COGNITIVE PSYCH, V14, pS43, DOI 10.1002/acp.770; Roche NL, 2002, BRAIN INJURY, V16, P931, DOI 10.1080/02699050210138581; Ruxton GD, 2006, BEHAV ECOL, V17, P688, DOI 10.1093/beheco/ark016; Schmitter-Edgecombe M, 2004, NEUROPSYCHOLOGY, V18, P353, DOI 10.1037/0894-4105.18.2.353; Shum D, 2004, SCHIZOPHRENIA BULL, V30, P693, DOI 10.1093/oxfordjournals.schbul.a007123; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P49, DOI 10.1076/jcen.21.1.49.943; Shum D., 2002, BRAIN IMPAIR, V3, DOI [https://doi.org/10.1375/brim.3.1.1, DOI 10.1375/BRIM.3.1.1]; SHUM D, 2006, PSYCHOL TESTING ASSE; Simons JS, 2006, NEUROPSYCHOLOGIA, V44, P1388, DOI 10.1016/j.neuropsychologia.2006.01.005; SUNDERLAND A, 1983, J VERB LEARN VERB BE, V22, P341, DOI 10.1016/S0022-5371(83)90229-3; Tabachnick BG, 2013, USING MULTIVARIATE S; WEST RL, 1988, PRACTICAL ASPECTS ME, V2, P119; Wilson, 1991, NATL ADULT READING T; Wilson B., 2005, CAMBRIDGE PROSPECTIV; Wilson B. A., 1985, RIVERMEAD BEHAV MEMO; WILSON BA, 2004, BRAIN IMPAIRMENT S, V5, P44; Wilson BA, 2003, RIVERMEAD BEHAV MEMO; Woods SP, 2008, CLIN NEUROPSYCHOL, V22, P864, DOI 10.1080/13854040701595999	43	34	35	0	8	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2011	25	1					127	140		10.1080/13854046.2010.529463			14	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	722FM	WOS:000287417100009	21108144				2021-06-18	
J	Salottolo, K; Offner, P; Levy, AS; Mains, CW; Slone, DS; Bar-Or, D				Salottolo, Kristin; Offner, Patrick; Levy, A. Stewart; Mains, Charles W.; Slone, Denetta S.; Bar-Or, David			Interrupted Pharmocologic Thromboprophylaxis Increases Venous Thromboembolism in Traumatic Brain Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	69th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 22-25, 2010	Boston, MA	Amer Assoc Surg Trauma (AAST)		Pharmacologic thromboprophylaxis; Traumatic brain injury; Thromboembolism; Coagulation	MOLECULAR-WEIGHT HEPARIN; DVT HOSPITAL PRACTICE; FACTORS-AN ANALYSIS; DATA-BANK NTDB; MAJOR TRAUMA; 1602 EPISODES; PROPHYLAXIS; PATIENT; COAGULOPATHY; PREDICTORS	Background: Pharmacologic thromboprophylaxis (PTP) is frequently withheld, begun late, or interrupted in patients with traumatic brain injury (TBI). The purpose of this study was to analyze whether late or interrupted PTP increases the risk of venous thromboembolism (VTE) after TBI. Methods: We retrospectively studied patients with blunt TBI and stable head computed tomography (CT) scans who were admitted to two Level I trauma centers. PTP use was analyzed as an independent risk factor for VTE using separate logistic regression models for each definition of PTP use: (1) administration of PTP; (2) timing of PTP (early [<72 hours] vs. late [>= 72 hours]); and (3) continuous versus interrupted use of PTP. Results: Four hundred eighty patients with TBI were identified. VTE occurred in 15 patients (3.13%). VTE developed in six patients despite early PTP (5.56%), four patients with late PTP (2.72%), and five with no PTP (2.22%). Neither administration of PTP nor timing of PTP was independent predictor of developing a VTE (PTP vs. none: odds ratio [OR] = 0.36, p = 0.18; early PTP vs. late PTP: OR = 2.00, p = 0.41). PTP was administered continuously in 188 patients (73.7%). Patients with interrupted PTP had a significant increased odds of developing VTE compared with patients with continuous PTP (OR = 7.07, p = 0.04). Walking before discharge significantly decreased the odds of developing a VTE (OR = 0.19, p = 0.02). Conclusions: Interrupted administration of PTP in patients with TBI is associated with significantly increased risk of VTE. These findings underscore the importance of continuous PTP administration, and every effort should be made to avoid interruption if possible.	[Salottolo, Kristin; Bar-Or, David] Swedish Med Ctr, Trauma Res Dept, Englewood, CO 80113 USA; [Salottolo, Kristin; Offner, Patrick; Mains, Charles W.; Bar-Or, David] St Anthony Cent Hosp, Trauma Res Dept, Denver, CO USA; [Offner, Patrick; Mains, Charles W.] St Anthony Cent Hosp, Trauma Serv Dept, Denver, CO USA; [Levy, A. Stewart] St Anthony Cent Hosp, Div Neurosurg, Denver, CO USA; [Slone, Denetta S.] Swedish Med Ctr, Trauma Serv Dept, Englewood, CO 80113 USA; [Offner, Patrick; Mains, Charles W.; Bar-Or, David] Rocky Vista Univ, Parker, CO 80134 USA	Bar-Or, D (corresponding author), Swedish Med Ctr, Trauma Res Dept, 501 E Hampden Ave Room 4-454, Englewood, CO 80113 USA.	dbaror@dmibio.com	Bar-Or, David/AAE-9328-2020				Cothren CC, 2007, WORLD J SURG, V31, P98, DOI 10.1007/s00268-006-0304-1; Datta Indraneel, 2010, J Trauma Manag Outcomes, V4, P1, DOI 10.1186/1752-2897-4-1; Depew AJ, 2008, AM SURGEON, V74, P906; Ekeh AP, 2010, J TRAUMA, V68, P912, DOI 10.1097/TA.0b013e3181b21cad; Eppsteiner RW, 2010, WORLD J SURG, V34, P10, DOI 10.1007/s00268-009-0284-z; GEERTS WH, 1994, NEW ENGL J MED, V331, P1601, DOI 10.1056/NEJM199412153312401; Geerts William H, 2006, Hematology Am Soc Hematol Educ Program, P462; Haut ER, 2009, J TRAUMA, V66, P994, DOI 10.1097/TA.0b013e3181991adc; Kim J, 2002, J TRAUMA, V53, P38, DOI 10.1097/00005373-200207000-00008; Knudson MM, 1996, J TRAUMA, V41, P446, DOI 10.1097/00005373-199609000-00010; Knudson MM, 2004, ANN SURG, V240, P490, DOI 10.1097/01.sla.0000137138.40116.6c; Levy AS, 2010, J TRAUMA, V68, P886, DOI 10.1097/TA.0b013e3181d27dd5; Lozance K, 1998, J CLIN NEUROSCI, V5, P394, DOI 10.1016/S0967-5868(98)90269-7; Nathens AB, 2007, J TRAUMA, V62, P557, DOI 10.1097/TA.0b013e318031b5f5; Nekludov M, 2007, J NEUROTRAUM, V24, P174, DOI 10.1089/neu.2006.0173; Norwood SH, 2008, J TRAUMA, V65, P1021, DOI 10.1097/TA.0b013e31818a0e74; Reiff DA, 2009, J TRAUMA, V66, P1436, DOI 10.1097/TA.0b013e31817fdf1c; Rogers SO, 2007, J TRAUMA, V62, P562; Scales DC, 2010, CRIT CARE, V14, DOI 10.1186/cc8980; Shackford SR, 2004, ANN SURG, V240, P496; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; Velmahos GC, 2000, J TRAUMA, V49, P140, DOI 10.1097/00005373-200007000-00021; Vergouwen MDI, 2008, CURR OPIN CRIT CARE, V14, P149, DOI 10.1097/MCC.0b013e3282f57540	23	34	35	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JAN	2011	70	1					19	26		10.1097/TA.0b013e318207c54d			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	707WD	WOS:000286320300007	21217476				2021-06-18	
J	Thomas, CA; Moffett, BS; Wagner, JL; Mott, AR; Feig, DI				Thomas, Christopher A.; Moffett, Brady S.; Wagner, Jeffrey L.; Mott, Antonio R.; Feig, Daniel I.			Safety and efficacy of intravenous labetalol for hypertensive crisis in infants and small children	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						malignant hypertension; hypertensive urgency; labetalol; neonate; nicardipine; nitroprusside	SODIUM-NITROPRUSSIDE; NICARDIPINE; MANAGEMENT; DIAGNOSIS; THERAPY; DRUG	Objective: To determine the efficacy and safety of labetalol for hypertensive crisis in children <= 24 months of age. Design: Retrospective chart review. Statistical analysis utilized analysis of variance for continuous data, chi-square tests for nominal data, and linear regression. Setting: A 737-bed pediatric teaching institution. Patients: Twenty-seven patients <= 24 months of age were treated with 37 intravenous infusions of labetalol, nicardipine, or nitroprusside for hypertensive crisis or hypertensive urgency. Interventions: None. Measurements and Main Results: The primary end point consisted of time to 20% reduction in systolic blood pressure. Primary safety end points measured the prevalence of deleterious effects of labetalol. Continuous infusion of labetalol reduced mean systolic blood pressure by at least 20% in <8 hrs. This effect was similar to nicardipine and nitroprusside infusions. The reported side effects were similar in each group. Patients receiving labetalol and presenting with ischemic or traumatic brain injury were likely to develop hypotension requiring infusion discontinuation. Conclusions: Continuous intravenous labetalol infusion is efficacious for treatment of hypertensive crisis in children <= 24 months of age. Aside from patients presenting with ischemic or traumatic brain injury, labetalol was safe to use in this population for hypertensive emergencies and had a satisfactory adverse effect profile. Labetalol may reach dose saturation at a much lower dose in young children in comparison to adults. Clinicians should use caution when initiating labetalol infusions in young patients with brain injury. (Pediatr Crit Care Med 2011; 12:28-32)	[Thomas, Christopher A.; Moffett, Brady S.; Wagner, Jeffrey L.] Texas Childrens Hosp, Dept Pharm, Houston, TX 77030 USA; [Mott, Antonio R.] Texas Childrens Hosp, Dept Pediat Cardiol, Houston, TX 77030 USA; [Feig, Daniel I.] Texas Childrens Hosp, Dept Pediat Nephrol, Houston, TX 77030 USA; [Mott, Antonio R.; Feig, Daniel I.] Baylor Coll Med, Houston, TX 77030 USA	Thomas, CA (corresponding author), Texas Childrens Hosp, Dept Pharm, Houston, TX 77030 USA.	cthoma15@clarian.org		Thomas, Christopher/0000-0002-9630-8506; Feig, Daniel/0000-0002-0017-6335			[Anonymous], 2000, LAB HYDR INJ PACK IN; Benedetti MS, 2003, FUND CLIN PHARMACOL, V17, P281, DOI 10.1046/j.1472-8206.2003.00140.x; BUNCHMAN TE, 1992, J PEDIATR-US, V120, P140, DOI 10.1016/S0022-3476(05)80619-5; DEAL JE, 1992, ARCH DIS CHILD, V67, P1089, DOI 10.1136/adc.67.9.1089; Flynn JT, 2009, PEDIATR NEPHROL, V24, P1101, DOI 10.1007/s00467-008-1000-1; Flynn JT, 2000, PEDIATR NEPHROL, V14, P332, DOI 10.1007/s004670050771; Flynn JT, 2001, J PEDIATR-US, V139, P38, DOI 10.1067/mpd.2001.114030; Immink RV, 2008, HYPERTENSION, V52, P236, DOI 10.1161/HYPERTENSIONAHA.108.110395; Jivraj S, 2006, CAN J ANAESTH, V53, P678, DOI 10.1007/BF03021626; Liu-DeRyke X, 2008, NEUROCRIT CARE, V9, P167, DOI 10.1007/s12028-008-9057-z; Milou C, 2000, INTENS CARE MED, V26, P956, DOI 10.1007/s001340051287; Natl High Blood Pressure Educ Prog, 2004, PEDIATRICS, V114, P555; NEUTEL JM, 1994, AM J HYPERTENS, V7, P623, DOI 10.1093/ajh/7.7.623; Nishina K, 2001, ANESTH ANALG, V93, P641, DOI 10.1097/00000539-200109000-00021; Patel HP, 2005, CURR OPIN PEDIATR, V17, P210, DOI 10.1097/01.mop.0000150769.38484.b3; SCHWARTZ GJ, 1987, PEDIATR CLIN N AM, V34, P571; Temple ME, 2000, PHARMACOTHERAPY, V20, P140, DOI 10.1592/phco.20.3.140.34782; Tenney F, 2000, AM J KIDNEY DIS, V35, part. no., DOI 10.1016/S0272-6386(00)70285-X; Varon J, 2000, CHEST, V118, P214, DOI 10.1378/chest.118.1.214; Wintergerst KA, 2006, PEDIATRICS, V118, P173, DOI 10.1542/peds.2005-1819; Yang HJ, 2004, J INT MED RES, V32, P118, DOI 10.1177/147323000403200203	21	34	35	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	JAN	2011	12	1					28	32		10.1097/PCC.0b013e3181e328d8			5	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	703FT	WOS:000285964500015	20495503				2021-06-18	
J	Widome, R; Kehle, SM; Carlson, KF; Laska, MN; Gulden, A; Lust, K				Widome, Rachel; Kehle, Shannon M.; Carlson, Kathleen F.; Laska, Melissa Nelson; Gulden, Ashley; Lust, Katherine			Post-traumatic Stress Disorder and Health Risk Behaviors Among Afghanistan and Iraq War Veterans Attending College	AMERICAN JOURNAL OF HEALTH BEHAVIOR			English	Article						veterans; tobacco; alcohol; health behaviors; OEF/OIF	TRAUMATIC BRAIN-INJURY; COMBAT DEPLOYMENT; AGGRESSION; DIAGNOSES; SYMPTOMS; STUDENTS; SMOKING; COHORT; PTSD; CARE	Objective: To determine if posttraumatic stress disorder (PTSD) is associated with health risk behaviors among Operations Enduring and Iraqi Freedom (OEF/OIF) veterans attending college. Method: Using 2008 Boynton College Student Health Survey data, we tested associations between self-reported PTSD diagnosis and self-reported risk behaviors (n=406). Results: We found PTSD diagnosis to be significantly associated with reporting involvement in a physical fight in the past year (ARR = 3.1; 95% CI: 2.2, 4.4) and marginally associated with high-risk drinking (ARR = 1.3; 95% CI: 1.1, 1.6). However, no association was seen between PTSD and the tobacco use and other safety behaviors that we examined. Conclusion: PTSD is likely a factor that contributes to the relationship between military service and certain health risk behaviors.	[Widome, Rachel; Kehle, Shannon M.; Gulden, Ashley] Univ Minnesota, Ctr Chron Dis Outcomes Res, Minneapolis, MN 55455 USA; [Widome, Rachel] Univ Minnesota, Dept Med, Minneapolis, MN USA; [Carlson, Kathleen F.] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland Ctr Study Chron Comorbid Mental & Phys D, Portland, OR 97201 USA; [Carlson, Kathleen F.] Oregon Hlth & Sci Univ, Dept Publ Hlth & Preventat Med, Portland, OR 97201 USA; [Laska, Melissa Nelson] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN USA; [Lust, Katherine] Univ Minnesota, Boynton Hlth Serv, Minneapolis, MN USA	Widome, R (corresponding author), Univ Minnesota, Ctr Chron Dis Outcomes Res, Minneapolis, MN 55455 USA.	chel@umn.edu		Laska, Melissa/0000-0002-3836-0269	NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [U54 CA116849, U54CA116849] Funding Source: Medline; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [U54CA116849] Funding Source: NIH RePORTER		American College Health Association, AM COLL HLTH ASS NAT; Borsari B, 2008, J COLL STUD PSYCH, V22, P61, DOI 10.1080/87568220801960720; Cohen BE, 2009, JAMA-J AM MED ASSOC, V302, P489, DOI 10.1001/jama.2009.1084; Flood AM, 2009, J BEHAV MED, V32, P234, DOI 10.1007/s10865-008-9195-y; Fu SS, 2007, NICOTINE TOB RES, V9, P1071, DOI 10.1080/14622200701488418; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jacobson IG, 2008, JAMA-J AM MED ASSOC, V300, P663, DOI 10.1001/jama.300.6.663; Jakupcak M, 2007, J TRAUMA STRESS, V20, P945, DOI 10.1002/jts.20258; Karney BR., 2008, INVISIBLE WOUNDS WAR, P119; Killgore WDS, 2008, J PSYCHIATR RES, V42, P1112, DOI 10.1016/j.jpsychires.2008.01.001; Kirby AC, 2008, ADDICT BEHAV, V33, P1448, DOI 10.1016/j.addbeh.2008.05.007; Knight JR, 2002, J STUD ALCOHOL, V63, P263, DOI 10.15288/jsa.2002.63.263; LeardMann CA, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b1273; Maze R, 2009, ARMY TIMES, P7; McNutt LA, 2003, AM J EPIDEMIOL, V157, P940, DOI 10.1093/aje/kwg074; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; Raudenbush S., 2002, HIERACHICAL LINEAR M; Rheingold AA, 2004, TRAUMA HLTH PHYS HLT, P217, DOI [DOI 10.1037/10723-009, 10.1037/0278-6133.22.6.638]; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Seal KH, 2009, AM J PUBLIC HEALTH, V99, P1651, DOI 10.2105/AJPH.2008.150284; Substance Abuse and Mental Health Services Administration, 2009, NSDUH SER H; Taft CT, 2007, J ABNORM PSYCHOL, V116, P498, DOI 10.1037/0021-843X.116.3.498; United States Army, 2009, 700 SCH PARTN VA HEL; Widome R, AM J HLTH P IN PRESS	24	34	34	0	17	PNG PUBLICATIONS	OAK RIDGE	2205-K OAK RIDGE RD, #115, OAK RIDGE, NC 27310 USA	1945-7359			AM J HEALTH BEHAV	Am. J. Health Behav.		2011	35	4					387	392		10.5993/AJHB.35.4.1			6	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	909MA	WOS:000301567400001	22040585				2021-06-18	
J	Chang, YJ; Wang, TY				Chang, Yao-Jen; Wang, Tsen-Yung			Comparing picture and video prompting in autonomous indoor wayfinding for individuals with cognitive impairments	PERSONAL AND UBIQUITOUS COMPUTING			English	Article						Cognitive impairments; Ubiquitous computing; User interface; Bluetooth	DAILY LIVING SKILLS; SYSTEMS; PEOPLE; TECHNOLOGY; ADULTS	A challenge to individuals with cognitive impairments in wayfinding is how to remain oriented, recall routines, and travel in unfamiliar areas in a way relying on limited cognitive capacity. According to psychological model of spatial navigation and the requirements of rehabilitation professionals, a novel wayfinding system is presented with an aim to increase workplace and life independence for people with traumatic brain injury, cerebral palsy, intellectual and developmental disabilities, schizophrenia, Down syndromes, and Alzheimer's disease. An architecture is proposed based on Bluetooth tags and scanning PDAs. A prototype is built and tested in field experiments with real patients. Two modalities, video and picture prompts, were compared by 20 subjects with cognitive impairments. The experimental results show the computer-human interface is friendly and the capabilities of wayfinding are reliable. Video prompts performed better by 25-28% than picture prompts at the price of users feeling slightly more rushed.	[Chang, Yao-Jen] Chung Yuan Christian Univ, Dept Elect Engn, Chungli 320, Taiwan; [Wang, Tsen-Yung] Natl Yang Ming Univ, Inst Hlth & Welf Policy, Taipei 112, Taiwan	Chang, YJ (corresponding author), Chung Yuan Christian Univ, Dept Elect Engn, Chungli 320, Taiwan.	yjchang@cycu.edu.tw; tywang@ym.edu.tw			National Science CouncilMinistry of Science and Technology, Taiwan [NSC 95-2627-E-008-002-, NSC 96-2627-E-008-001-, NSC 97-2627-E-008-001-]	The work presented in this paper has been funded by the National Science Council under grant numbers NSC 95-2627-E-008-002-, NSC 96-2627-E-008-001-, and NSC 97-2627-E-008-001-. Thanks for all the participating job coaches who have served the mentally impaired heartily and truthfully. Thanks for all the participating individuals with cognitive impairments, who have shown us deeper values of life. We thank the anonymous reviewers for their comments and suggestions which greatly improve the presentation of the paper. We also would like to extend our special thanks to a reviewer who suggests the idea of adaptive video framerate in the future work.	Allen GL, 1999, WAYFINDING BEHAVIOR, P46; BAUCHET J, 2005, P 3 INT C SMART HOM, P3; Baus J., 2001, COGNITIVE PROCESSING, V2, P323; Baus J, 2007, 2007 INTERNATIONAL CONFERENCE ON INTELLIGENT USER INTERFACES, P302; Bluetooth SIG, 2004, BLUET SPEC V2 0; Boger J, 2005, 19TH INTERNATIONAL JOINT CONFERENCE ON ARTIFICIAL INTELLIGENCE (IJCAI-05), P1293; BOHONOS S, 2007, P 1 ACM SIGMOBILE IN, P83; BOND GR, 1996, SUPPORTED EMPLOYMENT; BOND GR, 1992, VOCATIONAL REHABILIT; Cannella HI, 2005, RES DEV DISABIL, V26, P1, DOI 10.1016/j.ridd.2004.01.006; Cannella-Malone H, 2006, EDUC TRAIN DEV DISAB, V41, P344; Carmien S., 2005, ACM Transactions on Computer-Human Interaction, V12, P233, DOI 10.1145/1067860.1067865; Chan Y K, 2008, Progress In Electromagnetics Research B, V2, P27, DOI 10.2528/PIERB07110101; Chang YJ, 2008, 2008 3RD INTERNATIONAL SYMPOSIUM ON WIRELESS PERVASIVE COMPUTING, VOLS 1-2, P622; Chang YJ, 2009, IEEE WIREL COMMUN, V16, P34, DOI 10.1109/MWC.2009.5109462; Chang YJ, 2008, 2008 2ND INTERNATIONAL CONFERENCE ON PERVASIVE COMPUTING TECHNOLOGIES FOR HEALTHCARE, P101; Chang YJ, 2007, ASSETS'07: PROCEEDINGS OF THE NINTH INTERNATIONAL ACM SIGACCESS CONFERENCE ON COMPUTERS AND ACCESSIBILITY, P231; Cihak DF, 2008, EDUC TRAIN DEV DISAB, V43, P102; Cihak DF, 2007, RES DEV DISABIL, V28, P397, DOI 10.1016/j.ridd.2006.05.003; Cook A. M., 2008, ASSISTIVE TECHNOLOGY; Dijkstra E.W., 1959, NUMER MATH, V1, P269, DOI [DOI 10.1007/BF01386390, 10.1007/bf01386390]; Dutton GN, 2003, EYE, V17, P289, DOI 10.1038/sj.eye.6700344; FATIHA L, 2005, P 3 INT C SMART HOM, P245; GENTRY T, 2007, BRAIN INJURY     DEC, P19; Giroux S., 2005, P 3 INT C SMART HOM; Golledge R. G., 1999, WAYFINDING BEHAV COG; Goodman J, 2005, BEHAV INFORM TECHNOL, V24, P3, DOI 10.1080/01449290512331319021; Goodwin S, 1997, COMP MENTAL HLTH POL; Gu YY, 2009, IEEE COMMUN SURV TUT, V11, P13, DOI 10.1109/SURV.2009.090103; Hazas M, 2006, IEEE T MOBILE COMPUT, V5, P536, DOI 10.1109/TMC.2006.57; KRAY C, 2002, P SPAT COGN 2002 TUT; Liao L, 2007, ARTIF INTELL, V171, P311, DOI 10.1016/j.artint.2007.01.006; Liu AL, 2008, DISABIL REHABIL-ASSI, V3, P69, DOI 10.1080/17483100701500173; Liu H, 2007, IEEE T SYST MAN CY C, V37, P1067, DOI 10.1109/TSMCC.2007.905750; LIU L, 2006, P COMP ACC ASSETS 20, P95; LoPresti EF, 2004, NEUROPSYCHOL REHABIL, V14, P5, DOI 10.1080/09602010343000101; Ni LM, 2004, WIREL NETW, V10, P701, DOI 10.1023/B:WINE.0000044029.06344.dd; Nothegger C., 2004, SPAT COGN COMPUT, V4, P113, DOI [10.1207/s15427633scc0402_1, DOI 10.1207/S15427633SCC0402_1]; O'Connell ME, 2003, NEUROREHABILITATION, V18, P9; Passini R, 1996, DESIGN STUD, V17, P319, DOI DOI 10.1016/0142-694X(96)00001-4; Pigot H, 2003, ADV COMP BIOENG, V7, P507; Raubal M., 2001, COGNITIVE PROCESSING, V2, P363, DOI DOI 10.1007/S00779-008-0207-2; ROSS DA, 2005, P 28 RESNA C JUN; Sohlberg MM, 2007, BRAIN INJURY, V21, P531, DOI 10.1080/02699050701311000; Sohlberg MM, 2003, BRAIN INJURY, V17, P609, DOI 10.1080/0269905031000070189; Sutcliffe A, 2003, INTERACT COMPUT, V15, P577, DOI 10.1016/S0953-5438(03)00051-1; Van Laarhoven T, 2006, EDUC TRAIN DEV DISAB, V41, P365; WAHLSTER W, 2001, P INT WORKSH INF PRE, P5; WU M, 2005, P SIGCHI C HUM FACT, P511, DOI DOI 10.1145/1054972.1055043	49	34	34	1	15	SPRINGER LONDON LTD	LONDON	236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND	1617-4909	1617-4917		PERS UBIQUIT COMPUT	Pers. Ubiquitous Comput.	DEC	2010	14	8					737	747		10.1007/s00779-010-0285-9			11	Computer Science, Information Systems; Telecommunications	Computer Science; Telecommunications	679DL	WOS:000284139500007					2021-06-18	
J	Koch, H; Huh, SE; Elsen, FP; Carroll, MS; Hodge, RD; Bedogni, F; Turner, MS; Hevner, RF; Ramirez, JM				Koch, Henner; Huh, Sung-Eun; Elsen, Frank P.; Carroll, Michael S.; Hodge, Rebecca D.; Bedogni, Francesco; Turner, Michael S.; Hevner, Robert F.; Ramirez, Jan-Marino			Prostaglandin E2-Induced Synaptic Plasticity in Neocortical Networks of Organotypic Slice Cultures	JOURNAL OF NEUROSCIENCE			English	Article							DEPENDENT PROTEIN-KINASE; SLEEP-WAKE CYCLE; GLIAL TNF-ALPHA; IN-VIVO; CEREBRAL-CORTEX; HOMEOSTATIC PLASTICITY; NEURONAL APOPTOSIS; PYRAMIDAL NEURONS; CELL-DEATH; SEIZURES	Traumatic brain injury (TBI) is a major cause of epilepsy, yet the mechanisms underlying the progression from TBI to epilepsy are unknown. TBI induces the expression of COX-2 (cyclooxygenase-2) and increases levels of prostaglandin E2 (PGE2). Here, we demonstrate that acutely applied PGE2 (2 mu M) decreases neocortical network activity by postsynaptically reducing excitatory synaptic transmission in acute and organotypic neocortical slices of mice. In contrast, long-term exposure to PGE2 (2 mu M; 48 h) presynaptically increases excitatory synaptic transmission, leading to a hyperexcitable network state that is characterized by the generation of paroxysmal depolarization shifts (PDSs). PDSs were also evoked as a result of depriving organotypic slices of activity by treating them with tetrodotoxin (TTX, 1 mu M; 48 h). This treatment predominantly increased postsynaptically excitatory synaptic transmission. The network and cellular effects of PGE2 and TTX treatments reversed within 1 week. Differences in the underlying mechanisms (presynaptic vs postsynaptic) as well as occlusion experiments in which slices were exposed to TTX plus PGE2 suggest that the two substances evoke distinct forms of homeostatic plasticity, both of which result in a hyperexcitable network state. PGE2 and TTX (alone or together with PGE2) also increased levels of apoptotic cell death in organotypic slices. Thus, we hypothesize that the increase in excitability and apoptosis may constitute the first steps in a cascade of events that eventually lead to epileptogenesis triggered by TBI.	[Koch, Henner; Huh, Sung-Eun; Elsen, Frank P.; Carroll, Michael S.; Hodge, Rebecca D.; Bedogni, Francesco; Hevner, Robert F.; Ramirez, Jan-Marino] Seattle Childrens Res Inst, Ctr Integrat Brain Res, Seattle, WA 98101 USA; [Koch, Henner; Hodge, Rebecca D.; Hevner, Robert F.; Ramirez, Jan-Marino] Univ Washington, Sch Med, Dept Neurol Surg, Seattle, WA 98104 USA; [Turner, Michael S.] Univ Chicago, Neurosurg Sect, Chicago, IL 60637 USA	Koch, H (corresponding author), Seattle Childrens Res Inst, Ctr Integrat Brain Res, 1900 9th Ave, Seattle, WA 98101 USA.	henner.koch@seattlechildrens.org	Bedogni, Francesco/ABE-1509-2020	Bedogni, Francesco/0000-0002-4975-6605; Carroll, Michael/0000-0002-0526-7543; Ramirez, Jan-Marino/0000-0002-5626-3999; bedogni, francesco/0000-0002-6651-0041	Tarrson family; Falk Foundation	This work was supported in part by the Tarrson family and the Falk Foundation.	Ahmadi S, 2002, NAT NEUROSCI, V5, P34, DOI 10.1038/nn778; Aizenman CD, 2003, NEURON, V39, P831, DOI 10.1016/S0896-6273(03)00527-0; Akaneya Y, 2006, J NEUROSCI, V26, P10209, DOI 10.1523/JNEUROSCI.3028-06.2006; Annegers JF, 2000, SEIZURE-EUR J EPILEP, V9, P453, DOI 10.1053/seiz.2000.0458; ARMSTRONG CM, 1992, METHOD ENZYMOL, V207, P100; Avramescu S, 2008, J NEUROSCI, V28, P6760, DOI 10.1523/JNEUROSCI.0643-08.2008; Beattie EC, 2002, SCIENCE, V295, P2282, DOI 10.1126/science.1067859; Chandrasekaran AR, 2007, J NEUROSCI, V27, P1746, DOI 10.1523/JNEUROSCI.4383-06.2007; Chen C, 2005, J NEUROPHYSIOL, V93, P929, DOI 10.1152/jn.00696.2004; CONTRERAS D, 1995, J NEUROSCI, V15, P604; Davis GW, 2001, ANNU REV PHYSIOL, V63, P847, DOI 10.1146/annurev.physiol.63.1.847; Desai NS, 1999, NAT NEUROSCI, V2, P515; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; FERRER I, 1990, NEUROSCIENCE, V39, P451, DOI 10.1016/0306-4522(90)90281-8; Haider B, 2006, J NEUROSCI, V26, P4535, DOI 10.1523/JNEUROSCI.5297-05.2006; Heck N, 2008, CEREB CORTEX, V18, P1335, DOI 10.1093/cercor/bhm165; Hevner RF, 2001, NEURON, V29, P353, DOI 10.1016/S0896-6273(01)00211-2; Hodge RD, 2008, J NEUROSCI, V28, P3707, DOI 10.1523/JNEUROSCI.4280-07.2008; Hodge RD, 2007, INT J DEV NEUROSCI, V25, P233, DOI 10.1016/j.ijdevneu.2007.03.004; Houweling AR, 2005, CEREB CORTEX, V15, P834, DOI 10.1093/cercor/bhh184; Johnson HA, 2007, J NEUROSCI, V27, P5915, DOI 10.1523/JNEUROSCI.0447-07.2007; Kaufmann WE, 1996, P NATL ACAD SCI USA, V93, P2317, DOI 10.1073/pnas.93.6.2317; Kessels HW, 2009, NEURON, V61, P340, DOI 10.1016/j.neuron.2009.01.015; Liang FY, 1997, J NEUROSCI, V17, P2168; Maffei A, 2008, J NEUROSCI, V28, P4377, DOI 10.1523/JNEUROSCI.5298-07.2008; Maffei A, 2006, NATURE, V443, P81, DOI 10.1038/nature05079; Mahon S, 2006, J NEUROSCI, V26, P12587, DOI 10.1523/JNEUROSCI.3987-06.2006; MCGLADEMCCULLOH E, 1993, NATURE, V362, P640, DOI 10.1038/362640a0; Nelson SB, 2008, NEURON, V60, P477, DOI 10.1016/j.neuron.2008.10.020; Newpher TM, 2008, NEURON, V58, P472, DOI 10.1016/j.neuron.2008.04.030; Nita DA, 2006, J NEUROPHYSIOL, V95, P902, DOI 10.1152/jn.00742.2005; O'Brien RJ, 1998, NEURON, V21, P1067, DOI 10.1016/S0896-6273(00)80624-8; Okun M, 2010, J NEUROSCI, V30, P4440, DOI 10.1523/JNEUROSCI.5062-09.2010; PRINCE DA, 1993, J NEUROPHYSIOL, V69, P1276; Reig R, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000670; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Sanchez-Vives MV, 2000, NAT NEUROSCI, V3, P1027; Sang N, 2005, J NEUROSCI, V25, P9858, DOI 10.1523/JNEUROSCI.2392-05.2005; Stellwagen D, 2006, NATURE, V440, P1054, DOI 10.1038/nature04671; Steriade M, 2001, ARCH ITAL BIOL, V139, P37; Timofeev I, 2001, P NATL ACAD SCI USA, V98, P1924, DOI 10.1073/pnas.041430398; Topolnik L, 2003, EUR J NEUROSCI, V18, P486, DOI 10.1046/j.1460-9568.2003.02742.x; Trasande CA, 2007, J CLIN NEUROPHYSIOL, V24, P154, DOI 10.1097/WNP.0b013e318033787f; Turrigiano GG, 1998, NATURE, V391, P892, DOI 10.1038/36103; van Drongelen W, 2003, J NEUROPHYSIOL, V90, P1571, DOI 10.1152/jn.00392.2003; van Drongelen W, 2006, J NEUROPHYSIOL, V96, P2564, DOI 10.1152/jn.00446.2006; Verney C, 2000, DEV NEUROSCI-BASEL, V22, P125, DOI 10.1159/000017434; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Wierenga CJ, 2006, J NEUROPHYSIOL, V96, P2127, DOI 10.1152/jn.00107.2006; Williams PA, 2009, J NEUROSCI, V29, P2103, DOI 10.1523/JNEUROSCI.0980-08.2009; Wuarin JP, 2001, J NEUROPHYSIOL, V85, P1067; YAMAGATA K, 1993, NEURON, V11, P371, DOI 10.1016/0896-6273(93)90192-T; Yang HW, 2008, MOL CELL NEUROSCI, V37, P682, DOI 10.1016/j.mcn.2007.12.019	53	34	35	0	3	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	SEP 1	2010	30	35					11678	11687		10.1523/JNEUROSCI.4665-09.2010			10	Neurosciences	Neurosciences & Neurology	647GV	WOS:000281607300014	20810888	Green Published, Bronze			2021-06-18	
J	Rahme, R; Weil, AG; Sabbagh, M; Moumdjian, R; Bouthillier, A; Bojanowski, MW				Rahme, Ralph; Weil, Alexander G.; Sabbagh, Mike; Moumdjian, Robert; Bouthillier, Alain; Bojanowski, Michel W.			Decompressive Craniectomy Is Not an Independent Risk Factor for Communicating Hydrocephalus in Patients With Increased Intracranial Pressure	NEUROSURGERY			English	Article						Cerebrovascular accident; Cranioplasty; Decompressive craniectomy; Hemicraniectomy; Hydrocephalus; Intracranial pressure; Malignant middle cerebral artery territory infarction	ANEURYSMAL SUBARACHNOID HEMORRHAGE; TRAUMATIC BRAIN-INJURY; MIDDLE CEREBRAL-ARTERY; SINUS THROMBOSIS; HEMICRANIECTOMY; INFARCTION	BACKGROUND: It was recently suggested that communicating hydrocephalus is an almost universal finding after hemicraniectomy and that early cranioplasty may prevent the need for permanent cerebrospinal fluid diversion in these patients. OBJECTIVE: To conduct a study in an attempt to verify these findings. METHODS: The medical records of all patients who underwent decompressive craniectomy for medically refractory elevated intracranial pressure between 2001 and 2009 were retrospectively reviewed. Patients with subarachnoid hemorrhage, intraventricular hemorrhage, or head trauma were excluded. Hydrocephalus was classified as internal or external and as clinically significant or asymptomatic. RESULTS: The patient population consisted of 17 patients, 8 men and 9 women, with a median age of 44 years (range, 27-53 years). Etiologies included malignant middle cerebral artery territory infarction in 12 patients, hemorrhagic transformation of ischemic cerebrovascular accident in 2 patients, dural sinus thrombosis in 2 patients, and hemorrhagic cerebrovascular accident in 1 patient. The extent of craniectomy ranged from a large bone flap in 4 patients to a standard hemicraniectomy in 13 patients. Two patients died and 1 was lost to follow-up during the acute stage. The remaining 14 patients underwent cranioplasty after a median interval of 21 days (range, 3-42 days). In none of these patients did clinically significant hydrocephalus develop requiring cerebrospinal fluid diversion. Asymptomatic extra-axial cerebrospinal fluid collections developed in 2 patients that resolved spontaneously after cranioplasty. CONCLUSION: Our results suggest that, contrary to some beliefs, hydrocephalus does not frequently occur after decompressive craniectomy.	[Rahme, Ralph; Weil, Alexander G.; Sabbagh, Mike; Moumdjian, Robert; Bouthillier, Alain; Bojanowski, Michel W.] Univ Montreal, Div Neurosurg, Hop Notre Dame CHUM, Montreal, PQ H2L 4M1, Canada	Bojanowski, MW (corresponding author), Univ Montreal, Div Neurosurg, Hop Notre Dame CHUM, Montreal, PQ H2L 4M1, Canada.	michel.bojanowski.chum@ssss.gouv.qc.ca	Rahme, Ralph/I-6932-2019	Rahme, Ralph/0000-0003-1796-7296; Weil, Alexander/0000-0003-4162-6096			Coutinho JM, 2009, STROKE, V40, P2233, DOI 10.1161/STROKEAHA.108.543421; D'Ambrosio AL, 2005, NEUROSURGERY, V56, P12, DOI 10.1227/01.NEU.0000144820.38439.63; Gupta R, 2004, STROKE, V35, P539, DOI 10.1161/01.STR.0000109772.64650.18; Keller E, 2005, ACTA NEUROCHIR SUPPL, V94, P177; Morgalla MH, 2008, J NEUROSURG, V109, P685, DOI 10.3171/JNS/2008/109/10/0685; Olivecrona M, 2007, J NEUROTRAUM, V24, P927, DOI 10.1089/neu.2005.356E; Schirmer CM, 2007, STROKE, V38, P987, DOI 10.1161/01.STR.0000257962.58269.e2; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4; Waziri A, 2007, NEUROSURGERY, V61, P489, DOI 10.1227/01.NEU.0000290894.85072.37	9	34	38	0	2	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	SEP	2010	67	3					675	678		10.1227/01.NEU.0000383142.10103.0B			4	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	641TS	WOS:000281153200016	20651634				2021-06-18	
J	Hoh, NZ; Wagner, AK; Alexander, SA; Clark, RB; Beers, SR; Okonkwo, DO; Ren, DX; Conley, YP				Hoh, Nicole Zangrilli; Wagner, Amy K.; Alexander, Sheila A.; Clark, Robert B.; Beers, Sue R.; Okonkwo, David O.; Ren, Dianxu; Conley, Yvette P.			BCL2 Genotypes: Functional and Neurobehavioral Outcomes after Severe Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						apoptosis; BCL2; genotype; outcomes; traumatic brain injury	PROGRAMMED CELL-DEATH; SEVERE HEAD-INJURY; RATING-SCALE; APOPTOSIS; GENE; EXPRESSION; PROTOONCOGENE; INCREASES; PROMOTER; SURVIVAL	Traumatic brain injury (TBI) triggers a cascade of apoptotic-related events that include BCL2 expression, a pro-survival protein in the apoptosis pathway. The purpose of this study was to use tagging single nucleotide polymorphism (tSNP) genotypes to screen the BCL2 gene to determine if genetic variability in the BCL2 gene influences outcomes in 205 patients with severe TBI. Outcomes (Glasgow Outcome Scale [GOS], Disability Rating Scale [DRS], mortality, and Neurobehavioral Rating Scale-Revised [NRS-R]) were analyzed at 3, 6, 12, and 24 months. Multivariate analysis demonstrates that there were four tSNPs of significant interest: rs17759659, rs1801018, rs7236090, and rs949037. Presence of the variant allele for rs17759659 was associated with poorer outcomes (GOS p=0.001; DRS p=0.002), higher mortality (p=0.02; OR=4.23; CI 1.31,13.61), and worse NRS-R scores (p=0.05). Presence of the variant allele for rs1801018 was associated with poorer outcomes (GOS p=0.02; DRS p=0.009), and mortality (p=0.03; OR=3.86; CI 1.18,12.59). Being homozygous for the wild-type allele for rs7236090 was associated with favorable outcomes on the NRS-R (p=0.007), while homozygosity for the variant genotype was associated with favorable outcomes on the GOS (p=0.007) and DRS (p=0.006). The homozygous variant for rs949037 was associated with favorable outcomes (GOS p=0.04; DRS p=0.03), and the homozygous wild-type was associated with increased mortality at 3 months (p=0.005; OR=3.67; CI 1.08,12.49). The only finding that stood up to Bonferroni correction was rs17759659 for GOS. These data support the possibility that genetic variability for pro-survival proteins, particularly genetic variation in the BCL2 gene, impacts outcomes after severe TBI.	[Hoh, Nicole Zangrilli; Conley, Yvette P.] Univ Pittsburgh, Sch Nursing, Dept Hlth Promot & Dev, Pittsburgh, PA 15261 USA; [Alexander, Sheila A.] Acute & Tertiary Care, Pittsburgh, PA USA; [Ren, Dianxu] Hlth & Community Syst, Pittsburgh, PA USA; [Wagner, Amy K.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15261 USA; [Clark, Robert B.] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15261 USA; [Beers, Sue R.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15261 USA; [Okonkwo, David O.] Univ Pittsburgh, Dept Neurol Surg, Med Ctr, Pittsburgh, PA 15261 USA; [Conley, Yvette P.] Univ Pittsburgh, Dept Human Genet, Pittsburgh, PA 15261 USA	Hoh, NZ (corresponding author), Univ Pittsburgh, Sch Nursing, Dept Hlth Promot & Dev, 440 Victoria Bldg,3500 Victoria St, Pittsburgh, PA 15261 USA.	nmzst1@pitt.edu			University of Pittsburgh School of Nursing [T32 NR009759];  [R01NR04801];  [NR008424];  [5P50NS30318];  [R49/CCR 323155-03]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01NR008424, T32NR009759, R01NR004801] Funding Source: NIH RePORTER	This study utilized biological samples and data collected from federally-funded studies that examined genes and gene products in TBI patients, and how they related to outcomes attained by TBI patients (R01NR04801, NR008424, 5P50NS30318, and R49/CCR 323155-03). We thank the nurses of the neurotrauma intensive care unit for their assistance with sample collection and support of our work. Genotype data collection was supported by the Leslie A. Hoffman Endowed Research Award at the University of Pittsburgh School of Nursing, and the Sigma Theta Tau Eta Chapter at the University of Pittsburgh. Postdoctoral fellowship is funded by the University of Pittsburgh School of Nursing, Targeted Research and Academic Training Program for Nurses in Genomics (T32 NR009759).	Bahr M, 2000, TRENDS NEUROSCI, V23, P483, DOI 10.1016/S0166-2236(00)01637-4; BARRETT JC, 2005, BIOINFORMATICS  0115; Bredesen DE, 2000, J NEUROTRAUM, V17, P801, DOI 10.1089/neu.2000.17.801; Bredow S, 2007, GENE, V404, P110, DOI 10.1016/j.gene.2007.09.005; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Clark RSB, 1997, J NEUROSCI, V17, P9172; Clark RSB, 1999, FASEB J, V13, P813; Clark RSB, 2000, J PEDIATR-US, V137, P197, DOI 10.1067/mpd.2000.106903; Corrigan JD, 2004, J HEAD TRAUMA REHAB, V19, P205, DOI 10.1097/00001199-200405000-00002; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; Graham SH, 2000, J NEUROTRAUM, V17, P831, DOI 10.1089/neu.2000.17.831; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; JENNETT B, 1976, MED J AUSTRALIA, V2, P475, DOI 10.5694/j.1326-5377.1976.tb130352.x; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1976, P ROY SOC MED, V69, P140, DOI 10.1177/003591577606900229; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Kim DH, 2009, BLOOD, V113, P2517, DOI 10.1182/blood-2008-07-169110; Langlois JA, 2006, TRAUMATIC BRAIN INJU; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEZEK MD, 2004, NEUROPSYCHOLOGICAL A; Liao ZB, 2008, EUR J NEUROL, V15, P140, DOI 10.1111/j.1468-1331.2007.02013.x; Liu Zhan, 2006, Chin J Traumatol, V9, P168; MAH SP, 1993, J NEUROCHEM, V60, P1183, DOI 10.1111/j.1471-4159.1993.tb03275.x; McCauley SR, 2001, J NEUROL NEUROSUR PS, V71, P643, DOI 10.1136/jnnp.71.5.643; Minambres E, 2008, J NEUROTRAUM, V25, P581, DOI 10.1089/neu.2007.0398; MYERS KM, 1995, J NEUROCHEM, V65, P2432; Nakamura M, 1999, J COMP NEUROL, V412, P681, DOI 10.1002/(SICI)1096-9861(19991004)412:4<681::AID-CNE9>3.0.CO;2-F; NUNEZ G, 1990, J IMMUNOL, V144, P3602; Panizzon KL, 1998, NEUROREPORT, V9, P4131, DOI 10.1097/00001756-199812210-00024; POLVISHOCK JTE, 2004, J NEUROTRAUM, V24, pS1; POVLISHOCK EJT, 2000, J NEUROTRAUM, V17, P451; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Vlodavsky E, 2005, ACTA NEUROPATHOL, V110, P120, DOI 10.1007/s00401-004-0946-8; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yang Shu-Yuan, 2004, Chin J Traumatol, V7, P159; Yang Xiao-feng, 2006, Chin J Traumatol, V9, P276; YOUNG RL, 1993, MOL CELL BIOL, V13, P3686, DOI 10.1128/MCB.13.6.3686; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950	40	34	36	0	4	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	2010	27	8					1413	1427		10.1089/neu.2009.1256			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	639OU	WOS:000280984900006	20504155	Green Published			2021-06-18	
J	Ong, WY; Kim, JH; He, X; Chen, P; Farooqui, AA; Jenner, AM				Ong, Wei-Yi; Kim, Ji-Hyun; He, Xin; Chen, Peng; Farooqui, Akhlaq A.; Jenner, Andrew M.			Changes in Brain Cholesterol Metabolome After Excitotoxicity	MOLECULAR NEUROBIOLOGY			English	Article						Cholesterol; Oxysterols; Cholesterol oxidation products; Brain injury; Kainate; Excitotoxicity	INDUCED NEURONAL INJURY; LIVER-X-RECEPTOR; CENTRAL-NERVOUS-SYSTEM; CYTOPLASMIC PHOSPHOLIPASE A(2); APOLIPOPROTEIN-E; ALZHEIMERS-DISEASE; RAT HIPPOCAMPUS; STRESS RESISTANCE; KAINATE INJURY; GLIAL-CELLS	Excitotoxicity due to excess stimulation of glutamate receptors in neurons is accompanied by increased Ca2+ influx, stimulation of Ca2+-dependent enzymes, ATP depletion, increase in lipid peroxidation products, and loss of glutathione. These changes resemble neurochemical alterations in acute neuronal injury (stroke, spinal cord injury, and traumatic brain injury) and chronic neurodegenerative diseases such as Alzheimer's disease. Intracerebroventricular injection of the potent glutamate analog kainate in rats results in increased cholesterol concentration in the hippocampus at short to medium time intervals, i.e., 3 days-1 week post-injection, as detected by gas chromatography-mass spectrometry in the lesioned hippocampus. This is accompanied by an early increase in levels of cholesterol biosynthetic precursors and increases in both enzymatically derived oxysterols such as 24-hydroxycholesterol and cholesterol oxidation products (COPs) generated by reactive oxygen species, including cholesterol epoxides and 7-ketocholesterol. In contrast to COPs, no change in concentration of the neurosteroid pregnenolone was found after KA injury. Cholesterol and COPs significantly increase exocytosis in cultured PC12 cells and neurons, and both oxysterols and COPs are able to induce cytotoxic and apoptotic injuries in different cell types, including neurons. Together, the findings suggest that increased cholesterol and COPs after KA excitotoxicity could themselves lead to disturbed neuronal ion homeostasis, increased neurotransmitter release, and propagation of excitotoxicity.	[Ong, Wei-Yi; Kim, Ji-Hyun] Natl Univ Singapore, Dept Anat, Singapore 119260, Singapore; [Ong, Wei-Yi; Jenner, Andrew M.] Natl Univ Singapore, Aging Neurobiol Res Programme, Singapore 119260, Singapore; [He, Xin] Beijing Univ Chinese Med, Dept Anat, Beijing, Peoples R China; [Chen, Peng] Nanyang Technol Univ, Sch Chem & Biomed Engn, Singapore, Singapore; [Farooqui, Akhlaq A.] Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA; [Jenner, Andrew M.] Natl Univ Singapore, Dept Biochem, Singapore 119260, Singapore	Ong, WY (corresponding author), Natl Univ Singapore, Dept Anat, Singapore 119260, Singapore.	antongwy@nus.edu.sg; bchjam@nus.edu.sg	Chen, Peng/G-6202-2010; jenner, andrew M/H-4791-2016; chen, peng/G-6224-2014; Chen, Peng/D-3993-2009	Chen, Peng/0000-0003-3730-1846; jenner, andrew M/0000-0003-1767-2033; 	National Medical Research Council of SingaporeNational Medical Research Council, Singapore [NMRC/EDG/0012/2007, NMRC/EDG/0060/2009]	This work was supported by grants from the National Medical Research Council of Singapore (NMRC/EDG/0012/2007 and NMRC/EDG/0060/2009).	Abildayeva K, 2006, J BIOL CHEM, V281, P12799, DOI 10.1074/jbc.M601019200; Alexandrov P, 2005, NEUROREPORT, V16, P909, DOI 10.1097/00001756-200506210-00007; Berthier A, 2005, FEBS J, V272, P3093, DOI 10.1111/j.1742-4658.2005.04723.x; Biagini G, 2009, EPILEPSIA, V50, P53, DOI 10.1111/j.1528-1167.2008.01971.x; Bjorkhem I, 2006, ACTA NEUROL SCAND, V114, P43, DOI 10.1111/j.1600-0404.2006.00684.x; Bjorkhem I, 1998, J LIPID RES, V39, P1594; BOTOLOTTO ZA, 2003, PHILOS T R SOC B, V358, P657; Brown J, 2004, J BIOL CHEM, V279, P34674, DOI 10.1074/jbc.M402324200; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; Cartagena CM, 2008, J NEUROTRAUM, V25, P1087, DOI 10.1089/neu.2007.0444; Chang JY, 2009, BIOPHYS J, V96, P1839, DOI 10.1016/j.bpj.2008.11.033; Chang TY, 2006, ANNU REV CELL DEV BI, V22, P129, DOI 10.1146/annurev.cellbio.22.010305.104656; Chia WJ, 2008, EXP BRAIN RES, V186, P143, DOI 10.1007/s00221-007-1209-4; Cutler RG, 2004, P NATL ACAD SCI USA, V101, P2070, DOI 10.1073/pnas.0305799101; DeBose-Boyd RA, 2008, CELL RES, V18, P609, DOI 10.1038/cr.2008.61; Dietschy JM, 2004, J LIPID RES, V45, P1375, DOI 10.1194/jlr.R400004-JLR200; Eckert GP, 2007, NEUROSCI LETT, V423, P47, DOI 10.1016/j.neulet.2007.05.063; Farooqui A. A., 2008, NEUROCHEMICAL ASPECT; Farooqui AA, 2001, BRAIN RES REV, V38, P61, DOI 10.1016/S0169-328X(01)00214-5; Farooqui AA, 2007, GLYCEROPHOSPHOLIPIDS; Farooqui AA, 2007, J NEUROSCI RES, V85, P1834, DOI 10.1002/jnr.21268; Farooqui Akhlaq A, 2004, Curr Drug Targets Cardiovasc Haematol Disord, V4, P85, DOI 10.2174/1568006043481239; Fernandez A, 2009, J NEUROSCI, V29, P6394, DOI 10.1523/JNEUROSCI.4909-08.2009; Frank C, 2008, EXP NEUROL, V212, P407, DOI 10.1016/j.expneurol.2008.04.019; Fukumoto H, 2002, J BIOL CHEM, V277, P48508, DOI 10.1074/jbc.M209085200; Ganfornina MD, 2008, AGING CELL, V7, P506, DOI 10.1111/j.1474-9726.2008.00395.x; Gong JS, 2007, MOL NEURODEGENER, V2, DOI 10.1186/1750-1326-2-9; Gosselet F, 2009, BRAIN RES, V1249, P34, DOI 10.1016/j.brainres.2008.10.036; Guan XL, 2006, FASEB J, V20, P1152, DOI 10.1096/fj.05-5362com; Guirland C, 2007, ADV EXP MED BIOL, V621, P144, DOI 10.1007/978-0-387-76715-4_11; Han JH, 2007, BRAIN RES, V1137, P11, DOI 10.1016/j.brainres.2006.12.041; He X, 2007, J NEUROSCI RES, V85, P423, DOI 10.1002/jnr.21107; He X, 2006, J NEUROPATH EXP NEUR, V65, P652, DOI 10.1097/01.jnen.0000225906.82428.69; He X, 2009, NEUROSCI LETT, V455, P183, DOI 10.1016/j.neulet.2009.03.038; Heverin M, 2005, J LIPID RES, V46, P1047, DOI 10.1194/jlr.M500024-JLR200; Hirsch-Reinshagen V, 2009, J LIPID RES, V50, P885, DOI 10.1194/jlr.M800584-JLR200; Hu CY, 2000, J NEUROCYTOL, V29, P765, DOI 10.1023/A:1010942521671; Igbavboa U, 1997, J NEUROCHEM, V69, P1661; Infante RE, 2008, J BIOL CHEM, V283, P1064, DOI 10.1074/jbc.M707944200; Iuliano L, 2003, ANAL BIOCHEM, V312, P217, DOI 10.1016/S0003-2697(02)00467-0; Jenner A, 2007, FREE RADICAL BIO MED, V42, P559, DOI 10.1016/j.freeradbiomed.2006.11.024; JUREVICS H, 1995, J NEUROCHEM, V64, P895; Jurevics HA, 1997, J LIPID RES, V38, P723; Karasinska JM, 2009, J NEUROSCI, V29, P3579, DOI 10.1523/JNEUROSCI.4741-08.2009; Kim JH, 2010, J NEUROCHEM, V112, P34, DOI 10.1111/j.1471-4159.2009.06449.x; Kim JH, 2009, J CHEM NEUROANAT, V37, P71, DOI 10.1016/j.jchemneu.2008.12.004; Kohchi C, 1998, BRAIN RES, V801, P233, DOI 10.1016/S0006-8993(98)00585-X; Kojima M, 2004, TOXICOL LETT, V154, P35, DOI 10.1016/j.toxlet.2004.06.010; Korade Z, 2007, NEUROBIOL AGING, V28, P1522, DOI 10.1016/j.neurobiolaging.2006.06.026; Koyrakh L, 2005, J NEUROSCI, V25, P11468, DOI 10.1523/JNEUROSCI.3484-05.2005; Lee CYJ, 2008, FREE RADICAL BIO MED, V44, P1314, DOI 10.1016/j.freeradbiomed.2007.12.026; Lemaire-Ewing S, 2005, CELL BIOL TOXICOL, V21, P97, DOI 10.1007/s10565-005-0141-2; Leoni V, 2005, J LIPID RES, V46, P191, DOI 10.1194/jlr.C400005-JLR200; Levi O, 2005, J NEUROCHEM, V95, P987, DOI 10.1111/j.1471-4159.2005.03441.x; Liang Y, 2004, J NEUROCHEM, V88, P623, DOI 10.1111/j.1471-4159.2004.02183.x; Liou HL, 2006, J BIOL CHEM, V281, P36710, DOI 10.1074/jbc.M608743200; Lizard G, 2000, FREE RADICAL BIO MED, V28, P743, DOI 10.1016/S0891-5849(00)00163-5; Lu XR, 2001, FREE RADICAL BIO MED, V30, P1263, DOI 10.1016/S0891-5849(01)00528-7; Lund EG, 1999, P NATL ACAD SCI USA, V96, P7238, DOI 10.1073/pnas.96.13.7238; Luthra S, 2008, MICROVASC RES, V75, P343, DOI 10.1016/j.mvr.2007.10.003; Lutjohann D, 2002, J LIPID RES, V43, P1078, DOI 10.1194/jlr.M200071-JLR200; Lutjohann D, 1996, P NATL ACAD SCI USA, V93, P9799, DOI 10.1073/pnas.93.18.9799; MacDonald John F., 2006, Critical Reviews in Neurobiology, V18, P71; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Massey JB, 2006, CURR OPIN LIPIDOL, V17, P296, DOI 10.1097/01.mol.0000226123.17629.ab; Meaney S, 2007, J LIPID RES, V48, P944, DOI 10.1194/jlr.M600529-JLR200; Mishra S, 2007, J NEUROCHEM, V103, P135, DOI 10.1111/j.1471-4159.2007.04720.x; Miyamoto E, 2006, J PHARMACOL SCI, V100, P433, DOI 10.1254/jphs.CPJ06007X; Morello F, 2009, ATHEROSCLEROSIS, V207, P38, DOI 10.1016/j.atherosclerosis.2009.04.001; Muffat J, 2008, P NATL ACAD SCI USA, V105, P7088, DOI 10.1073/pnas.0800896105; Nieweg K, 2009, J NEUROCHEM, V109, P125, DOI 10.1111/j.1471-4159.2009.05917.x; Nohturfft A, 2000, CELL, V102, P315, DOI 10.1016/S0092-8674(00)00037-4; Ong WY, 1997, NEUROSCIENCE, V79, P359, DOI 10.1016/S0306-4522(96)00608-2; Ong WY, 2000, NEUROSCIENCE, V97, P143, DOI 10.1016/S0306-4522(00)00031-2; Ong WY, 2004, NEUROSCIENCE, V128, P561, DOI 10.1016/j.neuroscience.2004.07.001; Ong WY, 2003, BRAIN PATHOL, V13, P250; Ong WY, 2003, EXP BRAIN RES, V148, P521, DOI 10.1007/s00221-002-1315-2; Patel SC, 1999, P NATL ACAD SCI USA, V96, P1657, DOI 10.1073/pnas.96.4.1657; Pendse AA, 2009, J LIPID RES, V50, pS178, DOI 10.1194/jlr.R800070-JLR200; Perez-Otano I, 2004, NEUROSIGNALS, V13, P175, DOI 10.1159/000077524; Pfrieger FW, 2003, BIOESSAYS, V25, P72, DOI 10.1002/bies.10195; POIRIER J, 1993, LANCET, V342, P697, DOI 10.1016/0140-6736(93)91705-Q; Rassart E, 2000, BBA-PROTEIN STRUCT M, V1482, P185, DOI 10.1016/S0167-4838(00)00162-X; Recuero M, 2009, AGING CELL, V8, P128, DOI 10.1111/j.1474-9726.2009.00457.x; Reid CA, 2000, TRENDS PHARMACOL SCI, V21, P159, DOI 10.1016/S0165-6147(00)01479-6; Rickhag M, 2008, J CEREBR BLOOD F MET, V28, P551, DOI 10.1038/sj.jcbfm.9600552; Riddell DR, 2008, J NEUROSCI, V28, P11445, DOI 10.1523/JNEUROSCI.1972-08.2008; Rise P, 2004, PROSTAG LEUKOTR ESS, V71, P79, DOI 10.1016/j.plefa.2003.12.005; Russell DW, 2009, ANNU REV BIOCHEM, V78, P1017, DOI 10.1146/annurev.biochem.78.072407.103859; Ryan L, 2006, INT J TOXICOL, V25, P35, DOI 10.1080/10915810500488387; Ryan L, 2004, CELL BIOL TOXICOL, V20, P313, DOI 10.1007/s10565-004-5066-7; SAITO M, 1987, J NEUROSCI RES, V18, P319, DOI 10.1002/jnr.490180208; Sanchez D, 2006, CURR BIOL, V16, P680, DOI 10.1016/j.cub.2006.03.024; Sandhya TL, 1998, BRAIN RES, V788, P223, DOI 10.1016/S0006-8993(97)01552-7; Simons K, 2000, SCIENCE, V290, P1721, DOI 10.1126/science.290.5497.1721; Stefani M, 2009, CURR ALZHEIMER RES, V6, P15, DOI 10.2174/156720509787313899; Strittmatter WJ, 1996, ANNU REV NEUROSCI, V19, P53, DOI 10.1146/annurev.ne.19.030196.000413; Suzuki S, 2007, J NEUROSCI, V27, P6417, DOI 10.1523/JNEUROSCI.0690-07.2007; TANG Y, 2010, CLIN EXP PH IN PRESS; Tarr PT, 2008, J LIPID RES, V49, P169, DOI 10.1194/jlr.M700364-JLR200; Thelen KM, 2006, NEUROSCI LETT, V403, P15, DOI 10.1016/j.neulet.2006.04.034; Thwin MM, 2003, EXP BRAIN RES, V150, P427, DOI 10.1007/s00221-003-1476-7; Trousson A, 2009, J NEUROCHEM, V109, P945, DOI 10.1111/j.1471-4159.2009.06009.x; Vaya J, 2007, J NEUROCHEM, V102, P1727, DOI 10.1111/j.1471-4159.2007.04689.x; Walker DW, 2006, CURR BIOL, V16, P674, DOI 10.1016/j.cub.2006.01.057; Walkley SU, 2004, BBA-MOL CELL BIOL L, V1685, P48, DOI 10.1016/j.bbalip.2004.08.011; Wang H, 2002, MOL CELL BIOL, V22, P8478, DOI 10.1128/MCB.22.24.8478-8490.2002; Wang Q, 2005, MOL NEUROBIOL, V31, P3, DOI 10.1385/MN:31:1-3:003; Wang YQ, 2008, J PROTEOME RES, V7, P1606, DOI 10.1021/pr7006076; Yu ZF, 2002, NEUROBIOL DIS, V11, P199, DOI 10.1006/nbdi.2002.0530; Zhang J, 1997, BIOCHEM J, V322, P175, DOI 10.1042/bj3220175; Zhang J, 2009, BIOPHYS J, V97, P1371, DOI 10.1016/j.bpj.2009.06.025	113	34	35	1	12	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	JUN	2010	41	2-3			SI		299	313		10.1007/s12035-010-8099-3			15	Neurosciences	Neurosciences & Neurology	601WI	WOS:000278095800025	20140539				2021-06-18	
J	Yang, FG; Fuller, J; Khodaparast, N; Krawczyk, DC				Yang, Fanpei Gloria; Fuller, Jerome; Khodaparast, Navid; Krawczyk, Daniel C.			Figurative language processing after traumatic brain injury in adults: A preliminary study	NEUROPSYCHOLOGIA			English	Article						Semantic; Memory; Control; Prefrontal cortex; Left inferior frontal gyrus; Abstraction; Traumatic brain injury; Metaphor; Figurative; Language; fMRI	PREFRONTAL CORTEX; METAPHOR; REGIONS; METAANALYSIS; ACTIVATION; KNOWLEDGE; FMRI	Figurative speech (e.g., proverb, irony, metaphor, and idiom) has been reported to be particularly sensitive to measurement of abstract thinking in patients who suffer from impaired abstraction and language abilities. Metaphor processing was investigated with fMRI in adults with moderate to severe post-acute traumatic brain injury (TBI) and healthy age-matched controls using a valence-judgment task. We hypothesized that TBI patients would display decreased activation of the left inferior frontal gyrus (LIFG), which is considered central to semantic memory retrieval and abstract thought, in comparison with healthy controls. We also predicted that decreased activation in TBI individuals would correlate with their behavioral response times. A whole-brain analysis across the two participant groups revealed that patients did not strongly engage frontal and temporal regions related to semantic processing for novel metaphor comprehension, whereas control participants exhibited more intensive and concentrated activation within frontal and temporal areas. A region of interest (ROI) analysis verified that the LIFG was underactivated in TBI patients compared to controls across all conditions. TBI patients' impaired abstraction of novel stimuli may stem from reduced prefrontal control of semantic memory as well as disrupted interconnectivity of prefrontal cortex with other regions. (C) 2010 Elsevier Ltd. All rights reserved.	[Yang, Fanpei Gloria] Univ Texas Dallas, Sch Brain & Behav Sci, Ctr Brain Hlth, Dallas, TX 75230 USA; [Krawczyk, Daniel C.] Univ Texas SW Med Ctr Dallas, Dept Psychiat, Dallas, TX USA; [Yang, Fanpei Gloria] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA	Yang, FG (corresponding author), Univ Texas Dallas, Sch Brain & Behav Sci, Ctr Brain Hlth, 2200 Mockingbird, Dallas, TX 75230 USA.	fbyang@gmail.com					Badre D, 2007, NEUROPSYCHOLOGIA, V45, P2883, DOI 10.1016/j.neuropsychologia.2007.06.015; Bedny M, 2008, CEREB CORTEX, V18, P2574, DOI 10.1093/cercor/bhn018; Binder JR, 2009, CEREB CORTEX, V19, P2767, DOI 10.1093/cercor/bhp055; BLUE CM, 1981, LANG SPEECH HEAR SER, V12, P120; Chee MWL, 1999, HUM BRAIN MAPP, V7, P15, DOI 10.1002/(SICI)1097-0193(1999)7:1<15::AID-HBM2>3.0.CO;2-6; Costafreda S, 2003, SCHIZOPHR RES, V60, P215, DOI 10.1016/S0920-9964(03)81173-8; De Carli D, 2007, MAGN RESON IMAGING, V25, P933, DOI 10.1016/j.mri.2007.03.031; Dikmen S, 2001, J NEUROTRAUM, V18, P127, DOI 10.1089/08977150150502578; Donahue M, 1984, TOP LANG DISORD, V4, P10; Duncan J, 2000, TRENDS NEUROSCI, V23, P475, DOI 10.1016/S0166-2236(00)01633-7; ELMORE CM, 1957, J CLIN PSYCHOL, V13, P263, DOI 10.1002/1097-4679(195707)13:3<263::AID-JCLP2270130308>3.0.CO;2-C; FIEZ JA, 1992, BRAIN, V115, P155, DOI 10.1093/brain/115.1.155; Giora R, 1997, COGN LINGUIST, V8, P183, DOI 10.1515/cogl.1997.8.3.183; Giora R, 2007, BRAIN LANG, V100, P111, DOI 10.1016/j.bandl.2006.08.001; GROHER M, 1983, REHABILITATION HEAD; HAGEN C, 1984, LANGUAGE DISORDERS A; HEILMAN KM, 1971, J NEUROL NEUROSUR PS, V34, P265, DOI 10.1136/jnnp.34.3.265; Holland A., 1982, CLIN APH P C, P345; Kasher, 2000, METAPHOR SYMBOL, V15, P63, DOI [DOI 10.1080/10926488.2000.9678865, 10.1080/10926488.2000.9678865]; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; Mashal N, 2007, BRAIN LANG, V100, P115, DOI 10.1016/j.bandl.2005.10.005; Mashal N, 2009, LATERALITY, V14, P30, DOI 10.1080/13576500802049433; McDermott KB, 2003, NEUROPSYCHOLOGIA, V41, P293, DOI 10.1016/S0028-3932(02)00162-8; NEARY D, 1988, J NEUROL NEUROSUR PS, V51, P353, DOI 10.1136/jnnp.51.3.353; Newsome MR, 2008, NEUROPSYCHOLOGY, V22, P419, DOI 10.1037/0894-4105.22.4.419; PAULESU E, 1993, NATURE, V362, P342, DOI 10.1038/362342a0; Pobric G, 2008, J COGNITIVE NEUROSCI, V20, P170, DOI 10.1162/jocn.2008.20005; Rapp AM, 2004, COGNITIVE BRAIN RES, V20, P395, DOI 10.1016/j.cogbrainres.2004.03.017; Stringaris AK, 2007, BRAIN LANG, V100, P150, DOI 10.1016/j.bandl.2005.08.001; Stringaris AK, 2006, NEUROIMAGE, V33, P784, DOI 10.1016/j.neuroimage.2006.06.057; Thompson-Schill SL, 1999, J EXP PSYCHOL LEARN, V25, P41, DOI 10.1037/0278-7393.25.1.41; Thompson-Schill SL, 1997, P NATL ACAD SCI USA, V94, P14792, DOI 10.1073/pnas.94.26.14792; TOWNE RL, 1993, LANG SPEECH HEAR SER, V24, P100; Wagner AD, 2001, NEURON, V31, P329, DOI 10.1016/S0896-6273(01)00359-2; WIG E, 1984, LANGUAGE ASSESSMENT; Wigg E. H., 1988, NEUROPSYCHOLOGICAL S; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; WINNER E, 1980, J EXP CHILD PSYCHOL, V30, P22, DOI 10.1016/0022-0965(80)90072-7; WINNER E, 1977, BRAIN, V100, P717, DOI 10.1093/brain/100.4.717; Yang FG, 2009, BRAIN LANG, V111, P114, DOI 10.1016/j.bandl.2009.08.006	40	34	36	1	32	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia	JUN	2010	48	7					1923	1929		10.1016/j.neuropsychologia.2010.03.011			7	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	613ZD	WOS:000279023100006	20230844				2021-06-18	
J	Yang, JS; You, ZR; Kim, HH; Hwang, SK; Khuman, J; Guo, SZ; Lo, EH; Whalen, MJ				Yang, Jinsheng; You, Zerong; Kim, Hyung-Hwan; Hwang, Seo-Kyoung; Khuman, Jugta; Guo, Shuzhen; Lo, Eng H.; Whalen, Michael J.			Genetic Analysis of the Role of Tumor Necrosis Factor Receptors in Functional Outcome after Traumatic Brain Injury in Mice	JOURNAL OF NEUROTRAUMA			English	Article						controlled cortical impact; gene knockout; inflammation; mice; tumor necrosis factor; traumatic brain injury	NF-KAPPA-B; CONTROLLED CORTICAL IMPACT; NONAPOPTOTIC CELL-DEATH; LACKING TNF RECEPTORS; FACTOR-ALPHA; ACTIVATION; EXPRESSION; DAMAGE; INHIBITOR; PATHWAY	We previously reported that tumor necrosis factor-alpha (TNF-alpha) and Fas receptor induce acute cellular injury, tissue damage, and motor and cognitive deficits after controlled cortical impact (CCI) in mice (Bermpohl et al. 2007); however, the TNF receptors (TNFR) involved are unknown. Using a CCI model and novel mutant mice deficient in TNFR1/Fas, TNFR2/Fas, or TNFR1/TNFR2/Fas, we tested the hypothesis that the combination of TNFR2/Fas is protective, whereas TNFR1/Fas is detrimental after CCI. Uninjured knockout (KO) mice showed no differences in baseline physiological variables or motor or cognitive function. Following CCI, mice deficient in TNFR2/Fas had worse post-injury motor and Morris water maze (MWM) performance than wild-type (WT) mice (p < 0.05 group effect for wire grip score and MWM performance by repeated measures ANOVA). No differences in motor or cognitive outcome were observed in TNFR1/Fas KO, or in TNFR2 or TNFR1 single KO mice, versus WT mice. Additionally, no differences in propidium iodide (PI)-positive cells (at 6 h) or lesion size (at 14 days) were observed between WT and TNFR1/Fas or TNFR2/Fas KO mice. Somewhat surprisingly, mice deficient in TNFR1/TNFR2/Fas also had PI-positive cells, lesion size, and motor and MWM deficits similar to those of WT mice. These data suggest a protective role for TNFR2/Fas in the pathogenesis of TBI. Further studies are needed to determine whether direct or indirect effects of TNFR1 deletion in TNFR2/Fas KO mice mediate improved functional outcome in TNFR1/TNFR2/Fas KO mice after CCI.	[Yang, Jinsheng; You, Zerong; Khuman, Jugta; Whalen, Michael J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pediat, Charlestown, MA 02129 USA; [Khuman, Jugta; Whalen, Michael J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Neurosci, Charlestown, MA 02129 USA; [Guo, Shuzhen; Lo, Eng H.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA 02129 USA; [Guo, Shuzhen; Lo, Eng H.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol, Charlestown, MA 02129 USA; [Kim, Hyung-Hwan; Hwang, Seo-Kyoung] Brigham & Womens Hosp, Vasc Med Res Unit, Boston, MA 02115 USA	Whalen, MJ (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pediat, Charlestown, MA 02129 USA.	mwhalen@partners.org			NIH/National Institute of Neurological Diseases and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [RO1NS47447]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS047447] Funding Source: NIH RePORTER	This work was supported by NIH/National Institute of Neurological Diseases and Stroke grant RO1NS47447 to M.J.W.	Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bermpohl D, 2007, J CEREBR BLOOD F MET, V27, P1806, DOI 10.1038/sj.jcbfm.9600487; Bermpohl D, 2006, J CEREBR BLOOD F MET, V26, P625, DOI 10.1038/sj.jcbfm.9600258; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; Bruce-Keller AJ, 1999, J NEUROIMMUNOL, V93, P53, DOI 10.1016/S0165-5728(98)00190-8; Carpentier I, 2004, CURR MED CHEM, V11, P2205, DOI 10.2174/0929867043364694; CHENG B, 1994, NEURON, V12, P139, DOI 10.1016/0896-6273(94)90159-7; Cho Y, 2009, CELL, V137, P1112, DOI 10.1016/j.cell.2009.05.037; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Costelli P, 2003, CELL DEATH DIFFER, V10, P997, DOI 10.1038/sj.cdd.4401281; Declercq W, 2009, CELL, V138, P229, DOI 10.1016/j.cell.2009.07.006; Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711; Degterev A, 2008, NAT CHEM BIOL, V4, P313, DOI 10.1038/nchembio.83; Dopp JM, 1997, J NEUROIMMUNOL, V75, P104, DOI 10.1016/S0165-5728(97)00009-X; Fotin-Mleczek M, 2002, J CELL SCI, V115, P2757; Gary DS, 1998, J CEREBR BLOOD F MET, V18, P1283, DOI 10.1097/00004647-199812000-00001; Gerlai R, 2001, BEHAV BRAIN RES, V125, P269, DOI 10.1016/S0166-4328(01)00296-0; Hailer NP, 2008, PROG NEUROBIOL, V84, P211, DOI 10.1016/j.pneurobio.2007.12.001; Kim GM, 2001, J NEUROSCI, V21, P6617; Lin Y, 2004, J BIOL CHEM, V279, P10822, DOI 10.1074/jbc.M313141200; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Longhi L, 2008, ACTA NEUROCHIR SUPPL, V102, P409, DOI 10.1007/978-3-211-85578-2_80; Lotocki G, 2004, J NEUROSCI, V24, P11010, DOI 10.1523/JNEUROSCI.3823-04.2004; Lotocki G, 2006, EUR J NEUROSCI, V24, P2283, DOI 10.1111/j.1460-9568.2006.05123.x; Marchetti L, 2004, J BIOL CHEM, V279, P32869, DOI 10.1074/jbc.M311766200; Martin-Villalba A, 2001, CELL DEATH DIFFER, V8, P679, DOI 10.1038/sj.cdd.4400882; Mccoy MK, 2006, J NEUROSCI, V26, P9365, DOI 10.1523/JNEUROSCI.1504-06.2006; Mccoy MK, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-45; Ortolano F, 2009, J NEUROPATH EXP NEUR, V68, P964, DOI 10.1097/NEN.0b013e3181b20670; Pejovic V, 2004, PROTEOMICS, V4, P1461, DOI 10.1002/pmic.200300687; Raivich G, 2002, EXP NEUROL, V178, P186, DOI 10.1006/exnr.2002.8024; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Tezel G, 2004, BRAIN RES, V996, P202, DOI 10.1016/j.brainres.2003.10.029; Thompson C, 2004, MOL BRAIN RES, V123, P126, DOI 10.1016/j.molbrainres.2004.01.009; Whalen MJ, 2008, J CEREBR BLOOD F MET, V28, P490, DOI 10.1038/sj.jcbfm.9600544; Yager PH, 2008, J CEREBR BLOOD F MET, V28, P1030, DOI 10.1038/sj.jcbfm.9600605; You ZR, 2008, J CEREBR BLOOD F MET, V28, P1564, DOI 10.1038/jcbfm.2008.44	39	34	34	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2010	27	6					1037	1046		10.1089/neu.2009.1229			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	612VO	WOS:000278933300007	20205514	Green Published			2021-06-18	
J	Brustovetsky, T; Bolshakov, A; Brustovetsky, N				Brustovetsky, Tatiana; Bolshakov, Alexey; Brustovetsky, Nickolay			Calpain Activation and Na+/Ca2+ Exchanger Degradation Occur Downstream of Calcium Deregulation in Hippocampal Neurons Exposed to Excitotoxic Glutamate	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						neuron; glutamate; calcium; excitotoxicity; calpain; calpeptin	CEREBELLAR GRANULE CELLS; PERMEANT CA2+ CHELATORS; NA+-CA2+ EXCHANGER; I ACTIVATION; 3-NITROPROPIONIC ACID; NMDA EXCITOTOXICITY; CEREBRAL-ISCHEMIA; RECEPTOR CHANNELS; CORTICAL-NEURONS; RAT	Delayed calcium deregulation (DOD) plays an essential role in glutamate excitotoxicity, a major detrimental factor in stroke, traumatic brain injury, and various neurodegenerations. In the present study, we examined the role of calpain activation and Na+/Ca2+ exchanger (NCX) degradation in DOD and excitotoxic cell death in cultured hippocampal neurons. Exposure of neurons to glutamate caused DOD accompanied by secondary mitochondrial depolarization. Activation of calpain was evidenced by detecting NCX isoform 3 (NCX3) degradation products. Degradation of NCX isoform 1 (NCX1) was below the detection limit of Western blotting. Degradation of NCX3 was detected only after 1 hr of incubation with glutamate, whereas DOD occurred on average within 15 min after glutamate application. Calpeptin, an inhibitor of calpain, significantly attenuated NCX3 degradation but failed to inhibit DOD and excitotoxic neuronal death. Calpain inhibitors I, III, and VI also failed to influence DOD and glutamate-induced neuronal death. On the other hand, MK801, an inhibitor of the NMDA subtype of glutamate receptors, added shortly after the initial glutamate-induced jump in cytosolic Ca2+, completely prevented DOD and activation of calpain and strongly protected neurons against excitotoxicity. Taken together, our results suggest that, in glutamate-treated hippocampal neurons, the initial increase in cytosolic Ca2+ that precedes DOD is insufficient for sustained calpain activation, which most likely occurs downstream of DOD. (C) 2009 Wiley-Liss, Inc.	[Brustovetsky, Tatiana; Bolshakov, Alexey; Brustovetsky, Nickolay] Indiana Univ Sch Med, Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA; [Brustovetsky, Nickolay] Indiana Univ Sch Med, Stark Neurosci Res Inst, Indianapolis, IN 46202 USA	Brustovetsky, N (corresponding author), Indiana Univ Sch Med, Dept Pharmacol & Toxicol, 633 Barnhill Dr,Med Sci Bldg 547, Indianapolis, IN 46202 USA.	nbrous@iupui.edu	Bolshakov, Alexey P/K-4173-2013		NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS 050131]; Indiana Spinal Cord and Brain Injury Research Fund; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS050131] Funding Source: NIH RePORTER	Contract grant sponsor: NIH/NINDS: Contract grant number: R01 NS 050131: Contract grant sponsor: Indiana Spinal Cord and Brain Injury Research Fund (to NIB.).	Adamec E, 1998, MOL BRAIN RES, V54, P35, DOI 10.1016/S0169-328X(97)00304-5; Araujo IM, 2007, CELL DEATH DIFFER, V14, P1635, DOI 10.1038/sj.cdd.4402171; Bano D, 2005, CELL, V120, P275, DOI 10.1016/j.cell.2004.11.049; BARTUS RT, 1995, NEUROL RES, V17, P249, DOI 10.1080/01616412.1995.11740322; Bevers MB, 2009, J NEUROCHEM, V108, P1237, DOI 10.1111/j.1471-4159.2008.05860.x; Blaustein MP, 1999, PHYSIOL REV, V79, P763; Brustovetsky T, 2004, EXP NEUROL, V189, P222, DOI 10.1016/j.expneurol.2004.03.021; Budd SL, 1996, J NEUROCHEM, V67, P2282; Carafoli E, 2001, CRIT REV BIOCHEM MOL, V36, P107, DOI 10.1080/20014091074183; Dineley KE, 2002, MOL PHARMACOL, V62, P618, DOI 10.1124/mol.62.3.618; DUBINSKY JM, 1995, J NEUROSCI, V15, P7071; DUBINSKY JM, 1993, J NEUROSCI, V13, P623; DUBINSKY JM, 1991, J NEUROSCI, V11, P2545; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Farooqui AA, 1997, J NEUROCHEM, V69, P889; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; KIEDROWSKI L, 1994, NEURON, V12, P295, DOI 10.1016/0896-6273(94)90272-0; Kiedrowski L, 2004, J NEUROCHEM, V90, P117, DOI 10.1111/j.1471-4159.2004.02462.x; Kushnareva YE, 2005, J BIOL CHEM, V280, P28894, DOI 10.1074/jbc.M503090200; Lankiewicz S, 2000, J BIOL CHEM, V275, P17064, DOI 10.1074/jbc.275.22.17064; Li V, 2009, EXP NEUROL, V218, P171, DOI 10.1016/j.expneurol.2009.02.007; LI ZP, 1994, J BIOL CHEM, V269, P17434; MANEV H, 1991, J NEUROCHEM, V57, P1288, DOI 10.1111/j.1471-4159.1991.tb08292.x; MANEV H, 1989, MOL PHARMACOL, V36, P106; MAYER ML, 1987, J PHYSIOL-LONDON, V394, P501, DOI 10.1113/jphysiol.1987.sp016883; Minelli A, 2007, CELL CALCIUM, V41, P221, DOI 10.1016/j.ceca.2006.06.004; Minger SL, 1998, BRAIN RES, V810, P181, DOI 10.1016/S0006-8993(98)00921-4; Moroni F, 2008, CURR OPIN PHARMACOL, V8, P96, DOI 10.1016/j.coph.2007.10.005; Nasr P, 2003, NEUROCHEM INT, V43, P89, DOI 10.1016/S0197-0186(02)00229-2; Nicholls DG, 2004, CURR MOL MED, V4, P149, DOI 10.2174/1566524043479239; Nicholls DG, 2000, PHYSIOL REV, V80, P315; Nicholls DG, 1998, BBA-BIOENERGETICS, V1366, P97, DOI 10.1016/S0005-2728(98)00123-6; Nicoll DA, 1996, J BIOL CHEM, V271, P24914, DOI 10.1074/jbc.271.40.24914; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; Pang Z, 2003, J NEUROPATH EXP NEUR, V62, P633, DOI 10.1093/jnen/62.6.633; PARTIN KM, 1993, NEURON, V11, P1069, DOI 10.1016/0896-6273(93)90220-L; Pottorf WJ, 2006, J NEUROCHEM, V98, P1646, DOI 10.1111/j.1471-4159.2006.04063.x; Sakaue M, 2000, BRAIN RES, V881, P212, DOI 10.1016/S0006-8993(00)02808-0; Secondo A, 2007, ANN NY ACAD SCI, V1099, P481, DOI 10.1196/annals.1387.052; Secondo A, 2007, CELL CALCIUM, V42, P521, DOI 10.1016/j.ceca.2007.01.006; SIMAN R, 1989, J NEUROSCI, V9, P1579; Sorimachi H, 2001, J BIOCHEM-TOKYO, V129, P653, DOI 10.1093/oxfordjournals.jbchem.a002903; Springer JE, 1997, J NEUROCHEM, V69, P1592, DOI 10.1046/j.1471-4159.1997.69041592.x; THAYER SA, 1990, J PHYSIOL-LONDON, V425, P85, DOI 10.1113/jphysiol.1990.sp018094; Thurneysen T, 2002, ANN NY ACAD SCI, V976, P367; Thurneysen T, 2002, MOL BRAIN RES, V107, P145, DOI 10.1016/S0169-328X(02)00461-8; TSUZUKI K, 1994, MOL BRAIN RES, V26, P37, DOI 10.1016/0169-328X(94)90071-X; TYMIANSKI M, 1993, BRAIN RES, V607, P319, DOI 10.1016/0006-8993(93)91523-U; TYMIANSKI M, 1994, J NEUROPHYSIOL, V72, P1973; TYMIANSKI M, 1993, NEURON, V11, P221, DOI 10.1016/0896-6273(93)90180-Y; TYMIANSKI M, 1993, J NEUROSCI, V13, P2085; Vanderklish PW, 2000, P NATL ACAD SCI USA, V97, P2253, DOI 10.1073/pnas.040565597; Vergun O, 2003, EXP NEUROL, V183, P682, DOI 10.1016/S0014-4886(03)00243-7; Wang GJ, 1996, J NEUROPHYSIOL, V76, P1611; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; White RJ, 1996, J NEUROSCI, V16, P5688; Wu HY, 2005, J BIOL CHEM, V280, P21588, DOI 10.1074/jbc.M501603200; Xu W, 2007, NEURON, V53, P399, DOI 10.1016/j.neuron.2006.12.020; YAMAGUCHI K, 1990, J PHYSIOL-LONDON, V420, P185, DOI 10.1113/jphysiol.1990.sp017907; Yuen EY, 2007, J PHYSIOL-LONDON, V580, P241, DOI 10.1113/jphysiol.2006.122754	61	34	36	0	6	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0360-4012			J NEUROSCI RES	J. Neurosci. Res.	MAY 1	2010	88	6					1317	1328		10.1002/jnr.22295			12	Neurosciences	Neurosciences & Neurology	575ZK	WOS:000276112600016	19937813	Green Accepted			2021-06-18	
J	Xue, S; Zhang, HT; Zhang, P; Luo, J; Chen, ZZ; Jang, XD; Xu, RX				Xue, Sha; Zhang, Hong-tian; Zhang, Peng; Luo, Jie; Chen, Zhen-zhou; Jang, Xiao-dan; Xu, Ru-xiang			Functional endothelial progenitor cells derived from adipose tissue show beneficial effect on cell therapy of traumatic brain injury	NEUROSCIENCE LETTERS			English	Article						Adipose tissue; Endothelial progenitor cells; Traumatic brain injury	MESENCHYMAL STEM-CELLS; UMBILICAL-CORD BLOOD; HUMAN BONE-MARROW; CEREBRAL-ISCHEMIA; TRANSPLANTATION; RAT; NEOVASCULARIZATION; EXPRESSION; MICE	Endothelial progenitor cells (EPCs) are responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Adipose tissue (AT) is an abundant source of mesenchymal stem cells (MSCs), which have multipotent differentiation ability. We successfully derived EPCs from AT, which maintained a strong proliferative capacity and demonstrated the characteristic endothelial function of uptaking of acetylated low-density lipoprotein. They formed tube-like structures in vitro. Endothelial nitric oxide synthase (eNOS) gene expression in EPCs was similar to that in mature endothelial cells. Transplantation of EPCs derived from AT after the acute phase was applied in rats with traumatic brain injury (TBI). Transplanted EPCs participated in the neovascularization of injured brain. Improving functional recovery, reducement of deficiency volume of brain, host astrogliosis and inflammation were found. These results suggest that adult AT derived stem cells can be induced to functional EPCs and have beneficial effect on cell therapy. (C) 2010 Elsevier Ireland Ltd. All rights reserved.	[Xue, Sha; Zhang, Hong-tian; Zhang, Peng; Luo, Jie; Chen, Zhen-zhou; Jang, Xiao-dan; Xu, Ru-xiang] So Med Univ, Zhujiang Hosp, Dept Neurosurg, Guangzhou 510282, Guangdong, Peoples R China; [Xue, Sha; Zhang, Hong-tian; Zhang, Peng; Luo, Jie; Chen, Zhen-zhou; Jang, Xiao-dan; Xu, Ru-xiang] So Med Univ, Inst Neurosurg, Key Lab Brain Funct Repair & Regenerat Guangdong, Guangzhou 510282, Guangdong, Peoples R China; [Xu, Ru-xiang] Mil Gen Hosp Beijing PLA, Dept Neurosurg, Beijing 100700, Peoples R China	Jang, XD (corresponding author), So Med Univ, Zhujiang Hosp, Dept Neurosurg, 253 Gongye Rd, Guangzhou 510282, Guangdong, Peoples R China.	jiangxiao_dan@163.com; zjxuruxiang@163.com			Natural Science Foundation of China (NSFC)National Natural Science Foundation of China (NSFC) [U0632008, 30772232, 30801184, 30500526]; Funds for Key Sci-Tech Research Projects of Guangdong Province [2006Z3-E522, YUE KEJIBAN (2007) 05/06-7005206, 05/06-7005213, YUECAIJIAO (2008) 258-2008A030201019]; Funds for Key Sci-Tech Research Projects of Guangzhou [YUEKETIAOZI (2008)3-2008A1-E4011-6, 09B52120112]	This research was supported by the Natural Science Foundation of China (NSFC) (U0632008, 30772232, 30801184, 30500526), Funds for Key Sci-Tech Research Projects of Guangdong Province [2006Z3-E522, YUE KEJIBAN (2007) 05/06-7005206, 05/06-7005213, YUECAIJIAO (2008) 258-2008A030201019], and Funds for Key Sci-Tech Research Projects of Guangzhou [YUEKETIAOZI (2008)3-2008A1-E4011-6, 09B52120112].	Asahara T, 1999, CIRC RES, V85, P221, DOI 10.1161/01.RES.85.3.221; Becerra GD, 2007, BEHAV BRAIN RES, V179, P118, DOI 10.1016/j.bbr.2007.01.024; Chen ZZ, 2008, NEUROSCI LETT, V445, P36, DOI 10.1016/j.neulet.2008.08.039; Cheng J, 1996, BLOOD, V87, P479, DOI 10.1182/blood.V87.2.479.bloodjournal872479; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Kawamoto Atsuhiko, 2002, Cardiovasc Radiat Med, V3, P221, DOI 10.1016/S1522-1865(03)00082-9; Kern S, 2006, STEM CELLS, V24, P1294, DOI 10.1634/stemcells.2005-0342; Lee RH, 2004, CELL PHYSIOL BIOCHEM, V14, P311, DOI 10.1159/000080341; Loomans CJM, 2006, ARTERIOSCL THROM VAS, V26, P1760, DOI 10.1161/01.ATV.0000229243.49320.c9; Qian C, 2007, CARDIOVASC PATHOL, V16, P127, DOI 10.1016/j.carpath.2006.11.008; Rebelatto CK, 2008, EXP BIOL MED, V233, P901, DOI 10.3181/0712-RM-356; Schatteman GC, 2007, AM J PHYSIOL-HEART C, V292, pH1, DOI 10.1152/ajpheart.00662.2006; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Shyu WC, 2006, J NEUROSCI, V26, P3444, DOI 10.1523/JNEUROSCI.5165-05.2006; Suzuki A, 1996, BLOOD, V87, P3550, DOI 10.1182/blood.V87.9.3550.bloodjournal8793550; Wagner W, 2005, EXP HEMATOL, V33, P1402, DOI 10.1016/j.exphem.2005.07.003; Yin T, 2008, CELL RES, V18, P792, DOI 10.1038/cr.2008.69; Zhang HT, 2009, NEUROSCI LETT, V458, P116, DOI 10.1016/j.neulet.2009.04.045; Zhang SJ, 2006, CELL RES, V16, P577, DOI 10.1038/sj.cr.7310075; Zhang ZG, 2002, CIRC RES, V90, P284, DOI 10.1161/hh0302.104460; Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859	21	34	39	0	4	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	APR 12	2010	473	3					186	191		10.1016/j.neulet.2010.02.035			6	Neurosciences	Neurosciences & Neurology	588ML	WOS:000277074300006	20178832				2021-06-18	
J	Goffus, AM; Anderson, GD; Hoane, MR				Goffus, Andrea M.; Anderson, Gail D.; Hoane, Michael R.			Sustained delivery of nicotinamide limits cortical injury and improves functional recovery following traumatic brain injury	OXIDATIVE MEDICINE AND CELLULAR LONGEVITY			English	Article						neurorehabilitation; therapy; brain injury; behavior; restorative neurology	FOCAL CEREBRAL-ISCHEMIA; NAD(+); PERFORMANCE; INHIBITOR; NEUROPROTECTION; MITOCHONDRIAL; VITAMIN-B-3; INFARCTION; APOPTOSIS; TRANSPORT	Previously, we have demonstrated that nicotinamide (NAM), a neuroprotective soluble B-group vitamin, improves recovery of function following traumatic brain injury (TBI). However, no prior studies have examined whether NAM is beneficial following continuous infusions over 7 days post-TBI. The purpose of this study was to investigate the preclinical efficacy of NAM treatment as it might be delivered clinically; over several days by slow infusion. Rats were prepared with either unilateral controlled cortical impact (CCI) injuries or sham procedures and divided into three groups: CCI-NAM, CCI-vehicle and sham. Thirty minutes following CCI, Alzet osmotic mini-pumps were implanted subcutaneously. NAM was delivered at a rate of 50 mg/kg/day for 7 days immediately post-CCI. On day 7 following injury, the pumps were removed and blood draws were collected for serum NAM and nicotinamide adenine dinucleotide (NAD(+)) analyses. Starting on day 2 post-CCI, animals were tested on a battery of sensorimotor tests (bilateral tactile adhesive removal, locomotor placing and limb-use asymmetry). Continuous infusion of NAM resulted in a significant serum elevation in NAM, but not NAD+. Statistical analyses of the tactile removal and locomotor placing data revealed that continuous administration of NAM significantly reduced the initial magnitude of the injury deficit and improved overall recovery compared to the vehicle-treated animals. NAM treatment also significantly decreased limb-use asymmetries compared to vehicle-treated animals. The overall extent of the cortical damage was also reduced by NAM treatment. No detrimental effects were seen following continuous infusion. The present results suggest that NAM delivered via a clinically relevant therapeutic regimen may truncate behavioral damage following TBI. Thus our results offer strong support for translation into the clinical population.	[Goffus, Andrea M.; Hoane, Michael R.] So Illinois Univ, Dept Psychol, Ctr Integrat Res Cognit & Neural Sci, Restorat Neurosci Lab, Carbondale, IL 62901 USA; [Anderson, Gail D.] Univ Washington, Dept Pharm, Seattle, WA 98195 USA	Hoane, MR (corresponding author), So Illinois Univ, Dept Psychol, Ctr Integrat Res Cognit & Neural Sci, Restorat Neurosci Lab, Carbondale, IL 62901 USA.	mhoane@siu.edu		Hoane, Michael/0000-0001-7779-2657	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS045647]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R15NS045647] Funding Source: NIH RePORTER	We would like to thank Nicholas Kaufman for his help on this project. This research was funded by NIH grant NS045647 to M.R.H.	Ayoub IA, 1999, NEUROSCI LETT, V259, P21, DOI 10.1016/S0304-3940(98)00881-7; Ayoub IA, 2002, NEUROREPORT, V13, P213, DOI 10.1097/00001756-200202110-00008; Chong ZZ, 2008, CURR NEUROVASC RES, V5, P159, DOI 10.2174/156720208785425666; Clark RSB, 2007, J NEUROTRAUM, V24, P1399, DOI 10.1089/neu.2007.0305; COGGESHALL RE, 1992, TRENDS NEUROSCI, V15, P9, DOI 10.1016/0166-2236(92)90339-A; Cutler SM, 2005, EXP NEUROL, V195, P423, DOI 10.1016/j.expneurol.2005.06.003; Gondusky JS, 2005, MIL MED, V170, P546, DOI 10.7205/MILMED.170.6.546; Hoane MR, 2008, NEUROSCIENCE, V154, P861, DOI 10.1016/j.neuroscience.2008.04.044; Hoane MR, 2007, J NEUROTRAUM, V24, P1108, DOI 10.1089/neu.2006.0254; Hoane MR, 2006, BRAIN RES, V1125, P185, DOI 10.1016/j.brainres.2006.10.019; Hoane MR, 2006, NEUROSCI LETT, V408, P35, DOI 10.1016/j.neulet.2006.07.011; Hoane MR, 2006, J NEUROTRAUM, V23, P1535, DOI 10.1089/neu.2006.23.1535; Hoane MR, 2008, OXID MED CELL LONGEV, V1, P46, DOI 10.4161/oxim.1.1.6694; Hoane MR, 2003, J NEUROTRAUM, V20, P1189, DOI 10.1089/089771503770802871; Holland MA, 2008, J NEUROTRAUM, V25, P140, DOI 10.1089/neu.2007.0312; KALHORN TF, 1985, ANAL BIOCHEM, V151, P343, DOI 10.1016/0003-2697(85)90185-X; Klaidman L, 2003, PHARMACOLOGY, V69, P150, DOI 10.1159/000072668; LANGLOIS JA, 2006, J HEAD TRAUMA REHAB, V21, P10; Li FQ, 2006, CURR MED CHEM, V13, P883, DOI 10.2174/092986706776361058; Maiese K, 2003, TRENDS PHARMACOL SCI, V24, P228, DOI 10.1016/S0165-6147(03)00078-6; Maiese K, 2009, MOLECULES, V14, P3446, DOI 10.3390/molecules14093446; Maynard KI, 2001, ANN NY ACAD SCI, V939, P416; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Paxinos G., 2005, RAT BRAIN STEREOTAXI; Quigley A, 2009, BRAIN RES, V1304, P138, DOI 10.1016/j.brainres.2009.09.062; Royo NC, 2003, CURR OPIN PHARMACOL, V3, P27, DOI 10.1016/S1471-4892(02)00006-1; Sauve AA, 2008, J PHARMACOL EXP THER, V324, P883, DOI 10.1124/jpet.107.120758; SPECTOR R, 1979, J NEUROCHEM, V33, P895, DOI 10.1111/j.1471-4159.1979.tb09919.x; Statler KD, 2001, J NEUROTRAUM, V18, P1195, DOI 10.1089/089771501317095232; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Ungerstedt JS, 2003, CLIN EXP IMMUNOL, V131, P48, DOI 10.1046/j.1365-2249.2003.02031.x; Verbois SL, 2003, NEUROPHARMACOLOGY, V44, P224, DOI 10.1016/S0028-3908(02)00366-0; Woodlee M.T., 2005, BEHAV LAB RAT HDB TE, P129; Yang J, 2002, MINI-REV MED CHEM, V2, P125, DOI 10.2174/1389557024605483; Yang J, 2002, PHARMACOL BIOCHEM BE, V73, P901, DOI 10.1016/S0091-3057(02)00939-5	36	34	35	0	6	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	1942-0900	1942-0994		OXID MED CELL LONGEV	Oxidative Med. Cell. Longev.	MAR-APR	2010	3	2					145	152		10.4161/oxim.3.2.11315			8	Cell Biology	Cell Biology	644OW	WOS:000281389700008	20716938	DOAJ Gold, Green Published			2021-06-18	
J	Aaen, GS; Holshouser, BA; Sheridan, C; Colbert, C; McKenney, M; Kido, D; Ashwal, S				Aaen, Gregory S.; Holshouser, Barbara A.; Sheridan, Clare; Colbert, Cherie; McKenney, Melinda; Kido, Daniel; Ashwal, Stephen			Magnetic Resonance Spectroscopy Predicts Outcomes for Children With Nonaccidental Trauma	PEDIATRICS			English	Article						children; infants; nonaccidental trauma; MRI; magnetic resonance spectroscopy; traumatic brain injury	INFLICTED HEAD-INJURY; PROTON MR SPECTROSCOPY; BRAIN-INJURY; YOUNG-CHILDREN; HYPOXIC ENCEPHALOPATHY; N-ACETYLASPARTATE; PROGNOSTIC VALUE; AXONAL INJURY; NEURONAL LOSS; INFANTS	OBJECTIVE: We evaluated proton magnetic resonance spectroscopic imaging (MRSI) findings for children with traumatic brain injury attributable to nonaccidental trauma (NAT) early after injury, to determine whether brain metabolite changes predicted outcomes. METHODS: Proton MRSI (1.5 T) was performed (mean: 5 days after injury [range: 1-30 days]) through the level of the corpus callosum for 90 children with confirmed NAT. Regional N-acetylaspartate/total creatine, N-acetylaspartate/total choline, and choline/creatine ratios and the presence of lactate were measured. Data on long-term outcomes defined at >= 6 months were collected for 44 of 90 infants. We grouped patients into good (normal, mild disability, or moderate disability; n = 32) and poor (severe disability, vegetative state, or dead; n = 12) outcome groups. RESULTS: We found that N-acetylaspartate/creatine and N-acetylaspartate/choline ratios (mean total, corpus callosum, and frontal white matter) were significantly decreased in patients with poor outcomes (P < .001). A logistic regression model using age, initial Glasgow Coma Scale score, presence of retinal hemorrhage, lactate on MRSI scans, and mean total N-acetylaspartate/creatine ratio predicted outcomes accurately in 100% of cases. CONCLUSIONS: Reduced N-acetylaspartate levels (ie, neuronal loss/dysfunction) and elevated lactate levels (altered energy metabolism) correlated with poor neurologic outcomes for infants with NAT. Elevated lactate levels may reflect primary or secondary hypoxic-ischemic injury, which may occur with NAT. Our data suggest that MRSI performed early after injury can be used for long-term prognosis. Pediatrics 2010; 125: 295-303	[Ashwal, Stephen] Loma Linda Univ, Sch Med, Dept Pediat, Div Child Neurol, Loma Linda, CA 92354 USA; [Sheridan, Clare] Loma Linda Univ, Sch Med, Dept Pediat, Div Forens Med, Loma Linda, CA 92354 USA; [Holshouser, Barbara A.; Colbert, Cherie; McKenney, Melinda; Kido, Daniel] Loma Linda Univ, Sch Med, Dept Radiol, Loma Linda, CA 92354 USA	Ashwal, S (corresponding author), Loma Linda Univ, Sch Med, Dept Pediat, Div Child Neurol, 11175 Campus St,Room A1120, Loma Linda, CA 92354 USA.	sashwal@llu.edu					Adelson PD, 1999, TRAUMATIC BRAIN INJU, P283; Ashwal S, 2000, PEDIATR NEUROL, V23, P114, DOI 10.1016/S0887-8994(00)00176-4; Atkinson JLD, 1998, J TRAUMA, V45, P941, DOI 10.1097/00005373-199811000-00016; Babikian T, 2006, J MAGN RESON IMAGING, V24, P801, DOI 10.1002/jmri.20696; Barlow KM, 1999, DEV MED CHILD NEUROL, V41, P220, DOI 10.1017/S0012162299000481; Brenner T, 2003, PEDIATR NEUROL, V28, P104, DOI 10.1016/S0887-8994(02)00491-5; Broman S. H., 1995, TRAUMATIC HEAD INJUR; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; Clark JB, 1998, DEV NEUROSCI-BASEL, V20, P271, DOI 10.1159/000017321; Dashti SR, 1999, PEDIATR NEUROSURG, V31, P302, DOI 10.1159/000028880; Demougeot C, 2001, J NEUROCHEM, V77, P408, DOI 10.1046/j.1471-4159.2001.00285.x; Dolinak D, 2006, ARCH PATHOL LAB MED, V130, P712; Dubowitz DJ, 1998, AM J NEURORADIOL, V19, P1617; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Duhaime AC, 1996, PEDIATR NEUROSURG, V24, P292, DOI 10.1159/000121058; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; Gill JR, 2009, ARCH PATHOL LAB MED, V133, P619, DOI 10.1043/1543-2165-133.4.619; Gilles EE, 1998, PEDIATR NEUROL, V19, P119, DOI 10.1016/S0887-8994(98)00038-1; HOLMES G, 1982, ELECTROEN CLIN NEURO, V53, P60, DOI 10.1016/0013-4694(82)90106-7; Holshouser BA, 1997, RADIOLOGY, V202, P487, DOI 10.1148/radiology.202.2.9015079; Holshouser BA, 2005, AM J NEURORADIOL, V26, P1276; HOVDA DA, 1992, J NEUROTRAUMA S1, V9, P47; Hymel KP, 2007, PEDIATRICS, V119, P922, DOI 10.1542/peds.2006-3111; Ichord RN, 2007, J NEUROTRAUM, V24, P106, DOI 10.1089/neu.2006.0087; JENNETT B, 1975, LANCET, V1, P480; Johnson DL, 1995, PEDIATR NEUROSURG, V23, P305, DOI 10.1159/000120976; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Kreis R, 1996, J CLIN INVEST, V97, P1142, DOI 10.1172/JCI118528; Krishnappa IK, 1999, J NEUROTRAUM, V16, P213, DOI 10.1089/neu.1999.16.213; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; Makaroff KL, 2003, DEV MED CHILD NEUROL, V45, P497, DOI 10.1017/S0012162203000926; Makoroff KL, 2005, PEDIATR RADIOL, V35, P668, DOI 10.1007/s00247-005-1441-7; Moffett JR, 2007, PROG NEUROBIOL, V81, P89, DOI 10.1016/j.pneurobio.2006.12.003; PRASAD MR, 1994, J NEUROCHEM, V63, P1086; Signoretti S, 2002, ACT NEUR S, V81, P373; *US ADM CHILDR YOU, 2008, CHILD MALTR 2006; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; Yeo RA, 2006, J NEUROTRAUM, V23, P1427, DOI 10.1089/neu.2006.23.1427	41	34	35	0	6	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	FEB	2010	125	2					295	303		10.1542/peds.2008-3312			9	Pediatrics	Pediatrics	573VH	WOS:000275942900014	20123781				2021-06-18	
J	Chesik, D; De Keyser, J				Chesik, Daniel; De Keyser, Jacques			Progesterone and dexamethasone differentially regulate the IGF-system in glial cells	NEUROSCIENCE LETTERS			English	Article						Insulin-like growth factor; Progesterone; Dexamethasone; Astrocytes; Oligodendrocytes; Multiple sclerosis	TRAUMATIC BRAIN-INJURY; FACTOR BINDING PROTEIN-2; MULTIPLE-SCLEROSIS; SPINAL-CORD; RAT-BRAIN; ESTROGEN; CULTURES; CNS; NEUROPROTECTION; PROLIFERATION	IGF-1 is an important factor for myelin synthesis and hence possesses therapeutic potential in treating demyelinating disease such as multiple sclerosis. However, IGF-1 poorly crosses the blood-brain barrier. In this study, we investigated the effects of the sex steroid progesterone and the glucocorticoid dexamethasone on regulation of the IGF-system in glial cells. By means of quantitative PCR analysis, we demonstrate that progesterone upregulates IGF-1, the type 1 IGF receptor and IGFBP-2 in primary rat astrocytes and both IGF-1 and IGFBP-6 in OLN-93 oligodendroglial progenitor cells. In contrast, dexamethasone showed a negative effect on expression of IGF-1, the type I IGF receptor and the respective IGF binding proteins in both cell types. In oligodendrocytes, the differentiation marker CNPase was positively regulated by progesterone and negatively regulated by dexamethasone. Further, oligodendroglial cell migration was enhanced approximately 4-fold by progesterone. This study implicates progesterone as a positive regulator of IGF-system in glial cells and demonstrates a further biological function of progesterone in oligodendrocyte biology, namely stimulation of progenitor cell migration. Dexamethasone, on the other hand. is a negative regulator of the IGF-system in glial cells. (C) 2009 Elsevier Ireland Ltd. All rights reserved.	[Chesik, Daniel; De Keyser, Jacques] Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, NL-9713 GZ Groningen, Netherlands; [De Keyser, Jacques] Univ Hosp Brussels, Dept Neurol, B-1090 Brussels, Belgium	Chesik, D (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, Hanzepl 1, NL-9713 GZ Groningen, Netherlands.	d.chesik@med.umcg.nl	De Keyser, Jacques/D-3725-2013; De Keyser, Jacques/AAA-8721-2021	De Keyser, Jacques/0000-0002-3394-7757; De Keyser, Jacques/0000-0002-3394-7757	Dutch foundation	Daniel Chesik is a grant recipient from the Dutch foundation "Stichting Multiple Sclerose Anders" to which authors are indebted for financial support of this investigation. Authors would also like to thank Reinier Bron for assistance with the migration assays.	Chan JR, 1998, P NATL ACAD SCI USA, V95, P10459, DOI 10.1073/pnas.95.18.10459; Chesik D, 2004, J NEUROSCI RES, V77, P354, DOI 10.1002/jnr.20172; Chesik D, 2008, J MOL NEUROSCI, V35, P81, DOI 10.1007/s12031-008-9041-2; Chesik D, 2007, CYTOKINE GROWTH F R, V18, P267, DOI 10.1016/j.cytogfr.2007.04.001; Chesik D, 2006, EUR J NEUROSCI, V24, P1645, DOI 10.1111/j.1460-9568.2006.05034.x; COMPSTON S, 1997, J ANAT 2, V190, P161; Cutler SM, 2006, PHARMACOL BIOCHEM BE, V84, P420, DOI 10.1016/j.pbb.2006.05.029; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Franklin RJM, 2008, NAT REV NEUROSCI, V9, P839, DOI 10.1038/nrn2480; Garay L, 2007, J STEROID BIOCHEM, V107, P228, DOI 10.1016/j.jsbmb.2007.03.040; Garcia-Estrada J, 1999, INT J DEV NEUROSCI, V17, P145, DOI 10.1016/S0736-5748(98)00065-3; Ghoumari AM, 2005, NEUROSCIENCE, V135, P47, DOI 10.1016/j.neuroscience.2005.05.023; Gonzalez SL, 2004, NEUROSCIENCE, V125, P605, DOI 10.1016/j.neuroscience.2004.02.024; Gonzalez-Vidal MD, 1998, ARCH MED RES, V29, P117; Ibanez C, 2004, NEUROPATH APPL NEURO, V30, P80, DOI 10.1046/j.0305-1846.2003.00515.x; JONES JI, 1993, P NATL ACAD SCI USA, V90, P10553, DOI 10.1073/pnas.90.22.10553; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; JUNGTESTAS I, 1989, ENDOCRINOLOGY, V125, P2083; Kipp M, 2007, J NEUROENDOCRINOL, V19, P819, DOI 10.1111/j.1365-2826.2007.01588.x; Labombarda F, 2002, J NEUROTRAUM, V19, P343, DOI 10.1089/089771502753594918; Liu X, 1995, Mult Scler, V1, P2; Marin-Husstege M, 2004, DEV NEUROSCI-BASEL, V26, P245, DOI 10.1159/000082141; MCMORRIS FA, 1988, J NEUROSCI RES, V21, P199, DOI 10.1002/jnr.490210212; Micevych P, 2008, BRAIN RES REV, V57, P470, DOI 10.1016/j.brainresrev.2007.06.009; Miller L, 1998, J IMMUNOL, V160, P5098; Mohan S, 2002, J ENDOCRINOL, V175, P19, DOI 10.1677/joe.0.1750019; Moorthy K, 2005, EXP GERONTOL, V40, P295, DOI 10.1016/j.exger.2005.01.004; MOZELL RL, 1991, J NEUROSCI RES, V30, P382, DOI 10.1002/jnr.490300214; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Quesada A, 2004, J NEUROSCI RES, V75, P107, DOI 10.1002/jnr.10833; Quesada A, 2008, DEV NEUROBIOL, V68, P632, DOI 10.1002/dneu.20609; RichterLandsberg C, 1996, J NEUROSCI RES, V45, P161, DOI 10.1002/(SICI)1097-4547(19960715)45:2<161::AID-JNR8>3.0.CO;2-8; Schumacher M, 2007, PHARMACOL THERAPEUT, V116, P77, DOI 10.1016/j.pharmthera.2007.06.001; Sinchak K, 2003, DEV NEUROSCI-BASEL, V25, P343, DOI 10.1159/000073511; Wilczak N, 2008, NEUROCHEM INT, V52, P1431, DOI 10.1016/j.neuint.2008.03.004; YAO DL, 1995, P NATL ACAD SCI USA, V92, P6190, DOI 10.1073/pnas.92.13.6190	36	34	34	0	6	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	JAN 14	2010	468	3					178	182		10.1016/j.neulet.2009.10.051			5	Neurosciences	Neurosciences & Neurology	547HZ	WOS:000273879100002	19853640				2021-06-18	
J	Chang, MC; Kim, SH; Kim, OL; Bai, DS; Jang, SH				Chang, Min Cheol; Kim, Seong Ho; Kim, Oh Lyong; Bai, Dai Seg; Jang, Sung Ho			The relation between fornix injury and memory impairment in patients with diffuse axonal injury: A diffusion tensor imaging study	NEUROREHABILITATION			English	Article						Diffuse axonal injury; memory; diffuse tensor imaging; fornix; brain injury	CLOSED-HEAD TRAUMA; CORTICOSPINAL TRACT; FIBER TRACKING; TRACTOGRAPHY; LESIONS; BRAIN; INFARCTION; INTEGRITY; RECOVERY; FEATURES	Little is known about the relation between fornix injury and memory impairment in diffuse axonal injury (DAD. In the current study, we attempted to investigate fornix injury in patients with memory impairment following DAI, using diffusion tensor imaging (DTI). Nine patients with DAI and nine age-and sex-matched control subjects were recruited. The DTIs were acquired using a sensitivity-encoding head coil on a 1.5 T. Five regions of interest (ROI) were drawn manually on a color fractional anisotropy (FA) map: two ROIs for each column, one ROI for the body, and two ROIs for each crus. The FA and apparent diffusion coefficient (ADC) were measured in each of the ROIs. Cognitive function was evaluated using the Memory Assessment Scale, Wechsler Intelligence Scale, and Mini-Mental State Exam. In the DAI group, the FA value in the fornix body was significantly decreased compared with that of the control group. In contrast, we did not find significant differences in the column and crus of the fornix. Among all of the cognitive function scales, only the Memory Assessment Scale scores were significantly correlated with the FA values of the fornix body in the DAI group. We found that memory impairment in patients with DAI is closely related to neuronal injury of the fornix body among the three fornix regions that we assessed. DTI could be useful in the evaluation of patients with memory impairment following DAI.	[Chang, Min Cheol; Jang, Sung Ho] Yeungnam Univ, Coll Med, Dept Phys Med & Rehabil, Taegu 705717, South Korea; [Kim, Seong Ho; Kim, Oh Lyong] Yeungnam Univ, Coll Med, Dept Neurosurg, Taegu 705717, South Korea; [Bai, Dai Seg] Yeungnam Univ, Coll Med, Dept Psychiat, Taegu 705717, South Korea	Jang, SH (corresponding author), Yeungnam Univ, Coll Med, Dept Phys Med & Rehabil, 317-1 Daemyungdong, Taegu 705717, South Korea.	strokerehab@hanmail.net					ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADEL KA, 2005, FUNCTIONAL NEUROANAT, P271; Aggleton JP, 2000, BRAIN, V123, P800, DOI 10.1093/brain/123.4.800; Ahn YH, 2006, NEUROREHABILITATION, V21, P239; Alexander AL, 2007, NEUROTHERAPEUTICS, V4, P316, DOI 10.1016/j.nurt.2007.05.011; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Beaulieu C, 1996, MAGNET RESON MED, V36, P627, DOI 10.1002/mrm.1910360419; Concha L, 2005, AM J NEURORADIOL, V26, P2267; DESPOSITO M, 1995, NEUROLOGY, V45, P1546, DOI 10.1212/WNL.45.8.1546; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GRAFMAN J, 1985, ARCH NEUROL-CHICAGO, V42, P1162, DOI 10.1001/archneur.1985.04060110044014; GRAHAM DI, 1997, GREENFIELDS NEUROPAT, P104; Han BS, 2007, NEUROREHABILITATION, V22, P151; Hattingen E, 2007, J NEUROL NEUROSUR PS, V78, P655, DOI 10.1136/jnnp.2006.109801; Jang SH, 2009, ARCH NEUROL-CHICAGO, V66, P1424, DOI 10.1001/archneurol.2009.242; Kuroki N, 2006, BIOL PSYCHIAT, V60, P22, DOI 10.1016/j.biopsych.2005.09.021; Leclercq PD, 2001, J NEUROTRAUM, V18, P1, DOI 10.1089/089771501750055721; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Mori S, 2002, NMR BIOMED, V15, P468, DOI 10.1002/nbm.781; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; Park SA, 2000, NEUROLOGY, V54, P1379, DOI 10.1212/WNL.54.6.1379; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Sugiyama K, 2007, BRAIN INJURY, V21, P413, DOI 10.1080/02699050701311042; Takei K, 2008, SCHIZOPHR RES, V103, P52, DOI 10.1016/j.schres.2008.03.008; Tsivilis D, 2008, NAT NEUROSCI, V11, P834, DOI 10.1038/nn.2149; Wang JY, 2008, ARCH NEUROL-CHICAGO, V65, P619, DOI 10.1001/archneur.65.5.619; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Williams JM, 1991, MEMORY ASSESSMENT SC; Zahr NM, 2009, NEUROIMAGE, V44, P1050, DOI 10.1016/j.neuroimage.2008.09.046	34	34	35	0	6	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2010	26	4					347	353		10.3233/NRE-2010-0572			7	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	632NE	WOS:000280430600008	20555158				2021-06-18	
J	Chronister, J; Chan, F; Sasson-Gelman, EJ; Chiu, CY				Chronister, Julie; Chan, Fong; Sasson-Gelman, E. Joy; Chiu, Chung-Yi			The association of stress-coping variables to quality of life among caregivers of individuals with traumatic brain injury	NEUROREHABILITATION			English	Article							COMPETENCE RATING-SCALE; SOCIAL SUPPORT; FAMILY NEEDS; BURDEN; PREDICTORS; DISTRESS; HEALTH; TBI; STRATEGIES; APPRAISAL	The purpose of this study was to determine the degree to which stress-coping variables contribute to quality of life (QOL) among caregivers of individuals with traumatic brain injury (TBI). This study examined the direct effects of the following variables: functional competency, caregiving appraisal, coping, perceived social support, and family needs on QOL. In addition, the unique variance accounted for in QOL by each set was investigated, and whether perceived social support, coping, and family needs mediate or moderate the relationship between caregiving appraisal and QOL. The sample consisted of 108 caregivers recruited from support groups who were predominantly white females. The majority of care-recipients had a severe head injury. Measures administered were the Interpersonal Support Evaluation List, Family Needs Questionnaire, Modified Caregiving Appraisal Scale, and the World Health Organization Quality of Life - Brief Version. Results showed that the full model accounted for 68% of the variance in QOL; caregiving appraisal, perceived social support and family needs remained significant after other stress-coping variables were partialled; and of these sets, emotional social support, social needs, and perceived burden were the significant individual predictors. Emotional social support and social needs mediated the relationship between perceived burden and QOL.	[Chronister, Julie; Sasson-Gelman, E. Joy] San Francisco State Univ, Dept Counseling, San Francisco, CA 94131 USA; [Chan, Fong] Univ Wisconsin, Dept Rehabil Psychol & Special Educ, Madison, WI 53706 USA; [Chiu, Chung-Yi] Univ Texas SW Med Ctr Dallas, Dept Rehabil Counseling Psychol, Sch Hlth Profess, Dallas, TX 75390 USA	Chronister, J (corresponding author), San Francisco State Univ, Dept Counseling, 1600 Holloway Ave,Burk Hall 525, San Francisco, CA 94131 USA.	jcrhonis@sfsu.edu					Anderson MI, 2002, BRAIN INJURY, V16, P743, DOI 10.1080/02699050210128906; Aneshensel C.S., 1995, PROFILES CAREGIVING; Brissette I, 2002, J PERS SOC PSYCHOL, V82, P102, DOI 10.1037//0022-3514.82.1.102; Campbell C H, 1988, Rehabil Nurs, V13, P320; CARVER CS, 1989, J PERS SOC PSYCHOL, V56, P267, DOI 10.1037/0022-3514.56.2.267; Chandra Ashish, 2005, Hosp Top, V83, P33, DOI 10.3200/HTPS.83.1.33-37; Chronister J.A, 2009, UNDERSTANDING PSYCHO, P149; Chwalisz K, 1996, REHABIL PSYCHOL, V41, P91, DOI 10.1037/0090-5550.41.2.91; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; COHEN S, 1983, J APPL SOC PSYCHOL, V13, P99, DOI 10.1111/j.1559-1816.1983.tb02325.x; COHEN S, 1983, SOCIAL SUPPORT THEOR, P73; DOUGLAS JM, 2000, DISABILITY REHABILIT, V22, P683; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; Fallowfield L., 1990, QUALITY LIFE MISSING; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; Frazier PA, 2004, J COUNS PSYCHOL, V51, P115, DOI 10.1037/0022-0167.51.1.115; Hanks RA, 2007, NEUROREHABILITATION, V22, P43; Harper A, 1998, PSYCHOL MED, V28, P551, DOI 10.1017/S0033291798006667; Harris JKJ, 2001, BRAIN INJURY, V15, P223; HEILBRONNER RL, 1993, J CLIN EXP NEUROPSYC, V15, P67; Hoyt WT, 2008, REHABIL PSYCHOL, V53, P321, DOI 10.1037/a0013021; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; KREUTZER JS, 1994, J HEAD TRAUMA REHAB, V9, P104, DOI 10.1097/00001199-199409000-00009; LAWTON MP, 1991, J GERONTOL, V46, pP181, DOI 10.1093/geronj/46.4.P181; LAWTON MP, 1989, J GERONTOL, V44, pP61, DOI 10.1093/geronj/44.3.P61; Lazarus R. S., 1987, EUR J PERSONALITY, V1, P141, DOI 10.1002/per.2410010304; Lazarus R.S., 1984, STRESS APPRAISAL COP; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; Leathem JM, 1998, J CLIN EXP NEUROPSYC, V20, P694, DOI 10.1076/jcen.20.5.694.1122; Lim Jung-won, 2004, Health Qual Life Outcomes, V2, P50; LINN RT, 1994, BRAIN INJURY, V8, P135, DOI 10.3109/02699059409150965; Livneh H, 2003, REHABIL COUNS BULL, V46, P194, DOI 10.1177/003435520304600401; Machamer J, 2002, J CLIN EXP NEUROPSYC, V24, P420, DOI 10.1076/jcen.24.4.420.1040; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; Mason VL, 2004, QUAL LIFE RES, V13, P1139, DOI 10.1023/B:QURE.0000031344.53009.eb; Mathis M, 1984, J Neurosurg Nurs, V16, P36; Mauss-Clum N, 1981, J Neurosurg Nurs, V13, P165; Moos R., 1993, HDB STRESS THEORETIC, P234; Moules S, 1999, BRAIN INJURY, V13, P983; Nabors N, 2002, BRAIN INJURY, V16, P1039, DOI 10.1080/02699050210155285; PELLETIER PM, 2000, ROTTM I ABSTR, P45; Perlesz A, 1999, REHABIL PSYCHOL, V44, P6, DOI 10.1037/0090-5550.44.1.6; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Sander AM, 1997, BRAIN INJURY, V11, P235, DOI 10.1080/026990597123548; Serio CD, 1997, BRAIN INJURY, V11, P1, DOI 10.1080/026990597123764; Stebbins P, 2001, REHABIL PSYCHOL, V46, P178, DOI 10.1037/0090-5550.46.2.178; Struchen MA, 2002, J HEAD TRAUMA REHAB, V17, P132, DOI 10.1097/00001199-200204000-00005; Wade SL, 2001, J CONSULT CLIN PSYCH, V69, P406, DOI 10.1037//0022-006X.69.3.406; Wells R, 2005, BRAIN INJURY, V19, P1105, DOI 10.1080/02699050500150062; Wortman CB, 1985, SOCIAL SUPPORT HLTH, P281	52	34	35	0	5	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2010	27	1					49	62		10.3233/NRE-2010-0580			14	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	629GA	WOS:000280182000005	20634600				2021-06-18	
J	Hutchison, JS; Frndova, H; Lo, TYM; Guerguerian, AM				Hutchison, James S.; Frndova, Helena; Lo, Tsz-Yan M.; Guerguerian, Anne-Marie		Hypothermia Pediat Head Injury Tri; Canadian Critical Care Trials Grp	Impact of Hypotension and Low Cerebral Perfusion Pressure on Outcomes in Children Treated with Hypothermia Therapy following Severe Traumatic Brain Injury: A post hoc Analysis of the Hypothermia Pediatric Head Injury Trial	DEVELOPMENTAL NEUROSCIENCE			English	Article						Cerebral perfusion pressure; Children; Hypotension; Hypothermia therapy; Traumatic brain injury	INTRACRANIAL-PRESSURE; MODERATE HYPOTHERMIA; INTENSIVE-CARE; HYPOXIA; PHASE; RATS	Hypotension and low cerebral perfusion pressure are known to be associated with unfavorable outcome in children and adults with traumatic brain injury. Using the database from a previously published, randomized controlled trial of 24 h of hypothermia therapy in children with severe traumatic brain injury, we compared the number of patients with hypotension or low cerebral perfusion pressure between the hypothermia therapy and normothermia groups. We also determined the association between these physiologic insults and unfavorable outcome using regression analysis. There were more patients with episodes of hypotension or low cerebral perfusion pressure in the hypothermia therapy group than in the normothermia group. These physiologic insults were associated with unfavorable outcome in both intervention groups. Hypotension and low cerebral perfusion pressure should be anticipated and prevented in future trials of hypothermia therapy in patients with traumatic brain injury. Copyright (C) 2011 S. Karger AG, Basel	[Hutchison, James S.; Frndova, Helena; Lo, Tsz-Yan M.; Guerguerian, Anne-Marie] Hosp Sick Children, Dept Crit Care, Toronto, ON M5G 1X8, Canada; [Hutchison, James S.; Frndova, Helena; Lo, Tsz-Yan M.; Guerguerian, Anne-Marie] Hosp Sick Children, Dept Pediat, Toronto, ON M5G 1X8, Canada; [Hutchison, James S.; Lo, Tsz-Yan M.; Guerguerian, Anne-Marie] Hosp Sick Children, Neurosci & Mental Hlth Res Program, Res Inst, Toronto, ON M5G 1X8, Canada; [Hutchison, James S.; Guerguerian, Anne-Marie] Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A1, Canada	Hutchison, JS (corresponding author), Hosp Sick Children, Dept Crit Care Med, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	jamie.hutchison@sickkids.ca	Kirkham, Fenella/C-2442-2009; kasyan, george/M-4263-2014	Kirkham, Fenella/0000-0002-2443-7958; kasyan, george/0000-0001-7919-2217; Meyer, Philippe G/0000-0002-3829-6631	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [MCT50398]; Ontario Neurotrauma Foundation [ONBO-00009, ONRO-41]; Rick Hansen Institute; Hospital for Sick Children Foundation [XG 99-057]; Physicians Services Incorporated [98-62]; Fonds de la Recherche en Sante du QuebecFonds de la Recherche en Sante du Quebec [004095-104]; Children's Hospital of Eastern Ontario Research Institute [98/16S(E)]; Direction de la Recherche Clinique Assistance Publique - Hopitaux de Paris [P010208]	The Hypothermia Pediatric Head Injury Trial was funded by the Canadian Institutes of Health Research (Canadian Neurotrauma Research Program; MCT50398), the Ontario Neurotrauma Foundation (ONBO-00009 and ONRO-41), the Rick Hansen Institute, the Hospital for Sick Children Foundation (XG 99-057), the Physicians Services Incorporated (98-62), the Fonds de la Recherche en Sante du Quebec (004095-104), the Children's Hospital of Eastern Ontario Research Institute [98/16S(E)] and the Direction de la Recherche Clinique Assistance Publique - Hopitaux de Paris (P010208).	ABRAMSON NS, 1986, JAMA-J AM MED ASSOC, V255, P2466, DOI 10.1001/jama.255.18.2466; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS45; Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; [Anonymous], 2006, PEDIATRICS, V117, pe955; Biswas AK, 2002, CRIT CARE MED, V30, P2742, DOI 10.1097/00003246-200212000-00020; Brady KM, 2009, PEDIATRICS, V124, pE1205, DOI 10.1542/peds.2009-0550; Chaiwat O, 2009, J NEUROTRAUM, V26, P657, DOI 10.1089/neu.2008.0770; Chambers IR, 2006, J NEUROL NEUROSUR PS, V77, P234, DOI 10.1136/jnnp.2005.072215; Chambers IR, 2001, J NEUROSURG, V94, P412, DOI 10.3171/jns.2001.94.3.0412; Chesnut Randall M., 1997, Emergency Medicine Clinics of North America, V15, P581, DOI 10.1016/S0733-8627(05)70319-9; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clifton GL, 2009, J NEUROTRAUM, V26, P393, DOI 10.1089/neu.2008.0556; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; Fiser DH, 2000, CRIT CARE MED, V28, P1173, DOI 10.1097/00003246-200004000-00043; Haque IU, 2007, PEDIATR CRIT CARE ME, V8, P138, DOI 10.1097/01.PCC.0000257039.32593.DC; Hutchison J, 2006, DEV NEUROSCI-BASEL, V28, P291, DOI 10.1159/000094155; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; ISHIGE N, 1988, J NEUROSURG, V68, P129, DOI 10.3171/jns.1988.68.1.0129; Jones PA, 2005, ACT NEUR S, V95, P29; Kokoska ER, 1998, J PEDIATR SURG, V33, P333, DOI 10.1016/S0022-3468(98)90457-2; Mikrogianakis A, 2007, J NEUROTRAUM, V24, P338, DOI 10.1089/neu.2006.003615; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8	24	34	35	0	3	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0378-5866			DEV NEUROSCI-BASEL	Dev. Neurosci.		2010	32	5-6					406	412		10.1159/000323260			7	Developmental Biology; Neurosciences	Developmental Biology; Neurosciences & Neurology	725RO	WOS:000287663900008	21252486	Bronze			2021-06-18	
J	Leon-Carrion, J; Dominguez-Roldan, JM; Leon-Dominguez, U; Murillo-Cabezas, F				Leon-Carrion, Jose; Maria Dominguez-Roldan, Jose; Leon-Dominguez, Umberto; Murillo-Cabezas, Francisco			The Infrascanner, a handheld device for screening in situ for the presence of brain haematomas	BRAIN INJURY			English	Article						Critical care; emergency; neurotraumatology; traumatic brain injury; near-infrared spectroscopy; head injury	HEAD-INJURY; REHABILITATION; CONSEQUENCES; EPIDEMIOLOGY; PREDICTORS	Purpose: Early identification and treatment of intracranial haematomas in patients sustaining traumatic brain injury is fundamental to successful treatment. This pilot study evaluates the Infrascanner as a handheld medical screening tool for detection, in situ, of brain haematomas in patients with head injury. Methods: This study included 35 TBI patients aged 17-76 (M = 47.6), admitted to the neurosurgical intensive care unit and observation unit of a University Hospital in a Level 1 trauma centre. The Infrascanner(TM) NIRS device uses near infrared light measurements to calculate optical density in brain regions. Results: Results show Infrascanner sensitivity at 89.5% and specificity at 81.2%. PPV was 85% and NPV 86.7%. The device detected 90% of extra-axial, 88.9% of intra-axial and 93.3% of non-surgical haematomas (less than 25 mL). PPV for this classification was 82.3%; 87.5% sensitivity was found when the Infrascanner exam was performed within 12 hours post-trauma, whereas after 12 hours post-trauma, exams had 90.1% sensitivity. Conclusions: This study demonstrates that the Infrascanner is useful in initial examinations and screenings of patients with head injury as an adjunct to a CT scan or when it is not available and may allow earlier treatment and reduce secondary injury caused by present and delayed haematomas.	[Leon-Carrion, Jose] Univ Seville, Dept Expt Psychol, Human Neuropsychol Lab, Seville 41018, Spain; [Leon-Carrion, Jose; Leon-Dominguez, Umberto] Ctr Brain Injury Rehabil CRECER, Seville, Spain; [Maria Dominguez-Roldan, Jose; Murillo-Cabezas, Francisco] Univ Hosp Virgen del Rocio, Hosp Traumatol, Intens Care Unit, Seville, Spain	Leon-Carrion, J (corresponding author), Univ Seville, Dept Expt Psychol, Human Neuropsychol Lab, C Camilo Jose Cela S-N, Seville 41018, Spain.	leoncarrion@us.es	Dominguez-Roldan, Jose-Maria/M-1728-2016; Murillo-Cabezas, Francisco/AAO-3348-2021; IBIS, NEUROCRITICOS/C-1805-2016	Dominguez-Roldan, Jose-Maria/0000-0003-1933-1478; Leon-Dominguez, Umberto/0000-0001-5170-2553			BARON EM, 2006, BRAIN INJURY MED PRI, P265; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; CALZAVACCA P, 2003, INTENS CARE MED, V34, P2112; Davella D, 2000, J Neurosurg Sci, V44, P19; de Bruijn S F T M, 2004, Ned Tijdschr Geneeskd, V148, P2209; Esselman PC, 2004, ARCH PHYS MED REHAB, V85, P1445, DOI 10.1016/j.apmr.2003.10.018; Formisano R, 2004, ACTA NEUROCHIR, V146, P457, DOI 10.1007/s00701-004-0225-4; FOULKES MA, 1991, J NEUROSURG, V75, pS8, DOI 10.3171/sup.1991.75.1s.00s8; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; GOPINATH SP, 1995, J NEUROSURG, V83, P438, DOI 10.3171/jns.1995.83.3.0438; GOPINATH SP, 1993, J NEUROSURG, V79, P43, DOI 10.3171/jns.1993.79.1.0043; Gururaj G, 2004, J Indian Med Assoc, V102, P157; KLIMMEK R, 1988, ARCH TOXICOL, V62, P152, DOI 10.1007/BF00570133; Leon-Carrion J, 2003, BRAIN INJURY, V17, P207, DOI 10.1080/0269905021000010249; Leon-Carrion Jose, 2005, Pituitary, V8, P197, DOI 10.1007/s11102-006-6041-5; Leon-Carrion J, 2006, STUD NEUROPSYCH DEV, P117; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Santalucia P, 2008, NEUROL SCI, V29, pS271, DOI 10.1007/s10072-008-0961-y; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Strangman G, 2002, BIOL PSYCHIAT, V52, P679, DOI 10.1016/S0006-3223(02)01550-0; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Tang ME, 2009, MT SINAI J MED, V76, P119, DOI 10.1002/msj.20106; Tieves Kelly S, 2005, WMJ, V104, P22; Wright RO, 1999, ANN EMERG MED, V34, P646, DOI 10.1016/S0196-0644(99)70167-8; Xiang HY, 2005, J TRAUMA, V58, P112, DOI 10.1097/01.TA.0000151270.26634.DD; Zygun DA, 2005, CAN J NEUROL SCI, V32, P87, DOI 10.1017/S0317167100016930	27	34	35	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2010	24	10					1193	1201		10.3109/02699052.2010.506636			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	667MJ	WOS:000283197100006	20715889				2021-06-18	
J	Livingston, LA; Kennedy, RE; Marwitz, JH; Arango-Lasprilla, JC; Rapport, LJ; Bushnik, T; Gary, KW				Livingston, Lee A.; Kennedy, Richard E.; Marwitz, Jennifer H.; Arango-Lasprilla, Juan C.; Rapport, Lisa J.; Bushnik, Tamara; Gary, Kelli W.			Predictors of family caregivers' life satisfaction after traumatic brain injury at one and two years post-injury: A longitudinal multi-center investigation	NEUROREHABILITATION			English	Article						Traumatic brain injury; caregivers; life satisfaction; family functioning	DISABILITY RATING-SCALE; GALVESTON ORIENTATION; AMNESIA TEST; SOCIAL SUPPORT; UNITED-STATES; MISSING-DATA; HEAD-INJURY; REHABILITATION; RELIABILITY; MEDICINE	Objective: To determine predictors of family caregiver life satisfaction at one and two years after traumatic brain injury (TBI). Methods: Prospective collaborative longitudinal study of 336 family members caring for individuals with TBI participating in the National Institute on Disability and Rehabilitation Research (NIDRR) designated TBI Model Systems of Care (TBIMS). Survivors' medical and demographic information was obtained from the TBIMS database. Follow-up interviews were completed with both survivors and family caregivers at 1 year and 2 years post injury. The primary outcome variable, caregiver life satisfaction, was measured with the Satisfaction with Life Scale (SWLS). Results: Repeated measures ordinal logistic regression showed that survivors' functional status at discharge, drug use, and neurobehavioral problems were significant predictors of family caregivers' life satisfaction at 1 and 2 years post injury. Conclusions: Family members of individuals with TBI often experience reduced life satisfaction in the first 2 years following their relatives' TBI. Psychiatric and neurobehavioral problems, such as drug use and depression, as well as motor dysfunction in survivors may be important contributors to decreased life satisfaction among their caregivers.	[Marwitz, Jennifer H.; Arango-Lasprilla, Juan C.; Gary, Kelli W.] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA 23298 USA; [Livingston, Lee A.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Kennedy, Richard E.] Univ Alabama, Dept Biostat, Birmingham, AL 35294 USA; [Rapport, Lisa J.] Wayne State Univ, Dept Psychol, Detroit, MI 48202 USA; [Bushnik, Tamara] Santa Clara Valley Med Ctr, San Jose, CA 95128 USA; [Bushnik, Tamara] Rusk Inst Rehabil Med, San Jose, CA USA	Marwitz, JH (corresponding author), Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Box 980542, Richmond, VA 23298 USA.	jhmarwit@vcu.edu					Anderson MI, 2002, BRAIN INJURY, V16, P743, DOI 10.1080/02699050210128906; Arango-Lasprilla JC, 2009, NEUROREHABILITATION, V24, P5, DOI 10.3233/NRE-2009-0449; Bode RK, 2000, J HEAD TRAUMA REHAB, V15, P637, DOI 10.1097/00001199-200002000-00004; Brzuzy S, 1997, SOC WORK HEALTH CARE, V26, P77, DOI 10.1300/J010v26n01_05; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; *CRAIG HOSP NAT DA, 2006, TRAUM BRAIN INJ MOD; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Enders CK, 2006, PSYCHOSOM MED, V68, P427, DOI 10.1097/01.psy.0000221275.75056.d8; Ergh TC, 2003, J CLIN EXP NEUROPSYC, V25, P1090, DOI 10.1076/jcen.25.8.1090.16735; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; Granger CV, 1986, TOP GERIATR REHABIL, V1, P59, DOI 10.1097/00013614-198604000-00007; HALL KM, 1994, ARCH PHYSICAL MED RE, V75, P10; Hall KM., 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199308020-00008, 10.1097/00001199-199308020-00008]; HALLAHAN DP, 1997, ADV LEARN BEHAV DISA, V11, P27; Hanks RA, 2007, NEUROREHABILITATION, V22, P43; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; Heinemann AW, 1997, ARCH PHYS MED REHAB, V78, P143, DOI 10.1016/S0003-9993(97)90255-0; Kolakowsky-Hayner SA, 2001, J HEAD TRAUMA REHAB, V16, P374, DOI 10.1097/00001199-200108000-00007; Kreutzer JS, 2009, ARCH PHYS MED REHAB, V90, P939, DOI 10.1016/j.apmr.2009.01.010; Kreutzer JS, 1996, ARCH PHYS MED REHAB, V77, P116, DOI 10.1016/S0003-9993(96)90155-0; Langlois JA., 2004, TRAUMATIC BRAIN INJU; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; MALHOTRA NK, 1987, J MARKETING RES, V24, P74, DOI 10.2307/3151755; Novack TA, 2000, J HEAD TRAUMA REHAB, V15, P957, DOI 10.1097/00001199-200006000-00008; Pavot W., 1993, PSYCHOL ASSESSMENT, V5, P164, DOI DOI 10.1037/1040-3590.5.2.164; R Development Core Team, 2008, R LANGUAGE ENV STAT; Ragnarsson KT, 2006, J HEAD TRAUMA REHAB, V21, P379, DOI 10.1097/00001199-200609000-00002; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; RAYMOND MR, 1987, EDUC PSYCHOL MEAS, V47, P13, DOI 10.1177/0013164487471002; Riley GA, 2007, CLIN REHABIL, V21, P82, DOI 10.1177/0269215506071279; Roche V, 2009, AM J MED SCI, V337, P199, DOI 10.1097/MAJ.0b013e31818b114d; ROTH PL, 1994, PERS PSYCHOL, V47, P537, DOI 10.1111/j.1744-6570.1994.tb01736.x; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; *SAS I INC, 1999, SAS; Schafer JL., 1997, ANAL INCOMPLETE MULT; State University of New York at Buffalo, 1997, GUID UN DAT SET MED; Stineman MG, 1996, ARCH PHYS MED REHAB, V77, P1101, DOI 10.1016/S0003-9993(96)90130-6; Stumpf S.A., 1978, THE J, V4, P65, DOI [10.1177/014920637800400107, DOI 10.1177/014920637800400107]; VANBUUREN S, 2009, R PACK VERS 1 21; VITALIANO PP, 1991, GERONTOLOGIST, V31, P76, DOI 10.1093/geront/31.1.76; Wagner AK, 2003, AM J PHYS MED REHAB, V82, P526, DOI 10.1097/00002060-200307000-00006; Wells R, 2005, BRAIN INJURY, V19, P1105, DOI 10.1080/02699050500150062; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P364, DOI 10.1097/00002060-199609000-00012; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	46	34	34	0	8	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135			NEUROREHABILITATION	Neurorehabilitation		2010	27	1					73	81		10.3233/NRE-2010-0582			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	629GA	WOS:000280182000007	20634602				2021-06-18	
J	Norup, A; Siert, L; Mortensen, EL				Norup, Anne; Siert, Lars; Mortensen, Erik Lykke			Emotional distress and quality of life in relatives of patients with severe brain injury: The first month after injury	BRAIN INJURY			English	Article						Relatives; severe brain injury; anxiety; depression; quality of life; emotional distress	SEVERE HEAD-INJURY; FOLLOW-UP; REHABILITATION; POPULATION; PREDICTORS; CARERS; HEALTH; ADULTS; SCALE	Primary objective: To investigate emotional distress and quality of life in a sample of Danish relatives of patients with severe brain injury at admission to intensive rehabilitation in the sub-acute phase. Research design: Clinical convenience sample. Methods and procedures: Participants included 31 primary relatives of patients with severe brain injury. The participants were recruited at admission to Traumatic Brain Injury Unit, Copenhagen University Hospital, Glostrup. All relatives completed the depression and anxiety scales from SCL-90-R (Symptom Checklist) and the Role Emotional, Social Function, Mental Health and Vitality scale of the SF-36 similar to 36 days after injury. Data concerning severity of injury, the patients' level of consciousness and function was also collected. Main outcome and results: The participants had significantly lower scores on all quality of life scales (p<50.01) and significantly more symptoms of anxiety (p<0.01) and depression (p<0.01) than normal reference populations. Correlations were found between the patients' condition and the level of anxiety and depression in relatives. Conclusions: The majority of relatives had severely impaired quality of life and symptoms of anxiety and depression at the time of admission. Future research should focus on developing and evaluating interventions in the acute phase.	[Mortensen, Erik Lykke] Univ Copenhagen, Inst Publ Hlth, Copenhagen, Denmark; [Mortensen, Erik Lykke] Univ Copenhagen, Ctr Healthy Aging, Copenhagen, Denmark; [Norup, Anne; Siert, Lars] Copenhagen Univ Hosp, Dept Neurorehabil, Traumat Brain Injury Unit, Glostrup, Denmark	Norup, A (corresponding author), Copenhagen Univ Hosp, Dept Neurorehabil, Traumat Brain Injury Unit, Kettegard 30, DK-2650 Hvidovre, Denmark.	anne.norup@hvh.regionh.dk		Norup, Anne/0000-0002-5598-6116; Mortensen, Erik Lykke/0000-0002-6985-451X	The Ludvig and Sara Elsass Foundation; Aase and Ejnar Danielsens Foundation; Ostifterne Association	The authors would like to thank all participants in the study and additionally acknowledge the support of the staff at Department of Neurorehabilitation, Traumatic Brain Injury Unit, Copenhagen University Hospital, Glostrup, Denmark as well as MD, PhD Karen-Lise Welling, Neuro Intensive Care Unit, Department of Neuroanaesthesiology, Rigshospitalet, Copenhagen University Hospital and MD Vagn Eskesen, Department of Neurosurgery, Rigshospitalet, Copenhagen University Hospital. The study was funded by grants from The Ludvig and Sara Elsass Foundation, Ostifterne Association and Aase and Ejnar Danielsens Foundation	Anderson MI, 2002, BRAIN INJURY, V16, P743, DOI 10.1080/02699050210128906; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BECH P, 2006, SCL 90 R VEJLEDNING; Beck A.T., 1987, BECK DEPRESSION INVE; BjOrner JB, 1997, DANSK MANUAL SF 36 S; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; *COP HOSP CORP, 2000, TRAUM BRAIN INJ UN; Derogatis LR, 1994, SCL 90 R SYMPTOM CHE; Douglas JM, 1996, BRAIN INJURY, V10, P819, DOI 10.1080/026990596123936; Engberg Aase Worsaae, 2007, Ugeskr Laeger, V169, P199; Engberg Aase Worsaae, 2007, Ugeskr Laeger, V169, P204; Engberg AW, 2006, ACTA NEUROL SCAND, V113, P178, DOI 10.1111/j.1600-0404.2005.00570.x; Florian V, 1991, Int Disabil Stud, V13, P150; Gan C, 2006, BRAIN INJURY, V20, P587, DOI 10.1080/02699050600743725; Gervasio AH, 1997, J HEAD TRAUMA REHAB, V12, P14, DOI 10.1097/00001199-199706000-00003; Hagen C, 1984, LANGUAGE DISORDERS A, P245; Hagen C., 1972, LEVELS COGNITIVE FUN; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Hickey AM, 1997, PSYCHOL HEALTH, V12, P827, DOI 10.1080/08870449708406743; HICKEY AM, 1992, IRISH MED J, V84, P109; Keith R A, 1987, Adv Clin Rehabil, V1, P6; KREUTZER JS, 1992, ARCH PHYS MED REHAB, V73, P771; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; Leathem J, 1996, BRAIN INJURY, V10, P27; Mauss-Clum N, 1981, J Neurosurg Nurs, V13, P165; McPherson KM, 2000, DISABIL REHABIL, V22, P683, DOI 10.1080/096382800445489; Moules S, 1999, BRAIN INJURY, V13, P983; *NAT BOARD HLTH, 1997, TREATM TRAUM NONTR B; NOVACK TA, 1991, J HEAD TRAUMA REHAB, V6, P69, DOI DOI 10.1097/00001199-199112000-00014; ODDY M, 1978, B BRIT PSYCHOL SOC, V31, P183; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; ODDY M, 1985, J CLIN EXP NEUROPSYC, V7, P165; Olsen LR, 2006, ACTA PSYCHIAT SCAND, V113, P477, DOI 10.1111/j.1600-0447.2005.00743.x; Panting A., 1972, REHABILITATION, V38, P33; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; Sander AM, 2002, BRAIN INJURY, V16, P649, DOI 10.1080/02699050210128889; Schmidt, 2000, NEUROL REHABIL, V6, P125; TEASDALE G, 1974, LANCET, V2, P81; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; THOMSEN IV, 1983, FOLIA PHONIATR, V35, P179	42	34	35	0	5	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2010	24	2					81	88		10.3109/02699050903508200			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	597BF	WOS:000277729500003	20085445				2021-06-18	
J	Imer, M; Omay, B; Uzunkol, A; Erdem, T; Sabanci, PA; Karasu, A; Albayrak, SB; Sencer, A; Hepgul, K; Kaya, M				Imer, Murat; Omay, Bulent; Uzunkol, Ajlan; Erdem, Tulin; Sabanci, Pulat Akin; Karasu, Aykut; Albayrak, Serdar Baki; Sencer, Altay; Hepgul, Kemal; Kaya, Mehmet			Effect of magnesium, MK-801 and combination of magnesium and MK-801 on blood-brain barrier permeability and brain edema after experimental traumatic diffuse brain injury	NEUROLOGICAL RESEARCH			English	Article						Diffuse brain injury; blood-brain barrier; brain edema; magnesium; MK-801	FOCAL CEREBRAL-ISCHEMIA; EXPERIMENTAL HEAD TRAUMA; ACUTE SUBDURAL-HEMATOMA; D-ASPARTATE ANTAGONISTS; RATS; THERAPY; INFARCTION; SULFATE; MODEL; REDUCTION	Objective: Glutamate antagonists are very attractive drugs in laboratory works to protect neural tissue against ischemia. In this work, the effects of magnesium, MK-801 and combination of magnesium and MK-801 on blood-brain barrier (BBB) and brain edema after experimentally induced traumatic brain injury are evaluated. Methods: A standard closed head injury was induced on the rats by a controlled impact device using a 450-g free falling mass from a height of 2 m onto a metallic disc fixed to the intact skull. One of the following was injected to animals intraperitoneally 30 minutes after injury: saline, magnesium, MK-801 and magnesium plus MK-801. To quantify the brain edema, the specific gravity of the brain tissue was determined. To demonstrate the alteration of the BBB permeability, Evans blue dye was used as a tracer. Results: In all treatment groups, the specific gravity of brain tissue values was significantly higher compared with the control group. Evans blue dye content in the brain tissue was significantly reduced in all three treatment groups with respect to the control group. There was no significant difference of effect between the groups of magnesium alone and MK-801 alone when compared with each other and when compared with their combination. Conclusion: The present data demonstrate that treatment with magnesium, MK-801 and combination of magnesium and MK-801 can reduce formation of brain edema and can help restore BBB permeability after experimental diffuse brain injury. [Neurol Res 2009; 31: 977-981]	[Sabanci, Pulat Akin] Istanbul Univ, Istanbul Fac Med, Dept Neurosurg, Istanbul, Turkey	Sabanci, PA (corresponding author), Istanbul Univ, Istanbul Fac Med, Dept Neurosurg, Istanbul, Turkey.	sabanci.akin@gmail.com	SABANCI, PULAT AKIN/AAT-1325-2020; Sencer, Altay/AAD-8002-2020; Hepgul, Kemal Tanju/AAV-1510-2020				Bareyre FM, 2000, J NEUROTRAUM, V17, P1029, DOI 10.1089/neu.2000.17.1029; Bareyre FM, 1999, J NEUROCHEM, V73, P271, DOI 10.1046/j.1471-4159.1999.0730271.x; CHAN PH, 1991, ANN NEUROL, V29, P482, DOI 10.1002/ana.410290506; CHEN MH, 1991, J NEUROSURG, V74, P944, DOI 10.3171/jns.1991.74.6.0944; CHI OZ, 1991, CIRC RES, V69, P414, DOI 10.1161/01.RES.69.2.414; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Davis M, 1997, ACT NEUR S, V70, P30; Esen F, 2003, J NEUROSURG ANESTH, V15, P119, DOI 10.1097/00008506-200304000-00009; Feldman Z, 1996, J NEUROSURG, V85, P131, DOI 10.3171/jns.1996.85.1.0131; Gorgulu A, 2000, ACTA NEUROCHIR, V142, P1287, DOI 10.1007/s007010070027; Heath DL, 1998, J NEUROTRAUM, V15, P183, DOI 10.1089/neu.1998.15.183; Heath DL, 1999, J PHARMACOL EXP THER, V288, P1311; Heath DL, 1995, J NEUROTRAUM, V12, P1027, DOI 10.1089/neu.1995.12.1027; Heath DL, 1999, J NEUROSURG, V90, P504, DOI 10.3171/jns.1999.90.3.0504; Heath DL, 1999, MAGNESIUM RES, V12, P269; Hoane MR, 2001, MAGNESIUM RES, V14, P51; Ikonomidou C, 2000, P NATL ACAD SCI USA, V97, P12885, DOI 10.1073/pnas.220412197; Kaya M, 2001, CAN J PHYSIOL PHARM, V79, P793, DOI 10.1139/cjpp-79-9-793; KOENIG H, 1992, BRAIN RES, V588, P297, DOI 10.1016/0006-8993(92)91589-7; KURODA Y, 1994, NEUROSURGERY, V35, P106, DOI 10.1227/00006123-199407000-00016; MARMAROU A, 1978, J NEUROSURG, V49, P530, DOI 10.3171/jns.1978.49.4.0530; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; Schmid-Elsaesser R, 1999, NEUROSURGERY, V44, P163, DOI 10.1097/00006123-199901000-00100; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; Ustun ME, 2001, J NEUROSURG ANESTH, V13, P227; Ustun ME, 2001, INTENS CARE MED, V27, P264, DOI 10.1007/s001340000780; YANG GY, 1994, NEUROSURGERY, V34, P339, DOI 10.1097/00006123-199402000-00018	29	34	35	0	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	NOV	2009	31	9					977	981		10.1179/174313209X385617			5	Clinical Neurology; Neurosciences	Neurosciences & Neurology	530XQ	WOS:000272626700015	19215660				2021-06-18	
J	Novack, TA; Banos, JH; Brunner, R; Renfroe, S; Meythaler, JM				Novack, Thomas A.; Banos, James H.; Brunner, Robert; Renfroe, Sharon; Meythaler, Jay M.			Impact of Early Administration of Sertraline on Depressive Symptoms in the First Year after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						adult brain injury; clinical trial; head trauma	QUALITY-OF-LIFE; HEAD-INJURY; RATING-SCALE; MODEL SYSTEMS; DISORDERS; MOOD; PARTICIPATION; MORBIDITY; SEROTONIN; COMA	The potential for sertraline administered in the first 3 months after moderate to severe traumatic brain injury (TBI) to decrease the incidence of depression in the first year after injury was assessed in a double-blinded randomized control trial. Subjects were enrolled an average of 21 days after injury (none > 8 weeks) followed by oral administration of placebo (50 subjects) or sertraline 50 mg (49 subjects) for 3 months. Subjects were not depressed at the time of study initiation. Outcome was assessed using the Hamilton Depression Rating Scale (HDRS) and the Depression Scale of the Neurobehavioral Functioning Inventory (NFI). Based on intent-to-treat and efficacy subset analyses, those receiving placebo exhibited significantly greater depressive symptoms than those receiving sertraline during the first 3 months after injury while receiving placebo/drug (10% of placebo group achieving a score of 6 or greater on the HDRS, 0% of the sertraline group; p < 0.023.). There was no significant difference in depressive symptoms during the remainder of the year between the two groups. Sertraline is effective in diminishing depressive symptoms even among those not clinically depressed while the medication is being taken. However, the results do not support the idea that administration early in recovery diminishes the expression of depressive symptoms after the drug is stopped. There is no basis from this study to assume that sertraline administered early in recovery after TBI, when neurotransmitter functioning is often altered, has ongoing effects on the serotonin system after sertraline is discontinued.	[Novack, Thomas A.; Banos, James H.; Brunner, Robert; Renfroe, Sharon] Univ Alabama Birmingham, Dept Phys Med & Rehabil, Birmingham, AL 35249 USA; [Meythaler, Jay M.] Wayne State Univ, Dept Phys Med & Rehabil, Detroit, MI USA	Novack, TA (corresponding author), Univ Alabama Birmingham, Dept Phys Med & Rehabil, SRC 530,619 19th St S, Birmingham, AL 35249 USA.	Novack@uab.edu			National Institute of Disability and Rehabilitation Research [H133A980010]	This project was supported by the National Institute of Disability and Rehabilitation Research Grant H133A980010 Traumatic Brain Injury Model System Project.	Belmaker RH, 2008, NEW ENGL J MED, V358, P55, DOI 10.1056/NEJMra073096; Bowen A, 1998, BRAIN INJURY, V12, P177, DOI 10.1080/026990598122656; Bowen A, 1999, BRAIN INJURY, V13, P547; Breed ST, 2004, ARCH PHYS MED REHAB, V85, pS61, DOI 10.1016/j.apmr.2003.08.115; Brown M, 2003, REHABIL PSYCHOL, V48, P266, DOI 10.1037/0090-5550.48.4.266; CASSIDY JW, 1989, J HEAD TRAUMA REHAB, V4, P67; Deb S, 1999, AM J PSYCHIAT, V156, P374; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Douglas JM, 2000, BRAIN INJURY, V14, P71, DOI 10.1080/026990500120943; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; Fann JR, 2000, J NEUROPSYCH CLIN N, V12, P226, DOI 10.1176/appi.neuropsych.12.2.226; Faries D, 2000, J PSYCHIAT RES, V34, P3, DOI 10.1016/S0022-3956(99)00037-0; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; Glenn MB, 2001, BRAIN INJURY, V15, P811, DOI 10.1080/02699050010025777; GomezHernandez R, 1997, ARCH PHYS MED REHAB, V78, P1321, DOI 10.1016/S0003-9993(97)90304-X; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; Karakucuk EI, 1997, NEUROPEPTIDES, V31, P259, DOI 10.1016/S0143-4179(97)90057-3; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; Kreutzer JS., 1999, NEUROBEHAVIORAL FUNC; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; Lee H, 2005, HUM PSYCHOPHARM CLIN, V20, P97, DOI 10.1002/hup.668; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LINDEN M, 1995, ACTA PSYCHIAT SCAND, V92, P150, DOI 10.1111/j.1600-0447.1995.tb09559.x; MARKIANOS M, 1992, ACTA NEUROL SCAND, V86, P190, DOI 10.1111/j.1600-0404.1992.tb05064.x; Meythaler JM, 2001, BRAIN INJURY, V15, P321, DOI 10.1080/026990501750111274; Minderhoud JM., 1990, PHYS MED REHABILITAT, V4, P447; Moller HJ, 2001, EUR ARCH PSY CLIN N, V251, P13; NAYAK AK, 1980, J NEUROL SCI, V47, P211, DOI 10.1016/0022-510X(80)90005-2; O'Donnell ML, 2004, AM J PSYCHIAT, V161, P507, DOI 10.1176/appi.ajp.161.3.507; OSullivan RL, 1997, ACTA PSYCHIAT SCAND, V95, P379, DOI 10.1111/j.1600-0447.1997.tb09649.x; Perino C, 2001, BRAIN INJURY, V15, P139, DOI 10.1080/026990501458371; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Rogers JM, 2007, BRAIN INJURY, V21, P1321, DOI 10.1080/02699050701765700; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; SALZMAN SK, 1987, J NEUROSURG, V66, P431, DOI 10.3171/jns.1987.66.3.0431; SARAN AS, 1985, J CLIN PSYCHIAT, V46, P335; Seel RT, 1997, ARCH PHYS MED REHAB, V78, P1254, DOI 10.1016/S0003-9993(97)90340-3; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; SHARMA HS, 1989, PHARMACOLOGY OF CEREBRAL ISCHEMIA 1988, P317; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; SIMON G, 2003, J PSYCHIATR RES, V27, P247; Snaith RP, 1996, BRIT J PSYCHIAT, V168, P594, DOI 10.1192/bjp.168.5.594; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; Stein PN, 1996, CLIN NEUROPSYCHOL, V10, P141, DOI 10.1080/13854049608406674; WHITAKERAZMITIA PM, 1990, ANN NY ACAD SCI, V600, P315, DOI 10.1111/j.1749-6632.1990.tb16892.x; Williams JBW, 2001, EUR ARCH PSY CLIN N, V251, P6, DOI 10.1007/BF03035120; Zauner A, 1996, TRAUMATIC BRAIN INJU, P97	51	34	34	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2009	26	11					1921	1928		10.1089/neu.2009.0895			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	523CO	WOS:000272049600007	19929217				2021-06-18	
J	Shulga, A; Blaesse, A; Kysenius, K; Huttunen, HJ; Tanhuanpaa, K; Saarma, M; Rivera, C				Shulga, Anastasia; Blaesse, Anne; Kysenius, Kai; Huttunen, Henri J.; Tanhuanpaa, Kimmo; Saarma, Mart; Rivera, Claudio			Thyroxin regulates BDNF expression to promote survival of injured neurons	MOLECULAR AND CELLULAR NEUROSCIENCE			English	Article						BDNF; Thyroxin; KCC2; Trophic support; Axotomy; Time-lapse microscopy		A growing amount of evidence indicates that neuronal trauma can induce a recapitulation of developmental-like mechanisms for neuronal survival and regeneration. Concurringly, ontogenic dependency of central neurons for brain-derived neurotrophic factor (BDNF) is lost during maturation but is re-acquired after injury. Here we show in organotypic hippocampal slices that thyroxin, the thyroid hormone essential for normal CNS development, induces up-regulation of BDNF upon injury. This change in the effect of thyroxin is crucial to promote survival and regeneration of damaged central neurons. In addition, the effect of thyroxin on the expression of the K-Cl cotransporter (KCC2), a marker of neuronal maturation, is changed from down to up-regulation. Notably, previous results in humans have shown that during the first few days after traumatic brain injury or spinal cord injury, thyroid hormone levels are often diminished. Our data suggest that maintaining normal levels of thyroxin during the early post-traumatic phase of CNS injury could have a therapeutically positive effect. (C) 2009 Elsevier Inc. All rights reserved.	[Shulga, Anastasia; Blaesse, Anne; Tanhuanpaa, Kimmo; Saarma, Mart; Rivera, Claudio] Univ Helsinki, Inst Biotechnol, Viikki Bioctr, FIN-00014 Helsinki, Finland; [Kysenius, Kai; Huttunen, Henri J.] Univ Helsinki, Ctr Neurosci, FIN-00014 Helsinki, Finland	Rivera, C (corresponding author), Univ Helsinki, Inst Biotechnol, Viikki Bioctr, Viikinkaari 9, FIN-00014 Helsinki, Finland.	Claudio.rivera@helsinki.fi	Kysenius, Kai/U-6388-2019	Kysenius, Kai/0000-0003-1038-2850; Shulga, Anastasia/0000-0003-0262-3570; Huttunen, Henri/0000-0002-9867-4438; Rivera, Claudio/0000-0003-2462-6561	Academy of FinlandAcademy of FinlandEuropean Commission; University of Helsinki, Biocentrum Helsinki; Sigrid Juselius FoundationSigrid Juselius Foundation; Helsinki Biomedical Graduate School	We thank Pavel Uvarov for providing expertise for real-time PCR and Miika Palviainen and Marjo Heikura for excellent technical assistance. This work was supported by grants from the Academy of Finland, from the University of Helsinki, Biocentrum Helsinki and from the Sigrid Juselius Foundation and Helsinki Biomedical Graduate School.	Aguado F, 2003, DEVELOPMENT, V130, P1267, DOI 10.1242/dev.00351; Barakat-Walter I, 1999, J NEUROBIOL, V40, P541, DOI 10.1002/(SICI)1097-4695(19990915)40:4<541::AID-NEU10>3.0.CO;2-Q; Barakat-Walter I, 2007, J NEUROTRAUM, V24, P567, DOI 10.1089/neu.2006.0104; BAUMAN WA, 2000, PHYS MED REH CLIN N, V1, P109; Benowitz LI, 1997, TRENDS NEUROSCI, V20, P84, DOI 10.1016/S0166-2236(96)10072-2; Bernal J, 2005, VITAM HORM, V71, P95, DOI 10.1016/S0083-6729(05)71004-9; Blaesse P, 2009, NEURON, V61, P820, DOI 10.1016/j.neuron.2009.03.003; BRADLEY DJ, 1989, P NATL ACAD SCI USA, V86, P7250, DOI 10.1073/pnas.86.18.7250; BUGARESTI JM, 1992, PARAPLEGIA, V30, P401, DOI 10.1038/sc.1992.90; Burton A, 2005, LANCET NEUROL, V4, P18, DOI 10.1016/S1474-4422(04)00958-5; Calza L, 2005, BRAIN RES REV, V48, P339, DOI 10.1016/j.brainresrev.2004.12.022; Calza L, 2002, P NATL ACAD SCI USA, V99, P3258, DOI 10.1073/pnas.052704499; Camboni D, 2003, NEUROSCI LETT, V350, P141, DOI 10.1016/S0304-3940(03)00880-2; Carmona MA, 2006, CEREB CORTEX, V16, P47, DOI 10.1093/cercor/bhi083; Cernak I, 1999, BRAIN INJURY, V13, P1005; Chong JSWLV, 2000, INT J CLIN PRACT, V54, P621; Conner JM, 1997, J NEUROSCI, V17, P2295; Cramer SC, 2000, TRENDS NEUROSCI, V23, P265, DOI 10.1016/S0166-2236(00)01562-9; D'Intino G, 2006, NEUROL RES, V28, P513, DOI 10.1179/016164106X116773; De Groot LJ, 1999, J CLIN ENDOCR METAB, V84, P151, DOI 10.1210/jc.84.1.151; FACKTOR MA, 1993, RESUSCITATION, V26, P141, DOI 10.1016/0300-9572(93)90174-O; Fernandez M, 2004, P NATL ACAD SCI USA, V101, P16363, DOI 10.1073/pnas.0407262101; Finkbeiner S, 1997, NEURON, V19, P1031, DOI 10.1016/S0896-6273(00)80395-5; Friauf E, 2008, EUR J NEUROSCI, V28, P2371, DOI 10.1111/j.1460-9568.2008.06528.x; GENUTH SM, 2004, PHYSIOLOGY; Gonzalez SL, 2005, J STEROID BIOCHEM, V94, P143, DOI 10.1016/j.jsbmb.2005.01.016; Harel NY, 2006, NAT REV NEUROSCI, V7, P603, DOI 10.1038/nrn1957; JABBARI B, 1980, EPILEPSIA, V21, P91, DOI 10.1111/j.1528-1157.1980.tb04048.x; Kilby MD, 2003, CLIN ENDOCRINOL, V59, P280, DOI 10.1046/j.1365-2265.2003.01804.x; Koibuchi N, 2001, THYROID, V11, P205, DOI 10.1089/105072501750159534; KORCZYN AD, 1976, EPILEPSIA, V17, P33, DOI 10.1111/j.1528-1157.1976.tb03378.x; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; LINDHOLM D, 1994, J NEUROBIOL, V25, P1362, DOI 10.1002/neu.480251105; Lipska BK, 2001, EUR J NEUROSCI, V14, P135, DOI 10.1046/j.1460-9568.2001.01633.x; Ludwig A, 2003, EUR J NEUROSCI, V18, P3199, DOI 10.1111/j.1460-9568.2003.03069.x; Luesse HG, 1998, EXP BRAIN RES, V119, P1, DOI 10.1007/s002210050313; Mamounas LA, 2000, J NEUROSCI, V20, P771, DOI 10.1523/JNEUROSCI.20-02-00771.2000; Nabekura J, 2002, J NEUROSCI, V22, P4412, DOI 10.1523/JNEUROSCI.22-11-04412.2002; Neveu I, 1996, J CELL BIOL, V133, P631, DOI 10.1083/jcb.133.3.631; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Oble DA, 2004, EXP NEUROL, V189, P105, DOI 10.1016/j.expneurol.2004.05.024; Payne JA, 2003, TRENDS NEUROSCI, V26, P199, DOI 10.1016/S0166-2236(03)00068-7; Rivera C, 2004, J NEUROSCI, V24, P4683, DOI 10.1523/JNEUROSCI.5265-03.2004; Rivera C, 1999, NATURE, V397, P251; RIVERA C, 2005, J PHYSL, P27; Schenker M, 2003, EXP NEUROL, V184, P225, DOI 10.1016/S0014-4886(03)00255-3; Shulga A, 2008, J NEUROSCI, V28, P6996, DOI 10.1523/JNEUROSCI.5268-07.2008; SU YH, 1993, EPILEPSIA, V34, P488, DOI 10.1111/j.1528-1157.1993.tb02589.x; TATOR CH, 1983, J NEUROSURG, V58, P406, DOI 10.3171/jns.1983.58.3.0406; TATOR CH, 1980, J NEUROSURG, V53, P381, DOI 10.3171/jns.1980.53.3.0381; TATOR CH, 1982, SURG NEUROL, V18, P64, DOI 10.1016/0090-3019(82)90021-0; Tatsumi K, 2005, NEUROCHEM INT, V46, P381, DOI 10.1016/j.neuint.2004.12.007; Taylor AM, 2005, NAT METHODS, V2, P599, DOI 10.1038/NMETH777; Tenedieva V. D., 2000, V76, P385; Tentes I, 2003, IN VIVO, V17, P601; Tornberg J, 2005, EUR J NEUROSCI, V21, P1327, DOI 10.1111/j.1460-9568.2005.03959.x; Toyoda H, 2003, J NEUROPHYSIOL, V89, P1353, DOI 10.1152/jn.00721.2002; Uvarov P, 2005, J NEUROCHEM, V95, P1144, DOI 10.1111/j.1471-4159.2005.03434.x; Voria I, 2006, EXP NEUROL, V197, P258, DOI 10.1016/j.expneurol.2005.10.001; Willems E, 2006, INT J DEV BIOL, V50, P627, DOI 10.1387/ijdb.052130ew; Ying Z, 2005, EXP NEUROL, V193, P411, DOI 10.1016/j.expneurol.2005.01.015; ZHOU M, 2003, SICHUAN DAXUE XUEBAO, V4, P713	62	34	36	0	5	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1044-7431	1095-9327		MOL CELL NEUROSCI	Mol. Cell. Neurosci.	NOV	2009	42	4					408	418		10.1016/j.mcn.2009.09.002			11	Neurosciences	Neurosciences & Neurology	524CI	WOS:000272121000015	19765661				2021-06-18	
J	Wright, JK; Zant, E; Groom, K; Schlegel, RE; Gilliland, K				Wright, James K.; Zant, Eddie; Groom, Kevin; Schlegel, Robert E.; Gilliland, Kirby			Case report: Treatment of mild traumatic brain injury with hyperbaric oxygen	UNDERSEA AND HYPERBARIC MEDICINE			English	Article							NEUROPSYCHOLOGICAL ASSESSMENT METRICS; NEURAL STEM-CELLS; COGNITIVE RECOVERY; THERAPY; SPORTS; DAMAGE; RATS	Two United States Air Force Airmen were injured in a roadside improvised explosive device (IED) blast in Iraq in January 2008. Both airmen suffered concussive injuries and developed irritability, sleep disturbances, headaches, memory difficulties and cognitive difficulties as symptoms of mild traumatic brain injury (mTBI). Six months after injury, repeat Automated Neuropsychological Assessment Metrics (ANAM) testing showed deterioration, when compared to pre-injury baseline ANAM assessment, in all measured areas (simple reaction time, procedural reaction time, code substitution learning, code substitution delayed, mathematical processing, and matching to sample). The airmen were treated with hyperbaric oxygen in treatments of 100% oxygen for one hour at 1.5 atmospheres absolute, resulting in rapid improvement of headaches and sleep disturbances, improvement in all symptoms and resolution of most symptoms. Repeat ANAM testing after completion of the hyperbaric treatments - nine months after initial injury - showed improvement in all areas, with most measures improving to pre-injury baseline levels. The airmen received no other treatment besides medical monitoring. Repeat neuropsychologic testing confirmed the improvement. We conclude that the improvement in symptoms and ANAM performance is most likely attributable to HBO treatment.	[Wright, James K.] 720th Special Tact Grp, Hurlburt Field, FL USA; [Zant, Eddie] Hyperbar Med Inc, Ft Walton Beach, FL USA; [Groom, Kevin] Anchor Clin, Destin, FL USA; [Schlegel, Robert E.; Gilliland, Kirby] Univ Oklahoma, Ctr Study Human Operator Performance, Norman, OK 73019 USA	Wright, JK (corresponding author), 720th Special Tact Grp, Hurlburt Field, FL USA.						ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Andersson EE, 2007, ACTA NEUROCHIR, V149, P151, DOI 10.1007/s00701-006-1082-0; Andersson EE, 2006, J REHABIL MED, V38, P26, DOI 10.1080/16501970500310564; Arciniegas David B, 2005, Neuropsychiatr Dis Treat, V1, P311; *ASS SECR DEF HLTH, 2007, TRAUM BRAIN INJ DEF; Biasca N, 2007, PROG BRAIN RES, V161, P263, DOI 10.1016/S0079-6123(06)61019-4; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cernich A, 2007, ARCH CLIN NEUROPSYCH, V22, pS101, DOI 10.1016/j.acn.2006.10.008; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; *DEP VET AFF, 2004, VET HLTH IN TRAUM BR; Gamboa AM, 2006, NEUROREHABILITATION, V21, P327; Harch PG, 2007, BRAIN RES, V1174, P120, DOI 10.1016/j.brainres.2007.06.105; Harch Paul G, 2009, Cases J, V2, P6538, DOI 10.4076/1757-1626-2-6538; Kelly JP, 1997, NEUROLOGY, V48, P581; Lin JW, 2008, ACTA NEUROCHIR SUPPL, V101, P145; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Palzur E, 2008, BRAIN RES, V1221, P126, DOI 10.1016/j.brainres.2008.04.078; Peng ZY, 2008, BRAIN RES, V1212, P71, DOI 10.1016/j.brainres.2008.03.027; Randolph C, 1998, REPEATABLE BATTERY A; Rockswold SB, 2007, NEUROL RES, V29, P162, DOI 10.1179/016164107X181798; Segalowitz SJ, 2007, NEUROREHABILITATION, V22, P243; Shi Xiao-yan, 2003, Chin J Traumatol, V6, P346; Sigurdardottir S, 2009, J INT NEUROPSYCH SOC, V15, P740, DOI 10.1017/S1355617709990452; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Tinianow CL, 2000, BIOMED SCI INSTRUM, V395, P275; Vincent AS, 2008, MIL MED, V173, P836, DOI 10.7205/MILMED.173.9.836; Wang XL, 2008, BRAIN RES, V1222, P87, DOI 10.1016/j.brainres.2008.05.016; Wang XL, 2007, NEUROREPORT, V18, P1753, DOI 10.1097/WNR.0b013e3282f0ec09; Yang YJ, 2008, UNDERSEA HYPERBAR M, V35, P113; Zhou ZW, 2007, J NEUROSURG, V106, P687, DOI 10.3171/jns.2007.106.4.687	30	34	37	0	9	UNDERSEA & HYPERBARIC MEDICAL SOC INC	DURHAM	21 WEST COLONY PLACE, STE 280, DURHAM, NC 27705 USA	1066-2936			UNDERSEA HYPERBAR M	Undersea Hyperb. Med.	NOV-DEC	2009	36	6					391	399					9	Marine & Freshwater Biology; Medicine, Research & Experimental	Marine & Freshwater Biology; Research & Experimental Medicine	541IB	WOS:000273407400001	20112530				2021-06-18	
J	Castellani, G; Zweifel, C; Kim, DJ; Carrera, E; Radolovich, DK; Smielewski, P; Hutchinson, PJ; Pickard, JD; Czosnyka, M				Castellani, Gianluca; Zweifel, Christian; Kim, Dong-Joo; Carrera, Emmanuel; Radolovich, Danila K.; Smielewski, Piotr; Hutchinson, Peter J.; Pickard, John D.; Czosnyka, Marek			Plateau Waves in Head Injured Patients Requiring Neurocritical Care	NEUROCRITICAL CARE			English	Article						Intracranial pressure; Cerebral perfusion pressure; Traumatic brain injury; Cerebral autoregulation; Plateau waves; TBI outcome	CEREBROVASCULAR PRESSURE TRANSMISSION; CEREBRAL PERFUSION-PRESSURE; TRAUMATIC BRAIN-INJURY; INTRACRANIAL HYPERTENSION; COMPUTERIZED-TOMOGRAPHY; ONLINE ANALYSIS; SOFTWARE; MODEL	Plateau waves often develop in neurointensive care patients. They are sudden increases in intracranial pressure (ICP) that lead to dramatic decreases of cerebral perfusion pressure (CPP) and can therefore contribute to ischemic secondary brain insult. The aim of this study was to analyze the occurrence of plateau waves in head injured patients requiring neurocritical care, their relation with cerebral autoregulation and impact on outcome. Data were analyzed retrospectively in 444 head injured patients admitted to Neuroscience Critical Care Unit of Addenbrooke's Hospital in Cambridge, UK. Arterial blood pressure (ABP), intracranial pressure (ICP), heart rate (HR) were digitally recorded and derived indices calculated. Primary monitoring data, autoregulation indices, outcome of patients, initial CT findings (in a subgroup of patients), brain tissue monitoring data (in a subgroup) were compared between patients who developed plateau waves and those who did not. Plateau waves were observed in 109/444 patients (24.5%). They were significantly more frequent in younger patients. Impaired cerebrovascular pressure reactivity and depleted compensatory reserve were associated with vasodilatation on the top of the wave. Plateau waves were not associated with poorer outcome unless the episodes lasted for a long time (longer than 30-40 min). Plateau waves were more frequently seen in patients with lesser midline shift, lower volume of contusion on CT scan, absence of skull fractures, and lower brain tissue concentration of carbon dioxide. Plateau waves are frequent phenomenon. They are not associated with worse outcome unless they lead to sustained intracranial hypertension.	[Czosnyka, Marek] Univ Cambridge, Addenbrookes Hosp, Dept Clin Neurosci, Neurosurg Unit, Cambridge CB2 2QQ, England; [Castellani, Gianluca; Zweifel, Christian; Kim, Dong-Joo; Carrera, Emmanuel; Radolovich, Danila K.; Smielewski, Piotr; Hutchinson, Peter J.; Pickard, John D.; Czosnyka, Marek] Univ Cambridge, Addenbrookes Hosp, Acad Neurosurg Unit, Cambridge CB2 2QQ, England; [Castellani, Gianluca] Univ Pavia, Anaesthesia & Intens Care Sch, I-27100 Pavia, Italy; [Kim, Dong-Joo] Univ Cambridge, Dept Engn, Cambridge CB2 2QQ, England; [Radolovich, Danila K.] Policlin San Matteo, Serv Anestesia & Rianimaz 2, I-27100 Pavia, Italy	Czosnyka, M (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Clin Neurosci, Neurosurg Unit, Level 4,A Ward,Box 167, Cambridge CB2 2QQ, England.	g.l.castellani@tiscali.it; mc141@medschl.cam.ac.uk		Smielewski, Peter/0000-0001-5096-3938; Carrera, Emmanuel/0000-0003-0045-5382	National institute of Health Research Biomedical Research centerNational Institute for Health Research (NIHR); Cambridge University Hospital Foundation Trust-Neurosciences Theme; Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission [PBBSP3-125550, PASSMP3-124262]; SICPA Foundation, Lausanne, Switzerland.; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390, G0601025, G0600986, G0001237] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0508-10327] Funding Source: researchfish	The authors are in debt to all the team participating in data collection: Mrs. Pippa Al-Rawi, Mrs. Helen Seley, Mrs. Carole Turner, Dr. Marcella Balestreri, Dr. Magda Hiler, Dr. Luzius Steiner, Dr. Eric Schmidt, Dr. Stefan Piechnik, Dr. Andreas Raabe, Mr. Eric Guazzo, Dr. David Menon, Dr. Arun Gupta, Dr. Basil Matta, Mr. Peter Kirkpatrick, Mr. Ivan Timofyeyev, Mr. Pwawanjit Minhas, Mr. Rodney Laing, and all nursing and research staff of NCCU and Wolfson Brain Imaging Centre. The project was supported by National institute of Health Research Biomedical Research center, Cambridge University Hospital Foundation Trust-Neurosciences Theme. Further support was achieved from the Swiss National Science Foundation (PBBSP3-125550 to CZ and PASSMP3-124262 to EC), Bern, Switzerland. EC was additionally supported by the SICPA Foundation, Lausanne, Switzerland.	Balestreri M, 2006, NEUROCRIT CARE, V4, P8, DOI 10.1385/NCC:4:1:008; Czosnyka M, 1999, J NEUROSURG, V91, P11, DOI 10.3171/jns.1999.91.1.0011; Daley ML, 2006, ACTA NEUROCHIR SUPPL, V96, P103; Daley ML, 2005, ACT NEUR S, V95, P327; Guendling K, 2006, ACTA NEUROCHIR SUPPL, V96, P108; HAYASHI M, 1991, BRAIN, V114, P2693, DOI 10.1093/brain/114.6.2693; HAYASHI M, 1987, J NEUROSURG, V67, P97, DOI 10.3171/jns.1987.67.1.0097; HAYASHI M, 1991, BRAIN, V114, P2681, DOI 10.1093/brain/114.6.2681; HAYASHI M, 1984, J NEUROSURG, V61, P30, DOI 10.3171/jns.1984.61.1.0030; Hiler M, 2006, J NEUROSURG, V104, P731, DOI 10.3171/jns.2006.104.5.731; Imberti R, 2005, J NEUROSURG, V102, P455, DOI 10.3171/jns.2005.102.3.0455; LUNDBERG N, 1960, ACTA PSYCHIAT NEUROL, V149, P158; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; RENIER D, 1982, J NEUROSURG, V57, P370, DOI 10.3171/jns.1982.57.3.0370; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; ROSNER MJ, 1984, J NEUROSURG, V60, P312, DOI 10.3171/jns.1984.60.2.0312; Schmidt B, 1999, J CEREBR BLOOD F MET, V19, P990, DOI 10.1097/00004647-199909000-00006; Smielewski P, 2005, ACT NEUR S, V95, P43; Stevens SA, 2008, IEEE T BIO-MED ENG, V55, P388, DOI 10.1109/TBME.2007.900552; Vik A, 2008, J NEUROSURG, V109, P678, DOI 10.3171/JNS/2008/109/10/0678	21	34	37	0	6	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	OCT	2009	11	2					143	150		10.1007/s12028-009-9235-7			8	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	495OG	WOS:000269902300003	19565359				2021-06-18	
J	Diedler, J; Sykora, M; Bast, T; Poli, S; Veltkamp, R; Mellado, P; Steiner, T; Rupp, A				Diedler, Jennifer; Sykora, Marek; Bast, Thomas; Poli, Sven; Veltkamp, Roland; Mellado, Patricio; Steiner, Thorsten; Rupp, Andre			Quantitative EEG Correlates of Low Cerebral Perfusion in Severe Stroke	NEUROCRITICAL CARE			English	Article						Continuous EEG; Multimodality brain monitoring; Cerebral perfusion pressure; Stroke	ACUTE ISCHEMIC-STROKE; GRADE SUBARACHNOID HEMORRHAGE; TRAUMATIC BRAIN-INJURY; CAROTID-ENDARTERECTOMY; INTRACEREBRAL HEMORRHAGE; BLOOD-FLOW; BISPECTRAL INDEX; MALIGNANT COURSE; SYMMETRY-INDEX; PRESSURE	Continuous EEG provides the unique possibility to monitor neuronal function non-invasively. In our pilot study, we evaluated EEG spectral power during spontaneous drops in cerebral perfusion pressure (CPP) in deeply sedated and mechanically ventilated patients with severe stroke. We aimed to identify parameters that may be used for continuous monitoring even in patients with a burst-suppression baseline EEG pattern. Twenty ventilated and sedated patients with severe hemorrhagic or ischemic stroke underwent continuous EEG monitoring with synchronous CPP recording. EEG monitoring duration was 83.9 hours on average per patient. Spectral power of EEG during drops of CPP was compared with epochs during normal CPP under the same levels of sedation. We found a significant decrease in faster EEG activity (3.5-20.7 Hz) during phases of low CPP (unaffected hemisphere P < 0.01, affected hemisphere P < 0.01, both P < 0.01). Despite considerable changes in baseline activity due to deep sedation and severe brain injury, we found evidence for disturbed neuronal function during drops in CPP. Thus, continuous EEG monitoring may add clinically relevant information on neuronal function in the setting of multimodality brain monitoring. Further studies are needed to implement real-time data analysis in the ICU setting.	[Diedler, Jennifer; Sykora, Marek; Poli, Sven; Veltkamp, Roland; Mellado, Patricio; Steiner, Thorsten; Rupp, Andre] Heidelberg Univ, Dept Neurol, D-69120 Heidelberg, Germany; [Sykora, Marek] Comenius Univ, Dept Neurol, Bratislava 81369, Slovakia; [Bast, Thomas] Heidelberg Univ, Dept Pediat Neurol, D-69120 Heidelberg, Germany; [Mellado, Patricio] Pontificia Univ Catolica Chile, Dept Neurol, Santiago, Chile	Diedler, J (corresponding author), Heidelberg Univ, Dept Neurol, Neuenheimer Feld 400, D-69120 Heidelberg, Germany.	jennifer.diedler@med.uni-heidelberg.de	Steiner, Thorsten/A-7391-2014; Steiner, Thorsten/L-2868-2018	Steiner, Thorsten/0000-0002-5080-8222			ADAMS DC, 1995, ANESTH ANALG, V81, P80, DOI 10.1097/00000539-199507000-00016; Adams HP, 2007, CIRCULATION, V115, pE478, DOI 10.1161/CIRCULATIONAHA.107.181486; Berger C, 2005, STROKE, V36, pE4, DOI 10.1161/01.STR.0000151328.70519.e9; BERGER C, 2008, NEUROCRIT CARE; BLAIR RC, 1993, PSYCHOPHYSIOLOGY, V30, P518, DOI 10.1111/j.1469-8986.1993.tb02075.x; Blume WT, 2006, J CLIN NEUROPHYSIOL, V23, P306, DOI 10.1097/01.wnp.0000229137.94384.fa; BLUME WT, 1986, STROKE, V17, P891, DOI 10.1161/01.STR.17.5.891; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Broderick J, 2007, CIRCULATION, V116, pE391, DOI 10.1161/CIRCULATIONAHA.107.183689; BRODERICK JP, 1993, STROKE, V24, P987, DOI 10.1161/01.STR.24.7.987; Burghaus L, 2007, CLIN NEUROL NEUROSUR, V109, P45, DOI 10.1016/j.clineuro.2006.06.003; CHIAPPA KH, 1979, STROKE, V10, P381, DOI 10.1161/01.STR.10.4.381; Claassen J, 2006, NEUROCRIT CARE, V4, P103, DOI 10.1385/NCC:4:2:103; Claassen J, 2004, CLIN NEUROPHYSIOL, V115, P2699, DOI 10.1016/j.clinph.2004.06.017; Claassen Jan, 2002, Curr Neurol Neurosci Rep, V2, P534, DOI 10.1007/s11910-002-0042-1; de Vos CC, 2008, J CLIN NEUROPHYSIOL, V25, P77, DOI 10.1097/WNP.0b013e31816ef725; Diringer MN, 2001, CRIT CARE MED, V29, P635, DOI 10.1097/00003246-200103000-00031; Dohmen C, 2003, STROKE, V34, P2152, DOI 10.1161/01.STR.0000083624.74929.32; El-Dawlatly Abdelazeem Ali, 2003, Middle East Journal of Anesthesiology, V17, P287; Finnigan SP, 2007, CLIN NEUROPHYSIOL, V118, P2525, DOI 10.1016/j.clinph.2007.07.021; Finnigan SP, 2006, CLIN NEUROPHYSIOL, V117, P2338, DOI 10.1016/j.clinph.2006.06.718; Finnigan SP, 2004, STROKE, V35, P899, DOI 10.1161/01.STR.0000122622.73916.d2; Hans SS, 2007, J VASC SURG, V45, P511, DOI 10.1016/j.jvs.2006.11.035; Jordan KG, 2004, J CLIN NEUROPHYSIOL, V21, P341; LABAR DR, 1991, ELECTROEN CLIN NEURO, V78, P325, DOI 10.1016/0013-4694(91)90094-K; Merat S, 2001, CAN J ANAESTH, V48, P1066, DOI 10.1007/BF03020370; Morimoto Y, 2005, ANESTH ANALG, V100, P158, DOI 10.1213/01.ANE.0000139347.64944.95; NAGATA K, 1989, ELECTROEN CLIN NEURO, V72, P16, DOI 10.1016/0013-4694(89)90027-8; RAMPIL IJ, 1983, NEUROSURGERY, V13, P276, DOI 10.1227/00006123-198309000-00011; Scherg M, 2002, J CLIN NEUROPHYSIOL, V19, P91, DOI 10.1097/00004691-200203000-00001; Sharbrough FW, 1973, STROKE, V4, P674, DOI 10.1161/01.STR.4.4.674; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; STEINER T, 2002, IMPORTANCE MONITORIN, V73, P501, DOI DOI 10.1007/S00115-002-1280-9; Steiner T, 2006, CEREBROVASC DIS, V22, P294, DOI 10.1159/000094831; Stejskal L, 2007, ACTA NEUROCHIR, V149, P681, DOI 10.1007/s00701-007-1228-8; Sundt TM, 2007, J NEUROSURG, V107, P887, DOI 10.3171/JNS-0711010887; Theilen HJ, 2000, CRIT CARE MED, V28, P3522, DOI 10.1097/00003246-200010000-00029; Thomsen CE, 1996, BRIT J ANAESTH, V77, P172, DOI 10.1093/bja/77.2.172; TROJABOR.W, 1973, ELECTROEN CLIN NEURO, V34, P61, DOI 10.1016/0013-4694(73)90151-X; Umegaki N, 2003, J CLIN NEUROSCI, V10, P694, DOI 10.1016/j.jocn.2002.11.001; van Putten MJAM, 2004, STROKE, V35, P2489, DOI 10.1161/01.STR.0000144649.49861.1d; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Vespa PM, 1997, ELECTROEN CLIN NEURO, V103, P607, DOI 10.1016/S0013-4694(97)00071-0; Vespa PM, 2003, NEUROLOGY, V60, P1441, DOI 10.1212/01.WNL.0000063316.47591.B4; Wartenberg KE, 2005, J CLIN NEUROPHYSIOL, V22, P124, DOI 10.1097/01.WNP.0000154918.51389.B6; WHITTEMORE AD, 1983, ANN SURG, V197, P707, DOI 10.1097/00000658-198306000-00009	46	34	36	0	9	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	OCT	2009	11	2					210	216		10.1007/s12028-009-9236-6			7	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	495OG	WOS:000269902300012	19728178				2021-06-18	
J	Kreutziger, J; Schlaepfer, J; Wenzel, V; Constantinescu, MA				Kreutziger, Janett; Schlaepfer, Jessica; Wenzel, Volker; Constantinescu, Mihai Adrian			The Role of Admission Blood Glucose in Outcome Prediction of Surviving Patients With Multiple Injuries	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Multiple trauma; Blood glucose; Hyperglycemia; Outcome	INTENSIVE INSULIN THERAPY; TRAUMA-REGISTRY; BASE DEFICIT; BRAIN-INJURY; HYPERGLYCEMIA; MORTALITY; MORBIDITY; RISK; CARE	Background: Recent literature demonstrates hyperglycemia to be common in patients with trauma and associated with poor outcome in patients wit traumatic brain injury and critically ill patients. The goal of this study was to analyze the impact of admission blood glucose on the outcome of surviving patients with multiple injuries. Methods: Patients' charts (age > 16) admitted to the emergency room of the University Hospital of Berne, Switzerland, between January 1, 2002, and December 31, 2004, with an Injury Severity Score 2:17 and more than one severely injured organ system were reviewed retrospectively. Outcome measurements included morbidity, intensive care unit, and hospital length of stay. Results: The inclusion criteria were met by 555 patients, of which 108 (19.5%) patients died. After multiple regression analysis, admission blood glucose proved to be an independent predictor of posttraumatic morbidity (p < 0.0001), intensive care unit, and hospital length of stay (p < 0.0001), despite intensified insulin therapy on the intensive care unit. Conclusions: In this population of patients with multiple injuries, hyperglycemia on admission was strongly associated with increased morbidity, especially infections, prolonged intensive care unit, and hospital length of stay independent of injury severity, gender, age, and various biochemical parameters.	[Kreutziger, Janett; Wenzel, Volker] Innsbruck Med Univ, Dept Anesthesiol & Crit Care Med, Innsbruck, Austria; [Schlaepfer, Jessica] Spital Interlaken, Dept Surg, Unterseen, Switzerland; [Constantinescu, Mihai Adrian] Univ Hosp Bern, Inselspital, Dept Plast Reconstruct & Hand Surg, CH-3010 Bern, Switzerland	Kreutziger, J (corresponding author), Innsbruck Med Univ, Dept Anesthesiol & Crit Care Med, Innsbruck, Austria.	janett.kreutziger@uki.at	Constantinescu, Mihai A./AAC-6061-2020				*ASS ADV AUT MED, ABBR INJ SCAL 1990; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bennett-Guerrero E, 1999, ANESTH ANALG, V89, P514, DOI 10.1097/00000539-199908000-00050; Bochicchio GV, 2005, AM SURGEON, V71, P171; Bochicchio GV, 2005, J TRAUMA, V58, P921, DOI 10.1097/01.TA.0000162141.26392.07; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Bruno A, 2002, NEUROLOGY, V59, P669, DOI 10.1212/WNL.59.5.669; Capes SE, 2000, LANCET, V355, P773, DOI 10.1016/S0140-6736(99)08415-9; CHAMPION HR, 1990, J TRAUMA, V30, P539, DOI 10.1097/00005373-199005000-00003; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; Christiansen C, 2004, INTENS CARE MED, V30, P1685, DOI 10.1007/s00134-004-2325-2; FitzSullivan E, 2005, AM J SURG, V190, P941, DOI 10.1016/j.amjusrg.2005.08.024; Fynn-Thompson Francis, 2004, Semin Thorac Cardiovasc Surg, V16, P77, DOI 10.1053/j.semtcvs.2004.01.004; Gore DC, 2001, J TRAUMA, V51, P540, DOI 10.1097/00005373-200109000-00021; Grimble RF, 2002, CURR OPIN CLIN NUTR, V5, P551, DOI 10.1097/00075197-200209000-00015; Jeremitsky E, 2005, J TRAUMA, V58, P47, DOI 10.1097/01.TA.0000135158.42242.B1; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; Kinoshita K, 2002, J NEUROTRAUM, V19, P681, DOI 10.1089/08977150260139075; Kreutziger J, 2009, INTENS CARE MED, V35, P1234, DOI 10.1007/s00134-009-1446-z; Krinsley JS, 2008, CRIT CARE MED, V36, P3008, DOI 10.1097/CCM.0b013e31818b38d2; Laird AM, 2004, J TRAUMA, V56, P1058, DOI 10.1097/01.TA.0000123267.39011.9F; LORENZ RA, 2005, AORN J, V81, P147; LORENZ RA, 2005, AORN J, V81, P151; Lorenz Rebecca Ann, 2005, AORN J, V81, P126; Maegele M, 2007, INJURY, V38, P298, DOI 10.1016/j.injury.2006.10.003; Marette A, 2002, CURR OPIN CLIN NUTR, V5, P377, DOI 10.1097/00075197-200207000-00005; McCowen KC, 2001, CRIT CARE CLIN, V17, P107, DOI 10.1016/S0749-0704(05)70154-8; Nishikawa T, 2000, NATURE, V404, P787; Rixen D, 2000, J TRAUMA, V49, P392, DOI 10.1097/00005373-200009000-00003; Rixen D, 2001, SHOCK, V15, P83, DOI 10.1097/00024382-200115020-00001; SALZANO L, 61 ANN M AAST 2002 O; Sung J, 2005, J TRAUMA, V59, P80, DOI 10.1097/01.TA.0000171452.96585.84; Thorell A, 1999, Curr Opin Clin Nutr Metab Care, V2, P69, DOI 10.1097/00075197-199901000-00012; Turina M, 2005, CRIT CARE MED, V33, P1624, DOI 10.1097/01.CCM.0000170106.61978.D8; Turina M, 2006, ANN SURG, V243, P845, DOI 10.1097/01.sla.0000220041.68156.67; Van den Berghe G, 2004, J CLIN INVEST, V114, P1187, DOI 10.1172/JCI200423506; Van den Berghe G, 2006, NEW ENGL J MED, V354, P449, DOI 10.1056/NEJMoa052521; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; WOLFE RR, 1987, NEW ENGL J MED, V317, P403, DOI 10.1056/NEJM198708133170702; Yendamuri S, 2003, J TRAUMA, V55, P33, DOI 10.1097/01.TA.0000074434.39928.72; Yucel N, 2006, J TRAUMA, V60, P1228, DOI 10.1097/01.ta.0000220386.84012.bf	41	34	34	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	OCT	2009	67	4					704	708		10.1097/TA.0b013e3181b22e37			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	506BE	WOS:000270747000005	19820574				2021-06-18	
J	Foley, LM; Hitchens, TK; Ho, C; Janesko-Feldman, KL; Melick, JA; Bayir, H; Kochanek, PM				Foley, Lesley M.; Hitchens, T. Kevin; Ho, Chien; Janesko-Feldman, Keri L.; Melick, John A.; Bayir, Hulya; Kochanek, Patrick M.			Magnetic Resonance Imaging Assessment of Macrophage Accumulation in Mouse Brain after Experimental Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						head trauma; inflammation; MRI	CONTROLLED CORTICAL IMPACT; IRON-OXIDE; INFLAMMATORY RESPONSE; DEFICIENT MICE; STEM-CELLS; BLOOD-FLOW; MICROGLIA; RATS; PARTICLES; INFILTRATION	Macrophages contribute to secondary damage and repair after central nervous system (CNS) injury. Micronsized paramagnetic iron oxide (MPIO) particles can label macrophages in situ, facilitating three-dimensional (3D) mapping of macrophage accumulation following traumatic brain injury (TBI), via ex vivo magnetic resonance microscopy (MRM) and in vivo monitoring with magnetic resonance imaging (MRI). MPIO particles were injected intravenously (iv; 4.5mg Fe/Kg) in male C57BL/6J mice (n = 21). A controlled cortical impact (CCI) was delivered to the left parietal cortex. Five protocols were used in naive and injured mice to assess feasibility, specificity, and optimal labeling time. In vivo imaging was carried out at 4.7 Tesla (T). Brains were then excised for 3D MRM at 11.7 T. Triple-label immunofluorescence (MPIO via Dragon Green, macrophages via F480, and nuclei via 4,6-diamidino-2-phenylindole [DAPI]) of brain sections confirmed MPIO particles within macrophages. MRM of naives showed an even distribution of a small number of MPIO-labeled macrophages in the brain. MRM at 48-72 h after CCI and MPIO injection revealed MPIO-labeled macrophages accumulated in the trauma region. When MPIO particles were injected 6 days before CCI, MRM 48 h after CCI also revealed labeled cells at the injury site. In vivo studies of macrophage accumulation by MRI suggest that this approach is feasible, but requires additional optimization. We conclude that MPIO labeling and ex vivo MRM mapping of macrophage accumulation for assessment of TBI is readily accomplished. This new technique could serve as an adjunct to conventional MR approaches by defining inflammatory mechanisms and therapeutic efficacy of anti-inflammatory agents in experimental TBI.	[Janesko-Feldman, Keri L.; Melick, John A.; Bayir, Hulya; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; [Hitchens, T. Kevin; Ho, Chien] Carnegie Mellon Univ, Dept Biol Sci, Pittsburgh, PA 15213 USA; [Foley, Lesley M.; Hitchens, T. Kevin; Ho, Chien] Carnegie Mellon Univ, Pittsburgh NMR Ctr Biomed Res, Pittsburgh, PA 15213 USA; [Bayir, Hulya; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15260 USA; [Bayir, Hulya; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15260 USA; [Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA 15260 USA	Kochanek, PM (corresponding author), Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, 3434 5th Ave,Suite 101, Pittsburgh, PA 15260 USA.	Kochanekpm@ccm.upmc.edu	Kochanek, Patrick M/D-2371-2015; Ho, Chien/O-6112-2016	Kochanek, Patrick M/0000-0002-2627-913X; Ho, Chien/0000-0002-4094-9232	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS30318, NS38087, P41EB-001977]; Pittsburgh NMR Center for Biomedical Research; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41EB001977] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318, P20NS030318, P01NS030318, R01NS038087] Funding Source: NIH RePORTER	We thank Marci Provins and Fran Mistrick for editorial assistance. We also thank the National Institutes of Health for support (grants NS30318 to P. M. K.; NS38087 to P. M. K.; and P41EB-001977 to C. H.).; This work was performed at the Pittsburgh NMR Center for Biomedical Research, and NIH/NIBIB National Resource, P41EB-001977.	Abr`amoff M.D., 2005, BIOPHOTONICS INT, V11, P36, DOI [10.1117/1.3589100, DOI 10.1117/1.3589100]; BAETHMANN A, 1988, CRIT CARE MED, V16, P972, DOI 10.1097/00003246-198810000-00008; Barone FC, 1999, J CEREBR BLOOD F MET, V19, P819, DOI 10.1097/00004647-199908000-00001; Bayir H, 2005, J CEREBR BLOOD F MET, V25, P673, DOI 10.1038/sj.jcbfm.9600068; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Clark RSB, 1999, FASEB J, V13, P813; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Csuka E, 2000, NEUROREPORT, V11, P2587, DOI 10.1097/00001756-200008030-00047; DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x; Foley LM, 2005, MAGN RESON MED, V54, P798, DOI 10.1002/mrm.20621; FORD AL, 1995, J IMMUNOL, V154, P4309; Frank JA, 2003, RADIOLOGY, V228, P480, DOI 10.1148/radiol.2281020638; GIULIAN D, 1987, J NEUROSCI RES, V18, P155, DOI 10.1002/jnr.490180123; Gris D, 2004, J NEUROSCI, V24, P4043, DOI 10.1523/JNEUROSCI.5343-03.2004; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; HALLENBECK JM, 1986, STROKE, V17, P246, DOI 10.1161/01.STR.17.2.246; HALLENBECK JM, 1977, NEUROLOGY, V27, P3, DOI 10.1212/WNL.27.1.3; Hinds KA, 2003, BLOOD, V102, P867, DOI 10.1182/blood-2002-12-3669; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Hutchinson PJ, 2007, J NEUROTRAUM, V24, P1545, DOI 10.1089/neu.2007.0295; Kochanek PM, 2006, J CEREBR BLOOD F MET, V26, P565, DOI 10.1038/sj.jcbfm.9600218; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Longbrake EE, 2007, J NEUROCHEM, V102, P1083, DOI 10.1111/j.1471-4159.2007.04617.x; McIntosh TK, 1996, LAB INVEST, V74, P315; Mitrasinovic OM, 2005, J NEUROSCI, V25, P4442, DOI 10.1523/JNEUROSCI.0514-05.2005; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Berger RP, 2006, PEDIATR CRIT CARE ME, V7, P557, DOI 10.1097/01.PCC.0000244426.37793.23; Popovich PG, 2001, J NEUROPATH EXP NEUR, V60, P676, DOI 10.1093/jnen/60.7.676; Ricci A, 2000, GROWTH FACTORS, V18, P193, DOI 10.3109/08977190009003244; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; Schwartz M, 2006, J NEUROTRAUM, V23, P360, DOI 10.1089/neu.2006.23.360; Shapiro EM, 2006, MAGN RESON MED, V55, P242, DOI 10.1002/mrm.20718; Shapiro EM, 2004, P NATL ACAD SCI USA, V101, P10901, DOI 10.1073/pnas.0403918101; Shapiro EM, 2005, MAGNET RESON MED, V53, P329, DOI 10.1002/mrm.20342; Siglienti I, 2006, J NEUROIMMUNOL, V173, P166, DOI 10.1016/j.jneuroim.2005.11.011; Sinz EH, 1998, J CEREBR BLOOD F MET, V18, P610, DOI 10.1097/00004647-199806000-00002; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Soares HD, 1995, J NEUROSCI, V15, P8223; Tanaka R, 2003, NEUROSCIENCE, V117, P531, DOI 10.1016/S0306-4522(02)00954-5; Thomale UW, 2007, IMMUNOBIOLOGY, V212, P567, DOI 10.1016/j.imbio.2007.01.007; WEISSLEDER R, 1990, RADIOLOGY, V175, P489, DOI 10.1148/radiology.175.2.2326474; Whalen MJ, 1999, J NEUROTRAUM, V16, P299, DOI 10.1089/neu.1999.16.299; Wu YL, 2006, P NATL ACAD SCI USA, V103, P1852, DOI 10.1073/pnas.0507198103; Ye Q, 2008, CIRCULATION, V118, P149, DOI 10.1161/CIRCULATIONAHA.107.746354; Zhang Z, 2006, NEUROSCIENCE, V141, P637, DOI 10.1016/j.neuroscience.2006.04.027	48	34	35	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2009	26	9					1509	1519		10.1089/neu.2008.0747			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	489NG	WOS:000269426200008	19663686	Green Published			2021-06-18	
J	Sharma, HS; Patnaik, R; Sharma, A; Sjoqujst, PO; Lafuente, JV				Sharma, Hari Shanker; Patnaik, Ranjana; Sharma, Aruna; Sjoqujst, Per-Ove; Lafuente, Jose V.			Silicon Dioxide Nanoparticles (SiO(2), 40-50 nm) Exacerbate Pathophysiology of Traumatic Spinal Cord Injury and Deteriorate Functional Outcome in the Rat. An Experimental Study Using Pharmacological and Morphological Approaches	JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY			English	Article						Nanoparticles; Spinal Cord Injury; Silicon Dioxide; Motor Function; Blood-Spinal Cord Barrier; Spinal Cord Edema; Neuronal Injury; Antioxidants; H-290/51; Oxidative Stress	BLOOD-BRAIN-BARRIER; ANTIOXIDANT COMPOUND H-290/51; NITRIC-OXIDE SYNTHASE; EDEMA FORMATION; MICROVASCULAR PERMEABILITY; PARA-CHLOROPHENYLALANINE; ELECTRON-MICROSCOPY; OXIDATIVE DAMAGE; SEROTONIN LEVELS; STRESS	Silicon (SiO(2)) nanoparticles or silica dust is quite common form of exposure to soldiers engaged in gulf war that may influence their health and brain function. It is quite likely that traumatic injuries to the CNS may be influenced by exposure to these nanoparticles. However, the details of silicon nanoparticles on human health functions are still unknown. In this investigation we examined the effects of chronic silicon dioxide nanoparticles (SiO(2), 40-50 nm) exposure on spinal cord injury (SCI) induced alterations on the functional outcome and the cord pathology in a rat model. Since nanciparticles induce oxidative stress, the influence of an antioxidant compound H-290/51 was also examined in these nanoparticles treated injured rats as well. Rats treated with SiO(2) for 7 days did not show any significant alteration in behaviour on rota rod performances or on capacity angle tests. However, subjection of these nanciparticles exposed rats to SCI resulted in a profound deterioration in motor functions compared to normal rats with SCI. The magnitude of blood-spinal cord barrier (BSCB) disruption to Evans blue and radioiodine tracers and edema formation was much more aggravated following SCI in nanoparticles treated animals compared to untreated traumatized rats. Pretreatment with H-290/51 (50 mg/kg, p.o.) 30 min before SCI in nanoparticle treated rats did not alter spinal cord pathology or functional outcome, however, this dose of the compound was very effective in reducing pathophysiology of SCI in normal animals. These observations are the first to suggest that exposure of nanoparticles enhances the sensitivity of CNS to injuries and alter the effect of neuroprotective drugs.	[Sharma, Hari Shanker; Sharma, Aruna] Uppsala Univ, Univ Hosp, Dept Surg Sci Anaesthesiol & Intens Care Med, SE-75185 Uppsala, Sweden; [Patnaik, Ranjana] Banaras Hindu Univ, Sch Biomed Engn, Inst Technol, Dept Biomat, Varanasi 221005, Uttar Pradesh, India; [Sjoqujst, Per-Ove] Astra Zeneca, Integrat Pharmacol, SE-43183 Molndal, Sweden; [Lafuente, Jose V.] Univ Basque Country, Lab Clin & Expt Neurosci LaCEN, Dept Neurosci, Bilbao 48080, Spain	Sharma, HS (corresponding author), Uppsala Univ, Univ Hosp, Dept Surg Sci Anaesthesiol & Intens Care Med, SE-75185 Uppsala, Sweden.		Patnaik, Ranjana/AAZ-4440-2020; Sharma, Aruna/D-4430-2011; Lafuente, Jose-Vicente/O-6395-2014	Patnaik, Ranjana/0000-0002-8131-177X; Lafuente, Jose-Vicente/0000-0001-7246-0987			ALESSANDRINI F, 2009, AM J RESP CRIT CARE, V5; Apopa PL, 2009, PART FIBRE TOXICOL, V6, DOI 10.1186/1743-8977-6-1; Bao F, 2008, EXP NEUROL, V214, P160, DOI 10.1016/j.expneurol.2008.09.006; Bartunkova J, 2006, AM J IND MED, V49, P569, DOI 10.1002/ajim.20327; Bennett WD, 2002, AM J RESP CRIT CARE, V165, P1671, DOI 10.1164/rccm145; Brooking J, 2001, J DRUG TARGET, V9, P267, DOI 10.3109/10611860108997935; Chen Z, 2008, ENVIRON SCI TECHNOL, V42, P8985, DOI 10.1021/es800975u; Deng-Bryant Y, 2008, J CEREBR BLOOD F MET, V28, P1114, DOI 10.1038/jcbfm.2008.10; DRISCOLL KE, 1990, AM J RESP CELL MOL, V2, P381, DOI 10.1165/ajrcmb/2.4.381; FLORENCE AT, 1995, J DRUG TARGET, V3, P65, DOI 10.3109/10611869509015936; FUBINI B, 1990, TOXICOL IND HEALTH, V6, P571; Gao KP, 2006, INT J PHARMACEUT, V310, P213, DOI 10.1016/j.ijpharm.2005.11.040; Ichinose T, 2008, INHAL TOXICOL, V20, P685, DOI [10.1080/08958370801935133, 10.1080/08958370801935133 ]; Jia HY, 2009, J AM CHEM SOC, V131, P40, DOI 10.1021/ja808033w; Neretti N, 2009, P NATL ACAD SCI USA, V106, P2277, DOI 10.1073/pnas.0812484106; NICOLINI C, 1995, BIOSENS BIOELECTRON, V10, P723, DOI 10.1016/0956-5663(95)96963-Y; Oberlin O, 1996, ANN ONCOL, V7, P73; OLSSON Y, 1990, ACTA NEUROPATHOL, V79, P595, DOI 10.1007/BF00294236; Ostraat ML, 2008, J OCCUP ENVIRON HYG, V5, P390, DOI 10.1080/15459620802071646; Sharma HS, 2007, CURR PHARM DESIGN, V13, P1929; Sharma HS, 2006, ACTA NEUROCHIR SUPPL, V96, P288; Sharma HS, 2009, J NANOSCI NANOTECHNO, V9, P5014, DOI 10.1166/jnn.2009.GR04; Sharma HS, 2009, J NANOSCI NANOTECHNO, V9, P5055, DOI 10.1166/jnn.2009.GR09; Sharma HS, 2009, J CHEM NEUROANAT, V37, P18, DOI 10.1016/j.jchemneu.2008.08.002; Sharma HS, 2008, EXPERT OPIN PHARMACO, V9, P2773, DOI [10.1517/14656566.9.16.2773, 10.1517/14656566.9.16.2773 ]; Sharma HS, 2007, ANN NY ACAD SCI, V1122, P197, DOI 10.1196/annals.1403.014; Sharma HS, 2007, ANN NY ACAD SCI, V1122, P95, DOI 10.1196/annals.1403.007; Sharma HS, 2007, PROG BRAIN RES, V162, P245, DOI 10.1016/S0079-6123(06)62013-X; Sharma HS, 2007, CURR PHARM DESIGN, V13, P1841; Sharma HS, 2009, J NANOSCI NANOTECHNO, V9, P5073, DOI 10.1166/jnn.2009.GR10; SHARMA HS, 1993, NEUROSCIENCE, V57, P443, DOI 10.1016/0306-4522(93)90076-R; Sharma HS, 2006, J NEURAL TRANSM, V113, P497, DOI 10.1007/s00702-005-0406-1; Sharma HS, 2006, J NEURAL TRANSM, V113, P521, DOI 10.1007/s00702-005-0405-2; Sharma HS, 2005, CURR PHARM DESIGN, V11, P1353, DOI 10.2174/1381612053507837; Sharma HS, 2003, ACT NEUR S, V86, P415; Sharma HS, 2002, AMINO ACIDS, V23, P261, DOI 10.1007/s00726-001-0137-z; Sharma HS, 1998, AMINO ACIDS, V14, P121, DOI 10.1007/BF01345252; SHARMA HS, 1990, NEUROSCIENCE, V36, P725, DOI 10.1016/0306-4522(90)90014-U; SHARMA HS, 1993, ACTA NEUROPATHOL, V85, P145; SHARMA HS, 1992, NEUROSCIENCE, V50, P445, DOI 10.1016/0306-4522(92)90436-6; SHARMA HS, 1990, ACTA NEUROPATHOL, V79, P604, DOI 10.1007/BF00294237; Wang Z. G., 1994, Journal of Environmental Pathology Toxicology and Oncology, V13, P205; Xia T, 2008, ACS NANO, V2, P2592; Xia T, 2008, ACS NANO, V2, P2121, DOI 10.1021/nn800511k; Xiong YQ, 2009, EXP NEUROL, V216, P105, DOI 10.1016/j.expneurol.2008.11.025; Zhang Wen-Chang, 1997, Biomedical and Environmental Sciences, V10, P377	46	34	35	0	15	AMER SCIENTIFIC PUBLISHERS	STEVENSON RANCH	25650 NORTH LEWIS WAY, STEVENSON RANCH, CA 91381-1439 USA	1533-4880			J NANOSCI NANOTECHNO	J. Nanosci. Nanotechnol.	AUG	2009	9	8					4970	4980		10.1166/jnn.2009.1717			11	Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied; Physics, Condensed Matter	Chemistry; Science & Technology - Other Topics; Materials Science; Physics	470QO	WOS:000267994100061	19928175				2021-06-18	
J	Caulfield, EV; Dutton, RP; Floccare, DJ; Stansbury, LG; Scalea, TM; Esposito, TJ				Caulfield, Eileen V.; Dutton, Richard P.; Floccare, Douglas J.; Stansbury, Lynn G.; Scalea, Thomas M.; Esposito, Thomas J.			Prehospital Hypocapnia and Poor Outcome After Severe Traumatic Brain Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Traumatic brain injury; TBI; ETCO2; End-tidal capnometry	CEREBRAL-BLOOD-FLOW; CARBON-DIOXIDE; HEAD-INJURY; HYPERVENTILATION; SCORE; HUMANS; VOLUME; SCALE	Background: The Brain Trauma Foundation (BTF) Guidelines for prehospital management of traumatic brain injury (TBI) recommend a goal end-tidal carbon dioxide of 30 min Hg to 35 mm Hg in patients without signs of herniation. Methods: We examined prehospital concordance with BTF Guidelines, selected demographic and physiologic variables and outcomes for 100 consecutive admissions to a well-established Level I regional trauma center. All patients had blunt TBI with Glasgow Coma Score <= 8 without signs of herniation. All were transported by helicopter by flight paramedics experienced with BTF Guidelines and the continuous wave form capnometer. Patients, resumed spontaneous ventilation after intubation. Results: Concordance (prehospital endtidal carbon dioxide >29 nun Hg) was achieved in 65 of 100 cases. Mortality was 29% (19 of 65) among those in whom guideline levels were achieved prehospital and 46% (16 of 35) in those in whom guideline levels were not achieved prehospital (odds ratio, 0.49; p = 0.10). The "achieved" group was younger (p = 0.02), with higher calculated probability of survival (p = 0.01). Intracranial pressure was maintained under intensive care within acceptable limits in the hospital in both groups but was significantly higher in the "not achieved" group (p = 0.05). Conclusions. Our data, though not statistically significant, suggest that patients who are harder to keep Aithin the guidelines in the field are more likely to die, because of more severe TBI or complication by other factors such as age or injury severity. Whether increased awareness of this phenomenon can improve outcomes is unknown but suggests an approach to future education and research.	[Caulfield, Eileen V.; Dutton, Richard P.; Floccare, Douglas J.; Stansbury, Lynn G.; Scalea, Thomas M.] Univ Maryland Med Syst, R Adams Cowley Shock Trauma Ctr, Baltimore, MD 21201 USA; [Esposito, Thomas J.] Loyola Univ, Med Ctr, Dept Surg, Maywood, IL 60153 USA	Stansbury, LG (corresponding author), Univ Maryland Med Syst, R Adams Cowley Shock Trauma Ctr, Baltimore, MD 21201 USA.	lynn.stansbury@gmail.com					*AANS CNS AANS CNS, 2007, GUID MAN SEV TRAU S1; Bader M K, 2000, Crit Care Nurs Clin North Am, V12, P413; BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Brain Trauma Foundation, 2000, GUID PREH MAN TRAUM; *CDCP, 2006, FACTS TRAUM BRAIN IN; Chamberlain D J, 1998, Aust Crit Care, V11, P123, DOI 10.1016/S1036-7314(98)70499-0; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; Chi JH, 2006, J TRAUMA, V61, P1134, DOI 10.1097/01.ta.0000196644.64653.d8; Davis DP, 2006, CRIT CARE MED, V34, P1202, DOI 10.1097/01.CCM.0000208359.74623.1C; Davis DP, 2004, J TRAUMA, V56, P808, DOI 10.1097/01.TA.0000100217.05066.87; Eckstein M, 2000, J TRAUMA, V48, P643, DOI 10.1097/00005373-200004000-00010; Foreman BP, 2007, J TRAUMA, V62, P946, DOI 10.1097/01.ta.0000229796.14717.3a; FORTUNE JB, 1995, J TRAUMA, V39, P463; GRUBB RL, 1974, STROKE, V5, P630, DOI 10.1161/01.STR.5.5.630; Heath D L, 1999, J Neurosci Nurs, V31, P97; Henzler D, 2007, CRIT CARE MED, V35, P1027, DOI 10.1097/01.CCM.0000259526.45894.08; JENNETT B, 1975, LANCET, V1, P480; KETY SS, 1946, J CLIN INVEST, V25, P107, DOI 10.1172/JCI101680; Lal Dave, 2003, Prehosp Disaster Med, V18, P20; Lee Lorri A, 2002, Int Anesthesiol Clin, V40, P31; Mazzeo AT, 2006, J NEUROSURG ANESTH, V18, P170, DOI 10.1097/01.ana.0000210999.18033.f6; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; OSWALD V, 1999, J EMERG NURS, V25, P455; PERSSON A, 1988, PHYS REV B, V38, P5568, DOI 10.1103/PhysRevB.38.5568; RUTA TS, 1993, ANESTHESIOLOGY, V78, P134, DOI 10.1097/00000542-199301000-00019; Schouten JW, 2007, CURR OPIN CRIT CARE, V13, P134, DOI 10.1097/MCC.0b013e3280895d5c; Skippen P, 1997, CRIT CARE MED, V25, P1402, DOI 10.1097/00003246-199708000-00031; Soubani AO, 2001, AM J EMERG MED, V19, P141, DOI 10.1053/ajem.2001.21353; SPAITE DW, 1993, ANN EMERG MED, V22, P1310, DOI 10.1016/S0196-0644(05)80113-1; St John Robert E, 2003, Crit Care Nurse, V23, P83; TEASDALE C, 1974, LANCET, V304, P81; Thomas SH, 2002, J TRAUMA, V52, P47, DOI 10.1097/00005373-200201000-00010; Tobias JD, 1997, ANESTH ANALG, V85, P55, DOI 10.1097/00000539-199707000-00010; Weckesser M, 1999, MAGN RESON MED, V41, P213, DOI 10.1002/(SICI)1522-2594(199901)41:1<213::AID-MRM31>3.0.CO;2-S	35	34	38	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUN	2009	66	6					1577	1583		10.1097/TA.0b013e3181a3931d			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	457PN	WOS:000266944500010	19509617				2021-06-18	
J	Bigford, GE; Alonso, OF; Dietrich, WD; Keane, RW				Bigford, Gregory E.; Alonso, Ofelia F.; Dietrich, W. Dalton; Keane, Robert W.			A Novel Protein Complex in Membrane Rafts Linking the NR2B Glutamate Receptor and Autophagy Is Disrupted following Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						autophagy; excitotoxicity; membrane rafts; traumatic brain injury	EXCITATORY AMINO-ACIDS; LIPID RAFTS; NMDA RECEPTORS; CELL-DEATH; KINASE-II; POSTSYNAPTIC DENSITY-95; SIGNALING PATHWAYS; UP-REGULATION; RAT-BRAIN; IN-VITRO	Hyperactivation of N-methyl-D-aspartate receptors (NRs) is associated with neuronal cell death induced by traumatic brain injury (TBI) and many neurodegenerative conditions. NR signaling efficiency is dependent on receptor localization in membrane raft microdomains. Recently, excitotoxicity has been linked to autophagy, but mechanisms governing signal transduction remain unclear. Here we have identified protein interactions between NR2B signaling intermediates and the autophagic protein Beclin-1 in membrane rafts of the normal rat cerebral cortex. Moderate TBI induced rapid recruitment and association of NR2B and pCaMKII to membrane rafts, and translocation of Beclin-1 out of membrane microdomains. Furthermore, TBI caused significant increases in expression of key autophagic proteins and morphological hallmarks of autophagy that were significantly attenuated by treatment with the NR2B antagonist Ro 25-6981. Thus, stimulation of autophagy by NR2B signaling may be regulated by redistribution of Beclin-1 in membrane rafts after TBI.	[Bigford, Gregory E.; Keane, Robert W.] Univ Miami, Miller Sch Med, Dept Physiol & Biophys, Miami, FL 33136 USA; [Alonso, Ofelia F.; Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Neurol Surg & Miami Project Cure Paralysis, Miami, FL 33136 USA	Keane, RW (corresponding author), Univ Miami, Miller Sch Med, Dept Physiol & Biophys, 1600 NW 10th Ave, Miami, FL 33136 USA.	rkeane@miami.edu			NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30291, NS42133]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291, R01NS042133] Funding Source: NIH RePORTER	We thank Ana Gomez for help with transmission electron microscopy and Doris Nonner for preparation of rat primary neuronal cultures. This work was supported by the NIH/NINDS ( grants NS30291 and NS42133).	Aarts MM, 2004, CURR MOL MED, V4, P137, DOI 10.2174/1566524043479202; Abulrob A, 2005, J NEUROCHEM, V92, P1477, DOI 10.1111/j.1471-4159.2005.03001.x; Arundine M, 2003, J NEUROTRAUM, V20, P1377, DOI 10.1089/089771503322686166; Baehrecke EH, 2005, NAT REV MOL CELL BIO, V6, P505, DOI 10.1038/nrm1666; Barria A, 2005, NEURON, V48, P289, DOI 10.1016/j.neuron.2005.08.034; Besshoh S, 2005, J NEUROCHEM, V93, P186, DOI 10.1111/j.1471-4159.2004.03009.x; Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005; Clark RSB, 2008, AUTOPHAGY, V4, P88, DOI 10.4161/auto.5173; Davis AR, 2007, J NEUROTRAUM, V24, P823, DOI 10.1089/neu.2006.0227; Deisseroth K, 1996, NEURON, V16, P89, DOI 10.1016/S0896-6273(00)80026-4; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Diskin T, 2005, J NEUROTRAUM, V22, P750, DOI 10.1089/neu.2005.22.750; Dong YN, 2004, J NEUROSCI, V24, P11035, DOI 10.1523/JNEUROSCI.3722-04.2004; DUNN WA, 1990, J CELL BIOL, V110, P1923, DOI 10.1083/jcb.110.6.1923; Eskelinen EL, 2005, AUTOPHAGY, V1, P1, DOI 10.4161/auto.1.1.1270; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fischer G, 1997, J PHARMACOL EXP THER, V283, P1285; Fortin DL, 2004, J NEUROSCI, V24, P6715, DOI 10.1523/JNEUROSCI.1594-04.2004; Frank C, 2004, FEBS LETT, V566, P25, DOI 10.1016/j.febslet.2004.03.113; Gardoni F, 2006, EUR J NEUROSCI, V24, P2694, DOI 10.1111/j.1460-9568.2006.05140.x; Giza CC, 2006, J NEUROTRAUM, V23, P950, DOI 10.1089/neu.2006.23.950; Grant SGN, 2003, BIOESSAYS, V25, P1229, DOI 10.1002/bies.10381; Guirland C, 2004, NEURON, V42, P51, DOI 10.1016/S0896-6273(04)00157-6; Hardingham GE, 2001, NAT NEUROSCI, V4, P565, DOI 10.1038/88380; Hering H, 2003, J NEUROSCI, V23, P3262; Hetman M, 2006, CURR TOP MED CHEM, V6, P787, DOI 10.2174/156802606777057553; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HOLLMANN M, 1994, RENAL PHYSIOL BIOCH, V17, P182; Hu BR, 1998, J NEUROSCI, V18, P625; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Keane RW, 2006, J NEUROTRAUM, V23, P335, DOI 10.1089/neu.2006.23.335; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; Kihara A, 2001, EMBO REP, V2, P330, DOI 10.1093/embo-reports/kve061; Kim EJ, 2004, NAT REV NEUROSCI, V5, P771, DOI 10.1038/nrn1517; Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Lan JY, 2001, J NEUROSCI, V21, P6058; Larsen KE, 2002, HISTOL HISTOPATHOL, V17, P897, DOI 10.14670/HH-17.897; Lei ZG, 2006, NEUROSCI LETT, V407, P224, DOI 10.1016/j.neulet.2006.06.019; Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390; Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; LISMAN JE, 2001, J PHYSL, V532, P59; Liu CL, 2008, J CEREBR BLOOD F MET, V28, P674, DOI 10.1038/sj.jcbfm.9600587; Liu LD, 2004, SCIENCE, V304, P1021, DOI 10.1126/science.1096615; Liu YT, 2007, J NEUROSCI, V27, P2846, DOI 10.1523/JNEUROSCI.0116-07.2007; Lotocki G, 2004, J NEUROSCI, V24, P11010, DOI 10.1523/JNEUROSCI.3823-04.2004; Lotocki G, 2006, EUR J NEUROSCI, V24, P2283, DOI 10.1111/j.1460-9568.2006.05123.x; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; Luo S, 2007, CELL DEATH DIFFER, V14, P1247, DOI 10.1038/sj.cdd.4402149; Malinow R, 2002, ANNU REV NEUROSCI, V25, P103, DOI 10.1146/annurev.neuro.25.112701.142758; Meng FJ, 2004, ACTA PHARMACOL SIN, V25, P176; Meng FJ, 2003, BRAIN RES, V967, P161, DOI 10.1016/S0006-8993(02)04267-1; Migaud M, 1998, NATURE, V396, P433; Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; Mutel V, 1998, J NEUROCHEM, V70, P2147; NAKANISHI N, 1992, P NATL ACAD SCI USA, V89, P8552, DOI 10.1073/pnas.89.18.8552; Paratcha G, 2002, CURR OPIN NEUROBIOL, V12, P542, DOI 10.1016/S0959-4388(02)00363-X; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992; Pike LJ, 2006, J LIPID RES, V47, P1597, DOI 10.1194/jlr.E600002-JLR200; Pyo JO, 2005, J BIOL CHEM, V280, P20722, DOI 10.1074/jbc.M413934200; REGAN RF, 1994, BRAIN RES, V633, P236, DOI 10.1016/0006-8993(94)91544-X; Roche KW, 2001, NAT NEUROSCI, V4, P794, DOI 10.1038/90498; Sheng M, 2001, P NATL ACAD SCI USA, V98, P7058, DOI 10.1073/pnas.111146298; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Sprengel R, 1998, CELL, V92, P279, DOI 10.1016/S0092-8674(00)80921-6; Suzuki T, 2001, MOL BRAIN RES, V89, P20, DOI 10.1016/S0169-328X(01)00051-1; Takacs-Vellai K, 2005, CURR BIOL, V15, P1513, DOI 10.1016/j.cub.2005.07.035; Takadera T, 2004, BRAIN RES, V1020, P196, DOI 10.1016/j.brainres.2004.06.035; ULRICHBAYER K, 2006, J NEUROSCI, V26, P1164; ULRICHBAYER K, 2001, LETT NAT, V411, P801; Vissel B, 2001, NAT NEUROSCI, V4, P587, DOI 10.1038/88404; Wong W, 2004, J BIOL CHEM, V279, P444, DOI 10.1074/jbc.M304675200; Wu LJ, 2005, J NEUROSCI, V25, P11107, DOI 10.1523/JNEUROSCI.1678-05.2005; Xue LZ, 1999, MOL CELL NEUROSCI, V14, P180, DOI 10.1006/mcne.1999.0780; Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645; Yue ZY, 2002, NEURON, V35, P921, DOI 10.1016/S0896-6273(02)00861-9; Yurkewicz L, 2005, J NEUROTRAUM, V22, P1428, DOI 10.1089/neu.2005.22.1428; Zhang SJ, 2007, NEURON, V53, P549, DOI 10.1016/j.neuron.2007.01.025	84	34	35	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2009	26	5					703	720		10.1089/neu.2008.0783			18	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	452XM	WOS:000266574500006	19335206	Green Published			2021-06-18	
J	Putukian, M; Aubry, M; McCrory, P				Putukian, M.; Aubry, M.; McCrory, P.			Return to play after sports concussion in elite and non-elite athletes?	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article; Proceedings Paper	3rd International Conference on Concussion in Sport	NOV, 2008	Zurich, SWITZERLAND				NEUROPSYCHOLOGICAL TEST-PERFORMANCE; COLLEGIATE FOOTBALL PLAYERS; PROFESSIONAL FOOTBALL; MANAGEMENT; STATEMENT; DIAGNOSIS; RECOVERY; INJURIES; GAME	Objective: To examine the published literature relating to the difference in concussion management strategies between elite and non-elite athletes. Design: Systematic literature review of concussion management. Intervention: Pubmed, Medline, Psych Info, Cochrane Library and Sport Discus databases were reviewed using the MeSH keywords brain concussion and mild traumatic brain injury, combined with athletic injuries. Each were then refined by adding the keyword "return to play" (RTP). English language and human studies only were assessed. Results: For the Medline search, using "brain concussion" as a keyword, 4319 articles were found; this was decreased to 111 when RTP was used to refine the search. When "mild traumatic brain injury" was used, 2509 articles were found; this decreased to 39 when RTP was used to refine the search. Following initial review, these articles form the basis of the discussion below. Conclusions: The non-elite athlete may not have the same resources available as the elite athlete (such as the presence of trained medical staff during practice and competition, a concussion programme as part of sideline preparedness, the benefit of neuropsychological or postural testing, as well as consultants with expertise in concussion readily available) and as a result will generally be managed more conservatively. Younger athletes often have a greater incidence of concussion with longer recovery time frames; however, they are often managed with less expertise and with limited resources.	[Putukian, M.] Princeton Univ, Univ Hlth Serv, Princeton, NJ 08540 USA; [McCrory, P.] Univ Melbourne, Ctr Hlth Exercise & Sports Med, Parkville, Vic, Australia	Putukian, M (corresponding author), Princeton Univ, Univ Hlth Serv, Washington Rd, Princeton, NJ 08540 USA.	putukian@princeton.edu	McCrory, Paul/Q-8688-2019	McCrory, Paul/0000-0003-4850-0568			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Braham R, 2004, J SCI MED SPORT, V7, P451, DOI 10.1016/S1440-2440(04)80263-9; Cantu Robert C, 2006, Neurosurg Focus, V21, pE3; Collie A, 2003, BRIT J SPORT MED, V37, P2, DOI 10.1136/bjsm.37.1.2; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Echemendia RJ, 2001, NEUROPSYCHOL REV, V11, P69, DOI 10.1023/A:1016651217141; Emery CA, 2006, AM J SPORT MED, V34, P1960, DOI 10.1177/0363546506290061; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Guskiewicz KM, 2004, NEUROSURGERY, V55, P891, DOI 10.1227/01.NEU.0000143800.49798.19; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; HERRING S, 2006, MED SCI SPORTS EXERC, V38, P395, DOI DOI 10.1249/01.MSS.0000202025.48774.31; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Lovell M, 2004, CLIN SPORT MED, V23, P421, DOI 10.1016/j.csm.2004.04.001; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; Moser RS, 2007, ARCH CLIN NEUROPSYCH, V22, P909, DOI 10.1016/j.acn.2007.09.004; Orchard J, 1998, J Sci Med Sport, V1, P83, DOI 10.1016/S1440-2440(98)80016-9; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Pellman EJ, 2005, NEUROSURGERY, V56, P79, DOI 10.1227/01.NEU.0000150180.16552.8D; Pellman EJ, 2004, NEUROSURGERY, V55, P1290, DOI 10.1227/01.NEU.0000149244.97560.91; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832	29	34	34	0	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	MAY	2009	43			1			I28	I31		10.1136/bjsm.2009.058230			4	Sport Sciences	Sport Sciences	450YO	WOS:000266438100005	19433421				2021-06-18	
J	Boison, D				Boison, Detlev			Engineered Adenosine-Releasing Cells for Epilepsy Therapy: Human Mesenchymal Stem Cells and Human Embryonic Stem Cells	NEUROTHERAPEUTICS			English	Article; Proceedings Paper	4th Workshop on New Horizons in the Development of Antiepileptic Drugs	MAR 05-07, 2008	Dublin, IRELAND			Adenosine; epilepsy; cell therapy; stem cells; RNAi; rodent models	TEMPORAL-LOBE EPILEPSY; TRAUMATIC BRAIN-INJURY; NEURAL DIFFERENTIATION; REFRACTORY EPILEPSY; PARKINSONIAN RATS; GENE THERAPIES; DENTATE GYRUS; HIPPOCAMPUS; KINASE; RECEPTORS	Adenosine is a modulator of neuronal activity with anticonvulsant and neuroprotective properties. Conversely, focal deficiency in adenosine contributes to ictogenesis. Thus, focal reconstitution of adenosine within an epileptogenic brain region constitutes a rational therapeutic approach, whereas systemic augmentation of adenosine is precluded by side effects. To meet the therapeutic goal of focal adenosine augmentation, genetic disruption of the adenosine metabolizing enzyme, adenosine kinase (ADK) in rodent cells was used as a molecular strategy to induce adenosine release from cellular brain implants, which demonstrated antiepileptic and neuroprotective properties. Currently, the second generation of adenosine-releasing cells is under development based on the rationale to use human stem cell-derived brain implants to avoid xenotransplantation. To effectively engineer human stem cells to release adenosine, a lentiviral vector was constructed to express inhibitory micro-RNA directed against ADK. Lentiviral knockdown of ADK induced therapeutic adenosine release in human mesenchymal stem cells, which reduced acute injury and seizures, as well as chronic seizures, when grafted into the mouse hippocampus. The therapeutic potential of this approach suggests the feasibility to engineer autologous adenosine-releasing stem cells derived from a patient. Human embryonic stem cells (hESCs) have a high proliferative capacity and can be subjected to specific cellular differentiation pathways. hESCs, differentiated in vitro into neuroepithelial cells and grafted into the mouse brain, displayed intrahippocampal location and neuronal morphology. Using the same lentiviral micro-RNA vector, we demonstrated knockdown of ADK in hESCs. New developments and therapeutic challenges in using human mesenchymal stem cells and hESCs for epilepsy therapy will be critically evaluated.	Robert Stone Dow Neurobiol Labs, Portland, OR 97232 USA	Boison, D (corresponding author), Robert Stone Dow Neurobiol Labs, 1225 NE 2nd Ave, Portland, OR 97232 USA.	dboison@downeurobiology.org	Boison, Detlev/ABE-6302-2020	Boison, Detlev/0000-0002-7740-5781	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS058780-02, R01 NS058780, R21 NS057475-02, R21NS057475-01, R01NS058780-01, R21 NS057538, R21 NS057475, R21NS057538-01, R21 NS057538-02, R01 NS061844] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS058780, R21NS057538, R01NS061844, R21NS057475] Funding Source: NIH RePORTER		Abdallah BM, 2008, GENE THER, V15, P109, DOI 10.1038/sj.gt.3303067; Andrews EM, 2008, EXP NEUROL, V211, P588, DOI 10.1016/j.expneurol.2008.02.027; Ben-Hur T, 2004, STEM CELLS, V22, P1246, DOI 10.1634/stemcells.2004-0094; Benarroch EE, 2008, NEUROLOGY, V70, P231, DOI 10.1212/01.wnl.0000297939.18236.ec; Boison D, 2005, NEUROSCIENTIST, V11, P25, DOI 10.1177/1073858404269112; Boison D, 2002, P NATL ACAD SCI USA, V99, P6985, DOI 10.1073/pnas.092642899; Boison D, 2008, PROG NEUROBIOL, V84, P249, DOI 10.1016/j.pneurobio.2007.12.002; Boison D, 2008, CURR OPIN PHARMACOL, V8, P2, DOI 10.1016/j.coph.2007.09.002; Boison D, 2007, DRUG NEWS PERSPECT, V20, P607, DOI 10.1358/dnp.2007.20.10.1181353; Boison D, 2007, NEURODEGENER DIS, V4, P28, DOI 10.1159/000100356; Boison D, 2007, CURR NEUROPHARMACOL, V5, P115, DOI 10.2174/157015907780866938; Boison D, 2006, TRENDS PHARMACOL SCI, V27, P652, DOI 10.1016/j.tips.2006.10.008; CICCARELLI R, 1994, J NEUROSCI RES, V39, P556, DOI 10.1002/jnr.490390507; COHEN MA, 2007, CURR PROTOC CELL BIO, pCH23; Cunha Rodrigo A, 2005, Purinergic Signal, V1, P111, DOI 10.1007/s11302-005-0649-1; Cunha RA, 2008, NEUROCHEM INT, V52, P65, DOI 10.1016/j.neuint.2007.06.026; Dottori Mirella, 2008, V438, P19, DOI 10.1007/978-1-59745-133-8_3; DUNWIDDIE TV, 1980, EPILEPSIA, V21, P541, DOI 10.1111/j.1528-1157.1980.tb04305.x; Erion M.D., 2000, DRUG DEVELOP RES, V50, pS14; Fedele DE, 2004, NEUROSCI LETT, V370, P160, DOI 10.1016/j.neulet.2004.08.031; Fedele DE, 2006, EXP NEUROL, V200, P184, DOI 10.1016/j.expneurol.2006.02.133; Fredholm BB, 2005, INT REV NEUROBIOL, V63, P191, DOI 10.1016/S0074-7742(05)63007-3; Fredholm BB, 2001, PHARMACOL REV, V53, P527; Fredholm BB, 2005, ANNU REV PHARMACOL, V45, P385, DOI 10.1146/annurev.pharmtox.45.120403.095731; Gerrard L, 2005, STEM CELLS, V23, P1234, DOI 10.1634/stemcells.2005-0110; Gouder N, 2003, EPILEPSIA, V44, P877, DOI 10.1046/j.1528-1157.2003.03603.x; Gouder N, 2004, J NEUROSCI, V24, P692, DOI 10.1523/JNEUROSCI.4781-03.2004; Huber A, 2001, P NATL ACAD SCI USA, V98, P7611, DOI 10.1073/pnas.131102898; Kochanek PM, 2006, J CEREBR BLOOD F MET, V26, P565, DOI 10.1038/sj.jcbfm.9600218; Li JY, 2008, TRENDS NEUROSCI, V31, P146, DOI 10.1016/j.tins.2007.12.001; Li TF, 2008, J CLIN INVEST, V118, P571, DOI 10.1172/JCI33737; Li TF, 2007, BRAIN, V130, P1276, DOI 10.1093/brain/awm057; Loscher W, 2008, TRENDS NEUROSCI, V31, P62, DOI 10.1016/j.tins.2007.11.012; Mahmood A, 2005, NEUROSURGERY, V57, P1026, DOI 10.1227/01.NEU.0000181369.76323.50; Masino SA, 2008, TRENDS NEUROSCI, V31, P273, DOI 10.1016/j.tins.2008.02.009; MONOPOLI A, 1994, ARZNEIMITTEL-FORSCH, V44-2, P1305; Nilsen KE, 2004, BRAIN RES REV, V44, P141, DOI 10.1016/j.brainresrev.2003.11.003; Okabe S, 1996, MECH DEVELOP, V59, P89, DOI 10.1016/0925-4773(96)00572-2; Onda T, 2008, J CEREBR BLOOD F MET, V28, P329, DOI 10.1038/sj.jcbfm.9600527; Pankratz MT, 2007, STEM CELLS, V25, P1511, DOI 10.1634/stemcells.2006-0707; Pignataro G, 2007, J CEREBR BLOOD F MET, V27, P919, DOI 10.1038/sj.jcbfm.9600422; Raedt R, 2007, SEIZURE-EUR J EPILEP, V16, P565, DOI 10.1016/j.seizure.2007.05.003; Rao MS, 2006, NEUROBIOL DIS, V21, P276, DOI 10.1016/j.nbd.2005.07.009; Rao MS, 2007, NEUROBIOL DIS, V27, P117, DOI 10.1016/j.nbd.2007.03.016; Ren G, 2007, EXP NEUROL, V208, P26, DOI 10.1016/j.expneurol.2007.07.016; Reubinoff BE, 2001, NAT BIOTECHNOL, V19, P1134, DOI 10.1038/nbt1201-1134; Ribeiro JA, 2005, CNS NEUROL DISORD-DR, V4, P325, DOI 10.2174/1568007054546090; Ribeiro JA, 2003, DRUG NEWS PERSPECT, V16, P80, DOI 10.1358/dnp.2003.16.2.740246; Roy NS, 2006, NAT MED, V12, P1259, DOI 10.1038/nm1495; Shetty AK, 2005, J NEUROSCI, V25, P8391, DOI 10.1523/JNEUROSCI.1538-05.2005; Shetty AK, 2007, HIPPOCAMPUS, V17, P943, DOI 10.1002/hipo.20311; Shetty AK, 2007, STEM CELLS, V25, P2396, DOI 10.1634/stemcells.2007-0313; Thompson KW, 2005, NEUROSCIENCE, V133, P1029, DOI 10.1016/j.neuroscience.2005.03.003; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Vajda FJE, 2007, J CLIN NEUROSCI, V14, P813, DOI 10.1016/j.jocn.2007.02.008; Wilz A, 2008, BIOMATERIALS, V29, P3609, DOI 10.1016/j.biomaterials.2008.05.010; Yang DL, 2008, STEM CELLS, V26, P55, DOI 10.1634/stemcells.2007-0494; Zhang SC, 2008, PHILOS T R SOC B, V363, P87, DOI 10.1098/rstb.2006.2014	58	34	36	0	13	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1933-7213			NEUROTHERAPEUTICS	Neurotherapeutics	APR	2009	6	2					278	283		10.1016/j.nurt.2008.12.001			6	Clinical Neurology; Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	425TL	WOS:000264659900009	19332320	Green Published, Bronze, Green Accepted			2021-06-18	
J	Levin, AV				Levin, Alex V.			Retinal Hemorrhages: Advances in Understanding	PEDIATRIC CLINICS OF NORTH AMERICA			English	Article						Retinal hemorrhage; Child abuse; Shaken baby syndrome; Abusive head trauma; Retinoschisis	TRAUMATIC AXONAL INJURY; SUSPECTED CHILD-ABUSE; HEAD-INJURY; CARDIOPULMONARY-RESUSCITATION; OPTIC-NERVE; INFANT; MODEL; FOLDS; CONVULSIONS; RETINOPATHY	Retinal hemorrhage is a cardinal manifestation of abusive head injury characterized by repetitive acceleration-deceleration with or without blunt head impact. Detailed description of the hemorrhages and documentation are critical to diagnosis. Vitreoretinal traction appears to be the major causative factor. Outcome is largely dependent on brain and optic nerve injury.	Wills Eye Inst, Philadelphia, PA 19107 USA	Levin, AV (corresponding author), Wills Eye Inst, 840 Walnut St,12th Floor, Philadelphia, PA 19107 USA.	alevin@willseye.org					Agrawal A, 2006, SURV OPHTHALMOL, V51, P129, DOI 10.1016/j.survophthal.2005.12.003; Agrawal A, 2007, BRIT J OPHTHALMOL, V91, P1456, DOI 10.1136/bjo.2007.117408; Altinok D, 2009, PEDIATR RADIOL, V39, P290, DOI 10.1007/s00247-008-1086-4; Amberg R, 2001, FORENSIC SCI INT, V124, P157, DOI 10.1016/S0379-0738(01)00582-5; Bechtel K, 2004, PEDIATRICS, V114, P165, DOI 10.1542/peds.114.1.165; BHOLA R, 2005, INVEST OPHTH VIS SCI, V46, pE4090; Biron D, 2005, CHILD ABUSE NEGLECT, V29, P1347, DOI 10.1016/j.chiabu.2005.05.003; Bonnier C, 2002, BRAIN PATHOL, V12, P320; Bonnier Christine, 2004, Pediatr Rehabil, V7, P165, DOI 10.1080/13638490410001703325; BRAY GL, 1987, AM J DIS CHILD, V141, P1215, DOI 10.1001/archpedi.1987.04460110085030; ELNER SG, 1990, ARCH OPHTHALMOL-CHIC, V108, P1094, DOI 10.1001/archopht.1990.01070100050033; Emadi-Konjin P, 2005, CLIN BIOCHEM, V38, P450, DOI 10.1016/j.clinbiochem.2005.01.018; Emerson MV, 2007, OPHTHALMOLOGY, V114, P1384, DOI 10.1016/j.ophtha.2007.04.015; FACKLER JC, 1992, AM J DIS CHILD, V146, P1294, DOI 10.1001/archpedi.1992.02160230052014; Fenton S, 1999, ARCH OPHTHALMOL-CHIC, V117, P1432; Forbes BJ, 2008, J AAPOS, V12, P177, DOI 10.1016/j.jaapos.2007.07.009; Forbes BJ, 2007, J AAPOS, V11, P179, DOI 10.1016/j.jaapos.2006.08.006; GANGEMI M, 1987, NEUROCHIRURGIA, V30, P53; Geddes JF, 2003, NEUROPATH APPL NEURO, V29, P14, DOI 10.1046/j.1365-2990.2003.00434.x; Gilliland MGF, 2007, AM J FOREN MED PATH, V28, P323, DOI 10.1097/PAF.0b013e31815b4c00; GILLILAND MGF, 1992, FORENSIC SCI INT, V56, P77, DOI 10.1016/0379-0738(92)90149-Q; GILLILAND MGF, 1993, AM J FOREN MED PATH, V14, P187, DOI 10.1097/00000433-199309000-00003; Gnanaraj L, 2007, EYE, V21, P5, DOI 10.1038/sj.eye.6702174; GOETTING MG, 1990, PEDIATRICS, V85, P585; Goldman M, 2006, J PEDIATR-US, V148, P835, DOI 10.1016/j.jpeds.2005.12.052; GONZALEZ VI, 1995, EUR J OPHTHALMOL, V5, P247; GUTHKELCH AN, 1971, BMJ-BRIT MED J, V2, P430, DOI 10.1136/bmj.2.5759.430; HANSEN HC, 1994, NEURO-OPHTHALMOLOGY, V14, P345, DOI 10.3109/01658109409024061; Herr S, 2004, PEDIATRICS, V113, P1658, DOI 10.1542/peds.113.6.1658; HOFFMAN R, 2006, OPHTHALMOLOGY PHOTOG, P151; Huh JW, 2007, J NEUROTRAUM, V24, P15, DOI 10.1089/neu.2006.0072; Johnston CS, 1996, J AM COLL NUTR, V15, P586, DOI 10.1080/07315724.1996.10718634; KANTER RK, 1986, J PEDIATR-US, V108, P430, DOI 10.1016/S0022-3476(86)80890-3; Kivlin JD, 2008, ARCH OPHTHALMOL-CHIC, V126, P800, DOI 10.1001/archopht.126.6.800; Kivlin JD, 2000, OPHTHALMOLOGY, V107, P1246, DOI 10.1016/S0161-6420(00)00161-5; Lantz PE, 2005, J FORENSIC SCI, V50, P1450; Lantz PE, 2004, BRIT MED J, V328, P754, DOI 10.1136/bmj.328.7442.754; Leestma JE, 2005, AM J FOREN MED PATH, V26, P199, DOI 10.1097/01.paf.0000164228.79784.5a; Levin AV, 2006, ARCH OPHTHALMOL-CHIC, V124, P1773, DOI 10.1001/archopht.124.12.1773; Levin AV, 2001, AM J FOREN MED PATH, V22, P417, DOI 10.1097/00000433-200112000-00019; Levin AV, 2000, RECENT ADV PAEDIAT, P151; LEVIN AV, 2007, HOSP SICK CHILDRENS, P133; Lueder GT, 2006, ARCH OPHTHALMOL-CHIC, V124, P1782, DOI 10.1001/archopht.124.12.1782; MASSICOTTE SJ, 1991, OPHTHALMOLOGY, V98, P1124; MATSCHKE J, 2008, INT J LEGAL MED; Matthews GP, 1996, J PEDIATR OPHTHALMOL, V33, P260, DOI 10.3928/0191-3913-19960701-13; Mei-Zahav M, 2002, ARCH DIS CHILD, V86, P334, DOI 10.1136/adc.86.5.334; Morad Y, 2003, J PEDIATR-US, V142, P431, DOI 10.1067/mpd.2003.161; Morad Y, 2002, AM J OPHTHALMOL, V134, P354, DOI 10.1016/S0002-9394(02)01628-8; Nagaoka T, 2002, INVEST OPHTH VIS SCI, V43, P3037; Nolte KB, 1997, J FORENSIC SCI, V42, P935; OBI E, 2007, J AAPOS, V11, P99, DOI DOI 10.1016/J.JAAPOS.2007.01.031; Odom A, 1997, PEDIATRICS, V99, part. no., DOI 10.1542/peds.99.6.e3; Ozbay D, 2004, CAN J OPHTHALMOL, V39, P727, DOI 10.1016/S0008-4182(04)80066-8; Parsons MA, 2001, J CLIN PATHOL, V54, P417, DOI 10.1136/jcp.54.6.417; Pierre-Kahn V, 2003, OPHTHALMOLOGY, V110, P1718, DOI 10.1016/S0161-6420(03)00581-5; Raghupathi R, 2004, J NEUROTRAUM, V21, P307, DOI 10.1089/089771504322972095; RANGARAJAN N, J AAPOS IN PRESS; Richards PG, 2006, ARCH DIS CHILD, V91, P205, DOI 10.1136/adc.2005.090761; Sandramouli S, 1997, ARCH DIS CHILD, V76, P449, DOI 10.1136/adc.76.5.449; Schloff S, 2002, OPHTHALMOLOGY, V109, P1472, DOI 10.1016/S0161-6420(02)01086-2; SCHOENFELD A, 1985, ARCH OPHTHALMOL-CHIC, V103, P932; Scott AW, 2009, AM J OPHTHALMOL, V147, P364, DOI 10.1016/j.ajo.2008.08.010; Serbanescu I, 2008, EYE, V22, P715, DOI 10.1038/eye.2008.6; Smith SL, 1998, J NEUROTRAUM, V15, P693, DOI 10.1089/neu.1998.15.693; Starling SP, 2004, ARCH PEDIAT ADOL MED, V158, P454, DOI 10.1001/archpedi.158.5.454; STURM V, 2008, EYE; TOMASI L, 1986, AM J DIS CHILD, V93, P1335; Tyagi AK, 1998, BRIT J OPHTHALMOL, V82, P659, DOI 10.1136/bjo.82.6.659; Vinchon M, 2002, PEDIATR NEUROSURG, V37, P245, DOI 10.1159/000066216; Wygnanski-Jaffe T, 2007, EYE, V21, P83, DOI 10.1038/sj.eye.6702163; Wygnanski-Jaffe T, 2006, AM J OPHTHALMOL, V142, P233, DOI 10.1016/j.ajo.2006.03.038	72	34	34	0	6	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0031-3955	1557-8240		PEDIATR CLIN N AM	Pediatr. Clin. N. Am.	APR	2009	56	2					333	+		10.1016/j.pcl.2009.02.003			13	Pediatrics	Pediatrics	441CA	WOS:000265745700003	19358919				2021-06-18	
J	Muller, K; Ingebrigtsen, T; Wilsgaard, T; Wikran, G; Fagerheim, T; Romner, B; Waterloo, K				Muller, Kay; Ingebrigtsen, Tor; Wilsgaard, Tom; Wikran, Gry; Fagerheim, Toril; Romner, Bertil; Waterloo, Knut			PREDICTION OF TIME TRENDS IN RECOVERY OF COGNITIVE FUNCTION AFTER MILD HEAD INJURY	NEUROSURGERY			English	Article						Brain trauma; Neuropsychological assessment; Risk factors in epidemiology	TRAUMATIC BRAIN-INJURY; APOLIPOPROTEIN-E; APOE GENOTYPE; NEUROPSYCHOLOGICAL FUNCTION; PROTEIN S-100B; EPSILON-4; SERUM; E4; ASSOCIATION; IMPAIRMENT	OBJECTIVE: To investigate relations between predictors and outcomes, and especially to identify predictors influencing the time trend in recovery after mild traumatic brain injury. METHODS: We included 59 patients with mild head injury in a prospective study. They underwent comprehensive assessment with neurological and neuroradiological examinations, serum S-100B analysis, and apolipoprotein E (APOE) genotyping. Neuropsychological testing was performed before and 6 months after discharge. Linear mixed models were used to assess associations between baseline predictors and neurocognitive performance and its change. RESULTS: A Glasgow Coma Scale score of less than 15, traumatic brain injury demonstrated with computed tomography, magnetic resonance imaging, and serum S-100B greater than 0.14 mu g/L predicted impaired cognitive performance both at baseline and after 6 months; APOE genotype did not. There was significant improvement of performance after 6 months. APOE-epsilon 4 genotype was the only independent factor significantly predicting less improvement. CONCLUSION: The presence of the APOE-epsilon A allele predicts less recovery of cognitive function after mild head injury.	[Muller, Kay] Univ Hosp N Norway, Dept Neurosurg, N-9038 Tromso, Norway; [Ingebrigtsen, Tor] Univ Tromso, Inst Clin Med, Tromso, Norway; [Wilsgaard, Tom] Univ Tromso, Inst Community Med, Tromso, Norway; [Wikran, Gry] Univ Hosp N Norway, Dept Radiol, N-9038 Tromso, Norway; [Fagerheim, Toril] Univ Hosp N Norway, Dept Med Genet, N-9038 Tromso, Norway; [Romner, Bertil] Univ Tromso, Inst Clin Med, Tromso, Norway	Muller, K (corresponding author), Univ Hosp N Norway, Dept Neurosurg, N-9038 Tromso, Norway.	kay.muller@unn.no		Ingebrigtsen, Tor/0000-0001-5966-9786			Aslanidis C, 1999, CLIN CHEM, V45, P1094; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; de Boussard CN, 2005, J REHABIL MED, V37, P53, DOI 10.1080/16501970410015587; DELIS D, 1987, CALIFORNIA VERBAL LE; Egge A, 2005, ACTA NEUROL SCAND, V112, P76, DOI 10.1111/j.1600-0404.2005.00449.x; Golden C., 1978, STROOP COLOR WORD TE; Han SD, 2007, J NEUROL NEUROSUR PS, V78, P1103, DOI 10.1136/jnnp.2006.108183; Heaton R., 1993, WISCONSIN CARD SORTI; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Houlden H, 2006, J NEUROL NEUROSUR PS, V77, P1106, DOI 10.1136/jnnp.2006.095513; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; Isoniemi H, 2006, NEUROLOGY, V67, P756, DOI 10.1212/01.wnl.0000234140.64954.12; Isoniemi H, 2006, J NEUROTRAUM, V23, P1600, DOI 10.1089/neu.2006.23.1600; Jakola AS, 2007, ACTA NEUROL SCAND, V115, P398, DOI 10.1111/j.1600-0404.2007.00827.x; Jiang Y, 2007, J NEUROTRAUM, V24, P1802, DOI 10.1089/neu.2007.0299; Liberman JN, 2002, NEUROLOGY, V58, P1038, DOI 10.1212/WNL.58.7.1038; Mahley RW, 2000, ANNU REV GENOM HUM G, V1, P507, DOI 10.1146/annurev.genom.1.1.507; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; Millar K, 2003, J NEUROL NEUROSUR PS, V74, P1047, DOI 10.1136/jnnp.74.8.1047; Muller K, 2006, CLIN CHEM LAB MED, V44, P1111, DOI 10.1515/CCLM.2006.211; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; PITAS RE, 1987, BIOCHIM BIOPHYS ACTA, V917, P148, DOI 10.1016/0005-2760(87)90295-5; Ponsford J, 2007, NEUROLOGY, V68, P619, DOI 10.1212/01.wnl.0000254609.04330.9d; Spreen O., 1998, COMPENDIUM NEUROPSYC; Sundstrom A, 2004, NEUROLOGY, V62, P1963, DOI 10.1212/01.WNL.0000129268.83927.A8; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Townend W, 2006, INJURY, V37, P1098, DOI 10.1016/j.injury.2006.07.014; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; Waterloo K, 1997, ACTA NEUROCHIR, V139, P26, DOI 10.1007/BF01850864; Wechsler D., 1987, WECHSLER MEMORY SCAL; White F, 2001, NEUROBIOL DIS, V8, P611, DOI 10.1006/nbdi.2001.0401; Wolfson D., 1993, HALSTEAD REITAN NEUR; Zhou WD, 2008, J NEUROTRAUM, V25, P279, DOI 10.1089/neu.2007.0489; ZIMMERMANN P, 1999, TEST ATTENTIONAL PER	37	34	40	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	APR	2009	64	4					698	704		10.1227/01.NEU.0000340978.42892.78			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	427MN	WOS:000264783500030	19349827	Bronze			2021-06-18	
J	McCauley, SR; McDaniel, MA; Pedroza, C; Chapman, SB; Levin, HS				McCauley, Stephen R.; McDaniel, Mark A.; Pedroza, Claudia; Chapman, Sandra B.; Levin, Harvey S.			Incentive Effects on Event-Based Prospective Memory Performance in Children and Adolescents With Traumatic Brain Injury	NEUROPSYCHOLOGY			English	Article; Proceedings Paper	32nd Annual Meeting of the International-Neuropsychological-Society	FEB 04-07, 2004	Baltimore, MD	Int Neuropsychol Soc		event-based prospective memory; traumatic brain injury; incentive; motivation; memory rehabilitation	CLOSED-HEAD-INJURY; ELECTRONIC MEMORY; ACADEMIC-ACHIEVEMENT; TASK INTERRUPTION; EVERYDAY MEMORY; POCKET MONEY; SHORT-TERM; AGE; ADULTS; IMPAIRMENT	Prospective memory (PM) is the formation of an intention and remembering to perform this intention at a future time or in response to specific cues. PM tasks are a ubiquitous part of daily life. Currently, there is a paucity of information regarding PM impairments in children with traumatic brain injury (TBI) and less empirical evidence regarding effective remediation strategies to mitigate these impairments. The present study employed two levels of a motivational enhancement (i.e., a monetary incentive) to determine whether event-based PM could be improved in children with severe TBI. In a crossover design, children with orthopedic injuries and mild or severe TBI were compared on two levels of incentive (dollars vs. pennies) given in response to accurate performance. All three groups performed significantly better under the high- versus low-motivation conditions. However, the severe TBI group's high-motivation condition performance remained significantly below the low-motivation condition performance of the orthopedic injury group. PM scores were positively and significantly related to age-at-test, but there were no age-at-injury or time-postinjury effects. Overall, these results suggest that event-based PM can be significantly improved in children with severe TBI.	[McCauley, Stephen R.; Levin, Harvey S.] Univ Texas Houston, Sch Med, Houston, TX USA; [McDaniel, Mark A.] Washington Univ, Dept Psychol, St Louis, MO 63130 USA; [Pedroza, Claudia] Univ Texas Houston, Sch Publ Hlth, Div Biostat, Houston, TX USA; [Chapman, Sandra B.] Univ Texas Dallas, Ctr Brainhlth, Inst Biomed Sci & Technol, Dallas, TX 75230 USA; [McCauley, Stephen R.] Baylor Coll Med, Dept Pediat Hematol Oncol, Houston, TX 77030 USA	McCauley, SR (corresponding author), Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, 1709 Dryden Rd,Suite 725, Houston, TX 77030 USA.	mccauley@bcm.edu		Pedroza, Claudia/0000-0003-4235-1282	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23 HD040896-04, K23-HD40896, K23 HD040896-03, K23 HD040896-01A1, K23 HD040896-02, K23 HD040896] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS21899] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD040896] Funding Source: NIH RePORTER		Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Baddeley AD., 1990, HUMAN MEMORY; Barnes MA, 1999, DEV NEUROPSYCHOL, V15, P1, DOI 10.1080/87565649909540737; Barnet-Verzat C, 2002, J ECON PSYCHOL, V23, P339, DOI 10.1016/S0167-4870(02)00080-6; Best D. L., 1992, MEMORY IMPROVEMENT I, P122; BRANDIMONTE MA, 1994, Q J EXP PSYCHOL-A, V47, P565, DOI 10.1080/14640749408401128; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; Chapman S.B, 1995, TRAUMATIC HEAD INJUR, P95; Chapman S. B., 1997, AM J SPEECH-LANG PAT, V6, P66; Chapman SB, 1998, BRAIN LANG, V61, P420, DOI 10.1006/brln.1997.1885; Chapman SB, 2001, J HEAD TRAUMA REHAB, V16, P441, DOI 10.1097/00001199-200110000-00004; COCKBURN J, 1995, CORTEX, V31, P87, DOI 10.1016/S0010-9452(13)80107-4; CROVITZ HF, 1984, B PSYCHONOMIC SOC, V22, P413; Dennis M, 1996, DEV NEUROPSYCHOL, V12, P77, DOI 10.1080/87565649609540641; DENNIS M, 2000, PATIENT BASED APPROA; Dennis M., 1995, TRAUMATIC HEAD INJUR, P165; Driscoll I, 2005, NEUROPSYCHOLOGY, V19, P28, DOI 10.1037/0894-4105.19.1.28; Einstein G., 1996, PROSPECTIVE MEMORY T, P115; Einstein GO, 2005, J EXP PSYCHOL GEN, V134, P327, DOI 10.1037/0096-3445.134.3.327; EINSTEIN GO, 1990, J EXP PSYCHOL LEARN, V16, P717, DOI 10.1037/0278-7393.16.4.717; Ewing-Cobbs L, 1998, J CLIN EXP NEUROPSYC, V20, P769, DOI 10.1076/jcen.20.6.769.1109; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; Flannery M A, 1997, Pediatr Rehabil, V1, P239; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Fortin S, 2002, BRAIN COGNITION, V48, P361, DOI 10.1006/brcg.2001.1378; Fortin S, 2003, CORTEX, V39, P273, DOI 10.1016/S0010-9452(08)70109-6; Furnham A, 1999, BRIT J DEV PSYCHOL, V17, P585, DOI 10.1348/026151099165492; Furnham A, 2000, EUR PSYCHOL, V5, P202, DOI 10.1027//1016-9040.5.3.202; Furst C., 1986, COGNITIVE REHABILITA, V4, P24; GENTRY M, 1990, PERS SOC PSYCHOL B, V16, P241, DOI 10.1177/0146167290162005; Gronwall D, 1997, J Int Neuropsychol Soc, V3, P592; Groot YCT, 2002, J INT NEUROPSYCH SOC, V8, P645, DOI 10.1017/S1355617702801321; Guajardo NR, 2000, COGNITIVE DEV, V15, P75, DOI 10.1016/S0885-2014(00)00016-2; Hannon R, 1995, REHABIL PSYCHOL, V40, P289, DOI 10.1037/0090-5550.40.4.289; Harris J. E., 1984, EVERYDAY MEMORY ACTI, P71; Hart T, 2002, J HEAD TRAUMA REHAB, V17, P556, DOI 10.1097/00001199-200212000-00007; Henry JD, 2007, J CLIN EXP NEUROPSYC, V29, P457, DOI 10.1080/13803390600762717; Herrmann D., 1999, HDB APPL COGNITION, P377; Hersh N A, 1994, NeuroRehabilitation, V4, P187, DOI 10.3233/NRE-1994-4309; HUPPERT FA, 1993, J CLIN EXP NEUROPSYC, V15, P805, DOI 10.1080/01688639308402597; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; Kerns KA, 2001, CHILD NEUROPSYCHOL, V7, P162, DOI 10.1076/chin.7.3.162.8744; Kerns KA, 2000, J INT NEUROPSYCH SOC, V6, P62, DOI 10.1017/S1355617700611074; Kidder DP, 1997, AGING NEUROPSYCHOL C, V4, P93, DOI 10.1080/13825589708256639; Kim HJ, 2000, BRAIN INJURY, V14, P187, DOI 10.1080/026990500120844; Kinsella G, 1996, BRAIN INJURY, V10, P499, DOI 10.1080/026990596124214; Kliegel M, 2004, BRAIN COGNITION, V56, P43, DOI 10.1016/j.bandc.2004.05.005; Kliegel M, 2001, MEMORY, V9, P1, DOI 10.1080/09658210042000003; Kliegel M, 2004, MEMORY, V12, P553, DOI 10.1080/09658210344000099; Knight RG, 2006, J INT NEUROPSYCH SOC, V12, P8, DOI 10.1017/S1355617706060048; Knight RG, 2005, BRAIN INJURY, V19, P19, DOI 10.1080/02699050410001720022; KVAVILASHVILI L, 1987, BRIT J PSYCHOL, V78, P507, DOI 10.1111/j.2044-8295.1987.tb02265.x; Kvavilashvili L, 2001, DEV PSYCHOL, V37, P418, DOI 10.1037//0012-1649.37.3.418; LEVIN HS, 1995, TRAUMATIC HEAD INJUR, P70; LOUDA J, 2007, Z NEUROPSYCHOL, V18, P91; LYNCH WJ, 1995, J HEAD TRAUMA REHAB, V10, P94, DOI 10.1097/00001199-199502000-00011; Mateer C.A., 1987, J HEAD TRAUMA REHAB, V2, P74, DOI [10.1097/00001199-198709000-00009, DOI 10.1097/00001199-198709000-00009]; Mathias JL, 2005, BRAIN INJURY, V19, P271, DOI 10.1080/02699050400005028; Maujean A., 2003, BRAIN IMPAIR, V4, P135, DOI DOI 10.1375/BRIM.4.2.135.27024; MAYLOR EA, 1990, Q J EXP PSYCHOL-A, V42, P471, DOI 10.1080/14640749008401233; McCauley SR, 2004, DEV NEUROPSYCHOL, V25, P5, DOI 10.1207/s15326942dn2501&2_2; McDaniel M A, 1993, Memory, V1, P23, DOI 10.1080/09658219308258223; McDaniel M. A., 2007, PROSPECTIVE MEMORY O; McDaniel M. A., 2008, PUZZLE INCONSISTENT, P141; Meacham J. A., 1982, MEMORY OBSERVED REME, P327; MEACHAM JA, 1976, PROSPECTIVE REMEMBER; Neul SKT, 2001, CHILD FAM BEHAV THER, V23, P37, DOI 10.1300/J019v23n04_03; PASTORE DR, 1992, COMPREHENSIVE ADOLES; Reason J.T., 1977, ADULT LEARNING PSYCH; Roche NL, 2007, NEUROPSYCHOL REHABIL, V17, P314, DOI 10.1080/09602010600831004; Roche NL, 2002, BRAIN INJURY, V16, P931, DOI 10.1080/02699050210138581; RUTHER NM, 1993, M SE PSYCHOL ASS ATL; Salthouse TA, 2004, MEM COGNITION, V32, P1133, DOI 10.3758/BF03196887; *SAS I INC, 2003, STAT AN SOFTW WIND V; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P49, DOI 10.1076/jcen.21.1.49.943; SOMERVILLE SC, 1983, J GENET PSYCHOL, V143, P87, DOI 10.1080/00221325.1983.10533537; STOKES S, 2005, NAT C UND RES LEX VA; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor HG, 2004, DEV NEUROPSYCHOL, V25, P199, DOI 10.1207/s15326942dn2501&2_11; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TEASDALE G, 1974, LANCET, V2, P81; TERRY WS, 1988, PSYCHOL REP, V62, P299, DOI 10.2466/pr0.1988.62.1.299; THOMPSON NM, 1994, NEUROPSYCHOLOGY, V8, P333, DOI DOI 10.1037/0894-4105.8.3.333; Thone-Otto AIT, 2003, INT J PSYCHOL, V38, P236, DOI 10.1080/00207590344000169; van den Broek MD, 2000, BRAIN INJURY, V14, P455; Ward H, 2004, BRAIN INJURY, V18, P471, DOI 10.1080/02699050310001646107; Ward H, 2007, CHILD NEUROPSYCHOL, V13, P219, DOI 10.1080/09297040600910003; West R. L., 1984, M AM PSYCH ASS TOR; WILKINS AJ, 1978, PRACTICAL ASPECTS ME; Wilson B.A, 1987, REHABILITATION MEMOR; Winograd E., 1988, PRACTICAL ASPECTS ME, V1, P348; Yasuda K, 2002, NEUROPSYCHOL REHABIL, V12, P155, DOI 10.1080/09602010143000239; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514	100	34	35	0	9	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	MAR	2009	23	2					201	209		10.1037/a0014192			9	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	416VR	WOS:000264034100008	19254093	Green Accepted			2021-06-18	
J	Bottari, C; Dassa, C; Rainville, C; Dutil, E				Bottari, Carolina; Dassa, Clement; Rainville, Constant; Dutil, Elisabeth			The factorial validity and internal consistency of the Instrumental Activities of Daily Living Profile in individuals with a traumatic brain injury	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Brain injuries; Activities of daily living; Factor analysis; Executive functions; Ecological assessments	EXPLORATORY FACTOR-ANALYSIS; FRONTAL-LOBE DAMAGE; WORKING-MEMORY; COGNITIVE NEUROPSYCHOLOGY; PERFORMING ACTIVITIES; NATURALISTIC ACTION; EXECUTIVE DEFICITS; EVERYDAY ACTION; REHABILITATION; IMPAIRMENTS	The objective of the study was to investigate the factorial validity and internal consistency of the Instrumental Activities of Daily Living (IADL) Profile. A group of 96 patients aged 16 to 65 years, with moderate to severe traumatic brain injuries, was recruited from 12 rehabilitation hospitals in Quebec. The IADL Profile was administered by an occupational therapist in each subject's home and community environment. Principal axis factoring and confirmatory factor analysis provide preliminary support for six correlated factors (F): (F1) going to grocery store/shopping for groceries, (F2) having a meal with guests/cleaning up, (F3) putting on outdoor clothing, (F4) obtaining information, (F5) making a budget, (F6) preparing a hot meal for guests. Total explained variance was 73.6%. Cronbach's alpha analysis revealed high to very high internal consistency for all scales ranging from .81 to .98; internal consistency of the total scale was very high (0.95). The findings suggest that the IADL Profile is a promising means of documenting both IADL independence and the repercussions of executive function deficits on everyday tasks in real-world environments.	[Bottari, Carolina; Dassa, Clement; Dutil, Elisabeth] Univ Montreal, Fac Med, Montreal, PQ H3C 3J7, Canada; [Bottari, Carolina; Rainville, Constant; Dutil, Elisabeth] Ctr Interdisciplinary Res Rehabil Greater Montrea, Montreal, PQ, Canada; [Dassa, Clement] Grp Rech Interdisciplinaire Sante, Montreal, PQ, Canada; [Rainville, Constant] Univ Montreal, Dept Psychol, Montreal, PQ H3C 3J7, Canada; [Rainville, Constant] Inst Univ Geriatr Montreal, Montreal, PQ, Canada	Bottari, C (corresponding author), Montreal Neurol Inst, Room 276,3801 Univ, Montreal, PQ H3A 2B4, Canada.	carolina.bottari@umontreal.ca					Ashley MJ, 2001, BRAIN INJURY, V15, P435, DOI 10.1080/02699050010005896; Baddeley A, 1996, P NATL ACAD SCI USA, V93, P13468, DOI 10.1073/pnas.93.24.13468; BAUM C, 1993, AM J OCCUP THER, V47, P431, DOI 10.5014/ajot.47.5.431; Bentler P.M., 1995, EQS STRUCTURAL EQUAT; Boomsma A., 2001, STRUCTURAL EQUATION, V2, P139, DOI DOI 10.1007/BF02294248; BOTTARI C, 2007, THESIS U MONTREAL MO; BOTTARI C, 2004, PROFIL ACTIVITES INS; BOTTARI C, 2007, CANADIAN J OCCUPAT S; Bottari C, 2006, AUST OCCUP THER J, V53, P98, DOI DOI 10.1111/J.1440-1630.2006.00547.X; Bottari C, 2007, J HEAD TRAUMA REHAB, V22, P26, DOI 10.1097/00001199-200701000-00003; Brown M, 2004, J HEAD TRAUMA REHAB, V19, P459, DOI 10.1097/00001199-200411000-00004; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Burgess PW, 2006, J INT NEUROPSYCH SOC, V12, P194, DOI 10.1017/S1355617706060310; Burgess PW, 2000, PSYCHOL RES-PSYCH FO, V63, P279, DOI 10.1007/s004269900006; Busch RM, 2005, J CLIN EXP NEUROPSYC, V27, P1022, DOI 10.1080/13803390490919263; Chevignard M, 2000, CORTEX, V36, P649, DOI 10.1016/S0010-9452(08)70543-4; Comrey A., 1992, 1 COURSE FACTOR ANAL; Costello A., 2005, PRACT ASSESS RES EVA, V10, DOI 10.7275/jyj1-4868.; Crepeau F, 1997, NEUROPSYCHOL REHABIL, V7, P147, DOI 10.1080/713755525; Cripe L., 1996, ECOLOGICAL VALIDITY, P171; Crocker L., 1986, INTRO CLASSICAL MODE; DAWSON DR, 1995, BRAIN INJURY, V9, P339, DOI 10.3109/02699059509005774; De Vellis R, 1991, SCALE DEV APPL THEOR; DUTIL E, 1990, Occupational Therapy in Health Care, V7, P7, DOI 10.1080/J003v07n01_03; DUTIL E, 1994, P COMB ANN C EXP AM; Dutil E., 2005, ADL PROFILE DESCRIPT, V1; DUTIL E, 1991, CANADIAN J OCCUPATIO, V59, P40; Dutil E., 1995, EXPERIENCES ERGOTHER, P52; Fischer Helene, 2001, BMC Physiology, V1, P1, DOI 10.1186/1472-6793-1-1; Forde EME, 2000, BRAIN COGNITION, V44, P214, DOI 10.1006/brcg.2000.1229; Forde EME, 2002, NEUROCASE, V8, P59, DOI 10.1093/neucas/8.1.59; Fortin S, 2003, CORTEX, V39, P273, DOI 10.1016/S0010-9452(08)70109-6; Fougeyrollas P, 1998, INT J REHABIL RES, V21, P127, DOI 10.1097/00004356-199806000-00002; Gerbing DW, 1996, STRUCT EQU MODELING, V3, P62, DOI 10.1080/10705519609540030; Gitlin LN, 2001, GERONTOLOGIST, V41, P4, DOI 10.1093/geront/41.1.4; Gitlin LN, 2003, GERONTOLOGIST, V43, P628, DOI 10.1093/geront/43.5.628; Godbout L, 2005, BRAIN INJURY, V19, P337, DOI 10.1080/02699050400005093; Godbout L, 1995, NEUROPSYCHOLOGIA, V33, P1671, DOI 10.1016/0028-3932(95)00047-X; Goel V, 1997, BRAIN, V120, P1805, DOI 10.1093/brain/120.10.1805; Gordon WA, 2006, AM J PHYS MED REHAB, V85, P343, DOI 10.1097/01.phm.0000202106.01654.61; Grafman J., 1993, J HEAD TRAUMA REHAB, V8, P73, DOI DOI 10.1097/00001199-199303000-00008; Hart T, 1998, J HEAD TRAUMA REHAB, V13, P16, DOI 10.1097/00001199-199810000-00004; Hogarty KY, 2005, EDUC PSYCHOL MEAS, V65, P202, DOI 10.1177/0013164404267287; Hoppes S, 2003, AM J OCCUP THER, V57, P396, DOI 10.5014/ajot.57.4.396; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; Humphreys GW, 2001, NAT NEUROSCI, V4, P84, DOI 10.1038/82940; Humphreys GW, 1998, COGN NEUROPSYCHOL, V15, P771; HUMPHREYS GW, 2001, HDB COGNITIVE NEUROP, P565; JOHNSTON M V, 1991, Brain Injury, V5, P141, DOI 10.3109/02699059109008085; KAISER HF, 1974, PSYCHOMETRIKA, V39, P31, DOI 10.1007/BF02291575; Keith R A, 1987, Adv Clin Rehabil, V1, P6; Kielhofner G., 1995, MODEL HUMAN OCCUPATI; KIMBERG DY, 1993, J EXP PSYCHOL GEN, V122, P411, DOI 10.1037/0096-3445.122.4.411; Knight C, 2002, NEUROPSYCHOL REHABIL, V12, P231, DOI 10.1080/09602010244000039; Law M., 1996, CANADIAN J OCCUPATIO, V63, P9, DOI [10.1177/000841749606300103, DOI 10.1177/000841749606300103]; Le Thiec F., 1999, Annales de Readaptation et de Medecine Physique, V42, P1, DOI 10.1016/S0168-6054(99)80030-0; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lezak M. D., 1989, ASSESSMENT BEHAV CON, P113; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; LYSACK CL, 2000, AM J OCCUPATIONAL TH, V55, P433; MacNeill SE, 1997, ARCH PHYS MED REHAB, V78, P755, DOI 10.1016/S0003-9993(97)90085-X; MacNeill SE, 2000, REHABIL PSYCHOL, V45, P356, DOI 10.1037/0090-5550.45.4.356; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; NEISTADT ME, 1992, OCCUPATIONAL THERAPY, V12, P431; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Pedhazur E. J., 1991, MEASUREMENTS DESIGN; Ponsford J., 1995, TRAUMATIC BRAIN INJU; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Rempfer MV, 2003, PSYCHIAT RES, V117, P103, DOI 10.1016/S0165-1781(02)00318-9; ROGERS JC, 1982, AM J OCCUP THER, V36, P709, DOI 10.5014/ajot.36.11.709; Rousseau J., 1994, CANADIAN J OCCUPATIO, V61, P149, DOI DOI 10.1177/000841749406100304; ROUSSEAU J, 1994, CANADIAN J OCCUPATIO, V61, P159, DOI DOI 10.1177/000841749406100305; Sbordone RJ, 1999, STUD NEUROPSYCHOL DE, P227; Schermelleh-Engel K., 2003, METHODS PSYCHOL RES, V8, P23, DOI DOI 10.1002/0470010940; Schwartz MF, 2006, COGN NEUROPSYCHOL, V23, P202, DOI 10.1080/02643290500202623; Schwartz MF, 2002, NEUROPSYCHOL REHABIL, V12, P311, DOI 10.1080/09602010244000084; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Sirigu A, 1996, CORTEX, V32, P297, DOI 10.1016/S0010-9452(96)80052-9; Tabachnick BG, 2013, USING MULTIVARIATE S; TEASDALE G, 1974, LANCET, V2, P81; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Whiteneck G, 2004, ARCH PHYS MED REHAB, V85, pS73, DOI 10.1016/j.apmr.2003.08.107	85	34	34	0	13	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2009	19	2					177	207	PII 901753073	10.1080/09602010802188435			31	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	412HQ	WOS:000263716300002	18720231				2021-06-18	
J	Derwall, M; Stoppe, C; Brucken, D; Rossaint, R; Fries, M				Derwall, Matthias; Stoppe, Christian; Bruecken, David; Rossaint, Rolf; Fries, Michael			Changes in S-100 protein serum levels in survivors of out-of-hospital cardiac arrest treated with mild therapeutic hypothermia: a prospective, observational study	CRITICAL CARE			English	Article							NEURON-SPECIFIC ENOLASE; HYPOXIC BRAIN-DAMAGE; CARDIOPULMONARY-RESUSCITATION; REGAINING CONSCIOUSNESS; PREDICTION; MARKERS; STROKE; INJURY; BLOOD; S100B	Introduction Knowledge about the influence of current neuroprotective interventions on prognostic markers after survival from cardiac arrest is lacking. This study aimed to investigate the effects of mild therapeutic hypothermia on the release of the astroglial protein S-100 after cardiopulmonary resuscitation (CPR) in survivors of out-of-hospital cardiac arrest. Methods This was a prospective, observational study performed during a two-year period, involving medical emergency services and five collaborating hospitals at the city of Aachen, Germany. Sixty-eight subjects were enrolled by the emergency physician on duty by taking blood samples after successful attempts at resuscitation with return of spontaneous circulation (ROSC), followed by samples at 6, 12, 24, 72 and 120 hours post ROSC by the appropriate intensive care unit staff. Depending on the decision of the attending physician, subjects were cooled down to 33 degrees C (n = 37) for 24 hours or were held at 37 degrees C (n = 31). Patients were tracked for estimating mortality and gross neurological outcome for 14 days. Results S-100 levels in patients not receiving mild therapeutic hypothermia (normothermia (NT)) showed equivalent numbers as compared with cooled patients (mild therapeutic hypothermia (MTH)) on baseline (NT = 1.38 mu g/l versus MTH = 1.30 mu g/l; P = 0.886). S-100 levels on baseline were significantly lower in patients with a good neurological outcome at 14 days after the event in comparison to their peers with adverse outcome (P = 0.014). Although the difference in S-100 levels of MTH patients with adverse or favourable neurological outcome reached statistical significance, it did not in NT patients. Conclusions Although the predictive power of S-100 levels were best on admission but not at later time points, MTH had no influence on S-100 serum levels in survivors of non-traumatic out-of-hospital cardiac arrest in the particular setting of this investigation.	[Derwall, Matthias; Stoppe, Christian; Bruecken, David; Rossaint, Rolf; Fries, Michael] Univ Hosp RWTH Aachen, Dept Anaesthesiol, D-52074 Aachen, Germany; [Derwall, Matthias] Univ Hosp RWTH Aachen, Inst Neuropathol, D-52074 Aachen, Germany	Derwall, M (corresponding author), Univ Hosp RWTH Aachen, Dept Anaesthesiol, Pauwelsstr 30, D-52074 Aachen, Germany.	mderwall@ukaachen.de			Laerdal Foundation for Acute Medicine, Stavanger, Norway	Parts of the study were supported by the Laerdal Foundation for Acute Medicine, Stavanger, Norway. The sponsor had no involvement in the study design, or in the collection, analysis and interpretation of data, in the writing of the manuscript or in the decision to submit the manuscript for publication.	Anderson RE, 2001, ANN THORAC SURG, V71, P1512, DOI 10.1016/S0003-4975(01)02399-2; [Anonymous], 2005, CIRCULATION, V112, pIV1, DOI 10.1161/CIRCULATIONAHA.105.166550; BARGER SW, 1992, J BIOL CHEM, V267, P9689; Becker L, 2008, RESUSCITATION, V79, P22, DOI 10.1016/j.resuscitation.2008.06.019; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Bloomfield SM, 2007, NEUROCRIT CARE, V6, P121, DOI 10.1007/s12028-007-0008-x; Bottiger BW, 2001, CIRCULATION, V103, P2694; de Latorre F, 2001, RESUSCITATION, V48, P211, DOI 10.1016/S0300-9572(00)00379-8; deVreedeSwagemakers JJM, 1997, J AM COLL CARDIOL, V30, P1500, DOI 10.1016/S0735-1097(97)00355-0; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; Ekmektzoglou KA, 2007, RESUSCITATION, V75, P219, DOI 10.1016/j.resuscitation.2007.03.016; Elting JW, 2000, J NEUROL SCI, V181, P104, DOI 10.1016/S0022-510X(00)00442-1; Fries M, 2004, ANAESTHESIST, V53, P959, DOI 10.1007/s00101-004-0743-8; Fries M, 2003, RESUSCITATION, V59, P105, DOI 10.1016/S0300-9572(03)00164-3; Grasner JT, 2008, ANASTH INTENSIV NOTF, V43, P706, DOI 10.1055/s-0028-1102989; Grubb NR, 2007, HEART, V93, P1268, DOI 10.1136/hrt.2006.091314; Hachimi-Idrissi S, 2005, RESUSCITATION, V64, P187, DOI 10.1016/j.resuscitation.2004.08.008; Hachimi-Idrissi S, 2002, RESUSCITATION, V53, P251, DOI 10.1016/S0300-9572(02)00027-8; Holzer M, 2002, NEW ENGL J MED, V346, P549; Hsu AA, 2008, PEDIATR CRIT CARE ME, V9, P245, DOI 10.1097/PCC.0b013e3181727b22; Jonsson H, 2001, ANN THORAC SURG, V71, P1433, DOI 10.1016/S0003-4975(00)02612-6; Kapural M, 2002, BRAIN RES, V940, P102, DOI 10.1016/S0006-8993(02)02586-6; KARPIAK SE, 1976, BRAIN RES, V102, P313, DOI 10.1016/0006-8993(76)90885-4; Martens P, 1998, STROKE, V29, P2363, DOI 10.1161/01.STR.29.11.2363; Missler U, 1997, STROKE, V28, P1956, DOI 10.1161/01.STR.28.10.1956; Mussack T, 2001, WORLD J SURG, V25, P539, DOI 10.1007/s002680020082; Mussack T, 2001, RESUSCITATION, V49, P193, DOI 10.1016/S0300-9572(00)00346-4; Nguyen DN, 2006, CRIT CARE MED, V34, P1967, DOI 10.1097/01.CCM.0000217218.51381.49; Nolan JP, 2005, RESUSCITATION, V67, pS39, DOI 10.1016/j.resuscitation.2005.10.009; Pfeifer R, 2005, RESUSCITATION, V65, P49, DOI 10.1016/j.resuscitation.2004.10.011; Rosen H, 1998, STROKE, V29, P473, DOI 10.1161/01.STR.29.2.473; Rosen H, 2001, RESUSCITATION, V49, P183, DOI 10.1016/S0300-9572(00)00348-8; Safar P., 1981, BRAIN FAILURE RESUSC, P155; Tiainen M, 2003, STROKE, V34, P2881, DOI 10.1161/01.STR.0000103320.90706.35; van Alem AP, 2004, AM HEART J, V148, P416, DOI 10.1016/j.ahj.2004.01.031	35	34	35	0	2	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2009	13	2							R58	10.1186/cc7785			7	Critical Care Medicine	General & Internal Medicine	453UN	WOS:000266638500030	19368739	DOAJ Gold, Green Published			2021-06-18	
J	Kim, KT; Park, JK; Kang, SG; Cho, KS; Yoo, DS; Jang, DK; Huh, PW; Kim, DS				Kim, Ki-Tae; Park, Jin-Kyu; Kang, Seok-Gu; Cho, Kyung-Suck; Yoo, Do-Sung; Jang, Dong-Kyu; Huh, Pil-Woo; Kim, Dal-Soo			Comparison of the effect of decompressive craniectomy on different neurosurgical diseases	ACTA NEUROCHIRURGICA			English	Article						Decompressive craniectomy; Intracranial pressure; Traumatic brain injury; Cerebral infarction; Intracerebral haemorrhage	TRAUMATIC BRAIN-INJURY; MIDDLE CEREBRAL-ARTERY; REFRACTORY INTRACRANIAL HYPERTENSION; SUPRATENTORIAL INTRACEREBRAL HEMORRHAGE; SEVERE HEAD-INJURIES; SURGICAL DECOMPRESSION; HEMISPHERIC INFARCTION; CEREBELLAR INFARCTION; FUNCTIONAL RECOVERY; PROGNOSTIC-FACTORS	Many previous studies have reported that decompressive craniectomy has improved clinical outcomes in patients with intractable increased intracranial pressure (ICP) caused by various neurosurgical diseases. However there is no report that compares the effectiveness of the procedure in the different conditions. The authors performed decompressive craniectomy following a constant surgical indication and compared the clinical outcomes in different neurosurgical diseases. Seventy five patients who underwent decompressive craniectomy were analysed retrospectively. There were 28 with severe traumatic brain injury (TBI), 24 cases with massive intracerebral haemorrhage (ICH), and 23 cases with major infarction (MI). The surgical indications were GCS score less than 8 and/or a midline shift more than 6 mm on CT. The clinical outcomes were assessed on the basis of mortality and Glasgow Outcome Scale (GOS) scores. The changes of ventricular pressure related to the surgical intervention were also compared between the different disease groups. Clinical outcomes were evaluated 6 months after decompressive craniectomy. The mortality was 21.4% in patients with TBI, 25% in those with ICH and 60.9% in MI. A favourable outcome, i.e. GOS 4-5 (moderate disability or better) was observed in 16 (57.1%) patients with TBI, 12 (50%) with ICH and 7 (30.4%) with MI. The change of ventricular pressure after craniectomy and was 53.2 (reductions of 17.4%) and further reduced by 14.9% (with dural opening) and (24.8%) after returning to its recovery room, regardless of the diseases group. According to the mortality and GOS scores, decompressive craniectomy with dural expansion was found to be more effective in patients with ICH or TBI than in the MI group. However, the ventricular pressure change during the decompressive craniectomy was similar in the different disease groups. The authors thought that decompressive craniectomy should be performed earlier for the major infarction patients.	[Yoo, Do-Sung] Uijeongbu St Marys Hosp, Dept Neurosurg, Uijeongbu City 480130, Gyeonggi Do, South Korea; [Park, Jin-Kyu; Kang, Seok-Gu; Cho, Kyung-Suck; Yoo, Do-Sung; Jang, Dong-Kyu; Huh, Pil-Woo; Kim, Dal-Soo] Catholic Univ Korea, Coll Med, Dept Neurosurg, Uijeongbu St Marys Hosp, Seoul, South Korea; [Kim, Ki-Tae] Catholic Univ Korea, Coll Med, Dept Radiol, Uijeongbu St Marys Hosp, Seoul, South Korea	Yoo, DS (corresponding author), Uijeongbu St Marys Hosp, Dept Neurosurg, 65-1 Kumoh Dong, Uijeongbu City 480130, Gyeonggi Do, South Korea.	yooman@catholic.ac.kr		Kang, Seok-Gu/0000-0001-5676-2037	Catholic Institute of Cell Therapy Basic Science Programs Foundation	The author wish to acknowledge the financial support of the Catholic Institute of Cell Therapy Basic Science Programs Foundation made in the program year of 2007.	Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; Bayir H, 2003, CRIT CARE MED, V31, pS112, DOI 10.1097/01.CCM.0000042464.46603.0E; Berrouschot J, 1998, INTENS CARE MED, V24, P620, DOI 10.1007/s001340050625; Broderick JP, 1999, STROKE, V30, P905, DOI 10.1161/01.STR.30.4.905; BRODERICK JP, 1993, STROKE, V24, P987, DOI 10.1161/01.STR.24.7.987; Caroli M, 2001, SURG NEUROL, V56, P82, DOI 10.1016/S0090-3019(01)00540-7; Carter BS, 1997, NEUROSURGERY, V40, P1168, DOI 10.1097/00006123-199706000-00010; Cho DY, 2003, SURG NEUROL, V60, P227, DOI 10.1016/S0090-3019(03)00266-0; CLARK K, 1968, J NEUROSURG, V29, P367, DOI 10.3171/jns.1968.29.4.0367; Coplin WM, 2001, J TRAUMA, V50, P1050, DOI 10.1097/00005373-200106000-00013; Coplin WM, 2001, NEUROL RES, V23, P277, DOI 10.1179/016164101101198433; De Luca GP, 2000, ACTA NEUROCHIR SUPPL, V76, P401; DELASHAW JB, 1990, STROKE, V21, P874, DOI 10.1161/01.STR.21.6.874; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Fandino Y, 2004, SWISS MED WKLY, V134, P423; Figaji AA, 2003, CHILD NERV SYST, V19, P666, DOI 10.1007/s00381-003-0804-3; Georgiadis D, 2002, STROKE, V33, P1584, DOI 10.1161/01.STR.0000016970.51004.D9; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Hejazi N, 2002, EUR J PEDIATR, V161, P99, DOI 10.1007/s00431-001-0864-x; Hofmeijer J, 2003, CRIT CARE MED, V31, P617, DOI 10.1097/01.CCM.0000050446.16158.80; Holtkamp M, 2001, J NEUROL NEUROSUR PS, V70, P226, DOI 10.1136/jnnp.70.2.226; Hutchinson P J, 2004, Curr Opin Crit Care, V10, P101, DOI 10.1097/00075198-200404000-00004; IVAMOTO HS, 1974, STROKE, V5, P365, DOI 10.1161/01.STR.5.3.365; Jaeger M, 2003, J NEUROL NEUROSUR PS, V74, P513, DOI 10.1136/jnnp.74.4.513; Jiang JY, 2005, J NEUROTRAUM, V22, P623, DOI 10.1089/neu.2005.22.623; JUVELA S, 1989, J NEUROSURG, V70, P755, DOI 10.3171/jns.1989.70.5.0755; KERR FWL, 1963, MAYO CLIN P, V43, P852; Kilincer C, 2005, ACTA NEUROCHIR, V147, P587, DOI 10.1007/s00701-005-0493-7; KOBAYASHI S, 1994, NEUROSURGERY, V34, P246, DOI 10.1227/00006123-199402000-00006; Koh MS, 2000, SURG NEUROL, V53, P225, DOI 10.1016/S0090-3019(00)00163-4; KONDZIOLKA D, 1988, NEUROSURGERY, V23, P143, DOI 10.1227/00006123-198808000-00002; Kontopoulos V, 2002, ACTA NEUROCHIR, V144, P791, DOI 10.1007/s00701-002-0948-z; MACDONELL RAL, 1987, STROKE, V18, P849, DOI 10.1161/01.STR.18.5.849; Maira G, 2002, NEUROL RES, V24, P54, DOI 10.1179/016164102101199549; Marmarou A, 1996, J NEUROSURG, V85, P1026, DOI 10.3171/jns.1996.85.6.1026; MARMAROU A, 2004, YOUMANS NEUROLOGICAL, V4, P175; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Mazzini L, 2003, ARCH PHYS MED REHAB, V84, P1637, DOI 10.1053/S0003-9993(03)00314-9; Meier U, 2003, ACTA NEUROCHIR SUPPL, V86, P367; Meier U, 2000, ACTA NEUROCHIR SUPPL, V76, P475; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; Mori K, 2004, SURG NEUROL, V62, P420, DOI 10.1016/j.surneu.2003.12.017; Munch E, 2000, NEUROSURGERY, V47, P315; Ong YK, 2002, CHILD NERV SYST, V18, P340, DOI 10.1007/s00381-002-0597-9; Piek Jurgen, 2002, Curr Opin Crit Care, V8, P134, DOI 10.1097/00075198-200204000-00008; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Raco A, 2003, NEUROSURGERY, V53, P1061, DOI 10.1227/01.NEU.0000088766.34559.3E; RENGACHARY SS, 1981, NEUROSURGERY, V8, P321, DOI 10.1227/00006123-198103000-00004; RIEKE K, 1995, CRIT CARE MED, V23, P1576, DOI 10.1097/00003246-199509000-00019; ROBERTSON C, 2004, YOUMANS NEUROLOGICAL, V4, P5103; Robertson SC, 2004, NEUROSURGERY, V55, P55, DOI 10.1227/01.NEU.0000126875.02630.36; Ruf B, 2003, CRIT CARE, V7, pR133, DOI 10.1186/cc2361; Sakai K, 1998, NEUROL MED-CHIR, V38, P131, DOI 10.2176/nmc.38.131; Schwab S, 1996, NEUROLOGY, V47, P393, DOI 10.1212/WNL.47.2.393; Schwab S, 1998, STROKE, V29, P1888, DOI 10.1161/01.STR.29.9.1888; Schwarz S, 1997, ACTA NEUROCHIR, V139, P897, DOI 10.1007/BF01411297; Smith ER, 2002, NEUROSURGERY, V51, P117, DOI 10.1097/00006123-200207000-00018; Soukiasian HJ, 2002, AM SURGEON, V68, P1066; Stefini R, 1999, NEUROSURGERY, V45, P626, DOI 10.1097/00006123-199909000-00038; Steiner T, 2001, NEUROLOGY, V57, pS61, DOI 10.1212/WNL.57.suppl_2.S61; Stiefel MF, 2004, J NEUROSURG, V101, P241, DOI 10.3171/jns.2004.101.2.0241; Strege RJ, 2003, NEUROL RES, V25, P510, DOI 10.1179/016164103101201742; TABADDOR K, 1982, SURG NEUROL, V18, P212, DOI 10.1016/0090-3019(82)90395-0; TEITHMEIER T, 2005, CHILD NERV SYST, V21, P249; Uhl E, 2004, J NEUROL NEUROSUR PS, V75, P270; Unwin D H, 1992, Neurosurg Clin N Am, V3, P533; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4; Whitfield PC, 2001, BRIT J NEUROSURG, V15, P500, DOI 10.1080/02688690120105110; Winter CD, 2005, J CLIN NEUROSCI, V12, P619, DOI 10.1016/j.jocn.2005.02.002; Woertgen C, 2004, ACTA NEUROCHIR, V146, P691, DOI 10.1007/s00701-004-0280-x; Yao Y, 2005, SURG NEUROL, V64, P165, DOI 10.1016/j.surneu.2004.10.021; Yoo DS, 1999, J NEUROSURG, V91, P953, DOI 10.3171/jns.1999.91.6.0953; Zazulia AR, 1999, STROKE, V30, P1167, DOI 10.1161/01.STR.30.6.1167; Ziai WC, 2003, J NEUROSURG ANESTH, V15, P25, DOI 10.1097/00008506-200301000-00005; Zuccarello M, 1999, STROKE, V30, P1833, DOI 10.1161/01.STR.30.9.1833	75	34	34	0	2	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	JAN	2009	151	1					21	30		10.1007/s00701-008-0164-6			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	399EY	WOS:000262784400003	19096757				2021-06-18	
J	Tellier, A; Marshall, SC; Wilson, KG; Smith, A; Perugini, M; Stiell, IG				Tellier, Andree; Marshall, Shawn C.; Wilson, Keith G.; Smith, Andra; Perugini, Mary; Stiell, Ian Gilmour			The heterogeneity of mild traumatic brain injury: Where do we stand?	BRAIN INJURY			English	Article						Glasgow Coma Scale; mild brain injury; outcome; traumatic brain injury	MINOR HEAD-INJURY; LIFE SATISFACTION; FOLLOW-UP; COMPLAINTS; SYMPTOMS; CONSCIOUSNESS; DISABILITY; SUPPORT; COMA	Primary objective: To explore the heterogeneity of mild traumatic brain injury (mTBI). Methods and procedures: Hospital-based prospective follow-up study of 125 patients with mTBI sub-divided into 'severity' sub-groups on the basis of GCS scores (GCS of 15 = mild sub-group; GCS of 13-14 = moderate sub-group). Post-traumatic amnesia (PTA) duration (30 minutes used as a cut-off) was also used to define group membership for secondary analyses. The follow-up assessment consisted of a brief neuropsychological battery as well as measures of neurobehavioural functioning, community integration and post-concussive symptomatology. CT scanning was also obtained when clinically relevant. Main outcomes and results: The two mTBI sub-groups, as defined by GCS scores, did not differ with respect to post-concussive symptomatology, neurobehavioural symptoms, neuropsychological performance or CT scan abnormalities. In contrast, when group membership was redefined on the basis of PTA, the two sub-groups differed significantly with respect to intracranial abnormalities and report of aggressive or disinhibited behaviours at the 6-month mark. Conclusions: While the notion of heterogeneity in mTBI was not supported when severity was based on GCS scores, there was partial support when PTA duration was used as a measure of severity.	[Tellier, Andree] Univ Ottawa, Dept Psychol, Neuropsychol Serv, Ottawa Hosp, Ottawa, ON K1Y 4E9, Canada; [Marshall, Shawn C.] Univ Ottawa, Rehabil Ctr, Dept Med, Ottawa Hosp, Ottawa, ON K1Y 4E9, Canada; [Wilson, Keith G.; Perugini, Mary] Univ Ottawa, Rehabil Ctr, Dept Psychol, Ottawa Hosp, Ottawa, ON K1Y 4E9, Canada; [Stiell, Ian Gilmour] Univ Ottawa, Loeb Res Inst, Clin Epidemiol Unit, Ottawa, ON K1Y 4E9, Canada; [Smith, Andra] Univ Ottawa, Sch Psychol, Ottawa, ON K1Y 4E9, Canada	Tellier, A (corresponding author), Univ Ottawa, Dept Psychol, Neuropsychol Serv, Ottawa Hosp, Civ Campus,1053 Carling Ave, Ottawa, ON K1Y 4E9, Canada.	atellier@ottawahospital.on.ca		Stiell, Ian/0000-0002-2583-6408	Ontario Neurotrauma Foundation	This research was supported by funding from the Ontario Neurotrauma Foundation.	Abu-Judeh HH, 1999, NUCL MED COMMUN, V20, P505, DOI 10.1097/00006231-199906000-00003; AMMONS RB, 1962, PSYCHOL REP, V11, P111, DOI 10.1177/003329416201100106; Bailey B. N., 1989, TXB HEAD INJURY, P308; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; BROWN J, 1958, Q J EXP PSYCHOL, V10, P12, DOI 10.1080/17470215808416249; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABIL MED, V36, P15, DOI 10.1080/16501960410023688; Chen SHA, 2003, J NEUROL NEUROSUR PS, V74, P326, DOI 10.1136/jnnp.74.3.326; Cohen BA, 2007, AM J NEURORADIOL, V28, P907; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; Deb S, 1998, J NEUROL NEUROSUR PS, V65, P899, DOI 10.1136/jnnp.65.6.899; Feinstein A, 2001, MED SCI LAW, V41, P116, DOI 10.1177/002580240104100206; Finlayson MAJ, 2004, STUD NEUROPSYCHOL DE, P417; Friedland JF, 2001, J NERV MENT DIS, V189, P426, DOI 10.1097/00005053-200107000-00003; GERBER DJ, 1995, J HEAD TRAUMA REHAB, V10, P28, DOI 10.1097/00001199-199508000-00004; Golden C., 1978, STROOP COLOR WORD TE; Gomez PA, 1996, BRIT J NEUROSURG, V10, P453, DOI 10.1080/02688699647078; Hsiang JNK, 1997, J NEUROSURG, V87, P234, DOI 10.3171/jns.1997.87.2.0234; IVERSON GL, 1998, 21 ITEM TEST RES MAN; Kashluba S, 2004, ARCH CLIN NEUROPSYCH, V19, P805, DOI 10.1016/j.acn.2003.09.005; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kennedy RE, 2006, J HEAD TRAUMA REHAB, V21, P260, DOI 10.1097/00001199-200605000-00006; Kraus J, 2005, J HEAD TRAUMA REHAB, V20, P239, DOI 10.1097/00001199-200505000-00007; Kreutzer JS., 1999, NEUROBEHAVIORAL FUNC; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; Miller LJ, 2001, BRAIN INJURY, V15, P297, DOI 10.1080/026990501750111238; Paniak C, 1999, J HEAD TRAUMA REHAB, V14, P211, DOI 10.1097/00001199-199906000-00002; Paniak C, 2000, J MUSCULOSKELET PAIN, V8, P193, DOI 10.1300/J094v08n01_16; Paniak C, 2002, J CLIN EXP NEUROPSYC, V24, P187, DOI 10.1076/jcen.24.2.187.999; Paniak C, 2000, BRAIN INJURY, V14, P219; PETERSON LR, 1959, J EXP PSYCHOL, V58, P193, DOI 10.1037/h0049234; Raskin SA, 1997, BRAIN INJURY, V11, P587, DOI 10.1080/026990597123287; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; RUTHERFORD WH, 1977, LANCET, V1, P1; Sadowski-Cron C, 2006, BRAIN INJURY, V20, P1131, DOI 10.1080/02699050600832569; Stalnacke BM, 2007, BRAIN INJURY, V21, P933, DOI 10.1080/02699050701553189; Stalnacke BM, 2007, J REHABIL MED, V39, P405, DOI 10.2340/16501977-0057; TEASDALE G, 1974, LANCET, V2, P81; Tellier A, 1999, BRAIN INJURY, V13, P463; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Wechsler D, 1997, WAIS 3 ADM SCORING M; Willer B., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI DOI 10.1097/00001199-199308020-00009; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; WRIGHTSON P, 1989, MILD HEAD INJURY, P245	56	34	34	0	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	11					879	887	PII 915242992	10.1080/02699050903200555			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	498JY	WOS:000270137300004	20100124				2021-06-18	
J	Yip, BCB; Man, DWK				Yip, Ben C. B.; Man, David W. K.			Virtual reality (VR)-based community living skills training for people with acquired brain injury: A pilot study	BRAIN INJURY			English	Article						Brain injury; rehabilitation; cognition; virtual reality; community-living	COGNITIVE STATUS EXAMINATION; LIFE SATISFACTION; INSTRUMENTAL ACTIVITIES; CHINESE VERSION; REHABILITATION; STROKE; INTEGRATION; PERFORMANCE; IMPAIRMENT; VALIDATION	Primary objective: The purpose of the present study was to test the usability and effectiveness of a newly-developed virtual reality (VR)-based community living skills training program for people with acquired brain injury (ABI). Method: A small-sample, pre- and post-quasi experimental design was adopted to initially study the efficacy of the VR-based training program. Its usability was also investigated through interviewing subjects. Outcomes were documented in terms of subjects' skills acquisition, self-efficacy in applying the learnt skills and the transfer ratio of the learnt skills to the real environment. Global cognitive ability and the functional independence level were also assessed. Results: Four subjects with ABI (one traumatic brain injury and three stroke subjects) were successfully recruited and received 10 sessions of VR-based community living skills training. All four subjects showed improvement in skills acquisition and memory performance, while three out of four also showed improvement in self-efficacy and demonstrated transfer of skills to the real environment. Usability was initially supported. Conclusions: Preliminary results suggested positive changes in ABI subjects. The proposed virtual reality (VR) community living skills training software will be further investigated in a randomized controlled trial.	[Yip, Ben C. B.; Man, David W. K.] Hong Kong Polytech Univ, Dept Rehabil Sci, Kowloon, Hong Kong, Peoples R China	Man, DWK (corresponding author), Hong Kong Polytech Univ, Dept Rehabil Sci, Kowloon, Hong Kong, Peoples R China.	david.man@polyu.edu.hk			Research Grants Council of Hong KongHong Kong Research Grants Council [523205]	The project was funded by The Competitive Earmarked Research Grant (now known as the General Research Fund or GRF), of the Research Grants Council of Hong Kong (#523205).	Brooks BM, 2003, NEUROREHABILITATION, V18, P147; Burleigh SA, 1998, AM J OCCUP THER, V52, P45, DOI 10.5014/ajot.52.1.45; CERVELLI L, 1990, REHABILITATION ADULT, P463; Chan CCH, 2002, BRAIN INJURY, V16, P873, DOI 10.1080/02699050210131975; Chan CHC, 1999, ARCH CLIN NEUROPSYCH, V14, P71, DOI 10.1093/arclin/14.1.71; Cheng SKW, 2006, BRAIN INJURY, V20, P621, DOI 10.1080/02699050600677196; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Doig E, 2001, BRAIN INJURY, V15, P747, DOI 10.1080/02699050110034343; Duncan PW, 2002, CLIN REHABIL, V16, P493, DOI 10.1191/0269215502cr510oa; Fisher WW, 2003, J APPL BEHAV ANAL, V36, P387, DOI 10.1901/jaba.2003.36-387; GLYSKY EL, 1987, NEUROPSYCHOLOGIA, V25, P839; GOUVIER W, 1997, NEUROPSYCHOLOGY HDB, P3; Gregg L, 2007, SOC PSYCH PSYCH EPID, V42, P343, DOI 10.1007/s00127-007-0173-4; Gurka JA, 1999, J HEAD TRAUMA REHAB, V14, P247, DOI 10.1097/00001199-199906000-00005; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; Johnson DA, 1998, SCOT MED J, V43, P81, DOI 10.1177/003693309804300307; Katz N, 2005, DISABIL REHABIL, V27, P1235, DOI 10.1080/09638280500076079; Lam YS, 2006, NEUROREHABILITATION, V21, P245; Lee JH, 2003, CYBERPSYCHOL BEHAV, V6, P383, DOI 10.1089/109493103322278763; LEZAK MD, 1990, TRAUMATIC BRAIN INJU, P365; LOOMIS JM, 1992, J EXP PSYCHOL HUMAN, V18, P906, DOI 10.1037/0096-1523.18.4.906; Lynch B, 2002, J HEAD TRAUMA REHAB, V17, P446, DOI 10.1097/00001199-200210000-00006; LYNCH W, 1992, J HEAD TRAUMA REHAB, V7, P36; MALIA K, 2004, RECOMMENDATIONS BEST; Man DWK, 2006, BRAIN INJURY, V20, P981, DOI 10.1080/13561820600909852; Man DWK, 2006, BRAIN INJURY, V20, P205, DOI 10.1080/02699050500454621; Mariani E, 2008, INT J GERIATR PSYCH, V23, P523, DOI 10.1002/gps.1932; McColl MA, 1998, BRAIN INJURY, V12, P15, DOI 10.1080/026990598122827; Nabors NA, 1997, J HEAD TRAUMA REHAB, V12, P79, DOI 10.1097/00001199-199706000-00008; NEISTADT ME, 1990, AM J OCCUP THER, V44, P299, DOI 10.5014/ajot.44.4.299; Odhuba RA, 2005, BRIT J CLIN PSYCHOL, V44, P269, DOI 10.1348/014466505X29431; Rizzo AA, 2000, CYBERPSYCHOL BEHAV, V3, P483, DOI 10.1089/10949310050078940; Rizzo AA, 2001, PRESENCE-TELEOP VIRT, V10, P359, DOI 10.1162/1054746011470226; Rose FD, 2000, ERGONOMICS, V43, P494, DOI 10.1080/001401300184378; Schultheis MT, 2001, REHABIL PSYCHOL, V46, P296, DOI 10.1037/0090-5550.46.3.296; SCHWAMM LH, 1987, ANN INTERN MED, V107, P486, DOI 10.7326/0003-4819-107-4-486; Sohlberg M. M., 1989, INTRO COGNITIVE REHA; Sohlberg MM, 2005, BRAIN INJURY, V19, P1249, DOI 10.1080/02699050500309510; SOHLBERG MM, 2001, COGNITIVE REHABILITA, P4; Tam SF, 2005, REHABIL PSYCHOL, V50, P285, DOI 10.1037/0090-5550.50.3.285; Tate RL, 1997, BRAIN INJURY, V11, P907, DOI 10.1080/026990597122972; Tong AYC, 2002, OTJR-OCCUP PART HEAL, V22, P132, DOI 10.1177/153944920202200402; Wallace JJ, 2000, BRAIN INJURY, V14, P63, DOI 10.1080/026990500120934; WATERS J, 1996, COGNITIVE REHABILITA, P425; Weiss Patrice L Tamar, 2003, Occup Ther Int, V10, P39, DOI 10.1002/oti.176; White O. R., 1980, EXCEPTIONAL TEACHING; You SH, 2005, STROKE, V36, P1166, DOI 10.1161/01.STR.0000162715.43417.91; Zencius AH, 1999, BRAIN INJURY, V13, P723	50	34	36	0	19	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	13-14					1017	1026		10.3109/02699050903379412			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	529YR	WOS:000272556000004	19891532				2021-06-18	
J	Dickin, DC; Doan, JB				Dickin, D. C.; Doan, J. B.			Postural stability in altered and unaltered sensory environments following fatiguing exercise of lower extremity joints	SCANDINAVIAN JOURNAL OF MEDICINE & SCIENCE IN SPORTS			English	Article						recovery; sensory perturbation; sway-referenced support; posturography	MUSCLE FATIGUE; BALANCE; CONTRACTIONS; CONCUSSION; SWAY; PROPRIOCEPTION; POSITION; DEFICITS; SCORES; INJURY	Investigations of postural recovery following controlled external perturbations have provided models for healthy and pathological balance behavior. Less work, however, has investigated postural responses related to internal perturbations of the balance system. In this study, lower extremity joint (knee, or ankle) and overall fatigue of the dominant leg provided the internal perturbations to the balance system. Postural sway was examined during unilateral dominant leg standing before and immediately following fatiguing exercise, as well as at 10, 20, and 30 min post-fatigue activity. Sway was measured in both firm and sway-referenced support surface (external perturbation) conditions. Both joint-localized fatigue and overall fatigue were found to induce impairments in postural control, which were further exacerbated by external postural perturbations. Follow-up pairwise comparisons indicated that these impairments persisted at 10 and 30 min post-fatigue. No differences in postural sway were found between fatigue locations or across any interactions between sway and fatigue location. The results indicated that muscular fatigue imposed a prolonged internal perturbation to postural control, regardless of any individual or combined joint fatigue localization. This global effect, combined with the prolonged impairment in postural response, provides support for critical contributions from a central mechanism to postural deficits due to fatigue.	[Dickin, D. C.] Univ Idaho, Dept Hlth Phys Educ Recreat & Dance, Moscow, ID 83844 USA; [Doan, J. B.] Univ Lethbridge, Dept Kinesiol, Lethbridge, AB T1K 3M4, Canada	Dickin, DC (corresponding author), Univ Idaho, Dept Hlth Phys Educ Recreat & Dance, POB 442401, Moscow, ID 83844 USA.	cdickin@uidaho.edu	Dickin, D. Clark/A-8303-2009	Dickin, D. Clark/0000-0002-3104-4167			Baechle T, 2000, ESSENTIALS STRENGTH; BOTTAS R, 2001, EUR J APPL PHYSL, V94, P62; Brown LA, 2006, PARKINSONISM RELAT D, V12, P376, DOI 10.1016/j.parkreldis.2006.03.004; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Condron JE, 2002, J AM GERIATR SOC, V50, P157, DOI 10.1046/j.1532-5415.2002.50022.x; DAVIDSON BS, 2001, EUR J APPL PHYSL, V93, P183; Dickin D, 2004, EXP AGING RES, V30, P373, DOI 10.1080/03610730490484416; DUNCAN PW, 1990, PHYS THER, V70, P88, DOI 10.1093/ptj/70.2.88; Enoka RM, 1996, J APPL PHYSIOL, V81, P2339; Fu ASN, 2005, AM J SPORT MED, V33, P1174, DOI 10.1177/0363546504271976; Gandevia SC, 2001, PHYSIOL REV, V81, P1725; Goerlick M, 2003, APPL ERGON, V34, P317, DOI 10.1016/S0003-6870(03)00039-5; Gribble PA, 2004, ARCH PHYS MED REHAB, V85, P589, DOI 10.1016/j.apmr.2003.06.031; Grindstaff TL, 2006, PERCEPT MOTOR SKILL, V102, P379; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Johnson B, 1998, BANK MARKETING, V30, P12; Karlsson A, 1997, COMPUT METH PROG BIO, V52, P165, DOI 10.1016/S0169-2607(96)01794-4; Ledin T, 2004, GAIT POSTURE, V19, P184, DOI 10.1016/S0966-6362(03)00061-4; Lysholm M, 1998, SCAND J MED SCI SPOR, V8, P432; Mair SD, 1996, AM J SPORT MED, V24, P137, DOI 10.1177/036354659602400203; MARKS R, 1993, PERCEPT MOTOR SKILL, V77, P1195, DOI 10.2466/pms.1993.77.3f.1195; Melnyk M, 2007, KNEE SURG SPORT TR A, V15, P525, DOI 10.1007/s00167-006-0226-3; MILLER PK, 1976, PERCEPT MOTOR SKILL, V42, P135, DOI 10.2466/pms.1976.42.1.135; Miura K, 2004, ARTHROSCOPY, V20, P414, DOI 10.1016/j.arthro.2004.01.007; Nardone A, 1997, ELECTROMYOGR MOTOR C, V105, P309, DOI 10.1016/S0924-980X(97)00040-4; NASHNER LM, 1990, P APTA FOR NASHV TEN, P5; Paasuke M, 1999, ACTA PHYSIOL SCAND, V166, P319; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Pline KM, 2006, ERGONOMICS, V49, P1639, DOI 10.1080/00140130600901678; Rose DJ, 2000, J AM GERIATR SOC, V48, P275, DOI 10.1111/j.1532-5415.2000.tb02646.x; Schieppati M, 2003, NEUROSCIENCE, V121, P277, DOI 10.1016/S0306-4522(03)00439-1; Smith ICH, 2007, J APPL PHYSIOL, V102, P207, DOI 10.1152/japplphysiol.00571.2006; Stauber WT, 2004, J ELECTROMYOGR KINES, V14, P61, DOI 10.1016/j.jelekin.2003.09.010; Vuillerme N, 2007, INT J SPORTS MED, V28, P243, DOI 10.1055/s-2006-924292; Vuillerme N, 2003, ARCH PHYS MED REHAB, V84, P1560, DOI 10.1016/S0003-9993(03)00235-1; Vuillerme N, 2002, NEUROSCI LETT, V333, P131, DOI 10.1016/S0304-3940(02)00999-0; Walsh LD, 2004, J PHYSIOL-LONDON, V558, P705, DOI 10.1113/jphysiol.2004.062703; Yaggie JA, 2002, ARCH PHYS MED REHAB, V83, P224, DOI 10.1053/apmr.2002.28032	38	34	35	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0905-7188	1600-0838		SCAND J MED SCI SPOR	Scand. J. Med. Sci. Sports	DEC	2008	18	6					765	772		10.1111/j.1600-0838.2007.00760.x			8	Sport Sciences	Sport Sciences	376US	WOS:000261209100013	18248536				2021-06-18	
J	Christian, E; Zada, G; Sung, G; Giannotta, SL				Christian, Eisha; Zada, Gabriel; Sung, Gene; Giannotta, Steven L.			A review of selective hypothermia in the management of traumatic brain injury	NEUROSURGICAL FOCUS			English	Article						hypothermia; intracranial pressure; neuroprotection; selective brain cooling; traumatic brain injury	PROLONGED POSTISCHEMIC HYPOTHERMIA; UPPER RESPIRATORY-TRACT; MILD HYPOTHERMIA; THERAPEUTIC HYPOTHERMIA; MODERATE HYPOTHERMIA; CEREBRAL HYPOTHERMIA; MARKED PROTECTION; AIR-FLOW; HEAD; ISCHEMIA	Object. Traumatic brain injury (TBI) remains a significant cause of morbidity and death in the US and worldwide. Resuscitative systemic hypothermia following TBI has been established as an effective neuroprotective treatment in multiple studies in animals and humans, although this intervention carries with it a significant risk profile as well. Selective, or preferential, methods of inducing cerebral hypothermia have taken precedence over the past few years in order to minimize systemic adverse effects. In this report, the authors explore the current methods available for inducing selective cerebral hypothermia following TBI and review the literature regarding the results of animal and human trials in which these methods have been implemented. Methods. A search of the PubMed archive (National Library of Medicine) and the reference lists of all relevant articles was conducted to identify all animal and human studies pertaining to the use of selective brain cooling, selective hypothermia, preferential hypothermia, or regional hypothermia following TBI. Results. Multiple methods of inducing selective cerebral hypothermia are currently in the experimental phases, including surface cooling, intranasal selective hypothermia, transarterial or transvenous endovascular cooling, extraluminal vascular cooling, and epidural cerebral cooling. Conclusions. Several methods of conferring preferential neuroprotection via selective hypothermia currently are being tested. Class I prospective clinical trials are required to assess the safety and efficacy of these methods.	[Christian, Eisha; Zada, Gabriel; Giannotta, Steven L.] Univ So Calif, Keck Sch Med, Dept Neurosurg, Los Angeles, CA 90089 USA; [Sung, Gene] Univ So Calif, Keck Sch Med, Dept Neurol, Los Angeles, CA 90089 USA	Zada, G (corresponding author), Univ So Calif, Keck Sch Med, Dept Neurosurg, 1200 N State St,Suite 5046, Los Angeles, CA 90089 USA.	gzada@usc.edu					Andrews PJD, 2005, BRIT J ANAESTH, V94, P330, DOI 10.1093/bja/aei025; Barone FC, 1997, NEUROSCI BIOBEHAV R, V21, P31, DOI 10.1016/0149-7634(95)00080-1; Bayir H, 2003, CRIT CARE MED, V31, pS112, DOI 10.1097/01.CCM.0000042464.46603.0E; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS21; CARROLL M, 1992, METAB BRAIN DIS, V7, P45, DOI 10.1007/BF01000440; Cheng H, 2006, ACTA NEUROCHIR, V148, P559, DOI 10.1007/s00701-006-0735-3; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; COIMBRA C, 1994, ACTA NEUROPATHOL, V87, P325, DOI 10.1007/bf00313599; COLBOURNE F, 1994, BRAIN RES, V654, P265, DOI 10.1016/0006-8993(94)90488-X; COLBOURNE F, 1995, J NEUROSCI, V15, P7250; Corbett D, 2000, EXP NEUROL, V163, P200, DOI 10.1006/exnr.2000.7369; Covaciu L, 2008, RESUSCITATION, V76, P83, DOI 10.1016/j.resuscitation.2007.07.002; Ehrlich MP, 2002, ANN THORAC SURG, V73, P191, DOI 10.1016/S0003-4975(01)03273-8; Gal R, 2002, CLIN NEUROL NEUROSUR, V104, P318, DOI 10.1016/S0303-8467(02)00023-9; GINSBERG MD, 1992, CEREBROVAS BRAIN MET, V4, P189; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; Gunn AJ, 1997, J CLIN INVEST, V99, P248, DOI 10.1172/JCI119153; Harris BA, 2007, BRIT J ANAESTH, V98, P93, DOI 10.1093/bja/ael308; Henderson WR, 2003, INTENS CARE MED, V29, P1637, DOI 10.1007/s00134-003-1848-2; Jiang JY, 2006, J NEUROTRAUM, V23, P1847, DOI 10.1089/neu.2006.23.1847; Jiang JY, 2006, J CEREBR BLOOD F MET, V26, P771, DOI 10.1038/sj.jcbfm.9600253; Jordan JD, 2007, J NEUROL SCI, V261, P35, DOI 10.1016/j.jns.2007.04.029; Kochanek PA, 2003, JAMA-J AM MED ASSOC, V289, P3007, DOI 10.1001/jama.289.22.3007; Liu WG, 2006, J INT MED RES, V34, P58, DOI 10.1177/147323000603400107; Maier CM, 2002, NEUROBIOL DIS, V11, P28, DOI 10.1006/nbdi.2002.0513; Markgraf CG, 2001, J NEUROSURG, V95, P979, DOI 10.3171/jns.2001.95.6.0979; McIntyre LA, 2003, JAMA-J AM MED ASSOC, V289, P2992, DOI 10.1001/jama.289.22.2992; OHTA T, 1992, NEUROSURGERY, V31, P1049, DOI 10.1227/00006123-199212000-00010; PARKINS WM, 1954, ANN SURG, V140, P284, DOI 10.1097/00000658-195409000-00004; Peterson K, 2008, J NEUROTRAUM, V25, P62, DOI 10.1089/neu.2007.0424; Phelps C., 1897, TRAUMATIC INJURIES B; Qiu Wu-si, 2006, Chin J Traumatol, V9, P238; Qiu WS, 2006, J CLIN NEUROSCI, V13, P995, DOI 10.1016/j.jocn.2006.02.027; Schmitt FC, 2006, NEUROBIOL DIS, V23, P689, DOI 10.1016/j.nbd.2006.05.008; Schwartz AE, 1996, NEUROSURGERY, V39, P577; Takeda Y, 2003, CRIT CARE MED, V31, P255, DOI 10.1097/00003246-200301000-00040; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tsai MS, 2008, J AM COLL CARDIOL, V51, P1988, DOI 10.1016/j.jacc.2007.12.057; Wang GJ, 2002, NEUROSCIENCE, V114, P1081, DOI 10.1016/S0306-4522(02)00350-0; Wang H, 2004, J NEUROSURG, V100, P272, DOI 10.3171/jns.2004.100.2.0272; Wei G, 2008, J NEUROTRAUM, V25, P549, DOI 10.1089/neu.2007.0498; Wen YS, 2005, J TRAUMA, V58, P577, DOI 10.1097/01.TA.0000152635.99243.30; Wolfson MR, 2008, NEUROCRIT CARE, V8, P437, DOI 10.1007/s12028-008-9064-0; Zhang LH, 2007, SURG NEUROL, V67, P117, DOI 10.1016/j.surneu.2006.05.064	45	34	35	0	10	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	OCT	2008	25	4							E9	10.3171/FOC.2008.25.10.E9			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	355HX	WOS:000259701100009	18828707	Bronze			2021-06-18	
